ᐨ‫ޓޓޓ‬ᢥጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼㐳࡮කቇㇱ㐳 ‫›ޓ‬Ⴆ‫⾆ޓ‬ጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼࡮කቇㇱ࡮㒝ዻ∛㒮ߪ 1994 ᐕએ᧪㧘ᧂ᧪ߦะߌߡᱠ߻⿷႐ࠍ⏕߆߼ࠆߚ߼ߦ㧘3 ᐕᲤߦ‫⺖ߣ⁁⃻ޟ‬㗴‫੹ޕߚ߈ߡߒⴕ⊒ࠍޠ‬࿁߇ 7 ࿁⋡ ( ╙ 7 ภ ) ߢ޽ࠅ 2006 ᐕ߆ࠄ 2008 ᐕ
ߩ 3 ᐕಽߢ޽ࠆ‫ޕ‬21 ਎♿ߦ౉ࠅ‫ޟ‬⡛ၞߥ߈᭴ㅧᡷ㕟‫ࠍޠ‬⢛᥊ߦ㧘‫ ࡊ࠶࠻ޟ‬30‫ߥ⊛᠄ⴣ߁޿ߣޠ‬㆙ጊࡊ࡜ࡦ߇␜ߐࠇߚ‫ޕ‬2004 ᐕߦߪ࿖┙ᄢቇߩᴺੱൻ㧘ᒰ⎇ⓥ⑼ߩㇱዪൻ㧘ᩉᚭࠠࡖࡦࡄࠬ߳ߩᣂ▽⒖ォ㧘㜞ᐲߦ IT ൻߐࠇߚᣂ∛㒮㐿ᬺ㧘ᣂ⥃ᐥ⎇ୃක೙ᐲߩዉ౉ߣ޿߁ỗേߩᣣ‫߇ޘ‬ᆎ߹ߞߚ‫ޕ‬ᒰᤨߩᷡ᳓කቇ
ㇱ㐳ߪߓ߼ోࠬ࠲࠶ࡈߩദജߦࠃࠅ⒖ォ߇ή੐⚳ੌߒ㧘ߘߩᓟ㧘කቇㇱ↢๮⑼ቇ᫟㧘කቇㇱᢎ⢒࡮⑔೑᫟㧘කቇㇱ⸥ᔨળ㙚㧘කቇ࿑ᦠ㙚߇┫Ꮏߒߚ‫ޕ‬ቇ㐳߆ࠄ⽿છߣᮭ㒢ߩᆔછࠍฃߌߚ∛㒮㐳ߩദജߦࠃࠅ
㒝ዻ∛㒮ߩㆇ༡߽゠㆏ߦߩࠅ㧘޿ࠃ޿ࠃ⎇ⓥ૕೙ߩలታߦะߌߡ 2005 ᐕ߆ࠄ 3 ᐕ㑆㧘ㄭ⮮೨කቇㇱ㐳߇ၮ␆⎇ⓥߩᵴᕈൻ㧘⧯ᚻ⎇ⓥ⠪ߩ⢒ᚑ㧘࿾ၞක≮ߩ⏕଻ߦะߌߡḄりߩขࠅ⚵ߺࠍߐࠇߚ (p680-687
ෳᾖ )‫ޕ‬2008 ᐕ 4 ᦬߆ࠄ›Ⴆ߇ᒁ߈⛮޿ߢ޿ࠆ‫ߩࠄࠇߎޕ‬ขࠅ⚵ߺߪᧄ᧪㧘∛ߦ⧰ߒ߻ੱ‫ߩޘ‬ᢇᷣ㧘කቇ࡮ක≮ߩㅴᱠߥߤ਎ߩਛߩᦼᓙࠍ߼ߑߔ߽ߩߢ޽ࠆ߇㧘ᧄᦠ߇▸࿐ߣߔࠆߎߩ 3 ᐕ㑆ߦ㒢ߞߡߺࠇ߫㧘⿷ࠍᒁߞ߬ࠆᄢ߈ߥ㓚⎹ߣߩᚢ޿ߦᄙߊߩࠛࡀ࡞ࠡ࡯߇⾌߿ߐࠇߡ߈ߚࠃ߁ߦߺ߃ࠆ‫ߩߘޕ‬⢛᥊ߦߪᣂ⥃ᐥ⎇ୃක೙ᐲߩዉ౉ࠍ߈ߞ߆ߌߦᄢቇߦ⧯޿කᏧ߇ᚯࠅߦߊߊߥߞߚ⁁ᴫ߇޽ࠅ㧘࿾ၞߩਛᩭ∛㒮ࠍਥߣߔࠆක≮፣უ߇޽ࠆ‫ⷺࠆࠁࠄ޽ޕ‬ᐲ߆ࠄ⷗⋥ߒߚ⚿ᨐ㧘ත೨තᓟߩකቇᢎ⢒㧘ක≮⚻ᷣ㧘ක≮୶ℂ㧘␠ળⷙ▸ߩࠁ߇ߺ㧘࿾ၞක≮ߩ࿷ࠅ߆ߚ㧘කᏧߩㆊ㉃ߥഭ௛ߣᓙㆄߩታᘒ㧘޿ࠊࠁࠆකዪ೙ᐲߩഞ⟋㧘
OECD ⻉࿖ߩਛߢ߭ߣ߈ࠊૐ޿ක≮⾌᡽╷㧘ߥߤߐ߹ߑ߹ߥ໧㗴߇ᶋ߈ᓂࠅߦߐࠇߚ‫ߚߒ߁ߎޕ‬ਛߢ࿖ߪකᏧᢙᛥ೙߆ࠄჇຬ߳⥽ࠍᄢ߈ߊ߈ࠆߣ౒ߦ㧘කᏧߩ⏕ታߥ࿾ၞቯ⌕ߦ߻ߌߚขࠅ⚵ߺࠍᄢቇߦ᳞߼
ߡ߈ߚ‫⥃ߚ߹ޕ‬ᐥ⎇ୃ೙ᐲߩ⷗⋥ߒߣ㧘࡝ࡦࠢߔࠆත೨ᢎ⢒ߩᢛ஻ߦะߌߚᬌ⸛߇߹ߐߦㅴⴕਛߢ޽ࠆ‫ޕ‬৻ᣇ㧘ߎߩ 3 ᐕ㑆㧘iPS ⚦⢩ߩ⊒⷗ߥߤᄢ߈ߥࠗࡦࡄࠢ࠻߇↢๮⑼ቇߦ߽ߚࠄߐࠇ㧘㘩ߩ቟ో߿ࠛࡀ
࡞ࠡ࡯ߩෂᯏߩ໧㗴߇ⅣႺ⑼ቇ߳ߩᦼᓙࠍᒝ߼ߡ߈ߡ߅ࠅ㧘ᚒ‫⊒ߩࠄࠇߎ߽ޘ‬ዷߩ৻⠢ࠍᜂߞߡ߈ߚ‫ޕ‬ᣣᏱ⊛ߥᢎ⢒࡮⎇ⓥ࡮⸻≮ࠍㅢߒߡߪ߽ߜࠈࠎߩߎߣ㧘ⴕ᡽߿࿾ၞߦኻߒߡኾ㐷⊛⍮⼂߿ᛛⴚࠍᵴ߆ߒ
ߚ⋥ធ⊛ߥ␠ળ⽸₂߽ᨐߚߒߡ߈ߚ‫ޕ‬
2008 ᐕᧃߦߪᴺੱൻ (2004) ߦࠃߞߡࠬ࠲࡯࠻ߒߚ╙ 1 ᦼ 6 ᐕߩਛᦼ⋡ᮡߩ੐ታ਄ߩ⹏ଔ߇߹ߣ߼ࠄ
ࠇߚ‫ޕ‬කቇ♽⎇ⓥ⑼࡮කቇㇱߪ߶ߣࠎߤߩ㕙ߢᦼᓙߐࠇࠆ᳓Ḱߦ޽ࠆߣ޿߁⹏ଔߢ޽ߞߚ߇㧘ᢎ⢒࡮⎇ⓥߩ‫ߩ⾰ޟ‬ะ਄‫߁޿ߣޠ‬ὐߢ෩ߒ޿⹏ଔࠍᓧߚ‫⹏ޕ‬ଔ⠪ߦࠊ߆ࠅ߿ߔ޿⺑᣿ߣᩮ᜚⾗ᢱ߇ዯߊߎߣ߇⢄ⷐߢ޽ࠆߣᷓߊ⹺⼂ߒ㧘෻⋭ࠍㄟ߼ߡᧄᦠߢᡷ߼ߡ
‫ߩ⾰ޟ‬ะ਄‫ޠ‬ߦ㑐ߔࠆ⸥ㅀࠍឝタߒߚ(p691-696ෳᾖ)‫ޕ‬⃻࿷㧘㆏Ꮊ೙߿࿖┙ᄢቇߩ⛔ᑄวߩ⼏⺰߇ߥߐࠇߡ޿ࠆ߇㧘ᧄቇㇱ߇ฬ⹷޽ࠆ⁁ᘒߢ↢߈ᱷࠆߚ߼ߦ
⧯޿⎇ⓥ⠪࡮ࠕࠗ࠺ࠕ࡮⎇ⓥ⾌ࠍ⏕଻ߒ㧘␠ળߦะߌߚㆡಾߥ⊒ାߣᵴേ⚿ᨐߦኻߔࠆࠃࠅ⦟޿ቴⷰ⊛⹏ଔࠍฃߌࠆߎߣ߇ᔅ㗇ߢ޽ࠆ‫ޓޕ‬ᧄᦠߪߎߩ 3 ᐕ㑆㧘ᚒ‫┙ߩࠇߙࠇߘ߇ޘ‬႐ߢ޿߆ߦ⠨߃ߡⴕേߒ㧘⺖ߖࠄࠇߚᢎ⢒࡮⎇ⓥ࡮⸻≮࡮␠
ળ⽸₂ࠍᚑߒㆀߍ㧘⥄Ꮖᚑ㐳ߒߡ߈ߚ߆ߣ޿߁⸥㍳ߢ޽ࠅ㧘੹ᓟߩ⺖㗴ߣዷᦸࠍ␜ߒߚ߽ߩߢ޽ࠆ‫ޕ‬㧙⋡‫ޓޓޓޓ‬ᰴ㧙
ᐨᢥ

Σ
1
2
3

Τ

ᄢቇ㒮කቇ♽⎇ⓥ⑼࡮කቇㇱ࡮ห㒝ዻ∛㒮ߩ዁᧪᭴ᗐ
ක⑼ቇኾ᡹࡮ౣ↢ක⑼ቇኾ᡹෸߮කቇㇱකቇ⑼............................................................................ 1⋴⼔ቇኾ᡹෸߮කቇㇱ⋴⼔ቇ⑼ ..................................................................................................... 5කቇㇱ㒝ዻ∛㒮 .............................................................................................................................. 9ᄢቇ㒮කቇ♽⎇ⓥ⑼1 ኾ᡹ާකቇ♽⎇ⓥ⑼ක⑼ቇኾ᡹ި
1㧚 ᢎ⢒࡮⎇ⓥߩℂᔨ㧘⋡ᮡ .......................................................................................................... 112㧚 ක⑼ቇኾ᡹ߩ᭴ᚑ..................................................................................................................... 11㧔1㧕ಽሶ࡮᭴ㅧቇ⻠ᐳ
㧔2㧕∛ᘒ೙ᓮቇ⻠ᐳ
㧔3㧕␹⚻⛔ᓮቇ⻠ᐳ
㧔4㧕⣲≌೙ᓮቇ⻠ᐳ
㧔5㧕ක≮▤ℂቇ⻠ᐳ3㧚 ቇ↢ቯຬߣ౉ቇ⁁ᴫ ................................................................................................................. 13
4㧚 ࠞ࡝ࠠࡘ࡜ࡓߩ✬ᚑᣇ㊎ .......................................................................................................... 14㧔1㧕ጁୃන૏ၮḰ㧔2㧕ᢎ⢒ߩ․⦡
㧔3㧕␠ળੱቇ↢ߩߚ߼ߩភ⟎㧔4㧕ᢎ⢒⎇ⓥಽ㊁㧘ᜰዉᢎຬ
㧔5㧕ၮ␆ᛛⴚ࠻࡟࡯࠾ࡦࠣࠦ࡯ࠬ
㧔6㧕ᄢቇ㒮․೎⻠⟵
5㧚 ᢎ⢒ᵴേ .................................................................................................................................. 20㧔1㧕ᢎ⢒ᵴേߩታᣉౝኈߣᣇᴺ
6㧚 ⎇ⓥᵴേ ................................................................................................................................... 22ާಽሶ࡮᭴ㅧቇ⻠ᐳި
㧔1㧕⚦⢩ᖱႎቇಽ㊁ ................................................................................................................. 22㧔2㧕ಽሶ↢ℂቇಽ㊁ ................................................................................................................. 27
㧔3㧕⮎ℂ∛ᘒቇಽ㊁ ................................................................................................................. 31㧔4㧕ነ↢⯻ቇಽ㊁..................................................................................................................... 36㧔5㧕ㆮવ⊒↢ቇಽ㊁ ................................................................................................................. 41㧔6㧕ౝಽᴲઍ⻢∛ᘒቇಽ㊁ ...................................................................................................... 44㧔7㧕ዊఽ∛ᘒቇಽ㊁ ................................................................................................................. 53㧔8㧕∛ᘒᖱႎ⸃ᨆකቇಽ㊁ ...................................................................................................... 80ާ∛ᘒ೙ᓮቇ⻠ᐳި
㧔1㧕⸃೬ቇಽ㊁ ........................................................................................................................ 86㧔2㧕ಽሶ∛ᘒቇಽ㊁ ................................................................................................................. 90㧔3㧕㜞ᐲవㅴᄖ⑼ቇಽ㊁ .......................................................................................................... 93㧔4㧕ᢛᒻᄖ⑼ቇಽ㊁ ............................................................................................................... 101
㧔5㧕⊹⤏∛ᘒቇಽ㊁ ............................................................................................................... 118
㧔6㧕ᴲዩེ⑼ቇಽ㊁ ............................................................................................................... 128
㧔7㧕㤗㈮࡮−∩೙ᓮቇಽ㊁ .................................................................................................... 139
㧔8㧕⯃↢࡮㓸ਛᴦ≮ቇಽ㊁ .................................................................................................... 148
㧔9㧕ญ⣧∛ᘒቇಽ㊁ ............................................................................................................... 150
ާ␹⚻⛔ᓮቇ⻠ᐳި㧔1㧕㜞ᰴ␹⚻ᒻᘒቇಽ㊁ ........................................................................................................ 156
㧔2㧕↢ℂቇಽ㊁ ...................................................................................................................... 159
㧔3㧕ࠬࡐ࡯࠷ක⑼ቇಽ㊁ ........................................................................................................ 163
㧔4㧕␹⚻ౝ⑼࡮⠧ᐕቇಽ㊁ .................................................................................................... 167
㧔5㧕♖␹∛ℂቇಽ㊁ ............................................................................................................... 174
㧔6㧕⣖␹⚻ᄖ⑼ቇಽ㊁............................................................................................................ 179
㧔7㧕⡊㥦ຜ༄⑼ቇಽ㊁............................................................................................................ 188
㧔8㧕⌒⑼ቇಽ㊁ ...................................................................................................................... 194
ާ⣲≌೙ᓮቇ⻠ᐳި
㧔1㧕⣲≌∛ℂቇಽ㊁ ............................................................................................................... 203
㧔2㧕఺∉∛ℂቇಽ㊁ ............................................................................................................... 208
㧔3㧕⣲≌ᄖ⑼ቇಽ㊁ ............................................................................................................... 212
㧔4㧕ᶖൻེ∛ᘒቇಽ㊁............................................................................................................ 219
㧔5㧕ⴊᶧ∛ᘒቇಽ㊁ ............................................................................................................... 237
㧔6㧕↥⑼ᇚੱ⑼ቇಽ㊁............................................................................................................ 242
㧔7㧕᡼኿✢කቇಽ㊁ ............................................................................................................... 251
㧔8㧕∉ቇ࡮੍㒐කቇಽ㊁ ........................................................................................................ 260
㧔9㧕⥃ᐥ⣲≌ቇಽ㊁ ............................................................................................................... 266
ާක≮▤ℂቇ⻠ᐳި
㧔1㧕ක≮ᖱႎቇಽ㊁ ............................................................................................................... 271
㧔2㧕✚ว∛ᘒౝ⑼ቇಽ㊁ ........................................................................................................ 279
㧔3㧕⥃ᐥ⮎೷ቇಽ㊁ ............................................................................................................... 285
㧔4㧕ක≮⚻ᷣቇಽ㊁ ............................................................................................................... 290
㧔5㧕ᢇᕆ࡮ἴኂකቇಽ㊁ ........................................................................................................ 293
㧔6㧕ᴺකቇಽ㊁ ...................................................................................................................... 300
㧔7㧕↥ᬺⴡ↢ቇಽ㊁ ............................................................................................................... 303
㧔8㧕කቇᢎ⢒ቇಽ㊁ ............................................................................................................... 306
7㧚 ቇ૏ߩ᝼ਈ⁁ᴫߣ⎇ⓥᚑᨐ .................................................................................................... 311
8㧚 ቇ↢↢ᵴᡰេ .......................................................................................................................... 311
㧔1㧕ᅑቇ㊄ߩ↳⺧࡮ណᛯ⁁ᴫ
㧔2㧕᝼ᬺᢱ఺㒰ታᣉ⁁ᴫ9㧚 ⥄Ꮖ⹏ଔ࡮⺖㗴ߣዷᦸ............................................................................................................ 311
ާකቇ♽⎇ⓥ⑼ౣ↢ක⑼ቇኾ᡹ި
1㧚 ᢎ⢒࡮⎇ⓥߩℂᔨ㧘⋡ᮡ ........................................................................................................ 313
2㧚 ౣ↢ක⑼ቇኾ᡹ߩ᭴ᚑ............................................................................................................ 313
㧔1㧕ౣ↢ಽሶ⛔ᓮቇ⻠ᐳ
㧔2㧕ౣ↢Ꮏቇ⻠ᐳ
㧔3㧕ౣ↢ᔕ↪ቇ⻠ᐳ
3㧚 ቇ↢ቯຬߣ౉ቇ⁁ᴫ ............................................................................................................... 314
4㧚 ࠞ࡝ࠠࡘ࡜ࡓߩ✬ᚑᣇ㊎ ........................................................................................................ 315
㧔1㧕ጁୃၮḰ㧔2㧕ᢎ⢒⎇ⓥಽ㊁㧘ᜰዉᢎຬ㧔3㧕ၮ␆ᛛⴚ࠻࡟࡯࠾ࡦࠣࠦ࡯ࠬ
㧔4㧕ᄢቇ㒮․೎⻠⟵
5㧚 ᢎ⢒ᵴേ ................................................................................................................................. 318
㧔1㧕ᢎ⢒ᵴേߩታᣉౝኈߣᣇᴺ
6㧚 ⎇ⓥᵴേ ................................................................................................................................. 320
ާౣ↢ಽሶ⛔ᓮቇ⻠ᐳި
㧔1㧕⚵❱࡮ེቭᒻᚑಽ㊁ ........................................................................................................ 320
㧔2㧕␹⚻↢‛ಽ㊁................................................................................................................... 326
㧔3㧕∛ේ૕೙ᓮಽ㊁ ............................................................................................................... 330
ާౣ↢Ꮏቇ⻠ᐳި㧔1㧕↢๮ᯏ⢻ಽሶ⸳⸘ಽ㊁ .................................................................................................... 338
㧔2㧕⍮⢻ࠗࡔ࡯ࠫᖱႎಽ㊁ .................................................................................................... 342
ާౣ↢ᔕ↪ቇ⻠ᐳި
㧔1㧕ᓴⅣ∛ᘒቇಽ㊁ ............................................................................................................... 355
㧔2㧕๭ๆ∛ᘒቇಽ㊁ ............................................................................................................... 367
㧔3㧕කቇ♽୶ℂ࡮␠ળකቇಽ㊁ ............................................................................................. 371
7㧚 ቇ૏ߩ᝼ਈ⁁ᴫߣ⎇ⓥᚑᨐ .................................................................................................... 375
8㧚 ቇ↢↢ᵴᡰេ .......................................................................................................................... 375
㧔1㧕ᅑቇ㊄ߩ↳⺧࡮ណᛯ⁁ᴫ
㧔2㧕᝼ᬺᢱ఺㒰ታᣉ⁁ᴫ9㧚 ⥄Ꮖ⹏ଔ࡮⺖㗴ߣዷᦸ............................................................................................................ 376
ާකቇ♽⎇ⓥ⑼⋴⼔ቇኾ᡹ި1㧚 ᢎ⢒ߩℂᔨ㧘⋡ᮡ................................................................................................................... 377
2㧚 ⋴⼔ቇኾ᡹ߩ᭴ᚑ................................................................................................................... 377
㧔1㧕⋴⼔ቇᢎ⢒㗔ၞ
㧔2㧕ታ〣⋴⼔ቇ㗔ၞ
3㧚 ቇ↢ቯຬߣ౉ቇ⁁ᴫ ............................................................................................................... 378
4㧚 ࠞ࡝ࠠࡘ࡜ࡓߩ✬ᚑᣇ㊎ ........................................................................................................ 378
㧔1㧕ጁୃၮḰ㧔2㧕ᢎ⢒⎇ⓥಽ㊁㧘ᜰዉᢎຬ5㧚 ᢎ⢒ᵴേ ................................................................................................................................. 380
㧔1㧕ᢎ⢒ᵴേߩታᣉౝኈߣᣇᴺ
6㧚 ቇ૏ߩ᝼ਈ⁁ᴫߣ⎇ⓥᚑᨐ .................................................................................................... 381
7㧚 ቇ↢↢ᵴᡰេ .......................................................................................................................... 381
㧔1㧕ᅑቇ㊄ߩ↳⺧࡮ណᛯ⁁ᴫ
㧔2㧕᝼ᬺᢱ఺㒰ታᣉ⁁ᴫ㧔3㧕ቇ↢ߩ଻㒾ട౉8㧚 ⥄Ꮖ⹏ଔ࡮⺖㗴ߣዷᦸ............................................................................................................ 381
㧔1㧕⋴⼔ቇᢎ⢒㗔ၞ
㧔2㧕ታ〣⋴⼔ቇ㗔ၞާߘߩઁ㑐ㅪᣉ⸳╬⎇ⓥᵴേި㧔1㧕㒝ዻ∛㒮ャⴊㇱ................................................................................................................... 384
㧔2㧕㒝ዻ∛㒮∛ℂㇱ................................................................................................................... 388
㧔3㧕࿾ၞක≮කቇ࠮ࡦ࠲࡯㧔ౝ⑼♽ಽ㊁㧕................................................................................. 392
㧔4㧕࿾ၞක≮කቇ࠮ࡦ࠲࡯㧔ᄖ⑼ᢇᕆ♽ಽ㊁㧕......................................................................... 397
㧔5㧕࿾ၞක≮කቇ࠮ࡦ࠲࡯㧔ዊఽ♽ಽ㊁㧕................................................................................. 401
㧔6㧕࿾ၞක≮කቇ࠮ࡦ࠲࡯㧔↥⑼♽ಽ㊁㧕................................................................................. 404
㧔7㧕࿾ၞක≮කቇ࠮ࡦ࠲࡯㧔✚ว⥃ᐥ♽ಽ㊁㧕......................................................................... 407
㧔8㧕࿾ၞක≮කቇ࠮ࡦ࠲࡯㧔࿾ၞ߳߈࿾✚วක≮ಽ㊁㧕........................................................... 409
㧔9㧕කቇᢎ⢒㐿⊒⎇ⓥ࠮ࡦ࠲࡯㧔࠹ࡘ࠻࡯࡝ࠕ࡞ㇱ㐷㧕........................................................... 412
㧔10㧕කቇᢎ⢒㐿⊒⎇ⓥ࠮ࡦ࠲࡯㧔ࡃ࡯࠴ࡖ࡞ࠬࠠ࡞ㇱ㐷㧕....................................................... 419
㧔11㧕ነ㒝⻠ᐳ‫ޟ‬ஜᐽ㓚ኂඨᷫ⻠ᐳ㧔ጘ㒂⋵㧕‫ޠ‬........................................................................... 426
㧔12㧕ነ㒝⻠ᐳ‫ޟ‬㛽㑐▵ౣᑪᄖ⑼ቇ⻠ᐳ㧔ࠫࡦࡑ࡯㧕‫ޠ‬................................................................ 429
㧔13㧕ነ㒝⻠ᐳ‫ޟ‬࿾ၞක≮ቇ⻠ᐳ㧔ጘ㒂⋵㧕‫ޠ‬.............................................................................. 435
㧔14㧕଻ஜ▤ℂ࠮ࡦ࠲࡯㧔ቇౝᣉ⸳㧕........................................................................................... 439
㧔15㧕↢๮⑼ቇ✚ว⎇ⓥᡰេ࠮ࡦ࠲࡯㧔ࠥࡁࡓ⎇ⓥಽ㊁㧕........................................................... 453
㧔16㧕↢๮⑼ቇ✚ว⎇ⓥᡰេ࠮ࡦ࠲࡯㧔ህ᳇ᕈ⩶⎇ⓥಽ㊁㧕....................................................... 458
㧔17㧕ੱ₞ᗵᨴ㒐ᓮ⎇ⓥ࠮ࡦ࠲࡯㧔ࡊ࡝ࠝࡦ⎇ⓥㇱ㐷㧕.............................................................. 463
㧔18㧕ᄢቇ㒮ㅪวഃ⮎ක≮ᖱႎ⎇ⓥ⑼㧔ක≮ᖱႎቇኾ᡹㧕........................................................... 468
2ᢎຬ⚵❱1㧚 ኾછᢎຬߣ㕖Ᏹൕ⻠Ꮷ╬ߩ㈩⟎⁁ᴫ ...................................................................................... 477
㧔1㧕ኾછᢎຬߩ㈩⟎⁁ᴫ╬㧔2㧕㕖Ᏹൕ⻠Ꮷߩ㈩⟎⁁ᴫ㧔3㧕ቴຬ⥃ᐥ♽කቇᢎ᝼╬㧔4㧕⥃ᐥᢎ᝼╬2㧚 ᢎ⢒⵬ഥ⠪ߣ⎇ⓥ⵬ഥ⠪ߩ㈩⟎⁁ᴫ ...................................................................................... 479
㧔1㧕࠹ࠖ࡯࠴ࡦࠣ࡮ࠕࠪࠬ࠲ࡦ࠻ߩታᣉ෸߮ᵴ↪⁁ᴫ
㧔2㧕࡝ࠨ࡯࠴࡮ࠕࠪࠬ࠲ࡦ࠻ߩ㈩⟎⁁ᴫ3㧚 ណ↪㧘᣹છ╬ߩᣇᴺ ............................................................................................................... 480
㧔1㧕ណ↪㧘᣹છߩㆬ⠨ၮḰߣㆬ⠨ᣇᴺ
㧔2㧕㕖Ᏹൕ⻠Ꮷߩㆬ⠨ၮḰߣㆬ⠨ᣇᴺ
4㧚 ౗ᬺ࡮౗⡯ߩၮḰߣ⁁ᴫ ........................................................................................................ 480
㧔1㧕౗ᬺ࡮౗⡯ߩၮḰ
㧔2㧕౗ᬺ࡮౗⡯ߩ⁁ᴫ

Υ

3

ᣉ⸳࡮⸳஻
1㧚 ᣉ⸳࡮⸳஻ߩ⃻⁁࡮ᢛ஻⁁ᴫ................................................................................................. 481
㧔1㧕කቇㇱ࡮㒝ዻ∛㒮ߩ⒖ォᢛ஻ߩ⚻✲㧔2㧕කቇ⎇ⓥ⑼࡮කቇㇱᣂᣉ⸳ߩ․⦡
㧔3㧕ᣂ∛㒮ߩ․ᓽ╬㧔4㧕කቇㇱ⋴⼔ቇ⑼ᣂᣉ⸳ߩ․⦡

4࿖㓙੤ᵹ
1㧚 ⇐ቇ↢ߩฃ౉ࠇ૕೙ߣ⁁ᴫ .................................................................................................... 483
2㧚 ⇐ቇ↢ߩᢎ⢒࡮⎇ⓥᜰዉߩᣇᴺߣ૕೙ .................................................................................. 484
㧔1㧕⇐ቇ↢࠮ࡦ࠲࡯
㧔2㧕࠹ࡘ࡯࠲࡯
3㧚 ࿷ቇ↢ߩᶏᄖ⇐ቇ࡮⎇ୃߩ⁁ᴫ ............................................................................................. 484
4㧚 ᢎຬߩ࿷ᄖ⎇ⓥߩ⁁ᴫ............................................................................................................ 484
5㧚 ᄖ࿖ੱ⎇ⓥ⠪ߩ᜗⥌ߩ⁁ᴫ .................................................................................................... 485
6㧚 ᶏᄖߩᄢቇߣߩቇⴚ੤ᵹදቯߩ✦⚿⁁ᴫ............................................................................... 487

5␠ળߣߩㅪ៤
1㧚 ౏㐿⻠ᐳߩ㐿⸳ߩᣇ㊎ߣ⁁ᴫ................................................................................................. 487
2㧚 ࿾ၞ␠ળߢߩᵴേ⁁ᴫ............................................................................................................ 488
3㧚 ↢ᶦቇ⠌߳ߩኻᔕ⁁ᴫ............................................................................................................ 488
4㧚 ᅏⓄ㜞ጪᄐጊ⸻≮ᚲ ............................................................................................................... 490

6▤ℂㆇ༡㧘⽷᡽1㧚 ᢎ᝼ળ㧔ᢎ᝼ળ⼏㧕㧘ฦ⒳ᆔຬળߩ᭴ᚑߣᵴേ⁁ᴫ............................................................... 491
㧔1㧕ᢎ᝼ળ㧔ᢎ᝼ળ⼏㧕ߩ᭴ᚑຬ㧘છോ㧘ᗧᔒ᳿ቯᣇᴺ㧘ᗧᔒવ㆐ᣇᴺ
㧔2㧕ฦ⒳ᆔຬળߩ⸳⟎ᐕᐲ㧘છോ㧔ㆇ༡ᣇ㊎㧕㧘ᗧᔒ᳿ቯᣇᴺ㧘ᗧᔒવ㆐ᣇᴺ
2㧚 ᢎ⢒࡮⎇ⓥߦ㑐ߔࠆᗧᔒ᳿ቯᣇᴺߣ૕೙............................................................................... 493
㧔1㧕ᢎ⢒ߦ㑐ߔࠆᗧᔒ᳿ቯࠪࠬ࠹ࡓ
㧔2㧕⎇ⓥߦ㑐ߔࠆᗧᔒ᳿ቯࠪࠬ࠹ࡓ
3㧚 ੐ോ⚵❱ߣ੐ോ⡯ຬߩ㈩⟎⁁ᴫ ............................................................................................. 494
㧔1㧕⃻⁁
㧔2㧕ὐᬌ࡮⹏ଔ
㧔3㧕ᡷༀ࡮ᡷ㕟ߣዷᦸ4㧚 ੍▚✬ᚑߣၫⴕ㧔㈩ಽ㧕ߩᣇ㊎ߣ⁁ᴫ .................................................................................. 495

කቇㇱකቇ⑼ᢎ⢒ߩℂᔨ࡮⋡ᮡ╬1㧚 ᢎ⢒ߩℂᔨߣ⋡ᮡ................................................................................................................... 497
2㧚 ᢎ⢒ߩᵴᕈൻߣలታߩ⚻ㆊ .................................................................................................... 497
3㧚 ᢎ⢒ߩ዁᧪᭴ᗐ ...................................................................................................................... 498
㧔1㧕ၮᧄℂᔨ㧔2㧕ᢎ⢒૕೙
2 ᢎ⢒ᵴേ
1㧚 ቇ↢ߩฃ౉ࠇ .......................................................................................................................... 499
㧔1㧕ቇ↢൐㓸ߩᣇᴺ
㧔2㧕౉ቇ⠪ㆬᛮߩᣇᴺߣᣇ㊎㧔3㧕ቇ↢ߩฃ౉ࠇ⁁ᴫ
㧔4㧕✬౉ቇ೙ᐲߣታᘒ
㧔5㧕⎇ⓥ↢ߩฃ౉ࠇߣታᘒ
2㧚 ࠞ࡝ࠠࡘ࡜ࡓ .......................................................................................................................... 501
㧔1㧕ࠞ࡝ࠠࡘ࡜ࡓߩ✬ᚑᣇ㊎㧔2㧕ᢎ⢒ᵴേߩታᣉౝኈߣᣇᴺ
㧔3㧕⺖㗴ߣዷᦸ
3㧚 ᢎ⢒ᣇ㊎ ................................................................................................................................. 505
㧔1㧕ᢎ⢒ᡷ㕟
㧔2㧕ోቇ౒ㅢᢎ⢒㧔3㧕ฦ࠹ࡘ࠻࡯࡝ࠕ࡞ࠦ࡯ࠬߩ᝼ᬺ⸘↹㧔ࠪ࡜ࡃࠬ㧕ߩ૞ᚑ෸߮ቇ⠌ౝኈߩ⺞ᢛ
㧔4㧕⥃ᐥታ⠌㧔5㧕ᣂ౉↢วኋ⎇ୃ㧔6㧕࿷ቇ↢วኋ⎇ୃ㧔7㧕⥃ᐥታ⠌⾗ᩰ✚ว್ቯ⹜㛎㧔౒↪⹜㛎 CBT, OSCE㧕㧔8㧕ઁᄢቇߦ߅ߌࠆ᝼ᬺ⑼⋡ߩጁୃߩᣇ㊎ߣ⁁ᴫ㧔9㧕࿷☋㧘⇐ᐕ㧘ભቇ㧘ㅌቇߩ⁁ᴫ
㧔10㧕ᢎ⢒ᣉ⸳࡮⸳஻ߩ⃻⁁㧔11㧕ᚑ❣ߩ⹏ଔ㧘⹺ቯߩၮḰ㧔12㧕කᏧ࿖ኅ⹜㛎วᩰ⁁ᴫ
4㧚 ቇ↢↢ᵴ߳ߩ㈩ᘦ................................................................................................................... 509
㧔1㧕ᅑቇ㊄ߩ⒳㘃ߣណᛯ⁁ᴫ
㧔2㧕᝼ᬺᢱߩ఺㒰ߩ⁁ᴫ㧔3㧕ቇ↢↢ᵴ⋧⺣ߩ૕೙ߣታᘒ
㧔4㧕⺖ᄖᵴേߩታᘒ
1Φකቇㇱ⋴⼔ቇ⑼ᢎ⢒࡮⎇ⓥߩℂᔨ࡮⋡ᮡ╬1㧚 ᢎ⢒࡮⎇ⓥߩℂᔨߣ⋡ᮡ ........................................................................................................ 513
2㧚 ᢎ⢒࡮⎇ⓥߩᵴᕈൻߣలታߩ⚻ㆊ.......................................................................................... 513
3㧚 ᢎ⢒࡮⎇ⓥߩ዁᧪᭴ᗐ............................................................................................................ 513
㧔1㧕ၮᧄℂᔨ㧔2㧕ᢎ⢒૕೙
㧔3㧕⎇ⓥ૕೙
2 ᢎ⢒ᵴേ
1㧚 ቇ↢ߩฃ౉ࠇ .......................................................................................................................... 514
㧔1㧕ቇ↢൐㓸ߩᣇᴺ
㧔2㧕౉ቇ⠪ㆬᛮߩᣇᴺߣᣇ㊎㧔3㧕ቇ↢ߩฃ౉ࠇ⁁ᴫ
㧔4㧕✬౉ቇ೙ᐲߣታᘒ
㧔5㧕⎇ⓥ↢ߩฃ౉ࠇߣታᘒ
2㧚 ࠞ࡝ࠠࡘ࡜ࡓ .......................................................................................................................... 517

1㧔1㧕ࠞ࡝ࠠࡘ࡜ࡓߩ․ᓽ
㧔2㧕ࠞ࡝ࠠࡘ࡜ࡓߩ᭴▽㧔3㧕⺖㗴ߣዷᦸ
3㧚 ᢎ⢒ᣇ㊎ ................................................................................................................................. 518
㧔1㧕ᢎ⢒ᡷ㕟
㧔2㧕ోቇ౒ㅢᢎ⢒㧔3㧕ኾ㐷ᢎ⢒㧔࠹ࡘ࠻࡯࡝ࠕ࡞ᢎ⢒࡮⥃ᐥታ⠌㧕
㧔4㧕ઁᄢቇߦ߅ߌࠆ᝼ᬺ⑼⋡ߩጁୃᣇ㊎ߣ⁁ᴫ㧔5㧕࿷☋㧘⇐ᐕ㧘ભቇ㧘ㅌቇߩ⁁ᴫ
㧔6㧕ᢎ⢒ᣉ⸳࡮⸳஻ߩ⃻⁁㧔7㧕ᚑ❣ߩ⹏ଔ㧘⹺ቯߩၮḰ
㧔8㧕⋴⼔Ꮷ╬࿖ኅ⹜㛎วᩰ⁁ᴫ㧔9㧕ቇ↢ߩዞ⡯⁁ᴫ4㧚 ቇ↢↢ᵴ߳ߩ㈩ᘦ................................................................................................................... 522
㧔1㧕ᅑቇ㊄ߩ⒳㘃ߣណᛯ⁁ᴫ
㧔2㧕᝼ᬺᢱߩ఺㒰ߩ⁁ᴫ㧔3㧕ቇ↢↢ᵴ⋧⺣ߩ૕೙ߣታᘒ
㧔4㧕⺖ᄖᵴേߩታᘒ
5㧚 ⎇ⓥᵴേ
ާၮ␆⋴⼔ቇ⻠ᐳި
㧔1㧕ၮ␆⋴⼔ቇಽ㊁ ............................................................................................................... 524
㧔2㧕↢๮ᯏ⢻ቇಽ㊁ ............................................................................................................... 528
ާᲣሶ⋴⼔ቇ⻠ᐳި
㧔1㧕Უᕈ⋴⼔ቇಽ㊁ ............................................................................................................... 531
㧔2㧕ዊఽ⋴⼔ቇಽ㊁ ............................................................................................................... 534
ާᚑੱ࡮⠧ᐕ⋴⼔ቇ⻠ᐳި
㧔1㧕ᚑੱ⋴⼔ቇಽ㊁㧔ᘟᕈᦼ㧕............................................................................................... 538
㧔2㧕ᚑੱ⋴⼔ቇಽ㊁㧔ᕆᕈᦼ㧕............................................................................................... 541
㧔3㧕⠧ᐕ⋴⼔ቇಽ㊁ ............................................................................................................... 546
ާ࿾ၞ࡮♖␹⋴⼔ቇ⻠ᐳި
㧔1㧕࿾ၞ⋴⼔ቇಽ㊁ ............................................................................................................... 549
㧔2㧕♖␹⋴⼔ቇಽ㊁ ............................................................................................................... 553

Χ㒝ዻ∛㒮ߩ⃻⁁ߣ⺖㗴∛㒮ߩℂᔨ࡮⚵❱࡮ㆇ༡╬‫ޓ‬1㧚 ℂᔨ࡮ၮᧄᣇ㊎ ...................................................................................................................... 557
㧔1㧕ℂᔨ
㧔2㧕ၮᧄᣇ㊎㧔3㧕⡯ᬺ୶ℂ
㧔4㧕⥃ᐥᜰ㊎2㧚 ⚵❱㧘ㆇ༡‫ ޓ‬.......................................................................................................................... 557
㧔1㧕⚵❱
㧔2㧕⑼㐳ળ⼏㧔3㧕∛㒮ㆇ༡ળ⼏㧔4㧕∛㒮⚻༡ડ↹ળ⼏㧔5㧕㒝ዻ∛㒮ฦ⒳ᆔຬળߩ⸳⟎ᐕᐲ㧘છോ㧔ㆇ༡ᣇ㊎㧕㧘ᗧᔒ᳿ቯᣇᴺ㧘ᗧᔒવ㆐ᣇᴺ
㧔6㧕੐ോ⚵❱ߣ੐ോ⡯ຬߩ㈩⟎⁁ᴫ2 ⸻≮ᵴേߩ⃻⁁ߣ⺖㗴1㧚 ⸻≮૕೙ ................................................................................................................................. 562
㧔1㧕⤳ེ೎⸻≮㧔2㧕⸻≮⑼ߩㅪ៤
㧔3㧕㜞ᐲᢇ๮ᢇᕆ࠮ࡦ࠲࡯

1

2㧚 ᵴേ⁁ᴫ
㧔1㧕╙৻ౝ⑼.............................................................................................................................. 563
㧔2㧕╙ੑౝ⑼.............................................................................................................................. 567
㧔3㧕╙ਃౝ⑼.............................................................................................................................. 569
㧔4㧕␹⚻ౝ⑼࡮⠧ᐕ⑼ ............................................................................................................... 571
㧔5㧕✚วౝ⑼.............................................................................................................................. 573
㧔6㧕╙৻ᄖ⑼.............................................................................................................................. 575
㧔7㧕╙ੑᄖ⑼.............................................................................................................................. 577
㧔8㧕↥⑼ᇚੱ⑼ .......................................................................................................................... 580
㧔9㧕ᢛᒻᄖ⑼.............................................................................................................................. 583
㧔10㧕⣖␹⚻ᄖ⑼.......................................................................................................................... 586
㧔11㧕⌒⑼..................................................................................................................................... 588
㧔12㧕⡊㥦ຜ༄⑼.......................................................................................................................... 590
㧔13㧕⊹⤏⑼................................................................................................................................. 592
㧔14㧕
ᴲዩེ⑼ ............................................................................................................................. 594
㧔15㧕♖␹␹⚻⑼.......................................................................................................................... 597
㧔16㧕
ዊఽ⑼................................................................................................................................. 598
㧔17㧕᡼኿✢⑼ ............................................................................................................................. 602
㧔18㧕㤗㈮⑼−∩ᴦ≮⑼............................................................................................................... 604
㧔19㧕
ᱤ⑼ญ⣧ᄖ⑼ ...................................................................................................................... 606
㧔20㧕
ᬌᩏㇱ................................................................................................................................. 608
㧔21㧕ᚻⴚㇱ................................................................................................................................. 610
㧔22㧕᡼኿✢ㇱ ............................................................................................................................. 612
㧔23㧕
᧚ᢱㇱ................................................................................................................................. 614
㧔24㧕ャⴊㇱ................................................................................................................................. 616
㧔25㧕
∛ℂㇱ................................................................................................................................. 619
㧔26㧕✚ว⸻≮ㇱ.......................................................................................................................... 621
㧔27㧕ක≮ᖱႎㇱ.......................................................................................................................... 623
㧔28㧕శቇක≮⸻≮ㇱ .................................................................................................................. 624
㧔29㧕㜞ᰴᢇ๮ᴦ≮࠮ࡦ࠲࡯........................................................................................................ 627
㧔30㧕
ක≮ㅪ៤࠮ࡦ࠲࡯............................................................................................................... 628
㧔31㧕↢૕ᡰេ࠮ࡦ࠲࡯............................................................................................................... 631
㧔32㧕⣲≌࠮ࡦ࠲࡯ ...................................................................................................................... 635
㧔33㧕⢄∔ᖚ⸻≮ᡰេ࠮ࡦ࠲࡯ .................................................................................................... 638
㧔34㧕ࠛࠗ࠭ኻ╷ផㅴ࠮ࡦ࠲࡯ .................................................................................................... 640
㧔35㧕ಽᇂㇱ................................................................................................................................. 641
㧔36㧕࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦㇱ........................................................................................................ 642
㧔37㧕ක≮ᯏེ࠮ࡦ࠲࡯............................................................................................................... 643
㧔38㧕ᴦ㛎▤ℂ࠮ࡦ࠲࡯............................................................................................................... 645
㧔39㧕㜞ᰴ↹௝⸻ᢿ࠮ࡦ࠲࡯........................................................................................................ 646
㧔40㧕⮎೷ㇱ................................................................................................................................. 648
㧔41㧕⋴⼔ㇱ................................................................................................................................. 650
3㧚 ⸻≮ࠬ࠲࠶ࡈ .......................................................................................................................... 652
㧔1㧕⸻≮ⷐຬߩ㈩⟎⁁ᴫ㧔2㧕⸻≮ᡰេⷐຬߩ㈩⟎⁁ᴫ㧔3㧕⋴⼔ⷐຬߩ㈩⟎⁁ᴫ4㧚 వㅴක≮ ................................................................................................................................. 653
㧔1㧕వㅴක≮㧔2㧕వㅴක≮ᛛⴚߩ㐿⊒ዉ౉
5㧚 ࿾ၞක≮ߩขࠅ⚵ߺ ............................................................................................................... 654
㧔1㧕࿾ၞක≮ߩ⏕଻㧔2㧕㔍∛ක≮᜚ὐ∛㒮ߩᜰቯ
㧔3㧕ㇺ㆏ᐭ⋵߇ࠎ⸻≮ㅪ៤᜚ὐ∛㒮ߩᜰቯ㧔4㧕ࠛࠗ࠭ਛᩭ᜚ὐ∛㒮ߩㆬቯ
㧔5㧕⢄∔ᖚ⸻≮ㅪ៤᜚ὐ∛㒮ߩㆬቯ
㧔6㧕ጘ㒂⋵੍㒐ធ⒳࠮ࡦ࠲࡯ߩᯏ⢻㧔7㧕ਃᰴ๟↥ᦼක≮ࡀ࠶࠻ࡢ࡯ࠢጘ㒂⋵੍㒐ធ⒳࠮ࡦ࠲࡯ߩᯏ⢻㧔8㧕⤳ེឭଏㅪ⛊⺞ᢛຬߩ㈩⟎6㧚 තᓟ⥃ᐥ⎇ୃߩ⁁ᴫ ............................................................................................................... 655
㧔1㧕ೋᦼ⥃ᐥ⎇ୃ
㧔2㧕ᓟᦼ⥃ᐥ⎇ୃ
7㧚 ᄖ᧪ᖚ⠪ᢙ෸߮౉㒮ᖚ⠪ᢙ .................................................................................................... 658
㧔1㧕ᄖ᧪ᖚ⠪ᢙ
㧔2㧕౉㒮ᖚ⠪ᢙ㧘∛ᐥⒿ௛₸෸߮ᐔဋ࿷㒮ᣣᢙ8㧚 ⸻≮↪ᣉ⸳࡮⸳஻╬ߩᢛ஻ .................................................................................................... 658
9㧚 ∛㒮⚻༡࡮⽷ോߩ⁁ᴫ............................................................................................................ 659
㧔1㧕∛㒮⚻༡ߦߟ޿ߡ
㧔2㧕⽷ോ⁁ᴫ10㧚ฦ⒳≮ᴺ╬ߩዯ಴⁁ᴫ............................................................................................................ 661
11㧚ࠛࠗ࠭᜚ὐ∛㒮ߣߒߡߩ⸻≮૕೙.......................................................................................... 663
12㧚ක≮㑐ㅪ㧔㒮ౝ㧕ᗵᨴኻ╷ .................................................................................................... 664
13㧚ක≮቟ోኻ╷ .......................................................................................................................... 665
㧔1㧕ࠗࡦࠪ࠺ࡦ࠻ႎ๔ߣߘߩኻ╷㧔2㧕ක≮቟ోߦଥࠆ⡯ຬᢎ⢒
㧔3㧕㒮ౝ࡜࠙ࡦ࠼
㧔4㧕ක≮቟ోࡑ࠾ࡘࠕ࡞ߩ╷ቯ
㧔5㧕࠾ࡘ࡯ࠬ࡮࠻ࡇ࠶ࠢࠬߩ⊒ⴕ
㧔6㧕࿖┙ᄢቇ∛㒮㑆⋧੕࠴ࠚ࠶ࠢ࡮ක≮ᴺ╙ 25 ᧦ߦࠃࠆ┙౉ᬌᩏ
14㧚౉㒮ၮᧄᢱ࡮౉㒮ᤨ㘩੐≮㙃ߩ⁁ᴫ ...................................................................................... 668
㧔1㧕౉㒮ၮᧄᢱ
㧔2㧕౉㒮ᤨ㘩੐≮㙃
15㧚∛㒮ࡏ࡜ࡦ࠹ࠖࠕ................................................................................................................... 668
16㧚㒮ౝቇ⚖ ................................................................................................................................. 669
17㧚㒮ౝ࿑ᦠቶ.............................................................................................................................. 669
18㧚ක⮎ຠߩ⥃ᐥ⹜㛎ߩታᣉᣇ㊎................................................................................................. 669
19㧚ᐢႎ ........................................................................................................................................ 670
㧔1㧕ኾ㐷කߩขࠅ⚵ߺ
㧔2㧕ࡎ࡯ࡓࡍ࡯ࠫߩలታ
㧔3㧕ᐢႎ⹹‫ޟ‬㡻⥱‫ߩޠ‬ౣೀΨ⥄Ꮖ⹏ଔ ........................................................................................................................................ 671
1㧚 ක⑼ቇኾ᡹࡮ౣ↢ක⑼ቇኾ᡹෸߮කቇㇱකቇ⑼2㧚 ⋴⼔ቇኾ᡹෸߮කቇㇱ⋴⼔ቇ⑼3㧚 කቇㇱ㒝ዻ∛㒮
4㧚 ╙ 1 ᦼਛᦼ⋡ᮡᦼ㑆ߩᢎ⢒⎇ⓥ⹏ଔߦଥࠆ⃻ᴫ⺞ᩏ⴫ߩ⵬⿷⺑᣿Σ‫ޓ‬ᄢቇ㒮කቇ♽⎇ⓥ⑼࡮කቇㇱ࡮ห㒝ዻ∛㒮ߩ዁᧪᭴ᗐ

1

ක⑼ቇኾ᡹࡮ౣ↢ක⑼ቇኾ᡹෸߮කቇㇱකቇ⑼ᄢቇ㒮කቇ♽⎇ⓥ⑼㐳࡮කቇㇱ㐳 ‫›ޓ‬Ⴆ‫⾆ޓ‬⃻⁁߆ࠄ዁᧪᭴ᗐ߳
ᣂ⥃ᐥ⎇ୃක೙ᐲዉ౉ߩᓇ㗀ߣኻᔕᣂ⥃ᐥ⎇ୃක೙ᐲߩዉ౉ࠍ߈ߞ߆ߌߦ㧘ᧄቇߢ߽ᄢቇ∛㒮ߢ⎇ୃߔࠆ⧯޿කᏧߪዋߥߊߥࠅ㧘ઁ㒮ߢߩೋᦼ⎇ୃᓟ߽ᄢቇ ( කዪ ) ߦᚯࠆੱᢙߪ೙ᐲዉ౉એ೨ߣᲧセߒߡ⚂ 2/3 ߦᷫዋߒߡ޿ࠆ‫ޕ‬ᄢቇ߅ࠃ߮
㒝ዻ∛㒮ߩᯏ⢻⛽ᜬߩߚ߼ߦ㧘࿾ၞߩ∛㒮ߦᵷ㆜ߒߡ޿ߚකᏧࠍᒁ߈޽ߍߑࠆࠍᓧߥߊߥࠅ㧘ߘߩ⚿ᨐ߇࿾ၞߩ∛㒮ක≮ߩ፣უߩ৻࿃ߣߥߞߡ޿ࠆ‫ࠎࠈߜ߽ޕ‬ᩮᐩߦߪ㐳ᦼߦਗ਼ࠆૐක≮⾌᡽╷߇޽ࠆߎߣߪ
⸒߁߹ߢ߽ߥ޿‫ߚ߹ޕ‬ၮ␆ಽ㊁ߦ㒮↢߿⎇ⓥ↢ߣߒߡੱ᧚ࠍએ೨ߩࠃ߁ߦߪㅍࠇߥߊߥࠅ㧘ၮ␆⎇ⓥߩ૕೙ߩ⣀ᒙߐ߇㔺⷗ߐࠇߡߒ߹ߞߚ‫⎇޿⧯ޕ‬ⓥ⠪ߩᷫዋߪᰴ਎ઍߩᜰዉ⠪ߩ⢒ᚑߣ޿߁ὐߢᭂ߼ߡᷓೞ
ߥ໧㗴ߢ޽ࠆ‫ޕ‬ᄢቇ∛㒮ߩല₸ൻߣ቟ోᏗ᳞㧘㜞ᐲవㅴක≮߳ߩ᜸ᚢߪ㧘⥃ᐥ♽කᏧߩ⽶ᜂߩჇᄢࠍ᜗
߈⋧ኻ⊛ߦ⎇ⓥ߳ߩࠛࡀ࡞ࠡ࡯ߩᷫዋߦߥࠅ߆ߨߥ޿⁁ᴫߢ޽ࠆ‫ޕ‬ᣂ⥃ᐥ⎇ୃක೙ᐲ߇߽ߚࠄߒߚᦨᄢ
ߩ໧㗴ߪ㧘ൕോᣉ⸳ߣᓙㆄᏗ᳞ߩ⥄↱ൻߢ޽ࠅ㧘⎇ୃකߦኻߔࠆᏒ႐ේℂߩᦑ㔺ߢ޽ࠆ‫ᧄޕ‬ቇᄢቇ∛㒮ߪ㜞ᐲߦ IT ൻߐࠇ㧘ዮᜰߩ㜞ᰴᢇ๮ᴦ≮࠮ࡦ࠲࡯߇޽ࠅ㧘ࠛࠗ࠭࡮㔍∛࡮߇ࠎ࡮⢄∔ᖚߩ᜚ὐ∛㒮ߣߒߡᢛ஻ߒߡ߈ߡ߅ࠅ㧘లታߒߚ⎇ୃࡊࡠࠣ࡜ࡓ㧘ᜰዉකߦ߽ᕺ߹ࠇ㧘ኾ㐷කࠍ⋡ᜰߔකᏧߦߣߞߡ㝯ജ⊛ߥ߽ߩߦߒߡ߈ߡ޿ࠆ߇㧘Ꮢ႐ේℂߩოߪήⷞߢ߈ߥ޿‫ߦ౏ߢ߹ࠇߎޕ‬ญߦߔࠆߎߣߪㆱߌࠄࠇߡ
߈ߚᏒਛ∛㒮ߢ௛ߊකᏧߣ㧘ᄢቇᢎຬߩ⛎ᢱߩᩰᏅ㧘ߐࠄߦߪ⸻≮⑼ߦࠃߞߡߪਛᐕᦼ߹ߢᣣ㓹޿ ( කຬ ) ߢ௛ߊᄢቇ∛㒮කᏧߩ⁁ᴫ߇⧯޿਎ઍߩ⋡ߦߪ⇣᭽ߦᤋߞߡ߅ࠅ㧘කᏧߣߒߡᄢቇߢ௛ߊ⠪ߩᓙㆄࠍᡷༀߒߡ޿ߊߎߣߪ㧘ᦨ߽㊀ⷐߥߎߣߩ৻ߟߢ޽ࠆ‫ޕ‬ᣢߦᧄቇߩ㒝ዻ∛㒮ߢߪ 2009 ᐕᐲ߆ࠄࡐࠗࡦ
࠻ᄖߩഥᢎჇຬߩ⸘↹߇ߥߐࠇߡ޿ࠆ߇㧘∛㒮෼⋉ߣߩ౗ߨว޿ߢ੹ᓟߐࠄߥࠆჇຬߩᬌ⸛߇ᦼᓙߐࠇ
ࠆ‫ޕ‬Ꮢ႐ේℂߩᦑ㔺ߩᓇ㗀ߪ㧘࿾ၞක≮߿⎇ⓥ⡯߳ߩଔ୯ⷰߩࠁ߇ߺࠍ߽ߚࠄߔᕟࠇ߽޽ࠆ‫⥃ޕ‬ᐥ⎇ୃ೙ᐲߩ⷗⋥ߒߦࠃࠆᄢቇ࿁Ꮻ߇⹤㗴ߣߥߞߡ޿ࠆ߇㧘࿾ၞක≮߿⎇ⓥ⡯߳ߩ㑐ᔃߣෳടᏗᦸࠍ㜞߼ࠆߚ߼ߩᢎ⢒ࠍలታߔࠆᔅⷐ߇޽ࠆ‫ౕޕ‬૕⊛ߦߪ೎⸥ߐࠇߡ޿ࠆࠃ߁ߦ࿾ၞක≮කቇ࠮ࡦ࠲࡯ߦࠃࠆ࿾ၞක
≮ቇߩዷ㐿ߣቇ↢ෳടߩ MD-PhD ࡊࡠࠣ࡜ࡓߩታᣉ߇㊀ⷐߢ޽ࠆ‫ޕ‬࿾ၞක≮ߩ࿎㔍ߣኻᔕ࿾ၞߩ∛㒮ࠍਥߣߔࠆක≮ߩ፣უߪో࿖⊛ߥ໧㗴ߣߥࠅ㧘‫ޟ‬ᣂකᏧ⏕଻ኻ╷੐ᬺ‫ޠ‬㧘‫✕ޟ‬ᕆකᏧ⏕଻ኻ╷੐ᬺ‫ࠍ⋵ᧄߤߥޠ‬฽߻කᏧਇ⿷߇ᷓೞߥ࿾ၞߩߺߢዊᚻవߩኻᔕࠍߒߡ޿ߚ࿖߽㧘2008 ᐕߦߪ⛘ኻ⊛ߥකᏧਇ⿷ߣ޿߁⹺⼂ߦ⥋ࠅ㧘ో࿖⊛ߦකቇㇱ౉ቇቯຬჇࠍᛂߜ಴ߒߚ‫ޕ‬หᤨߦ‫ޟ‬ቯຬჇߦ઻߁࿾ၞ
ᨒߩ⸳ቯ߇㧘࿾ၞක≮ߩᜂ޿ᚻߣߒߡᵴべߢ߈ࠆකᏧߩ㙃ᚑߣ࿾ၞ߳ߩቯ⌕ߦߟߥ߇ࠆ⏕ታߥᣇ╷‫ࠍޠ‬␜ߔࠃ߁ᒝߊᜰ␜ߐࠇߚ‫ߒ߆ߒޕ‬㧘ߎࠇࠄ࿖ߩᣉ╷߇⃻႐ߦⴕ߈ᷰࠅ㧘⃻႐ߩක≮⠪߇ታᗵߔࠆ߹ߢߦ
ߪᤨ㑆ࠍⷐߔࠆߎߣߪ⸒߁߹ߢ߽ߥ޿‫ᧄޕ‬ቇߢߪ౉ቇቯຬ߇ 2008 ᐕᤐߦ 80 ฬ߆ࠄ 90 ฬߦ㧘2009 ᐕᤐ
ߦߪ 90 ฬ߆ࠄ 100 ฬߦჇຬߐࠇࠆߎߣߦߥߞߚ‫ޕ‬2008 ᐕᐲߪ 15 ฬߩ৻⥸ផ⮈ߩઁߦ 10 ฬ߇࿾ၞᨒ
ផ⮈ߣߥࠅ㧘ጘ㒂⋵޽ࠆ޿ߪ⋵ౝ߆ࠄㅢቇߒߡ޿ࠆ㜞ᩞ߆ࠄផ⮈ࠍฃߌߚ‫ޕ‬ᐘ޿ߦ߽ࠬ࠲࡯࠻ߩ 2008ᐕᐲ౉⹜ߢߪ㕖Ᏹߦఝ⑲ߥቇ↢߇ផ⮈ߐࠇߡ߈ߚ‫ޕ‬࿾ၞᨒߩቇ↢ߦߪ⋵ߩකቇ↢╙৻⒳ୃቇ⾗㊄ฃ⛎߇᧦ઙߠߌࠄࠇߡ޿ࠆ‫ᧄޕ‬ቇߢߪ‫ޟ‬ᣂකᏧ⏕଻ኻ╷੐ᬺ‫ߣޠ‬หᤨߦ㧘2007 ᐕ 4 ᦬ߦ࿾ၞක≮කቇ࠮ࡦ࠲࡯( ቇㇱౝភ⟎ ) ࠍ⸳⟎ߒ㧘⋵߆ࠄߩ㑐ㅪነ㒝⻠ᐳ߽ടࠊߞߚ‫ޟߪ࡯࠲ࡦ࠮ᧄޕ‬නߦ࿾ၞߩක≮߳ߩኻᔕߛ

㧙㧙ߌߢߥߊ㧘ᢎ⢒ߣ⾰ߩ㜞޿⎇ⓥߦⵣᛂߜߐࠇߚ߽ߩߦߔࠆ‫߁޿ߣޠ‬ℂᔨߢડ↹ߐࠇ㧘࿾ၞක≮ߦᔅⷐߥ⍮⼂㧘ᛛⴚ㧘⠨߃ᣇࠍ⠌ᓧߐߖ㧘࿾ၞක≮ߦኻᔕߢ߈ࠆߛߌߢߪߥߊ㧘࿾ၞߩක≮߿ⅣႺߩ໧㗴ὐࠍ᛽಴ߢ߈ࠆ⢻ജ㧘⎇ⓥߦ⊒ዷߢ߈ࠆ⢻ജ߽⢒ߡࠆᢎ⢒ࠍ߼ߑߒߡ޿ࠆ‫ޕ‬2008 ᐕᧃ⃻࿷㧘තᓟೋᦼ⎇ୃߩ࿾ၞ⎇ୃߩડ↹㧘ታⴕߩᡰេ߽ⴕߞߡ޿ࠆ߇㧘ᓟᦼ⎇ୃߣߒߡᄢቇ∛㒮㧘⎇ୃᜰቯ∛㒮㧘߳߈࿾᜚ὐ∛㒮࡮⸻≮ᚲࠍࡠ࡯࠹࡯࡚ࠪࡦߒߥ߇ࠄ㧘✚ว⊛ߥኻᔕജߩჇㅴߣታ〣߇ߢ߈ࠆࠃ߁ߥࡊࡠࠣ࡜ࡓ㧘߹ߚฦ୘ੱߩ࠾࡯࠭ߦᔕ߃ߚ᭽‫ߥޘ‬ቇળ⾗ᩰߩขᓧࠍ⠨ᘦߒߚࡊࡠࠣ࡜ࡓ߽ᬌ⸛ߒߡ޿ࠆ‫ޕ‬2008 ᐕᐲ߆ࠄ࿾ၞක≮ࠍᗧ⼂ߒߚᣂߒ޿ࠞ࡝ࠠࡘ࡜ࡓ߇ᣢߦ┙ߜ਄߇ߞߡ޿ࠆ߇㧘࿾ၞක≮ߦ߅ߌࠆ଻ஜ࡮ක≮࡮⑔
␩ಽ㊁ߩㅪ៤૕೙㧘කᏧߩ⎇ୃࡊࡠࠣ࡜ࡓ૞ᚑߥߤߩࠦ࡯࠺ࠖࡀ࡯࠻ࠍⴕ߁ߣߣ߽ߦ㧘⸻≮߿⧯ᚻකᏧ
ߩᜰዉࠍߒߥ߇ࠄ∛㒮ߣ⸻≮ᚲ㧘∛㒮㑆ߩᓎഀಽᜂ߿ㅪ៤ߩ઀⚵ߺߠߊࠅߩ⎇ⓥ߅ࠃ߮කᏧߩ௛ߊⅣႺᢛ஻ߩታ〣࡮⎇ⓥࠍⴕ߁㧘ࡈࠖ࡯࡞࠼ઃ߈ߩ࿾ၞක≮ቇߩ⎇ⓥಽ㊁ߩ⸳⟎߇㧘଀߃߫ㅪ៤ᄢቇ㒮ߥߤߩᒻߢታ⃻ߔࠆߎߣ߇ᦸ߹ࠇࠆ‫ޕ‬⎇ⓥߩᵴᕈൻ
ၮ␆⎇ⓥߩᵴᕈൻ㧘⧯ᚻ⎇ⓥ⠪ߩ⢒ᚑ㧘ᄙಽ㊁ㅪ៤⎇ⓥଦㅴߩߚ߼ߦ㧘⎇ⓥ⑼㐳ⵙ㊂⚻⾌ࠍ⎇ⓥഥᚑ
߿౒ㅢ⎇ⓥᯏེߩᢛ஻ߦలߡ㧘ቇㇱౝ⎇ⓥ⊒⴫ળ߿⺰ᢥࠛࡇ࠰࡯࠼㓸ߩೀⴕ㧘ࠬࠞ࡜ࠪ࠶ࡊ߿ၮ␆ಽ㊁㒮↢ߩᅑቇ㊄೙ᐲ㧘ࡆ࠶ࠣࠫࡖ࡯࠽࡞ឝタႎఘડ↹ߥߤߩᢛ஻ࠍⴕߞߚ‫ޕ‬ቇౝ࡮ᄖߩᄙಽ㊁ㅪ៤ߪ㧘ᓥ
᧪ߩಽ㊁߿㗔ၞߩ၂ᩮࠍ⿧߃ߡ⸛⺰࡮⎇ⓥߔࠆ㔓࿐᳇ࠍ૞ࠆߚ߼ߦᄢ੐ߢ޽ࠅ㧘ᄢဳߩᄖㇱ⎇ⓥ⾗㊄₪ᓧߦ߽ߟߥ߇ࠆߣ⠨߃ࠄࠇࠆ‫ߩߎޕ‬ὐߢ⃻࿷කቇㇱᧄ㙚ߦធ⛯ߔࠆᒻߢ⎇ⓥ᫟ߩᑪ⸳߇ㅴࠎߢ޿ࠆᏒ┙ጘ㒂⮎⑼ᄢቇߣߩㅪ៤ࠍߤ߁ᵴ߆ߔ߆ߣ޿ߎߣ߇ᭂ߼ߡ㊀ⷐߦߥߞߡߊࠆ‫ߦߢߔޕ‬ਔ⠪ߢవ┵ഃ⮎⎇ⓥ࠮ࡦ࠲࡯ߩ⚵❱ࠍഃ⸳ߒߡ޿ࠆ߇㧘2009 ᐕ⑺ߩ┫Ꮏߦะߌߡౕ૕ൻࠍᕆߋᔅⷐ߇޽ࠆ‫ߚ߹ޕ‬ၮ␆⎇ⓥߣ⥃ᐥᔕ↪ࠍߟߥߋ࠻࡜ࡦࠬ࡟࡯࡚ࠪ࠽࡞࡝ࠨ࡯࠴ߪකቇ♽⎇ⓥ⑼ߦᦨ߽⋧ᔕߒ޿⎇ⓥᚻᴺ࡮૕೙ߢ޽
ࠅ㧘㔍ᴦᕈ∔ᖚߩ∛ᘒ⸃᣿ߣᴦ≮ᴺߩ⏕┙ߥߤߦะߌߡផㅴߒߡⴕߊߴ߈ߢ޽ࠆ‫ޕ‬ᴺੱൻએ㒠ߪᣂಽ㊁ߩቇᐕㅴⴕߦࠃࠆᢛ஻߽ᦸ߼ߥ޿߫߆ࠅ߆㧘ੱઙ⾌೥ᷫ߇⏕ታߦㅴⴕߒ㧘ᄙߊߩ
ಽ㊁ߪ 3 ੱએਅߩᢎຬ᭴ᚑߣߥߞߡ޿ࠆ‫∛ޕ‬㒮ߣ⇣ߥࠅ⥄Ꮖ෼౉ߩߥ޿⎇ⓥ⑼ߢ⎇ⓥᵴᕈࠍ⏕଻ߔࠆߦߪ㧘ઁ⚵❱ߣߩ౒ห⎇ⓥ߿ࡊࡠࠫࠚࠢ࠻ࠍゲߦ⥃ᯏᔕᄌߦ⎇ⓥ࠴࡯ࡓࠍ⚵❱ߔࠆߎߣ߇ᔅⷐߦߥࠆ‫ޕ‬ᚗ޿ߪᄖㇱ⾗㊄₪ᓧߦࠃࠆࡐࠬ࠻ࠍ૞ࠆߒ߆ߥ޿‫ ߩߎޕ‬3 ᐕ㑆ߦߪߐ߹ߑ߹ߥᄢဳࡊࡠࠫࠚࠢ࠻ߩ₪ᓧ߇޽ࠅ (p675 ෳᾖ )㧘ᄖㇱ⾗㊄ߦࠃࠆᢎຬ߽ណ↪ߒߡ߈ߚ‫⃻ߚ߹ޕ‬ઍ⊛ᢎ⢒࠾࡯࠭ขࠅ⚵ߺᡰេࡊࡠࠣ࡜
ࡓ㧘߇ࠎࡊࡠࡈࠚ࡚ࠪ࠽࡞㙃ᚑࡊ࡜ࡦ㧘ᄢቇ∛㒮ㅪ៤ဳ㜞ᐲක≮ੱ㙃ᚑផㅴ੐ᬺߢᢥ⑼⋭㑐ㅪߩᣂߚߥ
ᢎຬࡐࠬ࠻߇↢߹ࠇߡ޿ࠆ‫੹ޕ‬ᓟ߽ COE ߪߓ߼ੱઙ⾌߇ߟߊ࿖߿ડᬺߩᄢဳࡊࡠࠫࠚࠢ࠻߿᡽╷ࡊࡠࠫࠚࠢ࠻ߩᖱႎ෼㓸ߣ㧘ߔߋߐ߹ᔕ൐ߢ߈ࠆ૕೙ࠍᏱᤨḰ஻ߔࠆߎߣ߇㊀ⷐߢ޽ࠆ‫ߩߎޕ‬ὐߢ୘‫ߩޘ‬ಽ
㊁ߪ߽ߜࠈࠎ㧘⎇ⓥ⑼ో૕ߢ੹ᓟ 5 ᐕ⒟ᐲߩᦼ㑆ߦߤߩࠃ߁ߥᣇะߩ⎇ⓥࠍ⋡ᜰߔߴ߈߆ᣧᕆߦ⼏⺰ߒ㧘ߘࠇߦᴪߞߚੱ੐㧘ၮ⋚ߣߥࠆታ❣ࠍⓍߺ਄ߍߡ޿߆ߥߌࠇ߫ߥࠄߥ޿‫ޕ‬ᩮᧄ⊛ߥขࠅ⚵ߺߣߒߡቇ↢ᤨઍ߆ࠄකቇ⎇ⓥߩ߅߽ߒࠈߐߦធߒ㧘዁᧪⎇ⓥߦ៤ࠊࠆ᳇ᜬߜࠍ⢒ߡࠆߚ߼ߦ㧘ቇ↢ߩෳടߢ߈ࠆᄢቇ㒮ࠦ࡯ࠬ (MD-PhD ࠦ࡯ࠬ ) ࠍ 2009 ᐕᤐߦ⸳⟎ߔࠆߎߣࠍ᳿߼ߚ‫ޕ‬චಽߥ੍▚ភ⟎ࠍⴕ޿㧘ᢎຬߣߩቇⴚ੤ᵹࠍᏱᘒൻߒߡၮ␆⎇ⓥߩᵴᕈൻߩ␆ߦߒߚ޿‫ޕ‬዁᧪㧘⥃ᐥ♽ߦㅴ߻⠪ߦߣߞߡ߽ physician scientist ߣߒߡߩ⾗⾰ࠍ߽ߡࠆࠃ߁ߦߒߚ޿‫ޕ‬
2008 ᐕߦߪ㜞ᰴ⣖ᯏ⢻㓚ኂߩ∛ᘒ⸃᣿߿⸻≮ᛛⴚߩ㐿⊒ࠍ⋡⊛ߣߔࠆㅪ៤ᄢቇ㒮㧔ㅪ៤ಽ㊁⣖∛ᘒ⸃ᨆቇ ) ࠍ㧘⁛┙ⴕ᡽ᴺੱ⥄േゞ੐᡿ኻ╷ᯏ᭴߅ࠃ߮␠ળක≮ᴺੱෘ↢ળߣ৻✜ߦ┙ߜ਄ߍߚ‫⋵ޕ‬ౝߦᄢቇߩ⎇ⓥߩ႐ࠍჇ߿ߔߎߣߪ⾆㊀ߥߎߣߢ޽ࠆ‫ޕ‬ⅣႺߣ㘩ߩ቟ోߦ㑐ߔࠆ⎇ⓥ੤ᵹଦㅴߩߚ߼㧘ࠦࡠ࡜࠼Ꮊ┙ᄢቇ₞කቇㇱ࡮ⅣႺකቇ࠮ࡦ࠲࡯ߣㇱዪ㑆දቯࠍ✦⚿ߒߚ‫⎇ޕ‬ⓥߩផㅴߣ౒ߦ࿖㓙ൻߦ߽⽸₂ߢ߈ࠆߎߣࠍᦼᓙߒߡ޿ࠆ‫ޕ‬
ߎߎ 3 ᐕߩ㑆ߦ㧘୘ੱᖱႎߩ଻⼔㧘⥃ᐥ⎇ⓥߩᜰ㊎ߩᄢ᏷ߥᡷቯ㧘೑⋉⋧෻㧘േ‛଻⼔ߥߤ୶ℂ⊛ⷰ㧙㧙ὐ߆ࠄ㧘ߐ߹ߑ߹ߥᚻ⛯߈߇ᔅⷐߦߥࠅ㧘⎇ⓥߩ┙᩺ߩᲑ㓏ߢ┙ߜᓔ↢ߒߡߒ߹߁ߎߣ߽ᄙߊߥߞߡ޿
ࠆ‫ߒ߆ߒޕ‬਎ߩਛߦኻߒߡᱜᒰߥขࠅ⚵ߺߢ޽ࠆߎߣࠍ଻⸽ߒߡ߽ࠄ߁ߎߣ߇㧘ᦨ⚳⊛ߦߪ⎇ⓥ⠪ߣ࿖᳃ߩ೑⋉ߦㆡ߁ߣ⠨߃ࠆߎߣ߇ᔅⷐߢ޽ࠆ‫ޕ‬ᢎ⢒ߦ߅ߌࠆ໧㗴ߣߘߩኻᔕ
ᧄቇߢߪో࿖ߦవ㚟ߌߡ⢻േ⊛ቇ⠌ߩ⠌ᘠࠍ⢒ߡࠆ⋡⊛ߢ㧘࠹ࡘ࠻࡯࡝ࠕ࡞ᢎ⢒ࠍዉ౉ߒࡕ࠺࡞ߣߒ
ߡᵈ⋡ࠍᶎ߮ߡ߈ߚ‫ޕ‬ዉ౉೨ߣߩᲧセߢ᝼ᬺෳടᘒᐲߩᡷༀ߿ዉ౉ᓟߩ 4 ቇᐕߢකᏧ࿖⹜ߩᚑ❣߇⦟߆ߞߚߣ޿߁ࠛࡇ࠰࡯࠼ߪ⡞߆ࠇߚ߇㧘࠹ࡘ࠻࡯࡝ࠕ࡞ᢎ⢒ߩቇ⠌ലᨐߦ㑐ߔࠆ౏ᑼ⊛⷗⸃ߪᧂߛ಴ߐ
ࠇߡ޿ߥ޿‫ޕ‬2007 ᐕᐲᧃߦߪᒰᄢቇ∛㒮ߢߩೋᦼ⥃ᐥ⎇ୃ⠪߇㕖Ᏹߦዋߥ޿ේ࿃ߩ৻ߟߣߒߡ㧘࠹ࡘ࠻࡯࡝ࠕ࡞ᢎ⢒߇᡼છ⊛ߥቇ⠌ߦߥߞߡ޿ߡᲣᩞ߳ߩᗲ⌕߇⢒߹ࠇߥ޿ߩߢߪߥ޿߆㧘ቇ↢ߩᢎຬߣߩ
ኒធߥធ⸅ࠍ㒖ࠎߢ޿ࠆߩߢߪߥ޿߆㧘ߣ޿߁ࠃ߁ߥᔃ㈩߇ነߖࠄࠇ㧘࠹ࡘ࠻࡯࡝ࠕ࡞ᢎ⢒ߩ⷗⋥ߒ߿ᰴ਎ઍᢎ⢒ࠪࠬ࠹ࡓߩ㐿⊒ߩឭ⸒ߥߤ߇಴ߐࠇߚ‫ޕ‬ቇ↢߇ⴕ߁᝼ᬺ⹏ଔࠕࡦࠤ࡯࠻ࠍၮߦฦࠦ࡯ࠬߩᬌ
⸽߇ᾲᔃߦߥߐࠇࠆࠃ߁ߦߥߞߚ߇㧘ߘߩઁߩ᝼ᬺ߽฽߼୘‫ߩޘ‬ᢎຬߦలಽࡈࠖ࡯࠼ࡃ࠶ࠢߐࠇߕᢎຬ
ߩⴕേᡷༀߦߟߥ߇ߞߡ޿ߥ޿ߣ޿߁ᜰ៰߇㧘2008 ᐕᐲᧃߩౝㇱ⋙ᩏߢߥߐࠇߡ޿ࠆ‫੹ޕ‬ᓟ㧘ᓥ᧪ߩࠞ࡝ࠠࡘ࡜ࡓᆔຬળߣකቇᢎ⢒ડ↹㐿⊒ቶࠍ⛔วߒ㧘ቇ↢ᢎ⢒ߩડ↹࡮ታᣉ࡮⹏ଔߣᡷༀߦะߌߚⴕേ
߇ߢ߈ࠆ⚵❱ߦߒߡ޿ߊߎߣ߇ᔅⷐߢ޽ࠆ‫ޕ‬ೋᦼ⥃ᐥ⎇ୃ⠪߇ዋߥ޿߽߁৻ߟߩේ࿃ߣߒߡ㧘5 ᐕ↢ߩ⥃ᐥታ⠌ࠍฃߌߚቇ↢߆ࠄ㧘තᓟߩ⎇ୃࠍᄢቇ∛㒮ߢฃߌߚ޿ߣ޿߁ශ⽎߇ᓧࠄࠇߥ޿ߎߣ߇㧘⇣ญห㖸ߦ಴ߡ޿ࠆߣ޿߁‫ޕ‬CBT ߿ OSCE ߦࠃߞߡቇ↢ߩ⍮⼂㧘ᚻᛛ㧘ᘒᐲߪ৻ቯߩ࡟ࡌ࡞ߦ㆐ߒߡ޿ࠆߣ
ᕁࠊࠇࠆ߇㧘ቇ↢ቯຬߩჇടࠍប߃ߡ޿ࠆߎߣ߽޽ࠅ㧘ᢎຬ஥ߩ⥃ᐥᜰዉ✚วജ߿ᜰዉᣇᴺߦߤߩࠃ߁
ߥᎿᄦ߇ᔅⷐߥߩ߆ᬌ⸛ߔࠆᔅⷐ߇޽ࠆ‫ޕ‬ᢥ⑼⋭ߩᙣ⺣ળߢ߽තᓟೋᦼ⎇ୃߩ⷗⋥ߒߣㅪേߒߡ㧘ත೨⥃ᐥᢎ⢒ߩ⷗⋥ߒ߇⋡ਅㅴⴕਛߢ޽ࠆ‫౉ߚ߹ޕ‬ዪ⠪ᷫዋߦෂᯏᗵࠍ൐ࠄߖߡ޿ࠆ⥃ᐥ♽ಽ㊁߆ࠄߪ㜞ቇᐕߢߩቇ↢ߣߩࠦࡦ࠲ࠢ࠻ࠍᦸ߻ჿ߇ᄢ߈ߊ㧘ᣂߒ޿ࠞ࡝ࠠࡘ࡜ࡓߢߪ 6 ᐕ↢ߦ߆ߌߡߩㆬᛯ೙⥃ᐥታ⠌ߣ⥃ᐥ⻠⟵ࠍᄢ᏷ߦჇ߿ߔߎߣߦߥߞߚ‫ޕ‬ቇ↢ߣߩᢎຬߩ㑐ࠊࠅߪ᝼ᬺߩ߶߆㧘⺖ᄖᵴേ߿㉿ⷫ೙ᐲߦ߅޿ߡ߽⠨ᘦߐࠇߡ޿ࠆ‫⃻ޕ‬࿷㧘කቇㇱ⸥ᔨળ㙚 1 㓏ߦ⺖ᄖᵴേߩ႐ߩᢛ஻ࠍᬌ⸛ߒߡ޿ࠆ‫ߚ߹ޕ‬㉿ⷫ೙ᐲ߇లಽᵴ߆ߐࠇߡߥ޿ߣ޿߁ᜰ៰߇޽ࠅ㧘ߎߩ೙ᐲߩᗧ⟵ࠍ⏕⹺ߒ㧘੍▚ភ⟎ࠍ฽߼ߡᡷༀߒߡ
޿ߊߎߣߦߒߡ޿ࠆ‫ޕ‬ᄙ㕙⊛ߥធ⸅ࠍ↪ᗧߒߥ߇ࠄ㧘ቇ↢ߩ໧㗴ߦㄦㅦߥኻᔕ㧘෩ᩰ߆ߟᢎ⢒⊛ߥኻᔕ߇ߢ߈ࠆࠃ߁ߦߒߡ޿ߊᔅⷐ߇޽ࠆ‫ޕ‬౉ቇ⹜㛎ߪ൐㓸ੱຬࠍᓟᦼߦࠪࡈ࠻ߒ㧘ੑᰴ⹜㛎ࠍ㊀ⷞߒ㧘⿷ಾࠅࠍ߅ߎߥࠊߥ޿ߎߣ߆ࠄ┹੎୚₸߇೨ᦼ㧘ᓟᦼ౒ߦో࿖ߩකቇ⑼ߩਛߢᦨ߽㜞ߊߥߞߚ‫⹜౉ޕ‬ታᣉߩ⽶ᜂߪᄢ߈޿߇㧘ో࿖⊛ߦᵈ⋡ࠍฃߌ㧘ఝ⑲ߥቇ↢߇ో࿖߆ࠄ㓸߹ࠆࠃ߁ߦߥߞߚ‫⹜౉ޕ‬ᬺോߪߘߩᕈᩰ߆ࠄ໧㗴ὐ߇ክࠄ߆ߦߐࠇߦߊ޿
߇㧘৻ㇱߩᢎຬߩᄙᔔൻࠍ᜗޿ߡ߅ࠅ㧘ቇౝᄖߩදജ૕೙ࠍᢛ஻ߒߡኾ㐷⊛⍮⼂ߣᛛⴚߦኻߔࠆ⹏ଔࠍ
㜞߼ࠆߎߣ߇ᕆോߢ޽ࠆ‫ޕ‬ᄢቇ㒮ߦߟ޿ߡߪ⻠⟵ߩታ⾰ൻ߇ࠁߞߊࠅߢ޽ࠆ߇ㅴࠎߢ޿ࠆ‫ޕ‬⢻േ⊛ߥቇ⠌࡮⎇ⓥⴕേ߇ၮᧄߣߥ
ࠆᄢቇ㒮ߩ࿷ࠅᣇߪᄙ᭽ߢ޽ࠆߴ߈ߢ޽ࠆ‫ޕ‬㒢ࠄࠇߚᢎຬߢᦨᄢߩ⎇ⓥᚑᨐࠍ޽ߍ㧘㝯ജ޽ࠆ߽ߩߦߔ
ࠆᎿᄦ߇ᄢಾߢ޽ࠆ‫ޕ‬࿖㓙ൻߦኻᔕߒߚ⧷⺆ߢߩ⎇ⓥ࡮ᢎ⢒߽Ⴧㅴߐߖߡ޿ߊ੍ቯߢ޽ࠆ‫ޕ‬೨ㅀߩߣ߅
ࠅᣂ⥃ᐥ⎇ୃක೙ᐲߩዉ౉ࠍ߈ߞ߆ߌߦ⎇ⓥߦෳ౉ߔࠆ⧯ᚻ߇ᷫዋߒߡ޿ࠆ߇㧘ත೨ߩၮ␆㈩ዻᦼ㑆ߩᑧ㐳㧘ቇ↢ߩෳടߢ߈ࠆᄢቇ㒮ࠦ࡯ࠬ (MD-PhD ࠦ࡯ࠬ ) ߩ⸳⟎㧘ᅑቇ㊄ߩలታ㧘ᄙಽ㊁ㅪ៤ࠍᒝ߼ࠆ
ߥߤߒߡ⎇ⓥߩ㝯ജߣᵴᕈࠍ㜞߼ߡⴕߊᔅⷐ߇޽ࠆ‫ޕ‬⸻≮ߣ⥃ᐥ⎇ୃߦߟ޿ߡ
⸻≮ߦߟ޿ߡߪ‫ޟ‬ᣂ⥃ᐥ⎇ୃක೙ᐲዉ౉ߩᓇ㗀ߣኻᔕ‫৻ߢޠ‬ㇱ೨ㅀߒߡ޽ࠆࠃ߁ߦ㧘㜞ᰴᢇ๮ᴦ≮࠮ࡦ࠲࡯߿ߐ߹ߑ߹ߥ∔ᖚߩ᜚ὐ∛㒮ߣߒߡ㧘߹ߚ․ቯᯏ⢻∛㒮ߣߒߡ࿾ၞߦ߅ߌࠆᦨᓟߩ⎏ߣߒߡᯏ⢻㧙㧙ߒߡ޿ࠆ (p677-679 ෳᾖ )‫ޕ‬ᄢቇ∛㒮ߩ㗄ߢ߽⹦ߒߊㅀߴࠄࠇࠆߣᕁ߁߇㧘⥃ᐥ⎇ୃߦߟ޿ߡㅀߴߡ߅
߈ߚ޿‫ޕ‬2007 ᐕᐲᧃߦᒰᄢቇ∛㒮ߢߩೋᦼ⥃ᐥ⎇ୃ⠪߇㕖Ᏹߦዋߥ޿ේ࿃ߩ৻ߟߣߒߡ⎇ୃකߦኻߔ
ࠆࠤࠕ߇ዋߥ޿ߩߢߪߥ޿߆ߣ޿߁ᜰ៰߇޽ߞߚ‫ޕ‬ฦ⸻≮⑼ߢߩขࠅ⚵ߺࠍଦߒߥ߇ࠄ㧘⎇ୃ࠮ࡦ࠲࡯
ߢ߽⎇ୃක߳ߩ᩺ౝᖱႎ㧘⋧⺣⓹ญߣߒߡߩᯏ⢻ࠍᡷༀߒߡ޿ࠆ‫ߚ߹ޕ‬ኻᄖ⊛ߦ⎇ୃౝኈ߿∛㒮ߩ㝯ജ⊛ߥ⸳஻ߣᯏ⢻ߥߤࠍࠕࡇ࡯࡞ߒߡ޿ࠆ‫ޕ‬ೋᦼ⥃ᐥ⎇ୃߦ㑐ߒߡߪ࿖ߩ࡟ࡌ࡞ߢ⷗⋥ߒ⺰⼏߇ㅴࠎߢ߅
ࠅ㧘ᄢቇ߳ߩ࿁Ꮻ߇⸒ࠊࠇߡ޿ࠆ߇㧘ጘ㒂⋵✚วක≮࠮ࡦ࠲࡯߿ጘ㒂Ꮢ᳃∛㒮ߣㅪ៤ߒߡขࠅ⚵ࠎߢ߈ߚ⚻✲߽ᄢ੐ߦߒߥ߇ࠄㅴࠎߢ޿ߊᔅⷐ߇޽ࠆ‫ࠆࠁࠊ޿ޕ‬ᓟᦼ⎇ୃ㧘ᚗ޿ߪኾ㐷ක⎇ୃߦߟ޿ߡ߽ฦ⸻
≮⑼ߩࡊࡠࠣ࡜ࡓ߇↪ᗧߐࠇߡ޿ࠆ‫౉ޕ‬ዪ࿁ㆱߩᏗᦸ⠪ߦኻߒߡߪ∛㒮㐳⋥ዻߣ޿߁ㆬᛯ߽↪ᗧߐࠇߡ޿ࠆ‫ޕ‬⸻≮ⴕὑߦ㑐ㅪߔࠆ੐᡿ߩේ࿃ⓥ᣿ߥߤࠍⴕ߁‫ޟ‬ක≮੐᡿⺞ᩏᆔຬળ‫߇⺰⼏ߩޠ‬࿖ߩ࡟ࡌ࡞ߢ⛯޿ߡ޿ࠆ߇߹ߛ⌕࿾ὐ߇⷗߃ߡ޿ߥ޿‫ޕ‬ᄢቇ∛㒮ߪߓ߼࿾ၞක≮ߩዷ㐿ߩߚ߼ߦ㧘කᏧ࡮ᖚ⠪㑐ଥߩା㗬ߩ⛽ᜬߣ቟ోߩᏗ᳞߇ᔅ㗇ߢ޽ࠅ㧘ᤚ㕖ߣ߽ᢛ஻߇ㅴ߻ߎߣࠍᏗᦸߒߡ޿ࠆ‫ޕ‬ᢎຬੱ੐㧘ᆔຬળ㧘੐ോ⚵❱2007 ᐕᐲ߆ࠄቇᩞᢎ⢒ᴺ਄ߩ⡯ߩ⒳㘃ߣ⡯ฬ࡮⡯ോౝኈ߇ᄌࠊࠅ㧘⡯ฬߪᢎ᝼㧘ಎᢎ᝼㧘⻠Ꮷ㧘ഥᢎ㧘ഥᚻߣߥࠅ㧘ᢎຬߩ⁛┙ᕈ߇㜞߹ߞߚ‫ᧄޕ‬ቇߢߪ 2005 ᐕᐲ߆ࠄᢎຬߩ୘ੱ⹏ଔ߇ᆎ߹ࠅ㧘ߐࠄߦ
35㧘41㧘47㧘53㧘59 ᚽߩ㑐㐷ᐕ㦂ࠍቯ߼ㇱዪ㐳࡮ቇ㐳ߦࠃࠆ✚ว⹏ଔࠍⴕߞߡ޿ࠆ߇㧘⡯ോౝኈߦㆡ
ߒߚ⹏ଔߩ㗄⋡㧘ᣇᴺߥߤࠍ⏕┙ߒ㧘⹏ଔ⚿ᨐ߇⦟ᅢߥ⠪ߦኻߒߡࠗࡦ࠮ࡦ࠹ࠖࡉࠍਈ߃ࠆߎߣ߇ᵴᕈ
ൻߦ⚿߮ߟߊߣᦼᓙߐࠇࠆ‫ޕ‬ᢎ᝼ߩㆬ⠨ߪᒰ⹥ಽ㊁ߩᵴജߦ⋥⚿ߔࠆ߽ߩߢ޽ࠅ㧘ᐢߊౝᄖ߆ࠄᄢቇߩ
⊒ዷߦነਈߔࠆੱ᧚ࠍ൐ࠅ㧘⎇ⓥ㗔ၞࠍᘕ㊀ߦᬌ⸛ߒߚ਄ߢ᳿߼ߡ޿ߊߎߣ߇㊀ⷐߢ޽ࠆ‫ࠢࠚࠫࡠࡊޕ‬࠻ဳഥᢎߩណ↪߇ขࠅ౉ࠇࠄࠇߚ߇㧘⥄ઁ౒ߦᚑᨐ߇ᗧ⼂ߐࠇࠃ޿ࡊࡠ࠳ࠢ࠻ߦߟߥ߇ߞߡ޿ࠆ‫ޕ‬ᄖㇱ⾗㊄ߦࠃࠆᢎຬណ↪߽Ⴧ߃ߡ޿ࠆ߇㧘ㅌ⡯ᚻᒰ㊄Ⓧ┙ߩ໧㗴ࠍ࿁ㆱߔࠆߚ߼ᐕ୊೙ߩዉ౉ࠍᬌ⸛ߔࠆߴ
߈ߢ޽ࠆ‫ߦ․ޕ‬⒖േߩᄙ޿⥃ᐥ♽ߩ⧯ᚻߩᢎຬߦߪⓍᭂ⊛ߦ⠨߃ࠆߴ߈ߢ޽ࠆ‫ޕ‬ቇౝ࡮ᄖߩ໧㗴ߦኻᔕߔࠆߚ߼ฦ⒳ᆔຬળ߇⸳⟎ߐࠇߡ޿ࠆ߇㧘ᔅⷐߦᔕߓᡷᑄߒߡ⢻₸⊛ߥㆇ༡ࠍߔࠆߴ߈ߢ޽ࠆ‫ޕ‬ᢎຬߣ੐ോ⡯ຬߪ೎┙ߡߩ⚵❱ߢ޽ࠆ߇㧘ᩞോߦ޽ߚߞߡߪ⋧੕ℂ⸃ߣදജ૕೙ߩ᭴▽߇߈ࠊ߼ߡ㊀ⷐߢ޽
ࠆ‫ޕ‬

㧙㧙

2

⋴⼔ቇኾ᡹෸߮කቇㇱ⋴⼔ቇ⑼කቇㇱ⋴⼔ቇ⑼㐳‫ޓ‬ᓟ㑄‫ޓ‬ኈሶකቇㇱ⋴⼔ቇ⑼ߦ߅޿ߡߪ㧘ᐔᚑ 13 ᐕ 4 ᦬ߦ㧝࿁↢ࠍฃߌ౉ࠇ㧘ᐔᚑ 17 ᐕ 3 ᦬ߦೋ߼ߡߩතᬺ↢ࠍ಴ߒߡ޿ࠆ‫ޕ‬ᐔᚑ 1 㧤ᐕ 3 ᦬߆ࠄ 20 ᐕ㧟᦬߹ߢߩ㧟ᐕ㑆ߦ⋴⼔ቇ⑼ߢߪ 260 ੱ૛ߩ⋴⼔ቇቇ჻ߩතᬺ
↢߇⺀↢ߒߚ‫ޕ‬ᄢቇ㒮කቇ♽⎇ⓥ⑼⋴⼔ቇኾ᡹ߢߪᐔᚑ 19 ᐕ 3 ᦬߅ࠃ߮ 20 ᐕ㧟᦬ߣߢ⸘ 13 ੱߩ⋴⼔ቇୃ჻߇⺀↢ߒߚ‫ߦ߁ࠃߩߎޕ‬㧘කቇㇱ⋴⼔ቇ⑼ߣකቇ♽⎇ⓥ⑼⋴⼔ቇኾ᡹㧔ୃ჻⺖⒟㧕ߩᱧผߪߣ߽
ߦ߹ߛᣣߩᵻ޿߽ߩߢ޽ࠅ㧘ߐ߹ߑ߹ߥ⺖㗴ࠍ߆߆߃ߡ޿ࠆ⁁ᴫߢ޽ࠆ߇㧘એਅߦᦨㄭ 3 ᐕ㑆ߦ߅ߌࠆ⋴⼔ቇ⑼ߩ⃻⁁ߣ੹ᓟߩ⺖㗴ߦߟ޿ߡㅀߴߚ޿‫ޕ‬1㧚⋴⼔ቇᢎ⢒ߩ⾰ߣߘߩ⃻⁁␠ળߦ߅ߌࠆᄌൻ㧘․ߦᕆㅦߥዋሶ࡮㜞㦂ൻ␠ળߩㅴዷ㧘↢ᵴ⠌ᘠ∛ࠍਛᔃߣߒߚᘟᕈ∔ᖚߩჇട㧘ஜᐽ߳ߩ㑐ᔃߩ㜞߹ࠅ㧘࿖㓙ൻ␠ળߥߤ㧘ක≮࡮␠ળ⊛ⅣႺߩᄌൻߪ⪺ߒߊ㧘⋴⼔ቇᢎ⢒ߦ߅޿ߡ߽
ߎࠇࠄߩᓇ㗀ߪᔅὼ⊛ߦ⹺߼ߑࠆࠍᓧߥ޿⁁ᴫߢ޽ࠆ‫⼔⋴ޕ‬ቇᢎ⢒߳ߩᓇ㗀ߣߒߡౕ૕⊛ߦ޽ߍࠆߥࠄ
߫㧘଻ஜᏧഥ↥Ꮷ⋴⼔Ꮷᴺߦၮߠߊ⋴⼔Ꮷ╬㙃ᚑቇᩞᜰቯⷙೣߩᄌᦝߦࠃࠆ⋴⼔ቇᢎ⢒⺖⒟ߩᡷቯ㧘౉ቇ⁁ᴫ߿౉ቇ⠪ߩ⃻⁁㧘⋴⼔Ꮷ㔛⛎ߩ໧㗴㧘ഥ↥Ꮷᢎ⢒෸߮଻ஜᏧᢎ⢒ࠍขࠅᏎߊ໧㗴ߥߤ߇޽ࠆ‫ޕ‬㧝㧕⋴⼔ቇ⑼ߦ߅ߌࠆᢎ⢒⺖⒟ߩᡷቯ
ᢎ⢒⺖⒟ߩᡷቯߪ㧘ᐔᚑ 18 ᐕᐲߣᐔᚑ 21 ᐕᐲߣ߇޽ࠆ‫ޕ‬
ᐔᚑ 18 ᐕᐲߩᢎ⢒⺖⒟ᡷቯߪ㧘ᐔᚑ 17 ᐕᐲߦ⸳⟎ᒰೋߩᢎ⢒⺖⒟ߩ⷗⋥ߒࠍⴕ޿㧘ၮ␆⋴⼔ቇ㧘ᚑੱ࡮⠧ᐕ⋴⼔ቇ㧘Უሶ⋴⼔ቇ㧘࿾ၞ࡮♖␹⋴⼔ቇߩฦ⻠ᐳߩ⚵❱ߪ⛮⛯ߒߟߟ㧘ߘࠇߙࠇߩ᝼ᬺ⑼⋡ࠍ⷗⋥ߒߚ‫߫߃଀ޕ‬㧘ฦಽ㊁ߢߩ⋴⼔ቇ᭎⺰㧘⋴⼔ቇᣇᴺ⺰ߩ᭴ᚑࠍ⛔৻ߒߡᢛวᕈࠍ᳞߼ߚߎߣ㧘᝼ᬺᤨ㑆ߣන૏ߩ⛔৻ࠍ࿑ߞߚߎߣߥߤߢ޽ࠆ‫ߦࠄߐޕ‬㧘࿖㓙⊛ߥⷞ㊁ߣ࿾ၞක≮߳ߩ⽸₂ࠍⷞ㊁ߦ౉ࠇߚ⋴⼔ࠍ⊒ዷߢ߈ࠆ⢻ജߩ⢒ᚑ㧘⋴⼔⎇ⓥߩၮ␆⊛⢻ജߩలታߦะߌߡ‫⊒ޡ‬ዷ⋴⼔ቇ‫ࠍޢ‬ኾ㐷⑼⋡ߩਛߦ㈩⟎ߒߚ‫ޕ‬ട߃ߡ㧘ᐔᚑ 18 ᐕᐲߩᢎ⢒⺖⒟ߢߪ㧘ጘ㒂ᄢቇోቇㇱߢⴕߞߚᢎ㙃ᢎ⢒ߩ⷗⋥ߒߦㅪേߒߚ߽ߩ߽฽߹ࠇߡ޿ࠆ‫ߪࠇߎޕ‬㧘ጘ㒂ᄢቇߦ߅ߌࠆᢎ㙃ᢎ⢒ࠍ㧘᏷ᐢߊᷓ޿ᢎ㙃ߣ⼾߆ߥੱ㑆ᕈࠍᶩ㙃ߔࠆߎߣࠍ⋡ᜰߒ㧘㊀ⷞߔࠆᣇ㊎ߦၮߠ޿ߡ޿ࠆ‫ޕ‬ᓥߞߡ㧘⋴⼔ቇ⑼ߢߪතᬺⷐઙߣߒ
ߡ㧘ᓥ᧪ߪᢎ㙃⑼⋡ 20 න૏ߛߞߚ߇㧘ᐔᚑ 18 ᐕᐲ౉ቇ↢߆ࠄ 30 න૏ߣߥߞߚ‫ߩࠄࠇߎޕ‬ᡷቯࠍฃߌߡ㧘ᐔᚑ 18 ᐕᐲ౉ቇ↢߆ࠄ㧘තᬺⷐઙߣߒߡ 133 න૏ߦߥࠅ㧘ߘߩౝ⸶ߪ㧘ᢎ㙃⑼⋡ 30 න૏㧘ၮ␆⑼⋡ 5 න૏㧘ኾ㐷⑼⋡ 98 න૏ߢ޽ࠆ‫ޕ‬
ᐔᚑ 21 ᐕߩᢎ⢒⺖⒟ᡷቯߪ㧘଻ஜᏧഥ↥Ꮷ⋴⼔Ꮷᴺߦၮߠߊ⋴⼔Ꮷ╬㙃ᚑቇᩞᜰቯⷙೣߩᄌᦝߦ
ࠃࠆ߽ߩߢ޽ࠆ‫ޕ‬ක≮ߦ߅ߌࠆ⋴⼔ߩᓎഀߪ㧘੹ᓟߐࠄߦ᜛ᄢ࡮ⶄ㔀ൻߒߡ޿ߊߎߣߪ᣿ࠄ߆ߢ޽ࠅ㧘⼾߆ߥᗵᕈߣੱ㑆ᕈࠍ஻߃ߚ⾗⾰ߩ㜞޿⋴⼔⡯ߩ⢒ᚑ߇ਇนᰳߣߥࠆ‫ޕ‬ᜰቯⷙೣߩᡷቯࠍฃߌߡ㧘⋴⼔ቇߩ᝼ᬺ⑼⋡ߩ⷗⋥ߒ㧘⛔ว⑼⋡ߩ⸳ቯߥߤߩᢎ⢒⺖⒟ߩᡷቯࠍⴕߞߚ‫ߦ․ޕ‬㧘⋴⼔Ꮷᢎ⢒⺖⒟ߦ
߅ߌࠆ⛔ว⑼⋡ߩ⸳ቯ㧘଻ஜᏧ࡮ഥ↥Ꮷᢎ⢒⺖⒟ߦ߅ߌࠆ᝼ᬺ⑼⋡߿ታ⠌න૏ᢙߩჇടߥߤ߇ᄢ߈ߥ
⷗⋥ߒߢ޽ࠆ‫ޕ‬ᣂߒ޿ᢎ⢒⺖⒟ߦࠃࠆጁୃߪᐔᚑ 21 ᐕᐲ౉ቇ↢߆ࠄߢ޽ࠅ㧘⋴⼔ቇ⑼ߢߪ㧘ᐔᚑ 18ᐕᐲᢎ⢒⺖⒟ߦࠃࠆጁୃ↢ߣ㧘ᐔᚑ 21 ᐕᐲᢎ⢒⺖⒟ߦࠃࠆጁୃ↢ߣߩ㧘㧞ߟߩᢎ⢒⺖⒟ߦࠃࠆᢎ⢒ㆇ༡ߣߥࠆ‫ޕ‬⋴⼔ቇኾ᡹㧔ୃ჻⺖⒟㧕ߦ߅޿ߡߪ㧘ᐔᚑ 19 ᐕ 3 ᦬ߦ╙ 1 ࿁ୃੌ↢߇⺀↢ߒ㧘⃻࿷㧘࿷☋⠪ᢙߪ
26 ੱߢ޽ࠆ‫ޕ‬ᐔᚑ 20 ᐕᐲ߆ࠄᢎ⢒⺖⒟ߩ⷗⋥ߒࠍⴕ޿㧘ᐔᚑ 21 ᐕᐲߦߪᣂߒ޿ᢎ⢒⺖⒟ߢታᣉߐ㧙㧙ࠇࠆ੍ቯߢ޽ࠆ‫ߩߎޕ‬ᢎ⢒⺖⒟⷗⋥ߒߩℂ↱ߣߒߡ㧘Ԙୃੌ↢߿⃻⡯⋴⼔⡯ߥߤߩ࠾࡯࠭ߦኻᔕߒߡ㧘ኾ㐷ಽ㊁ࠍౣ✬ᚑߒߚ㧘ԙ⺰ᢥᜰዉߣߒߡ⾗ᩰ⹺ቯߐࠇߚᢎຬᢙ߇Ⴧടߒ㧘ᣂߒ޿ኾ㐷ಽ㊁ࠍ᭴▽ߢ߈ߚ㧘Ԛᣂߚߦ 9 ᦬ୃੌߩᯏળࠍ⸳ߌߚ㧘ߥߤߢ޽ࠆ‫⼔⋴ޕ‬ቇኾ᡹ߣߒߡߪ␠ળੱ߇ᄙߊ㧘⋴⼔♽ᄢቇතᬺ↢ߩ౉ቇߪ߹ߛ 3 ੱߢ޽ࠆ‫੹ޕ‬ᓟ㧘ߐࠄߦ㧘⋴⼔ቇኾ᡹ߣߒߡ㧘␠ળੱߦߣߞߡቇ߮߿ߔ޿Ⅳ
Ⴚߠߊࠅ߿ቇ߱ᯏળࠍჇ߿ߔߎߣߥߤࠍ⋡ᜰߒߡ㧘⑺ቄ౉ቇߦ㑐ߔࠆ࠾࡯࠭ߩᛠី㧘⺖㗴ߩಽᨆߥߤ㧘⺞ᩏࠍⴕߞߡ޿ࠆߣߎࠈߢ޽ࠆ‫ޕ‬㧞㧕౉ቇ⁁ᴫ㧘౉ቇ⠪㧘⋴⼔Ꮷߩ㔛⛎ߩ⃻⁁౉ቇ⹜㛎ߩ⁁ᴫߦ㑐ߒߡߪ㧘ᦨㄭᄢ߈ߥᄌൻߪߥߊ㧘⋴⼔ቇ⑼ᔒ㗿⠪ᢙߪ߶߷቟ቯߒߡ߈ߡ޿ࠆ‫ޕ‬
ᐔᚑ 18 ᐕᐲ౉ቇ⹜㛎߆ࠄ㧘ᢥ♽ߣℂ♽ߩਔ⠪ߣ߽ߦฃߌ߿ߔ޿⑼⋡ㆬᛯ೙ߦߒߡ㧘ฃ㛎↢ߦߣߞߡ㧘ฃ㛎ߒ߿ߔ޿᧦ઙ૞ࠅࠍߒߚ‫౉ޕ‬ቇ⠪ߪጘ㒂⋵෸߮ᗲ⍮⋵಴り⠪߇ో౉ቇ⠪ߩ 80% ࠍߎ߃ࠆ‫∛ޕ‬㒮ߦ߅ߌࠆ⋴⼔૕೙ߩలታߩߚ߼ߦ 7 ኻ㧝ߩ⋴⼔૕೙߇ขࠅ౉ࠇࠄࠇ㧘ߘߩ⚿ᨐో࿖⊛ߥ⋴⼔Ꮷਇ⿷߇↢ߓߡ޿ࠆ‫ޕ‬ጘ㒂⋵ࠍߪߓ߼ߣߔࠆ᧲ᶏ࿾ၞߢ߽㧘⋴⼔Ꮷߩਇ⿷ߪᄢ߈ߥ␠ળ໧㗴ൻߒߡ޿ࠆ‫ߩߎޕ‬ࠃ߁ߥਛ㧘⋴⼔ቇ⑼ߪ㧘Ფᐕතᬺ↢ߩ 90% એ਄߇⋴⼔Ꮷߣߒߡዞ⡯ߒߡ޿ࠆ‫߽ᦨޕ‬ᄙᢙߩතᬺ↢߇ጘ㒂ᄢቇකቇㇱ㒝ዻ∛㒮ߦዞ⡯ߒߡ޿ࠆ߇㧘߹ߛ㧘ల⿷ߒߡ޿ࠆߣߪ⸒޿㔍޿⁁ᴫߢ޽ࠆ‫੹ޕ‬ᓟ㧘ᄙߊߩතᬺ↢߇ጘ㒂⋵ౝࠍߪߓ߼ߣߒߡ᧲ᶏ࿾ၞߥߤߢ㧘⋴⼔⡯ߣߒߡᵴべߔࠆߎߣࠍᦼᓙߒߚ޿‫ᦨޕ‬ㄭ㧘⋴⼔ቇ⑼ߩࠕ࠼ࡒ࠶࡚ࠪࡦ࡮ࡐ࡝ࠪ࡯㧘࠺ࡘࡊࡠࡑ࡮ࡐ࡝ࠪ࡯㧘ࠞ࡝ࠠࡘ࡜ࡓ࡮ࡐ࡝ࠪ࡯╬ߩౣᬌ⸛ࠍⴕߞߡ޿ࠆㅜਛߢ޽ࠅ㧘੹ᓟ㧘౉ቇᏗᦸ⠪߳ߩ๟⍮ࠍ࿑ࠆߣߣ߽ߦᢎ⢒ߩ⾰⊛ะ਄ࠍ⋡ᜰߒߡ޿ࠆ‫ޕ‬㧟㧕ഥ↥Ꮷᢎ⢒㧘଻ஜᏧᢎ⢒ࠍ߼ߋࠆᢎ⢒ߩ໧㗴ഥ↥Ꮷᢎ⢒ߪ㧘ㆬᛯᕈߣߒ㧘⋴⼔ቇ⑼ߩ 3 ᐕ↢ߩ߁ߜ߆ࠄ 8 ੱࠍ਄㒢ߦᏗᦸ⠪߆ࠄㆬᛮߒߡ޿ࠆ‫ޕ‬ᢎ⢒⺖⒟ߩㆇ༡ߢߪ㧘ᔅୃߢ޽ࠆഥ↥ቇታ⠌ߪਛᵤᎹᏒ᳃∛㒮㧘৻ችᏒ᳃∛㒮ߥߤ߆ߥࠅ㆙㓒࿾ߩ∛㒮ࠍታ⠌ᣉ⸳ߣߒߡ޿ࠆ‫ޕ‬ዋሶൻ㧘಴↥ᣉ⸳ߩ㓸ਛߥߤ㧘ഥ↥ቇታ⠌ߩߚ߼ߩታ⠌ᣉ⸳ࠍ⏕଻ߔࠆߎߣߪ㧘Ფᐕߩࠃ߁ߦ㔍㗴ߦߥߞߡ޿ࠆ‫ޕ‬଻ஜᏧᢎ⢒ߪ㧘4 ᐕ೙ᄢቇߢߪ㧘⋴⼔Ꮷᢎ⢒⺖⒟ߣ଻ஜᏧᢎ⢒⺖⒟ߣ߇⛔วൻߒߚᢎ⢒⺖⒟ߦߥߞ
ߡ޿ࠆ‫ޕ‬㧠ᐕ㑆ߢ㧞ߟߩ࿖ኅ⹜㛎ࠍฃ㛎ߔࠆ⾗ᩰࠍᓧࠆߦߪ㧘㧠ᐕߩᢎ⢒ᐕ㒢ߣߒߡߪ߆ߥࠅㆊኒߥ
ࠬࠤࠫࡘ࡯࡞ߦߥࠄߑࠆࠍᓧߥ޿‫ޕ‬᝼ᬺ⑼⋡ߩਛߦߪ㧘߭ߣߟߩ᝼ᬺ⑼⋡ࠍ⋴⼔Ꮷᢎ⢒⺖⒟ߦ߽଻ஜ
Ꮷᢎ⢒⺖⒟ߦ߽⹥ᒰߔࠆ⑼⋡ߣߒߡ⸳ቯߒߡ޿ࠆ‫ߥ߁ࠃߩߎޕ‬Ꮏᄦࠍߒߡ߽ߥ߅㧘଻ஜᏧᢎ⢒ߦ߅ߌࠆ᝼ᬺ⑼⋡ߢߪ଻ஜᏧၮ␆ᢎ⢒ߣߒߡߩᢎ⢒ౝኈ߿ታ⠌ߣߒߡߩ૕㛎ߪචಽߢߪߥ޿‫ޕ‬
2㧚ᢎຬߦ㑐ߔࠆ⃻⁁ࠊ߇࿖ߦ߅ߌࠆ⋴⼔♽ᄢቇᢙߪᕆㅦߦჇടߒ㧘ᐔᚑ 18 ᐕᐲ߆ࠄᐔᚑ 20 ᐕᐲߩ㧟ᐕ㑆ߦ⸳⟎ߐࠇߚ⋴⼔♽ᄢቇᢙߪ 48 ᩞߦ਄ࠅ㧘ᐔᚑ 20 ᐕ 4 ᦬ߦߪ⋴⼔♽ᄢቇᢙߪో࿖ߢ 167 ᩞߦߥߞߚ‫⼔⋴ޕ‬ቇᢎ⢒ߩᄢቇൻ㧘4 ᐕ೙ൻߪ⋴⼔Ꮷߩ⾰ߩะ਄ߦߟߥ߇ࠆ‫ޕ‬㜞ᐲൻ㧘ኾ㐷ൻߒߚක≮ߦ߅޿ߡ㧘⋴⼔ߩᓎഀࠍᨐ
ߚߒ㧘ੱ‫ ߩޘ‬㧽㧻㧸 ߩะ਄ߩߚ߼ߦߪ㧘ߎߩࠃ߁ߥᢎ⢒ߩᄢቇൻߪᦸ߹ߒ޿߽ߩߢ޽ࠆ߇㧘ㆡಾߥᢎຬߩ⏕଻ߦฦᄢቇ߇࿎㔍ࠍ߈ߚߒߡ޿ࠆ‫ޕ‬ጘ㒂ᄢቇ⋴⼔ቇ⑼ߦ߅޿ߡ߽⋴⼔♽ᢎຬߩ⇣േߪ⪺ߒߊ㧘ㅌ⡯⠪ߩᓟࠍᏱߦᢎຬ౏൐ࠍߒߡ޿ࠆ⁁ᴫߢ޽ࠆ‫ޕ‬ᐔᚑ 20 ᐕ 12 ᦬⃻࿷ߢߪ㧘ᢎຬߪᢎ᝼ 13 ੱ㧘ಎᢎ᝼
9 ੱ㧘ഥᢎ 14 ੱ㧘ഥᚻ㧝ੱ㧘⸘ 37 ੱߩ᭴ᚑߣߥߞߡ޿ࠆ‫ޕ‬ᐔᚑ 21 ᐕ 4 ᦬ߦ㧘ಎᢎ᝼ 2 ੱ㧘ഥᢎ㧝ੱߩ⌕છ੍ቯ⠪߇⏕଻ߐࠇߡ߅ࠅ㧘ᢎຬߩ⏕଻ߪߢ߈ߡ޿ࠆ⃻⁁ߢ޽ࠆ‫ޕ‬ᢎຬߩ⎇ⓥᵴേߦ㑐ߒߡߪ㧘⋴⼔ቇ⑼ߣߒߡߩ⎇ⓥࡊࡠࠫࠚࠢ࠻߇޽ࠆࠃ߁ߥో૕⊛ߥ⎇ⓥᵴേ૕೙ߦߪߥߞߡ޿ߥ޿‫ߩࠇߙࠇߘޕ‬ᢎຬ߇㧘ฦ⥄ߩ⎇ⓥ࠹࡯ࡑߦߘߞߡ㧘ಽ㊁ࠍ⿥߃ߡ୘ੱ⊛ߦ౒ห⎇ⓥߔ
ࠆ႐ว߽ᄙ޿߇㧘⋴⼔ቇ⑼ߣߒߡߩ․ᓽ⊛ߥ⎇ⓥࡊࡠࠫࠚࠢ࠻߇޽ߞߡ߽ࠃ޿ᤨᦼߦ᧪ߡ޿ࠆߣ⠨߃
ࠆ‫ޕ‬

㧙㧙

ߥ߅㧘⋴⼔ቇ⑼ߩᢎຬ෸߮ᄢቇ㒮↢ߩ⺰ᢥ⊒⴫ߩ႐ߣߒߡ㧘ߐࠄߦ㧘⋴⼔ߣߒߡߩ⎇ⓥ⊒ዷߩߚ߼ߦ㧘⋴⼔ቇ⑼ߩᢎຬࠍਛᔃߣߒߡ᦭ᔒߢ㧘ጘ㒂⋴⼔⎇ⓥળ⹹ࠍഃ⸳ߒ㧘ᐔᚑ 21 ᐕ 2 ᦬ߦ╙㧝ภ߇⊒ೀߐࠇߚ‫ޕ‬
3㧚ᢎ⢒ㆇ༡૕೙
⋴⼔ቇ⑼ߦ߅޿ߡߪ㧘ᢎ⢒ㆇ༡ߩਛᔃߪ㧘ᢎ᝼ળ⼏߇ද⼏ߒ᳿ቯࠍⴕߞߡ޿ࠆ߇㧘ᢎ⢒ㆇ༡ߩᬌ⸛㧘ታ〣ߪฦ⒳ᆔຬળߢ޽ࠆ‫⼔⋴ޕ‬ቇ⑼ߢߪ㧘ᢎോෘ↢ᆔຬળ㧘዁᧪⸘↹ᆔຬળ㧘౉⹜ᆔຬળ㧘ታ⠌ᆔຬળ㧘੍▚㈩ಽᆔຬળ㧘ᐢႎᖱႎᆔຬળߥߤ߇Ᏹ⸳ߐࠇߡ޿ࠆ‫⼔⋴ޕ‬ቇኾ᡹ߩᆔຬળߣߒߡߩቇോᆔຬળ߇޽
ࠆ‫ߦ߆߶ߩߎޕ‬ᐔᚑ 19 ᐕߦߪ㧘㧲㧰 ᆔຬળࠍᏱ⸳ᆔຬળߣߒߡ⸳⟎ߒ㧘ᢎຬߩ⾗⾰ะ਄ࠍ⋡ᜰߒߚᵴേࠍⴕߞߡ޿ࠆ‫ߦࠄߐޕ‬㧘ᔅⷐᤨߦ⥃ᤨ⊛ߥᆔຬળࠍ⸳⟎ߒߡ߅ࠅ㧘㙃⼔ᢎ⻀㙃ᚑ⺖⒟Ḱ஻ᆔຬળ㧘ᢎ⢒ᬌ⸛ᆔຬળ㧔␠ળੱၮ␆ജ⢒ᚑࡊࡠࠫࠚࠢ࠻㧘ᢎ㙃ᢎ⢒ᬌ⸛ߥߤ㧕㧘ᄢቇᢎ⢒ߩ⾰⊛ะ਄ߩߚ߼ߩ 㧳㧼ᬌ⸛ᆔຬળߥߤࠍߘࠇߙࠇᐔᚑ 20 ᐕ߆ࠄ⸳⟎ߒ㧘ᵴേߒߡ޿ࠆ‫⼔⋴ߩࠄࠇߎޕ‬ቇ⑼ౝᆔຬળߩ߶߆ߦ㧘කቇㇱߩᆔຬળ㧘ోቇߩᆔຬળߥߤᄙ⒳ᄙ᭽ߥᆔຬળ߇⸳⟎ߐࠇߡ޿ࠆߩߢ㧘ฦᢎຬߪⶄᢙߩᆔຬળߦ
ᚲዻߒߡ㧘ᄙᔔߥ⁁ᴫߢ߽޽ࠆ‫ޕ‬ቇ㐳࡮ᓎຬߣቇ↢ߣߩᙣ⺣ળߥߤࠍߣ߅ߒߡ㧘⋴⼔ቇ⑼ߢ․ߦᒝ⺞ߐࠇߚߩߪ㧘࿑ᦠߩᢛ஻ਇ⿷ߢ
޽ߞߚ‫ޕ‬ᢎോෘ↢ᆔຬળ߇ታᣉߒߚතᬺ↢⺞ᩏ෸߮㧘ቇോᆔຬળ߇ⴕߞߚᄢቇ㒮ୃੌ↢ߣ࿷ቇ㒮↢߳ߩ⺞ᩏߢ߽㧘ห᭽ߦ㧘⋴⼔ቇ⑼ߩኾ㐷࿑ᦠߩਇ⿷ߪᏱߦ⸒ࠊࠇߡ߈ߚߣߎࠈߢ޽ߞߚ‫߇ߣߎߩࠄࠇߎޕ‬㧘ᄢቇ࿑ᦠᆔຬળߢ߽ขࠅ਄ߍࠄࠇ㧘⋴⼔ቇ⑼ߩ࿑ᦠ⾌㈩ಽࠍ㈩ᘦߒߡ߽ࠄ߃ࠆߎߣߪᗵ⻢ߒߚ޿‫ޕ‬੹ᓟߩ⺖㗴ෘ↢ഭ௛⋭࡮ᢥㇱ⑼ቇ⋭߇଻ஜᏧᢎ⢒࡮ഥ↥Ꮷᢎ⢒࡮⋴⼔Ꮷᢎ⢒ߢߩ⋴⼔ၮ␆ᢎ⢒ߦ߅ߌࠆᛛⴚ㗄⋡ߩතᬺᤨߩ೔㆐ᐲࠍ᣿␜ߒߚ‫ࠍࠄࠇߎޕ‬ฃߌߡጘ㒂ᄢቇකቇㇱ⋴⼔ቇ⑼ߩࠞ࡝ࠠࡘ࡜ࡓ߽㧘ዋሶ㜞㦂ൻߩㅴዷ㧘ක≮ᛛⴚߩㅴᱠ㧘࿖᳃ߩᗧ⼂ߩᄌൻ㧘⋴⼔ᢎ⢒᳓Ḱߩะ਄ߥߤᤨઍߩⷐ⺧ߦᔕ߃ߡ㧘ᢎ⢒ౝኈ㧘
ᢎ᝼ᣇᴺߦߟ޿ߡᬌ⸛ࠍߒ㧘ᐔᚑ 21 ᐕᐲ߆ࠄᣂߒ޿ࠞ࡝ࠠࡘ࡜ࡓࠍታᣉߔࠆ੍ቯߢ޿ࠆ‫੹ޕ‬ᓟߎߩᣂߒ޿ࠞ࡝ࠠࡘ࡜ࡓߩߐࠄߥࠆలታ߇᳞߼ࠄࠇࠆ‫ޕ‬ߚߣ߃߫㧘㧲㧰 ᆔຬળߦ߅޿ߡ㧘ᢎຬߩᢎ⢒ജะ਄ߦะߌߚ⎇ୃᵴേߣߒߡ㧘᝼ᬺ⹏ଔ㧘᝼ᬺߩ౏㐿ߥߤࠍᬌ⸛ߒ㧘ࠃࠅࠃ޿ᢎ⢒ࠍ⋡ᜰߔߎߣ߇᳞߼ࠄࠇࠆ‫ޕ‬߹ߚ㧘⋴⼔ቇ⑼ߦ߅޿ߡߪ㧘଻ஜᏧߣ⋴⼔Ꮷߣߩ 2 ߟߩᢎ⢒⺖⒟ߦട߃㧘ㆬᛯߢߪ޽ࠆ߇ഥ↥Ꮷߩ᝼ᬺ⑼⋡߽޽ࠅ㧘තᬺߦߪ㕖Ᏹߦᄙߊߩขᓧන૏ᢙࠍᔅⷐߣߒߡ޿ࠆߣ޿ߞߚ໧㗴߇޽ࠆ‫ోޕ‬࿖⊛ߦߪዋᢙߢ޽ࠆ߇㧘ഥ↥Ꮷᢎ⢒ࠍᄢቇ㒮ୃ჻⺖⒟㧘ኾ㐷⡯ᄢቇ㒮㧘ᄢቇߩኾ᡹⑼ߥߤߢⴕ߁ᄢቇ߽಴ߡ߈ߡ޿
ࠆ‫ޕ‬ട߃ߡ㧘଻ஜᏧᢎ⢒ߦ߅޿ߡ߽㧘ᄢቇ㒮߿ኾ᡹⑼ߥߤᢎ⢒૕೙ߩ⷗⋥ߒ߇಴ߐࠇߟߟ޽ࠆ‫੹ޕ‬ᓟ㧘ᧄ⋴⼔ቇ⑼ߦ߅޿ߡ߽㧘଻ஜᏧ࡮ഥ↥Ꮷߩ᝼ᬺ⑼⋡ߦ㑐ߒߡ㧘ᢎ⢒਄ᦸ߹ߒ޿૏⟎ߠߌߦߟ޿ߡ㧘ᬌ⸛ߒߡ޿ߊᔅⷐ߇޽ࠆ‫ޕ‬ߥ߅㧘੹ᓟ㧘㙃⼔ᢎ⻀㙃ᚑ⺖⒟ࠍ⸳⟎ߒߡ޿ߊ߁߃ߢ㧘᝼ᬺ⑼⋡ߩ⸳ቯ㧘ታ⠌ߩታᣉ૕೙ߥߤᢎ⢒ㆇ༡ߩߐࠄߥࠆᬌ⸛߇⺖㗴ߢ޽ࠆ‫ޕ‬㙃⼔ᢎ⻀㙃ᚑ⺖⒟ߩ⸳⟎ߪ㜞╬ቇᩞߩㅴ〝ᜰዉᢎ⻀߿㜞ᩞ↢߆ࠄߩⷐᦸߢ߽޽ࠅ㧘߹ߚ㧘⋴⼔ቇ⑼ߦ߅޿ߡ߽㧘ᐢ޿ಽ㊁ߢᵴേߔࠆ⋴⼔⡯ࠍ⢒ᚑߔࠆߎߣߪ㧘ᢎ⢒ߩℂᔨߦ
߽߆ߥ߁ߎߣߢ޽ࠆ‫੹ޕ‬ᓟ㧘ᢎ⢒ቇㇱ߿ઁቇㇱߣߩදജࠍᓧߡ㧘లታߒߚᢎ⢒ౝኈߦߥࠆࠃ߁ᬌ⸛ߒߚ
޿‫ޕ‬ᢎຬߩᢎ⢒ജะ਄ߦะߌ㧘㧲㧰 ᆔຬળߩᵴേ߇ᦼᓙߐࠇࠆߣߎࠈߢ޽ࠆ߇㧘᝼ᬺ⹏ଔ߿౏㐿᝼ᬺߥߤ޿ߊߟ߆ߩ⺖㗴߇ౕ૕⊛ߦ␜ߐࠇߡ޿ࠆߩߢ㧘੹ᓟ㧘ߘߩᵴേߩలታࠍ࿑ࠅߚ޿‫ޕ‬ᢎຬߩ⎇ⓥᵴേߦ߅޿ߡߪ㧘೨ㅀߩߣ߅ࠅ㧘୘ੱ⎇ⓥ߽㊀ⷐߢ޽ࠆ߇㧘⋴⼔ቇ⑼ߦ߅ߌࠆฦኾ㐷ಽ㊁ࠍ⿥߃ߚ⛔ว⊛⎇ⓥࡊ
ࡠࠫࠚࠢ࠻߇ߢ߈㧘⎇ⓥߩ᏷ߣᷓ߹ࠅ߇ㅴዷߔࠆࠃ߁ߦߥࠆߎߣ߇⺖㗴ߢ޽ࠆ‫ޕ‬㧙㧙ୃ჻⺖⒟ߢ޽ࠆ⋴⼔ቇኾ᡹ߦ߅޿ߡߪ㧘౉ቇ⠪ߩᄙߊߪ␠ળੱߢ޽ࠅ㧘ᐔᚑ 21 ᐕᐲ౉ቇ⠪ 11 ੱߪߔߴߡ 3 ᐕ㑆ߩ㐳ᦼጁୃࠍᏗᦸߒߡ޿ࠆ‫ࠍ⁁⃻ߥ߁ࠃߩߎޕ‬㐓ߺ㧘␠ળੱߢ޽ࠆᄢቇ㒮↢߇ቇ߮߿ߔ޿Ⅳ
Ⴚߠߊࠅ㧘ࠞ࡝ࠠࡘ࡜ࡓㆇ༡ߩᎿᄦߥߤ߇⺖㗴ߢ޽ࠆ‫ߦࠄߐޕ‬㧘੹ᓟ㧘ጘ㒂ᄢቇකቇㇱ⋴⼔ቇ⑼තᬺ↢߽ᣢߦ 300 ੱࠍ⿥߃ࠆᤨᦼߣߥߞߚߩߢ㧘ߎࠇࠄߩතᬺ↢߇⥃ᐥ⚻㛎ࠍⓍߺ㧘ߘࠇߙࠇߩኾ㐷ಽ㊁ߢߩ
⎇ⓥ⺖㗴ࠍ⷗಴ߒߡ㧘ୃ჻⺖⒟ߦቇ߱ߎߣࠍᦼᓙߒߚ޿‫ޕ‬ᢎຬ߽ߎࠇࠄߩᗧ᰼ࠍᜬߟතᬺ↢߳ߩᡰេࠍ
ߒߚ޿ߣ⠨߃ࠆ‫ޕ‬

㧙㧙

3

කቇㇱ㒝ዻ∛㒮කቇㇱ㒝ዻ∛㒮㐳‫ޓ‬᫪⣁‫ޓ‬ਭ㓉කቇㇱ㒝ዻ∛㒮ߩ⸳⟎⋡⊛ߪ޿߁߹ߢ߽ߥߊකቇㇱቇ↢ߩᢎ⢒ߣ㧘ߘߩߚ߼ߦᔅⷐߥ⎇ⓥ࡮⸻≮ߦ޽ࠆ‫ߢ߃߁ߚ߃߹〯ࠍ⊛⋡ߩߎޕ‬ᄢቇ∛㒮ߣߒߡߩ዁᧪᭴ᗐࠍ⠨߃ࠆߣ㧘ߘߩ㗄⋡ߪ⥄ߕ߆ࠄԘක≮ߩ⾰ࠍะ਄ߐߖࠆߎߣ㧘ԙක≮ੱ⢒ᚑ㧘Ԛ⥃ᐥ⎇ⓥ㧘ԛߎࠇࠄߩ⋡⊛ࠍ㆐ᚑߔࠆὑߩㆇ༡㧘ߣߥࠆ‫ޕ‬ᐔᚑ 22
㧙 27 ᐕߩᰴᦼਛᦼ⸘↹ߢ㧘∛㒮ߪ਄⸥ߩฦ㗄ߦߟ޿ߡᰴߩࠃ߁ߦ⸥タߒߚ‫ޕ‬Ԙ ක≮ߩ⾰ߩะ਄㧦࿾ၞක≮ߩၮ⋚ߦ┙ߜ㧘㜞⾰ߥක≮ࠍឭଏߔࠆ‫ޕ‬ԙ 㧝‫⊛ੱోޓ‬ක≮ੱࠍ⢒ᚑߔࠆ‫ޕ‬㧞‫ޓ‬ኾ㐷⊛⎇ୃᡰេࠍⴕߥ߁‫ޕ‬Ԛ㧝‫ޓ‬᜚ὐ∛㒮ߩᯏ⢻ࠍᵴ↪ߒ㧘㧱㧮㧹 ࠍ⏕┙ߔࠆὑߩ⥃ᐥ⎇ⓥࠍផㅴߔࠆ‫ޕ‬㧞‫ޓ‬ᣂⷙක≮ᛛⴚ㐿⊒ࠍㆀⴕߔࠆ‫ޕ‬ԛ㧝‫ޓ‬ㄦㅦߥ⚻༡್ᢿߦၮߠ߈⚻༡ၮ⋚ࠍᒝൻߔࠆ‫ޕ‬㧞‫ޓ‬ല₸⊛ߥ⚵❱ㆇ༡ࠍ࿑ࠆ‫ޕ‬ߎࠇࠄߩ೔㆐ᐲ⹏ଔߪ߽ߜࠈࠎᐔᚑ 27 ᐕᐲߦⴕߥࠊࠇࠆ߇㧘ߘߎߦ޿ߚࠆḰ஻ߣߒߡᐔᚑ 18 ᐕ 4 ᦬㧔ዊ↢߇∛㒮㐳ࠍർፉᐽ㓶ᢎ᝼߆ࠄ⛮ᛚߒߚߣ߈㧕⸳ቯߒߚᐔᚑ 18࡮19 ᐕᐲߩ೔㆐⋡ᮡߪએਅߩㅢࠅߢ
޽ߞߚ‫ޕ‬
Ԙ᜚ὐ∛㒮ߩ₪ᓧԙ㜞ᐲߥ⸻≮ᯏ⢻ߩᢛ஻㧔7㧦1 ⋴⼔૕೙߳ߩ⒖ⴕ㧘㧟࠹ࠬ࡜ MRI㧘PET ╬ߩዉ౉㧕Ԛ⥃ᐥ⎇ⓥ૕೙ߩᢛ஻㧔ᄖㇱ clinical research clerk ߩዉ౉㧕ԛೋᦼ࡮ᓟᦼ⎇ୃකߩ⏕଻Ԝஜో⚻༡ߩ⛽ᜬߎࠇࠄߩ㆐ᚑᐲ⹏ଔߪ‫ޟ‬Φ‫⥄ޓ‬Ꮖ⹏ଔ‫߇߁ߥⴕߢࠈߎߣߩޠ‬㧘ߐࠄߦᐔᚑ 20 ᐕ 4 ᦬㧔2 ᦼ⋡ߩ∛㒮㐳᜙๮ᤨ㧕
㧘20࡮21 ᐕᐲߩ೔㆐⋡ᮡࠍㅊടߒߚ‫ޕ‬ԘIT ࠪࠬ࠹ࡓߩᦝᣂ

ԙࡊࡠࡈࠖ࠶࠻࠮ࡦ࠲࡯ߩᢛ஻㧔ਛᄩᚻⴚㇱ㐷㧘ICU࡮CCU㧘ᓴⅣེಽ㊁㧘⥃ᐥ⣲≌ㇱ㐷㧕Ԛᐔᚑ 20 ᐕᐲߩ෼ᡰ⋡ᮡ㧔141 ం౞㧕IT ࠪࠬ࠹ࡓߩᦝᣂߪਇนㆱߩ߽ߩߢ㧘ᐔᚑ 16 ᐕዉ౉એ᧪ᣢߦ 5 ᐕࠍ⚻ㆊߒ㧘ᄾ⚂㕙߆ࠄ߽ᯏ᪾㧔ࡂ࡯࠼㧕ߩ㕙߆ࠄ߽㒢⇇ߢ޽ࠆ‫࠻ࡈ࠰ߒߛߚޕ‬㕙ߩ⠧᧎ൻߪ߹ߛߥߊ㧘⃻࿷ߢ߽ో࿖ߢ৻⇟ᑫࠅߩ⦟޿㔚ሶࠞ࡞࠹ߣ޿߁๟࿐ߩ⹏ଔߪᄌࠊߞߡ޿ߥ޿‫ߚ߹ޕ‬㧘੹࿁ߩ⋡ᮡ⸳ቯߢࡊࡠࡈࠖ࠶࠻࠮ࡦ࠲࡯ࠍ᣿␜ߒߚ‫ޕ‬ක⢒ᯏ㑐㒝ዻ∛㒮ߢ޽ࠆએ਄㧘ో⸻≮ಽ㊁ߣߘࠇࠍࠨࡐ࡯࠻ߔࠆᯏ⢻ࠍਁోߦ஻߃ࠆᔅⷐ߇޽ࠅ㧘ᒰὼណ▚ㇱ㐷ߣਇណ▚ㇱ㐷߇಴ߡߊࠆ‫∛⥸৻ޕ‬㒮ߢ޽ࠇ߫ᓟ⠪ࠍಾࠅᝥߡࠃࠅ㜞޿ല₸ࠍ⋡ᜰߔ⚻༡ᣇ㊎ࠍណߞߡࠃ޿߇㧘ᄢቇ∛㒮ߪᎿᄦߣദജߢߎߩ໧㗴ࠍ⸃᳿ߒ㧘කቇ↢ߩᢎ⢒ߦ⪭ߜ߇ή޿ࠃ߁ਁోࠍᦼߐ
ߨ߫ߥࠄߥ޿‫∛ߦߎߎޕ‬㒮ో૕ࠍᡰ߃ࠆࡊࡠࡈࠖ࠶࠻࠮ࡦ࠲࡯ߩሽ࿷ᗧ⟵߇޽ࠅ㧘ᣧᕆߦᢛ஻࡮Ⓙേߐߖࠆᔅⷐ߇޽ࠆ‫ߚ߹ޕ‬㧘਄⸥ߩ㗄⋡߆ࠄᔅὼ⊛ߦ෼ᡰ⋡ᮡߩ⸳ቯ߇ᄢቇ∛㒮ߩᯏ⢻ࠍ⛽ᜬ࡮⊒ዷߐߖࠆ਄ߢᔅ㗇ߢ޽ࠆߎߣ߽ಽ߆ࠆ‫ޕ‬એ਄㧘ᭂ߼ߡ࠼࡜ࠗߥ዁᧪᭴ᗐߢ޽ࠆ߇㧘ᄢቇ∛㒮ᧄ᧪ߩ૶๮ࠍో߁ߔࠆὑ㧘ߎߎ߹ߢഀࠅಾߞߡข
ࠅ⚵߻ᔅⷐ߇޽ࠈ߁‫ޕ‬㧙㧙Τ‫ޓ‬ᄢቇ㒮කቇ♽⎇ⓥ⑼

1

ኾ᡹

㨇කቇ♽⎇ⓥ⑼ක⑼ቇኾ᡹㨉
1. ᢎ⢒࡮⎇ⓥߩℂᔨ㧘⋡ᮡᧄቇߦ߅޿ߡߪ㧘ᤘ๺ 36 ᐕ 5 ᦬ߦᄢቇ㒮කቇ⎇ⓥ⑼㧔ඳ჻⺖⒟㧕߇⸳⟎ߐࠇ㧘ߎࠇ߹ߢකቇߦ㑐ߔࠆ㜞ᐲߥᢎ⢒࡮⎇ⓥ⚵❱ߣߒߡవ┵⊛ߥකቇ⎇ⓥߩㆀⴕࠍㅢߒ㧘⁛ഃ⊛ߥ⎇ⓥ⢻ജߣߣ߽ߦ⼾߆ߥቇ⼂ߣੱ㑆ᕈࠍ஻߃ߚකቇᢎ⢒⠪࡮⎇ⓥ⠪㧘ߐࠄߦߪ࡝ࠨ࡯࠴ࡑࠗࡦ࠼ࠍ߽ߟක≮ᓥ੐⠪ࠍ㙃ᚑߒߡ߈ߚ‫ޕ‬21 ਎♿߇ᆎ߹ߞߚ⃻ઍ␠ળߩᕆㅦߢ⪺ߒ޿↢๮⑼ቇߩᄌኈߦኻᔕߔࠆߚ߼㧘ᐔᚑ 14 ᐕߦᣂߚߦౣ
↢ක⑼ቇኾ᡹ߣක⑼ቇኾ᡹߆ࠄᚑࠆකቇ⎇ⓥ⑼ߦᡷ⚵ߒߚ‫ޕ‬ᡷ⚵ᓟߩක⑼ቇኾ᡹ߪ㧘ᣥ᧪ߩዊ⻠ᐳࠍゲߣߒߚ❑ഀࠅߩቇ໧૕♽ࠍၮ⋚ߣߒߚ⚵❱߆ࠄᣂߒ޿ቇ໧૕♽ߦහߒߚᄢ⻠ᐳ೙ߦ⒖ⴕߒߚ‫ޕ‬ᐔᚑ
16 ᐕᐲߦߪᄢ߈ߥᄌൻ߇޽ߞߚ‫ޕ‬1 ߟߪ࿖┙ᄢቇߩᴺੱൻߢ޽ࠅ㧘߽߁ 1 ߟߪකቇㇱ࡮㒝ዻ∛㒮ߩᩉᚭ࿾඙߳ߩ⛔ว⒖ォߢ޽ߞߚ‫ߦࠄߐޕ‬㧘ᤨᦼࠍหߓߊߒߡㇱዪൻߦ〯ߺಾࠅ㧘ᄢቇ㒮ߦゲ⿷ࠍ⟎޿ߚ⚵❱ߣߥࠅ㧘5 ᄢ⻠ᐳߩ᜝ࠅߦ✬ᚑᄌ߃߽ⴕߞߚ‫ޕ‬ߎߩࠃ߁ߥ⚵❱ߩ✬ᚑᄌ߃ߩ㑆߽㧘1㧕ක≮ߣකቇ⎇ⓥߦ߅ߌࠆ࿖㓙⊛ㅢ↪ᕈߩ㜞޿ੱ᧚⢒ᚑࠪࠬ࠹ࡓߩ⏕┙㧘2㧕⎇ⓥᚑᨐߩ࿾ၞਗ߮ߦ࿖㓙␠ળ߳ߩ⊒ାߣዷ㐿㧘3㧕↢๮ක⑼ቇ⎇ⓥߩ⥃ᐥකቇ߳ߩ
ᔕ↪╬㧘ߩ㆐ᚑߦะߌߡࠃࠅ৻ጀᢎ⢒࡮⎇ⓥౝኈࠍలታߐߖࠆߣߣ߽ߦ㧘㜞ᐲߢవ┵⊛࡮ቇ㓙⊛࡮ഃㅧ⊛⎇ⓥࠍផㅴߒ㧘዁᧪ߩකቇࠍᜂ߁࡝࡯࠳࡯ߣߥࠆߴ߈ఝࠇߚ↢๮ක⑼ቇ⎇ⓥ⠪㧘⥃ᐥකቇ⎇ⓥ⠪㧘↢๮ක⑼ቇᢎ⢒⠪෸߮㜞ᐲߥකቇ⊛⚛㙃ࠍりߦઃߌߚ⥃ᐥකਗ߮ߦᕆㅦߦ⊒ዷߔࠆ⃻ઍක≮ߦኻᔕߢ߈ࠆක≮ⴕ᡽ߩኾ㐷ኅࠍ⢒ᚑߔࠆߎߣࠍ⋡ᮡߣߒߡ޿ࠆ‫ޕ‬ߥ߅㧘ᐔᚑ㧞㧜ᐕᐲ߆ࠄߪฦቇㇱ╬ߩⷙ⒟ߦᢎ⢒⎇ⓥ਄ߩ⋡⊛ࠍ᣿⸥ߔࠆߎߣߦ઻޿㧘ᒰᄢቇ㒮කቇ♽⎇ⓥ⑼ߢߪ ‫ޟ‬వ┵කቇ࡮ක≮ߩቇ⼂߿ᛛⴚࠍ߽ߜ , వㅴ⊛࡮ቇ㓙⊛࡮ഃㅧ⊛ߥត᳞ᔃߣ୶ℂⷰࠍ౗ߨ஻߃ߚ⎇ⓥ⠪෸߮㜞ᐲኾ㐷⡯ᬺੱࠍ⢒ᚑߔࠆ‫ޕ‬‫ࠍ⊛⋡߁޿ߣޠ‬ឝߍߡ޿ࠆ‫ޕ‬

2. ක⑼ቇኾ᡹ߩ᭴ᚑ
೨ㅀߩߣ߅ࠅ㧘ᐔᚑ 14 ᐕᐲߩᡷ⚵ߩ㓙㧘කቇ⎇ⓥ⑼㧔ඳ჻⺖⒟㧕ߪߎࠇ߹ߢߩ㧡ኾ᡹㧔ᒻᘒ♽㧘ᯏ⢻♽㧘␠ળකቇ♽㧘ౝ⑼♽㧘ᄖ⑼♽㧕ࠍᡷ߼ߡක⑼ቇኾ᡹ߩ㧝ኾ᡹ߣߒ㧘㧟ߟߩ㗔ၞ㧔᭴ㅧᯏ⢻ක⑼ቇ㧘∛ᘒ೙ᓮක⑼ቇ㧘⛔วᖱႎක⑼ቇ㧕ߦ඙ಽߒߚ‫ޕ‬ቇ↢ਛᔃߩᢎ⢒૕೙ࠍ⏕┙ߔࠆߣߣ߽ߦኾ᡹ߩ
ࡏ࡯࠳࡯࡟ࠬൻࠍ࿑ࠆߎߣߦࠃࠅ㧘㜞ᐲߩ⁛ഃᕈߣ࿖㓙ᕈࠍ૬ߖᜬߞߚක⑼ቇ⎇ⓥ⠪ਗ߮ߦኾ㐷⡯ᬺੱࠍ⢒ᚑߔࠆߎߣࠍ⋡ᜰߒߚ‫ޕ‬
ᐔᚑ 16 ᐕᐲ߆ࠄㇱዪࠍකቇㇱ߆ࠄᄢቇ㒮කቇ⎇ⓥ⑼ߦ⒖ⴕߒ㧘ක⑼ቇኾ᡹ࠍ㧟㗔ၞ߆ࠄ㧡ᄢ⻠ᐳ㧔ಽሶ࡮᭴ㅧቇ㧘∛ᘒ೙ᓮቇ㧘␹⚻⛔ᓮቇ㧘⣲≌೙ᓮቇ㧘ක≮▤ℂቇ㧕ߦᡷ⚵ߒߡ⎇ⓥ૕೙ߩᦝߥࠆ
లታࠍ࿑ߞߚ‫ߩߎޕ‬ㇱዪൻߦࠃࠅ㧘੹ᣣߩක⑼ቇࠍ⸃ᨆ㧘⛔ว㧘ᔕ↪ߘࠇߙࠇߩ஥㕙߆ࠄ㧘ࠃࠅല₸⊛ߦ⎇ⓥࠍዷ㐿ߒߡ޿ࠆ‫ޕ‬
ᐔᚑ 20 ᐕ㧠᦬ߦߪലᨐ⊛ߥකቇ࡮ක≮ᢎ⢒ࠍផㅴߢ߈ࠆᢎ⢒⠪෸߮⎇ⓥ⠪ߩ㙃ᚑࠍ⋡⊛ߣߒߚ‫ޟ‬කቇᢎ⢒ቇಽ㊁‫ࠍޠ‬ක≮▤ℂቇ⻠ᐳߦ⸳⟎ߔࠆߣߣ߽ߦ㧘หᐕ 10 ᦬ߦߪ⁛┙ⴕ᡽ᴺੱ⥄േゞ੐᡿ኻ╷ᯏ᭴෸߮␠ળක≮ᴺੱෘ↢ળߣߩ㑆ߢᢎ⢒⎇ⓥߦଥࠆㅪ៤࡮දജ㧔޿ࠊࠁࠆ‫ޟ‬ㅪ៤ᄢቇ㒮‫ޠ‬㧕ߦ㑐ߔࠆදቯࠍ✦⚿ߒߡ␹⚻⛔ᓮቇ⻠ᐳߦ‫ޟ‬ㅪ៤ಽ㊁‫ޓ‬⣖∛ᘒ⸃ᨆቇ‫ޕߚߒ⟎⸳ࠍޠ‬㧙㧙৻ᣇ㧘ᐔᚑ 19 ᐕᐲ߆ࠄᢥㇱ⑼ቇ⋭ߩ੐ᬺ‫࡞࠽࡚ࠪ࠶ࠚࡈࡠࡊࠎ߇ޟ‬㙃ᚑࡊ࡜ࡦ‫߇ޠ‬ታᣉߐࠇ㧘ᧄ
⎇ⓥ⑼ߪ᧲ᶏ࿾ၞߩᄢቇߦࠃࠆ౒หࡊࡠࠣ࡜ࡓ‫᧲ޟ‬ᶏ߇ࠎࡊࡠ‫ߦޠ‬ෳ↹ߒߡ޿ࠆ‫ޕ‬ᐔᚑ 20 ᐕ㧠᦬߆ࠄߪ㧘೨ᐕᐲߦ⸳⟎ߒߚ⣲≌೙ᓮቇ⻠ᐳߩ⥃ᐥ⣲≌ቇಽ㊁ߦ߅޿ߡ㧘‫ޟ‬ᮮᢿ⊛ߥൻቇ≮ᴺߩኾ㐷ක㙃ᚑࠦ࡯ࠬ‫ߩޠ‬ቇ↢ߦኻߒታ〣⊛ߥᢎ⢒ࠍታᣉߒߡ޿ࠆ‫ޕ‬
㧔1㧕ಽሶ࡮᭴ㅧቇ⻠ᐳ⚦⢩ᖱႎቇ㧘ಽሶ↢ℂቇ㧘⮎ℂ∛ᘒቇ㧘ነ↢⯻ቇ㧘ㆮવ⊒↢ቇ㧘ౝಽᴲઍ⻢∛ᘒቇ㧘ዊఽ∛ᘒቇ㧘∛ᘒᖱႎ⸃ᨆකቇߩ㧤ಽ㊁ߢ᭴ᚑߔࠆ‫ޕ‬↢๮ᯏ⢻ߩ⊒⃻ߩᧄ⾰ߣ߽޿߃ࠆ࠲ࡦࡄࠢ⾰⋧੕෻ᔕߩ⸃ᨆ߇∛࿃⸃᣿ߣᴦ≮ᴺ㐿⊒ߦ⚿߮ߟߊߎߣߪ᣿ࠄ߆ߢ޽ࠅ㧘ಽሶᖱႎ߆ࠄ┙૕᭴ㅧߣᄌ⇣┙૕᭴ㅧߩᲧセߦၮߠߊᣂߚߥഃ⮎࡮ᴦ≮ᴺߩ㐿⊒ࠍផㅴߒ㧘㧞㧝਎♿ဳ࠹࡯࡜࡯ࡔࠗ࠼ක≮ࠍታ⃻ߔࠆߣߣ߽ߦ㧘వ┵⊛ߥᢎ⢒࡮⎇ⓥ࡮⸻≮ࠍᜂ߁ఝࠇߚੱ᧚ࠍ⢒ᚑߔࠆᢎ⢒⎇ⓥࠍㅴ߼ࠆ‫ޕ‬
㧔2㧕∛ᘒ೙ᓮቇ⻠ᐳ⸃೬ቇ㧘ಽሶ∛ᘒቇ㧘㜞ᐲవㅴᄖ⑼ቇ㧘ᢛᒻᄖ⑼ቇ㧘⊹⤏∛ᘒቇ㧘ᴲዩེ⑼ቇ㧘㤗㈮࡮−∩೙ᓮቇ㧘⯃↢࡮㓸ਛᴦ≮ቇ㧘ญ⣧∛ᘒቇߩ㧥ಽ㊁ߢ᭴ᚑߔࠆ‫ޕ‬㜞ᐲߦ․ൻߐࠇߚኾ㐷ಽ㊁߆ࠄߥࠅ㧘ߘࠇߙࠇߩ⤳ེ᭴▽࡮∛ᘒߦ㑐ߔࠆᣂߚߥ⍮⷗ࠍ౒᦭ߒ㧘ࠃࠅ㜞ᐲߩవ┵⊛⸻ᢿ࡮ᴦ≮࡮੍㒐ᴺߩ⎇ⓥߣ㐿⊒ࠍታ⃻ߔࠆᢎ⢒⎇ⓥࠍⴕ߁‫ޕ‬
㧔3㧕␹⚻⛔ᓮቇ⻠ᐳ㜞ᰴ␹⚻ᒻᘒቇ㧘↢ℂቇ㧘ࠬࡐ࡯࠷ක⑼ቇ㧘␹⚻ౝ⑼࡮⠧ᐕቇ㧘♖␹∛ℂቇ㧘⣖␹⚻ᄖ⑼ቇ㧘⡊㥦
ຜ༄⑼ቇ㧘⌒⑼ቇߩ㧤ಽ㊁ߣ㧘ㅪ៤ಽ㊁‫ޓ‬⣖∛ᘒ⸃ᨆቇࠍട߃ߚ⸘㧥ಽ㊁ߢ᭴ᚑߔࠆ‫ޕ‬ⶄ㔀ൻ࡮㜞㦂ൻ߇ㅴ߻⃻ઍ␠ળߢߪ↢↥ഭ௛ജߩૐਅ߿ක≮⻉⾗Ḯߩᛩ౉ࠍჇടߐߖࠆ♖␹࡮␹⚻♽∔ᖚ߇Ⴧടߒ㧘␠ળ⊛ߦ߽ᄢ߈ߥ໧㗴ߣߥߞߡ޿ࠆ‫߼ߚߩߎޕ‬㧘♖␹࡮␹⚻♽ߩᯏ⢻ࠍ⸃ᨆߒ㧘ߘ
ߩᴦ≮ᴺ࡮੍㒐ᴺߩ⏕┙ߣᣂߒ޿ᴦ≮ᴺߩ㐿⊒ࠍ⋡ᜰߒ㧘⎇ⓥ࡮ᢎ⢒࡮⸻≮⢻ജߩ㜞޿ੱ᧚ࠍ⢒ᚑߔࠆᢎ⢒⎇ⓥࠍⴕ߁‫ޕ‬
㧔4㧕⣲≌೙ᓮቇ⻠ᐳ
⣲≌∛ℂቇ㧘఺∉∛ℂቇ㧘⣲≌ᄖ⑼ቇ㧘ᶖൻེ∛ᘒቇ㧘ⴊᶧ∛ᘒቇ㧘↥⑼ᇚੱ⑼ቇ㧘᡼኿✢කቇ㧘∉ቇ࡮੍㒐කቇ㧘⥃ᐥ⣲≌ቇߩ㧥ಽ㊁ߢ᭴ᚑߔࠆ‫ޕ‬ᱫ੢ේ࿃╙㧝૏ࠍභ߼ࠆ≸ߩస᦯ߪ㧘ࠊ߇࿖ߩߺߢߥߊవㅴ⻉࿖ߩᄢ߈ߥ໧㗴ߢ޽ࠅ㧘ᧄ㗔ၞߢߪ≸ߩ⎇ⓥࠍㅴ߼ߡ߈ߚၮ␆࡮␠ળ࡮⥃ᐥකቇ♽⎇ⓥ⠪߇㓸⚿ߒ㧘✚ജࠍ᜼ߍߡ≸ߩᴦ≮ᴺ࡮੍㒐ᴺࠍ
⏕┙ߔࠆߚ߼㧘వ㚟⊛ߥᢎ⢒࡮⎇ⓥࠍⴕ߁‫ޕ‬
㧔5㧕ක≮▤ℂቇ⻠ᐳ✚ว∛ᘒౝ⑼ቇ㧘⥃ᐥ⮎೷ቇ㧘ක≮⚻ᷣቇ㧘ᢇᕆ࡮ἴኂකቇ㧘ᴺකቇ㧘↥ᬺⴡ↢ቇ㧘කቇᢎ⢒ቇߩ㧣ಽ㊁ߢ᭴ᚑߔࠆ‫ޕ‬੹ᣣߢߪ㧘ߛࠇߢ߽࡮ߤߎߢ߽ㆡಾߥක≮ࠍฃߌ㧘ஜᐽ଻ᜬ࡮Ⴧㅴࠍㅴ߼ࠆߎߣߦኻߔࠆ␠ળ⊛ⷐ⺧߇㜞ߊ㧘৻ᣇ㧘ᧂᦦ᦭ߩਇ᷹ߩἴኂߦኻߔࠆක≮૕೙ߩᢛ஻߇ⷐ⺧ߐࠇߡ޿ࠆ‫ߩߘޕ‬ታ⃻ߩߚ߼ߦߪ㧘EBM㧔⑼ቇ⊛ᩮ᜚ߦၮߠߊක≮㧕ࠍ〯߹߃ߚ✚ว⊛ߥකቇ࡮ක≮㧘ක⮎ຠ㧘ᢇᕆ࡮ἴኂකቇߩߺ
ߥࠄߕ㧘ක≮⚻ᷣߩ⍮⼂ࠍ⛔ว࡮▤ℂߔࠆᣂߚߥࠪࠬ࠹ࡓߩ᭴▽߇ᔅ㗇ߢ޽ࠅ㧘ᧄ㗔ၞߢߪᣂߚߥක
≮▤ℂߦ㑐ߔࠆᢎ⢒⎇ⓥࠍផㅴߒߡߎࠇࠄߩ໧㗴ߦ⊛⏕ߦኻᔕߔࠆ૕೙ߩ᭴▽ߣੱ᧚ߩ⢒ᚑࠍⴕ߁‫ޕ‬㧙㧙

3. ቇ↢ቯຬߣ౉ቇ⁁ᴫ
ක⑼ቇኾ᡹ߩ౉ቇቯຬ㧘෼ኈቯຬ෸߮ㆊ෰㧡ᐕ㑆ߩ౉ቇ⁁ᴫߪ㧘ᰴ⴫ߩߣ߅ࠅߢ޽ࠆ‫ޕ‬ቯຬߩల⿷߇ᓥ೨߆ࠄߩ⺖㗴ߢ޽ࠅ㧘ࡎ࡯ࡓࡍ࡯ࠫߦࠃࠆ⊒ାߪ߽ߣࠃࠅ൐㓸ࡄࡦࡈ࡟࠶࠻ࠍ㑐ㅪ∛㒮ߦ㈩Ꮣߔࠆߥߤߩᐢႎᵴേߦࠃࠅ㧘ቯຬࠍల⿷ߔࠆߚ߼ߩขࠅ⚵ߺࠍⴕߞߡ޿ࠆ‫ߚ߹ޕ‬㧘൐㓸ᦼ㑆ࠍ㧝ㅳ㑆߆ࠄ㧞ㅳ㑆ߦિ߫ߒ㧘㧞ᰴ൐㓸ߢචಽߥల⿷₸߇ᓧࠄࠇߥ޿႐วߦߪ㧟ᰴ൐㓸߽ⴕ߁ߎߣ
ߣߒߚ‫ޕ‬
ක⑼ቇኾ᡹ߩ౉ቇቯຬ෸߮෼ኈቯຬ⎇ⓥ⑼ኾ‫ޓޓ‬᡹

⺖‫ޓޓ‬⒟౉ቇቯຬ෼ኈቯຬකቇ♽⎇ⓥ⑼

ක⑼ቇኾ᡹

ඳ჻⺖⒟

47*

200*

* ౉ቇቯຬߪ㧘ᐔᚑ 19 ᐕᐲ߆ࠄㅪวഃ⮎ක≮ᖱႎ⎇ⓥ⑼ߩ⸳⟎ߦ઻޿㧘㧠㧣ੱ㧔㧢ੱᷫ㧕ߣߥߞߚ‫ޕ‬

ㆊ෰ 5 ᐕ㑆ߩ౉⹜⛔⸘
੐㗄
ᐕᐲ

൐㓸
ੱຬ

ᐔᚑ 16 ᐕᐲᐔᚑ 17 ᐕᐲ

ᔒ㗿⠪ᢙ

53

53

ฃ㛎⠪ᢙ

43

㧔11㧕
<27>

39

43

㧔11㧕
<27>

‫ޝ‬7‫ޞ‬
㧔6㧕
<27>

39

53

40

㧔11㧕
<28>
‫ޝ‬1‫ޞ‬ᐔᚑ 19 ᐕᐲᐔᚑ 20 ᐕᐲ

47

㧔8㧕
<18>

34

47

44

43

‫ޝ‬7‫ޞ‬
㧔6㧕
<27>

37

㧔11㧕
<28>

40

㧔8㧕
<18>

42

㧔10㧕
<27>

‫ޝ‬7‫ޞ‬‫ޝ‬6‫ޞ‬

㧔5㧕
<25>

37

㧔5㧕
<25>

‫ޝ‬3‫ޞ‬
39

㧔11㧕
<27>

‫ޝ‬1‫ޞ‬
34

౉ቇ⠪ᢙ

㧔11㧕
<27>

‫ޝ‬3‫ޞ‬‫ޝ‬3‫ޞ‬ᐔᚑ 18 ᐕᐲวᩰ⠪ᢙ‫ޝ‬3‫ޞ‬
㧔11㧕
<27>

39

‫ޝ‬1‫ޞ‬
㧔8㧕
<18>

34

‫ޝ‬1‫ޞ‬
㧔8㧕
<17>

33

‫ޝ‬3‫ޞ‬‫ޝ‬3‫ޞ‬‫ޝ‬3‫ޞ‬‫ޝ‬3‫ޞ‬

㧔5㧕
<32>

㧔5㧕
<32>

㧔5㧕
<32>

㧔5㧕
<32>

44

‫ޝ‬4‫ޞ‬44‫ޝ‬4‫ޞ‬44‫ޝ‬4‫ޞ‬‫ޝ‬4‫ޞ‬㧔 㧕ߪᅚሶ㧘< > ߪ␠ળੱ㧘‫ߪޞ ޝ‬ᄖ࿖ੱ⇐ቇ↢ࠍߔߴߡౝᢙߢ⴫ߒ߹ߔ‫ޕ‬㧔ෳ⠨㧕
ක⑼ቇኾ᡹࡮ౣ↢ක⑼ቇኾ᡹ߩ౉ቇ⁁ᴫ

ᐕᐲ

੐㗄

൐㓸ੱຬ

ᔒ㗿⠪ᢙ

ᐔᚑ 19 ᐕᐲ64

64

ᐔᚑ 20 ᐕᐲ

64

75

ฃ㛎⠪ᢙ

(11)
<25>
ҋ4Ҍ
(10)
<44>
ҋ8Ҍ

63

75

(11)
<25>
ҋ4Ҍ
(10)
<44>
ҋ8Ҍ

㧔‫ޓ‬㧕ߪᅚሶ㧘㧨‫ޓ‬㧪ߪ␠ળੱ㧘ҋҌߪᄖ࿖ੱ⇐ቇ↢ࠍߔߴߡౝᢙߢ⴫ߒ߹ߔ‫ޕ‬

㧙㧙

วᩰ⠪ᢙ
61

71

(11)
<25>
ҋ4Ҍ
(10)
<43>
ҋ7Ҍ

౉ቇ⠪ᢙ
60

71

(11)
<24>
ҋ4Ҍ
(10)
<43>
ҋ7Ҍ

4. ࠞ࡝ࠠࡘ࡜ࡓߩ✬ᚑᣇ㊎
ᐔᚑ 17࡮18 ᐕᐲߦቇ↢ࠕࡦࠤ࡯࠻ࠍታᣉߒ㧘ߘߩ⚿ᨐࠍಽᨆߒߚ⚿ᨐ㧘ᔒᦸߒߚಽ㊁ߩኾ㐷⑼⋡ߩ㊀ෘᕈࠍ㜞߼ࠆߎߣ㧘෸߮⺰ᢥ૞ᚑߦ߆߆ࠆ⎇ⓥᵴേࠍන૏ൻߔࠆߥߤࠞ࡝ࠠࡘ࡜ࡓࠍ৻ㇱ⷗⋥ߒ㧘ᐔᚑ 19 ᐕᐲ౉ቇ↢߆ࠄㆡ↪ߒߡ޿ࠆ‫ޕ‬
㧔1㧕ጁୃන૏ၮḰ
ක⑼ቇኾ᡹ߩୃੌߦᔅⷐߥጁୃන૏ߪએਅߩߣ߅ࠅ޽ࠆ‫ޕ‬⑼‫ޓ⋡ޓ‬඙‫ޓ‬ಽᦨૐጁୃන૏ᢙ

౒‫ޓ‬ㅢ‫⋡ޓ⑼ޓ‬㧟ቇ‫ޓ‬㓙‫⋡ޓ⑼ޓ‬㧝ኾ‫ޓ‬㐷‫⋡ޓ⑼ޓ‬㧞㧜․‫ޓ‬೎‫ޓ⎇ޓ‬ⓥ㧢ว‫⸘ޓޓޓ‬㧟㧜஻‫ޓ‬⠨

ኾ᡹ಽ㊁߆ࠄᔅୃ⑼⋡ 14 න૏ࠍ฽߼㧘20 න૏એ਄

㧔2㧕ᢎ⢒ߩ․⦡
Ԙ ኾ᡹ಽ㊁ߩኾ㐷⑼⋡ߩ㊀ෘᕈࠍ㜞߼ࠆන૏⹺ቯ
ኾ᡹ಽ㊁߇㐿⻠ߔࠆ⻠⟵⑼⋡㧘Ṷ⠌⑼⋡㧘࠮ࡒ࠽࡯⑼⋡ࠍ૬ߖߡ㧟ᐕᰴ߹ߢߦ 14 න૏ࠍୃᓧߢ
߈ࠆࠃ߁ߥ᭴ᚑߣߒ㧘ᔒᦸಽ㊁ߩኾ㐷⑼⋡ߩ㊀ෘᕈࠍ㜞߼ࠆࠞ࡝ࠠࡘ࡜ࡓߣߒߡ޿ࠆ‫ޕ‬ԙઁኾ᡹ߩ᝼ᬺ⑼⋡ࠍጁୃන૏ߦ⹺ቯ
ක⑼ቇኾ᡹ߢߪ㧘ౣ↢ක⑼ቇኾ᡹㧔ඳ჻ᓟᦼ⺖⒟㧕ߩ౒ㅢ⑼⋡෸߮ኾ㐷⑼⋡ࠍୃੌߦᔅⷐߥන૏

ߣߒߡ⹺ቯߒߡ޿ࠆ‫ޕ‬Ԛ↢๮୶ℂ࡮ක≮୶ℂቇߩ⟵ോൻ
੹ᣣߩක⑼ቇ⎇ⓥࠍㅴ߼ࠆ਄ߢ㧘↢๮⑼ቇ㧘ㆮવ⊒↢ቇߩߺߥࠄߕ㧘ᄙߊߩ⎇ⓥ߇↢ᘒ♽ߦ෸߷ߔᄙᄢߥᓇ㗀ࠍ㐓ߺ㧘‫↢ޟ‬๮୶ℂ㑐ଥߩ⑼⋡‫ߩޠ‬ጁୃࠍᔅୃߣߒߡ޿ࠆ‫ޕ‬ԛቇ૏⺰ᢥ૞ᚑߦᔅⷐߥ⎇ⓥᵴേߩන૏⹺ቯ
㧝ᐕᰴ߆ࠄቇ૏⺰ᢥ૞ᚑߦᔅⷐߥ⎇ⓥᵴേࠍ㧘․೎⎇ⓥߣߒߡන૏ൻߒߡ޿ࠆ‫ޕ‬

㧔3㧕␠ળੱቇ↢ߩߚ߼ߩភ⟎ᄢቇ㒮⸳⟎ၮḰߩ╙㧝㧠᧦․଀ߦࠃࠅ㧘ᄛ㑆㧔㧢෸߮㧣ᤨ㒢⋡㧕㧘࿯ᦐᣣ෸߮ᄐቄભᬺᦼ㑆ਛߦ߅ߌࠆ㓸ਛ㐿⻠ߢታᣉߒߡ޿ࠆ‫ޕ‬߹ߚ㧘␠ળੱቇ↢߇ో૕ߩ㧣ഀㄭߊࠍභ߼ߡ޿ࠆ߅ࠅ㧘ൕോߩㇺวߢ⇐ᐕ෶ߪભቇߔࠆ⠪߇ᐕ‫ޘ‬Ⴧട௑ะߦ޽ࠆ‫ޕ‬ਥߦ⡯ᬺࠍ᦭ߒߡ޿ࠆቇ↢ࠍኻ⽎ߦ㧘ᐔᚑ 21 ᐕᐲ߆ࠄ㐳ᦼጁୃ೙ᐲࠍዉ౉ߔࠆߣߣ
߽ߦ㧘࿷ቇ↢㧔ᦨ⚳ቇᐕࠍ㒰ߊ㧕ߦ߽ㆡ↪ߔࠆߎߣߣߒߚ‫ޕ‬㧙㧙㧔4㧕ᢎ⢒⎇ⓥಽ㊁㧘ᜰዉᢎຬ
ක⑼ቇኾ᡹ߦ߅ߌࠆฦ㗔ၞ೎ߩᢎ⢒⎇ⓥಽ㊁㧘ᜰዉᢎຬ㧘ਥߥ⎇ⓥౝኈߪᰴ⴫ߩߣ߅ࠅߢ޽ࠆ‫ޕ‬
㗔ၞ
㧔⻠ᐳ㧕

ಽ
ሶ
࡮
᭴
ㅧ
ቇ

ಽ‫ޓ‬㊁

ᜰዉᢎຬ

⎇ⓥౝኈ

⚦⢩ᖱႎቇ

ਛ‫ޓ‬ፉ‫⨃ޓޓ‬1㧚⚦⢩↢࡮ᱫ㧔ࠕࡐ࠻࡯ࠪࠬ㧕ߩࠪࠣ࠽࡞વ㆐ࡔࠞ
࠾࠭ࡓ
2㧚⚦⢩ߩಽൻ࡮ࠕࡐ࠻࡯ࠪࠬߦ㑐ਈߔࠆㆮવሶߩត
⚝3㧚␹⚻⚦⢩ಽൻ⺃ዉ࿃ሶߩត⚝4㧚ㆮવሶᴦ≮ߩၮ␆⊛⎇ⓥ
5㧚ⴊ▤ౝ⊹⚦⢩ߩჇᱺߣ⚦⢩ᱫߩࠪࠣ࠽࡞ಽሶ↢ℂቇ

1㧚Ⱞ⊕⾰৻⥸ߩ㜞ᰴ᭴ㅧᒻᚑㆊ⒟ߩ‛ℂൻቇ⊛⎇ⓥ
2㧚Ⱞ⊕⾰࡮ࡍࡊ࠴࠼ߩ⇣Ᏹಝ㓸૕ᒻᚑߩಽሶࡔࠞ࠾
࠭ࡓᗆ‫ޓ⦟ޓ‬⡛‫ ৻ޓ‬3㧚↢૕ౝ㉄ൻࠬ࠻࡟ࠬߣ࡟࠼࠶ࠢࠬᔕ╵4㧚Ⱞ⊕⾰ߣ᳓ಽሶ㑆⋧੕૞↪ߩಽሶࡔࠞ࠾࠭ࡓ
㧔↢૕♽ߩ᳓ߩಽሶ↢ℂ㧕
5㧚MRI ᖱႎߣ↢૕⚵❱ߩಽሶ↢ℂ࡮ಽሶ∛ℂ⮎ℂ∛ᘒቇ1㧚ࠬ࠻࡟ࠬᔕ╵ߩࡔࠞ࠾࠭ࡓߩ⸃᣿ߣૐಽሶ㊂ࠬ࠻࡟ࠬⰮ⊕⾰ߩᓎഀߩ⸃᣿
2㧚㛽☻㝃∝ߩ∛ᘒߩ⸃᣿ߣ⮎‛ߩᓇ㗀
3㧚㛽⧘⚦⢩ߩ⚦⢩ౝᖱႎવ㆐ᯏ᭴ߩ⸃᣿ߣ㛽⺞▵࿃ሶߩ૞↪ᯏᐨߩ⸃᣿
ዊ‫ޓ‬Ỉ‫ ୃޓޓޓ‬4㧚⢄⚦⢩ߩ⚦⢩ౝᖱႎવ㆐ᯏ᭴ߩ⸃᣿ߣ⮎‛ߩᓇ㗀
5㧚ઍ⻢ᕈ∔ᖚ෸߮⢄∔ᖚߦ߅ߌࠆⴊዊ᧼ᯏ⢻ߦ㑐ߔࠆ⎇ⓥ
6㧚ᔃⴊ▤૞േ‛⾰ߩ૞↪ᯏᐨߩ⸃᣿
7㧚ࠕࡐ࠻࡯ࠪࠬ⊒⃻ᯏᐨߩ⸃᣿ߣ⮎‛ߩᓇ㗀ነ↢⯻ቇ‫ޓ‬ᯅ‫ޓ‬ఝ‫ޓ‬ਃ 1㧚ኋਥ̆ነ↢⯻⋧੕㑐ଥߩ⚦⢩↢‛ቇ⊛⎇ⓥ
2㧚఺∉⸻ᢿᴺ㧘DNA ⸻ᢿᴺߩ㐿⊒ㆮવ⊒↢ቇ

1㧚ಽሶㆮવቇ࡮఺∉ㆮવቇ⊛⎇ⓥ
2㧚ㆮવ∛ߩ∛࿃࡮∛ᘒ⸃᣿
3㧚ㆮવ∛ߩ∛࿃ㆮવሶߦ߽ߣߠߊࡐࠬ࠻ࠥࡁࡓ⸃
ᨆ㧘․ߦ࠲ࡦࡄࠢ┙૕᭴ㅧߩ⸃᣿ߣ⥃ᐥᔕ↪㧔᭴ㄭ‫ޓ⋥ޓ⮮ޓ‬ታㅧ↢‛කቇ㧕
4㧚Common diseases㧔ࠕ࡟࡞ࠡ࡯ߥߤ㧕ߩࠥࡁࡓ㧘࠻࡜ࡦࠬࠢ࡝ࡊ࠻࡯ࡓ㧘ࡊࡠ࠹ࠝ࡯ࡓ⸃ᨆߣᔕ↪
( ㆮવሶ࡮ಽሶ↢ᘒකቇ )ౝಽᴲઍ⻢∛ᘒቇ1㧚㧞ဳ♧ዩ∛ߩ⊒∝ᯏ᭴ߩ⸃᣿⎇ⓥ
2㧚♧ዩ∛㧘⢈ḩ㧘േ⣂⎬ൻߥߤߩ↢ᵴ⠌ᘠ∛ߩㆮવ
ሶ⸻ᢿᴺߩ㐿⊒3㧚♧ዩ∛ᴦ≮⮎ߩ૞↪ߦ㑐ߔࠆಽሶㆮવቇ⊛⎇ⓥ
ᱞ‫⚐ޓޓޓ↰ޓ‬
4㧚♧ዩ∛෸߮ว૬∝ߩౣ↢ක≮ߩ⎇ⓥ
5㧚ਅု૕೽⣢∔ᖚߩ⸻ᢿᴦ≮ߦ㑐ߔࠆ⎇ⓥ
6㧚㜞ⴊ࿶∝ߩ∛ᘒ⸃᣿⎇ⓥ
7㧚ౝಽᴲ⣲≌ߩᚑ࿃ߦ㑐ߔࠆ⎇ⓥዊఽ∛ᘒቇ

1㧚ࠕ࡟࡞ࠡ࡯∔ᖚߩ∛࿃∛ᘒߦ㑐ߔࠆ఺∉ቇ⊛㧘ㆮવሶቇ⊛㧘᭴ㅧ↢‛ቇ⊛㧘ⅣႺቇ⊛⎇ⓥ
2㧚వᄤᕈ఺∉ਇో∝ߩ∛࿃∛ᘒߦ㑐ߔࠆㆮવሶቇ
⊛㧘᭴ㅧ↢‛ቇ⊛⎇ⓥ
3㧚ࡍ࡞ࠝࠠࠪ࠰࡯ࡓ∛ߩ∛࿃∛ᘒߦ㑐ߔࠆಽሶㆮવ
ሶቇ⊛࡮᭴ㅧ↢‛ቇ⊛⎇ⓥㄭ‫ޓ⋥ޓ⮮ޓ‬ታ 4㧚ㆮવᕈࡓࠦᄙ♧∝ߩ∛࿃∛ᘒߦ㑐ߔࠆಽሶㆮવሶ
ቇ⊛⎇ⓥ
5㧚᦭ᯏ㉄ઍ⻢⇣Ᏹ∝ߩ∛࿃∛ᘒߦ㑐ߔࠆಽሶㆮવሶ
ቇ⊛⎇ⓥ
6㧚␹⚻࡮⊒㆐ߦ㑐ߔࠆಽሶㆮવቇ⊛⎇ⓥ
7㧚DNA ୃᓳ෸߮⚦⢩๟ᦼߣߘߩ⇣Ᏹߦ㑐ߔࠆಽሶㆮવቇ⊛⎇ⓥ

㧙㧙

㗔ၞ
㧔⻠ᐳ㧕
ಽ
ሶ
࡮
᭴
ㅧ
ቇ

ಽ‫ޓ‬㊁

∛ᘒᖱႎ⸃ᨆකቇ

ᜰዉᢎຬ

⎇ⓥౝኈ

1㧚࡝ࡐⰮ⊕ઍ⻢
2㧚࠙ࠗ࡞ࠬᕈ⢄Ἳߦ߅ߌࠆ఺∉ቇ⊛ᯏ᭴
3㧚㧺㧭㧿㧴 ߩ∛࿃∛ᘒ⸃᣿ᷡ‫ޓ‬ፉ‫ޓޓޓ‬ḩ 4㧚࠻࡝ࡊ࠻ࡈࠔࡦઍ⻢ߣ∛ᘒ5㧚ᣂߒ޿᷹ቯᴺߩ㐿⊒෸߮⹏ଔ
6㧚ࡊࡠ࠹ࠝ࡯ࡓ⸃ᨆ

⸃೬ቇ

1㧚ࡅ࠻ⴊ▤♽ߩಽᨑࡄ࠲࡯ࡦ⸃ᨆ
ᣧ‫ޓ‬Ꮉ‫ޓ‬ᄢ‫ޓ‬テ 2㧚ᶏ᫮ູ੃േ‛㧔․ߦ㟗㘃㧕ߩᲧセ⸃೬ቇ⊛⎇ⓥ
3㧚ലᨐ⊛ߥ⸃೬ቇᢎ⢒ᣇᴺߩᮨ⚝࡮㐿⊒ߦଥࠆ⎇ⓥ

ಽሶ∛ᘒቇ

1㧚Aurora ࠍߪߓ߼ߣߔࠆಽⵚᦼࠠ࠽࡯࠯ߩᯏ⢻⸃ᨆ
2㧚࡙ࡆࠠ࠴ࡦൻߦ㑐ㅪߔࠆ
RING-finger ࠲ࡦࡄࠢ⾰ጟ‫ޓ‬㊁‫ޓ‬ᐘ‫ޓ‬㓶ߩᯏ⢻⸃ᨆ
3㧚㧰㧺㧭 ୃᓳ♽ߦ߅ߌࠆࠪࠣ࠽࡞વ㆐ᯏ᭴ߩ⸃ᨆ
4㧚ᩭౝฃኈ૕ߩಽሶ∛ᘒቇ⊛⎇ⓥ

1㧚ᄖ⑼ᚻⴚߦ߅ߌࠆૐଚⷅൻߩ⎇ⓥ
2㧚ᔃ⤳ⴊ▤㧘๭ๆེ㧘ᶖൻེᄖ⑼ߩౣ↢ක≮㧘ㆮવሶᴦ≮ߩ⎇ⓥ㜞ᐲవㅴᄖ⑼ቇ ┻‫ޓ᧛ޓ‬ඳ‫ޓ‬ᢥ 3㧚ੱᎿ⤳ེߩ⎇ⓥ
4㧚ᔃ⤳ⴊ▤ᄖ⑼㧘๭ๆེᄖ⑼ߦ߅ߌࠆࡠࡏ࠶࠻ᚻⴚ
ߩ⎇ⓥ

∛
ᘒ
೙
ᓮ
ቇ

ᢛᒻᄖ⑼ቇ

1㧚࡙࡯ࠗࡦࠣ⡺⣲ߦኻߔࠆㆮવሶᴦ≮ߩၮ␆⎇ⓥ
2㧚ࡅ࠻⣄ᬁߩ↢૕ജቇ⎇ⓥ
3㧚㑐▵Ἳߦ߅ߌࠆࠞ࡞ࡄࠗࡦߩዪ࿷෸߮↢ℂ⊛ᯏ⢻ߩ⸃᣿ᷡ‫ޓ‬᳓‫ޓ‬స‫ᤨޓ‬
4㧚ࠞ࡞ࡄࠗࡦߦࠃࠆ․⇣⊛ࡊࡠ࠹ࠝࠣ࡝ࠞࡦಽ⸃
ࡑ࡯ࠞ࡯᛫૕ߩ૞ᚑ
5㧚エ㛽ࡑ࠻࡝࠶ࠢࠬ㧘ࡊࡠ࠹ࠝࠦࡦ࠼ࡠࠗ࠴ࡦ⎫㉄ߩエ㛽⚦⢩߳ߩ૞↪ߩ⎇ⓥ⊹⤏∛ᘒቇ1㧚⥄Ꮖ఺∉ᕈ᳓∊∝ߩ⊒∝ᯏᐨߣࠪࠣ࠽࡞વ㆐
2㧚వᄤᕈ⴫⊹᳓∊∝ߩಽሶ↢‛ቇ⊛⎇ⓥ
3㧚⴫⊹⚦⢩ߩ⚦⢩㛽ᩰߣ⚦⢩ធ⌕ߩᱜᏱߣ⇣Ᏹ
4㧚ⷺൻ∝ߣ⚦⢩ౝᖱႎવ㆐ᯏ᭴
ർ‫ޓ‬ፉ‫ޓ‬ᐽ‫ޓ‬㓶 5㧚⤔ේ∛ߩᴦ≮⎇ⓥߣ⊒∝∛ℂߩಽሶකቇ⊛⎇ⓥ
6㧚ࠕ࠻ࡇ࡯ᕈ⊹⤏Ἳߩ∛ᘒߣᴦ≮ߦ㑐ߔࠆ⎇ⓥ
7㧚⊹⤏ᖡᕈ⣲≌ߩ∛࿃∛ᘒ㧘⸻ᢿߣᴦ≮ߦ㑐ߔࠆಽሶ↢‛ቇ෸߮⚦⢩↢‛ቇ⊛⎇ⓥ
8㧚⊹⤏⌀⩶∝ߣ∛ේᕈ⌀⩶ߩ㔚㗼ߣ↢ൻቇ⊛⎇ⓥ

ᴲዩེ⑼ቇ

1㧚ዩ〝ᕈེᗵᨴ∝ߩၮ␆⊛࡮⥃ᐥ⊛⎇ⓥ
2㧚ዩ〝ᕈེᖡᕈ⣲≌ߩၮ␆⊛࡮⥃ᐥ⊛⎇ⓥ಴‫ޓ‬ญ‫ޓޓޓ‬㓉 3㧚ឃዩ㓚ኂߦኻߔࠆ⥃ᐥ⊛⎇ⓥ
4㧚ᴲዩེ⑼㗔ၞߩౝⷞ㏜ਅᚻⴚᚻᛛߩ㐿⊒⎇ⓥ
5㧚⣢⒖ᬀߦ߅ߌࠆ⥃ᐥ⊛⎇ⓥ

㤗㈮࡮−∩೙ᓮቇ

1㧚㤗㈮࡮ଚⷅਛߩ๭ๆ࡮ᓴⅣ෻኿ᕈ෻ᔕߦ㑐ߔࠆ⎇ⓥ
2㧚⣖࡮⣄㜑ᓸዊᓴⅣߦኻߔࠆ㤗㈮෸߮㑐ㅪ⮎ߦ㑐ߔࠆ⎇ⓥ࿯‫ޓ‬⢈‫ޓୃޓ‬ม 3㧚㤗㈮࡮−∩ࠪࠣ࠽࡞વ㆐㧦␹⚻ൻቇ⊛෸߮ࡄ࠶࠴
ࠢ࡜ࡦࡊᴺߦࠃࠆ⸃ᨆ
4㧚⣄㜑ߦᣈߌࠆ−∩ฃኈ࡮೙ᓮᯏ᭴㧦ࠗࠝࡦ࠻࡜ࡦ
ࠬࡐ࡯࠲࡯෸߮೙ᓮ⮎ߦ㑐ߔࠆ⎇ⓥ
5㧚ోり㤗㈮⮎࡮ዪᚲ㤗㈮⮎ߦ቟ోᕈߦ㑐ߔࠆ⎇ⓥ⯃↢࡮㓸ਛᴦ≮ቇ

1㧚ᣂߒ޿ᔃ⢖࡮⣖⯃↢ᴺߩ㐿⊒ߦ㑐ߔࠆ⎇ⓥ࿯‫ޓ‬⢈‫ޓୃޓ‬ม 2㧚ᔃ⤳ᯏ⢻ࡕ࠾࠲࡯ߩ㐿⊒3㧚⣄㜑ౣ↢ᴦ≮ߩ㐿⊒ߦ㑐ߔࠆ⎇ⓥ

㧙㧙

㗔ၞ
㧔⻠ᐳ㧕
∛
ᘒ
೙
ᓮ
ቇ

ಽ‫ޓ‬㊁

ญ⣧∛ᘒቇ

ᜰዉᢎຬ

⎇ⓥౝኈ

1㧚ญ⣧∛ᄌߩಽሶ∉ቇ⊛⎇ⓥ
2㧚ญ⣧߇ࠎߩᖡᕈൻㅴዷᯏᐨߩᬌ⚝ߣᛥ೙
3㧚㛽ઍ⻢ߦ߅ߌࠆࠪࠣ࠽࡞⸃ᨆ
ᩊ‫ޓ↰ޓ‬ᢅ‫ޓ‬ਯ
4㧚ญ⣧߇ࠎᴦ≮ߩၮ␆⊛࡮⥃ᐥ⊛㐿⊒5㧚㗶㑐▵∔ᖚߩၮ␆⊛࡮⥃ᐥ⊛⎇ⓥ
6㧚㗶࡮ญ⣧ᯏ⢻ᡷༀߦኻߔࠆ⚦⢩Ꮏቇߩᔕ↪

1㧚ᗵⷡᖱႎಣℂߩ␹⚻ᯏ᭴ߩ⸃ᨆ
㜞ᰴ␹⚻ᒻᘒቇ દ‫ޓ⮮ޓ‬๺‫ޓ‬ᄦ 2㧚㜞ᰴⷞⷡ㊁ߩ⸃ᨆ
3㧚㜞ᰴቇ⠌ᯏ⢻ߩ⠧ൻ㧦ᖱേ㧘ญ⣧ᯏ⢻
4㧚⸥ᙘᖱႎಣℂࠪࠬ࠹ࡓߩ⸃ᨆ㧦fMRI ෸߮ PET↢ℂቇ

1㧚ⴊ࿶⺞▵ߩࠪࠬ࠹ࡓ⸃ᨆ
2㧚ቝቮකቇ࡮㊀ജ↢ℂቇ᫪‫ޓ↰ޓ‬໪‫ޓ‬ਯ 3㧚㕒⣂ᓴⅣᡰេⵝ⟎ߩ㐿⊒
4㧚㜞㦂⠪⵬ഥⵝ⟎ߩ㐿⊒5㧚⦁ᄖቝቮ᦯ߩ㐿⊒1㧚ㆇേಣᣇߦ߅ߌࠆㆇേᒝᐲߩ⎇ⓥࠬࡐ࡯࠷ක⑼ቇ ᧻‫ޓ‬ጟ‫ޓ‬ᢅ‫ ↵ޓ‬2㧚┹ᛛㆬᚻߩ࠻࡟࡯࠾ࡦࠣലᨐߦ㑐ߔࠆ⎇ⓥ
3㧚ࠬࡐ࡯࠷㓚ኂ࡮ᄖ்ߩ੍㒐ߩ⎇ⓥ

␹⚻ౝ⑼࡮⠧ᐕቇ

␹
⚻
⛔
ᓮ
ቇ

1㧚␹⚻㓚ኂᯏᐨߩ⸃᣿ߣౣ↢ୃᓳ࡮␹⚻଻⼔⮎ߩ㐿
⊒2㧚఺∉ᕈ␹⚻∔ᖚߩᚑ࿃ߣᴦ≮ߦ㑐ߔࠆ⎇ⓥ›‫ޓ‬Ⴆ‫⾆ޓޓޓ‬3㧚␹⚻ᄌᕈ∔ᖚߩಽሶ∛ᘒߣᴦ≮ᴺߩ㐿⊒
4㧚⹺⍮∝ߩ⸻ᢿߣᴦ≮ߦ㑐ߔࠆ⎇ⓥ
5㧚㜞㦂⠪෸߮␹⚻㔍∛ߩක≮࡮⑔␩ߦ㑐ߔࠆ⎇ⓥ♖␹∛ℂቇ

1㧚♖␹∔ᖚߩ⣖ᯏ⢻↹௝⎇ⓥ
2㧚♖␹∔ᖚߩ⥄ᓞ␹⚻⎇ⓥ
Ⴎ‫ޓ౉ޓ‬ବ‫ޓ‬᮸ 3㧚♖␹⑼⸻ᢿቇߦ㑐ߔࠆ⎇ⓥ
4㧚⊒㆐㓚ኂߩ∉ቇ⎇ⓥ
5㧚ἴኂ♖␹කቇߦ㑐ߔࠆ⎇ⓥ⣖␹⚻ᄖ⑼ቇ

1㧚ᖡᕈ⣖⣲≌ߩ∛ᘒߣᴦ≮ߦ㑐ߔࠆ⎇ⓥ
2㧚⣖තਛߩ∛ᘒߣᴦ≮ጤ‫ޓ‬㑆‫ޓޓޓ‬੧ 3㧚MRI,PET ߦࠃࠆ㜞ᰴ⣖ᯏ⢻ߩ⸃ᨆ
4㧚⣖තਛߦ߅ߌࠆࠥࡁࡓ⸃ᨆߣㆮવሶᴦ≮ߩ㐿⊒5㧚␹⚻⚦⢩ౣ↢㧘⒖ᬀ

⡊㥦ຜ༄⑼ቇ

1㧚૕ᐔⴧᯏ⢻ᬌᩏᴺߩ⎇ⓥ
2㧚߼߹޿ᴦ≮ߩ⎇ⓥદ‫ޓ౎ޓ⮮ޓ‬ᰴ
3㧚೨ᐸ㓚ኂߩ࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦߦ㑐ߔࠆ⎇ⓥ
4㧚೨ᐸ㓚ኂߦ߅ߌࠆⓨ㑆⹺⍮㓚ኂߩ⎇ⓥ⌒⑼ቇ

1㧚✛ౝ㓚ᕈⷞ␹⚻㓚ኂߩ∛ᘒ↢ℂߦ㑐ߔࠆ⎇ⓥ
2㧚⌒࿶ਅ㒠ࠍ੺ߐߥ޿✛ౝ㓚ᴦ≮ߦ㑐ߔࠆၮ␆⊛⎇ⓥ
3㧚⌒ౝⴊᶧᓴⅣߦ㑐ߔࠆ↢ℂቇ⊛෸߮ᒻᘒቇ⊛⎇ⓥ
4㧚㤛᢬∔ᖚ߳ߩ↹௝⸃ᨆᴺߩᔕ↪ߦࠃࠆᣂߒ޿ᴦ≮ᴺߩ㐿⊒ጊ‫ޓືޓᧄޓ‬਽5㧚ฦ⒳࡟࡯ࠩ࡯ߩ⌒ౝ⚵❱ߦ෸߷ߔᓇ㗀ߦ㑐ߔࠆᒻᘒቇ⊛⎇ⓥ
6㧚✛ౝ㓚ᚻⴚߦ߅ߌࠆઍ⻢ᜟ᛫⮎ߩᔕ↪ߦ㑐ߔࠆ⎇ⓥ
7㧚⟠⤑ࠍ೑↪ߒߚⷺ⤑∔ᖚᴦ≮ߦ㑐ߔࠆ⎇ⓥ

̪ㅪ៤ಽ㊁⣖∛ᘒ⸃ᨆቇ

1㧚ㆫᑧᕈᗧ⼂㓚ኂ࡮㜞ᰴ⣖ᯏ⢻㓚ኂ࡮ߘߩઁ⥃ᐥ␹⚻⑼ቇ㗔ၞߩ∔ᖚ╬ߩ∛ᘒ⹏ଔߣᴦ≮ߦ㑐ߔࠆ⎇ⓥ◉‫ޓޓޓ↰ޓ‬ᷕ
2㧚PET㧘SPECT ࠍ↪޿ߡ⣖ߩᯏ⢻⸃ᨆ㧘MRI ࠍ↪
޿ߡ⣖ߩᒻᘒ⸃ᨆࠍⴕ޿㧘∛ᘒࠍ⹏ଔߒ㧘ߘࠇࠄߩ↹௝࠺࡯࠲ࠍᴦ≮ലᨐ್ቯߦᔕ↪ߔࠆ‫ޕ‬̪⁛┙ⴕ᡽ᴺੱ⥄േゞ੐᡿ኻ╷ᯏ᭴෸߮␠ળක≮ᴺੱෘ↢ળߣߩㅪ៤ᄢቇ㒮

㧙㧙

㗔ၞ
㧔⻠ᐳ㧕

⣲
≌
೙
ᓮ
ቇ

ಽ‫ޓ‬㊁

ᜰዉᢎຬ

⎇ⓥౝኈ

1㧚ㆮવሶᡷᄌࡑ࠙ࠬ૞⵾ᛛⴚࠍ↪޿ߚᄢ⣺⊒߇ࠎߩಽሶᯏ᭴⸃᣿
2㧚߇ࠎ⚦⢩࡝ࡊࡠࠣ࡜ࡒࡦࠣߦࠃࠆ߇ࠎࠛࡇࠫࠚࡀ
࠹ࠖ࠶ࠢ⇣Ᏹߩᗧ⟵⸃᣿‫ޓ‬᣿
3㧚DNA ࡔ࠴࡞ൻᯏ᭴ߣ⣲≌⊒↢ߩ⸃᣿4㧚ౣ↢ක≮ ,‫ޓ‬ᐙ⚦⢩කቇߦ㑐ㅪߔࠆ⣲≌⊒↢ߩ⸃᣿ߣߘߩ೙ᓮ
5㧚␹⚻ౣ↢⎇ⓥߩߚ߼ߩ␹⚻㓚ኂേ‛ࡕ࠺࡞ߩ㐿⊒

⣲≌∛ℂቇ

ේ‫ޓޓ‬

఺∉∛ℂቇ

1㧚࡝ࡦࡄჇᱺᕈ∔ᖚߩಽሶ⚦⢩∛ℂቇ
2㧚ᖡᕈ࡝ࡦࡄ⣲ߩ⚵❱⊒↢㜞‫ޓޓޓ⷗ޓ‬೰ 3㧚⣲≌ߩಽሶ఺∉ᴦ≮
4㧚ࡅ࠻⣲≌㑐ㅪᜎ⛘᛫ේߩ⸃ᨆ

⣲≌ᄖ⑼ቇ

1㧚㘩㆏≸࡮⢗≸࡮ᄢ⣺≸ߩ㏜ⷞਅᚻⴚߩ⥃ᐥ⎇ⓥ
2㧚ᶖൻེ≸࡮੃≸ߩൻቇ≮ᴺ෸߮ಽሶᮡ⊛ᴦ≮ߩ⥃ᐥ⎇ⓥߣ୘೎ൻ≮ᴺߩ⎇ⓥ
3㧚ᶖൻེ≸⊒≸ᯏ᭴ߩಽሶ↢‛ቇ⊛ᬌ⸛෸߮ߘߩ⥃ᐥᔕ↪
ศ‫ޓ↰ޓ‬๺‫ޓ‬ᒄ
4㧚᛫≸೷ߩ⠴ᕈߩࡔࠞ࠾࠭ࡓߩ⸃ᨆ
5㧚ᄢ⣺≸ᄙ⊒⢄ォ⒖ߦኻߔࠆᄖ⑼⊛ಾ㒰̆㒢⇇߳ߩ᜸ᚢ̆
6㧚⢄⣲≌ߦኻߔࠆಓ⚿≮ᴺߦࠃࠆ఺∉⾮ᵴߩࡔࠞ࠾
࠭ࡓᶖൻེ∛ᘒቇ

1㧚ᕆᕈ࡮ᘟᕈ⢄ਇోߩ∛ᘒߣᴦ≮ߦ㑐ߔࠆ⎇ⓥ
2㧚ࡃࠗࠝੱᎿ⢄⤳ߩ㐿⊒ߣ⥃ᐥᔕ↪ߦ㑐ߔࠆ⎇ⓥ᫪‫ޓ‬⣁‫ޓ‬ਭ‫ޓ‬㓉
3㧚ᩭฃኈ૕ࠍಽሶᮡ⊛ߣߒߚ⊒≸੍㒐࡮≸ߩಽൻ⺃ዉ≮ᴺߦ㑐ߔࠆၮ␆⊛࡮⥃ᐥ⊛⎇ⓥⴊᶧ∛ᘒቇ

1㧚ㅧⴊེ∔ᖚߩㆮવሶᴦ≮ߦ㑐ߔࠆၮ␆⊛⎇ⓥ᫪‫ޓ‬⣁‫ޓ‬ਭ‫ޓ‬㓉 2㧚ㅧⴊེᖡᕈ⣲≌ߦ㑐ߔࠆ⥃ᐥ∛ℂቇ⊛⎇ⓥ↥⑼ᇚੱ⑼ቇ

1㧚ᖡᕈ⣲≌⚦⢩ߢߩ⇣ᚲᕈࡎ࡞ࡕࡦฃኈ૕⊒⃻ߦ㑐ߔࠆ⎇ⓥ
2㧚⇣ᚲᕈࡎ࡞ࡕࡦฃኈ૕ߩฃኈᔕ╵ᯏ᭴ߣ᛫Ⴧᱺ૞
↪ߩ⸃᣿
3㧚⢽⾰↱᧪↢ℂᵴᕈ‛⾰㧔࡝࠱ࡎࠬࡈࠔ࠴ࠫࡦ㉄ߥ੹‫ޓ‬੗‫ޓ◊ޓ‬ᔒߤ㧕ߩ↢ᱺ⃻⽎ߦ߅ߌࠆᓎഀߩ⸃᣿
4㧚ㆮવሶ⇣Ᏹߦ⿠࿃ߒߚᕈಽൻ⇣Ᏹ෸߮ࡎ࡞ࡕࡦਇ
ᔕ∝ߦ߅ߌࠆ∛ᘒ⸃᣿
5㧚ൻቇ≮ᴺߦ઻߁ᕈ⣼㓚ኂߩ଻⼔ߩ㐿⊒ߣ⥃ᐥᔕ↪
ߩ⹜ߺ

᡼኿✢කቇ

1㧚ᶖൻ▤ᖡᕈ⣲≌ߩ↹௝⸻ᢿ
2㧚ᣧᦼ⢄≸↹௝⸻ᢿᤊ‫ޓޓޓ‬ඳ‫ޓ‬ᤘ 3㧚Interventional Radiology
4㧚ᖡᕈ⣲≌ߦኻߔࠆ᡼኿✢ᴦ≮
5㧚ᩭකቇߦࠃࠆ⣖ᯏ⢻᷹ቯ࡮≸ߩ⸻ᢿ

1㧚߇ࠎߩ∉ቇ⎇ⓥ
2㧚↢ᵴ⠌ᘠ∛ߩ∉ቇ⎇ⓥ∉ቇ࡮੍㒐කቇ ᳗‫ޓ↰ޓ‬⍮‫ޓ‬㉿3㧚ᩕ㙃∉ቇ⎇ⓥ
4㧚ᖚ⠪ߩⴕേකቇ⎇ⓥ⥃ᐥ⣲≌ቇ㧖

1㧚߇ࠎൻቇ≮ᴺߩℂ⺰ߣ᦭ኂ੐⽎᫪‫ޓ‬⣁‫ޓ‬ਭ‫ޓ‬㓉 2㧚ਥⷐ߇ࠎ⣲ߩൻቇ≮ᴺ෸߮▤ℂᴺદ‫ޓ⮮ޓ‬ༀ‫ ⷙޓ‬3㧚⥃ᐥ⹜㛎ߩታ㓙
4㧚߇ࠎߦ߅ߌࠆ✭๺ක≮㧖ᐔᚑ㧝㧥ᐕᐲ߆ࠄᆎ߹ߞߚ‫࡞࠽࡚ࠪ࠶ࠚࡈࡠࡊࠎ߇ޟ‬㙃ᚑࡊ࡜ࡦ‫ࠆࠃߦޠ‬ൻቇ≮ᴺࠍᜂ߁⥃ᐥ⣲≌කߩ㙃ᚑࠦ࡯ࠬߢቇ૏ߣߣ߽ߦኾ㐷ක⾗ᩰࠍ⋡ᜰߔ‫ޕ‬

㧙㧙

㗔ၞ
㧔⻠ᐳ㧕

ಽ‫ޓ‬㊁

ᜰዉᢎຬ

⎇ⓥౝኈ

1㧚㐳ኼ࿾ၞߦ߅ߌࠆ↢ᵴ⠌ᘠ∛ߩ⥃ᐥ∉ቇ⊛ᬌ⸛
2㧚EBM ࠍ↪޿ߚ⥃ᐥ∉ቇ⎇ⓥ
3㧚㧞ဳ♧ዩ∛⊒∝ᯏ᭴෸߮♧ዩ∛ว૬∝⊒∝ᯏ᭴ߩ✚ว∛ᘒౝ⑼ቇ ⍹‫ޓ‬Ⴆ‫ޓ‬㆐‫ޓ‬ᄦಽሶ↢‛ቇ⊛⎇ⓥ
4㧚↢ᵴ⠌ᘠ∛ߣⴊዊ᧼ಝ㓸⢻ߩ㑐ㅪ5㧚⢽⢌⚦⢩ߩࠨࠗ࠻ࠞࠗࡦㆮવሶ⊒⃻

ක
≮
▤
ℂ
ቇ

⥃ᐥ⮎೷ቇ

1㧚ක⮎ຠߦࠃࠆ೽૞↪ߩ⊒⃻ᯏ᭴ߣኻ╷ߦ㑐ߔࠆ⎇ⓥ
2㧚ක⮎ຠߩㆡᱜ૶↪ߦ㑐ߔࠆ⎇ⓥદ‫ޓ⮮ޓ‬ༀ‫ⷙޓ‬
3㧚⮎‛⋧੕૞↪ߩ⸃ᨆߦ㑐ߔࠆ⎇ⓥ
4㧚ᴦ≮⊛⮎‛ⴊਛỚᐲࡕ࠾࠲࡝ࡦࠣߦ㑐ߔࠆ⎇ⓥ
5㧚⮎ቇ⊛ࠤࠕߩ᦭↪ᕈߦ㑐ߔࠆ⥃ᐥ⎇ⓥක≮⚻ᷣቇ

1㧚ක≮ߦ߅ߌࠆ↢↥ᕈ෸߮ല₸ᕈ ߦ㑐ߔࠆ⎇ⓥ
2㧚ㆮવሶ⸻ᢿߦኻߔࠆ㔛ⷐಽᨆ᳗‫ޓ↰ޓ‬⍮‫ޓ‬㉿ 3㧚࿷㒮ᣣᢙ⍴❗ൻ߇ක≮ᯏ㑐ㆇ༡ߦਈ߃ࠆᓇ㗀ߦ㑐ߔࠆ⎇ⓥ
4㧚ක≮ߦ߅ߌࠆᖚ⠪⥄Ꮖ᳿ቯⷐ࿃ߦ㑐ߔࠆ⎇ⓥ

1㧚ᢇᕆἴኂක≮૕೙ߩ⎇ⓥ
2㧚ᢇᕆක≮ᖱႎߩ⎇ⓥ
3㧚ᢌⴊ∝ᕈ࡚ࠪ࠶ࠢߩ⎇ⓥᢇᕆ࡮ἴኂකቇ ዊ‫ޓ⌀ޓୖޓ‬ᴦ
4㧚ᄖ்ߦ㑐ߔࠆ⎇ⓥ
5㧚㊀∝ᕆᕈ⤟Ἳߦ㑐ߔࠆ⎇ⓥ
6㧚⥶ⓨක≮ߦ㑐ߔࠆ⎇ⓥ

ᴺකቇ

1㧚ᔃ⤳ᕈ⓭ὼᱫߦ㑐ߔࠆ∛ℂቇ⊛⎇ⓥ
2㧚SIDS ߩ∛ℂቇ⊛⎇ⓥᱞ‫ޓ‬ౝ‫ޓ‬ᐽ‫ޓ‬㓶 3㧚੤ㅢᄖ்ߦ㑐ߔࠆ⎇ⓥ
4㧚DNA ᄙဳߦ㑐ߔࠆ⎇ⓥ
5㧚࡚ࠪ࠶ࠢᤨᣧᦼߦ⊒⃻ߔࠆ⻉⤳ེߩᒻᘒቇ⊛ᄌൻ
ߩ⎇ⓥ

↥ᬺⴡ↢ቇ

᳗‫ޓ↰ޓ‬⍮‫ޓ‬㉿ 1㧚ደᄖഭ௛ߩᔟㆡൻߦ㑐ߔࠆ⎇ⓥ
2㧚‛ℂ⊛ⅣႺೝỗߩ↢૕ᓇ㗀ߦ㑐ߔࠆ⎇ⓥ
੗ᄹᵄ‫ ৻ޓ⦟ޓ‬3㧚⡯႐ߩࡔࡦ࠲࡞ࡋ࡞ࠬߦ㑐ߔࠆ⎇ⓥකቇᢎ⢒ቇ

1㧚ࠞ࡝ࠠࡘ࡜ࡓ㐿⊒ߣቇ↢⹏ଔᴺߩ⎇ⓥ
2㧚ࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦᢎ⢒ߦ㑐ߔࠆ⎇ⓥ
3㧚⢻േ⊛໧㗴ၮ⋚ဳቇ⠌ߦ㑐ߔࠆ⎇ⓥ㋈‫ޓᧁޓ‬ᐽ‫ޓ‬ਯ
4㧚Professionalism ᢎ⢒ߦ㑐ߔࠆ⎇ⓥ⮮‫ޓ‬ፒ‫ޓ‬๺‫ޓ‬ᒾ 5㧚࿾ၞၮ⋚ဳකቇᢎ⢒ߦ㑐ߔࠆ⎇ⓥ
6㧚ࠪࡒࡘ࡟࡯࡚ࠪࡦකቇᢎ⢒ߦ㑐ߔࠆ⎇ⓥ
7㧚කቇᢎ⢒ᜰዉ⠪ߩ⢒ᚑߦ㑐ߔࠆ⎇ⓥ㧙㧙㧔5㧕ၮ␆ᛛⴚ࠻࡟࡯࠾ࡦࠣࠦ࡯ࠬ
ᔅୃන૏ߩ߶߆ߦ㧘Ṷ⠌⑼⋡ߣߒߡᰴߩࠃ߁ߥၮ␆ᛛⴚ࠻࡟࡯࠾ࡦࠣࠦ࡯ࠬࠍ⸳ߌߡ޿ࠆ‫ޕ‬1 ࠦ࡯ࠬߪේೣߣߒߡ 1 ㅳ㑆ߣߔࠆ߇㧘ᦼ㑆ߣౝኈߦߟ޿ߡߪᜂᒰᢎຬߣ⋧⺣ߩ਄᳿߼ࠆ‫ߚ߹ޕ‬㧘ᢎຬ㧘⎇ⓥ↢ߢᏗᦸߔࠆ⠪߽ᧄࠦ࡯ࠬߦෳടߔࠆߎߣ߇ߢ߈ࠆ‫ޕ‬ၮ␆ᛛⴚ࠻࡟࡯࠾ࡦࠣࠦ࡯ࠬ
㧺㨛.

᝼ᬺ⑼⋡ฬ

ᢎ⢒⎇ⓥಽ㊁1ၮ␆ᛛⴚ㧔఺∉⚵❱ൻቇ 㧭㧕

఺∉∛ℂቇ

2

ၮ␆ᛛⴚ㧔఺∉⚵❱ൻቇ 㧮㧕㜞ᰴ␹⚻ᒻᘒቇ

3ၮ␆ᛛⴚ㧔㔚ሶ㗼ᓸ㏜ၮ␆ᛛⴚ㧕⸃೬ቇ

4ၮ␆ᛛⴚ㧔RI ታ㛎ᴺ㧕

⮎ℂ∛ᘒቇ

5

ၮ␆ᛛⴚ㧔ㆮવሶᠲ૞ၮ␆ᛛⴚ 㧭㧕

⚦⢩ᖱႎቇ

6

ၮ␆ᛛⴚ㧔ㆮવሶᠲ૞ၮ␆ᛛⴚ 㧮㧕∛ේ૕೙ᓮቇ

7ၮ␆ᛛⴚ㧔ή㤗㈮ή᜔᧤േ‛ߢߩታ㛎ᴺ㧕

↢ℂቇ

8ၮ␆ᛛⴚ㧔ਛᨔ␹⚻ታ㛎ᴺ 㧭㧕㜞ᰴ␹⚻ᒻᘒቇ

9ၮ␆ᛛⴚ㧔ਛᨔ␹⚻ታ㛎ᴺ 㧮㧕

␹⚻↢‛

10

ၮ␆ᛛⴚ㧔ᖱႎಣℂၮ␆㧕∉ቇ࡮੍㒐කቇ

11ၮ␆ᛛⴚ㧔⚵❱ၭ㙃ᛛⴚ 㧭㧕

఺∉∛ℂቇ

12

ၮ␆ᛛⴚ㧔⚵❱ၭ㙃ᛛⴚ 㧮㧕

ಽሶ∛ᘒቇ

13

ၮ␆ᛛⴚ㧔Ⱞ⊕⾰ಽᨆᴺ 㧭㧕Ⱞ⊕㜞ᰴᯏ⢻ቇ

14ၮ␆ᛛⴚ㧔Ⱞ⊕⾰ಽᨆᴺ 㧮㧕

ᴺකቇ

15

ၮ␆ᛛⴚ㧔↢૕ౝ‛⾰ಽᨆᴺ㧕

ᴺකቇ

16

ၮ␆ᛛⴚ㧔ᓸ↢‛ၭ㙃ᛛⴚ㧕

ህ᳇ᕈ⩶ታ㛎ಽ㊁㧔↢๮⑼ቇ✚วታ㛎࠮ࡦ࠲࡯㧕17ၮ␆ᛛⴚ㧔౏ⴐⴡ↢⸻ᢿቇ㧕

↥ᬺⴡ↢ቇ

18

ၮ␆ᛛⴚ㧔⊒≸ታ㛎ᴺ㧕

⣲≌∛ℂቇ

19

ၮ␆ᛛⴚ㧔ࠪࠣ࠽࡞વ㆐ታ㛎ᴺ㧕

⚦⢩ᖱႎቇ

20

ၮ␆ᛛⴚ㧔᛫૕૞⵾ᴺ㧕

ነ↢⯻ቇ

21

ၮ␆ᛛⴚ㧔ㆇേ↢ℂቇၮ␆ታ㛎㧕ࠬࡐ࡯࠷ක⑼ቇ

㧔6㧕ᄢቇ㒮․೎⻠⟵ᄢቇ㒮․೎⻠⟵ߪ㧘㓐ᤨ㧘ਥߣߒߡၮ␆කቇ♽⻠ᐳࠍਛᔃߦታᣉߒߡ޿ࠆ‫ޕ‬

5. ᢎ⢒ᵴേ
㧔1㧕ᢎ⢒ᵴേߩታᣉౝኈߣᣇᴺ
කቇ♽ᄢቇ㒮ߪᄢቇߦ߅ߌࠆකቇߦ㑐ߔࠆ㜞ᐲߩᢎ⢒࡮⎇ⓥ⚵❱ߢ㧘⥄ࠄవ┵⊛ߥකቇ⎇ⓥࠍⴕ߁ߣߣ߽ߦ㧘⁛ഃ⊛ߥ⎇ⓥ⢻ജ߿⼾߆ߥቇ⼂ߣੱ㑆ᕈࠍ஻߃ߚකቇᢎ⢒⠪࡮⎇ⓥ⠪޽ࠆ޿ߪක≮ᓥ੐⠪ߩ㙃ᚑࠍⴕ߁߽ߩߢ޽ࠆ‫ޕ‬Ԙᢎຬ⚵❱ߩᒝൻ
ᓥ᧪㧘කቇ♽ᄢቇ㒮ߩᢎຬ⚵❱ߪකቇㇱߩᢎຬ⚵❱ࠍၮߦߎࠇߦ㑐ㅪߔࠆ㒝⟎⎇ⓥᚲ෸߮ઁ♽߆ࠄߩ૬છᢎຬࠍട߃ߡ᭴ᚑߐࠇߡ߈ߚ߇㧘කቇ♽ᄢቇ㒮ߩᢎ⢒࡮⎇ⓥᯏ⢻ࠍలታߐߖࠆߚ߼ߦߪቇ
ㇱࠍ⿥߃ࠆ㈩ᘦ߇ᔅⷐߣߥߞߡ߈ߡ޿ࠆ‫ޕ‬ቇㇱ⻠ᐳߩᢎ᝼ࠍ౗છߒߥ޿ᄢቇ㒮ኾછߩᢎ᝼㧘ಎᢎ᝼㧘‫⎇߈⦟ޟ‬ⓥ⠪ߢߥ޿ߣ⦟߈ᢎ⢒⠪ߦߪߥࠇߥ
⻠Ꮷ㧘ഥᢎࠍ⟎ߊߥߤᢎຬ⚵❱ߩలታ߇ᔅⷐߢ޽ࠆ‫ޕ‬㧙㧙޿‫߁޿ߣޠ‬࿑ᑼ߇ቇㇱ࡟ࡌ࡞ߩᢎ⢒ߢߪᔅߕߒ߽ᚑ┙ߒߥ޿ߎߣ߇ᜰ៰ߐࠇߡ޿ࠆ߇㧘ᄢቇ㒮࡟ࡌ࡞ߦ޽ߞߡߪߎߩ࿑ᑼߪଐὼߣߒߡ⌀ℂߢ޽ࠆ‫ޕ‬1㧕 කቇㇱߦ߅ߌࠆᢎຬᢙߩ⛘ኻ⊛ਇ⿷ᢎຬߩᜬߜᤨ㑆ߩ㧘⎇ⓥ㧘ᢎ⢒㧘⸻≮㧘▤ℂ࡮ㆇ༡߳ߩࡃ࡜ࡦࠬߩߣࠇߚ㈩ಽߥߤ⺰ᄖߢ޽ࠅ㧘ቇㇱߢߩᢎ⢒⎇ⓥ⸻≮ߐ߃ḩ⿷ߦⴕ߃ߥ޿⁁ᘒߢᄢቇ㒮ߩᢎຬࠍ౗ോߒߡ޿ࠆ⁁ᴫߦ޽ࠅ㧘ߐࠄߦකቇ♽ᄢቇ㒮߇ᢛ஻࡮లታߐࠇߡ޿ߊᲑ㓏ߦ߅޿ߡ߹ߔ߹ߔᢎຬ߇ਇ⿷ߒᷓೞߥ໧㗴ߣߥࠈ߁‫ޕ‬2㧕 ᦭⢻ߥකቇᢎ⢒⠪࡮⎇ⓥ⠪ߩ⢒ᚑ୘‫ߩޘ‬ᢎຬߩᢎ⢒⎇ⓥᵴേ߇ᵴᕈൻߒߡೋ߼ߡ⚵❱ߣߒߡߩᄢቇ㒮߇ᵴᕈൻߔࠆ߽ߩߢ޽ࠆ
ߎߣߦ㐓ߺ㧘කቇㇱ⊒ዷߦ߽ߒ஗ṛ߇ߺࠄࠇࠆߣߒߚߥࠄ߫㧘ᢎ᝼ળਗ߮ߦᢎ᝼৻ੱ৻ੱߩ⽿છߢ޽ࠅ㧘⥄Ꮖὐᬌࠍၮ␆ߣߒߟߟ㧘⚵❱ߣߒߡߩ⥄Ꮖὐᬌ࡮⹏ଔࠍⴕߞߡ޿ࠆ‫ߟ߆ޕ‬㧘ᢎ᝼ㆬ⠨ߦ޽ߚߞߡߪ㧘ࠃࠅ᦭⢻ߥ⎇ⓥ⠪ࠍㆬ߱ࠃ߁ദ߼ߡ޿ࠆ‫ޕ‬ԙᢎ⢒ᯏ⢻ߩలታ

1㧕 ⧯ᚻᢎຬߩ⢒ᚑ⁛ഃ⊛ߢవ┵⊛ߥ⎇ⓥߩㆀⴕߦߪᣣ‫ޘ‬ᣂߚߥᛛⴚ㕟ᣂࠍขࠅ౉ࠇ㧘ߘࠇࠍᱞེߣߒߡవ⷗ᕈࠍ
߽ߞߡ࡙࠾࡯ࠢߥ⎇ⓥߦขࠅ⚵߻ߎߣ߇ᦸ߹ࠇࠆ‫߼ߚߩߘޕ‬࿖ౝਗ߮ߦ࿖ᄖߩ⎇ⓥᯏ㑐ߣ౒ห⎇ⓥࠍⴕ޿㧘⇐ቇߥߤⓍᭂ⊛ߦੱ੐੤ᵹࠍⴕ޿㧘⧯ᚻᢎຬߩ⢒ᚑࠍ⸘↹ߒߡ㧘ታ❣ࠍ޽ߍߡ޿ࠆಽ
㊁߽ዋߥߊߥ޿‫੹ޕ‬ᓟߪකቇ⎇ⓥ⑼ో૕ߢขࠅ⚵߻ߎߣ߇ᦸ߹ࠇ㧘⎇ⓥ⑼㐳㧔ቇㇱ㐳㧕ࠍਛᔃߦ⎇ⓥ⑼ߩᵴᕈൻߦߟߥ߇ࠆᚢ⇛ࠍㅴ߼ߡ޿ࠆ‫ޕ‬
2㧕 ᄢቇ㒮ቇ↢ߩᢎ⢒࡮⎇ⓥᯏ⢻ߩలታᢎ⢒㕙ߢߪ㧘ၮ␆ᛛⴚ࠻࡟࡯࠾ࡦࠣࠦ࡯ࠬ෸߮ᄢቇ㒮․೎⻠⟵ࠍታᣉߒ㧘౒ㅢ⑼⋡ߩਛߢࠃࠅవ
┵⊛⍮⼂࡮ᛛⴚߩ᥉ㆉൻߦദ߼ߡ޿ࠆ‫ޕ‬߹ߚ㧘ᄢቇ㒮ቇ↢ߩ⎇ⓥᯏ⢻ߩలታࠍ࿑ࠆᔅⷐ߇޽ࠅ㧘ᄢቇ㒮ቇ↢ߩ৻ㇱࠍઁ⻠ᐳ㧘ઁቇㇱ޽ࠆ޿ߪઁᄢቇ߳৻ቯᦼ㑆ᵷ㆜ߒઁᄢቇߣߩ౒ห⎇ⓥࠍⴕ߁ߥߤߒߡ⎇ⓥᯏ⢻ߩలታࠍ࿑ߞߡ޿ࠆ‫ޕ‬3㧕 ⎇ⓥ⾌ߩలታ㧘ᄢဳ⸳஻ߩᢛ஻
ᄢቇ㒮ቇ↢ߩᜰዉᢎຬߦߪᜰዉ⎇ⓥ↪ߩ⚻⾌ߩᄢ᏷ߥჇ㗵߇ᔅⷐߢ޽ࠆ߇㧘੹ᣣߩ␠ળ⚻ᷣ⁁ᴫߢߪ࿎㔍ߢ޽ࠅ㧘ᄢဳ⸳஻ߩዉ౉߽࿎㔍ߢ޽ࠆ‫ߒ߆ߒޕ‬㧘කቇㇱᧄ㙚㧘㒝ዻ∛㒮߇ᩉᚭ࿾඙߳ߩ⛔
ว⒖ォߒ㧘⛯޿ߡ↢๮⑼ቇ᫟߽ᣂ⸳ߐࠇߚ‫⸳ߪߦߎߘޕ‬஻ߩᢛߞߚࠕࠗ࠰࠻࡯ࡊᣉ⸳㧘േ‛㘺⢒ᣉ⸳㧘⸃೬ታ⠌ቶ߇޽ࠅ㧘NMR ߿ⓨ㑆⼂ታ㛎ቶ߽⸳⟎ߐࠇߡ޿ࠆ‫ޕ‬ᄢቇో૕ߩ⸳஻ߩᵴ↪߿㧘ಽ㊁߇ᚲ᦭ߔࠆᯏེߩ⾉୫╬߽ⴕ޿㧘⎇ⓥ߇౞Ṗߦㅴ߼ࠄࠇࠆࠃ߁ߥ࿯ფࠍၭ߅߁ߣߒߡ޿ࠆ‫ޕ‬㧙㧙6㧚 ⎇ⓥᵴേާಽሶ࡮᭴ㅧቇ⻠ᐳި
㧔1㧕⚦⢩ᖱႎቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
ၮ␆කቇ♽ߪੱຬ߇㒢ࠄࠇߡ޿ࠆߚ߼ߦ㧘⣖␹⚻ᄖ⑼ቇ㧘⣲≌ᄖ⑼ቇߥߤߩ⥃ᐥಽ㊁߆ࠄੱ⊛ᡰេࠍฃߌߥ߇ࠄ㧘⎇ⓥࠍ⛯ߌߡ߈ߚ‫⚦ޕ‬⢩ౝᖱႎવ㆐㧘ߥ߆ߢ߽⚦⢩ߩ↢ߣᱫߩ೙ᓮࡔࠞ࠾࠭ࡓࠍਥߚࠆ࠹࡯ࡑ
ߣߒߡ⎇ⓥࠍⴕߞߡ߈ߚ‫⎇ޕ‬ⓥኻ⽎ߣߒߡߪਥߣߒߡ␹⚻♽㧘ⴊ▤♽㧘߇ࠎࠍᛒߞߡ޿ࠆ‫⚦ࠎ߇ޕ‬⢩ߢߪࠕࡐ࠻࡯ࠪࠬࠍല₸ࠃߊ⺃ዉߔࠆߎߣ߇㧘৻ᣇ⣖᪪Ⴇߥߤߩ⯯ⴊㇱ૏ߢߪࠕࡐ࠻࡯ࠪࠬࠍᛥ೙ߔࠆߎߣ߇
੍㒐߿ᴦ≮ߦߟߥ߇ࠆ‫ߚ߹ޕ‬㧘ⴊ▤ߐࠄߦ⚵❱ౣ↢ߦߟ޿ߡߩ⎇ⓥ߽ㅴⴕਛߢ޽ࠆ‫ޕ‬⣖᪪Ⴇᓟߩ⚵❱㓚ኂߩシᷫ㧘߅ࠃ߮ⴊ▤࡮␹⚻⚵❱ౣ↢ߩ⎇ⓥࠍㅴ߼ߡ޿ࠆ‫ߚ߹ޕ‬㧘േ⣂⎬ൻߦኻߔࠆࠬ࠹ࡦ࠻ᴦ≮ߦࠃࠆⴊ▤ౝ⊹⚦⢩ߩ㓚ኂࡔࠞ࠾࠭ࡓߣߘߩ੍㒐ߦߟ޿ߡ߽㧘৻ቯߩᚑᨐࠍ਄ߍߡ޿ࠆ‫⚵࡮ེ⤳ߩߡߴߔߪ▤ⴊޕ‬❱߇ᚑ┙ߔࠆߚ߼ߩ㊀ⷐߥၮᧄන૏ߢ޽ࠅ㧘ࡐࠬ࠻ࠥࡁࡓᤨઍߩ㊀ⷐߥ⎇ⓥ࠹࡯ࡑߩ߭ߣߟߢ޽ࠆ‫ޕ‬࿖┙ᚑ⢒ක≮࠮ࡦ࠲࡯ߣߩ౒ห⎇ⓥߢ㧘ⴊ▤ߩ⊒↢࡮ౣ↢ߦ㊀ⷐߥㆮવሶࠍหቯߒߡ߅ࠅ㧘⹦⚦ߥᯏ⢻⸃ᨆࠍⴕߞߡ޿ࠆ‫ߦࠄߐޕ‬㧘߽߁৻ߟߩ⣂▤♽ߢ޽ࠆ࡝ࡦࡄ▤ߩ⊒↢㧘ౣ↢ᯏ᭴ߦߟ޿ߡ߽⎇ⓥࠍ㐿ᆎߒߚ‫ޕ‬
2㧚ฬ★
ਛፉ ⨃
ᢎ᝼㧦
ಎᢎ᝼㧦 ဈ㊁༑ሶᨋ⌀৻㇢ഥᢎ㧦

Shigeru Nakashima
Yoshiko Banno
Shin-ichiro Hayashi

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ਛፉ ⨃. ᄢፉᵏ㇢, ㋈ᧁ⚔৻, ⣄ጊᵗฝ, ᣂ੗ᵗ↱, ⍹ᶆ┨৻, ᄢ㓈⦟ౖ, ጯᧄஜ㓶, ᱜᧁᤐᒾ, ጊᧄ৻ᄦ✬㧚↢ൻቇ੐ౖ ╙ 4 , ᧲੩㧦᧲੩ൻቇหੱ㧧2007 ᐕ㧚
2㧕 ᨋ⌀৻㇢, ศ᧛⚩৻㧚᫪ਅ┥৻✬. ⯯ⴊᕈ⣖ⴊ▤∔ᖚߩౣ↢ᴦ≮㧔⚦⢩ᴦ≮㧕㧦ⴊ▤ߩౣ↢̅ⴊ▤ౣ↢කቇߩᄛ᣿ߌгㄭߠߊታ↪ൻг, ᧲੩㧦⌀⥝੤ᤃ㧔ᩣ㧕කᦠ಴ ㇱ㧧 2008 ᐕ㧦155㧙161㧚
3㧕 ਛፉ ⨃, ጟ㊁ᐘ㓶㧚৻ἑ⊕Ꮲ, ㋈ᧁብᴦ✬. ⚦⢩ౝࠪࠣ࠽࡞વ㆐ᯏ᭴㧦࿑⺑ಽሶ∛ᘒቇ ╙㧠 , ᧲੩㧦ਛᄖකቇ␠㧧2008 ᐕ㧦46㧙49㧚⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
ߥߒ✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
ߥߒේ⪺㧔᰷ᢥ㧕
1㧕 Yamada Y, Banno Y, Yoshida H, Kikuchi R, Akao Y, Murate T, Nozawa Y. Catalytic inactivation ofhuman phospholipase D2 by a naturally occurring Gly901Asp mutation. Arch Med Res.
2006;37:696-699.
2㧕 Akao Y, Banno Y, Nakagawa Y, Hasegawa N, Kim TJ, Murate T, Igarashi Y, Nozawa Y. High expressionof sphingosine kinase 1 and S1P receptors in chemotherapy-resistant prostate cancer PC3 cells and theircamptothecin-induced up-regulation. Biochem Biophys Res Commun. 2006;342:1284-1290.
3㧕 Morita M, Banno Y, Dohjima T, Nozawa S, Fushimi K, Fan DG, Ohno T, Miyazawa K, Liu N, Shimizu
K. -Calpain is involved in the regulation of TNF--induced matrix metalloproteinase-3 release in arheumatoid synovial cell line. Biochem Biophys Res Commun. 2006;343:937-942.
4㧕 Ohguchi K, Banno Y, Akao Y, Nozawa Y. Involvement of phospholipase D1 in collagen type I
production of human dermal fibroblasts. Biochem Biophys Res Commun. 2006;348:1398-1402.
5㧕 Akutagawa A, Fukami K, Banno Y, Takenawa T, Kannagi R, Yokoyama Y, Oda K, Nagino M, Nimura Y,
Yoshida S, Tamiya-Koizumi, K. Disruption of phospholipase CG4 gene modulates the liver㧙㧙

IF 1.772

IF 2.749

IF 2.749
IF 2.749

regeneration in cooperation with nuclear protein kinase C. J Biochem. 2006;140:619-625.
6㧕 Raymond MN, Bole-Feysot F, Banno Y, Tanfin Z, Robin P. Endothelin-1 inhibits apoptosis through asphingosine kinase 1-dependent mechanism in uterine leiomyoma ELT3 cells. Endocrinology.
2006;147:5873-5882.
7㧕 Sobue S, Iwasaki T, Sugisaki C, Nagata A, Kikuchi R, Murakami M, Takagi A, Kojima T, Banno Y,
Akao Y, Nozawa Y, Kannagi R, Suzuki M, Abe A, Naoe T, Murate T. Quantitative RT-PCR analysis ofsphingolipid metabolic enzymes in acute leukemia and myelodysplastic syndromes. Leuchemia.
2006;20:2042-2046.
8㧕 Ryu J, Kim HJ, Chang EJ, Huang H, Banno Y, Kim HH. Sphingosine 1-phosphate as a regulator ofosteoclast differentiation and osteoclast-osteoblast coupling. EMBO J. 2006;25:5840-5851.
9㧕 Masuda H, Kalka C, Takahashi T, Yoshida M, Wada M, Kobori M, Itoh R, Iwaguro H, Eguchi M, Iwami
Y, Tanaka R, Nakagawa Y, Sugimoto A, Ninomiya S, Hayashi S, Kato S, Asahara T. Estrogen-mediatedendothelial progenitor cell biology and kinetics for physiological postnatal vasculogenesis. Circ Res.
2007;101:598-606.
10㧕 You F, Osawa Y, Hayashi S, Nakashima S. Immediate early gene IEX-1 induces astrocytic
differentiation of U87-MG human glioma cells. J Cell Biochem. 2007;100:256-265.
11㧕 Leiber D, Banno Y, Tanfin Z. Exogenous sphingosine-1 phosphate and sphingosine kinase activated byendothelin-1 induced myometrial contraction through differential mechanisms. Am J Physiol Cell
Physiol. 2007;292:C240-C250.
12㧕 Jung ID, Lee JS, Kim YJ, Jeong YI, Lee CM, Baumruker T, Billlich A, Banno Y, Lee MG, Ahn SC, Park
WS, Han J, Park YM. Sphingosine kinase inhibitor suppresses a Th1 polarization via the inhibition of
immunostimulatory activity in murine bone marrow-derived dendritic cells. Int Immunol.
2007;19:411-426.
13㧕 Mizoguchi H, Yamada K, Niwa M, Mouri A, Mizuno T, Noda Y, Nitta A, Itohara S, Banno Y,
Nabeshima T. Reduction of methamphetamine-induced sensitization and reward in matrix
metalloproteinase-2 and -9 deficient mice. J Neurochem. 2007;100:1579-1588.
14㧕 Kikuchi R, Murakami M, Sobue S, Iwasaki T, Hagiwara K, Takagi A, Kojima T, Asano H, Suzuki M,
Banno Y, Nozawa Y, Murate T. Ewing’s sarcoma fusion protein, EWS/Fli-1and Fli-1 protein induce
PLD-2 but not PLD-1 gene expression by binding to an ETS domain of 5’ promoter. Oncogene
2007;26:1802-1810.
15㧕 Kikuchi R, Sobue S, Murakami M, Ito H, Kimura A, Iwasaki T, Shibayama S, Takagi A, Kojima T,
Suzuki M, Banno Y, Nozawa Y, Murrate T. The regulatory mechanism of Vitamine D3 induced increaseof PLD1 transcription of a human keratinocyte cell line, HaCaT. FEBS Lett. 2007;581:1800-1804.
16㧕 Mizoguchi H, Yamada K, Mouri A, Niwa M, Mizuno T, Noda Y, Nitta A, Itohara S, Banno Y,
Nabeshima T. Role of matrix metalloproteinase and tissue inhibitor of MMP in
methamphetamine-induced behavioral sensitization and reward: implications for dopamine receptor
down-regulation and dopamine release. J Neurochem. 2007;102:1548-1560.
17㧕 Murakami M, Ichihara M, Sobue S, Kikuchi R, Ito H, Kimura A, Iwasaki T, Takagi A, Kojima T,
Takahashi M, Suzuki M, Banno Y, Nozawa Y, Murate T. RET signaling-induced SPHK1 gene
expression plays a role in both GDNF-induced differentiation and MEN2-type oncogenesis. J
Neurochem. 2007;102:1585-1594.
18㧕 Fushimi K, Nakashima S, You F, Takigawa M, Shimizu K. Prostaglandin E2 downregulates
TNF-D-induced production of matrix metalloproteinase-1 in HCS-2/8 chondrocytes by inhibiting
Raf-1/MEK/ERK cascade through EP4 prostanoid receptor activation. J Cell Biochem.
2007;100:783-793.
19㧕 Yamashita K, Kotani Y, Nakajima Y, Shimozawa M, Yoshimura S, Nakashima S, Iwama T, Hara H.
Fasudil, a Rho kinase (ROCK) inhibitor, protects against ischemic neuronal damage in vitoro and invivo by acting directly on neurons. Brain Res. 2007;1154:215-224.
20㧕 Banno Y, Nemoto S, Murakami M, Kimura M, Ueno, Y, Ohguchi K, Hara A, Okano Y, Kitade Y, Onozuka
M, Murate T, Nozawa Y. Depolarization-induced differentiation of PC12 cells is mediated byphospholipase D2 through the transcription factor CREB pathway. J Neurochem. 2008;104:1372-1386.
21㧕 Sobue S, Nemoto S, Murakami M, Ito H, Kimura A, Gao S, Furuhata A, Takagi A, Kojima T,
Nakamura M, Ito Y, Suzuki M, Banno Y, Nozawa Y, Murate T. Implications of sphingosine kinase 1
expression level for the cellular sphingolipid rheostat -Relevance as a marker for daunorubicin
sensitivity of leukemia cells. Int J Hematol. 2008;87:266-275.
22㧕 Sobue S, Murakami M, Banno Y, Ito Y, Kimura A, Furuhata A, Gao S, Takagi A, Kojima T, Suzuki M,
Akao Y, Nozawa Y, Murate T. V-src oncogene increases sphingosine kinase 1 expression through its
mRNA stabilization -Alteration of AU-rich element binding proteins. Oncogene. 2008;27:6023-6033.
23㧕 Niinomi K, Banno Y, Iida H, Dohi S. Nicorandil, an adenosine triphosphate-sensitive potassiumchannel opener, inhibits muscarinic acetylcholine receptor-mediated activation of extracellularsignal-regulated kinases in PC12 cells. Anesth Analg. 2008;107:1892-1898.
24㧕 Soeda A, Inagaki A, Oka N, Ikegame Y, Aoki H, Yoshimura S, Nakashima S, Kunisada T, Iwama T.
Epidermal growth factor plays a crucial role in mitogenic regulation of human brain tumor stem cells.

㧙㧙

IF 2.020

IF 5.045

IF 6.612
IF 8.662

IF 9.721
IF 3.409

IF 4.230

IF 3.290

IF 4.451

IF 6.440

IF 3.263

IF 4.451

IF 4.451

IF 3.409

IF 2.212

IF 4.451

IF 1.491

IF 6.440

IF 2.214J Biol Chem. 2008;283:10958-10966.

IF 5.581

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦ဈ㊁༑ሶ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧧ࠬࡈࠖࡦࠧ⢽⾰ઍ⻢㉂⚛ߦࠃࠆ⚦⢩Ⴧᱺ࡮↢ሽߩ೙ᓮᯏ᭴⸃᣿㧧ᐔᚑ 17㧙18 ᐕᐲ㧧3,600 ජ౞(2,000㧦1,600 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦ᨋ⌀৻㇢㧧ጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼ߩ⎇ⓥᵴᕈൻ㧔ක㧕ߩߚ߼ߩᡰេ੐ᬺ㧧ᧃ᪳ⴊ▤ౝ⊹․⇣⊒⃻࿃ሶߩหቯ߅ࠃ߮ᴦ≮ᔕ↪㧧ᐔᚑ 17 ᐕᐲ㧧1,000 ජ౞3㧕 ⎇ⓥઍ⴫⠪㧦ᬢ 㚊⪇㧧ጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼ߩ⎇ⓥᵴᕈൻ㧔ක㧕ߩߚ߼ߩᡰេ੐ᬺ㧧ࡅ࠻ࠣ࡝ࠝ࡯ࡑ⚦⢩ߩᱫߣಽൻߩࠬࠗ࠶࠴ᯏ᭴ߩ⸃᣿㧧ᐔᚑ 17 ᐕᐲ㧧500 ජ౞4㧕 ⎇ⓥઍ⴫⠪㧦ᨋ⌀৻㇢㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌㧔⎇ⓥ㧕㧧ⴊ▤ౝ⊹೨㚟⚦⢩ߩേ㕒⣂ⴊ▤߳ߩಽൻ೙ᓮ
߅ࠃ߮ᴦ≮ᔕ↪㧧ᐔᚑ 18 ᐕᐲ㧧1,200 ජ౞5㧕 ⎇ⓥઍ⴫⠪㧦ᨋ⌀৻㇢㧧ጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼ߩ⎇ⓥᵴᕈൻ㧔ක㧕ߩߚ߼ߩᡰេ੐ᬺ㧔ಽ㊁ࠍߎ߃ߚ౒ห⎇ⓥ㧕㧧⣖⯯ⴊߣ␹⚻ᄌᕈ∔ᖚߩᣂߒ޿ᴦ≮ᴺߩ㐿⊒ߦะߌߚၮ␆⎇ⓥ㧔⣖⯯ⴊߦ߅ߌࠆ⚵❱ᐙ⚦⢩ߩಽൻ೙ᓮࠍ੺ߒߚ␹⚻ⴊ▤ୃᓳᴦ≮ᴺߩ⏕┙㧧ᐔᚑ 18 ᐕᐲ㧧1,000 ජ౞6㧕 ⎇ⓥઍ⴫⠪㧦ᬢ 㚊⪇㧧ጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼ߩ⎇ⓥᵴᕈൻ㧔ක㧕ߩߚ߼ߩᡰេ੐ᬺ㧧ࠟࡦ⚦⢩ߦ߅ߌࠆࠕࡐ࠻࡯ࠪࠬߣࠝ࡯࠻ࡈࠔࠫ࡯ߩࡃ࡜ࡦࠬ㧧ᐔᚑ 18 ᐕᐲ㧧200 ජ౞7㧕 ⎇ⓥઍ⴫⠪㧦೨ፉ㓷⟤㧧ጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼ߩ⎇ⓥᵴᕈൻ㧔ක㧕ߩߚ߼ߩᡰេ੐ᬺ㧧ࠟࡦ⚦⢩ߦ߅ߌࠆࠝ࡯࠻ࡈࠔࠫ࡯⺃ዉߣࠪࠣ࠽࡞વ㆐ᯏ᭴㧧ᐔᚑ 18 ᐕᐲ㧧500 ජ౞8㧕 ⎇ⓥઍ⴫⠪㧦ᨋ⌀৻㇢㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌㧔⎇ⓥ㧕㧦ⴊ▤␹⚻૞േ EphrinB ࡝ࠟࡦ࠼ࠍ೑↪ߒߚࠕ࡞࠷ࡂࠗࡑ࡯∛ߩ∛ᘒ⸃᣿߅ࠃ߮ᴦ≮ᔕ↪㧧ᐔᚑ 19 ᐕᐲ㧧1,130 ජ౞9㧕 ⎇ⓥઍ⴫⠪㧦᧛ᚻ㓉 (ฬฎደᄢቇකቇㇱ), ⎇ⓥಽᜂ⠪㧦ဈ㊁༑ሶ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦
ᖡᕈ⣲≌, ␹⚻ᄌᕈ∔ᖚߢߩࠬࡈࠖࡦࠧࠪࡦࠠ࠽࡯࠯ߩ⊒⃻⇣Ᏹߩ⸃ᨆߣ∛ᘒߢߩᗧ⟵㧧ᐔᚑ 18㧙
19 ᐕᐲ㧧4,050 ජ౞(2,200㧦1,850 ජ౞)
10㧕 ⎇ⓥઍ⴫⠪㧦ဈ㊁༑ሶ㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌㧔⎇ⓥ㧕㧦᛫≸೷⠴ᕈߩ↢ℂᵴᕈ⢽⾰ߦࠃࠆ⺞▵ᯏ᭴ߣࠤࡕ࠹࡜ࡇ࡯ߦ߅ߌࠆᜰᮡߩ⏕┙㧧ᐔᚑ 19 ᐕᐲ㧧1,130 ජ౞
11㧕 ⎇ⓥઍ⴫⠪㧦ਛፉ ⨃㧧ጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼ߩ⎇ⓥᵴᕈൻ㧔ක㧕ߩߚ߼ߩᡰេ੐ᬺ㧦⢽⢌⚵❱↱᧪㑆⪲♽ᐙ⚦⢩ߣ␹⚻ᩕ㙃࿃ሶࠍ↪޿ߚᣂߒ޿␹⚻∔ᖚᴦ≮ᴺߩ㐿⊒㧧ᐔᚑ 19 ᐕᐲ㧧100 ජ౞12㧕 ⎇ⓥઍ⴫⠪㧦਄↰ ᶈ (ጘ㒂ᄢቇᎿቇㇱ), ⎇ⓥಽᜂ⠪㧦ဈ㊁༑ሶ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦
ᣂⷙEJଐሽᕈ RhoGEF ߣ⋧੕૞↪ߔࠆ↢૕ಽሶߩหቯߣߘߩ↢ℂᯏ⢻ߩ⸃᣿㧧ᐔᚑ 20㧙22 ᐕᐲ㧧
4,200 ජ౞(1,400㧦1,400㧦1,400 ජ౞)
13㧕 ⎇ⓥઍ⴫⠪㧦਄↰ ᶈ (ጘ㒂ᄢቇᎿቇㇱ), ⎇ⓥಽᜂ⠪㧦ဈ㊁༑ሶ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄․ቯ⎇ⓥ‫ޟ‬G࠲ࡦࡄࠢ⾰‫ޠ‬㧦ੑߟߩ G ࠨࠗࠢ࡞ࠍ⚿߱ᣂⷙਃ㊂૕ G Ⱞ⊕⾰ࠪࠣ࠽࡞ଐሽᕈ RhoGEF ⟲ߩᯏ⢻⸃ᨆ㧧
ᐔᚑ 20㧙21 ᐕᐲ㧧5,200 ජ౞(2,600㧦2,600 ජ౞)
14㧕 ⎇ⓥઍ⴫⠪㧦ਛ᧛శᶈ㧔ጘ㒂⮎⑼ᄢቇ㧕, ⎇ⓥಽᜂ⠪㧦ဈ㊁༑ሶ㧧⑼ቇᛛⴚᝄ⥝ᯏ᭴ࠪ࡯࠭⊒ជ⹜㛎⎇ⓥ㧦⢽⾰ࡔ࠲ࡏࡠࡒ࠶ࠢࠬߦࠃࠆൻቇ≮ᴺࡃࠗࠝࡑ࡯ࠞ࡯ߩᬌ⚝ߣᬌ⸽㧧ᐔᚑ 20 ᐕᐲ㧧2,000 ජ౞
15㧕 ⎇ⓥઍ⴫⠪㧦ᨋ⌀৻㇢㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌㧔⎇ⓥ㧕㧦ⴊ▤␹⚻૞േ EphrinB ࡝ࠟࡦ࠼ࠍ೑↪ߒߚࠕ࡞࠷ࡂࠗࡑ࡯∛ߩ∛ᘒ⸃᣿߅ࠃ߮ᴦ≮ᔕ↪㧧ᐔᚑ 20 ᐕᐲ㧧1,060 ජ౞
16㧕 ⎇ⓥઍ⴫⠪㧦ᨋ⌀৻㇢㧧ጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼ߩ⎇ⓥᵴᕈൻ㧔ක㧕ߩߚ߼ߩᡰេ੐ᬺ:ᶖൻེ⣲≌ߦ߅ߌࠆ࡝ࡦࡄ▤ᣂ↢ߩࡔࠞ࠾࠭ࡓ⸃᣿߅ࠃ߮࡝ࡦࡄ▤ࠍ࠲࡯ࠥ࠶࠻ߣߒߚᴦ≮ᔕ↪㧧ᐔᚑ 20
ᐕᐲ㧧500 ජ౞
17㧕 ⎇ⓥઍ⴫⠪㧦ᳰ੉↱㚅, ಽᜂ⠪㧦ᨋ⌀৻㇢㧧ጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼ߩ⎇ⓥᵴᕈൻ㧔ක㧕ߩߚ߼ߩᡰេ੐ᬺ㧦ANGPT1 ߣ⚵❱ᐙ⚦⢩ࠍ೑↪ߒߚ⯯ⴊᕈ⣖ⴊ▤∔ᖚߦኻߔࠆᣂߒ޿ᴦ≮ᴺߩ㐿⊒㧧ᐔᚑ 20 ᐕᐲ㧧500 ජ౞
2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥ1㧕 ᨋ⌀৻㇢㧘ਛፉ⨃㧦ⴊ▤ౝ⊹ౣ↢ߦ߅ߌࠆ PDE3 㒖ኂ೷㧔ࠪࡠࠬ࠲࠱࡯࡞㧕ߩᓎഀ㧧ᐔᚑ 19 ᐕᐲ㧧
1,000 ජ౞㧦ᄢႦ⵾⮎㧔ᩣ㧕
2㧕 ဈ㊁༑ሶ㧦⊹⤏߅ࠃ߮⊹⤏⚦⢩ߩ࠮࡜ࡒ࠼േᘒߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 20 ᐕᐲ㧧500 ජ౞㧦ࠦ࡯࠮࡯㧔ᩣ㧕㧙㧙

5㧚⊒᣿࡮․⸵಴㗿⁁ᴫ
1㧕 ᨋ⌀৻㇢㧦Alzheimer ∛㑐ㅪ࠲ࡦࡄࠢ, Amyloid-E (AE-40)ߩⴊ▤ౣ↢㒖ኂ૞↪㧧࿖㓙౏㐿⇟ภ
㧔WO2006/05977㧕
6㧚ቇળᵴേ
1㧕ቇળᓎຬਛፉ ⨃㧦
1㧕 ᣣᧄ↢ൻቇળ⹏⼏ຬ࡮ෳਈ(㨪⃻࿷)2㧕 ᣣᧄ↢ൻቇળ ක⑼↢ൻቇ࡮ಽሶ↢‛ቇᢎ⢒ද⼏ળᆔຬ(㨪ᐔᚑ 19 ᐕ 8 ᦬)
3㧕 ╙ 20 ࿁࿖㓙↢ൻቇ࡮ಽሶ↢‛ቇળ⼏⊓㍳ផㅴᆔຬળᆔຬ(㨪ᐔᚑ 18 ᐕ 6 ᦬)
ဈ㊁༑ሶ㧦1㧕 ᣣᧄ↢ൻቇળਛㇱᡰㇱᐙ੐(ᐔᚑ 18 ᐕ 9 ᦬㨪ᐔᚑ 20 ᐕ 8 ᦬)
2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ਛፉ ⨃㧦
1㧕 ጘ㒂㜞ⴊ࿶∝ᴦ≮࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 1 ᦬, ጘ㒂, ᐳ㐳)2㧕 ጘ㒂㜞ⴊ࿶∝ᴦ≮࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 1 ᦬, ጘ㒂, ᐳ㐳)3㧕 ጘ㒂㜞ⴊ࿶∝ᴦ≮࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 9 ᦬, ጘ㒂, ᐳ㐳)4㧕 ጘ㒂㜞ⴊ࿶∝ᴦ≮࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 9 ᦬, ጘ㒂, ᐳ㐳)ဈ㊁༑ሶ㧦
1㧕 ╙㧝࿁ࠬࡈࠖࡦࠧ࠹࡜ࡇ࡯(STC)⎇ⓥળ(ᐔᚑ 18 ᐕ 5 ᦬, ☨ሶ, Ṷ⠪)2㧕 ╙ 2 ࿁ࠬࡈࠖࡦࠧ࠹࡜ࡇ࡯(STC)⎇ⓥળ(ᐔᚑ 19 ᐕ 5 ᦬, ☨ሶ, Ṷ⠪)
3㧕 ╙ 3 ࿁ࠬࡈࠖࡦࠧ࠹࡜ࡇ࡯(STC)⎇ⓥળ(ᐔᚑ 20 ᐕ 7 ᦬, ☨ሶ, Ṷ⠪)
8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേਛፉ ⨃㧦
1㧕 TIMA Foundation (Liechtenstein)

Adviser (㨪⃻࿷)ဈ㊁༑ሶ㧦
1㧕 ᣣᧄቇⴚᝄ⥝⑼ቇ⎇ⓥ⾌ᆔຬળኾ㐷ᆔຬ(ᐔᚑ 19 ᐕᐲ)ᨋ ⌀৻㇢㧦1㧕 ᣣᧄ૕⢒දળࠬࡐ࡯࠷࠼ࠢ࠲࡯(౓ᐶᡰㇱ)(ᐔᚑ 19 ᐕ 10 ᦬㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ဈ㊁༑ሶ㧦ࠬࡈࠖࡦࠧ⢽⾰ઍ⻢㉂⚛ߦࠃࠆ⚦⢩Ⴧᱺ࡮↢ሽߩ೙ᓮᯏ᭴ߩ⸃᣿㧦ᐔᚑ 17 ᐕᐲ㧙18 ᐕ
ᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)⎇ⓥᚑᨐႎ๔ᦠ(2007 ᐕ 5 ᦬)
11㧚ႎ㆏
ဈ㊁༑ሶ㧦
1㧕 ⚦⢩ߩ↢ᱫ⺞▵ᯏ᭴ࠍតࠆ㧦ጘ㒂ᣂ⡞(2007 ᐕ 3 ᦬ 13 ᣣ)㧙㧙12㧚⥄Ꮖ⹏ଔ
⹏ଔ⎇ⓥߦߟ޿ߡߪ೙㒢ߐࠇߚࡑࡦࡄࡢ࡯߿੍▚ߩਛߢ㊂ࠃࠅ߽⾰ߦߎߛࠊࠅ㧘߈ߜࠎߣ⹏ଔߐࠇࠆ⎇ⓥ
ࠍ⋡ᜰߒߡ߈ߚ‫߁߽ޕ‬ዋߒߢ⊒⴫ߢ߈ࠆ⎇ⓥᚑᨐ߽ᄙᢙ᦭ࠅ㧘৻ቯߩᚑᨐࠍ਄ߍࠆߎߣ߇ߢ߈ߚߣᕁ߁‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ၮ␆♽ಽ㊁౒ㅢߩ໧㗴ߢ޽ࠆᄢቇ㒮↢ߩ⏕଻ߪ㧘ೋᦼ⎇ୃߩ⟵ോൻߩታᣉߦࠃࠅ߹ߔ߹ߔ࿎㔍ߣߥߞߚ‫ୃ⎇ޕ‬කߩᄢㇺᏒ㓸ਛߪᣣᧄో૕ߩ໧㗴ߢ߽޽ࠆ߇㧘ᣧᕆߥኻ╷߇ߥߐࠇߥߌࠇ߫㧘ᣧ᥅㧘࿾ᣇߩක≮૕೙㧘߭޿ߡߪ࿾ᣇᄢቇߩၮ␆කቇ⎇ⓥߪੱ᧚⊛ߦ፣უߩෂᯏࠍㄫ߃ࠆߢ޽ࠈ߁‫ޕ‬ಽ㊁୘‫ߩޘ‬ദജߣߒߡ㧘ቇ↢߳ߩ௛߈߆ߌߩᒝൻߣ㧘⥃ᐥಽ㊁ߣߩ౒ห⎇ⓥ߇੹ᓟ߹ߔ߹ߔ㊀ⷐߦߥࠆߣᕁࠊࠇࠆ‫⊒ޕ‬ᗐߩᨵエߥ⧯ᚻ⎇ⓥ⠪ࠍ⏕଻ߔࠆᗧ๧ߢ߽㧘৻ಽ㊁ߩ⺖㗴ߢߥߊකቇ⎇ⓥ⑼ో૕ߢᣧᕆߦขࠅ⚵߻ߴ߈໧㗴ߢ޽ࠅ㧘ࠬࠞ࡜࡯ࠪ࠶ࡊߩഃ⸳ߪ㜞ߊ⹏ଔߢ߈ࠆ‫ߪࠄ߆ࠇߎޕ‬ฦಽ㊁߇੹એ਄ߦ⎇ⓥᬺ❣ࠍౝᄖߦࠕ
ࡇ࡯࡞ߒ㧘ቇ↢㆐ߦ⎇ⓥߩ㊀ⷐᕈ߿߅߽ߒࠈߐࠍ໪⫥ߒߡ޿ߊߎߣ߇㊀ⷐߦߥࠆߢ޽ࠈ߁‫ޕ‬කቇ⎇ⓥ⑼ో૕ߢߩ⎇ⓥ૕೙ߩᣧᕆߥౣᬌ⸛߇ᦸ߹ࠇࠆ‫ޕ‬ቇㇱቇ↢ࠍߺߡ޿ࠆߣ㧘ℂ♽ߦ߽߆߆ࠊࠄߕታ㛎߿⎇ⓥߦ⥝๧ࠍ␜ߐߥ޿߽ߩ߇ᕆჇߒߡ޿ࠆࠃ߁ߦᕁࠊࠇࠆ‫ޕ‬ീᒝળࠍડ↹ߒߡ߽ෳട⠪߇㓸߹ࠄߥ޿ߒ㧘ቇᬺᚑ❣ߣߒߡ⹏ଔߐࠇࠆߎߣએᄖߦߪ૛ࠅ⥝๧ࠍ␜ߐߕ㧘ᄞߣ߆Ꮧᦸߣ޿߁⸒⪲߇ᗵߓࠄࠇߥ޿ቇ↢߇ᕆჇߒߡ޿ࠆࠃ߁ߦᕁࠊࠇࠆ‫ޕ‬ᄢቇ౉ቇએ೨ߩኅᐸ޽ࠆ޿ߪቇᩞᢎ⢒ࠍ߈ߜࠎߣ⷗⋥ߒߡ޿߆ߥߌࠇ߫㧘කቇㇱ౉ቇቯຬࠍ޿ߊࠄჇ߿ߒߡ߽㧘ᧄᒰߦ₂り⊛ߥ௛߈ࠍߒߡߊࠇࠆකᏧࠍ⢒ߡࠆߩߪ૛ࠅᦼᓙߢ߈
ߥ޿ߩߢߪߥ޿߆ߣ޿߁ෂᯏᗵࠍᒝߊᗵߓߡ޿ࠆ‫ޕ‬੹ᓟߩዷᦸ⚦⢩ߩ↢ߣᱫߩ೙ᓮᯏ᭴߅ࠃ߮⚦⢩ߩಽൻࡔࠞ࠾࠭ࡓߩ⸃᣿ߪ㧘߇ࠎߩᴦ≮߿⚵❱ߩᒻᚑ࡮ౣ↢ߩၮ␆ߣߥࠅᓧࠆ⎇ⓥߢ޽ࠆ‫ߚ߹ޕ‬㧘ⴊ▤ߪ⤳ེ࡮⚵❱ߩ⛽ᜬߦᰳ߆ߖߥ޿㊀ⷐߥⷐ⚛ߢ޽ࠅ㧘ߘߩᒻᚑ࡮
ౣ↢ߪ↢૕ߩᯏ⢻⛽ᜬߦ⋥⚿ߒߡ޿ࠆ‫ߩߎޕ‬ਔ⎇ⓥ࠹࡯ࡑߪߔߴߡߩ⥃ᐥಽ㊁ߦ߽౒ㅢߒߚ໧㗴ߢ޽ࠅ㧘੹ᓟᧄቇ⥃ᐥ♽ಽ㊁ࠍߪߓ߼ߣߔࠆ౒ห⎇ⓥᯏ㑐ߣߩㅪ៤ࠍࠃࠅ৻ጀᷓ߼ߡ㧘ߎࠇࠄߩ⎇ⓥࠍߐࠄߦㅴ
߼ߡ޿߈ߚ޿ߣ⠨߃ߡ޿ࠆ‫⎇ߩࠄࠇߎޕ‬ⓥߩߐࠄߥࠆ⊒ዷࠍ߼ߑߒ㧘ක≮ᔕ↪ߩၮ␆⎇ⓥߣߥࠆߎߣࠍ
⋡ᮡߣߒߚ޿‫ޕ‬㧙㧙㧔2㧕ಽሶ↢ℂቇಽ㊁
1㧚⎇ⓥߩ᭎ⷐ
1㧕Ⱞ⊕⾰ߩ㜞ᰴ᭴ㅧߣᯏ⢻ߦ㑐ߔࠆ‛ℂൻቇ⊛⎇ⓥࡐࠬ࠻ࠥࡁࡓߦ⛯ߊ⎇ⓥ㗔ၞߪ‫ᤨߩ⾰⊕Ⱞޟ‬ઍ‫߇ࠆ޿ߡࠇࠊ⸒߽ߣޠ‬㧘ㆮવᖱႎߩ⠡⸶ߦࠃߞߡⰮ⊕⾰߇↢วᚑߐࠇߡߘߩᯏ⢻ࠍ⊒ើߔࠆ߹ߢߦ㧘Ⱞ⊕⾰ߪ㜞ᰴ᭴ㅧࠍᒻᚑߒߚᓟߦߐ߹ߑ߹ߥ⠡⸶ᓟୃ㘼
㧔post translational modification㧕ࠍฃߌࠆ‫ޕ‬ᢙ޽ࠆⰮ⊕⾰ߩਛߢࠕ࡞ࡉࡒࡦಽሶࠍ଀ߦߒߡ㧘ߐ߹ߑ߹ߥ⠡⸶ᓟୃ㘼߇ࠕ࡞ࡉࡒࡦߩ↢ℂᯏ⢻㧘ߚߣ߃߫࡝ࠟࡦ࠼⚿ว⢻ߥߤߦߤߩࠃ߁ߥᓇ㗀ࠍ෸߷ߔ߆ߣ޿
ߞߚ⎇ⓥࠍⴕ޿㧘∔ᖚߣߩ㑐ㅪᕈߦߟ޿ߡ⎇ⓥߒߡ޿ࠆ‫ޕ‬2㧕Ⱞ⊕⾰࡮ࡍࡊ࠴࠼ߩ⇣Ᏹಝ㓸૕ᒻᚑߩಽሶࡔࠞ࠾࠭ࡓ
Ⱞ⊕⾰ߩ┙૕᭴ㅧ㧔ࠦࡦࡈࠜࡔ࡯࡚ࠪࡦ㧕⇣Ᏹߦ⿠࿃ߔࠆ∔ᖚߣߒߡ㧘ࠕ࡞࠷ࡂࠗࡑ࡯∛߿ࡊ࡝ࠝࡦ∛߇ᵈ⋡ߐࠇߡ޿ࠆ‫․ߩߘޕ‬ᓽߣߒߡ㧘․ቯߩⰮ⊕⾰߇㐳޿ᤨ㑆߆߆ߞߡ⇣Ᏹߥಝ㓸૕ࠍᒻᚑߒߡ⚵❱ౝߦᴉ⌕ߒ㧘ᱜᏱ⚦⢩ߩᯏ⢻⇣Ᏹࠍ߈ߚߔߩߢ㧘ߎࠇࠄߩ∔ᖚࠍ✚⒓ߒߡ‫ߣޠ∛ࡦ࡚ࠪ࡯ࡔࠜࡈࡦࠦޟ‬๭ࠎߢ޿ࠆ‫ޕ‬਄⸥㧔1㧕ߩ⎇ⓥߦ㑐ㅪߒߡ㧘ߤߩࠃ߁ߥṁᇦ᧦ઙਅߢⰮ⊕⾰ߩ⇣Ᏹߥಝ㓸૕߇⊒↢ߔࠆ߆㧘޽ࠆ޿ߪಝ㓸૕⊒↢ࠍ㒐ߋߦߪߤߩࠃ߁ߦߒߚࠄࠃ޿߆㧘੹ᓟ‫∔ޟ‬ᖚ㑐ㅪⰮ⊕⾰‫ࠍޠ‬ኻ⽎ߣߒߡ⎇ⓥࠍㅴ߼ࠆ੍ቯ
ߢ޽ࠆ‫ޕ‬
3㧕↢૕ౝ㉄ൻࠬ࠻࡟ࠬߣ࡟࠼࠶ࠢࠬᔕ╵↢૕ߪߐ߹ߑ߹ߥᄖㇱⅣႺⷐ࿃ߦࠃߞߡߐ߹ߑ߹ߥࠬ࠻࡟ࠬࠍฃኈߒߡ޿ࠆ‫㉄ߦߊߣޕ‬ൻࠬ࠻࡟ࠬߪ⠧ൻ߿≸ൻߦኒធߦ㑐ㅪߒߡ޿ࠆ‫ޕ‬ⴊᷡࠕ࡞ࡉࡒࡦߪ↢૕ౝߢ߽ߞߣ߽ᄙ㊂ߦሽ࿷ߔࠆ໑৻ߩ SH ၮ฽᦭Ⱞ⊕⾰ߢ㧘⚦⢩ᄖ㉄ൻㆶర✭ⴣᯏ⢻ࠍ᦭ߒߡ޿ࠆ‫⚦ޕ‬⢩ᄖᶧ㧘ߣߊߦᓸዊⓨ㑆ౝߦሽ࿷ߔࠆࠕ࡞ࡉࡒࡦߩ㉄ൻㆶర⁁ᘒࠍ᷹ቯߔࠆߎߣߦࠃ
ߞߡ㧘୘૕ో૕ߣߒߡߩ࡟࠼࠶ࠢࠬᔕ╵ߩࡔࠞ࠾࠭ࡓߩ⸃᣿ߦขࠅ⚵ࠎߢ޿ࠆ‫ޕ‬4㧕Ⱞ⊕⾰ߣ᳓ಽሶ㑆⋧੕૞↪ߩಽሶࡔࠞ࠾࠭ࡓ
᳓ߪ↢૕ߩ⚂ 60㧑ࠍභ߼ࠆಽሶ㓸࿅ߢ㧘ߐ߹ߑ߹ߥ↢૕㜞ಽሶߦߘߩᵴേߩ႐ࠍឭଏߒߡ޿ࠆ‫ޕ‬NMR
ߣ޿߁⎇ⓥᚻᲑߦࠃߞߡ㧘Ⱞ⊕⾰๟ㄝߩ᳓ಽሶ㓸࿅ߩേ⊛᜼േ㧘ߔߥࠊߜⰮ⊕⾰̆᳓ಽሶ㑆⋧੕૞↪߇ᬌ಴ߐࠇ㧘ᧄ⎇ⓥ⺖㗴ߪ޽ࠄߚߦ‫ޟ‬ಽሶ࡮⚦⢩ࠗࡔ࡯ࠫࡦࠣᴺ‫ߩ┙⏕ޠ‬ၮ␆ߣߥࠅᓧࠆน⢻ᕈ߇ត⚝ߐࠇߡ
޿ࠆ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
ഥᢎ㧦
ഥᢎ㧦

ᕺ⦟⡛৻
ኹ↰⍮ᣂ
᧛ጊᐘ৻

Seiichi Era
Tomoyoshi Terada
Koichi Murayama

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ᕺ⦟⡛৻㧚ᣣᧄ↢ℂቇળᢎ⢒ᆔຬળ✬, CBT Ḱ᜚ MCQ ߦࠃࠆ↢ℂቇ໧㗴㓸㧚᧲੩㧦ᢥశၴ㧧2006 ᐕ.
2㧕 ᕺ⦟⡛৻㧚ⴊᷡ࠲ࡦࡄࠢ⾰㧔ⴊᷡࠕ࡞ࡉࡒࡦߩࠢ࡜ࠬ࠲࡯ᒻᚑ㧕㧚ᣣᧄ࡟ࠝࡠࠫ࡯ቇળ✬, ࡟ࠝࡠࠫ࡯࠺࡯
࠲ࡂࡦ࠼ࡉ࠶ࠢ, ᧲੩㧦ਣༀ㧧2006 ᐕ㧦392㧙394㧚
3㧕 ㋈ᧁ␽ผ㧘᧻ጊᐘᨑ㧘ᕺ⦟⡛৻㧘೽ፉᤘౖ㧚⣢ᯏ⢻ૐਅߦࠃࠆⴊẏ albumin ߩㆶర₸ߩૐਅ—⛽ᜬㅘᨆ଀ߣߩᲧセ㧦㕍ᩉ৻ᱜ㧘⪉↰ ᣿ ⋙ୃ㧚⣢ߣࡈ࡝࡯࡜ࠫࠞ࡞ ╙ 9 㓸㧘᧲੩㧦᧲੩ᢎቇ␠㧧2008 ᐕ㧦149
㧙153.
4㧕 ኹ⣁ඳਯ㧘ਛጊ᣽᣿㧘᧻ጊᐘᨑ㧘ችỈ♿ሶ㧘ਛጊᕺテ㧘⚦⼱㦖㓶㧘ᕺ⦟⡛৻㧘દ⮮⽵ཅ㧚ᘟᕈ⣢ਇోᖚ⠪ߦ߅ߌࠆ㉄ൻࠬ࠻࡟ࠬ㧦ࠕ࡞ࡉࡒࡦ㉄ൻㆶరᲧࠍᜰᮡߣߒߚᬌ⸛㧦㕍ᩉ৻ᱜ㧘⪉↰ ᣿ ⋙ୃ㧚⣢ߣࡈ࡝࡯࡜ࠫࠞ࡞ ╙ 9 㓸㧘᧲੩㧦᧲੩ᢎቇ␠㧧2008 ᐕ㧦154㧙158.
⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 ᦥᚒ⟤ ൎ, ᕺ⦟⡛৻, ᐔ᧻ብ৻, ᧛਄᡽㓉, ἑየ⧐ノ, ട⮮৻ᄦ, ⮮ᧄ ቞㧚↢ℂ⃻⽎ߣ㜞ಽሶឃ㒰૕Ⓧല
ᨐ㧔excluded volume effect㧕㧙㜞ಽሶᵴ㊂ଥᢙ㧔Σ㧕ᣣᧄ↢ℂቇ㔀⹹ 2006 ᐕ㧧68 Ꮞ㧦4㧙14㧚
2㧕 ᦥᚒ⟤ ൎ, ᕺ⦟⡛৻, ᐔ᧻ብ৻, ᧛਄᡽㓉, ἑየ⧐ノ, ട⮮৻ᄦ, ⮮ᧄ ቞㧚↢ℂ⃻⽎ߣ㜞ಽሶឃ㒰૕Ⓧല
ᨐ㧔excluded volume effect㧕㧙㜞ಽሶᵴ㊂ଥᢙ㧔Τ㧕ᣣᧄ↢ℂቇ㔀⹹ 2006 ᐕ㧧68 Ꮞ㧦47㧙57㧚
3㧕 ᕺ⦟⡛৻㧚ฦ⒳∔ᖚߦ߅ߌࠆ㉄ൻဳ࡮ㆶరဳࠕ࡞ࡉࡒࡦߩᄌേ㧔․㓸—ⴊᷡࠕ࡞ࡉࡒࡦࠍᎼࠆᦨㄭߩ⹤㗴㧕㧘ᩕ㙃⹏ଔߣᴦ≮ 2007 ᐕ㧧24 Ꮞ㧦139㧙143㧚㧙㧙4㧕 ᕺ⦟⡛৻㧚↢૕♽ߩ᳓ߩ✭๺ᤨ㑆㧙㜞ಽሶሽ࿷ਅߢߩ✭๺㧘ᣣ⏛ක⹹ 2008 ᐕ㧧28 Ꮞ㧦1㧙9㧚
5㧕 ኹਅᢘᰴ㇢, ᧛ጊᐘᏒ, ਭ↰ᶈผ, ⪭ว๟ศ㧚ㄭ⿒ᄖൻቇࠗࡔ࡯ࠫࡦࠣᴺ߅ࠃ߮࡟࡯ࠩ࡯ࡉ࡟࡯ࠢ࠳࠙ࡦಽ
శᴺߦࠃࠆ㍤೷᭴ᚑ☸ሶߩಽᢔᕈ⹏ଔ㧘ࡈࠔ࡯ࡓ࠹࠶ࠢࠫࡖࡄࡦ 2008 ᐕ㧧24 Ꮞ㧦1587㧙1595㧚✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ੹੗ ৻㧘ᕺ⦟⡛৻㧘ᴡᧄᢅ᣿㧚೶㆏ᒝൻวኋߦ߅ߌࠆᾫᚑ໊ㄆሶ៨ขߩᓇ㗀㧘ᢎ⢒කቇ 2007 ᐕ㧧53
Ꮞ㧦40㧙41㧚
2㧕 ㋈ᧁ␽ผ㧘㕍ᧁఝሶ㧘᧻ጊᐘᨑ㧘㐳⼱Ꮉ ᒄ㧘◉ේ૫ᒾ㧘ᯅᧄ㓉↵㧘ᕺ⦟⡛৻㧘೽ፉᤘౖ㧚⣢ᯏ⢻㓚ኂߦࠃࠆⴊẏࠕ࡞ࡉࡒࡦߩㆶరൻ₸ߩૐਅߣߘߩᯏᐨ଻ሽᦼ⣢ਇో଀ߣ⛽ᜬⴊᶧㅘᨆ଀ߩᲧセ㧘ᣣ⣢ળ⹹
2008 ᐕ 50 Ꮞ㧦513㧙520㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Suda K, Kato J, Nozawa M, Komabayashi T, Imai H, Era S. ANP content in rat myocardium during
and after swimming. Adv Exerc Sports Physiol. 2006;12:121-125.
2㧕 Negawa T, Murayama K, Ozaki Y, Hayashi T, Era S. Near-infrared spectroscopy study of heat-induced
gelation and hydration of bovine serum albumin in aqueous solution. ITE Lett Batt New Tech Med.
2006;7:42-48.
3㧕 Murayama K, Tomida M, Ootake Y, Mizuno T, Ishimaru J. Principal discriminant variate analysis fordiagnosis of temporomandibular joint disorders using capillary near-infrared spectroscopy of one dropof human temporomandibular joint synovial fluid. ITE Lett Batt New Tech Med. 2006;7:49-52.
4㧕 Murayama K, Tomida M, Hayashi M, Kawakami Y. Abnormal crystal growth of rat teeth by excessive
gamma knife irradiation of brain: microscope ATR/FT-IR spectroscopy study. ITE Lett Batt New TechMed. 2006;7:84-86.
5㧕 Tomida M, Hayashi M, Kawakami Y, Katayama Y, Kouyama N, Murayama K, Ando H, Asanuma N.
The sensitivity of the rat sciatic nerve after gamma knife irradiation. ITE Lett Batt New Tech Med.
2006;7:87-91.
6㧕 Terawaki H, Matsuyama Y, Era S, Matsuo N, Ikeda M, Ogura M, Yokoyama K, Yamamoto T, Hosoya T,
Nakayama M. Elevated oxidative stress measured as albumin redox state in continuous ambulatory
peritoneal dialysis patients correlates with small uraemic solutes. Nephrol Dial Transpl. 2007;22:968.
7㧕 Terawaki H, Nakayama K, Matsuyama Y, Nakayama M, Sato T, Hosoya T, Era S, Ito S. Dialyzable
uremic solutes contribute to enhanced oxidation of serum albumin in regular hemodialysis patients.
Blood Purif. 2007;25:274-279.
8㧕 Fukushima H, Miwa Y, Shiraki M, Gomi I, Toda K, Kuriyama S, Nakamura H, Wakahara T, Era S,
Moriwaki H. Oral branched-chain amino acid supplementation improves the oxidized/reduced
albumin ratio in patients with liver cirrhosis. Hepatol Res. 2007;37:765-770.
9㧕 Terada T, Murayama K, Ra C. Structural study of mutated FcǭRI Ǫ chain ITAM by circulardichroism spectroscopy. ITE Lett Batt New Tech Med. 2007;8:65-68.
10㧕 Terada T, Murayama K, Ra C. Structural study of FcǭRI Ǫ chain polymorphism by circulardichroism spectroscopy. ITE Lett Batt New Tech Med. 2007;8:84-87.
11㧕 Bo Y, Murayama, K, Yan, H. Study of thermal dynamics of defatted bovine serum albumin in D2O solution
by Fourier transform infrared spectra and evolving factor analysis. Appl Spectrosc. 2007; 61:921-927.
12㧕 Matsushima S, Nishiofuku H, Iwata H, Era S, Inaba Y, Kinosada Y. Equivalent cross-relaxation rate
imaging of axillary lymph nodes in breast cancer. J Magn Reson Imaging. 2008;27:1278-1283.
13㧕 Era S, Matsuyama Y, Terada T, Minami T. Heterogeneity of the redox state of commercial humanserum albumin products. FEBS J. 2008;275:209.
14㧕 Iwai I, Ikuta K, Murayama K, Hirao T. Change in optical properties of stratum corneum induced byprotein carbonylation in vitro. Int J Cosmet Sci. 2008;30:41-46.

IF 3.154

IF 1.493

IF 1.255

IF 1.531
IF 2.209
IF 3.396

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦೽ፉᤘౖ, ⎇ⓥಽᜂ⠪㧦ᕺ⦟⡛৻㧧ⅣႺౣ↢଻ోᯏ᭴㧦㊀㊄ዻ╬ߩஜᐽᓇ㗀ߦ㑐ߔࠆ✚ว⊛⎇ⓥ㧧ᐔᚑ 18 ᐕᐲ㧧4,000 ජ౞2㧕 ⎇ⓥઍ⴫⠪㧦೽ፉᤘౖ㧘⎇ⓥಽᜂ⠪㧦ᕺ⦟⡛৻㧧ⅣႺ⋭⎇ⓥ⾌⵬ഥ㊄㧦㊀㊄ዻ╬ߩஜᐽᓇ㗀ߦ㑐ߔࠆ✚ว⎇ⓥ㧧ᐔᚑ 19 ᐕᐲ㧧4,000 ජ౞3㧕 ⎇ⓥઍ⴫⠪㧦ኹ↰⍮ᣂ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦㜞ⷫ๺ᕈ IgE ฃኈ૕  ㎮ߩᯏ⢻⸃ᨆߣࠪࠣ࠽࡞વ㆐ߩ⸃᣿㧧ᐔᚑ 18㧙19 ᐕᐲ㧧3,400 ජ౞(2,100㧦1,300 ජ౞)
4㧕 ⎇ⓥઍ⴫⠪㧦ᕺ⦟⡛৻㧘⎇ⓥಽᜂ⠪㧦᧻ፉ ⑲㧘♿ࡁቯ଻⤿㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦⏛᳇౒㡆ᴺߦࠃࠆ↢૕⚵❱∛ᄌᬌ಴ߩߚ߼ߩಽሶࠗࡔ࡯ࠫࡦࠣߩ㐿⊒ߣ⥃ᐥᔕ↪㧧ᐔᚑ㧙㧙

19㧙20 ᐕᐲ㧧3,570 ජ౞(2,470㧦1,100 ජ౞)
2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥ1㧕 ᕺ⦟⡛৻㧦ᾫᚑ໊ㄆሶࠍࡅ࠻ߦᛩਈߒߚ㓙ߩ᛫㉄ൻ૞↪ߩ್ቯ㧔੍஻ታ㛎㧕㧧ᐔᚑ 18 ᐕᐲ㧧220 ජ౞㧦㘧㛗໊ㄆᎿᚱ㧔ᩣ㧕
2㧕 ᕺ⦟⡛৻㧦ࡅ࠻ߦኻߔࠆᾫᚑ໊ㄆሶߩ᛫㉄ൻലᨐߩᬌ⸛㧔ᧄታ㛎㧕㧧ᐔᚑ 18 ᐕᐲ㧧220 ජ౞㧦㘧㛗໊ㄆᎿᚱ㧔ᩣ㧕
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫ
1㧕 ᕺ⦟⡛৻㧘⑔ፉ⑲᮸㧘᫪⣁ਭ㓉㧦㉄ൻဳࠕ࡞ࡉࡒࡦૐਅ೷㧔⊒᣿㧕㧧ᐔᚑ 18 ᐕᐲ
2㧕 ᕺ⦟⡛৻㧘♿ࡁቯ଻⤿㧘᧻ፉ ⑲㧘㐳↰⌀ੑ㧦MR ⵝ⟎ߦࠃࠆ⏛ൻ⒖േലᨐᴺߣലᨐᲧṶ▚ࠍ૬↪
ߒߚ∛ᄌ⇣Ᏹߩᣧᦼᬌ಴ᴺ㧔⊒᣿㧕㧧ᐔᚑ 19 ᐕᐲ
6㧚ቇળᵴേ
1㧕ቇળᓎຬᕺ⦟⡛৻㧦
1㧕 ᣣᧄ↢ℂቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ∛ᘒ↢ℂቇળℂ੐(㨪⃻࿷)3㧕 ᣣᧄ∛ᘒ↢ℂቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄ⏛᳇౒㡆කቇળઍ⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ᕺ⦟⡛৻㧦
1㧕 ╙ 34 ࿁ᣣᧄ⏛᳇౒㡆කቇળᄢળ(2006 ᐕ 9 ᦬㧘ߟߊ߫, ᢎ⢒⻠Ṷ‫↢ޟ‬૕⚵❱ߩ✭๺ᤨ㑆㧙㜞ಽሶሽ࿷ਅߢߩ✭๺‫ޠ‬Ṷ⠪)
2㧕 ╙ 51 ࿁᧲ᶏቇᩞ଻ஜቇળ✚ળ(2008 ᐕ 9 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ಽሶ࡟ࡌ࡞ߢ⠨߃ࠆ∔ᖚߩ∛ᘒ↢ℂ㨪ಽሶකቇߩߺ߆ߚ࡮⠨߃ᣇ㨪‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ1㧕 ᕺ⦟⡛৻㧦↢૕කᎿቇࠪࡦࡐࠫ࠙ࡓࡌࠬ࠻࡝ࠨ࡯࠴ࠕࡢ࡯࠼(ᐔᚑ 20 ᐕᐲ)
9㧚␠ળᵴേ
ߥߒ
10㧚ႎ๔ᦠߥߒ11㧚ႎ㆏
1㧕 ᕺ⦟⡛৻㧘♿ࡁቯ଻⤿㧘᧻ፉ ⑲㧘㐳↰⌀ੑ㧦⢄⤳߇ࠎ㧘⢄⎬ᄌ ⦡ᄌൻߢ੍ళ⊒⷗㧦⺒ᄁᣂ⡞(2007ᐕ 5 ᦬ 1 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔ೨ภ߿೨‫ޘ‬ภߦ߅ߌࠆ⎇ⓥᬺ❣ߦᲧセߔࠆߣ㧘੹࿁ߩᬺ❣ߦ㑐ߒߡߪ㊰ൻ௑ะ߇ߺࠄࠇࠆ‫⃻ޟߒ߆ߒޕ‬㧙㧙⁁ߩ໧㗴ὐ‫⸥ߦޠ‬タߒߡ޿ࠆ෩ߒ޿⁁ᴫߩਛߢ㧘┹੎⊛ᄖㇱ⾗㊄ߩ₪ᓧ߿⊒᣿࡮․⸵಴㗿╬߽ⴕߞߡ߈
ߡ߅ࠅ㧘ߘࠇࠄߩὐߢ✚วߔࠆߣ߹ߕ߹ߕߩ⹏ଔߢ޽ࠈ߁߆‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ᐔᚑ 16 ᐕߩᄢቇᴺੱൻߩᐕߦ㧘ቇౝߩ੐ᖱߦࠃߞߡᒰ⹥ಽ㊁ߩഥᢎ᝼ࡐࠬ࠻ 1 ߇ᷫຬߐࠇߚ߹߹ 4ᐕ߇⚻ㆊߒߡ޿ࠆ‫ޕ‬ᢎ⢒࡮⎇ⓥߩ㊂ߣ⾰߇ߎࠇ߹ߢએ਄ߦⷐ᳞ߐࠇࠆ⃻࿷㧘ᢎቶຬᢙߩ࿶ୟ⊛ߥዋߥߐ㧔ᱜ㧦ᢎ᝼ 1㧘ഥᢎ 1㧕ߪᒰ⹥ಽ㊁ߩ੹ᓟߩ⊒ዷߦᄢ߈ߥࡉ࡟࡯ࠠߣߥࠆߢ޽ࠈ߁‫ߩߘޕ‬ታല⊛ߥኻᔕ╷߽෩ߒ޿ߩߢ㧘ቇౝᄖߢߩ౒ห⎇ⓥߣ޿߁߆ߚߜߢ᦭ᯏ⊛ߦᝄ⥰߁ߎߣߦࠃߞߡਸ਼ࠅಾߞߡ޿ߊࠃࠅઁ
ߪߥ޿ࠃ߁ߦᕁࠊࠇࠆ‫ޕ‬੹ᓟߩዷᦸ਄⸥ߩ໧㗴ߪනߦᒰ⹥ಽ㊁ߩ৻ಽ㊁ߦ㒢ߞߚ․ᱶߥ⁁ᴫߢߪߥ޿‫⸃ޕ‬᳿╷ߪ߿ߪࠅੱ⊛⾗Ḯߩ⏕଻߇ᕆോ߆ߟࠞࡦࡈ࡞೷ߣߥࠈ߁߇㧘ߘࠇ߽ታ⃻ߢ߈ߥ޿ߩߢ޽ࠇ߫㧘੹ᓟߩዷᦸߪ⃻⁁એ਄ߦ߹ߔ߹ߔ෩
ߒ޿߽ߩߣߥࠆߢ޽ࠈ߁‫ޕ‬㧙㧙㧔3㧕⮎ℂ∛ᘒቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
⮎ℂቇ⊛ᚻᴺ㧘⚦⢩↢‛ቇ⊛ᚻᴺ߅ࠃ߮ಽሶ↢‛ቇ⊛ᚻᴺࠍ↪޿⎇ⓥࠍⴕ޿㧘ઍ⻢ᕈ∔ᖚ࡮ⴊᩖ∝࡮േ⣂⎬ൻ∝࡮ᶖൻེ♽∔ᖚߩ∛ᘒߩ⸃᣿ࠍㅢߒߡࡅ࠻ߦ᦭↪ߥᣂߚߥഃ⮎ࠍ⋡ᜰߒ⎇ⓥࠍⴕߞߡ޿ࠆ‫ޕ‬1㧕⒳‫∛ߩޘ‬ᘒߦ߅ߌࠆૐಽሶ㊂ࠬ࠻࡟ࠬⰮ⊕⾰ߩᓎഀߩ⸃᣿
↢૕ߩࠬ࠻࡟ࠬᔕ╵ߦ߅޿ߡਛᔃ⊛ᓎഀࠍᜂ߁ߣ⠨߃ࠄࠇߡ޿ࠆࠬ࠻࡟ࠬⰮ⊕⾰ߦᵈ⋡ߒ,ਛߢ߽ಽሶ
㊂߇ 10-30kDa ߩૐಽሶ㊂ૐಽሶ㊂ߩᯏ⢻ࠍ⸃ᨆߒߡ޿ࠆ‫⾰⊕Ⱞࠬ࡟࠻ࠬޕ‬㧔low-molecular-weight heatshock protein㧕ߩࡈࠔࡒ࡝࡯ߩਛߢ㧘HSP20 ߣ B ࠢ࡝ࠬ࠲࡝ࡦ߇ᓥ᧪ߩ⚦⢩ౝࠪࡖࡍࡠࡦߣߒߡߩᯏ
⢻એᄖߦࠬ࠻࡟ࠬᔕ╵ߦ㓙ߒ㧘⚦⢩ᄖߦㆆ㔌ߐࠇⴊዊ᧼ᯏ⢻ࠍᛥ೙ߔࠆߎߣࠍ⊒⷗ߒ㧘ߘߩᵴᕈㇱ૏ࠍ⷗಴ߒߚ‫ᦨޕ‬ㄭ㧘HSP27 ߩ࡝ࡦ㉄ൻߩ⒟ᐲ߅ࠃ߮ HSP20 ߩ✚⊒⃻㊂߇ࡅ࠻⢄⚦⢩≸ߦ߅ߌࠆ TNM ࠬ࠹࡯ࠫߣㅒ⋧㑐ߔࠆߎߣࠍ⷗಴ߒ㧘⢄≸ߩ∛ᘒߦ߅޿ߡૐಽሶ㊂ HSP ߇≸⚦⢩ߩჇᱺ೙ᓮᯏ᭴ߦ㑐ਈߒߡ޿ࠆߎߣࠍ␜ߒߚ‫ߚ߹ޕ‬,ⴊዊ᧼߆ࠄߩ㗰☸ಽᴲࠍ HSP27 ߩ࡝ࡦ㉄ൻ߇೙ᓮߒߡ޿ࠆߎߣࠍ᣿ࠄ߆ߣߒߡ޿
ࠆ‫⃻ޕ‬࿷㧘ૐಽሶ㊂ࠬ࠻࡟ࠬⰮ⊕⾰㧔HSP27࡮HSP20࡮B ࠢ࡝ࠬ࠲࡝ࡦ㧕ߩ⚦⢩ౝ㧔㛽⧘⚦⢩࡮␹⚻⚦⢩࡮ⴊዊ᧼࡮⢄≸⚦⢩࡮⤟≸⚦⢩㧕࡮⚦⢩ᄖߢߩᯏ⢻෸߮ᓎഀߩᬌ⸛ࠍⴕߞߡ޿ࠆ‫ޕ‬
2㧕㛽⧘⚦⢩࡮␹⚻⚦⢩࡮⢄⚦⢩࡮⤟⚦⢩ߩ⚦⢩ౝᖱႎવ㆐ᯏ᭴ߩ⸃᣿
ೋઍၭ㙃⚦⢩߅ࠃ߮ࡕ࠺࡞ࠢࡠ࡯ࡦൻ⚦⢩ࠍ↪޿ߡ㧘⚦⢩Ⴧᱺ࿃ሶ࡮ࠨࠗ࠻ࠞࠗࡦ࡮ࡎ࡞ࡕࡦ╬⒳‫ߩޘ‬↢ℂᵴᕈ‛⾰ߩ⚦⢩ౝᖱႎવ㆐ᯏ᭴ߦߟ޿ߡᬌ⸛ࠍⴕߞߡ޿ࠆ‫⚦ޕ‬⢩ߩჇᱺ࡮ಽൻ߿ᱫߩࡔࠞ࠾࠭ࡓ࡮ߘ
ߩ೙ᓮ߅ߌࠆᓎഀࠍ⸃ᨆߒ㧘㛽☻㝃∝࡮ⴊᩖ∝࡮േ⣂⎬ൻ∝࡮ᕆᕈ౰∝୥⟲࡮⢄≸࡮⤟≸࡮ᄢ⣺≸ߩ∛ᘒߩ⸃᣿ࠍ⹜ߺߡ޿ࠆ‫ߦࠄߐޕ‬㧘ߎࠇࠄ∔ᖚߦ૶↪ߐࠇߡ޿ࠆ⒳‫ߩ‛⮎ߩޘ‬ᣂߚߥ૞↪ߩ⸃ᨆ߅ࠃ߮૞↪ᯏ᭴ߩᬌ⸛ࠍⴕߞߡ޿ࠆ‫ޕ‬
3㧕ઍ⻢∔ᖚ㧔♧ዩ∛࡮㛽☻㝃∝╬㧕߅ࠃ߮േ⣂⎬ൻ∝ߦ߅ߌࠆⴊዊ᧼ᯏ⢻ߩᄌൻߣ⺃⊒ߐࠇࠆ⒳‫∛ߩޘ‬
ᘒ↢ℂߩ⸃᣿
♧ዩ∛ߥߤߩઍ⻢∔ᖚߪ㧘ⴊᩖ∝㧔⯯ⴊ∔ᖚ㧕߿␹⚻࡮⤳ེ㓚ኂߥߤߩ 2 ᰴ⊛∔ᖚߩ⺃⊒₸߇㜞ߊ㧘ⴊዊ᧼ᯏ⢻ߩᄌൻߣⴊᩖ∝߿ฦ⤳ེ㓚ኂߣߩ㑐ଥࠍㅊ᳞ߒߡ޿ࠆ‫ᦨޕ‬ㄭ㧘㛽☻㝃∝ߩᴦ≮⮎ߣߒߡ૶↪ߐࠇ
ߡ޿ࠆ SERM ߩ৻ߟߢ޽ࠆ࡜ࡠࠠࠪࡈࠚࡦ߇ߘߩ೽૞↪ߣߒߡⴊዊ᧼ಝ㓸⢻ࠍ੣ㅴߐߖࠆߎߣࠍ᣿ࠄ߆
ߣߒߡ޿ࠆ‫⃻ޕ‬࿷㧘ઍ⻢∔ᖚ㧔♧ዩ∛࡮㛽☻㝃∝╬㧕߅ࠃ߮േ⣂⎬ൻ∝ߦ߅ߌࠆⴊዊ᧼ߩᯏ⢻߅ࠃ߮ⴊዊ
᧼⚦⢩ౝᖱႎવ㆐ᯏ᭴ߩ⸃ᨆࠍⴕߞߡ޿ࠆ‫ޕ‬
4㧕ࠕࡐ࠻࡯ࠪࠬ⊒⃻ᯏᐨߩ⸃᣿ߣߘߩ੍㒐ᴺߩ⏕┙⒳‫∔ߩޘ‬ᖚߦ㧘ࠕࡐ࠻࡯ࠪࠬߦ߅ߌࠆ⚦⢩ᱫ߇ᷓߊ㑐ਈߒߡ޿ࠆߎߣ߇᣿ࠄ߆ߣߥߞߡ߈ߡ޿ࠆ‫࠽ࠬޕ‬ࡀ࠭ࡒ߿ࡑ࠙ࠬߦ߅ߌࠆ⣖⯯ⴊ࡮ౣẑᵹߦߣ߽ߥ߁ᶏ㚍␹⚻⚦⢩ᱫࡕ࠺࡞߿✂⤑␹⚻⚦⢩ᱫࡕ࠺࡞㧘޽ࠆ޿ߪᅢਛ⃿⚦⢩ᱫࡕ࠺࡞╬ࠍᜰᮡߦ㧘ߘߩ⊒⃻ᯏ᭴ߩ⸃᣿ߥࠄ߮ߦ੍㒐ᴺߩត᳞ࠍⴕߞߡ޿ࠆ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
ዊỈ ୃ
ᢎ᝼(૬છ)㧦 ਤ⠀㓷ਯ
⿷┙᡽ᴦ
ഥᢎ㧦

Osamu Kozawa
Masayuki Niwa
Seiji Adachi

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
ߥߒ⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 㜞੗ ାᴦ, ⿒᧻ ❥, ቟↰ ㍈੺, ዊỈ ୃ. ૐಽሶ㊂ࠬ࠻࡟ࠬ࠲ࡦࡄࠢ⾰ߣࡃ࠰ࡊ࡟ࠪࡦ㧦HSP27ߣⴊ▤ᐔṖ╭, ᣣᧄ⮎ℂቇ㔀⹹ 2006 ᐕ㧧128 Ꮞ㧦141̆145.
2㧕 ዊỈ ୃ. ᔃⴊ▤૞േ‛⾰ߣߒߡߩࡃ࠰ࡊ࡟ࠪࡦ㧦ߘߩ૞↪ᯏᐨ, 㤗㈮ 2008 ᐕ㧧57 Ꮞ㧦S77̆S85.
✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔᰷ᢥ㧕
1㧕 Hanai Y, Tokuda H, Takai S, Harada A, Ohta T, Kozawa O. Minodronate suppresses prostaglandin
F2D-induced vascular endothelial growth factor synthesis in osteoblasts. Horm Metab Res.

㧙㧙

2006;38:152-158.
2㧕 Hanai Y, Tokuda H, Ishisaki A, Matsushima-Nishiwaki R, Nakamura N, Yoshida M, Takai S, Ohta T,
Kozawa O. Involvement of p44/p42 MAP kinase in insulin-like growth factor-I-induced alkaline
phosphatase activity in osteoblast-like MC3T3-E1 cells. Mol Cell Endocrinol. 2006;251:42-48.
3㧕 Takai S, Tokuda H, Matsushima-Nishiwaki R, Hanai Y, Kato K, Kozawa O. Phosphatidylinositol
3-kinase/Akt plays a role in sphingosine 1-phosphate-stimulated HSP27 induction in osteoblasts. J
Cell Biochem. 2006;98:1249-1256.
4㧕 Takai S, Tokuda H, Yoshida M, Yasuda E, Matsushima-Nishiwaki R, Harada A, Kato K, Kozawa O.
Prostaglandin D2 induces the phosphorylation of HSP27 in osteoblasts: function of the MAP kinasesuperfamily. Prostaglandins Leukot Essent Fatty Acids. 2006;75:61-67.
5㧕 Nakajima K, Suga H, Matsuno H, Ishisaki A, Hirade K, Kozawa O. Differential roles of MAP kinases
in atorvastatin-induced VEGF release in cardiac myocytes. Life Sci. 2006;79:1214-1220.
6㧕 Hara A, Niwa M, Kumada M, Aoki H, Kunisada T, Oyama T, Yamamoto T, Kozawa O, Mori H.
Intraocular injection of folate antagonist, methotrexate induces neuronal differentiation of embryonicstem cells transplanted in the adult mouse retina. Brain Res. 2006;1058:33-42.
7㧕 Takai S, Tokuda H, Hanai Y, Kozawa O. Phosphatidylinositol 3-kinase/Akt plays a part intumor-necrosis factor-D-induced interleukin-6 synthesis in osteoblasts. Horm Metab Res.
2006;38;563-569.
8㧕 Tanabe K, Tokuda H, Takai S, Matsushima-Nishiwaki R, Hanai Y, Hirade K, Katagiri Y, Dohi S,
Kozawa O. Modulation by the steroid/thyroid hormone superfamily of TGF-E-stimulated VEGF releasefrom vascular smooth muscle cells. J Cell Biochem. 2006;99:187-195.
9㧕 Hara A, Niwa M, Aoki H, Kumada M, Kunisada T, Oyama T, Yamamoto T, Kozawa O, Mori H. A newmodel of retinal photoreceptor cell degeneration by a chemical hypoxia-mimicking agent, cobalt
chloride. Brain Res. 2006;1109:192-200.
10㧕 Hanai Y, Tokuda H, Ohta T, Matsushima-Nishiwaki R, Takai S, Kozawa O. Phosphatidylinositol
3-kinase/Akt auto-regulates PDGF-BB-stimulated interleukin-6 synthesis in osteoblasts. J Cell
Biochem. 2006;99:1564-1571.
11㧕 Niwa M, Hotta K, Hara A, Hirade K, Ito H, Kato K, Kozawa O. TNF-D decreases HSP 27 in humanblood mononuclear cells: involvement of protein kinase C. Life Sci. 2006;80:181-186.
12㧕 Hanai Y, Tokuda H, Yasuda E, Noda T, Ohta T, Takai S, Kozawa O. Up-regulation by zinc of
FGF-2-induced VEGF release through enhancing p44/p42 MAP kinase activation in osteoblasts. Life
Sci. 2006;80:230-234.
13㧕 Tokuda H, Takai S, Matsushima-Nishiwaki R,Akamatsu S, Hanai Y, Hosoi T, Harada A, Ohta T,
Kozawa O. (-)-Epigallocatechin gallate enhances prostaglandin F2D-induced VEGF synthesis via
up-regulating SAPK/JNK activation in osteoblasts. J Cell Biochem. 2007;100:1146-1153.
14㧕 Takai S, Tokuda H, Hanai Y, Kozawa O. Limitation by p70 S6 Kinase of PDGF-BB-induced IL-6
synthesis in osteoblast-like MC3T3-E1 cells. Metabolism. 2007;56:476-483.
15㧕 Takai S, Tokuda H, Hanai Y, Kozawa O. Activation of phosphatidylinositol 3-kinase/Akt
limitsFGF-2-induced VEGF release in osteoblasts. Mol Cell Endocrinol. 2007;267:46-54.
16㧕 Takai S, Tokuda H, Hanai Y, Harada A, Yasuda E, Matsushima-Nishiwaki R, Kato H, Ogura S, Ohta T,
Kozawa O. Negative regulation by p70 S6 kinase of FGF-2-stimulated VEGF release throughstress-activated/c-JunN-terminal kinase in osteoblasts. J Bone Miner Res. 2007;22:337-346.
17㧕 Takai S, Nagaki M, Imao M, Kimura K, Kozawa O, Moriwaki H. Intrinsic resistance to TNF-D-induced
hepatocyte apoptosis in ICR mice correlates with expression of a short form of c-FLIP. Lab Invest.
2007;87:572-581.
18㧕 Noda T, Kumada T, Takai S, Matsushima-Nishiwaki R, Yoshimi N, Yasuda E, Kato K, Toyoda H,
Kaneoka Y, Yamaguchi A, Kozawa O. Expression levels of heat shock protein 20 decrease in parallelwith tumor progression in patients with hepatocellular carcinoma. Oncol Rep. 2007;17:1309-1314.
19㧕 Tokuda H, Takai S, Hanai Y, Matsushima-Nishiwaki R, Hosoi T, Harada A, Ohta T, Kozawa O.
(-)-Epigallocatechin gallate suppresses endothelin-1-induced interleukin-6 synthesis in osteoblasts:
inhibition of p44/p42 MAP kinase activation. FEBS Lett. 2007;581:1311-1316.
20㧕 Ochiai S, Sekiguchi S, Hayashi A, Shimadzu M, Ishiko H, Matsushima-Nishiwaki R, Kozawa O,
Yasuda M, Duguchi T. Decreased affinity of mosaic-structure recombinant penicillin-bindingprotein 2
for oral cephalosporins in Neisseria gonorrhoeae. J Antimicrob. 2007;60:54-60.
21㧕 Takai S, Matsushima-Nishiwaki R, Tokuda H, Yasuda E, Toyoda H, Kaneoka Y, Yamaguchi A, Kumada
T, Kozawa O. Protein kinase C Ǭ regulates the phosphorylation of heat shock protein 27 in humanhepatocellular carcinoma. Life Sci. 2007;81:585-591.
22㧕 Tokuda H, Hanai Y, Matsushima-Nishiwaki R, Yamauchi J, Doi T, Harada A, Takai S, Kozawa O.
Rho-kinase regulates endothelin-1-stimulated IL-6 synthesis via p38 MAP kinase in osteoblasts.
Biochem Biophys Res Commun. 2007;362:799-804.
23㧕 Yamauchi J, Takai S, Matsushima-Nishiwaki R, Hanai Y, Doi T, Kato H, Ogura S, Kato K, Tokuda H,
Kozawa O. (-)-Epigallocatechin gallate inhibits prostaglandin D2-stimulated HSP27 induction via
suppression of the p44/p42 MAP kinase pathway in osteoblasts. Prostaglandins Leukot Essent Fatty㧙㧙

IF 2.254

IF 2.971

IF 3.381

IF 2.000
IF 2.257

IF 2.218

IF 2.254

IF 3.381

IF 2.218

IF 3.381
IF 2.257

IF 2.257

IF 3.381
IF 2.647
IF 2.971

IF 6.004

IF 4.479

IF 1.597

IF 3.263

IF 4.038

IF 2.257

IF 2.749

Acids. 2007;77:173-179.
24㧕 Tokuda H, Takai S, Hanai Y, Harada A, Matsushima-Nishiwaki R, Akamatsu S, Ohta T, and Kozawa O.
Platelet-derived growth factor-BB amplifies PGF2-induced VEGF synthesis in osteoblasts: function ofphosphatidylinositol 3-kinase. Prostaglandins Leukot Essent Fatty Acids. 2007;77:187-193.
25㧕 Tokuda H, Takai S, Hanai Y, Harada A, Matsushima-Nishiwaki R, Kato H, Ogura S, Kozawa O.
Potentiation by platelet-derived growth factor-BB of FGF-2-stimulated VEGF release in osteoblasts. J
Bone Miner Metab. 2008;26:335-341.
26㧕 Tokuda H, Takai S, Hanai Y, Matsushima-Nishiwaki R, Yamauchi J, Harada A, Hosoi T, Ohta T,
Kozawa O. (-)-Epigallocatechin gallate inhibits basic fibroblast growth factor-induced interleukin-6
synthesis in osteoblasts. Horm Metab Res. 2008;40:674-678.
27㧕 Takai S, Hanai Y, Matushima-Nishiwaki R, Minamitani C, Otsuka T, Tokuda H, Kozawa O. p70 S6
kinase negatively regulates FGF-2-stimulated IL-6 synthesis in osteoblasts: function at a point
downstream from protein kinase C. J Endocrinol. 2008;197:131-137.
28㧕 Hayashi K, Takai S, Matsushima-Nishiwaki R, Hanai Y, Kato K, Tokuda H, Kozawa O.
(-)-Epigallocatechin gallate reduces transforming growth factor E-stimulated HSP27 induction
through the suppression of stress-activated protein kinase/c-Jun N-terminal kinase in osteoblasts. Life
Sci. 2008;82:1012-1017.
29㧕 Tanabe K, Takai S, Matsushima-Nishiwaki R, Kato K, Dohi S, Kozawa O. D2 Adrenoreceptor agonist
regulates protein kinase C-induced heat shock protein 27 phosphorylation in C6 glioma cells. J
Neurochem. 2008;106:519-528.
30㧕 Kato H, Takai S, Matushima-Nishiwaki R, Adachi S, Minamitani C, Otsuka T, Tokuda H, Akamatsu S,
Doi T, Ogura S, Kozawa O. HSP27 phosphorylation is correlated with ADP-induced platelet granulesecretion. Arch Biochem Biophys. 2008;475:80-86.
31㧕 Matsushima-Nishiwaki R, Takai S, Adachi S, Minamitani C, Yasuda E, Noda T, Kato K, Toyoda H,
Kaneoka Y, Yamaguchi A, Kumada T, Kozawa O. Phosphorylated heat shock protein 27 represses
growth of hepatocellular carcinoma via inhibition of extracellular-signal-regulated kinase. J Biol
Chem. 2008;283:18852-18860.
32㧕 Minamitani C, Otsuka T, Takai S, Matsushima-Nishiwaki R, Adachi S, Hanai Y, Mizutani J, Tokuda H,
Kozawa O. Involvement of Rho-kinase in prostaglandin F2-stimulated interleukin-6 synthesis via
p38 mitogen-activated protein kinase in osteoblasts. Mol Cell Endocrinol. 2008;291:27-32.
33㧕 Adachi S, Nagao T, To S, Joe AK, Shimizu M, Matsushima-Nishiwaki R, Kozawa O, Moriwaki H,
Maxfield FR, Weinstein IB. (-)-Epigallocatechin gallate causes internalization of the epidermal growth
factor receptor in human colon cancer cells. Carcinogenesis. 2008;29:1986-1993.
34㧕 Minamitani C, Takai S, Matsushima-Nishiwaki R, Hanai Y, Otsuka T, Kozawa O, Tokuda H. A case ofraloxifene-induced acceleration of platelet aggregation. Internal Med. 2008;47;1523-1528.
35㧕 Takai S, Matsushima-Nishiwaki R, Adachi S, Natsume H, Minamitani C, Mizutani J, Otsuka T, Tokuda
H, Kozawa O. (-)-Epigallocatechin gallate reduces platelet-derived growth factor-BB-stimulated
interleukin-6 synthesis in osteoblasts: suppression of SAPK/JNK. Mediators Inflamm.
2008;2008:291808.
36㧕 Tokuda H, Takai S, Matsushima-Nishiwaki R, Hanai Y, Adachi S, Minamitani C, Mizutani J, Otsuka T,
Kozawa O. Function of Rho-kinase in prostaglandin D2-induced interleukin-6 synthesis in osteoblasts.
Prostaglandins Leukot Essent Fatty Acids. 2008;79:41-46.

IF 2.000

IF 2.000

IF 1.425

IF 2.254

IF 2.636

IF 2.257

IF 4.451

IF 2.578

IF 5.581

IF 2.971

IF 5.406

IF 1.162

IF 2.000

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦⿒᧻ ❥, ⎇ⓥಽᜂ⠪㧦ዊỈ ୃ, ࿯⢈ୃม㧧⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦๟ⴚᦼᔃ╭⯯ⴊᓟߩᔃߩ࡝ࡕ࠺࡝ࡦࠣߦ߅ߌࠆ✢ṁ♽࿃ሶߩᓎഀߣ⥃ᐥ⊛ᗧ⟵㧧ᐔᚑ 17㧙18 ᐕᐲ㧧3,800
ජ౞(2,700㧦1,100 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦ዊỈ ୃ, ⎇ⓥಽᜂ⠪㧦㜞੗ାᴦ, ᓼ↰ᴦᒾ㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌(⎇ⓥ)㧦♧ዩ∛ᖚ⠪ߦ߅ߌࠆᓸዊⴊᩖᒻᚑ੣ㅴᯏᐨߩ⸃᣿ߣᴦ≮߳ߩᔕ↪㧧ᐔᚑ 18 ᐕᐲ㧧1,200 ජ౞3㧕 ⎇ⓥઍ⴫⠪㧦ᓼ↰ᴦᒾ, ⎇ⓥಽᜂ⠪㧦ዊỈ ୃ㧧ᗲ⍮⣢⤳⽷࿅⎇ⓥഥᚑ㧦♧ዩ∛ᕈ⣢∝ߩㅴዷߦኻߔ
ࠆⴊዊ᧼ᯏ⢻೙ᓮߩᓇ㗀ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18 ᐕᐲ㧧100 ජ౞4㧕 ⎇ⓥઍ⴫⠪㧦㜞੗ାᴦ, ⎇ⓥಽᜂ⠪㧦ዊỈ ୃ㧧⽷࿅ᴺੱᚑ㐳⑼ቇදળഥᚑ㊄㧦㛽ߩᚑ㐳ߦ߅ߌࠆࠞ
࠹ࠠࡦߩᓎഀߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18 ᐕᐲ㧧500 ජ౞5㧕 ⎇ⓥઍ⴫⠪㧦ዊỈ ୃ, ⎇ⓥಽᜂ⠪㧦㜞੗ାᴦ, ᓼ↰ᴦᒾ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦㛽ઍ⻢ߦ߅ߌࠆ↢૕㒐ᓮᯏ᭴ߩಽሶၮ⋚ߩ⸃ᨆ㧦ࠬ࠻࡟ࠬⰮ⊕⾰ߩᯏ⢻⸃ᨆ㧧ᐔᚑ 19 ᐕ㧙
20 ᐕᐲ㧧3,500 ජ౞(2,200㧦1,300 ජ౞)
6㧕 ⎇ⓥઍ⴫⠪㧦㜞੗ାᴦ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦ૐಽሶ㊂ࠬ࠻࡟ࠬⰮ⊕⾰ࠍᮡ⊛ߣߒߚᣂߚߥ≸ᴦ≮ᴺߩ⎇ⓥ㧧ᐔᚑ 19㧙20 ᐕᐲ㧧3,300 ජ౞(2,000㧦1,300 ජ౞)㧙㧙7㧕 ⎇ⓥઍ⴫⠪㧦ᓼ↰ᴦᒾ, ⎇ⓥಽᜂ⠪㧦⧎੗ᶻᤩ㧧⽷࿅ᴺੱᚑ㐳⑼ቇදળഥᚑ㊄㧦㛽ᚑ㐳ߦ߅ߌࠆ Wnt/
Ǫ-catenin ࠪࠣ࠽࡞વ㆐⚻〝ߩᓎഀߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 19 ᐕ㧧⎇ⓥ⾌ 500 ජ౞8㧕 ⎇ⓥઍ⴫⠪㧦㜞੗ାᴦ㧧╙ 25 ࿁ⴊᶧකቇᶏᄖ⇐ቇഥᚑ㊄㧦⚦⢩㓚ኂᕈ T ⚦⢩ߩᯏ⢻ୃ㘼ߦࠃࠆᣂߚ
ߥ≸఺∉≮ᴺߩ㐿⊒㧧ᐔᚑ 19 ᐕᐲ㧧2,000 ජ౞
9㧕⎇ⓥઍ⴫⠪㧦ዊỈ ୃ, ⎇ⓥಽᜂ⠪㧦㜞੗ାᴦ, ᓼ↰ᴦᒾ㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌(⎇ⓥ)㧦♧ዩ∛ᖚ⠪ߦ߅ߌࠆᓸዊⴊᩖᒻᚑ੣ㅴᯏᐨߩ⸃᣿ߣᴦ≮߳ߩᔕ↪㧧ᐔᚑ 18 ᐕᐲ㧧120 ජ౞
10㧕 ⎇ⓥઍ⴫⠪㧦ᓼ↰ᴦᒾ, ⎇ⓥಽᜂ⠪㧦ዊỈ ୃ㧧ᗲ⍮⣢⤳⽷࿅⎇ⓥഥᚑ㧦♧ዩ∛ᕈ⣢∝ߩㅴዷߦኻߔ
ࠆⴊዊ᧼ᯏ⢻೙ᓮߩᓇ㗀ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18 ᐕᐲ㧧10 ජ౞
11㧕 ⎇ⓥઍ⴫⠪㧦㜞੗ାᴦ, ⎇ⓥಽᜂ⠪㧦ዊỈ ୃ㧧⽷࿅ᴺੱᚑ㐳⑼ቇදળഥᚑ㊄㧦㛽ߩᚑ㐳ߦ߅ߌࠆࠞ
࠹ࠠࡦߩᓎഀߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18 ᐕᐲ㧧50 ජ౞
12㧕 ⎇ⓥઍ⴫⠪㧦ᓼ↰ᴦᒾ, ⎇ⓥಽᜂ⠪㧦ዊỈ ୃ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦♧ዩ∛ᖚ⠪ߦ߅ߌࠆⴊᩖᒻᚑ੣ㅴᯏᐨߩ⸃᣿ߣ◲ଢߥⴊዊ᧼ಝ㓸⢻ߩᬌᩏᴺߩ⏕┙㧧ᐔᚑ 20㧙22 ᐕᐲ㧧
3,700 ජ౞(1,500㧦1,100㧦1,100 ජ౞)
13㧕 ⎇ⓥઍ⴫⠪㧦⿒᧻ ❥, ⎇ⓥಽᜂ⠪㧦ዊỈ ୃ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦ᔃⴊ▤♽ߦ߅ߌࠆㆊᄢଚⷅߦኻߔࠆࠬ࠻࡟ࠬᔕ╵ߩಽሶၮ⋚ߩ⸃ᨆ㧧ᐔᚑ 20㧙22 ᐕᐲ㧧3,500 ජ౞(1,500㧦
1,000㧦1,000 ජ౞)
14㧕 ⎇ⓥઍ⴫⠪㧦↰ㄝਭ⟤ሶ, ⎇ⓥಽᜂ⠪㧦ዊỈ ୃ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦ਛᨔ␹⚻♽ߦ߅ߌࠆ␹⚻଻⼔૞↪ߩಽሶၮ⋚ߩ⸃ᨆ㧧ᐔᚑ 20㧙22 ᐕᐲ㧧3,600 ජ౞(1,900㧦1,000㧦70
ජ౞)15㧕 ⎇ⓥઍ⴫⠪㧦᳓⼱ Ả, ⎇ⓥಽᜂ⠪㧦ዊỈ ୃ, ධ⼱ජᏔ, ᄐ⋡⧷㓶㧧ฬฎደᏒ┙ᄢቇ․೎⎇ⓥᅑബ⾌㧦✛⨥ߩਥᚑಽ㧔ࠞ࠹ࠠࡦ㧕ߩ㛽☻㝃੍㒐ലᨐߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 20 ᐕᐲ㧧70 ජ౞
16㧕 ⎇ⓥઍ⴫⠪㧦ዊỈ ୃ, ⎇ⓥಽᜂ⠪㧦⿷┙᡽ᴦ㧧⽷࿅ᴺੱᚑ㐳⑼ቇදળഥᚑ㊄㧦㛽ߩᚑ㐳ߦ߅ߌࠆ↢૕㒐ᓮᯏ᭴ߩᓎഀߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 20 ᐕᐲ㧧50 ජ౞
17㧕 ⎇ⓥઍ⴫⠪㧦⿷┙᡽ᴦ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦⢽⾰࡜ࡈ࠻ࠍᮡ⊛ߣߒߚ EGCG
ߦࠃࠆᄢ⣺≸੍㒐ߩ⎇ⓥ㧧ᐔᚑ 20㧙21 ᐕᐲ㧧3,100 ජ౞(1,600㧦1,500 ජ౞)
2㧕ฃ⸤⎇ⓥ1㧕 ዊỈ ୃ, ዊୖ⌀ᴦ㧦ⴊዊ᧼ߦ߅ߌࠆࠕࡦ࠴࠻ࡠࡦࡆࡦΥߩ᛫ⴊᩖ૞↪ߩಽሶᯏᐨߩ⸃ᨆ㧧ᐔᚑ 18
㧙19 ᐕᐲ㧧1,000 ජ౞㧦ZLB ࡌ࡯࡝ࡦࠣ(ᩣ)
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬ
ዊỈ ୃ㧦
1㧕 ᣣᧄౝಽᴲቇળઍ⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ⮎ℂቇળ⹏⼏ຬ(㨪⃻࿷)ਤ⠀㓷ਯ㧦1㧕 ᣣᧄ⮎ℂቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄἻ∝࡮ౣ↢ቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ⥃ᐥ⮎ℂቇળ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹ߥߒ㧙㧙

7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ዊỈ ୃ㧦
1㧕 ╙ 55 ࿁ᣣᧄ㤗㈮⑼ቇળ(ᐔᚑ 20 ᐕ 6 ᦬, ᮮᵿ, ᢎ⢒⻠Ṷ‫ޟ‬ᔃⴊ▤૞↪‛⾰ߣߒߡߩࡃ࠰ࡊ࡟ࠪࡦ㧦ߘߩ૞↪ᯏᐨ‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേ
ߥߒ
10㧚ႎ๔ᦠ
1㧕 ዊỈ ୃ, ⍹ፒ ᣿㧦ㆮવሶࡁ࠶ࠢࠕ࠙࠻ࡑ࠙ࠬࠍ↪޿ߚ㛽ઍ⻢ߦ߅ߌࠆ✢ṁ♽࿃ሶߩಽሶၮ⋚ߩ⸃ᨆ㧦ᐔᚑ 16 ᐕᐲ㧙17 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)⎇ⓥᚑᨐႎ๔ᦠ(2006 ᐕ 3 ᦬)
2㧕 ⿒᧻ ❥, ዊỈ ୃ, ࿯⢈ୃม㧦๟ⴚᦼᔃ╭⯯ⴊᓟߩᔃߩ࡝ࡕ࠺࡝ࡦࠣߦ߅ߌࠆ✢ṁ♽ห჻ߩᓎഀߣ
⥃ᐥ⊛ᗧ⟵㧦ᐔᚑ 17 ᐕᐲ㧙18 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)⎇ⓥᚑᨐႎ๔ᦠ(2007 ᐕ 3 ᦬)11㧚ႎ㆏ߥߒ12㧚⥄Ꮖ⹏ଔ
⹏ଔߎߩਃᐕ㑆ߩ᰷ᢥේ⪺⺰ᢥߣߒߡߩࠕ࠙࠻ࡊ࠶࠻ߪ 36 ႎߢ޽ߞߚ‫⺰ ޕ‬ᢥߩ⾰ߣߒߡߩ৻ߟߩᜰᮡߢ
޽ࠆࠗࡦࡄࠢ࠻ࡈࠔࠢ࠲࡯ߩᐔဋ୯ߪ 2.807 ߢ޽ࠆ‫ⷰߩߎޕ‬ὐ߆ࠄ߹ߛ߹ߛࠕ࠙࠻ࡊ࠶࠻ߩ̌⾰̍ࠍ਄ߍࠆߎߣ߇ᔅⷐߣᕁࠊࠇࠆ‫৻ޕ‬ᣇ, ଶߦ‫ޟ‬publish or perish‫ ࠆߥ߆޿ߦ߁ࠃࠆࠇࠊ޿ߣޠ‬data ߽ᦨ⚳⊛ߦࠠ࠴ࡦߣߒߚේ⪺⺰ᢥߣߒߡ಴ߔߎߣߪ㕖Ᏹߦᄢಾߥߎߣߢ޽ࠆߎߣߪ޿߁߹ߢ߽ߥ޿‫ߩߎޕ‬ၮᧄ⊛ᆫ൓ߢ޽ࠆࠕ࠙࠻ࡊ࠶࠻ߩ“㊂”ߩⷰὐ߆ࠄ߽ࠕ࠶ࡊߐߖߡ޿߈ߚ޿‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷೨࿁ߩ╙ 6 ภߦ߽ᦠ޿ߚࠃ߁ߦ, ᦨ߽㊀ⷐߥὐߪ, ᣣ‫⎇ߩޘ‬ⓥࠍ৻✜ߦㅴ߼ߡߊࠇࠆఝ⑲ߥੱ᧚ߩ₪ᓧߢ޽ࠆ‫ࠅߪ߿ޕ‬, ⎇ⓥࠍㆀⴕߒߡ޿ߊ਄ߢ, ߎߩ৻ὐߦ ߆ߞߡ޿ࠆߣ޿ߞߡ߽ㆊ⸒ߢߪߥ޿‫ੱߩߎޕ‬ߚߜߩਛ߆ࠄ, ዁᧪ߩᜂ߁කቇ⎇ⓥ⠪߇৻ੱߢ߽⢒ᚑߢ߈ࠆࠃ߁ദജߒߡ޿߈ߚ޿‫ޕ‬੹ᓟߩዷᦸ⃻࿷ផߒㅴ߼ߡ޿ࠆ⎇ⓥᚑᨐ߆ࠄ, ዁᧪᦭ലߢ቟ోߥ⮎೷ࠍ㐿⊒ߔࠆߎߣ㧔ഃ⮎㧕ࠍ⋡ᜰߒ㧘޿ߟߩᣣ߆ᖚ⠪ߐࠎߦㆶరߒߚ޿ߣ⠨߃ߡ޿ࠆ‫ޕ‬㧙㧙㧔4㧕ነ↢⯻ቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
ኋਥነ↢⯻⋧੕૞↪ߦ㑐ߔࠆ⎇ⓥᗵᨴߩᯏળ߇޽ࠆߣነ↢⯻ߪኋਥߦᓇ㗀ࠍ෸߷ߒ, ኋਥߪነ↢⯻ߦᓇ㗀ࠍ෸߷ߔ‫ޕ‬ᓟ⠪ߪ, ᗵᨴ߇ᚑ┙ߔࠆ߆ุ߆ߩ᳿ቯⷐ࿃ߣߥࠆ‫ޕ‬೨⠪ߪ, ᗵᨴ∛ℂߦ⋥⚿ߔࠆ‫ޕ‬ᒰᢎቶߢߪ, ╭⡺ነ↢ᕈߩ✢⯻ߢ޽ࠆᣓᲫ
⯻ࠍ↪޿ߡነ↢⯻߇ኋਥߦ෸߷ߔᓇ㗀ࠍ, ಽሶ↢‛ቇ⊛, ⚦⢩↢‛ቇ⊛ߦ⸃ᨆߒߡ޿ࠆ‫ߚ߹ޕ‬, ᣓᲫ⯻߇ಽᴲߒ, ኋਥ߳ᓇ㗀ࠍਈ߃ࠆ↢ℂᵴᕈ‛⾰ߩㆮવሶᎿቇ⊛ߥวᚑࠍⴕߞߡ޿ࠆ‫ޕ‬એਅ, ⎇ⓥᚑᨐࠍౕ૕⊛ߦ⸥タߔࠆ‫ޕ‬ᣓᲫ⯻ߩᣂ↢ᐜ⯻ߪ, ╭⡺⚦⢩ౝߦଚ౉ߒ, ╭⡺⚦⢩ࠍᄌ⇣ߐߖࠆ‫╭ޕ‬⡺⚦⢩ߪ, ᄌ⇣ࠍଚ౉୘ᚲߦ㒢ዪߐߖࠆߚ߼ߦ⚦⢩⾰ߩㆤᢿࠍⴕ߁߇, ᣓᲫ⯻ߩਛߢ߽ T.pseudospiralis ߣ๭߫ࠇࠆ⒳ߩᗵᨴߢߪ, ߎߩㆤᢿ߇߅ߎࠄߕ, ଚ౉ߐࠇߚ╭⡺⚦⢩ో૕߇ᄌ⇣ߔࠆ‫╭ޕ‬⡺⚦⢩ߩᄌ⇣ߦ઻޿, ࠨ࠹࡜ࠗ࠻⚦⢩߇ಽⵚჇᱺߒ, ╭⡺⚦⢩ߦಽൻߒࠃ߁ߣߔࠆ߇, ᣓᲫ⯻ߪ╭⡺⚦ㇱ߳ߩಽൻࠍ⸵ߐߕ, ᣓᲫ⯻ߩᩕ㙃ߩߣឃᴭ‛ߩ਎⹤ࠍߔࠆ⚦⢩ߦᄌ⇣ߐߖࠆ‫߇ࠇߎޕ‬, ฎౖ⊛ߦⵍྙᒻᚑߣߒߡ⍮ࠄࠇߡ޿ߚ⃻⽎ߢ޽ࠆ߇, ߘߩ⹦⚦ߥ
∛ℂࠍᧄ⎇ⓥቶ߇᣿ࠄ߆ߦߒߚ‫ޕ‬ߐࠄߦ, ߎߩ╭⡺⚦⢩ߩᄌ⇣ߦ઻߁⊒⃻ㆮવሶߦߟ޿ߡᵈ⋡ߒ, ╭⡺⊒↢ߦ㑐ਈߔࠆ࿃ሶ MyoD,
myogenin, MRF4 ߩ᜼േࠍ᣿ࠄ߆ߦߒߚ‫ߚ߹ޕ‬, ྙሶᒻᚑߦ઻߁╭⡺⚦⢩ߩࠕࡐ࠻࡯ࠪࠬߦ㑐ਈߔࠆ࿃ሶ
ߩหቯࠍⴕߞߚ‫ޕ‬ᣓᲫ⯻ߩ cDNA ࡜ࠗࡉ࡜࡝࡯ࠍ૞⵾ߒ, ᦭↪ߥࡍࡊ࠲ࠗ࠼ߩㆮવሶࠍᰴ‫ࡦ࠾࡯ࡠࠢߦޘ‬ࠣߢ߈ߚ‫ߩߘޕ‬ਛߦߪ, ᣂߒ޿࠲ࠗࡊߩࡊࡠ࠹ࠕ࡯࠯㒖ኂ೷෸߮ࡊࡠ࠹ࠕ࡯࠯, ࡑࠢࡠࡈࠔ࡯ࠫㆆ⿛㒖ᱛ࿃ሶ߽޽ࠅ, ⃻࿷, 㑐ㅪߩ․⸵ขᓧ, ߹ߚߪ․⸵಴㗿ਛߢ޽ࠆ‫ޕ‬
2㧚ฬ★
㜞ᯅఝਃ
ᢎ᝼㧦
ಎᢎ᝼㧦 㐳㊁ഞ๓ᔒ⦟ഥᢎ㧦Yuzo Takahashi
Isao Nagano
ZhiLiang Wu

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 㜞ᯅఝਃ✬⪺㧚⥄Ꮖߣ⒳ᣖ଻ሽߩߚ߼ߩ઀⚵ߺ㧦ฬฎደ㧦ਃᕺ␠㧧2006 ᐕ㧚
2㧕 㜞ᯅఝਃ, ਛ੗೑ᤘ✬㓸ઍ⴫㧚ᬌᩏ୯ߩߺ߆ߚ㧙ઃ ࡄ࠾࠶ࠢ୯࡮⼊ᚓ୯㧙ᡷ⸓ 3 㧦᧲੩㧦ਛᄖකቇ␠㧧
2006㧦788㧙789㧚
3㧕 㐳㊁ ഞ, 㜞ᯅఝਃ, ᫪↰໪ਯ, ဈ ᣽▸㧚ࡅ࠻߇↢߈ᱷࠆߚ߼ߩ૕ߩߒߊߺ, ฬฎደ㧦ਃᕺ␠㧦29㧙47, 67
㧙86, 2007 ᐕ㧚
4㧕 㐳㊁ ഞ, 㜞ᯅఝਃ, ᫪↰໪ਯ, ဈ ᣽▸㧚ࡅ࠻߇↢߈ᱷࠆߚ߼ߩ૕ߩߒߊߺ㧘2 , ฬฎደ㧦ਃᕺ␠㧦2008ᐕ㧚⪺ᦠ㧔᰷ᢥ㧕
1㧕 Suzuki Y, Niwa M, Shibata T, Takahashi Y, Chirasak K, Ariyawardana A, Ramesh JC, Evans P. Tan
O-S, Problem-based Learning in eLearning Breakthroughs. Singapore: Thomson; 2006:131-146.
2㧕 Nagano I, Takahashi Y. Parasitic Zoonoses in Asian-Pacific Regions 2006. Nagoya: Sankeisha; 2006.
✚⺑㧔๺ᢥ㧕
1㧕 ᫃↰๺↵, ⍹Ⴆ㆐ᄦ. ♧ዩ∛, ౝಽᴲ∔ᖚߦࠃࠆ⓭ὼᱫ, ᴺක∛ℂ 2006 ᐕ㧧12 Ꮞ㧦17㧙21㧚
2㧕 㜞ᯅఝਃ, ኹ᎑ศ଻㧚ࠪࡒࡘ࡟࡯࡚ࠪࡦࠍ↪޿ߚකቇᢎ⢒ߩታ㓙ᣂߒ޿කቇᢎ⢒ߩᵹࠇ࡯, ╙ 23 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳, 2007㧦51㧙63㧚✚⺑㧔᰷ᢥ㧕
1㧕 Wu Z, Sofronic-Milosavljevic L, Nagano I, Takahashi Y. Trichinella spiralis: Nurse cell formation
with emphasis on analogy to muscle cell repair. Parasite and Vectors. 2008;27:1-8.
2㧕 Takahashi Y. Problem-Based Learning and Task-based Learning: A practical Synthesis. Kaoshiung
Medical Journal. 2008;24:S31-S34.
3㧕 Nagano I, Wu Z, Takahashi Y. Functional genes and proteins of Trichinella spp. Parasitol Res.
2008;104:197-207.
ේ⪺㧔๺ᢥ㧕
1㧕 㜞ᯅఝਃ㧚ත೨කቇᢎ⢒ߩᣂߒ޿േะ㧝㧙໧㗴┙⣉ဳ࠹ࡘ࠻࡯࡝ࠕ࡞㧙, කቇᢎ⢒೎ౠ කቇᢎ⢒⊕ᦠ
2006 ᐕ  2006 ᐕ㧧56㧙59.
2㧕 㜞ᯅఝਃ㧚ᢎ⢒ᯏ㑐ౝߩᢎ⢒㐿⊒⚵❱, කቇᢎ⢒೎ౠ කቇᢎ⢒⊕ᦠ 2006 ᐕ  2006 ᐕ; 110㧙113㧚㧙㧙3㧕 㜞ᯅఝਃ㧚ࠪࡒࡘ࡟࡯࡚ࠪࡦකቇᢎ⢒ߦዉ౉ߔࠆߦᒰߚߞߡ, ࡕ࠺࡞㧒ࠪࡒࡘ࡟࡯࡚ࠪࡦකቇᢎ⢒⎇ⓥળ
ႎ 2007 ᐕ㧧1 Ꮞ㧦47㧙60㧚
4㧕 㜞ᯅఝਃࠄ㧚ᖚ⠪ߩක≮ᖱႎࠍᢎ᧚ߦ೑↪ߔࠆߦᒰߚߞߡߩࠟࠗ࠼࡜ࠗࡦᆔຬળ᩺, කቇᢎ⢒㔀⹹ 2007
ᐕ㧧38 Ꮞ㧦173㧙177㧚
5㧕 ᅏᐘሶ, 㜞ᯅఝਃ. ࠪࡒࡘ࡟࡯࡚ࠪࡦࠍක≮⧷ળ⹤ߦ೑↪ߔࠆߚ߼ߩᢎ᧚ߩ૞ᚑ, ࡕ࠺࡞㧒ࠪࡒࡘ࡟࡯
࡚ࠪࡦ කቇᢎ⢒⎇ⓥળႎ 2008 ᐕ㧧2 Ꮞ㧦37㧙40.
6㧕 ᅏᐘሶ, 㜞ᯅఝਃ. ࠪࡒࡘ࡟࡯࡚ࠪࡦࠍක≮ᢎ⢒ߩᢎ᧚૞ࠅߦߟ޿ߡ, ࡕ࠺࡞㧒ࠪࡒࡘ࡟࡯࡚ࠪࡦකቇ
ᢎ⢒⎇ⓥળႎ 2008 ᐕ㧧2 Ꮞ㧦41㧙43.
7㧕 ᅏᐘሶ, 㜞ᯅఝਃ. ࠪࡒࡘ࡟࡯࡚ࠪࡦߢࠬ࠹࠶ࡊࠕ࠶ࡊߒߟߟቇ߱ක≮⧷ળ⹤ᢎ᧚ߩ૞ᚑ, ࡕ࠺࡞㧒ࠪࡒࡘ࡟࡯࡚ࠪࡦකቇᢎ⢒⎇ⓥળႎ 2008 ᐕ㧧2 Ꮞ㧦44㧙50.
8㧕 ㋈ᧁᐽਯ, ਤ⠀㓷ਯ, 㜞ᯅఝਃ. ࠹ࡘ࠻࡝ࠕ࡞ߣࠪࡒࡘ࡟࡯࡚ࠪࡦᢎ⢒ࠍ E-learning ߢⴕ߁ࠪࠬ࠹ࡓߩ
᭴▽ߦߟ޿ߡ, ࡕ࠺࡞㧒ࠪࡒࡘ࡟࡯࡚ࠪࡦකቇᢎ⢒⎇ⓥળႎ 2008 ᐕ㧧2 Ꮞ㧦51㧙56.
ේ⪺㧔᰷ᢥ㧕
1㧕 Wu Z, Nagano I, Boonmars T & Takahashi Y. Involvement of the c-Ski oncoprotein in cell cycle
arrest and transformation during nurse cell formation after Trichinella spiralis infection. Int J
Parasitol. 2006;36:1159-1166.
2㧕 Nagano I, Wu Z, Boonmars T. & Takahashi Y. Molecular cloning and characterization of an Rcd1-likeprotein in excretory-secretory products of Trichinella pseudospiralis. Parasitology. 2006;133:785-792.
3㧕 Pei F, Nagano I, Wu Z, Takahashi Y. Preparation of a recombinant cysteine proteinase of
Clonorchis sinensis and its applied study for immunodiagnosis of Clonorchiasis. Parsitic Zoonoses in
Asian-Pacific Regions. 2006;9:40-53.
4㧕 Wu Z, Nagano I, Boonmars T, Takahashi Y. Thermally induced and developmentally regulated
expression of a small heat shock protein in Trichinella spiralis. Parasitol Res. 2007;101:201-212.
5㧕 Wu Z, Snabel V, Pozio E, Hurnikova Z, Nareaho A, Nagano I, Takahashi Y. Genetic
relationships among Trichinella pseudospiralis isolates from Australian, Nearctic, and Palearctic
regions. Parasitol Res. 2007;101:1567-1573.
6㧕 Yoshikawa H, Wu Z, Howe J, Hashimoto T, Geok-Choo N, Tan KSW. Ultrastructural andPhylogenetic Studies on Blastocystis Isolates from Cockroaches. J Eukaryot Microbiol. 2007;54:33-37.
7㧕 Li LH, Zhou XN, Du ZW, Wang XZ, Wang LB, Jiang JY, Yoshikawa H, Steinmann P,
Utzinger J, Wu Z, Chen JX, Chen SH, Zhang L. Molecular epidemiology of human Blastocystis
in a village in Yunnan province, China. Parasitol Int. 2007;56:281-286.
8㧕 Li LH, Zhang XP, Lu S, Zhang L, Yoshikawa H, Wu Z, Steinmann P, Utzinger J, Tong XM,
Chen SH, Zhou XN. Cross-sectional surveys and subtype classification of human Blastocystis
isolates from four epidemiological settings in China. Parasitol Res. 2007;102:83-90.
9㧕 Nagano, I, Wu, Z, Takahashi, Y.: Species-specific antibody responses to the recombinant
53-kilodalton excretory and secretory proteins in mice infected with Trichinella spp. Clin Vaccine
Immunol. 2008;15:468-473.
10㧕 Wu Z, Nagano I, Takahashi Y. Candidate genes responsible for common and different pathologies ofinfected muscle tissues between Trichinella spiralis and T. pseudospiralis infection. Parasitol Int.
2008;57:368-378.

IF 3.392
IF 2.081

IF 1.512

IF 1.512
IF 2.288

IF 1.776

IF 1.512

IF 1.7764㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦㐳㊁ ഞ, ⎇ⓥಽᜂ⠪㧦๓ ᔒ⦟, 㚸 㓶ᚽ, ⵸ ⑔ో, ࠹ࠨ࠽࡮ࠨࡑ࡯ࡦ, ࠴࠳࡜࡮ࡉ࡯ࡦࡑ࡯ࠬ㧦ᐔ๺ਛፉ⽷࿅ ࠕࠫࠕ࿾ၞ㊀ὐቇⴚ⎇ⓥഥᚑ㧦⢄ๆ⯻㧔࠲ࠗ⢄ๆ⯻㧕⚵឵߃Ⱞ⊕᛫ේࠍ↪޿ߚਛ࿖߅ࠃ߮࠲ࠗ࿖ౝߦ߅ߌࠆⴊᷡ⸻ᢿᴺߩ⏕┙㧧2006 ᐕᐲ㧧1988 ජ౞2㧕 ⎇ⓥઍ⴫⠪㧦๓ ᔒ⦟, ⎇ⓥಽᜂ⠪㧦㐳㊁ ഞ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦ᣓᲫ⯻ᗵᨴߦࠃࠆኋਥ╭⡺⚦⢩ᄌ⇣ߩㆮવሶ⊒⃻േᘒߩ⸃ᨆߣߘߩಽሶᯏ᭴ߩ⸃᣿㧧ᐔᚑ 17㧙18 ᐕᐲ㧧
3500 ජ౞㧔2,100㧦1,400 ජ౞㧕3㧕 ⎇ⓥઍ⴫⠪㧦㐳㊁ഞ, ጘ㒂ᄢቇᵴᕈൻ⎇ⓥ⾌(⎇ⓥ)㧧ᣓᲫ⯻↱᧪ォ౮㑐ㅪ࿃ሶ Rcd1 ߇╭⡺⚦⢩ಽൻ⺃ዉߦ෸߷ߔᓇ㗀ߩಽሶ↢‛ቇ⊛⸃ᨆ㧧ᐔᚑ 19 ᐕᐲ㧧1,130 ජ౞4㧕 ⎇ⓥઍ⴫⠪㧦㐳㊁ഞ, ⎇ⓥಽᜂ⠪㧦㎨⿷㓶ม, ฎጊᶈሶ, ๓ᔒ⦟㧧ጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼, ᄙಽ㊁౒ห⎇ⓥ㧧ഃ⮎࡜ࠗࡉ࡜࡝࡯ߣߒߡߩነ↢✢⯻ࠍ↪޿ߚᣂⷙ↢ℂᵴᕈ‛⾰ߩត⚝㧧ᐔᚑ 19 ᐕᐲ㧧800 ජ౞5㧕 ⎇ⓥઍ⴫⠪㧦㐳㊁ഞ, ⎇ⓥಽᜂ⠪㧦๓ᔒ⦟㧧⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦ᣓᲫ⯻↱᧪ォ౮㑐ㅪ࿃
ሶ Rcd1 ߇╭⡺⚦⢩ಽൻ⺃ዉߦ෸߷ߔᓇ㗀ߩಽሶ↢‛ቇ⊛⸃ᨆ㧧ᐔᚑ 20㧙22 ᐕᐲ㧧3,960 ජ౞(1,560㧦1, 500㧦900 ජ౞)
6㧕 ⎇ⓥઍ⴫⠪㧦๓ ᔒ⦟㧧ᐔ๺ਛፉ⽷࿅ᄖ࿖ੱ᜗⥌ഥᚑ㧦࠲ࠗ⢄ๆ⯻ᗵᨴߦࠃࠆ⢙▤≸⊒↢ߩಽሶᯏ㧙㧙᭴㧧ᐔᚑ 20 ᐕ㧧2000 ජ౞
2㧕ฃ⸤⎇ⓥ1㧕 㜞ᯅఝਃ㧦ૐଚⷅᓸ⚦ᚻⴚᡰេ࡮ᢎ⢒⸠✵ࠪࠬ࠹ࡓߩ㐿⊒ ක≮ᢎ⢒⸠✵ࡠࡏ࠶࠻㧧ᐔᚑ 18 ᐕᐲ㧧
36, 943 ජ౞㧦⽷࿅ᴺੱጘ㒂⋵⎇ⓥ㐿⊒⽷࿅2㧕 㐳㊁ഞ㧦ጘ㒂ᄢቇ㒝ዻ∛㒮ߦ߅ߌࠆవ┵ක≮ᛛⴚᖱႎߦ㑐ߔࠆࠗࡦࡈࠜ࡯ࡓ࠼ࠦࡦ࠮ࡦ࠻↪࠺ࠫ࠲࡞ࠦࡦ࠹ࡦ࠷ߩ㐿⊒㧧ᐔᚑ 17㧙18 ᐕᐲ㧧3,000 ජ౞(1,500㧦1,500 ජ౞)㧦᦭㒢ળ␠ࡔ࠺ࠖࠞ࡞ᗲ
3㧕 㜞ᯅఝਃ㧦ૐଚⷅᓸ⚦ᚻⴚᡰេ࡮ᢎ⢒⸠✵ࠪࠬ࠹ࡓߩ㐿⊒㧧ᐔᚑ 19 ᐕᐲ㧧25,520 ජ౞㧦࿾ၞൻቇᛛⴚାઔ੐ᬺ⾌⵬ഥ㊄࡮⍮⊛ࠢ࡜ࠬ࠲࡯ഃᚑ੐ᬺ࡮ጘ㒂⋵⎇ⓥ㐿⊒⽷࿅
4㧕 㜞ᯅఝਃ㧦ૐଚⷅᓸ⚦ᚻⴚᡰេ࡮ᢎ⢒⸠✵ࠪࠬ࠹ࡓߩ㐿⊒ ක≮ᢎ⢒⸠✵ࡠࡏ࠶࠻㧧ᐔᚑ 20 ᐕᐲ㧧
25,555 ජ౞㧦⽷࿅ᴺੱጘ㒂⋵⎇ⓥ㐿⊒⽷࿅
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫ
1㧕 㐳㊁ ഞ, 㜞ᯅఝਃ, ๓ ᔒ⦟㧦ᣓᲫ⯻ߩ⒳․⇣⊛᛫ේ㧧߅ࠃ߮⹥᛫ේࠍ೑↪ߒߚᣓᲫ⯻ᗵᨴߩᬌᩏ
ᴺ(․⸵)㧧ᐔᚑ 20 ᐕᐲ⛮⛯಴㗿ਛ
2㧕 㜞ᯅఝਃ㧦⊹⤏㑐▵᭴ㅧ૕㧧ᐔᚑ 20 ᐕᐲ(․⸵಴㗿ਛ)3㧕 㜞ᯅఝਃ㧦૕േౣ⃻ⵝ⟎㧧ᐔᚑ 20 ᐕᐲ(․⸵಴㗿ਛ)4㧕 㜞ᯅఝਃ㧦࿁╬㖸ჿ⹺⼂ࠪࠬ࠹ࡓ㧧ᐔᚑ 20 ᐕᐲ(․⸵಴㗿ਛ)5㧕 㜞ᯅఝਃ㧦⸻ኤ⸠✵ࡕ࠾࠲࡝ࡦࠣⵝ⟎㧧ᐔᚑ 20 ᐕᐲ(․⸵಴㗿ਛ)6㧕 㜞ᯅఝਃ㧦ක≮↪⺆⠡⸶⴫␜ࠪࠬ࠹ࡓ㧧ᐔᚑ 20 ᐕᐲ(․⸵಴㗿ਛ)
6㧚ቇળᵴേ
1㧕ቇળᓎຬ㜞ᯅఝਃ㧦
1㧕 ᣣᧄකቇᢎ⢒ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄነ↢⯻ቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ⥃ᐥነ↢⯻ቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄⴡ↢േ‛ቇળᐙ੐(㨪⃻࿷)
5㧕 International Commission on Trichinellosis: active member(㨪⃻࿷)6㧕 ࡕ࠺࡞㧒ࠪࡒࡘ࡟࡯࡚ࠪࡦකቇᢎ⢒ቇળળ㐳(ᐔᚑ 18 ᐕᐲ㨪⃻࿷)7㧕 ⥃ᐥࠦ࡯࠴ࡦࠣ⎇ⓥળ೽ળ㐳(ᐔᚑ 18 ᐕᐲ㨪⃻࿷)8㧕 ᣣᧄක≮ᢎ᝼ࠪࠬ࠹ࡓቇળℂ੐(ᐔᚑ 20 ᐕᐲ㨪⃻࿷)
㐳㊁ഞ㧦
1㧕 ᣣᧄነ↢⯻ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄᗵᨴ∝ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅
㜞ᯅఝਃ㧦1㧕 The Ninth Asian-Pacific Congress for Parasitic Zoonoses(ᐔᚑ 18 ᐕ 8 ᦬, ጘ㒂)3㧕ቇⴚ㔀⹹
㜞ᯅఝਃ㧦
1㧕 Parasitology : Editorial Board(2007 ᐕ㨪⃻࿷)2㧕 Parasites & Vectors BioMed Central, Editatorial Board(㨪⃻࿷)7㧚ቇળ᜗ᓙ⻠Ṷ, ᜗ᓙࠪࡦࡐࠫࠬ࠻, ᐳ㐳㜞ᯅఝਃ㧦
1㧕 6th Asia-Pacific Conference on Problem-Based Learning(ᐔᚑ 18 ᐕ 5 ᦬, ᧲੩, ‫ޟ‬Needs of a set of
guiding questions to facilitate student’s scientific mind‫ޠ‬Ṷ⠪)㧙㧙

2㧕 ╙ 38 ࿁ᣣᧄකቇᢎ⢒ቇળ(ᐔᚑ 18 ᐕ 7 ᦬, ᄹ⦟, ‫޿⦟ࠅࠃޟ‬කቇᢎ⢒ߦะߌߡߩᣂߚߥⷞὔreflectionߩ૏⟎ߠߌ‫ޠ‬ᐳ㐳)
3㧕 ࡕ࠺࡞㧒ࠪࡒࡘ࡟࡯࡚ࠪࡦකቇᢎ⢒⎇ⓥળ(ᐔᚑ 18 ᐕ 8 ᦬, ‫࡞࠺ࡕޟ‬㧒ࠪࡒࡘ࡟࡯࡚ࠪࡦකቇᢎ⢒⎇ⓥળߩ⦁಴‫ޠ‬Ṷ⠪)
4㧕 ╙ 8 ࿁ᣣᧄ⋴⼔ක≮ቇળቇⴚ㓸ળ(ᐔᚑ 18 ᐕ 10 ᦬, ጘ㒂, ‫ޟ‬ක≮ᓥ੐⠪ߩᾫ✵ᒻᚑߦߪ૗߇ᔅⷐ
߆㧫‫ޠ‬Ṷ⠪)5㧕 ࠪࡒࡘ࡟࡯࡚ࠪࡦᢎ⢒ߩታ㓙ోੱ⊛ක≮ࠍታ〣ߢ߈ࠆක≮ੱߩ⢒ᚑࠍ⋡ᜰߒߡ㧙 ᐔᚑ 18 ᐕᐲᢥ
ㇱ⑼ቇ⋭ක≮ੱ GP ࠪࡦࡐࠫ࠙ࡓ(ᐔᚑ 18 ᐕ 11 ᦬, ᧲੩, ‫ࠍࡦ࡚ࠪ࡯࡟ࡘࡒࠪޟ‬කቇᢎ⢒ߦᓎ┙ߟᒻߦߔࠆߚ߼ߩᎿᄦ‫ޠ‬Ṷ⠪)
6㧕 KMU International conference and workshop on PBL 2008.(ᐔᚑ 20 ᐕ, ᜗ᓙ⻠Ṷ, Attractive
scenario writing for PBL Ṷ⠪)
7㧕 ╙ 28 ࿁ᣣᧄක≮ᖱႎቇㅪวᄢળ(᜗ᓙ⻠Ṷ ࠪࡒࡘ࡟࡯࡚ࠪࡦࠍකቇᢎ⢒ߦዉ౉ Ṷ⠪)
8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേ
ߥߒ
10㧚ႎ๔ᦠ
1㧕 㜞ᯅఝਃ㧦ࠦࠕ࡮ࠞ࡝ࠠࡘ࡜ࡓኻᔕဳߩකቇታ⠌ᢎ᧚ߩ㐿⊒ߣ᥉෸㧦ᐔᚑ 17 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ታ❣ႎ๔ᦠ ၮ⋚⎇ⓥ(B)(2006 ᐕ)2㧕 㐳㊁ ഞ㧦⢄ๆ⯻㧔࠲ࠗ⢄ๆ⯻㧕⚵឵߃Ⱞ⊕᛫ේࠍ↪޿ߚਛ࿖߅ࠃ߮࠲ࠗ࿖ౝߦ߅ߌࠆⴊᷡ⸻ᢿᴺ
ߩ⏕┙㧦ᐔᚑ 18 ᐕᐲᐔ๺ਛፉ⽷࿅ࠕࠫࠕ࿾ၞ㊀ὐቇⴚ⎇ⓥഥᚑႎ๔ᦠ(2007 ᐕ 5 ᦬)
3㧕 ๓ ᔒ⦟, 㐳㊁ ഞ㧦ᣓᲫ⯻ᗵᨴߦࠃࠆኋਥ╭⡺⚦⢩ᄌ⇣ߩㆮવሶ⊒⃻േᘒߩ⸃ᨆߣߘߩಽሶᯏ᭴ߩ
⸃᣿㧦ᐔᚑ 17 ᐕᐲ㧙18 ᐕᐲᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ႎ๔ᦠ(2007 ᐕ 5 ᦬)
11㧚ႎ㆏1㧕 㜞ᯅఝਃ㧦ᖚ⠪ࡠࡏ࠶࠻ ᘠࠇೋ߼ߐࠎ㧦ਛㇱ⚻ᷣᣂ⡞(2006 ᐕ 1 ᦬ 1 ᣣ)
2㧕 㜞ᯅఝਃ㧦ᖚ⠪ࡠࡏ࠶࠻ ᘠࠇೋ߼ߐࠎ㧦⺒ᄁᣂ⡞(2006 ᐕ 5 ᦬ 2 ᣣ)
3㧕 㜞ᯅఝਃ㧦ᖚ⠪ࡠࡏ࠶࠻ ᘠࠇೋ߼ߐࠎ㧦ฬฎደ࠹࡟ࡆࠬ࡯ࡄ࡯࠾ࡘ࡯ࠬ(2006 ᐕ 5 ᦬)
4㧕 㜞ᯅఝਃ㧦ᖚ⠪ࡠࡏ࠶࠻ ᘠࠇೋ߼ߐࠎ㧦Ფᣣ᡼ㅍ NEWS(2006 ᐕ 5 ᦬)
5㧕 㜞ᯅఝਃ㧦ᖚ⠪ࡠࡏ࠶࠻ ᘠࠇೋ߼ߐࠎ㧦ᦺᣣ᡼ㅍ(2006 ᐕ 5 ᦬)
6㧕 㜞ᯅఝਃ㧦ᖚ⠪ࡠࡏ࠶࠻ ᘠࠇೋ߼ߐࠎ㧦ਛ੩࠹࡟ࡆࡊ࡜ࠬࡢࡦ(2006 ᐕ 5 ᦬)
7㧕 㜞ᯅఝਃ㧦࠮࡞ࡈࠨࡐ࡯࠻࡮ࠦ࡯࠴ࡦࠣ࡮ࠗࡦ࠲ࡆࡘ࡯ ╙ 2 ࿁㧦JAMIC JOURNAL vol.26
No.6(2006 ᐕ 6 ᦬)
8㧕 㜞ᯅఝਃ㧦ᘠࠇೋ߼ߐࠎ㧦ጘ㒂᡼ㅍ࠾ࡘ࡯ࠬ(2006 ᐕ 6 ᦬)
9㧕 㜞ᯅఝਃ㧦ో࿖ࡃࠗࠝࠢ࡜ࠬ࠲࡯ត⸰ԙጘ㒂࡮ᄢ၂ࡠࡏ࠹ࠖ࠶ࠢవ┵ක≮ࠢ࡜ࠬ࠲࡯㧦Bionics(2006ᐕ 7 ᦬)
10㧕 㜞ᯅఝਃ㧦ᖚ⠪ࡠࡏ࠶࠻ ᘠࠇೋ߼ߐࠎ㧦᧲ᶏ࠹࡟ࡆࠬ࡯ࡄ࡯࠾ࡘ࡯ࠬ(2006 ᐕ 7 ᦬)
11㧕 㜞ᯅఝਃ㧦ᖚ⠪ࡠࡏ࠶࠻ ᘠࠇೋ߼ߐࠎ㧦ࡈࠫ࠹࡟ࡆࠬ࡯ࡄ࡯࠾ࡘ࡯ࠬ(2006 ᐕ 8 ᦬ 1 ᣣ)
12㧕 㐳㊁ഞ, 㜞ᯅఝਃ㧦ࠞ࡯ࡏࡦࡑࠗࠢࡠࠦࠗ࡞ᷝട ⊹⤏ࠤࡠࠗ࠼ᛥ೙ ጘ㒂ᄢ߇⊒⷗㧦ᣣೀᎿᬺᣂ⡞(2006 ᐕ 11 ᦬ 11 ᣣ)
13㧕 㜞ᯅఝਃ㧦ࠪࡒࡘ࡟࡯࡚ࠪࡦකቇߪ, ⃻ઍකቇᢎ⢒ߦ⊒⷗ߐࠇߚᣂᄢ㒽ߢ޽ࠆ‫ޕ‬㧦JMA ࡑࡀࠫࡔࡦ࠻
࡟ࡆࡘ࡯vol.12 No.11(2006 ᐕ 11 ᦬)
14㧕 㜞ᯅఝਃ㧦ነⓂ කቇᢎ⢒ߩ⻉໧㗴⸃᳿ߦࠪࡒࡘ࡟࡯࡚ࠪࡦߩᵴ↪ࠍ‫࡞࠺ࡕޟ‬㧒ࠪࡒࡘ࡟࡯࡚ࠪࡦ
කቇᢎ⢒⎇ⓥળ‫ߦ⿷⊒ޠ‬㓙ߒߡ㧦ㅳೀකቇ⇇ᣂ⡞(2006 ᐕ 12 ᦬ 4 ᣣ)
15㧕 㐳㊁ഞ, 㜞ᯅఝਃ㧦CMC ߢ߇ࠎჇᱺᛥ೙㧦ᣣೀᎿᬺᣂ⡞(2006 ᐕ 12 ᦬ 14 ᣣ)
16㧕 㜞ᯅఝਃ㧦ක≮ታ⠌↪ᖚ⠪ࡠࡏ࠶࠻㐿⊒㧦⺒ᄁᣂ⡞(2007 ᐕ 6 ᦬ 15 ᣣ)
17㧕 㜞ᯅఝਃ, 㐳㊁ഞ㧦CMC㧦ᣣೀᎿᬺᣂ⡞(2007 ᐕ 2 ᦬ 6 ᣣ)
18㧕 㜞ᯅఝਃ㧦ࠪࡒࡘ࡟࡯࡚ࠪࡦකቇᢎ⢒㧦ࠫࡖࡒ࠶ࠢࠫࡖ࡯࠽࡞(2007 ᐕ 3 ᦬)
19㧕 㐳㊁ഞ㧦὇⚛❫⛽ࠞ࡯ࡏࡦࡑࠗࠢࡠࠦࠗ࡞, ⊕ⴊ∛⚦⢩Ⴧᱺࠍᛥ೙㧦ਛᣣᣂ⡞(2008 ᐕ 3 ᦬ 12 ᣣ)
20㧕 㐳㊁ഞ㧦ነ↢⯻ߣੱ㑆ߩ౒↢ࠍតࠆ㧦ጘ㒂ᣂ⡞(2008 ᐕ 8 ᦬ 5 ᣣ)㧙㧙

21㧕 㐳㊁ഞ㧦CMC㧔ࠞ࡯ࡏࡦࡑࠗࠢࡠࠦࠗ࡞㧕, ⊕ⴊ∛ᴦ≮ߦലᨐ, ߇ࠎ⚦⢩ߩჇᱺᛥ೙㧦ᣣೀᎿᬺᣂ
⡞(2008 ᐕ 3 ᦬ 31 ᣣ)
22㧕 㜞ᯅఝਃ㧦ࡃ࡯࠴ࡖ࡞∛㒮㧦ฬฎደ࠹࡟ࡆႎ㆏(2008 ᐕ 2 ᦬ 15 ᣣ)
23㧕 㜞ᯅఝਃ㧦ᄢቇ⊒ࡌࡦ࠴ࡖ࡯ડᬺ ࡔ࠺ࠖࠞ࡞ᗲ㧦ਛᣣᣂ⡞(2008 ᐕ 4 ᦬ 12 ᣣ)
24㧕 㜞ᯅఝਃ㧦ࡃ࡯࠴ࡖ࡞∛㒮㧦਎⇇ࠍᄌ߃ࠆᣣᧄੱ 100 ฬ㧦࠹࡟ࡆ᧲੩(2008 ᐕ 10 ᦬ 17 ᣣ)
25㧕 㜞ᯅఝਃ㧦ࡃ࡯࠴ࡖ࡞∛㒮 ᖚ⠪ࡠࡏ࠶࠻ ᘠࠇೋ߼ߐࠎ㧦ਛᣣᣂ⡞(2008 ᐕ 12 ᦬ 4 ᣣ)
26㧕 㜞ᯅఝਃ㧦ࡃ࡯࠴ࡖ࡞∛㒮 ߅ߪࠃ߁ᣣᧄ㧦NHK ࠹࡟ࡆ(2008 ᐕ 11 ᦬ 14 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔᣓᲫ⯻ߩᗵᨴ∛ℂߦߟ޿ߡಽሶ↢‛ቇ⊛ߦ⸃ᨆࠍㅴ߼ߡ޿ࠆ‫ߩߘޕ‬ᚑᨐߪ, ᐢߊᶏᄖߦ⍮ࠄࠇᣓᲫ⯻∝ߩಽ㊁ߢߪ᣿ࠄ߆ߦࡄࠗࠝ࠾ࠕ⊛ߥᓎഀࠍᨐߚߒߡ޿ࠆ‫ޕ‬ጘ㒂ᄢቇౝߦ޽ߞߡߪ, ነ↢⯻ᗵᨴ∝ߩࠦࡦࠨ࡞࠲ࡦ࠻ᬺോࠍᜂߞߡ޿ࠆ‫ޕ‬ዋߥ޿ੱᢙߥ߇ࠄ, ነ↢⯻ቇળ߿ᄢቇ߳ߩ⽸₂ᐲߪᄢ߈޿‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷කቇㇱߢၮ␆කቇࠍᔒߔ⧯⠪ߪᷫዋߒߡ޿ࠆ‫ޕ‬ነ↢⯻ቇߩಽ㊁ߪ․ߦ⪺ߒ޿‫ᦨ߇ࠇߎޕ‬ᄢߩ໧㗴ߢ޽ࠅ, ኻᔕ╷ߪਲߒ޿‫ޕ‬੹ᓟߩዷᦸᣓᲫ⯻∝ߩᗵᨴ∛ℂ⎇ⓥߦ㑐ߒߡߪ, ᗵᨴ╭⡺ߩ⚵❱∛ℂ߆ࠄోりߩ෻ᔕ߳⸃ᨆߩ㊀ὐࠍ⒖ߒ, ߎߩಽ㊁ߢ߽਎⇇ߩ࡝࡯࠼ᓎࠍ⋡ᜰߔ‫ޕ‬㧙㧙㧔5㧕ㆮવ⊒↢ቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
ㆮવ⊒↢ಽ㊁ߩ⎇ⓥ⋡⊛ߪ↢๮ࠍㆮવߣ⊒↢ߩⷞὐ߆ࠄ⸃᣿ߒ㧘ߐࠄߦߘࠇࠍ∔ᖚߩ⸃᣿ߣ⸻ᢿᴦ≮ߦᔕ↪ߔࠆߎߣ㧘߅ࠃ߮ߎߩ⋡⊛ࠍㆀⴕߢ߈ࠆੱ᧚ࠍ⢒ᚑߔࠆߎߣߢ޽ࠆ‫ޕ‬⎇ⓥ㕙ߢߪ㧘ࠕ࡟࡞ࠡ࡯㧘వᄤᕈ఺∉ਇో∝㧘వᄤᕈઍ⻢⇣Ᏹ㧘≸㧘ࡅ࠻ߩ⊒↢㧘ಽൻ㧘␹⚻ߥߤߦߟ޿ߡ㧘↹ᦼ⊛㧘⁛ഃ⊛ߥ idea ߣ strategy ࠍ㚟૶ߒߡ㧘ಽሶㆮવቇ⊛߆ߟ᭴ㅧ↢‛ቇ⊛ߦ⸃ᨆߒߡ޿ࠆ‫ޕ‬ㄭᐕ㧘ㆮવᕈ∔ᖚߪ⸻ᢿ㧘ᴦ≮ߩߺߢߥߊ㧘ࠞ࠙ࡦ࠮࡝ࡦࠣ㧘ࠗࡦࡈࠜ࡯ࡓ࠼ࠦࡦ࠮ࡦ࠻㧘ᔃℂ⊛ࠤࠕ㧘␠ળ⊛ࠨࡐ࡯࠻ࠍ฽߼ߚ✚ว⊛ࡈࠜࡠ࡯ࠕ࠶ࡊߩ㊀ⷐᕈ߇ต߫ࠇߡ޿ࠆ‫⎇ޕ‬ⓥᚑᨐߩᔕ↪ߣߒߡᧄቇߦ߅
޿ߡ߽㧘ㆮવ∛⸻≮߇ߥߐࠇ㧘ቯᦼ⊛ߥ∝଀ࠞࡦࡈࠔ࡟ࡦࠬࠍ㐿௅ߒ㧘ࠃࠅ⦟޿ㆮવ∛⸻≮ࠍ⋡ᜰߒߡᵴേߒߡ޿ࠆ‫ߩߘޕ‬ౝኈߪਥߦ㧘ᖚ⠪߅ࠃ߮ࠢ࡜ࠗࠛࡦ࠻ߦኻߔࠆᖱႎឭଏ㧘ࠞ࠙ࡦ࠮࡝ࡦࠣᣇ㊎ߩᬌ⸛㧘⥃ᐥㆮવߦ㑐ߔࠆᦨᣂ⍮⷗㧘⻉⺖㗴ߦߟ޿ߡߩᖱႎᗧ⷗੤឵㧘⥃ᐥฦ⑼ߩ⋧⺣߳ߩኻᔕߥߤߢ޽ࠆ‫ޕ‬߹ߚ㧘2003 ᐕߦߪᣣᧄੱ㘃ㆮવቇળᣂ೙ᐲߦࠃࠆ⎇ୃᜰቯࠍ₪ᓧߒߚ‫ޕ‬2004 ᐕᤐࠃࠅᣂߚߦㆮવ⊒↢ಽ㊁ߣߒߡ⁛┙ߒߚߩࠍᯏળߦ㧘ߐࠄߦ⎇㐭ߦദ߼ߡ޿ࠆ‫ߩ࠻ࡅޕ‬಴↢೨ᦼߩㆮવ࡮⊒↢෸߮㧘಴↢ᓟߩᚑ㐳࡮⊒㆐ߦ߅ߌࠆ↢ℂ⊛߆ߟ∛⊛⁁ᘒࠍኻ⽎ߣߒߡ޿ࠆ‫ޕ‬ၮ␆⎇ⓥߦ߅޿ߡ㧘ᐞߟ߆ߩಽ㊁ߦ⛉ࠆߎߣߦࠃࠅ㧘ᅏᷓ޿⎇ⓥ߇ㅴ߼ࠄࠇߡ޿ࠆ‫࡯ࠡ࡞࡟ࠕޕ‬㧘఺∉ਇో㧘ઍ⻢⇣Ᏹߩฦಽ㊁ߢᐞߟ߆ߩ∔ᖚߩ∛࿃ㆮવሶ߇ᒰ⻠ᐳߢ਎⇇ߦవ㚟ߌࠢࡠ࡯࠾ࡦࠣߐࠇ㧘਎⇇ࠍ࡝࡯࠼ߔࠆᚑᨐ߇ᐞߟ߽ヘ಴ߐࠇ㧘ᣂ⡞⚕਄ߩ৻㕙ߢ߽ขࠅ਄ߍࠄࠇߡ޿ࠆ‫ޕ‬ฦ࠹࡯ࡑߦ౒ㅢߔࠆߎߣߪ㧘
ฦಽ㊁ߩ∔ᖚߩ∛࿃ߣ∛ᘒߩ⸃᣿ߢ޽ࠅ㧘ߘߩᚑᨐࠍ⸻ᢿ࡮ᴦ≮࡮੍⍮࡮੍㒐ߦㆡᔕߒߡ޿ߊߎߣߢ޽ࠆ‫ޕ‬ߐࠄߦߎࠇࠄࠍㅢߓߡ㧘ࡅ࠻ߩㆮવ࡮⊒↢㧘ᚑ㐳࡮⊒㆐ߩᣂߚߥ⸃᣿ߦߟߥߍߡ޿ࠆ‫ޕ‬ᣇᴺ⺰⊛ߦߪ㧘ᣣᏱ⥃ᐥߩਛ߆ࠄࡅࡦ࠻ߣ⊒ᗐ߇ᓧࠄࠇ㧘ㆮવሶቇ⊛ᚻᴺߦട߃㧘කቇ߳ߩ᭴ㅧ↢‛ቇߩዉ౉㧔21 ਎♿ဳࡐࠬ࠻ࠥࡁࡓߣߒߡߩ᭴ㅧ↢‛කቇ structure biological medicine ㄭ⮮ߦࠃࠆ㧕ࠍߒߡ޿ࠆ‫ࡓࡁࠥޕ‬ㆮવሶ⇣Ᏹ߆ࠄࠛࡇࠫࠚࡀ࠹ࠖࠢࠬ㧘ㆮવሶ⊒⃻⇣Ᏹࠍ⚻ߡ࠲ࡦࡄࠢ┙૕᭴ㅧߩ⇣Ᏹߣᯏ⢻⇣Ᏹߣߩ㑐ㅪࠍ⸃ᨆߒ㧘⸻ᢿ࡮ᴦ≮߳ߩᔕ↪ࠍㅴ߼ߡ޿ࠆ‫ޕ‬਎⇇⊛߆ߟ↹ᦼ⊛ߥᚑᨐ߇ᦼᓙߐࠇߡ޿ࠆ‫ߩࠄࠇߎޕ‬ᚑᨐߪᐞߟ߆ߩᄢဳ┹ว⊛⎇ⓥ⾌₪ᓧߦ⃻ࠇߡ޿ࠆ‫ޕ‬એਅ⹦⚦ߪ㧘ዊఽ∛ᘒቇߣ౒หߢ޽ࠆ‫ޕ‬1㧕ࠕ࡟࡞ࠡ࡯
Ԙࠕ࠻ࡇ࡯㧔ࠕ࡟࡞ࠡ࡯㧕ߩᛥ೙♽ߩ∛࿃ㆮવሶࠍ਎⇇ߢೋ߼ߡ᣿ࠄ߆ߦߒ㧔Lancet 1996 ᐕ㧘
BBRC1999 ᐕߦ⛯޿ߡ, JACI 2003 ᐕ㧕㧘IgE ↥↢ߩᛥ೙♽ IL-12IL-12 ࡟࠮ࡊ࠲࡯߹ߚߪ IL-18IL-18
࡟࠮ࡊ࠲࡯IFNJࠪࠣ࠽࡝ࡦࠣߩ㊀ⷐᕈࠍ␜ߒߚ‫ޕ‬ԙߎࠇࠄߩᚑᨐࠍ߽ߣߦߒߡ਎⇇ߦవ㚟ߌߡ㧘ᣂߚߦࠕ࠻ࡇ࡯㧔ࠕ࡟࡞ࠡ࡯㧕ࠍㆮવሶቇ⊛ߦಽ㘃ߒߚ‫ޕ‬Ԛߐࠄߦ㧘ߎࠇࠍ߽ߣߦࠕ࡟࡞ࠡ࡯㧔ࠕ࠻ࡇ࡯㧕ߩㆮવሶ⸻ᢿࠠ࠶࠻ࠍ㐿⊒ߒ㧘․⸵↳⺧ਛߢ޽ࠆ㧔2007㧘2008 ᐕ㧕‫ޕ‬ԛࡅ࠻ IL-18 ߩ࠲ࡦࡄࠢ┙૕᭴ㅧࠍ਎
⇇ߦవ㚟ߌߡ⸃᣿ߒ㧔Nature structure biology 2003㧕㧘ߘߩ⥃ᐥᔕ↪ߣߒߡߩૐಽሶഃ⮎ࠍㅴ߼ߡ޿ࠆ‫ޕ‬Ԝㆮવሶᖱႎߣ᛫ࠕ࡟࡞ࠡ࡯⮎ലᨐ߆ࠄ୘೎ൻක≮㧘ߔߥࠊߜ㧘ࠕ࡟࡞ࠡ࡯ߩࠝ࡯࠳࡯ࡔࠗ࠼ᴦ≮ߩ⏕┙
ࠍㅴ߼“᳇▤ᡰ༎ᕷߩ࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮▤ℂᴺߩߚ߼ߩᚻᒁ߈”ࠍ਎⇇ߢೋ߼ߡ૞ᚑߒߚ‫ޕ‬ԝㆮવሶ⊒⃻㧘RNA ࡊࡠ࠮࠶ࠪࡦࠣ․ߦ RNA editing ߣ alternative splicing ߇ࠕ࡟࡞ࠡ࡯⊒∝ߦ㑐ࠊߞߡ޿ࠆߎߣࠍ
਎⇇ߢೋ߼ߡ⸃᣿ߒߚ‫ޕ‬Ԟ㘩‛ࠕ࡟࡞ࠡ࡯ߩ᛫ේ․⇣ᕈߩ⊒⃻ᯏ᭴ߩ⸃᣿ߩߚ߼㧘T ⚦⢩ࠢࡠ࡯ࡦߩ᮸┙ߦ਎⇇ߢೋ߼ߡᚑഞߒ㧘ࠕ࡟࡞ࠡ࡯⊒∝ߦ߅ߌࠆ HLAࡍࡊ࠴࠼T ⚦⢩࡟࠮ࡊ࠲࡯ߩ․⇣ᕈߣ⚿วᕈࠍ⚻ญ఺∉ኡኈࠍ⺃ዉߔࠆᴦ≮ᴺ⏕┙૕᭴ㅧ߆ࠄ⸃᣿ߒߡ޿ࠆ‫ޕ‬
㧔PNAS 2008 ઁ㧕ԟߎߩᚑᨐߦၮߠ޿ߡ㧘⚻┙ߩߚ߼“㘩ߴߡᴦߔ㘩ຠߩ㐿⊒”ࡊࡠࠫࠚࠢ࠻߇⃻࿷ㅴⴕߒߡ޿ࠆ‫ޕ‬ԠⅣႺߣㆮવሶߦࠃࠆࠕ࡟࡞ࠡ࡯⊒∝ߩಽሶㆮવቇ⊛⸃᣿㧔21 ਎♿ဳࡐࠬ࠻ࠥࡁࡓߣߒߡߩㆮ
ㆮવሶ↢ᘒකቇ genetic ecological medicine -ㄭ⮮ߦࠃࠆ㧕‫ޕ‬᷷ᐲᄌൻߦࠃࠅ㧘NF-kappaB ߩᯏ⢻߇ᄌൻߒ㧘ࠨࠗ࠻ࠞࠗࡦ↥↢ࡄ࠲࡯ࡦ߇ᄌൻߔࠆߎߣࠍ
᣿ࠄ߆ߦߒߚ‫ߦࠄߐޕ‬᭎ᣣ࡝࠭ࡓߩⷞὐ߆ࠄ㧘శߣ૕ౝᤨ⸘ㆮવሶߣߩ㑐ㅪࠍᬌ⸛ߒߡ޿ࠆ‫ޕ‬ԡ⥄ὼ఺∉♽ߣ∔ᖚߣߩ㑐ㅪࠍត᳞ߒᴦ≮㐿⊒ߦߟߥߍࠆߚ߼ߦ㧘Toll like receptor㧔TLR㧕߅ࠃ߮ߘߩࠪࠣ࠽࡞વ
㆐♽ߩ MyD88 ಽሶߥߤߩಽሶ߅ࠃ߮ߘࠇࠄߩ⚿ว᭽ᑼࠍ᣿ࠄ߆ߦߒ㧘หᤨߦߘࠇࠄߩㆮવሶቇ⊛࠲ࡦࡄࠢ᭴ㅧቇ⊛⇣Ᏹࠍ᣿ࠄ߆ߦߒߡ޿ࠆ‫ޕ‬Ԣࠬ࠻࡟ࠬߣࠕ࡟࡞ࠡ࡯⊒∝ߩಽሶㆮવቇ⊛⸃᣿㧘࠙ࠗ࡞ࠬᗵᨴߦ
ࠃࠆࠕ࡟࡞ࠡ࡯⊒∝㧘ࠕ࡜ࠠ࠼ࡦ㉄ࠞࠬࠤ࡯࠼ߩ⹏ଔߣࠝ࡯࠳࡯ࡔࠗ࠼ᴦ≮㧘⾰ߩ㜞޿ QOL ⹏ଔ⴫ߩ૞
ᚑ㧘⤯Ꮺⴊࡊࡠࠫࠚࠢ࠻㧘FACS ࠍ↪޿ߚ⥄ὼ఺∉♽⺞▵ᕈ T ⚦⢩ߩ⸃ᨆߣ₪ᓧ఺∉♽ Th1࡮Th2 ࠕࡦࡃ࡜ࡦࠬߩ⸃᣿ߣᔕ↪ߥߤ‫ޕ‬ԣએ਄ߩࡊࡠࠫࠚࠢ࠻ߦ㑐ߒߡએਅߩᄢဳ┹ว⊛ᄖㇱ⾗㊄ࠍ₪ᓧߢ߈ߚ‫ޕ‬㧔ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌ߥߤߪ೎㗄ෳᾖ㧕
1. 㧨ᢥㇱ⑼ቇ⋭㜞╬ᢎ⢒ዪ㧪ᢥㇱ⑼ቇ⋭㜞ᐲవㅴක≮㐿⊒⚻⾌‫∔࡯ࠡ࡞࡟ࠕ࡮∉఺ޟ‬ᖚ∛࿃࠲ࡦࡄࠢ
⾰┙૕᭴ㅧߦၮߠ޿ߚ᭴ㅧ↢‛ቇ⊛ഃ⮎ߦࠃࠆᴦ≮ᴺߩ⏕┙‫⎇ޠ‬ⓥઍ⴫⠪ ㄭ⮮⋥ታ ⎇ⓥදജ⠪ ട⮮ༀ৻㇢㧘◉↰⚩ม㧘ኹᧄ⾆⧷㧘ਅỈિⴕ㧘㊄ሶ⧷㓶㧘ᷓየᢅᐘ㧘᧻੗᳗ሶ㧘᪀↰৻ᄦ㧘㋈ᧁᱜᤘ㧘⊕Ꮉ᣽㧙㧙ብ 㧔ᐔᚑ 13㧙15 ᐕ㧕
2. 㧨ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄㧪఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ‫∔࡯ࠡ࡞࡟ࠕޟ‬ᖚߩᴦ≮෻ᔕᕈ੍᷹࿃ሶߩ⏕┙෸߮࠹࡯࡜ࡔࠗ࠼ᴦ≮ᴺߩ⏕┙ߦ㑐ߔࠆ⎇ⓥ‫ޠ‬ਥછ⎇ⓥ⠪ ㄭ⮮ ⋥ታ ⃰ຬ ᧻੗ ᳗ሶ߶߆㧔ᐔᚑ 16㧙21 ᐕ㧕
3. 㧨↢‛♽↥ᬺഃ಴ߩߚ߼ߩ⇣ಽ㊁Ⲣว⎇ⓥᡰេ੐ᬺ㧪⇣ಽ㊁Ⲣว⎇ⓥ㐿⊒ဳ‫ޟ‬㘩‛ࠕ࡟࡞ࠡ࡯ኻ╷㘩ຠߩၮ␆⎇ⓥߦၮߠߊ↹ᦼ⊛ഃᚑ‫⎇ޠ‬ⓥઍ⴫⠪ ㄭ⮮⋥ታ ⃰ຬ ㊄ሶ⧷㓶߶߆㧔ᐔᚑ 17 ᐕࠃࠅ 5 ᐕ㑆㧕2㧕వᄤᕈ఺∉ਇో∝ߣ DNA ୃᓳ
IgG ࠨࡉࠢ࡜ࠬᰳ៊∝ߩ∛࿃ߣߥࠆㆮવሶ⇣Ᏹࠍ਎⇇ߦవ㚟ߌ᣿ࠄ߆ߦߒߚ㧔J Clin Invest ෸߮
JACI 㧕‫ޕ‬Ᏹᨴ⦡૕ఝᕈߩㆮવᒻᑼࠍߣࠆ㜞 IgM ∝୥⟲ߩ∛࿃ߦߟ޿ߡ߽ AID ߩ dominant negative ലᨐߦࠃࠆߎߣࠍ਎⇇ߢೋ߼ߡ᣿ࠄ߆ߦߒߚ (JACI 2003 ᐕ)‫ޕ‬Ყセ⊛㗫ᐲߩ㜞޿఺∉ਇో∝ߢ޽ࠆ IgA ᰳ៊∝ߦߟ޿ߡ⸃ᨆࠍⴕ޿ߘߩ B ⚦⢩ߩಽൻ㓚ኂㇱ૏ࠍ᣿ࠄ߆ߦߒߚ‫ߦࠄߐޕ‬㧘ᧄ㇌ 2 ଀⋡ߩ఺∉ࠣࡠࡉ
࡝ࡦ㊀㎮ㆮવሶߩᰳ៊ኅ♽ࠍႎ๔ߒߚ‫ޕ‬㜞⊒≸ߣ఺∉ਇోࠍ␜ߔ Bloom ∝୥⟲߿ Ataxia-telangiectasiaߩ∛࿃ㆮવሶ BLM ߣ ATM ߩᯏ⢻ߣ᭴ㅧߩ⸃ᨆࠍㅢߒߡ⚦⢩๟ᦼ㧘DNA ୃᓳ㧘ࠪࠣ࠽࡞વ㆐ߦߟ߈⸃
᣿ߒ⊒≸ᯏ᭴ߩ⸃᣿ࠍⴕߞߡ޿ࠆ㧔Blood ,CEI, PNAS ઁ㧕‫ߦࠄߐޕ‬ᄙᓀߥ⥄ὼ఺∉ਇో∝㧘⥄ᏆἻ∝ᕈ∔ᖚߩ∛࿃∛ᘒ⸃᣿ߣᴦ≮㐿⊒ߦ⌕ᚻߒߚ‫ޕ‬3㧕᦭ᯏ㉄ઍ⻢⇣Ᏹ∝ࠤ࠻ࡦ૕ઍ⻢⇣Ᏹ∝㧘․ߦࠨࠢࠪ࠾࡞-CoA:3-ࠤ࠻㉄ CoA ࠻࡜ࡦࠬࡈࠚ࡜࡯࠯(SCOT)ߣ  ࠤ࠻࠴ࠝ࡜
࡯࠯ᰳ៊∝ߩ㉂⚛⸻ᢿ߿ㆮવሶ⸻ᢿߦ߅޿ߡߪ㧘਎⇇ਛ߆ࠄߩଐ㗬ࠍ߁ߌߡ⸃ᨆࠍⴕߞߡ޿ࠆ‫ߢ߹ࠇߎޕ‬ᄙߊߩㆮવሶᄌ⇣ߣߘߩ․ᓽࠍ᣿ࠄ߆ߦߒߡ߈ߚ‫ޕ‬ᱷሽᵴᕈࠍ߽ߟシ∝ဳߩEࠤ࠻࠴ࠝ࡜࡯࠯ᰳ៊∝㧘
SCOT ᰳ៊∝ߩౖဳ଀ߣߩ⥃ᐥ௝ߩ㆑޿ߦߟ޿ߡ߽᣿ࠄ߆ߦߒߡ޿ࠆ‫౒ߩߣࡊ࡯࡞ࠣߩ࠼ࡦ࡜ࡦࠖࡈޕ‬ห⎇ⓥߢ㧘ࡅ࠻ߩ⚦⢩⾰࠴ࠝ࡜࡯࠯ߣࡒ࠻ࠦࡦ࠼࡝ࠕࠕ࠮࠻ࠕ࠮࠴࡞-CoA ࠴ࠝ࡜࡯࠯ߩ 3 ᰴ᭴ㅧࠍ᳿ቯߒ㧘ߐࠄߦࠕࡒࡁ㉄ᄌൻ߇Ⱞ⊕ߦਈ߃ࠆᓇ㗀ߦߟ޿ߡߩ⸃ᨆࠍㅴ߼ߡ޿ࠆ㧚ፉᩮᄢቇߣߩ౒ห⎇ⓥߢ㧘⢽⢌㉄
 ㉄ൻ♽⇣Ᏹ∝ߩⰮ⊕ㆮવሶ⸃ᨆ߽ⴕߞߡᚑᨐ߇಴ߡ߈ߡ޿ࠆ‫ޕ‬
4㧕ㆮવᕈࡓࠦᄙ♧∝ㆮવᕈࡓࠦᄙ♧∝ߦߟ޿ߡᣧᦼ⸻ᢿ㧘ಽሶ∛ᘒ⸃ᨆ㧘ᴦ≮ᴺ㐿⊒ߦขࠅ⚵ࠎߢ޿ࠆ‫ࠦࡓߦ․ޕ‬ᄙ♧∝ΦA ဳߩ⎇ⓥߢߪ㧘࿖㓙ࡊࡠࠫࠚࠢ࠻ߩ✚᜝⊛┙႐ߢ∔ᖚ⸃ᨆ࡮ᴦ≮ᴺ㐿⊒ࠍⴕߞߡ߅ࠅ㧘Τဳߩ⥄ὼᱧ⺞ᩏ߿㉂⚛⵬ల≮ᴺ㧘ࡓࠦᄙ♧∝ో⥸ߩᣧᦼࡑࠬࠬࠢ࡝࡯࠾ࡦࠣࠪࠬ࠹ࡓߩ㐿⊒߽૬ߖߡ㧘ࡌࡦ࠴ࡖ࡯ડᬺ
ߣߩ౒ห⎇ⓥ߽ㅴ߼ߡ޿ࠆ‫ޕ‬
5㧕ࡍ࡞ࠝࠠࠪ࠰࡯ࡓ∛వᄤᕈࡍ࡞ࠝࠠࠪ࠰࡯ࡓઍ⻢⇣Ᏹ∝ߩ∛࿃ߣᴦ≮ߦߟ޿ߡ⎇ⓥࠍㅴ߼ߡ߅ࠅ㧘ࡍ࡞ࠝࠠࠪ࠰࡯ࡓᰳ៊∝ߩᣂⷙ∛࿃ㆮવሶ PEX16,19,13,3,26 ߩหቯ㧘᷷ᐲᗵฃᕈ⃻⽎ߩ⊒⷗㧘ᣂߚߥE㉄ൻ㉂⚛ᰳ៊∝ߩ⊒⷗㧘೽⣢⊕⾰ࠫࠬ࠻ࡠࡈࠖ࡯ߩ㛽㜑⒖ᬀߩฦ‫ߡ޿ߟߦޘ‬਎⇇ࠍ࡝࡯࠼ߔࠆᚑᨐࠍ᜼ߍߡ޿ࠆ‫ޕ‬ㆮવሶ⸻ᢿߣߒ
ߡ PEX10 ㆮવሶߩ 2 Ⴎၮᰳᄬ㧘PEX16 ㆮવሶ⇣Ᏹ㧘PEX26 ㆮવሶ⇣Ᏹߥߤࠍ⸻ᢿߒߚ߶߆㧘㕖Ᏹߦ․߹ߚ㧘⇣ߥ଀ߣߒߡ㧘Zellweger ∝୥⟲ߩ⥃ᐥ௝ࠍ๒ߒ ALDP ㆮવሶࠍ฽߻ large deletion ଀ࠍ⸻ᢿߒߚ‫ޕ‬ࡍ࡞ࠝࠠࠪ࠰࡯ࡓᰳ៊∝ߩ᷷ᐲᗵฃᕈߦߟ޿ߡߪ࠲ࡦࡄࠢ┙૕᭴ㅧ⸃ᨆ߿シ∝ဳ᷷ᐲᗵฃᕈࡕ࠺࡞ࡑ࠙
ࠬߩ૞ᚑߥߤࠍⴕ޿㧘ᧄ∝ߩ∛ᘒ⸃᣿ߣᴦ≮ᴺߩ㐿⊒ߦขࠅ⚵ࠎߢ޿ࠆ‫৻ޕ‬ᣇߢ㧘ࡍ࡞ࠝࠠࠪ࠰࡯ࡓߩ␹
⚻⊒↢ㆊ⒟ߦ߅ߌࠆᓎഀߦߟ޿ߡ㧘఺∉⚵❱ൻቇ⊛ᚻᴺࠍ↪޿ߡ⸃ᨆਛߢ޽ࠆ‫ޕ‬
6㧕࠲ࡦࡄࠢ┙૕᭴ㅧ⸃ᨆ
ዊఽߩ∔ᖚ㑐ㅪⰮ⊕⾰ߩ┙૕᭴ㅧ⸃ᨆߦၮߠ޿ߚ∛ᘒ⸃ᨆ࡮ᴦ≮ᴺߩ㐿⊒ߥߤࠍⴕ߁”᭴ㅧකቇ”ߩ⏕┙ࠍ⋡ᜰߒ㧘ૐಽሶ࡝ࠟࡦ࠼ࠬࠢ࡝࡯࠾ࡦࠣ࡮Ⱞ⊕࡟ࡌ࡞ߢߩⰮ⊕Ꮏቇ⊛ࠕࡊࡠ࡯࠴ߦࠃࠆᴦ≮ᴺߩ㐿⊒ߦ㊀ὐࠍ⟎޿ߡ⎇ⓥࠍㅴ߼ߡ޿ࠆ‫ߚ߹ޕ‬㧘⥄ὼ఺∉߆ࠄ₪ᓧ఺∉ߦ⥋ࠆ⚻〝ߦ㑐ਈߔࠆ㧘IL-18㧘IL-1㧘෸߮ Toll-like Receptor ⟲ߦᔅ㗇ߥಽሶߢ޽ࠆࠪࠣ࠽࡞વ㆐ࠕ࠳ࡊ࠲࡯Ⱞ⊕ࠍਛᔃߦߒߚ᭴ㅧቇ⊛⎇ⓥࠍㅴ߼ߡ޿ࠆ‫ᦨޕ‬ㄭߩᚑᨐߩ৻ߟߣߒߡ㧘ᄙᰴరᩭ⏛᳇౒㡆ᴺߦߡ᳿ቯߒߚࡅ࠻ IL-18 ┙૕᭴ㅧࠍ߽ߣߦ㧘ᄌ⇣૕⸃ᨆࠍⴕ޿㧘ࠗࡦ࠲࡯ࡠࠗࠠࡦߦ߅ߌࠆᣂߒ޿⚿ว᭽ᑼߩ⸃᣿ߦ⥋ߞߚ‫ޕ‬2㧚ฬ★
ᢎ᝼(૬છ)㧦 ㄭ⮮⋥ታᢎ᝼(૬છ)㧦 ᪀↰৻ᄦ

Naomi Kondo
Kazuo Kuwata3㧚 ⎇ⓥᚑᨐߩ⊒⴫ዊఽ∛ᘒቇ㧘ੱ₞ᗵᨴ㒐ᓮ࠮ࡦ࠲࡯ෳᾖ㧙㧙4㧚 ⎇ⓥ⾌₪ᓧ⁁ᴫዊఽ∛ᘒቇ㧘ੱ₞ᗵᨴ㒐ᓮ࠮ࡦ࠲࡯ෳᾖ
5㧚 ⊒᣿࡮․⸵಴㗿⁁ᴫዊఽ∛ᘒቇ㧘ੱ₞ᗵᨴ㒐ᓮ࠮ࡦ࠲࡯ෳᾖ
6㧚 ቇળᵴേ
ዊఽ∛ᘒቇ㧘ੱ₞ᗵᨴ㒐ᓮ࠮ࡦ࠲࡯ෳᾖ
7㧚 ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ዊఽ∛ᘒቇ㧘ੱ₞ᗵᨴ㒐ᓮ࠮ࡦ࠲࡯ෳᾖ
8㧚 ቇⴚ⾨╬ߩฃ⾨⁁ᴫዊఽ∛ᘒቇ㧘ੱ₞ᗵᨴ㒐ᓮ࠮ࡦ࠲࡯ෳᾖ
9㧚 ␠ળᵴേ
ዊఽ∛ᘒቇ㧘ੱ₞ᗵᨴ㒐ᓮ࠮ࡦ࠲࡯ෳᾖ
10㧚ႎ๔ᦠ
ዊఽ∛ᘒቇ㧘ੱ₞ᗵᨴ㒐ᓮ࠮ࡦ࠲࡯ෳᾖ
11㧚ႎ㆏ዊఽ∛ᘒቇ㧘ੱ₞ᗵᨴ㒐ᓮ࠮ࡦ࠲࡯ෳᾖ
12㧚⥄Ꮖ⹏ଔ
⹏ଔ✚ว⊛ߦߪߘࠇߥࠅߩ⹏ଔߪߢ߈ࠆ‫੹ޕ‬ᓟ߽ᒁ߈⛯߈⎇ⓥᚑᨐߣᬺ❣ߩᦝߥࠆ⛽ᜬ㧘ะ਄߇ᦸ߹ࠇࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻ╷ዊఽ∛ᘒቇߣ౒หߒߡ޿ࠆ‫ోޕ‬㗔ၞࠍࠞࡃ࡯ߔࠆዊఽ⑼ߩ⥃ᐥ߆ࠄࠊ߈಴ࠆ⇼໧ߣ࠹࡯ࡑߩోߡߦ⌕ᚻߔࠆߎߣߪ࿎㔍ߢ޽ࠆ߇㧘ࠕ࡟࡞ࠡ࡯࡮఺∉࡮ઍ⻢ߦട߃ߡⅣႺ߿ᗵᨴߣㆮવሶߩࠃ߁ߥᣂߚߥࡊࡠ
ࠫࠚࠢ࠻ࠍ┙ߜ਄ߍߡㅴ߼ߡ޿ࠆ‫ޕ‬੹ᓟߩዷᦸ⃻࿷ߩ࠹࡯ࡑߣᣇะᕈߩᦝߥࠆలታߣ᜛ᄢ‫ߦࠄߐޕ‬㧘ߎࠇࠄߩᚑᨐࠍක≮ߦ⋥ធ⊛ߦᔕ↪ߔࠆ㧔࠻࡜ࡦࠬ࡟࡯࡚ࠪ࠽࡞࡝ࠨ࡯࠴㧕‫ޕ‬㧙㧙㧔6㧕ౝಽᴲઍ⻢∛ᘒቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
ᣣᧄੱߩ 2 ဳ♧ዩ∛ߪᲧセ⊛߿ߖဳߢࠗࡦࠬ࡝ࡦಽᴲਇోࠍ․ᓽߣߔࠆߩߢ㧘⤟ౝಽᴲᯏ⢻ߣ㑐ㅪߔࠆౝಽᴲࠪࠬ࠹ࡓࠍ✚ว⊛ߦℂ⸃ߒ㧘ᣣᧄੱߦ․᦭ߩ∔ᖚᗵฃᕈࠍ᳞߼ࠆ‫ޕ‬ᚢ⇛ߣߒߡ㧘∔ᖚ⊒∝ߩ⽿છㆮવሶࠍಽሶㆮવቇ⊛ߦหቯߔࠆߎߣߦࠃߞߡ㧘♧ዩ∛ߩ⊒∝ᯏ᭴ߩ⸃᣿ߣ⟕ᖚ૕⾰ߩㆮવሶ⸻ᢿᴺߩ㐿⊒ࠍ⋡ᜰߔ‫ߚ߹ޕ‬㧘♧ዩ∛⸻≮ߩ⋡⊛ߪว૬∝ߩ੍㒐ߦ޽ࠆߩߢ㧘⒳‫ߩޘ‬ઍ⻢⇣Ᏹ㧘േ⣂⎬ൻ㧘⚦ዊⴊ▤∛ᄌߩ∛ᘒ⸃᣿ߣᴦ≮ᴺߩ㐿⊒߽หᤨߦផㅴߔࠆ‫ޕ‬৻ᣇ㧘2 ဳ♧ዩ∛ߪ↢ᵴ⠌ᘠ∛ߩઍ⴫∔ᖚߢ޽ࠆߩߢ㧘㘩⠌ᘠ㧘ᣣᏱߩり૕ᵴേ㧘ࠬ࠻࡟ࠬᔕ╵ߥߤߩ⺞ᩏ⎇ⓥࠍ࿾ၞਥ૕ߦታᣉߔࠆߎߣߦࠃߞߡ㧘୘‫ߩޘ‬૕⾰ࠍ⠨ᘦߒߚࠝ࡯࠳࡯ࡔࠗ࠼⊛ߥ↢ᵴᜰዉᴺߩ㐿⊒߽ⷞ㊁ߦ⟎ߊ‫ޕ‬2㧚ฬ★
ᢎ᝼㧦ᢎ᝼(૬છ)㧦
ಎᢎ᝼㧦
ಎᢎ᝼(૬છ)㧦
ಎᢎ᝼(૬છ)㧦
⻠Ꮷ㧦
⻠Ꮷ(૬છ)㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
ഥᢎ㧦
කຬ㧦
කຬ㧦

ᱞ↰ ⚐
ጊᧄ⋿↱⟤
ട⚊సᓼ
㋈ᧁ⧷ม
ၳᎹᐘ↵
⺪⸰ື਽
૒‫ᧁޘ‬ᤘᒾ
Ꮉ࿾ᘕ৻
Ⴎ⼱⌀↱⟤
ᑝ↰ථ↵
ફ⷗ትବ
ằ⼱㜞ᔒ

Jun Takeda
Mayumi Yamamoto
Yoshinori Kano
Eiji Suzuki
Yukio Horikawa
Tetsuya Suwa
Akihiko Sasaki
Shin-ichi Kawachi
Mayumi Enya
Takuo Hirota
Nobutoshi Fushimi
Takashi Shibuya

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ቬ ෹ෘ㧚೽⣢㧙ࠕ࡞࠼ࠬ࠹ࡠࡦ⇣Ᏹ∝ ේ⊒ᕈࠕ࡞࠼ࠬ࠹ࡠࡦ∝߅ࠃ߮㘃✼∔ᖚ 11EHSD2 ᰳ៊∝(AME∝୥⟲)㧙ਛየ ৻๺✬㧚ᣣᧄ⥃ᐥ೎ౠ ᣂ㗔ၞ೎∝୥⟲ࠪ࡝࡯࠭ 1 Ꮞ㧘ᄢ㒋㧦ᣣᧄ⥃ᐥ␠㧧2006 ᐕ㧦
651㧙654㧚2㧕 ጊᧄ⋿↱⟤㧚╙Σ▵ ஜᐽ⸻ᢿ㧘╙Χ▵ ᗵᨴ∝㧘ઃ㍳ ක≮࡮⑔␩೙ᐲ㧦ࠠࡖࡦࡄࠬ࡜ࠗࡈߩஜᐽ▤ℂ㧘ጘ㒂㧦ጘ㒂⋵ᄢቇ଻ஜ▤ℂ⎇ⓥળ✬㧧2006 ᐕ㧦8㧙11㧘89㧙92㧘111㧙113㧚
3㧕 ૒‫ᧁޘ‬ᤘᒾ㧘ၳᎹᐘ↵㧘ᱞ↰ ⚐㧚♧ઍ⻢㧙MODY(1-6 ဳ) ਛየ ৻๺✬㧚ᣣᧄ⥃ᐥ೎ౠ ᣂ㗔ၞ೎∝୥⟲ࠪ࡝࡯࠭ 3 Ꮞ㧘ᄢ㒋㧦ᣣᧄ⥃ᐥ␠㧧2006 ᐕ㧦54㧙57㧚
4㧕 㘵Ⴆൎ⟤㧘ၳᎹᐘ↵㧚ࡔ࠲ࡏ࡝࠶ࠢࠪࡦ࠼ࡠ࡯ࡓ⊒∝ⷐ࿃ߣߒߡߩౝ⤳⢈ḩ࡮⢽⢌⚦⢩ᯏ⢻⇣Ᏹ㧙⢽⢌⚦⢩ߩಽൻ࡮Ⴧᱺߩ߆߆ࠊࠆ࿃ሶ ChREBP. ਛየ ৻๺✬㧚ᣣᧄ⥃ᐥჇೀ 64 Ꮞ㧘ᄢ㒋㧦ᣣᧄ⥃ᐥ␠㧧2006
ᐕ㧦249㧙253㧚
5㧕 ㋈ᧁ⧷ม㧚ၮ␆✬㧦PWV ࠍ⍮ࠆ ⤳ེ࡮ᯏ⢻㓚ኂߣ PWV㧚ਅ⢇ᓴⅣߣ PWV㧘ࡂࡦ࠭ࠝࡦࡉ࠶ࠢ PWVࠍ⍮ࠆ PWV ߢ⸻ࠆ ᧲੩㧦ਛጊᦠᐫ㧧2006 ᐕ㧦132㧙138㧚
6㧕 ၳᎹᐘ↵㧘Ⴎ⼱⌀↱⟤㧚∔ᖚᗵฃᕈㆮવሶ⸃᣿ߩ⃻⁁ ᴡ⋓ 㓉ㅧ✬. ᣣᧄ⥃ᐥᣂᤨઍߩ♧ዩ∛ቇ(1)㧧
2008 ᐕ㧦387㧙392㧚
7㧕 Ⴎ⼱⌀↱⟤, ၳᎹᐘ↵㧚♧ዩ∛ߣ NASH-C. ⢽⢌⢄㧘♧ዩ∛㧘⢈ḩ౒ㅢㆮવ⚛࿃ߦߟ޿ߡ ⷏ේ೑ᴦ✬.
NASH ⸻≮ ਛᄖකቇ␠㧧2008 ᐕ㧦98㧙103㧚
8㧕 ၳᎹᐘ↵, Ⴎ⼱⌀↱⟤. TCF7L2 ㆮવሶ ᴡ⋓ 㓉ㅧ✬. ᣣᧄ⥃ᐥ㧦2008 ᐕ㧦678㧙683.
9㧕 ㋈ᧁ⧷ม㧚C㧚♧ዩ∛ߩ∉ቇ࡮∛ᘒ࡮⸻ᢿቇߩㅴᱠ 㨂㧚♧ዩ∛ᬌᩏቇߩㅴᱠ ♧ዩ∛㑐ㅪ⻉ᬌᩏ᧩᷹ቯ
ᴺ㧘 ⥃ᐥ⊛ᗧ⟵㧘 ⹏ଔᴺ᧩↹௝ᬌᩏ MRA㧘 ᣣᧄ⥃ᐥ ╙ 66 Ꮞ Ⴧೀภ 4 ᣂᤨઍߩ♧ዩ∛ቇ 2 Ꮞᄢ㒋㧦ᣣᧄ⥃ᐥ␠㧧2008 ᐕ㧦546㧙550㧚⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 ㋈ᧁ⧷ม㧚㜞ⴊ♧ߣⴊ▤⎬ൻ㧘Medical View Point 2006 ᐕ㧧27 Ꮞ㧦2㧚2㧕 ᱞ↰ ⚐㧚♧ዩ∛ߣࠗࡦࠬ࡝ࡦᛶ᛫ᕈࠍ߼ߋࠆ࠻ࡇ࠶ࠢࠬ㧘Medical View Point 2006 ᐕ㧧27 Ꮞ㧦1㧚
3㧕 ၳᎹᐘ↵㧚♧ዩ∛ߣࠗࡦࠬ࡝ࡦᛶ᛫ᕈࠍ߼ߋࠆ࠻ࡇ࠶ࠢࠬ㧙ࠗࡦࠬ࡝ࡦᛶ᛫ᕈߣㆮવ⚛࿃㧘Medical View
Point 2006 ᐕ㧧27 Ꮞ㧦4㧚4㧕 ᱞ↰ ⚐㧚♧ዩ∛㧙⤳ེ㓚ኂߩ੍㒐ࠍਛᔃߦ㧘MEDICAMENT NEWS 2006 ᐕ㧧1858 Ꮞ㧦14㧙16㧚㧙㧙

5㧕 Ⴎ⼱⌀↱⟤㧘ၳᎹᐘ↵㧚⤟ፉ⊒⃻ㆮવሶߩࡊࡠࡈࠔࠗ࡝ࡦࠣ㧘ࠥࡁࡓකቇ 2006 ᐕ㧧5 Ꮞ㧦521㧙525㧚
6㧕 ጊᧄ⋿↱⟤㧚ൕഭ⠪ߩ♧ዩ∛ߩ∛ᘒߣ੍㒐㧘ᕺ㇊කᏧળߛࠃࠅ 2006 ᐕ㧧50 Ꮞ㧦35㧙41㧚
7㧕 ᱞ↰ ⚐㧚⚻ญᴦ≮⮎ߦࠃࠆⴊ♧▤ℂߩᦨ೨✢㧘ࡊ࡜ࠢ࠹ࠖࠬ 2006 ᐕ㧧23 Ꮞ㧦335㧙340㧚
8㧕 ૒ ਭ 㑆 ඳ ਽ 㧘 ᑝ ↰ ථ ↵ 㧘 ᧛ ᧻  ቇ 㧘 ቬ  ෹ ෘ 㧚 ේ ⊒ ᕈ ࠕ ࡞ ࠼ ࠬ ࠹ ࡠ ࡦ ∝ ߩ 㘃 ✼ ∔ ᖚ 㧙 Apparent
Mineralocorticoid Excess ∝୥⟲㧘ᣣᧄౝ⑼ቇળ㔀⹹ 2006 ᐕ㧧95 Ꮞ㧦50㧙55㧚
9㧕 ᱞ↰ ⚐㧚♧ዩ∛ߩ⮎‛ᴦ≮ߩࠦ࠷㧘ጘ㒂⋵කᏧળකቇ㔀⹹ 2006 ᐕ㧧19 Ꮞ㧦69㧙72㧚
10㧕 ጊᧄ⋿↱⟤㧚ጘ㒂⋵ߩ߅ߌࠆ♧ዩ∛ኻ╷ߩขࠅ⚵ߺߦߟ޿ߡ㧙♧ዩ∛ߩࡑࡀ࡯ࠫࡔࡦ࠻ࠍਛᔃߦ㧘ጘ㒂⋵කᏧળකቇ㔀⹹ 2006 ᐕ㧧19 Ꮞ㧦63㧙68㧚
11㧕 Ⴎ⼱⌀↱⟤㧘ၳᎹᐘ↵㧘ቬ ෹ෘ㧘ᱞ↰ ⚐㧚⧯ᐕ⊒∝ߩ♧ዩ∛ߦ߅ߌࠆㆮવሶࠬࠢ࡝࡯࠾ࡦࠣ㧘ጘ㒂⋵කᏧળකቇ 㔀⹹ 2006 ᐕ㧧20 Ꮞ㧦29㧙31㧚
12㧕 ጊᧄ⋿↱⟤㧘ᱞ↰ ⚐㧘♿ࡁቯ଻⤿㧚ోᯏ⒳ߩ⥄Ꮖⴊ♧᷹ቯེߩ࠺࡯࠲ࠍጘ㒂ᄢቇ∛㒮ߩ㔚ሶࠞ࡞࠹਄ߢ
ㆇ↪ߐߖࠆ⹜ߺ㧘Q&A ߢࠊ߆ࠆ‫ޟ‬⢈ḩߣ♧ዩ∛‫ ޠ‬2006 ᐕ㧧5 Ꮞ㧦47㧙51㧚
13㧕 ጟ቟િੑ㧘ᱞ↰ ⚐㧘ጊᧄ⋿↱⟤㧚ࠗࡦࠬ࡝ࡦߩ቟ో▤ℂ૕೙ᡷༀࠍ⋡⊛ߣߒߚ㒮ౝᮡḰᦠߩ૞ᚑߣߘߩ
⹏ଔ㧘ࡊ࡜ࠢ࠹ࠖࠬ 2006 ᐕ㧧23 Ꮞ㧦464㧙468㧚
14㧕 ᱞ↰ ⚐㧘ᧃᑝ ᱜ㧘ᨋ⊓ᔒ㓶㧚♧ዩ∛ᖚ⠪ߩ⢽⾰▤ℂߣേ⣂⎬ൻ Medical View Point 2006 ᐕ㧧27
Ꮞ㧦5㧙6㧚
15㧕 ᱞ↰ ⚐㧚ᣣᧄ♧ዩ∛දળߣߪߤࠎߥ࿅૕㧫㧙‫⊓ޟ‬㍳ක‫ߚߒ੺ࠍޠ‬ᣂߒ޿‫⸻∛ޟ‬ᖚㅪ៤‫ߜߚ߆ߩޠ‬㧘ጘ㒂⋵කᏧળႎ 2006 ᐕ㧧660 Ꮞ㧦18㧙19㧚
16㧕 ૒ਭ㑆ඳ਽㧘ᱞ↰ ⚐㧚SHP ߣ♧⢽⾰ઍ⻢㧘ౝಽᴲ࡮♧ዩ∛⑼ 2006 ᐕ㧧23 Ꮞ㧦52㧙56㧚
17㧕 ᱞ↰ ⚐㧚⧯޿ᅚᕈߩ∳ߖᔒะࠍᘷ޿ߡ㧘ጘ㒂⋵කᏧળႎ 2006 ᐕ㧧661 Ꮞ㧦25㧙26㧚
18㧕 Ꮉ࿾ᘕ৻㧘ᱞ↰ ⚐㧚ࡔ࠲ࡏ࡝࠶ࠢࠪࡦ࠼ࡠ࡯ࡓߩਥⷐ∛ᘒߣߘߩ▤ℂ㧙ࡔ࠲ࡏ࡝࠶ࠢࠪࡦ࠼ࡠ࡯ࡓߦ߅
ߌࠆⴊᩖᒻᚑ௑ะ㧘ᣣᧄ⥃ᐥ(Ⴧೀ) 2006 ᐕ㧧64 Ꮞ㧦445㧙448㧚
19㧕 ቬ ෹ෘ㧘ጊ↰ᣤሶ㧘ᑝ↰ථ↵㧘᧛᧻ ቇ㧘⺪⸰ື਽㧚ࡒࡀ࡜ࡠࠦ࡞࠴ࠦࠗ࠼ߩಽሶㆮવቇ㧘ౝಽᴲ࡮♧ዩ∛⑼ 2006 ᐕ㧧23 Ꮞ㧦643㧙647㧚
20㧕 ጊᧄ⋿↱⟤㧚ᗵᨴ∝ߣᄢቇ଻ஜ▤ℂ㧘ో࿖ᄢቇ଻ஜ▤ℂදળ᧲ᶏ࡮ർ㒽࿾ᣇㇱળႎ๔ᦠᐔᚑ 17 ᐕᐲ 2006
ᐕ㧧31㧙34㧚
21㧕 ᱞ↰ ⚐㧘ቬ ෹ෘ㧘ᄢᵢዏม㧘ᨋ ᘕ㧘ਃᶆ ᷕ㧚New Evidence for EVENT REDUCTION in
Hypertensive Patients ᦨᣂߩ ASCOT ⹜㛎߆ࠄ㒠࿶ᴦ≮ߦ߅ߌࠆࡌ࡯ࠬ⮎ߣߒߡߩࠕࡓࡠࠫࡇࡦߩ᦭↪
ᕈࠍᬌ⸽ߔࠆ Medical Tribune 2006 ᐕ㧧1㧙4㧚
22㧕 ᑝ↰ථ↵㧘᧛᧻ ቇ㧘૒ਭ㑆ඳ਽㧘⺪⸰ື਽㧘ቬ ෹ෘ㧘ᱞ↰ ⚐㧚னᕈࠕ࡞࠼ࠬ࠹ࡠࡦ∝㧦ᒝࡒࡁ C ߿↞⨲ࠍ฽߻ṽᣇ⮎ߪ૶ࠊࠇߡ޿ߥ޿߆㧫㧘ᴦ≮ቇ 2006 ᐕ㧧40 Ꮞ㧦893㧙894㧚
23㧕 ᓮ↰᧛⋧ᮨ㧘㐳ἑᳯ೑㧘ᧄᄙᕶሶ㧘↰ਛᓕ㓷㧘ᵻ↰ୃᏒ㧘ᱞ↰ ⚐㧘ጊᧄ⋿↱⟤㧚ጘ㒂ᄢቇߦ߅ߌࠆ༛ᾍ
ኻ╷ߩ᦭ലᕈߩᬌ⸛㧙࠾ࠦ࠴ࡦࡄ࠶࠴ߩቇ↢ήఘឭଏࠍ⹜ߺߡ㧘Campus Health 2006 ᐕ㧧43 Ꮞ㧦160㧚
24㧕 ᧄᄙᕶሶ㧘ᓮ↰᧛⋧ᮨ㧘㐳ἑᳯ೑㧘↰ਛ↢㓷㧘ᵻ↰ୃᏒ㧘’↰ᶈ᮸㧘࿯੗↰⺈㧘ᩊ↰ᢅਯ㧘ᱞ↰ ⚐㧘ጊᧄ⋿↱⟤㧚ᄢቇ↢ߩญ⣧ஜ⸻⚿ᨐߩᬌ⸛㧘Campus Health 2006 ᐕ㧧43 Ꮞ㧦211㧚
25㧕 㐳ἑᳯ೑㧘ᓮ↰᧛⋧ᮨ㧘ᧄᄙᕶሶ㧘↰ਛ↢㓷㧘ᵻ↰ୃᏒ㧘ᱞ↰ ⚐㧘ጊᧄ⋿↱⟤㧚ᄢቇ↢ߩ㗡∩ߩታᘒ⺞ᩏ㧙▤ℂᜰዉ૕೙ߦ㑐ߔࠆᬌ⸛㧘Campus Health 2006 ᐕ㧧43 Ꮞ㧦238㧚
26㧕 ↰ਛ↢㓷㧘᫃Ꮉᐘ਎㧘ᧄᄙᕶሶ㧘ᓮ↰᧛⋧ᮨ㧘㐳ἑᳯ೑㧘ᬀᧁ໪ᢥ㧘ᱞ↰ ⚐㧘ጊᧄ⋿↱⟤㧚UPI ߣ GHQ60
ߩหᤨ⺞ᩏ⚿ᨐࠃࠅ㧘 ቇ↢ஜᐽ⺞ᩏߦ߅ߌࠆ UPI ᦭↪ᕈߩᬌ⸛㧘Campus Health 2006 ᐕ㧧43 Ꮞ㧦269㧚
27㧕 ㋈ᧁ⧷ม㧚♧ዩ∛ࡑࠢࡠࠕࡦࠡࠝࡄࠪ࡯ߩᬌᩏ࡮⸻ᢿᴺߩㅴᱠ ⏛᳇౒㡆ᴺߦࠃࠆᣂߒ޿⸻ᢿᴺ㧘 ᣣᧄ⥃
ᐥ 2006 ᐕ㧧64 Ꮞ㧦2062㧙2068㧚
28㧕 ㋈ᧁ⧷ม㧚Technics Guide ⏛᳇౒㡆ࠍ↪޿ߚࡈ࠶࠻ࡊࡠ࠻ࠦ࡞ߦࠃࠆ♧ዩ∛⿷∛ᄌߩᣧᦼ⊒⷗㧘 Diabetes
Journal 2006 ᐕ㧧35 Ꮞ㧦31㧙35㧚
29㧕 ૒ ਭ㑆ඳ਽ 㧘ᑝ ↰ථ↵㧘 ᧛᧻  ቇ㧘ቬ  ෹ෘ 㧚ౝಽᴲᕈ㜞 ⴊ࿶∝ ⸻ᢿ ߣᴦ≮ߩㅴᱠ  Apparent
Mineralocorticoid Excess ∝୥⟲㧘ᣣᧄౝ⑼ቇળ㔀⹹ 2006 ᐕ㧧95 Ꮞ㧦662㧙667㧚
30㧕 ቬ ෹ෘ㧚ࠕ࡞࠼ࠬ࠹ࡠࡦࠞࠬࠤ࡯࠼ߣㆮવሶᄙဳ㧘කቇߩ޽ࠁߺ 2007 ᐕ㧧221㧦709㧙715㧚
31㧕 ቬ ෹ෘ㧚Cushing ∝୥⟲㧘Year Note ೎ౠ 2007 ᐕ㧧589㧙593㧚
32㧕 㘵Ⴆൎ⟤, ၳᎹᐘ↵. ࠞ࡞ࡄࠗࡦ 10, ࠞ࡜࡯  ♧ዩ∛ቇ̆ၮ␆ߣ⥃ᐥ̆ 2007 ᐕ㧧319㧙322.
33㧕 Ⴎ⼱⌀↱⟤, ၳᎹᐘ↵, ᱞ↰ ⚐. SHP ߣ♧⢽⾰ߦ㑐ߔࠆઍ⻢⇣Ᏹ, ᦨᣂකቇ 2007 ᐕ㧧62 Ꮞ㧦63㧙68㧚
34㧕 ㋈ᧁ⧷ม㧚ᧃ᪳ᓴⅣ㓚ኂߦኻߔࠆᣂߒ޿ࠕࡊࡠ࡯࠴㧘 Diabetes In The News(DITN) 2007 ᐕ㧧353 Ꮞ㧦
8㧚35㧕 ㋈ᧁ⧷ม㧚♧ዩ∛ᖚ⠪ߦ߅ߌࠆᧃ᪳ᓴⅣ㓚ኂߦኻߔࠆᣂߒ޿ࠕࡊࡠ࡯࠴㧘Angiology Frontier 2007 ᐕ㧧
6㧚
36㧕 ጊᧄ⋿↱⟤㧘♿ࡁቯ଻⤿㧘㜞Ⴆ⋥⢻. ක≮ࠍᄌ߃ࠆ IT ൻߩࡔ࡝࠶࠻㧘ක≮ኾ㐷⡯ߩࡑࡀࠫࡔࡦ࠻ᢎ⢒ߦ߅
ߌࠆ IT ᵴ↪ߩน⢻ᕈ ᣂක≮ 2007 ᐕ㧦54㧙57㧚
37㧕 ቬ ෹ෘ. JAC 2007 ᐕࠍᝄࠅ㄰ߞߡ࡯ᦨㄭߩࠕ࡞࠼ࠬ࠹ࡠࡦ⎇ⓥߩേะࠍតࠆ࡯Medical tribune, 2008
ᐕ㧦82㧙83㧚38㧕 ጊᧄ⋿↱⟤㧘Ⴎ⼱⌀↱⟤㧘ၳᎹᐘ↵㧘ᱞ↰ ⚐㧚ጘ㒂Ꮢߦ߅ߌࠆ♧ዩ∛⸻≮ߩታᘒ⺞ᩏ ጘ㒂⋵කᏧળකቇ㔀⹹ 2008 ᐕ㧧21 Ꮞ㧦89㧙94㧚
39㧕 ၳᎹᐘ↵. ♧ዩ∛ߩᣂߒ޿ㆮવ⚛࿃ Diabetes Frontier 2008 ᐕ㧧19 Ꮞ㧦441㧙452㧚 
40㧕 㐳ἑᳯ೑㧘 ᓮ↰᧛⋧ᮨ㧘 ↰ਛ↢㓷㧘 ᱞ↰ ⚐㧘 ጊᧄ⋿↱⟤. ᄢቇ↢ࠍኻ⽎ߦታᣉߒߚ㗡∩ታᘒ⺞ᩏ ቇᩞ଻ஜ⎇ⓥ 2008 ᐕ㧧50 Ꮞ㧦264㧚
41㧕 ጊᧄ⋿↱⟤㧘Ꮉ಴㕏ᒾ㧘ᚭ⼱ℂ⧷ሶ㧘ᱞ↰ ⚐㧘᪢ᧄᢘᄦ㧘♿ࡁቯ଻⤿ጘ㒂⋵කᏧળ∛⸻ㅪ៤ࠪࠬ࠹ࡓߦ߅㧙㧙ߌࠆ㧘♧ዩ∛⸻ㅪ៤ࠨࡐ࡯࠻ࠪࠬ࠹ࡓߩ⹜૞ ⢈ḩߣ♧ዩ∛ 2008 ᐕ㧧7 Ꮞ㧦556㧙561㧚42㧕 ㋈ᧁ⧷ม㧚♧ዩ∛ߣᧃ᪳ᓴⅣ㓚ኂ㧘৻ችකႎ 2008 ᐕ㧧172 Ꮞ㧦12㧙17㧚✚⺑㧔᰷ᢥ㧕
1㧕 Horikawa Y. Calpain-10(NIDDM1) as a susceptibility gene for common type 2 diabetes. Endocr. J.
2007;53:567-576.
2㧕 Iizuka K, Horikawa Y. ChREBP: A glucose-activated transcription factor involved in the developmentof metabolic syndrome Endocr. J .2008;55:617-624.
ේ⪺㧔๺ᢥ㧕
1㧕 ↰ਛ↢㓷㧘ጊᧄ⋿↱⟤㧚ᄢቇ↢ᵴߣࡔࡦ࠲࡞ࡈ࡞ࠬࠨࡐ࡯࠻㧙2005 ᐕጘ㒂ᄢቇቯᦼஜᐽ⸻ᢿᤨ UPI ⺞ᩏࠃࠅ⠨ኤ㧘߉߰♖␹଻ஜ⑔␩ 2006 ᐕ㧧42 Ꮞ㧦47㧙52㧚
2㧕 Ꮉ࿾ᘕ৻㧘ᱞ↰ ⚐㧚᛫ࠕ࡟࡞ࠡ࡯೷ߩ૬↪ߢ⣕ᗵᩏߦᚑഞߒߚහᤨဳోりࠗࡦࠬ࡝ࡦࠕ࡟࡞ࠡ࡯ߩ 1 ଀㧘♧ዩ∛ 2006 ᐕ㧧9 Ꮞ㧦441㧙444㧚
3㧕 ጊᧄ⋿↱⟤㧚࿾ၞක≮ㅪ៤ߣ↢ᵴᜰዉߩ੺౉㧘ౝಽᴲ࡮♧ዩ∛⑼ 2006 ᐕ㧧24 Ꮞ㧦32㧙37㧚
4㧕 ጊᧄ⋿↱⟤㧘ᓮ↰᧛⋧ᮨ㧘㐳ἑᳯ೑㧘↰ਛ↢㓷㧘ᵻ↰ୃᏒ㧘૒ᯅᢥੳ㧘’↰ᶈ᮸㧘࿯੗↰⺈㧘ᩊ↰ᢅਯ㧘ᱞ↰ ⚐㧚ጘ㒂ᄢቇ↢ߦᱤ⑼ஜᐽ⸻ᢿࠍታᣉߒߡ㧘Campus Health 2006 ᐕ㧧44 Ꮞ㧦109㧙114㧚
5㧕 ጊᧄ⋿↱⟤㧚࿾ၞක≮ㅪ៤ߣ↢ᵴᜰዉߩ੺౉㧘ౝಽᴲ࡮♧ዩ∛⑼ 2007 ᐕ㧧24 Ꮞ㧦32㧙37㧚
6㧕 ጊᧄ⋿↱⟤㧘ᓮ↰᧛⋧ᮨ㧘㐳ἑᳯ೑㧘↰ਛ↢㓷㧘ᵻ↰ୃᏒ㧘૒ᯅᢥੳ㧘’↰ᶈ᮸㧘࿯੗↰⺈㧘ᩊ↰ᢅਯ㧘ᱞ↰ ⚐㧚ጘ㒂ᄢቇ↢ᱤ⑼ஜᐽ⸻ᢿࠍታᣉߒߡ㧘Campus Health 2007 ᐕ㧧24 Ꮞ㧦109㧙114㧚
7㧕 ጊᧄ⋿↱⟤㧘ᱞ↰ ⚐㧘♿ࡁቯ଻⤿㧚SMBG ࠺࡯࠲ߩ㔚ሶࠞ࡞࠹਄ߢߩㆇ↪ߪ㧫⥄Ꮖⴊ♧᷹ቯེߩ࠺࡯࠲
ࠍ㔚ሶࠞ࡞࠹਄ߢㆇ↪ߐߖࠆ⹜ߺߦߟ޿ߡᢎ߃ߡߊߛߐ޿㧘⢈ḩߣ♧ዩ∛ 2007 ᐕ㧧6 Ꮞ㧦475㧙477㧚
8㧕 ᧄᄙᕶሶ㧘૒ᯅᢥੳ㧘ᓮ↰᧛⋧ᮨ㧘㐳ἑᳯ೑㧘⥓੗ࠆࠅሶ㧘↰ਛ↢㓷㧘’↰ᒄ᮸㧘࿯੗↰⺈㧘ᩊ↰ᢅਯ㧘ᱞ↰ ⚐㧘ጊᧄ⋿↱⟤㧚ᄢቇ↢ߦ߅ߌࠆญ⣧ߩஜᐽ⁁ᘒߣ↢ᵴ⠌ᘠߣߩ㑐ㅪߦߟ޿ߡ㧘ቇᩞ଻ஜ⎇ⓥ 2007
ᐕ㧧49 Ꮞ㧦112㧙116㧚
9㧕 ቬ ෹ෘ㧘ጊ↰ትሶ㧘ᑝ↰ථ↵㧘Ꮉ࿾ᘕ৻㧘૒‫ᧁޘ‬ᤘᒾ㧘⺪⸰ື਽㧘ᱞ↰ ⚐㧚㘩Ⴎᗵฃᕈㆮવሶ㧘ⴊ࿶
2007 ᐕ㧧14 Ꮞ㧦958㧙962㧚ౝ೨㕙⑌ᾍߦ㑐ߔࠆή⸥ฬ⥄⸥ᑼ⺞ᩏ㧘⑌ᾍ⑼ቇ 2007 ᐕ㧧1 Ꮞ㧦10㧙15㧚
10㧕 ጊᧄ⋿↱⟤㧘↰ਛ↢㓷㧘ᱞ↰ ⚐㧘㤥ᧁ⊓ᔒᄦ㧚ᄢቇߩቇ↢࡮⡯ຬోຬߦᣉⴕߒߚᢝ࿾ౝ೨㕙⑌ᾍߦ㑐ߔࠆή⸥ฬ⥄⸥ᑼ⺞ᩏ㧘⑌ᾍ⑼ቇ 2007 ᐕ㧧1 Ꮞ㧦10㧙15㧚
11㧕 ጊᧄ⋿↱⟤㧘↰ਛ↢㓷㧘ᱞ↰ ⚐㧘㤥ᧁ⊓ᔒᄦ㧚ᄢቇ⡯ຬߩ༛ᾍ⠪ࠍኻ⽎ߦታᣉߒߚ༛ᾍߩታᘒ⺞ᩏ㧙ᢝ࿾ౝో㕙⑌ᾍᣉⴕ 2 ᐕࠍ⚻ㆊߒߡ㧘ᣂක≮ 2007 ᐕ㧧1 Ꮞ㧦18㧙23㧚
12㧕 ⥓੗ࠆࠅሶ, ↰ਛ↢㓷, ૒ᯅᢥੳ, ᓮ↰᧛⋧ᮨ, 㐳ἑᳯ೑, ᱞ↰ ⚐, ጊᧄ⋿↱⟤. ஜᐽ⸻ᢿߩ⾰ߩะ਄ࠍ⋡ᜰߒߡ࡯ቇ↢ߩฃ⸻ḩ⿷ᐲߩⷰὐ߆ࠄ࡯, Campus Health 2007 ᐕ㧧1 Ꮞ㧦125㧚
13㧕 ૒ᯅᢥੳ㧘↰ਛ↢㓷㧘ᓮ↰᧛⋧ᮨ㧘㐳ἑᳯ೑㧘⥓੗ࠆࠅሶ㧘ᱞ↰ ⚐㧘ጊᧄ⋿↱⟤. ቇ↢㧘⡯ຬోຬߦᣉ
ⴕߒߚቇౝ⑌ᾍߩࠕࡦࠤ࡯࠻⺞ᩏ̆ᢝ࿾ౝ⑌ᾍታᣉ 2 ᐕࠍ⚻ㆊߒߡ࡯, Campus Health 2007 ᐕ㧧44
Ꮞ㧦149㧚
14㧕 ↰ਛ↢㓷, ᫃Ꮉᐘ਎, ᧄᄙᕶሶ㧘ᓮ↰᧛⋧ᮨ, 㐳ἑᳯ೑㧘⥓੗ࠆࠅሶ, ᱞ↰ ⚐, ጊᧄ⋿↱⟤. ቇ↢↢ᵴߢ᳞߼ࠄࠇࠆ଻ஜ▤ℂ࠮ࡦ࠲࡯ ࡯ࡔࡦ࠲࡞ࡋ࡞ࠬࠨࡐ࡯࠻ߩᓎഀߦ㑐ߔࠆᬌ⸛̆, Campus Health 2007
ᐕ㧧44 Ꮞ㧦196㧚
15㧕 ᫃Ꮉᐘ਎, ↰ਛ↢㓷, Ꮉፉᕺሶ, Ꮉㄝᢘሶ, ૒ᯅᢥੳ, ᓮ↰᧛⋧ᮨ, 㐳ἑᳯ೑, ᱞ↰ ⚐, ጊᧄ⋿↱⟤.
UPI ᓧὐߣ↢ᵴ⠌ᘠ⺞ᩏߩ㑐ㅪߦߟ޿ߡ, Campus Health 2007 ᐕ.㧧44 Ꮞ㧦198㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Yoshimura T, Suzuki E , Egawa K, Nishio Y, Maegawa H, Morikawa S, Inubushi T, Hisatomi A,
Fujimoto K, Kashiwagi K. Low blood flow estimates in lower-leg arteries predict cardiovascular event
in Japanese patients with type 2 diabetes with normal ankle-brachial indexes. Diabetes Care.
2006;29:1884-1890.
2㧕 Isomura Y, Mune T, Morita H, Suwa T, Takeda N, Yamamoto Y, Takeda J. Physiologic role of11Ǫ-hydroxysteroid dehydrogenase type 2 in kidney. Metabolism. 2006;55:1352-1357.
3㧕 Yokoi N, Kanamori M, Horikawa Y, Takeda J, Sanke T, Furuta H, Nanjo K, Mori H, Kasuga M, Hara K,
Kadowaki T, Tanizawa Y, Oka Y, Iwami Y, Ohgawara H, Yamada Y, Seino Y, Yano H, Cox NJ, Seino S.
Association studies of variants in the genes involved in pancreatic Ǫ-cell function in type 2 diabetes inJapanese. Diabetes. 2006;55:2379-2386.
4㧕 Gu N, Adachi T, Matsunaga T, Takeda J, Tsujimoto G, Ishihara A, Yasuda K, Tsuda K. Mutant HNF-1
ǩand mutant HNF-1 Ǫidentified in MODY3 and MODY5 downregulate DPP-IV gene expression in
Caco-2 cells. Biochem Biophys Res Commun. 2006;346:1016-1023.
5㧕 Gu N, Adachi T, Takeda J, Aoki N, Tsujimoto G, Ishihara A, Yasuda K, Tsuda K. Surrase-isomaltase
gene expression is inhibited by mutant hepatocyte nuclear factor (HNF)-1 ǩand mutant HNF-1 ǪinCaco-2 cells. J Nutr Sci Vitaminol. 2006;52:105-112.
6㧕 Moro H, Sato H, Ida I, Oshima A, Sakurai N, Shihara N, Horikawa Y, Mikuni M. Effect SKF-38393, adopamine D1 receptor agonist on expression of amphetamine-induced behavioral sensitization andexpression of immediate early gene are in prefrontal cortex of rats. Pharmacol Biochem Behav.
2007;87:56-64.

㧙㧙

IF 7.071
IF 2.143

IF 8.848

IF 2.904

IF 0.784

IF 2.092

7㧕 Hamaguchi M, Kojima T, Takeda N, Nagata C, Takeda J, Sarui H, Kawahito Y, Yoshida N, Suetsugu A,
Kato T, Okuda J, Ida K, Yoshokawa T. Nomalcoholic fatty liver disease is a novel predictor of
cardiovascular disease. World J Gastroenterol. 2007;13:1579-1584.
IF 3.318
8㧕 Yamada Y, Sekihara H, Omura M, Yanase T, Takayanagi R, Mune T, Yasuda K, Ishizuka T, Ueshiba H,
Miyachi Y, Iwasaki T, Nakajima A, Nawata H. Changes in serum sex hormone profiles after
short-term low-dose administration of dehydroepiandrosterone (DHEA)to young and elderlypersons.
Endocr J. 2007;54:153-162.
IF 1.1409㧕 Ishizuka T, Miura A, Kajita K, Matsumoto M, Sugiyama C, Matsubara K, Ikeda T, Mori I, Morita H,
Uno Y, Mune T, Kanoh Y, Ishizawa M. Effect of dehydroepiandrosterone on insulin sensitivity in
Otsuka Long-Evans Tokushima-fatty rats. Acta Diabetol. 2007;44:219-226.
IF 1.676
10㧕 Oda N, Imamura S, Fujita T, Inagaki K, Kakizawa H, Hayakawa N, Suzuki A, Takeda J, Horikawa Y,
Itoh M. The ratio of leptin / adiponectin can be used as an index of insulin resistance. Metabolism.
2008;57:268-273.
IF 2.647
11㧕 Miyake K, Horikawa Y, Hara K, Yasuda K, Osawa H, Furuta H, Hirota Y, Yamagata K, Hinokio Y, Oka
Y, Iwasaki N, Iwamoto Y, Yamada Y, Seino Y, Maegawa H, Kashiwagi A, Yamamoto K, Tokunaga K,
Takeda J, Makino H, Nanjo K, Kadowaki K, Kasuga M. Association of TCF7L2 polymorphisms withsusceptibility to type 2 diabetes in 4,087 Japanese subjects. J Hum Genet. 2008;53:174-180.
IF 2.275
12㧕 Zenibayashi M, Miyake K, Horikawa Y, Hirota Y, Teranishi T, Kouyama K, Sakaguchi K, Takeda J,
Kasuga M. Lack of association of LRP5 and LRP6 polymorphisms with type 2 diabetes mellitus in theJapanese population. Endocr J. 2008;55:699-707.
IF 1.572
13㧕 Horikawa Y, Miyake K, Yasuda K, Enya M, Hirota Y, Yamagata K, Hinokio Y, Oka Y, Iwasaki N,
Iwamoto Y, Yamada Y, Seino Y, Maegawa H, Kashiwagi A, Yamamoto K, Tokunaga K, Takeda J,
Kasuga M. Replication of genome-wide association studies of type 2 diabetes susceptibility in Japan. J
Clin Endocrinol Metab. 2008;93:3136-3141.
IF 5.493
14㧕 Sato H, Horikawa Y, Iizuka K, Sakurai N, Tanaka T, Shihara N, Ohshima A, Takeda J, Mikuni M.
Large-scale analysis of glucocorticoid target genes in rat hypothalamus. J Neurochem.
2008;106:805-814.
IF 4.451
15㧕 Enya M, Horikawa Y, Kuroda E, Yonemaru K, Tonooka N, Tomura H, Oda N, Shihara N, Iizuka K,
Saibara T, Takeda J. Mutations in the small heterodimer partner gene increase morbidity risk inJapanese type 2 diabetes patients. Hum Mutat. 2008;29:E271-E277.
IF 6.273
16㧕 Hirota T, Suzuki E, Ito I, Ishiyama M, Goto S, Horikawa Y, Asano T, Kanematsu M, Hoshi H, Takeda J.
Coronary artery calcification, arterial stiffness and renal insufficiency associate with serum levels oftumor necrosis factor-alpha in Japanese type 2 diabetic patients. Diabetes Res Clin Pract.
2008;82:58-65.
IF 1.823
17㧕 Iizuka K, Horikawa Y. Regulation of lipogenesis via BHLHB2/DEC1 and ChREBP feedback looping
Biochem Biophys Res Commun. 2008;374:95-100.
IF 2.749
18㧕 Okauchi Y, Iwahashi H, Okita K, Yuan M, Matsuda M, Tanaka T, Miyagawa J, Funahashi T, Horikawa
Y, Shimomura I, Yamagata K. PGC-1D Gly482Ser polymorphism is associated with the plasma
adiponectin level in type 2 diabetic men. Endocr J. 2008;55:991-997.
IF 1.572
19㧕 Yasuda K, Miyake K, Horikawa Y, Hara K, Osawa H, Furuta H, Hirota Y, Mori H, Jonsson A, Sato Y,
Yamagata K, Hinokio Y, Wang HY, Tanahashi T, Nakamura N, Oka Y, Iwasaki N, Iwamoto Y, Yamada Y,
Seino Y, Maegawa H, Kashiwagi A, Takeda J, Maed E, Shin HD , Cho YM, Park KS, Lee HK, Ng MCY,
Ma RCW, So WY, Chan JCN, Lyssenko V, Tuomi T, Nilsson P, Groop L, Kamatani N, Sekine A,
Nakamura Y, Yamamoto K, Yoshida T, Tokunaga K, Itakura M, Makino H, Nanjo K, Kadowaki T,
Kasuga M.A multistage genome-wide association study identifies SNPs in KCNQ1 associated withsusceptibility to type 2 diabetes mellitusNat Genet. 2008;40:1092-1097.
IF 25.556
20㧕 Tokunaga A, Horikawa Y, Fukuda-Akita E, Okita K, Iwahashi H, Shimomura I, Takeda J, Yamagata K.
A common polymorphism in the P2 promoter of hepatocyte nuclear factor-4ǩgene is associated withan index of the early-phase insulin secretion in Japanese subjects with type 2 diabetes. Endocr J.
2008;55:999-1004.
IF 1.572
21㧕 Sasaki A, Horikawa Y, Suwa T, Enya M, Kawachi S, Takeda J. Case report of familial Carney complex
due to novel frameshift mutation c.597del C (p.Phe200LeufsX6) in PRKAR1A. Mol Genet Metab.
2008;95:182-187.
IF 2.550
22㧕 Kajita K, Mune T, Ikeda T, Matsumoto M, Uno Y, Sugiyama C, Matsubara K, Morita H Takemura M,
Seishima M, Takeda J, Ishizuka T. Effect of fasting on PPARJ and AMPK activity in adipocytes.
Diabetes Res Clin Pract. 2008;81:144-149.
IF 1.8234㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦ᱞ↰ ⚐㧧⑼ቇᛛⴚᝄ⥝੐ᬺ࿅࡮ᚢ⇛⊛ഃㅧ⎇ⓥ (CREST)㧦ォ౮⺞▵♽ߩಽሶ⸃೬ߦ
ࠃࠆ♧ዩ∛⚛࿃ߩត⚝㧧ᐔᚑ 14㧙19 ᐕᐲ㧧455,970 ජ౞(52,000㧦106,200㧦107,500㧦107,270㧦
83,000 ජ౞)㧙㧙2㧕 ⎇ⓥઍ⴫⠪㧦ᱞ↰ ⚐㧧ᢥㇱ⑼ቇ⋭⑼⎇⾌․ቯ㗔ၞ㧦⤟ፉ․⇣⊛ㆮવሶߩ⊒⃻⺞▵ゲߦὶὐࠍ⛉ߞߚ♧ዩ∛ㆮવሶߩត⚝㧧ᐔᚑ 17㧙20 ᐕᐲ㧧21,000 ජ౞(5,900㧦5,400㧦5,700㧦4,000 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦ർ಴ᐘᄦ㧘⎇ⓥಽᜂ⠪㧦ᱞ↰ ⚐㧧⚻ᷣ↥ᬺ⋭࿾ၞᣂ↢ࠦࡦ࠰࡯ࠪࠕࡓ੐ᬺ㧦㜞ല₸ࡁ࠶ࠢ࠳࠙ࡦᯏ⢻ࠍ᦭ߔࠆ siRNA ⵾ㅧᴺߩ㐿⊒ߣᵴ↪㧧ᐔᚑ 17㧙18 ᐕᐲ㧧8,000 ජ౞(4,000㧦4,000ජ౞)
4㧕 ⎇ⓥઍ⴫⠪㧦ၳᎹᐘ↵㧧ෘ↢ഭ௛⋭ࡅ࠻ࠥࡁࡓ࡮ౣ↢ක≮⎇ⓥ੐ᬺ㧦ࠞ࡞ࡄࠗࡦ 10 㑐ㅪಽሶࠍ↪޿
ߚ 2 ဳ♧ዩ∛ㆮવሶ⸻ᢿᴺߣᣂⷙᴦ≮ᴺߩ㐿⊒㧧ᐔᚑ 16㧙18 ᐕᐲ㧧107,379 ජ౞(41,550㧦37,868㧦
27,961 ජ౞)
5㧕 ⎇ⓥઍ⴫⠪㧦ၳᎹᐘ↵㧧⚻ᷣ↥ᬺ⋭ࠥࡁࡓഃ⮎ടㅦൻᡰេࡃࠗࠝၮ⋚ᛛⴚ㐿⊒⾌㧦ൻว‛╬ࠍᵴ↪
ߒߚ↢‛ࠪࠬ࠹ࡓ೙ᓮၮ⋚ᛛⴚ㐿⊒㧧ᐔᚑ 18㧙20 ᐕᐲ㧧193,000 ජ౞(85,000㧦68,000㧦40, 000 ජ౞)6㧕 ⎇ⓥઍ⴫⠪㧦ၳᎹᐘ↵㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌㧦ᣂⷙ⤟ፉಽᴲ࠲ࡦࡄࠢߣ♧ዩ∛ᄢⴊ▤∝ߩ࡝ࡦࠢ㧧ᐔᚑ 18 ᐕᐲ㧧1,200 ජ౞7㧕 ⎇ⓥઍ⴫⠪㧦Ⴎ⼱⌀↱⟤㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌㧦ࠗࡦࠬ࡝ࡦಽᴲᛥ೙ㆮવሶ߆ࠄߺߚᣂⷙ 2 ဳ♧ዩ∛ᗵฃᕈㆮવሶߩ₪ᓧ㧧ᐔᚑ 18 ᐕᐲ㧧1,200 ජ౞8㧕 ⎇ⓥઍ⴫⠪㧦ၳᎹᐘ↵㧧ోᣣᧄࠦ࡯ࡅ࡯දળ⎇ⓥഥᚑ㊄㧦ᣂⷙࠦ࡯ࡅ࡯᛽಴ᚑಽߦࠃࠆࠗࡦࠬ࡝ࡦ
ಽᴲᵴᕈൻᯏ᭴ߩ⸃᣿㧧ᐔᚑ 19 ᐕᐲ㧧1,300 ජ౞9㧕 ⎇ⓥઍ⴫⠪㧦ၳᎹᐘ↵㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌(⎇ⓥ)㧦⢄ࠗࡦࠬ࡝ࡦࠢ࡝ࠕ࡜ࡦࠬᵴᕈൻߣ޿߁ᣂⷙ 2ဳ♧ዩ∛ᴦ≮᭎ᔨߩ⏕┙㧧ᐔᚑ 19 ᐕᐲ㧧600 ජ౞
10㧕 ⎇ⓥઍ⴫⠪㧦ᱞ↰ ⚐㧧ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄㧧ഃ⮎ၮ⋚ផㅴ⎇ⓥ੐ᬺ㧦૕⢽⢌ᷫዋ࿃ሶࠍ↪
޿ߚ 2 ဳ♧ዩ∛ߩᴦ≮㧧ᐔᚑ 19㧙20 ᐕᐲ㧧97,167 ජ౞(50,326㧦46,841 ජ౞)
11㧕 ⎇ⓥઍ⴫⠪㧦Ꮉ࿾ᘕ৻㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌(⎇ⓥ)㧦ォ౮࿃ሶ HNF-1ǩߣ HNF-1Ǫߩᮡ⊛ㆮવሶߩ✂⟜⊛⸃ᨆߦࠃࠆᯏ⢻Ꮕ⇣ߩ⸃᣿㧧ᐔᚑ 19 ᐕᐲ㧧1,130 ජ౞
12㧕 ⎇ⓥઍ⴫⠪㧦ቬ ෹ෘ㧧ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ 㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ㧦೽⣢ࡎ࡞ࡕࡦ↥↢⇣Ᏹߦ㑐ߔࠆ⺞ᩏ⎇ⓥ㧧ᐔᚑ 19 ᐕᐲ㧧500 ජ౞
13㧕 ⎇ⓥઍ⴫⠪㧦ᱞ↰ ⚐㧧ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄㧧ᓴⅣེ∔ᖚ╬↢ᵴ⠌ᘠ∛ኻ╷✚ว⎇ⓥ੐ᬺ㧦ᓴⅣེ࡝ࠬࠢߣ⠴♧⢻㓚ኂߩലᨐ⊛ߥஜ⸻ࡑ࡯ࠞ࡯ߩត⚝㧧ᐔᚑ 20 ᐕᐲ㧧18,945 ජ౞
14㧕 ⎇ⓥઍ⴫⠪㧦ᱞ↰ ⚐㧧ᣣᧄቇⴚᝄ⥝ળ⑼ቇ⎇ⓥ⾌⵬ഥ㊄⪚⧘⎇ⓥ㧦‫⤟ޟ‬ፉᯏ⢻ߦ㑐ㅪߔࠆࡑࠗࠢࡠ
ಽሶߩหቯߣᯏ⢻⸃ᨆ㧧ᐔᚑ 20 ᐕᐲ㧧1,900 ජ౞
2㧕ฃ⸤⎇ⓥ1㧕 ᱞ↰ ⚐㧦ࠗࡦࠬ࡝ࡦ૶↪ਛߩ 2 ဳ♧ዩ∛ᖚ⠪ࠍኻ⽎ߣߒߚᔃⴊ▤♽ࠗࡌࡦ࠻⊒↢࡝ࠬࠢߦ㑐ߔࠆᬌ⸛㧧ᐔᚑ 19㧙22 ᐕᐲ㧧1,500 ජ౞㧦ࠨࡁࡈࠖ࡮ࠕࡌࡦ࠹ࠖࠬᩣᑼળ␠
2㧕 ᱞ↰ ⚐㧦࡟ࡒࠤ࡯࠼ὐṢ㕒ᵈ↪ 100 ૶↪ᚑ❣⺞ᩏ㧧ᐔᚑ 19㧙20 ᐕᐲ㧧315 ජ౞㧦
3㧕 ᱞ↰ ⚐㧦‫ࠬࠪ࡯࠲ࠬޟ‬㍤‫᦭ޠ‬ኂ੐⽎⹦⚦⺞ᩏ㧧ᐔᚑ 19 ᐕᐲ㧧21 ජ౞㧦
4㧕 ᱞ↰ ⚐㧦ࡒࠞ࡞࠺ࠖࠬ㍤ ․ቯ૶↪ᚑ❣⺞ᩏ㨪㐳ᦼ૶↪ᤨߩ⣖࡮ᔃⴊ▤ࠗࡌࡦ࠻ߦ㑐ߔࠆ⺞ᩏ㧧
ᐔᚑ 18㧙21 ᐕᐲ㧧252 ජ౞
5㧕 ᱞ↰ ⚐㧦࠰ࡃࡑ࡯࠻․ቯ૶↪ᚑ❣⺞ᩏ̆㐳ᦼ૶↪ߦ㑐ߔࠆ⺞ᩏ̆(ࡊࡠ࠻ࠦ࡯࡞ No.A6291023㧧ᐔᚑ 20㧙25 ᐕᐲ㧧189 ජ౞
6㧕 ࡅࡘ࡯ࡑ࠻ࡠ࡯ࡊ․ቯ૶↪ᚑ❣⺞ᩏ̆ᚑੱᚑ㐳ࡎ࡞ࡕࡦಽᴲਇో∝(㊀∝ߦ㒢ࠆ)㧧ᐔᚑ 20㧙21 ᐕᐲ㧧126 ජ౞7㧕 ࠕࠢ࠹ࡓ࡜․ቯ૶↪ᚑ❣⺞ᩏ(ో଀⺞ᩏ)㑐▵࡝࠙ࡑ࠴̆ᄙ㑐▵ߦᵴേᕈࠍ᦭ߔࠆ⧯ᐕᕈ⓭⊒ᕈ㑐▵Ἳ̆㧧ᐔᚑ 20㧙25 ᐕᐲ㧧94,500 ජ౞㧦ਛᄖ⵾⮎ᩣᑼળ␠8㧕 ࠕࠢ࠹ࡓ࡜․ቯ૶↪ᚑ❣⺞ᩏ(㐳ᦼࡈࠜࡠ࡯ࠕ࠶ࡊ⺞ᩏ)㑐▵࡝࠙ࡑ࠴㧧ᐔᚑ 20㧙25 ᐕᐲ㧧31,500 ජ౞㧦ਛᄖ⵾⮎ᩣᑼળ␠
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫ
ߥߒ

㧙㧙

6㧚ቇળᵴേ
1㧕ቇળᓎຬ
ᱞ↰ ⚐㧦
1㧕 ᣣᧄౝ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ♧ዩ∛ቇળ⋙੐㧘⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ♧ዩ∛ว૬∝ቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄ♧ዩ∛ᅧᆼቇળℂ੐㧘⹏⼏ຬ(㨪⃻࿷)5㧕 ᣣᧄ∛ᘒᩕ㙃ቇળ⹏⼏ຬ(㨪⃻࿷)6㧕 ᣣᧄౝಽᴲቇળઍ⼏ຬ(㨪⃻࿷)7㧕 ᣣᧄ⠧ᐕ∛ቇળ⹏⼏ຬ(㨪⃻࿷)8㧕 ᣣᧄ♧ዩ∛⌒ቇળℂ੐(㨪⃻࿷)9㧕 ᣣᧄੱ㘃ㆮવቇળ⹏⼏ຬ(㨪⃻࿷)ቬ ෹ෘ㧦
1㧕 ᣣᧄౝಽᴲቇળઍ⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄࠬ࠹ࡠࠗ࠼ࡎ࡞ࡕࡦቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄᔃⴊ▤ౝಽᴲઍ⻢ቇળ⹏⼏ຬ(㨪⃻࿷)ၳᎹᐘ↵㧦1㧕 ᣣᧄ∛ᘒቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ♧ዩ∛ቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄੱ㘃ㆮવቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄౝಽᴲቇળઍ⼏ຬ(㨪⃻࿷)ጊᧄ⋿↱⟤㧦
1㧕 ᣣᧄ♧ዩ∛ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄౝ⑼ቇળ᧲ᶏ࿾ᣇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄౝಽᴲቇળઍ⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄ⥃ᐥᩕ㙃ቇળ⹏⼏ຬ(㨪⃻࿷)5㧕 ᣣᧄ∛ᘒᩕ㙃ቇળ⹏⼏ຬ(㨪⃻࿷)6㧕 ᣣᧄᴤൻቇળ᧲ᶏᡰㇱᏱછᓎຬ(㨪⃻࿷)㋈ᧁ⧷ม㧦1㧕 ᣣᧄ♧ዩ∛ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
ᱞ↰ ⚐㧦
1㧕 ᣣᧄੱ㘃ㆮવቇળ㧧✬㓸ᆔຬ(㨪⃻࿷)2㧕 ᣣᧄౝ⑼ቇળ㧦⧷ᢥ⹹✬㓸ᆔຬ(㨪⃻࿷)7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ᱞ↰ ⚐㧦
1㧕 ╙ 40 ࿁♧ዩ∛ቇߩㅴᱠ(2006 ᐕ 2 ᦬㧘㊄ᴛ㧘․೎⻠Ṷ‫⚻ޟ‬ญᴦ≮⮎ߦࠃࠆⴊ♧▤ℂߩᦨ೨✢‫ޠ‬Ṷ⠪)2㧕 2006 ᐕࡊ࡜ࠗࡑ࡝ࠤࠕቇળ(2006 ᐕ 5 ᦬㧘ฬฎደ㧘․೎⻠Ṷ‫♧ޟ‬ዩ∛ߣᔃⴊ▤∛࡝ࠬࠢ‫ޠ‬Ṷ⠪)
3㧕 ╙ 27 ࿁ᣣᧄ⢈ḩቇળ(2006 ᐕ 10 ᦬㧘␹ᚭ㧘․೎⻠Ṷ‫ࡦࡕࠦޟ‬ઍ⻢∛ߩᣣᧄੱ૕⾰‫ޠ‬Ṷ⠪)
4㧕 ╙ 43 ࿁ᣣᧄ♧ዩ∛ቇቇળㄭ⇰࿾ᣇળ(2006 ᐕ 11 ᦬㧘੩ㇺ㧘․೎⻠Ṷ‫ޟ‬ᣣᧄੱ 2 ဳ♧ዩ∛ߣᔃⴊ▤ࠗࡌࡦ࠻࡝ࠬࠢ‫ޠ‬Ṷ⠪)5㧕 ක⑼ቇᔕ↪⎇ⓥ⽷࿅╙ 50 ࿁ቇⴚ⻠Ṷળ(2006 ᐕ 11 ᦬㧘ฬฎደ㧘․೎⻠Ṷ‫♧ޟ‬ዩ∛ߣᔃⴊ▤ࠗࡌࡦ࠻‫ޠ‬Ṷ⠪)
6㧕 ╙ 6 ࿁ಽሶ੍㒐ⅣႺකቇ⎇ⓥળ(2006 ᐕ 12 ᦬㧘੩ㇺ㧘․೎⻠Ṷ‫♧ޟ‬ዩ∛ߩᣣᧄੱߩಽሶ∉ቇ‫ޠ‬Ṷ⠪)㧙㧙

7㧕 ╙ 3 ࿁౏㐿ࠪࡦࡐࠫ࠙ࡓ‫࠼ࠗࡔ࡯࡜࡯࠹ޟ‬ක≮ࠍ⋡ᜰߒߚࠥࡁࡓᖱႎᵴ↪ၮ⋚ᛛⴚ‫(ޠ‬2007 ᐕ 8 ᦬㧘᧲੩㧘‫ޟ‬ォ౮ࡀ࠶࠻ࡢ࡯ࠢߩಽሶ⸃೬ߦࠃࠆ♧ዩ∛⚛࿃ߩหቯ‫ޠ‬Ṷ⠪)8㧕 ╙ 42 ࿁♧ዩ∛ቇߩㅴᱠ(2008 ᐕ 2 ᦬㧘㜞᧻㧘․೎⻠Ṷ‫ޟ‬ォ౮࿃ሶ⇣Ᏹߦࠃࠆࠗࡦࠬ࡝ࡦวᚑಽᴲ㓚ኂ‫ޠ‬ᐳ㐳 
9㧕 ╙ 23 ࿁♧ዩ∛ว૬∝ቇળ(2008 ᐕ 10 ᦬㧘᧲੩㧘․೎⻠Ṷ‫ޟ‬2 ဳ♧ዩ∛ᖚ⠪ߩ࠻࡯࠲࡞࡝ࠬࠢࡑࡀ
࡯ࠫࡔࡦ࠻‫ޠ‬ᐳ㐳 ቬ ෹ෘ㧦
1㧕 International Symposium The Kidney and Hypertension(2006 ᐕ 10 ᦬㧘઄บ㧘․೎⻠Ṷ‫ޟ‬Common
genetic variation in the mineralocorticoid pathway‫ޠ‬Ṷ⠪)
2㧕 ISH Symposium for Aldosterone Hypertension(2006 ᐕ 10 ᦬㧘᧲੩㧘․೎⻠Ṷ‫ޟ‬Polymorphisms in
the aldosterone cascade‫ޠ‬Ṷ⠪)
3㧕 ╙ 29 ࿁ㄭ⇰ౝಽᴲߣ㜞ⴊ࿶⎇ⓥળ(2006 ᐕ 11 ᦬㧘ᄢ㒋㧘․೎⻠Ṷ‫ޟ‬Re-definition of 11ǪHSDs‫ޠ‬Ṷ⠪)ၳᎹ ᐘ↵㧦1㧕 ╙ 7 ࿁㒋␹ࡔ࠲ࡏ࡝࠭ࡓ⎇ⓥળ(2006 ᐕ 6 ᦬㧘ዦፒ㧘᜗ᓙ⻠Ṷ‫ޟ‬2 ဳ♧ዩ∛ߣㆮવ⚛࿃‫ޠ‬Ṷ⠪)2㧕 ᳯ⯃ᄢቇ⻠Ṷળ(2006 ᐕ 6 ᦬㧘ਛ࿖ᳯ⯃⋭㎾ᳯᏒ㧘᜗ᓙ⻠Ṷ‫♧ޟ‬ዩ∛ߩㆮવቇ⎇ⓥߩᣂߒ޿ዷ㐿‫ޠ‬Ṷ⠪)3㧕 ᳯ⯃ᄢቇ⻠Ṷળ(2006 ᐕ 6 ᦬㧘ਛ࿖ᳯ⯃⋭㎾ᳯᏒ㧘᜗ᓙ⻠Ṷ‫ޟ‬ᣣᧄߩ♧ዩ∛ᴦ≮ߩ⃻⁁‫ޠ‬Ṷ⠪)
4㧕 ࠥࡁࡓഃ⮎ࡈࠜ࡯࡜ࡓ╙ 9 ࿁ࠪࡦࡐࠫ࠙ࡓ(2006 ᐕ 11 ᦬㧘᧲੩㧘᜗ᓙ⻠Ṷ‫⋧⾰ࠢࡄࡦ࠲ޟ‬੕૞↪ὐ
ߦࠃࠆ 2 ဳ♧ዩ∛ㆮવሶࡄ࠭࡞ߩ⸃᣿‫ޠ‬Ṷ⠪)
5㧕 ╙ 12 ࿁ࠪࡦࡐࠫ࠙ࡓ♧ዩ∛(2008 ᐕ 4 ᦬㧘᧲੩㧘․೎⻠Ṷ‫♧ޟ‬ዩ∛⤟ፉಽᴲ࠲ࡦࡄࠢ(ࠝࠬ࠹ࠝࡀࠢ࠴ࡦ)ߣ♧ዩ∛ᄢⴊ▤∝ߩ࡝ࡦࠢ‫ޠ‬Ṷ⠪)
6㧕 ╙ 43 ࿁ㆮવකቇ⎇ⓥળ(2008 ᐕ 11 ᦬㧘᧲੩㧘․೎⻠Ṷ‫♧ޟ‬ዩ∛ᗵฃᕈㆮવሶหቯߩ⃻⁁ߣᧂ᧪௝‫ޠ‬Ṷ⠪)㋈ᧁ ⧷ม㧦1㧕 ╙ 3 ࿁੩ㇺᧃ᪳ᓴⅣ㓚ኂᬌ⸛ળ(2006 ᐕ 2 ᦬㧘੩ㇺ㧘᜗ᓙ⻠Ṷ‫♧ޟ‬ዩ∛ߣേ⣂⎬ൻ‫ޠ‬Ṷ⠪)2㧕 Management of PAD ਅ⢇ⴊ▤∛ᄌߦ㑐ߔࠆ∛⸻ㅪ៤(2006 ᐕ 6 ᦬㧘ጘ㒂㧘᜗ᓙ⻠Ṷ‫ࠖ࠺࡞ࡀࡄޟ‬ࠬࠞ࠶࡚ࠪࡦ ♧ዩ∛ᖚ⠪ߦ߅ߌࠆ⏛᳇౒㡆ࠍ↪޿ߚਅ⢇ⴊᵹ⸃ᨆ‫ޠ‬Ṷ⠪)ጊᧄ⋿↱⟤㧦
1㧕 ࠤ࡯ࠬᣉⴕ᝼ᬺ㜞ᐲක≮ࠦࡦ࠰࡯ࠪࠕࡓ(2006 ᐕ 2 ᦬㧘ᄢ㒋㧘᜗ᓙ⻠Ṷ‫ࡓ࡯࠴ޟ‬ක≮ߣක≮ࡕ࠺࡞㧙♧ዩ∛⸻≮ࡕ࠺࡞‫ޠ‬Ṷ⠪)
2㧕 ╙ 70 ࿁⸥ᔨᣣᧄᓴⅣེቇળ✚ળ (2006 ᐕ 3 ᦬㧘ฬฎደ㧘᜗ᓙ⻠Ṷ‫♧ޟ‬ዩ∛ߣേ⣂⎬ൻ∝㧙੍㒐ߩ㊀ⷐᕈ㧙‫ޠ‬Ṷ⠪)
3㧕 ో࿖ᄢቇ଻ஜ▤ℂදળ ᧲ᶏ࡮ർ㒽࿾ᣇㇱળ⎇ⓥ㓸ળ(2007 ᐕ 7 ᦬, ㊄ᴛ, ‫ࠬࡄࡦࡖࠠޟ‬ౝ⑌ᾍ 2 ᐕࠍ⚻ㆊߒߡ࡯⃻⁁ߣ⺖㗴̆‫⻠ޠ‬Ṷࠪࡦࡐࠫࠬ࠻)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേ
ᱞ↰ ⚐㧦
1㧕 ᣣᧄ⥃ᐥౝ⑼කળጘ㒂⋵೽ળ㐳(㨪⃻࿷)2㧕 ᢥㇱ⑼ቇ⋭ࠥࡁࡓࡀ࠶࠻ࡢ࡯ࠢផㅴᆔຬળᆔຬ(㨪⃻࿷)3㧕 ో࿖ᄢቇ଻ஜ▤ℂදળ⹏⼏ຬ(ᐔᚑ 19 ᐕᐲ)
4㧕 ᣣᧄ♧ዩ∛දળጘ㒂⋵ᡰㇱ㐳(㨪⃻࿷)5㧕 ᢥㇱ⑼ቇ⋭⑼ቇᛛⴚ࡮ቇⴚክ⼏ળኾ㐷ᆔຬ(㨪⃻࿷)6㧕 ጘ㒂⋵♧ዩ∛ኻ╷ផㅴ⹏⼏ળ೽ળ㐳(㨪⃻࿷)7㧕 ᣣᧄ♧ዩ∛දળ≮㙃ᜰዉᆔຬળᆔຬ㐳(㨪⃻࿷)㧙㧙ၳᎹ ᐘ↵㧦1㧕 ጘ㒂࿾ၞක≮ㅪ៤⎇ⓥળᐙ੐(㨪⃻࿷)2㧕 ጘ㒂࿾ၞකᏧળㅪ៤ࡄࠬㆇ༡ᆔຬળᆔຬ(㨪⃻࿷)3㧕 ጘ㒂⋵කᏧળ♧ዩ∛ኻ╷ᆔຬળᆔຬ(㨪⃻࿷)4㧕 ጘ㒂⋵කᏧળ♧ዩ∛࿾ၞㅪ៤ࡄࠬࡢ࡯ࠠࡦࠣࠣ࡞࡯ࡊᆔຬ㐳(㨪⃻࿷)5㧕 ᣣᧄ♧ዩ∛දળጘ㒂⋵ᡰㇱઍ⼏ຬ(㨪⃻࿷)ጊᧄ⋿↱⟤㧦
1㧕 ᕺ㇊࿾ၞ♧ዩ∛ද⼏ળᆔຬ(㨪⃻࿷)2㧕 ጘ㒂⋵ᚑੱ∛ᬌ⸻▤ℂᜰዉද⼏ળᓴⅣེ∔ᖚ╬ᆔຬળຬ(㨪⃻࿷)3㧕 ጘ㒂↢ᵴ⠌ᘠ∛ㆇേ≮ᴺ⎇ⓥળ਎⹤ੱ(㨪⃻࿷)4㧕 ጘ㒂⋵଻ஜක≮ផㅴද⼏ળᆔຬ(ᐔᚑ 20 ᐕ 10 ᦬)
5㧕 ጘ㒂⋵කᏧળ♧ዩ∛ኻ╷ᆔຬળᆔຬᐳ㐳(㨪⃻࿷)6㧕 ጘ㒂Ꮢஜᐽ↥ᬺᝄ⥝ಽ⑼ળᆔຬ(ᐔᚑ 19 ᐕ 8 ᦬㨪ᐔᚑ 20 ᐕ 3 ᦬)
7㧕 ጘ㒂⋵଻ஜක≮ផㅴද⼏ળᆔຬ෸߮࿾ၞ଻ஜ⸘↹ㇱળᆔຬ(ᐔᚑ 19 ᐕ 11 ᦬㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ၳᎹᐘ↵㧦ࠞ࡞ࡄࠗࡦ 10 㑐ㅪಽሶࠍ↪޿ߚ 2 ဳ♧ዩ∛ㆮવሶ⸻ᢿᴺߣᣂⷙᴦ≮ᴺߩ㐿⊒㧦ᐔᚑ 16
ᐕᐲ㧙18 ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ✚᜝ႎ๔ᦠ(2006 ᐕ 1 ᦬)
2㧕 ቬ ෹ෘ㧘⺪⸰ື਽㧘᧛᧻ ቇ㧘ᱞ↰ ⚐㧚Disabled-2 ߩ೽⣢⊹⾰ߦ߅ߌࠆᯏ⢻ߣ೽⣢⣼⣲ߢߩ⊒⃻㧘೽⣢ࡎ࡞ࡕࡦ↥↢⇣Ᏹߦ㑐ߔࠆ⺞ᩏ⎇ⓥ ᐔᚑ 17 ᐕᐲ⎇ⓥႎ๔ᦠ㧦109㧙112(2006 ᐕ 3 ᦬)
3㧕 ጊᧄ⋿↱⟤㧘♿ࡁቯ଻⤿㧘㋈ᧁᐽਯ㧘㜞Ⴆ⋥⢻㧚ක≮ᖱႎ▤ℂࠪࠬ࠹ࡓߣ⸻≮ࡕ࠺࡞㧙♧ዩ∛㧙ක≮⚻༡ੱ᧚⢒ᚑᢎ⢒ࡊࡠࠣ࡜ࡓ㐿⊒ࡊࡠࠫࠚࠢ࠻ 㜞ᐲක≮ᢎ⢒ࠦࡦ࠰࡯ࠪࡓ㧘ᐔᚑ 17 ᐕᐲ⚻ᷣ↥ᬺ⋭‫ޟ‬ක≮⚻༡ੱ᧚⢒ᚑ੐ᬺㆇ༡ߦଥࠆᢎ⢒ࡊࡠࠣ࡜ࡓ‫ޠ‬ታ❣ႎ๔ᦠ㧦141㧙176(2006 ᐕ 1 ᦬)
4㧕 ᱞ↰ ⚐㧦૕⢽⢌ᷫዋ࿃ሶࠍ↪޿ߚ 2 ဳ♧ዩ∛ߩᴦ≮㧦ᐔᚑ 19 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌ ഃ⮎ၮ⋚ផㅴ⎇ⓥ੐ᬺႎ๔ᦠ(2008 ᐕ 4 ᦬)
5㧕 ᱞ↰ ⚐㧦⤟ፉ․⇣⊛ㆮવሶߩ⊒⃻⺞▵ゲߦὶὐࠍ⛉ߞߚ♧ዩ∛ㆮવሶߩត⚝㧦ᐔᚑ 19 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ․ቯ㗔ၞႎ๔ᦠ(2008 ᐕ 4 ᦬)
6㧕 ቬ ෹ෘ㧦CYP11B1 common variants ߣ⴫⃻ဳߩ㑐ㅪ㧦ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ 㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ ೽⣢ࡎ࡞ࡕࡦ↥↢⇣Ᏹߦ㑐ߔࠆ⺞ᩏ⎇ⓥ⃰ ᐔᚑ 19 ᐕᐲ⎇ⓥႎ๔ᦠ(2008 ᐕ 3 ᦬)
7㧕 ၳᎹᐘ↵㧦ൻว‛╬ࠍᵴ↪ߒߚ↢‛ࠪࠬ࠹ࡓ೙ᓮၮ⋚ᛛⴚ㐿⊒㧦⚻ᷣ↥ᬺ⋭ࠥࡁࡓഃ⮎ടㅦൻᡰេ
ࡃࠗࠝၮ⋚ᛛⴚ㐿⊒⾌ ᐔᚑ 19 ᐕᐲ⎇ⓥႎ๔ᦠ
11㧚ႎ㆏
1㧕 ቬ ෹ෘ㧦‫⎇ޟ‬ⓥቶ߆ࠄᄢቇߪ޿߹‫⚛ޠ‬࿃߰߹߃ࠃࠅ⦟޿↢ᵴࠍ㧦ጘ㒂ᣂ⡞(2006 ᐕ 10 ᦬)2㧕 ㋈ᧁ⧷ม㧦‫⎇ޟ‬ⓥቶ߆ࠄᄢቇߪ޿߹‫↢ޠ‬ᵴ⠌ᘠ∛ߩ੍㒐ᴺࠍ⺞ᩏ㧦ጘ㒂ᣂ⡞(2007 ᐕ 4 ᦬)
3㧕 ጊᧄ⋿↱⟤㧦ጘ㒂ᄢቇ̆ቇ↢ᡰេ GP ߦㆬቯ̆↢ᶦஜᐽࠍ⋡ᜰߒߚቇ↢ஜᐽᡰេࡊࡠࠣ࡜ࡓ㧦ਛᣣᣂ⡞(2007 ᐕ 9 ᦬)
4㧕 ጊᧄ⋿↱⟤㧦ጘ㒂ᄢቇ̆ቇ↢ᡰេ GP ߦណᛯ̆ᄢቇߪ↢ᶦஜᐽߩࠬ࠲࡯࠻࿾ὐ㧦ᦺᣣᣂ⡞(2007 ᐕ
10 ᦬)
5㧕 ጊᧄ⋿↱⟤㧦ጘ㒂ᄢቇ̆↢ᶦஜᐽࠍ⋡ᜰߒߚቇ↢ஜᐽᡰេࡊࡠࠣ࡜ࡓ࡯↢ᶦஜᐽᢎ⢒ߩផㅴߣஜᐽ
ᡰេߩలታ㧦ᦺᣣᣂ⡞(2007 ᐕ 10 ᦬)
6㧕 ᱞ↰ ⚐㧦♧ዩ∛ක≮ㅪ៤ࠍ࡝࡯࠼ߔࠆ‫ޟ‬ጘ㒂ࠪࠬ࠹ࡓ‫ߊ⸃ߺ⺒ࠍޠ‬㧦DITN(2008 ᐕ 2 ᦬)
7㧕 ၳᎹᐘ↵㧦‫⎇ޟ‬ⓥቶ߆ࠄᄢቇߪ޿߹‫↢ޠ‬ᵴ⠌ᘠ∛ᴦ≮⮎ࠍ⎇ⓥ㧦ጘ㒂ᣂ⡞(2008 ᐕ 2 ᦬)
8㧕 ᱞ↰ ⚐㧦りㄭߥ∛᳇‫♧ޟ‬ዩ∛‫ߦ✜৻ࠍޠ‬⠨߃ࠆ㧦ਛᣣᣂ⡞(2008 ᐕ 11 ᦬)
12㧚⥄Ꮖ⹏ଔ
⹏ଔ⎇ⓥߦ㑐ߒߡߪ㧘ᄙᣉ⸳౒ห⎇ⓥߦࠃࠅᣂߒ޿♧ዩ∛ㆮવሶ KCNQ1㧔Nature Genetics 2008 ᐕ㧕ߥߤ޿ߊߟ߆ߩ⽿છㆮવሶࠍหቯߔࠆߎߣߦᚑഞߒߚ߇㧘೨ 3 ᐕߦᲧߒߡ਎⇇ࠍ࡝࡯࠼ߔࠆ⎇ⓥ⺰ᢥ߇ᷫߞߚߎߣߪ෻⋭ὐߢ޽ࠆ㧔᰷ᢥේ⪺ 22 ✬㧕‫৻ޕ‬ᣇ㧘2008 ᐕ 3 ᦬ߦᄢဳ⎇ⓥߢ޽ࠆ CREST㧔ઍ⴫㧦ᱞ↰⚐㧕߇⚳ੌߒߚ߇㧘ߘߩᓟࠍ⵬ቢߔࠆ߆ߚߜߢ NEDO ⎇ⓥ㧔ઍ⴫㧦ၳᎹᐘ↵㧕ߣ 2 ߟߩෘ↢⑼⎇㧔ઍ⴫㧦ᱞ↰⚐㧕ߩᄢဳ⾗㊄ࠍ₪ᓧߢ߈ߚߎߣߪ㜞⹏ଔߦ୯ߔࠆ‫ޕ‬㧙㧙♧ዩ∛ߦ㑐ߔࠆ␠ળᵴേߣߒߡߪ㧘‫ޟ‬ጘ㒂ࡕ࠺࡞‫ߡߒߣޠ‬ጘ㒂⋵♧ዩ∛ኻ╷ផㅴද⼏ળߩਥዉ⊛ᓎഀࠍᨐߚߒߡ޿ࠆ‫ⴕޕ‬᡽ߣߩද⺞ߢߩᏒ᳃⻠ᐳ㧘໪⊒ࠠࡖࡦࡍ࡯ࡦߣߒߡߩ਎⇇♧ዩ∛࠺࡯ᵴേ㧔ጘ㒂ၔ࡜ࠗ࠻ࠕ࠶ࡊߥߤ㧕㧘ක≮ࠬ࠲࠶ࡈ⎇ୃ㧘⊓㍳ක࡮≮㙃ᜰዉක೙ᐲߩዉ౉ߥߤ߇ታᣉߐࠇߚ‫ޕ‬3 ᐕ㑆ߢ㧘ጘ㒂ߩ♧ዩ∛࿾ၞක≮ߦ㑐ߔࠆ⚂ 40 ࿁ߩ⻠Ṷଐ㗬߇ో࿖߆ࠄ޽ߞߚߎߣߪ⹏ଔߦ୯ߔࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷㒝ዻ∛㒮ߩ⸻≮⑼ㆇ༡ߦᢎቶੱຬ߇ഀ߆ࠇ㧘චಽߥ⎇ⓥ⠪ߣ⎇ⓥᤨ㑆߇⏕଻ߢ߈ߥ߆ߞߚߎߣ߇໧㗴ὐߢ޽ߞߚ‫ޕ‬ኻ╷ߣߒߡߪ㧘2009 ᐕ 4 ᦬ࠃࠅ⟲㚍ᄢቇߩ⎇ⓥ࠴࡯ࡓࠍᑄߒߡጘ㒂࠴࡯ࡓߦ⛔วߒ㧘ߐࠄߦᄢቇ㒮↢ߩ 1 ฬჇຬࠍ੍ቯߔࠆ‫ޕ‬ታ㛎⵬ഥຬߩᦝߥࠆ⏕଻ߩߚ߼ߦ㧘ᄖㇱ⾗㊄ࠍߐࠄߦ₪ᓧߔࠆࠃ߁
ദജߔࠆ‫ޕ‬੹ᓟߩዷᦸవ㚟⊛ߢ޽ࠆ‫⤟ޟ‬ፉ࠻࡜ࡦࠬࠢ࡝ࡊ࠻࡯ࡓ‫ߦޠ‬㑐ߔࠆࠥࡁࡓ⎇ⓥࠍផㅴߐߖࠆ‫ࡦ࡝ࠬࡦࠗޕ‬วᚑߣಽᴲߦ㑐ߔࠆᣂⷙߩ↢ℂᵴᕈ‛⾰ߩᯏ⢻⸃᣿ࠍㅢߓߡ♧ዩ∛ߩ⸻ᢿߣᴦ≮߳ߩዷ㐿ࠍ࿑ࠆ‫ౕޕ‬૕⊛ߦߪ㧘⤟ౝಽᴲߩ․ᕈߦ㑐ㅪߔࠆน⢻ᕈ߇޽ࠆᶧᕈ࿃ሶࠍหቯߒߡ޿ࠆߩߢ㧘ⴊਛ᷹ቯ⸻ᢿߣᴦ≮ᔕ↪ࠍ⋡ᜰߔ‫ޕ‬หᤨߦ㧘∔ᖚᗵฃᕈߩ୥⵬ㆮવሶᄙဳࠍ↪޿ߚ㑐ㅪ⸃ᨆߦࠃࠆ㧘⟕ᖚ૕⾰ߩ DNA ⸻ᢿᴺߩ㐿⊒ࠍⷞ㊁ߦ⟎ߊ‫ޕ‬ᶏᄖ৻ᵹ⹹ߢߩᚑᨐ⊒⴫ߣ․⸵ขᓧࠍᒰ㕙ߩ೔㆐⋡ᮡߣߔࠆ‫ޕ‬࿾ၞ♧ዩ∛ቇߣߒߡߪ㧘ⴕ᡽㧘කᏧળ㧘㑐ㅪ࿅૕ߣߩㅪ៤ߩ߽ߣߦ㧘∉ቇ⊛ߥ∛ᘒ⺞ᩏ⎇ⓥ㧘ᣧᦼ⊒⷗ߣ⊒∝੍㒐ߩ૕೙᭴▽㧘࿾ၞߢᵴ↪ߐࠇࠆ⮎‛≮ᴺߩ㐿⊒ߥߤࠍផㅴߒߡ޿ߊ੍ቯߢ޽ࠆ‫ޕ‬㧙㧙㧔7㧕ዊఽ∛ᘒቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
ᒰᢎቶߦ߅ߌࠆၮ␆⎇ⓥ࡮⥃ᐥ⎇ⓥߪ޿ߕࠇ߽⥃ᐥߦ┙⣉ߒ㧘ᭂ߼ߡၮ␆⊛ߥㅊ᳞߇ߥߐࠇ㧘ߘߩᚑᨐߪᔅߕ߿⥃ᐥߦㆶరߐࠇࠆ߽ߩߢ޽ࠆ‫ߩߘߚ߹ޕࠆ޽߽ߢ࠴࡯ࠨ࡝࡞࠽࡚ࠪ࡯࡟ࠬࡦ࡜࠻ޕ‬ౝኈߣᚻᴺߪ
Ᏹߦㆊ෰߆ࠄ⃻࿷ߩᱧผߦ┙⣉ߒߡ㧘዁᧪ࠍ⷗ᝪ߃ߚᭂ߼ߡ࡙࠾࡯ࠢߥ࠹࡯ࡑߢ޽ࠅ㧘߆ߟᚻᴺߢ޽ࠆ‫ޕ‬಴↢೨ዊఽᦼߩㆮવ࡮⊒↢෸߮㧘ዊఽߩᚑ㐳࡮⊒㆐ߣో⥃ᐥಽ㊁ߦࠊߚࠆ∛⊛⁁ᘒߩߔߴߡࠍኻ⽎ߣߒߡ޿ࠆ‫ޕ‬ၮ␆⎇ⓥߦ߅޿ߡߪ㧘ᐞߟ߆ߩಽ㊁ߦ⛉ࠆߎߣߦࠃࠅ㧘ᅏᷓ޿⎇ⓥ߇ㅴ߼ࠄࠇߡ޿ࠆ‫࡯ࠡ࡞࡟ࠕޕ‬㧘఺∉ਇో㧘ઍ⻢⇣Ᏹߩฦಽ㊁ߢᐞߟ߆ߩ∔ᖚߩ∛࿃ㆮવሶ߇ᒰᢎቶߢ਎⇇ߦవ㚟ߌࠢࡠ࡯࠾ࡦࠣߐࠇ㧘਎⇇ࠍ࡝࡯࠼ߔࠆᚑᨐ߇ᐞߟ߽ヘ಴ߐࠇ㧘ᣂ⡞⚕਄ߩ৻㕙ߢ߽ขࠅ਄ߍࠄࠇߡ޿ࠆ‫ޕ‬ฦ࠹࡯ࡑߦ౒ㅢߔࠆߎߣ
ߪ㧘ฦಽ㊁ߩ∔ᖚߩ∛࿃ߣ∛ᘒߩ⸃᣿ߢ޽ࠅ㧘ߘߩᚑᨐࠍ⸻ᢿ࡮ᴦ≮࡮੍⍮࡮੍㒐ߦㆡᔕߒߡ޿ߊߎߣߢ
޽ࠆ‫ࠍࠄࠇߎߦࠄߐޕ‬ㅢߓߡ㧘ࡅ࠻ߩㆮવ࡮⊒↢㧘ᚑ㐳࡮⊒㆐ߩᣂߚߥ⸃᣿ߦߟߥߍߡ޿ࠆ‫ޕ‬ᣇᴺ⺰⊛ߦߪ㧘ᣣᏱ⥃ᐥߩਛ߆ࠄࡅࡦ࠻ߣ⊒ᗐ߇ᓧࠄࠇ㧘ㆮવሶቇ⊛ᚻᴺߦട߃㧘කቇ߳ߩ᭴ㅧ↢‛ቇߩዉ౉㧔21਎♿ဳࡐࠬ࠻ࠥࡁࡓߣߒߡߩ᭴ㅧ↢‛කቇ structure biological medicine гㄭ⮮ߦࠃࠆ㧕ࠍߒߡ޿ࠆ‫ࠥޕ‬ࡁࡓㆮવሶ⇣Ᏹ߆ࠄࠛࡇࠫࠚࡀ࠹ࠖࠢࠬ㧘ㆮવሶ⊒⃻⇣Ᏹࠍ⚻ߡ࠲ࡦࡄࠢ┙૕᭴ㅧߩ⇣Ᏹߣᯏ⢻⇣Ᏹߣߩ㑐ㅪࠍ⸃ᨆߒ㧘⸻ᢿ㧘ᴦ≮߳ߩᔕ↪ࠍㅴ߼ߡ޿ࠆ‫ޕ‬਎⇇⊛߆ߟ↹ᦼ⊛ߥᚑᨐ߇ᓧࠄࠇ⊒⴫ߐࠇߡ޿ࠆ‫ޕ‬ߎࠇࠄߩᚑᨐߪᐞߟ߆ߩᄢဳ┹ว⊛⎇ⓥ⾌₪ᓧ㧘ᐕ㑆⺰ᢥ✚ᢙ⚂ 100 ✬㧘ߘߩ߁ߜ࿖㓙⹹ឝタߩ⧷ᢥ⺰ᢥᐕ㑆⚂ 30 ✬ߦ⃻ࠇߡ޿ࠆ‫ޕ‬1㧕ࠕ࡟࡞ࠡ࡯
Ԙࠕ࠻ࡇ࡯㧔ࠕ࡟࡞ࠡ࡯㧕ߩᛥ೙♽ߩ∛࿃ㆮવሶࠍ਎⇇ߢೋ߼ߡ᣿ࠄ߆ߦߒ㧔Lancet 1996 ᐕ㧘
BBRC1999 ᐕߦ⛯޿ߡ, JACI 2003 ᐕ㧕㧘
IgE ↥↢ߩᛥ೙♽ IL-12̆IL-12 ࡟࠮ࡊ࠲࡯߹ߚߪ IL-18̆IL-18
࡟࠮ࡊ࠲࡯̆IFNǫࠪࠣ࠽࡝ࡦࠣߩ㊀ⷐᕈࠍ␜ߒߚ‫ޕ‬ԙߎࠇࠄߩᚑᨐࠍ߽ߣߦߒߡ਎⇇ߦవ㚟ߌߡ㧘ᣂߚߦࠕ࠻ࡇ࡯㧔ࠕ࡟࡞ࠡ࡯㧕ࠍㆮવሶቇ⊛ߦಽ㘃ߒߚ‫ޕ‬Ԛߐࠄߦ㧘ߎࠇࠍ߽ߣߦࠕ࡟࡞ࠡ࡯㧔ࠕ࠻ࡇ࡯㧕ߩ‫ޕ‬ԛࡅ࠻ IL-18 ߩ࠲ࡦࡄࠢ┙૕᭴ㅧࠍㆮવሶ⸻ᢿࠠ࠶࠻ࠍ㐿⊒ߒ㧘․⸵↳⺧ਛߢ޽ࠆ㧔2007㧘2008 ᐕ㧕਎⇇ߦవ㚟ߌߡ⸃᣿ߒ㧔Nature structure biology 2003㧕㧘ߘߩ⥃ᐥᔕ↪ߣߒߡߩૐಽሶഃ⮎ࠍㅴ߼ߡࠕ࡟࡞ࠡ࡯ߩࠝ࡯࠳࡯ࡔࠗ࠼ᴦ≮޿ࠆ‫ޕ‬Ԝㆮવሶᖱႎߣ᛫ࠕ࡟࡞ࠡ࡯⮎ലᨐ߆ࠄ୘೎ൻක≮㧘ߔߥࠊߜ㧘ࠕߩ⏕┙ࠍㅴ߼̌᳇▤ᡰ༎ᕷߩ࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮▤ℂᴺߩߚ߼ߩᚻᒁ߈̍ࠍ਎⇇ߢೋ߼ߡ૞ᚑߒߚ‫ޕ‬ԝㆮવሶ⊒⃻㧘RNA ࡊࡠ࠮࠶ࠪࡦࠣ․ߦ RNA editing ߣ alternative splicing ߇ࠕ࡟࡞ࠡ࡯⊒∝ߦ㑐ࠊߞߡ޿ࠆߎߣࠍ਎⇇ߢೋ߼ߡ⸃᣿ߒߚ‫ޕ‬Ԟ㘩‛ࠕ࡟࡞ࠡ࡯ߩ᛫ේ․⇣ᕈߩ⊒⃻ᯏ᭴ߩ⸃᣿ߩߚ߼㧘T ⚦⢩ࠢࡠ࡯ࡦߩ᮸┙ߦ਎⇇ߢೋ߼ߡᚑഞߒ㧘ࠕ࡟࡞ࠡ࡯⊒∝ߦ߅ߌࠆ HLĂࡍࡊ࠴࠼̆T ⚦⢩࡟࠮ࡊ࠲࡯ߩ․⇣⚻ญ఺∉ኡኈࠍ⺃ዉᕈߣ⚿วᕈࠍ┙૕᭴ㅧ߆ࠄ⸃᣿ߒߡ޿ࠆ‫ޕ‬
㧔PNAS 2008 ઁ㧕ԟߎߩᚑᨐߦၮߠ޿ߡ㧘⚻
ߔࠆᴦ≮ᴺ⏕┙ߩߚ߼̌㘩ߴߡᴦߔ㘩ຠߩ㐿⊒̍ࡊࡠࠫࠚࠢ࠻߇⃻࿷ㅴⴕߒߡ޿ࠆ‫ޕ‬ԠⅣႺߣㆮવሶߦࠃㆮ વሶ↢ᘒකቇ geneticࠆࠕ࡟࡞ࠡ࡯⊒∝ߩಽሶㆮવቇ⊛⸃᣿㧔21 ਎♿ဳࡐࠬ࠻ࠥࡁࡓߣߒߡߩㆮ
ecological medicine -ㄭ⮮ߦࠃࠆ㧕‫ޕ‬᷷ᐲᄌൻߦࠃࠅ㧘NF-kappaB ߩᯏ⢻߇ᄌൻߒ㧘ࠨࠗ࠻ࠞࠗࡦ↥↢ࡄ࠲࡯ࡦ߇ᄌൻߔࠆߎߣࠍ᣿ࠄ߆ߦߒߚ‫ߦࠄߐޕ‬᭎ᣣ࡝࠭ࡓߩⷞὐ߆ࠄ㧘శߣ૕ౝᤨ⸘ㆮવሶߣߩ㑐ㅪࠍᬌ⸛ߒߡ޿ࠆ‫ޕ‬ԡ⥄ὼ఺∉♽ߣ∔ᖚߣߩ㑐ㅪࠍត᳞ߒᴦ≮㐿⊒ߦߟߥߍࠆߚ߼ߦ㧘Toll like receptor㧔TLR㧕
߅ࠃ߮ߘߩࠪࠣ࠽࡞વ㆐♽ߩ MyD88 ಽሶߥߤߩಽሶ߅ࠃ߮ߘࠇࠄߩ⚿ว᭽ᑼࠍ᣿ࠄ߆ߦߒ㧘หᤨߦߘࠇ
ࠄߩㆮવሶቇ⊛࠲ࡦࡄࠢ᭴ㅧቇ⊛⇣Ᏹࠍ᣿ࠄ߆ߦߒߡ޿ࠆ‫ޕ‬Ԣࠬ࠻࡟ࠬߣࠕ࡟࡞ࠡ࡯⊒∝ߩಽሶㆮવቇ⊛⸃᣿㧘࠙ࠗ࡞ࠬᗵᨴߦࠃࠆࠕ࡟࡞ࠡ࡯⊒∝㧘ࠕ࡜ࠠ࠼ࡦ㉄ࠞࠬࠤ࡯࠼ߩ⹏ଔߣࠝ࡯࠳࡯ࡔࠗ࠼ᴦ≮㧘⾰ߩ㜞޿ QOL ⹏ଔ⴫ߩ૞ᚑ㧘⤯Ꮺⴊࡊࡠࠫࠚࠢ࠻㧘FACS ࠍ↪޿ߚ⥄ὼ఺∉♽⺞▵ᕈ T ⚦⢩ߩ⸃ᨆߣ₪ᓧ఺∉♽ Th1࡮Th2 ࠕࡦࡃ࡜ࡦࠬߩ⸃᣿ߣᔕ↪ߥߤ‫ޕ‬ԣએ਄ߩࡊࡠࠫࠚࠢ࠻ߦ㑐ߒߡએਅߩᄢဳ┹ว⊛ᄖㇱ⾗㊄ࠍ₪ᓧߢ߈ߚ‫ޕ‬㧔ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌ߥߤߪ೎㗄ෳᾖ㧕
1. 㧨ᢥㇱ⑼ቇ⋭㜞╬ᢎ⢒ዪ㧪ᢥㇱ⑼ቇ⋭㜞ᐲవㅴක≮㐿⊒⚻⾌‫∔࡯ࠡ࡞࡟ࠕ࡮∉఺ޟ‬ᖚ∛࿃࠲ࡦࡄࠢ
⾰┙૕᭴ㅧߦၮߠ޿ߚ᭴ㅧ↢‛ቇ⊛ഃ⮎ߦࠃࠆᴦ≮ᴺߩ⏕┙‫⎇ޠ‬ⓥઍ⴫⠪ ㄭ⮮⋥ታ ⎇ⓥදജ⠪ ട⮮ༀ৻㇢㧘◉↰⚩ม㧘ኹᧄ⾆⧷㧘ਅỈિⴕ㧘㊄ሶ⧷㓶㧘ᷓየᢅᐘ㧘᧻੗᳗ሶ㧘᪀↰৻ᄦ㧘㋈ᧁᱜᤘ㧘⊕Ꮉ᣽ብ㧔ᐔᚑ 13̅15 ᐕ㧕
2. 㧨ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄㧪఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ‫∔࡯ࠡ࡞࡟ࠕޟ‬ᖚߩᴦ≮෻ᔕᕈ੍᷹࿃ሶߩ⏕┙෸߮࠹࡯࡜ࡔࠗ࠼ᴦ≮ᴺߩ⏕┙ߦ㑐ߔࠆ⎇ⓥ‫ޠ‬ਥછ⎇ⓥ⠪ ㄭ⮮ ⋥ታ ⃰ຬ ᧻੗ ᳗ሶ߶߆㧔ᐔᚑ 16̅21 ᐕ㧕
3. 㧨↢‛♽↥ᬺഃ಴ߩߚ߼ߩ⇣ಽ㊁Ⲣว⎇ⓥᡰេ੐ᬺ㧪⇣ಽ㊁Ⲣว⎇ⓥ㐿⊒ဳ‫ޟ‬㘩‛ࠕ࡟࡞ࠡ࡯ኻ╷㧔ᐔᚑ 17 ᐕࠃࠅ 5 ᐕ㑆㧕㘩ຠߩၮ␆⎇ⓥߦၮߠߊ↹ᦼ⊛ഃᚑ‫ޠ‬⎇ⓥઍ⴫⠪ ㄭ⮮⋥ታ ⃰ຬ ㊄ሶ⧷㓶߶߆㧙㧙2㧕వᄤᕈ఺∉ਇో∝ߣ DNA ୃᓳ
IgG ࠨࡉࠢ࡜ࠬᰳ៊∝ߩ∛࿃ߣߥࠆㆮવሶ⇣Ᏹࠍ਎⇇ߦవ㚟ߌ᣿ࠄ߆ߦߒߚ㧔J Clin Invest ෸߮
JACI㧕‫ޕ‬Ᏹᨴ⦡૕ఝᕈߩㆮવᒻᑼࠍߣࠆ㜞 IgM ∝୥⟲ߩ∛࿃ߦߟ޿ߡ߽ AID ߩ dominant negative ലᨐߦࠃࠆߎߣࠍ਎⇇ߢೋ߼ߡ᣿ࠄ߆ߦߒߚ㧔JACI 2003 ᐕ㧕‫ޕ‬Ყセ⊛㗫ᐲߩ㜞޿఺∉ਇో∝ߢ޽ࠆ IgA ᰳ៊∝ߦߟ޿ߡ⸃ᨆࠍⴕ޿ߘߩ B ⚦⢩ߩಽൻ㓚ኂㇱ૏ࠍ᣿ࠄ߆ߦߒߚ‫ߦࠄߐޕ‬㧘ᧄ㇌ 2 ଀⋡ߩ఺∉ࠣࡠࡉ࡝ࡦ㊀㎮ㆮવሶߩᰳ៊ኅ♽ࠍႎ๔ߒߚ‫ޕ‬㜞⊒≸ߣ఺∉ਇోࠍ␜ߔ Bloom ∝୥⟲߿ Ataxia-telangiectasia ߩ∛࿃ㆮવሶ BLM ߣ ATM ߩᯏ⢻ߣ᭴ㅧߩ⸃ᨆࠍㅢߒߡ⚦⢩๟ᦼ㧘DNA ୃᓳ㧘ࠪࠣ࠽࡞વ㆐ߦߟ߈⸃᣿
ߒ⊒≸ᯏ᭴ߩ⸃᣿ࠍⴕߞߡ޿ࠆ㧔Blood, CEI, PNAS ઁ㧕‫ߦࠄߐޕ‬ᄙᓀߥ⥄ὼ఺∉ਇో∝㧘⥄ᏆἻ∝ᕈ∔ᖚߩ∛࿃∛ᘒ⸃᣿ߣᴦ≮㐿⊒ߦ⌕ᚻߒߚ‫ޕ‬3㧕᦭ᯏ㉄ઍ⻢⇣Ᏹ∝ࠤ࠻ࡦ૕ઍ⻢⇣Ᏹ∝㧘․ߦࠨࠢࠪ࠾࡞-CoA:3-ࠤ࠻㉄ CoA ࠻࡜ࡦࠬࡈࠚ࡜࡯࠯㧔SCOT㧕ߣEࠤ࠻࠴ࠝ࡜࡯࠯ᰳ៊∝ߩ㉂⚛⸻ᢿ߿ㆮવሶ⸻ᢿߦ߅޿ߡߪ㧘਎⇇ਛ߆ࠄߩଐ㗬ࠍ߁ߌߡ⸃ᨆࠍⴕߞߡ޿ࠆ‫߹ࠇߎޕ‬ߢᄙߊߩㆮવሶᄌ⇣ߣߘߩ․ᓽࠍ᣿ࠄ߆ߦߒߡ߈ߚ‫ޕ‬ᱷሽᵴᕈࠍ߽ߟシ∝ဳߩEࠤ࠻࠴ࠝ࡜࡯࠯ᰳ៊∝㧘
SCOT ᰳ៊∝ߩౖဳ଀ߣߩ⥃ᐥ௝ߩ㆑޿ߦߟ޿ߡ߽᣿ࠄ߆ߦߒߡ޿ࠆ‫౒ߩߣࡊ࡯࡞ࠣߩ࠼ࡦ࡜ࡦࠖࡈޕ‬ห⎇ⓥߢ㧘ࡅ࠻ߩ⚦⢩⾰࠴ࠝ࡜࡯࠯ߣࡒ࠻ࠦࡦ࠼࡝ࠕࠕ࠮࠻ࠕ࠮࠴࡞-CoA ࠴ࠝ࡜࡯࠯ߩ 3 ᰴ᭴ㅧࠍ᳿ቯߒ㧘ߐࠄߦࠕࡒࡁ㉄ᄌൻ߇Ⱞ⊕ߦਈ߃ࠆᓇ㗀ߦߟ޿ߡߩ⸃ᨆࠍㅴ߼ߡ޿ࠆ㧚ፉᩮᄢቇߣߩ౒ห⎇ⓥߢ㧘⢽⢌㉄
E㉄ൻ♽⇣Ᏹ∝ߩⰮ⊕ㆮવሶ⸃ᨆ߽ⴕߞߡᚑᨐ߇಴ߡ߈ߡ޿ࠆ‫ޕ‬
4㧕ㆮવᕈࡓࠦᄙ♧∝ㆮવᕈࡓࠦᄙ♧∝ߦߟ޿ߡᣧᦼ⸻ᢿ㧘ಽሶ∛ᘒ⸃ᨆ㧘ᴦ≮ᴺ㐿⊒ߦขࠅ⚵ࠎߢ޿ࠆ‫ࠦࡓߦ․ޕ‬ᄙ♧∝ΦA ဳߩ⎇ⓥߢߪ㧘࿖㓙ࡊࡠࠫࠚࠢ࠻ߩ✚᜝⊛┙႐ߢ∔ᖚ⸃ᨆ࡮ᴦ≮ᴺ㐿⊒ࠍⴕߞߡ߅ࠅ㧘Τဳߩ⥄ὼᱧ⺞ᩏ߿㉂⚛⵬ల≮ᴺ㧘ࡓࠦᄙ♧∝ో⥸ߩᣧᦼࡑࠬࠬࠢ࡝࡯࠾ࡦࠣࠪࠬ࠹ࡓߩ㐿⊒߽૬ߖߡ㧘ࡌࡦ࠴ࡖ࡯ડᬺ
ߣߩ౒ห⎇ⓥ߽ㅴ߼ߡ޿ࠆ‫ޕ‬
5㧕ࡍ࡞ࠝࠠࠪ࠰࡯ࡓ∛వᄤᕈࡍ࡞ࠝࠠࠪ࠰࡯ࡓઍ⻢⇣Ᏹ∝ߩ∛࿃ߣᴦ≮ߦߟ޿ߡ⎇ⓥࠍㅴ߼ߡ߅ࠅ㧘ࡍ࡞ࠝࠠࠪ࠰࡯ࡓᰳ៊∝ߩᣂⷙ∛࿃ㆮવሶ PEX16,19,13,3,26 ߩหቯ㧘᷷ᐲᗵฃᕈ⃻⽎ߩ⊒⷗㧘ᣂߚߥE㉄ൻ㉂⚛ᰳ៊∝ߩ⊒⷗㧘೽⣢⊕⾰ࠫࠬ࠻ࡠࡈࠖ࡯ߩ㛽㜑⒖ᬀߩฦ‫ߡ޿ߟߦޘ‬਎⇇ࠍ࡝࡯࠼ߔࠆᚑᨐࠍ᜼ߍߡ޿ࠆ‫ޕ‬ㆮવሶ⸻ᢿߣߒ
ߡ PEX10 ㆮવሶߩ 2 Ⴎၮᰳᄬ㧘PEX16 ㆮવሶ⇣Ᏹ㧘PEX26 ㆮવሶ⇣Ᏹߥߤࠍ⸻ᢿߒߚ߶߆㧘㕖Ᏹߦ․⇣ߥ଀ߣߒߡ㧘Zellweger ∝୥⟲ߩ⥃ᐥ௝ࠍ๒ߒ ALDP ㆮવሶࠍ฽߻ large deletion ଀ࠍ⸻ᢿߒߚ‫ޕ‬߹ߚ㧘ࡍ࡞ࠝࠠࠪ࠰࡯ࡓᰳ៊∝ߩ᷷ᐲᗵฃᕈߦߟ޿ߡߪ࠲ࡦࡄࠢ┙૕᭴ㅧ⸃ᨆ߿シ∝ဳ᷷ᐲᗵฃᕈࡕ࠺࡞ࡑ࠙
ࠬߩ૞ᚑߥߤࠍⴕ޿㧘ᧄ∝ߩ∛ᘒ⸃᣿ߣᴦ≮ᴺߩ㐿⊒ߦขࠅ⚵ࠎߢ޿ࠆ‫৻ޕ‬ᣇߢ㧘ࡍ࡞ࠝࠠࠪ࠰࡯ࡓߩ␹
⚻⊒↢ㆊ⒟ߦ߅ߌࠆᓎഀߦߟ޿ߡ㧘఺∉⚵❱ൻቇ⊛ᚻᴺࠍ↪޿ߡ⸃ᨆਛߢ޽ࠆ‫ޕ‬
6㧕࠲ࡦࡄࠢ┙૕᭴ㅧ⸃ᨆ
ዊఽߩ∔ᖚ㑐ㅪⰮ⊕⾰ߩ┙૕᭴ㅧ⸃ᨆߦၮߠ޿ߚ∛ᘒ⸃ᨆ࡮ᴦ≮ᴺߩ㐿⊒ߥߤࠍⴕ߁̍᭴ㅧකቇ̍ߩ⏕┙ࠍ⋡ᜰߒ㧘ૐಽሶ࡝ࠟࡦ࠼ࠬࠢ࡝࡯࠾ࡦࠣ࡮Ⱞ⊕࡟ࡌ࡞ߢߩⰮ⊕Ꮏቇ⊛ࠕࡊࡠ࡯࠴ߦࠃࠆᴦ≮ᴺߩ㐿⊒
ߦ㊀ὐࠍ⟎޿ߡ⎇ⓥࠍㅴ߼ߡ޿ࠆ‫ߚ߹ޕ‬㧘⥄ὼ఺∉߆ࠄ₪ᓧ఺∉ߦ⥋ࠆ⚻〝ߦ㑐ਈߔࠆ㧘IL-18㧘IL-1㧘
෸߮ Toll-like Receptor ⟲ߦᔅ㗇ߥಽሶߢ޽ࠆࠪࠣ࠽࡞વ㆐ࠕ࠳ࡊ࠲࡯Ⱞ⊕ࠍਛᔃߦߒߚ᭴ㅧቇ⊛⎇ⓥࠍ
ㅴ߼ߡ޿ࠆ‫ᦨޕ‬ㄭߩᚑᨐߩ৻ߟߣߒߡ㧘ᄙᰴరᩭ⏛᳇౒㡆ᴺߦߡ᳿ቯߒߚࡅ࠻ IL-18 ┙૕᭴ㅧࠍ߽ߣߦ㧘ᄌ⇣૕⸃ᨆࠍⴕ޿㧘ࠗࡦ࠲࡯ࡠࠗࠠࡦߦ߅ߌࠆᣂߒ޿⚿ว᭽ᑼߩ⸃᣿ߦ⥋ߞߚ‫ޕ‬7㧕⃻࿷౒หߢⴕࠊࠇߡ޿ࠆࡊࡠࠫࠚࠢ࠻
IL-18 ߣߘߩ⚿วಽሶߩ࠲ࡦࡄࠢ┙૕᭴ㅧߣᯏ⢻㧦㧔ㄭ⮮⋥ታ㧘ട⮮ༀ৻㇢㧕੩ㇺᄢቇ ⊕Ꮉ᣽ብ㧘
Ataxia-telangiectasia ߣ Bloom ∝୥⟲ߩ∛ᘒ⸃ᨆ㧦㧔ㄭ⮮⋥ታ㧕ࠝ࡯ࠬ࠻࡜࡝ࠕ Queensland Instituteof Medical Research Professor M. Lavin㧘ዊఽ᳇▤ᡰ༎ᕷߩ QOL ⹏ଔ㧔ㄭ⮮⋥ታ㧘᧻੗᳗ሶ㧕ᐔጊ⠹৻㇢㧘᛫ࠕ࡟࡞ࠡ࡯⮎ߣㆮવሶߦ㑐ߔࠆ⎇ⓥ㧦㧔ㄭ⮮⋥ታ㧘᧻੗᳗ሶ㧕ᄢ㢈⮎ຠᎿᬺ㧘ࡓࠦᄙ♧∝ߩ㉂⚛⵬ల≮ᴺߩၮ␆⊛⎇ⓥ߅ࠃ߮⥃ᐥᔕ↪㧦㧔ㄭ⮮⋥ታ㧘᛬ዬᕡᴦ㧕USA St.Louis University ഥᢎ᝼ ᚭ᧻ବᴦ㧘᡼኿✢㜞ᗵฃᕈ∔ᖚߩಽሶ∛ᘒߦ㑐ߔࠆ⎇ⓥ㧦
㧔ᷓየᢅᐘ㧕ࠝ࡯ࠬ࠻࡜࡝ࠕ Queensland Institute ofMedical Research Professor M. Lavin㧘࠴ࠝ࡜࡯࠯Ⱞ⊕ߩ 3 ᰴ᭴ㅧߣᯏ⢻ߦ㑐ߔࠆ⎇ⓥ㧦
㧔ᷓየᢅᐘ㧕ࡈࠖࡦ࡜ࡦ࠼ Oulu University Professor R.Wierenga㧘CoA ࠻࡜ࡦࠬࡈࠚ࡜࡯࠯Ⱞ⊕ߩ 3 ᰴ᭴ㅧߣᯏ⢻ߦ㑐ߔࠆ⎇ⓥ㧦㧔ᷓየᢅᐘ㧕ࡈࠖࡦ࡜ࡦ࠼ Oulu University Dr.P.Kursula㧘వᄤᕈࠤ࠻ࡦ૕ઍ⻢⇣Ᏹ∝ߦ㑐ߔࠆ⎇ⓥ㧦㧔ᷓየᢅᐘ㧕ࠝ࡜ࡦ࠳ Amsterdam Medical Center Professor RJA Wanders㧘వᄤᕈࠤ࠻ࡦ
㧔ᷓየᢅᐘ㧕USA Oregon Heath and University Professor M. Gibson㧘వ૕ઍ⻢⇣Ᏹ∝ߦ㑐ߔࠆ⎇ⓥ㧦
ᄤᕈࠤ࠻ࡦ૕ઍ⻢⇣Ᏹ∝ߦ㑐ߔࠆ⎇ⓥ㧦㧔ᷓየᢅᐘ㧕ࠞ࠽࠳ Ste-Justine Hospital, Montreal, Professor
GA. Mitchell㧘Ძ⚦ⴊ▤᜛ᒛᕈㆇേᄬ⺞∝ߦ߅ߌࠆ␹⚻ᄌᕈᯏ᭴ࠍ⸃᣿ߔࠆߚ߼ߩၮ␆⊛⎇ⓥ㧦㧔᛬ዬᑪᴦ㧘ㄭ⮮⋥ታ㧕USA St.Jude Childrens Research Hospital Associate member Peter J. McKinnon㧘Ᏹᨴ㧙㧙⦡૕ഠᕈ㜞 IgE ∝୥⟲ߩේ࿃ㆮવሶߩᬌ⸛㧦
㧔㊄ሶ⧷㓶㧘ㄭ⮮⋥ታ㧕᧲੩ක⑼ᱤ⑼ᄢቇᄢቇ㒮 ఺∉ࠕ࡟࡞ࠡ࡯ ፃጯసⴕ㧘ATM ߣ BLM ߩળว㧦
㧔㊄ሶ⧷㓶㧕ࠝ࡯ࠬ࠻࡜࡝ࠕ Queensland Institute of Medical
Research Professor M. Lavin‫ޕ‬8㧕ᣂߚߥࡊࡠࠫࠚࠢ࠻
㔍ᴦᕈ␹⚻∔ᖚ㧔⣄㜑ᕈ╭⪜❗∝ߥߤ㧕ߩ⸻ᢿߣᴦ≮㐿⊒㧔ౣ↢ක≮ߥߤ㧕,⧯ᐕᕈ㑐▵࡝࠙ࡑ࠴ߣ⥄Ꮖ఺∉∔ᖚߩᴦ≮㐿⊒㧘ㆮવᕈ㜞⊒≸∔ᖚ㧔P53 ᰳ៊㧘ATM ᰳ៊㧘BLM ᰳ៊ߥߤ㧕ߦኻߔࠆㆮવሶ㑐ㅪᴦ≮㐿⊒ߥߤߦ⌕ᚻߒߡ޿ࠆ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
ㄭ⮮⋥ታ
ᢎ᝼(૬છ)㧦 ᷓየᢅᐘᢎ᝼(૬છ)㧦 ㊄ሶ⧷㓶
ട⮮ༀ৻㇢
⻠Ꮷ㧦
ኹᧄ⾆⧷
⻠Ꮷ㧦
᧻੗᳗ሶ
⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦 ᛬ዬᑪᴦ⥃ᐥ⻠Ꮷ㧦 ⥵ᚭ㆏ᓼ⥃ᐥ⻠Ꮷ㧦 ᄢ⷏⑲ౖ
Ꮉᧄ⟤ᄹሶ
කຬ㧦
ዊ㑐㆏ᄦ
කຬ㧦
㕍ᧁ㓶੺
කຬ㧦
᫪↰⑲ⴕ
කຬ㧦
ਭ଻↰৻↢
කຬ㧦
ᓼ⷗ືม
කຬ㧦
╣੗⧷㓶
කຬ㧦
ᢎ᝼(૬છ)㧦 ਅỈિⴕ

Naomi Kondo
Toshiyuki Fukao
Hideo Kaneko
Zenichiro Kato
Takahide Teramoto
Eiko Matsui
Kenji Orii
Michinori Funato
Hidenori Ohnishi
Minako Kawamoto
Michio Ozeki
Yusuke Aoki
Hideyuki Morita
Kazuo Kubota
Tetsuji Tokumi
Hideo Sasai
Nobuyuki Shimozawa

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ㄭ⮮⋥ታ㧘᪀ේᗲ⟤㧚㘩‛ࠕ࡟࡞ࠡ࡯ߩ⊒∝ᯏᐨߣᴦ≮࡮੍㒐㧦દ⮮ ᱞ㧘Ꮉᧄિ৻㧘᧖ጊ⚐৻㧘⷏ፉၮᒄ㧘☨⼱᳃㓶✬㧚㘩ຠᬌᩏߣ࡝ࠬࠢ࿁ㆱߩߚ߼ߩ㒐ᓮᛛⴚ㧘᧲੩㧦ࠪ࡯ࠛࡓࠪ࡯಴ 㧧2006 ᐕ㧦137㧙147㧚
2㧕 ㄭ⮮⋥ታ㧚ਇ᣿ᾲ㧦ਃᴡᤐ᮸㧘᧻የቱᱞ㧘᫪Ꮉᤘᑝ✬㧚㐓೎⸻ᢿߩᚻᒁ߈࡯‫ޟ‬ዊఽᢇᕆߩᚻᒁ߈‫࡯ࡠࡈޠ‬࠴ࡖ࡯࠻ࠃࠅ࡯㧘᧲੩㧦⥃ᐥක⮎⎇ⓥදળ㧧2006 ᐕ㧦50㧚
3㧕 ㄭ⮮⋥ታ㧚఺∉∔ᖚ㧦᫪Ꮉᤘᑝ㧘ౝጊ ⡛㧘ේ ኼ㇢✬㧚ᮡḰዊఽ⑼ቇ ╙ 6 㧧᧲੩㧦කቇᦠ㒮㧧2006
ᐕ㧦288㧙311㧚
4㧕 ㄭ⮮⋥ታ㧚╙ 1 ┨ࠕ࠻ࡇ࡯ᕈ⊹⤏Ἳߩቯ⟵࡮∔ᖚ᭎ᔨ㧘∛ᘒ↢ℂ࡮∛࿃ 3,∛࿃㧦ጊᧄ᣹ჽ㧘ᴡ㊁㓁৻✬㧚ࠕ࠻ࡇ࡯ᕈ⊹⤏Ἳ⸻≮ࠟࠗ࠼࡜ࠗࡦ 2006㧘᧲੩㧦ද๺ડ↹㧧2006 ᐕ㧦4㧙6㧚
5㧕 ㄭ⮮⋥ታ㧚ࠕ࡟࡞ࠡ࡯ᕈ∔ᖚ㧦ᷡ㊁૫♿㧘ዊᨋ㇌ᒾ㧘ේ↰⎇੺㧘᩶੗⋿㉿ሶ✬㧚NEW ዊఽ⑼ቇ ᡷ⸓╙ 2㧘᧲੩㧦ධశၴ㧧2006 ᐕ㧦286㧙304㧚
6㧕 ㄭ⮮⋥ታ㧘᧻੗᳗ሶ㧘᪀ේᗲ⟤㧚╙ 6 ┨ࠕ࡟࡞ࠡ࡯∔ᖚ㧦ጊᧄ㊀ᄦ✬㧚ࡃࠗࠝ⸃ᨆ࡮⸻ᢿᛛⴚߩ࠹࡯࡜࡯
ࡔࠗ࠼ක≮߳ߩᔕ↪㧘᧲੩㧦ࠪ㧙ࠛࡓࠪ࡯಴ 㧧2006 ᐕ㧦138㧙144㧚
7㧕 ㄭ⮮⋥ታ㧚ࠕ࠻ࡇ࡯ᕈ⊹⤏Ἳ㧦੖ච፲㓉✬㧚ዊఽ∔ᖚߩ⸻ᢿᴦ≮ၮḰ ╙ 3 㧘᧲੩㧦᧲੩කቇ␠㧧2006
ᐕ㧦258㧙259㧚
8㧕 ㄭ⮮⋥ታ㧚వᄤᕈ఺∉ਇో∝୥⟲㧦ᣣᧄ⊹⤏⑼ቇળ✬㧚ᐔᚑ 18 ᐕᐲ೨ታ❣⎇ୃળㆬᛯࠦ࡯ࠬ㧘᧲੩㧦ᣣᧄ⊹⤏⑼ቇળ㧧2006 ᐕ㧦1㧙27.
9㧕 ᷓየᢅᐘ㧚᦭ᯏ㉄ઍ⻢⇣Ᏹ∝㧦ᄢ㑐ᱞᒾ㧘ฎᎹ ẋ㧘ᮮ↰ବ৻㇢✬㧚੹ᣣߩዊఽᴦ≮ᜰ㊎ ╙ 14 㧘᧲੩㧦කቇᦠ㒮㧧2006 ᐕ㧦168㧙169.
10㧕 ㄭ⮮⋥ታ㧘᪀ේᗲ⟤㧚I-B ༎ᕷߩ∛ᘒߣ⊒∝ᯏᐨ㧚6㧚㑐ㅪߔࠆㆮવሶࠍ߼ߋߞߡ㧦ᄢ↰ ஜ㧘৻ࡁἑᱜ๺
✬㓸㧚๭ๆེ common disease ߩ⸻≮ ᳇▤ᡰ༎ᕷߩߔߴߡ㧘᧲੩㧦ᢥశၴ㧧2007 ᐕ㧦62㧙66㧚
11㧕 ㄭ⮮⋥ታ㧚⥃ᐥ✬Υ㧚∔ᖚߣᩕ㙃 5㧚ࠕ࡟࡞ࠡ࡯∔ᖚ㧦ጟ↰ ᱜ㧘㚍႐ᔘ㓶㧘ጊၔ㓶৻㇢✬㓸㧚ᣂ⥃ᐥᩕ㙃ቇ㧘᧲੩㧦කቇᦠ㒮 2007 ᐕ㧦362㧙368㧚
12㧕 ㄭ⮮⋥ታ㧚╙ 1 ┨ 㘩‛ࠕ࡟࡞ࠡ࡯ߩ∛ᘒߣ∝⁁㧦ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ✬㧚ࠕ࡟࡞ࠡ࡯∔ᖚ⸻ᢿ࡮ᴦ
≮ࠟࠗ࠼࡜ࠗࡦ㧘᧲੩㧦ද๺ડ↹㧧2007 ᐕ㧦317㧙322㧚
13㧕 ㄭ⮮⋥ታ㧚Φࠦࡦ࠻ࡠ࡯࡞ߐࠇߚๆ౉ࠬ࠹ࡠࠗ࠼ߩᷫ㊂ߣ㔌⣕ߩታ㓙 ⸛⺰㧦ਛፉ㊀ᓼ㧘ዊᨋ▵㓶㧘ችᧄᤘᱜ ✬㓸㧚᳇▤ᡰ༎ᕷߩࠃࠅࠃ޿ᴦ≮ߩߚ߼ߦ࡯Pharmaco Kinetics, Pharmaco Dynamics ߆ࠄ⷗ߚ༎ᕷ
ᴦ≮ߩౣ⠨㧘᧲੩㧦ਃႎ␠ශ೚ᩣᑼળ␠㧧2007 ᐕ㧦98㧙99.
14㧕 ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧦ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦1㧙1855.
15㧕 ㄭ⮮⋥ታ㧚ዊఽ∔ᖚߩᴦ≮✚⺰㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008㧙㧙ᐕ㧦85㧙86.
16㧕 ㄭ⮮⋥ታ㧚ਇ᣿ᾲ㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦267㧙273.
17㧕 ㄭ⮮⋥ታ㧚఺∉ᯏ᭴—↢૕㒐ᓮᯏ᭴㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧
2008 ᐕ㧦833㧙837.
18㧕 ㄭ⮮⋥ታ㧚఺∉ਇో∝ߩಽ㘃ߣ⸻ᢿ㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧
2008 ᐕ㧦837㧙850.
19㧕 ㄭ⮮⋥ታ㧚Wiskott-Aldrich ∝୥⟲(WAS)㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ 3 㧘᧲੩㧦කቇᦠ㒮㧧
2008 ᐕ㧦862㧙863.
20㧕 ㄭ⮮⋥ታ㧚Ძ⚦ⴊ▤᜛ᒛᕈዊ⣖ᄬ⺞∝㧘Louis-Bar ∝୥⟲㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦863㧙864.
21㧕 ㄭ⮮⋥ታ㧚Nijmegen breakage ∝୥⟲㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧
2008 ᐕ㧦864.
22㧕 ㄭ⮮⋥ታ㧚Artemis ᰳ៊∝㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦
864.
23㧕 ㄭ⮮⋥ታ㧚Bloom ∝୥⟲㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦
864.
24㧕 ㄭ⮮⋥ታ㧚DiGeorge ∝୥⟲㧘╙ 3࡮╙ 4 㟴ᑿ∝୥⟲㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦864.
25㧕 ㄭ⮮⋥ታ㧚ࠕ࡟࡞ࠡ࡯ߩ∛ᘒ㧘∛࿃㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧
2008 ᐕ㧦925㧙928.
26㧕 ㄭ⮮⋥ታ㧚ࠕ࠻ࡇ࡯ᕈ⊹⤏Ἳ㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦
948㧙952.
27㧕 ᷓየᢅᐘ㧚ᭂ㐳㎮ࠕࠪ࡞ - CoA ⣕᳓⚛㉂⚛(VLCAD)ᰳ៊∝㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚᧲੩㧦කቇᦠ
㒮㧧2008 ᐕ㧦475.
28㧕 ᷓየᢅᐘ㧚㐳㎮ 3 -ࡅ࠼ࡠࠠࠪࠕࠪ࡞ CoA ⣕᳓⚛㉂⚛(LCHAD)ᰳ៊∝ߣਃ㗡㉂⚛(MTP)ᰳ៊∝㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦476.
29㧕 ᷓየᢅᐘ㧚⍴㎮ 3 -ࡅ࠼ࡠࠠࠪࠕࠪ࡞ CoA ⣕᳓⚛㉂⚛(SCHAD)ᰳ៊∝㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊ
ఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦477.
30㧕 ᷓየᢅᐘ㧚2,4 -ࠫࠛࡁࠗ࡞- CoA ㆶర㉂⚛ᰳ៊∝㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦478.
31㧕 ᷓየᢅᐘ㧚ਛ㎮ࠕࠪ࡞- CoA ⣕᳓⚛㉂⚛(MCAD)ᰳ៊∝㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦477.
32㧕 ᷓየᢅᐘ㧚⍴㎮ࠕࠪ࡞- CoA ⣕᳓⚛㉂⚛(SCAD)ᰳ៊∝㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦478.
33㧕 ㊄ሶ⧷㓶㧚Chediak—Higashi ∝୥⟲㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧
2008 ᐕ㧦865㧙866.
34㧕 ㊄ሶ⧷㓶㧚Griscelli ∝୥⟲㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦
866.
35㧕 ㊄ሶ⧷㓶㧚X ㅪ㎮࡝ࡦࡄჇᱺᕈ∔ᖚ㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧
2008 ᐕ㧦866㧙867.
36㧕 ㊄ሶ⧷㓶㧚ߘߩઁߩ఺∉⺞▵ਇోߩ∔ᖚ㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ
㒮㧧2008 ᐕ㧦867.
37㧕 ㊄ሶ⧷㓶㧚⛯⊒ᕈ఺∉ਇో∝ ✚⺰㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧
2008 ᐕ㧦879㧙883.
38㧕 ㊄ሶ⧷㓶㧚Behcet ∛㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦910
㧙912.
39㧕 ㊄ሶ⧷㓶㧚Sjogren ∝୥⟲㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦
912㧙913.
40㧕 ㊄ሶ⧷㓶㧚⢷⤑Ἳ࡮⤥⢷㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦1018
㧙1020.
41㧕 ኹᧄ⾆⧷㧚ࠢ࡝࠾ࠞ࡞ࡄࠬ㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦
290㧙29242㧕 ᧻੗᳗ሶ㧚ᕆᕈ㥦ຜ㗡Ἳ(ᗵ౨∝୥⟲)㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧
2008 ᐕ㧦993.
43㧕 ᧻੗᳗ሶ㧚ᕆᕈຜ㗡ᚳ᩶Ἳ㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦
993㧙994.
44㧕 ᧻੗᳗ሶ㧚ᚳ᩶๟࿐⤥≌㧘ຜᓟ⤥≌㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧
2008 ᐕ㧦994.
45㧕 ᧻੗᳗ሶ㧚ᚳ᩶⢈ᄢ(ญ⬄ᚳ᩶㧘ࠕ࠺ࡁࠗ࠼)㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦994㧙995.
46㧕 ᧻੗᳗ሶ㧚․⊒ᕈ㑆⾰ᕈ⢖Ἳ㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦
1012㧙1014.
47㧕 ᧻੗᳗ሶ㧚⢖ࡋࡕࠫ࠺ࡠ࡯ࠪࠬ㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008㧙㧙ᐕ㧦1014㧙1015.
48㧕 ᧻੗᳗ሶ㧚⢖⢩Ⱞ⊕∝㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦1015
㧙1016.
49㧕 ᧻੗᳗ሶ㧚ㆊᢅᕈ⢖⤳Ἳ㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦1016
㧙1017.
50㧕 ᧻੗᳗ሶ㧚⢖ൻ⤥∝(⢖⤥≌)㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦
1017㧙1018.
51㧕 ㄭ⮮⋥ታ ઁ㧚Ϊ㧚Ⴧᖡᤨߩᴦ≮ᴺ ⸛⺰㧦ችᧄᤘᱜ㧘ዊᨋ▵㓶㧘ਛፉ㊀ᓼ ✬㓸㧚༎ᕷߩჇᖡൻߣߘߩኻ
ᔕ㧘࡜ࠗࡈࠨࠗࠛࡦࠬ㧧2008 ᐕ㧦106㧙119.
52㧕 ૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧧ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008ᐕ㧚
53㧕 ㄭ⮮⋥ታ㧚⊒ᾲ㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦70㧙73.
54㧕 ㄭ⮮⋥ታ㧚⊒∐㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦93㧙94.
55㧕 ㄭ⮮⋥ታ㧚ຕ㧘∷㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦108㧙109.
56㧕 ㄭ⮮⋥ታ㧚఺∉ਇో∝ߩಽ㘃㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦335㧙337.
57㧕 ㄭ⮮⋥ታ㧚ࠕ࡟࡞ࠡ࡯⸻≮ߩၮ␆⍮⼂㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦361㧙363.
58㧕 ㄭ⮮⋥ታ㧚ዊఽ᳇▤ᡰ༎ᕷ㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦364㧙367.
59㧕 ㄭ⮮⋥ታ㧚ࠕ࡟࡞ࠡ࡯ᕈ㥦Ἳ㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦368.
60㧕 ᷓየᢅᐘ㧚DNA㧘ㆮવሶ㧘ࠥࡁࡓ㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦181㧙184.
61㧕 ᷓየᢅᐘ㧚ㆮવᕈ∔ᖚߩಽ㘃ߣ㗫ᐲ㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦185㧙187.
62㧕 ᷓየᢅᐘ㧚න৻ㆮવሶ∛㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ㧙␠㧧2008 ᐕ㧦188㧙190.
63㧕 ᷓየᢅᐘ㧚ዩ⚛ࠨࠗࠢ࡞⇣Ᏹ∝㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ㧙␠㧧2008 ᐕ㧦221㧙222.
64㧕 ᷓየᢅᐘ㧚♧ઍ⻢⇣Ᏹ∝㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ㧙␠㧧2008 ᐕ㧦223㧙226.
65㧕 ᷓየᢅᐘ㧚ࡆ࡝࡞ࡆࡦઍ⻢⇣Ᏹ∝ߣࡐ࡞ࡈࠖ࡝ࡦઍ⻢⇣Ᏹ∝㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ㧙␠㧧2008 ᐕ㧦237㧙239.
66㧕 ᷓየᢅᐘ㧚Ძ⚦ⴊ▤᜛ᒛᕈᄬ⺞∝㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ㧙␠㧧2008 ᐕ㧦355㧙356.
67㧕 ᷓየᢅᐘ㧚ߘߩઁߩ఺∉⇣Ᏹ∝㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ㧙␠㧧2008 ᐕ㧦359㧙360.
68㧕 ㊄ሶ⧷㓶㧚఺∉ᯏ᭴㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧧ࡔࠫࠞ࡞ࡆࡘ㧙␠㧧2008 ᐕ㧦332㧙334.
69㧕 ㊄ሶ⧷㓶㧚ⶄว఺∉ਇో∝㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧧ࡔࠫࠞ࡞ࡆࡘ㧙␠㧧2008 ᐕ㧦338㧙339.
70㧕 ㊄ሶ⧷㓶㧚X ㅪ㎮ήࠟࡦࡑࠣࡠࡉ࡝ࡦⴊ∝㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧧ࡔࠫࠞ࡞ࡆࡘ㧙␠㧧2008 ᐕ㧦343㧙344.
71㧕 ㊄ሶ⧷㓶㧚ಽ㘃ਇ⢻ဳ఺∉ਇో∝㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧧ࡔࠫࠞ࡞ࡆࡘ㧙␠㧧2008 ᐕ㧦345㧙346.
72㧕 ㊄ሶ⧷㓶㧚IgA ᰳਲ∝㧘ㆬᛯ⊛ IgG ࠨࡉࠢ࡜ࠬᰳਲ∝㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ㧙␠㧧2008 ᐕ㧦347㧙348.
73㧕 ᧻੗᳗ሶ㧚ߓࠎ߹∐㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ㧙␠㧧2008 ᐕ㧦369㧙370.
74㧕 ᧻੗᳗ሶ㧚ࠕ࠻ࡇ㧙ᕈ⊹⤏Ἳ㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ㧙␠㧧2008 ᐕ㧦371㧙373.
75㧕 ᧻੗᳗ሶ㧚࠙ࠗ࡞ࠬᗵᨴ∝㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ㧙␠㧧2008 ᐕ㧦398㧙400.
76㧕 ᧻੗᳗ሶ㧚⚦⩶ᗵᨴ∝㧘ࡑࠗࠦࡊ࡜࠭ࡑ㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ㧙␠㧧2008 ᐕ㧦401㧙404.
77㧕 ᧻੗᳗ሶ㧚⌀⩶㧘ࠬࡇࡠࡋ㧙࠲㧘ࠢ࡜ࡒࠫࠕ㧘࡝ࠤ࠶࠴ࠕᗵᨴ∝㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧧ࡔࠫࠞ࡞ࡆࡘ㧙␠㧦2008 ᐕ㧦405㧙406.
78㧕 ᧻੗᳗ሶ㧚ャ౉ᗵᨴ∝㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧧ࡔࠫࠞ࡞ࡆࡘ㧙␠㧧2008 ᐕ㧦409㧙410.

㧙㧙79㧕 ᧻੗᳗ሶ㧚ㇱ૏೎ᗵᨴ∝㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ㧙␠㧧2008 ᐕ㧦411㧙413.
80㧕 ᧻੗᳗ሶ㧚ᢌⴊ∝㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ㧙␠㧧2008 ᐕ㧦414㧙415.
81㧕 ⥵ᚭ㆏ᓼ㧘ᄢႦ▵ሶ㧘ℙየᵏౖ㧚ャⴊߩታ㓙㧦MFICU Უ૕࡮⢝ఽࡑ࠾ࡘࠕ࡞㧘ࡔ࠺ࠖࠞ಴  ᄢ㒋㧧2008
ᐕ㧦368㧙374.
82㧕 ㄭ⮮⋥ታ㧚఺∉࡮ࠕ࡟࡞ࠡ㧙∔ᖚ㧦ጟ↰ ᱜ ⋙ୃ㧚᩟ਅ ᷕ㧘ጊ᧲ൕᒎ㧘↰ਛ⧐᣿㧘ᣧᎹ㤗ℂሶ ✬㓸㧚⥃ᐥᩕ㙃ቇᴦ≮ߩታ〣 ∛ᘒ೎✬㧘᧲੩㧦㊄ේ಴ 㧧2008 ᐕ㧦423㧙440.
83㧕 ㄭ⮮⋥ታ㧚᳇▤ᡰ༎ᕷ㧦᧻የ ℂ ⋙ୃ㧚㋈ᧁᐽਯ ✬㓸㧚ࠃߊࠊ߆ࠆ∛ᘒ↢ℂ 15 ዊఽ∔ᖚ㧘᧲੩㧦ᣣᧄක੐ᣂႎ␠㧧2008 ᐕ㧦122㧙126.
84㧕 ㄭ⮮⋥ታ㧚ࠕ࠻ࡇ㧙ᕈ⊹⤏Ἳ㧦᧻የ ℂ ⋙ୃ㧚㋈ᧁᐽਯ ✬㓸㧚ࠃߊࠊ߆ࠆ∛ᘒ↢ℂ 15 ዊఽ∔ᖚ㧘᧲੩㧦ᣣᧄක੐ᣂႎ␠㧧2008 ᐕ㧦127㧙130.
85㧕 ㄭ⮮⋥ታ㧚⭄㤗∐㧦᧻የ ℂ ⋙ୃ㧚㋈ᧁᐽਯ ✬㓸㧚ࠃߊࠊ߆ࠆ∛ᘒ↢ℂ 15 ዊఽ∔ᖚ㧘᧲੩㧦ᣣᧄක੐ᣂႎ␠㧧2008 ᐕ㧦131㧙132.
86㧕 ⥵ᚭ㆏ᓼ㧚╙ 5 ┨ ⇣Ᏹಽᇂߩ▤ℂߣಣ⟎㧦MFICU(๟↥ᦼක≮)ㅪ⛊ද⼏ળ ✬㓸㧚MFICU Უ૕࡮⢝ఽ
ICU ࡑ࠾ࡘࠕ࡞㧘᧲੩㧦ࡔ࠺ࠖࠞ಴ 㧧2008 ᐕ㧦368㧙374㧚
⪺ᦠ㧔᰷ᢥ㧕
1㧕 Kondo N, Kato Z, Kaneko H, Fukao T, Matsui E, Aoki M. Molecular mechanisms of hygiene hypothesis.
In: Holgate S, Marone G, Ring J, eds. Cellular and Molecular Targets in Allergy and Clinical
Immunology. Gottingen: Hogrefe & Huber Publishers; 2007:36-37.
2㧕 Matsuura N, Tada H, Nakamura Y, Uehara R, Kondo N, Yokota Y, Kaneko H, Fukushi M.Effects of
Dioxins in Breast Milk on Thyroid Function in Infants Born in Japan. Maatoshi Morita M et..
Persistent Organic Pollutants(POPS) Research in Asia, Tsukuba, 2008:368-374.
✚⺑㧔๺ᢥ㧕
1㧕 ㄭ⮮⋥ታ㧘᧻੗᳗ሶ㧘᪀ේᗲ⟤㧘Ꮉᧄౖ↢㧘㕍ᧁ⟤ᄹሶ㧘ኹᧄ⾆⧷㧘㊄ሶ⧷㓶㧘ᷓየᢅᐘ㧘ട⮮ༀ৻㇢㧘ᰞ੗㉿⟤㧘ᣂ੗㓉ᐢ㧘ዊỈ ੫㧘ᧁ᧛ ⽕㧚ࠕ࡟࡞ࠡ࡯∔ᖚߩ੍⍮࡮੍㒐ߪน⢻߆㧘ᣣᧄዊఽࠕ࡟࡞ࠡ࡯
ቇળ⹹ 2006 ᐕ㧧20 Ꮞ㧦44㧙54.
2㧕 ㄭ⮮⋥ታ㧚᣿⏕ߦቯ⟵ߐࠇߚ఺∉ਇో∝-Wiskott-Aldrich ∝୥⟲㧘Ძ⚦ⴊ▤᜛ᒛᕈᄬ⺞∝ߥߤ-㧘ዊఽ⑼⸻
≮ 2006 ᐕ㧧69 Ꮞ(Ⴧೀภ)㧦257㧙259.
3㧕 ㄭ⮮⋥ታ㧘᪀ේᗲ⟤㧚ዊఽࠕ࡟࡞ࠡ࡯∔ᖚߦ߅ߌࠆ QOL ⺞ᩏߩታ㓙㧘ࠕ࡟࡞ࠡ࡯࡮఺∉ 2006 ᐕ㧧13
Ꮞ㧦32㧙43.
4㧕 ㄭ⮮⋥ታ㧚1.ዊఽࠕ࡟࡞ࠡ࡯ߣ఺∉ㆮવቇ—ࠕ࡟࡞ࠡ࡯ߩ∛࿃࡮㑐ㅪㆮવሶߣㆮવሶቇ⊛ಽ㘃ߩ⹜ߺ࡯㧘
ዊఽ⑼⥃ᐥ 2006 ᐕ㧧59(Ⴧೀภ)㧦1209㧙1213.
5㧕 ะጊᓼሶ㧘⷏㑆ਃ㚌㧘᦭↰᣽ᒾ㧘દ⮮▵ሶ㧘ቝℂ㗇ෘ㓶㧘ᶏ⠧Ỉరብ㧘ㄭ⮮⋥ታ㧘ᩊ↰Ⅎ⟤ሶ㧘ฎᐣᏎผ㧘⋿ᑿశᢥ㧚㘩‛ࠕ࡟࡞ࠡ࡯⸻≮ࠟࠗ࠼࡜ࠗࡦ㧘ᣣᧄዊఽ⑼ቇળ⹹ 2006 ᐕ㧧110 Ꮞ㧦904㧙911.
6㧕 ㄭ⮮⋥ታ㧚ࠕ࡟࡞ࠡ࡯⊒∝ߪ੍⍮ߢ߈ࠆ㧫㧘Q&A ߢࠊ߆ࠆࠕ࡟࡞ࠡ࡯∔ᖚ 2006 ᐕ㧧2 Ꮞ㧦318㧙320.
7㧕 ㄭ⮮⋥ታ㧚ዊఽ᳇▤ᡰ༎ᕷᴦ≮࡮▤ℂࠟࠗ࠼࡜ࠗࡦ 2005 ࠍߤ߁⺒߻߆ ╙ 6 ┨ዊఽ᳇▤ᡰ༎ᕷߩෂ㒾࿃ሶߣߘߩ੍㒐㧘ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ⹹ 2006 ᐕ㧧20 Ꮞ㧦233㧙237.
8㧕 ㄭ⮮⋥ታ㧚㘩‛ࠕ࡟࡞ࠡ࡯⸻≮ࠟࠗ࠼࡜ࠗࡦ 2005 ⸃⺑ ╙ 3 ┨㘩‛ࠕ࡟࡞ࠡ࡯ߩ∛ᘒ㧘ᣣᧄዊఽࠕ࡟࡞
ࠡ࡯ቇળ⹹ 2006 ᐕ㧧20 Ꮞ㧦238㧙239.
9㧕 ㄭ⮮⋥ታ㧘⑔↰৻ੳ㧚Ataxia-telangiectasia㧚ౝಽᴲ∝୥⟲(╙ 2 )Υ㧘ᣣᧄ⥃ῼ 2006 ᐕ㧧3 Ꮞ㧦114
㧙118.
10㧕 ㄭ⮮⋥ታ㧘᪀ේᗲ⟤㧚੃ᐜఽᦼߦ߅ߌࠆㆮવ࡮ⅣႺⷐ࿃ߣࠕ࡟࡞ࠡ࡯∔ᖚ㧘⥃ᐥ఺∉࡮ࠕ࡟࡞ࠡ࡯⑼ 2006
ᐕ㧧46 Ꮞ㧦273㧙279㧚
11㧕 ㄭ⮮⋥ታ㧚ๆ౉ࠬ࠹ࡠࠗ࠼⮎ߩ⌒߳ߩᓇ㗀—ࡉ࠺࠰࠾࠼ๆ౉⵾೷ࠍਛᔃߦ㧘Pharma Medica 2006 ᐕ㧧
24 Ꮞ㧦49㧙53.
12㧕 ◉↰⚩ม㧘㊄ሶ⧷㓶㧘ㄭ⮮⋥ታ㧚Υ.㘩‛ࠕ࡟࡞ࠡ࡯ߩ∛ᘒ㧘ࠕ࡟࡞ࠡ࡯࡮఺∉ 2006 ᐕ㧧13 Ꮞ㧦22㧙28.
13㧕 ㄭ⮮⋥ታ㧚ᦨㄭߩࠕ࡟࡞ࠡ࡯⸻ኤࠟࠗ࠼࡜ࠗࡦ㧘ࠕ࡟࡞ࠡ࡯ࠕ 2006 ᐕ㧧35 Ꮞ㧦62㧙64㧚
14㧕 ㄭ⮮⋥ታ㧘᪀ේᗲ⟤㧚ዊఽ༎ᕷߩ৻ᰴ੍㒐㧘ੑᰴ੍㒐㧘ਃᰴ੍㒐ߩ⃻⁁ߣ໧㗴ὐ㧘⥃ᐥ఺∉࡮ࠕ࡟࡞ࠡ࡯
⑼ 2006 ᐕ㧧46 Ꮞ㧦501㧙508.
15㧕 ᷓየᢅᐘ㧘ㄭ⮮⋥ታ㧚ᵈ⋡ߔߴ߈ࠕ࡟࡞ࠥࡦߣߘߩ∛ᘒ ࠗ࠿㧘ࡀࠦ㘺⢒ߣࠕ࡟࡞ࠡ࡯ߩ⊒∝㧘⥃ᐥ఺∉࡮ࠕ࡟࡞ࠡ࡯⑼ 2006 ᐕ㧧46 Ꮞ㧦604㧙612.
16㧕 ㄭ⮮⋥ታ㧘᪀ේᗲ⟤, ᧻੗᳗ሶ㧚ㆮવߣࠕ࡟࡞ࠡ࡯㧘߆ࠄߛߩ⑼ቇ 2006 ᐕ㧧252 Ꮞ㧦24㧙28.
17㧕 દ⮮▵ሶ㧘ㄭ⮮⋥ታ㧚㘩‛ࠕ࡟࡞ࠡ࡯⸻≮ࠟࠗ࠼࡜ࠗࡦ 2005 ⸃⺑ ╙ 5 ┨ 㘩‛ࠕ࡟࡞ࠡ࡯ߩ⸻ᢿ㧘ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ⹹ 2006 ᐕ㧧20 Ꮞ㧦526㧙530.
18㧕 ਅỈિⴕ㧘㋈ᧁᐽਯ㧚ࡍ࡞ࠝࠠࠪ࠰࡯ࡓ∛㧚ࠊ߇࿖ߢ∛࿃߇⸃᣿ߐࠇߚవᄤઍ⻢⇣Ᏹ∝㧘ዊఽ⑼⸻≮ 2006
ᐕ㧧69 Ꮞ㧦1646㧙1652.
19㧕 ㋈ᧁᐽਯ㧚㛽∝⁁ߢ⷗ߟ߆ࠆవᄤઍ⻢⇣Ᏹ∝㧚ᣣᏱ⸻≮ߢߩవᄤઍ⻢⇣Ᏹ∝㧘ዊఽ⑼⸻≮ 2006 ᐕ㧧69
Ꮞ㧦1590㧙1594.
20㧕 ᛬ዬᕡᴦ㧘ᷓየᢅᐘ㧚ߌ޿ࠇࠎ㧘ᗧ⼂㓚ኂࠍ⿠ߎߔ∔ᖚߩᴦ≮࡮▤ℂߩࡐࠗࡦ࠻㧚᦭ᯏ㉄ઍ⻢⇣Ᏹ∝㧘ዊఽౝ⑼ 2006 ᐕ㧧38 Ꮞ㧦452㧙454.

㧙㧙21㧕 ᷓየᢅᐘ㧚ዊఽ∔ᖚߩ⸻ᢿᴦ≮ၮḰ ataxia telangiectasia㧘ዊఽౝ⑼ 2006 ᐕ㧧38 Ꮞ(⥃ᤨჇೀภ)㧦232
㧙233.
22㧕 ኹᧄ⾆⧷㧘㕍ᧁ⟤ᄹሶ㧘᧻੗᳗ሶ㧘ㄭ⮮ ᙥ㧘Ꮉᧄౖ↢㧘㊄ሶ⧷㓶㧘ᷓየᢅᐘ㧘ㄭ⮮⋥ታ㧚RS ࠙ࠗ࡞ࠬᗵ
ᨴߣ༎ᕷ⊒∝—ᗵᨴߦࠃࠆ༎ᕷߩ⊒∝㧘Ⴧᖡߩᯏᐨ—, ࠕ࡟࡞ࠡ࡯࡮఺∉ 2006 ᐕ㧧13 Ꮞ㧦1031㧙1037.
23㧕 ੹੗৾㊀㧘⑔ን⌀ᥓሶ㧘᭑ᧄ߭ߣߺ㧘ᐔᨋ⹞ሶ㧘ጤ⿧ᶈሶ㧘ᧁ᧛ ⽕㧘ዊỈ ੫㧘ᰞ੗㉿⟤㧘ᷓየᢅᐘ㧘⑔ንᖈ㧘᛬ዬᔘᄦ㧚∛ఽ଻⢒࿦ߢߩ଻⢒ਛߩ∝⁁ߩᄌൻߦߟ޿ߡߩᬌ⸛㧘଻⢒ߣ଻ஜ 2006 ᐕ㧧12 Ꮞ㧦
31㧙33.
24㧕 ⑔ን ᖈ㧘ฬ↰ආ೑㧘㕍ᧁ㓶੺㧘㋈ᧁ໪ሶ㧘ᣂ੗㓉ᐢ㧘ᷓየᢅᐘ㧘ㄭ᧻↱⟤ሶ㧘ጤ⿧ᶈሶ㧚㤗㤛ḡߩࠗࡦࡈ࡞ࠛࡦࠩߩว૬∝⁁ߦኻߔࠆലᨐߩᬌ⸛㧘ṽᣇߣ఺∉࡮ࠕ࡟࡞ࠡ࡯ 2006 ᐕ㧧20 Ꮞ㧦44㧙53.
25㧕 ጟᧄ⟤ቁ㧘ᴡ㊁㓁৻㧘ㄭ⮮⋥ታ㧚ᐳ⺣ળ‫∔࡯ࠡ࡞࡟ࠕޟ‬ᖚߩ⊒∝੍⍮ߣ੍㒐ߪน⢻߆㧫‫ޠ‬
㧘Q&A ߢࠊ߆ࠆ
ࠕ࡟࡞ࠡ࡯∔ᖚ 2006 ᐕ㧧2 Ꮞ㧦337㧙350.
26㧕 ㄭ⮮⋥ታ㧘᧻੗᳗ሶ㧘᪀ේᗲ⟤㧘Ꮉᧄౖ↢㧘㕍ᧁ⟤ᄹሶ㧘ኹᧄ⾆⧷㧘㊄ሶ⧷㓶㧘ᷓየᢅᐘ㧚᳇▤ᡰ༎ᕷߩ⊒∝੍㒐㧘ᣣᧄዊఽ⑼ቇળ㔀⹹ 2007 ᐕ㧧111 Ꮞ㧦23㧙27㧚
27㧕 ㄭ⮮⋥ታ㧚ࠕ࠻ࡇ࡯ᕈ⊹⤏Ἳ㧘ዊఽౝ⑼ ዊఽ∔ᖚߩ⸻ᢿᴦ≮ၮḰ ╙ 3  2007 ᐕ㧧38 Ꮞ(Ⴧೀภ)㧦258
㧙259.
28㧕 ㄭ⮮⋥ታ㧚༎ᕷߩ࠹࡯࡜࡯ࡔࠗ࠼(୘೎ൻ)ක≮ߩ⃻⁁ߣ዁᧪߳ߩࠕࡊࡠ㧙࠴㧘International Review of
Asthma 2007 ᐕ㧧9 Ꮞ㧦8㧙29.
29㧕 ㄭ⮮⋥ታ㧚ࠕ࡟࡞ࠡ࡯⊒∝ߦ߅ߌࠆㆮવሶߣⅣႺ㧘ࠕ࡟࡞ࠡ࡯ 2007 ᐕ㧧56 Ꮞ㧦94㧙100㧚
30㧕 ㄭ⮮⋥ታ㧚Q&A ⧎☳∝ߦ߅ߌࠆዪᚲ∝⁁ߣోり⊛ߥ∝⁁ߪ㧘ߤߩࠃ߁ߦኻᔕߒߚࠄࠃ޿ߢߔ߆㧚Allergy
From the Nose to the Lung 2007 ᐕ㧧5 Ꮞ㧦17㧚
31㧕 ㄭ⮮⋥ታ㧘᧻੗᳗ሶ㧘㕍ᧁ⟤ᄹሶ㧘ᣂ੗㓉ᐢ㧘㊄ሶ⧷㓶㧘ᷓየᢅᐘ㧘᪀ේᗲ⟤㧚ⅣႺ߇↢૕ߦ෸߷ߔᓇ㗀㧘ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ⹹ 2007 ᐕ㧧21 Ꮞ㧦92㧙95㧚
32㧕 ⿷┙㓶৻㧘੗਄ᄈ⨃㧘ᯅᧄశม㧘ㄭ⮮⋥ታ㧘⋿ᑿశᢥ㧘᫪Ꮉᤘᑝ㧘⷏㑆ਃ㚌㧚ዊఽ᳇▤ᡰ༎ᕷᴦ≮࡮▤ℂࠟࠗ࠼࡜ࠗࡦ 2005 ߇੃ఽ༎ᕷߩᴦ≮⃻႐ߦਈ߃ߚ߽ߩ㧙╙ 15 ࿁ዊఽ᳇㆏ࠕ࡟࡞ࠡ࡯⎇ⓥળߢߩࠕࡦࠤ࡯
࠻⺞ᩏ⚿ᨐࠃࠅ㧙㧘ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ⹹ 2007 ᐕ㧧21 Ꮞ㧦116㧙123.
33㧕 ㄭ⮮⋥ታ㧚㘩‛ߦኻߔࠆ఺∉ᔕ╵ߩ⇣Ᏹߣ㘩‛ࠕ࡟࡞ࠡ࡯㧘ዊఽౝ⑼ 2007 ᐕ㧧39 Ꮞ㧦545㧙548.
34㧕 ㄭ⮮⋥ታ㧘᪀ේᗲ⟤㧚ࠕ࠽ࡈࠖ࡜ࠠࠪ࡯㧘ዊఽ⑼⸻≮ 2007 ᐕ㧧70 Ꮞ(Ⴧೀภ)㧦111㧙112.
35㧕 ㄭ⮮⋥ታ㧚ㆮવሶ⸻ᢿ㧘⛱ว⥃ᐥ 2007 ᐕ㧧56 Ꮞ㧦1883㧙1890.
36㧕 ㄭ⮮⋥ታ㧚㘩‛ࠕ࡟࡞ࠡ࡯ߩ∛ᘒ↢ℂ㧘ࠕ࡟࡞ࠡ࡯ 2007 ᐕ㧧56 Ꮞ㧦439㧙444.
37㧕 ㄭ⮮⋥ታ㧚 Q&A ࠕ࠻ࡇ࡯ᕈ⊹⤏Ἳߩሶଏ߇༎ᕷߦߥࠄߥ޿ߚ߼ߦߪ㧫 Answer㧘 Q&A ߢࠊ߆ࠆࠕ࡟࡞
ࠡ࡯∔ᖚ 2007 ᐕ㧧3 Ꮞ㧦273㧙274㧚
38㧕 ㄭ⮮⋥ታ㧚ᐳ⺣ળ ዊఽࠕ࡟࡞ࠡ࡯ߩ QOL ⹏ଔᴺߣ⥃ᐥߦ߅ߌࠆᗧ⟵㧘Pediatric Allergy for Clinicians
2007 ᐕ㧧3 Ꮞ㧦5㧙11㧚
39㧕 ᷓየᢅᐘ㧚ࠤ࠻ࡦ૕ઍ⻢⇣Ᏹ∝ ․ߦࠕ࠮࠻ࡦⴊᕈཌྷฯ∝ߣ㐓೎ߔߴ߈ࠨࠢࠪ࠾࡞㧙CoA㧦3㧙ࠤ࠻㉄ CoA࠻࡜ࡦࠬࡈࠚ࡜㧙࠯ᰳ៊∝ࠍਛᔃߦ㧘ᣣᧄዊఽ⑼ቇળ㔀⹹ 2007 ᐕ㧧111 Ꮞ㧦727㧙739.
40㧕 ᷓየᢅᐘ㧚ࡍ࠶࠻㘺⢒ⅣႺߣዊఽࠕ࡟࡞ࠡ࡯㧘ࠕ࡟࡞ࠡ࡯ߩ⥃ᐥ 2007 ᐕ㧧356 Ꮞ㧦129㧙135.
41㧕 ㋈ᧁ໪ሶ㧘㊄ሶ⧷㓶㧘ㄭ⮮⋥ታ㧚IgA ࠨࡉࠢ࡜ࠬ(IgA1, IgA2)ߩ․ᕈ㧘⥃ᐥ఺∉࡮ࠕ࡟࡞ࠡ࡯⑼ 2007 ᐕ㧧
473 Ꮞ㧦652㧙657㧚
42㧕 Ꮉᧄౖ↢㧘ᷓየᢅᐘ㧘᧻੗᳗ሶ㧘Ꮉᧄ⟤ᄹሶ㧘㊄ሶ⧷㓶㧘ㄭ⮮⋥ታ㧚⤯Ꮺⴊࠍ↪޿ߚ಴↢ࠦࡎ࡯࠻⎇ⓥߦ
ࠃࠆዊఽࠕ࡟࡞ࠡ࡯∔ᖚߩ⹏ଔ㧘ࠕ࡟࡞ࠡ࡯ߩ⥃ᐥ 2007 ᐕ㧧27 Ꮞ㧦77㧙82㧚
43㧕 ㄭ⮮⋥ታ㧚㘩‛ࠕ࡟࡞ࠡ࡯ߣߘߩኻ╷㧘߰ߚ߫ 2007 ᐕ㧧71 Ꮞ㧦11㧙15.
44㧕 ㄭ⮮⋥ታ㧚࿾ၞක≮⏕଻ߩߚ߼ߩ౐ߟߩ⊒ᗐォ឵—ጘ㒂ᄢ‫ޟ‬࿾ၞක≮කቇ࠮ࡦ࠲࡯‫—┙⸳ߩޠ‬㧘ᣣᧄක੐ᣂႎ 2007 ᐕ㧧4364 Ꮞ㧦80㧙85㧚
45㧕 ㄭ⮮⋥ታ㧚⮎‛ࠕ࡟࡞ࠡ࡯ߩ⸻ᢿߣᴦ≮㧘ዊఽ⑼⥃ᐥ 2007 ᐕ㧧60 Ꮞ㧦2319㧙2327㧚
46㧕 ㄭ⮮⋥ታ㧚㘩ຠߣࠕ࡟࡞ࠡ࡯㧘FOODS & FOOD INGREDIENTS JOURNAL OF JAPAN 2007 ᐕ㧧212
Ꮞ㧦997㧙1001㧚
47㧕 ㄭ⮮⋥ታ㧘᧻੗᳗ሶ㧘⷏᧛޽߆ߨ㧚᳇▤ᡰ༎ᕷᖚఽߦኻߔࠆ࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮㧘ዊఽ⑼ 2007 ᐕ㧧48
Ꮞ㧦1981㧙1988.
48㧕 ㄭ⮮⋥ታ㧚↢૕ⷐ࿃ߣⅣႺⷐ࿃ߣߩ㑐ࠊࠅ߆ࠄ∛᳇ߩኻ╷ࠍ⠨߃ࠆ㧘ᣣᧄක੐ᣂႎ 2008 ᐕ㧧4367 Ꮞ㧦
49㧙50.
49㧕 ᧻੗᳗ሶ㧘Ꮉᧄౖ↢㧘ᷓየᢅᐘ㧘ㄭ⮮⋥ታ㧦੃ᐜఽᦼߩ఺∉ᔕ╵ᕈߩᄌㆫߣࠕ࡟࡞ࠡ࡯∔ᖚ⊒∝㧘ࠕ࡟࡞ࠡ࡯࡮఺∉ 2008 ᐕ㧧15 Ꮞ㧦170㧙174. 
50㧕 ㄭ⮮⋥ታ㧚㘩ຠࠕ࡟࡞ࠡ࡯ߣߘߩᴦ≮ᚢ⇛㧘Milk Science 2008 ᐕ㧧56 Ꮞ㧦138㧙140㧚
51㧕 ㄭ⮮⋥ታ㧘᧻੗᳗ሶ㧘⷏᧛޽߆ߨ㧚ዊఽ᳇▤ᡰ༎ᕷߩ࠹࡯࡜࡯ࡔࠗ࠼ක≮㧘༎ᕷ 2008 ᐕ㧧21 Ꮞ㧦40㧙
46.
52㧕 ᄢ⷏⑲ౖ㧘ട⮮ༀ৻㇢㧘ቄ ᗲ⬒㧘ᧁ᧛ ⽕㧘ฬ↰ආ೑㧘ᓼ⷗ືม㧘⋧㚍๺૫㧘᧻੗᳗ሶ㧘㊄ሶ⧷㓶㧘ㄭ⮮⋥ታ㧘᧩የ⽕ੱ㧘⊕Ꮉ᣽ብ㧚ಽሶ↢‛ቇ⊛ࠕࡊࡠ࡯࠴ߩࠗࡦࡄࠢ࠻ IL㧙18 ෸߮ࠪࠣ࠽࡞વ㆐♽࠲ࡦࡄࠢ⾰᭴ㅧ⸃ᨆߦၮߠߊഃ⮎߳ߩࠕࡊࡠ࡯࠴㧘ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ⹹ 2008 ᐕ㧧22 Ꮞ㧦63㧙70㧚
53㧕 ㄭ⮮⋥ታ㧚ߥߗࠕ࡟࡞ࠡ࡯߇Ⴧടߒߚߩ߆㧘BIO INDUSTRY 2008 ᐕ㧧25 Ꮞ㧦7㧙14.
54㧕 ㄭ⮮⋥ታ㧚✬㓸ᓟ⸥㧘ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ⹹ 2008 ᐕ㧧22 Ꮞ㧦464㧚
55㧕 ㄭ⮮⋥ታ㧘ችᧄᤘᱜ㧘ᄢ↰ ஜ㧚࠻ࠪ࡞㉄ࠬࡊ࡜࠲ࠬ࠻㥊⺣ ༎ᕷᴦ≮ߦ߅ߌࠆ Th2 ࠨࠗ࠻ࠞࠗࡦ㒖ኂ⮎ߩ૏⟎ߠߌ㧘PROGRESS IN MEDICINE 2008 ᐕ㧧28 Ꮞ㧦2167㧙2173.
56㧕 ㊄ሶ⧷㓶㧘ㄭ⮮⋥ታ㧚ಽ㘃ਇ⢻ဳ఺∉ਇో∝㧚ࠕ࡟࡞ࠡ࡯࡮఺∉ 2008 ᐕ㧧15 Ꮞ㧦2㧙9.

㧙㧙

57㧕 ⑔ን ᖈ㧘㊄ሶ⧷㓶㧘ᄢ⷏⑲ౖ㧘═ේ⾆⟤ሶ㧘ㄭ⮮⋥ታ㧚ዊఽࠗࡦࡈ࡞ࠛࡦࠩߦ߅ߌࠆ㤗㤛ḡߩലᨐߣᴦ
≮ߩㆬᛯߦߟ޿ߡߩᬌ⸛㧘ṽᣇߣ఺∉࡮ࠕ࡟࡞ࠡ࡯ 2008 ᐕ㧧27 Ꮞ㧦22㧙33.
58㧕 ㄭ⮮⋥ታ㧚QOL ⺞ᩏ␿ߩ૶޿ᣇ㧘Pediatric Allergy for Clinicians 2008 ᐕ㧧4 Ꮞ㧦31㧙35.
59㧕 ᷓየᢅᐘ㧚⾰⇼ᔕ╵ ዊఽߩࠤ࠻࡯ࠪࠬ㧘 ᣣᧄක੐ᣂႎ 2008 ᐕ㧧4329 Ꮞ㧦89㧙90㧚
60㧕 ㊄ሶ⧷㓶㧚ᶧᕈ఺∉ߩ⇣Ᏹߦࠃࠆ఺∉ਇో∝㧚ߎߎ߹ߢಽ߆ߞߡ޿ࠆ఺∉ਇో∝୥⟲㧘ዊఽ⑼⸻≮ 2008
ᐕ㧧61 Ꮞ㧦1775㧙1782㧚
61㧕 ᷓየᢅᐘ㧚IgG ࠨࡉࠢ࡜ࠬᰳ៊∝ߣ IgA ᰳ៊∝㧘ዊఽ∔ᖚ⸻≮ߩߚ߼ߩ∛ᘒ↢ℂ㧚╙ 4  ዊఽౝ⑼ 2008
ᐕ㧧40 Ꮞ(Ⴧೀภ)㧦1288㧙1293㧚
62㧕 ㊄ሶ⧷㓶㧚Ataxia-telangiectasia ߣߘߩ㘃✼∔ᖚ㧘ዊఽ∔ᖚ⸻≮ߩߚ߼ߩ∛ᘒ↢ℂ㧚╙ 4 ዊఽౝ⑼
2008 ᐕ㧧40 Ꮞ(Ⴧೀภ)㧦1314㧙1317.
✚⺑㧔᰷ᢥ㧕
1㧕 Matsui E, Kaneko H㧘Fukao T㧘Teramoto T㧘Kondo N. Tailor-made edicine and gene polymorphisms
in bronchial asthma. Int Rev Asthma. 2006;8:64-72.
2㧕 Shimozawa N. Molecular and clinical aspects of peroxisomal diseases. J Inher Metab Dis.
2007;30:193-197.
3㧕 Kondo N㧘Munakata M㧘Rosenwasser LJ. Round table discussion㧘tailor-made(personalized)medicine
for asthma-current situation and future vision㧚Int Rev Asthma. 2007;9:7-29.
4㧕 Kondo N. Current position of Japanese and Chinese medicine in regard to tailor-made medicine -Fromthe viewpoint of allergic disorders-. J Tradit Med. 2007;24:43-46.
5㧕 Kondo N, Matsui E, Nishimura A. A genetic classification and a tailor-made medicine in allergic
disorders. Korean J Asthma, Allergy and Clin Immunol. 2007;27:83-86.
6㧕 Mukoyama T, Nishima S, Arita M, Ito S, Urisu A, Ebisawa M, Ogura H, Kohno Y, Kondo N, Shibata R,
Hurusho M, Mayumi M, Morikawa A. Food Allergy Committee, Japanese Society of Pediatric Allergy
and Clinical Immunology Guidelines for diagnosis and management of pediatric food allergy inJapan. Allergol Int. 2007;56:349-361.
7㧕 Kondo N. From the Editorial Committee. Int Rev Asthma. 2008;10:4.
8㧕 Kondo N, Hae Sim Park, Soo Jong Hong. Round Table Discussion-clinical application of molecular
genetics of allergy. Int Rev Asthma. 2008;10:5-21.
ේ⪺㧔๺ᢥ㧕
1㧕 ⷏㑆ਃ㚌㧘ፒጊᐘ㓶㧘᫪Ꮉߺ߈㧘ⷺ↰๺ᒾ㧘ศේ㊀⟤㧘᫪Ꮉᤘᑝ㧘ᴡ㊁㓁৻㧘⷏—↰ᢅਯ㧘චሼᢥሶ㧘⋧ේ㓶ᐘ㧘❐ ◊㧘દ⮮ᶈ᣿㧘ቝℂ㗇ෘ㓶㧘ㄭ⮮⋥ታ㧘⋿ᑿశᢥ㧘ᐔኅବ↵㧘દ⮮▵ሶ㧘ᧃᑝ ⼾㧘᦭↰᣽ᒾ㧘ฎᎹ ẋ㧘ựፒ㓶ᐔ㧚ዊఽࠕ࡟࡞ࠡ࡯∔ᖚߦ߅ߌࠆࠕ࡟࡞ࠥࡦᗵ૞ߩో࿖⺞ᩏ㧘ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇ
ળ⹹ 2006 ᐕ㧧20 Ꮞ㧦109㧙118.
2㧕 ૒‫ᧁޘ‬⡛㧘Ḵญ᣽ሶ㧘ㄭ⮮⋥ታ㧘ቝℂ㗇ෘ㓶㧘ᄢਭ଻౏⵨㧚ࠕ࡟࡞ࠡ࡯∔ᖚߩᣧᦼ੺౉(early intervention)ߩታ㓙ߣ⹏ଔ㧘⥃ᐥ఺∉࡮ࠕ࡟࡞ࠡ࡯⑼ 2006 ᐕ㧧46 Ꮞ㧦3㧙20.
3㧕 ዊ㑐㆏ᄦ㧘᳗↰ᥓሶ㧘દ⮮⾆⟤ሶ㧘㐳ደ⡡৻㇢㧘ጤ↰᥏ሶ㧘ጤ↰⑲᮸㧘ㄭ⮮ን㓶㧘ᷡፉ⋿ℂሶ㧘ጊਛᣂ਽㧘⮮Ỉᥓ⟤㧚㗖ㇱ⚿ᩭᕈ࡝ࡦࡄ▵Ἳ߆ࠄ⊹⤏⣼∛ࠍ⊒∝ߒߚዊఽ଀㧘ᣣᧄዊఽ⊹⤏⑼ቇળ㔀⹹ 2006 ᐕ㧧25
Ꮞ㧦101㧙104.
4㧕 ᧻੗᳗ሶ㧘㕍ᧁ⟤ᄹሶ㧘◉↰⚩ม㧘⑔ን ᖈ㧘ᓟ⮮ടኼ⟤㧘ㄭ⮮⋥ታ㧚QOL ⹏ଔߩታ଀⚫੺㧘PediatricAllergy for Clinicians 2007㧧3 Ꮞ㧦25㧙29.
5㧕 ㄭ⮮⋥ታ㧘ᐔጊ⠹৻㇢㧘᧻੗᳗ሶ㧘ኹᧄ⾆⧷㧘㊄ሶ⧷㓶㧘ᷓየᢅᐘ㧘᛬ዬᑪᴦ㧘Ꮉᧄ⟤ᄹሶ㧘⥵ᚭ㆏ᓼ㧘
ᄢ⷏⑲ౖ㧘Ꮉᧄౖ↢㧘᫪↰⑲ⴕ㧘ᧁ᧛⽕㧘ฬ↰ආ೑㧘ᓼ⷗ືม㧘ၳ෹ඳ㧘ᷰㆻ୶ሶ㧚ዊఽ᳇▤ᡰ༎ᕷᖚఽ
ߣⷫ෶ߪ଻⼔⠪ߩ QOL ⺞ᩏ␿◲ᤃᡷ⸓ 2008(GIFU)㧘ࠕ࡟࡞ࠡ࡯ 2008 ᐕ㧧57 Ꮞ㧦1022㧙1033.
6㧕 ㄭ⮮⋥ታ㧚ዊఽක≮೙ᐲߢߩ⃻⁁ߣ໧㗴ὐ—ᄢቇዊఽ⑼ൕോක㧘ዊఽ⑼⸻≮ 2008 ᐕ㧧71 Ꮞ㧦1879㧙1881.
7㧕 ᐔᨋ⹞ሶ㧘᎑੗⌀ᄹ⟤㧘⨹Ꮉౖሶ㧘⑔ን⌀ᥓሶ㧘ጤ⿧ᶈሶ㧘ᷓየᢅᐘ㧘቟⮮ᕺ⟤ሶ㧘ኹỈᄢ␭㧘ዊ㑐㆏ᄦ㧘⑔ንᖈ㧚∛ఽ଻⢒ߦ߅ߌࠆ∝⁁ߦวࠊߖߚㆆ߮ߩᬌ⸛㧘଻⢒ߣ଻ஜ 2008 ᐕ㧧14 Ꮞ㧦46㧙49.
8㧕 ᫪↰⑲ⴕ㧘㊄ሶ⧷㓶㧘ᄢ⷏⑲ౖ㧘ㄭ⮮ᙥ㧘᧻੗᳗ሶ㧘ᷓየᢅᐘ㧘ㄭ⮮⋥ታ㧚఺∉ኡኈ⺃ዉߩߚ߼ߩ㘩‛ࠕ࡟࡞ࠡ࡯ਥⷐ᛫ේ࠲ࡦࡄࠢߩၮ␆⊛ᬌ⸛㧘ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ⹹ 2008 ᐕ㧧22 Ꮞ㧦233㧙238.
9㧕 ⑔ንᖈ㧘㊄ሶ⧷㓶㧘ᄢ⷏⑲ౖ㧘═ේ⾆⟤ሶ㧘ㄭ⮮⋥ታ㧚ዊఽࠗࡦࡈ࡞ࠛࡦࠩߦ߅ߌࠆ㤗㤛ḡߩലᨐߣᴦ≮ߩㆬᛯߦߟ޿ߡߩᬌ⸛㧘ṽᣇߣ఺∉࡮ࠕ࡟࡞ࠡ࡯ 2008 ᐕ㧧27 Ꮞ㧦22㧙32㧚
10㧕 㕍ᧁ㓶੺㧘Ⴚ⟤Ⓞ㧘⊕਄ ㆆ㧘ဈ੗ᢕሶ㧘ጟᧄඳਯ㧘᧖ጊብ㧘ౝ↰㕏㧚ਛ⡊Ἳᴦ≮ᓟ 40 ᣣ⚻ߡ⊒∝ߒߚன⤑ᕈ⣺Ἳߩ 1 ଀㧘ዊఽ⑼⥃ᐥ 2008 ᐕ㧧61 Ꮞ㧦2307㧙2311㧚
11㧕 ട⮮ༀ৻㇢㧚ࡅ࠻ࡋ࡞ࡍࠬ࠙ࠗ࡞ࠬ6 ߦࠃࠆᕆᕈዊ⣖Ἳ㧘ዊఽౝ⑼ 2008 ᐕ㧧40 Ꮞ㧦586㧙588.
ේ⪺㧔᰷ᢥ㧕
1㧕 Gueven N, Fukao T, Luff J, Paterson C, Kay G, Kondo N, Lavin MF. Regulation of the Atm promoter invivo. Genes Chromosomes Cancer. 2006;45:61-71.
IF 4.532
2㧕 Matsukuma E, Kato Z, Omoya K, Hashimoto K, Li A, Yamamoto Y, Ohnishi H, Hiranuma H, Komine
H, Kondo N. Development of fluorescence linked immunosorbent assay (FLISA) for high throughput
screening (HTS) of interferon-gamma. Allergol Int. 2006;55:49-54.
3㧕 Uehara R, Peng G, Nakamura Y, Matsuura N, Kondo N, Tada H. Human milk survey for dioxins in the㧙㧙general population in Japan.Chemosphere. 2006;62:1135-1141.
4㧕 Kaneko H, Matsui E, Shinoda S, Kawamoto N, Nakamura Y, Uehara R, Matsuura N, Morita M, Tada
H, Kondo N. Effects of dioxins on the quantitative levels of immune components in infants. Toxicol Ind
Health. 2006;22:131-136.
5㧕 Funato M, Shimozawa N, Nagase T, Takemoto Y, Suzuki Y, Imamura Y, Matsumoto T, Tsukamoto T,
Kojidani T, Osumi T, Fukao T, Kondo N. Aberrant peroxisome morphology in peroxisomal
beta-oxidation enzyme deficiencies. Brain Dev. 2006;28:287-292.
6㧕 Kaneko H, Matsui E, Asano T, Kato Z, Teramoto T, Aoki M, Kawamoto N, Lian LA, Kasahara K, Kondo
N. Suppression of IFN-gamma production in atopic group at the acute phase of RSV infection. Pediatr
Allergy Immunol. 2006;17:370-375.
7㧕 Kato Z, Asano T, Kondo N. Inosiplex affects the spectra of proton magnetic resonance spectroscopy insubacute sclerosing panencephalitis. J Child Neurol. 2006;21:177-178.
8㧕 Kaneko H, Isogai K, Kondo M, Hosoi K, Asano T, Funato M, Kondo N. Autologous peripheral blood
stem cell transplantation in a patient with relapsed pleuropulmonary blastoma. J Pediatr Hematol
Oncol. 2006;28:383-385.
9㧕 Teramoto T, Fukao T, Tomita Y, Terauchi Y, Hosoi K, Matsui E, Aoki M, Kondo N, Mikawa H.
Pharmacokinetics of beclomethasone dipropionate in an hydrofluoroalkane-134a propellant system injapanese children with bronchial asthma. Allergol Int. 2006;55:317-320.
10㧕 Kondo N, Katsunuma T, Odajima Y, Morikawa A. A randomized open-label comparative study ofmontelukast versus theophlline added to inhaled corticosteroid in asthmatic children. Allergol Int.
2006;55:287-293.
11㧕 Kato T, Isogai K, Orii K, Kuratsubo I, Kondo N, Orii T, Suzuki Y. Portal hypertension in a patient withHunter disease. J Inherit Metab Dis. 2006;29:686.
12㧕 Minegishi Y, Saito M, Morio T, Watanabe K, Agematsu K, Tsuchiya S, Takada H, Hara T, Kawamura N,
Ariga T, Kaneko H, Kondo N, Tsuge I, Yachie A, Sakiyama Y, Iwata T, Bessho F, Ohishi T, Joh K, Imai
K, Kogawa K, Shinohara M, Fujieda M, Wakiguchi H, Pasic S, Abinun M, Ochs HD, Renner ED,
Jansson A, Belohradsky BH, Metin A, Shimizu N, Mizutani S, Miyawaki T, Nonoyama S, Karasuyama
H. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved
in innate and acquired immunity. Immunity. 2006;25:745-755.
13㧕 Zhang G, Fukao T, Sakurai S, Yamada K, Michael Gibson K, Kondo N. Identification of Alu-mediated,large deletion-spanning exons 2-4 in a patient with mitochondrial acetoacetyl-CoA thiolase deficiency.
Mol Genet Metab. 2006;89:222-226.
14㧕 Shiozawa K, Goda N, Shimizu T, Mizuguchi K, Kondo N, Shimozawa N, Shirakawa M, Hiroaki H. The
common phospholipid-binding activity of the N-terminal domains of PEX1 and VCP/p97. FEBS J.
2006;273:4959-4971.
15㧕 Orii KE, Lee Y, Kondo N, McKinnon PJ. Selective utilization of nonhomologous end-joining andhomologous recombination DNA repair pathways during nervous system development. Proc Natl Acad
Sci U S A. 2006;103:10017-10022.
16㧕 Kawamoto N, Kaneko H, Takemura M, Seishima M, Sakurai S, Fukao T, Kasahara K, Iwasa S, Kondo
N. Age-related changes in intracellular cytokine profiles and Th2 dominance in allergic children.
Pediatr Allergy Immunol. 2006;17:125-133.
17㧕 Fukao T, Sakurai S, Rolland MO, Zabot MT, Schulze A, Yamada K, Kondo N. A 6-bp deletion at the
splice donor site of the first intron resulted in aberrant splicing using a cryptic splice site within exon 1
in a patient with succinyl-CoA: 3-ketoacid CoA transferase (SCOT) deficiency. Mol Genet Metab.
2006;89:280-282.
18㧕 Sukegawa-Hayasaka K, Kato Z, Nakamura H, Tomatsu S, Fukao T, Kuwata K, Orii T, Kondo N. Effectof Hunter disease (mucopolysaccharidosis type II) mutations on molecular phenotypes of
iduronate-2-sulfatase: enzymatic activity, protein processing and structural analysis. J Inherit MetabDis. 2006;29:755-761.
19㧕 Kato Z, Saito K, Isogai K, Kondo N. Magnetic resonance imaging and spectroscopy in FCMD. J Ped
Neurol. 2006;4:261-264.
20㧕 Kato Z, Omoya K, Orii KE, Kondo N. Acute disseminated encephalomyelitis associated withenterovirus 71. Pediatr Infect Dis J. 2006;1:115-118.
21㧕 Horikoshi H, Kato Z, Masuno M, Asano T, Nagase T, Yamagishi Y, Kozawa R, Arai T, Aoki M, Teramoto
T, Omoya K, Matsumoto N, Kurotaki N, Shimokawa O, Kurosawa K, Kondo N. Neuroradiologic
findings in Sotos syndrome. J Child Neurol. 2006;21:614-618.
22㧕 Takahashi Y, Matsuda K, Kubota Y, Shimomura J, Yamasaki E, Kudo T, Fukushima K, Osaka H,
Akasaka N, Imamura A, Yamada S, Kondo N, Fujiwara T.Vaccination and infection as causative
factors in Japanese patients with rasmussen syndrome: Molecular mimicry and HLA class I. Clin Dev
Immunol. 2006;13:381-387.
23㧕 Tomatsu S, Sukegawa K, Trandafirescu GG, Gutierrez MA, Nishioka T, Yamaguchi S, Orii T, Froissart
R,Maire I, Chabas A, Cooper A, Di Natale P,Gal A, Noguchi A, Sly WS. Differences in methylation
patterns in the methylation boundary region of IDS gene in hunter syndrome patients: implications㧙㧙

IF 2.739

IF 0.731

IF 1.464

IF 2.454
IF 1.240

IF 1.278

IF 1.668

IF 19.266

IF 2.550

IF 6.791

IF 9.598

IF 2.454

IF 2.550

IF 1.668

IF 3.086

IF 1.240

for CpG hot spot mutations.Eur J Hum Genet. 2006;14:838-845.
24㧕 Tomatsu S, Montano AM, Lopez P, Trandafirescu G, Gutierrez MA, Oikawa H, Nishioka T, Vieira MB,
Orii T, Noguchi A. Determinant factors of spectrum of missense variants in mucopolysaccharidosis IVA
gene.Mol Genet Metab. 2006;89:139-149.
25㧕 Sakurai S, Fukao T, Haapalainen AM, Zhang G, Yamada S, Lilliu F, Yano S, Robinson P, Gibson MK,
Wanders RJA, Mitchell GA, Wierenga RK, Kondo N. Kinetic and Expression Analyses of Seven Novel
Mutations in Mitochondrial Acetoacetyl-CoA Thiolase (T2): Identification of a Km Mutant and an
Analysis of the Mutational Sites in the Structure. Mol Genet Metab. 2007;90:370-378.
26㧕 Kondo M, Fukao T, Shinoda S, Kawamoto N, Kaneko H, Kato Z, Matsui E, Teramoto T, Nakano T,
Kondo N. Lymphocyte responses to chymotrypsin- or trypsin V-digested E-lactoglobulin in patientswith cow’s milk allergy. Allergy Asthma Clin Immunol. 2007;3:1-9.
27㧕 Kato T, Kato Z, Kuratsubo I, Ota T, Orii T, Kondo N, Suzuki Y. Evaluation of ADL in patients withHunter disease using FIM score. Brain Develop. 2007;29:298-305.
28㧕 Ochiai T, Suzuki Y, Kato T, Shichino H, Chin M, Mugishima H, Orii T. Naturalhistory of extensive
Mongolian spots in mucopolysaccharidosis type II(Huntersyndrome): a survey amond 52 Japanesepatients. J Eur Acad Dermatol Venereol. 2007;21:1082-1085.
29㧕 Takahashi N, Morita M, Maeda T, Harayama Y, Shimozawa N, Suzuki Y, Furuya H, Sato R,
Kashiwayama Y, Imanaka T. Adrenoleukodystrophy: subcellular localization and degradation ofadrenoleukodystrophy protein(ALDP/ABCD1) with naturally occurring missense mutations. J
Neurochem. 2007;101:1632-1643.
30㧕 Yamada K, Fukao T, Zhang G, Sakurai S, Ruiter JPN, Wanders RJA, Kondo N. Single-basesubstitution at the last nucleotide of exon 6 (c.671G >A), resulting in the skipping of exon 6, and exons
6 and 7 in human Succinyl-CoA:3-ketoacid CoA transferase (SCOT) gene. Mol Genet Metab.
2007;90:291-297.
31㧕 Haapalainen A, Merilinen G, Piril P, Kondo N, Fukao T, Wierenga R. Crystallographic and kinetic
studies of human mitochondrial acetoacetyl-CoA thiolase (T2): the importance of potassium andchloride ions for its structure and function. Biochemistry. 2007;46:4305-4321.
32㧕 Yamada K, Fukao T, Suzuki H, Inoue R, Kondo T, Kondo N. Vitamin K-Deficient Intracranial
Hemorrhage as the First Symptom of Cytomegalovirus Hepatitis with Cholestasis. Tohoku J Exp Med.
2007;212:335-339.
33㧕 Funato M, Kaneko H, Matsui E, Teramoto T, Kato Z, Fukao T, Okusu K, Kondo N. Refractoryosteomyelitis caused by bacille Calmette-Guerin vaccination: a case report. Diagn Microbiol Infect Dis.
2007;59:89-99.
34㧕 Kondo N, Matsui E, Nishimura A. A genetic classification and a tailor-made medicine in allergic
disorders. Korean Journal of Asthma, Allergy and Clinical Immunology. 2007;27:83-86.
35㧕 Ohya Y, Watanabe H, Kojima N. Katsunuma T, Kondo N, Akasawa A. Impact of Pediatric Asthma andtreatment on care-givers visiting specialist clinics in Japan. J Allergy Clini Immunol.
2007;119:S41-S42.
36㧕 Tomatsu S, Montano AM, Gutierrez M, Grubb JH, Oikawa H, Dung VC, Ohashi A, Nishioka T,
Yamada M, Tosaka Y, Trandafirescu GG, Orii T. Characterization and pharmacokinetic study ofrecombinant human N-acetyl galactosamine-6-sulfate sulfatase. Mol Genet Metab. 2007;91:69-78.
37㧕 Montano AM, Tomatsu S, Gottesman GS, Smith M, Orii T.International Morquio A registry:clinicalmanifestation and natural course of Morquio A disease. J Inherit Metab Dis. 2007;30:165-174.
38㧕 Tomatsu S, Vogler C, Montano AM, Gutierrez M, Oikawa H, Dung VC, Orii T, Noguchi N, Sly WS.
Murine model(Galnstm(C76S)slu)of MPS IVA with a missense mutation at the active site cysteineconserved among sulfatase proteins. Mol Genet Metab. 2007;91:251-258.
39㧕 Montaño AM, Sukegawa K, Kato Z, Carrozzo R, Di Natale P, Christensen E, Orii KO, Orii T, Kondo N,
Tomatsu S. Effect of 'attenuated' mutations in mucopolysaccharidosis IVA on molecular phenotypes ofN-acetylgalactosamine-6-sulfate sulfatase. J Inherit Metab Dis. 2007;30:758-767.
40㧕 Kato Z, Yamagishi A, Kondo N. Interstitial deletion of 1q42.13-q43 with Duane retraction syndrome. J
AAPOS. 2007;11:62-64.
41㧕 Kato Z, Nakamura M, Funato M, Kuwabara H, Kondo N. Accidental etizolam ingestion in a child.
Pediatr Emerg Care. 2007;23:472-473.
42㧕 Uehara R, Nakamura Y, Matsuura N, Kondo N, Tada H. Dioxins in human milk and smoking of
mothers. Chemosphere 2007;68:915-920.
43㧕 Aoki M, Fukao T, Kaneko H, Mizunaga S, Mitsuyama J, Sawamura H, Seishima M, Kondo N. Clinicaland bacteriological evaluation of the efficacy of piperacillin in children with pneumonia. J InfectChemother. 2007;13:224-229.
44㧕 Fukao T, Zhang G, Aoki Y, Arai T, Teramoto T, Kaneko H, Sugie H, Kondo N. Identification of
Alu-mediated, large deletion-spanning introns 19-26 in PHKA2 in a patient with X-linked liver
glycogenosis (hepatic phosphorylase kinase deficiency). Mol Genet Metab. 2007;92:179-182.
45㧕 Matsuo N, Imamura A, Ito R, Sugawara K, Takahashi Y, Kondo N. The correlation between 1H-MR
spectroscopy and clinical manifestation with tuberous sclerosis complex. Neuropediatrics.

㧙㧙

IF 4.003

IF 2.550

IF 2.550

IF 1.464

IF 1.437

IF 4.451

IF 2.550

IF 3.368

IF 1.133

IF 2.448

IF 8.115

IF 2.550
IF 1.668

IF 2.550

IF 1.668
IF 0.983
IF 0.581
IF 2.739

IF 2.550

2007;38:126-129.
46㧕 Ozeki M, Funato M, Kanda K, Ito M, Teramoto T, Kaneko H, Fukao T, Kondo N. Clinical improvementof diffuse lymphangiomatosis with pegylated interferon alfa-2b therapy: Case report and review of theliterature. Pediatr Hematol Oncol. 2007;24:513-524.
47㧕 Funato M, Kaneko H, Ozeki M, Suzuki H, Orii K, Teramoto T, Fukao T, Kondo N. A positive
Donath-Landsteiner test in paroxysmal cold haemoglobinuria. Eur J Haematol. 2007;79:462.
48㧕 Aoyama Y, Asai K, Hioki K, Funato M, Kondo N, Kitajima Y. Herpes gestationis in a mother andnewborn: immunoclinical perspectives based on a weekly follow-up of the enzyme-linked
immunosorbent assay index of a bullous pemphigoid antigen noncollagenous domain. Arch Dermatol.
2007;143:1168-1172.
49㧕 Fukao T, Kursula P, Owen EP, Kondo N. Identification and characterization of a temperature-sensitive
R268H mutation in the human succinyl-CoA:3-ketoacid CoA transferase (SCOT) gene. Mol Genet
Metab. 2007;92:216-221.
50㧕 Fukao T, Zhang G, Rolland M-O, Zabot M-T, Guffon N, Aoki Y, Kondo N. Identification of an
Alu-mediated tandem duplication of exons 8 and 9 in a patient with mitochondrial acetoacetyl-CoA
thiolase (T2) deficiency. Mol Genet Metab. 2007;92:375-378.
51㧕 Gobin-Limballe S, Djouadi F, Aubey F, Olpin S, Andresen BS, Yamaguchi S, Mandel H, Fukao T,
Ruiter JP, Wanders RJ, McAndrew R, Kim JJ, Bastin J.Genetic basis for correction of very-long-chain
acyl-coenzyme A dehydrogenase deficiency by bezafibrate in patient fibroblasts: toward a
genotype-based therapy. Am J Hum Genet. 2007;81:1133-1143.
52㧕 Kondo M, Fukao T, Omoya K, Kawamoto N, Aoki M, Teramoto T, Kaneko H, Kondo N. Protein-losing
enteropathy associated with egg allergy in a 5-month-old boy. J Investig Allergol Clin Immunol.
2008;18:63-66.
53㧕 Funato M, Kaneko H, Ozeki M, Kanda K, Fukao T, Kondo N. Anaphylactoid transfusion reactions
associated with a positively charged white-cell reduction filter: a case report. Transfus Apher Sci.
2008;38:199-201.
54㧕 Jin R, Kaneko H, Suzuki H, Arai T, Teramoto T, Fukao T, Kondo N. Age-related changes in BAFF andAPRIL profiles and upregulation of BAFF and APRIL expression in patients with primary antibody
deficiency. Int J Mol Med. 2008;21:233-238.
55㧕 Bai CY, Matsui E, Ohnishi H, Kimata K, Kasahara K, Kaneko H, Kato Z, Fukao T, Kondo N. A novel
polymorphism in the 5-lipoxygenase gene associated with bronchial asthma in Japanese children. Int
J Mol Med. 2008;21:139-144.
56㧕 Kondo M, Kaneko H, Fukao T, Suzuki K, Sakaguchi H, Shinoda S, Kato Z, Matsui E, Teramoto T,
Nakano T, Kondo N. The response of bovine beta-lactoglobulin-specific T-cell clones to single aminoacid substitutions of T-cell core epitope. Pediatric Allergy and Immunology. 2008;19:592-598.
57㧕 Yamada K, Yamamoto Y, Uchiyama A, Ito R, Aoki Y, Uchida Y Nagasawa H, Kimura H, Ichiyama T,
Fukao T, Kohno Y. A successfully treated case of neonatal herpes simplex type 1 infection complicatedby hemophagocytic lymphohistiocytosis and acute hepatic failure. Tohoku J Exp Med. 2008;214:1-5.
58㧕 Suzuki H, Kaneko H, Rong J, Kawamoto N, Asano T, Matsui E, Kasahara K, Fukao T, Kondo N.
Induction of D1 and D2 gene expression in selective IgA deficiency. Molecular Medicine Report.
2008;1:395-399.
59㧕 Yotsumoto Y, Hasegawa Y, Fukuda S, Kobayashi H, Endo M, Fukao T, Yamaguchi S: Clinical andmolecular investigations of Japanese cases of glutaric acidemia type 2. Mol Genet Metab.
2008;94:61-67.
60㧕 Funato M, Kaneko H, Ozeki M, Kanda K, Fukao T, Kondo N. Pediatric synovial sarcoma of the rightmasseter muscle: A case report and review of the literature. Int J Pediatr Otorhinolaryngol Extra.
2008;3:105-108.
61㧕 Fukao T, Boneh A, Aoki Y, Kondo N. A Novel Single-Base Substitution (c.1124A>G) that Activates a
5-Base Upstream Cryptic Splice Donor Site within Exon 11 in the Human Mitochondrial
Acetoacetyl-CoA Thiolase Gene. Mol Genet Metab. 2008;94:417-421.
62㧕 Kuratsubo I, Suzuki Y, Shimozawa N, Kondo N. Parents of childhood X-linked adrenoleukodystrophy:
High risk for depression and neurosis. Brain Dev. 2008;30:477-482.
63㧕 Orii KE, Fukao T, Song X-Q, Mitchell GA, Kondo N. Liver-Specific Silencing of the Human Gene
Encoding Succinyl-CoA: 3-Ketoacid CoA Transferase. Tohoku J Exp Med. 2008;215:227-236.
64㧕 Taneichi H, Kanegane H, Sira MM, Futatani T, Agematsu K, Sako M, Kaneko H, Kondo N, Kaisho T,
Miyawaki T. Toll-like receptor signaling is impaired in dendritic cells from patients with X-linked
agammagloblinemia. Clinical Immunology. 2008;126:148-154.
65㧕 Purevsuren J, Fukao, T, Hasegawa Y, Fukuda S, Kobayashi H, Yamaguchi S. Study of deep intronic
sequence exonization in a Japanese neonate with a mitochondrial trifunctional protein deficiency. Mol
Genet Metab. 2008;95:46-51.
66㧕 Kato Z, Stern JN, Nakamura HK, Kuwata K, Kondo N, Strominger JL. Positioning of autoimmune
TCR-Ob.2F3 and TCR-Ob.3D1 on the MBP85-99/HLA-DR2 complex. Proc Natl Acad Sci U S A.
2008;105:15523-15528.

㧙㧙

IF 1.225

IF 0.720
IF 2.163

IF 2.845

IF 2.550

IF 2.550

IF 11.092

IF 1.254

IF 0.970

IF 1.847

IF 1.847

IF 2.454

IF 1.133

IF 2.550

IF 0.851

IF 2.550
IF 1.464
IF 1.133

IF 3.551

IF 2.550

IF 9.59867㧕 Kawamoto M, Matsui E, Kaneko H, Fukao T, Teramoto T, Kasahara K, Kondo N. IL-10 plays animportant role as an immune-modulator in the pathogenesis of atopic diseases. Mol Med Reports.
2008;1:837-842.
68㧕 Arai T, Kaneko H, Ohnishi H, Matsui E, Fukao T, Kawamoto N, Kasahara K, Kondo N. Hypothermia
augments NF-kappa B activity and the production of IL-12 and IFN-gamma. Allergol Int.
2008;57:331-338.
69㧕 Kimura T, Kato Z, Ohnishi H, Tochio H, Shirakawa M, Kondo N. Expression, purification andstructural analysis of human IL-18 binding protein: a potent therapeutic molecule for allergy. Allergol
Int. 2008;57:367-376.
70㧕 Montaño AM, Tomatsu S, Brusius A, Smith M, Orii T. Growth charts for patients affected with
Morquio A disease. Am J Med Genet A. 2008;146A:1286-1295.
71㧕 Tomatsu S, Montaño AM, Ohashi A, Gutierrez MA, Oikawa H, Oguma T, Dung VC, Nishioka T, Orii T,
Sly WS. Enzyme replacement therapy in a murine model of Morquio A syndrome. Hum Mol Genet.
2008;17:815-824.
72㧕 Montaño AM, Oikawa H, Tomatsu S, Nishioka T, Vogler C, Gutierrez MA, Oguma T, Tan Y, Grubb JH,
Dung VC, Ohashi A, Miyamoto K, Orii T, Yoneda Y, Sly WS. Acidic amino acid tag enhances response
to enzyme replacement in mucopolysaccharidosis type VII mice. Mol Genet Metab. 2008;94:178-189.
73㧕 Egawa K, Takahashi Y, Kubota Y, Kubota H, Inoue Y, Fujiwara T, Onodera O. Electroclinical featuresof epilepsy in patients with juvenile type dentatorubral-pallidoluysian atrophy. Epilepsia.
2008;49:2041-2049.
74㧕 Matsukuma E, Kato Z, Orii K, Asano T, Orii K, Matsui E, Kaneko H, Kondo N. Acute mumps
cerebellitis with abnormal findings in MRI diffusion-weighted images. Eur J Pediatr.
2008;167:829-830.
75㧕 Teramoto T, Fukao T, Hirayama K, Asano T, Aoki Y, Kondo N. Escherichia coli O-157-induced
hemolytic uremic syndrome: Usefulness of SCWP score for the prediction of neurological complication.
Pediatr Int. 2008;50:1-3.

IF 2.440

IF 7.806

IF 2.550

IF 3.569

IF 1.277

IF 0.7374㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦ㄭ⮮⋥ታ㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ㧦ࠕ࡟࡞ࠡ࡯∔ᖚߩᴦ≮෻ᔕᕈ੍᷹࿃ሶߩ⏕┙෸߮࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮ᴺߩ⏕┙ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 16
㧙18 ᐕᐲ㧧83,000 ජ౞(24,000㧦30,000㧦29,000 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦ㄭ⮮⋥ታ㧘⎇ⓥಽᜂ⠪㧦᧻੗᳗ሶ㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ㧦ࠕ࡟࡞ࠡ࡯∔ᖚߩᴦ≮෻ᔕᕈ੍᷹࿃ሶߩ⏕┙෸߮࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮ᴺߩ⏕┙ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 16㧙18 ᐕᐲ㧧10,600 ජ౞(3,400㧦3,800㧦3,400 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦ᐔጊቬብ(㜞ፒஜᐽ⑔␩ᄢቇ)㧘⎇ⓥಽᜂ⠪㧦ㄭ⮮⋥ታ㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄੍㒐ធ⒳⎇ⓥ⃰㧦੍㒐ធ⒳ߩലᨐ⊛ታᣉߣ೽෻ᔕߦ㑐ߔࠆ✚ว⊛⎇ⓥ㧧ᐔᚑ 15㧙18 ᐕᐲ㧧260 ජ౞(100㧦80㧦80 ජ౞)
4㧕 ⎇ⓥઍ⴫⠪㧧ች⣁೑↵(ንጊᄢቇᄢቇ㒮කቇ⮎ቇ⎇ⓥㇱ කቇㇱ)㧘⎇ⓥಽᜂ⠪㧦ㄭ⮮⋥ታ㧧ෘ↢ഭ௛⋭㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ㧦ේ⊒ᕈ఺∉ਇో∝୥⟲ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ㧧ᐔᚑ 17㧙19 ᐕᐲ㧧6,500 ජ
౞(2,300㧦2,200㧦2,000 ජ౞)
5㧕 ⎇ⓥઍ⴫⠪㧦ᄙ↰⵨(ታ〣ᅚሶᄢቇ)㧘⎇ⓥಽᜂ⠪㧦ㄭ⮮⋥ታ㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄㘩ຠߩ቟ోᕈ㜞ᐲൻផㅴ⎇ⓥ੐ᬺ㧦࠳ࠗࠝࠠࠪࡦߩ੃ᐜఽ߳ߩᓇ㗀ߘߩઁߩᳪᨴታᘒߩ⸃᣿ߦ㑐ߔࠆ⎇ⓥ㧧
ᐔᚑ 15㧙18 ᐕᐲ㧧5,000 ජ౞(2,000㧦1,500㧦750㧦750 ජ౞)
6㧕 ⎇ⓥઍ⴫⠪㧦ㄭ⮮⋥ታ㧧⁛┙ⴕ᡽ᴺੱㄘᬺ࡮↢‛♽․ቯ↥ᬺᛛⴚ⎇ⓥᯏ᭴ ↢‛♽․ቯ↥ᬺᛛⴚ⎇ⓥᡰេ࠮ࡦ࠲࡯ ↢‛♽↥ᬺഃ಴ߩߚ߼ߩ⇣ಽ㊁Ⲣว⎇ⓥᡰេ੐ᬺ㧧㘩‛ࠕ࡟࡞ࠡ࡯ߩ∛࿃∛ᘒߩㆮવሶቇ⊛߅ࠃ߮࠲ࡦࡄࠢ⾰᭴ㅧቇ⊛⸃᣿㧧ᐔᚑ 17㧙21 ᐕᐲ㧧105,000 ජ౞(21,000㧦21,000㧦21,000㧦
21,000㧦21,000 ජ౞)
7㧕 ⎇ⓥઍ⴫⠪㧦㊄ሶ⧷㓶㧧⁛┙ⴕ᡽ᴺੱㄘᬺ࡮↢‛♽․ቯ↥ᬺᛛⴚ⎇ⓥᯏ᭴ ↢‛♽․ቯ↥ᬺᛛⴚ⎇ⓥᡰេ࠮ࡦ࠲࡯ ↢‛♽↥ᬺഃ಴ߩߚ߼ߩ⇣ಽ㊁Ⲣว⎇ⓥᡰេ੐ᬺ㧧㘩‛ࠕ࡟࡞ࠡ࡯ᖚ⠪ߩ⥃ᐥ௝ߩ⸃᣿߅ࠃ߮ᣂⷙᴦ≮ᴺߩ㐿⊒㧧ᐔᚑ 17㧙21 ᐕᐲ㧧95,000 ජ౞(19,000㧦19,000㧦19,000㧦19,000㧦19,000ජ౞)
8㧕 ⎇ⓥઍ⴫⠪㧦ᶏ⠧Ỉరብ(࿖┙∛㒮ᯏ᭴ ⋧ᮨේ∛㒮)㧘⎇ⓥಽᜂ⠪㧦ㄭ⮮⋥ታ㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ
⾌⵬ഥ㊄఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮੐ᬺ㧦ࠕ࡟࡞ࠡ࡯ᕈ∔ᖚߩ⊒∝࡮ㅴዷ࡮㊀∝ൻߩ੍㒐ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18㧙20 ᐕᐲ㧧12,000 ජ౞(4,000㧦4,000㧦4,000 ජ౞)
9㧕 ⎇ⓥઍ⴫⠪㧦ᴡ㊁㓁৻(ජ⪲ᄢቇᄢቇ㒮කቇ⎇ⓥ㒮 කቇㇱ)㧘⎇ⓥಽᜂ⠪㧦ㄭ⮮⋥ታ㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮੐ᬺ㧦ࠕ࠻ࡇ࡯ᕈ⊹⤏Ἳߩ⊒∝߅ࠃ߮ᖡൻ࿃ሶߩห

㧙㧙ቯߣ⊒∝੍㒐࡮∝⁁ᖡൻ㒐ᱛߩߚ߼ߩ↢ᵴⅣႺᢛ஻ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18㧙20 ᐕᐲ㧧6,600 ජ౞(2,000㧦2,000㧦2,500 ජ౞)
10㧕 ⎇ⓥઍ⴫⠪㧦ᄢ↰ஜ(Ꮲ੩ᄢቇකቇㇱ)㧘⎇ⓥಽᜂ⠪㧦ㄭ⮮⋥ታ㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ㧦ࠕ࡟࡞ࠡ࡯∔ᖚߩ⥄Ꮖ▤ℂߣ୘೎ൻක≮ࠍ⋡ᜰߒߚᣧᦼ⸻ᢿၮ
Ḱߣᣧᦼᴦ≮ᴺߩ⏕┙෸߮ߘߩ᦭ലᕈߣ᦭ኂ੐⽎ߩ⹏ଔߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18㧙20 ᐕᐲ㧧12,500
ජ౞(4,000㧦4,000㧦4,500 ජ౞)
11㧕 ⎇ⓥઍ⴫⠪㧦ᐔጊቬብ(㜞ፒஜᐽ⑔␩ᄢቇ)㧘⎇ⓥಽᜂ⠪㧦ㄭ⮮⋥ታ㧧ෘ↢ഭ௛⋭੍㒐ធ⒳⎇ⓥ⃰㧦੍㒐ធ⒳ߩലᨐ⊛ታᣉߣ೽෻ᔕߦ㑐ߔࠆ✚ว⊛⎇ⓥ㧧ᐔᚑ 17㧙19 ᐕᐲ㧧150(100㧦50 ජ౞)
12㧕 ⎇ⓥઍ⴫⠪㧦㗇↲᧻ା(᧲੩⮫ⴚᄢቇ଻ஜ▤ℂ࠮ࡦ࠲㧙)㧘⎇ⓥಽᜂ⠪㧦ㄭ⮮⋥ታ㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ක≮ᛛⴚ⹏ଔ✚ว⎇ⓥ੐ᬺ㧦ࠟࠗ࠼࡜ࠗࡦ᥉෸ߩߚ߼ߩኻ╷ߣߘࠇߦ઻߁ QOL ะ਄ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18㧙19 ᐕᐲ㧧700(0㧦700 ජ౞)
13㧕 ⎇ⓥઍ⴫⠪㧦ㄭ⮮⋥ታ㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ‫ࠕޟ‬࡟࡞ࠡ࡯ߩ࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮▤ℂࠟࠗ࠼࡜ࠗࡦߩ⏕┙ߣታ↪ൻ‫ޠ‬ᐔᚑ 19㧙21 ᐕᐲ 51,000 ජ౞(24,000㧦27,000 ජ౞)
14㧕 ⎇ⓥઍ⴫⠪㧦ㄭ⮮⋥ታ㧧⎇ⓥಽᜂ⠪㧦᧻੗᳗ሶ㧧ෘ↢ഭ௛⋭఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ㧦ࠕ࡟࡞ࠡ࡯ߩ࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮▤ℂࠟࠗ࠼࡜ࠗࡦߩ⏕┙ߣታ↪ൻ㧧ᐔᚑ 19㧙21 ᐕᐲ㧧5,700
ජ౞(3,000㧧2,700 ජ౞)
15㧕 ⎇ⓥઍ⴫⠪㧦ᄙ↰⵨(ታ〣ᅚሶᄢቇ)㧘⎇ⓥಽᜂ⠪㧦ㄭ⮮⋥ታ㧧ෘ↢ഭ௛⋭㘩ຠߩ቟ోᕈ㜞ᐲൻផㅴ⎇ⓥ੐ᬺ㧦࠳ࠗࠝࠠࠪࡦߩ੃ᐜఽ߳ߩᓇ㗀ߘߩઁߩᳪᨴታᘒߩ⸃᣿ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 19㧙21 ᐕᐲ㧧
1,250 ජ౞(500㧦750 ජ౞)
16㧕 ⎇ⓥઍ⴫⠪㧧ጊญᷡᰴ(ፉᩮᄢቇකቇㇱ)㧘⎇ⓥදജ⠪㧦ᷓየᢅᐘ㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ሶߤ߽ኅᐸ✚ว⎇ⓥ੐ᬺ㧦࠲ࡦ࠺ࡓࡑࠬ╬ߩᣂᛛⴚࠍዉ౉ߒߚᣂߒ޿ᣂ↢ఽࡑࠬࠬࠢ࡝࡯࠾ࡦࠣ૕೙ߩ
⏕┙ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 19㧙21 ᐕᐲ㧧700 ජ౞(400㧦300 ජ౞)
17㧕 ⎇ⓥઍ⴫⠪㧦ේኼ㇢(਻Ꮊᄢቇකቇ⎇ⓥ㒮)㧧⎇ⓥಽᜂ⠪㧦ㄭ⮮⋥ታ㧦ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ‫ޟ‬ේ⊒ᕈ఺∉ਇో∝୥⟲ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ‫ޠ‬ᐔᚑ 20㧙22 ᐕᐲ㧧2,000 ජ౞(2,000 ජ౞)
18㧕 ⎇ⓥઍ⴫⠪㧦ട⮮ༀ৻㇢㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧧࠲ࡦࡄࠢ┙૕᭴ㅧߦၮߠߊ
ᣂⷙഃ⮎ಽሶ⥃ᐥᔕ↪߳ะߌߚࡅ࠻ဳ࡟࠮ࡊ࠲࡯ࡑ࠙ࠬߩ㐿⊒㧧ᐔᚑ 17㧙18 ᐕᐲ㧧2,700 ජ౞(1,800㧧900 ජ౞)
19㧕 ⎇ⓥઍ⴫⠪㧦ጊᧄ⵨㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧧࠲ࡦࡄࠢ┙૕᭴ㅧߦၮߠߊᣂⷙ
ഃ⮎ಽሶ⥃ᐥᔕ↪߳ะߌߚࡅ࠻ဳ࡟࠮ࡊ࠲࡯ࡑ࠙ࠬߩ㐿⊒㧧ᐔᚑ 19 ᐕᐲ㧧1,040 ජ౞
20㧕 ⎇ⓥઍ⴫⠪㧦᧻੗᳗ሶ㧧ᢥㇱ⑼ቇ⋭⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧧ࠕ࡟࡞ࠡ࡯∔ᖚߩ∛ᘒ⸃ᨆߦၮߠ
޿ߚᣂߚߥ⸻ᢿᴺߩ⏕┙㧧ᐔᚑ 17㧙18 ᐕᐲ㧧3,000 ජ౞(1,900㧦1,100 ජ౞)
21㧕 ⎇ⓥઍ⴫⠪㧦㊄ሶ⧷㓶㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧧᛫૕↥↢ᯏ᭴ߩ⸃᣿㧙᛫૕↥↢ਇో∝‫ ߦ․ޔ‬IgA ᰳ៊∝ࠍࡕ࠺࡞ߦߒߡ㧙㧧ᐔᚑ 18㧙19 ᐕᐲ㧧3,500 ජ౞(2,100㧦1,400 ජ౞)
22㧕 ⎇ⓥઍ⴫⠪㧦ᷓየᢅᐘ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧧ࠤ࠻ࡦ૕ઍ⻢⇣Ᏹ∝ߩಽሶ∛ᘒ㧙Ⱞ⊕ 3 ᰴᯏㅧᄌൻߣࠬࡊ࡜ࠗࠪࡦࠣ⇣Ᏹࠍਛᔃߦ㧙㧧ᐔᚑ 18㧙19 ᐕᐲ㧧3,500 ජ౞(1,900㧦1,600
ජ౞)23㧕 ⎇ⓥઍ⴫⠪㧦᛬ዬᑪᴦ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧧Ძ⚦ⴊ▤᜛ᒛᕈㆇേᄬ⺞∝ߦ߅ߌࠆ␹⚻ᄌᕈᯏ᭴ࠍ⸃᣿ߔࠆߚ߼ߩၮ⋚⎇ⓥ㧧ᐔᚑ 17㧙18 ᐕᐲ 3,400 ජ౞(2,000㧦1,400 ජ౞)
24㧕 ⎇ⓥઍ⴫⠪㧦᛬ዬᕡᴦ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧧ࠤࡒࠞ࡞ࠪࡖࡍࡠࡦࠍ↪޿ߚࡍ࡞ࠝࠠࠪ࠰࡯ࡓ∛ᴦ≮ߩၮ⋚⎇ⓥ㧧ᐔᚑ 17㧙18 ᐕᐲ㧧3,400 ජ౞(1,400㧦2,000 ජ౞)
25㧕 ⎇ⓥઍ⴫⠪㧦ᄢ⷏⑲ౖ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧧⥄ὼ఺∉࡮₪ᓧ఺∉ࠬࠗ࠶࠴ࡦ
ࠣᯏ᭴ߩ᭴ㅧ↢‛ቇ⊛⸃ᨆߦၮߠߊ᛫ࠕ࡟࡞ࠡ࡯⮎㐿⊒㧧ᐔᚑ 17㧙19 ᐕᐲ㧧2,800 ජ౞(1,200㧦900㧦
700 ජ౞)26㧕 ⎇ⓥઍ⴫⠪㧦᧘ᗲ⬒㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧧ࠕࡦ࠲ࠧ࠾ࠬ࠻⵾೷㐿⊒߳ะߌߚ᭴ㅧ↢‛ቇ⊛ᡷᄌ෸߮ࠬࠢ࡝࡯࠾ࡦࠣߩ᭴▽㧧ᐔᚑ 17㧙18 ᐕᐲ㧧200 ජ౞(100㧦100 ජ౞)
27㧕 ⎇ⓥઍ⴫⠪㧦㕍ᧁ⟤ᄹሶ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧧RS ࠙ࠖ࡞ࠬᗵᨴߩಽሶㆮવ
ቇ⊛⸃ᨆߦၮߠߊዊఽ᳇▤ᡰ༎ᕷߩᣂߚߥ੍㒐ᴦ≮ᴺߩ㐿⊒㧧ᐔᚑ 18㧙19 ᐕᐲ㧧3,400 ජ౞(2,000㧦
1,400 ජ౞)28㧕 ⎇ⓥઍ⴫⠪㧦ㄭ⮮ᙥ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧧㘩‛ࠕ࡟࡞ࠡ࡯ߩ఺∉≮ᴺ‫ࡊࡍޔ‬
࠴࠼≮ᴺ‫ޔ‬ᷫᗵ૞≮ᴺߦࠃࠆ఺∉ኡኈ⺃ዉᯏᐨߩ⸃᣿㧧ᐔᚑ 18㧙19 ᐕᐲ㧧3,400 ජ౞(2,100㧦1,300
ජ౞)

㧙㧙

29㧕 ⎇ⓥઍ⴫⠪㧦᧻㓊⧷ᴦ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧧࠲ࡦࡄࠢ┙૕᭴ㅧߦၮߠߊᣂⷙ
ࠕ࡟࡞ࠡ࡯ᴦ≮⮎ߩࡂࠗࠬ࡞࡯ࡊ࠶࠻ࠬࠢ࡝࡯࠾ࡦࠣ㧧ᐔᚑ 18㧙19 ᐕᐲ㧧3,100 ජ౞(1,800㧦1,300ජ౞)30㧕 ⎇ⓥઍ⴫⠪㧦㋈ᧁ໪ሶ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧧ㆬᛯ⊛ IgA ᰳ៊∝ߩ∛ᘒ⸃᣿ߣ
IgA ࠨࡉࠢ࡜ࠬߩᬌ⸛㧧ᐔᚑ 19 ᐕᐲ㧧1,700 ජ౞
31㧕 ⎇ⓥઍ⴫⠪㧦᛬ዬᑪᴦ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦ዊ⣖ᄌᕈࠍ᧪ߔవᄤᕈㆮવሶୃᓳ⇣Ᏹ∝ߩ∛ᘒ‫ޔ‬ᴦ≮ᴺߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 20 ᐕᐲ㧧1,400 ජ౞
32㧕 ⎇ⓥઍ⴫⠪㧦ᄢ⷏⑲ౖ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦᭴ㅧ↢‛ቇ⊛ᚻᴺߦࠃࠆ⥄ὼ఺∉෸߮ IL-18
ᯏ⢻೙ᓮߣᣂⷙ఺∉⺞▵⮎ߩ㐿⊒㧧ᐔᚑ 20 ᐕᐲ㧧1,700 ජ౞
33㧕 ⎇ⓥઍ⴫⠪㧦ᄢ⷏⑲ౖ㧧ᐔᚑ 20 ᐕᐲ⎇ⓥ⑼㐳࡮කቇㇱ㐳ⵙ㊂⚻⾌ߦࠃࠆ⎇ⓥ⾌㧦MyD88 ࠪࠣ࠽࡞․⇣⊛㒖ኂ೷ߩ㐿⊒ߦะߌߚ⚦⢩⤑⺃ዉᕈࠕ࠳ࡊ࠲࡯ಽሶߩ࠲ࡦࡄࠢ᭴ㅧ࡮ᯏ⢻⸃ᨆ㧧250 ජ౞
34㧕 ⎇ⓥઍ⴫⠪㧦ᧁ᧛⽕㧧ᐔᚑ 20 ᐕᐲ JST ࠪ࡯࠭⊒ជ⹜㛎⎇ⓥ㧦఺∉࡮ࠕ࡟࡞ࠡ࡯∔ᖚᴦ≮⮎ࠍ⋡ᜰߒߚᣂⷙࡅ࠻ࠗࡦ࠲࡯ࡠࠗࠠࡦ-18 ೙ᓮᴺߩ㐿⊒㧧2,000 ජ౞
35㧕 ⎇ⓥઍ⴫⠪:ዊ㑐㆏ᄦ㧧ᐔᚑ 20 ᐕᐲᄢቇᵴᕈൻ⚻⾌(⎇ⓥ㧦⑼⎇ណᛯᡰេ)㧧1,060 ජ౞
2㧕ฃ⸤⎇ⓥ1㧕 ㄭ⮮⋥ታ㧘᧻੗᳗ሶ㧘㊄ሶ⧷㓶㧘᦯ㇱᶈ᣿㧦ࠕ࡟࡞ࠡ࡯ߩේ࿃ߣߥࠆࡎࠬ࠻ߦ߅ߌࠆㆮવ࿃ሶߩห
ቯ‫⮎ߩߘ߮ࠃ߅ޔ‬೷ᴦ≮ᴺߩ⏕┙㧧ᐔᚑ 17㧙18 ᐕᐲ㧧300 ජ౞(300㧦0 ජ౞)㧦ᩣᑼળ␠ࡆ࡯࡮ࠛࡓ࡮
ࠛ࡞✚ว⎇ⓥᚲ2㧕 ㄭ⮮⋥ታ㧘᧻੗᳗ሶ㧦੃ᐜఽ༎ᕷߩ㐳ᦼ▤ℂߦ߅ߌࠆ࠷ࡠࡉ࠹ࡠ࡯࡞⾍ઃ⮎ߩ᦭↪ᕈߦ㑐ߔࠆᬌ⸛㧧ᐔᚑ 18 ᐕᐲ㧧0 ජ౞㧦ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ
3㧕 ㄭ⮮⋥ታ㧘㊄ሶ⧷㓶㧘᧻੗᳗ሶ㧘㕍ᧁ⟤ᄹሶ㧦ࠕ࡟࡞ࠡ࡯ㄦㅦࠠ࠶࠻ߦࠃࠆࠕ࡟࡞ࠥࡦ․⇣⊛ IgE
᷹ቯᴺߩ⹏ଔ㧧ᐔᚑ 17㧙18 ᐕᐲ㧧700 ජ౞(700㧦0 ජ౞)㧦ᩣᑼળ␠ਃ⪉ൻቇࡗ࠻ࡠࡦ
4㧕 ㄭ⮮⋥ታ㧘᧻੗᳗ሶ㧘ጟବ▸㧦ዊఽࠕ࡟࡞ࠡ࡯∔ᖚᖚ⠪ߩ࠹࡯࡜࡯ࡔࠗ࠼ක≮ࠍ⋡ᜰߒߚㆮવሶᄙ
ဳ⸃ᨆ⎇ⓥ㧧ᐔᚑ 18㧙19 ᐕᐲ㧧1,500 ජ౞(1,500㧦0 ජ౞)㧦ᄢ㢈⮎ຠᎿᬺᩣᑼળ␠
3㧕౒ห⎇ⓥ1㧕 ㄭ⮮⋥ታ㧦⺞Ḩᑪ᧚ߩஜᐽߦ෸߷ߔᓇ㗀⺞ᩏ㧧ᐔᚑ 18㧙19 ᐕᐲ㧧100 ජ౞㧦ᣣᧄࠗࡦࠪࡘ࡟࡯࡚ࠪࡦᩣᑼળ␠2㧕 ㄭ⮮⋥ታ㧘᧻੗᳗ሶ㧘㊄ሶ⧷㓶㧘᦯ㇱᶈ᣿㧦ࠕ࡟࡞ࠡ࡯ߩේ࿃ߣߥࠆࡎࠬ࠻ߦ߅ߌࠆㆮવ࿃ሶߩห
ቯ㧘߅ࠃ߮ߘߩ⮎೷ᴦ≮ᴺߩ⏕┙㧧ᐔᚑ 17㧙20 ᐕᐲ㧧300 ජ౞㧦ᩣᑼળ␠ࡆ࡯࡮ࠛࡓ࡮ࠛ࡞✚ว⎇ⓥᚲ
3㧕 ㄭ⮮⋥ታ㧘㊄ሶ⧷㓶㧦వᄤᕈ఺∉ਇో∝ߩේ࿃ㆮવሶหቯ߅ࠃ߮∛ᘒᒻᚑᯏᐨߩ⸃᣿㧦ᐔᚑ 18㧙21
ᐕᐲ㧧⁛┙ⴕ᡽ᴺੱℂൻቇ⎇ⓥᚲ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫ
1㧕 ㄭ⮮⋥ታ㧘㊄ሶ⧷㓶㧘᧻੗᳗ሶ㧘ㄭ⮮ᙥ㧘ਛၛᜏ㧘ട⮮᥍ᒾ㧦⚻ญ఺∉ኡኈࠍ⺃ዉߔࠆࡍࡊ࠴࠼⚵ᚑ‛෸߮ߘߩ⺞ᢛᣇᴺ(⊒᣿)(․⸵಴㗿)㧧ᐔᚑ 19 ᐕᐲ
2㧕 ㄭ⮮⋥ታ㧘ട⮮ༀ৻㇢㧘ᄢ⷏⑲ౖ㧘⊕Ꮉ᣽ብ㧘᧩የ⽕ੱ㧦ᄌ⇣ዉ౉ MyD88 Ⱞ⊕ߦࠃࠆ Toll like receptor/ Interleukin-18 ࠪࠣ࠽࡞ߩ․⇣⊛೙ᓮᴺ(⊒᣿)(࿖㓙․⸵಴㗿ਛ)㧧ᐔᚑ 20 ᐕᐲ
6㧚ቇળᵴേ
1㧕ቇળᓎຬㄭ⮮⋥ታ㧦
1㧕 ᣣᧄዊఽ⑼ቇળℂ੐(ᐔᚑ 18 ᐕ 4 ᦬㨪ᐔᚑ 20 ᐕ 4 ᦬)
2㧕 ᣣᧄዊఽ⑼ቇળઍ⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄዊఽ⑼ቇળᣉ⸳⹺ቯ࡮ᜰዉ⽿છක(㨪⃻࿷)4㧕 ᣣᧄዊఽ⑼ቇળኾ㐷ක(㨪⃻࿷)5㧕 ᣣᧄዊఽ⑼ቇળ዁᧪⸘↹ᆔຬળᆔຬ(ᐔᚑ 18 ᐕ 5 ᦬㨪ᐔᚑ 20 ᐕ 5 ᦬)
6㧕 ᣣᧄዊఽ⑼ቇળᐢႎᆔຬળᆔຬ(ᐔᚑ 18 ᐕ 5 ᦬㨪ᐔᚑ 20 ᐕ 5 ᦬)
7㧕 ᣣᧄዊఽ⑼ቇળ᧲ᶏ࿾ᣇળℂ੐(㨪⃻࿷)8㧕 ᣣᧄዊఽ⑼ቇળ᧲ᶏ࿾ᣇળᐙ੐(㨪⃻࿷)9㧕 ᣣᧄࠕ࡟࡞ࠡ࡯ቇળℂ੐(㨪⃻࿷)㧙㧙10㧕 ᣣᧄࠕ࡟࡞ࠡ࡯ቇળᣉ⸳⹺ቯ࡮ᜰዉක(㨪⃻࿷)11㧕 ᣣᧄࠕ࡟࡞ࠡ࡯ቇળ⹺ቯක(㨪⃻࿷)12㧕 ᣣᧄࠕ࡟࡞ࠡ࡯ቇળ࿖㓙੤ᵹᆔຬ㐳(㨪ᐔᚑ 19 ᐕ 3 ᦬)
13㧕 ᣣᧄࠕ࡟࡞ࠡ࡯ቇળᢎ⢒⎇ୃᆔຬ(㨪ᐔᚑ 19 ᐕ 3 ᦬)
14㧕 ᣣᧄࠕ࡟࡞ࠡ࡯ቇળኾ㐷ක೙ᐲᢎ⢒⎇ୃᆔຬ(㨪ᐔᚑ 19 ᐕ 3 ᦬)
15㧕 ᣣᧄࠕ࡟࡞ࠡ࡯ቇળࠕ࠻ࡇ࡯ᕈ⊹⤏Ἳࠟࠗ࠼࡜ࠗࡦኾ㐷ㇱᆔຬ(㨪⃻࿷)16㧕 ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળℂ੐(㨪⃻࿷)17㧕 ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળℂ੐㐳(ᐔᚑ 20 ᐕ 12 ᦬㨪⃻࿷)18㧕 ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળᴦ≮࡮▤ℂࠟࠗ࠼࡜ࠗࡦᆔຬ(㨪⃻࿷)19㧕 ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ㘩‛ࠕ࡟࡞ࠡ࡯ᆔຬ(㨪⃻࿷)20㧕 ᣣᧄੱ㘃ㆮવቇળ⹏⼏ຬ(㨪⃻࿷)21㧕 ᣣᧄੱ㘃ㆮવቇળᣉ⸳⹺ቯ࡮ᜰዉක(㨪⃻࿷)22㧕 ᣣᧄੱ㘃ㆮવቇળ⹺ቯක(㨪⃻࿷)23㧕 ᣣᧄዊఽㆮવකቇળᐙ੐(㨪⃻࿷)24㧕 ᣣᧄㆮવሶ⸻≮ቇળ⹏⼏ຬ(㨪⃻࿷)25㧕 ᣣᧄㆮવሶ⸻≮ቇળቇⴚᆔຬ(㨪ᐔᚑ 19 ᐕ 3 ᦬)
26㧕 ᣣᧄዊఽ଻ஜදળ⹏⼏ຬ࡮ᡰㇱ㐳(㨪⃻࿷)ᷓየᢅᐘ㧦1㧕 ᣣᧄవᄤઍ⻢⇣Ᏹቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄੱ㘃ㆮવቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄዊఽ⑼ቇળ᧲ᶏ࿾ᣇળᐙ੐(ᐔᚑ 18 ᐕ 4 ᦬㨪⃻࿷)
4㧕 ᣣᧄੱ㘃ㆮવቇળᜰዉක(ᐔᚑ 18 ᐕ 4 ᦬㨪⃻࿷)
5㧕 ᣣᧄዊఽ⑼ቇળઍ⼏ຬ(ᐔᚑ 20 ᐕ 4 ᦬㨪⃻࿷)㊄ሶ⧷㓶㧦
1㧕 ᣣᧄࠕ࡟࡞ࠡ࡯ቇળઍ⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄࠕ࡟࡞ࠡ࡯දળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄዊఽ⑼ቇળ᧲ᶏ࿾ᣇળᐙ੐(ᐔᚑ 18 ᐕ 4 ᦬㨪⃻࿷)
4㧕 ᣣᧄዊఽ⑼ቇળઍ⼏ຬ(ᐔᚑ 18 ᐕ 4 ᦬㨪⃻࿷)ട⮮ༀ৻㇢㧦
1㧕 ᣣᧄዊఽ␹⚻ቇળ⹏⼏ຬ(ᐔᚑ 18 ᐕ 4 ᦬㨪⃻࿷)2㧕 ᣣᧄੱ㘃ㆮવቇળ⹏⼏ຬ(ᐔᚑ 19 ᐕ 4 ᦬㨪⃻࿷)᧻੗᳗ሶ㧦
1㧕 ᣣᧄࠕ࡟࡞ࠡ࡯ቇળઍ⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄዊఽ⑼ቇળઍ⼏ຬ(ᐔᚑ 18 ᐕ 4 ᦬㨪⃻࿷)2㧕ቇળ㐿௅ㄭ⮮⋥ታ㧦
1㧕 ╙ 5 ࿁ో࿖ዊఽ⑼࠴ࠚࠕࡑࡦද⼏ળ(ᐔᚑ 19 ᐕ 7 ᦬㧘ጘ㒂)2㧕 ╙ 18 ࿁ጘ㒂⋵ߎߤ߽ߩஜᐽࠍ⠨߃ࠆߟߤ޿(ᐔᚑ 19 ᐕ 10 ᦬㧘ጘ㒂)
3㧕 ╙ 241 ࿁ᣣᧄዊఽ⑼ቇળ᧲ᶏ࿾ᣇળ(ᐔᚑ 19 ᐕ 10 ᦬㧘ጘ㒂)
4㧕 ╙ 19 ࿁ጘ㒂⋵ߎߤ߽ߩஜᐽࠍ⠨߃ࠆߟߤ޿(ᐔᚑ 20 ᐕ 10 ᦬㧘ጘ㒂)
5㧕 ╙ 21 ࿁ᣣᧄࠕ࡟࡞ࠡ࡯ቇળᤐቄ⥃ᐥᄢળ(ᐔᚑ 21 ᐕ 6 ᦬㧘ጘ㒂)
3㧕ቇⴚ㔀⹹
ㄭ⮮⋥ታ㧦
1㧕 Journal of Investigational Allergology & Clinical Immunology:✬㓸ᆔຬ(㨪⃻࿷)2㧕 ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ⹹;✬㓸ᆔຬ㐳(㨪⃻࿷)3㧕 ࠕ࡟࡞ࠡ࡯ߩ㗔ၞ;✬㓸㘈໧(㨪⃻࿷)
4㧕 International Review of Asthma:✬㓸ᆔຬ(㨪⃻࿷)㧙㧙5㧕 Allergy From the Nose to the Lung ⹹: Editorial Board(✬㓸ᐙ੐)(㨪⃻࿷)6㧕 ࠕ࡟࡞ࠡࠕ㧧✬㓸ᆔຬ㐳(㨪⃻࿷)7㧕 Pediatric Allergy for Clinicians: 㘈໧(㨪⃻࿷)ട⮮ༀ৻㇢㧦
1㧕 Journal of Pediatric Neurology :Editorial Board(ᐔᚑ 18 ᐕ 1 ᦬㨪⃻࿷)7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ㄭ⮮⋥ታ㧦
1㧕 26th Symposium of the Collegium Internationale Allergologicum(2006.05, Malta, Molecular
Mechanism of Th1㨯Th2 Imbalance and Hygiene Hypothesis; Ṷ⠪)2㧕 KAAACI-WAO Joint Congress 2006 & the 9th WPAS(2006.11㧘㖧࿖㧘࠰࠙࡞㧘‫ޟ‬Genetic factors andenvironmental factors in allergy‫ޠ‬Ṷ⠪㧘ᐳ㐳)
3㧕 ╙ 109 ࿁ᣣᧄዊఽ⑼ቇળ(ᐔᚑ 18 ᐕ 4 ᦬㧘㊄ᴛ㧘ಽ㊁೎ࠪࡦࡐࠫ࠙ࡓ 5‫ޟ‬᳇▤ᡰ༎ᕷߩ⊒∝੍㒐‫ޠ‬Ṷ⠪)
4㧕 ╙ 18 ࿁ᣣᧄࠕ࡟࡞ࠡ࡯ቇળᤐቄ⥃ᐥᄢળ(ᐔᚑ 18 ᐕ 5 ᦬㧘᧲੩㧘ࠗࡉ࠾ࡦࠣࠪࡦࡐࠫ࠙ࡓ 7‫ޟ‬ฦ਎ઍߢ߽༎ᕷ∝⁁ߦߤ߁ኻᔕߔࠆ߆‫ޠ‬Ṷ⠪)
5㧕 ╙ 23 ࿁๺ṽක⮎ቇળᄢળ(ᐔᚑ 18 ᐕ 8 ᦬㧘ጘ㒂㧘․೎⻠ṶΤ‫࠼ࠗࡔ࡯࠳࡯ࠝޟ‬ක≮ߦ߅ߌࠆ๺ṽක⮎ቇߩ૏⟎ߠߌ –ࠕ࡟࡞ࠡ࡯ߩⷞὐ߆ࠄ-‫ޠ‬Ṷ⠪)
6㧕 ╙ 56 ࿁ᣣᧄࠕ࡟࡞ࠡ࡯ቇળ(ᐔᚑ 18 ᐕ 11 ᦬㧘᧲੩㧘ᢎ⢒⻠Ṷ 10‫ࠆߌ߅ߦ∝⊒࡯ࠡ࡞࡟ࠕޟ‬ㆮવሶ
ߣⅣႺ‫ޠ‬Ṷ⠪)7㧕 ╙ 4 ࿁᳇㆏∔ᖚኻ╷࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 1 ᦬㧘઄บ㧘․೎⻠Ṷ‫ޟ‬᳇▤ᡰ༎ᕷߩࠝ࡯࠳࡯ࡔࠗ࠼⸻≮㐿⊒ —QOL ะ਄ࠍ߼ߑߒߡ࡯‫ޠ‬Ṷ⠪)8㧕 ╙ 2 ࿁ Osaka IPOD Allergy Seminar(ᐔᚑ 18 ᐕ 2 ᦬㧘ᄢ㒋㧘․೎⻠Ṷ‫࡝࡞࠽࡚ࠪ࡯࡟ࠬࡦ࡜࠻ޟ‬ࠨ࡯࠴ߦ߽ߣߠߊࠕ࡟࡞ࠡ࡯⸻≮ߣߘߩ㐿⊒‫ޠ‬Ṷ⠪)9㧕 ╙ 2 ࿁ዊఽ᳇▤ᡰ༎ᕷ⎇ⓥળ(ᐔᚑ 18 ᐕ 3 ᦬㧘ᄢ㒋㧘․೎⻠Ṷ‫ޟ‬ዊఽ᳇▤ᡰ༎ᕷߩࠟࠗ࠼࡜ࠗࡦ 2005
ࠍ޿߆ߦᵴ↪ዷ㐿ߔࠆ߆ -⑳ߪߎ߁⠨߃ࠆ-‫ޠ‬Ṷ⠪)10㧕 ╙ 43 ࿁ጘ㒂⋵ౝ⑼කળࡊࡠࠣ࡜ࡓ(ᐔᚑ 18 ᐕ 4 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ࠍ≮⸻࡯ࠡ࡞࡟ࠕߩࠄ߆ࠇߎޟ‬⠨߃ࠆ-ᚑੱ࡮ዊఽࠍߎ߃ߡ-‫ޠ‬Ṷ⠪)11㧕 ╙ 2 ࿁㐳ፒዊఽ⊹߰⎇ⓥળ(ᐔᚑ 18 ᐕ 5 ᦬㧘㐳ፒ㧘․೎⻠Ṷ‫࠼ࠗࡔ࡯࡜࡯࠹ߩ࡯ࠡ࡞࡟ࠕޟ‬ක≮ߣ
21 ਎ဳࡐࠬ࠻ࠥࡁࡓ‫ޠ‬Ṷ⠪)12㧕 ╙ 11 ࿁ၔ᧲࿾඙ዊఽࠕ࡟࡞ࠡ࡯ᙣ⹤ળ(ᐔᚑ 18 ᐕ 7 ᦬㧘᧲੩㧘․೎⻠ṶΥ‫࡯ࠡ࡞࡟ࠕޟ‬ᖚఽߩ QOL
ߣߘߩะ਄ࠍ߼ߑߒߡ࡯ㆮવߣⅣႺߩⷞὐ߆ࠄ࡯‫ޠ‬Ṷ⠪)
13㧕 ╙ 16 ࿁࿖㓙༎ᕷቇળᣣᧄർࠕࠫࠕㇱળ(ᐔᚑ 18 ᐕ 4 ᦬㧘᧲੩㧘ࡒ࡯࠻ࠩࡊࡠࡈࠚ࠶ࠨ࡯3 ᐳ㐳)14㧕 ╙ 14 ࿁ዊఽ᳇㆏ࠕ࡟࡞ࠡ࡯⎇ⓥળ(ᐔᚑ 18 ᐕ 4 ᦬㧘㜞⍮㧘࠮࠶࡚ࠪࡦ 2 ᐳ㐳)15㧕 ╙ 235 ࿁ᣣᧄዊఽ⑼ቇળ᧲ᶏ࿾ᣇળ(ᐔᚑ 18 ᐕ 5 ᦬㧘ጘ㒂㧘․೎⻠Ṷ ᐳ㐳)16㧕 ╙ 15 ࿁ Airway Club in Sendai(ᐔᚑ 18 ᐕ 9 ᦬㧘઄บ㧘ળ㐳⻠Ṷ ᐳ㐳)17㧕 ╙ 15 ࿁ዊఽ᳇㆏ࠕ࡟࡞ࠡ࡯⎇ⓥળ(ᐔᚑ 18 ᐕ 10 ᦬㧘␹ᚭ㧘࠮࠶࡚ࠪࡦΤ ᐳ㐳)18㧕 ╙ 38 ࿁ᣣᧄዊఽᗵᨴ∝ቇળᢎ⢒࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 11 ᦬㧘㜞⍮㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯11 ᐳ㐳)19㧕 ╙ 43 ࿁ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ(ᐔᚑ 18 ᐕ 11 ᦬㧘᧲੩㧘․೎⻠Ṷ 1‫∉఺⤑☼ޟ‬㧦఺∉ߣࠕ࡟࡞ࠡ
࡯ߩធὐ‫ޠ‬ᐳ㐳)20㧕 ᐔᚑ 18 ᐕᐲᣣᧄ⊹⤏⑼ቇળ೨ታ❣⎇ୃ⻠⠌ળ(ᐔᚑ 19 ᐕ 1 ᦬㧘᧲੩㧘‫ޟ‬వᄤᕈ఺∉ਇో∝୥⟲‫ޠ‬Ṷ
⠪)21㧕 ╙ 15 ࿁ዊఽ⥃ᐥ⮎ℂ࡮ࠕ࡟࡞ࠡ࡯࡮఺∉⎇ⓥળ(ᐔᚑ 19 ᐕ 1 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ 2 2010 ᐕߩࠕ࡟࡞ࠡ࡯ᴦ≮ᚢ⇛‫ޟ‬㘩‛ࠕ࡟࡞ࠡ࡯ᴦ≮‫ޠ‬Ṷ⠪)22㧕 ╙ 14 ࿁ᄢ㒋ዊఽ⑼කળ∛⸻ㅪ៤ᙣ⺣ળ(ᐔᚑ 19 ᐕ 2 ᦬㧘ᄢ㒋㧘․೎⻠Ṷ‫ࡔ࡯࡜࡯࠹ߩ࡯ࠡ࡞࡟ࠕޟ‬ࠗ࠼ක≮ࠍߤߩࠃ߁ߦዷ㐿ߔࠆ߆‫ޠ‬Ṷ⠪)
23㧕 US-Japan Asthma Summit 2007(ᐔᚑ 19 ᐕ 4 ᦬㧘᧲੩㧘‫ޟ‬ᣣᧄߩ੃ᐜఽ༎ᕷࠍขࠅᏎߊ⃻⁁ߣ⺖㗴‫ޠ‬Ṷ⠪)24㧕 ╙ 110 ࿁ᣣᧄዊఽ⑼ቇળቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 4 ᦬㧘੩ㇺ㧘ᢎ⢒⻠Ṷ 4 ᐳ㐳)
25㧕 ᣣᧄࠕ࡟࡞ࠡ࡯දળਛ࿖ᡰㇱ ᐢፉቇⴚ⻠Ṷળ(ᐔᚑ 19 ᐕ 5 ᦬㧘ᐢፉ㧘․೎⻠Ṷ‫߅ߦ࡯ࠡ࡞࡟ࠕޟ‬ߌࠆ࠹࡯࡜࡯ࡔࠗ࠼ක≮ߩ㐿⊒ߣታ〣‫ޠ‬Ṷ⠪)26㧕 ╙ 7 ࿁༎ᕷ Early Intervention ⎇ⓥળ(ᐔᚑ 19 ᐕ 6 ᦬㧘᧲੩㧘⻠Ṷ‫࡯࡜࡯࠹ࠆߌ߅ߦ࡯ࠡ࡞࡟ࠕޟ‬㧙㧙ࡔࠗ࠼ක≮ߩ㐿⊒ߣታ〣‫ޠ‬Ṷ⠪)27㧕 ╙ 19 ࿁ᣣᧄࠕ࡟࡞ࠡ࡯ቇળᤐቄ⥃ᐥᄢળ(ᐔᚑ 19 ᐕ 6 ᦬㧘ᮮᵿ㧘ࠪࡦࡐࠫ࠙ࡓ 1‫࡯ࠡ࡞࡟ࠕ‛⮎ޟ‬ߩ⃻⁁ߣኻ╷ ዊఽ⑼ߦ߅ߌࠆ⮎‛ࠕ࡟࡞ࠡ࡯ߩ⃻⁁ߣኻ╷‫ޠ‬Ṷ⠪)28㧕 ╙ 19 ࿁ᣣᧄࠕ࡟࡞ࠡ࡯ቇળᤐቄ⥃ᐥᄢળ(ᐔᚑ 19 ᐕ 6 ᦬㧘ᮮᵿ㧘ࠗࡉ࠾ࡦࠣࠪࡦࡐࠫ࠙ࡓ 8‫ޟ‬༎ᕷᱫ࠯ࡠࠍ⋡ᜰߒߚᴦ≮ᚢ⇛ —᳇▤ᡰ༎ᕷߩᴦ≮⋡ᮡߩ㆐ᚑߦะߌߡ‫ޠ‬ᐳ㐳)29㧕 ╙ 17 ࿁࿖㓙༎ᕷቇળᣣᧄർࠕࠫࠕㇱળ(ᐔᚑ 19 ᐕ 7 ᦬㧘᧲੩㧘․೎⻠Ṷ‫∝⊒࡯ࠡ࡞࡟ࠕޟ‬ㆮવሶߣⅣႺߩ㑐ࠊࠅ‫ޠ‬Ṷ⠪)30㧕 ╙ 27 ࿁౐↲ࠞࡦࡈࠔ࡟ࡦࠬ(ᐔᚑ 19 ᐕ 8 ᦬㧘੩ㇺ㧘Ϊ‫ޟ‬Ⴧᖡᦼߩ∛ᘒ‫ޠ‬ᐳ㐳)31㧕 ᐔᚑ 19 ᐕᐲᣣᧄ㈼ㄘ⑼ቇࠪࡦࡐࠫ࠙ࡓ(ᐔᚑ 19 ᐕ 8 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬㘩ຠࠕ࡟࡞ࠡ࡯ߣߘߩᴦ
≮ᚢ⇛‫ޠ‬Ṷ⠪)32㧕 ᾢᧄ⋵ዊఽ⑼කળ⻠Ṷળ(ᐔᚑ 19 ᐕ 10 ᦬㧘ᾢᧄ㧘․೎⻠Ṷ‫࠼ࠗࡔ࡯࡜࡯࠹ߩ࡯ࠡ࡞࡟ࠕޟ‬ක≮ߩᣂዷ㐿ߣታ〣‫ޠ‬Ṷ⠪)33㧕 ╙ 17 ࿁ዊఽ᳇㆏ࠕ࡟࡞ࠡ࡯⎇ⓥળ(ᐔᚑ 19 ᐕ 10 ᦬㧘᧲੩㧘࠮࠶࡚ࠪࡦΣ ᐳ㐳)34㧕 ╙ 18 ࿁ጘ㒂⋵ߎߤ߽ߩஜᐽࠍ⠨߃ࠆߟߤ޿(ᐔᚑ 19 ᐕ 10 ᦬㧘ጘ㒂㧘‫ޟ‬ጘ㒂ᄢቇߦᣂ⸳ߐࠇߚ࿾ၞක
≮කቇ࠮ࡦ࠲࡯ߩ࡙࠾࡯ࠢߥ᭴ㅧߣᓎഀ‫ޠ‬Ṷ⠪)35㧕 ╙ 241 ࿁ᣣᧄዊఽ⑼ቇળ᧲ᶏ࿾ᣇળ(ᐔᚑ 19 ᐕ 10 ᦬㧘ጘ㒂㧘․೎⻠Ṷ ᐳ㐳)36㧕 ╙ 57 ࿁ᣣᧄࠕ࡟࡞ࠡ࡯ቇળ⑺ቄቇⴚᄢળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ᮮᵿ㧘ࠗࡉ࠾ࡦࠣࠪࡦࡐࠫ࠙ࡓ 4‫ࠕޟ‬࠻ࡇ࡯ᕈ⊹⤏Ἳ̆߆ࠁߺߣว૬∝߳ߩࠕࡊࡠ࡯࠴߆ࠄ̆‫ޠ‬ᐳ㐳)37㧕 ╙ 57 ࿁ᣣᧄࠕ࡟࡞ࠡ࡯ᄢળቇળ⑺ቄቇⴚᄢળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ᮮᵿ㧘ࠪࡦࡐࠫ࠙ࡓ 2(English
session)ࠕ࠻ࡇ࡯∔ᖚߣ⮎೷ㆊᢅ∝ߦ߅ߌࠆ Pharmacogenomics‫ޟ‬Pharmacogenomics in treatment
of atopic disease and drug hypersensitivity‫ޠ‬มળ)38㧕 The World Allergy Organization̉
s 20th World Allergy Congress (WAC) (ᐔᚑ 19 ᐕ 12 ᦬㧘Bangkok㧘࿖㓙ቇળࠪࡦࡐࠫ࠙ࡓ‫ޟ‬Symposium -Genetics- Implications for Asthma and Allergy‫ޠ‬ᐳ㐳)39㧕 The World Allergy Organization’s 20th World Allergy Congress (WAC) (ᐔᚑ 19 ᐕ 12 ᦬㧘Bangkok㧘࿖㓙ቇળࠪࡦࡐࠫ࠙ࡓ,᜗ᓙ⻠Ṷ‫ޟ‬Symposium –Genetic Evaluation of Allergic Diseases andAsthma –Japanese session: Genetic variations of interleukin 12 signaling and other cytokine
genes in allergy and asthma‫ޠ‬Ṷ⠪)40㧕 ╙ 44 ࿁ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ✚ળ(ᐔᚑ 19 ᐕ 12 ᦬㧘ฬฎደ㧘ࠪࡦࡐࠫ࠙ࡓ 7‫∔࡯ࠡ࡞࡟ࠕޟ‬ᖚߩಽሶ↢‛ቇ⊛ࠕࡊࡠ࡯࠴‫ޠ‬ᐳ㐳)41㧕 ╙ 16 ࿁ዊఽ⥃ᐥ⮎ℂ࡮ࠕ࡟࡞ࠡг࡮఺∉⎇ⓥળ(ᐔᚑ 20 ᐕ 1 ᦬㧘⑔ጟ㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯2 ᐳ㐳)42㧕 ╙ 30 ࿁ችၔ⋵කᏧળቇᩞ଻ஜ⎇ୃળ(ᐔᚑ 20 ᐕ 2 ᦬㧘ችၔ㧘‫ޟ‬ዊఽߩࠕ࡟࡞ࠡ࡯ߣߘߩኻ╷ ᦨㄭߩㅴᱠ߽฽߼ߡ‫ޠ‬Ṷ⠪)43㧕 ╙ 8 ࿁㘩‛ࠕ࡟࡞ࠡ࡯⎇ⓥળ(ᐔᚑ 20 ᐕ 2 ᦬㧘᧲੩㧘ᐳ㐳)44㧕 ╙ 9 ࿁㘩‛ࠕ࡟࡞ࠡ࡯⎇ⓥળ(ᐔᚑ 20 ᐕ 2 ᦬㧘᧲੩㧘ᐳ㐳)45㧕 ╙ 11 ࿁ൕോකㇱળቇⴚ⎇ୃળ(ᐔᚑ 20 ᐕ 3 ᦬㧘ጘ㒂㧘ၮ⺞⻠Ṷ‫ޟ‬ጘ㒂ᄢቇߩขࠅ⚵ߺ‫ޠ‬㧘Ṷ⠪)46㧕 ╙ 5 ࿁ጘ㒂⋵ዊఽ⑼කળ⻠Ṷળ㨪ࠕ࡟࡞ࠡ࡯࠮ࡒ࠽࡯㨪(ᐔᚑ 20 ᐕ 3 ᦬㧘ጘ㒂㧘․೎⻠Ṷ ᐳ㐳)47㧕 ╙ 5 ࿁ዊఽ᳇㆏ࠕ࡟࡞ࠡ࡯⎇ⓥળ(ᐔᚑ 20 ᐕ 4 ᦬㧘⑔ጟ㧘࠮࠶࡚ࠪࡦΦ ᐳ㐳)48㧕 ╙ 61 ࿁⥃ᐥࠕ࡟࡞ࠡ࡯⎇ⓥળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ᄢ㒋㧘․೎⻠ṶΤ‫ߩ≮⸻ߩ࡯ࠡ࡞࡟ࠕޟ‬ᣂዷ㐿ߣታ〣‫ޠ‬Ṷ⠪)
49㧕 The 1st Asthma Meeting in Tokyo(ᐔᚑ 20 ᐕ 5 ᦬㧘᧲੩㧘Session2 (English) ᐳ㐳)50㧕 ╙ 20 ࿁ᣣᧄࠕ࡟࡞ࠡ࡯ቇળᤐቄ⥃ᐥᄢળ(ᐔᚑ 20 ᐕ 6 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ 9‫∔࡯ࠡ࡞࡟ࠕޟ‬ᖚߩㆮવሶߣಽሶ↢‛ቇ‫ޠ‬ᐳ㐳)51㧕 ╙ 3 ࿁ጘ㒂ዊఽࠕ࡟࡞ࠡ࡯࡮༎ᕷ⎇ⓥળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ࡓ࠭࡝ࡦࠕࠖ࠺ࠞ࡯ࠨޟ‬ࠍมࠆಽሶᤨ⸘ߣߘߩశ૏⋧೙ᓮ‫ޠ‬Ṷ⠪)52㧕 ╙ 20 ࿁ᣣᧄࠕ࡟࡞ࠡ࡯ቇળᤐቄ⥃ᐥᄢળ(ᐔᚑ 20 ᐕ 6 ᦬㧘᧲੩㧘ᢎ⢒࠮ࡒ࠽࡯1‫߅ߦ࡯ࠡ࡞࡟ࠕޟ‬ߌࠆ࠹࡯࡜࡯ࡔࠗ࠼ක≮ߩ㐿⊒ߣታ〣‫ޠ‬Ṷ⠪)53㧕 ╙ 18 ࿁ ࿖ 㓙 ༎ ᕷ ቇ ળ ᣣ ᧄ ർ ࠕ ࠫ ࠕ ㇱ ળ ( ᐔ ᚑ 20 ᐕ 7 ᦬ 㧘 ᄢ 㒋 , Meet-the-professor 2‫ޟ‬Understanding combination therapy for asthma‫ޠ‬Chair)54㧕 ╙ 11 ࿁ Forum on Allergy in Nagoya(ᐔᚑ 20 ᐕ 10 ᦬㧘ฬฎደ ਎⹤ੱ)55㧕 ╙ 40 ࿁ᣣᧄዊఽᗵᨴ∝ቇળቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 11 ᦬㧘ฬฎደ㧘․೎⻠Ṷ ᐳ㐳)56㧕 23rd International Scientific Forum(ᐔᚑ 20 ᐕ 11 ᦬㧘᧲੩㧘Lecture 3‫ޟ‬Food Allergy ofChildhoos-Pathogenesis and Strategy of Management‫ޠ‬Ṷ⠪)57㧕 ╙ 58 ࿁ᣣᧄࠕ࡟࡞ࠡ࡯ቇળ⑺ቄቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 11 ᦬㧘᧲੩㧘․೎⻠Ṷ ᐳ㐳)㧙㧙58㧕 ╙ 4 ࿁㑐⷏༎ᕷ࡮COPD ⎇ⓥળ(ᐔᚑ 20 ᐕ 12 ᦬㧘ᄢ㒋㧘․೎⻠Ṷ‫ޟ‬ዊఽ᳇▤ᡰ༎ᕷߩ․ᓽߣኻᔕ㨪ᚑੱ༎ᕷߣߩ㆑޿ࠍ฽߼ߡ㨪‫ޠ‬Ṷ⠪)59㧕 ╙ 45 ࿁ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 12 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ 7 ‫∛࡯ࠡ࡞࡟ࠕޟ‬ᘒߩಽሶ↢‛ቇ⊛⸃᣿‫ޠ‬ᐳ㐳)60㧕 ╙ 45 ࿁ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 12 ᦬㧘᧲੩㧘ᢎ⢒࠮ࡒ࠽࡯8 ᐳ㐳)ᷓየᢅᐘ㧦
1㧕 The 10th International congress of inborn errors of metabolism(2006.09, Chiba, Mutation updateof human mitochondrial acetoacetyl-CoA thiolase (T2) deficiency; Ṷ⠪)2㧕 The 10th International congress of inborn errors of metabolism(2006.09, Chiba, Mutation updateof succinyl-CoA:3-ketoacid CoA transferase deficiency; Ṷ⠪)3㧕 ╙ 11 ࿁ᐢፉవᄤઍ⻢⇣Ᏹ⎇ⓥળ(ᐔᚑ 20 ᐕ 2 ᦬㧘ᐢፉ㧘․೎⻠Ṷ‫ࡦ࠻ࠤޟ‬૕ઍ⻢ߣߘߩ⇣Ᏹ∝‫ޠ‬Ṷ
⠪)
4㧕 ╙ 7 ࿁᧲ർઍ⻢⇣Ᏹ∝ᴦ≮⎇ⓥળ(ᐔᚑ 20 ᐕ 7 ᦬㧘઄บ㧘․೎⻠Ṷ‫ࡦ࠻ࠤޟ‬૕ઍ⻢ߣߘߩ⇣Ᏹ∝‫ޠ‬Ṷ⠪)
5㧕 ╙ 10 ࿁ጘ㒂ࡊ࡜ࠗࡑ࡝࡯ࠤࠕࠞࡦࡈࠔ࡜ࡦࠬ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ૐⴊ♧㧘㜞ࠕࡦࡕ࠾ࠕⴊ∝㧘ઍ⻢ᕈࠕࠪ࠼࡯ࠪࠬ‫ޠ‬Ṷ⠪)6㧕 2008 Annual symposium of Society for the Study of Inborn Errors of Metabolism.(2008.09,‫ޟ‬CpG
islands around exon 1 in succinyl-CoA:3-ketoacid CoA transferase (SCOT) gene were
hypomethylated even in human and mouse hepatic tissues where SCOT gene expression wascompletely suppressed‫ޠ‬Ṷ⠪)7㧕 2008 Annual symposium of Society for the Study of Inborn Errors of Metabolism.(2008.09,‫ޟ‬A
novel single-base substitution(c.1124A>G)that activates 5-base upstream cryptic splice donorsite within exon 11 in the human mitochondrial acetoacetyl-CoA thiolase gene‫ޠ‬Ṷ⠪)8㧕 వ┵ഃ⮎ක≮ࠪࡦࡐࠫ࠙ࡓ(ᐔᚑ 20 ᐕ 10 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ㆮવሶߣ∛᳇‫ޠ‬Ṷ⠪)9㧕 ╙ 45 ࿁ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ(ᐔᚑ 20 ᐕ 12 ᦬㧘ᮮᵿ㧘ࠪࡦࡐࠫ࠙ࡓ 10‫ߩࡦࠥ࡞࡟ࠕޟ‬ᗧ⟵ߣߘߩᄙ᭽ߥᯏ⢻‫ޠ‬Ṷ⠪)㊄ሶ⧷㓶㧦
1㧕 ╙ 18 ࿁ᣣᧄࠕ࡟࡞ࠡ࡯ቇળᤐቄ⥃ᐥᄢળ(ᐔᚑ 18 ᐕ 5 ᦬㧘᧲੩㧘‫ޟ‬᛫૕↥↢ਇో∝ߩ⥃ᐥ⚻ㆊߣ∛ᘒߩᄙ᭽ᕈ‫ޠ‬Ṷ⠪)
2㧕 ╙ 56 ࿁ᣣᧄࠕ࡟࡞ࠡ࡯ቇળ✚ળ(ᐔᚑ 18 ᐕ 11 ᦬㧘᧲੩㧘‫ߩ࡯ࠡ࡞࡟ࠕ੃‐ޟ‬ၮ␆⊛⸃ᨆߦၮߠߊᣂ
ⷙᴦ≮ᴺߩ㐿⊒‫ޠ‬Ṷ⠪)
3㧕 ╙ 43 ࿁ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ(ᐔᚑ 18 ᐕ 11 ᦬㧘᧲੩㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ 1‫ߩ࡯ࠡ࡞࡟ࠕ੃‐ޟ‬ၮ␆⊛⸃ᨆߣ఺∉ኡኈ⺃ዉߦࠃࠆᣂⷙᴦ≮ᴺ‫ޠ‬Ṷ⠪)4㧕 Pathogenesis of primary antibody deficiency Symposium for PID in Asia Riken RCAI(2008,12
Yokohama, Ṷ⠪)
5㧕 ╙ 45 ࿁ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ(ᐔᚑ 20 ᐕ 12 ᦬㧘ᮮᵿ㧘ࡒ࠾ࠪࡦࡐࠫ࠙ࡓ 4 ‫ޟ‬㘩‛ࠕ࡟࡞ࠡ࡯
⸻≮ߩᣂߒ޿ዷ㐿.‐੃ࠕ࡟࡞ࠡ࡯ߦ߅ߌࠆ⚻ญ఺∉ኡኈ⺃ዉ㘩ຠߩ૞ᚑ‫ޠ‬Ṷ⠪)ട⮮ༀ৻㇢㧦
1㧕 ╙ 58 ࿁ᣣᧄࠕ࡟࡞ࠡ࡯ቇળ⑺ᦼቇⴚᄢળ(ᐔᚑ 20 ᐕ 11 ᦬㧘᧲੩㧘ࡒ࠾ࠪࡦࡐࠫ࠙ࡓ 17‫⥄ޟ‬Ꮖ఺∉∔ᖚ T ⚦⢩ࠪࠣ࠽࡞વ㆐ᯏ᭴⸃᣿ߦะߌߚ TCR/peptide/HLA ⶄว૕࠲ࡦࡄࠢ┙૕᭴ㅧ⸃ᨆ‫ޠ‬Ṷ⠪)
2㧕 ╙ 38 ࿁ᣣᧄ఺∉ቇળ✚ળ࡮ቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 12 ᦬㧘੩ㇺ㧘Symposium 12‫ޟ‬Structural basis of
signaling via MyD88‫ޠ‬Ṷ⠪)᧻੗᳗ሶ㧦
1㧕 ╙ 56 ࿁ᣣᧄࠕ࡟࡞ࠡ࡯ቇળ(ᐔᚑ 18 ᐕ 11 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ 12‫ߦ∝⊒ޟ‬෸߷ߔ࠙ࠗ࡞ࠬᗵᨴ
ߩᓇ㗀ߣ⢝ౝ࿃ሶ‫ޠ‬Ṷ⠪)
2㧕 ╙ 18 ࿁ጘ㒂⋵ߎߤ߽ߩஜᐽࠍ⠨߃ࠆߟߤ޿(ᐔᚑ 19 ᐕ 10 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓ 3‫ޟ‬࿾ၞߩዊఽ
ක≮ߣዊఽ଻ஜ‫ޠ‬ᐳ㐳)㧙㧙Ꮉᧄ⟤ᄹሶ㧦1㧕 ╙ 45 ࿁ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ(ᐔᚑ 20 ᐕ 12 ᦬㧘ᮮᵿ㧘ࠪࡦࡐࠫ࠙ࡓ 3‫ޟ‬Უ੃ᩕ㙃ߣࠕ࡟࡞ࠡ࡯
∔ᖚ⊒∝ߣߩ㑐ㅪߦߟ޿ߡ‫ޠ‬Ṷ⠪)
ᄢ⷏⑲ౖ㧦
1㧕 ╙ 44 ࿁ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ(ᐔᚑ 19 ᐕ 12 ᦬㧘ฬฎደ㧘ࠪࡦࡐࠫ࠙ࡓ 7‫ޟ‬ಽሶ↢‛ቇ⊛ࠕࡊࡠ࡯࠴ߩ⥃ᐥ߳ߩࠗࡦࡄࠢ࠻ IL-18 ෸߮ࠪࠣ࠽࡞વ㆐♽࠲ࡦࡄࠢ⾰᭴ㅧ⸃ᨆߦၮߠߊഃ⮎߳ߩࠕࡊࡠ
࡯࠴‫ޠ‬Ṷ⠪)Ꮉᧄౖ↢㧦
1㧕 ╙ 19 ࿁ᣣᧄࠕ࡟࡞ࠡ࡯ቇળᤐቄ⥃ᐥᄢળ(ᐔᚑ 19 ᐕ 6 ᦬㧘ᮮᵿ㧘ࠪࡦࡐࠫ࠙ࡓ 3‫ޟ‬಴↢ࠦࡎ࡯࠻⎇ⓥߦࠃࠆዊఽࠕ࡟࡞ࠡ࡯∔ᖚߩ⊒∝ߦ㑐ࠊࠆ࿃ሶߩᬌ⸛‫ޠ‬Ṷ⠪)ฬ↰ආ೑㧦
1㧕 ╙ 19 ࿁ᣣᧄࠕ࡟࡞ࠡ࡯ቇળᤐቄ⥃ᐥᄢળ(ᐔᚑ 19 ᐕ 6 ᦬㧘ᮮᵿ㧘ࡒ࠾ࠪࡦࡐࠫ࠙ࡓ 4‫⥄ޟ‬ὼ఺∉♽⚦⢩ౝࠕ࠳ࡊ࠲࡯ಽሶߩ᭴ㅧ↢‛ቇ⊛ᯏ⢻⸃ᨆߣ⥃ᐥᔕ↪߳ߩዷᦸ‫ޠ‬Ṷ⠪)᫪↰⑲ⴕ㧦
1㧕 ╙ 57 ࿁ᣣᧄࠕ࡟࡞ࠡ࡯ᄢળቇળ⑺ቄቇⴚᄢળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ᮮᵿ㧘ࡒ࠾ࠪࡦࡐࠫ࠙ࡓ 12‫ޟ‬ᄢ⼺ࠕ࡟࡞ࠡ࡯ਥⷐ᛫ේ p34 ߩ࠲ࡦࡄࠢ᭴ㅧߩ⸃᣿ߣ⥃ᐥᔕ↪‫ޠ‬Ṷ⠪)
2㧕 ╙ 44 ࿁ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ(ᐔᚑ 19 ᐕ 12 ᦬㧘ฬฎደ㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ 1‫∉఺ޟ‬ኡኈ⺃ዉߩߚ߼ߩ㘩‛ࠕ࡟࡞ࠡ࡯ਥⷐ᛫ේ࠲ࡦࡄࠢߩ᭴ㅧ⸃᣿‫ޠ‬Ṷ⠪)ᧁ᧛⽕㧦
1㧕 Joint Singapore Paediatric Congress & APAPARI Meeting 2008(2008.10, ‫ ޟ‬Expression,
Purification and Structural Analysis of Human IL-18 Binding Protein: A Potent Therapeutic
Molecule for Allergy‫ޠ‬Ṷ⠪ )ᓼ⷗ືม㧦1㧕 Joint Singapore Paediatric Congress & APAPARI Meeting 2008(2008.10㧘
‫ޟ‬Molecular Analyses
Of Interaction Between Myd88-Adaptor- Like And The Other TIR Proteins In Toll-Like Receptor
Signaling‫ޠ‬Ṷ⠪ )2㧕 ╙ 111 ࿁ᣣᧄዊఽ⑼ቇળቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 4 ᦬㧘᧲੩‫ޟ‬Molecular analyses of protein-protein
interactions of intra-cellular signaling in innate immunity‫ޠ‬Ṷ⠪ )ਅỈિⴕ㧦1㧕 ╙ 48 ࿁ᣣᧄዊఽ␹⚻ቇળ(ᐔᚑ 18 ᐕ 1 ᦬㧘ᶆ቟㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ‫ޟ‬ㆮવᕈ␹⚻╭∔ᖚߩ⸻ᢿ࡮ᴦ≮ᚢ⇛‫ޠ‬Ṷ⠪)2㧕 10th International Congress of Inborn Errors of Metabolism(2006.09, Chiba, ࿖㓙ቇળၮ⺞⻠Ṷ㧘‫ޟ‬Molecular and clinical aspects of peroxisomal disease‫ޠ‬Ṷ⠪)3㧕 10th International Congress of Inborn Errors of Metabolism(2006.09, Chiba,‫ޟ‬A second case of
PEX14 deficiency with prolonged survival and renal tubular dysfunction‫ޠ‬Ṷ⠪)
4㧕 ╙ 49 ࿁ᣣᧄవᄤઍ⻢⇣Ᏹቇળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ጊᒻ㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ‫ޟ‬೽⣢⊕⾰ࠫࠬ࠻ࡠࡈࠖ࡯
ߩㅧⴊᐙ⚦⢩⒖ᬀ≮ᴺߩ⃻⁁ߣ໧㗴ὐ∔ᖚߩస᦯ߦะߌߡ‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ1㧕 ᛬ዬᑪᴦ㧦᫪᳗ᄺ઀ળ⎇ⓥᅑബ㊄(ᐔᚑ 18 ᐕᐲ)
2㧕 ⥵ᚭ㆏ᓼ㧦᫪᳗ᄺ઀ળ⎇ⓥᅑബ㊄(ᐔᚑ 19 ᐕᐲ)
3㧕 ᓼ⷗ືม: Young Investigator Award (╙ 111 ࿁ᣣᧄዊఽ⑼ቇળቇⴚ㓸ળ)(ᐔᚑ 19 ᐕᐲ)
4㧕 ㊄ሶ⧷㓶㧦╙ 9 ࿁ዊఽකቇᎹ㊁⾨ ዊఽၮ␆කቇಽ㊁ ዊఽߩ㔍ᴦᕈࠕ࡟࡞ࠡ࡯࡮఺∉∔ᖚߩ∛ᘒ⸃ᨆߣᣂⷙᴦ≮ᴺߩ㐿⊒(ᐔᚑ 20 ᐕᐲ)㧙㧙9㧚␠ળᵴേㄭ⮮⋥ታ㧦
1㧕 ᣣᧄࠕ࡟࡞ࠡ࡯දળℂ੐(㨪⃻࿷)2㧕 ో࿖කቇㇱ㐳∛㒮㐳ળ⼏Ᏹછℂ੐(ᐔᚑ 18㨪19 ᐕᐲ)
3㧕 ⷏ᣣᧄක⑼ቇ↢૕⢒ㅪ⋖೽ળ㐳(ᐔᚑ 18 ᐕᐲ)
4㧕 ᣣᧄቇⴚᝄ⥝ળ․೎⎇ⓥຬ╬ክᩏᆔຬળኾ㐷ᆔຬ෸߮࿖㓙੐ᬺᆔຬળᦠ㕙ክᩏᆔຬ(ᐔᚑ 17 ᐕ㨪19ᐕᐲ)
5㧕 ⽷࿅ᴺੱකቇᢎ⢒ᝄ⥝⽷࿅⹏⼏ຬ(ᐔᚑ 19 ᐕᐲ)
6㧕 ⽷࿅ᴺੱᲣሶஜᐽදળዊఽකቇ⎇ⓥഥᚑክᩏળክᩏຬ(ᐔᚑ 17㨪19 ᐕᐲ)
7㧕 ጘ㒂⋵ዊఽ଻ஜදળળ㐳(㨪⃻࿷)8㧕 ጘ㒂⋵ᗵᨴ∝੍㒐ኻ╷ᆔຬળ੍㒐ធ⒳ㇱળᆔຬ(㨪ᐔᚑ 19 ᐕᐲ)
9㧕 ጘ㒂⋵ᗵᨴ∝੍㒐ኻ╷ᆔຬળࠛࠗ࠭ኻ╷ㇱળᆔຬ(㨪ᐔᚑ 19 ᐕᐲ)
10㧕 ጘ㒂⋵੍㒐ធ⒳ஜᐽⵍኂ⺞ᩏኾ㐷ᆔຬ(㨪ᐔᚑ 19 ᐕᐲ)
11㧕 ጘ㒂⋵࿾ၞක≮᡽╷ද⼏ળᆔຬ(ᐔᚑ 19 ᐕᐲ)
12㧕 ጘ㒂⋵࿾ၞක≮᡽╷ද⼏ળಽ⑼ળㇱળ㐳(ᐔᚑ 19 ᐕᐲ)
13㧕 ጘ㒂⋵කᏧળ੍㒐ធ⒳ᆔຬળᆔຬ(㨪ᐔᚑ 19 ᐕᐲ)
14㧕 ጘ㒂⋵කᏧળൕോකㇱળቇⴚᆔຬળ㘈໧(㨪ᐔᚑ 19 ᐕᐲ)
15㧕 ጘ㒂Ꮢ੍㒐ធ⒳ஜᐽⵍኂ⺞ᩏᆔຬળᆔຬ(㨪⃻࿷)
16㧕 ⽷࿅ᴺੱጘ㒂⋵⎇ⓥ㐿⊒⽷࿅⍮⊛ࠢ࡜ࠬ࠲࡯ഃᚑ੐ᬺጘ㒂࡮ᄢ၂࿾ၞߦ߅ߌࠆᧄㇱળ⼏ᆔຬ(ᐔᚑ 18ᐕᐲ)17㧕 ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળℂ੐㐳(ᐔᚑ 20 ᐕ 12 ᦬㨪⃻࿷)ᷓየᢅᐘ㧦1㧕 ጘ㒂⋵ዊఽ଻ஜදળᏱછℂ੐(㨪⃻࿷)2㧕 ጘ㒂⋵੍㒐ធ⒳ஜᐽⵍኂ⺞ᩏኾ㐷කᏧ㓸࿅ኾ㐷කᏧ(㨪⃻࿷)3㧕 ጘ㒂Ꮢ଻⢒ᚲఽ┬ߩஜᐽࠍ⠨߃ࠆળᆔຬ(ᆔຬ㐳)(㨪⃻࿷)4㧕 ጘ㒂⋵ዊఽᢇᕆක≮ද⼏ળᆔຬ(㨪⃻࿷)5㧕 ጘ㒂Ꮢ଻ஜක≮ክ⼏ળᆔຬ(㨪⃻࿷)㊄ሶ⧷㓶㧦1㧕 ጘ㒂࿾ၞዊఽᢇᕆක≮૕೙ㅪ⛊ળ⼏ᆔຬ(㨪⃻࿷)ട⮮ༀ৻㇢㧦
1㧕 ࡏࠬ࠻ࡦ✚㗔੐㙚ᣂဳࠗࡦࡈ࡞ࠛࡦࠩኻ╷ supervisor(ᐔᚑ 18 ᐕᐲ㨪⃻࿷)2㧕 ࡏࠬ࠻ࡦ✚㗔੐㙚ਥ௅ᣂဳࠗࡦࡈ࡞ࠛࡦࠩኻ╷⻠Ṷળ⻠Ꮷ(ᐔᚑ 18 ᐕᐲ㨪⃻࿷)᧻੗᳗ሶ㧦1㧕 ⊒㆐㓚ኂߩᣧᦼ⊒⷗ߦ߻ߌߚ੃ᐜఽஜ⸻ᬌ⸛ᆔຬ(ᐔᚑ 20 ᐕᐲ)
2㧕 ጘ㒂⋵ኅᐸᢎ⢒ផㅴᆔຬ(ᐔᚑ 19 ᐕᐲ㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ㄭ⮮⋥ታ㧘⑺ጊ৻↵㧘ᄢ↰ஜ㧘⿒Ỉᤩ㧘ጊญᖝ㇢㧘⊕Ꮉᄥ㇢㧘᧻੗᳗ሶ㧦ࠕ࡟࡞ࠡ࡯∔ᖚߩᴦ≮෻ᔕᕈ੍᷹࿃ሶߩ⏕┙෸߮࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮ᴺߩ⏕┙ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 17 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ
⾌⵬ഥ㊄ ⎇ⓥႎ๔ᦠ╙ 2 ಽౠ(ㄭ⮮⃰)㧦205㧙207(2006 ᐕ 3 ᦬)
2㧕 ㄭ⮮⋥ታ㧘ട⮮ༀ৻㇢㧘ኹᧄ⾆⧷㧦ࠕ࡟࡞ࠡ࡯ߩ∛࿃ㆮવሶ࡮∛ᘒ࡮ᴦ≮෻ᔕᕈ੍᷹࿃ሶߩ⸃᣿ߣ
࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮ᴺߩ⏕┙߅ࠃ߮ഃ⮎ߩᬌ⸛㧦ᐔᚑ 17 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ⎇ⓥႎ๔ᦠ╙ 2 ಽౠ(ㄭ⮮⃰)㧦208㧙210(2006 ᐕ 3 ᦬)
3㧕 ᧻੗᳗ሶ㧘㊄ሶ⧷㓶㧦ㆮવሶᖱႎߩ✂⟜⊛⸃ᨆ߅ࠃ߮ዊఽ∛ᘒߦ߅ߌࠆࡠࠗࠦ࠻࡝ࠛࡦฃኈ૕ᜟ᛫
⮎ߩᴦ≮෻ᔕᕈ੍᷹ㆮવሶ࿃ሶߣ࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮㐿⊒㧦ᐔᚑ 17 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄⎇ⓥႎ๔ᦠ╙ 2 ಽౠ(ㄭ⮮⃰)㧦226㧙228(2006 ᐕ 3 ᦬)
4㧕 ㄭ⮮⋥ታ㧘⑺ጊ৻↵㧘ᄢ↰ஜ㧘⿒Ỉᤩ㧘ጊญᖝ㇢㧘⊕Ꮉᄥ㇢㧘᧻੗᳗ሶ㧦ࠕ࡟࡞ࠡ࡯∔ᖚߩᴦ≮෻ᔕᕈ੍᷹࿃ሶߩ⏕┙෸߮࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮ᴺߩ⏕┙ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 17 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ
⾌⵬ഥ㊄ ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ(ㄭ⮮⃰)㧦1㧙4(2006 ᐕ 3 ᦬)㧙㧙

5㧕 ㄭ⮮⋥ታ㧘ട⮮ༀ৻㇢㧘ኹᧄ⾆⧷㧦ࠕ࡟࡞ࠡ࡯ߩ∛࿃ㆮવሶ࡮∛ᘒ࡮ᴦ≮෻ᔕᕈ੍᷹࿃ሶߩ⸃᣿ߣ
࠹㧙࡜㧙ࡔࠗ࠼ᴦ≮ᴺߩ⏕┙߅ࠃ߮ഃ⮎ߩᬌ⸛㧦ᐔᚑ 17 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ✚᜝࡮ಽ
ᜂ⎇ⓥႎ๔ᦠ(ㄭ⮮⃰)㧦5㧙7(2006 ᐕ 3 ᦬)
6㧕 ᧻੗᳗ሶ㧘㊄ሶ⧷㓶㧦ㆮવሶᖱႎߩ✂⟜⊛⸃ᨆ߅ࠃ߮ዊఽ∛ᘒߦ߅ߌࠆࡠࠗࠦ࠻࡝ࠛࡦฃኈ૕ᜟ᛫
⮎ߩᴦ≮෻ᔕᕈ੍᷹ㆮવሶ࿃ሶߣ࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮㐿⊒㧦ᐔᚑ 17 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ(ㄭ⮮⃰)㧦37㧙39(2006 ᐕ 3 ᦬)
7㧕 ㄭ⮮⋥ታ㧘㊄ሶ⧷㓶㧘ㄭ⮮ᙥ㧘ᷓየᢅᐘ㧘◉↰⚩ม㧘ട⮮ༀ৻㇢㧘㕍ᧁ⟤ᄹሶ㧘Ꮉᧄౖ↢㧦㘩‛╬ߦࠃࠆࠕ࠽ࡈࠖ࡜ࠠࠪ࡯෻ᔕߩේ࿃‛⾰(ࠕ࡟࡞ࠥࡦ)ߩ⏕ቯ㧘੍㒐࡮੍⍮ᴺߩ⏕┙ߦ㑐ߔࠆ⎇ⓥ 㘩‛ࠕ࡟࡞ࠥࡦߩ఺∉ᔕ╵߅ࠃ߮㕖හᤨဳ෻ᔕߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 17 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄⎇ⓥႎ๔ᦠ╙ 1 ಽౠ(ᶏ⠧Ỉ⃰)㧦90㧙92(2006 ᐕ 3 ᦬)
8㧕 ㄭ⮮⋥ታ㧘㊄ሶ⧷㓶㧘ㄭ⮮ᙥ㧘ᷓየᢅᐘ㧘◉↰⚩ม㧘ട⮮ༀ৻㇢㧘㕍ᧁ⟤ᄹሶ㧘Ꮉᧄౖ↢㧦㘩‛ࠕ࡟࡞ࠥࡦߩ఺∉ᔕ╵߅ࠃ߮㕖හᤨဳ෻ᔕߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 15 ᐕᐲ㧙17 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌
⵬ഥ㊄ ✚᜝⎇ⓥႎ๔ᦠ(ᶏ⠧Ỉ⃰)㧦22㧙24(2006 ᐕ 3 ᦬)
9㧕 ㄭ⮮⋥ታ㧘㕍ᧁ⟤ᄹሶ㧘㊄ሶ⧷㓶㧘᧻੗᳗ሶ㧘Ꮉᧄౖ↢㧦఺∉ࠕ࡟࡞ࠡ࡯ߦଥࠊࠆ⢝ౝ࡮⢝ᄖ࿃ሶߩหቯߦ㑐ߔࠆ⎇ⓥ RS ࠙ࠗ࡞ࠬᗵᨴ߇ࠕ࡟࡞ࠡ࡯⊒∝ߦ෸߷ߔᓇ㗀߅ࠃ߮⤯Ꮺⴊࠍ↪޿ߚࠕ࡟࡞ࠡ࡯∔ᖚߩ੍⍮࡮੍㒐ᴺߩ⏕┙㧦ᐔᚑ 17 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ⎇ⓥႎ๔ᦠ╙ 1 ಽౠ(᫪Ꮉ⃰)㧦41㧙43(2006 ᐕ 3 ᦬)
10㧕 ㄭ⮮⋥ታ㧘㕍ᧁ⟤ᄹሶ㧘㊄ሶ⧷㓶㧘᧻੗᳗ሶ㧘Ꮉᧄౖ↢㧦RS ࠙ࠗ࡞ࠬᗵᨴ߇ࠕ࡟࡞ࠡ࡯⊒∝ߦ෸߷ߔᓇ㗀߅ࠃ߮⤯Ꮺⴊࠍ↪޿ߚࠕ࡟࡞ࠡ࡯∔ᖚߩ੍⍮࡮੍㒐ᴺߩ⏕┙㧦ᐔᚑ 17 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ
⾌⵬ഥ㊄ ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ(᫪Ꮉ⃰)㧦9㧙17(2006 ᐕ 3 ᦬)
11㧕 ㄭ⮮⋥ታ㧘㕍ᧁ⟤ᄹሶ㧘㊄ሶ⧷㓶㧘᧻੗᳗ሶ㧘Ꮉᧄౖ↢㧦RS ࠙ࠗ࡞ࠬᗵᨴ߇ࠕ࡟࡞ࠡ࡯⊒∝ߦ෸߷ߔᓇ㗀߅ࠃ߮⤯Ꮺⴊࠍ↪޿ߚࠕ࡟࡞ࠡ࡯∔ᖚߩ੍⍮࡮੍㒐ᴺߩ⏕┙㧦ᐔᚑ 15 ᐕᐲ㧙17 ᐕᐲෘ↢ഭ
௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ✚ว⎇ⓥႎ๔ᦠ(᫪Ꮉ⃰)㧦12㧙
16(2006 ᐕ 3 ᦬)
12㧕 ᛬ዬᑪᴦ㧘ᷓየᢅᐘ, ㊄ሶ⧷㓶, ㄭ⮮⋥ታ㧦Ataxia telangiectasia(Ძ⚦ⴊ▤᜛ᒛᕈㆇേᄬ⺞∝)ߩ∛ᘒߦ㑐ߔಽሶ↢‛ቇ⊛⸃ᨆ㧦ᐔᚑ 17 ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄ 㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ ✚᜝࡮ಽ
ᜂ⎇ⓥႎ๔ᦠ(ች⣁⃰)㧦49㧙51(2006 ᐕ 3 ᦬)
13㧕 ㄭ⮮⋥ታ, Ꮉᧄౖ↢, ᧻੗᳗ሶ, ㊄ሶ⧷㓶㧦Უ੃ਛߩ࠳ࠗࠝࠠࠪࡦ㘃Ớᐲߣ఺∉ᯏ⢻,ࠕ࡟࡞ࠡ࡯ߦ㑐ߔࠆᬌ⸛㧦ᐔᚑ 17 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ(ᄙ↰⃰)㧦77㧙79(2006ᐕ 3 ᦬)
14㧕 ㄭ⮮⋥ታ㧦ጘ㒂ᄢቇකቇㇱ ዊఽ⑼ߦ߅ߌࠆࠕ࡟࡞ࠡ࡯⸻≮ㅪ៤㧦ࠕ࡟࡞ࠡ࡯⸻≮ᣉ⸳੐଀㓸 ᐔ
ᚑ 18 ᐕ 10 ᦬ෘ↢ഭ௛⑼ቇ⎇ⓥ ࠟࠗ࠼࡜ࠗࡦ᥉෸ߩߚ߼ߩኻ╷ߣߘࠇߦ઻߁ QOL ߩะ਄ߦ㑐ߔࠆ⎇ⓥ⃰(㗇↲⃰)㧦210(2006 ᐕ 10 ᦬)
15㧕 ട⮮ༀ৻㇢㧘ㄭ⮮⋥ታ㧦ࠕ࡟࡞ࠡ࡯∔ᖚߦ߅ߌࠆ࠹࡯࡜࡯ࡔࠗ࠼੍㒐࡮ᴦ≮ᴺ㐿⊒ߩߚ߼ߩ HLA ┙૕᭴ㅧߦၮߠ޿ߚࡍࡊ࠴࠼ࡐ࡝ࡑ㧙ഃ⮎ߩ⎇ⓥ㧦⽷࿅ᴺੱᣣᧄ੍㒐කቇදળᐔᚑ 17 ᐕ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥផㅴ੐ᬺႎ๔ᦠ(ㄭ⮮⃰)㧦14㧙19(2006 ᐕ 3 ᦬)
16㧕 ᄢ⷏⑲ౖ㧘ㄭ⮮⋥ታ㧦ࠕ࡟࡞ࠡ࡯∔ᖚߩᴦ≮෻ᔕᕈ੍᷹࿃ሶߩ⏕┙෸߮࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮ᴺߩ⏕┙ߦ㑐ߔࠆ⎇ⓥ㧦⽷࿅ᴺੱᣣᧄ੍㒐කቇදળ㧦ᐔᚑ 17 ᐕ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥផㅴ੐
ᬺႎ๔ᦠ(ㄭ⮮⃰)㧦87㧙103(2006 ᐕ 3 ᦬)
17㧕 ㄭ⮮⋥ታ㧘⥵ᚭ㆏ᓼ㧘⏷⽴శᴦ㧘㊁ਛਁ␭ሶ㧘㕙ኅஜᄥ㇢㧘ኹᧄ⾆⧷㧘᧻੗᳗ሶ㧘᛬ዬᑪᴦ㧘Ꮉᧄౖ↢㧘ട⮮ༀ৻㇢㧘㊄ሶ⧷㓶㧘ᷓየᢅᐘ㧦Ꮐ⣊㛽ߦ⊒∝ߒߚ BCG 㛽㜑Ἳߩ৻଀IFN㧙J⚻〝ߩ⸃ᨆࠍ฽߼ߡ㧦ᐔᚑ 17 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥක⮎ຠ࡮ක≮ᯏེ╬࡟ࠡࡘ࡜࠻࡝࡯ࠨࠗࠛࡦࠬ✚ว⎇ⓥ
੐ᬺ ⎇ⓥႎ๔ᦠ(ਅ↰⃰)㧦105㧙107(2006 ᐕ 3 ᦬)
18㧕 ㊄ሶ⧷㓶㧘㋈ᧁ໪ሶ㧘㊄ ᩕ㧘ᷓየᢅᐘ㧘ㄭ⮮⋥ታ㧦IgA ᰳ៊∝ߩ∛ᘒߣ∛࿃ㆮવሶߩ⸃ᨆ㧦ෘ↢ഭ௛⋭ 㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ ේ⊒ᕈ఺∉ਇో∝୥⟲ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ ᐔᚑ 18 ᐕᐲ╙ 1 ࿁⃰ળ⼏✚ળࡊࡠࠣ࡜ࡓ(ች⣁⃰)㧦6(2007 ᐕ 1 ᦬)
19㧕 ㄭ⮮⋥ታ㧘⑺ጊ৻↵㧘ᄢ↰ ஜ㧘⿒Ỉ ᤩ㧘ጊญᖝ㇢㧘⊕Ꮉᄥ㇢㧘ᶏ⠧Ỉరብ㧘⮮Ỉ㓉ᄦ㧘᧻੗᳗ሶ㧦ࠕ࡟࡞ࠡ࡯∔ᖚߩᴦ≮෻ᔕᕈ੍᷹࿃ሶߩ⏕┙෸߮࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮ᴺߩ⏕┙ߦ㑐ߔࠆ⎇ⓥ㧦
ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ળᛞ㍳
㓸(ㄭ⮮⃰)㧦1㧙3(2007 ᐕ 2 ᦬)
20㧕 ㄭ⮮⋥ታ㧘ട⮮ༀ৻㇢㧘ᄢ⷏⑲ౖ㧦ࠕ࡟࡞ࠡ࡯ߩ∛࿃ㆮવሶ࡮∛ᘒ࡮ᴦ≮෻ᔕᕈ੍᷹࿃ሶߩ⸃᣿ߣ
࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮ᴺߩ⏕┙߅ࠃ߮ഃ⮎ߩᬌ⸛㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ળᛞ㍳㓸(ㄭ⮮⃰)㧦4(2007 ᐕ 2 ᦬)㧙㧙21㧕 ᧻੗᳗ሶ㧦ㆮવሶᖱႎߩ✂⟜⊛⸃ᨆ‫߮ࠃ߅ޔ‬ዊఽ༎ᕷߦ߅ߌࠆࡠࠗࠦ࠻࡝ࠛࡦฃኈ૕ᜟ᛫⮎ߩᴦ≮෻ᔕᕈ੍᷹ㆮવሶ࿃ሶߣ࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮㐿⊒㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ળᛞ㍳㓸(ㄭ⮮⃰)㧦11(2007 ᐕ 2 ᦬)
22㧕 ㄭ⮮⋥ታ㧘ᷓየᢅᐘ㧘᧻੗᳗ሶ㧘㊄ሶ⧷㓶㧘㕍ᧁ⟤ᄹሶ㧘ㄭ⮮ ᙥ㧘Ꮉᧄౖ↢㧦ࠕ࡟࡞ࠡ࡯ᕈ∔ᖚߩ⊒∝࡮㊀∝ൻߩ੍⍮ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ળᛞ㍳㓸(ᶏ⠧Ỉ⃰)㧦125(2007 ᐕ 2 ᦬)
23㧕 ㄭ⮮⋥ታ㧘ᷓየᢅᐘ㧘㊄ሶ⧷㓶㧘᧻੗᳗ሶ㧘㕍ᧁ⟤ᄹሶ㧦ࠕ࠻ࡇ࡯ᕈ⊹⤏Ἳ⊒∝ߣᲣ੃ߩ㑐ㅪ‫․ޔ‬ߦᲣ੃ᚑಽߩ⸃ᨆߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ળᛞ㍳㓸(ᴡ㊁⃰)㧦143(2007 ᐕ 2 ᦬)
24㧕 ㄭ⮮⋥ታ㧘⑺ጊ৻↵㧘ᄢ↰ ஜ㧘⿒Ỉ ᤩ㧘ጊญᖝ㇢㧘ᶏ⠧Ỉరብ㧘⮮Ỉ㓉ᄦ㧘᧻੗᳗ሶ㧦ࠕ࡟࡞ࠡ࡯∔ᖚߩᴦ≮෻ᔕᕈ੍᷹࿃ሶߩ⏕┙෸߮࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮ᴺߩ⏕┙ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ(ㄭ⮮⃰)㧦1㧙4(2007 ᐕ 3 ᦬)
25㧕 ㄭ⮮⋥ታ㧘ട⮮ༀ৻㇢㧘ኹᧄ⾆⧷㧦ࠕ࡟࡞ࠡ࡯ߩ∛࿃ㆮવሶ࡮∛ᘒ࡮ᴦ≮෻ᔕᕈ੍᷹࿃ሶߩ⸃᣿ߣ
࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮ᴺߩ⏕┙߅ࠃ߮ഃ⮎ߩᬌ⸛㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ(ㄭ⮮⃰)㧦5㧙8(2007 ᐕ 3 ᦬)
26㧕 ᧻੗᳗ሶ㧦ㆮવሶᖱႎߩ✂⟜⊛⸃ᨆ‫߮ࠃ߅ޔ‬ዊఽ༎ᕷߦ߅ߌࠆࡠࠗࠦ࠻࡝ࠛࡦฃኈ૕ᜟ᛫⮎ߩᴦ≮෻ᔕᕈ੍᷹ㆮવሶ࿃ሶߣ࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮㐿⊒㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ(ㄭ⮮⃰)㧦39㧙41(2007 ᐕ 3 ᦬)
27㧕 ㄭ⮮⋥ታ㧘⑺ጊ৻↵㧘ᄢ↰ ஜ㧘⿒Ỉ ᤩ㧘ጊญᖝ㇢㧘⊕Ꮉᄥ㇢㧘ᶏ⠧Ỉరብ㧘⮮Ỉ㓉ᄦ㧘᧻੗᳗ሶ㧦ࠕ࡟࡞ࠡ࡯∔ᖚߩᴦ≮෻ᔕᕈ੍᷹࿃ሶߩ⏕┙෸߮࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮ᴺߩ⏕┙ߦ㑐ߔࠆ⎇ⓥ㧦
ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ✚ว⎇ⓥႎ๔ᦠ(ㄭ⮮⃰)㧦1㧙4(2007 ᐕ 3 ᦬)
28㧕 ㄭ⮮⋥ታ㧘ട⮮ༀ৻㇢㧦ࠕ࡟࡞ࠡ࡯ߩ∛࿃ㆮવሶ࡮∛ᘒ࡮ᴦ≮෻ᔕᕈ੍᷹࿃ሶߩ⸃᣿ߣ࠹࡯࡜࡯ࡔ
ࠗ࠼ᴦ≮ᴺߩ⏕┙߅ࠃ߮ഃ⮎ߩᬌ⸛㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ✚ว⎇ⓥႎ๔ᦠ(ㄭ⮮⃰)㧦5㧙9(2007 ᐕ 3 ᦬)
29㧕 ᧻੗᳗ሶ㧦ㆮવሶᖱႎߩ✂⟜⊛⸃ᨆ㧘߅ࠃ߮ዊఽ༎ᕷߦ߅ߌࠆࡠࠗࠦ࠻࡝ࠛࡦฃኈ૕ᜟ᛫⮎ߩᴦ≮෻ᔕᕈ੍᷹ㆮવሶ࿃ሶߣ࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮㐿⊒㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ✚ว⎇ⓥႎ๔ᦠ(ㄭ⮮⃰)㧦53㧙59(2007 ᐕ 3 ᦬)30㧕 ㊄ሶ⧷㓶㧘㋈ᧁ໪ሶ㧘ᷓየᢅᐘ㧘ㄭ⮮⋥ታ㧦IgA ᰳ៊∝ߩ∛ᘒߣ∛࿃ㆮવሶߩ⸃ᨆ ේ⊒ᕈ఺∉ਇో∝୥⟲ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ㧦ᐔᚑ 18 ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄ 㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ(ች⣁⃰)㧦41㧙43(2007 ᐕ 3 ᦬)
31㧕 ㄭ⮮⋥ታ㧘Ꮉᧄౖ↢㧘᧻੗᳗ሶ㧘㊄ሶ⧷㓶㧦Უ੃ਛߩ࠳ࠗࠝࠠࠪࡦ㘃Ớᐲߣ఺∉ᯏ⢻㧘ࠕ࡟࡞ࠡ࡯
ߦ㑐ߔࠆᬌ⸛ ࠳ࠗࠝࠠࠪࡦߩ੃ᐜఽ߳ߩᓇ㗀ߘߩઁߩᳪᨴታᘒߩ⸃᣿ߦ㑐ߔࠆ⎇ⓥ ․ߦᲣ੃ਛ
ߩ࠳ࠗࠝࠠࠪࡦ㘃Ớᐲߩ⚻ᐕ⊛ᄌൻߣᐜఽ⊒⢒⊒㆐ߦ෸߷ߔᓇ㗀㧦ᐔᚑ 16 ᐕᐲ㧙18 ᐕᐲ ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ 㘩ຠߩ቟ᔃ࡮቟ో⏕଻ផㅴ⎇ⓥ੐ᬺ ✚ว⎇ⓥႎ๔ᦠ(ᄙ↰⃰)㧦43㧙46(2007ᐕ 3 ᦬)
32㧕 ㄭ⮮⋥ታ㧘᧻੗᳗ሶ㧘㊄ሶ⧷㓶㧘㕍ᧁ⟤ᄹሶ㧘ㄭ⮮ ᙥ㧦ࠕ࡟࡞ࠡ࡯∔ᖚߩ⥄Ꮖ▤ℂߣ୘೎ൻක≮ࠍ⋡ᜰߒߚᣧᦼ⸻ᢿၮḰߣᣧᦼᴦ≮ᴺߩ⏕┙෸߮ߘߩ᦭ലᕈߣ᦭ኂ੐⽎ߩ⹏ଔߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ✚᜝࡮ಽᜂ⎇ⓥႎ๔
ᦠ(ᄢ↰⃰)㧦20㧙24(2007 ᐕ 3 ᦬)
33㧕 ㄭ⮮⋥ታ㧘ᷓየᢅᐘ㧘ጤ⍾⋿৻㧘⊕ᧁ ⺈㧘᧻੗᳗ሶ㧘㊄ሶ⧷㓶㧘㕍ᧁ⟤ᄹሶ㧘ㄭ⮮ ᙥ㧘Ꮉᧄౖ↢㧦ࠕ࡟࡞ࠡ࡯∔ᖚߩ⊒∝࡮㊀∝ൻߩ੍⍮ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ(ᶏ⠧Ỉ⃰)㧦9㧙11(2007 ᐕ 3 ᦬)
34㧕 ㄭ⮮⋥ታ㧘ᷓየᢅᐘ㧘㊄ሶ⧷㓶㧘᧻੗᳗ሶ㧘㕍ᧁ⟤ᄹሶ㧦ࠕ࠻ࡇ㧙ᕈ⊹⤏Ἳ⊒∝ߣᲣ੃ߩ㑐ㅪ‫․ޔ‬ߦᲣ੃ᚑಽߩ⸃ᨆߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ(ᴡ㊁⃰)㧦20㧙22(2007 ᐕ 4 ᦬)
35㧕 ㄭ⮮⋥ታ㧘⑺ጊ৻↵㧘ᄢ↰ ஜ㧘⿒Ỉ ᤩ㧘ጊญᖝ㇢㧘ᶏ⠧Ỉరብ㧘⮮Ỉ㓉ᄦ㧘᧻੗᳗ሶ㧦ࠕ࡟࡞ࠡ࡯∔ᖚߩᴦ≮෻ᔕᕈ੍᷹࿃ሶߩ⏕┙෸߮࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮ᴺߩ⏕┙ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ᦠ ෘ↢ഭ௛⑼ቇ
⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ੐ോዪ⊒ⴕ ╙ 1 ಽౠ(ㄭ⮮⃰)㧦177㧙
180(2007 ᐕ 3 ᦬)
36㧕 ㄭ⮮⋥ታ㧘ട⮮ༀ৻㇢㧘ኹᧄ⾆⧷㧦ࠕ࡟࡞ࠡ࡯ߩ∛࿃ㆮવሶ࡮∛ᘒ࡮ᴦ≮෻ᔕᕈ੍᷹࿃ሶߩ⸃᣿ߣ

㧙㧙࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮ᴺߩ⏕┙߅ࠃ߮ഃ⮎ߩᬌ⸛㧦ᐔᚑ 18 ᐕᐲ ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ᦠ ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ੐ോዪ ⊒ⴕ╙ 1 ಽౠ(ㄭ⮮⃰)㧦181㧙184(2007 ᐕ 3 ᦬)
37㧕 ㄭ⮮⋥ታ㧘ᷓየᢅᐘ㧘ጤ⍾⋿৻㧘⊕ᧁ ⺈㧘᧻੗᳗ሶ㧘㊄ሶ⧷㓶㧘㕍ᧁ⟤ᄹሶ㧘ㄭ⮮ ᙥ㧘Ꮉᧄౖ↢㧦ࠕ࡟࡞ࠡ࡯ᕈ∔ᖚߩ⊒∝࡮㊀∝ൻߩ੍⍮ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ᦠ ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ੐ോዪ ⊒ⴕ ╙ 3 ಽౠ(ᶏ⠧Ỉ⃰)㧦161㧙163(2007 ᐕ 3 ᦬)
38㧕 ㄭ⮮⋥ታ㧘ᷓየᢅᐘ㧘㊄ሶ⧷㓶㧘᧻੗᳗ሶ㧘㕍ᧁ⟤ᄹሶ㧦ࠕ࠻ࡇ࡯ᕈ⊹⤏Ἳ⊒∝ߣᲣ੃ߩ㑐ㅪ‫․ޔ‬ߦᲣ੃ᚑಽߩ⸃ᨆߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ᦠ ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ੐ോዪ ⊒ⴕ ╙ 3 ಽౠ(ᴡ㊁⃰)㧦210㧙212(2007 ᐕ 3 ᦬)
39㧕 ㄭ⮮⋥ታ㧘᧻੗᳗ሶ㧘㊄ሶ⧷㓶㧘㕍ᧁ⟤ᄹሶ㧘ㄭ⮮ ᙥ㧦ࠕ࡟࡞ࠡ࡯∔ᖚߩ⥄Ꮖ▤ℂߣ୘೎ൻක≮ࠍ⋡ᜰߒߚᣧᦼ⸻ᢿၮḰߣᣧᦼᴦ≮ᴺߩ⏕┙෸߮ߘߩ᦭ലᕈߣ᦭ኂ੐⽎ߩ⹏ଔߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ᦠ ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ੐ോዪ ⊒ⴕ ╙ 3 ಽౠ(ᄢ↰⃰)㧦302
㧙306(2007 ᐕ 3 ᦬)
40㧕 ㄭ⮮⋥ታ㧘◉↰⚩ม㧘㊄ሶ⧷㓶㧘㕍ᧁ⟤ᄹሶ㧘᧻੗᳗ሶ㧘ኹᧄ⾆⧷㧘ᷓየᢅᐘ㧦఺∉ᯏ⢻ૐਅࠍ᦭ߔࠆዊఽߦኻߔࠆ੍㒐ធ⒳ߩᬌ⸛(╙ 3 ႎ)఺∉⛽ᜬߦ㑐ߔࠆᬌ⸛㧦ᐔᚑ 18 ᐕᐲ ෘ↢ഭ௛⑼ቇ⎇ⓥ
⾌⵬ഥ㊄ ක⮎ຠ࡮ක≮ᯏེ╬࡟ࠡࡘ࡜࡯ࠨࠗࠛࡦࠬ✚ว⎇ⓥ੐ᬺ ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ(ਅ↰⃰)㧦85㧙87(2007 ᐕ 4 ᦬)
41㧕 ᧘ ᗲ⬒㧘ㄭ⮮⋥ታ㧦ࠕ࡟࡞ࠡ࡯∔ᖚߩᴦ≮෻ᔕᕈ੍᷹࿃ሶߩ⏕┙෸߮࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮ᴺ⏕┙ߩߚ߼ߩ᭴ㅧ↢‛ቇ⊛ഃ⮎ߦ㑐ߔࠆ⎇ⓥ㧦⽷࿅ᴺੱᣣᧄ੍㒐කቇදળ ᐔᚑ 18 ᐕᐲ఺∉ࠕ࡟࡞ࠡ࡯
∔ᖚ੍㒐࡮ᴦ≮⎇ⓥផㅴ੐ᬺ(⧯ᚻ⎇ⓥ⠪⢒ᚑᵴ↪੐ᬺ)⎇ⓥႎ๔ᦠ(ㄭ⮮⃰)㧦42㧙45(2007 ᐕ 7 ᦬)
42㧕 Ohnishi H㧘Tochio H㧘Hiroaki H㧘Kato Z㧘Kondo N㧘Shirakawa M㧦Deposition㧦Protein Data
Bank ⊓㍳㧦Accession number㧦2z5v ‘Solution structure of the TIR domain of human MyD88’
Date㧦(2007㧙07㧙19)43㧕 ㄭ⮮⋥ታ㧦ࠕ࡟࡞ࠡ࡯∔ᖚߩᴦ≮෻ᔕᕈ੍᷹࿃ሶߩ⏕┙෸߮࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮ᴺߩ⏕┙ߦ㑐ߔࠆ
⎇ⓥ㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺࡄࡦࡈ࡟࠶
࠻(ㄭ⮮⃰)㧦15㧙16(2007 ᐕ 8 ᦬)
44㧕 ㄭ⮮⋥ታ㧘⑺ጊ৻↵㧘ᄢ↰ ஜ㧘⿒Ỉ ᤩ㧘ጊญᖝ㇢㧘ᶏ⠧Ỉరብ㧘⮮Ỉ㓉ᄦ㧘᧻੗᳗ሶ㧦ࠕ࡟࡞ࠡ࡯ߩ࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮▤ℂࠟࠗ࠼࡜ࠗࡦߩ⏕┙ߣታ↪ൻߦ㑐ߔࠆ⎇ⓥ㧚ᐔᚑ 19 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ળᛞ㍳㓸(ㄭ⮮⃰)㧦165㧙
167(2008 ᐕ 1 ᦬)
45㧕 ㄭ⮮⋥ታ㧦ࠕ࡟࡞ࠡ࡯ߩㆮવⷐ࿃࡮ⅣႺⷐ࿃ߩ⾰ߣ㊂ߩ⹏ଔᴺߩ⏕┙ߣ࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮▤ℂࠟ
ࠗ࠼࡜ࠗࡦߩ⏕┙‫✚߮ࠃ߅ޔ‬᜝㧦ᐔᚑ 19 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ળᛞ㍳㓸(ㄭ⮮⃰)㧦168(2008 ᐕ 2 ᦬)
46㧕 ㄭ⮮⋥ታ㧘ᷓየᢅᐘ㧘᧻੗᳗ሶ㧘㊄ሶ⧷㓶㧘Ꮉᧄ⟤ᄹሶ㧘Ꮉᧄౖ↢㧦ࠕ࡟࡞ࠡ࡯ᕈ∔ᖚߩ⊒∝࡮㊀∝ൻߩ੍⍮ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 19 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ળᛞ㍳㓸(ᶏ⠧Ỉ⃰)㧦98(2008 ᐕ 2 ᦬)
47㧕 ㄭ⮮⋥ታ㧘◉↰⚩ม㧘᧻੗᳗ሶ㧘Ꮉᧄ⟤ᄹሶ㧦ዊఽ༎ᕷ QOL ⎇ⓥߩ✚᜝ ࠟࠗ࠼࡜ࠗࡦ᥉෸ߩߚ߼
ߩኻ╷ߣߘࠇߦ઻߁ QOL ߩะ਄ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 19 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ળᛞ㍳㓸(㗇↲⃰)㧦73(2008 ᐕ 2 ᦬)48㧕 ㄭ⮮⋥ታ㧘Ꮉᧄ⟤ᄹሶ㧘ᷓየᢅᐘ㧘㊄ሶ⧷㓶㧘᧻੗᳗ሶ㧘ᄢ⷏⑲ౖ㧦ࠕ࠻ࡇ㧙ᕈ⊹⤏Ἳ⊒∝ߣᲣ੃ߩ㑐ㅪ‫ߦ․ޔ‬Უ੃ᚑಽߩ⸃ᨆߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 19 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ળᛞ㍳㓸(ᴡ㊁⃰)㧦8(2008 ᐕ 2 ᦬)
49㧕 ㄭ⮮⋥ታ㧘᧻੗᳗ሶ㧦ዊఽ᳇▤ᡰ༎ᕷߩᣧᦼ⸻ᢿ࡮ᣧᦼᴦ≮ߩᜰ㊎ߩ૞ᚑߣ⹏ଔ߅ࠃ߮᳇▤ᡰ༎ᕷߦ㑐ㅪߔࠆㆮવሶ⸃ᨆ ࠕ࡟࡞ࠡ࡯∔ᖚߩ⥄Ꮖ▤ℂߣ୘೎ൻක≮ࠍ⋡ᜰߒߚᣧᦼ⸻ᢿၮḰߣᣧᦼᴦ≮ᴺߩ⏕┙෸߮ߘߩ᦭ലᕈߣ᦭ኂ੐⽎ߩ⹏ଔߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 19 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ળᛞ㍳㓸(ᄢ↰⃰)㧦204(2008 ᐕ 2 ᦬)
50㧕 ㄭ⮮⋥ታ㧦ࠕ࡟࡞ࠡ࡯ߩ࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮▤ℂࠟࠗ࠼࡜ࠗࡦߩ⏕┙ߣታ↪ൻ㧦ᐔᚑ 19 ᐕᐲ ෘ↢
ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ᦠ ╙ 3 ಽౠ(ㄭ⮮⃰)㧦359
㧙362(2008 ᐕ 3 ᦬)
51㧕 ㄭ⮮⋥ታ㧘ട⮮ༀ৻㇢㧘ኹᧄ⾆⧷㧦ࠕ࡟࡞ࠡ࡯ߩㆮવⷐ࿃࡮ⅣႺⷐ࿃ߩ⾰ߣ㊂ߩ⹏ଔᴺߩ⏕┙ߣ࠹㧙㧙࡯࡜࡯ࡔࠗ࠼ᴦ≮▤ℂࠟࠗ࠼࡜ࠗࡦߩ⏕┙㧘߅ࠃ߮✚᜝㧦ᐔᚑ 19 ᐕᐲ ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ᦠ ╙ 3 ಽౠ(ㄭ⮮⃰)㧦363㧙365(2008 ᐕ 3 ᦬)
52㧕 ㄭ⮮⋥ታ㧘◉↰⚩ม㧘᧻੗᳗ሶ㧘Ꮉᧄ⟤ᄹሶ㧦ዊఽ᳇▤ᡰ༎ᕷ⎇ⓥߩ✚᜝㧦ᐔᚑ 19 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ಽᜂ⎇ⓥႎ๔ᦠ ╙ 1 ಽౠ(㗇↲⃰)㧦
496㧙498(2008 ᐕ 3 ᦬)
53㧕 ㄭ⮮⋥ታ㧘ᷓየᢅᐘ㧘᧻੗᳗ሶ㧘㊄ሶ⧷㓶㧘Ꮉᧄ⟤ᄹሶ㧘Ꮉᧄౖ↢㧦ࠕ࡟࡞ࠡ࡯ᕈ∔ᖚߩ⊒∝࡮㊀∝ൻߩ੍⍮ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 19 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ಽᜂ⎇ⓥႎ๔ᦠ ╙ 2 ಽౠ(ᶏ⠧Ỉ⃰)㧦154㧙156(2008 ᐕ 3 ᦬)
54㧕 ㄭ⮮⋥ታ㧘Ꮉᧄ⟤ᄹሶ㧘ᄢ⷏⑲ౖ㧘᫪↰⑲ⴕ㧦ࠕ࠻ࡇ㧙ᕈ⊹⤏Ἳ⊒∝ߣᲣ੃ߩ㑐ㅪ㧘․ߦᲣ੃ᚑಽ
ߩ⸃ᨆߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 19 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ
੐ᬺ ಽᜂ⎇ⓥႎ๔ᦠ ╙ 2 ಽౠ(ᴡ㊁⃰)㧦200㧙202(2008 ᐕ 3 ᦬)
55㧕 ㄭ⮮⋥ታ㧘᧻੗᳗ሶ㧦ዊఽ᳇▤ᡰ༎ᕷߩᣧᦼ⸻ᢿ࡮ᣧᦼᴦ≮ߩᜰ㊎ߩ૞ᚑߣ⹏ଔ߅ࠃ߮᳇▤ᡰ༎ᕷߦ㑐ߔࠆㆮવሶ⸃ᨆ㧦ᐔᚑ 19 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ
੐ᬺ ಽᜂ⎇ⓥႎ๔ᦠ ╙ 2 ಽౠ(ᄢ↰⃰)㧦309㧙311(2008 ᐕ 3 ᦬)
11㧚ႎ㆏1㧕 ㄭ⮮⋥ታ㧦વᨴᕈ⤥∘∐(ߣ߮߭)߳ߩᣂߚߥࠕࡊࡠ࡯࠴‫߭߮ߣޟ‬ᴦ≮‫ࠍ⁁⃻ߩޠ‬⠨߃ࠆ㧦Acuatim
Forum in Gifu ᐳ⺣ળ 6(2006 ᐕ 1 ᦬ 1 ᣣ)
2㧕 ㋈ᧁᐽਯ㧦ጘ㒂ᄢቇකቇㇱකቇᢎ⢒㐿⊒⎇ⓥ࠮ࡦ࠲࡯(ో࿖౒ห೑↪ᣉ⸳)࡮කቇᢎ⢒ડ↹㐿⊒ቶ㧦කቇᢎ⢒ 37㧦54㧙55(2006 ᐕ 1 ᦬ 1 ᣣ)
3㧕 ㄭ⮮⋥ታ㧘㊄ሶ⧷㓶㧦‐੃࡮ᄢ⼺ࠕ࡟࡞ࠡ࡯‫ޟ‬㘩ߴߡᴦߔ‫ޠ‬㘩ຠ㐿⊒߳㧦ᦺᣣᣂ⡞(2006 ᐕ 1 ᦬ 13
ᣣ)4㧕 ㄭ⮮⋥ታ㧦ጘ㒂ᄢቇ㧘කቇㇱ㐳ㄭ⮮ᢎ᝼㧦ጘ㒂ᣂ⡞(2006 ᐕ 1 ᦬ 20 ᣣ)
5㧕 ㄭ⮮⋥ታ㧦ᬌᩏߢ⊒∝੍੍᷹㒐ߦലᨐ㧦⺒ᄁᣂ⡞(2006 ᐕ 2 ᦬ 9 ᣣ)
6㧕 ㄭ⮮⋥ታ㧦ߎߣߒߪߤ߁ߥࠆ㧫⧎☳∝ኻ╷ᦨ೨✢ ᣂ㞲⚵㧦ࠃߺ߁ࠅ࠹࡟ࡆ࠾ࡘ࡯ࠬࠬࠢ࡜ࡦࡉ࡞
(2006 ᐕ 2 ᦬ 24 ᣣ)
7㧕 ㄭ⮮⋥ታ㧦╙ 6 ࿁㘩‛ࠕ࡟࡞ࠡ࡯⎇ⓥળ ࠕ࠽ࡈࠖ࡜ࠠࠪ࡯෻ᔕߦ㑐ߔࠆ⎇ⓥᚑᨐ 㨪‐੃ࠕ࡟࡞ࠡ࡯㨪㉄⚛ಣℂࠍߒߚ‐੃ࡍࡊ࠴࠼ߦࠃࠅ఺∉ኡኈࠍ⺃ዉ㧦Medical Tribune(2006 ᐕ 3 ᦬ 23 ᣣ)
8㧕 ㄭ⮮⋥ታ㧘᧻੗᳗ሶ㧦ࠕ࡟࡞ࠡ࡯૕⾰ࠍㆮવሶߢ್ቯ㧦ਛ੩࠹࡟ࡆ࠾ࡘ࡯ࠬࡊ࡜ࠬ 1(2006 ᐕ 3 ᦬
28 ᣣ)
9㧕 ㄭ⮮⋥ታ㧘᧻੗᳗ሶ㧦ࠕ࡟࡞ࠡ࡯⚛࿃ߩㆮવሶᬌᩏࠠ࠶࠻ߩ㐿⊒ጘ㒂ᄢቇዊఽ∛ᘒቇ⎇ⓥࡊࡠࠫࠚࠢ࠻⚫੺㧦ጘᄢߩ޿߱߈(2006 ᐕ 4 ᦬ 1 ᣣ)
10㧕 ᷓየᢅᐘ㧦⎇ⓥቶ߆ࠄ㧦ጘ㒂ᣂ⡞(2006 ᐕ 4 ᦬ 4 ᣣ)
11㧕 ኹᧄ⾆⧷㧦ዊఽߗࠎߘߊᴦ≮ᴺࠍ⸃⺑㧦ᦺᣣᣂ⡞(2006 ᐕ 9 ᦬ 25 ᣣ)
12㧕 ㊄ሶ⧷㓶㧦ᢇᕆක≮ߦ߽ᓇ㗀 ஍࿷㧘࿾ၞᩰᏅ⸃ᶖ߇⺖㗴㧦⺒ᄁᣂ⡞(2006 ᐕ 11 ᦬ 8 ᣣ)
13㧕 ㄭ⮮⋥ታ㧦⚵❱࿑㧦ጘ㒂ᄢቇవ┵ഃ⮎⎇ⓥ࠮ࡦ࠲࡯ࡄࡦࡈ࡟࠶࠻(2006 ᐕ 12 ᦬)
14㧕 ㄭ⮮⋥ታ㧦කቇㇱߩ⃻⁁ߦߟ޿ߡ㧦ጘ㒂කቇળ㙚ߛࠃࠅ 82㧘3㧙5(2007 ᐕ 1 ᦬ 1 ᣣ)
15㧕 ㄭ⮮⋥ታ㧦ㇺᏒ஍࿷ ో࿖ࡢ࡯ࠬ࠻ 5 ૏㧦ጘ㒂  ᦺᣣᣂ⡞(2007 ᐕ 1 ᦬ 1 ᣣ)
16㧕 ㄭ⮮⋥ታ㧘᧻੗᳗ሶ㧦ߎߎ߹ߢࠊ߆ߞߚ⧎☳∝⎇ⓥᦨ೨✢㧦NHK ࠨࠗࠛࡦࠬ ZERO(2007 ᐕ 2 ᦬
13 ᣣ)
17㧕 ㄭ⮮⋥ታ㧦ጘ㒂ᄢߣㅪ៤㧘࿾ၞක≮ᡷༀ㧦ጘ㒂  ጘ㒂ᣂ⡞(2007 ᐕ 2 ᦬ 16 ᣣ)
18㧕 ㄭ⮮⋥ታ㧦㜞ጊߩකᏧਇ⿷ᢇ߃㧦ጘ㒂  ጘ㒂ᣂ⡞(2007 ᐕ 2 ᦬ 17 ᣣ)
19㧕 ㄭ⮮⋥ታ㧘᧻੗᳗ሶ㧦‫ޟ‬ᕆჇߔࠆࠕ࡟࡞ࠡ࡯ࠍస᦯ߖࠃ㨪⧎☳∝࡮ߗࠎᕷ ᴦ≮ᦨ೨✢㨪‫ޠ‬㧦NHK ࠢ
ࡠ࡯࠭ࠕ࠶ࡊ⃻ઍ(2007 ᐕ 3 ᦬ 8 ᣣ)
20㧕 ㄭ⮮⋥ታ㧦࿾ၞක≮කቇ࠮ࡦ࠲࡯⸳⟎㧦ጘ㒂  ⺒ᄁᣂ⡞(2007 ᐕ 4 ᦬ 25 ᣣ)
21㧕 ㄭ⮮⋥ታ㧦࿾ၞߩකᏧਇ⿷⸃ᶖࠍ ጘ㒂ᄢකቇㇱ ో࿖ೋ ࠮ࡦ࠲࡯㐿⸳㧦ጘ㒂  ਛᣣᣂ⡞(2007ᐕ 4 ᦬ 25 ᣣ)
22㧕 ㄭ⮮⋥ታ㧦ጘ㒂ᄢቇ㧘කቇ࠮ࡦ࠲࡯ᆎേ‫ޟ‬࿾ၞක≮ࠍᡰ߃ࠆ‫ޠ‬㧦ጘ㒂ᣂ⡞(2007 ᐕ 4 ᦬ 25 ᣣ)
23㧕 ㄭ⮮⋥ታ㧦ጘ㒂ᄢቇකቇㇱ කᏧਇ⿷⸃᳿ߩಾࠅᧅ㧦ਛ੩࠹࡟ࡆ ࡝ࠕ࡞࠲ࠗࡓ(2007 ᐕ 4 ᦬ 25 ᣣ)
24㧕 ㄭ⮮⋥ታ㧦කᏧਇ⿷⸃᳿ߦක≮࠮ࡦ࠲࡯⸳⟎㧦ጘ㒂᡼ㅍ ᄕ߇ߚደ࠹㧍(2007 ᐕ 4 ᦬ 25 ᣣ)
25㧕 ㄭ⮮⋥ታ㧦⋵࿾ၞක≮ኻ╷ද߇ೋળว㧦ጘ㒂ᣂ⡞(2007 ᐕ 4 ᦬ 27 ᣣ)
26㧕 ㄭ⮮⋥ታ㧦੐ᬺߩ⁁ᴫ ࡒ࡟࠾ࠕࡓ⸥ᔨ⾨ ᦨఝ⑲⎇ⓥ⾨㧦⽷࿅ᴺੱ᫪᳗ᄺ઀ળ ⸳┙ 50 ๟ᐕ⸥ᔨ⹹ 50 ᐕߩ޽ࠁߺ㧘20㧙21(2007 ᐕ 6 ᦬)㧙㧙27㧕 ㄭ⮮⋥ታ㧦ጘ㒂ᄢ,࿾ၞක≮කቇ࠮ࡦ࠲࡯ࠍ⸳⟎㧦ᢥᢎᣂ⡞(2007 ᐕ 6 ᦬ 13 ᣣ)
28㧕 ㄭ⮮⋥ታ㧦ጘ㒂ᄢቇ ࿾ၞක≮කቇ࠮ࡦ࠲࡯ࠍ⸳⟎㧦ᢥᢎ࠾ࡘ࡯ࠬ(2007 ᐕ 6 ᦬ 18 ᣣ)
29㧕 ㄭ⮮⋥ታ㧦කᏧਇ⿷ ⃻႐ߩദജ↢߆ߔ᡽╷ࠍ㧦ਛᣣᣂ⡞(2007 ᐕ 7 ᦬ 9 ᣣ)
30㧕 ኹᧄ⾆⧷㧦ࠕ࡟࡞ࠡ࡯ߣߘߩኻᔕ㧦᧲੩ TBS ࡜ࠫࠝ(2007 ᐕ 8 ᦬ 20㨪24 ᣣ)
31㧕 ㄭ⮮⋥ታ㧦ሶߤ߽ߩஜᐽ ࠹࡯ࡑߦ⻠Ṷ㧦⺒ᄁᣂ⡞(2007 ᐕ 10 ᦬ 12 ᣣ)
32㧕 ㊄ሶ⧷㓶㧦ዊఽᄛ㑆ක≮⠨߃ࠆ කᏧ㧘⋴⼔Ꮷࠄ߇⃻⁁ႎ๔㧦ጘ㒂ᣂ⡞(2007 ᐕ 10 ᦬ 12 ᣣ)
33㧕 ㄭ⮮⋥ታ㧦࿾ၞක≮⏕଻߳⺞ᩏ⎇ⓥ කᏧ㙃ᚑ㧘૕೙ࠍᢛ஻㧦ጘ㒂ᣂ⡞(2007 ᐕ 10 ᦬ 18 ᣣ)
34㧕 ㄭ⮮⋥ታ㧦ጘ㒂ᄢቇߦ⻠ᐳ㐿⸳ ⋵߇ነ㒝㊄ ࿾ၞߩ૕೙ࠍ⎇ⓥ㧦ਛᣣᣂ⡞(2007 ᐕ 10 ᦬ 18 ᣣ)
35㧕 ㄭ⮮⋥ታ㧦࿾ၞᨒផ⮈౉⹜ࠍ⺑᣿ ᧪ᐕᐲታᣉߩጘ㒂ᄢቇකቇㇱ㧦ਛᣣᣂ⡞(2007 ᐕ 11 ᦬ 6 ᣣ)
36㧕 ㄭ⮮⋥ታ㧦“ო”⿥߃ੱ᧚߿ࠅߊࠅ කᏧ⏕଻ᦨ೨✢ ਄㧦ਛᣣᣂ⡞(2007 ᐕ 12 ᦬ 13 ᣣ)
37㧕 ㄭ⮮⋥ታ㧦ጘ㒂ᄢ‫ޔ‬කቇㇱ࿾ၞᨒផ⮈౉⹜⺑᣿ળࠍ㐿௅㧦ᢥᢎㅦႎ(2007 ᐕ 12 ᦬ 14 ᣣ)
38㧕 ㄭ⮮⋥ታ㧦⃻⁁ᛂ㐿߳ᜰዉකᵷ㆜ කᏧ⏕଻ᦨ೨✢ ਅ㧦ਛᣣᣂ⡞(2007 ᐕ 12 ᦬ 15 ᣣ)
39㧕 ㄭ⮮⋥ታ㧦කᏧ⏕଻ߩ㆏ࠍᮨ⚝ ጘ㒂ᄢቇߢࠪࡦࡐࠫ࠙ࡓ㧦ਛᣣᣂ⡞(2007 ᐕ 12 ᦬ 16 ᣣ)
40㧕 ᧻੗᳗ሶ㧦ࠕ࡟࡞ࠡ࡯ᕈ∔ᖚߩ੍㒐ߦะߌߚ⢝ౝ࡮⢝ᄖ࿃ሶߩ⸃᣿㧦╙ 56 ࿁ᣣᧄࠕ࡟࡞ࠡ࡯ቇળ⑺ቄቇⴚᄢળ Medical Tribune㧚40㧘16(2007 ᐕ 1 ᦬ 4 ᣣ)
41㧕 Ꮉᧄౖ↢㧦̆ࠕ࡟࡞ࠡ࡯∔ᖚߣㆮવሶᄙဳ̆ LTC4S A-444C ߦᄌ⇣ࠍᜬߟ⟲ߢ᳇▤ᡰ༎ᕷߩ᦭∛₸㜞޿㧦╙ 19 ࿁ᣣᧄࠕ࡟࡞ࠡ࡯ቇળᤐቄ⥃ᐥᄢળ․㓸 Medical Tribune㧚2㧘104(2007 ᐕ 7 ᦬ 19
ᣣ)42㧕 ㄭ⮮⋥ታ㧦↢ᵴⅣႺ〯߹߃⸻ᢿ ๮ࠍߟߥߋ࡮ጘ㒂ߩක≮⃻႐߆ࠄ㧦ጘ㒂  ጘ㒂ᣂ⡞(2008 ᐕ 1
᦬ 4 ᣣ)
43㧕 ㄭ⮮⋥ታ㧦ၮ␆කቇ⎇ⓥ㒮↢ߦᅑቇ㊄㧦ጘ㒂  ጘ㒂ᣂ⡞(2008 ᐕ 1 ᦬ 8 ᣣ)
44㧕 ㄭ⮮⋥ታ㧦ၮ␆කቇ⎇ⓥ⠪ᷫዋߦᱤᱛ߼ ጘᄢ߇ኾ᡹㒮↢ߦᅑቇ㊄㧦ጘ㒂  ਛᣣᣂ⡞(2008 ᐕ 1
᦬ 8 ᣣ)
45㧕 ㄭ⮮⋥ታ㧘ᄢ⷏⑲ౖ㧦ࠕ࡟࡞ࠡ࡯∔ᖚߩಽሶ↢‛ቇ ̆⥃ᐥߦ⽸₂ߔࠆᦨㄭߩ⎇ⓥᚑᨐߣㆮવሶᄙ
ဳ̆㧦Medical Tribune㧚41㧘31(2008 ᐕ 2 ᦬ 7 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔ✚ว⊛ߦߪߘࠇߥࠅߩ⹏ଔߪߢ߈ࠆ‫੹ޕ‬ᓟ߽ᒁ߈⛯߈⎇ⓥᚑᨐߣᬺ❣ߩᦝߥࠆ⛽ᜬ㧘ะ਄߇ᦸ߹ࠇࠆ‫ޕ‬ᰴ਎ઍࠍᜂ߁⧯ᚻ⎇ⓥ⠪㧘⧯ᚻዊఽ⑼කߩ⢒ᚑߦജࠍ౉ࠇߡ޿ࠆߎߣߪ⹏ଔߦ୯ߔࠆ‫ߦࠄߐޕ‬ᒝൻߒߚ޿‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ᦨᄢߩ໧㗴ὐߪ⎇ⓥቶߩࠬࡍ࡯ࠬ߇⁜ዊߢ޽ߞߚ߇ 2004 ᐕ 4 ᦬ߩකቇㇱ⒖ォ⛔วߦࠃࠅ✭๺ߐࠇߚ‫ޕ‬ᄢቇ㒮ߩ౉ቇߪᲤᐕ 4㨪5 ੱߢ㧘ዊఽ∛ᘒቇߩᄢቇ㒮↢ߪోቇᐕ޽ࠊߖߡᏱߦ 20 ੱ೨ᓟߢ޽ࠆ‫ోޕ‬㗔ၞࠍࠞࡃ࡯ߔࠆዊఽ⑼ߩ⥃ᐥ߆ࠄࠊ߈಴ࠆ⇼໧ߣ࠹࡯ࡑߩోߡߦ⌕ᚻߔࠆߎߣߪ࿎㔍ߢ޽ࠆ߇㧘ࠕ࡟࡞ࠡ࡯࡮఺∉࡮ઍ⻢ߦട߃ߡⅣႺ߿ᗵᨴߣㆮવሶߩࠃ߁ߥᣂߚߥࡊࡠࠫࠚࠢ࠻ࠍ┙ߜ਄ߍߡㅴ߼ߡ޿ࠆ‫ޕ‬੹ᓟߩዷᦸ⃻࿷ߩ࠹࡯ࡑߣᣇะᕈߩᦝߥࠆలታߣ᜛ᄢ‫ߦࠄߐޕ‬㧘ߎࠇࠄߩᚑᨐࠍක≮ߦ⋥ធ⊛ߦᔕ↪ߔࠆ㧔࠻࡜㧔࿑ 1㧕ߣోኈ㧔㧔࿑ 2㧕ߣᣂ⡞ႎ㆏㧔࿑ 3㧕ࠍࡦࠬ࡟࡯࡚ࠪ࠽࡞࡝ࠨ࡯࠴㧕‫⃻ޕ‬࿷߹ߢߩ⎇ⓥߩਥߥᵹࠇ㧔࿑␜ߔࠆ‫̌ޕ‬࿾⃿ߣ࿾ၞߦะߌߚఝࠇߚකቇ⎇ⓥ⠪ߣࠃࠅࠃ޿කᏧߩ⢒ᚑߣታ〣̍ࠍ⋡ᮡߦߒߡ޿ࠆ‫ޕ‬

㧙㧙

㧙㧙

㧙㧙

㧔8㧕∛ᘒᖱႎ⸃ᨆකቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
1㧕࡝ࡐⰮ⊕ઍ⻢ߣേ⣂⎬ൻࠦ࡟ࠬ࠹ࡠ࡯࡞ૐਅ⮎ߢ޽ࠆ HMGCoA reductase 㒖ኂ೷ߢ޽ࠆ޿ࠊࠁࠆࠬ࠲࠴ࡦ♽⮎೷ߩ೽૞↪ߢ޽ࠆᮮ⚉╭Ⲣ⸃∝ߣㆮવሶᄙဳߣߩ㑐ㅪᕈߦߟ޿ߡᬌ⸛ߒ㧘ߐࠄߦ೽૞↪⊒∝ᯏᐨߩ⸃᣿‫ޕ‬
2㧕ࡊࡠ࠹ࠝ࡯ࡓ⸃ᨆ
⒳‫∔ޘ‬ᖚߦ߅ߌࠆⴊᷡࠍ⸃ᨆߒ㧘∛ᘒࠍ෻ᤋߔࠆᣂߒ޿ࡑ࡯ࠞ࡯ࠍ⷗޿಴ߒหቯߔࠆ‫ޕ‬
3㧕⢄Ἳ⊒∝ᯏᐨ
CH-B㧔B ဳᘟᕈ⢄Ἳ㧕ߦ߅ߌࠆ Impaired CTL proligeration ߩᯏᐨߩ⸃᣿㧘෸߮ IDO ߩ⢄Ἳ⊒∝ߦ߅ߌࠆᓎഀ‫ޕ‬
4㧕⢄⚦⢩ࠕࡐ࠻࡯ࠪࠬ߅ࠃ߮✢⛽ൻᯏᐨߦߟ޿ߡ
േ‛ࡕ࠺࡞ࠍ↪޿ߡ㧘ಽሶ↢‛ቇ⊛⷗࿾߆ࠄࠕࡐ࠻࡯ࠪࠬ߅ࠃ߮✢⛽ൻࠍ⹏ଔ‫ޕ‬
5㧕ᔃ╭⚦⢩ߦ߅ߌࠆࠝ࡯࠻ࡈࠔࠫ࡯
ࠝ࡯࠻ࡈࠔࠫ࡯ߩᓎഀߣᔃᯏ⢻ߦਈ߃ࠆᓇ㗀ࠍ⛘㘩߅ࠃ߮ᔃ╭᪪Ⴇࡕ࠺࡞ࠍ↪޿ߡᬌ⸛‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦

ᷡፉ ḩ
દ⮮ᒄᐽ
ᄢỈ㓁੺
㊄᫪ኡల

Mitsuru Seishima
Hiroyasu Ito
Yousuke Osawa
Hiromitsu Kanamori3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ᷡፉ ḩ㧘᦯ㇱ㜞ᐘ㧘㗇⮮㚅❱㧚࡝ࡐⰮ⊕ߣߘߩಽ↹㧦ਛ੗೑ᤘ✬㓸㧚‫ޟ‬ᬌᩏ୯ߩߺ߆ߚ‫́ޠ‬㧘᧲੩㧦ਛᄖකቇ␠㧧2006 ᐕ㧦173㧙176㧚
2㧕 ᷡፉ ḩ㧘㜞ᯅ㚅ᄹሶ, ᦯ㇱ㜞ᐘ㧚p(a)㧦ਛ੗೑ᤘ✬㓸㧚́‫ޟ‬ᬌᩏ୯ߩߺ߆ߚ‫́ޠ‬㧘᧲੩㧦ਛᄖකቇ␠㧧2006ᐕ㧦177㧙179.
3㧕 ᷡፉ ḩ㧘Ꮭ૒శᵗ, 㜞ᯅ㚅ᄹሶ㧚Lp(a)㧦ਛ੗೑ᤘ✬㓸.́ࠕࡐⰮ⊕ߣߘߩಽ↹́㧘᧲੩㧦ਛᄖකቇ␠㧧2006
ᐕ㧦187㧙189.
4㧕 ᷡፉ ḩ㧘ⁿ⁚ ᷕ㧚ਛේ৻ᒾ✬㧚‫ޟ‬ᮡḰ⥃ᐥᬌᩏකቇ ╙ 3 ‫ޠ‬㧘᧲੩㧦කቇᦠ㒮㧧2006 ᐕ㧦168㧙180.
5㧕 Ỉ᧛ᴦ᮸㧚ਃ㡞ᑝ❥✬㧚ᓸ↢‛ฦ⺰‫ޟ‬Microbial Handbook‫ޠ‬, 㔚ㅢࠨ࠼࡜࡯࡮ࠕࡦ࠼࡮߳ࡀࠪ࡯ᩣᑼળ␠㧧2007 ᐕ㧦5㧙76.
6㧕 ᷡፉ ḩ㧘ᰞᨋ㇚ਯ੺㧚ᾢဈ৻ᚑ⋙ୃ㧚࡝ࡐⰮ⊕ ߶߆ 12 㗄⋡㧘⥃ᐥᬌᩏ㗄⋡ㄉౖ㧘᧲੩㧦කᱤ⮎಴ ᩣᑼળ␠㧧2008 ᐕ㧦237㧙245.
7㧕 ㊄᫪ኡల㧘ᷡፉ ḩ㧚ᔃᯏ⢻ᬌᩏ㧦Ꮟ ౖਯ⋙ୃ㧚✕ᕆኻಣࠟࠗ࠼ࡉ࠶ࠢ㧘㊄⧐ၴ㧧2008 ᐕ㧦163㧙165.
8㧕 ㊄᫪ኡల㧘ᷡፉ ḩ㧚ᔃࠛࠦ࡯㧦Ꮟ ౖਯ⋙ୃ㧚✕ᕆኻಣࠟࠗ࠼ࡉ࠶ࠢ㧘㊄⧐ၴ㧧2008 ᐕ㧦166㧙167.
9㧕 ┻᧛ᱜ↵㧘ᷡፉ ḩ㧚⣲≌ࡑ࡯ࠞ࡯㧦ਅ᧦ᢥᱞ✬㓸㧚ࡔ࠺ࠖࠞ࡞ࡁ࡯࠻‫ޟ‬ᬌᩏߩၮᧄ‫ޠ‬㧘⷏᧛ᦠᐫ㧧2008ᐕ㧦59㧙65.
10㧕 Ỉ᧛ᴦ᮸㧚ᄢቇᬌᩏ⑼ቇኾ᡹ᓸ↢‛ቇᢎຬᙣ⺣ળ✬㧚૕⴫ㇱᗵᨴ∝‫ࠬࡦࠛࠗࠨ࡞ࠞࠖ࠺ࡔޟ‬ᓸ↢‛ᬌᩏቇ‫ޠ‬㧘ㄭઍ಴ 㧧2008 ᐕ㧦269㧙277.
⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 ⮮၂⧷༹㧘ᢧ⮮㇌᣿㧚࠻࡝ࡊ࠻ࡈࠔࡦઍ⻢㉂⚛ߩ⠡⸶ᓟୃ㘼㧘ᔅ㗇ࠕࡒࡁ㉄⎇ⓥ 2006 ᐕ㧧176 Ꮞ㧦20
㧙26.
2㧕 ᄥ↰ᶈᢅ㧚ᬌᩏઃടଔ୯ᖱႎߩឭଏ㧘ᬌᩏߣᛛⴚ 2007 ᐕ㧧35 Ꮞ㧦479㧙480㧚
3㧕 ┻᧛ᱜ↵㧘ᢧ⮮㇌᣿㧚㑐▵࡝࠙ࡑ࠴ᬌᩏ࡮⸻≮ߩᣂዷ㐿㧘Medical Technology 2008 ᐕ㧧36 Ꮞ㧦27㧙30.
4㧕 ᤊ 㓷ੱ㧚⥃ᐥᬌᩏ Yearbook 2008 ৻⥸ᬌᩏ✬㧘⥃ᐥ∛ℂ࡟ࡆࡘ࡯․㓸 2008 ᐕ㧧140 ภ㧦167㧙169.
5㧕 ᄢỈ㓁੺㧘ᧃᰴ ᷕ㧘Ⴆ↰⦟ᒾ㧘᳗ᧁᱜੳ㧘᫪⣁ਭ㓉㧚⢙▤⚿⚤ߦࠃࠅ⺃ዉߐࠇߚᘟᕈ⢄㓚ኂࡑ࠙ࠬࡕ࠺
࡞ߦ߅ߌࠆࠕࡐ࠻࡯ࠪࠬ₪ᓧᯏᐨ㧘Minophagen medical review 2008 ᐕ㧧53㧦123㧙125.
6㧕 ᷡፉ ḩ㧚․㓸 ․ቯஜ⸻೙ᐲ ․ቯஜ⸻ߦ߆߆ࠊࠆᬌᩏߣᗧ⟵㧘ஜᐽ㘩ຠ▤ℂ჻⹺ቯදળળႎ 2008 ᐕ㧧
3 Ꮞ㧦11㧙20.
✚⺑㧔᰷ᢥ㧕
1㧕 Osawa Y, Nagaki M. Cyclooxygenase-2: its paradoxical roles in liver inflammation and fibrosis.

㧙㧙Hepatol Res. 2008;38:772-774.
ේ⪺㧔๺ᢥ㧕
1㧕 Ꮉἑ᥍⟤㧘೨↰ ቇ㧘ᵢ੗ବᄦ㧘๺↰ਭᵏ㧘ർፉᐽ㓶㧘ᷡፉ ḩ㧚ᔃᜉᄌേ߆ࠄߺߚోりᕈᒝ⊹∝ߩ⥄ᓞ␹⚻ᯏ⢻㧘⥃ᐥ∛ℂ 2006 ᐕ㧧54 Ꮞ㧦325㧙328.
2㧕 Ꮉἑ᥍⟤㧘ᣧᎹᕶᳯ㧘ട⮮⟵ᒄ㧘᧻ጟᢅ↵㧘ᷡፉ ḩ㧚╭ࠫࠬ࠻ࡠࡈࠖ࡯ᖚ⠪ߦ߅ߌࠆᔃቶᕈᦼᄖ෼❗ߩ㊀∝ᐲಽ㘃ߣฦ⒳ࡄ࡜ࡔ࡯࠲ᬌᩏ⚿ᨐߩ㑐ଥᬌ⸛㧘කቇᬌᩏ 2006 ᐕ㧧55 Ꮞ㧦639㧙643.
3㧕 ᄢᯅ⪲ᵤᏗ㧘ᄥ↰ᶈᢅ㧘ฎ↰િⴕ㧘⍹ጊߣߒሶ㧘᦯ㇱ㜞ᐘ㧘㐳ደ᣽ᐘ㧘ਣᧄ㓷ᄦ㧘೨↰ᖗม㧘┻᧛ᱜ↵㧘ᷡፉ ḩ㧚࡝ࠦࡦࡆ࠽ࡦ࠻ TP ᛫ේࠍ↪޿ߚ᪢Ქᬌᩏߩᬌ⸛ ́ᣣ┙ 7170 ᒻಽᨆⵝ⟎߳ߩᔕ↪㧘ක≮ߣᬌᩏᯏེ࡮⹜⮎ 2006 ᐕ㧧29 Ꮞ㧦603㧙607.
4㧕 ᄥ↰ᶈᢅ㧘┻᧛ᱜ↵㧘ฎ↰િⴕ㧘ਛየ⌀ℂ㧘ዊᳰ♿ሶ㧘᦯ㇱ㜞ᐘ㧘ᢧ⮮ᄢテ㧘⑺ጊ⋿Ẵ㧘ᷡፉ ḩ㧚㜞ᗵᐲൻቇ⊒శ㉂⚛఺∉᷹ቯᴺߦࠃࠆ interleukin-8 (IL-8) ᷹ቯߩ⥃ᐥ⊛᦭↪ᕈߦߟ޿ߡ㧘කቇߣ⮎ቇ 2006ᐕ㧧55 Ꮞ㧦437㧙442.
5㧕 ྾ᚭ㓉ၮ㧘૒⮮ᱜᄦ㧘┻᧛ᱜ↵㧘ᢧ⮮㇌᣿㧘ᷡፉ ḩ㧚᛫૕⺃ዉࡑ࠙ࠬ㑐▵Ἳࡕ࠺࡞ߦ߅ߌࠆࠨࠗ࠻ࠞࠗ
ࡦߩᄌേ㧘ਛㇱ࡝࠙ࡑ࠴ 2006 ᐕ㧧37 Ꮞ㧦8㧙9.
6㧕 ૒⮮ᱜᄦ㧘྾ᚭ㓉ၮ㧘㚍႐ጪᔒ㧘ⷺ↰ ᕡ㧘┻᧛ᱜ↵㧘ᢧ⮮㇌᣿㧘ᷡፉ ḩ㧚㑐▵࡝࠙ࡑ࠴⤒㑐▵ਛߩ᛫
CCP ᛫૕᷹ቯߩᗧ⟵㧘⥃ᐥ࡝࠙ࡑ࠴ 2006 ᐕ㧧18 Ꮞ㧦158㧙162.
7㧕 ૒⮮ᱜᄦ㧘྾ᚭ㓉ၮ㧘㚍႐ጪᔒ㧘ⷺ↰ ᕡ㧘┻᧛ᱜ↵㧚⤒㑐▵ᶧਛߩ Cartilage Oligomeric Matrix ProteinỚᐲߩ᷹ቯ㧘ਛㇱ࡝࠙ࡑ࠴ 2006 ᐕ㧧37 Ꮞ㧦76㧙77.
8㧕 ૒⮮ᱜᄦ㧘྾ᚭ㓉ၮ㧘㚍႐ጪᔒ㧘ⷺ↰ ᕡ㧘┻᧛ᱜ↵㧚㑐▵࡝࠙ࡑ࠴ߦኻߔࠆࠛ࠲ࡀ࡟࠮ࡊ࠻ߩᛩਈ࿁ᢙ
ߣ቟ోᕈ㧘᦭ലᕈߦ㑐ߔࠆᬌ⸛㧘ਛㇱᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2006 ᐕ㧧49 Ꮞ㧦923㧙924㧚
9㧕 ᧻ᯅᑧᄈ㧘౎ᐈ๺ᙗ㧘ᳰ੉↱㚅㧘᪀ේ⑲ᰴ㧘┻᧛ᱜ↵㧘᧛਄໪㓶㧘⼾↰ ᴰ㧘ዊୖ⌀ᴦ㧚-Dࠣ࡞ࠞࡦ୯
ࠍᜰᮡߣߒߚᷓ࿷ᕈ⌀⩶∝ߦኻߔࠆࡒࠞࡈࠔࡦࠡࡦߩ᦭ലᕈߩᬌ⸛㧘ᣣ㓸ਛක⹹ 2007 ᐕ㧧14 Ꮞ㧦77㧙
80㧚
10㧕 ᧻Ꮉᵗሶ㧘ችㇱ㜞ౖ㧘Ỉ᧛ᴦ᮸㧘Ყཅ⟤਽ሶ㧘ጊᩮ⺈ਭ㧘ᶆᐩᗲሶ㧘㆙⮮㓉৻㧚⍴ᦼ㑆(6 ᤨ㑆)೨ၭ㙃ߒߚ
Haemophilis influenzae ࠍ⹜㛎ኻ⽎ߣߔࠆో⥄േ⚦⩶ᬌᩏⵝ⟎࡜ࠗࠨࠬߢߩ⮎೷ᗵฃᕈ⹜㛎ߩㆡᱜൻ㧙ⶄᢙᣉ⸳ߢߩ౒ห⹏ଔ㧘⥃ᐥ∛ℂ 2007 ᐕ㧧55 Ꮞ㧦611㧙618㧚
11㧕 ᦯ㇱ㜞ᐘ㧘┻᧛ᱜ↵㧘ട⮮ೣᑝ㧘ጊ↰㋕਽㧘౷↰ᩕ৻㧘೨↰ᖗม㧘દ⮮ᒄᐽ㧘ᢧ⮮㇌᣿㧘ᷡፉ ḩ㧚㜞ಽ
ሶ㊂ࠕ࠺ࠖࡐࡀࠢ࠴ࡦ᷹ቯߦ㑐ߔࠆၮ␆⊛ᬌ⸛㧘ක≮ߣᬌᩏᯏེ࡮⹜⮎ 2007 ᐕ㧧30 Ꮞ㧦499㧙503.
12㧕 ૒⮮ᱜᄦ㧘┻᧛ᱜ↵㧘྾ᚭ㓉ၮ㧘ᢧ⮮㇌᣿㧘ᷡፉ ḩ㧚㑐▵࡝࠙ࡑ࠴ߦኻߔࠆ TNF- ࠍᮡ⊛ߣߒߚ↢‛ቇ⊛⵾೷ᴦ≮㧘Biotherapy 2007 ᐕ㧧21 Ꮞ㧦176㧙180㧚
13㧕 ૒⮮ᱜᄦ㧘྾ᚭ㓉ၮ㧘┻᧛ᱜ↵㧘㚍႐ጪᔒ㧘ⷺ↰ ᕡ㧚ࠨࠗ࠻ࠞࠗࡦỚᐲ߆ࠄߺߚ㑐▵࡝࠙ࡑ࠴ߦኻߔࠆ
ࠗࡦࡈ࡝ࠠࠪࡑࡉߩ⥃ᐥലᨐ㧘ਛㇱᢛἴ⹹ 2007 ᐕ㧧50 Ꮞ㧦633㧙634㧚
14㧕 ૒⮮ᱜᄦ㧘྾ᚭ㓉ၮ㧘㚍႐ጪᔒ㧘ⷺ↰ ᕡ㧘┻᧛ᱜ↵㧚㑐▵࡝࠙ࡑ࠴ߦኻߔࠆࠛ࠲ࡀ࡞࠮ࡊ࠻ߩᛩਈ࿁ᢙ
ߣ᦭ലᕈ‫ޔ‬቟ోᕈߦߟ޿ߡ㧘ਛㇱ࡝࠙ࡑ࠴ቇળ 2007 ᐕ㧧38 Ꮞ㧦24㧙25㧚
15㧕 ૒⮮ᱜᄦ㧘྾ᚭ㓉ၮ㧘┻᧛ᱜ↵㧘ᢪ⮮㇌᣿㧘ᷡፉ ḩ㧚㑐▵࡝࠙ࡑ࠴ߦኻߔࠆࠛ࠲ࡀ࡞࠮ࡊ࠻ߩᛩਈ࿁ᢙ
ߩᬌ⸛㧘⥃ᐥ࡝࠙ࡑ࠴ቇળ 2007 ᐕ㧧19 Ꮞ㧦164㧙169㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Fujigaki H, Saito K, Lin F, Fujigaki S, Takahashi K, Martin BM, Chen CY, Masuda J, Kowalak J,
Takikawa O, Seishima M, Markey SP. Nitration and inactivation of IDO by peroxynitrite. J Immunol.
2006;176:372-379.
2㧕 Zhu Y, Saito K, Murakami Y, Asano M, Iwakura Y, Seishima M. Early increase in mRNA levels ofpro-inflammatory cytokines and their interactions in the mouse hippocampus after transient global
ischemia. Neurosci Lett. 2006;393:122-126.
3㧕 Kawamoto N, Kaneko H, Takemura M, Seishima M, Sakurai S, Fukao T, Kasahara K, Iwasaki S,
and Kondo N. Age-related changes in intracellular cytokine profiles and Th2 dominance in allergic
children. Pediatr Allergy and Immunol. 2006;17:125-133.
4㧕 Fujigaki H, Saito K, Fujigaki S, Takemura M, Sudo K, Ishiguro H, Seishima M. The signal transducer
and activator of trenscription 1 and interferon regulatory factor 1 are not essential for the inductionof indoleamine 2,3-dioxygenase by lipopolysaccharide: involvement of p38 mitogen-activated protein
kinase and nuclear factor-B pathways, and synergistic effect of several proinflammatory cytokines. J
Biochem. 2006;139:655-662.
5㧕 Goto N, Tsurumi H, Takemura M, Hara T, Sawada M, Kasahara S, Kanemura N, Yamada T, Shimizu
M, Takahashi T, Tomita M, Seishima M, Takami T, Moriwaki H. Serum-soluble tumor factor receptor 2(sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin’s lymphoma.
Eur J Haematol. 2006;77:217-225.
6㧕 Cen X, Nitta A, Ohya S, Zhao Y, Ozawa N, Mouri A, Ibi D, Wang L, Suzuki M, Saito K, Ito Y, Kawagoe
T, Noda Y, Ito Y, Furukawa S, Nabeshima T. An analogue of dipeptide-like structure of FK506
increases GDNF expression through CREB activated by Hsp90/Akt signaling pathway. J Neurosci.
2006;26:3335-3344.
7㧕 Niwa M, Nitta A, Yamada Y, Nakajima A, Saito K, Seishima M, Shen L, Noda Y, Furukawa S,
Nabeshima T. An inducer for glial cell line-derived neurotrophic factor and tumor necrosis factor-alpha㧙㧙

IF 6.068

IF 2.085

IF 2.454

IF 2.020

IF 2.163

IF 7.490

protects against methamphetamine-induced rewarding effects and sensitization. Biol Psychiatry.
2007;61:890-901.
8㧕 Li Y, Takemura G, Okada H, Miyata S, Kanamori H, Maruyama R, Esaki M, Li L, Ogino A, Ohno T,
Kondo T, Nakagawa M, Minatoguchi S, Fujiwara T, Fujiwara H. ANG II type 1A receptor signaling
causes unfavorable scar dynamics in the postinfarct heart. Am J Physiol Heart Circ Physiol.
2007;292:946-953.
9㧕 Li Y, Takemura G, Okada H, Miyata S, Maruyama R, Esaki M, Kanamori H, Li L,Ogino A, Ohno T,
Kondo T, Nakagawa M, Minatoguchi S, Fujiwara T, Fujiwara H. Molecular signaling mediated byangiotensin II type 1A receptor blockade leading to attenuation of renal dysfunction-associated heart
failure. J Card Fail. 2007;13:155-62.
10㧕 Niwa M, Nitta A, Yamada Y, Nakajima A, Saito K, Seishima M, Shen L, Noda Y, Furukawa S,
Nabeshima T. An inducer for glial cell line-derived neurotrophic factor and tumor necrosis factor-alphaprotects against methamphetamine-induced rewarding effects and sensitization. Biol Psychiatry.
2007;61:890-901.
11㧕 Kanamori H, Takemura G, Li Y, Okada H, Maruyama R, Aoyama T, Miyata S, Esaki M, Ogino A,
Nakagawa M, Ushikoshi H, Kawasaki M, Minatoguchi S, Fujiwara H. Inhibition of Fas-associatedapoptosis in granulation tissue cells accompanies attenuation of postinfarction left ventricularremodeling by olmesartan. Am J Physiol Heart Circ Physiol. 2007;292:2184-2194.
12㧕 Li L, Takemura G, Li Y, Miyata S, Esaki M, Okada H, Kanamori H, Ogino A, Maruyama R, Nakagawa
M, Minatoguchi S, Fujiwara T, Fujiwara H. Granulocyte colony-stimulating factor improves left
ventricular function of doxorubicin-induced cardiomyopathy. Lab Invest. 2007;87:440-455.
13㧕 Takahashi K, Saito K, Masuda J, Fujigaki S, Takemura M, Ito H, Seishima M.Changes in neuronalprotein expression in LP-BM5-infected mice. Neurosci Lett. 2007;422:114-118.
14㧕 Aoki M, Fukao T, Kaneko H, Mizunaga S, Mitsuyama J, Sawamura H, Seishima M, Kondo N.Clinicaland bacteriological evaluation of the efficacy of piperacillin in children with pneumonia. J InfectChemother. 2007;13:224-229.
15㧕 Niwa M, Nitta A, Yamada Y, Nakajima A, Saito K, Seishima M, Noda Y, Nabeshima T. Tumor necrosis
factor-alpha and its inducer inhibit morphine-induced, Rewarding effects and sensitization. Biol
Psychiatry. 2007;62:658-668.
16㧕 Ogino A, Takemura G, Kanamori H, Okada H, Maruyama R, Miyata S, Esaki M, Nakagawa M,
Aoyama T, Ushikoshi H, Kawasaki M, Minatoguchi S, Fujiwara T, Fujiwara H. Amlodipine inhibits
granulation tissue cell apoptosis through reducing calcineurin activity to attenuate postinfarction
cardiac remodeling. Am J Physiol Heart Circ Physiol. 2007;293:2271-2280.
17㧕 Kimura A, Sakurai T, Tanaka Y, Hozumi I, Takahashi K, Takemura M, Saito K, Seishima M, Inuzuka
T. Proteomic analysis of autoantibodies in neuropsychiatric systemic lupus erythematosus patientwith white matter hyperintensities on brain MRI. Lupus. 2008;17:16-20.
18㧕 Shinohe R, Sato M, Takemura M, Shimizu K, Koishi H , Tanaka R, Saito K, Seishima M. Cytokine
profiles in mice with arthritis induced by anti-type II collagen monoclonal antibody plus
lipopolysaccharide. Jpn J Clin Chem. 2008;37:53-62.
19㧕 Kajita K, Mune T, Ikeda T, Matsumoto M, Uno Y, Sugiyama C, Matsubara K, Morita H, Takemura M,
Seishima M, Takeda J, Ishizuka T. Effect of fasting on PPARgamma and AMPK activity in adipocytes.
Diabetes Res Clin Pract. 2008;81:144-149.
20㧕 Sakashita F, Osada S, Takemura M, Imai H, Tomita H, Nonaka K, Takahashi T, Seishima M. The
effect of p53 gene expression on the inhibition of cell proliferation by paclitaxel. Cancer ChemotherPharmacol. 2008;62:379-385.
21㧕 Maruyama R, Goto K, Takemura G, Ono K, Nagao K, Horie T, Tsujimoto A, Kanamori H, Miyata S,
Ushikoshi H, Nagashima K, Minatoguchi S, Fujiwara T, Fujiwara H. Morphological and biochemical
characterization of basal and starvation-induced autophagy in isolated adult rat cardiomyocytes. Am J
Physiol Heart Circ Physiol. 2008;295:H1599-607.
22㧕 Nakagawa M, Takemura G, Kanamori H, Goto K, Maruyama R, Tsujimoto A, Ohno T, Okada H, Ogino
A, Esaki M, Miyata S, Li L, Ushikoshi H, Aoyama T, Kawasaki M, Nagashima K, Fujiwara T,
Mintoguchi S, Fujiwara H. Mechanisms by which late coronary reperfusion mitigates post infarction
cardiac remodeling. Circ Res. 2008;103:98-106.
23㧕 Okada H, Takemura G, Li Y, Ohno T, Li L, Maruyama R, Esaki M, Miyata S, Kanamori H, Ogino A,
Nakagawa M, Minatoguchi S, Fujiwara T, Fujiwara H. Effect of a long-term treatment with a low dose
granulocyte colony-stimulating factor on post-infarction process in the heart. J Cell Mol Med.
2008;12:98-106.
24㧕 Taguchi A, Hara A, Saito K, Hoshi M, Niwa M, Seishima M, Mori H. Localization and spatiotemporal
expression of IDO following transient forebrain ischemia in gerbils. Brain Res. 2008;1217:78-85.
25㧕 Chousa M, Ito H, Saito K, Takahashi K, Takemura M, Takahashi T, Tomita E, Seishima M. The
measurement of serum ceruloplasmin is useful for diagnostic differentiation of immune
thrombocytopenic purpura. Clin Chim Acta. 2008;389:132-138.
26㧕 Ito H, Ando K, Ishikawa T, Nakayama T, Taniguchi M, Saito K, Imawari M, Moriwaki H, Yokochi T,㧙㧙

IF 8.456

IF 3.973

IF 3.067

IF 8.456

IF 3.973

IF 4.479
IF 2.085

IF 8.456

IF 3.973

IF 2.248

IF 1.823

IF 2.568

IF 3.973

IF 9.721

IF 6.807
IF 2.218

IF 2.601

Kakumu S, Seishima M. Role of Valpha14+ NKT cells in the development of Hepatitis B virus-specific
CTL: activation of Valpha14+ NKT cells promotes the breakage of CTL tolerance. Int Immunol.
2008;20:869-879.
IF 3.290
27㧕 Sudo K, Yamada Y, Saito K, Shimizu S, Ohashi H, Kato T, Moriwaki H, Ito H, Seishima M. TNF-alphaand IL-6 signals from the bone marrow derived cells are necessary for normal murine liver
regeneration. Biochim Biophys Acta. 2008;1782:671-679.
IF 4.0414㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦ᷡፉ ḩ㧘⎇ⓥಽᜂ⠪㧦ᢪ⮮㇌᣿㧘๺↰ਭᵏ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(B)㧦
2 ᰴర࠽ࡁ LC/MS ࠍ↪޿ߚ⥄Ꮖ఺∉∔ᖚߩ∛ᘒ⸃ᨆࠪࠬ࠹ࡓߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 17㧙19 ᐕᐲ㧧
14,400 ජ౞(5,500㧦5,200㧦3,700 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦ᢪ⮮㇌᣿㧧ᐔᚑ 18 ᐕᐲጘ㒂ᄢቇᵴᕈൻ⚻⾌㧦఺∉ᕈ␹⚻∔ᖚߦ߅ߌࠆᣂߚߥ఺∉೙ᓮ࿃ሶߣߒߡߩ Indoleamine-2,3-dioxygenase ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18 ᐕᐲ㧧1,200 ජ౞3㧕 ⎇ⓥઍ⴫⠪㧦┻᧛ᱜ↵㧘⎇ⓥಽᜂ⠪㧦ᷡፉ ḩ㧘ᢪ⮮㇌᣿, ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦
ࠬ࠲࠴ࡦߦࠃࠆᮮ⚉╭Ⲣ⸃⊒∝ߩࡔࠞ࠾࠭ࡓߩ⸃᣿ߣㆮવሶᬌᩏࠍ↪޿ߚ੍᷹ᴺߩ⏕┙㧧ᐔᚑ 18㧙
19 ᐕᐲ㧧3,500 ජ౞(1,800㧦1,700 ජ౞)
4㧕 ⎇ⓥઍ⴫⠪㧦ᄢỈ㓁੺㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦ᘟᕈ⢄㓚ኂߦ߅ߌࠆࠬࡈࠖࡦࠧ⢽⾰ࠪࠣ࠽࡞ߩ⢄⚦⢩ߩ↢ᱫ᳿ቯᯏᐨߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 19㧙20 ᐕᐲ㧧3,300 ජ౞(1,800㧦1,500 ජ౞)5㧕 ⎇ⓥઍ⴫⠪㧦દ⮮ᒄᐽ㧧ᐔᚑ 20 ᐕᐲጘ㒂ᄢቇᵴᕈൻ⚻⾌㧦⢄⚦⢩㓚ኂߦ߅ߌࠆ࠻࡝ࡊ࠻ࡈࠔࡦઍ⻢೙ᓮߩ⸃᣿ߣ⢄∔ᖚ߳ߩᴦ≮ᔕ↪㧧ᐔᚑ 20 ᐕᐲ㧧1,050 ජ౞6㧕 ⎇ⓥઍ⴫⠪㧦㊄᫪ኡల㧧ᐔᚑ 20 ᐕᐲጘ㒂ᄢቇᵴᕈൻ⚻⾌㧦ᚑ૕ᔃ╭ߦ߅ߌࠆࠝ࡯࠻ࡈࠔࠫ࡯ߩᯏ⢻⊛ߥࠄ߮ߦᒻᘒቇ⊛ᬌ⸛㧧ᐔᚑ 20 ᐕᐲ㧧1,050 ජ౞
2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥ1㧕 ᷡፉ ḩ, ᢪ⮮㇌᣿㧦ᰴ਎ઍ⥃ᐥᬌᩏᖱႎࠪࠬ࠹ࡓߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18 ᐕᐲ㧧500 ජ౞㧦ᩣᑼળ␠ࠛࠗࠕࡦ࠼࠹ࠖ࡯
2㧕 ᢪ⮮㇌᣿: ᣂⷙ㐿⊒࠺ࡃࠗࠬࠍ↪޿ߚ⥃ᐥࡊࡠ࠹ࠝ࡯ࡓ⸃ᨆߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18 ᐕᐲ㧧100 ජ౞:᧲࡟ᩣᑼળ␠
3㧕 ᷡፉ ḩ㧦ࡉࠪ࡜ࡒࡦߩ૞↪ᯏᐨ⸃ᨆ㧧ᐔᚑ 19 ᐕᐲ㧧1,819 ජ౞㧦ෳᄤ⵾⮎ࢃ
4㧕 ᷡፉ ḩ, દ⮮ᒄᐽ㧦࠽ࡁࡇࠕ D ࠳ࠗࡑ࡯⹜⮎߅ࠃ߮ࠦࠕࠣࡇࠕ Fig ⹜⮎ߩၮ␆⊛ᬌ⸛㧧ᐔᚑ 19 ᐕᐲ㧧180 ජ౞㧦╙৻ൻቇ⮎ຠࢃ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬᷡፉ ḩ㧦
1㧕 ᣣᧄ⥃ᐥᬌᩏකቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ⥃ᐥൻቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ⥃ᐥᬌᩏ⥄േൻቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄേ⣂⎬ൻቇળ⹏⼏ຬ(㨪⃻࿷)5㧕 ᣣᧄ⥃ᐥಽሶකቇળ⹏⼏ຬ(㨪⃻࿷)6㧕 ᣣᧄ⥃ᐥᬌᩏකቇળቇⴚផㅴൻᆔຬ(㨪⃻࿷)7㧕 ᣣᧄ⥃ᐥᬌᩏකቇળቇળ⾨ᆔຬ(㨪⃻࿷)8㧕 ో࿖࿖┙ᄢቇ∛㒮ᬌᩏㇱળ⼏ᐙ੐(᧲ᶏ࡮ർ㒽ࡉࡠ࠶ࠢ)(㨪ᐔᚑ 18 ᐕ)
9㧕 ᣣᧄ⥃ᐥᬌᩏකቇળቇળ⾨ᆔຬ(㨪⃻࿷)10㧕 ᣣᧄ⥃ᐥൻቇળ࿖㓙੤ᵹᆔຬ(ᐔᚑ 19 ᐕ 4 ᦬㨪⃻࿷)㧙㧙

2㧕ቇળ㐿௅ߥߒ
3㧕ቇⴚ㔀⹹ᷡፉ ḩ㧦
1㧕 ක≮ߣᬌᩏᯏེ࡮⹜⮎㧧✬㓸ᆔຬ(㨪ᐔᚑ 18 ᐕ)
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ᷡፉ ḩ㧦
1㧕 ౏⋉ା⸤⥃ᐥᬌᩏකቇ⎇ⓥᝄ⥝ၮ㊄ ᐔᚑ 18 ᐕᐲዊ㈬੗ᦸ⾨ฃ⾨⸥ᔨ⻠Ṷળ(2007 ᐕ 2 ᦬㧘᧲੩㧘⸥ᔨ⻠Ṷ‫↢ߩ⊕Ⱞࡐ࡝ࡐࠕޟ‬ℂ⊛ᯏ⢻ߣ∔ᖚߣߩ㑐ࠊࠅ‫ޠ‬Ṷ⠪)
2㧕 ஜᐽ㘩ຠ▤ℂ჻ળਛㇱᡰㇱ⸳┙✚ળ(2007 ᐕ 10 ᦬㧘ጘ㒂㧘ᢎ⢒⻠Ṷ‫ߣࡓ࡯ࡠ࠼ࡦࠪࠢ࠶࡝ࡏ࠲ࡔޟ‬㘩↢ᵴ‫ޠ‬Ṷ⠪)દ⮮ᒄᐽ㧦
1㧕 ╙ 43 ࿁ᣣᧄ⚦⩶ቇળਛㇱᡰㇱ✚ળ(2006 ᐕ 10 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᓸ↢‛ᗵᨴ߇ේ࿃㨯Ⴧᖡ࿃ሶߣߥࠆ∔ᖚߦߟ޿ߡߩᦨㄭߩ⹤㗴‫ࠆࠃߦࡦࠪࠠ࠻࠼ࡦࠛ́ޠ‬๭ๆེਇోࡑ࠙ࠬࡕ࠺࡞ߩ㐿⊒‫́ޠ‬Ṷ⠪)2㧕 ஜᐽ㘩ຠ▤ℂ჻ળ ਛㇱᡰㇱ⸳┙⸥ᔨࠪࡦࡐࠫ࠙ࡓ(Ꮢ᳃౏㐿⻠ᐳ)(2007 ᐕ 10 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓ‫ ޟ‬㘩ߩ቟ో࡮቟ᔃߪ቞ࠄࠇߡ޿ࠆ߆㧫‫ޠ‬㧙‫ޟ‬ஜᐽ㘩ຠߩഞ⟋‫⥃ޠ‬ᐥකߩ┙႐߆ࠄஜᐽ㘩ຠࠍ⠨߃ࠆ㧙Ṷ⠪)
ᢪ⮮㇌᣿㧦1㧕 The 11th Meeting of International society for Tryptophan research(2006.06, Tokyo, Physiologicalsignificances of tryptophan-kynurenine pathway metabolism. In CNS Opening remark: What is
the new in the kynurenine pathway in CNS.–In the past, present and future; Speaker)
2㧕 The 6th Korea-Japan Gerontologist Joint Meeting(2006.06, Korea, Oxidative stress,
inflammation and aging: The physiological significance of cerebral indoleamine-2,3-dioxygenase
following transient cerebral ischemia in gerbil; Speaker)
3㧕 ᣣᧄ⥃ᐥൻቇળ᧲ᶏർ㒽ᡰㇱ✚ળ(2006 ᐕ 6 ᦬, ฬฎደᏒ, ࠪࡦࡐࠫ࠙ࡓ‫∛ޟ‬ᘒࠍᝒ߃ࠆ⥃ᐥൻቇᬌᩏߩ New Marker TNF- ߣߘߩ㑐ㅪಽሶࠍ࠲࡯ࠥ࠶࠻ߣߒߚ⥃ᐥࡊࡠ࠹ࠝ࡯ࡓ⸃ᨆ‫ޠ‬Ṷ⠪)4㧕 Recent advances in kynurenine pathway metabolism in CNS. ISTRY 2006, (2006.07, Tokyo,
Significance of IDO in CNS : Inhibition of increased indoleamine-2, 3-dioxygenase activity
exacerbates neuronal cell death in various CNS disorders; Panelist)5㧕 ╙ 1 ࿁⥃ᐥᬌᩏቇᢎ⢒ቇળ(2006 ᐕ 8 ᦬, ᧲੩, ࠪࡦࡐࠫ࠙ࡓ ⥃ᐥᬌᩏᛛᏧᢎ⢒‫߇⑳ޟ‬ᱠ޿ߡ᧪ߚ
㆏ : ⥃ᐥᬌᩏᛛᏧᢎ⢒ߩℂᗐ௝‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ1㧕 દ⮮ᒄᐽ㧘቟⮮㊂ၮ㧘⍹Ꮉື਽㧘ਛጊବᙗ㧘⼱ญ స㧘ᢧ⮮㇌᣿㧘੗ᑫ㆏ᄦ㧘᫪⣁ਭ㓉㧘ฦോિ৻㧘ᷡፉ ḩ㧦The 5th JSH Single Topic Conference Young Investigator Award (ᐔᚑ 18 ᐕᐲ)
2㧕 ᷡፉ ḩ㧦ዊ㈬੗ᦸ⾨ฃ⾨(ᐔᚑ 19 ᐕᐲ)
3㧕 દ⮮ᒄᐽ㧘ጤᧄ⋥᮸㧘㜞ᯅ㚅ᄹሶ㧘቟⮮㊂ၮ㧘⍹Ꮉື਽㧘ᢧ⮮㇌᣿㧘┻᧛ᱜ↵㧘੗ᑫ㆏ᄦ㧘᫪⣁ਭ㓉㧘ᷡፉ ḩ㧦The 6th JSH Single Topic Conference Best Poster Award (ᐔᚑ 19 ᐕᐲ)
4㧕 ᷰㆺᕡᄦ㧘᫪↰✍ሶ㧘ቝ㊁↱㉿ሶ㧘ᨋ ᕶሶ㧘ᵻ㊁㤗⴩㧘Ꮉἑ᥍⟤㧘ട⮮⟵ᒄ㧘᧻ጟᢅ↵㧘દ⮮ᒄᐽ㧘ᷡፉ ḩ㧦╙ 33 ࿁ᣣᧄ⿥㖸ᵄᬌᩏቇળ YIA(Young Investigator’s Award)ఝ⑲⾨(ᐔᚑ 20 ᐕᐲ)
5㧕 ㊄᫪ኡల㧘┻᧛రਃ㧘ਣጊ⇐⟤㧘ᓟ⮮๺ሶ㧘᧘ 㦖⯥㧘ᷡፉ ḩ㧘Ḋญା਽㧘⮮ේਭ⟵㧦╙ 12 ࿁ᣣᧄᔃਇోቇⴚ㓸ળ YIA(Young Investigator’s Award)ఝ⑲⾨(ᐔᚑ 20 ᐕᐲ)
6㧕 ㊄᫪ኡల㧘┻᧛రਃ㧘Ꮉญᥓೣ㧘┻ጊବᤘ㧘Ꮉ᧛৻ᄥ㧘ᓟ⮮๺ሶ㧘᧘ 㦖⯥㧘⮮ේਭ⟵㧘ᷡፉ ḩ㧘Ḋญା਽㧦╙ 30 ࿁ᔃ╭↢ᬌ⎇ⓥળ⧯ᚻᅑബ⾨(ᐔᚑ 20 ᐕᐲ)
9㧚␠ળᵴേ
1㧕 ጘ㒂⋵♖ᐲ▤ℂኾ㐷ᆔຬ(ጘ㒂⋵)(㨪⃻࿷)2㧕 ጘ㒂Ꮢ♖ᐲ▤ℂኾ㐷ᆔຬ(ጘ㒂Ꮢ)(㨪⃻࿷)㧙㧙3㧕 ጘ㒂⋵කᏧળ⥃ᐥᬌᩏ♖ᐲ▤ℂᆔຬળᆔຬ(ጘ㒂⋵කᏧળ)(㨪⃻࿷)4㧕 ⥃ᐥᬌᩏᛛᏧ⹜㛎ᆔຬળᆔຬ㐳(ෘ↢ഭ௛⋭)(㨪ᐔᚑ 19 ᐕ 6 ᦬)
5㧕 ⸻ᢿᛛⴚ⎇ⓥផㅴᆔຬળᆔຬ(⽷࿅ᴺੱጘ㒂⋵౏ⴐⴡ↢࠮ࡦ࠲࡯)(㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ᷡፉ ḩ㧘ᢪ⮮㇌᣿㧘๺↰ਭᵏ㧦2 ᰴర࠽ࡁ LC/MS ࠍ↪޿ߚ⥄Ꮖ఺∉∔ᖚߩ∛ᘒ⸃ᨆࠪࠬ࠹ࡓߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 18 ᐕᐲᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(B)㧦⎇ⓥᚑᨐႎ๔ᦠ(2006 ᐕ 3 ᦬)
2㧕 ᷡፉ ḩ㧘ᢧ⮮㇌᣿㧘๺↰ਭᵏ㧦2 ᰴర࠽ࡁ LC/MS ࠍ↪޿ߚ⥄Ꮖ఺∉∔ᖚߩ∛ᘒ⸃ᨆࠪࠬ࠹ࡓߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 19 ᐕᐲᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(B)㧦⎇ⓥᚑᨐႎ๔ᦠ(2007 ᐕ 3 ᦬)
3㧕 ๺↰ਭᵏ㧘ᷡፉ ḩ㧘ᢧ⮮㇌᣿㧘┻᧛ᱜ↵㧦ࠬ࠲࠴ࡦߦࠃࠆᮮ⚉╭Ⲣ⸃⊒∝ߩࡔࠞ࠾࠭ࡓߩ⸃᣿ߣ
ㆮવሶᬌᩏࠍ↪޿ߚ੍᷹ᴺߩ⏕┙㧦ᐔᚑ 18 ᐕᐲᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦⎇ⓥᚑᨐ
ႎ๔ᦠ(2006 ᐕ 3 ᦬)
4㧕 ┻᧛ᱜ↵㧘ᷡፉ ḩ㧘ᢧ⮮㇌᣿㧦ࠬ࠲࠴ࡦߦࠃࠆᮮ⚉╭Ⲣ⸃⊒∝ߩࡔࠞ࠾࠭ࡓߩ⸃᣿ߣㆮવሶᬌᩏ
ࠍ↪޿ߚ੍᷹ᴺߩ⏕┙㧦ᐔᚑ 19 ᐕᐲᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦⎇ⓥᚑᨐႎ๔ᦠ(2007ᐕ 3 ᦬)
11㧚ႎ㆏
1㧕 ᷡፉ ḩ㧦੺⼔⡯ຬߩࠬ࠻࡟ࠬᢙ୯ൻ㧦ጘ㒂ᣂ⡞(2006 ᐕ 2 ᦬ 24 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔ⎇ⓥᬺ❣ߪᓟඨߦߥߞߡዋߒࡍ࡯ࠬࠕ࠶ࡊߒߚᗵ߇޽ࠅ㧘૗ߣ߆੍ቯߒߡ޿ߚ⋡ᮡࠍࠢ࡝ࠕߒߚߣᕁ
ࠊࠇࠆ‫ޕ‬ᄖㇱ⾗㊄ߦߟ޿ߡߪ⑼ቇ⎇ⓥ⾌ࠍਛᔃߦ߽߁ዋߒ₪ᓧߔࠆࠃ߁ദജߒߥߌࠇ߫ߥࠄߥ޿߇㧘ቇ
ⴚ⾨ߩฃ⾨߽޽ࠅ㧘ో૕⊛ߦߪ⋡ᮡߦ㆐ߒߚߣ⹏ଔߒ߁ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻ╷ዋੱᢙߩߚ߼㧘㒮↢ߩ⏕଻ߣหᤨߦ޿߆ߦല₸⊛ߥ⎇ⓥࡊࡠ࠻ࠦ࡯࡞ࠍߚߡࠆ߆߇㊀ⷐߥ⺖㗴ߢ޽ࠆ‫ޕ‬੹ᓟߩዷᦸ⎇ⓥౝኈߪᄙጘߦࠊߚࠆ߇㧘ߥࠆߴߊઁ⻠ᐳ߅ࠃ߮ઁᣉ⸳ߣߩ౒ห⎇ⓥࠍⓍᭂ⊛ߦⴕ޿㧘ല₸⊛ߥ⎇ⓥࠍ⋡ᜰߒߚ޿‫ޕ‬㧙㧙ާ∛ᘒ೙ᓮቇ⻠ᐳި
㧔1㧕⸃೬ቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
ߎࠇ߹ߢߣห᭽㧘⡺⌒⥃ᐥ⸃೬ቇ⊛⎇ⓥߣ㧘㛽ߣࠞ࡞ࠪ࠙ࡓઍ⻢ེቭߩታ㛎ᒻᘒቇ⊛⎇ⓥࠍࡔࠗࡦߣߒ
ߡ㧘એਅߩ⎇ⓥࠍዷ㐿ߒߚ‫ޕ‬1㧕ࡅ࠻ⴊ▤♽࡮╭♽࡮ᧃ᪳␹⚻♽ߩ⡺⌒⸃೬ቇ⊛⸃ᨆ㧦⸃೬ታ⠌ㆮ૕ࠍ↪޿㧘ⴊ▤♽࡮╭♽࡮ᧃ᪳␹⚻♽ߩᄌ⇣಴⃻ࡄ࠲࡯ࡦߩ࠺࡯࠲⸃ᨆࠍⴕߞߚ‫ޕ‬
2㧕⡺⌒⥃ᐥ⸃೬ቇߩᢎ⢒ࠪࠬ࠹ࡓ߅ࠃ߮ᢎ᧚ߩ㐿⊒㧦කቇㇱቇ↢ߦኻߔࠆലᨐ⊛ߥ⸃೬ቇᢎ⢒㧔⥃ᐥ਄․ߦᔅⷐߣߐࠇࠆ⸃೬ቇ㧕ࠍⴕ߁ߚ߼ߩᣇᴺ߅ࠃ߮ᢎ᧚ߩᮨ⚝࡮㐿⊒ࠍⴕߞߚ‫ޕ‬ᐔᚑ 18 ᐕᐲ߅ࠃ߮ 19ᐕᐲߩጘ㒂ᄢቇᵴᕈൻ⚻⾌㧔ᢎ⢒㧕ߦណᛯߐࠇ㧘ቇ↢߇┙૕⊛ߦℂ⸃ߔࠆߩ߇࿎㔍ߢ޽ࠆㇱ૏ߩᮨဳ૞⵾㧘⡺⌒⸃೬ታ⠌ߩᚻ㗅╬ࠍ⸃⺑ߔࠆࡆ࠺ࠝߩ૞⵾ࠍⴕߞߚ‫ޕ‬
3㧕⠧ᐕᕈ㛽☻㝃∝ࡕ࠺࡞ࡑ࠙ࠬ㧔SAMP6㧕ࠍ↪޿ߚ㧘ṽᣇ⮎߇㛽ߩᓸ⚦᭴ㅧߦ෸߷ߔᓇ㗀ߩᒻᘒቇ⊛⎇ⓥ‫ޕ‬4㧕ࡅ࠻ᄢ⣽㛽㗪ㇱߩᒻᘒቇ⊛⸃ᨆ‫ޕ‬
5㧕ࡅ࠻↪ኻᶏ✎㛽ߩᒻᘒቇ⊛⸃ᨆ‫ޕ‬
2㧚ฬ★
ಎᢎ᝼㧦 ᣧᎹᄢテ
⻠Ꮷ㧦
᧲ ⪇ጪ

Daisuke Hayakawa
Kagaku Azuma

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ᣧᎹᄢテ㧚᫪ጊᘮሶ㧘Ⴎፒ ⛽✬㧚ੱ૕ߩߒߊߺ߇ࠃߊࠊ߆ࠆ㧍Q&A㧔PART㧞‫ޟ‬ౝಽᴲ࡮╭࡮㛽࡮ᗵེⷡ࡮↢ᱺེ࡮ߘߩઁߩ Q&A㧕㧦ࡊ࠴࠽࡯ࠬ ╙ 16 Ꮞ㧘᧲੩㧦ᾖᨋ␠㧧2007 ᐕ㧦30㧙41㧚
2㧕 ᣧᎹᄢテ㧚ᓟ⮮⧷ม㧘ᧁ᧛৻㓶㧘ዊ⷏⌀ੱ✬㧚᭴ㅧߣᯏ⢻㧦ᓴⅣེ♽ ࠦࠕ࡮ࠞ࡝ࠠࡘ࡜ࡓ࠹ࠠࠬ࠻㧘᧲੩㧦ᢥశၴ㧧2008 ᐕ㧦20㧙32㧘36㧙37㧚⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
ߥߒ✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 Ꮉዥ வ㧘๟ ะᩕ㧘㒸 ⪇ጪ㧘ේ ᱞผ㧘⮮↰ᑝᔒ㧘ᮮጊ㦖ੑ㇢㧘᩿↢ᜏม㧘ᤊ ඳᤘ. 3 ᰴరㅧᓇ CT↹௝ߦ߅ߌࠆᐔ㕙ಽഀࠍ↪޿ߚᔃ⤳᭴ㅧߩ⹺⼂ߣ⢖ⴊ▤ಽ㘃߳ߩᔕ↪㧘ାቇᛛႎ 2006 ᐕ㧧MI2005-135㧦
109㧙112㧚
2㧕 ዊፉᘕᐔ㧘๟ ะᩕ㧘ේ ᱞผ㧘⮮↰ᑝᔒ㧘㒸 ⪇ጪ㧘ᮮጊ㦖ੑ㇢㧘ᤊ ඳᤘ. ੱ૕ߩ⸃೬ቇ⊛᭴ㅧ⹺⼂ߩߚ߼ߩ૕ᐙㇱ X ✢ CT ↹௝ߦ߅ߌࠆ㛽ᩰ᭴ㅧߩ⥄േ⸃ᨆ㧘ାቇᛛႎ 2006 ᐕ㧧MI2006-77㧦43㧙48㧚
3㧕 ᳯ᧛ᱜ৻㧘ᅏ᧛ᐕᒾ㧘㒸 ⪇ጪ㧚࠾ࡎࡦࠩ࡞⥠੃㗡ߩ⚿ว❱⧌ߩⷰኤ㧘ᒻᘒ࡮ᯏ⢻ 2007 ᐕ㧧5 Ꮞ㧦69㧙
73㧚
4㧕 ᨋ ㆐㇢㧘๟ ะᩕ㧘㒸 ⪇ጪ㧘ේ ᱞผ㧘⮮↰ᐢᔒ㧘ᮮጊ㦖ੑ㇢㧘᩿↢ᜏม㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚X
✢ CT ௝ߦ߅ߌࠆᬁ૕㑆ߩ㛽ኒᐲ୯ߩ⋧㑐ᕈߩ⎇ⓥ㧘㔚ሶᖱႎㅢାቇળᛛⴚ⎇ⓥႎ๔ 2007 ᐕ㧧107 Ꮞ㧦
53㧙57㧚
5㧕 ␹⼱⋥Ꮧ㧘๟ ะᩕ㧘㒸 ⪇ጪ㧘ේ ᱞผ㧘⮮↰ᐢᔒ㧘ᮮጊ㦖ੑ㇢㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚૕ᐙㇱ X ✢CT ↹௝ߦ߅ߌࠆ㛽ᩰߩ૏⟎ᖱႎࠍ↪޿ߚ஥⣻╭ߣᄢ⣶╭ߩ⥄േ⹺⼂㧘㔚ሶᖱႎㅢାቇળᛛⴚ⎇ⓥႎ๔
2007 ᐕ㧧107 Ꮞ㧦23㧙27㧚
6㧕 ᨋ ㆐㇢㧘๟ ะᩕ㧘㒸 ⪇ጪ㧘ේ ᱞผ㧘⮮↰ᐢᔒ㧘ᮮጊ㦖ੑ㇢㧘᩿↢ᜏม㧘ᤊ ඳᤘ㧚X ✢ CT ௝ߦ߅ߌࠆ⣄ᬁᬁ૕ㇱߩ㛽ኒᐲߩ⺞ᩏ㧘ක↪↢૕Ꮏቇ 2007 ᐕ㧧45 Ꮞ㧦256㧙266㧚
7㧕 ᨋ ㆐㇢㧘๟ ะᩕ㧘㒸 ⪇ጪ㧘ේ ᱞผ㧘⮮↰ᐢᔒ㧘ᮮጊ㦖ੑ㇢㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚X ✢ CT ௝ߦ߅ߌࠆੱ૕ߩᬁ૕ᶏ✎㛽ߩ㛽ኒᐲߩਇဋ⾰ᕈߦ㑐ߔࠆ⎇ⓥ㧘ାቇᛛႎ 2008 ᐕ㧧MI2007-143㧦435㧙438㧚
8㧕 ᳯ᧛ᱜ৻㧘ᅏ᧛ᐕᒾ㧘㒸 ⪇ጪ㧚࠲࠿ࠠ߅ࠃ߮ࡂࠢࡆࠪࡦ⥠੃㗡ߩ⚿ว❱⧌ߩ⿛ᩏဳ㔚ሶ㗼ᓸ㏜ߦࠃࠆⷰኤ㧘ᒻᘒ࡮ᯏ⢻ 2008 ᐕ㧧6 Ꮞ㧦75㧙81㧚㧙㧙

9㧕 ੑች໪ᓆ㧘๟ ะᩕ㧘㒸 ⪇ጪ㧘ේ ᱞผ㧘⮮↰ᐢᔒ㧘ᮮጊ㦖ੑ㇢㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚X ✢ CT ↹௝ߦ߅ߌࠆ⢷ㇳਅญߩ⥄േ᛽಴ߣᮮ㓒⤑ߩ⥄േផቯ߳ߩᔕ↪㧘ାቇᛛႎ 2008 ᐕ㧧MI2007-85㧦107㧙110㧚
10㧕 㖧 ᣿ᣩ㧘ᨋ ㆐㇢㧘๟ ะᩕ㧘㒸 ⪇ጪ㧘ේ ᱞผ㧘⮮↰ᐢᔒ㧘ᮮጊ㦖ੑ㇢㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚૕ᐙㇱ㨄✢ CT ↹௝ߦ߅ߌࠆ⸃೬ቇ⊛૏⟎ᖱႎߦၮߠߊਅ⢇㛽ߩ⥄േ⹺⼂㧘ାቇᛛႎ 2008 ᐕ㧧MI2008-14㧦
75㧙80㧚
11㧕 ␹⼱⋥Ꮧ㧘๟ ะᩕ㧘㒸 ⪇ጪ㧘ේ ᱞผ㧘⮮↰ᐢᔒ㧘ᮮጊ㦖ੑ㇢㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚૕ᐙㇱ X ✢CT ↹௝ߦ߅ߌࠆᮮ㓒⤑ߩ૏⟎ᖱႎࠍ↪޿ߚᄢ⣶╭⥄േ⹺⼂ᴺߩᡷ⦟㧘ାቇᛛႎ 2008 ᐕ㧧MI2008-13㧦
71㧙74㧚
12㧕 ᨋ ㆐㇢㧘๟ ะᩕ㧘㒸 ⪇ጪ㧘ේ ᱞผ㧘⮮↰ᐢᔒ㧘ᮮጊ㦖ੑ㇢㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚X ✢ CT ௝ߦ߅ߌࠆ᳇▤࡮᳇▤ᡰߩᒻ⁁ᖱႎߩ⸘᷹㧘ක↪↹௝ᖱႎቇળ㔀⹹ 2008 ᐕ㧧25 Ꮞ㧦18㧙21㧚
13㧕 ᨋ ㆐㇢㧘๟ ะᩕ㧘㒸 ⪇ጪ㧘ේ ᱞผ㧘⮮↰ᐢᔒ㧘ᮮጊ㦖ੑ㇢㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚X ✢ CT ↹௝߆ࠄߩᬁ૕ᶏ✎㛽ㇱߦ߅ߌࠆ㛽ኒᐲߩಽᏓߩ⸃ᨆ㧘ାቇᛛႎ 2008 ᐕ㧧MI2008-26㧦35㧙40㧚
14㧕 ๟ ะᩕ㧘Song Wang㧘Pahal Dalal㧘Mike McLaughlin㧘㒸 ⪇ጪ㧘ේ ᱞผ㧘⮮↰ᐢᔒ㧘ᮮጊ㦖ੑ㇢㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚3 ᰴరߩ㕙࿑ᒻߩ૏⟎วࠊߖߦࠃࠆᮮ㓒⤑ߩᒻ⁁ࡕ࠺࡞ߩ᭴▽㧘ାቇᛛႎ 2008 ᐕ㧧
MI2008-34㧦73㧙78㧚
15㧕 ᳯ᧛ᱜ৻㧘ᅏ᧛ᐕᒾ㧘㒸 ⪇ጪ㧚ࠬ࠭ࡔߩ⥠੃㗡ߣߘߩ⚿ว❱⧌ߩ⿛ᩏဳ㔚ሶ㗼ᓸ㏜ߦࠃࠆⷰኤ㧘ᒻᘒ࡮ᯏ⢻ 2008 ᐕ㧧7 Ꮞ㧦7㧙12㧚
16㧕 ᳯ᧛ᱜ৻㧘ᅏ᧛ᐕᒾ㧘㒸 ⪇ጪ㧚ࠝࠝ࠲ࠞߩ⥠੃㗡ߣߘߩ⚿ว❱⧌ߩ⿛ᩏဳ㔚ሶ㗼ᓸ㏜ߦࠃࠆⷰኤ㧘⸃೬
⹹ 2008 ᐕ㧧83 Ꮞ㧦77㧙80㧚
17㧕 ␹⼱⋥Ꮧ㧘๟ ะᩕ㧘㒸 ⪇ጪ㧘ේ ᱞผ㧘⮮↰ᐢᔒ㧘ᮮጊ㦖ੑ㇢㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚㛽ᩰߣ㛽ᩰ╭ߩ⸃೬ቇ⊛૏⟎㑐ଥߦၮߠߊ૕ᐙㇱ X ✢ CT ↹௝߆ࠄߩ㛽ᩰ╭ߩ⥄േ᛽಴㧘㔚ሶᖱႎㅢାቇળ⺰ᢥ⹹
2008 ᐕ㧧J91-D㧦1918㧙1922㧚
18㧕 ᨋ ㆐㇢㧘๟ ะᩕ㧘㒸 ⪇ጪ㧘ේ ᱞผ㧘⮮↰ ᐢᔒ㧘ᮮጊ㦖ੑ㇢㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚X ✢ CT ↹௝߆ࠄߩੱ૕ߩᬁ૕ᶏ✎㛽ㇱߦ߅ߌࠆૐ㛽ኒᐲ㗔ၞߩಽᏓߦ㑐ߔࠆ⎇ⓥ㧘↢૕කᎿቇ 2008 ᐕ㧧46 Ꮞ㧦451
㧙457㧚
ේ⪺㧔᰷ᢥ㧕
1㧕 Chen H, Shoumura S, Emura S. Bilateral thoracic ducts with coexistent persistent left superior vena
cava. Clin Anat. 2006;19:350-353.
2㧕 Chen H, Emura S, Shoumura S. Ultrastructure of the water-clear cell in the parathyroid gland of
SAMP6 mice. Tissue Cell. 2006;38:187-192.
3㧕 Taguchi H, Chen H, Yano R, Shoumura S. Comparative effects of milk and soymilk on bone loss inadult ovariectomized osteoporosis rat. Okajimas Folia Anat Jpn. 2006;83:53-59.
4㧕 Chen H, Yao XF, Emura S, Shoumura S. Morphological changes of skeletal muscle, tendon andperiosteum in the senescence-accelerated mouse (SAMP6): a murine model for senile osteoporosis.
Tissue Cell. 2006;38:325-335.
5㧕 Yao XF, Chen H, Ohtake N, Shoumura S. The morphological alterations in the growth plate cartilageof ovariectomized mice. Medical Mol. Morphol. 2006;39:193-197.
6㧕 Emura S, Okumura T, Chen H, Shoumura S. Morphology of the lingual papillae in the raccoon dog andfox. Okajimas Folia Anat. Jpn. 2006;83:73-76.
7㧕 Yao XF, Chen H, Emura S, Otake N, Shoumura S. Effects of hPTH (1-34) and Gosga-jinki-gan on thetrabecular bone microarchitecture in ovariectomized rat tibia. Okajimas Folia Anat. Jpn. 2007;83:
107-114.
8㧕 Otake N, Chen H, Yao XF, Shoumura S. Morphologic study of the lateral and medial collateral
Ligaments of the human knee. Okajimas Folia Anat Jpn. 2007;83:115-122.
9㧕 Abe C, Tanaka K, Awazu C, Chen H, Morita H. Plastic alteration of vestibulo-cardiovascular reflex
induced by 2 weeks of 3-G load in conscious rats. Exp Brain Res. 2007;181:639-646.
10㧕 Zhou X, Ninomiya H, Hara T, Fujita H, Yokoyama R, Chen H, Kiryu T, Hoshi H. Automated estimationof the upper surface of the diaphragm in 3-D CT images. IEEE Transactions on Biomedical
Engineering. 2008;55:351-353.
11㧕 Chen H, Okumura T, Emura S, Shoumura S. Scanning electron microscopic study of the human
auditory ossicles. Ann Anat. 2008;190:53-58.
12㧕 Chen H, Shoumura S, Emura S, Bunai Y. Regional variations of vertebral trabecular bone
microstructure with age and gender. Osteoporos Int. 2008;19:1473-1483.
13㧕 Chen H, Zhou X, Washimi Y, Shoumura S. Three-dimensional microstructure of the bone in a hamster
model of senile osteoporosis. Bone. 2008;43:494-500.
14㧕 Emura S, Okumura T, Chen H. Scanning electron microscopic study of the tongue in the peregrine
falcon and common kestrel. Okajimas Folia Anat Jpn. 2008;85:11-15.
15㧕 Emura S, Okumura T, Chen H. Morphology of the lingual papillae and their connective tissue cores in
the cape hyrax. Okajimas Folia Anat Jpn. 2008;85:29-34.
16㧕 Zhou X, Han M, Hara T, Fujita H, Sugisaki K, Chen H, Lee G, Yokoyama R,Kanematsu M, Hoshi H.
Automated segmentation of mammary gland regions in non-contrast X-ray CT images. Comput Med
Imaging Graph. 2008;32:699-709.

㧙㧙

IF 0.702
IF 1.132

IF 1.132

IF 2.302
IF 0.672
IF 3.718
IF 3.829

IF 0.909

17㧕 Aoki H, Hara A, Motohashi T, Chen H, Kunisada T. Iris as a recipient tissue for pigment cells:organized in vivo differentiation of melanocytes and pigmented epithelium derived from embryonicstem cells in vitro. Dev Dyn. 2008;237:2394-2404.
IF 3.16918㧕 Emura S, Chen H. Scanning electron microscopic study of the Tongue in the Owl (Strix uralensis).
Anat Histol Embryol. 2008;37:475-478.
IF 0.593

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦ᣧᎹᄢテ㧧ᐔᚑ 18 ᐕᐲጘ㒂ᄢቇᵴᕈൻ⚻⾌(ᢎ⢒)㧦ੱ૕᭴ㅧࠦ࡯ࠬ(ࡑࠢࡠ✬)(ࡆ࠺ࠝߩ૞⵾╬)㧧ᐔᚑ 18 ᐕᐲ㧧430 ජ౞2㧕 ⎇ⓥઍ⴫⠪㧦ᣧᎹᄢテ㧧ᐔᚑ 19 ᐕᐲጘ㒂ᄢቇᵴᕈൻ⚻⾌(ᢎ⢒)㧦ੱ૕᭴ㅧࠦ࡯ࠬ(ࡑࠢࡠ✬)(ࡆ࠺ࠝߩ૞⵾╬)㧧ᐔᚑ 19 ᐕᐲ㧧355 ජ౞
2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬ᧲ ⪇ጪ㧦
1㧕 ᣣᧄ⥃ᐥಽሶᒻᘒቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ㗼ᓸ㏜ቇળ㑐⷏ᡰㇱᐙ੐(ᐔᚑ 20 ᐕ 4 ᦬㨪⃻࿷)2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳᧲ ⪇ጪ㧦
1㧕 Convention of the pharmaceutical society of Korea (2008.10, Soul,‫ޟ‬Herbal medicines in theprevention and treatment of osteoporosis.‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ1㧕 ᨋ ㆐㇢㧘๟ ะᩕ㧘ේ ᱞผ㧘⮮↰ᐢᔒ㧘ᮮጊ㦖ੑ㇢㧘᩿↢ᜏม㧘㒸 ⪇ጪ㧘ᤊ ඳᤘ㧦㔚ሶᖱႎㅢାቇળᐔᚑ 19 ᐕᐲቇⴚᅑബ⾨(ᐔᚑ 20 ᐕᐲ)9㧚␠ળᵴേ᧲ ⪇ጪ㧦
1㧕 ጘ㒂⋵ಎ⋴⼔Ꮷ⹜㛎ᆔຬ(㨪⃻࿷)10㧚ႎ๔ᦠ
ߥߒ
11㧚ႎ㆏
1㧕 ⏷㊁ᣣ಴ᄦ㧘ᱜ᧛㕒ሶ㧘᧲ ⪇ጪ㧦ࠕࡑ࠼ࠦࡠߦ⟤⡼ലᨐ ࡑ࠙ࠬታ㛎ߢ⏕⹺㧦Ფᣣᣂ⡞(2006 ᐕ
10 ᦬ 19 ᣣ)
2㧕 ጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼ߩ᧲⪇ጪ⻠Ꮷࠄߩ⎇ⓥࠣ࡞࡯ࡊ㧦࡙࡝⑼ߩࠕࡑ࠼ࠦࡠߦ⟤ኈലᨐࡑ࠙㧙㧙ࠬታ㛎ߢ⏕⹺㧦ᣣᧄㄘᬺᣂ⡞(2007 ᐕ 9 ᦬ 21 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔቇౝᄖߦ߅ߌࠆ▤ℂ࡮ㆇ༡╬ߦ㑐ߔࠆᬺോߦߣࠄࠇࠆᤨ㑆߇Ⴧടߒߚਛߢ㧘ᢎ⢒ߩᲧ㊀߇ᭂ߼ߡᄢ߈
޿ಽ㊁ߢ޽ࠆ‫ޕ‬ᐔᚑ 19 ᐕᐲࠃࠅᢎຬߪ 2 ฬߣߥࠅ㧘ᄢቇ㒮↢߅ࠃ߮⎇ⓥ↢ߣ޿ߞߚ⎇ⓥࠬ࠲࠶ࡈ߽ᣂߚ
ߦㄫ߃ߡ޿ߥ޿‫ߥ߁ࠃߩߎޕ‬෩ߒ޿⃻⁁ߩਛ㧘ᬺ❣ߩਇ⿷ߪุ߼ߥ޿‫ޕ‬ᢎ⢒ߦゲ⿷ࠍ߅޿ߚ⎇ⓥߦ㧘৻ጀߩദജ߇ᔅⷐߣᕁࠊࠇࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ᷓೞߥࡑࡦࡄࡢ࡯ਇ⿷ࠍᛴ߃ߡ޿ࠆ߇㧘᳿ቯ⊛ߥ⸃᳿╷ߪߥ޿‫ߚ߹ޕ‬㧘⡺⌒⸃೬ቇ⊛⎇ⓥߪ㧘ᄙߊߩᤨ㑆ߣഭജࠍⷐߔࠆഀߦ㧘ᓧࠄࠇࠆ⚿ᨐ߇ዋߥߊ㧘ᚑᨐ߇⋡┙ߚߥ޿‫ోޕ‬࿖⊛࡮ో਎⇇⊛ߦ㧘⡺⌒⸃೬ቇࠍኾ㐷ߣߔࠆ⸃೬ቇ⠪ߪᷫዋߩ৻ㅜࠍㄡࠅ㧘ߘߩሽ⛯߇ෂ߱߹ࠇߡ޿ࠆ‫ߒ߆ߒޕ‬㧘⥃ᐥකߩߺߥࠄߕ
ࠦࡔ࠺ࠖࠞ࡞㗔ၞߩක≮ᓥ੐⠪ߦߣߞߡߘߩᔅⷐᕈ࡮㊀ⷐᕈߪ⸒߁߹ߢ߽ߥ޿‫⊛ੱߚߒ߁ߎޕ‬ਇ⿷ߣ⃻ታߩ࠾࡯࠭ߣߩਵ㔌߇ᦨᄢߩ໧㗴ߢ޽ࠆߣ⠨߃ࠆ߇㧘ౕ૕⊛ߥ⸃᳿╷ߪ⷗಴ߐࠇߥ޿‫ޕ‬⥃ᐥ⸃೬ቇᢎ⢒߅ࠃ߮ߘߩ⎇ⓥߦ㑐ߒ㧘ᐔᚑ 19 ᐕᐲߦ⊒⿷ߒߚ‫ޟ‬කቇᢎ⢒࡙࠾࠶࠻㧔⸃೬♽㧕‫ߩޠ‬ᵴേߪᧂߛᧄᩰ⊛ߥ゠㆏ߦਸ਼ߞߡ޿ߥ޿߇㧘ᓢ‫ߩߘߦޘ‬ᵴേࠍᵴᕈൻߒߡ޿ߊḰ஻ࠍㅴ߼ߡ޿ࠆ‫ޕ‬੹ᓟߩዷᦸ⡺⌒⸃೬ቇ߅ࠃ߮⥃ᐥ⸃೬ቇߩᢎ⢒࡮⎇ⓥߦ៤ࠊࠆ⸃೬ቇ⠪߇⪺ߒߊᷫዋߒߡ޿ࠆᤓ੹㧘ߎࠇࠄߩ㗔ၞߦ⥝๧ࠍᜬߟੱ᧚ࠍᄙߊ⏕଻ߒ㧘⢒ᚑߔࠆߎߣ߇ᕆോߢ޽ࠆ‫ઁޕ‬ᄢቇߩ⸃೬ቇಽ㊁╬޽ࠆ޿ߪࠦࡔ࠺
ࠖࠞ࡞♽ኾ㐷ቇᩞ╬ߣߩኒធߥㅪ៤ߦࠃࠆ౒ห⎇ⓥ߽ᔅⷐߣᕁࠊࠇࠆ‫ߚ߹ޕ‬㧘ቇౝߦ߅޿ߡ‫⥃ޡ‬ᐥ⸃೬ቇ⎇ⓥળ‫ߜ┙ࠍߩ߽ߥ߁ࠃߩޢ‬਄ߍࠆߥߤߒߡ㧘⥃ᐥ♽ಽ㊁ߣߩㅪ៤ࠍ৻ጀኒߦߒ㧘౒ห⎇ⓥࠍㅴ߼ߡ޿ߊน⢻ᕈࠍតࠅߚ޿‫ߪߦࠄߐޕ‬㧘ᮨဳ߿ࠦࡦࡇࡘ࡯࠲ࠣ࡜ࡈࠖ࠶ࠢࠬ㧘ฦ⒳↹௝⸃೬ቇ⊛ᚻᴺࠍ㚟૶ߒ㧘ࠪࡒࡘ࡟࡯࡚ࠪࡦකቇᢎ᧚ࠍ߽฽߼ߚ✚วකቇ⊛ߥ⥃ᐥ⸃೬ቇᢎ⢒ߩࠪࠬ࠹ࡓࠍ㐿⊒࡮ታ〣ߒߚ޿‫ޕ‬㧙㧙㧔2㧕ಽሶ∛ᘒቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
ᒰᢎቶߢߪ㧘ࡅ࠻ Aurora ㆮવሶߩ 3 ⒳ࠍ਎⇇ߦవ㚟ߌߡࠢࡠ࡯࠾ࡦࠣߒ㧘ߘߩ⚦⢩↢‛ቇ⊛ߥᯏ⢻ࠍ᣿ࠄ߆ߦߒࠃ߁ߣ⎇ⓥࠍㅴ߼ߡ᧪ߚ‫ޕ‬Aurora A ߪਛᔃ૕ߦዪ࿷ߒߡߘߩᚑᾫ߿ಽ㔌ߦ㑐ਈߒߡ⚦⢩ಽⵚߩዉ౉ࠍଦㅴߒߡ⚜㍝૕ᒻᚑߦᭂ߼ߡ㊀ⷐߥᓎഀࠍᨐߚߔ‫ޕ‬Aurora B ߪᨴ⦡૕ߩ࠮ࡦ࠻ࡠࡔࠕߦዪ࿷ߒ
ߡ⚦⢩ಽⵚೋᦼߩ੐⽎ߣߒߡߩࡅࠬ࠻ࡦ H3 ߩ࡝ࡦ㉄ൻ߿ᨴ⦡૕ߩಝ❗ߦ㑐ࠊࠅ㧘ಽⵚᓟᦼએ㒠ߪ෼❗ベߩᒻᚑ߿⚜㍝૕ߩ⣕㊀วߦ㊀ⷐߥᓎഀࠍᨐߚߔ‫ޕ‬Aurora C ߪ㧘ၮᧄ⊛ߦ Aurora B ߣห᭽ߩᓎഀࠍᨐߚߔ‫ޕ‬⒳‫⚦ࠎ߇ߩޘ‬⢩߿߇ࠎ⚵❱ߢ Aurora ࠠ࠽࡯࠯ࡈࠔࡒ࡝࡯࠲ࡦࡄࠢ⾰߇㜞⊒⃻ߒߡ޿ࠆߎߣ߽⍮ࠄࠇ㧘
ή⒎ᐨߥ⚦⢩Ⴧᱺ߳ߣ❬߇ࠆߣ⠨߃ࠄࠇߡ޿ࠆ‫ޕ‬ᚒ‫ ߪޘ‬Aurora A ߿ Aurora B ߩࡊࡠࡕ࡯࠲࡯㗔ၞࠍࠢࡠ࡯࠾ࡦࠣߒ㧘ߘߩ⊒⃻⺞▵ߦ㑐ࠊࠆ࠲ࡦࡄࠢ⾰ᕈォ౮࿃ሶߢ޽ࠆ Ets ࡈࠔࡒ࡝࡯㧘․ߦ㛽⡺⣲ߦ㑐ਈߔࠆ EWS-Fli1 ߦࠃࠆォ౮⺞▵ࠍ⸃ᨆߒߚ‫ޕ‬RNA ᐓᷤߦࠃࠆㆮવሶࡁ࠶ࠢ࠳࠙ࡦߩᚻᴺߪ㧘࠲ࡦࡄࠢ⾰ߩᯏ⢻ࠍ⸃ᨆߔࠆ਄ߢᭂ߼ߡ᦭↪ߥᚻᲑߢ޽ࠆ‫ޕ‬ਛᔃ૕ࠠ࠽࡯࠯ Aurora A ߩ siRNA ߦࠃࠆࡁ࠶ࠢ࠳࠙ࡦߦࠃࠅ⚦⢩ᱫ㧔apoptosis㧕߇߽ߚࠄߐࠇ
ࠆ߇㧘ઁߩਛᔃ૕࠲ࡦࡄࠢ⾰ߣߩ࠳ࡉ࡞ࡁ࠶ࠢ࠳࠙ࡦ߿߇ࠎᛥ೙ㆮવሶ p53 ߣߩ㑐ㅪߦߟ޿ߡ⸃ᨆߒߡ
޿ࠆ‫ޕ‬⋴⼔ቇ⑼࡮ᱞ⮮ศᓼᢎ᝼ߪ㧘ᚒ‫ߣޘ‬หߓߊਛᔃ૕ߦ⥝๧ࠍ߽ߞߡ߅ࠄࠇ㧘౒ห⎇ⓥࠍⴕߞߡ޿ࠆ‫ޕ‬ᱞ⮮ᢎ᝼ߪ㧘ਛᔃ૕ߩਛߢ߽ਛᔃዊ૕ߦዪ࿷ߒߡ coiled-coil ߿ leucine zipper ᭴ㅧࠍ߽ߟᣂⷙࡅ࠻ CLERC ㆮવሶࠍࠢࡠ࡯࠾ࡦࠣߒߚ‫ߩߘޕ‬ㆮવሶዉ౉ߦࠃࠆㆊ೾⊒⃻߿㧘siRNA ዉ౉ߦࠃࠆࡁ࠶ࠢ࠳࠙ࡦ߇⚦⢩ಽⵚߩ⇣Ᏹࠍ߽ߚࠄߔߎߣࠍ᣿ࠄ߆ߦߒߚ‫ޕ‬⚦⢩ౝߩㆬᛯ⊛ߥ࠲ࡦࡄࠢ⾰ಽ⸃ߦ࡙ࡆࠠ࠴ࡦ-ࡊࡠ࠹ࠕ࠰࡯ࡓ♽߇㊀ⷐߥᓎഀࠍᨐߚߒߡ޿ࠆ‫ޕ‬ᒰᢎ
ቶߢߪ N ᧃિ㐳ဳ࡙ࡆࠠ࠴ࡦઃട㉂⚛㧔ubiquitin-conjugating enzyme, E2㧕ߩ UBE2E2 ߿ UBE2E3ߩㆮવሶࠍࠢࡠ࡯࠾ࡦࠣߒ㧘ߘߩ⚦⢩↢‛ቇ⊛ߥᯏ⢻ࠍ᣿ࠄ߆ߦߒࠃ߁ߣ⎇ⓥࠍㅴ߼ߡ᧪ߚ‫ޕ‬㉂Უ
two-hybrid system ࠍ↪޿ߡ UBE2E2 ߩ⚿วࡄ࡯࠻࠽࡯ߣߒߡ࡙ࡆࠠ࠴ࡦ࡝ࠟ࡯࠯ (ubiquitin ligase,E3) ߩ RNF8 ࠍࠢࡠ࡯࠾ࡦࠣߒߡߘߩᯏ⢻ࠍ⸃ᨆߒࠃ߁ߣߒߡ޿ࠆ‫ޕ‬2007 ᐕᧃߦ 4 ߟߩࠣ࡞࡯ࡊ߆ࠄ
RNF8 ߇㧘᡼኿✢ߦࠃࠆ DNA2 ᧄ㎮ಾᢿߦ㓙ߒߡࡅࠬ࠻ࡦ H2A ߿ H2AX ࠍ࡙ࡆࠠ࠴ࡦൻߒߡ㧘៊்ㇱ૏ߦୃᓳ࠲ࡦࡄࠢ⾰ࠍ㓸߼ࠆߚ߼ߦ㊀ⷐߥᓎഀࠍᨐߚߒߡ޿ࠆߎߣ߇ႎ๔ߐࠇߚ‫⚡ޕ‬ᄖ✢߿ฦ⒳⮎೷ߥߤߦࠃࠆ DNA ்ኂߦ߅ߌࠆ RNF8 ߩᓎഀ߿㧘ߘߩਅᵹߩࠪࠣ࠽࡞♽ߦߟ޿ߡ⸃ᨆߒߡ޿ࠆ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
ഥᢎ㧦
ഥᢎ㧦

ጟ㊁ᐘ㓶
ᧁ᧛ᱜᔒ
ศጟ ቁ

Yukio Okano
Masashi Kimura
Takashi Yoshioka

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ਛፉ ⨃㧘ጟ㊁ᐘ㓶㧚৻ἑ⊕Ꮲ㧘㋈ᧁብᴦ✬⪺㧚࿑⺑ ಽሶ∛ᘒቇ㧙Τಽሶ∛ᘒቇၮ␆⍮⼂ ⚦⢩ౝࠪࠣ࠽࡞વ㆐㧙 ╙ 4 㧘᧲੩㧦ਛᄖකቇ␠㧧2008 ᐕ㧦46㧙49㧚⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
ߥߒ✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
ߥߒේ⪺㧔᰷ᢥ㧕
1㧕 Kuwata H, Yoshioka T, Muto Y, Kuwata K, Okano Y. Structural and functional characterization of
NP25, a single CH domain protein. Acta Schol Med Univ Gifu. 2006;54:1-7.
2㧕 Plans V, Scheper J, Soler M, Loukili N, Okano Y, Thomson TM. The RING finger protein RNF8
recruitsUBC13 for Lysine 63-based self polyubiquitylation. J Cell Biochem. 2006;97:572-582.
IF 3.381

㧙㧙3㧕 Kimura M, Okano Y. Human Misato regulates mitochondrial distribution and morphology. Exp Cell
Res. 2007;313:1393-1404.
4㧕 Yoshimura K, Muto Y, Shimizu M, Matsushima-Nishiwaki R, Okuno M, Takano Y, Tsurumi H, Kojima
S, Okano Y, Moriwaki H. Phosphorylated retinoid X receptor D loses its heterodimeric activity withretinoic acid receptor E. Cancer Sci. 2007;98:1868-1874.
5㧕 Banno Y, Nemoto S, Murakami M, Kimura M, Ueno Y, Ohguchi K, Hara A, Okano Y, Kitade Y,
Onozuka M, Murata T, Nozawa Y. Depolarization㧙induced differentiation of PC12 cells is mediatedby phospholipase D2 through the transcription factor CREB pathway. J Neurochem.
2008;104:1372-1386.
6㧕 Muto Y, Yoshioka T, Kimura M, Matsunami M, Saya H, Okano Y. An evolutionarily conserved
leucine-rich repeat protein CLERC is a centrosomal protein required for spindle pole integrity. Cell
Cycle. 2008;7:2738-2748.
7㧕 Wakahara K, Ohno T, Kimura M, Masuda T, Nozawa S, Dohjima T, Yamamoto T, Nagano A, Kawai G,
Matsuhashi A, Saitoh M, Takigami I, Okano Y, Shimizu K. EWS-Fli1 up-regulates expression of theaurora a and aurora B kinases. Mol Cancer Res. 2008;6:1937-1945.

IF 3.695

IF 3.165

IF 4.451

IF 3.314

IF 4.3174㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦ጟ㊁ᐘ㓶㧘⎇ⓥಽᜂ⠪㧦ᱞ⮮ศᓼ㧘ศጟ ቁ㧧ᢥㇱ⑼ቇ⋭ൻቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦࡟࠴ࡁࠗ࠼ X ฃኈ૕ߣ RING ࠲ࡦࡄࠢ⾰ߩ⋧੕૞↪ߣߘߩ࡙ࡆࠠ࠴ࡦൻ࡮ォ౮߳ߩലᨐ㧧ᐔᚑ 16㧙17 ᐕᐲ㧧3,700 ජ౞(1,900㧦1,800 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦᫪⣁ਭ㓉㧘⎇ⓥಽᜂ⠪㧦ጟ㊁ᐘ㓶㧘↰ਛථੑ㧘ዊ᎑⡡৻㧘⷏ญୃᐔ㧘ᷡ᳓㓷ੳ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄․ቯ㗔ၞ⎇ⓥ㧦ᩭౝฃኈ૕Ⱞ⊕ࠍᮡ⊛ߣߒߚ⢄≸ൻቇ੍㒐ߦ㑐ߔࠆ⎇ⓥ㧧
ᐔᚑ 17㧙21 ᐕᐲ㧧82,300 ජ౞(16,300㧦16,300㧦16,300㧦16,300㧦17,100 ජ౞)
3㧕⎇ⓥઍ⴫⠪㧦ᧁ᧛ᱜᔒ㧘⎇ⓥಽᜂ⠪㧦ጟ㊁ᐘ㓶㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌(⎇ⓥ)㧦ࠝ࡯ࡠ࡜ࠠ࠽࡯࠯ߩ⚦⢩ಽⵚߦ߅ߌࠆ⊒߇ࠎߩ㑐ㅪߩ⸃ᨆ㧧ᐔᚑ 19 ᐕᐲ㧧1,130 ජ౞
2㧕ฃ⸤⎇ⓥߥߒ

3㧕౒ห⎇ⓥߥߒ

5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬ
ጟ㊁ ᐘ㓶㧦
1㧕 ᣣᧄ↢ൻቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᐔᚑ 19 ᐕᐲᣣᧄ↢ൻቇળਛㇱᡰㇱ࡮ᡰㇱ㐳(ᐔᚑ 19 ᐕ 9 ᦬㨪20 ᐕ 8 ᦬)
2㧕ቇળ㐿௅
ጟ㊁ᐘ㓶㧦
1㧕 ╙ 72 ࿁ᣣᧄ↢ൻቇળਛㇱᡰㇱ଀ળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ࠪࡦࡐࠫ࠙ࡓ‫⚦ޟ‬⢩๟ᦼ೙ᓮߩᦨ೨✢‫ޠ‬㧘ጘ㒂)
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳
ጟ㊁ᐘ㓶㧦
1㧕 ╙ 72 ࿁ᣣᧄ↢ൻቇળਛㇱᡰㇱ଀ળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓ‫⚦ޟ‬⢩๟ᦼ೙ᓮߩᦨ೨✢‫ޠ‬ᐳ㐳)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ
ߥߒ

㧙㧙

9㧚␠ળᵴേ
ߥߒ
10㧚ႎ๔ᦠ
1㧕 ጟ㊁ᐘ㓶㧘ᱞ⮮ศᓼ㧘ศጟቁ㧦࡟࠴ࡁࠗ࠼ X ฃኈ૕ߣ RING ࠲ࡦࡄࠢ⾰ߩ⋧੕૞↪ߣߘߩ࡙ࡆࠠ࠴
ࡦൻ࡮ォ౮߳ߩലᨐ㧦ᐔᚑ 16 ᐕᐲ㧙17 ᐕᐲᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2) ⎇ⓥᚑᨐႎ๔ᦠ㧦1㧙53(2006 ᐕ 4 ᦬)11㧚ႎ㆏ߥߒ12㧚⥄Ꮖ⹏ଔ
⹏ଔ
ᐔᚑ 20 ᐕ 5 ᦬ߦጘ㒂ߢᣣᧄ↢ൻቇળਛㇱᡰㇱ଀ળ࡮ࠪࡦࡐࠫ࠙ࡓࠍ㐿௅ߢ߈ߚߩߪ㧘⚦⢩๟ᦼ೙ᓮߩ
㗔ၞߢߩ⪺᣿ߥࠪࡦࡐࠫࠬ࠻ߦߏ⻠Ṷ޿ߚߛߌߚߎߣߦട߃ߡ㧘ᢎቶຬ৻ห෸߮ቇౝߦ⇐߹ࠄߕቇᄖߩ
㑐ଥฦ૏ߦ߽ߏදജ޿ߚߛ޿ߚ⾦‛ߣᗵ⻢ߒߡ޿ࠆ‫ޕ‬ᚻ૞ࠅߩዊߐߥቇળߣ޿߁ශ⽎ߢߪ޽ߞߚ߇㧘ጘ㒂ߢߩ㐿௅ߦ᜔߽ࠊࠄߕቇౝᄖ߆ࠄߩදജߦࠃࠅ 50 㗴ࠍ⿧߃ࠆ৻⥸Ṷ㗴߇㓸߹ࠅ㧘ෳട⠪ߦߪᭉߒࠎߢ
޿ߚߛߌߚߎߣߣ⏕ାߒߡ޿ࠆ‫ޕ‬ᢎቶຬ৻ห߇ജࠍวࠊߖߡ⎇ⓥߩផㅴ߿ᢎቶߩ⊒ዷߦദ߼ࠆߎߣߩ㊀ⷐᕈࠍታᗵߢ߈ߚ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷⾗㊄㕙෸߮ੱ⊛⾗Ḯ㕙ߢ⧰ᚢߒߡ޿ࠆ߇㧘ᄢቇ㒮↢ߩ₪ᓧߥߤࠍ⋡ᜰߒߡቇㇱቇ↢ߣߩធ⸅ߩᯏળࠍ
Ⴧ߿ߔദജ߇ᔅⷐߢ޽ࠆ‫ޕ‬ၮ␆࡮␠ળකቇ♽ᢎቶ߳㈩ዻߐࠇࠆೋᦼ૕㛎ታ⠌Τߩᦼ㑆߇ 2008 ᐕᐲ߆ࠄ 6ㅳ㑆ߦჇ߃ࠆߎߣ߿㧘MD. PhD.ࠦ࡯ࠬߩ⹜ߺ߇ᆎ߹ࠈ߁ߣߒߡ߅ࠅ㧘ၮ␆♽ᢎຬ߇ቇ↢₪ᓧߦߐࠄߦദ
ജߔࠆᔅⷐ߇޽ࠆ‫ޕ‬੹ᓟߩዷᦸ
Aurora ߪ⚦⢩๟ᦼߩ೙ᓮߦ㊀ⷐߥࠠ࠽࡯࠯ߢ޽ࠅ㧘ߘߩ⎇ⓥߪ⪺ߒ޿⊒ዷࠍ␜ߒߡ޿ࠆ‫ࡦ࠴ࠠࡆ࡙ޕ‬-ࡊࡠ࠹ࠕ࠰࡯ࡓ♽ߪ㧘⚦⢩๟ᦼߩ೙ᓮߩߺߥࠄߕ⒳‫ߦ⽎⃻‛↢ߩޘ‬㑐ㅪߒߡ޿ࠆ‫ޕ‬RNF8 ߪ DNA ୃᓳ
ߦ㊀ⷐߥ࠲ࡦࡄࠢ⾰ߢ޽ࠆߎߣ߽᣿ࠄ߆ߣߥߞߚ‫⎇ޕ‬ⓥ࠹࡯ࡑߣߒߡߪ⚦⢩Ⴧᱺ߿߇ࠎߩࠠ࡯ࡢ࡯࠼ߦ
❬߇ࠆ⎇ⓥಽ㊁ߢ޽ࠆ‫ޕ‬୘‫ࠆߡ߽߇࡯ࡃࡦࡔߩޘ‬ജࠍචಽߦ⊒ើߒߡ㧘ߘࠇߙࠇߩ⎇ⓥࠍ௖߆ߕߟߢ߽
ㅴ߼ࠆ࿾㆏ߥദജࠍ㊀ߨߡⴕ߈ߚ޿‫ޕ‬㧙㧙㧔3㧕㜞ᐲవㅴᄖ⑼ቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
౰േ⣂ࡃࠗࡄࠬⴚߦ߅ߌࠆࠣ࡜ࡈ࠻ㆬᛯߪ㊀ⷐߥ⺖㗴ߢ޽ࠅ㧘㐳ᦼ੍ᓟࠍ᳿ቯߔࠆ‫ޕ‬ౝ⢷േ⣂ߪᣢߦ㐳ᦼ㐿ሽ߇⦟ᅢߢ޽ࠆߎߣ߇⸽᣿ߐࠇߡ޿ࠆ߇㧘ߘߩ૶↪ߦߪᢙߩ೙㒢㧘ᐕ㦂ߦࠃࠆ೙㒢߇޽ࠆ‫৻ޕ‬ᣇ㕒⣂ࠣ࡜ࡈ࠻ߩ㐳ᦼ㐿ሽ₸ߪਇ⦟ߢ޽ࠆ߇㧘ᧂߛߦ᦭↪ߥࠣ࡜ࡈ࠻ߢ޽ࠆ‫ߩߘޕ‬㕒⣂ࠣ࡜ࡈ࠻ߩ㐳ᦼ㐿ሽߩᡷༀߩߚ߼ߦ㧘ౝ⊹Ⴧᱺ㧘ਛ⤑Ⴧᱺࠍᛥ೙ߢ߈ࠇ߫↹ᦼ⊛ߥ⎇ⓥߦߥࠆ‫ޕ‬ᢎቶߢߪേ‛ࡃࠗࡄࠬࡕ࠺࡞ࠍ૞
⵾ߒ㧘᛫≸೷㧘᛫↢‛⾰ߩᛩਈ߇㧘ౝ⤑Ⴧᱺࠍᛥ೙ߔࠆߎߣࠍ⸽᣿ߒߚ‫੹ޕ‬ᓟ⥃ᐥᔕ↪߳ߩ⊒ዷࠍ࿑ࠆ‫ޕ‬߹ߚ౰േ⣂޽ࠆ޿ߪਅ⢇േ⣂ߦ߅ߌࠆⴊ▤ᣂ↢ක≮ߪ੹ᓟ߽㊀ⷐߥ࠹࡯ࡑߢ޽ࠆ‫ޕ‬ᢎቶߢߪᄢ✂ߩ VEGFߦ⌕⋡ߒ㧘ᔃ╭᪪Ⴇࡕ࠺࡞ࠍ૞⵾ߒ㧘G-CSF ోりᛩਈߣᄢ✂࡜࠶ࡇࡦࠣߦࠃࠆⴊ▤ᣂ↢ߩ⋧ਸ਼ലᨐࠍ⸽
᣿ߒߚ‫ޕ‬
ᶖൻེᄖ⑼ߢߪ㧘㓚ኂ⢄ߩᴦ≮߿ⴚᓟ⢄ౣ↢ߦ㑐ߔࠆ⎇ⓥࠍਛᔃߦㅴ߼ߡ޿ࠆ‫ޕ‬㓚ኂ⢄ߩᴦ≮ߪ㧘NASH⢄⎬ᄌߦኻߒ h-HGF ࠍㆮવሶዉ౉ߔࠆߎߣߦࠃࠅ⢄✢⛽ൻߩᛥ೙߇น⢻ߢ޽ࠆߎߣࠍ⏕⹺ߒߚ‫ⴚޕ‬ᓟ⢄ౣ↢ߦ㑐ߔࠆ⎇ⓥߪ㧘⢄⒖ᬀᤨߩ⢄㕒⣂ౣᑪਇ⦟ߢ໧㗴ߣߥࠆ߁ߞⴊߦࠃࠆ⢄ౣ↢ਇ⦟ㇱಽࠍ G-CSF ߢᡷༀߢ߈ࠆߎߣࠍ␜ߒߚ‫ߚ߹ޕ‬㧘ᄢ㊂⢄ಾ㒰೨ߦⴕ߁㐷⣂ႧᩖⴚࠍੑᲑ㓏ߦಽߌߡⴕ߁ߎߣߦࠃࠅ㧘ࠃࠅᄢ߈ߥ⢄ౣ↢߇ᓧࠄࠇࠆߎߣࠍ᣿ࠄ߆ߦߒߚ‫⃻ޕ‬࿷ NFǲB 㒖ኂ೷ߦࠃࠆ NASH ⢄ߩ⯯ⴊ⠴ኈ⢻ᡷༀ㧘
LPS ᗵ૞ߦࠃࠆⴚᓟ⢄ਇో੍㒐㧘ᄢᑪਛḡߦࠃࠆᄢ㊂⢄ಾ㒰ᓟ⢄ౣ↢ᡷༀ㧘PGI2 ߦࠃࠆ㐽Ⴇᕈᄢ⣺Ἳߩᴦ≮㧘᛫⩶ࡍࡊ࠴࠼ߦࠃࠆ૕ౝੱᎿ‛ᗵᨴߩᴦ≮ࠍ⎇ⓥਛߢ޽ࠆ‫ޕ‬⢖⪲ಾ㒰ᓟߩ⢖േ⣂ⴊ▤ᐥᷫዋߦࠃࠆฝᔃ⽶⩄ߪߒ߫ߒ߫ㆣㆄߔࠆว૬∝ߢ޽ࠆ‫ޕ‬േ‛ߢߩ⢖⪲ಾ㒰ࡕ࠺࡞ࠍ૞⵾ߒ㧘G-CSF ࠍ↪޿ߚ⢖ಾ㒰ᓟߩ⢖ౣ↢ଦㅴലᨐࠍᬌ⸛ߒߚ⚿ᨐ㧘ฝᔃਇนߩシᷫ㧘ฝቶᔃ╭㊀㊂Ⴧടߩᛥ೙߇ߢ߈㧘⢖േ⣂ᣂ↢ߩ⸽᣿߇ߢ߈ߚ‫੹ޕ‬ᓟ߽Ⴧടߔࠆ COPD ว૬⢖ಾ㒰ߥߤߦኻߒߡߩ
ᴦ≮ᚢ⇛਄㧘㊀ⷐߥ⎇ⓥߢ޽ࠅ㧘੹ᓟߪ⢖⢩ᣂ↢ߦ㑐ߒߡ߽⎇ⓥࠍ⛯ߌࠆ‫ޕ‬એ਄㧘⥃ᐥ਄ߩ⺖㗴ߦኻߒߡၮ␆ታ㛎ࠍⴕ޿ߟߟ㧘ᔃ⤳ⴊ▤ᄖ⑼㧘๭ๆེᄖ⑼㧘ᶖൻེᄖ⑼ߩ㗔ၞߢ⥃ᐥᔕ↪ࠍ⋡ᜰߒߚ⎇ⓥࠍⴕߞߡ޿ࠆ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
┻᧛ඳᢥ
ᢎ᝼(૬છ)㧦 ጊ↰ථ਽
ጤ↰ ዏ
⻠Ꮷ㧦
ፉⴼൎ਽
⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦 ⊕ᯅᐘᵗ⥃ᐥ⻠Ꮷ㧦 ศ↰⋥ఝ⥃ᐥ⻠Ꮷ㧦 ᳓㊁ศ㓷⥃ᐥ⻠Ꮷ㧦 㑸㊁⠨ผ
⍹↰ᚑฮᵗ
කຬ㧦
ᧁ᧛⌀᮸
කຬ㧦
᧻෹዁⚐
කຬ㧦
ฬ⍮ ␽
කຬ㧦
ട⮮༑ᒾ
කຬ㧦

Hirofumi Takemura
Takuya Yamada
Hisashi Iwata
Katsuya Shimabukuro
Koyo Shirahashi
Naomasa Yoshida
Yoshimasa Mizuno
Takafumi Sekino
Narihiro Ishida
Masaki Kimura
Masasumi Matsutomo
Syo Nachi
Yoshihiko Katou

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ೨ේᱜ᣿㧘ဈ↰㓉ㅧ㧘ፉᧄశ⤿㧘㜞ේༀᴦ㧘┻᧛ඳᢥ㧚⁜ዊᑯベߦኻߔࠆᄢേ⣂ᑯ⟎឵ⴚ੍̆ቯ⸛⺰̆㧦⢷ㇱᄖ⑼ߦ߅޿ߡ૗߇ᮡḰⴚᑼߣߥࠅ߁ࠆ߆㧦ᣣᧄ⢷ㇱᄖ⑼ቇળතᓟᢎ⢒ᆔຬળ✬㧚᧲੩㧦․ቯ㕖༡೑ᴺ
ੱᣣᧄ⢷ㇱᄖ⑼ቇળ㧧2007 ᐕ㧦52㧙70㧚
2㧕 ┻᧛ඳᢥ㧚ᄖ⑼∔ᖚࠍ⷗ㅏߔߥ㧍ߎࠎߥᖚ⠪ߤ߁ߔࠆ㧫́⢷߇∩޿㧍́㧦ች࿾⦟᮸✬㓸ਥᐙ㧘㇭ ⟵᣿㧘਄↰⵨৻㧚᦯ㇱ㓉৻✬㧚⥃ᐥ⎇ୃࡊ࡜ࠢ࠹ࠖࠬ㧘᧲੩㧦ᢥశၴ㧧2007 ᐕ㧦14㧙20㧚
3㧕 ┻᧛ඳᢥ㧚౰ⴊⴕౣᑪⴚ́ⴚ೨࡮ⴚਛ࡮ⴚᓟ▤ℂ́㧦㦖㊁ൎᒾ㧘㊀᧻ ብ㧘᐀ౝ᥍ᦶ㧘྾ᵤ⦟ᐔ㧚቟⮮⑲㓶✬㧚ᔃ⤳ⴊ▤ᄖ⑼࠹ࠠࠬ࠻㧘᧲੩㧦ਛᄖකቇ␠㧧2007 ᐕ㧦236㧙242㧚⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 ጤ↰ ዏ㧘┻᧛ඳᢥ㧚⢖≸́ⴚ೨⸻ᢿߦ߅ߌࠆ FDG-PET ߩ᦭↪ᕈ́㧘⥃ᐥ㔀⹹‫ޟ‬ᄖ⑼‫ޠ‬2006 ᐕ㧧68 Ꮞ㧦㧙㧙661㧙666㧚
2㧕 ጤ↰ ዏ㧘⊕ᯅᐘᵗ㧘᧻ᧄ⌀੺㧘᧻੗㓷ผ㧘┻᧛ඳᢥ㧚ᄖ⑼ߩᏱ⼂࡮㕖Ᏹ⼂́ੱߦߪ⡞ߌߥ޿⚛ᧉߥ⇼໧
42́㐿⢷ᚻⴚߪᓟ஥ᣇಾ㐿߇ᮡḰ߆㧘⥃ᐥᄖ⑼ 2007 ᐕ㧧62 Ꮞ㧦822㧙823㧚
3㧕 ᾢ↰ᕺ੺㧘ศ↰㓉ᶈ㧘⼾↰ᴰ㧘ዊୖ⌀ᴦ㧘ጊ↰ථ਽㧘᧛਄໪㓶㧘⑔↰లብ㧚࿾ᣇߦ߅ߌࠆᢇᕆක≮૕೙ߩ⃻⁁ߣ໧㗴ὐ ੹㧘૗߇ᔅⷐᕆോߢ޽ࠆ߆㧘߳߈࿾࡮㔌ፉᢇᕆක≮⎇ⓥળ⹹ 2008 ᐕ㧧9 Ꮞ㧦75㧙78㧚✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ችේ೑ⴕ㧘㘵↰ㄖ⟤㧘᳓⼱ᙗᆭ㧘቟᧛ᐙᄩ㧘ጊ↰ථ਽㧘┻᧛ඳᢥ㧚3 ᐲߩ㐿⣻ᚻⴚߦࠃࠅᢇ๮ߒߚ഍∝ဳࠕࡔ࡯ࡃᕈᄢ⣺Ἳߩ 1 ଀㧘ᣣᧄ⥃ᐥᄖ⑼ቇળ㔀⹹ 2006 ᐕ㧧67 Ꮞ㧦122㧙126㧚
2㧕 ችේ೑ⴕ㧘㘵↰ㄖ⟤㧘᳓⼱ᙗᆭ㧘቟᧛ᐙᄩ㧘ጊ↰ථ਽㧘┻᧛ඳᢥ㧚⿥㖸ᵄౝⷞ㏜ਅๆᒁ⚦⢩⸻߇᦭ലߢ޽
ߞߚ㕖ᯏ⢻ᕈ⤟ፉ⚦⢩⣲ߩ 1 ଀㧘ᣣᧄ⥃ᐥᄖ⑼ቇળ㔀⹹ 2006 ᐕ㧧67 Ꮞ㧦429㧙433㧚
3㧕 ችේ೑ⴕ㧘㘵↰ㄖ⟤㧘ᓟ⮮ోብ㧘᳓⼱ᙗᆭ㧘቟᧛ᐙᄩ㧘᫜ᯅବ੺㧘ጊ↰ථ਽㧘┻᧛ඳᢥ㧚㥘ᓘࡋ࡞࠾ࠕ߇
㑐ਈߒߚߣ⠨߃ࠄࠇࠆ㊎㊄ߦࠃࠆ࿁⣺⓫ሹߩ 1 ଀㧘ᣣᧄ⣻ㇱᢇᕆකቇળ㔀⹹ 2006 ᐕ㧧26 Ꮞ㧦455㧙458㧚
4㧕 ᧻የ ᶈ㧘ጊ↰ථ਽㧘㑸㊁⠨ผ㧘ศ↰⋥ఝ㧘ᧁጊ ⨃㧘ጤ↰ ዏ㧘⊕ᯅᐘᵗ㧘┻᧛ඳᢥ㧚Hand-assisted
laparoscopic surgery(HALS)ਅߦ⣛⤳៰಴ⴚࠍⴕߞߚ⣛Ἳ∝ᕈன⣲≌ߩ 1 ଀㧘ᣣᧄౝⷞ㏜ᄖ⑼ቇળ㔀⹹
2006 ᐕ㧧11 Ꮞ㧦185㧙189㧚
5㧕 ጤਅᜏม㧘቟↰৻ᦶ㧘ਛ੗ ታ㧘ᄢፉ㕏ᐢ㧘⊕ᧁ ੫㧘᫪⣁ਭ㓉㧘᧻የ ᶈ㧘㑸㊁⠨ผ㧘ጊ↰ථ਽㧘ᑝἑༀା㧚ਥ⤟▤⁜⓰ࠍ߈ߚߒߚ⤟ౝಽᴲ⣲≌ߩ 1 ଀㧘⢄⢙⤟ᴦ≮⎇ⓥળ⹹ 2006 ᐕ㧧4 Ꮞ㧦63㧙68㧚
6㧕 ᧁ᧛⌀᮸㧘ጊ↰ථ਽㧘㑸㊁⺈ผ㇢㧘ᧁጊ ⨃㧘ฬ⍮ ␽㧘㑸㊁⠨ผ㧘㒋ᧄ⎇৻㧘┻᧛ඳᢥ㧚ⴚᓟ 4 ᐕ㑆ήౣ⊒↢ሽਛߢ޽ࠆ⍹Ἧൻ⢗≸ߩ 1 ଀㧘ᣣᧄᄖ⑼♽ㅪวቇળ⹹ 2006 ᐕ㧧31 Ꮞ㧦841㧙844㧚
7㧕 ችේ೑ⴕ㧘ᧁጊ ⨃㧘᧻የ ᶈ㧘㑸㊁⠨ผ㧘ጊ↰ථ਽㧘┻᧛ඳᢥ㧚ǩ-fetoprotein ↥↢⚿⣺≸ߩ 1 ଀㧘ᣣᧄ⥃ᐥᄖ⑼ቇળ㔀⹹ 2006 ᐕ㧧67 Ꮞ㧦149㧙153㧚
8㧕 ᧁ᧛⌀᮸㧘ጊ↰ථ਽㧘ᧁጊ ⨃㧘㑸㊁⠨ผ㧘᧻የ ᶈ㧘┻᧛ඳᢥ㧚⤟ౝ೽⣛ߦว૬ߒߚ㘃਄⊹⣲ߩ 2 ଀㧘ᣣᧄ⥃ᐥᄖ⑼ቇળ㔀⹹ 2006 ᐕ㧧67 Ꮞ㧦196㧙200㧚
9㧕 ጊ↰ථ਽㧘㑸㊁⠨ผ㧘᧻የ ᶈ㧘੗ේ 㗉㧘ᧁ᧛⌀᮸㧘ᧁጊ ⨃㧘┻᧛ඳᢥ㧚ೋ࿁ᚻⴚᄢ㊂಴ⴊᓟ㧘ੑᦼ⊛ߦಾ㒰ߒߚ㛽⋚⊒↢ Solitary fibrous tumor ߩ 1 ଀㧘ᣣᧄ⣻ㇱᢇᕆකቇળ㔀⹹ 2006 ᐕ㧧26 Ꮞ㧦889
㧙892㧚
10㧕 㑸㊁⠨ผ㧘ጊ↰ථ਽㧘ศ↰⋥ఝ㧘ችේ೑ⴕ㧘ᧁጊ ⨃㧘┻᧛ඳᢥ㧚ᕆᕈ㛽㜑න⃿ᕈ⊕ⴊ∛ᴦ≮ਛߦ⊒↢ߒߚ⢄⤥≌ߦኻߒ㧘⣻⣧㏜ਅ⤥≌㐿⓹ⴚࠍᣉⴕߒߚ 1 ଀㧘ᣣᧄᄖ⑼♽ㅪวቇળ⹹ 2006 ᐕ㧧31 Ꮞ㧦975㧙978㧚11㧕 ᧁ᧛⌀᮸㧘ጊ↰ථ਽㧘ᧁጊ ⨃㧘㑸㊁⠨ผ㧘┻᧛ඳᢥ㧚ERCP ᓟ⤟Ἳߩᓟߦ⢄Ꮐ⪲ಾ㒰ⴚࠍᣉⴕߒⴚᓟ⤟⤥≌ࠍ⊒↢ߒߚ⢄ౝ⢙▤≸ߩ 1 ଀㧘ᣣᧄᄖ⑼♽ㅪวቇળ⹹ 2006 ᐕ㧧31 Ꮞ㧦979-982㧚
12㧕 ᣧᎹ㤗ℂሶ㧘᧛ἑ૫ઍሶ㧘ጊ↰ථ਽㧘ጤ↰ ዏ㧘┻᧛ඳᢥ㧚ዊఽ NST ߦ߅ߌࠆᩕ㙃჻ߩᓎഀ́ᩕ㙃㓚ኂᖚఽߦኻߔࠆ๟ⴚᦼᩕ㙃▤ℂ́㧘ዊఽᄖ⑼ 2007 ᐕ㧧39 Ꮞ㧦823㧙827㧚
13㧕 ፉⴼൎ਽㧘ችౝᔘ㓷㧘⑔ᧄⴕ⤿㧘ೋ㖸ବ᮸㧘᧛਄ᩕม㧘⍹↰ᚑฮᵗ㧘⌀㍿⑲᣿㧘┻᧛ඳᢥ㧚ㅧᓇ CT ࠍ↪
޿ߚ஥೽ⴊⴕ〝⊒㆐ߩ⹏ଔ́㐽Ⴇᕈേ⣂⎬ൻ∝(ASO)ߦႮ㉄ࠨ࡞ࡐࠣ࡟࡜࡯࠻ࠍ૶↪ߒߚ∝଀ߢߩᬌ⸛́㧘
Angiology Frontier 2007 ᐕ㧧6 Ꮞ㧦66㧙69㧚
14㧕 ችౝᔘ㓷㧘ፉⴼൎ਽㧘੹ᴰ᧻ਭ㧘⑔ᧄⴕ⤿㧘┻᧛ඳᢥ㧚౰⁁േ⣂ࡃࠗࡄࠬⴚߦ߅ߌࠆㄭ૏஥ㆤᢿ⹜㛎ߦࠃࠆⴚਛࠣ࡜ࡈ࠻⹏ଔ㧘ᣣᧄ౰∔ᖚቇળ㔀⹹ 2007 ᐕ㧧13 Ꮞ㧦195㧙200㧚
15㧕 ᧻ᧄ⌀੺㧘ጤ↰ ዏ㧘⊕ᯅᐘᵗ㧘ᑝἑༀା㧘᳓㊁ศ㓷㧘᧻੗㓷ผ㧘┻᧛ඳᢥ㧚FDG-PET ߢ⇣ߥࠆᚲ⷗ࠍ
␜ߒߚ⢖⎬ൻᕈⴊ▤⣲ߩ 2 ଀㧘ᣣᧄ๭ๆེᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧21 Ꮞ㧦86㧙91㧚
16㧕 ችౝᔘ㓷㧘ፉⴼൎ਽㧘᧛਄ᩕม㧘⑔ᧄⴕ⤿㧘⍹↰ᚑฮᵗ㧘ೋ㖸ବ᮸㧘⌀㍿⑲᣿㧘┻᧛ඳᢥ㧚ቢోᚱቶࡉࡠ
࠶ࠢ㧘ᔃਇోࠍᄾᯏߦ⸻ᢿߐࠇߚᚑੱᄢേ⣂❗⓰∝ߩ 1 ᚻⴚ଀㧘ᣣᧄᔃ⤳ⴊ▤ᄖ⑼ቇળ㔀⹹ 2008 ᐕ㧧37
Ꮞ㧦247㧙251㧚
17㧕 ᧛਄ᩕม㧘ፉⴼൎ਽㧘ችౝᔘ㓷㧘┻᧛ඳᢥ㧘᧻ᯅᑧᄈ㧘⼾↰ ᴰ㧘⊕੗㇌ඳ㧘࿯੗ᥓ┨㧘ዊୖ⌀ᴦ㧚ᄖ்ᕈ⢷ㇱᄢേ⣂៊் 9 ଀ߩᬌ⸛㧘ᣣᧄᄖ்ቇળ㔀⹹ 2008 ᐕ㧧22 Ꮞ㧦322㧙325㧚
18㧕 ᧛਄ᩕม㧘ട⮮ਭ᥏㧘┻᧛ඳᢥ㧘ፉⴼൎ਽㧘ችౝᔘ㓷㧘Ṛ⼱ඳᔒ㧘᧻ᯅᑧᄈ㧘⼾↰ ᴰ㧘ዊୖ⌀ᴦ㧚චಽߥೋᦼᴦ≮ߩᓧࠄࠇߥ߆ߞߚ㊰⊛ᔃ៊்ߩ 4 ᢇ๮଀㧘ᣣᧄᄖ்ቇળ㔀⹹ 2008 ᐕ㧧22 Ꮞ㧦326㧙329㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Iwata H, Itokazu M, Shirahashi K, Matsumoto S, Mizuta K, Takemura H. Sterilization using
antibiotic-impregnated porous hydroxyapatite block for osteomyelitis of rib and sternum : A casereport. J Jpn Coll Surg. 2007;32:150-152.
2㧕 Shimabukuro K, Miyauchi T, Takemura H. Rupture of left common iliac artery aneurysm. J Vasc Surg.
2007;45:1083.
IF 3.311
3㧕 Takemura H, Fukumoto Y, Miyauchi T, Shimabukuro K, Imaizumi M, Ishida N. Easy technique formounting the heartstring system into the sheath. Asian Cardiovasc Thorac Ann. 2007;15:444-445.
4㧕 Iwata H, Kiryu T, Shirahashi K, Matsumoto S, Matsui M, Takemura H. Right lower lobectomy afterright upper lobectomy for multiple metastases in lung cancer of the right lower lobe: benefit of middle
lobe preservation. J Thorac Cardiovasc Surg. 2007;134:1078-1080.
IF 3.560
5㧕 Yoshida N, Iwata H, Yamada T , Sekino T, Matsuo H, Shirahashi K, Miyahara T, Kiyama S, Takemura㧙㧙

H. Improvement of the survival rate after rat massive hepatectomy due to the reduction of apoptosis
by caspase inhibitor. J Gastroenterol Hepatol. 2007;22:2015-2021.
6㧕 Mizuno Y, Iwata H, Matsumoto S, Shirahashi K, Maui T, Takemura H. Three pulmonary resections formetastatic lung cancer from hepatocellular carcinoma. J Hepatobiliary Pancreat Surg. 2007;14:582585.
7㧕 Marui T, Iwata H, Shirahashi K, Matsumoto S, Mizuno Y, Matsui M, Takemura H. Histologic damageof lung allografts according to magnitude of acute rejection in the re-isotransplant model. J Heart
Lung Transplant. 2008;27:642-648.
8㧕 Kato H, Kanematsu M, Kiryu T, Iwata H, Shirahashi K, Matsumoto S, Hirose Y, Matsutomo H,
Sasaoka I. Nonfunctional mediastinal parathyroid cyst: imaging finding in two cases. Clin Imaging.
2008;32:310-313.
9㧕 Kiyama S, Yamada T, Iwata H, Sekino T, Matsuo H, Yoshida N, Miyahara T, Matsuno Y, Kimura M,
Matsumoto K, Nakamura T, Takemura H. Reduction of fibrosis in a rat model of non-alcoholicsteatohepatitis cirrhosis by human HGF gene transfection using electroporation. J Gastroenterol
Hepatol. 2008;23:471-476.

IF 1.785

IF 1.182

IF 2.830

IF 1.7854㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦ጊ↰ථ਽㧘⎇ⓥಽᜂ⠪㧦㑸㊁⠨ผ㧘᧻የ ᶈ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦ࠗࡦࡇ࡯࠳ࡦࠬ CT ࠍ↪޿ߚ࠮ࡦ࠴ࡀ࡞࡝ࡦࡄ▵ᬌ಴ᴺߩ⏕┙ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 15㧙18 ᐕᐲ㧧3,800
ජ౞(2,900㧦200㧦300㧦400 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦ጤ↰ ዏ㧘⎇ⓥಽᜂ⠪㧦┻᧛ඳᢥ㧘⊕ᯅᐘᵗ㧘᧻ᧄ⌀੺㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦࠼࠽࡯⢖߳ߩ⥄Ꮖ㛽㜑⚦⢩≹วߦࠃࠆ⢖ౣ↢ߦ㑐ߔࠆታ㛎⊛ᬌ⸛㧧ᐔᚑ 18㧙19 ᐕᐲ㧧3,600
ජ౞(3,100㧦500 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦⊕ᯅᐘᵗ㧘⎇ⓥಽᜂ⠪㧦┻᧛ඳᢥ㧘ጤ↰ ዏ㧘᧻ᧄ⌀੺㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄⪚⧘⎇ⓥ㧦
COPD ߦኻߔࠆ intrathoracic balloon pumping ߩ㐿⊒㧧ᐔᚑ 18㧙19 ᐕᐲ㧧3,300 ජ౞(2,300㧦1,000ජ౞)
4㧕 ⎇ⓥઍ⴫⠪㧦੹ᴰ᧻ਭ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦ࡏ࠷࡝࠿ࠬ࠻ࠠࠪࡦߦࠃࠆേ⣂ࠣ࡜ࡈ࠻ᡨ
❗੍㒐ߣ᜛ᒛലᨐߦ㑐ߔࠆታ㛎⊛ᬌ⸛㧧ᐔᚑ 18㧙19 ᐕᐲ㧧3,500 ජ౞(2,900㧦600 ජ౞)
5㧕 ⎇ⓥઍ⴫⠪㧦ችౝᔘ㓷㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦౰േ⣂ࡃࠗࡄࠬᚻⴚߦ߅ߌࠆᔃ╭⺃㔚․ᕈ
ߦࠃࠆㆡᱜࡃࠗࡄࠬᚻⴚߩ᳿ቯߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 19㧙20 ᐕᐲ㧧3,300 ජ౞(3,200㧦100 ජ౞)
6㧕 ⎇ⓥઍ⴫⠪㧦┻᧛ඳᢥ㧘⎇ⓥಽᜂ⠪㧦ፉⴼൎ਽㧘ችౝᔘ㓷㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄⪚⧘⎇ⓥ㧦⮎೷ᓢ᡼ࠥ࡞ࠪ࡯࠻ࠍ↪޿ߚࠕ࠼࡝ࠕࡑࠗࠪࡦߦࠃࠆⴊ▤่วㇱᣂ↢ౝ⤑⢈ෘᛥ೙ߩᬌ⸛㧧ᐔᚑ 20㧙21 ᐕᐲ㧧3,400 ජ౞(3,000㧦400 ජ౞)
7㧕 ⎇ⓥઍ⴫⠪㧦ጊ↰ථ਽㧘⎇ⓥಽᜂ⠪㧦ጤ↰ ዏ㧘㑸㊁⠨ผ㧘ᧁ᧛⌀᮸㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦
ⴚ೨ൻቇ≮ᴺᓟ⢽⢌ᕈ⢄Ἳߦኻߔࠆ᛫ࡅ࠻ TNF ࡕࡁࠢࡠ࠽࡯࡞᛫૕≮ᴺߩ㐿⊒㧧ᐔᚑ 20㧙22 ᐕᐲ㧧3,800 ජ౞(3,400㧦300㧦100 ජ౞)
8㧕 ⎇ⓥઍ⴫⠪㧦᧻ᧄ⌀੺㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦⢖ಾ㒰ⴚ೨ߩᏱ࿶ૐ㉄⚛࠻࡟࡯࠾ࡦࠣߩ᦭
↪ᕈߩᬌ⸽㧧ᐔᚑ 20㧙21 ᐕᐲ㧧3,400 ජ౞(2,900㧦500 ජ౞)
9㧕 ⎇ⓥઍ⴫⠪㧦⍹↰ᚑฮᵗ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦ᘟᕈ⯯ⴊᕈᔃ∔ᖚߦ߅ߌࠆౣ↢ක≮ࠍ૬ᣉߒߚᄖ⑼⊛ⴊⴕౣᑪⴚߩታ㛎⊛ᬌ⸛㧧ᐔᚑ 20㧙21 ᐕᐲ㧧3,300 ජ౞(2,500㧦800 ජ౞)
2㧕ฃ⸤⎇ⓥ1㧕 ┻᧛ඳᢥ㧦ૐଚⷅᓸ⚦ᚻⴚᡰេ࡮ᢎ⢒⸠✵ࠪࠬ࠹ࡓߩ㐿⊒㨪CMC ⸅ⷡ࠮ࡦࠨߣߘߩᔕ↪㨪㧧ᐔᚑ
16㧙20 ᐕᐲ㧧(6,937㧦6,937㧦2,531㧦4,273㧦3,786 ජ౞(৻⥸▤ℂ⾌㒰ߊ))㧦⽷࿅ᴺੱጘ㒂⋵⎇ⓥ㐿⊒⽷࿅
2㧕 ┻᧛ඳᢥ㧘ጊ↰ථ਽㧘㑸㊁⠨ผ㧘᧻የ ᶈ㧦ࠛ࡞ࡊ࡜࠶࠻ᵈ኿↪ 100mg ૶↪ᚑ❣⺞ᩏ㧧ᐔᚑ 17㧙
18 ᐕᐲ㧧150,150 ౞㧦ᩣᑼળ␠ࡗࠢ࡞࠻ᧄ␠
3㧕 ┻᧛ඳᢥ㧘੹ᴰ᧻ਭ㧦ࠞ࡯ࡍࡦ࠲࡯ࠛ࠼ࡢ࡯࠭‐ᔃߩ߁⤑↢૕ᑯ ⁜ዊࠢ࡝࠾ࠞ࡞ࠬ࠲࠺ࠖ㧧ᐔᚑ17㧙18 ᐕᐲ㧧163,800 ౞㧦ࠛ࠼ࡢ࡯࠭࡜ࠗࡈࠨࠗࠛࡦࠬᩣᑼળ␠
4㧕 ┻᧛ඳᢥ㧘੹ᴰ᧻ਭ㧦ࠪ࡝ࠦࡦࠦ࡯࠻ੱᎿ⢖ߩ⥃ᐥലᨐߣ⠴ਭᕈ(૶↪ᚑ❣⺞ᩏ)㧧ᐔᚑ 17㧙18 ᐕᐲ㧧
300,300 ౞㧦ᴰᎿක⑼Ꮏᬺᩣᑼળ␠
5㧕 ┻᧛ඳᢥ㧘ፉⴼൎ਽㧦ᮨဳੱᎿ⢖ࡂࠗ࡜ࠗ࠻ 7000 ߩ․ቯ૶↪ᚑ❣⺞ᩏ㧧ᐔᚑ 19㧙20 ᐕᐲ㧧675,675
౞㧦ᩣᑼળ␠࠻࡜ࠗ࠹࠶ࠢ
6㧕 ጊ↰ථ਽㧦ࠕࡃࠬ࠴ࡦὐṢ㕒ᵈ↪ 100mg/4mL, ห 400mg/16mL ․ቯ૶↪ᚑ❣⺞ᩏ㧧ᐔᚑ 19㧙20㧙㧙ᐕᐲ㧧225,225 ౞㧦ਛᄖ⵾⮎ᩣᑼળ␠7㧕 ጊ↰ථ਽㧘㑸㊁⠨ผ㧘ศ↰⋥ఝ㧘ᧁ᧛⌀᮸㧘᧖ᧄ℉຦㧦࠯ࡠ࡯࠳®㍤ 300 ․ቯ૶↪ᚑ❣⺞ᩏ‫ޟ‬DukesC⚿⣺≸ߦ߅ߌࠆⴚᓟ⵬ഥൻቇ≮ᴺ‫ޠ‬㧧ᐔᚑ 20㧙21 ᐕᐲ㧧225,225 ౞㧦ਛᄖ⵾⮎ᩣᑼળ␠8㧕 ጊ↰ථ਽㧘ጤ↰ ዏ㧘ፉⴼൎ਽㧘(ઁ 8 ฬ)㧦₂ⴊࡌ࠾ࡠࡦ-I ૶↪ᚑ❣⺞ᩏ(ૐ෶ߪήࠟࡦࡑࠣࡠࡉ࡝
ࡦⴊ∝㧘㊀∝ᗵᨴ∝ߦ߅ߌࠆ᛫↢‛⾰ߣߩ૬↪㧘․⊒ᕈⴊዊ᧼ᷫዋᕈ⚡᢬∛㧘Ꮉፒ∛ߩᕆᕈᦼ)㧧ᐔᚑ 20㧙22 ᐕᐲ㧧300,300 ౞㧦Ꮲੱࡈࠔ࡯ࡑᩣᑼળ␠
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬ┻᧛ඳᢥ㧦
1㧕 ᣣᧄᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄⴊ▤ᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ౰േ⣂ᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄ↲⁁⣼ᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)5㧕 ᣣᧄᔃ⤳ⴊ▤ᄖ⑼ቇળ⹏⼏ຬ(ᐔᚑ 18 ᐕ 2 ᦬㨪⃻࿷)
6㧕 ᣣᧄ⢷ㇱᄖ⑼ቇળ⹏⼏ຬ(ᐔᚑ 18 ᐕ 4 ᦬㨪⃻࿷)7㧕 ᣣᧄ౰∔ᖚቇળ⹏⼏ຬ(ᐔᚑ 18 ᐕ 12 ᦬㨪⃻࿷)8㧕 ᣣᧄᓴⅣེቇળ⹏⼏ຬ(ᐔᚑ 20 ᐕ 4 ᦬㨪⃻࿷)9㧕 ᣣᧄᓴⅣེቇળ᧲ᶏᡰㇱ⹏⼏ຬ(㨪⃻࿷)10㧕 㑐⷏⢷ㇱᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)11㧕 ᧲ᶏᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)12㧕 ᣣᧄ Off-pump CABG ⎇ⓥળᐙ੐(㨪⃻࿷)13㧕 ᣣᧄᄖ⑼ቇળጘ㒂⋵ක≮቟ో▤ℂ⽿છ⠪(ᐔᚑ 19 ᐕ 2 ᦬㨪⃻࿷)
14㧕 ᣣᧄᄖ⑼ቇળਛㇱ࿾඙࿾ၞ቟ో▤ℂㆇ༡ᆔຬળᆔຬ(ᐔᚑ 19 ᐕ 2 ᦬㨪⃻࿷)ጊ↰ථ਽㧦
1㧕 ᣣᧄᄖ⑼ቇળઍ⼏ຬ(ᐔᚑ 18 ᐕ 2 ᦬㨪ᐔᚑ 20 ᐕ 2 ᦬)
2㧕 ᣣᧄ⢄⢙⤟ᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ⢗≸ቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᧲ᶏᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)ጤ↰ ዏ㧦
1㧕 ᣣᧄ⢷ㇱᄖ⑼ቇળ⹏⼏ຬ(ᐔᚑ 18 ᐕ 4 ᦬㨪⃻࿷)2㧕 㑐⷏⢷ㇱᄖ⑼ቇળ⹏⼏ຬ(ᐔᚑ 19 ᐕ 6 ᦬㨪⃻࿷)
3㧕 ᧲ᶏᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄ⤳ེ⒖ᬀࡀ࠶࠻ࡢ࡯ࠢਛᣣᧄᡰㇱㆇ༡ᆔຬ(㨪⃻࿷)ፉⴼൎ਽㧦1㧕 ᣣᧄⴊ▤ᄖ⑼ቇળ᧲ᶏ࡮ർ㒽࿾ᣇળ਎⹤ੱ(ᐔᚑ 20 ᐕ 3 ᦬㨪⃻࿷)2㧕ቇળ㐿௅┻᧛ඳᢥ㧦
1㧕 ╙ 85 ࿁᧲ᶏᔃ⤳ᄖ⑼ᙣ⹤ળ(ᐔᚑ 18 ᐕ 9 ᦬㧘ጘ㒂)
3㧕ቇⴚ㔀⹹
ߥߒ㧙㧙

7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳┻᧛ඳᢥ㧦
1㧕 52nd Annual Conference IACTS(2006.02, Bangalore, ᜗ᓙ⻠Ṷ‫ޟ‬Total arch replacement utilizing
home-made branched graft for the cerebral aiming for no cerebral circulatory arrest‫ޠ‬Ṷ⠪)
2㧕 ╙ 70 ࿁⸥ᔨᣣᧄᓴⅣེቇળ✚ળ࡮ቇⴚ㓸ળ(ᐔᚑ 18 ᐕ 3 ᦬㧘ᗲ⍮㧘․೎࠮࠶࡚ࠪࡦ‫ޟ‬CABG&Mild
MR ߩ Strategy‫ޠ‬ᐳ㐳)
3㧕 ᐔᚑ 18 ᐕᤐቄጘ㒂ᄖ⑼ᙣ⹤ળ(ᐔᚑ 18 ᐕ 4 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ᒻᚑᄖ⑼ߩ⃻⁁ߦߟ޿ߡ‫ޠ‬ᐳ㐳)
4㧕 ᣣක↢ᶦᢎ⢒දജ⻠ᐳ ࠮ࡒ࠽࡯⣖࡮ᔃⴊ▤∔ᖚ⻠ᐳ(ᐔᚑ 18 ᐕ 4 ᦬㧘ጘ㒂㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪ
ࡦ‫ޟ‬౰േ⣂∔ᖚᴦ≮ߩࡐࠗࡦ࠻㨪∝଀ࠍਛᔃߦ㨪 3㧚⁜ᔃ∝ߣ CABG‫ޠ‬Ṷ⠪)
5㧕 ╙ 206 ࿁ጘ㒂ᄖ⑼㓸⺣ળጘ㒂⋵කᏧળᄖ⑼කㇱળ․೎⻠Ṷળ(ᐔᚑ 18 ᐕ 4 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ᄖ⑼ቇߩߎࠇ߆ࠄ‫ޠ‬มળ)6㧕 The 14th Annual Meeting of the Asian Society for Cardiovascular Surgery(ᐔᚑ 18 ᐕ 6 ᦬㧘ᄢ㒋㧘ࡈࠜ࡯࡜ࡓ‫ޟ‬CABG 9‫ޠ‬ᐳ㐳)7㧕 ╙ 10 ࿁ጘ㒂ࠪࡦࡐࠫ࠙ࡓ(ᐔᚑ 18 ᐕ 7 ᦬㧘ጘ㒂㧘‫ޟ‬ᔃ⤳ᄖ⑼ߦ߅ߌࠆࡠࡏ࠶࠻ᚻⴚߩ⃻ᴫߣ዁᧪‫ޠ‬Ṷ⠪)8㧕 ╙ 85 ࿁᧲ᶏᔃ⤳ᄖ⑼ᙣ⹤ળ(ᐔᚑ 18 ᐕ 9 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫⿥ޟ‬ૐଚⷅᔃ⤳ᚻⴚ‫ޠ‬ᐳ㐳)
9㧕 CCT2006 Surgical(ᐔᚑ 18 ᐕ 9 ᦬㧘␹ᚭ㧘࠺ࠖ࠽࡯ࠞࡦࡈࠔ࡟ࡦࠬ‫ޟ‬ᔃ⤳ⴊ▤ᄖ⑼㗔ၞߢૐଚⷅߪ
ߤߎ߹ߢน⢻߆㧫 ࠣ࡜ࡈ࠻ណข‫ޠ‬Ṷ⠪)10㧕 ╙ 4 ࿁የᒛ↢ᵴ⠌ᘠ∛⎇ⓥળ(ᐔᚑ 18 ᐕ 11 ᦬㧘ᗲ⍮㧘․೎⻠Ṷ‫ޟ‬ᔃ⤳ᄖ⑼ߩ⃻⁁ߣᧂ᧪‫ޠ‬Ṷ⠪)11㧕 ╙ 31 ࿁ CNP ⎇ⓥળ(ᐔᚑ 18 ᐕ 12 ᦬㧘ᗲ⍮㧘ᢎ⢒⻠Ṷ‫ޟ‬ᩕ㙃▤ℂߦᔅⷐߥᔃ⤳ⴊ▤ᄖ⑼ߩ⍮⼂‫ޠ‬Ṷ⠪)12㧕 2 ᄖ࡮ᧄᎽߩળ(ᐔᚑ 19 ᐕ 1 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ᔃ⤳ᚻⴚߩૐଚⷅൻࠍ⋡ᜰߒߡ‫ޠ‬Ṷ⠪)
13㧕 ╙ 35 ࿁ᣣᧄⴊ▤ᄖ⑼ቇળ✚ળ(ᐔᚑ 19 ᐕ 5 ᦬㧘ฬฎደ㧘ળ㐳ⷐᦸṶ㗴‫⿥ޟ‬㜞㦂⠪(80 ᱦએ਄)ߩᄢേ
⣂≜ߦኻߔࠆᴦ≮ᣇ㊎ߣⴚᓟߩ QOL‫ޠ‬ᐳ㐳)
14㧕 ╙ 4 ࿁⢷ㇱᄖ⑼ࡈࠜ࡯࡜ࡓ(ᐔᚑ 19 ᐕ 6 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ᄢേ⣂ၮㇱ⟎឵ⴚߩ Up to Date‫ޠ‬ᐳ㐳)15㧕 Fighting Vascular Events in Gifu 2007(ᐔᚑ 19 ᐕ 6 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫∛ޟ‬ᘒ߆ࠄߺߚ㐽Ⴇᕈേ⣂⎬ൻ∝ߩᴦ≮㧙ᦨᣂߩࠟࠗ࠼࡜ࠗࡦ TASKΤࠍ߰߹߃ߡ㧙‫ޠ‬ᐳ㐳)16㧕 ╙ 32 ࿁ᣣᧄᄖ⑼♽ㅪวቇળቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 6 ᦬㧘᧲੩㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ‫ޟ‬ᒰ⑼ߦ߅ߌ
ࠆ maze ᚻⴚ∝଀ߩᬌ⸛‫ޠ‬Ṷ⠪)17㧕 ╙ 114 ࿁ᣣᧄᓴⅣེቇળർ㒽࿾ᣇળ(ᐔᚑ 19 ᐕ 7 ᦬㧘㊄ᴛ㧘ᢎ⢒⻠Ṷ‫ޟ‬ጘ㒂ߦ߅ߌࠆᔃ⤳ᄖ⑼ߩ⃻⁁ߣ⹜ߺ㧙OPCAB, ௯ᚱᑯᒻᚑ, ᑿㇱ⟎឵㧙‫ޠ‬Ṷ⠪)18㧕 ╙ 2 ࿁ GIFU Surgical Metabolic Club(ᐔᚑ 19 ᐕ 7 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ᄖ⑼ⴚᓟߩᩕ㙃▤ℂ‫ޠ‬มળ)19㧕 ╙ 12 ࿁ᣣᧄ౰േ⣂ᄖ⑼ቇળቇⴚᄢળ(ᐔᚑ 19 ᐕ 7 ᦬㧘᧲੩㧘ࠗࡦ࠲࡯࠽࡚ࠪ࠽࡞ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬DES
ᤨઍߩℂᗐߩⴚᑼߣߪ㧫‫ޠ‬Ṷ⠪)20㧕 ᐔᚑ 19 ᐕᐲጘ㒂⋵කᏧળഭἴᜰቯකㇱળᤐቄ✚ળ(ᐔᚑ 19 ᐕ 7 ᦬㧘⻠Ṷ‫ޟ‬ᄬᢌߦቇ߱‫ޠ‬ᐳ㐳)21㧕 ╙ 209 ࿁ጘ㒂ᄖ⑼㓸⺣ળ(ᐔᚑ 19 ᐕ 10 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬਄ㇱᶖൻེ≸ᴦ≮ߩᦨ೨✢‫ޠ‬มળ)22㧕 ╙ 21 ࿁ᣣᧄ౰∔ᖚቇળቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 12 ᦬㧘੩ㇺ㧘ᄖ⑼ࡆ࠺ࠝࠪࡦࡐࠫ࠙ࡓ‫ޟ‬CABG ߦ߅ߌ
ࠆ⑳ߩᎿᄦ㧙㐿⢷ེ㧘ౝⷞ㏜ RA ណข㧘ฝ㐿⢷࿁ㆱߣ IABP ૶↪ߦࠃࠆ OPCAB ₸ߩჇട㧙‫ޠ‬Ṷ⠪)23㧕 ╙ 22 ࿁ᔃ⤳ⴊ▤ᄖ⑼࠙ࠖࡦ࠲࡯࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 1 ᦬㧘⑔ፉ㧘ࡆ࠺ࠝࡈࠜ࡯࡜ࡓ‫ޟ‬౰േ⣂ࡃࠗࡄࠬⴚߦ߅ߌࠆ㧘ߎ߹ߏ߹ߣߒߚᎿᄦ‫ޠ‬Ṷ⠪)24㧕 ╙ 19 ࿁ਅํකᏧળቇⴚ⻠Ṷળ(ᐔᚑ 20 ᐕ 3 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬㜞㦂ൻ␠ળߦ߅ߌࠆᔃ⤳ⴊ▤ᄖ⑼ߩᓎഀ‫ޠ‬Ṷ⠪)25㧕 ╙ 13 ࿁ጘ㒂⢷ㇱ∔ᖚᴦ≮⎇ⓥળ(ᐔᚑ 20 ᐕ 3 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬EGFR-TKI ᴦ≮ߩᦨㆡൻࠍ⋡ᜰߒߡ‫ޠ‬ᐳ㐳)26㧕 Veritas Cor Cirurugie 㨪࠺ࠖࡌ࡯࠻ࠠࡖ࡜ࡃࡦ in Nagoya㨪(ᐔᚑ 20 ᐕ 4 ᦬㧘ฬฎደ㧘࠮࠶࡚ࠪࡦ‫ⴊ⯯ޟ‬ᕈ MR ߦኻߔࠆᔃᜉേਅᑯベᒻᚑⴚ‫ޠ‬Ṷ⠪)27㧕 ╙ 36 ࿁ᣣᧄⴊ▤ᄖ⑼ቇળቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 4 ᦬㧘᧲੩㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯‫ޟ‬๟ⴚᦼ▤ℂߦ߅ߌࠆᣂߚߥᔃ╭଻⼔ᚢ⇛㨪⍴ᤨ㑆૞↪ဳǪㆤᢿ⮎ߩ૶޿ᣇߪ࡮࡮࡮㧫‫ޠ‬ᐳ㐳)28㧕 ᧲ᶏਇᢛ⣂ᄖ⑼⻠Ṷળ(ᐔᚑ 20 ᐕ 4 ᦬㧘ฬฎደ㧘⻠Ṷ‫ޟ‬ᔃᚱ⚦േᄖ⑼ᴦ≮́MAZE ᚻⴚේὐߩౣ⏕⹺ߣ Device ᚻⴚ‫ޟޠ‬Surgical Management of Atrial Fibrillatiońᄖ⑼⊛ᔃᚱ⚦േߩᴦ≮‫ޠ‬ᐳ㐳)29㧕 ╙ 49 ࿁⑔੗ᓴⅣེหᅢળቇⴚ⎇ⓥળ(ᐔᚑ 20 ᐕ 5 ᦬㧘⑔੗㧘․೎⻠Ṷ‫੹ޟ‬ᣣߩ౰േ⣂ࡃࠗࡄࠬⴚ́

㧙㧙ࠣ࡜ࡈ࠻ㆬᛯ߆ࠄࡠࡏ࠶࠻߹ߢ́‫ޠ‬Ṷ⠪)30㧕 ╙ 51 ࿁㑐⷏⢷ㇱᄖ⑼ቇળቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 6 ᦬㧘ንጊ㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯‫ޟ‬㐿ᔃⴚᓟߩਇᢛ⣂(ᔃᚱ⚦േ)ߦኻߔࠆᴦ≮ᚢ⇛-⎬⤑ᄖ㤗㈮ߣǪㆤᢿ⮎ߩ૶↪́‫ޠ‬ᐳ㐳)31㧕 ╙ 210 ࿁ጘ㒂ᄖ⑼㓸⺣ળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬਄ㇱᶖൻ▤ᖡᕈ∔ᖚߦኻߔࠆౝⷞ㏜ਅ
ᚻⴚߩᦨ೨✢‫ޠ‬มળ)32㧕 ╙ 75 ࿁ጘ㒂ᓴⅣེ∔ᖚ⎇ⓥળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ᔃᚱ⚦േߩᄖ⑼ᴦ≮‫ޠ‬ᐳ㐳)33㧕 ╙ 10 ࿁ᣣᧄ OFF-PUMP CABG ⎇ⓥળ(ᐔᚑ 20 ᐕ 7 ᦬㧘᧲੩㧘ࠬࡍࠪࡖ࡞ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬Techniquein CABG-Indication of OPCAB-‫ޠ‬Ṷ⠪)34㧕 ╙ 61 ࿁ᣣᧄ⢷ㇱᄖ⑼ቇળቯᦼቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 10 ᦬㧘⑔ጟ㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯‫ޟ‬Transit time
ultrasound flow meter ߣ Doppler ᴺߦࠃࠆࠣ࡜ࡈ࠻⹏ଔ‫ޠ‬Ṷ⠪)35㧕 ╙ 6 ࿁ർ㒽ᓴⅣ㓚ኂ⎇ⓥળ(ᐔᚑ 20 ᐕ 11 ᦬㧘㊄ᴛ㧘․೎⻠Ṷ‫ޟ‬ᄢⴊ▤᛹ᶖⴊ▤ᓴⅣਇోߦኻߔࠆᄖ
⑼ᴦ≮‫ޠ‬Ṷ⠪)36㧕 ╙ 211 ࿁ጘ㒂ᄖ⑼㓸⺣ળ(ᐔᚑ 20 ᐕ 11 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫⋥ޟ‬⣺≸ߦኻߔࠆ⣻⣧㏜ਅᚻⴚߩㅴᱠ‫ޠ‬มળ)37㧕 ATCVS stage5(ᐔᚑ 20 ᐕ 11 ᦬㧘ᴒ✽㧘‫ޟ‬Wet lab workshop in CABG, arrhythmia & valve‫ޠ‬Task
Force)
38㧕 ISMICS2008 Winter Workshop(ᐔᚑ 20 ᐕ 11 ᦬㧘ᴒ✽㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬What is the optimal CABG
in DES era-Bliateral internal thoracic ateries and endoscopically-harvested radial artery as the
optimal graft selection for CABǴ‫ޠ‬Ṷ⠪)39㧕 ISMICS2008 Winter Workshop(ᐔᚑ 20 ᐕ 11 ᦬㧘ᴒ✽㧘Invited Lecture‫ޟ‬The analysis of 125 casesof robotic heart surgery‫ޠ‬ᐳ㐳)40㧕 ISMICS2008 Winter Workshop(ᐔᚑ 20 ᐕ 11 ᦬㧘ᴒ✽㧘Morning Seminar ᐳ㐳)41㧕 ╙ 7 ࿁ᔃ⤳ⴊ▤ᄖ⑼ᚻⴚᚻᛛ࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 11 ᦬㧘᧲੩㧘․೎⻠Ṷ‫ࠗ࡜ࠝ࠺ࡆ࡞ࡖ࠴࡯ࠔࡧޟ‬ࡉ㧦௯Ᏺᑯᚻⴚ́‫ࠆߔ߁ߤࠄߥߚߥ޽ޟ‬㧫‫ޠ‬‫ޠ‬ᐳ㐳)
42㧕 ╙ 9 ࿁⸘᷹⥄േ೙ᓮቇળ(ᐔᚑ 20 ᐕ 12 ᦬㧘ጘ㒂㧘ၮ⺞⻠Ṷ‫ޟ‬ጘ㒂࡮ᄢ၂࿾඙ࡠࡏ࠹ࠖ࠶ࠢవ┵ක≮ࠢ࡜ࠬ࠲࡯ߦ߅ߌࠆ⎇ⓥ᭎ⷐ‫ޠ‬Ṷ⠪)ጊ↰ථ਽㧦
1㧕 ╙ 106 ࿁ᣣᧄᄖ⑼ቇળ(ᐔᚑ 18 ᐕ 3 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬౰േ⣂ࡃࠗࡄࠬⴚ࡮≸ಾ㒰 1 ᦼ⊛ᚻⴚߩᚑ❣ߣⴚਛ࿁෼ⴊ૶↪ߩᤚ㕖ߦߟ޿ߡ‫ޠ‬Ṷ⠪)
2㧕 International College of Surgeons 17th Joint Congress of Asia & Pacific Federations & 53rd
Annual Congress of the Japan Section(ᐔᚑ 19 ᐕ 6 ᦬㧘੩ㇺ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬Our strategy for thepatients of both coronary artery disease and malignant neoplasm, and the feasibility of
intraoperative autotransfusion.‫ޠ‬Ṷ⠪)
3㧕 ╙ 44 ࿁ᣣᧄ⣻ㇱᢇᕆකቇળ✚ળ(ᐔᚑ 20 ᐕ 3 ᦬㧘ᮮᵿ㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ‫ޟ‬⣻ㇱᄢേ⣂≜⎕ⵚߦኻߔࠆ࠴࡯ࡓක≮ᚢ⇛́․ߦ⣺▤⯯ⴊუᱫߦߟ޿ߡ́‫ޠ‬Ṷ⠪)
4㧕 ╙ 108 ࿁ᣣᧄᄖ⑼ቇળ(ᐔᚑ 20 ᐕ 5 ᦬㧘㐳ፒ㧘ࠨ࡯ࠫࠞ࡞ࡈࠜ࡯࡜ࡓ‫ޟ‬⢗(ㆮવሶ⸻ᢿ)‫ޠ‬ᐳ㐳)
5㧕 ᶖൻེ≸ൻቇ≮ᴺࠪࡦࡐࠫ࠙ࡓ́࠴࡯ࡓක≮́(ᐔᚑ 20 ᐕ 5 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬ᄖ᧪ൻቇ≮ᴺߩታ㓙́੩ㇺᄢቇߢߩขࠅ⚵ߺ́‫ޠ‬ᐳ㐳)
6㧕 ╙ 35 ࿁ CNP ⎇ⓥળ‫⥃ޟ‬ᐥᩕ㙃ᛛ⢻ࠬࠠ࡞ࠕ࠶ࡊ࠮ࡒ࠽࡯‫(ޠ‬ᣣᧄ⥃ᐥᩕ㙃≮ᴺ⎇ⓥળ)(ᐔᚑ 20 ᐕ
12 ᦬㧘ᗲ⍮㧘⻠Ṷ‫ޟ‬ᩕ㙃▤ℂߦᔅⷐߥᶖൻེᄖ⑼ߩ⍮⼂‫ޠ‬Ṷ⠪)ጤ↰ ዏ㧦
1㧕 ╙ 50 ࿁㑐⷏⢷ㇱᄖ⑼ቇળቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 6 ᦬㧘ᄢ㒋㧘ࡆ࠺ࠝࠪࡦࡐࠫ࠙ࡓ‫ޟ‬High vision వ┵エᕈ㏜ࠍ↪޿ߚ᜛ᄢ⢷⣼៰㒰ⴚ‫ޠ‬Ṷ⠪)2㧕 7 ᦬ጘ㒂ᄖ⑼ᙣ⺣ળ(ᐔᚑ 19 ᐕ 7 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ૐଚⷅࠍ⋡ᜰߒߚ๭ๆེᄖ⑼ᚻⴚ‫ޠ‬Ṷ⠪)
3㧕 ╙ 6 ࿁ጘ㒂⋵⑌ᾍផㅴ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 11 ᦬㧘ጘ㒂㧘Lecture‫ⴚޟ‬೨ᓟߦ߅ߌࠆ⑌ᾍߩ⁁ᴫߦߟ޿ߡ‫ޠ‬Ṷ⠪)4㧕 6th Technical Seminar for Thoracic Surgery(ᐔᚑ 19 ᐕ 11 ᦬㧘ጘ㒂㧘⻠⟵‫ޟ‬ᒰ⑼ߢᣉⴕߒߡ޿ࠆ⢷⣧㏜ᚻⴚߦ߅޿ߡᵈᗧߒߡ޿ࠆߎߣ ․ߦࠬ࠹࡯ࡊ࡜࡯ߩ૶↪ᤨߦ߅޿ߡ‫ޠ‬Ṷ⠪)5㧕 The 19th International Conference of Society for Medcal Innovation and Technology(ᐔᚑ 19 ᐕ 11᦬㧘ችၔ㧘TUBERO/SMIT Joint Symposium‫ޟ‬Thoracoscopic thymectomy using high vision flexible
thoraco-videoscope‫ޠ‬Ṷ⠪)㧙㧙6㧕 ╙ 33 ࿁ CNP ⎇ⓥળ‫⥃ޟ‬ᐥᩕ㙃ᛛ⢻ࠬࠠ࡞ࠕ࠶ࡊ࠮ࡒ࠽࡯‫(ޠ‬ᣣᧄ⥃ᐥᩕ㙃≮ᴺ⎇ⓥળ)(ᐔᚑ 19 ᐕ
12 ᦬㧘ᗲ⍮㧘⻠Ṷ‫ޟ‬ᩕ㙃▤ℂߦᔅⷐߥ⢷ㇱᄖ⑼⍮⼂‫ޠ‬Ṷ⠪)7㧕 ╙ 51 ࿁㑐⷏⢷ㇱᄖ⑼ቇળቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 6 ᦬㧘ንጊ㧘ࡆ࠺ࠝࠪࡦࡐࠫ࠙ࡓ‫ޟ‬᳇▤ᡰᢿ┵≪ߦኻߔࠆᶖൻེᄖ⑼ߣߩᒝ⺞ᚻⴚ‫ޠ‬Ṷ⠪)8㧕 ╙ 51 ࿁㑐⷏⢷ㇱᄖ⑼ቇળቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 6 ᦬㧘ንጊ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬⢷⣧㏜ਅ⢖⪲ಾ㒰ⴚߩⴊ
▤ಣℂߩᎿᄦ́High vision ᜛ᄢⷞ㊁ߢߩ⚵❱೸㔌ߣ stapler ᠲ૞́‫ޠ‬Ṷ⠪)9㧕 ╙ 16 ࿁๭ๆེᄖ⑼⢷⣧㏜࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 7 ᦬㧘㕒ጟ㧘⻠Ṷ‫ޟ‬ᒰ⑼ߢᣉⴕߒߡ޿ࠆ⢷⣧㏜ਅ⢖⪲ಾ㒰ⴚߢᵈᗧߒߡ޿ࠆߎߣ ․ߦࠬ࠹࡯ࡊ࡜࡯૶↪ᤨߦ߅޿ߡ‫ޠ‬Ṷ⠪)10㧕 Professional Education Seminar Σ‫ޟ‬VATS-Lobectomy‫(ޠ‬ᐔᚑ 20 ᐕ 9 ᦬㧘⑔ፉ㧘⻠Ṷ‫ޟ‬⢷⣧㏜ਅ
⢖⪲ಾ㒰ߦ߅ߌࠆ቟ోߥࠬ࠹࡯ࡊ࡜࡯ᠲ૞‫ޠ‬Ṷ⠪)11㧕 ╙ 17 ࿁๭ๆེᄖ⑼⢷⣧㏜࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 10 ᦬㧘⑔ፉ㧘⻠Ṷ‫ޟ‬⢷⣧㏜ਅ⢖⪲ಾ㒰ⴚࠍ቟ోߦⴕ
߁਄ߢᵈᗧߒߡ޿ࠆߎߣ‫ޠ‬Ṷ⠪)12㧕 ጘ㒂⢖߇ࠎᏒ᳃࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 10 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬⢖≸㨪ᖚ⠪ߐࠎߦ߿ߐߒ޿ᚻⴚࠍ⋡ᜰߒߡ㨪‫ޠ‬Ṷ⠪)
13㧕 ISMICS2008 Winter Workshop(ᐔᚑ 20 ᐕ 11 ᦬㧘ᴒ✽㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬Safe stapler procedure forthe pulmonary artery and vein in video-assisted thoracoscopic lobectomy‫ޠ‬Ṷ⠪)
14㧕 ISMICS2008 Winter Workshop(ᐔᚑ 20 ᐕ 11 ᦬㧘ᴒ✽㧘ࠗࡉ࠾ࡦࠣ࠮ࡒ࠽࡯
‫ޟ‬Hybid VATS lobectomy& Segmentectomy by the close vision through high vision flexible thoracoscope‫ޠ‬Ṷ⠪)
㑸㊁⠨ผ㧦
1㧕 ╙ 109 ࿁ᣣᧄᶖൻེ∛ቇળ᧲ᶏᡰㇱ଀ળ(ᐔᚑ 20 ᐕ 11 ᦬㧘ฬฎደ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᣧᦼᄢ⣺≸ߦኻ
ߔࠆౝⷞ㏜⊛ಾ㒰ⴚᓟߩㅊടᄖ⑼ᴦ≮́⣻⣧㏜ਅᚻⴚࠍਛᔃߦ́‫ޠ‬Ṷ⠪)ችౝᔘ㓷㧦
1㧕 Fighting Vascular Events in Gifu 2007(ᐔᚑ 19 ᐕ 6 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬ਅ⢇㐽Ⴇᕈേ⣂⎬ൻ∝ߦኻߔ
ࠆᒰ⑼ߦ߅ߌࠆᄖ⑼⊛ᴦ≮ᚢ⇛‫ޠ‬Ṷ⠪)
2㧕 ╙ 74 ࿁ጘ㒂ᓴⅣེ∔ᖚ⎇ⓥળ(ᐔᚑ 20 ᐕ 2 ᦬㧘ጘ㒂㧘ᢎ⢒⻠Ṷ‫ޟ‬౰േ⣂ࡃࠗࡄࠬⴚߦ߅ߌࠆⴊᵹ㊂߅ࠃ߮ⴊᵹㅦᐲߦࠃࠆⴚਛࠣ࡜ࡈ࠻⹏ଔ‫ޠ‬Ṷ⠪)⊕ᯅᐘᵗ㧦
1㧕 ISMICS2008 Winter Workshop( ᐔ ᚑ 20 ᐕ 11 ᦬ 㧘 ᴒ ✽ 㧘 ࠪ ࡦ ࡐ ࠫ ࠙ ࡓ ‫ ޟ‬Identification ofintersegmental plane with physiological function of oxygen absorption in the lung segmental
resection‫ޠ‬Ṷ⠪)
᧖ᧄ℉຦㧦
1㧕 ጘ㒂ᄢᑪਛḡࡈࠜ࡯࡜ࡓ(ᐔᚑ 20 ᐕ 3 ᦬㧘ጘ㒂㧘ᢎ⢒⻠Ṷ‫ޟ‬ᄢᑪਛḡߦࠃࠆ⢄ౣ↢ଦㅴലᨐߩᬌ⸛‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേ┻᧛ඳᢥ㧦
1㧕 ጘ㒂⋵කᏧળഭἴᜰቯකㇱળ㘈໧(㨪⃻࿷)2㧕 ጘ㒂⋵り૕㓚ኂ⠪⋧⺣ᚲᦝ↢ක≮್ᢿක(㨪⃻࿷)3㧕 ጘ㒂⋵කᏧળᄖ⑼කㇱળㇱળ㐳(ᐔᚑ 18 ᐕ 4 ᦬㨪⃻࿷)4㧕 ጘ㒂⋵␠ળ⑔␩ክ⼏ળᆔຬ(ᐔᚑ 18 ᐕ 11 ᦬㨪⃻࿷)5㧕 ጘ㒂Ꮢ␠ળ⑔␩ክ⼏ળᆔຬ(ᐔᚑ 18 ᐕ 11 ᦬㨪⃻࿷)
6㧕 ⍮⊛ࠢ࡜ࠬ࠲࡯ഃᚑ੐ᬺ ጘ㒂࡮ᄢ၂࿾ၞߦ߅ߌࠆ⍮⊛ࠢ࡜ࠬ࠲࡯ᧄㇱ⎇ⓥ⛔᜝(ᐔᚑ 19 ᐕ 4 ᦬㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ጊ↰ථ਽㧘㑸㊁⠨ผ㧘᧻የ ᶈ㧦ࠗࡦࡇ࡯࠳ࡦࠬ CT ࠍ↪޿ߚ࠮ࡦ࠴ࡀ࡞࡝ࡦࡄ▵ᬌ಴ᴺߩ⏕┙ߦ㧙㧙㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 15 ᐕᐲ㧙18 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄⎇ⓥᚑᨐႎ๔ᦠ(2007 ᐕ 3 ᦬)
2㧕 ጤ↰ ዏ㧘┻᧛ඳᢥ㧘⊕ᯅᐘᵗ㧘᧻ᧄ⌀੺㧦࠼࠽࡯⢖߳ߩ⥄Ꮖ㛽㜑⚦⢩≹วߦࠃࠆ⢖ౣ↢ߦ㑐ߔࠆታ㛎⊛ᬌ⸛㧦ᐔᚑ 18 ᐕᐲ㧙19 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄⎇ⓥᚑᨐႎ๔ᦠ(2008 ᐕ 3 ᦬)
11㧚ႎ㆏1㧕 ┻᧛ඳᢥ㧦‫⚕ޟ‬਄⸻ኤቶ‫ޠ‬᣿ߌᣇߩߎ߻ࠄ㄰ࠅ⮎ߢ߽ᡷༀߖߕ ਅ⢇ߩ⣲ࠇߥߤ࠴ࠚ࠶ࠢࠍ㧦ਛᣣᣂ
⡞(2006 ᐕ 8 ᦬ 25 ᣣ)
2㧕 ጊ↰ථ਽㧦‫ޟ‬ᄢ⣺≸ൻቇ≮ᴺߩ⃻⁁ߣ੹ᓟ‫́ޠ‬ጘ㒂࿾඙ߦ߅ߌࠆᄢ⣺≸ൻቇ≮ᴺߩ᥉෸ߣቯ⌕́㧦
MEDICAMENT NEWS(2007 ᐕ 9 ᦬ 15 ᣣ)
3㧕 ጊ↰ථ਽㧦࿾ၞක≮කቇ࠮ࡦ࠲࡯ ᄖ⑼ᢇᕆ♽ಽ㊁ ᢎ᝼ዞછ᜿ᜦ㧦ጘ㒂⋵∛㒮ᤨႎ╙ 45 ภ(2008ᐕ 3 ᦬ 31 ᣣ)
4㧕 ጊ↰ථ਽㧦‫⎇ޟ‬ⓥቶ߆ࠄ ᄢቇߪ޿߹‫ޠ‬⢄⤳߇ࠎᚻⴚ㧘ౣ↢ࠍ⠨ᘦ㧦ጘ㒂ᣂ⡞(2008 ᐕ 7 ᦬ 22 ᣣ)
5㧕 ┻᧛ඳᢥ㧦ᔃᜉߦวࠊߖౝⷞ㏜ㅪേ ᔃ⤳ᱛ߼ߕ቟ోߦᚻⴚ ᣧᄢ࡮ጘ㒂ᄢᡰេࡠࡏ㐿⊒ ᖚ⠪ߩ்ญዊߐߊ㧦ᣣᧄ⚻ᷣᣂ⡞(2008 ᐕ 8 ᦬ 4 ᣣ)
6㧕 ┻᧛ඳᢥ㧦ᔃ⤳ࡃࠗࡄࠬᚻⴚ࡮⢝ఽᴦ≮㨯㨯㨯ක≮ࡠࡏታ↪ൻ߳⌕‫ ޘ‬ክᩏ૕೙ߥߤ࿖߽ᡰេ㧦ᣣ⚻↥ᬺᣂ⡞(2008 ᐕ 8 ᦬ 19 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔᄙߊߩᄢቇ㒮↢߇౉ቇߒߡ㧘⎇ⓥ㕙ߢᄢ߈ߥᚑᨐ߇޽ߞߚ‫ޕ‬േ⣂ࡃࠗࡄࠬߦ߅ߌࠆ㕒⣂ࠣ࡜ࡈ࠻ߩౝ
⤑ᛥ೙㧘⢄ᄢ㊂ಾ㒰ᓟߩࠕࡐ࠻࡯ࠪࠬᛥ೙ߦࠃࠆ⢄ౣ↢ଦㅴߣ↢ሽ₸ߩᡷༀ㧘NASH ࡕ࠺࡞ߦ߅ߌࠆ
HGF ߦࠃࠆ⢄✢⛽ൻᛥ೙㧘⢖⒖ᬀߦ߅ߌࠆᕆᕈᦼ఺∉ᛥ೙ߦࠃࠆ㆙㓒ᦼ఺∉ᛥ೙߳ߩലᨐ╬ߩቇ૏⺰ᢥ߇ቢᚑߒߚ‫ⴊߞ߁ߚ߹ޕ‬⢄ಾ㒰ᓟߩ⢄ౣ↢㧘⢖ಾ㒰ᓟߩ⢖ౣ↢ߩ⎇ⓥ߽߹ߣ߹ߞߚ‫⎇ߩࠄࠇߘޕ‬ⓥࠍᡰ߃ࠆᄖㇱ⾗㊄₪ᓧ߽೨ᦼߦᲧߒჇടߒߚ‫ߩࠄࠇߎޕ‬ᚑᨐߪ࿖ౝᄖߩቇળߢ⊒⴫ߐࠇ㧘⹏ଔߐࠇߚ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ၮ␆⎇ⓥࠍㅴ߼ࠆߦߪ㧘ᄢቇ㒮↢ߩ⏕଻߇㊀ⷐߢ޽ࠆ߇㧘ᣂ⎇ୃක೙ᐲ߇㐿ᆎߒߡ߆ࠄߩᄢቇ㒮౉ቇ߇ᷫዋߒߡ޿ࠆߩߪุ߼ߥ޿‫␠ޕ‬ળੱᄢቇ㒮೙ᐲࠍᵴ↪ߒߥ߇ࠄ㧘ੱຬߩ⏕଻ߦദ߼ࠆ‫⎇ޕ‬ⓥຬ⵬ഥຬߩੱઙ⾌╬ߩ໧㗴߇޽ࠅ㧘⎇ⓥ᧚ᢱࠍᄖᵈߦ࿁ߐߑࠆࠍᓧߕ㧘⎇ⓥ⾌ߩ⤘ᄢൻ߽⺖㗴ߢ޽ࠆ‫ޕ‬ቇౝߩੱ᧚౒ห೑↪߽ᬌ⸛ߒߡ޿߆ߥߌࠇ߫ߥࠄߥ޿‫ޕ‬੹ᓟߩዷᦸേ‛ታ㛎ᣉ⸳ߪలታߒߡ߅ࠅ㧘⎇ⓥߩ߿ࠅ߿ߔ޿ⅣႺߪᢛߞߡ޿ࠆ‫੹ޕ‬ᓟ߽ᔃ⤳ⴊ▤㧘ᶖൻེ㧘๭ๆེߔߴߡߩ⤳ེߩౣ↢ක≮ࠍਥゲߦ⎇ⓥࠍⴕ߁‫ޕ‬translational research ߦゲࠍ߅޿ߡ⥃ᐥᔕ↪߳ߩ㆏ࠍᮨ⚝ߔࠆ‫ޕ‬㧙㧙㧔4㧕ᢛᒻᄖ⑼ቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
1㧕エ㛽ࡊࡠ࠹ࠝࠣ࡝ࠞࡦઍ⻢ߦ߅ߌࠆࠞ࡞ࡄࠗࡦߩᓎഀߣ⸃᣿
ࡅ࠻ߩエ㛽⚦⢩ߦ߅޿ߡ㧘ࠞ࡞ࡄࠗࡦߦࠃߞߡಾᢿߐࠇߚࡊࡠ࠹ࠝࠣ࡝ࠞࡦಽ⸃↥‛ߩሽ࿷ࠍ⸽᣿ߒ㧘ࠞ࡞ࡄࠗࡦ߇ࡊࡠ࠹ࠝࠣ࡝ࠞࡦઍ⻢ߦ߅޿ߡ㊀ⷐߥᓎഀࠍߪߚߒߡ޿ࠆߎߣࠍ᣿ࠄ߆ߦߒߚ‫ޕ‬
2㧕࡝࠙ࡑ࠴Ṗ⤑⚦⢩ߦ߅ߌࠆࠞ࡞ࡄࠗࡦߩᓎഀߩ⸃᣿
siRNA ࠍ↪޿ߡࠞ࡞ࡄࠗࡦߩ⊒⃻ࠍᛥ೙ߔࠆߎߣߦࠃࠅ㧘࡝࠙ࡑ࠴Ṗ⤑⚦⢩ߩჇᱺ߅ࠃ߮Ṗ⤑Ἳ߇ᛥ೙ߢ߈ࠆߎߣࠍ⸽᣿ߒߚ‫ޕ‬
3㧕࡙࡯ࠗࡦࠣ⡺⣲ㆮવሶ߇ࠝ࡯ࡠ࡜ࠠ࠽࡯࠯ߩォ౮ߦߪߚߔᓎഀߩ⸃᣿
࡙࡯ࠗࡦࠣ⡺⣲ߦ․⇣⊛ߦ⊒⃻ߔࠆⲢวㆮવሶ EWS/Fli1 ߇㧘⚦⢩᦭♻ಽⵚᦼ⺞▵ࠠ࠽࡯࠯ߢ޽ࠆࠝ
࡯ࡠ࡜ࠠ࠽࡯࠯ߩࡊࡠࡕ࡯࠲࡯ߦ⋥ធ⚿วߒ㧘ߘߩォ౮ࠍଦㅴߔࠆߎߣ߇㧘࡙࡯ࠗࡦࠣ⡺⣲ߩ⊒↢ߦᷓߊ㑐ਈߒߡ޿ࠆߎߣࠍ᣿ࠄ߆ߦߒߚ‫ޕ‬
4㧕EWS/Fli1 ߩ⚦⢩ౝࠪࠣ࠽࡞વ㆐࿃ሶࠍ੺ߒߚࠕࡐ࠻࡯ࠪࠬߩ⸃ᨆ
EWS/Fli1 ߇ฦ⒳⚦⢩Ⴧᱺࠪࠣ࠽࡞વ㆐࿃ሶߩ⊒⃻ࠍ⺞▵ߒߡ޿ࠆߎߣࠍ᣿ࠄ߆ߦߒߚ‫ࠇߘߦࠄߐޕ‬ࠄߩ࿃ሶࠍᛥ೙ߔࠆߎߣߦࠃࠅ㧘ࠕࡐ࠻࡯ࠪࠬࠍ⺃ዉߒᓧࠆߎߣࠍ⸽᣿ߒߚ‫ޕ‬
5㧕࡙࡯ࠗࡦࠣ⡺⣲ߩಽሶᮡ⊛ᴦ≮ߩ⎇ⓥ࡙࡯ࠗࡦࠣ⡺⣲ㆮવሶ EWS/Fli1㧘⚦⢩Ⴧᱺࠪࠣ࠽࡞વ㆐࿃ሶ㧘ⴊ▤ౝ⊹Ⴧᱺ࿃ሶ㧔VEGF㧕㧘ࠝ࡯ࡠ࡜ࠠ࠽࡯࠯╬ࠍᮡ⊛ߣߒ㧘ߘࠇࠄߦኻߔࠆ siRNA ߿ฦ⒳㒖ኂ೷ࠍ↪޿ߡ㧘዁᧪ߩಽሶᮡ⊛ᴦ≮ࠍ⋡ᜰߒߚ⎇ⓥࠍㅴ߼ߡ޿ࠆ‫ޕ‬
6㧕㛽エㇱ⣲≌ߦ߅ߌࠆㆮવሶ⸃ᨆ
Ṗ⤑⡺⣲߿᣿⚦⢩⡺⣲ߦ․⇣⊛ߦ⊒⃻ߔࠆㆮવሶߩᯏ⢻ࠍ㧘․ߦォ౮⺞▵ߩⷰὐ߆ࠄ⸃ᨆߒߡ޿ࠆ‫ޕ‬߹ߚㆮવሶᡷᄌࡑ࠙ࠬߩ᮸┙ࠍ⹜ߺߡ޿ࠆ‫ޕ‬7㧕ᱤ㜑⚦⢩ࠍ↪޿ߚன㑐▵ᴦ≮ߩ⎇ⓥᱤ㜑⚦⢩ࠍன㑐▵ㇱ૏ߦ⒖ᬀߔࠆߎߣߦࠃࠅ㧘ᴦ≹ߩଦㅴࠍ࿑ࠆ⎇ⓥࠍㅴ߼ߡ޿ࠆ‫ޕ‬8㧕⣄㜑៊்ߩᴦ≮ߦ㑐ߔࠆ⎇ⓥ⣄㜑៊்ߩࡕ࠺࡞࡜࠶࠻ߦ߅޿ߡࡇࡠࡠࠠࡁ࡝ࡦࠠࡁࡦ㧔PQQ㧕߇៊்ㇱߩ iNOS ߩ⊒⃻ࠍᛥ೙ߒ㧘ᯏ⢻࿁ᓳߦ᦭ലߢ޽ࠆߎߣࠍ᣿ࠄ߆ߦߒߚ‫ޕ‬
9㧕ࠦࡦ࠼ࡠࠗ࠴ࡦ⎫㉄ߩ㛽ᩰᒻᚑ㑐ਈߦ㑐ߔࠆ⎇ⓥࠦࡦ࠼ࡠࠗ࠴ࡦ⎫㉄วᚑ㉂⚛ߩᯏ⢻⸃ᨆ‫㉄⎫ࡦ࠴ࠗࡠ࠼ࡦࠦޕ‬วᚑ㉂⚛ㆮવሶᡷᄌࡑ࠙ࠬࠍ↪޿ߚࠦࡦ࠼ࡠࠗ࠴ࡦ⎫㉄ߩ㛽ᩰᒻᚑ߳ߩ㑐ਈߩ⸃᣿‫ޕ‬10㧕 ᬁ㑆᧼⚵❱ߦ߅ߌࠆࠞ࡞ࡄࠗࡦߩዪ࿷ߩᬌ⸽
࠙ࠪ෸߮ࡅ࠻ߩᬁ㑆᧼⚵❱ߦ߅޿ߡ㧘ࠞ࡞ࡄࠗࡦߩዪ࿷ߩᬌ⸽ࠍⴕߞߚ‫ޕ‬ᬁ㑆᧼ᄌᕈߣࠞ࡞ࡄࠗࡦߩ
⊒⃻߇㑐ㅪߒߡ޿ࠆߎߣ߇᣿ࠄ߆ߣߥߞߚ‫ޕ‬11㧕 ᬁ㑆᧼⚦⢩ᄖၮ⾰ઍ⻢ߦ߅ߌࠆࠞ࡞ࡄࠗࡦߩᓎഀߣ⸃᣿
࠙ࠪ෸߮ࡅ࠻ߩᬁ㑆᧼⚦⢩ࠍ↪޿㧘Ἳ∝࡮ᬁ㑆᧼ᄌᕈߣ޿߁ዪ㕙ߦ߅޿ߡࠞ࡞ࡄࠗࡦ߇ᬁ㑆᧼ၮ⾰ಽ⸃ߦ޿߆ߦ㑐ਈߔࠆ߆ߦߟ޿ߡ⎇ⓥࠍߔߔ߼ߡ޿ࠆ‫ޕ‬12㧕 ࡅ࠻⣶ᬁ⩄㊀⽶⩄ߦ߅ߌࠆᬁ㑆᧼࡮ᬁ㑆㑐▵ߩᒻᘒᄌൻߦ㑐ߔࠆ⎇ⓥ
ࡅ࠻⣶ᬁߩ┙૏⩄㊀⁁ᘒࠍࠪࡒࡘ࡟࡯࠻ߔࠆⵝ⟎ࠍ૶↪ߒ㧘CT ᠟ᓇߦࠃߞߡᓧࠄࠇߚ⣶ᬁ↹௝ࠍ 3ᰴర⸃ᨆߒ㧘ᬁ㑆᧼࡮ᬁ㑆㑐▵ߩ 3 ᰴర⊛ᒻᘒᄌൻࠍ⸃ᨆߒߡ޿ࠆ‫ޕ‬
13㧕 ⣶ᬁⵝౕߩ૕ᐙ૏⟎ⷡ㧘ࠬࡐ࡯࠷ࡄࡈࠜ࡯ࡑࡦࠬߦਈ߃ࠆᓇ㗀ߩᬌ⸛⣶ᬁⵝౕ߇߽ߟ૕ᐙ૏⟎ⷡะ਄ലᨐ߇ࠬࡐ࡯࠷ࡄࡈࠜ࡯ࡑࡦࠬ㧔ࠧ࡞ࡈ㧘࠙ࠜ࡯ࠠࡦࠣ╬㧕ߦ޿߆ߥࠆᓇ㗀ࠍਈ߃ࠆ߆ࠍ 3 ᰴరേ૞⸃ᨆߦߡᬌ⸽ߒߡ޿ࠆ‫ޕ‬
14㧕 ⣶ᬁᄌᕈ஥ᒭ∝ߦኻߔࠆᓟᣇᬁ૕㑆࿕ቯⴚߦࠃࠆᄌᒻ⍶ᱜߩ 3 ᰴర⸃ᨆ⣶ᬁᄌᕈ஥ᒭ∝ߦኻߔࠆࡉ࡯ࡔ࡜ࡦဳࠬࡍ࡯ࠨ࡯ࠍ↪޿ߚᓟᣇᬁ૕㑆࿕ቯⴚߦࠃࠆᄌᒻ⍶ᱜ߇ᬁ㑆᧼ⷺ㧘ᬁ㑆㑐▵ᒻᘒߦਈ߃ࠆലᨐࠍ 3 ᰴర↹௝⸃ᨆߦࠃࠅᬌ⸽ߒߡ޿ࠆ‫ޕ‬
15㧕 ࡅ࠻㗪ᬁߩዮᦛિዷേᘒߦ߅ߌࠆ⎬⤑▤࡮㗪ㇱ⣄㜑ߩ 3 ᰴర⊛േᘒ⸃ᨆ⣄㜑ㅧᓇᬌᩏᓟߩࡈࠔࡦ࡚ࠢࠪ࠽࡞ CT ࠍ↪޿㧘ࡅ࠻㗪ᬁߩዮᦛિዷേᘒߦ߅ߌࠆ⎬⤑▤࡮㗪ㇱ⣄㜑
ߩ 3 ᰴర⊛േᘒ⸃ᨆࠍฦ⒳∛ᘒߣߩ㑐ㅪߦߡᬌ⸽ߒߡ޿ࠆ‫ޕ‬
16㧕 ⣶ᬁᄌᕈ஥ᒭ∝ߦኻߔࠆᓟᣇᬁ૕㑆࿕ቯⴚߦࠃࠆᄌᒻ⍶ᱜߩ 3 ᰴర⸃ᨆ⣶ᬁᄌᕈ஥ᒭ∝ߦኻߔࠆࡉ࡯ࡔ࡜ࡦဳࠬࡍ࡯ࠨ࡯ࠍ↪޿ߚᓟᣇᬁ૕㑆࿕ቯⴚߦࠃࠆᄌᒻ⍶ᱜ߇ᬁ㑆᧼ⷺ㧘ᬁ㑆㑐▵ᒻᘒߦਈ߃ࠆലᨐࠍ 3 ᰴర↹௝⸃ᨆߦࠃࠅᬌ⸽ߒߡ޿ࠆ‫ޕ‬17㧕 㗪ᬁ㒰࿶ᚻⴚ㧔೨ᣇ㒰࿶㧘ᓟᣇ㒰࿶㧕߇⎬⤑▤࡮㗪ㇱ⣄㜑ߦਈ߃ࠆᒻᘒᄌൻߩᬌ⸛

㧙㧙㗪ᬁ೨ᣇ㒰࿶ⴚ㧘㗖ᬁᓟᣇ㒰࿶ⴚߩ 2 ⴚᑼ߇⎬⤑▤࡮㗪ㇱ⣄㜑ߦਈ߃ࠆᒻᘒᄌൻߩ⋧㆑ߦߟ޿ߡ
ultrasonography ࠍ↪޿ߡ㧘⥃ᐥᚑ❣ߣ㑐ㅪߐߖߡᬌ⸛ߒߡ޿ࠆ‫ޕ‬18㧕 MRI ߣ⣄㜑ㅧᓇᓟ CT ߩ⎬⤑▤࡮⣄㜑࡮㚍የ␹⚻ᒻᘒ⹏ଔߩ⋧㆑ߦ㑐ߔࠆ⎇ⓥ⣄ᬁ⣄㜑∔ᖚߦኻߔࠆ↹௝⸻ᢿߦ߅ߌࠆ 2 ߟߩઍ⴫⊛ᚻᴺߢ޽ࠆ MRI ߣ⣄㜑ㅧᓇᓟ CT ߦߟ޿ߡ㧘⎬⤑▤࡮⣄㜑࡮㚍የ␹⚻ᒻᘒ⹏ଔߩ⾰⊛࡮㊂⊛⋧㆑ࠍ᣿ࠄ߆ߦߒߚ‫ޕ‬
19㧕 ࡅ࠻⣄㜑ᶧߦ߅ߌࠆㆶరဳ࡮㉄ൻဳࠕ࡞ࡉࡒࡦߩേᘒߩ⎇ⓥ
ࡅ࠻⣖⣄㜑ᶧߦ߅ߌࠆㆶరဳ࡮㉄ൻဳࠕ࡞ࡉࡒࡦߩሽ࿷Ყ₸ߦߟ޿ߡ㧘ᐕ㦂㧘∔ᖚ╬ߩ࿃ሶࠍ฽߼ߡ
ᬌ⸽ࠍⴕߞߡ޿ࠆ‫ޕ‬2㧚ฬ★
ᢎ᝼㧦ᢎ᝼(૬છ)㧦
ಎᢎ᝼㧦
⻠Ꮷ㧦
⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦

ᷡ᳓సᤨ
⷏ᧄ ⵨
ᄢ㊁⾆ᢅ
⚦ᳯ⧷ᄦ
ᄢ㊁⟵ᐘ
દ⮮⧐Პ
㕍ᧁ㓉᣿
ᄢፉᐽม
↰ਛஜ৻㇢
᫪ ᢕᐘ
ᷡ᳓ቁᔒ
ኹᨋિᄦ
ጊญ⦟ᄢ
┻ౝஜᄥ㇢
ጊጯብᳯ

Katsuji Shimizu
Yutaka Nishimoto
Takatoshi Ohno
Hideo Hosoe
Yoshiyuki Ohno
Yoshiki Itoh
Takaaki Aoki
Koji Oshima
Kenichiro Tanaka
Nobuyuki Mori
Takashi Shimizu
Nobuo Terabayashi
Yoshihiro Yamaguchi
Kentaro Takeuchi
Hiroe Yamagishi

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ⚦ᳯ⧷ᄦ㧚⣶ㇱ⣄ᩇ▤⁜⓰∝ߩᴦ≮㧦ᷡ᳓సᤨ✬㧚ߎࠇߛߌߪ⍮ߞߡ߅߈ߚ޿ ⿷⣶ߩ∩ߺߩ⥄Ꮖ▤ℂ㧘ᄢ㒋㧦ක⮎ࠫࡖ㧙࠽࡞㧧2006 ᐕ㧦22㧙37㧚
2㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧚⣄ᩇ஥ᒗ∝㧦⩵࿾⤿৻ࠄ✬㧚ᢛᒻᄖ⑼ኾ㐷කࠍ߼ߑߔߚ߼ߩ ⚻㛎ߔߴ߈ᄖ்࡮∔ᖚ 97㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2006 ᐕ㧦127㧙133㧚
3㧕 ⚦ᳯ⧷ᄦ㧚⣶ᬁߩ࿕ቯⴚ(PLF‫ޔ‬PLIF)㧦቞ደ⑲❥ࠄ✬㧚ᢛᒻᄖ⑼⸻≮ታ〣ࠟࠗ࠼㧘᧲੩㧦ᢥశၴ㧧2006 ᐕ㧦
225㧙226㧚
4㧕 ᨋ ౖ㓶㧚㕍ᧁ㓉᣿⋙ୃ㧚ᯏ⢻⸃೬ቇ⊛⸅⸻ᛛⴚ ਄ਅ⢇㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ㧙␠㧧2006 ᐕ㧚
5㧕 ⷏ᧄ ⵨㧘ᄢ㊁⾆ᢅ㧚2 ┨‫ޟ‬㛽⣲≌ฦ⺰‫ ޠ‬㘃㛽㛽⣲ 㛽⧘⚦⢩⣲㧦ศᎹ⑲᮸✬㧚ᦨᣂᢛᒻᄖ⑼ቇ૕♽╙ 20Ꮞ‫ޟ‬㛽࡮エㇱ⣲≌߅ࠃ߮㑐ㅪ∔ᖚ‫ޠ‬㧘᧲੩㧦ਛጊᦠᐫ㧧2007 ᐕ㧦201㧙205㧚
6㧕 ⷏ᧄ ⵨㧘ᄢ㊁⾆ᢅ㧚2 ┨‫ޟ‬㛽⣲≌ฦ⺰‫ ޠ‬㕖㛽ൻᕈ✢⛽⣲(✢⛽ᕈ㛽⊹⾰ᰳ៊)㧦ศᎹ⑲᮸✬㧚ᦨᣂᢛᒻᄖ⑼ቇ૕♽╙ 20 Ꮞ‫ޟ‬㛽࡮エㇱ⣲≌߅ࠃ߮㑐ㅪ∔ᖚ‫ޠ‬㧘᧲੩㧦ਛጊᦠᐫ㧧2007 ᐕ㧦233㧙236㧚
7㧕 ⚦ᳯ⧷ᄦ㧚⣶ㇱ⣄ᩇ▤⁜⓰∝ߩᴦ≮㧦ᷡ᳓సᤨ✬㧚ࡐࠤ࠶࠻  ߎࠇߛߌߪ⍮ߞߡ߅߈ߚ޿ ⿷⣶ߩ∩ߺߩ⥄Ꮖ▤ℂ㧘ᄢ㒋㧦ක⮎ࠫࡖ㧙࠽࡞㧧2007 ᐕ㧦38㧙66㧚
8㧕 ⚦ᳯ⧷ᄦ㧚⢷ᬁᄖ் ਄૏⢷ᬁ೨ᣇ⋥㆐ᚻⴚ㧦㚍႐ਭᢅ✬㧚0S NOW INSTRUCTION No.4, ᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ㧙␠㧧2007 ᐕ㧦103㧙106㧚
9㧕 ᷡ᳓సᤨ㧚⣶ᬁᄌᕈߔߴࠅ∝㧙⑳ߩࠗࡦࡈࠜ㧙ࡓ࠼ࠦࡦ࠮ࡦ࠻㧦࠻࡜ࡉ࡞ߦߥࠄߥ޿ᢛᒻᄖ⑼ࠗࡦࡈࠜ㧙ࡓ࠼ࠦࡦ࠮ࡦ࠻㧘᧲੩㧦㊄ේ಴ 㧧2007 ᐕ㧦212㧙213㧚
10㧕 ਛ᧛ᱜ↢㧘ᷡ᳓సᤨ㧚⣶ㇱ⣄ᬁ⣄ᩇ▤⁜⓰∝㧙⸻ᢿߣᴦ≮㧙㧦⠧ᐕකቇ update2007㧙08㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ㧙␠㧧2007 ᐕ㧦14㧙24㧚
11㧕 ⚦ᳯ⧷ᄦ㧚ォ⒖ᕈ⣄ᬁ⣲≌㧦ᷡ᳓సᤨ✬㧚⣶∩ ⍮ࠆ⸻ࠆᴦߔ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ㧙␠㧧2008 ᐕ㧦105
㧙115㧚
12㧕 㕍ᧁ㓉᣿㧚⣶∩ߩㆇേ≮ᴺ㧦ᷡ᳓సᤨ✬㧚⣶∩ ⍮ࠆ⸻ࠆᴦߔ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ㧙␠㧧2008 ᐕ㧦130
㧙155㧚
⪺ᦠ㧔᰷ᢥ㧕
1㧕 Shimizu K, Miyamoto K. Inflammatory Diseases of the Spine: Juvenile Rheumatoid Arthritis. In:
Surgery of the Pediatric Spine. New York: Thieme;2007:375-380.
✚⺑㧔๺ᢥ㧕
1㧕 ᷡ᳓సᤨ㧚․㓸 ᚻߩ∩ߺߩ⸻ᢿߣᴦ≮ ᐨ㧘∩ߺߣ⥃ᐥ 2006 ᐕ㧧6 Ꮞ㧦1㧚㧙㧙

2㧕 ㊄᫪ᐽᄦ㧘ᷡ᳓సᤨ㧚⣶∩ ᕆᕈ⣶∩ߣᘟᕈ⣶∩㧘⥃ᐥߣ⎇ⓥ 2006 ᐕ㧧83 Ꮞ㧦12㧙15㧚
3㧕 ᷡ᳓సᤨ㧚ࠪࡦࡐࠫ࠙ࡓ ⣶ㇱ⣄ᩇ▤⁜⓰∝㧙ᦨㄭߩㅴᱠ㧙 ✜⸒㧘⥃ᐥᢛᒻᄖ⑼ 2006 ᐕ㧧41 Ꮞ㧦852㧚
4㧕 ᷡ᳓సᤨ㧚ᣣᧄ⣄ᬁ⣄㜑∛ቇળߣർ☨⣄ᬁ㑐ㅪቇળߣߩ੤ᵹ 㧙Spine Across the Sea ႎ๔㧙㧘⣄ᬁ⣄㜑ࠫࡖ࡯࠽࡞ 2006 ᐕ㧧19 Ꮞ㧦1174㧙1175㧚
5㧕 ᷡ᳓సᤨ㧚ጘ㒂⟤Ớ⥄ォゞ↢ᵴ㧘ᢛᒻᄖ⑼ 2006 ᐕ㧧57 Ꮞ㧦1798㧚
6㧕 ᷡ᳓సᤨ㧚৻⥸ౝ⑼ක߇⍮ߞߡ߅߈ߚ޿⣶∩ߩ⸻ᢿᴦ≮㧘ጘ㒂ᏒකᏧળߛࠃࠅ 2007 ᐕ㧧39 Ꮞ㧦25㧙27㧚
7㧕 ⑔↰┨ੑ㧘ᷡ᳓సᤨ㧚⣄ᬁ㛽㜑Ἳߩ⸻ᢿߣᴦ≮㧘㛽࡮㑐▵࡮㕤Ꮺ 2007 ᐕ㧧20 Ꮞ㧦455㧙461㧚
8㧕 ᷡ᳓సᤨ㧚⣄ᬁౝⷞ㏜ਅᚻⴚ‫ޠ‬㧙ၮᧄᚻᛛ߆ࠄᛛⴚ⹺ቯ߹ߢ㧘ᢛᒻᄖ⑼ 2007 ᐕ㧧58 Ꮞ㧦1656㧚
9㧕 ᷡ᳓సᤨ㧚⣶ߩ∩ߺ(⣶ㇱ⣄ᩇ▤⁜⓰∝)ࠍ㒐ߋ㧘ࠢ࠶ࠢ㧒࡜ࠗࡈ 2007 ᐕ㧧433 Ꮞ㧦8㧙9㧚
10㧕 ㉿⷗๺ᒾ㧘⍹ฬ↰ᵗ৻㧘ᦸ᦬৻↵㧘દ⮮⧐Პ㧘Ꮉ਄♿᣿㧚ICD ᡷቯߣᢛᒻᄖ⑼ක≮㧘⥃ᐥᢛᒻᄖ⑼ 2008ᐕ㧧43 Ꮞ㧦581㧙589㧚
11㧕 ೨ේ⑲੫㧘ᷡ᳓సᤨ㧚ࠞ࡞ࡄࠗࡦߣᄌᕈᕈ㑐▵∝㧘೎ౠᢛᒻᄖ⑼‫ޛ‬ᄌᕈᕈ㑐▵∝㧙ᦨㄭߩ⍮⼂‫ ޜ‬2008 ᐕ㧧
53 Ꮞ㧦38㧙41㧚
12㧕 ᧻ᧄ቞㓶㧘ජ⪲৻⵨㧘ᚭጊ⧐ᤘ㧘┻ਅసᔒ㧘ᤊ࿾੝ㇺม㧘ਛ᧛⠹ਃ㧘᦭᳓ ᷕ㧘⮮ᨋବ੺㧘ᐔᨋ ⨃㧘ᐔ㊁ ᔀ㧘ጤፒᐙቄ㧘㊄ጟᕡᴦ㧘Ꮉญༀᴦ㧘੗ዥᐘᚑ㧘೨↰ ᑪ㧘᧻ጊᐘᒄ㧘ਃ਄㕏ᄦ㧘᧛਄⧷᮸㧘᳗ፉ⧷᮸㧘᳗↰⷗↢㧘ਛේㅴਯ੺㧘㊁ේ ⵨㧘ጟ ผᦶ㧘㒋ᧄ᩵ㅧ㧘₎ᯅᐽ㓶㧘╣↢ ⼾㧘ᷡ᳓సᤨ㧘↰ญᢅᒾ㧘㜞ᯅ ⺈㧘↰ਛ㕏ਭ㧘⼱ ବ৻㧘ᓼᯅᵏ᣿㧘ౝ↰⎇ㅧ㧘ጊᧄ⻞๋㧘ጊፒᱜᔒ㧘ᮮጊ ᔀ㧘ศ↰ቬੱ㧘⷏⣁␭ม㧚⢷ᬁᓟ❑㕤Ꮺ㛽ൻ∝ߦኻߔࠆᚻⴚᚑ❣ߦᓇ㗀ࠍਈ߃ࠆ࿃ሶߩᬌ⸛㧙ઁᣉ⸳ᓟࠈะ߈⎇ⓥ㧙 ⹹਄ࠪࡦࡐࠫ࠙ࡓ ⢷ᬁᓟ❑㕤Ꮺ㛽ൻ∝ߩᴦ≮㧙ᦨㄭߩㅴᱠ㧘⥃ᐥᢛᒻᄖ⑼ 2008 ᐕ㧧43 Ꮞ㧦531㧙538㧚
13㧕 ᷡ᳓సᤨ㧚㗖ᬁ∝㧘OPLL ߩᚻⴚᴦ≮㧘᧲ᶏ࡮ਛㇱធ㛽ቇળ⹹ 2008 ᐕ㧧89 ภ㧦19㧚✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘㊄᫪ᐽᄦ㧚㗖ᬁᓟ❑㕤Ꮺ㛽ൻ∝ߦኻߔࠆᣂߒ޿ゲᬁㇱᓟᣇ㒰࿶ᴺ㧘⣄ᬁ࡮⣄㜑␹⚻ᚻⴚᚻᛛ 2006 ᐕ㧧8 Ꮞ㧦79㧙82㧚
2㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘㊄᫪ᐽᄦ㧘ዊේ᣿㧚⣶ᬁᄌᕈߔߴࠅ∝ߦኻߔࠆ⚻ᬁ㑆ሹ⣶ᬁᬁ૕㑆࿕ቯⴚ(cantilever㧙TLIF)ߩ⚻㛎㧘ਛㇱᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2006 ᐕ㧧49 Ꮞ㧦31㧙32㧚
3㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘ችᧄ ᢘ㧘⷏ᧄඳᢥ㧚㛽☻㝃∝ᕈ㛽᛬ߦኻߔࠆ⣄ᬁ⍴❗ⴚߩⴚᓟ⚻ㆊ㧘ਛㇱᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2006 ᐕ㧧49 Ꮞ㧦967㧙968㧚
4㧕 ⚦ᳯ⧷ᄦ㧚․㓸㧦Ყセߢಽ߆ࠆ⣶ᬁ 2 ᄢ∔ᖚ㧙⣶ㇱ⣄ᩇ▤⁜⓰∝ߣ⣶ᬁᬁ㑆᧼ࡋ࡞࠾ࠕ ᚻⴚ≮ᴺ㧙㧘ᢛᒻᄖ⑼⋴⼔ 2006 ᐕ㧧11 Ꮞ㧦24㧙26㧚
5㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘ችᧄ ᢘ㧘⷏ᧄඳᢥ㧚㗖ᬁᓟ❑㕤Ꮺ㛽ൻ∝ߦኻߔࠆⴚᑼㆬᛯ㧘ᣣᧄ⣄ᬁ⣄㜑∛ቇળ㔀⹹ 2006 ᐕ㧧17 Ꮞ㧦525㧚
6㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘㊄᫪ᐽᄦ㧘ችᧄ ᢘ㧘ዊේ ᣿㧚⣶ᬁᄌᕈߔߴࠅ∝ߦኻߔࠆ⚻ᬁ㑆ሹ⣶ᬁᬁ૕㑆࿕ቯⴚ(cantilever㧙TLIF)㧙PLIF ߣߩᲧセ㧙㧘ᣣᧄᢛᒻᄖ⑼ቇળ㔀⹹ 2006 ᐕ㧧80 Ꮞ㧦S285㧚
7㧕 ↰ਛ㗔㧘ᄢ㊁⾆ᢅ㧘ᄢ㊁⟵ᐘ㧘ᷡ᳓సᤨ㧘⷏ᧄ⵨㧘ᑝἑༀା㧘᧻᳗⎇๋㧚ᧃ▵㛽㛽⣲≌ߩ 1 ଀㧘᧲ᶏ㛽エㇱ⣲≌ 2006 ᐕ㧧18 Ꮞ㧦43㧙44㧚
8㧕 ㋈ᧁ⋥᮸㧘㊄᫪ᐽᄦ㧘᧖ጊ⺈৻㧘⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧚਄૏⣶ᬁᬁ㑆᧼ࡋ࡞࠾ࠕᓟᣇ៰಴ⴚᓟߦ೨ᣇ࿕ቯ
ࠍⷐߒߚ 1 ଀㧘᧲ᶏ⣄ᬁᄖ⑼ 2006 ᐕ㧧20 Ꮞ㧦5㧙9㧚
9㧕 ㋈ᧁ⋥᮸㧘㊄᫪ᐽᄦ㧘᧖ጊ⺈৻㧘⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧚⣶ᬁᄌᕈ஥ᒗߦ೨ᣇ࿕ቯࠍⴕߞߚ 2 ∝଀㧘᧲ᶏ⣄
ᬁᄖ⑼ 2006 ᐕ㧧20 Ꮞ㧦102㧙108㧚
10㧕 ᷡ᳓సᤨ㧘⚦ᳯ⧷ᄦ㧘᧖ጊ⺈৻㧘⧯ᨋ ⧷㧘㊁‫⻀᧛ޘ‬㚅㧚Informed Consent ߩታ㓙㧘ᣣᧄᢛᒻᄖ⑼ቇળ
㔀⹹ 2006 ᐕ㧧80 Ꮞ㧦33㧙34㧚
11㧕 Ⴧ↰೰ብ㧘ᷡ᳓సᤨ㧚ᗵᨴᕈ⣄ᬁἻߦኻߔࠆ⣄ᬁࠗࡦࠬ࠷࡞ࡔࡦ࠹㧙࡚ࠪࡦᚻⴚ㧘Orthopaedics 2006ᐕ㧧19 Ꮞ㧦25㧙32㧚
12㧕 ㊁Ỉ ⡡㧘ᷡ᳓సᤨ㧚ࠬࡐ㧙࠷ㆬᚻߦ߅ߌࠆ⣶ᬁಽ㔌∝ߦኻߔࠆᚻⴚ≮ᴺ㧙segmental wire fixation ᴺ㧙㧘
Orthopaedics 2006 ᐕ㧧19 Ꮞ㧦15㧙21㧚
13㧕 ફ⷗৻ᚑ㧘ᷡ᳓సᤨ㧚ᄌᒻᕈ㑐▵∝エ㛽ߦ߅ߌࠆࠞ࡞ࡄࠗࡦߩ⊒⃻㧘ጘ㒂⋵කᏧળකቇ㔀⹹ 2006 ᐕ㧧19
Ꮞ㧦81㧙84㧚
14㧕 ᧻ᧄ ๺㧘દ⮮⧐Პ㧘♻ᢙਁᱜ㧘ᱞౝ┨ੑ㧘ᷡ᳓సᤨ㧚㒸ᣥᕈ೸㔌㛽 ߦࠃࠅ↢ߓߚ⤒⬄㛽੝⣕⥓ߩ 1 ଀㧘ᢛᒻᄖ⑼ 2006 ᐕ㧧57 Ꮞ㧦1623㧙1625㧚
15㧕 ᧻ᧄ ๺㧘દ⮮⧐Პ㧘⑔↰ 㓷㧘♻ᢙਁᱜ㧘ᷡ᳓సᤨ㧚Smith㧙Petersen ㅴ౉ᴺ߇᦭↪ߢ޽ߞߚੱᎿ⢆㑐▵ౣ⟎឵ⴚߩ 2 ଀㧘Hip Joint ೎೚ 2006 ᐕ㧧32 Ꮞ㧦411㧙414㧚
16㧕 Ἇ਄દ❱㧘᧻ᧄ ๺㧚ᄢ⣽㛽ォሶㇱ㛽᛬ߦኻߔࠆ PFNA(proximal femoral nail antirotation)ߩ૶↪⚻㛎㧘
Hip Joint ೎೚ 2006 ᐕ㧧32 Ꮞ㧦234㧙236㧚
17㧕 㕍ᧁ㓉᣿㧘ኹፉብ᣿㧘♻ᢙਁᱜ㧘ᷡ᳓సᤨ㧘ਤ⠀᡽⟤㧘ዊ㊁Ⴆኪ㧚⣶ㇱ⣄ᩇ▤⁜⓰∝ᖚ⠪ߩ⚻ญ PGE1 ⺃ዉ૕⵾೷ᛩਈߦ߅ߌࠆ࠻࡟࠶࠼ࡒ࡞⹏ଔ㧘ᣂ⮎ߣ⥃ᐥ 2006 ᐕ㧧55 Ꮞ㧦74㧙76㧚
18㧕 ᄢ㊁⟵ᐘ㧘ᐔᎹ᣿ᒄ㧘ᷡ᳓సᤨ㧚ᚻ㑐▵⚿ᩭߩᚻⴚᴦ≮ߩ⚻㛎㧘ᣣᧄ㛽࡮㑐▵ᗵᨴ∝ቇળ㔀⹹ 2006 ᐕ㧧
20 Ꮞ㧦29㧙31㧚
19㧕 ᄢ㊁⟵ᐘ㧘ᐔᎹ᣿ᒄ㧘ᷡ᳓సᤨ㧚ᧃ▵㛽߇㔺಴ߒߚᜰውㇱ⊹⤏ᰳ៊ߦኻߔࠆㆆ㔌⊹ᑯ⒖ᬀߩ⚻㛎㧘ᣣᧄᚻ
ߩᄖ⑼ቇળ㔀⹹ 2006 ᐕ㧧23 Ꮞ㧦209㧙212㧚㧙㧙

20㧕 ᄢፉᐽม㧘ਃቛᥓ㧘ᷡ᳓సᤨ㧘ᄢ㊁⾆ᢅ㧘⷏ᧄ⵨㧚㛽ේ⊒ⴊ▤⡺⣲ߩ৻೬ᬌ଀㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ
⑼ቇળ㔀⹹ 2007 ᐕ㧧50 Ꮞ㧦463㧙464㧚
21㧕 ⑔↰┨ੑ㧘ᄢ㊁⾆ᢅ㧘⷏ᧄ⵨㧘ᷡ᳓సᤨ㧚⿷⢛ߦ⊒↢ߒߚ⍹Ἧൻࠍ઻ߞߚᏂᄢߥⴊ▤ᐔṖ╭⣲ߩ৻଀㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧50 Ꮞ㧦515㧙516㧚
22㧕 ᳗㊁ᤘੳ㧘ᄢ㊁⾆ᢅ㧘⷏ᧄ⵨㧘ጊ↰৻ᚑ㧘ᷡ᳓సᤨ㧚㛽ᄖᕈ㛽⡺⣲ߩ 1 ೬ᬌ଀㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ
⑼ቇળ㔀⹹ 2007 ᐕ㧧50 Ꮞ㧦525㧙526㧚
23㧕 ᄢ㊁⾆ᢅ㧘ᄢፉᐽม㧘ᷡ᳓సᤨ㧘⷏ᧄ⵨㧚ੱᎿ㛽ࠍ↪޿ߚ⦟ᕈ㛽⣲≌ߩⴚᓟᚑ❣㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂ
ᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧50 Ꮞ㧦627㧙628㧚
24㧕 ᮮ↰ᴦ㧘ᄢ㊁⾆ᢅ㧘ᄢ㊁⟵ᐘ㧘ᷡ᳓సᤨ㧘⷏ᧄ⵨㧘ᑝἑༀା㧘᧻᳗⎇๋㧚ᄢ⣽エㇱ⣲≌ߩ 1 ଀㧘᧲ᶏ㛽エㇱ⣲≌ 2007 ᐕ㧧19 Ꮞ㧦1㧙2㧚
25㧕 ᄢፉᐽม㧘ᢧ⮮ḩ㧘ᄢ㊁⟵ᐘ㧘ᷡ᳓సᤨ㧘ᄢ㊁⾆ᢅ㧘⷏ᧄ⵨㧘㜞⷗⑲৻㇢㧘᧻᳗⎇๋㧘ᑝἑༀା㧚ᏀᲚㇱ⣲≌ߩ 1 ଀㧘᧲ᶏ㛽エㇱ⣲≌ 2007 ᐕ㧧19 Ꮞ㧦37㧙38㧚
26㧕 Ꮉ㦮᥍ਭ㧘ᩕᨑ⵨ᢥ㧘ጤ᧛⌀੐㧘◉ፒ᣽ੱ㧘ᧁ᧛ብ᮸㧘⷏ᧄ⵨㧘દ⮮⡡㧚ࡃ㧙࠴ࡖ࡞࡝ࠕ࡝࠹ࠖࠍᔕ↪ߒߚᚻᜰ࡝ࡂࡆ࡝࠹㧙࡚ࠪࡦᡰេࠪࠬ࠹ࡓߩ⎇ⓥ㧘VR කቇ 2007 ᐕ㧧5 Ꮞ㧦32㧙39㧚
27㧕 ᄢ㊁⟵ᐘ㧘ᐔᎹ᣿ᒄ㧘ᷡ᳓సᤨ㧚ᛥ೙Ꮺߦࠃࠅ⊒↢ߒߚᚻߦ㒢ዪߒߚ㒖ⴊᕈ᜔❗ߩ 1 ଀㧘ਛㇱᣣᧄᢛᒻᄖ
⑼ἴኂᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧50 Ꮞ㧦861㧙862㧚
28㧕 ᫪⟵ᒄ㧘ᄢ㊁⟵ᐘ㧘㕍ᧁ㓉᣿㧚ᚻᜰિ╭⣷⒖ⴕⴚᓟߦ߅ߌࠆᣧᦼㆇേ≮ᴺߩ⚻㛎㧘ጘ㒂૞ᬺ≮ᴺ 2007 ᐕ㧧
10 Ꮞ㧦36㧙37㧚
29㧕 ౝደ⚐㧘ᄢ㊁⟵ᐘ㧘㕍ᧁ㓉᣿㧚ᚻ㑐▵ቢోಾᢿౣធ⌕ᓟߩ 1 ∝଀㧘ጘ㒂૞ᬺ≮ᴺ 2007 ᐕ㧧10 Ꮞ㧦38㧙
39㧚
30㧕 દ⮮⧐Პ߶߆㧚THA 㜞૏⣕⥓⢆ ⣕⥓ᕈ⢆㑐▵∝ߦኻߔࠆォሶਅ⍴❗㛽ಾࠅ૬↪ੱᎿ⢆㑐▵⟎឵ⴚߩ⍴ᦼᚑ❣㧘ᣣᧄੱᎿ㑐▵ቇળ⹹ 2007 ᐕ㧧37 Ꮞ㧦90㧙91㧚
31㧕 ㋈ᧁᓀ㧘♻ᢙਁᱜ㧘દ⮮⧐Პ߶߆㧚㜞㦂⠪(75 ᱦએ਄)ߦ߅ߌࠆੱᎿ⢆㑐▵ౣ⟎឵ⴚߩᚑ❣㧘ᣣᧄੱᎿ㑐▵ቇળ⹹ 2007 ᐕ㧧37 Ꮞ㧦370㧙371㧚
32㧕 ᫪ᢕᐘ㧘♻ᢙਁᱜ㧘દ⮮⧐Პ߶߆㧚RA ⤒ߦኻߔࠆੱᎿ㑐▵⟎឵ⴚ 㑐▵࡝࠙ࡑ࠴ᖚ⠪ߦ߅ߌࠆ࠮ࡔࡦ࠻
࡟ࠬੱᎿ⤒㑐▵ో⟎឵ⴚߩਛᦼᚑ❣㧘ᣣᧄੱᎿ㑐▵ቇળ⹹ 2007 ᐕ㧧37 Ꮞ㧦60㧙61㧚
33㧕 㥱⮮ḩ㧘♻ᢙਁᱜ㧘દ⮮⧐Პ߶߆㧚㜞㦂⠪ߩੱᎿ⢆㑐▵⟎឵ⴚ 75 ᱦએ਄ߩ㜞㦂⠪ߦ߅ߌࠆ࠮ࡔࡦ࠻࡟ࠬ
THA ߩⴚᓟᚑ❣㧘ᣣᧄੱᎿ㑐▵ቇળ⹹ 2007 ᐕ㧧37 Ꮞ㧦34㧙35㧚
34㧕 ♻ᢙਁᱜ㧘દ⮮⧐Პ߶߆㧚㑐▵࡝࠙ࡑ࠴ᴦ≮⮎࠲ࠢࡠ࡝ࡓࠬߩലᨐߣ SF㧙8(Short Form㧙8)ࠍ↪޿ߚ QOL
⹏ଔ㧘ᣣᧄ࡝࠙ࡑ࠴࡮㑐▵ᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧26 Ꮞ㧦403㧙411㧚
35㧕 ᫪ᢕᐘ㧘♻ᢙਁᱜ㧘દ⮮⧐Პ߶߆㧚ᄢ⣽㛽㗰਄㛽᛬ࠍ઻ߞߚ RA ⤒ߦኻߒߡ৻ᦼ⊛ੱᎿ⤒㑐▵ో⟎឵ⴚࠍᣉⴕߒߚ 1 ଀㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧50 Ꮞ㧦1083㧙1084㧚
36㧕 ↰ਛ⮍㧘દ⮮⧐Პ߶߆㧚㜞㦂⠪ߩ㛽⋚࡮ኡ㛽⥓㛽᛬ߩᴦ≮⚻㛎㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2007
ᐕ㧧50 Ꮞ㧦1051㧙1052㧚
37㧕 ༑ਭ↢ஜᄥ㧘♻ᢙਁᱜ㧘દ⮮⧐Პ߶߆㧚⣊㛽㜞ේ㒱ᴚ㛽᛬ߦኻߔࠆࡂࠗ࠼ࡠࠠࠪࠕࡄ࠲ࠗ࠻ࡉࡠ࠶ࠢࠍ↪
޿ߚᴦ≮ᴺ㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧50 Ꮞ㧦873㧙874㧚
38㧕 ㋈ᧁᓀ㧘♻ᢙਁᱜ㧘દ⮮⧐Პ߶߆㧚㛽⋚ᓟ௑ࠍ઻߁ᖚ⠪ߦኻߔࠆੱᎿ⢆㑐▵ౣ⟎឵ⴚߩᬌ⸛㧘ਛㇱᣣᧄᢛ
ᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧50 Ꮞ㧦685㧙686㧚
39㧕 ዊᎹኡᕶ㧘♻ᢙਁᱜ㧘દ⮮⧐Პ߶߆㧚ஜᐽᚑੱߦ⊒∝ߒߚේ⊒ᕈൻ⤥ᕈ⢆㑐▵Ἳߩ 2 ଀㧘ਛㇱᣣᧄᢛᒻᄖ
⑼ἴኂᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧50 Ꮞ㧦749㧙750㧚
40㧕 ጊ↰৻ᚑ㧘દ⮮⧐Პ߶߆㧚⥓⬄ࠦࡦࡐ㧙ࡀࡦ࠻ߩਛᔃᕈ⣕⥓ߦኻߒᓟ⣻⤑ㅴ౉ᴺߢᄖ⣺㛽േ⣂ࠍ⏕଻ߒߚߩߜߦ৻ᦼ⊛ߦౣ⟎឵ⴚࠍⴕߞߚ 1 ଀㧘ᢛᒻᄖ⑼ 2007 ᐕ㧧58 Ꮞ㧦674㧙676㧚
41㧕 ᧛ἑༀᓆ㧘♻ᢙਁᱜ㧘દ⮮⧐Პ߶߆㧚ᧃ┵⢈ᄢ∝ߦ⊒∝ߒߚᕆㅦ⎕უဳ⢆㑐▵∝ߦኻߔࠆ THA ᣉⴕ∝଀㧘࿖┙ᄢቇᴺੱ࡝ࡂࡆ࡝࠹㧙࡚ࠪࡦ ࠦ࡮ࡔ࠺ࠖࠞ࡞ቇⴚᄢળ⹹ 2007 ᐕ㧧28 Ꮞ㧦38㧙41㧚
42㧕 ᧻ᧄ๺㧘♻ᢙਁᱜ㧘દ⮮⧐Პ߶߆㧚ㅘᨆᖚ⠪ߦኻߔࠆੱᎿ⢆㑐▵ᚻⴚߩ๟ⴚᦼว૬∝㧘ᢛᒻᄖ⑼ 2007 ᐕ㧧
58 Ꮞ㧦511㧙515㧚
43㧕 ♻ᢙਁᱜ㧘દ⮮⧐Პ߶߆㧚ᄢ⣽㛽⣕⥓㛽᛬ߦ Austin㧙Moore ੱᎿ㛽㗡⟎឵ⴚࠍᣉⴕߒⴚᓟ 31 ᐕ⚻ㆊߒߚ
1 ଀㧘ᢛᒻᄖ⑼ 2007 ᐕ㧧58 Ꮞ㧦273㧙276㧚
44㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘ችᧄ ᢘ㧘ጤ੗ᥓ቞↵㧚⣶ᬁᄌᕈ஥ᒗ∝ߦኻߔࠆ⚻ᬁ㑆ሹ⣶ᬁᬁ૕㑆࿕ቯⴚ㧘ਛㇱᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧50 Ꮞ㧦353㧙354㧚
45㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘ችᧄ ᢘ㧘⑔↰┨ੑ㧘ጤ੗ᥓ቞↵㧚㗖ㇱ⣄㜑∝ᚻⴚߩว૬∝㧙೨ᣇᴺ㧘
ᓟᣇᴺߩᲧセ㧙㧘ਛㇱᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧50 Ꮞ㧦579㧙580㧚
46㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘ችᧄ ᢘ㧘⑔↰┨ੑ㧘ጤ੗ᥓ቞↵㧚㛽☻㝃∝ᕈᬁ૕㛽᛬ߦኻߔࠆࡀࠬࡊ
ࡠࡦࠤ㧙ࡉ࡞ࠍ૶↪ߒߚ⣄ᬁ⍴❗ⴚ㧘ᣣᧄ⣄ᬁࠗࡦࠬ࠻࠘࡞ࡔࡦ࠹㧙࡚ࠪࡦቇળ⹹ 2007 ᐕ㧧6 Ꮞ㧦25㧙
28㧚
47㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘ችᧄ ᢘ㧘ጤ੗ᥓ቞↵㧘⑔↰┨ੑ㧚⣶ᬁᄌᕈ஥ᒗ∝ߦኻߔࠆ⚻ᬁ㑆ሹ⣶ᬁᬁ૕㑆࿕ቯ㧘ᣣᧄ⣄ᬁ⣄㜑∛ቇળ㔀⹹ 2007 ᐕ㧧18 Ꮞ㧦223㧚
48㧕 㕍ᧁ㓉᣿㧘ᷰㄝ๺ሶ㧘ਤ⠀᡽⟤㧘⮮↰㓷ᢥ㧘♻ᢙਁᱜ㧘ᷡ᳓సᤨ㧘ዊ㊁Ⴆኪ㧚functionalMRI ߇᦭↪ߢ޽ߞߚᘟᕈᦼ⣖᪪Ⴇ 㤗∽ߩ 1 ∝଀㧘Journal of Clinical Rehabilitation 2007 ᐕ㧧16 Ꮞ㧦558㧙561㧚
49㧕 ዊᎹኡᕶ㧘㜞ᴛ⌀㧘⷏ᧄඳᢥ㧘♻ᢙਁᱜ㧘દ⮮⧐Პ㧚ஜᐽᚑੱߦ⊒∝ߒߚේ⊒ᕈൻ⤥ᕈ⢆㑐▵Ἳߩ 2 ଀㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧50 Ꮞ㧦749㧙750㧚
50㧕 ዊᎹኡᕶ㧘⍹ਣᄢ࿾㧘ጊ↰৻ᚑ㧘ᷡ᳓ቁᔒ㧚ਇ቟ቯᄖ஥ඨ᦬᧼ߦኻߒ㏜ⷞਅ thermal shrinkage ࠍᣉⴕߒߚ 1 ଀㧘ᢛᒻᄖ⑼ 2007 ᐕ㧧58 Ꮞ㧦1357㧙1359㧚

㧙㧙51㧕 ዊᎹኡᕶ㧘ᷡ᳓ቁᔒ㧘ዊጊ༑਽㧘⿒ᳰᢕ㧘ၳ⵨ᒾ㧚㜞㦂⠪㗪ㇱ(ォሶㇱ)㛽᛬ᓟߩ╭⪜❗࡮⒖േ⢻ജ࡮㛽᛬ဳ࡮ⴚᑼߩ⋧㑐㑐ଥߦߟ޿ߡߩᬌ⸛㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧50 Ꮞ㧦47㧙48㧚
52㧕 ⍹ਣᄢ࿾㧘ᄢ㊁⾆ᢅ㧘ዊᎹኡᕶ㧘⷏ᧄ⵨㧘ᷡ᳓సᤨ㧚ᓟ㗖ㇱߦ⊒↢ߒߚ infantile fibromatosis ߩ৻଀㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧50 Ꮞ㧦90㧙91㧚
53㧕 ᧻ᧄ ๺㧘♻ᢙਁᱜ㧘દ⮮⧐Პ㧘⑔↰ 㓷㧘Ꮉ੗ ⽕㧘ᷡ᳓సᤨ㧚ㅘᨆᖚ⠪ߦኻߔࠆੱᎿ⢆㑐▵ᚻⴚߩ๟ⴚᦼว૬∝㧘ᢛᒻᄖ⑼ 2007 ᐕ㧧58 Ꮞ㧦511㧙515㧚
54㧕 ↰ਛ 㗔㧘૒⮮ᱜᄦ㧘┻᧛ᱜ↵㧘྾ᚭ㓉ၮ㧘ᢧ⮮㇌᣿㧘ᷡ᳓ సᤨ㧘ᷡፉ ḩ㧚㑐▵࡝࠙ࡑ࠴ߦኻߔࠆ↢‛ቇ⊛⵾೷ᴦ≮ߣ࠻࡝ࡊ࠻ࡈࠔࡦઍ⻢ߦߟ޿ߡ㧘ਛㇱ࡝࠙ࡑ࠴(J Chubu Rhuum Assoc) 2007 ᐕ㧧38 Ꮞ㧦
12㧙13㧚
55㧕 ਭፉᵏੳ㧘⍹੗శ৻㧘ᷡ᳓సᤨ㧘૒‫ᤩᧁޘ‬㧘ጊᧄᙗม㧘ᱞౝ┨ੑ㧘ᣣᲧ㊁శ↵㧘ᬢ ਛੳ㧘ᷡ᳓ᢅੱ㧘ᄢᯅീ㧘⥓੗ᱜ᣿㧘⪉↰ ⼾㧘੹੗⑲ᴦ㧘Ᏹ↰᣽ᒄ㧘㋈ᧁ⹷㧘ᐔ᧻ື㧘⋉↰๺᣿㧘የਅ૫ผ㧘⑔↰㓷㧘਄᧛ୃ৻㧘ᷰㄝᢙੱ㧘᫪ஜᄥ㇢㧘⠀႐ℂᒾ㧘⷏ၳᒄ⸥㧚ේ⊒ᕈ㛽☻㝃∝ߦኻߔࠆ࡝࠮࠼ࡠࡀ㧙࠻ߣࡆ࠲ࡒࡦ K2
ߩ૬↪ലᨐߦ㑐ߔࠆᄙᣉ⸳౒ห⎇ⓥ㧙1 ᐕ⚻ㆊ∝଀ߩਛ㑆⸃ᨆ㧙㧘Osteoporosis Japan 2007 ᐕ㧧15 Ꮞ㧚
56㧕 ᳗㊁ᤘੳ㧘㋈ᧁ⋥᮸㧘㊄᫪ᐽᄦ㧘⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧚ᕆᕈ㛽㜑ᕈ⊕ⴊ∛ൻቇ≮ᴺਛߦ⊒∝ߒߚ⣄ᬁ㛽㜑
Ἳߩ 1 ଀㧘ᢛᒻᄖ⑼ 2007 ᐕ㧧58 Ꮞ㧦1699㧙1702㧚
57㧕 㕍ᧁ㓉᣿㧚⣶ㇱ⣄ᩇ▤⁜⓰∝ߦ߅ߌࠆࠛ࡞ࠞ࠻࠾ࡦߩ SF8 ⹏ଔ㧘ᣂ⮎ߣ⥃ᐥ 2008 ᐕ㧧57 Ꮞ㧦65㧙70㧚
58㧕 ਛ᧛ᱜ↢㧘ᷡ᳓సᤨ㧚⣶ਅ⢇∩ࠍ઻߁㛽☻㝃∝∝଀ߦኻߔࠆᣣᧄ⺆
Roland㧙 Morris Disability
Questionnaire ࠍ↪޿ߚ QOL ⹏ଔ㧙ࠛ࡞ࠞ࠻࠾ࡦ⵾೷ᛩਈਅߢߩ−∩ߦ㑐ㅪߔࠆ QOL ᡷༀߦߟ޿ߡߩᬌ
⸛㧙㧘Osteoporosis Japan 2008 ᐕ㧧16 Ꮞ㧦207㧙215㧚
59㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧚⣶ਅ⢇∩࡮ߒ߮ࠇߦኻߔࠆᚻⴚԜ⚻ᬁ㑆ሹ⣶ᬁᬁ૕㑆࿕ቯⴚ(TLIF)㧘MB Orthop
2008 ᐕ㧧21 Ꮞ㧦63㧙68㧚
60㧕 ⚦ᳯ⧷ᄦ㧚࿖㓙ቇળශ⽎⸥ ╙ 4 ࿁਎⇇⣄ᬁቇળ(World Spine Φ)ߦෳടߒߡ㧘⥃ᐥᢛᒻᄖ⑼ 2008 ᐕ㧧
43 Ꮞ㧦152㧙153㧚
61㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘ችᧄᢘ㧘↰ਛஜ৻㇢㧘ጤ੗ᥓ቞↵㧘⑔↰┨ੑ㧚㛽☻㝃∝ᕈᬁ૕࿶ẩߦኻߔࠆᬁᑿࠍ
ߣࠄ߃ࠆ⣄ᬁ⍴❗ⴚ㧙ⴚᓟ㛽᛬ߣᓟᒗ㧙㧘ਛㇱᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ⹹ 2008 ᐕ㧧51 Ꮞ㧦643㧙644㧚
62㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘ችᧄᢘ㧘⑔↰┨ੑ㧘ጤ੗ᥓ቞↵㧚㗖ᬁ੝ో៰೨ᣇ࿕ቯⴚᓟߩ⣦㛽ቯ⌕ߣౝ࿕ቯ᧚ᢱߩᄌൻ㧙X ✢⹏ଔ㧙㧘⣄ᬁ࡮⣄㜑␹⚻ᚻⴚᚻᛛ ࡌࠬ࠻ࡍ࡯ࡄ࡯⾨ 2008 ᐕ㧧10 Ꮞ㧦117㧙119㧚
63㧕 ᄢፉᐽม㧘⑔↰┨ੑ㧘ᷡ᳓సᤨ㧘ᄢ㊁⾆ᢅ㧘⷏ᧄ⵨㧘᧻᳗⎇๋㧘ᑝἑༀା㧚㗖ㇱ⣲≌ߩ 1 ଀㧘᧲ᶏ㛽エㇱ⣲≌ 2008 ᐕ㧧20 Ꮞ㧦15㧙16㧚
64㧕 ᷡ᳓ቁᔒ㧘ᄢ㊁⾆ᢅ㧘ᄢፉᐽม㧘ᄢ㊁⟵ᐘ㧘ਅᎹ㇌ᵏ㧘ᷡ᳓సᤨ㧘⷏ᧄ⵨㧘◉ፒ᣽ੱ㧘ᵻ㊁ᄹ⟤㧘᧻᳗⎇๋㧘ᑝἑༀା㧚ฝ⢀エㇱ⣲≌ߩ 1 ଀㧘᧲ᶏ㛽エㇱ⣲≌ 2008 ᐕ㧧20 Ꮞ㧦27㧙28㧚
65㧕 ᄢ㊁⾆ᢅ㧘ᄢፉᐽม㧘ᷡ᳓సᤨ㧘⷏ᧄ⵨㧚㘃㛽㛽⣲ߦኻߔࠆ CT ࠟࠗ࠼ਅ࡜ࠫࠝᵄ὾ἳⴚߦࠃࠆૐଚⷅᚻ
ⴚߩ⚻㛎㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2008 ᐕ㧧51 Ꮞ㧦913㧙914㧚
66㧕 ᄢ㊁⾆ᢅ㧚╙ 6 ࿁ᣣ☨ട᰷ᢛᒻᄖ⑼ၮ␆ቇળวหળ⼏ቇળ࡟ࡐ㧙࠻㧘Arthritis 2008 2008 ᐕ㧧9 Ꮞ㧦50
㧙51㧚67㧕 ⍹ਣᄢ࿾㧘ᄢ㊁⾆ᢅ㧘ዊᎹኡᕶ㧘⷏ᧄ⵨㧘ᷡ᳓సᤨ㧚ᓟ㗖ㇱߦ⊒↢ߒߚ infantile fibromatosis ߩ৻଀㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2008 ᐕ㧧51 Ꮞ㧦93㧙94㧚
68㧕 ᄢ㊁⾆ᢅ㧘ᄢፉᐽม㧘ᷡ᳓సᤨ㧘⷏ᧄ⵨㧚㘃㛽㛽⣲ߦኻߔࠆ CT ࠟࠗ࠼ਅ࡜ࠫࠝᵄ὾ἳⴚߦࠃࠆૐଚⷅᚻ
ⴚߩ⚻㛎㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2008 ᐕ㧧51 Ꮞ㧦913㧙914㧚
69㧕 ⷏ᧄ ⵨㧘᧻↰ᅢ⟤㧘ᧄ㑆ජ⛗⟤㧘ጊ⾐ኡ㧘ᷰㄝ㇚㓶㧚┹ᛛࠬࡐ㧙࠷ߦ߅ߌࠆ⋴⼔Ꮷߩᓎഀ㧙࿖૕ㆬᚻߥߤ
ߦኻߔࠆࠕࡦࠤ㧙࠻⺞ᩏߦࠃࠆᬌ⸛㧙㧘ጘ㒂ᄢቇකቇㇱ♿ⷐ 2008 ᐕ㧧55 Ꮞ㧦1㧙16㧚
70㧕 ᴡ᧛⌀๋㧘♻ᢙਁᱜ㧘દ⮮⧐Პ߶߆㧚㑐▵࡝࠙ࡑ࠴೨⿷ㇱᄌᒻߦኻߔࠆ╙ 2㧙5 ⿾ MTP 㑐▵᷷ሽᢛᓳⴚߩ
⍴ᦼᚑ❣㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2008 ᐕ㧧51 Ꮞ㧦545㧙546㧚
71㧕 ᷡ᳓ቁᔒ㧘♻ᢙਁᱜ㧘દ⮮⧐Პ߶߆㧚ᓟᣇ㑐▵൮ᒆ✭ߦࠃࠆ෻ᒛ⤒ߦኻߒߡⷰⴊ⊛ᴦ≮(Piriou ᴺ)ࠍᣉⴕ
ߒߚ 1 ଀㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2008 ᐕ㧧51 Ꮞ㧦447㧙448㧚
72㧕 ㉿⷗๺ᒾ㧘⍹ฬ↰ᵗ৻㧘ᦸ᦬৻↵㧘દ⮮⧐Პ㧘Ꮉ਄♿᣿㧘ICD ᡷ⸓ߣᢛᒻᄖ⑼ක≮(ᐳ⺣ળ)㧘⥃ᐥᢛᒻᄖ⑼ 2008 ᐕ㧧43 Ꮞ㧦581㧙589㧚
73㧕 ዊᎹኡᕶ㧘દ⮮⧐Პ߶߆㧚Vancouver type B3 ࠬ࠹ࡓ๟࿐㛽᛬ߦኻߒ allograft㧙stem composite ࠍ૶↪
ߒߚੱᎿ⢆㑐▵ౣ⟎឵ⴚߩ 1 ଀㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2008 ᐕ㧧51 Ꮞ㧦1151㧙1152㧚
ේ⪺㧔᰷ᢥ㧕
1㧕 Hosoe H, Miyamoto K, Wada E, Shimizu K. A surgical treatment of scoliosis in Larsen's syndrome withbilateral hip dislocation: A case report. Spine. 2006;31:E302-306.
2㧕 Futani H, Minamizaki T, Nishimoto Y, Abe S, Yabe H, Ueda T. Long-Term Follow-up After Limb
Salvage in Skeletally Immature Children with a Primary Malignant Tumor of the Distal End of the
Femur. J Bone Joint Surg AM. 2006;88:595-603.
3㧕 Morita M, Banno Y, Dohjima T, Nozawa S, Fushimi K , Fan D, Ohno T, Miyazawa K, Liu N, Shimizu K.
Ǵ-Calpain is involved in the regulation of TNF--induced matrix metalloproteinase-3 release in arheumatoid synovial cell line. Biochem Bioph Res Commun. 2006;343:937-942.
4㧕 Ohnishi K, Miyamoto K, Hashimoto K, Hosoe H, Shimizu K. Surgical Treatment for Atlantoaxial
Subluxation Associated With Mixed Connective Tissue Disease. Orthopedics. 2006;29:369-370.
5㧕 Masuda T, Miyamoto K, Shimizu K. Intramuscular hemodynamics in bilateral erector spinase muscles
in symmetrical and asymmetrical postures with and without loading. Clin Biomecha. 2006;21:245-253.

㧙㧙

IF 2.499

IF 2.487

IF 2.749
IF 0.581
IF 1.642

6㧕 Matsumoto K, Kamiya N, Suwan K, Atsumi F, Shimizu K, Shinomura T, Yamada Y, Kimata K,
Watanabe H. Identification and Characterization of Versican/PG-M Aggregates in Cartilage. J Biol
Chem. 2006;281:18257-18263.
7㧕 Yoshida M, Kida K, Kodama H, Itokazu M, Shimizu K. Calcitonin treatment for calcifying tendinitis of
the shoulder. J Orthopaed Traumatol. 2006;7:6-11.
8㧕 Masuda T, Miyamoto K, Hosoe H, Sakaeda H, Tanaka M, Shimizu K. Surgical treatment with spinal
instrumentation for pyogenic spondylodiscitis due to menthicillin-resistant Staphylococcus
aureus(MRSA): a report of five cases. Arch Orthop Trauma Surg. 2006;126:339-349.
9㧕 Kamiya N, Watanabe H, Habuchi H, Takagi H, Shinomura T, Shimizu K, Kimata K. Versican/PG-M
Regulates Chondrogenesis as an Extracellular Matrix Molecule Crucial for Mesenchymal
Condensation. J Biol Chem. 2006;281:2390-2400.
10㧕 Wakahara K, Matsumoto K, Sumi H, Sumi Y, Shimizu K. Traumatic Spinal Cord Injuries From
Snowboarding. Am J Sports Med. 2006;34:1670-1674.
11㧕 Matsumoto K, Wakahara K, Sumi H, Shimizu K. Central Cord Syndrome in Patients With Klippel-Feil
Syndrome Resulting From Winter Sports. Am J Sports Med. 2006;34:1685-1689.
12㧕 Ogawa H, Itokazu M, Ito Y, Fukuta M, Shimizu K. The therapeutic outcome of minimally invasive
synovectomy assisted witharthroscopy in the rheumatoid knee. Mod Rheumatol. 2006;16:360-363.
13㧕 Matsumoto K, Itokazu M, Uemura S, Takigami I, Naganawa T, Shimizu K. Successful joint
arthroplasty after treatment of destructive MRSA arthritis of the knee using antibiotic-loadedhydroxyapatite blocks: a case report. Arch Orthop Trauma Surg. 2006;127:47-50.
14㧕 Ogawa H, Itokazu M, Ito Y, Fukuta M, Simizu K. An unusual meniscal ganglion cyst that triggered
recurrent hemarthrosis of the knee. Arthroscopy. 2006;22:455.e1-4.
15㧕 Akeda K, An HS, Okuma M, Attawia M, Miyamoto K, Thonar EJMA, Lenz ME, Sah RL, Masuda K.
Platelet-rich Plasma Stimulates Porcine Articular Chondrocyte Proliferation and Matrix Biosynthesis.
Osteoarthritis and Cartilage. 2006;14:1272-1280.
16㧕 Miyamoto K, Masuda K, Kim JG, Inoue N, Akeda K, Andersson GBJ, An HS. Intradiscal Injections ofOsteogenic Protein-1 Restore the Viscoelastic Properties of Degenerated Intervertebral Discs. Spine
Journal. 2006;6:692-703.
17㧕 Chujo T, An HS, Akeda K, Miyamoto K, Muehleman C, Attawia M, Andersson GBJ, Masuda K. Effects
of growth differentiation factor-5 (GDF-5) on the intervertebral disc - in vitro bovine study and in vivo
rabbit disc degeneration model study-. Spine. 2006;31:2909-2917.
18㧕 Ohara A, Miyamoto K, Naganawa T, Matsumoto K, Shimizu K. Sagittal alignment of the cervicalspine: comparison of five standard methods of measurement. Spine. 2006;31:2585-2591.
19㧕 Fushimi K, Miyamoto K, Nishimoto H, Hosoe H, Kodama H, Shimizu K. Clinical outcomes ofmultilevel anterior corpectomy and fusion as a revision surgery of the cervical spine. Report of sevencases. Spinal Cord. 2006;44:449-456.
20㧕 Miyamoto K, Masuda K, Inoue N, Okuma M, Meuhlmam C, An HS. Anti-adhesion properties ofthrombin-based hemostatic gelatin in a canine laminectomy model. –a biomechanical, biochemical,
and histological study. Spine. 2006;31:E91-E97.
21㧕 Sasaki T, Miyamoto K, Hosoe H, Shimizu K. Transoral Anterior Approach Used for Extensive Anterior
Decompression of C3 Vertebrae Level in a Patient with Severe Atlantoaxial Vertical Subluxation andRheumatoid Arthritis - A Case Report - Spinal Cord. 2006;44:52-55.
22㧕 Shimizu T, Miyamoto K, Masuda K, Miyata T, Hori H, Shimizu K, Maeda M. The clinical significanceof impaction at the femoral neck fracture site in the elderly. Arch Orthop Trauma Surg.
2007;127:515-521.
23㧕 Hosoe H, Shimizu K, Miyamoto K, Fukuta S, Iwai C. Cantilever-TLIF for patients with degenerative
scoliosis. Eur Spine J. 2007;16:S51.
24㧕 Aoki T, Terashima H, Itokazu M, Miyamoto K, Shimizu K. Stimulation of Music Prolonged
Disturbance of Consciousness Patients in Early Rehabilitation. J Saitama Kenou Rehabilitation.
2007;7:50-53.
25㧕 Ogawa H, Nishimoto H, Hosoe H, Suzuki N, Kanamori Y, Shimizu K. Clinical outcome aftersegmental wire fixation and bone grafting for repair of the defects in multiple level lumbar
spondylolysis. J Spinal Disord Tech. 2007;20:521-525.
26㧕 Ogawa H, Akaike A, Ishimaru D, Yamada K, Shimizu T, Koyama Y, Hori H. Posterior interosseous
nerve palsy related to rheumatoid synovitis of the elbow. Mod Rheumatol. 2007;17:327-329.
27㧕 Nagano A, Miyamoto K, Fushimi K, Hosoe H and Shimizu K. Failure of reconstruction surgery using
anterior fibular strut grafting for postlaminectomy kyphosis A case report. J Clin Neurosci.
2007;14:376-379.
28㧕 Inoue T, Miyamoto K, Kodama H, Hosoe H and Shimizu K. Total spondylectomy for treatment of asymptomatic hemangioma of the lumbar spine - A case report. J Clin Neurosci. 2007;14:806-809.
29㧕 Yamada K, Miyamoto K, Hosoe H, Mizutani M and Shimizu K. Scoliosis associated with Prader-Willi
syndrome A case report. Spine J. 2007;7:345-348.
30㧕 Miyamoto K, Shimizu K, Matsumoto S, Sumida H, Iida H, Hosoe H. Surgical treatment of scoliosis㧙㧙

IF 5.581

IF 0.913

IF 5.581
IF 3.397
IF 3.397

IF 0.913
IF 2.296

IF 3.793

IF 2.499
IF 2.499

IF 1.578

IF 2.499

IF 1.578

IF 0.913
IF 2.021

IF 1.303

IF 0.801
IF 0.801

associated with central core disease: Minimizing the effects of malignant hyperthermia withprovocation tests - Report of a case -. J Pediatr Orthoped B. 2007;16:239-242.
31㧕 Shimizu T, Miyamoto K, Masuda K, Miyata Y, Hori H, Shimizu K, Maeda M. The clinical significanceof impaction at the femoral neck fracture site in the elderly. Arch Orthop Trauma Surg.
2007;127:515-521.
32㧕 Fushimi K, Nakashima S, You F, Takigawa M, Shimizu K. Prostaglandin E2 Downregulates TNF-ǩ
-Induced Production of Matrix Metalloproteinase-1 in HCS-2/8 Chondrocytes by Inhibiting
Raf-1/MEK/ERK Cascade Through EP4 Prostanoid Receptor Activation. J Cell Biochem.
2007;100:783-793.
33㧕 Maehara H, Suzuki K, Sasaki T, Oshita H, Wada E, Inoue T , Shimizu K. G1-G2 Aggrecan Productthat can be Generated by M-calpain on Truncationat 709-Ala710 is Present Abundantly in Human
Articular Cartilage. J Biochem. 2007;141:469-477.
34㧕 Takeuchi A, Yamamoto Y, Tsuneyama K, Cheng C, Yonekura H, Watanabe T, Shimizu K, Tomita K,
Yamomoto H, Tsuchiya H. Endogenous secretory receptor for advanced glycation endproducts as anovel prognostic marker in chondrosarcoma. Cancer. 2007;9:2532-2540.
35㧕 Ogawa H, Nishimoto H, Hosoe H, Suzuki N, Kanamori Y, Shimizu K. Clinical outcome aftersegmental wire fixation and bone grafting for repair of the defects in multiple level lumbar
spondylolysis. J Spinal Disord Tech. 2007;20:521-525.
36㧕 Matsumoto K, Itokazu M, Uemura S, Takigami I, Naganawa T, Shimizu K. Successful joint
arthroplasty after treatment of destructive MRSA arthritis of the knee using antibiotic-loadedhydroxyapatite blocks -a case report-. Arch Orthop Trauma Surg. 2007;127:47-50.
37㧕 Hioki A, Miyamoto K, Hosoe H, Shimizu K. Two-staged decompression for thoracic paraparesis due tothe combined ossification of the posterior longitudinal ligament and the ligamentum flavum a casereport. Arch Orthop Trauma Surg. 2008;128:175-177.
38㧕 Yamamoto T,Inoue N, Miyamoto K, Sugiyama S, Nozawa S, Hosoe H, Shimizu K. Segmental wire
fixation for lumbar spondylolysis associated with spina bifida occulta. Arch Orthop Trauma Surg.
2008;128:1177-1182.
39㧕 Hashimoto K, Miyamoto K, Hosoe H, Kawai G, Kikuike K, Shimokawa K, Suzuki N, Matsuo M,
Kodama H, Shimizu K. Solitary fibrous tumor in the cervical spine with destructive vertebral
involvement:A case report and review of the literature. Arch Orthop Trauma Surg. 2008;128:1111-1116.
40㧕 Takigami I, Itoh Y, Itokazu M, Shimizu K. Radio-opaque marker of a surgical sponge appearing as an
intra-articular foreign body after total hip arthroplasty.
Arch
Orthop Trauma Surg.
2008;128:1167-1168.
41㧕 Chi D, Miyamoto K, Hosoe H, Kawai G, Ohnishi K, Suzuki N, Sumi H, Shimizu K. Symptomatic
lumbar mobile segment with spinal canal stenosis in fused spine associated with diffused idiopathic
skeletal hyperostosis A case report. Spine J. 2008;8:1019-1023.
42㧕 Hioki A, Ohnishi K, Miyamoto K, Hosoe H and Shimizu K. Spondylolysis of the second lumbar
vertebra treated with segmental wiring and bone grafting:a case report. Orthopaedics. 2008;31:287.
43㧕 Terabayashi N, Miyamoto K, Sasaki H, Hosoe H, Shimizu K. Multiple steroid-induced vertebral
fracture with paraparesis associated with Wegener’s granulomatosis treated with posterior spinal
instrumentation. Journal of Neurological Sciences(Turkish). 2008;25:67-71.
44㧕 Hioki A, Miyamoto K, Hosoe H, Fukuta S, Shimizu K. Two-stage decompression for combined epiconus
and cauda equina syndrome due to multilevel spinal canal stenosis of the thoracolumbar spine-a casereport. Arch Orthop Trauma Surg. 2008;128:955-958.
45㧕 Kawaguchi A, Chiba K, Tanimura Y, Motohashi T, Aoki H, Takeda T, Hayashi S, Shimizu K and
Kunisada T. Isolation and characterization of Kit-independent melanocyte precursors induced in theskin of Steel factor transgenic mice. Dev Growth Differ. 2008;50:63-69.
46㧕 Shinohe R. Sato M, Takemura M, Shimizu K, Koishi H, Tanaka R, Saito K, Seishima M. Cytokine
profiles in mice with arthritis induced by anti-type Τ collagen monoclonal antibody plus
lipopolysaccharide. Japanese Journal of Clinical Chemistry. 2008;37:53-62.
47㧕 Hirakawa A, Miyamoto K, Ohno Y, Hioki A, Ogawa H, Nishimoto H, Yokoi H, Shimizu K. Two-stage(posterior and anterior) surgical treatment of spinal osteomyelitis due to antypical mycobacteria andassociated thoracolumbar kyphoscoliosis in a nonimmunocompromised patient. Spine.
2008;33:E221-224.
48㧕 Matsumoto M, Chiba K, Toyama Y, Takeshita K, Seichi A, Nkamura K, Arimizu J, Fujibayashi S,
Hirabayashi S, Hirano T, Iwasaki M, Kaneoka K, Kawaguchi Y, Ijiri K, Maeda T, Matsuyama
Y,Mikami Y, Murakami H, Nagashima H, Nagata K, Nakahara S, Nohara Y, Oka S, Sakamoto K,
Saruhashi Y, Sasao Y, Shimizu K, Taguchi T, Takahashi M, Tanaka Y, Tani T, Tokuhashi Y, Uchida K,
Yamamoto K, Yamazaki M, Yokoyama T, Yoshida M,and Nishiwaki Y: Surgical results and related
factors for ossification of prosterior longitudinal ligament of the thoracic spinea multi-institutional
retrospective study. Spine. 2008;33:1034-1041.
49㧕 Hayashi Y, Sakurai T, Kimura A, Ikeda T, Masuyama Z, Suzuki Y, Tanaka Y, Hozumi I, Hosoe H,
Takahashi H, Inuzuka T. Selective cauda equina hypertrophy with ideiopathic inflammation, Muscle

㧙㧙

IF 0.619

IF 0.913

IF 3.381

IF 2.020

IF 4.632

IF 1.303

IF 0.913

IF 0.913

IF 0.913

IF 0.913

IF 0.913

IF 0.581

IF 0.913

IF 1.908

IF 2.499

IF 2.499

Nerve. 2008;38:105-1069.
IF 2.424
50㧕 Wakahara K, Ohno T, Kimura M, Masuda T, Nozawa S, Dohjima T, Yamamoto T, Nagano A, Kawai G,
Matsuhashi A, Saitoh M, Takigami I, Okano Y, Shimizu K. EWS-Fli1 up-regulates expression of the
Aurora A and Aurora B kinases. Mol. Cancer Res. 2008;6:1937-1945.
IF 7.672
51㧕 Takigami I, Itokazu M, Itoh Y, Matsumoto K, Yamamoto T, Shimizu K. Limb-length measurement in
total hip arthroplasty using a calipers dual pin retractor. Bull NYU Hosp Jt Dis. 2008;66:107-110.
52㧕 Ogawa H, Ito Y, Itokazu M, Mori N, Shimizu T, Terabayashi N, Ishimaru D, Shimizu K. Morcellized
Bone Grafting for Acetabular Deficiency in Cementless Total Hip Arthroplasty. Orthopedics.
2008;31:986.
IF 0.581

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦ਛ᧛⠹ਃ㧘⎇ⓥಽᜂ⠪㧦ᷡ᳓సᤨ㧧ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄㧦⣄ᬁᩇ㕢Ꮺ㛽ൻ∝ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ㧧ᐔᚑ 17㧙18 ᐕᐲ㧧1,300 ජ౞(500㧦800 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦⷏ᧄ ⵨㧧ᐔᚑ 18 ᐕᐲጘ㒂ᄢቇᵴᕈൻ⎇ⓥ⾌㧦⣖᪪Ⴇᓟߩ⵬ഥᚻߦኻߔࠆࡃ࡯࠴ࡖ࡞
࡝ࠕ࡝࠹ࠖࠍ೑↪ߒߚࠗࡔ࡯ࠫ࠻࡟࡯࠾ࡦࠣߩ᦭↪ᕈ㧧770 ජ౞3㧕 ⎇ⓥઍ⴫⠪㧦⚦ᳯ⧷ᄦ㧘⎇ⓥಽᜂ⠪㧦ᄢ㊁⾆ᢅ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄⪚⧘⎇ⓥ㧦࡙࡯ࠗࡦࠣ⡺⣲ࡑ࠙ࠬࡕ࠺࡞ߩ᮸┙ߣ⸃ᨆ㧧ᐔᚑ 18㧙19 ᐕᐲ㧧3,300 ජ౞(2,600㧦700 ජ౞)
4㧕 ⎇ⓥઍ⴫⠪㧦ᄢ㊁⾆ᢅ㧧ᐔᚑ 19 ᐕᐲጘ㒂ᄢቇ⎇ⓥ⑼㐳࡮කቇㇱ㐳ⵙ㊂⚻⾌㧦߇ࠎ⚦⢩ߦኻߔࠆ᛫߇
ࠎ೷ᴦ≮⮎ߣ⚦⢩ᱫ-EWS/Fli-1 Ⲣวㆮવሶߦࠃࠆ Aurora kinase ߩォ౮ᵴᕈൻᯏ᭴-㧧ᐔᚑ 19 ᐕᐲ㧧
500 ජ౞
5㧕 ⎇ⓥઍ⴫⠪㧦ਛ᧛⠹ਃ㧘⎇ⓥಽᜂ⠪㧦ᷡ᳓సᤨ㧧ᐔᚑ 19 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄㧦⣄ᩇ㕢Ꮺ㛽ൻ∝ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ㧧ᐔᚑ 19 ᐕᐲ㧧1,000 ජ౞6㧕 ⎇ⓥઍ⴫⠪㧦ᄢ㊁⾆ᢅ㧘⎇ⓥಽᜂ⠪㧦ᧁ᧛ᱜᔒ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦㛽エㇱ⣲≌ߦ߅ߌࠆࠝ࡯ࡠ࡜ࠠ࠽࡯࠯ߩ⸃ᨆ㧧ᐔᚑ 18 ᐕ㧙20 ᐕᐲ㧧3,600 ජ౞(2,600㧦500㧦500 ජ౞)
7㧕 ⎇ⓥઍ⴫⠪㧦ᚭጊ⧐ᤘ㧘⎇ⓥಽᜂ⠪㧦ᷡ᳓సᤨ㧧ᐔᚑ 20 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄㧦㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ㧦⣄ᩇ㕤Ꮺ㛽ൻ∝ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ㧦ᐔᚑ 20 ᐕᐲ㧧1,000 ජ౞8㧕 ⎇ⓥઍ⴫⠪㧦ᷡ᳓సᤨ㧧2008 ᐕᣣᧄ⣄ᬁ⣄㜑∛ቇળ Visiting Scholar Program㧧1,000 ජ౞9㧕 ⎇ⓥઍ⴫⠪㧦ᄢ㊁⾆ᢅ㧘⎇ⓥಽᜂ⠪㧦ᚻႦᑪ৻㧘ේ ᣿㧧ᐔᚑ 20 ᐕᐲጘ㒂ᄢቇ⎇ⓥ⑼㐳ⵙ㊂⚻⾌ ᄙ
ಽ㊁౒ห⎇ⓥ‫ޠࡓ࡯࠴࠻ࠢࠚࠫࡠࡊޟ‬㧦ᱤ㜑⚦⢩ߦࠃࠆ㛽ౣ↢ࡊࡠࠫࠚࠢ࠻ ࡅ࠻ᱤ㜑⚦⢩ࠍ↪޿ߚ఺∉ਇో࡜࠶࠻ᄢ⣽㛽㛽ன㑐▵ࡕ࠺࡞ߦ߅ߌࠆ㛽ౣ↢㧦ᐔᚑ 20 ᐕᐲ㧧1,000 ජ౞
2㧕ฃ⸤⎇ⓥ
1㧕 ⎇ⓥઍ⴫⠪㧦⮮ᳯᱜస㧘Ꮉ㦮᥍ਭ㧘⎇ⓥಽᜂ⠪㧦㊁↰ඳ㧘ਅ᧛ዏਯ㧘ᩕᨑ⵨ᢥ㧘⷏ᧄ⵨㧘቟୚ၮᐘ㧚ᣂࠛࡀ࡞ࠡ࡯࡮↥ᬺᛛⴚ✚ว㐿⊒ᯏ᭴ ੱ㑆ᡰេဳࡠࡏ࠶࠻ታ↪ൻၮ⋚ᛛⴚ㐿⊒੐ᬺ㧘ࠗࡔ࡯ࠫ࠻
࡟࡯࠾ࡦࠣᯏ⢻ઃ߈ᚻᜰ਄⢇࡝ࡂࡆ࡝ᡰេࠪࠬ࠹ࡓߩ⎇ⓥ㐿⊒㧧ᐔᚑ 17㧙19 ᐕᐲ㧧7,580 ජ౞(328㧦
4,854㧦2,398)㧦ਣን♖Ꮏ(ᩣ)
2㧕 ⎇ⓥઍ⴫⠪㧦㕍ᧁ㓉᣿㧚ࡑࠗࠢࡠࡃࡉ࡞ߩり૕߳ߩലᨐߦߟ޿ߡߩ⎇ⓥ㧧ᐔᚑ 19㧙20 ᐕᐲ㧧1,000ජ౞㧦ᦺᣣ⥝ᬺ(ᩣ)
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫ
1㧕 㕍ᧁ㓉᣿㧦೨⣨࿁ౝᄖㆇേ↪ⵝౕߩ㐿⊒㧧ᐔᚑ 19 ᐕᐲ
6㧚ቇળᵴേ
1㧕ቇળᓎຬᷡ᳓సᤨ㧦
1㧕 ᣣᧄᚻߩᄖ⑼ቇળ୶ℂᆔຬળᆔຬ(ᐔᚑ 18 ᐕ 5 ᦬㨪⃻࿷)2㧕 ᣣᧄᚻߩᄖ⑼ቇળ⹏⼏ຬ(ᐔᚑ 18 ᐕ 5 ᦬㨪⃻࿷)
3㧕 ᣣᧄᢛᒻᄖ⑼ቇળ╙ 19 ࿁ኾ㐷ක⹜㛎ญ㗡⹜㛎ᆔຬ(ᐔᚑ 18 ᐕ 10 ᦬㨪⃻࿷)
4㧕 ╙ 5 ࿁ᢛᒻᄖ⑼㐳⦟࡝ࡃ࡯ࠨࠗ࠼ࡈࠜ࡯࡜ࡓઍ⴫਎⹤ੱ(ᐔᚑ 19 ᐕ 1 ᦬㨪⃻࿷)
5㧕 ᣣᧄ⣄ᬁ⣄㜑∛ቇળ⹏⼏ຬ(ᐔᚑ 19 ᐕ 4 ᦬㨪⃻࿷)㧙㧙6㧕 ᣣᧄᚻߩᄖ⑼ቇળ୶ℂᆔຬળᆔຬ(ᐔᚑ 19 ᐕ 5 ᦬㨪⃻࿷)7㧕 ᣣᧄ⣄ᬁ⣄㜑∛ቇળᜰዉක೙ᐲᬌ⸛ᆔຬળᆔຬ(ᐔᚑ 19 ᐕ 6 ᦬㨪⃻࿷)8㧕 ᣣᧄ⣄ᬁ⣄㜑∛ቇળ࿖㓙ᆔຬળᆔຬ(ᐔᚑ 19 ᐕ 6 ᦬㨪⃻࿷)9㧕 ᣣᧄ⣄ᬁ⣄㜑∛ቇળ୶ℂᆔຬળᆔຬ(ᐔᚑ 19 ᐕ 6 ᦬㨪⃻࿷)10㧕 ᣣᧄ⣄ᬁ⣄㜑∛ቇળ⽷ോᆔຬળᆔຬ(ᐔᚑ 19 ᐕ 6 ᦬㨪⃻࿷)11㧕 Fighting Vascular Events in Gifu 2007 ਎⹤ੱ(ᐔᚑ 19 ᐕ 6 ᦬㨪⃻࿷)12㧕 ╙ 37 ࿁ᣣᧄ⣄ᬁ⣄㜑∛ቇળࡊࡠࠣ࡜ࡓᆔຬ(ᐔᚑ 19 ᐕ 10 ᦬㨪⃻࿷)13㧕 ᣣᧄᢛᒻᄖ⑼ቇળ╙ 20 ࿁ኾ㐷ක⹜㛎ญ㗡⹜㛎ᆔຬ(ᐔᚑ 19 ᐕ 10 ᦬ 24 ᣣ)
14㧕 ╙ 1 ࿁᧲ᶏ㕒⣂ⴊᩖႧᩖ∝(VTE)੍㒐ࡀ࠶࠻ࡢ࡯ࠢࠪࡦࡐࠫ࠙ࡓ਎⹤ੱ(ᐔᚑ 19 ᐕ 12 ᦬ 8 ᣣ)
15㧕 ᐔᚑ 20 ᐕᐲᣣᧄᚻߩᄖ⑼ቇળ⹏⼏ຬ(ᐔᚑ 20 ᐕ 5 ᦬㨪⃻࿷)16㧕 ᐔᚑ 20 ᐕᐲᣣᧄᚻߩᄖ⑼ቇળ୶ℂᆔຬળᆔຬ(ᐔᚑ 20 ᐕ 5 ᦬㨪⃻࿷)17㧕 ╙ 21 ࿁ኾ㐷ක⹜㛎ญ㗡⹜㛎ᆔຬ(ᐔᚑ 20 ᐕ 10 ᦬ 22 ᣣ)
18㧕 ᣣᧄ⣄ᬁ⣄㜑∛ቇળ 2009 SAS scientific program reviewer(ᐔᚑ 20 ᐕ 10 ᦬ 24 ᣣ)
19㧕 ᣣᧄᢛᒻᄖ⑼ቇળ╭㛽ᩰ♽ TAG ⚵❱ᆔຬળᆔຬ(ᐔᚑ 20 ᐕ 11 ᦬㨪⃻࿷)ᄢ㊁⾆ᢅ㧦
1㧕 ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᧲ᶏ㛽エㇱ⣲≌⎇ⓥળᐙ੐(ᐔᚑ 18 ᐕᐲ㨪⃻࿷)3㧕 㛽エㇱ⣲≌ᴦ≮ᬌ⸛ળᐙ੐(ᐔᚑ 20 ᐕᐲ㨪⃻࿷)
4㧕 ᣣᧄㆇേེ⒖ᬀ࡮ౣ↢කቇ⎇ⓥળᐙ੐(ᐔᚑ 20 ᐕᐲ㨪⃻࿷)⚦ᳯ⧷ᄦ㧦
1㧕 ᣣᧄᢛᒻᄖ⑼ቇળኾ㐷කญ㗡⹜㛎⹜㛎ቭ(ᐔᚑ 18 ᐕ 1 ᦬ 20 ᣣ)
2㧕 ᣣᧄᢛᒻᄖ⑼ቇળ⣄ᬁౝⷞ㏜ਅᚻⴚࠗࡦࠪ࠺ࡦ࠻࡮ࡢ࡯ࠠࡦࠣࠣ࡞࡯ࡊ(ᐔᚑ 18 ᐕᐲ㨪⃻࿷)
3㧕 ᣣᧄ஥ᒭ∝ቇળ 2010 SRS ታⴕᆔຬળᆔຬ(ᐔᚑ 18 ᐕᐲ㨪⃻࿷)
4㧕 ᣣᧄ⣄ᬁࠗࡦࠬ࠻࠘࡞ࡔࡦ࠹࡯࡚ࠪࡦቇળᐙ੐(ᐔᚑ 18 ᐕᐲ㨪⃻࿷)5㧕 ጘ㒂⋵␠ળ⑔␩ክ⼏ળᆔຬ(ᐔᚑ 19 ᐕᐲ㨪⃻࿷)6㧕 ጘ㒂Ꮢ␠ળ⑔␩ክ⼏ળᆔຬ(ᐔᚑ 19 ᐕᐲ㨪⃻࿷)7㧕 ࿖᳃ஜᐽ଻㒾ክᩏຬ(ᐔᚑ 20 ᐕᐲ㨪⃻࿷)8㧕 㓚ኂᐕ㊄ክᩏຬ(ᐔᚑ 20 ᐕᐲ㨪⃻࿷)9㧕 ஥ᒗ∝ቇળᐙ੐(ᐔᚑ 20 ᐕᐲ㨪⃻࿷)10㧕 ᣣᧄᢛᒻᄖ⑼ቇળઍ⼏ຬㆬ᜼▤ℂᆔຬળᆔຬ(㨪⃻࿷)11㧕 ᣣᧄ⣄ᬁ࡮⣄㜑∛ቇળ⹏⼏ຬ(㨪⃻࿷)12㧕 ᣣᧄ੃࡮ᐜఽ஥ᒗ∝⎇ⓥળ਎⹤ੱ(㨪⃻࿷)13㧕 ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)14㧕 ᧲ᶏ⣄ᬁᄖ⑼⎇ⓥળᏱછᐙ੐(㨪⃻࿷)⷏ᧄ ⵨㧦
1㧕 ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄᢛᒻᄖ⑼ቇળઍ⼏ຬ(㨪⃻࿷)ᄢ㊁⟵ᐘ㧦1㧕 ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)દ⮮⧐Პ㧦1㧕 ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄੱᎿ㑐▵ቇળ⹏⼏ຬ(ᐔᚑ 20 ᐕᐲ㨪⃻࿷)
3㧕 ᣣᧄ⢆㑐▵ቇળ⹏⼏ຬ(ᐔᚑ 20 ᐕᐲ㨪⃻࿷)
4㧕 ᧲ᶏ㑐▵ᄖ⑼⎇ⓥળᐙ੐(㨪⃻࿷)5㧕 ᧲ᶏዊఽᢛᒻᄖ⑼ᙣ⹤ળᏱછᐙ੐(㨪⃻࿷)6㧕 ᧲ᶏੱᎿ㑐▵⎇ⓥળᏱછ਎⹤ੱ(ᐔᚑ 20 ᐕᐲ㨪⃻࿷)7㧕 㑐⷏⤒㑐▵㏜⎇ⓥળᐙ੐(㨪⃻࿷)8㧕 ╙ 11 ࿁᧲ᶏ⿷ߣ㕦ߩ⎇ⓥળᐙ੐(ᐔᚑ 19 ᐕ 10 ᦬ 20 ᣣ)㧙㧙9㧕 ᧲ᶏ⢆㑐▵⎇ⓥળઍ⴫ᐙ੐(ᐔᚑ 19 ᐕᐲ㨪⃻࿷)10㧕 ጘ㒂ੱᎿ㑐▵ࡈࠜ࡯࡜ࡓᐙ੐(㨪⃻࿷)11㧕 ᣣᧄᢛᒻᄖ⑼ቇળ ICD-11 ᬌ⸛ᆔຬળᆔຬ(ᐔᚑ 19 ᐕᐲ㨪⃻࿷)㕍ᧁ㓉᣿㧦
1㧕 ᣣᧄ⟵⢇ⵝౕቇળળೣᬌ⸛ᆔຬ(ᐔᚑ 18 ᐕ 10 ᦬ 20 ᣣ)
2㧕 ᣣᧄ࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦࡀ࠶࠻ࡢ࡯ࠢ⎇ⓥળℂ੐(ᐔᚑ 18 ᐕ 12 ᦬ 3 ᣣ)
3㧕 ᢛᒻᄖ⑼࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦቇળ㘈໧(ᐔᚑ 18 ᐕ 12 ᦬㨪⃻࿷)
4㧕 ᣣᧄ⟵⢇ⵝౕቇળળೣᆔຬ(㨪⃻࿷)5㧕 ᣣᧄ࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦࡀ࠶࠻ࡢ࡯ࠢቇળℂ੐(㨪⃻࿷)6㧕 ᣣᧄ࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦකቇળ᧲ᶏਛㇱ࿾ᣇળᐙ੐(㨪⃻࿷)7㧕 ጘ㒂࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦ⎇ⓥળ⹏⼏ຬ(㨪⃻࿷)ኹᨋિᄦ㧦1㧕 ᧲ᶏ㑐▵㏜⎇ⓥળᐙ੐(ᐔᚑ 19 ᐕ 6 ᦬㨪⃻࿷)2㧕ቇળ㐿௅ᷡ᳓సᤨ㧦
1㧕 ╙ 8 ࿁ጘ㒂ᢛᒻᄖ⑼තᓟᄐᦼ࠮ࡒ࠽࡯2006(ᐔᚑ 18 ᐕ 7 ᦬㧘ጘ㒂)2㧕 ╙ 9 ࿁ጘ㒂ᢛᒻᄖ⑼තᓟᄐᦼ࠮ࡒ࠽࡯2007(ᐔᚑ 19 ᐕ 7 ᦬㧘ጘ㒂)
3㧕 ╙ 10 ࿁ጘ㒂ᢛᒻᄖ⑼තᓟᄐᦼ࠮ࡒ࠽࡯2008(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂)દ⮮⧐Პ㧦
1㧕 ╙ 11 ࿁᧲ᶏ⿷ߣ㕦ߩ⎇ⓥળ(ᐔᚑ 19 ᐕ 10 ᦬㧘ጘ㒂)㕍ᧁ㓉᣿㧦
1㧕 ጘ㒂࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦ⎇ⓥળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ጘ㒂)2㧕 ጘ㒂࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦ⎇ⓥળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ጘ㒂)
3㧕ቇⴚ㔀⹹ᷡ᳓సᤨ㧦
1㧕 ᩣᑼળ␠කቇᦠ㒮‫⥃ޟ‬ᐥᢛᒻᄖ⑼‫ޠ‬㧧✬㓸ᆔຬ(㨪⃻࿷)
2㧕 Orthopaedic International: Editor(㨪⃻࿷)
3㧕 Orthopaedic Today: Editor(㨪⃻࿷)4㧕 ᩣᑼળ␠ࡔ࠺ࠖࠞ಴ ‫ޟ‬ᢛᒻᄖ⑼⋴⼔‫ޠ‬㧦✬㓸หੱ(㨪⃻࿷)7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ᷡ᳓సᤨ㧦
1㧕 ࡌࡀ࠶࠻㛽☻㝃∝ቇⴚ⻠Ṷળ(ᐔᚑ 18 ᐕ 1 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬㛽☻㝃∝ߪᤃߒߊߥ޿㧙․ߦ㛽☻㝃∝߆ࠄ⿠ߎࠆᄌᒻᕈ⣄ᬁ∝㧙‫ޠ‬ᐳ㐳)2㧕 ጘ㒂⋵කᏧળஜᐽࠬࡐ࡯࠷කቇ⎇ୃળ(ᐔᚑ 18 ᐕ 1 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫࠷࡯ࡐࠬޟ‬ㆬᚻߦ߅ߌࠆ⣶ᬁಽ㔌∝‫ޠ‬Ṷ⠪)3㧕 ጘ㒂⋵ᄖ்ᢇ๮ᢇᕆ࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 1 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫⃻ޟ‬ઍߩ㜞ᐲᄖ்ක≮‫ޠ‬ᐳ㐳)4㧕 ᴒ✽⣶∩࡮ਅ⢇∩ࡈࠜ࡯࡜ࡓ 2006(ᐔᚑ 18 ᐕ 1 ᦬㧘ᴒ✽㧘․೎⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩᴦ≮‫ޠ‬Ṷ
⠪)
5㧕 කᏧળቇⴚ⻠Ṷળ(ᐔᚑ 18 ᐕ 2 ᦬㧘ਃ㊀㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)
6㧕 ችፒ⋵⣶ㇱ⣄ᩇ▤⁜⓰∝ࡈࠜ࡯࡜ࡓ(ᐔᚑ 18 ᐕ 2 ᦬㧘ችፒ㧘․೎⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩᴦ≮‫ޠ‬Ṷ⠪)7㧕 ╙ 16 ࿁⑔ፉ⋵ᢛᒻᄖ⑼කߩ㓸޿(ᐔᚑ 18 ᐕ 2 ᦬㧘⑔ፉ㧘․೎⻠Ṷ‫ޟ‬⣄ᬁࠗࡦࠬ࠻࠘࡞ࡔࡦ࠹࡯࡚ࠪ
ࡦߦࠃࠆᄌᒻ⍶ᱜ‫ޠ‬Ṷ⠪)
8㧕 ⣶∩࡮ਅ⢇∩∔ᖚࡈࠜ࡯࡜ࡓ in ᾢᧄ(ᐔᚑ 18 ᐕ 2 ᦬㧘ᾢᧄ㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)9㧕 ጘ㒂⋵⥃ᐥᢛᒻᄖ⑼කળ⻠Ṷળ(ᐔᚑ 18 ᐕ 3 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ዊఽߩ⣄ᩇᄌᒻ‫ޠ‬Ṷ⠪)10㧕 ᧻ᳯᏒකᏧળቇⴚ⻠Ṷળ(ᐔᚑ 18 ᐕ 3 ᦬㧘㠽ข㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)㧙㧙

11㧕 ╙ 392 ࿁ጤᚻᢛᒻἴኂᄖ⑼ᙣ⺣ળ(ᐔᚑ 18 ᐕ 4 ᦬㧘ጤᚻ㧘․೎⻠Ṷ‫࠷࡯ࡐࠬޟ‬ㆬᚻߦ߅ߌࠆ⣶ᬁಽ㔌∝ߩᚻⴚ‫ޠ‬Ṷ⠪)12㧕 ╙ 35 ࿁㐿᡼ဳ∛ᐥࠞࡦࡈࠔ࡟ࡦࠬ(ᐔᚑ 18 ᐕ 4 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)
13㧕 ᕺ㇊කᏧળᤐᦼቇળ(ᐔᚑ 18 ᐕ 4 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)
14㧕 ࡕ࡯࡜ࠬ࠹࡯ࡊ⊒ᄁ 10 ๟ᐕ⸥ᔨቇⴚᢥൻ⻠Ṷળ(ᐔᚑ 18 ᐕ 5 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ߩ⑳ޟ‬ข᧚ᚻᏭ߆
ࠄ㨪ࠊߚߒ߇಴ળߞߚ⚛ᢜߥੱߚߜ㨪‫ޠ‬ᐳ㐳)15㧕 ╙ 79 ࿁ᣣᧄᢛᒻᄖ⑼ቇળቇⴚ✚ળ(ᐔᚑ 18 ᐕ 5 ᦬㧘␹ᄹᎹ㧘ᢎ⢒⎇ୃ⻠Ṷ‫ޟ‬⢋ߎࠅߩකቇ‫ޠ‬ᐳ㐳)16㧕 㠽ข⋵᧲ㇱකᏧળቇⴚ⻠Ṷળ(ᐔᚑ 18 ᐕ 5 ᦬㧘㠽ข㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)17㧕 ╙ 8 ࿁ጘ㒂ᄢቇᢛᒻᄖ⑼ᢎ⢒⎇ୃળ(ᐔᚑ 18 ᐕ 5 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ᄌᒻᕈ㑐▵∝ߩ∛ᘒߣᴦ≮‫ޠ‬ᐳ㐳)18㧕 ⣶∩࠮ࡒ࠽࡯in ၔධ(ᐔᚑ 18 ᐕ 6 ᦬㧘᧲੩㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)
19㧕 ⟲㚍⋵⣶࡮⿷ߩߒ߮ࠇ∩ߺ࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 6 ᦬㧘⟲㚍㧘․೎⻠Ṷ‫ޟ‬⣶ㇱᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)20㧕 ጘ㒂⋵කᏧળᄖ⑼කㇱળ࡮ഭἴᜰቯකㇱળ✚ળ(ᐔᚑ 18 ᐕ 7 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ᧃޟ‬᪳␹⚻㓚ኂߩᴦ≮ߣ࡝ࡂࡆ࡝‫ޠ‬ᐳ㐳)21㧕 ╳ᓟ⥃ᐥᢛᒻᄖ⑼කળቇⴚ⻠Ṷળ(ᐔᚑ 18 ᐕ 7 ᦬㧘⑔ጟ㧘․೎⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩᴦ≮‫ޠ‬Ṷ⠪)22㧕 ╙ 33 ࿁ࠬࡐ࡯࠷කቇ⎇ୃળ(ᐔᚑ 18 ᐕ 8 ᦬㧘᧲੩㧘․೎⻠Ṷ‫ޟ‬⣄ᩇ㧘⢷࡮⣶ᬁߩᄖ்ߣ㓚ኂ‫ޠ‬Ṷ⠪)23㧕 ⣶∩࡮ਅ⢇∩∔ᖚࡈࠜ࡯࡜ࡓᾢᧄ(ᐔᚑ 18 ᐕ 9 ᦬㧘ᾢᧄ㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)24㧕 ࠝࠬ࠹ࠝࡐࡠ࡯ࠪࠬ࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 9 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬㛽☻㝃∝ᕈ⣄ᬁ㛽᛬ߩᴦ≹ㆊ⒟߆
ࠄߺߚᚢ⇛⊛଻ሽ࡮ᚻⴚᴦ≮ߩታ㓙ߣዷᦸ‫ޠ‬ᐳ㐳)25㧕 㛽☻㝃∝ᦨᣂ⻠Ṷળ(ᐔᚑ 18 ᐕ 9 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬㛽☻㝃∝ߩࠣࡠ࡯ࡃ࡞ࠬ࠲ࡦ࠳࡯࠼ߣᚒ࿖
ߩ⃻⁁‫ޠ‬ᐳ㐳)26㧕 ጘ㒂⋵⣶∩ࡈࠜ࡯࡜ࡓ(ᐔᚑ 18 ᐕ 9 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)27㧕 ╙ 107 ࿁ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ(ᐔᚑ 18 ᐕ 10 ᦬㧘౓ᐶ㧘‫ޟ‬㛽☻㝃∝ᕈ࿶ㄼ㛽᛬ߦኻߔࠆᴦ
≮‫ޠ‬ᐳ㐳)28㧕 㒋␹ LCS ࡈࠜ࡯࡜ࡓ(ᐔᚑ 18 ᐕ 10 ᦬㧘౓ᐶ㧘․೎⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩᴦ≮‫ޠ‬Ṷ⠪)29㧕 ╙ 5 ࿁ጘ㒂࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦ⎇ⓥળ(ᐔᚑ 18 ᐕ 11 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫╭ޟ‬ജჇᒝലᨐߩࠛࡆ࠺ࡦ
ࠬ‫ޠ‬ᐳ㐳)30㧕 ╙ 87 ࿁๺᱌ጊ⥃ᐥᢛᒻᄖ⑼කળ⎇ୃળ(ᐔᚑ 18 ᐕ 11 ᦬㧘․೎⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩᴦ≮‫ޠ‬Ṷ
⠪)31㧕 ࠕ࡞ࡈࠔࡠ࡯࡞⊒ᄁ 25 ๟ᐕ⸥ᔨ⻠Ṷળ(ᐔᚑ 18 ᐕ 11 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬㛽᛬੍㒐ߩⷰὐߦၮߠ
ߊᦨᣂߩ㛽☻㝃∝ᴦ≮ᜰ㊎‫ޠ‬ᐳ㐳)32㧕 ╙ 34 ࿁᧲ᶏ࿾඙ᢛᒻᄖ⑼ᢎ⢒⎇ୃળ(ᐔᚑ 18 ᐕ 11 ᦬㧘ᗲ⍮㧘․೎⻠Ṷ‫ޟ‬⢆㑐▵ߣ⣄ᬁߦ߅ߌࠆᚻ
ⴚᚻᛛߩᎿᄦߣታ㓙‫ޠ‬ᐳ㐳)33㧕 ࡊ࡜ࠗࡑ࡝࡮ࠤࠕ࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 12 ᦬㧘੩ㇺ㧘․೎⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩ∛ᘒ㧘⸻ᢿߣᴦ≮㧙⸻ᢿࠨࡐ࡯࠻࠷࡯࡞ࠍ฽߼ߡ㧙‫ޠ‬Ṷ⠪)34㧕 ⣶∩∔ᖚ࠮ࡒ࠽࡯2006(ᐔᚑ 18 ᐕ 12 ᦬㧘ṑ⾐㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)35㧕 ╙ 8 ࿁ Latest Orthopedics ⎇ⓥળ(ᐔᚑ 18 ᐕ 12 ᦬㧘ጟጊ㧘․೎⻠Ṷ‫ޟ‬⣄ᬁ㛽㜑Ἳߩ⸻ᢿߣᴦ≮‫ޠ‬Ṷ⠪)36㧕 ╙ 166 ࿁⑔ጊᄖ⑼ળ(ᐔᚑ 18 ᐕ 12 ᦬㧘ᐢፉ㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)37㧕 ╙ 5 ࿁ᢛᒻᄖ⑼㐳⦟࡝ࡃ࡯ࠨࠗ࠼ࡈࠜ࡯࡜ࡓ(ᐔᚑ 19 ᐕ 1 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ߦ࡞࡯ࡎ࠻࠶ࡇޟ‬፰ࠄߥ޿⿷∔ᖚ࡮ᄖ்ߩ⷗ᣇ‫ޠ‬ᐳ㐳)38㧕 ╙ 6 ࿁ጘ㒂㛽☻㝃∝ࡈࠜ࡯࡜ࡓ(ᐔᚑ 19 ᐕ 1 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬㜞㦂⠪ߦ߅ߌࠆ᦯⮎ᜰዉߩታ〣㨪㛽☻㝃∝ᴦ≮⮎ࠍਛᔃߦ㨪‫ޠ‬ᐳ㐳)39㧕 㖧ᣣ⣄ᬁᄖ⑼ᙣ⹤ળ(ᐔᚑ 19 ᐕ 2 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬㖧࿖ߦ߅ߌࠆ⣄ᬁᄖ⑼࠻ࡇ࠶ࠢࠬ‫ޠ‬ᐳ㐳)40㧕 2 ᦬ౝ⑼ળ(ᐔᚑ 19 ᐕ 2 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫⥸৻ޟ‬ౝ⑼ක߇⍮ߞߡ߅߈ߚ޿⣶∩ߩ⸻ᢿᴦ≮‫ޠ‬Ṷ⠪)41㧕 ╙ 5 ࿁৾㓊 LCS ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 2 ᦬㧘⑔ጟ㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)42㧕 ╙ 3 ࿁ጘ㒂ㆇേེ㩖ࡊ࡜ࠗࡑ࡝࡯ࠤࠕ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 2 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ᣣᏱㆣㆄߔࠆエㇱ⣲≌㧙⸻≮ߩⷐὐߣ⋤ὐ㧙‫ޠ‬ᐳ㐳)43㧕 ವ㙚ᢛᒻᄖ⑼ળቇⴚ⻠Ṷળ(ᐔᚑ 19 ᐕ 3 ᦬㧘ವ㙚㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)44㧕 ╙ 10 ࿁ጘ㒂⣄ᬁ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 3 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬⣄ᬁ㛽㜑Ἳߩ⸻ᢿߣᴦ≮‫ޠ‬Ṷ⠪)45㧕 Medical Tribune ࡊ࡜ࠗࡑ࡝࡯ࠤࠕ࡮࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 3 ᦬㧘ฬฎደ㧘․೎⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩ∛ᘒ㧘⸻ᢿߣᴦ≮㧙⸻ᢿࠨࡐ࡯࠻࠷࡯࡞ࠍ฽߼ߡ㧙‫ޠ‬Ṷ⠪)㧙㧙

46㧕 ࡊ࡜ࠗࡑ࡝࡮ࠤࠕ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 3 ᦬㧘ฬฎደ㧘․೎⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩ∛ᘒ㧘⸻ᢿߣᴦ≮㧙⸻ᢿࠨࡐ࡯࠻࠷࡯࡞ࠍ฽߼ߡ㧙‫ޠ‬Ṷ⠪)47㧕 ⥄ォゞߦࠃࠆஜᐽߠߊࠅ⻠Ṷળ(ᐔᚑ 19 ᐕ 3 ᦬㧘⟤Ớ㧘․೎⻠Ṷ‫⥄ޟ‬ォゞߣஜᐽ‫ޠ‬Ṷ⠪)48㧕 ╙ 4 ࿁ጘ㒂ㆇേེࡊ࡜ࠗࡑ࡝࡯ࠤࠕ࡮࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 3 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬㗖ᬁ∔ᖚߩ∛⸻ㅪ៤㧙ߚ߆߇⢋ߎࠅ㧘ߐࠇߤ⢋ߎࠅ㧙‫ޠ‬ᐳ㐳)49㧕 ╙ 4 ࿁ጘ㒂ㆇേེࡊ࡜ࠗࡑ࡝࡯ࠤࠕ࡮࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 3 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬⣶∩⸻ᢿߩ⪭ߣߒⓣ‫ޠ‬ᐳ㐳)50㧕 ╙ 108 ࿁ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 4 ᦬㧘ᐢፉ㧘․೎⻠Ṷ‫ޟ‬਄૏㗖ᬁㇱ்∛ߩ⸻≮ߩⷐὐ‫ޠ‬ᐳ㐳)51㧕 ⠀ፉ㇭ࡔ࠺ࠖࠞ࡞࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 4 ᦬㧘⠀ፉ㇭㧘․೎⻠Ṷ‫⥸৻ޟ‬ౝ⑼ක߇⍮ߞߡ߅߈ߚ޿⣶∩ߩ⸻ᢿᴦ≮‫ޠ‬Ṷ⠪)52㧕 ╙ 6 ࿁߮ࠊߎࠬࡐ࡯࠷㓚ኂࡈࠜ࡯࡜ࡓ(ᐔᚑ 19 ᐕ 4 ᦬㧘ᄢᵤ㧘․೎⻠Ṷ‫ޟ‬⣶ߩ∩ߺߣࠬࡐ࡯࠷㓚ኂ‫ޠ‬Ṷ⠪)53㧕 ࠪࠞࠧ㨯ጘ㒂 ⣄ᬁ⣄㜑∛࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 4 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ᄌᕈᬁ㑆᧼ߩᴦ≮ ☨࿖ߢߩᦨㄭߩ⹤㗴߆ࠄ‫ޠ‬ᐳ㐳)54㧕 ╙ 9 ࿁ጘ㒂ᄢቇᢛᒻᄖ⑼ᢎ⢒⎇ୃળ(ᐔᚑ 19 ᐕ 5 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫࠷࡯ࡐࠬ⤒ޟ‬㓚ኂᴦ≮ߩ࠻ࡇ࠶ࠢࠬ‫ޠ‬ᐳ㐳)55㧕 Inspiration Asia(2007.06㧘Bali㧘Long term complications after cervical fusion; chairperson)
56㧕 Fighting Vascular Events in Gifu 2007(ᐔᚑ 19 ᐕ 6 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝⸻ᢿߩⷞὐ߆ࠄߺߚ㧘ABI ߩᝒ߃ᣇ‫ޠ‬ᐳ㐳)57㧕 Fighting Vascular Events in Gifu 2007(ᐔᚑ 19 ᐕ 6 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬PAD ߦኻߔࠆᄖ⑼ᴦ≮ᚢ⇛㧙ઁ⑼ߣߩㅪ៤ߦࠃࠆ integrated therapy㧙‫ޠ‬ᐳ㐳)58㧕 ╙ 63 ࿁⷏ᣣᧄ⣄ᬁ⎇ⓥળ(ᐔᚑ 19 ᐕ 6 ᦬㧘⑔ጟ㧘․೎⻠Ṷ‫ޟ‬⣶ᬁᄌᕈ஥ᒭ∝ߩᚻⴚ‫ޠ‬Ṷ⠪)59㧕 ጘ㒂 biological ⎇ⓥળ(ᐔᚑ 19 ᐕ 6 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ᣂߒ޿ RA ᴦ≮ߩน⢻ᕈ㧙↢‛ቇ⊛⵾೷ߣエ㛽⎕უ㧙‫ޠ‬ᐳ㐳)60㧕 ࡌࡀ࠶࠻ Weeklyjy ㍤ᣂ⊒ᄁ⸥ᔨ⻠Ṷળ(ᐔᚑ 19 ᐕ 6 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬㛽☻㝃∝ߩ⮎‛≮ᴺ㧦2006
ᐕ ࠟࠗ࠼࡜ࠗࡦࠍ〯߹߃ߡ‫ޠ‬ᐳ㐳)61㧕 ╙ 7 ࿁ ATST ࡒ࡯࠹ࠖࡦࠣ(ᐔᚑ 19 ᐕ 6 ᦬㧘᧲੩㧘․೎⻠Ṷ‫ޟ‬⣶ᬁᄌᕈ∔ᖚ߳ߩࡠ࡯ࡊࡠࡈࠔࠗ࡞
ࠪࠬ࠹ࡓߦߟ޿ߡ‫ޠ‬ᐳ㐳)62㧕 The 17th Korean-Japanese Combined Orthpaedic Symposium(2007.07, Soul, Free paper
12:Spine 1; chairperson)
63㧕 ᄢಽ⣶ㇱ⣄ᩇ▤⁜⓰∝ࡈࠜ࡯࡜ࡓ 2007(ᐔᚑ 19 ᐕ 7 ᦬㧘ᄢಽ㧘․೎⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩᴦ≮‫ޠ‬Ṷ⠪)64㧕 ጘ㒂㛽☻㝃∝ᴦ≮⎇ⓥળ․೎⻠Ṷળ(ᐔᚑ 19 ᐕ 7 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ਛਅ૏㗖ᬁߩ೨ᣇᚻⴚ‫ޠ‬Ṷ⠪)65㧕 ࡔ࠼࠻ࡠ࠾࠶ࠢࠬࡄࠗࡦ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 8 ᦬㧘␹ᚭ㧘․೎⻠Ṷ‫ޟ‬MINI-OPEN TLIF‫ޠ‬ᐳ㐳)66㧕 ࡔ࠼࠻ࡠ࠾࠶ࠢࠬࡄࠗࡦ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 8 ᦬㧘␹ᚭ㧘․೎⻠Ṷ‫ޟ‬TLIF ߦࠃࠆ⣶ᬁᄌᕈ஥ᒗߩᴦ
≮‫⻠ޠ‬Ṷ)67㧕 SICOT ࿖㓙ᢛᒻᄖ⑼ቇળ(2007.08-09, Morocco, SURGICAL TREATMENT FOR SPONDYLOLYSISIN YOUNG ATHLETES; Lecturer)
68㧕 SICOT ࿖㓙ᢛᒻᄖ⑼ቇળ(2007.08-09, Morocco, Session 05: Spine degenerative; chairperson)
69㧕 ╙ 14 ࿁ᣣᧄ⣄ᬁ࡮⣄㜑␹⚻ᚻⴚᚻᛛቇળ(ᐔᚑ 19 ᐕ 9 ᦬㧘ฬฎደ㧘․೎⻠Ṷ‫ޟ‬㜞㦂⠪㗖㜑∝ߩ∛ᘒ߅ࠃ߮೨ᣇ㒰࿶࿕ቯⴚߩᚑ❣-dynamic plate ߩ᦭↪ᕈߦߟ޿ߡ-‫ޠ‬ᐳ㐳)70㧕 ╙ 14 ࿁ᣣᧄ⣄ᬁ࡮⣄㜑␹⚻ᚻⴚᚻᛛቇળ(ᐔᚑ 19 ᐕ 9 ᦬㧘ฬฎደ㧘․೎⻠Ṷ‫ޟ‬ABC 㗖ᬁ࠳ࠗ࠽ࡒ
࠶ࠢࡊ࡟࡯࠻ߩᚻⴚᚻᛛߩ⚫੺ߣᵈᗧὐ(ࡂࡦ࠭ࠝࡦ࠮࠶࡚ࠪࡦ B)‫ޠ‬ᐳ㐳)71㧕 ࠝࠬ࠹ࠝࡐࡠ࡯ࠪࠬ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 9 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬㛽☻㝃∝ߦ઻߁㛽᛬ߩ੍㒐‫ޠ‬ᐳ㐳)72㧕 ╙ 109 ࿁ᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 10 ᦬㧘ᄹ⦟㧘․೎⻠Ṷ‫ޟ‬ᄢ੽࠮ࡒ࠽࡯9 ⣶∩ᴦ≮ Up to Date㧙⣶ㇱ⣄ᩇ▤⁜⓰∝ࠍਛᔃߦ㧙‫ޠ‬ᐳ㐳)73㧕 ၯ₹⣶∩ࡈࠜ࡯࡜ࡓ 2007(ᐔᚑ 19 ᐕ 10 ᦬㧘ᎹญᏒ㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)74㧕 6th Combined Meeting of Orthopaedic Reseach Societies(2007.10, Hawaii, Session 22:
Intervertebral Disc; chairperson)75㧕 ╙ 36 ࿁᧲ᶏ࿾඙ᢛᒻᄖ⑼ᢎ⢒⎇ୃળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ฬฎደ㧘․೎⻠Ṷ‫ޟ‬⣶ᬁᬁ㑆᧼㓚ኂߩၮ␆ߣ⥃ᐥ‫ޠ‬ᐳ㐳)㧙㧙

76㧕 㛽☻㝃∝ࡈࠜ࡯࡜ࡓ(ᐔᚑ 19 ᐕ 11 ᦬㧘⑔੗㧘․೎⻠Ṷ‫ޟ‬㛽☻㝃∝ᕈᬁ૕㛽᛬ߩᚻⴚ‫ޠ‬ᐳ㐳)77㧕 ዊ’ᏒකᏧળ↢ᶦᢎ⢒⎇ୃળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ዊ’㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)78㧕 ᐔᚑ 19 ᐕᐲ╙ 4 ࿁᧲੩ㇺ⥃ᐥᢛᒻᄖ⑼කળ⛔ว⎇ୃળ(ᐔᚑ 19 ᐕ 11 ᦬㧘᧲੩㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)79㧕 ASEAN OA27 VOA06 SSHV12(2007.12, Vietnam, Two staged(posterior and anterior) surgicaltreatment for pyogenic abd tuberculotic spondylitis; Lecturer)
80㧕 ␹ᄹᎹ LCS ࡈࠜ࡯࡜ࡓ 2008(ᐔᚑ 20 ᐕ 4 ᦬㧘ᮮᵿᏒ㧘⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ⁜⓰∝ߩᴦ≮‫ޠ‬Ṷ⠪)81㧕 ╙ 110 ࿁ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 4 ᦬㧘ᄢᵤᏒ㧘⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩ∛ᘒߣᴦ≮‫ޠ‬ᐳ㐳)82㧕 ⼾↰ട⨃ᢛᒻᄖ⑼ቇⴚ⻠Ṷળ(ᐔᚑ 20 ᐕ 4 ᦬㧘⼾↰Ꮢ㧘⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)83㧕 ዊᵿᏒකᏧળቇⴚ⻠Ṷળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ዊᵿᏒ㧘․೎⻠Ṷ‫ޟ‬㛽☻㝃∝ᕈᬁ૕㛽᛬ߩᚻⴚ‫ޠ‬Ṷ⠪)84㧕 ╙ 14 ࿁ጊญ⋵⣶∩⎇ⓥળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ጊญᏒ㧘․೎⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩᚻⴚ⊛ᴦ≮‫ޠ‬Ṷ
⠪)85㧕 ╙ 10 ࿁ጘ㒂ᄢቇᢛᒻᄖ⑼ᢎ⢒⎇ୃળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ጘ㒂Ꮢ㧘․೎⻠Ṷ‫ޟ‬਄⢇ߩ⛉ᛗᕈᧃ᪳␹⚻㓚ኂߦߟ޿ߡ‫ޠ‬ᐳ㐳)86㧕 APOA,the Spine and Pediatric Sections 2008(2008.06, Jeju Island, Symposium 2㧦Cervicalspondylotic myelopethy; chairperson)
87㧕 APOA,the Spine and Pediatric Sections 2008(2008.06, Jeju Island, Surgical treatment forspondylolysis in young Athletes. Lecture)88㧕 ጘ㒂㛽☻㝃∝࡝ࡃ࡯ࠨࠗ࠼ࠞࡦࡈࠔ࡟ࡦࠬ(ᐔᚑ 20 ᐕ 6 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬㜞㦂⠪ߩ㛽᛬੍㒐ߣォୟ੍‫ޠ‬ᐳ㐳)89㧕 ጘ㒂⋵ VTE ੍㒐࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘‫ޟ‬ᒰ㒮ߦ߅ߌࠆࡈࠜࡦ࠳ࡄ࡝࠿ࠢࠬߩ૶↪⚻㛎‫ޠ‬‫ޟ‬ਅ⢇ᢛᒻᄖ⑼๟ⴚᦼ੍㒐ߩᦨᣂࠬ࠻࡜࠹ࠫ࡯‫ޠ‬ᐳ㐳)90㧕 ᄖ⑼කㇱળ࡮ഭἴᜰቯකㇱળวห⻠Ṷળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬⣄ᬁߩࠬࡐ࡯࠷㓚ኂ‫ޠ‬Ṷ⠪)91㧕 ╙ 41 ࿁ᣣᧄᢛᒻᄖ⑼ቇળ㛽࡮エㇱ⣲≌ቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ᵿ᧻㧘ᢎ⢒⎇ୃ⻠Ṷ
‫ޟ‬Current statusof spinal tumors in the USA‫ޠ‬ᐳ㐳)92㧕 ᢛᒻᄖ⑼ቇⴚ⻠Ṷળ(ᐔᚑ 20 ᐕ 7 ᦬㧘㇊ⷓᏒ㧘⻠Ṷ‫ޟ‬⣄ᬁᗵᨴ∝ߩ⸻ᢿߣᴦ≮‫ޠ‬Ṷ⠪)93㧕 The 18th Japanese-Korean Combined Orthopaedic Symposium(2008.07-08, Nagasaki,
Symposium 1:spondyloarthropathy following hemodialysis. chairperson)
94㧕 ╙ 7 ࿁የᒛ↢ᵴ⠌ᘠ∛⎇ⓥળ(ᐔᚑ 20 ᐕ 8 ᦬㧘ฬฎደᏒ㧘⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)95㧕 ጘ㒂⋵࿖᳃ஜᐽ଻㒾ㆇ༡ද⼏ળળ㐳ㅪ⛊ද⼏ળ(ᐔᚑ 20 ᐕ 8 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬⣶∩㧙ㆇേེߩ↢ᵴ⠌ᘠ∛‫ޠ‬Ṷ⠪)96㧕 ᄢ↰⣶ㇱ⣄ᩇ▤⁜⓰∝࠮ࡒ࠽࡯2008(2008.08, ᄢ↰Ꮢ(Korea), Hospital-clinic partership in low
back pain practice. Lecture)97㧕 SICOT/SIROT2008 XX Φ
Triennial World Congress(2008.08, Hong Kong, Free
Papers-Spine:Cervical Spine Τ. chairperson)
98㧕 ∩ߺߩᴦ≮ࡈࠜ࡜ࡓ in ጘ㒂(ᐔᚑ 20 ᐕ 9 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬⣶∩ߩ∛ᘒߣᴦ≮㧙ᣂߒ޿᭎ᔨߣᚢ⇛㧙‫ޠ‬Ṷ⠪)99㧕 ߉߰㊄⪇ጊᢛᒻᄖ⑼࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 9 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬ᢛᒻᄖ⑼කߩ⍮ߞߡ߅ߊߴ߈ක≮⸷⸩ߣ࡝ࠬࠢࡑࡀࠫࡔࡦ࠻ߩ⍮⼂㧙ᢛᒻᄖ⑼කߣᖚ⠪ߩ቟ోߣ቟ᔃߩߚ߼ߦ㧙‫ޠ‬ᐳ㐳)100㧕 ╙ 6 ࿁ᢛᒻᄖ⑼㐳⦟࡝ࡃ࡯ࠨࠗ࠼ࡈࠜ࡯࡜ࡓ(ᐔᚑ 20 ᐕ 9 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬⢋↲Ꮺ⣲≌ߩౣᑪߣᯏ
⢻‫ޠ‬ᐳ㐳)101㧕 ╙ 15 ࿁ᣣᧄ⣄ᬁ࡮⣄㜑␹⚻ᚻⴚᚻᛛቇળቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 9 ᦬㧘ᄢᵤᏒ㧘․೎⻠Ṷ‫ޟ‬Percutaneousvertebroplasty‫ޠ‬ᐳ㐳)102㧕 ࡕ࡯࡜ࠬࡄ࠶ࡊ⊒ᄁ 20 ๟ᐕ⸥ᔨ⻠Ṷળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ጘ㒂Ꮢ㧘ᵤᎹ㓷ᒾ⻠Ṷ‫ޟ‬ᓎ⠪↢ᵴࠍᡰ߃ࠆᔃߣ૕ߩஜᐽ‫ޠ‬ᐳ㐳)103㧕 ST360° Surgical Technique Seminar(ᐔᚑ 20 ᐕ 10 ᦬㧘ฬฎደᏒ㧘⽸Ꮉᢛᒻᄖ⑼∛㒮㒮㐳ᳰ਄ੳᔒ⻠Ṷ ᐳ㐳)
104㧕 ╙ 42 ࿁ᣣᧄ஥ᒭ∝ቇળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ᄹ⦟㧘⻠Ṷ‫ޟ‬஥ᒗ∝ᴦ≮ߩࠦ࠷ ᚻⴚ(೨ᣇᴺ)‫ޠ‬Ṷ⠪)105㧕 ╙ 23 ࿁ᣣᧄᢛᒻᄖ⑼ቇળၮ␆ቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 10 ᦬㧘੩ㇺ㧘⻠Ṷ‫ޟ‬㗖ᬁ೨ᣇᚻⴚߦᓎ┙ߟᯏ⢻⸃೬‫ޠ‬Ṷ⠪)106㧕 8th Inspiration Meeting(2008.10, Rome, Round-table discussionn of clinical cases : Anteriorstabilization of degenerative cervical spinal lesions. chairperson )㧙㧙107㧕 ╙ 43 ࿁᧲ᶏធ㛽ቇળ࡮╙ 90 ࿁ਛㇱធ㛽ቇળ(ᐔᚑ 20 ᐕ 11 ᦬㧘⠀ፉᏒ㧘․೎⻠Ṷ‫ޟ‬㗖ᬁ∝㧘OPLLߩᚻⴚᴦ≮‫ޠ‬Ṷ⠪)108㧕 ⣶ㇱ⣄ᩇ▤⁜⓰∝ߣⴊ▤∔ᖚቇⴚ⻠Ṷળ(ᐔᚑ 20 ᐕ 11 ᦬㧘ጘ㒂Ꮢ㧘⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩ∛ᘒߣᴦ≮‫ޠ‬ᐳ㐳)109㧕 ฬᏒᄢᢛᒻᄖ⑼࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 12 ᦬㧘ฬฎደᏒ㧘․೎⻠Ṷ‫࠷࡯ࡐࠬޟ‬ㆬᚻߩ⣶ᬁಽ㔌∝‫ޠ‬Ṷ⠪)110㧕 ଻㒾⸻≮ߦ㑐ߔࠆ⻠⠌ળ(ᐔᚑ 20 ᐕ 12 ᦬㧘ጘ㒂㧘⻠Ṷ‫଻ޟ‬㒾කߣ⸻≮ႎ㈽ߩክᩏ‫ޠ‬ᐳ㐳)ᄢ㊁⾆ᢅ㧦
1㧕 ╙ 8 ࿁ጘ㒂ᄢቇᢛᒻᄖ⑼ᢎ⢒⎇ୃળ(ᐔᚑ 18 ᐕ 5 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ᦨޟ‬ㄭⴕߞߡ޿ࠆ⣲≌ౣᑪⴚ‫ޠ‬ᐳ㐳)2㧕 ጘ㒂⋵⥃ᐥᢛᒻᄖ⑼කળ(ᐔᚑ 18 ᐕ 7 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬㛽エㇱ⣲≌ߩ⸻≮‫ޠ‬Ṷ⠪)3㧕 ጘ㒂⥃ᐥ⣲≌⎇ⓥળ(ᐔᚑ 18 ᐕ 11 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬㛽エㇱ⣲≌ߦߟ޿ߡ‫ޠ‬Ṷ⠪)
4㧕 ╙ 3 ࿁ጘ㒂ㆇേེࡊ࡜ࠗࡑ࡝࡯ࠤࠕ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 2 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ᣣᏱㆣㆄߔࠆ㛽⣲≌㧙⸻≮ߩⷐὐߣ⋤ὐ㧙‫ޠ‬ᐳ㐳)
5㧕 ╙ 6 ࿁ᢛᒻᄖ⑼㐳⦟࡝ࡃ࡯ࠨࠗ࠼ࡈࠜ࡯࡜ࡓ(ᐔᚑ 20 ᐕ 9 ᦬㧘ጘ㒂㧘᜗ᓙ⻠Ṷ‫ޟ‬⢋↲Ꮺ⣲≌ߩౣᑪߣᯏ⢻‫ޠ‬ᐳ㐳)
6㧕 ╙ 32 ࿁ᄢ၂Ꮢᄖ⑼ㅪวળቇⴚ⻠Ṷળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ᄢ၂㧘․೎⻠Ṷ‫ޟ‬㛽エㇱ⣲≌ߩ⸻≮‫ޠ‬Ṷ⠪)7㧕 ╙ 23 ࿁ᣣᧄᢛᒻᄖ⑼ቇળၮ␆ቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 10 ᦬㧘੩ㇺ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬㛽エㇱ⣲≌ߩᴦ≮㧦
Future perspecrives‫ ࠻ࠬࠫࡐࡦࠪޠ‬ಽሶᮡ⊛ߣߒߡߩ EWS Ⲣวㆮવሶ)8㧕 ╙ 2 ࿁઻ଛേ‛ߩ⥃ᐥකቇ⎇ⓥળ(ᐔᚑ 20 ᐕ 12 ᦬㧘ጟፒ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬㛽エ㛽⣲≌ߩ⥃ᐥ⹜㛎ߣකቇ₞කቇㅪ៤‫ޠ‬Ṷ⠪)9㧕 ╙ 2 ࿁઻ଛേ‛ߩ⥃ᐥකቇ⎇ⓥળ(ᐔᚑ 20 ᐕ 12 ᦬㧘ጟፒ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬㛽エ㛽⣲≌ߩ⺖㗴‫ޠ‬ᐳ㐳)10㧕 ጘ㒂ᄖ⑼ᙣ⺣ળ(ᐔᚑ 20 ᐕ 12 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬エㇱ⣲≌ߩⷐὐ࡮⋤ὐ‫ޠ‬Ṷ⠪)⚦ᳯ⧷ᄦ㧦
1㧕 ᐔᚑ 17 ᐕᐲዊఽᢛᒻᄖ⑼࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 3 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ዊఽ⣄ᬁ∔ᖚ㧦ቇᩞ଻ஜ߿ᴦ
≮਄ߩ⻉໧㗴ߣߘߩኻ╷‫ޠ‬ᐳ㐳)2㧕 ╙ 5 ࿁᧲Ớ࡮ട⨃⣄ᬁᄖ⑼࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 2 ᦬㧘ᄙᴦ⷗㧘⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩᴦ≮ᚢ⇛‫ޠ‬Ṷ⠪)3㧕 ╙ 4 ࿁ጘ㒂ㆇേེࡊ࡜ࠗࡑ࡝࡯ࠤࠕ࡮࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 3 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬⣶∩⸻ᢿߩ⪭ߣߒⓣ‫ޠ‬Ṷ⠪)4㧕 ╙ 80 ࿁ਅํᏒකᏧળቇⴚ⻠Ṷળ(ᐔᚑ 19 ᐕ 5 ᦬㧘ਅํ㧘⻠Ṷ‫ޟ‬⣶∩⸻≮ߩ⪭ߣߒⓣ‫ޠ‬Ṷ⠪
5㧕 ╙ 19 ࿁ጤᚻ⣄ᬁ⣄㜑ᄖ⑼ᙣ⹤ળ㧘╙ 407 ࿁ጤᚻᢛᒻἴኂᄖ⑼ᙣ⹤ળ(ᐔᚑ 19 ᐕ 10 ᦬ 20 ᣣ㧘⋓ጟ㧘⻠Ṷ‫ޟ‬㛽☻㝃∝ᕈ⣄ᬁ㛽᛬ߦኻߔࠆ⣄ᬁ⍴❗ⴚ‫ޠ‬Ṷ⠪)
6㧕 ╙ 6 ࿁ጘ㒂࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦ⎇ⓥળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޡ‬㓚ኂస᦯ߩߚ߼ߩ࠾ࡘ࡯
ࡠࡃࠗࠝ࠾ࠢࠬ‫ޢ‬ᐳ㐳)7㧕 ᐔᚑ 19 ᐕᐲጘ㒂⣄ᬁ․೎⻠Ṷળ(ᐔᚑ 20 ᐕ 1 ᦬㧘ጘ㒂Ꮢ㧘⻠Ṷ‫ޟ‬⣄ᬁᄖ⑼㧙⑳ߩᎿᄦߣⴚਛ MRIᚻⴚ㧙‫ޠ‬ᐳ㐳)8㧕 ᢛᒻᄖ⑼࡝ࡃ࡯ࠨࠗ࠼ࡈࠜ࡯࡜ࡓ(ᐔᚑ 20 ᐕ 1 ᦬㧘ጘ㒂㧘⻠Ṷ‫⚻ޟ‬ᬁ㑆ሹ⣶ᬁᬁ૕㑆࿕ቯⴚ TLIFߩታ㓙‫ޠ‬ᐳ㐳)9㧕 KAPSS ᔕ↪⣄ᩇౣᑪ࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 4 ᦬㧘᧲੩㧘⻠Ṷ‫ޟ‬⣄ᩇ஥ᒭ∝⍶ᱜ࿕ቯ߳ߩᔕ↪‫ޠ‬Ṷ⠪)10㧕 ࡂࠗࡍࡦ⻠Ṷળ(ᐔᚑ 20 ᐕ 9 ᦬㧘⻠Ṷ‫ޟ‬ᢛᒻᄖ⑼ߢᛒ߁⣄㜑∔ᖚߩ⸻ᢿߣᴦ≮‫ޠ‬ᐳ㐳)11㧕 ╙ 15 ࿁⣄ᬁ࡮⣄㜑␹⚻ᚻⴚᚻᛛ⎇ⓥળ(ᐔᚑ 20 ᐕ 9 ᦬㧘ᄢᵤᏒ㧘Spine Leader's lecture‫ޟ‬ᣂߒ޿᭎ᔨߩ㗖ᬁ೨ᣇ Dynamic Plate ߣߘߩ᦭↪ᕈ‫ޠ‬Ṷ⠪㧘⻠Ṷ‫ޟ‬ᣂߒ޿᭎ᔨߩ㗖ᬁ೨ᣇ Dynamic Plate㨪ߘߩ᦭↪ᕈߣᚻⴚᚻᛛ㨪‫ޠ‬Ṷ⠪)12㧕 ╙ 7 ࿁ጘ㒂࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦ⎇ⓥળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ጘ㒂Ꮢ㧘․೎⻠Ṷ‫ᧃޟ‬᪳␹⚻ᄖ⑼ߩ࡝ࡂࡆ
࡝࠹࡯࡚ࠪࡦ‫ޠ‬ᐳ㐳)13㧕 ⣶ㇱ⣄ᩇ▤⁜⓰∝ߣⴊ▤∔ᖚቇⴚ⻠Ṷળ(ᐔᚑ 20 ᐕ 11 ᦬㧘ጘ㒂Ꮢ㧘⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߣ PADߩว૬ߪ޽ࠆߩ߆㧫‫ޠ‬ᐳ㐳)⷏ᧄ ⵨㧦
1㧕 ⷏Ớ⥃ᐥᢛᒻᄖ⑼කળ(ᐔᚑ 18 ᐕ 11 ᦬㧘ᄢ၂㧘ᢎ⢒⎇ୃ⻠Ṷ‫ޟ‬㛽㨯エㇱ⣲≌ᴦ≮ߩࠦ࠷ߣ⪭ߣߒⓣ‫ޠ‬
Ṷ⠪)

㧙㧙

2㧕 ╙ 115 ࿁஻ᓟᢛᒻᄖ⑼කળ(ᐔᚑ 20 ᐕ 4 ᦬㧘⑔ጊ㧘⻠Ṷ‫ޟ‬㛽㨯エㇱ⣲≌㧙⸻ᢿ߆ࠄ㓚ኂ⠪ࠬࡐ࡯࠷߹
ߢ㧙‫ޠ‬Ṷ⠪)ᄢ㊁⟵ᐘ㧦
1㧕 ╙ 2 ࿁ጘ㒂ㆇേེࡊ࡜ࠗࡑ࡝࡯ࠤࠕ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 2 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ᧃޟ‬᪳␹⚻៊்ߩ⸻ᢿߣᴦ≮‫ޠ‬Ṷ⠪)દ⮮⧐Პ㧦
1㧕 ╙ 1 ࿁᧲ᶏ⢆㑐▵ᄖ⑼⎇ⓥળ(ᐔᚑ 18 ᐕ 6 ᦬㧘ᗲ⍮㧘․೎⻠Ṷ‫ޟ‬1.㛽⋚㛽᛬ߩᴦ≮࡮ᣇ㊎㧘2.⢆㑐▵∔ᖚ⸻ᢿߩࠦ࠷‫ޠ‬ᐳ㐳)2㧕 ╙ 8 ࿁ฬฎደ⢆㑐▵࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 2 ᦬㧘ฬฎደ㧘․೎⻠Ṷ‫ޟ‬⢆㑐▵∔ᖚߦኻߔࠆ THA‫ޠ‬Ṷ⠪)
3㧕 ╙ 9 ࿁ฬฎደ⢆㑐▵࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 6 ᦬㧘ฬฎደ㧘․೎⻠Ṷ‫ޟ‬ᄌᒻᕈ⢆㑐▵∝ߦኻߔࠆ㛽㗡᷷ሽᚻⴚ(✚⺰)‫ޠ‬Ṷ⠪)
4㧕 ╙ 11 ࿁ฬฎደ⢆㑐▵࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 2 ᦬㧘ฬฎደ㧘⻠Ṷ‫⬄⥓ߚ޿↪ࠍ࡯࠲࡯ࡐࠨࡊ࠶ࠞޟ‬ౣᑪⴚ‫ޠ‬Ṷ⠪)
5㧕 ╙ 12 ࿁ฬฎደ⢆㑐▵࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 6 ᦬㧘ฬฎደ㧘⻠Ṷ‫ޟ‬ᄌᒻᕈ⢆㑐▵∝ߦኻߔࠆ㛽㗡᷷ሽᚻⴚ(✚⺰)‫ޠ‬Ṷ⠪)㕍ᧁ㓉᣿㧦
1㧕 ጘ㒂⋵ធ㛽ቇળ(ᐔᚑ 18 ᐕ 9 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫∔⚻␹ޟ‬ᖚߩ࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦ‫ޠ‬Ṷ⠪)
2㧕 ╙ 3 ࿁ጘ㒂࿁ᓳᦼ࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 9 ᦬㧘ጘ㒂㧘‫ߩࡦ࡚ࠪ࡯࠹࡝ࡆࡂ࡝ޟ‬࿾ၞㅪ៤‫)࠻ࠬࠫࡐࡦࠪޠ‬3㧕 ጘ㒂⥃ᐥᢛᒻᄖ⑼(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ᄖ்ᕈ㗪ㇱ∝୥⟲ߩ࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦ‫ޠ‬Ṷ
⠪)
4㧕 㜞㦂⠪ォୟࠍ⠨߃ࠆ⻠Ṷળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬㜞㦂⠪ߩォୟ࡮㛽᛬੍㒐ߦߟ޿ߡ‫ޠ‬
ᐳ㐳)
ᄢፉᐽม㧦
1㧕 ᐔᚑ 20 ᐕᐲ↢ℂቇ⎇ⓥᚲ⎇ⓥળ‫ ╙ޟ‬2 ࿁઻ଛേ‛ߩ⥃ᐥකቇ⎇ⓥળ‫ࡑ࡯࠹ޠ‬㧦Ყセ⣲≌ቇ㧧㛽エ㛽⣲≌ࠍస᦯ߔࠆ-㛽⡺⣲ࠍਛᔃߦ-(ᐔᚑ 20 ᐕ 12 ᦬㧘ጟፒ㧘ࠪࡦࡐࠫ࠙ࡓ 4‫ޟ‬㛽エ㛽⣲≌ߩ⺖㗴‫ޠ‬Ṷ⠪)᫪ ᢕᐘ㧦
1㧕 LCS ⸥ᔨ⻠Ṷ(ᐔᚑ 19 ᐕ 1 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ᒰ⑼ߦ߅ߌࠆ LCS ߩ૶↪⚻㛎‫ޠ‬Ṷ⠪)2㧕 ጘ㒂Ꮢ᳃ஜᐽ⻠ᐳ(ᐔᚑ 19 ᐕ 1 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫⤒ޟ‬㑐▵∩ߦߟ޿ߡ(ᄌᒻᕈ⤒㑐▵∝ࠍਛᔃߦ)‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ1㧕 ⚦ᳯ⧷ᄦ㧦╙ 15 ࿁⣄ᬁ࡮⣄㜑␹⚻ᚻⴚᚻᛛ⎇ⓥળࡌࠬ࠻࡮ࡍ࡯ࡄ࡯⾨(ᐔᚑ 20 ᐕᐲ)
9㧚␠ળᵴേᷡ᳓సᤨ㧦
1㧕 ⁛┙ⴕ᡽ᴺੱᣣᧄቇⴚᝄ⥝ળ⑼ቇ⎇ⓥ⾌ᆔຬળኾ㐷ᆔຬ(ᐔᚑ 18 ᐕ 1 ᦬㨪ᐔᚑ 19 ᐕ 12 ᦬)
2㧕 ᣣᧄࠬ࠻࡜ࠗࠞ࡯ᩣᑼળ␠⥃ᐥ㐿⊒ㇱ⥃ᐥᴦ㛎ߦ㑐ߔࠆකቇኾ㐷ኅ(ᐔᚑ 18 ᐕ 4 ᦬㨪ᐔᚑ 19 ᐕ 3 ᦬)
3㧕 ㆇേེߩ 10 ᐕᣣᧄᆔຬળ࿖㓙ᆔຬળᆔຬ(ᐔᚑ 18 ᐕ 9 ᦬)
4㧕 ⥃ᐥᴦ㛎ߦ㑐ߔࠆකቇኾ㐷ኅ(㨪⃻࿷)5㧕 ᢛᒻἴኂᄖ⑼ቇ⎇ⓥഥᚑ⽷࿅ㆬ⠨ᆔຬ(㨪⃻࿷)6㧕 ᢛᒻἴኂᄖ⑼⑼ቇ⎇ⓥഥᚑ⽷࿅ડ↹㨯൐㊄ᆔຬળᆔຬ(ᐔᚑ 19 ᐕ 5 ᦬ 23 ᣣ)
7㧕 ⽷࿅ᴺੱᢛᒻἴኂ⑼ቇ⎇ⓥഥᚑ⽷࿅ℂ੐(ᐔᚑ 19 ᐕ 5 ᦬㨪⃻࿷)8㧕 ጘ㒂㔍∛ㅪ㔍∛ක≮⑔␩⋧⺣ળ⋧⺣ຬ(ᐔᚑ 20 ᐕ 10 ᦬ 5 ᣣ)
9㧕 ╙ 10 ࿁࿖㓙࠹࠾ࠬ࡮ࠬࡐ࡯࠷කቇળ⼏⚵❱ᆔຬ(ᐔᚑ 20 ᐕ 10 ᦬ 2 ᣣ㧙4 ᣣ)㧙㧙⚦ᳯ⧷ᄦ㧦
1㧕 ᣣᧄᢛᒻᄖ⑼ቇળኾ㐷කญ㗡⹜㛎(ᐔᚑ 19 ᐕ 1 ᦬ 19 ᣣ)દ⮮⧐Პ㧦1㧕 ⽷࿅ᴺੱᗲ⍮㛽エㇱ⚵❱⒖ᬀᝄ⥝⽷࿅⹏⼏ຬ(㨪⃻࿷)㕍ᧁ㓉᣿㧦1㧕 ࠫࡖࡄࡦࡄ࡜࡝ࡦࡇ࠶ࠢ᳓ᵒ ࡔ࠺ࠖࠞ࡞࠼࡯ࡇࡦࠣࠝࡈࠖࠨ࡯(ᐔᚑ 18 ᐕ 7 ᦬ 16 ᣣ㧙17 ᣣ)
2㧕 ࡈࠚࠪࡇ࠶ࠢ 2006 㓚ኂ⠪ࠬࡐ࡯࠷ࠕࠫࠕᄢળᏪห࠼ࠢ࠲࡯(ᐔᚑ 18 ᐕ 11 ᦬ 21 ᣣ㧙12 ᦬ 3 ᣣ)
3㧕 ࡗࡑࡂ⊒േᯏ㧙IPC 㓚ኂ⠪ࠕ࡞ࡍࡦࠬࠠ࡯ࡢ࡯࡞࠼ࠞ࠶ࡊ ࡔ࠺ࠖࠞ࡞࡮࠼࡯ࡇࡦࠣ࡮ࠝࡈࠖࠨ࡯(ᐔᚑ 18 ᐕ 1 ᦬ 28 ᣣ㧙2 ᦬ 1 ᣣ)
4㧕 㓚ኂ⠪ࠬࡐ࡯࠷ᜰዉຬ⻠⠌ળ⻠⟵(ᐔᚑ 19 ᐕ 3 ᦬ 10 ᣣ)
5㧕 CP ࠨ࠶ࠞ࡯ో࿖ㆬᚻᮭᄢળᄢળක(ᐔᚑ 19 ᐕ 6 ᦬ 16㧙17 ᣣ)
6㧕 㑐᧲り૕㓚ኂ⠪㒽਄┹ᛛㆬᚻᮭᄢળ࠼࡯ࡇࡦࠣකᏧ(ᐔᚑ 19 ᐕ 7 ᦬ 1 ᣣ)
7㧕 ࠫࡖࡄࡦࡄ࡜࡝ࡦࡇ࠶ࠢࠕ࡯࠴ࠚ࡝࡯࠼࡯ࡇࡦࠣකᏧ(ᐔᚑ 19 ᐕ 7 ᦬ 22 ᣣ)
8㧕 ᄢಽゞ᫹ሶࡑ࡜࠰ࡦ࠼࡯ࡇࡦࠣකᏧ(ᐔᚑ 19 ᐕ 10 ᦬ 28 ᣣ)
9㧕 US ࠝ࡯ࡊࡦ㓚ኂ⠪᳓ᵒ࿖㓙ᄢળᏪหක(ᐔᚑ 19 ᐕ 12 ᦬ 3 ᣣ㧙10 ᣣ)
10㧕 ᣣᧄࠕࡦ࠴࠼࡯ࡇࡦࠣදળ DCO(㨪⃻࿷)ᄢ㊁⟵ᐘ㧦1㧕 ᧲ᶏࡑࠗࠢࡠࠨ࡯ࠫࡖ࡝࡯⎇ⓥળ਎⹤ੱ(㨪⃻࿷)2㧕 ጘ㒂ᚻߩᄖ⑼∝଀ᬌ⸛ળᐙ੐(㨪⃻࿷)⷏ᧄ⵨㧦1㧕 ጘ㒂⋵␠ળ଻㒾⸻≮ႎ㈽⺧᳞ᦠክᩏᆔຬળክᩏᆔຬ(㨪⃻࿷)2㧕 ጘ㒂⋵૕⢒දળක⑼ቇᆔຬ(ᐔᚑ 19 ᐕᐲ㨪ᐔᚑ 20 ᐕᐲ)
3㧕 ጘ㒂⋵૕⢒දળක⑼ቇᆔຬ(ᐔᚑ 19 ᐕ 4 ᦬㨪⃻࿷)4㧕 ጘ㒂ഭ௛ዪഭἴ଻㒾⸻≮ද⼏ળᆔຬ(ᐔᚑ 20 ᐕᐲ㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ᷡ᳓సᤨ㧚㗖ᬁᓟ❑㕤Ꮺ㛽ൻ∝ߦ㑐ߔࠆᩮᴦ⊛ᴦ≮ߦ㑐ߔࠆ⎇ⓥ ╙ 2 ႎ ᣂߒ޿ゲᬁㇱᓟᣇ㒰࿶
ᴺ㧦ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ ⣄ᩇ㕤Ꮺ㛽ൻ∝ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ ᐔ
ᚑ 18 ᐕᐲ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ㧦129(2007 ᐕ 3 ᦬)
2㧕 ᷡ᳓సᤨ㧚㗖ᬁ੝ో៰೨ᣇ࿕ቯⴚᓟߩ⣦㛽ቯ⌕ߣౝ࿕ቯ᧚ᢱߩᄌൻߦ㑐ߔࠆ⎇ⓥ㧦ෘ↢ഭ௛⋭⑼ቇ
⎇ⓥ⾌⵬ഥ㊄㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ ⣄ᩇ㕤Ꮺ㛽ൻ∝ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ ᐔᚑ 19 ᐕᐲ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ㧦106㧙107(2008 ᐕ 3 ᦬)11㧚ႎ㆏1㧕 ᄢ㊁⾆ᢅ㧦‫⎇ޟ‬ⓥቶ߆ࠄ ᄢቇߪ޿߹‫ޠ‬㛽⡺⣲ߩቢᴦࠍ⋡ᜰߒߡ㧦ጘ㒂ᣂ⡞(2006 ᐕ 5 ᦬ 16 ᣣ)
2㧕 ⷏ᧄ⵨㧦‫⎇ޟ‬ⓥቶ߆ࠄ ᄢቇߪ޿߹‫ޠ‬ᄢಾߥᕆᕈᦼߩ࡝ࡂࡆ࡝㧦ጘ㒂ᣂ⡞(2006 ᐕ 6 ᦬ 20 ᣣ)
3㧕 ᷡ᳓సᤨ㧦⥄ォゞߢᔃ߽ஜᐽߦ ࠷ࠕ࡯࡮ࠝࡉ࡮ࠫࡖࡄࡦ㐿௅⸥ᔨ㧦ጘ㒂ᣂ⡞(2007 ᐕ 3 ᦬ 2 ᣣ)
4㧕 㕍ᧁ㓉᣿㧘⷏ᧄ⵨㧘Ꮉፒ᥍ਭ㧦ᚻᜰ਄⢇࡝ࡂࡆ࡝ᡰេࠪࠬ࠹ࡓ㧦ᢛᒻῥẂ(2007 ᐕ 12 ᦬)
5㧕 ᷡ᳓సᤨ㧦ࡑ࡞ࡎᢛᒻᄖ⑼࠮ࡒ࠽࡯㧦࡜ࠫࠝ NIKKEI ᧄ␠ࠬ࠲ࠫࠝ(2008 ᐕ 9 ᦬ 3 ᣣ᡼ㅍ)12㧚⥄Ꮖ⹏ଔ
⹏ଔ޿ߕࠇߩ⎇ⓥࠣ࡞࡯ࡊߣ߽㧘ᓢ‫ߦޘ‬లታߒߚ⎇ⓥᚑᨐࠍ᜼ߍߟߟ޽ࠆ߇㧘వㅴᕈࠍ㆐ᚑߔࠆߚ߼㧘ࠃࠅ৻ጀߩദജࠍⷐߔࠆ‫ޕ‬㆏ߩࠅ߇㐳ߊ㧘ߔߋߦߪᚑᨐ߇⃻ࠇߥ޿⺖㗴߽޽ࠆ߇㧘࿾㆏ߥദജࠍ⛮⛯ߒߡ߅ࠅ㧘੹ᓟߩዷ㐿߇ᦼᓙߢ߈ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ੱຬਇ⿷߇ᦨ߽ᄢ߈ߥ໧㗴ߢ޽ࠅ㧘ᣂ⥃ᐥ⎇ୃࠪࠬ࠹ࡓߦ⒖ⴕߒߡએ᧪⛯޿ߡ޿ࠆ‫੹ޕ‬ᓟߘߩᓇ㗀߇ߐࠄߦ㗼⪺ߣߥࠅ㧘ᄢቇ㒮↢ߩ⏕଻߇࿎㔍ߣߥࠆߎߣ߇੍ᗐߐࠇࠆ‫ߦࠇߘޕ‬෻ߒࠬ࠲࠶ࡈߩ⥃ᐥ㕙ߢߩ㧙㧙

duty ߇Ⴧടߒߡ߅ࠅ㧘৻ጀߩല₸ൻ߇ᦸ߹ࠇࠆ߇㧘හല⊛ߥ⸃᳿╷ߪߥ޿ߩ߇⃻⁁ߢ޽ࠆ‫ޕ‬੹ᓟߩዷᦸవߩ໧㗴ὐߪ޽ࠆ߇㧘੹ᓟ߽⾰ߩ㜞޿⎇ⓥࠍ⋡ᜰߒߡ޿߈ߚ޿‫ޕ‬ᢛᒻᄖ⑼߇ᜂ߁㗔ၞߪ㕖Ᏹߦᐢߊ㧘᣿ࠄ߆ߦߔߴ߈໧㗴ὐ߇ᢙᄙߊሽ࿷ߔࠆ‫ࠍࠄࠇߘޕ‬ਤᔨߦ♖ᩏߒߡ㧘ᖚ⠪ߩ QOL ะ਄ߦ❬߇ࠆᣂߚߥࡔ
࠶࠮࡯ࠫࠍ㧘਎⇇ߦะߌߡ⊒ାߒߚ޿ߣ⠨߃ࠆ‫ޕ‬㧙㧙㧔5㧕⊹⤏∛ᘒቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
1㧕ർፉᐽ㓶ᢎ᝼ߪෘ↢ഭ௛⋭․ቯ∔ᖚᏗዋ㔍ᴦᕈ∔ᖚߦ㑐ߔࠆ⺞ᩏ⎇ⓥ⃰ਥછ⎇ⓥ⠪ߣߒߡ㧘ᄤ∊≙㧘వᄤᕈ⴫⊹᳓∊∝㧘⤥∊ᕈੇ⊈㧘᳓∊ဳ㝼㠦⊈᭽⚃⊹∝ߩ 4 ∔ᖚߦߟ޿ߡ 2002 ᐕ߆ࠄ 2004 ᐕߩ 3 ᐕ㑆ߦᒁ߈⛯߈㧘2005 ᐕ߆ࠄ 2007 ᐕߩ 3 ᐕ㑆ߦ߅޿ߡ߽⸻ᢿၮḰ㧘⊒∝ᯏᐨ㧘ᴦ≮ᴺߩ㐿⊒ߦߟ޿ߡߩ⎇ⓥࠍⴕߥߞߚ‫ߚ߹ޕ‬᳗੗⟤⾆⥃ᐥ⻠Ꮷ߇කቇ⎇ⓥ⑼㐳ࡊ࡯࡞ഥᚻߩ㊀ὐൻഥᚻߣߒߡ 2006 ᐕ 2 ᦬߆ࠄណ↪ߐࠇᧄ⎇ⓥߩਥⷐࡔࡦࡃ࡯ߣߒߡෳടߒߚ‫ޕ‬
2㧕ᄤ∊≙ߦ㑐ߔࠆ⎇ⓥᄤ∊≙࡮㘃ᄤ∊≙ߪోりߦ߮ࠄࠎ᳓∊ࠍᒻᚑߔࠆ⥄Ꮖ఺∉᳓∊∝ߢ޽ࠆ‫⚦ޕ‬⢩㑆ធ⌕᭴ㅧ㧔࠺ࠬࡕ࠰࡯
ࡓ㧕᭴ᚑᚑಽ߿㧘⴫⊹⌀⊹Ⴚ⇇ធว᭴ㅧ㧔ࡋࡒ࠺ࠬࡕ࠰࡯ࡓ㧕ߦኻߔࠆ⥄Ꮖ᛫૕ߦࠃࠅ⊒∝ߔࠆ‫ޕ‬ᒰ⑼ߢ
ߪ⥄Ꮖ఺∉ᕈ᳓∊∝ߩ⊒∝ࡔࠞ࠾࠭ࡓߩ⸃᣿ߦขࠅ⚵ࠎߢ޿ࠆ‫ޕ‬㘃ᄤ∊≙ߦߟ޿ߡߪർፉᐽ㓶ᢎ᝼ࠍਛᔃ
ߦ␹የዏሶ㧔⎇ⓥ⵬૒ຬ 2008 ᐕ߹ߢ࿷☋㧕㧘ጤ↰ᶈ᣿ഥᢎ߇㘃ᄤ∊≙ߩ∛ᘒ⎇ⓥࠍⴕߞߡ߅ࠅ㧘㘃ᄤ∊≙᛫૕ߦࠃࠅ᛫ේߢ޽ࠆ BP180 ᛫ේ߇ಽ⸃ߔࠆߎߣࠍ↢ൻቇ⊛ߦ⸽᣿ߒߚ‫ޕ‬ᄤ∊≙⎇ⓥߢߪ㧘ർፉᐽ㓶ᢎ᝼ߣ㕍ጊ⵨⟤⻠Ꮷࠍਛᔃߦદ૒଻㚅㧔⎇ⓥ⵬૒ຬ㧕᧛ἑ㚅ᄹ㧔ᄢቇ㒮㧕߇⎇ⓥࠍⴕߞߡ޿ࠆ‫ޕ‬ਥߥ⎇ⓥ࠹࡯ࡑߪᄤ∊≙᛫૕ߦࠃࠆ p120catenin 㑐ㅪ࠺ࠬࡕࠣ࡟ࠗࡦ 3 ߩಽ⸃⺃ዉࠪࠣ࠽࡞ߩ⸃ᨆߢ޽ࠆ‫ޕ‬๟౞
ഥᢎ߇ 2007 ᐕ߆ࠄ৻ᐕ㑆ࠗ࠲࡝ࠕࡕ࠺࠽ᄢቇ⊹⤏⑼㧔Carlo Pincelli ඳ჻㧕ߦࡐࠬ࠼ࠢߣߒߡ⇐ቇߒᄤ∊≙᛫૕ߦࠃࠆࠕࡐ࠻࡯ࠪࠬ⺃ዉᯏ᭴ߩ⸃ᨆߩ౒ห⎇ⓥࠍⴕߞߚ‫ޕ‬2008 ᐕ 5 ᦬࿖㓙⎇ⓥ⊹⤏⑼ቇળࠨ࠹
࡜ࠗ࠻ࠪࡦࡐࠫ࠙ࡓ‫ޡ‬Post IID 5th Joint Meeting of SSSR and SCUR, and International Meeting on
Autoimmune Bullous Disease 2008‫ࠍޢ‬ᄢᵤߢਥ௅ߒߚ‫ᧄޕ‬ቇળߪᣣᧄ㧘☨࿖㧘࡛࡯ࡠ࠶ࡄࠍਛᔃߦ⥄Ꮖ఺∉ᕈ᳓∊∝ߩ⎇ⓥ⠪߇ෳടߒᚒ‫⎇ߩߢ߹ࠇߎ߽ޘ‬ⓥᚑᨐࠍႎ๔ߒߚ‫ޕ‬
3㧕వᄤᕈ⴫⊹᳓∊∝ർፉᐽ㓶ᢎ᝼ࠍਛᔃߦᄢ㒋ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼ㆮવሶᴦ≮ቇᢎቶ₹੗సੱಎᢎ᝼߅ࠃ߮ጘ㒂ᄢቇ⊹⤏∛ᘒቇᄢቇ㒮↢ߩ⍮㊁೰⋥ߣߩ౒หߢㆮવሶᴦ≮ߩၮ␆⎇ⓥࠍⴕߞߚ‫ߦ․ޕ‬⢝ఽᦼߦ఺∉ኡኈࠍ⺃ዉߔࠆߎߣߦᚑഞߒߚ‫ޕ‬
4㧕ࠕ࠻ࡇ࡯ᕈ⊹⤏Ἳߦ㑐ߔࠆ⎇ⓥ㜞ᧁ⡸೨ഥᢎ᝼㧘㓶ጊℰᩕ⥃ᐥ⻠Ꮷࠍਛᔃߦᴦ≮ᴺ㧘଻Ḩ⢻ߥߤߩ⥃ᐥ⊛⎇ⓥࠍⴕߥߞߚ‫ޕ‬
5㧕⊹⤏ᖡᕈ⣲≌ߦ㑐ߔࠆ⎇ⓥෘ↢ഭ௛⋭≸⎇ⓥࡔ࡜ࡁ࡯ࡑ⃰ળ⼏ߩ⎇ⓥදജ⠪㧔ർፉᐽ㓶ᢎ᝼㧕ߣߒߡෳടߒ㧘␹⼱⑲༑⻠Ꮷ㧘ጤ↰ᶈ᣿⥃ᐥ⻠Ꮷ㧘㕍ጊ⵨⟤⻠Ꮷࠍਛᔃߦᖡᕈ⣲≌ߦ㑐ߔࠆၮ␆⊛߅ࠃ߮⥃ᐥ⊛⎇ⓥࠍⴕߥߞߚ‫ޕ‬
6㧕ੇ⊈ߦ㑐ߔࠆ⎇ⓥ
㓶ጊℰᩕഥᢎࠍਛᔃߦ㧘⊹∐ㇱߩⷺጀߦ߅ߌࠆ࠺ࠬࡕࠣ࡟ࠗࡦ 1 ߩಽᏓߦߟ޿ߡ࠹࡯ࡊࠬ࠻࡝࠶ࡇࡦࠣ
ᴺࠍ↪޿ߡⷰኤߒ㧘ੇ⊈ߩ⸻ᢿ࡮ᴦ≮ߩ⹏ଔߥߤߦߟ޿ߡ᳃㑆ߩൻ♆ຠ㑐ㅪળ␠ߣ౒ห⎇ⓥࠍⴕߞߚ‫ޕ‬㧔ർፉᐽ㓶ᢎ᝼ߪᣣᧄੇ⊈ቇળߩℂ੐㧕7㧕⊹⤏⌀⩶∝ߦ㑐ߔࠆ⎇ⓥ㕍ጊ⵨⟤⻠Ꮷࠍਛᔃߦ⸻ᢿߣᴦ≮ᴺߩ㐿⊒⎇ⓥࠍⴕߥߞߚ‫ޕ‬㧔ർፉᢎ᝼ߪᣣᧄක⌀⩶ቇળߩℂ੐㧕
8㧕ᒝ⊹∝ߦ㑐ߔࠆ⎇ⓥᏒૼༀ㇢ಎᢎ᝼ࠍਛᔃߦ㧘ᒝ⊹∝ߦ߅ߌࠆᧃ᪳ᓴⅣ㓚ኂߩ∛ᘒ⸃᣿ߩ⎇ⓥࠍⴕߥߞߚ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
ಎᢎ᝼㧦
⻠Ꮷ㧦
⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦

ർፉᐽ㓶
Ꮢ᧪ༀ㇢
␹⼱⑲༑
㕍ጊ⵨⟤
᳗੗⟤⾆
㓶ጊℰᩕ
ጤ↰ᶈ᣿
๟ ౞
ᄥ๺↰⍮㉿
᧻ጊ߆ߥߎ
ᐔశ⵨ሶ
⮮ដ⌀ℂሶ
ᄢᯅఝᢥ
቞ደᥓᨑ

Yasuo Kitajima
Yoshiro Ichiki
Hideki Kamiya
Yumi Aoyama
Miki Nagai
Zuiei Oyama
Hiroaki Iwata
En ShuChisato Tawada
Kanako Matsuyama
Yuuko Hiramitsu
Mariko Fujikake
Masafumi Ohhashi
Chie Moriya㧙㧙3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ർፉᐽ㓶㧘⷏ጟ ᷡ✬㧚ࠤ࡞ࠬࠬ⑱≙ߣߩ㐓೎߇㔍ߒ޿଀࡯⚦⩶࡮⌀⩶ᗵᨴ∝࡯㧦⊹⤏⑼⸻≮ߩࠦ࠷ߣ⪭ߣߒⓣ㧘᧲੩㧦ਛጊᦠᐫ㧧2006 ᐕ㧦48㧙49.
2㧕 ർፉᐽ㓶㧚ṚᎹ㓷ᶈ࡮ᷰㄝ᤯৻✬㧚㘃ᄤ∊≙࡯᳓∊∝࡯㧦⊹⤏∔ᖚᦨᣂߩᴦ≮ 2007-2008㧘᧲੩㧦ධᳯၴ㧧
2006 ᐕ㧦115㧙117.
3㧕 Ꮢૼༀ㇢㧘⷏ጟ ᷡ✬㧚SLE ᄖ᧪⸻≮ߢߩ⪭ߣߒⓣ࡯∛ᘒᄌൻࠍ⷗ㅏߐߥ޿ߚ߼ߦ࡯㧦⊹⤏⑼⸻≮ߩࠦ࠷ߣ⪭ߣߒⓣ㧘᧲੩㧦ਛጊᦠᐫ㧧2006 ᐕ㧦29㧙31.
4㧕 ␹⼱⑲༑㧘ᷡේ␽ᄦ࡮ጊፒ⋥਽✬㧚㒶⢆ㇱ㧦Visual Dermatology࡯ᚻⴚߦᓎ┙ߟ࡝ࡦࡄᵹࠕ࠻࡜ࠬ࡯㧘᧲੩㧦⑲Ả␠㧧2006 ᐕ㧦148㧙149.
5㧕 ␹⼱⑲༑㧘 ጊ৻ᦶ࡮࿯↰ື਽࡮ᯅᧄ 㓉࡮ฎᳯჇ㓉࡮ᷰㄝ᤯৻✬㧚‛ℂൻቇ⊛㓚ኂ࡯╙ 7 ┨࡯㧦⊹⤏⑼
ቇᢎ⑼ᦠ㧘᧲੩㧦ᢥశၴ㧧2006 ᐕ㧦281㧙295.
6㧕 㕍ጊ⵨⟤㧘⷏ጟ ᷡ✬㧚ᄤ∊≙ߩ⪭ߣߒⓣ࡯㕖ౖဳ଀ࠍ⷗ㅏߐߥ޿࡯㧦⊹⤏⑼⸻≮ߩࠦ࠷ߣ⪭ߣߒⓣ㧘᧲੩㧦ਛጊᦠᐫ㧧2006 ᐕ㧦142㧙143.
7㧕 ጤ↰ᶈ᣿㧘ᷡේ␽ᄦ࡮ጊፒ⋥਽✬㧚⢛⣶⤦ㇱ㧦Visual Dermatology࡯ᚻⴚߦᓎ┙ߟ࡝ࡦࡄᵹࠕ࠻࡜ࠬ࡯᧲
੩㧦⑲Ả␠㧧2006 ᐕ 128㧙129.
8㧕 ␹⼱⑲༑ઁ 16 ฬ㧘⑼ቇ⊛ᩮ᜚ߦၮߠߊ⊹⤏ᖡᕈ⣲≌⸻≮ࠟࠗ࠼࡜ࠗࡦ ╙ 1 㧘᧲੩㧦㊄ේ಴ 㧧2007ᐕ
9㧕 㕍ጊ⵨⟤㧚⪭⪲⁁ᄤ∊≙㧦⋡ߢ⷗ࠆࠕ࡟࡞ࠡ࡯ᕈ⊹⤏∔ᖚ㧘᧲੩㧦ධᳯၴ㧧2007 ᐕ㧦267㧙275㧚
10㧕 Ꮢૼༀ㇢㧘ጊญ ᔀ✬㧚⊕⊈㧘⊹⤏♻⁁⩶∝㧦੹ᣣߩᴦ≮ᜰ㊎ 2008 ᐕ 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦898㧚
11㧕 Ꮢૼༀ㇢㧘ർፉᐽ㓶㧚Ḵญ᣽ሶઁ✬㧚⊹⤏ߩߒߊߺ㧦⊹⤏ߩ੐ౖ㧘᧲੩㧦ᦺୖᦠᐫ㧧2008 ᐕ㧦4㧙15㧚
12㧕 Ꮢૼༀ㇢㧘Ỉ᧛ᴦ᮸㧘ർፉᐽ㓶㧚ᄥ↰೑ሶઁ✬㧚૕⴫ㇱᗵᨴ∝㧦ᓸ↢‛ᬌᩏቇ㧘᧲੩㧦ㄭઍ಴ 㧧2008 ᐕ㧦
269㧙279㧚
13㧕 ጤ↰ᶈ᣿㧚₹⟎㇌ᒾ✚✬㧚Primary dermal melanoma㧦ᦨᣂ⊹⤏⑼ቇ૕♽㧘᧲੩㧦ਛጊᦠᐫ㧧2008 ᐕ㧦
205㧙210.
⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 ർፉᐽ㓶㧚᳓∊ဳవᄤᕈ㝼ῂ⊈᭽⚃⊹∝࡯᳓∊ࠍ๒ߔࠆవᄤᕈ⊹⤏∔ᖚ㧘Visual Dermatology 2008 ᐕ㧧
798㧙799㧚
2㧕 ർፉᐽ㓶㧘㕍ጊ⵨⟤㧚⴫⊹ߩ᭴ㅧߣᯏ⢻㧘Visual Dermatology 2006 ᐕ㧧2 Ꮞ㧦56㧙63㧚
3㧕 㕍ጊ⵨⟤㧘ർፉᐽ㓶㧚⌀⊹ߩ᭴ㅧߣᯏ⢻㧘Visual Dermatology 2006 ᐕ㧧2 Ꮞ㧦341㧙345㧚
4㧕 ർፉᐽ㓶㧚⊹⤏ࡃ࡝ࠕᯏ⢻ߣߘߩ೙ᓮ㧦⴫⊹᭴ㅧߩⷰὐ߆ࠄ࡯․㓸 ⊹⤏ࡃ࡝ࠕᯏ⢻ߣ⊹⤏ࠍ੺ߔࠆ DDS
ߩㅴᱠ㧙㧘Drug Delivery System 2007 ᐕ㧧22 Ꮞ㧦424㧙432㧚
5㧕 ർፉᐽ㓶㧚⥄Ꮖ఺∉ᕈ᳓∊∝ߩᴦ≮ߣታ㓙㧘ᣣᧄ⊹⤏⑼ቇળ㔀⹹ 2007 ᐕ㧧117 Ꮞ㧦2099㧙2101㧚
6㧕 ർፉᐽ㓶࡮ἏᎹ㓷ᶈ࡮દ⮮㓷┨࡮દ⮮ 㓉㧚⊹⤏⑼ኾ㐷ක೙ᐲߩ໧㗴ߣ੹ᓟߩᣇะᕈ㧘ᣣᧄ⊹⤏⑼ቇળ㔀⹹ 2007 ᐕ㧧117 Ꮞ㧦2229㧙2235㧚
7㧕 ർፉᐽ㓶࡮㕍ጊ⵨⟤㧚⥄Ꮖ఺∉ᕈ᳓∊∝㧘Ἳ∝ߣ఺∉ 2007 ᐕ㧧5 Ꮞ㧦633㧙638㧚
8㧕 ർፉᐽ㓶㧚⭄㤗∐࡮ⴊ▤ᕈᶋ⣲ߩᴦ≮ࠟࠗ࠼࡜ࠗࡦ࡯ᣣᧄ⊹⤏⑼ቇળ 2005 ᐕ ߩ⑳ߩ⸃㉼ߣ૶↪࡯㧘ዊఽ⑼⥃ᐥ 2007 ᐕ㧧Ⴧೀ 60 ภ㧦1437㧙1445㧚
9㧕 ␹⼱⑲༑㧚⊹⤏ᄖ⑼ߢ૗߇ߢ߈ࠆ߆࡯ᬀ⊹ߩߎߟ࡯㧔ᢎ⢒⻠Ṷᛞ㍳㓸㧕
㧘ᣣᧄ⊹⤏⑼ቇળ㔀⹹ 2007 ᐕ㧧
117 Ꮞ㧦2206㧙2207㧚
10㧕 㕍ጊ⵨⟤㧘ർፉᐽ㓶㧚Structure and function of hair follicle, sebaceous gland, and sweat grand㧙Ძ൮ઃዻེ♽ߩ᭴ㅧߣᯏ⢻㧘Visual Dermatology 2007 ᐕ㧧3 Ꮞ㧦51㧙55㧚
11㧕 ർፉᐽ㓶㧚✬㓸ડ↹㧘᳓∊∝ߩ⸻ᢿߣᴦ≮㧘Monthly Book Derma㧦ోᣣᧄ∛㒮಴ ળ 2008 ᐕ㧧137 ภ㧦
1㧙69㧚
12㧕 ർፉᐽ㓶㧘㕍ጊ⵨⟤㧚᳓∊∝ߩ⸻ᢿߣᴦ≮㧦⥄Ꮖ఺∉ᕈ᳓∊∝㧙዆Ᏹᕈᄤ∊≙ߣ⪭⪲⁁ᄤ∊≙ߩ⸻ᢿߣᴦ
≮㧙㧘Monthly Book Derma 2008 ᐕ㧧137 ภ㧦27㧙34.
13㧕 ർፉᐽ㓶㧚⊹⤏⑼කߦᔅⷐߥ዆Ᏹᕈੇ⊈ߩ⍮⼂㧙ੇ⊈⴫⊹∛ᘒߩ⠨߃ᣇ㧦⴫⊹ࡎࡔࠝࠬ࠲࡯ࠪࠬੇ⊈ࠪࡈ࠻㧙㧘ᣣᧄ⊹⤏⑼ቇળ㔀⹹ 2008 ᐕ㧧118㧦2527㧙2530.
14㧕 ർፉᐽ㓶㧚කቇᢎ⢒ߦ߅ߌࠆ⊹⤏⑼ቇ㧦⊹⤏⑼ቇߩකቇᢎ⢒ߣ⸻≮ߦ߅ߌࠆၮ⋚᜛ᄢߩߚ߼ߦ㧙ጘ㒂ᄢቇߢߩ⊹⤏⑼࠴ࡘ࡯࠻࡝ࠕ࡞ᢎ⢒ߣࠢ࡝࠾ࠞ࡞ࠢ࡜࡯ࠢࠪ࠶ࡊ⊹⤏⑼ᢎ⢒㧙㧘ᣣᧄ⊹⤏⑼ቇળ㔀⹹ 2008ᐕ㧧118㧦3004㧙3005.
15㧕 ർፉᐽ㓶㧚᳓∊∝ߣ᳓∊ߩߢ߈ࠆ⊹⤏∔ᖚ㧘ஜᐽᢎቶ 2008 ᐕ㧧59 Ꮞ㧦77㧙80㧚
16㧕 ␹⼱⑲༑㧚⊹⤏ᖡᕈ⣲≌ࠟࠗ࠼࡜ࠗࡦ㧦ၮᐩ⚦⢩≸ߩ⸻≮ࠟࠗ࠼࡜ࠗࡦ㧘Skin Cancer 2008 ᐕ㧧22 Ꮞ㧦
233㧙238.
17㧕 ␹⼱⑲༑㧚ၮᐩ⚦⢩≸㧘ᣣశⷺൻ∝ߦ 5-FU ᄖ↪ߪ᦭↪߆㧙ᖡᕈ⣲≌㧙㧘EBM ⊹⤏∔ᖚߩᴦ≮ 2008-2009㧧
253㧙256.
18㧕 ␹⼱⑲༑㧚੃ᚱᄖ Paget ∛ߩ⥃ᐥ⊛․㐳ߣಾ㒰▸࿐㧙⊹⤏ᖡᕈ⣲≌㧦⸻≮ࠟࠗ࠼࡜ࠗࡦߣ࠻ࡇ࠶ࠢࠬ㧙㧘කቇߩ޽ࠁߺ 2008 ᐕ㧧226 Ꮞ㧦219㧙222.

㧙㧙

19㧕 ␹⼱⑲༑㧘ᄢේ࿡┨㧚59. Tumoral calcinosis㧙♖ㆬ Clonicolor ࡌࠬ࠻ 180㧙㧘⊹⤏⑼ߩ⥃ᐥ೎ౠ 2008
ᐕ㧦116㧙117.
20㧕 ␹⼱⑲༑㧘ᄢේ࿡┨㧚119. Blepharochalasis㧙♖ㆬ Clonicolor ࡌࠬ࠻ 180㧙㧘⊹⤏⑼ߩ⥃ᐥ೎ౠ 2008ᐕ㧦232㧙233.
21㧕 ␹⼱⑲༑㧚࡝ࡦࡄ▵ㇳᷡߩ᦭ήߢ↢ሽ₸ߦᏅߥߒ㧙੃ᚱᄖࡄࠫࠚ࠶࠻∛㧙㧘Medical Tribune 2008 ᐕ㧧
41 Ꮞ㧦21.
22㧕 㕍ጊ⵨⟤㧘ർፉᐽ㓶㧚᳓∊∝ߩ⸻ᢿߣᴦ≮㧦⥄Ꮖ఺∉ᕈ᳓∊∝㧙ᅧᆼᕈ∊∐ߣᣂ↢ఽ㘃ᄤ∊≙ߩ⸻ᢿߣᴦ
≮㧙㧘Monthly Book Derma 2008 ᐕ㧧137 ภ㧦49㧙54.
23㧕 㕍ጊ⵨⟤㧘ർፉᐽ㓶㧘ⷺൻ∝⸻≮ࡑ࠾ࡘࠕ࡞㧙᳓∊ဳవᄤᕈ㝼ῂ⊈᭽⚃⦡∝㧙㧘Monthly Book Derma
2008 ᐕ㧧142 ภ㧦21㧙29.
✚⺑㧔᰷ᢥ㧕
1㧕 Kitajima Y. New perspective of autoimmune bullous diseases : Molecular cell biology of blistering
mechanisms and logical treatment. Dermatologica Sinica. 2008;26:52-64.
2㧕 Kitajima Y. Desmoglein 3 as a crucial component for investigating the regulation of desmosome
remodelling. J Stomatol Invest. 2008;1:3-5.
ේ⪺㧔๺ᢥ㧕
1㧕 Ꮢૼༀ㇢㧚∣ߺࠍ઻߁⊹⤏∔ᖚ㧘ጘ㒂⋵කᏧળකቇ㔀⹹ 2006 ᐕ㧧19 Ꮞ㧦47㧙50.
2㧕 ␹⼱⑲༑㧘ጤ↰ᶈ᣿㧘ർፉᐽ㓶㧘Ꮷ੗ᵗ৻㧚੃ᚱᄖ Paget ∛ࠣ࡞࡯ࡊࠬ࠲࠺ࠖ 2005 ᐕᐲႎ๔㧘ᣣᧄ⊹⤏
ᄖ⑼ቇળ⹹ 2006 ᐕ㧧10 Ꮞ㧦24㧙27.
3㧕 㕍ጊ⵨⟤㧘ዊ↰⌀༑ሶ㧘๟ ౞㧘᳓⼱㓁ሶ㧘ർፉᐽ㓶㧚ోりᕈᒻ⾰⚦⢩Ⴧᄙ∝ߩ 1 ଀㧘⊹⤏⑼ߩ⥃ᐥ 2006
ᐕ㧧48 Ꮞ㧦691㧙696.
4㧕 ᳗੗⟤⾆㧘㕍ጊ⵨⟤㧚ᄤ∊≙ߣ᳓∊ᕈ㘃ᄤ∊≙ߩ⸻ᢿߦ߅ߌࠆ ELISA ᴺ㧘කቇߩ޽ࠁߺ 2006 ᐕ㧧218
Ꮞ㧦937㧙940.
5㧕 ጤ↰ᶈ᣿㧘ട⮮ఝ૫㧘㓶ጊℰᩕ㧘Ꮢ᧪ༀ㇢㧘ർፉᐽ㓶㧚ᕆㅦߦㅴⴕߒߚ㜞㦂⊒∝ߩ⩶⁁ᕷ⡺∝ߩ 1 ଀㧘⊹⤏⑼ߩ⥃ᐥ 2006 ᐕ㧧48 Ꮞ㧦581㧙584.
6㧕 ᧖㊁૫ᄹ㧘㓶ጊℰᩕ㧘␹⼱⑲༑㧘Ꮢ᧪ༀ㇢㧘㜞ᧁ ⡸㧘ർፉᐽ㓶㧘ᄢ㊁ ᐽ㧚ᴦ≮⚻ㆊਛߦ⢖ࠕࠬࡍ࡞ࠡ
࡞ࠬ∝ࠍว૬ߒߚ⊹⤏╭Ἳߩ 1 ଀㧘⊹⤏⑼ߩ⥃ᐥ 2006 ᐕ㧧48 Ꮞ㧦877㧙881.
7㧕 ᧖㊁૫ᄹ㧘␹⼱⑲༑㧘ർፉᐽ㓶㧘ဈ ᣽▸㧚㜞㦂⠪ߦ⊒∝ߒߚ malignant trichilemmoma ߩ 2 ଀㧘⊹⤏⑼ߩ⥃ᐥ 2006 ᐕ㧧48 Ꮞ㧦1641㧙1645.
8㧕 ᵻᎹ⛗ℂ㧘␹⼱⑲༑㧘๟ ౞㧘ᳯፒᥓ㚅ሶ㧘Ꮢ᧪ༀ㇢㧘㜞ᧁ ⡸㧘ർፉᐽ㓶㧘⮮ᐢḩᥓሶ㧚ળ㒶ㇱ߅ࠃ߮ਔ⣠┃ߦ∛ᄌࠍ⹺߼ߚ Triple Paget ∛ߩ 1 ଀㧘⊹⤏⑼ߩ⥃ᐥ 2006 ᐕ㧧48 Ꮞ㧦437㧙440.
9㧕 ဈ ⟵⚻㧘ᷡ᳓⧷᮸㧘␹⼱⑲༑㧘Ꮢ᧪ༀ㇢㧘ർፉᐽ㓶㧚⚵❱ቇ⊛ߦᄙᢙߩ balloon cell ࠍ⹺߼ߚ Superficial
Spreading Melanoma(SSM)ߩ 1 ଀㧘⊹⤏⑼ߩ⥃ᐥ(ࡒ࠾࡟ࡐ࡯࠻) 2006 ᐕ㧧48 Ꮞ㧦598㧙599.
10㧕 ဈ ⟵⚻㧘␹⼱⑲༑㧘ർፉᐽ㓶㧚ᐢ▸࿐ߩㅒⴕᕈ⊹⤏ォ⒖ࠍ᧪ߒߚ eccrine porocarcinoma(EPC)ߩ 1 ଀㧘Skin Cancer 2006 ᐕ㧧21 Ꮞ㧦81㧙84.
11㧕 Ꮢ᧪ༀ㇢㧚⤔ේ∛ᄖ᧪㧘⊹⤏⑼ߩ⥃ᐥ 2007 ᐕ㧧49 Ꮞ㧦999㧙1000.
12㧕 ␹⼱⑲༑㧘ጤ↰ᶈ᣿㧘ർፉᐽ㓶㧘Ꮷ੗ᵗ৻㧚੃ᚱᄖ Paget ∛ࠣ࡞࡯ࡊࠬ࠲࠺ࠖ㧙2006 ᐕᐲႎ๔㧘ᣣᧄ⊹⤏
ᄖ⑼ቇળ⹹ 2007 ᐕ㧧11 Ꮞ㧦18㧙21.
13㧕 ␹⼱⑲༑㧘ᣣ⟎ടᄹ㧘ർፉᐽ㓶㧚ᖡᕈ㤥⦡⣲࡯․㓸㧦⤯ㇱߩ⊹⤏∛࡯㧘⊹⤏∛⸻≮ 2007 ᐕ㧧29 Ꮞ㧦833
㧙836.
14㧕 ᢪ↰ବ᣿㧘ᐘ㊁ ஜ㧘⌀㍿ ᳞㧘࿯↰ື਽㧘ጊᧄ᣿ผ㧘ጊፒ⋥਽㧘ᷡේ␽ᄦ㧘┻ਯౝㄖ਽㧘౎↰ዏੱ㧘␹
⼱⑲༑㧘ᷡේ㓉ብ㧘Ꮷ੗ᵗ৻㧘㣮㑆⋥ੱ㧘㜞↰ ታ㧘ቝේ ਭ㧘ฎ⾐ᒄᔒ㧚ᣣᧄ⊹⤏⑼ቇળࠟࠗ࠼࡜ࠗࡦ࡮
⊹⤏ᖡᕈ⣲≌⸻≮ࠟࠗ࠼࡜ࠗࡦ㧘ᣣᧄ⤏⑼ቇળ㔀⹹ 2007 ᐕ㧧117 Ꮞ㧦1855㧙1925.
15㧕 ጤ↰ᶈ᣿㧘ዊ᎑ਃ૫㧘ᵻᎹ⛗ℂ㧘Ꮢ᧪ༀ㇢㧘ർፉᐽ㓶㧚⚃⊹∝ࠍ߈ߚߒߚ⊹⤏╭Ἳߩ 1 ଀㧘⊹⤏⑼ߩ⥃ᐥ
2007 ᐕ㧧49 Ꮞ㧦165㧙169.
16㧕 ጤ↰ᶈ᣿㧘␹⼱⑲༑㧘Ꮢ᧪ༀ㇢㧘ർፉᐽ㓶㧚ᒰ⑼ߦ߅ߌࠆࡑࠗࡏ࡯ࡓ⣼≸ߩ߹ߣ߼㧘⊹⤏⑼ߩ⥃ᐥ 2007
ᐕ㧧49 Ꮞ㧦567㧙570.
17㧕 ᵻ੗߆ߥߎ㧘ጤ↰ᶈ᣿㧘␹⼱⑲༑㧘ർፉᐽ㓶㧚㆙㓒ォ⒖ࠍ᧪ߒߚ⎕უဳၮᐩ⚦⢩≸ߩ 1 ଀㧘Skin Cancer
2007 ᐕ㧧22 Ꮞ㧦57㧙61.
18㧕 ㋈ᧁᥓሶ㧘ጤ↰ᶈ᣿㧘㓶ጊℰᩕ㧘␹⼱⑲༑㧘Ꮢ᧪ༀ㇢㧘ർፉᐽ㓶㧚ⴊ▤⡺⣲ߩ 2 ଀ߣᒰ⑼ߦ߅ߌࠆᴦ≮ߩᄌㆫ㧘Skin Cancer 2007 ᐕ㧧22 Ꮞ㧦130㧙135.
19㧕 㘸㊁ ᓀ㧘ᵻ੗߆ߥߎ㧘ጤ↰ᶈ᣿㧘␹⼱⑲༑㧘Ꮢ᧪ༀ㇢㧘ർፉᐽ㓶㧚23 ᐕᓟߦ⢖ォ⒖ࠍ᧪ߒߚ ultra-laterecurrence ߣ⠨߃ߚᖡᕈ㤥⦡⣲ߩ 1 ଀㧘⊹⤏⑼ߩ⥃ᐥ 2007 ᐕ㧧49 Ꮞ㧦633㧙636.
20㧕 ␹⼱⑲༑㧘ጤ↰ᶈ᣿㧘ർፉᐽ㓶㧘Ꮷ੗ᵗ৻㧚੃ᚱᄖ Paget ∛ࠣ࡞࡯ࡊࠬ࠲࠺ࠖ-2007 ᐕᐲႎ๔㧘ᣣᧄ⊹⤏
ᄖ⑼ቇળ⹹ 2008 ᐕ㧧12 Ꮞ㧦140㧙143.
21㧕 㘸㊁ ᓀ㧘ᏒᎹ⵨ሶ㧘㕍ጊ⵨⟤㧘ർፉᐽ㓶㧘ᴡౝ㓉ᒄ㧘ጊ↰ବ᮸㧘᫪⣁ਭ㓉㧚B ⚦⢩࡝ࡦࡄ⣲ߦ઻ߞߚ⣲≌㓐઻ᕈᄤ∊≙ߩ 1 ଀㧘⊹⤏⑼ߩ⥃ᐥ 2008 ᐕ㧧50 Ꮞ㧦31㧙34.
22㧕 㘸㊁ ᓀ㧘ᏒᎹ⵨ሶ㧘㕍ጊ⵨⟤㧘ർፉᐽ㓶㧘ේ ᱞᔒ㧘᫪⣁ਭ㓉㧚Narrow-Band UVB ≮ᴺߦࠃࠆᴦ≮ߢ৻ᤨ⊛ߥലᨐࠍᓧࠄࠇߚᚑੱ T ⚦⢩⊕ⴊ∛/࡝ࡦࡄ⣲ߩ 1 ଀㧘⊹⤏⑼ߩ⥃ᐥ 2008 ᐕ㧧50 Ꮞ㧦133㧙136.
23㧕 ૒⮮ਃ૫㧘㕍ጊ⵨⟤㧘ർፉᐽ㓶㧚ࠨ࡝࠴࡞㉄ࠣ࡝ࠦ࡯࡞߅ࠃ߮ 1-ࡔࡦ࠻࡯࡞ߦࠃࠆὐ⁁⚡᢬ࠍ઻ߞߚធ⸅
ᕈ⊹⤏Ἳߩ 1 ଀㧘⊹⤏⑼ߩ⥃ᐥ 2008 ᐕ㧧50 Ꮞ㧦727㧙731.

㧙㧙24㧕 ᵻ੗߆ߥߎ㧘ᣣ⟎ടᄹ㧘ᨋ ⟤Ⓞ㧘☨↰๺ผ㧘㕍ጊ⵨⟤㧘ർፉᐽ㓶㧚ᓟᄤᕈ⴫⊹᳓∊∝ߩ 1 ଀㧘⊹⤏⑼ߩ
⥃ᐥ 2008 ᐕ㧧50 Ꮞ㧦1613㧙1616.
25㧕 ᳰ↰ᔒᢦ㧘㤥ᴛ⟤ᥓሶ㧘ጊᧄ᣿⟤㧘₹੗సੱ㧘☨↰⠹ㅧ㧘㕍ጊ⵨⟤㧘ർፉᐽ㓶㧔ᣣᧄ⊹⤏⑼ቇળࠟࠗ࠼࡜
ࠗࡦ૞ᚑᆔຬળ㧕㧚ᣣᧄ⊹⤏⑼ቇળ⸻≮ࠟࠗ࠼࡜ࠗࡦ㧙᳓∊ဳవᄤᕈ㝼ῂ⊈᭽⚃⦡∝㧘ᣣᧄ⊹⤏⑼ቇળ㔀⹹
2008 ᐕ㧧118 Ꮞ㧦343㧙346.
26㧕 ᵻᎹ⛗ℂ㧘⨹ᧁ㤗㉿㧘᳗੗⟤⾆㧘␹⼱⑲༑㧘ർፉᐽ㓶㧘ဈ ᣽▸㧚਄⣨ߦ↢ߓߚ⊹ਅဳࡔ࡞ࠤ࡞⚦⢩≸ߩ
1 ଀㧘⊹⤏⑼ߩ⥃ᐥ 2008 ᐕ㧧50 Ꮞ㧦405㧙408.
27㧕 ጤ↰ᶈ᣿㧘૒⮮ਃ૫㧘㕍ጊ⵨⟤㧘Ꮢ᧪ༀ㇢㧘ർፉᐽ㓶㧚BCG ធ⒳ㇱ૏ߦ⊹⤏ẩ≌ࠍ↢ߓߚ 1 ଀㧘⊹⤏⑼ߩ
⥃ᐥ 2008 ᐕ㧧50 Ꮞ㧦420㧙421.
28㧕 ጤ↰ᶈ᣿㧘㕍ጊ⵨⟤㧘␹⼱⑲༑㧘Ꮢ᧪ༀ㇢㧘ർፉᐽ㓶㧚ᒰ⑼ߦ߅ߌࠆญໃ≸㧔᦭᫚⚦⢩≸㧕ߩ߹ߣ߼㧘⊹⤏⑼ߩ⥃ᐥ 2008 ᐕ㧧50 Ꮞ㧦1139㧙1142.
ේ⪺㧔᰷ᢥ㧕
1㧕 Amagai M, Ahmed AR, Kitajima Y, Bystryn JC, Milner Y, Gniadecki R, Hertl M, Pincelli C, Kurzen H,
Fridkis-Hareli M, Aoyama Y, Frusic-Zlotkin M, Muller E, David M, Mimouni D, Vind-Kezunovic D,
Michel B, Mahoney M, Grando S. Are desmoglein autoantibodies essential for the
immunopathogenesis of pemphigus vulgaris, or just “witnesses of disease” ?. Exp Dermatol.
2006;15:815-831.
2㧕 Kamiya H, Kitajima Y, Ban M. Bowen’s disease with invasive adnexal carcinoma: the pluripotential
nature of Bowen’s disease cells. J Dermatol. 2006;33:858-864.
3㧕 Kawasaki Y, Aoyama Y, Tsunoda K, Amagai M, Kitajima Y. Pathogenic monoclonal antibody against
desmoglein3 augments desmoglein 3 and p38 MARK phosphorylation in human squamous carcinoma
cell line. Autoimmunity. 2006;39:587-590.
4㧕 Tosaki H, Kunisada T, Motohashi T, Aoki H, Yoshida H, Kitajima Y. Mice transgenic for kitV620A:
recapitulation of piebaldism but not progressive depigmentation seen in humans with this mutation. J
Invest Dermatol. 2006;126:1111-1118.
5㧕 Chernyavsky AI, Arredondo J, Kitajima Y, Sato-Nagai M, Grando SA. Desmoglein vs non-desmoglein
signailing in pemphigus acantholysis: characterization of novel signaling pathways downstream of
pemphigus vulgaris antigens. J Biol Chem. 2007;282:13804-11382.
6㧕 Kitajima Y, Aoyama Y. A perspective of pemphigus from bedside and laboratory-bench. Clin Rev Allerg
Immu. 2007;33:57-66.
7㧕 Ichiki Y, Kitajima Y. Thrombotic thrombocytopenic purpura associated with systemic lupus
erythematosus. EurJDermatol. 2007;17:548-549.
8㧕 Aoyama Y, Asai K, Hioki K, Funato M, Kondo N, Kitajima Y. Herpes gestationis in a mother andnewborn: immunoclinical perspectives based on a weekly follow-up the enzyme-linked immunosorbent
assay index of a bullous pemphigoid antigen noncollageous domain. Arch Dermatol.
2007;143:1168-1172.
9㧕 Suzuki N, Suzuki T, Inagaki K, Ito S, Kono M, Horikawa T, Fujiwara S, Ishiko A, Matsunaga K,
Aoyama Y, Tosaki-Ichikawa H, Tomita Y. Ten novel mutations of the ADARI gene in Japanese patientswith dyschromatosis symmetrica hereditaria. J Invest Dermatol. 2007;127:309-311.
10㧕 Iwata H, Aoyama Y, Esaki C, Kitajima Y. Cicatricial pemphigoid with prominent alopecia. Eur J
Dermatol. 2007;17:338-339.
11㧕 Shu E, Yamamoto Y, Aoyama Y, Kitajima Y. Intraperitoneal injection of pemphigus vulgaris-IgG into
mouse depletes epidermal keratinocytes of desmoglein 3 associated with generation of acantholysis.
Arch Dermatol Res. 2007;299:165-167.
12㧕 Yamamoto Y, Aoyama Y, Shu E, Tsunoda K, Amagai M, Kitajima Y. Anti-desmoglein3(Dsg3)
monoclonal antibodies deplete desmosomes of Dsg3 and differ in their Dsg3-depleting activities
related to pathogenicity. J Biol Chem. 2007;282:17866-17876.
13㧕 Yamamoto Y, Aoyama Y, Shu E, Tsunoda Y, Amagai M, Kitajima Y. No activation of urokinase
plasminogen activator by anti-desmoglein 3 monoclonal IgG antibodies in cultured humankeratinocytes. J Dermatol Sci. 2007;47:119-125.
14㧕 Ichiki Y, Kato Y, Kitajima Y. Assessment of burn area: most objective method. Burns. 2008;34:425-426.
15㧕 Ichiki Y, Kitajima Y. Ulcerative sarcoidosis; case report and review of Japanese literature. Acta Derm
Venereol. 2008;88:526-528.
16㧕 Ichiki Y, Kitajima Y. Successful treatment of scleroderma-related cutaneous ulcer with suction blistergrafting. Rheumatol Int. 2008;28:299-301.
17㧕 Kato Y, Ichiki Y, Kitajima Y. A case of systemic lupus erythematosus presenting as hypoglycemia due
to anti-insulin receptor antibodies Rheumatol Int. 2008;29:103-105.
18㧕 Aoyama Y, Nagasawa C, Nagai M, Kitajima Y. Severe pemphigus vulgaris: successful combination
therapy of plasmapheresis followed by intravenous high-dose immunoglobulin to prevent reboundincrease in pathogenic IgG. Eur J Dermatol. 2008;18:557-560.
19㧕 Kanno M, Aoyama Y. Yamoto Y, Kitajima Y. p120 catenin is associated with desmogleins when
desmosomes are assembled in high-Ca2+ medium but not when disassembled in low- Ca2+medium in㧙㧙

IF 2.951
IF 0.694

IF 2.887

IF 4.829

IF 5.581
IF 2.077
IF 1.294

IF 2.845

IF 4.829
IF 1.294

IF 1.596

IF 5.581

IF 2.500
IF 1.220
IF 1.927
IF 1.270
IF 1.270

IF 1.294

DJM-1 cells. J Dermatol. 2008;35:317-324.
IF 0.694
20㧕 Kanno M, Isa Y, Aoyama Y, Yamamoto Y, Nagai M, Ozawa M, Kitajima Y. p120-catenin is a novel
desmoglein 3 interacting partner: identification of p120-catenin association site of desmoglein 3. Exp
Cell Res. 2008;314:1683-1692.
IF 3.6954㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦ർፉᐽ㓶㧘⎇ⓥಽᜂ⠪㧦Ꮢ᧪ༀ㇢㧘㕍ጊ⵨⟤㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(B)㧦
⴫⊹⚦⢩㑆ធ⌕࡮⚦⢩㛽ᩰಽሶ㑆⚿ว೙ᓮߣฦ⒳᳓∊∝⊒∝ᯏᐨߩಽሶ↢‛ቇ⊛⎇ⓥ㧧ᐔᚑ 16㧙18
ᐕᐲ㧧14,500 ජ౞(10,100㧦2,300㧦2,100 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦ർፉᐽ㓶㧘⎇ⓥಽᜂ⠪㧦ᯅᧄ 㓉㧘ᄤ⼱㓷ⴕ㧘ጤ᦬໪᳁㧘⸵ ධᶈ㧘ዊችᩮ⌀ᑿ㧘ᷡ᳓ ብ㧘ᯅᧄ౏ੑ㧘㊄↰቟ผ㧘ᳰ↰ᔒᢦ㧘ጊᧄ᣿⟤㧘㤥ᴛ⟤ᥓሶ㧘ዊỈ ᣿㧘ፉ↰⋿〝㧘ᾖ੗ ᱜ㧘ᣂ㑐ኡᓼ㧘₹੗సੱ㧘☨↰᭴ㅧ㧘㕍ጊ⵨⟤㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄․ቯ∔ᖚኻ╷⎇ⓥ੐ᬺ㧦⒘ዋ㔍ᴦᕈ⊹⤏∔ᖚߦ㑐ߔࠆ⺞ᩏ⎇ⓥ㧧ᐔᚑ 17㧙19 ᐕᐲ㧧154,700 ජ౞(39,000㧦57,200㧦58,500
ජ౞)3㧕 ⎇ⓥઍ⴫⠪㧦ᢪ↰ବ᣿㧘⎇ⓥಽᜂ⠪㧦ർፉᐽ㓶㧧ෘ↢ഭ௛⋭߇ࠎ⎇ⓥഥᚑ㊄㧦ᖡᕈ㤥⦡⣲ߩᴦ≮㧧
ᐔᚑ 18 ᐕᐲ㧧200 ජ౞4㧕 ⎇ⓥઍ⴫⠪㧦Ꮢ᧪ༀ㇢㧘⎇ⓥಽᜂ⠪㧦㜞ᧁ ⡸㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦ㆆ⿛
ᕈⅣ⁁⚃᢬㓍઻ᕈవᄤᕈ⴫⊹᳓∊∝ࠍࡕ࠺࡞ߣߒߚࠤ࡜࠴ࡦ∛ߩಽሶ↢‛ቇ⊛⸃ᨆ㧧ᐔᚑ 17㧙18 ᐕᐲ㧧3,600 ජ౞(3,000㧦600 ජ౞)
5㧕 ⎇ⓥઍ⴫⠪㧦㕍ጊ⵨⟤㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦ᄤ∊≙ߦ߅ߌࠆ∛ේᕈࠪࠣ࠽
࡞વ㆐⚻〝ߩᬌ⸛㧧ᐔᚑ 17㧙18 ᐕᐲ㧧3,700 ජ౞(3,200㧦500 ජ౞)
6㧕 ⎇ⓥઍ⴫⠪㧦㕍ጊ⵨⟤㧧ጘ㒂ᄢቇකቇㇱ㐳ⵙ㊂⚻⾌㧧ᐔᚑ 18 ᐕᐲ㧧200 ජ౞7㧕 ⎇ⓥઍ⴫⠪㧦㕍ጊ⵨⟤㧧ጘ㒂ᄢቇ∛㒮㐳ⵙ㊂⚻⾌㧦ᖚ⠪ⴊᷡਛߩ᛫ BP180 ᛫૕ߩ᷹ቯ㧘⥄Ꮖ᛫૕ߩ᛫ේ᳿ቯ㧧ᐔᚑ 18 ᐕᐲ㧧2,100 ජ౞8㧕 ⎇ⓥઍ⴫⠪㧦ർፉᐽ㓶㧘⎇ⓥදജ⠪㧦㕍ጊ⵨⟤㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄․ቯ∔ᖚኻ╷⎇ⓥ੐
ᬺ㧦⒘ዋ㔍ᴦᕈ⊹⤏∔ᖚߦ㑐ߔࠆ⺞ᩏ⎇ⓥ㧧ᐔᚑ 18 ᐕᐲ㧧1,000 ජ౞9㧕 ⎇ⓥઍ⴫⠪㧦᳗੗⟤⾆㧧ጘ㒂ᄢቇකቇㇱ㐳ⵙ㊂⚻⾌㧧ᐔᚑ 18 ᐕᐲ㧧200 ජ౞
10㧕 ⎇ⓥઍ⴫⠪㧦ጤ↰ᶈ᣿㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦੃ᚱᄖࡄࠫࠚ࠶࠻∛ߣ⴫⊹ౝ≸ߩᶐẢ࡮ォ⒖₪ᓧᯏᐨߩ MIA ⊒⃻ߣᯏ⢻߆ࠄ⷗ߚ⸃ᨆ㧧ᐔᚑ 18㧙19 ᐕᐲ㧧3,600 ජ౞(3,100㧦500ජ౞)11㧕 ⎇ⓥઍ⴫⠪㧦ጊፒ⋥਽㧘⎇ⓥಽᜂ⠪㧦ർፉᐽ㓶㧧ෘ↢ഭ௛⋭߇ࠎ⎇ⓥഥᚑ㊄㧦ᖡᕈ㤥⦡⣲ߩᴦ≮㧧
ᐔᚑ 19 ᐕᐲ㧧200 ජ౞
12㧕 ⎇ⓥઍ⴫⠪㧦㕍ጊ⵨⟤㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦ᄤ∊≙᛫૕ߦࠃࠆ࠺ࠬࡕࠣ࡟ࠗ
ࡦ 3 ⚿วဳ p120ctn 㑐ㅪࠪࠣ࠽࡞વ㆐ᯏ᭴ߩ⸃ᨆ㧧ᐔᚑ 19㧙20 ᐕᐲ㧧3,700 ජ౞(3,200㧦500 ජ౞)
13㧕 ⎇ⓥઍ⴫⠪㧦ർፉᐽ㓶㧘⎇ⓥදജ⠪㧦㕍ጊ⵨⟤㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄․ቯ∔ᖚኻ╷⎇ⓥ੐
ᬺ㧦⒘ዋ㔍ᴦᕈ⊹⤏∔ᖚߦ㑐ߔࠆ⺞ᩏ⎇ⓥ㧧ᐔᚑ 19 ᐕᐲ㧧1,500 ජ౞
14㧕 ⎇ⓥઍ⴫⠪㧦㕍ጊ⵨⟤㧧ጘ㒂ᄢቇකቇㇱ㐳ⵙ㊂⚻⾌㧧ᐔᚑ 19 ᐕᐲ㧧500 ජ౞
15㧕 ⎇ⓥઍ⴫⠪㧦㕍ጊ⵨⟤㧧ጘ㒂ᄢቇ∛㒮㐳ⵙ㊂⚻⾌㧦ᖚ⠪ⴊᷡਛߩ᛫ BP180 ᛫૕ߩ᷹ቯ㧘⥄Ꮖ᛫૕ߩ᛫ේ᳿ቯ㧧ᐔᚑ 19 ᐕᐲ㧧2,100 ජ౞
16㧕 ⎇ⓥઍ⴫⠪㧦ጊፒ⋥਽㧘⎇ⓥಽᜂ⠪㧦ർፉᐽ㓶㧧ෘ↢ഭ௛⋭߇ࠎ⎇ⓥഥᚑ㊄㧦ᖡᕈ㤥⦡⣲ߩᴦ≮㧧
ᐔᚑ 20 ᐕᐲ㧧200 ජ౞
17㧕 ⎇ⓥઍ⴫⠪㧦ጤ᦬໪᳁㧘⃰ຬ㧦㕍ጊ⵨⟤㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄․ቯ∔ᖚኻ╷⎇ⓥ੐ᬺ㧦⒘ዋ㔍ᴦᕈ⊹⤏∔ᖚߦ㑐ߔࠆ⺞ᩏ⎇ⓥ㧧ᐔᚑ 20 ᐕᐲ㧧2,000 ජ౞
18㧕 ⎇ⓥઍ⴫⠪㧦㕍ጊ⵨⟤㧧ጘ㒂ᄢቇ∛㒮㐳ⵙ㊂⚻⾌㧦⒘ዋ㔍ᴦᕈ⊹⤏∔ᖚ㧔⥄Ꮖ఺∉ᕈ᳓∊∝࡮వᄤᕈ㝼㠦⊈᭽⚃⊹∝࡮వᄤᕈ⴫⊹ធ⌕ಽሶ⇣Ᏹ∝㧕ߩಽሶቇ⊛⸻ᢿ㧧ᐔᚑ 20 ᐕᐲ㧧2,000 ජ౞
19㧕 ⎇ⓥઍ⴫⠪㧦ጤ↰ᶈ᣿㧧ጘ㒂ᄢቇකቇㇱ㐳ⵙ㊂⚻⾌㧦᳓∊ᕈ㘃ᄤ∊≙ߩ᳓∊ᒻᚑᯏᐨ⸃᣿ߩታ㛎㧧ᐔᚑ 20 ᐕᐲ㧧500 ජ౞
2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥߥߒ㧙㧙5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬർፉᐽ㓶㧦
1㧕 ᣣᧄ⊹⤏⑼ቇળℂ੐࡮೽ℂ੐㐳(㨪ᐔᚑ 18 ᐕ 4 ᦬)
2㧕 ᣣᧄ⊹⤏⑼ቇળਛㇱᡰㇱ㐳(㨪ᐔᚑ 19 ᐕ 3 ᦬)
3㧕 ᣣᧄකቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄੇ⊈ቇળℂ੐(㨪⃻࿷)5㧕 㖧࿖⎇ⓥ⊹⤏⑼ቇળฬ⹷ળຬ(㨪⃻࿷)6㧕 ᣣᧄක⌀⩶ቇળℂ੐(㨪⃻࿷)7㧕 ᣣᧄᖡᕈ⣲≌ቇળℂ੐(㨪⃻࿷)8㧕 ᣣᧄ⎇ⓥ⊹⤏⑼ቇળ⹏⼏ຬ(㨪⃻࿷)9㧕 ᣣᧄ⚿ว❱ቇળ⹏⼏ຬ(㨪⃻࿷)10㧕 ᣣᧄ㔚㗼⊹⤏↢‛ቇળㆇ༡ᆔຬ(㨪⃻࿷)11㧕 ⷺൻ∝⎇ⓥળℂ੐㧘᳓∊∝⎇ⓥળળ㐳࡮਎⹤ੱᐙ੐(㨪⃻࿷)Ꮢૼༀ㇢㧦1㧕 ᣣᧄ⥃ᐥ⊹⤏⑼කળ᧲ᶏർ㒽ᡰㇱㆇ༡ᆔຬ(㨪⃻࿷)␹⼱⑲༑㧦
1㧕 ╙ 24 ࿁ᣣᧄ⊹⤏ᖡᕈ⣲≌ቇળ੐ോዪ㐳(㨪ᐔᚑ 20 ᐕ 7 ᦬)
2㧕 ᣣᧄ⊹⤏ᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ⊹⤏ᖡᕈ⣲≌ቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄ⊹⤏⑼ቇળ࡮⊹⤏ᖡᕈ⣲≌ᜰዉኾ㐷කᆔຬ(㨪⃻࿷)5㧕 ੃ᚱᄖ Paget ∛⎇ⓥળ਎⹤ੱ(㨪⃻࿷)㕍ጊ⵨⟤㧦1㧕 Post IID 5th Joint Meeting of SSSR & SCUR, and International Meeting on Autoimmune Bullous
Disease 2008 ੐ോዪ㐳(㨪ᐔᚑ 20 ᐕ 5 ᦬)
2㧕 ᣣᧄ⎇ⓥ⊹⤏⑼ቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ⊹⤏⑼ቇળ᧲ᶏ࿾ᣇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᳓∊∝⎇ⓥળ੐ോዪ(㨪⃻࿷)2㧕ቇળ㐿௅ർፉᐽ㓶㧦
1㧕 ╙ 235 ࿁ᣣᧄ⊹⤏⑼ቇળ᧲ᶏ࿾ᣇળ(ᐔᚑ 18 ᐕ 3 ᦬㧘ฬฎደ)2㧕 ╙ 237 ࿁ᣣᧄ⊹⤏⑼ቇળ᧲ᶏ࿾ᣇળ(ᐔᚑ 18 ᐕ 9 ᦬㧘ฬฎደ)3㧕 ╙ 51 ࿁ᣣᧄක⌀⩶ቇળ✚ળ(ᐔᚑ 19 ᐕ 11 ᦬㧘㜞ጊ)4㧕 SSSR & SCUR Joint Meeting2008 as a post IID 2008(ᐔᚑ 20 ᐕ 5 ᦬㧘ᄢᵤ)5㧕 Post IID Autoimmune Bullous Disease 2008(ᐔᚑ 20 ᐕ 5 ᦬㧘ᄢᵤ)6㧕 ╙ 24 ࿁ᣣᧄ⊹⤏ᖡᕈ⣲≌ቇળ✚ળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂)7㧕 ╙ 246 ࿁ᣣᧄ⊹⤏⑼ቇળ᧲ᶏ࿾ᣇળ(ᐔᚑ 20 ᐕ 12 ᦬㧘ฬฎደ)
3㧕ቇⴚ㔀⹹ർፉᐽ㓶㧦
1㧕 ᣣᧄ⊹⤏⑼ቇળ㔀⹹㧧✬㓸ᆔຬ(㨪ᐔᚑ 19 ᐕ 3 ᦬)
2㧕 Journal of Dermatology㧧Editor(㨪⃻࿷)␹⼱⑲༑㧦
1㧕 ᣣᧄ⊹⤏⑼ቇળ࡮⊹⤏ᖡᕈ⣲≌⸻≮ࠟࠗ࠼࡜ࠗࡦ૞ᚑᆔຬ(㨪ᐔᚑ 20 ᐕ 3 ᦬)㧙㧙㕍ጊ⵨⟤㧦
1㧕 Journal of Dermatology㧧Section Editor, Faculty of 1000 Medicine(㨪⃻࿷)7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ർፉᐽ㓶㧦
1㧕 ╙ 69 ࿁ᣣᧄ⊹⤏⑼ቇળ᧲੩ᡰㇱቇળ(ᐔᚑ 18 ᐕ 2 ᦬㧘᧲੩㧘․೎࠮࠶࡚ࠪࡦ‫⑼⤏⊹ޟ‬ᢎ⢒࡮⎇ୃߩ⃻⁁ߣ዁᧪‫ޠ‬Ṷ⠪)
2㧕 ╙ 31 ࿁ᣣᧄ⎇ⓥ⊹⤏⑼ቇળ(ᐔᚑ 18 ᐕ 5 ᦬㧘੩ㇺ㧘Concurrent Oral Session‫ޟ‬Carcinogenesis, Gene
Expression, Transaction Regulation‫ޠ‬ᐳ㐳)
3㧕 ╙ 105 ࿁ᣣᧄ⊹⤏⑼ቇળ✚ળ(ᐔᚑ 18 ᐕ 6 ᦬㧘੩ㇺ㧘ᢎ⢒⻠Ṷ 5‫ޟ‬᳓∊∝㧦ᦨㄭߩㅴᱠ‫ޠ‬ᐳ㐳)4㧕 33rd Annual Meeting of the Society for Cutaneous Ultrastructurrer Research(2006 ᐕ 6 ᦬㧘Warszawa, Porland㧘․೎⻠Ṷ‫ޟ‬Blistering mechanisms of pemphigus vulgaris: biochemical andultrastractual studies‫ޠ‬Ṷ⠪)
5㧕 ⊹⤏ၮ␆⎇ⓥᚲࠢ࡜ࠬ࠲࡯ࡈࠜ࡯࡜ࡓ(ᐔᚑ 18 ᐕ 7 ᦬㧘᧲੩㧘․೎⻠Ṷ‫⚦࠻ࠗࠨࡁ࠴࡜ࠤ⊹⴫ޟ‬⢩㑆ធ⌕ߩᯏ᭴‫ޠ‬Ṷ⠪)
6㧕 ╙ 21 ࿁ⷺൻ∝⎇ⓥળ(ᐔᚑ 18 ᐕ 8 ᦬㧘᧲੩㧘․೎⻠Ṷ‫⊹⴫ޟ‬ጀ᧼㗰☸ࠍ߼ߋࠆᦨㄭߩ⍮⷗‫ޠ‬ᐳ㐳)7㧕 ᣣᧄ⊹⤏⑼ቇળ╙ 338 ࿁⑔ጟ࿾ᣇળ(ᐔᚑ 18 ᐕ 9 ᦬㧘౎ᐈ㧘․೎⻠Ṷ‫ޟ‬ᄤ∊≙ߩ⊒∝ᯏᐨߣᴦ≮ߩታ㓙㧦ⴊẏ੤឵㧘ࠬ࠹ࡠࠗ࠼ࡄ࡞ࠬ㧘఺∉ᛥ೙೷‫ޠ‬Ṷ⠪)8㧕 ╙ 56 ࿁ᣣᧄ⊹⤏⑼ቇળਛㇱᡰㇱቇળ(ᐔᚑ 18 ᐕ 10 ᦬㧘ฬฎደ㧘ᢎ⢒⻠Ṷ‫ޟ‬㘃ᄤ∊≙ߣߘߩ㘃∝ߩ∛ᘒߣᴦ≮‫ޠ‬ᐳ㐳)9㧕 ╙ 70 ࿁ቇળᣣᧄ⊹⤏⑼ቇળ᧲੩ᡰㇱቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 2 ᦬㧘᧲੩㧘․೎⻠Ṷ‫∛ޟ‬㒮߆ࠄ⷗ߚ⊹⤏⑼ߩක≮⚻ᷣቇ㧦⃻⁁ߣኻ╷㧙ጘ㒂ᄢቇ∛㒮ࠍ଀ߦߒߡ‫ޠ‬Ṷ⠪㧕10㧕 ╙ 106 ࿁ᣣᧄ⊹⤏⑼ቇળ✚ળ(ᐔᚑ 19 ᐕ 4 ᦬㧘ᮮᵿ㧘ᢎ⢒⻠Ṷ‫⥄ޟ‬Ꮖ఺∉᳓∊∝ߩᴦ≮ߩታ㓙㧦᳓∊∝ߩၮ␆⍮⼂‫ޠ‬Ṷ⠪)11㧕 ╙ 106 ࿁ᣣᧄ⊹⤏⑼ቇળ✚ળ(ᐔᚑ 19 ᐕ 4 ᦬㧘ᮮᵿ㧘ᢎ⢒⻠Ṷ‫⑼⤏⊹ޟ‬ኾ㐷ක೙ᐲߩ໧㗴ߣ੹ᓟߩᣇะᕈ‫ޠ‬ᐳ㐳)12㧕 ╙ 58 ࿁ᣣᧄ⊹⤏⑼ቇળਛㇱᡰㇱቇⴚᄢળ(ᐔᚑ 19 ᐕ 10 ᦬㧘੩ㇺ㧘ᢎ⢒⻠Ṷ‫⸻࡯ࡇࠦࠬࡕ࡯࠳ޟ‬ᢿṶ⠌‫ޠ‬ᐳ㐳㧕13㧕 33rd Annual Meeting of the Taiwanese Dermatological ssociation(2007 ᐕ 11 ᦬㧘Taipei,Taiwan㧘
Professor Lu Yau-Chin Memorial Lectureship ฃ⾨⻠Ṷ‫ޟ‬A new perspective of autoimmune
bullous diseases: molecular cell biology of blistering mechanisms and logical treatments‫ޠ‬Ṷ⠪㧕
14㧕 ╙ 71 ࿁ᣣᧄ⊹⤏⑼ቇળ᧲੩ᡰㇱቇળ(ᐔᚑ 20 ᐕ 2 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ 5‫ޟ‬ක≮⚻ᷣߣක≮⚻ℂߩ㆑޿ߦߟ޿ߡ㧙ᖚ⠪ߩߚ߼ߩක≮⚻ᷣߣක≮⚻༡ߩ㆑޿‫ޠ‬Ṷ⠪)
15㧕 ╙ 90 ࿁ᣣᧄ⊹⤏⑼ቇળ㕒ጟ࿾ᣇળ(ᐔᚑ 20 ᐕ 2 ᦬㧘ᵿ᧻㧘․೎⻠Ṷ‫ޟ‬ᄤ∊≙ߩ᳓∊ᒻᚑᯏᐨߣᴦ≮㧦ᄤ∊≙ߪ࠺ࠬࡕ࠰࡯ࡓ࡝ࡕ࠺࡝ࡦࠣ∛ߩⷞὐ߆ࠄ‫ޠ‬Ṷ⠪)
16㧕 ╙ 60 ࿁ᣣᧄ⊹⤏⑼ቇળጊ᪸࿾ᣇળ(ᐔᚑ 20 ᐕ 4 ᦬㧘↲ᐭ㧘․೎⻠Ṷ 1.‫ޟ‬ᄤ∊≙ߣ㘃ᄤ∊≙ߪ࠺ࠬࡕ࠰࡯ࡓ࡮ࡋࡒ࠺ࠬࡕ࠰࡯ࡓ࡝ࡕ࠺࡝ࡦࠣ∛‫ޠ‬2.‫ޟ‬ක≮⚻ᷣߣක≮ㆇ༡㧦∛㒮ߣ⊹⤏⑼㧙ጘ㒂ᄢቇ∛㒮㐳⚻㛎߆ࠄቇࠎߛߎߣ‫ޠ‬Ṷ⠪)17㧕 ╙ 60 ࿁ᣣᧄ⊹⤏⑼ቇળጊ᪸࿾ᣇળ(ᐔᚑ 20 ᐕ 4 ᦬㧘↲ᐭ㧘․೎⻠Ṷ 2.‫ޟ‬ක≮⚻ᷣߣක≮ㆇ༡㧦∛㒮ߣ⊹⤏⑼㧙ጘ㒂ᄢቇ∛㒮㐳⚻㛎߆ࠄቇࠎߛߎߣ‫ޠ‬Ṷ⠪)18㧕 ╙ 107 ࿁ᣣᧄ⊹⤏⑼ቇળ✚ળ(ᐔᚑ 20 ᐕ 4 ᦬㧘੩ㇺ㧘ᢎ⢒⻠Ṷ 1-1‫∛⊹⴫⊈ੇޟ‬ᘒߩ⠨߃ᣇ㧦⴫⊹ࡎࡔࠝࠬ࠲࡯ࠪࠬੇ⊈ࠪࡈ࠻‫ޠ‬Ṷ⠪)
19㧕 ╙ 107 ࿁ᣣᧄ⊹⤏⑼ቇળ✚ળ(ᐔᚑ 20 ᐕ 4 ᦬㧘੩ㇺ㧘ᢎ⢒⻠Ṷ 40‫ޟ‬කቇᢎ⢒ߦ߅ߌࠆ⊹⤏⑼ቇ㧦⊹⤏⑼ቇߩකቇᢎ⢒ߣ⸻≮ߦ߅ߌࠆၮ␆᜛ᄢߩߚ߼ߦ‫ޠ‬ᐳ㐳)20㧕 ╙ 107 ࿁ᣣᧄ⊹⤏⑼ቇળ✚ળ(ᐔᚑ 20 ᐕ 4 ᦬㧘੩ㇺ㧘ᢎ⢒⻠Ṷ 40-2‫ޟ‬තᓟᢎ⢒㧦ጘ㒂ᄢቇߢߩ࠴ࡘ
࡯࠻࡝ࠕ࡞ߣࠢ࡝࠾ࠞ࡞ࠢ࡜࡯࡚ࠢࠪ࠶ࡊ⊹⤏⑼ᢎ⢒‫ޠ‬Ṷ⠪)
21㧕 ⊹⤏ၮ␆⎇ⓥࠢ࡜ࠬ࠲࡯ࡈࠜ࡯࡜ࡓ(ᐔᚑ 20 ᐕ 7 ᦬㧘᧲੩㧘․೎⻠Ṷ‫⚦⊹⴫ޟ‬⢩ߩⷺൻߣ⊹⤏∔ᖚ‫ޠ‬ᐳ㐳)22㧕 ╙ 23 ࿁ᣣᧄੇ⊈ቇળ(ᐔᚑ 20 ᐕ 9 ᦬㧘ᣩᎹ㧘ࠪࡦࡐࠫ࠙ࡓ‫⎇ߩ⊈ੇޟ‬ⓥߣᴦ≮ߩዷ㐿‫ޠ‬ᐳ㐳)23㧕 ╙ 18 ࿁ᣣᧄญ⣧☼⤑ቇળ(ᐔᚑ 20 ᐕ 9 ᦬㧘᧲੩㧘․೎⻠Ṷ‫࠺ࡕ࡝ࡓ࡯࠰ࡕࠬ࠺ߩ࠻ࠗࠨࡁ࠴࡜ࠤޟ‬࡝ࡦࠣ㓚ኂߦࠃࠆ਄⊹∔ᖚ㧦᳓∊∝࡮ⷺൻ⇣Ᏹ∝࡮ಽൻ⇣Ᏹ∝‫ޠ‬Ṷ⠪)24㧕 ╙ 72 ࿁ᣣᧄ⊹⤏⑼ቇળ᧲ㇱᡰㇱቇળ(ᐔᚑ 20 ᐕ 9 ᦬㧘⑺↰㧘ࠬࡐࡦࠨ࡯࠼ࠪࡦࡐࠫ࠙ࡓ 8‫ޟ‬᳓⯻㧔⿷⊕⊈)⸻ᢿ࡮ᴦ≮ᴺߩᭂᗧ㧦⌀⩶ᗵᨴ∝‫ޠ‬Ṷ⠪㧕㧙㧙

25㧕 ╙ 59 ࿁ᣣᧄ⊹⤏⑼ቇળਛㇱᡰㇱቇળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ฬฎደ㧘ᢎ⢒⻠Ṷ 8‫ޟ‬዆Ᏹᕈੇ⊈ߩ∛ᘒߣᴦ≮㧦ᣂߒ޿᭎ᔨߣᣂⷙߩᴦ≮ᴺ‫ޠ‬ᐳ㐳)26㧕 ᄤ∊≙ Forum(ᐔᚑ 20 ᐕ 10 ᦬㧘ᮮᵿ㧘․೎⻠Ṷ‫ޟ‬ᄤ∊≙ߩ∛࿃ߣᴦ≮‫ޠ‬Ṷ⠪)␹⼱⑲༑㧦
1㧕 ╙ 106 ࿁ᣣᧄ⊹⤏⑼ቇળ✚ળ(ᐔᚑ 19 ᐕ 4 ᦬㧘ᮮᵿ㧘ᢎ⢒⻠Ṷ‫ޟ‬ᬀ⊹ߩߎߟ㧦⊹⤏ᄖ⑼ߢ૗߇ߢ߈
ࠆ߆‫ޠ‬Ṷ⠪)2㧕 ╙ 23 ࿁ᣣᧄ⊹⤏ᖡᕈ⣲≌ቇળ(ᐔᚑ 19 ᐕ 5 ᦬㧘ᣂẟ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ၮᐩ⚦⢩≸ߩ⸻≮ࠟࠗ࠼࡜ࠗ
ࡦ㧦⊹⤏ᖡᕈ⣲≌ࠟࠗ࠼࡜ࠗࡦ‫ޠ‬Ṷ⠪)
3㧕 ╙ 24 ࿁ᣣᧄ⊹⤏ᖡᕈ⣲≌ቇળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓΤ‫੃ޟ‬ᚱᄖ Paget ∛ߩ∛ᦼಽ㘃ߩቯ⌕ߣㅴⴕ଀ߦኻߔࠆᴦ≮ᣇ㊎ߩᬌ⸛‫)࡯ࠩࠗ࠽ࠟ࡯ࠝޠ‬4㧕 ╙ 24 ࿁ᣣᧄ⊹⤏ᖡᕈ⣲≌ቇળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯‫ࠎ߇ޟ‬ᕈ−∩ߣߘߩኻ╷‫ޠ‬ᐳ㐳)
5㧕 ╙ 59 ࿁ᣣᧄ⊹⤏⑼ቇળਛㇱᡰㇱቇⴚᄢળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ฬฎደ㧘ࠪࡦࡐࠫ࠙ࡓΣ‫ޟ‬ᖡᕈ㤥⦡⣲㧦⥃ᐥߩᦨ೨✢‫)࡯ࠩࠗ࠽ࠟ࡯ࠝޠ‬㕍ጊ⵨⟤㧦
1㧕 ╙ 31 ࿁ᣣᧄ⎇ⓥ⊹⤏⑼ቇળ(ᐔᚑ 18 ᐕ 5 ᦬㧘੩ㇺ㧘Concurrent Oral Session‫ޟ‬Bullous Disease,
Regeneration, Extracellular Matrix‫ޠ‬ᐳ㐳)2㧕 ╙ 106 ࿁ᣣᧄ⊹⤏⑼ቇળ✚ળ(ᐔᚑ 19 ᐕ 4 ᦬㧘ᮮᵿ㧘ᢎ⢒⻠Ṷ‫ޟ‬ᄤ∊≙ߩ∛ᘒ UP-TO-DATE㧦᳓∊∝ߩᦨవ┵‫ޠ‬Ṷ⠪)
3㧕 ╙ 71 ࿁ᣣᧄ⊹⤏⑼ቇળ᧲੩ᡰㇱ✚ળ(ᐔᚑ 20 ᐕ 2 ᦬㧘᧲੩㧘ᢎ⢒⻠Ṷ‫⥄ޟ‬Ꮖ఺∉ᕈ᳓∊∝㧦⥄Ꮖ᛫૕ߩ᛫ේߩหቯߣ᛫૕ଔࠍࡕ࠾࠲࡝ࡦࠣߒߚᴦ≮ߩታ㓙଀‫ޠ‬Ṷ⠪)
4㧕 Post IID 2008 Satellite International Meeting on Autoimmune Bullous Disease(2008 ᐕ 5 ᦬㧘ᄢᵤ 㧘 ࠪ ࡦ ࡐ ࠫ ࠙ ࡓ ‫ ޟ‬p120-catenin, a possible new intracellular signal mediator in
pemphigus-acantholysis‫ޠ‬Ṷ⠪)
5㧕 ᐔᚑ 20 ᐕᐲᣣᧄ⊹⤏⑼ቇળ᧲ᶏ࿾ᣇળ(ᐔᚑ 20 ᐕ 12 ᦬㧘ฬฎደ㧘↢ᶦᢎ⢒⻠Ṷ‫ޟ‬ᄤ∊≙ߩ∛࿃ߩᦨᣂߩ⍮⷗ߣ⥄Ꮖ఺∉ᕈ᳓∊∝ߩ⸻ᢿᴺ㧦ELISA ᴺߢ㒶ᕈߩᤨߦߎ߁⠨߃ࠆ‫ޠ‬Ṷ⠪)᳗੗⟤⾆㧦
1㧕 ╙ 106 ࿁ᣣᧄ⊹⤏⑼ቇળ✚ળ(ᐔᚑ 19 ᐕ 4 ᦬㧘ᮮᵿ㧘ᢎ⢒⻠Ṷ‫ޟ‬㔚㗼߇ߥߊߡ߽⷗ࠄࠇࠆ㔚㗼౮⌀㧦
∛ℂᮡᧄࠍḰ஻ߔࠆߚ߼ߩࠦ࠷‫ޠ‬Ṷ⠪)
2㧕 ╙ 107 ࿁ᣣᧄ⊹⤏⑼ቇળ✚ળ(ᐔᚑ 20 ᐕ 4 ᦬㧘੩ㇺ㧘ᢎ⢒⻠Ṷ‫ޟ‬㔚㗼߇ߥߊߡ߽⷗ࠄࠇࠆ㔚㗼౮⌀‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ1㧕 ർፉᐽ㓶㧦╙ 21 ࿁቟↰࡮㒋ᧄ⸥ᔨ⾨(ᐔᚑ 19 ᐕᐲ)
2㧕 ർፉᐽ㓶㧦Prof. Lu Yau-Chin Memorial Lectureship(ᐔᚑ 19 ᐕᐲ)
9㧚␠ળᵴേർፉᐽ㓶㧦
1㧕 ጘ㒂⋵଻ஜක≮ផㅴද⼏ળᆔຬ෸߮ක≮⸘↹ㇱળᆔຬ(㨪ᐔᚑ 18 ᐕ 3 ᦬)
2㧕 ጘ㒂⋵ක≮ኻ╷ද⼏ળᆔຬ(㨪ᐔᚑ 18 ᐕ 3 ᦬)
3㧕 ਛㇱේሶജᙣ⺣ળᓎຬ(㨪ᐔᚑ 18 ᐕ 3 ᦬)
4㧕 ጘ㒂⋵ක≮ࠕࠢ࠮ࠬኾ㐷ᆔຬ(㨪ᐔᚑ 18 ᐕ 3 ᦬)
5㧕 ጘ㒂⋵ᖱႎࠪࠬ࠹ࡓኾ㐷ᆔຬ(㨪ᐔᚑ 18 ᐕ 3 ᦬)
6㧕 ෘ↢ഭ௛⋭㔍∛ኻ╷⎇ⓥ⃰࡮⒘ዋ㔍ᴦᕈ⊹⤏∔ᖚߦ㑐ߔࠆ⺞ᩏ⎇ⓥ⃰⃰㐳(㨪ᐔᚑ 20 ᐕ 3 ᦬)
7㧕 ෘ↢ഭ௛⋭․ቯ∔ᖚኻ╷ᙣ⺣ળᆔຬ(㨪⃻࿷)8㧕 ౏⋉ା⸤Ⓑේ⸥ᔨක࡮ᱤቇ⇐ቇ↢េഥၮ㊄ㆇ༡ᆔຬ(㨪⃻࿷)9㧕 ጘ㒂Ꮢ᳃∛㒮ᡷ▽ၮᧄ⸘↹㊀ὐ㗄⋡ᬌ⸛ᆔຬળᆔຬ(㨪⃻࿷)10㧕 JICA ╙ਃ࿖㓸࿅⎇ୃ⍴ᦼ୘೎ኾ㐷ኅᵷ㆜ຬ(㨪⃻࿷)11㧕 A Chair Professor, Kaohsiung Medical University(Taiwan)(ᐔᚑ 20 ᐕ 7 ᦬㨪⃻࿷)㧙㧙Ꮢૼༀ㇢㧦
1㧕 ጘ㒂⋵․ቯ∔ᖚ╬ኻ╷ද⼏ળᆔຬ(㨪⃻࿷)㕍ጊ⵨⟤㧦1㧕 ෘ↢ഭ௛⋭㔍∛ኻ╷⎇ⓥ⃰࡮⒘ዋ㔍ᴦᕈ⊹⤏∔ᖚߦ㑐ߔࠆ⺞ᩏ⎇ⓥ⃰⎇ⓥදജ⠪߅ࠃ߮੐ോዪ(㨪ᐔᚑ 20 ᐕ 3 ᦬)
2㧕 ෘ↢ഭ௛⋭㔍∛ኻ╷⎇ⓥ⃰࡮⒘ዋ㔍ᴦᕈ⊹⤏∔ᖚߦ㑐ߔࠆ⺞ᩏ⎇ⓥ⃰⃰ຬ(㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ർፉᐽ㓶㧦⒘ዋ㔍ᴦᕈ⊹⤏∔ᖚߦ㑐ߔࠆ⺞ᩏ⎇ⓥ⃰ ✚᜝⎇ⓥႎ๔ᦠ㧦ᐔᚑ 18 ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌
⵬ഥ㊄ ✚᜝࡮ಽᜂႎ๔ᦠ㧔ർፉ⃰㧕㧦3㧙13(2006 ᐕ 3 ᦬)
2㧕 ർፉᐽ㓶㧘ጊᧄࠁ߆ࠅ㧘㕍ጊ⵨⟤㧦ᄤ∊≙᛫૕㧘᛫࠺ࠬࡕࠣ࡟ࠗࡦ(Dsg)3 ࡕࡁࠢࡠ࡯࠽࡞᛫૕ೝỗߦࠃࠆ DJM-1 ⚦⢩ߦ߅ߌࠆ Dsg3 ಽሶߩᷫዋ₸ߣ⚦⢩㑆⚿วജߩᷫᒙ㧦ᐔᚑ 18 ᐕᐲෘ↢⑼ቇ⎇ⓥ
⾌⵬ഥ㊄ ✚᜝࡮ಽᜂႎ๔ᦠ㧔ർፉ⃰㧕㧦15㧙19(2006 ᐕ 3 ᦬)
3㧕 ർፉᐽ㓶㧦⴫⊹⚦⢩㑆ធ⌕࡮⚦⢩㛽ᩰಽሶ㑆⚿ว೙ᓮߣฦ⒳᳓∊∝ᯏᐨߩಽሶ↢‛ቇ⊛⎇ⓥ㧦ᐔᚑ
16 ᐕᐲ㧙18 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(B)⎇ⓥᚑᨐႎ๔ᦠ㧦1㧙79(2006 ᐕ 3 ᦬)
4㧕 ᢪ↰ବ᣿㧘ᐘ㊁ ஜ㧘⌀㍿ ᳞㧘࿯↰ື਽㧘ጊᧄ᣿ผ㧘ጊፒ⋥਽㧘ᷡේ␽ᄦ㧘┻ਯౝㄖ਽㧘౎↰ዏੱ㧘␹⼱⑲༑㧘ᷡේ㓉ብ㧘Ꮷ੗ᵗ৻㧘㣮㑆⋥ੱ㧘㜞↰ ታ㧘ቝේ ਭ㧘ฎ⾐ᒄᔒ㧦⊹⤏ᖡᕈ⣲≌⸻≮ࠟࠗ࠼࡜ࠗࡦߩ૞ᚑߣ Web ൻߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 17 ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ಽᜂ⎇ⓥႎ๔ᦠ㧔ᢪ↰⃰㧕㧦242㧙248(2006 ᐕ 1 ᦬)
5㧕 㕍ጊ⵨⟤㧘ർፉᐽ㓶㧘ᴡፒఝᏗ㧘ᄤ⼱㓷ⴕ㧘ⷺ↰๺ਯ㧦ᄤ∊≙᛫૕㧘᛫࠺ࠬࡕࠣ࡟ࠗࡦ 3 ࡕࡁࠢࡠ࡯࠽࡞᛫૕ߦࠃࠆ⚦⢩ౝࠪࠣ࠽࡞વ㆐⚻〝ߩ⸃ᨆ㧦ᐔᚑ 18 ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ✚᜝࡮ಽᜂႎ๔ᦠ㧔ർፉ⃰㧕
㧦67㧙71(2006 ᐕ 3 ᦬)
6㧕 ർፉᐽ㓶㧦⒘ዋ㔍ᴦᕈ⊹⤏∔ᖚߦ㑐ߔࠆ⺞ᩏ⎇ⓥ㧦ᐔᚑ 18 ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ✚᜝⎇ⓥႎ
㧦3㧙13(2007 ᐕ 3 ᦬)๔ᦠ㧔ർፉ⃰㧕7㧕 ർፉᐽ㓶㧘ጊᧄࠁ߆ࠅ㧘㕍ጊ⵨⟤㧘ᄤ⼱㓷ⴕ㧘ⷺ↰๺ਯ㧦ฦ⒳ Dsg3 ࡕࡁࠢࡠ࡯࠽࡞᛫૕ᷙวೝỗߦࠃࠆࠤ࡜࠴ࡁࠨࠗ࠻ߦ߅ߌࠆ Dsg3 ಽሶߩᷫዋ₸ߣ⚦⢩㑆ធ⌕ജᷫዋ(Dissociation assay)㧦ᐔᚑ 18ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ㧔ർፉ⃰㧕㧦15㧙23(2007 ᐕ 3 ᦬)
8㧕 ർፉᐽ㓶㧦⴫⊹⚦⢩㑆ធ⌕࡮⚦⢩㛽ᩰಽሶ㑆⚿ว೙ᓮߣฦ⒳᳓∊∝ᯏᐨߩಽሶ↢‛ቇ⊛⎇ⓥ㧦ᐔᚑ
16 ᐕᐲ㧙18 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(B)⎇ⓥᚑᨐႎ๔ᦠ㧦1㧙79(2007 ᐕ 3 ᦬)
9㧕 ᢪ↰ବ᣿㧘ᐘ㊁ ஜ㧘⌀㍿ ᳞㧘࿯↰ື਽㧘ጊᧄ᣿ผ㧘ጊፒ⋥਽㧘ᷡේ␽ᄦ㧘┻ਯౝㄖ਽㧘౎↰ዏੱ㧘␹⼱⑲༑㧘ᷡේ㓉ብ㧘Ꮷ੗ᵗ৻㧘㣮㑆⋥ੱ㧘㜞↰ ታ㧘ቝේ ਭ㧘ฎ⾐ᒄᔒ㧦⊹⤏ᖡᕈ⣲≌⸻≮ࠟࠗ࠼࡜ࠗࡦߩ૞ᚑߣ Web ൻߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 17 ᐕᐲ㧙18 ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ✚ว⎇ⓥႎ๔ᦠ㧔ᢪ↰⃰㧕㧦1141㧙1695(2007 ᐕ 3 ᦬)
10㧕 㕍ጊ⵨⟤㧘ർፉᐽ㓶㧘ᴡፒఝᏗ㧦᛫࠺ࠬࡕࠣ࡟ࠗࡦ 3 ࡕࡁࠢࡠ࡯࠽࡞᛫૕ߦࠃࠆ⚦⢩ౝࠪࠣ࠽࡞વ
㆐ᯏ᭴ߩᬌ⸛㧦ᐔᚑ 18 ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄✚᜝⎇ⓥႎ๔ᦠ㧔ർፉ⃰㧕
㧦71㧙75(2007 ᐕ 3 ᦬)
11㧕 ർፉᐽ㓶㧦⒘ዋ㔍ᴦᕈ⊹⤏∔ᖚߦ㑐ߔࠆ⺞ᩏ⎇ⓥ㧦ᐔᚑ 17 ᐕᐲ㧙19 ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ✚ว⎇ⓥႎ๔ᦠ㧔ർፉ⃰㧕㧦1㧙77(2008 ᐕ 3 ᦬)
12㧕 ർፉᐽ㓶㧦⒘ዋ㔍ᴦᕈ⊹⤏∔ᖚߦ㑐ߔࠆ⺞ᩏ⎇ⓥ㧦ᐔᚑ 19 ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ✚᜝⎇ⓥႎ๔ᦠ㧔ർፉ⃰㧕㧦3㧙12(2008 ᐕ 3 ᦬)
13㧕 ർፉᐽ㓶㧘㕍ጊ⵨⟤㧘ጊᧄࠁ߆ࠅ㧘␹የዏሶ㧦዆Ᏹᕈᄤ∊≙ߪ࠺ࠬࡕ࠰࡯ࡓ࡝ࡕ࠺࡝ࡦࠣ∛ߣ޿߁ⷞὐ߆ࠄߩ᳓∊ᒻᚑᯏᐨߩ⸃᣿㧦ᐔᚑ 19 ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ✚᜝࡮ಽᜂႎ๔ᦠ㧔ർፉ⃰㧕㧦31㧙39(2008 ᐕ 3 ᦬)
14㧕 ㊄↰቟ผ㧘₹੗సੱ㧘⍮㊁೰⋥㧘ർፉᐽ㓶㧦⴫⊹᳓∊∝ߦኻߔࠆㆮવሶᴦ≮ߩ㐿⊒㧦ᐔᚑ 19 ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ✚᜝࡮ಽᜂႎ๔ᦠ㧔ർፉ⃰㧕㧦128㧙130(2008 ᐕ 3 ᦬)
15㧕 ㊄↰቟ผ㧘₹੗సੱ㧘⍮㊁೰⋥㧘ർፉᐽ㓶㧦⴫⊹᳓∊∝ߦኻߔࠆ⚦⢩≮ᴺߩน⢻ᕈߩᬌ⸛㧦ᐔᚑ 19ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ✚᜝࡮ಽᜂႎ๔ᦠ㧔ർፉ⃰㧕
㧦131㧙132(2008 ᐕ 3 ᦬)
16㧕 ₹੗సੱ㧘㊄↰቟ผ㧘⍮㊁೰⋥㧘ർፉᐽ㓶㧦㛽㜑⚦⢩ߦࠃࠆ⴫⊹ౣ↢ᯏᐨ⸃᣿ߣ⴫⊹᳓∊∝ᴦ≮߳ߩᔕ↪㧦ᐔᚑ 19 ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ✚᜝࡮ಽᜂႎ๔ᦠ㧔ർፉ⃰㧕
㧦133㧙136(2008 ᐕ 3 ᦬)
17㧕 㕍ጊ⵨⟤㧘ർፉᐽ㓶㧘દ૒଻㚅㧦∛ේᕈ᛫࠺ࠬࡕࠣ࡟ࠗࡦ 3 ࡕࡁࠢࡠ࡯࠽࡞᛫૕ߦࠃࠆ࠺ࠬࡕࠣ࡟
㧦88㧙92(2008ࠗࡦߩಽ⸃ߩᬌ⸛㧦ᐔᚑ 19 ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ✚᜝࡮ಽᜂႎ๔ᦠ㧔ർፉ⃰㧕
ᐕ 3 ᦬)
18㧕 ᾖ੗ ᱜ㧘ᮮጊ ᗲ㧘ේ ᒄਯ㧘᭱ፉ ⺈㧘㕍ጊ⵨⟤㧦⤥∊ᕈੇ⊈ߩ∛࿃ߣᴦ≮㧙⾗⾰ઍ⻢ߦ㑐ߔ㧙㧙ࠆ⸃ᨆ㧙㧦ᐔᚑ 19 ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ✚᜝࡮ಽᜂႎ๔ᦠ㧔ർፉ⃰㧕㧦99㧙105(2008 ᐕ 3᦬)19㧕 ᄤ⼱㓷ⴕ㧘⼱Ꮉℭሶ㧘ᷡ᳓ᥓሶ㧘ᯅᧄ 㓉㧘ᳰ↰ᔒᢦ㧘ᣂ㑐ኡᓼ㧘㤥ᴛ⟤ᥓሶ㧘㕍ጊ⵨⟤㧘ർፉᐽ㓶㧦ᄤ∊≙ߩ⸻ᢿߣᴦ≮ࠟࠗ࠼࡜ࠗࡦ㧦ᐔᚑ 19 ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄ႎ๔ᦠ㧔ർፉ⃰㧕೎ᷝ⾗ᢱ 1㧦1㧙14(2008 ᐕ 3 ᦬)
20㧕 ᯅᧄ 㓉㧘ự↰ዏብ㧘ᳰ↰ᔒᢦ㧘ᄤ⼱㓷ⴕ㧘ᣂ㑐ኡᓼ㧘㤥ᴛ⟤ᥓሶ㧘㕍ጊ⵨⟤㧘ർፉᐽ㓶㧦᳓∊∝㘃ᄤ∊≙ࠟࠗ࠼࡜ࠗࡦ㧦ᐔᚑ 19 ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄ႎ๔ᦠ㧔ർፉ⃰㧕೎ᷝ⾗ᢱ 1㧦15㧙34(2008ᐕ 3 ᦬)
21㧕 ጤ↰໪᳁㧘ᾖ੗ ᱜ㧘ዊỈ ᣿㧘ዊችᩮ⌀ᑿ㧘᪢Ỉᘮ♿㧘ਛ⷏ ర㧘ේ ᒄਯ㧘㚍ᷨᥓ↢㧘㕍ጊ⵨⟤㧘ർፉᐽ㓶㧦⤥∊ᕈੇ⊈㧔᳢⊒ဳ㧕⸻≮ࠟࠗ࠼࡜ࠗࡦ㧦ᐔᚑ 19 ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄ႎ๔ᦠ㧔ർፉ⃰㧕೎ᷝ⾗ᢱ 1㧦35㧙92(2008 ᐕ 3 ᦬)
22㧕 ᷡ᳓ ብ㧘ᯅᧄ౏ੑ㧘₹੗సੱ㧘㤥ᴛ⟤ᥓሶ㧘㕍ጊ⵨⟤㧘ർፉᐽ㓶㧦⴫⊹᳓∊∝⸻ᢿߣᴦ≮ߩࠟࠗ࠼࡜ࠗࡦ㧦ᐔᚑ 19 ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄ႎ๔ᦠ㧔ർፉ⃰㧕೎ᷝ⾗ᢱ 1㧦93㧙103(2008 ᐕ 3 ᦬)11㧚ႎ㆏ߥߒ12㧚⥄Ꮖ⹏ଔ
⹏ଔ1㧕ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ߪ⛮⛯ࠍ฽߼ 5 ઙ㧔ၮ⋚ B1 ઙ㧘C3 ઙ㧘⧯ᚻ B1 ઙ㧕㊄㗵ߪ 1050 ౞ߢ޽ߞߚ‫ޕ‬
2㧕ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ߪ⒘ዋ㔍ᴦᕈ⊹⤏∔ᖚߩ⃰㐳ࠍߒߡ޿ߚߚ߼ᐔᚑ 17 ᐕ߆ࠄ 19 ᐕߦ✚㗵 1 ం 5470 ਁ౞㧘18 ᐕ߆ࠄ 19 ᐕߛߌߢ߽ 1 ం 1570 ਁ౞ࠍ₪ᓧߒߚ‫┹ߩ߆ߟߊ޿ઁߩߘޕ‬੎⊛⎇ⓥ⾌
ࠍ⸘ 1270 ਁ౞ᓧߡ޿ࠆ‫ߪࠇߎޕ‬ᚒ‫ߩޘ‬ᢎቶߩ⎇ⓥ⾌ࠍߎߩಽ㊁ߢ₪ᓧߢ߈ࠆ࡟ࡌ࡞ߢ޽ߞߚߎߣࠍ␜
ߒߡ޿ࠆ‫ޕ‬3㧕⺰ᢥ⊒⴫ᢙߦߟ޿ߡߪ㧘⧷ᢥ࿖㓙⹹ߪ৻ᦼ೨ 3 ᐕ㑆㧔ᐔᚑ 15 ᐕ㨪17 ᐕ㧕ߩ 20 ႎ߆ࠄ 22 ႎߦჇടߒߚ‫ޕ‬ᣣᧄ⺆⺰ᢥ߿∝଀ႎ๔ߪ 48 ႎ߆ࠄ 64 ႎߦჇടߒߡ޿ࠆߩߢ⎇ⓥᚑᨐ߽లಽߦ᜼ߍߡ޿ࠆߎߣࠍ
␜ߒߡ޿ࠆ‫ޕ‬4㧕ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄⒘ዋ㔍ᴦᕈ⊹⤏∔ᖚߦ㑐ߔࠆ⺞ᩏ⎇ⓥ⃰⃰㐳ߣߒߡ2 ᦼ⋡3 ᐕ㑆ߩ⛮⛯੍▚ࠍ੤ઃߐࠇࠆᚑ❣ࠍ᜼ߍߚߩߢ৻ቯߩ⹏ଔߣ⠨߃ࠄࠇࠆ‫ޕ‬
5㧕ർፉᢎ᝼߇࿖㓙⎇ⓥ⊹⤏⑼ቇળࠨ࠹࡜ࠗ࠻ࠪࡦࡐࠫ࠙ࡓ‫ޡ‬Post IID 5th Joint Meeting of SSSR and
SCUR, and International Meeting on Autoimmune Bullous Disease 2008‫ߩޢ‬ળ㐳ࠍോ߼㧘ቇળࠍਥቿ
ߒߚߎߣߪ⹏ଔߐࠇࠆ‫ޕ‬
6㧕ർፉᢎ᝼߇╙ 51 ࿁ᣣᧄක⌀⩶ቇળ✚ળ㧔ᐔᚑ 19 ᐕ 11 ᦬㧘㜞ጊ㧕ߩળ㐳ࠍോ߼㧘ቇળࠍਥቿߒߚߎ
ߣߪ⹏ଔߐࠇࠆ‫ޕ‬7㧕ർፉᢎ᝼߇╙ 24 ࿁ᣣᧄ⊹⤏ᖡᕈ⣲≌ቇળ✚ળ㧔ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧕ߩળ㐳ࠍോ߼㧘ቇળࠍਥቿ
ߒߚߎߣߪ⹏ଔߐࠇࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ᴺੱൻᓟߪ⥃ᐥ߳ߩᤨ㑆㈩ಽߣ♖␹⊛㈩ಽ߇ᄙߊߥࠅ㧘⎇ⓥታⴕߩⅣႺߪᖡൻߒߚ‫ߪߡ޿ߟߦࠇߎޕ‬ኻ╷߇ᔅⷐߢ޽ࠆ‫ޕ‬තᓟ⥃ᐥ⎇ୃᔅୃൻߦࠃࠅ 3 ᐕ⋡ߩ⊹⤏⑼ᧂ⚻㛎⠪߇౉ዪߔࠆߎߣߦߥࠅᜰዉ⊛කᏧߩᢙ߇ᷫዋߒߚ‫ޕ‬ᓟᦼ⎇ୃࠍ㒮ᄖߣදജߒߡᢎ⢒ߔࠆᔅⷐ߇޽ࠆ‫ޕ‬੹ᓟߩዷᦸጘ㒂ᄢቇකቇㇱߪᄢቇ㒮ൻߐࠇߚߚ߼㧘੹߹ߢએ਄ߦ⎇ⓥታ❣ࠍ਄ߍࠆᔅⷐ߇޽ࠆ‫ߟ߆ޕ‬ᴺੱൻߐࠇߚ∛㒮ߢߪක≮෼⋉ߩჇ෼ߣߣ߽ߦ㜞ᐲవㅴක≮ߩ㐿⊒㧘කቇㇱ↢㧘⎇ୃක㧘කຬߩᢎ⢒ࠍⴕߥ߁ᔅⷐ
߇޽ࠆ‫੹ޕ‬ᓟߪߎࠇࠄߦ․ൻߒߚ⋡⊛ࠍ⸳ቯߔࠆᔅⷐ߇޽ࠆ‫ޕ‬㧙㧙㧔6㧕ᴲዩེ⑼ቇಽ㊁1㧚 ⎇ⓥߩ᭎ⷐ
1㧕ዩ〝↢ᱺེ⣲≌ߩᴦ≮ߣ੍ᓟߦ㑐ߔࠆၮ␆⊛࡮⥃ᐥ⊛⎇ⓥ
Ԙ᛫≸೷ᗵฃᕈ㧘᛫≸೷⠴ᕈ࿃ሶߦ㑐ߔࠆ⎇ⓥ⥃ᐥ᧚ᢱࠍ↪޿ߡ㧘ATP ᵴᕈࠍ↪޿ߚ᛫≸೷ᗵฃᕈ⹜㛎ᚑ❣ߣ㧘⠴ᕈㆮવሶ⊒⃻㊂ߣߩ㑐ㅪࠍ⎇ⓥߒߡ޿ࠆ‫ޕ‬
ԙዩ〝↢ᱺེ≸ߩ੍ᓟ੍᷹࿃ሶߦ㑐ߔࠆ∛ℂቇ⊛⎇ⓥ≸⚵❱ߦ߅ߌࠆ․ቯߩㆮવሶ㧘⧯ߒߊߪㆮવሶ↥‛ߩ⊒⃻ߩ㧘੍ᓟ੍᷹࿃ሶߣߒߡߩน⢻ᕈࠍ⎇ⓥߒ㧘୘‫ߩߢ଀∝ߩޘ‬ᴦ≮ᣇ㊎᳿ቯߦ߅޿ߡߩߘߩ᦭↪ᕈࠍ⎇ⓥߒߡ޿ࠆ‫ޕ‬Ԛ೨┙⣼≸ߩ᛫≸೷⠴ᕈᯏᐨߩၮ␆⊛⎇ⓥ
ࡎ࡞ࡕࡦ≮ᴺ⠴ᕈ೨┙⣼≸ߦኻߔࠆ᛫≸೷ᴦ≮ߩ⏕┙ࠍ⋡ᜰߒ㧘ၭ㙃⚦⢩෸߮ታ㛎േ‛ࠍ↪޿ߚ᛫≸೷⠴ᕈߦ㑐ㅪߒߚㆮવሶߩหቯߣ㧘ߘߩ⊒⃻㒖ᱛߦߟ޿ߡߩၮ␆⎇ⓥࠍⴕߞߡ޿ࠆ‫ޕ‬ԛ೨┙⣼≸ᴦ≮ߦ㑐ߔࠆ⥃ᐥ⊛⎇ⓥᣣᧄߦ߅ߌࠆ೨┙⣼≸ߦኻߔࠆ࡛࠙⚛ 125 ኒኽዊ✢Ḯ᳗ਭᝌ౉≮ᴺߦ㑐ߔࠆ೨ะ߈ࠦࡎ࡯࠻⎇ⓥ߅ࠃ߮㒢ዪᕈ೨┙⣼≸ߦኻߔࠆࡎ࡞ࡕࡦ≮ᴺߩ᦭ലᕈߦ㑐ߔࠆⷰኤ⎇ⓥࠍⴕߞߡ޿ࠆ‫ޕ‬
2㧕ዩ〝ᗵᨴ∝ߩၮ␆⊛࡮⥃ᐥ⊛⎇ⓥ
Ԙᄢⷙᮨ⺞ᩏߦࠃࠆ⿠࿃⩶ߩ⥃ᐥ⊛⎇ⓥ
㑐ㅪᣉ⸳ࠍ฽߼ߡᲤᐕⶄ㔀ᕈዩ〝ᗵᨴ∝ߩ⿠࿃⩶ࠍ෼㓸ߒ㧘߹ߚ㧘⥃ᐥ⢛᥊߿⥃ᐥ∛⁁ߣߩ㑐ㅪࠍ⎇ⓥ
ߒߡ޿ࠆ‫ ߦࠄߐޕ‬4 ᐕᲤߦᅚሶᕆᕈන⚐ᕈ⣾⢲Ἳߩ✚ว⺞ᩏࠍ⛮⛯ਛߢ޽ࠆ‫ޕ‬ԙ⮎೷⠴ᕈ⩶ߩ಴⃻⁁ᴫ㧘⠴ᕈᯏᐨߩ⸃᣿
⥃ᐥ଀ࠃࠅᓧࠄࠇߚ⿠࿃⩶ࠍ↪޿ߡ㧘⓭ὼᄌ⇣ߥߤߩㆮવሶ࡟ࡌ࡞ߢߩ⮎೷⠴ᕈᯏᐨࠍ⎇ⓥߒߡ޿ࠆ‫ޕ‬߹ߚ㧘᛫⩶೷ߩ૶↪ߣㆮવሶᄌ⇣ߣߩ㑐ㅪ߽⎇ⓥߒߡ޿ࠆ‫ޕ‬Ԛዩ〝ᗵᨴ∝ߦኻߔࠆ⮎‛≮ᴺߦߟ޿ߡߩ⥃ᐥ⊛⎇ⓥ㑐ㅪ∛㒮ߣදജߒዩ〝ᗵᨴ∝ߦኻߔࠆฦ⒳᛫⩶೷ߩ᦭ലᕈߦߟ޿ߡᬌ⸛ࠍⴕߞߡ޿ࠆ‫ޕ‬
3㧕↵ሶዩ㆏Ἳߩၮ␆⊛࡮⥃ᐥ⊛⎇ⓥ
Ԙಽሶ↢‛ቇ⊛ᚻᴺࠍ↪޿ߚ⿠Ἳ⩶ߩᬌ಴ᴺߩ㐿⊒⃻࿷߹ߢߦ⸃᣿ߐࠇߡ޿ߥ޿㕖ᶷ⩶ᕈዩ㆏Ἳߩ⿠Ἳ⩶ߩหቯߣ㧘ߘߩ⸻ᢿᴺߩ㐿⊒㧘․ߦᩭ㉄Ⴧ᏷ࠍ↪
޿ߚᚻᴺࠍ⎇ⓥߒߡ޿ࠆ‫ޕ‬ԙ⮎೷⠴ᕈ⩶ᶷ⩶ߩ∉ቇ⎇ⓥ㑐ㅪᣉ⸳ࠍ฽߼ߡᐕᰴ⊛ߦ⥃ᐥಽ㔌ᩣࠍ෼㓸ߒ㧘ߘࠇࠄߩ᛫⩶೷ᗵฃᕈࠍ᷹ቯߒ㧘ᐕᰴ⊛ߥᄌ⒖ࠍ⎇ⓥ
ߒߡ޿ࠆ‫ޕ‬Ԛ⮎೷⠴ᕈ⩶ᶷ⩶ߩ⮎೷⠴ᕈᯏᐨߩ⸃᣿
⮎೷⠴ᕈ⩶ᶷ⩶ߩౝߢ⚻ญ࠮ࡈࠚࡓ೷⠴ᕈᶷ⩶ߦ⌕⋡ߒ㧘ߘߩ⠴ᕈᯏᐨࠍㆮવሶ࡟ࡌ࡞ߢ⎇ⓥߒߡ޿ࠆ‫ޕ‬ԛ↵ሶዩ㆏Ἳߦኻߔࠆ⮎‛≮ᴺߦߟ޿ߡߩ⥃ᐥ⊛⎇ⓥ㑐ㅪ∛㒮ߣදജߒ↵ሶዩ㆏Ἳߦኻߔࠆฦ⒳᛫⩶೷ߩ᦭ലᕈߦߟ޿ߡᬌ⸛ࠍⴕߞߡ޿ࠆ‫ޕ‬4㧕⣢⒖ᬀߦ߅ߌࠆ⥃ᐥ⊛⎇ⓥ
Ԙ఺∉ᛥ೙೷ߩㆡᱜൻ
ᜎ⛘෻ᔕࠍ㒐߉㧘ᣣ๺⷗ᗵᨴ∝ࠍᒁ߈⿠ߎߐߥ޿ㆡᱜߥ఺∉ᛥ೙೷ߩᛩਈᣇᴺߦ㑐ߔࠆ⥃ᐥ⊛⎇ⓥࠍⴕߞߡ޿ࠆ‫ޕ‬ԙ⒖ᬀ⣢ߩ∛ℂቇ⊛⎇ⓥ⒖ᬀ⣢ߦኻߒߡቯᦼ⊛ߥ↢ᬌࠍᣉⴕߒߡ㧘⒖ᬀ⣢ᯏ⢻ߦ෸߷ߔẜ࿷⊛ߥᜎ⛘෻ᔕ㧘࠙ࠗ࡞ࠬᗵᨴࠍ∛ℂ
௝߆ࠄ⎇ⓥߒߡ޿ࠆ‫ߦࠄߐޕ‬㧘∛ℂ⚵❱௝߆ࠄ⒖ᬀ⣢ߩ㐳ᦼ↢⌕ࠍ⋡ᜰߒߚ࠹࡯࡜࡯ࡔࠗ࠼ߥ఺∉ᛥ೙≮ᴺࠍⴕߞߡ޿ࠆ‫ޕ‬
5㧕㏜ⷞਅᚻⴚᚻᛛߩ㐿⊒⎇ⓥ⣻⣧㏜ਅ೽⣢៰಴ⴚ㧘⣻⣧㏜ਅ⣢៰಴ⴚߪ㧘ߔߢߦᮡḰⴚᑼߣߥࠅߟߟ޽ࠆ߇㧘⋵ਅߢታᣉߒߡ޿ࠆᣉ
⸳ߪዋߥ޿‫ᧄޕ‬ᚻᛛࠍ቟ో߆ߟ⏕ታߦⴕ߁ߚ߼ߩᚻᛛ߅ࠃ߮ᧄⴚᑼࠍᔕ↪ߒߚᣂߚߥⴚᑼߩ㐿⊒㧘ߥࠄ߮ߦౕེ㧘ེ᧚ߩ㐿⊒⎇ⓥࠍⴕߞߡ޿ࠆ‫ޕ‬
6㧕ឃዩ㓚ኂಽ㊁ߦ߅ߌࠆ⥃ᐥ⊛⎇ⓥԘ↵ᕈ೨┙⣼⢈ᄢ∝ᖚ⠪ߩਅㇱዩ〝∝⁁ߦኻߔࠆ⮎೷ߩലᨐߦߟ޿ߡ㧘೨┙⣼⢈ᄢ∝ߦ઻߁ㆊᵴേ⣾⢲∝⁁㧘೨┙⣼⢈ᄢ∝ᖚ⠪ߦว૬ߔࠆᄛ㑆㗫ዩ㧘೨┙⣼⢈ᄢ∝ߦኻߔࠆᴦ≮ᛶ᛫ᕈߩਇቯᗜ⸷ߦኻߔࠆ⮎‛≮ᴺࠍ⥄ⷡ⊛㧘ઁⷡ⊛ߦ⹏ଔߒ㧘ᦨㆡߥᛩਈᣇᴺࠍᬌ⸛ߒߡ޿ࠆ‫ޕ‬ԙᄛ㑆㗫ዩߩේ࿃ߪᄙ࿃ሶߢ޽ࠅ㧘ਅㇱዩ〝ߩ⇣Ᏹએᄖߦ߽ోり⊛ߥ໧㗴߇ᓇ㗀ߒߡ޿ࠆ‫ᤨ⌁⌧ޕ‬ή๭㧙㧙ๆ∝୥⟲㧔SAS㧕߽ߘߩේ࿃ߩ 1 ߟߣߐࠇߡ߅ࠅ㧘ߘࠇࠍ⥃ᐥ⊛ߦ⸽᣿ߔࠆߚ߼ SAS ⇼޿ߩᖚ⠪ߦኻߒឃዩࡄ࡜ࡔ࡯࠲࡯ߩ⹏ଔࠍⴕ޿㧘SAS ᴦ≮ᓟߦ߽⹏ଔࠍߒ㑐ㅪࠍ⺞ߴߡ޿ࠆ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
ಎᢎ᝼㧦
⻠Ꮷ㧦
⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦

಴ญ 㓉
ᳯේ⧷ବ
દ⮮ᘕ৻
ખ㊁ᱜඳ
ᮮ੗❥᣿
቟↰ ḩ
ධ⥪ ⻞
ጊᧄ⋥᮸
ਃベᅢ↢
࿯ደ᦮ᄢ
Ⴧᩕቁሶ
⩵࿾⟤ᄹ
᳗੗⌀๋
ၳᳯᙗ๋

Takashi Deguchi
Hidetoshi Ehara
Shin-ichi Ito
Masahiro Nakano
Shigeaki Yokoi
Mitsuru Yasuda
Yuzuru Minamidate
Naoki Yamamoto
Kousei Miwa
Tomohiro Tsuchiya
Takako Masue
Mina Kikuchi
Shingo Nagai
Kengo Horie

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ಴ญ 㓉㧚൮⨍㧘੉㗡൮⊹Ἳ㧦ጊญ ᔀ㧘ർේశᄦ㧘⑔੗ᰴ⍫✚✬㓸㧚 TODAY’S THERAPY 2006 ੹ᣣߩᴦ≮ᜰ㊎㧘᧲੩㧦කቇᦠ㒮㧧2006 ᐕ㧦815㧚
2㧕 ಴ญ 㓉㧘ᮮ੗❥᣿㧘቟↰ ḩ㧚⣾⢲Ἳ㧔⚦⩶ᕈ߅ࠃ߮㕖⚦⩶ᕈ⣾⢲Ἳ㧕㧦ർጟᑪ᮸㧘㘵㊁㕏ᒾ㧘੖ච፲ 㓉㧘ᧁ᧛ஜੑ㇢㧘ၳᳯ㊀㇢✬㓸㧚⣢࡮ዩ〝∔ᖚߩ⸻≮ᜰ㊎‘06㧘᧲੩㧦᧲੩කቇ␠㧧2006 ᐕ㧦403㧙405㧚
3㧕 ಴ญ 㓉㧚ዩ〝ᕈེᗵᨴ∝ ̆᛫⩶⮎૶↪ࠟࠗ࠼࡜ࠗࡦߦᴪߞߚ᛫⩶⮎ߩ૶޿ᣇ̆ ߪߓ߼ߦ㧦ᣣᧄᴲዩེ⑼ቇળ 2007 ᐕ තᓟ࡮↢ᶦᢎ⢒࠹ࠠࠬ࠻㧘᧲੩㧦ᣣᧄᴲዩེ⑼ቇળ㧧2007 ᐕ㧦69㧚
4㧕 ಴ญ 㓉㧚ዩ〝ᕈེᗵᨴ∝ ̆᛫⩶⮎૶↪ࠟࠗ࠼࡜ࠗࡦߦᴪߞߚ᛫⩶⮎ߩ૶޿ᣇ̆ ᕈེᗵᨴ∝㧦ᣣᧄᴲዩེ⑼ቇળ 2007 ᐕ තᓟ࡮↢ᶦᢎ⢒࠹ࠠࠬ࠻㧘᧲੩㧦ᣣᧄᴲዩེ⑼ቇળ㧧2007 ᐕ㧦75㧙81㧚
5㧕 ቟↰ ḩ㧚ዩ〝ᕈེᗵᨴ∝ ̆᛫⩶⮎૶↪ࠟࠗ࠼࡜ࠗࡦߦᴪߞߚ᛫⩶⮎ߩ૶޿ᣇ̆ ዩ〝ᕈེᗵᨴ∝㧦ᣣᧄᴲዩེ⑼ቇળ 2007 ᐕ තᓟ࡮↢ᶦᢎ⢒࠹ࠠࠬ࠻㧘᧲੩㧦ᣣᧄᴲዩེ⑼ቇળ㧧2007 ᐕ㧦70㧙74㧚
6㧕 ಴ญ 㓉㧚ጊญ ᔀ㧘ർේశᄦ㧘⑔੗ᰴ⍫✚✬㓸㧚⣾⢲Ἳ㧦TODAY’S THERAPY 2008 ੹ᣣߩᴦ≮ᜰ㊎㧘᧲੩㧦කቇᦠ㒮㧧2008㧦834㧙835㧚
7㧕 ಴ญ 㓉㧚࿯⢈⟵⢬㧘ጊᧄኈᱜ㧘ቝ⾐ᤘੑ✬㧚ᴲዩ↢ᱺེᗵᨴ∝㧦ࠬ࠲ࡦ࠳࡯࠼ ᓸ↢‛ቇ ╙ 2 㧘᧲੩㧦ᢥశၴ㧧2008 ᐕ㧦172㧙182㧚
8㧕 ಴ญ 㓉㧘቟↰ ḩ㧘೨↰⌀৻㧚↰ਛᱜ೑✬㓸㧚ࡑࠗࠦࡊ࡜࠭ࡑ㧦ᕈᗵᨴ∝ STD ᡷ⸓ 2 㧘᧲੩㧦ධጊၴ㧧2008 ᐕ㧦179㧙186㧚
9㧕 ಴ญ 㓉㧚ࡑࠗࠦࡊ࡜࠭ࡑ㧦቟రᘕ৻㇢✬㓸㧚STD㧔ᕈᗵᨴ∝㧕ࠕ࠻࡜ࠬ㧘᧲੩㧦⑲Ả␠㧧2008 ᐕ㧦133.
10㧕 ಴ญ 㓉㧚࠙࡟ࠕࡊ࡜࠭ࡑ㧦቟రᘕ৻㇢✬㓸㧚STD㧔ᕈᗵᨴ∝㧕ࠕ࠻࡜ࠬ㧘᧲੩㧦⑲Ả␠㧧2008 ᐕ㧦133㧚⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 ಴ญ 㓉㧚↵ሶዩ㆏Ἳߩ⸻ᢿߣᴦ≮ߩᦨㄭߩ⹤㗴㧘ᴲዩེ⑼ቇߩᦨㄭߩㅴᱠ 2006 ᐕ㧧22 Ꮞ㧦1㧙5㧚
2㧕 㜞ᯅ⟵ੱ㧘ᮮ੗❥᣿, ੉੗ା๋, ಴ญ 㓉㧚ᚻⴚᚻᛛ ዩ〝ౝⷞ㏜ᚻⴚ ⚻ዩ㆏⊛⣾⢲⚿⍹៰಴ⴚ ⚻⊹⊛⣾⢲⚿⍹៰಴ⴚ㧘⥃ᐥᴲዩེ⑼ 2006 ᐕ㧧60 Ꮞ㧦361㧙367㧚
3㧕 ಴ญ 㓉㧚೨┙⣼∔ᖚ ᣂߒ޿ᴦ≮ᴺࠍℂ⸃ߔࠆߚ߼ߦ-೨┙⣼Ἳ ᕆᕈ೨┙⣼Ἳߩ⸻ᢿߣᴦ≮㧘Modern
Physician 2006 ᐕ㧧26 Ꮞ㧦1007㧙1010㧚
4㧕 ᳯේ⧷ବ㧘ખ㊁ᱜඳ, ಴ญ 㓉㧚ዪᚲᶐẢ೨┙⣼≸ߩᴦ≮ᚢ⇛ ࡎ࡞ࡕࡦ≮ᴺߩ૏⟎ઃߌ㧘ᴲዩེ⑼♿ⷐ2006 ᐕ㧧52 Ꮞ㧦473㧙477㧚
5㧕 ಴ญ 㓉, ⪤ේᓼᐽ, દ⮮ᘕ৻㧚ᴲዩེ⑼⥃ᐥߩ㔍໧ࠍ⸃ߊ EBM ࠍ⠨ᘦߒߚ⸃⺑-ᘟᕈ೨┙⣼Ἳߩᴦ≮㧘⥃ᐥᴲዩེ⑼ 2006 ᐕ㧧60 Ꮞ㧦549㧙554㧚
6㧕 ಴ญ 㓉㧚ዩ〝ᗵᨴ∝ߩ∛ᘒߣ⸻ᢿ࡮ᴦ≮ߣ੍㒐 ⇐⟎ࠞ࠹࡯࠹࡞߽฽߼ߡ㧚ᗵᨴ㒐ᱛ 2007 ᐕ㧧17 Ꮞ㧦
9㧙15㧚
7㧕 ಴ญ 㓉㧚∛᳇ߣ⮎ߩ⺑᣿ࠟࠗ࠼ 2007㧘ᗵᨴᕈ∔ᖚ ⮎‛≮ᴺ✬ ක⮎ຠᖱႎ✬ ᕈེᗵᨴ∝㧚⮎ዪ 2007
ᐕ㧧58 Ꮞ㧦1563㧙1569㧚
8㧕 ᮮ੗❥᣿㧘಴ญ 㓉㧚ᴲዩེ⑼−∩ኻ╷㧘ዩ〝ᕈེᗵᨴ∝࡮㛽⋚ౝ−∩∝୥⟲ߦኻߔࠆ−∩ኻ╷㧚Urology
View 2007 ᐕ㧧5 Ꮞ㧦30㧙33㧚㧙㧙9㧕 㜞ᯅ⟵ੱ, ਛᩮᘮᄥ, ᮮ੗❥᣿㧚ᚻⴚᚻᛛ ⣻⣧㏜ਅᚻⴚᤨઍߦ߅ߌࠆ㐿᡼ᚻⴚ න⚐⣢៰㒰ⴚ㧚⥃ᐥᴲዩ
ེ⑼ 2007 ᐕ㧧61 Ꮞ㧦117㧙124㧚
10㧕 ቟↰ ḩ㧚ᕈᗵᨴ∝ߩ⃻⁁㧘ਥⷐ∔ᖚߩࡊ࡜ࠗࡑ࡝ࠤࠕ⸻≮ ᶷ⩶ᗵᨴ∝ߩ⸻ᢿߣᴦ≮ ࠢ࡝࠾ࠞ࡞ࡊ࡜
ࠢ࠹ࠖࠬ 2007 ᐕ㧧26 Ꮞ㧦304㧙307㧚
11㧕 દ⮮ᘕ৻, ࿯ደ᦮ᄢ, ቞ጊᵗม, Ⓑ၂ാᄦ, ಴ญ 㓉㧚⣢⒖ᬀᓟ BK ࠙ࠗ࡞ࠬ⣢∝ߣ࠺ࠦࠗ࠮࡞ߩᗧ⟵㧘ᬌᩏߣᛛⴚ 2007 ᐕ㧧35 Ꮞ㧦407㧙410㧚
12㧕 ಴ญ 㓉, ⪤ේᓼᐽ, ቟↰ ḩ, ೨↰⌀৻㧚ᕈᗵᨴ∝ ੹㧘ߥߦ߇໧㗴߆㧘ᕈᗵᨴ∝ ⸻ᢿ࡮ᴦ≮ 㕖ࠢ࡜ࡒࠫࠕᕈ㕖ᶷ⩶ᕈዩ㆏Ἳ㧚⥃ῼߣ⎇ⓥ 2007 ᐕ㧧84 Ꮞ㧦673㧙676㧚
13㧕 ቟↰ ḩ㧚ᕈᗵᨴ∝ߩ⃻⁁㧘ᄙ೷⠴ᕈᶷ⩶ᗵᨴ∝ߩᴦ≮ ⥃ᐥᴲዩེ⑼ 2007 ᐕ㧧61 Ꮞ㧦773㧙779㧚
14㧕 ጤਅ᣿ሶ, ಴ญ 㓉㧚ᴲዩེࠤࠕߩ Do & Do Not㧘ᴲዩེ⑼ߩࠞ࠹࡯࠹࡞▤ℂߩ Do & Do Not ⣾⢲ᵞᵺ࡮⣢⋃ᵞᵺ Do Not 㐽㎮ᑼ⇐⟎ࠞ࠹࡯࠹࡞ߢߪ߻߿ߺ߿ߚࠄߦ⣾⢲ᵞᵺࠍߒߡߪ޿ߌߥ޿! ࠞ࠹࡯࠹࡞⇐⟎ᤨ㧘ࠞ࠹࡯࠹࡞㐽Ⴇᤨߥߤ․ᱶߥ႐วࠍ㒰޿ߡߪ⣾⢲ᵞᵺߔߴ߈ߢߪߥ޿㧚ᴲዩེࠤࠕ 2007 ᐕ㧧౻ቄჇೀ㧦128㧙130㧚
15㧕 ጟ↰ᒄ⟤, ಴ญ 㓉㧚ᴲዩེࠤࠕߩ Do & Do Not㧘ᴲዩེ⑼ߩࠞ࠹࡯࠹࡞▤ℂߩ Do & Do Not ⣾⢲ᵞᵺ࡮⣢⋃ᵞᵺ Do ⣾⢲ᵞᵺ߇࿎㔍ߥ႐ว㧘ߘߩℂ↱ࠍ⠨߃ߥߌࠇ߫ߥࠄߥ޿! ᴲዩེࠤࠕ 2007 ᐕ㧧౻ቄჇೀ㧦131㧙134㧚
16㧕 ጟ↰ᒄ⟤, ಴ญ 㓉㧚ᴲዩེࠤࠕߩ Do & Do Not㧘ᴲዩེ⑼ߩࠞ࠹࡯࠹࡞▤ℂߩ Do & Do Not ⣾⢲ᵞᵺ࡮⣢⋃ᵞᵺ Do Not ᗵᨴ㒐ᱛ⋡⊛ߢࠗ࠰ࠫࡦᶧߢ⣾⢲ᵞᵺࠍߒߡߪ޿ߌߥ޿! ᴲዩེࠤࠕ 2007 ᐕ㧧౻ቄჇೀ㧦135㧙137㧚
17㧕 ᐔጟ૒❱, ખ㊁ᱜඳ㧚ᴲዩེࠤࠕߩ Do & Do Not㧘ᴲዩེ⑼ߩࠞ࠹࡯࠹࡞▤ℂߩ Do & Do Not ⣾⢲ᵞᵺ࡮⣢⋃ᵞᵺ Do Not ⴊዩ߇Ớ޿ߣ߈ߦᜬ⛯⣾⢲ᵞᵺߩㅦᐲࠍㆃߊߒߡߪ޿ߌߥ޿! ᴲዩེࠤࠕ 2007ᐕ㧧౻ቄჇೀ㧦138㧙141㧚
18㧕 ᐔጟ૒❱, ખ㊁ᱜඳ㧚ᴲዩེࠤࠕߩ Do & Do Not㧘ᴲዩེ⑼ߩࠞ࠹࡯࠹࡞▤ℂߩ Do & Do Not ⣾⢲ᵞᵺ࡮⣢⋃ᵞᵺ Do ᜬ⛯⣾⢲ᵞᵺᤨߪࠗࡦࠕ࠙࠻㊂㧘ਅ⣻ㇱߩ⁁ᘒߦᵈᗧߒߥߌࠇ߫ߥࠄߥ޿! ᴲዩེࠤࠕ
2007 ᐕ㧧౻ቄჇೀ㧦142㧙145㧚
19㧕 ੹੗⟤๺ሶ, ખ㊁ᱜඳ㧚ᴲዩེࠤࠕߩ Do & Do Not㧘ᴲዩེ⑼ߩࠞ࠹࡯࠹࡞▤ℂߩ Do & Do Not ⣾⢲ᵞ
ᵺ࡮⣢⋃ᵞᵺ Do Not ⣢≪ㅧ⸳ᓟ㧘ಝⴊ႙ߢ⣢≪߇㐽Ⴇߒߡ߽ᵞᵺߒߡߪ޿ߌߥ޿! ᴲዩེࠤࠕ 2007ᐕ㧧౻ቄჇೀ㧦146㧙150㧚
20㧕 ੹੗⟤๺ሶ, ખ㊁ᱜඳ㧚ᴲዩེࠤࠕߩ Do & Do Not㧘ᴲዩེ⑼ߩࠞ࠹࡯࠹࡞▤ℂߩ Do & Do Not ⣾⢲ᵞ
ᵺ࡮⣢⋃ᵞᵺ Do Not ⣢⋃ᵞᵺᤨߦ㧘⣾⢲ᵞᵺߣหߓࠃ߁ߦ 30㨪50mL ߩ↢ℂ㘩Ⴎ᳓ࠍᵈ౉ߒߡߪ޿ߌ
ߥ޿! ᴲዩེࠤࠕ 2007 ᐕ㧧౻ቄჇೀ㧦151㧙153㧚
21㧕 ┻ౝᢅⷞ, ಴ญ 㓉㧚ᴲዩེ⑼ᢇᕆ㧘ዩ〝ᗵᨴ∝࡮ࡈ࡞࠾ࠛუ∓㧚⥃ᐥᴲዩེ⑼ 2007 ᐕ㧧61 Ꮞ㧦1079
㧙1085㧚
22㧕 ᳯේ⧷ବ, ಴ญ 㓉㧚ᄖ⑼⊛ಣ⟎ࠍⷐߔࠆᴲዩེ⑼㗔ၞߩ㊀∝ᗵᨴ∝㧘೨┙⣼⤥≌㧘♖Ꮍ਄૕⤥≌㧘㒶⨍⤥≌㧚ᴲዩེᄖ⑼ 2008 ᐕ㧧21 Ꮞ㧦453㧙459㧚
23㧕 ቟↰ ḩ㧚ᴲዩེ⑼ᄖ᧪ࡌࠬ࠻࠽ࡆࠥ࡯࡚ࠪࡦ㧘ዩ〝࡮ᕈེߩἻ∝ᕈ∔ᖚ 㕖ᶷ⩶ᕈዩ㆏Ἳ㧘ࠢ࡜ࡒࠫࠕ
ᗵᨴ∝߇⇼ࠊࠇࠆᖚ⠪ߢߔ‫ޕ‬ኻಣߣಣᣇߦߟ޿ߡᢎ߃ߡߊߛߐ޿‫ޕ‬2008 ᐕ㧧62 Ꮞ㧦95㧙97㧚
24㧕 ቟↰ ḩ㧚ᴲዩེ⑼ᄖ᧪ࡌࠬ࠻࠽ࡆࠥ࡯࡚ࠪࡦ㧘〝࡮ᕈེߩἻ∝ᕈ∔ᖚ ࠻࡝ࠦࡕ࠽ࠬ㧘‫࠻߇࡯࠽࠻࡯ࡄޟ‬࡝ࠦࡕ࠽ࠬ⣪Ἳߢᴦ≮߇㐿ᆎߐࠇߚ‫߁޿ߣޠ‬ᖚ⠪ߢߔ‫ޕ‬ኻಣߣಣᣇߦߟ޿ߡᢎ߃ߡߊߛߐ޿‫⥃ޕ‬ᐥᴲዩེ⑼ 2008 ᐕ㧧62 Ꮞ㧦98㧙100㧚
25㧕 ቟↰ ḩ㧚ᴲዩེ⑼ᄖ᧪ࡌࠬ࠻࠽ࡆࠥ࡯࡚ࠪࡦ㧘ዩ〝࡮ᕈེߩἻ∝ᕈ∔ᖚ ೨┙⣼∩㧘㗎࿕ߥ೨┙⣼∩ߩ⥄ⷡ∝⁁ࠍ⸷߃ࠆᖚ⠪ߢߔ‫ޕ‬ኻಣߣಣᣇߦߟ޿ߡᢎ߃ߡߊߛߐ޿‫⥃ޕ‬ᐥᴲዩེ⑼ 2008 ᐕ㧧62 Ꮞ㧦101
㧙104㧚
26㧕 ቟↰ ḩ㧚ᕈᗵᨴ∝ߦ߅ߌࠆᲣሶᗵᨴኻ╷㧘ᶷ⩶ᗵᨴ∝㧚ᣣᧄᕈᗵᨴ∝ቇળ⹹ 2008 ᐕ㧧19 Ꮞ㧦43㧙49㧚
27㧕 ቟↰ ḩ, ಴ญ 㓉㧚ᕈᗵᨴ∝㧘߅߽ߥᕈᗵᨴ∝ 㕖ࠢ࡜ࡒࠫࠕ࡮㕖ᶷ⩶ᗵᨴ㧘ߘߩઁ HB㧘⿒∯ࠕࡔ࡯ࡃ㧘᪢Ქߥߤ㧚ዊఽ⑼⸻≮ 2008 ᐕ㧧71 Ꮞ㧦1301㧙1310㧚
28㧕 ቟↰ ḩ㧚ᗵᨴ∝ߩᴦ≮ ᛫⩶⮎ࠍ૶޿ߎߥߘ߁㧘ᣣᏱ⊛ߥ⸻≮ߦ߅ߌࠆ᛫⩶⮎ߩ૶޿ᣇ ࠛࡦࡇ࡝࠶ࠢ
ߥ᛫⩶⮎ߩ૶޿ᣇߣ⪭ߣߒⓣ ዩ〝ᗵᨴ∝ߦ߅ߌࠆ᛫⩶⮎㧚ౝ⑼ 2008 ᐕ㧧102 Ꮞ㧦878㧙883㧚✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ጊ↰ ᔀ㧘࿯ደ᦮ᄢ㧘੉੗ା๋㧘ᬢ ⌬ᱜ㧘⷏㊁ᅢೣ㧘⷏↰ᵏᐘ㧘⼱ญశብ㧘᳗੗ ม㧘┻ౝᢅⷞ㧘ᳯේ⧷ବ㧘㜞ᯅ⟵ੱ㧘಴ญ 㓉㧘ጘ㒂ዩ〝਄⊹≸⎇ⓥࠣ࡞࡯ࡊ㧚⴫࿷ᕈ⣾⢲≸ߩౣ⊒࿃ሶ㧘੍ᓟ࿃ሶߩᬌ⸛ 800
଀ߩᬌ⸛㧘ᣣᧄᴲዩེ⑼ቇળ㔀⹹ 2006 ᐕ㧧97 Ꮞ㧦33㧙41㧚
2㧕 Ⴧᩕቁሶ㧘ട⮮ ථ㧘⪤ේᓼᐽ㧘ᮮ੗❥᣿㧘ᳯේ⧷ବ㧘಴ญ 㓉㧚ዩ㆏ᄖ⣕಴ࠍ઻ߞߚዩ▤≜ߩකේᕈ⎕ⵚ㧘⥃ᐥᴲዩེ⑼ 2006 ᐕ㧧60 Ꮞ㧦143㧙145㧚
3㧕 ቝ㊁⵨Ꮘ㧘㜞ᯅ⟵ੱ㧘಴ญ 㓉㧚Gray zone ∝଀ߦ߅ߌࠆ⚻⋥⣺ᑼ೨┙⣼ᄙᢙ▎ᚲ↢ᬌߩㆡᔕߦ㑐ߔࠆᬌ⸛㧘ᣣᧄ߇ࠎᬌ⸻࡮⸻ᢿቇળ⹹ 2006 ᐕ㧧13 Ꮞ㧦179㧙182㧚
4㧕 ਭ଻↰ᕺ┨㧘࿯ደ᦮ᄢ㧘੉੗ା๋㧘ᳯේ⧷ବ㧘㜞ᯅ⟵ੱ㧘಴ญ 㓉㧘੖ፉ ⡡㧘౗᧻㓷ਯ㧚Ⴇᩖⴚ߇᦭ല
ߢ޽ߞߚ⣢േ⣂≜ಾㄼ⎕ⵚߩ 1 ଀㧘ᴲዩེ⑼♿ⷐ 2006 ᐕ㧧52 Ꮞ㧦349㧙352㧚
5㧕 ᾢᧄᖝ᣿㧘Ⴆᧄᵏม㧘᧻Ꮉ㓷ೣ㧘࿖ፉᐽ᥍㧘ᐢἑፏ⥝㧘⨃↰჻㇢㧘ጊญ ⣑㧘⍹ᯅ ໪㧘㍯⼱㆐ᄦ㧘ศ↰㧙㧙ᶈ㧘੹⑔⵨ม㧘᧛੗ ൎ㧘ᷰㄝᷡ᣿㧘ዊᨋ⧐ᄦ㧘ౝ↰ ඳ㧘᧻↰㕒ᴦ㧘૒⮮ᣂ৻㧘⮮⋡ ⌀㧘⮮↰๺ᒾ㧘ⁿ⁚ ᷕ㧘ዊᩙ⼾ሶ㧘ጊญᗆਃ㧘ฎ⼱ାᒾ㧘಴ญ 㓉㧘⍹ේ ື㧘ᄢᳯ ብ㧘ጟ ⡛ᰴ㧘ർ᧛㓷຦㧘⑔ේศౖ㧘቞Ლ⽵ᄦ㧘⨹Ꮉഃ৻㧘౏ᢥ⵨Ꮘ㧘㐷↰ᤩ৻㧚ዩ〝ᗵᨴ∝ಽ㔌⩶ߦኻߔࠆ⚻ญߥࠄ߮ߦᵈ኿↪᛫⩶⮎
ߩ᛫⩶ജᲧセ(╙ 26 ႎ 2004 ᐕ) (ߘߩ 1.) ᗵฃᕈߦߟ޿ߡ㧘The Japanese Journal of Antibiotics
2006 ᐕ㧧59 Ꮞ㧦177㧙200㧚
6㧕 ᾢᧄᖝ᣿㧘Ⴆᧄᵏม㧘᧻Ꮉ㓷ೣ㧘࿖ፉᐽ᥍㧘ᐢἑፏ⥝㧘⨃↰჻㇢㧘ጊญ ⣑㧘⍹ᯅ ໪㧘㍯⼱㆐ᄦ㧘ศ↰ᶈ㧘੹⑔⵨ม㧘᧛੗ ൎ㧘ᷰㄝᷡ᣿㧘ዊᨋ⧐ᄦ㧘ౝ↰ ඳ㧘᧻↰㕒ᴦ㧘૒⮮ᣂ৻㧘⮮⋡ ⌀㧘⮮↰๺ᒾ㧘ⁿ⁚ ᷕ㧘ዊᩙ⼾ሶ㧘ጊญᗆਃ㧘ฎ⼱ାᒾ㧘಴ญ 㓉㧘⍹ේ ື㧘ᄢᳯ ብ㧘ጟ ⡛ᰴ㧘ർ᧛㓷຦㧘⑔ේศౖ㧘቞Ლ⽵ᄦ㧘⨹Ꮉഃ৻㧘౏ᢥ⵨Ꮘ㧘㐷↰ᤩ৻㧚ዩ〝ᗵᨴ∝ಽ㔌⩶ߦኻߔࠆ⚻ญߥࠄ߮ߦᵈ኿↪᛫⩶⮎
ߩ᛫⩶ജᲧセ(╙ 26 ႎ 2004 ᐕ) (ߘߩ 2.) ᖚ⠪⢛᥊㧘The Japanese Journal of Antibiotics 2006 ᐕ㧧
59 Ꮞ㧦201㧙213㧚
7㧕 ᾢᧄᖝ᣿㧘Ⴆᧄᵏม㧘᧻Ꮉ㓷ೣ㧘࿖ፉᐽ᥍㧘ᐢἑፏ⥝㧘⨃↰჻㇢㧘ጊญ ⣑㧘⍹ᯅ ໪㧘㍯⼱㆐ᄦ㧘ศ↰ᶈ㧘੹⑔⵨ม㧘᧛੗ ൎ㧘ᷰㄝᷡ᣿㧘ዊᨋ⧐ᄦ㧘ౝ↰ ඳ㧘᧻↰㕒ᴦ㧘૒⮮ᣂ৻㧘⮮⋡ ⌀㧘⮮↰๺ᒾ㧘ⁿ⁚ ᷕ㧘ዊᩙ⼾ሶ㧘ጊญᗆਃ㧘ฎ⼱ାᒾ㧘಴ญ 㓉㧘⍹ේ ື㧘ᄢᳯ ብ㧘ጟ ⡛ᰴ㧘ർ᧛㓷຦㧘⑔ේศౖ㧘቞Ლ⽵ᄦ㧘⨹Ꮉഃ৻㧘౏ᢥ⵨Ꮘ㧘㐷↰ᤩ৻㧘᧻ᧄືᦶ㧘᧛⼱ື㇢㧘ౝ⮮⺈ੑ㧘ᳯ㗡⒤ਭ㧘ዊ⷏㜞ବ㧘
ᴡ㊁ ⨃㧘ᐔẟᵗ৻㧘ㄭ⮮ ᤩ㧘᧻↰ᷕ৻㧘ਛ㊁〝ሶ㧚ዩ〝ᗵᨴ∝ಽ㔌⩶ߦኻߔࠆ⚻ญߥࠄ߮ߦᵈ኿↪᛫⩶⮎ߩ᛫⩶ജᲧセ(╙ 26 ႎ 2004 ᐕ) (ߘߩ 3.) ᗵฃᕈߩផ⒖㧘The Japanese Journal of Antibiotics
2006 ᐕ㧧59 Ꮞ㧦217㧙315㧚
8㧕 ᨋ ⟤૫㧘቟↰ ḩ㧘಴ญ 㓉㧚㜑⤑Ἳ⩶ߦࠃࠆ↵ሶዩ㆏Ἳߩ৻଀㧘ᣣᧄᕈᗵᨴ∝ቇળ⹹ 2006 ᐕ㧧17
Ꮞ㧦78㧙81㧚
9㧕 Ⴧᩕᚑᵏ㧘቟⮮౏㓉㧘⼾↰ ᴰ㧘᫪ ⟵㓶㧘ዊୖ⌀ᴦ㧘ਛᩮᘮᄥ㧘⪤ේᓼᐽ㧘㜞ᯅ⟵ੱ㧘಴ญ 㓉㧚వᄤᕈ⣢⋃ዩ▤⒖ⴕㇱ⁜⓰∝ߦว૬ߒߚᄖ்ᕈ⣢៊்ߩ 1 ଀㧘ᢇᕆකቇ 2007 ᐕ㧧31 Ꮞ㧦111㧙113㧚
10㧕 㜞ᯅ⟵ੱ㧘ਛᩮᘮᄥ㧘⼱ญశብ㧘ᄙ↰ᤩม㧘ᮮ੗❥᣿㧘ખ㊁ᱜඳ㧘᳓⼱ᤩテ㧘಴ญ 㓉㧘┻ౝᢅⷞ㧚ᴲዩེ⣻⣧㏜ᚻⴚߩ⥃ᐥ⊛ᬌ⸛ ጘ㒂ᄢቇ߅ࠃ߮㑐ㅪᣉ⸳ߦ߅ߌࠆ 9 ᐕ㑆ߩ⚻㛎㧘ጘ㒂⋵කᏧળකቇ㔀⹹
2007 ᐕ㧧20 Ꮞ㧦93㧙99㧚
11㧕 ੉੗ା๋㧘ᮮ੗❥᣿㧘㜞ᯅ⟵ੱ㧘಴ญ 㓉㧘┻ౝᢅⷞ㧘Ⳝᧄ㓶ฝ㧘⮮ᧄ૫ೣ㧚⣻⣧㏜ਅ೽⣢៰㒰ⴚ ೋᦼ
50 ∝଀ߩ⚻㛎㧘ᴲዩེ⑼♿ⷐ 2007 ᐕ㧧53 Ꮞ㧦107㧙112㧚
12㧕 ട⮮ ථ, 㜞ᯅ⟵ੱ㧘ਛᩮᘮᄥ㧘ᮮ੗❥᣿㧘ᳯේ⧷ବ㧘◉↰⢒↵㧘಴ญ 㓉㧚ᄙ⊒ᕈྙ⢩⣢ߦว૬ߒߚਔ
஥⣢⚦⢩≸ߩ 1 ଀㧘ᴲዩེ⑼♿ⷐ 2007 ᐕ㧧53 Ꮞ㧦117㧙119㧚
13㧕 ਭ଻↰ᕺ┨㧘࿯ደ᦮ᄢ㧘੉੗ା๋㧘ᳯේ⧷ବ㧘㜞ᯅ⟵ੱ㧘಴ญ 㓉㧘੖ፉ ⡡㧘౗᧻㓷ਯ㧚N-butyl2-cyanoacrylate(hystoacryl)ߦߡ 2 ᦼ⊛ߦႧᩖⴚࠍⷐߒߚᏂᄢ⣢േ㕒⣂ᄸᒻߩ 1 ଀㧘ᴲዩེ⑼♿ⷐ 2007
ᐕ㧧53 Ꮞ㧦307㧙310㧚
14㧕 ☨↰ዏ↢㧘⮮ᧄ૫ೣ㧘ቝ㊁㓷ඳ㧘Ⴧᩕቁሶ㧘᦯ㇱᘅ৻㧚ᩮᴦ⊛೨┙⣼ో៰಴ⴚᓟౣ⊒ߦߟ޿ߡߩᬌ⸛㧘ో࿖⥄ᴦ૕∛㒮ද⼏ળ㔀⹹ 2007 ᐕ㧧46 Ꮞ㧦395㧙396㧚
15㧕 ቝ㊁㓷ඳ㧘ጊ↰૫ノ㧘Ⴧᩕቁሶ㧘☨↰ዏ↢㧘⮮ᧄ૫ೣ㧚࠮ࡒࡁ࡯ࡑ stage I ߩ㐳ᦼᴦ≮ᚑ❣㧘ᴲዩེᄖ⑼ 2007
ᐕ㧧20 Ꮞ㧦179㧙182㧚
16㧕 Ⴧᩕቁሶ㧘ጊ↰૫ノ㧘᦯ㇱᘅ৻㧘ቝ㊁㓷ඳ㧘☨↰ዏ↢㧘⮮ᧄ૫ೣ㧚ዊఽዊ㒶ໃ≹⌕∝ߩ 1 ଀㧘ጘ㒂⋵කᏧળකቇ㔀⹹ 2007 ᐕ㧧20 Ꮞ㧦133㧙134㧚
17㧕 ⍹↰ஜ৻㇢㧘ේ↰ศ዁㧘㈕ ṽᓃ㧘᳓⼱ᤩテ㧘ᮮ੗❥᣿㧘಴ญ 㓉㧘㜞ᯅ⟵ੱ㧘ᨹේ৻຦㧘Ⳝᧄ㓶ฝ㧚㕖⸅⍮♖Ꮍߦኻߔࠆ⣻⣧㏜ᬌᩏߩ⚻㛎㧘ᴲዩེ⑼♿ⷐ 2007 ᐕ㧧53 Ꮞ㧦795㧙799㧚
18㧕 ቟↰ ḩ㧘ᄢᬮᷡᢥ㧘ਃ㡞ᑝ❥㧘ᓟ⮮ජኼ㧘Ỉ᧛ᴦ᮸㧘᧛਄໪㓶㧘಴ญ 㓉㧘᫪⣁ਭ㓉㧚ጘ㒂ᄢቇ㒝ዻ∛㒮ߢಽ㔌ߐࠇߚ✛⤥⩶ߩ⮎೷ᗵฃᕈߩᐕᰴផ⒖ߦߟ޿ߡ㧘✛⤥⩶ᗵᨴ∝⎇ⓥળ⻠Ṷ⸥㍳ 2007 ᐕ㧧41 Ꮞ㧦
47㧙51㧚
19㧕 ⩲ේ ፏ㧘᳗੗⌀๋㧘቞ጊᵗม㧘⮮ᐢ ⨃㧚2,8-dihydroxyadenine ⚿⍹ߩ 1 ଀㧘ጘ㒂⿒චሼ∛㒮කቇ㔀⹹
2007 ᐕ㧧19 Ꮞ㧦11㧙14㧚
20㧕 ᦯ㇱᘅ৻㧘⮮ᧄ૫ೣ㧘☨↰ዏ↢㧘ቝ㊁㓷ඳ㧘Ⴧᩕቁሶ㧚12 ᱦ↵ሶߦ⊒↢ߒߚ♖ሶ⡺⧘⣲ߩ 1 ଀㧘⷏ᣣᧄᴲ
ዩེ⑼ 2007 ᐕ㧧69 Ꮞ㧦640㧙643㧚
21㧕 ₹ᧁᱜ⟵㧘ᷡኅஜ૞㧘⷏↰ᵏᐘ㧘೨↰⌀৻㧘ਭ଻↰ᕺ┨㧘಴ญ 㓉㧚࠻࡛࠲⸥ᔨ∛㒮ߦ߅ߌࠆ೨┙⣼≸ߦኻߔࠆ೨┙⣼ో៰㒰ⴚߩ⥃ᐥ⊛ᬌ⸛㧘࠻࡛࠲කႎ 2007 ᐕ㧧17 Ꮞ㧦23㧙28㧚
22㧕 ᴡ↰ᐘ㆏㧘቟↰ ḩ㧘↰ਛ৻ᔒ㧘㐷↰ᤩ৻㧘⿒ဈ⡡৻㇢㧘ᳯ㗡⒤ਭ㧘⾐᧪ḩᄦ㧘ၳ ⺈ᴦ㧚ⶄ㔀ᕈዩ〝ᗵᨴ∝ࠍኻ⽎ߣߒߚ sitafloxacin ߩ↪㊂Ყセ⹜㛎㧘ᣣᧄൻቇ≮ᴺቇળ㔀⹹ 2008 ᐕ㧧56 Ꮞ㧔Ⴧೀ 1 ภ㧕
㧦92
㧙102㧚
23㧕 ቝ㊁㓷ඳ㧘☨↰ዏ↢㧘᦯ㇱᘅ৻㧘ᩮ╣ା৻㧘⮮ᧄ૫ೣ㧘Ⴧᩕቁሶ㧚Stone cone ዉ౉ߦࠃࠆ⚻ዩ㆏⊛ዩ▤⎈⍹ⴚߩ⥃ᐥ⊛ᬌ⸛㧘Japanese Journal of Endourology and ESWL 2008 ᐕ㧧21 Ꮞ㧦209㧙213㧚
24㧕 ਃベᅢ↢㧘቞ጊᵗม㧘Ⴧᩕቁሶ㧘⷏㊁ᅢೣ㧘᦯ㇱᘅ৻㧘ട⮮ᚑ৻㧘⍹↰ஜ৻㇢㧘Ⴧᩕᚑᵏ㧘቟↰ ḩ㧘ቝ㊁㓷ඳ㧘⼱ญశብ㧘₹ᧁᱜ⟵㧘ᳯේ⧷ବ㧘☨↰ዏ↢㧘ጟ㊁ ቇ㧘┻ౝᢅⷞ㧘ᄙ↰ᤩม㧘⮮ᧄ૫ೣ㧘೨↰⌀৻㧘㐳⼱Ꮉ⟵๺㧘⮮ᐢ ⨃㧘㈬੗ବഥ㧘ဈ ⟵ੱ㧘಴ญ 㓉㧚೨┙⣼⢈ᄢ∝ᖚ⠪ߦߺࠄࠇࠆ㛽⋚ㇱਇᔟᗵߦኻߔࠆࠛࡆࡊࡠࠬ࠲࠶࠻ߩ᦭ലᕈߩᬌ⸛㧘ᴲዩེᄖ⑼ 2008 ᐕ㧧21 Ꮞ㧦807㧙814㧚
25㧕 ⷏㊁ᅢೣ㧘಴ญ 㓉㧚ᅚᕈߩㆊᵴേ⣾⢲ߦኻߔࠆ᛫ࠦ࡝ࡦ⮎ࠗࡒ࠳ࡈࠚ࠽ࠪࡦߣ࠰࡝ࡈࠚ࠽ࠪࡦߩή૞ὑ
ഀઃߦࠃࠆᲧセᬌ⸛㧘ᴲዩེᄖ⑼ 2008 ᐕ㧧21 Ꮞ㧦815㧙822㧚
26㧕 ᳓⼱ᤩテ㧘⩵࿾⟤ᄹ㧘ㄭ⮮ᶈผ㧘቞ጊᵗม㧘࿯ደ᦮ᄢ㧘ખ㊁ᱜඳ㧘ᳯේ⧷ବ㧘಴ญ 㓉㧘◉↰⢒↵㧚ಽ▵ᕈേ⣂ਛ⤑Ⲣ⸃߇⇼ࠊࠇߚ⣢઒ᕈേ⣂≜⎕ⵚߩ 1 ଀㧘ᴲዩེ⑼♿ⷐ 2008 ᐕ 54 Ꮞ㧦489㧙491㧚
27㧕 ⩵࿾⟤ᄹ㧘੉੗ା๋㧘቞ጊᵗม㧘࿯ደ᦮ᄢ㧘ਃベᅢ↢㧘ᮮ੗❥᣿㧘ખ㊁ᱜඳ㧘ᳯේ⧷ବ㧘಴ญ 㓉㧘ᑝἑ㧙㧙ༀା㧚FOLFOX4(ࠝࠠࠨ࡝ࡊ࡜࠴ࡦ㧘ࡠࠗࠦࡏ࡝ࡦ㧘5-FU)ࠍⴚ೨᛫≸ൻቇ≮ᴺߦ↪޿ߚዩ⤑▤≸ߩ 1 ଀㧘ᴲዩེ⑼♿ⷐ 2008 ᐕ㧧54 Ꮞ㧦557㧙559㧚
28㧕 Ⴧᩕቁሶ㧘᦯ㇱᘅ৻㧘㜞ᧁ౏ᥙ㧘ቝ㊁㓷ඳ㧘☨↰ዏ↢㧘⮮ᧄ૫ೣ㧚⢷᳓⾂⇐ߦߡ⊒⷗ߐࠇߚ೨┙⣼≸ߩ 2଀㧘ᴲዩེ⑼♿ⷐ 2008 ᐕ㧧54 Ꮞ㧦565㧙568㧚
29㧕 ⷏↰ᵏᐘ㧘ᷡኅஜ૞㧘ጊᧄ⋥᮸㧘೨↰⌀৻㧘㜞᪀ᐽᚑ㧘↰ઍ๺ᒄ㧘₹ᧁᱜ⟵㧚ᓟ⣢ᕈ⣼⣲ߩ 1 ଀㧘࠻࡛࠲
කႎ 2008 ᐕ㧧18 Ꮞ㧦100㧙104㧚
30㧕 ട⮮ ථ㧘ખ㊁ᱜඳ㧘ቝ㊁⵨Ꮘ㧘ᷡኅஜ૞㧘ዊፉ࿻ᄥ㇢㧘ਭ଻↰ᕺ┨㧘ᓟ⮮㜞ᐢ㧘ጊᧄ⋥᮸㧘ᳯේ⧷ବ㧘Ⳝᧄ㓶ฝ㧘㜞ᯅ⟵ੱ㧘಴ญ 㓉㧘ጘ㒂೨┙⣼≸⎇ⓥࠣ࡞࡯ࡊ㧚೨┙⣼㊎↢ᬌᮡᧄߣ೨┙⣼ో៰ᮡᧄߦ߅ߌ
ࠆࠣ࡝࠰ࡦࠬࠦࠕߩਵ㔌ߦߟ޿ߡߩᬌ⸛ ৻⥸∛ℂකߩ⃻⁁㧘ᴲዩེ⑼♿ⷐ 2008 ᐕ㧧54 Ꮞ㧦641㧙645㧚
31㧕 ᳯේ⧷ବ㧘દ⮮ᘕ৻㧘㜞↰ବᒾ㧘࿯ደ᦮ᄢ㧘቞ጊᵗม㧘੉੗ା๋㧘Ⴧᩕᚑᵏ㧘ጊ↰ ᔀ㧘⬉ፉ⻞৻㧘᳗੗ม㧘☨↰ዏ↢㧘ᨋ ⑲ᴦ㧘⍹ේ ື㧘ၳᳯᱜት㧘಴ญ 㓉㧚ੑᰴᕈ೽↲⁁⣼ᯏ⢻੣ㅴ∝ߦኻߔࠆࡑࠠࠨࠞ
࡞ࠪ࠻࡯࡞㐳ᦼ૶↪ߩ੍ᓟ⺞ᩏ㧘ᣣᧄㅘᨆකቇળ㔀⹹ 2008 ᐕ㧧41 Ꮞ㧦717㧙722㧚
32㧕 ᷡኅஜ૞㧘⷏↰ᵏᐘ㧘ጊᧄ⋥᮸㧘೨↰⌀৻㧚㉄ᕈዩ㉄ࠕࡦࡕ࠾࠙ࡓ⚿⍹ߩ 1 ଀㧘ᴲዩེ⑼♿ⷐ 2008 ᐕ㧧
54 Ꮞ㧦689㧙692㧚
33㧕 ዊፉ࿻ᄥ㇢㧘੉੗ା๋㧘಴ญ 㓉㧚ⴚ೨ᬌᩏߦߡ⣾⢲⣲≌߇⇼ࠊࠇߚ TUR ᓟߩ೨┙⣼ౣ⢈ᄢ㧘⥃ᐥᴲዩ
ེ⑼ 2008 ᐕ㧧62 Ꮞ㧦1088㧙1090㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Hasegawa N, Mizutani K, Suzuki T, Deguchi T, Nozawa Y. A comparative study of protein profiling byproteomic analysis in camptothecin-resistant PC3 and camptothecin-sensitive LNCaP human prostatecancer cells. Urol Int. 2006;77:347-354.
2㧕 Nakano M, Uno H, Gotoh T, Kubota Y, Ishihara S, Deguchi T, Hayashi S, Matsuo M, Tanaka O, Hoshi
H. Migration of prostate brachytherapy seeds to the vertebral venous plexus. Brachytherapy.
2006:127-130.
3㧕 Nishino Y, Masue T, Miwa K, Takahashi Y, Ishihara S, Deguchi T. Comparison of twoalpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower
urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. BJU Int.
2006;97:747-751, discussion 751.
4㧕 Mizutani K, Matsumoto K, Hasegawa N, Deguchi T, Nozawa Y. Expression of clusterin, XIAP andsurvivin, and their changes by camptothecin (CPT) treatment in CPT-resistant PC-3 and
CPT-sensitive LNCaP cells. Exp Oncol. 2006;28:209-215.
5㧕 Ito H, Iwamoto I, Mizutani K, Morishita R, Deguchi T, Nozawa Y, Asano T, Nagata K. Possible
interaction of a Rho effector, Rhotekin, with a PDZ-protein, PIST, at synapses of hippocampal neurons.
Neurosci Res. 2006;56:165-171.
6㧕 Tanaka O, Hayashi S, Matsuo M, Sakurai K, Nakano M, Maeda S, Kajita K, Deguchi T, Hoshi H.
Comparison of MRI-based and CT/MRI fusion-based postimplant dosimetric analysis of prostatebrachytherapy. Int J Radiat Oncol Biol Phys. 2006;66:597-602.
7㧕 Maeda S, Kubota Y, Senda Y, Tamaki M, Yasuda M, Deguchi T. Failure to detect urethral Trichomonas
vaginalis in Japanese men with or without urethritis. Int J Urol. 2006;13:1418-1420.
8㧕 Tanaka O, Hayashi S, Sakurai K, Matsuo M, Nakano M, Maeda S, Hoshi H, Deguchi T. Importance of
the CT/MRI fusion method as a learning tool for CT-based postimplant dosimetry in prostatebrachytherapy. Radiother Oncol. 2006;81:303-308.
9㧕 Masue N, Deguchi, Yokoi S, Yamada T, Ohkusu K, Ezaki T. System for simultaneous detection of 16
pathogens related to urethritis to diagnose mixed infection. Int J Urol. 2007;14:39-42.
10㧕 Masue N, Hasegawa Y, Moriyama Y, Ikeda Y, Gotoh T, Deguchi T. Spontaneous disappearance ofmultiple lung metastases after nephroureterectomy from sarcomatoid carcinoma of the renal pelvis:
a case report. Int J Urol. 2007;14:75-78.
11㧕 Tanaka O, Hayashi S, Kanematsu M, Matsuo M, Nakano M, Maeda S, Deguchi T, Hoshi H. CT-based
postimplant dosimetry of prostate brachytherapy: comparison of 1-mm and 5-mm section CT. Radiat
Med. 2007;25:22-26.
12㧕 Ito H, Usuda N, Atsuzawa K, Iwamoto I, Sudo K, Katoh-Semba R, Mizutani K, Morishita R, Deguchi T,
Nozawa Y, Asano T, Nagata K. Phosphorylation by extracellular signal-regulated kinase of amultidomain adaptor protein, vinexin, at synapses. J Neurochem. 2007;100:545-554.
13㧕 Ehara H, KojimaK, Hagiwara N, Phuoc NB, Deguchi T. Abscess of the corpus cavernosum. Int J InfectDis. 2007;11:553-554.
14㧕 Phuoc NB, Ehara H, Gotoh T, Nakano M, Yokoi S, Deguchi T, Hirose Y. Immunohistochemical analysis
with multiple antibodies in search of prognostic markers for clear cell renal cell carcinoma. Urology.
2007;69:843-848.
15㧕 Mizutani K, Ito H, Iwamoto I, Morishita R, Deguchi T, Nozawa Y, Asano T, Nagata KI. Essential rolesof ERK-mediated phosphorylation of vinexin in cell spreading, migration and anchorage-independent
growth. Oncogene. 2007;26:7122-7131.
16㧕 Maeda S, Tamaki M, Kubota Y, Nguyen PB, Yasuda M, Deguchi T. Treatment of men with urethritis
negative for Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, Mycoplasma㧙㧙

IF 0.820

IF 2.751

IF 2.121

IF 4.290
IF 0.769

IF 4.074
IF 0.769

IF 0.769

IF 4.451
IF 2.250

IF 2.134

IF 6.440hominis, Ureaplasma parvum and Ureaplasma urealyticum. Int J Urol. 2007;14:422-425.
17㧕 Yoshida T, Deguchi T, Maeda S, Kubota Y, Tamaki M, Yokoi S, Yasuda M, Ishiko H. Quantitative
detection of Ureaplasma parvum (biovar 1) and Ureaplasma urealyticum (biovar 2) in urine specimensfrom men with and without urethritis by real-time polymerase chain reaction. Sex Transm Dis.
2007;34:416-419.
18㧕 Ochiai S, Sekiguchi Y, Hayashi A, Shimadzu M, Ishiko H, Matsushima-Nishiwaki R, Kozawa O,
Yasuda M, Deguchi T. Decreased affinity of mosaic-structure recombinant penicillin-binding protein 2
for oral cephalosporins in Neisseria gonorrhoeae. J Antimicrob Chemother. 2007;60:54-60.
19㧕 Goto T, Nakano M, Ito S, Ehara H, Yamamoto N, Deguchi T. Significance of an E-cadherin genepromoter polymorphism for risk and disease severity of prostate cancer in a Japanese population.
Urology. 2007;70:127-130.
20㧕 Tanaka O, Hayashi S, Matsuo M, Nakano M, Kubota Y, Maeda S, Ohtakara K, Deguchi T, Hoshi H.
Comparison of urethral diameters for calculating the urethral dose after permanent prostatebrachytherapy. Radiat Med. 2007;25:329-334.
21㧕 Yokoi S, Maeda S, Kubota Y, Tamaki M, Mizutani K, Yasuda M, Ito S, Nakano M, Ehara H, Deguchi T.
The role of Mycoplasma genitalium and Ureaplasma urealyticum biovar 2 in postgonococcal urethritis.
Clin Infect Dis. 2007;45:866-871.
22㧕 Tanaka O, Hayashi S, Matsuo M, Nakano M, Uno H, Ohtakara K, Miyoshi T, Deguchi T, Hoshi H.
Effect of edema on postimplant dosimetry in prostate brachytherapy using CT/MRI fusion. Int J
Radiat Oncol Biol Phys. 2007;69:614-618.
23㧕 Tanaka O, Hayashi S, Matsuo M, Nakano M, Kubota Y, Maeda S, Ohtakara K, Deguchi T, Hoshi H.
MRI-based preplanning in low-dose-rate prostate brachytherapy. Radiother Oncol. 2008;88:115-120.
24㧕 Yokoi S, Deguchi T, Ozawa T, Yasuda M, Ito S, Kubota Y, Tamaki M, Maeda S. Threat to cefixime
treatment for gonorrhea. Emerg Infect Dis. 2007;13:1275-1277.
25㧕 Mizutani K, Nagata KI, Ito H, Ehara H, Nozawa Y, Deguchi T. Possible Roles of Vinexinbeta in Growthand Paclitaxel Sensitivity in Human Prostate Cancer PC-3 Cells. Cancer Biol Ther. 2007;6:1800-1804.
26㧕 Mizutani K, Ehara H, Yokoi S, Phuoc NB, Deguchi T, Hirose Y. Treatment-related ureteral cancer
following stage II testicular seminoma. Int J Clin Oncol. 2007;12:469-471.
27㧕 Kubota Y, Kawai A, Tsuchiya T, Kozima K, Yokoi S, Deguchi T. Bilateral primary malignant lymphomaof the ureter. Int J Clin Oncol. 2007;12:482-484.
28㧕 Mizokami A, Ueno S, Fukagai T, Ito K, Ehara H, Kinbara H, Origasa H, Usami M, Namiki M, Akaza H.
Global update on defining and treating high-risk localized prostate cancer with leuprorelin: an Asian
perspective. BJU Int. 2007;99 Suppl 1:6-9.
29㧕 Kubota Y, Kamei S, Ehara H, Takahashi Y, Deguchi T. Anterior urethral valve in the fossa navicularispresenting as a sprit urinary stream in a child. Hinyokika Kiyo. 2008;54:135-138.
30㧕 Uno H, Nakano M, Ehara H, Deguchi T. Indications for extended 14-core transrectal
ultrasound-guided prostate biopsy. Urology. 2008;71:23-27.
31㧕 Ochiai S, Ishiko H, Yasuda M, Deguchi T. Rapid detection of the mosaic structure of the Neisseria
gonorrhoeae penA Gene, which is associated with decreased susceptibilities to oral cephalosporins. J
Clin Microbiol. 2008;46:1804-1810.
32㧕 Kubota Y, Kamei S, Nakano M, Ehara H, Deguchi T, Tanaka O. The potential role of prebiopsy
magnetic resonance imaging combined with prostate-specific antigen density in the detection of
prostate cancer. Int J Urol. 2008;15:322-326; discussion 327.
33㧕 Goto T, Nguyen BP, Nakano M, Ehara H, Yamamoto N, Deguchi T. Utility of Bcl-2, P53, Ki-67, andcaveolin-1 immunostaining in the prediction of biochemical failure after radical prostatectomy in a
Japanese population. Urology. 2008;72:167-171.
34㧕 Moriyama Y, Miwa K, Tanaka H, Fujihiro S, Nishino Y, Deguchi T. Nocturia in men less than 50 yearsof age may be associated with obstructive sleep apnea syndrome. Urology. 2008;71:1096-1098.
35㧕 Kojima K, Ohhashi R, Fujita Y, Hamada N, Akao Y, Nozawa Y, Deguchi T, Ito M. A role for SIRT1 incell growth and chemoresistance in prostate cancer PC3 and DU145 cells. Biochem Biophys Res
Commun. 2008;373:423-428.
36㧕 Moriyama Y, Minamidate Y, Yasuda M, Ehara H, Kikuchi M, Tsuchiya T, Deguchi T, Tsurumi H. Acuterenal failure due to bilateral ureteral stone impaction in an HIV-positive patient. Urol Res.
2008;36:275-277.
37㧕 Phuoc NB, Ehara H, Gotoh T, Nakano M, Kamei S, Deguchi T, Hirose Y. Prognostic value of theco-expression of carbonic anhydrase IX and vascular endothelial growth factor in patients with clear
cell renal cell carcinoma. Oncol Rep. 2008;20:525-530.
38㧕 Deguchi T, Yasuda M, Maeda S. Lack of nationwide surveillance of antimicrobial resistance of
Neisseria gonorrhoeae in Japan. Ann Intern Med. 2008;149:363-364.
39㧕 Fujita Y, Kojima K, Hamada N, Ohhashi R, Akao Y, Nozawa Y, Deguchi T, Ito M. Effects of miR-34a on
cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun.
2008;377:114-119.

㧙㧙

IF 0.769

IF 2.928

IF 4.038

IF 2.134

IF 6.750

IF 4.290
IF 4.074
IF 5.755
IF 2.873

IF 2.751

IF 2.134

IF 3.708

IF 0.769

IF 2.134
IF 2.134

IF 2.749

IF 1.385

IF 1.597
IF 15.516

IF 2.749

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦દ⮮ᘕ৻㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦⣢⒖ᬀߦ߅ߌࠆᕆᕈᜎ⛘෻ᔕߩ࡝ࠕ࡞࠲ࠗࡓቯ㊂⊛ PCR ᴺࠍ↪޿ߚᣧᦼ⸻ᢿᴺߩ⏕┙㧧ᐔᚑ 16㧙18 ᐕᐲ㧧2,500 ජ౞(1,400㧦800㧦
300 ජ౞)2㧕 ⎇ⓥઍ⴫⠪㧦દ⮮ᘕ৻㧘⎇ⓥಽᜂ⠪㧦಴ญ 㓉㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦CD8 KOࡑ࠙ࠬߢߩห⒳⊹⤏⒖ᬀ ߩᜎ⛘෻ᔕߩࠛࡈࠚࠢ࠲࡯⚦⢩ߩหቯ㧧ᐔᚑ 19㧙20 ᐕᐲ㧧5,000 ජ౞(2,800㧦2,200 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦ዊፉ࿻ᄥ㇢㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦೨┙⣼≸⚦⢩ߦ߅ߌࠆ⮎೷⠴ᕈᯏᐨߩ⸃᣿㧧ᐔᚑ 20㧙21 ᐕᐲ㧧3,900 ජ౞(2,600㧦1,300 ජ౞)
2㧕ฃ⸤⎇ⓥ1㧕 ಴ญ 㓉㧦DU-6859a ╙Υ⋧⥃ᐥ⹜㛎㧙ⶄ㔀ᕈዩ〝ᗵᨴ∝ࠍኻ⽎ߣߒߚੑ㊀⋤ᬌ↪㊂Ყセ⹜㛎㧙㧧ᐔᚑ 17㧙18 ᐕᐲ㧧3,806,712 ౞㧦╙৻⵾⮎㧔ᩣ㧕
2㧕 ಴ญ 㓉㧦YM617 ╙Υ⋧⹜㛎㧔↵ᕈ㧕㧧ᐔᚑ 17㧙18 ᐕᐲ㧧3,036,384 ౞㧦ࠕࠬ࠹࡜ࠬ⵾⮎㧔ᩣ㧕
3㧕 ಴ญ 㓉㧦YM617 ╙Υ⋧⹜㛎㧔ᅚᕈ㧕㧧ᐔᚑ 17㧙18 ᐕᐲ㧧4,956,120 ౞㧦ࠕࠬ࠹࡜ࠬ⵾⮎㧔ᩣ㧕
4㧕 ಴ญ 㓉㧦YP-18 ߩⶄ㔀ᕈዩ〝ᗵᨴ∝ࠍኻ⽎ߣߒߚ⥃ᐥ╙Υ⋧⹜㛎㧙ࠝ࡯ࡊࡦ࡜ࡌ࡞ᄙᣉ⸳౒ห⹜
㛎㧙㧧ᐔᚑ 17㧙18 ᐕᐲ㧧2,895,984 ౞㧦ᄢᱜንጊක⮎ຠ㧔ᩣ㧕
5㧕 ಴ญ 㓉㧦YP-18 ߩᢌⴊ∝࡮ᗵᨴᕈᔃౝ⤑Ἳࠍኻ⽎ߣߒߚ⥃ᐥ╙Υ⋧⹜㛎㧙ࠝ࡯ࡊࡦ࡜ࡌ࡞ᄙᣉ⸳
౒ห⹜㛎㧙㧧ᐔᚑ 17㧙18 ᐕᐲ㧧1,998,360 ౞㧦ᄢᱜንጊක⮎ຠ㧔ᩣ㧕
6㧕 ಴ญ 㓉㧦CS-023 ╙Τ⋧⹜㛎-ⶄ㔀ᕈዩ〝ᗵᨴ∝ࠍኻ∝ߣߒߚ৻⥸⹜㛎-㧧ᐔᚑ 18 ᐕᐲ㧧1,260,000౞㧦ਃ౒㧔ᩣ㧕7㧕 ಴ญ 㓉㧦ࡊࡠࠣ࡜ࡈࠞࡊ࠮࡞᦭ኂ੐⽎⹦⚦⺞ᩏ㧧ᐔᚑ 18 ᐕᐲ㧧42,000 ౞㧦ࠕࠬ࠹࡜ࠬ⵾⮎㧔ᩣ㧕8㧕 ಴ญ 㓉㧦DR-3355 ߩⶄ㔀ᕈዩ〝ᗵᨴ∝ࠍኻ∝ߣߒߚ৻⥸⹜㛎㧔╙Υ⋧㧕㧧ᐔᚑ 18㧙20 ᐕᐲ㧧
1,486,800 ౞㧦╙৻⵾⮎㧔ᩣ㧕
9㧕 ಴ญ 㓉㧦ࡃ࠶ࡊࡈࠜ࡯․ቯ૶↪ᚑ❣⺞ᩏ㧔ᱷዩ㊂ࠍᜰᮡߣߒߚ᦭↪ᕈߩᬌ⸛㧕㧧ᐔᚑ 18㧙19 ᐕᐲ㧧
315,000 ౞㧦ᄢ㢈⮎ຠᎿᬺ㧔ᩣ㧕
10㧕 ಴ญ 㓉㧦ࡊࡠࠣ࡜ࡈࠞࡊ࠮࡞᦭ኂ੐⽎⹦⚦⺞ᩏ㧧ᐔᚑ 18㧙19 ᐕᐲ㧧21,000 ౞㧦ࠕࠬ࠹࡜ࠬ⵾⮎㧔ᩣ㧕11㧕 ಴ญ 㓉㧦࡝ࡘ࡯ࡊ࡝ࡦ SR ᵈ኿↪ 11.25mg ․ቯ૶↪ᚑ❣⺞ᩏ㧧ᐔᚑ 19㧙21 ᐕᐲ㧧945,000 ౞㧦ᱞ↰⮎ຠᎿᬺ㧔ᩣ㧕12㧕 ಴ญ 㓉㧦ࡃࠪ࡝ࠠࠪࡑࡉ෸߮ࠬ࠹ࡠࠗ࠼೷ࠍ૬↪ߔࠆᣂⷙᚑੱ⣢⒖ᬀᖚ⠪ࠍኻ⽎ߣߒߡᷫ㊂ࡀࠝ࡯࡜࡞ߣ૬↪ߒߚࠛࡌࡠ࡝ࡓࠬ㧔ⴊਛỚᐲߦၮߠ߈ᛩਈ㊂ࠍ⺞ᢛߔࠆ㧕ߣᮡḰ㊂ࡀࠝ࡯࡜࡞ߣ૬↪
ߒߚࡒࠦࡈࠚࡁ࡯࡞㉄ࡕࡈࠚ࠴࡞ߩ᦭ലᕈ෸߮቟ోᕈࠍᲧセߔࠆ㧘12 ࡩ᦬㧘ᄙᣉ⸳౒ห㧘࡜ࡦ࠳ࡓൻ㧘ࠝ࡯ࡊࡦ࡜ࡌ࡞⹜㛎㧧ᐔᚑ 19㧙22 ᐕᐲ㧧1,990,800 ౞㧦ࡁࡃ࡞࠹ࠖࠬࡈࠔ࡯ࡑ㧔ᩣ㧕
13㧕 ಴ญ 㓉㧦ࡌࠪࠤࠕ㍤૶↪ᚑ❣⺞ᩏ㧧ᐔᚑ 19㧙21 ᐕᐲ㧧105,000 ౞㧦ࠕࠬ࠹࡜ࠬ⵾⮎㧔ᩣ㧕
14㧕 ಴ญ 㓉㧦࡝ࠩࡌࡦ೽૞↪⹦⚦⺞ᩏ㧧ᐔᚑ 20 ᐕᐲ㧧21,000 ౞㧦ࠠ࠶࠮ࠗ⮎ຠᎿᬺ㧔ᩣ㧕
15㧕 ಴ญ 㓉㧦ࡃ࠶ࡊࡈࠜ࡯․ቯ૶↪ᚑ❣⺞ᩏ гૐኈ㊂ 10 mg/ᣣ 㐿ᆎ଀ߦ߅ߌࠆ᦭↪ᕈߩᬌ⸛г㧧ᐔᚑ 19㧙20 ᐕᐲ㧧 315,000 ౞㧦ᄢ㢈⮎ຠᎿᬺ㧔ᩣ㧕
16㧕 ಴ญ 㓉㧦ࠝ࡯ࠕࠗࠛࡈ․ቯ૶↪ᚑ❣⺞ᩏ㧔⊹ਅᵈ㧕㧧ᐔᚑ 19㧙20 ᐕᐲ㧧94,500 ౞㧦ᄢႦ⵾⮎㧔ᩣ㧕
17㧕 ಴ญ 㓉㧦DC-159a ߩ Mycoplasma genitalium ߦኻߔࠆ᛫⩶ᵴᕈߩ⹏ଔ㧧ᐔᚑ 20㧙21 ᐕᐲ㧧
2,310,000 ౞㧦╙৻ਃ౒㧔ᩣ㧕
18㧕 ಴ญ 㓉㧦ࠢ࡜ࡆ࠶࠻㍤࡮⚦☸ ․ቯ૶↪ᚑ❣⺞ᩏ‫ޟ‬ዩ〝ᗵᨴ∝ߩਥⷐේ࿃⩶ߩฦ⒳᛫⩶⮎ߦኻߔࠆᗵฃᕈᬌ⸛‫ޠ‬㧧ᐔᚑ 20 ᐕᐲ㧧315,000 ౞㧦╙৻ਃ౒㧔ᩣ㧕
19㧕 ಴ญ 㓉㧦ࡀࠢࠨࡃ࡯࡞㍤ ․ቯ૶↪ᚑ❣⺞ᩏ㧔㐳ᦼ૶↪㧕㧧ᐔᚑ 20㧙22 ᐕᐲ㧧157,500 ౞㧦ࡃࠗࠛ࡞⮎ຠ㧔ᩣ㧕
20㧕 ಴ญ 㓉㧦ࠬ࡯࠹ࡦ࠻ࠞࡊ࠮࡞ 12.5 mg ․ቯ૶↪ᚑ❣⺞ᩏ г‫ޟ‬⣢⚦⢩≸ߦኻߔࠆ⺞ᩏ‫ޠ‬г㧧ᐔᚑ
20㧙24 ᐕᐲ㧧378,000 ౞㧦ࡈࠔࠗࠩ࡯㧔ᩣ㧕
3㧕౒ห⎇ⓥߥߒ㧙㧙5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬ಴ญ 㓉㧦
1㧕 ᣣᧄᴲዩེ⑼ቇળ⋙੐(㨪⃻࿷)2㧕 ᣣᧄൻቇ≮ᴺቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄൻቇ≮ᴺቇળ⷏ᣣᧄᡰㇱᐙ੐(㨪⃻࿷)4㧕 ᣣᧄᕈᗵᨴ∝ቇળℂ੐(㨪⃻࿷)5㧕 ᣣᧄᗵᨴ∝ቇળ⹏⼏ຬ(㨪⃻࿷)6㧕 ዩ〝ᗵᨴ∝⎇ⓥળᐙ੐(㨪⃻࿷)7㧕 ᣣᧄᴲዩེ⑼ቇળ᧲ᶏ࿾ᣇળㆇ༡ᆔຬ㐳(㨪⃻࿷)8㧕 ᴲዩེ⑼ಽሶ࡮⚦⢩⎇ⓥળ਎⹤ੱ(㨪⃻࿷)9㧕 ᧲ᶏࠬ࠻࡯ࡑ࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦ⎇ⓥળ਎⹤ੱ(㨪⃻࿷)10㧕 J-POPS ㆇ༡ᆔຬ(㨪⃻࿷)ᳯේ⧷ବ㧦1㧕 ᣣᧄᴲዩེ⑼ቇળࡏ࡯࠺ࠖࡦࠣࡔࡦࡃ࡯(㨪⃻࿷)2㧕 ᧲ᶏ⣻⤑ㅘᨆ⎇ⓥળ਎⹤ੱ(㨪⃻࿷)3㧕 ᴲዩེಽሶ࡮⚦⢩⎇ⓥળ⹏⼏ຬ(㨪⃻࿷)4㧕 ጘ㒂⋵ㅘᨆ≮ᴺ⎇ⓥળቇⴚᆔຬ(㨪⃻࿷)5㧕 ᧲ᶏࠬ࠻࡯ࡑ࡮࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦ⎇ⓥળ਎⹤ੱ(㨪⃻࿷)દ⮮ᘕ৻㧦1㧕 ᣣᧄᴲዩེ⑼ቇળࡏ࡯࠺ࠖࡦࠣࡔࡦࡃ࡯(㨪⃻࿷)2㧕 ᣣᧄ⒖ᬀቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ⣢⒖ᬀⴊ▤ᄖ⑼⎇ⓥળ਎⹤ੱ(㨪⃻࿷)ખ㊁ᱜඳ㧦
1㧕 ᣣᧄᴲዩེ⑼ቇળࡏ࡯࠺ࠖࡦࠣࡔࡦࡃ࡯(㨪⃻࿷)2㧕 ᣣᧄ Endourology࡮ESWL ቇળ⹏⼏ຬ(㨪⃻࿷)ᮮ੗❥᣿㧦1㧕 ᣣᧄᴲዩེ⑼ቇળࡏ࡯࠺ࠖࡦࠣࡔࡦࡃ࡯(㨪⃻࿷)2㧕 ᣣᧄ Endourology࡮ESWL ቇળ⹏⼏ຬ(㨪⃻࿷)቟↰ ḩ㧦
1㧕 ᣣᧄᴲዩེ⑼ቇળࡏ࡯࠺ࠖࡦࠣࡔࡦࡃ࡯(㨪⃻࿷)2㧕 ᣣᧄൻቇ≮ᴺቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄᕈᗵᨴ∝ቇળ⹏⼏ຬ(ᐔᚑ 17 ᐕ 12 ᦬㨪⃻࿷)
4㧕 ᣣᧄൻቇ≮ᴺቇળ᛫⩶⮎⥃ᐥ⹏ଔࠟࠗ࠼࡜ࠗࡦᡷቯᆔຬળᆔຬ(㨪⃻࿷)5㧕 ᣣᧄൻቇ≮ᴺቇળࠨ࡯ࡌࠗ࡜ࡦࠬᆔຬળᆔຬ(㨪⃻࿷)6㧕 ᣣᧄൻቇ≮ᴺቇળ UTI ⮎ല⹏ଔၮḰ⷗⋥ߒߩߚ߼ߩᆔຬળᆔຬ(㨪⃻࿷)2㧕ቇળ㐿௅಴ญ 㓉㧦
1㧕 ╙ 234 ࿁ᣣᧄᴲዩེ⑼ቇળ᧲ᶏ࿾ᣇળ(ᐔᚑ 18 ᐕ 12 ᦬㧘ฬฎደ)2㧕 ╙ 241 ࿁ᣣᧄᴲዩེ⑼ቇળ᧲ᶏ࿾ᣇળ(ᐔᚑ 20 ᐕ 9 ᦬㧘ฬฎደ)
3㧕ቇⴚ㔀⹹಴ญ 㓉㧦
1㧕 ᴲዩེ⑼♿ⷐ㧧✬㓸ᆔຬ(㨪⃻࿷)㧙㧙2㧕 Int. J. Urol.㧦Editor(㨪⃻࿷)቟↰ ḩ㧦
1㧕 ᣣᧄᕈᗵᨴ∝ቇળ㧧✬㓸ᆔຬ(㨪⃻࿷)2㧕 ᣣᧄൻቇ≮ᴺቇળ㧧✬㓸ᆔຬ(ᐔᚑ 20 ᐕ㨪⃻࿷)7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳಴ญ 㓉㧦
1㧕 ╙ 56 ࿁ᣣᧄᴲዩེ⑼ቇળਛㇱ✚ળ(ᐔᚑ 18 ᐕ 10 ᦬㧘ฬฎደ㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ‫ޟ‬අߩᚻⴚ࡮ᧂ᧪ߩ   ᛛ‫ޠ‬ᐳ㐳)
2㧕 ╙ 56 ࿁ᣣᧄᴲዩེ⑼ቇળਛㇱ✚ળ(ᐔᚑ 18 ᐕ 10 ᦬㧘ฬฎደ㧘ࠨ࠹࡜ࠗ࠻ࠪࡦࡐࠫ࠙ࡓ 2‫ޟ‬ㄭᧂ᧪⊛೨┙⣼≸ኻ╷‫ޠ‬ᐳ㐳)
3㧕 ╙ 341 ࿁ᣣᧄᴲዩེ⑼ቇળᣂẟ࿾ᣇળ(ᐔᚑ 19 ᐕ 3 ᦬㧘ᣂẟ㧘․೎⻠Ṷ‫⮎ޟ‬೷⠴ᕈ⩶ߪߎ߁ߒߡ಴
⃻ߔࠆ㧙ዩ〝ᕈེᗵᨴ∝ߩ႐ว㧙‫ޠ‬Ṷ⠪)
4㧕 ╙ 95 ࿁ᣣᧄᴲዩེ⑼ቇળ✚ળ(ᐔᚑ 19 ᐕ 4 ᦬㧘␹ᚭ㧘තᓟᢎ⢒ࡊࡠࠣ࡜ࡓ‫ޟ‬ዩ〝ᕈེᗵᨴ∝—᛫⩶೷૶↪ࠟࠗ࠼࡜ࠗࡦߦᴪߞߚ᛫⩶೷ߩ૶޿ᣇ- ᕈེᗵᨴ∝‫ޠ‬Ṷ⠪)
5㧕 ╙ 111 ࿁ᣣᧄ⌒⑼ቇળ✚ળ ኾ㐷೎⎇ⓥળ ╙ 8 ࿁⌒⑼ DNA ࠴࠶ࡊ⎇ⓥળ(ᐔᚑ 19 ᐕ 4 ᦬㧘ᄢ㒋㧘․೎⻠Ṷ‫ޟ‬ᗵᨴ∝ߩㆮવሶ⸻ᢿ —ዩ〝ᕈེᗵᨴ∝ߢߩᔕ↪—‫ޠ‬Ṷ⠪)
6㧕 ᣣᧄᕈᗵᨴ∝ቇળ╙ 20 ࿁ቇⴚᄢળ(ᐔᚑ 19 ᐕ 12 ᦬㧘᧲੩㧘ᢎ⢒࠮ࡒ࠽࡯‫ޟ‬Mycoplasma genitaliumᗵᨴ∝ߩ update‫ޠ‬Ṷ⠪)7㧕 ╙ 58 ࿁ᣣᧄᴲዩེ⑼ቇળਛㇱ✚ળ(ᐔᚑ 20 ᐕ 11 ᦬㧘ṑ⾐㧘․೎⻠Ṷ‫ޟ‬ᴲዩེ⑼⣲≌ߦ߅ߌࠆ PET↹௝⸻ᢿߩᓎഀ‫ޠ‬ᐳ㐳)દ⮮ᘕ৻㧦
1㧕 ╙ 56 ࿁ᣣᧄᴲዩེ⑼ቇળਛㇱ✚ળ(ᐔᚑ 18 ᐕ 10 ᦬㧘ฬฎደ㧘⎇ୃක࡮කቇ↢ߩߚ߼ߩᢎ⢒࠮ࡒ࠽࡯‫৻╙ޣ‬ㇱ‫ޟޤ‬ノߊ⥄ಽࠍ⷗ߟߌࠃ߁‫ޠ‬Ṷ⠪)
ખ㊁ᱜඳ㧦
1㧕 ╙ 56 ࿁ᣣᧄᴲዩེ⑼ቇળਛㇱ✚ળ(ᐔᚑ 18 ᐕ 10 ᦬㧘ฬฎደ㧘⎇ୃක࡮කቇ↢ߩߚ߼ߩᢎ⢒࠮ࡒ࠽࡯‫৻╙ޣ‬ㇱ‫ޟޤ‬ノߊ⥄ಽࠍ⷗ߟߌࠃ߁‫ޠ‬Ṷ⠪)
2㧕 ╙ 235 ࿁ᣣᧄᴲዩེ⑼ቇળ᧲ᶏ࿾ᣇળ(ᐔᚑ 19 ᐕ 3 ᦬㧘ฬฎደ㧘․೎ડ↹‫ޟ‬㒢ዪᕈ೨┙⣼≸㧔T1c orT2)࡛࠙⚛ 125 ኒኽዊ✢Ḯ᳗ਭᝌ౉≮ᴺ‫ޠ‬Ṷ⠪㧕
3㧕 ╙ 236 ࿁ᣣᧄᴲዩེ⑼ቇળ᧲ᶏ࿾ᣇળ(ᐔᚑ 19 ᐕ 6 ᦬㧘ฬฎደ㧘․೎ડ↹‫ޟ‬ૐ࡝ࠬࠢ⟲ߦኻߔࠆኒ
ኽዊ✢Ḯ᳗ਭᝌ౉≮ᴺߩᚑ❣‫ޠ‬Ṷ⠪)
4㧕 ╙ 242 ࿁ᣣᧄᴲዩེ⑼ቇળ᧲ᶏ࿾ᣇળ(ᐔᚑ 20 ᐕ 12 ᦬㧘ฬฎደ㧘․೎ડ↹‫ޟ‬ಽሶᮡ⊛ᴦ≮ᤨઍߩㅴⴕᕈ⣢≸ᴦ≮ ࠰࡜ࡈࠚ࠾ࡉ߇᦭ലߢ޽ߞߚᄙ⊒ォ⒖ߩ 1 ଀‫ޠ‬Ṷ⠪)ᮮ੗❥᣿㧦
1㧕 ╙ 56 ࿁ᣣᧄᴲዩེ⑼ቇળਛㇱ✚ળ(ᐔᚑ 18 ᐕ 10 ᦬㧘ฬฎደ㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ‫ޟ‬අߩᚻⴚ࡮ᧂ᧪ߩ
ᛛ‫ޠ‬‫ޟ‬HoLEP ዉ౉ߦ㓙ߒߡߩᛛ‫ޠ‬Ṷ⠪)
2㧕 ╙ 95 ࿁ᣣᧄᴲዩེቇળ✚ળ(ᐔᚑ 19 ᐕ 4 ᦬㧘␹ᚭ㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ ⣻⣧㏜ᚻⴚ⧯ᚻ⸛⺰ળ‫ޟ‬⣻⣧㏜࠻࡟࡯࠾ࡦࠣ‫ޠ‬Ṷ⠪)቟↰ ḩ㧦
1㧕 ᣣᧄᕈᗵᨴ∝ቇળ ╙ 19 ࿁ቇⴚᄢળ(ᐔᚑ 18 ᐕ 12 ᦬㧘㊄ᴛ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᕈᗵᨴ∝೙࿶ߦะߌ
ߡ㧦⥃ᐥකቇ߆ࠄߩࠕࡊࡠ࡯࠴‫ޟޠ‬ᕈᗵᨴ∝೙࿶ߦะߌߡߩࠊࠇࠊࠇߩขࠅ⚵ߺߦߟ޿ߡ‫✼ޠ‬⠪)2㧕 ╙ 95 ࿁ᣣᧄᴲዩེ⑼ቇળ✚ળ(ᐔᚑ 19 ᐕ 4 ᦬㧘␹ᚭ㧘තᓟᢎ⢒ࡊࡠࠣ࡜ࡓ‫ޟ‬ዩ〝ᕈེᗵᨴ∝㧙᛫⩶೷૶↪ࠟࠗ࠼࡜ࠗࡦߦᴪߞߚ᛫⩶೷ߩ૶޿ᣇ㧙 ዩ〝ᕈེᗵᨴ∝‫ޠ‬Ṷ⠪)
3㧕 ᣣᧄᕈᗵᨴ∝ቇળ╙ 20 ࿁ቇⴚᄢળ(ᐔᚑ 19 ᐕ 12 ᦬㧘᧲੩㧘ᢎ⢒࠮ࡒ࠽࡯‫ޟ‬ᶷ⩶㧘ࠢ࡜ࡒࠫࠕ㧘ࡑࠗࠦࡊ࡜࠭ࡑߩ᜛ᄢ㒐ᱛ╷‫ޠ‬Ṷ⠪)
4㧕 ᣣᧄᕈᗵᨴ∝ቇળ╙ 20 ࿁ቇⴚᄢળ(ᐔᚑ 19 ᐕ 12 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬Უሶု⋥ᗵᨴߩ੍㒐 ᶷ⩶ᗵᨴ∝‫ޠ‬Ṷ⠪)
5㧕 ╙ 241 ࿁ᣣᧄᴲዩེ⑼ቇળ᧲ᶏ࿾ᣇળ(ᐔᚑ 20 ᐕ 9 ᦬㧘ฬฎደ㧘․೎ડ↹‫♧ޟ‬ዩ∛ߣᴲዩེ⑼∔ᖚ㧙㧙೨┙⣼↢ᬌߣ♧ዩ∛‫ޠ‬Ṷ⠪)
6㧕 ╙ 49 ࿁ᄢ㖧⸻ᢿකቇᬌᩏቇળ(ᐔᚑ 20 ᐕ 10 ᦬㧘Korea㧘Industry-Sponsored Lecture & Dinner‫ޟ‬The criteria for evaluation of clinical efficacy of antimicrobial agents on urinary tract infection– The diagnosis of urinary tract infections -‫ޠ‬Speaker)
7㧕 ╙ 26 ࿁ᣣᧄࠢ࡜ࡒࠫࠕ⎇ⓥળ㧘╙ 15 ࿁࡝ࠤ࠶࠴ࠕ⎇ⓥળวห⎇ⓥ⊒⴫ળ(ᐔᚑ 20 ᐕ 11 ᦬㧘ጘ㒂㧘ࡕ࡯࠾ࡦࠣ࠮ࡒ࠽࡯‫⥃ޟ‬ᐥߦ߅ߌࠆࠢ࡜ࡒࠫࠕᕈዩ㆏Ἳߩ⸻ᢿ࡮ᴦ≮ߩታ㓙‫ޠ‬Ṷ⠪)8㧕 ╙ 58 ࿁ᣣᧄᴲዩེ⑼ቇળਛㇱ✚ળ(ᐔᚑ 20 ᐕ 11 ᦬㧘ṑ⾐㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯‫ޟ‬ዩ㆏Ἳᴦ≮ߦ߅ߌࠆ໧㗴ὐߣߘߩ⸃᳿╷ г㕖ᶷ⩶ᕈዩ㆏Ἳࠍਛᔃߣߒߡ‫ޠ‬Ṷ⠪)9㧕 11th Western Pacific Congress on Chemotherapy and Infectious Disease(ᐔᚑ 20 ᐕ 12 ᦬, Taiwan,
Symposium: Management of Complicated UTI, Complex Renal Infection; Symposist)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേ಴ญ 㓉㧦
1㧕 ጘ㒂⋵り૕㓚ኂ⠪කቇ⊛್ቯབྷ⸤කᏧ(㨪⃻࿷)2㧕 ጘ㒂⋵ᗵᨴ∝੍㒐ኻ╷ࠛࠗ࠭ኻ╷ㇱળᆔຬ(㨪⃻࿷)3㧕 ጘ㒂⋵೨┙⣼߇ࠎᬌ⸻ኾ㐷ᆔຬળᆔຬ㐳(㨪⃻࿷)4㧕 ጘ㒂⋵ࠫࡦ࡮ࠕࠗࡃࡦࠢදળ೽ℂ੐㐳(㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ಴ญ 㓉㧦ዩ〝࡮ᕈེᗵᨴ∝∛ේᓸ↢‛ߩㄦㅦ߆ߟ൮᜝⊛ㆮવሶ⸻ᢿࠪࠬ࠹ࡓߩ㐿⊒㧦ᐔᚑ 16 ᐕᐲ㧙ᐔᚑ 17 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)⎇ⓥᚑᨐႎ๔ᦠ㧦1㧙45(2006 ᐕ 3 ᦬)
11㧚ႎ㆏
1㧕 ಴ญ 㓉㧘⷏㊁ᅢೣ㧘Ⴧᩕቁሶ㧘㜞ᧁኡᴦ㧦ㆊᵴേ⣾⢲ߩ⸻ᢿߣᴦ≮㧦Medical Tribune(2007 ᐕ 1
᦬)2㧕 ಴ญ 㓉㧦⚕਄⸻ኤቶ PSA 㜞ߊ೨┙⣼೥ࠆᬌᩏ൘߼ࠄࠇ㧦ਛᣣᣂ⡞(2007 ᐕ 2 ᦬ 16 ᣣ)
3㧕 ಴ญ 㓉㧦ឃዩ㓚ኂኻ╷ࠍ⚫੺㧦ጘ㒂ᣂ⡞(2007 ᐕ 6 ᦬ 12 ᣣ)
4㧕 ⩵ᳰ ⾫㧘Ỉ᧛ᱜਯ㧘಴ญ 㓉㧘ự⍾⦟৻㧘ዊᨋኑ༁㧦ᐳ⺣ળ ᕈᗵᨴ∝ߩ໧㗴ὐߣᬌᩏቶߩኻᔕ㧦
BioScan (2008 ᐕ)
5㧕 ᚭႦᕶ৻㧘᧻ᧄືᦶ㧘಴ญ 㓉㧦ᐳ⺣ળ ᴲዩེ⑼㗔ၞߦ߅ߌࠆࠠࡁࡠࡦ♽⮎ߩᦨㆡߥᛩਈᴺߣߪ㧦
Medical Tribune (2008 ᐕ 8 ᦬ 14 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔዩ〝ᕈེᗵᨴ∝ߩಽ㊁ߢߪ㧘వㅴ⊛ߥ⎇ⓥᚑᨐࠍ޽ߍࠆߎߣ߇ߢ߈ߡ߅ࠅ⹏ଔࠍฃߌߡ޿ࠆ‫ߒ߆ߒޕ‬ߥ߇ࠄ㧘ઁߩ⎇ⓥ⺖㗴ߦ߅޿ߡߪ⌕ታߦ⎇ⓥߪㅴⴕߒߡ޿ࠆ߽ߩߩ㧘ᚑᨐߣߒߡߪ޽ࠄࠊࠇߡ߅ࠄߕࠃ
ࠅ৻ጀߩദജࠍⷐߔࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ᦨᄢߩ໧㗴ὐߪ㑐ㅪᣉ⸳߽฽߼ߚੱຬਇ⿷ߢ޽ࠆ‫ߦࠄߐޕ‬㧘ᣂ∛㒮߳ߩ⒖ォᓟߩ⥃ᐥᵴേߩ࠙ࠚࠗ࠻
߇Ⴧߒߚߎߣߦ઻ߞߡ㧘⋉‫⎇ޘ‬ⓥߦഀߌࠆຬᢙߣᤨ㑆ߦᓇ㗀߇಴ߡ޿ࠆ‫ޕ‬හലᕈߩ޽ࠆኻᔕ╷ߪߥߊ㧘߹ߚ㧘ᒰಽ㊁ߛߌߩ໧㗴ߢߪߥ޿ߣ⠨߃ߡ޿ࠆ‫ޕ‬ᒰಽ㊁ߣߒߡߪ㧘એ೨ߦ߽Ⴧߒߡᧄቇකቇㇱ↢෸߮ઁᄢቇߩቇ↢ߦⓍᭂ⊛ߦࠕࡇ࡯࡞ߒ㧘⇐ቇ↢߿ቇᄖડᬺ߆ࠄߩ␠ળੱᄢቇ
㒮↢ࠍⓍᭂ⊛ߦฃ౉ࠍⴕߞߡ޿ࠆ‫ޕ‬੹ᓟߩዷᦸ
1㧕ዩ〝↢ᱺེ⣲≌ߩᴦ≮ߣ੍ᓟߦ㑐ߔࠆၮ␆⊛࡮⥃ᐥ⊛⎇ⓥ
ዩ〝↢ᱺེ≸ߦ߅ߌࠆㆮવሶᄌ⇣ߩ൮᜝⊛ߥ⹏ଔߣߘߩ⥃ᐥᔕ↪ࠍ⋡ᜰߔ‫ޕ‬
2㧕ዩ〝ᗵᨴ∝ߩၮ␆⊛࡮⥃ᐥ⊛⎇ⓥ⃻࿷ߩ⎇ⓥࠍㅴ߼㧘߹ߚ㧘ㆮવሶ⸃ᨆߦࠃࠆ⮎೷ᗵฃᕈ್ቯᴺߩ㐿⊒ࠍ⋡ᜰߔ‫ߩࠄࠇߎޕ‬ၮ␆⊛⎇ⓥ㧙㧙ᚑᨐߦၮߠ޿ߚㆡᱜߥ᛫⩶ൻቇ≮ᴺߩ⏕┙ࠍ⋡ᜰߔ‫ޕ‬
3㧕↵ሶዩ㆏Ἳߩၮ␆⊛࡮⥃ᐥ⊛⎇ⓥ
ዩ㆏Ἳߩ∛ේᓸ↢‛ߩ⸃᣿ࠍߐࠄߦㅴ߼ࠆߣߣ߽ߦ㧘ዩ㆏Ἳߦኻߔࠆㆡᱜߥ᛫⩶ൻቇ≮ᴺߩ⏕┙ࠍ⋡ᜰߔ‫ޕ‬4㧕⣢⒖ᬀߦ߅ߌࠆ⥃ᐥ⊛⎇ⓥ
఺∉ᛥ೙೷ߩㆡᱜ૶↪ߩ⏕┙ߣ⒖ᬀ⣢ߩ㐳ᦼᯏ⢻⛽ᜬࠍ⋡ᜰߔ‫ޕ‬
5㧕㏜ⷞਅᚻⴚᚻᛛߩ㐿⊒⎇ⓥᣂߚߥᛛⴚ߅ࠃౕེ߮㧘ེ᧚ߩ㐿⊒ߦࠃࠅ㧘㏜ⷞਅᚻⴚߩㆡᔕߩ᜛ᄢࠍ⋡ᜰߔ‫ޕ‬㧙㧙㧔7㧕㤗㈮࡮−∩೙ᓮቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
㤗㈮࡮−∩೙ᓮቇಽ㊁ߩਥߥ⎇ⓥ⺖㗴ߪ㧘⥃ᐥ㤗㈮ߩ቟ోᕈߣ㔍ᴦᕈ−∩ᴦ≮ߩ㐿⊒ߣࠍਥ⌒ߦ⟎޿ߚ
⎇ⓥߢ޽ࠆ‫ޕ‬෻኿ᕈߩ๭ๆᓴⅣ෻ᔕߣ⣖⣄㜑ߩᓸዊᓴⅣ߆ࠄ๟ⴚᦼߩ⣖଻⼔ߦ㑐ߔࠆ⍮⷗ߩ෼㓸߿㧘㤗㈮ߣ−∩ߩࠪࠣ࠽࡞વ㆐ᯏ᭴ߣߘߩ೙ᓮ㧘㔍ᴦᕈ−∩ߩࡔࠞ࠾࠭ࡓࠍࠝࡇࠝࠗ࠼㧘ǩ2 ࠕࠧ࠾ࠬ࠻㧘Ion
transporter ╬ߩ⣄㜑㎾∩ᯏ᭴ࠍ⸃᣿ߔࠆၮ␆⊛⎇ⓥࠍⴕߞߡ߅ࠅ㧘એਅߩࠃ߁ߦ߹ߣ߼ࠆߎߣ߇ߢ߈ࠆ‫ޕ‬
1㧕㤗㈮࡮ଚⷅਛߩ๭ๆ࡮ᓴⅣ෻ᔕᕈ෻ᔕߦ㑐ߔࠆ⥃ᐥ⊛⎇ⓥ
2㧕⣖࡮⣄㜑ᓴⅣߦኻߔࠆ㤗㈮෸߮ߘߩ㑐ㅪ⮎ߦ㑐ߔࠆ⎇ⓥ
3㧕−∩೙ᓮᯏ᭴ߩ␹⚻ൻቇ⊛⎇ⓥߣ㤗㈮⮎㧘ࠝࡇࠝࠗ࠼㧘ǩ2 ࠕࠧ࠾ࠬ࠻ K+࠴ࡖࡀ࡞㐿ญ⮎㧘ࠗࠝࡦ࠻࡜ࡦࠬࡐ࡯࠲࡯㧘NSAIDs ߥߤߩ૞↪ᯏᐨߦ㑐ߔࠆ⎇ⓥ
ㆊ෰ 10 ᐕ㑆㧘⑼ቇ⎇ⓥ⾌ߩ㈩ಽࠍฃߌ㧘㗡⬄ౝ෸߮⣄㜑⣧ౝ᦭⓹ᴺࠍ↪޿ߡ㧘⣖෸߮⣄㜑ߩᓸዊᓴⅣ
ߦኻߔࠆ㤗㈮⮎ߘߩઁߩ૞↪ᯏᐨߦ㑐ߔࠆᵴ⊒ߥ⎇ⓥࠍⴕ޿㧘ᦨㄭߪ⥃ᐥ߹ߢ઀੐ߩ᏷ࠍᐢߍߡ߈ߚ‫ࠝޕ‬ࡇࠝࠗ࠼㧘ǩ2 ࠕࠧ࠾ࠬ࠻ K+࠴ࡖࡀ࡞㐿ญ⮎㧘ࠗࠝࡦ࠻࡜ࡦࠬࡐ࡯࠲࡯ߥߤߩ⣄㜑㎾∩ᯏ᭴߳ߩᓇ㗀ߦኻߔࠆᣂߒ޿⍮⷗߽ᄙߊߥߞߡ߈ߚ‫ߚ߹ޕ‬㧘ࡄ࠶࠴ࠢ࡜ࡦࡊᴺࠍ↪޿ߡ㧘⣄㜑ᓟᩮ⚦⢩ߩ Na+࠴ࡖࡀ࡞߳
ߩ૞↪㧘K+࠴ࡖࡀ࡞㧘޽ࠆ޿ߪዪᚲ㤗㈮⮎߿㎾∩⵬ഥ⮎ߩࠪࠣ࠽࡞ಽሶᯏ᭴߳ߩ૞↪߽ᬌ⸛ߒ㧘ࠕࡐ࠻࡯ࠪࠬࠍ⺃⊒ߔࠆߎߣ߽᣿ࠄ߆ߦߒߚ‫ޕ‬2㧚ฬ★
࿯⢈ ୃมᢎ᝼㧦㘵↰ ብ᮸ಎᢎ᝼㧦┻ਛ రᐽ⻠Ꮷ㧦ᄢ⇗ ඳੱ
⻠Ꮷ㧦
㐳ἑ ᷡ
⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦 ↰ㄝ ਭ⟤ሶ⥃ᐥ⻠Ꮷ㧦 ㆏㊁ ᦮ᵗ⥃ᐥ⻠Ꮷ㧦 ᧖ጊ 㓁ሶ⥃ᐥ⻠Ꮷ㧦 ᾢỈ ᣽ᒾ⥃ᐥ⻠Ꮷ㧦 ᩉ⥪ ን⟤㣐⷗ ๺ⴕ
කຬ㧦
ጊญ ᔋ
කຬ㧦
㘵↰ ⟤♿
කຬ㧦⑔ጟ ዏ๺කຬ㧦ችᧄ ⌀♿
කຬ㧦
ධ ౏ੱ
කຬ㧦
㋈ᧁ ෹Ꮧකຬ㧦ਛ᧛ ᅢ⟤
කຬ㧦

Shuji Dohi
Hiroki Iida
Motoyasu Takenaka
Hiroto Ohata
Kiyoshi Nagase
Kumiko Tanabe
Tomohiro Michino
Yoko Sugiyama
Masahiko Kumazawa
Fumi Yanagidate
Kazuyuki Sumi
Shinobu Yamaguchi
Miki Iida
Naokazu Fukuoka
Maki Miyamoto
Kimito Minami
Yuki Suzuki
Yoshimi Nakamura

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ࿯⢈ୃม㧘ઁ౒⪺㧚8. 㤗㈮ߣ⣖␹⚻ᯏ⢻㧦ᄤ⠀ᢘ␭⋙ୃ㧚㤗㈮⑼ቇ࡟ࡆࡘ࡯2006ᦨᣂਥⷐᢥ₂㓸㧘᧲੩㧦✚วකቇ␠㧧2006 ᐕ㧦46㧙55㧚
2㧕 ࿯⢈ୃม㧘ઁ౒⪺㧚9. 㤗⮎㧛ⷡ㉕೷㧛⣕ᴺ࠼࡜࠶ࠣ ࡔ࠲ࡦࡈࠚ࠲ࡒࡦ㧦㤥Ꮉ㗼✬㧚ਛᲥ∝ߩߔߴߡ޿
ߑߣ޿߁ᤨߦᓎ┙ߟ‫ߥ⏕⊛ޔ‬ᴦ≮ߩߚ߼ߦ㧘᧲੩㧦᳗੗ᦠᐫ㧧2006 ᐕ㧦385㧚
3㧕 ࿯⢈ୃม✬⪺㧚Σ-01 㤗㈮⑼࠹ࠢ࠾࠶ࠢߩ቟ోߥᣉⴕߩߚ߼ߩේೣ㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦14㧙15㧚
4㧕 ࿯⢈ୃม✬⪺㧚Σ-03 㤗㈮⑼⸘↹ߩታ㓙㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006ᐕ㧦18㧙19㧚
5㧕 ࿯⢈ୃม✬⪺㧚Σ-04 ᖚ⠪࡮ኅᣖ߳ߩ⺑᣿࡮หᗧᦠขᓧ㧔ࠗࡦࡈࠜ࡯ࡓ࠼ࠦࡦ࠮ࡦ࠻㧕ߩ࠹ࠢ࠾࠶ࠢ㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦20㧙21㧚
6㧕 ࿯⢈ୃม✬⪺㧚Σ-05 㤗㈮ེߩၮᧄ᭴ㅧߣ㤗㈮ߩḰ஻㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦22㧙23㧚
7㧕 ࿯⢈ୃม✬⪺㧚Σ-09 㤗㈮ਛߩ૕ᶧ࡮ઍ⻢▤ℂߩ࠹ࠢ࠾࠶ࠢ㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦30㧙31㧚
8㧕 ࿯⢈ୃม✬⪺㧚Σ-10 ∝଀ࡊ࡟࠯ࡦ࠹࡯࡚ࠪࡦߩ࠹ࠢ࠾࠶ࠢ㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦32㧙33㧚㧙㧙

9㧕 ࿯⢈ୃม✬⪺㧚Τ-01 ࡑࠬࠢ࡮ࡃ࠶ࠢ↪ᚻ឵᳇ߩࠦ࠷㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦34㧙35㧚
10㧕 ࿯⢈ୃม✬⪺㧚Τ-09 ᗧ⼂ൻᝌ▤㧔awake intubation㧕,᳇㆏㤗㈮㧘TTI㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦50㧙51㧚
11㧕 ࿯⢈ୃม✬⪺㧚Υ-01 ㉄⚛ᛩਈ㧔⚻ญ㧘⚻㥦㧘⚻᳇▤㧕ߩᣇᴺ㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦56㧙57㧚
12㧕 ࿯⢈ୃม✬⪺㧚Υ-09 NG ࠴ࡘ࡯ࡉߩᝌ౉࠹ࠢ࠾࠶ࠢ㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦74㧙75.
13㧕 ࿯⢈ୃม✬⪺㧚Υ-11 㤗㈮࿁ᓳߩ⹏ଔ㧔࡝ࠞࡃ࡝࡯ࠬࠦࠕ‫ࠢ࠶ࠚ࠴ޔ‬㗄⋡㧘ౣᝌ▤ߩㆡᔕ㧕㧦ࠗ࡜ࠬ࠻ߢ
ࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦78㧙79.
14㧕 ࿯⢈ୃม✬⪺㧚Φ-01 ᧃ᪳㕒⣂ࠞ࠹࡯࠹࡞ߩ⇐⟎㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦80㧙81.
15㧕 ࿯⢈ୃม✬⪺㧚Φ-02 ౝ㗪㕒⣂ࠞ࠹࡯࠹࡞ᝌ౉㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧
2006 ᐕ㧦84㧙85.
16㧕 ࿯⢈ୃม✬⪺㧚Χ-01 ࡞࡯࠴ࡦࡕ࠾࠲࡯㧔ᔃ㔚࿑㧘SpO2㧘ⴊ࿶㧕㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦94㧙95.
17㧕 ࿯⢈ୃม✬⪺㧚Χ-04 ᳇㆏ౝ࿶㧘๭᳇ੑ㉄ൻ὇⚛Ớᐲ㧔ETCO2㧕ߩ⹏ଔ㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦100㧙101.
18㧕 ࿯⢈ୃม✬⪺㧚Χ-05 േ࡮㕒⣂ⴊࠟࠬᖱႎߩ⹏ଔ㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦102㧙103.
19㧕 ࿯⢈ୃม✬⪺㧚Χ-10 㤗㈮ਛߩ⣖࡮␹⚻ᯏ⢻ߩࡕ࠾࠲࡯ D)⥄ᓞ␹⚻ᵴേ⹏ଔߩ࠹ࠢ࠾࠶ࠢ㧦ࠗ࡜ࠬ࠻ߢ
ࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦126㧙127.
20㧕 ࿯⢈ୃม✬⪺㧚Ω-02 ⎬⤑ᄖ㤗㈮㧦⓫ೝߣࠞ࠹࠹࡝ࠩ࡯࡚ࠪࡦާࡄ࡜ࡔ࠺ࠕࡦ‫ޔ‬ᄖ஥ᴺ‫ޔ‬ᱜਛᴺ㧔ᛶ᛫‫ޔ‬ࡃ࡞࡯ࡦ‫ޔ‬᳓Ṣ㧕ި㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦154㧙155㧚
21㧕 ࿯⢈ୃม✬⪺㧚Ω-03 㗪ㇱ⎬⤑ᄖ⣧⓫ೝߣࠞ࠹࡯࠹࡞ߩᝌ౉㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦156㧙157㧚
22㧕 ࿯⢈ୃม✬⪺㧚Ϊ-01 ∩ߺߩቯ⟵ߣ−∩વ㆐⚻〝㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦168㧙169.
23㧕 ࿯⢈ୃม✬⪺㧚Ϊ-02 ∩ߺߩ⹏ଔߣㆬᛯ⊛␹⚻ࡉࡠ࠶ࠢߦࠃࠆ⹏ଔ㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦170㧙171.
24㧕 ࿯⢈ୃม✬⪺㧚Ϊ-09 ߇ࠎᖚ⠪ߩ−∩▤ℂ࠹ࠢ࠾࠶ࠢ A)ၮᧄ㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦186㧙187.
25㧕 ࿯⢈ୃม✬⪺㧚Ϊ-12 ᤊ⁁␹⚻▵ࡉࡠ࠶ࠢ㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006
ᐕ㧦194㧙195.
26㧕 ࿯⢈ୃม✬⪺㧚Ϊ-29 ࠗࠝࡦ࠻ࡈࠜ࡟࡯ࠪࠬ㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧
2006 ᐕ㧦228㧙229.
27㧕 ࿯⢈ୃม✬⪺㧚Ϋ-02 ᖡᔃ࡮ཌྷฯߩ੍㒐ߣᴦ≮㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧
2006 ᐕ㧦234㧙235.
28㧕 ࿯⢈ୃม✬⪺㧚Ϋ-03 ⴚᓟૐ㉄⚛ⴊ∝㧔᳇㆏㐽Ⴇ㧘╭ᒆ✭⮎ߩᱷሽ㧕㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦236㧙237.
29㧕 ࿯⢈ୃม✬⪺㧚Ϋ-10 ⢖ⴊᩖႧᩖ∝ߩ੍㒐ߩ࠹ࠢ࠾࠶ࠢ㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦252㧙253㧚
30㧕 ࿯⢈ୃม✬⪺㧚ά-06 ૕ᶧ࡮㔚⸃⾰⇣Ᏹߩ⵬ᱜ࠹ࠢ࠾࠶ࠢ㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦270㧙271㧚
31㧕 ࿯⢈ୃม✬⪺㧚ά 㤗㈮ਛ߿✕ᕆᤨߩᬌᩏߩၮḰ୯ߣࡄ࠾࠶ࠢ୯৻ⷩ㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦277㧚
32㧕 㘵↰ብ᮸㧚Σ-07 ๆ౉㤗㈮ᴺߩ࠹ࠢ࠾࠶ࠢ㧦࿯⢈ୃม✬㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦26㧙27㧚
33㧕 㘵↰ብ᮸㧚Ω-05 ㅘⷞਅࠞ࠹࡯࠹࡝࠯࡯࡚ࠪࡦߩ࠹ࠢ࠾࠶ࠢ㧦࿯⢈ୃม✬㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦160㧙161㧚
34㧕 㘵↰ብ᮸㧚Ϊ-11 ␹⚻ࡉࡠ࠶ࠢߩዪᚲ㤗㈮࡮ࠬ࠹ࡠࠗ࠼࡮␹⚻⎕უ⮎࡮ಝ࿕ᾲ㧦࿯⢈ୃม✬㧚ࠗ࡜ࠬ࠻ߢ
ࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦192㧙193.
35㧕 㘵↰ብ᮸㧚Ϊ-15 ਃ෷␹⚻ࡉࡠ࠶ࠢ㧔ࠟ࠶࠮࡞␹⚻▵ࡉࡠ࠶ࠢ㧕㧦࿯⢈ୃม✬㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦200㧙201.
36㧕 㘵↰ብ᮸㧚Ϊ-15 ਃ෷␹⚻ࡉࡠ࠶ࠢ㧔਄࡮ਅ㗶␹⚻ࡉࡠ࠶ࠢ㧕㧦࿯⢈ୃม✬㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ
㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦202㧙203.
37㧕 㘵↰ብ᮸㧚Ϊ-22 ᬁ㑆㑐▵㧔ࡈࠔ࠮࠶࠻㧕ࡉࡠ࠶ࠢ㧦࿯⢈ୃม✬㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦214㧙215.
38㧕 㘵↰ብ᮸㧚Ϋ-11 Anticoagulant ᖚ⠪߳ߩᴦ≮࠹ࠢ࠾࠶ࠢ㧦࿯⢈ୃม✬㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦254㧙255㧚
39㧕 㘵↰ብ᮸㧘ጊญᔋ㧚╙ 3 ┨㧚⎬⤑ᄖ㤗㈮ B.4.⎬⤑ᄖ㤗㈮ᓟ⣶⢛ㇱ∩ߩ․ᓽߣኻ╷㧦ጤፒኡઁ✬㧚ߎߎ߇ࡐࠗࡦ࠻ 㤗㈮ᚻᛛ਄㆐ߩࠦ࠷㧘᧲੩㧦ධᳯၴ㧧2006 ᐕ㧦237㧙239㧚
40㧕 㘵↰ብ᮸㧚╙ 3 ┨㧚⎬⤑ᄖ㤗㈮ B.5.⎬⤑ᄖ㤗㈮ᓟߩ⎬⤑ᄖ⣧ߩⴊ⣲࡮⤥≌ᒻᚑᤨߩ∝⁁ߣኻ╷㧦ጤፒኡ㧙㧙ઁ✬㧚ߎߎ߇ࡐࠗࡦ࠻ 㤗㈮ᚻᛛ਄㆐ߩࠦ࠷㧘᧲੩㧦ධᳯၴ㧧2006 ᐕ㧦240㧙243㧚
41㧕 㘵↰ብ᮸㧚20.⥃ᐥ㤗㈮ߩ⇼໧ߦ╵߃ࠆ↢ℂቇ I㧚⣖␹⚻ 7.㤗㈮ߢ⣖ⴊᵹߣ⣖ઍ⻢ࠍࠦࡦ࠻ࡠ࡯࡞ߢ߈ࠆ
߆㧦㜞ᯅ⌀ᑿ✬㧚㤗㈮⑼⸻≮ࡊ࡜ࠢ࠹ࠖࠬ㧘᧲੩㧦ᢥశၴ㧧2006 ᐕ㧦48㧙51㧚
42㧕 ┻ਛరᐽ㧚Τ-07 ༄㗡㏜ߩ⒳㘃㧘࠻࡜ࠠ࡜ࠗߩㆡᔕ㧦࿯⢈ୃม✬㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦46㧙47.
43㧕 ┻ਛరᐽ㧚Ϊ-24 ⢷ㇱற⣄ᬁࡉࡠ࠶ࠢ㧔thoracic paravertebral block㧕㧦࿯⢈ୃม✬㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ
㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦218㧙219.
44㧕 ┻ਛరᐽ㧚Ϊ-25 ⢷ㇱ੤ᗵ␹⚻ࡉࡠ࠶ࠢ㧦࿯⢈ୃม✬㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦220㧙221.
45㧕 ┻ਛరᐽ㧚Ϊ-26 ⣶ㇱ੤ᗵ␹⚻▵ࡉࡠ࠶ࠢ㧦࿯⢈ୃม✬㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦222㧙223.
46㧕 ᄢ⇗ඳੱ㧚Σ-02 ᖚ⠪⹏ଔߣ㤗㈮⸘↹㧦࿯⢈ୃม✬⪺㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦16㧙17㧚
47㧕 ᄢ⇗ඳੱ㧚Υ-08
⢖឵᳇ߩ࠹ࠢ࠾࠶ࠢ㧔ಽ㔌⢖឵᳇ߩ࠹ࠢ࠾࠶ࠢ㧕㧦࿯⢈ୃม✬㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦70㧙71.
48㧕 ᄢ⇗ඳੱ㧚Ϋ-06 ᔃ╭⯯ⴊ⊒૞㧦࿯⢈ୃม✬㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧
2006 ᐕ㧦242㧙243.
49㧕 ↰ㄝਭ⟤ሶ㧚Υ-03 㤗㈮⮎ߩㆬᛯ㧦࿯⢈ୃม✬㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧
2006 ᐕ㧦60㧙61.
50㧕 㐳ἑ ᷡ㧚Χ-08 ⚻㘩㆏ᔃࠛࠦ࡯ࡊࡠ࡯ࡉߩᝌ౉ߣᔃᯏ⢻ߩ⹏ଔߩ࠹ࠢ࠾࠶ࠢ㧦࿯⢈ୃม✬㧚ࠗ࡜ࠬ࠻ߢ
ࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦1114㧙1115.
51㧕 㐳ἑ ᷡ㧚Χ-09 ௯ᚱᑯ‫ޔ‬ᄢേ⣂ᑯ‫ޔ‬Ꮐቶ‫ޔ‬ᄢേ⣂ߩᯏ⢻⹏ଔ㧦࿯⢈ୃม✬㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ
㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦1116㧙117.
52㧕 ㆏㊁᦮ᵗ㧚Χ-03 ૕᷷ߩ᷹ቯߣ૕᷷⛽ᜬߩ࠹ࠢ࠾࠶ࠢ㧦࿯⢈ୃม✬㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦98㧙99.
53㧕 ᄢỈ㓁ሶ㧚Τ-08 ㄦㅦ᳇▤ౝᝌ▤㧔with cricoid pressure Columbia㧕㧦࿯⢈ୃม✬㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦48㧙49.
54㧕 ᄢỈ㓁ሶ㧚Ψ-02 ⢈ḩᖚ⠪ߩ㤗㈮㧦࿯⢈ୃม✬㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧
2006 ᐕ㧦132㧚
55㧕 ᾢᴛ᣽ᒾ㧚Τ-04 ⚻㥦ᝌ▤㧦࿯⢈ୃม✬⪺㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006ᐕ㧦40㧙41㧚
56㧕 ᩉ⥪౷⟤㧚Σ-06 㤗㈮೨ᛩ⮎ߣߘߩ⹏ଔ㧦࿯⢈ୃม✬㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦24㧙25㧚
57㧕 ᫜ᯅ㊀⡡㧚Ψ-07 ᔃ⤳∔ᖚ㧔㐿ᔃⴚ㧕㧦࿯⢈ୃม✬⪺㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦142㧙144㧚
58㧕 ᧻ᧄ⨃⟤㧚Ϊ-20 ⢋↲⁁␹⚻ࡉࡠ࠶ࠢ㧦࿯⢈ୃม✬㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦210㧙211.
59㧕 ᧻ᧄ⨃⟤㧚Ϊ-21 ⡻㑆␹⚻ࡉࡠ࠶ࠢ㧦࿯⢈ୃม✬⪺㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦212㧙213.
60㧕 ጊญ ᔋ㧚Ω-08 㐽㎮␹⚻ࡉࡠ࠶ࠢ‫ޔ‬ᄢ⣽␹⚻ࡉࡠ࠶ࠢ㧦࿯⢈ୃม✬⪺㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦166㧙167㧚
61㧕 ጊญᔋ㧚Ϊ-18 ᓟ㗡␹⚻ࡉࡠ࠶ࠢ㧦࿯⢈ୃม✬㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧
2006 ᐕ㧦206㧙207.
62㧕 㣐⷗๺ⴕ㧚࿯⢈ୃม✬⪺㧚Ϊ-17 ᵻㇱ࡮ᷓㇱ㗪␹⚻ฌࡉࡠ࠶ࠢ㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦204㧙205.
63㧕 㘵↰⟤♿㧚࿯⢈ୃม✬⪺㧚Φ-02 േ⣂ౝࠞ࠹࡯࠹࡞ߩ⇐⟎ߣ࡜ࠗࡦߩ▤ℂ㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦82㧙83.
64㧕 ⑔ጟዏ๺㧚࿯⢈ୃม✬⪺㧚Τ-10 ࠳ࡉ࡞࡞࡯ࡔࡦ࠴ࡘ࡯ࡉߩᝌ౉㧔ฝ࡮Ꮐ㧕㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ
㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦52㧙53.
65㧕 ⑔ጟዏ๺㧚࿯⢈ୃม✬⪺㧚Ϋ-01 ༄㗡∨ᡨ࡮᳇▤ᡰ∨ᡨ㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦232㧙233.
66㧕 ᳗ဈ↱♿ሶ㧚࿯⢈ୃม✬⪺㧚Ϋ-04 ᧃ᪳␹⚻㓚ኂ㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦238㧙239.
67㧕 ↰ญ૫ᐢ㧚࿯⢈ୃม✬⪺㧚Τ-03 ⚻ญᝌ▤ (฽߻࠴ࡘ࡯ࡉߩㆬᛯ) 㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦38㧙39.
68㧕 ᴡ᧛ਃජ㚅㧚࿯⢈ୃม✬⪺㧚Τ-02 ࠛࠕ࠙ࠛࠗ㧔⚻ญ‫⚻ޔ‬㥦㧕ߩᝌ౉㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦36㧙37.
69㧕 ࿯⢈ୃม㧚1.ᘟᕈ∩ߪߥߗ⿠ߎࠆߩ߆㧦⷏ጟਭኼ᮸✬㧚✢⛽╭∩∝ࡂࡦ࠼ࡉ࠶ࠢ 2 ┨ ၮ␆㧘᧲੩㧦ᣣᧄක੐ᣂႎ␠㧧2007 ᐕ㧦14㧙25㧚
70㧕 㘵↰ብ᮸㧘㣐⷗๺ⴕ㧚ࡍࠗࡦࠢ࡝࠾ࠪࡖࡦߩߚ߼ߩ∩ߺ⸻≮ߩࠦ࠷ߣ⪭ߣߒⓣ㧦ችፒ᧲ᵗ✬㧚቟ోߢ⧰∩ߩዋߥ޿⣶ㇱ␹⚻ᩮࡉࡠ࠶ࠢߩᎿᄦ,᧲੩㧦ਛጊᦠᐫ㧧2007 ᐕ㧦146㧙148.
71㧕 㐳ἑᷡ㧘㜞Ⴆ⋥⢻㧘♿ࡁቯ଻⤿㧘ጊᧄ⋿↱⟤㧚ᕆᕈᦼ∛㒮⚻༡ߦ߅ߌࠆᚻⴚㇱࡑࡀࠫࡔࡦ࠻․ቯᯏ⢻∛㒮ᚻⴚቶߩࠤ࡯ࠬ㧘᧲੩㧦⚻ᷣ↥ᬺ⋭ක≮⚻༡ੱ᧚⢒ᚑࠤ࡯ࠬᢎ᧚㐿⊒ࡊࡠࠫࠚࠢ࠻㧧2007 ᐕ㧦1㧙58㧚㧙㧙72㧕 ࿯⢈ୃม㧚․㓸ߦ޽ߚߞߡߪߓ߼ߡߩ㤗㈮⑼⎇ୃ㧦ች࿾⦟᮸✬㧚⥃ᐥ⎇ୃࡊ࡜ࠢ࠹ࠖࠬ 5 Ꮞ㧘᧲੩㧦ᢥశၴ㧧2008 ᐕ㧦5.
73㧕 ᄢ⇗ඳੱ㧚ᚻⴚᖚ⠪ߩ⹏ଔߣ㤗㈮ࡊ࡜ࡦߩ૞ᚑߩࡐࠗࡦ࠻㧦ች࿾⦟᮸✬㧚⥃ᐥ⎇ୃࡊ࡜ࠢ࠹ࠖࠬ 5 Ꮞ㧘᧲੩㧦ᢥశၴ㧧2008 ᐕ㧦6㧙14.
74㧕 ᄢ⇗ඳੱ㧚ᚻⴚᖚ⠪ߩ⹏ଔߣ㤗㈮ࡊ࡜ࡦߩ૞ᚑߩࡐࠗࡦ࠻㧙ࡒ࠾࡟ࠢ࠴ࡖ࡯ ᵈᗧߔߴ߈∔ᖚ࡮ᖚ⠪㧦ች࿾⦟᮸✬㧚⥃ᐥ⎇ୃࡊ࡜ࠢ࠹ࠖࠬ 5 Ꮞ㧘᧲੩㧦ᢥశၴ㧧2008 ᐕ㧦15㧚
75㧕 ᄢ⇗ඳੱ㧚ᚻⴚᖚ⠪ߩ⹏ଔߣ㤗㈮ࡊ࡜ࡦߩ૞ᚑߩࡐࠗࡦ࠻㧙ࡒ࠾࡟ࠢ࠴ࡖ࡯ ✕ᕆᚻⴚߩ㤗㈮ࠍᚻવ߁
㧦ች࿾⦟᮸✬㧚⥃ᐥ⎇ୃࡊ࡜ࠢ࠹ࠖࠬ 5 Ꮞ㧘᧲੩㧦ᢥశၴ㧧2008 ᐕ㧦16㧙17㧚
76㧕 㘵↰⟤♿㧚㕒⣂〝࡮േ⣂〝ߩ⏕଻㧦ࠬࡑ࡯࠻ߥࠕࡊࡠ࡯࠴㧦ች࿾⦟᮸✬㧚⥃ᐥ⎇ୃࡊ࡜ࠢ࠹ࠖࠬ 5 Ꮞ㧘᧲੩㧦ᢥశၴ㧧2008 ᐕ㧦28㧙33㧚
77㧕 ࿯⢈ୃม㧚᳇㆏࡮๭ๆ▤ℂߩታ㓙ߣࠦ࠷㧦ች࿾⦟᮸✬㧚⥃ᐥ⎇ୃࡊ࡜ࠢ࠹ࠖࠬ 5 Ꮞ㧘᧲੩㧦ᢥశၴ㧧2008ᐕ㧦36㧙46㧚78㧕 ㆏㊁᦮ᵗ㧚ች૕૏ߪߤ߁ߔࠆ㧫㧦࿾⦟᮸✬㧚⥃ᐥ⎇ୃࡊ࡜ࠢ࠹ࠖࠬ 5 Ꮞ㧘᧲੩㧦ᢥశၴ㧧2008 ᐕ㧦49㧙
51㧚
79㧕 Ⴧᳯ㆐ᒾ㧚ᓴⅣ▤ℂ㧔ⴊ࿶ૐਅ‫ޔ‬ഥ⣂߳ߩኻᔕ㧕ߩታ㓙㧦ች࿾⦟᮸✬㧚⥃ᐥ⎇ୃࡊ࡜ࠢ࠹ࠖࠬ 5 Ꮞ㧘᧲੩㧦ᢥశၴ㧧2008 ᐕ㧦52㧙55㧚
80㧕 ᾢỈ᣽ᒾ㧚૕ᶧ࡮ઍ⻢▤ℂߩታ㓙ߣࠦ࠷㧦ች࿾⦟᮸✬㧚⥃ᐥ⎇ୃࡊ࡜ࠢ࠹ࠖࠬ 5 Ꮞ㧘᧲੩㧦ᢥశၴ㧧2008ᐕ㧦58㧙61㧚81㧕 㣐⷗๺ⴕ㧚⎬⤑ᄖ㤗㈮ߩታ㓙ߣࠦ࠷㧦ች࿾⦟᮸✬㧚⥃ᐥ⎇ୃࡊ࡜ࠢ࠹ࠖࠬ 5 Ꮞ㧘᧲੩㧦ᢥశၴ㧧2008 ᐕ㧦
76㧙79㧚
⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 ࿯⢈ୃม㧚−∩ࠪࠣ࠽࡞વ㆐ߣ೙ᓮᯏ᭴㧘Pharma Medica 2006 ᐕ㧧6 Ꮞ㧦25㧙30㧚
2㧕 ࿯⢈ୃม㧚ߪߓ߼ߦ㧘කቇߩ޽ࠁߺ 2008 ᐕ㧧225 Ꮞ㧦985㧚
3㧕 ࿯⢈ୃม㧚㤗㈮ਛߩⷡ㉕ߣᄞ㧘කቇߩ޽ࠁߺ 2008 ᐕ㧧225 Ꮞ㧦1023㧙1028㧚
4㧕 ࿯⢈ୃม㧚㤗㈮⑼ቇߩㆊ෰࡮⃻࿷࡮ㄭᧂ᧪́ቇⴚߩㅴᱠߣ㤗㈮⑼ක≮ߩዷ㐿́㧘㤗㈮ 2008 ᐕ㧧57 Ꮞ㧔Ⴧೀ㧕
㧦S1㧙S7㧚
5㧕 㘵↰ብ᮸㧘ઁ౒⪺㧚᧻ᨐ૕∛ᄌߦኻߔࠆ infratentorial supracerebellar approach, No Shinkei Geka 2007
ᐕ㧧35 Ꮞ㧦453㧙466㧚
6㧕 㘵↰ብ᮸㧚⣖㧔⣄㜑㧕⯯ⴊߩᴦ≮ߣ㤗㈮́㤗㈮⮎߅ࠃ߮㤗㈮㑐ㅪ⮎ߣ⣖⣄㜑ⴊ▤́㧘⯃↢㧘᧲੩ 2008 ᐕ㧧
27 Ꮞ㧧106㧙117㧚
7㧕 㘵↰ඳ᮸㧚㤗㈮⑼කߪߤߎ߹ߢ⤳ེ଻⼔ߦ㑐ਈߢ߈ࠆ߆㧫́⣄㜑଻⼔ߦ㑐ߒߡ́㧘ᣣᧄ⥃ᐥ㤗㈮ቇળ⹹
2008 ᐕ㧧೎ౠ㧦599㧙607㧚
✚⺑㧔᰷ᢥ㧕
1㧕 Iida H, Iida M. Effects of spinal analgesics on spinal circulation the safety standpoint. J Neurosurg
Anesthesiol Rev. 2008;20:180-187.
ේ⪺㧔๺ᢥ㧕
1㧕 ጊญᔋ㧘┻ਛరᐽ㧘⑔ጟዏ๺㧘᫜ᯅ㊀⡡㧘㘵↰ብ᮸㧘࿯⢈ୃม㧚ਛᔃ㕒⣂ࠞ࠹࡯࠹࡞⇐ᗧଐ㗬∝଀ߢ⿠߈ߚࠗࡦࠪ࠺ࡦ࠻ߦኻߔࠆ㤗㈮⑼ᄖ᧪ߢߩኻᔕ㧘ᣣᧄ⥃ᐥ㤗㈮ቇળ⹹ 2006 ᐕ㧧26 Ꮞ㧦713㧙717㧚
2㧕 ↰ญ૫ᐢ㧘㘵↰ብ᮸㧘ጊญᔋ㧘㣐⷗๺ⴕ㧘᫜ᯅ㊀⡡㧘┻ਛరᐽ㧘࿯⢈ୃม㧚ᄖ்ᕈ㗪ㇱ∝୥⟲ߦ઻߁㗡ߦ⎬⤑ᄖ⥄Ꮖⴊࡄ࠶࠴߇᦭ലߢ޽ߞߚ 1 ∝଀́⣖⣄㜑ᶧᷫዋ∝ߩ⸻ᢿߦ߅ߌࠆ⎬⤑ᄖ↢ℂ㘩Ⴎ᳓ᵈ౉ߩ᦭ലᕈ́㧘ࡍࠗࡦࠢ࡝࠾࠶ࠢ 2006 ᐕ㧧27 Ꮞ㧦1451㧙1455㧚
3㧕 ᬀᧁ໪ᢥ㧘ዊᎹ⋥ᔒ㧘㘵↰ብ᮸㧚߁ߟ∛ߩᱷㆮ∝⁁ߦኻߒߡ ECT ߇⪺ലߒߚ 1 ଀㧘⥃ᐥ♖␹කቇ 2006
ᐕ㧦35 Ꮞ㧦1195㧙1200.
4㧕 ᄢ⇗ඳੱ㧘࿯⢈ୃม㧚Ⴎ㉄࡜ࠫࠝࡠ࡯࡞㧘ࠢ࡝࠾ࠞ࡞ࡊ࡜ࠢ࠹ࠖࠬ 2007 ᐕ㧧26 Ꮞ㧦62㧙64㧚
5㧕 ᄢ⇗ඳੱ㧘࿯⢈ୃม㧚౰േ⣂∔ᖚᖚ⠪ߦ߅ߌࠆ╭ᒆ✭⮎ߩᜟ᛫㧘Lisa 2007 ᐕ㧧14 Ꮞ㧦460㧙466㧚
6㧕 ᄢ⇗ඳੱ㧘⒳᧛⴩㉿ሶ㧘࿯⢈ୃม㧚㜞↪㊂࠺ࠢࠬࡔ࠺࠻ࡒࠫࡦࠍ↪޿ߚ㕖ᝌ▤࡮⥄⊒๭ๆਅߢߩ࡜࡝ࡦࠧ
ࡑࠗࠢࡠᚻⴚߩ㤗㈮⚻㛎㧘㤗㈮ 2008 ᐕ㧧57 Ꮞ㧦427㧙432㧚
7㧕 ᄢ⇗ඳੱ㧘ጊ↰ᔘೣ㧘࿯⢈ୃม㧚߽߿߽߿∛ᖚ⠪ߩᵻ஥㗡േ⣂́ਛᄢേ⣂่วਛⴚਛߦᕆᕈ⎬⤑ᄖⴊ⣲ࠍ↢ߓߚ 1 ଀㧘㤗㈮ 2008 ᐕ㧧57 Ꮞ㧦755㧙760㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Yanagidate F, Dohi S. Modified nasal cannula for simultaneous oxygen delivery and end-tidal CO 2
monitoring during spontaneous breathing. Eur J Anaesthesiol. 2006;23:257-260.
IF 1.4352㧕 Iida H, Iida M, Takenaka M, Fujiwara H, Dohi S. Angiotensin II type 1 (AT1)-receptor blocker
prevents impairment of endothelium-dependent cerebral vasodilation by acute cigarette smoking inrats. Life Sci. 2006;78:1310-1316.
IF 2.257
3㧕 Tanahashi S,Iida H,Dohi S. An anaphy lactoid reaction after administration of fluorescein sodium㧙㧙during neurosurgery. Anesth Analg. 2006;103:503.
4㧕 Yamakawa H, Yamada K, Sumi K, Iida H, Iwama T. Preoperative assessment of microvascularcompression of cranial nerve IX and X using 3D fast imaging employing steady-state acquisition
resonance imaging in glossopharyngeal neuralgia. Neurosurg Q. 2006;16:166-168.
5㧕 Iida H㧘Iida M㧘Ohata H, Michino T, Dohi S. Effect of dexmedetomidine on cerebral circulation andsystemic hemodynamics after cardiopulmonary resuscitation in dogs. J Anesth. 2006;20:202-207.
6㧕 Tanemura E, Masue T, Sugimoto J, Dohi S. Repetitive acute shock following tracheal extubations after
neurosurgery for a cerebellar tumor. J Anesth. 2006;20:255-256.
7㧕 Tanabe K, Tokuda H, Takai S, Matsushima-Nishiwaki R, Hanai Y, Hirade K, Katagiri Y, Dohi S,
Kozawa O. Modulation by the steroid/thyroid hormone superfamily of TGF-E-stimulated VEGF releasefrom vascular smooth muscle cells. J Cell Biochem. 2006;99:187-195.
8㧕 Oshima T, Kasuya Y, Okumura Y, Murakami T, Dohi S. Identification of independent risk factors forfentany-induced cough. Can J Anesth. 2006;53:753-758.
9㧕 Zeng W, Chen X, Dohi S. Antinociceptive Synergisic Interaction Between Clonidine and Ouabain On
thermal Nociceptive tests in the Rat. J Pain. 2007;8:983-988.
10㧕 Dohi S, Iida M, Iida H, Nagase K, Nagata C. Implementation of smoke-free policy in university
hospital decreases carboxyhemoglobin level in inpatients undergoing surgery. Anesthesiology.
2007;106:406-407.
11㧕 Kumazawa M, Iida H, Uchida M, Iida M, Takenaka M, Dohi S. The comparative effects of intravenous
nicardipine and prostaglandin E1 on the cerebral pial arteriolar constriction seen after unclamping ofan aortic cross-clamp in rabbits. Anesth Analg. 2007;104:659-665.
12㧕 Tanahashi S, Iida H, Oda A, osawa Y, Uchida M, Dohi S. Effects of ifenprodil on valtage-gatedtetrodtoxin-resistant Na+ Channels in rat sensory neurons. Eur J Anaesth. 2007;24:782-788.
13㧕 Miyamoto K, Shimizu K, Matsumoto S, Sumida H, Iida H, Hosoe H. Surgical treatment of scoliosis
assiciated with central core disease: minimizing the effects of malignant hyperthermia withprovocation tests. J Pediatric Orthopaedics B. 2007;16:239-242.
14㧕 Oshima T, Utsunomiya H, Kasuya Y, Sugimoto J, Maruyama K, Dohi S. Identification of independent
predictors for intravenous thiopental-induced yawning. J Anesth. 2007;21:131-135.
15㧕 Takada M, Dohi S, Akamatsu S, Suzuki A. Effects of pericardial lidocaine on hemodynamic
parameters and responses in dogs anesthetized with midazolam and fentanyl. J Cardiothorac vasc
Anesth. 2007;21:393-399.
16㧕 Oda A, Iida H, Tanahashi S, Osawa Y, Yamaguchi S, Dohi S. Effects of alph2 adrenoceptor agonists on
tetrodotoxin-resistant Na channels in rat dorsal root ganglion neurons. Eur J Anaesthesiol.
2007;24:934-941.
17㧕 Tanabe K, Takai S, Matsushima-Nishiwaki, Kato K, Dohi S, Kozawa O. 2 adrenoreceptor agonist
regulates protein kinase C-induced heat shock protein 27 phosphorylation in C6 glioma cells. J
Neurochem. 2008;106:519-528.
18㧕 Iida H, Iida M, Takenaka M, Fukuoka N, Dohi S. Rho-kinase inhibitor and nicotinamide adenine
dinucleotide phosphate oxidase inhibitor prevent impairment of endothelium-dependent cerebral
vasodilation by acute cigarette smoking in rats. J Renin Angiotensin Aldosterone Syst. 2008;9:89-94.
19㧕 Iida H, Iida M, Dohi S, Fukuoka N, Iida M. Preoperative smoking cessation and smoke-free policy in auniversity hospital in Japan. Can J Anaesth. 2008;55:316-318.
20㧕 Sumi K, Iida H, Yamaguchi S, Fukuoka N, Shimabukuro K, Dohi S. Human atrial natriuretic peptide
prevents the increase in pulmonary artery pressure associated with aortic unclamping during
abdominal aortic aneurysmectomy. J Cardiothorac Vasc Anesth. 2008;22:204-209.
21㧕 Kumazawa M, Iida H, Uchida M, Iida M, Fukuoka N, Michino T, Dohi S. The effects of transientcerebral ischemia on vasopressin-induced vasoconstriction in rabbit cerebral vessels. Anesth Analg.
2008;106:910-915.
22㧕 Niinomi K, Banno Y, Iida H, Dohi S. Nicorandil, an Adenosine Triphate-Sensitive Potassium Channel
Opener, Inhibits Muscarinic Acetylcholine Receptor-Mediated Activation of Extracellular
Signal-Regulated Kinases in PC12 Cell. Anesth Analg. 2008;107:1892-1898.
23㧕 Mizuta K, Osawa Y, Mizuta F, Xu D, Emala CW. Functional expression of GABAB receptors in airway
epithelium. Am J Respir Cell Mol Biol. 2008;39:296-304.

IF 2.214

IF 0.073

IF 3.381
IF 1.808
IF 3.578

IF 4.596

IF 2.214
IF 1.435

IF 0.937

IF 1.435

IF 4.451

IF 0.851
IF 1.808

IF 0.937

IF 2.214

IF 2.214
IF 1.1544㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦⿒᧻ ❥(᧻ᵄ✚ว∛㒮)㧘⎇ⓥಽᜂ⠪㧦ዊỈ ୃ㧘࿯⢈ୃม㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦෼ฃߟ߈๟ⴚᦼᔃ╭⯯ⴊᓟߩᔃߩ࡝ࡕ࠺࡝ࡦࠣߦ߅ߌࠆ✢ṁ♽࿃ሶߩᓎഀߣ⥃ᐥ⊛ᗧ⟵㧧ᐔ
ᚑ 17㧙18 ᐕᐲ㧧3,800 ජ౞(2,700㧦1,100 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦㘵↰ብ᮸㧘⎇ⓥಽᜂ⠪㧦㘵↰⌀⟤㧘࿯⢈ୃม㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦࡝ࡕ࡯࠻ࡊ࡟ࠦࡦ࠺࡚ࠖࠪ࠾ࡦࠣߦࠃࠆ⣄㜑଻⼔ᴺߩ⚦⢩ౝࡔࠞ࠾࠭ࡓߣ㑐ㅪ࿃ሶߩ⸃ᨆ㧧ᐔᚑ 18㧙19 ᐕ㧙㧙ᐲ㧧3,100 ජ౞(1,600㧦1,500 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦㐳ἑ ᷡ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ(B)㧦৻ㆊᕈో⣖⯯ⴊᓟߩ⣖ᓸዊᓴⅣ෻ᔕߦኻߔࠆ⣖ૐ૕᷷≮ᴺߩᓇ㗀㧧ᐔᚑ 16㧙17 ᐕᐲ㧧1,800 ජ౞(1,100㧦700 ජ౞)
4㧕 ⎇ⓥઍ⴫⠪㧦࿯⢈ୃม㧘⎇ⓥಽᜂ⠪㧦ᄢỈ㓁ሶ㧘ᩉ⥪ን⟤㧘↰ㄝਭ⟤ሶ㧧⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(A)㧦
㤗㈮⮎ࠪࠣ࠽࡞વ㆐ᯏ᭴ߦ߅ߌࠆ࠽࠻࡝࠙ࡓࠞ࡝࠙ࡓࡐࡦࡊߩᓎഀߣߘߩ᭴ㅧᄌൻߩ⸃ᨆ㧧ᐔᚑ 19
㧙21 ᐕᐲ㧧21,760 ජ౞(8,660㧦6200㧦6900 ජ౞)
5㧕 ⎇ⓥઍ⴫⠪㧦㐳ἑ ᷡ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ(B)㧦৻ㆊᕈో⣖⯯ⴊࡕ࠺࡞ߦ߅ߌࠆ Rho ࠠ࠽࡯࠯㒖ኂ⮎ࡈࠔࠬࠫ࡞ߩ⣖ᓸዊᓴⅣ߳ߩᓇ㗀㧧ᐔᚑ 19㧙21 ᐕᐲ㧧3,650 ජ౞(1,750㧦1,000㧦900 ජ౞)
6㧕 ⎇ⓥઍ⴫⠪㧦ᩉ⥪ን⟤㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ(B)㧦ዪᚲ㤗㈮⮎ߣࠝࡇࠝࠗ࠼ߩ⣄㜑−∩೙ᓮᯏ᭴ߦ
߅ߌࠆ⋧੕૞↪ߩᯏᐨߩ⸃᣿㧧ᐔᚑ 19 ᐕᐲ㧧800 ජ౞7㧕 ⎇ⓥઍ⴫⠪㧦ጊᧄ⌀↱⟤㧘⎇ⓥಽᜂ⠪㧦㐳ἑ ᷡ㧘㜞Ⴆ⋥⢻㧘♿ࡁቯ଻⤿㧧⚻ᷣ↥ᬺ⋭ක≮⚻༡ੱ᧚⢒ᚑ੐ᬺߦ߅ߌࠆࠤ࡯ࠬࠬ࠲࠺ࠖᢎ᧚㐿⊒ࡊࡠࠫࠚࠢ࠻㧧ᐔᚑ 19 ᐕᐲ㧧238 ජ౞8㧕 ⎇ⓥઍ⴫⠪㧦㘵↰⌀⟤㧘⎇ⓥಽᜂ⠪㧦㘵↰ብ᮸㧘࿯⢈ୃม㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦ᔃ⢖⯃↢ᤨߩ⣖଻⼔ߦ߅ߌࠆᕈࡎ࡞ࡕࡦߩᗧ⟵ߣᓎഀ㧙৻ㆊᕈో⣖⯯ⴊࡕ࠺࡞ߢߩᬌ⸛㧙㧧ᐔᚑ 20㧙22 ᐕᐲ㧧3,914 ජ౞(1,814㧦1,100㧦1,000 ජ౞)
9㧕 ⎇ⓥઍ⴫⠪㧦ᄢ⇗ඳੱ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)ࠣ࡞࠲ࡒࡦ㉄ฃኈ૕૞േ⮎ߩ⣖ᓸዊⴊ▤߅ࠃ
߮ AQP-4 ߦਈ߃ࠆᓇ㗀ߦ㑐ߔࠆᬌ⸛㧧ᐔᚑ 20㧙22 ᐕᐲ㧧2,450 ජ౞(1,050㧦700㧦700 ජ౞)
10㧕 ⎇ⓥઍ⴫⠪㧦↰ㄝਭ⟤ሶ㧘⎇ⓥಽᜂ⠪㧦ዊỈ ୃ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦ਛᨔ␹⚻♽ߦ߅ߌࠆ␹⚻଻⼔૞↪ߩಽሶၮ⋚ߩ⸃ᨆ㧧ᐔᚑ 20㧙22 ᐕᐲ㧧4,200 ජ౞(2,500㧦1,000㧦700 ජ౞)
2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫ
1㧕 㘵↰ብ᮸㧦ⴊ▤ౝ⊹ᯏ⢻᷹ቯⵝ⟎㧧ᐔᚑ 20 ᐕ(․㗿 2007́138493)
6㧚ቇળᵴേ
1㧕ቇળᓎຬ࿯⢈ୃม㧦
1㧕 ᣣᧄ㤗㈮⑼ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ⥃ᐥࡕ࠾࠲࡯ቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ⥃ᐥ㤗㈮ቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄ㓸ਛᴦ≮ቇળ⹏⼏ຬ(㨪⃻࿷)5㧕 ᣣᧄ⯃↢ቇળ⹏⼏ຬ(㨪⃻࿷)6㧕 ᣣᧄᓴⅣ೙ᓮකቇળ⹏⼏ຬ(㨪⃻࿷)7㧕 ᣣᧄࡍࠗࡦࠢ࡝࠾࠶ࠢቇળ⹏⼏ຬ(㨪⃻࿷)8㧕 ᣣᧄዪᚲ㤗㈮ቇળ⹏⼏ຬ(㨪⃻࿷)9㧕 ᣣᧄ−∩ቇળ⹏⼏ຬ(㨪⃻࿷)10㧕 ᣣᧄዊఽ㤗㈮ቇળ⹏⼏ຬ(㨪⃻࿷)㘵↰ብ᮸㧦1㧕 ᣣᧄ㤗㈮⑼ቇળઍ⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄࡍࠗࡦࠢ࡝࠾࠶ࠢቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ−∩ቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄ␹⚻㤗㈮㓸ਛᴦ≮⎇ⓥળ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅࿯⢈ୃม㧦
1㧕 ᣣᧄ㤗㈮⑼ቇળ╙ 55 ࿁ቇⴚᄢળ(ᐔᚑ 20 ᐕ 6 ᦬㧘ᮮᵿ)
2㧕 ╙ 11 ࿁ᣣᧄ⣖ૐ᷷≮ᴺቇળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂)㧙㧙┻ਛరᐽ㧦
1㧕 ╙ 19 ࿁᧲ᶏࡍࠗࡦࠢ࡝࠾࠶ࠢ⎇ⓥળ(ᣣᧄࡍࠗࡦࠢ࡝࠾࠶ࠢቇળ᧲ᶏ࿾ᣇળ)(ᐔᚑ 20 ᐕ 5 ᦬㧘ฬฎደ)3㧕ቇⴚ㔀⹹
࿯⢈ୃม㧦
1㧕 Jounal of Anesthesia(ᣣᧄ㤗㈮ቇળ⹹);Editor(㨪⃻࿷)2㧕 Regional Anesthesia & Pain Medicine;Editor(㨪⃻࿷)7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳࿯⢈ୃม㧦
1㧕 ✢⛽╭∩∝ߩ∛࿃࡮∛ᘒ⸃᣿ߦ㑐ߔࠆಽ⑼ળ౏㐿ࠪࡦࡐࠫ࠙ࡓ(ᐔᚑ 18 ᐕ 3 ᦬㧘᧲੩㧘․೎⻠Ṷ‫ޟ‬−∩ߩࠪࠣ࠽࡞વ㆐࡮೙ᓮᯏ᭴‫ޠ‬Ṷ⠪)
2㧕 ╙ 10 ࿁ᣣᧄ㤗㈮࡮㓸ਛᴦ≮⎇ⓥળ(ᐔᚑ 18 ᐕ 4 ᦬㧘ᄢ㒋㧘ᐳ㐳)
3㧕 ╙ 13 ࿁‫⎇ߩߺ∩ޟ‬ⓥળ‫(ޠ‬ᐔᚑ 18 ᐕ 6 ᦬㧘ᗲ⍮㧘․೎⻠Ṷ‫⥃ߩߺ∩ޟ‬ᐥߣ⣄㜑ࡔࠞ࠾࠭ࡓ‫ޠ‬Ṷ⠪)
4㧕 ╙ 13 ࿁⑺↰−∩⎇ⓥળ(ᐔᚑ 18 ᐕ 6 ᦬㧘⑺↰㧘․೎⻠Ṷ‫ߩߺ∩ޟ‬⣄㜑ࡔࠞ࠾࠭ࡓߣߘߩᴦ≮‫⻠ޠ‬Ṷ⠪)
5㧕 ᣣᧄ㤗㈮⑼ቇળ╙ 53 ࿁ቇⴚ㓸ળ(ᐔᚑ 18 ᐕ 6 ᦬㧘␹ᚭ㧘ቇⴚ⻠Ṷ ᐳ㐳)6㧕 ᣣᧄ㤗㈮⑼ቇળ╙ 53 ࿁ቇⴚ㓸ળ(ᐔᚑ 18 ᐕ 6 ᦬㧘␹ᚭ㧘ࠪࡦࡐࠫ࠙ࡓ‫↢ޟ‬๮ߣ㉄⚛‫ޔ‬ᵴᕈ㉄⚛‫ޔ‬ᵴᕈ⓸⚛‫ޠ‬ᐳ㐳)7㧕 ᣣᧄ㤗㈮⑼ቇળ╙ 53 ࿁ቇⴚ㓸ળ(ᐔᚑ 18 ᐕ 6 ᦬㧘␹ᚭ㧘․೎⻠Ṷ ᐳ㐳)8㧕 ╙ 9 ࿁ᣣᧄ⣖ૐ᷷≮ᴺቇળ(ᐔᚑ 18 ᐕ 7 ᦬㧘᧲੩㧘࠮࠶࡚ࠪࡦ ᐳ㐳)
9㧕 ᣣᧄࡍࠗࡦࠢ࡝࠾࠶ࠢቇળ╙ 40 ࿁ᄢળ(ᐔᚑ 18 ᐕ 7 ᦬㧘␹ᚭ㧘․೎⻠Ṷ ᐳ㐳)10㧕 ╙ 5 ࿁᧲ᶏ㤗㈮ኾ㐷කળ‫ޟ‬ቇⴚ⻠Ṷળ‫(ޠ‬ᐔᚑ 18 ᐕ 8 ᦬㧘ฬฎደ㧘․೎⻠Ṷ‫㉄ࡁࡒࠕޟ‬ャᶧߦࠃࠆⴚਛ૕᷷⛽ᜬ‫ޠ‬Ṷ⠪)11㧕 ╙ 9 ࿁ጘ㒂ᕆᕈⴊᶧᵺൻ⎇ⓥળ(ᐔᚑ 18 ᐕ 9 ᦬㧘ጘ㒂㧘․೎⻠Ṷ ᐳ㐳)12㧕 ╙ 11 ࿁ᣣᧄᔃ⤳ⴊ▤㤗㈮ቇળቇⴚᄢળ(ᐔᚑ 18 ᐕ 9 ᦬㧘㐳ፒ㧘ᢎ⢒⻠Ṷ‫ᦨޟ‬ㄭߩᔃᚱ⚦േࡑࡀࠫࡔ
ࡦ࠻‫ޠ‬ᐳ㐳)13㧕 ╙ 73 ࿁ਅํᏒකᏧળቇⴚ⻠Ṷળ(ᐔᚑ 18 ᐕ 10 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫⥃ߩߺ∩ޟ‬ᐥߣ⣄㜑−∩ฃኈᯏ᭴‫ޠ‬ᐳ㐳)14㧕 ᣣᧄ⥃ᐥ㤗㈮ቇળ╙ 26 ࿁ᄢળ(ᐔᚑ 18 ᐕ 10 ᦬㧘ᣩᎹ㧘ࠪࡦࡐࠫ࠙ࡓ ᐳ㐳)15㧕 ᣣᧄ⥃ᐥ㤗㈮ቇળ╙ 26 ࿁ᄢળ(ᐔᚑ 18 ᐕ 10 ᦬㧘ᣩᎹ㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯ ᐳ㐳)16㧕 ᣣᧄ⯃↢ቇળ╙ 25 ࿁ᄢળ(ᐔᚑ 18 ᐕ 12 ᦬㧘ᵿ᧻㧘․೎⻠Ṷ ᐳ㐳)17㧕 ╙ 10 ࿁ጘ㒂๟ⴚᦼᓴⅣ▤ℂ⎇ⓥળ(ᐔᚑ 19 ᐕ 1 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬⍴ᤨ㑆૞↪E1 ㆤᢿ⮎ߩ⃻⁁ߣᣂߚߥㆡᔕ‫ޠ‬ᐳ㐳)18㧕 ᣣᧄ㤗㈮⑼ቇળ᧲ᶏ࡮ർ㒽ᡰㇱ╙ 4 ࿁ቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 2 ᦬㧘ฬฎደ㧘ᢎ⢒⻠Ṷ ᐳ㐳)19㧕 ╙ 11 ࿁ᣣᧄ␹⚻㤗㈮࡮㓸ਛᴦ≮⎇ⓥળ(ᐔᚑ 19 ᐕ 4 ᦬㧘⑺↰㧘ࠗࡉ࠾ࡦࠣ࠮ࡒ࠽࡯ ᐳ㐳)20㧕 ╙ 8 ࿁✭๺ࠤࠕ࡮ࡊ࡜ࠢ࠹ࠖࠬ(ᐔᚑ 19 ᐕ 8 ᦬㧘ጘ㒂㧘․೎⻠Ṷ ᐳ㐳)21㧕 ╙ 10 ࿁ጘ㒂ᕆᕈⴊᶧᵺൻ⎇ⓥળ(ᐔᚑ 19 ᐕ 9 ᦬㧘ጘ㒂㧘․೎⻠Ṷ ᐳ㐳)22㧕 ╙ 11 ࿁ጘ㒂๟ⴚᦼᓴⅣ▤ℂ⎇ⓥળ(ᐔᚑ 20 ᐕ 1 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬๟ⴚᦼ▤ℂߦ߅ߌࠆᔃࠛࠦ࡯
ߩ᦭↪ᕈ‫ޠ‬ᐳ㐳)23㧕 ᣣᧄ㤗㈮⑼ቇળ╙ 55 ࿁ቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 6 ᦬㧘ᮮᵿ㧘․೎⻠Ṷ‫ޟ‬කᏧߩຠᩰ‫ޠ‬ᐳ㐳)24㧕 ╙ 11 ࿁ᣣᧄ⣖ૐ᷷≮ᴺቇળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘᜗⺧⻠Ṷ‫↢ߩࠄ߆ࡦ࡜ࡉࡦࡕޟ‬ㆶ㧙⊓ጊߢ஧⊒ᕈૐ૕᷷∝㧙‫ޠ‬ᐳ㐳)25㧕 ╙ 16 ࿁ᣣᧄ㓸ਛᴦ≮කቇળ᧲ᶏർ㒽࿾ᣇળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘ળ㐳⻠Ṷ‫⑼ޟ‬ቇߒㅪ៤ߔࠆ㓸ਛᴦ≮‫ޠ‬ᐳ㐳)26㧕 ╙ 9 ࿁✭๺ࠤࠕ࡮ࡊ࡜ࠢ࠹ࠖࠬ(ᐔᚑ 20 ᐕ 8 ᦬㧘ጘ㒂㧘․೎⻠Ṷ ᐳ㐳)27㧕 ᣣᧄ⥃ᐥ㤗㈮ቇળ╙ 28 ࿁ᄢળ(ᐔᚑ 20 ᐕ 11 ᦬㧘੩ㇺ㧘᜗⺧⻠Ṷ ᐳ㐳)㘵↰ብ᮸㧦1㧕 ጘ㒂๟ⴚᓴⅣ▤ℂ࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 5 ᦬㧘ጘ㒂㧘ᢎ⢒⻠Ṷ ᐳ㐳)2㧕 ᣣᧄ⥃ᐥ㤗㈮ቇળ╙ 26 ࿁ᄢળ(ᐔᚑ 18 ᐕ 10 ᦬㧘ᣩᎹ㧘ࠪࡦࡐࠫ࠙ࡓ Ṷ⠪)
3㧕 ╙ 11 ࿁ᣣᧄ␹⚻㤗㈮࡮㓸ਛᴦ≮⎇ⓥળ(ᐔᚑ 19 ᐕ 4 ᦬㧘⑺↰㧘ࠪࡦࡐࠫ࠙ࡓ‫▤ⴊޟ‬૞േ⮎ߩ⣖⣄㜑㧙㧙ⴊᵹ(ⴊ▤)ߦਈ߃ࠆᓇ㗀‫ޠ‬Ṷ⠪)
4㧕 ᣣᧄ⯃↢ቇળ╙ 26 ࿁ᄢળ(ᐔᚑ 19 ᐕ 10 ᦬㧘ጟጊ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬㤗㈮⮎߅ࠃ߮㤗㈮㑐ㅪ⮎ߣ⣖⣄㜑ⴊ▤‫ޠ‬Ṷ⠪)
5㧕 ╙ 11 ࿁ጘ㒂๟ⴚᦼᓴⅣ▤ℂ⎇ⓥળ(ᐔᚑ 20 ᐕ 1 ᦬㧘ጘ㒂㧘ᢎ⢒⻠Ṷ‫ޟ‬DPC ኻ⽎᳃㑆✚ว∛㒮ߦ߅ߌࠆ․ቯ㓸ਛᴦ≮ቶนേߦߟ޿ߡ‫ޠ‬ᐳ㐳)
6㧕 ᣣᧄ㤗㈮⑼ቇળ╙ 55 ࿁ᄢળ(ᐔᚑ 20 ᐕ 6 ᦬㧘ᮮᵿ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬㤗㈮࡮ᚻⴚ೨⑌ᾍ㧦ߘߩലᨐߣ
outcome‫ޠ‬Ṷ⠪)7㧕 ᣣᧄ㤗㈮⑼ቇળ╙ 55 ࿁ᄢળ(ᐔᚑ 20 ᐕ 6 ᦬㧘ᮮᵿ㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ‫ޟ‬㤗㈮ኾ㐷කߩᔅୃ࠹ࠢ࠾࠶ࠢ
ࠪ࡝࡯࠭ 2‫ޠ‬ᐳ㐳)8㧕 ᣣᧄ㤗㈮⑼ቇળ᧲ᶏ࡮ർ㒽ᡰㇱ╙ 6 ࿁ቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 9 ᦬㧘ጘ㒂㧘ᢎ⢒⻠Ṷ‫ޟ‬๟ⴚᦼߩᗵᨴ▤ℂ 㨪☨࿖ߩ SCIP ߆ࠄቇ߱㨪‫ޠ‬ᐳ㐳)┻ਛరᐽ㧦
1㧕 ╙ 16 ࿁ᣣᧄࡎࠬࡇࠬ࡮࿷ቛࠤࠕ⎇ⓥળో࿖ᄢળ(ᐔᚑ 19 ᐕ 6 ᦬㧘㜞ጊ㧘․೎⻠Ṷ‫≸ޟ‬−∩ᴦ≮
update‫ޠ‬Ṷ⠪)
2㧕 ╙ 19 ࿁᧲ᶏࡍࠗࡦࠢ࡝࠾࠶ࠢ⎇ⓥળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ฬฎደ㧘․೎⻠Ṷ‫ޟ‬ᘟᕈ∩ࡕ࠺࡞ߩ⥄ᓞ␹⚻ᯏ⢻ߣ᳇⽎ⷐ⚛ᄌൻߦኻߔࠆ෻ᔕᕈߦߟ޿ߡ‫ޠ‬ᐳ㐳)
3㧕 ╙ 24 ࿁ᣣᧄ⊹⤏ᖡᕈ⣲≌ቇળቇⴚᄢળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓ‫≸ޟ‬ᕈ−∩ߣߘߩኻ╷‫ޠ‬Ṷ⠪)㐳ἑ ᷡ㧦
1㧕 ╙ 18 ࿁ᣣᧄ⥃ᐥࡕ࠾࠲࡯ቇળ✚ળ(ᐔᚑ 19 ᐕ 4 ᦬㧘ฬฎደ㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯‫ޟ‬ᰴ਎ઍߩ㤗㈮⸥
㍳ࠍ⋡ᜰߒߡ㨪⥃ᐥ⃻႐߆ࠄߩឭ᩺㨪‫ޠ‬Ṷ⠪)2㧕 ጘ㒂ᄢቇච౐㌁ⴕ↥ቇㅪ៤࡮ක≮⚻༡ࠪࡦࡐࠫ࠙ࡓ(ᐔᚑ 19 ᐕ 6 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᚻⴚቶߩല₸⊛ߥㆇ༡ࠍ⋡ᜰߒߡ‫ޠ‬Ṷ⠪)
3㧕 ╙ 55 ࿁ᣣᧄ㤗㈮⑼ቇળ✚ળ(ᐔᚑ 20 ᐕ 6 ᦬㧘ᮮᵿ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ቢో㔚ሶࠞ࡞࠹ࠪࠬ࠹ࡓࠍᵴ↪
ߒߚක≮ߩ⾰ߩะ਄‫ޔ‬ല₸ൻᮡḰൻߩᡷༀ㧘ක≮ㆊ⺋㒐ᱛߦะߌߚ 3 ᐕ㑆ߩขࠅ⚵ߺ‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേ㘵↰ብ᮸㧦
1㧕 ጘ㒂⋵ࡔ࠺ࠖࠞ࡞ࠦࡦ࠻ࡠ࡯࡞ᆔຬ(ᐔᚑ 20 ᐕᐲ)
10㧚ႎ๔ᦠ
1㧕 ࿯⢈ୃม㧦㤗㈮࡮−∩ࠪࠣ࠽࡞વ㆐ߦ߅ߌࠆࠗࠝࡦ࠴ࡖࡀ࡞ߣࠗࠝࡦ࡮࠻࡜ࡦࠬࡐ࡯࠲࡯ߩ೙ᓮᯏ
᭴㧦ᐔᚑ 14㧙17 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(A)⎇ⓥᚑᨐႎ๔ᦠ㧦1㧙102(2006 ᐕ 3 ᦬)
2㧕 㘵↰ብ᮸㧦࡝ࡕ࡯࠻ࡊ࡟ࠦࡦ࠺࡚ࠖࠪ࠾ࡦࠣߦࠃࠆ⣄㜑଻⼔ᴺߩ⚦⢩ౝࡔࠞ࠾࠭ࡓߣ㑐ㅪ࿃ሶߩ⸃
ᨆ㧦ᐔᚑ 18㧙19 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)⎇ⓥᚑᨐႎ๔ᦠ㧦1㧙60(2008 ᐕ 3 ᦬)11㧚ႎ㆏ߥߒ12㧚⥄Ꮖ⹏ଔ
⹏ଔ೨࿁ߩႎ๔ᦠ߆ࠄߩ⪺᣿ߥᄌൻߪ㧘ᄢቇ∛㒮ߪ߽ߣࠃࠅ㑐ㅪ∛㒮ߩ㤗㈮⑼ߩᬺോߩჇടߥߤߦࠃࠆੱ
ᚻਇ⿷ߢ㧘⎇ⓥߦㆱߌࠆᤨ㑆߇㕖Ᏹߦᷫߞߚߎߣ㧘ߥߤ߇㊀ߥߞߚ߇㧘޿ߊߟ߆ߩ㕙ߢߩ⺖㗴ߪలಽߦߣߪ޿߃ߥ޿߇㧘ࠕࡔ࡝ࠞ㤗㈮ቇળߢߩ⊒⴫㧘࡛࡯ࡠ࠶ࡄ㤗㈮ቇળ㧔Ṷ㗴ᔕ൐ਛ㧕ߘߒߡᣣᧄ㤗㈮⑼ቇ
ળ߳ߩ⊒⴫ࠍㅢߒߡ㧘㆐ᚑߢ߈ߚߣ⹏ଔߒߡ޿ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷කቇㇱ߅ࠃ߮∛㒮ߩో㕙⒖ォ߆ࠄ 5 ᐕࠍ⚻ߡ㧘⸻≮૕೙ਗ߮ߦ⎇ⓥ૕೙߽ᢛ஻ߐࠇߡ߈ߚ‫߇ߛޕ‬㧘ੱ㧙㧙⊛໧㗴ߥߤ⎇ⓥࠍㆀⴕߒߡ޿ࠆ਄ߢߩታ㓙⊛ߥ໧㗴ߢ޽ࠆ‫⃻ޕ‬࿷⎇ⓥࠍᏗᦸߒߡᄢቇ㒮ߦ౉ቇߒߡ޿ࠆ
කᏧߦ߽㧘ቇ⾌ࠍᛄ޿ߥ߇ࠄ㧘⥃ᐥᬺോࠍ⟵ോൻߒߡㆀⴕߖߑࠆࠍᓧߥ޿ߎߣߢ޽ߞߚ߇㧘⃻࿷ߪᡷༀߒߡ޿ࠆ‫ߩߎޕ‬ኻᔕߦߪ㧘␠ળੱᄢቇ㒮↢߽ቯ⌕ߒ㧘∛㒮⸻≮ᬺോߣߩ౒ሽߥน⢻ߣߥߞߡ߈ߚߣ޿߃
ࠆ‫ޕ‬ᛮᧄ⊛ߥᡷ㕟ߪ੹ᓟߩ໧㗴ߣߒߡᱷߐࠇߡ޿ࠆ‫⎇ޕ‬ⓥ⾌ߪ㧘ᐘߦ߽⑼ቇ⎇ⓥ⾌ߩ㈩ಽࠍฃߌ㧘⎇ⓥቶߩᢛ஻߽ߥࠅ㧘ᒰ㕙ߪᵴ⊒ߥ⎇ⓥᵴേ߇ᦼᓙߢ߈ࠆ‫ޕ‬੹ᓟߩዷᦸ⃻࿷ߒߡ޿ࠆ⎇ⓥ࡟ࡌ࡞ࠍዋߥ޿⎇ⓥຬߢߤ߁⛽ᜬߒ㧘⊒ዷߐߖߡ޿ߊ߆㧘߇ᒁ߈⛯޿ߡߩ⺖㗴ߢ޽ࠆ‫ޕ‬ᄢቇ∛㒮ߩ␠ળ⊛૶๮ߩ৻ߟ㧘ఝࠇߚ⥃ᐥකࠍ㑐ㅪߔࠆක≮ᯏ㑐ߦᵷ㆜ߔࠆߣ޿߁⋡⊛߇޽ࠆߛߌ
ߦ㧘ᒰ㕙ߩࡑࡦࡄࡢ࡯ߩల⿷ߪᦼᓙߢ߈ߥ޿ߩߢ㧘ᣂߒ޿ᚻᛛࠍዉ౉ߒ㧘৻ㇱⴕߞߡ޿ࠆઁ⎇ⓥᯏ㑐ߣߩ౒ห⎇ⓥߦࠃߞߡ㧘ࠃࠅല₸⊛ߦ⎇ⓥࠍㆀⴕߔࠆߎߣߢ޽ࠆ‫⎇ޕ‬ⓥ⠪ߩ⣄㜑㎾∩ᯏ᭴߳ߩࠪࠣ࠽࡞વ
㆐ߦ㑐ߔࠆ⎇ⓥߩ┹੎߽ᵴ⊒ߦߥߞߡ߈ߚ‫⃻ޕ‬࿷㧘⣄㜑ᓟᩮ␹⚻࠾ࡘ࡯ࡠࡦߢዷ㐿ߒߡ߈ߚ⎇ⓥࠍࡒࠢࡠࠣ࡝ࠕ⚦⢩ߦ⊒ዷߐߖ㧘ᚑᨐ߽਄߇ߞߡ޿ࠆߩߢ㧘ߎߩಽ㊁ߢߩᵴ⊒ߥᚑᨐ߇ᦼᓙߐࠇࠆ‫ߚ߹ޕ‬㧘ࠞࡊࠨࠗࠪࡦ⺃⊒ߩ⣄㜑ᓟᩮ⚦⢩ߦ߅ߌࠆ⚦⢩ౝࠪࠣ࠽࡞વ㆐ ERK ߩ࡝ࡦ㉄ൻࠍ㧘ࡠࡇࡃࠞࠗࡦߥߤߩዪᚲ㤗㈮⮎㧘޽ࠆ޿ߪ Na+㧙K+㧙2Cl-࠻࡜ࡦࠬࡐ࡯࠲࡯ߩ㒖ኂ⮎ߢ޽ࠆࡈࡠ࠮ࡒ࠼߇ߤ߁ୃ㘼ߔࠆ߆ߩᬌ
⸛߳ߣㅴ߼ߡ޿ߊ‫ޕ‬⎇ⓥቶߢߩ⎇ⓥㆀⴕߩᛮᧄ⊛ߥ⸃᳿߇⷗಴ߐࠇߥ޿߹߹ߢ޽ࠆ߇㧘㤗㈮࡮ᚻⴚਛߩャᶧ㧔♧฽᦭ャᶧ㧕ߩ೑ὐߥߤࠍዩਛࠕࠢࠕࡐ࡝ࡦߩേᘒ߆ࠄ㧘ᄢⴊ▤ㆤᢿߦࠃࠆᧃ᪳⯯ⴊ໧㗴ࠍࡃ࠰ࡊ࡟࠶ࠪࡦߩേᘒ߿
⯯ⴊ⠴ᕈ㧔ischemic preconditioning㧕߆ࠄ⸃᣿ߔࠆߥߤߩ㧘⥃ᐥߩ቟ోᕈߩᬌ⸛ࠍᲤᣣߩ⥃ᐥᬺോߢ⸃
᳿ࠍ࿑ࠆߴ߈⎇ⓥࡊࡠࠫࠚࠢ࠻ࠍផㅴߒߡ޿ࠆ‫ޕ‬㧙㧙㧔8㧕⯃↢࡮㓸ਛᴦ≮ቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
ߎߩಽ㊁ߪ㧘‫ޟ‬㤗㈮⮎ߦࠃߞߡᛥ೙ߐࠇ↢๮ߩ᏷ࠍᭂ┵ߦ⁜ߊߒߡ޿ࠆ⁁ᘒ㧘߆ߟᚻⴚߣ޿߁ỗߒ޿ࠬ࠻࡟ࠬਅߦ޽ࠆᖚ⠪ߩ๭ๆ࡮ᓴⅣ࡮૕ᶧ࡮ઍ⻢▤ℂߢ޽ࠆ‫ߣ߽ߩ⼂⹺ࠆ޽ߢޠ‬㧘⯃↢ߩജ㊂߇ߥߊߡߪ቟
ోߦ㤗㈮ࠍ߆ߌࠆߎߣ߇ߢ߈ߥ޿ߣ޿߁ⷞὐ߆ࠄߩ⎇ⓥߢ޽ࠅ㧘⋡⊛ࠍᣂߒ޿ᔃ⢖⯃↢ᴺߣᔃ⤳ᯏ⢻ࡕ࠾࠲࡯ߩ㐿⊒ߣ޿߁ᓥ᧪⯃↢࡮㓸ਛᴦ≮ߦ߅ߌࠆਛᔃ⊛ߥ⺖㗴ߦ߅޿ߡ߈ߚ‫ޕ‬2㧚ฬ★
ᢎ᝼(૬છ)㧦 ࿯⢈ୃมShuji Dohi

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
㤗㈮࡮−∩೙ᓮቇಽ㊁ෳᾖ⪺ᦠ㧔᰷ᢥ㧕
㤗㈮࡮−∩೙ᓮቇಽ㊁ෳᾖ✚⺑㧔๺ᢥ㧕
㤗㈮࡮−∩೙ᓮቇಽ㊁ෳᾖ✚⺑㧔᰷ᢥ㧕
㤗㈮࡮−∩೙ᓮቇಽ㊁ෳᾖේ⪺㧔๺ᢥ㧕
㤗㈮࡮−∩೙ᓮቇಽ㊁ෳᾖේ⪺㧔᰷ᢥ㧕
㤗㈮࡮−∩೙ᓮቇಽ㊁ෳᾖ

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄㤗㈮࡮−∩೙ᓮቇಽ㊁ෳᾖ
2㧕ฃ⸤⎇ⓥ
㤗㈮࡮−∩೙ᓮቇಽ㊁ෳᾖ
3㧕౒ห⎇ⓥ
㤗㈮࡮−∩೙ᓮቇಽ㊁ෳᾖ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫ㤗㈮࡮−∩೙ᓮቇಽ㊁ෳᾖ
6㧚ቇળᵴേ
1㧕ቇળᓎຬ
㤗㈮࡮−∩೙ᓮቇಽ㊁ෳᾖ
2㧕ቇળ㐿௅
㤗㈮࡮−∩೙ᓮቇಽ㊁ෳᾖ
3㧕ቇⴚ㔀⹹
㤗㈮࡮−∩೙ᓮቇಽ㊁ෳᾖ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳㤗㈮࡮−∩೙ᓮቇಽ㊁ෳᾖ㧙㧙8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ㤗㈮࡮−∩೙ᓮቇಽ㊁ෳᾖ
9㧚␠ળᵴേ
㤗㈮࡮−∩೙ᓮቇಽ㊁ෳᾖ
10㧚ႎ๔ᦠ
㤗㈮࡮−∩೙ᓮቇಽ㊁ෳᾖ11㧚ႎ㆏
㤗㈮࡮−∩೙ᓮቇಽ㊁ෳᾖ12㧚⥄Ꮖ⹏ଔ
⹏ଔቴຬ⥃ᐥᢎ᝼ߢ޽ࠆ೨࿁ߩ⿒᧻ࠍਛᔃߦ㧘⮎ℂ∛ᘒቇ㧔ዊỈᢎ᝼㧕ߩᜰዉࠍฃߌ㧘⎇ⓥࠍㆀⴕߒߡ޿
ࠆ‫ޕ‬ᄢቇ∛㒮ߪ߽ߣࠃࠅ㑐ㅪ∛㒮ߩ㤗㈮⑼ߩᬺോߩჇടߥߤߦࠃࠆੱᚻਇ⿷ߢ㧘⎇ⓥߦㆱߌࠆᤨ㑆߇㕖Ᏹߦᷫߞߚߎߣ㧘ߥߤ߇㊀ߥߞߡ㧘⺖㗴ߪలಽߦ㆐ᚑߢ߈ߥ߆ߞߚ߇㧘৻ㇱ㧘⥃ᐥ⊛ߥⷞὐߩ⎇ⓥ㧘ਗ߮ߦ⣖ૐ᷷≮ᴺߩ⎇ⓥߩᚑᨐ߇ߺࠄࠇߡ߈ߚ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷⎇ⓥ਄ߩ໧㗴ߪᄙ޿‫⎇ޕ‬ⓥᣉ⸳ߣⅣႺ㧘ੱ⊛໧㗴ߥߤ⎇ⓥࠍㆀⴕߒߡ޿ࠆ਄ߢߩታ㓙⊛ߥ໧㗴ߢ޽ࠆ‫ޕ‬කቇㇱ߅ࠃ߮∛㒮ߩో㕙⒖ォ㧘ߐࠄߦ․ߦᴺੱൻᓟߩ৻ᤓᐕ㧘ᤓᐕߪ⥃ᐥᬺോ߇ᄙᔔࠍᭂ߼㧘ߎߩ㕙ߢ
⎇ⓥߪㆀⴕߢ߈ߥ߆ߞߚ‫ޕ‬ᐘ޿㧘ᣂߒߊടࠊߞߚᄢቇ㒮↢߇ߣ৻✜ߦ⎇ⓥࠍౣ㐿ߔࠆ‫ޕ‬੹ᓟߩዷᦸ⥃ᐥߦ߅ߌࠆ㊀ⷐߥࡕ࠾࠲࡯ᯏེߩᣂߒ޿⊒ዷߣߒߡ㧘േ⣂࿶ᦛ✢߆ࠄᔃ৻࿁ᜉ಴㊂ࠍផ᷹ߔࠆᣇᴺ
ࠍ㧘ߐ߹ߑ߹ߥⴊ▤∛ᘒߦ߅ߌࠆା㗬ᕈࠍ⹏ଔߒ㧘ߘࠇࠍ⥃ᐥߦ߅ߌࠆ቟ోᕈߦ❬ߍࠆ⎇ⓥࠍㅴ߼ߡ޿ࠆ‫ޕ‬㤗㈮࡮−∩೙ᓮቇಽ㊁ߣ৻✜ߦߔߔ߼ߡ޿ࠆ㧘⣖ᓸዊᓴⅣࠍ㗡⬄ౝ᦭⓹ᴺߦ↪޿ߡߩᔃ⢖⯃↢ਛߩ⣖
ᓴⅣߦᐢߍߡᬌ⸛ߔࠆߎߣߦട߃ߡ㧘ᔃ⢖⯃↢ᴺߢߩലᨐ߇⏕ታⷞߐࠇߡ߈ߚࡄ࠰ࡊ࡟࠶ࠪࡦߩ⣖エ⤑ⴊ▤߳ߩ૞↪㧘ᄢⴊ▤ㆤᢿ߅ࠃ߮ㆤᢿᓟߩࡄ࠰ࡊ࡟࠶ࠪࡦ߿ࠛࡦ࠼࠮࡟ࡦߩേᘒߦᵈ⋡ߒߡ⎇ⓥࠍ㐿ᆎߔࠆ‫ߩߎޕ‬ಽ㊁ߢ߽㧘ᓥ᧪એ਄ߦ⮎ℂ∛ᘒ㧔ዊỈᢎ᝼㧕ߥߤߩᧄቇၮ␆♽ಽ㊁ߩᜰዉࠍઔ߉㧘⎇ⓥߩ⾰ߩะ਄ߦദ߼ࠆ‫ޕ‬㧙㧙㧔9㧕ญ⣧∛ᘒቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
⃻࿷㧘ᒰಽ㊁ߦ߅޿ߡዷ㐿ਛߩ⎇ⓥ⺖㗴ࠍ⥃ᐥ⎇ⓥߣၮ␆⎇ⓥߦᄢ೎ߒߡㅀߴࠆ‫ޕ‬⥃ᐥ⎇ⓥ㧦ᦨㄭߩಽሶ↢‛ቇߩ⊒ዷߦࠃࠅ㧘ᄙߊߩ∔ᖚߦ߅޿ߡಽሶ↢‛ቇ⊛ᯏᐨ߇᣿ࠄ߆ߣߐࠇߡ᧪
ߡ޿ࠆ‫ߚ߹ޕ‬㧘ㄭᐕߩౣ↢ක≮⎇ⓥߩ⊒ዷ߽⪺ߒߊ㧘ญ⣧ක≮߳ߩᔕ↪߽᭽‫ߥޘ‬㕙ߢㅴዷߒߡ᧪ߡ޿ࠆ‫ޕ‬ߎߩ⃻⁁ࠍ㐓ߺ㧘ᒰಽ㊁ߢߪ㧘ญ⣧∛ᄌ㧔ญ⣧߇ࠎ㧘⊕᧼∝㧘ᚳᐔ⧡⊈㧘ߘߩઁᱤේᕈ⣲≌ߥߤ㧕ߩ⸃ᨆߣ㧘ౣ↢ක≮ߩ⥃ᐥዷ㐿ߦゲ⿷ࠍ⟎߈એਅߩ⎇ⓥ⺖㗴ߦขࠅ⚵ࠎߢ޿ࠆ‫ޕ‬1㧕ญ⣧∛ᄌߩಽሶ∉ቇ⊛⸃ᨆ
2㧕ญ⣧ᯏ⢻ౣᑪ㧔⒖ᬀ࡮ౣ↢ක≮㧕
3㧕ญ⣧ੇ῎∝ߩ∛ᘒߣᴦ≮4㧕ญ⣧߇ࠎߩ㓸ቇ⊛ᴦ≮5㧕ࡅ࠻ᱤ⢦࡮ᱤ㜑߆ࠄߩᐙ⚦⢩ណขߣ iPS ⚦⢩ൻ࡮ࡃࡦࠢൻ੐ᬺ
ၮ␆⎇ⓥ㧦ญ⣧߇ࠎߩᰴ਎ઍᴦ≮ᴺ㐿⊒ࠍ⋡ᜰߒ㧘⊒߇ࠎ࡮ᖡᕈൻㅴዷࡊࡠ࠮ࠬߦ߅ߌࠆ Initiation,
Promotion, Progression ߩฦ Phase ߦᣈߌࠆ೙ᓮߩน⢻ᕈߣ㗶࡮ญ⣧ᯏ⢻ߩᡷༀ࡮ౣ↢ߦኻߔࠆ⚦⢩Ꮏቇ⊛ᬌ⸛ࠍⷞ㊁ߦએਅߩᬌ⸛ࠍⴕߥߞߡ޿ࠆ‫ޕ‬1㧕߇ࠎᖡᕈൻㅴዷᯏᐨߩ⸃ᨆ
2㧕㛽ઍ⻢࡮ౣ↢ක≮ߩᣂᛛⴚ㐿⊒3㧕ญ⣧߇ࠎൻቇ੍㒐ᴺߩ㐿⊒
4㧕ࡅ࠻ᱤ⢦࡮ᱤ㜑߆ࠄߩᐙ⚦⢩ណขߣ iPS ⚦⢩ൻ࡮ࡃࡦࠢൻ੐ᬺ
2㧚ฬ★
ᢎ᝼㧦
ಎᢎ᝼㧦
⻠Ꮷ㧦
⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
කຬ㧦
කຬ㧦

ᩊ↰ᢅਯ
࿯੗↰ ⺈
ጊਅ⍮Ꮘ
’↰ᶈ᮸
ട⮮ᕺਃ
☨ᧄ๺ᒄ
⇗ጊᄢੑ㇢
ᵻ㚅㓶৻㇢
ᱞ↰⍮ሶ
ችፒᐽ㓶

Toshiyuki Shibata
Makoto Toida
Tomomi Yamashita
Hiroki Makita
Keizo Kato
Kazuhiro Yonemoto
Daijiro Hatakeyama
Yuichiro Asaka
Tomoko Takeda
Yasuo Miyazaki3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ⮮Ⴆ⑲᮸㧘࿯੗↰ ⺈㧘ᩊ↰ᢅਯ㧚ᴡว㆐ᔒ㧘ᢪ⮮ ⺈㧘⼾ጊᵗテ✬㧚ߎߎ߹ߢ߈ߚ㔚⣖∛㒮ࠪࠬ࠹ࡓ㧦
Dental IT Navigation 2006㧘᧲੩㧦࠺ࡦ࠲࡞࠳ࠗࡗࡕࡦ࠼␠㧧2006 ᐕ㧘112㧙115㧚
2㧕 ᩊ↰ᢅਯ㧚ਛ᧛ᐽ↢(࠮ࠞࡦ࠼࡮ࠝࡇ࠾ࠝࡦࠍផㅴߐߖࠆળ)✬㧚ታജකߩጁᱧᦠ ᄖ⑼♽ III ⣖␹⚻ᄖ⑼ߩ∛᳇ 㗡㗪ㇱ࡮ญ⣧ߩ≸ ↲⁁⣼≸㧘᧲੩㧦࡜ࠗࡈડ↹㧧2008 ᐕ㧦409㧚
3㧕 ᩊ↰ᢅਯ㧚ਛ᧛ᐽ↢(࠮ࠞࡦ࠼࡮ࠝࡇ࠾ࠝࡦࠍផㅴߐߖࠆળ)✬㧚ක⠪߇ߔߔ߼ࠆኾ㐷∛㒮࡮᧲ᶏ 㧘᧲੩㧦࡜ࠗࡈડ↹㧧2008 ᐕ㧦423㧚
4㧕 ᩊ↰ᢅਯ㧚ᣣᧄญ⣧ࠤࠕቇળ✬㧚ญ⣧≸ߣญ⣧ࠤࠕ㧦ญ⣧ࠤࠕ ၮ␆⍮⼂ ญ⣧ࠤࠕ 4 ⚖࡮5 ⚖⹺ቯ⾗ᩰၮḰḰ᜚㧘᧲੩㧦᳗ᧃᦠᐫ㧧2008 ᐕ㧦27㧙28㧚⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 ᩊ↰ᢅਯ㧚ࡆࠬࡈࠔࠬࡈࠜࡀ࡯࠻⵾೷ߣᱤ⑼ᴦ≮̆㗶㛽უᱫߩෂ㒾ᕈߣකᱤ⮎ㅪ៤ߩᔅⷐᕈ㧘ጘᱤᣂႎ
2007 ᐕ㧧742 ภ㧦30㧙36㧚
2㧕 ᩊ↰ᢅਯ㧚ࡆࠬࡈࠔࠬࡈࠜࡀ࡯࠻⵾೷ߦࠃࠆ㗶㛽უᱫߩෂ㒾ᕈߣකᱤ⮎ㅪ៤ߩᔅⷐᕈ㧘ጘ㒂⋵කᏧળႎ
2007 ᐕ㧧672 ภ㧦14㧙15㧚
3㧕 ࿯੗↰ ⺈㧚ᱤ⑼࡮ญ⣧ᄖ⑼ߦ߅ߌࠆᘟᕈ−∩̆․ߦ⥠∩∝ߦߟ޿ߡ㧘ࠕ࡞ࠞࡠࠗ࠼⎇ⓥળળ⹹ 2008 ᐕ㧧
34 Ꮞ㧦19㧙25㧚㧙㧙✚⺑㧔᰷ᢥ㧕ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ’↰ᶈ᮸㧘ችፒᐽ㓶㧘ጊਅ⍮Ꮘ㧘࿯੗↰ ⺈㧘ᩊ↰ᢅਯ㧚㗠☼⤑ߦォ⒖ߒߚ⣢⚦⢩≸ߩ৻଀㧘ᣣᧄญ⣧⸻ᢿቇળ㔀⹹ 2006 ᐕ㧧19 Ꮞ㧦306㧙309㧚
2㧕 ࿯੗↰ ⺈㧘ട⮮ᕺਃ㧘☨ᧄ๺ᒄ㧘’↰ᶈ᮸㧘⇗ጊᄢੑ㇢㧘ᬮ ᐘඳ㧘ችᧄ ⻞㧘⮮Ⴆ⑲᮸㧘ጊਅ⍮Ꮘ㧘⍹ਣ⚐৻㧘ᩊ↰ᢅਯ㧚ࠪࠚ࡯ࠣ࡟ࡦ∝୥⟲ᖚ⠪ߩญ⣧ੇ῎∝ᴦ≮ߦ߅ߌࠆႮ㉄࠮ࡆࡔ࡝ࡦ᳓๺‛ߩ೽૞↪⊒⃻ߣߘߩ੍㒐ߦ㑐ߔࠆ⥃ᐥ⊛ᬌ⸛㧘ᣣᧄญ⣧⑼ቇળ㔀⹹ 2006 ᐕ㧧55 Ꮞ㧦246㧙252㧚
3㧕 ᄢਭ଻ᕡᱜ㧘↰ਛብผ㧘੹੗ ദ㧘⋉↰ᄢテ㧘ᩊ↰ᢅਯ㧚߁ߟ∛ߦ઻߁ญ⣧ౝ࠮ࡀࠬ࠻ࡄ࠴࡯㧘㜞ጊ⿒චሼ∛㒮♿ⷐ㧘2006 ᐕ㧧30 ภ㧦18㧙21㧚
4㧕 ੹੗ ദ㧘ᄢỈ዁਽㧘ᄢਭ଻ᕡᱜ㧘ጟᧄᷡዏ㧘ᩊ↰ᢅਯ㧚ฝ㗠ㇱߦ⊒∝ߒߚ㘃⴫⊹ྙ⢩ߩ 1 ଀㧘㜞ጊ⿒චሼ∛㒮♿ⷐ 2006 ᐕ㧧30 ภ㧦40㧙43㧚
5㧕 ᵻ㚅㓶৻㇢㧘ጊਅᔀ㇢㧘਄↰୶ᒄ㧘ਛ᎑㗬ବ㧘ᨋ ା㧘⮮↰᣽ብ㧘ᩊ↰ᢅਯ㧚ᣧᦼߦਅ㗶㛽ォ⒖ࠍ᧪ߒߚ
⢖≸ߩ 2 ଀㧘ᣣᧄญ⣧⸻ᢿቇળ㔀⹹ 2007 ᐕ㧧20 Ꮞ㧦354㧙359㧚
6㧕 ጊᧄ⌀↱⟤㧘ᓮ↰᧛⋧ᮨ㧘㐳ἑᳯ೑㧘↰ਛ↢㓷㧘ᵻ↰ୃᏒ㧘૒ᯅᢥੳ㧘’↰ᶈ᮸㧘࿯੗↰ ⺈㧘ᩊ↰ᢅਯ㧘ᱞ↰ ⚐㧚ጘ㒂ᄢቇ↢ߦᱤ⑼ஜᐽ⸻ᢿࠍታᣉߒߡ㧘Campus Health 2007 ᐕ㧧44 Ꮞ㧦109㧙114㧚
7㧕 ᧄᄙᕶሶ㧘૒ᯅᢥੳ㧘ᓮ↰᧛⋧ᮨ㧘㐳ἑᳯ೑㧘⥓੗ࠆࠅሶ㧘↰ਛ↢㓷㧘’↰ᶈ᮸㧘࿯੗↰ ⺈㧘ᩊ↰ᢅਯ㧘ᱞ↰ ⚐㧘ጊᧄ⌀↱⟤㧚ᄢቇ↢ߦ߅ߌࠆญ⣧ߩஜᐽ⁁ᘒߣ↢ᵴ⠌ᘠߣߩ㑐ㅪߦߟ޿ߡ㧘ቇᩞ଻ஜ⎇ⓥ 2007
ᐕ㧧49 Ꮞ㧦112㧙116㧚
8㧕 ࿯੗↰ ⺈㧘ධ⼱␭Ꮧ㧘ᮮ᫪⾆ሶ㧘㘵↰Ꮢⷙ㧘દ⮮ ᖘ㧘㚍႐᡽ม㧘ା↰᥉ፏ㧘᪢᧛⋥Ꮖ㧘᧻ᧁብ◊㧘㊄శᘷሶ㧘ᄥ↰᣽⑲㧘ട⮮ᕺਃ㧘’↰ᶈ᮸㧘ጊਅ⍮Ꮘ㧘ᩊ↰ᢅਯ㧚ጘ㒂Ꮢㄭ㇠ߩ৻⥸૑᳃ߦ߅ߌࠆ࠼࡜ࠗࡑ
࠙ࠬߩታᘒߦ㑐ߔࠆ⎇ⓥ㧘ᣣᧄญ⣧⑼ቇળ㔀⹹ 2007 ᐕ㧧56 Ꮞ㧦301㧙308㧚
9㧕 㘵↰৻ⷙ㧘’↰ᶈ᮸㧘☨ᧄ๺ᒄ㧘ጊਅ⍮Ꮘ㧘࿯੗↰ ⺈㧘ᩊ↰ᢅਯ㧚⒖ᬀ⣺㛽ߦౣ‫࡞ࡔ࠽ࠛߚߒ⊒ޘ‬਄⊹⣲ߩ 1 ଀㧘ᣣᧄญ⣧ᄖ⑼ቇળ㔀⹹ 2008 ᐕ㧧54 Ꮞ㧦435439㧚
10㧕 ༑ਭ↰೑ᒄ㧘ฎ↰ ൠ㧘ศỈାᄦ㧘ᄢ⷏ ⌀㧘ᚸౝ⑲᮸㧘ᩊ↰ᢅਯ㧘ፉේ᡽ม㧘ᩙ↰⾫৻㧘ᩊේቁᒾ㧘ἑᚭ⊧৻㧚ᣣᧄญ⣧ᄖ⑼ቇળᜰቯ⎇ୃᯏ㑐ߢߩ⑌ᾍኻ╷߅ࠃ߮ળຬߩ༛ᾍߦ㑐ߔࠆ⾰໧␿⺞ᩏ㧘ᣣᧄญ⣧ᄖ⑼ቇળ㔀⹹ 2008 ᐕ㧧54 Ꮞ㧦400408㧚
11㧕 ⇗ጊᄢੑ㇢㧘ᬮ ᐘඳ㧘’↰ᶈ᮸㧘ጊਅ⍮Ꮘ㧘࿯੗↰ ⺈㧘ᩊ↰ᢅਯ㧚ⴚᓟߦறຜ㗡࡝ࡦࡄ▵ߦォ⒖ࠍ߈ߚߒߚญ⣧ᚳᐔ਄⊹≸ߩ 2 ଀㧘ᣣᧄญ⣧⸻ᢿቇળ㔀⹹ 2008 ᐕ㧧21 Ꮞ㧦4548㧚
12㧕 ጊਅ⍮Ꮘ㧘᧻ᧄ␭᮸㧘ᵻ㚅㓶৻㇢㧘’↰ᶈ᮸㧘࿯੗↰ ⺈㧘ᩊ↰ᢅਯ㧚⚻ญࡆࠬࡈࠜࠬࡈࠜࡀ࡯࠻⵾೷ߦ
㑐ㅪߒߚਅ㗶㛽უᱫߩᴦ≹⚻㛎㧘ᣣᧄญ⣧ᄖ⑼ቇળ㔀⹹ 2008 ᐕ㧧54 Ꮞ㧦243247㧚
13㧕 ☨ᧄ๺ᒄ㧘㚍႐᡽ม㧘ጊਅ⍮Ꮘ㧘࿯੗↰ ⺈㧘ᩊ↰ᢅਯ㧚Ⴧᱺ᭽ᑼ߇㘃ផߐࠇߚ㓸วᕈᱤ‎⣲ߩ 1 ଀㧘ᣣᧄญ⣧⸻ᢿቇળ㔀⹹ 2008 ᐕ㧧21 Ꮞ㧦103106㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Kato K, Hara A, Kuno T, Mori H, Yamashita T, Toida M, Shibata T. Aberrant promoter
hypermethylation of p16 and MGMT genes in oral squamous cell carcinomas and the surrounding
normal mucosa. J Cancer Res Clin Oncol. 2006;132:735-743.
2㧕 Kato Y, Shibata T, Yamashita T, Kobayashi A, Yonemoto K, Makita H, Mizuta K, Hayashi S, Toida M.
Parapharyngeal and retropharyngeal space infection of odontogenic origin. Asian J Oral Maxillofac
Surg. 2006;18:224-227.
3㧕 Suwa T, Saio M, Umemura N, Yamashita T, Toida M, Shibata T, Takami T. Preoperative radiotherapy
contributes to induction of proliferative activity of CD8+ tumor-infiltrating T-cells in oral squamouscell carcinoma. Oncol Rep. 2006;15:757-763.
4㧕 Yamashita T, Toida M, Hatakeyama D, Yonemoto K, Kusunoki Y, Shibata T. Schwannoma of the oralcavity. Asian J Oral Maxillofac Surg. 2006;18:75-78.
5㧕 Shibata T, Nagayasu H, Kitajo H, Arisue M, Yamashita T, Hatakeyama D, Iwasaki T, Kobayashi H.
Inhibitory effects of fermented brown rice and rice bran on the development of acute hepatitis inLong-Evans Cinnamon rats. Oncol Rep. 2006;15:869-874.
6㧕 Matsuo M, Hayashi S, Maeda S, Tanaka O, Mizuta K, Shibata T, Itou Y, Hoshi H. 4 Gy single fraction
palliative radiotherapy for the treatment of painful recurrent soft palate carcinoma by high-dose-ratemold branchytherapy: a case report. Oral Oncol. 2006;42:305-307.
7㧕 Kobayashi A, Tomida M, Ishimaru JI, Negawa T, Murayama K, Era S, Shibata T. Correlation between
the oxidative state of the synovial fluid and the radiological morphorogy of the temporomandibular
joint disorder. Asian J Oral Maxillofac Surg. 2006;18:185-190.
8㧕 Imai H, Saio M, Nonaka K, Suwa T, Umemura N, Ouyang GF, Nakagawa J, Tomita H, Osada S,
Sugiyama Y, Adachi Y, Takami T. Depletion of CD4+CD25+regulatory T cells enhancesinterleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma. Cancer Sci.
2007;98:416-423.
9㧕 Kato H, Kanematsu M, Kusunoki Y, Shibata T, Murakami H, Mizuta K, Ito Y, Hirose Y. Nasoalveolar
cyst: imaging findings in three cases. Clinical Imaging. 2007;31:206-209.
10㧕 Long NK, Makita H, Yamashita T, Toida M, Kato K, Hatakeyama D, Shibata T. Chemopreventive㧙㧙

IF 2.366

IF 1.597

IF 1.597

IF 2.569

IF 3.165
IF 0.742effect of fermented brown rice and rice bran on 4-nitroquinoline 1-oxide-induced oral carcinogenesis inrats. Oncol Rep. 2007;17:879-885.
11㧕 Makita H, Mutoh M, Murayama T, Yonemoto K, Kobayashi A, Fujitsuka H, Toida M, Shibata T,
Miyamoto S, Yasui Y, Suzuki R, Wakabayashi K, Tanaka T. A prostaglandin E2 receptor subtype
EP1-selective antagonist, ONO-8711, suppresses 4-nitroquinoline 1-oxide-induced rat tongue
carcinogenesis. Carcinogenesis. 2007;28:677-684.
12㧕 Nakagawa J, Saio M, Tamakawa N, Suwa T, Frey AB, Nonaka K, Umemura N, Imai H, Ouyang GF,
Ohe N, Yano H, Yoshimura S, Iwama T, Takami T. TNF expressed by tumor-associated macropfages,
but not microglia, can eliminate glioma. Int J Oncol. 2007;30:803-811.
13㧕 Tanaka K, Mikamo H, Nakao K, Watanabe K. In vitro antianaerobic activity of DX-619, a new
des-fluoro(6) quinolone. Antimicrob Agents Chemother. 2006;50:3908-3913.
14㧕 Yura S, Terahara S, Ohga N, Yamashita T. A case of carcinosarcoma arising in the submandibular
gland. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103:820-824.
15㧕 Zhi H, Yamada Y, Hirose Y, Kato K, Sheng HO, Zheng Q, Oyama T, Asano N, Kuno T, Hara A, Mori H.
Effect of 2-(carboxyphenyl)retinamide and genistein on the formation of early lesions in
1,2-dimethylhydrazine-induced colon carcinogenesis in rats. Asian Pacific Journal of Cancer
Prevention. 2007;8:33-38.
16㧕 Haniffa A.M., Saitoh M, Abiko Y, Takeshima M, Nishimura M, Yamazaki M, Nagayasu H, Sugiura C,
Muthumala M, Kaku T, Chiba I, Shibata T. Expression pattern of p63 in oral epithelial lesions andsubmucous fibrosis associated with betel-quid chewing in Sri Lanka. Med Mol Morphol.
2007;40:203-207.
17㧕 Kato K, Long NK, Makita H, Toida M, Yamashita T, Hatakeyama D, Hara A, Mori H, Shibata T.
Effects of green tea polyphenol on methylation status of RECK gene and cancer cell invasion in oral
squamous cell carcinoma cells. Br J Cancer. 2008;99:647-654.
18㧕 Long NK, Kato K, Yamashita T, Makita H, Toida M, Hatakeyama D, Hara A, Mori H, Shibata T.
Hypermethylation of the RECK gene predicts poor prognosis in oral squamous cell carcinomas. Oral
Oncol. 2008;44:1052-1058.
19㧕 Miyazaki Y, Hara A, Kato K, Oyama T, Yamada Y, Mori H, Shibata T. The effect of hypoxic
microenvironment on matrix metalloproteinase expression in xenografts of human oral squamous cell
carcinoma. Int J Oncol. 2008;32:145-151.
20㧕 Takeda T, Tezuka Y, Horiuchi M, Hosono K, Iida K, Hatakeyama D, Miyaki S, Kunisada T, Shibata T,
Tezuka K. Characterization of dental pulp stem cells of human tooth germs. J Dent Res
2008;87:676-681.
21㧕 Takeshima M, Saitoh M, Kusano K, Nagayasu H, Kurashige Y, Malsantha M, Arakawa T, Takuma T,
Chiba I, Kaku T, Shibata T, Abiko Y. High frequency of hypermethylation of p14, p15 and p16 in oral
pre-cancerous lesions associated with betel-quid chewing in Sri Lanka. J Oral Pathol Med.
2008;37:475-479.
22㧕 Umemura N, Saio M, Suwa T, Kitoh Y, Nonaka K, Ouyang GF, Okada M, Balazs M, Adany R, Shibata
T, Takami T. Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamedmonocytes/macrophages that bear M1- and M2-type characteristics. J Leukoc Biol. 2008;83:1136-1144.

IF 1.597

IF 5.406

IF 2.295
IF 4.390
IF 1.597

IF 1.338

IF 4.635

IF 2.569

IF 2.295

IF 3.496

IF 1.711

IF 4.1284㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦ᩊ↰ᢅਯ㧘⎇ⓥಽᜂ⠪㧦ජ⪲ㅺᦶ㧘࿯੗↰⺈㧘⍹ፒ᣿㧘A. ࡜ࠪ࠽ࡂ㧘ㇳ⧷㓶㧘๟ᝄ⧷㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(B)(2)㧦ࠬ࡝࡜ࡦࠞ࡮บḧߦ߅ߌࠆญ⣧߇ࠎߩಽሶ∉ቇ⊛Ყセ⺞ᩏ㧧ᐔᚑ
16㧙19 ᐕᐲ㧧13,000 ජ౞(3,500㧦3,300㧦3,100㧦3,100 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦⇗ጊᄢੑ㇢㧘⎇ⓥಽᜂ⠪㧦ᩊ↰ᢅਯ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦㛽ᒻᚑߦ߅ߌࠆ
ⴊ▤ౝ⊹Ⴧᱺ࿃ሶ(VEGF)⺃ዉᯏ᭴ߩ⸃ᨆ㧧ᐔᚑ 17㧙19 ᐕᐲ㧧3,400 ජ౞(1,800㧦800㧦800 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦ട⮮ᕺਃ㧘⎇ⓥಽᜂ⠪㧦ጊਅ⍮Ꮘ㧘࿯੗↰⺈㧘ᩊ↰ᢅਯ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦
ญ⣧ᚳᐔ਄⊹≸ߦ߅ߌࠆ RECK ㆮવሶߩ㑐ࠊࠅߣ⣕ࡔ࠴࡞ൻߦࠃࠆ⊒≸࡮ᶐẢߩ೙ᓮ㧧ᐔᚑ 17㧙
18 ᐕᐲ㧧2,400 ජ౞(1,900㧦500 ජ౞)
4㧕 ⎇ⓥઍ⴫⠪㧦ᩊ↰ᢅਯ㧘⎇ⓥಽᜂ⠪㧦⇗ጊᄢੑ㇢㧘’↰ᶈ᮸㧘ട⮮ᕺਃ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄⪚⧘⎇ⓥ㧦ᥓᱤᱤ⢦߆ࠄߩ⚵❱ᐙ⚦⢩ߩ᮸┙ߣಽൻ࡮Ⴧᱺ⢻ߩ⹏ଔ㧧ᐔᚑ 18㧙19 ᐕᐲ㧧3,200 ජ౞(1,600㧦
1,600 ජ౞)5㧕 ⎇ⓥઍ⴫⠪㧦ᩊ↰ᢅਯ㧘⎇ⓥಽᜂ⠪㧦ጊਅ⍮Ꮘ㧘࿯੗↰⺈㧘ട⮮ᕺਃ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(B)㧦
ࡅ࠻ญ⣧☼⤑∛ᄌߦ߅ߌࠆㆮવሶࡔ࠴࡞ൻ⇣Ᏹߩ㑐ਈ㧧ᐔᚑ 18㧙21 ᐕᐲ㧧13,200 ජ౞(3,200㧦
3,300㧦3,300㧦3,400 ජ౞)
6㧕 ⎇ⓥઍ⴫⠪㧦’↰ᶈ᮸㧘⎇ⓥಽᜂ⠪㧦ᩊ↰ᢅਯ㧘࿯੗↰ ⺈㧘ട⮮ᕺਃ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ㧙㧙

(C)㧦4NQO ⺃⊒࡜࠶࠻⥠⊒≸ߦ߅ߌࠆㆮવሶࡔ࠴࡞ൻ⇣Ᏹߩ⸃ᨆ㧧ᐔᚑ 19㧙20 ᐕᐲ㧧2,200 ජ౞(1,100㧦1,100 ජ౞)
7㧕 ⎇ⓥઍ⴫⠪㧦࿯੗↰ ⺈㧘⎇ⓥಽᜂ⠪㧦ട⮮ᕺਃ㧘’↰ᶈ᮸㧘ጊਅ⍮Ꮘ㧘ᩊ↰ᢅਯ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦ญ⣧ᚳᐔ਄⊹≸ߩ㗪ㇱ࡝ࡦࡄ▵ォ⒖ߦ㑐ߔࠆᨴ⦡૕࡮ㆮવሶ⇣Ᏹߩ⸃ᨆ㧧ᐔᚑ 19
㧙21 ᐕᐲ㧧3,100 ජ౞(1,200㧦900㧦1,000 ජ౞)
8㧕 ⎇ⓥઍ⴫⠪㧦ጊਅ⍮Ꮘ㧘⎇ⓥಽᜂ⠪㧦ട⮮ᕺਃ㧘’↰ᶈ᮸㧘⇗ጊᄢੑ㇢㧘࿯੗↰ ⺈㧘ᩊ↰ᢅਯ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦ญ⣧≸ߦ߅ߌࠆⴊẏਛߩࡔ࠴࡞ൻ⇣Ᏹㆮવሶᢿ ߩᬌ⚝ߣ⥃ᐥ∛ᘒߣߩ⋧㑐㧧ᐔᚑ 20㧙22 ᐕᐲ㧧3,500 ජ౞(1,700㧦900㧦900 ජ౞)
9㧕 ⎇ⓥઍ⴫⠪㧦ᱞ↰⍮ሶ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦ࡅ࠻ᱤ㜑⚵❱ᐙ⚦⢩ߩ᮸┙ല₸ะ਄ߣ iPS⚦⢩ൻߩᬌ⸛㧧ᐔᚑ 20㧙21 ᐕᐲ㧧2,540 ජ౞(1,360㧦1,180 ජ౞)
10㧕 ⎇ⓥઍ⴫⠪㧦ችፒᐽ㓶㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦ૐ㉄⚛ⅣႺߦࠃࠆࡅ࠻ญ⣧߇ࠎߩ EMT ⺃ዉ㧧ᐔᚑ 20㧙21 ᐕᐲ㧧2,540 ජ౞(1,340㧦1,200 ජ౞)
11㧕 ⎇ⓥઍ⴫⠪㧦⇗ጊᄢੑ㇢㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦ࡅ࠻ᱤ⢦⚵❱ᐙ⚦⢩ߦ߅ߌࠆࠝࠬ࠹ࠝࠞ
࡞ࠪࡦ⊒⃻ߣⴊ▤ౝ⊹Ⴧᱺ࿃ሶ⺃ዉᯏ᭴ߩ⸃ᨆ㧧ᐔᚑ 20㧙22 ᐕᐲ㧧3,100 ජ౞(1,100㧦1,000㧦1,000ජ౞)
12㧕 ⎇ⓥઍ⴫⠪㧦ᵻ㚅㓶৻㇢㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦ࡅ࠻ญ⣧≸ Bcl-2 ࡈࠔࡒ࡝࡯ㆮવሶߩ⊒⃻᭽ᑼߣᴦ≮ലᨐߩᬌ⸛㧧ᐔᚑ 20㧙22 ᐕᐲ㧧2,800 ජ౞(1,000㧦900㧦900 ජ౞)
2㧕ฃ⸤⎇ⓥ1㧕 ࿯੗↰⺈㧘ട⮮ᕺਃ㧘☨ᧄ๺ᒄ㧘’↰ᶈ᮸㧘⇗ጊᄢੑ㇢㧘ᬮᐘඳ㧘ችᧄ⻞㧘⮮Ⴆ⑲᮸㧘ጊਅ⍮Ꮘ㧘⍹ਣ⚐৻㧘ᩊ↰ᢅਯ㧦ࠪࠚ࡯ࠣ࡟ࡦ∝୥⟲ᖚ⠪ߩญ⣧ੇ῎∝ᴦ≮ߦ߅ߌࠆႮ㉄࠮ࡆࡔ࡝ࡦ᳓๺‛ߩ೽૞↪⊒⃻ߣߘߩ੍㒐ߦ㑐ߔࠆ⥃ᐥ⊛⎇ⓥ㧧ᐔᚑ 18 ᐕᐲ㧧120 ජ౞(120 ජ౞)㧦ᣣᧄൻ⮎(ᩣ)
2㧕 ᩊ↰ᢅਯ㧘࿯੗↰ ⺈㧘ጊਅ⍮Ꮘ㧘’↰ᶈ᮸㧘ട⮮ᕺਃ㧘⇗ጊᄢੑ㇢㧘ᬮ ᐘඳ㧘☨ᧄ๺ᒄ㧘ᵻ㚅㓶৻㇢㧦ࠗ࠻࡝࠱࡯࡞ౝ↪ᶧ 1%૶↪ᚑ❣⺞ᩏ㧧ᐔᚑ 18 ᐕᐲ㧧200 ජ౞(200 ජ౞)㧦ࡗࡦ࠮ࡦࡈࠔ࡯ࡑ(ᩣ)
3㧕 ᩊ↰ᢅਯ, ࿯੗↰ ⺈㧦ญ⣧ੇ῎∝࡮⥠∩∝ߩ⎇ⓥ㧧ᐔᚑ 20 ᐕᐲ㧧200 ජ౞(200 ජ౞)㧦ᄢᱜንጊක⮎ຠ(ᩣ)
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫ
1㧕 ᚻႦᑪ৻࡮ᩊ↰ᢅਯ࡮࿡⽵㓉ᒄ࡮₹⟎਽೰࡮ጊਛિᒎ࡮㜞ᯅ๺೑㧦ࡅ࠻ᱤ⢦ᐙ⚦⢩߆ࠄߩੱᎿᄙ⢻ᕈᐙ⚦⢩(iPS ⚦⢩)ߩ㜞ല₸⺃ዉᴺ㧧ᐔᚑ 20 ᐕᐲ(․⸵಴㗿ਛ)
6㧚ቇળᵴേ
1㧕ቇળᓎຬᩊ↰ᢅਯ㧦
1㧕 ᣣᧄญ⣧ᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄญ⣧ᄖ⑼ቇળࠞ࡝ࠠࡘ࡜ࡓᆔຬળᆔຬ(㨪⃻࿷)3㧕 ᣣᧄญ⣧ᄖ⑼ቇળ࠲ࡃࠦኻ╷ᆔຬળᆔຬ(㨪⃻࿷)4㧕 ᣣᧄญ⣧ᄖ⑼ቇળኾ㐷ක⹺ቯᆔຬળᆔຬ(㨪⃻࿷)5㧕 ᣣᧄญ⣧ᄖ⑼ቇળ㔀⹹✬㓸ᩏ⺒ᆔຬળᆔຬ(ᐔᚑ 18 ᐕ 9 ᦬㨪⃻࿷)
6㧕 ᣣᧄญ⣧⑼ቇળ⹏⼏ຬ(㨪⃻࿷)7㧕 ᣣᧄญ⣧⣲≌ቇળ⹏⼏ຬ(ᐔᚑ 17 ᐕ 9 ᦬㨪⃻࿷)8㧕 ᣣᧄญ⣧㗶㗻㕙ᄖ்ቇળℂ੐(㨪⃻࿷)9㧕 ᣣᧄญ⣧ࠤࠕቇળ⹏⼏ຬ(ᐔᚑ 19 ᐕ 9 ᦬㨪⃻࿷)࿯੗↰ ⺈㧦
1㧕 ᣣᧄ∛ℂቇળ⹏⼏ຬ(㨪⃻࿷)㧙㧙2㧕ቇળ㐿௅ᩊ↰ᢅਯ㧦
1㧕 ╙ 33 ࿁ᣣᧄญ⣧ᄖ⑼ቇળਛㇱ࿾ᣇળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ጘ㒂)
3㧕ቇⴚ㔀⹹ᩊ↰ᢅਯ㧦
1㧕 ᣣᧄญ⣧ᄖ⑼ቇળ㔀⹹㧦✬㓸ᩏ⺒ᆔຬ(ᐔᚑ 18 ᐕ 9 ᦬㨪⃻࿷)7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙṶ⠪㧘ᐳ㐳ᩊ↰ᢅਯ㧦
1㧕 ╙ 61 ࿁ᣣᧄญ⣧⑼ቇળ✚ળ(ᐔᚑ 19 ᐕ 4 ᦬㧘␹ᚭ㧘ࡒ࠾ࠪࡦࡐࠫ࠙ࡓ‫(≸ޟ‬ၮ␆)6‫ޠ‬ᐳ㐳)2㧕 ᣣᧄ⡊㥦ຜ༄⑼කળ ╙ 32 ࿁⥃ᐥኅࡈࠜ࡯࡜ࡓ(ᐔᚑ 19 ᐕ 8 ᦬㧘㜞ጊ㧘․೎⻠Ṷ‫ޟ‬ญ⣧ੇ῎∝ߣญ⣧☼⤑∔ᖚߩ⸻ᢿߣᴦ≮㧦㜞㦂ൻ␠ળࠍ߰߹߃ߚญ⣧ੇ῎∝࡮⥠∩∝߳ߩኻᔕ‫ޠ‬Ṷ⠪)3㧕 ጘ㒂⋵ਃᏧળวหቇⴚ⻠Ṷળг㛽☻㝃∝ᴦ≮ߣᱤ⑼⸻≮(ᐔᚑ 20 ᐕ 3 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ࠬࡎࠬࡆޟ‬ࡎࡀ࡯࠻⵾೷ߦࠃࠆ㗶㛽უᱫߩෂ㒾ᕈߣක࡮ᱤ࡮⮎ㅪ៤ߩᔅⷐᕈ‫ޠ‬Ṷ⠪)
4㧕 ╙ 6 ࿁ᣣᧄ㛽☻㝃∝⎇ⓥળቇⴚᄢળ(ᐔᚑ 20 ᐕ 3 ᦬㧘ጘ㒂㧘ᢎ⢒⻠Ṷ‫ޟ‬㛽☻㝃∝ᴦ≮⮎(ࡆࠬࡎࠬࡎ
ࡀ࡯࠻⵾೷)ߣᱤ⑼ᴦ≮—㗶㛽უᱫߩෂ㒾ᕈߣකᱤ⮎ㅪ៤ߩᔅⷐᕈ‫ޠ‬Ṷ⠪)
5㧕 ╙ 1 ࿁ጘ㒂⋵ญ⣧ࠤࠕࡈࠜ࡯࡜ࡓ(ᐔᚑ 20 ᐕ 3 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬ญ⣧ࠤࠕ࡯ߘߩᣂߒ޿น⢻ᕈߦߟ޿ߡ‫ޠ‬ᐳ㐳)
6㧕 ╙ 1 ࿁ጘ㒂⋵ญ⣧ࠤࠕࡈࠜ࡯࡜ࡓ(ᐔᚑ 20 ᐕ 3 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬ญ⣧ࠤࠕߩ޿ࠈߪ࡯ᕆᕈᦼ㧘᦭∛⠪ߦኻߔࠆญ⣧ࠤࠕ‫ޠ‬ᐳ㐳)7㧕 ╙ 11 ࿁ጘ㒂✭๺ක≮⎇ⓥળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ጘ㒂㧘․೎⻠Ṷ࡮㑐ㅪ⻠Ṷ‫✭ޟ‬๺ක≮ߦ߅ߌࠆญ⣧ࠤࠕ‫ޠ‬ᐳ㐳)8㧕 ╙ 33 ࿁ᣣᧄญ⣧ᄖ⑼ቇળਛㇱ࿾ᣇળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫⥃ޟ‬ᐥ㤗㈮ߩㅴᱠߣᖚ⠪ߩ቟ోᕈ‫ޠ‬ᐳ㐳)9㧕 ╙ 33 ࿁ᣣᧄญ⣧ᄖ⑼ቇળਛㇱ࿾ᣇળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ጘ㒂㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯‫ޟ‬PK-PD ℂ⺰ߦၮߠߊᗵᨴ∝ᴦ≮⮎ߩㆡᱜ૶↪ᷝઃᢥᦠߤ߅ࠅߢߪᖚ⠪ࠍᢇ߃ߥ޿‫ޠ‬ᐳ㐳)10㧕 ╙ 33 ࿁ᣣᧄญ⣧ᄖ⑼ቇળਛㇱ࿾ᣇળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ጘ㒂㧘࡝ࡈ࡟࠶ࠪࡘ࠮ࡒ࠽࡯‫࡯ࡀࡑࠢࠬ࡝ޟ‬ࠫࡔࡦ࠻੍⍮ᕈߩะ਄‫ޠ‬ᐳ㐳)11㧕 ጘ㒂⋵଻㒾කදળ ᱤ⑼⎇ⓥળ(ᐔᚑ 20 ᐕ 9 ᦬㧘ጘ㒂㧘⻠Ṷ‫⸻∛ޟ‬ㅪ៤ߦࠃࠆࠗࡦࡊ࡜ࡦߣᴦ≮ߩዷ㐿቟ᔃ࡮቟ోߩࠗࡦࡊ࡜ࡦߣᴦ≮ࠍ⋡ᜰߒߡ‫ޠ‬Ṷ⠪)࿯੗↰ ⺈㧦
1㧕 ╙ 60 ࿁ᣣᧄญ⣧⑼ቇળ✚ળ(ᐔᚑ 18 ᐕ 5 ᦬㧘ฬฎደ㧘ࡒ࠾ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᔃりකቇ‫ޠ‬Ṷ⠪)
2㧕 ╙ 61 ࿁ᣣᧄญ⣧⑼ቇળ✚ળ(ᐔᚑ 19 ᐕ 4 ᦬㧘␹ᚭ㧘ࡒ࠾ࠪࡦࡐࠫ࠙ࡓ‫⥃(⤑☼ޟ‬ᐥ)‫ޠ‬Ṷ⠪)
3㧕 ╙ 18 ࿁ᣣᧄญ⣧∛ℂቇળ✚ળ(ᐔᚑ 19 ᐕ 8 ᦬㧘ጘ㒂㧘ࠬ࡜ࠗ࠼࠮ࡒ࠽࡯‫ޟ‬ญ⣧∛ᄌߩ⡺⌒ᚲ⷗‫ޠ‬Ṷ
⠪)
4㧕 AGORA21—ᣂ਎ઍ H2 ࡉࡠ࠶ࠞ࡯ߩㅴൻ⺰(ᐔᚑ 20 ᐕ 4 ᦬㧘ᄢ㒋㧘⻠Ṷ‫(∝∩⥠ޟ‬ญ⣧☼⤑ἳᾲᗵ)ߦኻߔࠆ࡜ࡈ࠴ࠫࡦߩ✭๺ലᨐߦߟ޿ߡ‫ޠ‬Ṷ⠪)
5㧕 ╙ 33 ࿁ᣣᧄญ⣧ᄖ⑼ቇળਛㇱ࿾ᣇળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ጘ㒂㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯‫∝ࡦ࡟ࠣ࡯ࠚࠪޟ‬୥⟲ߦ઻߁ญ⣧ੇ῎∝ߦኻߔࠆฦ⒳ᴦ≮ᚑ❣ߣߘߩᗧ⟵‫ޠ‬ᐳ㐳)
6㧕 ╙ 34 ࿁ࠕ࡞ࠞࡠࠗ࠼⎇ⓥળ(ᐔᚑ 20 ᐕ 6 ᦬㧘ᄢ㒋㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ‫ޟ‬ᣣᏱ⸻≮ߦ߅ߌࠆᘟᕈ−∩ߩ
▤ℂ‫ޠ‬Ṷ⠪)7㧕 ╙ 19 ࿁ᣣᧄ⥃ᐥญ⣧∛ℂቇળࠬ࡜ࠗ࠼࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 8 ᦬㧘᧲੩㧘⻠Ṷ‫ޟ‬ญ⣧∛ᄌߩ⡺⌒ᚲ⷗‫ޠ‬
Ṷ⠪)
ጊਅ⍮Ꮘ㧦
1㧕 ╙ 25 ࿁ᣣᧄญ⣧⣲≌ቇળ✚ળ(ᐔᚑ 19 ᐕ 2 ᦬㧘ฬฎደ㧘ࡒ࠾ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ญ⣧≸ᴦ≮ߩ⃻⁁ߣߎࠇ߆ࠄ‫ޠ‬Ṷ⠪)2㧕 ╙ 61 ࿁ᣣᧄญ⣧⑼ቇળ✚ળ(ᐔᚑ 19 ᐕ 4 ᦬㧘␹ᚭ㧘ࡒ࠾ࠪࡦࡐࠫ࠙ࡓ‫⥃(≸ޟ‬ᐥ)3‫ޠ‬Ṷ⠪)ᵻ㚅㓶৻㇢㧦
1㧕 ╙ 61 ࿁ᣣᧄญ⣧⑼ቇળ✚ળ(ᐔᚑ 19 ᐕ 4 ᦬㧘␹ᚭ㧘ࡒ࠾ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᄖ்‫ޠ‬Ṷ⠪)㧙㧙⺪⸰㆐ᒾ㧦
1㧕 ╙ 60 ࿁ᣣᧄญ⣧⑼ቇળ✚ળ(ᐔᚑ 18 ᐕ 5 ᦬㧘ฬฎደ㧘ࡒ࠾ࠪࡦࡐࠫ࠙ࡓ‫ ∉఺ߩ≸ޟ‬1‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ1㧕 ട⮮ᕺਃ㧦ࠧ࡯࡞࠼࡝ࡏࡦ⾨(ᐔᚑ 19 ᐕ 10 ᦬ 5 ᣣ)
9㧚␠ળᵴേᩊ↰ᢅਯ㧦
1㧕 ⑼⎇⾌ክᩏᆔຬ(ᐔᚑ 18 ᐕ 9 ᦬㨪⃻࿷)2㧕 ࿖଻ክᩏળᆔຬ(㨪⃻࿷)3㧕 ጘ㒂⋵ᱤ⑼ᛛᎿ჻⹜㛎ᆔຬ(㨪⃻࿷)࿯੗↰ ⺈㧦
1㧕 ጘ㒂⋵ᱤ⑼ᛛᎿ჻⹜㛎ᆔຬ(ᐔᚑ 16 ᐕ 12 ᦬㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ᩊ↰ᢅਯ㧦EGF ฃኈ૕࡮ࠪࠣ࠽࡞વ㆐ࠍಽሶᮡ⊛ߣߔࠆญ⣧߇ࠎᴦ≮ߩၮ␆⊛ᬌ⸛㧦ᐔᚑ 15 ᐕᐲ
㧙17 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ⎇ⓥᚑᨐႎ๔ᦠ㧦1㧙102(2006 ᐕ 1 ᦬)
2㧕 ᩊ↰ᢅਯ㧦ࠬ࡝࡜ࡦࠞ࡮บḧߦ߅ߌࠆญ⣧߇ࠎߩಽሶ∉ቇ⊛Ყセ⺞ᩏ㧦ᐔᚑ 16 ᐕᐲ㧙19 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ⎇ⓥᚑᨐႎ๔ᦠ㧦1㧙50(2008 ᐕ 4 ᦬)
11㧚ႎ㆏1㧕 ᩊ↰ᢅਯ㧦DICOM Viewer(࠳ࠗࠦࡓ࡮ࡆࡘ࡯ࡢ࡯)ߣߪ㧦ጘᱤᣂႎ(2006 ᐕ 4 ᦬ 22 ᣣ)
2㧕 ࿯੗↰ ⺈㧘ᩊ↰ᢅਯ㧦৻⥸Ꮢ᳃ߩ 3 ഀߦ࠼࡜ࠗࡑ࠙ࠬ㧦Medical Tribune(2006 ᐕ 6 ᦬ 8 ᣣ)
3㧕 ᩊ↰ᢅਯ㧦∛㒮ᱤ⑼⚫੺Ԛ㧦ጘ㒂⋵଻㒾කᣂ⡞(2006 ᐕ 8 ᦬ 10 ᣣ)
4㧕 ᩊ↰ᢅਯ㧦ࡆࠬࡈࠔࠬࡈࠜࡀ࡯࠻⵾೷ߣᱤ⑼ᴦ≮—㗶㛽უᱫߩෂ㒾ᕈߣකᱤ⮎ㅪ៤ߩᔅⷐᕈ㧦ጘᱤᣂႎ(2007 ᐕ 10 ᦬ 22 ᣣ)
5㧕 ᩊ↰ᢅਯ㧦ࡆࠬࡈࠔࠬࡈࠜࡀ࡯࠻⵾೷ߦࠃࠆ㗶㛽უᱫߩෂ㒾ᕈߣකᱤ⮎ㅪ៤ߩᔅⷐᕈ㧦ጘ㒂⋵කᏧળႎ(2007 ᐕ 11 ᦬ 1 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔญ⣧∛ᘒቇಽ㊁ߣߒߡߩ✚ว⊛⹏ଔߣߒߡ㧘᭎ߨ⋡ᮡࠍ㆐ᚑߒߡ޿ࠆߣ⠨߃ߡ޿ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷․ߦᵴേࠍផㅴߔࠆߚ߼ߦᦨ߽ᔅⷐߢ޽ࠆ⾗㊄㕙ߪ㧘ᐔᚑ 15 ᐕᐲએ㒠⃻࿷߹ߢㅪ⛯ߒߡ⑼ቇ⎇ⓥ⾌
1000 ਁએ਄ߩ₪ᓧ⋡ᮡࠍ㆐ᚑߒߡ᧪ߡ޿ࠆ‫ߚ߹ޕ‬㧘⎇ⓥ᧚ᢱ㧔⥃ᐥ᧚ᢱ㧕ߩ㓸Ⓧ߽⚻ᤨ⊛ߦⓍߺ㊀ߥߞߡ᧪ߡ޿ࠆ‫ߩࠄࠇߎޕ‬㕙ߢߪ㧘ߎߩ߹߹ߩദജࠍ⛮⛯ߔࠆߎߣߦࠃࠅ⏕ታߦᚑᨐ߇ᓧࠄࠇࠆߣ⠨߃ࠄࠇࠆ‫ࠄ߇ߥߒ߆ߒޕ‬㧘⑼⎇⾌ߪߘߩ㗵࡮ᦼ㑆ߣ߽ߦ⎇ⓥࠍᄢ߈ߊዷ㐿ߔࠆߦߪዊ㗵߆ߟ⍴ᦼߢ޽ࠅ㧘ᦝߥࠆᄢဳߩᄖㇱ⎇ⓥ⾗㊄ࠍ₪ᓧߔࠆᔅⷐᕈࠍ∩ಾߦᗵߓߡ޿ࠆ‫ߚ߹ޕ‬㧘⃻᦭ੱຬߩ࡝ࠨ࡯࠴ࡑࠗࡦ࠼ࠍೝ
ỗߔࠆߎߣ߽㕖Ᏹߦ㊀ⷐߣ⠨߃㧘2004 ᐕࠃࠅ⛮⛯ߒߡ޿ࠆಽ㊁ౝ࡝ࠨ࡯࠴ࠞࡦࡈࠔ࡜ࡦࠬࠍᒝൻ࡮⊒ዷߐߖࠆߚ߼ߦၮ␆ߩฦಽ㊁ߣߩㅪ៤߽㊀ⷐߣ⠨߃ߡ޿ࠆ‫ޕ‬੹ᓟߩዷᦸ⃻࿷㧘ࡅ࠻ᱤ⢦࡮ᱤ㜑߆ࠄߩ⚵❱ᐙ⚦⢩ߩ㓸Ⓧ࡮ࡃࡦࠢൻߣ iPS ⚦⢩ൻࠍዷ㐿ਛߢ޽ࠅ㧘᦭ᦸߥ⚿ᨐࠍ␜ߒߟߟ޽ࠆ‫ࠍࠇߎޕ‬ᚑ㐳ࠛࡦࠫࡦߩᩇߩ৻ߟߣߒߡട߃㧘㑐ㅪಽ㊁ߣߩ⊒ዷࠍᮨ⚝ߒߡ޿ࠆ㧔ᄢᄌ᦭ᦸߥ⎇ⓥ⾗Ḯߣߥࠆน⢻ᕈ߇㜞ߊ㧘ㅴ᝞ߦࠃࠅᄙᄢߥࠆᚑᨐࠍᓧࠆߣᦼᓙߒߡ޿ࠆ㧕
‫ޕ‬

㧙㧙

ާ␹⚻⛔ᓮቇ⻠ᐳި
㧔1㧕㜞ᰴ␹⚻ᒻᘒቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
1. ⷞⷡ⊹⾰␹⚻࿁〝ߩ⸃᣿
2. ญ⣧ᗵⷡߣᖱേ♽࿁〝ㅪ⛊ߩ⎇ⓥ
3. ᄢ⣖⊹⾰⊒↢ᯏ᭴ߩ⸃ᨆ
4. ࠬ࠻࡟ࠬߦࠃࠆ␹⚻࿁〝ᄌൻߩ⎇ⓥ
5. 㜞ᰴ⣖ᯏ⢻ࡀ࠶࠻ࡢ࡯ࠢࠍᵴᕈൻߔࠆᣇ╷ߩ㐿⊒
2㧚ฬ★
દ⮮๺ᄦ
ᢎ᝼㧦
ಎᢎ᝼㧦 ਛ᧛ᶈᐘ
⮮↰㓷ᢥ⻠Ꮷ㧦Kazuo Itoh
Hiroyuki Nakamura
Masafumi Fujita

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
ߥߒ⪺ᦠ㧔᰷ᢥ㧕
1㧕 Watanabe K, Kubo K, Nakamura H, Tachibana A, Kim W, Ono Y, Sasaguri K, Onozuka M.
Involvement if Dysfunctional Mastication in Congnitive System Deficits in the Mouse. In: Onozuka M,
Yen C, eds. Novel Trends in Brain Science. Tokyo: Springer; 2008:115-129.
✚⺑㧔๺ᢥ㧕
ߥߒ✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
ߥߒේ⪺㧔᰷ᢥ㧕
1㧕 Nakamura H, Wu R, Watanabe K, Onozuka M, Itoh K. Projections of glutamate decarboxylase positive
and negative cerebellar neurons to the pretectum in the cat. Neurosci Lett. 2006;403:30-34.
2㧕 Fukumitsu H, Ohtsuka M, Murai R, Nakamura H, Itoh K, Furukawa S. Brain-derived neurotrophic
factor participates in determination of neuronal laminar fate in the developing mouse cerebral cortex.
J Neurosci. 2006;26:13218-13230.
3㧕 Hirano Y, Fujita M, Watanabe K, Niwa M, Takahashi T, Kanematsu M, Ido Y, Tomida M, Onozuka M.
Effect of unpleasant loud noise on hippocampal activities during picture encoding: an fMRI study.
Brain Cogn. 2006;61:280-285.
4㧕 Kubo K, Yamada Y, Iinuma M, Iwaku F, Tamura Y, Watanabe K, Nakamura H, Onozuka M. Occlusal
disharmony induces spatial memory impairment and hippocampal neuron degeneration via stress in
SAMP8 mice. Neurosci Lett. 2007;414:188-191.
5㧕 Nakamura H, Chaumon M, Klijn F, Innocenti GM. Dynamic properties of the representation of thevisual field midline in the visual areas 17 and 18 of the ferret (Mustela putorius). Cereb Cortex.
2008;18:1941-1950.

IF 2.019

IF 7.506

IF 1.845

IF 2.092

IF 6.3684㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦⮮↰㓷ᢥ㧘⎇ⓥಽᜂ⠪㧦౗᧻㓷ਯ㧘ട⮮ೣᑝ㧘⮮ේ ๟㧘ਭ଻㊄ᒎ㧧ᢥㇱ⑼ቇ⋭⑼ቇ
⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(B)(2)㧦㜞㦂␠ળߦ߅޿ߡ⠧ᐕᱤ⑼කቇ߇ᜂ߁␠ળ⊛㊀ⷐᕈࠍ⣖⑼ቇ⊛ߦታ⸽ߔࠆ㧧ᐔᚑ 18㧙19 ᐕᐲ㧧20,410 ජ౞(16,900㧦3,510 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦ਛ᧛ᶈᐘ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦ⷞⷡ⊹⾰ third tier visual cortex ߩⷞ㊁ౣ⃻ߣࠛ࡝ࠕ඙ಽ㧧ᐔᚑ 18㧙20 ᐕᐲ㧧3,790 ජ౞(1,400㧦1,690㧦700 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦ਛ᧛ᶈᐘ㧧⥄ὼ⑼ቇ⎇ⓥᯏ᭴↢ℂቇ⎇ⓥᚲ ౒ห೑↪⎇ⓥ㧦ࡅ࠻ᄢ⣖⊹⾰ߦ߅ߌࠆ㧟㧙㧙ᰴⷞⷡ⊹⾰ⶄว૕(third tier visual complex)ߩ૏⟎ߣⷞⷡౣ⃻㧧ᐔᚑ 19 ᐕᐲ㧧72 ජ౞4㧕 ⎇ⓥઍ⴫⠪㧦દ⮮๺ᄦ㧧੩ㇺᄢቇ㔤㐳㘃⎇ⓥᚲ ౒ห೑↪⎇ⓥ㧦Ꮐฝᄢ⣖ඨ⃿⊹⾰ߩᯏ⢻ಽൻߩ⿠Ḯࠍតࠆ㧧ᐔᚑ 19 ᐕᐲ㧧32 ජ౞5㧕 ⎇ⓥઍ⴫⠪㧦ਛ᧛ᶈᐘ㧧⥄ὼ⑼ቇ⎇ⓥᯏ᭴↢ℂቇ⎇ⓥᚲ ౒ห೑↪⎇ⓥ㧦⟤ߒߐࠍ್ᢿߔࠆ⣖̆ⷞⷡߣ⡬ⷡߩⶄวೝỗߦࠃࠆ⣖⾮ᵴㇱ૏ߩ⸃᣿㧧ᐔᚑ 20 ᐕᐲ㧧100 ජ౞6㧕 ⎇ⓥઍ⴫⠪㧦દ⮮๺ᄦ, ⎇ⓥಽᜂ⠪㧦ਛ᧛ᶈᐘ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦ࠬ࠻࡟ࠬߦࠃࠅᗖ⿠ߐࠇࠆญ⣧ᗵⷡ⇣Ᏹߩ␹⚻ၮ⋚ߩ⸃᣿㧧ᐔᚑ 20㧙22 ᐕᐲ㧧3,700 ජ౞(2,200㧦900㧦
600 ජ౞)7㧕 ⎇ⓥઍ⴫⠪㧦⮮↰㓷ᢥ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦⢻േ⊛ⷞ⡬ⷡ⸥ᙘ࠻࡟࡯࠾ࡦ
ࠣߩ߽ߚࠄߔ⍮⢻ะ਄ലᨐߩᬌ⸽㧧ᐔᚑ 20㧙22 ᐕᐲ㧧3,970 ජ౞(2,470㧦600㧦900 ජ౞)
2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥ
1㧕 ⎇ⓥઍ⴫⠪㧦દ⮮๺ᄦ㧘⎇ⓥಽᜂ⠪㧦ਛ᧛ᶈᐘ㧦㗶࡮ญ⣧ᯏ⢻ߩ␹⚻ᯏ᭴ߩ⸃᣿㧧ᐔᚑ 18㧙20 ᐕᐲ㧧
6,000 ජ౞(2,000㧦2,000㧦2,000 ජ౞)㧦␹ᄹᎹᱤ⑼ᄢቇ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ਛ᧛ᶈᐘ㧦
1㧕 ╙ 10 ࿁ᣣᧄຏวቇળቇⴚᄢળ(2006 ᐕ 1 ᦬㧘᧲੩㧘․೎⻠Ṷ‫ޟ‬๰ྨེቭߣ⣖ߩ⍮⊛ᯏ⢻‫౒ޠ‬หṶ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേદ⮮๺ᄦ㧦
1㧕 ↢ℂቇ⎇ⓥᚲㆇ༡ᆔຬ(㨪⃻࿷)2㧕 㜞⍮ᄢቇකቇㇱකቇᢎ⢒ࡢ࡯࡚ࠢࠪ࠶ࡊ ࠲ࠬࠢࡈࠜ࡯ࠬ(㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 દ⮮๺ᄦ㧦Ꮐฝᄢ⣖ඨ⃿⊹⾰ߩᯏ⢻ಽൻߩ⿠Ḯࠍតࠆ㧦੩ㇺᄢቇ㔤㐳㘃⎇ⓥᚲᐕႎ 38㧦21(2008ᐕ 8 ᦬)
2㧕 ਛ᧛ᶈᐘ㧦ࡑࠞࠢࠩ࡞ⷞⷡ⊹⾰ Third tier visual cortex ߩⷞ㊁ౣ⃻ߣࠛ࡝ࠕ඙ಽ㧦੩ㇺᄢቇ㔤㐳㘃⎇ⓥᚲᐕႎ 37㧦136(2007 ᐕ 7 ᦬)
3㧕 ਛ᧛ᶈᐘ㧦ࡑࠞࠢࠩ࡞ਅ㗡㗂ㅪว㊁㧔7 ㊁㧕ߦ߅ߌࠆᄙ㊀ᗵⷡ౉ജ⛔วߩᒻᘒቇ⊛⎇ⓥ㧦੩ㇺᄢቇ㔤㐳㘃⎇ⓥᚲᐕႎ 36㧦115 (2006 ᐕ 7 ᦬)
11㧚ႎ㆏
1㧕 ਛ᧛ᶈᐘ㧦⣖߇਎⇇ࠍ⷗ࠆ઀⚵ߺ㧦ጘ㒂ᣂ⡞(2007 ᐕ 3 ᦬ 27 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔᢎ⢒߿ᄢቇㆇ༡ߥߤߦᢎቭߩᄙᄢߥഭജࠍᔅⷐߣߐࠇࠆߎߣࠍ⠨ᘦߔࠆߣ㧘ߘࠇߥࠅߩ⎇ⓥᚑᨐࠍ਄ߍߡ޿ࠆ‫ޕ‬ᄢቇ㒮↢߿․೎දജ⎇ⓥຬߩ࠻࡟࡯࠾ࡦ߽ࠣߘࠇߥࠅߩᚑᨐࠍ਄ߍߡ޿ࠆ‫ޕ‬㧙㧙⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷⎇ⓥ⾌₪ᓧߦᄙᄢߥᤨ㑆ࠍⷐߒߡ޿ࠆ‫ޕ‬౒ห⎇ⓥߦࠃࠆ⎇ⓥ⾌ߩ⏕଻߇ᦸ߹ߒ޿‫ޕ‬੹ᓟߩዷᦸ⣖ߩ௛߈ࠍ⸃ᨆߔࠆߦߪ␹⚻࿁〝ࠍℂ⸃ߔࠆߎߣ߇㊀ⷐߢ޽ࠆ‫ߩ࡯࠲ࠢࡌࠬ࡞ࠖ࠙ޕ‬ዉ౉ߦࠃࠅ㧘⚦⢩࡟ࡌ࡞ߩ␹⚻࿁〝⸃ᨆࠍㅴ߼ߚ޿‫ޕ‬㧙㧙㧔2㧕↢ℂቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
ᔃ࡮ᓴⅣ↢ℂቇ㧘ⅣႺ↢ℂቇ㧘ቝቮකቇ․ߦ㊀ജකቇಽ㊁ߩ⎇ⓥࠍਥ૕ߣߒ㧘วࠊߖߡᧃ᪳ᓴⅣᡷༀⵝ⟎㐿⊒㧘⿠┙⵬ഥⵝ⟎㐿⊒㧘㔚᳇ೝỗߦࠃࠆ࡝ࡂࡆ࡝ᯏེ㐿⊒㧘ᣂⷙቝቮ᦯㐿⊒ߥߤ․⸵ߦၮߠ޿ߚ‛ㅧࠅࠍⴕߞߡ޿ࠆ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
⻠Ꮷ㧦

᫪↰໪ਯ
↰ਛ㇌ᒾ

Hironobu Morita
Kunihiko Tanaka

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ᫪↰໪ਯ㧚ࡅ࠻߇↢߈ᱷࠆߚ߼ߩ૕ߩߒߊߺ ╙ 2㧧ฬฎደ㧔ਃᕺ␠㧕
㧧2008 ᐕ㧦4㧙17.

⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 ᷰㆻ๺ሶ㧘ን↰⟤Ⓞሶ㧘ዊ㊁Ⴆታ㧚⹺⍮ߣญߩᓎഀ㧘ᱤ⇇ዷᦸ ೎ౠ ․೎ડ↹ ญ⣧ᯏ⢻ቇߩᄛ᣿ߌ㧙ญߩᓎഀࠍ⑼ቇߔࠆ 2006 ᐕ㧧107 Ꮞ㧦586㧙589.
2㧕 ᫪↰໪ਯ㧘቟ㇱജ㧘↰ਛ㇌ᒾ㧚ቝቮⅣႺਅߢߩᓴⅣ⺞▵㧙㊀ജᄌൻߦኻߔࠆേ⣂ⴊ࿶ᔕ╵ 㤗㈮ 2008 ᐕ㧧
57 Ꮞ㧦S66㧙S76.
3㧕 ቟ㇱജ㧘↰ਛ㇌ᒾ㧘᫪↰໪ਯ㧚ਅ⢇㕒⣂ⴊⴕേᘒߩ․ᕈ߆ࠄ⷗ߚᷓㇱ㕒⣂ⴊᩖ∝㧘ᣣᧄⴊᩖᱛⴊቇળ⹹
2008 ᐕ㧧19 Ꮞ㧦495㧙500.
✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ጊ↰ብዏ㧘᫪↰໪ਯ㧘↰ਛ㇌ᒾ㧘ဈ᧲⋥ⴕ㧚⿠┙േ૞․ᕈߩ⸃ᨆߦၮߠߊ⿠┙⵬ഥⵝ⟎ߩ㐿⊒ ᣣᧄᯏ᪾ቇળ⺰ᢥ㓸㧔C ✬㧕
㧘2008 ᐕ㧧74 Ꮞ㧦154㧙162.
ේ⪺㧔᰷ᢥ㧕
1㧕 Tanaka K, Gotoh MT, Awazu C, Morita H. Roles of vestibular system in controlling arterial pressure inconscious rats during a short period of microgravity. Neurosci Lett. 2006;397:40-43.
2㧕 Morita H, Abe C, Tanaka K, Shiratori M, Oguri M, Shiga T. Neuromuscular electrical stimulation andottoman-type seat effectively improve popliteal venous flow in sitting position. J Physil Sci.
2006;56:183-186.
3㧕 Fujio T, Fujihara H, Shibata M, Yamada S, Onaka T, Tanaka K, Morita H, Dayanithi G, Kawata M,
Murphy D, Ueta Y. Exaggerated response of arginine vasopressin-enhanced green fluorescent protein
fusion gene to salt loading without disturbance of body fluid homeostasis in rats. J Neuroendocrinol,
2006;18:776-785.
4㧕 Hirano, Y, Fujita, M, Watanabe, K, Niwa, M, Takahashi, T, Kanematsu, M, Ido, Y, Tomida, M,
Onozuka, M. Effect of unpleasant loud noise on hippocampal activities during picture encording: an
fMRI study. Brain Cog. 2006;61:280-285.
5㧕 Nakamura, H, Wu, R, Watanabe, K, Onozuka, M. Projections of glutamate decaboxylase positive andnegative cerebellar neurons to the pretectum in the cat. Neurosci Lett. 2006;403:30-34.
6㧕 Tanaka K, Gotoh MT, Awazu C, Morita H. Roles of vestibular system in controlling arterial pressure inconscious rats during a short period of microgravity. Neuroscience Letters. 2006;397:40-43.
7㧕 Morita H, Abe C, Tanaka K, Shiratori M, Oguri M, Shiga T. Neuromuscular electrical stimulation andottoman-type seat effectively improve popliteal venous flow in sitting position. J Physiol Sci.
2006;56:183-186.
8㧕 Morita H, Abe C, Awazu C, Tanaka K. Long-term hypergravity induces plastic alterations investibulo-cardiovascular reflex in conscious rats. Neurosci Lett. 2007;412:201-205.
9㧕 Abe C, Awazu C, Tanaka K, Chen H, Morita H. Two weeks of 3-G load attenuates pressor response to
microgravity in conscious rats. Exp Brain Res. 2007;181:639-646.
10㧕 Abe C, Tanaka K, Awazu C, Morita H. Strong galvanic vestibular stimulation obscures arterialpressure response to gravitational change in conscious rats. J Appl Physiol. 2008;104:34-40.
11㧕 Shinozaki K, Shimizu Y, Shiina T, Morita H, Takewaki T. Relationship between taste-induced㧙㧙

IF 2.085

IF 0.726

IF 2.920

IF 1.148
IF 2.085
IF 2.085

IF 0.726
IF 2.085
IF 2.027
IF 3.632

physiological reflexes and temperature of sweet taste. Physiology & Behavior. 2008;93:1000-1004.
12㧕 Abe C, Tanaka K, Awazu C, Morita H. Impairment of vestibular-mediated cardiovascular response andmotor coordination in rats born and reared under hypergravity. Am J Physiol. 2008;295:R173-R180.
13㧕 Miyazawa S, Shimizu Y, Shiina T, Hirayama H, Morita H, Takewaki T. Central A1-receptor activation
associated with onset of torpor protects the heart against low temperature in the Syrian hamster. Am
J Physiol. 2008;295:R991-R996.
14㧕 Abe C, Tanaka K, Morita H. The vestibular system is integral in regulating plastic alterations in thepressor response to free drop mediated by the nonvestibular system. Neurosci Lett. 2008;445:149-152.

IF 2.445
IF 3.661

IF 3.661
IF 2.0854㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦᫪↰໪ਯ㧧ቝቮⅣႺ೑↪ߦ㑐ߔࠆ౏൐࿾਄⎇ⓥ㧦೨ᐸ㧙േ⣂ⴊ࿶⺞▵♽ߩน႟ᕈߦ㑐ߔࠆၮ␆⊛߅ࠃ߮⥃ᐥ⊛⎇ⓥ㧧ᐔᚑ 17㧙19 ᐕᐲ㧧35,000 ජ౞(13,000㧦11,000㧦11,000 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦↰ਛ㇌ᒾ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦㊀ജᄌൻᤨߩᓴⅣ⺞▵ߦ߅ߌࠆౝ
⡊೨ᐸ♽ᯏ⢻ߩ⸃᣿ߣᔕ↪㧧ᐔᚑ 17㧙20 ᐕᐲ㧧2,800 ජ౞(800㧦700㧦800㧦500 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦᫪↰໪ਯ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦⿠┙૕ᕈૐਅߦ߅ߌࠆ೨ᐸ♽ߩ㑐ਈ㧧ᐔᚑ 20㧙22 ᐕᐲ㧧(1,690 ජ౞)
4㧕 ⎇ⓥઍ⴫⠪㧦቟ㇱജ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄․೎⎇ⓥຬᅑബ⾌㧦㊀ജⅣႺᄌൻߦኻߔࠆ↢૕ㆡᔕ࡮዁᧪᦬㕙ၮ࿾ߢ↢ᵴߔࠆߚ߼ߦ㧧ᐔᚑ 20㧙21 ᐕᐲ㧧1,600 ජ౞(800㧦800 ජ౞)
5㧕 ⎇ⓥಽᜂ⠪㧦᫪↰໪ਯ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦ⷞᐥਅㇱߦ߅ߌࠆ㘩᰼ਛᨔߩ MRI
ߦࠃࠆ 3 ᰴర↹௝ൻߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 20 ᐕᐲ㧧650 ජ౞
2㧕ฃ⸤⎇ⓥ1㧕 ᫪↰໪ਯ㧦ᷓㇱ㕒⣂ⴊᵹㅦᐲࠍჇടߐߖࠆᦨㆡೝỗࡄ࠲࡯ࡦߩ⸃᣿ߣೝỗⵝ⟎ߩ㐿⊒㧧ᐔᚑ 18 ᐕ
ᐲ㧧1,000 ජ౞㧦ࠝࡓࡠࡦࡋ࡞ࠬࠤࠕᩣᑼળ␠
3㧕౒ห⎇ⓥ1㧕 ᫪↰໪ਯ㧦⥄േゞ↪ࠪ࡯࠻ߩ㐳ᤨ㑆⌕ᐳߦ߅ߌࠆ∋ഭߩ⸃᣿㧧ᐔᚑ 18 ᐕᐲ㧧5,250 ජ౞㧦࠻࡛࠲⥄േゞᩣᑼળ␠
2㧕 ᫪↰໪ਯ㧦ゞਔౝⵝຠ߇ੱ૕ߦ෸߷ߔᓇ㗀㧧ᐔᚑ 18 ᐕᐲ㧧710 ජ౞㧦࠻࡛࠲⚜❱ᩣᑼળ␠3㧕 ᫪↰໪ਯ㧦⥄േゞ↪ࠪ࡯࠻ߩ㐳ᤨ㑆⌕ᐳߦ߅ߌࠆ∋ഭߩ⸃᣿㧧ᐔᚑ 19 ᐕᐲ㧧5,500 ජ౞㧦࠻࡛࠲⥄േゞᩣᑼળ␠
4㧕 ᫪↰໪ਯ㧦ゞਔౝⵝຠ߇ੱ૕ߦ෸߷ߔᓇ㗀㧧ᐔᚑ 19 ᐕᐲ㧧836 ජ౞㧦࠻࡛࠲⚜❱ᩣᑼળ␠5㧕 ᫪↰໪ਯ㧦ࠗࡦࡊ࡜ࡦ࠻ᴦ≮ߦ↪޿ࠆ⿥㖸ᵄࠍ೑↪ߒߚⵝ⟎㐿⊒㧧ᐔᚑ 19 ᐕᐲ㧧740 ජ౞㧦ਣཅᎿᬺᩣᑼળ␠
6㧕 ᫪↰໪ਯ㧦ᐔᚑ 19 ᐕᐲᰴ਎ઍవ┵ቝቮ᦯ⷐ⚛ᛛⴚ㧔ࠣࡠ࡯ࡉ㧕ߩ⎇ⓥ㧧ᐔᚑ 19 ᐕᐲ㧧595,160 ౞㧦⁛┙ⴕ᡽ᴺੱቝቮ⥶ⓨ⎇ⓥ㐿⊒ᯏ᭴
7㧕 ᫪↰໪ਯ㧦⥄ὼ⑼ቇ⎇ⓥᯏ᭴↢ℂቇ⎇ⓥᚲ౒ห೑↪⎇ⓥ㧧ᐔᚑ 20 ᐕᐲ㧧600 ජ౞㧦⥄ὼ⑼ቇ⎇ⓥᯏ
᭴8㧕 ᫪↰໪ਯ㧦⥄േゞ↪ࠪ࡯࠻ߩ㐳ᤨ㑆⌕ᐳߦ߅ߌࠆ∋ഭߩ⸃᣿㧧ᐔᚑ 20 ᐕᐲ㧧5,500 ජ౞㧦࠻࡛࠲⥄േゞᩣᑼળ␠
9㧕 ᫪↰໪ਯ㧦ゞਔౝⵝຠ߇ੱ૕ߦ෸߷ߔᓇ㗀㧧ᐔᚑ 20 ᐕᐲ㧧935 ජ౞㧦࠻࡛࠲⚜❱ᩣᑼળ␠
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫ
1㧕 ጊ↰ብዏ㧘᫪↰໪ਯ㧘↰ਛ㇌ᒾ㧦⿠┙⵬ഥⵝ⟎㧧ᐔᚑ 18 ᐕᐲ
2㧕 ဈ᧲⋥ⴕ㧘ᚑἑື຦㧘⮮Ꮞ๋ᦶ㧘቟⮮ᢅᒄ㧘᧛਄᣿ብ㧘ጊ↰ብዏ㧘᫪↰໪ਯ㧘↰ਛ㇌ᒾ㧘᧲ᐣ⽕㧦ᐳ㕙㚟േᣂᯏ᭴㧧ᐔᚑ 19 ᐕᐲ
3㧕 ዊᩙᚑੱ㧘᫪↰໪ਯ㧘↰ਛ㇌ᒾ㧘቟ㇱജ㧦ࡈ࠶࠻࡟ࠬ࠻ⵝ⟎㧧ᐔᚑ 20 ᐕᐲ
4㧕 ဈ᧲⋥ⴕ㧘ጊ↰ብዏ㧘᫪↰໪ਯ㧘↰ਛ㇌ᒾ㧘᧲ᐣ⽕㧦⿠┙⵬ഥⵝ⟎ߩ㚟േᣇᑼ㧧ᐔᚑ 20 ᐕᐲ
6㧚ቇળᵴേ
1㧕ቇળᓎຬ᫪↰໪ਯ㧦
1㧕 ᣣᧄ∛ᘒ↢ℂቇળℂ੐(㨪⃻࿷)㧙㧙2㧕 ᣣᧄ↢ℂቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄቝቮ⥶ⓨⅣႺකቇળ⹏⼏ຬ(ᐔᚑ 19 ᐕᐲ㨪⃻࿷)
4㧕 ᣣᧄ⥄ᓞ␹⚻ቇળ⹏⼏ຬ(㨪⃻࿷)↰ਛ㇌ᒾ㧦1㧕 ᣣᧄ∛ᘒ↢ℂቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ↢ℂቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄቝቮ⥶ⓨⅣႺකቇળ⹏⼏ຬ(ᐔᚑ 19 ᐕᐲ㨪⃻࿷)2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳᫪↰໪ਯ㧦
1㧕 International Society for Gravitational Physiology(ᐔᚑ 18 ᐕ 4 ᦬㧘Osaka㧘Invited Symposium:
Role of the vestibular system in arterial pressure response to gravitational stress; ᐳ㐳㧘Ṷ⠪)
2㧕 International Congress of Pathophysiology (ᐔᚑ 18 ᐕ 6 ᦬㧘Beijing㧘Invited Symposium: Role ofthe vestibular system in cardiovascular responses to gravitational stress; Ṷ⠪)3㧕 ╙ 52 ࿁ᣣᧄቝቮ⥶ⓨⅣႺකቇળᄢળ(ᐔᚑ 18 ᐕ 11 ᦬㧘☨ሶ㧘ᢎ⢒⻠Ṷ‫ޟ‬㊀ജᄌൻᤨߩⴊ࿶⺞▵ߦ߅ߌࠆ೨ᐸ♽ߩᓎഀߣߘߩน႟ᕈ‫ޠ‬Ṷ⠪)
4㧕 International Space Medicine Symposium in Sapporo(ᐔᚑ 19 ᐕ 2 ᦬㧘Sapporo, Plastic alterationof vestibulo-cardiovascular system induced by different gravitational environment; Ṷ⠪)
5㧕 ╙ 84 ࿁ᣣᧄ↢ℂቇળᄢળ(ᐔᚑ 19 ᐕ 3 ᦬㧘Osaka㧘Feedforward arterial pressure control by thevestibular system; Ṷ⠪)
6㧕 ╙ 18 ࿁ᣣᧄ∛ᘒ↢ℂቇળᄢળ(ᐔᚑ 20 ᐕ 1 ᦬㧘␹ᚭ㧘ࠬ࠻࡟ࠬ⎇ⓥߩᣂዷ㐿㧙∛ᘒ↢ℂቇ⊛ⷞὐ߆ࠄߩࠕࡊࡠ࡯࠴‫ޟ‬㊀ജࠬ࠻࡟ࠬߦኻߔࠆᓴⅣ⺞▵㧙೨ᐸ♽ߩᓎഀߣߘߩน႟ᕈ‫ޠ‬ᐳ㐳㧘Ṷ⠪)7㧕 ╙ 85 ࿁ᣣᧄ↢ℂቇળᄢળ(ᐔᚑ 20 ᐕ 3 ᦬㧘Tokyo, Approach to whole body-New stream to study
autonomic nervous and neuroendocrine system: Autonomic control of arterial pressure during
gravitational stress; ᐳ㐳㧘Ṷ⠪)8㧕 ╙ 85 ࿁ᣣᧄ↢ℂቇળᄢળ(ᐔᚑ 20 ᐕ 3 ᦬㧘᧲੩㧘ᢎ⢒ᆔຬળࠪࡦࡐࠫ࠙ࡓ ↢ℂቇળࡕ࠺࡞⻠⟵‫ޟ‬ᔃ࡮ᓴⅣ♽‫ޠ‬Ṷ⠪)9㧕 ╙ 85 ࿁ᣣᧄ↢ℂቇળᄢળ(ᐔᚑ 20 ᐕ 3 ᦬㧘Tokyo, Pathophysiology of deep venous thrombosis andits prophylaxis: Property of lower limbs venous hemodynamics and risk for deep veinthrombosis; ᐳ㐳㧘Ṷ⠪)10㧕 ᣣᧄ㤗㈮⑼ቇળ╙ 55 ࿁ቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 6 ᦬㧘ᮮᵿ㧘ᢎ⢒⻠Ṷ‫ޟ‬ቝቮⓨ㑆ߣᓴⅣ↢ℂ㧙㊀ജᄌൻߦኻߔࠆᔕ╵‫ޠ‬Ṷ⠪)↰ਛ㇌ᒾ㧦
1㧕 International Congress of Pathophysiology(ᐔᚑ 18 ᐕ 6 ᦬, Beijing, Symposium: Correlation
Between Compliance and high frequency centroid of pressure waveform in the abdominal aorta.;Ṷ⠪)2㧕 ᒻߩ⑼ቇળ ᒻࠪࡘ࡯࡟ 2006(ᐔᚑ 18 ᐕ 9 ᦬ ጘ㒂㧘᜗ᓙ⻠Ṷ‫ޟ‬⡊ߣⴊ࿶ߣቝቮකቇ‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ1㧕 ቟ㇱജ㧦ᣣᧄ∛ᘒ↢ℂቇળᅑബ⾨(ᐔᚑ 20 ᐕᐲ)
9㧚␠ળᵴേ᫪↰໪ਯ㧦
1㧕 ᣣᧄቇⴚᝄ⥝ળ⑼ቇ⎇ⓥ⾌ᆔຬળኾ㐷ᆔຬ(ᐔᚑ 18 ᐕᐲ㧘ᐔᚑ 20 ᐕᐲ)
2㧕 ࠰࡞࠻ࠨࠗࠛࡦࠬ⎇ⓥ⽷࿅⎇ⓥㆇ༡ክ⼏ળᆔຬ(㨪⃻࿷)㧙㧙10㧚ႎ๔ᦠ
1㧕 ᫪↰໪ਯ㧦ᐔᚑ 15 ᐕᐲ㧙17 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(B)(2)⎇ⓥᚑᨐႎ๔ᦠ㧦㐳ᦼ㑆㊀ജᄌൻߦኻߔࠆᓴⅣ㧘⥄ᓞ␹⚻㧘ਛᨔᔕ╵ߩࡕ࠺࡞૞ᚑ(2006 ᐕ 3 ᦬)
2㧕 ᫪↰໪ਯ㧦╙ 8 ࿁㧔ᐔᚑ 17 ᐕᐲ㧙19 ᐕᐲ㧕ㆬቯቝቮⅣႺ೑↪ߦ㑐ߔࠆ౏൐࿾਄⎇ⓥᚑᨐႎ๔ᦠ㧦೨ᐸ㧙േ⣂ⴊ࿶⺞▵♽ߩน႟ᕈߦ㑐ߔࠆၮ␆⊛߅ࠃ߮⥃ᐥ⊛⎇ⓥ(2008 ᐕ 7 ᦬)
3㧕 ↰ਛ㇌ᒾ㧘᫪↰໪ਯ㧦ᐔᚑ 19 ᐕᐲᰴ਎ઍవ┵ቝቮ᦯ⷐ⚛ᛛⴚ㧔ࠣࡠ࡯ࡉ㧕ߩ⎇ⓥ11㧚ႎ㆏
1㧕 ᫪↰໪ਯ㧦‫ⴊޟ‬ᩖ∝㕦ਅߢ੍㒐㧦㔚ᵹߢ╭⡺ೝỗ‫ޠ‬㧦ᦺᣣᣂ⡞(2006 ᐕ 1 ᦬ 10 ᣣ)
2㧕 ↰ਛ㇌ᒾ㧦㐿ዪ 7 ๟ᐕ⸥ᔨ⇟⚵‫ޟ‬The Moon‫ޠ‬㧦ᰴ਎ઍ࿖↥ቝቮ᦯㐿⊒㧦BS ࠫࡖࡄࡦ(2008 ᐕ 3 ᦬ 8ᣣ)12㧚⥄Ꮖ⹏ଔ
⹏ଔ
ᐔᚑ 17~19 ᐕᐲߦᄢቇ㒮↢ߣߒߡ࿷ቇߒߚቇ↢ߪ㧘ᄢቇ㒮තᬺᓟ㧘ᣣᧄቇⴚᝄ⥝ળ․೎⎇ⓥຬߣߒߡ
↢ℂቇಽ㊁ߢ⎇ⓥࠍ⛮⛯ߒߡ޿ࠆ‫ߚ߹ޕ‬㧘ઁᄢቇߩකቇㇱቇ↢ߩၮ␆㈩ዻࠍᒁ߈ฃߌߚ‫ߩߘޕ‬ቇ↢ߪ㧘තᓟ⎇ୃవߣߒߡጘ㒂ᄢቇࠍㆬᛯߒ㧘⎇ୃ⚳ੌᓟጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼ߦ౉ቇ੍ቯߢ޽ࠆ‫ޕ‬ၮ␆කቇ♽ߩᷓೞߥ⧯ᚻ⎇ⓥ⠪ਇ⿷߆ࠄ㐓ߺߡ㧘ዊߐߥ⧘ߢ޽ࠆ߇⧯ᚻ⎇ⓥ⠪ࠍฃߌ౉ࠇࠄࠇࠆ⎇ⓥⅣႺࠍᢛ߃ߟߟ޽ࠆߎߣߪ⹏ଔߦ୯ߔࠆ‫ߚ߹ޕ‬㧘ጘ㒂ᄢቇઁቇㇱߩቇㇱቇ↢߿ᄢቇ㒮↢߳ߩ⎇ⓥᜰዉ߽Ⓧᭂ⊛ߦⴕ޿㧘ቇㇱߩᨒࠍ⿥߃ߚ⎇ⓥᵴേࠍᐢߍߟߟ޽ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ᚒ‫߇ޘ‬ቇ↢ߩ㗃㧘ᄢቇߢ௛ߊᢎቭ㧘⎇ⓥ⠪ࠍ⷗ߡ㧘‫ޟ‬ᭉߒߘ߁ߛߥ࡯㧘௢ߚߜ߽ᄢቇߢ௛߈ߚ޿ߥ࡯‫ޠ‬ߣᙏࠇߚ߽ߩߢ޽ࠆ‫ߡߒߚߪޕ‬㧘⃻࿷ߩቇ↢߇ᚒ‫ߩޘ‬ᆫࠍ⷗ߡ㧘‫ޟ‬ᭉߒߘ߁ߛߥ࡯㧘௢ߚߜ߽ᄢቇߦᱷࠅ
ߚ޿㧘⎇ⓥߒߡߺߚ޿‫ߣޠ‬ᕁߞߡߊࠇࠆ߆㧫ᄙಽ㧘no ߢ޽ࠈ߁‫߽ᦨ߇ߣߎߩߎޕ‬ᷓೞߥ໧㗴ߢ޽ࠆ‫ޕ‬ኻᔕ╷㧦ࡑ࡯ࡏ࠴ࡏ࠴ᭉߒߊ߿ࠅ߹ߔ‫ޕ‬੹ᓟߩዷᦸ੹ᓟ߽ߎࠇ߹ߢห᭽㧘⛔ว⊛ⷞὐߦ┙ߜ㧘⥄ᓞ␹⚻♽㧘ᔃ࡮ᓴⅣ♽㧘ਛᨔ␹⚻♽ߩࠪࠬ࠹ࡓ⸃ᨆࠍⴕ
޿㧘ᦨ⚳⊛ߦߪ㧘⸃ᨆ࠺࡯࠲ࠍၮߦߎࠇࠄߩᯏ⢻ࠍᢙቇ⊛ߦ⸥ㅀߒ㧘↢૕ࠍ೙ᓮߔࠆߎߣࠍ⋡ᮡߣߔࠆ‫ޕ‬ක↪Ꮏቇ޽ࠆ޿ߪౣ↢කቇߩᛛⴚࠍ↪޿㧘ᄬࠊࠇߚ⤳ེᯏ⢻ࠍ࿁ᓳߐߖࠆߎߣ߇⃻ታ๧ࠍ߅߮ߡ߈ߚ‫ޕ‬ߒ߆ߒ㧘ߎࠇࠄߩᛛⴚࠍ↪޿ߡ૞ᚑߐࠇߚੱᎿ⤳ེߪ㧘↢૕ᧄ᧪ߩ೙ᓮ♽߆ࠄਵ㔌ߔࠆน⢻ᕈ߇޽ࠆ‫ޕ‬ᓥߞߡ㧘ੱᎿ⤳ེ߇ቢᚑߒߚᰴߩᲑ㓏ߣߒߡ㧘ߎࠇࠄߩ⤳ེࠍߤߩࠃ߁ߦ೙ᓮߔࠆ߆߇㎛ࠍីࠆᛛⴚߣ
ߥࠆ‫ޕ‬ᚒ‫⸃ࡓ࠹ࠬࠪࠆ޿ߡߞⴕߩޘ‬ᨆᚻᴺࠍ↪޿ߚ↢૕⎇ⓥߪ㧘ߎࠇࠄߩ⤳ེࠍ೙ᓮߔࠆࡁ࠙ࡂ࠙ࠍឭ
ଏߔࠆ߽ߩߣ⏕ାߔࠆ‫ޕ‬㧙㧙㧔3㧕ࠬࡐ࡯࠷ක⑼ቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
⇣ߥࠆⅣႺਅߦ߅޿ߡㆇേࠍⴕ߁ߎߣߦࠃࠆߐ߹ߑ߹ߥ↢ℂ⊛ᄌൻߦߟ޿ߡߩ⎇ⓥࠍⴕߞߡ޿ࠆ‫ޕ‬߅߽ߥ⎇ⓥ࠹࡯ࡑߪ
1㧕ㄭ⿒ᄖ✢ಽశᴺࠍ↪޿ߡ㧘㜞࿾߹ߚߪૐ㉄⚛ⅣႺߦ߅ߌࠆㆇേ߇╭ౝ㉄⚛േᘒߦ෸߷ߔᓇ㗀
2㧕ㆇേ߇⥄ᓞ␹⚻♽ߦ෸߷ߔᓇ㗀
3㧕㜞㦂⠪ߩᐔⴧᯏ⢻ߦ㑐ߔࠆ⎇ⓥ
4㧕⊓ጊߦ߅ߌࠆකቇ⊛ࠟࠗ࠼࡜ࠗࡦ૞ᚑߦะߌߚၮ␆⊛⎇ⓥߘߩઁߦߪ㜞㦂⠪ߩ⠌ᘠ⊛ߥㆇേ߇ᱠⴕ⢻ജ㧘ోりߩ╭⡺㊂㧘ᐔⴧᯏ⢻ߦ෸߷ߔᓇ㗀ߩ⎇ⓥࠍⴕ޿㧘ㆇേᒝᐲ࡮㗫ᐲߩ㆑޿߇り૕ߦਈ߃ࠆᓇ㗀ߦߟ޿ߡ⎇ⓥࠍⴕߞߡ޿ࠆ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
⻠Ꮷ㧦
ഥᢎ㧦

᧻ጟᢅ↵
㐳ፒᐘ㓶
ട⮮⟵ᒄ

Toshio Matsuoka
Sachio Nagasaki
Yoshihiro Kato

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
ߥߒ⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
ߥߒ✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ዊᩙ๺㓶㧘ട⮮⟵ᒄ㧘㤥Ꮉᷕ৻㧘੗਄ᐢ࿖㧘ᷰㄝ㇚㓶㧘᧻ጟᢅ↵㧚㜞ᩞ 1 ᐕ↢↵ᅚߦ߅ߌࠆ㓝ࠇ⢈ḩ⠪ߩⴊᷡ⢽⾰ᕈ⁁㧘૕ജ⑼ቇ 2006 ᐕ㧧55 Ꮞ㧦155㧙164㧚
2㧕 ᣁℙ㧘㐳ፒᐘ㓶㧘ᳯଐᴺ㧘ട⮮⟵ᒄ㧘ฎ↰ༀષ㧘᧻ጟᢅ↵㧚┙૏ᆫ൓ᤨߩり૕േំ೙ᓮ߅ࠃ߮ⷞⷡߩᓇ㗀ߦߟ޿ߡ㧘૕ജ⑼ቇ 2006 ᐕ㧧55㧦469㧙476㧚
3㧕 㐳ፒᐘ㓶㧘ᳯଐᴺ㧘ᣁℙ㧘ᧁ᧛⧷♿㧘ࡒ࡞ࡏ࠼࡮࠮ࠗ࠼࡮ࡕࡂࡑ࠼㧘ട⮮⟵ᒄ㧘᧻ጟᢅ↵㧘ฎ↰ༀષ㧚㛽⋚ߩേജቇࡕ࠺࡞ߦၮߠߊࡅ࠻⥄ὼ┙૏ᤨり૕േំߩ⸃ᨆ㧘ᢎ⢒කቇ 2006 ᐕ㧧51 Ꮞ㧦242㧙252㧚
4㧕 ട⮮⟵ᒄ㧘᧻ጟᢅ↵㧘ၔᒉ⍮ᳯ㧘㜞⷗೰㧚࿖ౝ⊓ጊߢߩ㜞ጊ∛㧙ᅏⓄ㜞⸻≮ᚲߢߩ⚻㛎ࠃࠅ㧙㧘ᣣᧄක੐ᣂႎ 2006 ᐕ㧧4286 ภ㧦66㧙70㧚
5㧕 ᳯଐᴺ㧘㐳ፒᐘ㓶㧘ኹፉᱜᏆ㧘ᧁ᧛⧷♿㧚ࡅ࠻ᐔⴧ⢻ജߦ㑐ߔࠆ⎇ⓥ㧦ォୟ੍㒐ߦะߌߡ㧘ੱ㑆⑔␩ቇળ⹹ 2006 ᐕ㧧6 Ꮞ㧦58㧙62㧚
6㧕 Ꮉἑ᥍⟤㧘ᣧᎹᕶᳯ㧘ട⮮⟵ᒄ㧘᧻ጟᢅ↵㧘ᷡፉḩ㧚╭ࠫࠬ࠻ࡠࡈࠖ࡯ᖚ⠪ߦ߅ߌࠆᔃቶᕈᦼᄖ෼❗ߩ㊀∝ᐲಽ㘃ߣฦ⒳ࡄ࡜ࡔ࡯࠲࡯ᬌᩏ⚿ᨐߩ㑐ଥᬌ⸛㧘කቇᬌᩏ 2006 ᐕ㧧55 Ꮞ㧦639㧙643㧚
7㧕 㤥Ꮉᷕ৻㧘ዊᩙ๺㓶㧘ട⮮⟵ᒄ㧘੗਄⌀ੱ㧘’㊁๺ᒾ㧘ᷰㄝ㇚㓶㧘᧻ጟᢅ↵㧚㘧㛗ᓮᎪ㜞ේ㜞ᚲ࠻࡟࡯࠾
ࡦࠣวኋߦ߅ߌࠆ 3 ᐕ㑆ߩ POMS ૶↪⚻㛎㧘⥃ᐥࠬࡐ࡯࠷කቇ 2007 ᐕ㧧15 Ꮞ㧦291㧙296㧚
8㧕 ട⮮⟵ᒄ㧘ᄢᐔᐘሶ㧘᧻ጟᢅ↵㧘ᷰㆻ㇚㓶㧚࠻࡟࠶ࠠࡦࠣߩഞ⟋̆ૐ࿶ૐ㉄⚛ⅣႺߣ㜞ጊ∛̆㧘଻ஜߩ⑼ቇ 2007 ᐕ㧧49 Ꮞ㧦541㧙544㧚
9㧕 ᄢᐔᐘሶ㧘ട⮮⟵ᒄ㧘᧻ጟᢅ↵㧘㜞⷗೰㧚ਛ㜞ᐕ⊓ጊ⠪ߩታᘒ⺞ᩏ̆ᅏⓄ㜞ጪ⊓ጊ⠪ࠍኻ⽎ߣߒߡ࡯㧘⊓ጊකቇ 2007 ᐕ㧧27 Ꮞ㧦39㧙42㧚
10㧕 ᳯଐᴺ, 㐳ፒᐘ㓶, ኹፉᱜᏆ, ᧁ᧛⧷♿. ᜛ᢔࡕ࠺࡞ߦࠃࠆାภߩᚑಽಽᨆߣ⥄ᓞ␹⚻♽ᯏ⢻⹏ଔ߳ߩᔕ↪,ੱ㑆⑔␩ቇળ⹹ 2008 ᐕ㧧7 Ꮞ㧦107㧙112㧚
11㧕 ട⮮⟵ᒄ㧘ᄢᐔᐘሶ㧘᧻ጟᢅ↵㧚ᶏᄖᷰ⥶⠪㑐ㅪ∔ᖚߩኻ╷㧙㜞ጊ∛㧙㧘⥃ᐥߣ⎇ⓥ 2008 ᐕ㧧85 Ꮞ 9ภ㧦19㧙22㧚
12㧕 ᷰㆺᕡᄦ, ᫪↰✍ሶ, ቝ㊁↱㉿ሶ, ᨋᕶሶ, Ꮉἑ᥍⟤, ട⮮⟵ᒄ, ᧻ጟᢅ↵, દ⮮ᒄᐽ, ᷡፉḩ㧚ዊఽߦ߅ߌ
ࠆ⢽⢌⢄ߣࡊ࡟ࡔ࠲ࡏ࡝࠶ࠢࠪࡦ࠼ࡠ࡯ࡓߩ㑐ㅪᕈߦߟ޿ߡ㧘⿥㖸ᵄᬌᩏᛛⴚ 2008 ᐕ㧧33 Ꮞ㧦18㧙25㧚
13㧕 ട⮮⟵ᒄ, ᄢᐔᐘሶ, ၔᒉ⍮ᳯ, ᧻ጟᢅ↵㧚ᓮᎪ⚃⪲⊓ጊෳട⠪ߩࡔ࠺ࠖࠞ࡞࠴ࠚ࠶ࠢ㧘⊓ጊකቇ 2008ᐕ㧧28 Ꮞ㧦135㧙140㧚
14㧕 ጯ㗅ᴦ, ㋈ᧁჽ, 㤥Ꮉᷕ৻, 㜞ᯅᱜ♿, ᧻ጟᢅ↵㧚General Health Questionnaire(GHQ)߆ࠄߺߚࠕࠬ࡝࡯
࠻ߩ♖␹ஜᐽᐲߩ․ᓽ㧘ጘ㒂⚻ᷣᄢቇ⺰㓸 2008 ᐕ㧧41 Ꮞ㧦25㧙36㧚㧙㧙

15㧕 ⮳ᧄ଻, ⑔ንᖈ, ⷏᧛ᱜ᣿, ጤ⿧ᐽ⌀, ᩊ↰␭ᨐ, ᷰㆻ㓶੺, ฎ↰ༀષ, ੹੗৻, ᧻ጟᢅ↵㧚᛫㊀ജᆫ൓ᵴേ
ࠍਛᔃߣߒߚ࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦ೨ᓟߦ߅ߌࠆ⣖ᕈ߹߭ఽߩ⥄ᓞ␹⚻♽ߩᄌൻߣஜᐽఽߣߩᲧセ, ℂቇ≮ᴺ⑼ቇ 2008 ᐕ㧧23 Ꮞ㧦647㧙651㧚
ේ⪺㧔᰷ᢥ㧕
1㧕 Jiang Y, Nagasaki S, Kimura H. A dynamic model of body sway control during upright stance inhuman. Jpn J Phys Fitness Sports Med. 2006;55:231-236.
2㧕 Jiang Y, Nagasaki S, Matsuura Y, Zhou J. Dynamic studies on human body sway by using a simple
model with special concerns on the pelvic and muscle roles. Asian J Control. 2006;8:297-306.
3㧕 Kazuo Oguri, Hajime Fujimoto, Hiroyuki Sugimori, Kei Miyamoto, Toshiki Tachi, Sachio
Nagasaki,Yoshihiro Kato, Toshio Matsuoka, Pronouced muscle deoxygenation during supramaximal
exercise under simulated hypoxia in sprint athletes. J Sports Sci Med. 2008;3:182-189.

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦᧻ጟᢅ↵㧧⁛┙ⴕ᡽ᴺੱᣣᧄቇⴚᝄ⥝ળ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦㜞࿾ⅣႺਅߩή㉄⚛ᕈㆇേ߇╭ౝ㉄⚛േᘒߦ෸߷ߔᓇ㗀㧧ᐔᚑ 17㧙18 ᐕᐲ㧧3,700 ජ౞(3,100㧦600 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦ട⮮⟵ᒄ㧧⁛┙ⴕ᡽ᴺੱᣣᧄቇⴚᝄ⥝ળ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦ਛ㜞ᐕ⊓ጊ⠪ߩߚ߼ߩකቇ⊛ࠟࠗ࠼࡜ࠗࡦ૞ᚑߦะߌߚၮ␆⊛⎇ⓥ㧧ᐔᚑ 18㧙19 ᐕᐲ㧧2,200 ජ౞(1,000㧦1,200ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦᧻ጟᢅ↵㧧⁛┙ⴕ᡽ᴺੱᣣᧄቇⴚᝄ⥝ળ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦ਛ࡮㜞㦂⠪ߩૐ㉄⚛ⅣႺਅ㧔ૐ㉄⚛ቶ㧕ߩㆇേ߇ࠛࡀ࡞ࠡ࡯ᶖ⾌㊂෸߮╭ߦ෸߷ߔᓇ㗀㧧ᐔᚑ 19㧙20 ᐕᐲ㧧2,860
ජ౞(1,560㧦1,300 ජ౞)
2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬ᧻ጟᢅ↵㧦
1㧕 ᣣᧄᢎ⢒කቇળ⹏⼏ຬ(㨪⃻࿷)㐳ፒᐘ㓶㧦1㧕 ᣣᧄ↢ℂቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄㆇേ↢ℂቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄᢎ⢒කቇળ⹏⼏ຬ(㨪⃻࿷)ട⮮⟵ᒄ㧦1㧕 ᣣᧄ⥃ᐥࠬࡐ࡯࠷කቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ⧯ᐕ⠪ᔃ∔ᖚኻ╷ද⼏ળ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅
1㧕 ╙ 4 ࿁ 2006 ᐕጘ㒂ࠕࠬ࡟࠹ࠖ࠶ࠢ࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦ⎇ⓥળ(ᐔᚑ 18 ᐕ 2 ᦬㧘ጘ㒂)2㧕 ╙ 5 ࿁ 2007 ᐕጘ㒂ࠕࠬ࡟࠹ࠖ࠶ࠢ࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦ⎇ⓥળ(ᐔᚑ 19 ᐕ 2 ᦬㧘ጘ㒂)
3㧕 ╙ 6 ࿁ 2008 ᐕጘ㒂ࠕࠬ࡟࠹ࠖ࠶ࠢ࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦ⎇ⓥળ(ᐔᚑ 20 ᐕ 2 ᦬㧘ጘ㒂)
3㧕ቇⴚ㔀⹹ߥߒ㧙㧙

7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳᧻ጟᢅ↵㧦
1㧕 ᐔᚑ 17 ᐕᐲࡆࠢ࠻࡝࡯ࠨࡒ࠶࠻(ᐔᚑ 18 ᐕ 2 ᦬㧘ጘ㒂㐳⦟Ꮉࠬࡐ࡯࠷ࡊ࡜ࠩ㧘㆏਄㕒㚅․೎⻠Ṷ‫ޟ‬ᣣᧄ࠹࠾ࠬㆬᚻߩ⢒ᚑ࡮ᒝൻ‫ޠ‬ᐳ㐳)2㧕 ╙ 10 ࿁ᣣᧄ૕ജකቇળ᧲ᶏ࿾ᣇળ(ᐔᚑ 18 ᐕ 3 ᦬㧘ᦺᣣᄢቇ㧘․೎⻠Ṷ‫ޟ‬り૕ߦ⴫⃻ߐࠇߚߎߎࠈ‫ޠ‬ᐳ㐳)3㧕 ጘ㒂⋵␠ળ଻㒾ㇱ(ᐔᚑ 18 ᐕ 8 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬㜞㦂⠪ߩ૕ജߣߪ㧫ߤߩࠃ߁ߦ⹏ଔߔߴ߈߆㧫‫ޠ‬Ṷ⠪)
4㧕 นఽᏒஜᐽߠߊࠅㆇേ᥉෸ផㅴද⼏ળ(ᐔᚑ 18 ᐕ 10 ᦬㧘นఽ㧘⻠Ṷ‫ޟ‬ਛ㜞ᐕߩ↢ᵴ⠌ᘠ∛ߣㆇേ‫ޠ‬Ṷ⠪)5㧕 ጘ㒂⋵ஜᐽ⑔␩ㇱ(ᐔᚑ 18 ᐕ 8 ᦬㧘ጘ㒂㧘⻠Ṷ‫⥄ޟ‬ቛߢ◲න㧍ࠄߊࠄߊ╭ജ૕ᠲ‫ޠ‬Ṷ⠪)6㧕 ⪇᧲Ꮷ▸ᄢቇ૕⢒ஜᐽቇ㒮(ᐔᚑ 18 ᐕ 10 ᦬㧘ਛ࿖਄ᶏ㧘․೎⻠Ṷ‫ޟ‬ᣣᧄߦ߅ߌࠆ㜞ᚲ࠻࡟࡯࠾ࡦࠣ‫ޠ‬Ṷ⠪)7㧕 ฦോේᏒᢎ⢒ᆔຬળቇᩞᢎ⢒଻ஜળ(ᐔᚑ 18 ᐕ 11 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬ஜᐽߣㆇേ‫ޠ‬Ṷ⠪)8㧕 ╙ 12 ࿁ᣣ࡮㖧ஜᐽᢎ⢒ࠪࡦࡐࠫ࠙ࡓ౗╙ 55 ࿁ᣣᧄᢎ⢒කቇળ(ᐔᚑ 19 ᐕ 8 ᦬㧘ฬฎደᏒ┙ᄢቇ㧘ࠪࡦࡐࠫ࠙ࡓᐳ㐳)9㧕 ฦോේᏒᢎ⢒ᆔຬળ(ᐔᚑ 19 ᐕ 9 ᦬㧘ጘ㒂㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ‫੹ޟ‬ᣣ߆ࠄᆎ߼ࠃ߁ᣧኢᣧ⿠
߈ᦺߏߪࠎ‫ޠ‬Ṷ⠪)10㧕 ጘ㒂⋵ℂቇ≮ᴺቇળ(ᐔᚑ 20 ᐕ 3 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬㜞㦂⠪ߩㆇേߣ․ᕈ‫ޠ‬Ṷ⠪)11㧕 ጘ㒂ᄢቇࠪ࠾ࠕࠞ࡟࠶ࠫ(ᐔᚑ 20 ᐕ 10 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬㜞㦂⠪ߩஜᐽߣ૕ജ‫ޠ‬Ṷ⠪)ട⮮⟵ᒄ㧦
1㧕 ╙ 10 ࿁ᣣᧄ૕ജකቇળ᧲ᶏ࿾ᣇળ(ᐔᚑ 18 ᐕ 3 ᦬㧘ᦺᣣᄢቇ㧘․೎⻠Ṷ‫ޟ‬ጘ㒂⋵ߦ߅ߌࠆࠬࡐ࡯࠷
⃻႐ߣࠬࡐ࡯࠷ක⑼ቇߩㅪ៤‫ޠ‬ᐳ㐳)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേ᧻ጟᢅ↵㧦
1㧕 ᣣᧄቇⴚᝄ⥝⑼ቇ⎇ⓥ⾌ᆔຬળኾ㐷ᆔຬ(ᐔᚑ 19 ᐕᐲ㨪20 ᐕᐲ)
2㧕 ጘ㒂⋵૕⢒දળࠬࡐ࡯࠷ක⑼ቇකຬળᆔຬ(㨪⃻࿷)3㧕 ጘ㒂ࠕࠬ࡟࠹ࠖ࠶ࠢ࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦ⎇ⓥળળ㐳(㨪⃻࿷)4㧕 ጘ㒂⋵࠻࡟࡯࠾ࡦࠣ⑼ቇ࠮ࡦ࠲࡯㜞࿾࠻࡟࡯࠾ࡦࠣࠬ࡯ࡄ࡯ࡃࠗࠩ࡯(㨪⃻࿷)5㧕 ጘ㒂⋵ஜᐽ㐳ኼ⽷࿅੍㒐੐ᬺࡕ࠺࡞ታᣉᡰេ੐ᬺࠕ࠼ࡃࠗࠩ࡯(ᐔᚑ 18 ᐕᐲ)
6㧕 ጘ㒂⋵㊁⃿ද⼏ળ⋧⺣ᓎ(ᐔᚑ 19 ᐕᐲ㨪⃻࿷)7㧕 ጘ㒂⋵කᏧળቇᩞᔃ⤳ᬌ⸻ᆔຬળᆔຬ(㨪⃻࿷)8㧕 ጘ㒂⋵ᔃ⣢∔ᖚኻ╷ᆔຬળᆔຬ(㨪⃻࿷)9㧕 ጘ㒂⋵࡜ࠣࡆ࡯ࡈ࠶࠻ࡏ࡯࡞දળℂ੐㐳(ᐔᚑ 19 ᐕᐲ㨪⃻࿷)10㧕 㑐⷏࡜ࠣࡆ࡯ࡈ࠶࠻ࡏ࡯࡞දળℂ੐(ᐔᚑ 19 ᐕᐲ)
11㧕 ጘ㒂᧲ᵗකቇ⎇ⓥળ਎⹤ੱ(ᐔᚑ 20 ᐕᐲ㨪⃻࿷)㐳ፒᐘ㓶㧦1㧕 ጘ㒂⋵ᨵ㆏දળක⑼ቇᆔຬ(㨪⃻࿷)2㧕 ጘ㒂⋵ቇ↢ᨵ㆏ㅪ⋖ℂ੐(㨪⃻࿷)ട⮮⟵ᒄ㧦1㧕 ጘ㒂⋵ࠬࡐ࡯࠷࠼ࠢ࠲࡯ද⼏ળℂ੐(㨪⃻࿷)2㧕 ጘ㒂⋵ቇ↢ᨵ㆏ㅪ⋖ℂ੐(㨪⃻࿷)3㧕 ጘ㒂⋵කᏧળᔃ⤳ᬌ⸻ᆔຬળᆔຬ(㨪⃻࿷)4㧕 ጘ㒂⋵කᏧળᔃ㔚࿑್ቯᆔຬળᆔຬ(㨪⃻࿷)5㧕 ጘ㒂⋵ᔃ⣢∔ᖚኻ╷ᆔຬળᆔຬ(㨪⃻࿷)6㧕 ጘ㒂⋵ᨵ㆏දળක⑼ቇᆔຬ(㨪⃻࿷)㧙㧙7㧕 ጘ㒂⋵૕⢒දળක⑼ቇකຬળᆔຬ(㨪⃻࿷)8㧕 ࠬ࠹ࠖ࠶ࠢ࡞ࡃ࠶ࠢࠬࡐ࡯࠷ࠢ࡜ࡉℂ੐(㨪⃻࿷)9㧕 ጘ㒂⋵࡜ࠣࡆ࡯දળකോᆔຬ(㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 㐳ፒᐘ㓶㧦㜞㦂⠪ߩᐔⴧ⢻ജߣォୟߩ㑐ଥ߅ࠃ߮ォୟ੍㒐ᴺߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 15 ᐕᐲ㧙17 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ၮ⋚⎇ⓥ(C)✚᜝ႎ๔ᦠ㧦1㧙58(2006 ᐕ 3 ᦬)
2㧕 ᧻ጟᢅ↵㧦㜞࿾ⅣႺਅߩή㉄⚛ᕈㆇേ߇╭ౝ㉄⚛േᘒߦ෸߷ߔᓇ㗀㧦⁛┙ⴕ᡽ᴺੱᣣᧄቇⴚᝄ⥝ળ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)✚᜝ႎ๔ᦠ㧦1㧙58(2008 ᐕ 3 ᦬)
11㧚ႎ㆏
1㧕 ᧻ጟᢅ↵㧦᳓ಽ៨ข㧦ጘ㒂⋵૕⢒දળࠬࡐ࡯࠷ක⑼ቇᆔຬળ࡟ࡐ࡯࠻(2007 ᐕ 3 ᦬)
12㧚⥄Ꮖ⹏ଔ
⹏ଔᢎ⢒ߦ㑐ߒߡߪ౒ㅢᢎ⢒㧘කቇㇱᢎ⢒ߦᄙᄢߥ⽸₂ࠍߒߡ޿ࠆ‫ࠍࠬ࡯ࠦ࡞ࠕ࡝࠻࡯ࡘ࠹ߚ߹ޕ‬ᜂᒰߒߡ߅ࠅ㧘໧㗴ߪߥ޿ߣᕁࠊࠇࠆ‫ޕ‬ᄖㇱ⾗㊄ߦ㑐ߒߡߪ⑼ቇ⎇ⓥ⾌ߪᲤᐕ₪ᓧߒߡ߅ࠅ㧘⋡ᮡߪ㆐ᚑߢ߈ߡ޿ࠆߣᕁࠊࠇࠆ‫ޕ‬ᄢቇߩᵴᕈൻ⚻⾌╬ߦ߽Ⓧᭂ⊛ߦᔕ൐ߒߡ޿ࠆ߇₪ᓧߢ߈ߡ޿ߥ޿‫ޕ‬ᅑቇነ㒝㊄ߦ㑐ߒߡߪᲤᐕหߓ
ߣߎࠈ߆ࠄ㗂޿ߡ޿ࠆ߇㧘ദജߒߡ޿ࠆ߇Ⴧടߔࠆ߹ߢߦߪ⥋ߞߡ޿ߥ޿‫ޕ‬໧㗴ὐߪ⺰ᢥᢙ߇․ߦ⧷ᢥߩ⺰ᢥᢙ߇ዋߥ޿ࠃ߁ߦᕁࠊࠇ㧘ദജࠍⷐߔࠆ‫ޕ‬ᄢቇ㒮↢ߪߎߎᢙᐕ౉ቇߒߡ޿ࠆ߇␠ળੱ౉ቇ↢߇ᄙߊ㧘૛ࠅᜰዉߢ߈ߡ߅ࠄߕ㧘⺰ᢥ߽ᦠߌߡ޿ߥ
޿‫੹ޕ‬ᓟߪߒߞ߆ࠅߒߚᜰዉ૕೙ߩਅߢᜰዉߔࠆߎߣ߇ᔅⷐߣᕁࠊࠇࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ࠬ࠲࠶ࡈ߇ዋߥ޿ߎߣߢ޽ࠆ‫ޕ‬ነઃ㊄߇ᄙߌࠇ߫㧘㓹↪ߔࠆߎߣ߽น⢻ߢ޽ࠆ߇㧘ߘߩ⾗㊄ߪਇน⢻ߦㄭ޿‫ޕ‬ቇᝄߩᄖ࿖ੱ․೎⎇ⓥ⠪ߥߤߩ൐㓸ߦኻߒߡ߽ᔕ൐ࠍߒߡ޿ࠆ߇㧘ੱ᧚⏕଻ߪ㔍ߒ޿‫ޕ‬ᄢቇ㒮↢߽ᤤ㑆ࠦ࡯ࠬߩੱ᧚⏕଻߇㊀ⷐߢ޽ࠆߣᕁࠊࠇࠆ‫ޕ‬੹ᓟߩዷᦸߎߎᢙᐕߪࠬࡐ࡯࠷ㆬᚻߩ┹ᛛജะ਄ࠍ⋡ᜰߔ⎇ⓥࠃࠅ㧘⊓ጊߦ㑐ߔࠆ⎇ⓥ߿㜞㦂⠪ߩᣣᏱ↢ᵴߢߩஜᐽჇㅴ㧘∔∛੍㒐ߦ㑐ߔࠆ㜞㦂⠪ࠍኻ⽎ߣߒߡ⎇ⓥࠍㅴ߼ߡ߅ࠅ㧘੍㒐කቇߦ߅ߌࠆࠬࡐ࡯࠷කቇߩ
㊀ⷐᕈࠍᮨ⚝ߒߡ޿ࠆ‫␠ߦࠄߐޕ‬ળ⊛ߦ⽸₂ߔߴ߈ߎߣߩ⎇ⓥࠍㅴ߼ߥߌࠇ߫ߣ⠨߃ߡ޿ࠆ‫ޕ‬㧙㧙㧔4㧕␹⚻ౝ⑼࡮⠧ᐕቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
ੱ㑆ߩዅ෩ࠍ౨ߔ⹺⍮ᯏ⢻߿ㆇേᯏ⢻ߩ㓚ኂࠍᒁ߈⿠ߎߔ⣖␹⚻♽ߩ∔ᖚߩᴦ≮ߪὶ⋲ߩ⊛ߢ޽ࠆ‫␹ޕ‬⚻♽ߩ㓚ኂ࿃ሶ㧘ୃᓳଦㅴ࿃ሶࠍ᣿ࠄ߆ߦߒߡᴦ≮߳ߩᔕ↪ࠍ߼ߑߒߡขࠅ⚵ࠎߢ߈ߚ‫৻ޕ‬ᣇ㧘␹⚻㔍∛߿㜞㦂␠ળࠍᡰ߃ࠆߚ߼ߦ㧘ක≮࡮⑔␩࡮଻ஜߩㅪ៤ࠍ⢒ߡࠆขࠅ⚵ߺ߽ߔߔ߼ߡ߈ߚ‫ޕ‬ᓥ᧪߆ࠄߩ‫❱⚵⚻␹ޟ‬㓚ኂᯏᐨߩ⸃᣿ߣୃᓳ࡮ౣ↢‫ߦޠ‬ᴪߞߡ㧘ࡔ࠲ࡠ࠴ࠝࡀࠗࡦ㑐ㅪ⎇ⓥ߇ᢥ⑼⋭ߩ⑼⎇(B)㧘ቇౝ⎇ⓥᵴᕈൻ⚻⾌㧘↥ቭቇ౒หផㅴ⚻⾌ࠍขᓧߒ㧘ᄢቇ㒮↢ߩ੤ᵹࠍㅢߓᄢቇ㑆ߩ౒ห⎇ⓥࠍᷓ߼ߡ߈ߚ‫∉఺ߩ♽⚻␹ޕ‬ቇ⊛㓚ኂᯏᐨߩ⸃᣿ࠍ⋡ᜰߒߚ᛫␹⚻᛫૕ߩ⹺⼂᛫ේߩᬌ⚝߇㧘ᢥ⑼⋭ߣෘഭ⋭ߩ⑼⎇㧘㜞ᯏ⢻ߩ LC-MS/MS ᯏེߩ౒ห೑↪ߦࠃߞߡㅴ᝞ߒ㧘৻ㇱߩ᛫ේ߇᣿ࠄ߆ߦߐࠇߚ‫⚻␹ޕ‬ᄌᕈ∔ᖚߩ⥄ᓞ␹⚻♽ᯏ⢻㓚ኂߦ㑐ߔࠆ࡙࠾࡯ࠢߥ⎇ⓥ߽ቇౝ⎇ⓥᵴᕈൻ⚻⾌ߣቇౝߩදജࠍᓧߡⴕࠊ
ࠇߡ߈ߚ‫ޕ‬ᢥ⑼⋭⑼⎇(⪚⧘)ߦࠃࠆ‫⚻␹ޟ‬㔍∛ᖚ⠪ߩ࠾࡯࠭ߦㆡวߒߚ IT ᯏེᵴ↪ߣᔃߩࡅࡘ࡯ࡑࡦࡀ
࠶࠻ࡢ࡯ࠢ‫ߪޠ‬㧘ቇౝ࡮࿾ၞߩ㑐ଥ⠪ࠍᏎ߈ㄟߺ⎇ⓥࠍㅢߓߡᄢ߈ߥੱߩベࠍ૞ࠆߦ⥋ߞߚ‫ޕ‬
2005 ᐕᐲ߆ࠄෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄㧘㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ‫ޟ‬㊀∝㔍∛ᖚ⠪ߩ࿾ၞක≮૕೙ߩ᭴▽ߦ㑐ߔࠆ⎇ⓥ⃰‫ޠ‬㧘߅ࠃ߮ห⵬ഥ㊄㧘ߎߎࠈߩஜᐽ⑼ቇ⎇ⓥ੐ᬺ ‫ޟ‬ᕆᕈ⣖Ἳߩࠣ࡞࠲ࡒࡦ㉄ฃኈ૕⥄Ꮖ఺∉∛ᘒߩ⸃᣿߆ࠄᣂߚߥᴦ≮ᴺ⏕┙ߦะߌߚ⎇ⓥ⃰(ᕆᕈ⣖Ἳߩ⥄Ꮖ఺∉࡮ᴦ≮⎇ⓥ⃰)‫ߦޠ‬ෳടߔࠆߎߣߦߥߞߚ‫ߦࡦࡕࠬߦࠄߐޕ‬㑐ߔࠆ⺞ᩏ⎇ⓥ㧘ࡊ࡝ࠝࡦ∛ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ߇ടࠊࠅ㧘ᒰ㒮ߩ㔍∛᜚ὐ∛㒮ᜰฬߣ⋧߹ߞߡⴕ᡽ࠍᏎ߈ㄟࠎߛ⋵ౝ␹⚻ౝ⑼ක≮ߩᢛ஻లታߦߟߥ߇ࠆ⎇ⓥ߇⛮⛯ਛߢ޽ࠆ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
ಎᢎ᝼㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
කຬ㧦
කຬ㧦

›Ⴆ ⾆
଻૑ ഞ
↰ਛఝม
ᧁ᧛ᥙᄦ
ᨋ ␭৻
ᰞ੗ጪ㇢
ጊ↰ ᕺ

Takashi Inuzuka
Isao Hozumi
Yuji Tanaka
Akio Kimura
Yuichi Hayashi
Takeo Sakurai
Megumi Yamada

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ›Ⴆ ⾆㧚ற⣲≌ᕈ␹⚻∝୥⟲㧦ዊᨋ␽ᵏ࡮᳓Ỉ⧷ᵗ ✬㧚␹⚻∔ᖚ ᦨᣂߩᴦ≮ 2006-2008, ᧲੩㧦ධᳯၴ㧧
2006 ᐕ㧦292㧙294㧚
2㧕 ›Ⴆ ⾆㧚ౝ⑼∔ᖚߦ઻߁␹⚻㓚ኂ㧦ᬮ ㅴ ✬㧚⥃ᐥ∛ᘒቇ㧘᧲੩㧦NOUVELLE HIROKAWA㧧2006 ᐕ㧦
221㧙227㧚3㧕 ›Ⴆ ⾆㧚ࡄ࡯ࠠࡦ࠰ࡦ∛ߣࡄ࡯ࠠࡦ࠰ࡦ∝୥⟲㧦ᄢౝዄ⟵ ⋙ୃ㧚ᣣᏱ⸻≮ߦᵴ߆ߔ⠧ᐕ∛ࠟࠗ࠼ࡉ࠶ࠢ
╙ 6 Ꮞ 㜞㦂⠪ߦᄙ޿∔ᖚߩ⸻≮ߩታ㓙㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯㧧2006 ᐕ㧦2㧙5㧚
4㧕 ↰ਛఝม㧘›Ⴆ ⾆㧚⢽ṁᕈࡆ࠲ࡒࡦᰳਲ∝ߩᴦ≮ߪ㧦ጟᧄᐘᏒ࡮᫜ᯅ♿ᄦ࡮᳓Ỉ⧷ᵗ ✬㧚 EBM ␹⚻∔ᖚߩᴦ≮ 2007-2008㧘᧲੩㧦ਛᄖකቇ␠㧧2007 ᐕ㧦293㧙301㧚
5㧕 ↰ਛఝม㧘›Ⴆ ⾆㧚࿷ቛ⚻▤ᩕ㙃೷ߩ⒳㘃ߣ․ᓽ㧦㒙ㇱᐽੑ ✬㧚␹⚻㔍∛ߩߔߴߡ㨪∝⁁࡮⸻ᢿ߆ࠄᦨ
వ┵ᴦ≮㧘⑔␩ߩታ㓙߹ߢ㧘᧲੩㧦ᣂ⥝කቇ಴ 㧧2007 ᐕ㧦331㧙341㧚
6㧕 ›Ⴆ ⾆㧚㗡∩㧦ᣣᧄ⠧ᐕකቇળ ✬㧚⠧ᐕකቇ࠹ࠠࠬ࠻ᡷ⸓╙ 3 㧘᧲੩㧦ࡔ࠵ࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦
83㧙85㧚
7㧕 ›Ⴆ ⾆㧚⸒⺆㓚ኂ㧦ᣣᧄ⠧ᐕකቇળ ✬㧚⠧ᐕකቇ࠹ࠠࠬ࠻ᡷ⸓╙ 3 㧘᧲੩㧦ࡔ࠵ࠞ࡞ࡆࡘ࡯␠㧧2008ᐕ㧦95㧙96㧚8㧕 ›Ⴆ ⾆㧚ᱠⴕ㓚ኂ㧦ᣣᧄ⠧ᐕකቇળ ✬㧚⠧ᐕකቇ࠹ࠠࠬ࠻ᡷ⸓╙ 3 㧘᧲੩㧦ࡔ࠵ࠞ࡞ࡆࡘ࡯␠㧧2008ᐕ㧦101㧙103㧚
9㧕 ଻૑ ഞ㧚ᚻ⿷ߩߒ߮ࠇ㧦ᣣᧄ⠧ᐕකቇળ ✬㧚⠧ᐕකቇ࠹ࠠࠬ࠻ᡷ⸓╙ 3 㧘᧲੩㧦ࡔ࠵ࠞ࡞ࡆࡘ࡯␠㧧
2008 ᐕ㧦90㧙94㧚
10㧕 ↰ਛఝม㧘›Ⴆ ⾆㧚ᄙ⊒ᕈ⎬ൻ∝ߩ㐓೎⸻ᢿ㧦ศ⦟Ả৻ ✬㧚ᄙ⊒ᕈ⎬ൻ∝ߩ⸻ᢿߣᴦ≮㧘᧲੩㧦ᣂ⥝කቇ಴ 㧧2008 ᐕ㧦93㧙99㧚⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 ›Ⴆ ⾆㧚਄⌒┃ⵚ∝୥⟲㧦⌒┃వ┵∝୥⟲㧘Clinical Neuroscience 2007 ᐕ㧧25 Ꮞ㧦1030㧙1031㧚
2㧕 ᧁ᧛ᥙᄦ㧘଻૑ ഞ㧘㜞ᯅᐘ೑㧘›Ⴆ ⾆㧚᛫ GluR2 ᛫૕㓁ᕈᚑੱᕆᕈ⣖Ἳᖚ⠪ߩ⥃ᐥ⊛․ᓽߥࠄ߮ߦ఺

㧙㧙∉⚵❱ቇ⊛⸃ᨆ㧘කቇߩ޽ࠁߺ 2007 ᐕ㧧223 Ꮞ㧦300㧙301㧚
3㧕 ›Ⴆ ⾆㧚᛫␹⚻᛫૕㓁ᕈㄝ✼♽⣖Ἳߩ∛ᘒ㧘Clinical Neuroscience 2008 ᐕ㧧26 Ꮞ㧦506㧙507㧚
4㧕 ›Ⴆ ⾆㧘᪊↰㆏ੱ㧘ᰞ੗ጪ㇢㧘ศ㊁ ⧷㧘᦯ㇱ⋥᮸㧚ற⣲≌ᕈ␹⚻∝୥⟲ߩ⸻ᢿ࡮∛ℂ∛ᘒ࡮ᴦ≮㧘ᣣౝ
ળ⹹ 2008 ᐕ㧧97 Ꮞ㧦1855㧙1866㧚
5㧕 ଻૑ ഞ㧚ࡔ࠲ࡠ࠴ࠝࡀࠗࡦߣ␹⚻∔ᖚ-ᣂዷ㐿ߔࠆࡔ࠲ࡠ࠴ࠝࡀࠗࡦ⎇ⓥ-㧘කቇߩ޽ࠁߺ 2008 ᐕ㧧224
Ꮞ㧦482㧙483㧚
6㧕 ↰ਛఝม㧘›Ⴆ ⾆㧚ᧃ᪳␹⚻㓚ኂ(CIDP ࠍ฽߻)㧘Modern Physician 2008 ᐕ㧧28 Ꮞ㧦664㧙673㧚✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ↰ਛఝม㧘⷏↰ ᶈ㧘ᨋ⇐⟤ሶ㧘›Ⴆ ⾆㧘ᄢᮎ⟤૫㧚ᕆᕈᢔ࿷ᕈ⣖⣄㜑Ἳߦࠃࠆ⣖᪞㔌ᢿ∝୥⟲㧘⥃ᐥ␹⚻ቇ 2006 ᐕ㧧46 Ꮞ㧦50㧙54㧚
2㧕 ↰ਛఝม㧘଻૑ ഞ㧘›Ⴆ ⾆㧚ᖡᕈ࡝ࡦࡄ⣲ߩ⚻ㆊਛߦᕆᕈゲ⚝㓚ኂဳᄙ⊒␹⚻Ἳࠍ߈ߚߒߚ 1 ଀㧘ᧃ᪳␹⚻ 2006 ᐕ㧧17 Ꮞ㧦225㧙227㧚
3㧕 ᧁ᧛ᥙᄦ㧘ᰞ੗ጪ㇢㧘㚅᧛ᓆብ㧘㋈ᧁᰵብ㧘↰ਛఝม㧘଻૑ ഞ㧘›Ⴆ ⾆㧚ᄙ⊒࠾ࡘ࡯ࡠࡄ࠴࡯ߦߡ⊒∝ߒ㧘㗡ㇱ MRI ਄ኻ⒓ᕈ߮߹ࠎᕈ∛Ꮍࠍ๒ߒߚ CNS ࡞࡯ࡊࠬߩ 1 ଀㧘Neuroimmunology 2006 ᐕ㧧14
Ꮞ㧦169㧙174㧚
4㧕 ᰞ੗ጪ㇢㧘ᧁ᧛ᥙᄦ㧘↰ਛఝม㧘଻૑ ഞ㧘›Ⴆ ⾆㧚ᕆᕈዊ⣖ᄬ⺞ߢ HIV ᗵᨴࠍ઻߁␹⚻᪢Ქߩ 1 ଀㧘␹⚻ౝ⑼ 2006 ᐕ㧧64 Ꮞ㧦609㧙613㧚
5㧕 ᫪↰ᶈਯ㧘ቝ㊁ཅᒄ㧘⍹Ⴆ㆐ᄦ㧘଻૑ ഞ㧘›Ⴆ ⾆㧚කቇ↢ߩ⸰໧⋴⼔૕㛎ታ⠌ߩ⹏ଔ㧘කቇᢎ⢒ 2006ᐕ㧧37 Ꮞ㧦311㧙315㧚
6㧕 ↰ਛఝม㧘⷏↰ ᶈ㧘›Ⴆ ⾆㧚㗖㜑⎬⤑ᄖ⤥≌ᓟߦ⣄㜑ⓨᵢᒻᚑࠍ߈ߚߒߚ 1 ଀㧘⥃ᐥ␹⚻ 2007 ᐕ㧧47
Ꮞ㧦90㧙95㧚
7㧕 ↰ਛఝม㧘⷏↰ ᶈ㧘›Ⴆ ⾆㧚⚻ᤨ⊛ MRA ߢਥᐙേ⣂ߩ㐽Ⴇࠍ⹺߼ߚ⚿ᩭᕈ㜑⤑Ἳߦࠃࠆ⣖᪪Ⴇ㧘⣖ත
ਛ 2007 ᐕ㧧29 Ꮞ㧦635㧙641㧚
8㧕 ᰞ੗ጪ㇢㧘ᧁ᧛ᥙᄦ㧘↰ਛఝม㧘଻૑ ഞ㧘ዊୖ⌀ᴦ㧘›Ⴆ ⾆㧚㓸ቇ⊛ೋᦼᴦ≮ߦࠃࠅᴦ≹ߒߚᚑੱࠗࡦ
ࡈ࡞ࠛࡦࠩ⣖∝ߩ 1 ଀㧘⥃ᐥ␹⚻ 2007 ᐕ㧧47 Ꮞ㧦639㧙643㧚
9㧕 ㋈ᧁ(ᱞ੗)⌀ℂሶ㧘ᨋ ␭৻㧘ᧁ᧛ᥙᄦ㧘᳗ᴛ ቞㧘㚅᧛ᓆብ㧘ᰞ੗ጪ㇢㧘↰ਛఝม㧘଻૑ ഞ㧘›Ⴆ ⾆㧚੺⼔ᓥ੐⠪ߦߺࠄࠇߚ᳓∧⣄㜑Ἳ㧘⣖ߣ␹⚻ 2008 ᐕ㧧60 Ꮞ㧦79㧙83㧚
10㧕 ᰞ੗ጪ㇢㧘↰ਛఝม㧘㚅᧛ᓆብ㧘ᨋ ␭৻㧘ᧁ᧛ᥙᄦ㧘଻૑ ഞ㧘☨↰ ⺈㧘›Ⴆ ⾆㧚Creutzfeldt-Jakob∛ߣ㘃ૃߩ⥃ᐥ⚻ㆊࠍ␜ߒߚ㧘Basedow ∛ࠍ઻ߞߚᯅᧄ⣖∝ߩ 1 ଀㧘⣖ߣ␹⚻ 2008 ᐕ㧧60 Ꮞ㧦559㧙
565㧚
11㧕 ⍫㊁ᄢੳ㧘᪢᧛ ᷕ㧘ਛጊೣਯ㧘ᄢᳯ⋥ⴕ㧘౎චᎹ㓶࿑㧘ᨋ ␭৻㧘଻૑ ഞ㧘›Ⴆ ⾆㧘ጤ㑆 ੧㧚᷆⫷⃿ౝ▵ೝỗⴚ߇ᄼഞߒߚ᦭᫚⿒ⴊ⃿⥰〯∛ߩ 1 ଀㧘ᯏ⢻⣖␹⚻ᄖ⑼ 2008 ᐕ㧧47 Ꮞ㧦114㧙118㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Hozumi I, Uchida Y, Watabe K, Sakamoto T, Inuzuka T. Growth inhibitory factor (GIF㧕can protectfrom brain damage due to stab wounds in rat brain. Neurosci Lett. 2006;395:220-223.
2㧕 Hayashi Y, Hashizume T, Wakida K, Satoh M, Uchida Y, Watabe K, Matsuyama Z, Kimura A, Inuzuka
T, Hozumi I. Association between metallothionein genes polymorphisms and sporadic amyotrophic
lateral sclerosis. Amyotroph Lateral Sc. 2006;7:22-26.
3㧕 Hayashi Y, Kawazoe Y, Sakamoto T, Ojima M, Wang W, Takazawa T, Miyazawa D, Ohya W, Funakoshi
H, Nakamura T, Watabe K. Adenoviral gene transfer of hepatocyte growth factor prevents death of
injured adult motoneurons after peripheral nerve avulsion. Brain Res. 2006;1111:187-195.
4㧕 Wakida K, Morimoto N, Shimazawa M, Hozumi I, Nagase H, Inuzuka T, Hara H. Cilostazol reducesischemic brain damage partly by inducing metallothionein-1 and -2. Brain Res. 2006;1116:187-193.
5㧕 Hozumi I. Care and care-education system foe elderly people with dementia in Japan and Sweden.
Geriatr Gerontrol Int. 2007;7:89-90.
6㧕 Kimura A, Sakurai T, Suzuki Y, Hayashi Y, Hozumi I, Watanabe O, Arimura K, Takahashi Y, Inuzuka
T. Autoantibodies against glutamate receptor 2 subunit detected in a subgroup of patients withreversible autoimmune limbic encephalitis. Eur J Neurol. 2007;58:152-158.
7㧕 Wakida K, Shimazawa M, Hozumi I, Satoh M, Nagase H, Inuzuka T, Hara H. Neuroprotective effect oferythropoietin, and role of metallothionein-1 and -2, in permanent focal cerebral ischemia. Neurol Sci.
2007;148:105-114.
8㧕 Ichiyama T, Shoji H, Takahashi Y, Matsushige T, Kajimoto M, Inuzuka T, Furukawa S. Cerebrospinal
fluid levels of cytokines in non-herpetic limbic encephalitis: Comparison with herpes simplex
encephalitis. Cytokine. 2008;44:149-153.
9㧕 Hozumi I, Yamada M, Uchida Y, Ozawa K, Takahashi H, Inuzuka T. The expression of
metallothioneins is diminished in the spinal cords of patients with sporadic ALS. Amyotroph LateralSc. 2008;9:294-298.
10㧕 Hozumi I, Suzuki JS, Kanazawa H, Hara A, Saio M, Inuzuka T, Miyairi S, Naganuma A, Tohyama C.

㧙㧙

IF 2.085

IF 2.754

IF 2.218
IF 2.218

IF 2.580

IF 1.006

IF 1.986

IF 2.754

Metallothionein-3 is expressed in the brain and various peripheral organs of the rat. Neurosci Lett.
2008;438:54-58.
11㧕 Kimura A, Sakurai T, Tanaka Y, Hozumi I, Takahashi K, Takemura M, Saito K, Seishima M, Inuzuka
T. Proteomic analysis of autoantibodies in neuropsychiatric systemic lupus erythematosus patientwith white matter hyperintensities on brain MRI. Lupus. 2008;17:16-20.
12㧕 Kimura A, Sakurai T, Koumura A, Suzuki Y, Tanaka Y, Hozumi I, Nakajima H, Ichiyama T, Inuzuka T.
Longitudinal analysis of cytokines and chemokines in cerebrospinal fluid of patient with neuro-Sweet
disease presenting with recurrent encephalomeningitis. Intern Med. 2008;47:135-141.
13㧕 Hayashi Y, Kimura A, Kato S, Koumura A, Sakurai T, Tanaka Y, Hozumi I, Sunden Y, Orba Y, Sawa H,
Takahasi H, Inuzuka T. Progressive multifocal leukoencephalopathy and CD4+ T- lymphocytopenia ina patient with Sjoogren syndrome. J Neurol Sci. 2008;268:195-198.
14㧕 Hayashi Y, Sakurai T, Kimura A, Ikeda T, Matsuyama Z, Suzuki Y, Tanaka Y, Hozumi I, Takahasi H,
Inuzuka T. Selective cauda equine hypertrophy with idiopathic inflammation. Muscle Nerve.
2008;38:1065-1069.
15㧕 Nagasao J, Hayashi Y, Kawazoe Y, Kawakami E, Watabe K, Oyanagi K. Relationship between
ribosomal RNA gene transcription activity and motoneuron death: Observations of avulsion andaxotomy of the facial nerve in rats. J Neurosci Res. 2008;86:435-442.
16㧕 Koumura A, Nonaka Y, Hyakkoku K, Oka T, Shimazawa M, Hozumi I, Inuzuka T, Hara H. A novel
calpain inhibitor, ((1S)- 1((((1S)- 1- benzyl- 3- cyclopropylamino- 2,3- di- oxopropyl) amino) carbonyl)- 3methylbutyl) carbamic acid 5-methoxy-3-oxapentyl ester, protects neuronal cells from cerebral
ischemia-induced damage in mice. Neuroscience. 2008;157:309-318.

IF 2.085

IF 2.248

IF 2.315

IF 2.424

IF 3.268

IF 3.352

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦଻૑ ഞ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ ⪚⧘⎇ⓥ㧦␹⚻㔍∛㧔ALS㧕ᖚ⠪ߩ࠾࡯࠭ߦㆡ
วߒߚ IT ᯏེᵴ↪ߣᔃߩࡅࡘ࡯ࡑࡦࠤࠕ࡮ࡀ࠶࠻ࡢ࡯ࠢ᭴▽ߩ⎇ⓥ㧧ᐔᚑ 17㧙18 ᐕᐲ㧧3,598 ජ౞(1,968㧦1,630 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦ᧁ᧛ᥙᄦ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ ⧯ᚻ⎇ⓥ B㧦᛫ GluR2 ᛫૕㓁ᕈᚑੱ⣖Ἳߩ⥃
ᐥߣ᛫ GluR2 ᛫૕ߩ․⇣ᕈߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 16㧙18 ᐕᐲ㧧2,800 ජ౞(1,200㧦1,000㧦600 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦㜞ᯅᐘ೑㧘⎇ⓥಽᜂ⠪㧦›Ⴆ ⾆㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ߎߎࠈߩஜᐽ⑼ቇ⎇ⓥ੐ᬺ㧦ᕆᕈ⣖Ἳߩࠣ࡞࠲ࡒࡦ㉄ฃኈ૕⥄Ꮖ఺∉∛ᘒߩ⸃᣿߆ࠄᣂߚߥᴦ≮ᴺ⏕┙ߦะߌߚ⎇ⓥ⃰(ᕆᕈ⣖Ἳߩ⥄Ꮖ఺∉࡮ᴦ≮⎇ⓥ⃰) [㜞ᯅ⃰]㧦ᐔᚑ 18㧙20 ᐕᐲ㧧2,400 ජ౞(800㧦600㧦1,000 ජ౞)
4㧕 ⎇ⓥઍ⴫⠪㧦♻ጊᵏੱ㧘⎇ⓥಽᜂ⠪㧦›Ⴆ ⾆㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ 㔍ᴦᕈ∔ᖚస᦯⎇ⓥ
੐ᬺ㧦㊀∝㔍∛ᖚ⠪ߩ࿾ၞක≮૕೙ߩ᭴▽ߦ㑐ߔࠆ⎇ⓥ⃰ [♻ጊ⃰]㧦ᐔᚑ 18㧙20 ᐕᐲ㧧2,200 ජ౞(700㧦700㧦800 ජ౞)
5㧕 ⎇ⓥઍ⴫⠪㧦᧻ጟᐘᒾ㧘⎇ⓥಽᜂ⠪㧦›Ⴆ ⾆㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ 㔍ᴦᕈ∔ᖚస᦯⎇ⓥ
੐ᬺ㧦ࠬࡕࡦߦ㑐ߔࠆ⎇ⓥ⃰ [᧻ጟ⃰]㧦ᐔᚑ 18㧙20 ᐕᐲ㧧2,100 ජ౞(700㧦700㧦700 ජ౞)
6㧕 ⎇ⓥઍ⴫⠪㧦ᧁ᧛ᥙᄦ㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ߎߎࠈߩஜᐽ⑼ቇ⎇ⓥ੐ᬺ㧦⥄Ꮖ఺∉∔ᖚߦ઻߁ਛᨔ␹⚻㓚ኂߦ㑐ㅪߔࠆ᛫␹⚻᛫૕ߩᬌ⚝ߣ᛫ේᯏ⢻ߩ⸃ᨆ㧦∛ᘒߩ⸃᣿߆ࠄᴦ≮ᴺ⏕┙ߦะߌߡ㧧ᐔᚑ 18㧙20 ᐕᐲ㧧18,000 ජ౞(600㧦600㧦600 ජ౞)
7㧕 ⎇ⓥઍ⴫⠪㧦଻૑ ഞ㧧ጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼⎇ⓥᵴᕈൻᡰេ੐ᬺ㧦⣖⯯ⴊ㧘␹⚻ᄌᕈ∔ᖚࡕ࠺࡞േ‛ߦ߅ߌࠆᣂߚߥⷞὐߢߩ␹⚻ౣ↢ᴦ≮ߩ⹜ߺ㧧ᐔᚑ 18 ᐕᐲ㧧1,000 ජ౞8㧕 ⎇ⓥઍ⴫⠪㧦↰ਛఝม㧧ጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼⎇ⓥᵴᕈൻᡰេ੐ᬺ㧦ࡄ࡯ࠠࡦ࠰ࡦ∛(PD)ߩ
⿥ᣧᦼ⸻ᢿߦ㑐ߔࠆ⎇ⓥ -ᧂᴦ≮ߩᣧᦼࡄ࡯ࠠࡦ࠰ࡦ∛ߦ߅ߌࠆᶖൻ▤ᯏ⢻ߦ㑐ߔࠆᬌ⸛-㧧ᐔᚑ 18
ᐕᐲ㧧200 ජ౞
9㧕 ⎇ⓥઍ⴫⠪㧦ᨋ ␭৻㧧ᬞ␹⚻∔ᖚ⎇ⓥၮ㊄⎇ⓥ⾌⵬ഥ㊄㧦╭⪜❗ᕈ஥⚝⎬ൻ∝ߦኻߔࠆ᛫㉄ൻ‛⾰ߣㆇേ≮ᴺߩലᨐ㧦ᐔᚑ 18 ᐕᐲ㧧300 ජ౞
10㧕 ⎇ⓥઍ⴫⠪㧦଻૑ ഞ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ ၮ⋚⎇ⓥ(B)㧦⠧ൻ㧘⣖⯯ⴊ߅ࠃ߮ࡔ࠲ࡏ࡝࠶ࠢ
∝୥⟲ߦ߅ߌࠆࡔ࠲ࡠ࠴ࠝࡀࠗࡦߩᓎഀߣഃ⮎ߩ⎇ⓥ㧧ᐔᚑ 19㧙21 ᐕᐲ㧧17,540 ජ౞(12,740㧦
2,700㧦2,100 ජ౞)
11㧕 ⎇ⓥઍ⴫⠪㧦ᨋ ␭৻㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ ⧯ᚻ⎇ⓥ(B)㧦╭⪜❗ᕈ஥⚝⎬ൻ∝ࡕ࠺࡞ࡑ࠙ࠬ
ߦኻߔࠆㆇേ≮ᴺߣ᛫㉄ൻ‛⾰ߩ૬↪ᴦ≮ലᨐߦߟ޿ߡ㧧ᐔᚑ 19㧙21 ᐕᐲ㧧3,200 ජ౞(1,600㧦800㧦
800 ජ౞)12㧕 ⎇ⓥઍ⴫⠪㧦ᧁ᧛ᥙᄦ㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌㧦ᄙ⊒ᕈ⎬ൻ∝ᖚ⠪ߦ߅ߌࠆᣂⷙ᛫␹⚻᛫૕ߩᬌ⚝߅ࠃ߮⹺⼂᛫ේߩหቯ-⸻ᢿ߅ࠃ߮ᴦ≮ᴺߩ㐿⊒ߦะߌߡ-㧧ᐔᚑ 19 ᐕᐲ㧧1,130 ජ౞
13㧕 ⎇ⓥઍ⴫⠪㧦᳓Ỉ⧷ᵗ㧘⎇ⓥಽᜂ⠪㧦›Ⴆ ⾆㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ 㔍ᴦᕈ∔ᖚస᦯⎇ⓥ㧙㧙੐ᬺ㧦ࡊ࡝ࠝࡦ∛෸߮ㆃ⊒ᕈ࠙ࠗ࡞ࠬᗵᨴ∝ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ⃰ [᳓Ỉ⃰]㧧ᐔᚑ 20㧙22 ᐕᐲ㧧3,000ජ౞(1,000㧦1,000㧦1,000 ජ౞)
14㧕 ⎇ⓥઍ⴫⠪㧦›Ⴆ ⾆㧦ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦ࡊࡠ࠹ࠝࡒࠢࠬߦࠃࠆ╭ήജ∝࡮╭Ἳ․⇣⊛⥄Ꮖ᛫૕ߩᬌ⚝ߣࡃࠗࠝࡑ࡯ࠞ࡯ߩ⏕┙㧧ᐔᚑ 20 ᐕᐲ㧧1,600 ජ౞
15㧕 ⎇ⓥઍ⴫⠪㧦଻૑ ഞ㧧ਃ੗૑෹ᶏ਄⑔␩⽷࿅⎇ⓥഥᚑ ࠕ࡞࠷ࡂࠗࡑ࡯∛╬㜞㦂⠪␹⚻ᄌᕈ∔ᖚᖚ⠪ߦ߅ߌࠆ㜑ᶧ㊀㊄ዻߣ᛫㉄ൻ‛⾰ߩ᷹ቯߣഃ⮎߳ߩᔕ↪㧦ᐔᚑ 20 ᐕᐲ㧧1,550 ජ౞
16㧕 ⎇ⓥઍ⴫⠪㧦଻૑ ഞ㧧ᐔᚑ 20 ᐕᐲጘ㒂ᄢቇᛛⴚ੤ᵹ⎇ⓥળડ↹൐㓸 ᧲ᶏࡔ࠲ࡠ࠴ࠝࡀࠗࡦ⎇ⓥ
ળ㧦ᐔᚑ 20 ᐕᐲ㧧150 ජ౞
17㧕 ⎇ⓥઍ⴫⠪㧦଻૑ ഞ㧧ᐔᚑ 20 ᐕᐲጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼ၮ␆කቇ⎇ⓥᵴᕈൻ࡮⧯ᚻ⢒ᚑ࡙࠾࠶࠻ ࡔ࠲ࡠ࠴ࠝࡀࠗࡦ߅ࠃ߮ࡔ࠲࡞ࡃࠗࠝࠨࠗࠛࡦࠬ㧦ᐔᚑ 20 ᐕᐲ㧧1,000 ජ౞
18㧕 ⎇ⓥઍ⴫⠪㧦ᧁ᧛ᥙᄦ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧧ᄙ⊒ᕈ⎬ൻ∝ߦ߅ߌࠆᄢ⣖⤑Ⱞ⊕ߦኻߔࠆᣂⷙ⥄Ꮖ᛫૕ߩᬌ⚝ߣࡃࠗࠝࡑ࡯ࠞ࡯ߩ⏕┙㧦ᐔᚑ 20 ᐕᐲ㧧2,600 ජ౞)
2㧕ฃ⸤⎇ⓥߥߒ

3㧕౒ห⎇ⓥߥߒ

5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ

6㧚ቇળᵴേ
1㧕ቇળᓎຬ›Ⴆ ⾆㧦
1㧕 ᣣᧄ␹⚻ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ␹⚻ቇળ↢ᶦᢎ⢒ᆔຬ(㨪⃻࿷)3㧕 ᣣᧄౝ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄ⠧ᐕකቇળ⹏⼏ຬ(㨪⃻࿷)5㧕 ᣣᧄ⠧ᐕකቇળᢎ⢒ᆔຬ(㨪⃻࿷)6㧕 ᣣᧄ⠧ᐕකቇળ✬㓸ᆔຬ(㨪ᐔᚑ 19 ᐕ 3 ᦬)
7㧕 ᣣᧄ⠧ᐕකቇળࡁࡃ࡞࠹ࠖࠬ⎇ⓥၮ㊄ㆬ⠨ᆔຬ(㨪⃻࿷)8㧕 ᣣᧄ␹⚻ᴦ≮ቇળ⹏⼏ຬ(㨪⃻࿷)9㧕 ᣣᧄ␹⚻఺∉ቇળℂ੐(ᐔᚑ 20 ᐕ 4 ᦬㨪⃻࿷)10㧕 ᣣᧄ␹⚻఺∉ቇળ⹏⼏ຬ(㨪⃻࿷)11㧕 ᣣᧄ␹⚻఺∉ቇળ✬㓸ᆔຬ(㨪⃻࿷)12㧕 ᣣᧄ␹⚻ᗵᨴ∝ቇળ⹏⼏ຬ(㨪⃻࿷)଻૑ ഞ㧦1㧕 ᣣᧄ␹⚻ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄౝ⑼ቇળౝ⑼ኾ㐷කળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄౝ⑼ቇળ∛ᱧⷐ⚂⹏ଔᆔຬ(㨪⃻࿷)4㧕 ᣣᧄ⠧ᐕකቇળ⹏⼏ຬ(㨪⃻࿷)5㧕 ᣣᧄ⠧ᐕකቇળ੐଀ᬌ⸛ᆔຬ(ᐔᚑ 20 ᐕᐲ㨪⃻࿷)
6㧕 ࡔ࠲ࡠ࠴ࠝࡀࠗࡦ⎇ⓥળᐙ੐(㨪⃻࿷)2㧕ቇળ㐿௅›Ⴆ ⾆㧦
1㧕 ᐔᚑ 17 ᐕᐲᣣᧄ␹⚻ቇળ᧲ᶏർ㒽࿾඙↢ᶦᢎ⢒⻠Ṷળ(ᐔᚑ 18 ᐕ 1 ᦬㧘ฬฎደ)2㧕 ᐔᚑ 18 ᐕᐲᣣᧄ␹⚻ቇળ᧲ᶏർ㒽࿾඙↢ᶦᢎ⢒⻠Ṷળ(ᐔᚑ 19 ᐕ 3 ᦬㧘ฬฎደ)3㧕 ╙ 203 ࿁ᣣᧄౝ⑼ቇળ᧲ᶏ࿾ᣇળ(ᐔᚑ 19 ᐕ 10 ᦬㧘ฬฎደ)
4㧕 ᐔᚑ 19 ᐕᐲᣣᧄౝ⑼ቇળ᧲ᶏᡰㇱᏒ᳃౏㐿⻠ᐳ(ᐔᚑ 19 ᐕ 10 ᦬㧘ጘ㒂)
5㧕 ᐔᚑ 19 ᐕᐲᣣᧄ␹⚻ቇળ᧲ᶏർ㒽࿾඙↢ᶦᢎ⢒⻠Ṷળ(ᐔᚑ 20 ᐕ 3 ᦬㧘ฬฎደ)㧙㧙6㧕 ╙ 9 ࿁⠧ᐕ∔ᖚ⎇ⓥળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂)7㧕 ╙ 19 ࿁ᣣᧄ⠧ᐕකቇળ᧲ᶏ࿾ᣇળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ฬฎደ)଻૑ ഞ㧦
1㧕 ╙ 120 ࿁ᣣᧄ␹⚻ቇળ᧲ᶏർ㒽࿾ᣇળ(ᐔᚑ 20 ᐕ 3 ᦬㧘ฬฎደ)
3㧕ቇⴚ㔀⹹›Ⴆ ⾆㧦
1㧕 ᣣᧄౝ⑼ቇળ㔀⹹㧧✬㓸ᆔຬ(ᐔᚑ 19 ᐕ 4 ᦬㨪⃻࿷)2㧕 ᣣᧄ⠧ᐕකቇળ⹹㧧✬㓸ᆔຬ(㨪ᐔᚑ 19 ᐕ 3 ᦬)
3㧕 Geriatrics Gerontology International, Associate Editor(ᐔᚑ 18 ᐕ 4 ᦬㨪⃻࿷)
4㧕 ᣣᧄ␹⚻఺∉ቇળ⹹㧧✬㓸ᆔຬ(㨪⃻࿷)5㧕 කቇߩ޽ࠁߺ㧧✬㓸දജ⠪(ᐔᚑ 19 ᐕ 4 ᦬㨪⃻࿷)7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳›Ⴆ ⾆㧦
1㧕 ╙ 47 ࿁ᣣᧄ␹⚻ቇળ✚ળ(ᐔᚑ 18 ᐕ 5 ᦬㧘᧲੩㧘⻠Ṷળ‫ޟ‬AD એᄖߩ Dementia࡮⥃ᐥᓽ୥࡮⣖ᵄ࡮⺃⊒㔚૏‫ޠ‬ᐳ㐳)2㧕 ╙ 43 ࿁ᣣᧄ⠧ᐕකቇળ✚ળ(ᐔᚑ 18 ᐕ 6 ᦬㧘㊄ᴛ㧘⻠Ṷળ‫⹺ဳ࡯ࡑࠗࡂ࠷࡞ࠕޟ‬⍮∝⎇ⓥߩᦨㄭߩㅴᱠ-ࠕࡐ࡝ࡐⰮ⊕ E ࡈࠚࡁ࠲ࠗࡊߣߩ㑐ଥ-‫ޠ‬ᐳ㐳)
3㧕 ╙ 11 ࿁ᣣᧄ␹⚻ᗵᨴ∝ቇળ(ᐔᚑ 18 ᐕ 10 ᦬㧘દ൓㧘⻠Ṷળ‫ޠࠕ࡝࠹ࠬ࡝ޟ‬ᐳ㐳)
4㧕 ╙ 104 ࿁ᣣᧄౝ⑼ቇળ✚ળ(ᐔᚑ 19 ᐕ 4 ᦬㧘᧲੩㧘⻠Ṷળ‫⚻␹ޟ‬ԛ‫ޠ‬ᐳ㐳)
5㧕 ╙ 48 ࿁ᣣᧄ␹⚻ቇળ✚ળ(ᐔᚑ 19 ᐕ 5 ᦬㧘ฬฎደ㧘ࠪࡦࡐࠫ࠙ࡓ‫∔⚻␹ޟ‬ᖚߣ⥄Ꮖ᛫૕‫ޠ‬ᐳ㐳)
6㧕 ╙ 44 ࿁ᣣᧄ⠧ᐕකቇળ✚ળ(ᐔᚑ 19 ᐕ 6 ᦬㧘ᧅᏻ㧘⻠Ṷળ‫⹺ޟ‬⍮∝ԙ‫ޠ‬ᐳ㐳)7㧕 ╙ 8 ࿁⠧ᐕ∔ᖚ⎇ⓥળ(ᐔᚑ 19 ᐕ 7 ᦬㧘シ੗ᴛ㧘⻠Ṷળᐳ㐳)8㧕 ╙ 12 ࿁ᣣᧄ␹⚻ᗵᨴ∝ቇળ✚ળ(ᐔᚑ 19 ᐕ 10 ᦬㧘⑔ጟ㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ‫ޟ‬ㅴⴕᕈᄙᎽᕈ⊕⾰⣖∝(PML)‫ޠ‬ᐳ㐳)9㧕 ╙ 19 ࿁ᣣᧄ⠧ᐕකቇળ᧲ᶏ࿾ᣇળ(ᐔᚑ 19 ᐕ 10 ᦬㧘ฬฎደ㧘․೎⻠Ṷ‫੍⼔੺ޟ‬㒐ߩࠛࡆ࠺ࡦࠬ‫ޠ‬ᐳ㐳)
10㧕 ╙ 19 ࿁ᣣᧄ⠧ᐕකቇળ᧲ᶏ࿾ᣇળ(ᐔᚑ 19 ᐕ 10 ᦬㧘ฬฎደ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᓟᦼ㜞㦂⠪ක≮೙ᐲ߇ዉ౉ߐࠇߡ‫ޠ‬ᐳ㐳)଻૑ ഞ㧦
1㧕 ╙ 2 ࿁᧲ᶏࡔ࠲ࡠ࠴ࠝࡀࠗࡦ⎇ⓥળ(ᐔᚑ 18 ᐕ 9 ᦬㧘ฬฎደ㧘․೎⻠Ṷ‫❗⪜╭ޟ‬ᕈ஥⚝⎬ൻ∝ߣࡔ࠲ࡠ࠴ࠝࡀࠗࡦ‫ޠ‬Ṷ⠪)
2㧕 ╙ 4 ࿁᧲ᶏࡔ࠲ࡠ࠴ࠝࡀࠗࡦ⎇ⓥળ(ᐔᚑ 19 ᐕ 3 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬⢈ḩ࡮ࠬ࠻࡟ࠬ߆ࠄࡔ࠲ࡠ
࠴ࠝࡀࠗࡦߩ↢ℂ⊛ᓎഀࠍ⠨߃ࠆ‫ޠ‬ᐳ㐳)
3㧕 ࡔ࠲ࡠ࠴ࠝࡀࠗࡦ߅ࠃ߮ࡔ࠲࡞ࡃࠗࠝࠨࠗࠛࡦࠬ⎇ⓥળ(ᐔᚑ 19 ᐕ 9 ᦬㧘ᓼፉ㧘ࠪࡦࡐࠫ࠙ࡓ․೎
⻠Ṷ‫⚻␹ޟ‬ᄌᕈ∔ᖚߦ߅ߌࠆࡔ࠲ࡠ࠴ࠝࡀࠗࡦߣࡔ࠲࡞ߩᓎഀ‫ޠ‬Ṷ⠪)
4㧕 ╙ 41 ࿁ᣣᧄౝ⑼ቇળ᧲ᶏᡰㇱ↢ᶦᢎ⢒⻠Ṷળ(ᐔᚑ 19 ᐕ 10 ᦬㧘ฬฎደ㧘․೎⻠Ṷ‫∔⚻␹ޟ‬ᖚߣࡔ࠲ࡠ࠴ࠝࡀࠗࡦ‫ޠ‬Ṷ⠪)
5㧕 ᣣᧄ⮎ቇળ᧲ᶏᡰㇱ⻠Ṷળ(╙ 12 ࿁⮎ቇ࠮ࡒ࠽࡯)(ᐔᚑ 19 ᐕ 12 ᦬㧘ฬฎደ㧘․೎⻠Ṷ‫∔⚻␹ޟ‬ᖚߣࡔ࠲ࡠ࠴ࠝࡀࠗࡦ-ᣂዷ㐿ߔࠆࡔ࠲ࡠ࠴ࠝࡀࠗࡦ⎇ⓥ-‫ޠ‬Ṷ⠪)
6㧕 ╙ 120 ࿁ᣣᧄ␹⚻ቇળ᧲ᶏർ㒽࿾ᣇળ(ᐔᚑ 20 ᐕ 3 ᦬㧘ฬฎደ㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯‫⚻␹ޟ‬ᄌᕈ∔ᖚߩࠨࠗࠛࡦࠬ-⃻⁁ߣ੹ᓟߩዷᦸ-‫ޠ‬ᐳ㐳)ᨋ ␭৻㧦
1㧕 ╙ 12 ࿁ᣣᧄ␹⚻ᗵᨴ∝ቇળ✚ળ(ᐔᚑ 19 ᐕ 10 ᦬㧘⑔ጟ㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ‫ޟ‬Sjogren ∝୥⟲ߦࠃࠆ
ੑᰴᕈ CD4 㓁ᕈ T ⚦⢩ᷫዋ∝ߣㅴⴕᕈᄙᎽᕈ⊕⾰⣖∝‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ
ߥߒ

㧙㧙

9㧚␠ળᵴേ›Ⴆ ⾆㧦
1㧕 ጘ㒂⋵࿖᳃ஜᐽ଻㒾࿅૕ㅪวળ੺⼔⛎ઃ⾌ክᩏᆔຬ(㨪ᐔᚑ 20 ᐕ 3 ᦬)
2㧕 ਛㇱ≮⼔࠮ࡦ࠲࡯౉㒮ክᩏᆔຬ(㨪⃻࿷)3㧕 ጘ㒂⋵㔍∛ක≮ㅪ⛊ද⼏ળ೽ળ㐳(㨪⃻࿷)4㧕 ጘ㒂⋵කᏧળ੺⼔⑔␩ᆔຬ(㨪⃻࿷)5㧕 ጘ㒂⋵කᏧળઍ⼏ຬ(㨪⃻࿷)6㧕 ጘ㒂⋵⹺⍮∝࿾ၞᡰេ૕೙᭴▽╬ផㅴᆔຬળᆔຬ(ᐔᚑ 19 ᐕ㨪⃻࿷)7㧕 ᣣᧄ ALS දળጘ㒂⋵ᡰㇱ․೎㘈໧(ᐔᚑ 20 ᐕ 4 ᦬㨪⃻࿷)8㧕 ࠢࡠࠗ࠷ࡈࠚ࡞࠼ࡗࠦࡉ∛ࠨ࡯ࡌࠗ࡜ࡦࠬᆔຬ(ో࿖)(ᐔᚑ 20 ᐕ 4 ᦬㨪⃻࿷)9㧕 ࠢࡠࠗ࠷ࡈࠚ࡞࠼ࡗࠦࡉ∛ࠨ࡯ࡌࠗ࡜ࡦࠬᆔຬ(ጘ㒂⋵ᜂᒰ)(㨪⃻࿷)଻૑ ഞ㧦1㧕 ᣣᧄ ALS දળጘ㒂⋵ᡰㇱ․೎㘈໧(㨪⃻࿷)↰ਛఝม㧦1㧕 ጘ㒂⋵࿖᳃ஜᐽ଻㒾࿅૕ㅪวળ੺⼔⛎ઃ⾌ክᩏᆔຬ(ᐔᚑ 20 ᐕ 4 ᦬㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ›Ⴆ ⾆㧘↰ਛఝม㧘ᧁ᧛ᥙᄦ㧘଻૑ ഞ㧘቟⮮᥍⟤㧘᧻↰ਯ೑㧦ጘ㒂⋵ߦ߅ߌࠆ␹⚻㔍∛ߣߘߩ≮㙃ᡰេߩ⃻⁁㧚ᐔᚑ 17 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ 㔍ᴦᕈ∔ᖚస᦯੐ᬺ ㊀∝㔍∛ᖚ⠪ߩ࿾ၞක≮૕೙ߩ᭴▽ߦ㑐ߔࠆ⎇ⓥ⃰ ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ㧦42㧙43(2006 ᐕ 3 ᦬)
2㧕 ›Ⴆ ⾆㧘↰ਛఝม㧘ᧁ᧛ᥙᄦ㧘଻૑ ഞ㧘ၳ↰޽ߌߺ㧦ጘ㒂⋵ߦ߅ߌࠆ࡟ࠬࡄࠗ࠻౉㒮ߩฃߌ౉ࠇ
⁁ᴫߦ㑐ߔࠆ⃻⁁ߣ⺖㗴㧦ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ 㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ ㊀∝㔍∛ᖚ⠪ߩ࿾ၞක≮૕೙ߩ᭴▽ߦ㑐ߔࠆ⎇ⓥ⃰ ᐔᚑ 18 ᐕᐲ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ㧦51㧙52 (2007 ᐕ 3 ᦬)
3㧕 ›Ⴆ ⾆㧘ᧁ᧛ᥙᄦ㧘↰ਛఝม㧘଻૑ ഞ㧦㕖ற⣲≌ᕈ㕖ࡋ࡞ࡍࠬᕈㄝ✼♽⣖Ἳᖚ⠪ߦ߅ߌࠆੑᰴర
఺∉ࡉࡠ࠶࠹ࠖࡦࠣ߅ࠃ߮㜞ᗵᐲ࠽ࡁ LC-MS/MS ࠪࠬ࠹ࡓࠍ↪޿ߚⴊᷡਛ᛫␹⚻⚵❱᛫૕ߩ✂⟜⊛⸃ᨆ㧦ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ߎߎࠈߩஜᐽ⑼ቇ⎇ⓥ੐ᬺ ᕆᕈ⣖Ἳߩࠣ࡞࠲ࡒࡦ㉄ฃኈ૕⥄Ꮖ఺∉∛ᘒߩ⸃᣿߆ࠄᣂߚߥᴦ≮ᴺ⏕┙ߦะߌߚ⎇ⓥ⃰ ᐔᚑ 18 ᐕᐲ✚᜝࡮ಽᜂႎ๔ᦠ㧦45㧙
46(2007 ᐕ 3 ᦬)
4㧕 ␲ῳᳯర㧘᦯ㇱ⋥᮸㧘ዊᳰᤐ᮸㧘ᳰ↰ୃ৻㧘᎑↰ ⼾㧘ᨋ ᱜ↵㧘ᩙጊ ൎ㧘›Ⴆ ⾆㧘ᯅᧄୃੑ㧘Ḵญഞ৻㧘㣐⷗ᐘᒾ㧘኷⃨ጊ⒤㧘Ⴧ੗ᕡᄦ㧘᳁ᐔ㜞ᢅ㧘ች↰๺᣿㧘ዊ㐳⼱ᱜ᣿㧘᧻ጟᐘᒾ㧦ᐔᚑ 18 ᐕᐲਛㇱ࿾඙ࠬࡕࡦᖚ⠪ߩታᘒ㧦ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ 㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ ࠬࡕࡦߦ㑐ߔࠆ⎇ⓥ⃰ ᐔᚑ 18 ᐕᐲ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ㧦29㧙31 (2007 ᐕ 3 ᦬)
5㧕 ଻૑ ഞ㧦㔍∛ᖚ⠪ߩ࠾࡯࠭ߦㆡวߒߚ IT ᯏེᵴ↪ߣᔃߩࠤࠕߦ㑐ߔࠆࡀ࠶࠻ࡢ࡯ࠢ᭴▽㧦ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄(⪚⧘⎇ⓥ) ᐔᚑ 18 ᐕᐲ㧙19 ᐕᐲ✚᜝⎇ⓥႎ๔ᦠ(2007 ᐕ 3 ᦬)
6㧕 ᧁ᧛ᥙᄦ㧦⥄Ꮖ఺∉∔ᖚߦ઻߁ਛᨔ␹⚻㓚ኂߦ㑐ㅪߔࠆ᛫␹⚻᛫૕ߩᬌ⚝ߣ᛫ේᯏ⢻ߩ⸃ᨆ-∛ᘒߩ⸃᣿߆ࠄᴦ≮ᴺ⏕┙ߦะߌߡ- ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ߎߎࠈߩஜᐽ⑼ቇ⎇ⓥ੐ᬺ ᐔᚑ 18 ᐕᐲ✚᜝⎇ⓥႎ๔ᦠ(2007 ᐕ 3 ᦬)
7㧕 ›Ⴆ ⾆㧘ᧁ᧛ᥙᄦ㧘↰ਛఝม㧘଻૑ ഞ㧦CNS ࡞࡯ࡊࠬᖚ⠪ߦ߅ߌࠆᣂⷙ᛫␹⚻᛫૕ߩᬌ಴ߣ⹺⼂᛫ේߩหቯ. ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ߎߎࠈߩஜᐽ⑼ቇ⎇ⓥ੐ᬺ ᕆᕈ⣖Ἳߩࠣ࡞࠲ࡒࡦ㉄ฃኈ૕⥄Ꮖ఺∉∛ᘒߩ⸃᣿߆ࠄᣂߚߥᴦ≮ᴺ⏕┙ߦะߌߚ⎇ⓥ⃰ ᐔᚑ 19 ᐕᐲ✚᜝࡮ಽᜂႎ๔ᦠ㧦68㧙
69(2008 ᐕ 3 ᦬)
8㧕 ␲ῳᳯర㧘᦯ㇱ⋥᮸㧘ዊᳰᤐ᮸㧘ᳰ↰ୃ৻㧘᎑↰ ⼾㧘ᨋ ᱜ↵㧘ᩙጊ ൎ㧘›Ⴆ ⾆㧘ᯅᧄୃੑ㧘Ḵญഞ৻㧘㣐⷗ᐘᒾ㧘኷⃨ጊ⒤㧘ਣጊ᤯ੑ㧘Ⓑ⪲㕒ઍ㧘ች↰๺᣿㧘ዊ㐳⼱ᱜ᣿㧘᧻ጟᐘᒾ㧦ᐔᚑ 19 ᐕᐲਛㇱ࿾඙ࠬࡕࡦᖚ⠪ߩታᘒ㧚ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ 㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ ࠬࡕࡦߦ㑐ߔࠆ⎇ⓥ⃰ ᐔᚑ 19 ᐕᐲ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ㧦27㧙29(2008 ᐕ 3 ᦬)
11㧚ႎ㆏
1㧕 ଻૑ ഞ㧦৻⥸ౝ⑼ක߇⍮ߞߡ߅߈ߚ޿⹺⍮∝ߩ㐓೎ߣ๟ㄝ∝⁁㧦ጘ㒂කᏧળߛࠃࠅ(ᐔᚑ 19 ᐕ 1 ᦬)
2㧕 ଻૑ ഞ㧦ࡄ࡯ࠠࡦ࠰ࡦ∛ߣ㘃✼∔ᖚ㧙㐓೎ߣᦨᣂߩᴦ≮㧙㧦KNG(ᐔᚑ 19 ᐕ 1 ᦬)
3㧕 ›Ⴆ ⾆㧦╙ 18 ࿁ NPO ᴺੱጘ㒂⋵㔍∛࿅૕ㅪ⛊ද⼏ળ⸳┙⸥ᔨᄢળߦ޽ߚߞߡ㧦KNG(ᐔᚑ 19 ᐕ
5 ᦬)

㧙㧙

4㧕 ›Ⴆ ⾆㧦ࡄ࡯ࠠࡦ࠰ࡦ∛ߩೋᦼ⸻ᢿߣᴦ≮㧦ጘ㒂⋵଻㒾කᣂ⡞(ᐔᚑ 19 ᐕ 10 ᦬ 10 ᣣ)
5㧕 ଻૑ ഞ㧦∛᳇ㅴⴕࠍㆃࠄߖࠆ⮎೷㐿⊒㧦ጘ㒂ᣂ⡞(ᐔᚑ 19 ᐕ 12 ᦬ 4 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔ‫⎇ޣ‬ⓥ‫ޤ‬ᩉᚭࠠࡖࡦࡄࠬ߳ߩᣂ▽⒖ォ㧔2004㧕ߦࠃߞߡ㧘ೋ߼ߡ⥄೨ߩታ㛎ቶ߇ߢ߈㧘⠉ᐕߦߪേ‛㘺⢒߇น⢻ߦߥߞߚ߇㧘ߎߩ 3 ᐕ㑆㧘ߘߩᚑᨐ߇⺰ᢥߣߒߡ಴ߡߊࠆࠃ߁ߦߥߞߡ߈ߚ‫ޕ‬ታ㛎࡮⚿ᨐߩᬌ⸛࡮ቇળ⊒⴫࡮⎇ⓥ⾌↳⺧ߣ޿ߞߚᣣᏱ⊛⎇ⓥᵴേ߇ᰴ╙ߦቯ⌕ߒ㧘వⴕߒߡ޿ߚ⸻≮㧘ᢎ⢒㧘␠ળᵴേߣ૬ߖ㧘ࠃ߁߿ߊࡃ࡜ࡦࠬߩߣࠇߚᢎቶߦߥߞߡ߈ߚ‫߽ࠇߕ޿ޕ‬ℂᗐߦߪ߹ߛ㆙޿߇㧘ߎߎ 2 ᐕ㑆㧘ᣂ౉ዪකᏧ߇ߥߊᢎቶຬฦ⥄ߩᚑ㐳ߣ♖৻᧰ߩദജߦࠃࠆ⾦‛ߢ޽ࠆ‫⮎ߚ߹ޕ‬ቇ߆ࠄߩ㒮↢౉ቇ߽ᄢ߈
ߥജߢ޽ߞߚ‫ޕ‬ᢥㇱ⑼ቇ⋭߅ࠃ߮ෘ↢ഭ௛⋭ߩ⑼ቇ⎇ⓥ⾌㧘ෘഭ⋭⃰ળ⼏ࠍߪߓ߼┹੎⊛⎇ⓥ⾌ߩ₪ᓧߪ⋡ᮡ࡟ࡌ࡞⋧ᒰߢ޽ߞߚ‫ޕ‬‫ޤ≮⸻ޣ‬㒢ࠄࠇߚᢎຬ/කຬᢙߣ∛ᐥᢙߢⷙᮨ⊛ߦߪ㒢⇇߇޽ࠆ߇㧘ᄢቇ∛㒮ߦ߅ߌࠆ⸻≮ౝኈߪ⼾ንߢ㧘␹⚻ᢇᕆ߆ࠄ㔍∛ߩ⏕ቯ⸻ᢿ࡮␠ળ⾗Ḯߩ⺞ᢛ߹ߢ᏷ᐢߊኻᔕߒߡ߈ߚ‫ ߩߎޕ‬3 ᐕ㑆㧘ᒰಽ㊁↢߃ᛮ߈ߩ␹⚻ౝ⑼ኾ㐷ක߇ 4 ฬ㧘⠧ᐕ∛ኾ㐷ක 2 ฬ߇޿ߕࠇ߽⹜㛎ࠍ 1 ࿁ߢวᩰߒߡ⺀↢ߒߚ‫ޕ‬කᏧ㧘⋴⼔Ꮷ㧘ㅪ៤࠮ࡦ࠲࡯㧘⮎೷Ꮷ㧘ℂቇ/૞ᬺ≮ᴺ჻ࠍ੤߃ߚቯᦼ⊛∛᫟ળ⼏㧘࿾ၞߩක≮/⑔␩ࠬ࠲࠶ࡈࠍ੤߃ߚ᜛
ᄢࠞࡦࡈࠔ࡟ࡦࠬ࡜ࡦࠬߩ㓐ᤨ㐿௅㧘߆߆ࠅߟߌකߣߩ⸻≮ㅪ៤߇ㅴߺ㧘ቇౝᄖߩ␹⚻ౝ⑼⸻≮ߪ᣿ࠄ߆ߦෘߺࠍჇߒߚ‫ޕ‬‫ޣ‬ᢎ⢒‫⥃ޤ‬ᐥታ⠌߽㒢ࠄࠇߚᢎຬ/කຬߣዋߥ޿∛ᐥߢᎿᄦࠍಝࠄߒߡขࠅ⚵ߺ㧘6 ᐕ↢ߩࠢ࡝࠾ࠞ࡞ࠢ࡜
࡯ࠢࠪ࠶ࡊߪ߶߷ታ⃻ߒߡ޿ࠆ‫࡞ࠕ࡝࠻ࡘ࠴ޕ‬㑐ㅪ⻠⟵㧘⥃ᐥ౉㐷ታ⠌ߥߤߪ㧘ዋߥ޿ᢎቶຬ✚಴ߢኻᔕߒߡ߈ߚ‫⸰ߚ߹ޕ‬໧⋴⼔૕㛎ታ⠌ߪጘ㒂Ꮢ෸߮ᧄᎽකᏧળߩߏදജࠍᓧߡ㧘2000 ᐕ߆ࠄ⛮⛯⊛ߦⴕࠊࠇߡ޿ࠆ߇ቇ↢ߩ⹏ଔ߽㜞޿‫ޕ‬‫␠ޣ‬ળᵴേ‫ޤ‬ᄢቇ∛㒮߇㔍∛᜚ὐ∛㒮ߦᜰቯߐࠇ㧘㔍∛ኾ㐷ຬ߇⸳⟎ߐࠇߚߎߣ߆ࠄ␹⚻㔍∛ߩኻᔕߪᩰ
Ბߦᡷༀߐࠇߚ‫ޕ‬㔍∛ኾ㐷ຬߣ౒หߒߡ⑔␩ⴕ᡽ࠬ࠲࠶ࡈ㧘⸰໧⋴⼔Ꮷ࡮ࡋ࡞ࡄ࡯ߩᢎ⢒߇ߔߔࠎߢ޿
ࠆ‫ߦࠄߐޕ‬ጘ㒂⋵㔍∛ㅪߩขࠅ⚵ߺߦ߽Ⓧᭂ⊛ߦෳടߒ㧘࿾ၞߩ␹⚻㔍∛ኻᔕߩᐩ਄ߍߦ⽸₂ߒߡ߈ߚ‫ޕ‬␹⚻㔍∛╬ߦ߅޿ߡ㧘߆߆ࠅߟߌකߣߩㅪ៤ࠍᷓ߼ 2 ੱਥᴦක೙ࠍផㅴߒߡ␹⚻ౝ⑼ක≮ࠍᐢ߼ࠆߣߣ
߽ߦ㧘ᄢቇ∛㒮ߩᣂᖚ࡮㊀∝⠪ኻᔕജࠍ⏕଻ߒߡ߈ߚ‫ߌߟࠅ߆߆ޕ‬කߩ⹺⍮∝ኻᔕജะ਄⎇ୃ㧘࿾ၞߩ⹺⍮∝ࡀ࠶࠻ࡢ࡯ࠢߟߊࠅߩᵴേߦ㧘⻠Ꮷ߿ડ↹ߩ৻ㇱࠍᜂᒰߔࠆߥߤⓍᭂ⊛ߦෳടߒ㧘ጘ㒂⋵ߩ⹺⍮∝ኻᔕߩၮ⋚૞ࠅߦ⽸₂ߒߡ߈ߚ‫ޕ‬ቇౝᄖߩ⋴⼔Ꮷ㧘≮ᴺ჻ߩ㙃ᚑߦ߽⻠⟵╬ߦࠃࠅⓍᭂ⊛ߦ⽸₂ߒߚ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷૗ࠃࠅ߽ੱ᧚ߩ⏕଻߇໧㗴ߢ޽ࠆ‫⎇ޕ‬ⓥ࡮⸻≮࡮ᢎ⢒╬㧘૗ࠍ߿ࠆߦߒߡ߽߹ߕੱ᧚ߢ޽ࠆ‫⚻␹ޕ‬ౝ⑼ක≮߇࿾ၞߦᢛ஻ߐࠇߡ޿ߥ޿ᚲ߶ߤ㧘࿾ၞߩ∛㒮⎇ୃකߦ౉ዪߩ௛߈߆ߌ߇ߢ߈ߕ㧘ߐࠄߦᢛ஻߇
ㆃࠇࠆ᭴࿑ߪ㧘ᣂකᏧ⥃ᐥ⎇ୃ೙ᐲ߇ᚒ‫ߚߒࠄߚ߽ߦޘ‬෩ߒߔ߉ࠆ⹜✵ߢ޽ࠆߣᗵߓߡ޿ࠆ‫ޕ‬ኻ╷ߣߒߡߪ㧘ᣢߦขࠅ⚵ࠎߢ߈ߚߎߣߢߪ޽ࠆ߇㧘ታ⠌╬ߢߩቇ↢ߣߩ✕ኒߥធ⸅ߣߘߩ⛮⛯ࠍ࿑ࠆߎߣߢ޽
ࠆ‫ߛߚޕ‬තᓟ⎇ୃߩ 2 ᐕ㑆㧘లಽߥࠕࡊࡠ࡯࠴߇ߢ߈ߥ޿ߎߣߪଐὼ໧㗴ߢ޽ࠆ‫ޕ‬એਅߩ໧㗴ὐߦ౒ㅢߔࠆߩߪੱ᧚ਇ⿷ߢ޽ࠆ‫ޕ‬1㧕ᄖ᧪ኻᔕജ߇ਇචಽߢ޽ࠅᣂᖚ੍⚂ᦼ㑆㧘⸻ኤᓙߜᤨ㑆߇㐳ߊᡷༀ߇᳞߼ࠄࠇߡ޿ࠆߎߣ‫ߩߎޕ‬ὐߪ㧘 ߆߆ࠅߟߌකߣߩㅪ៤ࠍߐࠄߦᷓ߼ࠆᔅⷐ߽޽ࠆ‫ޕ‬
2㧕౉㒮࿷㒮ᣣᢙ߇㐳ߊ㧘౉㒮ᓙᯏ⠪߇Ᏹᤨᄙ޿ߎߣ‫ߩߎޕ‬ὐߪㅪ៤࠮ࡦ࠲࡯ߣㅌ㒮⺞ᢛࠍߐࠄߦㅴ߼ࠆ‫ޕ‬
3㧕࿾ၞߩ␹⚻ౝ⑼ኾ㐷ක߇߹ߞߚߊਇ⿷ߒߡ߅ࠅ㧘࿾ၞක≮ᯏ㑐߳ߩࡄ࡯࠻಴ᒛࠨࡐ࡯࠻߽࠾࡯࠭ߦㅊ
޿ߟ߆ߕ㧘ᄢᄌㆮᙝߦᗵߓߡ޿ࠆ‫ޕ‬4㧕ቇ↢ᢎ⢒ߦ߅޿ߡ 5 ᐕ↢ߩࠢ࡝࠾ࠞ࡞ࠢ࡜࡯ࠢࠪ࠶ࡊߩቢోታᣉ
ߦߪ߹ߛ㆙޿ߎߣ‫ޕ‬5㧕⸻≮࡮ᢎ⢒ߩᄙᔔൻ߽޽ࠅ⎇ⓥߦኾᔨߢ߈ࠆᤨ㑆߇ዋߥ޿ߎߣ‫ޕ‬એ਄㧘ੱ᧚ߩ⏕଻ߣ૬ߖߡ∛㒮ߩᢎຬࡐࠬ࠻㧔⃻࿷⥃ᐥ⻠Ꮷ 1㧕ߩჇ⸳߇㊀ⷐߢ޽ࠆ‫ޕ‬੹ᓟߩዷᦸోജࠍ޽ߍߡ૗ߣߒߡ߽ㄭ޿዁᧪㧘ᣂߚߥ౉ዪ⠪ࠍ᱑ㄫߒߚ޿‫ޕ‬㓞ធ⒖ォߒߡߊࠆ⮎⑼ᄢቇ߅ࠃ߮ቇ
ㇱౝಽ㊁ߣߩㅪ៤ࠍߐࠄߦᷓ߼㧘㔍ᴦᕈ␹⚻∔ᖚߩ⸃᳿ߦะߌߚ⎇ⓥߩિዷࠍ࿑ࠅߚ޿‫ߡ޿ߟߦ≮⸻ޕ‬ߪᄙ⡯⒳ߦࠃࠆቯᦼ⊛∛᫟ળ⼏㧘߆߆ࠅߟߌකߣߩㅪ៤ࠍᦝߦㅴ߼㧘ᣣᏱ߅ࠃ߮ᢇᕆ⸻≮ኻᔕജࠍ⏕଻ߒߡ޿ߊ‫∛ߦࠄߐޕ‬㒮ߩᢎຬࡐࠬ࠻ߩჇ⸳ࠍ᳞߼ߡ޿ߊ‫ޕ‬ቇ↢ᢎ⢒ߢߪᢎ᧚ߩᢛ஻㐿⊒ࠍㅴ߼ࠆߣ౒ߦ㧘㔍∛ߦኻߔࠆ⎇ⓥߩ㝯ജߣᔅⷐᕈ㧘␹⚻ౝ⑼߇✚ว⊛ක≮޽ࠅ㧘࿾ၞㅪ៤߇㊀ⷐߢ޽ࠆߎߣࠍᒝ⺞ߒߡ޿߈ߚ޿‫ޕ‬㔍∛ኾ㐷ຬߣදജߒߡ࿾ၞ␠ળߩ㔍∛ኻᔕജࠍ㜞߼ࠆദജࠍ⛯ߌߚ޿‫ߚ߹ޕ‬࿾ၞߩ⹺⍮∝ኻᔕജߩะ਄㧘ࠦࡔ࠺㨲ࠞ࡞ࠬ࠲࠶ࡈߩ␹⚻ౝ⑼࡮⠧ᐕ⑼ᢎ⢒ߦᒁ߈⛯߈⽸₂ߒߡ޿ߊ‫ޕ‬㧙㧙㧔5㧕♖␹∛ℂቇಽ㊁
1㧚⎇ⓥߩ᭎ⷐ
♖␹∛ℂቇಽ㊁ߦ߅ߌࠆ⎇ⓥߪ㧘2008 ᐕ 6 ᦬ߦ╙ 5 ઍႮ౉ବ᮸ᢎ᝼߇ዞછߒ㧘ᣂߚߥࠬ࠲࡯࠻ࠍㄫ߃
ߚ‫ߢ߹ࠇߎޕ‬ੑචᢙᐕ㑆ߦࠊߚࠅ㧘৻⽾ߒߡ⥃ᐥࠍ㊀ⷞߒ㧘ߘߎߦၮ⋚ࠍ⟎޿ߚ⎇ⓥࠍ⋡ᜰߒߡ߈ߚ‫੹ޕ‬
ᓟ߽ᒰಽ㊁ߩવ⛔ࠍ↢߆ߒߟߟ㧘ᦨᣂߩ࠾ࡘ࡯ࡠࠨࠗࠛࡦࠬߩ᭽‫ߥޘ‬ᚻᴺࠍขࠅ౉ࠇߡ㧘ᣂߚߥ⎇ⓥࠍⴕ
ߞߡࠁߊ੍ቯߢ޽ࠆ‫ޕ‬⤳ེ⒖ᬀ╬ߦઍ⴫ߐࠇࠆ㜞ᐲవㅴක≮߇น⢻ߣߥߞߚ৻ᣇ㧘ଔ୯ⷰ߿↢๮୶ℂߩᄙ᭽ൻࠍ⢛᥊ߣߒߡࠃ
ࠅ㐿߆ࠇߚක≮߇᳞߼ࠄࠇߡ޿ࠆ‫ߚ߹ޕ‬㧘㜞ᐲᖱႎൻߦࠃࠆㆊࠬ࠻࡟ࠬ␠ળߩ಴⃻㧘ዋሶ㜞㦂ൻ߿ㆊ⇹ൻ㧘
ⅣႺ໧㗴╬ߣ޿ߞߚ⻉໧㗴ߦኻߒ㧘ක≮ߪ੹߹ߢએ਄ߦㆡಾ߆ߟචಽߥኻᔕࠍߔߴ߈ߢ޽ࠆ‫ޕ‬ᄢቇߦ☋ࠍ⟎ߊක≮ੱߩ⡯ോߪ㧘వ┵⊛↢๮⑼ቇߦ㑐ߔࠆᢎ⢒࡮⎇ⓥߦ㊀߈ࠍ⟎߈ߟߟ߽㧘⥃ᐥߦ⋥⚿ߒߚ∔∛ߩ⸻ᢿ࡮ᴦ≮ߦᓎ┙ߟត⚝ဳ⎇ⓥࠍផㅴߒ㧘࿾ၞ␠ળߣ਎⇇ߩක≮ߦ⽸₂ߔࠆߎߣߢ޽ࠆ‫৻ޕ‬ᣇ㧘⥃ᐥ⻠ᐳߢߩ⎇ⓥߪ㧘਎⇇ߦㅢ↪ߔࠆ⎇ⓥ⠪ࠍ૞ࠆߎߣߛߌ߇⋡⊛ߢߪߥߊ㧘ߘ߁ߒߚ⎇ⓥࠍㅢߒߡ⥃ᐥ⢻ജࠍ⎇߈㧘⚿ᨐ⊛ߦᖚ⠪᭽ߩߚ߼ߦߥࠆ߽ߩߢߥߌࠇ߫ߥࠄߥ޿‫ޕ‬ᓥߞߡ㧘‫ߕ߹ޟ‬ೋ߼ߦ㧘⥃ᐥ޽ࠅ߈‫߁޿ߣޠ‬㧘⥃
ᐥ㊀ⷞߩᆫ൓ߪᦨ߽㊀ⷐߢ޽ࠆ‫ޕ‬ᒰಽ㊁ߢߪ㧘ᣣᏱ⥃ᐥߩਛߦ⎇ⓥߩ㐹߈ࠍᗵߓขࠇࠆක≮ੱࠍヘ಴ߔࠆߎߣࠍ⋡ᮡߣߒߡ㧘એਅߩ⎇ⓥࠍⴕߞߡ޿ߊ‫ޕ‬1㧕♖␹∔ᖚߩ Neuroimaging ⎇ⓥ㧔PET㧘f-MRI㧘MRS㧘NIRS ╬㧕
2㧕♖␹∔ᖚߩ⥄ᓞ␹⚻⎇ⓥ㧔Baroreflex㧘Papillary light reflex ╬㧕3㧕♖␹⑼⸻ᢿቇߦ㑐ߔࠆ⎇ⓥ㧔DSM-Φ㧘ICD-10 ╬㧕4㧕♖␹∔ᖚߣ↢ᵴ⠌ᘠ∛ߦ㑐ߔࠆ⎇ⓥ㧔DM ߿⯯ⴊᕈᔃ∔ᖚ ╬㧕5㧕⊒㆐㓚ኂߩ∉ቇ෸߮ Neuroimaging ⎇ⓥ㧔⥄㐽ᕈ㓚ኂ㧘Asperger 㓚ኂ㧘ADHD ╬㧕
6㧕ἴኂ♖␹කቇߦ㑐ߔࠆ⎇ⓥ
7㧕♖␹∔ᖚߩㆮવሶ⎇ⓥ
2㧚ฬ★
Ⴎ౉ବ᮸
ᢎ᝼㧦
㜞ጟ ஜ
ಎᢎ᝼㧦
⻠Ꮷ㧦
ᬀᧁ໪ᢥ
⻠Ꮷ㧦
㜞↰⍮ੑ
⥃ᐥ⻠Ꮷ㧦 ᷓየ ℉⥃ᐥ⻠Ꮷ㧦 ᚭፒᘕᄥ㇢
⥃ᐥ⻠Ꮷ㧦 ᄤ㊁㓶ᐔ⥃ᐥ⻠Ꮷ㧦 ᓟ⮮߹ߤ߆
කຬ㧦
➚➓ᘕ਽
කຬ㧦
ᰞᐸ ᵏ

Toshiki Shioiri
Ken Takaoka
Hirofumi Ueki
Tomoji Takata
Taku Fukao
Shintaro Tosaki
Yuhei Amano
Madoka Goto
Shinya Kouketsu
Akira Sakuraba

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ࠫࡖ࠶ࠢ㧩ࠕ࡜ࡦ࡮ࡒ࡟࡯࡞✬㧚ዊ಴ᶈਯ㧘㋈ᧁ࿡ᢥ㧘⩲ේ⺈৻⸶㧘ࠫࡖ࠶ࠢ࡮࡜ࠞࡦኻ⽎㑐ଥ(਄/ਅ)㧘
᧲੩㧦ጤᵄᦠᐫ㧧2006 ᐕ㧚
2㧕 㜞ጟ ஜ✬⪺㧚<ᣂⵝჇ⵬ᡷ⸓ >ቅ┙ࠍᕟࠇࠆߥ㧍㧘᧲੩㧦ᛕ⹏␠㧧2006 ᐕ㧚
3㧕 㜞ጟ ஜ㧘౎ᨰ㦖♿⪺㧚ᚢᓟ⁁ᴫ⺰㧘᧲੩㧦㔕Უᦠᚱ㧧2006 ᐕ㧚
4㧕 ⍹Ꮉᙗᒾ㧘㜞ጟ ஜ⪺㧚ߎߎࠈߩ∛ߪߎ߁ߒߡߟߊࠄࠇࠆ㧘᧲੩㧦ᛕ⹏␠㧧2006 ᐕ㧚
5㧕 㜞ጟ ஜ㧘ችบ⌀ม✬⪺㧚ߎߎࠈߩ⌀⺰㧘᧲੩㧦࠙ࠚࠗ࠷㧧2006 ᐕ㧚
6㧕 ᬀᧁ໪ᢥ㧚ᛥ߁ߟߩ⇣⒳ᕈ㧦ർ᧛ବ஥✬㧚ᛥ߁ߟߩ⃻ઍ⊛⻉⋧㧙ᔃℂ⊛࡮␠ળ⊛஥㕙߆ࠄ⑼ቇߔࠆ㧙㧘᧲੩㧦ࠁ߹ߦᦠᚱ㧧2006 ᐕ㧚
7㧕 㜞ጟ ஜ㧚ᒁ߈ߎ߽ࠅ⁚ࠅ㧦㜞ጟ ஜ㧘⧔ᴛବ੺✬㧘ᒁ߈ߎ߽ࠅ⁚ࠅ㧘᧲੩㧦㔕Უᦠᚱ㧧2007 ᐕ㧦113㧙
148㧚
8㧕 㜞ጟ ஜ㧚り૕ߪߥߗ᛫߁ߟ⮎ࠍ㘩ߴ⛯ߌࠆߩ߆㧦㜞ጟ ஜ㧘⍹Ꮉ ಎ✬㧚り૕ࠍ߼ߋࠆ࡟࠶ࠬࡦ 3 ⣂ᛂߟり૕㧘᧲੩㧦ጤᵄᦠᐫ㧧2007 ᐕ㧦49㧙73㧚
9㧕 㜞ጟ ஜ㧚⥄㐽∝⺰ߩේὐ㧘᧲੩㧦㔕Უᦠᚱ㧧2007 ᐕ㧚
10㧕 㜞ጟ ஜ㧚ㄭઍߩ⚳ࠊࠅ㧙ዋᐕᴺ߳ߩㆮ೙ߩᷙᶳߣᣂ⥄↱ਥ⟵㧙㧦૒⮮ᐙᄦ㧘ጊᧄ⼑ม✬㧚ዋᐕ‽⟋෩⟏
ൻ⑳ߪߎ߁⠨߃ࠆ㧘᧲੩㧦ᵗᴰ␠㧧2007 ᐕ㧦222㧙239㧚
11㧕 㜞ጟ ஜ㧚ࡔࡦ࠲࡞ࡋ࡞ࠬߞߡ㨯㨯㨯㧫㧦⮮ᧄ ⼾㧘㜞ᯅ ৻㧘ᨋ ৻ᅢ✬㧚ࠦࡔ࠺ࠖࠞ࡞ࠬ࠲࠶ࡈߩߚ߼ߩ
♖␹㓚ኂ Q㧒A㧘᧲੩㧦ਛᄩᴺⷙ㧧2007 ᐕ㧦26㧙27㧚
12㧕 㜞ጟ ஜ㧚ᢎ⢒⃻႐ߢߩ㓚ኂ㧦⮮ᧄ ⼾㧘㜞ᯅ ৻㧘ᨋ ৻ᅢ✬㧚ࠦࡔ࠺ࠖࠞ࡞ࠬ࠲࠶ࡈߩߚ߼ߩ♖␹㓚㧙㧙ኂ Q㧒A㧘᧲੩㧦ਛᄩᴺⷙ㧧2007 ᐕ㧦76㧙77㧚
13㧕 㜞ጟ ஜ㧚ᕁᤐᦼߩ♖␹㓚ኂ㧦♖␹଻ஜ⑔␩⊕ᦠ✬㓸ᆔຬળ✬㧚♖␹଻ஜ⑔␩⊕ᦠ 2008 ᐕ 㧘᧲੩㧦ਛ
ᄩᴺⷙ㧧2007 ᐕ㧦168㧚
14㧕 ᬀᧁ໪ᢥ㧚ౝ࿃ᕈ♖␹∛ߩ੍ᓟቇ㧘ᴦ≮ߣ∝⁁ᡷༀߦኻߔࠆ߁ߟ∛⠪ߩ૕㛎ߦߟ޿ߡ㧦 Max-PaulEngelmeier㧘Horst Mester㧘㘵↰ ⋿㧘࡜ࠗ࠽࡯࡮࠹࡟✬㧚ᄙᰴర♖␹කቇ㧙࠴ࡘ࡯ࡆࡦࠥࡦቇᵷߣߘߩ
⃻ઍ⊛ᗧ⟵㧙㧘᧲੩㧦ጤፒቇⴚ಴ ␠㧧2007 ᐕ㧦125㧙175㧘247㧙263㧘345㧙347㧘349㧙350㧚
15㧕 ዊ಴ᶈਯ㧘⷏የᓆᵏ㧚ᅦᗐߪߥߗᔅⷐ߆㧙࡜ࠞࡦᵷߩ♖␹∛⥃ᐥ㧙㧘᧲੩㧦ጤᵄᦠᐫ㧧2008 ᐕ㧚
16㧕 ዊ಴ᶈਯ㧚♖␹∛ℂቇ౉㐷㧦ዊ಴ᶈਯᢎ᝼ㅌቭ⸥ᔨ⺰ᢥ㓸✬㓸ᆔຬળ(ઍ⴫ 㜞ጟ ஜ)✬㧚♖␹∛ℂቇߩ
⫷ⓧ㧘᧲੩㧦㊄೰಴ 㧧2008 ᐕ㧦11㧙38㧚
17㧕 ዊ಴ᶈਯ㧚⛯㨯♖␹∛ℂቇ౉㐷㧦ᴦ≮✬㧦ዊ಴ᶈਯᢎ᝼ㅌቭ⸥ᔨ⺰ᢥ㓸✬㓸ᆔຬળ(ઍ⴫ 㜞ጟ ஜ)✬㧚♖
␹∛ℂቇߩ⫷ⓧ㧘᧲੩㧦㊄೰಴ 㧧2008 ᐕ㧦39㧙84㧚
18㧕 㜞ጟ ஜ㧚߿ߐߒ޿⊒㆐㓚ኂ⺰㧘᧲੩㧦ᛕ⹏␠㧧2008 ᐕ㧚
19㧕 㜞ጟ ஜ㧚⸻ᢿ⺰ࡁ࡯࠻㧦ዊ಴ᶈਯᢎ᝼ㅌቭ⸥ᔨ⺰ᢥ㓸✬㓸ᆔຬળ(ઍ⴫ 㜞ጟ ஜ)✬㧚♖␹∛ℂቇߩ⫷ⓧ㧘᧲੩㧦㊄೰಴ 㧧2008 ᐕ㧦87㧙96㧚
20㧕 ᧻ᧄ㓷ᒾ㧘㜞ጟ ஜ✬㧚⊒㆐㓚ኂߣ޿߁⸥ภ㧘᧲੩㧦ᛕ⹏␠㧧2008 ᐕ㧚
21㧕 㜞ጟ ஜ㧚∛ℂ㧦ጘ㒂ᄢቇᢎ⢒ቇㇱ․೎ᡰេᢎ⢒⎇ⓥળ(ઍ⴫ ဈᧄ ⵨)✬㧚․೎ᡰេᢎ⢒ࠍቇ߱[╙ 2 ]㧘੩ㇺ㧦࠽ࠞ࠾ࠪࡗ಴ 㧧2008 ᐕ㧚
22㧕 ᬀᧁ໪ᢥ㧚␠ળ㨯ᢥൻ⊛໧㗴㧦਄ፉ࿖೑㧘ᮘญノᒾ㧘㊁᧛✚৻㇢㧘ᄢ㊁ ⵨㧘␹ᐸ㊀ା㧘የፒ♿ᄦ✬㧚᳇ಽ㓚ኂ㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦328㧙332㧚
23㧕 ᬀᧁ໪ᢥ㧚⡯ၞߩ໧㗴ߦ߅޿ߡ⥃ᐥ♖␹කቇ߇ᨐߚߔᓎഀ㧙‫ࠬ࡟࠻ࠬޟ‬㧙⣀ᒙᕈ‫ⷰߩ࡞࠺ࡕޠ‬ὐ߆ࠄ㧙㧦ዊ಴ᶈਯᢎ᝼ㅌቭ⸥ᔨ⺰ᢥ㓸✬㓸ᆔຬળ(ઍ⴫ 㜞ጟ ஜ)✬㧚♖␹∛ℂቇߩ⫷ⓧ㧘᧲੩㧦㊄೰಴ 㧧2008ᐕ㧦126㧙134㧚
24㧕 ㊁፸ ℂ㧘ᬀᧁ໪ᢥ㧚᳇ಽ㓚ኂߣ⸥ᙘ㧘᰼േ㧦ዊ಴ᶈਯᢎ᝼ㅌቭ⸥ᔨ⺰ᢥ㓸✬㓸ᆔຬળ(ઍ⴫ 㜞ጟ ஜ)✬㧚♖␹∛ℂቇߩ⫷ⓧ㧘᧲੩㧦㊄೰಴ 㧧2008 ᐕ㧦117㧙125㧚
25㧕 㜞↰⍮ੑ㧚⹺⍮∝ᖚ⠪ߩᤨ㑆ߣ਎⇇㧦ዊ಴ᶈਯᢎ᝼ㅌቭ⸥ᔨ⺰ᢥ㓸✬㓸ᆔຬળ(ઍ⴫ 㜞ጟ ஜ)✬㧚♖␹
∛ℂቇߩ⫷ⓧ㧘᧲੩㧦㊄೰಴ 㧧2008 ᐕ㧦173㧙182㧚
26㧕 ᷓየ ℉㧚ੱᩰ㓚ኂߩ෻ᓳ⥄்ߣකᏧߩᔕถ⟵ോ㧦ዊ಴ᶈਯᢎ᝼ㅌቭ⸥ᔨ⺰ᢥ㓸✬㓸ᆔຬળ(ઍ⴫ 㜞ጟஜ)✬㧚♖␹∛ℂቇߩ⫷ⓧ㧘᧲੩㧦㊄೰಴ 㧧2008 ᐕ㧦147㧙152㧚⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 㜞ጟ ஜ㧚✚⺰㧦ࡔ࡜ࡦࠦ࡝࡯ߩᓐጯ߳㧙シ∝ൻ࡮ᷙว⁁ᘒ࡮㕖ቯဳൻ㧙㧘♖␹ක≮ 2008 ᐕ㧧52 Ꮞ㧦
25㧙32㧚
✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 㜞ጟ ஜ㧚⊒㆐㓚ኂߪ‽⟋ࠍᗖ⿠ߔࠆ߆㧘ᢎ⢒ߣᢥൻ 2006 ᐕ㧧42 Ꮞ㧦6㧙14㧚
2㧕 ᬀᧁ໪ᢥ㧘ዊᎹ⋥ᔒ㧘㘵↰ብ᮸㧚߁ߟ∛ߩᱷㆮ∝⁁ߦኻߒߡ ECT ߇⪺ߒߚ 1 ଀㧘⥃ᐥ♖␹කቇ 2006 ᐕ㧧
35 Ꮞ㧦1195㧙1200㧚
3㧕 ᬀᧁ໪ᢥ㧚ᣣᧄੱߩ߁ߟ∛ߣᄖ࿖ੱߩ߁ߟ∛㧙ᣣᧄੱߩ߁ߟ∛ᖚ⠪ߣ⻉ᄖ࿖ߩ߁ߟ∛ᖚ⠪㑆ߦߪᕈᩰ㕙ߣ∝⁁㕙ߦ߅߅ߌࠆ㆑޿ߪ޽ࠆߩ߆㧙㧘කቇߩ޽ࠁߺ 2006 ᐕ㧧219 Ꮞ㧦930㧙934㧚
4㧕 ᷓየ ℉㧚࿎㔍ߥ∝଀߆ࠄቇ߱㧙ᴦ≮࠴࡯ࡓ߇ᅦᗐߦขࠅㄟ߹ࠇߡߒ߹ߞߚࠤ࡯ࠬ㧙㧘Schizophrenia
Frontier 2006 ᐕ㧧7 Ꮞ㧦50㧙53㧚
5㧕 ⷏የᓆᵏ㧚‫౉⸃⺒ࡦࠞ࡜ޟ‬㐷‫ޠ‬I.R.S.㧙ࠫࡖ࠶ࠢ࡮࡜ࠞࡦ⎇ⓥ㧙No.5㧘ᣣᧄ࡜ࠞࡦදળ 2006 ᐕ㧧250㧙265㧚
6㧕 ⮮၂㤗⴩ሶ㧘㜞↰⍮ੑ㧘ዊ಴ᶈਯ㧚ᣧᦼߦ↢ᵴ⁁ᴫߦᡷༀࠍ⹺߼ߚᕁᤐᦼᅦᗐ∝ߩ 1 ଀㧘♖␹⑼ 2006 ᐕ㧧
8 Ꮞ㧦408㧙412㧚
7㧕 㜞ጟ ஜ㧚♖␹කቇℂ⺰ߩෂᯏࠍ߼ߋࠆᢿ┨㧘♖␹ක≮ 2007 ᐕ㧧45 Ꮞ㧦92㧙99㧚
8㧕 㜞ጟ ஜ㧚ࠕࠬࡍ࡞ࠟ࡯∝୥⟲ߣ෻␠ળ⊛ⴕേ㧙มᴺ੐଀߆ࠄ㧙㧘♖␹≮ᴺ 2007 ᐕ㧧33 Ꮞ㧦462㧙467㧚
9㧕 㑐 ᱜ᮸㧘㜞ጟ ஜ㧚ቯဳ⊒㆐ఽߩਇ⊓ᩞߣᐢ᳢ᕈ⊒㆐㓚ኂఽߩਇ⊓ᩞߩᲧセ㧘ᦨᣂ♖␹කቇ 2007 ᐕ㧧
12 Ꮞ㧦461㧙465㧚
10㧕 ᬀᧁ໪ᢥ㧘⷏የᓆᵏ㧘ዊᎹ⋥ᔒ㧚⡯႐ߩࡔࡦ࠲࡞ࡋ࡞ࠬߦ߅ߌࠆ⥄Ვߩࡐࠬ࠻ࡌࡦ࡚ࠪࡦᵴേߦ㑐ߔࠆ৻⠨ኤ㧘ᦨᣂ♖␹කቇ 2007 ᐕ㧧13 Ꮞ㧦103㧙110㧚
11㧕 㒸 ፋᢥ㧘ᬀᧁ໪ᢥ㧘㜞੗ᤘ⵨㧘ฎᎹᄈ੫㧚㜞㦂⠪߁ߟ∛ߩ⹺⍮㨯ⴕേ⊛․ᓽߩᬌ⸛㧙⹺⍮ⴕേ≮ᴺࡊࡠࠣ࡜ࡓߩ㐿⊒ߦะߌߡ㧙㧘ฎᎹ⽷࿅ᴺੱ᣿ᴦ቟↰ߎߎࠈߩஜᐽ⽷࿅ 2006 ᐕᐲ⎇ⓥഥᚑ⺰ᢥ㓸 2007 ᐕ㧧171
㧙180㧚
12㧕 㜞↰⍮ੑ㧘㜞ጟ ஜ㧘㊄ጟ❥⵨㧚⑳⊛♖␹㐓ቯߩᗧ⟵㧘⥃ᐥ♖␹කቇ 2007 ᐕ㧧36 Ꮞ㧦1075㧙1081㧚
13㧕 㜞↰⍮ੑ㧘㜞ጟ ஜ㧘㊄ጟ❥⵨㧚ⶄ㔀㈻㈦ߣ⽿છ⢻ജ㧘♖␹කቇ 2007 ᐕ㧧49 Ꮞ㧦1263㧙1273㧚
14㧕 ⷏የᓆᵏ㧘ᓟ⮮ᄥ㇢㧘ᬀᧁ໪ᢥ㧚♖␹⑼ߢߩり૕᜔᧤ᖚ⠪ߦ߅ߌࠆᷓㇱ㕒⣂ⴊᩖ∝㧘♖␹␹⚻ቇ㔀⹹ 2007
ᐕ㧧109 Ꮞ㧦998㧙1007㧚㧙㧙15㧕 ⷏የᓆᵏ㧘ᬀᧁ໪ᢥ㧚ᘟᕈ߁ߟ∛ߦኻߔࠆ⡊੺≮ᴺ㧘ᦨᣂ♖␹කቇ 2007 ᐕ㧧12 Ꮞ㧦55㧙56㧚
16㧕 Ⴎ౉ବ᮸㧘ICD-10 ߩ໧㗴ὐߣ ICD-11 ߦะߌߡߩ⺖㗴:F4 ␹⚻∝ᕈ㓚ኂ㧘ࠬ࠻࡟ࠬ㑐ㅪ㓚ኂ߅ࠃ߮り૕⴫⃻ᕈ㓚ኂ㧘♖␹␹⚻ቇ㔀⹹ 2008 ᐕ㧧110 Ꮞ㧦887㧙979㧚
17㧕 ㆙⮮ᄥ㇢㧘Ⴎ౉ବ᮸㧘ᨴ⍫ବᐘ㧘ᐢ᳢ᕈ⊒㆐㓚ኂߩ⣖ౝ↢ൻቇઍ⻢⇣Ᏹ㧘♖␹␹⚻ቇ㔀⹹ 2008 ᐕ㧧110
Ꮞ㧦797㧙804㧚
18㧕 㜞ጟ ஜ㧘㜞↰⍮ੑ㧘ⵙ್ຬ೙ᐲߣ♖␹㐓ቯ㨯㐓ቯੱ዆໧(Letter)㧘♖␹කቇ 2008 ᐕ㧧50 Ꮞ㧦826㧚
19㧕 㜞ጟ ஜ㧘␠ળᕟᔺ(␠ળਇ቟㓚ኂ)㧘♖␹⑼ᴦ≮ቇ 2008 ᐕ㧧23 Ꮞ㧦341㧙344㧚
20㧕 㜞ጟ ஜ㧚ᐢ᳢ᕈ⊒㆐㓚ኂߣ♖␹㐓ቯ㧘ᔃߣ␠ળ 2008 ᐕ㧧39 Ꮞ㧦22㧙26㧚
21㧕 ᬀᧁ໪ᢥ㧘⷏የᓆᵏ㧘ዊᎹ⋥ᔒ㧚⡯႐ߩࡔࡦ࠲࡞ࡋ࡞ࠬߦ߅ߌࠆ⥄Ვߩࡐࠬ࠻ࡌࡦ࡚ࠪࡦᵴേߦ㑐ߔࠆ৻⠨ኤ㧘ᦨᣂ♖␹කቇ 2008 ᐕ㧧13 Ꮞ㧦83㧙90㧚
22㧕 ⷏የᓆᵏ㧘ᬀᧁ໪ᢥ㧘♖␹⑼ᖚ⠪ߦ߅ߌࠆᘟᕈଢ⒁ߩᴦ≮㧘♖␹⑼ᴦ≮ቇ 2008 ᐕ㧧23 Ꮞ㧦1271㧙1278㧚
23㧕 㜞↰⍮ੑ㧘㜞ጟ ஜ㧘ౝ↰޽߅޿㧘ዊፉਭౖ㧘Paroxetine ߩㅌ⮎ߢੑ㊀り߇಴⃻ߒߚ 1 ଀㧘⥃ᐥ♖␹⮎ℂ
2008 ᐕ㧧11 Ꮞ㧦155㧙158㧚
24㧕 㜞↰⍮ੑ㧘㜞ጟ ஜ㧘㊄ጟ❥⵨㧚⑳⊛♖␹㐓ቯߩᗧ⟵㧘ቄೀೃ੐ᑯ⼔ 2008 ᐕ㧧53 Ꮞ㧦134㧙140㧚
25㧕 㜞↰⍮ੑ㧘㜞ጟ ஜ㧚㜞㦂⠪ߩࡄ࡜ࡁࠗࠕ⁁ᘒ㧙♖␹㐓ቯ଀߆ࠄߩᬌ⸛㧙㧘⥃ᐥ♖␹∛ℂ 2008 ᐕ㧧28
Ꮞ㧦257㧙264㧚
26㧕 㜞↰⍮ੑ㧘㜞ጟ ஜ㧚Aripiprazole ߇ᄼലߒߚญ⣧ౝ࠮ࡀࠬ࠻ࡄ࠴࡯ߩ 1 ∝଀㧘⥃ᐥ♖␹කቇ 2008 ᐕ㧧
37 Ꮞ㧦825㧙829㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Ueki H, C Holzapfel, Sakado K, Washino K, Inoue M, Ogawa N, Ietsugu T, Takai A. Prevalance ofTypus Melancholicus in Healthy Germans. Psychopathology. 2006;39:113-119.
IF 0.750
2㧕 Takaoka K, Takata T. Catatonia in high-functioning autism spectrum disorders:case report and review
of literature. Psychological Rep. 2007;101:961-969.
IF 0.364
3㧕 Ogawa N, Ueki H. Clinical importance of caffeine dependence and abuse. Psychia Clin Neurosci.
2007;61:263-268.
IF 1.1324㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦Ⴎ౉ବ᮸㧧⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦ࡄ࠾࠶ࠢ㓚ኂᖚ⠪ᚳ᩶૕ߦ߅ߌࠆࠣ࡞࠲ࡒ
ࡦ㉄෸߮ǫ㧙ࠕࡒࡁ㈼㉄ઍ⻢⇣Ᏹߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 19㧙20 ᐕᐲ㧧3,500 ජ౞(2,100㧦1,400 ජ౞)
2㧕 ⎇ⓥಽᜂ⠪㧦Ⴎ౉ବ᮸㧧⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(A)㧦ἴኂᤨߦ߅ߌࠆലᨐ⊛ᔃℂ⊛ᡰេߚ߼ߩㅪ៤
දജߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 19㧙21 ᐕᐲ㧧1,960 ජ౞(1,160㧦800 ජ౞)
2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬႮ౉ବ᮸㧦
1㧕 ᣣᧄ↢‛ቇ⊛♖␹කቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ♖␹⑼⸻ᢿቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ✚ว∛㒮♖␹කቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄ⛔วᄬ⺞∝ቇળ⹏⼏ຬ(㨪⃻࿷)5㧕 ᣣᧄਇ቟㓚ኂቇળ⹏⼏ຬ(㨪⃻࿷)㜞ጟ ஜ㧦
1㧕 ᣣᧄ♖␹␹⚻ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄఽ┬㕍ᐕ♖␹කቇળ⹏⼏ຬ(~⃻࿷)
3㧕 ᣣᧄ✚ว∛㒮♖␹කቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄ♖␹∛ℂቇળ⹏⼏ຬ(㨪⃻࿷)㧙㧙ᬀᧁ໪ᢥ㧦
1㧕 ᣣᧄ♖␹␹⚻ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄࡊ࡜ࠗࡑ࡝㨯ࠤࠕቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ✚ว∛㒮♖␹කቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄ♖␹⑼⸻ᢿቇળ⹏⼏ຬ(㨪⃻࿷)5㧕 ᣣᧄᔃりකቇળઍ⼏ຬ(㨪⃻࿷)㜞↰⍮ੑ㧦1㧕 ᣣᧄ✚ว∛㒮♖␹කቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ⠧ᐕ♖␹කቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ✚ว∛㒮♖␹කቇળ᦭ᐥ✚ว∛㒮♖␹ක≮໧㗴ᆔຬળᆔຬ(㨪⃻࿷)4㧕 ᣣᧄ✚ว∛㒮♖␹කቇળ⸻≮ႎ㈽ᆔຬળᆔຬ(㨪⃻࿷)5㧕 ᧲ᶏ♖␹␹⚻ቇળㆇ༡ᆔຬ(㨪⃻࿷)ᷓየ ℉㧦
1㧕 ᣣᧄఽ┬㕍ᐕ♖␹කቇળ⹏⼏ຬ(~⃻࿷)
2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳Ⴎ౉ବ᮸㧦
1㧕 ╙ 28 ࿁ᣣᧄ♖␹⑼⸻ᢿቇળ(2008 ᐕ 10 ᦬㧘ᧅᏻ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ICD-11 ߳ะߌߡࠕࠫࠕ࡮ᣣᧄ߆
ࠄߩឭ⸒㧦␹⚻∝ᕈ㓚ኂ㑐ㅪ∔ᖚ‫ޠ‬Ṷ⠪)㜞ጟ ஜ㧦
1㧕 ᣣᧄሶߤ߽࠰࡯ࠪࡖ࡞ࡢ࡯ࠢදળ(2006 ᐕ 2 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ‫⯦ޟ‬ᓙߣࠕ࠳࡞࠻࠴࡞࠼࡟ࡦ
ࠍ⠨߃ࠆ‫ޠ‬Ṷ⠪)
2㧕 ᣣᧄሶߤ߽࠰࡯ࠪࡖ࡞ࡢ࡯ࠢදળ(2006 ᐕ 6 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ሶߤ߽ߦߣߞߡߩᄢੱ໧㗴‫ޠ‬Ṷ⠪)3㧕 ‫࡞࡯ࠢࠬ࡞࠲ࡦࡔ࡮ࠗࠕޟ‬੐ઙ‫ࠍޠ‬⠨߃ࠆᗲ⍮ߩળ(2006 ᐕ 7 ᦬㧘ฬฎደ㧘ࠪࡦࡐࠫ࠙ࡓ‫࡮ࠗࠕޟ‬ࡔࡦ࠲࡞ࠬࠢ࡯࡞ኰ↢ᱫ੢੐ઙࠍ⠨߃ࠆ㓸޿‫ޠ‬Ṷ⠪)
4㧕 ╙ 47 ࿁ᣣᧄఽ┬㕍ᐕ♖␹කቇળ(2006 ᐕ 10 ᦬㧘ජ⪲㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦมળ)5㧕 ᣣᧄሶߤ߽࠰࡯ࠪࡖ࡞ࡢ࡯ࠢදળ(2006 ᐕ 12 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ‫ⷫޟ‬Ვߒࠍߖߑࠆࠍ߃ߥ޿ዋ
ᐕ‫ޠ‬Ṷ⠪)
6㧕 18th World Congress of IACAPAP (2007.04㧙05㧘Istanbul㧘Competency to stand trial in autism.)7㧕 ╙ 35 ࿁ᣣᧄ‽⟋␠ળቇળ(2008 ᐕ 10 ᦬㧘᧲੩㧘ዋᐕ㕖ⴕߣ‫ޟ‬ᐢ᳢ᕈ⊒㆐㓚ኂ‫࡞ࡉ࡯࠹࠼ࡦ࠙࡜ޠ‬࠺ࠖࠬࠞ࠶࡚ࠪࡦ⹤㗴ឭଏ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേႮ౉ବ᮸㧦
1㧕 ጘ㒂⋵♖␹଻ஜ⑔␩දળ೽ળ㐳(㨪⃻࿷)2㧕 ጘ㒂⋵♖␹ක≮ክᩏળᆔຬ(㨪⃻࿷)㜞ጟ ஜ㧦
1㧕 ጘ㒂⋵♖␹ක≮ክᩏળᆔຬ(㨪⃻࿷)㧙㧙ᬀᧁ໪ᢥ㧦
1㧕 ጘ㒂ഭ௛ዪ࿾ᣇഭἴᆔຬ(㨪⃻࿷)2㧕 ጘ㒂Ꮢ↢ᵴ଻⼔ᴺක≮ᛔഥክᩏળᆔຬ(㨪⃻࿷)3㧕 ጘ㒂⋵♖␹଻ஜ⑔␩දળක≮ኾ㐷ᆔຬળᆔຬ(㨪⃻࿷)ᷓየ ℉㧦
1㧕 ጘ㒂ഭ௛ዪ࿾ᣇഭἴᆔຬ(㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 㜞ጟ ஜ㧚มᴺ㧦৻⥸♖␹⑼කߩߚ߼ߩሶߤ߽ߩᔃߩၮ␆⍮⼂㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄(ሶߤ߽ኅᐸ✚ว⎇ⓥ੐ᬺ)‫ޟ‬ሶߤ߽ߩᔃߩ⸻≮ߦ៤ࠊࠆኾ㐷⊛ੱ᧚ߩ⢒ᚑߦ㑐ߔࠆ⎇ⓥ‫ޠ‬㧘2007ᐕ㧧44㧙45㧚2㧕 㤥Ꮉᷕ৻㧘ጤ↰ᒄᢅ㧘ᬀᧁ໪ᢥ㧘੗ᄹᵄ⦟৻㧘੗਄⋿ੱ㧘✎⽾࡞ࡒሶ㧘᦯ㇱ౏ᒾ㧘ᳰ↰ਭၮ㧘૒⮮Ẵሶ㧚♖␹∔ᖚߢભ⡯ߒߚഭ௛⠪ߦኻߔࠆ⡯႐ᓳᏫᡰេߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 19 ᐕᐲ↥ᬺ଻ஜ⺞ᩏ⎇ⓥႎ๔ᦠ㧘2008 ᐕ㧚
11㧚ႎ㆏
1㧕 㜞ጟ ஜ㧦‫ᤨޟ‬ઍ∛‫⑼␹♖┬ఽޠ‬ක߇⺆ࠆ੹ߩሶߤ߽㧦ᢎ⢒ක੐ᣂ⡞(2006 ᐕ㧘256(ઃ㍳)3)
2㧕 㜞ጟ ஜ㧦ᤨઍᤋߔ♖␹㐓ቯ ⵙ್ࠍᄌ߃ࠆ㧫㧦↥⚻ᣂ⡞(2006 ᐕ 1 ᦬ 16 ᣣ)
3㧕 㜞ጟ ஜ㧦૒਎଻੐ઙ࡮ടኂዋᅚ㧦⷏ᣣᧄᣂ⡞(2006 ᐕ 1 ᦬ 16 ᣣ)
4㧕 㜞ጟ ஜ㧦ዋᅚߩᦝᱜ㗅⺞ߣ⹏ଔ㧦⷏ᣣᧄᣂ⡞(2006 ᐕ 5 ᦬ 27 ᣣ)
5㧕 㜞ጟ ஜ㧦ήℂ߿ࠅߢߪ⁁ᴫᖡൻ㧦ਛᣣᣂ⡞(2006 ᐕ 5 ᦬ 30 ᣣ)
6㧕 ᬀᧁ໪ᢥ㧦㜞㦂⠪ߩ߁ߟ∛ߣߪ㧦ጘ㒂᡼ㅍ‫᦬ޟ‬㊄࡜ࠫࠝ 2 ᤨ 6 ᤨ‫(ޠ‬2007 ᐕ 4 ᦬ 5 ᣣ)
7㧕 ᬀᧁ໪ᢥ㧦㜞㦂⠪ߩ߁ߟ∛ߩ੍㒐㧦ጘ㒂᡼ㅍ‫᦬ޟ‬㊄࡜ࠫࠝ 2 ᤨ 6 ᤨ‫(ޠ‬2007 ᐕ 4 ᦬ 12 ᣣ)
8㧕 㜞ጟ ஜ㧦‫ ߨ߻߅߅ޟ‬12 ᱦ‫ޠ‬ᡷᱜዋᐕᴺࠍ⠨߃ࠆ(਄)㧦㐳ፒᣂ⡞(౒หㅢା㈩ା)(2007 ᐕ 5 ᦬ 29 ᣣ)
9㧕 㜞ጟ ஜ㧦Უߣߩ㑐ଥ⸅ࠇߕਇචಽ㧦⑔ፉ᳃෹(౒หㅢା㈩ା)(2008 ᐕ 2 ᦬ 27 ᣣ)
10㧕 㜞ጟ ஜ㧦ᒁ߈ߎ߽ࠅߣ⧯⠪ߩੱᮭ㧦ᄢੱදㅢା No.8(2008 ᐕ)
11㧕 㜞ጟ ஜ㧦⡯႐ߩℂ⸃ᄢಾ㧦ᦺᣣᣂ⡞(2008 ᐕ 7 ᦬ 25 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔ਄⸥ߩࠃ߁ߦ㧘♖␹∛ℂቇ⊛⎇ⓥߩਅ㧘᭽‫⎇ߥޘ‬ⓥᚑᨐ߇਄߇ߞߡ߈ߡ޿ࠆ‫ߪࠄࠇߘޕ‬㧘ᣣᏱ⥃ᐥߦ⋥⚿ߔࠆ߽ߩߢ޽ࠅ㧘࿾ၞߢߩ♖␹ක≮ߩዷ㐿ߦ߅޿ߡ߽ᄢ߈ߥೝỗߣߥߞߡ޿ࠆ‫ߚ߹ޕ‬㧘਄⸥ߩႎ๔
ߩઁߦ㧘♖␹∛ℂቇಽ㊁ࠍ᜼ߍߡⓍᭂ⊛ߦมᴺ♖␹㐓ቯࠍⴕߞߡ߅ࠅ㧘ߘ߁޿ߞߚὐߢ߽␠ળ⊛⽸₂ࠍ
ᨐߚߒߡ޿ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ᄢቇ߽ੱຬਇ⿷ߩߚ߼㧘ฦࠬ࠲࠶ࡈ߇⥃ᐥ㧘ᢎ⢒㧘⎇ⓥߣ⿛ࠅ࿁ߞߡ޿ࠆ‫ߦࠄࠇߎޕ‬㑐ߒߡߪ㧘ᛮᧄ
⊛ߥ⸃᳿ᴺࠍᬌ⸛ߒߡ޿ߊߎߣ߇⺖㗴ߢ޽ࠆ‫ޕ‬੹ᓟߩዷᦸ⃻࿷ߩකᏧ⥃ᐥ⎇ୃ೙ᐲߢߪ㧘♖␹⑼⎇ୃߪᔅୃߣߥߞߡ޿ࠆ‫ߪߩࠆ޿ߡࠇ߹ᦸߢߎߘޕ‬㧘ࡊ࡜ࠗࡑ
࡝ࠤࠕࠍ㊀ⷞߒߚㅢᏱߩ♖␹ක≮ߢ޽ࠅ㧘ߘࠇߪ♖␹∛ℂቇߦ┙⣉ߒߡߎߘน⢻ߣߥࠆ߽ߩߢ޽ࠆ‫ߎޕ‬ߩ㗔ၞߦὶὐࠍᝪ߃⎇ⓥࠍㅴ߼ߡ޿ࠆᄢቇߪᱷᔨߥ߇ࠄዋߥ޿‫߃ࠁࠇߘޕ‬㧘ᒰ♖␹∛ℂቇಽ㊁ߩሽ࿷ᗧ⟵ߪ㧘࿖᳃ߩ࠾࡯࠭ߣ޿ߞߚὐ߆ࠄ߽㧘੹ᓟ߹ߔ߹ߔ㜞߹ߞߡ޿ߊ߽ߩߣᦼᓙߢ߈ࠆ‫ޕ‬㧙㧙㧔6㧕⣖␹⚻ᄖ⑼ቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
⣖⯯ⴊߦ㑐ߔࠆ⎇ⓥߣߒߡ㧘ࡑ࠙ࠬ⣖⯯ⴊࡕ࠺࡞ࠍ↪޿ߡࡈ࡝࡯࡜ࠫࠞ࡞ࠬࠞࡌࡦࠫࡖ࡯ߢ޽ࠆࠛ࠳࡜
ࡏࡦ߅ࠃ߮᛫ⴊዊ᧼⮎ߢ޽ࠆࠪࡠࠬ࠲࠱࡯࡞ߣᏱ࿶㜞㉄⚛≮ᴺߩ૬↪≮ᴺߩᕆᕈᦼ⣖⯯ⴊ଻⼔૞↪ߩ⹏ଔࠍⴕ޿㧘ਔ⮎೷ߣ߽㜞㉄⚛≮ᴺߣߩ૬↪ߢ᦭ᗧߥ⣖଻⼔૞↪ࠍ␜ߔߎߣ߇᣿ࠄ߆ߣߥߞߚ㧔ጘ㒂⮎⑼ᄢ
ቇ⮎ല⸃ᨆቇ⻠ᐳߣߩ౒ห⎇ⓥ㧕‫ߚ߹ޕ‬ห᭽ߦࡑ࠙ࠬ⣖⯯ⴊࡕ࠺࡞ࠍ↪޿ߡ⣖⯯ⴊᕆᕈᦼߩ⢽⢌↱᧪ᐙ⚦⢩ߩ㕒⣂ᛩਈߦ߅ߌࠆ␹⚻଻⼔૞↪ࠍᬌ⸛ߒߚ‫ޕ‬⢽⢌↱᧪ᐙ⚦⢩ߩ㕒⣂ౝᛩਈ⟲ߢߪࠦࡦ࠻ࡠ࡯࡞⟲ߥࠄ߮ߦ㛽㜑↱᧪ᐙ⚦⢩ᛩਈ⟲ߣᲧセߒߡ᦭ᗧߥᯏ⢻੍ᓟߩᡷༀ߇ߺࠄࠇࠆߎߣ߇᣿ࠄ߆ߣߥߞߚ㧔⚦⢩ᖱႎቇ⻠ᐳߣߩ౒ห⎇ⓥ㧕‫ޕ‬േ⣂⎬ൻᕈ∔ᖚߩᴦ≮ߣ੍㒐ߦ㑐ߔࠆ⎇ⓥߣߒߡ㧘ⴊዊ᧼߆ࠄ᡼಴ߐࠇേ⣂⎬ൻߣߩ㑐ㅪ߇ᵈ⋡ߐࠇߡ޿ࠆ sCD40L ╬ߩἻ∝ᕈࠨࠗ࠻ࠞࠗࡦߩ᡼಴ᯏᐨߣฦ⒳᛫ⴊዊ᧼⮎ߩലᨐߦ㑐ߒߡ⸃ᨆࠍⴕߥߞߚ⚿ᨐ㧘᛫Ἳ∝ലᨐࠍ᦭ߔࠆࠕࠬࡇ࡝ࡦߪἻ∝ᕈࠨࠗ࠻ࠞࠗࡦߩ᡼಴ߦኻߒߡ⪺᣿ߥᛥ೙ലᨐࠍ᦭ߔࠆ߇㧘หߓ᛫ⴊዊ᧼೷ߢ߽࠴ࠛࡁࡇ࡝ࠫࡦ♽⮎೷ߪᛥ೙ലᨐࠍ߽ߚߥ޿ߎߣ߇᣿ࠄ߆ߣߥߞߚ㧔⮎ℂ∛ᘒቇ⻠ᐳߣߩ౒ห⎇ⓥ㧕‫ޕ‬ᖡᕈࠣ࡝ࠝ࡯ࡑߦ㑐ߔࠆၮ␆⎇ⓥߣߒߡ㧘ࡅ࠻ࠣ࡝ࠝ࡯ࡑᮡᧄࠍ↪޿ߡᖡᕈ⣲≌ౝࡑࠢࡠࡈࠔ࡯ࠫߣ⣲≌ߩ↥↢ߔࠆࠤࡕࠞࠗࡦߩ㑐ଥࠍ఺∉⚵❱ቇ⊛ߦ⹏ଔߒߚ⚿ᨐ㧘⣲≌ౝ߳ߩࡑࠢࡠࡈࠔ࡯ࠫߩㆆ⿛ߦ㑐ਈߔࠆࠤࡕࠞࠗࡦߣߒߡ㧘ߎࠇ߹ߢߦᜰ៰ߐࠇߡ߈ߚ MCP-1 એᄖߦ MCP-3 ߽㑐ਈߒߡ޿ࠆน⢻ᕈ߇⷗޿ߛߐࠇߚ㧔఺∉∛ℂቇ⻠ᐳߣߩ౒ห⎇ⓥ㧕‫ޕ‬ࡅ࠻ࠣ࡝ࠝ࡯ࡑߦ߅ߌࠆ⥃ᐥ⎇ⓥߣߒߡ㧘᡼኿✢ᴦ≮ᓟߦߺࠄࠇࠆ᡼኿✢უᱫߣࠣ࡝ࠝ࡯ࡑౣ⊒ߣࠍ
PET ↹௝ࠍ↪޿ߡ㐓೎ߔࠆᣇᴺࠍᬌ⸛ߒߚ‫ޕ‬CHO㧔choline㧕-PET ߦࠃߞߡ᳞߼ࠄࠇࠆⴊᵹᚑಽࠍ MET
㧔methionine㧕-PET ↹௝߆ࠄᏅߒᒁ޿ߚᄌ឵↹௝ߦࠃࠅ᡼኿✢უᱫߣ⣲≌ౣ⊒ࠍⷞⷡ⊛ߦ᣿⍎ߦ⼂೎ߢ߈ࠆน⢻ᕈ߇␜ߐࠇߚ㧔ਛㇱ≮⼔࠮ࡦ࠲࡯ߦ߅ߌࠆ⎇ⓥ㧕
‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
ಎᢎ᝼㧦
⻠Ꮷ㧦
⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦

ጤ㑆 ੧
ศ᧛⚩৻
⍫㊁ᄢੳ
ᄢᳯ⋥ⴕ
ਛጊೣਯ
㊁ਛ⵨ᐽ
⍹㤥శ♿
᭑ᧄ↱⾆ሶ
ጟ↰ ⺈
ጊ↰ᷡᢥ
ᳰ੉↱㚅
ጊౝ࿻ᄥ
ㄞᧄ⌀▸

Toru Iwama
Shin-ichi Yoshimura
Hirohito Yano
Naoyuki Ohe
Noriyuki Nakayama
Yuko Nonaka
Mitsunori Ishiguro
Yukiko Enomoto
Makoto Okada
Kiyofumi Yamada
Yuka Ikegame
Keita Yamauchi
Masanori Tsujimoto3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ጤ㑆 ੧㧚⣖␹⚻ᄖ⑼⥃ᐥߦ߅ߌࠆ PET, SPECT ⸻ᢿ ᧲ർ⣖ SPECT ⎇ⓥળ⻠Ṷ㓸 2006 ᐕ㧦15 Ꮞ㧧7㧙12.
2㧕 ศ᧛⚩৻㧘ർፉ⧷⤿㧘ጊ↰ᷡᢥ㧘ᳰ੉↱㚅㧘᭑ᧄ↱⾆ሶ㧘቟⮮ᒄ㆏㧘⍫㊁ᄢੳ㧘ጤ㑆 ੧㧚⣖ਥᐙേ⣂㐽Ⴇߦࠃࠆㅴⴕᕈ⣖තਛ-Perfusion CT ߦࠃࠆ੍᷹ߣᕆᕈᦼࡃࠗࡄࠬߩೋᦼᴦ≮ᚑ❣-㧦⣖තਛߩ࠴࡯ࡓක≮-EC-IC ࡃࠗࡄࠬߩᄛ᣿ߌ-㧧╙ 24 ࿁ The Mt. Fuji Workshop on CVD ⻠Ṷ㓸㧘᧲੩㧦ߦࠀ࡯ࠈࠎ␠㧧2006ᐕ㧦85㧙89.
3㧕 ◉↰ ᷕ㧘ᅏ᧛ ᱠ㧘⍫㊁ᄢੳ㧘ጤ㑆 ੧㧚ᚻⴚว૬∝ߩ㗫ᐲߣߘߩኻ╷㧙࠹ࡦ࠻਄㜑ౝ⣲≌㧙㧦㤥ጤᢅᒾ✬㧚⣖⣲≌ߩᄖ⑼㧙ว૬∝ߩߥ޿⣖⣲≌ߩᄖ⑼ࠍ⋡ᜰߒߡ̅㧘ᄢ㒋㧦ࡔ࠺ࠖࠞ಴ 㧧2007 ᐕ㧦80㧙89㧚
4㧕 ศ᧛⚩৻㧚ᬁ㛽േ⣂࡮㎮㛽ਅേ⣂ߦኻߔࠆⴊ▤ᒻᚑⴚ㧦⩵ᳰ᥍ᒾ✬㧚⣖␹⚻ⴊ▤ౝᴦ≮ߩߔߴߡ㧙ᦨᣂ∝଀߆ࠄቇ߱㧙㧘᧲੩㧦ߦࠀ࡯ࠈࠎ␠㧧2007 ᐕ㧦176㧙179㧚
5㧕 ศ᧛⚩৻㧚ᬁ㛽േ⣂⿠ᆎㇱ⁜⓰ߦኻߔࠆⴊ▤ᒻᚑⴚ㧦⩵ᳰ᥍ᒾ✬㧚⣖␹⚻ⴊ▤ౝᴦ≮ߩߔߴߡ㧙ᦨᣂ∝଀߆ࠄቇ߱㧙㧘᧲੩㧦ߦࠀ࡯ࠈࠎ␠㧧2007 ᐕ㧦286㧙287㧚
6㧕 ศ᧛⚩৻㧚CAS ߩㆡᔕߣ⑌ᔊ㧦ਛේ৻㇢✬㧘Ṛ ๺ᦶ⋙ୃ㧚㗪േ⣂ࠬ࠹ࡦ࠻⇐⟎ⴚ -Carotid Artery
Srenting(CAS)ߩߔߴߡ-㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦45㧙50.

㧙㧙7㧕 ⍫㊁ᄢੳ㧘ᄢᳯ⋥ⴕ㧘ਛጊೣਯ㧘ศ᧛⚩৻㧘ጤ㑆 ੧㧚⣖ᷓㇱ⣲≌៰಴ⴚߦ߅ߌࠆⴚਛ Fluorescein-Na㕒⣂ౝᛩਈߩ᦭↪ᕈߦߟ޿ߡ㧦↲᧛⧷ੑ✬㧚⣖⣲≌ߩᄖ⑼࡯ၮᧄߣ᜸ᚢ࡯ 2008 ᐕ㧦77㧙86.
8㧕 ጊ↰ᷡᢥ㧘ศ᧛⚩৻㧚VH-IVUS㧦㗪േ⣂ࠬ࠹ࡦ࠻⇐⟎ⴚ㧦ਛේ৻㇢✬㧘Ṛ ๺ᦶ⋙ୃ㧚-Carotid Artery
Srenting(CAS)ߩߔߴߡ- 2008 ᐕ㧧80㧙81.
9㧕 ᨋ⌀৻㇢㧘ศ᧛⚩৻㧚╙ 4 ┨ ⥃ᐥᔕ↪ߩㅴ߻ⴊ▤㑐ㅪߩౣ↢කቇⴊ▤ߩౣ↢㧦᫪ਅ┥৻✬⪺㧚ⴊ▤ౣ↢කቇߩᄛ᣿ߌ-ㄭߠߊታ↪ൻ-㧘᧲੩㧦⌀⥝੤ᤃ(ᩣ)කᦠ಴ ㇱ㧧2008 ᐕ㧦154г161.
⪺ᦠ㧔᰷ᢥ㧕
1㧕 Uchiyama Y, Yamauchi M, Ando H, Yokoyama R, Hara T, Fujita H, Iwama T. Automated Classificationof Cerebral Arteries in MRA Images and Its Application to Maximum Intensity Projection. Proc of 28th
Annual International Conference of the IEEE Engineering In Medicine and Biology Society.
2006:4865-4868.
2㧕 Uchiyama Y, Yokoyama R, Fujita H, Hara T, Zhou X, Hayashi Y, Ando H, Iwama T, Asano T, Kato H,
Hoshi H. Development of CAD Scheme for Detection of Unruptured Intracranial Aneurysms in MRA
images. Innervision. 2006;21:76-77.
3㧕 Uchiyama Y, Yokoyama R, Ando H, Asano T, Kato H, Yamakawa H, Yamakawa H, Hara T, Iwama T,
Hoshi H Fujita H. Improvement of automated detection method of lacunar infarcts in brain MR
images. In: Conf Proc IEEE Eng Med Biol Soc, CA: The printing House Inc; 2007:1599-1602.
4㧕 Yamauchi M, Uchiyama Y, Yokoyama R, Hara T, Fujita H, Ando H, Yamakawa H, Iwama T, Hoshi H.
Computerized scheme for detection of arterial occlusion in brain MRA images. In: Proc. SPIE Medical
Imaging, Proc. SPIE Medical Imaging, pt6514, WA: The international Society for Optical Engineering;
2007:65142C-1-65142C-9.
5㧕 Uchiyama Y, Kunieda T, Hara T, Fujita H, Ando H, Yamakawa H, Asano T, Kato H, Iwama T,
Kanematu M, Hoshi H. Automatic segmentation of different-sized leukoaraiosis regions in brain MR
images. In: Giger ML, Karssemeijer N , ed. Proc. of SPIE Medical Imaging: Computer-aided diagnosis,
2008:69151S-1-69151S-8.
6㧕 Uchiyama Y, Gao X, Hara T, Fujita H, Ando H, Yamakawa H, Asano T, Kato H, Iwama T, Kanematu M,
Hoshi H. Computerized detection of unruptured aneurysms in MRA images: Reduction of false
positives using anatomical location feature. In: Giger ML, Karssemeijer N.ed. Proc. of SPIE Medical
Imaging: Computer-aided diagnosis, 2008:69151Q-1-69151Q-8.
✚⺑㧔๺ᢥ㧕
1㧕 ጤ㑆 ੧㧚ᄖ⑼⊛ᴦ≮ߦᔅⷐߥ↹௝⸻ᢿߩㅴᱠ㧘⣖ߣᓴⅣ 2006 ᐕ㧧11 Ꮞ㧦43㧙48.
2㧕 ጤ㑆 ੧㧚߽߿߽߿∛ߦኻߔࠆᄖ⑼ᴦ≮ߩታ㓙ߣⷐὐ㧘Neurological Surgery 2006 ᐕ㧧34 Ꮞ㧦557㧙564.
3㧕 ศ᧛⚩৻㧘ጤ㑆 ੧㧚⣖៊்ᓟߩ Neurogenesis ೙ᓮᯏ᭴ߩ⸃ᨆ—ౣ↢ක≮߳ߩዷᦸ—㧘⣖ᓴⅣઍ⻢ 2006
ᐕ㧧18 Ꮞ㧦176㧙179.
4㧕 ጤ㑆 ੧㧚⣖േ㕒⣂ᄸᒻߩᚻⴚ㧚⑳ߩᚻⴚᚢ⇛㧘⣖␹⚻ᄖ⑼ㅦႎ 2007 ᐕ㧧17 Ꮞ㧦284㧙294㧚
5㧕 ጤ㑆 ੧㧘ศ᧛⚩৻㧘⍫㊁ᄢੳ㧘ᄢᳯ⋥ⴕ㧘┻ਛరᐽ㧘㘵↰ብ᮸㧚᧻ᨐ૕∛ᄌߦኻߔࠆ infratentorial
supracerebellar approach㧘⣖␹⚻ᄖ⑼ 2007 ᐕ㧧35 Ꮞ㧦453㧙466㧚
6㧕 ጤ㑆 ੧㧚ᚺ㧙ᅏⓄ㜞ጪᄐጊ⸻≮ᚲ߳ߩ㆏㧙㧘⣖␹⚻ᄖ⑼ 2007 ᐕ㧧35 Ꮞ㧦961㧙962㧚
7㧕 ጤ㑆 ੧㧚Editorial Comment: ㆊἠᵹ∝୥⟲ߦኻߔࠆ⓫㗡ਅ⚻㗡⬄࠼ࡊ࡜ࡕ࠾࠲࡝ࡦࠣ㧘⣖ᄖ⹹ 2007
ᐕ㧧16 Ꮞ㧦798㧚
8㧕 ጊᎹᤐ᮸㧘ጤ㑆 ੧㧚ᦨᣂߩࠛࡆ࠺ࡦࠬᄖ⑼♽ԝ MASH: ߊ߽⤑ਅ಴ⴊᓟߩㆃ⊒ᕈ␹⚻⣕⪭∝⁁ߦኻߔࠆࠕࠬࡇ࡝ࡦߩᛥ೙ലᨐߦ㑐ߔࠆ࡜ࡦ࠳ࡓൻᲧセ⹜㛎㧦ಽሶ⣖ⴊ▤∛ 2007 ᐕ㧧6 Ꮞ㧦219㧙222㧚
9㧕 ጊౝᐽ㓶㧘ጤ㑆 ੧㧘ᣂ੗ ৻㧚ᐳ㐳✚᜝ ࠪࡦࡐࠫ࠙ࡓ 1 ੑಽ⣄ᬁ‫ޟ‬ᚑ㐳㧘⊒㆐ߦ઻߁໧㗴ߣߘߩኻ╷‫ޠ‬㧘ዊఽߩ⣖␹⚻ 2007 ᐕ㧧32 Ꮞ㧦302㧙303㧚
10㧕 ጤ㑆 ੧㧚⣖␹⚻∔ᖚߦⴕࠊࠇࠆᚻⴚߣᴦ≮৻ⷩ㧦ࡉ࡟ࠗࡦ࠽࡯ࠪࡦࠣ 2008 ᐕ㧧24 Ꮞ㧦932.
11㧕 ጤ㑆 ੧㧚㗡⬄ຜ㗡⣲ߦኻߔࠆ pterional approach ࠍၮᧄߣߒߚ஥ᣇ߆ࠄߩࠕࡊࡠ࡯࠴㧘⣖␹⚻ᄖ⑼ㅦႎ
2008 ᐕ㧧18 Ꮞ㧦278㧙286.
12㧕 ศ᧛⚩৻㧘ጤ㑆 ੧㧚㗪േ⣂ࠬ࠹ࡦ࠻⇐⟎ⴚ -ߘߩ⃻⁁ߣዷᦸ-㧘⣖ߣᓴⅣ 2008 ᐕ㧧13 Ꮞ㧦21㧙25.
13㧕 ⍫㊁ᄢੳ㧚᡼኿✢ᴦ≮㧦ࡉ࡟ࠗࡦ࠽࡯ࠪࡦࠣ 2008 ᐕ㧧24 Ꮞ㧦978㧙981.
14㧕 ᄢᳯ⋥ⴕ㧚ⴊ⣲㒰෰ⴚ㨪ౝⷞ㏜/ቯ૏⣖ᚻⴚࠍ฽߻㨪㧦ࡉ࡟ࠗࡦ࠽࡯ࠪࡦࠣ 2008 ᐕ㧧24 Ꮞ㧦944㧙946.
15㧕 ዊ⼱ཅೣ㧚㐿㗡ⴚ৻⥸㧦ࡉ࡟ࠗࡦ࠽࡯ࠪࡦࠣ 2008 ᐕ㧧24 Ꮞ㧦933㧙935.
16㧕 ਛጊೣਯ㧚ᄖᷫ࿶ⴚ㨪ᕆᕈ⎬⤑ਅⴊ⣲㧘⣖ᝂ்㨪㧦ࡉ࡟ࠗࡦ࠽࡯ࠪࡦࠣ 2008 ᐕ㧧24 Ꮞ㧦951㧙954.
17㧕 㜞ᧁବ▸㧘ศ᧛⚩৻㧚㜞㦂⠪ߦ߅ߌࠆᕆᕈᦼ⣖᪪Ⴇᴦ≮㧦ಽሶᔃⴊ▤∛ 2008 ᐕ㧧9 Ꮞ㧦166㧙169.
✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ศ᧛⚩৻㧘ጊ↰ Ả㧘⍹Ỉ㍤ੑ㧘Ỉ↰రผ㧘ㇳ ᵏᒾ㧘ጤ㑆 ੧㧚㜞㦂⠪㊀∝ߊ߽⤑ਅ಴ⴊߦኻߔࠆᕆᕈ
ᦼ⣖ⴊ▤ౝᚻⴚߩᴦ≮ᚑ❣㧘⣖තਛߩᄖ⑼ 2006 ᐕ㧧34 Ꮞ㧦86㧙90.
2㧕 ട⮮⾆ਯ㧘౎චᎹ㓶࿑㧘ᅏ᧛ ᱠ㧘◉↰ ᷕ㧘ਛጊೣਯ㧘ጤ㑆 ੧㧚㗡ㇱᄖ்ᘟᕈᦼߦ߅ߌࠆ⣖♧ઍ⻢ߩ㧙㧙⛔⸘ቇ⊛↹௝⸃ᨆ㧘␹⚻ᄖ் 2006 ᐕ㧧29 Ꮞ㧦15㧙19㧚
3㧕 ᧻੗ ◊㧘ౝጊ⦟৻㧘ᮮጊ㦖ੑ㇢㧘ේ ᱞผ㧘๟ ะᩕ㧘⮮↰ᐢᔒ㧘቟⮮ᒄ㆏㧘ጤ㑆 ੧㧘ട⮮ඳၮ㧘ᵻ
㊁㓉ᒾ㧘ᤊ ඳᤘ㧚⣖ MR ↹௝ࠍ↪޿ߚ࡜ࠢ࠽᪪Ⴇᬌ಴ߩᡰេ⸻ᢿࠪࠬ࠹ࡓߩ㐿⊒㧘ାቇᛛႎ 2006 ᐕ㧧
107 Ꮞ㧦25㧙28㧚
4㧕 ᧻੗ ◊㧘ౝጊ⦟৻㧘ᮮጊ㦖ੑ㇢㧘ේ ᱞผ㧘๟ ะᩕ㧘⮮↰ᐢᔒ㧘቟⮮ᒄ㆏㧘ጤ㑆 ੧㧘ട⮮ඳၮ㧘ᵻ
㊁㓉ᒾ㧘ᤊ ඳᤘ㧚⣖ MR ↹௝ࠍ↪޿ߚ࡜ࠢ࠽᪪Ⴇᬌ಴ߩᡰេ⸻ᢿࠪࠬ࠹ࡓߩ㐿⊒㧘㔚ሶᖱႎㅢାቇળᛛ
ⴚ⎇ⓥႎ๔㧘㔚ሶᖱႎㅢାቇળᛛⴚ⎇ⓥႎ๔(IEICE Technical Report) 2006 ᐕ㧧105 Ꮞ㧦25㧙28㧚
5㧕 ⨹ᧁ᦭ਃ㧘㊁ୖብᤩ㧘દ⮮ Პ㧘ฎᏒ᣽ብ㧘ጤ↰ㄖᄦ㧘ጤ㑆 ੧㧚ᱜਛ⣖᪞േ⣂㐽Ⴇߦࠃࠆో⣖᪞᪪Ⴇߩ1 ଀㧘⣖තਛ 2007 ᐕ㧧3 Ꮞ㧦463㧙468㧚
6㧕 ጤ㑆 ੧㧘ศ᧛⚩৻㧘቟⮮ᒄ㆏㧘᭑ᧄ↱⾆ሶ㧚቟ో‫⏕ޔ‬ታߥ⣖േ⣂≜ᚻⴚߩᚻ㗅ߣᎿᄦ㧙േ⣂≜ᚻⴚߩᦨ⚳Ბ㓏ߦ߅ߌࠆ dome puncture ߩᓎഀ㧙㧘⣖තਛߩᄖ⑼ 2007 ᐕ㧧35 Ꮞ㧦411㧙416㧚
7㧕 ጊ↰ታ⾆ੱ㧘⼾↰ ᴰ㧘ศ᧛⚩৻㧘ጤ㑆 ੧㧘ᅏኹ ᢘ㧘ዊୖ⌀ᴦ㧚⣖තਛᢇᕆߦ߅ߌࠆ⣖තਛೋᦼ⸻≮(ISLS)
ࠦ࡯ࠬߩ㊀ⷐᕈ㧘⣖␹⚻ᄖ⑼ㅦႎ 2007 ᐕ㧦945㧙952㧚
8㧕 ጊౝ዁ผ, ౝጊ⦟৻, ዊ᫾ Ả, ᮮጊ㦖ੑ㇢, ේ ᱞผ, ቟⮮ᒄ㆏, ጊᎹᒄ଻, ጤ㑆 ੧, ᤊ ඳᤘ, ⮮↰ᐢᔒ㧚
MRA ↹௝ߦ߅ߌࠆ⣖ⴊ▤ฬߩ⥄േኻᔕઃߌᚻᴺߩ㐿⊒㧘↢૕කᎿቇ 2007 ᐕ㧧45 Ꮞ㧦27㧙35㧚
9㧕 ዊ᫾ Ả, ౝጊ⦟৻, ጊౝ዁ผ, ᮮጊ㦖ੑ㇢, ේ ᱞผ, ጊᎹᒄ଻, ቟⮮ᒄ㆏, ጤ㑆 ੧, ᤊ ඳᤘ, ⮮↰ᐢᔒ㧚ࡌࠢ࠻࡞㓸ਛᐲࡈࠖ࡞࠲ࠍ↪޿ߚ MRA ↹௝ߦ߅ߌࠆ⣖േ⣂≜ߩᬌ಴ᴺ㧘ක↪↹௝ᖱႎቇળ㔀⹹ 2007
ᐕ㧧24 Ꮞ㧦84㧙89㧚
10㧕 ౝጊ⦟৻㧘᧻੗ ◊㧘ᮮጊ㦖ੑ㇢㧘๟ ะᩕ㧘ේ ᱞผ㧘቟⮮ᒄ㆏㧘ᵻ㊁㓉ᒾ㧘ട⮮ඳၮ㧘ጤ㑆 ੧㧘ᤊ ඳᤘ㧘⮮↰ᐢᔒ㧚⣖ MR ↹௝ߦ߅ߌࠆ࡜ࠢ࠽᪪Ⴇߩᬌ಴ᴺ㧘㔚ሶᖱႎㅢାቇળ⺰ᢥ⹹ 2007 ᐕ㧧J90㧙D㧦1820
㧙1829㧚
11㧕 ศ᧛⚩৻, ጊ↰ᷡᢥ, ᭑ᧄ↱⾆ሶ, ਛጊೣਯ, ᄢᳯ⋥ⴕ, ⍫㊁ᄢੳ, ጤ㑆 ੧㧚⎕ⵚ⣖േ⣂≜ߦ߅ߌࠆ EBM
ߩ⸃㉼ߣᴦ≮ㆬᛯ, ⣖␹⚻ᄖ⑼ࠫࡖ࡯࠽࡞ 2008 ᐕ㧧17 Ꮞ㧦805㧙854.
12㧕 ศ᧛⚩৻, ጊ↰ᷡᢥ, ᭑ᧄ↱⾆ሶ, ਛጊೣਯ, ᄢᳯ⋥ⴕ, ⍫㊁ᄢੳ, ጤ㑆 ੧. ⎕ⵚ⣖േ⣂≜ߦ߅ߌࠆ EBM
ߩ⸃㉼ߣᴦ≮ㆬᛯ⎕ⵚ⣖േ⣂≜ߦ߅ߌࠆ EBM ߩ⸃㉼ߣᴦ≮ㆬᛯ, ⣖␹⚻ᄖ⑼ࠫࡖ࡯࠽࡞೎ౠ ․㓸‫ޟ‬⣖ⴊ▤㓚ኂߦ߅ߌࠆ EBM‫ޠ‬17 Ꮞ㧘᧲੩㧦ਃベᦠᐫ㧧2008 ᐕ㧧850㧙854.
13㧕 ⍫㊁ᄢੳ, ᪢᧛ ᷕ, ਛጊೣਯ, ᄢᳯ⋥ⴕ, ౎චᎹ㓶࿑, ᨋ ␭৻, ଻૑ ഞ, ጤ㑆 ੧㧚᷆⫷⃿ౝ▵ೝỗⴚ߇ᄼഞߒߚ᦭᫚⿒ⴊ⃿⥰〯∛ߩ 1 ଀㧘ᣣᧄቯ૏࡮ᯏ⢻␹⚻ᄖ⑼ቇળᯏ㑐⹹ ᯏ⢻⊛⣖␹⚻ᄖ⑼㧘2008 ᐕ㧧
47 Ꮞ㧦114㧙118.
14㧕 ᭑ᧄ↱⾆ሶ㧚㗪ㇱ㗪േ⣂ࠬ࠹ࡦ࠻⇐⟎ⴚߦ߅ߌࠆⴚ೨ⴊዊ᧼ಝ㓸⢻᷹ቯߩ᦭↪ᕈ㧘⣖␹⚻ⴊ▤ౝᴦ≮ 2008
ᐕ㧧2 Ꮞ㧦188㧙192.
15㧕 ጊ↰ᷡᢥ, ศ᧛⚩৻, ጊᎹᤐ᮸, ጤ㑆 ੧㧚⣖᪪Ⴇࠍ᧪ߒ㗪േ⣂ߦนേᕈࡊ࡜࡯ࠢࠍ⹺߼ߚᧄᘒᕈⴊዊ᧼ⴊ
∝ߩ 1 ଀㧘Journal of neuroendovascular therapy ⣖␹⚻ⴊ▤ౝᴦ≮㧘2008 ᐕ㧧2 Ꮞ㧦62㧙67.
16㧕 ࿡ᨑ℉਽, ౝጊ⦟৻, ේ ᱞผ, ⮮↰ᐢᔒ, ട⮮ඳၮ, ᵻ㊁㓉ᒾ, ᤊ ඳᤘ, ጊᎹᒄ଻, ቟⮮ᒄ㆏, ጤ㑆 ੧㧚ࠢ࡜ࠬ࠲࡝ࡦࠣࠍ↪޿ߚ⣖࠼࠶ࠢ MR ↹௝ߦ߅ߌࠆή∝୥ᕈᄢ⣖⊕⾰∛ᄌߩᬌ಴ᴺ㧘Medical Imaging
Technology 2008 ᐕ㧧26 Ꮞ㧦39㧙47.
ේ⪺㧔᰷ᢥ㧕
1㧕 Yoshimura S, Enomoto Y, Kitajima H, Yamada J, Kaku Y, Iwama T. Carotid-compression technique forthe insertion of guiding catheters. Am J Neuroradiol. 2006;27:1710-1711.
IF
2㧕 Yamakawa H, Yamada K, Sumi K, Iida H, Iwama T. Preoperative assessment of microvascularcompression of cranial nerve XI and X using 3D fast imaging employing steady-state acquisition
magnetic resonance imaging in glossopharyngeal neuralgia. Neurosurg Quart. 2006;16:166-168.
IF
3㧕 Nakayama N, Okumura A, Shinoda J, Nakashima T, Iwama T. Relationship between regional cerebral
metabolism and consciousness disturbance in traumatic diffuse brain injury without large focal
lesions㧦an FDG-PET study with statistical parametric mapping analysis. J Neurol Neurosur Psych.
2006;77:856-862.
IF
4㧕 Nakayama N, Okumura A, Shinoda J, Yasokawa Y, Miwa K, Yoshimura S, Iwama T. Evidence forwhite matter disruption in traumatic brain injury without macroscopic lesions. J Neurol Neuros Psych.
2006;77:850-855.
IF
5㧕 Shimamura M, Sato N, Yoshimura S, Kaneda Y, Morishita R. HVJ-based non-viral gene transfer
method: successful gene therapy using HGF and VEGF genes in experimental ischemia. Front Biosci.
2006;11:753-759.
IF
6㧕 Otani N, Muroi C, Yano H, Khan N, Pangalu A, Yonekawa Y. Surgical management of tuberculum
sellae meningioma 㧦 Role of selective extradural anterior clinoidectomy. Brit J Neurosurg.
2006;20:129-138.
IF
7㧕 Uchiyama Y, Matsui A, Yokoyama R, Fujita H, Hara T, Zhou X, Ando H, Iwama T, Asano T, Kato H,
Hoshi H. CAD Scheme for Detection of Lacunar infarcts in Brain MR images. Int J Com Assist Radiol
Surg. 2006;1:382-385.
8㧕 Nakashima T, Nakayama N, Miwa K, Okumura A, Soeda A, Iwama T. Focal brain glucose
hypometabolism in patients with neuropsychologic deficits after diffuse axonal injury. Am J
Neuroradiol. 2007;28:236-242.
IF
9㧕 Yamakawa H, Kato M, Yoshimura S. Vertebral arteriovenous fistula following attempt at central line

㧙㧙

2.338

0.073

3.857

3.857

2.989

0.542

2.338

placement and successfully treated with sequential endovascular coil embolization. Neurosurg Q.
2007;17:138-141.
10㧕 Miwa K, Shinoda J, Yano H, Iwama T. Relatively decreased 11C-methionine uptake within theanaplastic component of a mixed-grade oligodendroglioma: a case study. Am J Neuroradiol.
2007;28:2005-2007.
11㧕 Kato T, Nakayama N, Yasokawa Y, Okumura A, Shinoda J, Iwama T. Statistical image analysis of
cerebral glucose metabolism in patients with cognitive impairment following diffuse traumatic brain
injury. J Neurotrauma. 2007;24:919-926.
12㧕 Kotani Y, Morimoto N, Oida Y, Tamura Y, Tamura S, Inoue T, Shimazawa M, Yoshimura S, Iwama T,
Hara H. Prevention of in vitro and in vivo acute ischemic neuronal damage by (2S)-1-(4-amino-2, 3,5-trimethylphenoxy)-3-{4-[4-(4-fluorobenzyl)phenyl]-1-piperazinyl}-2-propanol
dimethanesulfonate(SUN N8075), a novel neuroprotective agent with antioxidant properties. Neuroscience.
2007;149:779-788.
13㧕 Nakagawa J, Saio M, Tamakawa N, Suwa T, Frey AB, Nonaka K, Umemura N, Imai H, Ouyang GF,
Ohe N, Yano H, Yoshimura S, Iwama T, Takami T. TNF expressed by tumor-associated macrophages,
but not microglia, can eliminate glioma. Int J Oncol. 2007;30:803-811.
14㧕 Yasokawa YT, Shinoda J, Okumura A, Nakayama N, Miwa K, Iwama T. Correlation between
diffusion-tensor magnetic resonance imaging and motor-evoked potential in chronic severe diffuse
axonal injury. J Neurotrauma. 2007;24:163-173.
15㧕 Yamashita K, Kotani Y, Nakajima Y, Shimazawa M, Yoshimura S, Nakashima S, Iwama T, Hara H.
Fasudil, a Rho Kinase(ROCK)inhibitor, protects against ischemic neuronal damage in vitro and in vivo
by acting directly on neurons. Brain Res. 2007;1154:215-224.
16㧕 Yamashita K, Ohe N, Yoshimura S, Iwama T. Intracranial Pial Arteriovenous Fistula. Neurologia
medico-chirurgica. 2007;47:550-554.
17㧕 Oka N, Soeda A, Inagaki A, Onodera M, Maruyama H, Hara A, Kunisada T, Mori H, Iwama T. VEGF
promotes tumorigenesis and angiogenesis of human glioblastoma stem cells. Biochem Biophys Res
Commun. 2007;360:553-559.
18㧕 Inagaki A, Soeda A, Oka N, Kitajima H, Nakagawa J, Motohashi T, Kunisada T, Iwama T. Long-term
maintenance of brain tumor stem cell properties under at non-adherent and adherent culture
conditions. Biochem Biophys Res Commun. 2007;361:586-592.
19㧕 Uchiyama Y, Yokoyama R, Ando H, Asano T, Kato H, Yamakawa H, Yamakawa H, Hara T, Iwama
T,Hoshi H, Fujita H. Computer-aided diagnosis scheme for detection of lacunar infarcts on MR images.
Acad Radiol. 2007;14:1554-1561.
20㧕 Yokoyama R, Zhang X, Uchiyama Y, Fujita H, Hara T, Zhou X, Kanematsu M, Asano T, Kondo H,
Goshima S, Hoshi H, Iwama T. Development of an automated method for the detection of chronic
lacunar infarct regions in brain MR images. IEICE Trans Inf & Syst. 2007;E90-D:943-954.
21㧕 Ogawa A, Mori E, Minematsu K, Taki W, Takahashi A, Nemoto S, Miyamoto S, Sasaki M, Inoue T, The
MELT Japan Study Group. Randomized traial of intraarterial infusion of urokinase within 6 hours of
middle cerebral artery stroke. The middle cerebral artery embolism local fibrinolytic intervention trial(MELT) Japan. Stroke. 2007;38:2633-2639.
22㧕 Uchiyama Y, Yokoyama R, Asano T, Kato H, Yamakawa H, Ando H, Yamakawa H, Hara T, Iwama T,
Hoshi H, Fujita H. Performance of computer-aided diagnosis for detection of lacunar infarcts on brain
MR images: ROC analysis of radiologists̉detection. Int J Computer Assisted Radiology and Surgery.
2007;2:S395-S397.
23㧕 Yoshimura S, Enomoto Y, Yamada K, Iwama T. Initial experience of balloon catheter disruption of thethrombus in an unrecanalized intracranial artery after intravenous recombinant tissue plasminogenactivator. JNET. 2008;2:207-211.
24㧕 Yamakawa H, Ohe N, Yano H, Yoshimura S, Iwama T. Venous drainage patterns in perimesencephalicnonaneurysmal subarachnoid hemorrhage. Clin Neurol Neurosurg. 2008;110:587-591.
25㧕 Yamakawa H, Yoshimura S, Enomoto Y, Nakayama N, Iwama T. Aneurysm arising from the corticalsegment of the superior cerebellar artery: a case report and reveiw of the literatures. Surgi Neurol.
2008;70:421-424.
26㧕 Miwa K, Matsuo M, Shinoda J, Oka N, Kato T, Okumura A, Ueda T, Yokoyama K, Yamada J, Yano H,
Yoshimura S, Iwama T. Simultaneous integrated boost technique by helical tomotherapy for thetreatment of glioblastoma multiforme with (11)C-methionine PET: report of three cases. J Neurooncol.
2008;87:333-339.
27㧕 Soeda A, Inagaki A, Oka N, Ikegame Y, Aoki H, Yoshimura S, Nakashima S, Kunisada T, Iwama T.
Epidermal growth factor plays a crucial role in mitogenic regulation of human brain tumor stem cells.
J Biol Chem. 2008;83:10958-10966.
28㧕 Kotani Y, Nakajima Y, Hasegawa T, Satoh M, Nagase H, Shimazawa M, Yoshimura S, Iwama T, Hara
H. Propofol exerts greater neuroprotection with disodium edetate than without it. J Cereb Blood Flow
Metab. 2008;28:354-366.
29㧕 Kotani Y, Shimazawa M, Yoshimura S, Iwama T, Hara H. The experimental and clinical pharmacology㧙㧙

IF 0.073

IF 2.338

IF 3.640

IF 3.352

IF 2.295

IF 3.640

IF 2.218
IF 0.473

IF 2.749

IF 2.749

IF 2.094

IF 0.245

IF 6.296

IF 1.553

IF 1.112

IF 1.856

IF 5.581

IF 5.147

of propofol, an anesthetic agent with neuroprotective properties. CNS Neurosci Ther. 2008;14:95-106.
30㧕 Kato T, Shinoda J, Nakayama N, Miwa K, Okumura A, Yano H, Yoshimura S, Maruyama T, Muragaki
Y, Iwama T. Metabolic Assessment of Gliomas Using 11C-Methionine, [18F] Fluorodeoxyglucose, and11C-Choline Positron-Emission Tomography. Am J Neuroradiol. 2008;29:1176-1182.
IF 2.338
31㧕 Yamada K, Yoshimura S, Enomoto Y, Yamakawa H, Iwama T. Effectiveness of combining continuous
cerebrospinal drainage and intermittent intrathecal urokinase injection therapy in preventing
symptomatic vasospasm following aneurysmal subarachonoid haemorrhage. British journal of
Neurosurgery. 2008;22:649-653.
IF 0.542

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦ศ᧛⚩৻㧘⎇ⓥಽᜂ⠪㧦ጤ㑆 ੧㧘⍫㊁ᄢੳ㧘ᄢᳯ⋥ⴕ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(B)(2)㧦㗡ㇱᄖ்‫ޔ‬⣖⯯ⴊᓟߩ neurogenesis ೙ᓮᯏ᭴ߩ⸃ᨆ㧦␹⚻ᩕ㙃࿃ሶߣߩ㑐ㅪ㧧
ᐔᚑ 16㧙18 ᐕᐲ㧧10,500 ජ౞(5,000㧦3,300㧦2,200 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦ጤ㑆 ੧㧧ጘ㒂ᄢቇᵴᕈൻ⎇ⓥ⾌㧦⣖⣲≌⎇ⓥࡕ࠺࡞ߩ⏕┙ߣ࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮߳ߩᔕ↪㧧ᐔᚑ 18 ᐕᐲ㧧1,200 ජ౞3㧕 ⎇ⓥઍ⴫⠪㧦ጤ㑆 ੧㧘⎇ⓥಽᜂ⠪㧦ศ᧛⚩৻㧘ጊਅஜᄥ㇢㧧ጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼ߩ⎇ⓥ
ᵴᕈൻ(ක)⎇ⓥ⾌㧦⣖⯯ⴊߦ߅ߌࠆฦ⒳ᐙ⚦⢩ߩಽൻ‫⚦߮ࠃ߅ޔ‬⢩⒖ᬀߦࠃࠆ␹⚻ⴊ▤ౣ↢ᴦ≮ᴺߩ
⏕┙㧧ᐔᚑ 18 ᐕᐲ㧧1,000 ජ౞4㧕 ⎇ⓥઍ⴫⠪㧦೽↰᣿↵㧧ጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼ߩ⎇ⓥᵴᕈൻ(ක)⎇ⓥ⾌㧦⣖⣲≌ᐙ⚦⢩ߦၮߠߊ⣖⣲≌ᴦ≮㧧ᐔᚑ 18 ᐕᐲ㧧200 ජ౞5㧕 ⎇ⓥઍ⴫⠪㧦ጊਅஜᄥ㇢㧧ጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼ߩ⎇ⓥᵴᕈൻ(ක)⎇ⓥ⾌㧦⣖៊்߳ߩ␹⚻ⴊ▤ౣ↢≮ᴺߩ⏕┙̆⢽⢌↱᧪㑆⪲♽ᐙ⚦⢩ߩ᦭↪ᕈߩᬌ⸛̆㧧ᐔᚑ 18 ᐕᐲ㧧200 ජ౞6㧕 ⎇ⓥઍ⴫⠪㧦ጤ㑆 ੧㧘⎇ⓥಽᜂ⠪㧦೽↰᣿↵㧧⁛┙ⴕ᡽ᴺੱᣣᧄቇⴚᝄ⥝ળ⑼ቇ⎇ⓥ⾌⵬ഥ㊄⪚⧘⎇ⓥ㧦EGF, EGFR ߇⣖⣲≌ᐙ⚦⢩ߦ෸߷ߔᓇ㗀㧧ᐔᚑ 19㧙20 ᐕᐲ㧧3,300 ජ౞(1,700㧦1,600
ජ౞)7㧕 ⎇ⓥઍ⴫⠪㧦ศ᧛⚩৻㧘⎇ⓥಽᜂ⠪㧦ጤ㑆 ੧, ᄢᳯ⋥ⴕ, ᭑ᧄ↱⾆ሶ, ጊ↰ᷡᢥ㧧⁛┙ⴕ᡽ᴺੱᣣ
ᧄቇⴚᝄ⥝ળ⑼ቇ⎇ⓥ⾌⵬ഥ㊄⪚⧘⎇ⓥ㧦⢽⢌↱᧪㑆⪲♽ᐙ⚦⢩ࠍ↪޿ߚ⣖⯯ⴊߦኻߔࠆ⒖ᬀౣ↢≮ᴺߩ⏕┙㧧ᐔᚑ 19㧙21 ᐕᐲ㧧3,200 ජ౞(1,000㧦1,300㧦900 ජ౞)
8㧕 ⎇ⓥઍ⴫⠪㧦ਛጊೣਯ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦⣖⣲≌ᐙ⚦⢩ߩዪ࿷ߩ⸃᣿㧧ᐔᚑ
19㧙20 ᐕᐲ㧧3,300 ජ౞(1,700㧦1,600 ජ౞)
9㧕 ⎇ⓥઍ⴫⠪㧦ศ᧛⚩৻㧧⎇ⓥ⑼㐳࡮කቇㇱ㐳ⵙ㊂⚻⾌ߦࠃࠆ⎇ⓥ⾌(ක)㧦⢽⢌⚵❱↱᧪㑆⪲♽ᐙ⚦⢩ߣ␹⚻ᩕ㙃࿃ሶࠍ↪޿ߚᣂߒ޿␹⚻∔ᖚᴦ≮ᴺߩ㐿⊒㧧ᐔᚑ 19 ᐕᐲ㧧100 ජ౞
10㧕 ⎇ⓥઍ⴫⠪㧦ጊ↰ᷡᢥ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦⣖⣲≌ߩ࡞࡯࠷㧧ᐔᚑ 20㧙21 ᐕᐲ㧧2,210 ජ౞(1,700㧦510 ජ౞)
11㧕 ઍ⴫⎇ⓥ⠪㧦ጟ↰ ⺈㧧ᵴᕈൻ⚻⾌㧦㕖ਛᨔ␹⚻⚵❱ࡑࠢࡠࡈࠔ࡯ࠫߦࠃࠆᖡᕈ␹⚻⤔⣲⹺⼂⢻ജߩᏅ⇣ߩᬌ⸛㧧ᐔᚑ 20 ᐕᐲ㧧890 ජ౞
12㧕 ઍ⴫⎇ⓥ⠪㧦᭑ᧄ↱⾆ሶ㧧ᐔᚑ 20 ᐕᐲ⎇ⓥ⑼㐳࡮කቇㇱ㐳ⵙ㊂⚻⾌㧦㗖േ⣂ࠬ࠹ࡦ࠻⇐⟎ⴚ(CAS)ߩ๟ⴚᦼ᛫ⴊዊ᧼≮ᴺߦ߅ߌࠆ⥋ㆡ᛫ⴊዊ᧼⮎࡮⥋ㆡᛩਈ㊂߅ࠃ߮ࡕ࠾࠲࡝ࡦࠣᴺߩ⏕┙㧧ᐔᚑ 20
ᐕᐲ㧧250 ජ౞
13㧕 ઍ⴫⎇ⓥ⠪㧦ᳰ੉↱㚅㧧ANGPT1 ߣ⚵❱ᐙ⚦⢩ࠍ೑↪ߒߚ⯯ⴊᕈ⣖ⴊ▤∔ᖚߦኻߔࠆᣂߒ޿ᴦ≮ᴺߩ㐿⊒㧧ᐔᚑ 20 ᐕᐲ㧧250 ජ౞
2㧕ฃ⸤⎇ⓥ1㧕 ጤ㑆 ੧㧦࡜ࠫࠞ࠶࠻ᵈ ․ቯᚑ❣૶↪⺞ᩏ(ዊఽߦኻߔࠆ⺞ᩏ)㧧ᐔᚑ 18 ᐕᐲ㧧31,500 ౞㧦ਃ⪉࠙ࠚ࡞ࡈࠔ࡯ࡑ(ᩣ)
2㧕 ጤ㑆 ੧㧦PAV ≮ᴺ ૶↪ᚑ❣⺞ᩏ㧧ᐔᚑ 18 ᐕᐲ㧧105 ජ౞㧦ਛᄖ⵾⮎(ᩣ)
3㧕 ጤ㑆 ੧㧦ࠣ࡞࠻ࡄᵈ(⯯ⴊᕈ⣖ⴊ▤㓚ኂᕆᕈᦼ)૶↪ᚑ❣⺞ᩏ㧧ᐔᚑ 17㧙19 ᐕᐲ㧧315 ජ౞㧦ਃ⪉࠙ࠚ࡞ࡈࠔ࡯ࡑ(ᩣ)
4㧕 ጤ㑆 ੧㧦ࠪࡠࠬ࠲࠱࡯࡞ߩᏒ⽼ᓟ⥃ᐥ⹜㛎̆⣖᪪Ⴇߦኻߔࠆࠕࠬࡇ࡝ࡦߣߩᲧセߦ߅ߌࠆᬌ⸽⊛⹜㛎࡯㧧ᐔᚑ 16㧙20 ᐕᐲ㧧4,066,560 ౞㧦ᄢႦ⵾⮎(ᩣ)
5㧕 ጤ㑆 ੧㧦࠹ࡕ࠳࡯࡞ࠞࡊ࠮࡞ో଀⺞ᩏ(․ቯ૶↪ᚑ❣⺞ᩏ)㧧ᐔᚑ 18㧙20 ᐕᐲ㧧1,417,500 ౞㧦ࠪࠚ࡝ࡦࠣࡊ࡜࠙(ᩣ)
6㧕 ศ᧛⚩৻㧦⣖േ⣂≜↪ࠬ࠹ࡦ࠻ߩ㐿⊒㧧ᐔᚑ 18 ᐕᐲ㧧1,050 ජ౞㧦(ᩣ)ࠞࡀࠞ

㧙㧙7㧕 ጤ㑆 ੧㧦ࠣ࡞࠻ࡃᵈ(⯯ⴊᕈ⣖ⴊ▤㓚ኂᕆᕈᦼ)૶↪ᚑ❣⺞ᩏ㧧ᐔᚑ 17㧙19 ᐕᐲ㧧315 ජ౞(105㧦
210㧦0 ජ౞)㧦ਃ⪉࠙ࠚ࡞ࡈࠔ࡯ࡑ(ᩣ)
8㧕 ጤ㑆 ੧㧦ࠟࡃࡍࡦ㍤૶↪ᚑ❣⺞ᩏ㧧ᐔᚑ 19㧙21 ᐕᐲ㧧210 ජ౞(210㧦0㧦0 ජ౞)㧦ࡈࠔࠗࠩ࡯⵾⮎(ᩣ)
9㧕 ጤ㑆 ੧㧦㗪േ⣂↪ࡊ࡝ࠨࠗࠬ࡮ࠕࡦࠫࠝࠟ࡯࠼ XP ૶↪ᚑ❣⺞ᩏ㧧ᐔᚑ 20㧙22 ᐕᐲ㧧420 ජ౞㧦࡚ࠫࡦ࠰ࡦ࡮ࠛࡦ࠼࡮࡚ࠫࡦ࠰ࡦ(ᩣ)
10㧕 ศ᧛⚩৻㧦㗪േ⣂ࠬ࠹ࡦ࠻⇐⟎ⴚᓟߩⴊ▤ࠗࡌࡦ࠻ߩ⊒∝ߦ㑐ߔࠆ೨ะ߈ⷰኤ⎇ⓥ(IDEALCAST)㧧
ᐔᚑ 20㧙22 ᐕᐲ㧧726,900 ౞㧦⽷࿅ᴺੱవ┵ක≮ᝄ⥝⽷࿅
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫ
1㧕 ⮮↰ᐢᔒ㧘ౝጊ⦟৻㧘ጤ㑆 ੧㧘቟⮮ᒄ㆏㧦ක↪↹௝ಣℂⵝ⟎෸߮↹௝ಣℂᣇᴺ㧘PCT ಴㗿㧘
PCT/JP2006/316595(․⸵)㧧ᐔᚑ 18 ᐕᐲ
2㧕 ⮮↰ᐢᔒ㧘ౝጊ⦟৻㧘ጤ㑆 ੧㧘቟⮮ᒄ㆏㧘ੑ᧛ ੳ㧦ක↪↹௝ಣℂⵝ⟎㧧ᐔᚑ 18 ᐕᐲ(․㗿
2007-533204)
6㧚ቇળᵴേ
1㧕ቇળᓎຬ
ጤ㑆 ੧㧦
1㧕 ␠࿅ᴺੱᣣᧄ⣖␹⚻ᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ⣖තਛቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ␠࿅ᴺੱᣣᧄ⣖␹⚻ᄖ⑼ቇળઍ⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄ⣖තਛߩᄖ⑼ቇળㆇ༡ᆔຬ(㨪⃻࿷)5㧕 ␠࿅ᴺੱᣣᧄ⣖␹⚻ᄖ⑼ቇળਛㇱᡰㇱℂ੐(㨪⃻࿷)6㧕 ᣣᧄዊఽ␹⚻ᄖ⑼ቇળ਎⹤ੱ(㨪⃻࿷)7㧕 ᣣᧄ⣖⣲≌ߩᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)8㧕 ᣣᧄ⣖࠼࠶ࠢቇળ⹏⼏ຬ(㨪⃻࿷)9㧕 ᣣᧄ⣖␹⚻ᄖ⑼ࠦࡦࠣ࡟ࠬㆇ༡ᆔຬ(ᐔᚑ 18 ᐕ 5 ᦬㨪⃻࿷)ศ᧛⚩৻㧦
1㧕 ᣣᧄ⣖␹⚻ⴊ▤ౝᴦ≮ቇળㆇ༡ᆔຬ(㨪⃻࿷)2㧕 ␠࿅ᴺੱᣣᧄ⣖␹⚻ᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)⍫㊁ᄢੳ㧦1㧕 ␠࿅ᴺੱᣣᧄ⣖␹⚻ᄖ⑼ቇળ⹏⼏ຬ(ᐔᚑ 19 ᐕ 9 ᦬㨪⃻࿷)2㧕ቇળ㐿௅
1㧕 ጤ㑆 ੧㧦ᣣᧄ⣖␹⚻ᄖ⑼ቇળਛㇱᡰㇱቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 4 ᦬)
3㧕ቇⴚ㔀⹹
ጤ㑆 ੧㧦
1㧕 ⣖␹⚻ᄖ⑼㧧✬㓸หੱ(㨪⃻࿷)2㧕 ⣖␹⚻ᄖ⑼ࠫࡖ࡯࠽࡞㧧✬㓸ᆔຬ(ᐔᚑ 18 ᐕ 5 ᦬㨪⃻࿷)3㧕 Neurologia medico-chirurgica㧧Review Board(ᐔᚑ 18 ᐕ 5 ᦬㨪⃻࿷)4㧕 ⣖ߣᓴⅣ㧧✬㓸ࠕ࠼ࡃࠗࠩ࡯(ᐔᚑ 19 ᐕ 1 ᦬㨪⃻࿷)ศ᧛⚩৻㧦
1㧕 Neurotrauma Research㧧Editional Board(㨪⃻࿷)2㧕 Journal of Neuroendovascular Therapy㧧✬㓸ᆔຬ(ᐔᚑ 19 ᐕ 4 ᦬㨪⃻࿷)3㧕 Neurologia medico-chirurgica㧧Review Board(ᐔᚑ 19 ᐕ 11 ᦬㨪⃻࿷)㧙㧙

7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ጤ㑆 ੧㧦
1㧕 The 4th International Mt. BANDAI Symposium for Neuroscience&The 5th Pan-Pacific
Neurosurgery Congress (2006.01, Hawaii, Ischemia and Cerebrovascular surgery-2. joint
Neurosurgical Convention 2006; ᐳ㐳)2㧕 ╙ 26 ࿁ᣣᧄ⣖␹⚻ᄖ⑼ࠦࡦࠣ࡟ࠬ✚ળ(ᐔᚑ 18 ᐕ 5 ᦬㧘᧲੩㧘ࡕ࡯࠾ࡦࠣ࠮ࡒ࠽࡯‫ޟ‬STA-MCA
bypass.ⴊⴕౣᑪⴚߩၮᧄᚻᛛ‫ޠ‬Ṷ⠪)3㧕 3th European-Japanese Joint Conference for Stroke Surgery and Satellite Symposium on
Moyamoya Angiopathy (2006.07, Zurich, Moyamoya symposium; ᐳ㐳)4㧕 3th European-Japanese Joint Conference for Stroke Surgery and Satellite Symposium on
Moyamoya Angiopathy (2006.07, Zurich, Moyamoya disease: Present status in Japan; ࠪࡦࡐࠫࠬ࠻)5㧕 The 8th Korean and Japanese Friendship Conference on Surgery for Cerebral Stroke(2006.08,
Sendai, EC-IC bypass; ᐳ㐳)
6㧕 ╙ 27 ࿁ᣣᧄ⣖␹⚻ᄖ⑼ࠦࡦࠣ࡟ࠬ✚ળࡂࡦ࠭ࠝࡦࠦ࡯ࠬ(ᐔᚑ 19 ᐕ 5 ᦬㧘઄บ㧘ࡒ࠾࡟ࠢ࠴ࡖ࡯‫ޟ‬⣖ⴊⴕౣᑪߩ᭎ᔨ㧙ⴊ▤่ว‫ޠ‬Ṷ⠪)7㧕 ╙ 27 ࿁ ᣣ ᧄ ⣖ ␹ ⚻ ᄖ ⑼ ࠦ ࡦ ࠣ ࡟ ࠬ ✚ ળ ( ᐔ ᚑ 19 ᐕ 5 ᦬ 㧘 ઄ บ 㧘 ࡕ ࡯ ࠾ ࡦ ࠣ ࠮ ࡒ ࠽ ࡯‫ޟ‬Interhemispheric approach ߩ㐳ᚲߣ⍴ᚲ㧙೨੤ㅢേ⣂≜ߩၮᧄ‫ޠ‬Ṷ⠪)8㧕 ╙ 35 ࿁ᣣᧄዊఽ␹⚻ᄖ⑼ቇળ(ᐔᚑ 19 ᐕ 5 ᦬㧘ᧁᦝᵤ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ੑಽ⣄ᬁ㧧ᚑ㐳, ⊒㆐ߦ઻߁໧㗴ߣߘߩኻ╷‫ޠ‬ᐳ㐳)
9㧕 Congress of Neurological Surgeons 2007 Annual Meeting(ᐔᚑ 19 ᐕ 9 ᦬, San Diego, Luncheon
Seminar‫ޟ‬Cerebral ischemic disease: current management strategies‫ޠ‬Ṷ⠪)10㧕 ╙ 66 ࿁␠࿅ᴺੱᣣᧄᣣᧄ⣖␹⚻ᄖ⑼ቇળ✚ળ(ᐔᚑ 19 ᐕ 10 ᦬㧘᧲੩㧘ᢎ⢒࠮ࡒ࠽࡯‫ޟ‬㐽Ⴇᕈ⣖ⴊ▤㓚ኂߩ⸻ᢿ࡮ᴦ≮㧦EC-IC ࡃࠗࡄࠬⴚߩၮᧄᚻᛛ‫ޠ‬Ṷ⠪)11㧕 ╙ 66 ࿁␠࿅ᴺੱᣣᧄᣣᧄ⣖␹⚻ᄖ⑼ቇળ✚ળ(ᐔᚑ 19 ᐕ 10 ᦬㧘᧲੩㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯‫ޟ‬⣖ⴊ▤㓚ኂߩᴦ≮ᚢ⇛㧦⎕ⵚ⣖േ⣂≜ߦኻߔࠆᴦ≮ᚢ⇛‫ޠ‬Ṷ⠪)12㧕 ╙ 6 ࿁ᣣᧄᢇᕆකቇળਛㇱ࿾ᣇળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ጘ㒂㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯‫ޟ‬⣖තਛߩᕆᕈᦼᴦ
≮‫ޠ‬Ṷ⠪)
13㧕 The 12th Asian Australasian Congress of Neurosurgical Societies/World Federation of
Neurosurgical Societies, 13th Interim Meeting(ᐔᚑ 19 ᐕ 11 ᦬, Nagoya, Luncheon Seminar‫ޟ‬Endarterectomy: indication, technique, complication.‫ޠ‬Ṷ⠪)
14㧕 The 12th Asian Australasian Congress of Neurosurgical Societies/World Federation of
Neurosurgical Societies, 13th Interim Meeting(ᐔᚑ 19 ᐕ 11 ᦬, Nagoya, Evening Video Seminar‫ޟ‬Management of Low Grade Gliomas: Current Strategies and Dilemmas.‫ޠ‬ᐳ㐳)15㧕 Memorial International Neuro-Oncology Forum in Nagoya 2007(ᐔᚑ 19 ᐕ 11 ᦬, Nagoya, ᐳ㐳)
16㧕 ╙ 40 ࿁ਛㇱ⣄㜑ᄖ⑼ࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 20 ᐕ 3 ᦬㧘ฬฎደ㧘․೎⻠Ṷ‫ޟ‬⣄㜑ᄖ⑼ߦ߅ߌࠆⴚਛࡕ
࠾࠲࡝ࡦࠣ ၮ␆ߣ⥃ᐥ‫ޠ‬ᐳ㐳)17㧕 ╙ 28 ࿁ᣣᧄ⣖␹⚻ᄖ⑼ࠦࡦࠣ࡟ࠬ✚ળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ᮮᵿ㧘ࡊ࡟࠽࡝࡯࠮࠶࡚ࠪࡦ‫ోޟ‬り⣂▤∛ߣߒߡߩ⣖තਛ‫ޠ‬ᐳ㐳)18㧕 ╙ 36 ࿁ᣣᧄዊఽ␹⚻ᄖ⑼ቇળ(ᐔᚑ 20 ᐕ 5 ᦬㧘᧲੩㧘‫▤ⴊޟ‬㓚ኂ‫ޠ‬ᐳ㐳)19㧕 ╙ 13 ࿁ᣣᧄ⣖⣲≌ߩᄖ⑼ቇળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ᄢ㒋㧘ࠪࡦࡐࠫ࠙ࡓ 6‫ޟ‬Tentorial Meningioma ߩᴦ≮ᚢ⇛‫ޠ‬ᐳ㐳)ศ᧛⚩৻㧦
1㧕 ╙ 35 ࿁ᣣᧄ⣖තਛߩᄖ⑼ቇળ(ᐔᚑ 18 ᐕ 3 ᦬㧘ᮮᵿ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᕆᕈᦼ⎕ⵚ⣖േ⣂≜ߩᴦ≮ㆬᛯߩ⃻⁁‫ޠ‬Ṷ⠪)2㧕 Complex Catheter Therapeutics(CCT2006)(ᐔᚑ 18 ᐕ 9 ᦬㧘␹ᚭ㧘᜗ᓙ⻠Ṷ‫ޟ‬CAS ᓟ Hyperperfusion㧦ߘߩ੍⍮ߣኻ╷‫ޠ‬Ṷ⠪)3㧕 Complex Catheter Therapeutics (CCT2006)(ᐔᚑ 18 ᐕ 9 ᦬㧘␹ᚭ㧘᜗ᓙ⻠Ṷ‫ޟ‬Proximal protection in
the CAS Parodi ᴺ㧦ㆡᔕߣ೑ὐ࡮ᰳὐ‫ޠ‬Ṷ⠪)
4㧕 ╙ 9 ࿁ᣣᧄᩖሶᬌ಴ߣᴦ≮ቇળ(ࠛࡦࡏ࡜ࠬቇળ)(ᐔᚑ 18 ᐕ 11 ᦬㧘੩ㇺ㧘ࠪࡦࡐࠫ࠙ࡓ‫ⴚޟ‬೨ࡊ࡜࡯ࠢ⸻ᢿߣႧᩖᕈว૬∝‫ޠ‬Ṷ⠪)5㧕 The 4th international Intracranial Stent Meeting(ᐔᚑ 19 ᐕ 4 ᦬㧘Kyoto㧘ᐳ㐳)㧙㧙6㧕 ╙ 66 ࿁␠࿅ᴺੱᣣᧄᣣᧄ⣖␹⚻ᄖ⑼ቇળ✚ળ(ᐔᚑ 19 ᐕ 10 ᦬㧘᧲੩㧘ࠗࡉࠗࡦࠣ࠮ࡒ࠽࡯‫ⴚޟ‬⠪ᢎ⢒ߩࠦ࠷ߣ㔍ߒߐ‫ޠ‬Ṷ⠪)7㧕 ╙ 23 ࿁ᣣᧄ⣖␹⚻ⴊ▤ౝᴦ≮ቇળ✚ળ(ᐔᚑ 19 ᐕ 11 ᦬㧘␹ᚭ㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯‫ޟ‬㗪േ⣂⁜⓰∝ᴦ≮ߩᦨ೨✢㧦ว૬∝࠯ࡠࠍ⋡ᜰߒߚ CAS ߣ best medical treatment‫ޠ‬Ṷ⠪)8㧕 ╙ 23 ࿁ᣣᧄ⣖␹⚻ⴊ▤ౝᴦ≮ቇળ✚ળ(ᐔᚑ 19 ᐕ 11 ᦬㧘␹ᚭ㧘ࠪࡦࡐࠫ࠙ࡓ 4‫ޟ‬CAS ᤨઍࠍㄫ߃
ߚ㗪േ⣂⁜⓰⸽ߩᴦ≮ᚢ⇛㧙ࠃࠅ቟ోߥⴊⴕౣᑪࠍ⋡ᜰߒߡ‫ޠ‬ᐳ㐳)9㧕 The 12th Asian Australasian Congress of Neurosurgical Societies/World Federation of
Neurosurgical Societies, 13th Interim Meeting(ᐔᚑ 19 ᐕ 11 ᦬, Nagoya, Luncheon Seminar‫ ޟ‬Management of Unruptured Intracranial Aneurysms: Understanding and Developing
Treatment Options/ Clipping, coiling, and their combinations for unruptured intracranial
aneurysms ‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ1㧕 ᭑ᧄ↱⾆ሶ㧦╙ 5 ࿁ᣣᧄ㗖ㇱ⣖ⴊ▤ᴦ≮ቇળఝ⑲ࡐࠬ࠲࡯⾨(ᐔᚑ 18 ᐕᐲ)
2㧕 ጊ↰ᷡᢥ㧦╙ 71 ࿁ᣣᧄ⣖␹⚻ᄖ⑼ቇળਛㇱᡰㇱળఝ⑲⺰ᢥ⾨(ᐔᚑ 18 ᐕᐲ)
9㧚␠ળᵴേ
ጤ㑆 ੧㧦
1㧕 ጘ㒂ഭ௛ዪ࿾ᣇഭἴකຬ(㨪⃻࿷)2㧕 ጘ㒂⋵කᏧળᄖ⑼කㇱળ㘈໧(㨪⃻࿷)3㧕 ጘ㒂⋵කᏧળഭἴᜰቯකㇱળ㘈໧(㨪⃻࿷)4㧕 ጘ㒂⋵ᚑੱ∛ᬌ⸻▤ℂᜰዉද⼏ળᓴⅣེ∔ᖚ╬ᆔຬળᆔຬ(㨪⃻࿷)5㧕 ጘ㒂࿾ᣇⵙ್ᚲᚲዻኾ㐷ᆔຬ(㨪⃻࿷)6㧕 ਛㇱ≮⼔࠮ࡦ࠲࡯౉㒮ክᩏᆔຬળᆔຬ㐳(㨪⃻࿷)7㧕 ⁛┙ⴕ᡽ᴺੱ⥄േゞ੐᡿ኻ╷ᯏ᭴㊀ᐲᓟㆮ㓚ኂ⹺ቯክᩏᆔຬળ࿾ᣇᆔຬ(㨪ᐔᚑ 19 ᐕ 3 ᦬)
8㧕 ␠࿅ᴺੱᣣᧄ⣖තਛදળጘ㒂⋵ᡰㇱᡰㇱ㐳(㨪⃻࿷)9㧕 ጘ㒂ᄢቇකቇㇱห⓹ળℂ੐(ળ⸘)(ᐔᚑ 18 ᐕ 5 ᦬㨪ᐔᚑ 20 ᐕ 5 ᦬)
10㧕 ጘ㒂⋵┙∛㒮ක≮੐᡿ክᩏᆔຬળᆔຬ(㨪⃻࿷)11㧕 ⑺↰⋵┙⣖ⴊ▤⎇ⓥ࠮ࡦ࠲࡯⎇ⓥᄖㇱ⹏ଔᆔຬ(㨪⃻࿷)ศ᧛⚩৻㧦1㧕 ␠࿅ᴺੱᣣᧄ⣖තਛදળጘ㒂⋵ᡰㇱ೽ᡰㇱ㐳(㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ศ᧛⚩৻㧦㗡ㇱᄖ்‫ޔ‬⣖⯯ⴊᓟߩ neurogenesis ೙ᓮᯏ᭴ߩ⸃ᨆ㧦␹⚻ᩕ㙃࿃ሶߣߩ㑐ㅪ㧦ᐔᚑ 16ᐕᐲ㧙ᐔᚑ 18 ᐕᐲᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(B)(2)⎇ⓥᚑᨐႎ๔ᦠ(2007 ᐕ 3 ᦬)
11㧚ႎ㆏1㧕 ೽↰᣿↵㧦‫ࠎ߇ޟ‬ᐙ⚦⢩‫⎇ޠ‬ⓥᵴ⊒ߦ㧦ᣣᧄ⚻ᷣᣂ⡞(2006 ᐕ 9 ᦬ 18 ᣣ)
2㧕 ೽↰᣿↵㧦߇ࠎߦૃߖߚ⚵❱߇ࠎᐙ⚦⢩߆ࠄ૞⵾㧦ᣣ⚻↥ᬺᣂ⡞(2006 ᐕ 9 ᦬ 22 ᣣ)
3㧕 ೽↰᣿↵㧦21 ਎♿ߩ᳇㍈ ᚻⴚቶߣ⎇ⓥቶᯅᷰߒ㧦ᣣ⚻↥ᬺᣂ⡞(2006 ᐕ 11 ᦬ 30 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔᕆᕈᦼ⣖⯯ⴊߦኻߔࠆฦ⒳⮎೷ߥࠄ߮ߦ⢽⢌⚵❱↱᧪ᐙ⚦⢩ᛩਈߦ߅ߌࠆ⣖଻⼔ലᨐߦ㑐ߒߡᣂߚߥ
⍮⷗߇ᓧࠄࠇ㧘੹ᓟߐࠄߥࠆ⊒ዷߣ⥃ᐥ߳ߩᔕ↪߇ᦼᓙߐࠇࠆ‫ⴊޕ‬ዊ᧼᡼಴࿃ሶߣേ⣂⎬ൻߣߩ㑐ㅪ㧘ߥࠄ߮ߦฦ⒳᛫ⴊዊ᧼೷ߩᓇ㗀ߦ㑐ߔࠆ⎇ⓥߦ߅޿ߡ߽⥃ᐥᔕ↪ߦ⋥⚿ߔࠆᚑᨐ߇ᓧࠄࠇߡ޿ࠆ‫ޕ‬ᖡᕈ⣖⣲≌ߩౣ⊒ߣ᡼኿✢უᱫߩ㐓೎ߦ㑐ߔࠆ⥃ᐥ⎇ⓥߦ߅޿ߡᣂߚߥ⸻ᢿᴺ߇㐿⊒ߐࠇߟߟ޽ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ߘࠇߙࠇߩ࠹࡯ࡑߦ߅޿ߡᦝߥࠆ⎇ⓥߩዷ㐿߇ᦼᓙߐࠇࠆਛߢ㧘⃻࿷ߩᦨᄢߩ໧㗴ὐߪ⎇ⓥੱຬߩਇ⿷ߣ⎇ⓥ૕೙ߩ⏕┙ߦ޽ࠆ‫ޕ‬⎇ⓥੱຬߩჇടࠍ⍴ᦼ㑆ߦ㆐ᚑߔࠆ੐ߪ࿎㔍ߢ޽ࠆߚ߼㧘㐳ᦼ⊛ዷᦸߦ┙ߞߡ⎇ⓥ⠪ࠍ⢒ᚑߒߡ޿ߊ

㧙㧙ᔅⷐ߇޽ࠆ‫ߚ߹ޕ‬㧘⃻࿷ߘࠇߙࠇ⇣ߥߞߚၮ␆⻠ᐳߣߩ౒ห⎇ⓥ߇ਥ૕ߣߥߞߡ޿ࠆ߇㧘࠻࡜ࡦࠬ࡟࡯
࡚ࠪ࠽࡞࡝ࠨ࡯࠴ࠍߐࠄߦㅴ߼ࠆߚ߼ߦ߽㧘⣖␹⚻ᄖ⑼ߦᚲዻߔࠆ⥃ᐥක㧘ၮ␆⎇ⓥ⠪߇Ᏹߦ㗻ࠍวࠊߖߡ⎇ⓥߦ㑐ߔࠆ⸛⺰߇⥄ὼߦ↢߹ࠇࠆߎߣ߇ᄢಾߢ㧘⎇ⓥ᜚ὐࠍ⣖␹⚻ᄖ⑼ౝߦ⸳┙ߔߴߊᢛ஻ࠍㅴ
߼ߡ޿ࠆ‫ޕ‬੹ᓟߩዷᦸ⃻࿷ߥ߅ᴦ≮ᚑ❣߇ਇ⦟ߢ޽ࠆᖡᕈ⣖⣲≌ߣ㧘߹ߔ߹ߔߩჇട߇੍ᗐߐࠇࠆ⣖⯯ⴊߦኻߔࠆᣂߚߥᴦ
≮ᴺߩ㐿⊒ߪ㧘⣖␹⚻ᄖ⑼ቇ㗔ၞߦ߅޿ߡ੹ᓟ߽㊀ⷐߥ⺖㗴ߢ޽ࠆ‫ޕ‬ᖡᕈ⣖⣲≌ߩ⥃ᐥ⊛ᴦ≮ᚑ❣ߪ⛔ว⊛↹௝⸻ᢿߩᔕ↪ߢዋߒߕߟㅴᱠߒߡ޿ࠆ߇㧘ᦝߥࠆᴦ≮ലᨐࠍᓧࠆߚ߼ߦߪ఺∉≮ᴺ㧘⣖≌ᐙ⚦⢩ߩಽ㔌ࠍၮߦߒߚ࠹࡯࡜࡯ࡔ࡯࠼ᴦ≮ߥߤ߇ᔅⷐߢ޽ࠅ㧘ၮ␆⎇ⓥ
ߣߣ߽ߦ⥃ᐥᔕ↪ࠍ⋡ᜰߒߚ࠻࡜ࡦࠬ࡟࡯࡚ࠪ࠽࡞࡝ࠨ࡯࠴ࠍߐࠄߦㅴ߼ࠆᔅⷐ߇޽ࠆ‫ޕ‬⣖⯯ⴊߩᴦ≮ߦ㑐ߒߡߪ㧘ߎࠇ߹ߢߩ⯯ⴊߦኻߔࠆ⣖଻⼔ߣ޿߁ฃേ⊛ⷰὐ߆ࠄ㧘㓚ኂߐࠇߚᯏ⢻ࠍขࠅᚯߔߣ޿߁ౣ↢ක≮ߩዉ౉㧘ߐࠄߦߪ㧘⣖⯯ⴊߩේ࿃ߢ޽ࠆ⣖േ⣂⎬ൻࠍⓍᭂ⊛ߦᛥ೙ߔࠆߣ޿߁
ᚢ⇛ߩࠪࡈ࠻߇੍ᗐߐࠇࠆ‫ޕ‬⣖⯯ⴊ଻⼔ߦ㑐ߔࠆߎࠇ߹ߢߩ⎇ⓥᚑᨐߩ⥃ᐥᔕ↪ࠍㅴ߼ࠆߣหᤨߦ㧘␹⚻ౣ↢㧘⣖േ⣂⎬೙ᓮࠍ⋡ᜰߒߚၮ␆⊛㧘⥃ᐥ⊛⎇ⓥߦขࠅ⚵ࠎߢ޿߈ߚ޿‫ޕ‬㧙㧙㧔7㧕⡊㥦ຜ༄⑼ቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
1㧕߼߹޿࡮ᐔⴧ㓚ኂߦ㑐ߔࠆ߽ߩ߼߹޿࡮ᐔⴧ㓚ኂᖚ⠪ߦฦ⒳ᐔⴧᯏ⢻ᬌᩏࠍⴕ޿㧘∔ᖚߩ⚛࿃߿∛௝㧘߼߹޿ᐔⴧ㓚ኂߩ⥃ᐥ⊛∛ᘒࠍߣࠄ߃㧘ߘߩᚑᨐࠍᴦ≮ߦࡈࠖ࡯࠼ࡃ࠶ࠢߒߡ޿ࠆ‫ޕ‬㕒⊛ᐔⴧᯏ⢻ᬌᩏߩ৻ߟߢ޽ࠆ㊀ᔃേំᬌᩏߢߪᐔ
ⴧ㓚ኂߩ∛Ꮍ⸻ᢿ♖ᐲะ਄ߩߚ߼㧘ࡑࡂ࡜ࡁࡆࠬ࡮࠲ࠣ࠴ᴺ߿ᦨᄢ࡝ࠕࡊࡁࡈᜰᢙߦࠃࠆ⸃ᨆ⹏ଔࠍ⹜ߺ
ߡ޿ࠆ‫ޕ‬േ⊛ᐔⴧᯏ⢻ᬌᩏߩ⿷〯ߺᬌᩏߢߪ㧘ࡈࠜ࡯ࠬࡊ࡟࡯࠻ࠍዉ౉ߒ⿷ᐩ࿶ᄌൻߣ〯ߺᦧ߃࡝࠭ࡓߩ
⹏ଔࠍน⢻ߣߒߚ‫ޕ‬ᱠⴕ೙ᓮᯏ⢻⸃ᨆߦ߽ᔕ↪น⢻ߢ޽ࠆ‫ߚ߹ޕ‬㧘㔍ᴦߥᐔⴧ㓚ኂᖚ⠪ߦߪᐔⴧ⸠✵ࠍ࿖ౝߢߪ޿ߜᣧߊዉ౉ߒ㧘ߘߩ⥃ᐥ⊛࠺࡯࠲ࠍಽᨆ⹏ଔߒߥ߇ࠄ㧘᦭ലߥ⸠✵ᣇᴺ㧘⹏ଔᣇᴺࠍ⎇ⓥߒߡ޿ࠆ‫ޕ‬┙૏ᤨߩり૕േំࠍ᷹ቯߒ㧘ࡃࠗࠝࡔࠞ࠾ࠞ࡞ࡕ࠺࡞ࠍ᭴▽ߒ㧘り૕േំߩ␹⚻೙ᓮᯏ᭴ࠍ PID
㧔proportional integral derivative㧕೙ᓮᣇᑼࠍណ↪ߒߡᬌ⸽ߒߡ޿ࠆ‫ࠆࠃߦࠇߎޕ‬ฦ⒳ࡄ࡜ࡔ࡯࠲࡯ࠍ↪
޿ߡ∛Ꮍ⸻ᢿߦᔕ↪ߒߡ޿ࠆ‫ߚ߹ޕ‬㧘ᒰ⑼ߢⓍᭂ⊛ߦขࠅ౉ࠇߡ޿ࠆ̌߼߹޿࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦ̍ߩᴦ
≮ലᨐ್ቯߦ⥃ᐥᔕ↪ߒ㧘ߘߩ᦭↪ᕈࠍᬌ⸽ߒߡ޿ࠆ‫ޕ‬߹ߚ㧘ࡔ࠾ࠛ࡯࡞∛ߩ∛ᘒߢ޽ࠆౝ࡝ࡦࡄ᳓⣲ߦ㑐ㅪᕈ߇޽ࠆ᳓ઍ⻢♽ࡎ࡞ࡕࡦߩࡃ࠱ࡊ࡟࠶ࠪࡦߦߟ
޿ߡ⎇ⓥߒߡ޿ࠆ‫∝⊒ޕ‬࿃ሶߣߒߡߩᓎഀ߿㧘ࡔ࠾ࠛ࡯࡞∛ߩ⊒∝࿃ሶߥࠄ߮ߦ੍ᓟ࿃ሶߣߒߡߩᓎഀߦ
ߟ޿ߡ㧘⥃ᐥ߅ࠃ߮ၮ␆⎇ⓥࠍⴕߞߡ޿ࠆ‫ߡߒߣ࡯࠲࡯ࡔ࡜ࡄࠍࡦࠪ࠶࡟ࡊ࠱ࡃޕ‬㧘ౝ⡊࿶೙ᓮࠍ⋡⊛ߦߒߚ㥏⤑࠴ࡘ࡯ࡉ⇐⟎ⴚ߅ࠃ߮ਛ⡊ട࿶ᴦ≮ࠍⴕ޿㧘⦟ᅢߥ⚿ᨐࠍᓧߡ޿ࠆ‫ޕ‬⿠┙ᕈᓴⅣ⺞▵ߦߪ࿶ฃኈེ෻኿ߦࠃࠆࡀࠟ࠹ࠖࡉࡈࠖ࡯࠼ࡃ࠶ࠢᯏ᭴߇㊀ⷐߢ޽ࠆ߇㧘೨ᐸེߦࠃࠆ
ࡈࠖ࡯࠼ࡈࠜࡢ࡯࠼♽೙ᓮߢ޽ࠆ೨ᐸ੤ᗵ␹⚻෻኿߇㑐ਈߒߡ޿ࠆߎߣࠍႎ๔ߒߚ‫ߚ߹ޕ‬㧘߼߹޿∝଀߇ߒ߫ߒ߫⸷߃ࠆ⿠┙ᕈ⺞▵㓚ኂߦ߅ߌࠆ೨ᐸ੤ᗵ␹⚻෻኿ߩ㑐ਈࠍᬌ⸽ߔࠆߣ߽ߦ㧘೨ᐸ㔚᳇ೝỗߦࠃࠆ߼߹޿ᴦ≮ߩ⥃ᐥᔕ↪ࠍᬌ⸛ߒߡ޿ࠆ‫ޕ‬⠧ൻଦㅴࡑ࠙ࠬࠍ↪޿㧘⠧ੱᕈ㔍⡬ߥࠄ߮ߦ⠧ൻߦߣ߽ߥ߁ᐔⴧ㓚ኂߩ⊒↢ᯏᐨߥࠄ߮ߦ⊒↢੍㒐ߦߟ޿ߡౝಽᴲࡎ࡞ࡕࡦߥߤߩⷰὐ߆ࠄᬌ⸛ߒߡ޿ࠆ‫ޕ‬߼߹޿࡮ᐔⴧකቇߩലᨐ⊛ߥත೨ᢎ⢒ࠍ࠴ࡘ࠻࡯࡝ࠕ࡞ࠦ࡯ࠬߣ⥃ᐥታ⠌ߦ߅޿ߡታ⃻ߔࠆᣇᴺࠍ⎇ⓥߒߡ޿ࠆ‫ޕ‬2㧕㗡㗪ㇱ⣲≌ߦ㑐ߔࠆ߽ߩ㗡㗪ㇱ≸ߦኻߔࠆൻቇ᡼኿✢ᴦ≮ߩ᦭ലᕈ㧘቟ోᕈߦ㑐ߒߡ㧘ߥࠄ߮ߦᯏ⢻᷷ሽߦ㑐ߒߡ㧘⥃ᐥᬌ⸛ࠍⴕߞߡ޿ࠆ‫ޕ‬㗡㗪ㇱ≸ᚻⴚⴚᓟߩᖚ⠪ߩ QOL ૐਅߩ㒐ᱛߦ㑐ߒߡ㧘ౣᑪⴚᑼߩ⥃ᐥ⊛ᬌ⸛ࠍⴕߞߡ޿ࠆ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
ಎᢎ᝼㧦
⻠Ꮷ㧦
⻠Ꮷ㧦
⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦

દ⮮౎ᰴ
᳓↰໪੺
㕍ᧁశᐢ
ਭ਎ᢥ਽
ട⮮ਭ๺
ጊ↰ධᤊ
಴ේ໪৻
㕍ᧁ㚅❱
⷏ၳਂ⚐
ᨋ ኼశ
ᵻ੗㓷ᐘ
ဈ੗↰⼑
ട⮮ผ㐷

Yatsuji Ito
Keisuke Mizuta
Mitsuhiro Aoki
Bunya Kuze
Hisakazu Kato
Nansei Yamada
Keiichi Izuhara
Kaori Aoki
Takesumi Nishihori
Hisamitsu Hayashi
Masayuki Asai
Yuzuru Sakaida
Shimon Kato

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ᳓↰໪੺㧚೽㥦⣧๟ㄝ⣲≌(⠢ญ⬄┃࡮஥㗡ਅ┃⣲≌)߳ߩࠕࡊࡠ࡯࠴㧦␹ፒੳ✬㧚⡊㥦ຜ༄⑼࡮㗡㗪ㇱᄖ⑼⸻≮ߩࠦ࠷ߣ⪭ߣߒⓣ 2 㥦࡮೽㥦⣧∔ᖚ㧘᧲੩㧦ਛጊᦠᐫ㧧2006 ᐕ㧦152㧙153㧚
2㧕 ᳓↰໪੺㧘᧛੗㆏ౖ㧚ᶐẢဳ೽㥦⣧⌀⩶∝ߩᴦ≮㧦␹ፒੳ✬㧚⡊㥦ຜ༄⑼࡮㗡㗪ㇱᄖ⑼⸻≮ߩࠦ࠷ߣ⪭ߣ
ߒⓣ 2 㥦࡮೽㥦⣧∔ᖚ㧘᧲੩㧦ਛጊᦠᐫ㧧2006 ᐕ㧦88㧙89㧚
3㧕 દ⮮౎ᰴ㧚ᬁ㛽⣖ᐩേ⣂ᓴⅣਇో㧦᫪ጊኡ㧘ጯᧄ⺈ม㧘ዊᨋବశ㧘Ꮉౝ⑲ਯ✬㧚੹ᣣߩ⡊㥦ຜ༄⑼࡮㗡㗪ㇱᄖ⑼ᴦ≮ᜰ㊎ ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦185㧚㧙㧙⪺ᦠ㧔᰷ᢥ㧕ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 દ⮮౎ᰴ㧚㜞㦂⠪ߩ߼߹޿㧘ᣣᧄ⡊㥦ຜ༄⑼ቇળኾ㐷කㅢା 2006 ᐕ㧧86 Ꮞ㧦6㧙7㧚
2㧕 દ⮮౎ᰴ㧚MLF syndrome㧘⡊㥦ຜ༄⑼࡮㗡㗪ㇱᄖ⑼ 2006 ᐕ㧧78 Ꮞ㧦186㧚
3㧕 દ⮮౎ᰴ㧚Moebius syndrome㧘⡊㥦ຜ༄⑼࡮㗡㗪ㇱᄖ⑼ 2006 ᐕ㧧78 Ꮞ㧦187㧚
4㧕 ᳓↰໪੺㧚߼߹޿ᄖ᧪ߦභ߼ࠆ BPPV ߩታᘒ㧘ENTONI 2006 ᐕ㧧60 Ꮞ㧦1㧙6㧚
5㧕 ᳓↰໪੺㧚ᓟඨⷙ▤ဳ BPPV ߩ⸻ᢿߣᴦ≮̆㗡૏ᕈ߼߹޿ࠍ߼ߋߞߡ㧘JOHNS 2006 ᐕ㧧22 Ꮞ㧦167㧙
171㧚
6㧕 દ⮮౎ᰴ㧚ᕆᕈ߼߹޿ߣᘟᕈ߼߹޿㧙⸻ᢿ࡮ᴦ≮ߩᏅ㧙 ✬㓸ડ↹㧘ENTONI 2007 ᐕ㧧75 Ꮞ㧦1㧚
7㧕 દ⮮౎ᰴ㧚ട㦂ߦࠃࠆᄌൻߣߘߩࠕࡦ࠴ࠛࠗࠫࡦࠣ ᐔⴧⷡ㧘JOHNS 2007 ᐕ㧧23 Ꮞ㧦1551㧙1553㧚
8㧕 ᳓↰໪੺㧚ౝ࡝ࡦࡄ᳓⣲ࠍ߈ߚߔ∔ᖚ㧘ENTONI 2007 ᐕ㧧81 Ꮞ㧦67㧙72㧚
9㧕 ᳓↰໪੺㧚߼߹޿㧘⡊㥦ຜ༄⑼ߦ߅ߌࠆዊఽ߳ߩᛩ⮎㧘ENTONI 2007 ᐕ㧧79 Ꮞ㧦39㧙44㧚
10㧕 㕍ᧁశᐢ㧚߼߹޿࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦߣ EBM ⹏ଔ ᕆᕈ߼߹޿ߣᘟᕈ߼߹޿㧙⸻ᢿ࡮ᴦ≮ߩᏅ㧙㧘
ENTONI 2007 ᐕ㧧75 Ꮞ㧦45㧙49㧚
11㧕 દ⮮౎ᰴ㧚㊀ᔃേំᬌᩏ㧘⥃ᐥᬌᩏ 2008 ᐕ㧧52 Ꮞ㧦1465㧙1470㧚
✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ᳓↰໪੺㧘቟⮮ஜ৻㧘ਭ਎ᢥ਽㧘᧛੗㆏ౖ㧘ᮮ↰㓁৻㧘ጊ↰ධᤊ㧘㕍ᧁశᐢ㧘દ⮮౎ᰴ㧚߼߹޿ᖚ⠪ߩᄢ⣖ MRI ⊹⾰ਅ⊕⾰ᄌൻߩᬌ⸛㧘Equilibrium Res 2006 ᐕ㧧65 Ꮞ㧦181㧙185㧚
2㧕 ᳓↰໪੺㧘ᤨ↰ ༜㧘ਭ਎ᢥ਽㧘᧛੗㆏ౖ㧘ᮮ↰㓁৻㧘ጊ↰ධᤊ㧘㕍ᧁశᐢ㧘દ⮮౎ᰴ㧚㜞㦂߼߹޿ᖚ⠪ߦ߅ߌࠆᄢ⣖ MRI ⊹⾰ਅ⊕⾰ᄌൻߣ㊀ᔃേំ㧘Equilibrium Res 2006 ᐕ㧧65 Ꮞ㧦186㧙190㧚
3㧕 ᳓↰໪੺㧘⮮၂ ᾊ㧘ᄢ੗⋉৻㧘᦯ㇱᓀ᮸㧘᫜ᯅ⡨ሶ㧘⷏ၳਂ⚐㧘↰ਛ㓶৻㧘ᮮ↰ ᣿㧘ᩊ↰ᐽᚑ㧘ᷰㄝᔘᒾ㧘દ⮮౎ᰴ㧘┻ౝ⑲ⴕ㧘ጊፒ ᄥ㧘ዊᧁᦥᱜノ㧘㜞ᯅᐢᔒ㧘ർ᧛ᵏብ㧚ጘ㒂⋵ߦ߅ߌࠆ 2005 ᐕߩࠬࠡ⧎☳㘧ᢔ⁁ᴫߣ 2006 ᐕߩࠬࠡ⧎☳㘧ᢔ੍ᗐ㧘᧲ᶏ⧎☳∝ 2006 ᐕ㧧17 Ꮞ㧦24㧙27㧚
4㧕 㕍ᧁశᐢ㧚ࡔ࠾ࠛ࡯࡞∛ᴦ≮ߦ߅ߌࠆ᦯⮎ࠦࡦࡊ࡜ࠗࠕࡦࠬߩᡷༀ㧘ࡔ࠺ࠖࠞ࡞࠻࡝ࡆࡘ࡯ࡦ 2006 ᐕ㧧
39 Ꮞ㧦29㧚5㧕 㕍ᧁశᐢ㧘ᮮ↰㓁৻㧘቟⮮ஜ৻㧘ᵻ੗㓷ᐘ㧘᳓↰໪੺㧘દ⮮౎ᰴ㧚㜞቟േ⣂Ἳ∝଀ߦኻߔࠆੱᎿౝ⡊ᚻⴚ㧘⡊㥦⥃ᐥ 2006 ᐕ㧧99 Ꮞ㧦275㧙278㧚
6㧕 㕍ᧁశᐢ㧚ࡅ࠻ߢߩ㊀ജฃኈེ♽੤ᗵ␹⚻෻኿ߩᬌ⸛㧘ቝቮ⥶ⓨⅣႺකቇ 2006 ᐕ㧧43 Ꮞ㧦205㧚
7㧕 ਭ਎ᢥ਽㧘ᮮ↰㓁৻㧘ᵻ੗㓷ᐘ㧚ᒰ⑼ߦ߅ߌࠆ㥏⤑࡮㥏ቶᒻᚑⴚߩⴚᓟᚑ❣㧘㜞ጊ⿒චሼ∛㒮♿ⷐ 2006
ᐕ㧧30 Ꮞ㧦13㧙17㧚
8㧕 ᤨ↰ ༜㧘દ⮮౎ᰴ㧘᳓↰໪੺㧚⋥┙೙ᓮ♽ߩ⸃ᨆ㧙ⶄ㔀♽ߩⷰὐࠃࠅ㧙㧘Equilibrium Res 2007 ᐕ㧧
66 Ꮞ㧦17㧙25㧚
9㧕 ᳓↰໪੺㧚ዊఽ߼߹޿ߩขࠅᛒ޿㧘⡊㥦⥃ᐥ 2007 ᐕ㧧100 Ꮞ㧦506㧙507㧚
10㧕 ᳓↰໪੺㧘ᤨ↰ ༜㧘᫪ ⧐㇢㧘⷏ၳਂ⚐㧘቟⮮ஜ৻㧘ਭ਎ᢥ਽㧘᧛੗㆏ౖ㧘ᮮ↰㓁৻㧘㕍ᧁశᐢ㧘દ⮮౎ᰴ㧚ੱ㑆࠼࠶ࠢஜ⸻⠪ߦ߅ߌࠆᄢ⣖ MRI ⊹⾰ਅ⊕⾰ᄌൻߣ㊀ᔃേំᚑ❣㧘Equilibrium Res 2007 ᐕ㧧
66 Ꮞ㧦110㧙115㧚
11㧕 ᳓↰໪੺㧘⮮၂ ᾊ㧘ᄢ੗⋉৻㧘᦯ㇱᓀ᮸㧘᫜ᯅ⡨ሶ㧘⷏ၳਂ⚐㧘ᮮጊᄈ৻㧘↰ਛ㓶৻㧘ᮮ↰ ᣿㧘ᩊ↰ᐽᚑ㧘ᷰㄝᔘᒾ㧘દ⮮౎ᰴ㧘ጊፒ ᄥ㧘↰ਛቁᴦ㧘ዊᧁᦥᱜノ㧘㜞ᯅᐢᔒ㧘ർ᧛ᵏብ㧚ጘ㒂⋵ߦ߅ߌࠆ 2006ᐕߩࠬࠡ⧎☳㘧ᢔ⁁ᴫߣ 2007 ᐕߩࠬࠡ⧎☳㘧ᢔ੍ᗐ㧘᧲ᶏ⧎☳∝ 2007 ᐕ㧧18 Ꮞ㧦21㧙24㧚
12㧕 㕍ᧁశᐢ㧘቟⮮ஜ৻㧘ጊ↰ධᤊ㧘᧛੗㆏ౖ㧘㕍ᧁ⻞ᄥ㧘᳓↰໪੺㧘દ⮮౎ᰴ㧚ⲕ‐⡊⎬ൻ∝ߦኻߔࠆੱᎿ
ౝ⡊ߩ໧㗴㧘ᣣᧄ⡊㥦ຜ༄⑼ቇળળႎ 2007 ᐕ㧧110 Ꮞ㧦752㧙757㧚
13㧕 ጊ↰ධᤊ㧘દ⮮౎ᰴ㧚వᄤᕈ㗻㕙␹⚻㤗∽ߩ 2 ∝଀㧘FACIAL NERVE RESEARCH JAPAN 2007 ᐕ㧧
27 Ꮞ㧦225㧙228㧚
14㧕 ട⮮ඳၮ㧘ᤊ ඳᤘ㧘ጊ↰ධᤊ㧘㕍ᧁ⻞ᄥ㧘᳓↰໪੺㧘દ⮮౎ᰴ㧘᧻᳗⎇๋㧘ᑝἑༀା㧚৻஥⡊ਅ⣼ߦ⊒↢ߒߚᄙ⊒⡊ਅ⣼ౝ␹⚻㕽⣲ߩ 1 ଀㧘⥃ᐥ᡼኿✢ 2007 ᐕ㧧52 Ꮞ㧦312㧙317㧚
15㧕 ㊁‫↰ޘ‬ጪᄦ㧘಴ේ໪৻㧘ᄢᯅᢅల㧘ᄢ⷏዁⟤㧘ጊ↰ධᤊ㧚ᕆᕈߦ⊒∝ߒߚ≚∥ᕈ㘃ᄤ∊≙଀㧘⡊㥦⥃ᐥ 2007
ᐕ㧧100 Ꮞ㧦579㧙585㧚
16㧕 ᳓↰໪੺㧘⮮၂ ᾊ㧘ᄢ੗⋉৻㧘᦯ㇱᓀ᮸㧘᫜ᯅ⡨ሶ㧘ട⮮ᵗᴦ㧘↰ਛ㓶৻㧘ᮮ↰ ᣿㧘ᩊ↰ᐽᚑ㧘ᷰㄝᔘᒾ㧘દ⮮౎ᰴ㧘┻ౝ⑲ⴕ㧘ጊፒ ᄥ㧘↰ਛቁᴦ㧘ዊᧁᦥᱜノ㧘㜞ᯅᐢᔒ㧘ർ᧛ᵏብ㧚ጘ㒂⋵ߦ߅ߌࠆ 2007ᐕࠬࠡ࡮ࡅࡁࠠ⧎☳㘧ᢔ⚿ᨐߣ 2008 ᐕߩࠬࠡ㘧ᢔ੍᷹㧘᧲ᶏ⧎☳∝ 2008 ᐕ㧧19 Ꮞ㧦22㧙25㧚
17㧕 㕍ᧁశᐢ㧚ࡔ࠾ࠛ࡯࡞∛⊒∝ߦ߅ߌࠆࡃ࠱ࡊ࡟࠶ࠪࡦߩ㑐ਈ ጘ㒂කቇᅑബ⾨㧘ጘ㒂ᄢቇකቇㇱห⓹ળ⹹
2008 ᐕ㧧87 Ꮞ㧦7㧙8㧚
18㧕 㕍ᧁశᐢ㧚߼߹޿ᴦ≮ߣߒߡߩᐔⴧ࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦ ߼߹޿ߩᴦ≮ᚢ⇛㧘Medical View Points 2008ᐕ㧧29 Ꮞ㧦1㧙3㧚
19㧕 㕍ᧁశᐢ㧚߼߹޿⊒∝ߩᯏᐨ ⥄ᓞ␹⚻⇣Ᏹߩ㑐ਈ㧘Equilibrium Res 2008 ᐕ㧧67 Ꮞ㧦234㧙241㧚
20㧕 㕍ᧁ㚅❱㧘᳓↰໪੺㧘દ⮮౎ᰴ㧚㗪ㇱ⤥≌∝଀ߩᬌ⸛㧘ᣣᧄ⡊㥦ຜ༄⑼ᗵᨴ∝⎇ⓥળ⹹ 2008 ᐕ㧧26 Ꮞ㧦
247㧙250㧚㧙㧙ේ⪺㧔᰷ᢥ㧕1㧕 Kato Y, Shibata T, Yamashita T, Kobayashi A, Yonemoto K, Makita H, Mizuta K, Hayashi S, Toida M.
Parapharyngeal and retropharyngeal space infection of odontogenic origin. Asian J Oral Maxillofac
Surg. 2006;18:224-227.
2㧕 Matsuo M, Hayashi S, Maeda S, Tanaka O, Mizuta K, Shibata T, Ito Y, Hoshi H. 4 Gy single fraction
palliative radiotherapy for the treatment of painful recurrent soft plate carcinoma by high-dose-ratemold brachytherapy: A case of report. Oral Oncol. 2006;42:305-307.
3㧕 Aoki M, Yokota Y, Kuze B, Mizuta K, Ito Y. Disorder of the saliva melatonin circardian rhythm inpatients with Meniere’s disease. Acta Neurol Scand. 2006;113:256-261.
4㧕 Iwata H, Itokazu M, Shirahashi K, Matsumoto S, Mizuta K, Takemura H. Sterilization using
Antibiotic-impregnated Porous Hydroxyapatite Block for Osteomyelitis of Rib and Sternum: A Case
Report. J Jpn Coll Surg. 2007;32:150-152.
5㧕 Kato H, Kanematsu M, Kusunoki Y, Shibata T, Murakami H, Mizuta K, Ito Y, Hirose Y. Nasoalveolar
cyst: imaging findings in three cases. Clin Imag. 2007;31:206-209.
6㧕 Kato H, Kanematsu M, Ando K, Mizuta K, Ito Y, Hirose Y, Hoshi H. Ossifying pleomorphic adenoma of
the parotid gland: a case report and review. Australas Radiol. 2007;51:B173-175.
7㧕 Aoki M, Asai M, Nishihori T, Mizuta K, Ito Y, Ando K. The relevance of an elevation in the plasma
vasopressin levels to the pathogenesis of Meniere’s attack. J Neuroendocrinol. 2007;19:901-906.
8㧕 Funato M, Kaneko H, Ozeki M, Kanda K, Fukao T, Mizuta K, Kondo N. Pediatric synovial sarcoma of
the right masseter muscle: A case report. Int J Pediat Otorhinolaryngol. 2008;3:105-108.
9㧕 Kato H, Kanematsu M, Mizuta K, Ito Y, Hirose Y. Carcinoma ex pleomorphic adenoma of the parotid
gland: radiologic-pathologic correlation with MR imaging including diffusion-weighted imaging. Am J
Neuroradiol. 2008;29:865-867.
10㧕 Hayashi H, Kunisada T, Takakura N, Aoki M, Mizuta K, Ito Y. Involvement of platelet-derived growth
factor receptor- in maintenance of mesenchyme and sensory epithelium of the neonatal mouse innerear. Hear Res. 2008;245:73-81.

IF 2.569
IF 2.099

IF 0.742

IF 2.588
IF 0.851

IF 2.338

IF 2.0624㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦㕍ᧁశᐢ㧧ਛጊ㓳㓶⑼ቇᛛⴚᢥൻ⽷࿅ ⎇ⓥ㐿⊒ഥᚑ A㧦ࠥ࡯ࡓ㈮޿ߩቯ㊂⊛⹏ଔ㨪੍㒐ࠪࠬ࠹ࡓߩ㐿⊒ߩߚ߼ߦ㨪㧧ᐔᚑ 18 ᐕᐲ㧧800 ජ౞2㧕 ⎇ⓥઍ⴫⠪㧦㕍ᧁ⻞ᄥ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦㗡㗪ㇱᚳᐔ਄⊹≸ߦኻߔࠆ᛫≸೷ߩ⠴ᕈࡔࠞ࠾࠭ࡓ㧧ᐔᚑ 17㧙18 ᐕᐲ㧧3,500 ජ౞(2,100㧦1,400 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦ᨋ ኼశ㧘౒ห⎇ⓥ⠪㧦቟⮮ஜ৻㧘⷏ၳਂ⚐㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌(⎇ⓥ)㧦⠧ੱᕈ㔍⡬∛ᘒ⸃᣿ߦะߌߚ p16INK4a ߩౝ⡊߅ߌࠆᓎഀ㧧ᐔᚑ 19 ᐕᐲ㧧270 ජ౞4㧕 ⎇ⓥઍ⴫⠪㧦㕍ᧁశᐢ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦ࠨ࡯ࠞ࠺ࠖࠕࡦ࡝࠭ࡓ߆ࠄߺߚࡔ࠾ࠛ࡯࡞
∛∛ᘒߩ⸃᣿㧧ᐔᚑ 20㧙22 ᐕᐲ㧧3,220 ජ౞(1,820㧦800㧦600 ජ౞)
5㧕 ⎇ⓥ⽿છ⠪㧦㕍ᧁశᐢ㧘⎇ⓥᜂᒰ⠪㧦᫪↰໪ਯ㧘↰ਛ㇌ᒾ㧘ဈ੗↰⼑㧧ጘ㒂ᄢቇᄢቇ㒮කቇ⎇ⓥ⑼㐳ⵙ㊂⚻⾌ߦࠃࠆ⎇ⓥ⾌㧦ౝ⡊∔ᖚ∝଀ߦ߅ߌࠆ೨ᐸ̆േ⣂ⴊ࿶⺞▵♽ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 20 ᐕᐲ㧧500 ජ౞6㧕 ⎇ⓥઍ⴫⠪㧦ᧄᯅജ㧘ᨋኼశ㧧ጘ㒂ᄢቇᄢቇ㒮කቇ⎇ⓥ⑼㐳ⵙ㊂⚻⾌ߦࠃࠆ⎇ⓥ⾌㧦ᚑ૕⚵❱ߦሽ࿷ߔࠆᄙಽൻ⢻ࠍ᦭ߔࠆ␹⚻ႇ⚦⢩ߩหቯ߅ࠃ߮ߘߩ⸃ᨆ㧧ᐔᚑ 20 ᐕᐲ㧧500 ජ౞
2㧕ฃ⸤⎇ⓥ1㧕 ᳓↰໪੺㧦㗡㗪ㇱᚳᐔ਄⊹≸ᩮᴦᴦ≮ᓟߩ TS-1 ⵬ഥൻቇ≮ᴺߩᬌ⸛㧧ᐔᚑ 18㧙24 ᐕᐲ㧧1,365 ජ౞㧦⽷࿅ᴺੱవ┵ක≮ᝄ⥝⽷࿅
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬદ⮮౎ᰴ㧦
1㧕 ᣣᧄ߼߹޿ᐔⴧකቇળℂ੐(㨪ᐔᚑ 19 ᐕ 11 ᦬)㧙㧙

2㧕 ᣣᧄ⡊㥦ຜ༄⑼ቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ߼߹޿ᐔⴧකቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄ⡊⑼ቇળ⹏⼏ຬ(㨪⃻࿷)5㧕 ᣣᧄ㥦⑼ቇળ⹏⼏ຬ(㨪⃻࿷)6㧕 ᣣᧄ᳇▤㘩㆏⑼ቇળ⹏⼏ຬ(㨪⃻࿷)7㧕 ⡊㥦ຜ༄⑼⥃ᐥቇળㆇ༡ᆔຬ(㨪⃻࿷)8㧕 ᣣᧄ⡊㥦ຜ༄⑼఺∉ࠕ࡟࡞ࠡ࡯ቇળ⹏⼏ຬ(㨪⃻࿷)9㧕 ᣣᧄญ⣧࡮ຜ㗡⑼ቇળ⹏⼏ຬ(㨪⃻࿷)10㧕 ᣣᧄ༄㗡⑼ቇળ⹏⼏ຬ(㨪⃻࿷)11㧕 ᣣᧄྚਅකቇળ⹏⼏ຬ(㨪⃻࿷)᳓↰໪੺㧦1㧕 ᣣᧄ⡊㥦ຜ༄⑼ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ߼߹޿ᐔⴧකቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ᳇▤㘩㆏⑼ቇળ⹏⼏ຬ(㨪⃻࿷)㕍ᧁశᐢ㧦1㧕 ᣣᧄ߼߹޿ᐔⴧකቇળ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅દ⮮౎ᰴ㧦
1㧕 ╙ 31 ࿁ᣣᧄ⡊㥦ຜ༄⑼ቇળጘ㒂⋵࿾ᣇㇱળ✚ળߥࠄ߮ߦቇⴚ⻠Ṷળ(ᐔᚑ 18 ᐕ 5 ᦬㧘ጘ㒂)2㧕 ╙ 36 ࿁ᣣᧄ߼߹޿ᐔⴧකቇળᐔⴧᯏ⢻ᬌᩏᛛⴚ⻠⠌ળ(ᐔᚑ 18 ᐕ 7 ᦬㧘ጘ㒂)
3㧕 ╙ 32 ࿁ᣣᧄ⡊㥦ຜ༄⑼ቇળጘ㒂⋵࿾ᣇㇱળ✚ળߥࠄ߮ߦቇⴚ⻠Ṷળ(ᐔᚑ 19 ᐕ 5 ᦬㧘ጘ㒂)
4㧕 ╙ 129 ࿁ᣣᧄ⡊㥦ຜ༄⑼ቇળ᧲ᶏ࿾ᣇㇱળㅪว⻠Ṷળ(ᐔᚑ 19 ᐕ 6 ᦬㧘ጘ㒂)
5㧕 ╙ 33 ࿁ᣣᧄ⡊㥦ຜ༄⑼ቇળጘ㒂⋵࿾ᣇㇱળ✚ળߥࠄ߮ߦቇⴚ⻠Ṷળ(ᐔᚑ 20 ᐕ 6 ᦬㧘ጘ㒂)
6㧕 ╙ 56 ࿁ᣣᧄ⡊㥦ຜ༄⑼ቇળਛㇱ࿾ᣇㇱળㅪวળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂)
3㧕ቇⴚ㔀⹹
દ⮮౎ᰴ㧦
1㧕 Equilibrium Research㧦ળႎᜂᒰℂ੐(㨪ᐔᚑ 19 ᐕ 11 ᦬)
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳દ⮮౎ᰴ㧦
1㧕 ╙ 31 ࿁ᣣᧄ⡊㥦ຜ༄⑼ቇળጘ㒂⋵࿾ᣇㇱળ✚ળ(ᐔᚑ 18 ᐕ 5 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ᚳ᩶ߣ IgA ⣢∝‫ޠ‬ᐳ㐳)
2㧕 ╙ 32 ࿁ᣣᧄ⡊㥦ຜ༄⑼ቇળᄐᦼ⻠⠌ળ(ᐔᚑ 18 ᐕ 7 ᦬㧘ᄢ㒋㧘․೎⻠Ṷ‫⦟ޟ‬ᕈ⊒૞ᕈ㗡૏߼߹޿∝‫ޠ‬มળ)
3㧕 Baylor Oto-Research-Conference(ᐔᚑ 18 ᐕ 7 ᦬, ᧲੩, ᜗ᓙ⻠Ṷ‫ޟ‬૕ᐔⴧ⎇ⓥߣߩઃ߈ว޿‫ޠ‬Ṷ⠪)
4㧕 ╙ 36 ࿁ᣣᧄ߼߹޿ᐔⴧකቇળᐔⴧᯏ⢻ᬌᩏᛛⴚ⻠⠌ળ(ᐔᚑ 18 ᐕ 7 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬㊀ᔃേំᬌᩏ‫ޠ‬Ṷ⠪)5㧕 ╙ 23 ࿁ᣣᧄ߼߹޿ᐔⴧකቇળකᏧ⻠⠌ળ(ᐔᚑ 18 ᐕ 7 ᦬, ೨ᯅ, ․೎⻠Ṷ‫޿߹߼ޟ‬ᬌᩏ࡮⸻ᢿߩㅴ
߼ᣇ‫ޠ‬Ṷ⠪)6㧕 ╙ 32 ࿁ᣣᧄ⡊㥦ຜ༄⑼ቇળጘ㒂⋵࿾ᣇㇱળ✚ળ(ᐔᚑ 19 ᐕ 5 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ ࠕ࡟ࡈޟ‬MRI ߢⷰኤߒߚౝ⡊∔ᖚ‫ޠ‬ᐳ㐳)7㧕 ╙ 24 ࿁ᣣᧄ߼߹޿ᐔⴧකቇળකᏧ⻠⠌ળ(ᐔᚑ 19 ᐕ 6 ᦬㧘ᄢ㒋㧘․೎⻠Ṷ‫ޟ‬૕ᐔⴧߩࡔࠞ࠾࠭ࡓ‫ޠ‬Ṷ⠪)8㧕 ╙ 33 ࿁ᣣᧄ⡊㥦ຜ༄⑼ቇળᄐᦼ⻠⠌ળ(ᐔᚑ 19 ᐕ 7 ᦬㧘᧲੩㧘․೎⻠Ṷ‫ޟ‬ENG ߩၮᧄᚻᛛߣᣣᏱ
ߢࠃߊ⷗ࠄࠇࠆ⌒ᝄ‫ޠ‬มળ)9㧕 ╙ 33 ࿁ᣣᧄ⡊㥦ຜ༄⑼ቇળጘ㒂⋵࿾ᣇㇱળ✚ળ(ᐔᚑ 20 ᐕ 6 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ߣ߃ߎ߈ޟ‬ㆮવሶ̆㔍⡬ߩㆮવሶ⸻ᢿߣㆮવࠞ࠙ࡦ࠮࡝ࡦࠣ̆‫ޠ‬ᐳ㐳)10㧕 ╙ 25 ࿁ᣣᧄ߼߹޿ᐔⴧකቇળකᏧ⻠⠌ળ(ᐔᚑ 20 ᐕ 7 ᦬㧘᧲੩㧘․೎⻠Ṷ‫ޟ‬૕ᐔⴧᯏ⢻ᬌᩏߣ㊀ᔃേំᬌᩏ‫ޠ‬Ṷ⠪)㧙㧙

11㧕 ╙ 56 ࿁ᣣᧄ⡊㥦ຜ༄⑼ቇળਛㇱ࿾ᣇㇱળㅪวળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫⺰ޟ‬ℂ⊛ഃ⮎ᴺߩ⏕┙ߣࡊ࡝ࠝࡦ∛߳ߩᔕ↪‫ޠ‬มળ)12㧕 ╙ 34 ࿁ᣣᧄ⡊㥦ຜ༄⑼ቇળᄐᦼ⻠⠌ળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ᄢ㒋㧘․೎⻠Ṷ‫ޟ‬ᚳ᩶Ἳߩᦨᣂ⍮⼂‫ޠ‬มળ)᳓↰໪੺㧦
1㧕 ╙ 36 ࿁ᣣᧄ߼߹޿ᐔⴧකቇળᐔⴧᯏ⢻ᬌᩏᛛⴚ⻠⠌ળ(ᐔᚑ 18 ᐕ 7 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ⷞޟ‬ೝỗᬌᩏ‫ޠ‬Ṷ⠪)㕍ᧁశᐢ㧦
1㧕 ╙ 36 ࿁ᣣᧄ߼߹޿ᐔⴧකቇળᐔⴧᯏ⢻ᬌᩏᛛⴚ⻠⠌ળ(ᐔᚑ 18 ᐕ 7 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ㅅ〝ೝỗᬌᩏ‫ޠ‬Ṷ⠪)2㧕 ╙ 52 ࿁ᣣᧄቝቮ⥶ⓨⅣႺකቇળ ࠪࡦࡐࠫ࠙ࡓ
‫ޟ‬ౝ⡊೨ᐸ♽ߣᓴⅣ೙ᓮ‫(ޠ‬ᐔᚑ 18 ᐕ 11 ᦬, 㠽ข, ᜗ᓙ⻠Ṷ‫ߩߢ࠻ࡅޟ‬㊀ജฃኈེ♽㧙੤ᗵ␹⚻෻኿ߩᬌ⸛‫ޠ‬Ṷ⠪)
3㧕 ╙ 66 ࿁ᣣᧄ߼߹޿ᐔⴧකቇળ✚ળ࡮ቇⴚ⻠Ṷળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ᄢ㒋㧘ࠪࡦࡐࠫ࠙ࡓ‫ߩ޿߹߼ޟ‬⊒∝ᯏᐨࠍ⠨߃ࠆ‫⥄ޠ‬ᓞ␹⚻⇣Ᏹߩ㑐ਈ Ṷ⠪)
4㧕 άάΧ Barany society meeting(2008.04㧘Kyoto㧘Symposium㧦Autonomic Function and Migraine
The Influence of Vestibular Dysfunctions on Autonomic Regulation of Orthostatic Tolerance in
Human㧧Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ1㧕 㕍ᧁశᐢ㧦ጘ㒂කቇᅑബ⾨(ᐔᚑ 20 ᐕᐲ)
9㧚␠ળᵴേદ⮮౎ᰴ㧦
1㧕 ጘ㒂⋵␠ળ⑔␩ክ⼏ળᆔຬ(㨪⃻࿷)2㧕 ጘ㒂⋵⧎☳∝ኻ╷ᆔຬળᆔຬ(㨪ᐔᚑ 19 ᐕᐲ)
3㧕 ጘ㒂⋵ᣂ↢ఽ⡬ⷡᬌᩏ੐ᬺᬌ⸛ᆔຬળᆔຬ(㨪⃻࿷)4㧕 ጘ㒂Ꮢ␠ળ⑔␩ክ⼏ળᆔຬ(㨪⃻࿷)5㧕 㔍∛ක≮࠹࡟ࡈࠜࡦ࡮ࡔ࡯࡞ࠨ࡯ࡆࠬ‫(ޠߤߥ∛࡞࡯ࠛ࠾ࡔޟ‬ᐔᚑ 19 ᐕ 11 ᦬ 30 ᣣ)᳓↰໪੺㧦1㧕 ጘ㒂⋵⧎☳∝ኻ╷ᆔຬળᆔຬ(㨪ᐔᚑ 19 ᐕᐲ)
2㧕 ጘ㒂⋵࿖᳃ஜᐽ଻㒾⸻≮ႎ㈽ክᩏᆔຬળᆔຬ(㨪⃻࿷)⷏ၳਂ⚐㧦1㧕 ጘ㒂Ꮢ┙ᐜ⒩࿦ߎߣ߫ߩᢎቶᢎ⢒⋧⺣ᆔຬ(ᐔᚑ 19 ᐕᐲ㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 㕍ᧁశᐢ㧘቟⮮ஜ৻㧘᳓↰໪੺㧘દ⮮౎ᰴ㧦ࡔ࠾ࠛ࡯࡞∛⊒૞ߦ߅ߌࠆⴊẏ ADH㧘ࠬ࠻࡟ࠬ㧘ᔃℂ⊛஥㕙ߩ㑐ㅪᕈ㧦ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ 㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ ೨ᐸᯏ⢻⇣Ᏹߦ㑐ߔࠆ⺞ᩏ⎇ⓥ ᐔᚑ 18 ᐕᐲ ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ㧦81㧙83(ᐔᚑ 19 ᐕ 3 ᦬)
2㧕 㕍ᧁశᐢ㧘ᵻ੗㓷ᐘ㧘㕍ᧁ㚅❱㧘᳓↰໪੺㧘દ⮮౎ᰴ㧦৻஥ᕈ೨ᐸ㓚ኂ∝଀ߦ߅ߌࠆ⿠┙ᕈ⥄ᓞ␹⚻⺞▵ߩᬌ⸛㧦ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ 㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ ೨ᐸᯏ⢻⇣Ᏹߦ㑐ߔࠆ⺞ᩏ⎇ⓥ ᐔᚑ 19 ᐕᐲ ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ㧦181㧙182(ᐔᚑ 20 ᐕ 3 ᦬)
3㧕 㕍ᧁశᐢ㧘ᨋ ኼశ㧘᳓↰໪੺㧘દ⮮౎ᰴ㧦ᚻⴚട≮ߦߡ∝⁁ᡷༀࠍ⹺߼ߚ਄ඨⷙ▤ⵚ㓗∝୥⟲∝଀㧦ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ 㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ ೨ᐸᯏ⢻⇣Ᏹߦ㑐ߔࠆ⺞ᩏ⎇ⓥ ᐔᚑ
19 ᐕᐲ ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ㧦201㧙203(ᐔᚑ 20 ᐕ 3 ᦬)
4㧕 㕍ᧁశᐢ㧘ᳯ ଐᴺ㧦ࠥ࡯ࡓ㈮޿ߩቯ㊂⊛⹏ଔ 㨪੍㒐ࠪࠬ࠹ࡓߩ㐿⊒ߩߚ߼ߦ㨪 ਛጊ㓳㓶⑼ቇ
ᛛⴚ⽷࿅ ⎇ⓥ㐿⊒ഥᚑ ᐔᚑ 19 ᐕᐲႎ๔ᦠ㧦24㧙25(ᐔᚑ 20 ᐕ 10 ᦬)
11㧚ႎ㆏1㧕 દ⮮౎ᰴ㧦‫ޟ‬⡊ߩᣣ‫ޠ‬㑐ㅪ⸥੐㧦ጘ㒂ᣂ⡞(2006 ᐕ 3 ᦬ 3 ᣣ)
2㧕 દ⮮౎ᰴ㧦‫ޟ‬㥦ߩᣣ‫ޠ‬㑐ㅪ⸥੐㧦ਛᣣᣂ⡞(2006 ᐕ 8 ᦬ 7 ᣣ)㧙㧙

3㧕 ᳓↰໪੺㧦‫⎇ޟ‬ⓥቶ߆ࠄᄢቇߪ޿߹‫ޠ‬㧦ጘ㒂ᣂ⡞(2006 ᐕ 12 ᦬ 12 ᣣ)
4㧕 દ⮮౎ᰴ㧦‫ޟ‬⡊ߩᣣ‫ޠ‬㑐ㅪ⸥੐㧦ጘ㒂ᣂ⡞(2007 ᐕ 3 ᦬ 3 ᣣ)
5㧕 દ⮮౎ᰴ㧦‫ޟ‬㥦ߩᣣ‫ޠ‬㑐ㅪ⸥੐㧦ਛᣣᣂ⡞(2007 ᐕ 8 ᦬ 7 ᣣ)
6㧕 દ⮮౎ᰴ㧦‫ޟ‬⡊ߩᣣ‫ޠ‬㑐ㅪ⸥੐㧦ጘ㒂ᣂ⡞(2008 ᐕ 3 ᦬ 3 ᣣ)
7㧕 દ⮮౎ᰴ㧦‫ޟ‬㥦ߩᣣ‫ޠ‬㑐ㅪ⸥੐㧦ਛᣣᣂ⡞(2008 ᐕ 8 ᦬ 7 ᣣ)
8㧕 ᳓↰໪੺㧦ࠬࠡ࡮ࡅࡁࠠ⑼⧎☳∝ߩᴦ≮ߣጘ㒂⋵ߦ߅ߌࠆࠬࠡ࡮ࡅࡁࠠ⑼㘧ᢔߩേะ㧦ጘ㒂⋵଻㒾කᣂ⡞(2008 ᐕ 3 ᦬ 10 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔ࿖ౝߢߪో࿖࡟ࡌ࡞ߩ⡊㥦ຜ༄⑼㑐ㅪቇળߢⓍᭂ⊛ߦෳട⊒⴫ߒߡ޿ࠆ‫ޕ‬ᶏᄖߢߩቇળ⊒⴫ߣ⺰ᢥᛩ
Ⓜ߇ਇ⿷ߒߡ޿ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ࡠ࡯࠹࡯࠻⎇ୃ೙ᐲዉ౉ᓟߩੱຬਇ⿷߇⸃ᶖߢ߈ߡ޿ߥ޿‫⎇ޕ‬ⓥߪ⥃ᐥߣᐔⴕߦⴕߞߡ߅ࠅ㧘≸ᖚ⠪ߥߤߩ㊀∝ߥ∔ᖚߩᄙ޿∛᫟ߩᴦ≮ࠍㅴ߼ߥ߇ࠄߩ⎇ⓥߦߪ೙⚂߇ᄙ޿‫ޕ‬ᄢቇ㒮↢߽␠ળੱᄢቇ㒮↢ߣߒߡ⥃ᐥࠍ⛽ᜬߒߡ޿ࠆߩߢ㧘ၮ␆⎇ⓥߦᔅⷐߥ➙߹ߞߚᤨ㑆ࠍ⏕଻ߢ߈ߥ޿⃻⁁ߢ޽ࠆ‫ޕ‬ኻᔕ╷ߣߒߡߪ㧘ක≮⡯એᄖ߿ᄖ࿖ੱᄢቇ㒮↢߅ࠃ߮⎇ⓥ↢ߩჇຬࠍ࿑ࠅ㧘⎇ⓥߦኾᔨߢ߈ࠆੱ᧚ࠍ
⏕଻ߔࠆ‫ߪߦࠄߐޕ‬㧘ၮ␆⻠ᐳ߿ઁߩ⎇ⓥᯏ㑐ߣߩ੤ᵹࠍኒߦߒߡዋߥ޿⎇ⓥ⠪ߩࠕࠗ࠺ࠕࠍ↢߆ߖࠆࠃ߁ߦߒߚ޿‫ޕ‬੹ᓟߩዷᦸጘ㒂ᄢቇ⡊㥦ຜ༄⑼ߦ⫾Ⓧߐࠇߚ߼߹޿ᐔⴧ㓚ኂߩ⎇ⓥᚑᨐࠍၮ␆ߦ㧘߼߹޿࡮ᐔⴧ㓚ኂࠍਛᔃߣߔ
ࠆ⎇ⓥࠍ᛼ߒㅴ߼ࠆ‫ߦ∛࡞࡯ࠛ࠾ࡔޕ‬ઍ⴫ߐࠇࠆ㔍ᴦᕈ߼߹޿ᴦ≮ߦࡈࠖ࡯࠼ࡃ࠶ࠢߢ߈ࠆᚑᨐࠍ᜼ߍ㧘߼߹޿ᐔⴧ㓚ኂᖚ⠪߿㜞㦂⠪ߩり૕ᐔⴧᯏ⢻ᡷༀߦነਈߔࠆലᨐ⊛ᐔⴧ⸠✵ᣇᴺ㐿⊒ࠍ⋡ᮡߣߔࠆ‫߹ޕ‬ߚ㧘㗡㗪ㇱ߇ࠎߩᴦ≮ᚢ⇛ߦ߅ߌࠆᯏ⢻᷷ሽࠍ㊀ὐൻߒ㧘㑐ㅪߔࠆ⥃ᐥ⎇ⓥࠍㅴ߼ࠆ‫ޕ‬㧙㧙㧔8㧕⌒⑼ቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
ᒰᢎቶߪ㧘✛ౝ㓚ࠍࡔࠗࡦ࠹࡯ࡑߣߒߚၮ␆߅ࠃ߮⥃ᐥ⎇ⓥࠍਥߦⴕ޿㧘ߎߩ㗔ၞߦ߅޿ߡߪ㧘⌒࿶࡮
ⷞ㊁࡮↹௝⸃ᨆ࡮⮎‛≮ᴺ࡮ᚻⴚ≮ᴺ࡮␹⚻଻⼔࡮✂⤑ౣ↢࡮ㆮવሶ⸃ᨆߥߤ⎇ⓥߪᄙጘߦࠊߚࠆ‫ޕ‬
ⷞ㊁⸃ᨆߢߪ㧘✛ౝ㓚⸻≮ߩ⺖㗴ߩ߭ߣߟߢ޽ࠆᣧᦼ⊒⷗ࠍ߼ߑߒ㧘VERIS ࠍ↪޿ߚᄙዪᚲ✂⤑㔚࿑㧘ᄙዪᚲⷞⷡ⺃⊒㔚૏ߦࠃࠆ✛ౝ㓚⌒ߩⷰኤࠍⴕߞߡ߅ࠅ㧘ઁⷡ⊛ᬌᩏߦࠃࠆ✛ౝ㓚ᬌ಴⢻ജࠍᬌ⸛ߒߡ޿
ࠆ‫ޕ‬↹௝⸃ᨆߦ߅޿ߡߪ㧘ⷞ␹⚻੃㗡⸃ᨆⵝ⟎ߢ޽ࠆ Heidelberg Retina Tomograph㧔HRT㧕߿శᐓᷤᢿ
ጀ⸘㧔OCT㧕ࠍ↪޿ߡ㧘✛ౝ㓚⌒ߢߩⷞ␹⚻ᒻᘒ߅ࠃ߮✂⤑␹⚻✢⛽ጀෘߩ⸃ᨆࠍⴕߞߡ޿ࠆ‫ߦࠄߐޕ‬㧘⼾ንߥ⥃ᐥ∝଀ࠍၮߦ㧘⮎‛ᴦ≮ലᨐߩ್ቯ߿㧘࡟࡯ࠩ࡯ߥࠄ߮ߦᚻⴚ≮ᴺߩലᨐ್ቯ߽ⴕߞߡ޿ࠆ‫ޕ‬߹ߚၮ␆㗔ၞߦ߅޿ߡߪ㧘NMDA ⎣ሶ૕ᛩਈᓟߩ✂⤑߳ߩ ES ⚦⢩ߩ↢⌕₸㧘ಽൻࠍ⺞ߴ✂⤑ౣ↢ߩน⢻ᕈ߿㧘✛ౝ㓚㑐ㅪㆮવሶߩ⸃᣿ࠍ࠹࡯ࡑߦ⎇ⓥ߇ㆀⴕߐࠇߡ޿ࠆ‫ޕ‬ࡠ࡯ࡆ࡚ࠫࡦࠤࠕߪ㧘ⷞ⢻⸠✵჻ࠍਛᔃߦ⎇ⓥࠍⴕߞߡ߅ࠅ㧘✛ౝ㓚࡮♧ዩ∛✂⤑∝ᖚ⠪ߢߩᣣᏱ↢ᵴߢߩ Quality of Vision㧔QOV㧕ߩㆡಾߥ⹏ଔᣇᴺࠍᬌ⸛ߒߡ޿ࠆ‫ޕ‬ߘߩઁ㧘✂⤑⎣ሶ૕∔ᖚ㧘ⷺ⤑∔ᖚ㧘ᗵᨴ∝㧘߱ߤ߁⤑Ἳߥߤߦ߅޿ߡ㧘ႎ๔ߦ୯ߔࠆ∝଀ߢߪ⌕ታߦႎ๔ࠍⴕߞߡ޿ࠆ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
ಎᢎ᝼㧦
ಎᢎ᝼㧦
⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦

ጊᧄື਽
Ꮉἑ๺⑲
ᦸ᦬ᷡᢥ
㕍ጊ⵨⟤ሶ
Ỉ↰ ᣿
ᧃ᫪᤯ౖ
ቝ࿯৻ᚑ
⊕ᧁ⢒⟤
ዊ࿡ ോ
ဈ 㓉⵨
ዊ᫪િ਽
ฬୖ┨ᢅ

Tetsuya Yamamoto
Kazuhide Kawase
Kiyofumi Mochizuki
Yumiko Aoyama
Akira Sawada
Shinsuke Suemori
Kazunari Udo
Ikumi Shiraki
Tsutomu Oguni
Takahiro Ban
Shinya Komori
Akitoshi Nagura

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ጊᧄື਽㧚೨ᚱ࡮㓈ⷺߩ⸻߆ߚ㧦๟ㄝⰂᓀ೨≹⌕㧘ⴊ▤ᣂ↢㧘⚿▵ߩⷰኤߣ⹏ଔ㧘⸥タᴺ㧚⌒⑼ࠗࡦࠬ࠻
࡜࡚ࠢࠪࡦࠦ࡯ࠬ 7 ✛ౝ㓚⚦㓗Ἦ㗼ᓸ㏜ቢోࡑࠬ࠲࡯㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯㧧2006 ᐕ㧦72㧙77㧚
2㧕 ጊᧄື਽㧚✛ౝ㓚㧦⃻ઍߩ⌒⑼ቇ ᡷ⸓╙ 9  Section 10 ᧲੩㧦㊄ේ಴ 㧧2006 ᐕ㧦187㧙205㧚
3㧕 Ꮉ਄⑲ᤘ㧘ጊᧄື਽㧚⸻ኤቶ(ᄢቇ∛㒮)㧦⌒⑼ࡊ࡜ࠢ࠹ࠖࠬ 10 ⌒⑼ᄖ᧪ᔅ៤㧘᧲੩㧧ᢥశၴ㧦2006 ᐕ㧦
31㧙37㧚
4㧕 ጊᧄື਽㧚ᱜᏱ⌒࿶✛ౝ㓚㧦⌒⑼ࡊ࡜ࠢ࠹ࠖࠬ 11 ✛ౝ㓚⸻≮ߩㅴ߼߆ߚ㧘᧲੩㧦ᢥశၴ㧧2006 ᐕ㧦34
㧙37㧚
5㧕 ጊᧄື਽㧚㓈ⷺಾ㐿ⴚ㧦⌒⑼ࡊ࡜ࠢ࠹ࠖࠬ 11 ✛ౝ㓚⸻≮ߩㅴ߼߆ߚ㧘᧲੩㧦ᢥశၴ㧧2006 ᐕ㧦312㧙
313㧚
6㧕 ㄭ⮮㓶ม㧚ታ଀ߢ⷗ࠆ✛ౝ㓚ⷞ␹⚻∝ߩᒻ⁁ߣᯏ⢻(2)ᱜᏱ⌒࿶✛ౝ㓚㧦⌒⑼ࠗࡦࠬ࠻࡜࡚ࠢࠪࡦࠦ࡯ࠬ 10⸻≮ࠟࠗ࠼࡜ࠗࡦߦḰ᜚ߒߚⷞ␹⚻ߣⷞ㊁ߦࠃࠆ✛ౝ㓚⸻ᢿቢోࡑࠬ࠲࡯㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯㧧2006ᐕ㧦146㧙149㧚
7㧕 ⍹↰ᕶሶ㧚✛ౝ㓚⌒ᐩ⺒ᓇീᒝળ࠹ࠠࠬ࠻㧘᧲੩㧦✛ౝ㓚⌒ᐩ⺒ᓇീᒝળ࠹ࠠࠬ࠻⵾૞ᆔຬળ㧧2006 ᐕ㧦
34㧙37, 82㧙83㧚
8㧕 ጊᧄື਽㧚ⷞ␹⚻๟࿐⚵❱ߩᚲ⷗ ⷞ␹⚻੃㗡಴ⴊߩ∛⊛ᗧ⟵㧦⌒⑼ࠗࡦࠬ࠻࡜࡚ࠢࠪࡦࠦ࡯ࠬ 10 ⸻≮ࠟࠗ࠼࡜ࠗࡦߦḰ᜚ߒߚⷞ␹⚻ߣⷞ㊁ߦࠃࠆ✛ౝ㓚⸻ᢿቢోࡑࠬ࠲࡯㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯㧧2007 ᐕ
74㧙75㧚
9㧕 ጊᧄື਽㧚✛ౝ㓚㧦ࠟࠗ࠼࡜ࠗࡦᄖ᧪⸻≮ 2007㧘᧲੩㧦ᣣ⚻ࡔ࠺ࠖࠞ࡞㐿⊒㧧2007 ᐕ㧦478㧙480㧚
10㧕 ጊᧄື਽㧚ⷞ㊁ᬌᩏ㧦⌒⑼⸻≮ଢ೑ᚻᏝᡷ⸓╙ 2 㧘᧲੩㧦⸻ᢿߣᴦ≮␠㧧2007 ᐕ㧦274㧙275㧚
11㧕 Ꮉἑ๺⑲㧚‫ⷞޣ‬㊁‫߻⺒ޤ‬ὑߩၮ␆⍮⼂㧦Humphrey ⷞ㊁⸃㉼ߩၮᧄ ⷞ㊁ᬌᩏߦᓇ㗀ߔࠆ࿃ሶ ࿕ⷞਇ⦟ ⌒⑼ࡊ࡜ࠢ࠹ࠖࠬ 15㧘᧲੩㧦ᢥశၴ㧧2007 ᐕ㧦62㧙63㧚
‫ⷞޣ‬㊁‫߻⺒ޤ‬ὑߩၮ␆⍮⼂㧦Humphrey ⷞ㊁⸃㉼ߩၮᧄ ⷞ㊁ᬌᩏߦᓇ㗀ߔࠆ࿃ሶ ዮ᛬⇣Ᏹ ⌒12㧕 Ꮉἑ๺⑲㧚⑼ࡊ࡜ࠢ࠹ࠖࠬ 15㧘᧲੩㧦ᢥశၴ㧧2007 ᐕ㧦67㧙69㧚㧙㧙

13㧕 ศ᧛㐳ਭ㧘ችᧄ๺᣿㧘ጊᧄື਽㧘ਅ᧛ཅ৻㧘ਃ᧛ᴦ㧘㤥ဈᄢᰴ㇢(✬㓸)㧚࿑⸃⌒⑼ 2008㧦Σㇱ ✚⺰㧙ᯏ⢻㧙㧘੩ㇺ㧦㊄⧐ၴ㧧2008 ᐕ㧦15㧙25㧚
14㧕 ศ᧛㐳ਭ㧘ችᧄ๺᣿㧘ጊᧄື਽㧘ਅ᧛ཅ৻㧘ਃ᧛ᴦ㧘㤥ဈᄢᰴ㇢(✬㓸)㧚࿑⸃⌒⑼ 2008㧦Τㇱ ਥⷐ⌒⑼∔ᖚ㧙✛ౝ㓚㧙㧘੩ㇺ㧦㊄⧐ၴ㧧2008 ᐕ㧦96㧙103㧚
15㧕 ጊᧄື਽㧚✛ౝ㓚ᚻⴚ㧦⋴⼔ߩߚ߼ߩᦨᣂකቇ⻠ᐳ ╙ 2  ╙ 20 Ꮞ ⌒⑼∔ᖚ㧘᧲੩㧦ਛጊᦠᐫ㧧2008ᐕ㧦273㧙279㧚
16㧕 ጊᧄື਽㧚⌒࿶࡮㓈ⷺ࡮೨ᚱ࡮ᚱ᳓േᘒߩട㦂ᄌൻ㧦⌒⑼ࡊ࡜ࠢ࠹ࠖࠬ 22 ᛫ട㦂⌒⑼ቇ㧘᧲੩㧦ᢥశၴ㧧2008 ᐕ㧦40㧙43㧚
17㧕 ጊᧄື਽㧚ᱜᏱ⌒࿶✛ౝ㓚ߪᄬ᣿ᕈ⌒∔ᖚߥߩ߆㧫 ߔߴ߈⺑᣿ߣߔߴ߈ߢߥ޿⺑᣿㧦⌒⑼ࠗࡦࠬ࠻࡜ࠢ
࡚ࠪࡦࠦ࡯ࠬ 17 ⌒⑼⸻≮ߩࠬࠠ࡞ࠕ࠶ࡊ ✛ౝ㓚✬㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯㧧2008 ᐕ㧦58㧙63㧚
18㧕 ጊᧄື਽㧚㓈ⷺᬌᩏߩᛛⴚะ਄ࠍ⋡ᜰߒߡ㧦⌒⑼⸻≮ߩࠦ࠷ߣ⪭ߣߒⓣ 3 ᬌᩏ࡮⸻ᢿ㧘᧲੩㧦ਛጊᦠᐫ㧧
2008 ᐕ㧦60㧚
19㧕 ጊᧄື਽㧚✛ౝ㓚ߩ㐓೎⸻ᢿߣߒߡߩ superior segmental optic hypoplasia㧦⌒⑼⸻≮ߩࠦ࠷ߣ⪭ߣߒⓣ
3 ᬌᩏ࡮⸻ᢿ㧘᧲੩㧦ਛጊᦠᐫ㧧2008 ᐕ㧦87㧚
20㧕 Ꮉἑ๺⑲㧚⌒⑼⸻≮ߩࠦ࠷ߣ⪭ߣߒⓣ㧦ᮘ↰ືᄦ㧘ᳯญ⑲৻㇢✬㧚ࠟ࡯࠼࠽ࠗࡈࠍ૶↪ߒߚ 2 ㊀ᒝ⤑ᑯ૞ᚑ㧘᧲੩㧦ਛጊᦠᐫ㧧2008 ᐕ㧦184㧙185㧚
21㧕 Ꮉἑ๺⑲㧚࠻࡜ࡌࠢ࡟ࠢ࠻ࡒ࡯ቢోࡑࠬ࠲࡯㧦⼱ේ⑲ା✬㧚೨ᚱ᳓߇ṳ಴ߒߡߊࠆ႐วߩ MMC ႣᏓߣઍ↪ᒝ⤑ᑯ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦80㧙81㧚
22㧕 Ꮉἑ๺⑲㧚ᱜᏱ⌒࿶✛ౝ㓚ߪ‫ᧄޔ‬ᒰߦ⌒࿶߇ᱜᏱ߆㧫⌒࿶ߩᄌേߣᣣౝᄌേߩᗧ⟵ߣ㒢⇇㧦⼱ේ⑲ା✬㧚⌒⑼⸻≮ߩࠬࠠ࡞ࠕ࠶ࡊ✛ౝ㓚✬㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦64㧙69㧚
23㧕 ⍹↰ᕶሶ㧘Ꮉἑ๺⑲㧚௑ᢳ੃㗡∝୥⟲ߣ௑ᢳ੃㗡㧦Ỉ ల✬㧚‫∔⑼⌒ޣ‬ᖚࠕ࠻࡜ࠬ‫✛ޤ‬ౝ㓚 ⌒⑼ 50 Ꮞ 10ภ㧘᧲੩㧦㊄ේ಴ 㧧2008 ᐕ㧦1454㧙1455㧚
24㧕 ⍹↰ᕶሶ㧘Ꮉἑ๺⑲㧚੃㗡ࠨࠗ࠭⇣Ᏹߦว૬ߒߚ✛ౝ㓚㧦Ỉ ల✬㧚‫∔⑼⌒ޣ‬ᖚࠕ࠻࡜ࠬ‫✛ޤ‬ౝ㓚 ⌒⑼50 Ꮞ 10 ภ㧘᧲੩㧦㊄ේ಴ 㧧2008 ᐕ㧦1456㧙1457㧚
25㧕 Ꮉἑ๺⑲㧘⍹↰ᕶሶ㧘ᩮᧁᤘ✬㧚
‫‛⮎⑼⌒ޣ‬ᴦ≮ A to Z‫ ޤ‬࿑⺑૞↪ᯏᐨ ࠞ࡞ࠪ࠙ࡓᜟ᛫⮎ ⌒⑼ࡊ࡜ࠢ
࠹ࠖࠬ 23 Ꮞ㧘᧲੩㧦శᢥၴ㧧 2008 ᐕ㧦552㧙555㧚
⪺ᦠ㧔᰷ᢥ㧕
1㧕 Quigley H, Yamamoto T. Management of acute angle closure crisis. In: Weinreb RN, Friedman DS, eds.
Angle Closure and Angle Closure Glaucoma. Kugler Publications, The Hague, The Netherlands;
2006:21-26.
2㧕 Hong C, Yamamoto T, eds. Angle Closure Glaucoma. Kugler Publications, Amsterdam, The
Netherlands;2007.
3㧕 Hong C, Yamamoto T. Preface. In: Hong C, Yamamoto T, eds. Angle Closure Glaucoma. vii-viii, Kugler
Publications, Amsterdam, The Netherlands;2007.
4㧕 Kondo Y, Yamamoto T. Epidemiology of angle closure glaucoma. In: Hong C, Yamamoto T, eds. Angle
Closure Glaucoma. Kugler Publications, Amsterdam, The Netherlands;2007:11-18.
5㧕 Kondo Y, Yamamoto T. Trabeculectomy. In: Hong C, Yamamoto T, eds. Angle Closure Glaucoma. Kugler
Publications, Amsterdam, The Netherlands;2007:225-238.
✚⺑㧔๺ᢥ㧕
1㧕 ጊᧄື਽㧚✛ౝ㓚ߩዷᦸ̆2003 ᐕᐲ̆㧘⌒⑼ 2006 ᐕ㧧48 Ꮞ㧦1㧙36㧚
2㧕 ㄭ⮮㓶ม㧘ጊᧄື਽㧚✛ౝ㓚ߩᬌᩏߣᚲ⷗㧘ᣣᧄක੐ᣂႎ 2006 ᐕ㧧4268 ภ㧦33㧙36㧚
3㧕 ᦸ᦬ᷡᢥ㧘ጊᧄື਽㧘⍹↰ᕶሶ㧚ỹㆊᚻⴚᓟߩᗵᨴ∝ߩ⃻⁁ߣኻ╷㧘⌒⑼ 2006 ᐕ㧧48 Ꮞ㧦763㧙768㧚
4㧕 ⊕ᧁ⃍ሶ㧘ㄭ⮮㓶ม㧘ጊᧄື਽㧚↹௝ࡈࠔࠗ࡝ࡦࠣࠪࠬ࠹ࡓ㧘⌒⑼ 2006 ᐕ㧧48 Ꮞ㧦1131㧙1139㧚
5㧕 ᣣᧄ✛ౝ㓚ቇળ✛ౝ㓚⸻≮ࠟࠗ࠼࡜ࠗࡦ૞ᚑᆔຬળ(ၫ╩⠪㧦ጊᧄື਽㧘ઁ)㧚✛ౝ㓚⸻≮ࠟࠗ࠼࡜ࠗࡦ╙ 2 ᣣ⌒ળ⹹ 2006 ᐕ㧧110 Ꮞ㧦777㧙814㧚
6㧕 ဈ㓉⵨㧘ጊᧄື਽㧚✛ౝ㓚ߩᴦ≮㧘ᣣᧄක੐ᣂႎ 2006 ᐕ㧧4273 ภ㧦33㧙36㧚
7㧕 ㄭ⮮㓶ม㧚ỹㆊᚻⴚ ⎕უᚻⴚ߆ࠗࡦࡊ࡜ࡦ࠻ᚻⴚ߆㧘⥃ᐥ⌒⑼ 2006 ᐕ㧧60 Ꮞ㧦70㧙74㧚
8㧕 ⍹↰ᕶሶ㧚✛ౝ㓚ߣઁߩⷞ␹⚻∔ᖚߩ⌒ᐩᚲ⷗ߣⷞ␹⚻ᚲ⷗ߦࠃࠆ㐓೎, ޽ߚࠄߒ޿⌒⑼ 2006 ᐕ㧧23 Ꮞ㧦
599㧙615㧚
9㧕 Ỉ↰᣿㧘ᦸ᦬ᷡᢥ㧚✛ౝ㓚⸻≮ߩㅴ߼߆ߚΤ. ᬌᩏߩታ㓙ߣ⹏ଔߩࡐࠗࡦ࠻ 5 ߘߩઁߩⷞᯏ⢻ᬌᩏ 㔚᳇↢ℂቇ⊛ᬌᩏ ⌒⑼ࡊ࡜ࠢ࠹ࠖࠬ 11㧘᧲੩㧦ᢥశၴ㧧2006 ᐕ㧦242㧙244㧚
10㧕 Ỉ↰᣿㧚✛ౝ㓚⸻≮ߩㅴ߼߆ߚΥ. ▤ℂߩၮᧄߣⷐὐ 1 ⮎‛ᴦ≮ 2) ⮎‛ߩ․ᕈߣ૶↪਄ߩᵈᗧὐ One
Point Advice ὐ⌒ലᨐߩ⹏ଔ ⌒⑼ࡊ࡜ࠢ࠹ࠖࠬ 11㧘᧲੩㧦ᢥశၴ㧧2006 ᐕ㧦274㧙275㧚
11㧕 ጊᧄື਽㧚ේ⊒㐽Ⴇ㓈ⷺ∝ߣේ⊒㐽Ⴇ㓈ⷺ✛ౝ㓚㧙ᣂߒ޿∔ᖚ᭎ᔨߣ▤ℂၮḰࠍਛᔃߦ㧙㧘ᣣ⌒ળ⹹
2007 ᐕ㧧111 Ꮞ㧦59㧙67㧚
12㧕 ጊᧄື਽㧚ᵈ⋡ߐࠇࠆ∔ᖚ̌ᱜᏱ⌒࿶✛ౝ㓚̍ߣߪ㧫㧘Medical Practice 2007 ᐕ㧧24 Ꮞ㧦390㧙391㧚
13㧕 ጊᧄື਽㧚✛ౝ㓚ᬌ⸻㧘EBM ࠫࡖ࡯࠽࡞ 2007 ᐕ㧧8 Ꮞ㧦132㧙135㧚
14㧕 ጊᧄື਽㧚♧ዩ∛ߩ✛ౝ㓚ᴦ≮ߪ㧫㧘⢈ḩߣ♧ዩ∛ 2007 ᐕ㧧6 Ꮞ㧦213㧙215㧚
15㧕 ㄭ⮮㓶ม㧘ጊᧄື਽㧚࡟࡯ࠩ࡯Ⰲᓀಾ㐿ⴚߩㆡᔕߣ㒢⇇̆✛ౝ㓚ኾ㐷කߩ┙႐߆ࠄ̆㧘޽ߚࠄߒ޿⌒⑼
2007 ᐕ㧧24 Ꮞ㧦855㧙859㧚
16㧕 ጊᧄື਽㧚ේ⊒㐽Ⴇ㓈ⷺ✛ౝ㓚ᴦ≮ߩ╙৻ㆬᛯߪ࡟࡯ࠩ࡯Ⰲᓀಾ㐿ⴚ߆ PEA+IOL ߆㧫࡟࡯ࠩ࡯Ⰲᓀಾ㐿㧙㧙ⴚᠩ⼔ߩ┙႐߆ࠄ㧘޽ߚࠄߒ޿⌒⑼ 2007 ᐕ㧧24 Ꮞ㧦1021㧙1025㧚
17㧕 Ỉ↰ ᣿㧚೨⌒ㇱࠕ࠻࡜ࠬΦ Ⰲᓀ 㓈ⷺ ೨ᚱ 1 Ⰲᓀ 8) ᕆᕈේ⊒㐽Ⴇ㓈ⷺ✛ౝ㓚㧘⌒⑼ࡊ࡜ࠢ࠹ࠖ
ࠬ 18 2007 ᐕ㧧337㧚
18㧕 ᦸ᦬ᷡᢥ㧚ỹㆊᚻⴚᓟߩ᥅ᦼᗵᨴߩᴦ≮㧚↰㊁଻㓶✬㧦ߺࠎߥߩ⎣ሶ૕ᚻⴚ㧘⌒⑼ࡊ࡜ࠢ࠹ࠖࠬ 17 2007
ᐕ㧧298㧙300㧚
19㧕 Ꮉἑ๺⑲㧚∛᳇ߣ⮎ߩ⺑᣿ࠟࠗ࠼ 2007 ᗵེⷡ∔ᖚ ⮎‛≮ᴺ✬ ක⮎ຠᖱႎ✬ ✛ౝ㓚㧘⮎ዪ 2007 ᐕ㧧
58 Ꮞ㧦1138㧙114㧚
20㧕 Ꮉἑ๺⑲㧚✛ౝ㓚࠮ࡒ࠽࡯ "ࠟ࡯࠼ઃ߈࠽ࠗࡈ"ߦࠃࠆ 2 ㊀ᒝ⤑ᑯ૞⵾㧘ᣂߒ޿⌒⑼ 2007 ᐕ㧧24 Ꮞ㧦
1319㧙1320㧚
21㧕 Ꮉἑ๺⑲㧚೨⌒ㇱࠕ࠻࡜ࠬ ⷺ⤑ Axenfeld-Rieger ∝୥⟲㧘⌒⑼ࡊ࡜ࠢ࠹ࠖࠬ 18 2007 ᐕ㧧148㧙150㧚
22㧕 Ꮉἑ๺⑲㧚Ⰲᓀ࡮㓈ⷺ࡮೨ᚱ 㓈ⷺᚲ⷗ߩಽ㘃㧘⌒⑼ࡊ࡜ࠢ࠹ࠖࠬ 18 2007 ᐕ㧧364㧙366㧚
23㧕 ဈ㓉⵨㧘ጊᧄື਽㧚ỹㆊ⢩ᗵᨴ⺞ᩏ⎇ⓥ߆ࠄᓧࠄࠇࠆ߽ߩߪ㧫޽ߚࠄߒ޿⌒⑼⥃ᤨჇೀภ ✛ౝ㓚 Now1
2008 ᐕ㧧25(⥃Ⴧ)㧦27㧙29㧚
24㧕 ㋈ᧁᐽਯ㧘ጊᧄື਽㧘ᣂኅ⋿㧘ጤἑᗲሶ㧘ንᚲᢕ↵㧘㒙ㇱᤐ᮸㧘⊕࿯ၔᾖ㧘᪀ጊᵏ᣿㧘ਃ᎑ᒄ㧘ᷡ᳓ᒄਯ㧘౷↰೰ม㧘੗਄ᵗ৻㧘ർỈస᣿㧚ᣣᧄ✛ౝ㓚ቇળᄙᴦ⷗∉ቇ⺞ᩏ(ᄙᴦ⷗ࠬ࠲࠺ࠖ)✚᜝ႎ๔㧘ᣣ⌒ળ⹹ 2008
ᐕ㧧112 Ꮞ㧦1039㧙1058㧚
25㧕 Ỉ↰᣿㧚࿑⸃⌒⑼ Σㇱ ✚⺰ 4 ┨ ⸻ኤߣᬌᩏ 4㧙13㧚ᔀᾖᴺ㧘ᢳᾖᴺ 4㧙14㧚⚦㓗᾽㗼ᓸ㏜ᬌᩏ 4㧙15㧚೨ᚱ㓈ⷺᬌᩏ 4㧙16㧚⌒࿶ᬌᩏ 4㧙17㧚⌒ᐩᬌᩏ 4㧙18㧚㔚᳇↢ℂቇ⊛ᬌᩏ 4㧙19㧚Ⱟశ⌒ᐩㅧᓇ
ᬌᩏ 4㧙20㧚⿥㖸ᵄᬌᩏ 4㧙21㧚శᐓᷤᢿጀᴺ 4㧙22㧚CT㧘MRI ᬌᩏ㧦᧲੩㧦㊄⧐ၴ㧧2008 ᐕ㧧48㧙60㧚
26㧕 Ỉ↰᣿㧚✛ౝ㓚 Now!Τ ✛ౝ㓚ߩᬌᩏ࡮⸻ᢿ A ⌒࿶ 4. ⷺ⤑ෘߪ⌒࿶᷹ቯ୯ߦߤߩ⒟ᐲᓇ㗀ߔࠆߩ߆?㧘
޽ߚࠄߒ޿⌒⑼ 2008 ᐕ㧧25(⥃Ⴧ)㧦49㧙51.
27㧕 Ꮉἑ๺⑲㧚✛ౝ㓚 Now!㧚㧙✛ౝ㓚ߩᴦ≮ ၮᧄ⊛ᣇ㊎ ✛ౝ㓚ߩࡠ࡯ࡆ࡚ࠫࡦࠤࠕߪߤ߁ⴕ߁ߩ߆?㧘޽ߚࠄߒ޿⌒⑼ 2008 ᐕ㧧25 Ꮞ(⥃Ⴧ)㧦138㧙141㧚
28㧕 Ꮉἑ๺⑲㧚✛ౝ㓚ߩᣂಽ㘃㧘⌒⑼ᚻⴚ 2008 ᐕ㧧21 Ꮞ㧦323㧙324㧚
29㧕 㚍႐ᕺሶ㧘Ꮉἑ๺⑲㧚ࡠ࡯ࡆ࡚ࠫࡦࠤࠕ ∔ᖚ೎ ࠃߊ޽ࠆ࠾࡯࠭ߣߘߩኻᔕ 㧙✛ౝ㓚ߩᖚ⠪ߐࠎ߆ࠄ
ࠃߊ޽ࠆ࠾࡯࠭ߣߘߩኻᔕ㧘⌒⑼ࠤࠕ 2008 ᐕ㧧10 Ꮞ㧦709㧙711㧚
30㧕 Ꮉἑ๺⑲㧚ࡢࡦࡐࠗࡦ࠻ࠕ࠼ࡃࠗࠬ㧙✛ౝ㓚⌒ߢߩ⊕ౝ㓚ᚻⴚ ỹㆊ⢩ߩ޽ࠆ⌒㧘⌒⑼ᚻⴚ 2008 ᐕ㧧21
Ꮞ㧦220㧙221✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ᵻ㊁♿⟤ᳯ㧘Ꮉἑ๺⑲㧘ጊᧄື਽㧚✛ౝ㓚ᖚ⠪ߩ Quality of Life ߩ⹏ଔ㧘޽ߚࠄߒ޿⌒⑼ 2006 ᐕ㧧23
Ꮞ㧦655㧙659㧚
2㧕 ⍹Ỉ⡡ሶ㧘ㄭ⮮㓶ม㧘ጊᧄື਽㧚৻ᄢቇ㒝ዻ∛㒮ߦ߅ߌࠆ✛ౝ㓚ᴦ≮⮎ㆬᛯߩታᘒ⺞ᩏ㧘⥃⌒ 2006 ᐕ㧧
60 Ꮞ㧦1679㧙1684㧚
3㧕 ਛᎹବ᣿㧘ᨋ૫ౖ㧘⇌ਛ⵨ม㧘㕍ጊ㓁㧘᳓⨲⼾㧘⮮↰᣿ብ㧘ടฎᎹᱜൎ㧘ේᱞผ㧘⮮↰ᐢᔒ㧘ጊᧄື਽㧚1
ᨎߩ 2 ᰴర⌒ᐩ↹௝ࠍ↪޿ߚ 3 ᰴర⌒ᐩ↹௝ߩ᭴▽㧘ක↪↹௝ᖱႎቇળ㔀⹹ 2006 ᐕ㧧23 Ꮞ㧦85㧙90㧚
4㧕 ਛᎹବ᣿㧘ᨋ૫ౖ㧘⇌ਛ⵨ม㧘㕍ጊ㓁㧘᳓⨲⼾㧘⮮↰᣿ብ㧘ടฎᎹᱜൎ㧘ේᱞผ㧘⮮↰ᐢᔒ㧘ጊᧄື਽㧚⌒ᐩ↹௝⸻ᢿᡰេࠪࠬ࠹ࡓߩߚ߼ߩⴊ▤ᶖ෰↹௝ࠍ↪޿ߚⷞ␹⚻੃㗡ߩ⥄േ⹺⼂෸߮ᡆૃ┙૕↹௝↢ᚑ߳ߩᔕ↪㧘㔚ሶᖱႎㅢାቇળ⺰ᢥ⹹ 2006 ᐕ㧧J89-D㧦2491㧙2501㧚
5㧕 ၷ↰೑ᒾ㧘Ꮉ਄⑲ᤘ㧘ਤ⠀⟵᣿㧘ᦸ᦬ᷡᢥ㧘㐳㊁ഞ㧘㜞ᯅఝਃ㧚᭽‫⥃ߥޘ‬ᐥ௝ࠍ๒ߒߚ⌒࠻ࠠ࠰ࠞ࡜∝ߩ
6 ଀㧘⌒⑼⥃ᐥකႎ 2006 ᐕ㧧100 Ꮞ㧦580㧙586㧚
6㧕 ᾢ↰㓷ሶ㧘⍹Ỉ⡡ሶ㧘Ꮉ਄⑲ᤘ㧘㋈ᧁፏ㧘ᦸ᦬ᷡᢥ㧚Group B Streptococcus ߦࠃࠆౝ࿃ᕈ⌒ౝἻߩ 1 ଀㧘޽ߚࠄߒ޿⌒⑼ 2006 ᐕ㧧23 Ꮞ㧦1377㧙1380㧚
7㧕 ጊᧄື਽㧘ࠞ࡞࠹ࠝࡠ࡯࡞ᜬ⛯ᕈὐ⌒ᶧ⎇ⓥળ㧚Ⴎ㉄ࠞ࡞࠹ࠝࡠ࡯࡞ 1㧑ᜬ⛯ᕈὐ⌒ᶧߩ⌒࿶ਅ㒠ലᨐߩᬌ⸛́Ⴎ㉄ࠞ࡞࠹ࠝࡠ࡯࡞ 1㧑ὐ⌒ᶧࠍᲧセኻᾖߣߒߚ㜞⌒࿶ᖚ⠪ߦ߅ߌࠆή૞ὑൻੑ㊀⋤ᬌ╙Υ⋧⥃ᐥ⹜㛎́㧘ᣣ⌒ળ⹹ 2007 ᐕ㧧111 Ꮞ㧦463㧙472㧚
8㧕 ᵻ㊁⧷ੑ㇢㧘ᦸ᦬ᷡᢥ㧘Ỉ↰᣿㧘㐳ဈ⧷৻㇢㧘ㄭ⮮㓶ม㧘ጊᧄື਽㧚ᱜᏱ⌒࿶✛ౝ㓚ߦ߅ߌࠆᄙዪᚲⷞⷡ
⺃⊒㔚૏㧘޽ߚࠄߒ޿⌒⑼ 2007 ᐕ㧧24 Ꮞ㧦1653㧙1659㧚
9㧕 ᧛ἑኡ♿㧘ၳ↱⿠ሶ㧘ၷ↰೑ᒾ㧘᧲᧻ᢕሶ㧘ᦸ᦬ᷡᢥ㧘ᄥ↰ବᴦ㧘ጊ↰ାੑ㧘Ỉ↰᣿㧘ਃ㡞ᑝ❥㧚ᣂ↢ఽࠢ࡜ࡒࠫࠕ⚿⤑Ἳ 8 ଀ߩᬌ⸛㧘⥃ᐥ⌒⑼ 2007 ᐕ㧧61 Ꮞ㧦1431㧙1435㧚
10㧕 ᦸ᦬ᷡᢥ㧘ㄭ⮮િᒾ㧘᫪⦟㓶㧘ጊ↰ቁብ㧘᫪㊁ᶈᄥ㇢㧚஥㗡േ⣂Ἳߦࠃࠆ೨ㇱ⯯ⴊᕈⷞ␹⚻∝ߩ 1 ଀㧘⌒⑼ 2007 ᐕ㧧49 Ꮞ㧦1851㧙1856㧚
11㧕 ᧛ἑኡ♿㧘ၳ↱⿠ሶ㧘ᦸ᦬ᷡᢥ㧘ᄥ↰ବᴦ㧘㜞ᧁᢕᔒ㧘દ⮮✍ሶ㧘ጊ↰ାੑ㧘ጊጯ↱૫㧘ਃ㡞ᑝ❥㧚ሶች㗪▤ࠬࠢ࡝࡯࠾ࡦࠣᬌᩏᓟߦ⊒∝ߒߚᣂ↢ఽࠢ࡜ࡒࠫࠕ⚿⤑Ἳߩ 2 ଀㧘⥃⌒ 2007 ᐕ㧧61 Ꮞ㧦2037㧙
2042㧚
12㧕 ዊ࿡ോ㧘Ꮉἑ๺⑲㧚࠻ࠠ࠰ࡊ࡜࠭ࡑߦࠃࠆ੃㗡㓞ធ✂⣂⛊⤑Ἳ(Edmund-Jensen)ߩ 1 ଀㧘⌒⑼⥃ᐥක 2007
ᐕ㧧101 Ꮞ㧦786㧙789㧚
13㧕 ၳ↱⿠ሶ㧘ᦸ᦬ᷡᢥ㧘ᧃ᧻ኡਯ㧘⷏᧛๺ሶ㧚Paecilomyces lilacinus ߦࠃࠆⷺ⤑⌀⩶∝ߩ 1 ଀㧘޽ߚࠄߒ޿⌒⑼ 2008 ᐕ㧧25 Ꮞ㧦1139㧙1142㧚
14㧕 ၳ↱⿠ሶ㧘ᦸ᦬ᷡᢥ㧚✛ౝ㓚ࠍ઻ߞߡஜᏱᚑੱߦ⊒∝ߒߚࠨࠗ࠻ࡔࠟࡠ࠙ࠗ࡞ࠬ✂⤑Ἳߩ 1 ଀㧘޽ߚࠄߒ㧙㧙޿⌒⑼ 2008 ᐕ㧧25 Ꮞ㧦1315㧙1318㧚
15㧕 ᧛ἑኡ♿㧘ᦸ᦬ᷡᢥ㧘Ỉ↰᣿㧘㋈ᧁፏ㧘Ꮉ਄⑲ᤘ㧚⧯ᐕ↵ᕈߩਔ⌒ߦჇᱺᄌൻࠍ߈ߚߒߚ Eales ∛ߩ 1 ଀㧘޽ߚࠄߒ޿⌒⑼ 2008 ᐕ㧧25 Ꮞ㧦1731㧙1735㧚
16㧕 ဈ㓉⵨㧘ᾢ↰㓷ሶ㧘Ꮉἑ๺⑲㧚MMC ✢⛽ᩇᏪಾ㒰ⴚᓟߩᒝ⤑Ⲣ⸃ߦኻߔࠆ಄ಓ଻ሽⷺ⤑ ߦࠃࠆỹㆊ⢩ߩୃᓳ㧘⌒⑼⥃ᐥ♿ⷐ 2008 ᐕ㧧1 Ꮞ㧦569㧙572㧚
ේ⪺㧔᰷ᢥ㧕
1㧕 Kondo N, Sawada A, Yamamoto T, Taniguchi T. Correlation between individual differences inintraocular pressure reduction and outflow facility due to latanoprost in normal-tension glaucoma
patients. Jpn J Ophthalmol. 2006;50:20-24.
IF2㧕 Miyake T, Sawada A, Yamamoto T, Miyake K, Sugiyama K, Kitazawa Y. The incidence of dischemorrhage in open-angle glaucoma before and after trabeculectomy. J Glaucoma. 2006;15:164-171.
IF
3㧕 Hara A, Niwa M, Kumada M, Aoki H, Kunisada T, Oyama T, Yamamoto T, Kozawa O, Mori H.
Intraocular injection of folate antagonist methotrexate induces neuronal differentiation of embryonicstem cells transplanted in the adult mouse retina. Brain Res. 2006;1085:33-42.
IF
4㧕 Karim MZ, Sawada A, Kawakami H, Yamamoto T, Taniguchi T. A new calcium channel antagonist,
lomerizine, alleviates secondary retinal ganglion cell death after optic nerve injury in the rat. Curr
Eye Res. 2006;31:273-283.
IF5㧕 Iwase A, Araie M, Tomidokoro A, Yamamoto T, Shimizu H, Kitazawa Y. Tajimi Study Group:
Prevalence and causes of low vision and blindness in a Japanese adult population: the Tajimi Study.
Ophthalmology. 2006;113:1354-1362.
IF
6㧕 Suemori S, Shimazawa M, Kawase K, Satoh M, Nagase H, Yamamoto T, Hara H. Metallothionein, an
endogenous antioxidant, protects against retinal neuron damage in mice. Invest Ophthalmol Vis Sci.
2006;47:3975-3982.
IF7㧕 Suzuki Y, Iwase A, Araie M, Yamamoto T, Abe H, Shirato S, Kuwayama Y, Mishima HK, Shimizu H,
Tomita G, Inoue Y, Kitazawa Y. Tajimi Study Group: Risk factors for open-angle glaucoma in a
Japanese population. The Tajimi Study. Ophthalmology. 2006;113:1613-1617.
IF
8㧕 Hasegawa K, Ishida K, Sawada A, Kawase K, Yamamoto T. Diurnal variation of intraocular pressure
in suspected normal-tension glaucoma. Jpn J Ophthalmol. 2006;50:449-454.
IF
9㧕 Hara A, Niwa M, Aoki H, Kumada M, Kunisada T, Oyama T, Yamamoto T, Kozawa O, Mori H. A newmodel of retinal photoreceptor cell degeneration induced by a chemical hypoxia-mimicking agent,cobalt chloride. Brain Res. 2006;1109:192-200.
IF
10㧕 Ishida K, Netland PA. Ahmed Glaucoma Valve Implantation in African-American and CaucasianPatients. Arch Ophthalmol. 2006;124:800-806.
IF
11㧕 Ishida K, Netland PA, Costa VP, Shiroma L, Khan B, Ahmed IIK: Comparison of polypropylene andsilicone Ahmed Glaucoma Valves. Ophthalmology. 2006;113:1320-1326.
IF
12㧕 Karim MZ, Sawada A, Kawakami H, Yamamoto T. A new calcium channel antagonist, lomerizine,
alleviates secondary retinal ganglion cell death after optic nerve injury in the rat. Current Eye
Research. 2006;31:273-283.
IF
13㧕 Mochizuki K, Murase H, Imose M, Kawakami H, Sawada A. Improvement of scotopic
electroretinograms and night blindness with recovery of serum zinc levels. Jpn J Ophthalmol.
2006;50:532-536.
IF
14㧕 Suemori S, Shimazawa M, Kawase K, Satoh M, Nagase H, Yamamoto T, Hara H. Metallothionein, an
Endogenous Antioxidant, Protects against Retinal Neuron Damage in Mice. Invest Ophthalmol Vis Sci.
2006;47:3975-3982.
IF
15㧕 Hewitt AW, Bennett SL, Richards JE, Dimasi DP, Booth AP, Inglehearn C, Anwar R, Yamamoto T,
Fingert JH, Héon E, Craig JE, Mackey DA. The Myocilin Gly252Arg mutation and glaucoma ofintermediate severity in Caucasians individuals. Arch Ophthalmol. 2007;125:98-104.
IF
16㧕 Nakagawa T, Hayashi Y, Hatanaka Y, Aoyama A, Hara T, Fujita A, Kakogawa M, Fujita H, Yamamoto
T. Three-dimensional reconstruction of optic nerve head from stereo fundus images and its
quantitative estimation. Proceedings of the 29th Annual International Conference of the IEEE EMBS
2007;6747-6750.
17㧕 Sawada A, Aoyama A, Yamamoto T, Takatsuka N. Long-term therapeutic outcome of acute primary
angle closure in Japanese. Jpn J Ophthalmol. 2007;51:353-359.
IF
18㧕 Asano E, Mochizuki K, Sawada A, Nagasaka E, Kondo Y, Yamamoto T. Decreased nasal-temporal
asymmetry of the second-order kernel response of multifocal electroretinograms in eyes withnormal-tension glaucoma. Jpn J Ophthalmol. 2007;51:379-389㧚
IF
19㧕 Mochizuki K, Murase, H, Sawada A, Suzuki T. Detection of Staphylococcus Species by Polymerase
Chain Reaction in Late Onset Endophthalmitis after Cataract Surgery and Posterior Capsulotomy.
Clin Exp Ophthalmol. 2007;35:873-875.
IF
20㧕 Takashi Suzuki, Nobuhide Hori, Tomoko Miyake, Yukiko Hori, Kiyofumi Mochizuki. Keratitis Caused
by a Rare Fungus, Malassezia restricta. Jpn J Ophthalmol. 2007;51:292-294.
IF
21㧕 Sawada A, Tomidokoro A, Araie M, Iwase A, Yamamoto T. Tajimi Study Group. Refractive errors in an

㧙㧙

0.888
0.207

2.218

1.443

4.621

3.528

4.621
0.888

2.218
2.984
4.621

1.443

0.888

3.528

2.984

0.888

0.888

1.253
0.888

elderly Japanese population. The Tajimi Study. Ophthalmol. 2008;115:363-370.
22㧕 Akiyama M, Yatsu K, Ota M, Katsuyama Y, Kashiwagi K, Mabuchi F, Iijima H, Kawase K, Yamamoto
T, Nakamura M, Negi A, Sagara T, Kumagai N, Nishida T, Inatani M, Tanihara H, Ohno S, Inoko H,
Mizuki N. Microsatellite analysis of the GLC1B locus on chromosome 2 points to NCK2 as a new
candidate gene for normal tension glaucoma. Br J Ophthalmol. 2008;92:1293-1296.
23㧕 Mochizuki K, Katada T, Kawakami H, Sawada A, Mikamo H. Polymicrobial endogenous
endophthalmitis. Retinal Cases & Brief Reports. 2008;2:342-343.
24㧕 Mochizuki K, Yamada T, Mori Y, Sawada A, Mori I, Ohnishi Y. Case of atypical fibroxanthoma in thepalpebral conjunctiva. Jpn J Ophthalmol. 2008;52:404-406.
25㧕 Kawase K, Tomidokoro A, Araie M, Iwase A, Yamamoto T. Tajimi Study Group; Japan Glaucoma
Society. Ocular and systemic factors related to intraocular pressure in Japanese adults:the Tajimi
study. Br J Ophthalmol. 2008;92:1175-1179.

IF 4.621

IF 2.689
IF 0.888
IF 0.888

IF 2.6894㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦ጊᧄື਽㧘⎇ⓥಽᜂ⠪㧦Ꮉἑ๺⑲㧘㕍ጊ⵨⟤ሶ㧘ㄭ⮮㓶ม㧘ᧃ᫪᤯ౖ㧘Ỉ↰᣿㧘⍹↰ᕶሶ㧘㕍ጊ㓁㧧⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦✛ౝ㓚േ‛ࡕ࠺࡞ߦࠃࠆᣂⷙ⮎‛ᴦ≮ߩ㐿⊒ߣ⃻࿷ߩ✛ౝ㓚⸻≮ߩวℂᕈߩᬌ⸛㧧ᐔᚑ 17㧙19 ᐕᐲ㧧4600 ජ౞(1,700㧦700㧦2,200 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦⼱ේ⑲ା(ᾢᧄᄢቇකቇㇱ)㧘⎇ⓥಽᜂ⠪㧦ጊᧄື਽㧘߶߆㧧ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄(ᗵེⷡ㓚ኂ⎇ⓥ੐ᬺ)㧦ᱜᏱ⌒࿶✛ౝ㓚ߦኻߔࠆᣧᦼ⊒⷗ߩࠬࠢ࡝࡯࠾ࡦࠣࠪࠬ࠹ࡓ᭴▽ߣᦨㆡൻߐ
ࠇߚ⸻≮ᜰ㊎ߩ⏕┙ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 17㧙19 ᐕᐲ㧧9,600 ජ౞(4,800㧦2,800㧦2,800 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦Ỉ↰᣿㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦࡜࠶࠻ⷞ␹⚻ᝂṌࡕ࠺࡞ߦ߅ߌࠆ࠾ࡊ࡜ࠫࡠ
࡯࡞ߩ␹⚻଻⼔ലᨐ㧧ᐔᚑ 17㧙19 ᐕᐲ㧧3,700 ජਁ౞(3,100㧦300㧦300 ජ౞)
4㧕 ⎇ⓥ⠪ઍ⴫㧦⍹↰ᕶሶ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦⋡ᮡ⌒࿶ߩౣ⹏ଔߣᣂߒ޿ⷞ㊁ࡊࡠࠣ࡜ࡓ
෸߮ࠗࡦࡊ࡜ࡦ࠻ᚻⴚߩน⢻ᕈߦߟ޿ߡ㧧ᐔᚑ 18㧙20 ᐕᐲ㧧3,500 ජਁ౞(1,900㧦1,200㧦400 ජ౞)
2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬጊᧄື਽㧦
1㧕 ᣣᧄ⌒⑼ቇળℂ੐(ᐔᚑ 19 ᐕ 6 ᦬㨪⃻࿷)2㧕 ᣣᧄ⌒⑼ቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ⌒⑼ቇળኾ㐷ක೙ᐲ↢ᶦᢎ⢒ᆔຬળᆔຬ㐳(ᐔᚑ 19 ᐕ 6 ᦬㨪⃻࿷)
4㧕 ᣣᧄ⌒⑼ቇળኾ㐷ක೙ᐲᆔຬળᆔຬ(㨪⃻࿷)5㧕 ᣣᧄ⌒⑼ቇળኾ㐷೎⎇ⓥળ⹏ଔᆔຬળᆔຬ(ᐔᚑ 18 ᐕ 8 ᦬㨪⃻࿷)
6㧕 ᣣᧄ⌒⑼ቇળ✚㓸ળࡊࡠࠣ࡜ࡓᆔຬળᆔຬ(㨪ᐔᚑ 19 ᐕ 10 ᦬)
7㧕 ᣣᧄ✛ౝ㓚ቇળℂ੐(㨪⃻࿷)8㧕 ᣣᧄ✛ౝ㓚ቇળ⹏⼏ຬ(㨪⃻࿷)9㧕 ᣣᧄ✛ౝ㓚ቇળ࠺࡯࠲⸃ᨆᆔຬળᆔຬ(㨪⃻࿷)10㧕 ᣣᧄ⌒⑼ᚻⴚቇળℂ੐(㨪⃻࿷)11㧕 ᣣᧄ⌒⮎ℂቇળ⹏⼏ຬ(㨪⃻࿷)12㧕 Glaucoma Research Society, Executive Committee Member(ᐔᚑ 20 ᐕ 2 ᦬㨪⃻࿷)
13㧕 World Glaucoma Association, Cochairman of the WGA Committee on Global Research andScreening(ᐔᚑ 20 ᐕ 4 ᦬㨪⃻࿷)
14㧕 World Glaucoma Association, Member of the WGA Code of Practice Committee(ᐔᚑ 20 ᐕ 4 ᦬㨪⃻࿷)
15㧕 Asian Angle-closure Glaucoma Club, President(ᐔᚑ 20 ᐕ 9 ᦬㨪⃻࿷)㧙㧙

16㧕 Asian Angle-closure Glaucoma Club, Vice-President(㨪ᐔᚑ 20 ᐕ 9 ᦬)Ꮉἑ๺⑲㧦
1㧕 ᣣᧄ✛ౝ㓚⹏⼏ຬ(ᐔᚑ 19 ᐕ 6 ᦬㨪⃻࿷)2㧕ቇળ㐿௅ጊᧄື਽㧦
1㧕 ╙ 18 ࿁ᣣᧄ✛ౝ㓚ቇળ(ᐔᚑ 19 ᐕ 9 ᦬㧘ጘ㒂)2㧕 The 5th Meeting of the Asian Angle㧙Closure Glaucoma Club(ᐔᚑ 19 ᐕ 9 ᦬㧘ጘ㒂)
3㧕 ╙ 417 ࿁᧲ᶏ⌒⑼ቇળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ጘ㒂)
3㧕ቇⴚ㔀⹹
ጊᧄື਽㧦
1㧕 Japanese Journal of Ophthalmology; Glaucoma Section Chief (㨪⃻࿷)2㧕 Asian Journal of Ophthalmology; editor (㨪⃻࿷)3㧕 ޽ߚࠄߒ޿⌒⑼㧧✬㓸ᆔຬ(ᐔᚑ 19 ᐕ 10 ᦬㨪⃻࿷)4㧕 ጘ㒂⋵කᏧળකቇ㔀⹹㧧✬㓸ᆔຬ(ᐔᚑ 20 ᐕ 4 ᦬㨪⃻࿷)7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ጊᧄື਽㧦
1㧕 ╙ 29 ࿁ᣣᧄ⌒⑼ᚻⴚቇળ(ᐔᚑ 18 ᐕ 1 ᦬㧘᧲੩㧘ᢎ⢒࠮ࡒ࠽࡯5‫࡯ࡒ࠻ࠢ࡟ࠢࡌ࡜࠻ޟ‬1 ⴚᑼߣㆡᔕ㧚✛ౝ㓚㧙ઍ⴫⊛ߥⴚᑼߩㆡᔕߣၮᧄᚻᛛ‫ޠ‬ᐳ㐳)2㧕 ╙ 29 ࿁ᣣᧄ⌒⑼ᚻⴚቇળ(ᐔᚑ 18 ᐕ 1 ᦬㧘᧲੩㧘ᢎ⢒࠮ࡒ࠽࡯5‫࡯ࡒ࠻ࠢ࡟ࠢࡌ࡜࠻ޟ‬1 ⴚᑼߣㆡᔕ㧚✛ౝ㓚㧙ઍ⴫⊛ߥⴚᑼߩㆡᔕߣၮᧄᚻᛛ‫ޠ‬Ṷ⠪)
3㧕 World Ophthalmology Congress 2006(2006.02, Sao Paulo, Brazil, My choice of therapy.
Symposium “Practical Strategies in Glaucoma Managemenťinvited speaker)
4㧕 World Ophthalmology Congress 2006(2006.02, Sao Paulo, Brazil, Etiology of open-angle
glaucoma: Importance of disc hemorrhage. Symposium “Basic and Clinical Aspects ofOpen-angle Glaucoma” invited speaker )5㧕 World Ophthalmology Congress 2006(2006.02, Sao Paulo, Brazil, Surgical options and outcomesof angle-closure glaucoma. Angle-closure Glaucoma - APAO ;Symposium)
6㧕 The 3rd Global AIGS Consensus Meeting.(2006.05, Hollywood, USA Consensus report on
management of acute angle closure crisis. invited speaker)
7㧕 The 21st Congress of the Asia-Pacific Academy of Ophthalmology Symposium 21 – Glaucoma“Glaucoma Challenges in the Asia Pacific(2006.06 , Singapore, Is Japanese glaucoma different?
invited speaker)
8㧕 ╙ 17 ࿁ᣣᧄ✛ౝ㓚ቇળ(ᐔᚑ 18 ᐕ 9 ᦬㧘␹ᚭ㧘ࠪࡦࡐࠫ࠙ࡓ 2 ⋡ᮡ⌒࿶ߩ᦭↪ᕈߣ㒢⇇㧦㐳ᦼ⚻ㆊ߆ࠄ⷗ߚ⠨ኤ‫ޠ‬ᐳ㐳)9㧕 ╙ 60 ࿁ᣣᧄ⥃ᐥ⌒⑼ቇળ(ᐔᚑ 18 ᐕ 10 ᦬㧘੩ㇺ㧘ࠗࡦࠬ࠻࡜࡚ࠢࠪࡦࠦ࡯ࠬ IC2-20‫ޟ‬ᱜᏱ⌒࿶✛ౝ㓚ߩ⸻ᢿߣ▤ℂ 2006‫)࡯࠲ࠢ࡜࠻ࠬࡦࠗޠ‬10㧕 ╙ 60 ࿁ᣣᧄ⥃ᐥ⌒⑼ቇળ(ᐔᚑ 18 ᐕ 10 ᦬㧘੩ㇺ㧘ࠪࡦࡐࠫ࠙ࡓ 14‫✛ޟ‬ౝ㓚ᬌᩏߪߤߎ߹ߢᔅⷐ߆‫ޠ‬ᐳ㐳)
11㧕 AAO 2006 instruction course #268 Office Management of Asian Glaucoma Update. (2006.11. Las
Vegas, USA)Course chairman)
12㧕 The 6th WHO Inter-country Workshop(2006.11, Korat, Thailand Current status of PACG
management and prevention of blindness - Japan & the World)13㧕 ╙ 30 ࿁ᣣᧄ⌒⑼ᚻⴚቇળ(ᐔᚑ 19 ᐕ 1 ᦬㧘੩ㇺ㧘ࠪࡦࡐࠫ࠙ࡓ 1‫Ⰲ࡯ࠩ࡯࡟ޟ‬ᓀಾ㐿ⴚߩഞ⟋‫ޠ‬ᐳ㐳)
14㧕 ╙ 30 ࿁ᣣᧄ⌒⑼ᚻⴚቇળ(ᐔᚑ 19 ᐕ 1 ᦬㧘੩ㇺ㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ‫ޟ‬ᚻⴚߩಽጘὐ㧙޽ߥߚߥࠄߤ߁ߔࠆ㧫ߎߩ∝଀‫ޠ‬ᐳ㐳)15㧕 Asia ARVO Meeting 2007(2007.03, Singapore, Symposium 5 Ocular Epidemiology/International
Ophthalmology: Rates and causes of visual impairment in Japan; Symposist)16㧕 The 4th Global AIGS Consensus Meeting(2007.05, Ft. Lauderdale USA, Consensus report on
IOP as risk factor for glaucoma development and progression invited speaker)

㧙㧙

17㧕 WGC 2007 (2007.07, Singapore, Didactic Morning Session 3+4. IOP consensus:invited
Epidemiology of intraocular pressure (IOP); Speaker)
18㧕 WGC 2007(2007.07, Singapore, Course 27. Impact of Western clinical trials : Impact ofCollaborative Normal-tension Glaucoma Study on glaucoma management in Japan ; Current
medical treatment for glaucoma in Japan)
19㧕 WGC 2007(2007.07, Singapore, Symposium 21: Normal pressure glaucoma; Symposist)20㧕 WGC 2007(2007.07, Singapore, Course 53. Secondary open angle glaucoma: Introduction anddiagnostic tips for SOAG; Invited speaker)
21㧕 WGC 2007(2007.07, Singapore, Course 69. Normal pressure glaucoma: Ocular hypotensive
therapy for normal-tension glaucoma; Invited speaker)
22㧕 Glaucoma Summer Camp(2007.08, Awajishima, What can we expect following successful
trabeculectomy in NTG cases?; Invited speaker)
23㧕 The 12th Congress of Chinese Ophthalmological Society(2007.08, Zhengzhou, China, The firstJapan-China Glaucoma Symposium: Current medical treatment for glaucoma in Japan ; Invited
symposist)24㧕 ╙ 18 ࿁ᣣᧄ✛ౝ㓚ቇળ(ᐔᚑ 19 ᐕ 9 ᦬㧘ጘ㒂㧘․೎ડ↹✛ౝ㓚ࠝ࡯࡞ࠬ࠲࡯࠭ 2007 ᐳ㐳)
25㧕 ╙ 18 ࿁ᣣᧄ✛ౝ㓚ቇળ(ᐔᚑ 19 ᐕ 9 ᦬㧘ጘ㒂㧘․೎ડ↹✛ౝ㓚ࠝ࡯࡞ࠬ࠲࡯࠭ 2007 ᱜᏱ⌒࿶✛ౝ㓚ߩ㐓೎∔ᖚߣߒߡߩ superior segmental optic hypoplasia ߩ㊀ⷐᕈ㧚Ṷ⠪)26㧕 ╙ 18 ࿁ᣣᧄ✛ౝ㓚ቇળ࡮╙ 5 ࿁ࠕࠫࠕ㐽Ⴇ㓈ⷺ✛ౝ㓚ࠢ࡜ࡉળ⼏(ᐔᚑ 19 ᐕ 9 ᦬㧘ጘ㒂㧘วหࠪࡦࡐࠫ࠙ࡓ ̌Primaru angle-closure ̄ Asian view̍ᐳ㐳)27㧕 ╙ 61 ࿁ᣣᧄ⥃ᐥ⌒⑼ቇળ(ᐔᚑ 19 ᐕ 10 ᦬㧘੩ㇺ㧘ࠪࡦࡐࠫ࠙ࡓ‫⌒ޟ‬࿶ߩ⠨߃ᣇߩㅴᱠ‫ޠ‬ᐳ㐳)28㧕 The Asian Oceanic Glaucoma Society Meeting 2007(2007.12, Bangkok Thailand, Modern
management of primary angle-closure; Invited speaker)
29㧕 The Asian Oceanic Glaucoma Society Meeting 2007(2007.12, Bangkok Thailand , Glaucoma risk
reduction in PACG and NTG; Invited speaker)
30㧕 The Asian Oceanic Glaucoma Society Meeting 2007(2007.12, Bangkok Thailand, Current
management strategy for open-angle glaucoma in Japan; Invited speaker)
31㧕 ╙ 31 ࿁ᣣᧄ⌒⑼ᚻⴚቇળ(ᐔᚑ 20 ᐕ 2 ᦬㧘ᢎ⢒࠮ࡒ࠽࡯16 ᮮᵿ࠻࡜ࡌࠢ࡟ࠢ࠻ࡒ࡯ߩว૬∝ኻ╷㧚‫✛ޟ‬ౝ㓚ᚻⴚ㧙࠻࡜ࡉ࡞ࠪࡘ࡯࠹ࠖࡦࠣ‫ޠ‬Ṷ⠪)32㧕 ╙ 112 ࿁ᣣᧄ⌒⑼ቇળ✚ળ(ᐔᚑ 20 ᐕ 4 ᦬㧘ᮮᵿ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᄙᣉ⸳ᄢⷙᮨ⥃ᐥ⎇ⓥ‫ޠ‬ᣣᧄ✛ౝ㓚ቇળ‫ޟ‬ỹㆊ⢩ᗵᨴߦ㑐ߔࠆ೨ะ߈⺞ᩏ⎇ⓥ‫ޠ‬Ṷ⠪)33㧕 ╙ 112 ࿁ᣣᧄ⌒⑼ቇળ✚ળ(ᐔᚑ 20 ᐕ 4 ᦬㧘ᮮᵿ㧘࠮ࡒ࠽࡯‫✛ޟ‬ౝ㓚ᕈⷞ␹⚻∝ࡑࠬ࠲࡯ࠦ࡯ࠬ‫ޠ‬ᐳ㐳)34㧕 ╙ 112 ࿁ᣣᧄ⌒⑼ቇળ✚ળ(ᐔᚑ 20 ᐕ 4 ᦬㧘ᮮᵿ㧘ࠨࡉࠬࡍࠪࡖ࡝࠹ࠖࠨࡦ࠺ࠗ‫✛ޟ‬ౝ㓚⸻ᢿߩࠦ࠷ߣ⪭ߣߒⓣ‫ޠ‬ᐳ㐳)35㧕 2008 Japan-Sino Glaucoma(2008.06, Hong Kong, Long-term management of open-angle
glaucoma in Japan. Symposium.; Invited speaker)
36㧕 World Ophthalmology Congress 2008(2008.07, Hong Kong, Symposium̌Practical Strategies in
the Management of Open-angle Glaucoma̍course instructor)
37㧕 ╙ 19 ࿁ᣣᧄ✛ౝ㓚ቇળ(ᐔᚑ 20 ᐕ 9 ᦬㧘ᄢ㒋㧘࠺࡯࠲⸃ᨆᆔຬળ․೎࠮࠶࡚ࠪࡦ㧚ᣣᧄ✛ౝ㓚ቇળỹㆊ⢩ᗵᨴ⺞ᩏ⎇ⓥߩ⃻⁁ႎ๔ Ṷ⠪)38㧕 ╙ 19 ࿁ᣣᧄ✛ౝ㓚ቇળ(ᐔᚑ 20 ᐕ 9 ᦬㧘ᄢ㒋㧘ࠪࡦࡐࠫ࠙ࡓ 5‫ߩ⾰ޟ‬㜞޿⌒࿶ᴦ≮ࠍ⋡ᜰߒߡ‫ޠ‬ᐳ㐳)39㧕 2008 SEAGIG/AACGC(2008.09, Seoul Korea, Joint Congress. Symposium 3 ̌ Medical
Treatment̍ course instructor)
40㧕 2008 SEAGIG/AACGC Joint Congress(2008.09, Seoul Korea, Is the role of surgical treatmentchanging? ;Invited speaker)
41㧕 2008 SEAGIG/AACGC Joint Congress(2008.09, Seoul Korea, PAS detection by indentation
gonioscopy. ; Invited speaker)
42㧕 2008 SEAGIG/AACGC Joint Congress.(2008.09, Seoul Korea, Symposium ̌Epidemiology andTretmant of Primary Angle-closure̍ course instructor)
43㧕 ╙ 62 ࿁ᣣᧄ⥃ᐥ⌒⑼ቇળ(ᐔᚑ 20 ᐕ 10 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ 17‫ޟ‬㐽Ⴇ㓈ⷺ✛ౝ㓚ߩᣂߒ޿⠨߃ᣇߣᴦ≮ᚢ⇛‫ޠ‬ᐳ㐳)44㧕 The Asian Oceanic Glaucoma Society Meeting2008(2008.12, Guangzhou China Relationship㧙㧙between central corneal thickness and visual field in glaucoma; Iinvited speaker)
45㧕 The Asian Oceanic Glaucoma Society Meeting 2008(2008.12, Guangzhou China Symposium 3
̌Imaging/Visual Field̍course instructor)
Ꮉἑ๺⑲㧦
1㧕 ੩ṑ✛ౝ㓚ࠞࡦࡈࠔ࡟ࡦࠬ(ᐔᚑ 18 ᐕ 3 ᦬㧘੩ㇺ㧘᜗ᓙ⻠Ṷ‫ޟ‬ၮ␆㧦✛ౝ㓚ߣㆮવሶ‫ޠ‬Ṷ⠪)
2㧕 ᧲ᶏ✛ౝ㓚ቇⴚ⻠Ṷળ(ᐔᚑ 18 ᐕ 3 ᦬㧘ฬฎደ㧘∝଀ឭ␜‫ޟ‬SSOH‫ޠ‬Ṷ⠪)3㧕 ጘ㒂✛ౝ㓚ߩળ(ᐔᚑ 18 ᐕ 5 ᦬㧘ጘ㒂㧘᜗ᓙ⻠Ṷ‫ⷞޟ‬㊁▤ℂ࠰ࡈ࠻ߦࠃࠆⷞ㊁ߩⷰኤ㧙㔚ሶࠞ࡞࠹ൻߣ✛ౝ㓚ߩ∛⸻ㅪ៤㧙‫ޠ‬Ṷ⠪)
4㧕 ╙ 17 ࿁ᣣᧄ✛ౝ㓚ቇળ(ᐔᚑ 18 ᐕ 9 ᦬㧘␹ᚭ㧘‫ޟ‬ỹㆊ⢩ᒻ⁁‫ޠ‬ᐳ㐳)
5㧕 ╙ 18 ࿁ᣣᧄ✛ౝ㓚ቇળ(ᐔᚑ 19 ᐕ 9 ᦬㧘ጘ㒂‫✛ޟ‬ౝ㓚ᬌᩏ 㧙߅㗿޿ߔࠆ஥ߣ߅㗿޿ߐࠇࠆ஥㧙‫ޠ‬ࠝ࡯ࠟ࠽ࠗࠩ࡯)6㧕 ╙ 112 ࿁ᣣᧄ⌒⑼ቇળ✚ળ(ᐔᚑ 20 ᐕ 4 ᦬㧘ᮮᵿ㧘ࠪࡦࡐࠫ࠙ࡓ‫⌒ޟ‬࿶ࠍ⑼ቇߔࠆ㧙⌒࿶㑐ㅪ࿃ሶߩൻቇ‫ޠ‬Ṷ⠪)7㧕 ᧲ᶏ✛ౝ㓚ߩળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ฬฎደ㧘᜗ᓙ⻠Ṷ‫✛ޟ‬ౝ㓚ᴦ≮⮎ߩᣂߒ޿ዷᦸ‫ޠ‬Ṷ⠪)8㧕 ╙ 19 ࿁ᣣᧄ✛ౝ㓚ቇળ(ᐔᚑ 20 ᐕ 9 ᦬㧘ᄢ㒋㧘৻⥸⻠Ṷ ỹㆊᚻⴚ 3 ᐳ㐳)
9㧕 ⌒⮎ℂቇળ ࠪࡦࡐࠫ࠙ࡓ(ᐔᚑ 20 ᐕ 9 ᦬㧘ጟጊ㧘‫ࡦࠫࡦ࡜ࠣ࠲ࠬࡠࡊޟ‬ὐ⌒⮎ߩ⌒⴫㕙ߦ෸߷ߔᓇ
㗀‫ޠ‬Ṷ⠪)
8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ1㧕 ጊᧄື਽㧦ᣣᧄ⌒⑼ቇળ⹏⼏ຬળ⾨(ᐔᚑ 19 ᐕᐲ)
9㧚␠ળᵴേጊᧄື਽㧦
1㧕 ᣣᧄᄬ᣿੍㒐දળ⎇ⓥഥᚑㆬ⠨ᆔຬળᆔຬ(ᐔᚑ 19 ᐕᐲ㨪⃻࿷)2㧕 ᣣᧄቇⴚᝄ⥝ળ⑼ቇ⎇ⓥ⾌ᆔຬળኾ㐷ᆔຬ(ᐔᚑ 19 ᐕᐲ㨪⃻࿷)
3㧕 ᣣᧄቇⴚᝄ⥝ળ⑼ቇ⎇ⓥ⾌ᆔຬળኾ㐷ᆔຬ(ᐔᚑ 19 ᐕᐲ㨪⃻࿷)4㧕 ጘ㒂⋵␠ળ⑔␩ክ⼏ળᆔຬ(ᐔᚑ 18 ᐕᐲ㨪⃻࿷)5㧕 ጘ㒂Ꮢ␠ળ⑔␩ክ⼏ળᆔຬ(ᐔᚑ 18 ᐕᐲ㨪⃻࿷)
6㧕 ࿖᳃ᐕ㊄㓚ኂክᩏᆔຬ(ᐔᚑ 18 ᐕᐲ㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ጊᧄື਽㧦✛ౝ㓚േ‛ࡕ࠺࡞ߦࠃࠆᣂⷙ⮎‛ᴦ≮ߩ㐿⊒ߣ⃻࿷ߩ✛ౝ㓚⸻≮ߩวℂᕈߩᬌ⸛㧦ᐔᚑ
17 ᐕᐲ㧙19 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄⎇ⓥᚑᨐႎ๔ᦠ(2008 ᐕ 3 ᦬)
2㧕 ጊᧄື਽㧦ᱜᏱ⌒࿶✛ౝ㓚ߩ࡝ࠬࠢࠕ࠮ࠬࡔࡦ࠻㧦ᐔᚑ 17 ᐕᐲ㧙19 ᐕᐲෘ↢ഭ௛⑼ቇ⵬ഥ㊄ᗵེⷡ㓚ኂ⎇ⓥ੐ᬺ ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ(⼱ේ⃰)㧦7㧙14(2008 ᐕ 4 ᦬)11㧚ႎ㆏ߥߒ12㧚⥄Ꮖ⹏ଔ
⹏ଔᤓ੹ߩකዪຬߩᷫዋߦࠃࠅ⥃ᐥᬺോߩ⽶ᜂ߇ฦකᏧߦჇ߃ࠆਛ㧘ቇળ⊒⴫㧘⺰ᢥ૞ᚑߥߤ♖ജ⊛ߦᵴേߒߡ޿ࠆߣᕁࠊࠇࠆ‫ࠄ߇ߥߒ߆ߒޕ‬㧘⎇ⓥᵴേߩߐࠄߥࠆዷ㐿ࠍᮨ⚝ߔࠆᔅⷐ߇޽ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ᣂ⥃ᐥ⎇ୃක೙ᐲዉ౉ߦࠃࠆᣂߒ޿කዪ౉ዪ⠪ߩᷫዋߦ઻޿㧘කຬᢙ߇ᷫዋߔࠆ௑ะߦ޽ࠆ‫⚿ߩߎޕ‬ᨐ㧘⥃ᐥᬺോᤨ㑆ߩ⋧ኻ⊛Ⴧടߦࠃࠅ㧘⎇ⓥߦలߡࠆᤨ㑆߇ᷫዋߒߚ‫߼ߚߩߎޕ‬ᒰ⑼ߢߪ㧘⥃ᐥᬺോߦ೙㒢ࠍ⸳ߌ㧘⋧ኻ⊛ߦ⎇ⓥᤨ㑆ߩჇടߦߟ޿ߡᮨ⚝ߒߡ޿ࠆ‫ߚ߹ޕ‬㧘ጘ㒂ᄢቇߩ߶߆ߩၮ␆⻠ᐳ߿ઁ⎇ⓥᯏ㑐ߣ౒ห⎇ⓥߩଦㅴߥߤࠍⴕߞߡ޿ࠆ‫ޕ‬੹ᓟߩዷᦸࠃࠅࠃ޿⎇ⓥᚑᨐࠍ᳞߼ࠆ਄ߢ㧘කᏧ߭ߣࠅ߭ߣࠅߩ⥃ᐥᬺോߦࠁߣࠅࠍᜬߚߖࠆߎߣߪᔅⷐߢ޽ࠆ‫ޕ‬㧙㧙ߒߚ߇ߞߡᣂ౉කዪຬߩ⺃⥌߇ߘࠇࠍ㆐ᚑߔࠆ਄ߢᔅⷐਇนᰳߢ޽ࠆߣ⠨߃ࠆ‫߇ࠇߘޕ‬ᡷༀߐࠇߥ޿㒢ࠅ㧘⃻⁁ࠍᛂ⎕ߔࠆߎߣߪ㔍ߒ޿‫ޕ‬㧙㧙ާ⣲≌೙ᓮቇ⻠ᐳި
㧔1㧕⣲≌∛ℂቇಽ㊁
1㧚⎇ⓥߩ᭎ⷐ
∛ℂቇߦ߅ߌࠆ⎇ⓥߪ㧘ㆮવሶ࡟ࡌ࡞ߩၮ␆⊛ߥ߽ߩ߆ࠄੱ૕៰಴ᬌ૕ࠍ᧚ᢱߣߔࠆ⥃ᐥ∛ℂ⊛ߥ߽ߩ߹ߢߩᐢ▸ߥ㗔ၞࠍභ߼ࠆ‫ޕ‬ᢎቶߩવ⛔⊛ߥਥⷐ࠹࡯ࡑߢ޽ࠆ㧘⣲≌ߩ⊒↢߆ࠄ੍㒐߹ߢߩ∛ℂቇ⊛⎇ⓥࠍ⛮⛯ߒߡ⎇ⓥߔࠆߣߣ߽ߦ㧘ౣ↢ක≮㧘ᐙ⚦⢩කቇߦ߽㑐ㅪߒߚᣂⷙ∛ℂቇಽ㊁ߩ⎇ⓥࠍⴕߞߡ޿ࠆ‫ޕ‬1㧕ㆮવሶᡷᄌࡑ࠙ࠬ૞⵾ᛛⴚࠍ↪޿ߚᄢ⣺⊒߇ࠎߩಽሶᯏ᭴⸃᣿
ES ⚦⢩ߢߩ⋧ห⚵ߺ឵߃ᛛⴚࠍ೑↪ߒߚ㧘ࠦࡦ࠺࡚ࠖࠪ࠽࡞ࡁ࠶ࠢࠕ࠙࠻ࡑ࠙ࠬ㧘ㆮવሶ⊒⃻⺃ዉࡑ࠙ࠬࠍ૞⵾‫ޕ‬ᄢ⣺⊒߇ࠎߩࡔࠞ࠾࠭ࡓ⸃᣿ࠍ⋡ᜰߒߡ޿ࠆ‫ޕ‬
2㧕߇ࠎ⚦⢩࡝ࡊࡠࠣ࡜ࡒࡦࠣߦࠃࠆ߇ࠎࠛࡇࠫࠚࡀ࠹ࠖ࠶ࠢ⇣Ᏹߩᗧ⟵⸃᣿
Oct4, Sox2, Myc, Klf4 ߣ޿߁ 4 ࿃ሶ⊒⃻ߦࠃࠅ㧘ಽൻ⚦⢩ߩೋᦼൻ߇น⢻ߣߥߞߚ㧔iPS ⚦⢩㧕‫ࠎ߇ޕ‬⚦⢩ߦߎߩᛛⴚࠍᔕ↪ߒ㧘߇ࠎ⚦⢩ߢߩࠛࡇࠫࠚࡀ࠹ࠖ࠶ࠢ⁁ᘒࠍᄌൻߐߖ㧘߇ࠎ⚦⢩․⇣⊛ߥᄌൻࠍห
ቯߔࠆߎߣߢ㧘߇ࠎ⚦⢩ߢߩࠛࡇࠫࠚࡀ࠹ࠖ࠶ࠢ⇣Ᏹߩᗧ⟵ࠍ᣿ࠄ߆ߦߔࠆ‫ޕ‬
3㧕DNA ࡔ࠴࡞ൻᯏ᭴ߣ⣲≌⊒↢ߩ⸃᣿ㆮવሶ⊒⃻⺞▵ߩⷐ㧘ࠛࡇࠫࠚࡀ࠹ࠖࠢࠬ೙ᓮᯏ᭴ߩ 1 ߟߢ޽ࠆ DNA ࡔ࠴࡞ൻᯏ᭴ߣ⣲≌⊒↢ࠍੑߟߩⷞὐ[1]Site specific DNA hypermethylation [2]Global DNA hypomethylation ߦᵈ⋡ߒߡ⎇ⓥߒߡ޿ࠆ‫[ޕ‬1]ߪญ⣧ᚳᐔ਄⊹≸ࠍ᧚ᢱߦ≸ᛥ೙ㆮવሶߩ⊒⃻ࡊࡠࡕ࡯࠲࡯ㇱ૏ߦ߅ߌࠆ DNA ࡔ࠴࡞ൻߣ⣲≌⊒↢ߩ㑐ଥࠍ⎇ⓥߒ㧘[2]ߦߟ޿ߡߪ㧘DNA ૐࡔ࠴࡞ൻࡑ࠙ࠬ㧔⛽ᜬࡔ࠴࡞ၮォ⒖㉂⚛ߢ޽ࠆ Dnmt1 ߩૐ⊒⃻ࡑ࠙ࠬ㧕ࠍ↪޿ߡ㧘ฦ⒳⣲≌⊒↢ߦ߅ߌࠆ DNA ࡔ࠴࡞ൻߩᗧ⟵⸃᣿ߦขࠅ⚵ࠎߢ޿ࠆ‫ޕ‬
4㧕ౣ↢ක≮㧘ᐙ⚦⢩කቇߦ㑐ㅪߔࠆ⣲≌⊒↢ߩ⸃᣿ߣߘߩ੍㒐ౣ↢කቇߩ⥃ᐥᔕ↪߇ㅴࠎߢ޿ߥ޿ℂ↱ߩ৻ߟߦ㧘in vitro ߢߩ⍮⷗߇ᔅߕߒ߽ in vivo ߢߪታ⃻ߢ߈ߡ޿ߥ޿ߎߣ㧘ߘߒߡ㧘⢦ᕈᐙ⚦⢩㧔ES ⚦⢩㧕ࠍ⚵❱ౣ↢ߦ೑↪ߒߚ႐ว㧘ߒ߫ߒ߫ᄸᒻ⣲ߣߒߡᱜᏱ
⚵❱߹ߢ⎕უߔࠆ⣲≌ᕈჇᱺࠍ߈ߚߔߎߣ߇޽ߍࠄࠇࠆ‫ޕ‬ᒰᢎቶߢߪ⣲≌∛ℂߩ⍮⼂ࠍ߽ߣߦౣ↢කቇߩ⥃ᐥᔕ↪ߩ㓙ߦ໧㗴ߣߥࠆ⣲≌⊒↢ࠍ㧘߇ࠎᐙ⚦⢩㧔cancer stem cell㧕ߣ㑐ㅪߐߖߡ⎇ⓥߒߡ޿ࠆ‫ޕ‬5㧕␹⚻ౣ↢⎇ⓥߩߚ߼ߩ␹⚻㓚ኂേ‛ࡕ࠺࡞ߩ㐿⊒␹⚻ゲ⚝ౝࠍᢿ ൻ DNA ߇࠳ࠗ࠽ࡒ࠶ࠢߦࠪ࠽ࡊࠬㇱ߹ߢ⒖േߔࠆߎߣࠍ␹⚻ߩࠕࡐ࠻࡯ࠪࠬߦ․⇣⊛⃻⽎ߣߒߡႎ๔ߒ㧘৻ㆊᕈ⣖⯯ⴊߦ઻߁ᶏ㚍 CA1 㗔ၞߩㆃ⊒ᕈ⚦⢩ᱫ߇ࠕࡐ࠻࡯ࠪࠬߢ޽ࠆߎߣࠍ⸽
᣿ߒߚ‫∔⚻␹ޕ‬ᖚࡕ࠺࡞ߣߒߡߩᛒ޿߿ߔߐ߆ࠄ㧘ࡑ࠙ࠬ✂⤑ߦᵈ⋡ߒ㧘␹⚻⚦⢩ᱫߣࠕࡐ࠻࡯ࠪࠬߩ㑐ଥࠍ᣿ࠄ߆ߦߔࠆ৻ᣇ㧘✂⤑␹⚻⚦⢩ߩㆬᛯ⊛㓚ኂࡕ࠺࡞ࠍ⏕┙ߒ㧘␹⚻ౣ↢කቇ߳ߩᔕ↪ߦขࠅ⚵ࠎߢ
޿ࠆ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
ේ ᣿
ಎᢎ᝼㧦 ጊ↰ᵏᐢ

Akira Hara
Yasuhiro Yamada

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
ߥߒ⪺ᦠ㧔᰷ᢥ㧕
1㧕 Mori H, Yamada Y, Kuno T, Oyama T, Hara A. Precursor lesions for stomach and colonic carcinomas inanimal models. In: Bamba H, Ota S, eds. Recent Advances in Gastrointestinal Carcinogenesis. Kerela:
Research Signpost; 2006:215-229.
2㧕 Hara A, Niwa M, Aoki H, Taguchi A, Yamada Y, Mori H. New research on neuronal networks. In:
Neuronal Network Research Horizons, ed by Weiss ML, New York: Nova Science Publish; 2007:99-118.
3㧕 Yamada Y, Oyama T, Tomita H, Taguchi A, Hara A and Mori H. Premalignant lesions of the colon inrodents. In: Tanaka T, ed. Cancer: Disease Progression and Chemoprevention. Kerala: Research
Signpost; 2007:1-13.
4㧕 Niwa K, Mori H, Tamaya T. Endometrial precancerous conditions in mouse carcinogenesis. A review.
In: Litchfield JE, ed. Precancerous condition: new research. New York Nova Science Publishers;
2007:245-252.
5㧕 Mori H, Yamada Y, Hirose Y, Hara A. Precancerous conditions of the colon; multistage carcinogenesis
in animal models. A review. In: RP Arroye, ed. Cancer Prevention Research Progress. New York Nova
Science Publishers; 2008:97-116.

㧙㧙6㧕 Hara A, Oka N, Aoki H, Taguchi A, Yamada Y, Niwa M, Mori H. OCT-3/4 Expressing Cells as Cancer
Stem Cells in Human Immature Teratoma: Cancer Differentiation Potential. In Saitama H, ed. New
Cell Differentiation Research Topics. New York Nova Science Publish; 2008:1-6.
✚⺑㧔๺ᢥ㧕
1㧕 ේ ᣿㧘᫪ ⑲᮸㧚ⴚਛㄦㅦ⸻ᢿ࡮ಓ⚿⚵❱ᮡᧄߩᱧผ㧘ᣣᧄක੐ᣂႎ 2007 ᐕ㧧4319 ภ㧦114㧙115.
✚⺑㧔᰷ᢥ㧕
1㧕 Yamada Y, Mori H. Multistep carcinogenesis in the colon of Apc Min/+ mouse. Cancer Sci.
2007;98:6-10.
ේ⪺㧔๺ᢥ㧕
1㧕 ጊ↰ᵏᐢ㧚ߎߣ߫ߩࠞ࡞࠹ 177гOct3/4㧦ࡔ࠺ࠖࠞ࡞࠻࡝ࡆࡘ࡯ࡦ 2008 ᐕ㧧41 Ꮞ㧦46㧚
2㧕 ጊ↰ᵏᐢ㧘ේ ᣿㧘᫪ ⑲᮸㧚∔ᖚࡕ࠺࡞േ‛ࠍ↪޿ߚࠛࡇࠫࠚࡀ࠹ࠖࠢࠬ⎇ⓥгᄢ⣺ᄙᲑ㓏⊒߇ࠎߦ߅ߌ
ࠆ㧰㧺㧭ࡔ࠴࡞ൻ⇣Ᏹߩᗧ⟵㧘ᦨᣂකቇ 2008 ᐕ㧧63 Ꮞ㧦772㧙777㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Hara A, Niwa M, Aoki H, Kumada M, Kunisada T, Oyama T, Yamamoto T, Kozawa O, Mori H. A newmodel of retinal photoreceptor cell degeneration induced by a chemical hypoxia-mimicking agent,cobalt chloride. Brain Res. 2006;1109:192-200.
2㧕 Hara A, Niwa M, Kumada M, Aoki H, Kunisada T, Oyama T, Yamamoto T, Kozawa O, Mori H.
Intraocular injection of folate antagonist, methotrexate induces neuronal differentiation of embryonicstem cells transplanted in the adult mouse retina. Brain Res. 2006;1085:33-42.
3㧕 Suzui M, Tanaka T, Mori H, Nakayama T, Aonahara M, Yoshimi N. Pulmonary hypoplasia andchondrocyte p21CIPI expression in patients with lethal short-limbed dwarfism. Ryukyu Med J.
2006;25:31-46.
4㧕 Hata K, Tanaka T, Kohno H, Suzuki R, Qiang SH, Yamada Y, Oyama T, Kuno T, Hirose Y, Hara A,
Mori H. beta-Catenin-accumulated crypts in the colonic mucosa of juvenile Apc(Min/+) mice. Cancer
Lett. 2006;239:123-128.
5㧕 Hata K, Tanaka T, Kohno H, Suzuki R, Qiang SH, Kuno T, Hirose Y, Hara A, Mori H. Lack ofenhancing effects of degraded lambda-carrageenan on the development of beta-catenin-accumulated
crypts in male DBA/2J mice initiated with azoxymethane. Cancer Lett. 2006;238:69-75.
6㧕 Mori Y, Tatematsu K, Koide A, Sugie S, Tanaka T, Mori H. Modification by curcumin of mutagenic
activation of carcinogenic N-nitrosamine by extrahepatic cytochromes P-450 2B1 and 2E1 in rats.
Cancer Sci. 2006;97:896-904.
7㧕 Kuno T, Hirose Y, Yamada Y, Hata K, Qiang SH, Asano N, Oyama T, Zhi H, Iwasaki T, Kobayashi H,
Mori H. Chemoprevention of mouse urinary bladder carcinogenesis by the fermented brown rice andrice bran. Oncol Rep. 2006;15:533-538.
8㧕 Lian Z, Niwa K, Onogi K, Mori H, Harrigan RC, Tamaya T. Anti-tumor effects of herbal medicines on
endometrial
carcinomas
via
estrigen
receptor-alpha-related
mechanism.
Oncol
Rep.
2006;15:1133-1136.
9㧕 Kato K, Hara A, Kuno T, Mori H, Toida M, Shibata T. Aberrant promoter hypermethylation of p16 and
MGMT genes in oral squamous cell carcinomas and the surrounding normal mucosa. J Cancer Res
Clin Oncol. 2006;132:735-743.
10㧕 Aoki H, Hara A, Nakagawa S, Motohashi T, Hirano M, Takahashi Y, Kunisada T. Embryonic stem cells
that differentiate into RPE cell precursors in vitro develop into RPE cell monolayers in vivo. Exp Eye
Res. 2006;82:265-274.
11㧕 Niwa M, Hotta K, Hara A, Hirade K, Ito H, Kato K, Kozawa O. TNF-alpha decreases hsp 27 in humanblood mononuclear cells: Involvement of protein kinase C. Life Sci. 2006;80:181-186.
12㧕 Onogi K. Niwa K, Tang L, Yun W, Mori H, Tamaya T. Inhibitory effects of Hocyu-ekki-to on
endometrial carcinogenesis induced by N-methyl-N-nitrosourea and 17beta̅estradiol in mice. Oncol
Rep. 2006;16:343-1348.
13㧕 Asano N, Kuno T, Hirose Y, Yamada Y, Yoshida K, Tomita H, Nakamura Y, Mori H. Preventive Effects
of a Flavonoid Myricitrin on the Formation of Azoxymethane-induced Premalignant Lesions in Colonsof Rats. Asian Pac J Cancer Prev. 2007;8:73-76.
14㧕 Hara A, Taguchi A, Niwa H, Aoki H, Yamada Y, Ito H, Nagata K, Kunisada T, Mori H. Localization of
septin 8 in murine retina, and spatiotemporal expression of septin 8 in a murine model ofphotoreceptor cell degeneration. Neurosci Lett. 2007;423:205-210.
15㧕 Tomita H, Yamada Y, Oyama T, Hata K, Hirose Y, Hara A, Kunisada T, Sugiyama Y, Adachi Y, Linhart
H, Mori H Development of gastric tumors in Apc Min/+ mice by the activation of the Ǫ-catenin/Tcf
signaling pathway. Cancer Res. 2007;67:4079-4087.
16㧕 Oka N, Soeda A, Inagaki A, Onodera M, Maruyama H, Hara A, Kunisada T, Mori H, Iwama T. VEGF
promotes tumorigenesis and angiogenesis of human glioblastoma stem cells. Biochem Biophys Res㧙㧙

IF 2.218

IF 2.218

IF 3.398

IF 3.398

IF 3.165

IF 1.597

IF 1.597

IF 2.366

IF 2.651
IF 2.257

IF 1.597

IF 2.121

IF 7.672

Commun. 2007;360:553-559.
17㧕 Zhi H, Yamada Y, Hirose Y, Kato K, Sheng H, Zheng Q, Oyama T, Asano N, Kuno T, Hara A, Mori H.
Effect of 2-(carboxyphenyl) retinamide and genistein on the formation of early lesions in
1,2-dimethylhydrazine-induced colon carcinogenesis in rats. Asian Pac J Cancer Prev. 2007;8:33-38.
18㧕 Sheng HQ, Hirose Y, Hata K, Zheng Q,T Kuno T, Asano N, Yamada Y, Hara A, Osawa T, Mori H.
Modifying effect of dietary sesaminol glucosides on the formation of azoxymethane-inducedpremalignant lesions of rat colon. Cancer Lett. 2007;246:63-68.
19㧕 Aoki H, Hara A, Niwa M, Motohashi T, Suzuki T, Kunisada T. An in vitro mouse model for retinal
ganglion cell replacement therapy using eye-like structures differentiated from ES cells. Exp Eye Res.
2007;84:868-875.
20㧕 Yun W, Niwa K, Onogi K, Tang L, Mori H, Tamaya T. Effects of selective estrogen receptor modulatorsand genistein on ERalpha/beta and COX-1/2 expressions in ovarectomized mice uteri. Eur J Gynaecol
Oncol. 2007;28:89-94.
21㧕 Miyazaki Y, Hara A, Kato K, Oyama T, Yamada Y, Mori H, Shibata T. The effect of hypoxic
microenvironment on matrix metalloproteinase expression in xenografts of human oral squamous cell
carcinoma. Int J Oncol. 2008;32:145-151.
22㧕 Taguchi A, Hara A, Saito K, Hoshi M, Niwa M, Seishima M, Mori H. Localization and spatiotemporal
expression of IDO following transient forebrain ischemia in gerbils. Brain Res. 2008;1217:78-85.
23㧕 Tomita H, Kuno T, Yamada Y, Oyama T, Asano N, Miyazaki Y, Baba S, Taguchi A, Hara A, Iwasaki T,
Kobayashi H, Mori H. Preventive effect of fermented brown rice and rice bran on
N-methyl-N'-nitro-N-nitrosoguanidine-induced gastric carcinogenesis in rats. Oncol Rep.
2008;19:11-15.
24㧕 Hozumi I, Suzuki JS, Kanazawa H, Hara A, Saio M, Inuzuka T, Miyairi S, Naganuma A, Tohyama C.
Metallothionein-3 (GIF) is expressed in the brain and various peripheral organs of the rat. Neurosci
Lett. 2008;438:54-58.
25㧕 Kato K, Long NK, Makita H, Toida M, Yamashita T, Hatakeyama D, Hara A, Mori H, Shibata T.
Effects of green tea polyphenol on methylation status of RECK gene and cancer cell invasion in oral
squamous cell carcinoma cells. Br J Cancer. 2008;99:647-654.
26㧕 Aoki H, Hara A, Motohashi T, Chem H, Kunisada T. Iris as a recipient tissue for pigment cells:organized in vivo differentiation of melanocytes and pigmented epithelium derived from embryonicstem cells in vitro. Dev Dynam. 2008;237:2394-2404.
27㧕 Oyama T, Yamada Y, Hata K, Tomita H, Hirata A, Sheng HQ, Hara A, Aoki H, Kunisada T, Yamashita
S, Mori H. Further upregulation of Ǫ-catenin/Tcf transcription is involved in the development ofmacroscopic tumors in the colon of Apc Min/+ mice. Carcinogenesis 2008;29:666-672.
28㧕 Aoki H, Hara A, Niwa M, Motohashi T, Suzuki T, Kunisada T. Transplantation of cells from eye-likestructures differentiated from embryonic stem cells in vitro and in vivo regeneration of retinal
ganglion-like cells. Graefes Arch Clin Exp Ophthalmol. 2008;246:255-265.
29㧕 Aoki H, Yoshida H, Hara A, Suzuki T, Kunisada T. Transplantation of Melanocytes into Iris: Method
for Iris Re-pigmentation. Transplantation. 2008;85:492-494.
30㧕 Hara A, Aoki H, Taguchi A, Niwa M, Yamada Y, Kunisada T, Mori H. Neuron-like Differentiation and
Selective Ablation of Undifferentiated Embryonic Stem Cells Containing Suicide Gene with Oct-4
Promoter. Stem Cells Dev. 2008;17:619-627.
31㧕 Linhart HG, Lin H, Yamada Y, Moran E, Steine EJ, Gokhale S, Lo G, Cantu E, Ehrich M, He T,
Meissner A, Jaenisch R. Dnmt3b promotes tumorigenesis in vivo by gene-specific de novo methylationand transcriptional silencing. Genes Dev. 2008;21:3110-3122.
32㧕 Long NK, Kato K, Yamashita T, Makita H, Toida M, Hatakeyama D, Hara A, Mori H, Shibata T.
Hypermethylation of the RECK gene predicts poor prognosis in oral squamous cell carcinomas. Oral
Oncol. 2008;44:1052-1058.

IF 2.749

IF 3.398

IF 2.265

IF 0.587

IF 2.295
IF 2.218

IF 1.597

IF 2.121

IF 4.635

IF 3.084

IF 5.406

IF 1.590
IF 3.641

IF 3.224

IF 14.795

IF 2.1034㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦᫪⑲᮸㧘⎇ⓥಽᜂ⠪㧦ጊ↰ᵏᐢ㧘ᑝἑༀା㧘᧻᳗⎇๋㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(B)㧦 ࠞ࠹࠾ࡦ/TCF pathway ࠍนⷞൻߒߚㆮવሶዉ౉ࡑ࠙ࠬߦࠃࠆ೨≸∛ᄌߩ⎇ⓥ㧧ᐔᚑ
17㧙19 ᐕᐲ㧧13,600 ජ౞(8,200㧦3,300㧦2,100 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦ጊ↰ᵏᐢ㧘⎇ⓥಽᜂ⠪㧦᫪⑲᮸㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄․ቯ㗔ၞ⎇ⓥ㧦DNA ૐࡔ࠴࡞ൻߣ⊒≸㧧ᐔᚑ 18㧙19 ᐕᐲ㧧5,700 ජ౞(3,900㧦1,800 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦ጊ↰ᵏᐢ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄⧯ᚻ⎇ⓥ(A)㧦૕⚦⢩ߦ߅ߌࠆᧂಽൻᕈ⛽ᜬᯏ᭴⸃᣿ߣߘߩ⊒≸ࡔࠞ࠾࠭ࡓ⸃᣿߳ߩᔕ↪㧧ᐔᚑ 19㧙21 ᐕᐲ㧧14,000 ජ౞(6,000㧦4,300㧦3,700 ජ౞)4㧕 ⎇ⓥઍ⴫⠪㧦ේ ᣿㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦ࡑ࠙ࠬ✂⤑␹⚻ᄌᕈᓟߩ⥄Ვㆮવሶ㧙㧙ዉ౉⢦ᕈᐙ⚦⢩ߦࠃࠆ␹⚻ౣ↢ߣ⣲≌ൻߩᛥ೙㧧ᐔᚑ 19㧙20 ᐕᐲ㧧2,900 ජ౞(1,800㧦1,100 ජ౞)
5㧕 ⎇ⓥઍ⴫⠪㧦‐ፉବ๺㧚⎇ⓥಽᜂ⠪㧦ጊ↰ᵏᐢ㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄㧧ࡅ࠻ᄙᲑ㓏⊒߇ࠎㆊ⒟ߦ߅ߌࠆࠛࡇࠫࠚࡀ࠹ࠖ࠶ࠢߥ⇣Ᏹߩ✂⟜⊛⸃᣿ߣ⥃ᐥᔕ↪ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 19㧙21 ᐕᐲ㧧
12,000 ජ౞(4,000㧦4,000㧦4,000 ජ౞)
6㧕 ⎇ⓥઍ⴫⠪㧦ጊ↰ᵏᐢ㧧․ቯ㗔ၞ⎇ⓥ㧧⣺▤਄⊹ߩჇᱺ࡮ಽൻߦ߅ߌࠆࠛࡇࠫࠚࡀ࠹ࠖ࠶ࠢ೙ᓮᯏ
᭴⸃᣿ߣߘߩ⊒߇ࠎ⎇ⓥ߳ߩᔕ↪㧧ᐔᚑ 20㧙21 ᐕᐲ㧧10,200 ජ౞(5,100㧦5,100 ජ౞)
7㧕 ⎇ⓥઍ⴫⠪㧦ጊ↰ᵏᐢ㧧⑼ቇᛛⴚᝄ⥝ᯏ᭴(JST)ߐ߈߇ߌ⎇ⓥ㧧࡝ࡊࡠࠣ࡜ࡒࡦࠣߦࠃࠆ߇ࠎ⚦⢩ࠛࡇࠫࠚࡀ࠹ࠖ࠶ࠢ⇣Ᏹߩ⿠Ḯ⸃᣿ߣߘߩ⥃ᐥᔕ↪ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 20㧙23 ᐕᐲ㧧39,900 ජ౞(10,000㧦10,000㧦10,000㧦9,900 ජ౞)
2㧕ฃ⸤⎇ⓥ1㧕 ᫪⑲᮸㧦∛ℂ⸻ᢿߩࠦࡦࠨ࡞࠲ࡦ࠻㧧ᐔᚑ 18 ᐕᐲ㧧4,581 ජ౞㧦(ᩣ)଻ஜ⑼ቇ⎇ⓥᚲ
2㧕 ᫪⑲᮸㧦∛ℂ⸻ᢿߩࠦࡦࠨ࡞࠲ࡦ࠻㧧ᐔᚑ 19 ᐕᐲ㧧4,548 ජ౞㧦(ᩣ)଻ஜ⑼ቇ⎇ⓥᚲ
3㧕 ᫪⑲᮸㧦∛ℂ⸻ᢿߩࠦࡦࠨ࡞࠲ࡦ࠻㧧ᐔᚑ 19 ᐕᐲ㧧2,496 ජ౞㧦(ᩣ)᧲ᶏ⚦⢩⎇ⓥᚲ
4㧕 ේ ᣿㧦∛ℂ⸻ᢿߩࠦࡦࠨ࡞࠲ࡦ࠻㧧ᐔᚑ 20 ᐕᐲ㧧4,497 ජ౞㧦(ᩣ)଻ஜ⑼ቇ⎇ⓥᚲ
5㧕 ේ ᣿㧦∛ℂ⸻ᢿߩࠦࡦࠨ࡞࠲ࡦ࠻㧧ᐔᚑ 20 ᐕᐲ㧧492 ජ౞㧦(ᩣ)᧲ᶏ⚦⢩⎇ⓥᚲ
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬේ ᣿㧦
1㧕 ᣣᧄ∛ℂቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ⣖␹⚻ᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ጊ↰ᵏᐢ㧦
1㧕 ╙ 3 ࿁ᣣᧄ≸ቇળࠞࡦࡈࠔ࡟ࡦࠬ(ᐔᚑ 18 ᐕ 3 ᦬㧘‫ޟ‬േ‛ࡕ࠺࡞ߦࠃࠆᣂᤨઍߩ߇ࠎ⎇ⓥг⊒∝ᯏ᭴߆ࠄᴦ≮߹ߢ‫ޠ‬᜗ᓙ⻠Ṷ‫ޟ‬DNA ࡔ࠴࡞ൻߩᄢ⣺⊒≸߳ߩୃ㘼‫ޠ‬Ṷ⠪)
2㧕 ╙ 65 ࿁ᣣᧄ≸ቇળቇⴚ✚ળ ࠪࡦࡐࠫ࠙ࡓ(ᐔᚑ 18 ᐕ 9 ᦬㧘‫⇣ߥࠢ࠶ࠖ࠹ࡀࠚࠫࡇࠛޟ‬Ᏹߩ⿠Ḯߣടㅦ‫ޠ‬᜗ᓙࠪࡦࡐࠫࠬ࠻ ‫ޟ‬DNMT ߩ⇣Ᏹߦࠃࠆ⊒߇ࠎߩଦㅴߣᛥ೙‫ޠ‬Ṷ⠪)‫ޟ‬Multistep carcinogenesis of the3㧕 ╙ 38 ࿁㜞᧻ችᅥ≸⎇ⓥၮ㊄࿖㓙ࠪࡦࡐࠫ࠙ࡓ(ᐔᚑ 19 ᐕ 11 ᦬㧘colon in Apc Min mouse‫ޠ‬Ṷ⠪)
4㧕 ╙ 66 ࿁ᣣᧄ≸ቇળ(ᐔᚑ 19 ᐕ 10 ᦬㧘ࠪࡦࡐࠫ࠙ࡓᐳ㐳߅ࠃ߮ࠪࡦࡐࠫࠬ࠻‫ᧂޟ‬ಽൻᕈ⛽ᜬᯏ᭴ߩᄢ⣺⊒߇ࠎㆊ⒟⸃᣿߳ߩᔕ↪‫ޠ‬ᐳ㐳㧘Ṷ⠪)
5㧕 ╙ 58 ࿁ᣣᧄ㔚᳇ᵒേቇળ(ᐔᚑ 19 ᐕ 11 ᦬㧘
‫ޟ‬DNA ࡔ࠴࡞ൻ⇣Ᏹߩᄢ⣺⊒߇ࠎ߳ߩୃ㘼‫ޠ‬Ṷ⠪)
6㧕 Northeastern Asian Symposium oňCancer Epigenetics̍(2008.11㧘Jeju㧘Korea㧘Symposium‫ޟ‬Role of DNA methylation in multistage colon carcinogenesis‫ޠ‬Ṷ⠪)7㧕 ╙ 67 ࿁ ᣣᧄ≸ቇળቇⴚ✚ળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ฬฎደ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬The role of DNA methylationin carcinogenesis in digestive tract‫ޠ‬Ṷ⠪)8㧕 ╙ 97 ࿁ ᣣᧄ∛ℂቇળ✚ળ(ᐔᚑ 20 ᐕ 4 ᦬㧘㊄ᴛ㧘ࠪࡦࡐࠫ࠙ࡓ‫ᧂޟ‬ಽൻᕈߩ⛽ᜬߣ⊒߇ࠎ‫ޠ‬Ṷ⠪)㧙㧙8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ1㧕 ጊ↰ᵏᐢ㧦╙ 23 ࿁ᣣᧄᲥᕈ∛ℂቇળળ㐳⾨(ᐔᚑ 19 ᐕᐲ)
9㧚␠ળᵴേේ ᣿㧦
1㧕 ጘ㒂⋵౏ⴐⴡ↢ᬌᩏ࠮ࡦ࠲࡯ᜰዉ⋙〈ක(ᐔᚑ 18 ᐕᐲ)
2㧕 ጘ㒂⋵ᚑੱ∛⸻ᢿ▤ℂᜰዉද⼏ળ߇ࠎ⊓㍳⹏ଔㇱળᆔຬ(ᐔᚑ 18 ᐕ㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ጊ↰ᵏᐢ㧦DNA ૐࡔ࠴࡞ൻߣ⊒≸㧦ᐔᚑ 18 ᐕᐲᢥㇱ⑼ቇ⋭․ቯ㗔ၞ⎇ⓥ‫⎇ޠࠎ߇ޟ‬ⓥႎ๔㓸㍳㧦
122(2007 ᐕ)
2㧕 ጊ↰ᵏᐢ㧦DNA ૐࡔ࠴࡞ൻߣ⊒≸㧦ᐔᚑ 19 ᐕᐲᢥㇱ⑼ቇ⋭․ቯ㗔ၞ⎇ⓥ‫⎇ޠࠎ߇ޟ‬ⓥႎ๔㓸㍳㧦
122(2008 ᐕ)
3㧕 ጊ↰ᵏᐢ㧦ࡅ࠻ᄙᲑ㓏⊒߇ࠎㆊ⒟ߦ߅ߌࠆࠛࡇࠫࠚࡀ࠹ࠖ࠶ࠢߥ⇣Ᏹߩ✂⟜⊛⸃᣿ߣ⥃ᐥᔕ↪ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 19 ᐕᐲ╙ 3 ᰴኻ߇ࠎ✚วᚢ⇛⎇ⓥ੐ᬺ ⎇ⓥႎ๔ᛞ㍳㓸㧔‐ፉ⃰㧕㧦7㧙10(2008 ᐕ)
11㧚ႎ㆏
1㧕 ᫪ ⑲᮸㧦ߏ߹ߩ฽᦭ᚑಽ‫ߩޠ࡞࡯ࡁࡒࠨ࠮ޟ‬㧘ᄢ⣺߇ࠎᛥ೙㧦ਛᣣᣂ⡞(2006 ᐕ 5 ᦬ 13 ᣣ)
2㧕 ේ ᣿㧦ES ⚦⢩ࠍ✂⤑⚦⢩ߦ᛫߇ࠎ೷↪޿ಽൻߦᚑഞ㧙ࡑ࠙ࠬ⌒⃿ౝߢ㧦ᣣೀᎿᬺᣂ⡞(2006 ᐕ 9
᦬ 5 ᣣ)
3㧕 ේ ᣿㧦߇ࠎൻߐߖߕߦ ES ⚦⢩ࠍᵴ↪㧙⊕ⴊ∛⮎૶߁㧦ᣣᧄ⚻ᷣᣂ⡞(2006 ᐕ 9 ᦬ 25 ᣣ)
4㧕 ේ ᣿㧦⣲≌ൻߒߘ߁ߥ ES ⚦⢩ࠍㆬᛯ⊛ߦឃ㒰 ␹⚻⚦⢩ࠍౣ↢㧦ᣣೀᎿᬺᣂ⡞ឝタ(2007 ᐕ 9 ᦬
27 ᣣ)
5㧕 ේ ᣿㧦‫ࠎ߇ޟ‬ᐙ⚦⢩‫ ⺑ޠ‬⣉శᶎ߮ࠆ ᣂߚߥᴦ≮ᚢ⇛ߦ㆏ ౣ↢කቇߣⲢวㅴ߻ ਛㇱ⚻ᷣᣂ⡞(2007 ᐕ 2 ᦬ 3 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔකቇ⍮⼂㧘කቇ⎇ⓥߩ࿖㓙᳓Ḱࠍ⛽ᜬߒ߁ࠆ࡟ࡌ࡞ߩ࿖㓙㔀⹹߳ߩ⎇ⓥ⊒⴫ߪ⋡ᮡㅢࠅߢ߈ߡ޿ࠆߣ
ᕁࠊࠇࠆ‫ߒߛߚޕ‬㧘ੱ⊛૛⵨߇ߥ޿ߚ߼㧘⧯ᚻߩ⢒ᚑߥߤ⺖㗴߇ᱷࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ጘ㒂ᄢቇቇ㐳ࠍヘ಴ߒ㧘⃻⁁ߢߪ㧘ᐔᚑ 20 ᐕߦ߅ߌࠆᏱൕ⎇ⓥ⡯ 2 ฬߢ޽ࠅ㧘ੱ⊛૛⵨߇ߥ߆ߞߚ‫ޕ‬ߒ߆ࠆߴ߈⎇ⓥ⠪ߩ⢒ᚑ㧘⵬ల߇✕ᕆߩ⺖㗴ߢ޽ࠆ‫ߚ߹ޕ‬㧘ᐔᚑ 20 ᐕ 4 ᦬ 1 ᣣࠃࠅ‫ޟ‬ක≮ᴺᣉⴕ઎ߩ৻
ㇱࠍᡷᱜߔࠆ᡽઎‫߮ࠃ߅ޠ‬ෘ↢ഭ௛⋭઎ߦࠃࠅ㧘∛ℂ⸻ᢿ⑼߇කᬺߦ㑐ߒߡᐢ๔ߢ߈ࠆ⸻≮ᮡ᭙⑼ฬߣ
ߥߞߚ‫੹ޕ‬ᓟ㧘∛ℂ⸻ᢿᬺോߩක≮㧘␠ળߦᨐߚߔ⽿છ߇ߎࠇ߹ߢએ਄ߦჇߒߡࠁߊߣ⠨߃ࠄࠇࠆ‫∛ޕ‬ℂኾ㐷ක㧘⚦⢩⸻ኾ㐷කߩᵷ㆜߇⃻ታ⊛ߦᦸ߹ࠇߡ߅ࠅ㧘࿾ၞක≮߳ߩ⽸₂ߣ޿߁ὐߦ߅޿ߡ߽⧯ᚻ∛ℂකߩ⢒ᚑ߇✕ᕆ⺖㗴ߢ޽ࠆ‫ޕ‬੹ᓟߩዷᦸᢎቶߩવ⛔⊛ߥ࠹࡯ࡑߢ޽ࠆ㧘⣲≌ߩ⊒↢߆ࠄ੍㒐߹ߢߩ∛ℂቇ⊛⎇ⓥ૕೙ࠍ⛽ᜬߔࠆߣߣ߽ߦ㧘ౣ↢ක≮㧘ᐙ⚦⢩කቇߦ߽㑐ㅪߒߚᣂⷙ∛ℂቇಽ㊁ࠍ㐿ᜏߔࠆ‫ޕ‬න⁛ಽ㊁ߢߩ⁛┙ߒߚ⎇ⓥ૕೙ߦߪ㒢⇇߇޽ࠆߚ߼㧘ᄢቇౝߢߩⶄᢙಽ㊁ߣߩදജ૕೙ࠍⓍᭂ⊛ߦ࿑ࠆ‫ߚ߹ޕ‬㧘∛ℂቇߩၮ␆ߣߒߡੱ૕∛ℂ㧔⸻ᢿ∛ℂ㧕ࠍ㊀ⷞߒ㧘∛㒮∛ℂㇱߣㅪ៤ߒߚ਄ߢ࿾ၞක≮ߦ⽸₂ߢ߈ࠆ∛ℂකࠍ⢒ߡࠆ‫ޕ‬㧙㧙㧔2㧕఺∉∛ℂቇಽ㊁
1㧚⎇ⓥߩ᭎ⷐ
ߎࠇ߹ߢߣห᭽ߦ఺∉෻ᔕߩ઀⚵ߺࠍ⸃᣿ߔࠆߎߣࠍ⋡⊛ߦ⎇ⓥࠍⴕ߁߇, ᒁ߈⛯߈ᰴߩ 2 ὐߦὶὐࠍ
ᒰߡߡ⎇ⓥࠍㅴ߼ࠆ‫ޕ‬1㧕఺∉⚦⢩Ⴧᱺ∝୥⟲ߩ⸻ᢿ╬ߦ㑐ߔࠆ⎇ⓥ㧦ᖡᕈ࡝ࡦࡄ⣲ߩ੍ᓟߪ⚵❱੝ဳߦḰߓߡᄢ߈ߊ⇣ߥࠆߎߣ߆ࠄ, ఺∉ቇߩᦨᣂߩ⍮⷗ࠍᔕ↪ߒ, ᣂߚߥ⸻ᢿᴺߥࠄ߮ߦ੍ᓟߩ⏕ቯᴺࠍ㐿⊒ߔࠆ‫ޕ‬
2㧕᛫⣲≌఺∉෻ᔕߩ⎇ⓥ㧦ࡅ࠻⣲≌ߩ఺∉ቇ⊛ᴦ≮, ᧂߛචಽߥᆭജࠍ⊒ើߔࠆߦ⥋ߞߡ޿ߥ޿‫ߩߎޕ‬ේ࿃ࠍ⚵❱ᒻᘒቇߥࠄ߮ߦಽሶ↢‛ቇ⊛ᚻᴺࠍ㚟૶ߒߡ᣿ࠄ߆ߦߒ, ࠃࠅᒝജߥ᛫⣲≌఺∉≮ᴺߩ⏕┙ࠍ⋡ᜰߔ‫ޕ‬
2㧚ฬ★
㜞⷗ ೰
ᢎ᝼㧦
ಎᢎ᝼㧦 㥱የᓕ⋥ᓟ⮮ዏ⛗ഥᢎ㧦

Tsuyoshi Takami
Masanao Saio
Naoe Goto3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
ߥߒ⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
ߥߒ✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ᄢᐔᐘሶ㧘᧻ጟᢅ↵㧘㜞⷗೰㧚ਛ㜞ᐕ⊓ጊ⠪ߩታᘒ⺞ᩏ̆ᅏⓄ㜞ጪ⊓ጊ⠪ࠍኻ⽎ߣߒߡ㧙㧚Japn J Mountain
Medicine 2007 ᐕ㧧27 Ꮞ㧦31㧙42㧚
2㧕 ଻㉿ᗆ৻㧘ᚑ↰ᵗ㧘㥱የᓕ⋥㧚੃⣼ glycogen-rich clear cell carcinoma ߩ৻଀㧘ᣣᧄ⥃ᐥᄖ⑼ቇળ⹹ 2008
ᐕ㧧69 Ꮞ㧦25㧙29㧚
3㧕 㝩㗡ാテ㧘ᵄᄙ㊁⵨৻㇢㧘᧻᳗⎇๋㧘ᑝἑༀା㧘㥱የᓕ⋥㧘᧻ᧄ⌀੺㧘⊕ᯅᐘᵗ㧘ጤ↰ዏ㧘㜞⷗೰㧚Micronodular
thymoma with lymphoid stroma ߩ৻଀㧘⸻ᢿ∛ℂ 2008 ᐕ㧧25 Ꮞ㧦267㧙271㧚
4㧕 ═ේජ༹㧘ේᱞᔒ㧘㢬⷗ኼ㧘ᓟ⮮ዏ⛗㧘౗᧛ାብ㧘ศᎹᱞᔒ㧘ጊ↰ବ᮸㧘Ỉ↰㆏ᄦ㧘㜞ᯅஜ㧘᫪⣁ਭ㓉㧚ㅧⴊེ⣲≌ߦว૬ߒߚ⊒ᾲᕈᅢਛ⃿ᷫዋ∝ߦኻߔࠆ Biapenem ߩ᦭↪ᕈߦ㑐ߔࠆ⥃ᐥ⊛ᬌ⸛㧘Japn J
Antibiot 2008 ᐕ㧧61 Ꮞ㧦115㧙21㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Suwa T, Saio M, Umemura N, Yamashita T, Toida M, Shibata T, Takami T. Preoperative radiotherapy
contributes to induction of proliferative activity of CD8+ tumor-infiltrating T-cells in oral squamouscell carcinoma. Oncol Rep. 2006;15:757-763.
2㧕 Ouyang GF, Saio M, Suwa T, Imai H, Nakagawa J, Nonaka K, Umemura N, Mika K, Takami T.
Interleukin-2 augmented activation of tumor associated macrophage plays the main role in MHC class
I in vivo induction in tumor cells that are MHC negative in vitro. Int J Oncol. 2006;28:1201-1208.
3㧕 Kojima Y, Tsurumi H, Goto N, Shimizu M, Kasahara S, Yamada T, Kanemura N, Hara T, Sawada M,
Saio M, Yamada T, Takahashi T, Tomita E, Takami T, Moriwaki H. Fas and Fas ligand expression on
germinal center type-diffuse large B-cell lymphoma is associated with the clinical outcome. Eur J
Haematol. 2006;76:465-472.
4㧕 Amaoka N, Saio M, Nonaka K, Imai H, Tomita H, Sakashita F, Takahashi T, Sugiyama Y, Takami T,
Adachi Y. Expression of vascular endothelial growth factor receptors is closely related to thehistological grade of hepatocellular carcinoma. Oncol Rep. 2006;16:3-10.
5㧕 Goto N, Tsurumi H, Takemura M, Hara T, Sawada M, Kasahara S, Kanemura N, Yamada T, Shimizu
M, Takahashi T, Tomita E, Seishima M, Takami T, Moriwaki H. Serum-soluble tumor necrosis factor
receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin’s
lymphoma. Eur J Haematol. 2006;77:217-225.
6㧕 Yasuda I, Tsurumi H, Omar S, Iwashita T, Kojima Y, Yamada T, Sawada M, Takami T, Moriwaki H,
Soehendro N. Endoscopic ultrasound-guided fine-needle aspiration biopsy for lymphadenopathy of㧙㧙

IF 1.597

IF 2.295

IF 2.163

IF 1.597

IF 2.163

unknown origin. Endoscopy. 2006;38:919-924.
7㧕 Kimura K, Moriwaki H, Nagaki M, Saio M, Nakamoto Y, Naito M, Kuwata K, Chisari FV. Pathogenicrole of B cells in anti-CD40-induced necroinflammatory liver disease. Am J Pathol. 2006;168:786-795.
8㧕 Nakagawa J, Saio M, Tamakawa N, Suwa T, Frey AB, Nonaka K, Umemura N, Imai H, Ouyang GF,
Ohe N, Yano H, Yoshimura S, Iwama T, Takami T. TNF expressed by tumor-associated macrophages,
but not microglia, can eliminate glioma. Int J Oncol. 2007;30:803-811.
9㧕 Toita N, Hatano N, Ono S, Yamada M, Kobayashi R, Kobayashi I, Kawamura N, Okano M, Satoh A,
Nakagawa A, Ohshima K, Shindoh M, Takami T, Kobayashi K, Ariga T. Epstein-Barr virus-AssociatedB-cell lymphoma in a patient with DNA ligase IV (LIG4) syndrome. Am J Med Genet A.
2007;143:742-745.
10㧕 Imai H, Saio M, Nonaka K, Suwa T, Umemura N, Ouyang GF, Nakagawa J, Tomita H, Osada S,
Sugiyama Y, Adachi Y, Takami T. Depletion of CD4+CD25+ regulatory T cells enhancesinterleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma. Cancer Sci.
2007;98:416-423.
11㧕 Kimura A, Tan CF, Wakida K, Saio M, Hozumi I, Inuzuka T, Takahashi H. Venous congestive
myelopathy of the cervical spinal cord: an autopsy case showing a rapidly progressive clinical course.
Neuropathology. 2007;27:284-289.
12㧕 Kato H, Kanematsu M, Zhang X, Saio M, Kondo H, Goshima S, Fujita H. Computer-aided diagnosis ofhepatic fibrosis: preliminary evaluation of MRI texture analysis using the finite difference method andan artificial neural network. Am J Roentgenol. 2007;189:117-122.
13㧕 Tsurumi H, Hara T, Goto N, Kanemura N, Kasahara S, Sawada M, Yasuda I, Yamada T, Shimizu M,
Takami T, Moriwaki H. A phase II study of a THP-COP regimen for the treatment of elderly patients
aged 70 years or older with diffuse large B-cell lymphoma. Hematol Oncol. 2007;25:107-114.
14㧕 Umemura N, Saio M, Suwa T, Kitoh Y, Bai J, Nonaka K, Ouyang G F, Okada M, Balazs M, Adany R,
Shibata T, Takami T. Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamedmonocytes/macrophages that bear M1- and M2-type characteristics. J Leukoc Biol. 2008;83:1136-1144.
15㧕 Okubo M, Kawasaki M, Ishihara Y, Takeyama U, Yasuda S, Kubota T, Tanaka S, Yamaki T, Ojio S,
Nishigaki K, Takemura G, Saio M, Takami T, Fujiwara H, Minatoguchi S. Tissue characterization ofcoronary plaques. Circ J. 2008;72:1631-1639.
16㧕 Okubo M, Kawasaki M, Ishihara Y, Takeyama U, Kubota T, Yamaki T, Ojio S, Nishigaki K, Takemura
G, Saio M, Takami T, Minatoguchi S, Fujiwara H. Development of integrated backscatter
intravascular ultrasound for tissue characterization of coronary plaques. Ultrasound Med Biol.
2008;34:655-663.
17㧕 Nonaka K, Saio M, Suwa T, Frey A B, Umemura N, Imai H, Ouyang G F, Osada S, Balazs M, Adany R,
Kawaguchi Y, Yoshida K, Takami T. Skewing the Th cell phenotype toward Th1 alters the maturationof tumor-infiltrating mononuclear phagocytes. J Leukoc Biol. 2008;84:679-688.
18㧕 Kimura K, Nagaki M, Kakimi K, Saio M, Saeki T, Okuda Y, Kuwata K, Moriwaki H. Critical role ofCD44 in hepatotoxin-mediated liver injury. J Hepatol. 2008;48:952-961.
19㧕 Hozumi I, Suzuki J, S, Kanazawa H, Hara A, Saio M, Inuzuka T, Miyairi S, Naganuma A, Tohyama C.
Metallothionein-3 is expressed in the brain and various peripheral organs of the rat. Neurosci Lett.
2008;438:54-58.
20㧕 Hara T, Tsurumi H, Kato T, Imao Y, Kojima Y, Kojima K, Kitagawa J, Katsumura N, Araki H, Takami
T, Moriwaki H. Immunoproliferative small intestinal disease with protein loss complicated withduodenal T cell lymphoma during progression. Intern Med. 2008;47:299-303.
21㧕 Kanemura N, Tsurumi H, Kasahara S, Hara T, Yamada T, Sawada M, Goto N, Kitagawa J, Shimizu M,
Oyama M, Moriwaki, H. Continuous drip infusion of low dose cytarabine and etoposide with
granulocyte colony-stimulating factor for elderly patients with acute myeloid leukaemia ineligible forintensive chemotherapy. Hematol Oncol. 2008;26:33-38.

IF 4.166
IF 5.487

IF 2.295

IF 2.440

IF 3.115

IF 1.326

IF 2.470

IF 2.180

IF 4.128

IF 2.373

IF 1.922

IF 4.128
IF 6.620

IF 2.085

IF 2.1804㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦㥱የᓕ⋥㧘⎇ⓥಽᜂ⠪㧦㜞⷗೰㧘ᄢᳯ⋥ⴕ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(B)(2)㧦⤔⚦⢩⣲≌ౝᶐẢ᮸⁁⚦⢩ߩ⣖․⇣⊛ಽൻ࡮ᚑᾫᯏᐨߩ⸃᣿㧧ᐔᚑ 18㧙20 ᐕᐲ㧧21,080 ජ౞(12,040㧦6,240㧦2,800 ජ౞)
2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥߥߒ㧙㧙5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬ㜞⷗೰㧦
1㧕 ᣣᧄ∛ℂቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ఺∉ቇળ⹏⼏ຬ࡮ㆇ༡ᆔຬ(㨪⃻࿷)3㧕 ᣣᧄ∛ℂቇળਛㇱᡰㇱᐙ੐(㨪⃻࿷)㥱የᓕ⋥㧦1㧕 ᣣᧄ∛ℂቇળ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅㜞⷗೰㧦
1㧕 ╙ੑ࿁ᣣᧄ∛ℂቇળਛㇱᡰㇱᄐߩቇᩞ(ᐔᚑ 20 ᐕ 8 ᦬㧘ጘ㒂)
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳㜞⷗೰㧦
1㧕 ╙ 97 ࿁ᣣᧄ∛ℂቇળ✚ળ(ᐔᚑ 20 ᐕ 5 ᦬㧘㊄ᴛ㧘ኋ㗴ႎ๔Τ‫∉఺ࠎ߇࠻ࡅޟ‬೙ᓮߩಽሶ∛ℂቇ⊛ၮ⋚‫ޠ‬ᐳ㐳㧕
8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ㥱የᓕ⋥㧦
1㧕 ╙ 11 ࿁≸⎇ⓥߩㅴᱠ਎⇇ળ⼏ቇળ⾨(2006.10.14)
9㧚␠ળᵴേ
㜞⷗೰㧦
1㧕 2006 ᐕᐲ㨪2008 ᐕᐲጘ㒂ᄢቇකቇㇱᅏⓄ㜞ጪᄐጊ⸻≮ᚲㆇ༡ᆔຬળᆔຬ㐳2㧕 ጘ㒂ᄢቇකቇㇱᅏⓄ㜞ጪᄐጊ⸻≮ᚲ 50 ๟ᐕ⸥ᔨ⻠Ṷળ(2008 ᐕ 11 ᦬ 30 ᣣ㧘ጘ㒂)
3㧕 ಴೨⻠⟵㧦ਛᵤ㜞ᩞ(2008 ᐕ 11 ᦬ 13 ᣣ)㧘ศၔ㜞ᩞ(2008 ᐕ 12 ᦬ 11 ᣣ)
10㧚ႎ๔ᦠ
1㧕 㥱የᓕ⋥㧘㜞⷗೰㧘ᄢᳯ⋥ⴕ㧦ή⚦⢩Ⱞ⊕⊒⃻♽ࠍ↪޿ߚࡊࡠ࠹ࠝࡒࠢࠬᤨઍߩ⤔⚦⢩⣲≌఺∉ᴦ
≮ᴺߩ㐿⊒㧦ᐔᚑ 16 ᐕᐲ㧙ᐔᚑ 17 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)⎇ⓥᚑᨐႎ๔ᦠ(2006 ᐕ 3
᦬ 31 ᣣ)11㧚ႎ㆏
1㧕 㜞⷗೰㧦∛ℂቇળਛㇱᡰㇱ‫ޟ‬ᄐߩቇᩞ‫∛ޠ‬ℂቇߩ㝯ജ㧦ਛᣣᣂ⡞(2008 ᐕ 8 ᦬ 31 ᣣ)
2㧕 㜞⷗೰㧦ᅏⓄ㜞ጪᄐጊ⸻≮ᚲ 50 ๟ᐕ⸥ᔨ⻠Ṷળ㧦ጘ㒂ᣂ⡞(2008 ᐕ 12 ᦬ 1 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔᖡᕈ࡝ࡦࡄ⣲ߩ⎇ⓥߪ, දห⎇ⓥ⠪ߢ޽ࠆⴊᶧ∛ᘒቇࠣ࡞࡯ࡊߣߩදജߩਅ, ᣂߚߥ੍ᓟ࿃ሶߩหቯ
ߥߤߩᚑᨐߦߟߥ߇ࠅ⺰ᢥߣߒߡᖱႎࠍ⊒ାߢ߈ߚ߇, ᄖㇱ⾗㊄ߩ₪ᓧ, ․⸵಴㗿߹ߢ⊒ዷߐߖࠆߎߣ
߇ߢ߈ߡ޿ߥ޿ߎߣ߇੹ᓟߩ⺖㗴ߣߒߡᱷߐࠇߚ‫ޕ‬᛫⣲≌఺∉෻ᔕߩ⸃᣿ߪ㥱የಎᢎ᝼߇ਛᔃߦ♖ജ⊛ߦㅴ߼ࠄࠇ, ⹏ଔߩ㜞޿㔀⹹ߦឝタߐࠇࠆߣߣ߽ߦᄖㇱ⾗㊄߽₪ᓧߢ߈, චಽߦ⹏ଔߢ߈ࠆ߽ߩߣ⠨߃ߡ޿ࠆ‫ޕ‬
೨ภߢ޽ߍߚቇળᵴേ߿␠ળᵴേߦ߽ജࠍᵈ޿ߛ‫∛ޕ‬ℂක₪ᓧࠍ⋡ᜰߒߚ‫ޟ‬ᄐߩቇᩞ‫߅ࠍޠ‬਎⹤ߔࠆߣߣ߽ߦ, ᅏⓄ㜞ጪᄐጊ⸻≮ᚲߦ㑐ߔࠆකቇㇱߩࡎ࡯ࡓࡍ࡯ࠫߦᖱႎࠍタߖ, 50 ๟ᐕ⸥ᔨ⻠Ṷળࠍ㐿௅㧙㧙ߒߡஜᐽߩ⛽ᜬߣჇᒝߦ㑐ߔࠆࡔ࠶࠮࡯ࠫࠍ⊒ାߔࠆߎߣ߇ߢ߈ߚ‫ߪߦࠄߐޕ‬, 2 ࿁ߩ಴೨⻠⟵ࠍᜂᒰߒ,㜞ᩞ↢ߩකቇ࡮ක≮ߩߺߥࠄߕࠨࠗࠛࡦࠬߦኻߔࠆ⥝๧߇Ⴧߔࠃ߁ദജߒߚ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ᢎቶຬߩዋߥ޿⃻⁁ߢߪ޽ࠆ߇, ⎇ⓥߣᢎ⢒࡮␠ળᵴേࠍߘࠇߙࠇಽᜂߒߡദജߔࠆߎߣߦࠃࠅ, Ყセ⊛ߦࡃ࡜ࡦࠬߩߣࠇߚᵴേࠍߔࠆߎߣ߇ߢ߈ߚ‫ߒ߆ߒޕ‬, ᢎቶຬࠍჇ߿ߔ߹ߢߦߪ⥋ࠄߕ, ᒁ߈⛯߈∛ℂක޽ࠆ޿ߪၮ␆ቇ໧ࠍᔒߔੱ᧚ߩ⊒ជߦദജߔࠆߎߣ߇ᔅⷐߣ⠨߃ߡ޿ࠆ‫ߩߘޕ‬ᣇ╷ߣߒߡ, ‫ޟ‬ᄐߩቇᩞ‫ߦޠ‬කቇㇱቇ↢߿⎇ୃකࠍᏎ߈ㄟ߻ߎߣ, 㐳ᦼ⊛ߦߪ‫ޟ‬಴೨⻠⟵‫ࠆࠃߦߤߥޠ‬໪⫥ࠍ࿾㆏ߦ⛯ߌࠆߎߣ߇ᔅⷐߣ⠨߃ࠆ‫ޕ‬੹ᓟߩዷᦸ╙৻ߦᖡᕈ࡝ࡦࡄ⣲ߩ੍ᓟࠍⷙቯߔࠆ࿃ሶߣ఺∉෻ᔕߣߩ㑐ଥࠍ⸃᣿ߔࠆߎߣߢ, ᣂߚߥ⸻ᢿᴺߥࠄ
߮ߦᴦ≮ᴺߩ㐿⊒ࠍㅴ߼ࠆ‫ޕ‬᛫⣲≌఺∉ߢߪ⣲≌ዪᚲߢ఺∉ᛥ೙ᕈߦ௛ߊ⚦⢩ߩ⸃ᨆࠍㅴ߼, ᛥ೙ࠪࠣ࠽࡞ߩ⸃㒰ߣ఺∉੣ㅴࠪࠣ࠽࡞߳ߩᄌ឵ࠍታ⃻ߔࠆࠃ߁ߥಽሶ෻ᔕᯏᐨࠍ᣿ࠄ߆ߦߒߚ޿‫ޕ‬㧙㧙㧔3㧕⣲≌ᄖ⑼ቇಽ㊁1㧚⎇ⓥߩ᭎ⷐศ↰๺ᒄ㧦
1㧕㘩㆏≸࡮⢗≸ߦ߅ߌࠆ⣻⣧㏜ᚻⴚߩ᦭↪ᕈߦ㑐ߔࠆ⎇ⓥ
2㧕ಾ㒰ਇ⢻⢗≸ߦኻߔࠆ S-1+Docetaxel ≮ᴺߩ᦭↪ᕈߦ㑐ߔࠆ⎇ⓥ
3㧕㘩㆏≸ߦ߅ߌࠆ Docetaxel+5-Fu+Radiation ߩ᦭↪ᕈߦ㑐ߔࠆ⎇ⓥ
4㧕⢗≸ߦ߅ߌࠆ 5-FU ⠴ᕈߩࡔࠞ࠾࠭ࡓߩ⸃ᨆ
5㧕ᶖൻེ≸ߦ߅ߌࠆ Adjuvant Surgery ߩ᦭↪ᕈߦ㑐ߔࠆ⎇ⓥ
6㧕⢗≸ⴚᓟ⵬ഥ≮ᴺߦ㑐ߔࠆᄢⷙᮨ⥃ᐥ⹜㛎
7㧕ᶖൻེ≸ߦ߅ߌࠆಽሶᮡ⊛ᴦ≮ߣ᛫≸೷૬↪ߦࠃࠆലᨐჇᒝലᨐߦ㑐ߔࠆ⎇ⓥ㐳↰⌀ੑ㧦
1㧕ಾ㒰ਇ⢻⤟≸ߦኻߔࠆ Vitamin K3 ዪᚲᛩਈߩၮ␆⎇ⓥ‫ޕ‬2㧕ォ⒖ᕈ⢄߇ࠎߩᄖ⑼ಾ㒰ߩᴦ≮ㆡᔕ᜛ᄢ‫ޕ‬
3㧕㜞ᐲㅴⴕ⢄≸ߦኻߔࠆಓ⚿ᴦ≮ߩၮ␆⊛࡮⥃ᐥ⊛⎇ⓥ‫ޕ‬ጊญ๺਽㧦1㧕⢗≸ߦ߅ߌࠆ⣻⣧㏜ਅಾ㒰ⴚߩⴚᓟᶖൻ▤ᯏ⢻ߦ㑐ߔࠆ⎇ⓥ㜞ᯅቁᄦ㧦
1㧕ᄢ⣺≸ߦ߅ߌࠆ DNA ࡊࡠࡕ࡯࠲࡯㗔ၞ⇣Ᏹࡔ࠴࡞ൻࠍ↪޿ߚᣧᦼ⸻ᢿ߳ߩᔕ↪‫ޕ‬ဈਅᢥᄦ㧦
1㧕⢗≸ൻቇ≮ᴺߩၮ␆⊛⎇ⓥ‫ޕ‬ᓼጊᵏᴦ㧦
1㧕ᄢ⣺≸ߦ߅ߌࠆ߇ࠎᛥ೙ㆮવሶࡊࡠࡕ࡯࠲࡯㗔ၞߦ߅ߌࠆࡔ࠴࡞ൻߩᬌ⸛‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
ศ↰๺ᒄ
ಎᢎ᝼㧦
㐳↰⌀ੑ
ಎᢎ᝼(૬છ)㧦 Ꮉญ㗅ᢘ
ጊญ๺਽
⻠Ꮷ㧦
㜞ᯅቁᄦ
⻠Ꮷ㧦
ဈਅᢥᄦ
⥃ᐥ⻠Ꮷ㧦
⚦㊁⧐᮸
⥃ᐥ⻠Ꮷ㧦
ᓼጊᵏᴦ
ഥᢎ㧦
ᅏ᧛⋥᮸
ഥᢎ㧦
↰ਛༀብ
කຬ㧦
ฬ๺ᱜੱ
කຬ㧦
੗Ꮉᗲሶ
කຬ㧦
⋿↰㓶Ꮢ
කຬ㧦
ጊ↰㗅ሶ
කຬ㧦

Kazuhiro Yoshida
Shinji Osada
Yoshihiro Kawaguchi
Kazuya Yamaguchi
Takao Takahashi
Fumio Sakashita
Yoshiki Hosono
Yasuharu Tokuyama
Naoki Okumura
Yoshihiro Tanaka
Masahito Nawa
Aiko Ikawa
Yuichi Sanada
Junko Yamada

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ቟㆐ᵗ␭✬⪺㧚කᏧߩ઀੐ߣ⸻≮⑼ࠟࠗ࠼㧘᧲੩㧦㊄ේ಴ 㧧2006 ᐕ㧚
2㧕 ቟㆐ᵗ␭㧚ᦨᣂࠛࡆ࠺ࡦࠬߦၮߠߊᄢ⣺߇ࠎ⸻≮ࠟࠗ࠼㧘᧲੩㧦㊄ේ಴ 㧧2006 ᐕ䋮
3㧕 ศ↰๺ᒄ㧚ᶖൻེ≸ߩൻቇ≮ᴺߩታ㓙,ࠝࡦࠦࡠࠫ࡯ࠢ࡝࠾ࠞ࡞ࠟࠗ࠼㧘ධጊၴ㧧2007 ᐕ㧦57㧙61.
⪺ᦠ㧔᰷ᢥ㧕ߥߒ㧙㧙✚⺑㧔๺ᢥ㧕1㧕 ቟㆐ᵗ␭㧘ጊญ๺਽㧘ጊ↰ ⺈㧘⒳᧛ᑝᏈ㧘࿡ᨑసⴕ㧚ᱷ⢗ߩ≸ߩᴦ≮ߣ੍㒐 ᱷ⢗≸ߩ੍㒐ߣᣧᦼ⊒⷗㧘ᄖ⑼ᴦ≮ 2006 ᐕ㧧94 Ꮞ㧦280㧙285㧚
2㧕 ቟㆐ᵗ␭㧘᧻੗ᐽม㧘቟↰㚅❱㧘㋈ᧁ෹Ꮧ㧘㐷੗⛗⟤㧘੗ᷓᄼม㧚ᄢ⣺≸ߩ⣻⣧㏜ᚻⴚ ᦨᣂᢥ₂࡟ࡆࡘ࡯㧘ᄖ⑼ᴦ≮ 2006 ᐕ㧧94 Ꮞ㧦751㧙753㧚
3㧕 ቟㆐ᵗ␭㧘ᴡว㓷ᒾ㧘⩲㊁ᤘብ㧘ᾢᴛદ๺↢㧘ጊญ๺਽㧚ࠢ࡝࠾ࠞ࡞ࡄࠬߦၮߠ޿ߚⴚᓟ▤ℂߩߔߴߡ ᐝ㐷஥⢗ಾ㒰㧘ᶖൻེᄖ⑼ 2006 ᐕ㧧29 Ꮞ㧦591㧙606㧚
4㧕 ᧖ጊ଻ᐘ㧚ᖚ⠪ℂ⸃ߩ∝⁁࡮ᬌᩏ୯ࡉ࠶ࠢ ࠤ࡯ࠬԘ ♧ዩ∛ࠍว૬ߒߡ޿ࠆ႐ว㧘ᄖ⑼ᷙว∛᫟ࠤࠕ
2006 ᐕ㧧1 Ꮞ(ഃೀ⸥ᔨภ)㧦4㧙11㧚
5㧕 ᧖ጊ଻ᐘ㧚ᖚ⠪ℂ⸃ߩ∝⁁࡮ᬌᩏ୯ࡉ࠶ࠢ ࠤ࡯ࠬԚ ᓴⅣེ∔ᖚ(ᔃ∔ᖚ‫ޔ‬㜞ⴊ࿶∝)ࠍว૬ߒߡ޿ࠆ႐
ว㧘ᄖ⑼ᷙว∛᫟ࠤࠕ 2006 ᐕ㧧1 Ꮞ(ഃೀ⸥ᔨภ)㧦24㧙33㧚
6㧕 ᧖ጊ଻ᐘ㧚ᖚ⠪ℂ⸃ߩ∝⁁࡮ᬌᩏ୯ࡉ࠶ࠢ ࠤ࡯ࠬԜ ⣢ᯏ⢻㓚ኂࠍว૬ߒߡ޿ࠆ႐ว㧘ᄖ⑼ᷙว∛᫟ࠤ
ࠕ 2006 ᐕ㧧1 Ꮞ(ഃೀ⸥ᔨภ)㧦48㧙55㧚
7㧕 ቟㆐ᵗ␭㧘Ꮉญ㗅ᢘ㧘⚦㊁⧐᮸㧘㐳የ⢒ሶ㧘ᮯႦ⊓⟤↵㧘ጊᧄ ᖗ㧚૶↪ߔࠆ┙႐߆ࠄߺߚ≸⸻≮ࠟࠗ࠼࡜ࠗࡦߩࡐࠗࡦ࠻ ੃≸⸻≮ࠟࠗ࠼࡜ࠗࡦ㧘ᄖ⑼ᴦ≮ 2006 ᐕ㧧94 Ꮞ㧦157㧙163㧚
8㧕 ቟㆐ᵗ␭㧘Ꮉญ㗅ᢘ㧘㐳የ⢒ሶ㧘ਛ↰℉Ꮘ㧘⚦㊁⧐᮸㧘੗Ꮉᗲሶ㧘᫪శ⪇Ẵ㧘ቝ૒⟤┨㕏㧚⤳ེ೎≸⸻≮ࠟࠗ࠼࡜ࠗࡦⷐ⚂㓸 ੃≸⸻≮ࠟࠗ࠼࡜ࠗࡦ㧘ᄖ⑼ 2006 ᐕ㧧68 Ꮞ㧦173㧙180㧚
9㧕 ศ↰๺ᒄ.ᶖൻེ≸ⴚᓟ⵬ഥൻቇ≮ᴺߩ⃻⁁ߣ໧㗴ὐ,ᣣᧄᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧108 Ꮞ㧦302㧙303.
✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ᧖ጊ଻ᐘ㧘㐳↰⌀ੑ㧘ጊญ๺਽㧘㐳የᚑᢅ㧘㜞ᯅቁᄦ㧘᧻੗ᐽม㧘↰ਛජᒄ㧘ဈਅᢥᄦ㧘ᅏ᧛⋥᮸㧘ᓼጊᵏᴦ㧚ಾ㒰ਇ⢻ㅴⴕᶖൻེ≸ߦኻߔࠆಓ⚿ᴦ≮ߩ᦭↪ᕈ㧘ᶖൻེ⑼ 2006 ᐕ㧧42 Ꮞ㧦178㧙185㧚
2㧕 ᧖ጊ଻ᐘ㧘㐳↰⌀ੑ㧘ጊญ๺਽㧘㐳የᚑᢅ㧘㜞ᯅቁᄦ㧘ဈਅᢥᄦ㧚ࠛࡆ࠺ࡦࠬߦၮߠ޿ߚࡃࠗࠝ࠮࡜ࡇࠖ
㧙ࠢ࡟ࠬ࠴ࡦߦ߅ߌࠆࠛࡆ࠺ࡦࠬ㧘Biotherapy 2006 ᐕ㧧20 Ꮞ㧦396㧙402㧚
3㧕 ᧖ጊ଻ᐘ㧘᧻ᯅᑧᄈ㧘ဈਅᢥᄦ㧘㜞ᯅቁᄦ㧚ቢో IT ൻ∛㒮ߦ߅ߌࠆᖱႎࠪࠬ࠹ࡓߩ⣻ㇱᢇᕆ⸻≮߳ߩ⽸₂㧘ᣣᧄ⣻ㇱᢇᕆකቇળ㔀⹹ 2006 ᐕ㧧26 Ꮞ㧦637㧙641㧚
4㧕 ᧖ጊ଻ᐘ㧘᧻ᯅᑧᄈ㧘ဈਅᢥᄦ㧘㜞ᯅቁᄦ㧚࡝ࠬࠢࡑࡀ࡯ࠫࡔࡦ࠻ߩⷰὐ߆ࠄߺߚ⣻ㇱᢇᕆක≮ߦ߅ߌࠆ㔚ሶࠞ࡞࠹⸻≮ߩഞ⟋㧘ᣣᧄ⣻ㇱᢇᕆකቇળ㔀⹹ 2006 ᐕ㧧26 Ꮞ㧦753㧙756㧚
5㧕 ဈਅᢥᄦ㧘᫜ᯅ೑ⴕ㧘ጊญ๺਽㧘㐳↰⌀ੑ㧘᧖ጊ଻ᐘ㧘቟㆐ᵗ␭㧚⥄Ꮖ఺∉ᕈ⤟Ἳߦ૬⊒ߒߚ⤟የㇱ≸ߩ
1 ଀㧘ᣣᧄᶖൻེᄖ⑼ቇળ⹹ 2006 ᐕ㧧39 Ꮞ㧦78㧙83㧚
6㧕 ጊญ๺਽㧘ᅏ᧛⋥᮸㧘ᓼጊᵏᴦ㧘ဈਅᢥᄦ㧘㐳የᚑᢅ㧘᧖ጊ଻ᐘ㧘቟㆐ᵗ␭㧚⢗▤ౣᑪߦࠃࠆ⣻⣧㏜⵬ഥਅྃ㐷஥⢗ಾ㒰ⴚ㧘ᄖ⑼ᴦ≮ 2006 ᐕ㧧95 Ꮞ㧦449㧙453㧚
7㧕 ጊญ๺਽㧘ᅏ᧛⋥᮸㧘ᓼጊᵏᴦ㧘ဈਅᢥᄦ㧘㜞ᯅቁᄦ㧘㐳የᚑᢅ㧘㐳↰⌀ੑ㧘᧖ጊ଻ᐘ㧘቟㆐ᵗ␭㧚⣻⣧㏜⵬ഥਅྃ㐷஥⢗ಾ㒰ⴚࠍߒߚ⢗ࠞ࡞࠴ࡁࠗ࠼⣲≌ߩ 1 ଀㧘ᄖ⑼ᴦ≮ 2007 ᐕ㧧96 Ꮞ㧦106㧙109㧚
8㧕 ጊญ๺਽㧘ዊ᫪ల༹㧘᧻੗ ⡡㧘૒‫⟵ᧁޘ‬ਯ㧘↰ਛ⑲ౖ㧘ᓼጊᵏᴦ㧘ဈਅᢥᄦ㧘㜞ᯅቁᄦ㧘㐳የᚑᢅ㧘㐳↰⌀ੑ㧘቟㆐ᵗ␭㧘⨹ᧁኡม㧘ᑝἑༀା㧚B࡮⢗࡮චੑᜰ⣺ߩ⣲≌ᕈ∔ᖚ⒘ߥ⚵❱ဳߩ⢗ߩ⣲≌㧘ᄖ⑼ᴦ
≮ 2007 ᐕ㧧96 Ꮞ㧦467㧙472㧚
9㧕 ጊญ๺਽㧘ဈਅᢥᄦ㧘㜞ᯅቁᄦ㧘㐳የᚑᢅ㧘㐳↰⌀ੑ㧘Ꮉญ㗅ᢘ㧚⢗๟࿐ߩ␹⚻⸃೬ߣᯏ⢻ߩⷐὐ㧘ᚻⴚ
2007 ᐕ㧧61 Ꮞ㧦957㧙961㧚
10㧕 㜞ᯅቁᄦ㧘ᓼጊᵏᴦ㧘ဈਅᢥᄦ㧘㐳የᚑᢅ㧘ጊญ๺਽㧘㐳↰⌀ੑ㧘⨹ᧁኡม㧘᧖ጊ଻ᐘ㧘ን↰ᒄਯ㧘ᑝἑༀା㧚ਅㇱ⋥⣺ᚳᐔ਄⊹≸߇਄ㇱ⋥⣺ߦหᤨᕈოౝォ⒖ࠍ߈ߚߒߚ 1 ಾ㒰଀㧘ᣣᧄᄢ⣺⢂㐷∛ળ⹹ 2007
ᐕ㧧60 Ꮞ㧦105㧙109㧚
11㧕 㜞ᯅቁᄦ㧘᧖ጊ଻ᐘ㧚ੱᎿ⢂㐷ߪᓟ⣻⤑⚻〝߇ᮡḰ߆㧘⥃ᐥᄖ⑼ 2007 ᐕ㧧62 Ꮞ㧦1578㧙1580㧚
12㧕 ဈਅᢥᄦ㧘㐳↰⌀ੑ㧘ዊ᫪ల༹㧘᧻੗ ⡡㧘ᓼጊᵏᴦ㧘ᅏ᧛⋥᮸㧘↰ਛ⑲ౖ㧘⚦㊁⧐᮸㧘᧖ጊ଻ᐘ㧘቟㆐ᵗ␭㧚⤟ౝಽᴲ⣲≌ᩭ಴ᓟ 4 ᐕ⋡ߦ⊒∝ߒߚࠣ࡞ࠞࠧࡦ↥↢⣲≌૬ሽࠗࡦࠬ࡝ࡁ࡯ࡑߩ 1 ଀㧘ᣣᧄᶖൻེ
ᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧40 Ꮞ㧦634㧙638㧚
13㧕 ဈਅᢥᄦ㧘㜞ᯅቁᄦ㧘↰ਛ⑲ౖ㧘ዊ᫪ల༹㧘᧻੗ ⡡㧘㐳↰⌀ੑ㧚ⴊᩖᕈⴊዊ᧼ᷫዋᕈ⚡᢬∛ߩᴦ≮ਛߦ૬⊒ߒߚ᳇⣲ᕈ⢙ྙἻߩ 1 ଀㧘ᣣᧄ⥃ᐥᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧68 Ꮞ㧦1262㧙1265㧚
14㧕 ᓼጊᵏᴦ㧘㐳↰⌀ੑ㧘૒‫⟵ᧁޘ‬ਯ㧘੹੗ ኼ㧘᧻੗ ⡡㧘ዊ᫪ల༹㧘㜞੗శᴦ㧘ౝᧁ㓉ᢥ㧘੹੗ஜੑ㧘ㄭ⮮ᶈผ㧘੖ፉ ⡡㧘౗᧻㓷ਯᑝἑༀା㧚ⴚ೨ߦ⢄⚦⢩≸ߣߩ㐓೎߇໧㗴ߣߥߞߚ⢄⚦⢩⣼⣲ߩ 1 ଀㧘⢄⢙⤟ᴦ⎇⹹ 2007 ᐕ㧧5 Ꮞ㧦35㧙40㧚
15㧕 ศ↰๺ᒄ㧘ጊญ๺਽㧘ဈਅᢥᄦ㧘↰ਛༀብ㧘ᯫේ ᷕ㧘↰ㄝ๺ᾖ㧚⢗ో៰ߦ߅ߌࠆ቟ోߥེ᪾่วߩࡐࠗࡦ
࠻㧘⥃ᐥᄖ⑼ 2008 ᐕ㧧63 Ꮞ㧦203㧙207㧚
16㧕 ศ↰๺ᒄ㧘ጊญ๺਽㧘ဈਅᢥᄦ㧘↰ਛༀብ㧘ᯫේ ᷕ㧘↰ㄝ๺ᾖ㧚ⴚ೨ൻቇ≮ᴺ㧘ᶖൻེᄖ⑼ 2008 ᐕ㧧31
Ꮞ㧦820㧙826㧚
17㧕 ศ↰๺ᒄ㧘ጊญ๺਽㧘ဈਅᢥᄦ㧘↰ਛༀብ㧘ᯫේ ᷕ㧘↰ㄝ๺ᾖ㧚⢗≸-ၮ␆࡮⥃ᐥ⎇ⓥߩࠕ࠶ࡊ࠺࡯࠻-㧘ᣣᧄ⥃ῼ 2008 ᐕ㧧66 Ꮞ㧦409㧙413㧚
18㧕 ศ↰๺ᒄ㧘ጊญ๺਽㧘ဈਅᢥᄦ㧘↰ਛༀብ㧘㜞ᯅቁᄦ㧘㐳↰⌀ੑ㧚DIF ߣ⢗≸㧚ࠦࡦ࠮ࡦࠨࠬ≸ᴦ≮ 2008
ᐕ㧧7 Ꮞ㧦220㧙223㧚
19㧕 㜞ᯅቁᄦ㧘ᓼጊᵏᴦ㧘ဈਅᢥᄦ㧘㐳የᚑᢅ㧘ጊญ๺਽㧘㐳↰⌀ੑ㧘⨹ᧁኡม㧘᧖ጊ଻ᐘ㧘ን↰ᒄਯ㧘ᑝἑ㧙㧙ༀା㧚ਅㇱ⋥⣺ᚳᐔ਄⊹≸߇਄ㇱ⋥⣺ߦหᤨᕈოౝォ⒖ࠍ߈ߚߒߚ 1 ಾ㒰଀㧘ᣣᧄᄢ⣺⢂㐷∛ቇળ㔀⹹
2008 ᐕ㧧61 Ꮞ㧦33㧙38㧚
20㧕 ᧻੗ ⡡㧘㐳↰⌀ੑ㧘ዊ᫪ల༹㧘ᓼጊᵏᴦ㧘ဈਅᢥᄦ㧘㜞ᯅቁᄦ㧘ጊญ๺਽㧘ศ↰๺ᒄ㧚⣲≜ᒻᚑᕈ⤟Ἳ
ߩ 2 ಾ㒰଀㧘ᣣᧄᄖ⑼♽ㅪวቇળ⹹ 2008 ᐕ㧧33 Ꮞ㧦78㧙83㧚
21㧕 ጊญ๺਽㧘ศ↰๺ᒄ㧘㐳↰⌀ੑ㧘㜞ᯅቁᄦ㧘ဈਅᢥᄦ㧘↰ਛༀብ㧚⢗ྃ㐷ㇱ㧘ᚻⴚ 2008 ᐕ㧧62 Ꮞ㧦739
㧙743㧚
22㧕 ዊ᫪ల༹㧘㐳↰⌀ੑ㧘ᓼጊᵏᴦ㧘ศ↰๺ᒄ㧚⤟઒ᕈྙ⢩ౝ≪ⴚᓟߦ࡚ࠪ࠶ࠢࠍ઻߁ᄢ㊂ߩྙ⢩ౝ಴ⴊࠍ᧪
ߒߚ৻଀㧘ጘ㒂ᄢቇකቇㇱ♿ⷐ 2008 ᐕ㧧55 Ꮞ㧦51㧙54㧚
24㧕 㐳↰⌀ੑ㧘ศ↰๺ᒄ㧚ㅴⴕ⤟≸ᴦ≮ߦ߅ߌࠆ⚦⢩ౝࠪࠣ࠽࡞࿃ሶߩᔕ↪㧘Biotherapy 2008 ᐕ㧧22 Ꮞ㧦233
㧙240㧚
25㧕 ጊญ๺਽㧘ศ↰๺ᒄ㧘㐳↰⌀ੑ㧘㜞ᯅቁᄦ㧘ဈਅᢥᄦ㧘↰ਛༀብ㧘⨹ᧁኡม㧚⢗≸㧘ᄖ⑼ᴦ≮ 2008 ᐕ㧧
99 Ꮞ㧦120㧙126㧚
26㧕 㜞ᯅቁᄦ㧘ศ↰๺ᒄ㧚⢖≸-ၮ␆࡮⥃ᐥ⎇ⓥߩࠕ࠶ࡊ࠺࡯࠻- ᣣᧄ⥃ῼ 2008 ᐕ㧧66 Ꮞ㧦162㧙166㧚
27㧕 㜞ᯅቁᄦ㧘ጊ↰㗅ሶ㧘ฬ๺ᱜੱ㧘↰ਛༀብ㧘ᓼጊᵏᴦ㧘ဈਅᢥᄦ㧘ጊญ๺਽㧘㐳↰⌀ੑ㧘ศ↰๺ᒄ㧚ㅴⴕౣ⊒ᄢ⣺≸ߦ߅ߌࠆᣂⷙ᛫≸೷ᴦ≮⚻㛎㧘≸ߩ⥃ᐥ 2008 ᐕ㧧54 Ꮞ㧦763㧙769㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Sakashita F, Osada S, Yawata K, Sugiyama Y. A case report of duodenal stenosis due to a ruptured
aneurysm of the pancreaticoduodenal artery. J Jpn Coll Surg. 2006;31:54-55.
2㧕 Amaoka N, Saio M, Nonaka K, Imai H, Tomita H, Sakashita F, Takahashi T, Sugiyama Y, Takami T,
Adachi Y. Expression of vascular endothelial growth factor receptors is closely related to thehistological grade of hepatocellular carcinoma. Oncol Rep. 2006;16:3-10.
IF3㧕 Osada S, Tomita H, Imai H, Okumura N, Tokuyama Y, Sakashita F, Nonaka K, Sugiyama Y. A
resected cace of icteric type hepatoma with tumor thrombi in common bile duct. J Jpn Coll Surg
2006;31:240-244.
4㧕 Osada S, Imai H, Okumura N, Tokuyama Y, Hosono Y, Sakashita F, Sugiyama Y. A modified
reconstruction method to prevent critical complications after pancreatoduodenectomy.
Hepato-Gastroenterol. 2006;53:296-300.
IF5㧕 Osada S, Imai H, Tomita H, Tokuyama Y, Okumura N, Sakashita F, Nonaka K, Sugiyama Y. Vascularendothelial growth factor protects hepatoma cells against oxidative stress-induced cell death. J
Gastroen Hepatol. 2006;21:988-993.
IF
6㧕 Takahashi T, Shigematsu H, Shivapurkar N, Reddy J, Zheng Y, Feng Z, Suzuki M, Nomura M,
Augustus M, Yin J, Meltzer SJ, Gazdar AF. Aberrant promoter methylation of multiple genrs duringmultistep pathogenesis of colorectal cancers. Int J Cancer. 2006;118:924-931.
IF
7㧕 Sanada Y, Yoshida K,Ohara M, Tsutani Y. Expression of orotate phosphorybosyltransferase (OPRT)in
hepatobiliary and pancreatic carcinoma. Pathology Oncology Research. 2007;13:105-113.
8㧕 Osada S, Imai H, Tomita H, Tokuyama Y, Okumura N, Matsuhashi N, Sakashita F, Nonaka K.Serumcytokine levels in response to hepatic cryoablation. J Surg Oncol. 2007;95:491-498.
IF9㧕 Osada S, Sakashita F, Hosono Y, Nonaka K, Tokuyama Y, Tanaka H, Sasaki Y, Tomita H, Komori S,
Matsui S, Takahashi T. Extracellular signal 㧙 regulated Kinase phosphorylation due tomenadione-inducd arylation mediates growth inhibition of pancreas cancer cells. Cancer ChemotherPharmacol. 2007;62:315-320.
IF
10㧕 Amaoka N, Osada S,Kanematsu M, Imai H, Tomita H, Tokuyama Y, Sakashita F, Nonaka K, Goshima
S, Kondoh H, Adachi Y. Clinicopathological features of hepatocellul ar carcinoma evaluated by
vascular endothelial growth factor expression. J Gastroenterol Hepatology. 2007;22:2202-2207.
IF
11㧕 Suzuki M, Shigematsu H, Shames DS, Sunaga N, Takahashi T, Shivapurkar N, Iizasa T, Minna JD,
Fujisawa T, Gazdar A.F, Frenkel EP. Methylation and Gene Silencing of the Ras㧙Related GTP ase
Gene in Lung and Breast Cancers. Ann Surg Oncol. 2007;14:1397-1404.
IF
12㧕 Nomura M, Shigematsu H, LiL, Suzuki M, Takahashi T, Estess P, Siegelman M, Feng Z, Kato H,
Marchetti A, Shay JW, Spitz MR, Wistuba II, Minna JD, Gazdar AF. Polymorphisms, Mutations, andAmplification of the EGFR Gene in Non㧙Small Cell Lung Cancers. PloS Med. 2007.
13㧕 Sakashita F, Osada S, Takemura M, Imai H, Tomita H, Nonaka K, Takahashi T, Seishima M. The
effect of p53gene expression on the inhibition of cell proliferation by paclitaxel. Cancer ChemotherPharmacol. 2007;62:379-385.
IF
14㧕 Yoshida K, Yamaguchi K, Osada S, Kawaguchi Y, Takahashi T, Sakashita F, Tanaka Y.Challenge for abetter combination with basic evidence. Int J Clin Oncol. 2008;13:212-219.
15㧕 Nonaka K, Saio M, Suwa T, Alan B.Frey, Umemura N, Imai H, Guan-Feng Ouyang, Osada S, Margit
Balazs, Roza Adany, Kawaguchi Y, Yoshida K, Takami T. Skewing the Th cell phenotype Th1 alters thematuration of tumor-infiltrating mononuclear phagocytes. J Leukocyte Biol. 2008;84:679-688.
IF
16㧕 Osada S, Tomita H, Tanaka Y, Tokuyama Y, Tanaka H, Sakashita F, Takahashi T. The utility ofvitamin K3(menadione)against pancreatic cancer. Anti-Cancer Res. 2008;28:45-50.
IF
17㧕 Osada S, Sakashita F, Hosono Y, Nonaka K, Tokuyama Y, Tanaka H, Sasaki Y, Tomita H, Komori S,
Matsui S, Takahashi T. Extracellular signal-regulated kinase phosphorylation due to

㧙㧙

1.597

0.904

1.673

4.555

2.384

2.568

2.052

3.917

2.568

4.128
1.414

menadione-induced arylation mediates growth inhibition of pancreatic cancer cells. Cancer Chemoth
Pharm. 2008;62:315-320.
IF 2.56818㧕 Osada S, Imai H, Yawata K, Tanahashi T, Sakashita F, Tanaka C, Sugiyama Y. Growth inhibition ofunresectable tumors induced by hepatic cryoablation. Hepato-Gastroenterol. 2008;55:231-234.
IF 0.904
19㧕 Osada S, Kanematsu M, Imai H, Goshima S.Clinical significance of serum HGF and c-Met expression
in tumor tissue for evaluation of properties and treatment of hepatocellular carcinoma
Hepatogastroenterology. 2008;55:544-549.
IF 0.9044㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦㜞ᯅቁᄦ㧘⎇ⓥಽᜂ⠪㧦ᓼጊᵏᴦ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦≸ᛥ೙ㆮવሶߩࡊࡠࡕ࡯࠲࡯㗔ၞ⇣Ᏹࡔ࠴࡞ൻࠍ↪޿ߚ≸ߩᣧᦼ⸻ᢿ߳ߩ⥃ᐥᔕ↪㧧ᐔᚑ 18㧙20 ᐕᐲ㧧
3,400 ජ౞(1,300㧦1,300㧦800 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦ศ↰๺ᒄ㧧ᐔᚑ 19 ᐕᐲጘ㒂ᄢቇකቇㇱ ⎇ⓥ⑼㐳࡮කቇㇱ㐳ⵙ㊂⚻⾌ߦࠃࠆ⎇ⓥ⾌㧦
≸ォ⒖㑐ㅪㆮવሶߩࠢࡠ࡯࠾ࡦࠣ(Molecular cloning of metastasis associated gene)㧧ᐔᚑ 19 ᐕᐲ㧧1,000 ජ౞3㧕 ⎇ⓥઍ⴫⠪㧦Ꮉญ㗅ᢘ㧧ᐔᚑ 19 ᐕᐲጘ㒂ᄢቇකቇㇱ ⎇ⓥ⑼㐳࡮කቇㇱ㐳ⵙ㊂⚻⾌ߦࠃࠆ⎇ⓥ⾌㧦੃≸⚦⢩ᩣߦ߅ߌࠆ Herceptin ߣ SERM(selective estrogen receptor modulator)ߩ૬↪ലᨐ㧧ᐔᚑ
19 ᐕᐲ㧧10 ਁ౞4㧕 ⎇ⓥઍ⴫⠪㧦㐳↰⌀ੑ㧧ᐔᚑ 19 ᐕᐲጘ㒂ᄢቇකቇㇱ ⎇ⓥ⑼㐳࡮කቇㇱ㐳ⵙ㊂⚻⾌ߦࠃࠆ⎇ⓥ⾌㧦
Vitamin K3 ߦࠃࠆ⚦⢩ౝࠪࠣ࠽࡞વ㆐ᵴᕈߩㅴⴕ⤟≸ᴦ≮߳ߩᔕ↪㧧ᐔᚑ 19 ᐕᐲ㧧20 ਁ౞5㧕 ⎇ⓥઍ⴫⠪㧦㐳↰⌀ੑ㧧౏⋉ା⸤ᄖ⑼ቇ⎇ⓥഥᚑၮ㊄(૑෹ା⸤㌁ⴕᩣᑼળ␠)㧦ᄢ⣺≸ᄙ⊒⢄ォ⒖ߦ
ኻߔࠆᄖ⑼⊛ᷫ㊂ಾ㒰ⴚߩᗧ⟵㧧ᐔᚑ 19 ᐕᐲ㧧50 ਁ౞6㧕 ⎇ⓥઍ⴫⠪㧦ጊญ๺਽㧧ᐔᚑ 19 ᐕᐲጘ㒂ᄢቇකቇㇱ ⎇ⓥ⑼㐳࡮කቇㇱ㐳ⵙ㊂⚻⾌ߦࠃࠆ⎇ⓥ⾌㧦
⢗≸ߦ߅ߌࠆ mTOR ࠍ࠲࡯ࠥ࠶࠻ߣߒߚಽሶᮡ⊛ᴦ≮ߩᬌ⸛㧧ᐔᚑ 19 ᐕᐲ㧧10 ਁ౞7㧕 ⎇ⓥઍ⴫⠪㧦㜞ᯅቁᄦ, ⎇ⓥಽᜂ⠪㧦ᓼጊᵏᴦ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦≸ᛥ೙ㆮવሶߩࡊࡠࡕ࡯࠲࡯㗔ၞ⇣Ᏹࡔ࠴࡞ൻࠍ↪޿ߚ≸ߩᣧᦼ⸻ᢿ߳ߩ⥃ᐥᔕ↪㧧ᐔᚑ 18㧙20 ᐕᐲ㧧
3,400 ජ౞(1,300㧦1,300㧦800 ජ౞)
8㧕 ⎇ⓥઍ⴫⠪㧦㜞ᯅቁᄦ㧧ᐔᚑ 19 ᐕᐲጘ㒂ᄢቇකቇㇱ ⎇ⓥ⑼㐳࡮කቇㇱ㐳ⵙ㊂⚻⾌ߦࠃࠆ⎇ⓥ⾌㧦ᶖൻེ≸ߦ߅ߌࠆ≸㑐ㅪㆮવሶߩ Aberrant promoter methylation ߩ㑐ਈ㧙ᣧᦼ⸻ᢿ߳ߩᔕ↪㧙㧧
ᐔᚑ 19 ᐕᐲ㧧50 ਁ౞9㧕 ⎇ⓥઍ⴫⠪㧦ဈਅᢥᄦ㧧ᐔᚑ 19 ᐕᐲጘ㒂ᄢቇකቇㇱ ⎇ⓥ⑼㐳࡮කቇㇱ㐳ⵙ㊂⚻⾌ߦࠃࠆ⎇ⓥ⾌㧦
⢗≸⚦⢩ߦኻߔࠆ paclitaxel ߩലᨐ(the effect of paclitaxel for gastric cancer cells)㧧ᐔᚑ 19 ᐕᐲ㧧
20 ਁ౞
10㧕 ⎇ⓥ⠪㧧ဈਅᢥᄦ㧧ᐔᚑ 20 ᐕᐲᄢቇᵴᕈൻ⚻⾌㧦⢗≸⣻⤑᠞⣲ߦኻߔࠆ paclitaxel ߩലᨐ㧧ᐔᚑ
20 ᐕᐲ㧧1,060 ජ౞
11㧕 ⎇ⓥઍ⴫⠪㧦ศ↰๺ᒄ㧧ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄㧦ᶖൻ▤ᄖ⑼ᚻⴚߦ߅ߌࠆวᚑๆ෼♻૶↪ߩᚻⴚㇱ૏ᗵᨴᛥ೙ലᨐߦ㑐ߔࠆᄙᣉ⸳౒หਗⴕ⟲㑆ή૞ὑൻᲧセ⹜㛎࡮⢄ಾ㒰߅ࠃ߮⤟㗡චੑᜰ⣺ಾ㒰ߦ߅ߌࠆวᚑๆ෼♻૶↪ߩᚻⴚㇱ૏ᗵᨴᛥ೙ലᨐߦ㑐ߔࠆᄙᣉ⸳౒หਗⴕ⟲㑆ή૞ὑൻᲧセ⹜㛎㧧ᐔᚑ 20㧙23 ᐕᐲ㧧100 ਁ౞
2㧕ฃ⸤⎇ⓥ1㧕 㜞ᯅቁᄦ㧦ⴚᓟ⵬ഥൻቇ≮ᴺߦ߅ߌࠆࡈ࠶ൻࡇ࡝ࡒࠫࡦ♽⮎೷ߩ᦭↪ᕈߦ㑐ߔࠆᲧセ⥃ᐥ⹜㛎(ᴦ≹ಾ㒰⋥⣺≸ߦኻߔࠆ UFT ≮ᴺߣ TS-1 ≮ᴺߣߩᲧセᬌ⸛)㧧ᐔᚑ 18㧙20 ᐕᐲ㧧2,457 ජ౞(819㧦819㧦
819 ජ౞)㧦߇ࠎ㓸ቇ⊛ᴦ≮⎇ⓥ⽷࿅2㧕 ศ↰๺ᒄ㧦StageΥ⚿⣺≸ᴦ≹ಾ㒰଀ߦኻߔࠆⴚᓟ⵬ഥൻቇ≮ᴺߣߒߡ UFT/Leucovorin ≮ᴺߣ TS-1
≮ᴺߩ╙Υ⋧Ყセ⥃ᐥ⹜㛎߅ࠃ߮ㆮવሶ⊒⃻ߦၮߠߊലᨐ੍᷹࿃ሶߩត⚝⊛⎇ⓥ㧧ᐔᚑ 20㧙24 ᐕᐲ㧧1,102 ජ౞㧦(⽷)వ┵ක≮ᝄ⥝⽷࿅
3㧕 ศ↰๺ᒄ㧦ೋ࿁ TS-1 ≮ᴺߦᴦ≮ᛶ᛫ᕈࠍ␜ߒߚㅴⴕ࡮ౣ⊒⢗≸ߦኻߔࠆੑᰴൻቇ≮ᴺ㧙CPT-11 න⁛≮ᴺ vsTS-1㧗CPT-11 ૬↪ൻቇ≮ᴺߩή૞ὑൻᲧセ╙Τ/Υ⋧⥃ᐥ⹜㛎㧙㧧ᐔᚑ 20㧙24 ᐕᐲ㧧1,160
ජ౞㧦NPO ᴺੱᣣᧄ߇ࠎ⥃ᐥ⹜㛎ផㅴᯏ᭴
3㧕౒ห⎇ⓥ1㧕 ศ↰๺ᒄ㧦ᄢ⣺≸ᖚ⠪ߦ߅ߌࠆ᛫≸೷ലᨐ੍᷹࿃ሶߩ mRNA ⊒⃻ಽᏓ⺞ᩏ㧧ᐔᚑ 20㧙23 ᐕᐲ㧧110㧙㧙ਁ౞㧦ᄢ㢈⮎ຠᎿᬺࢃ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫ
1㧕 㐳↰⌀ੑ㧦‫ޟ‬㜞ᐲㅴⴕ⢄≸ߦኻߔࠆ᛫⣲≌఺∉⾮ᵴࠍ⋡⊛ߣߒߚಓ⚿ᴦ≮‫ޠ‬㜞ᐲක≮⹏ଔ೙ᐲ↳⺧ਛ
6㧚ቇળᵴേ
1㧕ቇળᓎຬศ↰๺ᒄ㧦
1㧕 ᣣᧄᄖ⑼ቇળઍ⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄᶖൻེᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄᄖ⑼ቇળ⥃ᐥ⹜㛎ផㅴᆔຬ(㨪⃻࿷)4㧕 ᣣᧄ≸ᴦ≮ቇળᢎ⢒ᆔຬ(㨪⃻࿷)5㧕 ᣣᧄ⢗≸ቇળ⹏⼏ຬ(㨪⃻࿷)6㧕 ᣣᧄ⢗≸ቇળ⽷ോᆔຬળ(ᐔᚑ 20 ᐕ 8 ᦬㨪⃻࿷)7㧕 ᣣᧄ㘩㆏ቇળ⹏⼏ຬ(㨪⃻࿷)8㧕 ᣣᧄᶖൻེ≸⊒↢ቇળ⹏⼏ຬ(㨪⃻࿷)9㧕 ᣣᧄᶖൻེᄖ⑼ቇળ⹏⼏ຬㆬ಴ᆔຬ(㨪⃻࿷)10㧕 ᧲ᶏᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)11㧕 ᣣᧄ⥃ᐥᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)12㧕 ᣣᧄࡃࠗࠝ࠮࡜ࡇࠖቇળ⹏⼏ຬ(㨪⃻࿷)13㧕 ᣣᧄ≸∛૕ᴦ≮⎇ⓥળ਎⹤ੱ(㨪⃻࿷)14㧕 ᣣᧄ≸ዪᚲ≮ᴺ⎇ⓥળ਎⹤ੱ(㨪⃻࿷)15㧕 ᣣᧄ≸఺∉ᄖ⑼⎇ⓥળ਎⹤ੱ(㨪⃻࿷)16㧕 ᣣᧄᄖ⑼ቇળ࿾ၞක≮቟ో▤ℂᆔຬળᆔຬ(㨪⃻࿷)17㧕 ᣣᧄᶖൻེ∛ቇળ᧲ᶏᡰㇱᐙ੐(㨪⃻࿷)18㧕 ᣣᧄᄖ⑼ቇળኾ㐷ක⹺ቯᆔຬળ⹜㛎ᆔຬ(㨪⃻࿷)19㧕 ᣣᧄ⢈ḩ∝ᴦ≮ቇળℂ੐(㨪⃻࿷)Ꮉญ㗅ᢘ㧦1㧕 ᣣᧄ੃≸ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ≸ᴦ≮ቇળ⹏⼏ຬ(㨪⃻࿷)㐳↰⌀ੑ㧦1㧕 ᣣᧄ⢄⢙⤟ᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ⥃ᐥᄖ⑼ቇળ⹏⼏ຬ(ᐔᚑ 18 ᐕ 1 ᦬㨪⃻࿷)
3㧕 ᣣᧄૐ᷷කቇቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄᄖ⑼♽ㅪวቇળ⹏⼏ຬ(ᐔᚑ 19 ᐕ 4 ᦬㨪⃻࿷)
5㧕 ᣣᧄᄖ⑼ቇળઍ⼏ຬ(㨪⃻࿷)6㧕 ᧲ᶏᄖ⑼ቇળ⹏⼏ຬ(ᐔᚑ 19 ᐕ 11 ᦬㨪⃻࿷)ጊญ๺਽㧦
1㧕 ᣣᧄ⢗≸ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅㐳↰⌀ੑ㧦
1㧕 ╙ 2 ࿁ጘ㒂ᚻⴚᚻᛛ⎇ⓥળ(ᐔᚑ 18 ᐕ 3 ᦬㧘ጘ㒂)2㧕 ╙ 3 ࿁ጘ㒂ᚻⴚᚻᛛ⎇ⓥળ(ᐔᚑ 18 ᐕ 10 ᦬㧘ጘ㒂)
3㧕ቇⴚ㔀⹹
ศ↰๺ᒄ㧦
1㧕 International Jouranl of Clinical Oncology 㧧Editorial board member(ᐔᚑ 19 ᐕ 1 ᦬㨪⃻࿷)2㧕 ⢗≸ perspective㧧✬㓸ਥᐙ(ᐔᚑ 20 ᐕ 12 ᦬㨪⃻࿷)㧙㧙㐳↰⌀ੑ㧦
1㧕 Anti㧙Cancer Agents㧧Editorial Board Member(㨪⃻࿷)2㧕 Hepatogastroenterology㧧Co-Editor(㨪⃻࿷)7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙṶ⠪㧘ᐳ㐳ศ↰๺ᒄ㧦
1㧕 ╙ 79 ࿁⢗≸ቇળ✚ળ(ᐔᚑ 19 ᐕ 3 ᦬㧘ฬฎደ㧘㨬ൻቇ≮ᴺ 2㨭ᐳ㐳)
2㧕 ╙ 107 ࿁ᣣᧄᄖ⑼ቇળቇⴚ✚ળ(ᐔᚑ 19 ᐕ 4 ᦬㧘ᄢ㒋㧘㨬⢗≸(ಽሶ↢‛ቇ 2)㨭ᐳ㐳)
3㧕 ╙ 107 ࿁ᣣᧄᄖ⑼ቇળ⊛ቇⴚ㓸ળ࡮╙ 5 ࿁⥃ᐥ⎇ⓥ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 4 ᦬㧘ᄢ㒋㧘‫ޟ‬ᶖൻ▤ⴚᓟ⵬
ഥൻቇ≮ᴺߩ⃻⁁ߣ໧㗴ὐ‫ޠ‬Ṷ⠪)
4㧕 ╙ 62 ࿁ᶖൻེᄖ⑼ቇળቇⴚ✚ળ(ᐔᚑ 19 ᐕ 7 ᦬㧘᧲੩㧘㨬⢗≸࡮ಽሶ↢‛ቇ㨭ᐳ㐳)5㧕 45 ࿁ᣣᧄ≸ᴦ≮ቇળ✚ળ(ᐔᚑ 19 ᐕ 10 ᦬㧘੩ㇺ㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯‫ޟ‬⢗≸ߦ߅ߌࠆᮡḰᴦ≮⏕┙߳ߩ㆏ߩࠅߣዷᦸ‫ޠ‬Ṷ⠪)
6㧕 ╙ 45 ࿁ᣣᧄ≸ᴦ≮ቇળቇⴚ✚ળ(ᐔᚑ 19 ᐕ㧘੩ㇺ㧘㨬⢗ ㅴⴕ࡮ౣ⊒ ᴦ≮㨭ᐳ㐳)7㧕 ᣣᧄᶖൻེ∛ቇળ᧲ᶏᡰㇱઍ 108 ࿁଀ળ(ᐔᚑ 20 ᐕ 6 ᦬㧘ጘ㒂㧘ᢎ⢒⻠Ṷ‫ޟ‬㘩㆏≸‫ޔ‬⢗≸ᴦ≮ߩㅴᱠߣዷᦸ‫ޠ‬Ṷ⠪)8㧕 ╙ 63 ࿁ᣣᧄᶖൻེᄖ⑼ቇળቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ᧅᏻ‫ޔ‬㨬⢗≸‫ᦸⷐޔ‬Ṷ㗴‫ེޔ‬᪾่วࠍ↪޿ߚ⢗ಾ㒰ᓟౣᑪᴺߩഞ⟋ 1㨭ᐳ㐳)
9㧕 ╙ 46 ࿁ᣣᧄ≸ᴦ≮ቇળ✚ળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ฬฎደ㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ 17 ‫ޟ‬ㅴⴕ࡮ౣ⊒⢗≸ߦኻߔࠆᮡḰᴦ≮ߩࠦࡦ࠮ࡦࠨࠬߪᓧࠄࠇߚ߆‫ޠ‬ᐳ㐳)10㧕 ╙ 38 ࿁⢗ᄖ⑼࡮ⴚᓟ㓚ኂ⎇ⓥળ㧚(ᐔᚑ 20 ᐕ 11 ᦬㧘᧲੩㧘㨬ਥ㗴 II ⴚᓟൻ≮㨭ᐳ㐳)11㧕 ╙ 21 ࿁ᣣᧄࡃࠗࠝ࠮࡜ࡇ࡯ቇળቇⴚ㓸ળ✚ળ(ᐔᚑ 20 ᐕ 11 ᦬㧘᧲੩㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ㨬᛫≸೷(2)㨭
ᐳ㐳)12㧕 The 6th International Symposium on Cancer Research and Therapy.(2008, Tokyo‫ޟ‬Molecular-Targeting
Therapy for Cancer and Cancer Stem Cell. Session 5. Basic Research and prognostic factor.‫ޠ‬ᐳ㐳)13㧕 ╙ 70 ࿁ᣣᧄ⥃ᐥᄖ⑼ቇળ(ᐔᚑ 20 ᐕ 11 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ 5㨬- ᣧᦼ⢗≸ߦኻߔࠆ⣻⣧㏜⵬ഥਅ⢗ಾ㒰ⴚ࡯ዉ౉ߦ߅ߌࠆࡐࠗࡦ࠻࡯㨭Ṷ⠪)
14㧕 ᣣᧄකᏧળ↢ᶦᢎ⢒⻠ᐳ‫ޔ‬ጘ㒂ᏒකᏧળ(ᐔᚑ 20 ᐕ 12 ᦬㧘ጘ㒂㧘㨬ᶖൻེ≸ߩಽሶᮡ⊛ᴦ≮ߩᦨ೨
✢㨭Ṷ⠪)
Ꮉญ㗅ᢘ㧦
1㧕 ╙ 38 ࿁ᣣᧄᲧセ⥃ᐥකቇળቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 12 ᦬㧘ጟፒ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬Ἳ∝ᕈ੃߇ࠎߩ⃻⁁ߣ⺖㗴‫ޠ‬Ṷ⠪)2㧕 ╙ 38 ࿁ᣣᧄᲧセ⥃ᐥකቇળቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 12 ᦬㧘ጟፒ㧘ࠪࡦࡐࠫ࠙ࡓ‫ᦨߩࠎ߇੃ޟ‬ᣂ࠻ࡇ࠶ࠢࠬ‫ޠ‬Ṷ⠪)3㧕 ߇ࠎߩ࡝ࡦࡄᶋ⣲⎇ⓥળ(ᐔᚑ 19 ᐕ 12 ᦬㧘ฬฎደ㧘‫ⴚ≸੃ޟ‬ᓟ਄⢇࡝ࡦࡄᶋ⣲ߦኻߔࠆᄖ᧪ᜰዉߩ
⃻⁁ߣ໧㗴ὐ‫ޠ‬Ṷ⠪)㐳↰⌀ੑ㧦
1㧕 ╙ 32 ࿁ᣣᧄᄖ⑼♽ㅪวળቇળቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 6 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᄖ⑼㗔ၞߦ߅ߌࠆಽ
ሶ↢‛ቇߩᔕ↪‫ޠ‬Ṷ⠪)
2㧕 ╙ 276 ࿁᧲ᶏᄖ⑼ቇળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ਃ㊀㧘‫ޟ‬⢄࡮⢙ 2‫ޠ‬ᐳ㐳)㜞ᯅቁᄦ㧦
1㧕 ╙ 32 ࿁ᣣᧄᄖ⑼♽ㅪวળቇળቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 6 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᶖൻེ≸ߦ߅ߌࠆⴚ
೨࡮ⴚᓟൻቇ≮ᴺߩㅴᱠ‫ޠ‬Ṷ⠪)⚦㊁⧐᮸㧦
1㧕 ╙ 38 ࿁ᣣᧄᲧセ⥃ᐥකቇળቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ጟፒ㧘ࠪࡦࡐࠫ࠙ࡓ‫⥃ߩࠎ߇੃ޟ‬ᐥߦ߅ߌࠆ⃻⁁‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ1㧕 㐳↰⌀ੑ㧦╙ 19 ࿁ᣣᧄ⢄⢙⤟ᄖ⑼ቇળ࡮ળ㐳⾨(ᐔᚑ 19 ᐕᐲ)㧙㧙9㧚␠ળᵴേศ↰๺ᒄ㧦
1㧕 NOKIA ࠬࡁ࡯ࡏ࡯࠼ FIS ࡢ࡯࡞࠼ࠞ࠶ࡊ 2008GIFU/GUJO ᄢળ․೎㘈໧(ᐔᚑ 19 ᐕᐲ)
2㧕 ጘ㒂⋵≸ᬌ⸻♖ᐲ▤ℂᆔຬ(ᐔᚑ 20 ᐕᐲ)
3㧕 ੃≸Ꮢ᳃࠮ࡒ࠽࡯ߩ㐿௅(ᐔᚑ 20 ᐕ 5 ᦬ 24 ᣣ㧘ጘ㒂Ꮢ)4㧕 ጘ㒂⋵↢ᵴ⠌ᘠ∛ᬌ⸻▤ℂᜰዉද⼏ળ⢗߇ࠎㇱળᆔຬ5㧕 ጘ㒂⋵කᏧળᄖ⑼කㇱળ㘈໧
6㧕 (⽷)߇ࠎ㓸ቇ⊛ᴦ≮⎇ⓥ⽷࿅⹜㛎⺞ᢛᆔຬ࡮⹏⼏ຬ㐳↰⌀ੑ㧦
1㧕 Current Medicinal Chemistry Anti㧙Cancer Agents࡮Editorial Member(㨪ᐔᚑ 19 ᐕᐲ)
2㧕 International Surgical School࡮International Faculty Member(Professor Emeritus)(ᐔᚑ 19 ᐕᐲ)
3㧕 ጘ㒂⋵࿖᳃଻㒾ㅪวળክᩏᆔຬ(ᐔᚑ 19 ᐕᐲ)
4㧕 ࿖᳃ஜᐽ଻㒾ㅪวክᩏຬ(㨪⃻࿷)ဈਅᢥᄦ㧦1㧕 ࿖଻⸻≮ႎ㈽ክᩏᆔຬ(㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 㐳↰⌀ੑ㧦≸ߩᨴ⦡૕ਇ቟ቯᕈߦ㑐ਈߔࠆ HsAIRK ߣ PLK ㆮવሶߩ⸃ᨆߣߘߩ⥃ᐥᔕ↪㧦ᐔᚑ 14ᐕᐲ㧙ᐔᚑ 17 ᐕᐲᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ⎇ⓥᚑᨐႎ๔ᦠ㧦1㧙7(2006 ᐕ 3 ᦬)
2㧕 ᧖ጊ଻ᐘ㧦ᶖൻེ≸∝଀ߦ߅ߌࠆᧃ᪳ⴊ᮸⁁⚦⢩ߩ᛫ේ๒␜ᯏ⢻Ⴧᒝᴺߩ㐿⊒ߣߘߩ⥃ᐥᔕ↪㧦ᐔ
ᚑ 14 ᐕᐲ㧙ᐔᚑ 17 ᐕᐲᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ⎇ⓥᚑᨐႎ๔ᦠ㧦1㧙8(2006 ᐕ 3 ᦬)
11㧚ႎ㆏1㧕 㐳↰⌀ੑ㧦‫⦡ޟ‬ᄌൻߢ੍ళ⊒⷗㧙MRI ᣂࠪࠬ࠹ࡓ㐿⊒‫ޠ‬࡮౒ห⎇ⓥ㧦⺒ᄁᣂ⡞(2007 ᐕ 5 ᦬ 11 ᣣ)
2㧕 ศ↰๺ᒄ㧘Ꮉญ㗅ᢘ㧦‫∛ޟ‬㒮ߩታജ㨪ጘ㒂✬ 1 ੃߇ࠎ‫ޠ‬㧦⺒ᄁᣂ⡞(2008 ᐕ 1 ᦬ 6 ᣣ)
3㧕 ศ↰๺ᒄ㧦‫ޟ‬ᄢቇߪ޿߹ ⎇ⓥቶ߆ࠄ‫ ޠ‬ᣂߚߥ߇ࠎᴦ≮㐿⊒ㅴ߼ࠆ㧦ጘ㒂ᣂ⡞(2008 ᐕ 6 ᦬ 10 ᣣ)
4㧕 ศ↰๺ᒄ㧦‫ࠎ߇੃ޟ‬ᴦ≮⠨߃ࠆ‫ޠ‬㧦ጘ㒂ᣂ⡞(2008 ᐕ 7 ᦬ 7 ᣣ)
5㧕 ศ↰๺ᒄ㧘Ꮉญ㗅ᢘ㧘㐳↰⌀ੑ㧘ጊญ๺਽㧘㜞ᯅቁᄦ㧦‫ޟ‬ᖚ⠪ᧄ૏ߩ≸ᴦ≮ߦߟ޿ߡ⠨߃ࠆ‫ޠ‬㧦ᦺᣣᣂ⡞(2008 ᐕ 7 ᦬ 31 ᣣ)
6㧕 㐳↰⌀ੑ㧦‫ޟ‬㜞ᐲㅴⴕ⢄≸ߩಓ⚿ᴦ≮‫ޠ‬㧦ਛᣣᣂ⡞╬ో࿖࿾ᣇ⚕(2008 ᐕ 11 ᦬ 6 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔᢎቶߣߒߡߩ⎇ⓥ࠹࡯ࡑࠍ⏕┙ߒߟߟ޽ࠅ㧘ㄭᐕߢߪቇળ⊒⴫ᢙߩჇട߇⹺߼ࠄࠇࠆ‫⺰޿઻ߦࠇߎޕ‬ᢥᢙߩჇട߇ᦼᓙߐࠇࠆ‫␠ߚߒߣࡑ࡯࠹ࠍ≸ޕ‬ળ⽸₂߿㧘ක≮ᓥ੐⠪߳ߩᢎ⢒ᵴേߐࠄߦߪߎࠇࠄߦ઻
߁␠ળႎ㆏ߥߤ߽ขࠅ਄ߍࠄࠇࠆߦ޿ߚߞߡ޿ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ߅ࠃ߮ߘߩኻᔕ╷ᄖ⑼ቇᢎቶߣߒߡߐࠄߦ≸ኾ㐷ಽ㊁ߣߒߡ࿾ၞ߆ࠄߩା㗬ࠍᓧࠄࠇࠆߎߣߦࠃࠅᚻⴚ∝଀ᢙߩჇട߇
⹺߼ࠄࠇࠆ߽ߩߩ㧘ߘࠇߦ⷗ว߁ߛߌߩࠬ࠲࠶ࡈᢙ߇㒢ࠄࠇ㧘⎇ⓥߦኻߒߡߩᦝߥࠆ⊒ዷߦᡰ㓚߇ ᔨߐࠇࠆ‫ޕ‬ല₸ࠃߊ⸻≮㧘⎇ⓥࠍⴕ߁ኻ╷ࠍ⻠ߓߡ޿ࠆ‫ޕ‬੹ᓟߩዷᦸᢎቶߣߒߡߩ࠹࡯ࡑߣߒߡ㧘ᣧᦼ≸ߦኻߔࠆૐଚⷅᚻⴚߩ㐿⊒㧘㜞ᐲㅴⴕ߇ࠎߦኻߔࠆಽሶᮡ⊛ᴦ≮ߣߘߩჇᒝ૞↪ߩࡔࠞ࠾࠭ࡓߩ⸃ᨆߥߤࠍ㊀ὐ⊛ߦត⚝ߔࠆ‫ߦᦝޕ‬㧘ᢎቶ⁛⥄ߩᣂߚߥᴦ≮ᴺߥߤߩ㐿⊒ࠍ⹜ߺࠆ‫ޕ‬㧙㧙㧔4㧕ᶖൻེ∛ᘒቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
⊒≸ߩᯏᐨߣߘߩ೙ᓮ㧘⢄ਇోߩ∛ᘒߣᴦ≮㧘ᶖൻེ∔ᖚߩ∛ᘒᩕ㙃ߣ੺౉㧘ᶖൻ▤∔ᖚߦኻߔࠆౝⷞ
㏜ᴦ≮ߩ㐿⊒߇ਥⷐ࠹࡯ࡑߢ޽ࠆ‫ޕ‬
1. ⊒≸ߩᯏᐨߣߘߩ೙ᓮߦߟ޿ߡߪ㧘ߣߊߦᩭౝฃኈ૕ࠍಽሶᮡ⊛ߣߒߚ⎇ⓥࠍㅴ߼ߡ޿ࠆ‫ޕ‬⢄≸ߦ߅ߌࠆᩭౝฃኈ૕ RXR ߦ㑐ߔࠆၮ␆⎇ⓥߪ߶߷⚳ੌߒ㧘ᄢ⣺≸㧘⤟≸ߥߤઁߩ≸⒳߳Ṷ➈ࠍ㐿ᆎߒߚ‫ޕ‬⢄≸ߦኻߒߡ RXR ࡝ࠟࡦ࠼ࠍ↪޿ߚ⊒≸೙ᓮ㧔੍㒐㧕ߩᄢⷙᮨ⥃ᐥ⹜㛎ࠍቢੌߢ߈ࠆ੍ቯߢ޽ࠆ‫ޕ‬
2. ⢄ਇోߩ߁ߜ㧘ᕆᕈ⢄ਇోߦߟ޿ߡ⢄⚦⢩ߩ↢ሽߣᱫ੢ࠍ᳿ቯߔࠆࡔࠞ࠾࠭ࡓߩ⸃᣿ࠍ⚦⢩ౝࠪࠣ࠽࡞㧘⚦⢩ᄖࡑ࠻࡝࠶ࠢࠬߩਔ㕙߆ࠄㅴ߼ߡ޿ࠆ‫ޕ‬ォ౮࿃ሶ HNF-4 ߇ࠠ࡯ߣߥࠆน⢻ᕈߦ೔㆐ߒ㧘࠻࡜ࡦࠬ࡟࡯࡚ࠪ࠽࡞࡮࡝ࠨ࡯࠴㧔⢄ౣ↢ᴦ≮㧕߳ߩዷ㐿߇ⷞ㊁ߦ౉ߞߚ‫ޕ‬
3. ᘟᕈ⢄ਇోߢߪኋਥߩᩕ㙃⁁ᘒ߇⢄ਇోߩ∛ᘒㅴዷ࡮⊒≸ߦ᦭ᗧߥᗧ⟵ࠍ᦭ߔࠆߎߣࠍ⥃ᐥ⊛ߦ⸽᣿ߒ㧘ᣣ᰷ߩࠟࠗ࠼࡜ࠗࡦߦណ↪ߐࠇߚ‫੹ޕ‬ᓟ㧘ߘߩ᥉෸ࠍߐࠄߦ࿑ࠆ‫ޕ‬
4. ᶖൻ▤∔ᖚߩౝⷞ㏜ᴦ≮ߪ㧘ᦨᣂߩ࠺ࡃࠗࠬࠍ↪޿ߚ⸻≮ࠍㅴⴕߒߡ߅ࠅ㧘⥃ᐥ⎇ⓥ⺰ᢥߦߟߥߍߡ
޿ࠆ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
ಎᢎ᝼㧦
⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦

᫪⣁ਭ㓉
᳗ᧁᱜੳ
቟↰৻ᦶ
ౝᧁ㓉ᢥ
ᷡ᳓㓷ੳ
ศᎹᱞᔒ
౗᧛ାብ
੗ᷓ⾆჻
ጤਅᜏม
੹੗ஜੑ
ኹୖ㓁৻
ਭ଻↰ో຦
㜞↰ ᷕ
਄᧛⌀਽
ዊᧁᦥ⧷੺
㚍႐ ෘ

Hisataka Moriwaki
Masahito Nagaki
Ichiro Yasuda
Takafumi Naiki
Masahito Shimizu
Takeshi Yoshikawa
Nobuhiro Kanemura
Takashi Ibuka
Takuji Iwashita
Kenji Imai
Youichi Terakura
Masaya Kubota
Jun Takada
Shinya Uemura
Eisuke Ogiso
Atsushi Baba3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ᫪⣁ਭ㓉㧚⢄ਇో࡮⢄ᕈ⣖∝ –Τ⸻ᢿߣ∝୥-㧦੗ᑫ㆏ᄦ㧘ᾢ↰ඳశ㧘ဝౝඳੳ㧘ᨋ ♿ᄦ✬㧚⢄⤳∛ቇ㧘᧲੩㧦ᦺୖᦠᐫ㧧2006 ᐕ㧦149㧙154.
2㧕 ᫪⣁ਭ㓉. 3.⢄ᕈ⣖∝㧦੗ᑫ㆏ᄦ㧘ᣣᲧ♿ᢥ✬㧚࿑⸃ ᶖൻེౝ⑼ቇ࠹ࠠࠬ࠻㧘᧲੩㧦ਛᄖකቇ␠㧧2006ᐕ㧦68㧙70.
3㧕 ᫪⣁ਭ㓉㧚∉ቇ⎇ⓥ߆ࠄߺߚ⢄߇ࠎߩൻቇ੍㒐ߣㅴዷᛥ೙㧦↰ፉ๺㓶㧘ฎ㊁♿ౖ✬㧚߇ࠎ⎇ⓥߩ޿߹г߇ࠎߩ∉ቇ-㧘᧲੩㧦᧲੩ᄢቇ಴ ળ㧧2006 ᐕ㧦174㧙182.
4㧕 ᫪⣁ਭ㓉㧚BCAA㧦ਛደ ⼾✬⪺㧚NST ↪⺆ࡂࡦ࠼ࡉ࠶ࠢ㧘᧲੩㧦ࡔ࠺ࠖࠞ࡞࡟ࡆࡘ࡯␠㧧2006 ᐕ㧦34
㧙35.5㧕 ട⮮ೣᑝ㧘⑔ንዄ㧚⣺▤಴ⴊᕈᄢ⣺⩶ᗵᨴ∝(O-157)㧦ᓟ⮮⑲ታ⋙ୃ. ਤ⠀ᐽᱜ✬㧚∝଀߆ࠄߺߚᶖൻེ∔ᖚߩ⸻ᢿߣᴦ≮㧘᧲੩㧦⸻ᢿߣᴦ≮␠㧧2006 ᐕ㧦109㧙112.
6㧕 ട⮮ೣᑝ㧘ጊ↰ථ਽㧚⸃㔌ᕈᄢേ⣂≜ߦࠃࠆ਄⣺▤⤑േ⣂㐽Ⴇ∝㧦ᓟ⮮⑲ታ⋙ୃ. ਤ⠀ᐽᱜ✬㧚∝଀߆ࠄߺߚᶖൻེ∔ᖚߩ⸻ᢿߣᴦ≮㧘᧲੩㧦⸻ᢿߣᴦ≮␠㧧2006 ᐕ㧦143㧙146.
7㧕 ᧛਄໪㓶㧘᫪⣁ਭ㓉㧚⢄—⢄ᕈ⣖∝ߩ⸻ᢿၮḰߣ∛ဳಽ㘃—㧦᫟ᣇᤘඳ㧘ዊᳰ๺ᒾ㧘↰ዥਭ㓶✬㧚⥃ᐥߦᓎ┙ߟᶖൻེ∔ᖚߩ⸻ᢿၮḰ࡮∛ဳಽ㘃࡮㊀∝ᐲߩ↪޿ᣇ㧘᧲੩㧦ࡔ࠺ࠖࠞ࡞ࡆࡘ࡯␠㧧2006 ᐕ㧦227㧙
231㧚
8㧕 ᳗ᧁᱜੳ㧘᫪⣁ਭ㓉㧚⢄ౣ↢㧦ᚭ↰೰ᄥ㇢㧘⒢ᚲብశ㧘ኹ㊁ᓆ㧘᐀ౝ㓷ᢅ✬㧚Annual Review ᶖൻེ 2006㧘᧲੩㧦ਛᄖකቇ␠㧧2006 ᐕ㧦112㧙116㧚
9㧕 ᳗ᧁᱜੳ㧚⢄ᕈᤀ⌧㧦ጊญᔀ㧘ർේశᄦ㧘⑔੗ᰴ⍫✬㧚੹ᣣߩᴦ≮ᜰ㊎ 2006 ᐕ 㧘᧲੩㧦කቇᦠ㒮㧧2006
ᐕ㧦384㧙385㧚
10㧕 ᳗ᧁᱜੳ㧚⢄Ἳ഍∝ൻߩࡔࠞ࠾࠭ࡓ㧦┻੗⻞ਯ㧘Ꮉፒ⺈ᴦ✬㧚೎ౠ࡮කቇߩ޽ࠁߺ㧙ᶖൻེ∔ᖚ-state of arts㧙㧙II. ⢄⢙⤟㧘᧲੩㧦කᱤ⮎಴ ᩣᑼળ␠㧧2006 ᐕ㧦112㧙116㧚
11㧕 㢬⷗ ኼ㧘᫪⣁ਭ㓉㧚․ᱶ∛ᘒ(⁁ᘒ)ߦ߅ߌࠆᩕ㙃≮ᴺ㧙(ᚑੱ࡮ዊఽ)ⴊᶧ∔ᖚ㧙㧦ዊ⿧┨ᐔ⋙ୃ㧚ᩕ㙃≮ᴺ ࡒ࠾ࡑࡓࠛ࠶࠮ࡦࠪࡖ࡞㧘᧲੩㧦ධᳯၴ㧧2006 ᐕ㧦186㧙196㧚
12㧕 ቟↰৻ᦶ㧘ਛ੗ ታ㧘⊕ᧁ ੫㧘ᄢፉ㕏ᐢ㧘ጤਅᜏม㧘੖ፉ ⡡㧘౗᧻㓷ਯ㧘᫪⣁ਭ㓉㧚⢙㆏∔ᖚ⸻≮ߩ࠻ࡇ࠶ࠢࠬ㧦ਛỈਃ㇢⋙ୃ㧚ੇ ๺㇢✬㧚⢄⢙⤟∔ᖚߩ⸻ᢿߣᴦ≮࠻ࡇ࠶ࠢࠬ 2006㧘᧲੩㧦ࠕ࡯ࠢࡔ࠺ࠖ
ࠕ㧧2006 ᐕ㧦45㧙52㧚
13㧕 ะ੗ ᒝ㧘቟↰৻ᦶ㧘౷↰ᩕ৻㧘᫪⣁ਭ㓉㧚⢙࡮⤟ ⤟⊒↢⇣Ᏹ(⤟≹วਇో)ߩ∛ဳಽ㘃㧦᫟ᣇᤘඳ㧘ዊᳰ๺ᒾ㧘↰ዥਭ㓶✬㧚⥃ᐥߦᓎ┙ߟᶖൻེ∔ᖚߩ⸻ᢿၮḰ࡮∛ဳಽ㘃࡮㊀∝ᐲߩ↪޿ᣇ㧘᧲੩㧦ᣣᧄࡔ࠺ࠖࠞ࡞࠮ࡦ࠲࡯㧧2006 ᐕ㧦355㧙357㧚
14㧕 ౝᧁ㓉ᢥ㧘᫪⣁ਭ㓉㧚44㧚഍∝⢄Ἳ㧙Common Disease ࠗࡦࠬ࠻࡜࡚ࠢࠪࡦ࡮ࡑ࠾ࡘࠕ࡞-ᖚ⠪ߦ૗ࠍߤ߁⺑᣿ߔࠆ߆㧙㧦Medicina ✬㧚Medicina㧘᧲੩㧦කቇᦠ㒮㧧2006 ᐕ㧦168㧙171.
15㧕 ⑔ፉ⑲᮸㧚Ω. ࠕ࡟࡞ࠡ࡯ᕈ∔ᖚ㧦ዊ⿧┨ᐔ⋙㧚᫪⣁ਭ㓉㧘ᄢ᧛ஜੑ㧘੗਄ༀᢥ✬㧚ᩕ㙃≮ᴺ ࡒ࠾ࡑࡓࠛ࠶࠮ࡦࠪࡖ࡞㧘᧲੩㧦ධᳯၴ㧧2006 ᐕ㧦119㧙125㧚
16㧕 ⑔ፉ⑲᮸㧚Ԙ∔ᖚ೎ߩ⸻ᢿ࡮ᴦ≮ᜰ㊎ B.∔ᖚ೎ߩᴦ≮ 6)㕖ઍఘᕈ⢄⎬ᄌ 1.⣻᳓ࠍว૬ߒߡ޿ࠆ႐ว㧦⢄ߣᩕ㙃ߩળ✬㧚ታ〣 ⢄∔ᖚߩᩕ㙃≮ᴺ㧘᧲੩㧦ධᳯၴ㧧2006 ᐕ㧦68㧙73㧚
17㧕 ⑔ፉ⑲᮸㧘⊕ᧁ ੫㧘ᚭ↰ൎਭ㧘ਛ᧛ඳᑼ㧘⧯ේ೑㆐㧘੖๧㇚ሶ㧘ਃベ૫ⴕ㧘ᕺ⦟⡛৻㧘᫪⣁ਭ㓉㧚Τ ⢄ߩ✢⛽ൻ࡮Ἳ∝࡮ᴦ≮ 4㧚⢄⎬ᄌᖚ⠪ߦ߅ߌࠆ BCAA ⵾೷ᛩਈᤨߩ㉄ൻဳࠕ࡞ࡉࡒࡦߩᬌ⸛㧦⼱Ꮉਭ৻✬㧚╙ 2 ࿁‫㉄ޟ‬ൻࠬ࠻࡟ࠬߣ⢄‫⎇ޠ‬ⓥળ⸥㍳ 㧙㉄ൻࠬ࠻࡟ࠬߣ⢄∔ᖚ㧙 ╙ 2 Ꮞ㧘᧲੩㧦ᩣᑼળ␠ࠕ࡯
ࠢࡔ࠺ࠖࠕ㧧2006 ᐕ㧦79㧙84㧚
18㧕 ᧛਄໪㓶㧘᫪⣁ਭ㓉㧚⢄㧙⢄ᕈ⣖∝ߩ⸻ᢿၮḰߣ∛ဳಽ㘃㧙㧦᫟ᣇᤘඳ㧘ዊᳰ๺ᒾ㧘↰ዥਭ㓶✬㧚⥃ᐥߦᓎ┙ߟᶖൻེ∔ᖚߩ⸻ᢿၮḰ࡮∛ဳಽ㘃࡮㊀∝ᐲߩ↪޿ᣇ㧘᧲੩㧦ᣣᧄࡔ࠺ࠖࠞ࡞࠮ࡦ࠲࡯␠㧧2006 ᐕ㧦
227㧙231㧚
19㧕 ᳗ᧁᱜੳ㧚DNA ࡑࠗࠢࡠࠕ࡟ࠗࠍ↪޿ߚㆮવሶ⊒⃻⸃ᨆߦࠃࠆ⢄⚦⢩ᱫ࡮ಽൻᯏ᭴ߩ⸃᣿ߣォ౮⺞▵㧦
Liver Forum in Kyoto ╙ 8 ࿁ቇⴚ㓸ળ㧘᧲੩㧦ࡔ࠺ࠖࠞ࡞࠻࡝ࡆࡘ࡯ࡦ㧧2006 ᐕ㧦29㧙34.
20㧕 ᫪⣁ਭ㓉㧚LC/HCC㧦ጟ↰ᱜ㧘㚍႐ᔘ㓶㧘ጊၔ㓶৻㇢✬㧚ᣂ⥃ᐥᩕ㙃ቇ㧘᧲੩㧦කቇᦠ㒮㧧2007 ᐕ㧦502
㧙506.
21㧕 ᫪⣁ਭ㓉㧚LC,HCC㧦ᱞ↰⧷ੑ㧘㐳⼱ㇱᱜ᥍✬㧚⥃ᐥᩕ㙃੍㒐࡮ᴦ≮ቇ㧘ᄢ㒋㧦᳗੗ᦠᐫ㧧2007 ᐕ㧦231
㧙233.
22㧕 ᫪⣁ਭ㓉㧚ᣣᧄᩕ㙃࡮㘩♳ቇળ✬㧚ᩕ㙃࡮㘩♳ቇ↪⺆ㄉౖ㧘᧲੩㧦ᑪᏡ␠㧧2007 ᐕ㧚
23㧕 ᫪⣁ਭ㓉㧚⢄ਇో࡮⢄ᕈ⣖∝㧦᧖ᧄᕡ᣿㧘⍫ፒ⟵㓶✬㧚ౝ⑼ቇ(╙ 9 )㧘᧲੩㧦ᦺୖᦠᐫ㧧2007 ᐕ㧦933
㧙936.
24㧕 ᫪⣁ਭ㓉㧚⢄⎬ᄌ㧙a.৻⥸⊛ᴦ≮㧘ᄖ᧪▤ℂ╬㧙㧦▤㊁ஜᄥ㇢㧘਄⷏♿ᄦ㧘੗ᑫ㆏ᄦ✬㧚ᶖൻེ∔ᖚᦨᣂߩᴦ≮㧘᧲੩㧦ධᳯၴ㧧2007 ᐕ㧦308㧙311.
25㧕 ᫪⣁ਭ㓉㧚↢ᵴᜰዉ㧦ጊญᔀ㧘ർේశᄦ㧘⑔੗ᰴ⍫✬㧚੹ᣣߩᴦ≮ᜰ㊎㧘᧲੩㧦කቇᦠ㒮㧧2007 ᐕ㧦416.
26㧕 ᫪⣁ਭ㓉㧚ࡆ࠲ࡒࡦ A㧦Medical Practice ✬㧚⥃ᐥᬌᩏࠟࠗ࠼ 2007㨪2008㧘᧲੩㧦ᢥశၴ㧧2007 ᐕ㧦265
㧙266.
27㧕 ᫪⣁ਭ㓉㧚⢄⎬ᄌ࡮⢄⤳≸㧦⍫ࡩፒ৻ਃ㧘㐷⣁ၮੑ㧘⥭㊀ᱜ৻㧘ᮮ⿧⑲ᒾ✬㧚ࠕࡒࡁ㉄ߩᯏ⢻․ᕈ㧘᧲੩㧦ஜᏡ␠㧧2007 ᐕ㧦261㧙722.
28㧕 ᫪⣁ਭ㓉㧚Pio̖NASH㧦Review Gastroenterol CGH㧘2007;1:62㧙64.
29㧕 ᫪⣁ਭ㓉㧚BCAA㧦〔⷗⵨㧘⊕㠽ᢘሶ㧘ᱜᧁዏᒾ㧘਄᧛⋥Ꮘ✬㧚⥃ᐥߦ⋥⚿ߔࠆ⢄࡮⢙࡮⤟∔ᖚᴦ≮ߩࠛࡆ࠺ࡦࠬ㧘᧲੩㧦ᢥశၴ㧧2007 ᐕ㧦67㧙68.
30㧕 ᳗ᧁᱜੳ㧚ᣣᧄᩕ㙃࡮㘩♳ቇળ✬㧚ᩕ㙃࡮㘩♳ቇ↪⺆ㄉౖ㧘᧲੩㧦ᑪᏡ␠㧧2007 ᐕ.
31㧕 ቟↰৻ᦶ㧘᫪⣁ਭ㓉㧚╙ 4 ┨㧚⢙㆏∔ᖚ㧦᧻የ ℂ⋙㧚᫪⣁ਭ㓉✬㧚ࠃߊࠊ߆ࠆ∛ᘒ↢ℂ 3 㧙ᶖൻེ∔ᖚ-㧘᧲੩㧦ᣣᧄක੐ᣂႎ␠㧧2007 ᐕ㧦113㧙136.
32㧕 ቟↰৻ᦶ㧚⿥㖸ᵄౝⷞ㏜ߦࠃࠆ❑㓒㗔ၞ߳ߩࠕࡊࡠ࡯࠴ 㧙EBUS-TBNA, EUS-FNA ߩታ㓙㧙㧦቟⑔๺ᒄ⋙㧚೙૞දജ ࠝ࡝ࡦࡄࠬࡔ࠺ࠖࠞ࡞ࠪࠬ࠹ࡓᩣᑼળ␠㧚33㧕 ⑔ፉ⑲᮸㧘᫪⣁ਭ㓉㧚╙ 2 ┨ ⚻⣺ᩕ㙃೷ߩၮᧄߣᔕ↪ ․ᱶߥ∛ᘒߩ⚻⣺ᩕ㙃▤ℂ—⢄∔ᖚ—㧦૒‫ᧁޘ‬㓷਽✬㧚NST ߩߚ߼ߩ⚻⣺ᩕ㙃 ታ〣࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦ᾖᨋ␠㧧2007 ᐕ㧦51㧙55.
34㧕 ᷡ᳓㓷ੳ㧘᫪⣁ਭ㓉㧚㕖Ⅳᑼ࡟࠴ࡁࠗ࠼ߦࠃࠆ⢄⊒≸ߩ੍㒐㧦⷏ญୃᐔ✬㧚⢄⎬ᄌߩࡑࡀࠫࡔࡦ࠻㧚᧲੩㧦ක⮎ࠫࡖ࡯࠽࡞␠㧧2007 ᐕ㧦84㧙89㧚
35㧕 ⊕ᧁ ੫㧘᫪⣁ਭ㓉㧚Φ. ⢄⎬ᄌߩᴦ≮—ᩕ㙃ቇ⊛≮ᴺ—1. ಽጘ㎮ࠕࡒࡁ㉄(BCAA)—㧦⷏ญୃᐔ✬㧚ࡑࡀࠫࡔࡦ࠻ࠪ࡝࡯࠭ ⢄⎬ᄌߩࡑࡀࠫࡔࡦ࠻㧘᧲੩㧦ක⮎ࠫࡖ࡯࠽࡞␠㧧2007 ᐕ㧦66㧙72.
36㧕 ⊕ᧁ ੫㧘᫪⣁ਭ㓉㧚╙ 4 ┨▤ℂ࡮ᴦ≮ ↢ᵴ▤ℂ(ᩕ㙃▤ℂࠍ฽߻) 44 ⢄⎬ᄌ㧦ᴒ↰ ᭂ✬㧚ᦨᣂකቇ೎ౠ ᣂߒ޿⸻ᢿߣᴦ≮ߩ ABC㧘ᄢ㒋㧦ᦨᣂකቇ␠㧧2007 ᐕ㧦72㧙78.
37㧕 ⊕ᧁ ੫㧘⑔ፉ⑲᮸㧘᫪⣁ਭ㓉㧚ࠕࡒࡁ㉄ߣߘߩಽ↹㧦Medical Practice ✬㧚⥃ᐥᬌᩏࠟࠗ࠼ 2007㨪2008㧘᧲੩㧦ᢥశၴ㧧2007 ᐕ㧦203㧙208.
38㧕 ᫪⣁ਭ㓉㧚∛ᘒ೎ߩᩕ㙃▤ℂ ⢄Ἳ㧘⢄⎬ᄌ㧘⢄ਇో㧦ጊ᧲ൕᒎ㧘ᐊᙗ৻㇢㧘଻ᧁ᣽ᓼ✬㧚࡟ࠫ࠺ࡦ࠻ߩߚ
߼ߩᩕ㙃▤ℂࡑ࠾ࡘࠕ࡞㧘᧲੩㧦ᢥశၴ㧧2008 ᐕ㧦201㧙206.
39㧕 ᫪⣁ਭ㓉㧚D.⢄∔ᖚߦኻߔࠆᩕ㙃≮ᴺ(⢄⎬ᄌ߽฽߻)㧦JASPEN ✬㧚ࠦࡔ࠺ࠖࠞ࡞ߩߚ߼ߩ㕒⣂⚻⣺ᩕ㙃࠮ࡒ࠽࡯㧘᧲੩㧦ධᳯၴ㧧2008 ᐕ㧦299㧙304.
40㧕 ᫪⣁ਭ㓉㧚╙ 5 ┨ ∛ᘒᩕ㙃ߣᩕ㙃≮ᴺ㧘7 ߘߩઁߩ∔ᖚ㧘Ԝ߇ࠎ㧦ᣣᧄ∛ᘒᩕ㙃ቇળ✬㧚ᡷ⸓╙ 2 
⹺ቯ ∛ᘒᩕ㙃ኾ㐷Ꮷߩߚ߼ߩ∛ᘒᩕ㙃ࠟࠗ࠼ࡉ࠶ࠢ㧘᧲੩㧦ࡔ࠺ࠖࠞ࡞࡟ࡆࡘ࡯␠㧧2008 ᐕ㧦248㧙249.
41㧕 ⊕ᧁ ੫㧘ኹୖ㓁৻㧘ጤ⍾ᷕᐔ㧘ౝᧁ㓉ᢥ㧘᳗ᧁᱜੳ㧘᫪⣁ਭ㓉㧚⢄⎬ᄌᖚ⠪ߦ߅ߌࠆᚑ࿃೎ᬌ⸛㧦㕍ᩉ㧙㧙⼾㧘⷏ญୃᐔ㧘㆏ႌᶈੑ㇢✬㧚⢄⎬ᄌߩᚑ࿃೎ታᘒ㧘᧲੩㧦ਛᄖකቇ␠㧧2008 ᐕ㧦174㧙177㧚
42㧕 ቟↰৻ᦶ㧚II. ᔕ↪✬ B. ERCP 㑐ㅪᚻᛛ ฦ⺰ d. ERCP 㑐ㅪᚻᛛߦᔅⷐߥಣ⟎ౕߣᚻᛛߩታ㓙(⢙㆏
✬)2. EPBD(ౝⷞ㏜⊛੃㗡ࡃ࡞࡯ࡦ᜛ᒛⴚ)㧦♻੗㓉ᄦ✬㧚⢙⤟ౝⷞ㏜ߩ⸻ᢿ࡮ᴦ≮ߩၮᧄᚻᛛ㧘᧲੩㧦⟠࿯␠㧧2008 ᐕ㧦150㧙153㧚
43㧕 ቟↰৻ᦶ㧚Part1 h3. ⢙⤟∔ᖚߦኻߔࠆࠗࡦ࠲࡯ࡌࡦ࡚ࠪࡦ A. ERCP ߣ㑐ㅪᬌᩏᚻᛛ(ࡉ࡜࠶ࠪࡦࠣ⚦⢩⸻㧘⚻੃㗡⊛↢ᬌ㧘POCS/POPS㧘IDUS)㧦ዊୀ᡽↵⋙㧚દ૒ጊᶈㅢ㧘ศ↰᥍ᒾ㧘ᬁฬ⑲৻ᦶ✬㧚⢄⢙⤟⸻≮ࠛࠠࠬࡄ࡯࠻ࡑ࠾ࡘࠕ࡞㧘᧲੩㧦⟠࿯␠㧧2008 ᐕ㧦98㧙103㧚
44㧕 ቟↰৻ᦶ㧚Part3 h2. ⢙㆏࡮⤟⤳∔ᖚ 2) ✚⢙▤⚿⍹㧦ዊୀ᡽↵⋙㧚દ૒ጊᶈㅢ㧘ศ↰᥍ᒾ㧘ᬁฬ⑲৻ᦶ✬㧚⢄⢙⤟⸻≮ࠛࠠࠬࡄ࡯࠻ࡑ࠾ࡘࠕ࡞㧘᧲੩㧦⟠࿯␠㧧2008 ᐕ㧦291㧙294㧚
45㧕 ะ੗ ᒝ㧘቟↰৻ᦶ㧚Part3 h2. ⢙㆏࡮⤟⤳∔ᖚ 10) ERCP ߣ㑐ㅪᬌᩏᚻᛛ(ࡉ࡜࠶ࠪࡦࠣ⚦⢩⸻㧘⚻੃㗡⊛↢ᬌ㧘POCS/POPS㧘IDUS)㧦ዊୀ᡽↵⋙㧚દ૒ጊᶈㅢ㧘ศ↰᥍ᒾ㧘ᬁฬ⑲৻ᦶ✬㧚⢄⢙⤟⸻≮ࠛࠠࠬࡄ࡯࠻ࡑ࠾ࡘࠕ࡞㧘᧲੩㧦⟠࿯␠㧧2008 ᐕ㧦338㧙343㧚
46㧕 ⊕ᧁ ੫㧘᫪⣁ਭ㓉㧘↰᧛ቁᔒ㧚⢄Ἳ㧦ᷰㄝ᣿ᴦ㧘⑔੗ንⓄ✬㧚੹ᣣߩ∛ᘒᩕ㙃≮ᴺ(ᡷ⸓╙ 2 )㧘᧲੩㧦ධᳯၴ㧧2008 ᐕ㧦166㧙170㧚
47㧕 ⊕ᧁ ੫㧘᫪⣁ਭ㓉㧚⢄࡮⢙㆏∔ᖚߦኻߔࠆᩕ㙃▤ℂ㧦ᣣᧄ∛ᘒᩕ㙃ቇળ✬㧚⹺ቯ NST ࠟࠗ࠼ࡉ࠶ࠢ 2008ᡷ⸓ 㧘᧲੩㧦ࡔ࠺ࠖࠞ࡞࡟ࡆࡘ࡯␠㧧2008 ᐕ㧦119㧙126㧚⪺ᦠ㧔᰷ᢥ㧕
1㧕 Shimizu M, Weinstein IB, Moriwaki H. Targeting receptor tyrosine kinases and multiple downstream
signaling pathways by green tea catechin EGCG. In:Pandalai SG, ed. Cancer -Disease Progression andChemoprevention, India:Research Signpost;2006:203-206.
2㧕 Yasuda I, Iwashita T, Moriwaki H. Strategy for the endoscopic treatment of common bile duct stones-Should we cut or dilate the papilla?. In:Tajiri H, Nakajima M, Yasuda K. eds. New Challenges in
Gastrointestinal Endoscopy, Tokyo: Springer; 2008:379-384.
✚⺑㧔๺ᢥ㧕
1㧕 ᫪⣁ਭ㓉㧚⢄⤳ᩕ㙃ᴦ≮ߦ㑐ߔࠆᗧ⼂⺞ᩏ㧘ᩕ㙃⹏ଔߣᴦ≮ 2006 ᐕ㧧23 Ꮞ㧦79㧙81.
2㧕 ᫪⣁ਭ㓉㧚⢄⎬ᄌᖚ⠪ߩᩕ㙃≮ᴺߩㅴ߼߆ߚ -ฦ⒳ࠕࡒࡁ㉄⵾೷ߩ૶޿ಽߌߩࠦ࠷㧘Medical Practice2006 ᐕ㧧23 Ꮞ㧦133㧙135.
3㧕 ᫪⣁ਭ㓉㧚․㓸 ᶖൻེ≸ߩ੍㒐කቇ 㧙⢄⤳≸ߩൻቇ੍㒐㧘⥃ᐥᶖൻེౝ⑼ 2006 ᐕ㧧21 Ꮞ㧦695㧙698.
4㧕 ᫪⣁ਭ㓉㧚⢄⊒≸ -ൻቇ੍㒐㧘⥃ᐥᶖൻེౝ⑼ 2006 ᐕ㧧21 Ꮞ㧦1090㧙1095.
5㧕 ᫪⣁ਭ㓉㧘ጊ↰ବ᮸㧚․㓸/⢄ᯏ⢻ᬌᩏ୯ -ߘߩ਄ᚻߥ⺒ߺᣇ ⴊᷡⰮ⊕࡮⤔⾰෻ᔕߩᬌᩏ୯ߩ⺒ߺᣇ㧘⥃ᐥߣ⎇ⓥ 2006 ᐕ㧧83 Ꮞ㧦180㧙182.
6㧕 ᫪⣁ਭ㓉㧚⢄⚦⢩≸ߩ੍㒐ᴦ≮(ᐳ⺣ળ)㧘⢄⢙⤟ 2006 ᐕ㧧52 Ꮞ㧦457㧙474.
7㧕 ᅏ㊁ᱜ㓉㧘᫪⣁ਭ㓉㧚࡟࠴ࡁࠗ࠼ߦࠃࠆ⊒≸੍㒐ߣߘߩℂ⺰⊛⢛᥊㧘⢄⢙⤟ 2006 ᐕ㧧52 Ꮞ㧦393㧙402.
8㧕 ᧛਄໪㓶㧘⑔ፉ⑲᮸㧘⊕ᧁ ੫㧘㢬⷗ ኼ㧘᧻ᶆసᒾ㧘ᷓየ੝↱⟤㧘ᧁਅᐘሶ㧘᧛ἑ૫ઍሶ㧘㋈ᧁ㤗Ꮧሶ㧘᫪⣁ਭ㓉㧚ቇળ࡟ࡐ࡯࠻ ╙ 21 ࿁ᣣᧄ㕒⣂⚻⣺ᩕ㙃ቇળ㧘ᩕ㙃⹏ଔߣᴦ≮ 2006 ᐕ㧧23 Ꮞ㧦174㧙176㧚
9㧕 㢬⷗ ኼ㧘᫪⣁ਭ㓉㧚৻⥸⥃ᐥක߇ࠃߊㆣㆄߔࠆ⽺ⴊߩ⸻߆ߚ㧙ᶖൻེ∔ᖚߣ⽺ⴊ㧘⸻ᢿߣᴦ≮ 2006 ᐕ㧧
94 Ꮞ㧦2050㧙2053.
10㧕 㢬⷗ ኼ㧘᫪⣁ਭ㓉㧚࡟࠴ࡁࠗ࠼ߦࠃࠆ⊕ⴊ∛ߩಽൻ⺃ዉ≮ᴺ㧘Biotherapy 2006 ᐕ㧧20 Ꮞ㧦150㧙157.
11㧕 ቟↰৻ᦶ㧘᫪⣁ਭ㓉㧚ᢎ⢒࠮ࡒ࠽࡯‫ޟ‬⢙㆏ౝⷞ㏜ᴦ≮ߩࠦ࠷ߣ pitfall‫✚ޠ‬⢙▤⚿⍹ߩౝⷞ㏜ᴦ≮㧙ౝⷞ㏜⊛੃㗡ಾ㐿ⴚ(EST)ߣౝⷞ㏜⊛੃㗡ࡃ࡞࡯ࡦ᜛ᒛⴚ(EPBD)㧘⢙㆏ 2006 ᐕ㧧20 Ꮞ㧦159㧙164㧚
12㧕 ቟↰৻ᦶ㧘ะ੗ ᒝ㧘ᄢ⷏㓉຦㧘౷↰ᩕ৻㧘᫪⣁ਭ㓉㧚࡟ࠫ࠺ࡦ࠻ߩߚ߼ߩౝⷞ㏜⸻≮ࡑ࠾ࡘࠕ࡞ 㧙ౝⷞ㏜⊛⢙㆏࠼࡟࠽࡯ࠫⴚ㧙EBD(ࡊ࡜ࠬ࠴࠶ࠢࠬ࠹ࡦ࠻㧘㊄ዻࠬ࠹ࡦ࠻)㧘ᶖൻེౝⷞ㏜ 2006 ᐕ㧧18 Ꮞ㧦
869㧙871㧚
13㧕 ቟↰৻ᦶ㧚ᣂ⷏ᵗౝⷞ㏜⸻≮੐ᖱ㧙Master of Endoscopy㧘ᶖൻེౝⷞ㏜ 2006 ᐕ㧧18 Ꮞ㧦1037㧙1039㧚
14㧕 ቟↰৻ᦶ㧚ERCP 㑐ㅪᚻᛛߩࠦ࠷㧙⑳ߪߎ߁ߒߡ޿ࠆгEST ߣ EPBD㧘ᶖൻེ↹௝ 2006 ᐕ㧧8 Ꮞ㧦641
㧙646㧚
15㧕 ᄢ⷏㓉຦㧘቟↰৻ᦶ㧘ะ੗ ᒝ㧘Ⴎደᱜ㆏㧘౷↰ᩕ৻㧘᫪⣁ਭ㓉㧚․㓸㧦⤟≸ᣧᦼ⸻ᢿߩࠬ࠻࡜࠹ࠫ࡯г9㧚
EUS㧘EUS-FNA㧘⥃ᐥᶖൻེౝ⑼ 2006 ᐕ㧧21 Ꮞ㧦13.
16㧕 ⑔ፉ⑲᮸㧘᫪⣁ਭ㓉㧚੹᦬ߩਥ㗴 ⚻㕒⣂࡮⚻⣺ᩕ㙃 ࡊ࡜ࡦ࠾ࡦࠣߣߘߩታ〣гࠊ߇࿖ߩᩕ㙃≮ᴺߩ⃻⁁гᩕ㙃≮ᴺ⊒ዷߩᱧผ⊛⢛᥊㧘Medicina 2006 ᐕ㧧43 Ꮞ㧦718㧙721.
17㧕 ⑔ፉ⑲᮸㧘᫪⣁ਭ㓉㧚ᴦ≮ᛶ᛫ᕈ⢄∔ᖚ߳ߩࠕࡊࡠ࡯࠴г⢄⎬ᄌߩว૬∝ߩ∛ᘒߣᴦ≮г⢄ᕈ⣖∝ߩ∛ᘒߣᴦ≮㧘Modern Physician 2006 ᐕ㧧26 Ꮞ㧦1276㧙1280.
18㧕 ⑔ፉ⑲᮸, ᫪⣁ਭ㓉㧚Subjective global assessment(SGA)ߩታ㓙ߣߘߩᗧ⟵㧘කቇߩ޽ࠁߺ 2006 ᐕ㧧218
Ꮞ㧦496㧙500.
19㧕 ะ੗ ᒝ㧘቟↰৻ᦶ㧘Ⴎደᱜ㆏㧘ᄢ⷏㓉຦㧘౷↰ᩕ৻㧚⤟≸࡮⢙㆏≸ߩ⸻ᢿߣᴦ≮гᦨᣂߩ⎇ⓥേะ B. ⢙㆏≸ IX. ⢙㆏≸ᴦ≮ߦ߅ߌࠆ QOL㧘⢙㆏≸ߩ㕖ᚻⴚ≮ᴺߣ QOL㧘ᣣᧄ⥃ᐥ 2006 ᐕ㧧64 Ꮞ㧦560㧙564㧚
20㧕 ะ੗ ᒝ㧘Ⴎደᱜ㆏㧘቟↰৻ᦶ㧘౷↰ᩕ৻㧚㕖ಾ㒰⢄㐷ㇱᖡᕈ⢙▤㐽Ⴇߦ߅ߌࠆ⢙㆏࠼࡟࠽࡯ࠫ㧦
up-to-date—⢄㐷ㇱᖡᕈ⢙▤㐽Ⴇߦ߅ߌࠆ Matallic stent ߩഞ⟋—⢙ߣ⤟ 2006 ᐕ㧧27 Ꮞ㧦379㧙382㧚
21㧕 ᷡ᳓㓷ੳ㧘᫪⣁ਭ㓉㧚㕖Ⅳᑼ࡟࠴ࡁࠗ࠼ߦࠃࠆ⢄⊒≸ൻቇ੍㒐㧘೎ౠ‫ޟ‬කቇߩ޽ࠁߺ‫ޠ‬ᶖൻེ∔ᖚ II.⢄࡮⢙࡮⤟ 2006 ᐕ㧧3 Ꮞ㧦481㧙484.
22㧕 ᷡ᳓㓷ੳ㧘᫪⣁ਭ㓉㧚㕖Ⅳᑼ࡟࠴ࡁࠗ࠼ߦࠃࠆ⢄ౣ⊒≸ߩൻቇ੍㒐㧘⢄⢙⤟ 2006 ᐕ㧧53 Ꮞ㧦843㧙850.

㧙㧙

23㧕 ጊፒஜ〝㧘㐳✽ ⡡㧘┵ጊᥰ㇢㧘⑺↰࿡ᴦ㧘⨹ᧁኡม㧘ፉፒ ା㧘ട⮮ೣᑝ㧘᫪⣁ਭ㓉㧚ㄦㅦߥౝⷞ㏜⸻
ᢿ࡮ᴦ≮ߦㅘ᣿ࡈ࡯࠼߇᦭↪ߢ޽ߞߚචੑᜰ⣺ᙑቶ಴ⴊߩ 1 ଀㧘ᶖൻེౝⷞ㏜ 2006 ᐕ㧧18 Ꮞ㧦379㧙383㧚
24㧕 ᧛਄໪㓶㧘⑔ፉ⑲᮸㧘⊕ᧁ ੫㧘᫪⣁ਭ㓉㧚․㓸 ᩕ㙃ᛩਈ࡞࡯࠻ߩᎿᄦߣㅴᱠгක≮቟ో▤ℂ߆ࠄߺߚᩕ
㙃ᛩਈ࡞࡯࠻ߩᄌ㕟ߣ᦭↪ᕈ㧘ᩕ㙃⹏ଔߣᴦ≮ 2006 ᐕ㧧23 Ꮞ㧦426㧙431.
25㧕 ቟↰৻ᦶ㧘Ⴎደᱜ㆏㧘ะ੗ ᒝ㧘ᄢ⷏㓉຦㧘ጤਅᜏม㧘࿯੗᤯ᐔ㧘Ⴚ ᶈᐽ㧘౷↰ᩕ৻㧘᫪⣁ਭ㓉㧚⤟∔ᖚߩ↹௝⸻ᢿ㧦ᦨㄭߩ࠻࡟ࡦ࠼г⤟ߩౝⷞ㏜⊛ࠗࡦ࠲࡯ࡌࡦ࡚ࠪࡦ㧘⥃ᐥ↹௝ 2006 ᐕ㧧22 Ꮞ㧦1376㧙1383㧚
26㧕 ᄢ⷏㓉຦㧘቟↰৻ᦶ㧘ะ੗ ᒝ㧘Ⴎደᱜ㆏㧘౷↰ᩕ৻㧘᫪⣁ਭ㓉㧚⤟≸ᣧᦼ⸻ᢿߩࠬ࠻࡜࠹ࠫ࡯гEUS㧘
EUS-FNA ߦࠃࠆ⤟≸ᣧᦼ⸻ᢿ㧘⥃ᐥᶖൻེౝ⑼ 2006 ᐕ㧧21 Ꮞ㧦1771㧙1778.
27㧕 ᷡ᳓㓷ੳ㧘᫪⣁ਭ㓉㧚㕖Ⅳᑼ࡟࠴ࡁࠗ࠼ߦࠃࠆ⢄ౣ⊒≸ߩൻቇ੍㒐㧘⢄⢙⤟ 2006 ᐕ㧧53 Ꮞ㧦881㧙887.
28㧕 ะ੗ ᒝ㧘Ⴎደᱜ㆏㧘቟↰৻ᦶ㧘౷↰ᩕ৻㧚ಾ㒰ਇ⢻⢄㐷ㇱ⢙▤≸ߦ߅ߌࠆ⢙㆏ࠬ࠹ࡦ࠻ߩ⹏ଔ-Metallic
stent ߣ Tube stent—⢙㆏≸ߦኻߔࠆ IVR ߣౝⷞ㏜ᴦ≮㧘ᶖൻེ⑼ 2006 ᐕ㧧43 Ꮞ㧦345㧙349.
29㧕 ⊕ᧁ ੫, ⑔ፉ⑲᮸, ᫪⣁ਭ㓉. ⢄ᕈᶋ⣲㧘✚ว⥃ᐥ 2006 ᐕ㧧55 Ꮞ㧦2631㧙2635.
30㧕 ᫪⣁ਭ㓉㧚Care and Care Seriesг⢄࡮⢙࡮⤟∔ᖚߩᴦ≮ߣ⋴⼔㧘ౝ⑼ 2007 ᐕ㧧99 Ꮞ㧦686.
31㧕 ᫪⣁ਭ㓉㧘⊕ᧁ ੫㧚ࠞ࡜࡯ࠕ࠻࡜ࠬгり૕ᓽ୥߆ࠄߺࠆᩕ㙃⹏ଔ㧘⥃ᐥᩕ㙃 2007 ᐕ㧧110 Ꮞ㧦798㧙801.
32㧕 ᫪⣁ਭ㓉㧚♧ዩ∛ߦ߅ߌࠆㆬᛯߣߘߩታ㓙㧘ᩕ㙃⹏ଔߣᴦ≮ 2007 ᐕ㧧24 Ꮞ㧦53㧙55.
33㧕 ᫪⣁ਭ㓉㧚⢄ਇోᴦ≮ߩ⃻⁁ߣዷᦸ(ᐳ⺣ળ)㧘ᴦ≮ቇ 2007 ᐕ㧧41 Ꮞ㧦393㧙400.
34㧕 ᫪⣁ਭ㓉㧚LES(Late evening snack)ߦࠃࠆ⢄⤳ᩕ㙃≮ᴺߩ⃻⁁ߣዷᦸ(ᐳ⺣ળ)㧘ᩕ㙃⹏ଔߣᴦ≮ 2007
ᐕ㧧24 Ꮞ㧦64㧙73.
35㧕 ᫪⣁ਭ㓉㧚ࡆ࠲ࡒࡦ A ߩၮ␆㧘Modern Physician 2007 ᐕ㧧27 Ꮞ㧦1187㧙1188.
36㧕 ᫪⣁ਭ㓉㧚ࡆ࠲ࡒࡦ A ߩ⥃ᐥ㧘Modern Physician 2007 ᐕ㧧27 Ꮞ㧦1189㧙1190.
37㧕 ᫪⣁ਭ㓉㧚⢄ᕈ⣖∝㧘ᴦ≮ ᣣᶖ⹹ 2007 ᐕ㧧104 Ꮞ㧦352㧙356.
38㧕 ᧛਄໪㓶㧘᫪⣁ਭ㓉㧚․㓸 ⢄ਇో 2㧚ᘟᕈ⢄ਇో 1)⢄ᕈ⣖∝ߩ⊒∝ᯏᐨߣᴦ≮㧘ᴦ≮ቇ 2007 ᐕ㧧
41 Ꮞ㧦363㧙367.
39㧕 㢬⷗ ኼ㧚 ⥃ᐥ✬ II. ⸻ᢿᴺ ৻⥸ⴊᶧᬌᩏ࡮㛽㜑ᬌᩏ㧘ㅧⴊེ⣲≌—ၮ␆࡮⥃ᐥ㗔ၞߦ߅ߌࠆᦨᣂߩ⎇ⓥേะ㧘ᣣᧄ⥃ᐥ 2007 ᐕ㧧65 Ꮞ㧦288㧙292.
40㧕 ቟↰৻ᦶ㧘Ⴎደᱜ㆏㧘ะ੗ ᒝ㧘ᄢ⷏㓉຦㧘ᚭ↰ൎਭ㧘ጤ↰࿻੺㧘ጤਅᜏม㧘࿯੗᤯ᐔ㧘౷↰ᩕ৻㧘᫪⣁ਭ㓉㧚․㓸㧦૶޿ᾫߘ߁ EUS—⤟࡮⢙㆏㗔ၞߩᮡḰᢿጀᴺ—ࠦࡦࡌ࠶ࠢࠬᯏ⒳㧘ᶖൻེౝⷞ㏜ 2007 ᐕ㧧
19 Ꮞ㧦923㧙928.
41㧕 ቟↰৻ᦶ㧘ጤਅᜏม㧘࿯੗᤯ᐔ㧘᫪⣁ਭ㓉㧚ౝⷞ㏜ߩ቟ోቇ㧙⧯ᚻ߳ߩࡔ࠶࠮࡯ࠫ࡯቟ోߥ EUS㧘ᶖൻེౝⷞ㏜ 2007 ᐕ㧧19 Ꮞ㧦1340㧙1343.
42㧕 ቟↰৻ᦶ㧘࿯੗᤯ᐔ㧘ጤਅᜏม㧘ጤ↰࿻੺㧘ᚭ↰ൎਭ㧘ᄢ⷏㓉຦㧘ะ੗ ᒝ㧘Ⴎደᱜ㆏㧘౷↰ᩕ৻㧘᫪⣁ਭ㓉㧚✚⢙▤⚿⍹ណ⍹ߦ߅ߌࠆᎿᄦߣࡔࡕ࡝࡯8г✢ࡃࠬࠤ࠶࠻ߩ․ᓽߣ૶޿ᣇ㧘HIRATA NEWSLETTERS 2007 ᐕ㧧7 Ꮞ㧦1㧙7.
43㧕 ቟↰৻ᦶ㧚⿥㖸ᵄౝⷞ㏜ࠟࠗ࠼ਅ⓫ೝⴚ(EUS-FNA)-⑳ߩࠦ࠷࡯㧘ᶖൻེ↹௝ 2007 ᐕ㧧9 Ꮞ㧦615㧙620.
44㧕 ⑔ፉ⑲᮸㧘⊕ᧁ ੫㧘ౝᧁ㓉ᢥ㧘᳗ᧁᱜੳ㧘᫪⣁ਭ㓉. ․㓸 II ⢄⎬ᄌߩᩕ㙃≮ᴺгC ဳᘟᕈ⢄∔ᖚᖚ⠪ߦ߅ߌࠆ BMI ߩᗧ⟵㧘ᶖൻེ⑼ 2007 ᐕ㧧44 Ꮞ㧦603㧙608.
45㧕 ⊕ᧁ ੫, ᫪⣁ਭ㓉. ⢄ᕈ⣖∝㧘⢄⢙⤟ 2007 ᐕ㧧54 Ꮞ㧦109㧙114.
46㧕 ⊕ᧁ ੫, ᫪⣁ਭ㓉. ⢄⎬ᄌ㧘✚ว⥃ᐥ 2007 ᐕ㧧56 Ꮞ㧦1173㧙1179.
47㧕 ᧃᰴ ᷕ㧘᳗ᧁᱜੳ㧘᫪⣁ਭ㓉㧚⢄ౣ↢ߦ߆߆ࠊࠆಽሶ̅HNF ߪߤߩࠃ߁ߦ߆߆ࠊࠆߩ߆㧫㧘ಽሶᶖൻེ
∛ 2007 ᐕ㧧4 Ꮞ㧦322㧙326.
✚⺑㧔᰷ᢥ㧕
1㧕 Moriwaki H. Nutritional assessment in liver cirrhosis. J Gastroenterol. 2006;41:511-512.
2㧕 Shimomura Y, Honda T, Shiraki M, Murakami T, Sato J, Kobayashi H, Mawatari K, Obayashi M,
Harris RA.Branched-chain amino acid catabolism in exercise and liver disease. J Nutr.
2006;136:250S-253S.
3㧕 Moriwaki H, Shimizu M, Okuno M, Nishiwaki-Matsushima R. Chemoprevention of liver
carcinogenesis with retinoids -Basic and clinic aspects. Hepatol Res. 2007;37(Suppl.2):S299-S302.
ේ⪺㧔๺ᢥ㧕
1㧕 㜞ᯅ ஜ㧘ේ ᱞᔒ㧘ศᎹᱞᔒ㧘ਅ᧛㗅ሶ㧘㢬⷗ ኼ㧘ጊ↰㋕਽㧘౷↰ᩕ৻㧘᫪⣁ਭ㓉㧚ᣧᦼߦࡃ࡯ࠠ࠶
࠻࡝ࡦࡄ⣲ဳᒻ⾰ォ឵ࠍ␜ߒ㜞ᖡᕈᐲൻߒߚࠈ⢩ᕈ࡝ࡦࡄ⣲㧘⥃ᐥⴊᶧ 2006 ᐕ㧧46 Ꮞ㧦1055㧙1059.
2㧕 ጊፒஜ〝㧘⨹ᧁኡม㧘ᄢፉ㕏ᐢ㧘⊕ᧁ ੫㧘⑔ፉ⑲᮸㧘቟↰৻ᦶ㧘᳗ᧁᱜੳ㧘ട⮮ೣᑝ㧘᫪⣁ਭ㓉㧘ᑝἑༀା㧚චੑᜰ⣺㒱ಳဳ⣼⣲ߩ 1 ଀㧘Gastroenterological Endoscopy 2006 ᐕ㧧48 Ꮞ㧦1228㧙1230㧚
3㧕 ጤਅᜏม㧘቟↰৻ᦶ㧘ਛ੗ ታ㧘ᄢፉ㕏ᐢ㧘⊕ᧁ ੫㧘᫪⣁ਭ㓉㧘᧻የ ᶈ㧘㑐㊁ቁผ㧘ጊ↰ථ਽㧘ᑝἑༀା㧚ਥ⤟▤⁜⓰ࠍ߈ߚߒߚ⤟ౝಽᴲ⣲≌ߩ 1 ଀㧘⢄⢙⤟ᴦ≮⎇ⓥળ⹹ 2006 ᐕ㧧4 Ꮞ㧦63㧙68.
4㧕 㜞ᯅ ஜ㧘ේ ᱞᔒ㧘ਅ᧛㗅ሶ㧘ศᎹᱞᔒ㧘౷↰ᩕ৻㧚ᕆㅦߦㅴⴕߔࠆᗧ⼂㓚ኂࠍ઻߁⥄Ꮖ఺∉ᕈṁⴊᕈ⽺ⴊߦኻߔࠆⴊẏ੤឵≮ᴺ㧘⥃ᐥⴊᶧ 2006 ᐕ㧧47 Ꮞ㧦787㧙789㧚
5㧕 ጤਅᜏม㧘቟↰৻ᦶ㧘⊕਄ᵗᐔ㧘Ⴆ↰⦟ᒾ㧘᫪⣁ਭ㓉㧚ᐢ▸ߥ⎬ൻᕈ⢙▤Ἳ௝ࠍ๒ߒߚ⥄Ꮖ఺∉ᕈ⤟Ἳߩ
1 ଀㧘Gastroenterological Endoscopy 2007 ᐕ㧧49 Ꮞ㧦51㧙57㧚
6㧕 ⊕਄ᵗᐔ㧘ᓟ⮮ዏ⛗㧘⷏⣁િੑ㧘ਤ⠀ఝ૫㉿㧘ਭ଻↰ో຦㧘ጤਅ㓷⑲㧘ዊ㊁ᧁ໪ੱ㧘ᨋ 㓉ᄦ㧘೨↰ᤩ↵㧘㥲⮮౏ᔒ㇢㧚ஜᏱᚑੱߦ⊒∝ߒߚࠨࠗ࠻ࡔࠟࡠ࠙ࠗ࡞ࠬ⢗චੑᜰ⣺Ἳߩ 1 ଀㧘ᣣᧄᶖൻེ∛ቇળ㔀⹹ 2007
ᐕ㧧104 Ꮞ㧦1377㧙1382㧚

㧙㧙7㧕 ጊፒஜ〝㧘⨹ᧁኡม㧘᫪⣁ਭ㓉㧚㝼㛽ߦࠃࠆ⋤⣺ᘟᕈἻ∝ᕈ⡺⧘⣲㧘Gastroenterological Endoscopy 2008
ᐕ㧧50 Ꮞ㧦66㧙67㧚
8㧕 ═ේජ༹㧘ේ ᱞᔒ㧘㢬⷗ ኼ㧘ᓟ⮮ዏ⛗㧘౗᧛ାብ㧘ศᎹᱞᔒ㧘ጊ↰ବ᮸㧘Ỉ↰㆏ᄦ㧘㜞ᯅ ஜ㧘᫪⣁ਭ㓉㧚ㅧⴊེ⣲≌ߦว૬ߒߚ⊒ᾲᕈᅢਛ⃿ᷫዋ∝ߦኻߔࠆ Biapenem ߩ᦭↪ᕈߦ㑐ߔࠆ⥃ᐥ⊛ᬌ⸛㧘The
Japanese Journal of Antibiotics 2008 ᐕ㧧61 Ꮞ㧦115㧙121㧚
9㧕 ዊ㊁ᧁ┨ੱ㧘⨹ᧁኡม㧘ᧁ᧛⵨ሶ㧘੹੗ஜੑ㧘੗ᷓ⾆ᔒ㧘㜞੗శᴦ㧘ౝᧁ㓉ᢥ㧘᳗ᧁᱜੳ㧘᫪⣁ਭ㓉㧚⢄⚦⢩≸ߦኻߔࠆ⢄േ⣂ൻቇႧᩖ≮ᴺ㧙࡜ࠫࠝᵄ὾ἳ≮ᴺᓟ㐷⣂ⴊᩖߦࠃࠅᕆㅦߦჇᖡߒߚ⢗㘩㆏㕒⣂≜ߩ
1 ଀㧘ᣣᧄ㐷⣂࿶੣ㅴ∝ቇળ㔀⹹ 2007 ᐕ㧧13 Ꮞ㧦222㧙227㧚
10㧕 ᫪⣁ਭ㓉㧚㐷੣∝ߣᩕ㙃▤ℂ̅㐷੣∝∝଀ߦኻߔࠆࠕࡒࡁ㉄≮ᴺ㧘ᣣᧄ㐷⣂࿶੣ㅴ∝ቇળ㔀⹹ 2007 ᐕ㧧
13 Ꮞ㧦117㧙121㧚
11㧕 ะ੗ ᒝ㧘Ⴎደᱜ㆏㧘቟↰৻ᦶ㧘ጤ↰࿻੺㧘౷↰ᩕ৻㧘᫪⣁ਭ㓉㧚㕖ಾ㒰⢄㐷ㇱ⢙▤≸ߦኻߔࠆ⢙㆏ࠬ࠹ࡦ࠹ࠖࡦࠣߩᬌ⸛㧘⢙㆏ 2008 ᐕ㧧22 Ꮞ㧦47㧙55㧚
12㧕 ⊕ᧁ ੫㧘⑔ፉ⑲᮸㧘⧯ේ೑㆐㧘ౝᧁ㓉ᢥ㧘᳗ᧁᱜੳ㧘᫪⣁ਭ㓉㧚C ဳᘟᕈ⢄∔ᖚᖚ⠪ߦ߅ߌࠆ BMI ߅ࠃ߮ౝ⬿⢽⢌㕙Ⓧߩᬌ⸛㧘ᩕ㙃 ⹏ଔߣᴦ≮ 2007 ᐕ㧧24 Ꮞ㧦42㧙45㧚
13㧕 ⊕ᧁ ੫㧘᫪⣁ਭ㓉㧚C ဳᘟᕈ⢄∔ᖚߦ߅ߌࠆ⢈ḩߩᬌ⸛㧘ᶖൻེ⑼ 2008 ᐕ㧧47 Ꮞ㧦363㧙368㧚
14㧕 ࿯੗᤯ᐔ㧘቟↰৻ᦶ㧘ጤਅᜏม㧘ጊ↰ᢕሶ㧘↰ਛ⑲ౖ㧘㐳↰⌀ੑ㧘ᑝἑༀା㧘᫪⣁ਭ㓉㧚㤛⦡⡺⧘⣲ᕈ⢙ྙἻߣߩ㐓೎߇໧㗴ߣߥߞߚ⢙ྙ≸ߩ 1 ଀㧘⢄⢙⤟ᴦ⎇⹹ 2008 ᐕ㧧6 Ꮞ㧦49㧙54㧚
15㧕 ᧁ᧛␭ሶ㧘⨹ᧁኡม㧘ᄢ㊁ᥓᒾ㧘ዊ㊁ᧁ┨ੱ㧘੗ᷓ⾆჻㧘౗᧛ାብ㧘ᓟ⮮ዏ⛗㧘ᧃᰴ ᷕ㧘⊕ᧁ ੫㧘═ේජ༹㧘ᷡ᳓㓷ੳ㧘ጊ↰ବ᮸㧘㢬⷗ ኼ㧘᫪⣁ਭ㓉㧚਄ⴕ⚿⣺㕒⣂≜ࠍᄾᯏߦ⸻ᢿߐࠇߚᖡᕈ࡝ࡦࡄ⣲ߩ
1 ଀㧘ጘ㒂⋵ౝ⑼කળ㔀⹹ 2008 ᐕ㧧22 Ꮞ㧦59㧙61㧚
16㧕 ᴡౝ㓉ብ㧘⨹ᧁኡม㧘੹੗ஜੑ㧘ዊ㊁ᧁ┨ੱ㧘੗ᷓ⾆჻㧘㜞੗శᴦ㧘⊕ᧁ ੫㧘ౝᧁ㓉ᢥ㧘⑔ፉ⑲᮸㧘᳗ᧁᱜੳ㧘᫪⣁ਭ㓉㧚ㇱಽ⊛⣛േ⣂Ⴇᩖⴚ(PSE)ߦࠃࠅ㗼ᕈ㔍ᴦᕈ⢄ᕈ⣖∝߇ᡷༀߒߚ PBC ߩ৻଀㧘ᣣᧄ㐷⣂࿶੣ㅴ∝ቇળ㔀⹹ 2006 ᐕ㧧12 Ꮞ㧦296㧙301㧚
17㧕 㜞ᯅቁᄦ㧘ᓼጊᵏᴦ㧘ဈਅᢥᄦ㧘㐳የᚑᢅ㧘ጊญ๺਽㧘㐳↰⌀ੑ㧘⨹ᧁኡม㧘᧖ጊ଻ᐘ㧘ን↰ᒄਯ㧘ᑝἑༀା㧚ਅㇱ⋥⣺ᚳᐔ਄⊹≸߇਄ㇱ⋥⣺ߦหᤨᕈოౝォ⒖ࠍ߈ߚߒߚ 1 ಾ㒰଀㧘ᣣᧄᄢ⣺⢂㐷∛ቇળ㔀⹹
2008 ᐕ㧧61 Ꮞ㧦33㧙38㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Muto Y, Sato S, Watanabe A, Moriwaki H, Suzuki K, Kato A, Kato M, Nakamura T, Higuchi K,
Nishiguchi S, Kumada H, Ohashi Y. Overweight and obesity increase the risk for liver cancer inpatients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid
granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatol Res.
2006;35:204-214.
2㧕 Yasuda I, Iwashita T, Ohnishi T, Mukai T, Enya M, Tomita E, Moriwaki H. Endoscopic nasobiliary
drainage: current indications and evaluation of the products. Dig Endosc. 2006;18:S105-S108.
3㧕 Yasuda I, Tsurumi H, Omar S, Iwashita T, Kojima Y, Yamada T, Sawada M, Takami T, Moriwaki H,
Soehendra N. Endoscopic ultrasound-guided fine-needle aspiration biopsy for lymphadenopathy of
unknown origin. Endoscopy. 2006;38:919-924.
4㧕 Suzui M, Sunagawa N, Chiba I, Moriwaki H, Yoshimi N. Acyclic retinoid, a novel synthetic retinoid,
induces growth inhibition, apoptosis, and changes in mRNA expression of cell cycle-anddifferentiation-related molecules in human colon carcinoma cells. Int J Oncol. 2006;28:1193-1199.
5㧕 Kimura K, Moriwaki H, Nagaki M, Saio M, Nakamoto Y, Naito M, Kuwata K, Chisari FV. Pathogenicrole of B cells in anti-CD40-induced necroinflammatory liver disease. Am J Pathol. 2006;168:786-795.
6㧕 Kimura K, Nagaki M, Nishihira J, Kuwata K, Moriwaki H, Chisari FV. Role of macropharge migration
inhibitory factor in hepatitis B virus-specific cytotoxic-T-lymphocyte-induced liver injury. Clin Vaccine
Immunol. 2006;13:415-419.
7㧕 Ito H, Koide N, Hassan F, Islam S, Tumurkhuu G, Mori I, Yoshida T, Kakumu S, Moriwaki H, Yokochi
T. Lethal endotoxic shock using alpha-galactosylceramide sensitization as a new experimental modelof septic shock. Lab Invest. 2006;86:254-261.
8㧕 Fukuno K, Tsurumi H, Ando N, Kanemura N, Goto H, Tanabashi S, Okamoto K, Moriwaki H.
Late-onset neutropenia in patients with rituximab for non-Hodgkin’s lymphoma. Int J Hematol.
2006;84:242-247.
9㧕 Mukai T, Nagaki M, Imose M, Kimura K, Satake S, Takai S, Moriwaki H. Prevention of hepatic
fibrosis in nonobese diabetic mice: a critical role for interferon-J. Liver Int. 2006;26:1006-1014.
10㧕 Imao M, Nagaki M, Moriwaki H. Dual effects of heat stress on tumor necrosis factor-D-induced
hepatocyte apoptosis in mice. Lab Invest. 2006;86:959-967.
11㧕 Imao M, Nagaki M, Imose M, Moriwaki H. Differential caspase-9-dependent signaling pathway
between tumor necrosis factor receptor- and Fas-mediated hepatocyte apoptosis in mice. Liver Int.
2006;26:137-146
12㧕 Kimata T, Nagaki M, Ogiso T, Naiki T, Kato T, Moriwaki H. Actin organization and hepatocyte
differentiation are regulated by extracellular matrix via PI 4,5-bisphosphate in the rat. Hepatology.
2006;44:140-151.
13㧕 Kimata T, Nagaki M, Tsukada Y, Ogiso T, Moriwaki H. Hepatocyte nuclear factor-4a and –1 small㧙㧙

IF 1.892

IF 4.166

IF 2.295
IF 5.487

IF 1.995

IF 4.479

IF 1.491
IF 2.559
IF 4.479

IF 2.559

IF 10.734

interfering RNA inhibits hepatocyte differentiation induced by extracellular matrix. Hepatol Res.
2006;35:3-9.
14㧕 Kojima Y, Tsurumi H, Goto N, Shimizu M, Kasahara S, Yamada T, Kanemura N, Hara T, Sawada M,
Saio M, Yamada T, Takahashi T, Tomita E, Takami T, Moriwaki H. Fas and Fas ligand expression on
germinal center type-diffuse large B-cell lymphoma is associated with the clinical outcome. Eur J
Haematol. 2006;76:465-472.
15㧕 Goto N, Tsurumi H, Takemura M, Hara T, Sawada M, Kasahara S, Kanemura N, Yamada T, Shimizu
M, Takahashi T, Tomita E, Seishima M, Takami T, Moriwaki H. Serum-soluble tumor necrosis factor
receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's
lymphoma. Eur J Haematol. 2006;77:217-225.
16㧕 Ando N, Yasuda I, Saito M, Moriwaki H. Hilar lymphadenopathy associated with autoimmune
Pancreatitis. Pancreas. 2006;33:101-102.
17㧕 Yamaguchi M, Gabazza EC, Taguchi O, Yano Y, Ikoma J, Kaito M, Kojima Y, Imoto I, Satomi A,
D’Alessandro-Gabazza CN, Hayashi T, Moriwaki H, Suzuki K, Adachi Y. Decreased protein C
activation in patients with fulminant hepatic failure. Scand J Gastroenterol. 2006;41:331-337.
18㧕 Fukuno K, Tsurumi H, Kanemura N, Tanabashi S, Okamoto K, Moriwaki H. Chronic neutrophilia
preceding overt aggressive light chain multiple myeloma. Leuk Lymphoma. 2006;47:762-764.
19㧕 Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, Moriwaki H. Characterization of CD133+
hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Bioph Res Commun.
2006;351:820-824.
20㧕 Nakamura H, Fukushima H, Miwa Y, Shiraki M, Gomi I, Saito M, Mawatari K, Kobayashi H, Kato M,
Moriwaki H. A longitudinal study on the nutritional state of eldery women at a nursing home in japan.
Int Med. 2006;45:1113-1120.
21㧕 Tsurumi H, Kanemura N, Hara T, Kasahara S, Yamada T, Sawada M, Oyama M, Moriwaki H.
Therapeutic strategy of untreated de novo acute myeloid leukemia in the elderly: the efficacy ofcontinuous drip infusion with low dose cytarabine and etoposide. J Cancer Res Clin Oncol.
2007;133:547-553.
22㧕 Tsurumi H, Hara T, Goto N, Kanemura N, Kasahara S, Sawada M, Yasuda I, Yamada T, Shimizu M,
Takami T, Moriwaki H. A phase II study of a THP-COP regimen for the treatment of elderly patients
aged 70 years or older with diffuse large B-Cell lymphoma. Hematol Oncol. 2007;25:107-114.
23㧕 Fukushima H, Miwa Y, Shiraki M, Gomi I, Toda K, Kuriyama S, Nakamura H, Wakahara T, Era S,
Moriwaki H. Oral branched-chain amino acid supplementation improves the oxidized/reduced
albumin ratio in patients with liver cirrhosis. Hepatology Res. 2007;37:765-770.
24㧕 Yamazaki K, Shimizu M, Okuno M, Matsushima-Nishiwaki R, Kanemura N, Araki H, Tsurumi H,
Kojima S, Weinstein IB, Moriwaki H. Synergistic effects of RXRD and PPARJ ligands to inhibit growthin human colon cancer cells-phosphorylated RXRD is a critical target for colon cancer management.
Gut. 2007;56:1557-1563.
25㧕 Takai S, Nagaki M, Imao M, Kimura K, Kozawa O, Moriwaki H. Intrinsic resistance to TNF-D-induced
hepatocyte apoptosis in ICR mice correlates with expression of a short form of c-FLIP. Lab Invest.
2007;87:572-581.
26㧕 Kanamori T, Shimizu M, Okuno M, Matsushima-Nishiwaki R, Tsurumi H, Kojima S, Moriwaki H.
Synergistic growth inhibition by acyclic retinoid and vitamin K2 in human hepatocellular carcinoma
cells. Cancer Sci. 2007;98:431-437.
27㧕 Kuriyama S, Miwa Y, Fukushima H, Nakamura H, Toda K, Shiraki M, Nagaki M, Yamamoto M,
Tomita E, Moriwaki H. Prevalence of diabetes and incidence of angiopathy in patients with chronicviral liver disease. J Clin Biochem Nutr. 2007;40:116-122.
28㧕 Yoshimura K, Muto Y, Shimizu M, Matsushima-Nishiwaki R, Okuno M, Takano Y, Tsurumi H, Kojima
S, Okano Y, Moriwaki H. Phosphorylated retinoid X receptor D loses its heterodimeric activity withretinoic acid receptor Ǫ. Cancer Sci. 2007;98:1868-1874.
29㧕 Satake S, Nagaki M, Kimura K, Moriwaki H. Inhibition of nuclear factor-kappa B induces
inflammatory cell migration and exacerbates severe liver injury in hepatitis B virus transgenic mice.
Hepatol Res. 2007;37:524-530.
30㧕 Ando N, Shimizu M, Okuno M, Matsushima-Nishiwaki R, Tsurumi H, Tanaka T, Moriwaki H.
Expression of retinoid X receptor D is decreased in 3'-methyl-4-dimethylaminoazobenzene-induced
hepatocellular carcinoma in rats. Oncol Rep. 2007;18:879-884.
31㧕 Wakahara T, Shiraki M, Murase K, Fukushima H, Matsuura K, Fukao A, Kinoshita S, Kaifuku N,
Arakawa N, Tamura T, Iwasa J, Murakami N, Deguchi T, Moriwaki H. Nutritional screening withsubjective global assessment predicts hospital stay in patients with digestive diseases. Nutrition.
2007;23:634-639.
32㧕 Gomi I, Fukushima H, Shiraki M, Miwa Y, Ando T, Takai K, Moriwaki H. Relationship between serum
albumin level and aging in community-dwelling self-supported elderly population. J Nutr Sci
Vitaminol. 2007;53:37-42.
33㧕 Nakaya Y, Okita K, Suzuki K, Moriwaki H, Kato A, Miwa Y, Shiraishi K, Okuda H, Onji M, Kanazawa㧙㧙

IF 1.892

IF 2.163

IF 2.163
IF 2.300

IF 2.052
IF 1.512

IF 2.749

IF

2.366

IF 2.180

IF 1.892

IF 10.015

IF 4.479

IF 3.165

IF 0.824

IF 3.165

IF 1.892

IF 1.597

IF 2.104

IF 0.784

H, Tsubouchi H, Kato S, Kaito M, Watanabe A, Habu D, Ito S, Ishikawa T, Kawamura N, Arakawa Y.
Hepatic Nutritional Therapy(HNT)Study Group -BCAA-enriched snack improves nutritional state of
cirrhosis. Nutrition. 2007;23:113-120.
34㧕 Ogiso T, Nagaki M, Takai S, Tsukada Y, Mukai T, Kimura K, Moriwaki H. Granulocytecolony-stimulating factor impairs liver regeneration in mice through the up-regulation of interleukin-1
beta. J Hepatol. 2007;47:816-825.
35㧕 Kimura K, Nagaki M, Kakimi K, Saio M, Saeki T, Okuda Y, Kuwata K, Moriwaki H. Critical role ofCD44 in hepatotoxin-mediated liver injury. J Hepatol. 2008;48:952-961.
36㧕 Ohnishi T, Yasuda I, Nishigaki Y, Hayashi H, Otsuji K, Mukai T, Enya M, Salem Omar, Nib Soehendra,
Tomita E, Moriwaki H. Intraductal chilled saline perfusion to prevent bile duct injury duringpercutaneous radiofrequency ablation for hepatocellular carcinoma. J Gastroenterol Hepatol.
2008;23:e410-e415.
37㧕 Ito H, Ando K, Ishikawa T, Nakayama T, Taniguchi M, Saito K, Imawari M, Moriwaki H, Yokochi T,
Kakumu S, Seishima M. Role of Valpha14+ NKT cells in the development of Hepatitis B virus-specific
CTL: activation of Valpha14+ NKT cells promotes the breakage of CTL tolerance. Int Immunol.
2008;20:869-879.
38㧕 Shimizu M, Shirakami Y, Sakai H, Tatebe H, Nakagawa T, Hara Y, Weinstein IB, Moriwaki H. EGCG
inhibits activation of the insulin-like growth factor (IGF)/IGF-1 receptor axis in human hepatocellular
carcinoma cells. Cancer Lett. 2008;262:10-18.
39㧕 Shimizu M, Shirakami Y, Sakai H, Adachi S, Hata K, Hirose Y, Tsurumi H, Tanaka T, Moriwaki H.
(-)-Epigallocatechin gallate suppresses azoxymethane-induced colonic premalignant lesions in male
C57BL/KsJ-db/db mice. Cancer Prev Res. 2008;1:298-304.
40㧕 Shimizu M, Shirakami Y, Moriwaki H. Targeting Receptor Tyrosine kinases for chemoprevention bygreen tea catechin, EGCG. Int J Mol Sci. 2008;9:1034-1049.
41㧕 Shimizu M, Moriwaki H. Synergistic effects of PPARgamma ligands and retinoids in cancer treatment.
PPAR Res. 2008;2008:181047.
42㧕 Shimizu M, Fukutomi Y, Ninomiya M, Nagura K, Kato T, Araki H, Suganuma M, Fujiki H, Moriwaki
H. Green tea extracts for the prevention of metachronous colorectal adenomas: a pilot study. Cancer
Epidemiol Biomarkers Prev. 2008;17:3020-3025.
43㧕 Adachi S, Nagao T, To S, Joe AK, Shimizu M, Matsushima-Nishiwaki R, Kozawa O, Moriwaki H,
Maxfield FR, Weinstein IB. (-)-Epigallocatechin gallate causes internalization of the epidermal growth
factor receptor in human colon cancer cells. Carcinogenesis. 2008;29:1986-1993.
44㧕 Satake S, Nagaki M, Kimura K, Naiki T, Hayashi H, Sugihara J, Tomita E, Moriwaki H. Significant
effect of hepatitis C virus on viral clearance in patients with type C chronic hepatitis treated withantiviral agents. Hepatol Res. 2008;38:491-500.
45㧕 Kanemura N, Tsurumi H, Kasahara S, Hara T, Yamada T, Sawada M, Goto N, Kitagawa JI, Shimizu
M, Oyama M, Moriwaki H. Continuous drip infusion of low dose cytarabine and etoposide with
granulocyte colony-stimulating factor for elderly patients with acute myeloid leukaemia ineligible forintensive chemotherapy. Hematol Oncol. 2008;26:33-38.
46㧕 Kanemura N, Tsurumi H, Okuno M, Matsushima-Nishiwaki R, Shimizu M, Moriwaki H. Retinoid X
receptor alpha is highly phosphorylated in retinoic acid-resistant HL-60R cells and the combination of
9-cis retinoic acid plus MEK inhibitor induces apoptosis in the cells. Leuk Res. 2008;32:884-892.
47㧕 Tatebe H, Shimizu M, Shirakami Y, Tsurumi H, Moriwaki H. Synergistic growth inhibition by
9-cis-retinoic acid plus trastuzumab in human hepatocellular carcinoma cells. Clin Cancer Res.
2008;14:2806-2812.
48㧕 Iwashita T, Yasuda I, Doi S, Kato T, Sano K, Yasuda Y, Nakashima M, Hirose Y, Takami T, Moriwaki H.
The yield of endoscopic ultrasound-guided fine needle aspiration for histological diagnosis in patientssuspected of stage I sarcoidosis. Endoscopy. 2008;40:400-405.
49㧕 Shirakami Y, Shimizu M, Tsurumi H, Hara Y, Tanaka T, Moriwaki H. EGCG and Polyphenon E
attenuate inflammation-related mouse colon carcinogenesis induced by AOM plus DDS. Mol Med Rep.
2008;1:355-361.
50㧕 Hara T, Tsurumi H, Kato T, Imao Y, Kojima Y, Kojima K, Kitagawa J, Katsumura N, Araki H, Takami
T, Moriwaki H. Immunoproliferative small intestinal disease with protein loss complicated withduodenal T cell lymphoma during progression. Intern Med. 2008;47:299-303.
51㧕 Doi S, Yasuda I, Iwashita T, Ibuka T, Fukushima H, Araki H, Hirose Y, Moriwaki H. Needle tract
implantation on the esophageal wall after EUS-guided FNA of metastatic mediastinal
lymphadenopathy. Gastrointest Endoscopy. 2008;67:988-990.

IF 2.104

IF 6.642
IF 6.642

IF 1.673

IF 3.290

IF 3.398

IF 0.750

IF 5.406

IF 1.892

IF 2.180

IF 2.561

IF 6.250

IF 4.166

IF 5.8884㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦᫪⣁ਭ㓉㧘⎇ⓥಽᜂ⠪㧦ጟ㊁ᐘ㓶㧘↰ਛථੑ㧘ዊ᎑⡡৻㧘⷏ญୃᐔ㧘ᷡ᳓㓷ੳ㧦ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄․ቯ㗔ၞ⎇ⓥ㧦ᩭౝฃኈ૕Ⱞ⊕ࠍಽሶᮡ⊛ߣߒߚ⢄≸ൻቇ੍㒐ߦ㑐ߔࠆ⎇㧙㧙ⓥ㧦ᐔᚑ 17㧙21 ᐕᐲ㧧66,000 ජ౞(16,300㧦16,300㧦16,300㧦17,100 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦ᅏ㊁ᱜ㓉㧘⎇ⓥಽᜂ⠪㧦᫪⣁ਭ㓉㧦ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦ࠨࠗ࠻ࠞࠗࡦㅪ㎮ߦࠃࠆ⢄ౣ↢ਇో⊒∝ᯏᐨߩ⸃᣿ߣߘߩ೙ᓮߦࠃࠆᴦ≮ᴺߩ㐿⊒㧦ᐔᚑ 16㧙18 ᐕᐲ㧧
3,400 ජ౞(1,300㧦1,100㧦1,000 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦⊕㠽⟵ቬ㧘⎇ⓥಽᜂ⠪㧦᫪⣁ਭ㓉㧘♿ࡁቯ଻⤿㧘ඨ↰ ብ㧘྾┬ሶᅢᐢ㧦ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦≸⚦⢩ߦ߅ߌࠆᩭౝฃኈ૕ߥࠄ߮ߦ⤑ฃኈ૕ߩ⇣Ᏹߣߘߩ೙ᓮߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 16㧙18 ᐕᐲ㧧3,400 ජ౞(1,700㧦1,100㧦600 ජ౞)
4㧕 ⎇ⓥઍ⴫⠪㧦ᧁ᧛౏ೣ㧘⎇ⓥಽᜂ⠪㧦ችጯ ⌀㧘᳗ᧁᱜੳ㧘᫪⣁ਭ㓉㧦ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦B ဳ⢄Ἳ࠙ࠗ࡞ࠬߦኻߔࠆ RNA Ꮏቇࠍ↪޿ߚ᛫࠙ࠗ࡞ࠬ⮎ߩ㐿⊒;ᐔᚑ 17㧙19 ᐕᐲ㧧3,400 ජ౞(1,700㧦1,100㧦600 ජ౞)
5㧕 ⎇ⓥઍ⴫⠪㧦ᷡ᳓㓷ੳ㧦ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦ฃኈ૕ဳ࠴ࡠࠪࡦࠠ࠽࡯࠯ࠍᮡ
⊛ߣߒߚ EGCG ᄢ⣺⊒≸ᛥ೙ߩ⎇ⓥ㧧ᐔᚑ 18㧙20 ᐕᐲ㧧3,300 ජ౞(1,500㧦1,000㧦800 ජ౞)
6㧕 ⎇ⓥઍ⴫⠪㧦ᄢ⷏ਃᦶ㧘⎇ⓥಽᜂ⠪㧦᫪⣁ਭ㓉㧦ෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄(㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ)㧦
㔍ᴦᕈߩ⢄࡮⢙㆏∔ᖚߦ㑐ߔࠆ⺞ᩏ⎇ⓥ㧦ᐔᚑ 18㧙20 ᐕᐲ㧧1,200 ජ౞(400㧦400㧦400 ජ౞)
7㧕 ⎇ⓥઍ⴫⠪㧦⮮ේ⎇ม㧘⎇ⓥಽᜂ⠪㧦᫪⣁ਭ㓉㧦ෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄(⢄Ἳ╬స᦯✕ᕆኻ╷⎇ⓥ੐ᬺ)㧦⢄߇ࠎᖚ⠪ߩ QOL ะ਄ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18㧙20 ᐕᐲ㧧2,000 ජ౞(2,000㧦1,300㧦1,250 ජ౞)8㧕 ⎇ⓥઍ⴫⠪㧦቟↰৻ᦶ㧘⎇ⓥಽᜂ⠪㧦ጤਅᜏม㧦ᐔᚑ 18 ᐕᐲౝⷞ㏜කቇ⎇ⓥᝄ⥝⽷࿅⎇ⓥഥᚑ(B)㧦
EUS-FNA ᬌ ૕ ߦ ߅ ߌ ࠆ nucleoside transporter proteins ⊒ ⃻ ࠍ ᜰ ᮡ ߣ ߒ ߚ ⤟ ≸ ൻ ቇ ≮ ᴺ(Gemcitabine)ലᨐ੍᷹ߩ⹜ߺ㧧ᐔᚑ 18 ᐕᐲ㧧500 ජ౞9㧕 ⎇ⓥઍ⴫⠪㧦ᷡ᳓㓷ੳ㧦ᐔᚑ 18 ᐕᐲ⎇ⓥ⑼㐳࡮කቇㇱ㐳ⵙ㊂⎇ⓥ⾌ߦࠃࠆ⎇ⓥ⾌(╙ 2 ࿁ NaSNeL⎇ⓥળ)㧦ฃኈ૕ဳ࠴ࡠࠪࡦࠠ࠽࡯࠯ߣߘߩਅᵹࠪࠣ࠽࡞ࠍಽሶᮡ⊛ߣߒߚ✛⨥ࠞ࠹ࠠࡦ EGCG ߦࠃࠆᶖൻེ≸⚦⢩Ⴧᱺᛥ೙ߩ⎇ⓥ㧧ᐔᚑ 18 ᐕᐲ㧧500 ජ౞
10㧕 ⎇ⓥઍ⴫⠪㧦ᷡ᳓㓷ੳ㧦ᐔᚑ 18 ᐕᐲ Liver Forum in Kyoto ⎇ⓥᅑബ⾨㧦ᩭౝฃኈ૕ RXR ࠍಽሶᮡ⊛ߣߒߚ⢄⊒≸ൻቇ੍㒐ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18 ᐕᐲ㧧1,000 ජ౞
11㧕 ⎇ⓥઍ⴫⠪㧦ᷡ᳓㓷ੳ㧦ጘ㒂කቇᅑബ⾨㧦✛⨥ࡐ࡝ࡈࠚࡁ࡯࡞ EGCG ߦࠃࠆᄢ⣺≸⚦⢩Ⴧᱺᛥ೙ല
ᨐߩᬌ⸛࡯ฃኈ૕ဳ࠴ࡠࠪࡦࠠ࠽࡯࠯ߦᵈ⋡ߒߡ࡯; ᐔᚑ 18 ᐕᐲ㧧200 ජ౞
12㧕 ⎇ⓥઍ⴫⠪㧦᫪⣁ਭ㓉㧘⎇ⓥಽᜂ⠪㧦ᷡ᳓㓷ੳ㧘ጊ↰ᵏᐢ㧦ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦
ᩭౝฃኈ૕߅ࠃ߮ฃኈ૕ဳ࠴ࡠࠪࡦࠠ࠽࡯࠯ࠍᮡ⊛ಽሶߣߒߚ≸ൻቇ੍㒐ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 19㧙
20 ᐕ㧧3,400 ජ౞(1,800㧦1,600 ජ౞)
13㧕 ⎇ⓥઍ⴫⠪㧦ᄢỈ㓁੺㧦ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦ᘟᕈ⢄㓚ኂߦ߅ߌࠆࠬࡈࠖࡦࠧ
⢽⾰ࠪࠣ࠽࡞ߩ⢄⚦⢩ߩ↢ᱫ᳿ቯᯏᐨߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 19㧙20 ᐕᐲ㧧3,300 ජ౞(1,800㧦1,500ජ౞)14㧕 ⎇ⓥઍ⴫⠪㧦ᾢ↰ඳశ㧘⎇ⓥಽᜂ⠪㧦᫪⣁ਭ㓉㧦ෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄(⢄Ἳ╬స᦯✕ᕆኻ╷⎇ⓥ੐ᬺ)㧦⢄⎬ᄌࠍ฽߼ߚ࠙ࠗ࡞ࠬᕈ⢄∔ᖚߩᴦ≮ߩᮡḰൻߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 19㧙20 ᐕᐲ㧧4,000 ජ౞(2,000㧦2,000 ජ౞)
15㧕 ⎇ⓥઍ⴫⠪㧦᳗ᧁᱜੳ㧦ᐔᚑ 19 ᐕᐲ⎇ⓥ⑼㐳࡮කቇㇱ㐳ⵙ㊂⎇ⓥ⾌ߦࠃࠆ⎇ⓥ⾌㧧1,000 ජ౞
16㧕 ⎇ⓥઍ⴫⠪㧦ᷡ᳓㓷ੳ㧦ᐔᚑ 19 ᐕᐲ⎇ⓥ⑼㐳࡮කቇㇱ㐳ⵙ㊂⎇ⓥ⾌ߦࠃࠆ⎇ⓥ⾌㧧200 ජ౞
17㧕 ⎇ⓥઍ⴫⠪㧦቟↰৻ᦶ㧦╙ 19 ࿁ጘ㒂කቇᅑബ⾨㧦⿥㖸ᵄౝⷞ㏜ਅๆᒁ㊎↢ᬌ(EUS-FNA)ߦࠃࠆ❑㓒࡮⣻⣧ౝ⣲ᄢ࡝ࡦࡄ▵ߩ⸻ᢿ㧧300 ජ౞
18㧕 ⎇ⓥઍ⴫⠪㧦቟↰৻ᦶ㧦Asian Pacific Digestive Week 2006 (APDW2006), Young InvestigatorAward 㧦Clinical impact of EUS-guided fine-needle aspiration biopsy for making diagnosis oflymphoma㧧US$1,000
19㧕 ⎇ⓥઍ⴫⠪㧦᳗ᧁᱜੳ㧘⎇ⓥಽᜂ⠪㧦ᄢỈ㓁੺㧘ᧃᰴ ᷕ㧦ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦
ᩭౝฃኈ૕߅ࠃ߮ฃኈ૕ဳ࠴ࡠࠪࡦࠠ࠽࡯࠯ࠍᮡ⊛ಽሶߣߒߚ≸ൻቇ੍㒐ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 20㧙
22 ᐕᐲ㧧3,500 ජ౞(1,100㧦1,000㧦1,400 ජ౞)
20㧕 ⎇ⓥઍ⴫⠪㧦⊕㠽⟵ቬ㧘⎇ⓥಽᜂ⠪㧦᫪⣁ਭ㓉㧦ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦ᩭౝฃኈ૕߅ࠃ߮ฃኈ૕ဳ࠴ࡠࠪࡦࠠ࠽࡯࠯ࠍᮡ⊛ಽሶߣߒߚ≸ൻቇ੍㒐ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 20㧙22 ᐕᐲ㧧3,500 ජ౞(1,500㧦1,100㧦900 ජ౞)
21㧕 ⎇ⓥઍ⴫⠪㧦⿷┙᡽ᴦ㧦ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦⢽⾰࡜ࡈ࠻ࠍᮡ⊛ߣߒߚ EGCG
ߦࠃࠆᄢ⣺≸੍㒐ߩ⎇ⓥ㧧ᐔᚑ 19㧙20 ᐕᐲ㧧3,100 ජ౞(1,600㧦1,500 ජ౞)
22㧕 ⎇ⓥઍ⴫⠪㧦㋈ᧁ৻ᐘ㧘⎇ⓥಽᜂ⠪㧦᫪⣁ਭ㓉㧦ෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄(⢄Ἳ╬స᦯✕ᕆኻ╷⎇ⓥ੐ᬺ)㧦⢄⎬ᄌࠍ฽߼ߚ࠙ࠗ࡞ࠬᕈ⢄∔ᖚߩᴦ≮ߩᮡḰൻߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 20 ᐕᐲ㧧2,000 ජ౞㧙㧙23㧕 ⎇ⓥઍ⴫⠪㧦ᷡ᳓㓷ੳ㧦ᐔᚑ 20 ᐕᐲ Liver Forum in Kyoto ⎇ⓥᅑബ⾨㧦ฃኈ૕ဳ࠴ࡠࠪࡦࠠ࠽࡯
࠯ࠍᮡ⊛ߣߒߚ EGCG ߦࠃࠆ⢄✢⛽ൻ࡮⊒≸੍㒐ߩ⎇ⓥ㧧1,000 ජ౞
24㧕 ⎇ⓥઍ⴫⠪㧦⿷┙᡽ᴦ㧦ᐔᚑ 20 ᐕᐲጘ㒂ᄢቇකቇㇱ⎇ⓥ⑼㐳࡮කቇㇱ㐳ⵙ㊂⎇ⓥ⾌㧧1,000 ජ౞
25㧕 ⎇ⓥઍ⴫⠪㧦ᧃᰴ ᷕ㧦ᐔᚑ 20 ᐕᐲጘ㒂ᄢቇකቇㇱ⎇ⓥ⑼㐳࡮කቇㇱ㐳ⵙ㊂⎇ⓥ⾌㧧500 ජ౞
2㧕ฃ⸤⎇ⓥ1㧕 ᫪⣁ਭ㓉㧘ᷡ᳓㓷ੳ㧦วᚑ࡟࠴ࡁࠗ࠼ߣಽሶᮡ⊛ᴦ≮⮎ߣߩ૬↪ߦ㑐ߔࠆ⎇ⓥ(2)㧧ᐔᚑ 18㧙19 ᐕᐲ㧧6,000 ජ౞(3,000㧦3,000 ජ౞)㧦⥝๺ഃ⮎2㧕 ᫪⣁ਭ㓉㧘ᷡ᳓㓷ੳ㧦♧ዩ∛ࡕ࠺࡞ࡑ࠙ࠬߦ߅ߌࠆ EGCG ߩ Azoxymethane ⺃⊒ᄢ⣺೨≸∛ᄌᒻᚑᛥ೙ലᨐߩᬌ⸛гEffects of EGCG on Inhibition of Development of AOM-Induced ACF in db/db
Miceг㧧ᐔᚑ 18 ᐕᐲ㧧1,500 ජ౞㧦ਃ੗ㄘᨋ3㧕 ᫪⣁ਭ㓉㧘᧛਄໪㓶㧘㢬⷗ ኼ㧦HIV ᗵᨴ⠪╬଻ஜ⑔␩⋧⺣ផㅴ⎇ⓥ㧧ᐔᚑ 15㧙18 ᐕᐲ㧧1,950 ජ౞(650㧦650㧦650㧦325 ජ౞)㧦ࠛࠗ࠭⽷࿅ฃ⸤⎇ⓥ⾌
4㧕 ᫪⣁ਭ㓉㧦ᩭ࡟࠴ࡁࠗ࠼ฃኈ૕Ⱞ⊕ࠍಽሶᮡ⊛ߣߒߚ߇ࠎൻቇ੍㒐ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18㧙20 ᐕ
ᐲ㧧450 ජ౞㧧(150㧦150㧦150 ජ౞)㧦⢽ṁᕈࡆ࠲ࡒࡦ
5㧕 ᫪⣁ਭ㓉㧘⊕ᧁ ੫㧦ੱⴊᷡࠕ࡞ࡉࡒࡦᴦ≮ߦ㑐ߔࠆ⥃ᐥ⎇ⓥ㧧ᐔᚑ 19 ᐕᐲ㧧1,300 ජ౞㧦ൻቇ෸
ⴊᷡ≮ᴺ⎇ⓥᚲ6㧕 ᫪⣁ਭ㓉㧘ᷡ᳓㓷ੳ㧦⢈ḩ㑐ㅪ⢄⊒≸ߦ߅ߌࠆวᚑ࡟࠴ࡁࠗ࠼ߩ੍㒐ലᨐ㧧ᐔᚑ 20 ᐕᐲ㧧1,000 ජ౞㧦⥝๺ഃ⮎
7㧕 ᫪⣁ਭ㓉㧘ዊ᎑⡡৻㧦⢄∔ᖚߩಽሶ∛ᘒ⸃᣿ߦၮߠߊᣂⷙᴦ≮࡮੍㒐ᴺߩ⏕┙㧧ᐔᚑ 18㧙20 ᐕᐲ㧧
300 ජ౞(100㧦100㧦100 ජ౞)㧦ℂൻቇ⎇ⓥᚲ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬ᫪⣁ਭ㓉㧦
1㧕 ᣣᧄౝ⑼ቇળℂ੐(㨪⃻࿷)2㧕 ᣣᧄᶖൻེ∛ቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ⢄⤳ቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄࡆ࠲ࡒࡦቇળℂ੐(㨪⃻࿷)5㧕 ᣣᧄ⥃ᐥઍ⻢ቇળ⹏⼏ຬ(㨪⃻࿷)6㧕 ᣣᧄ≸ቇળ⹏⼏ຬ(㨪⃻࿷)7㧕 ᣣᧄᩕ㙃㘩♳ቇળ⹏⼏ຬ(㨪⃻࿷)8㧕 ᣣᧄ㕒⣂⚻⣺ᩕ㙃ቇળℂ੐(㨪⃻࿷)᳗ᧁᱜੳ㧦1㧕 ᣣᧄౝ⑼ቇળᡰㇱ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄᶖൻེ∛ቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ⢄⤳ቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄੱᎿ⤳ེቇળ⹏⼏ຬ(㨪⃻࿷)5㧕 ᣣᧄ⥃ᐥಽሶකቇળ⹏⼏ຬ(㨪⃻࿷)቟↰৻ᦶ㧦1㧕 ᣣᧄᶖൻེౝⷞ㏜ቇળቇⴚ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄᶖൻེ∛ቇળ᧲ᶏᡰㇱ⹏⼏ຬ(ᐔᚑ 18 ᐕᐲ㨪⃻࿷)
3㧕 ᣣᧄ⢙㆏ቇળ⹏⼏ຬ(ᐔᚑ 20 ᐕᐲ㨪⃻࿷)2㧕ቇળ㐿௅᫪⣁ਭ㓉㧦
1㧕 ╙ 21 ࿁ᣣᧄ㕒⣂⚻⣺ᩕ㙃ቇળ(ᐔᚑ 18 ᐕ 1 ᦬㧘ጘ㒂)2㧕 ╙ 29 ࿁ᣣᧄᩕ㙃ࠕ࠮ࠬࡔࡦ࠻⎇ⓥળ(ᐔᚑ 18 ᐕ 5 ᦬㧘ጘ㒂)㧙㧙3㧕 ᫪⣁ਭ㓉㧦╙ 8 ࿁ᣣ㖧߇ࠎ⠧ൻࠪࡦࡐࠫ࠙ࡓ(The 8th Japan-Korea Joint Symposium on Cancer andAgeing Research)(ᐔᚑ 19 ᐕ 8 ᦬㧘ጘ㒂)
4㧕 ╙ 8 ࿁ᣣᧄஜᐽᩕ㙃ࠪࠬ࠹ࡓቇળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂)
3㧕ቇⴚ㔀⹹᫪⣁ਭ㓉㧦
1㧕 ᣣᧄౝ⑼ቇળ⹹(⧷ᢥ)㧧✬㓸ᆔຬ(㨪⃻࿷)2㧕 ᣣᧄᶖൻེ∛ቇળ⹹(⧷ᢥ)㧧✬㓸ᆔຬ(㨪⃻࿷)3㧕 ᣣᧄ㕒⣂⚻⣺ᩕ㙃ቇળ⹹㧦✬㓸ᆔຬ(㨪⃻࿷)᳗ᧁᱜੳ㧦1㧕 ᣣᧄ⢄⤳ቇળ⧷ᢥ⹹㧦✬㓸ᆔຬ(ᐔᚑ 18 ᐕᐲ㨪⃻࿷)2㧕 ᣣᧄᶖൻེ∛ቇળ㧦⧷ᢥ⹹ᩏ⺒ᆔຬ(ᐔᚑ 18 ᐕᐲ㨪⃻࿷)
3㧕 ᰷Ꮊ⢄⤳ቇળ⹹㧦ᩏ⺒ᆔຬ(ᐔᚑ 19 ᐕᐲ㨪⃻࿷)
4㧕 ᣣᧄੱᎿ⤳ེቇળ㧦⺰ᢥ⾨ㆬ಴ᆔຬ(㨪ᐔᚑ 18 ᐕᐲ)቟↰৻ᦶ㧦1㧕 ⢄⢙⤟ᴦ≮⎇ⓥળ⹹㧦✬㓸ᆔຬ(㨪⃻࿷)7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳᫪⣁ਭ㓉㧦
1㧕 ╙ 103 ࿁ᣣᧄౝ⑼ቇળ✚ળ(ᐔᚑ 18 ᐕ 4 ᦬㧘ᮮᵿ㧘ᐳ㐳)2㧕 ╙ 92 ࿁ᣣᧄᶖൻེ∛ቇળ✚ળ(ᐔᚑ 18 ᐕ 4 ᦬㧘ዊୖ㧘ࠪࡦࡐ‫ޟ‬S7.ᶖൻེ∔ᖚߩ∛ᘒᩕ㙃ߣᴦ≮‫ޠ‬มળ)3㧕 HCMC’S Association Study of Liver Diseases(ᐔᚑ 18 ᐕ 5 ᦬㧘ࡎ࡯࠴ࡒࡦ㧘ࠪࡦࡐࠫ࠙ࡓ
‫ޟ‬Therapeutic Implication of Branch-Chain Amino Acid in Protein Energy Malnutrition in
Patients with Liver Cirrhosis‫ޠ‬Ṷ⠪)
4㧕 ╙ 42 ࿁ᣣᧄ⢄⤳ቇળ✚ળ(ᐔᚑ 18 ᐕ 5 ᦬㧘੩ㇺ㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ 4‫ޟ‬⢄ౣ↢ක≮‫ޠ‬มળ)
5㧕 ᐔᚑ 18 ᐕᐲᣣᧄ≸ቇળࠪࡦࡐࠫ࠙ࡓ(ᐔᚑ 18 ᐕ 7 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ‫⸻ޟ‬ᢿߣᴦ≮ߦߟ޿ߡ‫ޠ‬Ṷ⠪)
6㧕 ╙ 13 ࿁ᣣᧄ㐷⣂࿶੣ㅴ∝ቇળ✚ળࡕ࡯࠾ࡦࠣ࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 9 ᦬㧘᧲੩㧘⻠Ṷ‫ޟ‬⢄߇ࠎ೙࿶ࠍ
⋡ᜰߒߚ C ဳ⢄⎬ᄌߩᴦ≮ᚢ⇛‫ޠ‬Ṷ⠪)7㧕 ╙ 10 ࿁ᣣᧄ⢄⤳ቇળᄢળ(ᐔᚑ 18 ᐕ 10 ᦬㧘ᧅᏻ㧘⻠Ṷ‫ޟ‬⢄⎬ᄌߣᩕ㙃≮ᴺ‫ޠ‬Ṷ⠪)8㧕 ᣣᧄᶖൻེ∛ቇળ᧲ᶏᡰㇱ ╙ 16 ࿁ᢎ⢒⻠Ṷળ(ᐔᚑ 18 ᐕ 11 ᦬㧘ฬฎደ㧘ᢎ⢒⻠Ṷ มળ)
9㧕 ╙ 36 ࿁ᣣᧄ⢄⤳ቇળ᧲ㇱળ(ᐔᚑ 18 ᐕ 12 ᦬㧘᧲੩㧘ᢎ⢒⻠Ṷ㧘Ṷ⠪)10㧕 ╙ 36 ࿁ᣣᧄ⢄⤳ቇળ᧲ㇱળ(ᐔᚑ 18 ᐕ 12 ᦬㧘᧲੩㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯ มળ)
11㧕 ╙ 10 ࿁ᣣᧄ∛ᘒᩕ㙃ቇળᐕᰴቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 1 ᦬㧘ᮮᵿ㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯ มળ)
12㧕 ╙ 22 ࿁ᣣᧄ㕒⣂⚻⣺ᩕ㙃ቇળ(ᐔᚑ 19 ᐕ 2 ᦬㧘᧻ጊ㧘วหࠪࡦࡐࠫ࠙ࡓ มળ)
13㧕 ╙ 5 ࿁ᣣᧄ⥃ᐥ⣲≌ቇળ(ᐔᚑ 19 ᐕ 3 ᦬㧘ᧅᏻ㧘ࠪࡦࡐࠫ࠙ࡓ㧘Ṷ⠪)
14㧕 ╙ 17 ࿁ࠕࠫࠕ࡮ᄥᐔᵗ⢄⤳ળ⼏(ᐔᚑ 19 ᐕ 3 ᦬㧘੩ㇺ㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯‫ޟ‬Long-team outcomeof BCAA treatment in liver cirrhosis‫ޠ‬Ṷ⠪)
15㧕 ╙ 93 ࿁ᣣᧄᶖൻེ∛ቇળ✚ળ(ᐔᚑ 19 ᐕ 4 ᦬㧘㕍᫪㧘ࠪࡦࡐࠫ࠙ࡓ ᐳ㐳)16㧕 ᣣᧄࡆ࠲ࡒࡦቇળ╙ 59 ࿁ᄢળ(ᐔᚑ 19 ᐕ 5 ᦬㧘㐳ፒ㧘ࠪࡦࡐࠫ࠙ࡓ ᐳ㐳)17㧕 ╙ 33 ࿁ᣣᧄᕆᕈ⢄ਇో⎇ⓥળ(ᐔᚑ 19 ᐕ 5 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ Ṷ⠪)
18㧕 ╙ 43 ࿁ᣣᧄ⢄⤳ቇળ✚ળ(ᐔᚑ 19 ᐕ 5 ᦬㧘᧲੩㧘࠮࠶࡚ࠪࡦ 22‫ޟ‬⢄⎬ᄌ࡮⢄ᕈ⣖∝‫ޠ‬มળ)
19㧕 The 6th JHS Single Topic Conference(ᐔᚑ 19 ᐕ 9 ᦬㧘቟Ყ㜞ේ㧘Symposium‫ޟ‬Long-Term Outcomeof BCAA treatment in patients with liver cirrhosis‫ޠ‬Ṷ⠪)20㧕 ╙ 14 ࿁ᣣᧄ㐷⣂࿶੣ㅴ∝ቇળ✚ળ࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 9 ᦬㧘ᄢಽ㧘⻠Ṷ‫ޟ‬⢄ਇోߣ㐷⣂࿶੣ㅴ∝‫ޠ‬Ṷ⠪)
21㧕 ᣣᧄᶖൻེ∛ቇળ᧲ᶏᡰㇱ ╙ 66 ࿁Ꮢ᳃౏㐿⻠ᐳ⋵᳃ஜᐽ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 10 ᦬㧘ᄢ㒋㧘ၮ⺞⻠Ṷ㧘Ṷ⠪)
22㧕 APDW(ᐔᚑ 19 ᐕ 10 ᦬㧘␹ᚭ㧘ࠪࡦࡐࠫ࠙ࡓ ᐳ㐳)23㧕 DDW(ᐔᚑ 19 ᐕ 10 ᦬㧘␹ᚭ㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯ มળ)㧙㧙24㧕 DDW(ᐔᚑ 19 ᐕ 10 ᦬㧘␹ᚭ㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ มળ)
25㧕 DDW(ᐔᚑ 19 ᐕ 10 ᦬㧘␹ᚭ㧘ࠪࡦࡐࠫ࠙ࡓ ᐳ㐳)26㧕 ╙ 107 ࿁ᣣᧄᶖൻེ∛ቇળ᧲ᶏᡰㇱ଀ળ(ᐔᚑ 19 ᐕ 11 ᦬ 17 ᣣ㧘ฬฎደ㧘ᢎ⢒⻠Ṷ มળ)
27㧕 ╙ 37 ࿁ᣣᧄ⢄⤳ቇળ⷏ㇱળ(ᐔᚑ 19 ᐕ 12 ᦬㧘㐳ፒ㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ มળ)28㧕 ╙ 11 ࿁ᣣᧄ∛ᘒᩕ㙃ቇળᐕᰴቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 1 ᦬㧘੩ㇺ㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯13 ᐳ㐳)29㧕 ╙ 23 ࿁ᣣᧄ㕒⣂⚻⣺ᩕ㙃ቇળ(ᐔᚑ 20 ᐕ 2 ᦬㧘੩ㇺ㧘วหࠪࡦࡐࠫ࠙ࡓ มળ)30㧕 ߇ࠎౣ↢ක≮ቇળ(ᐔᚑ 20 ᐕ 3 ᦬㧘ฬฎደ㧘ࡒ࠾ࠪࡦࡐࠫ࠙ࡓ 1‫ޟ‬⢄⤳ߩౣ↢‫ޠ‬ᐳ㐳)31㧕 ╙ 1 ࿁ᣣᧄ㕒⣂⚻⣺ᩕ㙃ቇળ᧲ᶏᡰㇱቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 3 ᦬㧘ฬฎደ㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯ ᐳ㐳)32㧕 ╙ 31 ࿁ᣣᧄᩕ㙃ࠕ࠮ࠬࡔࡦ࠻⎇ⓥળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ᣂẟ㧘․೎⻠Ṷ‫ޟ‬⢄∔ᖚߣᩕ㙃ࠕ࠮ࠬࡔࡦ࠻‫ޠ‬Ṷ⠪)33㧕 ╙ 44 ࿁ᣣᧄ⢄⤳ቇળ✚ળ(ᐔᚑ 20 ᐕ 6 ᦬㧘᧻ጊ㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ 3‫ޟ‬⢄ߩ⊒≸ߣㅴዷߦ߅ߌࠆಽሶ
ઍ⻢ቇ⊛⎇ⓥ‫ޠ‬มળ)34㧕 ᣣᧄᶖൻེ∛ቇળ᧲ᶏᡰㇱ╙ 108 ࿁଀ળ(ᐔᚑ 20 ᐕ 6 ᦬㧘ጘ㒂㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯ ᐳ㐳)35㧕 ╙ 2 ࿁ᩕ㙃᧚ᒻ⁁ᯏ⢻⎇ⓥળ(ᐔᚑ 20 ᐕ 9 ᦬㧘᧲੩㧘․೎⻠Ṷ ᐳ㐳)36㧕 International Clinical Exchange in Hepatic Clinical Nutrition(ᐔᚑ 20 ᐕ 9 ᦬㧘᧲੩㧘․೎⻠Ṷ‫ޟ‬Update New Approach in Prevention of Liver Impairment by BCAA Therapy‫ޠ‬Ṷ⠪)37㧕 ╙ 11 ࿁⢄ਇోᴦ≮▤ℂ⎇ⓥળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ජ⪲㧘․೎⻠Ṷ‫ޟ‬⢄⎬ᄌߩᩕ㙃≮ᴺ㧙ࠛࡆ࠺ࡦࠬ
ߣࠟࠗ࠼࡜ࠗࡦ㧙‫ޠ‬Ṷ⠪)38㧕 ╙ 67 ࿁ᣣᧄ≸ቇળቇⴚ✚ળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ฬฎደ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬⢄߇ࠎ੍㒐ߩ✚วᚢ⇛ߣൻቇ੍㒐‫ޠ‬Ṷ⠪)᳗ᧁᱜੳ㧦
1㧕 Asian Pasific Association for the Study of the Liver 2007(ᐔᚑ 19 ᐕ 3 ᦬㧘੩ㇺ㧘Oral Session‫ޟ‬Liver: Biology 2‫ޠ‬มળ)2㧕 Asian Pasific Association for the Study of the Liver 2007(ᐔᚑ 19 ᐕ 3 ᦬㧘੩ㇺ㧘Oral Session‫ޟ‬Portal Hypertension and Other Complication of Cirrhosis 1‫ޠ‬มળ)
3㧕 ╙ 43 ࿁ᣣᧄ⢄⤳ቇળ✚ળ(ᐔᚑ 19 ᐕ 5 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬B ဳ⢄Ἳ㧦B ဳ⢄Ἳߩ⥄ὼ఺∉ߣ࠙ࠗ࡞ࠬឃ㒰‫ޠ‬Ṷ⠪)
4㧕 ╙ 14 ࿁⢄⚦⢩⎇ⓥળ(ᐔᚑ 19 ᐕ 6 ᦬㧘㣮ఽፉ㧘ࠪࡦࡐࠫ࠙ࡓ‫⚦ޟ‬⢩ᄖࡑ࠻࡝࠶ࠢࠬߦࠃࠆ⢄⚦⢩ಽൻߣ⚦⢩㛽ᩰ㑐ㅪࠪࠣ࠽࡞‫ޠ‬Ṷ⠪)5㧕 The 6th JHS Single Topic Conference(ᐔᚑ 19 ᐕ 9 ᦬㧘቟Ყ㜞ේ㧘Symposium‫ޟ‬P Implication ofcytokine: role of tumor necrosis factor in liver injury‫ޠ‬Ṷ⠪)
6㧕 ╙ 37 ࿁ᣣᧄ⢄⤳ቇળ⷏ㇱળ(ᐔᚑ 19 ᐕ 12 ᦬㧘㐳ፒ㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯‫ޟ‬ᕆᕈ⢄ਇోߩ∛ᘒ⸃᣿ߣ⢄ౣ↢≮ᴺ‫ޠ‬Ṷ⠪)቟↰৻ᦶ㧦
1㧕 ╙ 16 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ᧲ᶏ࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 1 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬⢙⤟ EUS ⷰኤߩታ㓙ߣ
EUS-FNA‫ޠ‬Ṷ⠪)
2㧕 ╙ 15 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ྾࿖࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 1 ᦬㧘ᓼፉ㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯‫ޟ‬EUS-FNAߣߘߩᔕ↪ᚻᛛ‫ޠ‬Ṷ⠪)
3㧕 ╙ 18 ࿁ᣣᧄᶖൻེ⚿⍹⸻≮⎇ⓥળ(ᐔᚑ 18 ᐕ 3 ᦬㧘ᾢᧄ㧘ࠪࡦࡐࠫ࠙ࡓ II‫ޟ‬⢙ྙ⚿⍹ว૬✚⢙▤⚿⍹ߦኻߔࠆౝⷞ㏜ᴦ≮(EST ߣ EPBD)ᓟߩ⢙ྙ៰಴ⴚߪᔅⷐ߆㧫‫ޠ‬Ṷ⠪)
4㧕 ╙ 71 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ(ᐔᚑ 18 ᐕ 5 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ 7 ‫ޟ‬⢙ྙ࡮⢙▤⚿⍹∝ߦኻߔࠆౝⷞ㏜⊛ᴦ≮(EST ߣ EPBD)‫ޠ‬Ṷ⠪)
5㧕 ╙ 71 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ(ᐔᚑ 18 ᐕ 5 ᦬㧘᧲੩㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ 1-4‫ޟ‬⢙࡮⤟‫ޠ‬Ṷ⠪)
6㧕 ╙ 71 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ(ᐔᚑ 18 ᐕ 5 ᦬㧘᧲੩㧘㒝⟎⎇ⓥળ㧦╙ 2 ࿁⿥㖸ᵄౝⷞ㏜ਅ↢ᬌᴺߩ⸻ᢿ♖ᐲะ਄ߩߚ߼ߩ⎇ⓥળ‫ ╙ޟ‬3 ㇱ EUS-FNA ߦࠃࠆᴦ≮ߣᣂߚߥ⹜ߺ‫ޠ‬ᐳ㐳)7㧕 Endoscopy Forum Japan 2006(ᐔᚑ 18 ᐕ 7 ᦬㧘Hakone㧘‫ޟ‬Risk management of Endoscopic
treatment for CBD stones -EST and EPBD-‫ޠ‬มળ)8㧕 ╙ 33 ࿁⢄⢙⤟ᴦ≮⎇ⓥળ(ᐔᚑ 18 ᐕ 8 ᦬㧘ฬฎደ㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ‫☼ޟ‬ᶧ↥↢⢙▤≸̆⢙▤ߩ IPMN ߣ MCN‫ޠ‬มળ)㧙㧙9㧕 DDW-Japan 2006(╙ 48 ࿁ᣣᧄᶖൻེ∛ቇળᄢળ㧘╙ 72 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ)(ᐔᚑ 18 ᐕ
10 ᦬㧘ᧅᏻ㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ 9‫ޟ‬⢖≸ⴚ೨∛ᦼ⸻ᢿߦ߅ߌࠆ EUS-FNA ߩ૏⟎ߠߌߣᚻᛛ
ߩᮡḰൻ‫ޠ‬Ṷ⠪)10㧕 DDW-Japan 2006(╙ 72 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ)(ᐔᚑ 18 ᐕ 10 ᦬㧘ᧅᏻ㧘ࠨ࠹࡜ࠗ࠻ࠪࡦࡐ
ࠫ࠙ࡓ 8‫ޟ‬ᕆᕈ⢙㆏Ἳ̆ౝ⑼࡮ᄖ⑼ߩᨒࠍ⿥߃ߚᴦ≮ᚢ⇛‫ޠ‬Ṷ⠪)11㧕 DDW-Japan 2006(╙ 72 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ)(ᐔᚑ 18 ᐕ 10 ᦬㧘ᧅᏻ㧘ࡒ࠾࡟ࠢ࠴ࡖ࡯
‫ޟ‬EUS-FNA ᣉⴕᤨߩࠦ࠷㨪ᬌ૕ណข߆ࠄ∛ℂ⸻ᢿ߹ߢ㨪‫ޠ‬Ṷ⠪)12㧕 DDW-Japan 2006(╙ 72 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ)(ᐔᚑ 18 ᐕ 10 ᦬㧘ᧅᏻ㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽
࡯50‫ޟ‬⢄㐷ㇱᖡᕈ⢙㆏⁜⓰ߩኻߔࠆ JOSTENT SelfX ࠍ↪޿ߚ⚻ౝⷞ㏜⊛ࡑ࡞࠴ࠬ࠹ࡦ࠹ࠖࡦࠣ㧙ᝌ౉ߩታ㓙ߣ㐽Ⴇᤨߩኻᔕ㧙‫ޠ‬ᐳ㐳)13㧕 Asia Endoscopy Future Forum 2007(ᐔᚑ 19 ᐕ 1 ᦬㧘Jeju (Korea)㧘Session I‫ޟ‬Pancreato-biliary
stenting‫ޠ‬มળ)  
14㧕 Asia Endoscopy Future Forum 2007(ᐔᚑ 19 ᐕ 1 ᦬㧘Jeju (Korea)㧘Session IV‫ޟ‬Brainstorming for
co-operative study and friendship with the three countries‫ޠ‬มળ)  
15㧕 ╙ 71 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ(ᐔᚑ 19 ᐕ 5 ᦬㧘᧲੩㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ‫⿥ޟ‬㖸ᵄౝⷞ㏜
ਅ↢ᬌᴺ(EUS-FNA)㧙਎⇇ߣᣣᧄ㧙‫ޠ‬Ṷ⠪)
16㧕 ╙ 73 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ(ᐔᚑ 19 ᐕ 5 ᦬㧘᧲੩㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ 8‫ޟ‬EUS-FNA ߩ⃻⁁ߣ዁᧪‫ޠ‬มળ)17㧕 ╙ 106 ࿁ᣣᧄᶖൻེ∛ቇળ᧲ᶏᡰㇱ଀ળ(ᐔᚑ 19 ᐕ 6 ᦬㧘ᵿ᧻㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᶖൻེ≸ߦኻߔࠆ㕖ⷰⴊ⊛ᴦ≮ߩ⃻ᴫߣዷᦸ‫ޠ‬มળ)18㧕 ╙ 7 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ᧲ᶏᡰㇱࠟࠗ࠼࡜ࠗࡦ⎇ୃળ(ᐔᚑ 19 ᐕ 7 ᦬㧘࿯ጘ㧘‫⿥ޟ‬㖸ᵄౝⷞ㏜ⷰ
ኤ(⢙⤟)ߩታ㓙ߣ EUS-FNA‫ޠ‬Ṷ⠪)
19㧕 Endoscopy Forum Japan 2007(ᐔᚑ 19 ᐕ 8 ᦬㧘ዊᮻ㧘Special session‫ޟ‬Next-generation endoscopic
technology doctors expect from engineers‫ޠ‬Ṷ⠪)
20㧕 Asian Pacific Digestive Week 2007 (APDW2007) (ᐔᚑ 19 ᐕ 10 ᦬㧘␹ᚭ㧘Symposium‫ޟ‬Strategy
of biliary stenting for non-resectable malignant biliary strictures‫ޠ‬Ṷ⠪)
21㧕 ╙ 48 ࿁ᣣᧄ⢖≸ቇળ✚ળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ฬฎደ㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯‫⚻ޟ‬㘩㆏⊛ࠕࡊࡠ࡯࠴
(EUS-FNA)‫ޠ‬Ṷ⠪)
22㧕 Asia Endoscopy Future Forum 2008(ᐔᚑ 20 ᐕ 1 ᦬㧘ᶏධ(ਛ࿖)㧘Symposium Υ ‫ޟ‬Extracorporeal
shock wave lithotripsy for clearance of bile duct stones resistant to endoscopic extraction‫ޠ‬Ṷ⠪)23㧕 ╙ 18 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ᧲ᶏ࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 1 ᦬㧘ฬฎደ㧘⻠Ṷ‫ޟ‬⢙⤟㗔ၞߩ⿥㖸ᵄౝⷞ㏜⸻ᢿ‫ޠ‬Ṷ⠪)24㧕 Asia Endoscopy Future Forum 2008(ᐔᚑ 20 ᐕ 1 ᦬㧘ᶏධ(ਛ࿖)㧘Symposium I: ‫ޟ‬Endoscopic
management of CBD stone‫ޠ‬Ṷ⠪)25㧕 ╙ 75 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ᮮᵿ㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ 6‫✚ޟ‬⢙▤⚿⍹
ߦኻߔࠆ EST ߣ EPBD ߩ㐳ᦼ੍ᓟߩᲧセ́Multi-center randomized controlled trial (JESED
study)‫ޠ‬Ṷ⠪)26㧕 ╙ 75 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ᮮᵿ㧘ࠨ࠹࡜ࠗ࠻ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬EST࡮EPBD(੃㗡ಣ⟎)ߩࠦ࠷ߣ࠻࡜ࡉ࡞ࠪࡘ࡯࠹ࠖࡦࠣ‫ޠ‬Ṷ⠪)27㧕 ╙ 75 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ᮮᵿ㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ 6‫ޟ‬⢙▤⚿⍹ߦኻߔࠆ EST࡮EPBD ߩ㐳ᦼ੍ᓟ‫ޠ‬มળ)28㧕 ᣣᧄᶖൻེ∛ቇળ᧲ᶏᡰㇱ╙ 19 ࿁ᢎ⢒⻠Ṷળ(ᐔᚑ 20 ᐕ 6 ᦬㧘ጘ㒂㧘ᢎ⢒⻠Ṷ‫ޟ‬EUS-FNA ߦࠃࠆ⸻ᢿ࡮ᴦ≮ߩ⃻⁁‫ޠ‬Ṷ⠪)29㧕 GIHep Singapore 2008(6th National Endoscopy Workshop)(ᐔᚑ 20 ᐕ 7 ᦬㧘ࠪࡦࠟࡐ࡯࡞㧘
Endoscopy Live Demonstration ‫ޟ‬EUS&EUS-FNA‫ޠ‬Ṷ⠪)30㧕 GIHep Singapore 2008 (Combined GESS & SCRS Annual Scientific Meeting) (ᐔᚑ 20 ᐕ 7 ᦬㧘ࠪࡦࠟࡐ࡯࡞㧘⻠Ṷ‫ޟ‬Clinical Symposium on Endoscopy㧙The roles of SEMS in biliary strictures‫ޠ‬Ṷ⠪)31㧕 ╙ 8 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ᧲ᶏᡰㇱࠟࠗ࠼࡜ࠗࡦ⎇ୃળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ฬฎደ㧘⻠Ṷ‫ޟ‬⢙⤟ EUS
ߩ࡞࡯࠴ࡦⷰኤߣ EUS-FNA‫ޠ‬Ṷ⠪)32㧕 Endoscopy Forum Japan 2008(ᐔᚑ 20 ᐕ 8 ᦬㧘ዊᮻ㧘Clinical symposium session‫ޟ‬Current status
and future perspective of interventional EUS‫ޠ‬Ṷ⠪)33㧕 JDDW2008(╙ 50 ࿁ᣣᧄᶖൻེ∛ቇળᄢળ㧘╙ 76 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ)(ᐔᚑ 20 ᐕ 10 ᦬㧘㧙㧙᧲੩㧘ࡆ࠺ࠝࠪࡦࡐࠫ࠙ࡓ 4‫ޟ‬EUS ⸻ᢿ࡮ᴦ≮ߩᣂߒ޿ዷ㐿‫ޠ‬ᐳ㐳)ౝᧁ㓉ᢥ㧦
1㧕 ╙ 10 ࿁ᣣᧄ⢄⤳ቇળᄢળ(ᐔᚑ 18 ᐕ 10 ᦬㧘ᧅᏻ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬㊀∝ B ဳ⢄Ἳߦ߅ߌࠆ᛫࠙ࠗ࡞
ࠬ≮ᴺߩ⹏ଔ‫ޠ‬Ṷ⠪)ᷡ᳓㓷ੳ㧦
1㧕 ╙ 67 ࿁ᣣᧄ≸ቇળቇⴚ✚ળ(ᐔᚑ 19 ᐕ 10 ᦬㧘ฬฎደ㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ 22‫ޟ‬Green Tea Catechins for
the Prevention of Metachronous Colorectal Adenomas‫ޠ‬Ṷ⠪)
2㧕 ╙ 94 ࿁ᣣᧄᶖൻེ∛ቇળ✚ળ(ᐔᚑ 20 ᐕ 5 ᦬㧘⑔ጟ㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ 8‫࠼ࠗࡁ࠴࡟ޟ‬ᩭౝฃኈ૕ RXRǩࠍᮡ⊛ಽሶߣߒߚ⢄⚦⢩≸ൻቇ੍㒐—㕖Ⅳᑼ࡟࠴ࡁࠗ࠼ߣ clonal deletion—‫ޠ‬Ṷ⠪)3㧕 JDDW2008(ᐔᚑ 20 ᐕ 10 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ 6‫ޟ‬Retinoid ᩭౝฃኈ૕ RXRǩࠍᮡ⊛ಽሶߣߒߚ Acyclic retinoid ߦࠃࠆ⢄≸ൻቇ੍㒐‫ޠ‬Ṷ⠪)4㧕 JDDW2008(ᐔᚑ 20 ᐕ 10 ᦬㧘᧲੩㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ 18‫ޟ‬IGF/IGF-1R ࠍᮡ⊛ߣߒߚ✛⨥ࠞ࠹ࠠࡦ
EGCG ߦࠃࠆ⢈ḩ㑐ㅪᄢ⣺⊒≸ߩᛥ೙‫ޠ‬Ṷ⠪)ጤਅᜏม㧦
1㧕 ╙ 73 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ(ᐔᚑ 19 ᐕ 5 ᦬㧘᧲੩㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ 8‫❑ޟ‬㓒∛ᄌߦኻߔࠆ
EUS-FNA ߩ᦭↪ᕈ‫ޠ‬Ṷ⠪)2㧕 JDDW2007(╙ 49 ࿁ᣣᧄᶖൻེ∛ቇળᄢળ㧘╙ 74 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ)(ᐔᚑ 19 ᐕ 10 ᦬㧘␹ᚭ㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ 22‫⦟ޟ‬ᕈ⢄ᄖ⢙▤⁜⓰ߦኻߔࠆࠬ࠹ࡦ࠻ᴦ≮‫ޠ‬Ṷ⠪)
3㧕 ╙ 50 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ᧲ᶏ࿾ᣇળ(ᐔᚑ 19 ᐕ 12 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓ 2‫ޟ‬㕖ಾ㒰ᖡᕈ⢙㆏⁜⓰ߦኻߔࠆ⢙㆏ࠬ࠹ࡦ࠻ߩㆬᛯᣇ㊎‫ޠ‬Ṷ⠪)
4㧕 ╙ 19 ࿁ᣣᧄᶖൻེ⚿⍹⸻≮⎇ⓥળ(ᐔᚑ 20 ᐕ 3 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ౝⷞ㏜⊛ᴦ≮࿎㔍ߥ✚⢙▤⚿⍹ߦኻߔࠆ ESWL ߩ᦭↪ᕈ‫ޠ‬Ṷ⠪)
5㧕 ╙ 75 ࿁ᣣᧄᶖൻེ∛ቇળ✚ળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ᮮᵿ㧘ࠪࡦࡐࠫ࠙ࡓ 5‫⤟ޟ‬઒ᕈྙ⢩㧘⤟⤥≌㧘ᗵᨴᕈ⤟უᱫߦኻߔࠆᴦ≮ᚢ⇛ߩਛߢߩ EUS ਅ࠼࡟࠽࡯ࠫߩ૏⟎ߠߌ‫ޠ‬Ṷ⠪)
6㧕 ╙ 44 ࿁ᣣᧄ⢙㆏ቇળቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 9 ᦬㧘ฬฎደ㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ 2‫⦟ޟ‬ᕈ⢄ᄖ⢙▤⁜⓰ߦኻߔࠆࠬ࠹ࡦ࠻ᴦ≮‫ޠ‬Ṷ⠪)7㧕 JDDW2008(╙ 50 ࿁ᣣᧄᶖൻེ∛ቇળᄢળ㧘╙ 76 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ)(ᐔᚑ 20 ᐕ 10 ᦬㧘᧲੩㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ 17‫⥄ޟ‬Ꮖ఺∉ᕈ⤟Ἳ⸻ᢿߦ߅ߌࠆ 19G ㊎ࠍ↪޿ߚ EUS-FNA ߩ᦭↪ᕈ‫ޠ‬Ṷ⠪)⨹ᧁኡม㧦
1㧕 ╙ 71 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ(ᐔᚑ 18 ᐕ 5 ᦬㧘᧲੩㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ 3‫ޟ‬ᒰ⑼ߦ߅ߌ
ࠆ㘩㆏㕒⣂≜ EVL ߩᬌ⸛(EVL න⁛ߣ࿾࿕߼૬↪ᴺߩᲧセ⹜㛎ࠍ฽߼ߡ)‫ޠ‬Ṷ⠪)
2㧕 ᣣᧄ∛ᘒᩕ㙃ቇળ᧲ᶏ࡮ർ㒽࿾඙ᐔᚑ 18 ᐕᐲᢎ⢒࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 6 ᦬㧘ጘ㒂㧘⻠Ṷ‫ࠬࠬ࡯ࠤޟ‬࠲࠺ࠖ࡯࡮⢄∔ᖚ‫ޠ‬Ṷ⠪)
3㧕 ╙ 49 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ᧲ᶏ࿾ᣇળ(ᐔᚑ 18 ᐕ 12 ᦬㧘ฬฎደ㧘ࠪࡦࡐࠫ࠙ࡓ 1‫ޟ‬ᒰ⑼ߦ߅ߌ
ࠆ਄ਅㇱᶖൻ▤ ESD ߩᬌ⸛‫ޠ‬Ṷ⠪)
4㧕 ╙ 43 ࿁ᣣᧄ⣻ㇱᢇᕆකቇળ✚ળ(ᐔᚑ 19 ᐕ 3 ᦬㧘᧲੩㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ 2‫ޟ‬ᒰ⑼ߦ߅ߌࠆ
㕒⣂≜ᴦ≮ߩᬌ⸛(㘩㆏⢗㕒⣂≜ߣ⇣ᚲᕈ㕒⣂≜)‫ޠ‬Ṷ⠪)
5㧕 ╙ 61 ࿁ᣣᧄ㘩㆏ቇળቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 6 ᦬㧘ᮮᵿ㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ 1‫ޟ‬ᒰ⑼ߦ߅ߌࠆ⢗㕒⣂≜ᴦ≮ߩᬌ⸛‫ޠ‬Ṷ⠪)
6㧕 ╙ 7 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ᧲ᶏᡰㇱࠟࠗ࠼࡜ࠗࡦ⎇ୃળ(ᐔᚑ 19 ᐕ 7 ᦬㧘࿯ጘ㧘⻠Ṷ‫ޟ‬ౝⷞ㏜⊛
ᱛⴊᴺ‫ޠ‬Ṷ⠪)7㧕 ╙ 14 ࿁ᣣᧄ㐷⣂࿶੣ㅴ∝ቇળ✚ળ(ᐔᚑ 19 ᐕ 9 ᦬㧘ᄢಽ㧘ࠪࡦࡐࠫ࠙ࡓ 1‫ޟ‬㘩㆏㕒⣂≜ߦኻߔࠆ
EVL ߢߩᴦ≮ᚑ❣ߣ EUS ߢߩ㘩㆏๟࿐ⴊ▤⟲ߩⷰኤ(EVL න⁛ߣ࿾࿕߼૬↪ᴺߣߩᲧセ)‫ޠ‬Ṷ⠪)8㧕 JDDW2007(╙ 74 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ)(ᐔᚑ 19 ᐕ 10 ᦬㧘␹ᚭ㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ 17‫ޟ‬⢗ྃ㐷ㇱ㕒⣂≜ว૬㘩㆏㕒⣂≜ߦኻߔࠆ EVL ߢߩᴦ≮ᚑ❣ߣ APC ࿾࿕߼≮ᴺߩ᦭↪ᕈ‫ޠ‬Ṷ⠪)9㧕 ᣣᧄᶖൻེ∛ቇળ᧲ᶏᡰㇱ╙ 66 ࿁Ꮢ᳃౏㐿⻠ᐳ ⋵᳃ஜᐽ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 10 ᦬㧘⠀ፉ㧘⻠Ṷ‫ߣ⩶࡝ࡠࡇޟ‬⢗≸‫ޠ‬Ṷ⠪)10㧕 ╙ 50 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ᧲ᶏ࿾ᣇળ(ᐔᚑ 19 ᐕ 12 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓ 1‫ޟ‬ᒰ⑼ߦ߅ߌࠆ

㧙㧙਄ਅㇱᶖൻ▤ ESD ߩᴦ≮ᚑ❣‫ޠ‬Ṷ⠪)11㧕 ╙ 75 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ᮮᵿ㧘ࠪࡦࡐࠫ࠙ࡓ 7 ‫ޟ‬ᒰ⑼ߦ߅ߌࠆ⢄≸ว૬㘩㆏㕒⣂≜ߦኻߔࠆ EVL ߩᴦ≮ᚑ❣‫ޠ‬Ṷ⠪)12㧕 ╙ 3 ࿁㕒⣂≜ᴦ≮ᮡḰൻ⎇ⓥળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ᮮᵿ㧘ࡆ࠺ࠝࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᒰ⑼ߦ߅ߌࠆ㘩㆏࡮⢗ྃ㐷ㇱ㕒⣂≜∝଀ߦኻߔࠆ EVL+APC ૬↪≮ᴺߩታ㓙‫ޠ‬Ṷ⠪)13㧕 GI Forum in Kanazawa(ᐔᚑ 20 ᐕ 6 ᦬㧘㊄ᴛ㧘⻠Ṷ‫ޟ‬ᒰ⑼ߦ߅ߌࠆ਄ਅㇱᶖൻ▤ ESD ߩ⚻㛎‫ޠ‬Ṷ
⠪)
14㧕 ᣣᧄᶖൻེ∛ቇળ᧲ᶏᡰㇱ╙ 68 ࿁Ꮢ᳃౏㐿⻠ᐳ ጘ㒂⋵කᏧળ⋵᳃ஜᐽ࠮ࡒ࠽࡯‫ޟ‬ᶖൻེߩ߇ࠎࠍ
ᱜߒߊ⍮ࠈ߁‫(ޠ‬ᐔᚑ 20 ᐕ 6 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬ᄢ⣺߇ࠎ‫ޠ‬Ṷ⠪)⊕ᧁ ੫㧦
1㧕 JDDW2007(╙ 49 ࿁ᣣᧄᶖൻེ∛ቇળᄢળ)(ᐔᚑ 19 ᐕ 10 ᦬㧘␹ᚭ㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ 3‫ޟ‬Cဳᘟᕈ⢄∔ᖚᖚ⠪ߦ߅ߌࠆ⢈ḩߩᬌ⸛‫ޠ‬Ṷ⠪)
2㧕 ╙ 29 ࿁ᣣᧄ⥃ᐥᩕ㙃ቇળ✚ળ࡮╙Χ࿁ᄢㅪวᄢળ(ᐔᚑ 19 ᐕ 11 ᦬㧘੩ㇺ㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪ
ࡦ‫ޟ‬⢄⎬ᄌߦ߅ߌࠆಽጘ㎮ࠕࡒࡁ㉄(branched chain amino acids: BCAA)≮ᴺ‫ޠ‬Ṷ⠪)
3㧕 ╙ 94 ࿁ᣣᧄᶖൻེ∛ቇળ✚ળ(ᐔᚑ 20 ᐕ 5 ᦬㧘⑔ጟ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᶖൻེౝ⑼౉㒮ᖚ⠪ߦ߅ߌࠆ
SGA ߣ࿷㒮ᦼ㑆ߩᬌ⸛‫ޠ‬Ṷ⠪)
4㧕 ᣣᧄ∛ᘒᩕ㙃ቇળ ∛ᘒᩕ㙃ኾ㐷Ꮷᦝᣂ⠪ᢎ⢒࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 6 ᦬㧘ጘ㒂㧘ࠤ࡯ࠬࠬ࠲࠺ࠖ 2‫ޟ‬⢄∔ᖚ‫ޠ‬Ṷ⠪)
5㧕 ╙ 44 ࿁ᣣᧄ⢄⤳ቇળ✚ળ(ᐔᚑ 20 ᐕ 6 ᦬㧘᧻ጊ㧘ਥ㗴ࡐࠬ࠲࡯1‫ޟ‬⢄⎬ᄌᖚ⠪ߩᚑ࿃೎ߦࠃࠆᬌ⸛‫ޠ‬Ṷ⠪)
6㧕 ╙ 8 ࿁ᣣᧄஜᐽ࡮ᩕ㙃ࠪࠬ࠹ࡓቇળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᶖൻེౝ⑼౉㒮ᖚ⠪ߦ߅ߌࠆ SGA ߣ࿷㒮ᦼ㑆ߩᬌ⸛‫ޠ‬Ṷ⠪)7㧕 ╙ 8 ࿁ᣣᧄஜᐽ࡮ᩕ㙃ࠪࠬ࠹ࡓቇળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫▤ޟ‬ℂᩕ㙃჻ߦ᳞߼ࠄࠇࠆ⍮⼂ߣᛛ⢻-NCM ផㅴߩߚ߼ߦ-‫ޠ‬ᐳ㐳)
8㧕 ╙ 8 ࿁ᣣᧄஜᐽ࡮ᩕ㙃ࠪࠬ࠹ࡓቇળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓ‫ߥ࡞ࡊࡦࠪࠅࠃޟ‬ᩕ㙃⹏ଔࠍ⋡ᜰߒߡ-ਥⷰ⊛൮᜝⊛⹏ଔ-‫ޠ‬ᐳ㐳)
9㧕 ╙ 16 ࿁ᣣᧄᶖൻེ㑐ㅪቇળㅳ㑆 JDDW 2008(ᐔᚑ 20 ᐕ 10 ᦬㧘᧲੩㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ 9‫ޟ‬Tumor Necrosis Factor Dߣ Leptin ߇⢄⎬ᄌᖚ⠪ߩࠛࡀ࡞ࠡ࡯ઍ⻢ߦ෸߷ߔᓇ㗀‫ޠ‬Ṷ⠪)═ේජ༹㧦
1㧕 ╙ 68 ࿁ᣣᧄⴊᶧቇળ࡮╙ 48 ࿁ᣣᧄ⥃ᐥⴊᶧቇળ࡮วห✚ળ(ᐔᚑ 18 ᐕ 10 ᦬㧘⑔ጟ㧘ࡢ࡯࡚ࠢࠪ࠶
ࡊ‫ޟ‬ㅧⴊེᖡᕈ∔ᖚߦว૬ߒߚ⊒ᾲᕈᅢਛ⃿ᷫዋ∝ߦኻߔࠆ Biapenem ߩ⥃ᐥ⊛ᬌ⸛‫ޠ‬Ṷ⠪)⿷┙᡽ᴦ㧦
1㧕 ╙ 94 ࿁ᣣᧄᶖൻེ∛ቇળ✚ળ(ᐔᚑ 20 ᐕ 5 ᦬㧘⑔ጟ㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ 4‫ߩࡦࠠ࠹ࠞ⨥✛ޟ‬ᄢ⣺≸⚦⢩Ⴧᱺᛥ೙ߩᣂⷙࡔࠞ࠾࠭ࡓ㨪⢽⾰࡜ࡈ࠻ߢߩ EGFR pathway ߩ㒖ኂ㨪‫ޠ‬Ṷ⠪)㜞੗శᴦ㧦
1㧕 ╙ 108 ࿁ᣣᧄᶖൻེ∛ቇળ᧲ᶏᡰㇱ଀ળ(ᐔᚑ 20 ᐕ 6 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ㅴⴕ⢄⚦⢩≸ߦኻߔࠆࠕࠗࠛ࡯ࠦ࡯࡞෻ᓳേᵈߩലᨐߦ㑐ߔࠆᬌ⸛‫ޠ‬Ṷ⠪)ᄢỈ㓁੺㧦
1㧕 The 16th International Symposium on Regulatory Peptides (REGPEP’06)(ᐔᚑ 18 ᐕ 9 ᦬㧘▫ᩮ㧘‫ޟ‬Roles of AKT and sphingosine kinase in the anti-apoptotic effects of bile duct ligation in mouse
liver‫ޠ‬Ṷ⠪)
2㧕 ╙ 43 ࿁ᣣᧄ⢄⤳ቇળ✚ળ(ᐔᚑ 19 ᐕ 6 ᦬㧘᧲੩㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ‫ޟ‬⢙▤⚿⚤ߦࠃࠅ⺃ዉߐࠇߚᘟᕈ
⢄㓚ኂࡑ࠙ࠬࡕ࠺࡞ߦ߅ߌࠆ᛫ࠕࡐ࠻࡯ࠪࠬ₪ᓧᯏᐨߩᬌ⸛‫ޠ‬Ṷ⠪)ਛፉ⾫ᙗ㧦
1㧕 JDDW2008(╙ 76 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ)(ᐔᚑ 20 ᐕ 10 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ 29‫❑ޟ‬㓒࡮⣻⣧ౝᖡᕈ࡝ࡦࡄ⣲ߦኻߔࠆൻቇ≮ᴺᓟ⹏ଔߩߚ߼ߩ EUS-FNA ߩ᦭↪ᕈ‫ޠ‬Ṷ⠪)2㧕 JDDW2008(╙ 50 ࿁ᣣᧄᶖൻེ∛ቇળᄢળ㧘╙ 76 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ)(ᐔᚑ 20 ᐕ 10 ᦬㧘㧙㧙᧲੩㧘ࡆ࠺ࠝࠪࡦࡐࠫ࠙ࡓ 4‫❑ޟ‬㓒∛ᄌߦኻߔࠆ EUS-FNA ߩታ㓙ߣ⸻ᢿ⢻‫ޠ‬Ṷ⠪)ട⮮ೣᑝ㧦
1㧕 ╙ 16 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ᧲ᶏ࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 1 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬㘩㆏ߩἻ∝ᕈ∔ᖚ‫ޠ‬Ṷ⠪)⷏⣁િੑ㧦
1㧕 JDDW2008(ᶖൻེౝⷞ㏜ቇળ࡮ᶖൻེ߇ࠎᬌ⸻ቇળวห)(ᐔᚑ 20 ᐕ 10 ᦬㧘᧲੩㧘ࡄࡀ࡞࠺ࠖࠬࠞ
࠶࡚ࠪࡦ 20‫⚦ޟ‬ᓘౝⷞ㏜ࠍ↪޿ߚ⚻⢗≪⊛ౝⷞ㏜ߦࠃࠆᴦ≮ᚻᛛߩ⚻㛎‫ޠ‬Ṷ⠪)᧖ጊᤘᒾ㧦
1㧕 ᣣᧄᶖൻེ∛ቇળ᧲ᶏᡰㇱ╙ 105 ࿁଀ળ(ᐔᚑ 18 ᐕ 11 ᦬㧘ฬฎደ㧘ࠪࡦࡐࠫ࠙ࡓΣ‫ޟ‬㘩㆏ࠕ࡜ࠞࠪ
ࠕߣ㘩㆏≸ߦ㑐ߔࠆᬌ⸛‫ޠ‬Ṷ⠪)ጊ↰ବ᮸㧦
1㧕 ╙ 50 ࿁ᣣᧄャⴊ࡮⚦⢩ᴦ≮ቇળ᧲ᶏᡰㇱળቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓ‫․ޟ‬ᱶ⁁ᴫਅߢߩⴊᶧ⵾೷ߩ૶↪-ⴊᶧ∔ᖚ-‫ޠ‬Ṷ⠪)Ⴎደᱜ㆏㧦
1㧕 ╙ 73 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ(ᐔᚑ 19 ᐕ 5 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ 6‫⿥ޟ‬㖸ᵄౝⷞ㏜ਅ⣻⣧␹⚻ฌࡉࡠ࠶ࠢ(EUS-CPN)ߩ⃻ᤨὐߦ߅ߌࠆ⹏ଔߣ੹ᓟߩዷᦸ‫ޠ‬Ṷ⠪)2㧕 JDDW2007(╙ 49 ࿁ᣣᧄᶖൻེ∛ቇળᄢળ㧘╙ 74 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ)(ᐔᚑ 19 ᐕ 10 ᦬㧘␹ᚭ㧘ࡆ࠺ࠝࠪࡦࡐࠫ࠙ࡓ 4‫⿥ޟ‬㖸ᵄౝⷞ㏜ਅ⣻⣧␹⚻ฌࡉࡠ࠶ࠢ(EUS-CPN)ߩ᦭↪ᕈߦ㑐ߔࠆᬌ⸛ߣᚻᛛߩᎿᄦ‫ޠ‬Ṷ⠪)
3㧕 ╙ 75 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ᮮᵿ㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ 1‫✭≸ޟ‬๺ක≮ߦ߅ߌࠆ⿥㖸ᵄౝⷞ㏜ਅ⣻⣧␹⚻ฌࡉࡠ࠶ࠢ(EUS-CPN)ߩ᦭↪ᕈߦ㑐ߔࠆᬌ⸛‫ޠ‬Ṷ⠪)ᧁ᧛౏ೣ㧦
1㧕 ╙ 44 ࿁ᣣᧄ⢄⤳ቇળ✚ળ(ᐔᚑ 20 ᐕ 6 ᦬㧘᧻ጊ㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ‫ޟ‬B ဳ⢄Ἳ࠻࡜ࡦࠬࠫࠚ࠾࠶ࠢࡑ
࠙ࠬࠍ↪޿ߚᕆᕈ⢄Ἳࡕ࠺࡞ߦ߅ߌࠆ CTL ߣ CD44 ߩ⋧੕૞↪‫ޠ‬Ṷ⠪)
2㧕 ╙ 12 ࿁ᣣᧄ⢄⤳ቇળᄢળ(ᐔᚑ 20 ᐕ 10 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬B ဳ⢄Ἳᴦ≮ߦ߅ߌࠆ⥄ὼ఺∉೙ᓮߩ᦭↪ᕈ‫ޠ‬Ṷ⠪)ะ੗ ᒝ㧦
1㧕 ╙ 71 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ(ᐔᚑ 18 ᐕ 5 ᦬㧘᧲੩㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ 3‫ޟ‬ౝⷞ㏜⊛⤟▤ࠬ࠹ࡦ࠹ࠖࡦࠣߩ᦭↪ᕈ‫ޠ‬Ṷ⠪)
2㧕 ╙ 73 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ(ᐔᚑ 19 ᐕ 5 ᦬㧘᧲੩㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ 10‫ޟ‬㕖ಾ㒰ᖡᕈ⢙㆏⁜⓰ߦኻߔࠆ⢙㆏ࠬ࠹ࡦ࠻ߩㆬᛯ‫ޠ‬Ṷ⠪)
3㧕 ╙ 106 ࿁ᣣᧄᶖൻེ∛ቇળ᧲ᶏᡰㇱ଀ળ(ᐔᚑ 19 ᐕ 6 ᦬㧘ᵿ᧻㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬㕖ಾ㒰ᖡᕈ⢙㆏⁜⓰ߦኻߔࠆ⢙㆏ࠬ࠹ࡦ࠻ߩㆬᛯ‫ޠ‬Ṷ⠪)
4㧕 ╙ 43 ࿁ᣣᧄ⢙㆏ቇળቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 9 ᦬㧘᧲੩㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ 2‫ޟ‬㕖ಾ㒰⢄㐷ㇱ⢙▤≸ߦ߅ߌࠆ Metallic stent ߦࠃࠆ⢙㆏ౝ≪ⴚ‫ޠ‬Ṷ⠪)5㧕 JDDW2007(╙ 49 ࿁ᣣᧄᶖൻེ∛ቇળᄢળ㧘╙ 74 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ)(ᐔᚑ 19 ᐕ 10 ᦬㧘␹ᚭ㧘ࡆ࠺ࠝࠪࡦࡐࠫ࠙ࡓ 3‫ޟ‬ᖡᕈ⢄ᄖ⢙㆏㐽Ⴇߦኻߔࠆ Covered Metallic Stent ߩౣ㐽Ⴇᤨᴦ≮
㧙ᛮ෰ᴺߩታ㓙㧙‫ޠ‬Ṷ⠪)
6㧕 ╙ 75 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ᮮᵿ㧘ࠪࡦࡐࠫ࠙ࡓ 2‫ޟ‬㕖ಾ㒰ᖡᕈ⢄㐷ㇱ⢙㆏⁜⓰ߦኻߔࠆ⢙㆏ౝ≪ⴚߩᬌ⸛́ౝⷞ㏜⊛ࠕࡊࡠ࡯࠴ߩ೑ὐߦߟ޿ߡ́‫ޠ‬Ṷ⠪)7㧕 JDDW2008(╙ 50 ࿁ᣣᧄᶖൻེ∛ቇળᄢળ)(ᐔᚑ 20 ᐕ 10 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ 5‫ޟ‬㐽Ⴇᕈ㤛∏ࠍ઻߁ಾ㒰ਇ⢻⤟≸ߦኻߔࠆൻቇ≮ᴺߣ⢙㆏ࠬ࠹ࡦ࠻ߩᬌ⸛‫ޠ‬Ṷ⠪)8㧕 JDDW2008(╙ 50 ࿁ᣣᧄᶖൻེ∛ቇળᄢળ㧘╙ 76 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ)(ᐔᚑ 20 ᐕ 10 ᦬㧘᧲੩㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ 18‫ޟ‬㕖ಾ㒰ᖡᕈ⢙㆏⁜⓰ߦኻߔࠆ⢙㆏ࠬ࠹ࡦ࠻ߩㆬᛯ‫ޠ‬Ṷ⠪)
⑔ፉ⑲᮸㧦
1㧕 ╙ 92 ࿁ᣣᧄᶖൻེ∛ቇળ✚ળ(ᐔᚑ 18 ᐕ 4 ᦬㧘ዊୖ㧘ࠪࡦࡐࠫ࠙ࡓ 6‫ޟ‬ᶖൻེౝ⑼ߦ߅ߌࠆ SGA㧙㧙ࠍ↪޿ߚᩕ㙃ࠬࠢ࡝࡯࠾ࡦࠣߣ࿷㒮ᦼ㑆‫ޠ‬Ṷ⠪)
2㧕 ╙ 29 ࿁ ᣣ ᧄ ᩕ 㙃 ࠕ ࠮ ࠬ ࡔ ࡦ ࠻ ⎇ ⓥ ળ ( ᐔ ᚑ 18 ᐕ 5 ᦬ 㧘 ጘ 㒂 㧘 ᢎ ⢒ ࠮ ࡒ ࠽ ࡯ 5 ‫ ޟ‬Albumin
microheterogeneity ߣ∔ᖚ‫ޠ‬Ṷ⠪)
3㧕 ╙ 10 ࿁ᣣᧄ⢄⤳ቇળᄢળ⻠Ṷ࡮ᶖൻེ∛ቇળวห(ᐔᚑ 18 ᐕ 10 ᦬㧘ᧅᏻ㧘ࠪࡦࡐࠫ࠙ࡓ 14‫ޟ‬C ဳᘟᕈ⢄∔ᖚᖚ⠪ߦ߅ߌࠆ⢈ḩߩ㗫ᐲߣ⢽⢌⢄ߩว૬‫ޠ‬Ṷ⠪)ጊፒஜ〝㧦
1㧕 ╙ 71 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ(ᐔᚑ 18 ᐕ 5 ᦬㧘᧲੩㧘ࡒ࠾ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬75 ᚽએ਄ߩ㜞㦂⠪ߢߩ਄ㇱᶖൻ▤ ESD ߩᬌ⸛(APC ᴦ≮ߣߩᲧセࠍ฽߼ߡ)‫ޠ‬Ṷ⠪)ᧃᰴ ᷕ㧦
1㧕 ╙ 42 ࿁ᣣᧄ⢄⤳ቇળ✚ળ(ᐔᚑ 18 ᐕ 5 ᦬㧘੩ㇺ㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ 4‫ޟ‬ォ౮࿃ሶ HNF-4 ㆮવሶዉ౉
⢝ఽ⢄೨㚟⚦⢩ߩಽൻ⺃ዉߣ⚦⢩⒖ᬀ≮ᴺ‫ޠ‬Ṷ⠪)
2㧕 ╙ 44 ࿁ᣣᧄ⢄⤳ቇળ✚ળ(ᐔᚑ 20 ᐕ 6 ᦬㧘᧻ጊ㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ‫ޟ‬HNF-4 ㆮવሶዉ౉ߦࠃࠆ⢄೨㚟⚦⢩ߩಽൻ⺃ዉߣ⚦⢩≮ᴺ߳ߩᔕ↪‫ޠ‬Ṷ⠪)
3㧕 ╙ 12 ࿁ᣣᧄ⢄⤳ቇળᄢળ(ᐔᚑ 20 ᐕ 10 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬⢄ᐙ⚦⢩ߦ߅ߌࠆ HNF-4 ߩᓎഀߣ≸ᐙ⚦⢩ߦ߅ߌࠆ CD133 㓁ᕈ⚦⢩ߩ․ᓽ‫ޠ‬Ṷ⠪)ᧁోፏਯ㧦
1㧕 ╙ 42 ࿁ᣣᧄ⢄⤳ቇળ✚ળ(ᐔᚑ 18 ᐕ 5 ᦬㧘੩ㇺ㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ‫⚦ޟ‬⢩ᄖࡑ࠻࡝࠶ࠢࠬߦࠃࠅ⺃ዉߐࠇࠆ⢄⚦⢩ಽൻᯏ᭴ߣォ౮࿃ሶ HNF-4 ߩᓎഀ‫ޠ‬Ṷ⠪)ጤ↰࿻੺㧦
1㧕 ╙ 75 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ᮮᵿ㧘ࡆ࠺ࠝࠪࡦࡐࠫ࠙ࡓ 2‫࡮⤟ޟ‬⢙㆏≸ߩ≸ᕈ−∩ߦኻߔࠆ⿥㖸ᵄౝⷞ㏜ਅ⣻⣧␹⚻ฌࡉࡠ࠶ࠢ(EUS-CPN)ߩ᦭↪ᕈߣᚻᛛߩᎿᄦ‫ޠ‬Ṷ⠪)2㧕 JDDW2008(╙ 76 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ㧘╙ 39 ࿁ᣣᧄᶖൻๆ෼ቇળ✚ળ)(ᐔᚑ 20 ᐕ 10 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ 15‫⤟ޟ‬઒ᕈྙ⢩ߦኻߔࠆౝⷞ㏜⊛ᴦ≮‫ޠ‬Ṷ⠪)3㧕 JDDW2008(╙ 50 ࿁ᣣᧄᶖൻེ∛ቇળᄢળ㧘╙ 76 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ)(ᐔᚑ 20 ᐕ 10 ᦬㧘᧲੩㧘ࡆ࠺ࠝࠪࡦࡐࠫ࠙ࡓ 1‫࡮⤟ޟ‬⢙㆏≸ߦࠃࠆ≸ᕈ−∩ߦኻߔࠆ⿥㖸ᵄౝⷞ㏜ਅ⣻⣧␹⚻ฌࡉࡠ࠶ࠢ‫ޠ‬Ṷ⠪)
ᄢ⷏㓉຦㧦1㧕 JDDW2007(╙ 49 ࿁ᣣᧄᶖൻེ∛ቇળᄢળ㧘╙ 74 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ)(ᐔᚑ 19 ᐕ 10 ᦬㧘␹ᚭ㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ 21‫ޟ‬80 ᱦએ਄ߩ㜞㦂⠪✚⢙▤⚿⍹∝ߦኻߔࠆౝⷞ㏜ᴦ≮‫ޠ‬Ṷ⠪)
2㧕 ╙ 44 ࿁ᣣᧄ⢙㆏ቇળቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 9 ᦬㧘ฬฎደ㧘ࠪࡦࡐࠫ࠙ࡓ 1‫ޟ‬80 ᱦએ਄ߩ㜞㦂⠪✚⢙▤⚿⍹∝ߦኻߔࠆౝⷞ㏜ᴦ≮‫ޠ‬Ṷ⠪)࿯੗᤯ᐔ㧦
1㧕 ╙ 43 ࿁ᣣᧄ⢙㆏ቇળቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 9 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ 1‫✚ޟ‬⢙▤⚿⍹ߦኻߔࠆౝⷞ㏜
ᴦ≮㧙㐳ᦼ੍ᓟߩᬌ⸛㧙‫ޠ‬Ṷ⠪)2㧕 JDDW2007(╙ 49 ࿁ᣣᧄᶖൻེ∛ቇળᄢળ㧘╙ 74 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ)(ᐔᚑ 19 ᐕ 10 ᦬㧘␹ᚭ㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ 6‫✚ޟ‬⢙▤⚿⍹ౝⷞ㏜ᴦ≮ᓟߩ੃㗡ᯏ⢻㓚ኂ߇㐳ᦼ੍ᓟߦਈ߃ࠆᓇ㗀‫ޠ‬Ṷ⠪)
3㧕 ╙ 75 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ᮮᵿ㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ 6‫ޟ‬EST࡮EPBD
ߩ㐳ᦼ੍ᓟ‫ޠ‬Ṷ⠪)4㧕 DDW2008(╙ 76 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ)(ᐔᚑ 20 ᐕ 10 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ 24‫ޟ‬EST࡮EPBD ߩ㐳ᦼ੍ᓟ߆ࠄߺߚ✚⢙▤⚿⍹ߩᴦ≮ᚢ⇛‫ޠ‬Ṷ⠪)㊄᫪ ၴ㧦
1㧕 ╙ 93 ࿁ᣣᧄᶖൻེ∛ቇળ✚ળ(ᐔᚑ 19 ᐕ 4 ᦬㧘㕍᫪㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ 5‫ޟ‬㕖Ⅳᑼ࡟࠴ࡁࠗ࠼ߣࡆ࠲
ࡒࡦ K2 ߩ૬↪ಣℂߦࠃࠆ⋧ਸ਼⊛ߥ⢄≸⚦⢩Ⴧᱺᛥ೙ലᨐߩᬌ⸛‫ޠ‬Ṷ⠪)㧙㧙8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ1㧕 ᷡ᳓㓷ੳ㧦ᐔᚑ 18 ᐕᐲ Liver Forum in Kyoto ⎇ⓥᅑബ⾨(ᐔᚑ 18 ᐕᐲ)
2㧕 ᷡ᳓㓷ੳ㧦ጘ㒂කቇ⎇ⓥᅑബ⾨(ᐔᚑ 18 ᐕᐲ)
3㧕 ቟↰৻ᦶ㧦ጘ㒂කቇ⎇ⓥᅑബ⾨(ᐔᚑ 19 ᐕᐲ)
4㧕 ᷡ᳓㓷ੳ㧦ᐔᚑ 20 ᐕᐲ Liver Forum in Kyoto ⎇ⓥᅑബ⾨(ᐔᚑ 20 ᐕᐲ)
9㧚␠ળᵴേ᫪⣁ਭ㓉㧦
1㧕 ጘ㒂⋵り૕㓚ኂ⠪⑔␩ද⼏ળᆔຬ(㨪⃻࿷)2㧕 ጘ㒂⋵㔍∛ක≮ㅪ⛊ද⼏ળᐳ㐳(㨪⃻࿷)3㧕 ጘ㒂⋵߇ࠎኻ╷ផㅴද⼏ળᐳ㐳(ᐔᚑ 19 ᐕᐲ㨪⃻࿷)4㧕 ጘ㒂⋵ࠛࠗ࠭ኻ╷ផㅴද⼏ળᐳ㐳(ᐔᚑ 19 ᐕᐲ㨪⃻࿷)5㧕 ጘ㒂⋵ක≮ክ⼏ળᆔຬ(ᐔᚑ 18 ᐕᐲ㨪⃻࿷)6㧕 ጘ㒂⋵ੱᮭᙣ⹤ળᆔຬ(㨪⃻࿷)᳗ᧁᱜੳ㧦1㧕 ጘ㒂⋵⢄Ἳᴦ≮ክᩏᆔຬળᆔຬ(ᐔᚑ 20 ᐕᐲ㨪⃻࿷)2㧕 ㇺ㆏ᐭ⋵⢄∔ᖚ⸻≮ㅪ៤᜚ὐ∛㒮㑆ㅪ⛊ද⼏ળᆔຬ(ᐔᚑ 20 ᐕᐲ㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ᫪⣁ਭ㓉㧘ᧃᰴ ᷕ㧘᳗ᧁᱜੳ㧦ォ౮࿃ሶ HNF-4 ㆮવሶዉ౉ߦࠃࠆ⢄೨㚟⚦⢩ߩಽൻ⺃ዉߣ⚦⢩≮ᴺߩ⏕┙㧦ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄‫ޟ‬㔍ᴦᕈߩ⢄∔ᖚ⺞ᩏ⎇ⓥ⃰‫ޠ‬ᐔᚑ 17 ᐕᐲ⎇ⓥႎ๔ᦠ㧦98㧙
100(2006 ᐕ)
2㧕 ⊕ᧁ ੫㧘⧯ේ೑㆐㧘᫪⣁ਭ㓉㧦SF-36 ࠍ↪޿ߚ⢄⎬ᄌ࡮⢄߇ࠎว૬⢄⎬ᄌᖚ⠪ߦ߅ߌࠆ QOL ⹏ଔߦ㑐ߔࠆ⎇ⓥ㧦ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ⢄Ἳ╬స᦯✕ᕆኻ╷⎇ⓥ੐ᬺ‫ޟ‬⢄߇ࠎᖚ⠪ QOL ะ਄ߦ㑐ߔࠆ⎇ⓥ‫ޠ‬ᐔᚑ 18 ᐕᐲ✚᜝⎇ⓥႎ๔ᦠ(2007 ᐕ)
3㧕 ᫪⣁ਭ㓉㧘᳗ᧁᱜੳ㧘ᧁోፏਯ㧦⚦⢩ᄖࡑ࠻࡝࠶ࠢࠬߦࠃࠅ⺃ዉߐࠇࠆ⚦⢩㛽ᩰߩᄌൻߣ⢄⚦⢩ಽൻᯏ⢻೙ᓮ㧦ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄‫ޟ‬㔍ᴦᕈߩ⢄∔ᖚ⺞ᩏ⎇ⓥ⃰‫ޠ‬ᐔᚑ 18 ᐕᐲ⎇ⓥႎ๔ᦠ㧦98㧙100(2007 ᐕ)
4㧕 ᫪⣁ਭ㓉㧘᳗ᧁᱜੳ㧘ዊᧁᦥን↢㧦G-CSF ߩ⢄ౣ↢ᛥ೙ലᨐ㧦IL-1Eߩᓎഀ㧦ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌
⵬ഥ㊄‫ޟ‬㔍ᴦᕈߩ⢄∔ᖚ⺞ᩏ⎇ⓥ⃰‫ޠ‬ᐔᚑ 19 ᐕᐲ⎇ⓥႎ๔ᦠ㧦117㧙119(2008 ᐕ)
11㧚ႎ㆏
1㧕 ᫪⣁ਭ㓉㧦⢈ḩ㨯㨯㨯⢄≸㧦ਛᣣᣂ⡞(2006 ᐕ 12 ᦬ 17 ᣣ)‫ޟ‬ጘ㒂ᄢቇකቇㇱ㒝ዻ∛㒮㧦ᬌᩏߩຠ⾰଻⸽ࠍ߼ߑߒߚ GPILS ߩ᭴▽‫ޠ‬ቢో㔚ሶൻ㧦A&T
2㧕 ⊕㠽⟵ቬ㧦ᬌᩏቶ⷗ቇ࠷ࠕ࡯(2006 ᐕ 12 ᦬)
3㧕 ᫪⣁ਭ㓉㧦ൕോක㧦ᾢකળႎ(2007 ᐕ)
4㧕 ᫪⣁ਭ㓉㧦⃻⁁㧦ห⓹ળႎ(2007 ᐕ 1 ᦬ 1 ᣣ)
5㧕 ᫪⣁ਭ㓉㧦․ቯᯏ⢻∛㒮㧦⋵∛㒮ᤨႎ 41 ภ(2007 ᐕ 3 ᦬ 31 ᣣ)
6㧕 ᫪⣁ਭ㓉㧦ൕോක㧦⋵කᏧળႎ(2007 ᐕ 4 ᦬ 1 ᣣ)
7㧕 ᫪⣁ਭ㓉㧦BCAA ᐳ⺣ળ㧦ࡔ࠺ࠖࠞ࡞ᦺᣣ(2007 ᐕ 5 ᦬ 1 ᣣ)
8㧕 ᫪⣁ਭ㓉㧦࠽࡯ࠬࠝࡉࠩࠗࡗ࡯㧦ਛᣣᣂ⡞࡮ጘ㒂ᣂ⡞(2007 ᐕ 5 ᦬ 8 ᣣ)
9㧕 ᧃᰴ ᷕ㧦ᴉ㤩ߩ⤳ེ⢄⤳㧦ᐢႎߺߩ(2007 ᐕ 8 ᦬ 1 ᣣภ)
10㧕 ᫪⣁ਭ㓉㧦∛㒮ߩ⃻⁁㧦⸥ᔨળ㙚ߛࠃࠅ(2007 ᐕ 9 ᦬ 1 ᣣ)
11㧕 ᫪⣁ਭ㓉㧦C ဳ⢄Ἳ/Ꮢ᳃౏㐿⻠ᐳ㧦ਛᣣᣂ⡞(2007 ᐕ 8 ᦬ 9 ᣣ)
12㧕 ᫪⣁ਭ㓉㧦ᄢቇකᏧળ㧦⋵කᏧળႎ(2007 ᐕ 9 ᦬ 1 ᣣ)
13㧕 ᫪⣁ਭ㓉㧦⢄⤳∛ߩᩕ㙃≮ᴺ㧦CN Hotline(2007 ᐕ 9 ᦬)
14㧕 ᫪⣁ਭ㓉㧦ᶖൻེ ౏㐿⻠ᐳ㧦ਛᣣᣂ⡞(2007 ᐕ 10 ᦬ 14 ᣣ)
15㧕 ⨹ᧁኡม㧦ᐳ⺣ળ‫ޟ‬ᄢ⣺≸ൻቇ≮ᴺߩ⃻⁁ߣ੹ᓟ‫ޠ‬㧦MEDICAMENT NEWS(2007 ᐕ 9 ᦬ 15 ᣣภ)16㧕 ቟↰৻ᦶ㧦⿥㖸ᵄౝⷞ㏜ਅ⓫ೝๆᒁᴺ㧙ࠊ߇࿖ߢ߽⌕ታߦ᥉෸ߩళߒࠍ␜ߔ㧦Medical Tribune vol.
40, No.27(2007 ᐕ 7 ᦬ 5 ᣣ)
17㧕 ቟↰৻ᦶ㧦⿥㖸ᵄౝⷞ㏜ਅๆᒁ㊎↢ᬌ(EUS-FNA)ߦࠃࠆ❑㓒࡮⣻⣧ౝ⣲ᄢ࡝ࡦࡄ▵ߩ⸻ᢿ㧦ጘ㒂ᄢቇකቇㇱ⸥ᔨળ㙚ߛࠃࠅ(2007 ᐕ㧧╙ 84 ภ㧦11㧙12)㧙㧙18㧕 ⊕㠽⟵ቬ㧦ක≮ᖱႎ IT ߢ౒᦭㧦ᦺᣣᣂ⡞(2007 ᐕ 10 ᦬ 17 ᣣ)
19㧕 ⊕㠽⟵ቬ㧦ጘ㒂⋵ౝోၞߢ⸻≮ᖱႎࠍ౒᦭㧦ᣣᧄ⚻ᷣᣂ⡞(2007 ᐕ 10 ᦬ 17 ᣣ)
20㧕 ⊕㠽⟵ቬ㧦∛㒮ߣㅪ៤ਃ੐ᬺ㧦⺒ᄁᣂ⡞(2007 ᐕ 10 ᦬ 17 ᣣ)
21㧕 ⊕㠽⟵ቬ㧦㔚ሶࠞ࡞࠹ߢᖚ⠪⚫੺㧦ਛᣣᣂ⡞(2007 ᐕ 10 ᦬ 17 ᣣ)
22㧕 ⊕㠽⟵ቬ㧦IT ᵴ↪㧘ක≮ㅪ៤㧦ጘ㒂ᣂ⡞(2007 ᐕ 10 ᦬ 17 ᣣ)
23㧕 ⊕㠽⟵ቬ㧦∛㒮ቢ⚿ဳ߆ࠄ࿾ၞቢ⚿ဳක≮߳ ࿾ၞㅪ៤ࡄࠬг㒮ౝ࠴࡯ࡓࠍ࿾ၞߦᐢߍࠆ㧦ㅳ㑆 කቇ⇇ᣂ⡞(2007 ᐕ 10 ᦬ 29 ᣣ)
24㧕 ᫪⣁ਭ㓉㧦ቯ଀ળ⷗㧦ਛᣣ࡮ጘ㒂࡮⺒ᄁ࡮ᦺᣣᣂ⡞(2007 ᐕ 11 ᦬ 27 ᣣ)
25㧕 ᫪⣁ਭ㓉㧦∛㒮ߩ⃻⁁㧦⸥ᔨળ㙚ߛࠃࠅ(2008 ᐕ 1 ᦬ 1 ᣣ)
26㧕 ᫪⣁ਭ㓉㧦∛ᘒᩕ㙃ቇળࠪࡦࡐࠫ࠙ࡓ㧦ࡔ࠺ࠖࠞ࡞࡮࠻࡝ࡆࡘ࡯ࡦ(2008 ᐕ 2 ᦬ 21 ᣣ)
27㧕 ᫪⣁ਭ㓉㧦⢄⎬ᄌߩࠢ࡝࠾ࠞ࡞ࡄࠬ㧦ጟፒකႎ(2008 ᐕ 7 ᦬ 15 ᣣ 300 ภ)
28㧕 ᫪⣁ਭ㓉㧦ቯ଀ળ⷗㧦ਛᣣ࡮ᦺᣣ࡮Ფᣣ࡮ᣣ⚻࡮⺒ᄁ࡮ጘ㒂ᣂ⡞(2008 ᐕ 7 ᦬ 24 ᣣ)
29㧕 ᫪⣁ਭ㓉㧦∛㒮ߩ⃻⁁ߣ዁᧪㧦⸥ᔨળ㙚ߛࠃࠅ(2008 ᐕ 9 ᦬ 1 ᣣ)
30㧕 ᷡ᳓㓷ੳ㧦✛⨥ࠞ࠹ࠠࡦߢࡐ࡝࡯ࡊౣ⊒੍㒐 ߇ࠎ੍㒐ߦน⢻ᕈ㧦ਛᣣ࡮ᣣ⚻ᣂ⡞(2008 ᐕ 10 ᦬ 12
ᣣ)31㧕 ቟↰৻ᦶ㧦⢙㆏߇ࠎ࡮⤟⤳߇ࠎ࡮ߘߩઁ⢙⤟∔ᖚ㧦ㅅߞߚߣ߈ߩක⠪ㆬ߮㧙᧲ᶏ㧙 ⷺᎹ SS ࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦ࠭㧘p53(2008 ᐕ 4 ᦬)
12㧚⥄Ꮖ⹏ଔ
⹏ଔ
1. ⎇ⓥߩ᭎ⷐ㧦ᶖൻེ∛ᘒቇߩ 1㧙4 ߪ޿ߕࠇ߽㧘߶߷㗅⺞ߦㅴⴕߒߡ޿ࠆ‫ߦߊߣޕ‬ਅ⸥ߩὐࠍ㜞ߊ⹏ଔߔࠆ㧔1㧕RXR ࡝ࠟࡦ࠼ߦࠃࠆ⢄⊒≸ᛥ೙ߩᄢⷙᮨ⥃ᐥ⹜㛎ࠍㅴⴕߒߡ޿ࠆ㧔2009 ᐕ㧘ࠠ࡯࡮ࠝ࡯ࡊࡦߩ
੍ቯ㧕
㧔2㧕ᘟᕈ⢄∔ᖚߦኻߔࠆಽጘ㎮ࠕࡒࡁ㉄ࠍ↪޿ߚᩕ㙃ࠨࡐ࡯࠻߇㧘⢈ḩ⠪ߦ߅ߌࠆ⢄≸ࠍ੍㒐ߔࠆߣߩ⚿ᨐࠍᓧ㧘࿖㓙⊛ߦ౏⴫ߒߚ㧔ේ⪺㧙⧷ᢥ㧘No.5㧕‫⚿ߩߎޕ‬ᨐߪ 2006 ᐕ᰷Ꮊ㕒⣂⚻⣺ᩕ㙃ቇળࠟࠗ࠼࡜ࠗࡦߦ㧘2008 ᐕᧄ㇌ෘ↢ഭ௛⋭ࠟࠗ࠼࡜ࠗࡦߦขࠅ౉ࠇࠄࠇߚ‫ޕ‬
3. ⎇ⓥᚑᨐߩ⊒⴫㧦਄⸥㧔1㧕㧘㧔2㧕ߩ⽸₂߇ᄢ߈޿‫ߨ߻߅߅ઁߩߘޕ‬㗅⺞ߣ⹏ଔߔࠆ‫ޕ‬
4. ⎇ⓥ⾌₪ᓧ⁁ᴫ㧦߅߅߻ߨ㗅⺞ߣ⹏ଔߔࠆ‫ޕ‬
5. ⊒᣿࡮․⸵಴㗿⁁ᴫ㧦good ߢߥߊ fair ߣ⹏ଔߔࠆ‫ޕ‬
6㧘7. ቇળᵴേ㧦߅߅߻ߨ㗅⺞ߣ⹏ଔߔࠆ‫ޕ‬
11. ႎ㆏㧦߅߅߻ߨ㗅⺞ߦᖱႎࠍ౏⴫ߢ߈ߡ޿ࠆߣ⹏ଔߔࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷⥃ᐥߩᣰ⋓ߥ㔛ⷐߦኻᔕߔߴߊ㧘ੱຬࠍᝄࠅะߌߑࠆࠍᓧߥ޿⁁ᴫߦ޽ࠆ‫ߒߛߚޕ‬㧘⎇ⓥࠬ࠲࠶ࡈߣ
ߊߦᄢቇ㒮↢ߦߟ޿ߡߪჇ൓ߦォߓߚ‫ޕ‬੹ᓟߩዷᦸ
1㧙1㧚ᶖൻེ∛ᘒቇ㧦㧔1㧕RXR ࡝ࠟࡦ࠼ߦࠃࠆ⢄⊒≸ᛥ೙ߩ⥃ᐥ⹜㛎߇⚳ੌߒ㧘⚿ᨐ߇್᣿ߔࠆ੍ቯߢ޽ࠆ‫ޕ‬ᚑഞߩᥙߦߪઁ
೷૬↪ᴦ≮߳ዷ㐿ߔࠆ‫ޕ‬
㧔3㧕ᘟᕈ⢄∔ᖚߦኻߔࠆࠕࡒࡁ㉄ᩕ㙃ࠨࡐ࡯࠻ߪ㧘⊒≸߿㕖ࠕ࡞ࠦ࡯࡞ᕈ⢽⢌ᕈ⢄㓚ኂߥߤߦߟ޿ߡ㧘ࠗࡦࠬ࡝ࡦᛶ᛫ᕈࠍᮡ⊛ߣߒߚᰴߩᲑ㓏ߦㅴ߻⷗ㄟߺߢ޽ࠆ‫ޕ‬㧙㧙㧔5㧕ⴊᶧ∛ᘒቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
ᖡᕈ࡝ࡦࡄ⣲ߩᴦ≮ᚢ⇛㧘㜞㦂⠪⊕ⴊ∛ߩᴦ≮ߥࠄ߮ߦ⊕ⴊ∛ߩಽൻ⺃ዉ≮ᴺ㧘㛽㜑⇣ᒻᚑ∝୥⟲ߩᴦ≮߇ਥⷐ࠹࡯ࡑߢ޽ࠆ‫ޕ‬1㧕ᖡᕈ࡝ࡦࡄ⣲ߩᴦ≮ᚢ⇛㧘․ߦ߮߹ࠎᕈᄢ⚦⢩㧮⚦⢩ᕈ࡝ࡦࡄ⣲ߩጀ೎ൻᴦ≮ࠍ⋡ᮡߦ㧘⥃ᐥ⊛߹ߚߪ∛ℂቇ⊛ߦ੍ᓟ࿃ሶ⸃ᨆࠍⴕߞߡ޿ࠆ‫੍ߦ․ޕ‬ᓟ࿃ሶ⸃ᨆߪ㧘ฦ⒳ TNF superfamily ߦዻߔࠆⴊᷡࠨ
ࠗ࠻ࠞࠗࡦ߿ࠠ࠿࡟࠾ࡦ⊒⃻ߥߤࠍᬌ⚝ߔࠆߎߣߦࠃࠅ੍ᓟਇ⦟⟲ߩㆡᩰߥ᛽಴ࠍ⋡⊛ߣߒ㧘ߎߩ⟲ߦኻߒߡߪ㧘Ⓧᭂ⊛ߦㅧⴊᐙ⚦⢩⒖ᬀⴚࠍขࠅ౉ࠇࠆߥߤߩጀ೎ൻᴦ≮ࠍⴕߞߡ޿ࠆ‫ ߚ߹ޕ‬B ⚦⢩࡝ࡦࡄ⣲ߩߺߥࠄߕ㨀⚦⢩࡝ࡦࡄ⣲ߦ߅޿ߡ߽㧘ฦ⒳ᴦ≮ࠍ⥃ᐥ⹜㛎ߣߒߡⴕߞߡ޿ࠆ‫ޕ‬
2㧕⊕ⴊ∛ߩਛߢ߽ᕆᕈ೨㛽㜑⃿ᕈ⊕ⴊ∛ߦኻߔࠆಽൻ⺃ዉ≮ᴺߣߒߡߩ࡟࠴ࡁࠗ࠼≮ᴺߩᯏᐨߣ⠴ᕈ⊒⃻ߩ⸃᣿ࠍⴕ޿㧘⠴ᕈస᦯ᴺࠍ㐿⊒ߔࠆ⎇ⓥࠍㅴ߼ߡ޿ࠆ‫ᦨޕ‬ㄭߪ㧘࡟࠴ࡁࠗ࠼ߩߺߥࠄߕ㧘ࡆ࠲ࡒࡦ
K2 ߥߤߦ߽ᵈ⋡ߒߡ޿ࠆ‫ޕ‬
3㧕㛽㜑⇣ᒻᚑ∝୥⟲ߩ఺∉∉ቇ⊛∛ᘒࠍ⸃᣿ߒ㧘ฦ⒳఺∉ᛥ೙೷ߦࠃࠆᴦ≮ᴺߩ㐿⊒ࠍⴕߞߡ޿ࠆ‫ޕ‬2㧚ฬ★
ᢎ᝼(૬છ)㧦
ಎᢎ᝼㧦

᫪⣁ਭ㓉
㢬⷗ ኼ

Hisataka Moriwaki
Hisashi Tsurumi

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 㢬⷗ ኼ㧘᫪⣁ਭ㓉㧚․ᱶ∛ᘒ(⁁ᘒ)ߦ߅ߌࠆᩕ㙃≮ᴺ(ᚑੱ࡮ዊఽ)ⴊᶧ∔ᖚ㧦ዊ⿧┨ᐔ⋙㧚ᩕ㙃≮ᴺ ࡒ࠾ࡑࡓࠛ࠶࠮ࡦࠪࡖ࡞㧘᧲੩㧦ධᳯၴ㧧2006 ᐕ㧦186㧙196㧚
2㧕 ᫪⣁ਭ㓉㧚ࡆ࠲ࡒࡦ A㧦Medical Practice ✬㧚⥃ᐥᬌᩏࠟࠗ࠼ 2007㨪2008㧘᧲੩㧦ᢥశၴ㧧2007 ᐕ㧦265
㧙266㧚
⪺ᦠ㧔᰷ᢥ㧕
1㧕 Shimizu M, Weinstein IB, Moriwaki H. Targeting receptor tyrosine kinases and multiple downstream
signaling pathways by green tea catechin EGCG. In:Pandalai SG, ed. Cancer -Disease Progression andChemoprevention, India:Research Signpost;2006:203-206.
✚⺑㧔๺ᢥ㧕
1㧕 ᅏ㊁ᱜ㓉㧘᫪⣁ਭ㓉㧚࡟࠴ࡁࠗ࠼ߦࠃࠆ⊒≸੍㒐ߣߘߩℂ⺰⊛⢛᥊㧘⢄⢙⤟ 2006 ᐕ㧧52 Ꮞ㧦393㧙402㧚
2㧕 㢬⷗ ኼ㧘᫪⣁ਭ㓉㧚৻⥸⥃ᐥක߇ࠃߊㆣㆄߔࠆ⽺ⴊߩ⸻߆ߚ-ᶖൻེ∔ᖚߣ⽺ⴊ-㧘⸻ᢿߣᴦ≮ 2006 ᐕ㧧
94 Ꮞ㧦2050㧙2053㧚
3㧕 㢬⷗ ኼ㧘᫪⣁ਭ㓉㧚࡟࠴ࡁࠗ࠼ߦࠃࠆ⊕ⴊ∛ߩಽൻ⺃ዉ≮ᴺ㧘Biotherapy 2006 ᐕ㧧20 Ꮞ㧦150㧙157㧚
4㧕 㢬⷗ ኼ㧚 ⥃ᐥ✬ II. ⸻ᢿᴺ ৻⥸ⴊᶧᬌᩏ࡮㛽㜑ᬌᩏ—ㅧⴊེ⣲≌—ၮ␆࡮⥃ᐥ㗔ၞߦ߅ߌࠆᦨᣂߩ⎇ⓥേะ—㧘ᣣᧄ⥃ᐥ 2007 ᐕ㧧65 Ꮞ㧦288㧙292㧚
✚⺑㧔᰷ᢥ㧕
1㧕 Moriwaki H, Shimizu M, Okuno M, Nishiwaki-Matsushima R. Chemoprevention of liver
carcinogenesis with retinoids -Basic and clinic aspects. Hepatol Res. 2007;37(Suppl.2):S299-S302.
ේ⪺㧔๺ᢥ㧕
1㧕 㜞ᯅ ஜ㧘ේ ᱞᔒ㧘ศᎹᱞᔒ㧘ਅ᧛㗅ሶ㧘㢬⷗ ኼ㧘ጊ↰㋕਽㧘౷↰ᩕ৻㧘᫪⣁ਭ㓉㧚ᣧᦼߦࡃ࡯ࠠ࠶
࠻࡝ࡦࡄ⣲ဳᒻ⾰ォ឵ࠍ␜ߒ㜞ᖡᕈᐲൻߒߚࠈ⢩ᕈ࡝ࡦࡄ⣲㧘⥃ᐥⴊᶧ 2006 ᐕ㧧46 Ꮞ㧦1055㧙1059㧚
2㧕 㜞ᯅ ஜ㧘ේ ᱞᔒ㧘ਅ᧛㗅ሶ㧘ศᎹᱞᔒ㧘౷↰ᩕ৻㧚ᕆㅦߦㅴⴕߔࠆᗧ⼂㓚ኂࠍ઻߁⥄Ꮖ఺∉ᕈṁⴊᕈ⽺ⴊߦኻߔࠆⴊẏ੤឵≮ᴺ㧘⥃ᐥⴊᶧ 2006 ᐕ㧧47 Ꮞ㧦787㧙789㧚
3㧕 ═ේජ༹㧘ේ ᱞᔒ㧘㢬⷗ ኼ㧘ᓟ⮮ዏ⛗㧘౗᧛ାብ㧘ศᎹᱞᔒ㧘ጊ↰ବ᮸㧘Ỉ↰㆏ᄦ㧘㜞ᯅ ஜ㧘᫪⣁ਭ㓉㧚ㅧⴊེ⣲≌ߦว૬ߒߚ⊒ᾲᕈᅢਛ⃿ᷫዋ∝ߦኻߔࠆ Biapenem ߩ᦭↪ᕈߦ㑐ߔࠆ⥃ᐥ⊛ᬌ⸛㧘JapanJ Antibiot 2008 ᐕ㧧61 Ꮞ㧦115㧙121㧚
4㧕 ᧁ᧛␭ሶ㧘⨹ᧁኡม㧘ᄢ㊁ᥓᒾ㧘ዊ㊁ᧁ┨ੱ㧘੗ᷓ⾆჻㧘౗᧛ାብ㧘ᓟ⮮ዏ⛗㧘ᧃᰴ ᷕ㧘⊕ᧁ ੫㧘═ේජ༹㧘ᷡ᳓㓷ੳ㧘ጊ↰ବ᮸㧘㢬⷗ኼ㧘᫪⣁ਭ㓉㧚਄ⴕ⚿⣺㕒⣂≜ࠍᄾᯏߦ⸻ᢿߐࠇߚᖡᕈ࡝ࡦࡄ⣲ߩ 1଀㧘ጘ㒂⋵ౝ⑼කળ㔀⹹ 2008 ᐕ㧧22 Ꮞ㧦59㧙61㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Yasuda I, Tsurumi H, Omar S, Iwashita T, Kojima Y, Yamada T, Sawada M, Takami T, Moriwaki H,
Soehendra N. Endoscopic ultrasound-guided fine-needle aspiration biopsy for lymphadenopathy of
unknown origin. Endoscopy. 2006;38:919-924.
IF 4.166㧙㧙2㧕 Fukuno K, Tsurumi H, Ando N, Kanemura N, Goto H, Tanabashi S, Okamoto K, Moriwaki H.
Late-onset neutropenia in patients with rituximab for non-Hodgkin’s lymphoma. Int J Hematol.
2006;84:242-247.
3㧕 Kojima Y, Tsurumi H, Goto N, Shimizu M, Kasahara S, Yamada T, Kanemura N, Hara T, Sawada M,
Saio M, Yamada T, Takahashi T, Tomita E, Takami T, Moriwaki H. Fas and Fas ligand expression on
germinal center type-diffuse large B-cell lymphoma is associated with the clinical outcome. Eur J
Haematol. 2006;76:465-472.
4㧕 Goto N, Tsurumi H, Takemura M, Hara T, Sawada M, Kasahara S, Kanemura N, Yamada T, Shimizu
M, Takahashi T, Tomita E, Seishima M, Takami T, Moriwaki H. Serum-soluble tumor necrosis factor
receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's
lymphoma. Eur J Haematol. 2006;77:217-225.
5㧕 Fukuno K, Tsurumi H, Kanemura N, Tanabashi S, Okamoto K, Moriwaki H. Chronic neutrophilia
preceding overt aggressive light chain multiple myeloma. Leuk Lymphoma. 2006;47:762-764.
6㧕 Tsurumi H, Kanemura N, Hara T, Kasahara S, Yamada T, Sawada M, Oyama M, Moriwaki H.
Therapeutic strategy of untreated de novo acute myeloid leukemia in the elderly -the efficacy ofcontinuous drip infusion with low dose cytarabine and etoposide. J Cancer Res Clin Oncol.
2007;133:547-553.
7㧕 Tsurumi H, Hara T, Goto N, Kanemura N, Kasahara S, Sawada M, Yasuda I, Yamada T, Shimizu M,
Takami T, Moriwaki H. A phase II study of a THP-COP regimen for the treatment of elderly patients
aged 70 years or older with diffuse large B-cell lymphoma. Hematol Oncol. 2007;25:107-114.
8㧕 Yamazaki K, Shimizu M, Okuno M, Matsushima-Nishiwaki R, Kanemura N, Araki H, Tsurumi H,
Kojima S, Weinstein IB, Moriwaki H. Synergistic effects of RXRD and PPARJ ligands to inhibit growthin human colon cancer cells-phosphorylated RXRD is a critical target for colon cancer management.
Gut. 2007;56:1557-1563.
9㧕 Kanamori T, Shimizu M, Okuno M, Matsushima-Nishiwaki R, Tsurumi H, Kojima S, Moriwaki H.
Synergistic growth inhibition by acyclic retinoid and vitamin K2 in human hepatocellular carcinoma
cells. Cancer Sci. 2007;98:431-437.
10㧕 Yoshimura K, Muto Y, Shimizu M, Matsushima-Nishiwaki R, Okuno M, Takano Y, Tsurumi H, Kojima
S, Okano Y, Moriwaki H. Phosphorylated retinoid X receptor D loses its heterodimeric activity withretinoic acid receptor E. Cancer Sci. 2007;98:1868-1874.
11㧕 Ando N, Shimizu M, Okuno M, Matsushima-Nishiwaki R, Tsurumi H, Tanaka T, Moriwaki H.
Expression of retinoid X receptor D is decreased in 3'-methyl-4-dimethylaminoazobenzene-induced
hepatocellular carcinoma in rats. Oncol Rep. 2007;18:879-884.
12㧕 Shimizu M, Shirakami Y, Sakai H, Tatebe H, Nakagawa T, Hara Y, Weinstein IB, Moriwaki H. EGCG
inhibits activation of the insulin-like growth factor (IGF)/IGF-1 receptor axis in human hepatocellular
carcinoma cells. Cancer Lett. 2008;262:10-18.
13㧕 Shimizu M, Shirakami Y, Sakai H, Adachi S, Hata K, Hirose Y, Tsurumi H, Tanaka T, Moriwaki H.
()-Epigallocatechin gallate suppresses azoxymethane-induced colonic premalignant lesions in male
C57BL/KsJ-db/db mice. Cancer Prev Res. 2008;1:298-304.
14㧕 Shimizu M, Shirakami Y, Moriwaki H. Targeting receptor tyrosine kinases for chemoprevention bygreen tea catechin, EGCG. Int J Mol Sci. 2008;9:1034-1049.
15㧕 Shimizu M, Moriwaki H. Synergistic effects of PPARgamma ligands and retinoids in cancer treatment.
PPAR Res. 2008;2008:181047.
16㧕 Kanemura N, Tsurumi H, Kasahara S, Hara T, Yamada T, Sawada M, Goto N, Kitagawa JI, Shimizu
M, Oyama M, Moriwaki H. Continuous drip infusion of low dose cytarabine and etoposide with
granulocyte colony-stimulating factor for elderly patients with acute myeloid leukaemia ineligible forintensive chemotherapy. Hematol Oncol. 2008;26:33-38.
17㧕 Kanemura N, Tsurumi H, Okuno M, Matsushima-Nishiwaki R, Shimizu M, Moriwaki H. Retinoid X
receptor alpha is highly phosphorylated in retinoic acid-resistant HL-60R cells and the combination of
9-cis retinoic acid plus MEK inhibitor induces apoptosis in the cells. Leukemia Res. 2008;32:884-892.
18㧕 Tatebe H, Shimizu M, Shirakami Y, Tsurumi H, Moriwaki H. Synergistic growth inhibition by
9-cis-retinoic acid plus trastuzumab in human hepatocellular carcinoma cells. Clin Cancer Res.
2008;14:2806-2812.
19㧕 Shirakami Y, Shimizu M, Tsurumi H, Hara Y, Tanaka T, Moriwaki H. EGCG and Polyphenon E
attenuate inflammation-related mouse colon carcinogenesis induced by AOM plus DDS. Mol Med Rep.
2008;1:355-361.
20㧕 Hara T, Tsurumi H, Kato T, Imao Y, Kojima Y, Kojima K, Kitagawa J, Katsumura N, Araki H, Takami
T, Moriwaki H. Immunoproliferative small intestinal disease with protein loss complicated withduodenal T cell lymphoma during progression. Intern Med. 2008;47:299-303.

㧙㧙

IF 1.491

IF 2.163

IF 2.163
IF 1.512

IF 2.366

IF 2.180

IF 10.015

IF 3.165

IF 3.165

IF 1.597

IF 3.398

IF 0.750

IF 2.180

IF 2.561

IF 6.2504㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄ߥߒ
2㧕ฃ⸤⎇ⓥ1㧕 ᫪⣁ਭ㓉㧘᧛਄໪㓶㧘㢬⷗ ኼ㧦 HIV ᗵᨴ⠪╬଻ஜ⑔␩⋧⺣ផㅴ⎇ⓥ㧧ᐔᚑ 15㧙18 ᐕᐲ㧧1,950
ජ౞(650㧦650㧦650㧦325 ජ౞)㧦ࠛࠗ࠭⽷࿅ฃ⸤⎇ⓥ⾌
2㧕 ᫪⣁ਭ㓉㧦ᩭ࡟࠴ࡁࠗ࠼ฃኈ૕Ⱞ⊕ࠍಽሶᮡ⊛ߣߒߚ߇ࠎൻቇ੍㒐ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18㧙20 ᐕ
ᐲ㧧450 ජ౞(150㧦150㧦150 ජ౞)㧦⢽ṁᕈࡆ࠲ࡒࡦ
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬ᫪⣁ਭ㓉㧦
1㧕 ᣣᧄౝ⑼ቇળℂ੐(㨪⃻࿷)2㧕 ᣣᧄᶖൻེ∛ቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ⢄⤳ቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄࡆ࠲ࡒࡦቇળℂ੐(㨪⃻࿷)5㧕 ᣣᧄ⥃ᐥઍ⻢ቇળ⹏⼏ຬ(㨪⃻࿷)6㧕 ᣣᧄ≸ቇળ⹏⼏ຬ(㨪⃻࿷)7㧕 ᣣᧄᩕ㙃㘩♳ቇળ⹏⼏ຬ(㨪⃻࿷)8㧕 ᣣᧄ㕒⣂⚻⣺ᩕ㙃ቇળℂ੐(㨪⃻࿷)㢬⷗ ኼ㧦
1㧕 ᣣᧄ⥃ᐥⴊᶧቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄⴊᶧቇળઍ⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄャⴊቇળ᧲ᶏᡰㇱ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅᫪⣁ਭ㓉㧦
1㧕 ╙ 21 ࿁ᣣᧄ㕒⣂⚻⣺ᩕ㙃ቇળ(ᐔᚑ 18 ᐕ 1 ᦬㧘ጘ㒂)2㧕 ╙ 29 ࿁ᣣᧄᩕ㙃ࠕ࠮ࠬࡔࡦ࠻⎇ⓥળ(ᐔᚑ 18 ᐕ 5 ᦬㧘ጘ㒂)
3㧕 ╙ 8 ࿁ᣣ㖧߇ࠎ⠧ൻࠪࡦࡐࠫ࠙ࡓ(The 8th Japan-Korea Joint Symposium on Cancer and Ageing
Research)(ᐔᚑ 19 ᐕ 8 ᦬㧘ጘ㒂)
4㧕 ╙ 8 ࿁ᣣᧄஜᐽᩕ㙃ࠪࠬ࠹ࡓቇળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂)
3㧕ቇⴚ㔀⹹᫪⣁ਭ㓉㧦
1㧕 ᣣᧄౝ⑼ቇળ⹹(⧷ᢥ)㧧✬㓸ᆔຬ(㨪⃻࿷)2㧕 ᣣᧄᶖൻེ∛ቇળ⹹(⧷ᢥ)㧧✬㓸ᆔຬ(㨪⃻࿷)3㧕 ᣣᧄ㕒⣂⚻⣺ᩕ㙃ቇળ⹹㧦✬㓸ᆔຬ(㨪⃻࿷)7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳㢬⷗ ኼ㧦
1㧕 ╙ 68 ࿁ᣣᧄⴊᶧቇળ࡮╙ 48 ࿁ᣣᧄ⥃ᐥⴊᶧቇળ࡮วห✚ળ(2006 ᐕ 10 ᦬㧘⑔ጟ㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ
‫ᧂޟ‬ᴦ≮ CD20 㓁ᕈૐᖡᕈᐲ࡝ࡦࡄ⣲ߦኻߔࠆ Rituximab ૬↪ THP-COP ≮ᴺ‫ޠ‬Ṷ⠪)㧙㧙ጊ↰ବ᮸㧦
1㧕 ╙ 50 ࿁ᣣᧄャⴊ࡮⚦⢩ᴦ≮ቇળ᧲ᶏᡰㇱળቇⴚ㓸ળ(2007 ᐕ 11 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓ‫․ޟ‬ᱶ⁁ᴫਅߢߩⴊᶧ⵾೷ߩ૶↪ -ⴊᶧ∔ᖚ-‫ޠ‬Ṷ⠪)═ේජ༹㧦
1㧕 ╙ 68 ࿁ᣣᧄⴊᶧቇળ࡮╙ 48 ࿁ᣣᧄ⥃ᐥⴊᶧቇળ࡮วห✚ળ(2006 ᐕ 10 ᦬㧘⑔ጟ㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ
‫ޟ‬ㅧⴊེᖡᕈ∔ᖚߦว૬ߒߚ⊒ᾲᕈᅢਛ⃿ᷫዋ∝ߦኻߔࠆ Biapenem ߩ⥃ᐥ⊛ᬌ⸛‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേ᫪⣁ਭ㓉㧦
1㧕 ጘ㒂⋵り૕㓚ኂ⠪⑔␩ද⼏ળᆔຬ(㨪⃻࿷)2㧕 ጘ㒂⋵㔍∛ක≮ㅪ⛊ද⼏ળᐳ㐳(㨪⃻࿷)3㧕 ጘ㒂⋵߇ࠎኻ╷ផㅴද⼏ળᐳ㐳(ᐔᚑ 19 ᐕ㨪⃻࿷)4㧕 ጘ㒂⋵ࠛࠗ࠭ኻ╷ផㅴද⼏ળᐳ㐳(ᐔᚑ 19 ᐕ㨪⃻࿷)5㧕 ጘ㒂⋵ක≮ክ⼏ળᆔຬ(ᐔᚑ 18 ᐕ㨪⃻࿷)6㧕 ጘ㒂⋵ੱᮭᙣ⹤ળᆔຬ(㨪⃻࿷)㢬⷗ ኼ㧦
1㧕 ጘ㒂⋵߇ࠎኻ╷ផㅴද⼏ળᆔຬ(ᐔᚑ 19 ᐕ 7 ᦬㨪⃻࿷)2㧕 ጘ㒂⋵ࠛࠗ࠭ኻ╷ផㅴද⼏ળᆔຬ(ᐔᚑ 19 ᐕ 1 ᦬㨪⃻࿷)10㧚ႎ๔ᦠߥߒ11㧚ႎ㆏ߥߒ12㧚⥄Ꮖ⹏ଔ
⹏ଔ1㧚 ⎇ⓥߩ᭎ⷐ㧦ⴊᶧ∛ᘒቇ 1㧙3 ߩ޿ߕࠇ߽㧘߶߷㗅⺞ߦㅴⴕߒߡ޿ࠆ‫ߦߊߣޕ‬ਅ⸥ߩὐࠍ㜞ߊ⹏ଔߔࠆ
㧔1㧕ᖡᕈ࡝ࡦࡄ⣲ߩ੍ᓟ࿃ሶ⸃ᨆߣߒߡ㧘ᣂߒ޿޿ߊߟ߆ߩ੍ᓟ࿃ሶࠍ᛽಴ߢ߈ߚ‫◲߽ࠇߕ޿ޕ‬ଢߥᬌᩏߢ޽ࠅ㧘ౣ⃻ᕈ߇㜞ߊ㧘⥃ᐥ⊛᦭↪ᕈ߇ᭂ߼ߡ㜞޿ߣᕁࠊࠇࠆ‫ޕ‬
㧔2㧕ᖡᕈ࡝ࡦࡄ⣲ߦኻߔࠆᣣᧄ⊒ߩ THP-COP ≮ᴺߦ㑐ߔࠆᚑ❣ࠍ࿖㓙⊛ߦ౏⴫ߒߚ㧔ේ⪺㧙⧷ᢥ㧘
No.10㧕‫ޕ‬
㧔3㧕㜞㦂⠪ᕆᕈ㛽㜑ᕈ⊕ⴊ∛߿ㅢᏱߩᮡḰ⊛ᒝജൻቇ≮ᴺߩㆀⴕ߇࿎㔍ߥ∝଀ࠍኻ⽎ߦ㧘ᣂⷙᴦ≮࡟ࠫࡔࡦࠍ┙᩺㧘ႎ๔ߒߚ㧔ේ⪺㧙⧷ᢥ㧘No.9࡮19㧕‫ ߦ․ޕ‬G-CSF ࠍ૬↪ߔࠆߣ޿߁࡙࠾࡯ࠢߥ࠺ࠩࠗ
ࡦ߽฽߹ࠇࠆ‫ߪࠄࠇߎޕ‬㧘ోり⁁ᘒਇ⦟ߩᖚ⠪ߦ߅޿ߡ߽቟ో߆ߟ᦭ലߥᴦ≮ߣ⸒߃ࠆ‫ޕ‬3㧚 ⎇ⓥᚑᨐߩ⊒⴫㧦਄⸥㧔2㧕㧘㧔3㧕ߩ⽸₂߇ᄢ߈޿‫ߨ߻߅߅ઁߩߘޕ‬㗅⺞ߣ⹏ଔߔࠆ‫ޕ‬4㧚 ⎇ⓥ⾌₪ᓧ⁁ᴫ㧦੹ᓟ㧘ࠃࠅ৻ጀߩขᓧߦะߌߡദജߔࠆ‫ޕ‬5㧚 ⊒᣿࡮․⸵಴㗿⁁ᴫ㧦਄⸥ᴦ≮ᴺߩ㐿⊒ߣ޿߁ὐߢ㧘fair ߣ⹏ଔߔࠆ‫ޕ‬
6㧘7㧚ቇળᵴേ㧦߅߅߻ߨ㗅⺞ߣ⹏ଔߔࠆ‫ޕ‬11㧚 ႎ㆏㧦߅߅߻ߨ㗅⺞ߦᖱႎࠍ౏⴫ߢ߈ߡ޿ࠆߣ⹏ଔߔࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷⥃ᐥߩᣰ⋓ߥ㔛ⷐߦኻᔕߔߴߊ㧘ੱຬࠍᝄࠅะߌߑࠆࠍᓧߥ޿⁁ᴫߦ޽ࠆ‫⎇ޕ‬ⓥࠬ࠲࠶ࡈߣߊߦᄢቇ
㒮↢ߩలታࠍ࿑ࠆᔅⷐ߇޽ࠆ‫ߚ߹ޕ‬㧘ⴊᶧᖡᕈ⣲≌ࠍ฽߻ Clinical Oncology ߪ㧘․ߦలታߒߚࠛࡆ࠺ࡦ
ࠬ߇ᦸ߹ࠇࠆಽ㊁ߢ޽ࠅ㧘ᣂⷙᴦ≮ߥߤߪනᣉ⸳ߢߪ㒢⇇߇޽ࠅ㧘ᴦ≮ߩ㐿⊒ࠍ⋡⊛ߣߒߚ⥃ᐥ⹜㛎ߩ┙᩺ߦߪ㧘ઁᣉ⸳ߣߩදജࠍኒߦߒߚᄙᣉ⸳౒ห⹜㛎߇ᔅⷐߢ޽ࠆ‫ޕ‬㧙㧙੹ᓟߩዷᦸ
1㧚ⴊᶧ∛ᘒቇ㧦ᴦ≮ᛶ᛫ᕈ⊕ⴊ∛ߩᯏᐨ⸃᣿ߣ㧘ᣂߒ޿ᴦ≮ᴺ㐿⊒ߩዷ㐿ࠍᦼߒߡ޿ࠆ‫ߚ߹ޕ‬㧘࡟ࡌ࡞ߩ㜞޿⥃ᐥ⹜㛎ࠍ┙᩺ߒ㧘ᄙᣉ⸳౒ห⹜㛎ߣߒߡⓍᭂ⊛ߦㅴ߼ࠆ‫ޕ‬
3㧚⎇ⓥᚑᨐߩ⊒⴫㧦IF5 ߥࠄ߮ߦ 10 એ਄ࠍ⋡቟ߣߒ㧘ߘࠇߙࠇࠍ਄࿁ࠆᬺ❣ߩჇടࠍ⋡ᜰߔ‫ޕ‬
4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ㧦චಽߥ⎇ⓥ⾌₪ᓧߦะߌߡദജߔࠆ‫ޕ‬
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫ㧦ᰴߩዷᦸߪⷞ㊁ߦ౉ߞߡ޿ߥ޿‫ޕ‬
6㧘7㧚ቇળᵴേ㧦ฦ⒳࿖㓙ቇળ㧘․ߦ☨࿖ⴊᶧળ⼏ߢߩ⛮⛯⊛ណᛯࠍ⋡ᜰߔ‫ޕ‬㧙㧙㧔6㧕↥⑼ᇚੱ⑼ቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
‫⎇߇ޠ≸ߣࡦࡕ࡞ࡎޟ‬ⓥ⺖㗴ߢ޽ࠆ㨫ߘߩ৻ߟߣߒߡ㧘ᅚᕈ↢ᱺ↢ℂਗ߮ߦᕈࠬ࠹ࡠࠗ࠼ࡎ࡞ࡕࡦߦ೙
ᓮߐࠇࠆᅚᕈ↢ᱺེ߿ߘࠇ↱᧪ߩ⣲≌ߩ⊒⢒Ⴧᱺߣ⊒⢒ᛥ೙ࠍ᣿ࠄ߆ߦߔࠆߎߣࠍ⋡ᜰߔ㨫߹ߚ㧘ࡎ࡞ࡕࡦਇᔕ∝߿ฃኈ૕∔ᖚߦߟ޿ߡ߽㧘∛ᘒߩℂ⸃߿ಽሶ࡟ࡌ࡞ߢߩㅊ᳞ࠍߒ㧘዁᧪⊛ߥㆮવሶᴦ≮ߩၮ␆ࠍ࿕߼ߟߟ޽ࠆ‫ޕ‬ᅧᆼߩᚑ┙߿⢝ఽ⇣Ᏹࠍߪߓ߼ߣߔࠆ๟↥ᦼߦߟ޿ߡ߽㧘ᣢ⍮ߩ⍮⷗ߩߺߥࠄߕᧂ⍮ߩ੐㗄ߩ⸃᣿ࠍ⋡ᜰߔ㨫․ߦ㧘ߎߩಽ㊁ߢߪታ㛎ቶ࡟ࡌ࡞ߢߪߥߊ㧘⚦߆ߥ⥃ᐥᚲ⷗ߩ㓸Ⓧࠍ㊀ߨ⥃ᐥߩ႐߳ߩㆶరࠍ⋡ᜰߒߡ޿ࠆ㨫2㧚ฬ★
ᢎ᝼(૬છ)㧦
⻠Ꮷ㧦
⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦

੹੗◊ᔒ
⮮ᧄᰴ⦟
દ⮮⋥᮸
ਤ⠀ᙗม
ฎ੗ㄖ㇢
Ꮢฎ ື
⼾ᧁ ᑝ
ੑችᦸ␽
᧖ጊਃ⍮ઍ
૒⮮⧷ℂሶ
᳓㊁ᥓሶ
ᠲᦇሶ
㋈ᧁ⌀ℂሶ

Atsushi ImaiJiro Fujimoto
Naoki Ito
Kenji Niwa
Tatsuro Furui
Satoshi Ichigo
Hiroshi Toyoki
Mochiyoshi Ninomiya
Michiyo Sugiyama
Eriko Sato
Tomoko Mizuno
Asako Misao
Mariko Suzuki

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ⮮ᧄᰴ⦟㧚ᇚੱ⑼≸ߩᶐẢ࡮ォ⒖ߦ߅ߌࠆⴊ▤ᣂ↢㧦ᱞ⼱㓶ੑઁ✬㧚↥⑼ᇚੱ⑼ߩᦨᣂක≮㧘᧲੩㧦వ┵ක≮ᛛⴚ⎇ⓥᚲ㧧2006 ᐕ㧦153㧙156㧚
2㧕 ₹⥢ノᒾ㧚ᣂߒ޿↥ᇚੱ⑼↪⮎೷㧦ᱞ⼱㓶ੑઁ✬㧚↥⑼ᇚੱ⑼ߩᦨᣂක≮㧘᧲੩㧦వ┵ක≮ᛛⴚ⎇ⓥᚲ㧧
2006 ᐕ㧦318㧙322㧚
3㧕 ₹⥢ノᒾ㧚ᇚੱ⑼߇ࠎ㧘੃߇ࠎ㧦ᄤ㊁ᕺሶઁ✬㧚ṽᣇߪᅚᕈߩஜᐽࠍߚߔߌࠆ㧘᧲੩㧦ጤᵄᦠᐫ㧧2006 ᐕ㧦
135㧙146㧚
4㧕 ₹⥢ノᒾ㧚ᅚᕈࡎ࡞ࡕࡦߩ૞↪ߣᕈᏅߩ಴⃻㧘੩ㇺ㧦㊄⧐ၴ㧧2006 ᐕ㧦3㧙261㧚
5㧕 ₹⥢ノᒾ㧚ౝᕈེᗵᨴ∝㧔ౝ⤑Ἳ࡮㒝ዻེἻ࡮PID㧕㧦⍹Ⴆᢥᐔઁ✬㧚↥ᇚੱ⑼⸻≮㧘᧲੩㧦᳗੗ᦠᐫ㧧2006
ᐕ㧦362㧙365㧚
6㧕 ⮮ᧄᰴ⦟㧚ᄙྱ⢩ᕈෆᎽ∝୥⟲㧦ᄢ㑐ᱞᒾઁ✬㧚੹ᣣߩዊఽᴦ≮ᜰ㊎㧘᧲੩㧦කቇᦠ㒮㧧2006 ᐕ㧦200㧙
201㧚
7㧕 ₹⥢ノᒾ㧚↥ᇚੱ⑼㧦ᓟ⮮ర✬㧚ᦨᣂ࡮ᗵᨴ∝ᴦ≮ᜰ㊎㧘ᄢ㒋㧦ක⮎ࠫࡖ࡯࠽࡞␠㧧2006 ᐕ㧦187㧙197㧚
8㧕 ਃ㡞ᑝ❥㧚Q27 ᄖ⑼㗔ၞߢᵈᗧߔߴ߈⌀⩶∝ߣ࡝ࠬࠢߪ㧫㧦ᷓ࿷ᕈ⌀⩶∝ Q&A㧘ᄢ㒋㧦ක⮎ࠫࡖ࡯࠽࡞
␠㧧2006 ᐕ㧦84㧙86㧚
9㧕 ਃ㡞ᑝ❥㧚╙Υ┨ Ꮢਛᗵᨴ∝ߦኻߔࠆᚻⴚᤨߩ᛫⩶⮎ߩ૶޿ᣇ㧙D㧚↥ᇚੱ⑼∔ᖚ㧚๟ⴚᦼᗵᨴኻ╷ࡑ࠾ࡘࠕ࡞㧦᛫⩶⮎૶↪ᴺ߆ࠄ๟ⴚᦼ▤ℂ߹ߢ㧘᧲੩㧦ධᳯၴ㧧2006 ᐕ㧦62㧙67㧚
10㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧚ᴡ㊁⨃㧘ᐔẟᵗ৻✬㧚7 ↥ᇚੱ⑼㗔ၞߩᗵᨴ∝߇⇼ࠊࠇߚߣ߈㧘ࡌ࠶࠼ࠨࠗ࠼ߢᓎ┙ߟᓸ↢‛ᬌᩏࠟࠗ࠼㧙╙ 1 ┨ ∝⁁࡮∝୥߆ࠄߤࠎߥᬌ૕ࠍណขߒߤߩࠃ߁ߦ⸻ᢿࠍㅴ߼ࠆ߆ ૗ߩᬌᩏࠍߔࠆ߆࡮⚿ᨐࠍߤ߁⹏ଔߔࠆ߆㧙㧘᧲੩㧦ᢥశၴ㧧2006 ᐕ㧦50㧙57㧚
11㧕 ਃ㡞ᑝ❥㧚ࡏ࠷࡝࠿ࠬਛᲥߩ․ᓽߣኻᔕ㧦ᷰㄝᴦ㓶✬㧚㘩ਛᲥᬌᩏ࡮⸻≮ߩࠦ࠷ߣ⪭ߣߒⓣ㧘᧲੩㧦ਛጊᦠᐫ㧧2006 ᐕ㧦20㧙21㧚
12㧕 ੹੗◊ᔒ㧚ᇚੱ⑼∔ᖚ㧦ሶች૕≸㧦␹ፒ⑲㓁✬㧚⋴⼔ߩߚ߼ߩᦨᣂකቇ⻠ᐳ㧔╙ 2 㧕16 Ꮞ㧘᧲੩㧦ਛጊᦠᐫ㧧2006 ᐕ㧦253㧙261㧚
13㧕 ੹੗◊ᔒ㧚ᇚੱ⑼∔ᖚ㧦ሶች⡺⣲㧦␹ፒ⑲㓁✬㧚⋴⼔ߩߚ߼ߩᦨᣂකቇ⻠ᐳ㧔╙ 2 㧕16 Ꮞ㧘᧲੩㧦ਛጊᦠᐫ㧧2006 ᐕ㧦261㧙269㧚
14㧕 ੹੗◊ᔒ㧚ࠣ࡞ࠦࠦ࡞࠴ࠦࠗ࠼ᛩਈᴺ㧦ᣣᧄ↢ᱺකቇળ✬㧚ᣂߒ޿↢ᱺක≮ᛛⴚߩࠟࠗ࠼࡜ࠗࡦ ╙ 3 㧘᧲੩㧦㊄ේ಴ 㧧2007 ᐕ㧦184㧙187㧚
15㧕 ₹⥢ノᒾ㧘⮮ᧄᰴ⦟㧚ᦨᣂ࡮ᗵᨴ∝ᴦ≮ᜰ㊎㧙6㧚↥ᇚੱ⑼㧙2008 ᐕᡷ⸓ 㧘ᄢ㒋㧦ක⮎ࠫࡖ࡯࠽࡞␠㧧
2008 ᐕ㧦178㧙188.
16㧕 ੹੗◊ᔒ㧚ක⠪߇ߔߔ߼ࠆኾ㐷∛㒮㧙᧲ᶏ (ᗲ⍮࡮ጘ㒂࡮ਃ㊀࡮㕒ጟ)㧙㧘␹ᄹᎹ㧦࡜ࠗࡈડ↹㧧2008 ᐕ㧦
324㧙324㧚㧙㧙⪺ᦠ㧔᰷ᢥ㧕1㧕 Fujimoto J, Alam SM, Jahan I, Sun W, Sakaguchi H, Toyoki H, Sato E, Tamaya T. Role ofimmunohistochemical Expression of ETS-1 Factor in Ovarian Carcinoma. In: Hayat MA, ed.
Immunohistochemistry of in situ Hybridization of Human Carcinomas. St. Louis: Academic Press;
2006:473-477.
2㧕 Imai A, Sugiyama M, Takahashi S, Furui T, Tamaya T. Role of membrane-associated serine/threonine
phosphatase in ovarian cancer cell survival: evidence for minor role of apoptosis in
gonadotropin-releasing hormone’s antiproliferative signaling. In: Bardos A P, ed. Ovarian Cancer: New
Research (E). New York: Nova Science Publishers; 2006:213-228.
3㧕 Furui T, Imai A. Testosterone level in pregnancy and gestational hyperandrogenemia-induced preterm
labor. Current Trends in Endocrinology, pt 2. India: Research Trends; 2006:15-18.
4㧕 Fujimoto J, Sakaguchi H, Toyoki H, Sato E, Jahan I, Alam SM, Tamaya T. Complicated angiogenesis
in uterine endometrial cancers. In: Fujimoto J, ed. Reproductive Oncology. Kerala: Research Signpost;
2007:193-203.
5㧕 Fujimoto J, Alam SM, Jahan I, Sato E, Sakaguchi H, Tamaya T. Estrogen-related receptor ingynecological cancers. In: Fujimoto J, ed. Reproductive Oncology. Kerala: Research Signpost;
2007:205-209.
6㧕 Sakaguchi H, Fujimoto J, Tamaya T. Expression of estrogen receptor  in estrogen-related
gynecological cancers. In: Fujimoto J, ed. Reproductive Oncology. Kerala: Research Signpost;
2007:211-221.
7㧕 Sakaguchi H, Fujimoto J, Sun W, Tamaya T. Clinical Implications of Steroid Receptor Coactivators in
Estrogen-Related Gynecological Cancers. In: Fujimoto J, ed. Reproductive Oncology. Kerala: Research
Signpost; 2007:223-233.
8㧕 Fujimoto J, Sakaguchi H, Toyoki H, Jahan I, Alam SM, Sato E, Tamaya T. Novel gentle therapeutic
trends for patients of uterine cervical cancer. In: Hector T, ed. Trends in Cervical Cancer. New York:
Nova Science; 2007:89-96.
✚⺑㧔๺ᢥ㧕
1㧕 ⮮ᧄᰴ⦟㧚ࠛࠬ࠻ࡠࠥࡦ㧘ࡊࡠࠥࠬ࠴ࡦߣ߇ࠎ㧘ᕈᏅߣක≮ 2006 ᐕ㧧3 Ꮞ㧧65㧙70㧚
2㧕 ₹⥢ノᒾ㧚ᅚᕈߩ⣶∩ߣߘߩኻ╷㧙↥ᇚੱ⑼ߣ⣶∩㧙㧘↥ᇚᴦ≮ 2006 ᐕ㧧92 Ꮞ㧦103㧙108㧚
3㧕 ₹⥢ノᒾ㧚ಽሶ⢄⤳∛ቇ㧙ಽሶ↢‛ቇ⊛ࠕࡊࡠ࡯࠴ߣಽሶ∛ᘒ↢ℂቇ㧙㧘ᣣᧄ⥃ῼ 2006 ᐕ㧧64 Ꮞ(Ⴧೀ)㧦
271㧙275㧚
4㧕 ₹⥢ノᒾ㧚ᇚੱ⑼ࠟࡦߣṽᣇ㧘ṽᣇߣᦨᣂᴦ≮ 2006 ᐕ㧧15 Ꮞ㧦33㧙39㧚
5㧕 ₹⥢ノᒾ㧚ᕈᏅߦ߅ߌࠆࠛࠬ࠻ࡠࠥࡦ૞↪ᯏᐨࠃࠅߺࠆᶖൻེ∔ᖚ㧘↥ᇚᴦ≮ 2006 ᐕ㧧92 Ꮞ㧦437㧙444.
6㧕 ₹⥢ノᒾ㧚ࠛࠬ࠻ࡠࠥࡦߣ↢ᱺ↢ℂ㧘⥃ᐥಽሶౝಽᴲቇ 2006 ᐕ㧧64 Ꮞ(Ⴧೀ)㧦355㧙360㧚
7㧕 ₹⥢ノᒾ㧚ࡊࡠࠥࠬ࠹ࡠࡦߣ↢ᱺ↢ℂ㧘⥃ᐥಽሶౝಽᴲቇ 2006 ᐕ㧧64 Ꮞ(Ⴧೀ)㧦434㧙439㧚
8㧕 ⮮ᧄᰴ⦟㧚᛫ࡊࡠࠥࠬ࠹ࡠࡦ೷ߩ⥃ᐥᔕ↪㧘⥃ᐥಽሶౝಽᴲቇ 2006 ᐕ㧧64 Ꮞ(Ⴧೀ)㧦447㧙451㧚
9㧕 ₹⥢ノᒾ㧚࡜ࠗࡈࠨࠗࠢ࡞ߦ߅ߌࠆᅚᕈߩᔃり∝㧙ᕈࠬ࠹ࡠࠗ࠼ߣߩ㑐ଥߦ߅޿ߡ㧙㧘ᅚᕈᔃり⹹ 2006
ᐕ㧧11 Ꮞ㧦20㧙23㧚
10㧕 ₹⥢ノᒾ㧚ᯏ⢻ᕈෆᎽ⣲≌㧘ᣣᧄ⥃ῼ ᣂ㗔ၞ೎∝୥⟲ࠪ࡝࡯࠭ 2006 ᐕ㧧2 Ꮞ(Ⴧೀ)㧦361㧙365㧚
11㧕 ₹⥢ノᒾ㧚ࡎ࡞ࡕࡦߣᇚੱ⑼⣲≌㧙੍㒐කቇ߅ࠃ߮ᴦ≮කቇߩ஥㕙ࠃࠅ㧙㧘ᣣᧄ↥⑼ᇚੱ⑼ቇળ㔀⹹
2006 ᐕ㧧58 Ꮞ㧦1279㧙1287㧚
12㧕 ₹⥢ノᒾ㧚ࠞࡦࠫ࠳∝ߩ⸻ᢿߣᴦ≮㧘ⴊᶧ࡮⣲≌⑼ 2006 ᐕ㧧53 Ꮞ㧦295㧙301㧚
13㧕 ₹⥢ノᒾ㧚ࡎ࡞ࡕࡦߣᇚੱ⑼⣲≌㧘↥ᇚੱ⑼ᴦ≮ 2006 ᐕ㧧10 Ꮞ㧦386㧙391㧚
14㧕 ₹⥢ノᒾ㧚↵ᅚߦ߅ߌࠆࠕࡦ࠼ࡠࠥࡦਇో∝୥⟲㧙ࠕࡦ࠼ࡠࠥࡦ⵬లߣ໧㗴ὐ㧙㧘↥ᇚੱ⑼ᴦ≮ 2006
ᐕ㧧11 Ꮞ㧦598㧙605㧚
15㧕 ₹⥢ノᒾ㧚࡜ࠗࡈࠬ࠹࡯ࠫߣᅚᕈࡎ࡞ࡕࡦ㧙ᅚᕈߩ࡜ࠗࡈࠬ࠹࡯ࠫߦ߅ߌࠆᕈᏅߩ಴⃻ߣࠛࠬ࠻ࡠࠥࡦ㧙㧘කቇߩ޽ࠁߺ 2006 ᐕ㧧5 Ꮞ㧦321㧙326㧚
16㧕 ⮮ᧄᰴ⦟㧚ሶችౝ⤑≸ߣࠛࠬ࠻ࡠࠥࡦฃኈ૕㧘Hormone Frontier in Gynecology ࡔ࠺ࠖࠞ࡞࡟ࡆࡘ࡯␠㧘
2006 ᐕ㧧13 Ꮞ㧦23㧙29㧚
17㧕 ₹⥢ノᒾ㧚ࡎ࡞ࡕࡦߣᇚੱ⑼⣲≌㧙੹㧘ᡷ߼ߡ“ሶች߇ࠎ”ࠍ⠨߃ࠆ㧙㧘↥ᇚੱ⑼ᴦ≮ 2006 ᐕ㧧12 Ꮞ㧦617
㧙621㧚
18㧕 ₹⥢ノᒾ㧚ࠛࡦ࠼ࠢ࡝ࡁࡄ࠴࡯ߣߒߡߩሶችౝ⤑≸㧘ࡔ࠺ࠖࠞ࡞࡟ࡆࡘ࡯␠ 2006 ᐕ㧧13 Ꮞ㧦11㧙16㧚
19㧕 ₹⥢ノᒾ㧚ࡇ࡞ߣ߇ࠎ㧘⥃ᐥᇚੱ⑼↥⑼ 2006 ᐕ㧧12 Ꮞ㧦1501㧙1505㧚
20㧕 ↰ਛ㚅߅㉿㧘ਃ㡞ᑝ❥㧘ᷰㆺ㇌෹㧚ࡃࠢ࠹ࡠࠗ࠺ࠬዻ㧘ᗵᨴߣ᛫⩶⮎ 2006 ᐕ㧧9 Ꮞ㧦 2㧙4㧚
21㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧚ᓸ↢‛ቇ⷗࿾߆ࠄߺߚ᛫⩶⮎ߩㆡᱜ૶↪ᴺߣ⮎೷⠴ᕈ⩶೙ᓮߩߚ߼ߩ
ᚢ⇛㧘࡝࠙ࡑ࠴⑼ 2006 ᐕ㧧35 Ꮞ㧦63㧙68㧚
22㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧚MRSA ᗵᨴ∝ߦ߅ߌࠆ࡝ࡀ࠱࡝࠼ߩ᦭ലᕈ㧘ᴦ≮ቇ 2006 ᐕ㧧40 Ꮞ㧦
83㧙84㧚
23㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧚ᵈᗧߔߴ߈ᗵᨴ∝ߣኻ╷ 5㧚↥ᇚੱ⑼㗔ၞߩᗵᨴ∝ߣኻ╷㧘ᢇᕆකቇ
2006 ᐕ㧧30 Ꮞ㧦216㧙220㧚
24㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧚ህ᳇ᕈ⩶ߦࠃࠆ࠮ࡊࠪࠬߪሽ࿷ߔࠆ߆㧘ᴦ≮ቇ 2006 ᐕ㧧40 Ꮞ㧦521
㧙524㧚

㧙㧙

25㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧚๟↥ᦼߦ߅ߌࠆ B ⟲ㅪ㎮⃿⩶ᗵᨴ∝ߩ੍㒐ߦ㑐ߔࠆ CDC ߩᡷ⸓ࠟࠗ
࠼࡜ࠗࡦ㧘ᣂߒߊ⊒⴫޽ࠆ޿ߪᡷ⸓ߐࠇߚᗵᨴ∝ߦ㑐ߔࠆࠟࠗ࠼࡜ࠗࡦ㧘ൻ≮ߩ㗔ၞ 2006 ᐕ㧧22 Ꮞ(Ⴧೀ)㧦134㧙137㧚
26㧕 ਃ㡞ᑝ❥㧚↥ᇚੱ⑼㗔ၞߦ߅ߌࠆ๟ⴚᦼߩᗵᨴ೙ᓮ㧘PHYSICIAN’S THERAPY MANUAL 2006 ᐕ㧧5Ꮞ㧦1㧙2㧚
27㧕 ਃ㡞ᑝ❥㧚ࠃߊㆣㆄߔࠆᗵᨴ∝㧘⃟ߒ޿߇⍮ߞߡ߅߈ߚ޿ᗵᨴ∝㧘ᇚੱ⑼ INFECTION FRONT 2006
ᐕ㧧7 Ꮞ㧦12㧙13㧚
28㧕 ਃ㡞ᑝ❥㧚․ᱶ∛ᘒߦ߅ߌࠆ᛫⩶ൻቇ≮ᴺ ᅧᇚ㧘ᣣᧄౝ⑼ቇળ㔀⹹ 2006 ᐕ㧧95 Ꮞ㧦2208㧙2213㧚
29㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧚ᣂߒ޿⥃ᐥᬌᩏ࡮ᧂ᧪ߩ⥃ᐥᬌᩏ ฦ⺰ 5㧚ᗵᨴ∝ᬌᩏ ࠢ࡜ࡒࠫࠕ࡮
࠻࡜ࠦࡑ࠴ࠬ/ᶷ⩶ᩭ㉄หᤨჇ᏷หቯᬌᩏ㧘ᬌᩏߣᛛⴚ 2006 ᐕ㧧34 Ꮞ㧦1293㧙1294㧚
30㧕 ฎ੗ㄖ㇢㧘੹੗◊ᔒ㧘₹⥢ノᒾ㧚↢ᱺකቇߦ߅ߌࠆ࡝࠱ࡎࠬࡈࠔ࠴ࠫࡦ㉄(LPA)ߩᓎഀ㧘᧲ᶏ↥⑼ᇚੱ⑼ቇ
ળ㔀⹹ 2007 ᐕ㧧43 Ꮞ㧦1㧙7㧚
31㧕 ਤ⠀ᙗม㧘ዊ㊁ᧁ੩ሶ㧘ὖ㔕㧘໊ᩉᨋ㧘ㅪჇᨋ㧘₹⥢ノᒾ㧚ሶችౝ⤑≸⚦⢩ߦኻߔࠆචోᄢ⵬ḡ㧘྾‛ḡߩ૞↪ߣ ER ⊒⃻ߣߩ㑐ㅪ㧘ṽᣇ⎇ⓥߩ޽ࠁߺ 2007 ᐕ㧧24 Ꮞ㧦39㧙42㧚
32㧕 ᑝἑ⃍ሶ㧘㐳የ⢒ሶ㧘ᷡ᳓ൎ㧘₹⥢ノᒾ㧚ᅚᕈᄖ᧪ㅢ㒮ਛߦᅧᆼߦ⥋ߞߚ 10 ∝଀ߦ߅ߌࠆṽᣇߩലᨐ㧘ṽᣇ⎇ⓥߩ޽ࠁߺ 2007 ᐕ㧧24 Ꮞ㧦55㧙58㧚
33㧕 ૒⮮ᵏ᣽㧘ᚑᎹᏗ㧘↰਄ᘮሶ㧘ᮮጊᐽብ㧘ጊ↰ᣂዏ㧚㗡∩ࠍਥ⸷ߣߔࠆᅚᕈᖚ⠪ߦኻߔࠆᒰᏫ ྾ㅒട๓⨠⪪↢ᆗḡߩ QOL ᡷༀലᨐ㧘ṽᣇ⎇ⓥߩ޽ࠁߺ 2007 ᐕ㧧24 Ꮞ㧦102㧙104㧚
34㧕 ⮮ᧄᰴ⦟㧚≸ᴦ≮ᓟߩࡎ࡞ࡕࡦ⵬ల≮ᴺ(HRT)㧘↥⑼ߣᇚੱ⑼ 2007 ᐕ㧧74 Ꮞ㧦1486㧙1490㧚
35㧕 ੹੗◊ᔒ㧚ጘ㒂࿾඙ߦ߅ߌࠆ๟↥ᦼක≮ࠍ⠨߃ࠆ(Უ૕៝ㅍߣ㓸⚂ൻ)㧘޿ߜ޿ 2007 ᐕ㧧49 Ꮞ㧦18㧙21㧚
36㧕 ੹੗◊ᔒ㧚ጘ㒂⋵↥⑼ᇚੱ⑼ක≮ߩ໧㗴ὐ(1)㧘޿ߜ޿ 2007 ᐕ㧧50 Ꮞ㧦23㧙26㧚
37㧕 ฎ੗ㄖ㇢㧘੹੗◊ᔒ㧚↥ᇚੱ⑼ᄖ᧪ࡌࠬ࠻࠽ࡆࠥ࡯࡚ࠪࡦ㧨ή᦬⚻㧪㧦⥃ᐥᇚੱ⑼↥⑼ 2007 ᐕ㧧61 Ꮞ
4 ภ(೎ౠ)㧦403㧙413㧚
38㧕 ੹੗◊ᔒ㧚Უ૕៝ㅍᢇᕆࡑ࠾ࡘࠕ࡞㧙↥⑼ක߆ࠄߩⷞὐ㧙㧘ጘ㒂⋵කᏧળႎ 2008 ᐕ㧧676 ภ㧦18㧙20㧚
39㧕 ⮮ᧄᰴ⦟㧚ሶችౝ⤑∝ߩჇᱺㅴዷߦ㑐ࠊࠆⴊ▤ᣂ↢ߣᕈࠬ࠹ࡠࠗ࠼㧘↥ᇚੱ⑼ߩታ㓙 2008 ᐕ㧧57 Ꮞ 2
ภ㧦227㧙232㧚✚⺑㧔᰷ᢥ㧕
1㧕 Furui T, Imai A . Testosterone level in pregnancy and gestational hyperandogenemia-induced preterm
labor. Curr Trends Endocrinol. 2006;2:15-18.
2㧕 Imai A, Furui T. Chemotherapy-induced female infertility and protective action of
gonadotropin-releasing hormone analogues. J Obstet Gynaecol. 2007;27:20-24.
3㧕 Imai A, Furui T, Yamamoto A. Preservation of female fertility during cancer treatment. Reprod Med
Biol. 2008;7:17-27.
4㧕 Fujimoto J. Novel therapeutic strategy for uterine endometrial cancers. Int J Clin Oncol.
2008;5:411-415.
5㧕 Imai A, Furui T, Hatano Y, Suzuki M, Suzuki N, Goshima S. Leiomyoma and rhabdomyoma of thevagina Vaginal myoma. J Obstet Gynaecol. 2008;28:563-566.
ේ⪺㧔๺ᢥ㧕
1㧕 ਃ㡞ᑝ❥㧘₹⥢ノᒾ㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧚ࠢ࡜ࡒࠫࠕຜ㗡ᗵᨴߩ⃻⁁ߣᴦ≮ᣇᴺߦ㑐ߔࠆᬌ⸛㧘Jpn J
Antibiot 2006 ᐕ㧧59 Ꮞ㧦35㧙40㧚
2㧕 㜞ᯅ㓶৻㇢㧘ੑችᦸ␽㧘Ꮉ㠈Ꮢ㇢㧘ጤ၂㊀♿㧘₹⥢ノᒾ㧚ጘ㒂⋵ߩ↥ᇚੱ⑼ߦ߅ߌࠆⴊᩖ∝⊒∝ߩ∉ቇ⊛⺞ᩏ㨪੍㒐ߩὑߩᣂࠟࠗ࠼࡜ࠗࡦዉ౉એ೨ߩ⊒∝₸㨪㧘᧲ᶏ↥⑼ᇚੱ⑼ቇળ⹹ 2006 ᐕ㧧42 Ꮞ(Ⴧೀ)㧦61
㧙65㧚
3㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧚⠴ᕈൻ㒐ᱛߩߚ߼ߩ᛫⩶⮎૶↪ ᛫⩶⮎ࠨࠗࠢ࡝ࡦࠣ≮ᴺ㧘᦬ೀ⮎੐
2006 ᐕ㧧48 Ꮞ㧦1521㧙1527㧚
4㧕 ਃ㡞ᑝ❥㧚PK/PD ߦၮߠ޿ߚ᛫⩶⮎ߩㆡᱜߥᛩਈ⸳⸘㧘PHYSICIAN’S THERAPY MANUAL 2006 ᐕ㧧
5 Ꮞ㧦9㧙10㧚
5㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧘ጊጟ৻ᷡ㧘ਃベ߹ࠁߺ㧘Ỉ᧛ᴦ᮸㧘᧻Ꮉᵗሶ㧘૒ષᶈ๺㧘ᵻ㊁⵨ሶ㧘⍹ㇹầ⟤㧘ᧃ᧻ኡਯ㧘᧻ේ⨃ⷙ㧘ᯅᷰᒾౖ㧘ኹ࿾⌀ᑿ㧘ች㉿ᱜ༹㧘ᏒᎹᖝม㧚ጘ㒂⋵ਅߦ߅޿ߡಽ㔌ߐࠇߚ✛⤥⩶ߦ㑐ߔࠆ∉ቇ⊛ᬌ⸛ 㨪2004 ᐕ㨪㧘Jpn J Antibiot 2006 ᐕ㧧59 Ꮞ㧦355㧙363㧚
6㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧘₹⥢ノᒾ㧘๺ᴰቁᴦ㧚PK/PD ℂ⺰ߦၮߠ޿ߚࠟ࠴ࡈࡠࠠࠨࠪࡦߩᛩਈ
ᣇᴺߦ㑐ߔࠆ⥃ᐥ⊛ᬌ⸛㧘Jpn J Antibiot 2006 ᐕ㧧59 Ꮞ㧦364㧙372㧚
7㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧚ጘ㒂⋵ਅߢ⥃ᐥಽ㔌ߐࠇߚ✛⤥⩶ 250 ᩣߦኻߔࠆࠞ࡞ࡃࡍࡀࡓ♽(ࡔࡠࡍࡀࡓ㧘࠼࡝ࡍࡀࡓ)ߩ᛫⩶ᵴᕈߣ Monte Carlo Simulation ࠍ↪޿ߚࡔࡠࡍࡀࡓ߅ࠃ߮࠼࡝ࡍࡀࡓߩ᦭ല
ᕈ⹏ଔ㧘╙ 40 ࿁✛⤥⩶ᗵᨴ∝⎇ⓥળ⻠Ṷ⸥㍳ 2006 ᐕ㧧40 Ꮞ㧦88㧙91㧚
8㧕 ਤ⠀ᙗม㧘໊ᩉᨋ㧘ὖ㔕㧘ዊ㊁ᧁ੩ሶ㧘₹⥢ノᒾ㧚ሶችౝ⤑⊒≸ߦኻߔࠆ⵬ਛḷ᳇ḡߩᛥ೙૞↪㧘↥ᇚṽᣇ⎇ⓥ 2006 ᐕ㧧23 Ꮞ㧦54㧙57㧚
9㧕 ਤ⠀ᙗม㧘ዊ㊁ᧁ੩ሶ㧘ὖ㔕㧘₹⥢ノᒾ㧚਄⊹ᕈෆᎽ≸ᴦ≮ߦ߅ߌࠆචోᄢ⵬ḡߩ㐳ᦼ੍ᓟߦኻߔࠆᓇ㗀ߣ CD34 ⊒⃻ߣߩ㑐ㅪ㧘ṽᣇ⎇ⓥߩ޽ࠁߺ 2008 ᐕ㧧25 Ꮞ㧦35㧙37㧚
10㧕 ጊ↰ᣂዏ㧘ዊဈ੗ᕺሶ㧘ᣣᳯ੗㚅ઍሶ㧘᳓㊁ᥓሶ㧘ዊ㊁ᧁ੩ሶ㧘↰਄ᘮሶ㧘૒⮮ᵏ᣽㧘ᮮጊᐽብ㧘੹੗◊ᔒ㧚ᅧᆼ 27 ㅳߢሶች⎕ⵚߦ⥋ߞߚ೨⟎≹⌕⢝⋚ߩ 1 ଀㧘⥃ᐥᇚੱ⑼↥⑼ 2008 ᐕ㧧62 Ꮞ㧦875㧙878㧚㧙㧙ේ⪺㧔᰷ᢥ㧕1㧕 Fujimoto J, Toyoki H, Sakaguchi H, Jahan I, Alam SM, Tamaya T. Clinical implications of expressionof cyclooxygenase-2 related to angiogenesis in ovarian cancer. Oncol Rep. 2006;15:21-25.
2㧕 Imai A, Sugiyama M, Furui T, Tamaya T. Gi protein-mediated translocation of serine/threonine
phosphatase to the plasma membrane and apoptosis of ovarian cancer cell in response togonadotropin-releasing hormone antagonist cetrorelix. J Obstet Gynaecol. 2006;26:37-41.
3㧕 Tang LL, Yokoyama Y, Wan X, Iwagaki S, Niwa K, Tamaya T. PTEN sensitizes epidermal growth
factor-mediated proliferation in endometrial carcinoma cells. Oncol Rep. 2006;15:855-859.
4㧕 Lian Z, Niwa K, Onogi K, Mori H, Harrigan RC, Tamaya T. Anti-tumor effects of herbal medicines on
endometrial carcinomas via estrogen receptor-alpha-related mechanism. Oncol Rep.
2006;15:1133-1136.
5㧕 Imai A, Onogi K, Sugiyama Y. Omental liposarcoma; a rare complication in neurofibromatosis type 1. J
Obstet Gynaecol. 2006;26:381-382.
6㧕 Imai A, Shinohara A, Narikawa N. Successful perinatal outcome following maternal comatose state. J
Obstet Gynaecol. 2006;26:469-470.
7㧕 Fujimoto J, Alam SM, Jahan I, Sato E, Toyoki H, Bao LH, Sakaguchi H, Tamaya T. Plausible linkage
of hypoxia inducible factor-1alpha in uterine cervical cancers. Cancer Sci. 2006;97:861-867.
8㧕 Matsubara K, Mikamo H, Numa M, Yamamoto G, Kusano H, Takamine Y. Three fatal cases of invasive
serotype VI group B streptococcal infection. J Infect. 2006;53:139-142.
9㧕 Nonaka M, Toyoki H, Imai A. Cesarean section scar pregnancy may be the cause of serious
hemorrhage after first-trimester abortion by dilatation and curettage. Int J Gynaecol Obstet.
2006;95:50-51.
10㧕 Fujimoto J, Toyoki H, Sato E, Sakaguchi H, Jahan I, Alam SM, TamayaT. Expression of
cyclooxygenase-2 related to angiogenesis in uterine cervical cancers. J Biomed Sci. 2006;13:825-832.
11㧕 Imai A, Sugiyama M, Furui T, Tamaya T, Ohno T. Direct Protection by a Gonadotropin-Releasing
Hormone Analog from Doxorubicin-Induced Granulosa Cell Damage. Gynecol Obstet Invest.
2006;63:102-106.
12㧕 Tanaka K, Mikamo H, Nakao K, Watanabe K. In vitro antianaerobic activity of X-619, a new des-fluoro(6) quinolone. Antimicrob. Agents Chemother. 2006;50:3908-3913.
13㧕 Onogi K, Niwa K, Tang L, Yun W, Mori H, Tamaya T. Inhibitory effects of Hochu-ekki-to on
endometrial carcinogenesis induced by N-methyl-N-nitrosourea and 17beta-estradiol in mice. Oncol
Rep. 2006;16:1343-1348.
14㧕 Sakaguchi H, Fujiomto J, Hong BL, Tamaya T. Clinical implications of osteopontin in metastatic
lesions of uterine cervical cancers. Cancer Lett. 2007;247:98-102.
15㧕 Mizuno T, Imai A, Hirose Y. Skeletal muscle metastatic and pelvic leiomyosarcomas following
hysterectomy. Int J Gynaecol Obstet. 2007;96:49-50.
16㧕 Furui T, Imai A, Ohno T : Pre-term labour in cases with high maternal testosterone levels. J Obstet
Gynaecol. 2007;27:155-156.
17㧕 Imai A, Itoh N, Matsushi K. Direct extension of a sigmoid colon cancer to a uterine leiomyoma andadherent small intestine. Oncologie. 2007;9:252-253.
18㧕 Imai A, Sugiyama M, Furui T, Tamaya T, Ohno T. Direct protection by a gonadotropin-releasing
hormone analog from doxorubicin-induced granulosa cell damage. Gynecol Obstet Invest.
2007;63:102-106.
19㧕 Alam SM, Fujimoto J, Jahan I, Sato E, Tamaya T. Overexpression of ephrinB2 and EphB4 in tumor
advancement of uterine endometrial cancers. Ann Oncol. 2007;18:485-490.
20㧕 Jahan I, Fujimoto J, Alam SM, Sato E, Sakaguchi H, Tamaya T. Expression of protease activatedreceptor-2 related to angiogenesis in tumor advancement of uterine endometrial cancers. Oncol Rep.
2007;17:345-350.
21㧕 Bao LH, Sakaguchi H, Fujimoto J, Tamaya T. Osteopontin in metastatic lesions as a prognostic
marker in ovarian cancers. J Biomed Sci. 2007:14;373-381.
22㧕 Niwa K, Lian Z, Onogi K, Yun W, Tang L, Mori H, Tamaya T. Preventive effects of glycyrrhizin on
estrogen-related endometrial carcinogenesis in mice. Oncol Rep. 2007;17:617-622.
23㧕 Fujimoto J, Sato E, Alam SM, Jahan I, Toyoki H, Bao LH, Sakaguchi H, Tamaya T. Plausible linkage
of hypoxia inducible factor (HIF) in uterine endometrial cancers. Oncology-Basel. 2007;71:95-101.
24㧕 Wu Y, Niwa K, Onogi K, Tang L, Mori H, Tamaya T. Effects of selective estrogen receptor modulatorsand genistein on the expression of ERalpha/beta and COX-1/2 in ovarectomized mouse uteri. Eur J
Gynaecol Oncol. 2007;8:89-94.
25㧕 Niwa K, Hirose R, Mizuno T, Hirose Y, Tamaya T. Pseudomyxoma peritonei and mucinous pyometral
fluid arising from an ovarian borderline mucinous tumor (case report). Eur J Gynaecol Oncol.
2007;28:145-146.
26㧕 Sato E, Fujimoto J, Toyoki H, Sakaguchi H, Alam SM, Jahan I, Tamaya T. Expression of IP-10 related
to angiogenesis in uterine cervical cancers. Brit J Cancer. 2007;96:1735-1739.
27㧕 Sakaguchi H, Fujimoto J, Sun WS, Tamaya T. Clinical implications of steroid receptor coactivator㧙㧙

IF 1.597

IF 0.833
IF 1.597

IF 1.597
IF 0.833
IF 0.833
IF 3.165
IF 2.844

IF 1.144
IF 2.024

IF 1.157
IF 4.390

IF 1.597
IF 3.398
IF 1.144
IF 0.833
IF 1.724

IF 1.157
IF 4.875

IF 1.597
IF 2.024
IF 1.597
IF 2.444

IF 0.587

IF 0.587
IF 4.635

(SRC) -3 in uterine endometrial cancers. J Steroid Biochem Mol Biol. 2007;104:237-240.
28㧕 Fujimoto J, Alam SM, Jahan I, Sato E, Sakaguchi H, Tamaya T. Clinical implication of
estrogen-related receptor (ERR) expression in ovarian cancers. J Steroid Biochem Mol Biol.
2007;104:301-304.
29㧕 Jahan I, Fujimoto J, Alam SM, Sato E, Sakaguchi H, Tamaya T. Role of protease activated receptor-2
in tumor advancement of ovarian cancers. Ann Oncol. 2007;18:1506-1512.
30㧕 Imai A, Toyoki H, Furui T. Electronic door interference mimicking distress in fetal monitoring. Int J
Gynaecol Obstet. 2007;99:60-61.
31㧕 Niwa K, Onogi K, Wu Y, Mori H, Tamaya T. Primary endodermal sinus tumor of the vulva in a 52-yearold woman with long-term survival: a cace report. Eur J Gynaec Oncol. 2007;28:506-508.
32㧕 Niwa K, Onogi K, Yun W, Hirose Y, Tamaya T. Primary lymphoma of the uterine corpus: An unusual
location for a common disease-case report. Eur J Gynaec Oncl. 2007;28:522-523.
33㧕 Imai A, Toyoki H, Furui T, Nagao N. Maternal small bowel volvulus hindered by prodromal labor.
Gynecol Surg. 2007;28:16-18.
34㧕 Imai A, Matsunami K, Takagi H. Preoperative value of CT angiography in the laparoscopic removal of
rudimentary uterine horn. Gynecol Surg. 2007;14:199-200.
35㧕 Furui T, Ohno T, Imai A. Preterm labor in cases with high testosterone condition. J Obstet Gynaecol.
2007;27:155-156.
36㧕 Mizuno T, Imai A, Hirose Y. Skeletal muscle metastatic and pelvic leiomyosarcomas following
hysterectomy. Int J Gynecol Obstet. 2007;96:49-50.
37㧕 Niwa K, Onogi K, Wu Y, Mori H, Inoue Y, Tamaya T. Prognostic implications of cimetidine on advanced
serous ovarian carcinoma related to cyclooxygenase-2 expression. Mol Med Rep. 2008;1:119-122.
38㧕 Alam SM, Fujimoto J, Jahan I, Sato E, Tamaya T. Coexpression of EphB4 and ephrinB2 in tumour
advancement of ovarian cancers. Brit J Cancer. 2008;98:845-851.
39㧕 Sato E, Fujimoto J, Tamaya T. Expression of IP-10 related to angiogenesis in uterine endometrial
cancers. Oncology-Basel. 2008;73:246-251.
40㧕 Niwa K, Onogi K, Wu Y, Mori H, Harrigan R C, Tamaya T. Clinical implication of
medroxyprogesterone acetate against advanced ovarian carcinoma: a pilot study. Eur J Gynaecol
Oncol. 2008;29:252-255.
41㧕 Jahan I, Fujimoto J, Mahfuzul Alam S, Sato E, Tamaya T. Role of protease activated receptor-2 inlymph node metastasis of uterine cervical cancers. BMC Cancer. 2008;8:301-307.
42㧕 Kato H, Kanematsu M, Furui T, Imai A, Hirose Y, Kondo H, Goshima S, Tsuge Y. Carcinosarcoma of
the uterus. radiologic-pathologic correlations with magnetic resonance imaging including
diffusion-weighted imaging. Magn Reson Imaging. 2008;26:1446-1450.
43㧕 Maw MK, Fujimoto J, Tamaya T: Expression of inhibitor of DNA binding (ID)-1 protein as anangiogenic mediator in tumor advancement of uterine cervical cancers. Brit J Cancer.
2008;99:1557-1563.

IF 2.799

IF 2.799
IF 4.875
IF 1.144
IF 0.587
IF 0.587

IF 0.883
IF 1.144

IF 4.635
IF 2.444

IF 0.587
IF 2.709

IF 1.486

IF 4.6354㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦ਤ⠀ᙗม㧘⎇ⓥಽᜂ⠪㧦₹⥢ノᒾ㧧ᐔᚑ 18 ᐕᐲ⽷࿅ᴺੱᣣᧄṽᣇකቇ⎇ⓥഥᚑ㊄㧦ṽᣇ⵾೷ߦࠃࠆォ⒖ᛥ೙૞↪ߣ㐳ᦼ੍ᓟ㧘ⴊ▤ᣂ↢࿃ሶ CD105㧘COX㧙2 ⊒⃻ߣߩ㑐ㅪ㧧ᐔᚑ 18 ᐕᐲ㧧500 ජ౞2㧕 ⎇ⓥઍ⴫⠪㧦ဈญ⧷᮸㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦ࠛࠬ࠻ࡠࠥࡦଐሽᕈᇚੱ⑼⣲≌ߦ߅ߌࠆォ౮࿃ሶߩ⊒⃻ߣߘߩ⥃ᐥ⊛ᗧ⟵㧧ᐔᚑ 19㧙20 ᐕᐲ㧧3,860 ජ౞(1,000㧦2,860 ජ౞)
3㧕 ੹੗◊ᔒ㧦⤑ฃኈ૕࡝ࠟࡦ࠼ߩ⚦⢩Ქᕈࠕ࠽ࡠࠣࠍ↪޿ߚ᛫≸ൻቇ≮ᴺߣࡔࠞ࠾࠭ࡓ㧧ᐔᚑ 19 ᐕᐲጘ㒂ᄢቇᵴᕈൻ⚻⾌(⎇ⓥ)㧧ᐔᚑ 19 ᐕᐲ㧧1,130 ජ౞
2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥ1㧕 ੹੗◊ᔒ㧦㇭਄Ꮢߦ߅ߌࠆ↥⑼ක≮ߩ⃻⁁ߣᡷༀ㧧ᐔᚑ 20 ᐕᐲ㧧2,000 ජ౞㧦㇭਄Ꮢ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫ
ߥߒ

㧙㧙

6㧚ቇળᵴേ
1㧕ቇળᓎຬ੹੗◊ᔒ㧦
1㧕 ᣣᧄ↥⑼ᇚੱ⑼ቇળઍ⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ↢ᱺකቇળઍ⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄౝಽᴲቇળઍ⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄ↢ᱺౝಽᴲቇળઍ⼏ຬ(㨪⃻࿷)5㧕 ᣣᧄᇚੱ⑼⣲≮ቇળ⹏⼏ຬ(㨪⃻࿷)⮮ᧄᰴ⦟㧦1㧕 ᣣᧄ↥⑼ᇚੱ⑼ቇળઍ⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄᇚੱ⑼⣲≌ቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᇚੱ⑼ᖡᕈ⣲≌⑼ቇ≮ᴺ⎇ⓥᯏ᭴ળᆔຬ(ᐔᚑ 19 ᐕ 1 ᦬ 31 ᣣ㨪⃻࿷)
4㧕 ᣣᧄౝಽᴲቇળઍ⼏ຬ(㨪⃻࿷)5㧕 ᣣᧄࠬ࠹ࡠࠗ࠼ࡎ࡞ࡕࡦቇળ⹏⼏ຬ(㨪⃻࿷)6㧕 ᣣᧄ↢ᱺౝಽᴲቇળ⹏⼏ຬ(㨪⃻࿷)દ⮮⋥᮸㧦1㧕 ᣣᧄᇚੱ⑼⣲≌ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄᲣᕈⴡ↢ቇળ⹏⼏ຬ(㨪⃻࿷)ਤ⠀ᙗม㧦1㧕 ᣣᧄᇚੱ⑼⣲≌ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄౝಽᴲቇળઍ⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ↢ᱺౝಽᴲቇળ⹏⼏ຬ(㨪⃻࿷)ฎ੗ㄖ㇢㧦1㧕 ᣣᧄ↢ᱺකቇળਛㇱᡰㇱ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ↥ᇚੱ⑼੃≸ቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ↢ᱺౝಽᴲቇળ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
⮮ᧄᰴ⦟㧦
1㧕 International Journal of Clinical Oncology: Editorial Board(㨪⃻࿷)7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳₹⥢ノᒾ㧦
1㧕 ╙ 58 ࿁ᣣᧄ↥⑼ᇚੱ⑼ቇળ(ᐔᚑ 18 ᐕ 4 ᦬㧘ᮮᵿ㧘․೎⻠Ṷ‫ߣࡦࡕ࡞ࡎޟ‬ᇚੱ⑼⣲≌㧙੍㒐කቇ෸߮ᴦ≮කቇߩ஥㕙ࠃࠅ㧙‫ޠ‬Ṷ⠪)
2㧕 ╙ 6 ࿁ਛㇱ᳇ಽ࡮ਇ቟㓚ኂ(ᐔᚑ 18 ᐕ 6 ᦬㧘ฬฎደ㧘․೎⻠Ṷ‫ޟ‬ᕈࠬ࠹ࡠࠗ࠼ߣᅚᕈᔃり∝‫ޠ‬Ṷ⠪)
3㧕 ╙ 40 ࿁ᣣᧄᇚੱ⑼⣲≌ቇળ(ᐔᚑ 18 ᐕ 7 ᦬㧘ጘ㒂㧘ળ㐳⻠Ṷ‫ޟ‬ሶች㗖≸ᚻⴚߩ▤ℂߦ߅ߌࠆឭ⸒ߣ
ߘߩᩮ᜚‫ޠ‬Ṷ⠪)ਃ㡞ᑝ❥㧦
1㧕 ╙ 54 ࿁ᣣᧄൻቇ≮ᴺቇળ✚ળ(ᐔᚑ 18 ᐕ 5 ᦬㧘੩ㇺ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ህ᳇ᕈ⩶ᗵᨴ∝ᴦ≮ߩࠟࠗ࠼࡜ࠗࡦ‫ޠ‬Ṷ⠪)2㧕 ╙ 54 ࿁ᣣᧄൻቇ≮ᴺቇળ⷏ᣣᧄᡰㇱ✚ળ(ᐔᚑ 18 ᐕ 12 ᦬㧘⑔ጟ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬᛫⩶⮎㑐ㅪਅ∯∝㧛⣺Ἳߩ⃻⁁ߣ⺖㗴㧙ᗵᨴ೙ᓮቇ߆ࠄߺߚൻቇ≮ᴺߩ޽ࠅᣇ㧙‫ޠ‬Ṷ⠪)3㧕 16th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) (2006.04,
Nice, Symposium: The penetration of telithromycin in gynaecological tissues and activity in㧙㧙cervicitis patients; Ṷ⠪)4㧕 44th Annual Meeting Infectious Diseases Society of America (2006.10, Toronto, Symposium:
Mycoplasma genitalium in Japanese patients with uterine cervicitis; Ṷ⠪)੹੗◊ᔒ㧦1㧕 ╙ 1 ࿁᧲੩੃߇ࠎࡈࠜ࡯࡜ࡓ(ᐔᚑ 19 ᐕ 2 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᅚᕈࡎ࡞ࡕࡦߣ੃߇ࠎ Q&A‫ޠ‬Ṷ⠪)
2㧕 ╙ 59 ࿁ᣣᧄ↥⑼ᇚੱ⑼ቇળቇⴚ⻠Ṷળ(ᐔᚑ 19 ᐕ 4 ᦬㧘੩ㇺ㧘ᢎ⢒⻠Ṷ‫ޟ‬ෆᎽ⣲≌‫ޠ‬ᐳ㐳)
3㧕 ╙ 8 ࿁↢ᱺකቇ࡮↢‛ቇ⎇ⓥળࠪࡦࡐࠫ࠙ࡓ(ᐔᚑ 19 ᐕ 7 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ൻቇ≮ᴺਛߩᕈ⣼଻⼔‫ޠ‬Ṷ⠪)⮮ᧄᰴ⦟㧦
1㧕 17th International Symposium of the Journal of Steroid Biochemistry and Molecular Biology(2006.05, Seefeld, Symposium: Estrogen-related receptor (ERR) expression in ovarian cancers;Ṷ⠪)2㧕 The 5th International Symposium on Cancer Research and Therapy (2006.02, Tokyo,Symposium: Novel therapeutic strategy for hormone-dependent endometrial cancers; Ṷ⠪)3㧕 ╙ 40 ࿁ᣣᧄᇚੱ⑼⣲≌ቇળ(ᐔᚑ 18 ᐕ 7 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ሶች૕≸ߦ߅ߌࠆⴊ▤ᣂ↢߆ࠄߺߚ੍ᓟ࿃ሶ‫ޠ‬Ṷ⠪)
4㧕 ╙ 80 ࿁ᣣᧄౝಽᴲቇળ(ᐔᚑ 19 ᐕ 6 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ሶችౝ⤑ߦ߅ߌࠆⴊ▤ᣂ↢ߣෆᎽࡎ࡞ࡕࡦ‫ޠ‬Ṷ⠪)
5㧕 ╙ 9 ࿁ࡎ࡞ࡕࡦߣ≸⎇ⓥળ(ᐔᚑ 20 ᐕ 6 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ሶችౝ⤑≸ߦ߅ߌࠆࡎ࡞ࡕࡦଐ
ሽᕈ༚ᄬߣⴊ▤ᣂ↢‫ޠ‬Ṷ⠪)6㧕 18th International Symposium of the Journal of Steroid Biochemistry and Molecular Biology(2008.09, Seefeld, Clinical implication of estrogen-related receptor (ERR) expression in uterine
endometrial cancers; Ṷ⠪)7㧕 8th International Conference of Anticancer Research (2008.10, Kos, Special lecture, Novel
strategy of anti-angiogenic therapy for uterine cervical cancers; Ṷ⠪)8㧕 The 6th International Symposium on Cancer Research and Therapy (2008.11, Tokyo,
Symposium, Anti-vasculr endothelial growth factor (VEGF) therapeutic strategy for
gynecological cancers; Ṷ⠪)ਤ⠀ᙗม㧦1㧕 ╙ 7 ࿁ࡎ࡞ࡕࡦߣ≸⎇ⓥળ(ᐔᚑ 18 ᐕ 6 ᦬㧘⟲㚍㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᬀ‛ࠛࠬ࠻ࡠࠥࡦߣሶች૕≸‫ޠ‬Ṷ⠪)
2㧕 ╙ 40 ࿁ᣣᧄᇚੱ⑼⣲≌ቇળ(ᐔᚑ 18 ᐕ 7 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓ‫⧯ޟ‬ᐕᕈሶችౝ⤑≸ߦኻߔࠆᅧሺ
᷷ሽᴦ≮ߣߘߩ outcome‫ޠ‬Ṷ⠪)
3㧕 ╙ 44 ࿁ᣣᧄ≸ᴦ≮ቇળ✚ળ(ᐔᚑ 18 ᐕ 10 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ሶች૕≸ߦኻߔࠆㆬᛯ⊛ COX
㧙2 ೙ᓮ೷ߣ MEKinhibitor ߦࠃࠆ೙ᓮ૞↪ߣൻቇ੍㒐‫ޠ‬Ṷ⠪)ฎ੗ㄖ㇢㧦
1㧕 ╙ 16 ࿁⥃ᐥౝಽᴲઍ⻢ Update(ᐔᚑ 18 ᐕ 3 ᦬㧘㊄ᴛ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᅧᆼਛߩࠕࡦ࠼ࡠࠥࡦㆊ೾
∝‫ޠ‬Ṷ⠪)
૒⮮⧷ℂሶ㧦
1㧕 ╙ 28 ࿁ࠛࡦ࠼ࡔ࠻࡝ࠝ࡯ࠪࠬ⎇ⓥળ(ᐔᚑ 19 ᐕ 1 ᦬㧘๺᱌ጊ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ሶችౝ⤑∝ߦ߅ߌࠆⴊ▤ᣂ↢‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ
ߥߒ

㧙㧙

9㧚␠ળᵴേ੹੗◊ᔒ㧦
1㧕 ጘ㒂࿾ᣇⵙ್ᚲኾ㐷ᆔຬ(㨪ᐔᚑ 20 ᐕ 6 ᦬)
2㧕 ጘ㒂⋵․ቯਇᅧᴦ≮ഥᚑ੐ᬺᜰቯක≮ᯏ㑐ክᩏᆔຬ(ᐔᚑ 19 ᐕ 12 ᦬㨪⃻࿷)3㧕 ጘ㒂⋵๟↥ᦼක≮ද⼏ળᆔຬ(ᐔᚑ 19 ᐕ 7 ᦬㨪⃻࿷)4㧕 ጘ㒂⋵ᅧ↥ᇚ✕ᕆ៝ㅍㅪ⛊ળ⼏ᆔຬ(㨪⃻࿷)5㧕 ጘ㒂⋵කᏧળᲣ૕଻⼔ᴺᜰቯකክᩏᆔຬળᆔຬ(ᐔᚑ 20 ᐕ 5 ᦬㨪⃻࿷)ฎ੗ㄖ㇢㧦1㧕 ጘ㒂⋵․ቯਇᅧᴦ≮ഥᚑ੐ᬺᣉ⸳ክᩏຬ(ᐔᚑ 19 ᐕᐲ㨪⃻࿷)2㧕 ጘ㒂⋵ᅧ↥ᇚ✕ᕆ៝ㅍㅪ⛊ળ⼏ᆔຬ(㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ਤ⠀ᙗม㧦㓸࿅ᬌ⸻ߦ߅ߌࠆሶችౝ⤑⚦⢩⸻ߦࠃࠆሶችౝ⤑∛ᄌߩᣧᦼ⊒⷗ߣ COX㧙2 ⊒⃻㧦╙ 33࿁ฬฎደ౏ⴐකቇ⎇ⓥᚲ 㓸࿅ᬌ⸻⎇ⓥ㐿⊒ഥᚑ㊄੤ઃႎ๔ᦠ(2006 ᐕ 3 ᦬)
2㧕 ਤ⠀ᙗม㧦ෆᎽ≸㧘ሶችౝ⤑⊒≸ߦኻߔࠆṽᣇ⵾೷ߩ૞↪ߣࠪࠣ࠽࡞વ㆐ߦ㑐ߔࠆ⎇ⓥ㧦ᣣᧄṽᣇකቇ⎇ⓥᚲ ᐔᚑ 17 ᐕᐲ⎇ⓥഥᚑߦ㑐ߔࠆႎ๔ᦠ(2007 ᐕ 1 ᦬)
11㧚ႎ㆏
1㧕 ੹੗◊ᔒ㧘₹⥢ノᒾ㧦ᚻⴚᢙߢࠊ߆ࠆ‫∛޿޿ޟ‬㒮‫ޠ‬㧙ᅚᕈߩ߇ࠎ㧙㧦ㅳ㑆ᦺᣣ(2006 ᐕ 12 ᦬ 15 ᣣ)
2㧕 ਤ⠀ᙗม㧦╙ 33 ࿁ฬฎደ౏ⴐකቇ⎇ⓥᚲ 㓸࿅ᬌ⸻⎇ⓥ㐿⊒ഥᚑ㊄⿅๒ᑼ㧦Ფᣣᣂ⡞(2006 ᐕ 3 ᦬
2 ᣣ)
3㧕 ੹੗◊ᔒ㧦ᚻⴚᢙߢࠊ߆ࠆ޿޿∛㒮(ో࿖㧒࿾ᣇ೎࡜ࡦࠠࡦࠣ)㧦ㅳೀᦺᣣ⥃ᤨჇೀภ(2007 ᐕ 3 ᦬ 5
ᣣ)4㧕 ੹੗◊ᔒ㧦⋵ౝ 6 ∛㒮 ↥⑼ 3 ∛㒮ߦ㓸⚂㧦ਛᣣᣂ⡞(2007 ᐕ 10 ᦬ 4 ᣣ)㧦ጘ㒂ᣂ⡞(2007 ᐕ 10 ᦬ 11 ᣣ)
5㧕 ੹੗◊ᔒ㧦⠀ፉᏒ᳃∛㒮↥⑼㧘ᐕౝߢભᱛ‫ޟ‬ㄭ㓞ߦ∛㒮లታ‫ޠ‬
6㧕 ੹੗◊ᔒ㧦⠀ፉᏒ᳃∛㒮಴↥ኻᔕ㧦ਛᣣᣂ⡞(2007 ᐕ 10 ᦬ 11 ᣣ)
7㧕 ੹੗◊ᔒ㧦⠀ፉᏒ᳃∛㒮޽ࠅᣇᆔຬળ㧦↥⑼ભᱛ㧘㓸⚂㧦Ფᣣᣂ⡞(2007 ᐕ 10 ᦬ 11 ᣣ)
8㧕 ੹੗◊ᔒ㧦3 ∛㒮߇↥⑼ભᱛ㧦⺒ᄁᣂ⡞(2007 ᐕ 10 ᦬ 11 ᣣ)
9㧕 ੹੗◊ᔒ㧦ᅧᇚ៝ㅍవ කᏧ߇್ᢿ ߚࠄ޿࿁ߒ㒐ᱛ㧦ᦺᣣᣂ⡞(2007 ᐕ 10 ᦬ 19 ᣣ)
10㧕 ੹੗◊ᔒ㧦ක≮ߪ੹‫ޟ‬ᅧᇚฃߌ౉ࠇ࿎㔍 ᰴߩ៝ㅍవ‫ޠ‬㧦ਛᣣᣂ⡞(2007 ᐕ 10 ᦬ 23 ᣣ)
11㧕 ੹੗◊ᔒ㧦߅↥ߩ቟ోߪ㧦ᦺᣣᣂ⡞(2007 ᐕ 10 ᦬ 26 ᣣ)
12㧕 ੹੗◊ᔒ㧦ᅧᇚ៝ㅍవ㧘↥⑼ක߇್ᢿ㧦⋵ౝోၞߦ᜛ᄢ߳㧦ᦺᣣᣂ⡞(2007 ᐕ 11 ᦬ 23 ᣣ)
13㧕 ੹੗◊ᔒ㧦∛㒮ߩታജ(ᇚੱ⑼≸)㧦⺒ᄁᣂ⡞(2007 ᐕ 12 ᦬ 23 ᣣ)
14㧕 ੹੗◊ᔒ㧦⋵ౝᅧᇚ៝ㅍࠪࠬ࠹ࡓ㧦ጘ㒂ᣂ⡞(2007 ᐕ 12 ᦬ 25 ᣣ)
15㧕 ੹੗◊ᔒ㧦[07 ߉߰ࠍᝄࠅ㄰ࠆ]㧨11㧪ᅧᇚߩߚࠄ޿࿁ߒ໧㗴㧦ᦺᣣᣂ⡞(2007 ᐕ 12 ᦬ 28 ᣣ)
16㧕 ੹੗◊ᔒ㧦޿޿∛㒮 2008㧦ㅳೀᦺᣣ MOOK(2008 ᐕ 1 ᦬ 30 ᣣ)
17㧕 ੹੗◊ᔒ㧦ኾ㐷ක߇ផ⮈‫᧲ޟ‬ᶏ࡮↲ା⿧ߩኅᐸක‫ޠ‬25 ੱ㧦AERA2008 ᐕ 2 ᦬ 18 ᣣภ(2008 ᐕ 2 ᦬
18 ᣣ)㧦ጘ㒂࡜ࠫࠝ(2008 ᐕ 4 ᦬ 2 ᣣ)
18㧕 ੹੗◊ᔒ㧦ጘ㒂⋵කᏧળ࡜ࠫࠝࡎ࡯ࡓ࠼ࠢ࠲࡯‫ޟ‬ೋ⚻(ೋầ)ߩㆃࠇ‫ޠ‬
19㧕 ੹੗◊ᔒ㧦ጘ㒂⋵කᏧળ࡜ࠫࠝࡎ࡯ࡓ࠼ࠢ࠲࡯‫ޟ‬ዊఽᦼߩᕈེ಴ⴊ‫ޠ‬㧦ጘ㒂࡜ࠫࠝ(2008 ᐕ 4 ᦬ 25
ᣣ)20㧕 ੹੗◊ᔒ㧦๮ࠍߟߥߋ㧨ਇᅧᴦ≮ߩⓨ⊕࿾Ꮺ㧪㧦ጘ㒂ᣂ⡞(2008 ᐕ 5 ᦬ 9 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔᒰೋߩ⋡ᮡߦㄭߠ߈ߟߟ޽ࠆ߇㧘ࡍ࡯ࠬ࠳࠙ࡦߩᗵ߇ߧߋ߃ߥ޿‫ޕ‬ᬺ❣ߢߪ‫ޟ‬ᢙ‫⋡ࠍޠ⾰ޟࠅࠃޠ‬ᜰߒߡ޿ࠆ߇㧘↥⑼ක≮ߩෂᯏ߇ต߫ࠇߡ޿ࠆᤨὐߢߪ‫ޟ‬น‫⹏ߣ߁ࠈ޽ߢޠ‬ଔߒߡ޿ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ࡑࡦࡄࡢ࡯ߩਇ⿷߇ᦨᄢߩ໧㗴ὐߢ޽ࠆ‫ୃ⎇ޕ‬ක೙ᐲ߇ࠬ࠲࡯࠻ߒߡ 5 ᐕ⋡ࠍㄫ߃㧘ᐕ‫ޘ‬ᄢቇ㒮↢ߩ⏕଻߇㔍ߒߊߥߞߡ߈ߡ޿ࠆ‫ޕ‬Ⓧᭂ⊛ߥ␠ળੱᨒߩዉ౉߿ᄖ࿖ੱ⇐ቇ↢ߩฃߌ౉ࠇߦࠃߞߡ㧘⎇ୃකᄢቇ㒮↢ߩ࡞࡯࠻߇⏕┙ߢ߈ࠆ߹ߢਸ਼ࠅಾࠅߚ޿‫ޕ‬㧙㧙⢻₸⊛ߥ⎇ⓥᤨ㑆ߩ⏕଻߇಴᧪ࠆࠃ߁੹߹ߢએ਄ߦദജߒߚ޿‫ޕ‬੹ᓟߩዷᦸ⥃ᐥ⑼ߦ߅ߌࠆ⎇ⓥߪ㧘⥃ᐥߩ႐ߦㆶరߔࠆߎߣ߇೨ឭߢ޽ࠆ‫ߪߦ߼ߚߩߘޕ‬㧘⥃ᐥኅߣߒߡߩ⍮⼂࡮
ᛛ㊂ߦട߃ߡ㧘৻ቯߩ࡟ࡌ࡞ߩၮ␆⊛ߥ⍮⼂࡮ᚻᴺ߇ᔅⷐߢ޽ࠆ‫߽߆ߒޕ‬㧘ࠃࠅ㜞޿࡟ࡌ࡞ߩၮ⋚ߪ㧘ᔕ↪ߩ▸࿐ࠍࠃࠅ৻ጀᐢߍࠆߎߣ߇಴᧪ࠆ‫ޕ‬ᓥߞߡ㧘ᄢቇ㒮ᢎ⢒ߢߪ㧘࿖㓙⊛ߥ┹੎ജߩ޽ࠆ⎇ⓥ⠪ߩ㙃ᚑࠍ⋡ᜰߒߚ޿‫ޕ‬⎇ⓥ⚻㛎ߪ໧㗴⸃᳿ဳᕁ⠨ߩṑ㙃ߣߥࠅ㧘߭޿ߡߪ㜞ᐲኾ㐷⡯ᬺੱߣߒߡߩఝࠇߚ⥃ᐥකࠍ㙃ᚑߔࠆߎߣߦ❬߇ࠈ߁‫↢ޕ‬๮⃻⽎ߩᩮరߦㄼࠆၮ␆⊛࡮⁛ഃ⊛ߥ⎇ⓥࠍ⋡ᜰߒߚ޿‫ޕ‬ᓧࠄࠇߚᚑᨐ߿ၭࠊࠇߚ
ᕁ⠨ㆊ⒟࡮⍮⼂࡮ᚻᴺߪ㧘ක♽ᄢቇߩ૶๮ߢ޽ࠆ㔍ᴦᕈ∔ᖚߩ∛࿃⸃᣿߿ᣂߒ޿⸻ᢿ࡮ᴦ≮ᣇᴺߩ㐿⊒ߦ⋥⚿ߒ㧘⥃ᐥߩ⃻႐߳ߩㆶర߇ᦼᓙߢ߈ࠆ‫ޕ‬⹜㛎▤⊛ߥၮ␆⎇ⓥߩ⥃ᐥᔕ↪ߩߺߥࠄߕ㧘㓸Ⓧߒߚ∝଀ߩౣ⠨߿ઁಽ㊁ߣߩ౒ห⎇ⓥߦ߽Ⓧᭂ⊛ߦෳടߒߚ޿‫⎇ޕ‬ⓥߪᧂ⍮߳ߩ࠴ࡖ࡟ࡦࠫߢ޽ࠆߚ߼㧘ၮ␆⎇ⓥ࡮⥃ᐥ⎇ⓥࠍㅢߓߡᓥ᧪ߩᚻᛛ࡮ᚻᴺࠍ
ౣ⠨ߢ߈㧘ࠃࠅ቟ోߢ⏕ታߥ⸻ᢿ࡮ᴦ≮ࠍᏱߦㅊ᳞ߔࠆࠪࠬ࠹ࡓ૞ࠅࠍߒߚ޿‫ޕ‬㧙㧙㧔7㧕᡼኿✢කቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
1㧕 ⣻ㇱ⤳ེ㑐ㅪ㧦⣻ㇱ⤳ེᖡᕈ⣲≌ߩ CT㧘MRI ⸻ᢿࠍਥߥ⎇ⓥ⺖㗴ߣߒߡ޿ࠆ‫▤ⴊߦ․ޕ‬ㅧᓇਅ CT㧘
࠳ࠗ࠽ࡒ࠶ࠢㅧᓇ MRI㧘⿥Ᏹ⏛ᕈ㉄ൻ㋕ㅧᓇ MRI ࠍ↪޿ߚ⢄߇ࠎ㧘⤟߇ࠎߩᣧᦼ⸻ᢿ㧘ⴚ೨⸻ᢿߦ
㑐ߔࠆ⎇ⓥߥࠄ߮ߦ✕ᕆႧᩖⴚ㧘ⴚ೨Ⴇᩖⴚߥߤߩࠗࡦ࠲࡯ࡌࡦ࡚ࠪ࠽࡞࡜ࠫࠝࡠࠫ࡯㧔IVR㧕ߪ㧘․╩ߒߚᬺ❣ࠍ޽ߍߡ߈ߚ‫ߚ߹ޕ‬㧘ᶖൻ▤㑐ㅪߦ㑐ߒߡ߽ MDCT ࠍ㚟૶ߒߚ઒ᗐౝⷞ㏜ߦ㑐ߔࠆ⎇ⓥ߽㗅⺞ߦㆀⴕߒߡ޿ࠆ‫ޕ‬
2㧕 ਛᨔ␹⚻࡮ᩭකቇ㑐ㅪ㧦ోಽ㊁㧘⸻≮⑼ߣߩ౒หߩర㧘⣖ MRI㧘⣖ⴊᵹ SPECT ߥߤਛᨔ␹⚻ߩ↹௝⸻ᢿ࡮ᩭකቇߩᬌ⸛ߥߤࠍਥ૕ߣߒߡ߈ߚ‫ߡߞ߇ߚߒޕ‬㧘functional MRI ߦࠃࠆ⣖ᯏ⢻⹏ଔ㧘⣖ⴊᵹߩ SPECT ߩቯ㊂ൻߥߤ㑐ߔࠆ⎇ⓥߦ߽ขࠅ⚵ࠎߢ߈ߚ‫ޕ‬
3㧕 ᡼኿✢ᴦ≮㑐ㅪ㧦3 ᰴరᾖ኿ߩ૕ᐙㇱ⣲≌߳ߩᔕ↪㧘ቯ૏ᚻⴚ⊛᡼኿✢ᴦ≮ߩ⣖⣲≌߳ߩᔕ↪㧘᦭∩ᕈ㛽ォ⒖ߦኻߔࠆ⥋ㆡᾖ኿ᴺߩᬌ⸛߿๟ⴚᦼ⚵❱ౝᾖ኿ߩᬌ⸛ߥߤࠍⴕߞߡ߈ߚ‫ߚ߹ޕ‬㧘೨┙⣼≸ߦኻߔࠆዊ✢Ḯᴦ≮ߪ 2004 ᐕߦ᧲ᶏ࿾඙ߢೋ߼ߡᣉⴕߐࠇ㧘ߘߩᓟ⦟ᅢߥᚑ❣ࠍ෼߼ߡ޿ࠆ߇㧘CT㧘
MRI ࠍ↪޿⥋ㆡ✢㊂⹏ଔᴺࠍ㐿⊒ߒߡ߈ߚߎߣ߽㜞޿⹏ଔࠍฃߌߡ޿ࠆ‫ޕ‬4㧕 CAD 㑐ㅪ㧦ࠦࡦࡇࡘ࡯࠲ߦࠃࠆ↹௝⸻ᢿᡰេࠪࠬ࠹ࡓߢ޽ࠆࠦࡦࡇࡘ࡯࠲⸻ᢿᡰេࠪࠬ࠹ࡓ㧔CAD㧕ߪ㧘ౣ↢ಽሶ⛔ᓮቇ⻠ᐳ㧘⍮⢻ᖱႎࠗࡔ࡯ࠫಽ㊁ߩᓧᗧߣߔࠆ⎇ⓥಽ㊁ߢ޽ࠅ㧘ᘟᕈ⢄∔ᖚߩ⸻ᢿ㧘੃≸ߩ⸻ᢿ㧘⥃ᐥᔕ↪ߦ౒ห⎇ⓥࠍⴕ޿㧘㜞ᐲߥᚑᨐࠍ᜼ߍߡ߈ߚ‫੹ޕ‬ᓟ㧘ߐࠄߦઁࡕ࠳࡝࠹ࠖ㧘ઁ⤳ེ߳ߩᔕ↪ࠍᬌ⸛ߒߡ޿ࠆ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
ᤊ ඳᤘ
ಎᢎ᝼㧦
ᨋ ⌀਽
ಎᢎ᝼(૬છ)㧦 ౗᧻㓷ਯ
ㄭ⮮ᶈผ
⻠Ꮷ㧦
ᵻ㊁㓉ᒾ
⻠Ꮷ㧦
ട⮮ඳၮ
⥃ᐥ⻠Ꮷ㧦
੖ፉ ⡡
⥃ᐥ⻠Ꮷ㧦
ᄢቲ๺ඳ
⥃ᐥ⻠Ꮷ㧦
㥱⮮⡡ሶ
⥃ᐥ⻠Ꮷ㧦
ዊፉኼਭ
⥃ᐥ⻠Ꮷ㧦
ᵻ↰ୃᏒ
ഥᢎ㧦
᧖ፒ࿻ሶ
කຬ㧦
ᨷᬀ⵨੺
කຬ㧦
ᷰㆻᤐᄦ
කຬ㧦
’↰ᥓ⹷ሶ
කຬ㧦
↰ਛ⑲๺
කຬ㧦

Hiroaki Hoshi
Shinya Hayashi
Masayuki Kanematsu
Hiroshi Kondo
Takahiko Asano
Hiroki Kato
Satoshi Goshima
Kazuhiro Ohtakara
Akiko Saitoh
Toshihisa Kojima
Syuichi Asada
Keiko Sugisaki
Yusuke Tuge
Haruo Watanabe
Chiyoko Makita
Hidekazu Tanaka

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ੖ፉ ⡡㧘౗᧻㓷ਯ㧚౗᧻㓷ਯ✬㧘㜞ᯅ㓷჻⋙㧚MRI㧙᠟௝ߩ⠨߃ᣇߣ⸻ᢿቇ࡟ࡆࡘ࡯㧙 ╙ 3 Ꮞ ߎࠇߛߌ߅ߐ߃ࠇ߫ᄢਂᄦ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2006 ᐕ㧦50㧙68㧚
2㧕 ౗᧻㓷ਯ㧘ㄭ⮮ᶈผ㧘੖ፉ ⡡㧘ᨷᬀ⵨੺㧘㋈ᧁ↱㉿㧚⷏᧛ᕡᒾ㧘ጊ↰ ᗆ㧚દ⮮ඳᢅ✬㧚⢄⤳ߩἠᵹ㧔࠳ࠗ࠽ࡒ࠶ࠢ㧕MRI㧦Diffusion࡮perfusion MRI ৻ᦸජ㉿ 3 Ꮞ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2006 ᐕ㧦
144㧙153㧚3㧕 ട⮮ඳၮ㧘౗᧻㓷ਯ㧚᪀㢬⦟ᐔ✬㧘࿯ደ৻ᵗ⋙㧚ߢ߈ࠆ㧍↹௝⸻ᢿ౉㐷ࠪ࡝࡯࠭⣻ㇱ࡮㛽⋚ ↹௝⸻ᢿߩߎߎ߇㐓೎ࡐࠗࡦ࠻ 3 Ꮞ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦36㧙53㧚⪺ᦠ㧔᰷ᢥ㧕
1㧕 Leonardou P, Pappas P, Kanematsu M. The role of US in the diagnosis of obstructive jaundice. Current
advances and perspectives. In: McMahon MJ, Filippou D, Skandalakis P, eds. Advances in obstructive
jaundice. Diagnosis and treatment. Athens: Paschalidis Medical Publications, Ltd; 2007:285-304.
2㧕 Onozuka M, Hirono Y, Tachibana A, Kim W, Ono Y, Sasaguri K, Kubo K, Niwa M, Kanematsu M,
Watanabe H. Interactions between chewing and brain activity in humans. In: Onozuka M, Yen CT, eds.
Novel trends in brain science. Brain imaging, learning and memery, stress and fear, and pain. Tokyo:
Springer; 2008:99-113.

㧙㧙✚⺑㧔๺ᢥ㧕1㧕 ੖ፉ ⡡㧘౗᧻㓷ਯ㧘ㄭ⮮ᶈผ㧘ᨷᬀ␭੺㧘ਃᅢ೑ᴦ㧘੗਄ᐽᒄ㧘⴩᢫⾫ม㧚਄⣻ㇱㅧᓇ MDCT ߩᦨㆡㅧᓇᴺ㧘INNERVISION 2006 ᐕ㧧21 Ꮞ㧦69㧙75㧚
2㧕 ᨷᬀ␭੺㧘౗᧻㓷ਯ㧘੖ፉ ⡡㧘ㄭ⮮ᶈผ㧘ട⮮ඳၮ㧘ᮮጊ㦖ੑ㇢㧘ਃᅢ೑ᴦ㧘᫃↰౏ඳ㧘੗਄ᐽᒄ㧘㜞੗శᴦ㧘⷏၂ᵗ৻㧘౷↰ᩕ৻㧘ᷡ᳓㆐ᴦ㧚⦟ᕈ⢄⣲≜߅ࠃ߮⣲≜᭽∛ᄌ㧘⥃ᐥ↹௝ 2006 ᐕ㧧22 Ꮞ㧦974
㧙984㧚
3㧕 ㄭ⮮ᶈผ㧘౗᧻㓷ਯ㧘੖ፉ ⡡㧘ട⮮ඳၮ㧘ᨷᬀ⵨੺㧚⢄ᖡᕈ⣲≌ߩⴊᵹേᘒ⸻ᢿ̆േᵈ CT ࠍਛᔃߦ㧘Radiology Frontier 2006 ᐕ㧧9 Ꮞ㧦25㧙30㧚
4㧕 ੖ፉ ⡡㧘౗᧻㓷ਯ㧚චੑᜰ⣺⣲≌ߩ 1 ଀㧘CLINICIAN 2007 ᐕ㧧55 Ꮞ㧦71㧙72㧘133㧙135㧚
5㧕 ട⮮ඳၮ㧘౗᧻㓷ਯ㧚㜞⏛႐ MRI ᤨઍߦ߅ߌࠆ㗡㗖ㇱ㗔ၞߩ↹௝⸻ᢿ㧘ᣣᧄ⏛᳇౒㡆ቇળ⹹ 2007 ᐕ㧧
27 Ꮞ㧦166㧙176㧚
6㧕 ዊፉኼਭ㧘ㄭ⮮ᶈผ㧘౗᧻㓷ਯ㧚੤ㅢᄖ்ᓟ㧘⁛ᱠߦߡ᧪㒮ߒߚ 60 ઍᅚᕈ㧘࡟ࠫ࠺ࡦ࠻ࡁ࡯࠻ 2007 ᐕ㧧
9 Ꮞ㧦1253㧙1254㧚
7㧕 ౗᧻㓷ਯ㧚ⓥᭂߩ਄⣻ㇱㅧᓇ CT ࠍ⋡ᜰߒߡ㧙ᵈ౉ᤨ㑆࿕ቯߣ Lean Body Weight ߢᦨㆡൻߒࠃ߁㧍㧘
Innervision 2007 ᐕ㧧22 Ꮞ㧦76㧙79㧚
8㧕 ㄭ⮮ᶈผ㧘౗᧻㓷ਯ㧘ᨷᬀ␭੺㧘੖ፉ ⡡㧚⢄㗔ၞߩ↹௝⸻ᢿ㧙MDCT ߦࠃࠆ⢄ߩᦨᣂ⸻ᢿ㧙㧘⥃ᐥ↹௝
2007 ᐕ㧧23 Ꮞ㧦850㧙858㧚
9㧕 ౗᧻㓷ਯ㧘ㄭ⮮ᶈผ㧘੖ፉ ⡡㧘ᨷᬀ␭੺㧘ᷰㄝᤐᄦ㧘ਃᅢ೑ᴦ㧘੗਄ᐽᒄ㧘⴩᢫⾫ม㧘౷↰㓶ᐔ㧘੗ᚭ㕏ม㧚․㓸 ㅧᓇ CT ߦ߅ߌࠆ⥋ㆡㅧᓇ೷ᛩਈᴺࠍតࠆ㧙⢄Ớᨴᒝᐲߣ࡛࡯࠼㊂ߩ㑐ଥ Lean Body
Weight㧔㒰⢽⢌૕㊀㧕ߢ⠨߃ࠃ߁㧍㧘ᤋ௝ᖱႎࡔ࠺ࠖࠞ࡞ 2007 ᐕ㧧39 Ꮞ㧦684㧙688㧚
10㧕 ㄭ⮮ᶈผ㧘౗᧻㓷ਯ㧘੖ፉ ⡡㧘ᨷᬀ␭੺㧘㐳↰⌀ੑ㧘ዊ᫪ల༹㧘ᑝἑༀା㧚Misdiagnosis ߦቇ߱ⴚ೨⸻
ᢿ㧙☼ᶧ↥↢⢙▤⚦⢩≸㧙㧘ᶖൻེ↹௝ 2007 ᐕ㧧9 Ꮞ㧦91㧙94㧚
11㧕 ᪀ේᅢㅧ㧘ㄭ⮮ᶈผ㧘੖ፉ ⡡㧘ᨷᬀ␭੺㧘౗᧻㓷ਯ㧚․㓸 ⢄඙ၞᕈ 㗔ၞᕈ⇣Ᏹߩ↹௝ߣ∛ᘒ 㕒⣂ⴊㆶᵹ⎕ᩰߩ↹௝ߣ∛ᘒ㧘ᶖൻེ↹௝ 2007 ᐕ㧧9 Ꮞ㧦167㧙172㧚
12㧕 ዊፉኼਭ㧘੖ፉ ⡡㧘౗᧻㓷ਯ㧚ᄙᓀߥᚲ⷗ࠍ๒ߔࠆ Common disease ߩ↹௝ᚲ⷗⢄㧙⚦⢩≸㧘ᶏ✎⁁ⴊ▤⣲㧘ォ⒖ᕈ⢄≸㧘⤟≸㧘ᘟᕈ⤟Ἳ㧘⥃ᐥ↹௝ 2008 ᐕ㧧24㧦1226㧙1235㧚
13㧕 ട⮮ඳၮ㧘౗᧻㓷ਯ㧘ㄭ⮮ᶈผ㧘੖ፉ ⡡㧘ᨷᬀ⵨੺㧘๟ ะᩕ㧘ේ ᱞผ㧘⮮↰ᑝᔒ㧚CAD ࠍ↪޿ߚ⢄⎬ᄌ∝ߩ MRI ⸻ᢿ㧘ᤋ௝ᖱႎ Medical 2008 ᐕ㧧40㧦470㧙473㧚
✚⺑㧔᰷ᢥ㧕
1㧕 Kanematsu M, Kondo H, Goshima S, Kato H, Tsuge U, Hirose Y, Kim MJ, Moriyama N. Imaging liver
metastases: Review and update. Eur J Radiol. 2006;58:217-228.
2㧕 Kanematsu M, Osada S, Amaoka N, Goshima S, Kondo H, Moriyama N. Expression of vascularendothelial growth factor in hepatocellular carcinoma and the surrounding liver: correlation with MR
imaging and angiographically assisted CT. Abdom Imaging. 2006;31:78-89.
ේ⪺㧔๺ᢥ㧕
1㧕 ੖ፉ ⡡㧘౗᧻㓷ਯ㧘ᬀ᧻ቁᐢ㧚Misdiagnosis ߦቇ߱㧘ⴚ೨⸻ᢿ㧙⢄⤥≌ࠍ⇼ߞߚ 1 ଀㧘ᶖൻེ↹௝ 2006
ᐕ㧧8 Ꮞ㧦5㧙8㧚
2㧕 Ꮉዥ வ㧘๟ ะᩕ㧘ᒛ ቇァ㧘ේ ᱞผ㧘⮮↰ᑝᔒ㧘ᮮጊ㦖ੑ㇢㧘ㄭ⮮ᶈผ㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚න
⚐ X ✢ CT ↹௝ߦ߅ߌࠆ⢄⤳ⴊ▤ߩ⥄௛᛽಴ᴺߩೋᦼᬌ⸛㧘ක↪↹௝ᖱႎቇળ㔀⹹ 2006 ᐕ㧧23 Ꮞ㧦141
㧙144㧚
3㧕 ᓼጊᵏᴦ㧘㐳↰⌀ੑ㧘૒‫⟵ᧁޘ‬ਯ㧘੹੗ ኼ㧘᧻੗ ⡡㧘ዊ᫪ల༹㧘㜞੗శᴦ㧘ౝᧁቁᢥ㧘੹੗ஜੑ㧘ㄭ⮮ᶈผ㧘੖ፉ ⡡㧘౗᧻㓷ਯ㧘ᑝἑༀା㧚ⴚ೨ߦᐙ⚦⢩≸ߣߩ㐓೎߇໧㗴ߣߥߞߚ⢄⚦⢩⣼⣲ߩ 1 ଀㧘⢄⢙㆏ᴦ≮⎇ⓥળ⹹ 2007 ᐕ㧧5 Ꮞ㧦35㧙40㧚
4㧕 ዊ᫾ Ả㧘ౝጊ⦟৻㧘ጊౝ዁ผ㧘ᮮጊ㦖ੑ㇢㧘ේ ᱞผ㧘ጊᎹᒄ଻㧘቟⮮ᒄ㆏㧘ጤ㑆 ੧㧘ᤊ ඳᤘ㧘⮮↰ᑝᔒ㧚ࡌࠢ࠻࡞㓸ਛᐲࡈࠖ࡞࠲ࠍ↪޿ߚ MRA ↹௝ߦ߅ߌࠆ⣖േ⣂≜ߩᬌ಴ᴺ㧘ක↪↹௝ᖱႎቇળ㔀⹹
2007 ᐕ㧧24 Ꮞ㧦84㧙89㧚
5㧕 ᩿↢ᜏม㧘Ꮉญ⌀ᐔ㧘ጤ↰ ዏ㧘ዊਭ଻శᒄ㧘ਅᎹ㇌ᵏ㧘᧻᳗⎇๋㧘᧻੗⧷੺㧘ᤊ ඳᤘ㧚ᧃ᪳⢖≸ߣߩ㐓೎߇࿎㔍ߢಾ㒰ߐࠇߚ⦟ᕈቅ┙⢖⚿▵∛ᄌߩ↹௝ᚲ⷗ߩᬌ⸛㧘⥃ᐥ᡼኿✢ 2007 ᐕ㧧52 Ꮞ㧦150㧙166㧚
6㧕 ട⮮ඳၮ㧘ᤊ ඳᤘ㧘ጊ↰ධᤊ㧘㕍ᧁ⻞ᄥ㧘᳓↰໪੺㧘દ⮮౎ᰴ㧘᧻᳗⎇๋㧘ᑝἑༀା㧚৻஥⡊ਅ✢ߦ⊒↢ߒߚᄙ⊒⡊ਅ✢ౝ␹⚻㕽⣲ߩ 1 ଀㧘⥃ᐥ᡼኿✢ 2007 ᐕ㧧52 Ꮞ㧦312㧙317㧚
7㧕 ᨋ ⌀਽㧘೨↰ߔߥ߶㧘ᄢቲ๺ඳ㧘↰ਛ ୃ㧘᧻የ᡽ਯ㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚ᚻⴚਇ⢻⢄⚦⢩≸ߩ᡼኿✢ᴦ≮㧘⢙ߣ⤟ 2007 ᐕ㧧28 Ꮞ㧦759㧙763㧚
8㧕 ౝጊ⦟৻㧘᧻੗ ◊㧘ᮮጊ㦖ੑ㇢㧘๟ ะᩕ㧘ේ ᱞผ㧘቟⮮ᒄ㆏㧘ᵻ㊁㓉ᒾ㧘ട⮮ඳၮ㧘ጤ㑆 ੧㧘ᤊඳᤘ㧘⮮↰ᑝᔒ㧚⣖ MR ↹௝ߦ߅ߌࠆ࡜ࠢ࠽᪪Ⴇߩᬌ಴ᴺ㧘㔚ሶᖱႎㅢାቇળ⺰ᢥ⹹ 2007 ᐕ㧧D㧘J90-D㧦
1820㧙1829㧚
9㧕 ጊౝ዁ผ㧘ౝጊ⦟৻㧘ዊ᫾ Ả㧘ᮮጊ㦖ੑ㇢㧘ේ ᱞผ㧘቟⮮ᒄ㆏㧘ጊᎹᒄ଻㧘ጤ㑆 ੧㧘ᤊ ඳᤘ㧘⮮↰ᑝᔒ㧚MRA ↹௝ߦ߅ߌࠆ⣖ⴊ▤ฬߩ⥄േኻᔕઃߌᚻᴺߩ㐿⊒㧘↢૕කᎿቇ 2007 ᐕ㧧45 Ꮞ㧦27㧙35㧚
10㧕 ᓟ⮮⵨ᄦ㧘᧖ፒ࿻ሶ㧘ᤊ ඳᤘ㧘ᑝἑༀା㧚ẩ≌≚∥㧫㧘ᣣᧄᶖൻེ߇ࠎᬌ⸻ቇળ㔀⹹ 2007 ᐕ㧧45 Ꮞ㧦
445㧙449㧚
11㧕 ർᎹノᒾ㧘๟ ะᩕ㧘ේ ᱞผ㧘⮮↰ᑝᔒ㧘ᮮጊ㦖ੑ㇢㧘ㄭ⮮ᶈผ㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚⢄⤳㔚ሶࠕ࠻࡜ࠬߣ✢ᒝ⺞ࡈࠖ࡞࠲ߦࠃࠆ૕ᐙㇱ㕖ㅧᓇ X ✢ CT ௝߆ࠄߩਛ⢄㕒⣂ߩ⥄േ᛽಴㧘ᣣᧄ᡼኿✢ᛛⴚቇળ㔀㧙㧙⹹ 2007 ᐕ㧧63 Ꮞ㧦1382㧙1387㧚
12㧕 ᨋ ㆐㇢㧘๟ ะᩕ㧘㒸 ⪇ጪ, ේ ᱞผ㧘⮮↰ᑝᔒ㧘ᮮጊ㦖ੑ㇢㧘᩿↢ᜏม㧘ᤊ ඳᤘ㧚X ✢ CT ௝ߦ߅ߌࠆ⣄ᬁᬁ૕ㇱߩ㛽ኒᐲߩ⺞ᩏ㧘ක↪↢૕Ꮏቇ 2007 ᐕ㧧45 Ꮞ㧦256㧙266㧚
13㧕 ᨋ ㆐㇢㧘๟ ะᩕ㧘㒸 ⪇ጪ, ේ ᱞผ㧘⮮↰ᑝᔒ㧘ᮮጊ㦖ੑ㇢㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚X ✢ CT ↹௝߆ࠄߩੱ૕ߩᬁ૕ᶏ✎㛽ㇱߦ߅ߌࠆૐ㛽ኒᐲ㗔ၞߩಽᏓߦ㑐ߔࠆ⎇ⓥ㧘ක↪↢૕Ꮏቇ 2007 ᐕ㧧45 Ꮞ㧦451
㧙457㧚
14㧕 ዊ᫾ Ả㧘ౝጊ⦟৻㧘ጊౝ዁ผ㧘ᮮጊ㦖ੑ㇢㧘ේ ᱞผ㧘ጊᎹᒄ଻㧘቟⮮ᒄ㆏㧘ጤ㑆 ੧㧘ᤊ ඳᤘ㧘⮮↰ᑝᔒ㧚ࡌࠢ࠻࡞㓸ਛᐲࡈࠖ࡞࠲ࠍ↪޿ߚ MRA ↹௝ߦ߅ߌࠆ⣖േ⣂≜ߩᬌ಴ᴺ㧘ක↪↹௝ᖱႎቇળ㔀⹹
2007 ᐕ㧧24 Ꮞ㧦84㧙89㧚
15㧕 ᨷᬀ⵨੺㧘౗᧻㓷ਯ㧘ㄭ⮮ᶈผ㧘੖ፉ ⡡㧘ട⮮ඳၮ㧘ᷰㆻᤐᄦ㧘ᮮጊ㦖ੑ㇢㧘᫃↰౏ඳ㧘⴩᢫⾫ม㧚MRIߦࠃࠆ⢄ߩ⸻ᢿ㧘↹௝⸻ᢿ 2007 ᐕ㧧27 Ꮞ㧦1299㧙1306㧚
16㧕 ੑች໪ᓆ㧘๟ ะᩕ㧘㒸 ⪇ጪ㧘ේ ᱞผ㧘⮮↰ᑝᔒ㧘ᮮጊ㦖ੑ㇢㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚X ✢ CT ↹௝ߦ߅ߌࠆ⢷ㇳਅญߩ⥄േ᛽಴ߣᮮ㓒⤑ߩ⥄േផቯ߳ߩᔕ↪㧘㔚ሶᖱႎㅢାቇળᛛⴚ⎇ⓥႎ๔ MI2007
2007 ᐕ㧧107 Ꮞ㧦107㧙110㧚
17㧕 ᨋ ⌀਽㧘ᄢቲ๺ඳ㧘↰ਛ ୃ㧘ᤊ ඳᤘ㧚ਃᰴర᡼኿✢ᴦ≮ߢߩ⢖⣲≌ዪᚲౣ⊒ߦኻߔࠆౣᾖ኿଀ߩᬌ
⸛㧘⥃ᐥ᡼኿✢ 2008 ᐕ㧧53 Ꮞ㧦449㧙445㧚
18㧕 ᨋ ㆐㇢㧘๟ ะᩕ㧘㒸 ⪇ጪ㧘ේ ᱞผ㧘⮮↰ᑝᔒ㧘ᮮጊ㦖ੑ㇢㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚X ✢ CT ↹௝߆ࠄߩੱ૕ߩᬁ૕ᶏ✎㛽ㇱߦ߅ߌࠆૐ㛽ኒᐲ㗔ၞߩಽᏓߦ㑐ߔࠆ⎇ⓥ㧘↢૕කᎿቇ 2008 ᐕ㧧46 Ꮞ㧦451
㧙457㧚
19㧕 ᄹ⦟᧛੖චᔒ㧘ᨋ ㆐㇢㧘๟ ะᩕ㧘ේ ᱞผ㧘㒸 ⪇ጪ㧘⮮↰ᑝᔒ㧘ᮮጊ㦖ੑ㇢㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚૕ᐙㇱ X ✢ CT ↹௝ߦ߅ߌࠆ૕⣧᭴ㅧߩ⥄േ⹺⼂㧘Medical Imaging Technology 2008 ᐕ㧧26 Ꮞ㧦261
㧙271㧚
20㧕 ᨋ ㆐㇢㧘๟ ะᩕ㧘㒸 ⪇ጪ㧘ේ ᱞผ㧘⮮↰ᑝᔒ㧘ᮮጊ㦖ੑ㇢㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚X ✢ CT ௝ߦ߅ߌࠆ᳇▤࡮᳇▤ᡰߩᒻ⁁ᖱႎߩ⸘᷹㧘ක↪↹௝ᖱႎቇળ㔀⹹ 2008 ᐕ㧧25 Ꮞ㧦18㧙21㧚
21㧕 ␹⼱⋥Ꮧ㧘๟ ะᩕ㧘㒸 ⪇ጪ㧘ේ ᱞผ㧘⮮↰ᑝᔒ㧘ᮮጊ㦖ੑ㇢㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚㛽ᩰߣ㛽ᩰ╭ߩ⸃೬ቇ⊛૏⟎㑐ଥߦၮߠߊ૕ᐙㇱ X ✢ CT ↹௝߆ࠄߩ㛽ᩰ╭ߩ⥄േឬ಴㧘㔚ሶᖱႎㅢାቇળ⺰ᢥ⹹
2008 ᐕ㧧J01-D㧦1918㧙1022㧚
22㧕 ർᎹノᒾ㧘๟ ะᩕ㧘ේ ᱞผ㧘⮮↰ᑝᔒ㧘ᮮጊ㦖ੑ㇢㧘ㄭ⮮ᶈผ㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚૕ᐙㇱ㕖ㅧᓇ
X ✢ CT ↹௝ߦ߅ߌࠆ⢄⤳ࠕ࠻࡜ࠬߩ᭴▽ߣߘߩ⢄⤳⥄േ᛽಴ᴺ߳ߩᔕ↪㧘㔚ሶᖱႎㅢାቇળ⺰ᢥ⹹
2008 ᐕ㧧J91-D㧦1837㧙1850㧚
ේ⪺㧔᰷ᢥ㧕
1㧕 Zhang X, Tajima T, Kitagawa T, Kanematsu M, Zhou X, Hara T, Fujita H, Yokoyama R, Kondo H,
Hoshi H. An automatic method for extracting the liver region with hepatic lesions on multi-phase CT
images. Skeletal Radiology. 2006;1:MI2005-87(2006-01):85-88.
2㧕 Nakano M, Uno H, Gotoh T, Kubota Y, Ishihara S, Deguchi T, Hayashi S, Matsuo M, Tanaka O, Hoshi
H. Migration of prostate brachytherapy seeds to the vertebral venous plexus. Brachytherapy. 2006;5:
127-130.
3㧕 Kanematsu M, Goshima S, Kondo H, Yokoyama R, Kajita K, Hoshi H, Onozuka M, Nozaki A, Hirano
M, Shiratori Y, Moriyama N. Double hepatic arterial phase MRI of the liver with switching of reversed
centric and centric K-space reordering. AJR Am Roentgenol. 2006;187:464-472.
4㧕 Tanaka O, Kiryu T, Hirose Y, Fujikake R, Sakurai K, Hoshi H. Chest wall Castleman’s disease: CT and
MRI findings. Radiat Med. 2006;24:529-533.
5㧕 Tanaka O, Hayashi S, Matsuo M, Sakurai K, Nakano M, Maeda S, Kajita K, Deguchi T, Hoshi H.
Comparison of MRI-based and CT/MRI fusion-based postimplant dosimetric analysis of prostatebrachytherapy. Int Radiat Oncol Biol Phys. 2006;66:597-602.
6㧕 Goshima S, Kanematsu M, Kondo H, Yokoyama R, Miyoshi T, Kato H, Tsuge Y, Shiratori Y, Hoshi H,
Onozuka M, Moriyama N, Bae KT. Pancreas: Optimal scan delay for contrast-enhanced multi-detector
row CT. Radiology. 2006;241:167-174.
7㧕 Matsuo M, Hayashi S, Maeda S, Tanaka O, Mizuta K, Shibata T, Itou Y, Hoshi H. 4 Gy single fraction
palliative radiotherapy for the treatment of painful recurrent soft plate carcinoma by high-dose-ratemold brachytherapy: A case report. Oral Oncology Extra. 2006;42:305-307.
8㧕 Tanaka O, Hayashi S, Sakurai K, Matsuo M, Nakano M, Maeda S, Hoshi H, Deguchi T. Importance of
the CT/MRI fusion method as a learning tool for CT-based postimplant dosimetry in prostatebrachytherapy. Radiotherapy and Oncology. 2006;81:303-308.
9㧕 Tanaka O, Hayashi S, Kanematsu M, Matsuo M, Nakano M, Maeda S, Deguchi T, Hoshi H. CT-based
postimplant dosimetry of prostate brachytherapy: comparison of 1-mm and 5-mm section CT. Radiat
Med. 2007;25:22-26.
10㧕 Zhou X, Kitagawa T, Hara T, Fujita H, Zhang X, Yokoyama R, Kondo H, Kanematsu M, Hoshi H.
Constructing a probabilistic model for automated liver region segmentation using non-contrast X-ray
torso CT images. Med Image Comput Comput Assist Interv Int Conf Med Image Comput Comput
Assist Interv. 2006;9:856-863.
11㧕 Matsuhashi N, Satake S, Yawata K, Asakawa E, Mizoguchi T, Kanematsu M, Kondo H, Yasuda I,㧙㧙

IF 0.980

IF 7.535

IF 0.253
IF 0.951

IF 0.800

IF 5.377

IF 3.304

IF 4.074

IF 0.951

IF 2.196

Nonaka K, Tanaka C, Misao A, Ogura S. Volvulus of the gall bladder diagnosed by ultrasonography,
computed tomography, coronal magnetic resonance imaging and magnetic resonancecholangio-pancreatography. World J Gastroenterol. 2006;28:4599-4601.
IF
12㧕 Goshima S, Kanematsu M, Kondo H, Yokoyama R, Miyoshi T, Nishibori H, Kato H, Hoshi H, Onozuka
M, Moriyama N. MDCT of the liver and hypervascular hepatocellular carcinomas: optimizing scandelays for bolus-tracking techniques of hepatic arterial and portal venous phases. Am J Roentgenol.
2006;187:W25-32.
IF
13㧕 Matsuhashi N, Mizoguchi T, Kanematsu M, Kondo H, Goshima S, Mitsuishi N, Yoshimura K, Ogiso T,
Tawada M, Kuwabara S, Ikegame Y, Kato M, Shirai K, Yamaguchi H, Toyoda I, Ogura S. A case ofdelayed rectal stenosis from severe pelvic fracture with massive bleeding successfully treated bybilateral internal iliac TAE: report on a patient survival. Int J Colorectal Dis. 2007;22:853-854.
IF
14㧕 Hirano Y, Fujita M, Watanabe K, Niwa M, Takahashi T, Kanematsu M, Ido Y, Tomida M, Onozuka M.
Effect of unpleasant loud noise on hippocampal activities during picture encoding: An fMRI study.
Brain Cogn. 2006;61:280-285.
IF
15㧕 Kato H, Kanematsu M, Ando K, Mizuta K, Ito Y, Hirose Y, Hoshi H. Ossifying pleomorphic adenoma of
the parotid gland: A case report and review. Australas Radiol. 2007;51:B173-175.
16㧕 Amaoka N, Osada S, Kanematsu M, Imai H, Tomita H, Tokuyama Y, Sakashita F, Nonaka K, Goshima
S, Kondo H, Adachi Y. Clinicopathological features of hepatocellular carcinoma evaluated by vascularendothelial growth factor expression. J Gastroenterol Hepatol. 2007;22:2202-2207.
IF
17㧕 Kato H, Kanematsu M, Zhang X, Saio M, Kondo H, Goshima S, Fujita H. Computer-aided diagnosis ofhepatic fibrosis: preliminary evaluation of MRI texture analysis using the finite difference method andan artificial neural network. Am J Roentgenol. 2007;189:117-122.
IF
18㧕 Kato H, Kanematsu M, Kusunoki Y, Shibata T, Murakami H, Mizuta K, Ito Y, Hirose Y. Nasoalveolar
cyst: imaging findings in three cases. Clin Imaging. 2007;31:206-209.
IF
19㧕 Kanematsu M, Goshima S, Kondo H, Tsuge Y, Yokoyama R, Kajita K, Onozuka M, Suzuki Y, Van
Cauteren M, Moriyama N. Gadolinium-enhanced multiphasic 3D MRI of the liver with prospective
adaptive navigator correction: phantom study and preliminary clinical evaluation. Am J Roentgenol.
2007;188:309-316.
IF
20㧕 Goshima S, Kanematsu M, Nishibori H, Kondo H, Tsuge Y, Yokoyama R, Miyoshi T, Onozuka M,
Shiratori Y, Moriyama N, Bae KT. Multi-detector row CT of the kidney: Optimizing scan delays forbolus tracking techniques of arterial, corticomedullary, and nephrographic phases. Eur J Radiol.
2007;63:420-426.
21㧕 Tajima T, Zhang X, Kitagawa T, Kanematsu M, Zhou X, Hara T, Fujita H, Yokoyama R, Kondo H,
Hoshi H. Computer-aided detection (CAD) of hepatocellular carcinoma on multiphase CT images, Proc.
of SPIE Medical Imaging. 2007: Computer-Aided Diagnosis, 6514, 65142Q-1-65142Q-10.
22㧕 Kondo H, Yamada T, Kanematsu M, Kako N, Goshima S, Yamamoto N. Related Articles, Embolization
for massive urethral hemorrhage. Abdom Imaging. 2007;32:262-263.
IF
23㧕 Kondo H, Kanematsu M, Goshima S, Miyoshi T, Shiratori Y, Onozuka M, Moriyama N, Bae KT. MDCTof the pancreas: optimizing scanning delay with a bolus-tracking technique for pancreatic,
peripancreatic vascular, and hepatic contrast enhancement. Am J Roentgenol. 2007;188:751-756.
IF
24㧕 Yokoyama R, Zhang X, Uchiyama Y, Fujita H, Hara T, Zhou X, Kanematsu M, Asano T, Kondo H,
Goshima S, Hoshi H, Iwata T. Develoment of an automated method for detection of chronic lacunar
infarct regions in brain MR images. IEICE T Inf Syst. 2007;E90-D:943-954.
IF
25㧕 Uchiyama Y, Yokoyama R, Ando H, Asano T, Kato H, Yamakawa H, Hara T, Iwama T, Hoshi H, Fujita
H. Computer-aided diagnosis scheme for detection of lacunar infarcts on MR images. Acad Radiol.
2007;1554-1561.
IF
26㧕 Tanaka O, Hayashi S, Matsuo M, Nakano M, Kubota Y, Maeda S, Ohtakara K, Deguchi T, Hoshi H.
Comparison of urethral diameters for calculating the urethral dose after permanent prostatebrachytherapy. Radiat Med. 2007;329-334.
27㧕 Zhou X, Kamiya N, Hara T, Fujita H, Chen H, Yokoyama R, Hoshi H. Automated segmentation andrecognition of abdominal wall muscles in X-ray torso CT images and its application in abdominal CAD.
Int J Computer Assisted Radiol and Surg. 2007;2:Supplement1: S388-S390.
28㧕 Uchiyama Y, Yokoyama R, Asano T, Kato H, Yamakawa H, Ando H, Yamakawa H, Hara T, Iwama T,
Hoshi H, Fujita H. Performance of computer-aided diagnosis for detection of lacunar infarcts on brain
MR images: ROC analysis of radiologists' detection. Int J Computer Assist Radiol and Surg.
2007;2:Supplement 1:S395-S397.
29㧕 Manabe T, Hirose Y, Kiryuu T, Kondo H, Hoshi H. Magnetic resonance imaging of endmetrial cancer
and clear cell cancer. J Comput Assist Tomogr. 2007;31:229-235.
IF
30㧕 Tanaka O, Hayashi S, Matsuo M, Nakano M, Uno H, Ohtakara K, Miyoshi T, Deguchi T, Hoshi H.
Effect of edema on postimplant dosimetry in prostate brachytherapy using CT/MRI fusion. Int J
Radiat Oncol Biol Phys. 2007;69:614-618.
IF
31㧕 Matsuo M, Shinoda J, Miwa K, Yano H, Iwama T, Hayashi S, Okada S, Tanaka O, Hoshi H.
Stereotactic radiosurgery for patients with newly diagnosed glioblastoma multiforme (GBM):

㧙㧙

0.634

2.209

1.749

1.845

1.785

2.117
0.742

2.117

1.213

2.117

0.280

1.781

1.530

4.463

comparison with intra-operative radiotherapy and evaluation of prognostic factors. J Radiotherapy inPractice. 2007;143-152.
32㧕 Matsuo M, Nakano M, Hayashi S, Ishihara S, Maeda S, Uno H, Tanaka O, Kanematsu M, Deguchi T,
Hoshi H, Aoyama T, Fujiwara H. Prostate brachytherapy seed migration to the right ventricle: Chest
radiographs and CT appearances. Eur J Radiol Extra. 2007;61:91-93.
33㧕 Shibamoto Y, Baba F, Oda K, Hayashi S, Kokubo M, Ishihara S, Itoh Y, Ogino H, Koizumi M. Incidenceof brain atrophy and decline in mini-mental state examination score after whole-brain radiotherpy inpatients with brain metastases: aprospective study. Int J Radiat Oncol Biol Phys. 2008;72:1168-1173.
34㧕 Tanaka O, Hayashi S, Matsuo M, Nakano M, Kubota Y, Maeda S, Ohtakara K, Deguchi T, Hoshi H.
MRI-based preplanning in low-dose-rate prostate brachytherapy. Radiotherapy Oncology.
2008;72:1168-1173.
35㧕 Kato H, Kanematsu M, Mizuta K, Ito Y, Hirose Y. Carcinoma Ex pleomorphic adenoma of the parotid
gland: Radiologic-pathologic correlation with MR imaging including diffusion-weighted imaging. Am J
Neuroradiol. 2008;29:865-867.
36㧕 Kato H, Kanematsu M, Kiryu T, Iwata H, Shirahashi K, Matsumoto S, Hirose Y, Matsutomo H,
Sasaoka I. Nonfunctional mediastinal parathyroid cyst: imaging findings in two cases. Clin Imaging.
2008;32:310-313.
37㧕 Kato H, Kanematsu M, Furui T, Imai A, Hirose Y, Kondo H, Goshima S, Tsuge Y. Carcinosarcoma of
the uterus: radiologic-pathologic correlations with magnetic resonance imaging including
diffusion-weighted imaging. Magn Reson Imaging. 2008;26:1446-1450.
38㧕 Bae KT, Shah AJ, Shang SS, Wang JH, Chang S, Kanematsu M, Hildebolt CF. Aortic and hepatic
contrast enhancement with abdominal 64-MDCT in pediatric patients: effect of body weight and iodine
dose. Am J Roentgenol. 2008;191:1589-1594.
39㧕 Zhou X, Han M, Hara T, Fujita H, Sugisaki K, Chen H, Lee G, Yokoyama R, Kanematsu M, Hoshi H.
Automated segmentation of mammary gland regions in non-contrast X-ray CT images. Comput Med
Imaging Graph. 2008;32:699-709.
40㧕 Miyoshi T, Kanematsu M, Kondo H, Goshima S, Tsuge Y, Hatcho A, Shiratori Y, Onozuka M,
Moriyama N, Bae KT. Abdomen: angiography with 16-detector CT- -comparison of image quality andradiation dose between studies with 0.625-mm and those with 1.25-mm collimation. Radiolgy.
2008;249:142-150.
41㧕 Goshima S, Kanematsu M, Kondo H, Yokoyama R, Kajita K, Tsuge Y, Watanabe H, Shiratori Y,
Onozuka M, Moriyama N. Diffusion-weighted imaging of the liver: optimizing b value for the detection
and characterization of benign and malignant hepatic lesions. J Magn Reson Imaging. 2008;28:691-697.
42㧕 Hong HS, Kim HS, Kim MJ, De Becker J, Mitchell DG, Kanematsu M. Single breath-holdmultiarterial dynamic MRI of the liver at 3T using a 3D fat-suppressed keyhole technique. J Magn
Reson Imaging. 2008;28:396-402.
43㧕 Osada S, Kanematsu M, Imai H, Goshima S. Clinical significance of serum HGF and c-Met expression
in tumor tissue for evaluation of properties and treatment of hepatocellular carcinoma.
Hepatogastroenterology. 2008;55:544-549.
44㧕 Kawajiri S, Zhou X, Zhang X, Hara T, Fujita H, Yokoyama R, Kondo H, Kanematsu M, Hoshi H.
Automated segmentation of hepatic vessels in non-contrast X-ray CT images. Radiol Phys Technol
2008;1:214-222.
45㧕 Kudo M, Zheng RQ, Kim SR, Okabe Y, Osaki Y, Iijima H, Itani T, Kasugai H, Kanematsu M, Ito K,
Usuki N, Shimamatsu K, Kage M, Kojiro M. Diagnostic accuracy of imaging for liver cirrhosis
compared to histologically proven liver cirrhosis. A multicenter collaborative study. Intervirology.
2008;51 Suppl 1:17-26.
46㧕 Hirota T, Suzuki E, Ito I, Ishiyama M, Goto S, Horikawa Y, Asano T, Kanematsu M, Hoshi H, Takeda J.
Coronary artery calcification, arterial stiffness and renal insufficiency associate with serum levels oftumor necrosis factor-alpha in Japanese type 2 diabetic patients. Diabetes Res Clin Pract.
2008;82:58-65.
47㧕 Goshima S, Kanematsu M, Kondo H, Yokoyama R, Tsuge Y, Shiratori Y, Onozuka M, Moriyama N.
Evaluating local hepatocellular carcinoma recurrence post-transcatheter arterial chemoembolization:is diffusion-weighted MRI reliable as an indicator? J Magn Reson Imaging. 2008;27:834-839.
48㧕 Bae KT, Seeck BA, Hildebolt CF, Tao C, Zhu F, Kanematsu M, Woodard PK. Contrast enhancement in
cardiovascular MDCT: effect of body weight, height, body surface area, body mass index, and obesity.
Am J Roentgenol. 2008;190:777-784.
49㧕 Kanematsu M, Goshima S, Kondo H, Bae KT. How should we optimize bolus tracking withmultidetector CT of the abdomen? Radiology. 2008;246:643; author reply 643-644.
50㧕 Osada S, Kanematsu M, Imai H, Goshima S, Sugiyama Y. Hepatic fibrosis influences the growth ofhepatocellular carcinoma. Hepatogastroenterology. 2008;55:184-187.
51㧕 Kubota Y, Kamei S, Nakano M, Ehara H, Deguchi T, Tanaka O. The potential role of prebiopsy
magnetic resonance imaging combined with prostate-specific antigen density in the detection of
prostate cancer. Int J Urol. 2008;15:322-327.

㧙㧙

IF 3.970

IF 1.330

IF 4.290

IF 4.074

IF 2.338

IF 0.742

IF 1.486

IF 2.470

IF 0.848

IF 5.661

IF 2.209

IF 2.209

IF 0.904

IF 1.827

IF 1.823

IF 2.209

IF 2.470
IF 0.904
IF 0.904

IF 0.769

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦౗᧻㓷ਯ㧘⎇ⓥಽᜂ⠪㧦ㄭ⮮ᶈผ㧘੖ፉ ⡡㧘㜞੗శᴦ㧧ᢥㇱ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ
⋚⎇ⓥ(C)㧦㜞⸃௝⢄ㅧᓇ MRI ߳ߩࡄ࡯ࡈࡘ࡯࡚ࠫࡦ⸃ᨆ⚵ㄟߺߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18㧙19 ᐕᐲ㧧
160 ජ౞(120㧦40 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦ዊ㊁Ⴆታ㧘⎇ⓥಽᜂ⠪㧦૒⮮⽵㓶㧘ᬀ᧻ ብ㧘ട⮮ೣᑝ㧘౗᧻㓷ਯ㧧ᢥㇱ⋭⑼ቇ⎇ⓥ
⾌⵬ഥ㊄ၮ⋚⎇ⓥ(A)㧦࠴ࡘ࡯ࠗࡦࠣߦࠃࠆ⣖ᯏ⢻࿁〝ߩ⾮ᵴൻߣౣ↢㧧ᐔᚑ 18㧙19 ᐕᐲ㧧40,43 0ජ౞(33,150㧦7,280 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦⮮↰㓷ᢥ㧘⎇ⓥಽᜂ⠪㧦౗᧻㓷ਯ㧘ട⮮ೣᑝ㧘⮮ේ ๟㧘ਭ଻㊄ᒎ㧧ᢥㇱ⋭⑼ቇ⎇ⓥ
⾌⵬ഥ㊄ၮ⋚⎇ⓥ(B)㧦㜞㦂␠ળߦ߅޿ߡ⠧ᐕᱤ⑼කቇ߇ᜂ߁␠ળ⊛㊀ⷐᕈࠍ⣖⑼ቇ⊛ߦታ⸽ߔࠆ㧧ᐔᚑ 18㧙19 ᐕᐲ㧧20,410 ජ౞(16,900㧦3,510 ජ౞)
4㧕 ⎇ⓥઍ⴫⠪㧦♿ࡁቯ଻⤿㧘⎇ⓥಽᜂ⠪㧦ᤊ ඳᤘ㧘ᗆ⦟⡛৻㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌㧔⎇ⓥ㧕
㧦MRI/RI
ࡑ࡞࠴ࠗࡔ࡯ࠫࡦࠣᴺߦࠃࠆࡅ࠻↢ℂᯏ⢻ߩቯ㊂⹏ଔ(Evaluation of tissue/cell functions using
MRI/RI multi-modality imaging technique)㧧ᐔᚑ 19 ᐕᐲ㧧60 ජ౞5㧕 ⎇ⓥઍ⴫⠪㧦ㄭ⮮ᶈผ㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌㧔⎇ⓥ㧕㧦⣻ㇱㅧᓇ MDCT ߦ߅ߌࠆ⥋ㆡㅧᓇ೷㊂㧘᠟௝ࡊࡠ࠻ࠦ࡯࡞ߩ⥄േ⸳ቯߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 20 ᐕᐲ㧧900 ජ౞6㧕 ⎇ⓥઍ⴫⠪㧦੖ፉ ⡡㧘⎇ⓥಽᜂ⠪㧦౗᧻㓷ਯ㧘ㄭ⮮ᶈผ㧘ᨷᬀ⵨੺㧧⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦
ᄙ೉ᬌ಴ེဳ CT ↹௝ߦ߅ߌࠆ㊄ዻࠕ࡯࠴ࡈࠔࠢ࠻シᷫࠕ࡞ࠧ࡝࠭ࡓߩ㐿⊒㧧ᐔᚑ 19㧙20 ᐕᐲ㧧
2,250 ජ౞(1,600㧦650 ජ౞)
7㧕 ⎇ⓥઍ⴫⠪㧦ᷰㆻᤐᄦ㧘⎇ⓥಽᜂ⠪㧦౗᧻㓷ਯ㧘੖ፉ ⡡㧘ㄭ⮮ᶈผ㧘ᨷᬀ⵨੺㧘⮮↰ᑝᔒ㧧⑼ቇ
⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦Cinetagging ↹௝ࠍ↪޿ߚ⢄✢⛽ൻ⹏ଔ㧧ᐔᚑ 20㧙22 ᐕᐲ㧧2,200 ජ౞(1,400㧦500㧦300 ජ౞)
2㧕ฃ⸤⎇ⓥ1㧕 ౗᧻㓷ਯ㧦ᰴᦼࡑࠗࠢࡠࠞ࠹࡯࠹࡞㐿⊒ߩὑߩ⃻ⴕࡑࠗࠢࡠࠞ࠹࡯࠹࡞㧔ࡊࡠࠣ࡟࡯࠻㧕ߩᕈ⢻⹏ଔ㧧ᐔᚑ 18 ᐕᐲ㧧130 ජ౞㧦࠹࡞ࡕᩣᑼળ␠ࠞ࠹࡯࠹࡞ࠞࡦࡄ࠾࡯
3㧕౒ห⎇ⓥ1㧕 ౗᧻㓷ਯ㧦Multi Detector row CT ߦ߅ߌࠆ⣻ㇱ᠟ᓇߩ↹⾰ᡷༀߦ㑐ߔࠆၮ␆ᬌ⸛㧧ᐔᚑ 18㧙19 ᐕᐲ㧧38.8 ජ౞(20㧦18.8 ජ౞)㧦ࠫ࡯ࠗ࡯ᮮᴡࡔ࠺ࠖࠞ࡞ࠪࠬ࠹ࡓᩣᑼળ␠
2㧕 ౗᧻㓷ਯ㧦ㅧᓇ೷⥄േᵈ౉ེࠍ↪޿ߚ࡛࡯࠼ㅧᓇ೷ߩ᦭ല೑↪ߦ㑐ߔࠆၮ␆⎇ⓥ㧘෸߮ߘߩᵈ౉ᴺߩ⎇ⓥ㧧ᐔᚑ 18㧙19 ᐕᐲ㧧42 ජ౞(22㧦20 ජ౞)㧦ᩮᧄ᧙ᨋၴ㧔ᩣ㧕
3㧕 ౗᧻㓷ਯ㧦Multi Detector row CT ߦ߅ߌࠆㅧᓇࡊࡠ࠻ࠦ࡞ᦨㆡൻߩၮ␆ᬌ⸛㧧ᐔᚑ 20 ᐕᐲ㧧182
ජ౞㧦ࠫ࡯ࠗ࡯ᮮᴡࡔ࠺ࠖࠞ࡞ࠪࠬ࠹ࡓᩣᑼળ␠
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬᤊ ඳᤘ㧦
1㧕 ᣣᧄකቇ᡼኿✢ቇળઍ⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄᩭකቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄᔃ⤳ᩭකቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄ↹௝කቇળ⹏⼏ຬ(㨪⃻࿷)5㧕 ർ㑐᧲කቇળ⹏⼏ຬ(㨪⃻࿷)6㧕 ᣣᧄකቇ᡼኿✢ቇળஜ଻ᆔຬ(㨪⃻࿷)౗᧻㓷ਯ㧦1㧕 ᣣᧄࠗࡦ࠲࡯ࡌࡦ࡚ࠪ࠽࡞࡜ࠫࠝࡠࠫ࡯ቇળઍ⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ⏛᳇౒㡆කቇળઍ⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄᩭකቇળ⹏⼏ຬ(㨪⃻࿷)㧙㧙ᨋ ⌀਽㧦1㧕 ᣣᧄ᡼኿✢⣲≌ቇળ⹏⼏ຬ(ᐔᚑ 20 ᐕ 10 ᦬㨪⃻࿷)2㧕ቇળ㐿௅ᤊ ඳᤘ㧦
1㧕 ᣣᧄකቇ᡼኿✢ቇળ╙ 140 ࿁ਛㇱ࿾ᣇળ(ᐔᚑ 18 ᐕ 6 ᦬㧘ጘ㒂)2㧕 ᣣᧄᩭකቇળ╙ 65 ࿁ਛㇱ࿾ᣇળ(ᐔᚑ 18 ᐕ 6 ᦬㧘ጘ㒂)౗᧻㓷ਯ㧦
1㧕 ᣣᧄ IVR ቇળ╙ 21 ࿁ਛㇱ࿾ᣇળ(ᐔᚑ 18 ᐕ 6 ᦬㧘ጘ㒂)
3㧕ቇⴚ㔀⹹ᤊ ඳᤘ㧦
1㧕 ᢿጀᤋ௝⎇ⓥળ㔀⹹㧘✬㓸ᆔຬ(㨪⃻࿷)2㧕 ක↪↹௝ᖱႎቇળ㔀⹹㧘✬㓸 Advisory board (㨪⃻࿷)
3㧕 Acta Oto-Laryngologica㧘Reviewer (ᐔᚑ 20 ᐕ 9 ᦬㨪⃻࿷)౗᧻㓷ਯ㧦
1㧕 ⥃ᐥ↹௝㧘✬㓸දജᆔຬ(㨪⃻࿷)2㧕 ᶖൻེ↹௝㧘✬㓸ᆔຬ(㨪⃻࿷)3㧕 Radiology, JCAT, JMRI, CVIR㧘⹹⊓㍳ᩏ⺒ຬ(㨪⃻࿷)7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ᤊ ඳᤘ㧦
1㧕 ╙ 60 ࿁᧲ᶏ✚ว↹௝කቇ⎇ⓥળ(ᐔᚑ 18 ᐕ 8 ᦬㧘ฬฎደ㧘․೎⻠Ṷ‫ޟ‬஥㗡㛽ߩ↹௝⸻ᢿ㧙߅ߐ߃ߡ߅߈ߚ޿ࡐࠗࡦ࠻‫ޠ‬ᐳ㐳)2㧕 ╙ 43 ࿁ᣣᧄකቇ᡼኿✢ቇળ⑺ቄ⥃ᐥᄢળ(ᐔᚑ 19 ᐕ 10 ᦬㧘ฬฎደ㧘࡝ࡈ࡟࠶ࠪࡖ࡯ࠦ࡯ࠬ‫ޟ‬ᩭකቇࠍ↪޿ߚ⸻ᢿߣᴦ≮‫ޠ‬ᐳ㐳)
3㧕 ╙ 74 ࿁᧲ᶏᩭකቇ࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 5 ᦬㧘ฬฎደ㧘․೎⻠Ṷ‫ࠆࠃߦࡦ࡝ࠔࡧ࠯ޟ‬᡼኿఺∉≮ᴺ㧙
․ᓽߣḰ஻߆ࠄታ㓙߹ߢ㧙‫ޠ‬ᐳ㐳)౗᧻㓷ਯ㧦
1㧕 MDCT symposium “MDCT Made Easy”, (2006.02, Seoul, Invited lecture: Contrast-enhanced
MDCT of the liver and pancreas –Focusing on fixed duration injection–; symposist)2㧕 ╙ 42 ࿁ ᣣᧄකቇ᡼኿✢ቇળ⑺ᦼ⥃ᐥᄢળ(ᐔᚑ 18 ᐕ 10 ᦬㧘⑔ጟ㧘࡝ࡈ࡟࠶ࠪࡖ࡯ࠦ࡯ࠬ‫ޟ‬⢄⦟ᕈ⣲≜ߩ↹௝⸻ᢿ‫ޠ‬㧘‫ޟ‬⢄ⴊ▤⣲ߩ↹௝⸻ᢿ㧙MRI ࠍਛᔃߦ㧙‫ޠ‬Ṷ⠪)
3㧕 ╙ 44 ࿁ᣣᧄ≸ᴦ≮ቇળ✚ળ(ᐔᚑ 18 ᐕ 10 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᶖൻེ≸ߦ߅ߌࠆ↹௝⸻ᢿߩㅴᱠߣᴦ≮߳ߩዷ㐿㧘MRI ߦࠃࠆ⢄∔ᖚ⸻ᢿᚢ⇛‫ޠ‬Ṷ⠪)
4㧕 ╙ 12 ࿁ Hepatologyfest in N43(ᐔᚑ 18 ᐕ 11 ᦬㧘ᧅᏻ㧘․೎⻠Ṷ‫ޟ‬⢄ߩ MRI 㧙ᦨㄭߩ⹤㗴ࠍ੤߃ߡ㧙‫ޠ‬Ṷ⠪)
5㧕 ╙ 67 ࿁ᣣᧄකቇ᡼኿✢ቇળ✚ળ(ᐔᚑ 20 ᐕ 4 ᦬㧘ᮮᵿ㧘․೎⻠Ṷ‫ޟ‬਄⣻ㇱߩㅧᓇ MDCT㧙㒰⢽⢌
૕㊀ߦࠃࠆ࡛࡯࠼⽶⩄ᦨㆡൻ㧙‫ޠ‬Ṷ⠪)
6㧕 ╙ 36 ࿁ᣣᧄ⏛᳇౒㡆කቇᄢળ(ᐔᚑ 20 ᐕ 6 ᦬㧘ᮮᵿ㧘․೎⻠Ṷ‫ޟ‬EOB࡮ࡊ࡝ࡕࡆࠬ࠻ㅧᓇ MRI-᠟௝ߩᦨㆡൻࠍਛᔃߦ‫ޠ‬Ṷ⠪)7㧕 The 5th. Japan-Korea Liver Symosium (2008.08, Osaka, Invited Lecture: Diagnostic strategy for
HCC-focused on MRI; symposist)8㧕 The 12th. Asian Oceanian Congress of Radiology (2008.10, Seoul, Symosium㧘Moderators ofdebate session: Optimization of contrast-enhanced liver CT which is best?; symposist)9㧕 The 12th. Asian Oceanian Congress of Radiology (2008.10, Seoul, Invited Lecture: Optimizationof iodine load by other than total body weight; symposist)10㧕 The 12th. Asian Oceanian Congress of Radiology (2008.10, Seoul, Invited Lecture: MR imaging
of hepatocellular carcinoma; speaker)
11㧕 The 2nd. International Forum for Liver MRI (2008.10, Kyoto, Invited Lecture: Optimization㧙㧙hepatic arterial-dominant phase imaging for the diagnosis of hepatocellular carcinomas;
speaker)ᨋ ⌀਽㧦
1㧕 ╙ 43 ࿁ᣣᧄකቇ᡼኿✢ቇળ⑺ቄ⥃ᐥᄢળ(ᐔᚑ 19 ᐕ 10 ᦬㧘ฬฎደ㧘࡝ࡈ࡟࠶ࠪࡖ࡯ࠦ࡯ࠬ‫ޟ‬㗡㗪ㇱ⣲≌ߩᴦ≮ᴺߩㆬᛯ‫ޠ‬ᐳ㐳)ㄭ⮮ᶈผ㧦
1㧕 ╙ 36 ࿁ᣣᧄ⏛᳇౒㡆ቇળ (ᐔᚑ 20 ᐕ 9 ᦬㧘ᣩᎹ㧘ᢎ⢒⻠Ṷ‫ࠎ߹߮ޟ‬ᕈ⢄∔ᖚ‫ޠ‬Ṷ⠪)੖ፉ ⡡㧦
1㧕 ╙ 35 ࿁ᣣᧄ⏛᳇౒㡆ቇળ (ᐔᚑ 19 ᐕ 9 ᦬㧘␹ᚭ㧘ᢎ⢒⻠Ṷ‫ޟ‬⢄㧙MRI‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ1㧕 ੖ፉ ⡡㧘౗᧻㓷ਯ㧘ㄭ⮮ᶈผ㧘ᨷᬀ␭੺㧦╙ 34 ࿁ᣣᧄ⏛᳇౒㡆කቇળᄢળࡐࠬ࠲࡯ㇱ㐷 ቇⴚᅑ
ബ⾨(ᐔᚑ 18 ᐕᐲ)
2㧕 ੖ፉ ⡡㧦ጘ㒂කቇ⎇ⓥද⼏ળᐔᚑ 18 ᐕᐲጘ㒂කቇᅑബ⾨(ᐔᚑ 18 ᐕᐲ)
3㧕 ੖ፉ ⡡㧦ᣣᧄකቇ᡼኿✢ቇળ᧼੗⎇ⓥᅑബ⾨(ᐔᚑ 18 ᐕᐲ)
4㧕 ౝጊ⦟৻㧘᧻੗ ◊㧘ᮮጊ㦖ੑ㇢㧘⮮↰ᑝᔒ㧘ේ ᱞผ㧘๟ ะᩕ㧘ᵻ㊁㓉ᒾ㧘ട⮮ඳၮ㧘ᤊ ඳᤘ㧘቟⮮ᒄ㆏㧘ጤ㑆 ੧㧦ᣣᧄ᡼኿✢ᛛⴚቇળ㌃⾨(ᐔᚑ 18 ᐕᐲ)
5㧕 Tanaka O㧦International Health Professional of the year 2006(ᐔᚑ 18 ᐕᐲ)
6㧕 ౗᧻㓷ਯ㧦Radiology Editor’s Recognition Award for Reviewing with Distinction(ᐔᚑ 18 ᐕᐲ)
7㧕 ౗᧻㓷ਯ㧦Radiology Editor’s Recognition Award for Reviewing with Distinction(ᐔᚑ 19 ᐕᐲ)
8㧕 Yamauchi M, Uchiyama Y, Yokoyama R, Hara T, Fujita H, Ando H, Yamakawa H, Iwama T,
Hoshi H㧦Cum Laude Poster Award, Computer Aided Diagnosis 6514, SPIE Medical Imaging
2007 Symposium(ᐔᚑ 19 ᐕᐲ)
9㧕 ↰ਛ ୃ㧦ᣣᧄ᡼኿✢⣲≌ቇળ᪢၂⾨(ᐔᚑ 19 ᐕᐲ)
10㧕 ↰ਛ ୃ㧦JASTRO Silver Prize(ᐔᚑ 19 ᐕᐲ)
11㧕 ᨋ ㆐㇢㧘๟ ะᩕ㧘ේ ᱞผ㧘⮮↰ᑝᔒ㧘ᮮጊ㦖ੑ㇢㧘᩿↢ᜏม㧘㒸 ⪇ጪ㧘ᤊ ඳᤘ㧦㔚ሶᖱႎㅢାቇળቇⴚᅑബ⾨(ᐔᚑ 19 ᐕᐲ)
12㧕 ౝጊ⦟৻㧘ᮮጊ㦖ੑ㇢㧘ේ ᱞผ㧘⮮↰ᑝᔒ㧘ട⮮ඳၮ㧘ᵻ㊁㓉ᒾ㧘ᤊ ඳᤘ㧦CyPos ㌃⾨(ᐔᚑ 20ᐕᐲ)13㧕 ዊ᫾ Ả㧘ౝጊ⦟৻㧘ጊౝ዁ผ㧘ᮮጊ㦖ੑ㇢㧘ේ ᱞผ㧘ጊᎹᒄ଻㧘቟⮮ᒄ㆏㧘ጤ㑆 ੧㧘ᤊ ඳᤘ㧘⮮↰ᑝᔒ㧦㊄᫪ᅑബ⾨(ᐔᚑ 20 ᐕᐲ)
14㧕 ౗᧻㓷ਯ㧦Radiology Editor’s Recognition Award for Reviewing with Distinction(ᐔᚑ 20 ᐕᐲ)
9㧚␠ળᵴേ
ߥߒ
10㧚ႎ๔ᦠ
1㧕 ౗᧻㓷ਯ㧘㐳↰⌀ੑ㧘ᄤጟ ᦸ㧘᧻የ᡽ਯ㧘ട⮮ඳၮ㧦᡼኿✢↹௝කቇߦࠃࠆ⢄≸ߩⴊ▤ᣂ↢∛ᘒ߳ߩࠕࡊࡠ࡯࠴ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 16 ᐕᐲ㧙17 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)⎇ⓥᚑᨐႎ๔ᦠ㧦1㧙64 (2006 ᐕ 6 ᦬)
2㧕 ౗᧻㓷ਯ㧘ㄭ⮮ᶈผ㧘੖ፉ ⡡㧘㜞੗శᴦ㧦㜞⸃௝⢄ㅧᓇ MRI ߳ߩࡄ࡯ࡈࡘ࡯࡚ࠫࡦ⸃ᨆ⚵ㄟߺߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 18㧙19 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)⎇ⓥᚑᨐႎ๔ᦠ㧦1㧙35(2008 ᐕ 3 ᦬)
3㧕 ዊ㊁Ⴆታ㧘૒⮮⽵㓶㧘ᬀ᧻ ብ㧘ട⮮ೣᑝ㧘౗᧻㓷ਯ㧦࠴ࡘ࡯ࠗࡦࠣߦࠃࠆ⣖ᯏ⢻࿁〝ߩ⾮ᵴൻߣౣ↢㧦ᐔᚑ 18㧙19 ᐕᐲᢥㇱ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(A)⎇ⓥᚑᨐႎ๔ᦠ(2008 ᐕ 6 ᦬)
11㧚ႎ㆏
1㧕 ᤊ ඳᤘ㧦૕ౝ⚦⢩ߩ௛߈೑↪ߒ⸻ᢿ㧦ጘ㒂ᣂ⡞(2007 ᐕ 9 ᦬ 18 ᣣ)㧙㧙12㧚⥄Ꮖ⹏ଔ
⹏ଔ↹௝⸻ᢿߩ⎇ⓥߪ㧘↹௝⸻ᢿߩߺߥࠄߕᯏེࠍ㚟૶ߒߚ᠟ᓇᛛⴚ㧘↹௝⸃ᨆ߽✂⟜ߐࠇࠆ߇㧘ㄭᐕߩᯏེ߿ࡀ࠶࠻ࡢ࡯ࠢߩㅴᱠߦࠃࠅ㧘⸻ᢿ⢻߇ᩰᲑߦะ਄ߒ㧘ᦨᣂߩ⥃ᐥ⊛⹏ଔࠍᄙߊⴕߞߡ߈ߚ‫ޕ‬⣻ㇱ⤳ེᖡᕈ⣲≌ߩ⎇ⓥߢߪ㧘CT㧘MRI ߩ⥋ㆡ᠟௝ᴺߩ㐿⊒㧘ⴊ▤ㅧᓇਅ CT㧘࠳ࠗ࠽ࡒ࠶ࠢㅧᓇ MRI㧘᜛ᢔᒝ⺞↹௝ߦࠃࠆ MRI ߥߤࠍ↪޿ߚ㧘⢄߇ࠎ㧘⤟߇ࠎࠍᆎ߼ߣߔࠆᣧᦼᖡᕈ⣲≌↹௝⸻ᢿߦ㑐ߔࠆ⎇ⓥᚑᨐࠍ᜼ߍߡ߈ߚߎߣߪ․╩ߦ୯ߔࠆߣ⠨߃ߡ޿ࠆ‫ߚ߹ޕ‬㧘ᩭකቇߦࠃࠆ⣖ⴊ⛔ SPECT ߽ eZIS ࠍᆎ߼ߣߔࠆᣂߒ޿ቯ㊂ൻߦ㑐ߔࠆ⎇ⓥߦขࠅ⚵ࠎߢ߅ࠅ㧘⥃ᐥ⊛ߦᔕ↪ߐࠇߡ޿ࠆ‫ޕ‬᡼኿✢ᴦ≮㑐ㅪߢߪ㧘3ᰴరᾖ኿ߩ૕ᐙㇱ⣲≌߳ߩᔕ↪㧔․ߦ IMRT ߩၮ␆⊛ᬌ⸛㧕㧘ቯ૏ᚻⴚ⊛᡼኿✢ᴦ≮ߩ⣖⣲≌߳ߩᔕ↪㧘᦭∩ᕈ㛽ォ⒖ߦኻߔࠆ⥋ㆡᾖ኿ᴺߩᬌ⸛ࠍⴕߞߡ߈ߚ‫ޕ‬ዊ✢Ḯᴦ≮ߦߟ޿ߡߪ᧲ᶏ࿾඙ߢೋ߼ߡ೨┙⣼߇ࠎߦ⥃ᐥᔕ↪ߐࠇ㧘⦟ᅢߥᚑᨐࠍ᜼ߍߡ߈ߚ‫⥋ߩߎޕ‬ㆡ✢㊂ࠍᓧࠆߚ߼ᣂߒ޿ CT㧘MRI ߩ࠰ࡈ࠻ߩ
㐿⊒߽ⴕߞߡ߈ߚ‫ߚ߹ޕ‬㧘↹௝⸻ᢿ↪ߩᣂߒ޿࠰ࡈ࠻ߣߒߡ⥃ᐥᔕ↪ߦะߌߡᕆㅦߦㅴᱠߒߡ߈ߚ CAD
ߦߟ޿ߡߪ㧘ౣ↢ಽሶ⛔ᓮቇ⻠ᐳ㧘⍮⢻ࠗࡔ࡯ࠫᖱႎಽ㊁ߣ౒ห⎇ⓥⴕ޿ߥ߇ࠄ㧘․ߦ੃≸㧘ᘟᕈ⢄∔ᖚߦߟ޿ߡ⎇ⓥᚑᨐࠍ᜼ߍߡ߈ߡ޿ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷⃻࿷ߩ⎇ⓥߪ⥃ᐥ⎇ⓥ߇ਥߥ߽ߩߢ޽ࠆ‫ᤨ⃻ޕ‬ὐߢߪၮ␆⎇ⓥ߇චಽⴕ߃ࠆⅣႺ߇ᢛߞߡ޿ߥ޿ߚ߼㧘੹ᓟ㧘዁᧪ߩ⥃ᐥᔕ↪ߦߟߥ߇ࠆࠃ߁ߥၮ␆⊛ᬌ⸛ࠍⴕ߁ߚ߼ߩᣉ⸳㧘ⵝ⟎ߩᢛ஻ࠍ࿑ߞߡ޿ߊᔅⷐ߇
޽ࠆ‫ߚ߹ޕ‬㧘ᘟᕈ⊛ߥࡑࡦࡄࡢ࡯ਇ⿷߇⛯޿ߡ޿ࠆߚ߼㧘዁᧪ߦะߌߡ⥃ᐥ㧘ᢎ⢒㧘⎇ⓥ߇චಽⴕ߃ࠆ
ੱ⊛లታ߇ᔅⷐߢ޽ࠆ‫߼ߚߩߎޕ‬㧘ౝᄖࠍ฽߼ߚฦ⸻≮⑼㧘ฦಽ㊁㧘ઁᣉ⸳ߣߩ౒ห⎇ⓥࠍᦝߦలታߐ
ߖࠆᔅⷐ߇޽ࠆ‫ߚ߹ޕ‬㧘ౕ૕⊛ࡊࡠࠫࠚࠢ࠻߅ࠃ߮ࠬ࠻࡜࠹ࠫ࡯ࠍᦝߦផᢚߒ㧘step by step ߢ⃻ታน⢻ߥ߽ߩߣߒߡ޿߆ߥߌࠇ߫ߥࠄߥ޿‫ޕ‬
੹ᓟߩዷᦸ
2004 ᐕ 6 ᦬ߦᣂ∛㒮߇Ⓙ௛ߒ㧘ቢో㔚ሶࠞ࡞࠹ൻߐࠇߚߚ߼㧘↹௝ᖱႎ࠺ࠫ࠲࡞ൻߦࠃࠅ㧘↹௝⸃ᨆߩᐢ▸࿐ߥᔕ↪߇น⢻ߣߥࠅ㧘∝଀Ფߩ↹௝Ყセ߿ห৻∝଀ߩ⚻ᤨ⊛ߥᄌൻߥߤ߽ኈᤃߦ್೎น⢻ߦߥߞߚ‫ߚ߹ޕ‬㧘ක≮ᯏེߩᦝߥࠆㅴᱠߦࠃࠅ㧘ฦ⒳↹௝⸻ᢿߩ⎇ⓥߪߐࠄߦ㜞ᐲൻߒ㧘߹ߔ߹ߔ⋓ࠎߦߥࠆߣ੍ᗐߐࠇࠆ‫ޕ‬2007 ᐕߦߪ PET-CT ߇Ⓙ௛ࠍߪߓ߼㧘2009 ᐕ߆ࠄߪ 64 ೉ CT ߇ዉ౉ߐࠇࠆ੍ቯߢ޽
ࠆ‫ߡߒߘޕ‬㧘ࠦࡦࡇࡘ࡯࠲ߦࠃࠆ↹௝ಣℂߣੱᎿ⍮⢻ࠍ↪޿ߚ↹௝⸻ᢿᡰេࠪࠬ࠹ࡓߩ⊒ዷߣ߽⋧଼ߞߡ㧘઒ᗐౝⷞ㏜ߦࠃࠆᶖൻ▤ᬌ⸻㧘੃≸⸻ᢿ㧘⣻ㇱ↹௝⸻ᢿߥߤߩ♖ᐲ߇ࠃࠅ৻ጀ㜞߹ࠆߎߣ߇ᦼᓙߐ
ࠇࠆ‫ᦨޕ‬ᣂߩ Interventional Radiology ᛛⴚߦࠃࠆૐଚⷅᴦ≮ߦ㑐ߔࠆ⎇ⓥ߽⋓ࠎߣߥࠆߢ޽ࠈ߁‫߹ޕ‬ߚ㧘⚦⢩߿ಽሶ࡟ࡌ࡞ߢߩᩭකቇ⤳ེᯏ⢻⹏ଔ߇ߢ߈ࠆࠃ߁ߦߥࠆߣ㧘ࠕࡐ࡯࠻ࠪࠬߩ↹௝ൻ߿ฦ⒳ઍ
⻢ߩ↹௝⴫␜߇น⢻ߣߥࠅ㧘ㄭ޿዁᧪⥃ᐥ߳ᔕ↪ߢ߈ࠆน⢻ᕈࠍ߽⒁߼ߡ޿ࠆ‫ޕ‬᡼኿✢ᴦ≮㑐ㅪߢߪ㧘᡼኿✢ᴦ≮ⵝ⟎߇ᦨᣂߩⵝ⟎߳ᦝᣂߐࠇࠆ੍ቯߢ޽ࠅ㧘ࠃࠅലᨐ⊛ߢ೽૞↪ߩዋߥ޿᡼኿✢ᴦ≮߇น⢻ߣߥࠆߢ޽ࠈ߁‫޿઻ߦࠇߎޕ‬ᒝᐲᄌ⺞᡼኿✢ᴦ≮ᴺ㧔IMRT㧕ߪ੹ᓟᄢ߈ߊ⊒ዷߔࠆߣᕁࠊࠇࠆ‫ޕ‬᡼኿✢ᴦ≮ߪ㧘Radiation Oncology ߣߒߡ㓸ቇ⊛ᴦ≮ߣߒߡ߽⊒ዷߒߡ߅ࠅ㧘੹ᓟ߽ߘߩᣇะᕈߪᄌࠊࠄߥ޿ߣᕁࠊࠇࠆ‫ߚ߹ޕ‬㧘↲⁁⣼ᯏ⢻੣ㅴ∝߿↲⁁⣼߇ࠎߦኻߒߡⴕࠊࠇߡ߈ߚ㕖ኒኽ᡼኿✢ᴦ≮ߪ㧘੹ᓟᣂߚߥ᡼኿ᕈක⮎ຠ߇㐿⊒ߐࠇߡ߅ࠅ㧘ߘߩਛߢߪ㧘89Sr㧔ࡔ࠲ࠬ࠻ࡠࡦ㧕ࠍ↪ ޿ ߚ 㛽 ォ ⒖ ߩ ᴦ ≮ ߿ 㕖 ࡎ ࠫ ࠠ ࡦ ࡝ ࡦ ࡄ ⣲ ߦ ኻ ߔ ࠆ ᛫ ේ ᛫ ૕ ෻ ᔕ ࠍ ೑ ↪ ߒ ߚ 90Y-Ibritumomab
Tiuxetan㧔࠯ࡃ࡝ࡦ㧕ߪ੹߹ߢߦߥ޿ᣂߒ޿ In Vivo ߦࠃࠆ᡼኿✢ᴦ≮ᴺߣߒߡᦼᓙߐࠇߡ޿ࠆ‫ޕ‬㧙㧙㧔8㧕∉ቇ࡮੍㒐කቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
∉ቇࠍᣇᴺ⺰ߣߒߡ↪޿ߚ߇ࠎߘߩઁߩ↢ᵴ⠌ᘠ∛ߩ࡝ࠬࠢⷐ࿃ࠍ᣿ࠄ߆ߦߔࠆ⎇ⓥ㧘ⴕേ⑼ቇ෸߮⚻ᷣቇ╬␠ળ⑼ቇߩᚻᴺߦၮߠߊක≮⹏ଔ⎇ⓥ߿ᖚ⠪ⴕേ㧘කᏧ࡮ᖚ⠪㑐ଥߦ㑐ߔࠆ⎇ⓥࠍ߅ߎߥߞߡ޿ࠆ‫ޕ‬޿ߕࠇ߽ੱ㑆ߩ࡜ࠗࡈࠬ࠲ࠗ࡞࡮ⴕേߦ㊀ὐࠍ߅߈㧘ੱ㑆㓸࿅ࠍኻ⽎ߣߒߡ޿ࠆ‫ޕ‬1㧕߇ࠎߩ∉ቇ⎇ⓥ
߇ࠎߩ∉ቇ⎇ⓥߩਛᔃߪ㧘ᐔᚑ 4 ᐕߦ㐿ᆎߒߚ㜞ጊᏒ૑᳃⚂ 3 ਁੱࠍኻ⽎ߣߒߚࠦࡎ࡯࠻⎇ⓥ㧔㜞ጊࠬ࠲࠺ࠖ㧕ߢ޽ࠆ‫ߦᤨࡦࠗ࡜ࠬ࡯ࡌޕ‬㘩↢ᵴࠍਛᔃߣߒߚஜᐽߣ↢ᵴ⠌ᘠߦ㑐ߔࠆ⺞ᩏࠍ߅ߎߥߞߡ߅ࠅ㧘ߘߩᓟߩ߇ࠎ⊒↢ߦߤߩࠃ߁ߥ↢ᵴⅣႺⷐ࿃߇㑐ㅪߔࠆ߆ࠍ⹏ଔߔࠆ‫ޕ‬ᣢߦᄢ⣺߇ࠎ㧘⢗߇ࠎߩ࡝ࠬࠢⷐ
࿃ߦߟ޿ߡႎ๔ߒߡ޿ࠆ߇㧘⃻࿷㧘ㅴⴕਛߢ㧘ઁߩ⤳ེߩ߇ࠎߦߟ޿ߡ߽੹ᓟႎ๔ࠍട߃ࠆ੍ቯߢ޽ࠆ‫ޕ‬੃߇ࠎߦ㑐ߒߡߪ㧘࡝ࠬࠢⷐ࿃୥⵬ߣߒߡᄢ⼺៨ข߿ࠗ࠰ࡈ࡜ࡏࡦઍ⻢‛㧘ᄛ㑆ᾖ᣿㧘ࡔ࡜࠻࠾ࡦߦ⌕⋡ߒ㧘ࠤ࡯ࠬ࡮ࠦࡦ࠻ࡠ࡯࡞⎇ⓥ߿ᮮᢿ⎇ⓥߩ࠺ࠩࠗࡦߢ੃߇ࠎ࡝ࠬࠢ߿ࠛࠬ࠻ࡠࠥࡦ୯㧘IGF-1 ୯㧘੃⣼⚵❱ኒᐲߥߤ੃߇ࠎߩ࡝ࠬࠢࡑ࡯ࠞ࡯ߣߩ㑐ㅪࠍ⹏ଔߒߡ޿ࠆ‫ߚ߹ޕ‬㧘੃߇ࠎ࡝ࠬࠢߩ⇣ߥࠆᣣᧄੱ㧘ᣣ♽☨࿖ੱ㧘☨࿖⊕ੱᅚᕈߦ߅޿ߡ੃⣼⚵❱ኒᐲࠍ฽߻੃߇ࠎ࡝ࠬࠢߩࡑ࡯ࠞ࡯Ყセ⎇ⓥ߽ࡂࡢࠗ≸࠮ࡦ࠲࡯ߣߩ౒ห⎇ⓥߣߒߡ߅ߎߥߞߡ޿ࠆ‫ޕ‬ሶች㗪ㇱ߇ࠎߦ㑐ߔࠆ⎇ⓥߢߪ㧘ઁᄢቇߣߩ౒หߦࠃࠆሶች㗪ㇱ⇣ᒻᚑᖚ⠪ߩㅊ〔⎇ⓥߦෳടߒ㧘HPV ᗵᨴࠍਛᔃߦሶች㗪ㇱ߇ࠎߩෂ㒾࿃ሶߩหቯࠍ߅ߎߥߞߡ޿ࠆ‫ޕ‬
2㧕↢ᵴ⠌ᘠ∛╬ߩ∉ቇ⎇ⓥ߇ࠎએᄖߦ㧘ᔃⴊ▤㓚ኂ㧘⣖තਛ㧘♧ዩ∛㧘㜞⢽ⴊ∝㧘㜞ⴊ࿶∝ߥߤߩ↢ᵴ⠌ᘠ∛߿⊕ౝ㓚㧘⡊㡆㧘⧎☳∝ߥߤ↢ᵴ⠌ᘠ߇㑐ਈߔࠆߣ⠨߃ࠄࠇࠆ∔ᖚߦߟ޿ߡ߽㜞ጊࠬ࠲࠺ࠖ߿৻⥸ஜᐽᚑੱࠍኻ⽎ߣߒߚᮮᢿ⎇ⓥߢ㧘࡝ࠬࠢⷐ࿃ߩหቯߣ੍㒐ߩ޽ࠅᣇߦߟ޿ߡ⎇ⓥࠍ߅ߎߥߞߡ޿ࠆ‫ߚ߹ޕ‬㧘ᐜఽࠍኻ⽎ߦᮮᢿ⎇ⓥ㧘ㅊ〔⎇ⓥߢࠕ࡟࡞ࠡ࡯ߩ࡝ࠬࠢⷐ࿃ߦߟ޿ߡߩ⎇ⓥ߽ⴕߞߡ޿ࠆ‫ޕ‬
3㧕ᩕ㙃∉ቇ⎇ⓥ㘩ຠ㧘ᩕ㙃⚛㧘․ߦࠗ࠰ࡈ࡜ࡏࡦ៨ขࠍਛᔃߦࡎ࡞ࡕࡦߦ㑐ㅪߔࠆ∔ᖚ߿∝⁁ߦߟ޿ߡ㑐ㅪᕈࠍ⎇ⓥߒߡ޿ࠆ‫ޕ‬㘩੐߆ࠄ៨ขߐࠇࠆࡔ࡜࠻࠾ࡦߦߟ޿ߡ߽⌕⋡ߒ㧘ߘߩஜᐽᓇ㗀ࠍ⹏ଔߔࠆ⎇ⓥࠍ㐿ᆎߒߡ޿ࠆ‫ޕ‬
4㧕ᖚ⠪ߩⴕേකቇ⎇ⓥ
߇ࠎᖚ⠪ߩ♖␹⊛ߥㆡᔕᐲߦ㑐ਈߔࠆᔃℂቇ⊛㧘ⴕേቇ⊛࿃ሶࠍ⷗಴ߘ߁ߣߒߡ޿ࠆ‫ߚ߹ޕ‬㧘ᴦ≮߿⮎೷ߦኻߔࠆᖚ⠪ߩᗧᕁ᳿ቯ߿ߘࠇߦ෸߷ߔⷐ࿃ߩಽᨆࠍⴕߞߡ޿ࠆ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
᳗↰⍮㉿
ಎᢎ᝼(૬છ)㧦 㜞Ⴆ⋥⢻
ਛ᧛ߎߕᨑ
ഥᢎ㧦
๺↰ᕺሶ
ഥᢎ㧦

Chisato Nagata
Naoyoshi Takatsuka
Kozue Nakamura
Keiko Wada

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ᳗↰⍮㉿. ੃߇ࠎߩ∉ቇߣ੍㒐㧦↰ፉ๺㓶㧘ฎ㊁⚐ౖ ✬㧘߇ࠎ⎇ⓥߩ޿߹ ╙ 4 Ꮞ㧘߇ࠎߩ∉ቇ㧘᧲੩㧦᧲੩಴ ળ㧧2006 ᐕ㧦51㧙60㧚
2㧕 ᳗↰⍮㉿. ࠗ࠰ࡈ࡜ࡏࡦߩࡅ࠻ஜᐽߦ߅ߌࠆᓎഀ̆∉ቇ⎇ⓥ߆ࠄ㧦⷏Ꮉ⎇ᰴ㇢ ⋙ୃ㧘㘩ຠᯏ⢻ᕈߩ⑼ቇ㧘↥ᬺᛛⴚࠨ࡯ࡆࠬ࠮ࡦ࠲࡯㧘᧲੩㧧2008 ᐕ㧚⪺ᦠ㧔᰷ᢥ㧕
1㧕 Nagata C. Soyfood consumption in Asian countries versus western countries and epidemiologicalevidence for soy health effects. In: Discover the World of Soy: Impact on Health. Belgium:Alpro
Soya;2008:22-25.
✚⺑㧔๺ᢥ㧕
1㧕 ᳗↰⍮㉿㧚ᣂⷙ࡝ࠬࠢࡈࠔࠢ࠲࡯ߣ੍㒐⎇ⓥ. ᣣᧄ⥃ᐥ 2006 ᐕ㧧64 Ꮞ㧦437㧙441.
2㧕 ᳗↰⍮㉿㧚㜞⢽ⴊ∝ ࠗ࠰ࡈ࡜ࡏࡦߣࠦ࡟ࠬ࠹ࡠ࡯࡞ߩ㑐ଥߪ㧫Q&A ߢࠊ߆ࠆ. ⢈ḩߣ♧ዩ∛㧚2006㧧5
Ꮞ㧦433㧙434㧚
✚⺑㧔᰷ᢥ㧕ߥߒ㧙㧙ේ⪺㧔๺ᢥ㧕ߥߒේ⪺㧔᰷ᢥ㧕
1㧕 Matsumoto K, Yasugi T, Oki A, Fujii T, Nagata C, Sekiya S, Hoshiai H, Taketani Y, Kanda T, Kawana
T, Yoshikawa H. IgG antibodies to HPV16, 52, 58 and 6 L1-capsids and spontaneous regression of
cervical intraepithelial neoplasia. Cancer Lett. 2006;231:309-313.
2㧕 Mizoue T, Inoue M, Tanaka K, Tsuji I, Wakai K, Nagata C, Tsugane S, Research Group for theDevelopment and Evaluation of Cancer Prevention Strategies in Japan. Tobacco smoking andcolorectal cancer risk: an evaluation based on a systematic review of epidemiologic evidence among theJapanese population. Jpn J Clin Oncol. 2006;36:25-39.
3㧕 Wakai K, Inoue M, Mizoue T, Tanaka K, Tsuji I, Nagata C, Tsugane S, Research Group for theDevelopment and Evaluation of Cancer Prevention Strategies in Japan. Tobacco smoking and lungcancer risk: an evaluation based on a systematic review of epidemiological evidence among theJapanese population. Jpn J Clin Oncol. 2006;36:309-324.
4㧕 Nagata C, Mizoue T, Tanaka K, Tsuji I, Wakai K, Inoue M, Tsugane S, Research Group for theDevelopment and Evaluation of Cancer Prevention Strategies in Japan: Tobacco smoking and breast
cancer risk: an evaluation based on a systematic review of epidemiological evidence among theJapanese population. Jpn J Clin Oncol. 2006;36:387-394.
5㧕 Messina M, Nagata C, Wu AH. Estimated Asian adult soy protein and isoflavone intakes. Nutr Cancer.
2006;55:1-12.
6㧕 Tanaka K, Tsuji I, Wakai K, Mizoue T, Nagata C, Inoue M, Tsugane S, Research Group for theDevelopment and Evaluation of Cancer Prevention Strategies in Japan. Cigarette smoking and livercancer risk: an evaluation based on a systematic review of epidemiologic evidence among Japanese.
Jpn J Clin Oncol. 2006;36:445-456
7㧕 Mizoue T, Tanaka K, Tsuji I, Wakai K, Nagata C, Otani T, Inoue M, Tsugane S, Research Group for theDevelopment and Evaluation of Cancer Prevention Strategies in Japan. Alcohol drinking andcolorectal cancer risk: an evaluation based on a systematic review of epidemiologic evidence among theJapanese population. Jpn J Clin Oncol. 2006;36:582-597.
8㧕 Nagata C, Oba S, Shimizu H. Associations of menstrual cycle length with intake of soy, fat, and dietaryfiber in Japanese women. Nutr Cancer. 2006;54:166-170.
9㧕 Oba S, Shimizu N, Nagata C, Shimizu H, Kametani M, Takeyama N, Ohnuma T, Matsushita S. The
relationship between the consumption of meat, fat, and coffee and the risk of colon cancer: A
prospective study in Japan. Cancer Lett. 2006;244:260-267.
10㧕 Nagata, C, Iwasa S, Shiraki M, Shimizu H. estrogen and ǩ-fetoprotein levels in maternal andumbilical cord blood samples in relation to birth weight. Cancer Epidemiol Biomarkers Prev.
2006;15:1469-1472.
11㧕 Nagata, C, Iwasa S, Shiraki M, Ueno T, Uchiyama S, Urata K, Sahashi Y, Shimizu H. Associations
among maternal soy intake, isoflavone levels in urine and blood samples, and maternal and umbilicalhormone concentrations (Japan). Cancer Causes Control. 2006;17:1107-1113.
12㧕 Nishino Y, Inoue M, Tsuji I, Wakai K, Nagata C, Mizoue T, Tanaka K, Tsugane S, Research Group forthe Development and Evaluation of Cancer Prevention Strategies in Japan. Alcohol Tobacco smoking
and gastric cancer risk: an evaluation based on a systematic review of epidemiologic evidence among
the Japanese population. Jpn J Clin Oncol. 2006;36:800-807.
13㧕 Maskarinec G, Paganol I, Chen Z, Nagata C, Gram IT. Ethnic and geographic differences inmammographic density and their association with breast cancer incidence.Breast Cancer Res Treat.
2007;104:47-56.
14㧕 Wakai K, Nagata C, Mizoue T, Tanaka K, Tsuji I , Inoue M, Tsugane S, Research Group for theDevelopment and Evaluation of Cancer Prevention Strategies in Japan. Alcohol drinking and lungcancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese
population. Jpn J Clin Oncol. 2007;37:168-174.
15㧕 Nagata C, Iwasa S, Shiraki M, Sahashi Y, Shimizu H. Association of maternal fat and alcohol intake
with maternal and umbilical hormone levels and birth weight. Cancer Sci. 2007;98:869-873.
16㧕 Hamaguchi M, Kojima T, Takeda N, Nagata C, Takeda J, Sarui H, Kawashita Y, Yoshida N, Suetsugu
A, Kato T, Okuda J, Ida K. Nonalcoholic fatty liver disease is a novel predictor of cardiovasculardisease. World J Gastroenterol. 2007;13:1579-1584.
17㧕 Takata Y, Maskarinec G, Rinaldi S, Kaarks R, Nagata C. Serum insulin-like growth factor-I levels
among women in Hawaii and Japan with different levels of tofu intake. Nutr Cancer. 2006;56:136-142.
18㧕 Maskarinec G, Takata Y, Chen Z, Nagata C, Pagano I, Hayashi K, Arendell L, Skeir G, Rinaldi S,
Kaaks S. IGF-I and mammographic density in four geographic locations: A pooled analysis. Int J
Cancer. 2007;121:1786-1792.
19㧕 Oba S, Nagata C, Snimizu N, Shimizu H, Kametani M, Takayama N, Ohmura T, Matsushita S. Soy
product consumption and the risk of colon cancer: a prospective study in Takayama, Japan. Nutr㧙㧙

IF 3.398

IF 1.269

IF 1.269

IF 1.269
IF 2.361

IF 1.269

IF 1.269
IF 2.361

IF 3.398

IF 4.500

IF 2.847

IF 1.269

IF 4.671

IF 1.376
IF 3.869

IF 2.361

IF 4.693

Cancer. 2007;57:151-157.
20㧕 Nagata C, Mizoue T, Tanaka K, Tsuji I , Wakai K, Inoue M, Tsugane S, Research Group for theDevelopment and Evaluation of Cancer Prevention Strategies in Japan. Alcohol drinking and breast
cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese
population. Jpn J Clin Oncol. 2007;37:568-574.
21㧕 Inoue M, Wakai K, Nagata C, Mizoue T, Tanaka K, Tsuji I , Tsugane S, Research Group for theDevelopment and Evaluation of Cancer Prevention Strategies in Japan. Alcohol drinking and totalcancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese
population. Jpn J Clin Oncol. 2007;37:692-700.
22㧕 Tanaka T, Nagata C, Oba S, Takatsuka N, Shimizu H. Prospective cohort study of body mass index inadolescence and death from stomach cancer in Japan. Cancer Sci. 2007;98:1785-1789.
23㧕 Sawada A, Aoyama A, Yamamoto T, Takatsuka N. Long-term therapeutic outcome of acute primary
angle closure in Japanese. Jpn J Ophthalmol. 2007;51:353-359.
24㧕 Nagata C, Matsubara T, Hara T, Fujita H, Nagao Y, Yamamoto S, Shibuya C, Kashiki Y, Shimizu H.
Urinary 6-sulfatoxymelatonin and mammographic density in Japanese women. Cancer Epidemiol
Biomarkers Prev. 2007;16:2509-2512.
25㧕 Shimazu T, Tsuji I, Inoue M, Wakai K, Nagata C, Mizoue T, Tanaka K, Tsugane S; Research Group forthe Development and Evaluation of Cancer Prevention Strategies in Japan. Alcohol drinking andgastric cancer risk: an evaluation based on a systematic review of epidemiologic evidence among theJapanese population. Jpn J Clin Oncol. 2008;38:8-25.
26㧕 Nagata C, Ueno T, Uchiyama S, Nagao Y, Yamamoto S, Shibuya C, Kashiki Y, Shimizu H. Dietary andlifestyle correlates of urinary excretion status of equol in Japanese women. Nutr Cancer.
2008;60:49-54.
27㧕 Mizoue T, Inoue M, Wakai K, Nagata C, Shimazu T, Tsuji I, Otani T, Tanaka K, Matsuo K, Tamakoshi
A, Sasazuki S, Tsugane S; Research Group for Development and Evaluation of Cancer Prevention
Strategies in Japan. Alcohol drinking and colorectal cancer in Japanese: a pooled analysis of resultsfrom five cohort studies. Am J Epidemiol. 2008;167:1397-1406.
28㧕 Oba S, Nakamura K, Sahashi Y, Hattori A, Nagata C. Consumption of vegetables alters morning
urinary 6-sulfatoxymelatonin concentration. Nutr Cancer. 2008;45:17-23.
29㧕 Nakamura K, Nagata C, Oba S, Takatsuka N, Shimizu H. Fruit and vegetable intake and mortality
from cardiovascular disease are inversely associated in Japanese women but not in men. J Nutr.
2008;138:1129-1134.
30㧕 Nagata C, Nakamura K, Fujii K, Kawachi T, Takatsuka N, Oba S, Shimizu H. Smoking and risk ofcedar pollinosis in Japanese men and women. Int Arch Allergy Immunol. 2008;147:117-124.
31㧕 Nagata C, Nagao Y, Yamamoto S, Shibuya C, Kashiki Y, Shimizu H. Light exposure at night, urinary
6-sulfatoxymelatonin, and serum estrogens and androgens in postmenopausal Japanese women.
Cancer Epidemiol Biomarkers Prev. 2008;17:1418-1423.
32㧕 Nagata C, Nakamura K, Fujii K, Kawachi T, Takatsuka N, Oba S, Shimizu H. Soy isoflavone intake is
not associated with the development of cedar pollinosis in adults. J Nutr. 2008;138:1372-1376.
33㧕 Hirokawa K, Nagata C, Takatsuka N, Shimizu N, Shimizu H. Rationality/anti-emotionality
personality and dietary habits in a community population in Japan. J Epidemiol. 2008;18:183-190.
34㧕 Oba S, Nagata C, Nakamura K, Takatsuka N, Shimizu H. Self-reported diabetes mellitus and risk ofmortality from all causes, cardiovascular disease, and cancer in Takayama: a population-based
prospective cohort study in Japan. J Epidemiol. 2008;18:197-203.
35㧕 Tanaka K, Tsuji I, Wakai K, Nagata C, Mizoue T, Inoue M, Tsugane S; Research Group for theDevelopment and Evaluation of Cancer Prevention Strategies in Japan. Alcohol drinking and livercancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese
population. Jpn J Clin Oncol. 2008;38:816-838.

IF 2.361

IF 1.269

IF 1.269
IF 3.869
IF 0.770

IF 4.642

IF 1.269

IF 2.361

IF 5.285
IF 2.361

IF 3.771

IF 4.642
IF 3.771
IF 1.906

IF 1.906

IF 1.2694㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦᳗↰⍮㉿㧘⎇ⓥಽᜂ⠪㧦ᷡ᳓ᒄਯ㧘ᱞ↰ೣਯ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(B)㧦
ᾖ᣿ⅣႺߣ੃߇ࠎ࡝ࠬࠢߩ㑐ଥߦ੺࿷ߔࠆࡔ࡜࠻࠾ࡦߩᓎഀ㧧ᐔᚑ 18 ᐕᐲ㧧4,500 ජ౞2㧕 ⎇ⓥઍ⴫⠪㧦᳗↰⍮㉿㧘⎇ⓥಽᜂ⠪㧦ᳯፒቁⴕ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄․ቯ⎇ⓥ㧦ࠛࠢࠝ࡯࡞
↥↢ߣ੃߇ࠎ࡝ࠬࠢߩ㑐ㅪ߅ࠃ߮ࠛࠢࠝ࡯࡞↥↢⢻ߩⷙቯ࿃ሶߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18㧙19 ᐕᐲ㧧
9,900 ජ౞(4,800㧦5,100 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦ᵤ㊄᣽৻㇢㧘⎇ⓥಽᜂ⠪㧦᳗↰⍮㉿ઁ㧘ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄㧘╙ 3 ᰴኻ߇ࠎ✚วᚢ⇛⎇ⓥ੐ᬺ㧧↢ᵴ⠌ᘠᡷༀߦࠃࠆ߇ࠎ੍㒐ᴺߩ㐿⊒ߣ⹏ଔ㧧ᐔᚑ 18㧙20 ᐕᐲ㧧20,000 ජ౞(7,000㧧7,000㧧6,000 ජ౞)
4㧕 ⎇ⓥઍ⴫⠪㧦ศᎹ⵨ਯ㧘⎇ⓥಽᜂ⠪㧦㜞Ⴆ⋥⢻ઁ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄․ቯ㗔ၞ⎇ⓥ㧦ሶ㧙㧙ች㗖ㇱ⊒߇ࠎߩኋਥⷐ࿃ߣߒߡߩ HLA ㆮવሶᄙဳߦ㑐ߔࠆ᳃ᣖ∉ቇ⊛⎇ⓥ㧧ᐔᚑ 18㧙19 ᐕᐲ㧧
1,600 ජ౞(800㧦800 ජ౞)
5㧕 ⎇ⓥઍ⴫⠪㧦㜞Ⴆ⋥⢻㧘⎇ⓥಽᜂ⠪㧦⷏᧛๟ਃ㧧ක≮⚻ᷣ⎇ⓥᯏ᭴⎇ⓥഥᚑ㊄㧘ක≮ᖱႎࠪࠬ࠹ࡓ
߇∛㒮↢↥ᕈ㧘∛㒮ౝㇱⅣႺ෸߮ᄖㇱⅣႺߦ෸߷ߔᓇ㗀ߩ⹏ଔ㧧ᐔᚑ 18 ᐕᐲ㧧750 ජ౞6㧕 ⎇ⓥઍ⴫⠪㧦ਛ᧛ߎߕᨑ㧘⎇ⓥಽᜂ⠪㧦᳗↰⍮㉿㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌(⎇ⓥ)㧦Უሶߦ߅ߌࠆ⢽⾰෸߮ࠗ࠰ࡈ࡜ࡏࡦࠍਛᔃߣߒߚᩕ㙃៨ขߣࠕ࡟࡞ࠡ࡯∔ᖚߣߩ㑐ㅪᕈߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 19 ᐕᐲ㧧
1,130 ජ౞7㧕 ⎇ⓥઍ⴫⠪㧦᳗↰⍮㉿㧘⎇ⓥಽᜂ⠪㧦ᷡ᳓ᒄਯ㧘ᱞ↰ೣਯ, ⮮↰ᐢᔒ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(B)㧦੃߇ࠎ࡝ࠬࠢߣߒߡߩࠛࠬ࠻ࡠࠥࡦ㧘ࡔ࡜࠻࠾ࡦߣࠨ࡯ࠞ࠺ࠖࠕࡦ࡝࠭ࡓߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 19㧙20 ᐕᐲ㧧10,000 ජ౞(5,200㧧4,800 ජ౞)
8㧕 ⎇ⓥઍ⴫⠪㧦᳗↰⍮㉿, ⎇ⓥಽᜂ⠪㧦ᷡ᳓ᒄਯ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄․ቯ㗔ၞ⎇ⓥ㧦ฦ⒳ࠕࡒ
ࡁ㉄߅ࠃ߮ DNA ࡔ࠴࡞ൻߦ㑐ਈߔࠆ㘩੐࿃ሶߣ߇ࠎ⟕ᖚߦ㑐ߔࠆࠦࡎ࡯࠻⎇ⓥ㧧ᐔᚑ 20 ᐕᐲ㧧
4,400 ජ౞9㧕 ⎇ⓥઍ⴫⠪㧦ਛ᧛ߎߕᨑ㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌(࿾ၞㅪ៤㧦৻⥸)㧦౏⊛ᣉ⸳ߢߩ࡝࠭ࡓㆆ߮ߣኾ㐷⊛⋧⺣ࠍㅢߓߚ⢒ఽᡰេᵴേ㧧ᐔᚑ 20 ᐕᐲ㧧260 ජ౞2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥ1㧕 ᄢႦ⵾⮎ᩣᑼળ␠ ዩਛࠗ࠰ࡈ࡜ࡏࡦઍ⻢‛᷹ቯߩߚ߼ߩ౒ห⎇ⓥ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬ᳗↰⍮㉿㧦
1㧕 ᧲ᶏ౏ⴐⴡ↢ቇℂ੐(㨪⃻࿷)2㧕 ᣣᧄ౏ⴐⴡ↢ቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ∉ቇળ⹏⼏ຬ(㨪⃻࿷)ਛ᧛ߎߕᨑ㧦
1㧕 ᧲ᶏ౏ⴐⴡ↢ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙṶ⠪㧘ᐳ㐳᳗↰⍮㉿㧦
1㧕 The 73rd Annual Meeting of KoSFoST Korea-China-Japan International Symposium “Asian
Summit for World Foods” (2006.06, Jeju, Korea.:Soy intake and biomarkers of breast cancer risk
among Japanese women; symposist)2㧕 ╙ 8 ࿁ᣣᧄ≸ቇળᏒ᳃౏㐿⻠ᐳ(2006 ᐕ 9 ᦬㧘ᮮᵿ㧘߇ࠎߦߥࠄߥ޿ߚ߼ߦ㧘߇ࠎࠍᣧߊߺߟߌࠆ
ߚ߼ߦ‫ࠍࠎ߇ޟ‬㒐ߋ㘩੐‫ޠ‬Ṷ⠪)3㧕 The National Institute of Environmental Health Sciences (NIEHS) Workshop, "Circadian
Rhythms in Human Health and Disorders" (2006.09, Georgetown, Washington, DC.: Light
exposure at night, melatonin, and cancer; speaker)
4㧕 ╙ 44 ࿁ᣣᧄ≸ᴦ≮ቇળ(2006 ᐕ 10 ᦬㧘᧲੩㧘߇ࠎ੍㒐ߩᦨ೨✢‫ޠࡦࡏ࡜ࡈ࠰ࠗߣࠎ߇੃ޟ‬Ṷ⠪)‫∉ࠎ߇ޟ‬ቇߩ⚫੺‫ޠ‬Ṷ⠪)
5㧕 ‫․ࠎ߇ޟ‬ቯ‫ޠ‬㕍ዋᐕ࡮Ꮢ᳃౏㐿⻠ᐳ(2006 ᐕ 11 ᦬㧘ᓼፉ㧘㧙㧙6㧕 ╙ 4 ࿁ᣣᧄ੍㒐කቇળ(2006 ᐕ 12 ᦬㧘ߐ޿ߚ߹Ꮢ㧘‫ޟ‬ᄢ⼺࡮ࠗ࠰ࡈ࡜ࡏࡦߣᅚᕈߩஜᐽ‫ޠ‬Ṷ⠪)
7㧕 Soy Nutrition Institute Japan (2007 ᐕ 2 ᦬㧘᧲੩ ‫ᦝޟ‬ᐕᦼᅚᕈߣࠗ࠰ࡈ࡜ࡏࡦ‫ޠ‬Ṷ⠪)8㧕 7th International Symposium Role of Soy in health and disease prevention.(2007.05, Bangkok.
Studies on soy intake and risk of breast cancer in Japanese women; speaker)
9㧕 3rd International Conference on Polyphenols and Health (2007.11, Kyoto, Dietary soy and riskof breast cancer; symposist)10㧕 ␹ᄹᎹ⋵߇ࠎ࠮ࡦ࠲࡯߇ࠎࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᅚᕈߣ߇ࠎ‫(ޠ‬2007 ᐕ 12 ᦬㧘ᮮᵿ‫ޟ‬ᅚᕈߣ੃߇ࠎ‫ޠ‬Ṷ⠪)11㧕 ╙ 13 ࿁ᗲ⍮⋵߇ࠎ࠮ࡦ࠲࡯࿖㓙ࠪࡦࡐࠫ࠙ࡓ‫∉ࠎ߇੃ޟ‬ቇ੍㒐ߣ୘೎ൻ⸻ᢿ࡮ᴦ≮ߩዷᦸ‫(ޠ‬2008ᐕ 2 ᦬㧘ᐳ㐳)12㧕 JCA-AACR Cancer Research Conference. The Latest Advances in Breast Cancer Research:
From Basic Science to Therapeutics (2008.07, Hyogo, Japan :Hormone-related risk factors forbreast cancer in Japanese women; speaker)
13㧕 8th International Symposium Role of Soy in Health and Disease Prevention (2008.11, Tokyo,
Chairperson)㜞Ⴆ⋥⢻㧦
1㧕 ጘ㒂⋵࿖଻੐ᬺផㅴ࠻࠶ࡊ࠮ࡒ࠽࡯(2006 ᐕ 1 ᦬㧘ጘ㒂㧘‫♧ޟ‬ዩ∛੍㒐ߣ࿾ၞߩขࠅ⚵ߺ‫ޠ‬Ṷ⠪)
2㧕 ᴤൻቇ⻠Ṷળ‫ޟ‬ᯏ⢻ᕈ㘩ຠߩ⑼ቇߣዷᦸ‫(ޠ‬2006 ᐕ 11 ᦬㧘ጘ㒂㧘‫ⴊޟ‬ᷡ⢽⾰ߦኻߔࠆᄢ⼺ߩᓇ㗀‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ1㧕 ᳗↰⍮㉿㧦For Outstanding Contribution to Increasing Scientific Understanding of the Health
Effects of Soyfoods and Soybean Constituents. 8th International Symposium Role of Soy in
Health and Disease Prevention (2008)9㧚␠ળᵴേ᳗↰⍮㉿㧦
1㧕 ᳗↰⍮㉿㧦ౝ㑑ᐭ㘩ຠ቟ోᆔຬળኾ㐷ຬ(㨪⃻࿷)2㧕 ᳗↰⍮㉿㧦ᣣᧄቇⴚળ⼏ㅪ៤ળຬ(㨪⃻࿷)3㧕 ᳗↰⍮㉿㧦ጘ㒂Ꮢ଻ஜක≮ክ⼏ળᆔຬ(㨪⃻࿷)4㧕 ᳗↰⍮㉿㧦ጘ㒂⋵ᑪ▽ክᩏᆔຬળᆔຬ(㨪⃻࿷)5㧕 ᳗↰⍮㉿㧦ጘ㒂⋵߇ࠎኻ╷ផㅴද⼏ળᆔຬ(㨪⃻࿷)6㧕 ᳗↰⍮㉿㧦ጘ㒂⋵ⅣႺᓇ㗀⹏ଔክᩏળᆔຬ(㨪⃻࿷)㜞Ⴆ⋥⢻㧦ක≮⚻ᷣቇಽ㊁ෳᾖਛ᧛ߎߕᨑ㧦
1㧕 Უሶ↢ᵴᡰេᣉ⸳‫⪇࡯ࡢ࡜ࡈ࡮ࡦࠨޟ‬㓁‫(ޠ‬㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ᳗↰⍮㉿㧦↢ᵴ⠌ᘠᡷༀߦࠃࠆ੃߇ࠎ੍㒐ᴺߩ㐿⊒ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 18 ᐕᐲ㧘ᐔᚑ 19 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ(ਥછ⎇ⓥ⠪ᵤ㊄᣽৻㇢)㧦53㧙60(2007 ᐕ 4 ᦬)㧘73
㧙80(2008 ᐕ 4 ᦬)
11㧚ႎ㆏1㧕 ᳗↰⍮㉿㧦߇ࠎߩේ࿃ 3 ഀ߇㘩੐㧦ᦺᣣᣂ⡞(2006 ᐕ 10 ᦬ 30 ᣣ)
2㧕 ᳗↰⍮㉿㧦ᄢ⼺ߣᦝᐕᦼ∝⁁㧦ᦺᣣᣂ⡞(2008 ᐕ 10 ᦬ 20 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔ
ᬺ❣Ⓧ਄ߍߣ⎇ⓥ⾌ߩ⏕଻ࠍ⋡ᜰߔᔅⷐ߇޽ࠆ‫ޕ‬㧙㧙⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ࡔࠞ࠾࠭ࡓㅊ᳞ࠍ㊀ⷞߒ߇ߜߢ޽ࠆකቇ⎇ⓥಽ㊁ߦ߅޿ߡ㧘ᒰቇ໧ಽ㊁ߩࠃ߁ߦੱ㑆㓸࿅ࠍኻ⽎ߦ࿃ᨐ㑐ଥߩᛠីࠍਛᔃߣߔࠆ⎇ⓥߩ㊀ⷐᕈࠍᒝ⺞ߔࠆ‫⥃ޕ‬ᐥ∉ቇࠍ฽߼∉ቇ⊛ᣇᴺ⺰ߩ⚫੺߽᦭↪ߢ޽ࠈ
߁‫ޕ‬
੹ᓟߩዷᦸ
ࠛࡆ࠺ࡦࠬᕈߩ㜞޿∉ቇ⎇ⓥߣߒߡᄢⷙᮨࠦࡎ࡯࠻⎇ⓥߩᔅⷐᕈ߽⹺⼂ߐࠇߡ߈ߚ߇㧘⎇ⓥෳട⠪ߩ⏕଻㧘୘ੱᖱႎ଻⼔ߩ໧㗴ߪ㧘⎇ⓥ⠪୘ੱߩദജߦଐሽߔࠆߦߪ㒢ᐲ߇޽ࠅ㧘࿖ኅ⊛ࡊࡠࠫࠚࠢ࠻ߣߒ
ߡ૏⟎ߠߌ߇ᦸ߹ߒ޿‫ޕ‬ታ㓙㧘㖧࿖ߢߪ㧘ߘߩࠃ߁ߥᣇᴺߢ∉ቇ⎇ⓥ߇㘧べ⊛ߦ⊒ዷߒߟߟ޽ࠆ‫ޕ‬࿖ߩਥዉߦࠃࠆ⎇ⓥ߇ⴕࠊࠇࠆ႐ว㧘ᄢቇߪߘࠇߦᔅⷐߥኾ㐷ኅ㓸࿅ߩଏ⛎Ḯߣߒߡߩᓎഀࠍᜬߟߢ޽ࠈ߁‫ޕ‬ߘߩ৻ᣇ㧘ᄢቇߪዊⷙᮨߢ޽ࠆ߇઒⺑ᕈߩ㜞޿⎇ⓥ߿ᣇᴺ⺰ߦ㑐ࠊࠆ⎇ⓥߥߤ㧘⁛⥄⦡޽ࠆᚑᨐ߇ⷐ᳞
ߐࠇࠆߣ⠨߃ࠄࠇࠆ‫ߥ⊛ੱޕ‬ల⿷߽฽߼ᣇᴺ⺰ߦ♖ㅢߒߚ⎇ⓥ⠪ߩ⢒ᚑߦദ߼ࠆߣߣ߽ߦ㧘ࠝ࡝ࠫ࠽࡝
࠹ࠖߩ㜞޿⎇ⓥࠍ⋡ᜰߔ‫ޕ‬㧙㧙㧔9㧕⥃ᐥ⣲≌ቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
2008 ᐕ 11 ᦬ߩ┙ߜ਄ߍߚᣂߒ޿ಽ㊁ߢ޽ࠅ㧘ᦨㄭߣߺߦ㊀ⷐᕈࠍჇߒߡ޿ࠆ⥃ᐥ⣲≌ቇ ClinicalOncology ࠍขࠅᛒ߁‫ޕ‬
1. ࿕ᒻ⣲≌ߦߟ޿ߡᚻⴚ㧘ౝⷞ㏜ᴦ≮㧘ൻቇ≮ᴺ㧘᡼኿✢ᴦ≮ߥߤ㧘㓸ቇ⊛ᴦ≮ߩ᭴▽ߣᚑ❣ߩಽᨆࠍⴕߥ߁‫ޕ‬
2. ⴊᶧ⣲≌ߦߟ޿ߡᣂߒ޿࡟ࠫࡔߩ㐿⊒ࠍⴕߥ߁‫ޕ‬
3. 1㧘2 ࠍ㆐ᚑߔࠆ਄ߢᔅⷐߥ⥃ᐥ⹜㛎࠺ࠩࠗࡦߩ⎇ⓥࠍⴕߥ߁‫ޕ‬2㧚ฬ★
ᢎ᝼(૬છ)㧦 ᫪⣁ਭ㓉ᢎ᝼(૬છ)㧦 દ⮮ༀⷙಎᢎ᝼(૬છ)㧦 㢬⷗ ኼ
ේ ᱞᔒ
⥃ᐥ⻠Ꮷ㧦

Hisataka Moriwaki
Yoshinori Ito
Hisashi Tsurumi
Takeshi Hara3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ᷡ᳓㓷ੳ㧘᫪⣁ਭ㓉㧚㕖Ⅳᑼ࡟࠴ࡁࠗ࠼ߦࠃࠆ⢄⊒≸ߩ੍㒐㧦⷏ญୃᐔ✬㧚⢄⎬ᄌߩࡑࡀࠫࡔࡦ࠻㧚᧲੩㧦ක⮎ࠫࡖ࡯࠽࡞␠㧧2007 ᐕ㧦84㧙89㧚
2㧕 ᫪⣁ਭ㓉㧚╙ 5 ┨ ∛ᘒᩕ㙃ߣᩕ㙃≮ᴺ㧘7 ߘߩઁߩ∔ᖚ㧘Ԝ߇ࠎ㧦ᣣᧄ∛ᘒᩕ㙃ቇળ✬㧚ᡷ⸓╙ 2 
⹺ቯ ∛ᘒᩕ㙃ኾ㐷Ꮷߩߚ߼ߩ∛ᘒᩕ㙃ࠟࠗ࠼ࡉ࠶ࠢ㧘᧲੩㧦ࡔ࠺ࠖࠞ࡞࡟ࡆࡘ࡯␠㧧2008 ᐕ㧦248㧙249㧚
3㧕 ቟↰ᶈੑ㧘દ⮮ༀⷙ㧚ᐔ㊁๺ⴕ✬㧚2008 ᐕታ⠌ߦⴕߊ೨ߩⷡ߃ࠆක⮎ຠ㓸㧙᦯⮎ᜰዉߦᓎ┙ߟ㧙㧘᧲੩㧦ᑝᎹᦠᐫ㧧2008 ᐕ㧚
4㧕 ᄢ⍹ੌਃ㧘ᳰᧃ⵨᣿㧘દ⮮ༀⷙ✬⪺㧘߇ࠎൻቇ≮ᴺࡢ࡯ࠢࠪ࡯࠻╙ 3 㧘᧲੩㧦ߓ߶߁㧧2008 ᐕ㧚⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
ߥߒ✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ጊፒஜ〝㧘⨹ᧁኡม㧘᫪⣁ਭ㓉㧚㝼㛽ߦࠃࠆ⋤⣺ᘟᕈἻ∝ᕈ⡺⧘⣲㧘Gastroenterological endoscopy 2008
ᐕ㧧50 Ꮞ㧦66㧙67㧚
2㧕 ═ේජ༹㧘ේ ᱞᔒ㧘㢬⷗ ኼ㧘ᓟ⮮ዏ⛗㧘౗᧛ାብ㧘ศᎹᱞᔒ㧘ጊ↰ବ᮸㧘Ỉ↰㆏ᄦ㧘㜞ᯅ ஜ㧘᫪⣁ਭ㓉㧚ㅧⴊེ⣲≌ߦว૬ߒߚ⊒ᾲᕈᅢਛ⃿ᷫዋ∝ߦኻߔࠆ Biapenem ߩ᦭↪ᕈߦ㑐ߔࠆ⥃ᐥ⊛ᬌ⸛㧘JapanJ Antibiotics 2008 ᐕ㧧61 Ꮞ㧦115㧙121㧚
3㧕 ะ੗ ᒝ㧘Ⴎደᱜ㆏㧘቟↰৻ᦶ㧘ጤ↰࿻੺㧘౷↰ᩕ৻㧘᫪⣁ਭ㓉㧚㕖ಾ㒰⢄㐷ㇱ⢙▤≸ߦኻߔࠆ⢙㆏ࠬ࠹ࡦ࠹ࠖࡦࠣߩᬌ⸛㧘⢙㆏ 2008 ᐕ㧧22 Ꮞ㧦47㧙55㧚
4㧕 ࿯੗᤯ᐔ㧘቟↰৻ᦶ㧘ጤਅᜏม㧘ጊ↰ᢕሶ㧘↰ਛ⑲ౖ㧘㐳↰⌀ੑ㧘ᑝἑༀା㧘᫪⣁ਭ㓉㧚㤛⦡⡺⧘⣲ᕈ⢙ྙἻߣߩ㐓೎߇໧㗴ߣߥߞߚ⢙ྙ≸ߩ 1 ଀㧘⢄⢙⤟ᴦ⎇⹹ 2008 ᐕ㧧6 Ꮞ㧦49㧙54㧚
5㧕 ᧁ᧛␭ሶ㧘⨹ᧁኡม㧘ᄢ㊁ᥓᒾ㧘ዊ㊁ᧁ┨ੱ㧘੗ᷓ⾆჻㧘౗᧛ାብ㧘ᓟ⮮ዏ⛗㧘ᧃᰴ ᷕ㧘⊕ᧁ ੫㧘═ේජ༹㧘ᷡ᳓㓷ੳ㧘ጊ↰ବ᮸㧘㢬⷗ኼ㧘᫪⣁ਭ㓉㧚਄ⴕ⚿⣺㕒⣂≜ࠍᄾᯏߦ⸻ᢿߐࠇߚᖡᕈ࡝ࡦࡄ⣲ߩ 1଀㧘ጘ㒂⋵ౝ⑼කળ㔀⹹ 2008 ᐕ㧧22 Ꮞ㧦59㧙61㧚
6㧕 ਤ⠀㓉㧘᧖ጊᱜ㧘ጟ቟િੑ㧘ጊౝᳯ㉿ሶ㧘⷏၂⟤ᄹሶ㧘᧻ᶆసᒾ㧘ᓟ⮮ජኼ㧘દ⮮ༀⷙ㧚㔚ሶࠞ࡞࠹ࠪࠬ
࠹ࡓߩ৻Ⅳߣߒߡߩ⮎೷▤ℂᜰዉᡰេࠪࠬ࠹ࡓߩ᭴▽㧘ක≮⮎ቇ 2008 ᐕ㧧34 Ꮞ㧦103㧙111㧚
7㧕 㘵ේᄢ⒤㧘᧻ᶆసᒾ㧘ศ᧛⍮ື㧘ᐔ಴⠹⍹㧘⍹ේᱜᔒ㧘ᓟ⮮ජኼ㧘દ⮮ༀⷙ㧚⢖߇ࠎᖚ⠪ߦ߅ߌࠆ Carboplatinᛩਈ㊂ߩ᳿ቯᣇᴺߣ೽૞↪⊒⃻ߦ㑐ߔࠆ retrospective study㧘ᣣᧄ∛㒮⮎೷Ꮷળ㔀⹹ 2008 ᐕ㧧44 Ꮞ㧦
428㧙431㧚
8㧕 ┄↰ᢅᄦ㧘㊁ਛᢅᴦ㧘⍫㊁⾆ਭ㧘૑᧛ᥓሶ㧘ᨋ ⚐㧘દ⮮ༀⷙ㧘ᄢ⍹ੌਃ㧚᛫ MRSA ⮎ߩㆡᱜ૶↪ࠍ⋡ᜰߒߚ⮎‛ⴊਛỚᐲࡕ࠾࠲࡝ࡦࠣታᣉ₸ะ਄߳ߩขࠅ⚵ߺ㧘ᣣᧄ∛㒮⮎೷Ꮷળ㔀⹹ 2008 ᐕ㧧44 Ꮞ㧦277
㧙280㧚
9㧕 ਅ↰ᶈᰵ㧘ጟ቟િੑ㧘♿ࡁቯ଻⤿㧘ᱞ↰ ⚐㧘ጊᧄ⋿↱⟤㧚㔚ሶࠞ࡞࠹ᖱႎ߆ࠄಽᨆߔࠆᄢቇ∛㒮ߩ♧ዩ∛∛᫟ᖚ⠪ߩ․ᓽಽᨆߩ⹜ⴕ㨪ᬺോࠍนⷞൻߔࠆ᦭↪ᕈߦߟ޿ߡ㨪㧘⢈ḩߣ♧ዩ∛ 2008 ᐕ㧧7 Ꮞ(೎ౠ)㧦
89㧙93㧚
10㧕 ጟ቟િੑ㧘ਅ↰ᶈᰵ㧘♿ࡁቯ଻⤿㧘ᱞ↰ ⚐㧘ጊᧄ⋿↱⟤㧚ࠗࡦࠬ࡝ࡦߩ቟ో▤ℂߦ㑐ߔࠆ㔚ሶࠞ࡞࠹ᯏ㧙㧙⢻ߩ᦭↪ᕈߣ໧㗴ὐ㧘⢈ḩߣ♧ዩ∛ 2008 ᐕ㧧7 Ꮞ(೎ౠ)㧦28㧙35㧚
11㧕 ਤ⠀ 㓉㧘ዊ᫪ༀᢥ㧘⍹ේᱜᔒ㧘㜞ᯅ㋈ઍ㧘᧻ᶆసᒾ㧘ᓟ⮮ජኼ㧘દ⮮ༀⷙ㧚࡝ࠬࠢ⹏ଔߦࠃࠆ⺞೷ㆊ⺋㒐ᱛኻ╷ߩ᦭ലᕈߩᬌ⸽㧘ᣣᧄ∛㒮⮎೷Ꮷળ㔀⹹ 2008 ᐕ㧧44 Ꮞ㧦1487㧙1490㧚
12㧕 ศ᧛⍮ື㧘ᐔ಴⠹⍹㧘㘵ේᄢ⒤㧘⍹ේᱜᔒ㧘ዊ᫪ༀᢥ㧘ጟ቟િੑ㧘᧻ᶆసᒾ㧘቟↰ᔘม㧘દ⮮ༀⷙ㧚Paclitaxelᛩਈᖚ⠪ߦ߅ߌࠆᛩਈ㊂࡮ᛩਈࠬࠤࠫࡘ࡯࡞ߦၮߠ޿ߚ೽૞↪⸃ᨆ㧘≸ߣൻቇ≮ᴺ 2008 ᐕ㧧35 Ꮞ㧦1721
㧙1726㧚
ේ⪺㧔᰷ᢥ㧕
1㧕 Ohnishi T, Yasuda I, Nishigaki Y, Hayashi H, Otsuji K, Mukai T, Enya M, Salem Omar, Nib Soehendra,
Tomita E, Moriwaki H. Intraductal chilled saline perfusion to prevent bile duct injury duringpercutaneous radiofrequency ablation for hepatocellular carcinoma. J Gastroen Hepatol.
2008;23:e410-415.
2㧕 Shimizu M, Shirakami Y, Sakai H, Tatebe H, Nakagawa T, Hara Y, Weinstein IB, Moriwaki H. EGCG
inhibits activation of the insulin-like growth factor (IGF)/IGF-1 receptor axis in human hepatocellular
carcinoma cells. Cancer Lett. 2008;262:10-18.
3㧕 Shimizu M, Shirakami Y, Sakai H, Adachi S, Hata K, Hirose Y, Tsurumi H, Tanaka T, Moriwaki H.
()-Epigallocatechin gallate suppresses azoxymethane-induced colonic premalignant lesions in male
C57BL/KsJ-db/db mice. Cancer Prev Res. 2008;1:298-304.
4㧕 Shimizu M, Shirakami Y, Moriwaki H. Targeting Receptor Tyrosine kinases for chemoprevention bygreen tea catechin, EGCG. Int J Mol Sci. 2008;9:1034-1049.
5㧕 Shimizu M, Moriwaki H. Synergistic effects of PPARgamma ligands and retinoids in cancer treatment.
PPAR Res. 2008;2008:181047.
6㧕 Shimizu M, Fukutomi Y, Ninomiya M, Nagura K, Kato T, Araki H, Suganuma M, Fujiki H, Moriwaki
H. Green tea extracts for the prevention of metachronous colorectal adenomas: a pilot study. Cancer
Epidemiol Biomarkers Prev. 2008;17:3020-3025.
7㧕 Adachi S, Nagao T, To S, Joe AK, Shimizu M, Matsushima-Nishiwaki R, Kozawa O, Moriwaki H,
Maxfield FR, Weinstein IB. (-)-Epigallocatechin gallate causes internalization of the epidermal growth
factor receptor in human colon cancer cells. Carcinogenesis. 2008;29:1986-1993.
8㧕 Kanemura N, Tsurumi H, Okuno M, Matsushima-Nishiwaki R, Shimizu M, Moriwaki H. Retinoid X
receptor alpha is highly phosphorylated in retinoic acid-resistant HL-60R cells and the combination of
9-cis retinoic acid plus MEK inhibitor induces apoptosis in the cells. Leukemia Res. 2008;32:884-892.
9㧕 Kanemura N, Tsurumi H, Kasahara S, Hara T, Yamada T, Sawada M, Goto N, Kitagawa JI, Shimizu
M, Oyama M, Moriwaki H. Continuous drip infusion of low dose cytarabine and etoposide with
granulocyte colony-stimulating factor for elderly patients with acute myeloid leukaemia ineligible forintensive chemotherapy. Hematol Oncol. 2008;26:33-38.
10㧕 Tatebe H, Shimizu M, Shirakami Y, Tsurumi H, Moriwaki H. Synergistic growth inhibition by
9-cis-retinoic acid plus trastuzumab in human hepatocellular carcinoma cells. Clin Cancer Res.
2008;14:2806-2812.
11㧕 Shirakami Y, Shimizu M, Tsurumi H, Hara Y, Tanaka T, Moriwaki H. EGCG and Polyphenon E
attenuate inflammation-related mouse colon carcinogenesis induced by AOM plus DDS. Mol Med Rep.
2008;1:355-361.
12㧕 Hara T, Tsurumi H, Kato T, Imao Y, Kojima Y, Kojima K, Kitagawa J, Katsumura N, Araki H,
Takami T, Moriwaki H. Immunoproliferative small intestinal disease with protein loss complicatedwith duodenal T cell lymphoma during progression. Intern Med. 2008;47:299-303.
13㧕 Doi S, Yasuda I, Iwashita T, Ibuka T, Fukushima H, Araki H, Hirose Y, Moriwaki H. Needle tract
implantation on the esophageal wall after EUS-guided FNA of metastatic mediastinal
lymphadenopathy. Gastrointest Endosc. 2008;67:988-990.
14㧕 Ohmori T, Nakamura M, Tada S, Sugiyama T, Itoh Y, Udagawa Y, Hirano K. A highly sensitive assay
for ritodrine in human serum by hydrophilic interaction chromatography-tandem mass spectrometry.
J Chromatogr. 2008;861:95-100.
15㧕 Sobue S, Nemoto S, Murakami M, Ito H, Kimura A, Gao S, Furuhata A, Takagi A, Kojima T,
Nakamura M, Itoh Y, Suzuki M, Banno Y, Nozawa Y, Murate T. Implications of sphingosine kinase 1
expression level for the cellular sphingolipid rheostat; relevance as a marker for daunorubicin
sensitivity of leukemia cell. Int J Hematol. 2008;87:266-275.
16㧕 Aki T, Egashira N, Hama M, Yamauchi Y, Yano T, Itoh Y, Oishi R. Characteristics of gabexate
mesilate-induced cell injury in porcine aorta endothelial cells. J Pharmacol Sci. 2008;106:415-422.
17㧕 Aki T, Egashira N, Yamauchi Y, Hama M, Yano T, Itoh Y, Yamada T, Oishi R. Protective effects ofamino acids against gabexate mesilate–induced cell injury in porcine aorta endothelial cells. J
Pharmacol Sci. 2008;107:238-245.
18㧕 Yano T, Itoh Y, Yamada M, Egashira N, Oishi R. Combined treatment with L-carnitine and apan-caspase inhibitor effectively reverses amiodarone-induced injury in cultured human lungepithelial cells. Apoptosis. 2008;13:543-552.
19㧕 Matsuura K, Ohmori T, Nakamura M, Itoh Y, Hirano K. A simple and rapid determination of valproic㧙㧙

IF 1.673

IF 3.398

IF 0.750

IF 5.406

IF 2.561

IF 2.180

IF 6.250

IF 5.888

IF 2.935

IF 1.491
IF 2.408

IF 2.408

IF 3.043

acid in human plasma using a non-porous silica column and liquid chromatography with tandem mass
spectrometric detection. Biomed Chromatogr. 2008;22:387-393.
IF 1.663

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦᫪⣁ਭ㓉㧘⎇ⓥಽᜂ⠪㧦ጟ㊁ᐘ㓶㧘↰ਛථੑ㧘ዊ᎑⡡৻㧘⷏ญୃᐔ㧘ᷡ᳓㓷ੳ㧦ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄․ቯ㗔ၞ⎇ⓥ㧦ᩭౝฃኈ૕Ⱞ⊕ࠍಽሶᮡ⊛ߣߒߚ⢄≸ൻቇ੍㒐ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 17㧙21 ᐕᐲ㧧66,000 ජ౞(16,300㧦16,300㧦16,300㧦17,100 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦⮮ේ⎇ม㧘⎇ⓥಽᜂ⠪㧦᫪⣁ਭ㓉㧦ෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄(⢄Ἳ╬స᦯✕ᕆኻ╷⎇ⓥ੐ᬺ)㧦⢄߇ࠎᖚ⠪ߩ QOL ะ਄ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18㧙20 ᐕᐲ㧧2,000 ජ౞(2,000㧦1,300㧦1,250 ජ౞)3㧕 ⎇ⓥઍ⴫⠪㧦᫪⣁ਭ㓉㧘⎇ⓥಽᜂ⠪㧦ᷡ᳓㓷ੳ㧘ጊ↰ᵏᐢ㧦ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦
ᩭౝฃኈ૕߅ࠃ߮ฃኈ૕ဳ࠴ࡠࠪࡦࠠ࠽࡯࠯ࠍᮡ⊛ಽሶߣߒߚ≸ൻቇ੍㒐ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 19㧙
20 ᐕᐲ㧧3,400 ජ౞(1,800㧦1,600 ජ౞)
4㧕 ⎇ⓥઍ⴫⠪㧦⊕㠽⟵ቬ㧘⎇ⓥಽᜂ⠪㧦᫪⣁ਭ㓉:ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦ᩭౝฃኈ૕߅ࠃ߮ฃኈ૕ဳ࠴ࡠࠪࡦࠠ࠽࡯࠯ࠍᮡ⊛ಽሶߣߒߚ≸ൻቇ੍㒐ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 20㧙22 ᐕᐲ㧧
3,500 ජ౞(1,500㧦1,100㧦900 ජ౞)
2㧕ฃ⸤⎇ⓥ1㧕 ᫪⣁ਭ㓉㧘ᷡ᳓㓷ੳ㧦วᚑ࡟࠴ࡁࠗ࠼ߣಽሶᮡ⊛ᴦ≮⮎ߣߩ૬↪ߦ㑐ߔࠆ⎇ⓥ(2)㧧ᐔᚑ 18㧙19 ᐕᐲ㧧6,000 ජ౞(3,000㧦3,000 ජ౞)㧦⥝๺ഃ⮎2㧕 ᫪⣁ਭ㓉㧦ᩭ࡟࠴ࡁࠗ࠼ฃኈ૕Ⱞ⊕ࠍಽሶᮡ⊛ߣߒߚ߇ࠎൻቇ੍㒐ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18㧙20 ᐕ
ᐲ㧧450 ජ౞(150㧦150㧦150 ජ౞)㧦⢽ṁᕈࡆ࠲ࡒࡦ
3㧕 ᫪⣁ਭ㓉㧘ᷡ᳓㓷ੳ㧦⢈ḩ㑐ㅪ⢄⊒≸ߦ߅ߌࠆวᚑ࡟࠴ࡁࠗ࠼ߩ੍㒐ലᨐ㧧ᐔᚑ 20 ᐕᐲ㧧1,000 ජ౞㧦⥝๺ഃ⮎
4㧕 ᫪⣁ਭ㓉㧘ዊ᎑⡡৻㧦⢄∔ᖚߩಽሶ∛ᘒ⸃᣿ߦၮߠߊᣂⷙᴦ≮࡮੍㒐ᴺߩ⏕┙㧧ᐔᚑ 18㧙20 ᐕᐲ㧧
300 ජ౞(100㧦100㧦100 ජ౞)ℂൻቇ⎇ⓥᚲ
5㧕 દ⮮ༀⷙ㧦⮎೷฽᦭ࡈࠖ࡞ࡓ⵾೷ߩ㐿⊒ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 20 ᐕᐲ㧧800 ජ౞㧦࠷ࠠࠝࠞ (ᩣ)
3㧕౒ห⎇ⓥ1㧕 ੹੗◊ᔒ㧘ਤ⠀ᙗม㧘દ⮮ༀⷙ㧘ᶉ᧻ᤘᄦ(ᣣᧄ⤳ེ⵾⮎ᩣᑼળ␠)㧦ࡄࠢ࡝࠲ࠠ࠮࡞ࠍ฽߻ൻቇ≮ᴺ
ᣉⴕᤨߦ⊒⃻ߒߚᧃ᪳␹⚻㓚ኂߦኻߔࠆ−∩ᴦ≮೷ࡁࠗࡠ࠻ࡠࡇࡦ㍤ߩ⥃ᐥ⹏ଔ㧧ᐔᚑ 20 ᐕᐲ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫ
1㧕 ᄢ⍹ੌਃ㧘દ⮮ༀⷙ㧘ᳯ㗡િᤘ㧘⮮੗㇚㇢㧦᛫߇ࠎ೷ߦࠃࠆᧃ᪳␹⚻㓚ኂߩ੍㒐෶ߪシᷫ೷(⊒᣿)㧧
ᐔᚑ 20 ᐕ(․㗿 2008-65399)
6㧚ቇળᵴേ
1㧕ቇળᓎຬ᫪⣁ਭ㓉㧦
1㧕 ᣣᧄౝ⑼ቇળℂ੐(㨪⃻࿷)2㧕 ᣣᧄᶖൻེ∛ቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ⢄⤳ቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄࡆ࠲ࡒࡦቇળℂ੐(㨪⃻࿷)5㧕 ᣣᧄ⥃ᐥઍ⻢ቇળ⹏⼏ຬ(㨪⃻࿷)6㧕 ᣣᧄ≸ቇળ⹏⼏ຬ(㨪⃻࿷)7㧕 ᣣᧄᩕ㙃㘩♳ቇળ⹏⼏ຬ(㨪⃻࿷)8㧕 ᣣᧄ㕒⣂⚻⣺ᩕ㙃ቇળℂ੐(㨪⃻࿷)દ⮮ༀⷙ㧦1㧕 ᣣᧄක≮⮎ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ⮎ℂቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ∛㒮⮎೷Ꮷળઍ⼏ຬ(㨪⃻࿷)㧙㧙4㧕 ᣣᧄ⮎ቇળ᧲ᶏᡰㇱળᐙ੐(㨪⃻࿷)㢬⷗ ኼ㧦
1㧕 ᣣᧄ⥃ᐥⴊᶧቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄⴊᶧቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄャⴊቇળ᧲ᶏᡰㇱ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅᫪⣁ਭ㓉㧦
1㧕 ╙ 8 ࿁ᣣᧄஜᐽᩕ㙃ࠪࠬ࠹ࡓቇળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂)
3㧕ቇⴚ㔀⹹᫪⣁ਭ㓉㧦
1㧕 ᣣᧄౝ⑼ቇળ⹹(⧷ᢥ)㧧✬㓸ᆔຬ(㨪⃻࿷)2㧕 ᣣᧄᶖൻེ∛ቇળ⹹(⧷ᢥ)㧧✬㓸ᆔຬ(㨪⃻࿷)3㧕 ᣣᧄ㕒⣂⚻⣺ᩕ㙃ቇળ⹹㧦✬㓸ᆔຬ(㨪⃻࿷)દ⮮ༀⷙ㧦1㧕 ᣣᧄ∛㒮⮎೷Ꮷળ㔀⹹࿾ၞ✬㓸ᆔຬ(㨪⃻࿷)7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳᫪⣁ਭ㓉㧦
1㧕 ╙ 67 ࿁ᣣᧄ≸ቇળቇⴚ✚ળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ฬฎደ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬⢄߇ࠎ੍㒐ߩ✚วᚢ⇛ߣൻቇ੍㒐‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേ᫪⣁ਭ㓉㧦
1㧕 ጘ㒂⋵り૕㓚ኂ⠪⑔␩ද⼏ળᆔຬ(㨪⃻࿷)2㧕 ጘ㒂⋵㔍∛ක≮ㅪ⛊ද⼏ળᐳ㐳(㨪⃻࿷)3㧕 ጘ㒂⋵߇ࠎኻ╷ផㅴද⼏ળᐳ㐳(ᐔᚑ 19 ᐕᐲ㨪⃻࿷)4㧕 ጘ㒂⋵ࠛࠗ࠭ኻ╷ផㅴද⼏ળᐳ㐳(ᐔᚑ 19 ᐕᐲ㨪⃻࿷)5㧕 ጘ㒂⋵ක≮ክ⼏ળᆔຬ(ᐔᚑ 18 ᐕᐲ㨪⃻࿷)6㧕 ጘ㒂⋵ੱᮭᙣ⹤ળᆔຬ(㨪⃻࿷)દ⮮ༀⷙ㧦1㧕 ጘ㒂⋵∛㒮⮎೷Ꮷળ೽ળ㐳(㨪⃻࿷)2㧕 ጘ㒂⋵⮎೷Ꮷળℂ੐(㨪⃻࿷)㢬⷗ ኼ㧦
1㧕 ጘ㒂⋵߇ࠎኻ╷ផㅴද⼏ળᆔຬ(ᐔᚑ 19 ᐕ 7 ᦬㨪⃻࿷)2㧕 ጘ㒂⋵ࠛࠗ࠭ኻ╷ផㅴද⼏ળᆔຬ(ᐔᚑ 19 ᐕ 1 ᦬㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ᫪⣁ਭ㓉㧘᳗ᧁᱜੳ㧘ዊᧁᦥን↢㧦G-CSF ߩ⢄ౣ↢ᛥ೙ലᨐ㧦IL-1 ߩᓎഀ㧦ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄‫ޟ‬㔍ᴦᕈߩ⢄∔ᖚ⺞ᩏ⎇ⓥ⃰‫ޠ‬ᐔᚑ 19 ᐕᐲ⎇ⓥႎ๔ᦠ㧦117㧙119(2008 ᐕ)
2㧕 દ⮮ༀⷙ㧦ࠪࠬࡊ࡜࠴ࡦ⣢㓚ኂߦኻߔࠆ⚦⢩ౝࠨࠗࠢ࡝࠶ࠢ AMP ࠍ੺ߔࠆ଻⼔૞↪ߦ㑐ߔࠆ⎇ⓥ㧦
ᐔᚑ 17㧙18 ᐕᐲ⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)⎇ⓥᚑᨐႎ๔ᦠ(⎇ⓥಽᜂ⠪㧦ᄢ⍹ੌਃ) (2007 ᐕ 3 ᦬)
11㧚ႎ㆏1㧕 ᫪⣁ਭ㓉㧦⢈ḩ㨯㨯㨯⢄≸㧦ਛᣣᣂ⡞(2006 ᐕ 12 ᦬ 17 ᣣ)㧙㧙

12㧚⥄Ꮖ⹏ଔ
⹏ଔ┙ߜ਄ߍ߆ࠄ߹ߛ 3 ࡩ᦬ߢ޽ࠆ߇㧘ᓥ᧪ߩ㑐ㅪಽ㊁߆ࠄታ❣ࠍᒁ߈⛮ߋᒻߢ㧘ᣢߦᬺ❣ࠍ᜼ߍᆎ߼ߡ
߅ࠅ㧘⦟ᅢߣߩ⹏ଔߦ୯ߔࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ੱ⊛ߦ㑐ㅪಽ㊁߆ࠄߩࠨࡐ࡯࠻߇ᔅ㗇ߢ޽ࠆ‫ߩ⥄⁛ޕ‬ᄢቇ㒮↢⏕଻߇✕ᕆߩ⺖㗴ߢ޽ࠆ‫ޕ‬੹ᓟߩዷᦸ
2009 ᐕᐲᣂⷙᄢቇ㒮౉ቇ↢ࠍ 2 ฬ⏕଻ߒߚ‫⎇ޕ‬ⓥߩ᭎ⷐ 1㧘2 ߦฦ 1 ฬࠍ޽ߡ㧘⎇ⓥࠍផㅴߔࠆ‫ޕ‬㧙㧙ާක≮▤ℂቇ⻠ᐳި㧔1㧕ක≮ᖱႎቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
ᖱႎㅢାᛛⴚ㧔ICT㧕ߩ⊒ዷߦࠃࠅ࡜ࠗࡈࠨࠗࠛࡦࠬߦ㑐ߔࠆᄢ㊂ߩ࠺࡯࠲߇⊒↢࡮࠺࡯࠲ࡌ࡯ࠬൻߐ
ࠇߟߟ޽ࠆ‫ߚ߹ޕ‬㧘EBM㧔evidence based medicine㧧⑼ቇ⊛ᩮ᜚ߦၮߠ޿ߚක≮ߩታ〣㧕߇ต߫ࠇࠆਛ㧘ࠦࡦࡇࡘ࡯࠲ᛛⴚ࡮ᖱႎಣℂಽ㊁߆ࠄߩᛛⴚ⒖ォߛߌߢߥߊ㧘⫾Ⓧߐࠇߚᄢⷙᮨ࠺࡯࠲ߩቯ㊂⊛ߥ⸃ᨆ࡮
ಽᨆᚻᴺߩ㐿⊒߿⸃㉼㧘୘೎ൻක≮߿ഃ⮎ߦᓎ┙ߟᣂߒ޿⍮⷗ߩ⊒⷗߇ᦸ߹ࠇߡ߅ࠅ㧘࡜ࠗࡈࠨࠗࠛࡦࠬ
ಽ㊁ߦ߅ߌࠆᣂߒ޿࠺࡯࠲ࠨࠗࠛࡦࠬߩ⏕┙߇ᕆ߇ࠇߡ޿ࠆ‫ޕ‬ක≮ᖱႎቇಽ㊁ߢߪ㧘ߎߩࠃ߁ߥ␠ળ⊛ⷐᦸߦᔕ߃ࠆߎߣ㧘․ߦ࡜ࠗࡈࠨࠗࠛࡦࠬಽ㊁ߢߩ࠺࡯࠲ࠨࠗ
ࠛࡦࠬࠍ᭴▽ߔࠆߎߣࠍ⋡ᜰߒ㧘ᣣᏱ⸻≮ߢ⊒↢ߔࠆฦ⒳ᖚ⠪ᖱႎ߿ஜ⸻ߢ⊒↢ߔࠆஜᐽᖱႎ╬ࠍ⛔ว⊛࡮૕♽⊛ߦ▤ℂ࡮ㆇ↪ߔࠆ⛔วࡃࠗࠝࡃࡦࠢࠪࠬ࠹ࡓߩ᭴▽ߣㆇ↪㧘୘೎ൻක≮߳ߩዷ㐿ࠍ⋡⊛ߣߒߚ⸻≮ࡊࡠ࠮ࠬߩ▤ℂ࡮ಽᨆᚻᴺߩ㐿⊒㧘ක⮎ຠߩㆡᱜ૶↪߿᦭ኂ੐⽎ಽᨆߩߚ߼ߩ⍮⼂⊒⷗ᚻᴺߩ㐿⊒㧘ක≮⚻ᷣ࡮ක≮⚻༡ੱ᧚⢒ᚑࡊࡠࠣ࡜ࡓߩ㐿⊒ߥߤࠍ⎇ⓥߒߡ޿ࠆ‫ߚ߹ޕ‬㧘ࠥࡁࡓ࡮ࡐࠬ࠻ࠥࡁࡓᤨઍߩ
ࠝࡒ࠶ࠢࠬක≮ߦᔅⷐߥࡃࠗࠝ࡮ࠗࡦࡈࠜࡑ࠹ࠖࠢࠬߩഃㅧߣ૕♽ൻ࡮᭴▽㧘molecular imaging ᚻᴺߩ㐿⊒㧘⸻≮ߩᚑᨐಽᨆᚻᴺߩ㐿⊒㧘╬ࠍ⎇ⓥߒߡ޿ࠆ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
♿ࡁቯ଻⤿
ಎᢎ᝼㧦 ౝጊ⦟৻

Yasutomi Kinosada
Yoshikazu Uchiyama

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ♿ࡁቯ଻⤿㧚Φකᬺ⚻༡▤ℂ૕೙᭴▽࡮ታᣉߦ㑐ߔࠆ⍮⼂ 9 කᬺ⚻༡▤ℂ⺰(3)㧦කᬺ⚻༡ࠦࡦࠨ࡞࠲ࡦ
࠻⹺ቯ⻠ᐳ࡮⹺ቯ⹜㛎࠹ࠠࠬ࠻㧘᧲੩㧦␠࿅ᴺੱᣣᧄකᬺ⚻༡ࠦࡦࠨ࡞࠲ࡦ࠻දળ㧧2007 ᐕ㧦317㧙359㧚
2㧕 ♿ࡁቯ଻⤿㧚⹺ቯ⊓㍳කᬺ⚻༡ࠦࡦࠨ࡞࠲ࡦ࠻਄⚖ࡆࠫࡀࠬࠦ࡯ࠬ⎇ୃᚲ ✬㓸㧚⚻༡▤ℂ૕೙ߩ᭴▽Ϋ(ᖱႎ▤ℂ૕೙ߩᢛ஻)㧦⹺ቯ⊓㍳කᬺ⚻༡ࠦࡦࠨ࡞࠲ࡦ࠻(਄⚖ࡆࠫࡀࠬࠦ࡯ࠬ)࠹ࠠࠬ࠻㧘᧲੩㧦␠࿅ᴺੱ
ᣣᧄකᬺ⚻༡ࠦࡦࠨ࡞࠲ࡦ࠻දળ㧧2007 ᐕ㧦17-4-1㧙17-4-9㧘17-5-1㧙17-5-8㧘17-9-1㧙17-9-8㧘17-10-1
㧙17-10-9㧚
3㧕 ♿ࡁቯ଻⤿㧚ࡌࡦ࠳࡯ㆬቯᚻ㗅ឭ᩺㧦ᖱႎൻ⹺ቯࠦࡦࠨ࡞࠲ࡦ࠻ᜰቯ⻠ᐳ࡮৻ᰴ⹜㛎࠹ࠠࠬ࠻㧘᧲੩㧦␠
࿅ᴺੱᣣᧄකᬺ⚻༡ࠦࡦࠨ࡞࠲ࡦ࠻දળ㧧2008 ᐕ㧦125㧙133㧚
4㧕 ♿ࡁቯ଻⤿㧚࠹ࠬ࠻࡮࡝ࡂ࡯ࠨ࡞ᡰេ㧦ᖱႎൻ⹺ቯࠦࡦࠨ࡞࠲ࡦ࠻ᜰቯ⻠ᐳ࡮৻ᰴ⹜㛎࠹ࠠࠬ࠻㧘᧲੩㧦
␠࿅ᴺੱᣣᧄකᬺ⚻༡ࠦࡦࠨ࡞࠲ࡦ࠻දળ㧧2008 ᐕ㧦177㧙180㧚
5㧕 ♿ࡁቯ଻⤿㧚ዉ౉ࠪࠬ࠹ࡓߩຠ⾰⹏ଔ㧦ᖱႎൻ⹺ቯࠦࡦࠨ࡞࠲ࡦ࠻ᜰቯ⻠ᐳ࡮৻ᰴ⹜㛎࠹ࠠࠬ࠻㧘᧲੩㧦
␠࿅ᴺੱᣣᧄකᬺ⚻༡ࠦࡦࠨ࡞࠲ࡦ࠻දળ㧧2008 ᐕ㧦181㧙188㧚
6㧕 ♿ࡁቯ଻⤿㧚ᗧᕁ᳿ቯᵴ↪ᡰេ㧦ᖱႎൻ⹺ቯࠦࡦࠨ࡞࠲ࡦ࠻ᜰቯ⻠ᐳ࡮৻ᰴ⹜㛎࠹ࠠࠬ࠻㧘᧲੩㧦␠࿅ᴺੱᣣᧄකᬺ⚻༡ࠦࡦࠨ࡞࠲ࡦ࠻දળ㧧2008 ᐕ㧦205㧙215㧚
7㧕 ♿ࡁቯ଻⤿㧚㔚ሶࠞ࡞࠹㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦286
㧙289㧚
8㧕 ♿ࡁቯ଻⤿㧚ක≮⚻༡ᢎ⢒ද⼏ળ‫ޟ‬ක≮ࡑࡀࠫࡔࡦ࠻‫ޠ‬ડ↹✬㓸ᆔຬળ✬㧚⚵❱ߩᵴᕈൻ㧙ࠝࡍ࡟࡯࡚ࠪ
ࡦࡑࡀࠫࡔࡦ࠻㧙㧦ක≮ࡑࡀࠫࡔࡦ࠻㧙ක≮ߩ⾰ะ਄ߩߚ߼ߩක≮⚻༡ቇ㧙㧘᧲੩㧦(ᩣ)ᣣ⚻ࡔ࠺ࠖࠞ࡞
㐿⊒㧧2008 ᐕ㧦206㧙229㧚
9㧕 ♿ࡁቯ଻⤿㧚ක≮ᯏ㑐ߩ ICT ᚢ⇛㧦ක≮⚻༡ᢎ⢒ද⼏ળ‫ޟ‬ක≮ࡑࡀࠫࡔࡦ࠻‫ޠ‬ડ↹✬㓸ᆔຬળ✬㧚ක≮ࡑࡀࠫࡔࡦ࠻㧙ක≮ߩ⾰ะ਄ߩߚ߼ߩක≮⚻༡ቇ㧙㧘᧲੩㧦 (ᩣ)ᣣ⚻ࡔ࠺ࠖࠞ࡞㐿⊒㧧2008 ᐕ㧦230㧙255㧚
10㧕 ᷓᵤඳ㧘቟⮮⵨㧘♿ࡁቯ଻⤿㧘ᅏ⌀਽㧘Ꮉᷨቁ৻㧘㤥ፒ㚌㧚Medical IT ߩ⃻࿷ߘߒߡᧂ᧪㧙‫ᤨޟ‬ઍߩᄌൻ‫ޠ‬ߦኻಣߔࠆߚ߼ߩಣᣇ▐㧙㧦Medical IT 2008-2009 MOOK㧘᧲੩㧦↥ᬺ㐿⊒ᯏ᭴ᩣᑼળ␠㧧2008 ᐕ㧦20
㧙37㧚
⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 ♿ࡁቯ଻⤿㧚IT ࠍᵴ↪ߒߚᣂᤨઍߩ∛㒮⚻༡Ԛ㧙ࠪࠬ࠹ࡓ⸳⸘ߩ⠨߃ᣇߣ᭴▽૕೙㧙㧘IT VISION 2006
ᐕ㧧10 Ꮞ㧦46㧙50㧚
2㧕 ർፉᐽ㓶㧘♿ࡁቯ଻⤿㧘⊕㠽⟵ቬ㧘ၳ⇌೑ᴦ㧚ጘ㒂ᄢቇකቇㇱ㒝ዻ∛㒮‫ޟ‬㔚ሶࠞ࡞࠹ࠪࠬ࠹ࡓዉ౉ߦߟ޿
ߡ‫(ޠ‬1)㧘࿖┙ᄢቇࡑࡀࠫࡔࡦ࠻ 2006 ᐕ㧧1 Ꮞ㧦2㧙12㧚
3㧕 ♿ࡁቯ଻⤿㧚ጘ㒂ᄢቇකቇㇱ㒝ዻ∛㒮ߩࠗࡦ࠹࡝ࠫࠚࡦ࠻ൻ㧙̌⷗߃ߑࠆ⽷↥ (intangible assets)̍ߩജ

㧙㧙ߣߘߩนⷞൻ߇ࠪࠬ࠹ࡓㆇ↪ߩࡐࠗࡦ࠻㧙㧘Kodak view 2006 ᐕ㧧7 Ꮞ㧦20㧙25㧚
4㧕 ർፉᐽ㓶㧘♿ࡁቯ଻⤿㧘⊕㠽⟵ቬ㧘ၳ⇌೑ᴦ㧚ጘ㒂ᄢቇකቇㇱ㒝ዻ∛㒮‫ޟ‬㔚ሶࠞ࡞࠹ࠪࠬ࠹ࡓዉ౉ߦߟ޿
ߡ‫(ޠ‬2)㧘࿖┙ᄢቇࡑࡀࠫࡔࡦ࠻ 2006 ᐕ㧧2 Ꮞ㧦12㧙24㧚
5㧕 ♿ࡁቯ଻⤿㧚㔚ሶࠞ࡞࠹ࠪࠬ࠹ࡓㆇ↪ߦࠃࠆ DPC ߳ߩኻᔕߣ࠺࡯࠲ᵴ↪㧘ᣂක≮ 2006 ᐕ㧧33 Ꮞ㧦118
㧙121㧚
6㧕 ♿ࡁቯ଻⤿㧚IT ࠍᵴ↪ߒߚᣂᤨઍߩ∛㒮⚻༡ԛ㧙ࠪࠬ࠹ࡓ߇ਈ߃ࠆࠗࡦࡄࠢ࠻㧙㧘IT VISION 2006 ᐕ㧧
11 Ꮞ㧦54㧙58㧚
7㧕 ♿ࡁቯ଻⤿㧚ㄦㅦ⸻ᢿߦࠃࠆല₸ൻߩⷞὐ߆ࠄߺߚ PACS ߩ૏⟎ߠߌࠍ໧߁㧘ᣂක≮ 2006 ᐕ㧧33 Ꮞ㧦
48㧙50㧚
8㧕 ♿ࡁቯ଻⤿㧚IT ࠍᵴ↪ߒߚක≮⚻༡ᡰេ㧙̌⷗߃ࠆൻ̍ߣ̌ᢙ୯ൻ̍㧘ߘߩᗧ๧㧙㧘ᣂක≮ 2006 ᐕ㧧33
Ꮞ㧦48㧙51㧚9㧕 ♿ࡁቯ଻⤿㧚ᓴⅣེක≮ߦ߅ߌࠆ IT ߩᓎഀߣน⢻ᕈࠍ⠨߃ࠆ㧘ᣣᧄᓴⅣེቇળኾ㐷ක⹹ ᓴⅣེኾ㐷ක
2006 ᐕ㧧14 Ꮞ㧦263㧙269㧚
10㧕 ♿ࡁቯ଻⤿㧚IT ࠍᵴ↪ߒߚᣂᤨઍߩ∛㒮⚻༡Ԝ㧙ක≮ߩ IT ൻ߇↢ߺ಴ߔᣂߚߥዷ㐿㧙㧘IT VISION 2006
ᐕ㧧12 Ꮞ㧦52㧙56㧚
11㧕 ♿ࡁቯ଻⤿㧚ᄢቇ∛㒮ߢߩ㔚ሶࠞ࡞࠹ߦࠃࠆ⸻≮ߩ⃻⁁㧘ᣣᧄකᏧળ㔀⹹ 2006 ᐕ㧧╙ 135 Ꮞ㧦1967㧙1971㧚
12㧕 ♿ࡁቯ଻⤿㧚☨࿖వㅴක≮ IT ੐ᖱߣᣣᧄߩㅴ߻ߴ߈ᣇะᕈߦߟ޿ߡߩ⠨ኤ㧘ᣂක≮ 2006 ᐕ㧧33 Ꮞ㧦150
㧙153㧚
13㧕 ♿ࡁቯ଻⤿㧚ᄢቇ∛㒮ߢߩ㔚ሶࠞ࡞࠹ߦࠃࠆ⸻≮ߩ⃻⁁㧘ᣣᧄකᏧળ㔀⹹ 2006 ᐕ㧧135 Ꮞ㧦1967㧙1971㧚
14㧕 ♿ࡁቯ଻⤿㧚ጘ㒂ᄢቇකቇㇱ㒝ዻ∛㒮 ℂᗐߩࠗࡦ࠹࡝ࠫࠚࡦ࠻࡮ࡎࠬࡇ࠲࡞ࠍ⋡ᜰߒߡ(࠮ࠠࡘ࡝࠹ࠖࠍਛᔃߦ)The Way to the Intelligent Hospital (⇟ᄖ✬)㧘Kodak view 8 2007 ᐕ㧧22㧙26㧚
15㧕 ♿ࡁቯ଻⤿㧚ක≮ߣ IT㧘bios 2007 ᐕ㧧12 Ꮞ㧦3㧙6㧚
16㧕 ᧻ፉ⑲㧘♿ࡁቯ଻⤿㧚ಽሶࠗࡔ࡯ࠫࡦࠣߩᦨᣂേะ㧙MRI ࠍਛᔃߦ㧙㧘INNERVISION 2007 ᐕ㧧22 Ꮞ㧦
30㧙31㧚
17㧕 ♿ࡁቯ଻⤿㧚∛㒮ߦ߅ߌࠆ IT ᵴ↪ߩ⃻⁁ߣ⺖㗴㧘ጘ㒂⋵∛㒮ᤨႎ 2007 ᐕ㧧╙ 41 ภ㧦3㧚
18㧕 ♿ࡁቯ଻⤿㧚⸻≮ᖱႎ▤ℂᯏ⢻ࠍ᦭ߔࠆ቟ోᕈ⏕଻ဳหᤨᦠㄟߺࠪࠬ࠹ࡓ CDBS (Clinical Data Backup
System)ߩ㐿⊒㧘G-NICE News Letter 2007 ᐕ㧧24 Ꮞ㧦2㧙3㧚
19㧕 ጊᧄ⋿↱⟤㧘ᱞ↰⚐㧘♿ࡁቯ଻⤿㧚SMBG ࠺࡯࠲ߩ㔚ሶࠞ࡞࠹਄ߢߩㆇ↪ߪ㧫㧘⢈ḩߣ♧ዩ∛ 2007 ᐕ㧧
6 Ꮞ㧦475㧙477㧚
20㧕 Ⓑጟೣሶ㧘♿ࡁቯ଻⤿㧘ቝㇺ↱⟤ሶ㧘⍹ේ⻞㧘ફ⷗ᷡ⑲㧚࠺࡯࠲࠙ࠚࠕࡂ࠙ࠬߣ࠺࡯࠲೑ᵴ↪㧘ක≮ᖱႎ
ቇ 2007 ᐕ㧧27 Ꮞ㧦261㧙268㧚
21㧕 ♿ࡁቯ଻⤿㧚ߎࠇ߆ࠄߩ∛㒮ᖱႎࠪࠬ࠹ࡓߩᣇะᕈߦߟ޿ߡ㧘╙ 92 ࿁ㄭ⇰∛ᱧ▤ℂ࠮ࡒ࠽࡯⸥㍳㓸 2007ᐕ㧧1㧙5㧚
22㧕 ♿ࡁቯ଻⤿㧘㈬੗㗅຦㧘ᐔᎹ⑲♿㧘␹㊁ᱜඳ㧚㔚ሶࠞ࡞࠹ࠍߎߎ߹ߢᵴ↪ߒߡ޿ࠆ㧘∛㒮 2007 ᐕ㧧66
Ꮞ㧦1013㧙1020㧚
23㧕 ♿ࡁቯ଻⤿㧚ක≮ߩ⾰ะ਄߳ߤߩࠃ߁ߦ⽸₂ߔࠆ߆㧘ᣣᧄ᡼኿✢ᛛᏧળ㔀⹹ 2008 ᐕ㧧55 Ꮞ㧦31㧙32㧚
24㧕 ♿ࡁቯ଻⤿㧚ࡈࠖ࡞ࡓ࡟ࠬߩലᨐࠍ‫ࠆ߃⷗ޟ‬ൻ‫ߒޠ‬ක≮ᯏ㑐⚻༡ߦ⽸₂ߔࠆ PACS ߩዉ౉߇᳞߼ࠄࠇߡ޿
ࠆ㧘IT Vision 2008 ᐕ㧧15 Ꮞ㧦26㧙27㧚
25㧕 ጊᧄ⋿↱⟤㧘♿ࡁቯ଻⤿㧘㜞Ⴆ⋥⢻㧚IT ߇ታ⃻ߔࠆක≮⃻႐ߢߩല₸ൻ‫ޟ‬ක≮ኾ㐷⡯ߩࡑࡀࠫࡔࡦ࠻ᢎ⢒ߦ߅ߌࠆ IT ᵴ↪ߩน⢻ᕈ‫ޠ‬㧘ᣂක≮ 2008 ᐕ㧧35 Ꮞ㧦54㧙57㧚
26㧕 ᧻ፉ⑲㧘♿ࡁቯ଻⤿㧚ಽሶࠗࡔ࡯ࠫࡦࠣߩᦨᣂേะ㧙MR ࠍਛᔃߦ㧙㧘INNERVISION 2008 ᐕ㧧23 Ꮞ㧦38㧙39㧚
27㧕 ᧻ፉ⑲㧘♿ࡁቯ଻⤿㧚੤Ꮕ✭๺₸ࠗࡔ࡯ࠫࡦࠣߦࠃࠆ߇ࠎ⸻ᢿ㧘ᤋ௝ᖱႎ MEDICAL 2008 ᐕ㧧40 Ꮞ㧦
480㧙484㧚
28㧕 ♿ࡁቯ଻⤿㧘ක≮ᯏ㑐ߦ߅ߌࠆ IT ᚢ⇛ߣ࠺࡯࠲ߩᵴ↪㧘᦬ೀࠫࡖ࡯ࡑ࠶ࠢ 2008 ᐕ㧧19 Ꮞ㧦23㧙26㧚
✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ጊᧄ⋿↱⟤㧘ᱞ↰⚐㧘♿ࡁቯ଻⤿㧚ోᯏ⒳ߩ⥄Ꮖⴊ♧᷹ቯེߩ࠺࡯࠲ࠍጘ㒂ᄢቇ∛㒮ߩ㔚ሶࠞ࡞࠹਄ߢㆇ
↪ߐߖࠆ⹜ߺ㧘⢈ḩߣ♧ዩ∛ 2006 ᐕ㧧5 Ꮞ೎ౠ 5㧦47㧙51㧚
2㧕 ♿ࡁቯ଻⤿㧘᪢ᧄᢘᄦ㧘ⁿญ᣿ඳ㧘ᱞ↰ᶈ৻㧘Ⓑጟೣሶ㧚ࡑࠗ࠾ࡦࠣᛛⴚࠍᵴ↪ߒߚቯ㊂⊛ߥ⸻≮ࡊࡠ࠮ࠬಽᨆ߳ߩ᜸ᚢ㧘ක≮ᖱႎቇ 2006 ᐕ㧧26 Ꮞ㧦191㧙199㧚
3㧕 ᄥ↰ᶈᢅ㧘ฎ↰િⴕ㧘᦯ㇱ㜞ᐘ㧘ਣᧄ㓷ᄦ㧘೨↰ᖗม㧘♿ࡁቯ଻⤿㧘┻᧛ᱜ↵㧘દ⮮ᒄᐽ㧘ᢧ⮮㇌᣿㧘ᷡፉḩ㧚ቢో㔚ሶൻ∛㒮ߦ߅ߌࠆᬌᩏઃടଔ୯ᖱႎឭଏߩ⹏ଔߦߟ޿ߡ㧙ࠕࡦࠤ࡯࠻⺞ᩏ⚿ᨐ߆ࠄ㧙㧘ᣣᧄ⥃ᐥᬌᩏ⥄േൻቇળળ⹹ 2008 ᐕ㧧33 Ꮞ㧦295㧙300㧚
4㧕 ጟ቟િੑ㧘ਅ↰ᶈᰵ㧘♿ࡁቯ଻⤿㧘ᱞ↰⚐㧘ጊᧄ⋿↱⟤㧚ࠗࡦࠬ࡝ࡦߩ቟ో▤ℂߦ㑐ߔࠆ㔚ሶࠞ࡞࠹ᯏ⢻ߩ᦭↪ᕈߣ໧㗴ὐ㧘⢈ḩߣ♧ዩ∛(ᣣᧄ♧ዩ∛ᖱႎቇળ⺰ᢥ⹹) 2008 ᐕ㧧7 Ꮞ㧦28㧙35㧚
5㧕 ጊᧄ⋿↱⟤㧘Ꮉ಴㕏ᒾ㧘ᚭ⼱ℂ⧷ሶ㧘ᱞ↰⚐㧘᪢ᧄᢘᄦ㧘♿ࡁቯ଻⤿㧚ጘ㒂⋵කᏧળ∛⸻ㅪ៤ࠪࠬ࠹ࡓߦ
߅ߌࠆ♧ዩ∛∛⸻ㅪ៤ࠨࡐ࡯࠻ࠪࠬ࠹ࡓߩ⹜૞㧘⢈ḩߣ♧ዩ∛(ᣣᧄ♧ዩ∛ᖱႎቇળ⺰ᢥ⹹) 2008 ᐕ㧧7Ꮞ㧦56㧙61㧚㧙㧙6㧕 ਅ↰ᶈᰵ㧘ጟ቟િੑ㧘♿ࡁቯ଻⤿㧘ᱞ↰⚐㧘ጊᧄ⋿↱⟤㧚㔚ሶࠞ࡞࠹ᖱႎ߆ࠄಽᨆߔࠆᄢቇ∛㒮ߩ♧ዩ∛∛᫟ᖚ⠪ߩ․ᓽಽᨆߩ⹜ⴕ㧙ᬺോࠍนⷞൻߔࠆ᦭↪ᕈߦߟ޿ߡ㧙㧘⢈ḩߣ♧ዩ∛(ᣣᧄ♧ዩ∛ᖱႎቇળ⺰ᢥ⹹) 2008 ᐕ㧧7 Ꮞ㧦89㧙93㧚
7㧕 ࿡ᨑ℉਽㧘ౝጊ⦟৻㧘ේᱞผ㧘⮮↰ᐢᔒ㧘ട⮮ඳၮ㧘ᵻ㊁㓉ᒾ㧘ᤊඳᤘ㧘ጊᎹᒄ଻㧘቟⮮ᒄ㆏㧘ጤ㑆੧㧚ࠢ࡜ࠬ࠲࡝ࡦࠣࠍ↪޿ߚ⣖࠼࠶ࠢ MR ↹௝ߦ߅ߌࠆή∝୥ᕈᄢ⣖⊕⾰∛ᄌߩᬌ಴ᴺ㧘Medical Imaging
Technology 2008 ᐕ㧧26 Ꮞ㧦39㧙47㧚
8㧕 ጊౝ዁ผ㧘ౝጊ⦟৻㧘ዊ᫾Ả㧘ᮮጊ㦖ੑ㇢㧘ේᱞผ㧘቟⮮ᒄ㆏㧘ጊᎹᒄ଻㧘ጤ㑆੧㧘ᤊඳᤘ㧘⮮↰ᐢᔒ㧚⣖ MRA ↹௝ߦ߅ߌࠆ㐽Ⴇߩᬌ಴㧘Medical Imaging Technology 2008 ᐕ㧧26 Ꮞ㧦251㧙260㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Inaba T, Nakano T, Tsutsumi M, Kawasaki S, Kinosada Y, Tokuda M . Quantitative Evaluation of Left
Ventricular Wall Motion in Patient with Coronary Artery Bypass Grafting Using Magnetic ResonanceTagging Technique, JSME International Journal. 2006;49:597-603.
IF 0.298
2㧕 Matsushima S, Nishiofuku H, Iwata H, Era S, Inaba Y, Kinosada Y. Equivalent cross-relaxation rate
imaging of axillary lymph nodes in breast cancer, J Mag Reson Imag. 2008;27:1278-1283.
IF 2.2093㧕 Uchiyama Y, Kunieda T, Asano T, Kato H, Hara T, Kanematsu M, Iwama T, Hoshi H, Kinosada Y,
Fujita H. Computer-aided diagnosis scheme for classification of lacunar infarcts and enlarged
Virchow-Robin spaces in brain MR images. Proc of IEEE Engineering in Medicine and Biology Society.
2008:3908-3911.
IF 1.0664㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦♿ࡁቯ଻⤿㧘⎇ⓥಽᜂ⠪㧦⊕㠽⟵ቬ㧘┻ౝ⊓⟤ሶ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(B)㧦
‫ޟ‬ᰴ਎ઍ㔚ሶࠞ࡞࠹ࠪࠬ࠹ࡓߦࠃࠆ⸻≮Ꮏ⒟࡮∛㒮ㆇ༡Ꮏ⒟ߩ⛔วಽᨆⅣႺߩ᭴▽ߣ⸃ᨆ‫ޠ‬㧧
ᐔᚑ 17㧙18 ᐕᐲ㧧12,100 ජ౞(7,400㧦4,700 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦᧻ፉ⑲㧧߇ࠎߘߩઁߩᖡᕈᣂ↢‛⎇ⓥഥᚑ㊄(⽷࿅ᴺੱᗲ⍮⋵߇ࠎ⎇ⓥᝄ⥝ળ)㧧
Equivalent cross relaxation image ߦࠃࠆ molecular lymph node imaging㧧ᐔᚑ 18 ᐕᐲ㧧500 ජ౞3㧕 ⎇ⓥઍ⴫⠪㧦⊕㠽⟵ቬ㧘⎇ⓥಽᜂ⠪㧦᫪⣁ਭ㓉㧘♿ࡁቯ଻⤿㧘ඨ↰ብ㧘྾┬ሶᅢᐢ㧧ၮ⋚⎇ⓥ(C)㧦
‫⚦≸ޟ‬⢩ߦ߅ߌࠆᩭౝฃኈ૕ߥࠄ߮ߦ⤑ฃኈ૕ߩ⇣Ᏹߣߘߩ೙ᓮߦ㑐ߔࠆ⎇ⓥ‫ޠ‬㧧ᐔᚑ 16㧙18 ᐕᐲ㧧3,400 ජ౞(1,700㧦1,100㧦600 ජ౞)‫ޟ‬MRI ࠍ↪޿ߚ⣲≌⚦4㧕 ⎇ⓥઍ⴫⠪㧦᧻ፉ⑲㧘⎇ⓥಽᜂ⠪㧦♿ࡁቯ଻⤿㧘ᗆ⦟⡛৻㧧ၮ⋚⎇ⓥ(C)(2)㧦
⢩ኒᐲࠍนⷞൻߔࠆಽሶ↹௝ߩ㐿⊒ߣ≸ᴦ≮߳ߩᔕ↪‫ޠ‬㧧ᐔᚑ 19㧙20 ᐕᐲ㧧3,300 ජ౞(2,200㧦1,100ජ౞)
5㧕 ⎇ⓥઍ⴫⠪㧦᧻ፉ⑲㧧߇ࠎߘߩઁߩᖡᕈᣂ↢‛⎇ⓥഥᚑ㊄(⽷࿅ᴺੱᗲ⍮⋵߇ࠎ⎇ⓥᝄ⥝ળ)㧦⢄⚦⢩≸ᖚ⠪ߦ߅ߌࠆ୘೎ൻක≮ࠍ⋡ᜰߒߚ MR-Cellular imaging㧧ᐔᚑ 19 ᐕᐲ㧧500 ජ౞6㧕 ⎇ⓥઍ⴫⠪㧦ᕺ⦟⡛৻㧘⎇ⓥಽᜂ⠪㧦᧻ፉ⑲㧘♿ࡁቯ଻⤿㧧ၮ⋚⎇ⓥ(C)(2)㧦‫⏛ޟ‬᳇౒㡆ᴺߦࠃࠆ↢૕⚵❱∛ᄌᬌ಴ߩߚ߼ߩಽሶࠗࡔ࡯ࠫࡦࠣߩ㐿⊒ߣ⥃ᐥᔕ↪‫ޠ‬㧧ᐔᚑ 19㧙20 ᐕᐲ㧧3,570 ජ౞(2,470㧦1,100 ජ౞)
7㧕 ⎇ⓥઍ⴫⠪㧦ਅ᧛⋿⟤(ᄢ㒋ᄢቇ㜞╬มᴺ⎇ⓥᚲ)㧘⎇ⓥಽᜂ⠪㧦⮮ᧄ೑৻(ᄢ㒋ᄢቇ)㧘♿ࡁቯ଻⤿㧧ၮ⋚⎇ⓥ(C)(2㧕㧦‫ޟ‬ක≮⸷⸩ߦ߅ߌࠆක≮ᖱႎࠪࠬ࠹ࡓߩ޽ࠅᣇߦ㑐ߔࠆ⎇ⓥ‫ޠ‬㧧ᐔᚑ 20㧙22 ᐕᐲ㧧
3,500 ජ౞(1,200㧦1,100㧦1,200 ජ౞)
8㧕 ⎇ⓥઍ⴫⠪㧦ౝጊ⦟৻㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(B)(⧯ᚻ)㧦࡜ࠢ࠽᪪Ⴇ㐓೎ߩߚ߼ߩ
ࠦࡦࡇࡘ࡯࠲ᡰេ⸻ᢿ㧧ᐔᚑ 20㧙21 ᐕᐲ㧧1,700 ජ౞(900㧦800 ජ౞)
2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫ
1㧕 ♿ࡁቯ଻⤿㧘᧻ፉ⑲㧘ᗆ⦟⡛৻㧘㐳↰⌀ੑ㧦MR ⵝ⟎ߦࠃࠆ⏛ൻ⒖േലᨐᴺߣലᨐᲧṶ▚ࠍ૬↪ߒߚ∛ᄌ⇣Ᏹߩᣧᦼᬌ಴ᴺ㧧ᐔᚑ 19 ᐕ(․⸵಴㗿ਛ)
2㧕 ⮮↰ᐢᔒ㧘ౝጊ⦟৻㧘ጤ㑆੧㧘቟⮮ᒄ㆏㧘ੑ᧛ੳ㧦ක↪↹௝ಣℂⵝ⟎(․⸵)㧧ᐔᚑ 20 ᐕ(․⸵ 4139869
ภ)

㧙㧙

3㧕 ⮮↰ᐢᔒ㧘ౝጊ⦟৻㧦ක↪↹௝ಣℂⵝ⟎෸߮⇣Ᏹ㒶ᓇᬌ಴ᣇᴺ(⊒᣿)㧧ᐔᚑ 20 ᐕ(․㗿 2008㧙75961)
6㧚ቇળᵴേ
1㧕ቇળᓎຬ
♿ࡁቯ଻⤿㧦
1㧕 ᣣᧄ⏛᳇౒㡆කቇળℂ੐(㨪⃻࿷)2㧕 ᣣᧄ↢૕කᎿቇળઍ⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄක≮ᖱႎቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄකቇ᡼኿✢ቇળ㔚ሶᖱႎᆔຬળᆔຬ(㨪⃻࿷)2㧕ቇળ㐿௅
♿ࡁቯ଻⤿㧦
1㧕 ╙ 29 ࿁ MR ၮ␆⻠ᐳ(ᐔᚑ 19 ᐕ 8 ᦬㧘᧲੩)
2㧕 ᐔᚑ 19 ᐕᐲᣣᧄ↢૕කᎿቇળ᧲ᶏᡰㇱቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 10 ᦬㧘᧲੩)
3㧕ቇⴚ㔀⹹ౝጊ⦟৻㧦
1㧕 ࠦࡦࡇࡘ࡯࠲ᡰេ↹௝⸻ᢿቇળ⹹㧧✬㓸ᆔຬ(㨪ᐔᚑ 20 ᐕ 10 ᦬)
2㧕 ක↪↹௝ᖱႎቇળ⹹㧧✬㓸ᆔຬ(ᐔᚑ 20 ᐕ 7 ᦬㨪⃻࿷)7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳♿ࡁቯ଻⤿㧦
1㧕 ᐔᚑ 17 ᐕᐲᄢቇ∛㒮ᖱႎࡑࡀࠫࡔࡦ࠻ㇱ㐷ㅪ⛊ળ⼏(ᐔᚑ 18 ᐕ 1 ᦬㧘㕒ጟ㧘ಽ⑼ળ 2‫ޟ‬㔚ሶࠞ࡞࠹࠺࡯࠲ࡌ࡯ࠬߩ⥃ᐥ⎇ⓥ࠺࡯࠲ࡌ࡯ࠬߣߒߡߩ೑ᵴ↪ 㧙ጘ㒂ᄢቇ∛㒮ߩ႐ว㧙‫ޠ‬Ṷ⠪)
2㧕 ╙ 15 ࿁ᣣᧄ⣖␹⚻ᄖ⑼ࠦࡦࡇࡘ࡯࠲⎇ⓥળ(ᐔᚑ 18 ᐕ 1 ᦬㧘ጊญ㧘․೎⻠Ṷ‫∛ޟ‬㒮ߩ IT ൻߣᄖ⑼ቇ߳ߩ⽸₂ࠍ⋡ᜰߒߡ‫ޠ‬Ṷ⠪)
3㧕 ╙ 12 ࿁ጘ㒂ක≮ᖱႎ⎇ⓥળ(ᐔᚑ 18 ᐕ 1 ᦬㧘ጘ㒂㧘ࡊ࡟࠽࡝࡯࠮࠶࡚ࠪࡦ‫ޟ‬IT ߣࡠࡏ࠶࠻ࠍߟߥ
ߋᣂߒ޿ᛛⴚ߇ᓴⅣེක≮ߩᧂ᧪ࠍߤߩࠃ߁ߦᜏ߆‫ޠ‬Ṷ⠪)
4㧕 ᐔᚑ 17 ᐕᐲጘ㒂⋵කᏧળ✚วක≮ᖱႎࡀ࠶࠻ࡢ࡯ࠢ࡮ጘ㒂࿾඙✚วක≮ᖱႎࡀ࠶࠻ࡢ࡯ࠢวห✚ળ(ᐔᚑ 18 ᐕ 2 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ጘ㒂⋵ߦ߅ߌࠆ IT ࠍᵴ↪ߒߚ∛⸻ㅪ៤ࠪࠬ࠹ࡓߩ੹ᓟ‫ޠ‬Ṷ⠪)
5㧕 ╙ 228 ࿁ක≮ߣ࠾ࡘ࡯ࡔ࠺ࠖࠕࠍ⠨߃ࠆળ(ᐔᚑ 18 ᐕ 2 ᦬㧘᧲੩㧘⻠Ṷ‫ޟ‬ጘ㒂ᄢቇ∛㒮ߦ߅ߌࠆ㔚ሶࠞ࡞࠹ࠪࠬ࠹ࡓዉ౉ߩᚑᨐ‫ޠ‬Ṷ⠪)
6㧕 ᐔᚑ 17 ᐕᐲ㑐᧲ IBM ࡙࡯ࠩ࡯⎇ⓥળ ╙ੑ࿁‫ޟ‬IT ࠰࡝ࡘ࡯࡚ࠪࡦ࡮࠮ࡒ࠽࡯‫(ޠ‬ᐔᚑ 18 ᐕ 3 ᦬㧘᧲੩㧘⻠Ṷ‫⚻ࠆߌ߅ߦ࡞࠲ࡇࠬࡎ࠻ࡦࠚࠫ࡝࠹ࡦࠗޟ‬༡▤ℂᚻᴺ‫ޠ‬Ṷ⠪)7㧕 ਛㇱࡎࠬࡇ࠲࡞࡚ࠪ࠙ 2006(ᐔᚑ 18 ᐕ 3 ᦬㧘ᗲ⍮㧘⻠Ṷ‫ޟ‬ᰴ਎ઍ㔚ሶࠞ࡞࠹ࠪࠬ࠹ࡓߢㅴൻߔࠆ∛㒮ࡑࡀࠫࡔࡦ࠻‫ޠ‬Ṷ⠪)8㧕 ╙ 70 ࿁⸥ᔨᣣᧄᓴⅣེቇળࡊ࡟࠽࡝࡯࠮࠶࡚ࠪࡦ(ᐔᚑ 18 ᐕ 3 ᦬㧘ᗲ⍮㧘⻠Ṷ‫ޟ‬IT Impact on the
Cardio-Vascular Robotic Surgery‫ޠ‬Ṷ⠪)9㧕 ක≮ᯏ㑐࠰࡝ࡘ࡯࡚ࠪࡦ࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 5 ᦬㧘㕒ጟ㧘⻠Ṷ‫∛ޟ‬㒮⚻༡ߦ߅ߌࠆ IT ߩᵴ↪‫ޠ‬Ṷ⠪)10㧕 ᄢ၂Ꮢ᳃∛㒮 ቇⴚ⎇ୃળ(ᐔᚑ 18 ᐕ 6 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬DPC ೙ᐲߩዉ౉ߣ∛㒮ㆇ༡ߩᄌൻߦߟ޿
ߡ‫ޠ‬Ṷ⠪)
11㧕 ጘᄢ࡮ච౐↥ቇㅪ៤ක≮ IT ࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 6 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬ක≮ಽ㊁ߦ߅ߌࠆ IT ᵴ↪ߩᣇะᕈ‫ޠ‬Ṷ⠪)12㧕 ᐔᚑ 18 ᐕᐲߺ߃ࡔ࠺ࠖࠞ࡞⎇ⓥળ✚ળ(ᐔᚑ 18 ᐕ 6 ᦬㧘ਃ㊀㧘⻠Ṷ‫ޟ‬ᣣᧄ EHR 㧙ᣂߚߥ↢ᶦဳஜᐽ࡮ක≮ᖱႎࠪࠬ࠹ࡓߩ᭴▽ߦะߌߡ㧙‫ޠ‬Ṷ⠪)
13㧕 㣐⷗∛㒮㧦቟ో▤ℂ⎇ୃળ(ᐔᚑ 18 ᐕ 9 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬㔚ሶࠞ࡞࠹ࠪࠬ࠹ࡓ㧦ߘߩ᭴▽ߣㆇ↪㧘ᵴ↪ߦߟ޿ߡ ‫ޠ‬Ṷ⠪)
14㧕 ጘᄢ࡮ච౐↥ቇㅪ៤ක≮ IT ࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 9 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬ක≮⚻༡ࠍᡰ߃ࠆᖱႎಽᨆᛛⴚ
-Information-based management-‫ޠ‬Ṷ⠪)
15㧕 ╙৻࿁᧲ᶏක≮ᖱႎࠪࠬ࠹ࡓᙣ⺣ળ(ᐔᚑ 18 ᐕ 9 ᦬㧘ᗲ⍮㧘ᢎ⢒⻠Ṷ‫ޟ‬㔚ሶࠞ࡞࠹࠺࡯࠲ࠍ᦭ലߦ
೑ᵴ↪ߔࠆߚ߼ߩᚻᴺߣࠪࠬ࠹ࡓ᭴▽ߦߟ޿ߡ‫ޠ‬Ṷ⠪)16㧕 InterSystems in Healthcare ࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 10 ᦬㧘᧲੩㧘⻠Ṷ‫ޟ‬ක≮ IT㧦ᣣ☨ᦨᣂ੐ᖱߩᲧセߣ੹ᓟߩขࠅ⚵ߺ‫ޠ‬Ṷ⠪)㧙㧙

17㧕 ╙ 44 ࿁ᣣᧄ∛㒮▤ℂቇળቇⴚ✚ળ(ᐔᚑ 18 ᐕ 10 ᦬㧘ᗲ⍮㧘ࠪࡦࡐࠫࡘ࡯ࡓ‫ޟ‬ක≮ࡑࡀࠫࡔࡦ࠻ߦ
⽸₂ߔࠆ㔚ሶࠞ࡞࠹ࠪࠬ࠹ࡓ‫ޠ‬Ṷ⠪)18㧕 ක≮ᯏ㑐࠰࡝ࡘ࡯࡚ࠪࡦ࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 10 ᦬㧘㕒ጟ㧘⻠Ṷ‫∛ޟ‬㒮⚻༡ߦ߅ߌࠆ IT ߩᵴ↪‫ޠ‬Ṷ
⠪)19㧕 㔚ሶᖱႎᛛⴚ↥ᬺදળ‫ࠣࡦࠪࡦ࠮ࠢ࡯ࡢ࠻࠶ࡀޟ‬ᛛⴚኾ㐷ᆔຬળ‫(ޠ‬ᐔᚑ 18 ᐕ 10 ᦬㧘᧲੩㧘⻠Ṷ‫ࡀޟ‬࠶࠻ࡢ࡯ࠢ࠮ࡦࠪࡦࠣᛛⴚࠍᔕ↪ߒߚ∛㒮ㆇ༡ᚻᴺߦߟ޿ߡ‫ޠ‬Ṷ⠪)20㧕 ឳ᢫ෘ↢∛㒮࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 10 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬DPC ೙ᐲߩዉ౉ߣ∛㒮ㆇ༡ߩᄌൻߦߟ޿ߡ‫ޠ‬Ṷ⠪)21㧕 ╙ 4 ࿁ᣣᧄ࡮ࡉ࡜ࠫ࡞㧛࿾ၞ࡮࿾ၞⅣႺ࿖㓙ࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 18 ᐕ 10 ᦬㧘ጘ㒂㧘⻠Ṷ‫ᦨޟ‬వ┵ක≮ߣጘ㒂ᄢቇ∛㒮‫ޠ‬Ṷ⠪)22㧕 ISACA ฬฎደᡰㇱ᦬଀ળ(ᐔᚑ 18 ᐕ 10 ᦬㧘ᗲ⍮㧘⻠Ṷ‫ޟ‬ጘ㒂ᄢቇ∛㒮ߦ⷗ࠆᖱႎࠪࠬ࠹ࡓߩ⸽᜚
଻ో⢻ߦߟ޿ߡ‫ޠ‬Ṷ⠪)23㧕 ᐔᚑ 18 ᐕᐲ⚻ᷣ↥ᬺ⋭‫ޟ‬ක≮⚻༡ੱ᧚⢒ᚑ੐ᬺ‫ޠ‬ක≮ኾ㐷⡯ߩߚ߼ߩක≮ࡑࡀࠫࡔࡦ࠻࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 10 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬ක≮ᖱႎ▤ℂߣ∛㒮⚻༡㧔ࠝࡍ࡟࡯࡚ࠪࡦ▤ℂ㧕‫ޠ‬Ṷ⠪)24㧕 ╙ 26 ࿁ක≮ᖱႎቇㅪวᄢળ(ᐔᚑ 18 ᐕ 11 ᦬㧘ർᶏ㆏㧘ࠪࡦࡐࠫࡘ࡯ࡓ‫࠻࠶ࡇࠢࠦ࡮࡞ࠞ࠾࡝ࠢޟ‬㧦ߘߩࠦࡦ࠮ࡊ࠻ߣㆇ↪‫ޠ‬Ṷ⠪)25㧕 ╙ 26 ࿁ක≮ᖱႎቇㅪวᄢળ(ᐔᚑ 18 ᐕ 11 ᦬㧘ർᶏ㆏㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯
‫ޟ‬㔚ሶࠞ࡞࠹ᤨઍߩ PACSᵴ↪੐଀‫ޠ‬ᐳ㐳)26㧕 ጘ㒂⋵කᏧળ㧦↥ᬺක⎇ୃળ(ᐔᚑ 18 ᐕ 11 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬⡯ၞߦ߅ߌࠆஜ⸻࠺࡯࠲ߩ㊀ⷐᕈ-↢ᵴ⠌ᘠ∛੍㒐ߩⷰὐ߆ࠄ-‫ޠ‬Ṷ⠪)27㧕 ᐔᚑ 18 ᐕᐲ‫(ޠ࡞ࡌ࡟࠼ࡦࠞ࠮ޟ‬ᐔᚑ 18 ᐕ 11 ᦬㧘౓ᐶ㧘⻠Ṷ‫▤⼔⋴ޟ‬ℂࠍᡰេߔࠆᖱႎᛛⴚ‫ޠ‬Ṷ⠪)28㧕 ጘᄢ࡮ච౐↥ቇㅪ៤ක≮ IT ࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 12 ᦬㧘ጘ㒂㧘⻠Ṷ‫ࠢ࡯ࡢ࠻࠶ࡀ࡯ࠨࡦ࠮ޟ‬ᛛⴚ‫ޠ‬Ṷ⠪)29㧕 ࿖଻੐ᬺផㅴ࠻࠶ࡊ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 1 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ஜ⸻ߩ⟵ോൻߦ㑐ࠊࠆஜ⸻࠺࡯࠲
╬ߩㆇ↪࡮▤ℂߦߟ޿ߡ‫ޠ‬Ṷ⠪)30㧕 ጘ㒂ᄢቇ∛㒮⋴⼔ㇱ⻠Ṷળ(ᐔᚑ 19 ᐕ 1 ᦬㧘ጘ㒂㧘⻠Ṷ‫∛ޟ‬㒮ࠍขࠅᏎߊක≮ᖱ൓‫ޠ‬Ṷ⠪)31㧕 ᐔᚑ 18 ᐕᐲ⚻ᷣ↥ᬺ⋭‫ޟ‬ක≮⚻༡ੱ᧚⢒ᚑ੐ᬺ‫ޠ‬ක≮ኾ㐷⡯ߩߚ߼ߩක≮ࡑࡀࠫࡔࡦ࠻࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 2 ᦬㧘ጘ㒂㧘⻠Ṷ‫∛ޟ‬㒮 IT ൻߣක≮ߩᄌൻ(ࠝࡍ࡟࡯࡚ࠪࡦ▤ℂ)‫ޠ‬Ṷ⠪㧕32㧕 ක੐㑐ଥ⸷⸩ߩㆇ༡ࠍ߼ߋࠆᙣ⺣ળ(ᐔᚑ 19 ᐕ 2 ᦬㧘ᄢ㒋㧘⻠Ṷ‫ޟ‬ጘ㒂ᄢቇ∛㒮ߩ㔚ሶࠞ࡞࠹ࠪࠬ
࠹ࡓߣᖱႎ࠮ࠠࡘ࡝࠹ࠖ㧘⸽᜚଻ోߦߟ޿ߡ‫ޠ‬Ṷ⠪)33㧕 ᐔᚑ 18 ᐕᐲጘ㒂⋵කᏧળ✚วක≮ᖱႎࡀ࠶࠻ࡢ࡯ࠢ࡮ጘ㒂࿾඙✚วක≮ᖱႎࡀ࠶࠻ࡢ࡯ࠢวห✚ળ(ᐔᚑ 19 ᐕ 2 ᦬㧘ጘ㒂㧘‫ޟ‬ක≮଻㒾೙ᐲߣක≮ࠨ࡯ࡆࠬ㧘IT ᵴ↪ߩᦨᣂ੐଀ߦߟ޿ߡ-․ߦᣣ☨⧷ࠍᲧセߔࠆ‫ޠ‬Ṷ⠪)34㧕 (␠)ᣣᧄකᬺ⚻༡ࠦࡦࠨ࡞࠲ࡦ࠻දળᐔᚑ 18 ᐕᐲ⛮⛯⎇ୃ(2 ᦬㧛㓸ਛ)(ᐔᚑ 19 ᐕ 2 ᦬㧘ᗲ⍮㧘⻠Ṷ‫ޟ‬ක≮ᯏ㑐ߦ߅ߌࠆ ICT ൻߩ⃻⁁ߣ੹ᓟߩᓎഀ㧙ක≮ࡑࡀࠫࡔࡦ࠻ࠍᡰ߃ࠆ ICT㧙‫ޠ‬Ṷ⠪)35㧕 ᴺੱ⡯ຬኻ⽎⻠Ṷળ(ᐔᚑ 19 ᐕ 2 ᦬㧘ᗲ⍮㧘⻠Ṷ‫ޟ‬㔚ሶࠞ࡞࠹ߩዉ౉ߣߘߩലᨐ‫ޠ‬Ṷ⠪)36㧕 ᐔᚑ 18 ᐕᐲ⚻ᷣ↥ᬺ⋭‫ޟ‬ක≮⚻༡ੱ᧚⢒ᚑ੐ᬺ‫ޠ‬ක≮ࡑࡀࠫࡔࡦ࠻ᦨᣂ੐ᖱ⻠Ṷળ(ᐔᚑ 19 ᐕ 3 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬ක≮⚻༡ߣ IT㧔ක≮ᖱႎቇ⠪ߩ┙႐߆ࠄ㧕‫ޠ‬Ṷ⠪)
37㧕 ක≮⚻༡ᦨᣂ੐ᖱ⻠Ṷળ(ᐔᚑ 19 ᐕ 3 ᦬㧘ᄢ㒋㧘⻠Ṷ‫ޟ‬ක≮⚻༡ߣ IT‫ޠ‬Ṷ⠪㧕38㧕 ጊ↰⿒චሼ∛㒮․೎⻠Ṷળ(ᐔᚑ 19 ᐕ 6 ᦬㧘ਃ㊀㧘․೎⻠Ṷ‫ޟ‬㔚ሶࠞ࡞࠹㧘↹௝ᬌᩏߩࡈࠖ࡞ࡓ࡟
ࠬㆇ↪ߩታ㓙㧙ዉ౉ߩ⸘↹߆ࠄㆇ↪߹ߢߩࡊࡠ࠮ࠬࠍਛᔃߦ㧙‫ޠ‬Ṷ⠪)39㧕 ╙ 23 ࿁ో࿖᡼኿✢ᛛᏧ✚วቇⴚᄢળ․೎ࡊࡠࠣ࡜ࡓ‫ޟ‬ක≮⚻༡ߦ߅ߌࠆ᡼኿✢ᛛᏧߩᓎഀ‫(ޠ‬ᐔᚑ19 ᐕ 6 ᦬㧘⍹Ꮉ㧘⻠Ṷ‫ޟ‬ක≮ߩ⾰ะ਄߳ߤߩࠃ߁ߦ⽸₂ߔࠆ߆‫ޠ‬Ṷ⠪)40㧕 ╙ 11 ࿁ᣣᧄක≮ᖱႎቇળᤐቄቇⴚᄢળ(ࠪࡦࡐࠫ࠙ࡓ 2007)‫࠲࡯࠺ߣࠬ࠙ࡂࠕࠚ࠙࠲࡯࠺ޟ‬೑ᵴ↪‫ޠ‬(ᐔᚑ 19 ᐕ 6 ᦬㧘ᄢ㒋㧘ࠪࡦࡐࠫࡘ࡯ࡓ‫ ߣࠬ࠙ࡂࠕࠚ࠙࠲࡯࠺ޟ‬Information-based Management‫ޠ‬ᐳ㐳࡮Ṷ⠪)
41㧕 ጘᄢ࡮ච౐↥ቇㅪ៤ක≮⚻༡ࠪࡦࡐࠫ࠙ࡓ(ᐔᚑ 19 ᐕ 6 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫࡘ࡯ࡓ‫ޟ‬ା㗬ߐࠇࠆ∛㒮ߣߪ‫ޠ‬ᐳ㐳)42㧕 ╙ 29 ࿁ MR ၮ␆⻠ᐳ(ᐔᚑ 19 ᐕ 8 ᦬㧘᧲੩㧘⻠Ṷ‫ޟ‬⢄ߩ MRI㧙ᦨㄭߩ⹤㗴ࠍ฽߼ߡ㧙‫ޠ‬ᐳ㐳)43㧕 ╙ 17 ࿁කᬺ⚻༡ࠦࡦࠨ࡞࠲ࡦ࠻⹺ቯ⻠ᐳ(ᐔᚑ 19 ᐕ 8 ᦬㧘᧲੩㧘‫ޟ‬ᖱႎ▤ℂ‫ޠ‬Ṷ⠪)44㧕 ⹺ቯ⋴⼔▤ℂ⠪೙ᐲᐔᚑ 19 ᐕᐲ‫࡞ࡌ࡟࠼ࡦࠞ࠮ޟ‬ᢎ⢒⺖⒟‫(ޠ‬ᐔᚑ 19 ᐕ 9 ᦬㧘౓ᐶ㧘‫▤⼔⋴ޟ‬ℂࠍᡰេߔࠆᖱႎᛛⴚ‫ޠ‬Ṷ⠪)㧙㧙

45㧕 ╙ 35 ࿁ᣣᧄ⏛᳇౒㡆කቇળᄢળ(ᐔᚑ 19 ᐕ 9 ᦬㧘౓ᐶ㧘ᢎ⢒⻠Ṷ‫ޟ‬ၮ␆Τ‫ޠ‬ᐳ㐳)46㧕 ጊ↰⿒චሼ∛㒮․೎⻠Ṷળ(ᐔᚑ 19 ᐕ 10 ᦬㧘ਃ㊀㧘․೎⻠Ṷ‫ޟ‬㔚ሶࠞ࡞࠹㧘↹௝ᬌᩏߩࡈࠖ࡞ࡓ࡟
ࠬㆇ↪ߩታ㓙㧙ዉ౉ߩ⸘↹߆ࠄㆇ↪߹ߢߩࡊࡠ࠮ࠬࠍਛᔃߦ㧙‫ޠ‬Ṷ⠪)47㧕 ᐔᚑ 19 ᐕᐲᣣᧄ↢૕කᎿቇળ᧲ᶏᡰㇱቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 10 ᦬㧘ᗲ⍮㧘․೎⻠Ṷ‫ޟ‬ᝄേಽశᴺߢ
㕖ଚⷅ⊛ߦੱ૕ߩઍ⻢ࠍⷰࠆ‫ޠ‬ᐳ㐳)48㧕 ╙ 92 ࿁ㄭ⇰∛ᱧ▤ℂ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 10 ᦬㧘ᄢ㒋㧘⻠Ṷ‫∛ߩࠄ߆ࠇߎޟ‬㒮ᖱႎࠪࠬ࠹ࡓߦ᳞߼
ࠄࠇࠆ߽ߩ‫ޠ‬Ṷ⠪)49㧕 ╙ 20 ࿁㔚ሶᖱႎ⎇ⓥળ(ᣣᧄකቇ᡼኿✢ቇળ)(ᐔᚑ 19 ᐕ 10 ᦬㧘ᗲ⍮㧘ࠪࡦࡐࠫࡘ࡯ࡓ‫ޟ‬᡼኿✢ㇱ㐷ߩ IT ൻ࡮ࠪࠬ࠹ࡓൻ‫ޠ‬ᐳ㐳)50㧕 ⹺ቯ⊓㍳කᬺ⚻༡ࠦࡦࠨ࡞࠲ࡦ࠻਄⚖ࡆࠫࡀࠬࠦ࡯ࠬ(ᐔᚑ 20 ᐕ 3 ᦬㧘᧲੩㧘⻠Ṷ‫ޟ‬ක≮ᖱႎ▤ℂߩၮᧄ㧛ᖱႎ࠮ࠠࡘ࡝࠹ࠖ‫ޠ‬Ṷ⠪)51㧕 ක≮⚻༡ੱ᧚⢒ᚑၮ␆⎇ୃࠦ࡯ࠬ(ᐔᚑ 20 ᐕ 3 ᦬㧘ᄢ㒋㧘⻠Ṷ‫ޟ‬ක≮ᯏ㑐ߩ IT ᚢ⇛‫ޠ‬Ṷ⠪)52㧕 ⹺ቯ⊓㍳කᬺ⚻༡ࠦࡦࠨ࡞࠲ࡦ࠻਄⚖ࡆࠫࡀࠬࠦ࡯ࠬ(ᐔᚑ 20 ᐕ 3 ᦬㧘᧲੩㧘⻠Ṷ‫ޟ‬ᖱႎࠦࡦࠨ࡞
࠹ࠖࡦࠣ㧛㒮ౝᖱႎൻߩㅴ߼ᣇ‫ޠ‬Ṷ⠪)53㧕 Cyberrad2008(ᣣᧄ࡜ࠫࠝࡠࠫ࡯දળ)(ᐔᚑ 20 ᐕ 4 ᦬㧘␹ᄹᎹ㧘⻠Ṷ‫ޟ‬᡼኿✢ㇱ㐷ࠍขࠅᏎߊ∛㒮ౝߩᖚ⠪േ✢‫ޠ‬Ṷ⠪)54㧕 ╙ 9 ࿁∛㒮ߩ⚻༡ࠍ⠨߃ࠆળ(ᐔᚑ 20 ᐕ 6 ᦬㧘ᄢ㒋㧘⻠Ṷ‫ޟ‬ක≮ᯏ㑐ߦ߅ߌࠆ ICT ᚢ⇛ߣࡑࡀࠫࡔ
ࡦ࠻ߩ⺞๺ࠍ᳞߼ߡ‫ޠ‬Ṷ⠪)55㧕 ╙ 7 ࿁࿖㓙ࡃࠗࠝࡈࠜ࡯࡜ࡓ(࿖㓙ࡃࠗࠝ 2008)(ᐔᚑ 20 ᐕ 7 ᦬㧘᧲੩㧘⻠Ṷ‫↢ޟ‬ᶦߦਗ਼ࠆஜᐽᖱႎ
ߩ▤ℂߣ቟ోߥฃ⸻≮ࠍᡰេߔࠆࠪࠬ࠹ࡓ‫ޠ‬Ṷ⠪)56㧕 ⹺ቯ⊓㍳කᬺ⚻༡ࠦࡦࠨ࡞࠲ࡦ࠻දળ ᐔᚑ 20 ᐕᐲ㓸ਛ⎇ୃ(ᐔᚑ 20 ᐕ 7 ᦬㧘᧲੩㧘⻠Ṷ‫ޟ‬ක≮ᯏ㑐ߦ߅ߌࠆ IT ᚢ⇛ߣ࠺࡯࠲ߩ᦭ലᵴ↪‫ޠ‬Ṷ⠪)57㧕 IBM ⵾⮎ᬺᄤၔ࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 7 ᦬㧘㕒ጟ㧘⻠Ṷ‫ޟ‬ක≮ IT ࠍขࠅᏎߊⅣႺߣ੹ᓟߩࠪࠬ࠹ࡓ
ߩ࿷ࠅᣇ‫ޠ‬Ṷ⠪)58㧕 ᐔᚑ 20 ᐕᐲో࿖ᄢቇ଻ஜ▤ℂදળ᧲ᶏ࡮ർ㒽࿾ᣇㇱળ⎇ⓥ㓸ળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘ၮ⺞⻠Ṷ‫ޟ‬ቇ↢ᡰេߦ߅ߌࠆ IT ൻߩ዁᧪ߦߟ޿ߡ‫ޠ‬Ṷ⠪)59㧕 ᐔᚑ 20 ᐕᐲ╙ 18 ࿁කᬺ⚻༡ࠦࡦࠨ࡞࠲ࡦ࠻ᜰቯ⻠ᐳ(ᐔᚑ 20 ᐕ 8 ᦬㧘᧲੩㧘⻠Ṷ‫ޟ‬කᬺ⚻༡▤ℂ⺰㧦ᖱႎ▤ℂ‫ޠ‬Ṷ⠪)60㧕 ᐔᚑ 20 ᐕᐲ╙ 19 ࿁කᬺ⚻༡ࠦࡦࠨ࡞࠲ࡦ࠻ᜰቯ⻠ᐳ(ᐔᚑ 20 ᐕ 8 ᦬㧘ᄢ㒋㧘⻠Ṷ‫ޟ‬කᬺ⚻༡▤ℂ⺰㧦ᖱႎ▤ℂ‫ޠ‬Ṷ⠪)61㧕 ᐔᚑ 20 ᐕᐲ⹺ቯ⋴⼔▤ℂ⠪೙ᐲ‫࡞ࡌ࡟࠼ࡦࠞ࠮ޟ‬ᢎ⢒⺖⒟‫(ޠ‬ᐔᚑ 20 ᐕ 8 ᦬㧘౓ᐶ㧘‫▤⼔⋴ޟ‬ℂࠍᡰេߔࠆᖱႎᛛⴚ‫ޠ‬Ṷ⠪)62㧕 ᖱႎൻ⹺ቯࠦࡦࠨ࡞࠲ࡦ࠻ᜰቯ⻠ᐳ(ᐔᚑ 20 ᐕ 9 ᦬㧘᧲੩㧘⻠Ṷ‫ޟ‬ᖱႎൻ⾗Ḯ⺞㆐ᡰេ ࡌࡦ࠳ㆬቯᚻ㗅ឭ᩺‫ޠ‬Ṷ⠪)63㧕 ᖱႎൻ⹺ቯࠦࡦࠨ࡞࠲ࡦ࠻ᜰቯ⻠ᐳ(ᐔᚑ 20 ᐕ 9 ᦬㧘᧲੩㧘⻠Ṷ‫ޟ‬ᖱႎൻㆇ↪ᡰេ ᗧᕁ᳿ቯᵴ↪
ᡰេ‫ޠ‬Ṷ⠪)64㧕 ╙ 36 ࿁ᣣᧄ⏛᳇౒㡆කቇળᄢળ(ᐔᚑ 20 ᐕ 9 ᦬㧘ᣩᎹ㧘ᢎ⢒⻠ṶΣၮ␆Ԙ‫ޠࠣࡦࠫ࡯ࡔࠗޟ‬ᐳ㐳)65㧕 ╙ 36 ࿁ᣣᧄ⏛᳇౒㡆කቇળᄢળ(ᐔᚑ 20 ᐕ 9 ᦬㧘ᣩᎹ㧘ᢎ⢒⻠ṶΦၮ␆ԙ‫ޠ࡯ࡇࠦࠬࡠ࠻ࠢࡍࠬޟ‬ᐳ㐳)66㧕 ᖱႎൻ⹺ቯࠦࡦࠨ࡞࠲ࡦ࠻ᜰቯ⻠ᐳ(ᐔᚑ 20 ᐕ 10 ᦬㧘᧲੩㧘⻠Ṷ‫ޟ‬ᖱႎൻ⾗Ḯ⺞㆐ᡰេ ࡌࡦ࠳ㆬቯᚻ㗅ឭ᩺‫ޠ‬Ṷ⠪)67㧕 ᖱႎൻ⹺ቯࠦࡦࠨ࡞࠲ࡦ࠻ᜰቯ⻠ᐳ(ᐔᚑ 20 ᐕ 10 ᦬㧘᧲੩㧘⻠Ṷ‫ޟ‬ᖱႎൻዉ౉ᡰេ ዉ౉Ḱ஻૞ᬺ㧘࠹ࠬ࠻࡮࡝ࡂ࡯ࠨ࡞ᡰេ㧘ዉ౉ࠪࠬ࠹ࡓߩຠ⾰⹏ଔ‫ޠ‬Ṷ⠪)68㧕 ᣣᧄ㆙㓒ක≮ቇળቇⴚᄢળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ࠊ߇߆ޟ‬㆙㓒ක≮ࡀ࠶࠻ࡢ࡯ࠢ߆ࠄᣣ
ᧄ
EHR ߳ߩ⊒ዷ㧙ක≮ᓥ੐⠪ਛᔃߩ㔚ሶࠞ࡞࠹ࡀ࠶࠻ࡢ࡯ࠢ߆ࠄ૑᳃ਛᔃߩ↢ᶦஜᐽࠞ࡞࠹߳
㧙‫ޠ‬ᐳ㐳)69㧕 ᣣᧄ㆙㓒ක≮ቇળቇⴚᄢળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ጘ㒂㧘ડ↹ࠪࡦࡐࠫࡘ࡯ࡓ‫↹ޟ‬௝㆙㓒ක≮‫ޠ‬ᐳ㐳)70㧕 ᣣᧄ㆙㓒ක≮ቇળቇⴚᄢળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ጘ㒂㧘‫↹ޟ‬௝㆙㓒ක≮߳ߩᦼᓙ‫ޠ‬Ṷ⠪)71㧕 ᖱႎൻ⹺ቯࠦࡦࠨ࡞࠲ࡦ࠻ᜰቯ⻠ᐳ(ᐔᚑ 20 ᐕ 10 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬ᖱႎൻㆇ↪ᡰេ ᗧᕁ᳿ቯᵴ↪
ᡰេ‫ޠ‬Ṷ⠪)72㧕 ᢙℂࠪࠬ࠹ࡓ࡙࡯ࠩ࡯ࠦࡦࡈࠔ࡟ࡦࠬ 2008(ᐔᚑ 20 ᐕ 11 ᦬㧘᧲੩㧘⻠Ṷ‫ޟ‬ක≮ಽ㊁ߢߩᗧᕁ᳿ቯ
ࠍᡰ߃ࠆ࠺࡯࠲ࠨࠗࠛࡦࠬ㧙VMS ߩᵴ↪ࠍਛᔃߦ㧙‫ޠ‬Ṷ⠪)73㧕 ක≮⚻༡ੱ᧚⢒ᚑၮ␆⎇ୃࠦ࡯ࠬ(ᐔᚑ 20 ᐕ 11 ᦬㧘ᄢ㒋㧘⻠Ṷ‫ޟ‬ක≮ᯏ㑐ߩ IT ᚢ⇛‫ޠ‬Ṷ⠪)㧙㧙74㧕 ╙ 28 ࿁ක≮ᖱႎቇㅪวᄢળ(ᐔᚑ 20 ᐕ 11 ᦬㧘␹ᄹᎹ㧘‫ޟ‬ක≮࠺࡯࠲ࡌ࡯ࠬ࡮࠺࡯࠲ࡑࠗ࠾ࡦࠣ‫ޠ‬ᐳ㐳)75㧕 The 2008 Annual Conference of the Japanese Society for Bioinformatics(ᐔᚑ 20 ᐕ 12 ᦬㧘ᄢ㒋㧘᜗ᓙ⻠Ṷ‫ޟ‬ICT Revolution and Paradigm Shift In Hospital‫ޠ‬Ṷ⠪)
᧻ፉ⑲㧦
1㧕 ╙ 54 ࿁ർᶏ㆏ MRI ↹௝⎇ⓥળ(ᐔᚑ 18 ᐕ 11 ᦬㧘ർᶏ㆏㧘⻠Ṷ‫ޟ‬ಽሶ᭴ㅧᄌൻߣ MRI ~ Tissue
imaging ߆ࠄ Cellular imaging ߳ ~‫ޠ‬Ṷ⠪)
2㧕 ᐔᚑ 19 ᐕᐲߺ߃ࡔ࠺ࠖࠞ࡞⎇ⓥળ‫ޟ‬ක↪Ꮏቇ⎇ⓥળ‫ ╙ޠ‬3 ࿁⎇ⓥ࡮⻠Ṷળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ਃ㊀㧘‫ᦨޟ‬ᣂߩක≮↹௝⸻ᢿⵝ⟎ߩၮ␆ߣᔕ↪‫ޠ‬Ṷ⠪)
3㧕 ╙ 15 ࿁࡜ࡏ࡮ࡈࠜ࡯࡜ࡓ(ᗲ⍮⋵⡯ຬ⥃ᐥᬌᩏᛛᏧળ)(ᐔᚑ 20 ᐕ 1 ᦬㧘ᗲ⍮㧘‫ޟ‬MRI ߩၮ␆ߦߟ޿
ߡ‫ޠ‬Ṷ⠪)ౝጊ⦟৻㧦1㧕 ක↪↹௝ᖱႎቇળ╙ 151 ࿁ᄢળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ጘ㒂㧘ฃ⾨⻠Ṷ‫࡞࠻ࠢࡌޟ‬㓸ਛᐲࡈࠖ࡞࠲ࠍ↪޿ߚ MRA ↹௝ߦ߅ߌࠆ⣖േ⣂≜ߩᬌ಴ᴺ‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ1㧕 ᧻ፉ⑲㧦╙ 66 ࿁ᣣᧄකቇ᡼኿✢ቇળ Gold Medal ⾨(ᐔᚑ 19 ᐕᐲ)
2㧕 㜞ᨋஜ⊓㧘ⁿญ᣿ඳ㧘㣐የ㓉㧘♿ࡁቯ଻⤿㧦ᖱႎಣℂቇળ DBS ⎇ⓥળ‫ ߣࠬ࡯ࡌ࠲࡯࠺ޟ‬Web ᖱႎࠪࠬ࠹ࡓߦ㑐ߔࠆࠪࡦࡐࠫ࠙ࡓ(DBWeb2007)‫ޠ‬㧘ቇ↢ᅑബ⾨(ᐔᚑ 19 ᐕᐲ)
3㧕 ౝጊ⦟৻㧦╙ 64 ࿁ᣣᧄ᡼኿✢ᛛⴚቇળ CyPos ㌃⾨(ᐔᚑ 20 ᐕᐲ)
4㧕 ౝጊ⦟৻㧦ක↪↹௝ᖱႎቇળ㊄᫪ᅑബ⾨(ᐔᚑ 20 ᐕᐲ)
5㧕 ᷡ᳓⑲ᐕ㧘ች᧛ᑝ᮸㧘᧻ፉ⑲㧘᧛਄᡽㓉㧘ᗆ⦟⡛৻㧘ౝጊ⦟৻㧘♿ࡁቯ଻⤿㧦↢૕කᎿቇࠪࡦࡐࠫ
࠙ࡓ 2008 ࡌࠬ࠻࡝ࠨ࡯࠴ࠕࡢ࡯࠼⾨(ᐔᚑ 20 ᐕᐲ)
9㧚␠ળᵴേ
♿ࡁቯ଻⤿㧦
1㧕 ጘ㒂⋵කᏧળൕോකㇱળ IT ᆔຬળᆔຬ㐳(㨪⃻࿷)2㧕 ጘ㒂⋵කᏧળᖱႎࠪࠬ࠹ࡓᆔຬળᆔຬ(㨪⃻࿷)3㧕 ో࿖ஜᐽ଻㒾දળጘ㒂ᡰㇱ⹏⼏ળᆔຬ(㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ጊᧄ⋿↱⟤㧘♿ࡁቯ଻⤿㧘㋈ᧁᐽਯ㧘㜞Ⴆ⋥⢻㧦⚻ᷣ↥ᬺ⋭ᐔᚑ 17 ᐕᐲ‫ޟ‬ක≮⚻༡ੱ᧚⢒ᚑ੐ᬺㆇ༡ߦ㑐ࠊࠆᢎ⢒ࡊࡠࠣ࡜ࡓ‫ ޠ‬ታ❣ႎ๔ᦠ ‫ޟ‬ක≮⚻༡ੱ᧚⢒ᚑᢎ⢒ࡊࡠࠣ࡜ࡓ㐿⊒ࡊࡠࠫࠚࠢ࠻
㜞ᐲක≮ᢎ⢒ࠦࡦ࠰࡯ࠪࠕࡓ (ઍ⴫࡮ᄢ㒋ᄢቇ)‫⵬ ޠ‬ഥᢎ᧚(ࠤ࡯ࠬ)㧦ක≮ᖱႎ▤ℂࠪࠬ࠹ࡓߣ⸻
≮ࡕ࠺࡞㧙♧ዩ∛㧙㧦141㧙176(2006 ᐕ 3 ᦬)
2㧕 ♿ࡁቯ଻⤿㧦ஜ⸻ߩ⟵ോൻߦ㑐ࠊࠆஜ⸻࠺࡯࠲╬ߩㆇ↪࡮▤ℂߦߟ޿ߡ㧘࿖଻੐ᬺផㅴ࠻࠶ࡊ࠮ࡒ
࠽࡯⻠Ṷ⸥㍳㧦32㧙40(2007 ᐕ 1 ᦬)
3㧕 ♿ࡁቯ଻⤿㧦ࡀ࠶࠻ࡢ࡯ࠢ࠮ࡦࠪࡦࠣᛛⴚࠍᔕ↪ߒߚ∛㒮ㆇ༡ᚻᴺߦߟ޿ߡ㧘ᐔᚑ 18 ᐕᐲ‫࠻࠶ࡀޟ‬ࡢ࡯ࠢ࠮ࡦࠪࡦࠣࠪࠬ࠹ࡓᛛⴚ⺞ᩏ⎇ⓥႎ๔ᦠ‫ޠ‬
㧦74㧙77(2007 ᐕ 3 ᦬)
4㧕 㜞Ⴆ⋥⢻㧘Ꮉญ㗅ᢘ㧘㜞ᯅቁᄦ㧘♿ࡁቯ଻⤿㧘ጊᧄ⋿↱⟤㧦ᕆᕈᦼ∛㒮⚻༡ߦ߅ߌࠆ∛ᐥࡑࡀࠫࡔࡦ࠻ 㧙․ቯᯏ⢻∛㒮ᶖൻེᄖ⑼ߩࠤ࡯ࠬ㧙㧘ᐔᚑ 18 ᐕᐲ⚻ᷣ↥ᬺ⋭‫ޟ‬ක≮⚻༡ੱ᧚⢒ᚑ੐ᬺ‫ޠ‬ႎ๔ᦠ 㜞ᐲක≮ᢎ⢒ࠦࡦ࠰࡯ࠪࠕࡓ(ઍ⴫࿅૕࡮ᄢ㒋ᄢቇ)(2007 ᐕ 3 ᦬)
5㧕 㐳ἑᷡ㧘㜞Ⴆ⋥⢻㧘♿ࡁቯ଻⤿㧘ጊᧄ⋿↱⟤㧦ᕆᕈᦼ∛㒮⚻༡ߦ߅ߌࠆᚻⴚㇱࡑࡀࠫࡔࡦ࠻ 㧙․ቯᯏ⢻∛㒮ᚻⴚቶߩࠤ࡯ࠬ㧙㧘⚻ᷣ↥ᬺ⋭ᐔᚑ 19 ᐕᐲࠨ࡯ࡆࠬ↥ᬺੱ᧚⢒ᚑ੐ᬺ(∛㒮ᬺോࡑࡀࠫ
ࡔࡦ࠻ߦ㑐ߔࠆࠤ࡯ࠬࠬ࠲࠺ࠖᢎ⢒㐿⊒ࡊࡠࠫࠚࠢ࠻)ႎ๔ᦠ(2008 ᐕ 3 ᦬)
11㧚ႎ㆏1㧕 ♿ࡁቯ଻⤿㧦IT ᵴ↪ߦࠃࠆක≮ᡷ㕟ߩᦨ೨✢ࠍㅊ߁㧦CIO(2006 ᐕ 10 ᦬ภ)
2㧕 ♿ࡁቯ଻⤿㧦ࠛࠠࠬࡄ࡯࠻ࠗࡦ࠲ࡆࡘ࡯‫ోޟ‬૕ᦨㆡࠍᔀᐩߐߖߚ৻ర▤ℂߣ౒᦭ߢ̌࠺࡯࠲̍߆ࠄ
ଔ୯ࠍ↢ߺ಴ߔㆇ↪ࠍ⋡ᜰߔ‫ޠ‬
㧦MELTOPIA(2006 ᐕ 11 ᦬ภ)
3㧕 ♿ࡁቯ଻⤿㧦ᚢ⇛⊛ߥࡑࡀࠫࡔࡦ࠻ߣ IT ൻߩផㅴ߇ਇนᰳ㧦ᣣ⚻ࠦࡦࡇࡘ࡯࠲(2006 ᐕ 11 ᦬ 27 ᣣ

㧙㧙

ภ)
4㧕 ♿ࡁቯ଻⤿㧦࠮ࡦࠨ࡯ࡀ࠶࠻ࡢ࡯ࠢᛛⴚ㧦ጘ㒂ᣂ⡞(2006 ᐕ 12 ᦬ 8 ᣣ)
5㧕 ♿ࡁቯ଻⤿㧦⢄⤳߇ࠎ ⢄⎬ᄌ ⦡ᄌൻߢ੍ళ⊒⷗㧘ጘ㒂ᄢ⎇ⓥࠣ࡞࡯ࡊ MRI ᣂࠪࠬ࠹ࡓ㐿⊒㧦⺒ᄁᣂ⡞(2007 ᐕ 5 ᦬ 1 ᣣ)
6㧕 ♿ࡁቯ଻⤿㧦‫ޟ‬ㆬ߫ࠇࠆ∛㒮ߣߪ‫ޠ‬㧘ච౐㌁ⴕ࡮ጘ㒂ᄢቇਥ௅‫ޟ‬ක≮⚻༡ࠪࡦࡐࠫ࠙ࡓ‫ޠ‬㧦ጘ㒂ᣂ⡞(2007ᐕ 7 ᦬ 1 ᣣ)
7㧕 ♿ࡁቯ଻⤿㧦ක≮ߩ IT ൻࠍ೨ㅴߐߖࠆᣂ⾗ᩰ೙ᐲ߇੹ㅳᆎേ㧦᦬ೀࠫࡖ࡯ࡑ࠶ࠢ Vol.9 No.9 11
㧙14(2008 ᐕ 9 ᦬ 1 ᣣ)
8㧕 ♿ࡁቯ଻⤿㧦∛㒮 IT ൻߢක≮ߩ⾰ߣ෼⋉ࠕ࠶ࡊࠍ᳞߼ࠆ㧦ITOKI Healthcare Facilities㧘8㧙9(2008
ᐕ 12 ᦬ 10 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔ
ᐔᚑ 19 ᐕᐲ߆ࠄߩᄢቇ㒮ㅪวഃ⮎ක≮ᖱႎ⎇ⓥ⑼ߩ┙ߜ਄ߍ߿ᄢቇ㒮↢ߩ⏕଻߽޽ࠅ㧘ో૕⊛ߦߪḩ⿷ߢ߈ࠆᚑᨐࠍ਄ߍࠆߎߣ߇ߢ߈ߚߣ⠨߃ߡ޿ࠆ‫ߚ߹ޕ‬㧘⎇ⓥߩਛᔃࠍᓥ೨ߩක≮ᖱႎࠪࠬ࠹ࡓߩ㐿⊒߆ࠄ⛔วࡃࠗࠝࡃࡦࠢࠪࠬ࠹ࡓߩ㐿⊒ߣᄢⷙᮨ࠺࡯࠲ߩಽᨆߦࠪࡈ࠻ߒ㧘ߎߩࠃ߁ߥᚑᨐߢᐞߟ߆ߩฃ
⾨ࠍᓧࠆߎߣ߇ߢ߈ߚ‫ޕ‬
ߎߩ 3 ᐕ㑆ߪ੹ᓟߩਥᵹߦߥࠆߣᕁࠊࠇࠆ࡜ࠗࡈࠨࠗࠛࡦࠬಽ㊁ߢߩࡃࠗࠝ࡮ࠗࡦࡈࠜࡑ࠹ࠖࠢࠬߦ
⎇ⓥߩゲ⿷ࠍࠪࡈ࠻ߔࠆߎߣࠍ⋡ᮡߣߒߡ⎇ⓥⅣႺߩᢛ஻ࠍⴕߥߞߡ߈ߚ‫⋡ߩߘޕ‬ᮡߪలಽߦ㆐ᚑߢ߈㧘੹ᓟߩᵴ⊒ߥ⎇ⓥߦᔅⷐߥⅣႺߪᢛߞߚߣ⠨߃ߡ޿ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷᰷ᢥߩේ⪺⺰ᢥ߇ዋߥ޿ߎߣ߇⃻⁁ߩ໧㗴ὐߢ޽ࠆ‫ߩߘޕ‬ኻ╷ߣߒߡ㧘੹ᓟߪ⛔วࡃࠗࠝࡃࡦࠢࠪࠬ
࠹ࡓߦ⫾Ⓧߐࠇߚ࠺࡯࠲ߩಽᨆᚑᨐࠍⓍᭂ⊛ߦේ⪺⺰ᢥൻߔࠆߎߣࠍ⋡ᮡߦ⎇ⓥᵴേࠍߐࠄߦᵴ⊒ൻߒߚ޿‫ߚ߹ޕ‬㧘⎇ⓥಽ㊁ࠍࡃࠗࠝ࡮ࠗࡦࡈࠜࡑ࠹ࠖࠢࠬߦ⇐߹ࠄߕ㧘ߘߩᔕ↪ಽ㊁ߢ޽ࠆഃ⮎࡮ක⮎ຠߩㆡᱜ૶↪߿᦭ኂ੐⽎ಽᨆ㧘ઍ⻢ࡄࠬߩಽᨆߥߤߦ߽᜛ᄢߒ㧘⺰ᢥൻߢ߈ࠆᚑᨐࠍჇ߿ߒߚ޿ߣ⸘↹ߒߡ
޿ࠆ‫ޕ‬
੹ᓟߩዷᦸ
ක≮ᖱႎቇಽ㊁ߦ߅ߌࠆ੹ᓟߩ⎇ⓥኻ⽎ߪᄢⷙᮨ࠺࡯࠲ߩಽᨆ߇ਛᔃߦߥࠆ‫߿࠲࡯࠺≮⸻ޕ‬ஜᐽ࠺࡯࠲㧘ࠥࡁࡓ࠺࡯࠲㧘ක⮎ຠᖱႎ߿↢૕ౝߩઍ⻢ᖱႎ㧘ߘߩઁߩ㑐ㅪߔࠆ࡜ࠗࡈࠨࠗࠛࡦࠬ࠺࡯࠲╬ࠍ⛔
วൻߒ㧘⛔วࡃࠗࠝࡃࡦࠢߣߒߡౣ᭴▽ߔࠆ‫ߡߒߦ߁ࠃߩߎޕ‬ᓧࠄࠇߚᄢⷙᮨ࠺࡯࠲ࠍ⋧੕ߦ㑐ㅪߔࠆ࠺࡯࠲ߣߒߡᝒ߃㧘ߘߩ㑐ㅪ᭴ㅧߣ࠳ࠗ࠽ࡒࠢࠬࠍ⸃ᨆߔࠆߎߣ߇㊀ⷐߢ޽ࠆ‫ޕ‬ߒߚ߇ߞߡ㧘Ԙ᷹ⷰߐࠇߚᬌᩏ୯㑆ߢߩ㑐ଥࡀ࠶࠻ࡢ࡯ࠢ࿑ߩ૞ᚑ㧘ԙ㑐ଥࡀ࠶࠻ࡢ࡯ࠢ਄ߢߩࡊࡠ
࠮ࠬಽᨆ㧘Ԛ㑐ଥࡀ࠶࠻ࡢ࡯ࠢ਄ߩ࠳ࠗ࠽ࡒࠢࠬಽᨆ㧘ԛ㑐ଥࡀ࠶࠻ࡢ࡯ࠢ਄ߩ᭴ㅧ᛽಴㧘Ԝ㑐ଥࡀ࠶࠻ࡢ࡯ࠢ࠺࡯࠲ߦၮߠ޿ߚ∔∛╬ߩᣧᦼ⊒⷗ᛛⴚ߳ߩᔕ↪㧘╬ࠍਥ⌒ߦߒߡᵴ⊒ߥ⎇ⓥᵴേࠍዷ㐿ߒߚ޿ߣ⠨߃ߡ޿ࠆ‫ߚ߹ޕ‬㧘ߎߩࠃ߁ߥᚑᨐࠍᢎ⢒ߦᵴ߆ߔߎߣࠍ⋡ᜰߔ‫ޕ‬㧙㧙㧔2㧕✚ว∛ᘒౝ⑼ቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
ߎࠇ߹ߢߣห᭽㧘એਅߩ࠹࡯ࡑࠍਛᔃߦ⎇ⓥࠍⴕߞߡ޿ࠆ‫ޕ‬1㧕ࠗࡦࠬ࡝ࡦ૞↪ᯏ᭴ߦ㑐ߔࠆ⎇ⓥ
2 ဳ♧ዩ∛㧘㜞ⴊ࿶∝㧘⢽⾰⇣Ᏹ∝㧘⢈ḩ㧘NASH ࠍ㗫❥ߦว૬ߔࠆࡔ࠲ࡏ࡝࠶ࠢࠪࡦ࠼ࡠ࡯ࡓߪ↢ᵴ⠌ᘠ∛ߩᄢㇱಽࠍභ߼㧘ࡊ࡜ࠗࡑ࡝࡮ࠤࠕߢߩ common disease ߢ޽ࠆ‫∛ߩࠄࠇߎޕ‬ᘒߦߪࠗࡦࠬ࡝ࡦᛶ
᛫ᕈ߇ᒝߊ㑐ਈߒߡ޿ࠆߚ߼㧘ࠗࡦࠬ࡝ࡦᛶ᛫ᕈࠍ⥃ᐥ⊛㧘ၮ␆⊛ߦ⸃᣿ߔࠆߚ߼ߩ⎇ⓥߪᭂ߼ߡ㊀ⷐߢ޽ࠆ‫ࠍ࠻ࡅޕ‬ኻ⽎ߣߒߚ⥃ᐥ⎇ⓥߛߌߢߥߊ㧘࡜࠶࠻߿࡜࠶࠻⢽⢌⚦⢩ࠍ૶↪ߒߚၮ␆⊛⎇ⓥ߽ⴕߞߡ޿
ࠆ‫ࡦ࡝ࠬࡦࠗޕ‬૞↪ᯏ᭴߿㧘dehydroepiandrosterone㧔DHEA㧕ߦࠃࠆࠗࡦࠬ࡝ࡦᗵฃᕈᡷༀᯏ᭴ࠍ㧘ࡑࠗࠢࡠࠕ࡟ࠗ࡮఺∉⚵❱ൻቇ࡮࡝ࠕ࡞࠲ࠗࡓ PCR ߥߤࠍ૶ߞߡߘߩ㑐ਈ࿃ሶࠍតࠆߎߣࠍታ〣ߒߡ޿ࠆ‫ߚ߹ޕ‬㧘ઁߩࠗࡦࠬ࡝ࡦᗵฃᕈᡷༀ࿃ሶߢ޽ࠆࠕ࠺ࠖࡐࡀࠢ࠴ࡦ㧘࡟ࡊ࠴ࡦ㧘DHEA ߿ AMP-kinaseߥߤߣߩ㑐ㅪ߽ᬌ⸛ߒߡ޿ࠆ‫ޕ‬
2㧕↢ᵴ⠌ᘠ∛ߦ߅ߌࠆⴊዊ᧼ಝ㓸ߣⴊẏ࡟ࡊ࠴ࡦỚᐲߣߩ㑐ㅪ⢈ḩࠍਥᓽߣߔࠆᖚ⠪ߪⴊẏ࡟ࡊ࠴ࡦỚᐲ߇㜞޿߇㧘࡟ࡊ࠴ࡦᛶ᛫ᕈ߇޽ࠆߣ⠨߃ࠄࠇߡ޿ࠆ‫৻ޕ‬ᣇ㧘ⴊዊ᧼ߦ࡟ࡊ࠴ࡦฃኈ૕߇⊒⃻ߒߡ߅ࠅ㧘⢈ḩࠍ๒ߔࠆᖚ⠪ߩⴊ▤ว૬∝ߣߩ㑐ㅪߩ⸃᣿߇ᔅⷐߢ޽ࠆ‫ޕ‬
3㧕㐳ኼߦ㑐ߔࠆ⥃ᐥ∉ቇ⊛⎇ⓥ↢ᵴ⠌ᘠ㧔㘩੐㧘ㆇേ㧘༛ᾍ㧘⌧⌁ߥߤ㧕߿േ⣂⎬ൻߦ㑐ㅪߔࠆߣ⠨߃ࠄࠇࠆⴊᷡࡑ࡯ࠞ࡯ࠍ㧘㐳ኼ࿾඙ߣ㕖㐳ኼ࿾඙ߩ૑᳃ߢ⺞ᩏߒᲧセߔࠆ∉ቇ⎇ⓥࠍ㧘ࠗ࠮࠶࠻ᩣᑼળ␠㧘᫪᳗੃ᬺᩣᑼળ␠㧘ࠕࡇᩣᑼળ
␠ߣߩ౒หߢ 2000 ᐕ߆ࠄ㜞ጊᏒߢᲤᐕⴕߞߡ޿ࠆ‫⎇ߩߎޕ‬ⓥ߆ࠄ㧘㐳ኼߦ⚿߮ߟߊ↢ᵴ⠌ᘠ߇૗ߢ޽ࠆ
߆ࠍ᣿ࠄ߆ߦߔࠆߎߣ߇ᦼᓙߐࠇࠆ‫ߦࠄߐޕ‬㧘ߘࠇࠄߩ࿃ሶࠍᡷༀߐߖࠆ੺౉⎇ⓥࠍⴕߞߡ߅ࠅ㧘ஜᐽኼ๮ߩᑧ㐳ࠍ⋡ᜰߒߡ޿ࠆ‫ޕ‬
4㧕േ⣂⎬ൻ࡮ࡔ࠲ࡏ࡝࠶ࠢࠪࡦ࠼ࡠ࡯ࡓߦ㑐ߔࠆ᷹ቯᯏེ㐿⊒⎇ⓥ
Ꮏቇㇱࠪࠬ࠹ࡓᎿቇ⑼ߩ㊁ᣇᢥ㓶ᢎ᝼ߣߩ⍮⊛ࠢ࡜ࠬ࠲࡯ഃ↢੐ᬺߢߩ౒ห⎇ⓥߢ㧘2004 ᐕ߆ࠄขࠅ
⚵ࠎߢ޿ࠆ‫ߦߢ߹ࠇߎޕ‬㧘㗪േ⣂ࠛࠦ࡯߆ࠄേ⣂ߩࠦࡦࡊ࡜ࠗࠕࡦࠬࠍ⍴ᤨ㑆ߦ᷹ቯߔࠆᯏེࠍ㐿⊒ߒߚ‫ޕ‬⃻࿷㧘ⴊ▤ౝ⊹ᯏ⢻᷹ቯⵝ⟎ߣ⣻ㇱౝⵝ⢽⢌᷹ቯⵝ⟎ߩ㐿⊒ࠍᩣᑼળ␠ࡄ࡜ࡑ࡮࠹࠶ࠢߣ౒ห㐿⊒ਛߢ޽ࠆ‫ޕ‬5㧕ฦ⒳↢ᵴ⠌ᘠ∛ᴦ≮⮎ߩࡒ࠻ࠦࡦ࠼࡝ࠕᲥᕈߦ㑐ߔࠆ⎇ⓥᣢߦ☨࿖♧ዩ∛ቇળߢ߽᣿ࠄ߆ߦߒߚ᭽ߦ⢄ࡒ࠻ࠦࡦ࠼࡝ࠕ㓚ኂࠍ troglitazone ߇ᒁ߈⿠ߎߒߚࡒ࠻
ࠦࡦ࠼࡝ࠕᲥᕈߦ㑐ߔࠆᯏ᭴ࠍ᣿ࠄ߆ߦߒߚ‫ߦᦝޕ‬ฦ⒳᛫㜞⢽ⴊẏ⮎೷߿᛫♧ዩ∛⮎೷ߩࡒ࠻ࠦࡦ࠼࡝ࠕ
Ქᕈࠬࠢ࡝࡯࠾ࡦࠣᬌᩏߩ㐿⊒ࠍᬌ⸛ߒߡ޿ࠆ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
ಎᢎ᝼㧦
⻠Ꮷ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦

⍹Ⴆ㆐ᄦ
᫪↰ᶈਯ
᫃↰๺↵
ችౝ࡞ࡒሶ
ᳰ↰⾆⧷
᫪ ৻㇢
⮮ጟ ࿻
ጟ↰⧷ਯ
⮮ដ⾆ᢅ

Tatsuo Ishizuka
Hiroyuki Morita
Kazuo Kajita
Rumiko Miyauchi
Takahide Ikeda
Ichiro Mori
Kei Fujioka
Hideyuki Okada
Takatoshi Fujikake

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ⍹Ⴆ㆐ᄦ㧚ᶖൻེ㧦ኾ㐷කㇱળ✬㧚↢ᶦᢎ⢒ߩߚ߼ߩ࠮࡞ࡈ࠻࡟࡯࠾ࡦࠣ໧㗴ߣ⸃⺑㧘᧲੩㧦␠࿅ᴺੱᣣ
ᧄౝ⑼ቇળ㧧2008 ᐕ㧦4㧙12㧚⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 ⍹Ⴆ㆐ᄦ㧚Doctor's view Vol. 5 ↢ᵴ⠌ᘠ∛੍㒐ߦ㑐ߒߡ㧘ጘ㒂ߩ࿖଻ 2006 ᐕ㧧281 Ꮞ㧦9㧚
2㧕 ⍹Ⴆ㆐ᄦ㧚Doctor's view Vol. 6 ↢ᵴ⠌ᘠ∛੍㒐ߦ㑐ߒߡ㧙21 ਎♿ߩ♧ዩ∛੍㒐㧙㧘ጘ㒂ߩ࿖଻ 2006ᐕ㧧282 Ꮞ㧦11㧚㧙㧙

3㧕 ⍹Ⴆ㆐ᄦ㧚Doctor's view Vol. 7 ↢ᵴ⠌ᘠ∛੍㒐ߦ㑐ߒߡ㧙↢ᵴ⠌ᘠ∛ߣࡊ࡜ࠗࡑ࡝ࠤࠕ㧙㧘ጘ㒂ߩ࿖଻
2006 ᐕ㧧283 Ꮞ㧦1㧚
4㧕 ᫃↰๺↵㧘⍹Ⴆ㆐ᄦ㧚♧ዩ∛࡮ౝಽᴲ∔ᖚߦࠃࠆ⓭ὼᱫ㧘ᴺක∛ℂ 2006 ᐕ㧧12 Ꮞ㧦17㧙21㧚
5㧕 ⍹Ⴆ㆐ᄦ㧚Doctor's view Vol. 8 ↢ᵴ⠌ᘠ∛੍㒐ߦ㑐ߒߡ㧙♧ዩ∛㧘㜞ⴊ࿶㧘㜞⢽ⴊ∝⸻≮ࠟࠗ࠼࡜ࠗࡦ
㧙㧘ጘ㒂ߩ࿖଻ 2007 ᐕ㧧284 Ꮞ㧦14㧙15㧚
6㧕 ⍹Ⴆ㆐ᄦ㧚Doctor's view Vol. 9 ↢ᵴ⠌ᘠ∛੍㒐ߦ㑐ߒߡ㧙ࡔ࠲ࡏ࡝࠶ࠢࠪࡦ࠼ࡠ࡯ࡓߣ⢽⢌⢄㧙㧘ጘ㒂ߩ࿖଻ 2007 ᐕ㧧285 Ꮞ㧦16㧙17㧚
7㧕 ⍹Ⴆ㆐ᄦ㧚Doctor's view Vol. 10 ↢ᵴ⠌ᘠ∛੍㒐ߦ㑐ߒߡ㧙਎⇇♧ዩ∛࠺࡯㧙㧘ጘ㒂ߩ࿖଻ 2007 ᐕ㧧
286 Ꮞ㧦16㧙17㧚
8㧕 ⍹Ⴆ㆐ᄦ㧚Doctor's view Vol. 11 ↢ᵴ⠌ᘠ∛੍㒐ߦ㑐ߒߡ㧙㜞ⴊ࿶ᴦ≮ࠟࠗ࠼࡜ࠗࡦ㧙㧘ጘ㒂ߩ࿖଻2007 ᐕ㧧287 Ꮞ㧦10㧙11㧚
9㧕 ⍹Ⴆ㆐ᄦ㧚↢ᵴ⠌ᘠ∛ߣߪ૗߆ ․㓸․ቯஜ⸻ᤨઍߩ↢ᵴ⠌ᘠ∛ኻ╷㧘JIM 2008 ᐕ㧧18 Ꮞ㧦14㧙19㧚
10㧕 ⍹Ⴆ㆐ᄦ㧚Doctor's view Vol. 12 ↢ᵴ⠌ᘠ∛੍㒐ߦ㑐ߒߡ㧙㑐▵࡝࠙ࡑ࠴ߣ↢ᵴ⠌ᘠ∛㧙㧘ጘ㒂ߩ࿖଻
2008 ᐕ㧧288 Ꮞ㧦16㧙17㧚
11㧕 ⍹Ⴆ㆐ᄦ㧚ࠗࡦࠬ࡝ࡦฃኈ૕᛫૕ ᣂᤨઍߩ♧ዩ∛ቇ(2)㧙∛࿃࡮⸻ᢿ࡮ᴦ≮⎇ⓥߩㅴᱠ㧙㧘ᣣᧄ⥃ᐥ 2008
ᐕ㧧66 Ꮞ(Ⴧೀ 4)㧦310㧙313㧚
12㧕 ⍹Ⴆ㆐ᄦ㧚ᣣ♧ද࡮࿖㓙ᆔຬળߛࠃࠅ(2) ╙ 43 ࿁ EASD(᰷Ꮊ♧ዩ∛ળ⼏)ߦෳടߒߡ㧘ߐ߆߃ 4 ᦬ภ㧧2008 ᐕ㧦64㧚
13㧕 ᫪↰ᶈਯ㧚කቇ↢ߦࠃࠆ⸰໧⋴⼔૕㛎ታ⠌㧘කቇߩ޽ࠁߺ 2008 ᐕ㧧224 Ꮞ㧦163㧙165㧚
14㧕 ⍹Ⴆ㆐ᄦ㧚⮎‛ᜰዉߦ߅ߌࠆ⻉໧㗴 ♧ዩ∛ߩ≮㙃ᜰዉ㧦♧ዩ∛ቇߩㅴᱠ 42 ࿁ 2008 ᐕ㧦86㧙91㧚
15㧕 ⍹Ⴆ㆐ᄦ㧚✚วౝ⑼ኾ㐷කߣࠨࡉࠬࡍࠪࡖ࡝࠹ࠖ㧘ᣣᧄౝ⑼ቇળ㔀⹹ 2008 ᐕ㧧97 Ꮞ㧦222㧙226㧚
16㧕 ⍹Ⴆ㆐ᄦ㧚♧ዩ∛߳ᬌᩏߣᜰᮡ߆ࠄࠕࡊࡠ㧙࠴ ࠗࡦࠬ࡝ࡦᛶ᛫ᕈߩ◲ᤃ⸻ᢿᴺߣ㒢⇇㧘♧ዩ∛ UP࡮DATE
⾫ፉ࠮ࡒ࠽࡯24 2008 ᐕ㧦44㧙53㧚
17㧕 ⍹Ⴆ㆐ᄦ㧚ᴦ≮ਛߩ 2 ဳ♧ዩ∛ᖚ⠪ߪ߁ߟ∝⁁ࠍ⊒⃻ߒ߿ߔ޿㧙߁ߟ∝⁁ߣ♧ዩ∛ߩ෺ᣇะ㑐ㅪߦߟ޿ߡ
ߩᬌ⸛㧙㧘MMJ 2008 ᐕ㧧4 Ꮞ㧦840㧙841㧚
18㧕 ⍹Ⴆ㆐ᄦ㧚ࡊ࡜ࠗࡑ࡝ࠤࠕߣ↢ᵴ⠌ᘠ∛߆ࠄ࿾ၞක≮࡮㆙㓒ක≮߳ߩዷᦸ㧘ᣣᧄ㆙㓒ක≮ቇળ㔀⹹ 2008
ᐕ㧧4 Ꮞ㧦172㧙174㧚✚⺑㧔᰷ᢥ㧕
1㧕 Ishizuka T. Adrenal insufficiency complicated with antiphospholipid syndrome. Intern Med.
2006;45:1077-1078.
ේ⪺㧔๺ᢥ㧕
1㧕 ⑔ᴛཅቁ, ᩊ↰ᢕሶ, 㢬Ỉᱜੳ, ฦോિ৻, የ㑐ᢎ↢, ᫪↰ᶈਯ, ౝᧁ㓉ᢥ, ⊕ဈ๺ା, ዊᎹ㓁ሶ, ᦯ㇱᵏテ,቟↰৻ᦶ, ⍹Ⴆ㆐ᄦ, ේἑ৻㇢, ᫃↰๺↵, ᱞ↰ೣਯ㧚ోりୱᕃᗵࠍਥ⸷ߦ⪺᣿ߥ⢄ᯏ⢻㓚ኂࠍ๒ߒߚ 12ᱦ↵ఽ଀㧘ౝ⑼ኾ㐷කળ⹹ 2006 ᐕ㧧18 Ꮞ㧦255㧙268㧚
2㧕 ਣጊᢥᄦ㧘⍹Ⴆ㆐ᄦ㧘ᩙᧄ⑲ᒾ㧘ਃፉାᒾ㧘᦯ㇱ๺᮸㧘ਃỈஜᄥ㇢㧘ችፒੳ㧚⹺ቯౝ⑼ኾ㐷කߦࠃࠆᢎ⢒࠮ࡒ࠽࡯߹ߣ߼㧙޿߹ߎߘࡊࡠࡉ࡟ࡓ࡝ࠬ࠻ࠍ⷗⋥ߘ߁㧙㧘ౝ⑼ኾ㐷කળ⹹ 2006 ᐕ㧧18 Ꮞ㧦269㧙296㧚
3㧕 ᵻ㊁ᤘ㆏, ᫪↰ᶈਯ, ർ⼱⌀ሶ, ౎ᧁ㇌౏, ㋈ᧁ⮍, ጊ⑺⋥ੱ, ᱞ↰⟵ാ, ዊᴰ㗅ੑ, ᧻੗Ꮧઍሶ, Ⓑ၂⟤ᥓሶ㧚㜞ⴊ♧ߩߚ߼➅ࠅ㄰ߒᢎ⢒౉㒮ࠍⷐߒߚ 2 ဳ♧ዩ∛㧘♧ዩ∛ߩ≮㙃ᜰዉ㧦♧ዩ∛ቇߩㅴᱠ 40 ࿁ 2006
ᐕ㧦213㧙219㧚
4㧕 ᨋ⟤૫㧘ጤᧁඳ⟤㧘᫪↰ᶈਯ㧘ḡ਄⧷⤿㧘ቝ㊁ཅᒄ㧘᫃↰๺↵㧘᧻ᧄ㓷⟤㧘ᳰ↰⾆⧷㧘᫪৻㇢㧘᧻ේஜᴦ㧘๺↰␭Ὼ㧘⍹Ⴆ㆐ᄦ㧚࿷ቛஜᐽ▤ℂࠪࠬ࠹ࡓߦࠃࠆ㒠࿶ലᨐ㧙ஜᐽ⸻ᢿߢߩ㕖೑↪⠪ߣߩᲧセ⎇ⓥ㧙㧘ᣣᧄ㆙㓒ක≮ቇળ㔀⹹ 2006 ᐕ㧧2 Ꮞ㧦222㧙223㧚
5㧕 ጤᧁඳ⟤㧘ᨋ⟤૫㧘᫪↰ᶈਯ㧘ḡ਄⧷⤿㧘ቝ㊁ཅᒄ㧘᫃↰๺↵㧘᧻ᧄ㓷⟤㧘ᳰ↰⾆⧷㧘᫪৻㇢㧘᧻ේஜᴦ㧘๺↰␭Ὼ㧘⍹Ⴆ㆐ᄦ㧚࿷ቛஜᐽ▤ℂࠪࠬ࠹ࡓߩ᦭↪ᕈ㧙ᔃ㔚࿑ߦࠃࠆਇᢛ⣂ߩ᦬೎࡮ᐕઍ೎ᄌേ㧙㧘ᣣᧄ㆙㓒ක≮ቇળ㔀⹹ 2006 ᐕ㧧2 Ꮞ㧦224㧙225㧚
6㧕 ᫪↰ᶈਯ㧘ቝ㊁ཅᒄ㧘⍹Ⴆ㆐ᄦ㧘଻૑ഞ㧘›Ⴆ⾆㧚කቇ↢ߦࠃࠆ⸰໧⋴⼔૕㛎ታ⠌ߩ⹏ଔ㧘කቇᢎ⢒ 2006ᐕ㧧37 Ꮞ㧦311㧙315㧚
7㧕 ᫪↰ᶈਯ㧘᳓㊁ᥓሶ㧘᫃↰๺↵㧘ቝ㊁ཅᒄ㧘ᳰ↰⾆⧷㧘᫪৻㇢㧘᧻ේஜᴦ㧘᧻ᧄ㓷⟤㧘㐳੗ቁᄥ㇢㧘⍹Ⴆ㆐ᄦ㧚ਔ஥ߦ೽⣢⊹⾰⣼⣲߇⷗ࠄࠇߚේ⊒ᕈࠕ࡞࠼ࠬ࠹ࡠࡦ∝ߩ 1 ଀㧙ฝࠕ࡞࠼ࠬ࠹ࡠࡦ↥↢⣼⣲ߣᏀ㕖ᯏ⢻ᕈ⣼⣲㧙㧘ᣣᧄౝಽᴲቇળ㔀⹹ ╙ 16 ࿁⥃ᐥౝಽᴲઍ⻢ Update Proceeding 2006 ᐕ㧧82 Ꮞ㧦61
㧙63㧚
8㧕 ㊁ᣇᢥ㓶㧘ቝ㊁ཅᒄ㧘᫪↰ᶈਯ㧘⍹Ⴆ㆐ᄦ㧘ᴡ᧛ᵗሶ㧘ᮮ↰ᐽᚑ㧘ਅਛᥓ㧘↰ਛ㕏ື㧚ஜᐽ㜞㦂⠪ᬌᩏࠪࠬ࠹ࡓߩ㐿⊒㧘ᣣᧄࠦࡦࡇࡘ㧙࠲ᄖ⑼ቇળ㔀⹹ 2006 ᐕ㧧8 Ꮞ㧦134㧙135㧚
9㧕 ᧻ේஜᴦ, ᫪৻㇢, ᳰ↰⾆⧷, ᧻ᧄ㓷⟤, ᧖ጊජ਎, ᫃↰๺↵, ቝ㊁ཅᒄ, ᫪↰ᶈਯ, ⍹Ⴆ㆐ᄦ㧚㐳ኼߦᓇ㗀ࠍਈ߃ࠆ࿃ሶߩᬌ⸛ ࿖ᐭ࡮⟤ጊ࿾඙Ყセ⎇ⓥ㧘ጘ㒂⋵ౝ⑼කળ㔀⹹ 2007 ᐕ㧧21 Ꮞ㧦19㧙21㧚
10㧕 ⍹Ⴆ㆐ᄦ㧘Ḋญା਽㧘⑔ᴛཅቁ㧘ൎᧁ㗼㧘ቝ㊁ཅᒄ㧚ࡔ࠲ࡏ࡝࠶ࠢࠪࡦ࠼ࡠ࡯ࡓ㧙ኾ㐷㗔ၞ߆ࠄߩࡔ࠶࠮
㧙ࠫߣ⸛⺰㧙ᣣᧄౝ⑼ቇળኾ㐷කㇱળᡰㇱ࠮ࡒ࠽࡯߆ࠄ㧘ᣣᧄౝ⑼ቇળ㔀⹹ 2007 ᐕ㧧96 Ꮞ㧦174㧙180㧚
11㧕 ᫪↰ᶈਯ㧘ᨋ⟤૫㧘ቝ㊁ཅᒄ㧘᫃↰๺↵㧘⮮ጟ࿻㧘᫪৻㇢㧘ᳰ↰⾆⧷㧘᧻ේஜᴦ㧘๺↰␭Ὼ㧘ጤᧁඳ⟤㧘ḡ਄⧷⤿㧘⍹Ⴆ㆐ᄦ㧚࿷ቛஜᐽ▤ℂࠪࠬ࠹ࡓ೑↪ߦࠃࠆ↢ᵴ⠌ᘠ∛㑐ㅪᜰᮡ߳ߩലᨐ㧙ஜᐽ⸻ᢿߢߩ㕖೑↪⠪ߣߩᲧセ⎇ⓥ㧙㧘ᣣᧄ㆙㓒ක≮ቇળ㔀⹹ 2007 ᐕ㧧3 Ꮞ㧦229㧙230㧚
12㧕 㜞ᧁஜ⵨㧘᫪↰ᶈਯ㧘የㆺ೑⧷㧘᧛ጊᱜᙗ㧘ᯅᧄ⋥⚐㧘⍹Ⴆ㆐ᄦ㧚2 ᐕ㑆ߩ⚻ㆊߢᄌൻࠍ␜ߒߚ⢖⚿▵㒶㧙㧙ᓇߩ 1 ଀㧙ᣣᧄౝ⑼ቇળኾ㐷කㇱળᡰㇱ࠮ࡒ࠽࡯߆ࠄ㧙㧘ᣣᧄౝ⑼ቇળ㔀⹹ 2008 ᐕ㧧97 Ꮞ㧦849㧙856㧚
13㧕 ⍹Ⴆ㆐ᄦ㧘⑔ᴛཅቁ㧘ศን ⚐㧘᧖ᶆ ാ㧘ဈ㊁┨๋㧘᫪↰ᶈਯ㧚⊒ᾲ∔ᖚ߳ߩฦಽ㊁߆ࠄߩࠕࡊࡠ࡯࠴
㧙╙ 3 ࿁᧲ᶏᡰㇱౝ⑼ኾ㐷කㇱળᢎ⢒࠮ࡒ࠽࡯߆ࠄ㧙㧘ᣣᧄౝ⑼ቇળ㔀⹹ 2008 ᐕ㧧97 Ꮞ㧦1363㧙1370㧚
14㧕 ᳰ↰⾆⧷㧘᫪↰ᶈਯ㧘ቝ㊁ཅᒄ㧘᫃↰๺↵㧘ችౝ࡞ࡒሶ㧘᫪৻㇢㧘⮮ጟ࿻㧘ጟ↰⧷ਯ㧘⮮ដ⾆ᢅ㧘๺↰␭Ὼ㧘⍹Ⴆ㆐ᄦ㧘ᄢႦዅ㧚㆙㓒ක≮ߩ࠾࡯࠭ߣ࠲࡯ࠥ࠶࠻㧙ጊ㑆࿾ၞߢߩ࿷ቛஜᐽ▤ℂࠪࠬ࠹ࡓᄾ⚂⠪߳ߩࠕࡦࠤ㧙࠻⺞ᩏ㧙㧘ᣣᧄ㆙㓒ක≮ቇળ㔀⹹ 2008 ᐕ㧧4 Ꮞ㧦306㧙307㧚
15㧕 ᧛ጊᱜᙗ㧘ᄐ⋡૫ᐘ㧘ጟ↰⟤Ꮤ㧘㋈ᧁବᚑ㧘ⓄⓍብዏ㧘᫪৻㇢㧘ศ౷ᷕ㧘᫪↰ᶈਯ㧘౗᧻ቁᅢ㧚╙ 4 ࿁᧲ᶏᡰㇱᢎ⢒࠮ࡒ࠽࡯ ࡊࡠࡉ࡟ࡓߢ⠨߃ࠆ∝଀ᬌ⸛ળ㧘ᣣᧄౝ⑼ቇળ㔀⹹ 2008 ᐕ㧧97 Ꮞ㧦2811㧙2819㧚
ේ⪺㧔᰷ᢥ㧕
1㧕 Takahashi M, Minatoguchi S, Nishigaki K, Kawasaki M, Arai M, Uno Y, Fujiwara H. Long-term andstrict blood pressure lowering by imidapril reverses left ventricular hypertrophy in patients withessential hypertension: an evaluation using a novel indicator of burden on the left ventricle.
Hypertens Res. 2006;29:89-94.
2㧕 Lu C, Arai M, Misao Y, Chen X, Wang N, Onogi H, Kobayashi H, Uno Y, Takemura G, Minatoguchi S,
Fujiwara T, Fujiwara H. Autologous bone marrow cell transplantation improves left ventricularfunction in rabbit hearts with cardiomyopathy via myocardial regeneration-unrelated mechanisms.
Heart Vessels. 2006;21:180-187.
3㧕 Suzuki K, Nagashima K, Arai M, Uno Y, Misao Y, Takemura G, Nishigaki K, Minatoguchi S, Watanabe
S, Tei C, Fujiwara H. Effect of granulocyte colony-stimulating factor treatment at a low dose but for along duration in patients with coronary heart disease. Circ J. 2006;70:430-437.
4㧕 Arai M, Misao Y, Nagai H, Kawasaki M, Nagashima K, Suzuki K, Tsuchiya K, Otsuka S, Uno Y,
Takemura G, Nishigaki K, Minatoguchi S, Fujiwara H. Granulocyte colony-stimulating factor: anoninvasive regeneration therapy for treating atherosclerotic peripheral artery disease. Circ J.
2006;70:1093-1098.
5㧕 Isomura Y, Mune T, Morita H, Suwa T, Takada N, Yamamoto Y, Takeda J. Physiologic roles of
11-hydroxydehydrogenase type 2 in kidney. Metabolism. 2006;55:1352-1357.
6㧕 Onogi H, Minatoguchi S, Chen XH, Bao N, Kobayashi H, Misao Y, Yasuda S, Yamaki T, , Maruyama R,
Uno Y, Arai M, Takemura G, Fujiwara H. Edaravone reduces myocardial infarct size and improves
cardiac function and remodelling in rabbits. Clin Exp Pharmacol Physiol. 2006;33:1035-1041.
7㧕 Yamada Y, Sekihara H, Omura M, Yanase T, Takayanagi R, Mune T, Yasuda K, Ishizuka T, Ueshiba H,
Miyachi Y, Iwasaki T, Nakajima A, Nawata H. Changes in serum sex hormone profiles after
short-term low-dose administration of dehydroepiandrosterone (DHEA) to young and elderly persons.
Endocr J. 2007;54:153-162.
8㧕 Sugiyama C, Ishizawa M, Kajita K, Morita H, Uno Y, Matsubara K, Matsumoto M, Ikeda T, Ishizuka T.
Platelet aggregation in obese and diabetic subjects: association with leptin level. Platelets.
2007;18:128-134.
9㧕 Chen X, Minatoguchi S, Arai M, Wang N, Lu C, Narentuoya B, Uno Y, Misao Y, Takemura G, Fujiwara
T, Fujiwara H. Celiprolol, a selective beta1-blocker, reduces the infarct size through production of
nitric oxide in a rabbit model of myocardial infarction. Circ J. 2007;71:574-579.
10㧕 Ishizuka T, Miura A, Kajita K, Matsumoto M, Sugiyama C, Matsubara K, Ikeda T, Mori I, Morita H,
Uno Y, Mune T, Kanoh Y, Ishizawa M. Effect of dehydroepiandrosterone on insulin sensitivity in
Otsuka Long-Evans Tokushima fatty rats. Acta Diabetol. 2007;44:219-226.
11㧕 Kajita K, Mune T, Ikeda T, Matsumoto M, Uno Y, Sugiyama C, Matsubara k, Morita H, Takemura M,
Seishima M, Takeda J, Ishizuka T. Effect of fasting on PPAR and AMPK activity in adipocytes.
Diabetes Res Clin Pract. 2008;81:144-149.
12㧕 Mori I, Ishizuka T, Morita H, Matsumoto M, Uno Y, Kajita K, Ikeda T, Fujioka K, Matsubara K.
Comparison of biochemical data, blood pressure and physical activity between longevity andnon-longevity districts in Japan. Circ J. 2008;72:1680-1684.

IF 2.951

IF 1.043

IF 2.373

IF 2.373
IF 2.647

IF 2.038

IF 1.572

IF 1.915

IF 2.373

IF 1.619

IF 1.823

IF 2.373

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦᫪↰ᶈਯ㧘⎇ⓥಽᜂ⠪㧦⍹Ⴆ㆐ᄦ㧘ቝ㊁ཅᒄ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(B)(2)㧦㐳ኼߣ↢ᵴ⠌ᘠ㧙ጘ㒂↢ᵴ⠌ᘠ⺞ᩏ࡮੺౉ࡊࡠࠫࠚࠢ࠻㧙㧧ᐔᚑ 16㧙19 ᐕᐲ㧧14,900 ජ౞(7,600㧦4,000㧦1,900㧦1,400 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦㊁ᣇᢥ㓶㧘⎇ⓥಽᜂ⠪㧦᫪↰ᶈਯ㧘ቝ㊁ཅᒄ㧘㘵↰ብ᮸㧘㘵↰⌀⟤㧘ᮮ↰ᐽᚑ㧘⍹Ⴆ㆐ᄦ㧘ᷡፉḩ㧧⍮⊛ࠢ࡜ࠬ࠲࡯ഃ↢੐ᬺ㧙ࡠࡏ࠹࠶ࠢవ┵ක≮ࠢ࡜ࠬ࠲࡯㧙㧦ක≮⸻ᢿᡰេࠪࠬ࠹
ࡓߩ㐿⊒㧙േ⣂⎬ൻ⸃ᨆ࡮⸻ᢿࠪࠬ࠹ࡓ㧙㧧ᐔᚑ 17㧙20 ᐕᐲ㧧50,409 ජ౞(9,500㧦20,000㧦7,500㧦
13,409 ජ౞)3㧕 ⎇ⓥઍ⴫⠪㧦㈬Ꮞືᄦ㧘⎇ⓥಽᜂ⠪㧦᫪↰ᶈਯ㧘ጟ↰ብၮ㧘㐳⼱Ꮉ㜞ᔒ㧘ᧄ㑆⡡⿠㧘ศ↰ᤩᢅ㧘ㄞ㧙㧙ᱜᰴ㧘ේ㊂ብ㧧࿷ቛක≮߳ߩ㆙㓒ක≮ታ↪ታᣉᚻ㗅ߩ╷ቯ㧧ᐔᚑ 20 ᐕᐲ㧧500 ජ౞
2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥ1㧕 ⍹Ⴆ㆐ᄦ㧘᫪↰ᶈਯ㧘ቝ㊁ཅᒄ㧘᫃↰๺↵㧘᧻ේஜᴦ㧘᧻ᧄ㓷⟤㧘ᳰ↰⾆⧷㧘᫪৻㇢㧦ጘ㒂⋵ౝߩ㐳ኼ࿾ၞߣ㕖㐳ኼ࿾ၞߢߩ㧘り૕߅ࠃ߮↢ᵴ⠌ᘠ(㘩੐㧘ㆇേ╬)ߩ∉ቇ⊛⺞ᩏߦࠃࠆේ࿃ߩ⸃᣿㧧ᐔ
ᚑ 18 ᐕᐲ㧧2,000 ජ౞㧦ࠗ࠮࠶࠻(ᩣ)
2㧕 ⍹Ⴆ㆐ᄦ㧘᫪↰ᶈਯ㧘ቝ㊁ཅᒄ㧘᫃↰๺↵㧘ᳰ↰⾆⧷㧘᫪৻㇢㧘⮮ጟ࿻㧘ችౝ࡞ࡒሶ㧦ᵹേ㘩㐳ᦼ៨ขߦࠃࠆࡔ࠲ࡏ࡝࠶ࠢ∝୥⟲ߩ੍㒐࡮ᡷༀലᨐ㧧ᐔᚑ 19 ᐕᐲ㧧2,970 ජ౞㧦᫪᳗੃ᬺ(ᩣ)
3㧕 ⍹Ⴆ㆐ᄦ㧘᫪↰ᶈਯ㧦❫⛽࡝࠶࠴ᯏ⢻ᕈ㘩ຠࠍ૶↪ߒߚࡔ࠲ࡏኻ╷ലᨐߩᬌ⸽㧧ᐔᚑ 19 ᐕᐲ㧧2,000ජ౞㧦ࠗ࠮࠶࠻(ᩣ)
4㧕 ⍹Ⴆ㆐ᄦ㧘᫪↰ᶈਯ㧘᫃↰๺↵㧘⮮ጟ࿻㧘ችౝ࡞ࡒሶ㧘ᳰ↰⾆⧷㧘᫪৻㇢㧘ጟ↰⧷ਯ㧘⮮ដ⾆ᢅ㧦ࡠ࡯ࡗ࡞࠯࡝࡯฽᦭㘶ᢱߩ㐳ᦼ៨ขߦࠃࠆല⢻࡮ലᨐߩᬌ⸽㧦ᐔᚑ 20 ᐕᐲ㧧2,000 ජ౞㧦ࠗ࠮࠶࠻(ᩣ)
5㧕 ⍹Ⴆ㆐ᄦ㧘᫃↰๺↵㧦ࡠ࡯ࡗ࡞࠯࡝࡯៨ขߦࠃࠆࡔ࠲ࡏ࡝࠶ࠢ∝୥⟲ߩ੍㒐࡮ᡷༀലᨐ㧦ᐔᚑ 20 ᐕᐲ㧧2,970 ජ౞㧦ࠕࡇ(ᩣ)
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫ
1㧕 ㊁ᣇᢥ㓶㧘᫪↰ᶈਯ㧘ቝ㊁ཅᒄ㧦⵬ᱜⵝ⟎(⊒᣿)㧧ᐔᚑ 19 ᐕ(․㗿 2006-003862)
2㧕 㘵↰ብ᮸㧘㘵↰⌀⟤㧘᫪↰ᶈਯ㧘ቝ㊁ཅᒄ㧘ᮮ↰ᐽᚑ㧘㊁ᣇᢥ㓶㧦ⴊ▤ౝ⊹ᯏ⢻᷹ቯⵝ⟎(⊒᣿)㧧ᐔᚑ 20 ᐕ(․㗿 2007-138493)
3㧕 ㊁ᣇᢥ㓶㧘ᮮ↰ᐽᚑ㧘ᴡ᧛ᵗሶ㧘᫪↰ᶈਯ㧘ቝ㊁ཅᒄ㧦↢૕േ⣂⹏ଔᣇᴺ㧘෸߮↢૕േ⣂⹏ଔⵝ⟎(⊒᣿)㧧ᐔᚑ 20 ᐕ(․㗿 2008-015386)
6㧚ቇળᵴേ
1㧕ቇળᓎຬ⍹Ⴆ㆐ᄦ㧦
1㧕 ᣣᧄౝ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄౝ⑼ቇળ᧲ᶏᡰㇱ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄౝ⑼ቇળ⹺ቯක࡮ኾ㐷ක⹜㛎ᆔຬ(㨪ᐔᚑ 20 ᐕ 9 ᦬)
4㧕 ᣣᧄౝ⑼ቇળኾ㐷කㇱળ᧲ᶏᡰㇱ㐳(㨪⃻࿷)5㧕 ᣣᧄౝ⑼ቇળኾ㐷කㇱળᓎຬ(㨪⃻࿷)6㧕 ᣣᧄ♧ዩ∛ቇળ⹏⼏ຬ(㨪⃻࿷)7㧕 ᣣᧄ♧ዩ∛ቇળ≮㙃ᜰዉ჻⹺ቯᯏ᭴⹺ቯᆔຬ(㨪⃻࿷)8㧕 ᣣᧄ♧ዩ∛ቇળ♧ዩ∛↪⺆㓸✬㓸ᆔຬ㐳(㨪⃻࿷)9㧕 ᣣᧄౝಽᴲቇળઍ⼏ຬ(㨪⃻࿷)10㧕 ᣣᧄౝಽᴲቇળ᧲ᶏᡰㇱ⋙੐(ᐔᚑ 19 ᐕ 4 ᦬㨪⃻࿷)11㧕 ᣣᧄౝಽᴲቇળኾ㐷ක⹜㛎ᆔຬ(㨪ᐔᚑ 20 ᐕ 9 ᦬)
12㧕 ᣣᧄ∛ᘒᩕ㙃ቇળ⹏⼏ຬ(㨪⃻࿷)13㧕 ᣣᧄ㆙㓒ක≮ቇળℂ੐(ᐔᚑ 19 ᐕ 4 ᦬㨪⃻࿷)
ቝ㊁ཅᒄ㧦
1㧕 ᣣᧄౝ⑼ቇળ᧲ᶏᡰㇱ⹏⼏ຬ(㨪⃻࿷)᫪↰ᶈਯ㧦1㧕 ᣣᧄౝ⑼ቇળ᧲ᶏᡰㇱ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄౝ⑼ቇળ⹺ቯౝ⑼ක࡮✚วౝ⑼ኾ㐷ක⹜㛎໧㗴૞ᚑᆔຬળ਎⹤ੱ(ᐔᚑ 20 ᐕ 10 ᦬㨪⃻࿷)
3㧕 ᣣᧄ♧ዩ∛ቇળ⹏⼏ຬ(ᐔᚑ 20 ᐕ 4 ᦬㨪⃻࿷)
4㧕 ᣣᧄ♧ዩ∛ቇળ♧ዩ∛↪⺆㓸✬㓸ᆔຬ(ᐔᚑ 20 ᐕ 4 ᦬㨪⃻࿷)
5㧕 ᣣᧄౝಽᴲቇળઍ⼏ຬ(㨪⃻࿷)6㧕 ᣣᧄࠬ࠹ࡠࠗ࠼ࡎ࡞ࡕࡦቇળ⹏⼏ຬ(㨪⃻࿷)㧙㧙7㧕 ᣣᧄ∛ᘒᩕ㙃ቇળ⹏⼏ຬ(㨪⃻࿷)᫃↰๺↵㧦1㧕 ᣣᧄౝ⑼ቇળ᧲ᶏᡰㇱ⹏⼏ຬ(ᐔᚑ 19 ᐕ 4 ᦬㨪⃻࿷)2㧕 ᣣᧄౝಽᴲቇળઍ⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ∛ᘒᩕ㙃ቇળ⹏⼏ຬ(ᐔᚑ 20 ᐕ 4 ᦬㨪⃻࿷)2㧕ቇળ㐿௅⍹Ⴆ㆐ᄦ㧦
1㧕 ╙ 1 ࿁᧲ᶏᡰㇱኾ㐷කㇱળᢎ⢒࠮ࡒ࠽࡯(2006 ᐕ 6 ᦬㧘ฬฎደ)2㧕 ╙ 2 ࿁᧲ᶏᡰㇱኾ㐷කㇱળᢎ⢒࠮ࡒ࠽࡯(2007 ᐕ 2 ᦬㧘ᵤ)3㧕 ╙ 3 ࿁᧲ᶏᡰㇱኾ㐷කㇱળᢎ⢒࠮ࡒ࠽࡯(2007 ᐕ 10 ᦬㧘ฬฎደ)
4㧕 ╙ 4 ࿁᧲ᶏᡰㇱኾ㐷කㇱળᢎ⢒࠮ࡒ࠽࡯(2008 ᐕ 2 ᦬㧘ฬฎደ)
5㧕 ╙ 5 ࿁᧲ᶏᡰㇱኾ㐷කㇱળᢎ⢒࠮ࡒ࠽࡯(2008 ᐕ 6 ᦬㧘ᵿ᧻)
6㧕 ᐔᚑ 20 ᐕᐲᣣᧄ㆙㓒ක≮ቇળቇⴚᄢળ(2008 ᐕ 10 ᦬㧘ጘ㒂)
3㧕ቇⴚ㔀⹹᫪↰ᶈਯ㧦
1㧕 ᣣᧄ㆙㓒ක≮ቇળ㔀⹹㧧✬㓸ᆔຬ(ᐔᚑ 19 ᐕ 4 ᦬㨪⃻࿷)7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳⍹Ⴆ㆐ᄦ㧦
1㧕 ╙ 1 ࿁᧲ᶏᡰㇱኾ㐷කㇱળᢎ⢒࠮ࡒ࠽࡯(2006 ᐕ 10 ᦬㧘ฬฎደ㧘ࠪࡦࡐࠫ࠙ࡓ‫∝ࠢ࠶࡝ࡏ࠲ࡔޟ‬୥⟲ 㧙ኾ㐷㗔ၞ߆ࠄߩࡔ࠶࠮࡯ࠫߣ⸛⺰㧙‫ޠ‬ᐳ㐳)2㧕 ╙ 50 ࿁ᣣᧄ♧ዩ∛ቇળᐕᰴቇⴚ㓸ળ(2007 ᐕ 5 ᦬㧘઄บ㧘ᢎ⢒⻠Ṷ‫⚻␹ޟ‬㓚ኂߩ⸻ᢿߣᴦ≮‫ޠ‬ᐳ㐳)
3㧕 ╙ 24 ࿁♧ዩ∛ Up࡮Date ⾫ፉ࠮ࡒ࠽࡯(2007 ᐕ 8 ᦬㧘ᔒ៺㧘᜗ᓙ⻠Ṷ‫ࡦ࡝ࡦࠗޟ‬ᛶ᛫ᕈߩ◲ᤃ⸻ᢿ
ᴺߣ㒢⇇‫ޠ‬Ṷ⠪)
4㧕 ╙ 3 ࿁᧲ᶏᡰㇱኾ㐷කㇱળᢎ⢒࠮ࡒ࠽࡯(2007 ᐕ 10 ᦬㧘ฬฎደ㧘ࠪࡦࡐࠫ࠙ࡓ‫⊒ޟ‬ᾲ∔ᖚ߳ߩฦಽ
㊁߆ࠄߩࠕࡊࡠ࡯࠴‫ޠ‬ᐳ㐳)
5㧕 ╙ 5 ࿁᧲ᶏᡰㇱኾ㐷කㇱળᢎ⢒࠮ࡒ࠽࡯(2008 ᐕ 6 ᦬㧘ฬฎደ㧘ࠪࡦࡐࠫ࠙ࡓ‫ߦࠕࠤ࡝ࡑࠗ࡜ࡊޟ‬߅ߌࠆ−∩∔ᖚߩ⸻ᢿ‫ޠ‬ᐳ㐳)
6㧕 ╙ 25 ࿁♧ዩ∛ Up࡮Date ⾫ፉ࠮ࡒ࠽࡯(2008 ᐕ 8 ᦬㧘ᔒ៺㧘᜗ᓙ⻠Ṷ‫ޟ‬2 ဳ♧ዩ∛ࠍ઻ߞߚ⢽⢌⢄‫ޠ‬Ṷ⠪)7㧕 2nd World Conference on Magic Bullets Celebrating the 100th Anniversary of the Nobel PrizeAward to Paul Ehrich(2008.10, Nurnberg, Special Lecture ̌Dehydroepiandrosterone reduced
adiposity and insulin resistance”)
᫪↰ᶈਯ㧦
1㧕 ╙ 2 ࿁᧲ᶏᡰㇱኾ㐷කㇱળᢎ⢒࠮ࡒ࠽࡯(2007 ᐕ 2 ᦬㧘ᵤ㧘∝଀ᬌ⸛ળ‫ޟ‬ᬌ⸻⊒⷗ߢ 2 ᐕߩ⚻ㆊਛߦ㒶ᓇᄌൻࠍ␜ߒߚ 59 ᱦ↵ᕈ଀‫ޠ‬ᐳ㐳)2㧕 2007 ᐕᐲᣣᧄ㆙㓒ක≮ቇળቇⴚ㓸ળ(2007 ᐕ 10 ᦬㧘ጟጊ㧘ડ↹ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬㆙㓒ක≮ߩࡆࠫࡀࠬࡕ࠺࡞ ࠹࡟ࡋ࡞ࠬࠤࠕߩࡆࠫࡀࠬࡕ࠺࡞᭴▽ߦะߌߡ‫ޠ‬ᐳ㐳)
ቝ㊁ཅᒄ㧦
1㧕 ᐔᚑ 20 ᐕᐲᣣᧄ㆙㓒ක≮ቇળᄢળ(2008 ᐕ 10 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬࿾ၞක≮‫ޠ‬ᐳ㐳)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ1㧕 ᧻ේஜᴦ㧦╙ 44 ࿁ጘ㒂⋵ౝ⑼කળఝ⑲Ṷ㗴⾨(ᐔᚑ 18 ᐕᐲ)
2㧕 ችፒᷪ㧦╙ 205 ࿁ᣣᧄౝ⑼ቇળ᧲ᶏ࿾ᣇળఝ⑲Ṷ㗴⾨(ᐔᚑ 20 ᐕᐲ)
3㧕 ᳓㊁ᱜᏈ㧦╙ 206 ࿁ᣣᧄౝ⑼ቇળ᧲ᶏ࿾ᣇળఝ⑲Ṷ㗴⾨(ᐔᚑ 20 ᐕᐲ)
4㧕 ᳰ↰⾆⧷㧦ᐔᚑ 20 ᐕᐲᣣᧄ㆙㓒ක≮ቇળఝ⑲⺰ᢥ⾨(ᐔᚑ 20 ᐕᐲ)
5㧕 ᫪৻㇢㧦╙ 48 ࿁ጘ㒂⋵ౝ⑼කળఝ⑲Ṷ㗴⾨(ᐔᚑ 20 ᐕᐲ)㧙㧙9㧚␠ળᵴേ⍹Ⴆ㆐ᄦ㧦
1㧕 ᣣᧄ♧ዩ∛දળ࿖㓙ᆔຬ(㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ᫪↰ᶈਯ㧦㖸ჿࠞࠝࠬ⸃ᨆߦࠃࠆࠬ࠻࡟ࠬ⸻ᢿߣ∻๐ࠬࠢ࡝࡯࠾ࡦࠣ㧦(⽷)᧲ᶏ↥ᬺᛛⴚᝄ⥝⽷࿅╙ 17 ࿁ഥᚑ⎇ⓥቢੌႎ๔ᦠ㧦TFT ࠾ࡘ࡯ࠬ 49㧦37㧙43(2006 ᐕ 3 ᦬)
2㧕 ᫪↰ᶈਯ㧦㐳ኼߣ↢ᵴ⠌ᘠ∛ጘ㒂↢ᵴ⠌ᘠ⺞ᩏ࡮੺౉ࡊࡠࠫࠚࠢ࠻㧦ᐔᚑ 16 ᐕ㨪ᐔᚑ 19 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(B)⎇ⓥᚑᨐႎ๔ᦠ㧦1㧙73(2008 ᐕ 5 ᦬)
3㧕 ᫪↰ᶈਯ㧦ࠗࡦࡇ࡯࠳ࡦࠬ⸘᷹ߢ↢૕ᯏ⢻ࠍ⸻ᢿ㧍ⴊ▤ౝ⊹/⣻ㇱౝ⤳⢽⢌㧦ࡠࡏ࠹࠶ࠢవ┵ක≮ࠢ࡜ࠬ࠲࡯ᛛⴚࠪ࡯࠭㓸(ᐔᚑ 16 ᐕᐲ㨪ᐔᚑ 20 ᐕᐲ)㧦29㧙30(2008 ᐕ 11 ᦬)
11㧚ႎ㆏1㧕 ቝ㊁ཅᒄ㧘㊁ᣇᢥ㓶㧦5 ಽߢಽ߆ࠆⴊ▤ᐕ㦂 ጘ㒂ᄢ߇ᬌᩏࠪࠬ࠹ࡓ㐿⊒㧦ਛᣣࠬࡐ࡯࠷(2006 ᐕ 5
᦬ 31 ᣣ)2㧕 ᫪↰ᶈਯ㧦ਛㇱߩක≮ ࡔ࠲ࡏ࡝࠶ࠢࠪࡦ࠼ࡠ࡯ࡓ‫ⴊޟ‬ᶧਛߩක⠪‫ࠍޠ‬Ⴧ߿ߖ㧘⺒ᄁᣂ⡞(2006 ᐕ
12 ᦬ 12 ᣣ)3㧕 ቝ㊁ཅᒄ㧘㊁ᣇᢥ㓶㧦േ⣂⎬ൻᬌᩏ 5 ಽߦ⍴❗ ጘ㒂ᄢࠣ࡞࡯ࡊ㐿⊒㧦⺒ᄁᣂ⡞(2007 ᐕ 1 ᦬ 15 ᣣ)
4㧕 ᫪↰ᶈਯ㧦⎇ⓥቶ߆ࠄᄢቇߪ੹‫ޟ‬ஜᐽኼ๮ߣ↢ᵴ⠌ᘠ⠨߃ࠆ‫ޠ‬㧦ጘ㒂ᣂ⡞(2007 ᐕ 1 ᦬ 16 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔකቇㇱ߇⒖ォᓟ㧘⻠ᐳ㐿⸳߽⹺߼ࠄࠇ㧘⎇ⓥ㕙ߢߩ⸳஻߿ⅣႺ㕙ߢߩઁ⻠ᐳߣߩࡂࡦ࠺ࠖߪᓢ‫⸃ߦޘ‬ᶖߐࠇߡ߈ߡ޿ࠆ‫ߡߞ઻ߦࠇߘޕ‬㧘✚วౝ⑼⊛ߥ⷗࿾߆ࠄ․⦡ߩ޽ࠆ⎇ⓥ߇┙ߜ਄߇ࠅߟߟ޽ࠅ㧘੹ᓟߪߎࠇࠍߐࠄߦ⊒ዷߐߖߡࠁߊᔅⷐ߇޽ࠆ‫ޕ‬ዋߥ޿ᢎቶຬߩੱᢙࠍൊ᩺ߔࠆߣ㧘ᄢቇ㒮↢ߩ⎇ⓥᜰዉ㧘࿖㓙ቇળߢߩ⊒⴫㧘⺰ᢥᬺ❣ߦ㑐ߒߡߪᮡḰ࡟ࡌ࡞ߢ޽ࠆߣ⠨߃ߡ޿ࠆ‫ߒ߆ߒޕ‬㧘✚ว∛ᘒౝ⑼ቇಽ㊁ߣߒߡ␠ળ⊛ߥ⹺⍮߿⁛┙ᕈࠍ⠨߃ࠆߣ㧘ᄖㇱ⾗㊄₪ᓧ㧔․ߦ⑼ቇ⎇ⓥ⾌⵬ഥ㊄㧕߿㧘․⦡޽ࠆ⺰ᢥᬺ❣㧘⎇ⓥ߿⊒᣿ߦ㑐ߔࠆᣂ⡞ႎ㆏ߪ߹ߛ߹ߛዋߥ޿‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ੱ⊛૛⵨߇චಽߢߥߊ㧘⎇ⓥ┙᩺㧘⎇ⓥ⾌↳⺧㧘࠺࡯࠲෼㓸࡮⸃ᨆ㧘⺰ᢥ⸥タߥߤ⎇ⓥߦ⾌߿ߔᤨ㑆߇߆ߥࠅਇ⿷ߒߡ޿ࠆߩ߇⃻⁁ߢ޽ࠆ‫ޕ‬ᓎഀಽᜂࠍ᣿⏕ൻߒ㧘઀੐ߩ㊀ⶄ߇ዋߥߊߥࠆࠃ߁ߦ⷗⋥ߒ㧘ല₸ൻࠍ⸘ߞߡ⧷⺆⺰ᢥᢙࠍჇ߿ߒߡࠁ߈ߚ޿‫⊛ੱޕ‬ਇ⿷ߦ㑐ߒߡߪ㧘ᣣ㗃ߩ⥃ᐥ⎇ୃ߿⥃ᐥታ⠌ߦജࠍ౉ࠇࠆߎߣߦࠃߞߡ㧘✚วౝ⑼ߩᓎഀ߿㝯ജࠍలಽߦ⹺⼂ߒߡ߽ࠄ޿㧘ᄙߊߩ౉ዪ⠪ࠍㄫ߃ࠄࠇࠆࠃ
߁ߦദജߒߡࠁ߈ߚ޿‫␠ޕ‬ળ⊛ߥ⹺⍮ᐲਇ⿷ߦኻߒߡߪ㧘․ߦ࿾ၞක≮߿⥃ᐥ∉ቇߦߟ޿ߡቇળߢߩ⊒⴫߿⺰ᢥൻߣߣ߽ߦ㧘ᣂ⡞␠߳ߩႎ㆏ଐ㗬߽Ⓧᭂ⊛ߦⴕߞߡࠁ߈ߚ޿‫ߚ߹ޕ‬㧘ࡎ࡯ࡓࡍ࡯ࠫߦࠃࠆᖱႎ
ឭଏߪ᦭ലߥᚻᲑߢ޽ࠆߚ߼㧘ᤚ㕖లታߐߖߡ޿߈ߚ޿‫ޕ‬
੹ᓟߩዷᦸ
2006 ᐕ 4 ᦬߆ࠄකዪ߇㒝ዻ∛㒮 1 㓏߆ࠄකቇㇱᧄ㙚ߦකዪ߇⒖ォߒߚߎߣߦࠃߞߡ㧘කዪߩㄭߊߦ⎇ⓥቶ߇ᜬߡࠆࠃ߁ߦߥߞߚ‫੹ޕ‬ᓟ㧘․ߦၮ␆⊛ߥ⎇ⓥߩㅴ᝞߇ᦼᓙߢ߈ࠆ‫ߚ߹ޕ‬㧘⥃ᐥߩ႐߆ࠄ↢߹ࠇࠆ⇼໧ࠍ⊒┵ߣߒߚ✚วౝ⑼ߣߒߡ․ᓽ⊛ߥ⥃ᐥ⎇ⓥࠍផㅴߒߡࠁ߈ߚ޿‫ߦ․ޕ‬ጘ㒂⋵ౝߩ✚วౝ⑼ක
ߩࡀ࠶࠻ࡢ࡯ࠢࠍᒻᚑߒ㧘ᄙᣉ⸳ߢߩ౒ห⎇ⓥࠍⴕ޿㧘⥃ᐥ⊛ࠛࡆ࠺ࡦࠬࠍ 1 ߟߢ߽⊒ାߒߡࠁ߈ߚ޿‫ޕ‬㧙㧙㧔3㧕⥃ᐥ⮎೷ቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
⥃ᐥ⮎೷ቇಽ㊁ߦ߅ߌࠆ⎇ⓥ㗄⋡ߪ㧘1㧕ක⮎ຠ╬ߩቯ㊂ᴺߩ⏕┙ߦ㑐ߔࠆ⎇ⓥ㧘2㧕⮎‛૕ౝേᘒߩ⸃
ᨆߦၮߠߊක⮎ຠㆡᱜ૶↪ផㅴߦ㑐ߔࠆ⎇ⓥ㧘3㧕ක⮎ຠߩᣂⷙ೷ဳߩ㐿⊒ߣߘߩ⥃ᐥᔕ↪ߦ㑐ߔࠆ⎇ⓥ㧘
4㧕ක≮ᖱႎࠪࠬ࠹ࡓࠍᵴ↪ߒߚක≮቟ో⏕଻ߦ㑐ߔࠆ⎇ⓥ㧘5㧕᛫߇ࠎ೷ߦኻߔࠆ⠴ᕈ⊒⃻ߩ⚦⢩ౝࡔࠞ࠾࠭ࡓߩ⸃᣿ߦ㑐ߔࠆ⎇ⓥ㧘6㧕᛫߇ࠎ೷ߦࠃࠆ೽૞↪⊒⃻ࡔࠞ࠾࠭ࡓߩ⸃᣿ߣ᦭ലߥᴦ≮ᴺߩ⏕┙ߦ㑐ߔࠆ⎇ⓥ㧘ߥߤߢ޽ࠆ‫߫߃଀ޕ‬㧘ක⮎ຠ╬ߩቯ㊂ߦ㑐ߔࠆ⎇ⓥߢߪ㧘㜞ㅦᶧ૕ࠢࡠࡑ࠻ࠣ࡜ࡈࠖ࡯㧔HPLC㧕
ߣⰯశᬌ಴ེ㧘㔚᳇ൻቇᬌ಴ེ㧘⚡ᄖๆశశᐲ⸘㧘ࠛ࡟ࠢ࠻ࡠࠬࡊ࡟࡯࡮࠲ࡦ࠺ࡓࡑࠬࠬࡍࠢ࠻ࡠࡔ࡯࠲
߿ࠟࠬࠢࡠࡑ࠻ࠣ࡜ࡈࠖ࡯ߥߤߩ᷹ቯᯏེࠍ㚟૶ߔࠆߎߣߦࠃࠅ᭽‫ߥޘ‬ක⮎ຠ߿↢ℂᵴᕈ‛⾰ߩቯ㊂ߦᵴ↪ߒߡ޿ࠆ‫ߚ߹ޕ‬㧘⮎‛૕ౝേᘒߩ⸃ᨆߦၮߠߊක⮎ຠㆡᱜ૶↪ផㅴߦ㑐ߔࠆ⎇ⓥߢߪ㧘ᢇᕆ㗔ၞߦ߅
ߌࠆ㊀∝ᖚ⠪ߢߩ⣢ᯏ⢻ߩᜰᮡߣߒߡࠪࠬ࠲࠴ࡦ C ࠍ᷹ቯߒ㧘ߘߩ୯߆ࠄ♻⃿૕ࠈㆊ㊂ߩផ᷹ᑼ㧘ߐࠄߦߪ᛫⩶⮎ߩⴊਛỚᐲࠍផ᷹ߔࠆᑼࠍዉߊߎߣߦࠃߞߡ᛫⩶⮎ߩᛩਈ㊂߿ᛩਈ㑆㓒ࠍ᳿ቯߔࠆߣ޿ߞߚ
ᬌ⸛ࠍⴕߞߡ޿ࠆ‫ޕ‬ᣂⷙ೷ဳߩ㐿⊒ߦ㑐ߔࠆ⎇ⓥߢߪ㧘ጘ㒂⋵ౝߩડᬺߣߩ౒ห⎇ⓥߢ೙ฯ೷ߩ࠺ࠠࠨࡔ
࠲࠱ࡦ߿ࡊࡠࠢࡠ࡞ࡍ࡜ࠫࡦࠍ฽߻ญ⣧ౝㅦ፣უ⿥⭯ဳࡈࠖ࡞ࡓ೷ࠍ㐿⊒ߒ㧘ߎࠇࠍ᛫߇ࠎ೷ߦࠃࠆᖡ
ᔃ࡮ཌྷฯߩ੍㒐ߣߒߡㆡ↪ߔࠆߚ߼ߩ⎇ⓥࠍㅴ߼ߡ޿ࠆ‫ޕ‬ක≮ᖱႎࠪࠬ࠹ࡓࠍᵴ↪ߒߚක≮቟ో⏕଻ߦ㑐ߔࠆ⎇ⓥߢߪ㧘ࠦࡦࡇࡘ࡯࠲ࠍౝ⬿ߒߚ᛫߇ࠎ೷ᵈ኿⮎ߩᷙว⺞⵾ߩߚ߼ߩ቟ోࠠࡖࡆࡀ࠶࠻ࠍ਎⇇ߢೋ߼ߡ㐿⊒ߒ㧘᛫߇ࠎ೷ߩขࠅ㑆㆑޿߿ᛩਈ㊂㑆㆑޿ߦࠃࠆක≮ㆊ⺋ߩ㒐ᱛߦᓎ┙ߡߡ޿ࠆ‫ߚ߹ޕ‬㧘᛫߇ࠎ೷ߦኻߔࠆ⠴ᕈ⊒⃻ߦ㑐ߔࠆ⎇ⓥߢߪ㧘කቇㇱ߿ጘ㒂⮎⑼ᄢቇߣߩ౒ห⎇ⓥߦ߅޿ߡ㧘ᄢ⣺߇ࠎ⚦⢩ߢߩࠝࠠࠨ࡝ࡊ࡜࠴ࡦߦኻߔࠆ⠴ᕈߦ⚦⢩ౝ࠮࡜ࡒ࠼ઍ⻢㉂⚛ߩࠬࡈࠖࡦࠧࠪࡦࠠ࠽࡯࠯ߩㆊ೾⊒⃻߇㑐ਈߔࠆߎߣࠍ⷗޿಴ߒ㧘࠮࡜ࡒ࠼ߦ㑐ㅪߔࠆ⚦⢩ౝࠪࠣ࠽࡞ߣ⠴ᕈ⊒⃻ߣߩ㑐ㅪߦߟ޿ߡ⎇ⓥࠍㅴ߼ߡ޿ࠆ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦

દ⮮ ༀⷙ

Yoshinori Itoh3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ᄢ⍹ੌਃ㧘દ⮮ༀⷙ㧚߇ࠎൻቇ≮ᴺ࠮࡯ࡈ࠹ࠖࡑ࠾ࡘࠕ࡞㧦ศ↰↱⟤ሶ✬㧚᧲੩㧦ߓ߶߁㧧2007 ᐕ㧚
2㧕 ቟↰ᶈੑ㧘᧖ጊᱜ㧘દ⮮ༀⷙ㧘 ᩿⟵ඳ(ಽᜂၫ╩)㧚2007 ᐕታ⠌ߦⴕߊ೨ߩⷡ߃ࠆක⮎ຠ㓸㧙᦯⮎ᜰዉߦᓎ┙ߟ㧙㧦᧲੩㧦ᑝᎹᦠᐫ㧧2007 ᐕ㧚
3㧕 ቟↰ᶈੑ㧘દ⮮ༀⷙ(ಽᜂၫ╩)㧚2008 ᐕታ⠌ߦⴕߊ೨ߩⷡ߃ࠆක⮎ຠ㓸㧙᦯⮎ᜰዉߦᓎ┙ߟ㧙㧦᧲੩㧦ᑝᎹᦠᐫ㧧2008 ᐕ㧚
4㧕 ᄢ⍹ੌਃ㧘ᳰᧃ⵨᣿㧘દ⮮ༀⷙ✬㧚߇ࠎൻቇ≮ᴺࡢ࡯ࠢࠪ࡯࠻╙ 3 㧦᧲੩㧦ߓ߶߁㧧2008 ᐕ㧚⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 ᧖ጊᱜ㧘 ᩿⟵ඳ㧚∛᳇ߣ⮎ߩ⺑᣿ࠟࠗ࠼ 2006㧙ߘߩઁߩࡎ࡞ࡕࡦ᭽⮎㧘⮎ዪ 2006 ᐕ㧧57 Ꮞ㧦1807
㧙1821㧚
2㧕 ᧻ᶆసᒾ㧘᧖ጊᱜ㧚ᓟ⊒ක⮎ຠߩຠ⾰Ყセ⹜㛎̆ࠝࠩࠣ࡟࡞࠽࠻࡝࠙ࡓᵈ኿೷̆㧘Pharm Tech Japan
2006 ᐕ㧧22 Ꮞ㧦1606㧙1609㧚
3㧕 ᧖ጊᱜ㧘᧻ᶆసᒾ㧘⷏᧛⟤૒ᄦ㧘᦬ጟᔘᄦ㧚ྚਅ࿎㔍ߥᖚ⠪ࠍኻ⽎ߣߒߚੇ῎࠯࡝࡯⵾೷ߩၮ␆ᬌ⸛㧘
Pharmstage 2007 ᐕ㧧7 Ꮞ㧦31㧙34㧚
✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ᧻ᶆసᒾ㧘ᨋ⑲᮸㧘᧖ጊᱜ㧘 ᩿⟵ඳ㧚ᓟ⊒ක⮎ຠណ↪ߩߚ߼ߩຠ⾰⹏ଔ̆ࡑ࡟ࠗࡦ㉄ࠛ࠽࡜ࡊ࡝࡞㍤ߦ
߅ߌࠆᬌ⸛̆㧘ක≮⮎ቇ 2006 ᐕ㧧32 Ꮞ㧦306㧙313.
2㧕 ਤ⠀ 㓉㧘ᓟ⮮ජኼ㧘᧖ጊᱜ㧘 ᩿⟵ඳ㧚ICU ߦ߅ߌࠆ⮎೷Ꮷߦࠃࠆක⮎ຠᖱႎឭଏߣߘߩ⹏ଔ㧘ක≮⮎
ቇ 2006 ᐕ㧧32 Ꮞ㧦400㧙406.
3㧕 ਛ᧛శᶈ㧘ᐔ಴⠹⍹㧘ዊ᫪⟵ᢥ㧘᧖ጊᱜ㧘 ᩿⟵ඳ㧚㔚ሶࠞ࡞࠹ߦኻᔕߒߚ TDM ࠪࠬ࠹ࡓߩ㐿⊒㧘TDM⎇ⓥ 2006 ᐕ㧧23 Ꮞ㧦95㧙96㧚
4㧕 ਛ᧛శᶈ㧘੹⷏⟵♿㧘ᷓ๺ടᄹ㧘ᐔ಴⠹⍹㧘᧖ጊᱜ㧘 ᩿⟵ඳ㧚FPIA ᴺࠍၮḰߣߒߚోⴊਛࠪࠢࡠࠬࡐ
࡝ࡦỚᐲߩᲧセ㧘TDM ⎇ⓥ 2006 ᐕ㧧23 Ꮞ㧦233㧙237㧚
5㧕 ጟ቟િੑ㧘ᱞ↰ ⚐㧘ጊᧄ⋿↱⟤㧚ࠗࡦࠬ࡝ࡦߩ቟ో▤ℂ૕೙ᡷༀࠍ⋡⊛ߣߒߚ㒮ౝᮡḰᦠߩ૞ᚑߣߘߩ⹏㧙㧙ଔ㧘ࡊ࡜ࠢ࠹ࠖࠬ 2006 ᐕ㧧23 Ꮞ㧦464㧙468㧚
6㧕 ਛ᧛శᶈ㧘᧻ᶆసᒾ㧘࿯ደᾖ㓶㧘᧖ጊ ᱜ㧚ࡍ࡯ࡄ࡟ࠬ㔚ሶࠞ࡞࠹ߦኻᔕߒߚ TDM ࠪࠬ࠹ࡓߩ㐿⊒㧘TDM⎇ⓥ 2007 ᐕ㧘24 Ꮞ㧦104㧙112㧚
7㧕 ᷓ๺ടᄹ㧘ᓟ⮮ජኼ㧘᧻ᶆసᒾ㧘᧖ጊᱜ㧚⺞೷ߦ㑐ߔࠆᖱႎߩ㔚ሶൻ㧘ᣣᧄ∛㒮⮎೷Ꮷળ㔀⹹ 2007 ᐕ㧧
43 Ꮞ㧦938㧙941㧚
8㧕 ᓟ⮮ජኼ㧘቟↰ᶈੑ㧘᧖ጊᱜ㧚⥃ᐥᬌᩏ࠺࡯࠲ࠍ೑↪ߒߚಣᣇ㐓ᩏᡰេࠪࠬ࠹ࡓߩ㐿⊒ߣߘߩ᦭↪ᕈ㧘ක≮⮎ቇ 2007 ᐕ㧧33 Ꮞ㧦114㧙118㧚
9㧕 ጟ቟િੑ㧘ਛ᧛శᶈ㧘ජ⒳ᐽ৻㧘ᰞ੗ẖ㧘᧖ጊᱜ㧚ᣂ⸳⸘ࠢ࡝࡯ࡦࡌࡦ࠴࡮቟ోᕈࠠࡖࡆࡀ࠶࠻ߣᵈ኿ࠝ࡯࠳ᖱႎࠍ೑↪ߒߚᵈ኿೷⺞⵾㐓ᩏࠪࠬ࠹ࡓߩ㐿⊒㧘ක≮⮎ቇ 2007 ᐕ㧧33 Ꮞ㧦191㧙199㧚
10㧕 ਛ᧛శᶈ㧘ᷓ๺ടᄹ㧘ጤ↰ජ㚅㧘᧛ጟ᣿⟤㧘㑆ች␞ሶ㧘᧖ጊᱜ㧚ᵈ኿⮎᛫≸೷⺞⵾ᡰេࡊࡠࠣ࡜ࡓߩ㐿⊒ߣߘߩ⹏ଔ㧘ක⮎ຠᖱႎቇ 2007 ᐕ㧧8 Ꮞ㧦315㧙319㧚
11㧕 ศጟผ㇢㧘᧻ᶆసᒾ㧘᧖ጊᱜ㧘દ⮮ༀⷙ㧚⣢⒖ᬀ೨ᓟߦ߅ߌࠆಣᣇ⮎೷ߩᄌൻߦ㑐ߔࠆ⺞ᩏ㧘ක≮⮎ቇ 2007
ᐕ㧧33 Ꮞ㧦937㧙941㧚
12㧕 ᧻ᶆసᒾ㧘㘵ේᄢ⒤㧘⍹ේᱜᔒ㧘ዊ᫪ༀᢥ㧘ጊౝᳯ㉿ሶ㧘ᓟ⮮ජኼ㧘દ⮮ༀⷙ㧚߇ࠎᖚ⠪ߩᩕ㙃⁁ᘒߦ㑐ߔࠆ㒮ౝ⺞ᩏ㧘ᣣᧄ∛㒮⮎೷Ꮷળ 2007 ᐕ㧧43 Ꮞ㧦571㧙1574㧚
13㧕 ⷏᧛⟤૒ᄦ㧘᧖ጊᱜ㧘᧻ᶆసᒾ㧘᦬ጟᔘᄦ㧘દ⮮ༀⷙ㧚ྚਅ࿎㔍ᖚ⠪߳ߩㆡᔕࠍ⋡⊛ߣߒߚක⮎ຠߩੇ῎࠯࡝࡯⵾೷ൻߦ㑐ߔࠆၮ␆⊛ᬌ⸛㧘ක≮⮎ቇ 2007 ᐕ㧧33 Ꮞ㧦1007㧙1012㧚
14㧕 ᧃᰴ₺ථ㧘ฎ⾐෹৻㇢㧘ศ↰ታ㧘የ਄᪸ᴕ㧘ਛ᎑৻ᕺ㧘ਛፉ๺ඳ㧘࿦↰ᱜା㧘ᧃ቟ᱜౖ㧘⑺ศ⟤ઍሶ㧘ศᎹቇ㧘દ⮮ༀⷙ㧘ᄢ⍹ੌਃ㧚ISO9001 ຠ⾰▤ℂࠪࠬ࠹ࡓߦၮߠߊ⮎೷ឭଏߦ㑐ߔࠆ㘈ቴḩ⿷⺞ᩏߣᬺോᡷ
ༀ㧘ᣣᧄ∛㒮⮎೷Ꮷળ㔀⹹ 2007 ᐕ㧧43 Ꮞ㧦1543㧙1547㧚
15㧕 ਤ⠀㓉㧘᧖ጊᱜ㧘ጟ቟િੑ㧘ጊౝᳯ㉿ሶ㧘⷏၂⟤ᄹሶ㧘᧻ᶆసᒾ㧘ᓟ⮮ජኼ㧘દ⮮ༀⷙ㧚㔚ሶࠞ࡞࠹ࠪࠬ
࠹ࡓߩ৻Ⅳߣߒߡߩ⮎೷▤ℂᜰዉᡰេࠪࠬ࠹ࡓߩ᭴▽㧘ක≮⮎ቇ 2008 ᐕ㧧34 Ꮞ㧦103㧙111㧚
16㧕 㘵ේᄢ⒤㧘᧻ᶆసᒾ㧘ศ᧛⍮ື㧘ᐔ಴⠹⍹㧘⍹ේᱜᔒ㧘ᓟ⮮ජኼ㧘દ⮮ༀⷙ㧚⢖߇ࠎᖚ⠪ߦ߅ߌࠆ Carboplatinᛩਈ㊂ߩ᳿ቯᣇᴺߣ೽૞↪⊒⃻ߦ㑐ߔࠆ retrospective study㧘ᣣᧄ∛㒮⮎೷Ꮷળ㔀⹹ 2008 ᐕ㧧44 Ꮞ㧦
428㧙431㧚
17㧕 ┄↰ᢅᄦ㧘㊁ਛᢅᴦ㧘⍫㊁⾆ਭ㧘૑᧛ᥓሶ㧘ᨋ⚐㧘દ⮮ༀⷙ㧘ᄢ⍹ੌਃ㧚᛫ MRSA ⮎ߩㆡᱜ૶↪ࠍ⋡ᜰߒߚ⮎‛ⴊਛỚᐲࡕ࠾࠲࡝ࡦࠣታᣉ₸ะ਄߳ߩขࠅ⚵ߺ㧘ᣣᧄ∛㒮⮎೷Ꮷળ㔀⹹ 2008 ᐕ㧧44 Ꮞ㧦277㧙280㧚
18㧕 ጟ቟િੑ㧘ਅ↰ᶈᰵ㧘♿ࡁቯ଻⤿㧘ᱞ↰⚐㧘ጊᧄ⋿↱⟤㧚ࠗࡦࠬ࡝ࡦߩ቟ో▤ℂߦ㑐ߔࠆ㔚ሶࠞ࡞࠹ᯏ⢻ߩ᦭↪ᕈߣ໧㗴ὐ㧘⢈ḩߣ♧ዩ∛ 2008 ᐕ㧧7 Ꮞ(೎ౠ)㧦28㧙35㧚
19㧕 ਅ↰ᶈᰵ㧘ጟ቟િੑ㧘♿ࡁቯ଻⤿㧘ᱞ↰⚐㧘ጊᧄ⋿↱⟤㧚㔚ሶࠞ࡞࠹ᖱႎ߆ࠄಽᨆߔࠆᄢቇ∛㒮ߩ♧ዩ∛∛᫟ᖚ⠪ߩ․ᓽಽᨆߩ⹜ⴕ㨪ᬺോࠍนⷞൻߔࠆ᦭↪ᕈߦߟ޿ߡ㨪㧘⢈ḩߣ♧ዩ∛ 2008 ᐕ㧧7 Ꮞ(೎ౠ)㧦
89㧙93㧚
20㧕 ਤ⠀㓉㧘ዊ᫪ༀᢥ㧘⍹ේᱜᔒ㧘㜞ᯅ㋈ઍ㧘᧻ᶆసᒾ㧘ᓟ⮮ජኼ㧘દ⮮ༀⷙ㧚࡝ࠬࠢ⹏ଔߦࠃࠆ⺞೷ㆊ⺋㒐ᱛኻ╷ߩ᦭ലᕈߩᬌ⸽㧘ᣣᧄ∛㒮⮎೷Ꮷળ㔀⹹ 2008 ᐕ㧧44 Ꮞ㧦1487㧙1490㧚
21㧕 ศ᧛⍮ື㧘ᐔ಴⠹⍹㧘㘵ේᄢ⒤㧘⍹ේᱜᔒ㧘ዊ᫪ༀᢥ㧘ጟ቟િੑ㧘᧻ᶆసᒾ㧘቟↰ᔘม㧘દ⮮ༀⷙ㧚Paclitaxelᛩਈᖚ⠪ߦ߅ߌࠆᛩਈ㊂࡮ᛩਈࠬࠤࠫࡘ࡯࡞ߦၮߠ޿ߚ೽૞↪⸃ᨆ㧘≸ߣൻቇ≮ᴺ 2008 ᐕ㧧35 Ꮞ㧦1721
㧙1726㧚
ේ⪺㧔᰷ᢥ㧕
1㧕 Iihara H, Suzuki T, Kawamura Y, Ohkusu K, Inoue Y, Zhang W, Shah MM, Katagiri Y, Ohashi Y, Ezaki
T. Emerging multiple mutations and high-level fluoroquinolone resistance in methicillin-resistant
Staphylococcus aureus isolated from ocular infections. Diagn Microbiol Infect Dis. 2006;56:297-303.
IF
2㧕 Masaki T, Ohkusu K, Hata H, Fujiwara N, Iihara H, Yamada-Noda M, Nhung PH, Hayashi M, Yuko
Asano Y, Kawamura Y, Ezaki T. Mycobacterium kumamotonense Sp. Nov. recovered from clinicalspecimen and the first isolation report of Mycobacterium arupense in Japan: Novel slowly growing,
nonchromogenic clinical isolates related to Mycobacterium terrae complex. Microbiol Immunol.
2006;50:889-897.
IF
3㧕 Yano T, Itoh Y, Matsuo M, Kawashiri T, Egashira N, Oishi R. Involvement of both tumor necrosis
factor-a-induced necrosis and p53-mediated caspase-dependent apoptosis in nephrotoxicity of cisplatin.
Apoptosis. 2007;12:1901-1909.
IF
4㧕 Shah MM, Iihara H, Noda M, Xiaosong S, Nhung P H, Ohkusu K, Kawamura Y, Ezaki T. DNAJ genesequence-based assay for species identification and phylogenetic grouping in the genus Staphylococcus.
Int J Syst Evol Microbiol. 2007;57:25-30.
IF
5㧕 Kato Z, Nakamura M, Funato M, Kuwabara H, Kondo N. Accidental etizolam ingestion in a child.
Pediatr Emerg Care. 2007;23:472-473
IF
6㧕 Suzuki T, Iihara H, Uno T, Hara Y, Ohkusu K, Hata H, Shudo M, Ohashi Y. Suture-related keratitis
caused by Corynebacterium macginleyi. J Clin Microbiol. 2007;45:3833-3836.
IF7㧕 Nhung PH, Shah MM, Ohkusu K, Noda M, Hata H, Sun XS, Iihara H, Goto K, Masaki T, Miyasaka J,
Ezaki T. The dnaJ gene as a novel phylogenetic marker for identification of Vibrio species. Syst Appl
Microbiol. 2007;30:309-315.
IF8㧕 Iihara H, Niwa T, Shah MM, Nhung PH, Song SX, Hayashi M, Ohkusa K, Itoh Y, Makino S, Ezaki T.
Rapid multiplex immunofluorescent assay to detect antibodies against Burkholderia pseudomallei andtaxonomically closely related nonfermenters. Jpn J Infect Dis. 2007;60:230-234.
IF

㧙㧙

2.448

1.295

3.043

2.384
0.581
3.708

2.514

1.074

9㧕 Wakahara T, Shiraki M, Murase K, Fukushima H, Matsuura K, Fukao A, Kinoshita S, Kaifuku N,
Arakawa N, Tamura T, Iwasa J, Murakami N, Deguchi T, Moriwaki H. Nutritional screening with
Subjective Global Assessment predicts hospital stay in patients with digestive disease. Nutrition.
2007;23:639-643.
10㧕 Ohmori T, Nakamura M, Tada S, Sugiyama T, Itoh Y, Udagawa Y, Hirano K. A highly sensitive assay
for ritodrine in human serum by hydrophilic interaction chromatography-tandem mass spectrometry.
J Chromatogr (B). 2008;861:95-100.
11㧕 Sobue S, Nemoto S, Murakami M, Ito H, Kimura A, Gao S, Furuhata A, Takagi A, Kojima T,
Nakamura M, Itoh Y, Suzuki M, Banno Y, Nozawa Y, Murate T. Implications of sphingosine kinase 1
expression level for the cellular sphingolipid rheostat; relevance as a marker for daunorubicin
sensitivity of leukemia cell. Int J Hematol. 2008;87:266-275.
12㧕 Aki T, Egashira N, Hama M, Yamauchi Y, Yano T, Itoh Y, Oishi R. Characteristics of gabexate
mesilate-induced cell injury in porcine aorta endothelial cells. J Pharmacol Sci. 2008;106:415-422.
13㧕 Aki T, Egashira N, Yamauchi Y, Hama M, Yano T, Itoh Y, Yamada T, Oishi R. Protective effects ofamino acids against gabexate mesilate–induced cell injury in porcine aorta endothelial cells. J
Pharmacol Sci. 2008;107:238-245.
14㧕 Yano T, Itoh Y, Yamada M, Egashira N, Oishi R. Combined treatment with L-carnitine and apan-caspase inhibitor effectively reverses amiodarone-induced injury in cultured human lungepithelial cells. Apoptosis. 2008;13:543-552.
15㧕 Matsuura K, Ohmori T, Nakamura M, Itoh Y, Hirano K. A simple and rapid determination of valproic
acid in human plasma using a non-porous silica column and liquid chromatography with tandem mass
spectrometric detection. Biomed Chromatogr. 2008;22:387-393.

IF 2.104

IF 2.935

IF 1.491
IF 2.408

IF 2.408

IF 3.043

IF 1.663

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦દ⮮ༀⷙ㧘⎇ⓥಽᜂ⠪㧦ᄢ⍹ੌਃ㧧⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦ࠪࠬࡊ࡜࠴ࡦ⣢㓚ኂߦኻߔࠆ⚦⢩ౝࠨࠗࠢ࡝࠶ࠢ AMP ࠍ੺ߔࠆ଻⼔૞↪ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 17㧙18 ᐕᐲ㧧3,600 ජ౞(2,500㧦1,100 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦ᄢ⍹ੌਃ㧘⎇ⓥಽᜂ⠪㧦દ⮮ༀⷙ㧧⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦࡛㧙࠼ㅧᓇ೷ߦࠃࠆ
⣢㓚ኂ⊒⃻ᯏᐨߩ⸃᣿ߣ੍㒐╷ߩ⏕┙㧧ᐔᚑ 17㧙18 ᐕᐲ㧧3,400 ජ౞(2,100㧦1,300 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦ᷓ๺ ടᄹ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ᅑബ⎇ⓥ㧦STEC ᴺߦࠃࠆ CYP2C9 ᄙဳ㜞ㅦᬌ಴♽ߩ TDM ߳ߩᔕ↪㧧ᐔᚑ 18 ᐕᐲ㧧480 ජ౞4㧕 ⎇ⓥઍ⴫⠪㧦દ⮮ༀⷙ㧘⎇ⓥಽᜂ⠪㧦ᄢ⍹ੌਃ㧧⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦⮎೷ߦࠃࠆⴊ▤㓚ኂߩ⊒⃻ᯏᐨ⸃᣿ߣ੍㒐࡮ᴦ≮╷ߩ⏕┙ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 19㧙20 ᐕᐲ㧧3,400 ජ౞(2,100㧦1,300
ජ౞)5㧕 ⎇ⓥઍ⴫⠪㧦ᄢ⍹ੌਃ㧘⎇ⓥಽᜂ⠪㧦દ⮮ༀⷙ㧧⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦᛫⩶⮎ߦࠃࠆ⣢㓚ኂ⊒⃻ᯏᐨߩ⸃᣿㧧ᐔᚑ 19㧙20 ᐕᐲ㧧3,400 ජ౞(2,100㧦1,300 ජ౞)
6㧕 ⎇ⓥઍ⴫⠪㧦㘵ේ ᄢ⒤㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ᅑബ⎇ⓥ㧦⢖≸ᖚ⠪ߢߩ Carboplatin ᛩਈ㊂᳿ቯߦ߅ߌࠆⴊᷡࠪࠬ࠲࠴ࡦ C ߩ᦭↪ᕈߩᬌ⸛㧧ᐔᚑ 20 ᐕᐲ㧧550 ජ౞7㧕 ⎇ⓥઍ⴫⠪㧦ᄢ᫪ ᥓผ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ᅑബ⎇ⓥ㧦LC-MS/MS ࠍ↪޿ߚ↢૕⹜ᢱ⋥ធᵈ౉ᴺߦࠃࠆ⮎‛ࡂࠗࠬ࡞࡯ࡊ࠶࠻ಽᨆ♽ߩ㐿⊒㧧ᐔᚑ 20 ᐕᐲ㧧550 ජ౞8㧕 ⎇ⓥઍ⴫⠪㧦ᓟ⮮ ජኼ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ᅑബ⎇ⓥ㧦ࡄࠢ࡝࠲ࠠ࠮࡞ߦࠃࠆᧃ᪳␹⚻㓚ኂߦኻߔࠆ−∩ᴦ≮೷ࡁࠗࡠ࠻ࡠࡇࡦߩ⥃ᐥ⎇ⓥ㧧ᐔᚑ 20 ᐕᐲ㧧400 ජ౞
2㧕ฃ⸤⎇ⓥ1㧕 ಴ญ㓉㧦⮎೷ࠍ฽᦭ߒߚน㘩ᕈࡈࠖ࡞ࡓߩ቟ቯᕈߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18 ᐕᐲ㧧100 ජ౞㧦(ᩣ)࠷ࠠ
ࠝࠞ
2㧕 ಴ญ㓉㧦⮎೷ࠍ฽᦭ߒߚੇ῎࠯࡝࡯⵾೷ߩ㐿⊒ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18㧙19 ᐕᐲ㧧600 ජ౞(ⶄᢙᐕᰴᄾ⚂)㧦(ᩣ)࠷ࠠࠝࠞ
3㧕 દ⮮ༀⷙ㧦⮎೷฽᦭ࡈࠖ࡞ࡓ⵾೷ߩ㐿⊒ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 19 ᐕᐲ㧧600 ජ౞㧦࠷ࠠࠝࠞ (ᩣ)
4㧕 દ⮮ༀⷙ㧦⮎೷฽᦭ࡈࠖ࡞ࡓ⵾೷ߩ㐿⊒ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 20 ᐕᐲ㧧800 ජ౞㧦࠷ࠠࠝࠞ (ᩣ)
3㧕౒ห⎇ⓥߥߒ㧙㧙5㧚⊒᣿࡮․⸵಴㗿⁁ᴫ1㧕 ජ⒳ᐽ৻㧘 ᩿⟵ඳ㧘᧖ጊᱜ㧘ਛ᧛శᶈ㧘ጟ቟િੑ㧦቟ోࠠࡖࡆࡀ࠶࠻(⊒᣿)㧧ᐔᚑ 18 ᐕ(․㐿
2006-122816)
2㧕 ᧻ᶆసᒾ㧘᧖ጊᱜ㧘 ᩿⟵ඳ㧘᦬ጟᔘᄦ㧘⷏᧛⟤૒↵㧦ౝ᦯⮎(⊒᣿)㧧ᐔᚑ 18 ᐕ(․㗿 2006-206725)
3㧕 ᄢ⍹ੌਃ㧘દ⮮ༀⷙ㧘ᳯ㗡િᤘ㧘⮮੗㇚㇢㧦᛫߇ࠎ೷ߦࠃࠆᧃ᪳␹⚻㓚ኂߩ੍㒐෶ߪシᷫ೷(⊒᣿)㧧
ᐔᚑ 20 ᐕ(․㗿 2008-65399)
6㧚ቇળᵴേ
1㧕ቇળᓎຬ
દ⮮ ༀⷙ㧦1㧕 ᣣᧄ⮎ℂቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄක≮⮎ቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ∛㒮⮎೷Ꮷળઍ⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄ⮎ቇળ᧲ᶏᡰㇱળᐙ੐(㨪⃻࿷)2㧕ቇળ㐿௅
દ⮮ ༀⷙ㧦1㧕 ╙ 29 ࿁ᣣᧄක≮⮎ቇળක≮⮎ቇ౏㐿ࠪࡦࡐࠫ࠙ࡓ(2007 ᐕ 3 ᦬㧘ጘ㒂)
3㧕ቇⴚ㔀⹹
દ⮮ ༀⷙ㧦1㧕 ᣣᧄ∛㒮⮎೷Ꮷળ㔀⹹࿾ၞ✬㓸ᆔຬ(㨪⃻࿷)7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳᧖ጊᱜ㧦
1㧕 ╙ 70 ࿁ᣣᧄᓴⅣེቇળ✚ળ࡮ቇⴚᄢળ(ᐔᚑ 18 ᐕ 3 ᦬㧘ฬฎደ ࠦࡔ࠺ࠖࠞ࡞࠮࠶࡚ࠪࡦࠪࡦࡐࠫ
࠙ࡓ‫ޟ‬ᓴⅣེ㗔ၞߩ⮎‛≮ᴺߦ߅ߌࠆ∛㒮ߣ⺞೷⮎ዪߣߩㅪ៤‫ޠ‬ᐳ㐳)2㧕 ╙ 69 ࿁਻Ꮊጊญ⮎ቇᄢળ(ᐔᚑ 18 ᐕ 9 ᦬㧘㣮ఽፉ㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯‫ޟ‬ᓟ⊒ක⮎ຠߦ߅ߌࠆຠ⾰ߩ㊀ⷐᕈ‫ޠ‬Ṷ⠪)
3㧕 ᧲੩ㇺዊᐔ࿾඙⮎೷Ꮷળ⎇ୃળ(ᐔᚑ 18 ᐕ㧘᧲੩㧘‫ޟ‬వ⊒ක⮎ຠߣᓟ⊒ක⮎ຠߩ⮎೷ቇ⊛Ꮕ⇣ߦߟ޿ߡ‫ޠ‬Ṷ⠪)ᓟ⮮ජኼ㧦
1㧕 ╙ 28 ࿁ POS ක≮ቇળᄢળ(ᐔᚑ 18 ᐕ 3 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬㔚ሶࠞ࡞࠹ᤨઍߦ߅ߌࠆ⸥㍳ߣࠕ࠙࠻ࠞࡓ⹏ଔ‫ޠ‬Ṷ⠪)᧻ᶆసᒾ㧦
1㧕 ╙ 1 ࿁⺞೷ᬺോㆡᱜൻ⎇ୃળ(ᐔᚑ 20 ᐕ㧘ᗲ⍮㧘‫⮎ޟ‬ዪߦ߅ߌࠆຠ⾰▤ℂߦߟ޿ߡ‫ޠ‬Ṷ⠪)
2㧕 ᐔᚑ 20 ᐕᐲ ጘ㒂⮎⑼ᄢቇ㒝ዻ⮎ዪ࡝ࠞ࡟ࡦ࠻⻠ᐳΣ(ᐔᚑ 20 ᐕ㧘ጘ㒂㧘‫✭ޟ‬๺ࠤࠕߦ߅ߌࠆ⮎೷Ꮷߩᓎഀ‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ1㧕 ᧖ጊᱜ㧦ᣣᧄක≮⮎ቇળᅑബ⾨(ᐔᚑ 19 ᐕᐲ)
9㧚␠ળᵴേદ⮮ༀⷙ㧦
1㧕 ጘ㒂⋵∛㒮⮎೷Ꮷળ೽ળ㐳(ᐔᚑ 20 ᐕᐲ)
2㧕 ጘ㒂⋵⮎೷Ꮷળℂ੐(ᐔᚑ 20 ᐕᐲ)
10㧚ႎ๔ᦠ
1㧕 દ⮮ༀⷙ㧦ࠪࠬࡊ࡜࠴ࡦ⣢㓚ኂߦኻߔࠆ⚦⢩ౝࠨࠗࠢ࡝࠶ࠢ AMP ࠍ੺ߔࠆ଻⼔૞↪ߦ㑐ߔࠆ⎇ⓥ㧦
ᐔᚑ 17 ᐕᐲ㧙18 ᐕᐲ⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)⎇ⓥᚑᨐႎ๔ᦠ(⎇ⓥಽᜂ⠪㧦ᄢ⍹ੌਃ)(ᐔᚑ 19
ᐕ 3 ᦬)㧙㧙

2㧕 ᄢ⍹ੌਃ㧦࡛㧙࠼ㅧᓇ೷ߦࠃࠆ⣢㓚ኂ⊒⃻ᯏᐨߩ⸃᣿ߣ੍㒐╷ߩ⏕┙㧦ᐔᚑ 17 ᐕᐲ㧙18 ᐕᐲ⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)⎇ⓥᚑᨐႎ๔ᦠ(⎇ⓥಽᜂ⠪㧦દ⮮ༀⷙ)(ᐔᚑ 19 ᐕ 3 ᦬)
11㧚ႎ㆏
1㧕 ᧖ጊᱜ㧦⮎ߩ㊂߿⒳㘃㧘PC ߇⼊๔ ⺞ว⋙ᩏࠪࠬ࠹ࡓ㐿⊒ ጘ㒂ᄢߥߤ㧦ᦺᣣᣂ⡞(2006 ᐕ 2 ᦬ 28
ᣣ)2㧕 દ⮮ༀⷙ㧦࠮࡜ࡒ࠼ߣ᛫߇ࠎ೷૞↪តࠆ㧦ጘ㒂ᣂ⡞(2007 ᐕ 8 ᦬ 28 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔ⥃ᐥ⮎೷ቇಽ㊁ߢߩᢎຬ߇ᢎ᝼એᄖߦ޿ߥ޿ߣ޿߁⁁ᴫࠍ⠨ᘦߔࠇ߫㧘޽ࠆ⒟ᐲߩ⎇ⓥᚑᨐ߇ᓧࠄࠇ
ߚߣ⠨߃ࠆ‫ߩߘޕ‬ඨ㕙㧘✚⺑߿⪺ᦠ╬ߩၫ╩ߪዋߥ޿‫ߦࠄߐޕ‬㧘ቇળ╬ߩ․೎⻠Ṷ߿ࠪࡦࡐࠫࠬ࠻ߣ޿
ߞߚᬺ❣߇ਇචಽߢ޽ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷⥃ᐥ⮎೷ቇಽ㊁ߦ߅ߌࠆᢎຬߪᢎ᝼ߩߺߢ޽ࠆߣ޿߁ᷓೞߥੱ᧚ਇ⿷ߦട߃㧘ᢎ᝼߇⮎೷ㇱ㐳ࠍ૬છߔࠆߚ߼㧘චಽߥ⎇ⓥᵴേ߇ⴕ߃ߡ޿ߥ޿ߩ߇⃻⁁ߢ޽ࠆ‫ߩߘޕ‬ኻᔕ╷ߣߒߡߪ㧘ઁಽ㊁ߣߩ౒ห⎇ⓥ
ߩផㅴ㧘ጘ㒂⮎⑼ᄢቇߣߩㅪ៤ࠍផㅴߔࠆᔅⷐ߇޽ࠆ‫ޕ‬੹ᓟߩዷᦸߎࠇ߹ߢታᣉߒߡ߈ߚක⮎ຠߩᣂⷙ೷ဳ㐿⊒㧘ຠ⾰▤ℂ⹜㛎㧘ᣂⷙቯ㊂ᴺߩ㐿⊒╬ߩ⮎೷ቇ⊛⎇ⓥࠍ
ၮ␆ߥࠄ߮ߦ⥃ᐥߩਔಽ㊁ߢዷ㐿ߐߖࠆߣߣ߽ߦ㧘⥃ᐥ⃻႐ߦߡㆣㆄߔࠆක⮎ຠ᦭ኂ੐⽎ߦ㑐ࠊࠆ⊒⃻ࡔࠞ࠾࠭ࡓࠍ⸃᣿ߒ㧘᦭ലߥᴦ≮߽ߒߊߪ੍㒐ኻ╷ࠍ┙᩺ߔࠆߚ߼ߩၮ␆ߥࠄ߮ߦ⥃ᐥ⎇ⓥࠍዷ㐿ߔࠆ‫ޕ‬৻ᣇ㧘ᐔᚑ 21 ᐕᐲߦⴕࠊࠇࠆጘ㒂⮎⑼ᄢቇᣂቇ⥡ߩᧄቇࠠࡖࡦࡄࠬౝ߳ߩ⒖ォࠍᯏߦ⮎⑼ᄢቇߣߩᢎ⢒ߥࠄ߮ߦ⎇ⓥ㕙ߢߩㅪ៤ࠍᒝൻߒ㧘ഃ⮎࡮⢒⮎ߩߚ߼ߩၮ␆ߥࠄ߮ߦ⥃ᐥ⎇ⓥࠍផㅴߔࠆ‫ޕ‬㧙㧙㧔4㧕ක≮⚻ᷣቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
ᧄಽ㊁ߢߪല₸ᕈ߿౏ᐔᕈߥߤߩⷰὐ߆ࠄ⾗Ḯ㈩ಽ໧㗴ࠍ⠨߃ࠆ⚻ᷣቇࠍߪߓ߼㧘∉ቇ㧘ᔃℂ᷹ቯ╬ߩᣇᴺ⺰ࠍ↪޿ߡ㧘ᦸ߹ߒ޿଻ஜක≮ࠪࠬ࠹ࡓߩ޽ࠅᣇࠍ␜ߔߎߣࠍ⋡⊛ߣߒ㧘ᄢ߈ߊක≮᡽╷෸߮ක≮⹏ଔߦ㑐ߔࠆએਅߩ⎇ⓥࠍⴕߞߡ޿ࠆ‫ޕ‬1㧕ක≮ߦ߅ߌࠆ↢↥ᕈ෸߮ല₸ᕈߦ㑐ߔࠆ⎇ⓥ
ක≮ߦ߅ߌࠆ↢↥ⷐ⚛ߣ↢↥‛ࠍ᣿ࠄ߆ߦߒ㧘ߘࠇࠄࠃࠅ↢↥ᕈᜰᮡ෸߮ല₸ᕈᜰᮡߩ▚಴ࠍⴕ޿㧘ߘߩᓇ㗀ⷐ࿃ࠍ᣿ࠄ߆ߦߔࠆߣߣ߽ߦ㧘ක≮ߩࡄࡈࠜ࡯ࡑࡦࠬᜰᮡ߳ߩᔕ↪ࠍ⎇ⓥߒߡ޿ࠆ‫ߦ․ޕ‬㧘ᕆᕈᦼ∛㒮ߦ᳞߼ࠄࠇࠆ࿷㒮ᣣᢙߩ⍴❗ൻߣක≮ߦ߅ߌࠆ⾰ࠍ෻ᤋߢ߈ࠆࡄࡈࠜ࡯ࡑࡦࠬᜰᮡߩ㐿⊒ࠍ⋡ᮡߣߒߡ޿ࠆ‫ޕ‬2㧕ㆮવሶ⸻ᢿߩ㔛ⷐಽᨆ⎇ⓥ
ฦ⒳ㆮવሶ⸻ᢿߦߟ޿ߡ㧘ߘߩ㔛ⷐଔᩰߩផቯߣ㔛ⷐߦᓇ㗀ߔࠆⷐ࿃ߦߟ޿ߡ⎇ⓥߒߡ޿ࠆ‫ޕ‬
3㧕⸻≮ౝኈ࡮ක≮⾌ಽᨆ⎇ⓥ࡟࠮ࡊ࠻ᖱႎ╬ߩ⥃ᐥ∉ቇ⎇ⓥ߳ߩᔕ↪㧘෸߮㧘ක≮⾌࠺࡯࠲ߩ․ᕈߦᔕߓߚಽᨆᚻᴺࠍ⎇ⓥߒߡ޿ࠆ‫ޕ‬
4㧕੍㒐ක≮ߦኻߔࠆ⾌↪ኻലᨐಽᨆ⎇ⓥ
ᗵᨴ∝ࡢࠢ࠴ࡦ㧘․ቯ଻ஜᜰዉ╬ߩ৻ᰴ੍㒐ߦኻߔࠆ⾌↪ኻലᨐಽᨆߦߟ޿ߡ⎇ⓥߒߡ޿ࠆ‫ޕ‬2㧚ฬ★
ᢎ᝼(૬છ)㧦
ಎᢎ᝼㧦

᳗↰⍮㉿
㜞Ⴆ⋥⢻

Chisato Nagata
Naoyoshi Takatsuka

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 㜞Ⴆ⋥⢻㧚ක≮ኾ㐷⡯ߩߚ߼ߩක≮⚻ᷣቇ㧦ක≮⚻༡ᢎ⢒ද⼏ળ✬㧚ක≮ࡑࡀࠫࡔࡦ࠻㧘᧲੩㧦ᣣ⚻ࡔ࠺ࠖࠞ࡞㐿⊒㧧2008 ᐕ㧦58㧙82.
⪺ᦠ㧔᰷ᢥ㧕
∉ቇ࡮੍㒐කቇಽ㊁ෳᾖ✚⺑㧔๺ᢥ㧕
∉ቇ࡮੍㒐කቇಽ㊁ෳᾖ✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 㜞Ⴆ⋥⢻㧘⷏᧛๟ਃ㧚౉㒮ක≮ࠨ࡯ࡆࠬߩ↢↥ᕈ⹏ଔߦ↪޿ࠆࠕ࠙࠻ࡊ࠶࠻ᜰᮡߩᅷᒰᕈ⹏ଔ㧙৻ᐥᒰߚࠅᐕ㑆ㅌ㒮ᖚ⠪ᢙߣ∛ᐥ೑↪₸ߩᲧセ㧙㧘∛㒮▤ℂ 2006 ᐕ㧧43 Ꮞ㧦103㧙115㧚
2㧕 ጯ↰⎇૞㧘ᩑේᶈ᣿㧘㜞Ⴆ⋥⢻㧘ᓟ⮮ബ㧚ㆇേ⠌ᘠ㧘▵㈬⠌ᘠ㧘⦟޿㘩੐⠌ᘠߩታ〣ߦᓇ㗀ߔࠆⷐ࿃ߩಽ
ᨆ㧘ක≮ߣ␠ળ 2007 ᐕ㧧17 Ꮞ㧦329㧙338㧚
3㧕 㜞Ⴆ⋥⢻㧘⷏᧛๟ਃ㧚ࠝ࡯࠳࡝ࡦࠣࠪࠬ࠹ࡓ߇∛㒮↢↥ᕈ㧘ല₸ᕈߦ෸߷ߔᓇ㗀ߩ⹏ଔ㧘ක≮⚻ᷣ⎇ⓥ
2008 ᐕ㧧20 Ꮞ㧦15㧙33.
ේ⪺㧔᰷ᢥ㧕
∉ቇ࡮੍㒐කቇಽ㊁ෳᾖ

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄∉ቇ࡮੍㒐කቇಽ㊁ෳᾖ
2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥߥߒ㧙㧙5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬ
᳗↰⍮㉿㧦∉ቇ࡮੍㒐කቇಽ㊁ෳᾖ
2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳᳗↰⍮㉿㧦∉ቇ࡮੍㒐කቇಽ㊁ෳᾖ㜞Ⴆ⋥⢻㧦
1㧕 ጘᄢ࡮ච౐↥ቇㅪ៤ක≮⚻༡ࠪࡦࡐࠫ࠙ࡓ(2007 ᐕ 6 ᦬㧘ጘ㒂㧘‫ޟ‬ା㗬ߐࠇࠆ∛㒮ߣߪ‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ᳗↰⍮㉿㧦∉ቇ࡮੍㒐කቇಽ㊁ෳᾖ
9㧚␠ળᵴേ㜞Ⴆ⋥⢻㧦
1㧕 ጘ㒂⋵଻㒾⠪ද⼏ળ(ක≮⾌ಽᨆ⋧⺣)(㨪⃻࿷)2㧕 ጘ㒂⋵࿖଻ㅪวળ↢ᵴ⠌ᘠ∛੍㒐ኻ╷ᬌ⸛ᆔຬળ(ࠕ࠼ࡃࠗࠩ࡯)(㨪⃻࿷)3㧕 ጘ㒂⋵ᓟᦼ㜞㦂⠪ක≮ᐢၞㅪวㆇ༡ᙣ⹤ળᆔຬ(㨪⃻࿷)4㧕 ෘ↢ഭ௛⋭ ․ቯஜ⸻࡮․ቯ଻ஜᜰዉߦ㑐ߔࠆᬌ⸛ળ ᴦ≮ਛߩ⠪ߦኻߔࠆ଻ஜᜰዉߩലᨐߦ㑐ߔࠆ WG ᆔຬ(㨪⃻࿷)᳗↰⍮㉿㧦∉ቇ࡮੍㒐කቇಽ㊁ෳᾖ
10㧚ႎ๔ᦠ
1㧕 ጊᧄ⋿↱⟤㧘♿ࡁቯ଻⤿㧘㋈ᧁᐽਯ㧘㜞Ⴆ⋥⢻㧦ක≮ᖱႎ▤ℂࠪࠬ࠹ࡓߣ⸻ᢿࡕ࠺࡞㧙♧ዩ∛㧙㧦
ᐔᚑ 17 ᐕᐲ⚻ᷣ↥ᬺ⋭ක≮⚻༡ੱ᧚⢒ᚑᢎ⢒ࡊࡠࠣ࡜ࡓ㐿⊒ࡊࡠࠫࠚࠢ࠻ታ❣ႎ๔ᦠ(㜞ᐲක≮ᢎ⢒ࠦࡦ࠰࡯ࠪࠕࡓ(ઍ⴫࡮ጊᧄኈᱜ(ᄢ㒋ᄢቇ)))㧦141㧙176(2006 ᐕ 3 ᦬)
2㧕 ੹੗⼾㧘㜞Ⴆ⋥⢻㧘ᄢᣣᐽผ㧦࠹ࠠࠬ࠻ ╙ 1 ┨ක≮⚻ᷣቇߩၮ␆⍮⼂㧦ᐔᚑ 17 ᐕᐲ⚻ᷣ↥ᬺ⋭ක≮⚻༡ੱ᧚⢒ᚑᢎ⢒ࡊࡠࠣ࡜ࡓ㐿⊒ࡊࡠࠫࠚࠢ࠻ታ❣ႎ๔ᦠ(㜞ᐲක≮ᢎ⢒ࠦࡦ࠰࡯ࠪࠕࡓ(ઍ⴫࡮ጊᧄኈᱜ(ᄢ㒋ᄢቇ)))㧦191㧙240(2007 ᐕ 3 ᦬)
3㧕 㜞Ⴆ⋥⢻㧘Ꮉญ㗅ᢘ㧘㜞ᯅቁᄦ㧘♿ࡁቯ଻⤿㧘ጊᧄ⋿↱⟤㧦ࠤ࡯ࠬᢎ᧚ ᕆᕈᦼ∛㒮⚻༡ߦ߅ߌࠆ
∛ᐥࡑࡀࠫࡔࡦ࠻㧙․ቯᯏ⢻∛㒮ᶖൻེᄖ⑼ߩࠤ࡯ࠬ㧙㧦ᐔᚑ 17 ᐕᐲ⚻ᷣ↥ᬺ⋭ක≮⚻༡ੱ᧚⢒ᚑᢎ⢒ࡊࡠࠣ࡜ࡓ㐿⊒ࡊࡠࠫࠚࠢ࠻ታ❣ႎ๔ᦠ(㜞ᐲක≮ᢎ⢒ࠦࡦ࠰࡯ࠪࠕࡓ(ઍ⴫࡮ጊᧄኈᱜ(ᄢ㒋ᄢቇ)))㧦578㧙619(2007 ᐕ 3 ᦬)
4㧕 㐳ἑᷡ㧘㜞Ⴆ⋥⢻㧘♿ࡁቯ଻⤿㧘ጊᧄ⋿↱⟤㧦ᕆᕈᦼ∛㒮⚻༡ߦ߅ߌࠆᚻⴚㇱࡑࡀࠫࡔࡦ࠻=․ቯᯏ
⢻∛㒮ᚻⴚቶߩࠤ࡯ࠬ=㧦ᐔᚑ 19 ᐕᐲ⚻ᷣ↥ᬺ⋭ࠨ࡯ࡆࠬ↥ᬺੱ᧚⢒ᚑ੐ᬺ ∛㒮ᬺോࡑࡀࠫࡔࡦ
࠻ߦ㑐ߔࠆࠤ࡯ࠬࠬ࠲࠺ࠖᢎ᧚㐿⊒ࡊࡠࠫࠚࠢ࠻ႎ๔ᦠ(ઍ⴫࡮ጊᧄ⋿↱⟤)(2008 ᐕ 3 ᦬)
11㧚ႎ㆏∉ቇ࡮੍㒐කቇಽ㊁ෳᾖ㧙㧙

12㧚⥄Ꮖ⹏ଔ
⹏ଔ
ᬺ❣Ⓧ਄ߍߣࡑࡦࡄࡢ࡯㧘⎇ⓥ⾌ߩ⏕଻ࠍ⋡ᜰߔᔅⷐ߇޽ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ࡑࡦࡄࡢ࡯ߦ㒢ࠅ߇޽ࠆߚ߼㧘ᄢቇ㒮ᢎ⢒ࠍㅢߒߡቇ↢ߩ⥝๧ࠍ༐⿠ߒ㧘ߎߩಽ㊁ߦ៤ࠊࠆ⠪ࠍ⢒ߡߡ޿߈ߚ޿‫ߚ߹ޕ‬ක≮⾌╬ߩ࠺࡯࠲߳ߩࠕࠢ࠮ࠬߪ㒢ࠄࠇߡ޿ࠆߚ߼㧘ߘߩ⏕଻߇ᦨ㊀ⷐ⺖㗴ߢ޽ࠆ‫ޕ‬ߘߩ㓙㧘୘ੱᖱႎ଻⼔ߦ⇐ᗧߔࠆߎߣߪ൩⺰ߩߎߣߢ޽ࠆ‫ߪߦࠄߐޕ‬᰷ᢥ⺰ᢥࠍჇ߿ߔᔅⷐ߇޽ࠆ‫ᧄޕ‬
ಽ㊁ߩ⎇ⓥߪක≮೙ᐲߦ〯ߺㄟ߻ߚ߼⺰ᢥౝኈ߇࿖ౝߦ㒢ቯߐࠇࠆ௑ะ߇޽ࠆ߇㧘᰷ᢥ⹹߳ߩᛩⓂࠍ⛮⛯⊛ߦⴕ߁੍ቯߢ޽ࠆ‫ޕ‬੹ᓟߩዷᦸක≮ࠬ࠲࠶ࡈਇ⿷ߦࠃࠆක≮፣უ߇ต߫ࠇࠆࠃ߁ߦߥߞߡ㧘࿖ߪක≮⾌ᛥ೙ߩᣇ㊎ࠍᡷ߼ࠆߎߣߣߥ
ߞߚ‫ࠄ߇ߥߒ߆ߒޕ‬㧘⚻ᷣߩవⴕ߈ߪਇㅘ᣿ߢ޽ࠅ㧘੹ᓟ߽ක≮⽷Ḯߩ⏕଻ߦߪਇ⏕ቯⷐ⚛߇ઃ߈߹ߣ
߁߽ߩߣᕁࠊࠇࠆ‫ޕ‬᡿ߦ㧘㜞㦂ൻߣක≮ߩ⾰߳ߩᏗ᳞߇ㅴዷߔࠆ㒢ࠅ㧘ක≮ߦኻߔࠆ⚻ᷣ⊛ಽᨆⷞὐߩ
㊀ⷐᕈߪߎࠇ߆ࠄ߽㜞߹ߞߡ޿ߊ߽ߩߣ⠨߃ࠄࠇࠆ‫ޕ‬
ᧄಽ㊁ߪ౨㗡ߦㅀߴߚߣ߅ࠅ㧘ක≮᡽╷ߣක≮⹏ଔߦ㑐ߔࠆ⎇ⓥࠍਥ૕ߣߒߡ޿ࠆ‫੹ޕ‬ᓟߪකቇ♽⎇ⓥ⑼ߦ޽ࠆ೑ὐࠍࠃࠅ↢߆ߒ㧘⥃ᐥಽ㊁ߣߩ౒ห⎇ⓥࠍჇ߿ߒߡ޿߈ߚ޿‫ޕ‬හߜක≮ᛛⴚ߿࿾ၞක≮ឭଏ૕೙ߩ޽ࠅᣇ╬ߦߟ޿ߡࠛࡆ࠺ࡦࠬࠍ␜ߒߡ޿߈㧘଻ஜක≮᡽╷෸߮ක≮⃻႐߳ߩᖱႎㆶరࠍㅴ߼ߡ
޿ߊᚲሽߢ޽ࠆ‫ޕ‬㧙㧙㧔5㧕ᢇᕆ࡮ἴኂකቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
ᄖ⊛ଚⷅ೙ᓮߦߟ޿ߡၮ␆⎇ⓥ㧘⥃ᐥ⎇ⓥࠍㅢߓߡ㧘࿖㓙⊛ߦㅢ↪ߔࠆ⥄┙ߒߚ⎇ⓥ⠪ࠍ⢒ᚑߔࠆߎߣ
ࠍ⋡⊛ߣߔࠆ‫ౕޕ‬૕⊛ߥ࠹࡯ࡑߣߒߡߪ㧘ᄖ்㧘࡚ࠪ࠶ࠢ㧔฽߻ᢌⴊ∝㧕㧘ᢇᕆ៝ㅍ㧘ᢇᕆක≮ᖱႎߥߤߦߟ޿ߡߩ⥃ᐥኾ㐷ಽ㊁ߦ߅ߌࠆ⸻ᢿ㧘ᴦ≮ߦ㑐ߔࠆ߽ߩ߿㧘ᢇᕆකቇ㗔ၞߦ߅ߌࠆᄖ்㧘ᢌⴊ∝ߥߤߩᄖ⊛ଚⷅߩታ㛎ࡕ࠺࡞ࠍ૞ᚑߒߡၮ␆⊛ߥ⍮⷗ࠍᓧࠆ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
ಎᢎ᝼㧦
ಎᢎ᝼㧦
⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦

ዊୖ⌀ᴦ
⼾↰ ᴰ
ዊႮା੺
⊕੗㇌ඳ
㊄↰⧷Ꮘ
ศ↰⋭ㅧ
ᾢ↰ᕺ੺
ᷰㆺፏ㊂
ศ↰㓉ᶈ
Ⴧ↰೰ብ
㐳ደ⡡৻㇢
㥲⮮ผᦶ
࿯੗ᥓ┨
ട⮮ਭ᥏
ฬ⍮ ␽
᧻෹዁⚐
⧯ේ๺ᒾ
᪀ේ⑲ᰴ
⍹㤥శ♿
ਛፉ⾫ᙗ
ർᎹ㗅৻
ਛ㊁ᔒ଻
ศ⋿ ቁ
ᮮጊߜߪࠆ
ጊ↰ᴺ㗼
┻↰ ໪

Shinji Ogura
Izumi Toyoda
Shinsuke Ojio
Kunihiro Shirai
Hidemi Kanada
Shouzo Yoshida
Keisuke Kumada
Takatomo Watanabe
Takahiro Yoshida
Takahiro Masuda
Souitiro Nagaya
Shiro Saito
Tomoaki Doi
Katou Hisaaki
Shou Nachi
Masasumi Matutomo
Kazuhiko Wakahara
Shuji Kuwabara
Mitunori Ishiguro
Masanori Nakashima
Junichi Kitagawa
Shiho Nakano
Takashi Yoshizane
Chiharu Yokoyama
Noriaki Yamada
Hiromu Takeda

(ᓴⅣ∛ᘒቇ)(ᓴⅣ∛ᘒቇ)(ᢛᒻᄖ⑼ቇ)(ዊఽ∛ᘒቇ)(ᓴⅣ∛ᘒቇ)(㜞ᐲవㅴᄖ⑼ቇ)(㜞ᐲవㅴᄖ⑼ቇ)(ᢛᒻᄖ⑼ቇ)(ዊఽ∛ᘒቇ)(⣖␹⚻ᄖ⑼ቇ)(ᶖൻེ∛ᘒቇ)(ᶖൻེ∛ᘒቇ)(ᓴⅣ∛ᘒቇ)(ᓴⅣ∛ᘒቇ)

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ዊୖ⌀ᴦ㧚๭ๆེ♽∔ᖚ㧙᳇㆏⇣‛㧙㧦ᄢ㒋㧦MC ࡔ࠺ࠖࠞ಴ 㧧2006 ᐕ㧦196㧙203㧚
2㧕 ጊ↰ታ⾆ੱ㧘⼾↰ᴰ㧘ศ᧛⚩৻㧘ጤ㑆੧㧘ᅏኹᢘ㧘ዊୖ⌀ᴦ㧚ኾ㐷කߦ᳞߼ࠄࠇࠆᦨᣂߩ⍮⼂㧨⣖ⴊ▤㓚ኂ㧪⣖තਛᢇᕆߦ߅ߌࠆ⣖තਛೋᦼ⸻≮(ISLS)ࠦ࡯ࠬߩ㊀ⷐᕈ㧦᧲੩㧦ࡔ࠺ࠖࠞ಴ 㧧2007 ᐕ㧦945㧙952㧚
3㧕 ᾢ↰ᕺ੺㧚੹ᣣߩᴦ≮ᜰ㊎㧙๭ๆ♽ߩ✕ᕆಣ⟎ ᳇▤ᝌ▤ᴺ㧙㧦᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦78㧙80㧚
4㧕 ⼾↰ᴰ㧚ߔߋߦᓎ┙ߟ⣖␹⚻ᄖ⑼ᢇᕆࡂࡦ࠼ࡉ࠶ࠢ㧙CHAPTER3 ✕ᕆᴦ≮‫ޟ‬㜞૕᷷‫ޠ‬‫ޟ‬ૐ૕᷷‫ޠ‬㧦᧲੩㧦ࡔ࠺ࠖࠞ಴ 㧧2008 ᐕ㧦302㧙307㧚
5㧕 ᾢ↰ᕺ੺㧘⼾↰ᴰ㧘ዊୖ⌀ᴦ㧘⑔↰లብ㧚㗡ㇱᄖ்㧦᦬ೀ࡟ࠫ࠺ࡦ࠻㧘᧲੩㧦කቇ಴ 㧧2008 ᐕ㧦29㧙34㧚
‫ߣ߽ߟ޿ޟ‬㆑߁‫ߣޠ‬㕙ળ⠪߇⸷߃ߚᄛ㧘ᖚ⠪ߪᕆᄌ㧘ᔃ஗ᱛߦ㧙⋴⼔Ꮷ㧘⎇ୃකߩߚ߼ߩᕆᄌኻ
6㧕 ᾢ↰ᕺ੺㧚ᔕ 101 ߩ㋕ೣ㧙㧘᧲੩㧦ᾖᨋ␠㧧2008 ᐕ㧦46㧙47㧚
7㧕 ዊୖ⌀ᴦ㧚߳߈࿾࡮㔌ፉߩ޽ࠆㇺ㆏ᐭ⋵ߩᢇᕆක≮૕೙ߩ⃻⁁ߣ޽ࠅᣇ㧙ᢇᕆක≮ᡷ㕟㧙ᓎഀಽᜂ㧘ㅪ៤㧘㓸⚂ൻߣಽᢔ㧙㧘᧲੩㧦᧲੩ᴺ઎಴ 㧧2008 ᐕ㧦75㧙87㧚
8㧕 ኹᧄ⾆⧷㧘ዊୖ⌀ᴦ㧚㜞ᰴᢇ๮ᢇᕆ㧦ዊఽ⑼ቇ ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦259㧙265㧚
9㧕 ᾢ↰ᕺ੺㧚੹ᣣߩᴦ≮ᜰ㊎㧙๭ๆ♽ߩ✕ᕆಣ⟎ ᳇▤ᝌ▤ᴺ㧙㧦᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦78㧙80㧚
10㧕 ㊄↰⧷Ꮖ⋙⸶㧚ACLS ࡊࡠࡃࠗ࠳㧙ࡑ࠾ࡘࠕ࡞ AHA ࠟࠗ࠼࡜ࠗࡦ 2005 ᐕḰ᜚ᣣᧄ⺆ 㧘᧲੩㧦ᩣᑼળ␠ࠪ࠽ࠫ㧙㧧2008 ᐕ㧦199㧙210㧚
11㧕 ዊୖ⌀ᴦ㧚ᢛᒻᄖ⑼࡮ᒻᚑᄖ⑼ᚻⴚ߅ࠃ߮ᾲ்ߩ✕ᕆ㤗㈮ ✕ᕆ㤗㈮ߩᔃᓧ㧙ߎߎ߇⢄ᔃ࡮߅ߐ߃ߤߎ㧍㧙㧘᧲੩㧦స⺈ၴ಴ 㧧2008 ᐕ㧦117㧙137㧚
12㧕 ᾢ↰ᕺ੺㧘⼾↰ᴰ㧘ዊୖ⌀ᴦ㧘⑔↰లብ㧚㗡ㇱᄖ்㧦᦬ೀ࡟ࠫ࠺ࡦ࠻㧘᧲੩㧦කቇ಴ 㧧2008 ᐕ㧦29㧙34㧚㧙㧙

13㧕 ዊୖ⌀ᴦ㧚߳߈࿾࡮㔌ፉߩ޽ࠆㇺ㆏ᐭ⋵ߩᢇᕆක≮૕೙ߩ⃻⁁ߣ޽ࠅᣇ㧙ᢇᕆක≮ᡷ㕟㧙ᓎഀಽᜂ‫ޔ‬ㅪ៤‫ޔ‬㓸⚂ൻߣಽᢔ㧙㧘᧲੩㧦᧲੩ᴺ઎಴ 㧧2008 ᐕ㧦75㧙87㧚
14㧕 ኹᧄ⾆⧷㧘ዊୖ⌀ᴦ㧚㜞ᰴᢇ๮ᢇᕆ ዊఽ⑼ቇ ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦259㧙265㧚⪺ᦠ㧔᰷ᢥ㧕
1㧕 ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 ዊୖ⌀ᴦ㧚SIRS㧘ATΥ㧙SAC ߩᴦ≮ᚢ⇛㧙㧘Pharma Medica ೎ౠ 2006 ᐕ㧧70㧙79㧚
2㧕 ⊕੗㇌ඳ㧚⣺▤ᯏ⢻߆ࠄߺߚ㊀∝ᕆᕈ⤟Ἳߦኻߔࠆ㓸ቇ⊛ᴦ≮㧘ᣣᧄ⣻ㇱᢇᕆකቇળ㔀⹹ 2006 ᐕ㧧26
Ꮞ㧦2㧚
3㧕 ዊୖ⌀ᴦ㧚ᢇ๮ක≮㧙᷷᡿⍮ᣂ㧙㧘ጘ㒂⋵කᏧળකቇ㔀⹹ 2006 ᐕ㧧19 Ꮞ㧦59㧙61㧚
4㧕 ዊୖ⌀ᴦ㧚ታ〣 ᢇᕆක≮㧙╙Τ┨ ᢇᕆಣ⟎㧙࠺ࡊ࡝࠼ࡑࡦ㧘ᣣᧄකᏧળ㔀⹹ 2006 ᐕ㧧135 Ꮞ㧦82
㧙83㧚
5㧕 ዊୖ⌀ᴦ㧚ࡃࠗࠝ࠹ࡠⵍἴ⠪ߩᕆᕈᦼࠤࠕߩᜰ㊎㧘ᢇᕆ࡮㓸ਛᴦ≮ࠞࠗ࠼࡜ࠗࡦ 2006 ᐕ㧧18 Ꮞ㧦792
㧙793㧚
6㧕 ട⮮ਭ᥏㧘ዊୖ⌀ᴦ㧚ᢌⴊ∝㧘medicina 2006 ᐕ㧧43 ᏎჇೀภ㧦535㧙538㧚
7㧕 ⋧ᒁ⋿ᐘ㧘ዊୖ⌀ᴦ㧚㑐໪テ㧚᪢၂ୃ㧚࡚ࠪ࠶ࠢߦ߅ߌࠆ⥄ᓞ␹⚻♽ߩᓎഀ㧘ICU ߣ CCU 2006 ᐕ㧧29
Ꮞ㧦1015㧙1023㧚
8㧕 ጟᧄᅢม㧘ዊୖ⌀ᴦ㧚ၮ␆∔ᖚߦኻߔࠆᴦ≮㧘ᣣᧄⴊᩖᱛⴊቇળ⹹ 2006 ᐕ㧧17 Ꮞ㧦294㧙297㧚
9㧕 ዊୖ⌀ᴦ㧚∛ᘒ೎ߦߺߚ DIC ߩ⸻ᢿߣᴦ≮㧘ᴦ≮ቇ 2007 ᐕ㧧41 Ꮞ㧦249㧙251㧚
10㧕 ᾢ↰ᕺ੺㧘⼾↰ᴰ㧘ዊୖ⌀ᴦ㧘⑔↰లብ㧚ᶖ㒐㒐ἴࡋ࡝ߩ㒢⇇ߣ࠼ࠢ࠲㧙ࡋ࡝ߣߩදജ૕೙ߩ᭴▽ߦߟ޿ߡ㧙ᧄ㇌ߦ߅ߌࠆᢇᕆࡋ࡝ᵴേߣߘߩዷᦸ㧘ᣣᧄ⥶ⓨක≮ቇળ㔀⹹ 2008 ᐕ㧧9 Ꮞ㧦1㧙5㧚✚⺑㧔᰷ᢥ㧕1㧕 ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ౎ᐈ๺ᙗ㧘᧻ᯅᑧᄈ㧘ട⮮㓷ᐽ㧘ዊୖ⌀ᴦ㧚㊀∝ᗵᨴ∝ᓟߦ⊒∝ߒߚ⣺⣶╭⤥∴ߩ 2 ଀㧘ᣣᧄᄖ⑼♽ㅪวቇળ⹹ 2006 ᐕ㧧31 Ꮞ㧦253㧙257㧚
2㧕 ⼾↰ ᴰ㧘ട⮮ਭ᥏㧘᧻ᯅᑧᄈ㧘⊕੗㇌ඳ㧘㊄↰⧷Ꮘ㧘ዊୖ⌀ᴦ㧘ጟ↰⋿ੱ㧚ጘ㒂ᄢቇ∛㒮ߦ߅ߌࠆ㒐ἴࡋ࡝ߩ࠼ࠢ࠲࡯ࡋ࡝⊛ᵴ↪ߩ⃻⁁㧙Using of Fire fighting Helicopters Performed a Doctor Helicopter
in Gifu University Hospital㧙㧘ᣣᧄ⥶ⓨක≮ቇળ㔀⹹ 2006 ᐕ㧧7 Ꮞ㧦12㧙15㧚
3㧕 ጊ↰ ᔀ㧘ㄭ⮮ᶈผ㧘࿯੗ᥓ┨㧘દ⮮ᘕ৻㧘ጊᧄ⋥᮸㧘ᳯේ⧷ବ㧘ධ㙚 ⻞㧘⍹ේ ື㧘಴ญ 㓉㧚Vascularaccess intervention therapy ߩᣧᦼᣉⴕߪ‫ߩ࠻ࡦࡖࠪޔ‬ᕆᕈ㐽㎮ߣౣᑪⴚࠍᷫዋߐߖࠆ߆㧫㧘ᴲዩ♿ⷐ
2006 ᐕ㧧52 Ꮞ㧦699㧙703㧚
4㧕 ട⮮ ብ㧘ᧁ᧛ᤘᄦ㧘૒‫ᧁޘ‬੫㧘㊄ሶ⋥ਯ㧘ᱞ↰ቬ๺㧘㋈ᧁ ᔘ㧘ፉፒୃᰴ㧘⪤ේ┨ཅ㧘ዊୖ⌀ᴦ㧘Ḵญ㓉ม㧘᧻ጟື਽㧘ዊ㊁⑲ᢥ㧘᧻ᶆ⻞ੑ㧘᧻ፉ৻⧷㧚ά✢਄㛽்ਇฬ⍎ߥ㗖㜑៊்(SCIWORA)ߦ㑐ߔࠆᄙᣉ⸳ᓟࠈะ߈⺞ᩏ㧘ᣣᧄᄖ்ቇળ⹹ 2006 ᐕ㧧20 Ꮞ㧦333㧙339㧚
5㧕 ዊୖ⌀ᴦ㧚ጘ㒂ဳᢇᕆἴኂකቇࡋ࡝ࠍ↪޿ߚࡔ࠺ࠖࠞ࡞ࠦࡦ࠻ࡠ࡯࡞㧘∛㒮೨ᢇᕆ⸻≮⎇ⓥળ⹹ 2006
ᐕ㧧1 Ꮞ㧦47㧙55㧚
6㧕 ዊୖ⌀ᴦ㧘ઁቇⴚᮡḰൻᆔຬ㧚EBM ߦၮߠߊ DIC ࠟࠗ࠼࡜ࠗࡦ૞ᚑߦะߌߡߩ⺞ᩏ⎇ⓥ㧘ᣣᧄⴊᩖᱛⴊ
ቇળ⹹ 2006 ᐕ㧧17 Ꮞ㧦278㧙330㧚
7㧕 ⑔ጟᙗᵏ㧘Ⴆᧄ⼾ਭ㧘᫪↰ୃਯ㧘ዊୖ⌀ᴦ㧚㊀∝଀ߦኻߔࠆ࠹ࠗࠦࡊ࡜࠾ࡦߩ⽶⩄ᛩਈ㊂ߦߟ޿ߡߩᬌ⸛㧘
TDM ⎇ⓥ 2006 ᐕ㧧23 Ꮞ㧦6㧙9㧚
8㧕 Ⴧᩕᚑᵏ㧘቟⮮౏㓉㧘⼾↰ᴰ㧘᫪⟵㓶㧘ዊୖ⌀ᴦ㧘ਛᩮᘮᄥ㧘⪤ේᓼᐽ㧘㜞ᯅ⟵ੱ㧘಴ญ㓉㧚వᄤᕈ⣢⋃ዩ▤⒖ⴕㇱ⁜⓰∝ߦว૬ߒߚᄖ்ᕈ⣢៊்ߩ 1 ଀㧘ᢇᕆකቇ 2007 ᐕ㧧31 Ꮞ㧦111㧙113㧚
9㧕 ⊕੗㇌ඳ㧚㊀∝ᕆᕈ⤟Ἳߩᴦ≮㧘⥃ᐥ↹௝ 2007 ᐕ㧧23 Ꮞ㧦544㧙554㧚
10㧕 ⊕੗㇌ඳ㧘⼾↰ᴰ㧘ศ↰⋭ㅧ㧘㊄↰⧷Ꮘ㧘ᾢ↰ᕺ੺㧘ጊ↰ታ༑ੱ㧘ศ↰㓉ᶈ㧘ട⮮ਭ᥏㧘࿯੗ᥓ┨㧘ਛ㊁ᔒ଻㧘┻↰໪㧘ጊ↰ᴺ㗼㧘ዊୖ⌀ᴦ㧘᧻ᯅᑧᄈ㧚ᄖ்ᖚ⠪ߦ߅ߌࠆ౉㒮ᓟᗵᨴᕈว૬∝ߩෂ㒾࿃ሶߦߟ޿
ߡߩᬌ⸛㧘ᣣᧄᄖ்ቇળ㔀⹹ 2008 ᐕ㧧22 Ꮞ㧦403㧙409㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Kato M, Tanaka Y, Toyoda I, Ogura S, Yoshimura S, Iwata T. Delayed lower cranial nerve
palsy(Collet-Sicard syndrome) after head injury. Injury Extra. 2006;37:104-108.
IF 1.211
2㧕 Matsuhashi N, Mizoguchi T, Kanematsu M, Kondo H, Goshima S, Mitsuishi N, Yoshimura K, Ogiso T,
Tawada M, Kuwabara S, Ikegame Y, Kato M, Shirai K, Yamaguchi H, Toyoda I, Ogura S. A case ofdelayed rectal stenosis from severe pelvic fracture with massive bleeding successfully treated bybilateral internal iliac TAE: Report on a patient survival. Int J Colorectal Dis. 2006;22:853-4.
IF 1.848
3㧕 Matsuhashi N, Satake S, Yawata K, Asakawa E, MizoguchiT, Kanematsu M, Kondo H, Yasuda I,
Nonaka K, Tanaka C, Misao A, Ogura S. Volvulus of the gall bladder diagnosed byultrasonography,computed tomography, coronal magnetic resonance imaging and magnetic resonancecholangiópancreatography. World Gastroenterol. 2006;12:4599-4601.
IF 3.318

㧙㧙4㧕 Takamatsu T, Ogura S, Tamura S, Hayamizu S. GEMSIS, An introduction of Intelligent Information
Support System for Emergency and Disaster Medicine. J Health Tech Appl. 2007;5:12-17.
5㧕 Takai S, Tokuda H, Hanai T, Harada A, Yasuda E, Kato H, Ogura S, Ohta T, Kozawa O. Negative
Regulatoin by p70 S6 kinase of FGF-2-Stimulated VEGF Release Through Stress-Activated Protein
Kinase/c-Jun N-Terminal Kinase in Osteoblasts. J Bone Miner Res. 2007;5:337-346.
6㧕 Yamauchi J, Takai S, Matsushima-Nishiwaki R, Hanai Y, Doi T, Kato H, Ogura S, Kato K, Tokuda H,
Kozawa O. -epigallocatechin gallate inhibits prostaglandin D2-stimulated HSP27 induction via
suppression of the p44/p42 MAP kinase pathway in osteoblasts. Prostaglandins Leukot Essent Fatty
Acids. 2007;77:173-9.
7㧕 Kato H, Kimura A, Sasaki R, Kaneko N, Takeda M, Hagiwara A, Ogura S, Mizoguchi T, Matsuoka T,
Ono H, Matsuura K, Matsushima K, Kushimoto S. Cervical Spinal Cord Injury Without Bony Injury-A Multicenter Retrospective Study of Emergency and Critical Care Centers in Japan. J Trauma Inj
Infect Crit Care. 2008;65:373-379.
8㧕 Kato H, Takai S, Matsushima-Nishiwaki R, Adachi S, Minamitani C, Otsuka T, Tokuda H, Akamatsu
S, Doi T, Ogura S, Kozawa O. HSP27 phosphorylation is correlated with ADP-induced platelet granulesecretion. Arc Biochem Biophys. 2008;475:80-86.
9㧕 Tokuda H, Takai S, Hanai Y, Harada A, Matsushima-Nishiwaki R, Kato H, Ogura S, Kozawa O.
Potentiation by platelet-derived growth factor-BB of FGF-2-stimulated VEGF release in osteoblasts. J
Bone Miner Metab. 2008;26:335-341.

IF 6.635

IF 2.000

IF 2.334

IF 2.969

IF 1.4254㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦ጊ↰ᔀ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ⧯ᚻ⎇ⓥ(B)㧦ⴊᶧਛ‫ ⩶⚦ޔ‬DNA‫ޔ‬mRNA ቯ㊂ߦࠃࠆ‫ޔ‬ᢌⴊ∝ߩㄦㅦ⸻ᢿߣ㧘᛫⩶⮎ߩലᨐ್ቯ㧧ᐔᚑ 18㧙19 ᐕᐲ㧧1,100 ජ౞2㧕 ⎇ⓥઍ⴫⠪㧦ട⮮㓷ᐽ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ⧯ᚻ⎇ⓥ(B)㧦ࠨࠗ࠻ࠞࠗࡦ࡮ࡃ࡜ࡦࠬ߆ࠄ⷗ߚ㊀∝ᗵᨴ∝ߩ∛ᘒ⸃ᨆߣᴦ≮ᛶ᛫ᕈㆮવሶߩหቯ㧧ᐔᚑ 18㧙19 ᐕᐲ㧧1,600 ජ౞3㧕 ⎇ⓥઍ⴫⠪㧦᧻ᯅᑧᄈ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ⧯ᚻ⎇ⓥ(B)㧦ᢌⴊ∝ߦ߅ߌࠆࠕࡐ࠻࡯ࠪࠬߣࠨࠗ࠻ࠞ
ࠗࡦࡀ࠶࠻ࡢ࡯ࠢ෸߮ㆮવሶᄙဳߩ⸃ᨆ㧧ᐔᚑ 18㧙19 ᐕᐲ㧧1,700 ජ౞
2㧕ฃ⸤⎇ⓥ1㧕 ዊୖ⌀ᴦ㧦Hepatocyte ߦ߅ߌࠆࠕࡦ࠴࠻ࡠࡦࡆࡦ↥↢⢻ߦኻߔࠆࠣ࡜ࡓ㓁ᕈ⩶࡮㒶ᕈ⩶ೝỗߦࠃࠆ↢↥ᕈᓮࡔࠞ࠾࠭ࡓߩᬌ⸛㧧ᐔᚑ 17㧙19 ᐕᐲ㧧230 ජ౞(230㧦0㧦0 ජ౞)㧦ZLB ࡌ࡯࡝ࡦࠣ(ᩣ)
2㧕 ዊୖ⌀ᴦ㧘᫪↰໪ਯ㧦㔚᳇ೝỗᯏ⢻ઃ߈ᒢᕈࠬ࠻࠶ࠠࡦࠣߩ㕒⣂ⴊᩖ∝ߦኻߔࠆ੍㒐ലᨐߩᬌ⸛㧧ᐔᚑ 18 ᐕᐲ㧧2,000 ජ౞㧦ࠝࡓࡠࡦࡋ࡞ࠬࠤࠕ(ᩣ)
3㧕 ዊୖ⌀ᴦ㧘⼾↰ ᴰ㧘ട⮮ਭ᥏㧦ࡈࠖ࠾ࡃ࠶ࠢࠬὐṢ↪ 0.25g ૶↪ᚑ❣⺞ᩏ㧧ᐔᚑ 18 ᐕᐲ㧧300,300౞㧦Ⴎ㊁⟵⵾⮎(ᩣ)
4㧕 ዊୖ⌀ᴦ㧦ࠪࡌ࡟ࠬ࠲࠶࠻࠽࠻࡝࠙ࡓ᳓๺‛Ꮢ⽼ᓟ⥃ᐥታ㛎 ోりᕈἻ∝෻ᔕ∝୥⟲ߦ઻߁ᕆᕈ⢖㓚ኂߦኻߔࠆࠝ࡯ࡊࡦ⹜㛎(ࠪࡌ࡟ࠬ࠲࠶࠻࠽࠻࡝࠙ࡓ᳓๺‛ᛩਈ㇭)㧧ᐔᚑ 17㧙18 ᐕᐲ㧧932,400౞㧦ዊ㊁⮎ຠᎿᬺ(ᩣ)
5㧕 Hepatocyte ߦ߅ߌࠆࠕࡦ࠴࠻ࡠࡦࡆࡦ↥↢⢻ߦኻߔࠆࠣ࡜ࡓ㓁ᕈ⩶࡮㒶ᕈ⩶ೝỗߦࠃࠆ↢↥೙ᓮࡔࠞ࠾࠭ࡓߩᬌ⸛㧧ᐔᚑ 17㧙19 ᐕᐲ㧧230 ජ౞(230㧦0㧦0 ජ౞)㧦ZLB ࡌ࡯࡝ࡦࠣ(ᩣ)
6㧕 ዊୖ⌀ᴦ㧦ᄖ⑼ᢇᕆ㗔ၞߦ߅ߌࠆᷓ࿷ᕈ⌀⩶∝ߦ߆ࠎߔࠆ⺞ᩏ㧧ᐔᚑ 20㧙21 ᐕᐲ㧧154 ජ౞㧦੍㒐කቇ੐ᬺਛᄩળ
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬዊୖ⌀ᴦ㧦
1㧕 ᣣᧄᢇᕆකቇળ⹏⼏ຬ࡮⣖ᱫ⤳ེឭଏߦ㑐ߔࠆᆔຬ✬㓸ᆔຬળᆔຬ(㨪⃻࿷)2㧕 ᣣᧄ㓸ਛᴦ≮කቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ Shock ቇળ⹏⼏ຬ(㨪⃻࿷)㧙㧙4㧕 ᣣᧄ⥶ⓨක≮ቇળ⹏⼏ຬ࡮ᩏ⺒ᆔຬ(㨪⃻࿷)5㧕 ᣣᧄᄖ்ቇળ⹏⼏ຬ࡮዁᧪⸘↹ᆔຬ࡮ኾ㐷ක⹺ቯᆔຬ(㨪⃻࿷)6㧕 ᣣᧄᢇᕆකቇળ᧲ᶏ࿾ᣇળ⋙੐(㨪⃻࿷)7㧕 ᣣᧄ⥃ᐥᢇᕆකቇળ዁᧪⸘↹ᬌ⸛ᆔຬ࡮࠻࡝ࠕ࡯ࠫ࠽࡯ࠬ⢒ᚑᬌ⸛ዊᆔຬળᆔຬ(㨪⃻࿷)8㧕 ᣣᧄ㓸࿅ἴኂකቇળ⑺⪲ේ੐ઙ⺞ᩏ․೎ᆔຬળᆔຬ(ᐔᚑ 20 ᐕᐲ㨪⃻࿷)⼾↰ᴰ㧦
1㧕 ᣣᧄᢇᕆකቇળਛㇱ࿾ᣇળᐙ੐(㨪⃻࿷)2㧕 ᣣᧄ␹⚻ᄖ்ቇળ✬㓸ᐙ੐(㨪⃻࿷)3㧕 ᣣᧄ⣖␹⚻ᄖ⑼ᢇᕆකቇળᐙ੐(㨪⃻࿷)ᾢ↰ᕺ੺㧦1㧕 ᣣᧄᢇᕆකቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ⥃ᐥᢇᕆකቇળ⹏⼏ຬ(㨪⃻࿷)ዊႮା੺㧦1㧕 CCT2008 ⹏⼏ຬ(㨪⃻࿷)2㧕 ᧲ᶏ࡜ࠗࡉ⎇ⓥળᐙ੐(㨪⃻࿷)ศ↰⋭ㅧ㧦1㧕 ᣣᧄᢇᕆකቇળ㑐᧲࿾ᣇળᐙ੐(㨪⃻࿷)2㧕ቇળ㐿௅ዊୖ⌀ᴦ㧦
1㧕 JATEC ጘ㒂ࠦ࡯ࠬ(ᐔᚑ 18 ᐕ 5 ᦬㧘ጘ㒂)2㧕 ᣣᧄᢇᕆකቇળਛㇱ࿾ᣇળ✚ળ࡮ቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ጘ㒂)3㧕 JATEC ጘ㒂ࠦ࡯ࠬΤ(ᐔᚑ 20 ᐕ 5 ᦬㧘ጘ㒂)
3㧕ቇⴚ㔀⹹ዊୖ⌀ᴦ㧦
1㧕 ᣣᧄᢇᕆකቇળਛㇱ࿾ᣇળ✚ળ࡮ቇⴚ㓸ળ⹹(ᐔᚑ 19 ᐕ 11 ᦬㨪⃻࿷)2㧕 ᣣᧄᢇᕆකቇળ㧧✬㓸ᆔຬ(㨪⃻࿷)7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ዊୖ⌀ᴦ㧦
1㧕 The 70th Anniversary Annual Scientific Meeting of the Japanese Circulation Society(ᐔᚑ 18 ᐕ 3᦬㧘ฬฎደ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ἴኂᤨߩᓴⅣེ∔ᖚ‫ޠ‬ᐳ㐳)2㧕 ╙ 20 ࿁ᣣᧄᄖ்ቇ(ᐔᚑ 18 ᐕ 5 ᦬㧘ฬฎደ㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯‫ޟ‬ᱛⴊ࡮TAE㧘ઁ‫ޠ‬ᐳ㐳)
3㧕 ╙ 20 ࿁ᣣᧄᄖ்ቇ(ᐔᚑ 18 ᐕ 5 ᦬㧘ฬฎደ㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯‫ޟ‬ᢇᕆ㗔ၞߦ߅ߌࠆ๭ๆਇోߩ∛ᘒߣᴦ≮ᚢ⇛‫ޠ‬Ṷ⠪)
4㧕 ╙ 9 ࿁ᣣᧄ⥃ᐥᢇᕆකቇળ✚ળ(ᐔᚑ 18 ᐕ 5 ᦬㧘⋓ጟᏒ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ጘ㒂ᢇᕆක≮ᖱႎ౒᦭េ
ഥࠪࠬ࠹ࡓ(GEMSIS)ߩ㐿⊒‫ޠ‬Ṷ⠪)
5㧕 ╙ 66 ࿁ਅํᏒකᏧળቇⴚ⻠Ṷળ(ᐔᚑ 18 ᐕ 6 ᦬㧘ਅํ㧘․೎⻠Ṷ‫ޟ‬ᢇᕆ㗔ၞߦ߅ߌࠆ๭ๆ▤ℂ‫ޠ‬Ṷ⠪)
6㧕 ╙ 1 ࿁ጘ㒂ᢇᕆ㓸ਛᴦ≮࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 6 ᦬㧘ጘᄢ∛㒮㧘․೎⻠Ṷ‫ޟ‬ᢌⴊ∝ᕈ DIC ߩⴊ▤ౝ⊹⚦⢩଻⼔ᚢ⇛‫ޠ‬ᐳ㐳)7㧕 ╙ 14 ࿁ᣣᧄ㓸ਛᴦ≮කቇળ᧲ᶏർ㒽࿾ᣇળ(ᐔᚑ 18 ᐕ 6 ᦬㧘ንጊ㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯‫ޟ‬ᢌⴊ∝ߣᕆᕈ⢖㓚ኂߩᴦ≮‫ޠ‬Ṷ⠪)8㧕 ╙ 8 ࿁ጘ㒂ᄢቇᢇᕆකቇ⻠Ṷળ(ᐔᚑ 18 ᐕ 7 ᦬㧘ጘᄢ∛㒮㧘․೎⻠Ṷ‫ޟ‬ᕆᕈᦼ DIC ⸻ᢿၮḰߣ DIC
ᴦ≮ࠟࠗ࠼࡜ࠗࡦ‫ޠ‬ᐳ㐳)9㧕 ╙ 4 ࿁ᢇᕆ㗔ၞᗵᨴኻ╷࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 8 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬MRSA ᗵᨴ∝ߣ VCM ⠴ᕈ⩶‫ޠ‬ᐳ㐳)
10㧕 ╙ 2 ࿁࿾ၞක≮ㅪ៤⻠Ṷળ(ᐔᚑ 18 ᐕ 9 ᦬㧘㜞⍮㧘⻠Ṷળ‫ޟ‬ᢇᕆ㗔ၞߦ߅ߌࠆᕆᕈ๭ๆਇో‫ޠ‬Ṷ⠪)㧙㧙

11㧕 ╙ 9 ࿁ጘ㒂ᄢቇᢇᕆකቇ⻠Ṷળ(ᐔᚑ 18 ᐕ 11 ᦬㧘ጘᄢ∛㒮㧘․೎⻠Ṷ‫ޟ‬1)੩ᄢ∛㒮ೋᦼ⸻≮࡮ᢇᕆㇱߩ⃻⁁ 2)಴ⴊᕈ࡚ࠪ࠶ࠢᓟߩ⣺㑆⤑࡝ࡦࡄᶧਛߦሽ࿷ߔࠆ⢽⾰ࡔ࠺ࠗࠛ࡯࠲࡯ߩᬌ⸛‫ޠ‬ᐳ㐳)12㧕 ᣣᧄ㓸࿅ἴኂකቇળ(ᐔᚑ 19 ᐕ 1 ᦬㧘ฬฎደ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᢇᕆක≮ᖱႎ౒᦭ᡰេࠪࠬ࠹ࡓ(GEMSIS)ࠍ↪޿ߚࡑࠬࠡࡖࠩ࡝ࡦࠣᖱႎવ㆐ࠪࠬ࠹ࡓ㧙GEMSIS ╙ 3 ႎ㧙Ṷ⠪)
13㧕 ో࿖࿖┙ᄢቇ∛㒮ᢇᕆㇱㅪ⛊ද⼏ળ(ᐔᚑ 19 ᐕ 2 ᦬㧘᧻ᧄ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ጘ㒂ᄢቇකቇㇱ㒝ዻ∛㒮ߩ૶๮࡮ߘߩࠦࠬ࠻ߣࡄࡈࠜ࡯ࡑࡦࠬ‫ޠ‬Ṷ⠪)
14㧕 ╙ 34 ࿁ᣣᧄ㓸ਛᴦ≮ቇળቇⴚ✚ળ(ᐔᚑ 19 ᐕ 3 ᦬㧘␹ᚭ㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ‫ޟ‬ICU ߦ߅ߌࠆ㔚ሶࠞ࡞࠹ߩᎿᄦ‫ޠ‬ᐳ㐳)15㧕 ╙ 34 ࿁ᣣᧄ㓸ਛᴦ≮ቇળቇⴚ✚ળ(ᐔᚑ 19 ᐕ 3 ᦬㧘␹ᚭ㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ‫ޟ‬㓸ਛᴦ≮ߩ㔚ሶࠞ࡞࠹ߩᎿᄦ‫ޠ‬Ṷ⠪)
16㧕 ╙ 10 ࿁ᣣᧄ⥃ᐥᢇᕆකቇ✚ળ࡮ቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 5 ᦬㧘␹ᚭ㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ‫ޟ‬ⓨ᷼ἴኂᤨක≮૕೙ߩᣂߒ޿᭎ᔨߣߘࠇࠍᡰេߔࠆᖱႎࠪࠬ࠹ࡓ(GEMSIS)╙ 4 ႎ‫ޠ‬Ṷ⠪)17㧕 ╙ 21 ࿁ᣣᧄᄖ்ቇળ(ᐔᚑ 19 ᐕ 5 ᦬㧘ජ⪲㧘‫ޟ‬⣻ㇱᄖ்Σ(ታ⾰⤳ེ៊்)‫ޠ‬ᐳ㐳)18㧕 ߳߈࿾࡮㔌ፉᢇᕆක≮⎇ⓥળ╙ 11 ࿁ቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 10 ᦬㧘㜞⍮㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ጘ㒂⋵ߩ߳߈࿾ᢇᕆක≮ߩ⏕଻‫ޠ‬Ṷ⠪)
19㧕 ╙ 35 ࿁ᣣᧄᢇᕆකቇળ(ᐔᚑ 19 ᐕ 10 ᦬㧘ᄢ㒋㧘⻠Ṷ‫ޟ‬Frontier4‫ޟ‬ᢌⴊ∝ߩ∛ᘒߣᴦ≮̆Surviving
Sepsis Campaign guidelines ߩ∛ᘒ↢ℂቇ⊛⸃㉼̆‫ޠ‬ᐳ㐳)20㧕 ╙ 35 ࿁ᣣᧄᢇᕆකቇળ(ᐔᚑ 19 ᐕ 10 ᦬㧘ᄢ㒋㧘࠮࠶࡚ࠪࡦ‫ޟ‬࿾ၞක≮ߣᢇᕆක≮ߩធὐࠍᡰេߔ
ࠆᢇᕆක≮ᖱႎᡰេࠪࠬ࠹ࡓ GEMSIS㧙╙ 5 ႎ㧙‫ޠ‬Ṷ⠪)
21㧕 ᢇᕆࠞࡦࡈࠔ࡟ࡦࠬ(ᐔᚑ 19 ᐕ 10 ᦬㧘㕒ጟ㧘․೎⻠Ṷ‫ޟ‬ᢇᕆ㗔ၞߦ߅ߌࠆ๭ๆ▤ℂ‫ޠ‬Ṷ⠪)22㧕 ╙ 11 ࿁ጘ㒂ᄢቇᢇᕆකቇ⻠Ṷળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ጘ㒂㧘‫ޟ‬ἴኂᤨߦ߅ߌࠆ∛㒮ߩᓎഀ㨪੹ߛ߆ࠄ⹤ߖࠆ࿾ਅ㋕ࠨ࡝ࡦ੐ઙߩ෻⋭ὐ㨪‫ޠ‬ᐳ㐳)23㧕 ࿖㓙ᄖ்ࠞࡦࡈࠔ࡟ࡦࠬ(ᐔᚑ 20 ᐕ 5 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬࿾ᣇߦ߅ߌࠆᄖ்ක≮૕೙ߩ⏕┙‫ޠ‬ᐳ㐳)24㧕 ᣣᧄ㤗㈮⑼ቇળ╙ 55 ࿁ቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 6 ᦬㧘␹ᄹᎹ㧘‫ޟ‬Multiple Trauma Management‫ޠ‬ᐳ㐳)25㧕 ╙ 3 ࿁ጘ㒂ᢇᕆ㓸ਛᴦ≮࠮ࡒ࠽㧙(ᐔᚑ 20 ᐕ 8 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬2008 ᐕᢌⴊ∝߅ࠃ߮ DIC ▤ℂߩേะ‫ޠ‬ᐳ㐳)26㧕 ጊ᪸ᢇᕆ㓸ਛᴦ≮ࡈࠜ㧙࡜ࡓ 2008(ᐔᚑ 20 ᐕ 9 ᦬㧘↲ᐭ㧘᜗ᓙ⻠Ṷ‫ޟ‬㓸ਛᴦ≮ߦ߅ߌࠆ๭ๆ▤ℂߣᴦ≮ᚢ⇛‫ޠ‬Ṷ⠪)27㧕 ╙ 36 ࿁ᣣᧄᢇᕆකቇળ✚ળ࡮ቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ർᶏ㆏㧘ࡢ㧙࡚ࠢࠪ࠶ࡊ‫⥃ޟ‬ᐥ⎇ୃᔅୃൻߦ߅ߌࠆᢇᕆߩ⎇ୃലᨐะ਄ߩᎿᄦ‫ޠ‬ᐳ㐳)28㧕 ጘ㒂ᢇᕆᄖ்࠮ࡒ࠽㧙(ᐔᚑ 20 ᐕ 11 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬⣄ᬁ‫ޔ‬⣄㜑៊்ߩᕆᕈᦼᴦ≮‫ޠ‬ᐳ㐳)29㧕 ╙ 15 ࿁ᣣᧄ⥶ⓨක≮ቇળ(ᐔᚑ 20 ᐕ 11 ᦬㧘᧻ᳯᏒ㧘‫ޟ‬ਛᨔ␹⚻࡮ᓴⅣེ‫ޠ‬ᐳ㐳)⼾↰ᴰ㧦
1㧕 The 70th Anniversary Annual Scientific Meeting of the Japanese Circulation Society(ᐔᚑ 18 ᐕ 3᦬㧘ฬฎደ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬Emergency System for Circulatory Diseases During Disasters andAssociated Problems From the Standpoint of Emergency‫ޠ‬Ṷ⠪)
2㧕 ╙ 21 ࿁ᣣᧄ␹⚻ᢇᕆቇળቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 6 ᦬㧘੩ㇺ㧘⻠Ṷ‫ޟ‬ጘ㒂⋵ߦ߅ߌࠆ⣖තਛೋᦼ⸻≮(ISLS)ࠦ࡯ࠬ㐿௅ߩ⃻⁁ߣ੹ᓟ‫ޠ‬Ṷ⠪)
3㧕 ╙ 13 ࿁᧲ᶏ MODS ⎇ⓥળ(ᐔᚑ 19 ᐕ 12 ᦬㧘ጘ㒂㧘‫ޟޟ‬ἴኂ‫ޠ‬㒮ᄖߩἴኂኻ╷ߦߟ޿ߡ‫ޠ‬ᐳ㐳)⊕੗㇌ඳ㧦
1㧕 ╙ 34 ࿁ᣣᧄ㓸ਛᴦ≮කቇળቇⴚ✚ળ(ᐔᚑ 19 ᐕ 3 ᦬㧘␹ᚭ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬㊀∝ᕆᕈ⤟Ἳ(SAP)ߦ
߅ߌࠆ⤳ེ㓚ኂߦኻߔࠆἻ∝ߣಝ࿕✢ṁ♽‫ޠ‬Ṷ⠪)
2㧕 ╙ 107 ࿁ᣣᧄᄖ⑼ቇળቯᦼቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 4 ᦬㧘ᄢ㒋㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᒰ㒮ᢇ๮࠮ࡦ࠲࡯ߦ߅
ߌࠆ㊀∝ᕆᕈ⤟Ἳߦኻߔࠆᴦ≮ᚢ⇛ߩᬌ⸛㨪ෘ↢ഭ௛⋭㊀∝ᐲ stage ಽ㘃೎‫᧻ޔ‬㊁ CT grade ಽ㘃೎ߦ㨪‫ޠ‬Ṷ⠪)3㧕 ╙ 21 ࿁ᣣᧄᄖ்ቇળ(ᐔᚑ 19 ᐕ 5 ᦬㧘ජ⪲㧘⻠Ṷ‫ޟ‬ᒰ㒮ᢇ๮ᢇᕆ࠮ࡦ࠲࡯ߦ߅ߌࠆᄖ்ᖚ⠪ߩ౉㒮ᓟᗵᨴ∝ว૬∝ߩᬌ⸛‫ޠ‬Ṷ⠪)
4㧕 ╙ 62 ࿁ᣣᧄᶖൻེᄖ⑼ቇળቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 7 ᦬㧘᧲੩㧘⻠Ṷ‫ޟ‬㊀∝ᕆᕈ⤟Ἳߦ߅ߌࠆᗵᨴᕈว
૬∝ߩᬌ⸛‫ޠ‬Ṷ⠪)
5㧕 ╙ 1 ࿁᧲ᶏᢇ๮ᢇᕆ SBMN ⎇ⓥળቇⴚ⻠Ṷળ(ᐔᚑ 19 ᐕ 9 ᦬㧘ฬฎደ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬㊀∝ᕆᕈ⤟㧙㧙Ἳߦኻߔࠆᩕ㙃▤ℂ‫ޠ‬Ṷ⠪)
6㧕 ╙ 35 ࿁ᣣᧄᢇᕆකቇળ(ᐔᚑ 19 ᐕ 10 ᦬㧘ᄢ㒋㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ‫ޟ‬㊀∝ᕆᕈ⤟Ἳߦ߅ߌࠆᗵᨴᕈว
૬∝ߦኻߔࠆᴦ≮ᚢ⇛‫ޠ‬Ṷ⠪)7㧕 ╙ 20 ࿁ᣣᧄᄖ⑼ᗵᨴ∝ቇળ(ᐔᚑ 19 ᐕ 11 ᦬㧘᧲੩㧘⻠Ṷ‫ޟ‬ᄖ்ᖚ⠪ߩ౉㒮ᓟᗵᨴ∝ߦߟ޿ߡߩᬌ
⸛‫ޠ‬Ṷ⠪)
8㧕 ╙ 36 ࿁ᣣᧄᢇᕆකቇળ✚ળ࡮ቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ർᶏ㆏㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬㊀∝ᄖ்ߩ಴ⴊ
ߦኻߔࠆᴦ≮ᚢ⇛㨪✕ᕆᚻⴚߣ⚻ࠞ࠹࡯࠹࡞⊛േ⣂Ⴇᩖⴚ(TAE)ߣߩ૬↪≮ᴺߩᬌ⸛㨪‫ޠ‬Ṷ⠪)ᾢ↰ᕺ੺㧦
1㧕 ╙ 10 ࿁ᣣᧄ⥃ᐥᢇᕆකቇળ✚ળ(ᐔᚑ 19 ᐕ 5 ᦬㧘␹ᚭ㧘ࠪࡦࡐࠫ࠙ࡓ‫࡞ࡃࡦࡏޟ‬ᯏ⢵૕⌕㒽ߦ߅ߌࠆኻᔕ‫ޠ‬Ṷ⠪)2㧕 ╙ 35 ࿁ᣣᧄᢇᕆකቇળ(ᐔᚑ 19 ᐕ 10 ᦬㧘ᄢ㒋㧘‫ޟ‬ᢇᕆක≮૕೙‫ޠ‬ᐳ㐳)
3㧕 ╙ 15 ࿁ᣣᧄ⥶ⓨක≮ቇળ✚ળ(ᐔᚑ 20 ᐕ 11 ᦬㧘ፉᩮ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᶖ㒐㒐ἴࡋ࡝ߣ࠼ࠢ࠲࡯ࡋ
࡝ࠍᅤ૗ߦ᦭ലᵴ↪ߔߴ߈߆‫ޠ‬Ṷ⠪)㜞᧻㇌ᒾ㧦
1㧕 ╙ 21 ࿁ᄥᐔᵗቇⴚળ⼏(ᐔᚑ 19 ᐕ 6 ᦬㧘ᴒ✽㧘‫ޟ‬GEMSIS, An introduction of Intelligent Information
Support System for Emergency and Disaster Medicine By Prof Kunihiko Takamatsu‫ޠ‬Ṷ⠪)ศ↰⋭ㅧ㧦‫ޟ‬㊀∝ᕆᕈ⤟Ἳࠍว૬ߒߚ᦭ᯏῂਛ
1㧕 ╙ 18 ࿁ᣣᧄᕆᕈⴊᶧᵺൻቇળቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 10 ᦬㧘ᄢಽ㧘
Ქߩ 1 ଀‫ޠ‬Ṷ⠪)㐳ደ⡡৻㇢㧦
1㧕 ╙ 34 ࿁ᣣᧄ㓸ਛᴦ≮කቇળቇⴚ✚ળ(ᐔᚑ 19 ᐕ 3 ᦬㧘␹ᚭ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ጘ㒂ᄢቇකቇㇱ㒝ዻ∛㒮 ICU/HCU ߦ߅ߌࠆ㔚ሶࠞ࡞࠹ㆇ↪ߩ⃻⁁‫ޠ‬Ṷ⠪)ฬ⍮ ␽㧦
1㧕 ╙ 3 ࿁ ICLS ࠪࡦࡐࠫ࠙ࡓ(1st announcement)(ᐔᚑ 19 ᐕ 9 ᦬㧘ฬฎደ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ALS ᵴേࠍᐢ߼ࠆὑߩᣇᴺ⺰ ࠟࠗ࠼࡜ࠗࡦᡷቯᓟߩጘ㒂⋵ਅߩ⃻⁁㨪ACLS ጘ㒂ߩᵴേࠍㅢߒߡ㨪‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേዊୖ⌀ᴦ㧦
1㧕 ╙ 28 ᦼ᧲੩ᶖ㒐ᐡᢇᕆᬺോᙣ⹤ળᆔຬ(㨪⃻࿷)2㧕 ጘ㒂⋵࿖᳃଻⼔ද⼏ળᆔຬ(㨪⃻࿷)3㧕 ጘ㒂⋵ࡔ࠺ࠖࠞ࡞ࠦࡦ࠻ࡠ࡯࡞ද⼏ળᆔຬ(㨪⃻࿷)4㧕 ጘ㒂⋵ᶖ㒐ᬺോᐢၞൻᬌ⸛ᆔຬળᆔຬ(㨪⃻࿷)5㧕 ጘ㒂⋵ᐢၞἴኂ࡮ᢇᕆක≮ᖱႎࠪࠬ࠹ࡓㆇ༡ᆔຬળᆔຬ(㨪⃻࿷)6㧕 ጘ㒂Ꮢᢇᕆᬺോኻ╷ද⼏ળᆔຬ(㨪⃻࿷)7㧕 NPO ᴺੱጘ㒂ᢇᕆἴኂක≮⎇ⓥ㐿⊒ᯏ᭴Ᏹോℂ੐(㨪⃻࿷)8㧕 ጘ㒂᧲ᵗකቇ⎇ⓥળ਎⹤ੱ(㨪⃻࿷)9㧕 ጘ㒂⋵࿾㔡㒐ἴⴕേ⸘↹ࡈࠜࡠ࡯ࠕ࠶ࡊᆔຬળᆔຬ(㨪⃻࿷)⼾↰ᴰ㧦
1㧕 ጘ㒂Ꮢᢇᕆᬺോ㜞ᐲൻᬌ⸛ᆔຬળᆔຬ(㨪⃻࿷)2㧕 ጘ㒂࿾ၞࡔ࠺ࠖࠞ࡞ࠦࡦ࠻ࡠ࡯࡞ද⼏ળᆔຬ(㨪⃻࿷)
3㧕 NPO ᴺੱጘ㒂ᢇᕆἴኂක≮⎇ⓥ㐿⊒ᯏ᭴ℂ੐(㨪⃻࿷)ศ↰㓉ᶈ㧦1㧕 ጘ㒂࿾ၞࡔ࠺ࠖࠞ࡞ࠦࡦ࠻ࡠ࡯࡞૕೙ଥࠆᬌ⸽කᏧ(2007㨪⃻࿷)㧙㧙㜞ᰴᢇ๮ᴦ≮࠮ࡦ࠲࡯㧦1㧕 ࠗࡆ࠺ࡦࠬࡍࠪࡖ࡞ NOKIA ࠬࡁ࡯ࡏ࡯࠼ FIS ࡢ࡯࡞࠼ࠞ࠶ࡊ 2008GIFU/GUJO ᄢળ DMAT 㓌
ຬᵷ㆜(2008 ᐕ 2 ᦬ 22 ᣣ㨪2 ᦬ 24 ᣣ)
10㧚ႎ๔ᦠ
1㧕 ዊự໪ᰴ㧘⑔↰లብ㧘㋈Ꮉᱜਯ㧘ዊୖ⌀ᴦ㧘㜞ጊ㓳ੱ㧘੹㆏⧷⑺㧘Ỉ↰ദ㧦߳߈࿾࡮㔌ፉᢇᕆක≮૕೙ߦ߅ߌࠆᢇᕆක≮ᯏ㑐ߩㅪ៤ߣᖚ⠪ߣක≮⾗Ḯߩ㓸⚂ൻߦ㑐ߔࠆ⎇ⓥ㧦ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ಽᜂ⎇ⓥႎ๔ᦠ(⑔↰⃰)㧦97㧙107(2007 ᐕ 3 ᦬ 1 ᣣ)
11㧚ႎ㆏
1㧕 ዊୖ⌀ᴦ㧦࿯ᦐ࡜ࠫࠝ߆ࠊࠄ 㧦ጘ㒂࡜ࠫࠝ(2006 ᐕ 1 ᦬ 1 ᣣ㨪⃻࿷ Ფ᦬ 1 ࿁)
2㧕 ዊୖ⌀ᴦ㧦Weekly file ߉߰ ߉߰ࠍࠃ߻ 㜞ᐲᢇ๮ᢇᕆ࠮ࡦ࠲࡯⹺ቯ㧦ጘ㒂᡼ㅍ(2006 ᐕ 2 ᦬ 10 ᣣ)
3㧕 ጊ↰ታ⾆ੱ㧦4 ᣣߦో࿖⧎Ἣᄢળ ක≮࠴࡯ࡓᧄㇱߦᓙᯏ ጘ㒂ᄢਁ৻ߦ஻߃㧦ጘ㒂ᣂ⡞(2007 ᐕ 8
᦬ 2 ᣣ)
4㧕 ዊୖ⌀ᴦ㧦ᢇᕆක≮ߪᤨ㑆ߣߩ㑵޿㧦ጘ㒂ᣂ⡞(2007 ᐕ 10 ᦬ 28 ᣣ)
5㧕 ዊୖ⌀ᴦ㧦ᢇᕆක≮ߪᤨ㑆ߣߩ㑵޿㧦ਛᣣᣂ⡞(2007 ᐕ 10 ᦬ 30 ᣣ)
6㧕 ዊୖ⌀ᴦ㧦ഥ߆ࠆ๮ഥߌࠆ૶๮㧦⺒ᄁᣂ⡞(2008 ᐕ 1 ᦬ 4 ᣣ)
7㧕 ዊୖ⌀ᴦ㧦ᢇᕆߦᰳ߆ߖߧሽ࿷㧦ጘ㒂ᣂ⡞(2008 ᐕ 1 ᦬ 5 ᣣ)
8㧕 ዊୖ⌀ᴦ㧦ᕆ∛ੱᗐቯߒ៝ㅍ⸠✵㧦ጘ㒂ᣂ⡞(2008 ᐕ 1 ᦬ 23 ᣣ)
9㧕 ዊୖ⌀ᴦ㧦ᢇᕆߚࠄ޿࿁ߒ㒐ߍ㧦⺒ᄁᣂ⡞(2008 ᐕ 1 ᦬ 25 ᣣ)
10㧕 ዊୖ⌀ᴦ㧦࠾ࡘ㧙ࠬ 9㧦NHK(2008 ᐕ 3 ᦬ 10 ᣣ)
11㧕 ዊୖ⌀ᴦ㧦ႎ㆏ࠬ࠹㧙࡚ࠪࡦ㧦࠹࡟ࡆᦺᣣ(2008 ᐕ 3 ᦬ 20 ᣣ)
12㧕 ዊୖ⌀ᴦ㧦ࡎ࠶࠻ࠗࡉ࠾ࡦࠣ㧦NHK(2008 ᐕ 6 ᦬)
13㧕 ዊୖ⌀ᴦ㧦ႎ㆏ࠬ࠹㧙࡚ࠪࡦ㧦࠹࡟ࡆᦺᣣ(2008 ᐕ 10 ᦬ 20 ᣣ)
14㧕 ዊୖ⌀ᴦ㧦ἴኂႎ㆏࠼ࠠࡘࡔࡦ࠲࡝㧙㧦ᣣᧄ࠹࡟ࡆ(2008 ᐕ 12 ᦬ 7 ᣣ)
15㧕 ዊୖ⌀ᴦ㧦․࠳ࡀ ᅧᇚᢇᕆ૕೙㨪ߥߗጘ㒂⋵ߢ߁߹ߊ޿ߞߡ޿ࠆߩ߆㨪㧦ࡈࠫ࠹࡟ࡆ(2008 ᐕ 12
᦬ 8 ᣣ)
16㧕 ዊୖ⌀ᴦ㧦ࡎ࠶࠻ࠗࡉ࠾ࡦࠣ ੍▚ડ↹࡮ᢇᕆࠪࠬ࠹ࡓ㧦NHK(2008 ᐕ 12 ᦬ 22 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔ೨ㅀߩ⋡⊛ߦᴪߞߚ⎇ⓥࠍዷ㐿ߔࠆḰ஻߇ᢛ޿ᆎ߼ߡ߅ࠅ㧘⃻⁁ߢߩ⹏ଔߪࠃ߁߿ߊ෸╙ὐߢ޽ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷⥃ᐥᬺോ߇ᄙᔔߢ޽ࠅ㧘⎇ⓥߩߚ߼ߩᤨ㑆ࠍขࠅߠࠄ޿ߩ߇⃻⁁ߢ޽ࠆ‫੹ޕ‬ᓟߪ⥃ᐥ㕙ࠍ߅ࠈߘ߆ߦ
ߒߥ޿▸࿐ߢ㧘ࠬ࠲࠶ࡈࠍჇടߒߡ⎇ⓥࠍዷ㐿ߒߚ޿‫ޕ‬੹ᓟߩዷᦸ೨⸥ߩࠃ߁ߥ⃻⁁ߢ޽ࠆ߇㧘ᓢ‫ߦޘ‬ᢎ⢒ࠬ࠲࠶ࡈ߇Ⴧടߒߡ߅ࠅ੹ᓟߪߐࠄߦၮ␆⻠ᐳߣ߽ࠦ࡜ࡏ࡟
࡯࠻ߒߡ⎇ⓥࠍଦㅴߒߚ޿‫ޕ‬㧙㧙㧔6㧕ᴺකቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
ߎࠇ߹ߢߣห᭽‫ޕ‬ᴺක∛ℂቇ⊛ߥ⎇ⓥߣߒߡߪ㧘ᓥ᧪ߪᱫᓟߩⷺ⤑ᷙỘߩߚ߼㧘⌒⃿ࠍ೪಴ߒߥߌࠇ߫
ⷰኤߢ߈ߥ߆ߞߚ⌒ౝᚲ⷗ࠍ⌒⑼ᚻⴚ⊛ߦ㐿⊒ߐࠇߚవ┵ᓘ߇ 0.9 mm ߩౝⷞ㏜ࠍ↪޿ߡ⸃೬ᤨߦⷰኤߒ㧘⌒ᐩ಴ⴊ╬ߩ⊒↢ߣᱫ࿃߿ฃߌߚ៊்ߣߩ㑐ଥ㧘ߘߩᗧ⟵╬ߦߟ޿ߡᬌ⸛ߒ㧘⌒ᐩ಴ⴊߪ㗡⬄ౝ಴ⴊ߿㗪ㇱ࿶ㄼߦࠃࠆ⓸ᕷᱫ଀╬ߦ㜞㗫ᐲߦ⹺߼ࠄࠇࠆߩߦኻߒ㧘߁ߞⴊ੃㗡ߪ㗡⬄ౝ಴ⴊᱫ଀ߢߪ⹺߼ࠄࠇࠆ߇㧘㗪ㇱ࿶ㄼߦࠃࠆ⓸ᕷᱫ଀ߢߪ⹺߼ࠄࠇߥ޿ߎߣࠍ᣿ࠄ߆ߦߒ㧘߹ߚ㧘ṃᱫ଀ߦ߅޿ߡ߽㜞㗫ᐲߦ⌒ᐩ಴ⴊ߇⹺߼ࠄࠇࠆߎߣࠍᣂ⍮⷗ߣߒߡႎ๔ߔࠆߎߣ߇ߢ߈ߚ‫ߚ߹ޕ‬㧘⓭ὼᱫߩේ࿃ߣߒߡߩ౰േ⣂ᄸᒻߩᗧ⟵߿⥌๮⊛ਇᢛ⣂ߦ߅ߌࠆᔃ⤳ߩ⚵❱ቇ⊛ᄌൻߦߟ޿ߡ╬ߩ⎇ⓥࠍⴕߞߚ‫ޕ‬DNA ᄙဳߦ㑐ߔࠆ⎇ⓥߢߪ㧘ࡒ࠻ࠦࡦ࠼࡝ࠕ DNA 㜞ᄌ⇣㗔ၞߩႮၮ㈩೉⸃ᨆߥࠄ߮ߦ STR㧔short tandem repeat㧕ᄙဳߩ಴⃻㗫ᐲ߿ᄙဳ᭴ㅧߩ⸃ᨆࠍⴕ޿㧘DNA 㐓ቯߦ߅޿ߡᔅⷐߣߥࠆ㧘ጘ㒂⋵࿷૑ߩᣣᧄੱ㓸࿅ࠍኻ⽎ߣߒߚ࠺࡯࠲
ࡌ࡯ࠬࠍ᭴▽ߔࠆߎߣ߇ߢ߈ߚ‫ߚ߹ޕ‬㧘ࡒ࠻ࠦࡦ࠼࡝ࠕ DNA HVIII 㗔ၞߦሽ࿷ߔࠆ length heteroplasmyߩ᭴ㅧࠍ⸃ᨆߒ㧘ߘߩᴺකቇ⊛ᔕ↪ߦߟ޿ߡ⎇ⓥߒߚ߶߆㧘X ᨴ⦡૕਄ߩ STR ᐳ૏ߩᣣᧄੱ㓸࿅ߦ߅ߌࠆ㜞ᐲߥ᭴ㅧᄙဳࠍ᣿ࠄ߆ߦߒ㧘ߘߩੱ㘃ㆮવቇ⊛⸃ᨆ߽ⴕߞߚ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
ഥᢎ㧦

ᱞౝᐽ㓶
᳗੗ ᷕ

Yasuo Bunai
Atsushi Nagai

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
ߥߒ⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 ਛጊ㓷ᒄ㧘ਛᎹ ⡡㧘㕍ᧁᐽඳ㧘ട⮮Ⓑሶ㧘㥲⮮৻ਯ㧘㜞᎑ᐘ↵㧘ᚭ⧛ ഃ㧘⊛႐᪞ᰴ㧘ዊ଻ౝବ㓷㧘ർፉඳਯ㧘ዊᨋᐾᰴ㧘ੳᔒ↰ඳม㧘ᱞౝᐽ㓶㧘ጊධ⽵ᄦ㧚੃ᐜఽ⓭ὼᱫ∝୥⟲(SIDS)⸻ᢿߩᚻᒁ߈ ᡷ⸓╙
2 㧘ᣣᧄ SIDS ቇળ㔀⹹ 2006 ᐕ㧧6 Ꮞ㧦73㧙97㧚
2㧕 ᱞౝᐽ㓶㧚⓸ᕷ߹ߚߪ⯦ᓙߣ⓭ὼᱫ㧘ᣣᧄ SIDS ቇળ㔀⹹ 2007 ᐕ㧧7 Ꮞ㧦44㧙47㧚
✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
ߥߒේ⪺㧔᰷ᢥ㧕
1㧕 Tsujinaka M, Bunai Y. Postmortem ophthalmologic examination by endoscopy. Am J Forensic Med
Pathol. 2006;27:287-291.
2㧕 Nagai A, Nakamura I, Bunai Y. Analysis of the HVI, HVII and HVIII regions of mtDNA in 400
unrelated Japanese. Prog Forensic Genet. 2006;11:139-141.
3㧕 Endo S, Matsunaga T, Horie K, Tajima K, Bunai Y, Carbone V, El-Kabbani O, Hara A. Enzymaticcharacteristics of an aldo-keto reductase family protein (AKR1C15) and its localization in rat tissues.
Arch Biochem Biophys. 2007;465:136-147.
4㧕 Bunai Y, Akaza K, Tsujinaka M, Nakamura I, Nagai A, Jiang W-X, Mizoguchi Y, Ohya I. Sudden death
due to undiagnosed intracranial hemangiopericytoma. Am J Forensic Med Pathol. 2008;29:170-172.
5㧕 Bunai Y, Akaza K, Jiang WX, Nagai A. Fatal hyperthermia associated with excited delirium during anarrest. Leg Med. 2008;10:306-309.
6㧕 Chen H, Shoumura S, Emura S, Bunai Y. Regional variations of vertebral trabecular bone
microstructure with age and gender. Osteoporos Int. 2008;19:1473-1483.
7㧕 Nagai A, Bunai Y. Analysis of mtDNA HVIII length heteroplasmy. Forensic Science International:
Genetics Supplement Series. 2008;1:290-291.

㧙㧙

IF 0.603

IF 2.969
IF 0.603

IF 3.893

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦ᱞౝᐽ㓶㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)⌒⑼↪ౝⷞ㏜ࠍ↪޿ߡߩᴺක೬ᬌ଀ߦ߅ߌ
ࠆ⌒ᐩᚲ⷗ߩᗧ⟵ߩᬌ⸛㧧ᐔᚑ 19㧙20 ᐕᐲ㧧1,840 ජ౞(1,040 ජ౞㧦800 ජ౞)
2㧕ฃ⸤⎇ⓥ1㧕 ᱞౝᐽ㓶㧦⮎Ქ‛ᬌᩏ╬ฃ⸤੐ᬺ⾌㧧ᐔᚑ 18 ᐕᐲ㧧3,611 ජ౞㧦ጘ㒂⋵⼊ኤᧄㇱ
2㧕 ᱞౝᐽ㓶㧦⮎Ქ‛ᬌᩏ╬ฃ⸤੐ᬺ⾌㧧ᐔᚑ 19 ᐕᐲ㧧5,156 ජ౞㧦ጘ㒂⋵⼊ኤᧄㇱ
3㧕 ᱞౝᐽ㓶㧦⮎Ქ‛ᬌᩏ╬ฃ⸤੐ᬺ⾌㧧ᐔᚑ 20 ᐕᐲ㧧3,270 ජ౞(12 ᦬⃻࿷)㧦ጘ㒂⋵⼊ኤᧄㇱ3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬᱞౝᐽ㓶㧦
1㧕 ᣣᧄᴺකቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᴺක∛ℂ⎇ⓥળㆇ༡ᆔຬ(㨪⃻࿷)3㧕 ᣣᧄ SIDS ቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄ SIDS ቇળ∝଀ᬌ⸛ᆔຬ(㨪⃻࿷)5㧕 ᣣᧄ SIDS ቇળ⸻ᢿၮḰᬌ⸛ᆔຬ(㨪⃻࿷)2㧕ቇળ㐿௅ᱞౝᐽ㓶㧦
1㧕 ╙ 14 ࿁ᣣᧄ SIDS(੃ᐜఽ⓭ὼᱫ∝୥⟲)ቇળቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 3 ᦬㧘ጘ㒂)
3㧕ቇⴚ㔀⹹
ᱞౝᐽ㓶㧦
1㧕 ᴺක∛ℂ㧧✬㓸ᆔຬ㐳(㨪⃻࿷)2㧕 Legal Medicine㧧Editorial Board(㨪⃻࿷)7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ᱞౝᐽ㓶㧦
1㧕 ᴺක∛ℂ⎇ⓥળ╙ 13 ࿁ᄐᦼ࠮ࡒ࠽࡯(2006 ᐕ 7 ᦬㧘ጘ㒂㧘․೎⻠ṶΣ‫♧ޟ‬ዩ∛ౝಽᴲ∔ᖚߦࠃࠆ⓭ὼᱫ‫ޠ‬ᐳ㐳)2㧕 ᴺක∛ℂ⎇ⓥળ╙ 13 ࿁ᄐᦼ࠮ࡒ࠽࡯(2006 ᐕ 7 ᦬㧘ጘ㒂㧘․೎⻠ṶΥ‫ޟ‬SIDS ߣవᄤઍ⻢⇣Ᏹ‫ޠ‬ᐳ㐳)
3㧕 ╙ 13 ࿁ᣣᧄ SIDS(੃ᐜఽ⓭ὼᱫ∝୥⟲)ቇળቇⴚ㓸ળ(2007 ᐕ 3 ᦬㧘⑔ጟ㧘ࠪࡦࡐࠫ࠙ࡓ‫੃ޟ‬ᐜఽ⓭ὼᱫ∝୥⟲ߩ⊒↢ⷐ࿃ߣ੍㒐㧙㘃✼∔ᖚ‫ޔ‬੐᡿ᱫ߿⯦ᓙߣߩ㐓೎߽฽߼ߡ㧙‫ޠ‬Ṷ⠪)
4㧕 ╙ 14 ࿁ᣣᧄ SIDS(੃ᐜఽ⓭ὼᱫ∝୥⟲)ቇળቇⴚ㓸ળ(2008 ᐕ 3 ᦬㧘ጘ㒂㧘ᢎ⢒⻠Ṷ‫੹ޟ‬ᣣߩᐜఽ࡮
ఽ┬⯦ᓙߣߘߩ⢛᥊‫ޠ‬ᐳ㐳)᳗੗ ᷕ㧦
1㧕 ᣣᧄᲫ㜬⟤ኈቇળ╙ 2 ࿁ቇⴚᄢળ(2008 ᐕ 2 ᦬㧘ᵿ᧻㧘ᢎ⢒⻠Ṷ‫ޟ‬Ძ㜬ߣ⊹⤏㧙േ‛ߩਇᕁ⼏㧙‫ޠ‬ᐳ㐳)
2㧕 ᣣᧄᲫ㜬⟤ኈቇળ╙ 2 ࿁ቇⴚᄢળ(2008 ᐕ 2 ᦬㧘ᵿ᧻㧘ᢎ⢒⻠Ṷ‫ⴊޟ‬ᶧߢⷫሶࠍ᳿߼ࠆ‫ޠ‬ᐳ㐳)
3㧕 ᣣᧄᲫ㜬⟤ኈቇળ╙ 2 ࿁ቇⴚᄢળ(2008 ᐕ 2 ᦬㧘ᵿ᧻㧘ᢎ⢒⻠Ṷ‫ޟ‬㜬ߩᲫ 1 ᧄߢ“޽ߥߚ”߇ࠊ߆ࠆ㧙Ძ㜬ߣ DNA ಽᨆ㧙‫ޠ‬Ṷ⠪)㧙㧙8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേᱞౝᐽ㓶㧦
1㧕 ጘ㒂⋵౏ኂክᩏળᆔຬ(㨪⃻࿷)10㧚ႎ๔ᦠߥߒ11㧚ႎ㆏
1㧕 ᱞౝᐽ㓶㧦⓸ᕷ࡮⯦ᓙ㧙ᓸ⚦ߥᄌൻߦ߽ᵈᗧ߇ᔅⷐ㧦Medical Tribune(2007 ᐕ 5 ᦬ 17 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔᐕ㑆 70㨪80 ૕ߩᴺක⸃೬ߩ㐓ቯࠍབྷ⸤ߐࠇߡ߅ࠅ㧘⸃೬߿ߘߩᓟߩᬌᩏ㧘㐓ቯᦠ૞ᚑ╬ߩߚ߼⎇ⓥߩ
ߚ߼ߩᤨ㑆߇೙⚂ߐࠇߡ޿ࠆ߇㧘ߘࠇߥࠅߩᚑᨐࠍ޽ߍࠄࠇߚߣᕁߞߡ޿ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ᴺකቇಽ㊁ߢߪ㧘⃻࿷ 2 ฬߩᢎຬ߇ᢎ⢒࡮⎇ⓥ࡮ታോߦᓥ੐ߒߡ߅ࠅ㧘⎇ⓥߥߤߩ㕙ߢߪ࿖ౝᄖ߆ࠄ
⋧ᔕߩ⹏ଔࠍฃߌߡ޿ࠆ‫ࠄ߇ߥߒ߆ߒޕ‬㧘⎇ⓥ㗔ၞ߇߿߿࿕ቯൻߒߡ߈ߡ޿ࠆߎߣߪุ߼ߕ㧘߹ߚ㧘ੱ੐߇࿕ቯൻߒߟߟ޽ࠆߣ޿߁໧㗴ὐ߽޽ࠆ‫ߢߎߘޕ‬㧘੹ᓟߪቇᄖߣߩ౒ห⎇ⓥࠍ⋡ᜰߒߥ߇ࠄ㧘ቇ໧ߩㅴᱠߦೣߒᣂߒ޿⎇ⓥᚻᴺࠍขࠅ౉ࠇ㧘ᤨઍߩ௑ะߦೣߒߡ⎇ⓥಽ㊁ࠍᐢߍࠆᔅⷐ߇޽ࠆߣ⠨߃ࠄࠇࠆ‫ޕ‬߹ߚ㧘ᧄಽ㊁ߦᣂߒ޿ᕷ็ࠍᒁ߈⿠ߎߔߚ߼ߦ㧘ᄢቇ㒮↢߇౉ቇߒ߿ߔ޿ⅣႺߣ⸳஻ࠍᢛ߃ࠆߎߣ߇ᕆ
ോߢ޽ࠆߣ⠨߃ࠄࠇࠆ‫ޕ‬੹ᓟߩዷᦸᴺක∛ℂቇ⊛ߥ⎇ⓥߣߒߡ㧘੹ᓟᄖ்ߩ∛ℂ㧘․ߦ㧘ฃ்ᓟᣧᦼߦ⿠ߎࠆᄌൻߦߟ޿ߡ㧘ಽሶ∛ℂቇ
⊛⎇ⓥࠍᆎ߼ߚ޿‫ޕ‬DNA ᄙဳߦ㑐ߔࠆ⎇ⓥߢߪ㧘ᒁ߈⛯߈ᣣᧄੱ㓸࿅ߦ߅ߌࠆ DNA ᄙဳߩ࠺࡯࠲ࡌ࡯
ࠬൻࠍㅴ߼ࠆߣߣ߽ߦ㧘୘ੱ⼂೎ߦ᦭↪ߥ DNA ᄙဳ㗔ၞߩᬌ⸛ߥࠄ߮ߦ DNA ᄙဳߩࠃࠅല₸⊛ߥᬌ಴ᴺߩ㐿⊒╬㧘਎⇇ߩ⿲൓ߦㆃࠇߕ㧘⎇ⓥࠍផㅴߒߡ޿߈ߚ޿‫ޕ‬㧙㧙㧔7㧕↥ᬺⴡ↢ቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
ⴡ↢ቇߪᐢ޿ᗧ๧ߢߩⅣႺߣࡅ࠻ߩ㑐ࠊࠅࠍ⸃ᨆߒ㧘ࡅ࠻ߩஜᐽߩ଻ᜬ࡮Ⴧㅴߦነਈߔࠆߎߣࠍ⋡⊛ߣߒߚታቇߢ޽ࠆ‫↢ⴡޕ‬ቇߪ൮᜝⊛ߥᔕ↪⑼ቇߢ޽ߞߡ㧘ၮ␆කቇߦዻߔࠆ߽ߩߢߪߥߊ㧘␠ળකቇߩ৻ಽ
㊁ߢ޽ࠆ‫ޕ‬ᓥߞߡ㧘␠ળߩⷐ⺧ߦⓍᭂ⊛ߦ╵߃ߡ޿߆ߥߊߡߪߥࠄߥ޿ኋ๮ߦ޽ࠆ‫⃻ޕ‬࿷ߩ↥ᬺⴡ↢ቇಽ㊁ߩ⎇ⓥౝኈߪ㧘⡯႐ߦ߅ߌࠆታ〣ᵴേࠍㅢߓߚ߽ߩߢ㧘એਅߩࠃ߁ߥ⎇ⓥࠍⴕߞߡ޿ࠆ‫ޕ‬
㧔1㧕ᑪ⸳ഭ௛⠪㧘㔚ᩇ㔚✢Ꮏ੐ᓥ੐⠪ߥߤߩደᄖഭ௛⠪ࠍኻ⽎ߦஜᐽ໧㗴㧘૞ᬺⅣႺ㧘ഭ௛᧦ઙߩᬌ⸛
ࠍⴕ޿㧘ᔟㆡ⡯႐ߠߊࠅߩߚ߼ߩ⎇ⓥ㧘
㧔2㧕ᾲਛ∝㧘ᝄേ㓚ኂ㧘㛍㖸ᕈ㔍⡬ߩ੍㒐ߩ⎇ⓥ㧘
㧔3㧕ฦ⒳⡯႐ߦ߅ߌࠆ⣶∩ࠍߪߓ߼ߣߒߚ╭㛽ᩰ♽㓚ኂ੍㒐ߩ⎇ⓥ㧘
㧔4㧕⡯႐ߩࡔࡦ࠲࡞ࡋ࡞ࠬߩ⎇ⓥ㧘
㧔5㧕කᏧࠍߪ
ߓ߼ߣߒߚක≮ᓥ੐⠪ߩஜᐽ㓚ኂ੍㒐ߩ⎇ⓥࠍⴕߞߡ޿ࠆ‫ޕ‬
2㧚ฬ★
ಎᢎ᝼㧦 ੗ᄹᵄ⦟৻

Ryoichi Inaba

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ੗ᄹᵄ⦟৻㧚ഭ௛ⴡ↢ኻ╷ߩၮᧄ㧦↥ᬺ଻ஜࡂࡦ࠼ࡉ࠶ࠢ✬㓸ᆔຬળ✬㧘↥ᬺ଻ஜࡂࡦ࠼ࡉ࠶ࠢ ᡷ⸓ 4㧘᧲੩㧦ഭ௛⺞ᩏળ㧧2006 ᐕ㧦7.
2㧕 ੗ᄹᵄ⦟৻㧚‫ޟ‬ஜᐽߠߊࠅߩߚ߼ߩㆇേᜰ㊎ 2006‫ߡ޿ߟߦޠ‬㧦↥ᬺ଻ஜࡂࡦ࠼ࡉ࠶ࠢ✬㓸ᆔຬળ✬㧘↥ᬺ଻ஜࡂࡦ࠼ࡉ࠶ࠢ ᡷ⸓ 5 㧘᧲੩㧦ഭ௛⺞ᩏળ㧧2007 ᐕ㧦35.
3㧕 ੗ᄹᵄ⦟৻㧚⡯႐ߩஜᐽ▤ℂ㧘ጘ㒂㧘(⽷)ጘ㒂⋵Ꮢ↸᧛ⴕ᡽ᖱႎ࠮ࡦ࠲࡯㧘2007 ᐕ㧦1㧙27.
4㧕 ੗ᄹᵄ⦟৻㧚‫ޟ‬቟ⴡᴺ਄ߩஜ⸻࡮଻ஜᜰዉߣ․ቯஜ⸻࡮․ቯ଻ஜᜰዉ‫ޠ‬㧦↥ᬺ଻ஜࡂࡦ࠼ࡉ࠶ࠢ✬㓸ᆔຬળ✬㧘↥ᬺ଻ஜࡂࡦ࠼ࡉ࠶ࠢ ᡷ⸓ 6 㧘᧲੩㧦ഭ௛⺞ᩏળ㧧2008 ᐕ㧦24.
⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 ੗ᄹᵄ⦟৻㧚ㆮ〔⊒ជ⃻႐ߩഭ௛⽶ᜂ㧙ᄐᦼߩᾲਛ∝ኻ╷㧙㧘ഭ௛ߩ⑼ቇ 2006 ᐕ㧧61 Ꮞ㧦626㧙629㧚
2㧕 ੗ᄹᵄ⦟৻㧚ㆮ〔⊒ជ⃻႐ߩഭ௛⽶ᜂ㧙౻ᦼߩ㒐ኙኻ╷㧙㧘ഭ௛ߩ⑼ቇ 2007 ᐕ㧧62 Ꮞ㧦174㧙176.
✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ੗ᄹᵄ⦟৻㧘ᐢἑਁቲሶ㧘㤥Ꮉᷕ৻㧘੗਄⋿ੱ㧘ጤ↰ᒄᢅ㧚ᄢቇ↢ද⺞ℂ႐ᓥᬺຬߩᄐᦼߩ⥄ⷡ∝⁁ߣᥤᾲኻ╷㧘ᣣᧄ⡯ᬺ࡮ἴኂකቇળળ⹹ 2006 ᐕ㧧54 Ꮞ㧦18㧙24.
2㧕 ੗ᄹᵄ⦟৻㧘੗਄⋿ੱ㧚ၒ⬿ᢥൻ⽷⊒ជ⺞ᩏᯏ㑐ߦ߅ߌࠆഭ௛቟ోⴡ↢▤ℂߩታᘒ ╙ 2 ႎ㧘ᣣᧄ⡯ᬺ࡮ἴኂකቇળળ⹹ 2006 ᐕ㧧54 Ꮞ㧦262㧙267.
3㧕 ੗ᄹᵄ⦟৻㧘ᣣ⟎ᢕᏈ㧚⥄ᴦ૕ߦ߅ߌࠆ቟ోⴡ↢▤ℂᵴേߩታᘒ㧘ᣣᧄ⡯ᬺ࡮ἴኂකቇળળ⹹ 2007 ᐕ㧧
55 Ꮞ㧦39㧙48.
4㧕 ੗ᄹᵄ⦟৻㧘ᐢἑਁቲሶ㧘ዊ㊁᩵ሶ㧘㤥Ꮉᷕ৻㧘੗਄⋿ੱ㧚ደᄖ㔚ᩇ㔚✢Ꮏ੐ᓥ੐⠪ߩᄐᦼߩ⥄ⷡ∝⁁ߣᥤᾲኻ╷㧘ᣣᧄ⡯ᬺ࡮ἴኂකቇળળ⹹ 2007 ᐕ㧧55 Ꮞ㧦105㧙112.
5㧕 ੗ᄹᵄ⦟৻㧘ᮮጊ๺ੳ㧚⵾ㅧᎿ႐↵ᕈഭ௛⠪ߩ⡯႐ߩࡔࡦ࠲࡞ࡋ࡞ࠬኻ╷ߦ߅ߌࠆ࿾ၞߩ♖␹⑼࡮ක≮ᯏ㑐ߦኻߔࠆ㊀ⷞᐲߣḩ⿷ᐲߦ㑐ߔࠆ⺞ᩏ㧘ᣣᧄ⡯ᬺ࡮ἴኂකቇળળ⹹ 2007 ᐕ㧧55 Ꮞ㧦128㧙135.
6㧕 ੗ᄹᵄ⦟৻㧘㤥Ꮉᷕ৻㧘੗਄⋿ੱ㧚ᄢቇ∛㒮කᏧߩ㔌⡯㗿ᦸߣൕോ⁁ᴫ㧘ᣣᏱ↢ᵴ⠌ᘠ߅ࠃ߮⡯ᬺᕈࠬ࠻࡟ࠬߣߩ㑐ଥ㧘ᣣᧄ⡯ᬺ࡮ἴኂකቇળળ⹹ 2007 ᐕ㧧55 Ꮞ㧦219㧙225.
7㧕 ੗၂ㅢੱ㧘㒋ᧄ৻ᦶ㧘੗ᄹᵄ⦟৻㧚ᄐᦼߦ߅ߌࠆ಄ᚱⅣႺਅߩࠬ࡯ࡄ࡯ࡑ࡯ࠤ࠶࠻ᅚᕈᓥᬺຬࠍኻ⽎ߣߒߚ⫳᳇᷷ᾲࠪ㧙࠻ߩㆡ↪ലᨐ㧘ᣣᧄ⡯ᬺ࡮ἴኂකቇળળ⹹ 2007 ᐕ㧧55 Ꮞ㧦233㧙238.
8㧕 ੗ᄹᵄ⦟৻㧘੗਄⋿ੱ㧘ጤ↰ᒄᢅ㧚ᑪ‛⸃૕૞ᬺ⠪ߦ߅ߌࠆ౻ᦼߩ⥄ⷡ∝⁁⺞ᩏ ╙ 2 ႎ㧘ᣣᧄ⡯ᬺ࡮ἴኂකቇળળ⹹ 2007 ᐕ㧧55 Ꮞ㧦253㧙259.
9㧕 㤥Ꮉᷕ৻㧘੗਄⋿ੱ㧘੗ᄹᵄ⦟৻㧘ጤ↰ᒄᢅ㧚ࡔࡦ࠲࡞ࡋ࡞ࠬਇ⺞⠪߳ߩኻᔕ੐଀ࠍㅢߓߡ⡯႐ߢߩ໧㗴ὐࠍ⠨߃ࠆ㧘ᣣᧄ⡯ᬺ࡮ἴኂකቇળળ⹹ 2008 ᐕ㧧56 Ꮞ㧦53㧙61.
10㧕 ੗ᄹᵄ⦟৻㧘㤥Ꮉᷕ৻㧘੗਄⋿ੱ㧚᳃᦭ᨋᬺഭ௛⠪ߦ߅ߌࠆ౻ᦼߩ⥄ⷡ∝⁁ߣ㒐ኙኻ╷㧘ᣣᧄ⡯ᬺ࡮ἴኂකቇળળ⹹ 2008 ᐕ㧧56 Ꮞ㧦192㧙197.
ේ⪺㧔᰷ᢥ㧕
1㧕 Inaba R, Mirbod SM. Comparison of subjective symptoms and hot prevention measures in summer
between traffic control workers and construction workers in Japan. Ind Health. 2007;45:91-99.
IF 0.792㧙㧙4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦ᮮጊ๺ੳ(ਃ㊀ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼)㧘⎇ⓥಽᜂ⠪㧦੗ᄹᵄ⦟৻㧧ෘ↢ഭ௛⑼ቇ⎇ⓥ
⾌⵬ഥ㊄㧦ഭ௛⠪ߩࡔࡦ࠲࡞ࡋ࡞ࠬኻ╷ߦ߅ߌࠆ࿾ၞ଻ஜ࡮ක≮ߣߩㅪ៤ߩ޽ࠅᣇߦ㑐ߔࠆ⎇ⓥ㧧
ᐔᚑ 16㧙18 ᐕᐲ㧧3,000 ජ౞(1,000㧦1,000㧦1,000 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦ᮮጊ๺ੳ(ਃ㊀ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼)㧘⎇ⓥಽᜂ⠪㧦੗ᄹᵄ⦟৻㧧ෘ↢ഭ௛⑼ቇ⎇ⓥ
⾌⵬ഥ㊄㧦ഭ௛⠪ߩࡔࡦ࠲࡞ࡋ࡞ࠬਇ⺞ߩ੍㒐ߣᣧᦼᡰេ࡮੺౉ߩ޽ࠅᣇߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 20 ᐕᐲ㧧600 ජ౞2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥ1㧕 ੗ᄹᵄ⦟৻㧦߼ߋࠅ࠭ࡓ᷷ᾲࡄࡢ࡯ක≮ᯏེ෸߮ߘߩ᷷ᾲ㑐ㅪ㐿⊒ຠߩㆡ↪ലᨐ⺞ᩏ෸߮໪⊒㧧ᐔ
ᚑ 19 ᐕᐲ㧙20 ᐕᐲ㧧500 ජ౞㧦⧎₺ࡄ࡯࠰࠽࡞ࡋ࡞ࠬࠤࠕ⎇ⓥᚲ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬ
੗ᄹᵄ⦟৻㧦
1㧕 ᣣᧄⴡ↢ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ↥ᬺⴡ↢ቇળઍ⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ᳃ᣖⴡ↢ቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄ᷷ᴰ᳇୥‛ℂකቇળ⹏⼏ᆔຬ(㨪⃻࿷)2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
੗ᄹᵄ⦟৻㧦
1㧕 ᣣᧄ᷷ᴰ᳇୥‛ℂකቇળ㔀⹹㧧✬㓸ᆔຬ(ᐔᚑ 19 ᐕ 5 ᦬㨪⃻࿷)7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳੗ᄹᵄ⦟৻㧦
1㧕 ╙ 3 ࿁੤ㅢ⑼ቇࠪࡦࡐࠫ࠙ࡓ㧙⡯ᬺㆇォᚻࠍ߅ߘ߁∛᳇(ᐔᚑ 20 ᐕ 2 ᦬㧘᧲੩㧘‫ࠢ࠶࡜࠻ޟ‬ㆇォᚻߩ⌁᳇⊒∝ߣ੤ㅢ੐᡿‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേ
੗ᄹᵄ⦟৻㧦
1㧕 ᑪ⸳ᬺߦ߅ߌࠆஜᐽߠߊࠅߩ޽ࠅᣇߦ㑐ߔࠆ⺞ᩏ⎇ⓥᆔຬળᆔຬ(ᐔᚑ 18 ᐕᐲ)
2㧕 ᝄേ㓚ኂ╬ߩ㒐ᱛߦଥࠆ૞ᬺ▤ℂߩ޽ࠅᣇᬌ⸛ળᆔຬ(ෘ↢ഭ௛⋭)(ᐔᚑ 19 ᐕᐲ)
3㧕 ጘ㒂⋵⥄ὼⅣႺ଻ోᆔຬળᆔຬ(ᐔᚑ 20 ᐕᐲ)
4㧕 ጘ㒂ᏒⅣႺክ⼏ળᆔຬ(ᐔᚑ 20 ᐕᐲ)
5㧕 ↥ᬺ଻ஜ⋧⺣ຬ(ጘ㒂↥ᬺ଻ஜផㅴ࠮ࡦ࠲࡯)(ᐔᚑ 20 ᐕᐲ)
6㧕 ഭ௛ⴡ↢ᜰዉක(ጘ㒂ഭ௛ዪ)(ᐔᚑ 20 ᐕᐲ)
7㧕 ጘ㒂⋵ⅣႺᓇ㗀⹏ଔክᩏળᆔຬ(ᐔᚑ 20 ᐕᐲ)㧙㧙10㧚ႎ๔ᦠ
1㧕 ੗ᄹᵄ⦟৻㧦ഭ௛⠪ߩ⡯႐ߩࡔࡦ࠲࡞ࡋ࡞ࠬኻ╷ߦ߅ߌࠆ࿾ၞߩ♖␹⑼࡮ක≮ᯏ㑐ߦኻߔࠆ㊀ⷞᐲߣḩ⿷ᐲߦ㑐ߔࠆ⺞ᩏ ߘߩ 2㧦ᐔᚑ 17 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ㧦
97㧙111(2006 ᐕ 3 ᦬)
2㧕 ੗ᄹᵄ⦟৻㧦ഭ௛⠪ߩ⡯႐ߩࡔࡦ࠲࡞ࡋ࡞ࠬኻ╷ߦ߅ߌࠆ࿾ၞߩ♖␹⑼࡮ක≮ᯏ㑐ߦኻߔࠆ㊀ⷞᐲߣḩ⿷ᐲߦ㑐ߔࠆ⺞ᩏ ߘߩ 3㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ㧦
73㧙94(2007 ᐕ 3 ᦬)
11㧚ႎ㆏
1㧕 ੗ᄹᵄ⦟৻㧘੗၂ㅢੱ㧦‫ޟ‬ㇱಽ᷷߼‫ޠ‬಄߃ㆊ߉㒐ߋ㧦⼛⾬ᣂ⡞(2008 ᐕ 8 ᦬ 27 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔ᭎ⷐߦ␜ߒߚᒰಽ㊁ߩ⎇ⓥࠍታᣉߒ㧘⺰ᢥࠍ૞ᚑߒߚ‫⺰ޕ‬ᢥߦߟ޿ߡ㧘ో૕ߩᢙߪචಽߛߣ⠨߃ࠄࠇࠆ߇㧘᰷ᢥ⺰ᢥ߇ዋߥ޿ߩߢ㧘ߎߩὐߩ޿ߞߘ߁ߩദജ߇ᔅⷐߢ޽ࠆ‫ޕ‬ᄖㇱ⾗㊄ߦߟ޿ߡߪ㧘ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄㧘౒ห⎇ⓥ㧘ᅑቇነઃ㊄ࠍᓧߚ߇㧘੹ᓟᢥㇱ⑼ቇ⋭߆ࠄߩ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ࠍ₪ᓧߔࠆᔅⷐ߇޽ࠆ‫␠ޕ‬ળᵴേߦߟ޿ߡߪචಽⴕࠊࠇߡ޿ࠆߣ⠨߃ߡ޿ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ᢎຬ߇ 1 ฬߢࡑࡦࡄࡢ࡯ߦ໧㗴߇޽ࠅ㧘߹ߚ⎇ⓥቶ߇ᚻ⁜ߥߚ߼ታ㛎⊛⎇ⓥ߇߶ߣࠎߤߢ߈ߥ޿ߣ޿
߁໧㗴ὐ߇޽ࠆ‫ࠍࠇߎޕ‬ᛂ㐿ߔࠆߚ߼ߦᄢቇ㒮౉ቇߩ൘⺃߿㧘ઁಽ㊁㧘ઁᣉ⸳ߣߩ౒ห⎇ⓥߦജࠍ౉ࠇ
ߡ޿ࠆ‫ޕ‬
੹ᓟߩዷᦸ੹ᓟߣ߽㧘⡯႐ߩታ〣ᵴേࠍㅢߓߚ⎇ⓥࠍⴕ޿㧘ߘߩᚑᨐࠍ⡯႐ߦㆶరߒߚ޿‫ޕ‬ᒰ㕙㧘ᢎຬߩჇຬߪ
ᦸ߼ߥ޿ߩߢ㧘↥ᬺⴡ↢ߩ㊀ⷐᕈࠍᒝߊ⸷߃㧘߹ߚᄢቇ㒮↢㧘⎇ⓥ↢ߩฃߌ౉ࠇ߿ઁಽ㊁㧘ઁᣉ⸳ߣߩ
౒ห⎇ⓥߢᒰಽ㊁ߩ⊒ዷߩᵴ〝ࠍ⷗಴ߒߚ޿‫ޕ‬㧙㧙㧔8㧕කቇᢎ⢒ቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
ᐔᚑ 20 ᐕᐲ㧔2008 ᐕ 4 ᦬㧕ࠃࠅጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼ක≮▤ℂቇ⻠ᐳߦ‫ޟ‬කቇᢎ⢒ቇ‫ޠ‬ಽ㊁߇㐿⻠ߐࠇߚ‫ޕ‬කቇᢎ⢒ቇߪ㧘කቇ࡮ක≮ᢎ⢒ಽ㊁ߦ߅ߌࠆᄙ㕙⊛ߥ⺖㗴ࠍⓥ᣿ߒ㧘ലᨐ⊛ߥᢎ⢒ᣇᴺࠍ⎇ⓥߔࠆቇ໧㗔ၞߢ޽ࠅ㧘කቇ࡮ක≮ᢎ⢒ࠍⴕ߁ߚ߼ߩౕ૕⊛⍮⼂߿ࠬࠠ࡞ߩ⠌ᓧࠍ߼ߑߒߡ޿ࠆ‫⺖ᧄޕ‬⒟ࠍୃੌߒߚ⠪ߪ㧘කቇᢎ⢒ቇߩኾ㐷ኅߣߒߡ㧘ᢎຬ࡮කᏧ࡮ቇ↢╬ࠍᜰዉߔࠆ⢻ജࠍ᦭ߒ㧘ᢎ⢒ࠪࠬ࠹ࡓࠍ⥄ࠄ᭴▽࡮ᡷༀߒ㧘⎇ⓥࠍㆀⴕߢ߈ࠆߎߣࠍ⋡ᮡߣߔࠆ‫ޕ‬කቇᢎ⢒㐿⊒⎇ⓥ࠮ࡦ࠲࡯ߪో࿖౒ห೑↪ᣉ⸳ߣߒߡᵴേߒߡ߅ࠅ㧘੹ᓟ㧘ో࿖߆ࠄߩᄢቇ㒮ᢎ⢒Ꮧᦸ⠪ߩฃߌ⋁ߣߒߡ߽ᯏ⢻ߒߡⴕ߈ߚ޿ߣ⠨߃ߡ
޿ࠆ‫ޕ‬
2㧚ฬ★
ᢎ᝼(૬છ)㧦 ㋈ᧁ ᐽਯ
ᢎ᝼(૬છ)㧦 ⮮ፒ ๺ᒾ
ᢎ᝼(૬છ)㧦 ਤ⠀ 㓷ਯ

Yasuyuki Suzuki
Kazuhiko Fujisaki
Masayuki Niwa

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ㋈ᧁᐽਯ㧚කቇᢎ⢒㧦ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦309㧙313㧚
2㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ̉07 ⑺́╙ 26 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯ࠢࠪ
࡚࠶ࡊߩ⸥㍳́㧘ฬฎደ㧦ਃᕺ␠㧧2008 ᐕ㧦1㧙100㧚
3㧕 ⮮ፒ๺ᒾ㧚ⴕേᄌኈࠍ߁ߥ߇ߔߚ߼ߩ㕙ធࠬࠠ࡞́଻ஜᜰዉኻੱេഥࠬࠠ࡞ߩቇ⠌́㧦ᣣᧄ↢ᵴදห⚵วㅪวળක≮ㇱળ㧧2008 ᐕ㧦1㧙45㧚
4㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ̉08 ౻́╙ 27 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯ࠢࠪ
࡚࠶ࡊߩ⸥㍳́㧘ฬฎደ㧦ਃᕺ␠㧧2008 ᐕ㧦1㧙130㧚
5㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ̉08 ᤐ́╙ 28 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯ࠢࠪ
࡚࠶ࡊߩ⸥㍳́㧘ฬฎደ㧦ਃᕺ␠㧧2008 ᐕ㧦1㧙152㧚
6㧕 ⮮ፒ๺ᒾ㧚ᖚ⠪́ක≮⠪㑐ଥ́㧦ᣣᧄ↥ᬺࠞ࠙ࡦ࠮࡝ࡦࠣቇળ✬㧚↥ᬺࠞ࠙ࡦ࠮࡝ࡦࠣㄉౖ㧦㊄ሶᦠᚱ㧧2008 ᐕ㧦74㧚⪺ᦠ㧔᰷ᢥ㧕
1㧕 Suzuki Y, Niwa M, Shibata T, Chirasak K, Ariyawardana A, Ramesh JC, Evans P, Takahashi Y.
Internet PBL: International Collaborative Learning Experiences In: Oon-Seng Tan, ed. Problem-based
Learning in E-learning Breakthroughs. Singapore: Thomson Learning;2007:131-146.
✚⺑㧔๺ᢥ㧕
1㧕 Ꮉ਄ߜ߭ࠈ㧘⮮ፒ๺ᒾ㧚ᮨᡆᖚ⠪ߩߚ߼ߩ‫ߩޠ࠻࡯ࠪࠢ࡯ࡢࠢ࠶ࡃ࠼࡯ࠖࡈޟ‬ឭ᩺㧘කቇᢎ⢒ 2008 ᐕ㧧
39 Ꮞ㧦417㧙420㧚
2㧕 ᮯ↰⟤㓶㧘ጟ↰శᒄ㧘੖ච፲⚛ሶ㧘ችፒᓀሶ㧘⌀㍿㒽ᄥ㇢㧘⮮ፒ๺ᒾ㧘ർ᧛㓉ᙗ㧘㜞ጊᥓሶ㧘ᄥ↰⢻㧘₹⟎ବᤩ㧘ኹ᎑ศ଻㧘㒙ㇱᥓᕺሶ㧘ፉ↰ᤘੳ㧘ዊᴰ⑲᮸㧚㜞╬ᢎ⢒ᡷ㕟ߩ⋧੕ⴕὑಽᨆ́ࡆ࠺ࠝ࡮ࠛࠬࡁࠣ
࡜ࡈࠖ࡯⎇ⓥߩ⁓޿ߣᎿቇㇱㇺᏒᎿቇṶ⠌ߩታ㓙́㧘ᄢቇᢎ⢒⎇ⓥࠫࡖ࡯࠽࡞ 2008 ᐕ㧧5 ภ㧦93㧙104㧚✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ㋈ᧁᐽਯ㧘㜞ᯅቁ㓶㧘ਛ⇌㦖ବ㧘ᅏጊ⋿♿ሶ㧘᧻የ㓷ᢥ㧘ႇ ⵨ᐘ㧘੖ච፲㓉㧘ᴡ㊁㓁৻㧘ฎᎹ ẋ㧘ේኼ㇢㧚ᣣᧄዊఽ⑼ቇળᢎ⢒ᆔຬળႎ๔ ዊఽ⑼ත೨⥃ᐥታ⠌ߦ㑐ߔࠆࠕࡦࠤ࡯࠻⺞ᩏ⚿ᨐ㧘ᣣᧄዊఽ⑼ቇ
ળ㔀⹹ 2008 ᐕ㧧112 Ꮞ㧦793㧙801㧚
2㧕 㒙ㇱᕺሶ㧘⮮ፒ๺ᒾ㧘઻ାᄥ㇢㧚ᮨᡆᖚ⠪ߩදജࠍᓧߚり૕⸻ኤታ⠌ߩ੹ᓟߩᣇะᕈ㧘ᣣᧄ଻㒾ක≮ⴕേ⑼ቇቇળᐕႎ 2008 ᐕ㧧23 Ꮞ㧦59㧙73㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Evans P, Suzuki Y. “Beyond Competence”. Why Should Outcomes be Adopted in Favour ofCompetences? Medical Education (Japan). 2008;39:87-91.
2㧕 Evans P, Suzuki Y.̌Beyond Competence̍, Assessment for Capability. Medical Education (Japan).
2008;39:93-96.
3㧕 Evans P, Suzuki Y, Begg M, Lam W. Can medical students from two cultures learn effectively from ashared web-based learning environment? Medical Education. 2008;42:27-33.
IF 2.562㧙㧙4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦㜞ᯅఝਃ㧘⎇ⓥදജ⠪㧦ਤ⠀㓷ਯ㧧⍮⊛ࠢ࡜ࠬ࠲࡯ഃᚑ੐ᬺ㧦‫ࡑ࡯࠹ޟ‬Σ㧦ૐଚⷅᓸ⚦ᚻⴚᡰេ࡮ᢎ⢒⸠✵ࠪࠬ࠹ࡓߩ㐿⊒㧦ක≮ᢎ⢒⸠✵ࡠࡏ࠶࠻‫ޠ‬㧧ᐔᚑ 19㧙20 ᐕᐲ㧧46,432 ජ౞(23,200㧦23,232 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦㋈ᧁᐽਯ㧧ᐔᚑ 19 ᐕᐲ ⃻ઍ⊛ᢎ⢒࠾࡯࠭ข⚵ᡰេࡊࡠࠣ࡜ࡓ(⃻ઍ GP)㧦‫⥃ޟ‬ᐥකቇ
ᢎ⢒ࠍᒝൻะ਄ߐߖࠆ ICT㧦e-Learning ߢၭ߁කߩᔃߣᛛ‫ޠ‬㧧ᐔᚑ 19㧙21 ᐕᐲ㧧69,973 ජ౞(23,993㧦21,980㧦24,000 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦㋈ᧁᐽਯ㧘⎇ⓥಽᜂ⠪㧦ട⮮ᥓ⟤㧘㒙ㇱᕺሶ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦
ዊఽ㗔ၞߦ߅ߌࠆቴⷰ⊛⥃ᐥ⢻ജ⹏ଔࠪࠬ࠹ࡓߩ㐿⊒㧧ᐔᚑ 20㧙22 ᐕᐲ㧧4,800 ජ౞(2,300㧦1,100㧦
700 ජ౞)4㧕 ⎇ⓥઍ⴫⠪㧦ᮯ↰⟤㓶(ᓼፉᄢቇ✚ว⑼ቇㇱ)㧘⎇ⓥಽᜂ⠪㧦⮮ፒ๺ᒾ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(B)(2)㧦㜞╬ᢎ⢒ᡷ㕟ߩࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦಽᨆ́⃻႐ߦ߅ߌࠆᢥൻᄌኈߩ⾰⊛ᬌ⸛́㧧ᐔᚑ
18㧙20 ᐕᐲ㧧14,500 ජ౞(5,100㧦4,800㧦4,800 ජ౞)
5㧕 ⎇ⓥઍ⴫⠪㧦㋈ᧁን㓶(ฬฎደᄢቇකቇㇱ㒝ዻ∛㒮✚ว⸻≮ㇱ)㧘⎇ⓥಽᜂ⠪㧦㒙ㇱᕺሶ㧘઻ାᄥ㇢㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦ᣣᧄߩකቇᢎ⢒ߦ߅ߌࠆ 6 ᐕ㑆⛔วဳⴕേ⑼ቇᢎ⢒ࡊࡠࠣ࡜ࡓߩ㐿⊒ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18㧙20 ᐕᐲ㧧3,400 ජ౞(1,300㧦900㧦1,200 ජ౞)
6㧕 ⎇ⓥઍ⴫⠪㧦ᬀ᧛๺ᱜ(ฬฎደᄢቇකቇㇱකቇᢎ⢒࠮ࡦ࠲࡯)㧘⎇ⓥಽᜂ⠪㧦㒙ㇱᕺሶ㧘⨃ᧁ৾㚅㧧ᢥ
ㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦කቇ↢ߩ‫ޟ‬ᱫߩᢎ⢒‫ߩ߳ޠ‬ᮨᡆᖚ⠪ዉ౉ߩᢎ⢒⊛ലᨐߩ⎇ⓥ㧧ᐔᚑ 19㧙20 ᐕᐲ㧧2,870 ජ౞(1,417㧦1,453 ජ౞)
2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬ
㋈ᧁᐽਯ㧦1㧕 ᣣᧄකቇᢎ⢒ቇળℂ੐(㨪⃻࿷)⮮ፒ๺ᒾ㧦1㧕 ᣣᧄකቇᢎ⢒ቇળ⹏⼏ຬ㧘ℂ੐(㨪⃻࿷)2㧕 ᣣᧄකቇᢎ⢒ቇળᢎ᧚㐿⊒࡮SP ዊᆔຬળᆔຬ㐳(㨪⃻࿷)3㧕 ක≮ࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦ⎇ⓥળળ㐳(㨪⃻࿷)4㧕 ․ቯ㕖༡೑ᵴേᴺੱᣣᧄኅᐸක≮ቇળℂ੐(㨪ᐔᚑ 20 ᐕ 6 ᦬)
5㧕 ᣣᧄ␠ળකቇળ⹏⼏ຬ(㨪⃻࿷)6㧕 ᣣᧄක≮⚻ᷣቇળᐙ੐(㨪⃻࿷)7㧕 RIAS ⎇ⓥળળ㐳(ᐔᚑ 18 ᐕ 4 ᦬㨪⃻࿷)ਤ⠀㓷ਯ㧦
1㧕 ᣣᧄකቇᢎ⢒ቇળ⹏⼏ຬ(㨪⃻࿷)㒙ㇱᕺሶ㧦1㧕 Association of Standardized Patient Educators, International committee member(ᐔᚑ 19 ᐕ 11᦬㨪⃻࿷)2㧕 RIAS ⎇ⓥળᆔຬ(ᐔᚑ 18 ᐕ 4 ᦬㨪⃻࿷)㧙㧙

2㧕ቇળ㐿௅㋈ᧁᐽਯ㧦1㧕 ╙ 27 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 20 ᐕ 1 ᦬㧘ฬฎደ)2㧕 ╙ 28 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 20 ᐕ 5 ᦬㧘ᄢ㒋)3㧕 ጘ㒂ᄢቇᮨᡆᖚ⠪ߩળ 10 ๟ᐕ⸥ᔨࠪࡦࡐࠫ࠙ࡓ(ᐔᚑ 20 ᐕ 6 ᦬㧘ጘ㒂)
4㧕 ╙ 29 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 20 ᐕ 8 ᦬㧘ጘ㒂)
5㧕 ╙ 30 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 20 ᐕ 10 ᦬㧘᧲੩)⮮ፒ๺ᒾ㧘㒙ㇱᕺሶ㧦
1㧕 ╙ 3 ࿁ RIAS ࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 20 ᐕ 10 ᦬㧘11 ᦬㧘ฬฎደ)
3㧕ቇⴚ㔀⹹
㋈ᧁᐽਯ㧦1㧕 Medical Education: Editor(2008 ᐕ㨪⃻࿷)7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳
㋈ᧁᐽਯ㧦
1㧕 ╙ 111 ࿁ᣣᧄዊఽ⑼ቇળቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 4 ᦬㧘᧲੩㧘ᄢቇ∛㒮ߩ┙႐߆ࠄ⷗ߚᢎ⢒࡮⎇ⓥߦ߅ߌࠆ∛⸻ㅪ៤㧚✚วࠪࡦࡐࠫ࠙ࡓ 5‫࡮≮⸻ޟ‬ᢎ⢒࡮⎇ⓥࠍ߰߹߃ߚ∛⸻ㅪ៤ߩ⃻⁁ߣᧂ᧪‫ޠ‬Ṷ⠪)2㧕 23rd Annual Meeting of Korean Society of Medical Education. (2008.05, Seoul, Plenary Lecture:
Medical Education in Japan: past, present and future; Performer)
3㧕 ᧲ᶏർ㒽࿾඙⥃ᐥ⎇ୃ∛㒮⺑᣿ળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ฬฎደ㧘‫ߩ᧪ᧂޟ‬ᣣᧄࠍഃࠆዊఽ⑼ක‫ޠ‬Ṷ⠪)
4㧕 ᐔᚑ 20 ᐕᐲጘ㒂⋵⋴⼔ᢎ⢒ㅪ⛊ද⼏ળ✚ળ(ᐔᚑ 20 ᐕ 6 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫⼔⋴ޟ‬ᢎ⢒ߦ߅ߌࠆᮨ
ᡆᖚ⠪ዉ౉ߩᗧ⟵‫ޠ‬Ṷ⠪)
5㧕 ╙ 40 ࿁ᣣᧄකቇᢎ⢒ቇળᄢળ(ᐔᚑ 20 ᐕ 7 ᦬㧘᧲੩㧘Medical Education in Korea: The Historicalbackground and the influence of U.S. by Myung-Hyun Chung㧚ᐳ㐳)‫ޟ‬කቇᢎ⢒ߦ߅ߌࠆዊఽ⑼කߩᓎഀ‫ޠ‬
6㧕 ╙ 122 ࿁ᣣᧄዊఽ⑼ቇળጤᚻ࿾ᣇળ(ᐔᚑ 20 ᐕ 12 ᦬㧘⋓ጟ㧘
Ṷ⠪)
㒙ㇱᕺሶ㧦
1㧕 ᗲ⍮ක⑼ᄢቇ SP 㙃ᚑ࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 8 ᦬㧘ฬฎደ㧘⻠Ṷ‫ޟ‬ᣣᧄߣ਎⇇ߩ SP ੐ᖱ‫ޠ‬Ṷ⠪)2㧕 Association for Medical Education in Europe(2008.08, Prague Czech Republic, Pre-conference:High stakes, low stakes, the proof is in the pudding preparation for quality SP programs;
Performer)
3㧕 International Conference on Communication in Healthcare 2008 by European Association forCommunication in Healthcare (2008.09, Oslo Norway, Symposium-Developing a global networkof national RIAS centres-: RIAS Japan; Symposist)4㧕 ᐔᚑ 18㧙20 ᐕᣣᧄቇⴚᝄ⥝ળ⑼ቇ⎇ⓥ⵬ഥ㊄੤ઃ⎇ⓥ‫ޟ‬ᣣᧄߩකቇㇱᢎ⢒ߦ߅ߌࠆ 6 ᐕ㑆⛔วဳⴕ
േ⑼ቇᢎ⢒ࡊࡠࠣ࡜ࡓߩ㐿⊒ߦ㑐ߔࠆ⎇ⓥ‫ࡓ࠙ࠫࡐࡦࠪޠ‬㧦ත೨කቇᢎ⢒ߦ߅ߌࠆⴕേ⑼ቇᢎ⢒ࠪࡦࡐࠫ࠙ࡓ in NAGOYA(ᐔᚑ 20 ᐕ 11 ᦬㧘ฬฎደ㧘⻠Ṷ‫ޟ‬࿾ၞߢߩࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦᢎ⢒߇ᖱേߦਈ߃ࠆᓇ㗀ߣኅᣖ࡜ࠗࡈࠨࠗࠢ࡞ߣ޿߁ⷞὐߩᔅⷐᕈ㧦࿦ఽ࡮ᅧᇚߣߩ⛮⛯⊛੤ᵹ߆ࠄ‫ޠ‬Ṷ⠪)
5㧕 ╙ 2 ࿁ၯᮨᡆᖚ⠪㙃ᚑ࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 11 ᦬㧘ၯ₹㧘‫ߩࠢ࠶ࡃ࠼࡯ࠖࡈޟ‬ၮᧄ‫ޠ‬Ṷ⠪)
6㧕 ╙ 11 ࿁ᣣᧄࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦቇળਛㇱ྾࿖ᡰㇱᄢળ࡮ක≮ࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦᢎ⢒⎇ⓥ࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 11 ᦬㧘ᐢፉ㧘‫ޟ‬਎⇇ߩ SP ᵴേ㧦SP ߩṶᛛ࡮ࡈࠖ࡯࠼ࡃ࠶ࠢ‫ޠ‬Ṷ⠪)7㧕 ╙ 15 ࿁ක≮ࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦ⎇ⓥળ(ᐔᚑ 20 ᐕ 11 ᦬㧘ฬฎደ㧘‫ޟ‬AMEE࡮EACH ቇળႎ๔‫ޠ‬Ṷ⠪)8㧕 ╙ 2 ࿁ක≮ࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦ࡮ࡈࠔࠪ࡝࠹࡯࠲࡯㙃ᚑ࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 12 ᦬㧘ฬฎደ㧘‫ޟ‬਎⇇
ߩ SP ᵴേ‫ޠ‬Ṷ⠪)⧯ᨋ⧷᮸㧦
1㧕 ᐔᚑ 18㧙20 ᐕᣣᧄቇⴚᝄ⥝ળ⑼ቇ⎇ⓥ⵬ഥ㊄੤ઃ⎇ⓥ‫ޟ‬ᣣᧄߩකቇㇱᢎ⢒ߦ߅ߌࠆ 6 ᐕ㑆⛔วဳⴕ
േ⑼ቇᢎ⢒ࡊࡠࠣ࡜ࡓߩ㐿⊒ߦ㑐ߔࠆ⎇ⓥ‫ࡓ࠙ࠫࡐࡦࠪޠ‬㧦ත೨කቇᢎ⢒ߦ߅ߌࠆⴕേ⑼ቇᢎ⢒ࠪࡦࡐࠫ࠙ࡓ in NAGOYA(ᐔᚑ 20 ᐕ 11 ᦬㧘ฬฎደ㧘⻠Ṷ‫ޟ‬ᣣᧄߦ߅ߌࠆ੹ᓟߩ⛔วဳⴕേ⑼ቇᢎ⢒㧙㧙ࠍ⠨߃ࠆ‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേ
㋈ᧁᐽਯ㧦1㧕 ෘ↢ഭ௛⋭╙ 102 ࿁කᏧ࿖ኅ⹜㛎⹜㛎ᆔຬ(㨪⃻࿷)⮮ፒ๺ᒾ㧦1㧕 ක≮♽ᄢቇ㑆౒↪⹜㛎ታᣉ⹏ଔᯏ᭴කቇ♽ OSCE ੐ᓟ⹏ଔ⸃ᨆዊᆔຬળᆔຬ㧘ቇ⠌࡮⹏ଔ㗄⋡╬ᡷ⸓ኾ㐷ㇱળᆔຬ㧘⺖㗴ᡷ⸓ኾ㐷ㇱળᆔຬ(㨪⃻࿷)2㧕 ᄢቇၮḰදળ‫ࠆ޽⦡․ޟ‬ᄢቇᢎ⢒ᡰេࡊࡠࠣ࡜ࡓ‫(࡯࡝ࠚࡈ࡟࡯ࡄ࡯ࡍޠ‬㨪⃻࿷)3㧕 ෘ↢ഭ௛⋭╙ 101 ࿁කᏧ࿖ኅ⹜㛎 ⹜㛎ᆔຬ(㨪⃻࿷)4㧕 ෘ↢ഭ௛⋭╙ 102 ࿁කᏧ࿖ኅ⹜㛎 ⹜㛎ᆔຬ(㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ⮮ፒ๺ᒾ㧦⥃ᐥ୶ℂታ〣ߩߚ߼ߩࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦ㧦ᣣᧄකቇᢎ⢒ቇળ୶ℂ࡮ⴕേ⑼ቇዊᆔຬળ
╙ 3 ࿁⥃ᐥ⎇ୃᜰዉ⠪ߩߚ߼ߩ୶ℂᢎ⢒ࡢ࡯࡚ࠢࠪ࠶ࡊႎ๔ᦠ㧦55㧙58(2008 ᐕ 1 ᦬)
2㧕 ⮮ፒ๺ᒾ㧘਄↸੝Ꮧሶ㧦⮎ቇㇱ 6 ᐕ೙߳́ߎࠇ߆ࠄߩ⮎೷Ꮷߦ᳞߼ࠄࠇࠆࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦࠬࠠ
࡞㧦㒋␹࡮᷆〝ᄢ㔡ἴᓟߩ࿾ၞ␠ળߣߩ౒↢ࠍ߼ߑߒߚᄢቇߩᣂߒ޿ᓎഀߦ㑐ߔࠆታ〣⊛⎇ⓥႎ๔
ᦠ╙ 27 ภ㧦1㧙50(2008 ᐕ 1 ᦬)
3㧕 ਤ⠀㓷ਯ㧦╙ 28 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ ࠕ࠽࠙ࡦࠬࡔࡦ࠻㧦කቇᢎ⢒ 38㧦86(2008ᐕ 3 ᦬)
4㧕 ਤ⠀㓷ਯ㧦╙ 29 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ ࠾ࡘ࡯࠭㧦කቇᢎ⢒ 38㧦359(2008 ᐕ 10 ᦬)
5㧕 ਤ⠀㓷ਯ㧦╙ 30 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ ࠕ࠽࠙ࡦࠬࡔࡦ࠻㧦කቇᢎ⢒ 39㧦346(2008ᐕ 10 ᦬)6㧕 ਤ⠀㓷ਯ㧦╙ 31 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ ࠕ࠽࠙ࡦࠬࡔࡦ࠻㧦කቇᢎ⢒ 39㧦469(2008ᐕ 12 ᦬)7㧕 㒙ㇱᕺሶ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ㧘㋈ᧁᐽਯ㧘Phillip Evans㧦⁛⥄ᕈ⼾߆ߥ SP 㙃ᚑࡊࡠࠣ࡜ࡓ́ࠬ
ࠦ࠶࠻࡜ࡦ࠼ 5 ᄢቇⷞኤႎ๔́㧦කቇᢎ⢒ 39㧦199㧙204(2008 ᐕ)
8㧕 㒙ㇱᕺሶ㧘㋈ᧁን㓶㧘⮮ፒ๺ᒾ㧘઻ାᄥ㇢㧦ᮡḰᮨᡆᖚ⠪ߩ✵⠌⁁ᴫߣ OSCE ߦኻߔࠆᗧ⼂ ో࿖⺞ᩏ╙ 2 ႎ㧦කቇᢎ⢒ 39㧦259㧙266(2008 ᐕ)
11㧚ႎ㆏
1㧕 ⮮ፒ๺ᒾ㧦Ꮢ᳃߇ᮨᡆᖚ⠪ߣߒߡෳടߔࠆකቇᢎ⢒㧦Medical Tribune(2008 ᐕ 2 ᦬ 21 ᣣ)
2㧕 ⮮ፒ๺ᒾ㧦ᧂ᧪ߩකᏧ߇᧪ߥ޿㨪⎇ୃක࠯ࡠߩⴣ᠄㨪㧦NHK ࠽ࡆࠥ࡯࡚ࠪࡦ ࠬ࠲ࠫࠝ⸃⺑(2008ᐕ 6 ᦬ 6 ᣣ)
3㧕 㒙ㇱᕺሶ㧘⮮ፒ๺ᒾ㧦ᖚ⠪ࠍ↢߈ࠆ ᮨᡆᖚ⠪ ᖱႎ✬㧦ᦺᣣᣂ⡞(2008 ᐕ 10 ᦬ 5 ᣣ)
4㧕 ⮮ፒ๺ᒾ㧦ᖚ⠪ࠍ↢߈ࠆ ᮨᡆᖚ⠪ ᖱႎ✬㧦ᦺᣣᣂ⡞(2008 ᐕ 10 ᦬ 10 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔ
ᐔᚑ 20 ᐕ 4 ᦬ߦ㐿⻠ߒߡ㑆߽ߥ޿ߚ߼㧘߹ߛలಽߥ⹏ଔߪ಴᧪ߥ޿߇㧘એਅߩࠃ߁ߥ⎇ⓥࠍផㅴߔࠆ
⸘↹ߢ޽ࠆ‫ᧄޕ‬ᐕᐲ㧘ᄢቇ㒮↢㧔␠ળੱ㧕ࠍ 1 ฬฃߌ౉ࠇ㧘ᢎ⢒ࠍ㐿ᆎߒߚ‫ޕ‬1㧕ࠞ࡝ࠠࡘ࡜ࡓ㐿⊒ߣቇ↢⹏ଔᴺ
2㧕ࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦᢎ⢒ߣ Professionalism ᢎ⢒3㧕ࠃࠅലᨐ⊛ߥ⢻േ⊛໧㗴ၮ⋚ဳቇ⠌
4㧕ࠪࡒࡘ࡟࡯࡚ࠪࡦᢎ⢒࡮⥃ᐥࠬࠠ࡞ᢎ⢒ߣ E-learning ߩⲢว
5㧕࿾ၞၮ⋚ဳකቇᢎ⢒ߣ✚วකߩ⢒ᚑᣇᴺ
6㧕ࠃࠅലᨐ⊛ߥ⥃ᐥᢎ⢒ᴺ࡮ᜰዉᴺߩ㐿⊒7㧕ᣣᧄߦ߅ߌࠆකቇᢎ⢒ቇ⎇ⓥߩផㅴߣኾ㐷ኅ⢒ᚑ㧙㧙⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷කቇᢎ⢒ቇߩ⎇ⓥߩᱧผߪᵻߊ㧘߹ߚ⎇ⓥᚻᴺ߽৻⥸⊛ߥකቇ↢‛ቇ㗔ၞߩ⎇ⓥߣᄢ߈ߊ⇣ߥࠆ߇㧘᰷☨ߢߪ 1 ߟߩ⎇ⓥಽ㊁ߣߒߡቯ⌕ߒߡ޿ࠆ‫ᧄޕ‬㇌ߦ߅޿ߡ߽කቇᢎ⢒ቇಽ㊁ߩሽ࿷ߦ㑐ߒߡ⹺⼂ࠍᐢ߼ࠆᔅⷐᕈ߇޽ࠆ‫⎇ߚ߹ޕ‬ⓥᚻᴺࠍ⏕┙ߒ᥉෸ߔࠆᓎഀ߽ᜂߞߡ޿ࠆߣ⠨߃ߡ޿ࠆ‫ߪߢ⁁⃻ޕ‬කቇᢎ⢒⎇ⓥಽ㊁ߦ㑐ᔃࠍ␜ߔකᏧ࡮ක≮㑐ଥ⠪ߪ߹ߛዋߥ޿߇㧘ẜ࿷⊛࠾࡯࠭ߪᄢ߈޿ߣᦼᓙߐࠇࠆߩߢ㧘ߘߩ⊒ជߦദ߼ߚ޿‫ޕ‬੹ᓟߩዷᦸ
ᧄಽ㊁߇ᄢቇ㒮ߩ৻ಽ㊁ߣߒߡ⏕┙ߔࠆߎߣ߇ᒰ㕙ߩ⋡ᮡߢ޽ࠅ㧘⌕ታߥ⎇ⓥᚑᨐߩ⊒ାߣੱ᧚⢒ᚑࠍㅢߒߡ㧘ᣣᧄߦ߅ߌࠆකቇᢎ⢒ቇߩ⏕┙ߦ⽸₂ߔࠆߎߣ߇ਛ㐳ᦼ⊛ߥ⋡ᮡߢ޽ࠆ‫ߦࠄߐޕ‬࿖㓙੤ᵹࠍㅢߓߡ㧘ᣣᧄߩකቇᢎ⢒ࠍ਎⇇ߦ⊒ାߒߡⴕ߈ߚ޿ߣ⠨߃ߡ޿ࠆ‫ޕ‬㧙㧙

7. ቇ૏ߩ᝼ਈ⁁ᴫߣ⎇ⓥᚑᨐ
ක⑼ቇኾ᡹ߦ߅޿ߡㆊ෰ 5 ᐕ㑆ߦඳ჻㧔කቇ㧕ߩቇ૏ࠍ᝼ਈߒߚᢙߪ㧘ᰴ⴫ߩߣ߅ࠅߢ޽ࠆ‫ޕ‬඙ಽ

ᐔᚑ 15 ᐕᐲᐔᚑ 16 ᐕᐲᐔᚑ 17 ᐕᐲᐔᚑ 18 ᐕᐲᐔᚑ 19 ᐕᐲ

⺖⒟ඳ჻

38

35

44

29

37

⺰ᢥඳ჻

12

13

6

10

11

8. ቇ↢↢ᵴᡰេ
㧔1㧕ᅑቇ㊄ߩ↳⺧࡮ណᛯ⁁ᴫ٤ ᣣᧄ⢒⧷ળᅑቇ↢಴㗿࡮ណ↪⁁ᴫ
╙1⒳

ᐕ‫ޓ‬ᐲ

╙2⒳

಴㗿⠪ᢙ

ណ↪⠪ᢙ

಴㗿⠪ᢙ

ណ↪⠪ᢙ

ᐔᚑ 15 ᐕᐲ

2

2

0

0

ᐔᚑ 16 ᐕᐲ

2

2

0

0

ᐔᚑ 17 ᐕᐲ

2

2

0

0

ᐔᚑ 18 ᐕᐲ

1

1

0

0

ᐔᚑ 19 ᐕᐲ

2

2

0

0

ᐔᚑ 20 ᐕᐲ

2

2

0

0

㧔2㧕᝼ᬺᢱ఺㒰ታᣉ⁁ᴫ
೨ቇᦼ
ᐕ‫ޓ‬ᐲ

࿷☋⠪ᢙ

↳⺧

ᓟቇᦼ

఺㒰

↳⺧

ో㗵

ඨ㗵

఺㒰
ో㗵

ඨ㗵

ᐔᚑ 15 ᐕᐲ

193

22

20

0

21

19

0

ᐔᚑ 16 ᐕᐲ

183

20

0

20

19

0

17

ᐔᚑ 17 ᐕᐲ

173

21

0

20

20

4

14

ᐔᚑ 18 ᐕᐲ

171

16

0

15

11

0

11

ᐔᚑ 19 ᐕᐲ

173

14

10

4

15

11

4

ᐔᚑ 20 ᐕᐲ

184

18

6

9

15

7

8

9. ⥄Ꮖ⹏ଔ࡮⺖㗴ߣዷᦸߎࠇ߹ߢක⑼ቇኾ᡹ߪ⁛ഃ⊛ߥ⎇ⓥᚑᨐࠍ਄ߍ㧘ක⑼ቇ࡮ක≮ߩㅴᱠ࡮⊒ዷߦነਈߒߡ߈ߚ߇㧘੹ᓟ߽ߘߩታ❣ࠍᵴ߆ߒߡᣂߚߥᤨઍߩක⑼ቇ࡮ක≮ࠍ‧ᒁߔߴߊవ┵⊛⎇ⓥࠍቢㆀߒ㧘ߘߩᚑᨐࠍ਎
⇇ߦะߌߡ⊒ାߒߡ޿ߊᔅⷐ߇޽ࠆ‫ޕ‬
2007 ᐕ 11 ᦬ߦߪ੩ㇺᄢቇߩጊਛિᒎᢎ᝼ߩࠣ࡞࡯ࡊ߆ࠄᄙ⢻ᕈᐙ⚦⢩ iPS ⚦⢩ߩႎ๔߇ߥߐࠇ㧘ౣ↢කቇ߿ක≮ߩ㕙ߢᄢ߈ߥㅴᱠ߇ᦼᓙߐࠇ㧘⒳‫∔ߩޘ‬ᖚߩᖚ⠪ߐࠎߦ᣿ࠆ޿Ꮧᦸࠍ߽ߚࠄߔߎߣߣ
ߥߞߚ‫⎇ᧄޕ‬ⓥ⑼ߦ߅޿ߡ߽ጊਛࠣ࡞࡯ࡊߣߩ౒ห⎇ⓥࠍㅴ߼ࠆಽ㊁߇޽ࠅ㧘ౣ↢ක⑼ቇኾ᡹ߦ⇐߹
ࠄߕක⑼ቇኾ᡹ߦ߅޿ߡ߽㧘ౣ↢කቇ࡮ක≮ߩಽ㊁ߢߩ⎇ⓥߩ⊒ዷ߇ᦼᓙߐࠇࠆ‫ޕ‬㧙㧙৻ᣇߢߪ㧘ක≮፣უ߇ྫ߆ࠇᆎ߼㧘ߘߩ㗃ᧄቇߩࡔ࠺ࠖࠞ࡞ࡈࠜ࡯࡜ࡓߢߪ⯥ࡁ㐷∛㒮ߩዊ᧻⑲᮸వ↢ߩߏ⻠Ṷࠍ᜙⡬ߒߚ‫ߩߘޕ‬ᓟᖚ⠪ߐࠎߩ࠲࡜ࠗ࿁ߒ㧘තᓟ㧞ᐕ㑆ߩ⟵ോൻೋᦼ⎇ୃ߿⸻≮⑼ߦࠃ
ࠆකᏧਇ⿷ߥߤ߇␠ળ⊛ߥ໧㗴ߣߒߡ⴫㕙ൻߒ㧘කቇㇱቯຬჇߣ޿߁ᄢ߈ߥᄌൻߣߒߡᧄቇߦ߽߰ࠅ
߆߆ߞߡ߈ߚ‫ޕ‬කቇㇱ࡮කቇ♽⎇ⓥ⑼࡮㒝ዻ∛㒮ߪ㧘ᢎ⢒࡮⎇ⓥ࡮⸻≮ߩ㧟ᧄ┙ߡߢㅴ߼ࠆᔅⷐ߇޽
ࠅ㧘ߤߩಽ㊁߽㊀ⷐߢᚻࠍᛮߌߕ㧘ዋߥ޿ᢎ⡯ຬߩຬᢙߢ㑵ߞߡ޿ࠆ‫ޕ‬
2008 ᐕ 4 ᦬߆ࠄߪ㧘ᧄቇߩකቇ♽⎇ⓥ⑼ߣᎿቇ⎇ⓥ⑼ਗ߮ߦጘ㒂⮎⑼ᄢቇߣߩදജߢㅪวഃ⮎ක≮ᖱႎ⎇ⓥ⑼߇ᣂ⸳ߐࠇ㧘ߎࠇߦ઻޿ᧄක⑼ቇኾ᡹ߩቯຬࠍ৻ㇱᷫࠄߒߚ‫ޕ‬ㅪวഃ⮎ක≮ᖱႎ⎇ⓥ⑼ߪකቇ♽⎇ⓥ⑼ߣߪ⇣ߥࠆ⚵❱ߢ޽ࠆ߇㧘ᧄ⎇ⓥ⑼ߩᢎຬߩ৻ㇱ߇⒖☋ߒߚᒻߣߥߞߡ޿ࠆ‫ޕ‬หߓᤨᦼ߆ࠄ㧘ක≮▤ℂቇ⻠ᐳߦ‫ޟ‬කቇᢎ⢒ቇಽ㊁‫ࠇߐ⟎⸳߇ޠ‬㧘කቇᢎ⢒㐿⊒⎇ⓥ࠮ࡦ࠲࡯ (MEDC) ߩᢎຬ߽⎇ⓥᜰዉߦᒰߚࠆߎߣ߇ߢ߈ࠆࠃ߁ߦߥߞߚ‫ޕ‬10 ᦬߆ࠄߪ㧘⁛┙ⴕ᡽ᴺੱ⥄േゞ੐᡿ኻ╷ᯏ᭴
(NASVA) ߣ␠ળක≮ᴺੱෘ↢ળߣᧄ⎇ⓥ⑼ߣߩ㑆ߢ㧘ᢎ⢒⎇ⓥߦଥࠆㅪ៤࡮දജߩදቯࠍ⚿߮㧘‫ޟ‬ㅪ
៤ಽ㊁ ⣖∛ᘒ⸃ᨆቇ‫ࠍޠ‬ᣂ⸳ߒ㧘2009 ᐕ 4 ᦬߆ࠄߩቇ↢ฃ౉ߦะߌߡⒿേࠍᆎ߼ߚ‫ޕ‬ᧄ⎇ⓥ⑼ߩ⺖㗴ߩ㧝ߟߪ㧘ల⿷₸ߩ໧㗴߇޽ࠆ‫౉ޕ‬ቇ⠪ߩ₪ᓧ࡮⺑ᓧߩߚ߼ߦ൐㓸ᦼ㑆ࠍᓥ೨ߩ㧝ㅳ㑆߆ࠄ㧞ㅳ㑆ߦᑧ߫ߒ㧘㧞ᰴ൐㓸ߦࠃߞߡ߽ቯຬߦḩߚߥ޿ᤨߪ㧟ᰴ൐㓸ࠍⴕ߁ദജࠍߒߚ‫ޕ‬ᣂߒ
ߊㅪ៤ಽ㊁߇⸳┙ߐࠇߚߎߣ߽޽ࠅ㧘㜞޿ల⿷₸߇⛽ᜬߐࠇࠆߎߣ߇ᦼᓙߐࠇࠆ‫ޕ‬ቇ૏ክᩏߩ૕೙ߦ㑐ߔࠆ໧㗴߽೨ቇ㐳ߩ࡝࡯࠳࡯ࠪ࠶ࡊߩ߽ߣឭ᩺ߐࠇߚේ᩺ࠍၮߦోቇ⊛ߥክ⼏߇ⴕࠊࠇߡ޿ࠆ‫ޕ‬කቇ♽⎇ⓥ⑼ߩਛߢ߽ක⑼ቇኾ᡹ߢߪ㧘ઁߩ⎇ⓥ⑼ߦవ㚟ߌߡᜰዉᢎຬ߿౒⪺⠪ࠍክᩏᆔຬ߆ࠄ㒰ᄖߔࠆߣ޿߁೙ᐲࠍᆎ߼㧘ߎࠇ߹ߢߦ߽Ⴧߒߡ෩ߒ޿ክᩏࠍㅢㆊߒߚ⠪ߦቇ૏߇᝼
ਈߐࠇߡ޿ࠆ‫ޕ‬ల⿷₸ߣ߽㑐ㅪߔࠆ߇㧘ၮ␆࡮␠ળකቇ♽߳ㅴ߻කቇㇱතᬺ⠪߇ዋߥߊߥߞߡ޿ࠆߎߣ߽⋴ㆊߢ߈ߥ޿੐ታߣᕁࠊࠇࠆ‫ޕ‬තᓟ⎇ୃߩ⟵ോൻߦ઻޿㧘ᄢቇߦᱷࠆකᏧ߇ዋߥߊߥࠅ㧘⚿ᨐ⊛ߦᄢቇ㒮߳ㅴ߻ੱ߇ዋߥߊߥߞߡ޿ࠆߣ⠨߃ࠄࠇࠆ‫ߚ߹ޕ‬㧘⧯⠪ߩᄙߊ߇ၮ␆ࠃࠅߪ⥃ᐥᜰะߣߥࠅ㧘⎇ⓥ߿ቇ૏
ขᓧࠃࠅߪኾ㐷කߩขᓧߦ⋡߇ะߌࠄࠇ㧘ߘߜࠄߦ㝯ജࠍᗵߓࠆੱ߇Ⴧ߃ߡ޿ࠆߣ߽⠨߃ࠄࠇࠆ‫ߎޕ‬ࠇߦኻߒߡߪ㧘ᓥ೨߆ࠄߩࠬࠞ࡜ࠪ࠶ࡊ೙ᐲߦട߃ߡᅑቇ㊄೙ᐲࠍ⸳ߌߚ‫ޕ‬ၮ␆࡮␠ળකቇ♽ಽ㊁߳ㅴ߻කቇㇱතᬺ⠪ߦ౉ቇ㊄࡮᝼ᬺᢱ⋧ᒰ㗵ࠍ⛎ઃߔࠆ߽ߩߢ޽ࠆ‫ޕ‬೙ᐲࠍ㐿ᆎߒߚᐔᚑ 20 ᐕᐲ߆ࠄ㧞ฬߩฃ⛎⠪߇޽ߞߚ߇㧘㧝ฬߪਛㅌߒߡᢎຬߦណ↪ߐࠇߚ‫ߚ߹ޕ‬㧘ᄢቇ㒮ߩ FD ⻠Ṷળߦ߅ߌࠆ
‫ᧅޟ‬ᏻක⑼ᄢቇߦ߅ߌࠆ MD-PhD ࡊࡠࠣ࡜ࡓߩข⚵ߺ‫⻠ߩޠ‬Ṷࠍฃߌߡ㧘⎇ⓥ⑼㐳ߩᜰዉߩ߽ߣᧄቇ
ߦㆡߒߚ MD-PhD ࡊࡠࠣ࡜ࡓࠍᮨ⚝ߔࠆߎߣߣߥࠅ㧘ቇോᆔຬળ߿ᢎോෘ↢ᆔຬળߢክ⼏ࠍ㐿ᆎߒ
ߚ‫ޕ‬

㧙㧙

㨇කቇ♽⎇ⓥ⑼ౣ↢ක⑼ቇኾ᡹㨉
1. ᢎ⢒࡮⎇ⓥߩℂᔨ㧘⋡ᮡࡅ࠻ోㆮવሶߩႮၮ㈩೉ߩ⸃⺒߇⚳ੌߒߚ 21 ਎♿ߦ߅ߌࠆකቇ࡮ක≮ߩਛᔃ⺖㗴ߩ৻ߟߪ㧘㑆㆑޿ߥߊౣ↢කቇ࡮ක≮ߢ޽ࠆ‫ޕ‬2006 ᐕ 8 ᦬ߦࡑ࠙ࠬ߆ࠄ㧘2007 ᐕ 11 ᦬ߦߪࡅ࠻߆ࠄ㧘ฃ♖ෆࠍ૶ࠊߕߦ૕⚦⢩߆ࠄಽൻᄙ⢻ᕈࠍᜬߟ⚦⢩㧔iPS ⚦⢩㧕߇᮸┙ߐࠇ㧘ߎߩ㗔ၞߦᄢ߈ߥㅴᱠ߇⷗ࠄࠇߚ‫ޕ‬ౣ↢ක⑼ቇኾ᡹ߪකቇ㧘↢๮࡮ᖱႎᎿቇਗ߮ߦ↢๮୶ℂቇߣߩ࡙࠾࡯ࠢߥㅪ៤ߩਅ㧘⚦⢩↢‛ቇ࡮ಽሶㆮવකᎿቇ⊛ቇ໧૕♽ߦട߃㧘ߎࠇࠍ⥃ᐥߦᔕ↪ߔࠆߚ߼ߩౣ↢Ꮏቇ࡮ౣ↢ᔕ↪࡮୶ℂቇߩቇ໧૕♽߆ࠄߥࠆ‫ޕ‬කቇㇱ㧘Ꮏቇㇱ╬ߩ಴り⠪ߦవ┵⊛ౣ↢ක⑼ቇߩ⎇ⓥߣ࡙࠾࡯ࠢߥࠗࡦ࠲࡯ࡀ࠶࠻ᄢ
ቇ㒮ᢎ⢒ New Research Oriented Bidirectional Education Linkage(NOBEL) ࠍⴕ޿㧘ಽሶ↢‛ቇ㧘ක↪↢๮࡮ᖱႎᎿቇ㧘⥃ᐥකቇ߅ࠃ߮␠ળකቇߩฦಽ㊁ߢౣ↢ක⑼ቇࠍਛᔃ⊛ߦᜂ߁ߎߣߩߢ߈ࠆ⍮⊛ഃㅧᕈ࡮ኾ㐷ᕈߣ౒ߦ୶ℂᕈ࡮ੱ㑆ᕈ࡮␠ળᕈߩ⼾߆ߥੱ᧚ࠍ⢒ᚑߔࠆߎߣࠍ⋡ᮡߣߒߡ޿ࠆ‫ޕ‬

2. ౣ↢ක⑼ቇኾ᡹ߩ᭴ᚑ
↢‛ቇ⊛ౣ↢ක⑼ቇࠍ⋡ᜰߔ⁛┙ኾ᡹♽ౣ↢ක⑼ቇߦߪ␠ળ⊛࠾࡯࠭㧘ᧄቇߩታ❣ߣ⃻⁁ࠍ⠨ᘦߒ
ߡ 3 ߟߩ㗔ၞ߆ࠄߥࠆ⚵❱ࠍ⟎޿ߡ޿ࠆ‫ߜࠊߥߔޕ‬㧘ಽሶ↢‛ቇ㧘⊒↢ቇ㧘ㆮવሶᎿቇࠍࡌ࡯ࠬߣߒ
ߚౣ↢ಽሶ⛔ᓮቇ㧘ᦨᣂߩ↢๮Ꮏቇ࡮ᖱႎᎿቇࠍࡌ࡯ࠬߣߒߚౣ↢Ꮏቇ෸߮ߎࠇࠄࠍࡌ࡯ࠬߣߒߚ⥃ᐥᔕ↪ߣߘࠇߦ઻߁୶ℂ⊛໧㗴ࠍᛒ߁ౣ↢ᔕ↪࡮୶ℂቇߢ޽ࠆ‫ߢߎߘޕ‬㧘ᧄኾ᡹ߪ㧘એਅߩ 3 ߟߩ⻠ᐳߢ᭴ᚑߒ㧘㜞ᐲߩ⎇ⓥ⢻ജ߇޽ࠆ⎇ⓥ⠪ࠍಽ㊁೎ߦ 1 ߟߩ᦭ᯏ⊛⛔৻૕ߣߥࠆࠃ߁⚵❱ߒߡ޿ࠆ‫ޕ‬
㧔1㧕ౣ↢ಽሶ⛔ᓮቇ⻠ᐳౣ↢ಽሶ⛔ᓮቇ⻠ᐳߪ㧟ߟߩᢎ⢒⎇ⓥಽ㊁߆ࠄߥࠆ‫ޕ‬ᐙ⚦⢩߆ࠄ⚵❱࡮ེቭᒻᚑߩಽሶ೙ᓮࠍᜂᒰ
ߔࠆ⚵❱࡮ེቭᒻᚑಽ㊁㧘ᧄቇߦ߅ߌࠆ෻኿⎇ⓥᣉ⸳ߩવ⛔ࠍ〯߹߃ߚ␹⚻♽ߩౣ↢ࠍᜂᒰߔࠆ␹⚻↢‛ಽ㊁㧘ౣ↢ߦ߅ߌࠆᓸ↢‛ߩᓎഀࠍᜂᒰߔࠆ∛ේ૕೙ᓮቇಽ㊁ߢ޽ࠆ‫ߦࠄߐޕ‬㧘⚵❱࡮ེቭᒻᚑ
ಽ㊁ߦߪ㧘ߘߩ㊀ⷐᕈࠍ⠨ᘦߒߡㅪ៤⻠ᐳߣߒߡጟፒ࿖┙౒ห⎇ⓥᯏ᭴ၮ␆↢‛ቇ⎇ⓥᚲ⊒↢↢‛ቇ⎇ⓥ♽߇ෳടߒߡ޿ࠆ‫ޕ‬
㧔2㧕ౣ↢Ꮏቇ⻠ᐳౣ↢Ꮏቇ⻠ᐳߪ㧘㧞ߟߩᢎ⢒⎇ⓥಽ㊁߆ࠄߥࠆ‫ޕ‬ㆮવሶ࡮࠲ࡦࡄࠢߩಽሶ᭴ㅧ⸃ᨆߣ㧘ߘࠇߦၮߠ
ߊౣ↢ක≮ߦഃ⮎߿ಽሶࡊࡠ࡯ࡉߩ㐿⊒࡮ᔕ↪ࠍᜂᒰߔࠆ↢๮ᯏ⢻ಽሶ⸳⸘ಽ㊁ߣ㧘⚦⢩߆ࠄ⚵❱࡮ེቭ߇ᒻᚑߐࠇࠆࡊࡠ࠮ࠬߩ㧟ᰴర᭴▽ࠦࡦࡇࡘ࡯࠲ߦࠃࠆࠗࡔ࡯ࠫൻࠍਥߦਛᨔ␹⚻♽ߢᜂᒰߔࠆ⍮⢻ࠗࡔ࡯ࠫᖱႎಽ㊁ߢ޽ࠆ‫ޕ‬
㧔3㧕ౣ↢ᔕ↪ቇ⻠ᐳౣ↢ᔕ↪ቇ⻠ᐳߪ㧘3 ߟߩᢎ⢒⎇ⓥಽ㊁߆ࠄߥࠆ‫ޕ‬ਥߦᓴⅣེ࡮๭ๆེ♽ߩౣ↢ක≮ࠍᜂᒰߔࠆᓴ
Ⅳ∛ᘒቇߣ๭ๆ∛ᘒቇ㧘ߥࠄ߮ߦකቇ♽୶ℂ࡮␠ળකቇߢ޽ࠆ‫ޕ‬ߎࠇࠄߩ⚵❱ߪ㧘නߦਗ೉ߔࠆ⎬⋥ൻߒߚ⚵❱ߢߪߥߊ㧘ᖚ⠪ਗ߮ߦቇ↢㧘ડᬺࠍ฽߻␠ળ⊛࠾࡯࠭ߦᔕ߃ࠆᣂߒ޿ౣ↢ක≮ߩᢎ⢒࡮⎇ⓥࠍ⋡ᜰߒߚ 1 ߟߩ᦭ᯏ⊛⛔৻૕ߣߒߡ⚵❱ߐࠇߡ޿ࠆ‫ࠇߎޕ‬ߦࠃࠅ㧘⎇ⓥࠍࠝ࡯ࡊࡦߦߔࠆߎߣ߇ߢ߈㧘⎇ⓥ⠪㑆ߩ⋧੕࠴ࠚ࠶ࠢ૕೙ࠍᢛ߃㧘⎇ⓥߩ࡟ࡌ࡞ࠕ࠶
ࡊࠍ࿑ࠆ߽ߩߢ޽ࠆ‫ߚ߹ޕ‬㧘ᄢቇ㒮↢ߪ⥄ಽߩ⎇ⓥ߫߆ࠅߢߪߥߊ㧘᭽‫⎇ߩ࠻ࠢࠚࠫࡠࡊߥޘ‬ⓥߦធ
⸅ߔࠆߎߣ߇ߢ߈㧘୶ℂࠍ฽߼ߚᐢ޿ⷞ㊁ߣ⁛ഃ⊛ߥᕁ⠨ㆊ⒟ࠍᜬߟක⑼ቇ⎇ⓥ⠪ࠍ㙃ᚑߔࠆߎߣ߇
น⢻ߣߥࠆ‫ޕ‬㧙㧙

3. ቇ↢ቯຬߣ౉ቇ⁁ᴫౣ↢ක⑼ቇኾ᡹ߩ౉ቇቯຬ㧘෼ኈቯຬ෸߮ㆊ෰㧡ᐕ㑆ߩ౉ቇ⁁ᴫߪᰴ⴫ߩߣ߅ࠅߢ޽ࠆ‫ޕ‬೨ᦼ⺖⒟࡮
ᓟᦼ⺖⒟ߣ߽ߦ౉ቇቯຬࠍߪࠆ߆ߦ⿥߃ߚᔒ㗿⠪߇޽ࠆ‫ߚ߹ޕ‬㧘౉ቇ⠪ߪ౉ቇቯຬߩ⚂ 1.5 ୚ߢ޽ࠅ㧘߈ࠊ߼ߡ㗅⺞ߦផ⒖ߒߡ޿ࠆ‫ޕ‬ౣ↢ක⑼ቇኾ᡹ߩቇ↢ቯຬ෸߮෼ኈቯຬ⎇ⓥ⑼ኾ᡹කቇ♽⎇ⓥ⑼ౣ↢ක⑼ቇኾ᡹

⺖⒟

౉ቇቯຬ

෼ኈቯຬ

ඳ჻೨ᦼ⺖⒟1122ඳ჻ᓟᦼ⺖⒟

6

18

⸘

17

40

ౣ↢ක⑼ቇኾ᡹ߩ౉ቇ⁁ᴫ
ㆊ෰ 5 ᐕ㑆ߩ౉⹜⛔⸘㧔ඳ჻೨ᦼ⺖⒟㧕
੐㗄
ᐕᐲ

൐㓸ੱຬ

ᔒ㗿⠪ᢙ
23

ᐔᚑ 16 ᐕᐲᐔᚑ 17 ᐕᐲ

11

11

29

㧔4㧕
<0>

ฃ㛎⠪ᢙ
22

11

23

ᐔᚑ 19 ᐕᐲᐔᚑ 20 ᐕᐲ

11

20

16

㧔4㧕
<0>

21

㧔4㧕
<0>

‫ޝ‬0‫ޞ‬‫ޝ‬0‫ޞ‬‫ޝ‬0‫ޞ‬

㧔4㧕
<2>

㧔4㧕
<2>

㧔3㧕
<1>

㧔2㧕
<1>

29

㧔4㧕
<1>
㧔1㧕
<0>

23

‫ޝ‬1‫ޞ‬23‫ޝ‬2‫ޞ‬
11

22

౉ቇ⠪ᢙ

‫ޝ‬0‫ޞ‬‫ޝ‬1‫ޞ‬ᐔᚑ 18 ᐕᐲ

㧔4㧕
<0>

วᩰ⠪ᢙ

㧔4㧕
<1>

‫ޝ‬0‫ޞ‬20‫ޝ‬2‫ޞ‬
19

㧔1㧕
<0>

21

㧔3㧕
<1>

‫ޝ‬0‫ޞ‬19‫ޝ‬1‫ޞ‬
17

㧔1㧕
<0>

㧔3㧕
<1>
‫ޝ‬1‫ޞ‬

17

㧔1㧕
<0>

‫ޝ‬1‫ޞ‬‫ޝ‬1‫ޞ‬‫ޝ‬1‫ޞ‬‫ޝ‬1‫ޞ‬

㧔2㧕
<0>

㧔2㧕
<0>

㧔2㧕
<0>

㧔2㧕
<0>

16

‫ޝ‬2‫ޞ‬‫ޝ‬2‫ޞ‬㧔 㧕ߪᅚሶ㧘< > ߪ␠ળੱ㧘‫ߪޞ ޝ‬ᄖ࿖ੱ⇐ቇ↢ࠍߔߴߡౝᢙߢ⴫ߒ߹ߔ‫ޕ‬

㧙㧙

13

‫ޝ‬1‫ޞ‬13‫ޝ‬1‫ޞ‬ㆊ෰ 5 ᐕ㑆ߩ౉⹜⛔⸘㧔ඳ჻ᓟᦼ⺖⒟㧕
੐㗄
ᐕᐲ

൐㓸ੱຬ

ᐔᚑ 16 ᐕᐲ

6

ᔒ㗿⠪ᢙ

ฃ㛎⠪ᢙ

㧔4㧕
<8>

19

18

‫ޝ‬3‫ޞ‬ᐔᚑ 17 ᐕᐲ615

‫ޝ‬1‫ޞ‬ᐔᚑ 18 ᐕᐲ617

‫ޝ‬2‫ޞ‬ᐔᚑ 19 ᐕᐲᐔᚑ 20 ᐕᐲ

6

6

10

㧔2㧕
<6>

15

㧔1㧕
<9>
㧔1㧕
<10>

15

㧔2㧕
<6>

‫ޝ‬0‫ޞ‬
㧔3㧕
<12>

15

‫ޝ‬2‫ޞ‬

18

㧔1㧕
<9>

17

㧔1㧕
<10>

15

㧔2㧕
<6>

‫ޝ‬0‫ޞ‬
㧔3㧕
<12>

14

‫ޝ‬2‫ޞ‬㧔1㧕
<9>‫ޝ‬1‫ޞ‬16‫ޝ‬2‫ޞ‬10

㧔3㧕
<8>‫ޝ‬3‫ޞ‬‫ޝ‬1‫ޞ‬‫ޝ‬2‫ޞ‬
10

㧔3㧕
<8>

౉ቇ⠪ᢙ

‫ޝ‬3‫ޞ‬‫ޝ‬1‫ޞ‬

㧔1㧕
<10>

17

18

‫ޝ‬3‫ޞ‬

㧔1㧕
<9>

15

㧔3㧕
<8>

วᩰ⠪ᢙ

㧔1㧕
<10>
‫ޝ‬2‫ޞ‬

10

㧔2㧕
<6>

‫ޝ‬0‫ޞ‬‫ޝ‬0‫ޞ‬

㧔3㧕
<11>

14

㧔3㧕
<11>

‫ޝ‬2‫ޞ‬‫ޝ‬2‫ޞ‬㧔 㧕ߪᅚሶ㧘< > ߪ␠ળੱ㧘‫ߪޞ ޝ‬ᄖ࿖ੱ⇐ቇ↢ࠍߔߴߡౝᢙߢ⴫ߒ߹ߔ‫ޕ‬

4. ࠞ࡝ࠠࡘ࡜ࡓߩ✬ᚑᣇ㊎ᧄኾ᡹ߪ㧘↢๮୶ℂ࡮කቇਗ߮ߦ↢๮࡮ᖱႎᎿቇਔಽ㊁߇Ⲣวߒߚᣂߚߥⷞὐ߆ࠄߩౣ↢ක⑼ቇߦ
㑐ߔࠆ໧㗴⸃᳿ဳ⢻േᢎ⢒ࠍⴕ޿㧘㜞ㆳߥ↢๮୶ℂ࡮␠ળᕈ㧘ౣ↢ක⑼ቇ࡮ක≮ߩ⊒ዷߦ⽸₂ߔࠆ್ᢿജ㧘ታⴕജ෸߮⁛ഃᕈߦን߻ੱ㑆ᕈ⼾߆ߥ⎇ⓥ⠪㧔ඳ჻ᓟᦼ⺖⒟㧕ਗ߮ߦ㜞ᐲኾ㐷⡯ᬺੱ㧔೨ᦼ⺖⒟㧘ᓟᦼ⺖⒟㧕ࠍ⢒ᚑߔࠆߎߣࠍ⋡ᮡߣߒߡᢎ⢒⺖⒟ࠍ✬ᚑߒߡ޿ࠆ‫ޕ‬ߎߩࠞ࡝ࠠࡘ࡜ࡓ✬ᚑᣇ㊎ߦၮߠ߈㧘↢๮୶ℂ࡮ౣ↢ක≮ߩၮᧄ⊛ᢎ㙃ࠍりߦઃߌ㧘߆ߟ㧘ౣ↢කቇߩၮ␆࡮⥃ᐥਗ߮ߦౣ↢Ꮏቇߦߟ޿ߡߩᦨవ┵ߩᛛⴚࠍ᦭ߒ㧘ᣂߚߥౣ↢ක⑼ቇࠍవ㚟⊛ߦขࠅ⚵߻⢻ജࠍ᦭ߔࠆ⎇ⓥ⠪࡮㜞ᐲኾ㐷⡯ᬺੱࠍ⢒ᚑߔࠆ‫ޕ‬
㧔1㧕ጁୃၮḰԘඳ჻೨ᦼ⺖⒟2 ᐕ㑆ߩ㑆ߦว⸘ 30 න૏એ਄ࠍୃᓧߒቇ૏⺰ᢥክᩏߦวᩰߒߥߌࠇ߫ߥࠄߥ޿‫ߒߛߚޕ‬㧘․ߦఝࠇ
ߚ⎇ⓥᬺ❣ࠍ਄ߍߚ⠪ߪ㧘1 ᐕએ਄࿷ቇߒᚲቯߩⷐઙࠍḩߚߒߚ႐วߪ 2 ᐕᧂḩߢ޽ߞߡ߽ቇ૏ࠍ᝼
ਈߔࠆߎߣ߇޽ࠆ‫ޕ‬⑼‫ޓ⋡ޓ‬඙‫ޓ‬ಽᦨૐጁୃන૏ᢙ

౒‫ޓ‬ㅢ‫⋡ޓ⑼ޓ‬㧢ቇ‫ޓ‬㓙‫⋡ޓ⑼ޓ‬㧞ኾ‫ޓ‬㐷‫⋡ޓ⑼ޓ‬㧝㧠․‫ޓ‬೎‫ޓ⎇ޓ‬ⓥ㧤ว‫⸘ޓޓޓ‬㧟㧜஻‫ޓ‬⠨㧔ᵈ㧕තᬺߒߚቇㇱߦࠃࠅጁୃᣇᴺ߇⇣ߥࠆ‫ޕ‬
ኾ᡹ಽ㊁߆ࠄᔅୃ⑼⋡ 10 න૏ࠍ฽߼㧘14 න૏એ਄ᵈ㧕㧝㧚කቇ෶ߪᱤቇࠍጁୃߔࠆ⺖⒟ࠍතᬺߒߚ⠪ߪ㧘౒ㅢ⑼⋡ߩጁୃන૏ߦ↢๮Ꮏቇ෸߮ᖱႎᎿቇ
ߩ㧞න૏ࠍጁୃߒߥߌࠇ߫ߥࠄߥ޿‫ޕ‬㧙㧙㧞㧚೨㗄ߦ⹥ᒰߔࠆ⠪એᄖߩ⠪ߪ㧘౒ㅢ⑼⋡ߩጁୃන૏ߦ↢๮Ꮏቇ෶ߪᖱႎᎿቇߩ޿ߕࠇ߆㧝න૏ࠍ฽߼ߥߌࠇ߫ߥࠄߥ޿‫ޕ‬ԙඳ჻ᓟᦼ⺖⒟3 ᐕ㑆ߦᦨૐ㒢 10 න૏ࠍขᓧߒߥߌࠇ߫ߥࠄߥ޿‫ߒߛߚޕ‬㧘․ߦఝࠇߚ⎇ⓥᬺ❣ࠍ਄ߍߚ⠪ߪ㧘2ᐕએ਄࿷☋ߒᚲቯߩⷐઙࠍḩߚߒߚ႐ว㧘3 ᐕᧂḩߢ߽ቇ૏ࠍ᝼ਈߔࠆߎߣ߇޽ࠆ‫ޕ‬⑼‫ޓ⋡ޓ‬඙‫ޓ‬ಽᦨૐጁୃන૏ᢙ

౒‫ޓ‬ㅢ‫⋡ޓ⑼ޓ‬㧞㧔ᵈ㧕තᬺߒߚቇㇱߦࠃࠅጁୃᣇᴺ߇⇣ߥࠆ‫ޕ‬ቇ‫ޓ‬㓙‫⋡ޓ⑼ޓ‬㧞㧔ᵈ㧕තᬺߒߚቇㇱߦࠃࠅጁୃᣇᴺ߇⇣ߥࠆ‫ޕ‬
ኾ᡹ಽ㊁߆ࠄᔅୃ⑼⋡ 10 න૏ࠍ฽߼㧘14 න૏એ਄ኾ‫ޓ‬㐷‫⋡ޓ⑼ޓ‬㧞․‫ޓ‬೎‫ޓ⎇ޓ‬ⓥ㧠ว‫⸘ޓޓޓ‬

㧝㧜

஻‫ޓ‬⠨

ᵈ㧕
㧝㧚කቇ෶ߪᱤቇࠍጁୃߔࠆ⺖⒟ࠍතᬺߒߚ⠪ߪ㧘౒ㅢ⑼⋡ߩ↢๮Ꮏቇ෶ߪᖱႎᎿቇࠍ฽߼ߥߌ
ࠇ߫ߥࠄߥ޿‫ޕ‬㧞㧚೨㗄ߦ⹥ᒰߔࠆ⠪એᄖߩ߽ߩߪ㧘౒ㅢ⑼⋡ߩಽሶ↢‛⑼ቇ෶ߪ᭴ㅧ∛ᘒකቇࠍ฽߼ߥߌࠇ߫
ߥࠄߥ޿‫ޕ‬㧟㧚ౣ↢ක⑼ቇኾ᡹ඳ჻೨ᦼ⺖⒟߆ࠄㅴቇߒߚ⠪ߪ㧘౒ㅢ⑼⋡෸߮ቇ㓙⑼⋡ߩጁୃࠍ఺㒰ߔࠆ‫ޕ‬
㧔2㧕ᢎ⢒⎇ⓥಽ㊁㧘ᜰዉᢎຬౣ↢ක⑼ቇኾ᡹ߦ߅ߌࠆฦ㗔ၞ೎ߩᢎ⢒⎇ⓥಽ㊁㧘ᜰዉᢎຬ㧘ਥߥ⎇ⓥౝኈߪᰴߩ⴫ߩߣ߅ࠅߢ޽ࠆ‫ޕ‬٤ౣ↢ಽሶ⛔ᓮቇ㗔ၞ㧔⻠ᐳ㧕ಽ‫ޓޓޓ‬㊁⚵❱࡮ེቭᒻᚑ

␹⚻↢‛∛ේ૕೙ᓮቇ

ᜰዉᢎຬ⎇‫ޓޓޓ‬ⓥ‫ޓޓޓ‬ౝ‫ޓޓޓ‬ኈ࿡⽵㓉ᒄ⢦ᕈᐙ⚦⢩㧔ES ⚦⢩㧘iPS ⚦⢩㧕ࠍ฽߻ᐙ⚦⢩߆ࠄ⚵❱࡮ེቭᒻᚑߦ⥋ࠆ⚦⢩ߩჇᱺ࡮ಽൻߩࡔࠞ࠾࠭ࡓߦߟ޿ߡ㧘⚦⢩↢‛ቇ⊛ᚻᴺߣಽሶ↢‛ቇ⊛ᚻᴺࠍ↪޿ߡ⎇ⓥࠍⴕ߁‫․ޕ‬ቯߩ⚦⢩࡮⚵❱࡮⤳ེߦߣࠄࠊࠇࠆߎߣߥߊ㧘ᐙ⚦⢩߆ࠄߩ⚵❱࡮⤳ེߩᒻᚑㆊ⒟ߣᐙ⚦⢩⥄りߩಽൻ࡮Ⴧᱺ࡮⥄Ꮖౣ↢ᯏ᭴ߩ⸃ᨆ
ࠍㅢߒߡ㧘ౣ↢⃻⽎ߩಽሶ೙ᓮᯏ᭴ߩᦨ⚳⊛ߥ⸃᣿ߦะߌߡᢎ
⢒࡮⎇ⓥࠍⴕ߁‫ ࠻ࡅޕ‬ES ⚦⢩࡮iPS ⚦⢩߆ࠄ⚵❱࡮⤳ེࠍ⺃ዉߒౣ↢ක≮߳ㆡ↪ߔࠆ⎇ⓥ߽ㅴ߼ߡ޿ࠆ‫ޕ‬ਛᎹᢅᐘ␹⚻⑼ቇ㗔ၞߦ߅޿ߡ㧘␹⚻ᐙ⚦⢩ߩჇᱺ࡮ಽൻ⺃ዉ࡮ࠕࡐ࠻࡯ࠪࠬ㧔ᄌᕈ㧕ᯏ᭴ߩ⸃᣿ߪ␹⚻∔ᖚߩᴦ≮ᴺߩ㐿⊒ߦߣࠅ㊀ⷐߥ⺖㗴ߢ޽ࠆ‫‛↢⚻␹ޕ‬ಽ㊁ߢߪ␹⚻ᄌᕈ㧔ࠕࡐ࠻࡯ࠪࠬ㧕ߩಽሶ೙ᓮᯏ᭴ߦ㑐ਈߔࠆㆮવሶ⟲ࠍ✂⟜⊛ߦหቯߔࠆᣇᴺࠍ
⏕┙ߒ㧘␹⚻ᄌᕈ㑐ㅪㆮવሶߩ⚦⢩߆ࠄ࿕૕࡟ࡌ࡞ߢߩ૞↪ᯏ᭴ߦߟ߈㧘ಽሶ↢‛ቇ㧘⚦⢩↢‛ቇ㧘෸߮ࡑ࠙ࠬㆮવቇࠍ㚟૶ߒߚ⎇ⓥࠍⴕ߁‫ߦࠄߐޕ‬㧘ࠕ࡞࠷ࡂࠗࡑ࡯∛ߦઍ⴫ߐࠇࠆ␹⚻ᄌᕈ∔ᖚߩ∛ᘒߩ⸃᣿ߦߟ޿ߡ߽ขࠅ⚵߻‫ޕ‬ᳯፒቁⴕ∔∛෸߮㜞㦂ൻߦࠃࠅ఺∉♽߇⎕უߐࠇߡ޿ߊਛߢ㧘1,000 ⒳㘃ࠍ⿧ߔᓸ↢‛∛ේ૕ߦኻߔࠆ୘‫ߩޘ‬ኋਥߩᛶ᛫ᕈߩ࡟ࡌ࡞ࠍ
੍᷹ߒቯ㊂ൻߔࠆᣇᴺࠍ⎇ⓥ㐿⊒ߔࠆ‫ࠅࠃߦࠇߎޕ‬㜞ᐲߩ⤳ེౣ↢ක≮߇ታⴕߐࠇࠆ႐วߦㆣㆄߔࠆᗵᨴࠍ੍᷹ߒ㧘ᓸ↢‛ࠍ૶↪ߒߚ୘‫ߩޘ‬୘૕⁛⥄ߩᗵᨴᛶ᛫ᕈߩౣ↢ࠍⴕ߁ᴦ≮ᴺߩ⏕┙ࠍ⋡ᜰߔ‫ޕ‬㧙㧙٤ౣ↢Ꮏቇ㗔ၞ㧔⻠ᐳ㧕ಽ‫ޓޓޓ‬㊁⍮⢻ࠗࡔ࡯ࠫᖱႎ

ᜰዉᢎຬ⎇‫ޓޓޓ‬ⓥ‫ޓޓޓ‬ౝ‫ޓޓޓ‬ኈ⮮↰ᑝᔒࠦࡦࡇࡘ࡯࠲ࠍ㚟૶ߒߡ㧘ක↪↹௝ᖱႎࠍ޿ࠈ޿ࠈߥⷺᐲ߆ࠄ
ಣℂ࡮ടᎿߒ㧘ౣ↢ක⑼ቇࠍߪߓ߼᭽‫ߥޘ‬ක≮ಽ㊁ߦ߅ߌࠆ↹௝ᖱႎࠍขࠅᛒߞߚᢎ⢒࡮⎇ⓥࠍⴕ߁‫߫߃଀ޕ‬㧘ࠦࡦࡇࡘ࡯࠲ᡰេ
⸻ᢿ㧔CAD㧕ߣ๭߫ࠇߡ޿ࠆ߇㧘↹௝਄ߩ߇ࠎ∛ᄌߩ૏⟎ࠍࠦࡦࡇࡘ࡯࠲ߢᜰ៰ߒߚࠅ㧘∛ᄌㇱ૏ߩࠦࡦࡇࡘ࡯࠲ಽᨆߦࠃࠆ⚿ᨐࠍකᏧߦឭଏߔࠆߎߣߦࠃߞߡ㧘ࠃࠅᱜ⏕ߢ⏕ታߥකᏧߩ↹௝⸻ᢿ߇ⴕ߃ࠆࠃ߁ߦᡰេߔࠆࠪࠬ࠹ࡓߩ㐿⊒ߢ޽ࠆ‫↹ޕ‬௝ᖱႎಣℂᛛⴚ㧘ࡃ࡯࠴ࡖ࡞࡝ࠕ࡝࠹ࠖ㧔VR㧘઒ᗐ⃻ታ㧕㧘ੱᎿ⍮⢻ߥߤߩᦨవ┵ߩක≮↹௝ᖱႎቇߦ㑐ߔࠆၮ␆⎇ⓥࠍⴕ޿㧘߹ߚ㧘කᎿቇ
ಽ㊁ߩฦ⒳ߩቇ㓙㗔ၞߩ↹௝⎇ⓥߦᔕ↪ߔࠆ‫ޕ‬٤ౣ↢ᔕ↪ቇ㗔ၞ㧔⻠ᐳ㧕ಽ‫ޓޓޓ‬㊁

ᓴⅣ∛ᘒቇ

๭ๆ∛ᘒቇ

කቇ♽୶ℂ࡮␠ળකቇ

ᜰዉᢎຬ⎇‫ޓޓޓ‬ⓥ‫ޓޓޓ‬ౝ‫ޓޓޓ‬ኈḊญା਽ੱ࡮േ‛࡮ᬀ‛࡮㝼੺㘃ߩ∛ේᓸ↢‛ߩขࠅᛒ޿ࠍ⠌ᾫߐߖ㧘ߎࠇࠄߩᗵᨴ∝ࠍ੍㒐೙ᓮߔࠆᣇᴺ⺰ࠍୃᓧߐߖࠆ‫ࠗࡃߦ․ޕ‬ࠝ࠹ࡠኻ╷㧘㜞㦂ൻ␠ળߩᣣ๺⷗ᗵᨴ∝ࠍ೙ᓮߔࠆਔᭂ┵ߩᗵ
ᨴ೙ᓮᣇᴺࠍ⠌ᓧߐߖ㧘ᗵᨴ೙ᓮߩᜰዉ㧘⎇ⓥᜰዉ߇ߢ߈ࠆੱ
᧚ࠍ⢒ᚑߔࠆ‫ޕ‬Ḋญା਽ᄖ⇇ߣធߒߡ޿ࠆ๭ๆེ♽ߪ⒳‫∛ߩޘ‬ේ૕߿᦭ኂ‛⾰ߦߐࠄߐࠇ㧘ߘࠇߦࠃࠅᄙߊߩ᳇㆏߿⢖⢩ߩ்ኂࠍ↢ߓࠆ‫∉఺ߚ߹ޕ‬ᯏ᭴ߩ⊒㆐ߒߡ޿ࠆ๭ๆེ♽ߪ㧘૕ౝ߿ᄖ⇇߆ࠄߩ⒳‫ߩޘ‬ೝỗߦࠃࠆ఺∉ᔕ╵ߩ⇣Ᏹߦࠃࠆ்ኂ߽↢ߓࠆ‫ޕ‬৻ᣇ㧘்ኂᓟߩୃᓳߩࡊࡠ࠮ࠬߪಽൻ㧘Ⴧᱺ㧘ࠕࡐ࠻࡯ࠪࠬ
ߩࡊࡠ࠮ࠬߦࠃࠅౣ↢ߐࠇࠆ‫்ޕ‬ኂߦࠃࠅ↢ߓࠆ๭ๆེ♽ߩઍ⴫⊛∔ᖚߣߒߡ᳇㆏਄⊹ߩ்ኂࠍ᧪ߔᘟᕈ᳇▤ᡰἻ㧘⢖⢩்ኂࠍ᧪ߔ⢖᳇⣲㧘⚦⢩ߩㆮવሶᄌ⇣ࠍ᧪ߔ⢖߇ࠎ㧘఺∉ᯏ᭴ߩ⇣Ᏹ߆ࠄ↢ߓࠆ᳇▤ᡰ༎ᕷ߿㑆⾰ᕈ⢖Ἳ߇޽ࠆ‫்ࠄࠇߎޕ‬ኂࠍฃߌߚ๭ๆེ♽ߩ⚦⢩߿⚵❱ࠍ repair ߔࠆߚ߼ౣ↢කቇߔߥࠊߜ
∛⊛⚵❱㧘ེቭߩୃᓳߩߚ߼ᐙ⚦⢩⺃ዉ㧘⒖ᬀ㧘⚵❱㧘ེቭߩ⒖ᬀ㧘ಽൻ㧘Ⴧᱺ㧘ࠕࡐ࠻࡯ࠪࠬ⺃ዉࠍ⋥ធⴕ߁ߎߣ߿ㆮવሶ
ᴦ≮ߦࠃࠅౣ↢ࠍⴕ߁‫ޕ‬ၭ㙃♽ߣߒߡ᳇㆏਄⊹߿⢖⢩਄⊹⚦⢩ࠍ↪޿ߚၭ㙃ታ㛎♽㧘േ‛ࡕ࠺࡞ߣߒߡ⢖᳇⣲㧘⢖✢⛽∝㧘⢖߇ࠎ㧘᳇▤ᡰ༎ᕷࡕ࠺
࡞ࠍ↪޿ߚታ㛎♽ਗ߮ߦࡅ࠻ߩ∔ᖚࠍኻ⽎ߣߒߚ⎇ⓥࠍవ┵⊛⥃ᐥᔕ↪ࠍ⋡ᜰߒߡᢎ⢒ߣ⎇ⓥࠍⴕ߁‫ޕ‬Ⴆ↰ᢘ⟵

1978 ᐕߦ‫⑼⊖ࠬࠢ࠶ࠪࠛࠝࠗࡃޟ‬੐ౖ‫߇ޠ‬಴ ߐࠇߡ߅ࠅ㧘ߘߩ㗃ߦ‫↢ޟ‬๮୶ℂቇ‫߇ޠ‬ᚑ┙ߒߚߣ޿ࠊࠇߡ޿ࠆ‫ࠅࠃߣ߽ޕ‬කߩ୶ℂቇߪ㧘቟ᭉᱫ㧘⣖ᱫ࡮⤳ེ⒖ᬀ㧘ੱᎿᅧᆼਛ⛘ߥߤ㧘ᓥ᧪ߩක≮ⴕὑߩਛߢߪ⑌ᱛߐࠇߡ޿ߚⴕὑߩ⸵ኈၮḰࠍ᣿ࠄ߆ߦߔࠆ⋡⊛ߢ㓸⚂ߐࠇߡ߈ߚߣ⸃ߐࠇࠆ‫߇ࠈߎߣޕ‬㧘ᤓ੹ࠢࡠ࡯
ࡦ୘૕໧㗴߇ᶋ਄ߒ㧘↢๮୶ℂߩ㊀ᔃ߇୘ੱߩ⥄Ꮖ᳿ቯ߆ࠄ౏
౒ㆬᛯߦ⒖േߒߡ߈ߡ߅ࠅ㧘ߘߎߦߪࠕࡔ࡝ࠞဳߣ࡛࡯ࡠ࠶ࡄ
ဳߩኻ┙߽ㄭᐕߒߛ޿ߦ᣿ࠄ߆ߦߥߞߡ߈ߡ޿ࠆ‫ޕ‬කቇ࡮ක≮ߩታ㓙ࠍ⍮ࠆ⠪߇㧘ౣ↢ක⑼ቇߦ઻߁ోߡߩ୶ℂ⊛㧘␠ળකቇ⊛ߥ໧㗴ࠍ࠲࡯ࠥ࠶࠻ߣߒߡ㧘ᣣᧄߢߩὼࠆߴ߈↢๮୶ℂࠍ⠨ⓥߔߴߊߘߩᢎ⢒࡮⎇ⓥࠍⴕ߁‫ޕ‬

㧔3㧕ၮ␆ᛛⴚ࠻࡟࡯࠾ࡦࠣࠦ࡯ࠬ
ක⑼ቇኾ᡹ 4 ߩ㧔3㧕ߢ␜ߒߚၮ␆ᛛⴚ࠻࡟࡯࠾ࡦࠣࠦ࡯ࠬࠍⴕߞߡ޿ࠆ‫ޕ‬㧙㧙㧔4㧕ᄢቇ㒮․೎⻠⟵ฦ⻠ᐳߩ⎇ⓥ⊒⴫࡮․೎⻠Ṷ߆ࠄߥࠆవ┵ౣ↢ක⑼ቇ࠮ࡒ࠽࡯ࠍᐕ 6 ࿁㧘ౣ↢ක⑼ቇኾ᡹ߩో⻠ᐳ߇ෳടߒߡⴕߞߡ޿ࠆ‫ߚ߹ޕ‬ᄢቇ㒮․೎⻠⟵ߪ㧘ฦ⻠ᐳࠍਛᔃߦ㓐ᤨታᣉߒߡ޿ࠆ‫ޕ‬

5. ᢎ⢒ᵴേ
㧔1㧕ᢎ⢒ᵴേߩታᣉౝኈߣᣇᴺౣ↢ක⑼ቇኾ᡹߇㐿⻠ߒߡ޿ࠆ⻠⟵⑼⋡ࠍએਅߦ␜ߔ‫ޕ‬Ԙ ඳ჻೨ᦼ⺖⒟᝼‫ޓޓޓޓ‬ᬺ‫⋡ޓޓޓޓ⑼ޓޓޓޓ‬න૏ᢙㆬᛯ࡮ᔅୃߩ೎↢๮Ꮏቇ1ㆬ‫ޓޓ‬ᛯᖱႎᎿቇ1ㆬ‫ޓޓ‬ᛯ

᭴ㅧ↢‛කቇ

1ㆬ‫ޓޓ‬ᛯ

↢‛කቇ୶ℂ1ᔅ‫ୃޓޓ‬↢‛කቇ୶ℂṶ⠌1ᔅ‫ୃޓޓ‬⚵❱࡮ེቭ⊒↢

2

ㆬᛯᔅୃ

␹⚻↢‛ቇ

2

ㆬᛯᔅୃ

∛ේ૕೙ᓮቇ

2ㆬᛯᔅୃㆮવᖱႎഃ⮎

2ㆬᛯᔅୃක↪ᖱႎಣℂ2ㆬᛯᔅୃ⥃ᐥౣ↢කቇ

2ㆬᛯᔅୃකቇ♽୶ℂ࡮␠ળකቇ

2

ㆬᛯᔅୃ

න૏ᢙ

ㆬᛯ࡮ᔅୃߩ೎

౒‫ޓ‬ㅢ‫⋡ޓ⑼ޓ‬ቇ‫ޓ‬㓙‫⋡ޓ⑼ޓ‬ਥߥኾ㐷⑼⋡

ԙඳ჻ᓟᦼ⺖⒟᝼‫ޓޓޓޓ‬ᬺ‫⋡ޓޓޓޓ⑼ޓޓޓޓ‬౒‫ޓ‬ㅢ‫⋡ޓ⑼ޓ‬ቇ‫ޓ‬㓙‫⋡ޓ⑼ޓ‬ኾ‫ޓ‬㐷‫⋡ޓ⑼ޓ‬ၮ␆⥃ᐥౣ↢කቇ1ㆬ‫ޓޓ‬ᛯ

ౣ↢ක≮୶ℂ1ᔅ‫ୃޓޓ‬

ౣ↢ක≮୶ℂṶ⠌1ᔅ‫ୃޓޓ‬

ᐙ⚦⢩⚵❱ᎿቇṶ⠌2ㆬᛯᔅୃಽሶ␹⚻⚦⢩↢‛ቇṶ⠌

2

ㆬᛯᔅୃ

ᓸ↢‛ࡃࠗࠝࠗࡦࡈࠜࡑ࠹ࠖ࠶ࠢࠬṶ⠌

2

ㆬᛯᔅୃ

⍮⢻ࠗࡔ࡯ࠫᖱႎᔕ↪Ṷ⠌

2

ㆬᛯᔅୃ

⚦⢩࡮⚵❱࡮ེቭ⒖ᬀ࡮ㆮવሶᴦ≮Ṷ⠌

2

ㆬᛯᔅୃ

කቇ♽୶ℂṶ⠌2ㆬᛯᔅୃቇ↢ߪ㧘੍߼ᜰዉᢎຬߩᜰ␜ࠍฃߌߡጁୃߔࠆ᝼ᬺ⑼⋡ࠍ᳿ቯߔࠆ‫ߚ߹ޕ‬㧘ᜰዉᢎຬ߇ᔅⷐߣ⹺߼
ࠆᤨߪ㧘ቇㇱߩ᝼ᬺ⑼⋡㧘ઁߩኾ᡹࡮⎇ⓥ⑼╬ߩ᝼ᬺ⑼⋡ࠍጁୃߔࠆߎߣ߇ߢ߈ࠆ‫ޕ‬ቇ↢ߪᜰዉᢎຬ
ߩᜰዉߩਅߢ⎇ⓥ⸘↹ᦠࠍ૞ᚑߩ਄㧘ቇ૏⺰ᢥ૞ᚑߦᔅⷐߥ⎇ⓥᵴേࠍⴕ߁‫ޕ‬ౣ↢ක⑼ቇኾ᡹ߢߪ㧘ᢎቶߢߩ⻠⟵㧘ታ㛎ቶߢߩታ㛎ᜰዉ㧘࠮ࡒ࠽࡯ቶߢߩታ㛎࠺࡯࠲ߩ⸛⺰㧘⺰ᢥߩ⹦⺒ળࠍᲤㅳⴕߞߡ޿ࠆ‫ޕ‬ඳ჻೨ᦼ⺖⒟෸߮ᓟᦼ⺖⒟ߩᢎ⢒ߪ㧘ࠗࡦ࠲࡯ࡀ࠶࠻࡮ࡎ࡯ࡓࡍ࡯ࠫ "NOBEL" ࠍㅢߓߡⴕߞߡ޿
ࠆ‫ޕ‬㐿⻠ᦼ㑆ਛ㧘ฦ⑼⋡ࠍㆬᛯߒߚቇ↢ߪࠗࡦ࠲࡯ࡀ࠶࠻਄ߩࡎ࡯ࡓࡍ࡯ࠫ෸߮ࡔ࡯࡝ࡦࠣ࡝ࠬ࠻ࠍ
ㅢߓߡᢎຬߣᗧ⷗੤឵ࠍⴕ޿㧘ਈ߃ࠄࠇߚ⺖㗴ߦ㑐ߒߡᢎຬ෸߮ቇ↢߇⼏⺰ࠍⓍߺ㊀ߨࠆ‫ୃߩ⋡⑼ޕ‬㧙㧙ੌᤨߦߪ࡟ࡐ࡯࠻ࠍឭ಴ߒ㧘ቇ⠌ᚑᨐࠍ㧘ฦ⑼⋡ࠍㆬᛯߒߚቇ↢ߣᢎຬߦኻߒߡ⻠Ṷߒฦ⑼⋡ࠍୃੌߔࠆ‫ޕ‬1㧕 ೨ᦼ㧦4 ᦬㧙 7 ᦬㧘NOBEL ᴺߦߡࠗࡦ࠲࡯ࡀ࠶࠻਄ߢ⺖㗴ࠍቇ⠌
9 ᦬ߦᦨ⚳࡟ࡐ࡯࠻ឭ಴ߣ⊒⴫⻠Ṷ
2㧕 ᓟᦼ :10 ᦬㧙 1 ᦬㧘NOBEL ᴺߦߡࠗࡦ࠲࡯ࡀ࠶࠻਄ߢ⺖㗴ࠍቇ⠌
2 ᦬ߦᦨ⚳࡟ࡐ࡯࠻ឭ಴ߒ⊒⴫⻠Ṷ߹ߚ㧘ౝᄖߩᄢቇ࡮⎇ⓥᯏ㑐ߣߩ౒ห⎇ⓥਗ߮ߦ⇐ቇ↢੤឵߽Ⓧᭂ⊛ߦ᛼ߒㅴ߼㧘ቇ㓙⊛࡮✚ว⊛⎇ⓥߩផㅴߣߣ߽ߦ࿖㓙⊛ㅢ↪ᕈ࡮౒ㅢᕈߩ⏕଻ߦ߽ജࠍᵈ޿ߢ޿ࠆ‫ޕ‬ߎߩ߶߆㧘ᧄኾ᡹ߩᢎ⢒࡮⎇ⓥᵴേߩ․ᓽߣߒߡએਅߩ߽ߩࠍ᜼ߍࠆߎߣ߇ߢ߈ࠆ‫ޕ‬Ԙ⻠ᐳන૏ߢቇ↢ߩᢎ⢒࡮⎇ⓥᜰዉߦᒰߞߡ޿ࠆ߇㧘ᒰኾ᡹߇ቇ㓙⊛ಽ㊁ߢ޽ࠆߎߣ߽޽ࠅ㧘⻠ᐳߩᨒߦߣࠄࠊࠇߕකቇၮ␆♽࡮⥃ᐥ♽࡮Ꮏቇ♽߇౒หߒߡቇ↢ߩ⎇ⓥᜰዉࠍⴕ߁ߥߤ㧘ᨵエߥᜰዉ૕೙ࠍណ↪
ԙ ᄢቇ㒮⸳⟎ၮḰ╙ 14 ᧦․଀ߩᤤᄛ㐿⻠೙ࠍታᣉԚ↢๮࡮ක≮୶ℂࠍ㊀ⷞߒ㧘೨ᦼ⺖⒟ߢߪ↢‛කቇ୶ℂࠍ㧘ᓟᦼ⺖⒟ߢߪౣ↢ක≮୶ℂߩጁୃࠍᔅୃൻԛ೨ᦼ⺖⒟ߢߪ⚦⢩↢‛ቇ㧘ಽሶ⊒↢ቇ㧘ಽሶ↢‛ቇ╬ߩၮ␆↢๮⑼ቇߩᢎ⢒࡮⎇ⓥࠍ㧘ᓟᦼ⺖⒟ߢߪౣ↢ᔕ↪╬ߩᔕ↪↢๮⑼ቇߩᢎ⢒࡮⎇ⓥࠍታᣉ㧙㧙6㧚 ⎇ⓥᵴേާౣ↢ಽሶ⛔ᓮቇ⻠ᐳި
㧔1㧕⚵❱࡮ེቭᒻᚑಽ㊁1㧚⎇ⓥߩ᭎ⷐ
࿡⽵ߣᧄᯅߪ ES ⚦⢩߆ࠄ⺃ዉߒߚ⚦⢩࡮⚵❱࡮ེቭࠍౣ↢ක≮ߦㆡ↪ߔࠆߚ߼ߩၮ␆⎇ⓥࠍⴕߞߡ޿
ࠆ‫ޕ‬2000 ᐕએ㒠ߦࡑ࠙ࠬ ES ⚦⢩߆ࠄ࡟ࡦ࠭㧘✂⤑⚦⢩ࠍ฽߻⌒᭽᭴ㅧࠍ⺃ዉߔࠆᛛⴚߩ㐿⊒ߦᚑഞߒ㧘ES ⚦⢩߆ࠄ⹜㛎▤ౝߢ⚵❱࡮ེቭࠍ⺃ዉߢ߈ࠆߣ޿߁೨଀ߩߥ޿น⢻ᕈࠍ␜ߒߡએ᧪㧘⌒᭽᭴ㅧߩౣ↢ක≮߳ߩㆡ↪ࠍ߼ߑߒ㧘࠻࡝߿ࡑ࠙ࠬߩ⌒⃿߳⒖ᬀߒ↢⌕ߔࠆߎߣࠍ⏕⹺ߒߚ‫ᦨޕ‬ㄭ㧘ጘ㒂ᄢቇ⣲≌∛ℂߣߩ౒หߢࡅ࠻ ES ⚦⢩߆ࠄ✂⤑᭽᭴ㅧࠍ⺃ዉߔࠆߎߣߦᚑഞߒߚ‫ޕ‬␹⚻ႇ⚦⢩ߪ␹⚻▤߆ࠄ⊒↢ߔࠆᄖ⢦⪲↱᧪ߩ⚦⢩ߢ޽ࠅ㧘㕖Ᏹߦᄙ᭽ߥ⚦⢩㧔⦡⚛⚦⢩㧘ᐔṖ╭㧘㛽࡮エ㛽ߥߤߩ㑆⪲♽⚦⢩㧘␹⚻⚦⢩㧘ࠣ࡝ࠕ⚦⢩ߥߤߩᧃ᪳␹⚻♽⚦⢩㧘ౝಽᴲེቭ᭴ᚑ⚦⢩ߥߤ㧕ߦಽൻჇᱺߔࠆᄙಽൻ⢻ࠍ᦭ߒߡ޿ࠆ‫ޕ‬ᚒ‫ ߪޘ‬ES ⚦⢩߆ࠄߎߩ␹⚻ႇ⚦⢩ࠍ⺃ዉߔࠆߎߣߦᚑഞߒ㧘ߎߩ vitroߩಽൻჇᱺࠍ⹦⚦ߦ⸃ᨆߔࠆߎߣߢ㧘⃻࿷߹ߢߘߩో⽩߇᣿ࠄ߆ߦߐࠇߡ޿ߥ޿␹⚻ႇ⚦⢩ߩ⊒↢෸߮ಽൻߩࡔࠞ࠾࠭ࡓࠍ᣿ࠄ߆ߦߒߟߟ޽ࠆ‫ޕ‬ౣ↢ක≮߳ߩขࠅ⚵ߺߣߒߡ㧘␹⚻ႇ⚦⢩ߩ⇣Ᏹߦࠃߞߡ⊒∝ߔ
ࠆ㊀◊ߥᧃ᪳␹⚻⎕✋ߢ޽ࠆ Hirschsprung disease ߿ Waardenburg Syndrome ߥߤߩ␹⚻ႇ∝ߩ⚦⢩ᴦ≮ߦ⚿߮ߟߌߚ޿ߣ⠨߃ߡ޿ࠆ‫ޕ‬ߎࠇࠄߩ⎇ⓥߩ⥃ᐥᔕ↪ࠍⷞ㊁ߦ౉ࠇ㧘2003 ᐕߦࡅ࠻ ES ⚦⢩ߩ૶↪⸵นࠍฃߌ㧔ᣣᧄߢ 5 ⇟⋡ߩ૶↪ᯏ㑐㧕㧘⃻࿷߹ߢߦᔃ╭㧘ⴊᶧ⚦⢩㧘✂⤑⦡⚛⚦⢩ߥߤߩ⺃ዉߦᚑഞߒߡ޿ࠆ‫ޕ‬
2006ᐕ߆ࠄ㧘ᚻႦࠍਛᔃߦญ⣧∛ᘒቇߣߩ౒หߢⷫ⍮ࠄߕ߆ࠄ㑆⪲♽ᐙ⚦⢩ࠍណขߒ㧘⃻࿷߹ߢߦ⚂200ੱಽߩᱤ⢦ᐙ⚦⢩ࡃࡦࠢࠍ᮸┙ߒߡ޿ࠆ‫⚦ߩࠄࠇߎޕ‬⢩ࠍ↪޿ߡ዁᧪ᱤ߿㛽ߩౣ↢ක≮ࠍⴕ߁ߴߊ㧘
ᢛᒻᄖ⑼ቇߣߩ౒หࠍ฽߻ಽ㊁ᮮᢿ⊛ߥ⎇ⓥࠍㅴ߼ߡ޿ࠆ‫ߦࠢࡦࡃߩઁޕ‬Ყߴ቟ో࡮቟ଔ࡮ല₸⦟ߊ⚦⢩ࡃࡦࠢ߇᭴ᚑߢ߈ࠆ೑ὐࠍ↢߆ߒ㧘਎⇇ߢೋ߼ߡߩታ↪⊛ߥᐙ⚦⢩ࡃࡦࠢߦ⊒ዷߐߖߚ޿‫ޕ‬ญ⣧∛ᘒቇ㧘੩ㇺᄢቇౣ↢කቇ⎇ⓥ࠮ࡦ࠲࡯ߣߩ౒ห⎇ⓥߦࠃࠅࡅ࠻ᱤ⢦ᐙ⚦⢩ߪઁߩࡅ࠻⚦⢩ߦᲧߴߡੱᎿᄙ⢻ᕈᐙ⚦⢩㧔iPS ⚦⢩㧕ߦല₸ࠃߊ⺃ዉߐࠇࠆߎߣࠍ᣿ࠄ߆ߦߒߚ‫ߩߎޕ‬ᚑᨐࠍၮ␆ߦ㧘JST ጊਛ iPS ․೎ࡊࡠࠫࠚࠢ࠻ߩጘ㒂ᄢቇࠨ࠹࡜ࠗ࠻࠴࡯ࡓߣߒߡല₸⊛ߥ iPS ⚦⢩⺃ዉࠍ⋡ᜰߔ⎇ⓥ߇ 2008ᐕᐲࠃࠅ㐿ᆎߐࠇߚ‫ޕ‬ᚻႦߪⶄ㔀♽ࡕ࠺࡞ߩ߭ߣߟߢ޽ࠆ෻ᔕ᜛ᢔ♽ࠍ↪޿ߡ㧘઒ᗐ㛽࡝ࡕ࠺࡝ࡦࠣࡕ࠺࡞‫ޟ‬iBone‫ࠍޠ‬૞⵾ߒ㧘㛽ߦሽ࿷ߔࠆ⚦⢩߇ജቇⅣႺߦㆡᔕߒߚ㛽ᓸ⚦ᒻᘒࠍᒻᚑߔࠆㆊ⒟ࠍࠪࡒࡘ࡟࡯࠻ߒߚ‫⎇ߌ߇߈ߐޕ‬ⓥߥߤߩᄢဳቇᄖ୘ੱ⎇ⓥ⾌ߥߤࠍฃߌ㧘ᧄቇᢛᒻᄖ⑼㧘ญ⣧ᄖ⑼ߩදജࠍᓧߡ㧘ࡅ࠻ᄢ⣽㛽ㄭ૏┵ߩᒻ⁁ߩౣ⃻㧘㗶㛽ߩᒻᚑ࡮ୃᓳㆊ⒟߿㛽☻㝃∝ߩౣ⃻ߦ߽ᚑഞߒߡ޿ࠆ‫ߦࠄߐޕ‬㧘ᄢℂ⍹∛ߩࡕ࠺࡞ࡑ࠙ࠬ
ࠍ↪޿ߡߎߩ∛ᘒߩㅴⴕㆊ⒟ࠍࠪࡒࡘ࡟࡯࠻ߔࠆ⎇ⓥ߽㐿ᆎߒ㧘iBone ߩ᦭ലᕈࠍࠃࠅ⹦⚦ߦᬌ⸽ߒߡ޿
ࠆ‫ᦨޕ‬ㄭ㧘ߎߩࡊࡠࠣ࡜ࡒࡦࠣᛛⴚࠍ iPS ⚦⢩ߩ⺃ዉߦᔅⷐߥ⚦⢩ߩೋᦼൻߩࠪࡒࡘ࡟࡯࡚ࠪࡦߦㆡ↪ߔߴߊ㧘ᣂߚߥዷ㐿߽࿑ߞߡ޿ࠆ‫ޕ‬
2㧚ฬ★
࿡⽵㓉ᒄ
ᢎ᝼㧦
ಎᢎ᝼㧦 ᚻႦᑪ৻
ᧄᯅജ⻠Ꮷ㧦Takahiro Kunisada
Ken-ichi Tezuka
Tsutomu Motohashi

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ᚻႦᑪ৻㧘㐿␭ม㧚࠹ࠖ࠶ࠪࡘࠛࡦࠫ࠾ࠕ࡝ࡦࠣ 2006㧦↰⇌ᵏᒾ㧘ጟ㊁శᄦ✬㧚㛽࡮エ㛽ᒻᚑߢ௛ߊ⺃ዉ࿃ሶ, ᧲੩㧦ᣣᧄකቇ㙚㧧2006 ᐕ㧧18㧙23㧚
2㧕 ᚻႦᑪ৻㧚㤥ᧁ⊓ᔒᄦ㧘⸵ධᶈ✬㧚ᡷ⸓ၭ㙃⚦⢩ታ㛎ࡂࡦ࠼ࡉ࠶ࠢ, ᧲੩㧦⟠࿯␠㧧2008 ᐕ㧦314㧙318.
3㧕 ᚻႦᑪ৻㧘਄ጟኡ. ࡔࠞ࠾ࠞ࡞ࠬ࠻࡟ࠬߣ㛽㨪㛽⚦⢩ߩ↢‛ቇ߆ࠄ㛽࡝ࡕ࠺࡝ࡦࠣࠪࡒࡘ࡟࡯࡚ࠪࡦ߳㨪㛽☻㝃∝࡯⥃ᐥߣ⎇ⓥߩᦨᣂേะ, ᧲੩㧦කᱤ⮎಴ 㧧2008 ᐕ㧦76㧙80.
⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 ࿡⽵㓉ᒄ㧚ES ⚦⢩(ਁ⢻⚦⢩)ߩ⎇ⓥߩ⃻⁁㧘⃻ઍකቇ 2006 ᐕ㧧54 Ꮞ㧦9㧙14.

㧙㧙2㧕 㕍ᧁੳ⟤㧘࿡⽵㓉ᒄ㧚ES ⚦⢩ߣ⋡ߩེቭᒻᚑ㧘ࠕ࠾࠹࠶ࠢࠬ 2006 ᐕ㧧19 Ꮞ㧦6㧙14.
3㧕 ⮮Ꮞ੫ੑ㧘ᚻႦᑪ৻㧚Notch ࠪࠣ࠽࡞ߣ⚦⢩ಽൻ㧘CLINICAL CALCIUM 2006 ᐕ㧧16 Ꮞ㧦114㧙119㧚
4㧕 ࿡⽵㓉ᒄ㧚ౣ↢ක≮ࠍᎼࠆᣂߚߥዷ㐿㧘ᣣᧄ⥃ᐥౝ⑼ቇળળ⹹ 2008 ᐕ㧧22 Ꮞ㧦533㧙542.
5㧕 ࿡⽵㓉ᒄ㧚⊕㜬ߩಽሶᯏ᭴㧘ᣣᧄ⊹⤏⑼ቇળ⹹ 2008 ᐕ㧧117 Ꮞ㧦2177㧙2178.
6㧕 㕍ᧁੳ⟤㧘࿡⽵㓉ᒄ㧚ᦨᣂߩࡔ࡜࠾ࡦ⦡⚛⎇ⓥߦߟ޿ߡ㧘ࡈ࡟ࠣ࡜ࡦࠬࠫࡖ࡯࠽࡞ 2008 ᐕ㧧36 Ꮞ㧦10㧙16.
✚⺑㧔᰷ᢥ㧕
1㧕 Motohashi T, Aoki H, Yoshimura N, Kunisada T. Induction of melanocytes from embryonic stem cells
and their therapeutic potential. Pigment Cell Res. 2006;19:284-289.
2㧕 Aoki H, Kunisada T. Colourless side of the nude mutation: Foxn1 and hair pigmentation. Pigment Cell
Melanoma Res. 2008;21:338-339.
ේ⪺㧔๺ᢥ㧕
ߥߒේ⪺㧔᰷ᢥ㧕
1㧕 Takayanagi S, Hiroyama T, Yamazaki S, Nakajima T, Morita Y, Usui J, Eto K, Motohashi T, Shiomi K,
Keino-Masu K, Masu M, Oike Y, Mori S, Yoshida N, Iwama A, Nakauchi H. Genetic marking ofhematopoietic stem and endothelial cells: Identification of the Tmtsp gene encoding a novel
cell-surface protein with the thrombospondin-1 domain. Blood. 2006;107:4317-4325.
2㧕 Tezuka K, Takeda T, Wada Y, Takahashi A, Kikuchi M. Computer simulation of human mandible bone
structure by iBone, a novel reaction-diffusion bone remodeling model. Key Engineering Materials.
2006;306-308;1277-1282.
3㧕 Noguchi A, Watanabe N, Fujimaki R, Kitamura T, Hayashizaki Y, Miyaki S, Tezuka K, Hozumi N.
Identification of genes expressed at the condensation stage of a chondrogenic cell line, ATDC5, by the
SST-REX method. J. Bone Miner Metabol. 2006;24:153-157.
4㧕 Fujimaki R, Toyama Y, Hozumi N, Tezuka K. Involvement of Notch signaling in initiation ofprechondrogenic condensation and formation of nodules in limb bud micromass cultures. J. Bone
Miner Metabol. 2006;24:191-198.
5㧕 Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, Moriwaki H. Characterization of CD133+
hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun.
2006;351:820-824.
6㧕 D'Orazio JA, Nobuhisa T, Cui R, Arya M, Spry M, Wakamatsu K, Igras V, Kunisada T, Granter SR,
Nishimura EK, Ito S, Fisher DE. Topical drug rescue strategy and skin protection based on the role ofMc1r in UV-induced tanning. Nature. 2006;443:340-344.
7㧕 Hara A, Niwa M, Kumada M, Aoki H, Kunisada T, Oyama T, Yamamoto T, Kozawa O, Mori H.
Intraocular injection of folate antagonist methotrexate induces neuronal differentiation of embryonicstem cells transplanted in the adult mouse retina. Brain Res. 2006;1085:33-42.
8㧕 Hara A, Niwa M, Aoki H, Kumada M, Kunisada T, Oyama T, Yamamoto T, Kozawa O, Mori H. A newmodel of retinal photoreceptor cell degeneration induced by a chemical hypoxia-mimicking agent,cobalt chloride. Brain Res. 2006;1109:192-200.
9㧕 Takahashi T, Kawai T, Ushikoshi H, Nagano S, Oshika H, Inoue M, Kunisada T, Takemura G,
Fujiwara H, Kosai KI. Identification and Isolation of Embryonic Stem Cell-Derived Target Cells byAdenoviral Conditional Targeting. Mol Ther. 2006;14:673-683.
10㧕 Tosaki H, Kunisada T, Motohashi T, Aoki H, Yoshida H, Kitajima Y. Mice transgenic for Kit(V620A):
recapitulation of piebaldism but not progressive depigmentation seen in humans with this mutation. J
Invest Dermatol. 2006;126:1111-1118.
11㧕 Aoki H, Hara A, Nakagawa S, Motohashi T, Hirano M, Takahashi Y, Kunisada T. Embryonic stem
cells that differentiate into RPE cell precursors in vitro develop into RPE cell monolayers in vivo. Exp
Eye Res. 2006;82:265-274.
12㧕 Motohashi T, Aoki H, Chiba K, Yoshimura N, Kunisada T. Multipotent cell fate of neural crest-likecells derived from embryonic stem cells. Stem Cells. 2007;25:402-410.
13㧕 Miyazono A, Yamada A, Morimura N, Takami M, Suzuki D, Kobayashi M, Tezuka K, Yamamoto M,
Kamijo R: TGF-b suppresses POEM expression through ERK1/2 and JNK in osteoblasts. FEBS Lett.
2007;581:5321-5326.
14㧕 Oka N, Soeda A, Inagaki A, Onodera M, Maruyama H, Hara A, Kunisada T, Mori H, Iwama T. VEGF
promotes tumorigenesis and angiogenesis of human glioblastoma stem cells. Biochem Biophys Res
Commun. 2007;360:553-559.
15㧕 Inagaki A, Soeda A, Oka N, Kitajima H, Nakagawa J, Motohashi T, Kunisada T, Iwama T.
Long- term maintenance of brain tumor stem cell properties under at non-adherent and adherent
culture conditions. Biochem Biophys Res Commun. 2007;361:586-592.
16㧕 Hara A, Taguchi A, Niwa H, Aoki H, Yamada Y, Ito H, Nagata K, Kunisada T, Mori H. Localization of
septin 8 in murine retina, and spatiotemporal expression of septin 8 in a murine model of㧙㧙IF 10.896

IF 1.425

IF 1.425

IF 2.749

IF 28.751

IF 2.218

IF 2.218

IF 5.862

IF 4.829

IF 2.651
IF 7.531

IF 3.263

IF 2.904

IF 2.904photoreceptor cell degeneration. Neurosci Lett. 2007;423:205-210.
17㧕 Tomita H, Yamada Y, Oyama T, Hata K, Hirose Y, Hara A, Kunisada T, Sugiyama Y, Adachi Y,
Linhart H, Mori H. Development of gastric tumors in Apc Min/+ mice by the activation of theE-catenin/Tcf signaling pathway. Cancer Res. 2007;67:4079-4087.
18㧕 Miwa M, Inoue-Murayama M, Aoki H, Kunisada T, Hiragaki T, Mizutani M, Ito S. Endothelin receptor
B2 (EDNRB2) is associated with the panda plumage colour mutation in Japanese quail. Anim Genet.
2007;38:103-108.
19㧕 Aoki H, Hara A, Niwa M, Motohashi T, Suzuki T, Kunisada T. An in vitro mouse model for retinal
ganglion cell replacement therapy using eye-like structures differentiated from ES cells. Exp Eye Res.
2007;84:868-875.
20㧕 Takeda T, Tezuka Y, Horiuchi M, Hosono K, Iida K, Hatakeyama D, Miyaki S, Kunisada T, Shibata T,
Tezuka K: Characterization of Dental Pulp Stem Cells of Human Tooth Germs. J Dent Res.
2008;87:676-681.
21㧕 Aoki H, Hara A, Niwa M, Motohashi T, Suzuki T, Kunisada T. Transplantation of cells from eye-likestructures differentiated from embryonic stem cells in vitro and in vivo regeneration of retinal
ganglion-like cells. Graefes Arch Clin Exp Ophthalmol. 2008;246:255-265.
22㧕 Kawaguchi A, Chiba K, Tanimura Y, Motohashi T, Aoki H, Takeda T, Hayashi SI, Shimizu K,
Kunisada T. Isolation and characterization of Kit-independent melanocyte precursors induced in theskin of Steel factor transgenic mice. Dev Growth Differ. 2008;50:63-69.
23㧕 Oyama T, Yamada Y, Hata K, Tomita H, Hirata A, Sheng H, Hara A, Aoki H, Kunisada T, Yamashita S,
Mori H. Further upregulation of beta-catenin/Tcf transcription is involved in the development ofmacroscopic tumors in the colon of ApcMin/+ mice. Carcinogenesis. 2008;29:666-672.
24㧕 Soeda A, Inagaki A, Oka N, Ikegame Y, Aoki H, Yoshimura SI, Nakashima S, Kunisada T, Iwama T.
Epidermal growth factor plays a crucial role in mitogenic regulation of human brain tumor stem cells.
J Biol Chem. 2008;383:10958-10966.
25㧕 Aoki H, Yoshida H, Hara A, Suzuki T, Kunisada T. Transplantation of melanocytes into iris: method foriris repigmentation. Transplantation. 2008;85:492-494.
26㧕 Hara A, Aoki H, Taguchi A, Niwa M, Yamada Y, Kunisada T, Mori H. Neuron-like Differentiation and
Selective Ablation of Undifferentiated Embryonic Stem Cells Containing Suicide Gene with Oct-4
Promoter. Stem Cells Dev. 2008;17:619-628.
27㧕 Tsuji Y, Yoshimura N, Aoki H, Sharov AA, Ko MS, Motohashi T, Kunisada T. Maintenance of
undifferentiated mouse embryonic stem cells in suspension by the serum- and feeder-free defined
culture condition. Dev Dyn. 2008;237:2129-2138.
28㧕 Aoki H, Hara A, Motohashi T, Chem H, Kunisada T. Iris as a recipient tissue for pigment cells:
Organized in vivo differentiation of melanocytes and pigmented epithelium derived from embryonicstem cells in vitro. Dev Dyn. 2008;237:2394-2404.
29㧕 Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, Moriwaki H. Differentiation of mouse
hepatic progenitor cells induced by hepatocyte nuclear factor-4 and cell transplantation in mice withliver fibrosis. Transplantation. 2008;86:1178-86.

IF 2.085

IF 7.672

IF 2.640

IF 2.651

IF 3.496

IF 1.590

IF 1.908

IF 5.406

IF 5.581
IF 3.641

IF 3.224

IF 3.084

IF 3.084

IF 3.641

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦࿡⽵㓉ᒄ㧧ࠦࠬࡔ࠻ࡠࠫ࡯⎇ⓥ⽷࿅⎇ⓥഥᚑ㧦⦡⚛⚦⢩ᐙ⚦⢩ߩ೙ᓮߦࠃࠆ⊕᢬∝ᴦ≮ࡕ࠺࡞ߩ㐿⊒㧧ᐔᚑ 17㧙18 ᐕᐲ㧧1,000 ජ౞(500㧦500)ජ౞
2㧕 ⎇ⓥઍ⴫⠪㧦࿡⽵㓉ᒄ㧧ጘ㒂ᄢቇ․೎ᢎ⢒⎇ⓥ⚻⾌㧦ࡅ࠻ ES ⚦⢩࡮⚵❱ᐙ⚦⢩ࠍ↪޿ߚ✂⤑ౣ↢ක≮ࡕ࠺࡞(േ‛ࡕ࠺࡞)ߩ⏕┙㧧ᐔᚑ 18㧙20 ᐕᐲ㧧62,000 ජ౞(44,000㧦12,00㧦6,000 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦ᚻႦᑪ৻㧧ᐔᚑ 18 ᐕᐲጘ㒂ᄢቇ↥ቭቇࡑ࠶࠴ࡦࠣࡈࠔࡦ࠼೙ᐲ㧦↢૕ࠪࡒࡘ࡟࡯࡚ࠪ
ࡦࠍ೑↪ߒߚᰴ਎ઍ CT ࠺࡯࠲⸃ᨆࠪࠬ࠹ࡓߩታ↪ൻ㧦ᐔᚑ 18 ᐕᐲ㧧3,800 ජ౞(3,800 ජ౞)
4㧕 ⎇ⓥઍ⴫⠪㧦ᚻႦᑪ৻㧧ᚢ⇛⊛ഃㅧ⎇ⓥផㅴ੐ᬺ ୘ੱဳ⎇ⓥ‫⑼(ޠߌ߇߈ߐޟ‬ቇᛛⴚᝄ⥝ᯏ᭴)㧦㛽
࡝ࡕ࠺࡝ࡦࠣࠪࡒࡘ࡟࡯࡚ࠪࡦߢ᜸߻࠹࡯࡜࡯ࡔࠗ࠼ౣ↢ක≮㧧ᐔᚑ 16㧙19 ᐕᐲ㧦42,262 ජ౞(22,049㧦10,613㧦7,600㧦2,000 ජ౞)
5㧕 ⎇ⓥઍ⴫⠪㧦ᧄᯅ ജ㧧ᐔᚑ 18 ᐕᐲ ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ၮ⋚⎇ⓥ(C)㧦␹⚻ႇ∝ᴦ≮ߦะߌߚ ES⚦⢩↱᧪ߩ␹⚻ႇ⚦⢩ߩಽൻᯏ᭴ߩ⸃ᨆ㧧ᐔᚑ 18㧙20 ᐕᐲ㧧4,400 ජ౞(2,000㧦1,500㧦900 ජ౞)
6㧕 ⎇ⓥઍ⴫⠪㧦ᚻႦᑪ৻㧧ᐔᚑ 19 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ⪚⧘⎇ⓥ㧦ࡅ࠻㛽∔ᖚࠪࡒࡘ࡟࡯࡚ࠪࡦߩ
ߚ߼ߩ㛽ᚑ㐳ࡕ࠺࡞ߩ᭴▽㧦ᐔᚑ 19㧙20 ᐕᐲ㧦3,200 ජ౞(230㧦90 ජ౞)
7㧕 ⎇ⓥઍ⴫⠪㧦ᚻႦᑪ৻㧧ᐔᚑ 19 ᐕᐲጘ㒂ᄢቇ↥ቭቇࡑ࠶࠴ࡦࠣࡈࠔࡦ࠼೙ᐲ㧦↢૕ࠪࡒࡘ࡟࡯࡚ࠪ
ࡦࠍ೑↪ߒߚᰴ਎ઍ CT ࠺࡯࠲⸃ᨆࠪࠬ࠹ࡓߩታ↪ൻ㧦ᚻႦᑪ৻㧦ᐔᚑ 19 ᐕᐲ㧦900 ජ౞8㧕 ⎇ⓥઍ⴫⠪㧦ᧄᯅ ജ㧧ᐔᚑ 18 ᐕᐲ ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ၮ⋚⎇ⓥ(C)㧦␹⚻ႇ∝ᴦ≮ߦะߌߚ ES⚦⢩↱᧪ߩ␹⚻ႇ⚦⢩ߩಽൻᯏ᭴ߩ⸃ᨆ㧧ᐔᚑ 18㧙19 ᐕᐲ㧧3,500 ජ౞(2,000㧦1,500 ජ౞)㧙㧙9㧕 ⎇ⓥઍ⴫⠪㧦ᧄᯅ ജ㧧ᐔᚑ 20 ᐕᐲ ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ၮ⋚⎇ⓥ(C)㧦ES ⚦⢩ࠍ೑↪ߒߚ␹⚻ႇ∝ᴦ≮ࡕ࠺࡞ߩ⏕┙࡮␹⚻ႇ⚦⢩ߩಽൻᯏ᭴ߩ⸃ᨆ㧧ᐔᚑ 20㧙22 ᐕᐲ㧧3,600 ජ౞(1,500㧦1,400㧦
700 ජ౞)10㧕 ⎇ⓥઍ⴫⠪㧦ᧄᯅ ജ㧧ᐔᚑ 20 ᐕᐲ ጘ㒂ᄢቇකቇㇱ⎇ⓥ⑼㐳࡮ቇㇱ㐳ⵙ㊂⚻⾌‫ޟ‬ᚑ૕⚵❱ߦሽ࿷ߔࠆᄙಽൻ⢻ࠍ᦭ߔࠆ␹⚻ႇ⚦⢩ߩหቯ෸߮ߘߩ⸃ᨆ‫ޠ‬ᐔᚑ 20 ᐕᐲ㧧500 ජ౞
11㧕 ⎇ⓥઍ⴫⠪㧦࿡⽵㓉ᒄ㧧JST ጊਛ iPS ․೎ࡊࡠࠫࠚࠢ࠻(⑼ቇᛛⴚᝄ⥝ᯏ᭴)㧦ᱤ⢦ᐙ⚦⢩߆ࠄߩ iPS⚦⢩ߩ⺃ዉല₸ߩ⏕⹺ߣࡅ࠻ iPS ⚦⢩ߩ⺃ዉ࿃ሶᷫዋൻߩᬌ⸛㧧ᐔᚑ 20㧙24 ᐕᐲ㧦50,000 ජ౞(10,000㧦10,000㧦10,000㧦10,000 ජ౞)
2㧕ฃ⸤⎇ⓥ1㧕 ᚻႦᑪ৻㧦↢૕ࠪࡒࡘ࡟࡯࡚ࠪࡦࠍ೑↪ߒߚᰴ਎ઍ CT ࠺࡯࠲⸃ᨆࠪࠬ࠹ࡓߩታ↪ൻ㧦ᐔᚑ 18 ᐕᐲ㧧
1,900 ජ౞㧦࡜࠻࠶ࠢࠪࠬ࠹ࡓࠛࡦࠫ࠾ࠕ࡝ࡦࠣ(ᩣ)
2㧕 ᚻႦᑪ৻㧦↢૕ࠪࡒࡘ࡟࡯࡚ࠪࡦࠍ೑↪ߒߚᰴ਎ઍ CT ࠺࡯࠲⸃ᨆࠪࠬ࠹ࡓߩታ↪ൻ㧦ᐔᚑ 19 ᐕᐲ㧧
819 ජ౞㧦࡜࠻࠶ࠢࠪࠬ࠹ࡓࠛࡦࠫ࠾ࠕ࡝ࡦࠣ(ᩣ)
3㧕 ࿡⽵㓉ᒄ㧦ᐙ⚦⢩ߩಓ⚿଻ሽߦ߅ߌࠆಓኂ଻⼔೷߅ࠃ߮ಓ⚿ᣇᴺߩ㐿⊒㧦ᐔᚑ 20 ᐕᐲ㧧2,000 ජ౞㧦ᄢ㓁ᣣ㉄(ᩣ)3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫ
1㧕 ࿡⽵㓉ᒄ㧦ࡈࠖ࡯࠳࡯⚦⢩ߩ㕖ሽ࿷ਅ㧘ήⴊᷡၭ࿾ਛߢ⢦ᕈᐙ⚦⢩ࠍᶋㆆၭ㙃ߔࠆߎߣࠍ․ᓽߣߔ
ࠆ㧘⢦ᕈᐙ⚦⢩ߩ⛽ᜬᣇᴺ㧧ᐔᚑ 18 ᐕ(․㗿 2006-051115). 
2㧕 ᚻႦᑪ৻㧘ᩊ↰ᢅਯ㧘࿡⽵㓉ᒄ㧘₹⟎਽೰㧘ᱞ↰⍮ሶ㧘ጊਛિᒎ㧘㜞ᯅ๺೑:ࡅ࠻ᱤ⢦ᐙ⚦⢩߆ࠄߩੱᎿᄙ⢻ᕈᐙ⚦⢩(iPS ⚦⢩)ߩ㜞ല₸⺃ዉᴺ㧧ᐔᚑ 20 ᐕ(಴㗿ᷣ).
3㧕 Tezuka, K., Shibata, T., Kunisada, T., Tamaoki, N., Takeda, T., Yamanaka, S., Takahashi, K.:
Efficientmethodforestablishing
inducedpluripotent
stem
cells.;2008(PCT/JP2008/08320(PCT/JP2008/068320)).
6㧚ቇળᵴേ
1㧕ቇળᓎຬ
࿡⽵㓉ᒄ㧦
1㧕 ᣣᧄ⦡⚛⚦⢩ቇળ੐ോዪ㐳࿖㓙⦡⚛⚦⢩ቇળᜂᒰℂ੐(2007 ᐕ㨪⃻࿷)2㧕 ᣣᧄౣ↢ᆔਔቇળ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳࿡⽵㓉ᒄ㧦
1㧕 13th Meeting of the European Society for Pigment Cell Research (2006.09, Barcelona, Spain,
Symposium, Derivation of melanocyte precursors from embryonic stem cells and theirdifferentiation in vivo; Speaker)
2㧕 ╙ 82 ࿁ାᎺ⊹⤏⣲≌ᙣ⹤ળ(ᐔᚑ 18 ᐕ 2 ᦬㧘᧻ᧄ㧘․೎⻠Ṷ‫⚦⚛⦡ޟ‬⢩ᐙ⚦⢩ߩേᘒߣࡔ࡜ࡁ࡯ࡑ
ᐙ⚦⢩‫ޠ‬Ṷ⠪)3㧕 ╙ 3 ࿁ጘ㒂⣖⑼ቇ⎇ⓥળ(ᐔᚑ 18 ᐕ 11 ᦬㧘ጘ㒂㧘᜗ᓙ⻠Ṷ‫ޟ‬ES ⚦⢩ࠍ↪޿ߚ⌒ߩౣ↢ක≮ߩน⢻ᕈ‫ޠ‬Ṷ⠪)
4㧕 ╙ 106 ࿁ᣣᧄ⊹⤏⑼ቇળ✚ળ(ᐔᚑ 19 ᐕ 4 ᦬㧘ᮮᵿ㧘ᢎ⢒⻠Ṷ 12‫⚦⚛⦡ޟ‬⢩ߩ↢‛ቇ‫ޠ‬㧘⊕㜬ߩಽሶᯏ᭴(࿡⽵㧘ᧄᯅ㧘㕍ᧁ) Ṷ⠪)
5㧕 ╙ 28 ࿁ᣣᧄἻ∝࡮ౣ↢කቇળ(ᐔᚑ 19 ᐕ 8 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ 2‫⚻␹ޟ‬ႇ⚦⢩㧦↢૕ᐙ⚦⢩ߣ㧙㧙ߒߡߩน⢻ᕈ‫ޠ‬㧘ES ⚦⢩߆ࠄ⺃ዉߒߚ␹⚻ႇ᭽⚦⢩ߩಽൻ⢻ജ(ᧄᯅജ㧘㕍ᧁੳ⟤㧘࿡⽵㓉ᒄ) Ṷ⠪)
6㧕 ╙ 3 ࿁ᣣᧄ⥃ᐥౝ⑼කቇળ(ᐔᚑ 19 ᐕ 9 ᦬㧘․೎⻠ṶΧ‫ޟ‬ౣ↢ක≮ࠍᎼࠆᣂߚߥዷ㐿‫ޠ‬Ṷ⠪)7㧕 ╙ 21 ࿁ᣣᧄ⦡⚛⚦⢩ቇળᐕᰴቇⴚᄢળ(ᐔᚑ 19 ᐕ 12 ᦬㧘৻⥸Ṷ㗴 1.ࡔ࡜ࡁࠨࠗ࠻ߩಽൻ ᐳ㐳)8㧕 ᄢ㓁ᣣ㉄ࡔࠫࡖ࡯ࠢ࡜ࡉ ਛㇱࡔ࠺ࠖࠞ࡞ળ✚ળ(ᐔᚑ 19 ᐕ 6 ᦬㧘᜗ᓙ⻠Ṷ‫ޟ‬ౣ↢ක≮ߩㅴዷߣߘࠇ
ࠍᡰ߃ࠆࠟࠬᛛⴚ‫ޠ‬Ṷ⠪)9㧕 20th International Pigment Cell Conference and 5th International Melanoma Research Congress(2008.05, Hokkaido, ࠨ࠹࡜ࠗ࠻ࠪࡦࡐࠫ࠙ࡓ, Melanocytes in eye, harderian gland and ear:Different requirement of Kit and Endothelin 3 signalings for the development of non-cutaneous
melanocytes, invited co-author)
10㧕 20th International Pigment Cell Conference and 5th International Melanoma Research Congress(2008.05, Hokkaido, Signal transduction and life cycle of melanocytes, invited speaker)
11㧕 20th International Pigment Cell Conference and 5th International Melanoma Research Congress(2008.05, Hokkaido, CS-09:Signaling cascade in melanocyte and melanoma, co-chair person)
12㧕 ᖱႎᯏ᭴ਥ௅ߦࠃࠆౣ↢ක≮࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 7 ᦬㧘᧲੩㧘‫ޟ‬ᐙ⚦⢩ࠍ↪޿ߚౣ↢ක≮ߩน⢻ᕈ‫ޠ‬Ṷ⠪)
13㧕 ᾢᧄᄢቇࠣࡠ࡯ࡃ࡞ COE ࡝ࠛ࠱ࡦ࡜ࡏ⎇ⓥળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ᾢᧄ㧘᜗ᓙ⻠Ṷ‫ޟ‬Establishment of
iPS cell bank from dental pulp stem cells and its possible use for regenerative medicine‫ޠ‬Ṷ⠪)ජ
14㧕 ╙ 24 ࿁᡼ᓇ⎇㊀☸ሶක⑼ቇ࠮ࡦ࠲࡯⎇ⓥ੤ᵹળ(వ┵ㆮવሶ⊒⃻⎇ⓥࠣ࡞࡯ࡊ)(ᐔᚑ 20 ᐕ 10 ᦬㧘⪲㧘᜗ᓙ⻠Ṷ‫ޟ‬ጘ㒂ᄢቇᱤ⢦ᐙ⚦⢩ࡃࡦࠢ߅ࠃ߮ iPS ⚦⢩ࡃࡦࠢߩ᮸┙ߣ iPS ⚦⢩ࠍ↪޿ߚౣ↢ක≮ߩน⢻ᕈ‫ޠ‬Ṷ⠪)ᚻႦᑪ৻㧦
1㧕 ╙ 111 ࿁ᣣᧄ⸃೬ቇળ✚ળ(ᐔᚑ 18 ᐕ 3 ᦬㧘ᶆ๺(ർ㉿ᄢቇ)㧘᜗ᓙࠪࡦࡐࠫࠬ࠻‫ޟ‬㛽࡝ࡕ࠺࡝ࡦࠣࠪ
ࡒࡘ࡟࡯࡚ࠪࡦ‫ޟ‬iBone‫ޠ‬㨪⚦⢩ߦࠃࠆᦨㆡ᭴ㅧ⸳⸘㨪‫ޠ‬Ṷ⠪)2㧕 ↥ቇቭ࠹ࠢࡁࡊ࡜ࠩጘ㒂(ᐔᚑ 18 ᐕ 2 ᦬㧘›ጊ㧘᜗ᓙ⻠Ṷ‫ޟ‬㛽࡝ࡕ࠺࡝ࡦࠣࠪࡒࡘ࡟࡯࡚ࠪࡦࠍ೑
↪ߒߚᣂߒ޿ౣ↢ක≮ᛛⴚ‫ޠ‬Ṷ⠪)
3㧕 ࡃࠗࠝࡈ࡜ࠬࠦᚢ⇛ࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 19 ᐕ 3 ᦬㧘᧲੩(⑼ቇᛛⴚᝄ⥝ᯏ᭴ ⎇ⓥ㐿⊒ᚢ⇛࠮ࡦ࠲࡯)㧘⹤㗴ឭଏ‫↢ޟ‬๮ࠪࠬ࠹ࡓߩࡠࠫ࠶ࠢߩ᛽಴ ᯏ᪾ࠪࠬ࠹ࡓ߳ߩ⠡⸶࡮ォ౮‫ޠ‬Ṷ⠪)
4㧕 ᣣᧄᱤ⑼ℂᎿቇળਛㇱᡰㇱᄐᦼ࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 8 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫▚⸘ޟ‬ᯏࠪࡒࡘ࡟࡯࡚ࠪ
ࡦ iBone ࠍ૶ߞߚ࠹࡯࡜࡯ࡔࠗ࠼㛽ౣ↢ක≮‫ޠ‬Ṷ⠪)ᧄᯅ ജ㧦
1㧕 ╙ 44 ࿁ᣣᧄዊఽᄖ⑼ቇቇળ✚ળ(ᐔᚑ 19 ᐕ 5 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ‫∛ߩ∛ࠣࡦ࡞ࡊࠬࡘࠪ࡞ࡅޟ‬࿃⺰‫ޠ‬Ṷ⠪)2㧕 20th International Pigment Cell Conference and 5th International Melanoma Research Congress(2008.05, Hokkaido, Multipotent cell fates of melanocyte precursors isolated from embryonicand neonatal skin, speaker)
8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേᧄᯅ ജ㧦
1㧕 ๺᱌ጊ⋵┙ᣣ㜞㜞╬ቇᩞࠬ࡯ࡄ࡯ࠨࠗࠛࡦࠬࡂࠗࠬࠢ࡯࡞․೎⻠⟵‫ࠆ߆ࠊޟ‬ౣ↢කቇ ES ⚦⢩࡮iPS⚦⢩ࠍℂ⸃ߒࠃ߁‫(ޠ‬2008 ᐕ 10 ᦬ 27 ᣣ ๺᱌ጊ⋵ᓮဌᏒ ⋵┙ᣣ㜞㜞╬ቇᩞ)10㧚ႎ๔ᦠ
1㧕 ᚻႦᑪ৻㧦ⶄ㔀♽㛽࡝ࡕ࠺࡝ࡦࠣࠪࡒࡘ࡟࡯࡚ࠪࡦࠍ೑↪ߒߚࡅ࠻㛽∔ᖚࡕ࠺࡞ߩ⸃ᨆ㧦ᐔᚑ 16 ᐕᐲ㧙17 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄(ၮ⋚⎇ⓥ C)⎇ⓥᚑᨐႎ๔ᦠ㧦1㧙41(2006 ᐕ 3 ᦬)
2㧕 ᧄᯅ ജ㧦␹⚻ႇ∝ᴦ≮ߦะߌߚ ES ⚦⢩↱᧪ߩ␹⚻ႇ⚦⢩ߩಽൻᯏ᭴ߩ⸃ᨆ㧦ᐔᚑ 18 ᐕᐲ㧙19 ᐕ
ᐲ ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)ᚑᨐႎ๔ᦠ㧦1㧙49(2008 ᐕ 3 ᦬)㧙㧙

11㧚ႎ㆏
1㧕 ࿡⽵㓉ᒄ㧦⺒ᄁᣂ⡞ᦺೀ 㨬ᐙ⚦⢩ߩ੹㧘਎⇇ߩ⎇ⓥ࡟࡯ࠬടㅦ㨭(2006 ᐕ 5 ᦬ 29 ᣣ)2㧕 ࿡⽵㓉ᒄ㧦࡜ࠫࠝ NIKKEI‫⊕ޠ࡯࠽ࡒ࠮⑼⤏⊹ࡎ࡞ࡑޟ‬㜬ߩಽሶᯏ᭴(2007 ᐕ 10 ᦬ 23 ᣣ)
3㧕 ᚻႦᑪ৻㧦ጘ㒂ᣂ⡞ᦺೀ ‫ޟ‬㛽ߩᒻត᳞㧘ක≮ᔕ↪⋡ᜰߔ‫(ޠ‬2008 ᐕ 1 ᦬ 15 ᣣ)
4㧕 ࿡⽵㓉ᒄ㧦ጘ㒂ᣂ⡞ᦺೀ ‫ޟ‬ᣣᧄੱ⚦⢩߆ࠄਁ⢻⚦⢩‫(ޠ‬2008 ᐕ 4 ᦬ 9 ᣣ)
12㧚⥄Ꮖ⹏ଔ⹏ଔ
3 ᐕ㑆ߩ⎇ⓥ⺰ᢥߩᢙ㧘ࠗࡦࡄࠢ࠻ߦ㑐ߒߡߪਇ⿷ߪߥ޿‫⎇ޕ‬ⓥ⊒⴫ߦ㑐ߒߡߪ㧘࿖㓙ቇળߢߩ⊒⴫ࠍჇ߿ߔᔅⷐ߇޽ࠆ‫┹ޕ‬੎⊛⎇ⓥ⾌ߩ₪ᓧߪචಽߣߪ⸒߃ߥ޿߇㧘౒ห⎇ⓥ࡮౒ห೑↪ߦࠃࠅ⚻⾌ߩ▵ᷫࠍ࿑ߞߡ߽߅ࠅ㧘ᷓೞߥਇ⿷ߦߪ㒱ߞߡ޿ߥ޿‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷⎇ⓥኻ⽎߇᜛ᢔ᳇๧ߢ㧘⎇ⓥ⠪࡮ቇ↢ᢙࠍൊ᩺ߔࠇ߫චಽߥ⎇ⓥᚑᨐࠍ᜼ߍߡ޿ࠆ߇㧘ࠗࡦࡄࠢ࠻ߩ
㜞޿ᚑᨐ⊒⴫ߦߪߟߥ߇ߞߡ޿ߥ޿‫ߪߩ޿ߥࠇ߈ࠅ⛉ࠍࡑ࡯࠹ޕ‬㧘෩ߒ޿⎇ⓥ⾌₪ᓧߩ⁁ᴫ㧔ᒰಽ㊁ߩ⑼ቇ⎇ⓥ⾌ណᛯ₸߇ૐ޿㧕ࠍᛂ㐿ߔߴߊ㧘޽ࠆ⒟ᐲ⾗㊄ߩឭଏవߦวࠊߖߚ⎇ⓥࠍߖߑࠆࠍᓧߥ޿ߣ޿
߁⁁ᴫߩ෻ᤋߢ߽޽ࠅ㧘ࠫ࡟ࡦࡑߦ㒱ߞߡ޿ࠆ‫ޕ‬
ᒰಽ㊁ߩࠬ࠲࠶ࡈߪฦ⥄ᔅⷐߥദജࠍᕃߞߡߪ޿ߥ޿߇㧘ᄢቇ㒮౉ቇ⠪ߩᷫዋߣ߽㊀ߥࠅ㧘⥄ഥദജߢ഍⊛ߥࡄࡈࠜ࡯ࡑࡦࠬߩะ਄ࠍ⸘ࠇࠆ߆ߪ⇼໧ߢ޽ࠆ‫ޕ‬ઃട⊛ߥ⸥ㅀࠍ⸵ߒߡ߽ࠄ߃ࠆߥࠄ㧘ጘ㒂ᄢቇකቇㇱో૕ߦ߅ߌࠆ⎇ⓥᓥ੐⠪ߩᕆᷫߣ㧘ࠃࠅ⦟޿⎇ⓥⅣႺࠍ᳞߼ߡߩఝ⑲ߥቇౝ⎇ⓥ⠪ߩቇᄖ߳ߩᵹᄬߪ㧘ᒰಽ㊁ߦ㒢ࠄߕၮ␆ฦಽ㊁ߦ߅ߌࠆ⎇ⓥߩ㊂ߣ⾰ߩਔᣇࠍૐਅߐߖ㧘ጘ㒂ᄢቇකቇㇱߦ߅ߌࠆၮ␆⎇ⓥࠍუṌߐߖࠆᕟࠇ߇޽ࠆ‫ޕ‬ጘ㒂ᄢቇකቇㇱߩ⎇ⓥ⢻ജࠍ⛽ᜬߒ㧘ఝ⑲ߥᓟ⛮⠪ࠍ⢒ᚑߔࠆߚ߼ߩౕ૕⊛ߥࡊ࡜ࡦߩ૞⵾ߣታⴕ߇ᕆോߣ⠨߃ࠆ‫ޕ‬੹ᓟߩዷᦸᭉⷰ⊛ߥⷐ⚛ߪ⊝ήߢߪ޽ࠆ߇㧘iPS ⚦⢩ࠍਛᔃߦߒߚᣂߒ޿⎇ⓥ࠹࡯ࡑࠍᓥ᧪ߩౣ↢ක≮⎇ⓥߦขࠅㄟߺ㧘⎇ⓥߩ⾰ߣ㊂ߩࡃ࡜ࡦࠬߦ㈩ᘦߒߚ⁛⥄ߩ⎇ⓥࠍⴕ߁ߎߣߢ޽ࠆ⒟ᐲߪෂᯏ⊛⁁ᴫ߇࿁ㆱน⢻ߣ⠨߃ࠆ‫ޕ‬ቇౝߢലᨐ⊛ߥ౒ห⎇ⓥࠍⴕ޿㧘࡝࠰࡯ࠬߣᖱႎࠍ᦭ലߦᵴ↪ߔࠆߎߣ߽৻ጀⓍᭂ⊛ߦⴕ޿
ߚ޿‫ޕ‬

㧙㧙

㧔2㧕␹⚻↢‛ಽ㊁1㧚⎇ⓥߩ᭎ⷐ
ౣ↢ක⑼ቇኾ᡹ ౣ↢ಽሶ⛔ᓮቇ⻠ᐳ ␹⚻↢‛ಽ㊁ߢߪ㧘ಽሶ↢‛ቇ߅ࠃ߮⚦⢩↢‛ቇߦ߅ߌࠆᦨᣂߩ
ᛛⴚࠍ㚟૶ߒ㧘␹⚻ᄌᕈ∔ᖚߩ∛ᘒ⸃᣿㧘ߐࠄߦᴦ≮ᴺߩ㐿⊒ࠍ⋡ᜰߒߚᢎ⢒ߣ⎇ⓥࠍⴕߞߡ޿ࠆ‫⚻␹ޕ‬ᄌᕈ∔ᖚߩᄙߊߪ㔍ᴦᕈߢ޽ࠅ㧘ᴦ≮ᴺߩ㐿⊒߇ᕆോߢ޽ࠆ‫∛ߪߦ߼ߚߩߘޕ‬ᘒߩ⸃᣿߇ᦨఝవ⺖㗴ߢ޽ࠅ㧘කቇߩߺߥࠄߕ⚦⢩↢‛ቇ㧘ಽሶ↢‛ቇ㧘↢ൻቇߥߤฦኾ㐷ಽ㊁ࠍⲢวߒߚ Interdisciplinary
Research and Education㧔ቇ㓙⊛⎇ⓥ߅ࠃ߮ᢎ⢒㧕߇ᔅⷐߢ޽ࠆ‫ᧄޕ‬ಽ㊁ߩᢎ⢒ߣ⎇ⓥߪ⎇ⓥቶߩࡎ࡯ࡓࡍ࡯ࠫ㧔http://www1.gifu-u.ac.jp/~neurobio/㧕ߦ⸥タߒߡ޿ࠆ߇㧘એਅߦᦨᣂߩ㧔ᐔᚑ 20 ᐕ⃻࿷㧕⎇ⓥߣᢎ⢒ౝኈࠍ␜ߔ‫ޕ‬
A. ⎇ⓥ
1㧚㔍ᴦᕈ␹⚻ᄌᕈ∔ᖚߦ߅ߌࠆዊ⢩૕ࠬ࠻࡟ࠬߩᓎഀߩ⸃᣿
ዊ⢩૕ߪ⚦⢩ౝዊེቭߢ޽ࠅ㧘⚦⢩ౝࠞ࡞ࠪ࠙ࡓỚᐲ⺞▵߅ࠃ߮࠲ࡦࡄࠢ⾰ߩୃ㘼ࠍⴕ޿㧘↢๮⃻⽎ߦ߅ߌࠆ⚦⢩ᯏ⢻⛽ᜬ߅ࠃ߮ᖱႎવ㆐ߦ㊀ⷐߥᓎഀࠍᨐߚߒߡ޿ࠆ‫ߩߘޕ‬ᯏ⢻߇㓚ኂߐࠇࠆߣዊ⢩૕ࠬ࠻࡟ࠬߣ
๭߫ࠇࠆ⃻⽎߇߅ߎࠅ㧘ዊ⢩૕ౝߦ᛬ࠅ⇥ߺ⇣Ᏹࠍ⿠ߎߒߚ࠲ࡦࡄࠢ⾰߇⫾Ⓧߔࠆ‫⚦ޕ‬⢩ߪᯏ⢻ࠍᱜᏱߥ⁁ᘒߦᚯߔࠃ߁ߦዊ⢩૕⤑਄ߦሽ࿷ߔࠆ࠲ࡦࡄࠢ⾰ࠍᵴᕈൻ㧔ዊ⢩૕ࠬ࠻࡟ࠬᔕ╵㧕ߔࠆ߇㧘ߘߩ⎕✋ߦࠃࠅ⚦⢩ᱫ߇⺃ዉߐࠇࠆ㧔ਛᎹ╬, Nature 2000㧕‫ᧄޕ‬ಽ㊁ߢߪ㧘ዊ⢩૕ࠬ࠻࡟ࠬ೙ᓮ࿃ሶ߅ࠃ߮ࠕ࡞࠷ࡂࠗࡑ࡯
∛ߦ߅ߌࠆࠕࡒࡠࠗ࠼-ࡌ࡯࠲↥↢ߦ㑐ਈߔࠆࠟࡦࡑ-࠮ࠢ࡟࠲࡯࠯೙ᓮ࿃ሶࠍࠥࡁࡓࡢࠗ࠼ߦࠬࠢ࡝࡯࠾ࡦ
ࠣߔࠆᣇᴺࠍ⏕┙ߒ㧘ࠕ࡞࠷ࡂࠗࡑ࡯∛㧘ࡂࡦ࠴ࡦ࠻ࡦ∛ߩᴦ≮ᴺ㐿⊒ࠍ⋡ᜰߒߚᢎ⢒ߣ⎇ⓥࠍⴕߞߡ޿ࠆ‫ޕ‬㧔ࠕ㧕 ࡂࡦ࠴ࡦ࠻ࡦ∛㧦Ᏹᨴ⦡૕ఝᕈㆮવ᭽ᑼࠍ␜ߒ㧘ਇ㓐ᗧㆇേߣ♖␹␹⚻∝⁁ࠍ․ᓽߣߔࠆ␹⚻ᄌᕈ∔ᖚߢ޽ࠆ‫ޕ‬ㆮવሶᄌ⇣ߦࠃࠅࠣ࡞࠲ࡒࡦ߇ᄙᢙㅪ⛯ߒ㧘␹⚻ᄌᕈࠍ߈ߚߔߣ⠨߃ࠄࠇߡ޿ࠆ߇㧘ߘߩᯏ᭴ߩ⹦⚦ߪਇ᣿ߩ߹߹ߢ޽ࠆ‫ᧄޕ‬ಽ㊁ߢߪ㧘ࡂࡦ࠴ࡦ࠻ࡦ∛ࡕ࠺࡞ࡑ࠙ࠬߦ߅޿ߡ㧘ዊ⢩૕ߩᒻᘒ⇣Ᏹࠍ᣿ࠄ߆ߦߒ㧘ߘߩ⇣Ᏹ߆ࠄ∛ᘒߩ⸃᣿ࠍ⋡ᜰߒߡ޿ࠆ‫ޕ‬㧔ࠗ㧕 ࠕ࡞࠷ࡂࠗࡑ࡯∛㧦ᣣᧄ࿖ౝߛߌߢ߽ 205 ਁੱ㧔2005 ᐕ㧕㧘30 ᐕᓟߩ 2035 ᐕߦߪ⚂ 2.2 ୚ߩ 445ਁੱߩᖚ⠪ᢙߦ㆐ߔࠆߣ੍ᗐߐࠇࠆ⹺⍮∝ࠍ߈ߚߔઍ⴫⊛ߥ∔ᖚߢ޽ࠆ‫ߒ߆ߒޕ‬㧘ߘߩ 90 ࡄ࡯࠮ࡦ࠻એ਄ߪㆮવሶᄌ⇣ࠍ⹺߼ߥ޿ߚ߼㧘ේ࿃߽ਇ᣿ߩ߹߹ߢ޽ࠆ‫ߒ߆ߒޕ‬㧘ኅᣖᕈࠕ࡞࠷ࡂࠗࡑ࡯
∛ߩ⎇ⓥ߆ࠄ㧘ࠕࡒࡠࠗ࠼-ࡌ࡯࠲↥↢ߦ㑐ࠊࠆࠟࡦࡑ-࠮ࠢ࡟࠲࡯࠯ߩ∛ᘒ߳ߩ㑐ਈ߇␜ໂߐࠇߡ
޿ࠆ‫ᧄޕ‬ಽ㊁ߢߪ㧘㕖ኅᣖᕈࠕ࡞࠷ࡂࠗࡑ࡯∛ߩ∛ᘒߩ⸃᣿ࠍ⋡ᜰߒ㧘ࠟࡦࡑ-࠮ࠢ࡟࠲࡯࠯ᵴᕈߩ
೙ᓮᯏ᭴ߩ⸃᣿ߦ㑐ߔࠆ⎇ⓥࠍⴕߞߡ޿ࠆ‫ޕ‬
2㧚␹⚻⚦⢩․⇣⊛ߥ⚦⢩ᱫ㑐ㅪㆮવሶߩหቯߣᯏ⢻⸃ᨆࠞࠬࡍ࡯ࠬ㧔ࠪࠬ࠹ࠗࡦࡊࡠ࠹ࠕ࡯࠯㧕ߪ✢⯻߆ࠄູ੃㘃߹ߢ⋧หㆮવሶ߇ሽ࿷ߒ㧘ࠕࡐ࠻࡯ࠪࠬ㧔⚦⢩ᱫ㧕ࠍ⺃ዉߔࠆࡊࡠ࠹ࠕ࡯࠯ߣߒߡਛᔃ⊛ߥᓎഀࠍᨐߚߒߡ޿ࠆ‫ᧄޕ‬ಽ㊁ߢߪ㧘ࠞࠬࡍ࡯ࠬߩᓎഀ㧘․ߦ㔍ᴦᕈ␹⚻∔ᖚ㧔⣄㜑ዊ⣖ᄌᕈ∝㧕߳ߩ㑐ਈࠍ⸃᣿ߔࠆߚ߼㧘ࠬࡕ࡯࡞ࡊ࡯࡞ cDNA ࡜ࠗࡉ࡜࡝࡯ࠍ
૶ߞߚㆮવሶߩࠢࡠ࡯࠾ࡦࠣᴺߦࠃࠆㆮવሶߩหቯߣᯏ⢻⸃ᨆࠍⴕߞߡ޿ࠆ‫⸃ߩߎޕ‬ᨆߦߡ㧘␹⚻∔ᖚߩේ࿃ㆮવሶࠍหቯߒ㧘ᯏ⢻߅ࠃ߮∛ᘒߩ⸃ᨆ߆ࠄᴦ≮ᴺ㐿⊒ߦะߌߚᢎ⢒ߣ⎇ⓥࠍⴕߞߡ޿ࠆ‫ ޕ‬
3㧚ᄢ⣖⊹⾰ㆇേㅪว㊁߅ࠃ߮೨ᐸ␹⚻♽ߩਛᨔᯏᐨߩ⎇ⓥ
㔚᳇↢ℂቇ⊛ᚻᴺࠍ↪޿, ␹⚻ᯏ⢻ߩ⸃ᨆࠍⴕߞߡ޿ࠆ‫ޕ‬
B. ᢎ⢒
ᄢቇ㒮↢㧔ඳ჻೨ᦼ߅ࠃ߮ᓟᦼ㧕ߪ㧘዁᧪㧔ᰴ਎ઍ㧕ߩ⎇ⓥ⠪ߦߥࠆߚ߼ߦ㧘⻉ᄖ࿖ߢⴕࠊࠇߡ޿ࠆࡊ
ࡠࠣ࡜ࡓࠍෳ⠨ߦߒߚᢎ⢒ߣ⎇ⓥᜰዉ߇ᔅⷐߛߣ⠨߃ߡ޿ࠆ‫߼ߚߩߘޕ‬㧘ᧄಽ㊁ߢߪએਅߩ⢻ജࠍୃᓧߔ
ࠆߎߣࠍ⋡ᜰߒߚᢎ⢒ᜰዉࠍⴕߞߡ޿ࠆ‫ޕ‬x ୘‫ߩޘ‬ታ㛎⚿ᨐࠍ⠨ኤߔࠆ⢻ജx ⥄ಽߩ⎇ⓥᚑᨐࠍ߹ߣ߼ࠆ⢻ജx ⎇ⓥᚑᨐࠍ⊒⴫ߔࠆ⢻ജx ⸛⺰ߔࠆ⢻ജx ⧷⺆⢻ജ㧔⧷⺆ജࠍりߦߟߌࠆߚ߼㧘ᄢቇ㒮↢߇ਛᔃߣߥࠅ Molecular Biology of THE CELL, Cell
Biology ࠍᲤㅳ⺒ࠎߢ޿ࠆ‫ߚ߹ޕ‬㧘࡜ࡏࡒ࡯࠹ࠖࡦࠣࠍ฽߼㧘น⢻ߥ㒢ࠅ⧷⺆ߢߩࠦࡒࡘ࠾ࠤ࡯࡚ࠪ
ࡦࠍⴕߞߡ޿ࠆ‫ޕ‬
㧕
2㧚ฬ★
ਛᎹᢅᐘ
ᢎ᝼㧦
ಎᢎ᝼㧦 Ꮉፉ ථ
૒┻⵨ቁ
⻠Ꮷ㧦

Toshiyuki Nakagawa
Takashi Kawashima
Hirotaka Satake㧙㧙3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
ߥߒ⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
ߥߒ✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
ߥߒේ⪺㧔᰷ᢥ㧕
1㧕 Hayakawa Y, Itoh M, Yamada A, Mitsuda T, Nakagawa T. Expression and localization of Cayman
ataxia-related protein, Caytaxin, is regulated in a developmental- and spatial-dependent manner.
Brain Res. 2007;1129:100-109.
2㧕 Mitsuda T, Hayakawa Y, Itoh M, Ohta K, Nakagawa T. ATF4 regulates -secretase activity during
amino acid imbalance. Biochem Biophys Res Commun. 2007;352:722-727.
3㧕 Takai Y, Matikainen T, Jurisicova A, Kim MR, Trbovich AM, Fujita E, Nakagawa T, Lemmers B,
Flavell RA, Hakem R, Momoi T, Yuan J, Tilly JL, Perez GI. Caspase-12 compensates for lack of
caspase-2 and caspase-3 in female germ cells. Apoptosis. 2007;12:791-800.
4㧕 Hayakawa-Yano Y, Nishida K, Fukami S, Gotoh Y, Hirano T, Nakagawa T, Shimazaki T, Okano H.
Epidermal growth factor signaling mediated by grb2 associated binderl is required for the
spatiotemporally regulated proliferation of olig2-expressing progenitors in the embryonic spinal cord.
Stem Cells. 2007;25:1410-1422.
5㧕 Song S, Lee H, Kam TI, Tai ML, Lee JY, Noh JY, Shim SM, Seo SJ, Kong YY, Nakagawa T, Chung
CW, Choi DY, Oubrahim H, JungYK. E2-25K/Hip-2 regulates caspase-12 in ER stress-mediated A
neurotoxicity. J Cell Biol. 2008;182:675-684.

IF 2.218
IF 2.749

IF 3.043

IF 7.531

IF 9.5984㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄ਛᎹᢅᐘ㧦1㧕 ⎇ⓥઍ⴫⠪㧦ਛᎹᢅᐘ㧧ᐔᚑ 17 ᐕᐲ⥄ὼ⑼ቇ♽⎇ⓥഥᚑ㊄㧔ᣩ⎣ሶ⽷࿅㧕㧦ዊ⢩૕߆ࠄ⊒ାߐࠇࠆ⚦⢩ᱫࠪࠣ࠽࡞ߦࠃࠆࠞࠬࡄ࡯࠯ᵴᕈൻᯏ᭴ߩ⸃᣿㧧ᐔᚑ 17㧙18 ᐕᐲ㧧5,000 ජ౞(4,000㧦1,000ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦ਛᎹᢅᐘ㧘 ⎇ⓥಽᜂ⠪㧦ᣧᎹ૫⧐㧧⑼ቇ⎇ⓥ⾌․ቯ㗔ၞ⎇ⓥ㧦ᯏ⢻⊛ࠬࠢ࡝࡯࠾ࡦࠣ
ᴺߩ⏕┙ߦࠃࠆዊ⢩૕ࠬ࠻࡟ࠬ೙ᓮ࿃ሶߩ✂⟜⊛ត⚝࡮ᯏ⢻⸃ᨆ㧧ᐔᚑ 17㧙18 ᐕᐲ㧦5,800 ජ౞(2,900㧦2,900 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦ਛᎹᢅᐘ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄⪚⧘⎇ⓥ㧦ォ౮࿃ሶ ATF4 ߦࠃࠆࠟࡦࡑ࡯࠮ࠢ࡟࠲࡯࠯
ᵴᕈൻߩ೙ᓮᯏ᭴ߩ⸃᣿㧧ᐔᚑ 19㧙21 ᐕᐲ㧧3,100 ජ౞(1,500㧦900㧦700 ජ౞)
4㧕 ⎇ⓥઍ⴫⠪㧦ਛᎹᢅᐘ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(B)㧦⣖ౝࠕࡒࡁ㉄ࡃ࡜ࡦࠬ⇣Ᏹߦࠃࠆ⹺⍮∝⊒∝ᯏ᭴ߩ⸃᣿㧧ᐔᚑ 20㧙22 ᐕᐲ㧧14,200 ජ౞(7,800㧦3,600㧦2,800 ජ౞)⍫㊁(ᣧᎹ)૫⧐㧦1㧕 ⎇ⓥઍ⴫⠪㧦⍫㊁(ᣧᎹ)૫⧐㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄(⧯ᚻ⎇ⓥ B)㧦ࠪ࠽ࡊࠬߦ߅ߌࠆዊ⣖ㆇേᄬ⺞∝ේ࿃ಽሶ Caytaxin ߩᯏ⢻⸃ᨆ; ᐔᚑ 19 ᐕᐲ㧧1,300 ජ౞
2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥߥߒ㧙㧙5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬ
ߥߒ
2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ਛᎹᢅᐘ㧦
1㧕 ╙ 3 ࿁ዊ⢩૕ࠬ࠻࡟ࠬ⎇ⓥળ(2008 ᐕ 10 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ࠆߌ߅ߦ࡞࠽ࠣࠪࠬࠪ࡯࠻ࡐࠕޟ‬ዊ⢩૕ߩᓎഀ‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേ
ਛᎹᢅᐘ㧘⍫㊁(ᣧᎹ)⧐૫㧦
1㧕 ࠨࠗࠛࡦࠬࡢ࡯࡞࠼㧔ጘ㒂⋵㧕੐ᬺ‫ޡ‬㜞ᩞ↢ߩߚ߼ߩ‫ޟ‬ᄞߩߚ߹ߏ‫ࠍޠ‬⢒ߡࠆࠨࠗࠛࡦࠬࠠࡖࡦࡊ‫ޢ‬(ᐔᚑ 18 ᐕᐲ㧦6 ฬ㧘ᐔᚑ 19 ᐕᐲ㧦3 ฬ㧘ᐔᚑ 20 ᐕᐲ㧦3 ฬ)
10㧚ႎ๔ᦠਛᎹᢅᐘ㧦
1㧕 ਛᎹᢅᐘ㧦ዊ⢩૕ࠬ࠻࡟ࠬߦࠃࠆࠞࠬࡄ࡯࠯ᵴᕈൻߦ߅ߌࠆ Bcl-xL ଐሽᕈ೙ᓮᯏ᭴ߩ⸃᣿㧦ᐔᚑ 17
ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ✚᜝ታ❣ႎ๔ᦠ(2006 ᐕ 3 ᦬)
2㧕 ਛᎹᢅᐘ㧘ᣧᎹ૫⧐㧦ᯏ⢻⊛ࠬࠢ࡝࡯࠾ࡦࠣᴺߩ⏕┙ߦࠃࠆዊ⢩૕ࠬ࠻࡟ࠬ೙ᓮ࿃ሶߩ✂⟜⊛ត⚝࡮ᯏ⢻⸃ᨆ㧦ᐔᚑ 17 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ✚᜝ታ❣ႎ๔ᦠ(2006 ᐕ 3 ᦬)
3㧕 ਛᎹᢅᐘ㧘ᣧᎹ૫⧐㧦ᯏ⢻⊛ࠬࠢ࡝࡯࠾ࡦࠣᴺߩ⏕┙ߦࠃࠆዊ⢩૕ࠬ࠻࡟ࠬ೙ᓮ࿃ሶߩ✂⟜⊛ត⚝࡮ᯏ⢻⸃ᨆ㧦ᐔᚑ 18 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ✚᜝ታ❣ႎ๔ᦠ(2007 ᐕ 3 ᦬)
4㧕 ਛᎹᢅᐘ㧦ォ౮࿃ሶ ATF4 ߦࠃࠆࠟࡦࡑ࡯࠮ࠢ࡟࠲࡯࠯ᵴᕈൻߩ೙ᓮᯏ᭴ߩ⸃᣿:ᐔᚑ 19 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄(⪚⧘⎇ⓥ)✚᜝ታ❣ႎ๔ᦠ(2007 ᐕ 3 ᦬)
5㧕 ਛᎹᢅᐘ㧘ᣧᎹ૫⧐㧘દ⮮ᱜᓼ㧦ዊ⢩૕߆ࠄ⊒ାߐࠇࠆ⚦⢩ᱫࠪࠣ࠽࡞ߦࠃࠆࠞࠬࡄ࡯࠯ᵴᕈൻᯏ
᭴ߩ⸃᣿㧧ᐔᚑ 18 ᐕᐲ⥄ὼ⑼ቇ♽⎇ⓥഥᚑ㊄ႎ๔ᦠ㧦1㧙5(2007 ᐕ 5 ᦬)⍫㊁(ᣧᎹ)૫⧐㧦1㧕 ⍫㊁(ᣧᎹ)૫⧐㧦ࠪ࠽ࡊࠬߦ߅ߌࠆዊ⣖ㆇേᄬ⺞∝ේ࿃ಽሶ Caytaxin ߩᯏ⢻⸃ᨆ㧦ᐔᚑ 19 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄(⧯ᚻ⎇ⓥ B)✚᜝ታ❣ႎ๔ᦠ(2007 ᐕ 10 ᦬)11㧚ႎ㆏ߥߒ12㧚⥄Ꮖ⹏ଔ
⹏ଔ
⑼⎇⾌㧔․ቯ㗔ၞ⎇ⓥ㧘⪚⧘⎇ⓥ㧘ၮ⋚⎇ⓥ㧕߅ࠃ߮⽷࿅߆ࠄߩ⎇ⓥ⾌ࠍ₪ᓧߒ㧘ࠝ࡝ࠫ࠽࡞ߥ⎇ⓥࠍᐢߊⴕߞߡ޿ࠆ‫ޕ‬ඳ჻ᓟᦼ⺖⒟߅ࠃ߮ඳ჻೨ᦼ⺖⒟ߩᄢቇ㒮↢ߪ㗅⺞ߦჇ߃ߡ߅ࠅ㧘࿖㓙࡮࿖ౝቇળ
ߩ⊒⴫╬ߦࠃࠅ⋡ᮡࠍ᣿⏕ߦߒߚᢎ⢒ᵴേࠍⴕߞߡ޿ࠆ‫⎇ࠄࠇߎޕ‬ⓥ߅ࠃ߮ᄢቇ㒮ᢎ⢒ߦ㑐ߒߡߩㅴ᝞
⁁ᴫߪ㧘✚ߓߡ㗅⺞ߦ⊒ዷߒߡ޿ࠆ‫ޕ‬㧙㧙⃻⁁ߩ໧㗴ὐ߅ࠃ߮ߘߩኻᔕ╷2008 ᐕ⃻࿷߹ߢ㧘ᧄಽ㊁ߩ⎇ⓥߪ㧘ᢎຬ 2 ฬ㧔ᢎ᝼㧘ഥᢎ㧕ߣᄢቇ㒮↢ 6 ฬ㧔ඳ჻ᓟᦼ⺖⒟㧦4 ฬ㧧ඳ჻⺖⒟೨ᦼ⺖⒟㧦1 ฬ㧧␹⚻ౝ⑼ቇ࡮⠧ᐕቇಽ㊁ක⑼ቇ⺖⒟㧦1 ฬ㧘ᰴᐕᐲ߽ᄢቇ㒮↢ߩ౉ቇࠍ੍ቯߒ
ߡ޿ࠆ㧕ߢ⎇ⓥࠍⴕߞߡ޿ࠆ‫⃻ޕ‬࿷ߩᄢቇ㒮↢ߪ㧘⮎ቇ♽࡮Ꮏቇ♽࡮කቇ♽ߩઁᄢቇ಴り⠪߇ᄙߊ㧘ᧄቇකቇㇱ಴り⠪ߩᧄಽ㊁߳ߩᄢቇ㒮౉ቇߪ੹ߩߣߎࠈߥ޿‫⎇ޕ‬ⓥࠍᐢߊዷ㐿ߔࠆߚ߼ߦߪ㧘᭽‫ߥޘ‬ኾ㐷ಽ㊁಴り⠪ߩ㓸ว㧔Ⲣว㧕૕߇ᔅⷐߢ޽ࠆ‫੹߼ߚߩߘޕ‬ᓟߪઁᄢቇ࡮ઁಽ㊁಴り⠪ߩߺߥࠄߕᧄቇකቇㇱ಴りߩఝ⑲ߥቇ↢ߩ⏕଻ߦദജߒߚ޿‫ޕ‬⑼⎇⾌ขᓧߣᬺ❣㧔⺰ᢥ㧕߇⋧ᒰ㐳ᦼ㑆ߥ޿ 2 ฬߩᢎຬߪ㧘⃻࿷ߩකቇ⎇ⓥߩ਎⇇߆ࠄ߆ߌ㔌ࠇߡ޿ࠆߚ߼㧘ᄢቇ㒮↢ߩᢎ⢒ߣ⎇ⓥߪᢎ᝼ߣഥᢎߩ 2 ฬߢⴕߞߡ޿ࠆ‫ߥ߆⚦ࠅࠃޕ‬ᜰዉߣ਎⇇ߦㅢ↪ߔࠆ⎇ⓥ⠪⢒ᚑࠍല₸ࠃߊ㆐ᚑߔࠆߚ߼ߦ߽ఝ⑲ߥࠬ࠲࠶ࡈߩ⏕଻ߣ⵬ల߇ᦸ߹ࠇࠆ‫ߚ߹ޕ‬㧘ᄢቇ㒮↢ᢎ⢒ߩᤨ㑆⊛ߥలታߣ࿖㓙ൻࠍ⋡ᜰߒ㧘Ფㅳ࿯ᦐᣣߩඦ೨ਛߦ࡜ࡏࡒ࡯࠹ࠖࡦࠣࠍⴕ޿㧘⊒⴫߅ࠃ߮⾰⇼ᔕ╵ࠍోߡ⧷⺆ߢⴕߞߡ޿ࠆ‫੹ޕ‬ᓟᄖ࿖ੱ⎇ⓥ⠪ߣߩ੤ᵹ߿࠮ࡒ࠽࡯ߩలታࠍߪ߆ࠅߚ޿‫ޕ‬⎇ⓥᚑᨐߦ㑐ߒߡ㧘࿖㓙࡮࿖ౝቇળߢᲤᐕ⊒⴫ߒߡ޿ࠆ߇㧘⺰ᢥᢙࠍჇ߿ߔദജ߇ᔅⷐߢ޽ࠆ‫ޕ‬੹ᓟߩዷᦸಽሶ↢‛ቇ߅ࠃ߮⚦⢩↢‛ቇࠍ㚟૶ߒߥ߇ࠄ␹⚻ᄌᕈ∔ᖚߩ∛ᘒ⸃᣿ࠍⴕߞߡ޿ࠆ߇㧘⌕ታߦᚑᨐ߇
⃻ࠇߡ߈ߡ޿ࠆߚ߼㧘ᴦ≮ᴺ㐿⊒߳ߩᔕ↪㧔࠻࡜ࡦࠬ࡟࡯࡚ࠪ࠽࡞࡝ࠨ࡯࠴㧕ࠍ⋡ᜰߒߚ⎇ⓥ߽ขࠅ౉ࠇߚ޿ߣ⠨߃ߡ޿ࠆ‫ޕ‬ᢎ⢒࡮⎇ⓥࠍㅢߒߡ㧘ࠣࡠ࡯ࡃ࡞ߥⷞ㊁ߢ㧘⁛ഃ⊛ߥᕁ⠨߇಴᧪ࠆᄢቇ㒮↢ࠍ⢒ᚑߒߚ޿‫ޕ‬㧙㧙㧔3㧕∛ේ૕೙ᓮಽ㊁1㧚⎇ⓥߩ᭎ⷐ
∛ේ૕೙ᓮಽ㊁ߢߪ∛ේᓸ↢‛ߩಽሶ♽⛔ಽ㘃ߩ⎇ⓥࠍⴕ޿ߥ߇ࠄ㧘⎇ⓥቶߦᤘ๺ 25 ᐕ߆ࠄ 4 ઍߦࠊߚࠆᢎ᝼ߦࠃߞߡ଻ሽߐࠇߡ߈ߚ∛ේ⚦⩶㧘⚂ 2 ਁᩣࠍᚒ߇࿖ߩ⚦⩶ቇ⠪ߦಽ⼑ߔࠆࠨ࡯ࡆࠬࠍⴕߞߡ߈
ߚ‫ޕ‬ᐕ㑆 500 ᩣ߆ࠄ 1000 ᩣࠍಽ⼑ߒ㧘ㆮવቇ⊛ߥหቯଐ㗬ᩣ߽ᐕ㑆ᐔဋ 300 ᩣߦ㆐ߒߡ޿ࠆ‫⩶ޕ‬ᩣߩ♽⛔଻ሽߪ⎇ⓥಽ㊁ߩ⁛⥄ߩᵴേߣߐࠇ㧘ᄢቇߩេഥߪฃߌߡ޿ߥ޿߇㧘࿖ߩ National Bioresource Project
㧔NBRP㧕ߩᡰេࠍ߁ߌߡ⛽ᜬߒߡ޿ࠆ‫ޕ‬
ಽ㊁ߢߪߎࠇࠄߩ⾗↥ࠍ㊀ⷐߥ⎇ⓥၮ⋚ߣߒߡ⎇ⓥᵴേߦ೑↪ߒߡ߈ߚ‫∛ޕ‬ේᓸ↢‛ߩⅣႺࡕ࠾࠲࡯㧘ᗵᨴ∝ߩ✂⟜⊛ߥ⸻ᢿᛛⴚࠍ․⸵ൻߒ㧘⥃ᐥ⸻ᢿߩߺߥࠄߕ㧘ⅣႺᳪᨴߩࡕ࠾࠲࡯㧘⚵ߺᦧ߃૕೑↪ߩ቟ోᕈ⹏ଔᛛⴚ㧘㘩ຠߩᵹㅢࠪࠬ࠹ࡓߩ቟ో▤ℂߥߤߩ᏷ᐢ޿ಽ㊁ߢߩ೑↪ߦะߌߚขࠅ⚵ߺࠍⴕߞߡ޿ࠆ‫ޕ‬↢‛⾗Ḯߪߐࠄߦᓸ↢‛ߩᣂߒ޿♽⛔ಽ㘃ቇߩ᭴▽ߦ⽸₂ߒߡ߅ࠅ㧘ᚒ‫⎇ߩޘ‬ⓥቶ߇਎⇇ߢ໑৻ dnaJㆮવሶߩᄢ㊂࠺࡯࠲ࡌ࡯ࠬࠍ଻᦭ߒߡ߅ࠅ㧘ߎߩ࠺࡯࠲ߢ∛ේᓸ↢‛ߩ⒳ species ߩቯ⟵ߩឭ᩺ߦะߌߚ
Ⓧᭂ⊛ߥ⎇ⓥࠍዷ㐿ߒߡ߈ߚ‫ߚ߹ޕ‬㜞ᐲ∛ේ૕ࠍ଻᦭ߔࠆᢙዋߥ޿⎇ⓥቶߣߒߡୃ჻⺖⒟ߣ㧘ඳ჻⺖⒟ߢ
ߪ∛ේ૕ߩขࠅᛒ޿ߦᾫ✵ߒߚቇ↢ߩ⢒ᚑࠍ߅ߎߥ޿ኾ㐷ኅᢎ⢒ߦዧജߒߡ߈ߚ‫ޕ‬
2㧚ฬ★
ᳯፒቁⴕ
ᢎ᝼㧦
ಎᢎ᝼㧦 ᄢᬮᷡᢥ
↲⇌ବ㇢⻠Ꮷ㧦

Takayuki Ezaki
Kiyofumi Ohkusu
Shunro Kohbata

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ᳯፒቁⴕ㧘ᄢᬮᷡᢥ ⸶㧚శጟ⍮⿷✬㧚⣺ౝࡈࡠ࡯࡜ߩหቯ㧦DNA ࡊࡠ࡯ࡉߣࡊ࡜ࠗࡑ࡯㧦⣺ౝ⚦⩶ߩಽሶ↢‛ቇ⊛ታ㛎ᴺ㧘᧲੩㧦ᣣᧄࡆࡈࠖ࠭ࠬ⩶࠮ࡦ࠲࡯㧧2006 ᐕ㧦15㧙28㧚
2㧕 ᳯፒቁⴕ ⸶㧚శጟ⍮⿷✬㧚⣺ౝߦ↢ᕷߔࠆ⚦⩶ߩ♽⛔㧦㧚⣺ౝ⚦⩶ߩಽሶ↢‛ቇ⊛ታ㛎ᴺ㧘᧲੩㧦ᣣᧄࡆ
ࡈࠖ࠭ࠬ⩶࠮ࡦ࠲࡯㧧2006 ᐕ㧦7㧙14㧚
3㧕 ᳯፒቁⴕ㧘ᄢᬮᷡᢥ ⸶㧚ዊᳰ๺ᒾ✬㧘ⁿ⁚ᷕ✬㧚Emergency ߦኻᔕߢ߈ࠆㄦㅦᬌᩏᴺ㧦⥃ᐥᬌᩏ Yearbook
2006 ⥃ᐥᓸ↢‛ቇ㧔ᗵᨴ∝ቇ㧕ߦ㑐ߔࠆၮ␆⍮⼂㧘᧲੩㧦⥃ᐥ∛ℂೀⴕળ㧧2006 ᐕ㧦145㧙150㧚
4㧕 ᄢᬮᷡᢥ㧘ᳯፒቁⴕ ⸶㧚⑔੗ᰴ⍫㧘㤥Ꮉᷡ⋙ୃ㧦╙ 137 ┨ ࠨ࡞ࡕࡀ࡜∝㧦ࡂ࡝࠰ࡦౝ⑼ቇ ╙ 2 㧘᧲੩㧦ࡔ࠺ࠖࠞ࡞࡮ࠨࠗࠛࡦࠬ࡮ࠗࡦ࠲࡯࠽࡚ࠪ࠽࡞㧧2006 ᐕ㧦49㧙55㧚
5㧕 ᄢᬮᷡᢥ㧘ᳯፒቁⴕ ⸶㧚⑔੗ᰴ⍫㧘㤥Ꮉᷡ⋙ୃ㧦╙ 138 ┨ ⚦⩶ᕈ⿒∯ࡂ࡝࠰ࡦౝ⑼ቇ ╙ 2 㧘᧲੩㧦ࡔ࠺ࠖࠞ࡞࡮ࠨࠗࠛࡦࠬ࡮ࠗࡦ࠲࡯࠽࡚ࠪ࠽࡞㧧2006 ᐕ㧦55㧙59㧚
6㧕 ᳯፒቁⴕ㧘ᄢᬮᷡᢥ ⸶㧦ࡉ࡜࠶ࠢᓸ↢‛ቇ(2 )㧘╙ 9 ┨ ಽ㘃ቇ౉㐷㧦ࡃࠢ࠹࡝ࠕ㧘ਣༀᩣᑼળ␠㧘2007
ᐕ㧦240㧙271㧚
7㧕 ⑔᳗⡸㧘ᄢᬮᷡᢥ㧘ᳯፒቁⴕ㧦ᓸ↢‛ߩ੐ౖ㧦ᕈᗵᨴ∝㧘᧲੩㧦ᦺୖᦠᐫ㧧2008 ᐕ㧦491㧙495㧚
8㧕 ᄢᬮᷡᢥ㧘⑔᳗⡸㧘ᳯፒቁⴕ㧦ᓸ↢‛ߩ੐ౖ㧘࡟ࠫࠝࡀ࡜ᗵᨴ∝㧘Q ᾲ㧘᧲੩㧦ᦺୖᦠᐫ㧧2008 ᐕ㧦480
㧙484㧚
9㧕 ᄢᬮᷡᢥ㧘㊁↰ਁᏗሶ㧘ᳯፒቁⴕ㧦ᓸ↢‛ߩ੐ౖ㧘⣺▤ᗵᨴ∝㧘᧲੩㧦ᦺୖᦠᐫ㧧2008 ᐕ㧦471㧙480㧚⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 ᳯፒቁⴕ㧚ਃේ৻ఝ㧚⍹ᴤᳪᨴኻ╷ߦ߅ߌࠆࡃࠗࠝ࡟ࡔ࠵࡯ࠛ࡯࡚ࠪࡦߩ↢ᘒ♽ᓇ㗀⹏ଔᚻᴺ㧘↥ᬺߣⅣႺ 2006 ᐕ㧧4 Ꮞ㧦87㧙90㧚
2㧕 ᳯፒቁⴕ㧚ᄢᬮᷡᢥ.ᣂߒ޿⥃ᐥᬌᩏ࡮ᧂ᧪ߩ⥃ᐥᬌᩏ ᗵᨴ∝ᬌᩏ DNA ࠴࠶ࡊࠍ↪޿ߚ⚦⩶ߩหቯ㧘ᬌᩏߣᛛⴚ 2006 ᐕ㧧34 Ꮞ㧦1303㧙1307.
3㧕 ᳯፒቁⴕ㧚╙ 1 ࿁ ᡷቯ߇੍ቯߐࠇߡ޿ࠆᗵᨴ∝ᴺߣ∛ේ૕ߩ଻ሽಽ⼑㧘ㅪタ‫ޟ‬ᓸ↢‛ߩ቟ో▤ℂ‫ޠ‬
Microbiol.Cult.Coll. 2006 ᐕ㧧4 Ꮞ㧦125㧙128.
4㧕 ᄢᬮᷡᢥ㧘ᳯፒቁⴕ㧦ᗵᨴ∝⸻ᢿߩㄦㅦൻࠍ߼ߑߒߡ ㆮવሶ߅ࠃ߮ࠪࠣ࠽࡞Ⴧ᏷ᴺ ⥃ᐥߣᓸ↢‛
2007 ᐕ㧧34 Ꮞ㧦459㧙478.
5㧕 ᄢᬮᷡᢥ㧘ᳯፒቁⴕ㧦ᗵᨴ∝⸻ᢿߩㄦㅦൻࠍ߼ߑߒߡ Ⱟశࡑࠗࠢࡠࡆ࡯࠭ࠕ࡟ࠗ ⥃ᐥߣᓸ↢‛ 2007
ᐕ㧧34 Ꮞ㧦482㧙486.
6㧕 ᵄᄙብᐘ㧘ᄢᬮᷡᢥ㧘ᳯፒቁⴕ㧦ᗵᨴ∝⸻ᢿߩㄦㅦൻࠍ߼ߑߒߡ ࠪ࡯ࠢࠛࡦࠬ⸃ᨆ ⥃ᐥߣᓸ↢‛ 2007
ᐕ㧧34 Ꮞ㧦487㧙492.
7㧕 ᳯፒቁⴕ㧘ᄢᬮᷡᢥ㧦∛ේᕈ⚦⩶ߩᱜᑼ⊒⴫⩶ฬ࡝ࠬ࠻ ᣣᧄ⥃ᐥᓸ↢‛ቇ㔀⹹ 2007 ᐕ㧧17 Ꮞ㧦53㧙
108.
8㧕 ᄢᬮᷡᢥ㧘ᳯፒቁⴕ㧦ᗵᨴ∝ߩ⸻ᢿ ㆮવሶቇ⊛⸻ᢿᴺ ᣣᧄ⥃ᐥ 65 Ⴧೀภ 2007 ᐕ㧧2 Ꮞ㧦199㧙207.

㧙㧙9㧕 ᳯፒቁⴕ㧘ᄢᬮᷡᢥ㧦ዩ〝ᗵᨴ∝ߩㆮવሶᬌᩏ ⥃ᐥᬌᩏ 2007 ᐕ㧧51 Ꮞ㧦159㧙163.
10㧕 ᳯፒቁⴕ㧦ᓸ↢‛ߩෂ㒾ᐲಽ㘃. ⥃ᐥߣᓸ↢‛ 2008 ᐕ㧧35 Ꮞ㧦279㧙292.
11㧕 ᄢᬮᷡᢥ㧦ᗵᨴ∝⸻ᢿߦ߅ߌࠆㆮવሶ⸃ᨆᛛⴚߩㆡᔕ ᣣᧄ⥃ᐥᓸ↢‛ቇળ⹹ 2008 ᐕ㧧18 Ꮞ㧦163㧙176.
12㧕 ᄢᬮᷡᢥ㧘ᳯፒቁⴕ㧦ㆮવሶᬌᩏߦࠃࠆ᛫㉄⩶ᗵᨴ∝ߩㄦㅦ⸻ᢿ ⚿ᩭ 2008 ᐕ㧧83 Ꮞ㧦684㧙688.
✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 Ⓑ⷗↱♿ሶ㧘⍹๺↰⒤ᒾ㧘ᷓᴛජ⛗㧘ᄢᬮᷡᢥ㧘⪉ᧁߪࠆ߆㧘ᱞ↰⚩ᳯ㧘ᴡ㊁㓁৻㧚㜑ᶧᬌ૕ߦኻߔࠆ⢖Ἳ⃿⩶ዩਛ᛫ේㄦㅦᬌ಴ࠠ࠶࠻ߩ૶↪߇⸻ᢿ਄᦭↪ߢ޽ߞߚ⢖Ἳ⃿⩶ᕈ㜑⤑Ἳߩ 1 ଀㧘ዊఽᗵᨴ఺∉
2006 ᐕ㧧18 Ꮞ㧦405㧙409㧚
2㧕 ቟ጟ⍾❱㧘ዊ᫾ᱜ㆏㧘⍫㊁ਭሶ㧘๺↰㗅ሶ㧘ኹፉብ㧘ጟᧄౖሶ㧘⣁ᧄᐘᄦ㧘Ḵ਄㓷ผ㧘᫪㓷⟤㧘ᅏ૑ᝰሶ㧘ᄢᬮᷡᢥ㧘ᳯፒቁⴕ㧘㑆ች⚩৻㇢㧦㥦ຜ༄ౝⷞ㏜ߩᵞᵺ࡮ᶖᲥߩታᘒߣᗵᨴ੍㒐╷ߩᬌ⸛㧘ⅣႺᗵᨴ 2006
ᐕ㧧21 Ꮞ㧦263㧙268.
3㧕 ㊁᧛෹Ꮧሶ㧘౷↰ᐘᏗ㧘ᩊ↰㓷ᒾ㧘㕍ᩉື㧘⦼ᧁᤩᒾ㧘⣁ဈߜ߭ࠈ㧘ᄢᬮᷡᢥ㧘ᷡ᳓ብ㧦ᄙ⊒ᕈ⊹ਅ࡮╭⤥≌ࠍ๒ߒߚࡁࠞ࡞ࠫࠕ∝ ᣣᧄ⊹⤏⑼ቇળ㔀⹹ 2007 ᐕ㧧117 Ꮞ㧦1745㧙1751.
4㧕 ⷗਄⵨⟤ሶ㧘ᄢႦ༑ੱ㧘᧖ᶆ⑲ሶ㧘ᄢᬮᷡᢥ㧘ᳯፒቁⴕ㧘㗇᳗⦟㧘ၳਯౝ⑲ੑ㧘ฎᎹᕺ৻㧘ᱞ↰੩ሶ㧦
Anaerobiospirillum succiniciproducens ߦࠃࠆᢌⴊ∝ߩ 1 ଀ ⥃ᐥ∛ℂ 2007 ᐕ㧧55 Ꮞ㧦930㧙935.
5㧕 ખ㊁ᢕሶ㧘᦭ᧄ෹ቄሶ㧘Ꮏ⮮ౖઍ㧘ᤊ㊁⋥㧘ᄢᬮᷡᢥ㧦2 ࡩᚲߦ㗖ㇱ⤥≌ࠍᒻᚑߒߚ₀߭ߞ߆߈∛ߩዊఽ଀㧘ᣣᧄ⡊㥦ຜ༄⑼ᗵᨴ∝⎇ⓥળળ⹹ 2007 ᐕ㧧25 Ꮞ㧦157㧙160.
6㧕 ᧶ᷨ⾆ᵗ㧘ᄢႦ༑ੱ㧘ᄢᬮᷡᢥ㧘ਛ⷏੩ሶ㧘ቝ૒⟤๺↵㧘ᳯፒቁⴕ㧦Corynebacterium durum ߇⿠Ἳ⩶ߣߒߡ⇼ࠊࠇߚ⢖Ἳߩ 1 ଀㧘ᣣᧄ⥃ᐥᓸ↢‛ቇ㔀⹹ 2007 ᐕ㧧17 Ꮞ㧦1㧙7.
7㧕 㐳Ỉᥓ૫ሶ㧘ᷦ⼱૫⋥㧘᳓⼱㓁ሶ㧘ᷡፉ⌀ℂሶ㧘ᄢᬮᷡᢥ㧦㜞㦂⠪ߦ↢ߓߚ዆Ᏹᕈ⁤≙ߩ 2 ଀㧘⥃ᐥ⊹⤏⑼ 2007 ᐕ㧧61 Ꮞ㧦235㧙238.
8㧕 ട⾐⼱⌀⿠ሶ㧘㜞ᯅඳਯ㧘ਛ㊁⑲ᤘ㧘ᄢᬮᷡᢥ㧦ࡁࠞ࡞ࠫࠕߦࠃࠆᄙ⊒ᕈ╭⡺ౝ⤥≌ߩ 1 ଀ ⷏ᣣᧄ⊹⤏⑼ 2008 ᐕ㧧70 Ꮞ㧦286㧙291.
9㧕 ਃᶆ૒⍮ሶ㧘ᷰᥓਭ㧘቟↰◊ᔒ㧘᫪ᣧ⧣㧘የ᩟㓉㧘⇌ਛቬඳ㧘ᄢᬮᷡᢥ㧦ⴊᶧၭ㙃 10 ᣣ⋡ߦᬌ಴ߒᓧߚ
Helicobacter cinaedi ᢌⴊ∝ߩ 1 ଀ ർᶏ㆏⥃ᐥᬌᩏᛛᏧ⹹ 2008 ᐕ㧧6 Ꮞ㧦42㧙45.
10㧕 ㋈ᧁᥓሶ㧘⨹Ꮉᥓ૫ሶ㧘ᷦ⼱૫⋥㧘ᷡፉ⌀ℂሶ㧘ᵻ㊁⵨ሶ㧘ᄢᬮᷡᢥ㧦“M. ulcerans subsp. shinshuense”
ߦࠃࠆ⊹⤏ẩ≌ ⊹⤏∛⸻≮ 2008 ᐕ㧧30 Ꮞ㧦145㧙148.
11㧕 ⍹๺↰⒤ᒾ㧘⪉ᧁߪࠆ߆㧘ᷰㆻᱜᴦ㧘ᄢᬮᷡᢥ㧘ᴡ㊁㓁৻㧦BCG ⩶ߣࡅ࠻ဳ⚿ᩭ⩶ߩ㐓೎ߦ PCR ᴺ߇᦭
↪ߢ޽ߞߚ⢷ㇱ⊹ਅ⤥≌࡮⡻㛽㛽㜑Ἳߩ 1 ዊఽ଀ ᗵᨴ∝ቇ㔀⹹ 2008 ᐕ㧧82 Ꮞ㧦30㧙33.
12㧕 ᫪ᣧ⧣㧘ᷰᥓਭ㧘቟↰◊ᔒ㧘ਃᶆ૒⍮ሶ㧘የ᩟㓉㧘⇌ਛቬඳ㧘ᄢᬮᷡᢥ㧦Solobacterium moorei ᢌⴊ∝ߩ
1 ଀㧦ᧄ㇌ೋߩႎ๔∝଀ߣ⩶ᩣߩ․ᓽߦߟ޿ߡ ᣣᧄ⥃ᐥᓸ↢‛ቇ㔀⹹ 2008 ᐕ㧧18 Ꮞ㧦236㧙243.
ේ⪺㧔᰷ᢥ㧕
1㧕 Huang X, Xu H, Sha M.M, Zhao L, Ohkusu K, Kawamura Y, Ezaki T. Virulence-defective strains ofSalmonella enterica serover Typhi as candidates for education at level 2 facilites. Microbiol Immunol.
2006;50:273-279.
2㧕 Otsuka Y, Ohkusu K, Kawamura Y, Baba S, Ezaki T, Kimura S. Emergence of multidrug-resistant
Corynebacterium striatum as a nosocomial pathogen in long-term hospitalized patients with
underlying diseases. Diagnostic Microbiol Infect Dis. 2006;54:109-114.
3㧕 Fukasawa C, Ohkusu K, Sanayama, Y, Yasufuku K, Ishiwada N, Ezaki T, Kohno Y. A mixed bacterial
infection of bronchogenic lung cyst diagnosed by polymerase chain reaction. J Med Microbiol
2006;55:791-794.
4㧕 Itoh Y, Kawamura Y, Kasai H, Shah MM, Nhung PH, Yamada M, Sun X, Koyama, T, Ohkusu K, Ezaki
T. dnaJ and gyrB gene sequence relationship among species and strains of the genus Streptococcus.
Syst. Applied Microbiol. 2006;29:368-374.
5㧕 Maski T, Ohkusu K, Hata H, Fujiwara N, Iihara H, Noda MY, Nhung PH, Hayashi M, Asano Y,
Kawamura Y, Ezaki T. Mycobacterium kumamotonense sp. nov. and the first isolation report of
Mycobacterium arupense in Japan: novel slowly growing, nonchromognenic clinical isolates related to
Mycobacterium terrae complex. Microbiol Immunol. 2006;50:889-897.
6㧕 Iihara H, Suzuki T, Kawamura Y, Ohkusu K, Inoue Y, Zhang W, Shah MM, Katagiri Y, Ohashi Y, Ezaki
T. Emerging multiple mutations and high-level fluoroquinolone resistance in methicillin-resistant
Staphylococcus aureus isolated from ocular infections. Diagnostic Microbiol Infect Dis.
2006;56:297-303.
7㧕 Ichimura S, Nagano M, Ito N, Shimojima M, Egashira T, Miyamoto C, Ohkusu K, Ezaki T. Evaluationof the Invader assay with the BACTEC MGIT 960 system for prompt isolation and identification of
Mycobacteria from clinical specimens. J Clin Microbiol. 2007;45:3316-3322.
8㧕 Suzuki T, Iihara H, Uno T, Hara Y, Ohkusu K, Hata H, Shudo M, Ohashi Y. Suture-related keratidis
caused by Corynebacterium macginleyi. J Clin Microbiol. 2007;45:3833-3836.
9㧕 Funato M, Kaneko H, Matsui E, Teramoto T, Kato Z, Fukao T, Ohkusu K, Kondo N. Refractory㧙㧙

IF 1.440

IF 2.316

IF 2.484

IF 2.456

IF 1.440

IF 2.316

IF 3.445
IF 3.445

osteomyelitis caused by bacille Calmette-Guérin vaccination: a case report. Diag Microbiol Infect Dis.
2007;59:89-91.
IF
10㧕 Sakamoto M, Ohkusu K, Masaki T, Kato H, Ezaki T, Benno Y. Prevotella pleuritidis sp. nov., isolated
from pleural fluid. International J Systematic Evolutionary Microbiol. 2007;57:1725-1728.
IF
11㧕 Iihara H, Niwa T, Shah MM, Nhung PH, Sun XS, Hayashi M, Ohkusu K, Itoh Y, Makino S, Ezaki T.
Rapid multiplex immunofluorescent assay to detect antibodies against Burkholderia pseudomallei andtaxonomically closely related nonfermenters. Jpn J Infect Dis. 2007;60:230-234.
IF
12㧕 Noda YM, Ohkusu K, Hata H, Shah MM, Nhung PH, Sun X, Hayashi M, Ezaki T. Mycobacterium
species identification - A new approach via dnaJ gene sequencing. Systematic Applied Microbiol.
2007;30:453-462.
IF
13㧕 Nhung PH, Ohkusu K, Miyasaka J, Sun XS, Ezaki T. Rapid and specific identification of 5 humanpathogenic Vibrio species by multiplex polymerase chain reaction targeted to dnaJ gene. Diag
Microbiol Infect Dis. 2007;59:271-275.
IF
14㧕 Nhung PH, Hata H, Ohkusu K, Noda M, Shah MM, Goto K, Ezaki T. Novel phylogenetic marker dnaJand DNA-DNA hybridization for clarifying interrelationships among the genus Aeromonas.
International J Systematic Evolutionary Microbiol. 2007;57:1232-1237.
IF
15㧕 Nhung PH, Ohkusu K, Mishima N, Noda M, Shah MM, Sun X, Hayashi M, Ezaki T. Phylogeny andspecies identification of the family Enterobacteriaceae based on dnaJ sequences. Diag Microbiol InfectDis. 2007;58:153-161.
IF
16㧕 Nureki S, Miyazaki E, Matsuno O, Takenaka R, Ando M, Kumamoto T, Nakano, T, Ohkusu K, Ezaki T.
Corynebacterium ulcerans infection of the lung mimicking the histology of Churg-Strauss syndrome.
Chest. 2007;131:1237-1239.
IF
17㧕 Nhung PH, Shah MM, Ohkusu K, Noda M, Hata H, Sun X, Iihara H, Goto K, Masaki T, Ezaki T. dnaJ
gene as a novel phylogenetic marker for identification of Vibrio species. Systematic Applied Microbiol.
2007;30:309-315.
IF18㧕 Huang X, Xu H, Sun X, Ohkusu K, Kawamura Y, Ezaki T. Genome-wide scan of the gene expression
kinetics of Salmonella enterica serovar Typhi during hyperosmotic stress. Int J Mol Sci.
2007;8:116-135.
IF
19㧕 Masue N, Deguchi T, Yokoi S, Yamada T, Ohkusu K, Ezaki T. System for simultaneous detection of 16
pathogens related to urethritis to diagnose mixed infection. Int J Urology. 2007;14:39-42.
IF
20㧕 Kitamura T, Kawamura Y, Ohkusu K, Masaki T, Iwashita H, Sawa T, Fujii S, Okamoto T, Akaike T.
Helicobacter cinaedi cellutitis and bacteremia in immunocompetent hosts after orthopedic surgery. J
Clin Microbiol. 2007;45:31-38.
IF
21㧕 Shah MM, Iihara H, Noda M, Sun X, Nhung PH, Ohkusu K, Kawamura Y, Ezaki T. dnaJ genesequence-based assay for species identification and phylogenetic grouping in the genus Staphylococcus.
Int J Systematic Evolutionary Microbiol. 2007;57:25-30.
IF
22㧕 Kuroki H, Miyamoto H, Fukuda K, Iihara H, Kawamura Y, Ogawa M, Wang Y, Ezaki T, Taniguchi H.
Legionella impletisoli sp. nov. and Legionella yabuuchiae sp. nov., isolated from soils contaminatedwith industrial wastes in Japan. Systematic Applied Microbiol. 2007;30:273-279.
IF
23㧕 Ohtsuki,R., Kawamoto,K., Kato,Y., Sha, M.M., Ezaki,T., and Makino,S-I. Rapid detection of Brucellaspp. By the loop-mediated isothermal amplification method. J Appl Microbiol. 2008;1-7.
IF
24㧕 Ohno T, Kishimoto W, Chihara D, Sakamoto T, Miyamoto K, Takeoka T, Tsuji M, Kida K, Ohkusu K,
Ezaki T. First case report of sepsis caused by Mycobacterium wolinskyi in chronic myelogenous
leukemia. Diag Microbiol Infect Dis. 2008;62:433-436.
IF
25㧕 Yamamoto Y, Shioshita K, Takazono T, Seki M, Izumikawa K, Kakeya H, Yanagihara K, Tashiro T,
Otsuka Y, Ohkusu K, Kohno S. An autopsy case of Erysipelothrix rhusiopathiae endocarditis. Inter
Med. 2008;47:1437-1440.

2.553
2.662

0.910

2.037

2.553

2.662

2.553

3.924

2.037

0.679
0.691

3.445

2.662

2.037
2.501

2.553

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛ᄖㇱ⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦ᳯፒቁⴕ㧘⎇ⓥಽᜂ⠪㧦ᴡ᧛ᅢ┨㧘ᄢᬮᷡᢥ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(B)㧦
⚦⩶ߩᣂߒ޿⩶⒳ߩቯ⟵ࠍ૞ᚑߔࠆߚ߼ߩᄙဳㆮવሶ࠺࡯࠲ࡌ࡯ࠬߩ૞ᚑ㧧ᐔᚑ 16㧙18 ᐕᐲ㧧
14,200 ජ౞(5,600㧦4,300㧦4,300 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦ᳯፒቁⴕ㧘⎇ⓥಽᜂ⠪㧦ᴡ᧛ᅢ┨㧘ᄢᬮᷡᢥ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(B)㧦
⚦⩶ߩᣂߒ޿⩶⒳ߩቯ⟵ࠍ૞ᚑߔࠆߚ߼ߩᄙဳㆮવሶ࠺࡯࠲ࡌ࡯ࠬߩ૞ᚑ㧧ᐔᚑ 16㧙18 ᐕᐲ㧧
14,200 ජ౞(5,600㧦4,300㧦4,300 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦’㊁ჽ৻㧔Ꮺᐢ⇓↥ᄢቇ㧕㧘⎇ⓥಽᜂ⠪㧦ᳯፒቁⴕ㧔ጘ㒂ᄢቇ㧕㧧ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌
⵬ഥ㊄㧦↢‛࠹ࡠߦ૶↪ߐࠇࠆน⢻ᕈߩ㜞޿⚦⩶࡮࠙ࠖ࡞ࠬ╬ߦࠃࠆᗵᨴ∝ߩ⬧ᑧ㒐ᱛ‫੍ޔ‬㒐‫⸻ޔ‬ᢿ‫ޔ‬ᴦ≮ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 15㧙18 ᐕᐲ㧧16,500 ජ౞(5,600㧦4,300㧦4,300㧦2,300 ජ౞)
4㧕 ⎇ⓥઍ⴫⠪㧦ศ↰⌀৻㧔਻Ꮊᄢቇ㧕㧘⎇ⓥಽᜂ⠪㧦ᳯፒቁⴕ㧔ጘ㒂ᄢቇ㧕㧧ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㧙㧙㊄㧦⚦⩶ᕈ⣺▤ᗵᨴ∝ߩ∛ᘒ⸃ᨆ࡮⸻ᢿ࡮ᴦ≮࡮∉ቇ࡮੍㒐ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18 ᐕᐲ㧧500 ජ౞5㧕 ⎇ⓥઍ⴫⠪㧦’㊁ჽ৻㧔Ꮺᐢ⇓↥ᄢቇ㧕㧘⎇ⓥಽᜂ⠪㧦ᳯፒቁⴕ㧔ጘ㒂ᄢቇ㧕㧧ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌
⵬ഥ㊄㧦↢‛࠹ࡠߦ૶↪ߐࠇࠆน⢻ᕈߩ㜞޿⚦⩶࡮࠙ࠖ࡞ࠬ╬ߦࠃࠆᗵᨴ∝ߩ⬧ᑧ㒐ᱛ‫੍ޔ‬㒐‫⸻ޔ‬ᢿ‫ޔ‬ᴦ≮ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 19 ᐕᐲ㧧2,000 ජ౞6㧕 ⎇ⓥઍ⴫⠪㧦ศ↰⌀৻㧔਻Ꮊᄢቇ㧕㧘⎇ⓥಽᜂ⠪㧦ᳯፒቁⴕ㧔ጘ㒂ᄢቇ㧕㧧ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄㧦⚦⩶ᕈ⣺▤ᗵᨴ∝ߩ∛ᘒ⸃ᨆߣߘߩᔕ↪⊛⎇ⓥ㧧ᐔᚑ 19 ᐕᐲ㧧1,080 ජ౞7㧕 ⎇ⓥઍ⴫⠪㧦ᳯፒቁⴕ㧘⎇ⓥಽᜂ⠪㧦ᄢᬮᷡᢥ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(B)㧦ⵙቯᆔຬળߦ㜞ᐲ∛ේ૕ߩᣂಽ㘃ᴺࠍឭ᩺ߔࠆߚ߼ߩᩮ᜚ߣߔࠆㆮવᖱႎߩ෼㓸㧧ᐔᚑ 20㧙24 ᐕᐲ㧧15,440
ජ౞(6,240㧦2,800㧦2,100㧦2,200㧦2,100 ජ౞)
8㧕 ⎇ⓥઍ⴫⠪㧦’㊁ჽ৻㧔Ꮺᐢ⇓↥ᄢቇ㧕㧘⎇ⓥಽᜂ⠪㧦ᳯፒቁⴕ㧔ጘ㒂ᄢቇ㧕㧧ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌
⵬ഥ㊄㧦࠹ࡠߩน⢻ᕈߩ޽ࠆ∛ේ૕╬ߩᣧᦼᬌ⍮࡮ㄦㅦ⸻ᢿᴺߩ㐿⊒ߣߘߩ⹏ଔᴺߩ⏕┙ߦ㑐ࠊࠆ
⎇ⓥ㧧ᐔᚑ 20 ᐕᐲ㧧3,000 ජ౞9㧕 ⎇ⓥઍ⴫⠪㧦ᳯፒቁⴕ㧘⎇ⓥಽᜂ⠪㧦ᄢᬮᷡᢥ㧧࿾ၞࠗࡁࡌ࡯࡚ࠪࡦഃ಴⎇ⓥ㐿⊒੐ᬺ㧔▤ℂᴺੱ㧦ᩣᑼળ␠࠻࡜ࠬ࠻㧕㧦ᗵᨴ∝ߩ∛ᘒ೎‫ޔ‬ㄦㅦᄙ㗄⋡⸻ᢿࠪࠬ࠹ࡓߩ㐿⊒㧙⸻ᢿᣇᴺ㐿⊒㧧ᐔᚑ 20 ᐕᐲ㧧3,499,650 ౞
10㧕 ⎇ⓥઍ⴫⠪㧦ᳯፒቁⴕ㧘⎇ⓥಽᜂ⠪㧦ᄢᬮᷡᢥ㧧࿾ၞࠗࡁࡌ࡯࡚ࠪࡦഃ಴⎇ⓥ㐿⊒੐ᬺ㧔▤ℂᴺੱ㧦․ቯ㕖༡೑ᵴേᴺੱ ⾗Ḯ࡝ࠨࠗࠢ࡞ࠪࠬ࠹ࡓ࠮ࡦ࠲࡯㧕㧦PCR ߣࡊࡠ࡯ࡉ࿕ቯၮ᧼ࠍ↪޿ߚ◲ᤃㄦㅦᓸ↢‛ᬌᩏᛛⴚߩ㐿⊒㧧ᐔᚑ 20 ᐕᐲ㧧11,660,250 ౞
11㧕 ⎇ⓥઍ⴫⠪㧦ศ↰⌀৻㧔਻Ꮊᄢቇ㧕㧘⎇ⓥಽᜂ⠪㧦ᳯፒቁⴕ㧔ጘ㒂ᄢቇ㧕㧧ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄㧦ᗵᨴ∝ߩ∛ᘒ೎‫ޔ‬ㄦㅦᄙ㗄⋡⸻ᢿࠪࠬ࠹ࡓߩ㐿⊒㧙⸻ᢿᣇᴺ㐿⊒㧧ᐔᚑ 20 ᐕᐲ㧧950 ජ౞
12㧕 ⎇ⓥઍ⴫⠪㧦’㊁ჽ৻㧔Ꮺᐢ⇓↥ᄢቇ㧕㧘⎇ⓥಽᜂ⠪㧦ᳯፒቁⴕ㧔ጘ㒂ᄢቇ㧕㧧ᢥㇱ⑼ቇ⋭ ㇺᏒࠛ࡝ࠕ↥ቇቭㅪ៤ផㅴ੐ᬺ㧦㘩ߩⶄว⊛ᯏ⢻ᕈ࡮㜞ᐲߥ቟ోᕈߦଥࠆ㑐ㅪᛛⴚߩน⢻ᕈ⎇ⓥ෸߮⹜㛎࡮⺞ᩏ㧧ᐔᚑ 20 ᐕᐲ㧧5,000 ජ౞
2㧕ฃ⸤⎇ⓥ1㧕 ᳯፒቁⴕ㧦ᶖ⥇ലᨐߣᲕ⩶૞↪ߩ޽ࠆ቟ቯൻੑ㉄ൻႮ⚛ߩⅣႺ೑↪ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18 ᐕᐲ㧧800
ජ౞㧦(᦭)ጘ㒂ⴡ᧚
2㧕 ᳯፒቁⴕ㧦ᓸ↢‛ߩ㐿᡼♽೑↪ߦଥࠆ⹏ଔᚻᴺ╷ቯߩߚ߼ߩၮ␆⺞ᩏ㧧ᐔᚑ 18 ᐕᐲ㧧4,500 ජ౞㧦(⽷)ࡃࠗࠝࠗࡦ࠳ࠬ࠻࡝࡯දળ
3㧕 ᳯፒቁⴕ㧦∛ේᓸ↢‛ㆮવ⾗Ḯߩ෼㓸࡮଻ሽ࡮ឭଏ૕೙ߩ᭴▽㧧ᐔᚑ 14㧙18 ᐕᐲ㧧24,592 ජ౞(7,000㧦
7,000㧦4,762㧦3,130㧦2,700 ජ౞)㧦㧔⁛㧕⑼ቇᛛⴚᝄ⥝ᯏ᭴
4㧕 ᳯፒቁⴕ㧦ࡑࠗࠢࡠࠕ࡟ࠗࠍ↪޿ߚⅣႺਛߩ∛ේᓸ↢‛╬ߩࡕ࠾࠲࡝ࡦࠣ㧧ᐔᚑ 15㧙18 ᐕᐲ㧧48,041
ජ౞(9,114㧦12,631㧦12,600㧦13,696 ජ౞)㧦(⽷)ࡃࠗࠝࠗࡦ࠳ࠬ࠻࡝࡯දળ
5㧕 ᳯፒቁⴕ㧦๭ๆེ♽࠙ࠖ࡞ࠬᬌ಴↪ DNA ࠴࠶ࡊߩ㐿⊒⎇ⓥ㧙࠙ࠖ࡞ࠬࠬࠢ࡝࡯࠾ࡦࠣ↪ DNA ࠴࠶ࡊߩᬌ⸛㧙㧧ᐔᚑ 17㧙18 ᐕᐲ㧧1,000 ජ౞㧔500㧦500 ජ౞㧕㧦ጘ㒂⋵଻ஜⅣႺ⎇ⓥᚲ
6㧕 ᳯፒቁⴕ㧦ࡆ࡯࠭ࠕ࡟ࠗߢᄙ⒳㘃ߩ∛ේ૕ߩㆮવሶࠍ⸃ᨆߒᗵᨴ∝ࠍ⸻ᢿߔࠆᣇᴺߩᛛⴚ㐿⊒㧧ᐔᚑ 18㧙19 ᐕᐲ㧧3,000 ජ౞㧦ࠛ࡯ࠛࡓࠕ࡯࡞ࢃ
7㧕 ᳯፒቁⴕ㧦ࡆ࡯࠭ࠕ࡟ࠗߢᄙ⒳㘃ߩ∛ේ૕ߩㆮવሶࠍ⸃ᨆߒᗵᨴ∝ࠍ⸻ᢿߔࠆᣇᴺߩᛛⴚ㐿⊒㧧ᐔᚑ 19㧙20 ᐕᐲ㧧3,000 ජ౞㧦ࠛ࡯ࠛࡓࠕ࡯࡞ࢃ
8㧕 ᳯፒቁⴕ㧦ᓸ↢‛ߩ㐿᡼♽೑↪ߦଥࠆ⹏ଔᚻᴺ╷ቯߩߚ߼ߩၮ␆⺞ᩏ㧧ᐔᚑ 19 ᐕᐲ㧧4,000 ජ౞㧦(⽷)ࡃࠗࠝࠗࡦ࠳ࠬ࠻࡝࡯දળ㧔⁛㧕
9㧕 ᳯፒቁⴕ㧦∛ේᓸ↢‛ㆮવ⾗Ḯߩ෼㓸࡮଻ሽ࡮ឭଏ૕೙ߩ᭴▽㧧ᐔᚑ 19 ᐕᐲ㧧42,833 ජ౞㧦⑼ቇᛛⴚᝄ⥝ᯏ᭴10㧕 ᳯፒቁⴕ㧦㢚ෆ᛫૕ᛛⴚࠍ↪޿ߚฦ⒳∛ේ૕ߩᬌ಴෸߮ᗵᨴ੍㒐㧧ᐔᚑ 19 ᐕᐲ㧧819 ජ౞㧦㧔ᩣ㧕ࠗࡓࠫࠚࡦ
11㧕 ᳯፒቁⴕ㧦๭ๆེ♽࠙ࠖ࡞ࠬᬌ಴↪ DNA ࠴࠶ࡊߩ㐿⊒⎇ⓥ㧙࠙ࠖ࡞ࠬࠬࠢ࡝࡯࠾ࡦࠣ↪ DNA ࠴࠶ࡊߩᬌ⸛㧙㧧ᐔᚑ 19 ᐕᐲ㧧500 ජ౞㧦ጘ㒂⋵଻ஜⅣႺ⎇ⓥᚲ
12㧕 ᳯፒቁⴕ㧦⣺ౝ⚦⩶ߩ dnaJ ㆮવሶႮၮ㈩೉ߩ᳿ቯ෸߮⹏ଔ㧧ᐔᚑ 19 ᐕᐲ㧧1,882 ජ౞㧦㧔⁛㧕⵾ຠ⹏ଔᛛⴚၮ⋚ᯏ᭴13㧕 ᳯፒቁⴕ㧦᛫㉄⩶ㆮવሶหቯࡊࡠ࡯ࡉߩ․⇣ᕈߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 19 ᐕᐲ㧧3,000 ජ౞㧦᧲ᵗ⚜❣
㧔ᩣ㧕14㧕 ᳯፒቁⴕ㧦∛ේᓸ↢‛ㆮવ⾗Ḯߩ෼㓸࡮଻ሽ࡮ឭଏ૕೙ߩ᭴▽㧧ᐔᚑ 20 ᐕᐲ㧧3,900 ජ౞㧦㧔⁛㧕⑼ቇᛛⴚᝄ⥝ᯏ᭴㧙㧙

15㧕 ᳯፒቁⴕ㧦ⅣႺਛߩ∛ේᕈᓸ↢‛ߩᄌേࠍᛠីߔࠆߚ߼ߩᚻᴺߦ㑐ߔࠆၮ␆⺞ᩏ㧧ᐔᚑ 20 ᐕᐲ㧧
5,250 ජ౞㧦(⽷)ࡃࠗࠝࠗࡦ࠳ࠬ࠻࡝࡯දળ
16㧕 ᳯፒቁⴕ㧦ᶷ⩶߅ࠃ߮ࠢ࡜ࡒࠫࠕหቯࡊࡠ࡯ࡉߩ․⇣ᕈߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 20 ᐕᐲ㧧2,000 ජ౞㧦᧲ᵗ⚜❣㧔ᩣ㧕
3㧕౒ห⎇ⓥ1㧕 ᳯፒቁⴕ㧦ੱ⇓౒ㅢ∛ේ૕ߩ଻⩶⁁ᴫࠍࠬࠢ࡝࡯࠾ࡦࠣߔࠆᬌᩏᴺߩ㐿⊒㧧ᐔᚑ 20 ᐕᐲ㧧3,000 ජ౞㧦㧔ᩣ㧕ࠫ࡯ࠛ࡯ࡆ࡯
2㧕 ᳯፒቁⴕ㧦ㄦㅦ⢖Ἳ⸻ᢿࠍ⋡⊛ߣߒߚࠞ࠮࠶࠻ᑼ◲ᤃ⸻ᢿᯏེߩ㐿⊒㧧ᐔᚑ 20 ᐕᐲ㧧150 ජ౞㧦᦭㒢ળ␠ ጊญ࠹ࠖ࡯࡮ࠛ࡞࡮ࠝ࡯
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫ
1㧕 ᳯፒቁⴕ㧦ࠝ࡝ࠧ࠿ࠢ࡟ࠝ࠴࠼࠮࠶࠻෸߮ߘߩ೑↪ᴺ(․⸵)㧧ᐔᚑ 18 ᐕᐲ
2㧕 ᳯፒቁⴕ㧘ᄢᬮᷡᢥ㧦DnaJ ㈩೉ࠍ೑↪ߒߚ⚦⩶ߩᬌ಴࡮หቯᣇᴺ(․⸵)㧧ᐔᚑ 18 ᐕᐲ
3㧕 ᳯፒቁⴕ㧦∛ේᓸ↢‛ߩ࠲࡯ࠥ࠶࠻ᩭ㉄ Ⴧ᏷ᴺ෸߮Ⴧ᏷↪ࡊ࡜ࠗࡑ࡯ ᷙว‛(G1-H17-64)㧧ᐔᚑ
19 ᐕᐲ
4㧕 ᳯፒቁⴕ㧦↢⩶ߩ㜞ᗵᐲㆮવሶᬌᩏᴺ(G1-H19-9)㧧ᐔᚑ 19 ᐕᐲ
5㧕 ᳯፒቁⴕ㧦DnaJ ㆮવሶࠍ೑↪ߒߚ⚦⩶ߩᬌ಴߅ࠃ߮ߘߩ೑↪(G1-H17-64)㧧ᐔᚑ 19 ᐕᐲ
6㧚ቇળᵴേ
1㧕ቇળᓎຬᳯፒቁⴕ㧦
1㧕 ᣣᧄ⚦⩶ቇળ⹏⼏ᆔຬ(㨪⃻࿷)2㧕 ᣣᧄ⥃ᐥᓸ↢‛ቇળ೽ળ㐳(㨪⃻࿷)3㧕 ᣣᧄᗵᨴ∝ቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄⅣႺᗵᨴቇળ⹏⼏ຬ(㨪⃻࿷)5㧕 ࿖㓙ᓸ↢‛ㅪ⋖ National Organizing committee(2007 ᐕ㨪⃻࿷)㧘
ⵙቯᆔຬ Judicial committee(㨪⃻࿷)㧘
๮ฬዊᆔຬ Subcommittee of Staphylococcal and Streptococcal nomenclature(㨪⃻࿷)6㧕 ᣣᧄᓸ↢‛⾗Ḯቇળℂ੐(㨪⃻࿷)7㧕 ᣣᧄ♽⛔ಽ㘃⎇ⓥળળ㐳(㨪⃻࿷)ᄢᬮᷡᢥ㧦1㧕 ᣣᧄ⥃ᐥᓸ↢‛ቇળᐙ੐⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ⚦⩶ቇળਛㇱᡰㇱ⹏⼏ຬ(㨪⃻࿷)3㧕 ⥃ᐥᓸ↢‛ㄦㅦ⸻ᢿ⎇ⓥળᐙ੐(㨪⃻࿷)2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ᳯፒቁⴕ㧦
1㧕 ╙ 45 ࿁ᣣᧄ↢૕කᎿቇળᄢળ(ᐔᚑ 18 ᐕ 5 ᦬㧘ඳᄙ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ቝቮ⦁ౝߢߩᗵᨴ∝⸻ᢿ෸߮
⦁ౝ⩶ฌߩࡕ࠾࠲࡯ࠪࠬ࠹ࡓ‫ޠ‬Ṷ⠪)
2㧕 ╙ 13 ࿁ᣣᧄᓸ↢‛⾗Ḯቇળ(ᐔᚑ 18 ᐕ 6 ᦬㧘ၯ₹㧘ࠪࡦࡐࠫ࠙ࡓ‫∛ޟ‬ේ࿃ሶߩጁᱧࠍ៞タߒߚࠞ࡞࠴ࡖ࡯ࠦ࡟࡚ࠢࠪࡦߩ⩶ᩣᖱႎ⊒ାߣᓎഀ‫ޠ‬Ṷ⠪)
3㧕 ╙ 41 ࿁ᣣ☨ࠦ࡟࡜วหㇱળ(ᐔᚑ 18 ᐕ 11 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬E. coli (1)‫ޠ‬ᐳ㐳)
4㧕 ╙ 26 ࿁ᣣᧄᓸ↢‛♽⛔ಽ㘃⎇ⓥળ(ᐔᚑ 18 ᐕ 11 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᄙ᭽ߥㆮવሶࠍᜬߟ਄
૏ಽ㘃㓏⚖ߦߤߩࠃ߁ߥᯏ⢻ᖱႎࠍઃടߔࠆ߆‫ޠ‬Ṷ⠪)5㧕 ⅣႺࡆࠫࡀࠬࠦࠕഃ಴࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 8 ᦬㧘ᄢ㒋㧘⻠Ṷ)㧙㧙6㧕 ╙ 21 ࿁ International workshop in Space Microbiology(ᐔᚑ 19 ᐕ 9 ᦬㧘᧲੩㧘JAXA ࿖㓙ࠪࡦࡐࠫ࠙ࡓ)7㧕 ࠽࡚ࠪ࠽࡞ࡃࠗࠝࡊࡠࠫࠚࠢ࠻(ᐔᚑ 19 ᐕ 9 ᦬㧘ජ⪲‫ޟ‬ᣂᗵᨴ∝ᴺ߳ߩኻᔕ‫ޠ‬Ṷ⠪)8㧕 ICCC 11 Goslar Germany(ᐔᚑ 19 ᐕ 10 ᦬㧘࠼ࠗ࠷㧘̌DnaJ sequences as a new species
identification of bacteria̍Ṷ⠪)
9㧕 ╙ 27 ࿁ᣣᧄᓸ↢‛♽⛔ಽ㘃⎇ⓥળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ጊ᪸㧘‫ߩ⩶⚦ޟ‬਄૏ಽ㘃㓏⚖‫ޠ‬Ṷ⠪)10㧕 ╙ 27 ࿁ᣣᧄᓸ↢‛♽⛔ಽ㘃⎇ⓥળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ጊ᪸㧘‫ߩ⩶⚦ޟ‬਄૏ಽ㘃㓏⚖‫ޠ‬Ṷ⠪)11㧕 ╙ 52 ࿁ᣣᧄㄘ⧓ቇળ(ᐔᚑ 20 ᐕ 3 ᦬㧘ฬฎደ,‫ࠗ࡟ࠕࡠࠢࠗࡑޟ‬෸߮ቯ㊂ PCR ᴺࠍ૶ߞߚⅣႺਛߩ
∛ේ૕ߩࠬࠢ࡝࡯࠾ࡦࠣߣࡐࡇࡘ࡟࡯࡚ࠪࡦ⸃ᨆ‫ޠ‬Ṷ⠪)12㧕 ᣣᧄᗵᨴ∝ቇળ⻠Ṷ(‫ޟ‬㘩ਛᲥ⚦⩶ߩᬌ಴࡮หቯࠪࠬ࠹ࡓߩᣂዷ㐿‫ޠ‬Ṷ⠪)
13㧕 ᣣᧄㆮવሶ⸻≮ቇળ(ᐔᚑ 20 ᐕ㧘‫⩶⚦ޟ‬ᗵᨴ∝‫ޠ‬Ṷ⠪)
14㧕 ╙ 30 ࿁ᣣᧄ㘩ຠᓸ↢‛ቇળ(ᐔᚑ 20 ᐕ㧘ᐢፉ㧘‫ޟ‬㘩ਛᲥ⚦⩶ߩᬌ಴࡮หቯࠪࠬ࠹ࡓߩᣂዷ㐿‫ޠ‬Ṷ⠪)
15㧕 ᣣᧄᓸ↢‛⾗Ḯቇળ(ᐔᚑ 20 ᐕ㧘‫଻⛔♽ߩ⩶⚦ޟ‬ሽᵴേ߆ࠄ⷗߃ߡ߈ߚ⩶⒳ߩౣቯ⟵߳ߩ⺖㗴‫ޠ‬Ṷ⠪)ᄢᬮᷡᢥ㧦
1㧕 ජ⪲⋵⥃ᐥᓸ↢‛⎇ⓥ⃰⻠Ṷળ(ᐔᚑ 18 ᐕ 1 ᦬㧘ජ⪲㧘ᢎ⢒⻠Ṷቶ‫∛ޟ‬㒮ᬌᩏቶߦዉ౉น⢻ߥᗵᨴ∝ㆮવሶᬌᩏߩ᭴▽ࠍ⋡ᜰߒߡ㧦ㆮવሶᬌᩏ߇᦭↪ߢ޽ߞߚ∝଀ߩᢙ‫ޠޘ‬Ṷ⠪)2㧕 ᄢ㒋ᐭ⥃ᐥᬌᩏᛛᏧળቇⴚㇱᗵᨴ࡮఺∉ᬌᩏㇱ㐷ᓸ↢‛ᬌᩏಽ㊁↢ᶦᢎ⢒⎇ୃ(ᐔᚑ 18 ᐕ 1 ᦬㧘ᄢ㒋㧘ᢎ⢒⻠Ṷቶ‫ޟ‬ㆮવሶᬌᩏᵴ↪ⴚᢎ߃߹ߔ‫ޠ‬Ṷ⠪)
3㧕 ╙ 17 ࿁ᣣᧄ⥃ᐥᓸ↢‛ቇળ✚ળ(ᐔᚑ 18 ᐕ 1 ᦬㧘ᮮᵿ㧘․೎⻠Ṷ‫ⴕޟ‬೉ߩߢ߈ࠆㆮવሶ⎇ⓥቶ㧙⎇ⓥቶ߆ࠄᬌᩏቶ߳ߩࠕࡊࡠ࡯࠴ߘߒߡ࡜ࡦ࠺ࠖࡦࠣ㧙‫ޠ‬Ṷ⠪)
4㧕 ╙ 45 ࿁↢૕කᎿቇળᄢળ(ᐔᚑ 18 ᐕ 5 ᦬㧘ඳᄙ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ቝቮ⦁ౝߢߩᗵᨴ∝⸻ᢿ෸߮⦁ౝ
⩶ฌߩࡕ࠾࠲࡯ࠪࠬ࠹ࡓ‫ޠ‬Ṷ⠪)
5㧕 ╙ 10 ࿁ർᶏ㆏࡮᧲ർᓸ↢‛⎇ⓥળ(ᐔᚑ 18 ᐕ 5 ᦬㧘ᧅᏻ㧘ᢎ⢒⻠Ṷ‫ޟ‬ᣣᏱᬌᩏߢหቯ࿎㔍ߥ⩶ᩣߩหቯ㧙ᦨᣂߩᛛⴚࠍ㚟૶ߒߡ㧙‫ޠ‬Ṷ⠪)6㧕 ᣂẟ⋵⥃ᐥⴡ↢ᬌᩏᛛᏧળᗵᨴ೙ᓮㇱ㐷ᓸ↢‛㗔ၞ⎇ୃળ(ᐔᚑ 18 ᐕ 7 ᦬㧘ᣂẟ㧘․೎⻠Ṷ‫ࠆߥޟ‬߶ߤ㧍ᗵᨴ∝ߩㆮવሶᬌᩏ㨪ㆮવሶᬌᩏᴺߩၮ␆߆ࠄ⃻⁁ߘߒߡ੹ᓟߩዷᦸ‫ޠ‬Ṷ⠪)7㧕 2006 ᐕᐲ JICA ⥃ᐥᬌᩏᛛⴚ⎇ୃળ(ᐔᚑ 18 ᐕ 11 ᦬㧘᧲੩㧘․೎⻠Ṷ‫ⴊޟ‬ᶧ࡮㜑ᶧᬌᩏᴺ‫ޠ‬Ṷ⠪)8㧕 ╙ 22 ࿁ጟጊ⥃ᐥᓸ↢‛⎇ⓥળ(ᐔᚑ 18 ᐕ 11 ᦬㧘ጟጊ㧘․೎⻠Ṷ‫⩶⚦ޟ‬หቯߦ⧰ᘦߒߚ㓙ߦᓎ┙ߟಽሶ↢‛ቇ⊛หቯᣇᴺ‫ޠ‬Ṷ⠪)9㧕 ᣣᧄ⥃ᐥᬌᩏᛛᏧળ ᐔᚑ 18 ᐕᐲᗵᨴ೙ᓮㇱ㐷⎇ୃળ(ᐔᚑ 18 ᐕ 11 ᦬㧘╳ᵄ㧘․೎⻠Ṷ‫ޟ‬ᗵᨴ∝ㆮવሶᬌᩏߩ⥃ᐥᔕ↪ߩน⢻ᕈ‫ޠ‬Ṷ⠪)10㧕 ⑔ፉ⋵⥃ᐥⴡ↢ᬌᩏᛛᏧળ ᗵᨴ೙ᓮㇱ㐷ᓸ↢‛㗔ၞ⎇ୃળ(ᐔᚑ 18 ᐕ 12 ᦬㧘㇭ጊ㧘ᢎ⢒⻠Ṷ‫ޟ‬ᗵᨴ∝㗔ၞߦ߅ߌࠆㆮવሶᬌᩏߩ᦭↪ᕈ㧦ࡕࡗ࠶ߣߒߚ⩶ᩣ㧒ᬌ૕߽ㆮવሶᬌᩏߢࠬ࠶ࠠ࡝‫ޠ‬Ṷ⠪)11㧕 ⑔ፉ⋵⥃ᐥⴡ↢ᬌᩏᛛᏧળ ╙ 14 ࿁ቇⴚ⻠Ṷળ(ᐔᚑ 18 ᐕ 12 ᦬㧘㇭ጊ㧘․೎⻠Ṷ‫ޟ‬ᣣᧄߣ☨࿖ߩ⥃ᐥᬌᩏቶߢߩߔ߫ࠄߒ߈ੱ‫ߩߣޘ‬಴ㅩ޿㧙น⢻ᕈߩ޽ࠆࠊ߇࿖ߩ⥃ᐥᬌᩏᛛᏧ㧙‫ޠ‬Ṷ⠪)12㧕 ╙ 56 ࿁ᣣᧄකቇᬌᩏቇળ(ᐔᚑ 19 ᐕ 5 ᦬㧘ችፒ㧘ࠪࡦࡐࠫ࠙ࡓ‫⚻ޟ‬ᷣല₸ࠍㅊ෸ߒߚ⑳㆐ߩឭ᩺㧙☨࿖ߩ⃻⁁߆ࠄ⠨߃ࠆ㧙‫ޠ‬Ṷ⠪)
13㧕 ╙ 20 ࿁⥃ᐥᓸ↢‛ㄦㅦ⸻ᢿ⎇ⓥળ✚ળ(ᐔᚑ 19 ᐕ 7 ᦬㧘੩ㇺ㧘ࠪࡦࡐࠫ࠙ࡓ‫ߩࠄ߆ࠇߎޟ‬ᓸ↢‛ㄦㅦ⸻ᢿߩᣇะ㧙ㆮવሶᬌᩏ㧙‫ޠ‬Ṷ⠪)
14㧕 ౓ᐶ⋵⥃ᐥᬌᩏᛛᏧળᓸ↢‛ᬌᩏ⎇ୃળ(ᐔᚑ 19 ᐕ 9 ᦬㧘␹ᚭ㧘․೎⻠Ṷ‫ᦨޟ‬వ┵࡮ㆮવሶᬌᩏߦ
ࠃࠆ⚦⩶ߩหቯߣᗵᨴ∝⸻ᢿ‫ޠ‬Ṷ⠪)
15㧕 ᧲੩ㇺ⥃ᐥᬌᩏᛛᏧળᓸ↢‛ᬌᩏ⎇ୃળ(ᐔᚑ 19 ᐕ 10 ᦬㧘᧲੩㧘․೎⻠Ṷ‫ޟ‬ㆮવሶᬌᩏ‫ޠ‬Ṷ⠪)16㧕 2007 ᐕᐲ JICA ⥃ᐥᬌᩏᛛⴚ⎇ୃળ(ᐔᚑ 19 ᐕ 11 ᦬㧘․೎⻠Ṷ‫ⴊޟ‬ᶧ࡮㜑ᶧᬌᩏᴺ‫ޠ‬Ṷ⠪)17㧕 㒮ౝᗵᨴ⎇ୃળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ᾢᧄ㧘․೎⻠Ṷ‫ޟ‬ᣣᏱߩ⥃ᐥᓸ↢‛ᬌᩏߢㆮવሶᬌᩏߩഥߌ߇ᔅ
ⷐߥߩߪߤࠎߥᤨ㧫‫ޠ‬Ṷ⠪)18㧕 ᐔᚑ 19 ᐕᐲጘ㒂⋵⥃ᐥⴡ↢ᬌᩏᛛᏧળ⑺ቄ᜛ᄢ⎇ୃળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫☨ޟ‬࿖ߦ߅ߌࠆᬌᩏ૕೙ߩ⃻⁁߆ࠄ੹ᓟߩᗵᨴ∝ᬌᩏࠍ⠨߃ࠆ‫ޠ‬Ṷ⠪)
19㧕 ᄢಽ⋵⥃ᐥⴡ↢ᬌᩏᛛᏧળ ╙ 4 ࿁ᗵᨴ೙ᓮㇱ㐷⎇ୃળ(ᐔᚑ 20 ᐕ 1 ᦬㧘ᄢಽ㧘․೎⻠Ṷ‫ޟ‬ㆮવሶᬌᩏߩၮ␆߆ࠄᔕ↪‫ޠ‬Ṷ⠪)20㧕 ╙ 19 ࿁ᣣᧄ⥃ᐥᓸ↢‛ቇળ✚ળ(ᐔᚑ 20 ᐕ 1 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ㄦㅦ⸻ᢿᬌᩏ㧦ߘߩ᦭↪ᕈߣ዁᧪ዷᦸ 4㧚ㆮવሶᬌᩏԚ ㄦㅦㆮવሶ⸃ᨆߩ⩶⒳หቯ߳ߩኻᔕ‫ޠ‬Ṷ⠪)
21㧕 ╙ 23 ࿁ᣣᧄⅣႺᗵᨴቇળ✚ળ(ᐔᚑ 20 ᐕ 2 ᦬㧘㐳ፒ㧘ࠪࡦࡐࠫ࠙ࡓ‫⥃ޟ‬ᐥᬌᩏࠍߤߩࠃ߁ߦᗵᨴኻ㧙㧙╷ߦᓎ┙ߡࠆ߆ 4㧚ㆮવሶᬌᩏ㧦ᗵᨴ∝ߩㄦㅦ⸻ᢿߣಽሶ∉ቇ⸃ᨆ‫ޠ‬Ṷ⠪)22㧕 ╙ 82 ࿁ᣣᧄᗵᨴ∝ቇળ✚ળ(ᐔᚑ 20 ᐕ 4 ᦬㧘᧻ᳯ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᗵᨴ∝ߩㄦㅦ⸻ᢿᴺߩᣂߒ޿ዷ
㐿 4㧚ోりᗵᨴ∝ߩㄦㅦㆮવሶ⸻ᢿᴺ‫ޠ‬Ṷ⠪)23㧕 ╙ 83 ࿁ᣣᧄ⚿ᩭ∛ቇળ✚ળ(ᐔᚑ 20 ᐕ 4 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ‫⥃ޟ‬ᐥ᛫㉄⩶ቇߩᦨ೨✢ 2㧚ㆮવሶᬌᩏߦࠃࠆ᛫㉄⩶ᗵᨴ∝ߩㄦㅦ⸻ᢿ‫ޠ‬Ṷ⠪)24㧕 ᐔᚑ 20 ᐕᐲ ࿖┙ᄢቇ∛㒮ᗵᨴኻ╷ද⼏ળ කᏧ࡮⋴⼔Ꮷࡉࡠ࠶ࠢ೎⃰⎇ୃળ(ᐔᚑ 20 ᐕ 6 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ᗵᨴ∝ߩㄦㅦ⸻ᢿߣಽሶ∉ቇ⸃ᨆ‫ޠ‬Ṷ⠪)25㧕 ᐔᚑ 20 ᐕᐲ ╙ 2 ࿁ᓸ↢‛ᬌᩏ⎇ⓥ⃰⎇ୃળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ජ⪲㧘․೎⻠Ṷ‫ޟ‬ㆮવሶᬌᩏ߆ࠄ⥃ᐥ⸻ᢿ߳ߩࠕࡊࡠ࡯࠴‫ޠ‬Ṷ⠪)26㧕 ╙ 21 ࿁㑐᧲↲ା࿾඙ᓸ↢‛ᬌᩏ⎇ୃળ(ᐔᚑ 20 ᐕ 9 ᦬㧘㐳㊁㧘․೎⻠Ṷ‫ޟ‬ㆮવሶᬌᩏߩ዁᧪௝㧙ߘߩน⢻ᕈߣᔕ↪㧙‫ޠ‬Ṷ⠪)27㧕 ᐔᚑ 20 ᐕᐲ྾࿖࿾඙ᓸ↢‛ᬌᩏ⎇ୃળ(ᐔᚑ 20 ᐕ 9 ᦬㧘᧻ጊ㧘ᢎ⢒⻠Ṷ‫ޟ‬ᗵᨴ∝⸻ᢿߢㄦㅦㆮવሶ
ᬌᩏࠍᵴ↪ߔࠆߩߪߤࠎߥᤨ㧫‫ޠ‬Ṷ⠪)28㧕 ╙ 48 ࿁ㄭ⇰කቇᬌᩏቇળ(ᐔᚑ 20 ᐕ 10 ᦬㧘␹ᚭ㧘․೎⻠Ṷ‫☨ޟ‬࿖ߩ⥃ᐥᓸ↢‛ᬌᩏߩ⃻ᴫ߆ࠄ੹ᓟߩᬌᩏ૕೙ࠍ⠨߃ࠆ‫ޠ‬Ṷ⠪)29㧕 ╙ 15 ࿁ਛㇱᓸ↢‛ᬌᩏ⎇ⓥ⃰ኋᴱ⎇ୃળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ጘ㒂㧘ᢎ⢒⻠Ṷ‫ߩޘᤨޟ‬ㆮવሶᬌᩏ ᔓࠆߴ߆ࠄߕ㧙ㆮવሶᬌᩏࠍᵴ↪ߒߚᗵᨴ∝⸻≮ᡰេ㧙‫ޠ‬Ṷ⠪)↲⇌ବ㇢㧦
1㧕 ╙ 54 ࿁ᣣᧄൻቇ≮ᴺቇળ✚ળ(ᐔᚑ 18 ᐕ 5 ᦬㧘੩ㇺ㧘ࠪࡦࡐࠫ࠙ࡓ‫੹ޟ‬ᓟᵈ⋡ߐࠇࠆᗵᨴ∝ ࡄ࡯ࠠࡦ࠰ࡦ∛ߣࡁࠞ࡞ࠫࠕ‫ޠ‬Ṷ⠪)
2㧕 ╙ 43 ࿁ᣣᧄ⚦⩶ቇળਛㇱᡰㇱ✚ળ(ᐔᚑ 18 ᐕ 10 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᓸ↢‛߇ේ࿃࡮ᘾᖡ࿃
ሶߣߥࠆ∔ᖚߦߟ޿ߡߩᦨㄭߩ⹤㗴 ࡄ࡯ࠠࡦ࠰ࡦ∛㧧ߘߩේ࿃ߦ߅ߌࠆࡁࠞ࡞ࠫࠕᗵᨴ㑐ਈߩน⢻ᕈ‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ1㧕 ᳯፒቁⴕ㧦ᣣᧄᓸ↢‛⾗Ḯቇળ⾨(ᐔᚑ 20 ᐕᐲ)
9㧚␠ળᵴേᳯፒቁⴕ㧦
1㧕 ᣣᧄቇⴚળ⼏ㅪ៤ᆔຬ㧘࿖㓙੐ᬺᆔຬ㧘․೎⎇ⓥᆔຬ(㨪⃻࿷)2㧕 ㅢ↥⋭ ↥ᬺ᭴ㅧᆔຬ㧘ൻቇ࡮ࡃࠗࠝㇱળ⚵ߺᦧ߃ DNA ᛛⴚዊᆔຬ(㨪⃻࿷)3㧕 ࡃࠗࠝࠗࡦ࠳ࠬ࠻࡝࡯දળ㧘ⅣႺኻᔕᛛⴚ㐿⊒ᆔຬ(㨪⃻࿷)4㧕 ⁛┙ⴕ᡽ᴺੱ⵾ຠ⹏ᛛⴚၮ⋚ᯏ᭴ㆮવሶ⚵឵߃↢‛╬ߩᬌ಴ᛛⴚᬌ⸛ᆔຬ(㨪⃻࿷)5㧕 ⁛┙ⴕ᡽ᴺੱ⵾ຠ⹏ᛛⴚၮ⋚ᯏ᭴ᮡḰൻᬺോផㅴᆔຬ(㨪⃻࿷)6㧕 ⁛┙ⴕ᡽ᴺੱᴒ✽⑼ቇᛛⴚ⎇ⓥၮ⋚ᢛ஻ᯏ᭴ࡃࠗࠝ࠮࡯ࡈ࠹ࠖ࡯ᆔຬ(㨪⃻࿷)7㧕 Bergy’s manual ࿖㓙ℂ੐(㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ᳯፒቁⴕ㧦࡟ࠫࠝࡀ࡜ߩㆮવሶᬌᩏ߅ࠃ߮᛫૕ᬌᩏᴺߩ૞ᚑߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 15 ᐕᐲ㧙ᐔᚑ 17ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ✚᜝࡮ಽᜂ✚ว⎇ⓥႎ๔ᦠ(ศ↰⃰)㧦45㧙48 (2006 ᐕ 3 ᦬)
2㧕 ᳯፒቁⴕ㧦ࡑࠗࠢࡠࠕ࡟ࠗࠍ↪޿ߚⅣႺਛߩ∛ේᓸ↢‛╬ߩࡕ࠾࠲࡝ࡦࠣ㧦ㆮવሶ⚵ߺ឵߃૕ߩ↥ᬺ೑↪ߦ߅ߌࠆ࡝ࠬࠢ▤ℂߦ㑐ߔࠆ⎇ⓥ ᛛⴚ⾗ᢱ㓸㧦172㧙223 (2006 ᐕ 3 ᦬)
3㧕 ᳯፒቁⴕ࡮ᄢᬮᷡᢥ㧦࠽࡚ࠪ࠽࡞ࡃࠗࠝ࡝࠰࡯ࠬࡊࡠࠫࠚࠢ࠻ ᐔᚑ 17 ᐕᐲ⹏ଔႎ๔ᦠ㧘ᢥㇱ⑼ቇ
⋭ ᣂ਎♿㊀ὐ⎇ⓥഃ਎ࡊ࡜ࡦ㧦49㧙51 (2006 ᐕ 3 ᦬)
4㧕 ᳯፒቁⴕ㧦ᐔᚑ 17 ᐕᐲⅣႺኻᔕᛛⴚ㐿⊒╬ ࡃࠗࠝࠗࡦ࠳ࠬ࠻࡝࡯ ቟ోኻ╷⺞ᩏႎ๔ᦠ (2006ᐕ 3 ᦬)
5㧕 ᳯፒቁⴕ㧘ᄢᬮᷡᢥ㧦ਅ∯ߩ⣺ౝ⚦⩶ฌߩ⎇ⓥᣇᴺߩ㐿⊒㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌࿖㓙කቇදജ⎇ⓥ੐ᬺ ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ㧦153㧙159 (2006 ᐕ 12 ᦬)
6㧕 ᳯፒቁⴕ㧦ᐔᚑ 18 ᐕᐲⅣႺኻᔕᛛⴚ㐿⊒╬ ࡃࠗࠝࠗࡦ࠳ࠬ࠻࡝࡯ 213㧙241 ቟ోኻ╷⺞ᩏႎ๔ᦠ(2007 ᐕ 3 ᦬)
7㧕 ᳯፒቁⴕ࡮ᄢᬮᷡᢥ㧦࠽࡚ࠪ࠽࡞ࡃࠗࠝ࡝࠰࡯ࠬࡊࡠࠫࠚࠢ࠻ ᐔᚑ 18 ᐕᐲ⹏ଔႎ๔ᦠ㧘ᢥㇱ⑼ቇ
⋭ ᣂ਎♿㊀ὐ⎇ⓥഃ਎ࡊ࡜ࡦ㧦49㧙51 (2007 ᐕ 3 ᦬)㧙㧙

8㧕 ᳯፒቁⴕ㧘ᄢᬮᷡᢥ㧦⚦⩶ᕈ⣺▤ᗵᨴ∝ߩ∛ᘒ⸃ᨆߣߘߩᔕ↪⊛⎇ⓥ㧦ᐔᚑ 19 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌࿖㓙කቇදജ⎇ⓥ੐ᬺ ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ㧦102㧙104 (2007 ᐕ 12 ᦬)
9㧕 ᳯፒቁⴕ㧘ᄢᬮᷡᢥ㧦࠽࡚ࠪ࠽࡞ࡃࠗࠝ࡝࠰࡯ࠬࡊࡠࠫࠚࠢ࠻ ᐔᚑ 19 ᐕᐲ⹏ଔႎ๔ᦠ㧘ᢥㇱ⑼ቇ
⋭ ᣂ਎♿㊀ὐ⎇ⓥഃ਎ࡊ࡜ࡦ㧦49㧙51 (2008 ᐕ 3 ᦬)
11㧚ႎ㆏
1㧕 ᳯፒቁⴕ㧦㧔ࡁࡠߥߤਅ∯ᗵᨴ∝ኻ╷ߦ㧕࠙ࠗ࡞ࠬ 100 ⒳ 2 ᣣߢ․ቯ㧦ਛᣣᣂ⡞(2007 ᐕ 1 ᦬ 25 ᣣ)
2㧕 ᳯፒቁⴕ㧦ⅣႺ‫ޔ‬㘩ߩ቟ోߢ౒ห⎇ⓥ㧔ጘ㒂ᄢකቇㇱߣ☨ࠦࡠ࡜࠼Ꮊ┙ᄢឭ៤㧕㧦ጘ㒂ᣂ⡞(2008 ᐕ
11 ᦬ 19 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔౣ↢ක⑼ቇኾ᡹ߢ 2 ᐕߩୃ჻⺖⒟ߣ 3 ᐕߩඳ჻⺖⒟ߩቇ↢ߩᢎ⢒⎇ⓥߦᓥ੐ߒ㧘ᒰೋ⸘↹ߒߚୃ჻ߢ
∛ේᓸ↢‛ߩขࠅᛒ޿⚻㛎ߩ޽ࠆኾ㐷ኅࠍ⢒ᚑߒ␠ળߦㅍࠅ಴ߔ‫ޕ‬ඳ჻⺖⒟ߢߪ∛ේ⚦⩶ࠍ૶ߞߚ⎇ⓥߦᓥ੐ߐߖ㧘ኾ㐷ኅࠍ⢒ᚑߔࠆ⸘↹ࠍ┙ߡߚ‫ୃߪ⊛⋡ߩߎޕ‬჻⺖⒟ߩතᬺ↢ߪ∛ේ⚦⩶ߩขࠅᛒ޿߇ߢ
߈ࠆੱ᧚ߣߒߡዞ⡯ᵴേ߇ࠬࡓ࡯࠭ߦዷ㐿ߒ㧘ᒰೋߩ⸘↹߇㆐ᚑߐࠇߚ‫ߒ߆ߒޕ‬ඳ჻⺖⒟ߢߪ 3 ᐕ㑆ߣ޿߁⍴ᦼ㑆ߦኾ㐷ኅߩ⢒ᚑߪ࿎㔍ߢ޽ߞߚ‫߇ࡈ࠶࠲ࠬߦ․ޕ‬ዋߥ޿⃻⁁ߢ㧘ߔߴߡߩ∛ේ૕ߦኻߔࠆ৻
ቯ࡟ࡌ࡞ߩ⚻㛎ߣ⍮⼂ࠍ⠌ᓧߐߖߚੱ᧚⢒ᚑߦᚑഞߒߚߣߪ⸒߃ߥ޿‫ޕ‬♽⛔଻ሽ੐ᬺߪ࿖ߩᡰេࠍ߁ߌ㧘ࠗࡦࡈ࡜ߩᢛ஻ࠍផㅴߒ㧘∛ේ૕ࠍ଻᦭ߔࠆⅣႺߣߒߡߪ࿖㓙᳓Ḱߦ೔㆐ߒߚߣ⠨߃ߡ޿ࠆ‫ߩߎޕ‬ⅣႺࠍ⛽ᜬߔࠆ⚻ᷣ⊛ၮ⋚ࠍ੹ᓟ߽⛽ᜬߢ߈ࠆ⾗㊄ߩ⺞㆐߇ᔅⷐߦߥࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ࠊ߇࿖ߦߪ∛ේᓸ↢‛ࠍ♽⛔଻ሽߒ㧘⎇ⓥ⠪ߦࠨ࡯ࡆࠬߔࠆ࿖ߩᯏ㑐߇ሽ࿷ߒߥ޿ߚ߼㧘ࠊࠇࠊࠇ߇
ⴕߞߡ޿ࠆࠨ࡯ࡆࠬߪࠊ߇࿖ߩ⎇ⓥၮ⋚ࠍၮ␆߆ࠄᡰ߃ࠆ㊀ⷐߥၮ⋚ߦߥߞߡ޿ࠆ‫ޕ‬ᢥㇱ⑼ቇ⋭ߩၮ⋚ᢛ஻੐ᬺߦࠃࠆᡰេ૕೙ߪᐕᐲߏߣߩ੍▚ߢㆇ༡ߐࠇߡ߅ࠅ㧘ߎࠇ߹ߢߩᡰេߢࠗࡦࡈ࡜ᢛ஻ࠍ߅ߎߥ
ߞߚ߇㧘ᰴᐕᐲߩ੍▚ൻߪ⚂᧤ߐࠇߡ޿ߥ޿ߩߢ㧘ࠨ࡯ࡆࠬᬺോߦᓥ੐ߔࠆੱ᧚ߪ⎇ⓥ⾌߆ࠄࠕ࡞ࡃࠗ
࠻ߢ㓹↪ߔࠆߥߤ㧘ᭂ߼ߡਇ቟ቯߢ޽ࠆ‫ޕ‬⒖ォᓟ㧘ᄢቇ߇⩶ᩣ଻ሽቶߩ᦭ᢱൻࠍ᳿ቯߒ㧘⎇ⓥᡰេࠍⴕߥߞߡ޿ߥ޿⃻⁁ߢߪ㧘ᓸ↢‛⾗Ḯߩ᦭ᢱൻࠍଦㅴߒ㧘ੱ᧚ࠍ⏕଻ߒߥߌࠇ߫ߥࠄߥ޿‫ߦࠄߐޕ‬࿖࡟ࡌ࡞ߢߩ∛ේ૕ߩ♽⛔଻ሽ੐ᬺࠍᕡᏱ⊛ߥ੍▚ߦߔࠆ௛߈߆ߌ߇ᔅⷐߣ⠨߃ߡ޿ࠆ‫ޕ‬ᄢቇ㒮ᢎ⢒ߢߪඳ჻⺖⒟ᓟᦼߩතᬺ⠪ߩ㓹↪⏕଻߇੹ᓟߩ㊀ⷐߥ⺖㗴ߢ޽ࠆ߇㧘ᄢ߈ߥዷᦸߪ㐿ߌߡ޿ߥ޿‫⎇ޕ‬ⓥߩ㜞ᐲൻ㧘㓸ਛൻߢᄢဳߩ┹੎⊛⎇ⓥ⾗㊄ߩ⏕଻ߪ࿎㔍ߦߥߞߡ߅ࠅ㧘ࠃࠅ․⦡ߩ޽ࠆಽ
㊁߳⎇ⓥࠍ⛉ࠅㄟ߻ദജ߇ᔅⷐߣ⠨߃ߡ޿ࠆ‫ޕ‬੹ᓟߩዷᦸࠊ߇࿖ߢߪ∛ේᓸ↢‛ߩขࠅᛒ޿ߦ⠌ᾫߒߚੱ᧚߇ᷫዋߒߡ޿ࠆߩߢୃ჻㧘ඳ჻⺖⒟ߢߪ∛ේᓸ↢‛
ߦ․ൻߒߚੱ᧚ߩ⢒ᚑࠍ੹ᓟ߽⛮⛯ߔࠆ⸘↹ߢ޿ࠆ‫⎇ߚ߹ޕ‬ⓥቶ଻᦭ߩᓸ↢‛⾗Ḯࠍ⾗↥ߣߒߚᔕ↪ᛛⴚ㐿⊒ߪ੹ᓟ߽㊀ⷐߥ⎇ⓥ⾗㊄ߩ⺞㆐ᣇᴺߣ⠨߃ߡ߅ࠅ㧘ߎߩಽ㊁ߩ⎇ⓥࠍផㅴߔࠆ⸘↹ߢ޿ࠆ‫ߦ․ޕ‬㧘ࠊ߇࿖ߩၮ␆⎇ⓥߢߪ⺰ᢥ⊒⴫߇ఝవߒ㧘․⸵ߩขᓧߪᬺ❣ߣߒߡ޽߹ࠅ㊀ⷞߐࠇߡߎߥ߆ߞߚ߇㧘ᄢဳ┹੎⊛⎇ⓥ⾗㊄ߩ₪ᓧߦߪ․⸵ߩขᓧߪ㊀ⷐߥ⹏ଔ㗄⋡ߢ޽ࠆ‫ޕ‬Ⓧᭂ⊛ߦ⁛⥄ᕈࠍࠕࡇ࡯࡞ߢ߈ࠆಽ
㊁ߢߩ․⸵ࠍขᓧߒ㧘⎇ⓥ⾗㊄ߩ⺞㆐ߦߟߥߍߚ޿‫ޕ‬⎇ⓥߢߪ⃻࿷⫾Ⓧߒߡ޿ࠆ dnaJ ߩ࠺࡯࠲ࡌ࡯ࠬࠍߐࠄߦ᜛ᄢߒ㧘ᦨㄭߩ⒳ species ߩᣂߒ޿ㆮવቇ⊛᏷ࠍ⸘᷹ߒ㧘࿖㓙␠ળߦࠥࡁࡓᤨઍߩ⩶⒳ species ߩቯ⟵ࠍឭ᩺ߔࠆ‫ޕ‬㧙㧙ާౣ↢Ꮏቇ⻠ᐳި
㧔1㧕↢๮ᯏ⢻ಽሶ⸳⸘ಽ㊁1㧚⎇ⓥߩ᭎ⷐ
ᧄ⎇ⓥࠣ࡞࡯ࡊߢߪ㧘⣖࡮␹⚻ᯏ⢻ߩಽሶ࡟ࡌ࡞ߢߩ⸃᣿ߣߘࠇߦၮߠߊ∛ᘒᴦ≮⮎࡮⸻ᢿ⮎ߩ㐿⊒ࠍ⋡ᮡߦ㧘in vitro ߢߩࠪࠣ࠽࡞⸃ᨆࡊࡠ࡯ࡉ߆ࠄ୘૕ߩ߽ߟࠪࠬ࠹ࡓߣߒߡߩ in vivo ߢߩ↢૕ᯏ⢻ߩ⸃ᨆ࡮೙ᓮࠍታ⃻ߔࠆ㜞ᯏ⢻ૐಽሶࡊࡠ࡯ࡉ㧔PET ࡊࡠ࡯ࡉࠍ฽߻㧕ߩഃ⵾⎇ⓥࠍⴕߞߡ޿ࠆ‫ߩࠇߕ޿ޕ‬⎇ⓥ߽ࡅ࠻߳ߩᔕ↪㧔ഃ⮎㧕ࠍⷞ㊁ߦ౉ࠇ㧘කቇ࡮↢‛ቇ♽ߩ⎇ⓥࠣ࡞࡯ࡊߣߩቇ㓙࡮ቇⲢ⊛౒ห⎇ⓥࠍዷ㐿ߒߡ޿ࠆ‫ޕ‬1㧕ਛᨔ␹⚻଻⼔૞↪ࠍ␜ߔࡊࡠࠬ࠲ࠣ࡜ࡦࠫࡦಽሶࡊࡠ࡯ࡉߩഃ⵾
㜞㉄⚛⁁ᘒߢᒁ߈⿠ߎߐࠇࠆᶏ㚍␹⚻⚦⢩ߩࠕࡐ࠻࡯ࠪࠬࠍ㒖ኂߔࠆߥߤᒝജߥ␹⚻଻⼔૞↪ࠍ␜ߔࡊࡠࠬ࠲ࠣ࡜ࡦࠫࡦ㘃✼૕ 15R-TIC ࠍഃ⵾ߒ㧘㓁㔚ሶ᡼኿ᢿጀ↹௝᠟ᓇᴺ㧔PET㧕ߦࠃࠆࡅ࠻⣖ߢߩ invivo ⣖ౝേᘒߣฃኈ૕ߩ↹௝ൻߦᚑഞߒߚ‫ޕ‬15R-TIC ߪ⣖ౝਛᨔ␹⚻♽⚵❱ߦሽ࿷ߔࠆᣂⷙࡊࡠࠬ࠲ࠨ
ࠗࠢ࡝ࡦฃኈ૕ߦ․⇣⊛ߦ⚿วߔࠆߎߣࠍ⸽᣿ߒߡ޿ࠆ߇㧘ߘߩฃኈ૕᝝₪࡮หቯߩߚ߼ߩ non-RI ဳశⷫ๺ᕈᮡ⼂ࡊࡠ࡯ࡉ߿ࠕࡈࠖ࠾࠹ࠖࠥ࡞ߩಽሶ⸳⸘߅ࠃ߮วᚑ⎇ⓥࠍⴕߞߡ޿ࠆ‫ߚ߹ޕ‬㧘15R-TIC ߩ⣖ᯏ⢻ᡷༀ⮎࡮␹⚻ᄌᕈ∔ᖚߩᴦ≮⮎ߣߒߡߩ㐿⊒ߦะߌߡ㧘࡝࠴࠙ࡓࠛࡁ࡜࡯࠻ߩ᭴ㅧ߅ࠃ߮෻ᔕᕈߦ㑐ߔࠆၮ␆⎇ⓥࠍዷ㐿ߒ㧘3 ᚑಽㅪ⚿ࡊࡠࠬ࠲ࠣ࡜ࡦࠫࡦวᚑᴺࠍၮゲߣߔࠆࠣ࡝࡯ࡦࡊࡠ࠮ࠬߦࠃࠆᄢ㊂
วᚑᴺߩ⏕┙ࠍ߼ߑߒߡ޿ࠆ‫ߦࠄߐޕ‬㧘␹⚻⓭⿠િዷଦㅴ૞↪ߣ㉄ൻࠬ࠻࡟ࠬߦࠃࠆ␹⚻⚦⢩ᱫࠍᛥ೙ߔ
ࠆోߊᣂߒ޿૞↪ࠍᜬߟࡊࡠࠬ࠲ࠣ࡜ࡦࠫࡦ㘃✼૕ NEPP ߿㧘GDNF ⺃ዉଦㅴ૞↪ࠍ␜ߔᣂⷙࠪࠢࡠࡍ
ࡦ࠹ࡁࡦൻว‛ߩഃ⵾ߦᚑഞߒߡ߅ࠅ㧘ߘߩ↢૕ౝᮡ⊛ಽሶߩหቯߣ૞↪ࡔࠞ࠾࠭ࡓߩ⸃᣿㧘PET ߦࠃࠆࠗࡔ࡯ࠫࡦࠣߥߤࠍ߼ߑߒߚಽሶࡊࡠ࡯ࡉߩ⸳⸘࡮วᚑࠍⴕߞߡ޿ࠆ‫ޕ‬
2㧕㜞ㅦࡔ࠴࡞ൻ෻ᔕߦࠃࠆ PET ࡊࡠ࡯ࡉߩഃ⵾
PET ⎇ⓥߢ↪޿ࠄࠇࠆ⍴ኼ๮᡼኿ᩭߢ޽ࠆ 11C ࠍᜬߟࡔ࠴࡞ၮࠍ㧘᦭ᯏಽሶߦ⍴ᤨ㑆ߢ㜞ല₸⊛ߦዉ౉ߔࠆ↹ᦼ⊛ߥൻቇ෻ᔕࠍ㐿⊒ߒߚ‫ޕ‬㒢ቯߐࠇߚ᭴ㅧࠍᜬߟൻว‛ߩઍ⻢ਇ቟ቯߥㇱ૏ࠍ࡜ࡌ࡞ൻߔࠆᓥ
᧪ᴺߣߪ⇣ߥࠅ㧘ᧄᴺߪ὇⚛὇⚛⚿วࠍᒻᚑߔࠆߚ߼㧘߶ߣࠎߤ޽ࠄࠁࠆ᦭ᯏಽሶߦߟ޿ߡઍ⻢቟ቯߥ
PET ࡊࡠ࡯ࡉൻ߇น⢻ߢ޽ࠆ‫ߩߎޕ‬ᣂᛛⴚࠍၮ⋚ߦ㧘ߎࠇ߹ߢߩࠣ࡞ࠦ࡯ࠬ߿᳓ߩ࡜ࡌ࡞૕ࠍ↪޿ߚઍ⻢⊛ߥ⸃ᨆ⎇ⓥ߆ࠄ㧘ฃኈ૕߿࠲ࡦࡄࠢ⾰ߥߤߩ↢૕ౝಽሶ߿⮎೷ಽሶߘߩ߽ߩࠍนⷞൻߔࠆᣂ਎ઍ
PET ࠗࡔ࡯ࠫࡦࠣ⎇ⓥ߇ዷ㐿ߐࠇࠆ߽ߩߣ⠨߃ࠄࠇࠆ‫ᧄޕ‬ᚻᴺߩᔕ↪ߦࠃࠆᧃ᪳♽ࡊࡠࠬ࠲ࠨࠗࠢ࡝ࡦ
ฃኈ૕㧘ࡌࡦ࠱ࠫࠕ࠯ࡇࡦฃኈ૕㧘⣖ౝࠛࠬ࠻ࡠࠥࡦฃኈ૕㧘ᩭౝ࡟࠴ࡁࠗࡦ㉄ฃኈ૕ߩࠗࡔ࡯ࠫࡦࠣ㧘ᜂ≸ࡑ࠙ࠬࠍ↪޿ߚ⣲≌ࠗࡔ࡯ࠫࡦࠣ㧘ࠕ࡞࠷ࡂࠗࡑ࡯∛ߩ⸻ᢿߣߥࠆ⣖ౝࠕࡒࡠࠗ࠼Ǫࠗࡔ࡯ࠫࡦࠣߥ
ߤߦะߌߚ PET ࡊࡠ࡯ࡉߩวᚑࠍⴕߞߡ޿ࠆ‫ߚ߹ޕ‬㧘෻ᔕⵝ⟎ߩࡒࠢࡠൻ㧔ࡑࠗࠢࡠ࡝ࠕࠢ࠲࡯㐿⊒㧕ߣ㧘⾆㊀ߥၮ⾰ߩ૶↪㊂ߩ೥ᷫ㧘෻ᔕല₸ߩะ਄ߥߤࠍ߼ߑߒߚ㧘ᦨవ┵࠽ࡁ࠹ࠢࡁࡠࠫ࡯ᛛⴚߩᔕ↪ߦࠃࠆ PET ↪♖ኒวᚑⵝ⟎ߩ㐿⊒ࠍㅴ߼ߡ޿ࠆ‫ޕ‬
3㧕ਛᨔ␹⚻૞↪ࠍᜬߟࠡࡦࠧ࡜ࠗ࠼⺃ዉ૕ߩ⸳⸘ߣ⣖ౝಽሶࠗࡔ࡯ࠫࡦࠣ
ࠗ࠴࡚࠙⪲ࠛࠠࠬࠃࠅᓧࠄࠇࠆࠡࡦࠦ࡜ࠗ࠼ߪ⣖ᯏ⢻ᡷༀ૞↪ࠍ␜ߔߎߣ߆ࠄ⹺⍮∝㧔ࠕ࡞࠷ࡂࠗࡑ࡯
∛㧕ߥߤߩᴦ≮⮎ߣߥࠆߣᦼᓙߐࠇߡ޿ࠆ‫ ߪߦ࠼ࠗ࡜ࠦࡦࠡޕ‬A㧘B㧘C㧘J ߩฦ㘃✼૕߇ሽ࿷ߒ㧘in vitroߢߪࠣ࡝ࠪࡦฃኈ૕㧘GABA ฃኈ૕㧘PAF ฃኈ૕ߥߤߩᯏ⢻ࠍ೙ᓮߔࠆߎߣ߇ႎ๔ߐࠇߡ޿ࠆ߇㧘⹦⚦ߥಽሶᯏ᭴߿ in vivo ߦ߅޿ߡ⣖ౝߦ೔㆐ߒߡ޿ࠆ߆ߥߤߪਇ᣿ߢ޽ࠆ‫ߢߎߘޕ‬㧘ࠡࡦࠦ࡜ࠗ࠼ߩ૕ౝേ
ᘒ߿ᮡ⊛ฃኈ૕ߩ⣖ౝಽᏓߥߤߩ⹦⚦ࠍ⸃ᨆߔࠆߚ߼㧘ࡐࠫ࠻ࡠࡦࠗࡔ࡯ࠫࡦࠣᴺߦะߌߚ PET ࡊࡠ࡯ࡉߩ⸳⸘߅ࠃ߮วᚑ⎇ⓥࠍⴕߞߡ޿ࠆ‫ߚ߹ޕ‬㧘ᄤὼࠡࡦࠦ࡜ࠗ࠼ࠃࠅᮡ⊛ฃኈ૕߳ߩ⚿ว⢻߇㜞޿⺃ዉ૕ࠍวᚑߒ㧘ߘߩ PET ࡊࡠ࡯ࡉൻߣዊേ‛ࠍ↪޿ߚࠗࡔ࡯ࠫࡦࠣ⎇ⓥߦࠃࠅหൻว‛߇⣖ౝߦ⒖ⴕߒߡ޿
ࠆߎߣࠍ⸽᣿ߒߚ‫ޕ‬
4㧕␹⚻࿃ᕈ−∩ߩ⊒∝ᯏ᭴⸃᣿ߣᴦ≮࡮⸻ᢿ⮎㐿⊒ߦะߌߚ․⇣⊛ಽሶࡊࡠ࡯ࡉߩഃ⵾
ࠕࡠ࠺ࠖ࠾ࠕߥߤߩ␹⚻࿃ᕈ−∩ߪᣢሽߩ㎾∩೷߇ല߆ߥ޿㔍ᴦᕈߩ∛ᘒߢ޽ࠅ㧘ᴦ≮⮎ߩ㐿⊒ߦߪ∛ᘒߦ߆߆ࠊࠆฃኈ૕߿ࠪࠣ࠽࡞ಽሶߩหቯߥߤ㧘ಽሶࡔࠞ࠾࠭ࡓߩ⸃᣿߇ਇนᰳߢ޽ࠆ‫ޕ‬Ქࠠࡁࠦ߆ࠄ᛽
಴ߐࠇߚࠕࡠ࠺ࠖ࠾ࠕ⺃⊒૞↪ࠍ␜ߔࠕࡒࡁ㉄ߩ᭴ㅧࠍၮߦಽሶࡊࡠ࡯ࡉࠍ⸳⸘࡮วᚑߒ㧘ߘߩᵴ↪ߦࠃࠅࠕࡠ࠺ࠖ࠾ࠕߦ߆߆ࠊࠆᣂⷙฃኈ૕ߩหቯߣᯏ⢻⸃ᨆࠍⴕߞߡ޿ࠆ‫ߚ߹ޕ‬㧘⮎‛ߦࠃࠅ⺃⊒ߐࠇࠆࠕࡠ
࠺ࠖ࠾ࠕࠍૐ↪㊂ߢᛥ೙ߔࠆൻว‛ߩഃ⵾ߦᚑഞߒ㧔࿖㓙․⸵㧕㧘␹⚻࿃ᕈ−∩ᴦ≮⮎ߣߒߡߩ㐿⊒⎇ⓥ
ߦ⌕ᚻߒߡ޿ࠆ‫ޕ‬
5㧕␹⚻⚦⢩ᱫᛥ೙೷ߩഃ⵾
␹⚻ᄌᕈ∔ᖚᴦ≮⮎ߩ㐿⊒ࠍ߼ߑߒߡ␹⚻⚦⢩ᱫᛥ೙૞↪ࠍ␜ߔૐಽሶൻว‛ߩ⸳⸘࡮วᚑ⎇ⓥࠍⴕߞߡ޿ࠆ㧚ߎࠇ߹ߢߦ㉄ൻࠬ࠻࡟ࠬ߅ࠃ߮ዊ⢩૕ࠬ࠻࡟ࠬ⚦⢩ࡕ࠺࡞♽ߦኻߒߡᒝജߥ⚦⢩ᱫᛥ೙૞↪ࠍ␜㧙㧙ߔൻว‛ࠍวᚑߔࠆߎߣߦᚑഞߒߡ߅ࠅ㧔․⸵಴㗿Ḱ஻ਛ㧕㧘૞↪ᯏᐨߩ⸃ᨆࠍㅴ߼ࠆߣߣ߽ߦ㧘in vivoേ‛ࡕ࠺࡞ߢߩ᦭ലᕈߩታ⸽ߦะߌߚ⎇ⓥࠍ㐿ᆎߒߚ‫ޕ‬
6㧕ᩭౝฃኈ૕ߩಽሶࠗࡔ࡯ࠫࡦࠣࡊࡠ࡯ࡉߩഃ⵾
ㆮવሶ⊒⃻ߩ೙ᓮߣ↢૕ᯏ⢻ߩ㑐ㅪࠍ PET ᴺߦࠃࠅ in vivo ߢ⸃ᨆߔࠆߚ߼㧘ᩭౝฃኈ૕ࠍ੺ߒߡㆮવ
ሶォ౮ࠍ೙ᓮߒߡ޿ࠆ࡟࠴ࡁࠗ࠼߅ࠃ߮㑐ㅪൻว‛ߩ PET ࠻࡟࡯ࠨ࡯ߩ⸳⸘෸߮วᚑࠍⴕߞߡ޿ࠆ‫ޕ‬7㧕ᣂ૞↪ᯏ᭴ࠍᜬߟ᛫࠙ࠗ࡞ࠬ೷ߩ㐿⊒ߣ PET ࠻࡟࡯ࠨ࡯ൻmRNA ߩࠬࡊ࡜ࠗࠪࡦࠣ෻ᔕߦ㑐ࠊࠆ࡝ࡦ㉄ൻ㉂⚛㧔SRPK㧕ࠍ㒖ኂߒ㧘ᚑᾫ mRNA ߩᒻᚑㆊ⒟ߩㅴ
ⴕࠍߊ޿ᱛ߼ࠆᣂⷙ᛫࠙ࠖ࡞ࠬ೷ߩ㐿⊒ࠍⴕߞߡ޿ࠆ‫ߥ߁ࠃߩߎޕ‬૞↪ᯏᐨࠍ߽ߟ SIS-1 ࠍ࡝࡯࠼ൻว
‛ߣߒ㧘ࠃࠅㆬᛯᕈ࡮ᵴᕈߩ㜞޿ൻว‛ߩഃ⵾ߦᚑഞߒߡ߅ࠅ㧘PET ࠻࡟࡯ࠨ࡯ൻ߽ᬌ⸛ߒߡ޿ࠆ‫ޕ‬8㧕⿥ㆬᛯᕈ Rho ࠠ࠽࡯࠯㒖ኂ೷ߩ PET ࠻࡟࡯ࠨ࡯ൻ
ㆃ⊒ᕈ⣖ⴊ▤ᡨ❗㑐ㅪ⿥ㆬᛯ⊛ Rho ࠠ࠽࡯࠯㒖ኂ೷㧔H1152㧕߇ࡊࡠࠬ࠲ࠣ࡜ࡦࠫࡦฃኈ૕ EP3 ૞േ⮎ߦࠃࠆ NO ↥↢ࠍ㒖ኂߒ㧘Ἳ∝ᕈ−∩߿␹⚻࿃ᕈ−∩ࠍᛥ೙ߔࠆߎߣ߇ࠊ߆ߞߚ‫⮎ߩߎޕ‬೷ߩ␹⚻࿃ᕈ−∩ߦኻߔࠆലᨐࠍಽሶ࡟ࡌ࡞ߢᬌ⸽ߒ㧘∩ߺߩ⸻ᢿ޽ࠆ޿ߪᴦ≮⮎ߦᔕ↪ߔࠆߚ߼ PET ࡊࡠ࡯ࡉൻࠍ
ⴕߥߞߡ޿ࠆ‫ޕ‬
2㧚ฬ★
ಎᢎ᝼㧦 ฎ↰੨ผഥᢎ㧦ฎጊᶈሶ

Kyoji Furuta
Hiroko Koyama

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
ߥߒ⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
ߥߒ✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
ߥߒේ⪺㧔᰷ᢥ㧕
1㧕 Satoh T, Okamoto S.-i, Cui J, Watanabe Y, Furuta K, Suzuki M, Tohyama K, S. A. Lipton. Activation of
the Keap1/Nrf2 Pathway for Neuroprotection by Electrophilic Phase II Inducers. Proc Natl Acad Sci
USA. 2006;103:768-773.
2㧕 Sun P, Wang G. X, Furuta K, Suzuki M. Synthesis of a Bis-Azido Analogue of Acromelic Acid forRadioisotope-Free
Photoaffinity Labeling and Biochemical Studies. Bioorg Med Chem Lett.
2006;16:2433-2436.
3㧕 Kaneko S, Ando A, Okuda-Ashitaka E, Maeda M, Furuta K, Suzuki M, Matsumura M, Ito S. Ornithine
Transport Via Cationic Amino Acid Transporter-1 Is Involved in Ornithine Cytotoxicity in Retinal
Pigment Epithelial Cells. Invest Ophthalmol Vis Sci. 2007;48:464-471.
4㧕 Furuta K, Maeda M, Hirata Y, Shibata S, Kiuchi K, Suzuki M. Synthesis of Neuroprotective
Cyclopentenone Prostaglandin Analogs: Suppression of Manganese-induced Apoptosis of PC12 Cells.
Bioorg Med Chem Lett. 2007;17:5487-5491.
5㧕 Kaneko S, Okuda-Ashitaka E, Ando A, Nishimura K, Igarashi K, Suzuki M, Matsumura M, Ito S.
Polyamines Upregulate the mRNA Expression of Cationic Amino Acid Transporter-1 in Human
Retinal Pigment Epithelial Cells. Am J Physiol Cell Physiol. 2007;293:C729-C737.
6㧕 Soen M, Minami T, Tatsumi S, Mabuchi T, Furuta K, Maeda M, Suzuki.M, Ito S. A Synthetic Kainoid,(2S,3R,4R) -3-Carboxymethyl-4- (Phenylthio) Pyrrolidine-2-Carboxylic Acid (PSPA-1) Serves as a
Novel Anti-Allodynic Agent for Neuropathic Pain. Eur J Pharmacol. 2007;575:75-81.
7) Hao HL, Sun P, Wang GX, Furuta K, Suzuki M. Synthesis of Both Epimeric Triacid Analogs of Kainic
Acid. Chinese Chem Lett. 2008;19:269-272.

㧙㧙

IF 9.598

IF 2.604

IF 3.528

IF 2.604

IF 4.230

IF 2.376

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦⪤ේᱜᢅ㧔᧲੩ක⑼ᱤ⑼ᄢቇ㧕㧘⎇ⓥಽᜂ⠪㧦ฎጊᶈሶ㧘㋈ᧁᱜᤘ㧘੗਄ᢅ㧧଻ஜක≮
ಽ㊁ߦ߅ߌࠆၮ␆⎇ⓥផㅴ੐ᬺ⎇ⓥࡊࡠࠫࠚࠢ࠻㧧SR Ⱞ⊕࡝ࡦ㉄ൻ㉂⚛㒖ኂᵴᕈࠍ᦭ߔࠆᣂߒ޿᛫
࠙ࠖ࡞ࠬൻว‛ߩวᚑߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 16㧙20 ᐕᐲ㧧25,000 ජ౞(6,000㧦6,000㧦5,000㧦4,000㧦
4,000 ජ౞)2㧕 ⎇ⓥઍ⴫⠪㧦ฎ↰੨ผ㧘⎇ⓥಽᜂ⠪㧦ᐔ↰ᵗሶ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(B)㧦␹⚻⚦⢩଻⼔૞↪ࠍ␜ߔᣂⷙࠪࠢࡠࡍࡦ࠹ࡁࡦಽሶࡊࡠ࡯ࡉߩഃ⵾ߣᵴ↪㧧ᐔᚑ 17㧙19 ᐕᐲ㧧12,500 ජ
౞(5,700㧦3,800㧦3,000 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦ฎ↰੨ผ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄⪚⧘⎇ⓥ㧦∩ߺߩࠗࡔ࡯ࠫࡦࠣߦะߌߚࡊࡠ
࡯ࡉಽሶߩ⸳⸘㧧ᐔᚑ 18㧙19 ᐕᐲ㧧3,300 ජ౞(1,400㧦1,900 ජ౞)
4㧕 ⎇ⓥઍ⴫⠪㧦ฎ↰੨ผ㧘⎇ⓥಽᜂ⠪㧦⷏Ỉᐙ㓶㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄․ቯ㗔ၞ⎇ⓥ ౏൐⎇ⓥ㧦∩ⷡߦ㑐ࠊࠆࠕࠢࡠࡔ࡝ࡦ㉄ฃኈ૕ត⚝ࡊࡠ࡯ࡉߩഃ⵾㧦ᐔᚑ 18㧙20 ᐕᐲ㧧8,500 ජ౞(3,200㧦2,600㧦2,700 ජ౞)
5㧕 ⎇ⓥઍ⴫⠪㧦ฎ↰੨ผ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(B)㧦ࠕࡠ࠺ࠖ࠾ࠕ⺃⊒ߦ߆߆ࠊࠆᣂ
ⷙฃኈ૕ߩត⚝ࡊࡠ࡯ࡉߩഃ⵾㧧ᐔᚑ 20㧙22 ᐕᐲ㧧13,900 ජ౞(5,300㧦4,800㧦3,800 ජ౞)
2㧕ฃ⸤⎇ⓥ1㧕 ฎጊᶈሶ㧧⣖⣲≌ߩࠕ࡞ࠠ࡞ൻ᛫≸೷⠴ᕈ࠲ࡦࡄࠢᵴᕈߩ PET ࠗࡔ࡯ࠫࡦࠣ⸻ᢿߩ㐿⊒㧧ᐔᚑ 20
㧙21 ᐕᐲ㧧3,055 ජ౞(975 ජ౞㧦2,080 ජ౞)㧦JST
3㧕౒ห⎇ⓥ1㧕 ฎ↰੨ผ㧦ಽሶࡊࡠ࡯ࡉߩวᚑߣᯏ⢻⹏ଔߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 19㧙20 ᐕᐲ㧦ℂൻቇ⎇ⓥᚲ
2㧕 ฎ↰੨ผ㧘ᐔ↰ᵗሶ㧦ᣂⷙ␹⚻଻⼔⮎ߩ⎇ⓥ㧧ᐔᚑ 19 ᐕᐲ㧧100 ජ౞㧦ද๺㉙㉂Ꮏᬺ(ᩣ)
3㧕 ฎጊᶈሶ㧦ක⮎ຠ╬ߦ᦭ᦸߣ⠨߃ࠆ࡝ࡦ㉄ൻ㉂⚛㒖ኂ૞↪╬૗ࠄ߆ߩ↢ℂᵴᕈࠍ᦭ߔࠆൻว‛ߦ㘃✼ߒ‫ߪߚ߹ޔ‬ห᭽ߩ૞↪ࠍ᦭ߔࠆߎߣ߇ᦼᓙߐࠇࠆૐಽሶൻว‛ࠍวᚑߒ‫ޔ‬ක⮎ຠ╬ߣߒߡ㐿⊒ߔࠆߎߣ߇᦭ᦸߥ߽ߩࠍត⚝ߔࠆ㧧ᐔᚑ 20 ᐕᐲ㧧1,000 ජ౞㧦㧔ᩣ㧕ࠠࡁࡈࠔ࡯ࡑ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫ
1㧕 ㋈ᧁᱜᤘ㧘ฎ↰੨ผ㧘દ⮮⺈ੑ㧘ධᢅ᣿㧦ࡊࡠ࡝ࡦ㘃✼૕㧧ᐔᚑ 18 ᐕ(․㗿 2005㧙347711)
2㧕 ㋈ᧁᱜᤘ㧘ฎ↰੨ผ㧘દ⮮⺈ੑ㧘ධᢅ᣿㧦␹⚻࿃ᕈ−∩ࠍᛥ೙ߔࠆᣂⷙࡆࡠ࡝ࠫࡦ㘃✼૕߅ࠃ߮ߘ
ߩ⵾ㅧᣇᴺ㧧ᐔᚑ 19 ᐕ(․㗿 2006-157874, PCT/JP2007/60489, WO2007/142028)
6㧚ቇળᵴേ
1㧕ቇળᓎຬ
ߥߒ
2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ฎ↰੨ผ㧦
1㧕 ᣣᧄൻቇળ᧲ᶏᡰㇱ ᧲ᶏࠦࡦࡈࠔ࡟ࡦࠬ 2007㧙ഃ⮎࡮ක⮎߳ߩൻቇ߆ࠄߩ᜸ᚢ̆(ᐔᚑ 19 ᐕ 9 ᦬㧘ጘ㒂㧘ଐ㗬⻠Ṷ‫ࠕ࠾ࠖ࠺ࡠࠕޟ‬ᛥ೙ൻว‛ߩഃ⵾‫ޠ‬Ṷ⠪)ฎጊᶈሶ㧦
1㧕 ಽሶࠗࡔ࡯ࠫࡦࠣ⎇ⓥࠪࡦࡐࠫ࠙ࡓ 2008㧘‫␠ޟ‬ળߩ࠾࡯࠭ߦะߌߚಽሶࠗࡔ࡯ࠫࡦࠣ⎇ⓥߩዷ㐿‫(ޠ‬ᐔ
ᚑ 20 ᐕ 1 ᦬㧘᧲੩㧘᧲੩࿖㓙ࡈࠜ࡯࡜ࡓ㧘Poster Session‫ޟ‬㔍ᴦᗵᨴ∝ߦኻߔࠆᣂⷙᴦ≮⮎㐿⊒ߩߚ߼ߩࠗࡔ࡯ࠫࡦࠣ⎇ⓥ‫ޠ‬Ṷ⠪)㧙㧙8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേฎ↰੨ผ㧦
1㧕 ᣣᧄቇⴚᝄ⥝ળ⑼ቇ⎇ⓥ⾌ᆔຬળኾ㐷ᆔຬ(ᐔᚑ 18㨪19 ᐕᐲ)
10㧚ႎ๔ᦠ
1㧕 ฎ↰੨ผ㧦␹⚻⚦⢩଻⼔૞↪ࠍ␜ߔᣂⷙࠪࠢࡠࡍࡦ࠹ࡁࡦಽሶࡊࡠ࡯ࡉߩഃ⵾ߣᵴ↪㧦ᐔᚑ 17 ᐕᐲ
㧙19 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ၮ⋚⎇ⓥ(B)⎇ⓥᚑᨐႎ๔ᦠ(2008 ᐕ 5 ᦬)
11㧚ႎ㆏1㧕 ฎ↰੨ผ㧦⮎ߩ↢૕ౝߢߩേ߈ࠍㅊ〔㧦 ጘ㒂ᣂ⡞(2008 ᐕ 10 ᦬ 21 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔ⎇ⓥ㕙ߢߪ㧘⑼ቇ⎇ⓥ⾌ߦࠃࠆၮ␆⎇ⓥࠍਛᔃߦⴕߞߡ޿ࠆ߇㧘ታ↪ൻߦะߌߚ․⸵߽ขᓧߒߡ߅ࠅ
㧔࿖㓙․⸵ߢ JST ࠃࠅ 7 ࠞ࿖⒖ⴕߩᡰេࠍฃߌߚ㧕㧘㔍ᴦᕈ∔ᖚߩᴦ≮⮎୥⵬ߣߒߡᵈ⋡ࠍ㓸߼ߡ޿ࠆ‫ޕ‬ߎࠇࠄਥⷐ⎇ⓥ࠹࡯ࡑߢߩ․⸵಴㗿ߩߚ߼㧘⺰ᢥ߿ቇળ⊒⴫╬ࠍប߃ߡ޿ߚ߇㧘಴㗿ߩᷣࠎߛ߽ߩߦ㑐ߒߡߪ⺰ᢥߣߒߡߢ߈ࠆ㒢ࠅᣧߊᚑᨐࠍ౏⴫ߒߡ޿ߊ੍ቯߢ޽ࠆ‫ࠆ߈ߢ⴫౏ޕ‬ᚑᨐߦ㑐ߒߡߪ࿖ౝ࡮࿖
㓙ቇળߢᲤᐕ⊒⴫ߒߡ޿ࠆ‫ޕ‬ᄖㇱ⾗㊄ߢߪ⑼ቇ⎇ⓥ⾌ࠍᲤᐕ₪ᓧߒߡ޿ࠆ‫ߦࠄߐޕ‬㧘⽷࿅ߩ⎇ⓥ⾌߿ડᬺ߆ࠄߩ⾗㊄₪ᓧߦะߌߡ㧘․⸵ࠍ߽ߣߦߒߚ౒ห⎇ⓥࠍㅴ߼ࠆ⸘↹ߢ޽ࠆ‫੹ޕ‬ᓟ߽ቇⴚ⊛ߥ⎇ⓥࠍផ
ㅴߔࠆߣߣ߽ߦߘߩᚑᨐࠍ␠ળߦㆶరߦߒߡ޿߈ߚ޿‫ޕ‬ቇ↢ߩ⎇ⓥᜰዉ࡮ᢎ⢒㕙ߢߪ࿖ౝᄖߩቇળ⊒⴫ߩઁ㧘ઁᄢቇ߿ℂൻቇ⎇ⓥᚲߣߩ౒ห⎇ⓥߦෳടߐߖࠆߥߤ㧘ᣂᛛⴚߦኻᔕߢ߈ࠆቇ㓙࡮࿖㓙⊛⎇ⓥ࡮ᛛⴚ⠪ߩ⢒ᚑߦะߌߡദജߒߡ޿ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ᐔᚑ 17 ᐕ 9 ᦬ࠃࠅ㋈ᧁᱜᤘᢎ᝼߇ℂൻቇ⎇ⓥᚲࡈࡠࡦ࠹ࠖࠕ⎇ⓥࠪࠬ࠹ࡓಽሶࠗࡔ࡯ࠫࡦࠣࡊࡠࠣ࡜
ࡓ࡮࠴࡯ࡓ࡝࡯࠳࡯౗છߣߥࠅ㧘ᐔᚑ 20 ᐕ 4 ᦬ߦหኾછߣߒߡℂൻቇ⎇ⓥᚲߦォ಴ߣߥߞߚߚ߼⎇ⓥቶⷙᮨ߇❗ዊߒߡ޿ࠆ‫⃻ޕ‬࿷㧘ᧄಽ㊁ߢߪකቇ♽⎇ⓥ⑼ඳ჻೨ᦼ⺖⒟ߩቇ↢ߣᎿቇㇱ↢๮Ꮏቇ⑼ߩත⎇↢㧔4 ᐕ↢㧕߅ࠃ߮ഃ⮎ක≮ᖱႎ⎇ⓥ⑼ߩඳ჻ᓟᦼ⺖⒟ߩቇ↢ߩ⎇ⓥᜰዉࠍⴕߞߡ޿ࠆ‫ߩߢ߹ࠇߎޕ‬ඳ჻೨ᦼ⺖⒟ߩቇ↢ߪ 100%߇↢๮Ꮏቇ⑼߆ࠄ㈩ዻߐࠇߚත⎇↢ߩㅴቇߦࠃࠆ߽ߩߢ޽ࠅ㧘ઁᄢቇ߆ࠄߩ౉
ቇ⠪ߪ޿ߥ޿‫ޕ‬Ꮏቇㇱ߆ࠄߩ㈩ዻත⎇↢ߩᢙߪ⡯ຬ᭴ᚑߦࠃࠅ᳿߹ࠆߚ߼ᓥ᧪ߣᲧߴඨᷫߒߡ޿ࠆߎߣ
߆ࠄ㧘੹ᓟඳ჻೨ᦼ⺖⒟ߩቇ↢ᢙߩᷫዋ߇⷗ㄟ߹ࠇࠆ‫↢ޕ‬๮Ꮏቇ⑼ߦ߅޿ߡ߽ൻቇ♽ࠍᔒᦸߔࠆቇ↢ᢙ߇ᷫߞߡ߅ࠅ㧘ቇㇱᢎ⢒ߩᲑ㓏ߦ߅޿ߡᎿቇㇱߣߩㅪ៤ࠍᒝൻߔࠆᔅⷐ߇޽ࠆ‫ߚ߹ޕ‬㧘ઁᄢቇ╬߆ࠄߩቇ↢൐㓸߽Ⓧᭂ⊛ߦⴕ߁ᔅⷐ߇޽ࠆߣ⠨߃ߡ޿ࠆ‫⎇ޕ‬ⓥ㕙ߢ߽㧘ㅴⴕਛߩࡊࡠࠫࠚࠢ࠻ߩਥജ⵬ഥຬߣ
ߥࠆᄢቇ㒮↢ߩ⏕଻߇⺖㗴ߢ޽ࠆ‫ޕ‬੹ᓟߩዷᦸ࿖㓙․⸵ࠍขᓧߒߚ␹⚻࿃ᕈ−∩ᛥ೙೷ߩᴦ≮⮎ߣߒߡߩ㐿⊒ߦะߌߡ೨⥃ᐥ⹜㛎߳ߩዷ㐿ࠍ⋡ᜰߔ‫ޕ‬␹⚻⚦⢩ᱫᛥ೙೷ߦߟ޿ߡ߽ጘ㒂ᄢቇߩᡰេ߇᳿ቯߒߡ߅ࠅ㧘․⸵಴㗿ࠍߢ߈ࠆ㒢ࠅᣧߊⴕ߁‫ߚ߹ޕ‬㧘ߎࠇࠄൻว‛ߩ PET ࡊࡠ࡯ࡉൻߣಽሶࠗࡔ࡯ࠫࡦࠣߦࠃࠆᦨవ┵ഃ⮎⎇ⓥࠍផㅴߒߚ޿‫ߦࠄߐޕ‬㧘ᢎ⢒㕙ߢ߽ࠃࠅ߈߼⚦߆ߥᜰዉ૕೙ࠍ⏕┙ߒ㧘ၮ⋚ߣߥࠆวᚑᛛⴚߣචಽߥၮ␆ቇജࠍ஻߃ߚഃㅧᕈ⼾߆ߥቇ↢ࠍ⢒ᚑߒߚ޿‫ޕ‬㧙㧙㧔2㧕⍮⢻ࠗࡔ࡯ࠫᖱႎಽ㊁1㧚⎇ⓥߩ᭎ⷐ
ౣ↢ක⑼ቇኾ᡹ౣ↢Ꮏቇ⻠ᐳ⍮⢻ࠗࡔ࡯ࠫᖱႎಽ㊁ߢߪ㧘ࠦࡦࡇࡘ࡯࠲ࠍ㚟૶ߒߡක↪↹௝ᖱႎࠍ޿ࠈ
޿ࠈߥⷺᐲ߆ࠄಣℂ࡮ടᎿߒ㧘ౣ↢කቇࠍߪߓ߼᭽‫ߥޘ‬ක≮ಽ㊁ߦ߅ߌࠆ↹௝ᖱႎࠍขࠅᛒߞߚᢎ⢒࡮⎇ⓥࠍⴕߞߡ޿ࠆ‫߫߃଀ޕ‬㧘ࠦࡦࡇࡘ࡯࠲ᡰេ⸻ᢿ㧔computer-aided diagnosis, CAD㧕ߣ๭߫ࠇࠆ߇㧘↹௝਄ߩ∛ᄌߩ૏⟎ࠍࠦࡦࡇࡘ࡯࠲ಣℂߢᜰ៰ߒ㧘޽ࠆ޿ߪ∛ᄌㇱ૏ߩࠦࡦࡇࡘ࡯࠲ߦࠃࠆቯ㊂⊛ߥಽᨆᖱႎࠍකᏧߦឭଏߔࠆߎߣߦࠃߞߡ㧘ࠃࠅᱜ⏕ߢ⏕ታߥකᏧߩ↹௝⸻ᢿ߇ⴕ߃ࠆࠃ߁ߦᡰេߔࠆࠪࠬ࠹ࡓߩ
㐿⊒ߢ޽ࠆ‫ޕ‬ℂᎿቇ♽⎇ⓥ⠪ߣකᏧ߿ࠦ࡮ࡔ࠺ࠖࠞ࡞ࠬ࠲࠶ࡈߣߩ᦭ᯏ⊛ߥ౒ห⎇ⓥ߇․ᓽߢ޽ࠆ‫↹ޕ‬௝
ᖱႎಣℂ㧘ࡃ࡯࠴ࡖ࡞࡝ࠕ࡝࠹ࠖ㧔VR㧘઒ᗐ⃻ታ㧕㧘ੱᎿ⍮⢻ߥߤߩᦨవ┵ߩᎿቇᛛⴚߩᢎ⢒ࠍⴕ޿㧘߹ߚකᎿቇ⊛ߥቇ㓙㗔ၞߩ↹௝⎇ⓥߦᔕ↪ߔࠆ‫߅ߥޕ‬㧘⎇ⓥቶߩ⹦⚦߿⎇ⓥౝኈߥߤߦߟ޿ߡߪ㧘⎇ⓥቶߩ
ࡎ࡯ࡓࡍ࡯ࠫߦឝタߒߡ޽ࠆ㧔http://www.fjt.info.gifu-u.ac.jp/㧕‫ᧄޕ‬ಽ㊁ߩᦨㄭߩ㊀ὐ⊛ߥ⎇ⓥ⺖㗴ߢ޽ࠆ CAD ⎇ⓥߩ᭎ⷐߦߟ޿ߡ㧘એਅߦ◲නߦ⺑᣿ߔࠆ‫ޕ‬
1㧕3 ߟߩ↹௝⸻ᢿ㗔ၞߦ߅ߌࠆࠦࡦࡇࡘ࡯࠲ᡰេ⸻ᢿ㧔CAD㧕ࠪࠬ࠹ࡓߩታ↪ൻ⎇ⓥ
ᧄ⎇ⓥߪ㧘ᐔᚑ 16 ᐕᐲ߆ࠄ 5 ᐕ⸘↹ߢណ↪ߐࠇጘ㒂࡮ᄢ၂࿾ၞߢᆎ߹ߞߚᢥㇱ⑼ቇ⋭ߩ⍮⊛ࠢ࡜ࠬ࠲࡯ഃᚑ⎇ⓥߦࠃࠆ⎇ⓥ㧔ࡠࡏ࠹ࠖ࠶ࠢవ┵ක≮ࠢ࡜ࠬ࠲࡯㧕ߢ޽ࠆ㧔http://www.cluster-g.jp/what.html㧕
‫ޕ‬⍮⊛ࠢ࡜ࠬ࠲࡯ഃᚑ੐ᬺߣߪ㧘࿾ᣇ⥄ᴦ૕ߩਥ૕ᕈࠍ㊀ⷞߒ㧘⍮⊛ഃㅧߩ᜚ὐߚࠆᄢቇ㧘౏⊛⎇ⓥᯏ㑐╬ࠍᩭߣߒߚ㑐ㅪ⎇ⓥᯏ㑐㧘⎇ⓥ㐿⊒ဳડᬺ╬ߦࠃࠆ࿖㓙⊛ߥ┹੎ജߩ޽ࠆᛛⴚ㕟ᣂߩߚ߼ߩ㓸Ⓧߩഃᚑࠍ⋡ᜰߔᢥㇱ⑼ቇ⋭ߩ੐ᬺߢ޽ࠆ㨫ᧄቇߦ߅޿ߡ߽㧘ਛᦼ⸘↹ߢขࠅ਄ߍࠄࠇߡ޿ࠆ㊀ⷐ⎇ⓥࡊࡠࠫࠚࠢ࠻
ߢ޽ࠆ‫ޕ‬3 ߟߩࡔࠗࡦࡊࡠࠫࠚࠢ࠻㧔ૐଚⷅᓸ⚦ᚻⴚᡰេ࡮ᢎ⢒⸠✵ࠪࠬ࠹ࡓߩ㐿⊒㧘ක≮⸻ᢿᡰេࠪࠬ
࠹ࡓߩ㐿⊒㧘߅ࠃ߮ක≮੺⼔ᡰេࠪࠬ࠹ࡓߩ㐿⊒㧕߇ㅴⴕਛߢ޽ࠅ㧘ᧄ⎇ⓥቶߢߪ㧘ක≮⸻ᢿᡰេࠪࠬ࠹
ࡓߩਛߢ㧘‫↹ޟ‬௝⸻ᢿᡰេࠪࠬ࠹ࡓߩ㐿⊒‫ࠍޠ‬ᜂᒰߒߡ޿ࠆ‫ޕ‬⃻࿷㧘⣖ MR ↹௝㧘੃⣼⿥㖸ᵄ↹௝㧘߅ࠃ߮⌒ᐩ↹௝ߩߚ߼ߩ CAD ࠪࠬ࠹ࡓߩ㐿⊒ࠍ㧘ᧄቇ㒝ዻ∛㒮ࠍೋ߼ߣߒߚ⋵ౝᄖߩකቇ♽㑐ଥ⠪㧘⋵ౝߩᛛⴚ♽ᄢቇ㧘߅ࠃ߮⋵ౝᄖߩⶄᢙߩડᬺߣ౒ห⎇ⓥࠍⴕߞߡ޿ࠆ‫⋡ޕ‬ᮡࠍ㆔߆ߦ਄࿁ࠆ․⸵ൻ㧘⺰ᢥൻ߇㗅⺞ߦㅴࠎߢ߅ࠅ㧘㐿⊒ࠪࠬ࠹ࡓߩⶄᢙߩ੐ᬺൻ㧔໡ຠൻ㧕߽㗅⺞ߦ㆐ᚑਛߢ㧘ᄖㇱ⹏ଔᆔຬળ߆ࠄߪᏱߦᦨ㜞ߩ⹏ଔࠍ޿ߚߛ޿ߡ޿ࠆ㨫
2㧕૕ᐙㇱ X ✢ CT ↹௝ߩߚ߼ߩࠦࡦࡇࡘ࡯࠲ᡰេ⸻ᢿ㧔CAD㧕ࠪࠬ࠹ࡓߩ㐿⊒⎇ⓥߎߩࡊࡠࠫࠚࠢ࠻ߢߪ㧘૕ᐙㇱ㗔ၞߦ߅ߌࠆੱ૕⤳ེ╬ߩᱜᏱ᭴ㅧߩ⥄േ⸃ᨆߩ㐿⊒ࠍផㅴߒߡ߅ࠅ㧘ᱜᏱ᭴ㅧߩℂ⸃࡮⹺⼂ߩⷰὐ߆ࠄߩࠕࡊࡠ࡯࠴ߦ⌕⋡ߒߚ CAD ⎇ⓥߢ޽ࠆ‫ߪࡑ࡯࠹ߩߎޕ‬㧘ᐔᚑ 15 ᐕ㧔ᐔᚑ 15 ᐕᐲᐲ⊒⿷ߩᢥㇱ⑼ቇ⋭ߩ⑼ቇ⎇ⓥ⾌⵬ഥ㊄࡮․ቯ⎇ⓥ㗔ၞ‫ޟ‬ᄙᰴరක↪↹௝ߩ⍮⊛⸻ᢿᡰេ‫ޠ‬㨪ᐔᚑ 18 ᐕᐲ㧕ߦ߅ߌࠆ⸘↹⎇ⓥ࠹࡯ࡑߦណ↪ߐࠇ㧘4 ᐕ㑆ߦࠊߚߞߡ⺰ᢥൻࠍਛᔃߦᄙᄢߥᚑᨐࠍ᜼
ߍߚ‫⎇ᧄޕ‬ⓥߢ㐿⊒ߒߚฦ⤳ེߩ⥄േ⹺⼂࡮᛽಴ᚻᴺߪ㧘CAD ߳ߩᔕ↪ߩߺߥࠄߕ㧘ฦ⒳⎇ⓥࡊࡠࠫࠚࠢ࠻߳ߩ੹ᓟߩዷ㐿߽น⢻ߢ޽ࠆ‫߅ߥޕ‬㧘ห․ቯ㗔ၞ࠹࡯ࡑߪ㧘ᐔᚑ 19 ᐕᐲߦⴕࠊࠇߚ⚳ੌ⹏ଔߢ㧘ᦨ㜞૏ߩ⹏ଔࠍฃߌߡ޿ࠆ‫ޕ‬
3㧕੃߇ࠎ↹௝⸻ᢿߩߚ߼ߩࠦࡦࡇࡘ࡯࠲ᡰេ⸻ᢿ㧔CAD㧕ࠪࠬ࠹ࡓߩ㐿⊒⎇ⓥߎߩࡊࡠࠫࠚࠢ࠻ߪߔߢߦ 1995 ᐕ߆ࠄ 10 ᐕ㑆એ਄ࠊߚࠅડᬺߣߩ౒ห⎇ⓥࠍⴕߞߡ߅ࠅ㧘ㄭ‫ޘ‬㧘CAD
ࠪࠬ࠹ࡓ߇໡ຠߣߒߡታ↪ൻߐࠇࠃ߁ߣߒߡ޿ࠆ㧔౒ห⎇ⓥవડᬺࠃࠅ⮎੐⹺น↳⺧ਛ㧕‫ޕ‬㓸࿅ᬌ⸻߿♖ኒᬌᩏߢ੃߇ࠎߩ↹௝⸻ᢿߢ೑↪ߐࠇࠆ੃ᚱ X ✢↹௝ߦ߅ߌࠆ߇ࠎ୥⵬㒶ᓇߩ૏⟎ࠍࠦࡦࡇࡘ࡯࠲ߩ⸃
ᨆ⚿ᨐߦࠃࠅ⍫ශߥߤߢ↹௝਄ߦᜰ៰ߒ㧘කᏧߩ⺒ᓇߩᱜ⏕ᐲߣߩะ਄߿⸻ᢿ⚿ᨐߩࡃ࡜࠷ࠠߩᷫዋ㧘ߐࠄߦ↢↥ᕈߩะ਄㧔⸻ᢿᤨ㑆ߩ⍴❗㧕ߥߤࠍ⋡⊛ߣߡ޿ࠆ‫ߚ߹ޕ‬㧘ᬌ಴ߐࠇߚ୥⵬ߩ⦟ᖡᕈߩ㐓೎ಣℂ㧘
୥⵬㒶ᓇߩ⸃ᨆ⚿ᨐឭ␜ᯏ⢻㧘࠺ࠖࠬ࠻࡯࡚ࠪࡦ∛ᄌߩᬌ಴ㅊടᯏ⢻ߥߤߦߟ޿ߡ߽㧘㐿⊒ࠍ⛯ߌߡ޿ࠆ‫ޕ‬ߥ߅㧘࠺ࡦࠬࡉ࡟ࠬ࠻߇ᄙ޿ᧄ㇌ᅚᕈ੃ᚱߩᬌ⸻ߩߚ߼ߦߪ㧘⿥㖸ᵄ↹௝߽⦟ߊ೑↪ߐࠇߡ޿ࠆߚ߼㧘਄⸥ 1㧕ߩ⍮⊛ࠢ࡜ࠬ࠲࡯ࡊࡠࠫࠚࠢ࠻ߢߪ㧘੃⣼ 3 ᰴర⿥㖸ᵄ↹௝ߩߚ߼ߩ CAD ࠪࠬ࠹ࡓߩ㐿⊒߽ⴕߞߡ޿ࠆ‫ޕ‬
4㧕ߘߩઁ਄⸥એᄖߦ߽㧘MRI ↹௝ߦ߅ߌࠆ⢄⤳∔ᖚߩ⥄േᬌ಴߿⸃ᨆߩߚ߼ߩ CAD ⎇ⓥ㧘PET ߦ߅ߌࠆ߇ࠎ
∛ᄌᬌ಴ߩߚ߼ߩ CAD ⎇ⓥ㧘ᢇᕆක≮ߩߚ߼ߩ↹௝ᡰេ⸻ᢿߩߚ߼ߩ CAD ⎇ⓥߥߤߦߟ޿ߡ㧘ቇౝᄖߩᄙߊߩ౒ห⎇ⓥ⠪ߣߣ߽ߦ⎇ⓥ㐿⊒ࠍⴕߞߡ޿ࠆ‫߅ߥޕ‬㧘੃߇ࠎ↹௝⸻ᢿߩߚ߼ߩ CAD ߦߟ޿ߡߪෘ
↢ഭ௛⋭ߩ߇ࠎ⎇ⓥഥᚑ㊄࡮⍹ᯅ⃰⎇ⓥࡊࡠࠫࠚࠢ࠻㧔࠺ࠫ࠲࡞ࡑࡦࡕࠣ࡜ࡈࠖߦࠃࠆ੃߇ࠎᬌ⸻ߩല₸෸߮♖ᐲะ਄࡮⹏ଔߦ㑐ߔࠆ⎇ⓥ㧕ߣㅪ៤ߒߡ߅ࠅ㧘߹ߚ㧘ฦ⒳ߩ߇ࠎ↹௝⸻ᢿߩߚ߼ߩ CAD ࠪࠬ࠹ࡓߩ㐿⊒ߪ㧘ห⋭ߩ߇ࠎ⎇ⓥഥᚑ㊄࡮㐳⼱Ꮉ⃰⎇ⓥࡊࡠࠫࠚࠢ࠻‫↹࡞࠲ࠫ࠺ޟ‬௝ಣℂߦࠃࠆ߇ࠎ⸻ᢿᡰេࠪ
ࠬ࠹ࡓߩ㐿⊒ߣ೑↪ߦ㑐ߔࠆ⎇ⓥ‫ߣޠ‬ㅪ៤ߒߡ⎇ⓥᵴേࠍⴕߞߡ޿ࠆ‫ޕ‬

㧙㧙

2㧚ฬ★
⮮↰ᑝᔒ
ᢎ᝼㧦
ಎᢎ᝼㧦 ේ ᱞผ
๟ ะᩕ
ഥᢎ㧦

Hiroshi Fujita
Takeshi Hara
Xiangrong Zhou

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ⮮↰ᐢᔒ㧚CAD ࠪࠬ࠹ࡓߩᎿቇ⊛ⷰὐ߆ࠄߩ⃻⁁㧙ᛛⴚ⊛೔㆐ὐߣ੹ᓟ߳ߩ⺖㗴㧘ߘߒߡᧂ᧪̆㧦᦬ೀᣂක≮࠺࡯࠲ࡉ࠶ࠢ࡮ࠪ࡝࡯࠭ ක≮ᯏེࠪࠬ࠹ࡓ⊕ᦠ 2006㨪2007㧘᧲੩㧦㧔ᩣ㧕ࠛࡓ࡮ࠗ࡯ᝄ⥝දળ㧧2006
ᐕ㧦275㧙281㧚
2㧕 ⮮↰ᐢᔒ㧚࠺ࠫ࠲࡞ࡑࡦࡕߣ CAD㧘ታ〣 ࠺ࠫ࠲࡞ࡑࡦࡕࠣ࡜ࡈࠖ-ၮ␆߆ࠄ⸻ᢿ߹ߢ㧔✬㓸㧦ᄢౝᙗ᣿㧕㧘᧲੩㧦ਛጊᦠᐫ㧧2006 ᐕ㧦42㧙50㧚
3㧕 ⮮↰ᐢᔒ㧚X ✢↹௝ߩᒻᚑ㧦ක↪↹௝ᖱႎቇ㧔ᡷ⸓ 2 㧘᩵Ꮉ⨃ᒾ ✬⪺㧕㧘᧲੩㧦ධጊၴ㧧2006 ᐕ㧦27
㧙51㧚
4㧕 ⮮↰ᐢᔒ㧚ࠦࡦࡇࡘ࡯࠲ᡰេ⸻ᢿ㧔CAD㧕㧙੃ᚱ X ✢౮⌀ߩࠦࡦࡇࡘ࡯࠲ᡰេ⸻ᢿ㧙㧦ක↪↹௝ᖱႎቇ㧔ᡷ
⸓ 2 㧘᩵Ꮉ⨃ᒾ ✬⪺㧕㧘᧲੩㧦ධጊၴ㧧2006 ᐕ㧦191㧙208㧚
5㧕 ⮮↰ᐢᔒ㧚࠺ࠖࠫ࠲࡞↹௝ߩ⴫␜㧦࿑⸃ ⸻≮᡼኿✢ᛛⴚታ〣ࠟࠗ࠼㧙╙৻✢ߢᔅߕᓎ┙ߟ⍮⼂࡮ታ〣ߩߔߴߡ㧙㧔╙ 2 㧕㧘㜞ᯅᱜᴦ࡮㜞ᯅ 㓉 ✬㧘᧲੩㧦ᢥశၴ㧧2006 ᐕ㧦616㧙619㧚
6㧕 ⮮↰ᐢᔒ㧚ࡑࡦࡕࠣ࡜ࡈࠖߦ㑐ߔࠆࠦࡦࡇࡘ࡯࠲ᡰេ⸻ᢿ㧔CAD㧕㧦࿑⸃ ⸻≮᡼኿✢ᛛⴚታ〣ࠟࠗ࠼㧙╙৻✢ߢᔅߕᓎ┙ߟ⍮⼂࡮ታ〣ߩߔߴߡ㧙㧔╙ 2 㧕㧘㜞ᯅᱜᴦ࡮㜞ᯅ 㓉 ✬㧘᧲੩㧦ᢥశၴ㧧2006 ᐕ㧦625
㧙628㧚
⪺ᦠ㧔᰷ᢥ㧕
1㧕 Fukuoka D, Hara T, Fujita H. Detection, characterization, and visualization of breast cancer using 3-D
ultrasound images. In: eds. Suri, JS and Rangayyan, RM. Recent Advances in Breast Imaging,
Mammography, and Computer-Aided Diagnosis of Breast Cancer, Chapter 16, Press Monograph
PM155, SPIE Press;2006:563-572.
2㧕 Matsubara T, Hara T, Fujita H. Automated detection for architectural distortions with retraction andspeculation on mammograms. In: eds. Suri JS, Rangayyan RM, and Laxminarayan S. Emerging
Technologies in Breast Imaging and Mammography, Chapter 24, American Scientific Publishers;
2008:463-469.
✚⺑㧔๺ᢥ㧕
1㧕 ⮮↰ᐢᔒ㧚CAD ߩታ↪ൻߣ᥉෸ߦะߌߡ㧘ᣂක≮ 2006 ᐕ㧧33 Ꮞ㧦95㧙102㧚
2㧕 ⮮↰ᐢᔒ㧚੃ᚱ᠟ᓇᛛⴚߩ⃻⁁ߣ዁᧪㧙੃ᚱ↹௝ಣℂᛛⴚ㧙㧘ᣣᧄ౮⌀ቇળ⹹ 2006 ᐕ㧧69 Ꮞ㧦16㧙22㧚
3㧕 ⮮↰ᐢᔒ㧚࠺ࠖࠫ࠲࡞ࡑࡦࡕࠣ࡜ࡈࠖ⎇ⓥ߳ߩᦼᓙߣ⺖㗴㧘ᣣᧄ᡼኿✢ᛛⴚቇળ࡮↹௝ㅢା 2006 ᐕ㧧29Ꮞ㧦4㧙13㧚
4㧕 ේ ᱞผ㧘⮮↰ᐢᔒ㧚ࡑࡦࡕࠣ࡜ࡈࠖߦ߅ߌࠆ CAD ߩ⃻⁁ߣዷᦸ㧘Rad Fan 2006 ᐕ㧧4 Ꮞ㧦67㧙71㧚
5㧕 ๟ ะᩕ㧘⮮↰ᐢᔒ㧚૕ᐙㇱ㗔ၞߩන⚐ CT ↹௝ߦ߅ߌࠆ⸃೬ቇ⊛ᱜᏱ᭴ㅧߩ⹺⼂㧘Medical Imaging
Technology 2006 ᐕ㧧24 Ꮞ㧦167㧙172㧚
6㧕 ⮮↰ᐢᔒ㧘ේ ᱞผ㧘᧻ේ෹ሶ㧘⑔ጟᄢテ㧚੃߇ࠎ↹௝⸻ᢿ㗔ၞߦ߅ߌࠆࠦࡦࡇࡘ࡯࠲ᡰេ⸻ᢿ㧔CAD㧕㧘੃ᚱ↹௝․㓸࡮᜗ᓙ⺰ᢥ㧘ක↪↹௝ᖱႎቇળ㔀⹹ 2006 ᐕ㧧23 Ꮞ㧦19㧙26㧚
7㧕 ⮮↰ᐢᔒ㧚CAD ߩዷᦸ㧙ࡑࡦࡕࠣ࡜ࡈࠖߩ CAD㧘੃⣼⿥㖸ᵄ↹௝ߩ CAD㧘߅ࠃ߮੃⣼ MRI ߩ CAD㧘INNERVISION 2006 ᐕ㧧21 Ꮞ㧦38㧙42㧚
8㧕 ੳᧁ ⊓㧘⮮↰ᐢᔒ㧚ක↪↹௝ߩ⎇ⓥᦨ೨✢㧘㔚ሶᖱႎㅢାቇળᖱႎ࡮ࠪࠬ࠹ࡓ࠰ࠨࠗࠛ࠹ࠖ⹹ 2007 ᐕ㧧
12 Ꮞ㧦6㧙13㧚
9㧕 ⮮↰ᐢᔒ㧘ᖱႎಽ㊁ᜂᒰ ᣣᧄක↪‛ℂቇળ↪⺆ᆔຬળ✬㧚කቇ‛ℂ↪⺆㓸 2007㧘කቇ‛ℂ 2007 ᐕ㧧
27 Ꮞ㧚
10㧕 ኹᧄ◊ม, ጊ↰ቬ↵, ᧛⿧⾆ⴕ, ᵤဈ᣽೑, ⮮↰ᐢᔒ㧚௑ᢳဳ CT ࠍ↪޿ߚ㜞ኒᐲታⵝၮ᧼⸃ᨆ㧘ࠛ࡟ࠢ࠻ࡠ࠾ࠢࠬታⵝቇળ⹹ 2007 ᐕ㧧10 Ꮞ㧦528㧙532㧚
11㧕 ⮮↰ᐢᔒ㧚ක≮↹௝ߩࠦࡦࡇࡘ࡯࠲ᡰេ⸻ᢿ㧘․㓸ภ㧦ක≮ߣ੺⼔ࠍᡰេߔࠆᣂஜᐽࡈࡠࡦ࠹ࠖࠕ․㓸ภ㧘ࠪࠬ࠹ࡓ/೙ᓮ/ᖱႎ㧔ࠪࠬ࠹ࡓ೙ᓮቇળ⹹㧕 2007 ᐕ㧧51 Ꮞ㧦433㧙438㧚
12㧕 ⮮↰ᐢᔒ㧚ක≮↹௝⸻ᢿߣ࠺ࠖࠬࡊ࡟ࠗ㧘․㓸 2㧦ක≮ߣ࠺ࠖࠬࡊ࡟ࠗ㧘᦬ೀ࠺ࠖࠬࡊ࡟ࠗ 2007 ᐕ㧧13
Ꮞ㧦47㧙50㧚
13㧕 ⮮↰ᐢᔒ㧚ࠦࡦࡇࡘ࡯࠲ᡰេ⸻ᢿ㧔CAD㧕ߩ⃻⁁᭎ⷰ㧘ᣣᧄ᡼኿✢ᛛⴚቇળ㔀⹹ 2007 ᐕ㧧63 Ꮞ㧦1389
㧙1395㧚
14㧕 ๟ ะᩕ㧘ේ ᱞผ㧘⮮↰ᐢᔒ㧚ᱜᏱ᭴ㅧߩℂ⸃ߦၮߠߊ⍮⊛ CAD㧘․㓸 CAD ᦨ೨✢ 2007㧦ᰴ਎ઍ CAD
ࠪࠬ࠹ࡓ߳ߩ᜸ᚢ㧔ᄙ⤳ེ࡮ᄙ∔∛ CAD ࠪࠬ࠹ࡓ㐿⊒ࡊࡠࠫࠚࠢ࠻ߩᚑᨐ㧕㧘INNERVISION 2007 ᐕ㧧
22 Ꮞ㧦21㧙25㧚
15㧕 ⮮↰ᐢᔒ㧚ᬌ⸻ߦ߅ߌࠆ CAD㧘ᢎ⢒⻠Ṷ㧘᡼኿✢᠟ᓇಽ⑼ળ⹹㧔ᣣᧄ᡼኿✢ᛛⴚቇળ㧕 2008 ᐕ㧧50 ภ㧦
3㧙6㧚
16㧕 ട⮮ඳၮ㧘౗᧻㓷ਯ㧘ㄭ⮮ᶈผ㧘੖ፉ ⡡㧘ᨷᬀ⵨੺㧘๟ ะᩕ㧘ේ ᱞผ㧘⮮↰ᐢᔒ㧚CAD ࠍ↪޿ߚ⢄㧙㧙⎬ᄌ∝ߩ MRI ⸻ᢿ㧘ᤋ௝ᖱႎ Medical 2008 ᐕ㧧40 Ꮞ㧦470㧙473㧚
17㧕 ਛᎹବ᣿㧘⮮↰ᐢᔒ㧚ࠬ࠹࡟ࠝ⌒ᐩࠞࡔ࡜ߣߪ㧫㧔․㓸㧦⥃ᐥᬌᩏࠍ⍮ߞߡ޿߹ߔ߆㧫㧕㧘Q㧒A ߢࠊ߆ࠆ⢈ḩߣ♧ዩ∛ 2008 ᐕ㧧7 Ꮞ㧦413㧙415㧚
18㧕 ේ ᱞผ㧚ࠦࡦࡇࡘ࡯࠲ᡰេ⸻ᢿ㧔CAD㧕ߩၮ␆ 2㧚ⓨ㑆㗔ၞߢߩ↹௝ಣℂ㧘ᣣᧄ᡼኿✢ᛛⴚቇળ㔀⹹
2008 ᐕ㧧64 Ꮞ㧦638㧙646㧚
19㧕 ⮮↰ᐢᔒ㧚CAD ታ↪ൻ 10 ๟ᐕ㧙⥃ᐥ⃻႐߳ߩዉ౉ߩ⃻⁁ߣ⺖㗴㧙㧘ᣂක≮ 2008 ᐕ㧧35 Ꮞ㧦102㧙105㧚
20㧕 ๟ ะᩕ㧘⮮↰ᐢᔒ㧚㛽ᩰ࡮㛽ᩰ╭ߩ image-based model ߅ࠃ߮ CAD㧘․㓸‫ޟ‬㛽㑐▵↹௝⸻ᢿߩᦨ೨✢㧙MSK ࠍ❱ࠆ-‫ޠ‬㧘⥃ᐥ↹௝ 2008 ᐕ㧧24 Ꮞ㧦1361㧙1370㧚
21㧕 ⮮↰ᐢᔒ㧚੃ᚱ↹௝⸻ᢿ߳ߩ⸻ᢿᡰេߩ⠨߃ᣇߣ⃻⁁㧘ᤋ௝ᖱႎ Medical 2008 ᐕ㧧40 Ꮞ㧦1120㧙1126㧚
22㧕 ਛᎹବ᣿㧘⇌ਛ⵨ม㧘᧛᧻ජᏀሶ㧘⮮↰ᐢᔒ㧚⌒ᐩ↹௝ߩࠦࡦࡇࡘ࡯࠲ᡰេ⸻ᢿߩ⃻⁁ߣ⺖㗴㧘⸃⺑㧘ක↪↹௝ᖱႎቇળ㔀⹹ 2008 ᐕ㧧25 Ꮞ㧦70㧙77㧚✚⺑㧔᰷ᢥ㧕
1㧕 H. Fujita, Y. Uchiyama, T. Nakagawa, D. Fukuoka, Y. Hatanaka, T. Hara, Y. Hayashi, Y. Ikedo, G.N.
Lee, X. Gao, X. Zhou. CAD on brain, fundus, and breast images, eds. X.W. Gao, et al., Proc. ofInternational Conference on Medical Imaging and Informatics (MIMI2007), Middlesex University
Press, 2007;278-301 (skip 279-288).
2㧕 Fujita H, Uchiyama Y, Nakagawa T, Fukuoka D, Hatanaka Y, Hara T, Hayashi Y, Ikedo Y, Lee GN,
Gao X, Zhou X. CAD on brain, fundus, and breast images, Medical Imaging and Informatics, Lecture
Notes in Computer Science, Springer Berlin / Heidelberg, 2008;4987;358-366.
3㧕 Zhang X, Fujita H, Qin T, Zhao J, Kanematsu M, Hara T, Zhou X, Yokoyama R, Kondo H, Hoshi H.
CAD on liver using CT and MRI, Medical Imaging and Informatics, Lecture Notes in Computer
Science, Springer Berlin / Heidelberg. 2008;4987:367-376.
4㧕 Fujita H, Uchiyama Y, Nakagawa T, Fukuoka D, Hatanaka Y, Hara T, Lee GN, Hayashi Y, Ikedo Y,
Gao X, Zhou X. Computer-aided diagnosis: The emerging of three CAD systems induced by Japanese
health care needs, Review, Computer Methods and Programs in Biomedicine, 2008;92:238-248.
ේ⪺㧔๺ᢥ㧕
1㧕 ᏒᎹൎᒄ㧘ዊኹศⴤ㧘ᄢᯅ৻਽㧘᧖ጊ㓷ਯ㧘ች࿾೑᣿㧘⮮↰ᐢᔒ㧚╬⸃௝ᐲ↹௝ࠍ↪޿ߚ CT ߩᕈ⢻⹏ଔ㧘ᣣᧄ᡼኿✢ᛛⴚቇળ㔀⹹ 2006 ᐕ㧧62 Ꮞ㧦522㧙528㧚
2㧕 ਛᎹବ᣿㧘ᨋ ૫ౖ㧘⇌ਛ⵨ม㧘㕍ጊ 㓁㧘᳓⨲ ⼾㧘⮮↰᣿ብ㧘ടฎᎹᱜൎ㧘ේ ᱞผ㧘⮮↰ᐢᔒ㧘ጊᧄື਽㧚1 ᨎߩ 2 ᰴర⌒ᐩ↹௝ࠍ↪޿ߚ 3 ᰴర⌒ᐩ↹௝ߩ᭴▽㧘ක↪↹௝ᖱႎቇળ㔀⹹ 2006 ᐕ㧧23 Ꮞ㧦
85㧙90㧚
3㧕 㜞ᯅ ੫㧘⇌ਛ⵨ม㧘ਛᎹବ᣿㧘ᨋ ૫ౖ㧘㕍ጊ 㓁㧘᳓⨲ ⼾㧘⮮↰᣿ብ㧘ടฎᎹᱜൎ㧘ේ ᱞผ㧘⮮↰ᐢᔒ㧚⌒ᐩ↹௝ߦ߅ߌࠆ㜞ⴊ࿶∝⸻ᢿᡰេߩߚ߼ߩⴊ▤੤෷ㇱߩ⥄േ⸃ᨆ㧘Medical Imaging Technology
2006 ᐕ㧧24 Ꮞ㧦270㧙276㧚
4㧕 ਛᎹବ᣿㧘ᨋ ૫ౖ㧘⇌ਛ⵨ม㧘㕍ጊ 㓁㧘᳓⨲ ⼾㧘⮮↰᣿ብ㧘ടฎᎹᱜൎ㧘ේ ᱞผ㧘⮮↰ᐢᔒ㧘ጊᧄື਽㧚⌒ᐩ↹௝⸻ᢿᡰេࠪࠬ࠹ࡓߩߚ߼ߩⴊ▤ᶖ෰↹௝ࠍ↪޿ߚⷞ␹⚻੃㗡ߩ⥄േ⹺⼂෸߮ᡆૃ┙૕ⷞ↹௝↢ᚑ߳ߩᔕ↪㧘㔚ሶᖱႎㅢାቇળ⺰ᢥ⹹ D 2006 ᐕ㧧J89-D Ꮞ㧦2491㧙2501㧚
5㧕 ኹᧄ◊ม㧘᧛⿧⾆ⴕ㧘ᵤဈ᣽೑㧘⮮↰ᐢᔒ㧚ߪࠎߛࡃࡦࡊߦ⊒↢ߒߚᓸዊࡏࠗ࠼ߩ⥄േᬌ಴㧘㔚᳇ቇળ⺰ᢥ⹹ D 2006 ᐕ㧧126 Ꮞ㧦1514㧙1521㧚
6㧕 ᧻የ ᖗ㧘᧡ਅᷕᰴ㧘⮮↰ᐢᔒ㧘 ᷨືᦶ㧘᧖ጊᷕሶ㧚࠺ࠖࠫ࠲࡞૏⋧ࠦࡦ࠻࡜ࠬ࠻ࠗࡔ࡯ࠫࡦࠣߦ߅ߌ
ࠆࠛ࠶ࠫᒝ⺞ߩ⹏ଔ㧘ක↪↹௝ᖱႎቇળ㔀⹹ 2006 ᐕ㧧23 Ꮞ㧦120㧙123㧚
7㧕 Ꮉዥ வ㧘๟ ะᩕ㧘ᒛ ቇァ㧘ේ ᱞผ㧘⮮↰ᐢᔒ㧘ᮮጊ㦖ੑ㇢㧘ㄭ⮮ᶈผ㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚න
⚐ X ✢ CT ↹௝ߦ߅ߌࠆ⢄⤳ⴊ▤ߩ⥄േ᛽಴ᴺߩೋᦼᬌ⸛㧘 ක↪↹௝ᖱႎቇળ㔀⹹ 2006 ᐕ㧧23 Ꮞ㧦141
㧙144㧚
8㧕 ጊౝ዁ผ㧘ౝጊ⦟৻㧘ዊ᫾ Ả㧘ᮮጊ㦖ੑ㇢㧘ේ ᱞผ㧘቟⮮ᒄ㆏㧘ጊᎹᒄ଻㧘ጤ㑆 ੧㧘ᤊ ඳᤘ㧘⮮↰ᐢᔒ㧚MRA ↹௝ߦ߅ߌࠆ⣖ⴊ▤ฬߩ⥄േኻᔕઃߌᚻᴺߩ㐿⊒㧘↢૕කᎿቇ 2007 ᐕ㧧45 Ꮞ㧦27㧙35㧚
9㧕 ૒⮮⌀⍮ሶ㧘›੗ᱜ↵㧘๟ ะᩕ㧘ේ ᱞผ㧘⮮↰ᐢᔒ㧚ࡕ࠺࡞ࡑ࠶࠴ࡦࠣߦࠃࠆࡑ࡞࠴ࠬ࡜ࠗࠬ CT ↹௝߆ࠄߩ❑ㇳౝ⢖േ⣂ߩ᛽಴㧘ක↪↹௝ᖱႎቇળ㔀⹹ 2007 ᐕ㧧24 Ꮞ㧦13㧙18㧚
10㧕 ౝጊ⦟৻㧘᧻੗ ◊㧘ᮮጊ㦖ੑ㇢㧘๟ ะᩕ㧘ේ ᱞผ㧘቟⮮ᒄ㆏㧘ᵻ㊁㓉ᒾ㧘ട⮮ඳၮ㧘ጤ㑆 ੧㧘ᤊඳᤘ㧘⮮↰ᐢᔒ㧚⣖ MR ↹௝ߦ߅ߌࠆ࡜ࠢ࠽᪪Ⴇߩᬌ಴ᴺ㧘㔚ሶᖱႎㅢାቇળ⺰ᢥ⹹ D 2007 ᐕ㧧J90-D
Ꮞ㧦1820㧙1829㧚
11㧕 ዊ᫾ Ả㧘ౝጊ⦟৻㧘ጊౝ዁ผ㧘ᮮጊ㦖ੑ㇢㧘ේ ᱞผ㧘ጊᎹᒄ଻㧘቟⮮ᒄ㆏㧘ጤ㑆 ੧㧘ᤊ ඳᤘ㧘⮮↰ᐢᔒ㧚ࡌࠢ࠻࡞㓸ਛᐲࡈࠖ࡞࠲ࠍ↪޿ߚ MRA ↹௝ߦ߅ߌࠆ⣖േ⣂≜ߩᬌ಴ᴺ㧘ක↪↹௝ᖱႎቇળ㔀⹹
2007 ᐕ㧧24 Ꮞ㧦84㧙89㧚
12㧕 ർᎹノᒾ㧘๟ ะᩕ㧘ේ ᱞผ㧘⮮↰ᐢᔒ㧘ᮮጊ㦖ੑ㇢㧘ㄭ⮮ᶈผ㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚⢄⤳㔚ሶࠕ࠻࡜ࠬߣ✢ᒝ⺞ࡈࠖ࡞࠲ߦࠃࠆ૕ᐙㇱ㕖ㅧᓇ X ✢ CT ௝߆ࠄߩਛ⢄㕒⣂ߩ⥄േ᛽಴㧘ᣣᧄ᡼኿✢ᛛⴚቇળ㔀⹹ 2007 ᐕ㧧63 Ꮞ㧦1382㧙1387㧚
13㧕 ᨋ ㆐㇢㧘๟ ะᩕ㧘㒸 ⪇ጪ㧘ේ ᱞผ㧘⮮↰ᐢᔒ㧘ᮮጊ㦖ੑ㇢㧘᩿↢ᜏม㧘ᤊ ඳᤘ㧚X ✢ CT ௝ߦ߅ߌࠆ⣄ᬁᬁ૕ㇱߩ㛽ኒᐲߩ⺞ᩏ㧘ක↪↢૕Ꮏቇ 2007 ᐕ㧧45 Ꮞ㧦256㧙266㧚
14㧕 ࿡ᨑ℉਽㧘ౝጊ⦟৻㧘ේ ᱞผ㧘⮮↰ᐢᔒ㧘ട⮮ඳၮ㧘ᵻ㊁㓉ᒾ㧘ᤊ ඳᤘ㧘ጊᎹᒄ଻㧘቟⮮ᒄ㆏㧘ጤ㑆੧㧚ࠢ࡜ࠬ࠲࡝ࡦࠣࠍ↪޿ߚ⣖࠼࠶ࠢ MR ↹௝ߦ߅ߌࠆή∝୥ᕈᄢ⣖⊕⾰∛ᄌߩᬌ಴ᴺ㧘Medical Imaging

㧙㧙Technology 2008 ᐕ㧧26 Ꮞ㧦39㧙47㧚
15㧕 ᨋ ㆐㇢㧘๟ ะᩕ㧘㒸 ⪇ጪ㧘ේ ᱞผ㧘⮮↰ᐢᔒ㧘ᮮጊ㦖ੑ㇢㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚X ✢ CT ௝ߦ߅ߌࠆ᳇▤࡮᳇▤ᡰߩᒻ⁁ᖱႎߩ⸘᷹㧘ක↪↹௝ᖱႎቇળ㔀⹹ 2008 ᐕ㧧25 Ꮞ㧦18㧙21㧚
16㧕 ർᎹノᒾ㧘๟ ะᩕ㧘ේ ᱞผ㧘⮮↰ᐢᔒ㧘ᮮጊ㦖ੑ㇢㧘ㄭ⮮ᶈผ㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚૕ᐙㇱ㕖ㅧᓇ
X ✢ CT ↹௝ߦ߅ߌࠆ⢄⤳ࠕ࠻࡜ࠬߩ⥄േ↢ᚑᴺߩឭ᩺ߣߘߩ⢄⤳⥄േ᛽಴ᴺ߳ߩᔕ↪㧘㔚ሶᖱႎㅢାቇ
ળ⺰ᢥ⹹ D 2008 ᐕ㧧J91-D Ꮞ㧦1837㧙1850㧚
17㧕 ␹⼱⋥Ꮧ㧘๟ ะᩕ㧘㒸 ⪇ጪ㧘ේ ᱞผ㧘⮮↰ᐢᔒ㧘ᮮጊ㦖ੑ㇢㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚㛽ᩰߣ㛽ᩰ╭ߩ⸃೬ቇ⊛૏⟎㑐ଥߦၮߠߊ૕ᐙㇱ X ✢ CT ↹௝߆ࠄߩ㛽ᩰ╭ߩ⥄േ᛽಴㧘㔚ሶᖱႎㅢାቇળ⺰ᢥ⹹ D
2008 ᐕ㧧J91-D Ꮞ㧦1918㧙1922㧚
18㧕 ᳰᚭ␭ม㧘⑔ጟᄢテ㧘ේ ᱞผ㧘⮮↰ᐢᔒ㧘㜞↰ᖝ㓶㧘㆙⮮⊓༑ሶ㧘᫪↰ቁሶ㧚ో੃ᚱ⿥㖸ᵄ↹௝ߦ߅ߌࠆ⣲≜௝⥄േᬌ಴ࠪࠬ࠹ࡓߩߚ߼ߩᏀฝ੃ᚱ↹௝ߩᲧセߦࠃࠆன㓁ᕈ೥㒰ᴺ㧘㔚ሶᖱႎㅢାቇળ⺰ᢥ⹹ D
2008 ᐕ㧧J91-D Ꮞ㧦1923㧙1926㧚
19㧕 ጊౝ዁ผ㧘ౝጊ⦟৻㧘ዊ᫾ Ả㧘ේ ᱞผ㧘⮮↰ᐢᔒ㧘቟⮮ᒄ㆏㧘ጊᎹᒄ଻㧘ጤ㑆 ੧㧚⣖ MRA ↹௝ߦ߅ߌࠆ⋧ኻ⊛ⴊ▤㐳ߦၮߠ޿ߚ㐽Ⴇߩ⥄േᬌ಴ᴺ㧘Medical Imaging Technology 2008 ᐕ㧧26 Ꮞ㧦251
㧙260㧚
20㧕 ᄹ⦟᧛੖චᔒ㧘ᨋ ㆐㇢㧘๟ ะᩕ㧘ේ ᱞผ㧘㒸 ⪇ጪ㧘⮮↰ᐢᔒ㧘ᮮጊ㦖ੑ㇢㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚૕ᐙㇱ X ✢ CT ↹௝ߦ߅ߌࠆ૕⣧᭴ㅧߩ⥄േ⹺⼂㧘Medical Imaging Technology 2008 ᐕ㧧26 Ꮞ㧦261
㧙271㧚
21㧕 ᨋ ㆐㇢㧘๟ ะᩕ㧘㒸 ⪇ጪ, ේ ᱞผ㧘⮮↰ᐢᔒ㧘ᮮጊ㦖ੑ㇢㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚X ✢ CT ↹௝߆ࠄߩੱ૕ߩᬁ૕ᶏ✎㛽ㇱߦ߅ߌࠆૐ㛽ኒᐲ㗔ၞߩಽᏓߦ㑐ߔࠆ⎇ⓥ㧘↢૕කᎿቇ 2008 ᐕ㧧46 Ꮞ㧦451
㧙457㧚
22㧕 ⑔↰࿻૓㧘ਛᎹବ᣿㧘⇌ਛ⵨ม㧘ᨋ ૫ౖ㧘ේ ᱞผ㧘⮮↰ᐢᔒ㧚↢૕⹺⸽ߩߚ߼ߩ⌒ᐩ↹௝ߦ߅ߌࠆⴊ
▤௝ࠍ↪޿ߚ㘃ૃᐲ▚಴ᴺ㧘↹௝㔚ሶቇળ⹹ 2008 ᐕ㧧37 Ꮞ㧦1020㧙1028㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Nakagawa T, Hara T, Fujita H, Iwase T, Endo T. A novel automated contour extraction method of
mammographic mass shadow using an improved active contour model. Proc. 7th International
Workshop on Digital Mammography. 2006:618-622.
2㧕 Matsubara T, Ichikawa T, Hara T, Fujita H, Kasai S, Endo T, Iwase T. Automated detection methods
for architectural distortions based on concentration of mammary gland on mammograms. Proc. 7thInternational Workshop on Digital Mammography. 2006:646-650.
3㧕 Sano K㧘Kawasaki M㧘Ishihara Y㧘Okubo M㧘Tsuchiya K㧘Nishigaki K㧘Zhou X㧘Minatoguchi S㧘
Fujita H㧘Fujiwara H. Assessment of vulnerable plaques causing acute coronary syndrome using
integrated backscatter intravascular ultrasound. J Amer Coll Cardiol. 2006;47:734-741.
IF 11.054
4㧕 Lee GN, Hara T, Fujita H. Classifying masses as benign or malignant based on co-occurrence matrix
textures: A comparison study of different gray level quantizations. Digital Mammography, 8thInternational Workshop IWDM2006 Proceedings. Eds. S.M.Astley, M.Brady, C.Rose, and R.Zwiggelaar,
Lecture Notes in Computer Science. 2006;4046:332-339.
5㧕 Hara T, Makita T, Matsubara T, Fujita H, Inenaga Y, Endo T, Iwase T. Automated detection method forarchitectural distortion with spiculation based on distribution assessment of mammary gland on
mammogram. Digital Mammography, 8th International Workshop IWDM2006 Proceedings. Eds.
S.M.Astley, M.Brady, C.Rose, and R.Zwiggelaar, Lecture Notes in Computer Science.
2006;4046:370-3375.
6㧕 Fukuoka D, Ikedo Y, Hara T, Fujita H, Takeda E, Endo T, Morita T. Development of breast ultrasound
CAD system for screening. Digital Mammography. 8th International Workshop IWDM2006
Proceedings, Eds. S.M.Astley, M.Brady, C.Rose, and R.Zwiggelaar, Lecture Notes in Computer Science.
2006;4046:392-398.
7㧕 Sugisaki K, Fujita H, Goto H, Hoshi H. Complementary role of computer aided detection in
mammography. Digital Mammography, 8th International Workshop IWDM2006 Proceedings. Eds.
S.M.Astley, M.Brady, C. Rose, and R. Zwiggelaar, Lecture Notes in Computer Science.
2006;4046:504-508.
8㧕 Zhou X, Hayashi T, Hara T, Fujita H, Yokoyama R, Kiryu T, Hoshi H. Automatic segmentation andrecognition of anatomical lung structures from high-resolution chest CT images. Computerized
Medical Imaging and Graphics. 2006;30:299-313.
IF 0.848
9㧕 Uchiyama Y, Yamauchi M, Ando H, Yokoyama R, Hara T, Fujita H, Iwama T, Hoshi H. Automatedclassification of cerebral arteries in MRA images and its application to maximum intensity projection.
Proc. of the 28th IEEE EMBS Annual International Conferencs. 2006:4865-4868.
10㧕 Zhou X, Kitagawa T, Hara T, Fujita H, Zhang X, Yokoyama R, Kondo H, Kanematsu M, Hoshi H.
Constructing a probabilistic model for automated liver region segmentation using non-contrast X-ray
torso CT images. Proc. of 9th International Conference for Medical Image Computing andComputer-Assisted Intervention - MICCAI 2006, Part II. 2006:4191:856-863.
11㧕 Ichikawa K, Kodera Y, Fujita H. MTF measurement method for medical displays by using abar-pattern image. Journal of the Society for Information Display. 2006;14:831-837.

㧙㧙12㧕 Teramoto A, Murakoshi T, Tsuzaka M, Fujita H. Automated X-ray inspection method for fillet-lessmounted chip components. IEEJ Transactions of Electrical & Electronic Engineering (TEEE), letter.
2007;2:195-197.
13㧕 Yokoyama R, Zhang X, Uchiyama Y, Fujita H, Hara T, Zhou X, Kanematsu M, Asano T, Kondo H,
Goshima S, Hoshi H, Iwama T. Development of an automated method for the detection of lacunar
infarct regions in brain MR images. IEICE Trans. Inf. & Syst. 2007;E90-D:943-954.
14㧕 Kato H, Kanematsu M, Zhang X, Saio M, Kondo H, Goshima S, Fujita H. Computer-aided diagnosis ofhepatic fibrosis: Preliminary evaluation of MRI texture analysis using the finite difference method andan artificial neural network. AJR. 2007;189:117-122.
15㧕 Dalal P, Munsell BC, Wang S, Tang J, Oliver K, Ninomiya H, Zhou X, Fujita H. A fast 3D
correspondence method for statistical shape modeling. Proc. of IEEE Conference on Computer Vision
and Pattern Recognition (CVPR). 2007;1-8.
16㧕 Teramoto A, Murakoshi T, Tsuzaka M, Fujita H. Development of high speed oblique X-ray CT systemfor printed circuit board. SICE Trans. on Industrial Application. 2007;6:72-77.
17㧕 Uchiyama Y, Yokoyama R, Ando H, Asano T, Kato H, Yamakawa H, Yamakawa H, Hara T, Iwama T,
Hoshi H, Fujita H. Improvement of automated detection method of lacunar infarcts in brain MR
images. Proc. of 29th IEEE Engineering in Medicine and Biology Conference Management System(EMBS) Annual International Conference. 2007;1599-1602.
18㧕 Nakagawa T, Hayashi Y, Hatanaka Y, Aoyama A, Hara T, Fujita A, Kakogawa M, Fujita H,
Yamamoto T. Three-dimensional reconstruction of optic nerve head from stereo fundus images and its
quantitative estimation. Proc. of 29th IEEE Engineering in Medicine and Biology ConferenceManagement System (EMBS) Annual International Conference. 2007;6747-6750.
19㧕 Teramoto A, Murakoshi T, Tsuzaka M, Fujita H. Automated solder inspection method by means of
X-ray oblique computed tomography. Proc. of IEEE International Conference on Image Processing.
2007;V-433-V-436.
20㧕 Teramoto A, Murakoshi T, Tsuzaka M, Fujita H. Automated solder inspection technique for
BGA-mounted substrates by means of oblique computed tomography. IEEE Trans. Electronics
Packaging Manufacturing. 2007;30:285-292.
21㧕 Ikedo Y, Fukuoka D, Hara T, Fujita H, Takada E, Endo T, Morita T. Development of a fully automatic
scheme for detection of masses in whole breast ultrasound images. Medical Physics. 2007;34:4378-4388.
22㧕 Teramoto A, Yamada M, Murakoshi T, Tsuzaka M, Fujita H. High speed oblique CT system for solder
bump inspection. Proc. of the 33rd Annual Conference of the IEEE Industrial Electronics Society(IECON). 2007;2689-2693.
23㧕 Nagata C, Matsubara T, Hara T, Fujita H, Nagao Y, Yamamoto S, Shibuya C, Kashiki Y, Shimizu H.
Urinary 6-sulfatoxymelatonin and mammographic density in Japanese women. Cancer Epidemiolgy,
Biomarkers & Prevention. 2007;16:2509-2512.
24㧕 Uchiyama Y, Yokoyama R, Ando H, Asano T, Kato H, Yamakawa H, Yamakawa H, Hara T, Iwama T,
Hoshi H, Fujita H. Computer-aided diagnosis scheme for detection of lacunar infarcts in MR images.
Academic Radiology. 2007;14:1554-1561.
25㧕 Lee GN and Fujita H. K-means clustering for classifying unlabelled MRI data, Proc. of Digital Image
Computing Techniques and Applications (DICTA 2007). IEEE Computer Society. 2007;92-98.
26㧕 Zhou X, Ninomiya H, Hara T, Fujita H, Yokoyama R, Cheng H, Kiryu T, Hoshi H. Automatedestimation of the upper surface of the diaphragm in 3-D CT images. IEEE Transactions on Biomedical
Engineering. 2008;55:351-353.
27㧕 Zhang X, Fujita H, Qin T, Zhao J, Qin Y, Gao C, Long L, Zhang Z. A novel method for extraction of
spleen by using thin-plate splines (TPS) deformation and edge detection from abdominal CT images.
2008 International Conference on BioMedical Engineering and Informatics. 2008:830-834.
28㧕 Matsuo S, Fujita H, Morishita J, Katafuchi T, Honda C, Sugisaki J. Evaluation of a phase contrast
imaging with digital mammography, Digital Mammography, E.A.Krupinski (Ed.), Springer Lectures
Notes in Computer Science (LNCS) series; LNCS5116. 2008:130-136.
29㧕 Ikedo Y, Morita T, Fukuoka D, Hara T, Fujita H, Takada E, Endo T. Computerized classification ofwhole breast ultrasound images based on mammary gland patterns, Digital Mammography,
E.A.Krupinski (Ed.), Springer Lectures Notes in Computer Science (LNCS) series; LNCS5116.
2008:188-195.
30㧕 Lee GN, Fukuoka D, Ikedo Y, Hara T, Fujita H, Takada E, Endo T, Morita T. Classification of benign
and malignant masses in ultrasound breast image based on geometric and echo features, 9thInternational Workshop on Digital Mammography, Digital Mammography, E.A.Krupinski (Ed.),
Springer Lectures Notes in Computer Science (LNCS) series; LNCS5116. 2008:433-439.
31㧕 Hara T, Fukuoka D, Ikedo Y, Takada E, Fujita H, Endo T, Morita T. Development of whole breast
ultrasound viewer and automated mass detection system, Digital Mammography, E.A.Krupinski (Ed.),
Springer Lectures Notes in Computer Science (LNCS) series; LNCS5116. 2008:455-462.
32㧕 Nakagawa T㧘Hara T㧘Fujita H㧘Horita K㧘Iwase T, Endo T. Radial-searching contour extraction
method based on a modified active contour model for mammographic masses, Radiological Physics and㧙㧙

IF 0.245

IF 2.470

IF 0.903
IF 3.198

IF 4.642

IF 2.094

IF 1.622

Technology. 2008;1:151-161.
33㧕 Kawajiri S, Zhou X, Zhang X, Hara T, Fujita H, Yokoyama R, Kondo H, Kanematsu M, Hoshi H.
Automated segmentation of hepatic vessels in non-contrast X-ray CT images, Radiological Physics andTechnology. 2008;1:214-222.
34㧕 Uchiyama Y, Kunieda T, Asano T, Kato H, Hara T, Kanematsu M, Iwama T, Hoshi H, Kinosada Y,
Fujita H. Computer-aided diagnosis scheme for classification of lacunar infarcts and enlarged
Virchow-Robin spaces in brain MR image, Proc of 30th Annual International Conference of the IEEE
Engineering in Medicine and Biology Society. 2008:3908-3911.
35㧕 Hatanaka Y, Nakagawa T, Hayashi Y, Hara T, Fujita H. Improvement of automated detection methodof hemorrhages in fundus images, Proc of 30th Annual International Conference of the IEEE
Engineering in Medicine and Biology Society. 2008:5429-5432.
36㧕 Zhou X, Han M, Hara T, Fujita H, Sugisaki K, Chen H, Lee G, Yokoyama R, Kanematsu M, Hoshi H.
Automated segmentation of mammary gland regions in non-contrast X-ray CT images. Computerized
Medical Imaging and Graphics. 2008;32:699-709.
IF 0.848
37㧕 Nakagawa T, Suzuki T, Hayashi Y, Mizukusa Y, Hatanaka Y, Ishida K, Hara T, Fujita H, Yamamoto T.
Quantitative depth analysis of opticnerve head using stereo retinal fundus image pair. Journal of
Biomedical Optics. 2008;13:1-10.
IF 3.0844㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦⮮↰ᑝᔒ㧘⎇ⓥಽᜂ⠪㧦ᤊ ඳᤘ㧘ᓟ⮮⵨ᄦ㧘౗᧻㓷ਯ㧘᩿↢ᜏม㧘ේ ᱞผ㧘๟ ะᩕ㧘૒੗◊௾㧘᧻ේ෹ሶ㧘᧘ ㎬▸㧘⇌ਛ⵨ม㧘⑔ጟᄢテ㧘㆙⮮⊓༑ሶ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄․ቯ㗔ၞ⎇ⓥ㧔ᄙᰴరක↪↹௝ߩ⍮⊛⸻ᢿᡰេ㧕㧦ᱜᏱ᭴ㅧߩℂ⸃ߦၮߠߊ⍮⊛ CAD㧧ᐔᚑ 15
㧙18 ᐕᐲ㧧56,000 ජ౞(14,000㧦14,000㧦14,000㧦14,000 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦⮮↰ᑝᔒ㧘⎇ⓥಽᜂ⠪㧦G.N.Lee㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄㧔․೎⎇ⓥຬᅑബ⾌㧕㧦ක↪↹௝ߦ߅ߌࠆࠦࡦࡇࡘ࡯࠲ᡰេ߇ࠎ⥄േᬌ಴ࠪࠬ࠹ࡓߩ㐿⊒ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 17㧙18 ᐕᐲ㧧
2,400 ජ౞(1,200㧦1,200 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦✽㊁ ❥㧘⎇ⓥಽᜂ⠪㧦㐳⼱Ꮉ⚐৻㧘ᷡ᳓ᤘિ㧘ᧃ᳗ᐽੳ㧘⮮↰ᑝᔒ㧘ฬข ඳ㧘๺↰⌀৻㧘ੳᧁ ⊓㧘ౝጊ⩿ᥓሶ㧧ෘ↢ഭ௛⋭߇ࠎ⎇ⓥഥᚑ㊄㧦ᯏ᪾㐿⊒⎇ⓥ‫↹࡞࠲ࠫ࠺ޟ‬௝ࠍ೑↪
ߒߚ⸻ᢿᡰេࠪࠬ࠹ࡓߩ㐿⊒ߣ೑↪ߦ㑐ߔࠆ⎇ⓥ‫ޠ‬㧧ᐔᚑ 17㧙18 ᐕᐲ㧧2,400 ජ౞(1,200㧦1,200 ජ౞)㧔ಽᜂಽ㧕4㧕 ⎇ⓥઍ⴫⠪㧦ේ ᱞผ㧘⎇ⓥಽᜂ⠪㧦 ᷨືᦶ㧘⮮↰ᑝᔒ㧧⁛┙ⴕ᡽ᴺੱᣣᧄቇⴚᝄ⥝ળ⑼ቇ⎇ⓥ
⾌⵬ഥ㊄ၮ⋚⎇ⓥ࡮ડ↹㧦PET-CT ↹௝ߦ߅ߌࠆⶄᢙ PET ᩭ⒳ߩ㓸ⓍಽᏓ࠺࡯࠲ࡌ࡯ࠬൻߦ㑐ߔࠆ⺞ᩏ㧧ᐔᚑ 18 ᐕᐲ㧧1,800 ජ౞5㧕 ⎇ⓥઍ⴫⠪㧦๟ ะᩕ㧧⁛┙ⴕ᡽ᴺੱᣣᧄቇⴚᝄ⥝ળ⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦3 ᰴర૕ᐙㇱCT ↹௝߆ࠄߩੱ૕⚵❱࡮⤳ེ㗔ၞߩ⥄േ⹺⼂ߦ㑐ߔࠆၮ␆⊛⎇ⓥ㧧ᐔᚑ 17㧙19 ᐕᐲ㧧1,900 ජ౞(700㧦700㧦500 ජ౞)
6㧕 ⎇ⓥઍ⴫⠪㧦ේ ᱞผ㧧ᄢ๺⸽೛ࡋ࡞ࠬ⽷࿅㧦ਛ࡮㜞ᐕ⠪ߩ଻㒾࡮ක≮߅ࠃ߮⑔␩╬ߦ㑐ߔࠆ⎇ⓥ⺞ᩏ㧦⿥⸃௝ᛛⴚࠍ↪޿ߚࡐࠫ࠻ࡠࡦᢿጀ᠟௝㧔PET㧕ⵝ⟎ߩ㜞⸃௝ᐲൻ㧧ᐔᚑ 18㧙19 ᐕᐲ㧧1,000ජ౞7㧕 ⎇ⓥઍ⴫⠪㧦㐳⼱Ꮉ⚐৻㧘⎇ⓥಽᜂ⠪㧦ੳᧁ ⊓㧘⮮↰ᑝᔒ㧘ᷡ᳓ᤘિ㧘᫪ ஜ╷㧘✽㊁ ❥㧘᫪㓷᮸㧘◉ፒ⾫ᴦ㧘᧛᧻ᐘ↵㧘᧻ㄼᱜ᮸㧘ෘ↢ഭ௛⋭߇ࠎ⎇ⓥഥᚑ㊄㧦ᯏ᪾㐿⊒⎇ⓥ‫↹࡞࠲ࠫ࠺ޟ‬௝
ಣℂߦࠃࠆ߇ࠎ⸻ᢿᡰេࠪࠬ࠹ࡓߩ㐿⊒ߣ೑↪ߦ㑐ߔࠆ⎇ⓥ‫ޠ‬㧧ᐔᚑ 19㧙20 ᐕᐲ㧧2,900 ජ౞(1,400㧦1,500 ජ౞)㧔ಽᜂ㈩ಽ㗵㧕8㧕 ⎇ⓥઍ⴫⠪㧦⍹ᯅᔘม㧘⎇ⓥಽᜂ⠪㧦⍹↰ቁት㧘ᬀ᧻ቁᖝ㧘ጊ↰㓉ਯ㧘ౝጊ⩿ᥓሶ㧘ේ ᱞผ㧘ෘ‫ࠎ߇੃ࠆࠃߦࠖࡈ࡜ࠣࡕࡦࡑ࡞࠲ࠫ࠺ޟ‬ᬌ⸻ߩല₸෸߮♖ᐲะ਄࡮⹏ଔߦ
↢ഭ௛⋭߇ࠎ⎇ⓥഥᚑ㊄㧦㑐ߔࠆ⎇ⓥ‫ޠ‬㧧ᐔᚑ 19㧙20 ᐕᐲ㧧2,400 ජ౞(1,200㧦1,200 ජ౞)㧔ಽᜂ㈩ಽ㗵㧕9㧕 ⎇ⓥઍ⴫⠪㧦ේ ᱞผ㧘⎇ⓥಽᜂ⠪㧦 ᷨືᦶ㧘⮮↰ᑝᔒ㧘⁛┙ⴕ᡽ᴺੱᣣᧄቇⴚᝄ⥝ળ⑼ቇ⎇ⓥ
⾌⵬ഥ㊄㧦‫ⶄޟ‬ᢙ PET ᩭ⒳ߩ㓸ⓍಽᏓߩቯ㊂ൻߦࠃࠆੱ૕ઍ⻢ࠕ࠻࡜ࠬߩ᭴▽ߦ㑐ߔࠆ⎇ⓥ‫ޠ‬㧧ᐔᚑ19㧙22 ᐕᐲ(900 ජ౞㧦1,100 ජ౞㧦800 ජ౞㧦700 ජ౞)
10㧕 ⎇ⓥઍ⴫⠪㧦᳗↰⍮㉿㧘⎇ⓥಽᜂ⠪㧦ᷡ᳓ᒄਯ㧘⮮↰ᑝᔒ㧘ᱞ↰ೣਯ㧧⁛┙ⴕ᡽ᴺੱᣣᧄቇⴚᝄ⥝ળ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(B)㧦੃߇ࠎ࡝ࠬࠢߣߒߡߩࠛࠬ࠻ࡠࠥࡦ㧘ࡔ࡜࠻࠾ࡦߣࠨ࡯ࠞ࠺ࠖࠕ
ࡦ࡝࠭ࡓߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 19㧙21 ᐕᐲ㧧14,800 ජ౞(5,200㧦4,800㧦4,800 ජ౞)
11㧕 ⎇ⓥઍ⴫⠪㧦⮮↰ᑝᔒ㧧ᐔᚑ 19 ᐕᐲࠦ࠾ࠞࡒࡁ࡞࠲↹௝⑼ቇᝄ⥝⽷࿅⎇ⓥഥᚑ㊄㧧ᐔᚑ 19 ᐕ㧧300ජ౞
12㧕 ⎇ⓥઍ⴫⠪㧦๟ ะᩕ㧧ጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼⎇ⓥᵴᕈൻ㧔ක㧕ߩߚ߼ߩ⎇ⓥ⾌⵬ഥ㊄㧧ᐔ㧙㧙ᚑ 19 ᐕ㧧100 ජ౞
13㧕 ⎇ⓥઍ⴫⠪㧦๟ ะᩕ㧧ᨰ᫪ᖱႎ⑼ቇᝄ⥝⽷࿅‫ޟ‬ᐔᚑ 19 ᐕᐲ⎇ⓥഥᚑ㊄‫ޠ‬㧧ᐔᚑ 19 ᐕ㧧900 ජ౞
14㧕 ⎇ⓥઍ⴫⠪㧦ේ ᱞผ㧧ᐔᚑ 20 ᐕᐲ┙⍹⑼ቇᛛⴚᝄ⥝⽷࿅⎇ⓥഥᚑ㊄㧧ᐔᚑ 20 ᐕ㧧2,500 ජ౞
15㧕 ⎇ⓥઍ⴫⠪㧦ේ ᱞผ㧧ᐔᚑ 20 ᐕᐲ㔚᳇ㅢା᥉෸⽷࿅ᶏᄖᷰ⥶ᣏ⾌េഥ㊄㧧ᐔᚑ 20 ᐕ㧧230 ජ౞
16㧕 ⎇ⓥઍ⴫⠪㧦๟ ะᩕ㧧⽷࿅ᴺੱฬฎደ↥ᬺ⑼ቇ⎇ⓥᚲ‫ޟ‬ᐔᚑ 20 ᐕᐲ⎇ⓥ╬ഥᚑ㧔ᶏᄖᷰ⥶េഥ㧕‫ޠ‬㧧
ᐔᚑ 20 ᐕ㧧300 ජ౞
17㧕 ⎇ⓥઍ⴫⠪㧦ේ ᱞผ㧧੗਄⑼ቇᝄ⥝⽷࿅‫ޟ‬࿖㓙⎇ⓥ㓸ળ߳ߩ಴Ꮸᣏ⾌ߩ৻ㇱេഥ㊄‫ޠ‬㧧ᐔᚑ 20 ᐕ㧧
250 ජ౞
18㧕 ⎇ⓥઍ⴫⠪㧦๟ ะᩕ㧧ᐔᚑ 20 ᐕᐲጘ㒂ᄢቇ⎇ⓥᵴᕈൻ⚻⾌㧔⎇ⓥ㧦⑼⎇ណᛯᡰេ㧕㧧ᐔᚑ 20 ᐕ㧧
1,020 ජ౞2㧕ฃ⸤⎇ⓥ1㧕 ⮮↰ᑝᔒ㧦ක≮⸻ᢿᡰេࠪࠬ࠹ࡓߩ㐿⊒㨪↹௝⸻ᢿᡰេࠪࠬ࠹ࡓߩ㐿⊒㨪㧧ᐔᚑ 18 ᐕᐲ㧧59,729
ජ౞㧦⽷࿅ᴺੱጘ㒂⋵⎇ⓥ㐿⊒⽷࿅㧔ᢥ⑼⋭࿾ၞ⑼ቇᛛⴚᝄ⥝੐ᬺ⾌⵬ഥ㊄㧔⍮⊛ࠢ࡜ࠬ࠲࡯ഃᚑ
੐ᬺ㧦ጘ㒂࡮ᄢ၂࿾ၞ‫ࠢ࠶ࠖ࠹ࡏࡠޟ‬వ┵ක≮ࠢ࡜ࠬ࠲࡯‫ޠ‬㧕ߦࠃࠆᆔ⸤㧕2㧕 ⮮↰ᑝᔒ㧦ක≮⸻ᢿᡰេࠪࠬ࠹ࡓߩ㐿⊒㨪ࠬ࠹࡟ࠝ⌒ᐩ↹௝⸻ᢿᡰេࠪࠬ࠹ࡓߩ㐿⊒㨪㧧ᐔᚑ 18 ᐕᐲ㧧5,384 ජ౞㧦⽷࿅ᴺੱጘ㒂⋵⎇ⓥ㐿⊒⽷࿅㧔ᢥ⑼⋭࿾ၞ⑼ቇᛛⴚᝄ⥝੐ᬺ⾌⵬ഥ㊄㧔⍮⊛ࠢ࡜ࠬ࠲࡯ഃᚑ੐ᬺ㧦ጘ㒂࡮ᄢ၂࿾ၞ‫ࠢ࠶ࠖ࠹ࡏࡠޟ‬వ┵ක≮ࠢ࡜ࠬ࠲࡯‫ޠ‬㧕ߦࠃࠆᆔ⸤㧕3㧕 ⮮↰ᑝᔒ㧦⌒ᐩ┙૕↹௝ࠍ↪޿ߚ⌒⑼ஜᐽ⸻ᢿᡰេࠪࠬ࠹ࡓߩ㐿⊒㧧ᐔᚑ 18 ᐕᐲ㧧834 ජ౞㧦⽷࿅
ᴺੱጘ㒂⋵⎇ⓥ㐿⊒⽷࿅㧔⚻ᷣ↥ᬺ⋭࿾ၞᣂ↢ࠦࡦ࠰࡯ࠪࠕࡓ⎇ⓥ㐿⊒੐ᬺߦࠃࠆᆔ⸤㧕
4㧕 ⮮↰ᑝᔒ㧦↹௝⸻ᢿᡰេᛛⴚߩ⎇ⓥ㐿⊒㧧ᐔᚑ 18 ᐕᐲ㧧200 ජ౞㧦ࠦ࠾ࠞࡒࡁ࡞࠲ࠛࡓࠫ࡯㧔ᩣ㧕
5㧕 ⮮↰ᑝᔒ㧦ක≮⸻ᢿᡰេࠪࠬ࠹ࡓߩ㐿⊒㨪↹௝⸻ᢿᡰេࠪࠬ࠹ࡓߩ㐿⊒㨪㧧ᐔᚑ 19 ᐕᐲ㧧66,500
ජ౞㧦⽷࿅ᴺੱጘ㒂⋵⎇ⓥ㐿⊒⽷࿅㧔ᢥ⑼⋭࿾ၞ⑼ቇᛛⴚᝄ⥝੐ᬺ⾌⵬ഥ㊄㧔⍮⊛ࠢ࡜ࠬ࠲࡯ഃᚑ
੐ᬺ㧦ጘ㒂࡮ᄢ၂࿾ၞ‫ࠢ࠶ࠖ࠹ࡏࡠޟ‬వ┵ක≮ࠢ࡜ࠬ࠲࡯‫ޠ‬㧕ߦࠃࠆᆔ⸤㧕
6㧕 ⮮↰ᑝᔒ㧦⌒ᐩ┙૕↹௝ࠍ↪޿ߚ⌒⑼ஜᐽ⸻ᢿᡰេࠪࠬ࠹ࡓߩ㐿⊒㧧ᐔᚑ 19 ᐕᐲ㧧151 ජ౞㧦⽷࿅
ᴺੱጘ㒂⋵⎇ⓥ㐿⊒⽷࿅㧔⚻ᷣ↥ᬺ⋭࿾ၞᣂ↢ࠦࡦ࠰࡯ࠪࠕࡓ⎇ⓥ㐿⊒੐ᬺߦࠃࠆᆔ⸤㧕7㧕 ⮮↰ᑝᔒ㧦↹௝⸻ᢿᡰេᛛⴚߩ⎇ⓥ㐿⊒㧧ᐔᚑ 19 ᐕᐲ㧧200 ජ౞㧦ࠦ࠾ࠞࡒࡁ࡞࠲ࠛࡓࠫ࡯㧔ᩣ㧕
8㧕 ⮮↰ᑝᔒ㧦ක≮⸻ᢿᡰេࠪࠬ࠹ࡓߩ㐿⊒㨪↹௝⸻ᢿᡰេࠪࠬ࠹ࡓߩ㐿⊒㨪㧧ᐔᚑ 20 ᐕᐲ㧧46,779
ජ౞㧦⽷࿅ᴺੱጘ㒂⋵⎇ⓥ㐿⊒⽷࿅㧔ᢥ⑼⋭࿾ၞ⑼ቇᛛⴚᝄ⥝੐ᬺ⾌⵬ഥ㊄㧔⍮⊛ࠢ࡜ࠬ࠲࡯ഃᚑ
੐ᬺ㧦ጘ㒂࡮ᄢ၂࿾ၞ‫ࠢ࠶ࠖ࠹ࡏࡠޟ‬వ┵ක≮ࠢ࡜ࠬ࠲࡯‫ޠ‬㧕ߦࠃࠆᆔ⸤㧕9㧕 ⮮↰ᑝᔒ㧦↹௝⸻ᢿᡰេᛛⴚߩ⎇ⓥ㐿⊒㧧ᐔᚑ 20 ᐕᐲ㧧300 ජ౞㧦ࠦ࠾ࠞࡒࡁ࡞࠲ࠛࡓࠫ࡯㧔ᩣ㧕
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫ
1㧕 ⮮↰ᑝᔒ㧘ਛᎹବ᣿㧘ᨋ ૫ౖ㧦↹௝⸃ᨆࠪࠬ࠹ࡓ߅ࠃ߮↹௝⸃ᨆࡊࡠࠣ࡜ࡓ(⊒᣿)㧧ᐔᚑ 18 ᐕᐲ(․
㗿 2006-33562)
2㧕 ⮮↰ᑝᔒ㧘ਛᎹବ᣿㧘ᨋ ૫ౖ㧦↹௝ಣℂⵝ⟎߅ࠃ߮↹௝ಣℂࡊࡠࠣ࡜ࡓ(⊒᣿)㧧ᐔᚑ 18 ᐕᐲ(․㗿
2006-82323)
3㧕 ⮮↰ᑝᔒ㧘⑔ጟᄢテ㧘ේ ᱞผ㧦ක↪േ↹௝ߦࠃࠆ↹௝⸻ᢿࠪࠬ࠹ࡓ(⊒᣿)㧧ᐔᚑ 18 ᐕᐲ(․㗿
2006-83221)
4㧕 ⮮↰ᑝᔒ㧘ౝጊ⦟৻㧘ੑ᧛ ੳ㧦ක↪↹௝ಣℂⵝ⟎෸߮ࡊࡠࠣ࡜ࡓ(⊒᣿)㧧ᐔᚑ 18 ᐕᐲ(․㗿
2006-83950)
5㧕 ⮮↰ᑝᔒ㧘ਛᎹବ᣿㧘ᨋ ૫ౖ㧦↹௝⸃ᨆࠪࠬ࠹ࡓ‫↹߮ࠃ߅ޔ‬௝⸃ᨆࡊࡠࠣ࡜ࡓ(⊒᣿)㧧ᐔᚑ 18 ᐕᐲ(․㗿 2006-196322)
6㧕 ⮮↰ᑝᔒ㧘ਛᎹବ᣿㧘ᨋ ૫ౖ㧦↹௝⸃ᨆࠪࠬ࠹ࡓ‫↹߮ࠃ߅ޔ‬௝⸃ᨆࡊࡠࠣ࡜ࡓ(⊒᣿)㧧ᐔᚑ 18 ᐕᐲ(․㗿 2006-196323)
7㧕 ⮮↰ᑝᔒ㧘ౝጊ⦟৻㧘ጤ㑆 ੧㧘቟⮮ᒄ㆏㧘ੑ᧛ ੳ㧦ක↪↹௝ಣℂⵝ⟎(⊒᣿)㧧ᐔᚑ 18 ᐕᐲ(PCT/JP2006/316595㧦․㗿 2007-533204)8㧕 ⮮↰ᑝᔒ㧘ਛᎹବ᣿㧘ᨋ ૫ౖ㧦↹௝᠟ᓇⵝ⟎෸߮↹௝⸃ᨆࡊࡠࠣ࡜ࡓ(⊒᣿)㧧ᐔᚑ 18 ᐕᐲ(․㗿
2006-243484)
9㧕 ⮮↰ᑝᔒ㧘ਛᎹବ᣿㧘ᨋ ૫ౖ㧦↹௝᠟ᓇⵝ⟎෸߮↹௝⸃ᨆࡊࡠࠣ࡜ࡓ(⊒᣿)㧧ᐔᚑ 18 ᐕᐲ(․㗿㧙㧙2006-243485)
10㧕 ⮮↰ᑝᔒ㧘ਛᎹବ᣿㧘ᨋ ૫ౖ㧦↹௝⸃ᨆࠪࠬ࠹ࡓ߅ࠃ߮↹௝⸃ᨆࡊࡠࠣ࡜ࡓ(⊒᣿)㧧ᐔᚑ 18 ᐕᐲ(․
㗿 2006-255243)
11㧕 ⮮↰ᑝᔒ㧘ਛᎹବ᣿㧘ᨋ ૫ౖ㧦↹௝⸃ᨆࠪࠬ࠹ࡓ߅ࠃ߮↹௝⸃ᨆࡊࡠࠣ࡜ࡓ(⊒᣿)㧧ᐔᚑ 18 ᐕᐲ(PCT/JP2006/318761)
12㧕 ⮮↰ᑝᔒ㧘ౝጊ⦟৻㧘ੑ᧛ ੳ㧦ක↪↹௝ಣℂⵝ⟎‫↹ޔ‬௝ಣℂᣇᴺ෸߮ࡊࡠࠣ࡜ࡓ(⊒᣿)㧧ᐔᚑ 18
ᐕᐲ(․㗿 2006-257617)
13㧕 ⮮↰ᑝᔒ㧘ౝጊ⦟৻㧘ੑ᧛ ੳ㧦ක↪↹௝ಣℂⵝ⟎‫ޔ‬ක↪↹௝ಣℂᣇᴺ෸߮ࡊࡠࠣ࡜ࡓ(⊒᣿)㧧ᐔᚑ
18 ᐕᐲ(․㗿 2006-257695)
14㧕 ⮮↰ᑝᔒ㧘⑔ጟᄢテ㧘ේ ᱞผ㧘ട⮮ᕺม㧦⿥㖸ᵄ੃ᚱ⸻ᢿࠪࠬ࠹ࡓ(⊒᣿)㧧ᐔᚑ 18 ᐕᐲ(․㗿
2006-257169)
15㧕 ⮮↰ᑝᔒ㧘ਛᎹବ᣿㧘ᨋ ૫ౖ㧦↹௝⸃ᨆࠪࠬ࠹ࡓ߅ࠃ߮↹௝⸃ᨆࡊࡠࠣ࡜ࡓ(⊒᣿)㧧ᐔᚑ 18 ᐕᐲ(․
㗿 2006-260340)
16㧕 ⮮↰ᑝᔒ㧘ਛᎹବ᣿㧘ᨋ ૫ౖ㧦↹௝ಣℂⵝ⟎߅ࠃ߮↹௝ಣℂࡊࡠࠣ࡜ࡓ(⊒᣿)㧧ᐔᚑ 18 ᐕᐲ(PCT/JP2006/318912)
17㧕 ⮮↰ᑝᔒ㧘ਛᎹବ᣿㧘ᨋ ૫ౖ㧦↹௝⸃ᨆࠪࠬ࠹ࡓ‫↹߮ࠃ߅ޔ‬௝⸃ᨆࡊࡠࠣ࡜ࡓ(⊒᣿)㧧ᐔᚑ 18 ᐕ
ᐲ(PCT/JP2006/318911)
18㧕 ⮮↰ᑝᔒ㧘ਛᎹବ᣿㧘ᨋ ૫ౖ㧦↹௝⸃ᨆࠪࠬ࠹ࡓ‫↹߮ࠃ߅ޔ‬௝⸃ᨆࡊࡠࠣ࡜ࡓ(⊒᣿)㧧ᐔᚑ 18 ᐕ
ᐲ(PCT/JP2006/318910)
19㧕 ⮮↰ᑝᔒ㧘⑔ጟᄢテ㧘ේ ᱞผ㧘ട⮮ᕺม㧘ᨋ ૫ౖ㧦⿥㖸ᵄ੃ᚱ⸻ᢿࠪࠬ࠹ࡓ(⊒᣿)㧧ᐔᚑ 18 ᐕᐲ(․㗿 2006-257170)
20㧕 ⮮↰ᑝᔒ㧘⑔ጟᄢテ㧘ේ ᱞผ㧘ട⮮ᕺม㧘ᨋ ૫ౖ㧦⿥㖸ᵄ੃ᚱ⸻ᢿࠪࠬ࠹ࡓ(⊒᣿)㧧ᐔᚑ 18 ᐕ
ᐲ(PCT/JP2006/319165)
21㧕 ⮮↰ᑝᔒ㧘⑔ጟᄢテ㧘ේ ᱞผ㧘ട⮮ᕺม㧦⿥㖸ᵄ੃ᚱ⸻ᢿࠪࠬ࠹ࡓ(⊒᣿)㧧ᐔᚑ 18 ᐕᐲ(PCT/JP2006/319164)
22㧕 ⮮↰ᑝᔒ㧘ౝጊ⦟৻㧘ੑ᧛ ੳ㧦ක↪↹௝ಣℂⵝ⟎‫↹ޔ‬௝ಣℂᣇᴺ෸߮ࡊࡠࠣ࡜ࡓ(⊒᣿)㧧ᐔᚑ 18
ᐕᐲ(PCT/JP2006/319304)
23㧕 ⮮↰ᑝᔒ㧘ౝጊ⦟৻㧘ੑ᧛ ੳ㧦⺒ᓇᡰេⵝ⟎‫⺒ޔ‬ᓇᡰេᣇᴺ෸߮ࡊࡠࠣ࡜ࡓ(⊒᣿)㧧ᐔᚑ 18 ᐕᐲ(․
㗿 2006-262257)24㧕 ⮮↰ᑝᔒ㧘⑔ጟᄢテ㧘ේ ᱞผ㧘ട⮮ᕺม㧦੃ᚱ↹௝⸻ᢿࠪࠬ࠹ࡓ(⊒᣿)㧧ᐔᚑ 18 ᐕᐲ(․㗿
2006-268087)
25㧕 ⮮↰ᑝᔒ㧘ਛᎹବ᣿㧘㋈ᧁቁ૫㧦↹௝ಣℂⵝ⟎(⊒᣿)㧧ᐔᚑ 19 ᐕᐲ(․㗿 2007-41792)26㧕 ⮮↰ᑝᔒ㧘ਛᎹବ᣿㧘ᨋ ૫ౖ㧦⌒ᐩ↹௝⹺⸽ⵝ⟎෸߮⌒ᐩ↹௝⹺⸽ࡊࡠࠣ࡜ࡓ(⊒᣿)㧧ᐔᚑ 19 ᐕᐲ(․㗿 2007-48691)
27㧕 ⮮↰ᑝᔒ㧘ਛᎹବ᣿㧘ᨋ ૫ౖ㧦↹௝⸃ᨆࠪࠬ࠹ࡓ‫ޔ‬෸߮↹௝⸃ᨆࡊࡠࠣ࡜ࡓ(⊒᣿)㧧ᐔᚑ 19 ᐕᐲ(․
㗿 2007-62899)
28㧕 ⮮↰ᑝᔒ㧘ਛᎹବ᣿㧘ᨋ ૫ౖ㧦↹௝⸃ᨆࠪࠬ࠹ࡓ‫ޔ‬෸߮↹௝⸃ᨆࡊࡠࠣ࡜ࡓ(⊒᣿)㧧ᐔᚑ 19 ᐕᐲ(․
㗿 2007-86828)
29㧕 ⮮↰ᑝᔒ㧘ਛᎹବ᣿㧘ᨋ ૫ౖ㧦↹௝⸃ᨆࠪࠬ࠹ࡓ‫ޔ‬෸߮↹௝⸃ᨆࡊࡠࠣ࡜ࡓ(⊒᣿)㧧ᐔᚑ 19 ᐕᐲ(․
㗿 2007-86829)
30㧕 ⮮↰ᑝᔒ㧘ਛᎹବ᣿㧘ᨋ ૫ౖ㧦⌒ᐩᬌᩏ↹௝⸃ᨆࠪࠬ࠹ࡓ‫ޔ‬෸߮⌒ᐩᬌᩏ↹௝⸃ᨆࡊࡠࠣ࡜ࡓ(⊒᣿)㧧ᐔᚑ 19 ᐕᐲ(․㗿 2007-188419)
31㧕 ⮮↰ᑝᔒ㧘⑔ጟᄢテ㧘ේ ᱞผ㧘ട⮮ᕺม㧘㚍ᧁᷡ㓉㧦⿥㖸ᵄ੃ᚱ⸻ᢿᡰេࠪࠬ࠹ࡓ(⊒᣿)㧧ᐔᚑ
20 ᐕᐲ(․㗿 2008-72795)
32㧕 ⮮↰ᑝᔒ㧘⑔ጟᄢテ㧘ේ ᱞผ㧘ട⮮ᕺม㧘㚍ᧁᷡ㓉㧦⿥㖸ᵄ⸻ᢿᡰេࠪࠬ࠹ࡓ(⊒᣿)㧧ᐔᚑ 20 ᐕᐲ(․㗿 2008-72796)
33㧕 ⮮↰ᑝᔒ㧘ౝጊ⦟৻㧦ක↪↹௝ಣℂⵝ⟎෸߮⇣Ᏹ㒶ᓇᬌ಴ᣇᴺ(⊒᣿)㧧ᐔᚑ 20 ᐕᐲ(․㗿 2008-75961)
34㧕 ⮮↰ᑝᔒ㧘ਛᎹବ᣿㧘ᨋ ૫ౖ㧦↹௝⸃ᨆࠪࠬ࠹ࡓ‫ޔ‬෸߮↹௝⸃ᨆࡊࡠࠣ࡜ࡓ(⊒᣿)㧧ᐔᚑ 20 ᐕᐲ(PCT/JP2008/054272)

㧙㧙6㧚ቇળᵴേ
1㧕ቇળᓎຬ⮮↰ᑝᔒ㧦
1㧕 ᣣᧄක↪↹௝Ꮏቇળᐙ੐(㨪⃻࿷)2㧕 ᣣᧄ੃⣼࡮↲⁁⣼⿥㖸ᵄ⸻ᢿળ⼏ᐙ੐(㨪⃻࿷)3㧕 ᣣᧄ੃≸↹௝⎇ⓥળ࠺ࠫ࠲࡞ಽ⑼ળᆔຬ(㨪⃻࿷)4㧕 ࠦࡦࡇࡘ࡯࠲ᡰេ↹௝⸻ᢿቇળ೽ળ㐳(㨪ᐔᚑ 20 ᐕ 9 ᦬)
5㧕 㔚ሶᖱႎㅢାቇળක↪↹௝⎇ⓥળ೽ኾ㐷ᆔຬ㐳(㨪ᐔᚑ 19 ᐕ 5 ᦬)
6㧕 ක↪↹௝ᖱႎቇળળ㐳(㨪⃻࿷)7㧕 Computer Assisted Radiology and Surgery (CARS 2006), Program Committee member(㨪ᐔᚑ 18
ᐕ 6 ᦬)
8㧕 ᣣᧄක↪↹௝Ꮏቇળ JAMIT ᄢળ 2006 ࡊࡠࠣ࡜ࡓᆔຬ(ᐔᚑ 18 ᐕ 1 ᦬㨪ᐔᚑ 18 ᐕ 7 ᦬)
9㧕 6th Symposium of the Scandinavian Japan Radiological Society and 9th Nordic Japan PACS
Symposium, Scientific Advisory Board member (ᐔᚑ 18 ᐕ 1 ᦬㨪ᐔᚑ 18 ᐕ 9 ᦬)
10㧕 ᣣᧄ᡼኿✢ᛛⴚቇળ⹏⼏ຬ(ᐔᚑ 18 ᐕ 4 ᦬㨪ᐔᚑ 20 ᐕ 4 ᦬)
11㧕 ᣣᧄࠬࠞࡦࠫ࠽ࡆࠕ᡼኿✢කቇදળᐙ੐(ᐔᚑ 18 ᐕ 4 ᦬㨪⃻࿷)12㧕 ᣣᧄ੃≸ᬌ⸻ቇળ ╙ 16 ࿁✚ળࡊࡠࠣ࡜ࡓᆔຬ(ᐔᚑ 18 ᐕ 4 ᦬㨪ᐔᚑ 18 ᐕ 11 ᦬)
13㧕 International Workshop on Digital Mammography 2008, Scientific Committee member(ᐔᚑ 18
ᐕ 7 ᦬㨪ᐔᚑ 20 ᐕ 7 ᦬)
14㧕 Medical Imaging and Informatics (MIMI 2007), International Program Committee member(ᐔᚑ18 ᐕ 10 ᦬㨪ᐔᚑ 19 ᐕ 8 ᦬)
15㧕 Computer Assisted Radiology and Surgery (CARS 2007), Program Committee member(ᐔᚑ 18
ᐕ 12 ᦬㨪ᐔᚑ 19 ᐕ 6 ᦬)
16㧕 ᣣᧄක↪↹௝Ꮏቇળ JAMIT ᄢળ 2007 ࡊࡠࠣ࡜ࡓᆔຬ(ᐔᚑ 19 ᐕ 1 ᦬㨪ᐔᚑ 19 ᐕ 7 ᦬)
17㧕 ᣣᧄ↢૕කᎿቇળઍ⼏ຬ(ᐔᚑ 19 ᐕ 4 ᦬㨪⃻࿷)18㧕 㔚ሶᖱႎㅢାቇળක↪↹௝⎇ⓥળኾ㐷ᆔຬ㐳(ᐔᚑ 19 ᐕ 5 ᦬㨪⃻࿷)19㧕 Computer Assisted Radiology and Surgery (CARS 2008), Program Committee member(ᐔᚑ 19
ᐕ 12 ᦬㨪ᐔᚑ 20 ᐕ 6 ᦬)
20㧕 ጘ㒂᧲ᵗකቇ⎇ⓥળ਎⹤ੱ(ᐔᚑ 19 ᐕ 12 ᦬㨪⃻࿷)21㧕 SPIE Medical Imaging 2009 meeting(2009.2 in Kissimmee, Florida) Program committee
member(ᐔᚑ 20 ᐕ 5 ᦬㨪⃻࿷)22㧕 ᣣᧄ੃≸↹௝⎇ⓥળ࠺ࠫ࠲࡞ࡑࡦࡕࠣ࡜ࡈࠖಽ⑼ળ࡮࠺ࠫ࠲࡞ࡑࡦࡕࠣ࡜ࡈࠖ♖ᐲ▤ℂࡑ࠾ࡘࠕ࡞
૞ᚑࡢ࡯ࠠࡦࠣࠣ࡞࡯ࡊᆔຬ(ᐔᚑ 20 ᐕ 8 ᦬㨪⃻࿷)23㧕 International Forum on Medical Imaging in Asia 2009, Advisory Board member(ᐔᚑ 20 ᐕ 9 ᦬㨪⃻࿷)
24㧕 Computer Assisted Radiology and Surgery (CARS 2009), Program Committee member(ᐔᚑ 20
ᐕ 12 ᦬㨪⃻࿷)25㧕 ๭ๆᯏ⢻ࠗࡔ࡯ࠫࡦࠣ⎇ⓥળ਎⹤ੱ(ᐔᚑ 20 ᐕ 12 ᦬㨪⃻࿷)26㧕 ᣣᧄක↪↹௝Ꮏቇળ JAMIT ᄢળ 2009 ࡊࡠࠣ࡜ࡓᆔຬ(ᐔᚑ 20 ᐕ 12 ᦬㨪⃻࿷)ේ ᱞผ㧦
1㧕 ᣣᧄ᡼኿✢ᛛⴚቇળ↹௝ಽ⑼ળᆔຬ(㨪⃻࿷)2㧕 ක↪↹௝ᖱႎቇળᏱോℂ੐(㨪ᐔᚑ 20 ᐕ 5 ᦬)
3㧕 㔚ሶᖱႎㅢାቇળක↪↹௝⎇ⓥળኾ㐷ᆔຬ(㨪ᐔᚑ 19 ᐕ 5 ᦬)
4㧕 㔚ሶᖱႎㅢାቇળක↪↹௝⎇ⓥળᐙ੐⵬૒(ᐔᚑ 19 ᐕ 5 ᦬㨪⃻࿷)5㧕 ක↪↹௝ᖱႎቇળℂ੐(ᐔᚑ 20 ᐕ 5 ᦬㨪⃻࿷)๟ ะᩕ㧦
1㧕 International Forum on Medical Imaging in Asia 2009, Program Committee member(ᐔᚑ 20 ᐕ 9᦬㨪⃻࿷)2㧕 㔚ሶᖱႎㅢାቇળ 2009 ᐕ✚วᄢળࡊࡠࠣ࡜ࡓ✬ᚑᆔຬ(ᐔᚑ 20 ᐕ 12 ᦬㨪⃻࿷)㧙㧙

2㧕ቇળ㐿௅⮮↰ᑝᔒ㧦
1㧕 Asian Forum on Medical Imaging 2007 ᄢળ㐳(ᐔᚑ 19 ᐕ 1 ᦬㧘ᷣᎺፉ㧘㖧࿖)
3㧕ቇⴚ㔀⹹⮮↰ᑝᔒ㧦
1㧕 ࠦࡦࡇࡘ࡯࠲ᡰេ↹௝⸻ᢿቇળ✬㓸ᆔຬ㐳(㨪ᐔᚑ 20 ᐕ 9 ᦬)
2㧕 ᣣᧄ᡼኿✢ᛛⴚቇળ⧷⺆⺰ᢥ⹹✬㓸ᆔຬળᆔຬ(ᐔᚑ 19 ᐕ 4 ᦬㨪ᐔᚑ 20 ᐕ 4 ᦬)
3㧕 㔚ሶᖱႎㅢାቇળ࡮๺ᢥ⺰ᢥ⹹✬㓸ᆔຬળ࡮ක↪↹௝․㓸ภ✬㓸೽ᆔຬ㐳(ᐔᚑ 19 ᐕ 9 ᦬㨪ᐔᚑ 20ᐕ 7 ᦬)
ේ ᱞผ㧦
1㧕 ᣣᧄ᡼኿✢ᛛⴚቇળ✬㓸ᆔຬ(㨪ᐔᚑ 19 ᐕ 2 ᦬)
2㧕 ᣣᧄ᡼኿✢ᛛⴚቇળ✬㓸ડ↹ᆔຬ(ᐔᚑ 19 ᐕ 2 ᦬㨪ᐔᚑ 20 ᐕ 2 ᦬)
3㧕 ක↪↹௝ᖱႎቇળ✬㓸ᆔຬ㐳(㨪ᐔᚑ 20 ᐕ 5 ᦬)
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳⮮↰ᑝᔒ㧦1㧕 ක↪↹௝ㅪวࡈࠜ࡯࡜ࡓ(ᐔᚑ 18 ᐕ 1 ᦬㧘ችฎፉ㧘᜗ᓙ⻠Ṷ‫ޟ‬Clinical Application of Phase Contrast
X-ray‫ޠ‬㧒‫ޟ‬Solid State Thick Film X-ray Image Sensor‫ޠ‬ᐳ㐳)2㧕 ╙ 13 ࿁ Nishiowari Radiological Technology Seminar(2006 ᐕ 2 ᦬㧘৻ች㧘․೎⻠Ṷ‫࡯ࡘࡇࡦࠦޟ‬࠲ᡰេ⸻ᢿ(CAD㧕ߩ⃻⁁ߣ዁᧪‫ޠ‬Ṷ⠪)
3㧕 ᧲ᶏ࿾ၞࠢ࡜ࠬ࠲࡯ࡈࠜ࡯࡜ࡓ(ᐔᚑ 18 ᐕ 3 ᦬㧘ฬฎደ㧘‫ޟ‬ක≮↹௝⸻ᢿᡰេࠪࠬ࠹ࡓߩ੐ᬺൻ‫ޠ‬Ṷ⠪)‫࡜ࠣࡕࡦࡑ࡞࠲ࠫࠖ࠺ޟ‬4㧕 ᣣᧄ᡼኿✢ᛛⴚቇળቇⴚᄢળ࡮╙ 59 ࿁↹௝ಽ⑼ળ(ᐔᚑ 18 ᐕ 4 ᦬㧘ᮮᵿ㧘ࡈࠖ⎇ⓥ߳ߩᦼᓙߣ⺖㗴‫ޠ‬Ṷ⠪)5㧕 Neusoft Research in Northeastern University(2006.05, Shenyang, Development ofcomputer-aided diagnosis in Japan and at Fujita Lab.; Invited speaker)
6㧕 20th. International congress and exhibition of computer assisted radiology and surgery,CARS2006(2006.06, Osaka, Development of breast CAD and its clinical applications in Japan;
Invited speaker㧕
7㧕 2nd. International symposium on future CAD(2006.07, Osaka, Digital representation ofdiagnostic knowledge: Anatomical structure in human torso region; Speaker)
8㧕 ╙ 10 ࿁ጘ㒂ࠪࡦࡐࠫ࠙ࡓ‫ޡ‬IT ߣࡠࡏ࠶࠻ߢ⸻ࠆ࡮ᴦߔ̆ࡠࡏ࠹ࠖ࠶ࠢవ┵ක≮‫(ޢ‬ᐔᚑ 18 ᐕ 7 ᦬㧘ጘ㒂㧘‫∛ޟ‬ᄌ⊒⷗ߢฬකߦߖ߹ࠆ㧍㧙ࠦࡦࡇࡘ࡯࠲߇↹௝⸻ᢿࠍᡰេߒ߹ߔ㧙‫ޠ‬Ṷ⠪㧘ᐳ㐳)9㧕 ╙ 2 ࿁ᣣᧄ᡼኿✢ᛛⴚቇળ࡮ᣣᧄ౮⌀ቇળ౒ห㐿௅ࠪࡦࡐࠫ࠙ࡓ(ᐔᚑ 18 ᐕ 7 ᦬㧘ᄢ㒋㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ‫੃ޟ‬ᚱ↹௝ߩࡕ࠾࠲࡯⸻ᢿߩ⃻⁁ߣ዁᧪‫ޠ‬ᐳ㐳)‫ޟ‬਎⇇ߣᣣ
10㧕 ╙ 25 ࿁ᣣᧄක↪↹௝Ꮏቇળᄢળࠪࡦࡐࠫ࠙ࡓ‫ޟ‬CAD ߩᣂዷ㐿‫(ޠ‬ᐔᚑ 18 ᐕ 7 ᦬㧘੩ㇺ㧘ᧄߦ߅ߌࠆ CAD ߩ⃻⁁㧔✚᜝㧕‫ޠ‬Ṷ⠪)
11㧕 World congress on medical physics and biomedical engineering 2006, CAD workshop on “Toward
the realization of computer aided diagnosis in patient care: Experiences and future role ofacademic institutions and industry”(2006.08, Seoul, Recent CAD research projects in Japan,
Speaker & Chair)12㧕 6th Symposium of the Scandinavian Japan radiological society (2006.09, Stockholm, Opening
lecture: CAD in Japan; Speaker)
13㧕 ᣣᧄ᡼኿✢ᛛⴚቇળ╙ 22 ࿁ࠦࡦࡇࡘ࡯࠲ᡰេ⸻ᢿ㧔CAD㧕࠮ࡒ࠽࡯㧦ਛ⚖✬(ᐔᚑ 18 ᐕ 9 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬Recent CAD research projects in Japan‫ޠ‬Ṷ⠪)
14㧕 MeVis at the University of Bremen(2006.10, Bremen, Invited lecture based on a guest
professorship: Overview of CAD research at Fujita Lab. in Gifu University; Speaker)
15㧕 ╙ 15 ࿁ᣣᧄࠦࡦࡇࡘ࡯࠲ᄖ⑼ቇળᄢળ࡮╙ 16 ࿁ࠦࡦࡇࡘ࡯࠲ᡰេ↹௝⸻ᢿቇળᄢળ(ᐔᚑ 18 ᐕ 10᦬㧘᧲੩㧘วหࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ጘ㒂࡮ᄢ၂࿾ၞ ࡠࡏ࠹ࠖ࠶ࠢవ┵ක≮ࠢ࡜ࠬ࠲࡯ߩ⃻⁁ߣ዁᧪‫ޠ‬㧘‫↹ޟ‬௝⸻ᢿᡰេࠪࠬ࠹ࡓߩ㐿⊒‫ޠ‬Ṷ⠪㧘ᐳ㐳)16㧕 ㊄ᴛᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼଻ஜቇኾ᡹‫ޟ‬㝯ജ޽ࠆᄢቇ㒮ᢎ⢒ࠗ࠾ࠪࠕ࠹ࠖࡉ FD ࡈࠜ࡯࡜ࡓ‫(ޠ‬ᐔ㧙㧙ᚑ 18 ᐕ 12 ᦬㧘㊄ᴛ㧘‫ޟ‬ቇ㓙⊛⎇ⓥࡊࡠࠫࠚࠢ࠻ߦࠃࠆੱ᧚⢒ᚑ‫⻠ޠ‬Ṷ)17㧕 State-of-the-art on computer-aided diagnosis: Past, present, and future(2007.02, Invited speakerat the Department of Computer Science, the University of South Carolina)
18㧕 Latest research on computer-aided diagnosis in Gifu University (2007.04, ⪇௟ᄢቇ㧘⻠Ṷ)
19㧕 Medical Imaging and Informatics (MIMI 2007)(2007.08, Beijing, Workshop: Computer-aided
diagnosis (CAD), Workshop organizer, chair, and speaker)
20㧕 ╙ 35 ࿁ᣣᧄ᡼኿✢ᛛⴚቇળ⑺ቄቇⴚᄢળ࡮╙ 43 ࿁ᣣᧄකቇ᡼኿✢ቇળ⑺ቄ⥃ᐥᄢળ(ᐔᚑ 19 ᐕ 10᦬㧘ฬฎደ㧘วห․೎⻠Ṷ㧦࠻࡛࠲⥄േゞ㧔ᩣ㧕ᛛ⋙ ᨋ ධ౎ ᳁㧦‫↥↢࠲࡛࠻ޟ‬ᣇᑼߩᧄ⾰ߣㅴൻ(ᷓൻ) -ᬺ⒳ࠍ໧ࠊߕዷ㐿ߢ߈ࠆ㧦TOYOTA WAY-‫ޠ‬มળ)
21㧕 ╙ 17 ࿁ࠦࡦࡇࡘ࡯࠲ᡰេ↹௝⸻ᢿቇળᄢળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ᐢፉ㧘CADM ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬CAD
ߩ⮎੐ᛚ⹺‫ޠ‬ᐳ㐳)22㧕 㔚ሶᖱႎㅢାቇળක↪↹௝⎇ⓥળ㧔MI㧕(ᐔᚑ 19 ᐕ 9 ᦬㧘ඳᄙ㧘․೎⻠Ṷ‫ޟ‬᡼኿శߦࠃࠆකቇࠗࡔ
࡯ࠫࡦࠣ‫ޠ‬ᐳ㐳)23㧕 㔚ሶᖱႎㅢାቇળක↪↹௝⎇ⓥળ㧔MI㧕(ᐔᚑ 19 ᐕ 11 ᦬㧘㊄ᴛ㧘ࡈࠚࡠ࡯⸥ᔨ⻠Ṷ‫ߪ࡞࠻ࠗ࠲ޟ‬↢૕ᯏ⢻⸘᷹ߣߒߡߺ߹ߒߚ‫ޠ‬ᐳ㐳)24㧕 ╙ 17 ࿁ᣣᧄ੃≸ᬌ⸻ቇળ✚ળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ᮮᵿ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬New modality ߦࠃࠆ੃≸ᬌ⸻ߩน⢻ᕈࠍតࠆ‫)࠻ࠬࠫࡐࡦࠪޠ‬25㧕 㔚ሶᖱႎㅢାቇળ࡮ක↪↹௝⎇ⓥળ(ᐔᚑ 20 ᐕ 1 ᦬㧘ᴒ✽㧘․೎⻠Ṷ‫ޟ‬New Approaches for Ultrasonic
Breast Imaging‫ޠ‬෸߮‫ޟ‬Computer-aided Diagnosis for 2D, 3D, and Whole Breast Ultrasound‫ޠ‬มળ)26㧕 ක↪↹௝ᖱႎቇળᐔᚑ 19 ᐕᐲᤐቄ㧔╙ 150 ࿁㧕ᄢળ(ᐔᚑ 20 ᐕ 2 ᦬㧘ᄢ㒋㧘․೎⻠Ṷ‫ޟ‬ක↪↹௝ᖱႎቇળᄢળ 150 ࿁ߩᱠߺ‫ޠ‬ᐳ㐳)27㧕 ╙ 15 ࿁ᣣᧄ CT ᬌ⸻ቇળቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 2 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓΣ‫ޟ‬CAD ߣ CT ᬌ⸻‫ࠪޠ‬ࡦࡐࠫࠬ࠻)
28㧕 ╙ 11 ࿁ Radiology Update ⻠Ṷળ(ᐔᚑ 20 ᐕ 3 ᦬㧘ᄢ㒋㧘᜗ᓙ⻠Ṷ‫↹ޟ‬௝⸻ᢿߦ߅ߌࠆࠦࡦࡇࡘ࡯
࠲ᡰេ⸻ᢿ㧔CAD㧦Computer-aided diagnosis)ߩ⃻⁁ߣ዁᧪‫ޠ‬Ṷ⠪㧕29㧕 ╙ 64 ࿁ᣣᧄ᡼኿✢ᛛⴚቇળ✚ળቇⴚᄢળ(ᐔᚑ 20 ᐕ 4 ᦬㧘ᮮᵿ㧘ᢎ⢒⻠Ṷ‫ޟ‬ᬌ⸻ߦ߅ߌࠆ CAD‫ޠ‬Ṷ⠪)
30㧕 ᣣᧄ᡼኿✢ᛛⴚቇળ╙ 63 ࿁↹௝ಽ⑼ળ(ᐔᚑ 20 ᐕ 4 ᦬㧘ᮮᵿ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬⢷ㇱࠦࡦࡇࡘ࡯࠲ᡰ
េ⸻ᢿ㧔CAD)ߩ㜞ᐲൻߣ዁᧪‫࠻ࠬࠫࡐࡦࠪޠ‬㧕31㧕 ක↪↹௝ᖱႎᴺቇળᐔᚑ 20 ᐕᐲᐕᰴ㧔╙ 151 ࿁㧕ᄢળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ጘ㒂㧘ᛛⴚ࠮ࡒ࠽࡯ᐳ㐳)32㧕 ╙ 10 ࿁ᾢᧄ↹௝⸻ᢿ࠹ࠢࡁࡠࠫ࡯⎇ⓥળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ᾢᧄ㧘․೎⻠Ṷ‫࠲࡯ࡘࡇࡦࠦޟ‬ᡰេ⸻ᢿߩ⃻⁁ߣ⺖㗴‫ޠ‬Ṷ⠪)33㧕 MI ⎇(ᐔᚑ 20 ᐕ 7 ᦬㧘ᧅᏻ㧘․೎⻠Ṷ‫ޟ‬ᖱႎࡀ࠶࠻ࡢ࡯ࠢߦࠃࠆ࿾ၞක≮ࠨࡐ࡯࠻‫ޠ‬ᐳ㐳)34㧕 ᣣᧄ੃≸↹௝⎇ⓥળ╙ 10 ࿁࠺ࠫ࠲࡞ࡑࡦࡕࠣ࡜ࡈࠖಽ⑼ળ(ᐔᚑ 20 ᐕ 8 ᦬㧘ฬฎደ㧘․೎⻠Ṷ‫ޟ‬ን჻ࡈࠗ࡞ࡓߩ⋥ធᄌ឵ᣇᑼ࠺ࠫ࠲࡞ࡑࡦࡕࠣ࡜ࡈࠖߦߟ޿ߡ‫ޠ‬มળ)35㧕 ╙ 28 ࿁ක≮ᖱႎቇㅪวᄢળ㧔╙ 9 ࿁ᣣᧄක≮ᖱႎቇⴚᄢળ㧕(ᐔᚑ 20 ᐕ 11 ᦬㧘ᮮᵿ㧘ࠪࡦࡐࠫ࠙
ࡓ‫ޟ‬CAD ታ↪ൻߩ⃻⁁ߣ዁᧪ዷᦸ‫ޠ‬Ṷ⠪)ේ ᱞผ㧦
1㧕 ᣣᧄ᡼኿✢ᛛⴚቇળቇⴚᄢળ(ᐔᚑ 18 ᐕ 4 ᦬㧘ᮮᵿ㧘ࡕ࡯࠾ࡦࠣ࠮ࡒ࠽࡯‫࠲࡯ࡘࡇࡦࠦޟ‬ᡰេ⸻ᢿߦߟ޿ߡ‫ޠ‬㧘ᐳ㐳)2㧕 ᣣᧄ᡼኿✢ᛛⴚቇળቇⴚᄢળ(ᐔᚑ 20 ᐕ 4 ᦬㧘ᮮᵿ㧘ࠪࡦࡐࠫ࠙ࡓ‫ࡦࠝߣࡉࠚ࠙ࠢ࠶ࠖ࠹ࡦࡑ࠮ޟ‬㧘Ṷ⠪)࠻ࡠࠫ࡯ ᖱႎ῜⊒ᤨઍߩ㆏ᮡ‫ޠ‬๟ ะᩕ㧦
1㧕 ╙ਃ࿁․ቯ㗔ၞ‫ޟ‬⍮⊛↹௝⸻ᢿᡰេ‫(ࡓ࠙ࠫࡐࡦࠪޠ‬ᐔᚑ 18 ᐕ 1 ᦬㧘੩ㇺ㧘ᱜᏱ᭴ㅧߩℂ⸃ߦၮߠߊ⍮⊛ CAD㧙⎇ⓥᚑᨐ᭎ⷐ̆㧘Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ1㧕 Hara T, Fujita H, et al.: SPIE Medical Imaging 2006 ߦ߅޿ߡ Honorable Mention Poster Award⾨(ᐔᚑ 18 ᐕ 2 ᦬)
2㧕 Zhou X, Hara T, Fujita H, et al.: 2006 ᐕർ☨කቇ᡼኿✢ቇળ㧔RSNA2006㧕ߩ Education Exhibit㧙㧙Excellence in Design ⾨(ᐔᚑ 18 ᐕ 11 ᦬)
3㧕 Hara T, Fujita H, et al. : Cum Laude Poster Award (SPIE Medical Imaging 2007 Symposium) (ᐔᚑ 19 ᐕ 2 ᦬)
4㧕 Hara T, Fujita H, et al. : Honorable Mention Poster Award (SPIE Medical Imaging 2007
Symposium) (ᐔᚑ 19 ᐕ 2 ᦬)
5㧕 ේ ᱞผ㧘⮮↰ᑝᔒ㧘ઁ㧦╙ 63 ࿁ᣣᧄ᡼኿✢ᛛⴚቇળ✚ળቇⴚᄢળߦ߅޿ߡ㊄⾨㧔㔚ሶࡐࠬ࠲㧕(ᐔᚑ 19 ᐕ 4 ᦬)
6㧕 ේ ᱞผ㧘⮮↰ᑝᔒ㧘ઁ㧦╙ 64 ࿁ᣣᧄ᡼኿✢ᛛⴚቇળ✚ળቇⴚᄢળߦ߅޿ߡ㌃⾨㧔㔚ሶࡐࠬ࠲㧕(ᐔᚑ 19 ᐕ 4 ᦬)
7㧕 ේ ᱞผ㧘⮮↰ᑝᔒ㧘ઁ㧦ක↪↹௝ᖱႎቇળ ౝ↰⺰ᢥ⾨(ᐔᚑ 19 ᐕ 6 ᦬)
8㧕 ේ ᱞผ㧘๟ ะᩕ㧘ઁ㧦ක↪↹௝ᖱႎቇળ ㊄᫪ᅑബ⾨(ᐔᚑ 19 ᐕ 6 ᦬)
9㧕 ๟ ะᩕ㧘ේ ᱞผ㧘⮮↰ᑝᔒ㧘ઁ㧦㔚ሶᖱႎㅢାቇળ࡮ቇⴚᅑബ⾨㧔2007 ᐕ㔚ሶᖱႎㅢାቇળ✚ળᄢળ⻠Ṷߦኻߒߡ㧕(ᐔᚑ 20 ᐕ 3 ᦬)
10㧕 ⮮↰ᑝᔒ㧦ᣣᧄ᡼኿✢ᛛⴚቇળ࡮ቇⴚ⾨(ᐔᚑ 20 ᐕ 4 ᦬)
11㧕 Hara T, Fujita H, et al.: 2008 ᐕർ☨කቇ᡼኿✢ቇળ㧔RSNA2008㧕ߩ Education Exhibit ߦ߅޿ߡ‫ޟ‬Certificate of Merit‫(⾨ޠ‬ᐔᚑ 20 ᐕ 12 ᦬)
9㧚␠ળᵴേ
⮮↰ᑝᔒ㧦
1㧕 ⽷࿅ᴺੱ ጘ㒂⋵⎇ⓥ㐿⊒⽷࿅ ⍮⊛ࠢ࡜ࠬ࠲࡯ഃᚑ੐ᬺ ጘ㒂࡮ᄢ၂࿾ၞߦ߅ߌࠆ⍮⊛ࠢ࡜ࠬ࠲࡯ផ
ㅴળ⼏ᆔຬ(㨪ᐔᚑ 20 ᐕᐲ)
2㧕 ⽷࿅ᴺੱ ጘ㒂⋵⎇ⓥ㐿⊒⽷࿅ ⍮⊛ࠢ࡜ࠬ࠲࡯ഃᚑ੐ᬺ ጘ㒂࡮ᄢ၂࿾ၞߦ߅ߌࠆ⍮⊛ࠢ࡜ࠬ࠲࡯⍮⊛⽷↥ᚢ⇛ળ⼏ᆔຬ(ᐔᚑ 18 ᐕᐲ㨪ᐔᚑ 20 ᐕᐲ)
3㧕 ⽷࿅ᴺੱ ጘ㒂⋵⎇ⓥ㐿⊒⽷࿅ ᐔᚑ 18 ᐕᐲ࿾ၞᣂ↢ࠦࡦ࠰࡯ࠪࠕࡓ⎇ⓥ㐿⊒੐ᬺ㧔⌒ᐩ┙૕↹௝ࠍ↪޿ߚ⌒⑼ஜᐽ⸻ᢿᡰេࠪࠬ࠹ࡓߩ㐿⊒㧕ᆔຬળ㧔⌒ᐩ↹௝⸻ᢿ㐿⊒ᆔຬળ㧕ᆔຬ(ᐔᚑ 18 ᐕ 9᦬㨪ᐔᚑ 19 ᐕᐲ)ේ ᱞผ㧦
1㧕 ጘ㒂⋵ᢎ⢒ᆔຬળ IT ੱ᧚⢒ᚑࡊࡠࠫࠚࠢ࠻ㆇ༡ᜰዉᆔຬ(㨪ᐔᚑ 19 ᐕ 3 ᦬)
10㧚ႎ๔ᦠ
1㧕 ⍹၂ᱞ↵㧘ችဈ๺↵㧘⷏⼱ ᒄ㧘દ⮮ᤐᶏ㧘㆙⮮⊓༑ሶ㧘᧛↰༑ઍผ㧘቟⮮ ⵨㧘ዊኹศⴤ㧘ᳰ↰ల㧘ፉᧄ૫ኼᐢ㧘⮮↰ᐢᔒ㧘የㄞ⑲┨㧘ᬮᧄ᣽ᒾ㧘ේ ⋿ດ㧘૒‫ᧁޘ‬ᐽᄦ㧘ᷰㄝ⑲ᐘ㧘ട⮮సᒾ㧦ᮡḰ⊛㔚ሶࠞ࡞࠹ߦ߅ߌࠆ↹௝ⷰኤᶧ᥏ࡕ࠾࠲㧘᳢↪ᶧ᥏ࡕ࠾࠲ߩᮡḰൻߣ♖ᐲ▤ℂߦ㑐ߔࠆ⎇ⓥ㧘
ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄࡮ක≮ᛛⴚ⹏ଔ✚ว⎇ⓥ੐ᬺ㧘ᐔᚑ 15 ᐕᐲ㧙ᐔᚑ 17 ᐕᐲ✚ว⎇ⓥႎ๔ᦠ㧔⍹၂⃰㧕㧦1㧙88(2006 ᐕ 3 ᦬)
2㧕 ⍹၂ᱞ↵㧘ችဈ๺↵㧘⷏⼱ ᒄ㧘㆙⮮⊓༑ሶ㧘᧛↰༑ઍผ㧘቟⮮ ⵨㧘ዊኹศⴤ㧘ᳰ↰ ల㧘ፉᧄ૫ኼᐢ㧘⮮↰ᐢᔒ㧘የㄞ⑲┨㧘ᬮᧄ᣽ᒾ㧘ේ ⋿ດ㧘૒‫ᧁޘ‬ᐽᄦ㧘ᷰㄝ⑲ᐘ㧦ᮡḰ⊛㔚ሶࠞ࡞࠹ߦ
߅ߌࠆ↹௝ⷰኤᶧ᥏ࡕ࠾࠲㧘᳢↪ᶧ᥏ࡕ࠾࠲ߩᮡḰൻߣ♖ᐲ▤ℂߦ㑐ߔࠆ⎇ⓥ㧘ෘ↢ഭ௛⑼ቇ⎇ⓥ
⾌⵬ഥ㊄࡮ක≮ᛛⴚ⹏ଔ✚ว⎇ⓥ੐ᬺ㧘ᐔᚑ 17 ᐕᐲ✚᜝ႎ๔ᦠ㧔⍹၂⃰㧕㧦1㧙51(ᐔᚑ 18 ᐕ 3 ᦬)
3㧕 ✽㊁ ❥㧦࠺ࠫ࠲࡞↹௝ࠍ೑↪ߒߚ⸻ᢿᡰេࠪࠬ࠹ࡓߩ㐿⊒ߣ೑↪ߦ㑐ߔࠆ⎇ⓥ㧔✽㊁ ❥㧘㐳⼱Ꮉ⚐৻㧘ᷡ᳓ᤘિ㧘ᧃ᳗ᐽੳ㧘⮮↰ᐢᔒ㧘ฬข ඳ㧘๺↰⌀৻㧘ੳᧁ ⊓㧘◉ፒ⾫ᴦ㧕㧦ෘ↢ഭ௛⋭
߇ࠎ⎇ⓥഥᚑ㊄ߦࠃࠆ⎇ⓥႎ๔㓸㧔ᐔᚑ 17 ᐕᐲ㧕ᯏ᪾㐿⊒⎇ⓥ㧦467㧙471(ᐔᚑ 18 ᐕ 9 ᦬)
4㧕 ᄢౝᙗ᣿㧦ෘ↢ഭ௛⋭߇ࠎ⎇ⓥഥᚑ㊄ߦࠃࠆ੃߇ࠎᬌ⸻ߩ♖ᐲ෸߮ല₸ะ਄ߦ㑐ߔࠆ⎇ⓥ㧔15-14㧕㧘✚ว⎇ⓥႎ๔㧔ᐔᚑ 15㨪18 ᐕᐲ㧕㧘ಽᜂ㧦⮮↰ᑝᔒ㧦34㧙37㧘102㧙104(2007 ᐕ 3 ᦬)
5㧕 ✽㊁ ❥㧦࠺ࠫ࠲࡞↹௝ࠍ೑↪ߒߚ⸻ᢿᡰេࠪࠬ࠹ࡓߩ㐿⊒ߣ೑↪ߦ㑐ߔࠆ⎇ⓥ㧔✽㊁ ❥㧘㐳⼱Ꮉ⚐৻㧘ᷡ᳓ᤘિ㧘ᧃ᳗ᐽੳ㧘⮮↰ᐢᔒ㧘ฬข ඳ㧘๺↰⌀৻㧘ੳᧁ ⊓㧘◉ፒ⾫ᴦ㧕㧦ෘ↢ഭ௛⋭
߇ࠎ⎇ⓥഥᚑ㊄ߦࠃࠆ⎇ⓥႎ๔㓸㧔ᐔᚑ 18 ᐕᐲ㧕ᯏ᪾㐿⊒⎇ⓥ㧦405㧙409(2007 ᐕ 9 ᦬)
6㧕 ✽㊁ ❥㧦࠺ࠫ࠲࡞↹௝ࠍ೑↪ߒߚ⸻ᢿᡰេࠪࠬ࠹ࡓߩ㐿⊒ߣ೑↪ߦ㑐ߔࠆ⎇ⓥ㧔✽㊁ ❥㧘㐳⼱Ꮉ⚐৻㧘ዊ⇌⑲ᢥ㧘ᷡ᳓ᤘિ㧘ᧃ᳗ᐽੳ㧘ᳰ↰ ల㧘⮮↰ᐢᔒ㧘ฬข ඳ㧘᫪ 㓷᮸㧘๺↰⌀৻㧘ੳᧁ ⊓㧘ጊᧄ⋿ม㧘⑔ፉ㊀ᑝ㧘◉ፒ⾫ᴦ㧕㧦ෘ↢ഭ௛⋭߇ࠎ⎇ⓥഥᚑ㊄ߦࠃࠆ⎇ⓥႎ๔㓸(ᐔᚑ 18ᐕᐲ)ᯏ᪾㐿⊒⎇ⓥ㧦665㧙667(2007 ᐕ 9 ᦬)
7㧕 ⮮↰ᐢᔒ㧘ේ ᱞผ㧘๟ ะᩕ㧘᩿↢ᜏม㧘౗᧻㓷ਯ㧘ᓟ⮮⵨ᄦ㧘ᤊ ඳᤘ㧘᧘ ㎬▸㧘૒੗◊௾㧘㧙㧙⑔ጟᄢテ㧘⇌ਛ⵨ม㧘᧻ේ෹ሶ㧘㆙⮮⊓༑ሶ㧦ᱜᏱ᭴ㅧߩℂ⸃ߦၮߠߊ⍮⊛ CAD㧘II-109-II-121㧘
(2008)㧚
‫ޟ‬ᄙᰴరක↪↹௝ߩ⍮⊛⸻ᢿᡰេ‫ޠ‬㧔㗔ၞ 424㧕㧘ᐔᚑ 15 ᐕᐲ߆ࠄᐔᚑ 18 ᐕᐲ㧘⑼ቇ⎇ⓥ⾌
⵬ഥ㊄㧔․ቯ㗔ၞ⎇ⓥ㧕⎇ⓥᚑᨐႎ๔ᦠ㧘㗔ၞઍ⴫⠪࡮ዊ⇌⑲ᢥ(ᐔᚑ 20 ᐕ 3 ᦬)㧚
8㧕 㐳⼱Ꮉ⚐৻㧦࠺ࠫ࠲࡞↹௝ಣℂߦࠃࠆ߇ࠎ⸻ᢿᡰេࠪࠬ࠹ࡓߩ㐿⊒ߣ೑↪ߦ㑐ߔࠆ⎇ⓥ㧔㐳⼱Ꮉ⚐৻㧘ੳᧁ ⊓㧘⮮↰ᐢᔒ㧘ᷡ᳓ᤘિ㧘᫪ ஜ╷㧘✽㊁ ❥㧘᫪ 㓷᮸㧘◉ፒ⾫ᴦ㧘᧛᧻ᐘ↵㧘᧻ㄼᱜ᮸㧕㧦ෘ↢ഭ௛⋭߇ࠎ⎇ⓥഥᚑ㊄ߦࠃࠆ⎇ⓥႎ๔㓸㧔ᐔᚑ 19 ᐕᐲ㧕ᯏ᪾㐿⊒⎇ⓥ㧦396㧙401 (2008ᐕ 9 ᦬)
9㧕 ⍹ᯅᔘม㧦࠺ࠫ࠲࡞ࡑࡦࡕࠣ࡜ࡈࠖߦࠃࠆ੃߇ࠎᬌ⸻ߩല₸෸߮♖ᐲะ਄࡮⹏ଔߦ㑐ߔࠆ⎇ⓥ㧔⍹㧦ෘ↢ഭ௛⋭߇ࠎ⎇ⓥഥᚑ㊄ߦࠃᯅᔘม㧘ᄢ⽾ᐘੑ㧘ᬀ᧻ቁᖝ㧘᧻ᧄ᡽㓶㧘ౝጊ⩿ᥓሶ㧘ේ ᱞผ㧕ࠆ⎇ⓥႎ๔㓸㧔ᐔᚑ 19 ᐕᐲ㧕⸘↹⎇ⓥ㧦326㧙330(2008 ᐕ 9 ᦬)
11㧚ႎ㆏
1㧕 ⮮↰ᑝᔒ㧦ᦨవ┵ක≮ߩ㝯ജࠍ⚫੺‫ޟ‬IT ߣࡠࡏ࠶࠻ߢ⸻ࠆ࡮ᴦߔ‫ޠ‬㧦⺒ᄁᣂ⡞(2006 ᐕ 7 ᦬ 8 ᣣ)
2㧕 ⮮↰ᑝᔒ㧦੃߇ࠎࠍ⍫ශ⴫␜㧦ࠦࡦࡇࡘ࡯࠲࡯⸻ᢿࠍᚻഥߌ ⿥㖸ᵄ↹௝ಽᨆ㧦⺒ᄁᣂ⡞(2006 ᐕ 7
᦬ 26 ᣣ)3㧕 ේ ᱞผ㧦ᄢ๺⸽೛ࡋ࡞ࠬ⽷࿅ ᠟ᓇᴺ PET ⎇ⓥ㧦ጘ㒂ᣂ⡞(2006 ᐕ 11 ᦬ 10 ᣣ)
4㧕 㨪ࠬ࠹࡟ࠝ⌒ᐩࠞࡔ࡜㨪ⷞ␹⚻੃㗡ߩᒻ⁁⸃ᨆߦ᦭↪㧔╙ 18 ࿁ᣣᧄ✛ౝ㓚ቇળ㧕㧦Medical
Tribune(2007 ᐕ 11 ᦬ 22 ᣣ)
5㧕 ੃߇ࠎᬌᩏ߁ߟ߱ߖߢ ⿥㖸ᵄ⸻ᢿᡰេ ࠕࡠࠞߣጘ㒂ᄢ㐿⊒㧦ᣣ⚻↥ᬺᣂ⡞(2008 ᐕ 7 ᦬ 23 ᣣ)෸߮หᣣઃߌᣣ⚻࠽ࡆ
6㧕 ⮮↰ᑝᔒ㧦੃߇ࠎ⼂೎ ᡰេ࠰ࡈ࠻㧦ᦺᣣᣂ⡞㧔2008 ᐕ 12 ᦬ 26 ᣣ㧕෸߮ 12 ᦬ 31 ᣣઃߌ asahi.com
㧔੃߇ࠎ߆߽ ↹௝⸻ᢿ කᏧ⵬ഥߔࠆ࠰ࡈ࠻㐿⊒㧕12㧚⥄Ꮖ⹏ଔ
⹏ଔ⑼⎇⾌ߦࠃࠆၮ␆⎇ⓥ㧘↥ቭቇߦࠃࠆᄢဳ⎇ⓥ㧘߅ࠃ߮ડᬺߣߩ↥ቇ౒หߦࠃࠆታ↪ൻ⎇ⓥࠍ᏷ᐢߊⴕߞߡ߅ࠅ㧘ߎࠇࠄߩߔߴߡߦ߅޿ߡ⎇ⓥߩㅴ᝞⁁ᴫߪ㧘ᄖㇱ⹏ଔߩ⚿ᨐ߽㜞ߊ㧘✚ߓߡᭂ߼ߡ㗅⺞ߢ޽ࠆ‫੹ޕ‬ᓟ߽ߎߩࡍ࡯ࠬߢ㧘ߐࠄߦකᎿㅪ៤ࠍၮ⺞ߣߒߚ౒ห⎇ⓥࠍㅴ߼ࠆ⸘↹ߢ޽ࠅ㧘ක↪↹௝ᖱႎ
ಣℂಽ㊁ߦ߅ߌࠆ਎⇇⊛࡟ࡌ࡞ߩቇⴚ⎇ⓥߩផㅴ㧘߅ࠃ߮ߘߩ␠ળ߳ߩㆶరߦദജߒߡ޿߈ߚ޿‫ޕ‬ቇ↢ߩ⎇ⓥᜰዉ࡮ᢎ⢒㕙ߢߪ㧘ᐕ㑆 100 ઙࠍ⿥ߔ࿖ౝᄖߩቇળ╬ߦ߅ߌࠆ⎇ⓥ⊒⴫ߥߤߦࠃࠆ⢒ᚑㆊ⒟ࠍㅢ
ߓߡ㧘㜞޿࡟ࡌ࡞ߩᢎ⢒࡮⎇ⓥᵴേࠍⴕߞߡ߅ࠅ㧘ਥߥዞ⡯ડᬺవ߆ࠄߩ⹏್߽᭎ߒߡ⦟ᅢߢ޽ࠅ㧘㜞ߊ⹏ଔߐࠇߡ޿ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷⃻࿷㧘ᧄಽ㊁ߩᢎຬ 3 ฬ߇㧘Ꮏቇㇱᔕ↪ᖱႎቇ⑼ߦ಴ะ߈㧘ᄙߊߩ⻠⟵߿ታ㛎ࠍᜂᒰߒ㧘߆ߟතᬺ⎇ⓥߩᜰዉ㧔Ფᐕቇㇱ 3 ᐕᰴߩ⑺߆ࠄቇ↢㈩ዻ㧔Ფᐕ 10 ฬᒙ⒟ᐲ㧕߇ᆎ߹ࠅ㧘4 ᐕᰴතᬺ߹ߢߩ㑆ߩ 1 ᐕඨߩᦼ㑆㧕ࠍⴕߞߡ޿ࠆ‫ߩࠄࠇߎޕ‬ቇ↢߇ᄢቇ㒮ㅴቇᤨߦౣ↢ක⑼ቇኾ᡹ߩඳ჻೨ᦼ⺖⒟ߦ౉ቇߒ㧘৻ㇱߪᓟᦼ⺖⒟ߦ߹ߢㅴቇߒߡ޿ࠆ߇㧘ઁᄢቇ߆ࠄߩ౉ቇ⠪ᢙߪᭂ߼ߡዋߥ޿⃻⁁ߢ޽ࠆ‫੹ޕ‬ᓟߪઁᄢቇ
ߦ߽ᐢߊᐢႎࠍⴕ޿㧘᏷ᐢߊో࿖ⷙᮨߢఝ⑲ߥቇ↢ߩ൐㓸ߦോ߼ߚ޿‫ޕ‬໧㗴ὐߣߒߡߪ㧘ਥߦᎿቇ♽߆ࠄߩᄙߊߩቇ↢ࠍฃߌ౉ࠇߡ޿ࠆ߇㧔2008 ᐕᧃߢ㧘ඳ჻ᓟᦼ⺖⒟ 7 ฬ㧘ඳ჻೨ᦼ⺖⒟ 16 ฬ㧘ቇㇱ 4 ᐕ↢ 6 ฬ㧘ቇㇱ 3 ᐕ↢ 7 ฬ㧦⸘ 36 ฬ㧕㧘ߎࠇࠄߩቇ↢ߩᢎ⢒࡮⎇ⓥߦߪ㧘ᢎຬ 3 ฬߩߺ߇ਛᔃߣߥߞߡⴕߞߡ޿ࠆߩ߇⃻⁁ߢ㧘߈߼⚦߆ߥᜰዉࠍߔࠆߦߪࠬ࠲࠶ࡈਇ⿷ߪุ߼ߥ
޿⁁ᘒߢ޽ࠆ‫ߚ߹ޕ‬㧘⎇ⓥቶߣߒߡ೑↪ߢ߈ࠆ⎇ⓥቶ࡮ታ㛎ቶߩⷙᮨ߇ᎿቇㇱߦᲧߴߡዊߐߊ㧘ߎࠇࠄ߇ᡷༀߐࠇࠆߎߣ߇ᦸ߹ࠇࠆ‫ޕ‬කᎿቇ♽޽ࠆ޿ߪකቇ♽ߩ࿖㓙ળ⼏ߦ߅ߌࠆ⊒⴫Ṷ㗴ᢙߪᐕ㑆 30 ઙࠍ⿥߃ߡ߅ࠅ㧘ዷ␜╬ߢߪⶄᢙߩ
⾨ࠍฃ⾨ߒߡ޿ࠆ߇㧘ߎࠇࠄߩ࿖㓙⹹߳ߩ⺰ᢥൻ߇ዋߒㆃࠇߡ޿ࠆ⁁ᴫߢ޽ࠅ㧘ᡷༀߦദ߼ࠆ‫ޕ‬੹ᓟߩዷᦸ⍮⊛ࠢ࡜ࠬ࠲࡯ࡊࡠࠫࠚࠢ࠻⎇ⓥࠍߪߓ߼㧘ขࠅ⚵ࠎߢ޿ࠆฦ⒳⎇ⓥߦ߅ߌࠆࠦࡦࡇࡘ࡯࠲ᡰេ⸻ᢿ
㧔CAD㧕ࠪࠬ࠹ࡓߩ㐿⊒㧘෸߮ߘߩታ↪ൻࠍߐࠄߦㅴዷߐߖࠆ‫ߚ߹ޕ‬㧘⃻࿷ߪ㧘᡼኿✢කቇߢขࠅᛒࠊ
ࠇࠆ⸻ᢿ↪ߩ↹௝㗔ၞࠍኻ⽎ߩਛᔃߣߒߡ⎇ⓥࠍㅴ߼ߡ޿ࠆ߇㧘੹ᓟߪ㧘ౣ↢ක⑼ቇ㑐ଥߩ↹௝ಣℂ࡮
⸃ᨆ࡮⹺⼂ߦ㑐ߔࠆ⎇ⓥ࠹࡯ࡑ߳ߩߐࠄߥࠆⓍᭂ⊛ߥขࠅ⚵ߺࠍᬌ⸛ߔࠆ‫ޕ‬ᢎ⢒㕙ߢߪߐࠄߦ߈߼⚦߆ߥᜰዉ૕೙ࠍ⏕┙ߒ㧘⥄ਥᕈ㧘ഃㅧᕈ㧘࠴ࡖ࡟ࡦࠫ♖␹ߦንࠎߛቇ↢ߩ⢒ᚑࠍ⋡ᜰߔ‫ޕ‬㧙㧙ާౣ↢ᔕ↪ቇ⻠ᐳި
㧔1㧕ᓴⅣ∛ᘒቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
1㧕ౣ↢කቇ
1㧕㛽㜑⚦⢩⒖ᬀߦࠃࠆᔃ╭᪪Ⴇ㧘㐽Ⴇᕈേ⣂⎬ൻ∝ߦኻߔࠆౣ↢කቇ࡮ක≮2㧕G-CSF㧔㗰☸⃿ࠦࡠ࠾࡯ೝỗ࿃ሶ㧕ߥࠄ߮ߦ Erythropoietin ࠍ↪޿ߚ⁜ᔃ∝࡮ᔃ╭᪪Ⴇ࡮ᔃਇో
㐽Ⴇᕈേ⣂⎬ൻ∝ߦኻߔࠆౣ↢≮ᴺߩ㐿⊒
3㧕Gelatin hydrogel ߩ Drug Delivery System ࠍ↪޿ߚౣ↢≮ᴺߩ㐿⊒
4㧕࡝ࡐ࠱࡯ࡓࠍ↪޿ߚ࠽ࡁකቇߦࠃࠆౣ↢≮ᴺߩ㐿⊒
5㧕ࡎ࡯ࡒࡦࠣ㑐ㅪಽሶ⊒⃻ᐙ⚦⢩ߦࠃࠆᔃ╭᪪Ⴇ࡮ᔃਇో࡮㐽Ⴇᕈേ⣂⎬ൻ∝ߦኻߔࠆౣ↢කቇ࡮ක≮2㧕ࠕࡐ࠻࡯ࠪࠬ࡮ࠝ࡯࠻ࡈࠔࠫ࡯
1㧕ᓴⅣེ∔ᖚߣࠕࡐ࠻࡯ࠪࠬ
⡺⧘⚵❱⚦⢩ࠕࡐ࠻࡯ࠪࠬ㒖ኂߦࠃࠆᔃ╭᪪ႧᓟᏀቶ࡝ࡕ࠺࡝ࡦࠣߩ੍㒐
2㧕ᓴⅣེ∔ᖚߣࠝ࡯࠻ࡈࠔࠫ࡯
㘫㙈࡮⯯ⴊࠬ࠻࡟ࠬ㧘ᔃਇోߦ߅ߌࠆᔃ╭⚦⢩ࠝ࡯࠻ࡈࠔࠫ࡯ߩ∛ᘒ↢ℂ
3㧕⣢∔ᖚߣࠕࡐ࠻࡯ࠪࠬ
♧ዩ∛ᕈ⣢∝ߩ⊒∝ࡔࠞ࠾࠭ࡓߦ߅ߌࠆࠕࡐ࠻࡯ࠪࠬߩᓎഀߩ⸃᣿
3㧕⯯ⴊᔃ╭଻⼔ߩࡔࠞ࠾࠭ࡓ⸃᣿ߣ new drug ߩ㐿⊒1㧕Ischemic preconditioning ߣ ischemic postconditioning ߩࡔࠞ࠾࠭ࡓ⸃᣿
2㧕᛫♧ዩ∛⮎ߢ޽ࠆ miglitol, acarbose, voglibose ߥߤD-glucosidase 㒖ኂ⮎㧘pioglitazone ߦࠃࠆ⯯ⴊᔃ╭଻⼔૞↪ߩࡔࠞ࠾࠭ࡓ⸃᣿
3㧕ฦ⒳ᔃⴊ▤⮎㧔ฦ⒳㒠࿶⮎㧘ࠬ࠲࠴ࡦ㧘᛫ⴊዊ᧼⮎㧕ߩ⯯ⴊᔃ╭଻⼔૞↪ߩࡔࠞ࠾࠭ࡓ⸃᣿
4㧕ㆮવሶᴦ≮1㧕ᔃਇోߦኻߔࠆ HGF, sFas, นṁᕈ TGF-Eฃኈ૕, Decorin ߩㆮવሶᴦ≮2㧕ᔃ╭᪪Ⴇߦኻߔࠆ HGF, ࡋࡄ࡝ࡦ⚿วဳ EGF ᭽Ⴧᱺ࿃ሶߩㆮવሶᴦ≮3㧕♧ዩ∛ᕈ⣢∝ߦኻߔࠆ HGF ㆮવሶᴦ≮5㧕IB-IVUS ߅ࠃ߮ IB-ࠛࠦ࡯ߦࠃࠆ⚵❱ᕈ⁁⸻ᢿ
1㧕㜞⢽ⴊ∝ᴦ≮⮎㧘ACE 㒖ኂ⮎ߩ౰േ⣂߅ࠃ߮㗖േ⣂ࡊ࡜࡯ࠢᕈ⁁ߦਈ߃ࠆᓇ㗀ߩ⸃ᨆ
2㧕౰േ⣂⎬ൻ∛ᄌߩ progression ߣ⚵❱∛ᄌ
3㧕⣢∔ᖚ∛ᄌߩ⣢⚵❱ᕈ⁁⸻ᢿ
4㧕ᔃᚱ⚦േ∝଀ߩᔃᚱ⚵❱ᕈ⁁⸻ᢿ
5㧕IB-IVUS ↹௝ߩ 3 ᰴరൻ
6㧕േ⣂⎬ൻ∝ߩ∛ᘒߦኻߔࠆಽሶ↢‛ቇ⊛ࠕࡊࡠ࡯࠴
1㧕LOX-1
7㧕3D-CT ߦࠃࠆ౰േ⣂∛ᄌ⸻ᢿ
1㧕3D-CT ↹௝ߣ IB-IVUS ↹௝ߣߩ⚵❱ᕈ⁁⸻ᢿᲧセ8㧕ਇᢛ⣂1㧕ࠞ࠹࡯࠹࡞ࠕࡉ࡟࡯࡚ࠪࡦߦࠃࠆฦ⒳㗫⣂ᕈਇᢛ⣂ᴦ≮
2㧕T-wave alternans ߣ sleep apnea ߩ㑐ଥ9㧕౰േ⣂ࠗࡦ࠲࡯ࡌࡦ࡚ࠪࡦ
1㧕ᚒ߇࿖ߦ߅ߌࠆ CAG, PCI, CABG ߅ࠃ߮ AMI ߩో࿖⺞ᩏ
2㧕⁜ᔃ∝ߦኻߔࠆ⮎‛≮ᴺ㧘PCI ߅ࠃ߮ CABG ߩ⃻⁁ߣࠦࠬ࠻3㧕J-SAP ⎇ⓥ
4㧕ᔃ⣢ㅪ㑐ߦ㑐ߔࠆ⎇ⓥ
10㧕 ⥃ᐥᩭකቇ
1㧕ᔃ╭᪪Ⴇ㧘⁜ᔃ∝㧘⢈ᄢဳᔃ╭∝㧘ੑᰴᕈᔃ╭∔ᖚ㧔ࠨ࡞ࠦࠗ࠼࡯ࠪࠬߥߤ㧕ߩᩭකቇ⊛ᬌ⸛
2㧕D㧙ࠣ࡞ࠦࠪ࠳࡯࠯㒖ኂ⮎ߩ⯯ⴊᔃ╭଻⼔૞↪ߩᩭකቇ⊛ᬌ⸛11㧕 ᧲ᵗකቇ⊛ࠕࡊࡠ࡯࠴
1㧕ᄤบὖ⮎ߩ⣢∔ᖚߦኻߔࠆലᨐߩᬌ⸛
12㧕 㑐ㅪ∛㒮ߣߩᄢⷙᮨ⥃ᐥ⹜㛎
1㧕౰ᡨ❗ᕈ⁜ᔃ∝ߩ੍ᓟ࿃ሶߩᬌ⸛㧙㧙

2㧕DES㧔Drug Eluting Stent㧕ᤨઍߦ߅ߌࠆ⮎‛≮ᴺߩᬌ⸛
3㧕ᣧᦺ㜞ⴊ࿶ߩ⣂ᜉᢙߦ㑐ߔࠆ⎇ⓥ
2㧚ฬ★
ᢎ᝼㧦
ಎᢎ᝼㧦
ಎᢎ᝼㧦
⻠Ꮷ㧦
⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦

Ḋญା਽
┻᧛రਃ
⷏၂๺ᒾ
Ꮉፒ㓷ⷙ
㕍ጊ℉⏴
᧛↰৻⍮ᦶ
‐⿧ඳᤘ

Shinya Minatoguchi
Genzou Takemura
Kazuhiko Nishigaki
Masanori Kawasaki
Takuma Aoyama
Ichijiro Murata
Hiroaki Ushikoshi

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ⷏၂๺ᒾ㧘⮮ේਭ⟵㧚II. ౰േ⣂∔ᖚ 1㧚ᕆᕈᔃ╭᪪Ⴇ㧦ጊญᔀ㧘ၳᱜੑ✬㧚ᓴⅣེ∔ᖚ ᦨᣂߩᴦ≮
2006-2007㧘᧲੩㧦ධᳯၴ㧧2006 ᐕ㧦57г62㧚
2㧕 ⷏၂๺ᒾ㧚㧙⑳ߪߎ߁ᴦ≮ߒߡ޿ࠆ㧦቟ቯ⁜ᔃ∝㧔ౝ⑼㧕
㧦੹ᣣߩᴦ≮ᜰ㊎ 2006 ᐕ 㧘᧲੩㧦කቇᦠ㒮㧧
2006 ᐕ㧦265г268㧚
3㧕 ⷏၂๺ᒾ㧘⮮ේਭ⟵㧚PCI ߩㆡᔕߣ⑌ᔊ㧦శ⮮๺᣿✬㧚ᣂ⋡ߢ⷗ࠆᓴⅣེ∛ࠪ࡝࡯࠭ 20 ࠞ࠹࡯࠹࡞ࠗࡦ
࠲࡯ࡌࡦ࡚ࠪࡦ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2006 ᐕ㧦3642㧚
4㧕 ⷏၂๺ᒾ㧘⮮ේਭ⟵㧚╙ 2 ┨ ⁜ᔃᕈ ℂ⸃ߩࡐࠗࡦ࠻ 3 ⁜ᔃᕈߢߪߤߩࠃ߁ߥᴦ≮ߣ⋴⼔ࠍߔࠇ߫ࠃ
޿ߢߔ߆㧫 㧙ᴦ≮ߣ੍ᓟ㧙 ౝ⑼⊛ᴦ≮㧦ᐔጊ◊ᔒ✬㧚2006 ᐕࡂ࡯࠻࠽࡯ࠪࡦࠣ⑺ᦼჇೀ Q&A ࠃࠅߪߓ߼ࠃ߁㧍 ౰േ⣂ࡑࠬ࠲࡯ࡉ࠶ࠢ㧘ᄢ㒋㧦ࡔ࠺ࠖࠞ಴ 㧧2006 ᐕ㧦44㧙57㧚
5㧕 ┻᧛రਃ㧘Ḋญା਽㧘⮮ේਭ⟵㧚15. G-CSF ⯯ⴊ∔ᖚ㧦᧻ᧄ㇌ᄦ㧘↰⇌ᵏᒾ✬㧚IV. ⚦⢩Ⴧᱺ࿃ሶߩฦ⺰⚦⢩Ⴧᱺ࿃ሶߣౣ↢ක≮㧘ᄢ㒋㧦ࡔ࠺ࠖࠞ࡞࡟ࡆࡘ࡯␠㧧2006 ᐕ㧦374㧙379㧚
6㧕 ┻᧛రਃ㧘⮮ේਭ⟵㧚╙ 1 ┨ 2)⯯ⴊߦࠃࠆᔃ╭⚦⢩ᱫߪࡀࠢࡠ࡯ࠪࠬ߆ࠕࡐ࠻࡯ࠪࠬ߆‫࡯ࠫࠔࡈ࠻࡯ࠝޔ‬߆㧦ၳᱜੑ✬㧚౰േ⣂∔ᖚࡊࡠࡈࠚ࠶࡚ࠪࡦ 7 ‫ޟ‬౰േ⣂∔ᖚߩ New Concept‫ޠ‬㧘᧲੩㧦ਛጊᦠᐫ㧧2006ᐕ㧦7㧙16㧚
7㧕 ┻᧛రਃ㧘⮮ේਭ⟵㧚‫ޟ‬⢈ᄢဳᔃ╭∝ࡂࡦ࠼ࡉ࠶ࠢ –Life-long disease ߣߒߡߩࡑࡀࠫࡔࡦ࠻-‫ޠ‬7 ┨ ੍ᓟ࡮⥄ὼᱧ 5㧦੹ᴰീ⋙ୃ㧘ฎ⾐⟵ೣ✬㧚ᔃ╭࡝ࡕ࠺࡝ࡦࠣߩࡔࠞ࠾࠭ࡓ㧘᧲੩㧦ᣣᧄක੐ᣂႎ␠㧧2007
ᐕ㧦224㧙232㧚
8㧕 ┻᧛రਃ㧘⮮ේਭ⟵㧚‫ޡ‬ᔃ╭∝‫ޢ‬㧦᧻᫪ᤘ✬㧚[ᣂ⋡ߢߺࠆᓴⅣེ∛ࠪ࡝࡯࠭Ԧ] VIII. ᔃ╭∝⸻ᢿߩㅴᱠ㧦ᔃ╭∝ߩౣ↢ᴦ≮㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2007 ᐕ㧦331㧙336㧚
9㧕 ┻᧛రਃ㧘⮮ේਭ⟵㧚╙ 1 ┨ ᕆᕈ౰∝୥⟲ߩᚑ࿃㧦∛ℂߣ∛ᘒ↢ℂ㧦㜞㊁ᾖᄦ✬㧚ᦨᣂකቇ೎ౠ‫ޟ‬ᣂߒ޿⸻ᢿߣᴦ≮ߩ ABC ╙ 48 Ꮞ ᕆᕈ౰∝୥⟲‫ޠ‬㧘ᄢ㒋㧦ᦨᣂකቇ␠㧧2007 ᐕ㧦15㧙21.
10㧕 ┻᧛రਃ㧘Ḋญା਽㧚‫ޟ‬ౣ↢ක≮ߩ⃻⁁ࠍ⼂ࠆ‫[ ޠ‬ᴦߔ] 13㧚G-CSF ࠍ↪޿ߚⴊ▤ౣ↢≮ᴺ㧦᧲੩㧦Heart
View㧦2007 ᐕ㧦97㧙104㧚
11㧕 Ꮉፒ㓷ⷙ㧚Integrated Backscatter Intravascular Ultrasound㧦IVUS ࡂࡦ࠼ࡉ࠶ࠢ㧘᧲੩㧦ਛጊᦠᐫ㧧
2006 ᐕ㧦282㧙289㧚
12㧕 Ꮉፒ㓷ⷙ㧚Integrated Backscatter Intravascular Ultrasound (IB-IVUS)㧦Coronary Intervention 2 Ꮞ
No.1㧘᧲੩㧦ࡔ࠺ࠖࠕ࡞ࡈࠔ㧧2006 ᐕ㧦96㧙102㧚
13㧕 Ꮉፒ㓷ⷙ㧚Integrated Backscatter Intravascular Ultrasound (IB-IVUS)㧦Heart View 10 Ꮞ No.3㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2006 ᐕ㧦68㧙73㧚
14㧕 Ꮉፒ㓷ⷙ㧚ᓴⅣེ㗔ၞߦ߅ߌࠆᦨㄭߩක≮ᯏེ㧙౰േ⣂ࠗࡔ࡯ࠫࡦࠣⵝ⟎㧦ቇળᣂႎ 27 Ꮞ㧘No.1㧘᧲੩㧦ද᦭␠㧧2006 ᐕ㧦5㧙9㧚
15㧕 㘵↰⌀⟤㧘⮮ේਭ⟵㧚╙Υㇱ㧦ᔃ∔ᖚෂ㒾࿃ሶߩᴦ≮ 5㧚༛ᾍ㧦ᄤ㊁ᕺሶ㧘ጊญᔀ✬㧚ᕈᏅ߆ࠄߺߚᅚᕈ
ߩᓴⅣེ∔ᖚ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2006 ᐕ㧦148㧙154㧚
16㧕 㘵↰⌀⟤㧘⮮ේਭ⟵㧚Υ⸻ᢿߣᴦ≮ A.⯯ⴊᕈᔃ∔ᖚ 4㧚ᓴⅣེ∔ᖚߦ߅ߌࠆ༛ᾍߩ࡝ࠬࠢߣኻ╷㧦⍫ፒ⟵㓶㧘ጊญᔀ㧘㜞ᧄ⋿৻㧘ਛỈ⺈✬㧚Annual Review ᓴⅣེ㧘᧲੩㧦ਛᄖකቇ␠㧧2006 ᐕ㧦141㧙147㧚
17㧕 㘵↰⌀⟤㧘⮮ේਭ⟵㧚15㧕༛ᾍ㧦ઍ↰ᶈਯ✬㧚౰േ⣂∔ᖚࡊࡠࡈࠚ࠶࡚ࠪࡦ 5 ౰േ⣂∔ᖚߩ੍㒐ᚢ⇛୘‫ޘ‬ߩෂ㒾࿃ሶߩ∉ቇ㧘⹏ଔᴺ㧘ᴦ≮ᴺߣߘߩࠛࡆ࠺ࡦࠬ㧘᧲੩㧦ਛጊᦠᐫ㧧2006 ᐕ㧦70㧙73㧚
18㧕 㘵↰⌀⟤㧘⮮ේਭ⟵㧚Τേ⣂⎬ൻߩ੍㒐ߣᴦ≮ Step1 ෂ㒾࿃ሶߦኻߔࠆᴦ≮ D ࠲ࡃࠦࠍ߿߼ߐߖߚ޿
ߣ߈㧦ᢧ⮮ᐽᔒ㧘ጊ↰ାඳ✬㧚േ⣂⎬ൻ⸻≮ࡑ࠾ࡘࠕ࡞㧘᧲੩㧦ධᳯၴ㧧2006 ᐕ㧦132㧙136㧚
19㧕 ⮮ේਭ⟵㧘㘵↰⌀⟤㧘ਭᧁጊᷡ⾆㧘ᦳ໪ੑ㇢㧘㈕ᔘ๺㧚PASSPORT TO STOP SMOKING ╙ 2 㧘੩ㇺ㧦㧔␠㧕ᣣᧄᓴⅣེቇળ/ᣣᧄᓴⅣེቇળ⑌ᾍផㅴᆔຬળ㧧2006 ᐕ㧚
20㧕 㘵↰⌀⟤㧚ᣣᧄᓴⅣེቇળ㧘ᣣᧄ≸ቇળ㧘ᣣᧄ⢖≸ቇળ㧘╙ 3 ᰴኻ߇ࠎኻ╷✚วᚢ⇛⎇ⓥ⃰⑌ᾍᴦ≮ᮡḰᚻ㗅ᦠ૞ᚑࠣ࡞࡯ࡊ✬㧚⑌ᾍᴦ≮ߩߚ߼ߩᮡḰᚻ㗅ᦠ㧧2006 ᐕ㧚
21㧕 㘵↰⌀⟤㧚1.㕖⮎‛≮ᴺߦࠃࠆ੍㒐ߣ▤ℂ 2㧕⑌ᾍᵴേ‫ޡ‬ᔃਇోࠍ੍㒐ߔࠆ ⊒∝ߐߖߥ޿ ౣ⊒ߐߖߥ޿ߚ߼ߩ⸻≮ࠬ࠻࡜࠹ࠫ࡯‫ޢ‬㧦Φ.੍㒐ߣ▤ℂߩታ㓙㧘᧲੩㧦ਛጊᦠᐫ㧧2006 ᐕ㧦143㧙148㧚
22㧕 ⷏၂๺ᒾ㧚гᔃ╭∝ࠍ⼂ࠆ࡮⸻ࠆ࡮ᴦߔг㧦⏷ㇱశ┨㧘᧻ፒ⋉ᓼ✬㧚X㧚ᔃ╭∝ߩ㕖⮎‛ᴦ≮ߪߎߎ߹ߢㅴ

㧙㧙ᱠߒߚ 1㧚ᔃ⤳⒖ᬀߩㆡᔕߣ⃻ᴫ гᔃ⒖ᬀᖚ⠪ߩ⊓㍳ߩㅴ߼ᣇгᣂ࡮ᔃ⤳∛⸻≮ࡊ࡜ࠢ࠹ࠖࠬ 10.㧘᧲੩㧦ᢥశၴ㧧2007 ᐕ㧦356㧙358.
23㧕 ⷏၂๺ᒾ㧘⮮ේਭ⟵㧚IV. ⯯ⴊᕈᔃ∔ᖚ ᄢⷙᮨ⹜㛎 ⁜ᔃ∝ ‫ޡ‬JSAP Study‫ޢ‬㧘ᣣᧄ⥃ῼ ‫ޡ‬ᄢⷙᮨ⥃ᐥ⹜㛎 㧙ᓴⅣ࡮ઍ⻢♽ࠍਛᔃߦ㧙‫ޢ‬2008 ᐕ㧦68(Ⴧೀภ)㧦357㧙362㧚⪺ᦠ㧔᰷ᢥ㧕
1㧕 Takemura G, Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to
management. Prog Cardiovasc Dis. 2007;49:330-352.
✚⺑㧔๺ᢥ㧕
1㧕 ⷏၂๺ᒾ㧚․㓸‫߇ࠊޡ‬࿖ߩ౰േ⣂∔ᖚߩ⥃ᐥࠛࡆ࠺ࡦࠬ‫ޢ‬1㧚ࠊ߇࿖ߩ౰േ⣂∔ᖚߩ∉ቇ㧘Vascular Biology& Medicine 㧙ⴊ▤කቇ㧙 2006 ᐕ㧧33 Ꮞ㧦11㧙16㧚
2㧕 ⷏၂๺ᒾ㧘⮮ේਭ⟵㧚․㓸‫ޡ‬ᔃ╭᪪Ⴇߣ⣖᪪ႧߩኻᲧ гupdateг‫ ⺑⸃ޢ‬3㧚ᣣᧄੱߣ᰷☨ੱߩࠛࡆ࠺ࡦࠬ㧦㘃ૃὐߣ⋧㆑ὐ The evidence of the Japanese and the Westerner: The similarity and the difference. ᓴ
Ⅳ⑼ 2006 ᐕ㧧59 Ꮞ㧦503㧙509㧚
3㧕 ⷏၂๺ᒾ㧚Lecture ‫ޡ‬ᢛᒻᄖ⑼߇⺋ࠅ߿ߔ޿๟ⴚᦼ▤ℂߣ⢖Ⴇᩖ∝‫ޢ‬㧘⥃ᐥᢛᒻᄖ⑼ 2006 ᐕ㧧41 Ꮞ㧦1071
㧙1081㧚
4㧕 ⷏၂๺ᒾ㧚Sarpogrelate, a 5-HT2 receptor blocker, have an ischemic preconditioning-like effect.㧘
Angiology Frontier 2006 ᐕ㧧5 Ꮞ㧦74㧙78㧚
5㧕 ⷏၂๺ᒾ㧚Editorial Comment‫ޡ‬Ἳ∝ᕈ∔ᖚߣߒߡߩᕆᕈ౰∝୥⟲ hsCRP ߦࠃࠆ࡝ࠬࠢጀ೎ൻ‫ޢ‬㧘Japanese
Journal of Cardiovascular Catheter Therapeutics 2006 ᐕ㧧6 Ꮞ㧦344㧙345㧚
6㧕 ┻᧛రਃ㧚․㓸㧛ᘟᕈᔃਇోߩಽሶᯏ᭴㧦ᣂߒ޿ᴦ≮ᚢ⇛ࠍ᳞߼ߡ‫ߣࠬࠪ࡯࠻ࡐࠕޟ‬ᔃਇో‫ޠ‬㧘ᓴⅣེ⑼
2006 ᐕ㧧59 Ꮞ㧦547㧙554㧚
7㧕 ┻᧛రਃ㧘Ḋญା਽㧘⮮ේਭ⟵㧚․㓸㧛ᔃ⤳ⴊ▤♽ߩౣ↢කቇ㧦ᦨㄭߩㅴᱠߣ੹ᓟߩേะ‫ޟ‬ᔃ╭᪪Ⴇᴦ≮ߦ߅ߌࠆ G-CSF㧙᪪ႧᎽߦኻߔࠆ૞↪‫ޠ‬㧘ᓴⅣེ⑼ 2006 ᐕ㧧60 Ꮞ㧦33㧙38㧚
8㧕 ┻᧛రਃ㧘Ḋญା਽㧘⮮ේਭ⟵㧚․㓸‫▤ⴊޟ‬ᣂ↢ Update‫▤ⴊޠ‬ᣂ↢࿃ሶ G-CSF㧘⣂▤ቇ 2006 ᐕ㧧46
Ꮞ㧦317㧙325㧚
9㧕 ┻᧛రਃ㧚ᔃਇో UPDATE ᔃਇో⊒∝ߩࡔࠞ࠾࠭ࡓ ᔃਇోߣࠕࡐ࠻࡯ࠪࠬ㧙ᦨㄭߩㅴᱠ㧘කቇߩ޽ࠁ
ߺ 2006 ᐕ㧧218 Ꮞ㧦1117㧙1123㧚
10㧕 ┻᧛రਃ㧚ᔃ╭↢ᬌߩ੹ᣣ⊛ᗧ⟵㧘කቇߩ޽ࠁߺ 2006 ᐕ㧧219 Ꮞ㧦486㧙487㧚
11㧕 ┻᧛రਃ㧘⮮ේਭ⟵㧚․㓸‫ޟ‬ᔃਇోᴦ≮㧙Controversy 2006㧙‫ޠ‬VI. ౣ↢ක≮㧙⚦⢩߆㧫ࠨࠗ࠻ࠞࠗࡦ߆㧫㧙 (2) ࠨࠗ࠻ࠞࠗࡦ㧘Cardiovascular Med-Surg 2006 ᐕ㧧8 Ꮞ㧦59㧙67㧚
12㧕 㘵↰⌀⟤㧘⮮ේਭ⟵㧚࡜ࠗࡈࠬ࠲ࠗ࡞࠼࡜࠶ࠣ߆ࠄᴦ≮⮎߳ߩዷ㐿 ‫ޟ‬༛ᾍ∛ߩᴦ≮㧙⑌ᾍࠟࠗ࠼࡜ࠗࡦ
ߦ߅ߌࠆ⮎‛≮ᴺࠍਛᔃߦ㧙‫ޠ‬㧘⮎ዪ 2006 ᐕ㧧57 Ꮞ㧦98㧙104㧚
13㧕 㘵↰⌀⟤㧘⮮ේਭ⟵㧚༛ᾍߩஜᐽᓇ㗀ߣ‫⑌ޟ‬ᾍࠟࠗ࠼࡜ࠗࡦ‫ޠ‬㧘ో⮎ࠫࡖ࡯࠽࡞ 2006 ᐕ㧧224 ภ㧦12㧙
15㧚
14㧕 㘵↰⌀⟤㧘⮮ේਭ⟵㧚࠲ࡃࠦߩኂ࡯޽ߥߚ߽ᱛ߼ࠄࠇࠆ ‫⑌ޟ‬ᾍࠟࠗ࠼࡜ࠗࡦ࡯ࡊ࡜ࠗࡑ࡝ࠤࠕකߩ૶޿
ᣇ‫ޠ‬㧘ࠢ࡝࠾ࠞ࡞ࡊ࡜ࠢ࠹ࠖࠬ 2006 ᐕ㧧25 Ꮞ㧦734㧙738㧚
15㧕 㘵↰⌀⟤㧘⮮ේਭ⟵㧚⑌ᾍࠟࠗ࠼࡜ࠗࡦߩࡐࠗࡦ࠻ ㅪタ‫ޡ‬ᓴⅣེ∔ᖚߩ⹤㗴 TOPIC‫ޢ‬㧘ࡂ࡯࠻࠽࡯ࠪࡦ
ࠣ 19 2006 ᐕ.
16㧕 㘵↰⌀⟤㧚࠾ࠦ࠴ࡦଐሽ∝▤ℂᢱгᧄ▤ℂᢱߩో૕௝ࠍߣࠄ߃ࠆг‫⑌ޟ‬ᾍᴦ≮ߩߚ߼ߩᮡḰᚻ㗅ᦠ‫ޠ‬㧘ᴦ≮
2006 ᐕ㧧88 Ꮞ㧦2475㧙2480㧚
17㧕 ⮮ේਭ⟵㧘┻᧛రਃ㧚ᣣᧄ⥃ᐥჇೀภ ᔃਇో㧔਄㧕㧦̅ᦨㄭߩၮ␆࡮⥃ᐥ⎇ⓥߩㅴᱠ̅ ᔃਇోၮ␆⎇ⓥߩ
ㅴᱠߣ੹ᓟߩ⺖㗴㧘㧧ᣣᧄ⥃ᐥ㧧2007㧦65(Suppl 4)㧦9㧙16㧚
18㧕 ┻᧛రਃ㧚ᣣᧄ⥃ᐥჇೀภ ᔃਇో㧔਄㧕:̅ᦨㄭߩၮ␆࡮⥃ᐥ⎇ⓥߩㅴᱠ̅ ᔃ╭⚦⢩ߩࠕࡐ࠻࡯ࠪࠬߣࠝ
࡯࠻ࡈࠔࠫ࡯㧘᧲੩㧦ᣣᧄ⥃ᐥ㧧2007 ᐕ㧦65(Suppl 4)㧦143㧙148㧚
19㧕 ┻᧛రਃ㧚ᔃ╭ࠕࡐ࠻࡯ࠪࠬ㧦๭ๆߣᓴⅣ; 2007 ᐕ㧦55㧦429㧙440㧚
20㧕 ┻᧛రਃ㧚‫ޡ‬ᣣᧄ⥃ᐥ‫ޢ‬
㧦2007 ᐕ೎ౠ ᓴⅣེ∝୥⟲(╙ 2 ) (I) ̅ߘߩઁߩᓴⅣེ∔ᖚࠍ฽߼ߡ࡯: II ᔃਇో㧦᪪Ⴇᓟᔃਇో㧚ᄢ㒋㧦ᣣᧄ⥃ᐥ␠㧧2007 ᐕ㧦168㧙172㧚
21㧕 ┻᧛రਃ㧘Ḋญା਽㧚‫ޟ‬ౣ↢ක≮ߩ⃻⁁ࠍ⼂ࠆ‫[ ޠ‬ᴦߔ] 13㧚G-CSF ࠍ↪޿ߚⴊ▤ౣ↢≮ᴺ㧦᧲੩㧦Heart
View; 2007 ᐕ㧦97㧙104㧚 
22㧕 ┻᧛రਃ㧚․㓸㧦ᘟᕈᔃਇో⮎‛ᴦ≮ߩ⃻⁁ߣ੹ᓟߩዷᦸ 12. ⽺ⴊᴦ≮࡮ࠨࠗ࠻ࠞࠗࡦ≮ᴺ㧦ᓴⅣེ⑼㧘
᧲੩㧦⑼ቇ⹏⺰␠㧧2007 ᐕ㧦473㧙481㧚
23㧕 ⷏၂๺ᒾ㧚╙ 71 ࿁ᣣᧄᓴⅣེቇળቇⴚ㓸ળ ᓴⅣེᢎ⢒࠮࠶࡚ࠪࡦ III ACS ߩ࡝ࠬࠢጀ೎ൻߣᴦ≮ᚢ⇛
–PCI ߣ CABG ࠍਛᔃߦ-㧦‫ࠢࠬ࡝ߗߥޡ‬ጀ೎ൻ߇ᔅⷐ߆㧫 ̆࡝ࠬࠢጀ೎ൻߩᔅⷐᕈߣታ㓙̆‫ޢ‬㧘᧲੩㧦ᓴ
Ⅳེኾ㐷ක㧧2007 ᐕ㧦70㧙79㧚
24㧕 ⷏၂๺ᒾ㧘⮮ේਭ⟵㧚╙ 8 ࿁㊀∝ᔃਇోᴦ≮ࡈࠜ࡯࡜ࡓ ࠪࡦࡐࠫ࠙ࡓ ‫ޡ‬ᔃ⤳⒖ᬀߩⴚ೨ⴚᓟߣ㐳ᦼ▤ℂ‫ޢ‬㧦ࠊ߇࿖ߦ߅ߌࠆᔃ⤳⒖ᬀߩ⃻⁁ߣ໧㗴ὐ㧘᧲੩㧦๭ๆߣᓴⅣ㧧2007 ᐕ㧦S9㧙S17㧚
25㧕 ⷏၂๺ᒾ㧚ࠊ߇࿖ߪାߓ߇ߚ޿ᔃ⤳⒖ᬀ“ᓟㅴ࿖”㧘KNG ጘ㒂⋵ᔃ⤳∛ఽ⠪ߩળ㧔․㓸ภ㧕2008㧧332 Ꮞ㧦
4㧙5㧚
26㧕 ⷏၂๺ᒾ㧘⮮ේਭ⟵㧚⹤㗴ߩ⺰ᢥ‫ޡ‬COURAGE Trial: ቟ቯ౰േ⣂∔ᖚᖚ⠪ߦኻߔࠆೋᦼᴦ≮ߣߒߡ⥋ㆡ⮎‛ᴦ≮ߦ⚻⊹⊛౰േ⣂ࠗࡦ࠲࡯ࡌࡦ࡚ࠪࡦ㧔PCI㧕ࠍㅊടߒߡ߽ᱫ੢߅ࠃ߮ᔃ╭᪪Ⴇߩ࡝ࠬࠢࠍᛥ೙ߔࠆ
ലᨐߪߥ޿‫ޢ‬㧘ⴊᩖߣᓴⅣ 2008㧧16 Ꮞ㧦85㧙87㧚㧙㧙

27㧕 ⷏၂๺ᒾ㧘ጊፒ ജ㧚Japanese Coronary Artery Disease (JCAD)⎇ⓥߦ߅ߌࠆ⎣㉄⮎ߩᔃⴊ▤♽ࠗࡌࡦ࠻߳ߩᓇ㗀ߦߟ޿ߡ㧘Medicament News 2008 ᐕ㧧1953 ภ㧦29㧚✚⺑㧔᰷ᢥ㧕
1㧕 Takemura G, Fujiwara H. Morphological aspects of apoptosis in heart diseases. J Cell Mol Med.
2006;10:5-75.
ේ⪺㧔๺ᢥ㧕
1㧕 Ḋญା਽㧚ࠨࠗ࠻ࠞࠗࡦߦࠃࠆᔃⴊ▤ౣ↢≮ᴺ㧘േᘒᩭකቇ 2006 ᐕ㧧23 Ꮞ㧦11㧙16㧚
2㧕 ┻᧛రਃ㧘Ḋญା਽㧘⮮ේਭ⟵㧚ⴊ▤ᣂ↢࿃ሶ G-CSF㧘⣂▤ቇ 2006 ᐕ㧧46 Ꮞ㧦317㧙325㧚
3㧕 ⮮ේਭ⟵㧘⷏၂๺ᒾ㧚․㓸‫ߗߥޡ‬ౝ⑼කߪ⒖ᬀක≮ߦ߆߆ࠊࠄߥ޿߆㧫‫ޢ‬ᔃ⤳⒖ᬀߩ┙႐߆ࠄ 㧙ᚒ߇࿖ߪାߓ߇ߚ޿ᔃ⤳⒖ᬀᓟㅴ࿖㧙㧘ᣣᧄ⒖ᬀቇળ㔀⹹ ⒖ᬀ 2006 ᐕ㧧41 Ꮞ㧦2㧙9㧚
4㧕 ጟ↰⧷ᔒ㧘ዊႮା੺㧘ጤ૒዁ల㧘Ꮉ᧛৻ᄥ㧘ዊୖ⌀ᴦ㧘቟↰⌀ᥓ㧘ᦡ⻞ᰴ㧘᫪㤀㧘⷏၂๺ᒾ㧘┻᧛రਃ㧘Ḋญା਽㧘⮮ේਭ⟵㧘㜞ᧁᐘᶈ㧚කᏧหਸ਼ߦࠃࠆጘ㒂ဳᢇᕆࡋ࡝ߦࠃࠆㄦㅦߥ៝ㅍߦࠃߞߡᢇ๮ߒ߃ߚᕆ
ᕈᔃ╭᪪Ⴇߩ৻଀㧘ጘ㒂⋵කᏧળකቇ㔀⹹ 2007 ᐕ㧧20 Ꮞ㧦47㧙51㧚
5㧕 ዊᨋᶈਯ㧘Ḋญା਽㧘൮࠽࡟ࡦ࠻ࡗ㧘቟↰⌀ᥓ㧘ᠲ⵨㧘ዊ㊁ᧁᶈੱ㧘‐⿧ඳᤘ㧘⨹੗ᱜ⚐㧘ጤ૒዁ల㧘㣐⷗዁ᐔ㧘┻᧛రਃ㧘⮮ේਭ⟵㧘↰⇌ᵏᒾ㧘⮮ේహሶ㧚ࠛ࡝ࠬࡠࡐࠗࠛ࠴ࡦ⮎‛ᓢ᡼ࠪࠬ࠹ࡓ(Drug Delivery
System)ߩᔃ╭᪪Ⴇࠨࠗ࠭❗ዊ߅ࠃ߮࡝ࡕ࠺࡝ࡦࠣᛥ೙ലᨐ㧘ጘ㒂⋵ౝ⑼කળ㔀⹹ 2007 ᐕ㧧21 Ꮞ㧦23㧙
24㧚
6㧕 ↰ਛᣂ৻㇢㧘Ḋญା਽㧘⊝Ꮉᄥ㇢㧘⷏၂๺ᒾ㧘Ꮉ᧛৻ᄥ㧘㣐⷗዁ᐔ㧘ᮮጊߜߪࠆ㧘ศ⋿ ቁ㧘㆙ᷰ⚐ノ㧘┻ጊବᤘ㧘ฬ๺㓉⧷㧘ዊႮା੺㧘Ꮉፒ㓷ⷙ㧘┻᧛రਃ㧘⮮ේਭ⟵㧚ST ਄᣹ဳᕆᕈᔃ╭᪪Ⴇౣἠᵹᓟߩᣧᦼ
ㆇേ≮ᴺ੺౉߇ᏀቶኈⓍߦਈ߃ࠆᓇ㗀ߩᬌ⸛—ࠬ࠹ࡦ࠻ᤨઍߩᣧᦼㆇേ≮ᴺ—㧘ᔃ⤳࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦ㧔JJCR㧕2008 ᐕ㧧13 Ꮞ㧦189㧙194㧚
7㧕 ⷏၂๺ᒾ㧚Challenge QUIZ ⾆ᣇ߽ฬක‫ ଀∝ޡ‬27 ᱦ⊕ੱᅚᕈࡉ࡜ࠫ࡞಴り ਥ⸷:ᄬ␹⊒૞‫ޢ‬㧘CLINIC
magazine 2008 ᐕ㧧467 Ꮞ㧦72㧙73㧚
8㧕 ⷏၂๺ᒾ㧚․㓸‫ޡ‬ᓴⅣེ♽∔ᖚߩ࠻ࡇ࠶ࠢࠬ‫ޢ‬㧘౰ᡨ❗ᕈ⁜ᔃ∝ߩᦨᣂ⮎‛≮ᴺ Medicament News 2008ᐕ㧧1964 ภ㧦5㧙7.
ේ⪺㧔᰷ᢥ㧕
1㧕 Hirano T, Tsuchiya K, Nishigaki K, Sou K, Kubota T, Ojio S, Kawasaki M, Minatoguchi S, Fujiwara H,
Ueno K, Hosokawa H, Morita N, Nagano T, Suzuki T, Watanabe S. Clinical features of emergency
electrocardiography in patients with acute myocardial infarction caused by left main trunk
obstruction. Circ J. 2006;70:525-529.
2㧕 Miyata S, Takemura G, Kawase Y, Li Y, Okada H, Maruyama R, Ushikoshi H, Esaki M, Kanamori H,
Li L, Misao Y, Tezuka A, Toyo-Oka T, Minatoguchi S, Fujiwara T, Fujiwara H. Autophagiccardiomyocyte death in cardiomyopathic hamsters and its prevention by granulocytecolony-stimulating factor. Am J Pathol. 2006;168:386-397.
3㧕 Misao Y, Takemura G, Arai M, Sato S, Suzuki K, Miyata S, Kosai K, Minatoguchi S, Fujiwara T,
Fujiwara H. Bone marrow-derived myocyte like cells and regulation of repair-related cytokines after
bone marrow cell transplantation. Cardiovasc Res. 2006;69:476-490.
4㧕 Sano K, Kawasaki M, Ishihara Y, Okubo M, Tsuchiya K, Nishigaki K, Zhou X, Minatoguchi S, Fujita H,
Fujiwara H. Assessment of vulnerable plaques causing acute coronary syndrome using integrated
backscatter intravascular ultrasound. J Am Coll Cardiol. 2006;47:734-741.
5㧕 Li Y, Takemura G, Okada H, Miyata S, Esaki M, Maruyama R, Kanamori H,Li L, Ogino A, Misao Y,
Khai NC, Mikami A, Minatoguchi S, Fujiwara T, Fujiwara H. Treatment with granulocytecolony-stimulating factor ameliorates chronic heart failure. Lab Invest. 2006;86:32-44.
6㧕 Suzuki K, Nagashima K, Arai M, Uno Y, Misao U, Takemura G, Nishigaki K, Minatoguchi S, Watanabe
S, Tei C, Fujiwara H. Effect of granulocyte colony-stimulating factor treatment at a low dose but for along duration in patients with coronary heart disease –a pilot study-. Circ J. 2006;70:430-437.
7㧕 Tanihata S, Nishigaki K, Kawasaki M, Takemura G, Minatoguchi S, Fujiwara H. Outcomes of patientswith stable low –risk coronary artery disease receiving medical- and PCI- preceding therapies I Japan– J-SAP Study 1-1-. Circ J. 2006;70:365-369.
8㧕 Takahashi M, Minatoguchi S, Nishigaki K, Kawasaki M, Arai M, Uno Y, Fujiwara H. Long-term andstrict blood pressure lowering by imidapril reverses left ventricular hypertrophy in patients withessential hypertension: an evaluation using a novel indicator of burden on the left ventricle.
Hypertens Res. 2006;29:89-94.
9㧕 Li L, Takemura G, Li Yien, Miyata S, Esaki M, Okada H, Kanamori H, Khai NC, Maruyama R, Ogino
A, Minatoguchi S, Fujiwara T, Fuijiwara H. Preventive effect of erythropoietin on cardiac dysfunction
in doxorubicin-induced cardiomyopathy. Circulation. 2006;113:535-543.
10㧕 Onogi H, Minatoguchi S, Chen XH, Bao N, Kobayashi H, Misao Y, Yasuda S, Yamaki T, Maruyama R,
Masazumi A, Takemura G, Fujiwara H. Edaravone reduces the myocardial infarct size and improves
cardiac function and remodeling in Rabbits. Clin Exp Pharmacol Physiolol. 2006;33:1035-1041.
11㧕 Maruyama R, Takemura G, Tohse N, Ohkusa T, Ikeda Y, Tsuchiya K, Minatoguchi S, Matsuzaki M,㧙㧙IF 2.135

IF 0.333

IF 5.826

IF 9.701

IF 4.453

IF 2.135

IF 2.135

IF 3.177

IF 10.940

IF 1.780

FujiwaraT, Fujiwara H. Synchronous progression of calcium transient-dependent beating andsarcomere destruction inapoptotic adult cardiomyocytes. Am J Physiol Heart Circ Physiol.
2006;290:H1493-H1502.
IF
12㧕 Tadokoro M, Osumi Y, Minatoguchi S, Kariya T, Yokoyama H, Araki H, Sawada S, Ohashi S,
Watanabe S, Ito H, Fujiwara H. Plasma BNP level in chronic hemodialysis patients: a good indicator ofleft ventricular diastolic dysfunction. Dialysis&Transplantation. 2006;35:10-14.
IF13㧕 Koda M, Takemura G, Okada H, Kanoh M, Maruyama R, Esaki M, Li Y, Miyata S, Kanamori H, Li L,
Ogino A, Kondo T, Minatoguchi S, Fujiwara T, Fujiwara H. Nuclear hypertrophy reflects increased
biosynthetic activities in myocytes of human hypertrophic hearts. Circ J. 2006;70:710-718.
IF
14㧕 Misao Y, Takemura G, Arai M, Ohno T, Onogi H, Takahashi T, Minatoguchi S, Fujiwara T, Fujiwara H.
Importance of recruitment of bone marrow-derived CXCR4+ cells in post-infarct cardiac repair
mediated by G-CSF. Cardiovasc Res. 2006;71:455-465.
IF
15㧕 Li Y, Takemura G, Okada H, Miyata S, Maruyama R, Li L, Higuchi M, Minatoguchib S, Fujiwara T,
Fujiwara H. Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin
in chronic heart failure. Cardiovasc Res. 2006;71:684-694.
IF
16㧕 Fukunishi M, Nishigaki K, Okubo M, Kawasaki M, Takemura G, Minatoguchi S, Fujiwara H. J-SAP
Study 1-2: Outcome of patients with stable high-risk coronary artery disease receiving
medical-preceding therapy in Japan. Circ J. 2006;70:1012-1016.
IF
17㧕 Arai M, Misao Y, Nagai H, Kawasaki M, Nagashima K, Suzuki K, Tsuchiya K, Otsuka S, Uno Y,
Takemura G, Nishigaki K, Minatoguchi S, Fujiwara H. Granulocyte colony-stimulating Factor – anoninvasive regeneration therapy for treating atherosclerotic peripheral artery disease. Circ J.
2006;70:1093-1098.
IF
18㧕 Lu C, Minatoguchi S, Arai M, Wang N, MD; Chen X, Bao N, Kawamura I, Yasuda S, Kobayashi H, Wu
D, Takemura G, Fujiwara H. Nicorandil improves post-ischemic myocardial dysfunction in association
with opening the mitochondrial KATP channels and decreasing hydroxyl radicals in isolated rat hearts.
Circ J. 2006;70:1650-1654.
IF
19㧕 Yuhgetsu H, Ohno Y, Funaguchi N, Asai T, Sawada M, Takemura G, Minatoguchi S, Fujiwara T,
Fujiwara H. Beneficial effects of autologous bone marrow mononuclear cell transplantation via thetrachea against elastase-induced emphysema in rabbits. Exp Lung Res. 2006;32:413-426.
IF
20㧕 Tsujimoto A, Takemura G, Mikami A, Aoyama T, Ohno T, Maruyama R, Nakagawa M, Minatoguchi S,
Fujiwara H. A therapeutic dose of the lipophilic statin pitavastatin enhances oxidant-induced
apoptosis in human vascular smooth muscle cells. J Cardiovasc Pharmacol. 2006;48:160-165.
IF
21㧕 Kagawa T, Takemura G, Kosai K, Murata I, Ohno T, Takahashi T, Esaki M, Maruyama R, Fujiwara T,
Ohashi H, Fujiwara H. Hepatocyte growth factor gene therapy slows down the progression of diabetic
nephropathy in db/db mice. Nephron Physiol. 2006;102:92-102.
IF
22㧕 Takemura G, Miyata S, Kawase Y, Okada H, Maruyama R, Fujiwara H. Autophagic degeneration anddeath of cardiomyocytes in heart failure. Autophagy. 2006;2:212-214.
23㧕 Lu C, Arai M, Misao Y, Chen X, Wang N, Onogi H, Kobayashi H, Uno Y, Takemura G, Minatoguchi S,
Fujiwara T, Fujiwara H. Autologous bone marrow cell transplantation improves left ventricularfunction in rabbit hearts with cardiomyopathy via myocardial regeneration-unrelated mechanisms.
Heart Vessels. 2006;21:180-187.
IF
24㧕 Takahashi T, Kawai T, Ushikoshi H, Nagano S, Oshika H, Inoue M, Kunisada T, Takemura G,
Fujiwara H, Kosai KI. Identification and isolation of embryonic stem cell-derived target cells by
adenoviral conditional targeting. Mol Ther. 2006;14:673-683.
IF
25㧕 Kawasaki M, Bouma BE, Bressner J, Houser SL, Nadkarni SK, MacNeill BD, Jang IK, Fujiwara H,
Tearney GJ. Diagnostic accuracy of optical coherence tomography and integrated backscatter
intravascular ultrasound images for tissue characterization of human coronary plaques. J Am Coll
Cardiol. 2006;48:81-88.
IF
26㧕 Khai NC, Takahashi T, Nagano S, Yuge K, Esaki M, Kawai T, Goto K, Murofushi Y, Fujiwara T,
Fujiwara H, Kosai KI. In vivo hepatic HB-EGF gene transduction inhibits Fas-induced liver injury
and induces liver regeneration in mice: A comparative study to HGF. J Hepatol. 2006;44:1046-1054.
IF
27㧕 Iida H, Iida M, Takenaka M, Fujiwara H, Dohi S. Angiotensin II type 1(AT1)-receptor blocker prevents
impairment of endothelium-dependent cerebral vasodilation by acute cigarette smoking in rat. Life Sci.
2006;78:1310-1316.
IF
28㧕 Iida H, Iida M, Ohata H, Michino T, Dohi S. Effects of dexmedetomidine on cerebral circulation andsystematic hemodynamics after cardiopulmonary resuscitation in dogs. J Anesth. 2006;20:202-207.
29㧕 Li Y, Takemura G, Okada H, Miyata S, Maruyama R, Esaki M, Khai NC, Kanamori H, Li L, Ogino A,
Minatoguchi S, Fujiwara T, Fujiwara H.ANG II type 1A receptor signaling causes unfavorable scar
dynamics in the postinfarct heart.Am J Physiol. Heart Circ Physiol. 2007;292:H946-H953.
IF
30㧕 Li Y, Takemura G, Okada H, Miyata S, Maruyama R, Esaki M, Kanamori H, Li L, Ogino A, Ohno T,
Kondo T, Nakagawa M, Minatoguchi S, Fujiwara T, Fujiwara H. Molecular signaling mediated byangiotensin II type 1A receptor blockade leading to attenuation of renal dysfunction-associated heart
failure. J Card Fail. 2007;13:155-162.
IF

㧙㧙

3.724

0.248

2.135

5.826

5.826

2.135

2.135

2.135

1.427

1.625

1.462

1.056

5.841

9.701

6.073

2.389

3.724

2.737

31㧕 Miyajima K, Minatoguchi S, Ito Y, Fukunishi M, Matsuno Y, Kakami M, Kawasaki M, Nishigaki K,
Takemura G, Fujiwara H. The reduction of QTc dispersion by angiotensin II receptor blocker valsartan
may be related to its anti-oxidative stress effect in patients with essential hypertension. Hypertens
Res. 2007;30:307-313.
32㧕 Kanamori H, Takemura G, Li Y, Okada H, Maruyama R, Aoyama T, Miyata S, Esaki M, Ogino A,
Nakagawa M, Ushikoshi H, Kawasaki M, Minatoguchi S, Fujiwara H. Inhibition of Fas-associatedapoptosis in granulation tissue cells accompanies attenuation of postinfarction left ventricularremodeling by olmesartan. Am J Physiol Heart Circ Physiol. 2007;292:H2184-H2194.
33㧕 Chen XH, Minatoguchi S, Arai M, Wang N, Lu C, Bao N, Uno Y, Misao Y, Takemura G, Fujiwara T,
Fujiwara H. Celiprolol, a selective beta1-blocker, reduces the infarct size through production of nitricoxide in a rabbit model of myocardial infarction.Circ J. 2007;71:574-579.
34㧕 Asai T, Ohno Y, Minatoguchi S, Funaguchi N, Yuhgetsu H, Sawada M, Takemura G, Komada A,
Fujiwara T, Fujiwara H.The specific free radical scavenger edaravone suppresses bleomycin-induced
acute pulmonary injury in rabbits. Clin Exp Pharmacol Physiol. 2007;34:22-26.
35㧕 Misao Y, Arai M, Ohno T, Ushikoshi H, Onogi H, Kobayashi H, Takemura G, Minatoguchi S, Fujiwara
T, Fujiwara H. Modification of post-myocardial infarction granulocyte-colony stimulating factor
therapy with myelosuppressives. Circ J. 2007;71:580-590.
36㧕 Li L, Takemura G, Li Y, Miyata S, Esaki M, Okada H, Kanamori H, Ogino A, Maruyama R, Nakagawa
M, Minatoguchi S, Fujiwara T, Fujiwara H. Granulocyte colony-stimulating factor improves left
ventricular function of doxorubicin-induced cardiomyopathy. Lab Invest. 2007;87:440-455.
37㧕 Funaguchi N, Ohno Y, La BL, Asai T, Yuhgetsu H, Sawada M, Takemura G, Minatoguchi S, Fujiwara T,
Fujiwara H. Narirutin inhibits airway inflammation in an allergic mouse model. Clin Exp Pharmacol
Physiol. 2007;34:766-770.
38㧕 Sawada M, Ohno Y, La BL, Funaguchi N, Asai T, Yuhgetsu H, Takemura G, Minatoguchi S, Fujiwara
H, Fujiwara T. The fas/fas-ligand pathway does not mediate the apoptosis in elastase-induced
emphysema in mice. Exp Lung Res. 2007;33:277-288.
39㧕 Nakagawa M, Ohno T, Maruyama R, Okubo M, Nagatsu A, Inoue M, Tanabe H, Takemura G,
Minatoguchi S, Fujiwara H. Sesquiterpene lactone suppresses vascular smooth muscle cellproliferation and migration via inhibition of cell cycle progression. Biol Pharm Bull.
2007;30:1754-1757.
40㧕 Bao N, Minatoguchi S, Kobayashi H, Yasuda S, Kawamura I, Iwasa M, Yamaki T, Sumi S, Misao Y,
Arai M, Nishigaki K, Takemura G, Fujiwara T, Fujiwara H. Pravastatin reduces myocardial infarct
size via increasing protein kinase C-dependent nitric oxide, decreasing oxyradicals and opeing themitochondrial adenosine triphosphate-sensitive potassium channels in rabbits. Circ J.
2007;71:1622-1628.
41㧕 Ogino A, Takemura G, Kanamori H, Okada H, Maruyama R, Miyata S, Esaki M, Nakagawa M,
Aoyama T, Ushikoshi H, Kawasaki M, Minatoguchi S, Fujiwara T, Fujiwara H. Amlodipine inhibits
granulation tissue cell apoptosis through reducing calcineurin activity to attenuate postinfarction
cardiac remodeling. Am J Physiol Heart Circ Physiol. 2007;293:H2271-H2280.
42㧕 Io K, Minatoguchi S, Nishigaki K, Ojio S, Tanaka T, Segawa T, Matsuo H, Wtanabe S, Hattori A, Ueno
K, Ono H, Hiei K, Sato H, Morita N, Noda T, Kato T, Kawasaki M, Takemura G, Fujiwara H. Effects ofbenidipine and some other calcium channel blockers on the prognosis of patients with vasospastic
angina. Cohort study with evaluation of the ergonovine coronary spasm induction test.
Arzneimittelforschung. 2007;57:573-581.
43㧕 Chen X-H, Minatoguchi S, Kosai K, Yuge K, Takahashi T, Arai M, Wang N, Misao Y, Lu C, Onogi H,
Kobayashi H, Yasuda S, Esaki M, Ushikoshi H, Takemura G, Fujiwara T, Fujiwara H. In vivo
hepatocyte growth factor gene transfer reduces myocardial ischemia-reperfusion injury through its
multiple actions. J Card Fail. 2007;13:874-883.
44㧕 Okubo M, Masanori K, Ishihara Y, Takeyama U, Kubota T, Yamaki T, Ojio S, Nishigaki K, Takemura
G, Saio M, Takami T, Minatoguchi S, Fujiwara H. Development of integrated Backscatter
intravascular ultrasound for tissue characterization of coronary plaques. Ultrasound Med Biol
2008;34:655-663.
45㧕 Nishigaki K, Yamazaki T, Kitabatake A, Yamaguchi T, Kanmatsuse K, Kodama I, Takekoshi N,
Tomoike H, Hori M, Matsuzaki M, Takeshita A, Shimbo T, Fujiwara H, for the JSAP (Japanese Stable
Angina Pectoris) Study Investigators. Percutaneous coronary intervention plus medical therapy
reduces the incidence of acute coronary syndrome more effectively than initial medical therapy only
among patients with low-risk coronary artery disease: A randomized, comparative, multicenter study.
J Am Coll Cardiol: Cardiov Interv 2008;1:469-479.
46㧕 Tanaka S, K, Ojio S, Okubo M, Yasuda S, Ishihara Y, Kubota T, Takasugi N, Kawamura I, Yamaki T,
Ushikoshi H, Aoyama T, Kawasaki M, Takkemura G, Minatoguchi S. Can negative cardiac effect ofproton pump inhibitor and high-dose H2-blocker have clinical influence on patients with stableangina? J Cardiol 2008;52:39-48.
47㧕 Okubo M , Kawasaki M, Ishihara Y, Takeyama U, Yasuda S, Kubota T, Tanaka S, Yamaki T, Ojio S,㧙㧙

IF 3.177

IF 3.724

IF 2.135

IF 1.780

IF 2.135

IF 4.453

IF 1.780

IF 1.427

IF 1.522

IF 2.135

IF 3.724

IF 0.596

IF 2.737

Nishigaki K, Takemura G, Saio M, Takami T, Fujiwara H, Minatoguchi S. Tissue characterization ofcoronary plaques -Comparison of integrated Backscatter intravascular ultrasound with virtual
histology intravascular ultrasound. Circ J 2008;72:1631-1639.
IF 2.13548㧕 Tanaka S, Yokoyama C, Kawamura I, Takasugi N, Kubota T, Ushikoshi H, Aoyama T, Kawasaki M,
Nishigaki K, Takemura G, Minatoguchi S. Conservative medication follow-up for over 20 years of apatient with ischemic heart disease after diagnosis of chronic total occlusion of the 3 main coronary
arteries. Circ J 2008;72:1205-1209.
IF 2.135
49㧕 Kobayashi H, Minatoguchi S, Yasuda S, Bao N, Kawamura I, Iwasa M, Yamaki T, Sumi S, Misao Y,
Ushikoshi H, Nishigaki K, Takemura G, Fujiwara T, Tabata Y, Fujiwara H. Post-infarct treatment
with an erythropoietin-gelatin hydrogel drug delivery system for cardiac repair. Cardiov Res
2008:79:611-620.
IF 5.82650㧕 Tanaka S, Nishigaki K, Ojio S, Yasuda S, Okubo M, Yamaki T, Kubota T, Takasugi N, Ishihara Y,
Kawasaki M, Minatoguchi S. Transcatheter embolization by autologous blood clot is usefulmanagement for small side branch perforation due to percutaneous coronary intervention guide wire.
J Cardiol. 2008;52:285-289.

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦Ḋญା਽㧘⎇ⓥಽᜂ⠪㧦ߥߒ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦⯯ⴊᕈᔃ∔ᖚߦኻߔࠆ㗰☸⃿ࠦࡠ࠾࡯ೝỗ࿃ሶ⊹ਅᵈ኿ߦࠃࠆૐଚⷅ≮ᴺߩ㐿⊒㧧ᐔᚑ 18㧙19 ᐕᐲ㧧3,890
ජ౞(2,200㧦1,690 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦Ꮉፒ㓷ⷙ㧘⎇ⓥಽᜂ⠪㧦ߥߒ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄⪚⧘⎇ⓥ㧦᳇▤ᡰญ⣧ౝ⿥㖸ᵄᢿጀᴺߦ߅ߌࠆᓟᣇᢔੂᵄߦࠃࠆ⚵❱ᕈ⁁⸻ᢿࡊࡠࠣ࡜ࡓߩ㐿⊒㧧ᐔᚑ 18㧙19 ᐕᐲ㧧3,100
ජ౞(1,500㧦1,600 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦⊕ୖ⦟ᄥ(ᄢ㒋ᄢቇ)㧘⎇ⓥಽᜂ⠪㧦⮮ේਭ⟵㧧ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ࡅ࠻ࠥࡁࡓ࡮
ౣ↢ක≮╬⎇ⓥ੐ᬺ㧦⒖ᬀක≮ߦ㑐ߔࠆ࿖㓙Ყセಽᨆߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18 ᐕᐲ㧧2,000 ජ౞4㧕 ⎇ⓥઍ⴫⠪㧦෹ᳰੳᥰ(࿖┙ᓴⅣེ∛࠮ࡦ࠲࡯)㧘⎇ⓥಽᜂ⠪㧦╴੗ᶈਯ(ർᶏ㆏ᄢቇ)㧘ਭ଻↰᡹(ጊᒻᄢቇ)㧘᳗੗⦟ਃ(᧲੩ᄢቇ)㧘ዊᎹ⡡(ᘮᔕ⟵Ⴖᄢቇ)㧘๺ᴰᔀ(ർ㉿ᄢቇ)㧘⮮ේਭ⟵㧘᧻᫪ᤘ(੩ㇺᄢቇ)㧘
ਛ⼱ᱞ༹(࿖┙ᓴⅣེ∛࠮ࡦ࠲࡯)㧘ၳᱜੑ(ᄢ㒋ᄢቇ)㧘ᮮጊశብ(␹ᚭᄢቇ)㧘᧻㦮⋉ᓾ(ጊญᄢቇ)㧘⍾Ꮉ⾫ੑ(਻Ꮊᄢቇ)㧘੹ᴰീ(ਭ⇐☨ᄢቇ)㧘㈕ᔘ๺(㣮ఽፉᄢቇ)㧧ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ㧦․⊒ᕈᔃ╭∝ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ㧧ᐔᚑ 17㧙19 ᐕᐲ㧧2,500 ජ౞(1,500㧦1,000㧦ජ౞)
5㧕 ⎇ⓥઍ⴫⠪㧦╴੗ᶈਯ(ർᶏ㆏ᄢቇ)㧘⎇ⓥಽᜂ⠪㧦ጊญᔀ(⯥ߩ㐷∛㒮)㧘☨Ỉ৻਽(࿖┙∛㒮ᯏ᭴ವ㙚∛㒮)㧘ਅᎹብ᣿(᧲ർᄢቇ)㧘᳗੗⦟ਃ(᧲੩ᄢቇ)㧘๺ᴰᔀ(ർ㉿ᄢቇ)㧘ዊᎹ⡡(ᘮᔕ⟵Ⴖᄢቇ)㧘ᮮጊᐢⴕ(࿖┙∛㒮ᯏ᭴㕒ጟක≮࠮ࡦ࠲࡯)㧘⮮ේਭ⟵㧘෹ᳰੳᥰ(࿖┙ᓴⅣེ∛࠮ࡦ࠲࡯)㧘ၳᱜੑ(ᄢ㒋ᄢቇ)㧘ᮮጊశብ(␹ᚭᄢቇ)㧘⫌ጊ⒤(ᄢ㒋Ꮢ┙ᄢቇ)㧘᧻㦮⋉ᓾ(ጊญᄢቇ)㧘੹ᴰീ(ਭ⇐☨ᄢቇ)㧘᧻ᧄ㜞ብ(࿖┙∛㒮ᯏ᭴਻Ꮊක≮࠮ࡦ࠲࡯)㧘ጊፒജ(᧲੩ᄢቇ)㧘Ḵ਄ື਽(਻Ꮊᄢቇ)㧘ጯ⃍ሶ(ർᶏ㆏ᄢቇ)㧧
ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ᓴⅣེ∔ᖚ╬↢ᵴ⠌ᘠ∛ኻ╷✚ว⎇ⓥ੐ᬺ㧦ో࿖ᖚ⠪⊓㍳࠺࡯࠲ࠍ↪
޿ߚࠊ߇࿖ߩᘟᕈᔃਇోᖚ⠪ߩᕆᕈჇᖡ࡮㔍ᴦൻⷐ࿃ߩ⸃᣿ߣലᨐ⊛ᴦ≮ᴺߩ⏕┙㧧ᐔᚑ 17㧙19 ᐕᐲ㧧0 ජ౞(ਥછ⎇ⓥ⠪৻᜝⸘਄ߩߚ߼)6㧕 ⎇ⓥઍ⴫⠪㧦Ḋญା਽㧘⎇ⓥಽᜂ⠪㧦᧘㦖⯥㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄․೎⎇ⓥຬᅑബ⾌㧦ࠛ࡝ࠬࡠࡐࠛ࠴ࡦᓢ᡼ൻ࠼࡜࠶ࠣ࠺࡝ࡃ࡝࡯ࠪࠬ࠹ࡓߦࠃࠆ㐽Ⴇᕈേ⣂⎬ൻ∝ᴦ≮ᴺߩ㐿⊒㧧ᐔᚑ 19㧙20 ᐕᐲ㧧2,200 ජ౞(1,100㧦1,100 ජ౞)
7㧕 ⎇ⓥઍ⴫⠪㧦Ꮉፒ㓷ⷙ㧘⎇ⓥಽᜂ⠪㧦ߥߒ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚(C)⎇ⓥ㧧౰േ⣂ਇ቟ቯࡊ࡜࡯ࠢᬌ಴ߩߚ߼ߩᣂߒ޿ਃᰴర↹௝᭴▽ⵝ⟎ߩ㐿⊒ߣ⥃ᐥᔕ↪㧧ᐔᚑ 20㧙22 ᐕᐲ㧧3,600 ජ౞(1,300㧦1,400㧦900 ජ౞)
2㧕ฃ⸤⎇ⓥ1㧕 Ḋญା਽㧦ᄤบὖ⮎ߩ᛫േ⣂⎬ൻ૞↪ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18 ᐕᐲ㧧500 ජ౞㧦๺᱌ጊ⋵Ꮏᬺᛛⴚ࠮ࡦ࠲࡯2㧕 Ḋญା਽㧦ࠪࡦࡃࠬ࠲࠴ࡦߩ᪪Ⴇࠨࠗ࠭❗ዊലᨐ࡮࡝ࡕ࠺࡝ࡦࠣᡷༀലᨐߦߟ޿ߡߩᬌ⸛㧧ᐔᚑ 18
㧙19 ᐕᐲ㧧2,100 ජ౞㧦ਁ᦭⵾⮎ᩣᑼળ␠3㧕 ┻᧛రਃ㧦ࠛ࡝ࠬࡠࡐࠛ࠴ࡦߩᔃਇోᡷༀലᨐߩᬌ⸛㧧ᐔᚑ 17㧙19 ᐕᐲ㧧2,000 ජ౞(1,000㧦1,000㧦
0 ජ౞)㧦ਛᄖ⵾⮎ᩣᑼળ␠4㧕 ⮮ේਭ⟵㧦࡚ࠫ࡯ࠬ࠹ࡦ࠻ࠣ࡜ࡈ࠻ࡑࠬ࠲࡯Ꮢ⽼ᓟ૶↪ᚑ❣⺞ᩏ㧧ᐔᚑ 16㧙19 ᐕᐲ㧧21 ජ౞㧦ࠕ㧙㧙ࡏ࠶࠻࡮ࡧࠔࠬࠠࡘ࡜࡯࡮࠺ࡃࠗࠪࠬ࡮ࠫࡖࡄࡦᩣᑼળ␠
5㧕 ⮮ේਭ⟵㧘⷏၂๺ᒾ㧘࿯ደ㇌ᒾ㧘ਭ଻↰⍮Ꮧ㧦ࡔ࠼࠻ࡠ࠾࠶ࠢ InSync8040 ෸߮ࠕ࠹ࠗࡦ࡝࡯࠼ߩ
૶↪ᚑ❣⺞ᩏ㧧ᐔᚑ 16㧙20 ᐕᐲ㧧ᧂቯ(63㧦105㧦105㧦42 ජ౞)㧦ᣣᧄࡔ࠼࠻ࡠ࠾࠶ࠢᩣᑼળ␠
6㧕 Ḋญା਽㧦ࠢ࡟ࠬ࠻࡯࡞㍤૶↪ᚑ❣⺞ᩏ㧧ᐔᚑ 17㧙18 ᐕᐲ㧧210 ජ౞㧦Ⴎ㊁⟵⵾⮎ᩣᑼળ␠7㧕 ⷏၂๺ᒾ㧘Ḋญା਽㧘Ꮉፒ㓷ⷙ㧦౰േ⣂∔ᖚࠍ᦭ߔࠆ㜞ࠦ࡟ࠬ࠹ࡠ࡯࡞ⴊ∝ᖚ⠪ߦ߅ߌࠆࡠࠬࡃࠬ
࠲࠴ࡦ㐳ᦼᛩਈᤨߩⴊ▤ౝ⿥㖸ᵄᬌᩏᴺࠍ↪޿ߚ᦭ലᕈ߅ࠃ߮቟ోᕈߩᬌ⸛㧧ᐔᚑ 17㧙19 ᐕᐲ㧧
2,318.4 ජ౞(1,159.2㧦695.52㧦463.68 ජ౞)㧦Ⴎ㊁⟵⵾⮎ᩣᑼળ␠㧧ᐔᚑ 18 ᐕᐲ㧧472.5 ජ౞㧦
8㧕 Ḋญା਽㧦ࡉࡠࡊ࡟ࠬ㍤․ቯ૶↪ᚑ❣⺞ᩏ‫ޟ‬ᘟᕈᔃਇో㧦㐳ᦼ૶↪‫ޠ‬ᱞ↰⮎ຠᎿᬺᩣᑼળ␠
9㧕 ⷏၂๺ᒾ㧘࿯ደ㇌ᒾ㧘ਭ଻↰⍮Ꮧ㧦ࠕ࠹ࠗࡦ OTW ࡝࡯࠼ߩ૶↪ᚑ❣⺞ᩏ㧧ᐔᚑ 18㧙20 ᐕᐲ㧧315
ජ౞㧦ᣣᧄࡔ࠼࠻ࡠ࠾࠶ࠢᩣᑼળ␠
10㧕 Ḋญା਽㧦࡝ࡑ࠴࡞㍤ 100mg ߩ೽૞↪⺞ᩏ㧧ᐔᚑ 18㧙20 ᐕᐲ㧧21 ජ౞㧦ෳᄤ⵾⮎ᩣᑼળ␠11㧕 Ḋญା਽㧘᧛↰৻⍮ᦶ㧘᫪㤀㧦ࡉ࡟࠺ࠖ࠾ࡦ㍤ේ⊒ᕈ♻⃿૕∔ᖚࠍේ࿃ߣߔࠆࡀࡈࡠ࡯࠯∝୥⟲․ቯ૶↪ᚑ❣⺞ᩏ(㐳ᦼ૶↪ߦ㑐ߔࠆ⺞ᩏ)㧧ᐔᚑ 18㧙22 ᐕᐲ㧧630 ජ౞㧦ᣩൻᚑࡈࠔ࡯ࡑᩣᑼળ␠
12㧕 Ḋญା਽㧦࠲ࠠ࠰࠹࡯࡞ᵈ೽૞↪⹦⚦⺞ᩏ㧧ᐔᚑ 18 ᐕᐲ㧧21 ජ౞㧦ࠨࡁࡈࠖ࡮ࠕࡌࡦ࠹ࠖࠬᩣᑼ
ળ␠
13㧕 ⷏၂๺ᒾ㧘࿯ደ㇌ᒾ㧘ਭ଻↰⍮Ꮧ㧦ࡔ࠼࠻ࡠ࠾࠶ࠢ InSyncΥࡑ࡯ࠠ࡯ߩ૶↪ᚑ❣⺞ᩏ㧧ᐔᚑ 19㧙
20 ᐕᐲ㧧ᧂቯ(63 ජ౞)㧦ᣣᧄࡔ࠼࠻ࡠ࠾࠶ࠢᩣᑼળ␠
14㧕 ⷏၂๺ᒾ㧘ਭ଻↰⍮Ꮧ㧦ࠦࡦ࠲࠶ࠢ ࡝࠾ࡘ࡯ࠕ࡞ 4㧘ࠦࡦ࠲࠶ࠢ ࡝࠾ࡘ࡯ࠕ࡞ 4HE ෸߮㧛߽ߒߊߪࠗ࡯ࠫ࡯࠻࡜࠶ࠢ 2 ࡝࡯࠼㧘ࠗ࡯ࠫ࡯࠻࡜࠶ࠢ 2CS ࡝࡯࠼ߩ૶↪ᚑ❣⺞ᩏ㧧ᐔᚑ 19 ᐕᐲ㧧210
ජ౞㧦ᣣᧄࠟࠗ࠳ࡦ࠻ᩣᑼળ␠
15㧕 ⷏၂๺ᒾ㧘Ḋญା਽㧘Ꮉፒ㓷ⷙ㧦ࡠࠬࡃࠬ࠲࠴ࡦ⵾ㅧ⽼ᄁᓟ⥃ᐥ⹜㛎㧧ᐔᚑ 19 ᐕᐲ㧧463.68 ජ౞㧦Ⴎ㊁⟵⵾⮎ᩣᑼળ␠
16㧕 ⷏၂๺ᒾ㧦ࠪࠣࡑ࡯࠻ᵈ૶↪ᚑ❣⺞ᩏ㧙ᕆᕈᔃਇో㧙㧔ᘟᕈᔃਇోߩᕆᕈჇᖡᦼࠍ฽߻㧕㧧ᐔᚑ 20
ᐕᐲ㧙22 ᐕᐲ㧧ᧂቯ(210 ජ౞)㧦ਛᄖ⵾⮎ᩣᑼળ␠
3㧕౒ห⎇ⓥ1㧕 Ḋญା਽㧦ࠪࡦࡃࠬ࠲࠴ࡦߩ᪪Ⴇࠨࠗ࠭❗ዊലᨐ࡮࡝ࡕ࠺࡝ࡦࠣᡷༀലᨐߦߟ޿ߡߩᬌ⸛㧧ᐔᚑ 18
㧙19 ᐕᐲ㧧2,100 ජ౞㧦ਁ᦭⵾⮎ᩣᑼળ␠2㧕 ┻᧛రਃ㧦ࠛ࡝ࠬࡠࡐࠛ࠴ࡦߩᔃਇోᡷༀലᨐߩᬌ⸛㧧ᐔᚑ 17㧙19 ᐕᐲ㧧2,000 ජ౞(1,000㧦1,000㧦
0 ජ౞)㧦ਛᄖ⵾⮎ᩣᑼળ␠3㧕 Ḋญା਽㧘ᄢ㊁ᐽ㧦ߓ߾߫ࠄߩ᳇▤ᡰ༎ᕷߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 19 ᐕᐲ㧧1,000 ජ౞㧦๺᱌ጊ⋵᧲—ᇋ㇭ർጊ᧛
4㧕 Ḋญା਽㧘ᄢ㊁ᐽ㧦ߓ߾߫ࠄߩ᳇▤ᡰ༎ᕷߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 20 ᐕᐲ㧧1,000 ජ౞㧦๺᱌ጊ⋵᧲—ᇋ㇭ർጊ᧛5㧕 ┻᧛రਃ㧦ᓴⅣེ∔ᖚߦ߅ߌࠆⴊ▤ౣ↢ߩᓎഀ㧧ᐔᚑ 20 ᐕᐲ㧧5,500 ජ౞㧕㧦ᄢႦ⵾⮎ᩣᑼળ␠
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬḊญା਽㧦
1㧕 ᣣᧄᓴⅣེቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄᓴⅣེቇળ᧲ᶏᡰㇱ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄᓴⅣ೙ᓮකቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄᔃਇోቇળ⹏⼏ຬ(㨪⃻࿷)5㧕 ᣣᧄᔃ⤳∛ቇળ⹏⼏ຬ(㨪⃻࿷)6㧕 ᣣᧄౝ⑼ቇળ᧲ᶏᡰㇱ⹏⼏ຬ(㨪⃻࿷)7㧕 ᣣᧄ㜞ⴊ࿶ቇળ⹏⼏ຬ(㨪⃻࿷)8㧕 ᣣᧄᔃ⤳࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦቇળ⹏⼏ຬ(㨪⃻࿷)㧙㧙┻᧛రਃ㧦
1㧕 ᣣᧄᓴⅣེቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄᓴⅣེቇળ᧲ᶏᡰㇱ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄౝ⑼ቇળ᧲ᶏᡰㇱ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄᔃਇోቇળ⹏⼏ຬ(㨪⃻࿷)5㧕 ᣣᧄ⥃ᐥಽሶᒻᘒቇળ⹏⼏ຬ(㨪⃻࿷)6㧕 ᣣᧄࠕࡐ࠻࡯ࠪࠬ⎇ⓥળ⹏⼏ຬ(㨪⃻࿷)7㧕 ᔃ╭↢ᬌ⎇ⓥળᐙ੐(㨪⃻࿷)8㧕 ࠕࡔ࡝ࠞᔃ⤳∛ቇળ Fellow(㨪⃻࿷)⷏၂๺ᒾ㧦1㧕 ᣣᧄౝ⑼ቇળ᧲ᶏᡰㇱ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄᓴⅣེቇળᔃ⤳⒖ᬀᆔຬળ࡮ᔃ⤳⒖ᬀㆡᔕᬌ⸛ዊᆔຬળᐙ੐(㨪⃻࿷)3㧕 ᣣᧄᓴⅣེቇળ᧲ᶏᡰㇱ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄᔃⴊ▤ࠞ࠹࡯࠹࡞ᴦ≮ቇળ⹏⼏ຬ(㨪⃻࿷)5㧕 ᣣᧄᔃⴊ▤ࠞ࠹࡯࠹࡞ᴦ≮ቇળ᧲ᶏർ㒽࿾ᣇળ⹏⼏ຬ(㨪⃻࿷)6㧕 ᣣᧄᔃਇోቇળ⹏⼏ຬ(㨪⃻࿷)7㧕 ᣣᧄᔃ⤳∛ቇળ⹏⼏ຬ(㨪⃻࿷)8㧕 ᣣᧄᓴⅣེቇળ‫ޡ‬౰േ⣂∔ᖚߦ߅ߌࠆࠗࡦ࠲࡯ࡌࡦ࡚ࠪࡦᴦ≮ߩㆡᔕࠟࠗ࠼࡜ࠗࡦ㧔౰േ⣂ࡃࠗࡄࠬⴚߩㆡᔕࠍ฽߻㧕ᓙᯏ⊛ࠗࡦ࠲࡯ࡌࡦ࡚ࠪࡦ‫ޢ‬ᡷ⸓ ⃰ຬ࡮੐ോዪ(㨪⃻࿷)9㧕 ᣣᧄᓴⅣེቇળ‫ޡ‬Ꮉፒ∛ᔃ⤳ⴊ▤ᓟㆮ∝ߩ⸻ᢿߣᴦ≮ߦ㑐ߔࠆࠟࠗ࠼࡜ࠗࡦ‫ޢ‬ᡷ⸓ ⃰ຬ(㨪⃻࿷)Ꮉፒ㓷ⷙ㧦1㧕 ᣣᧄᓴⅣེቇળ᧲ᶏᡰㇱ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄౝ⑼ቇળ᧲ᶏᡰㇱ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄᔃⴊ▤↹௝േᘒቇળ⹏⼏ຬ(㨪⃻࿷)㕍ጊ℉⏴㧦1㧕 ᣣᧄᓴⅣེቇળ᧲ᶏᡰㇱ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄౝ⑼ቇળ᧲ᶏᡰㇱ⹏⼏ຬ(㨪⃻࿷)ᄢ㊁ᐽ㧦
1㧕 ᣣᧄ๭ๆེቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ⢖≸ቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄౝ⑼ቇળ᧲ᶏᡰㇱ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
Ḋญା਽㧦
1㧕 Circ.J. Editorial board (㨪⃻࿷)2㧕 Journal of Life Style Medicine‫ޡ‬Life Style Medicine‫✬ޢ‬㓸ᆔຬ(㨪⃻࿷)⷏၂๺ᒾ㧦1㧕 ᣣᧄᔃⴊ▤ࠞ࠹࡯࠹࡞ᴦ≮ቇળ㔀⹹‫ޡ‬JACCT‫✬ޢ‬㓸㘈໧(㨪⃻࿷)7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳⮮ේਭ⟵㧦
1㧕 ╙ 70 ࿁⸥ᔨᣣᧄᓴⅣེቇળ✚ળ࡮ቇⴚ㓸ળ(ᐔᚑ 18 ᐕ 3 ᦬㧘ฬฎደ㧘Late Breaking Clinical Trials
in Japan‫ޟ‬J-SAP Study Outcomes of Patients with Low Risk Angina Receiving Medical -and PCIPreceding Therapies in Japan‫ޠ‬Ṷ⠪)
2㧕 ╙ 70 ࿁⸥ᔨᣣᧄᓴⅣེቇળ✚ળ࡮ቇⴚ㓸ળ(ᐔᚑ 18 ᐕ 3 ᦬㧘ฬฎደ㧘ળ㐳⻠Ṷ‫ޟ‬Regeneration㧙㧙Medicine as the Ultimate Medicine‫ޠ‬Ṷ⠪)
3㧕 ╙ 70 ࿁⸥ᔨᣣᧄᓴⅣེቇળ✚ળ࡮ቇⴚ㓸ળ(ᐔᚑ 18 ᐕ 3 ᦬㧘ฬฎደ㧘ᣣᧄᔃ⤳⽷࿅૒⮮⾨ฃ⾨⸥ᔨ⻠Ṷ‫ޟ‬Identification of Genetic Factors and Development of Genetic Risk Diagnosis Systems for
Cardiovascular Deseases‫ޠ‬ᐳ㐳)
4㧕 ╙ 2 ࿁㧔ㅢ▚ 23 ࿁㧕ਛ㑆ᴺੱᣣᧄ⥃ᐥౝ⑼කળ✚ળ(ᐔᚑ 18 ᐕ 4 ᦬㧘ᮮᵿ㧘․೎⻠Ṷ‫ޟ‬༛ᾍߪ∔ᖚ㧘༛ᾍ⠪ߪᖚ⠪̆9 ቇળวห⑌ᾍࠟࠗ࠼࡜ࠗࡦࠍਛᔃߦ̆‫ޠ‬Ṷ⠪)
5㧕 ╙ 36 ࿁ᣣᧄౝ⑼ቇળർᶏ㆏ᡰㇱ↢ᶦᢎ⢒⻠Ṷળ(ᐔᚑ 18 ᐕ 9 ᦬㧘ᧅᏻ㧘․೎⻠Ṷ‫ޟ‬ᚒ߇࿖ߩ⁜ᔃ∝࡮ᔃ╭᪪Ⴇᴦ≮ߩ໧㗴ὐ‫ޠ‬Ṷ⠪)Ḋญା਽㧦
1㧕 ╙ 70 ࿁⸥ᔨᣣᧄᓴⅣེቇળ✚ળ࡮ቇⴚ㓸ળ(ᐔᚑ 18 ᐕ 3 ᦬㧘ฬฎደ㧘Symposium2(IHD)‫ޟ‬Pharmacological Intervention for Coronary Artery Disease‫ޠ‬ᐳ㐳)2㧕 ╙ 70 ࿁⸥ᔨᣣᧄᓴⅣེቇળ✚ળ࡮ቇⴚ㓸ળ(ᐔᚑ 18 ᐕ 3 ᦬㧘ฬฎደ㧘Symposium2(IHD)‫ޟ‬D㧙
Glucosdsse Inhibitorsane protective against ischemia / reperfusion injury‫ޠ‬Ṷ⠪)
3㧕 ᣣᧄ૕ജකቇળ✚ળ(ᐔᚑ 18 ᐕ 3 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬ౣ↢කቇ߆ࠄౣ↢ක≮߳㧙․ߦᓴⅣེ∔ᖚߦߟ޿ߡ㧙‫ޠ‬Ṷ⠪)
4㧕 ╙ 71 ࿁⸥ᔨᣣᧄᓴⅣེቇળ✚ળ࡮ቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 3 ᦬㧘␹ᚭ㧘Featured Research Session16(H)‫ޟ‬Vascular Injury and Neointimal Formation in Animal Models(basic) ‫ޠ‬ᐳ㐳)
5㧕 ╙ 71 ࿁⸥ᔨᣣᧄᓴⅣེቇળ✚ળ࡮ቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 3 ᦬㧘␹ᚭ㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯‫ⴊ⯯ޟ‬ᔃ╭଻⼔ߣ Ca ᜟ᛫⮎‫ޠ‬Ṷ⠪)
6㧕 ᣣᧄ NO ቇળ(ᐔᚑ 19 ᐕ 6 ᦬㧘ᄢᵤ㧘․೎⻠Ṷ 2‫ޟ‬NO ߣ⯯ⴊᔃ╭଻⼔‫ޠ‬Ṷ⠪)7㧕 ᣣᧄౝ⑼ቇળ᧲ᶏᡰㇱ↢ᶦᢎ⢒⻠Ṷળ(ᐔᚑ 19 ᐕ 10 ᦬㧘ฬฎደ㧘⻠Ṷ‫ޟ‬ฦ⒳ᓴⅣེ⮎ࠍ↪޿ߚ⯯ⴊᔃ╭଻⼔‫ޠ‬Ṷ⠪)8㧕 ╙ 72 ࿁⸥ᔨᣣᧄᓴⅣེቇળ✚ળ࡮ቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 3 ᦬㧘⑔ጟ㧘Symposium1(IHD)‫ޟ‬DES ᤨઍߩ⮎‛≮ᴺࠍౣ⹏ଔߔࠆ‫ޠ‬ᐳ㐳)9㧕 ╙ 72 ࿁⸥ᔨᣣᧄᓴⅣེቇળ✚ળ࡮ቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 3 ᦬㧘⑔ጟ㧘Plenary Session2(IHD)‫ޟ‬A Low
Dose but Long Duration Post-myocardial Infarction Treatment with Granulocyte
Colony-stimulating Factor Shows a Beneficial Effect without any Complications‫ޠ‬Ṷ⠪)⷏၂๺ᒾ㧦
1㧕 ╙ 70 ࿁⸥ᔨᣣᧄᓴⅣེቇળ✚ળ࡮ቇⴚ㓸ળ(ᐔᚑ 18 ᐕ 3 ᦬㧘ฬฎደ㧘Controversy1(IHD/M)‫ޟ‬ᣣᧄੱߩૐᏀቶᯏ⢻ᖚ⠪ߩ੍ᓟߣᴦ≮ㆬᛯ‫ޠ‬ᐳ㐳)2㧕 ╙ 70 ࿁⸥ᔨᣣᧄᓴⅣེቇળ✚ળ࡮ቇⴚ㓸ળ(ᐔᚑ 18 ᐕ 3 ᦬㧘ฬฎደ㧘Luncheon Seminar 38 ⯯ⴊᔃ╭଻⼔ -Pharmacological preconditioning ߣ ischemic postconditioning- ⻠Ṷ 1 ‫ޟ‬Sarpogrelate,a 5-HT2 receptor blocker, have an ischemic preconditioning-like effect‫ޠ‬Ṷ⠪)
3㧕 ╙ 70 ࿁⸥ᔨᣣᧄᓴⅣེቇળ✚ળ࡮ቇⴚ㓸ળ(ᐔᚑ 18 ᐕ 3 ᦬㧘ฬฎደ㧘ᣣᧄᓴⅣེቇળᆔຬળᵴേ㧔ᔃ
⤳⒖ᬀᆔຬળ㧕╙ 2 ࿁ᔃ⤳⒖ᬀ࠮ࡒ࠽࡯ ‫ޟ‬ᬀ߃ㄟߺဳ⵬ഥᔃ⤳ߩ⃻⁁ߣ੹ᓟߩ⺖㗴‫⻠ޠ‬Ṷ ႎ๔ 1‫߇ࠊޟ‬࿖ߦ߅ߌࠆᔃ⤳⒖ᬀߩ⃻ᴫ‫ޠ‬Ṷ⠪)
4㧕 ᣣᧄᓴⅣེቇળ╙ 128 ࿁᧲ᶏ࡮╙ 113 ࿁ർ㒽วห࿾ᣇળ ࠨ࠹࡜ࠗ࠻ᢎ⢒⻠Ṷ(ᐔᚑ 18 ᐕ 11 ᦬㧘ฬฎደ㧘‫ޟ‬㐳ᦼ੍ᓟ߆ࠄ⷗ߚ⁜ᔃ∝ߩᴦ≮ᚢ⇛‫⹤ޠ‬㗴ឭଏ 3 ‫ޟ‬ૐ࡝ࠬࠢ⁜ᔃ∝ߩ㐳ᦼ੍ᓟ гPCI వⴕ≮ᴺߣ⮎‛వⴕ≮ᴺߩᲧセг‫ޠ‬Ṷ⠪)┻᧛రਃ㧦
1㧕 ╙ 70 ࿁⸥ᔨᣣᧄᓴⅣེቇળ✚ળ࡮ቇⴚ㓸ળ(ᐔᚑ 18 ᐕ 3 ᦬㧘ฬฎደ㧘Meet the Expert3(M)‫ޟ‬Morphology Revisited㧙ᓴⅣེ∛⎇ⓥ࡮⥃ᐥߦ߅ߌࠆᒻᘒቇߩ૏⟎ઃߌ‫ޠ‬ᐳ㐳)2㧕 ╙ 70 ࿁⸥ᔨᣣᧄᓴⅣེቇળ✚ળ࡮ቇⴚ㓸ળ(ᐔᚑ 18 ᐕ 3 ᦬㧘ฬฎደ㧘Plenary Session-3㧦 Cell Deathand Repair –Regeneration in Cardiac and Vascular Diseases “Distinct Features of Apoptosis andRegeneration in Cardiac Myocytes and Nonmyocytes”Ṷ⠪)ฬฎደ㧘Meet the Expert-3㧦 Morphology
3㧕 ╙ 70 ࿁⸥ᔨᣣᧄᓴⅣེቇળ✚ળ࡮ቇⴚ㓸ળ(ᐔᚑ 18 ᐕ 3 ᦬㧘
Revisited: ᓴⅣེ∛⎇ⓥ࡮⥃ᐥߦ߅ߌࠆᒻᘒቇߩ૏⟎ઃߌ“Electron Microscopic Cytochemistry: A
Tool for Bridging Structures with Function and Molecular Events and for More”Ṷ⠪)4㧕 The Annual Scientific Meeting of American Heart Association (2006.11, Chicago, IL, USA,
Cardiovascular Seminar #59: AHA-JCS Joint Symposium: Myocyte Death in Heart㧙㧙failure-Autophagy, Apoptosis and Necrosis: “Apoptosis and autophagy in failing heart”;
Symposist)Ꮉፒ㓷ⷙ㧦1㧕 ╙ 70 ࿁⸥ᔨᣣᧄᓴⅣེቇળ✚ળ࡮ቇⴚ㓸ળ(ᐔᚑ 18 ᐕ 3 ᦬㧘ฬฎደ㧘TOPICS 5 Beyond Conventional
Signal Analysis ᐳ㐳)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ1㧕 Ꮉፒ㓷ⷙ㧦⽷࿅ᴺੱ࿾ၞකቇ⎇ⓥၮ㊄⎇ⓥഥᚑ․೎ᅑബ⾨(ᐔᚑ 18 ᐕᐲ)
2㧕 ਭ଻↰⍮Ꮧ㧦ᄖጊၮ㊄ߦࠃࠆ࿖㓙੤ᵹഥᚑ(ᐔᚑ 18 ᐕᐲ)
3㧕 ⍹ේ⟵ਯ㧦⽷࿅ᴺੱක⑼ቇᔕ↪⎇ⓥ࿅࿖㓙੤ᵹഥᚑ(ᐔᚑ 19 ᐕᐲ)
4㧕 Ꮉፒ㓷ⷙ㧦㜞ⴊ࿶ߣ౰േ⣂∔ᖚ⎇ⓥળ⎇ⓥഥᚑ⎇ⓥ․೎⾨(ᐔᚑ 19 ᐕᐲ)
5㧕 ┻᧛రਃ㧦ᐔᚑ 19 ᐕጘ㒂ᄢቇᵴᕈൻ⚻⾌(ᐔᚑ 19 ᐕᐲ)
6㧕 ⷏၂๺ᒾ㧦╙ 11 ࿁ᣣᧄᔃਇోቇળቇⴚ㓸ળఝ⑲Ṷ㗴⾨(ᐔᚑ 19 ᐕᐲ)
7㧕 Ḋญା਽㧦㋈ᧁ⻞ਃ⸥ᔨ⽷࿅ᴺੱක⑼ቇᔕ↪⎇ⓥ⽷࿅ ⎇ⓥഥᚑ㊄(ᐔᚑ 20 ᐕᐲ)
8㧕 ⩆㊁ᢕผ㧦╙ 46 ࿁ጘ㒂⋵ౝ⑼කળ⻠Ṷળጘ㒂⋵ౝ⑼කળᅑബ⾨(ᐔᚑ 20 ᐕᐲ)
9㧕 ㊄᫪ኡల㧦╙ 12 ࿁ᣣᧄᔃਇోቇળቇⴚ㓸ળ YIA ఝ⑲⾨(ᐔᚑ 20 ᐕᐲ)
10㧕 ㊄᫪ኡల㧦╙ 30 ࿁ᔃ╭↢ᬌ⎇ⓥળ⧯ᚻᅑബ⾨(ᐔᚑ 20 ᐕᐲ)
9㧚␠ળᵴേ
ߥߒ
10㧚ႎ๔ᦠ
1㧕 ⮮ේਭ⟵㧦᜛ᒛဳᔃ╭∝ߦኻߔࠆ㗰☸⃿ࠦࡠ࠾࡯ೝỗ࿃ሶࠍ↪޿ߚ㕖ଚⷅᕈౣ↢ක≮ߩ᜸ᚢ㧦ᐔᚑ
15 ᐕᐲ㧙17 ᐕᐲᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ⎇ⓥᚑᨐႎ๔ᦠ㧦1㧙150(2006 ᐕ 5 ᦬)
2㧕 Ḋญା਽㧦ᔃ╭᪪Ⴇߦኻߔࠆ G-CSF ലᨐߩᣂߒ޿ࡔࠞ࠾࠭ࡓ‫ޔ‬ᴦ≹ㆊ⒟ଦㅴലᨐߩಽሶᯏ᭴㧦ᐔᚑ
16 ᐕᐲ㧙17 ᐕᐲᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ⎇ⓥᚑᨐႎ๔ᦠ㧦1㧙11(2006 ᐕ 5 ᦬)
3㧕 ⷏၂๺ᒾ㧦㗰☸⃿ࠦࡠ࠾࡯ೝỗ࿃ሶ(G㧙CSF)ࠍ↪޿ߚ㔍ᴦᕈ⁜ᔃ∝ߦኻߔࠆౣ↢ක≮ߩ㐿⊒㧦ᐔᚑ
16 ᐕᐲ㧙17 ᐕᐲᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ⎇ⓥᚑᨐႎ๔ᦠ㧦1㧙52(2006 ᐕ 5 ᦬)
4㧕 ┻᧛రਃ㧦ᄢဳ᪪Ⴇᓟᔃਇోߦኻߔࠆࠕࡐ࠻࡯ࠪࠬ㒖ኂߥࠄ߮ߦᔃ╭ౣ↢ߩ૬↪≮ᴺߩ⹜ߺ㧦ᐔᚑ
16 ᐕᐲ㧙17 ᐕᐲᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ⎇ⓥᚑᨐႎ๔ᦠ㧦1㧙59(2006 ᐕ 5 ᦬)
11㧚ႎ㆏1㧕 ⮮ේਭ⟵㧦╙ 70 ࿁⸥ᔨᣣᧄᓴⅣེቇળ✚ળ࡮ቇⴚ㓸ળ‫ޟ‬Ꮢ᳃౏㐿⻠ᐳ‫ޠ‬㧦ᦺᣣᣂ⡞(2006 ᐕ 2 ᦬ 12
ᣣ)2㧕 ⮮ේਭ⟵㧦╙ 70 ࿁⸥ᔨᣣᧄᓴⅣེቇળ✚ળ࡮ቇⴚ㓸ળ‫ޟ‬Ꮢ᳃౏㐿⻠ᐳ‫ޠ‬㧦ᦺᣣᣂ⡞(2006 ᐕ 2 ᦬ 14
ᣣ)3㧕 ⮮ේਭ⟵㧦╙ 70 ࿁⸥ᔨᣣᧄᓴⅣེቇળ✚ળ࡮ቇⴚ㓸ળ‫ޟ‬Ꮢ᳃౏㐿⻠ᐳ‫ޠ‬㧦ᦺᣣᣂ⡞(2006 ᐕ 2 ᦬ 16
ᣣ)4㧕 ⮮ේਭ⟵㧦╙ 70 ࿁⸥ᔨᣣᧄᓴⅣེቇળ✚ળ࡮ቇⴚ㓸ળ‫ޟ‬Ꮢ᳃౏㐿⻠ᐳ‫ޠ‬㧦ᦺᣣᣂ⡞(2006 ᐕ 2 ᦬ 18
ᣣ)5㧕 ⮮ේਭ⟵㧦ᔃ⤳∛ࠞ࠹࡯࠹࡞ᴦ≮ᣣᧄߪታᣉㆊᄙ㧫࿖㓙ࠪࡦࡐߢႎ๔㧦ᣣᧄ⚻ᷣᣂ⡞(2006 ᐕ 2 ᦬
20 ᣣ)
6㧕 ⮮ේਭ⟵㧦╙ 70 ࿁⸥ᔨᣣᧄᓴⅣེቇળ✚ળ࡮ቇⴚ㓸ળ‫ޟ‬Ꮢ᳃౏㐿⻠ᐳ‫ޠ‬㧦ᦺᣣᣂ⡞(2006 ᐕ 2 ᦬ 22
ᣣ)7㧕 ⮮ේਭ⟵㧦ᕆᕈᔃ╭᪪Ⴇߩේ࿃‛⾰⿥㖸ᵄߢᣧᦼߦ․ቯ㧦ᦺᣣᣂ⡞(2006 ᐕ 2 ᦬ 23 ᣣ)
8㧕 ⮮ේਭ⟵㧦╙ 70 ࿁⸥ᔨᣣᧄᓴⅣེቇળ✚ળ࡮ቇⴚ㓸ળ‫ޟ‬Ꮢ᳃౏㐿⻠ᐳ‫ޠ‬㧦ᦺᣣᣂ⡞(2006 ᐕ 2 ᦬ 23
ᣣ)9㧕 ⮮ේਭ⟵㧦╙ 70 ࿁⸥ᔨᣣᧄᓴⅣེቇળ✚ળ࡮ቇⴚ㓸ળ‫ޟ‬Ꮢ᳃౏㐿⻠ᐳ‫ޠ‬㧦ᦺᣣᣂ⡞(2006 ᐕ 2 ᦬ 25
ᣣ)10㧕 ⮮ේਭ⟵㧦╙ 70 ࿁⸥ᔨᣣᧄᓴⅣེቇળ✚ળ࡮ቇⴚ㓸ળ‫ޟ‬Ꮢ᳃౏㐿⻠ᐳ‫ޠ‬㧦ਛᣣᣂ⡞(2006 ᐕ 2 ᦬ 25
ᣣ)11㧕 ⮮ේਭ⟵㧦╙ 70 ࿁⸥ᔨᣣᧄᓴⅣེቇળ✚ળ࡮ቇⴚ㓸ળ‫ޟ‬Ꮢ᳃౏㐿⻠ᐳ‫ޠ‬㧦ᦺᣣᣂ⡞(2006 ᐕ 2 ᦬ 26

㧙㧙

ᣣ)
12㧕 ⮮ේਭ⟵㧦ᓴⅣེක≮ߩߐࠄߥࠆ⊒ዷ࡮ㅴᱠࠍ߼ߑߒߡ㧦ਛᣣᣂ⡞(2006 ᐕ 2 ᦬ 28 ᣣ)
13㧕 ⮮ේਭ⟵㧦╙ 70 ࿁⸥ᔨᣣᧄᓴⅣེቇળ✚ળ࡮ቇⴚ㓸ળ‫ޟ‬Ꮢ᳃౏㐿⻠ᐳ‫ޠ‬㧦ᦺᣣᣂ⡞(2006 ᐕ 2 ᦬ 28
ᣣ)14㧕 ⮮ේਭ⟵㧦╙ 70 ࿁⸥ᔨᣣᧄᓴⅣེቇળ✚ળ࡮ቇⴚ㓸ળ‫ޟ‬Ꮢ᳃౏㐿⻠ᐳ‫ޠ‬㧦ᦺᣣᣂ⡞(2006 ᐕ 3 ᦬ 1ᣣ)15㧕 ⮮ේਭ⟵㧦╙ 70 ࿁⸥ᔨᣣᧄᓴⅣེቇળ✚ળ࡮ቇⴚ㓸ળ‫ޟ‬Ꮢ᳃౏㐿⻠ᐳ‫ޠ‬㧦ᦺᣣᣂ⡞(2006 ᐕ 3 ᦬ 2ᣣ)16㧕 ⮮ේਭ⟵㧦‫ޟ‬༛ᾍߪ∛᳇‫ߦޠ‬ᛶ᛫൓ജߩო㧦⺒ᄁᣂ⡞(2006 ᐕ 3 ᦬ 9 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔ
ฦಽ㊁ߢߩ⎇ⓥ߇㗅⺞ߦㅴⴕߒ㧘৻ᵹߩࠫࡖ࡯࠽࡞ߦ಴ ߐࠇ㧘2005 ᐕߪ⧷ᢥ⺰ᢥᢙ 17 ߢࠗࡦࡄࠢ
࠻ࡈࠔࠢ࠲࡯߇ 40 ὐ㧘2006 ᐕߪ⧷ᢥ⺰ᢥᢙ 26 ߢࠗࡦࡄࠢ࠻ࡈࠔࠢ࠲࡯߇ 85 ὐ㧘2007 ᐕߪ⧷ᢥ⺰ᢥ
ᢙ 17 ߢࠗࡦࡄࠢ࠻ࡈࠔࠢ࠲࡯߇ 47 ὐ㧘2008 ᐕߪ⧷ᢥ⺰ᢥᢙ 17 ߢ޽ߞߚ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ᄙᢙߩᄢቇ㒮↢߿⎇ⓥ⠪ࠍᛴ߃㧘࠺ࠬࠢ߿ࠬࡍ࡯ࠬࠍ⏕଻ߔࠆߎߣߦ࿎㔍ߒߡ޿ࠆ‫⥃ߚ߹ޕ‬ᐥ㧘ᢎ⢒,⎇ⓥߩ޿ߕࠇߦ߽ᤨ㑆ࠍ⾌߿ߔߚ߼㧘⎇ⓥߦචಽߥᤨ㑆߇޽ࠆߣߪ⸒޿㔍޿‫ޕ‬੹ᓟߩዷᦸ㜞㦂ൻߥࠄ߮ߦ↢ᵴ᭽ᑼߩ᰷☨ൻߦ઻޿㧘ᓴⅣེ∔ᖚ㧘⣢⤳∔ᖚߪჇടߩ৻ㅜࠍㄡߞߡ޿ࠆ‫ߙࠇߘޕ‬ࠇߩ∛᳇ߩࡔࠞ࠾࠭ࡓࠍേ‛ታ㛎㧘⥃ᐥ⎇ⓥࠍㅢߓߡ⸃᣿ߒ㧘ᴦ≮ߦᔕ↪ߒߡ޿ߊߎߣ߇㊀ⷐߢ޽ࠆ‫ޕ‬੹ᓟ㧘ᓴⅣེ∔ᖚ㧘⣢⤳∔ᖚߩಽ㊁ߦ߅޿ߡ⚦⢩ᱫߥࠄ߮ߦ⚦⢩ᄌᕈ㧔ࠕࡐ࠻࡯ࠪࠬ㧘ࠝ࡯࠻ࡈࠔࠫ࡯
╬㧕㧘⚦⢩ࠍౣ↢ߔࠆౣ↢කቇߥߤ߇߹ߔ߹ߔ㊀ⷐߥ⎇ⓥ࠹࡯ࡑߣߥࠆߎߣ߇੍ᗐߐࠇࠆ‫ޕ‬ᓥߞߡᚒ‫ߪޘ‬ߎߩὐࠍචಽ⹺⼂ߒ㧘⚦⢩↢‛ቇ⊛ᚻᴺࠍ㚟૶ߒᣂߒ޿࠺ࡃࠗࠬࠍዉ౉ߒߡ㧘ߐࠄߦᵴ⊒ߥ⎇ⓥᵴേࠍ
ⴕߞߡ޿߆ߥߊߡߪߥࠄߥ޿ߣ⠨߃ࠆ‫ޕ‬㧙㧙㧔2㧕๭ๆ∛ᘒቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
1㧕ౣ↢කቇ
1㧕COPD㧘⢖✢⛽∝ߦኻߔࠆ㛽㜑ᐙ⚦⢩⒖ᬀߦࠃࠆౣ↢කቇ࡮ක≮2㧕G-CSF㧔㗰☸⃿ࠦࡠ࠾࡯ೝỗ࿃ሶ㧕ࠍ↪޿ߚ COPD㧘⢖✢⛽∝ߦኻߔࠆౣ↢≮ᴺߩ㐿⊒
2㧕ࠕࡐ࠻࡯ࠪࠬ࡮ࠝ࡯࠻ࡈࠔࠫ࡯
1㧕๭ๆེ∔ᖚߣࠕࡐ࠻࡯ࠪࠬ
⢖⢩✢⛽⧘⚦⢩ࠕࡐ࠻࡯ࠪࠬ㒖ኂߦࠃࠆ࡝ࡕ࠺࡝ࡦࠣߩ੍㒐
3㧕COPD ߩࡔࠞ࠾࠭ࡓ⸃᣿ߣ new drug ߩ㐿⊒1㧕㉄ൻࠬ࠻࡟ࠬߣ๭ๆེ∔ᖚ㧔COPD㧘᳇▤ᡰ༎ᕷ㧘⢖✢⛽∝㧕ߩࡔࠞ࠾࠭ࡓ⸃᣿
2㧕᛫㉄ൻ⮎ߢ޽ࠆ Tetomilast ߦࠃࠆ⢖⢩଻⼔૞↪ߩࡔࠞ࠾࠭ࡓ⸃᣿
3㧕ࡠࠗࠦ࠻࡝ࠛࡦᜟ᛫⮎ߩ COPD ߦኻߔࠆ૞↪ߩࡔࠞ࠾࠭ࡓ⸃᣿
4㧕ㆮવሶᴦ≮1㧕⢖߇ࠎߦኻߔࠆ RhoC ߦࠃࠆㆮવሶᴦ≮2㧕⢖✢⛽∝ߦኻߔࠆ HGF ߩㆮવሶᴦ≮5㧕IB-EBUS ߅ࠃ߮ IB-ࠛࠦ࡯ߦࠃࠆ⚵❱ᕈ⁁⸻ᢿ
1㧕᛫㉄ൻ⮎ߩ᳇㆏਄⊹ߦਈ߃ࠆᓇ㗀ߩ⸃ᨆ
2㧕᳇㆏࡝ࡕ࠺࡝ࡦࠣߩ progression ߣ⚵❱∛ᄌ
3㧕⢖∛ᄌߩ⚵❱ᕈ⁁⸻ᢿ
4㧕⢖߇ࠎ∝଀ߩ⚵❱ᕈ⁁㧘࡝ࡦࡄ▵⸻ᢿ
6㧕COPD ߩ∛ᘒߦኻߔࠆಽሶ↢‛ቇ⊛ࠕࡊࡠ࡯࠴
1㧕Free Radical Scavenger ߦࠃࠆᴦ≮ᴺߩ㐿⊒
7㧕3D-CT ߦࠃࠆ᳇㆏∛ᄌ⸻ᢿ
1㧕3D-CT ↹௝ߣ IB-EBUS ↹௝ߣߩ⚵❱ᕈ⁁⸻ᢿᲧセ8㧕⌧⌁ᤨή๭ๆ
1㧕CPAP ߦࠃࠆ⌧⌁ᤨή๭ๆᴦ≮
2㧕COPD ߣ sleep apnea ߩ㑐ଥ9㧕᳇▤ᡰࠗࡦ࠲࡯ࡌࡦ࡚ࠪࡦ
1㧕⢖߇ࠎߦኻߔࠆ࡟࡯ࠩ࡯≮ᴺߩ㐿⊒
2㧕ᣂߚߥ᳇㆏ࠬ࠹ࡦ࠻≮ᴺߩ㐿⊒
3㧕⢖ᔃ⣢ㅪ㑐ߦ㑐ߔࠆ⎇ⓥ
10㧕 ⥃ᐥᩭකቇ
1㧕ࠨ࡞ࠦࠗ࠼࡯ࠪࠬߥߤߩᩭකቇ⊛ᬌ⸛
2㧕PET/CT ߦᣈߌࠆ IB-EBUS ߣߩ㑐ଥ11㧕 ᧲ᵗකቇ⊛ࠕࡊࡠ࡯࠴
1㧕ᄤบὖ⮎ߩ⢖߇ࠎߦኻߔࠆലᨐߩᬌ⸛
2㧕ߓ߾߫ࠄߩ᛫ࠕ࡟࡞ࠡ࡯૞↪ߩᬌ⸛Ԙࠕ࠻ࡇ࡯ᕈ⊹⤏Ἳࡕ࠺࡞ࡑ࠙ࠬߦࠃࠆᬌ⸛
ԙ᳇▤ᡰ༎ᕷࡑ࠙ࠬߦኻߔࠆᬌ⸛
Ԛ⧎☳∝ᖚ⠪ߦኻߔࠆᬌ⸛
12㧕 㑐ㅪ∛㒮ߣߩᄢⷙᮨ⥃ᐥ⹜㛎
1㧕ᘟᕈ⢖ࠕࠬࡍ࡞ࠡ࡞ࠬ∝ߩᄙᣉ⸳౒ห⎇ⓥ
2㧕⢖߇ࠎࠢ࡝࠾ࠞ࡞ࡄࠬߩ᦭ലᕈߩᬌ⸛
3㧕ᄤบὖ⮎ߩ⢖߇ࠎߦኻߔࠆ᦭ലᕈߩᬌ⸛
13㧕 ᳇▤ᡰౝⷞ㏜ᬌᩏ
2㧚ฬ★
ᢎ᝼(૬છ)㧦
⻠Ꮷ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦

Ḋญା਽
ᄢ㊁ ᐽ
⥱ญ␸ᒾ
᫪ ⑲ᴺ
㆙ᷰ⚐ノ
દ⮮ᢥ㓉

Shinya Minatoguchi
Yasushi Ohno
Norihiko Funaguchi
Hidenori Mori
Junki Endo
Fumitaka Ito㧙㧙3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
ߥߒ⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 ᄢ㊁ ᐽ㧚᳇▤ᡰࡆ࠺ࠝࠬࠦ࡯ࡊࠍ૶↪ߔࠆⰯశ᳇▤ᡰౝⷞ㏜↹௝ߦߟ޿ߡ ᣣᧄ⢖≸ቇળ᳇▤ᡰ㏜ᚲ⷗
ಽ㘃ᆔຬળ ⢖≸ 2007 ᐕ㧧47 Ꮞ㧦215㧙221㧚
2㧕 ᄢ㊁ ᐽ㧚⢖≸ⴚ೨࡝ࡦࡄ▵ォ⒖⸻ᢿߦ߅ߌࠆ‫⿛ࠬࠢ࠶ࡌࡦࠦޔ‬ᩏᑼ⿥㖸ᵄ᳇▤ᡰ㏜ࠟࠗ࠼ਅ↢ᬌ
㧔EBUS-TBNA㧕ߩታ㓙 ᣣᧄ⢖≸ቇળ᳇▤ᡰ㏜ᚲ⷗ಽ㘃ᆔຬળ ⢖≸ 2007 ᐕ㧧47 Ꮞ㧦207㧙214㧚✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ㋈ᧁ㓷㓶㧘ᄢ㊁ᐽ㧘ᄢ㊁ፏሶ㧘ᳯᎹ㓷ੱ㧘⧣᧛ஜᴦ㧘⿒የᷡ೰㧘⍫㊁ᔘ㧘⮮ේਭ⟵㧚㎞ᴦ≮߇᦭ലߢ޽ߞ
ߚ߮߹ࠎᕈ᳢⚦᳇▤ᡰἻߩ৻∝଀ ోᣣᧄ㎞ἲቇળ㔀⹹ 2007 ᐕ㧧57㧦621㧙632.
2㧕 ⥱ญ␸ᒾ㧘ᄢ㊁ᐽ㧘㆙ᷰ⚐ノ㧘દ⮮ᢥ㓉㧘᫪⑲ᴺ㧘↱᦬⧷ⴕ㧘Ỉ↰᣽ᶈ㧘⮮ේਭ⟵㧚ਛᨔᕈ๭ๆਇోࠍ߈
ߚߒߚዊ⚦⢩⢖≸ว૬᛫ Hu ᛫૕㓁ᕈற⣲≌␹⚻∝୥⟲ߩ 1 ଀ ᣣᧄ๭ๆེቇળ㔀⹹ 2008 ᐕ㧧46 Ꮞ㧦
314㧙318.
ේ⪺㧔᰷ᢥ㧕
1㧕 Yuhgetsu H, Ohno Y, Funaguchi N, Asai T, Sawada M, Takemura G, Minatoguchi S, Fujiwara T,
Fujiwara H. Beneficial effects of autologous bone marrow mononuclear cell transplantation via thetrachea against elastase-induced emphysema in rabbits. Exp Lung Res. 2006;32:413-426.
2㧕 Asai T, Ohno Y, Minatoguchi S, Funaguchi N, Yuhgetsu H, Sawada M, Takemura G, Komada A,
Fujiwara T, Fujiwara H. The specific free radical scavenger edaravone suppresses bleomycin-induced
acute pulmonary injury in rabbits. Clin Exp Pharmacol Physiol. 2007;34:22-26.
3㧕 Funaguchi N, Ohno Y, La BL, Asai T, Yuhgetsu H, Sawada M, Takemura G, Minatoguchi S, Fujiwara T,
Fujiwara H. Narirutin inhibits airway inflammation in an allergic mouse model. Clin Exp Pharmacol
Physiol. 2007;34:766-770.
4㧕 Sawada M, Ohno Y, La BL, Funaguchi N, Asai T, Yuhgetsu H, Takemura G, Minatoguchi S, Fujiwara
H, Fujiwara T. The fas/fas-ligand pathway does not mediate the apoptosis in elastase-induced
emphysema in mice. Exp Lung Res. 2007;33:277-288.

IF 1.427

IF 1.780

IF 1.780

IF 1.4274㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄ߥߒ
2㧕ฃ⸤⎇ⓥ
1㧕 ᄢ㊁ᐽ㧘⥱ญ␸ᒾ㧘ᧁ᧛ᥙᄦ㧦CSS࡮AGA ࠍኻ⽎ߣߒߚ GGS ߩੑ㊀⋤ᬌᛩਈᤨᦼή૞ὑൻ೨ᓟᲧセ⹜㛎(╙Υ⋧⥃ᐥ⹜㛎)㧧ᐔᚑ 18㧙19 ᐕᐲ㧧321.3 ජ౞㧦Ꮲੱࡈࠔ࡯ࡑᩣᑼળ␠
2㧕 ᄢ㊁ᐽ㧦ࠕ࡝ࡓ࠲ᵈ኿↪ 500mg ․ቯ૶↪ᚑ❣⺞ᩏ㧔ᖡᕈ⢷⤑ਛ⊹⣲㧕㧧ᐔᚑ 19㧙20 ᐕᐲ㧧126 ජ౞㧦ᣣᧄࠗ࡯࡜ࠗ࡝࡝࡯ᩣᑼળ␠
3㧕 ᄢ㊁ᐽ㧘⥱ญ␸ᒾ㧘㆙ᷰ⚐ノ㧘᫪⑲ᴺ㧘દ⮮ᢥ㓉㧦࠲࡞࠮ࡃ㍤․ቯ૶↪ᚑ❣⺞ᩏ㧧ᐔᚑ 19㧙20 ᐕᐲ㧧
472.5 ජ౞㧦ਛᄖ⵾⮎ᩣᑼળ␠4㧕 ᄢ㊁ᐽ㧘⥱ญ␸ᒾ㧘㆙ᷰ⚐ノ㧘᫪⑲ᴺ㧘દ⮮ᢥ㓉㧦ࠗ࠻࡝࠱࡯࡞ᵈ 1%૶↪ᚑ❣⺞ᩏ㧧ᐔᚑ 19㧙20
ᐕᐲ㧧210 ජ౞㧦ࡗࡦ࠮ࡦࡈࠔ࡯ࡑᩣᑼળ␠㧔╙ੑᦼ㧕㧧ᐔᚑ 20 ᐕ
5㧕 ᄢ㊁ᐽ㧦ࠢ࡝ࠕࠢ࠲࡯ᵈ․ቯ૶↪ᚑ❣⺞ᩏ‫ޟ‬ᕆᕈ⢖Ⴇᩖ∝ߦ㑐ߔࠆో଀⺞ᩏ‫ޠ‬ᐲ㧧157.5 ජ౞㧦ࠛ࡯ࠩࠗᩣᑼળ␠
6㧕 ᄢ㊁ᐽ㧘⥱ญ␸ᒾ㧘㆙ᷰ⚐ノ㧘᫪⑲ᴺ㧘દ⮮ᢥ㓉㧦ࠫࠚ࠾࠽࠶ࠢ㍤ 200mg ૶↪ᚑ❣⺞ᩏ㧧ᐔᚑ 20
ᐕᐲ㧧105 ජ౞㧦ᄢᱜንጊක⮎ຠᩣᑼળ␠
㧧ᐔᚑ
7㧕 ᄢ㊁ᐽ㧦࡙࡯ࠛࡈ࠹ࠖ․ቯ૶↪ᚑ❣⺞ᩏ㧔㕖ዊ⚦⢩⢖≸ⴚᓟ⵬ഥ≮ᴺߦ߅ߌࠆ೽⮎⁁ᴫ⺞ᩏ㧕
20 ᐕᐲ㧧157.5 ජ౞㧦ᄢ㢈⮎ຠᎿᬺᩣᑼળ␠㧙㧙3㧕౒ห⎇ⓥ
1㧕 ᄢ㊁ᐽ㧦๭ๆེ∔ᖚߦ߅ߌࠆ㉄ൻࠬ࠻࡟ࠬߩᓎഀ㧧ᐔᚑ 19 ᐕᐲ㧧5,920 ජ౞㧦ᄢႦ⵾⮎ᩣᑼળ␠2㧕 ᄢ㊁ᐽ㧦๭ๆེ∔ᖚߦ߅ߌࠆ㉄ൻࠬ࠻࡟ࠬߩᓎഀ㧧ᐔᚑ 20 ᐕᐲ㧧11,420 ජ౞㧦ᄢႦ⵾⮎ᩣᑼળ␠3㧕 ᄢ㊁ᐽ㧦Elastase 㓚ኂ⢖᳇⣲ࡕ࠺࡞ࡑ࠙ࠬߦኻߔࠆ Montelukast ߦࠃࠆ᦭ലᕈߩᬌ⸛㧧ᐔᚑ 20 ᐕ
ᐲ㧧2,600 ජ౞㧦ਁ᦭⵾⮎ᩣᑼળ␠
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬ
ᄢ㊁ ᐽ㧦
1㧕 ᣣᧄ๭ๆེቇળઍ⼏ຬ࡮ࡊࡠࠣ࡜ࡓᆔຬ(㨪⃻࿷)2㧕 ᣣᧄ๭ๆེౝⷞ㏜ቇળጘ㒂࿾඙ᐙ੐(㨪⃻࿷)3㧕 ᣣᧄ⢖≸ቇળ⹏⼏ຬ(㨪ᐔᚑ 20 ᐕ 11 ᦬)࡮᳇▤ᡰ㏜ᚲ⷗ಽ㘃ᆔຬ(㨪⃻࿷)4㧕 ᣣᧄౝ⑼ቇળ᧲ᶏᡰㇱ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ߥߒ
8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേ
ߥߒ
10㧚ႎ๔ᦠߥߒ11㧚ႎ㆏ߥߒ12㧚⥄Ꮖ⹏ଔ
⹏ଔ
๭ๆེಽ㊁ߢߩ⎇ⓥ߇㗅⺞ߦㅴⴕߒ㧘৻ᵹߩࠫࡖ࡯࠽࡞ߦ಴ ߐࠇ㧘࿖㓙ቇળߢ߽⊒⴫ࠍⴕߞߚ‫ᦨޕ‬ᣂߩක≮ᛛⴚߣߒߡࠟࠗ࠼ࠪ࡯ࠬᴺࠍ↪޿ߚᧃ᪳⢖∛ᄌߩ⸻ᢿ㧘ᭂ⚦ᓘ᳇▤ᡰ㏜ࠍ↪޿ߚ CT ࠟࠗ࠼ਅ᳇▤ᡰ㏜㧘ਛᨔ᳇▤ᡰߦኻߔࠆ᳇▤ᡰ⣧ౝᾖ኿㧘᳇▤ᡰ⿥㖸ᵄౝⷞ㏜ਅๆᒁ㊎↢ᬌ㧔EBUS-TBNA㧕ߥߤࠍⓍᭂ⊛ߦዉ౉ߒ㧘⋵ౝᄖ߆ࠄߏଐ㗬ࠍฃߌ㧘∝଀ߩ⫾Ⓧࠍߒߡ޿ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ߅ࠃ߮ߘߩኻᔕ╷ᄙᢙߩᄢቇ㒮↢߿⎇ⓥ⠪ࠍᛴ߃㧘࠺ࠬࠢ߿ࠬࡍ࡯ࠬࠍ⏕଻ߔࠆߎߣߦ࿎㔍ߒߡ޿ࠆ‫⥃ߚ߹ޕ‬ᐥ㧘ᢎ⢒㧘⎇ⓥߩ޿ߕࠇߦ߽ᤨ㑆ࠍ⾌߿ߔߚ߼㧘⎇ⓥߦචಽߥᤨ㑆߇޽ࠆߣߪ⸒޿㔍޿‫ޕ‬੹ᓟߩዷᦸ㜞㦂ൻߥࠄ߮ߦ↢ᵴ᭽ᑼߩ᰷☨ൻߦ઻޿㧘๭ๆེ∔ᖚߪჇടߩ৻ㅜࠍㄡߞߡ޿ࠆ‫∛ߩࠇߙࠇߘޕ‬᳇ߩࡔࠞ࠾࠭ࡓࠍേ‛ታ㛎㧘⥃ᐥ⎇ⓥࠍㅢߓߡ⸃᣿ߒ㧘ᴦ≮ߦᔕ↪ߒߡ޿ߊߎߣ߇㊀ⷐߢ޽ࠆ‫੹ޕ‬ᓟ㧘๭ๆེ∔ᖚߩಽ㊁ߦ߅޿ߡ⚦⢩ᱫߥࠄ߮ߦ⚦⢩ᄌᕈ㧔ࠕࡐ࠻࡯ࠪࠬ㧘ࠝ࡯࠻ࡈࠔࠫ࡯╬㧕㧘⚦⢩ࠍౣ↢ߔࠆౣ㧙㧙↢කቇߥߤ߇߹ߔ߹ߔ㊀ⷐߥ⎇ⓥ࠹࡯ࡑߣߥࠆߎߣ߇੍ᗐߐࠇࠆ‫ޕ‬ᓥߞߡᚒ‫ߩߎߪޘ‬ὐࠍචಽ⹺⼂ߒ㧘⚦⢩↢‛ቇ⊛ᚻᴺࠍ㚟૶ߒᣂߒ޿࠺ࡃࠗࠬࠍዉ౉ߒߡ㧘ߐࠄߦᵴ⊒ߥ⎇ⓥᵴേࠍⴕߞߡ޿߆ߥߊߡߪߥ
ࠄߥ޿ߣ⠨߃ࠆ‫ޕ‬㧙㧙㧔3㧕කቇ♽୶ℂ࡮␠ળකቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
ߎࠇ߹ߢߣห᭽㧘ౣ↢ක⑼ቇࠍ฽߻කቇ࡮ක≮ో⥸ߦ㑐ߔࠆ↢๮୶ℂߦ㑐ߔࠆ⻉໧㗴ࠍ⠨ⓥߒ㧘࡜ࠗࡈࠨࠗࠛࡦࠬ࡮ක≮࡮⋴⼔ߩၮ␆⊛෸߮ᔕ↪⊛ߥ⻉໧㗴ߦኻᔕߢ߈ࠆ↢๮୶ℂᢎ⢒ࠍዷ㐿ߢ߈ࠆࠃ߁㧘ᧄ㇌ߦ߅ߌࠆ Bioethics ߩ⏕┙ࠍ⋡ᜰߒߡ⎇ⓥᵴേࠍ⛮⛯ߒߡ߈ߚ‫ߩߘޕ‬ၮᧄℂᔨߪ㧘ᐔᚑ 14㧔2002㧕ᐕ 4᦬㧘ጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼ߦౣ↢ක⑼ቇኾ᡹߇ߢ߈㧘ᒰಽ㊁߇㐿⸳ߐࠇߡ߆ࠄ㧘⃻࿷߽㚂የ৻⽾ߒߡ޿ࠆ‫ޕ‬ᒰᦼߩ⎇ⓥᵴേߪ㧘೨ᦼ߆ࠄᒁ߈⛯޿ߡ㧘‫ߦ∛⚻␹ޟ‬ଥࠆၮ␆ౣ↢⎇ⓥߣ⸻ᢿᴦ≮㐿⊒ߩⷞὐߦ㑐ߔࠆ⎇ⓥ‫ޠ‬㧘ߐࠄߦක੐ᴺቇ⊛⷗࿾߆ࠄ‫ޟ‬කᏧߩ⟵ോߣⵙ㊂㧔ᮭ㧕ߦ㑐ߔࠆ⎇ⓥ‫␠ߣޠ‬ળቇ⊛⷗࿾߆ࠄ‫଻ޟ‬㒾⠪ᯏ⢻ᒝൻߣක≮೙ᐲᡷ㕟ߦ㑐ߔࠆ⎇ⓥ‫ࠍޠ‬ᣂߚߦ⸘↹ߒ㧘ᄢ߈ߊ࠹࡯ࡑࠍ 3 ߟߦಽߌߡ୶ℂ⊛࡮ᴺ⊛࡮␠ળ⊛໧㗴㧔ELSI㧦Ethical, Legal and Social Issues㧕ߣߒߡ໧㗴⟲ࠍᢛℂߒߥ߇ࠄ⎇ⓥᵴേࠍⴕߞߚ‫ ࠄࠇߎޕ‬3 ߟߩ࠹࡯ࡑߦߟ޿ߡߩ⎇ⓥߦ౒ㅢߔࠆߎߣߪ㧘‫ޟ‬୘ߩක≮‫␠⥸৻ޟߣޠ‬ળ‫ࠬࡦ࡜ࡃߩߣޠ‬ࠍᅤ૗ߦ଻ߜߟߟ↢๮୶ℂߩ໧㗴ࠍ⸃᳿ߦะࠊߖࠆ߆ߣ޿߁ߎߣߦዧ߈ࠆ‫ޕ‬ౣ↢ක≮ࠍ዁᧪ࠝ࡯࠳࡯ࡔࠗ
࠼ක≮ߦ߹ߢ⊒ዷߐߖࠆߚ߼ߦߪ㧘hES ⚦⢩߿ iPS ⚦⢩ߥߤߩవ┵ᛛⴚ╬ߩකቇ⊛೑↪߇ਇนᰳߢ޽ࠆ‫ޕ‬ߒ߆ߒ㧘⃻⁁ߪࠟࠗ࠼࡜ࠗࡦ╬ߩᡷ⸓߇ㅴ߼ࠄࠇߡ߈ߡ޿ࠆ߽ߩߩ㧘᰷☨ߣᲧߒߡᦝߥࠆ〯ߺㄟࠎߛ⼏⺰߇ᔅⷐߢ޽ࠆ‫ߚ߹ޕ‬㧘‫ޟ‬කᏧߩ⟵ോߣⵙ㊂㧔ᮭ㧕ߦ㑐ߔࠆ⎇ⓥ‫଻ޟߣޠ‬㒾⠪ᯏ⢻ᒝൻߣක≮೙ᐲᡷ㕟ߦ㑐ߔࠆ⎇ⓥ‫ߩޠ‬ฦ⎇ⓥ߆ࠄ߽㧘ᖚ⠪㧔ⵍ㛎⠪㧕ߩ⥄Ꮖ᳿ቯߩၮᧄේೣ߇ၷᜬߐࠇ⛯ߌࠄࠇࠆߚ߼ߦߪ㧘࠮࡯ࡈ࠹ࠖ࡯ࡀ࠶࠻ߣߒߡߩක≮೙ᐲ࡮කቇ⎇ⓥ૕೙ߩᩮᐙࠍ᭴▽ߒ㧘␠ળ⊛ߥᗧᕁ᳿ቯ߇ὑߐࠇࠆ࿯ფࠍ㉯ᚑߔࠆᔅⷐ߇޽ࠆ‫ޕ‬ᒰಽ㊁ߢߪ㧘ߎߩὐࠍਥᒛߔࠆߚ߼ߦ⛮⛯ߒߡ⪺૞࡮⺰ᢥ╬ࠍㅢߓߡ␠ળߦ⊒ାߒߡ޿ࠆ‫ߡߒߣ࠼࡯ࡢ࡯ࠠޕ‬㧘␠ળⴕὑⷙ▸ߩᒻᚑࠍឝߍ㧘⍦⋫ὐࠍ⼏⺰ᜰ៰ߒߟߟ␠ળߩᚑᾫᐲวߣᴺ೙ᐲ
╬ߩ␠ળࠪࠬ࠹ࡓ߇⺞๺ߢ߈ࠆࠃ߁㧘੹ᓟ߽࿖㓙␠ળߩേะߦᵈ⋡ߒߥ߇ࠄ⛮⛯ߒߡ⎇ⓥࠍㆀⴕߒߡ޿ߊ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
ഥᢎ㧦

㦭↰ᢘ⟵
⼱ญᵏᒄ

Yukiyoshi Tsukata
Yasuhiro Taniguchi

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
ߥߒ⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 ⼱ญᵏᒄ㧚ታ㛎⊛ක≮ߩታᣉߦะߌߚ↢๮୶ℂቇ⊛ᬌ⸛㧙࡝ࠬࠢࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦߩⷞὐ߆ࠄ㧙㧘␠ળක≮⎇ⓥ 2007 ᐕ㧧5 Ꮞ㧦27㧙35㧚
✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ⼱ญᵏᒄ㧚ࡃࠗࠝࠛࠪ࠶ࠢࠬߦ߅ߌࠆ␠ળ⊛ᗧᕁ᳿ቯⷐ࿃ߩേะ㧘␠ળක≮⎇ⓥ 2006 ᐕ㧧4 Ꮞ㧦11㧙17㧚
2㧕 ⼱ญᵏᒄ㧘㦭↰ᢘ⟵㧚HIV ᗵᨴ∝ߣ౏⊛ක≮଻㒾೙ᐲ㧙ක≮⾗Ḯߩ㈩ಽ߆ࠄߩⷞὐ㧙㧘The Journal of AIDS
Research(ᣣᧄࠛࠗ࠭ቇળ⹹) 2006 ᐕ㧧8 Ꮞ㧦140㧙145㧚
3㧕 ⼱ญᵏᒄ㧚ක≮⚻༡ਥ૕ߦ߅ߌࠆࡑࡀࠫࡔࡦ࠻୶ℂߩᔅⷐᕈ㧙ડᬺᵴേ߆ࠄߩ␜ໂ㧙㧘␠ળක≮⎇ⓥ 2007
ᐕ㧧5 Ꮞ㧦11㧙20㧚
4㧕 ⼱ญᵏᒄ㧚଻㒾⠪ᯏ⢻ᒝൻߣක≮೙ᐲᡷ㕟, ␠ળක≮⎇ⓥ 2008 ᐕ㧧6 Ꮞ㧦5㧙12㧚ේ⪺㧔᰷ᢥ㧕
ߥߒ

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦⼱ญᵏᒄ㧘⎇ⓥಽᜂ⠪㧦㦭↰ᢘ⟵㧧ጘ㒂ᄢቇᵴᕈൻ⎇ⓥ⾌㧦ක≮⚻༡ਥ૕ߦ߅ߌࠆ⚻ᷣ୶ℂߩ᭴▽ߦะߌߚ⎇ⓥ㧧ᐔᚑ 18 ᐕᐲ㧧377 ජ౞2㧕 ⎇ⓥઍ⴫⠪㧦㦭↰ᢘ⟵㧘⎇ⓥಽᜂ⠪㧦⼱ญᵏᒄ㧧ጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼ߩ⎇ⓥᵴᕈൻ(ක)ߩߚ

㧙㧙߼ߩᡰេ੐ᬺ(ࡊࡠࠫࠚࠢ࠻‫ߩ♽⚻␹ޟ‬ၮ␆⎇ⓥߣౣ↢⎇ⓥߣߘߩᔕ↪ߦၮߠߊ␹⚻∛⸻ᢿᴦ≮㐿⊒‫)ޠ‬㧦ᣂߒ޿ታ㛎⊛ක≮ࠍㆡᱜߦታᣉߔࠆߚ߼ߩ↢๮୶ℂቇ⊛ᬌ⸛㧙␹⚻∛ߦଥࠆၮ␆ౣ↢⎇ⓥߣ⸻ᢿᴦ≮㐿⊒߆ࠄߩⷞὐ㧙㧧ᐔᚑ 18 ᐕᐲ㧧200 ජ౞3㧕 ⎇ⓥઍ⴫⠪㧦㦭↰ᢘ⟵㧘⎇ⓥಽᜂ⠪㧦⼱ญᵏᒄ㧧⽷࿅ᴺੱ߇ࠎ㓸ቇ⊛ᴦ≮⎇ⓥ⽷࿅⎇ⓥഥᚑ㊄㧦߇ࠎ㓸ቇ⊛ᴦ≮૕೙ߩᢛ஻ߣ᜛లߦ㑐ߔࠆ⎇ⓥ㧙↢๮୶ℂ࡮␠ળකቇߩⷞὐ߆ࠄ㧙㧧ᐔᚑ 20 ᐕᐲ㧧
1,000 ජ౞2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬ㦭↰ᢘ⟵㧦
1㧕 ᣣᧄ␠ળක≮ቇળℂ੐(㨪⃻࿷)2㧕 ᣣᧄౣ↢ක≮ቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ⒖ᬀቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄ↢๮୶ℂቇળ⹏⼏ຬ(㨪⃻࿷)5㧕 ᣣᧄ DNA ᄙဳቇળ⹏⼏ຬ(ᐔᚑ 18 ᐕ 11 ᦬㨪⃻࿷)2㧕ቇળ㐿௅㦭↰ᢘ⟵㧦
1㧕 ᣣᧄ␠ળක≮ቇળ╙ 7 ࿁ቇⴚᄢળ(ᐔᚑ 18 ᐕ 10 ᦬㧘ᑧጟ)
3㧕ቇⴚ㔀⹹Ⴆ↰ᢘ⟵㧦1㧕 ౣ↢ක≮㧙ᣣᧄౣ↢ක≮ቇળ⹹㧧✬㓸หੱ(㨪⃻࿷)7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳㦭↰ᢘ⟵㧦
1㧕 ╙ 70 ࿁⸥ᔨᣣᧄᓴⅣེቇળ✚ળ࡮ቇⴚ㓸ળ(ᐔᚑ 18 ᐕ 3 ᦬㧘ฬฎደ㧘ᢎ⢒⻠Ṷ‫ޟ‬ᖱႎ୶ℂߣ⥃ᐥ∉ቇ⎇ⓥ‫ޠ‬Ṷ⠪)2㧕 ╙ 70 ࿁⸥ᔨᣣᧄᓴⅣེቇળ✚ળ࡮ቇⴚ㓸ળ(ᐔᚑ 18 ᐕ 3 ᦬㧘ฬฎደ㧘ᢎ⢒⻠Ṷ‫ޟ‬ᖱႎ୶ℂߣ⥃ᐥ∉ቇ⎇ⓥ‫ޠ‬ᐳ㐳)
3㧕 ╙ 31 ࿁ᮮᵿᏒ┙ᄢቇකቇળ࡮╙ 40 ࿁୾ㅴળวห✚ળ(ᐔᚑ 18 ᐕ 4 ᦬㧘ᮮᵿ㧘․೎⻠Ṷ‫ޟ‬ක≮ߩ㒢⇇ߣᖚ⠪ߩᦼᓙࠍ߼ߋࠆᴺ⊛໧㗴‫ޠ‬Ṷ⠪)
4㧕 ╙ 21 ࿁කቇᢎ⢒࠮ࡒ࠽࡯‫ޟ‬㔚ሶࠞ࡞࠹ߣකቇᢎ⢒(╙ 2 ࿁)㧙⸻≮㍳⸥タߩᢎ⢒㧙‫(ޠ‬ᐔᚑ 18 ᐕ 8 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ቇ↢ߩ⸻≮㍳⸥タߩᜰዉ࡮⋙ᩏߪߤߩࠃ߁ߦⴕ߁߆‫ޠ‬Ṷ⠪)
5㧕 ᣣᧄ␠ળක≮ቇળ╙ 7 ࿁ቇⴚᄢળ(ᐔᚑ 18 ᐕ 10 ᦬㧘ᑧጟ㧘ᢎ⢒⻠Ṷ‫ޟ‬ᓟㆮ∝ࠍ߼ߋࠆ⻉⋧ߦߟ޿ߡ
㧙PTSD ᳃੐⸷⸩ࠍਛᔃߦߒߡ‫ޠ‬Ṷ⠪)
6㧕 ╙ 19 ࿁ᣣᧄ↢๮୶ℂቇળᐕᰴᄢળ(ᐔᚑ 19 ᐕ 11 ᦬㧘᧲੩㧘࠮࠶࡚ࠪࡦ‫ޟ‬ක≮ߣ⚻ᷣ‫ޠ‬ᐳ㐳)7㧕 ᐔᚑ 20 ᐕᐲᣣᧄ㆙㓒ක≮ቇળቇⴚᄢળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬㆙㓒ක≮ߩࠟࠗ࠼࡜ࠗࡦ㧙ߘߩ୶ℂ⊛␠ળ⊛໧㗴㧙‫ޠ‬Ṷ⠪)8㧕 ᣣᧄ␠ળක≮ቇળ╙ 9 ࿁ቇⴚᄢળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ᑧጟ㧘ࠪࡦࡐࠫ࠙ࡓ‫޿ߒߐ߿ߦੱޟ‬ක≮ߣ࿾ၞ⑔␩ࠍ߼ߑߒߡ‫)࡯࠲࡯ࡀࠖ࠺࡯ࠦޠ‬8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ
ߥߒ

㧙㧙

9㧚␠ળᵴേ㦭↰ᢘ⟵㧦
1㧕 ᣣᧄㆮવሶ⸻≮ቇળ୶ℂ໧㗴ᆔຬળᆔຬ(㨪⃻࿷)2㧕 ᣣᧄ⒖ᬀቇળ୶ℂᆔຬળᆔຬ(㨪⃻࿷)3㧕 ⤟࡮⤟ፉ⒖ᬀ⎇ⓥળ਎⹤ੱ(㨪⃻࿷)4㧕 ㄭ⇰⤟⒖ᬀᬌ⸛ળ਎⹤ੱ(㨪⃻࿷)5㧕 ੩ㇺᄢቇౣ↢ක⑼ቇ⎇ⓥᚲකߩ୶ℂᆔຬળᆔຬ(㨪⃻࿷)6㧕 ⽷࿅ᴺੱᨵ㆏ᢛᓳ⎇ୃ⹜㛎⽷࿅࿖ኅ⹜㛎ᐙ੐ᆔຬ(㨪⃻࿷)7㧕 ⽷࿅ᴺੱ߇ࠎ㓸ቇ⊛ᴦ≮⎇ⓥ⽷࿅⹏⼏ຬ࡮୶ℂᆔຬળᆔຬ㐳(㨪⃻࿷)8㧕 ṑ⾐ක⑼ᄢቇേ‛↢๮⑼ቇ⎇ⓥ୶ℂᆔຬળᆔຬ(㨪⃻࿷)9㧕 ⁛┙ⴕ᡽ᴺੱ↥ᬺᛛⴚ✚ว⎇ⓥᚲකᎿቇᔕ↪ታ㛎୶ℂᆔຬળᆔຬ೽ᆔຬ㐳(㨪⃻࿷)10㧕 ጘ㒂⋵଻ஜᚲ╬୶ℂክᩏᆔຬળᆔຬ㐳(㨪⃻࿷)11㧕 ᧲ᵗ≮ᴺ⎇ୃ⹜㛎⽷࿅╙ 8 ᦼ޽ࠎ៺ࡑ࠶ࠨ࡯ࠫᜰ࿶Ꮷ‫ࠅߪޔ‬Ꮷ෸߮߈ࠀ߁Ꮷ⹜㛎ᆔຬ(ᐔᚑ 18 ᐕ 7᦬㨪⃻࿷)
12㧕 ᣣᧄ DNA ᄙဳቇળ୶ℂᆔຬળᆔຬ㐳(ᐔᚑ 18 ᐕ 11 ᦬㨪⃻࿷)13㧕 ጘ㒂⋵කᏧળᴦ㛎ክᩏᆔຬળᆔຬ(ᐔᚑ 19 ᐕ 4 ᦬㨪⃻࿷)
14㧕 ጘ㒂᧲ᵗකቇ⎇ⓥળ਎⹤ੱ(ᐔᚑ 19 ᐕ 12 ᦬㨪⃻࿷)15㧕 ᣣᧄᚻߩᄖ⑼ቇળ୶ℂᆔຬળࠕ࠼ࡃࠗࠩ࡯(ᐔᚑ 20 ᐕ 3 ᦬㨪⃻࿷)16㧕 ᣣᧄᢛᒻᄖ⑼ቇળ⣄ᬁౝⷞ㏜ਅᚻⴚ࡮ᛛⴚ⹺ቯ೙ᐲᆔຬળᆔຬ(ᐔᚑ 20 ᐕ 9 ᦬㨪⃻࿷)17㧕 ⤟࡮⤟ፉ⒖ᬀ⎇ⓥળ୶ℂᆔຬળᆔຬ(ᐔᚑ 20 ᐕ 12 ᦬㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ⼱ญᵏᒄ㧘㦭↰ᢘ⟵㧦ක≮⚻༡ਥ૕ߦ߅ߌࠆ⚻ᷣ୶ℂߩ᭴▽ߦะߌߚ⎇ⓥ㧦ጘ㒂ᄢቇᵴᕈൻ⎇ⓥ⾌ႎ๔ᦠ㧦1㧙2(2007 ᐕ 12 ᦬)
2㧕 㦭↰ᢘ⟵㧘⼱ญᵏᒄ㧦␹⚻∛ߦଥࠆၮ␆ౣ↢⎇ⓥߣ⸻ᢿᴦ≮㐿⊒ࠍ౞Ṗߦታᣉߔࠆߚ߼ߩ↢๮୶ℂቇ⊛ᬌ⸛㧙࡝ࠬࠢࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦߩⷞὐ߆ࠄ㧙㧦╙ 2 ࿁ጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼࡮කቇㇱ࡮㒝ዻ∛㒮ቇⴚ⎇ⓥ⊒⴫ળႎ๔㓸㧦66(2007 ᐕ 3 ᦬)
11㧚ႎ㆏1㧕 㦭↰ᢘ⟵㧦ᴦ≮ᜎุ଀ߢਥᴦක߇ᢌ⸷(ࠦࡔࡦ࠻)㧦ᣣ⚻ࡔ࠺ࠖࠞ࡞(2006 ᐕ 3 ᦬ 10 ᣣ)
2㧕 㦭↰ᢘ⟵㧦ࡅ࠻⢦㧘ES ⚦⢩ࠍ߼ߋࠆ↢๮୶ℂ(ࠦࡔࡦ࠻)㧦ㅳೀකቇ⇇ᣂ⡞(2006 ᐕ 4 ᦬ 3 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔ᭎ⷐߦ␜ߒߚᒰಽ㊁ߩ⋡ᮡߦᴪߞߡ㧘ᢎቶຬฦ⥄߇ฦ‫⎇ߩޘ‬ⓥ࠹࡯ࡑߦᴪߞߡ⎇ⓥࠍታᣉߒߚ‫ޕ‬‫⚻␹ޟ‬∛ߦଥࠆၮ␆ౣ↢⎇ⓥߣ⸻ᢿᴦ≮㐿⊒ߩⷞὐߦ㑐ߔࠆ⎇ⓥ‫ߪߡ޿ߟߦޠ‬㧘ቇౝࡊࡠࠫࠚࠢ࠻ߦෳടߒ㧘⎇ⓥࠍⴕߞߚ‫⎇ޕ‬ⓥߩᡰេߣߒߡ㧘ጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼ߩ⎇ⓥᵴᕈൻ㧔ක㧕ߩߚ߼ߩᡰេ੐ᬺ
㧔ࡊࡠࠫࠚࠢ࠻‫ߩ♽⚻␹ޟ‬ၮ␆⎇ⓥߣౣ↢⎇ⓥߣߘߩᔕ↪ߦၮߠߊ␹⚻∛⸻ᢿᴦ≮㐿⊒‫ޠ‬㧕ߩၮ㊄߆ࠄᐔ
ᚑ 18 ᐕᐲߦ 200 ජ౞ߩഥᚑࠍฃߌߚ‫ߚ߹ޕ‬㧘‫ޟ‬කᏧߩ⟵ോߣⵙ㊂㧔ᮭ㧕ߦ㑐ߔࠆ⎇ⓥ‫ߪߡ޿ߟߦޠ‬㧘ቇౝㆇ༡⾌㧔⻠ᐳ⾌㧕ࠍ↪޿ߡ⎇ⓥࠍⴕ޿㧘කቇㇱᢎ⢒㧔࠹ࡘ࠻࡯࡝ࠕ࡞↢๮୶ℂ࡮ᴺකቇࠦ࡯ࠬ㧕ߦౕ૕⊛ߥ੐଀ឭ␜ࠍⴕ޿㧘ㆶరߒߡ޿ࠆ‫ߦࠄߐޕ‬㧘‫଻ޟ‬㒾⠪ᯏ⢻ᒝൻߣක≮೙ᐲᡷ㕟ߦ㑐ߔࠆ⎇ⓥ‫ߦޠ‬㑐ߒߡߪ㧘ಽ㊁ౝ౒ห⎇ⓥࠍⴕ޿㧘⎇ⓥഥᚑߣߒߡ㧘ጘ㒂ᄢቇᵴᕈൻ⎇ⓥ⾌㧦ක≮⚻༡ਥ૕ߦ߅ߌࠆ⚻ᷣ୶
ℂߩ᭴▽ߦะߌߚ⎇ⓥ㧔ᐔᚑ 18 ᐕᐲ㧧377 ජ౞㧕ߣߒߡᡰេࠍฃߌߚ‫ޕ‬ᒰಽ㊁ߩ┙᩺ߒߚ⎇ⓥ⸘↹߇ክᩏࠍฃߌ⎇ⓥߩഥᚑࠍฃߌߡ޿ࠆߎߣ߆ࠄ㧘␠ળ⊛ߥᤨᵹߦᴪߞߚౝኈߢ޽ࠅ㧘␠ળߩ࠾࡯࠭߆ࠄㅺ⣕ߔࠆ߽ߩߢߪߥ޿‫⹏ߡߞࠃޕ‬ଔߐࠇߚ߽ߩߣ್ᢿߔࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ᒰಽ㊁߇ⴕߞߚ⎇ⓥߪ㧘ᢎቶຬߩฦ಴りಽ㊁ࠍ෻ᤋߒ㧘ਥߦ␠ળ⑼ቇ߆ࠄߩⷞὐࠍએߞߡ㧘↢๮୶ℂߦ㑐ߔࠆ㗔ၞߩ⻉໧㗴ࠍ⪺૞࡮⺰ᢥᒻᑼߢ␠ળߦ⊒ାߒߡ޿ࠆ‫ߒ߆ߒޕ‬㧘ታ㓙ߦක≮ឭଏࠍⴕ߁ᯏ㑐ߦᚲዻߔࠆ৻ኾ㐷ಽ㊁ߣߒߡ㧘ࠃࠅౕ૕⊛ߦ㧘ࠃࠅታലᕈࠍ઻ߞߡᚲዻᯏ㑐ౝߢ⍮⼂ߩ౒᦭ൻ߇࿑ࠄࠇࠆ
ࠃ߁ߥᓎഀ߇ᨐߚߖߡ޿ࠆ߆ߣ⠨߃ߚ႐ว㧘ᄙዋߩᡷༀߔߴ߈ὐ߽᜼ߍࠄࠇࠆ‫ߪߢ⁁⃻ޕ‬ቢోߦߪ໧㗴ߦኻಣߢ߈ߡ޿ߥ޿‫ޕ‬ᯏ㑐ౝߩ․ᱶߥಽ㊁ߣߩ૏⟎ߠߌߦ↞߃ࠆߎߣߥߊ㧘ቇౝᄖߢࠦࡒࡘ࠾ࠤ࡯࡚ࠪ
ࡦࠍขࠅߟߟ㧘↢๮୶ℂߦ㑐ߔࠆࠦࡦࠨ࡞࠹࡯࡚ࠪࡦࠍⴕ߁ߥߤߩ໧㗴ᗧ⼂ߩ౒᦭ൻࠍ࿑ࠆߎߣ߇⢄ⷐ㧙㧙ߢ޽ࠆ‫ߩߘޕ‬ኻ╷ߣߒߡ㧘ቇౝߩ Faculty Development ߦⓍᭂ⊛ߦෳടߒ㧘ᖱႎࠍ⊒⸒ߔࠆߎߣ߿㧘ઁ
ߩಽ㊁ߣ౒หߢ࠮ࡒ࠽࡯ࠍⴕ߁ߥߤߩⓍᭂ⊛ߥᵴേࠍዷ㐿ߔࠆᔅⷐ߇޽ࠆ‫ߚ߹ޕ‬㧘කቇ⎇ⓥ╬୶ℂክᩏ
ᆔຬળߦ߅ߌࠆክᩏㆊ⒟ߦ߅޿ߡ㧘⎇ⓥ⠪ߦኻߔࠆ⛮⛯ߒߚ↢๮୶ℂߦଥࠆᖱႎߩឭଏߣᢎ⢒໪⊒ࠍⴕ߁ᔅⷐ߽޽ࠆ‫ޕ‬੹ᓟߩዷᦸ೨࿁ߩᧄ⥄Ꮖὐᬌ⹏ଔႎ๔ᦠߩ૞ᚑᤨߦߪ㧘iPS ⚦⢩᮸┙ߩႎ๔ߪߥ߆ߞߚ‫ࠄ߆ࠇߎޕ‬వ߽ක≮࡮࡜ࠗࡈࠨࠗࠛࡦࠬߩᦝߥࠆㅴዷߦ઻޿㧘ᣂߒ޿⍮⷗ߣߘࠇߦઃ㓐ߔࠆ⚻㛎ߒߚߎߣߩߥ޿ࠃ߁ߥ↢๮୶ℂ໧㗴ߦ⋥㕙ߔࠆߎߣ߇੍᷹ߐࠇࠆ‫ޕ‬ᒰಽ㊁ߣߒߡ⫾Ⓧߒߡ߈ߚ⍮⼂ࠍᧄോᩞߣ␠ળߦㆶరߢ߈ࠆࠃ߁㧘ߎࠇ߹ߢߣห᭽ߦ⎇ⓥࠍ⛮⛯ߒ㧘ࡃࠗࠝࠛࠪ࠶ࠢࠬࠍ⎇ⓥߔࠆኾ㐷⊛ߥᢎቶߣߒߡ㧘⺰ᢥ࡮⪺૞ࠍㅢߓߡ␠ળߦ⊒ାࠍ⛯ߌߡ޿ߊ‫ߚ߹ޕ‬㧘ቇㇱᢎ⢒߅ࠃ߮ᄢቇ㒮ᢎ⢒ߩਛߦᦨᣂ࠻ࡇ࠶ࠢࠍណࠅ౉ࠇ㧘↢๮୶
ℂߦ♖ㅢߒߚੱ᧚ࠍ㙃ᚑߔࠆߎߣ߽⛮⛯ߒߡⴕ߁‫ߪߦࠄߐޕ‬㧘ᣣᧄߦ߅ߌࠆකቇ⎇ⓥ୶ℂክᩏᆔຬળߩ
ᦝߥࠆ⾰ߩะ਄ࠍ⋡ᜰߒߡ㧘ઁߩකቇㇱ࡮ක⑼ᄢቇߣ✕ኒߦㅪ⛊ࠍขߞߡ޿ߊߎߣ߽ⷞ㊁ߦ޿ࠇߡ޿ࠆ‫ޕ‬ⴕ᡽߿৻⥸␠ળࠍᏎ߈ㄟࠎߛో࿖⊛ⷞ㊁ߢߩ↢๮୶ℂߦ㑐ߔࠆ⎇ⓥ߅ࠃ߮ᢎ⢒ᵴേ߇ዷ㐿ߐࠇࠆࠃ߁㧘ߘߩ৻⠢ࠍᜂ߁ㇱ㐷ߣߒߡߩ␠ળ⊛⽿છ߇ᨐߚߖࠆࠃ߁ദജߒߡ޿ߊ‫ޕ‬㧙㧙

7. ቇ૏ߩ᝼ਈ⁁ᴫߣ⎇ⓥᚑᨐ
ౣ↢ක⑼ቇኾ᡹ߦ߅޿ߡඳ჻㧔ౣ↢ක⑼ቇ㧕ߩቇ૏ࠍ᝼ਈߒߚᢙߪ㧘ᰴ⴫ߩߣ߅ࠅߢ޽ࠆ‫ޕ‬඙ಽ

ᐔᚑ 16 ᐕᐲᐔᚑ 17 ᐕᐲᐔᚑ 18 ᐕᐲᐔᚑ 19 ᐕᐲ

⺖⒟ඳ჻

2

8

11

12

⺰ᢥඳ჻

0

0

0

1

8. ቇ↢↢ᵴᡰេ
㧔1㧕ᅑቇ㊄ߩ↳⺧࡮ណᛯ⁁ᴫ٤ ᣣᧄ⢒⧷ળᅑቇ↢಴㗿࡮ណ↪⁁ᴫᐕ‫ޓ‬ᐲ
ᐔᚑ 15 ᐕᐲᐔᚑ 16 ᐕᐲᐔᚑ 17 ᐕᐲᐔᚑ 18 ᐕᐲᐔᚑ 19 ᐕᐲᐔᚑ 20 ᐕᐲ

⺖⒟
ඳ჻೨ᦼ

╙1⒳

╙2⒳

಴㗿⠪ᢙ ណ↪⠪ᢙ ಴㗿⠪ᢙ ណ↪⠪ᢙ
1
1
0
0

ඳ჻ᓟᦼ

0

0

0

0

ඳ჻೨ᦼ

0

0

0

0

ඳ჻ᓟᦼ

0

0

0

0

ඳ჻೨ᦼ

3

3

0

0

ඳ჻ᓟᦼ

1

1

0

0

ඳ჻೨ᦼ

5

5

2

2

ඳ჻ᓟᦼ

1

1

0

0

ඳ჻೨ᦼ

7

7

2

2

ඳ჻ᓟᦼ

1

1

0

0

ඳ჻೨ᦼ

1

1

0

0

ඳ჻ᓟᦼ

0

0

0

0

㧔2㧕᝼ᬺᢱ఺㒰ታᣉ⁁ᴫ
೨ቇᦼ
ᐕ‫ޓ‬ᐲ

ᐔᚑ 15 ᐕᐲᐔᚑ 16 ᐕᐲᐔᚑ 17 ᐕᐲᐔᚑ 18 ᐕᐲᐔᚑ 19 ᐕᐲᐔᚑ 20 ᐕᐲ

⺖⒟

࿷☋⠪ᢙ

↳⺧

ᓟቇᦼ

఺㒰

఺㒰

ඳ჻೨ᦼ

29

5

ో㗵
5

5

ో㗵
4

ඳ჻ᓟᦼ

26

3

3

0

2

2

0

ඳ჻೨ᦼ

39

5

0

5

5

0

5

ඳ჻ᓟᦼ

45

8

1

7

7

1

6

ඳ჻೨ᦼ

42

8

0

5

8

2

3

ඳ჻ᓟᦼ

47

7

0

7

7

1

6

ඳ჻೨ᦼ

41

9

0

5

7

0

6

ඳ჻ᓟᦼ

52

10

1

8

8

0

8

ඳ჻೨ᦼ

34

8

4

4

8

4

4

ඳ჻ᓟᦼ

53

9

7

2

8

7

1

ඳ჻೨ᦼ

31

6

0

6

6

0

6

ඳ჻ᓟᦼ

55

9

4

3

8

4

4

㧙㧙

ඨ㗵
0

↳⺧

ඨ㗵
0

9. ⥄Ꮖ⹏ଔ࡮⺖㗴ߣዷᦸԘᢎຬ⚵❱ߩᒝൻߣ⥄Ꮖ⹏ଔߩᔀᐩ
ᐔᚑ 16 ᐕ 6 ᦬ߦᣂ▽ߐࠇߚකቇㇱ࡮㒝ዻ∛㒮߳ߩ⒖ォߦ઻޿㧘ౣ↢ක⑼ቇኾ᡹ߩోᢎຬ߇ห৻

ࡈࡠࠕ࡯ߦ㓸߹ࠅ㧘ኒធߥදജ߇ታᣉน⢻ߥᘒ൓߽ߢ߈ߚ‫৻ޕ‬ᣇ㧘කቇ♽⎇ⓥ⑼ߦ߅ߌࠆᢎຬᢙߩ
⛘ኻ⊛ਇ⿷ߪᷓೞߢ޽ࠅ㧘ᢎຬᢙߩჇຬ߇ᔅⷐߢ޽ࠆ‫ޕ‬߹ߚ㧘⥄Ꮖὐᬌࠍၮ␆ߣߒߟߟ㧘ୃੌ↢ߩᵴേ⁁ᴫ╬ߩᬌ⸽ࠍⴕ޿㧘ౣ↢ක⑼ቇኾ᡹ߣߒߡߩ⥄Ꮖὐᬌ࡮⹏ଔࠍⴕࠊߨ߫ߥࠄߥ޿‫ޕ‬ԙ ⎇ⓥᯏ⢻ߩలታ⺖㗴ߣ⸃᳿ᣇ╷ߦߟ޿ߡߪએਅߩߣ߅ࠅߢ޽ࠆ‫ޕ‬1㧕 ⧯ᚻᢎຬߩ⢒ᚑ : ⧯ᚻᢎຬ߇వ⷗ᕈࠍ߽ߞߡ࡙࠾࡯ࠢߥ⎇ⓥߦขࠅ⚵߻૕೙ࠍ૞ࠆ‫߼ߚߩߘޕ‬㧘࿖ౝਗ߮ߦ࿖ᄖߩ⎇ⓥᯏ㑐ߣ౒ห⎇ⓥࠍⴕ޿㧘߆ߟⓍᭂ⊛ߦੱ੐ߩ੤ᵹࠍⴕ߁‫ޕ‬
2㧕 ᄢቇ㒮ቇ↢ߩ⎇ⓥᯏ⢻ߩలታ : ౣ↢ක⑼ቇኾ᡹ߩ⎇ⓥᯏ⢻ߪ߆ߥࠅలታߒߡ߈ߡ߅ࠅ㧘࿖㓙⊛৻ᵹ⹹߳ߩᛩⓂࠍ⋡ᜰߔ‫ޕ‬3㧕 ⎇ⓥ⾌ߩలታ㧘ᄢဳ⸳஻ߩᢛ஻ : ⃻࿷߽ᢥㇱ⑼ቇ⋭㧘ෘ↢ഭ௛⋭╬߆ࠄᄢဳ⎇ⓥ⾌ࠍᓧߡ޿ࠆ
ᢎຬ߽޿ࠆ߇㧘ࠃࠅ৻ጀߩ₪ᓧࠍ⋡ᜰߒ㧘ᄢဳ⸳஻╬ߩలታࠍ࿑ࠆ‫ޕ‬ᐔᚑ 16 ᐕ 6 ᦬ߦකቇㇱ࡮㒝ዻ∛㒮߇⒖ォߒ㧘ᐔᚑ 17 ᐕᐲߦߪ↢๮⑼ቇ᫟߇ᣂ▽ߐࠇࠕࠗ࠰࠻࡯ࡊታ㛎ᣉ⸳㧘േ‛ታ㛎ᣉ⸳ߥߤߩᦨᣂ⸳஻߇ᢛߞߚᑪ‛߇ቢᚑߒ㧘ᄙߊߩ⎇ⓥ⠪ߦࠃߞߡ೑↪ߐࠇߡ޿ࠆ‫ེ࡮❱⚵ޕ‬ቭᒻ
ᚑಽ㊁߇ਛᔃߣߥߞߡ₪ᓧߒߚᄢဳ੍▚ߦࠃࠅ࠮࡞࠰࡯࠲࡯߇ዉ౉ߐࠇ㧘ઁ⒳㘃ߩ⚦⢩ᖱႎࠍ⍴ᤨ㑆ߦ⸃ᨆߒߟߟᔅⷐߥ⚦⢩ࠍ♖⵾ߢ߈ࠆࠃ߁ߦߥࠅ㧘వ┵⊛ߥ⎇ⓥ߇ㅴዷߒߡ޿ࠆ‫ޕ‬ᐔᚑ㧞㧜ᐕᐲਛߦߪᓴⅣ∛ᘒቇࠍਛᔃߦߒߡ₪ᓧߒߚෘ↢ഭ௛⋭ߩ⵬ഥ㊄ࠍᩭߦߒߡ㧘ౣ↢ක≮ߩታ↪ൻߦᔅ㗇ߥ࠮࡞ࡊࡠ࠮࠶ࠪࡦࠣ࠮ࡦ࠲࡯⸳஻߇ቢᚑ੍ቯߢ޽ࠆ‫ߚ߹ޕ‬㧘ቇㇱ㐳ⵙ㊂⚻⾌ߦࠃࠅ౒ㅢ
ᯏེ࠮ࡦ࠲࡯߇⸳⟎ߐࠇ㧘ዉ౉ߐࠇߚᄢဳᯏེ߇ౣ↢ක⑼ቇ෸߮ක⑼ቇኾ᡹ࠍ໧ࠊߕᄙߊߩ⎇ⓥ⠪߿ᄢቇ㒮↢ߦࠃߞߡᵴ↪ߐࠇߡ޿ࠆ‫ޕ‬Ԛᢎ⢒ᯏ⢻ߩలታ
ࠗࡦ࠲࡯ࡀ࠶࠻࡮ࡎ࡯ࡓࡍ࡯ࠫ̌NOBEL̍ࠍ੺ߒߚᣂߒ޿ 21 ਎♿⊛ᄢቇ㒮ᢎ⢒ߩ㐿⊒ߣలታࠍ

ⴕ߁‫ޕ‬

㧙㧙

㨇කቇ♽⎇ⓥ⑼⋴⼔ቇኾ᡹㨉1㧚 ᢎ⢒ߩℂᔨ㧘⋡ᮡ⋴⼔ቇኾ᡹ߢߪ㧘ㄭᐕߩක≮߳ߩ␠ળ⊛ⷐ⺧߇ᄙ᭽ൻߔࠆߥ߆ߢ㧘ኾ㐷ᕈ߇㜞ߊ⾰ߩࠃ޿ࠨ࡯ࡆࠬ
ࠍឭଏߔࠆߚ߼ߦ㧘㜞޿୶ℂⷰ߿⑼ቇ⊛ᕁ⠨ജࠍ⢒ߡࠆߣߣ߽ߦ㧘ቇ㓙⊛ⷞ㊁ࠍᐢߍ㧘⋴⼔ቇߣ⋴⼔ታ〣႐㕙ߢߩ⺖㗴ࠍ⥄⊒⊛ߦ࡮ౕ૕⊛ߦ⎇ⓥߒ㧘⾰ߩ㜞޿⋴⼔ߩታ〣⢻ജࠍ᦭ߔࠆ⋴⼔ኾ㐷⡯ᬺੱࠍ⢒ᚑߔࠆߎߣࠍ⋡⊛ߣߒߡ޿ࠆ‫ޕ‬ᢎ⢒⋡ᮡߣߒߡߪ㧘ᰴߩ 4 㗄⋡ࠍឝߍߡ޿ࠆ‫ޕ‬1㧕 ⋴⼔ቇᢎ⢒෸߮ታ〣⋴⼔ቇߦ㑐ߔࠆ໧㗴ࠍ⎇ⓥ⺖㗴ߣߒ㧘⋴⼔⎇ⓥࠍ⛮⛯ߒߡ޿ߌࠆၮ␆⊛⎇ⓥ⢻ജࠍ߽ߞߚੱ᧚ࠍ⢒ᚑߔࠆ‫ޕ‬
2㧕 ޽ࠄࠁࠆੱ‫ߩޘ‬ஜᐽߣ⑔␩ߩలታࠍ⋡ᜰߒߚታ〣⑼ቇߣߒߡߩ⋴⼔ቇࠍតⓥߒ㧘㜞ᐲߥ⋴⼔ታ〣⢻ജࠍ᦭ߔࠆੱ᧚ࠍ⢒ᚑߔࠆ‫ޕ‬3㧕 ⋴⼔ቇߦ߅ߌࠆℂ⺰ߣᔕ↪ࠍᢎ⢒࡮⎇ⓥߒ㧘⋴⼔ቇಽ㊁ߦ߅ߌࠆᢎ⢒⠪ߣߒߡᵴべߢ߈ࠆੱ᧚
ࠍ⢒ᚑߔࠆ‫ޕ‬4㧕 ⋴⼔ኾ㐷⡯ߣߒߡ࡝࡯࠳࡯⊛ᓎഀࠍᜂ޿㧘଻ஜක≮⑔␩ߩᄌൻߦኻߒᄌ㕟⊛ߦⴕേߔࠆᜰዉ⠪ߣߥࠅ߁ࠆੱ᧚ࠍ⢒ᚑߔࠆ‫ޕ‬2㧚 ⋴⼔ቇኾ᡹ߩ᭴ᚑ
⋴⼔ቇኾ᡹ߩᢎ⢒ℂᔨߩ߽ߣߦ㧘⋴⼔ቇኾ᡹ߦߪ‫⼔⋴ޟ‬ቇᢎ⢒‫ޟߣޠ‬ታ〣⋴⼔ቇ‫ ߩޠ‬2 㗔ၞࠍ⸳ߌ㧘⋴⼔ቇᢎ⢒㗔ၞߦߪ⋴⼔ቇᢎ⢒ಽ㊁ࠍ㧘ታ〣⋴⼔ቇ㗔ၞߦߪᲣᕈ࡮ዊఽ⋴⼔ቇಽ㊁㧘ᚑੱᕆᕈᦼ⋴⼔
ቇಽ㊁㧘࿾ၞ⋴⼔ቇಽ㊁ߩ 3 ಽ㊁ࠍ⸳ߌߡ޿ࠆ‫ޕ‬
㧔1㧕⋴⼔ቇᢎ⢒㗔ၞ⋴⼔ቇᢎ⢒㗔ၞߢߪ㧘⾰ߩ㜞޿⋴⼔ታ〣⠪߇᳞߼ࠄࠇߡ޿ࠆਛߢ㧘⋴⼔ኾ㐷⡯ߩ⢒ᚑߦ߅ߌࠆᢎ⢒ℂ⺰ߣᣇᴺࠍត᳞ߒ㧘㜞ᐲߥᢎ⢒ታ〣⢻ജࠍ⢒ᚑߔࠆߚ߼ߦᔅⷐߥ⍮⼂㧘ᛛⴚ㧘ᘒᐲߩត᳞ࠍਛᔃߣ
ߒߚᢎ⢒࡮⎇ⓥࠍⴕ߁‫ޕ‬ᧄ㗔ၞߢߪ⋴⼔ቇᢎ⢒ಽ㊁ࠍ⟎߈㧘ᦸ߹ߒ޿⋴⼔ၮ␆ᢎ⢒㧘⋴⼔ᛛⴚᢎ⢒෸߮⛮⛯ᢎ⢒ߩ޽ࠅᣇࠍ
ត᳞ߔࠆ‫ޕ‬㧔2㧕ታ〣⋴⼔ቇ㗔ၞታ〣⋴⼔ቇ㗔ၞߢߪ㧘↢ᱺක≮߿㜞ᰴᢇ๮ᴦ≮ߩ㜞ᐲవㅴක≮߇ㅴ߻ਛߢ㧘ᖚ⠪ਥ૕ߩක≮࡮⋴⼔ߣߪ૗߆ࠍ⠨ኤߒߥ߇ࠄ㧘ࠛࡆ࠺ࡦࠬߦၮߠ޿ߚ⾰ߩ㜞޿⋴⼔េഥ⺰ߦߟ޿ߡត᳞ߔࠆ‫ߚ߹ޕ‬㧘࿾ၞߩੱ‫ߦޘ‬ኻߔࠆ଻ஜᵴേ߿࿷ቛ≮㙃⠪ߣߘߩኅᣖࠍኻ⽎ߣߒߚ㧘ᐢ㗔ၞߥ⋴⼔ಽ㊁ߦ߅ߌࠆ⋴⼔េഥ⺰ߦߟ޿ߡត᳞ߔࠆ‫ޕ‬ᧄ㗔ၞߢߪ㧘Უᕈ࡮ዊఽ⋴⼔ቇಽ㊁㧘ᚑੱᕆᕈᦼ⋴⼔ቇಽ㊁㧘࿾ၞ⋴⼔ቇಽ㊁ߩ 3 ಽ㊁ࠍ⟎߈㧘᭽‫ޘ‬ߥⅣႺߦ޽ࠆᖚ⠪߿ߘߩኅᣖߦኻߔࠆ⋴⼔េഥ㧘࿾ၞ߿⡯႐ߩੱ‫ߡ޿ߟߦ╬ࠕࠤࠬ࡞ࡋߩޘ‬ត᳞ߔࠆ‫ޕ‬㧙㧙3㧚 ቇ↢ቯຬߣ౉ቇ⁁ᴫ⋴⼔ቇኾ᡹ߩ౉ቇቯຬ㧘෼ኈቯຬ෸߮ㆊ෰㧡ᐕ㑆ߩ౉ቇ⁁ᴫߪ㧘ᰴ⴫ߩߣ߅ࠅߢ޽ࠅ㧘ቯຬߪల⿷
ߐࠇߡ޿ࠆ‫ޕ‬⋴⼔ቇኾ᡹ߩ౉ቇቯຬߣ෼ኈቯຬ
⎇ⓥ⑼

ኾ᡹

⺖⒟

౉ቇቯຬ

෼ኈቯຬ

කቇ♽⎇ⓥ⑼

⋴⼔ቇኾ᡹

ୃ჻⺖⒟

8

16

⋴⼔ቇኾ᡹ߩ౉ቇ⁁ᴫᐕᐲ

ᐔᚑ 17 ᐕᐲᐔᚑ 18 ᐕᐲᐔᚑ 19 ᐕᐲᐔᚑ 20 ᐕᐲᐔᚑ 21 ᐕᐲ

౉ቇቯຬ

8

8

8

8

8

ᔒ㗿⠪ᢙ

14

13

12

19

16

ฃ㛎⠪ᢙ

14

13

11

18

16

วᩰ⠪ᢙ

10

9

10

12

11

౉ቇ⠪ᢙ

10

8

8

12

21 ᐕ 4 ᦬⏕ቯ

4㧚 ࠞ࡝ࠠࡘ࡜ࡓߩ✬ᚑᣇ㊎⋴⼔ቇኾ᡹㧔ୃ჻⺖⒟㧕ߩᢎ⢒⺖⒟ߪ㧘↢ᶦࠍㅢߓኾ㐷⡯ᬺੱߣߒߡ⋴⼔ቇ߳ߩㅊⓥᔃ߿ഃㅧᕈ㧘ᔕ↪ᕈࠍ㊀ⷞߒߚ⋴⼔ᵴേ߇ߢ߈ࠆࠃ߁ߦ㧘⥃࿾ታ〣⢻ജࠍ߽ߞߚ⋴⼔⡯෸߮ၮ␆⊛⎇ⓥ⢻ജࠍ߽ߞߚ⋴⼔⡯㧘⋴⼔ᢎ⢒⢻ജࠍ߽ߞߚ⋴⼔⡯ࠍ⢒ᚑߔࠆߎߣࠍ⋡ᜰߒߡ✬ᚑߐࠇߡ޿ࠆ‫ޕ‬᝼ᬺ⑼⋡ߪ㧘౒ㅢ⑼⋡ߣኾ㐷⑼⋡߆ࠄᚑࠅ㧘ቇ↢߇ਥ૕⊛ߦ⋴⼔ᵴേߩታ〣࡮ᢎ⢒ߦᔅⷐߥၮ␆⊛⢻ജࠍ૕ᓧߒߡ޿ߊߚ߼ߦᔅⷐߥ⑼⋡߇ୃᓧߢ߈ࠆࠃ߁ߦ⑼⋡⸳ቯࠍⴕߞߡ޿ࠆ‫ޕ‬౒ㅢ⑼⋡ߪ㧘⋴⼔ኾ㐷㗔ၞ⎇ⓥߩၮ␆ߣߥࠆ⑼⋡ߣߒߡ㧘⋴⼔ቇ⎇ⓥᣇᴺ⺰㧘⋴⼔ℂ⺰ߩ 2 ⑼⋡ࠍᔅୃߣߒߡ⸳ቯߒ㧘ߐࠄߦ⋴⼔ቇߩၮᧄߣߥࠆ⑼⋡ߣߒߡක≮࡮⑔␩ߩ⚻ᷣ⺰㧘⋴⼔ᖱႎቇ㧘↢๮୶ℂቇߥߤ 11 ⑼⋡ࠍㆬᛯߣߒߡ⸳ቯߒߡ޿ࠆ‫ޕ‬ኾ㐷⑼⋡ߪ⋴⼔ቇᢎ⢒㧘ታ〣⋴⼔ቇߩฦ㗔ၞߩኾ㐷ߦ߆߆ࠆℂ⺰࡮⎇ⓥ࡮ታ〣ߩ⻉᭎ᔨߦ㑐ߔࠆ⑼⋡ߣߒߡ․⺰㧘․೎Ṷ⠌㧘․೎⎇ⓥࠍ⸳ቯߒߡ޿ࠆ‫ޕ‬߹ߚ㧘ታ〣ᵴേߦ៤ࠊߞߡ޿ࠆ⋴⼔⡯߇㧘ኾ㐷⡯ᬺੱߣߒߡ↢ᶦߦࠊߚࠅ⋴⼔ቇ߳ߩㅊⓥ߇ߢ߈ࠆࠃ
߁ߦ㧘ᤤᄛ㐿⻠೙ࠍታᣉߒ㧘㐳ᦼጁୃߦ߽ኻᔕߢ߈ࠆࠃ߁ߦࠞ࡝ࠠࡘ࡜ࡓ✬ᚑࠍⴕ޿㧘ᄙ᭽ߥੱ᧚⢒ᚑߩ⋡⊛ߦኻᔕߒߡ޿ࠆ‫ޕ‬
㧔1㧕ጁୃၮḰᧄኾ᡹ߦ߅ߌࠆ᝼ᬺ⑼⋡ߪᔅୃ⑼⋡෸߮ㆬᛯ⑼⋡ߣߒߡ߅ࠅ㧘ୃੌߦᔅⷐߥන૏ᢙߪ㧘30 න૏એ਄ߣߥߞߡ޿ࠆ‫ޕ‬߹ߚ㧘౒ㅢ⑼⋡㧘ኾ㐷⑼⋡ߩᦨૐጁୃන૏ᢙߪᰴ⴫ߩࠃ߁ߦⷙቯߐࠇߡ޿ࠆ‫ޕ‬⋴⼔ቇኾ᡹ୃ჻⺖⒟⑼⋡඙ಽᦨૐጁୃන૏ᢙ

஻‫ޓޓޓ‬⠨

౒ㅢ⑼⋡

12 න૏

ᔅୃ 2 ⑼⋡ 4 න૏㧘ㆬᛯ 4 ⑼⋡ 8 න૏એ਄

ኾ㐷⑼⋡

18 න૏

ኾ᡹ಽ㊁߆ࠄᔅୃ⑼⋡ 12 න૏ࠍ฽߼ 14 න૏એ਄

⸘

30 න૏

㧙㧙

㧔2㧕ᢎ⢒⎇ⓥಽ㊁㧘ᜰዉᢎຬ⋴⼔ቇኾ᡹ߦ߅ߌࠆฦ㗔ၞ೎ߩᢎ⢒⎇ⓥಽ㊁㧘ᜰዉᢎຬ㧘ਥߥ⎇ⓥౝኈߪᰴ⴫ߩߣ߅ࠅߢ޽ࠆ‫ޕ‬⎇ⓥᜰዉᢎຬ෸߮⎇ⓥౝኈ٤ ⋴⼔ቇᢎ⢒㗔ၞಽ‫ޓޓ‬㊁ᜰ‫ޓ‬ዉ‫ޓ‬ᢎ‫ޓ‬ຬ⎇‫ޓ‬ⓥ‫ޓ‬ౝ‫ޓ‬ኈ
1㧚⋴⼔⡯ຬߩ⛮⛯ᢎ⢒ߦ㑐ߔࠆ⎇ⓥ

٤

⋴⼔ቇᢎ⢒

▘ᶆߣ߈ሶ

⋴⼔ቇᢎ⢒

Ṛౝ㓉ሶ

2㧚⋴⼔ᢎຬߩቇ⠌࠾࡯࠭ߣࡊࡠࠣ࡜ࡓߩ㐿⊒
3. ⋴⼔ߩ࿖㓙⽸₂ࠍᗧ࿑ߒߚ⇐ቇ↢߳ߩᡰេߦ㑐ߔࠆ⎇ⓥ
1㧚⋴⼔⡯ߩ⛮⛯ᢎ⢒ߦ㑐ߔࠆᱧผ⊛⎇ⓥ
2㧚࿷ቛߦ߅ߌࠆᗵᨴ▤ℂߦ㑐ߔࠆᢎ⢒ࡊࡠࠣ࡜ࡓߩ㐿⊒1㧚⋴⼔Ꮷߩ㔌⡯㒐ᱛߦ㑐ߔࠆ⎇ⓥ

⋴⼔ቇᢎ⢒

Ⴆේ▵ሶ

⋴⼔ቇᢎ⢒

ᳯ᧛ᱜ৻

ฦ⒳േ‛ߩ⥠ߩᒻᘒߣ㘩ᕈߣߩ㑐ଥ1㧚⚦⢩ಽⵚࠍ೙ᓮߔࠆਛᔃ૕࠲ࡦࡄࠢ⾰ߦߟ޿ߡߩ⎇ⓥ

⋴⼔ቇᢎ⢒

ᱞ⮮ศᓼ

2㧚Ⱟశ౒㡆ࠛࡀ࡞ࠡ࡯⒖േᴺߦࠃࠆ࠲ࡦࡄࠢ⾰㑆⋧੕૞
↪ߩ⎇ⓥ

⋴⼔ቇᢎ⢒

ዊ᧻ᅱሶ

2. ⋴⼔⡯ຬߩ⾗⾰ะ਄ߦ㑐ߔࠆ⎇ⓥ

1. ࿷ቛߦ߅ߌࠆᗵᨴ▤ℂߦ㑐ߔࠆᢎ⢒ࡊࡠࠣ࡜ࡓߩ㐿⊒
2. ࿷ቛ࠲࡯ࡒ࠽࡞ࠤࠕߦ㑐ߔࠆᢎ⢒ࡊࡠࠣ࡜ࡓ㐿⊒ታ〣⋴⼔ቇ㗔ၞಽ‫ޓޓ‬㊁ᜰ‫ޓ‬ዉ‫ޓ‬ᢎ‫ޓ‬ຬ⎇‫ޓ‬ⓥ‫ޓ‬ౝ‫ޓ‬ኈ
1. ᅚሶቇ↢ߩࡋ࡞ࠬ࡝ࠬࠢⴕേߣ࡝ࡊࡠ࠳ࠢ࠹ࠖࡉࡋ࡞
ࠬߦ㑐ߔࠆ⎇ⓥ

Უᕈ࡮ዊఽ⋴⼔ቇ㊁↰ᵗሶ

2. STI ੍㒐ߦ㑐ߔࠆ⎇ⓥ
3. ੑಽ⣄ᬁᅚᕈߩ᦬⚻ߣᕈߩஜᐽߦ㑐ߔࠆ⎇ⓥ
4. ഥ↥Ꮷᢎ⢒ߩᡷༀߦ㑐ߔࠆ⎇ⓥ
1. ࠕ࡟࡞ࠡ࡯∔ᖚࠍᜬߟሶߤ߽ߩ QOL ะ਄Უᕈ࡮ዊఽ⋴⼔ቇ᧖ᶆᄥ৻

2. ᕁᤐᦼߦ߅ߌࠆ≮㙃ⴕേߩ⥄ᓞេഥ
3. 㓚ኂߩ޽ࠆ෺ሶߩሶ⢒ߡࠨࡐ࡯࠻
1. ࠬࡐ࡯࠷ߦ߅ߌࠆ⋴⼔Ꮷߩᓎഀߦ㑐ߔࠆ⎇ⓥ‫ޓ‬ᚑੱᕆᕈᦼ⋴⼔ቇ⷏ᧄ⵨

2. 㓚ኂ⠪ࠬࡐ࡯࠷ߩ⎇ⓥ
3. ๟ᚻⴚᦼᖚ⠪ߩࠤࠕߦ㑐ㅪߔࠆ∛ᘒߩ⎇ⓥ
4. ක≮ᖱႎࠪࠬ࠹ࡓߦ߅ߌࠆ⋴⼔ᖱႎߦ㑐ߔࠆ⎇ⓥ
1. ᢇᕆᖚ⠪෸߮ኅᣖߦ㑐ߔࠆ⎇ⓥᚑੱᕆᕈᦼ⋴⼔ቇ᧻↰ᅢ⟤

2. ᚻⴚࠍฃߌࠆᖚ⠪෸߮ኅᣖߦ㑐ߔࠆ⎇ⓥ
3. ἴኂ⋴⼔ߦ㑐ߔࠆ⎇ⓥ
1㧚ⴕ᡽ߩᄌ㕟ߦ઻߁଻ஜᏧߩᓎഀߣᯏ⢻ߦ㑐ߔࠆ⎇ⓥ
2㧚଻ஜᏧᢎ⢒ߩ޽ࠅᣇ㧘ᢎ⢒ߩ⃻⁁ߣ⺖㗴

࿾ၞ⋴⼔ቇ

ᓟ㑄ኈሶ

3㧚⸰໧⋴⼔ߦ㑐ߔࠆ⎇ⓥ
4㧚⥄⸥ᑼ⾰໧⚕⺞ᩏߦࠃࠆஜᐽ⥄Ꮖ⹏ଔࠍ↪޿ߚ⎇ⓥ
㧔㜞㦂⠪㧘࿾ၞ૑᳃㧘㕍ᐕ╬㧕
5㧚࿾ၞ߅ߌࠆ⯦ᓙ੍㒐ߦ㑐ߔࠆ⎇ⓥ

㧙㧙

٤

ታ〣⋴⼔ቇ㗔ၞಽ‫ޓޓ‬㊁ᜰ‫ޓ‬ዉ‫ޓ‬ᢎ‫ޓ‬ຬ⎇‫ޓ‬ⓥ‫ޓ‬ౝ‫ޓ‬ኈ

࿾ၞ⋴⼔ቇ

’㊁⨃ᓼ

⡯ၞߦ߅ߌࠆஜᐽ▤ℂߦ㑐ߔࠆ⎇ⓥ
1㧕૞ᬺ㑐ㅪ∔ᖚߩ੍㒐ߦߟ޿ߡ
2㧕⡯ᬺᕈ∔∛ߩ੍㒐ߦߟ޿ߡ
3㧕ஜᐽߩ଻ᜬჇㅴߦߟ޿ߡ

࿾ၞ⋴⼔ቇ

⿷┙ਭሶ

ᘟᕈ∛ᖚ⠪ߩ QOL ߦ㑐ߔࠆ⎇ⓥ

࿾ၞ⋴⼔ቇ

⍹ේᄙ૫ሶ

࿾ၞ⋴⼔ቇ

ᅏ᧛ᄥᔒ

1. 㜞㦂⠪⯦ᓙ৻ᰴ੍㒐㧘ੑᰴ੍㒐ߦ㑐ߔࠆ⎇ⓥ
2. ⸰໧⋴⼔ߩᄙ᭽ᕈ㧘ኾ㐷ᕈߦ㑐ߔࠆ⎇ⓥ
1. ࡔࡦ࠲࡞ࡋ࡞ࠬࠤࠕࠪࠬ࠹ࡓߦ㑐ߔࠆ⎇ⓥ
2. ♖␹㓚ኂ⠪߳ߩࠨࡐ࡯࠻ߦ㑐ߔࠆ⎇ⓥ

5㧚 ᢎ⢒ᵴേ
㧔1㧕ᢎ⢒ᵴേߩታᣉౝኈߣᣇᴺ
⋴⼔ቇኾ᡹ߢߪ㧘ታ〣⑼ቇߣߒߡߩ⋴⼔ቇࠍតⓥߔࠆ㜞޿⢻ജߣߣ߽ߦ㧘ోੱ⊛ක≮ࠍᜂ޿ᓧࠆ⼾߆ߥᗵᕈߣੱ㑆ᕈࠍ஻߃ߚ㜞ᐲߥ⥃࿾ታ〣⢻ജࠍ߽ߞߚ⋴⼔⡯෸߮㧘⋴⼔ᢎ⢒⢻ജࠍ߽ߞߚ⋴⼔⡯ࠍ⢒ᚑߔࠆߎߣࠍ⋡ᜰߒߡᰴߩࠃ߁ߥᢎ⢒ᵴേࠍⴕߞߡ޿ࠆ‫ޕ‬Ԙ⋴⼔ቇᢎ⢒㗔ၞߦ߅޿ߡߪ㧘⋴⼔ኾ㐷⡯ߩ⢒ᚑߦ߅ߌࠆᢎ⢒ℂ⺰ߣᣇᴺࠍតⓥߒ㧘㜞ᐲߥᢎ⢒ታ〣⢻ജࠍ⢒ᚑߔࠆߚ߼ߦᔅⷐߥ⍮⼂㧘ᛛⴚ㧘ᘒᐲߩត᳞ࠍਛᔃߣߒߚᢎ⢒࡮⎇ⓥࠍⴕ޿㧘ᦸ߹ߒ޿⋴⼔ၮ␆ᢎ⢒㧘⋴⼔ᛛⴚᢎ⢒෸߮⛮⛯ᢎ⢒ߩ޽ࠅᣇࠍត᳞ߒߡ޿ࠆ‫ޕ‬ԙታ〣⋴⼔ቇ㗔ၞߦ߅޿ߡߪ㧘ᖚ⠪ਥ૕ߩක≮࡮⋴⼔ߣߪ૗߆ࠍ⠨ኤߒߥ߇ࠄ㧘ࠛࡆ࠺ࡦࠬߦၮߠ޿
ߚ⾰ߩ㜞޿⋴⼔េഥ⺰ߦߟ޿ߡត᳞ߒߡ޿ࠆ‫ߚ߹ޕ‬㧘࿾ၞߩੱ‫ߦޘ‬ኻߔࠆ଻ஜᵴേ߿࿷ቛ≮㙃⠪ߣߘߩኅᣖࠍኻ⽎ߣߒߚ㧘ᐢ㗔ၞߥ⋴⼔ಽ㊁ߦ߅ߌࠆ⋴⼔េഥ⺰ߦߟ޿ߡត᳞ߒ㧘᭽‫ߥޘ‬ⅣႺߦ޽ࠆᖚ⠪߿ߘߩኅᣖߦኻߔࠆ⋴⼔េഥ㧘࿾ၞ߿⡯႐ߩੱ‫ߡ޿ߟߦ╬ࠕࠤࠬ࡞ࡋߩޘ‬ត᳞ߒߡ޿ࠆ‫ޕ‬Ԛ ᢎ⢒ᣇᴺߪ㧘ฦ⋴⼔ቇಽ㊁ߩౝኈࠍᷓ߼㧘᏷ᐢ޿⍮⼂ࠍୃᓧߐߖࠆߚ߼ߦ㧘ኾછᢎຬ෸߮㕖Ᏹൕ⻠Ꮷߦࠃࠆࠝࡓ࠾ࡃࠬᒻᑼࠍᄙߊណ↪ߒ⻠⟵ࠍታᣉߒߡ޿ࠆ‫ߚ߹ޕ‬㧘⻠⟵ߢୃᓧߒߚ⍮⼂ࠍ߽ߣߦ㧘ᔕ↪࡮ዷ㐿࡮⹏ଔߒᓧࠆ㜞ᐲߥኾ㐷⡯ᬺੱࠍ⢒ᚑߔࠆߚ߼ߦ㧘ቇౝ෸߮࿾ၞ␠ળ㧘⥃ᐥߩ႐ߢṶ⠌ࠍⴕ޿㧘ኾ㐷ᛛⴚ߿ᘒᐲࠍᢎ᝼ߒߡ޿ࠆ‫ޕ‬ԛ౉ቇᓟߦࠝ࡝ࠛࡦ࠹࡯࡚ࠪࡦࠍታᣉߒ㧘ࠞ࡝ࠠࡘ࡜ࡓߩ᭎ⷐ㧘ጁୃߥߤߩ⻉ᚻ⛯㧘ቇ↢↢ᵴ㧘ቇ↢଻㒾㧘ஜᐽ⸻ᢿ㧘ฦ⒳⋧⺣⓹ญ㧘࿑ᦠ㙚╬ߦߟ޿ߡ⺑᣿ߒ㧘ቇ⠌߳ߩേᯏߠߌࠍ࿑ࠅ㧘ጁୃᜰዉࠍⴕߞߡ޿ࠆ‫ޕ‬૬ߖߡฦኾ㐷㗔ၞߩᢎຬ⚫੺ࠍⴕ޿⎇ⓥౝኈߦߟ޿ߡ⺑᣿ߒߡ޿ࠆ‫ߚ߹ޕ‬㧘․೎⎇ⓥᜰዉߪ㧘ේೣߣߒߡቇ↢߇ㆬᛯߒߚ⹥ᒰ⎇ⓥಽ㊁ᜂᒰߩᢎ᝼╬߇ⴕ߁߇㧘ࠃࠅലᨐ⊛ߥ⎇ⓥᜰዉ߇ߢ߈ࠆࠃ߁ߦቇ↢ߣ㕙ធߩ਄㧘ᜰዉᢎຬࠍ᳿ቯߒߡ޿ࠆ‫ޕ‬Ԝ ᄢቇ㒮ቇ↢߇ࠃࠅ⾰ߩ㜞޿ୃ჻⺰ᢥࠍ૞ᚑߔࠆߚ߼ߦ㧘‫⎇ޟ‬ⓥ᭴ᗐ⊒⴫ળ‫ߡߒߣޠ‬ᐕߦ 2 ࿁㧘⎇ⓥ⸘↹ࠍ⊒⴫ߔࠆ႐ࠍ⸳ߌߡ޿ࠆ‫ߩߘޕ‬ᓟߦ‫⼔⋴ޟ‬ቇኾ᡹ୃ჻⺰ᢥ୶ℂክᩏዊᆔຬળ‫ߡ޿߅ߦޠ‬⎇ⓥ୶ℂߩⷞὐ߆ࠄክᩏࠍⴕ޿㧘⎇ⓥ⸘↹ᦠߩ⾰ࠍࠃࠅ৻ጀ㜞߼㧘⎇ⓥߦขࠅ⚵߼ࠆࠃ߁ߦഥ⸒࡮
ᜰዉࠍⴕߞߡ޿ࠆ‫ޕ‬

㧙㧙

ԝ

␠ળੱቇ↢ߩୃቇࠍน⢻ߦߔࠆߚ߼ߦ㐳ᦼጁୃቇ↢೙ᐲࠍዉ౉ߒߡ޿ࠆ‫ޕ‬Ꮧᦸߔࠆ⠪ߦߪ㧘㐳ᦼጁୃ↳⺧ᦠ෸߮㐳ᦼጁୃ⸘↹ᦠࠍឭ಴ߐߖ㧘ฦಽ㊁ߦ߅޿ߡ㕙ធ╬ߦࠃࠅ㐳ᦼጁୃࠍᏗᦸߔࠆℂ↱ࠍ⡞߈ᜰዉߒߡ޿ࠆ‫ߩߘޕ‬ᓟ⋴⼔ቇኾ᡹ቇോᆔຬળ࡮⋴⼔ቇኾ᡹ᢎ᝼ળ⼏ߩክ⼏ࠍ⚻ߡ㧘⸵นߒߡ޿ࠆ‫ޕ‬⃻࿷㧘㐳ᦼጁୃߩ⸵นࠍฃߌߡ޿ࠆᄢቇ㒮ቇ↢ߩੱᢙߪ㧘ᰴ⴫ߩߣ߅ࠅߢ޽ࠆ‫ޕ‬㐳ᦼጁୃ೙ᐲߩ↳⺧⠪ᢙ෸߮⸵น⠪ᢙ
↳⺧⠪ᢙ

⸵น⠪ᢙ

஻‫ޓ‬⠨

ᐔᚑ 17 ᐕᐲ౉ቇ↢77⋴⼔Ꮷ 2㧘ഥ↥Ꮷ 2㧘଻ஜᏧ 1㧘ᄢቇᢎຬ 1㧘⍴ᦼᄢቇᢎຬ 1

ᐔᚑ 18 ᐕᐲ౉ቇ↢4

4⋴⼔Ꮷ 3㧘଻ஜᏧ 1

ᐔᚑ 19 ᐕᐲ౉ቇ↢5

5⋴⼔Ꮷ 1㧘ഥ↥Ꮷ 1㧘଻ஜᏧ 2㧘ᄢቇᢎຬ 1

ᐔᚑ 20 ᐕᐲ౉ቇ↢1111⋴⼔Ꮷ 5㧘ഥ↥Ꮷ 1㧘଻ஜᏧ 2㧘ኾ㐷ቇᩞᢎຬ 2㧘ᄢቇᢎຬ 1

6㧚 ቇ૏ߩ᝼ਈ⁁ᴫߣ⎇ⓥᚑᨐ
⋴⼔ቇኾ᡹ߦ߅ߌࠆቇ૏ߩ᝼ਈߪ㧘ᧄ⎇ⓥ⑼ߦ 2 ᐕએ਄㧔ᮡḰ㧕࿷ቇߒ㧘ୃ჻⺰ᢥࠍ૞ᚑ࡮ឭ಴ߒ㧘ክᩏߦวᩰߒߚቇ↢ߦୃ჻㧔⋴⼔ቇ㧕ߩቇ૏ࠍ᝼ਈߔࠆߎߣߦߥߞߡ޿ࠆ‫ߢ߹ࠇߎޕ‬㧘㧝㧟ฬߦኻߒቇ૏ࠍ᝼ਈߒߚ‫ޕ‬
඙‫ޓ‬ಽ

㧝㧤ᐕᐲ

ୃ჻㧔⋴⼔ቇ㧕

㧞

㧝㧥ᐕᐲ

஻‫ޓ‬⠨

㧝㧝㧔㧣㧕㧔‫ޓ‬㧕ߪ㐳ᦼጁୃቇ↢ࠍౝᢙߢ␜ߔ‫ޕ‬7㧚 ቇ↢↢ᵴᡰេ
㧔1㧕ᅑቇ㊄ߩ↳⺧࡮ណᛯ⁁ᴫ߶ߣࠎߤߩቇ↢߇␠ળੱߣ޿߁ߎߣ߽޽ࠅ㧘↳⺧ઙᢙߪዋߥ޿߇㧘㧞㧜ᐕᐲߦ㧝ฬ↳⺧ߒណᛯߐࠇ
ߚ‫ޕ‬㧔2㧕᝼ᬺᢱ఺㒰ታᣉ⁁ᴫ߶ߣࠎߤߩቇ↢߇␠ળੱߣ޿߁ߎߣ߽޽ࠅ㧘↳⺧ઙᢙߪዋߥ޿߇㧘㧝㧤ᐕᐲߣ㧞㧜ᐕᐲߦ㧝ฬ↳⺧ߒណᛯߐࠇߚ‫ޕ‬
㧔3㧕ቇ↢ߩ଻㒾ട౉ᣣᧄ⋴⼔ቇᩞ౒ᷣળߩ⋴⼔ቇᩞ✚ว⵬ఘ೙ᐲߦ㧘ฦቇ↢߇છᗧߢട౉ߒߡ޿ࠆ‫⎇ޕ‬ⓥ߿᝼ᬺߢ㧘⾩ఘ⽿છࠍ⽶߁ࠃ߁ߥߎߣ߇⠨߃ࠄࠇࠆ႐วߪ㧘ട౉ࠍ൘߼ߡ޿ࠆ‫ޕ‬8㧚 ⥄Ꮖ⹏ଔ࡮⺖㗴ߣዷᦸ⋴⼔ቇኾ᡹ో૕ߣߒߡ㧘ቇᐕㅴⴕ߽⚳߃㧘ߎࠇ߹ߢߦਛㅜㅌቇ⠪߽ߥߊ㧘ᱴߤߩቇ↢߇ⷙቯୃቇᦼ
㑆ߦ⺖⒟ࠍୃੌߒ㧘13 ฬߩୃ჻ቇ૏᝼ਈ⠪ࠍㅍࠅ಴ߔߎߣ߇ߢ߈ߚ‫ߚ߹ޕ‬㧘ᧄኾ᡹ߩᢎ⢒ߩታᣉ૕೙㧘ᢎ⢒ߩౝኈߣᣇᴺߦ㑐ߔࠆ࿷ቇ↢ߣୃੌ↢߆ࠄߩ⹏ଔߪߣ߽ߦ㜞ߊ㧘ᢎ⢒⋡ᮡߩ㆐ᚑᐲߪ㜞޿ߣ㧙㧙್ᢿߢ߈ࠆ‫ޕ‬ᒁ߈⛯߈੹ᓟ߽㧘ታ〣⑼ቇߣߒߡߩ⋴⼔ቇࠍតⓥߔࠆ㜞޿⢻ജࠍ᦭ߔࠆ⋴⼔ኾ㐷⡯ᬺੱߣߒߡߩୃ჻ቇ૏᝼ਈ⠪ࠍㅍࠅ಴ߖࠆࠃ߁ᢎ⢒㧘⎇ⓥᜰዉߦദജߒߡ޿ߊᔅⷐ߇޽ࠆ‫ޕ‬᧪ᐕᐲ߆ࠄ㧘␠ળߩᄌൻߣ࿾ၞ࡮␠ળ߆ࠄߩⷐ᳞ߦኻᔕߒ㧘⋴⼔ቇኾ᡹ߩߐࠄߥࠆ⊒ዷߩߚ߼ߦᡷ
ᱜࠞ࡝ࠠࡘ࡜ࡓࠍታᣉߒߡ޿ߊ‫ޕ‬ታᣉߦߣ߽ߥ޿㧘ቇ↢ߩ⾰ߩ଻⸽ߣะ਄㧘࿾ၞ࡮␠ળ߆ࠄߩⷐ᳞ߦ
ኻᔕߔࠆߚ߼ߦ㧘ᢎ⢒ߩታᣉ૕೙㧘ᢎ⢒ߩౝኈߣᣇᴺ㧘ᢎ⢒⊛ᡰេߥߤߩᢎ⢒⹏ଔࠍⴕ޿㧘⹏ଔ⚿ᨐࠍᢎ⢒ߣ⎇ⓥᜰዉߦ෻ᤋߔࠆࠃ߁ᣇ╷ߦߟ޿ߡᬌ⸛ߔࠆߎߣ߇⺖㗴ߣߥࠆ‫ߚ߹ޕ‬㧘㜞޿⢻ജࠍ᦭ߔࠆ
⋴⼔ኾ㐷⡯ᬺੱࠍ㙃ᚑߔࠆߚ߼ߦߪ㧘౉ቇᓟߩቇ↢ߩ⾰ߩ଻⸽ߣะ਄ߩߺߥࠄߕ㧘౉ቇᤨߩቇ↢ߩ⾰ߩ⏕଻߽㊀ⷐߦߥࠆ‫ޕ‬ᱴߤߩቇ↢߇␠ળੱ․೎ㆬᛮߢ޽ࠆ⃻⁁ࠍ㐓ߺ㧘ᧄ⋴⼔ቇ⑼තᬺ↢ߩ⏕଻ߣ␠
ળੱ․೎ㆬᛮߩ಴㗿⾗ᩰ㧘౉⹜⑼⋡ߥߤߩ౉⹜ߩ⷗⋥ߒ߇੹ᓟߩ⺖㗴ߣߥࠆ‫ޕ‬
ฦಽ㊁ߩ⥄Ꮖ⹏ଔ࡮⺖㗴ߣዷᦸߪᰴߩߣ߅ࠅߢ޽ࠆ‫ޕ‬
㧔1㧕⋴⼔ቇᢎ⢒㗔ၞԘ⋴⼔ቇᢎ⢒ಽ㊁⋴⼔ቇᢎ⢒ಽ㊁ߢߪ㧘⋴⼔ኾ㐷⡯⢒ᚑߦᔅⷐߥᢎ⢒ℂ⺰ߣᣇᴺߩត᳞ࠍ߼ߑߒ㧘㜞ᐲߥ⋴⼔ᢎ⢒ታ〣⢻ജߩ⢒ᚑߣ㧘⋴⼔ၮ␆ᢎ⢒߿⛮⛯⋴⼔ᢎ⢒ߦ⽸₂ߢ߈ࠆੱ᧚ߩ⢒ᚑࠍ⋡ᮡߣߒߡ޿ࠆ‫ߎߘޕ‬ߢ㧘⋴⼔ၮ␆ᢎ⢒ߣ⋴⼔⛮⛯ᢎ⢒ߩ㑐ㅪᕈࠍ߰߹߃ߟߟ㧘⋴⼔ᢎ⢒ߩ޽ࠅᣇࠍᬌ⸛ߒߡ߈ߚ‫ޕ‬ᦨㄭߎߩಽ㊁߳ߩᔕ൐⠪ߩ௑ะߪ㧘⋴⼔⛮⛯ᢎ⢒ߦ㑐ᔃࠍᜬߟ⋴⼔⡯ߩᔕ൐ࠃࠅߪ㧘ߔߢߦ⋴⼔ၮ␆ᢎ⢒ߦ៤ࠊߞߡ޿ࠆኾ㐷ቇᩞ߿⍴ᦼᄢቇߩ⋴⼔♽ᢎຬ߿㧘⋴⼔ၮ␆ᢎ⢒ߦ៤ࠊࠈ߁ߣߒߡ޿ࠆ
⋴⼔⡯⠪߇Ⴧടߒߡ޿ࠆ‫⼔⋴߼ߚߩߘޕ‬ቇᢎ⢒ಽ㊁ߢߪ⋴⼔ኾ㐷⡯ࠍ⢒ᚑߔࠆߚ߼ߩᢎ⢒ℂ⺰ߣᢎ⢒ᣇᴺ߅ࠃ߮ᢎ⢒⹏ଔࠍ฽߼ߚ⋴⼔ቇᢎ⢒ߩ૕♽⊛ត᳞ߩలታ߇᳞߼ࠄࠇߡ޿ࠆ‫ߚ߹ޕ‬㧘ක≮ᯏ㑐߆ࠄߪ⋴⼔▤ℂߦὶὐࠍᒰߡߚᢎ⢒࡮⎇ⓥߩଦㅴ߽᳞߼ࠄࠇߡ޿ࠆ‫੹ޕ‬ᓟߪߎࠇࠄࠍ߰߹߃⛮⛯⋴⼔ᢎ⢒ߦ㑐ᔃࠍ␜ߔ⋴⼔⡯⠪ߩᔕ൐߽㐓ߺ㧘⋴⼔ᢎ⢒ߩ⾰ߩㅊⓥ߿㧘⋴⼔▤ℂࠍ฽߻㜞ᐲߥ⋴⼔ታ〣⢻ജࠍ஻߃ߚ⋴⼔⡯ߩ⢒ᚑࠍ߽൮฽ߒߚ⋴⼔ቇᢎ⢒ߦ㑐ߔࠆᢎ⢒࡮⎇ⓥᵴേࠍㅴ߼ߡ޿ߊߎߣࠍ
⺖㗴ߣߒߡ޿ࠆ‫ޕ‬
㧔2㧕 ታ〣⋴⼔ቇ㗔ၞԘᲣᕈ • ዊఽ⋴⼔ቇಽ㊁Უᕈ࡮ዊఽ⋴⼔ቇಽ㊁ߢߪᧄᐕ 3 ᦬ߦ㐳ᦼጁୃ↢ࠍ฽߼ߚ 3 ੱ߇ୃੌߒߚ߶߆㧘⃻࿷ 3 ੱߩᄢቇ㒮↢߇࿷☋ߒߡ߅ࠅ㧘޿ߕࠇ߽Უᕈ࡮ഥ↥ቇࠍㆬᛯ㧘⎇ⓥ⸘↹ᦠࠍឭ಴ߒ⎇ⓥࠍㆀⴕߒߡ޿ࠆᲑ㓏ߢ޽ࠆ‫ޕ‬ᰴᐕᐲߩࠞ࡝ࠠࡘ࡜ࡓᡷᱜߦ઻޿ዊఽ⋴⼔ቇߢߩㆬᛯ߇น⢻ߣߥࠅ㧘ዊఽ⋴⼔ቇࠍᏗᦸߔࠆ㒮↢ߩ࠾࡯࠭ߦ߽ኻᔕߢ߈ࠆࠃ߁ߦߥߞߚ‫ޕ‬⃻࿷ߪቇㇱᢎ⢒ߢⴕߞߡ޿ࠆഥ↥Ꮷᢎ⢒ߩ⾰ߩะ਄ࠍ࿑ࠆߚ߼㧘ᄢቇ㒮ߢߩഥ↥Ꮷᢎ⢒ಽ㊁ߩᣂ⸳߇੹ᓟߩ⺖㗴ߢ޽ࠆߣหᤨߦ㧘ᄢቇ㒮↢ߩ⾰ߩะ਄ߦะߌߚ౉⹜૕೙ߩᡷༀ߇ᕆോߣ⠨߃ࠆ‫ߚ߹ޕ‬ᢎ
⢒ᣇᴺߩᬌ⸛߅ࠃ߮Უᕈ࡮ഥ↥ቇߩ⎇ⓥಽ㊁ߦ㑐ㅪߔࠆઁቇㇱ࡮ઁ㗔ၞߣߩ੤ᵹ㧘ઁᄢቇߣߩ੤ᵹߩ
ផㅴߦࠃࠅᢎ⢒ߩ⾰ߩะ਄ࠍ࿑ࠆߎߣ߇᳞߼ࠄࠇࠆ‫ޕ‬ԙᚑੱᕆᕈᦼ⋴⼔ቇಽ㊁ഃ⸳ᓟೋߩୃ჻ቇ૏᝼ਈ⠪ࠍ 2 ฬㅍࠅ಴ߒ㧘ߘࠇߦ⛯ߊ 4 ฬߩቇ↢߇ୃቇਛߢ޽ࠆ‫޿ߪ↢ੌୃޕ‬ߕࠇ߽㐳ᦼጁୃቇ↢ߢ޽ࠅ㧘ୃੌᓟ߽ᒁ߈⛯߈⋴⼔⡯ߣߒߡᵴべߒߡ޿ࠆߎߣ߆ࠄ㧘ฦ⡯႐ߦ߅ߌࠆᜰዉ⊛ᓎഀߦୃ჻⺖⒟ߩቇ߮߇ነਈߒߡ޿ࠆߣᕁࠊࠇࠆ‫ޕ‬ᕆᕈᦼ⋴⼔ߢߪᄙߊߩක≮ᯏེ㧘⮎೷߇૶ࠊࠇࠆਛߢ㧘ᖚ⠪㧘ኅᣖ㧘ක≮⡯ߩធὐߦ┙ߟ⋴⼔⡯߇㧘∛ᘒ㧘ᴦ≮ౝኈ㧘ᴦ≮ⅣႺߦ♖ㅢߒ㧘⺑᣿ߢ߈ࠆታ〣⋴⼔߇ⷐ᳞ߐࠇߡ޿ࠆ‫੹ޕ‬ᓟߣ߽ઁቇㇱ㧘㧙㧙ઁᄢቇߩᄙߊߩ⡯⒳㧘⎇ⓥ⠪ߣߩㅪ៤ࠍ଻ߜߟߟ㧘ᢎ⢒࡮⎇ⓥࠍㅴ߼ߡ޿ߊ‫ߚ߹ޕ‬ᕆᕈᦼ⋴⼔ߩᢎ
⢒ᣇᴺߦߟ޿ߡ߽ක≮⃻႐ߢߩታ㓙⊛ߥᢎ⢒ࠍⷞ㊁ߦ⑼ቇ⊛ߥ᦭ലᕈߩᬌ⸛ࠍⴕ߁ߚ߼ߦ㧘ࠦࡦࡇࡘ࡯࠲ࠍ೑↪ߒߚᢎ᧚㐿⊒㧘ක≮ല₸ߩะ਄ߦ㑐ࠊࠆฦ⒳⡯⒳ߣߩㅪ៤߇ᰳ߆ߖߥ޿ߣ⠨߃ࠄࠇࠆ‫ߩߎߒ߆ߒޕ‬ᣇ㕙ߢߩㅪ៤ߪᒙߊ੹ᓟ᜛ᄢᒝൻߔࠆᔅⷐ߇޽ࠆߣ⠨߃ࠆ‫ޕ‬৻ᣇᢇᕆ⋴⼔ߩ㗔ၞߢߪ㧘ᐕ‫ޘ‬ㅴᱠߒᄌᦝߐࠇࠆࠟࠗ࠼࡜ࠗࡦߦ⠌ᾫߔࠆߎߣߦߣߤ߹ࠄߕ㧘ߘߩᩮ᜚ࠍត᳞ߒᦝߦ᦭↪ߥኻᔕᣇᴺࠍᬌ⸛ߔࠆ⢻ജࠍᦼᓙߐࠇߡ޿ࠆ‫ޕ‬ᢇᕆ⋴⼔ߩ࡟ࡌ࡞ࠕ࠶ࡊߩ
ߚ߼ߦߪ㧘ᢇᕆ⋴⼔ࠕ࠮ࠬࡔࡦ࠻ߩ⍮⼂ߣᛛⴚ㧘ᖚ⠪෸߮ኅᣖߩᔃℂ⊛ߥࠕ࠮ࠬࡔࡦ࠻ߣࠤࠕ㧘ᢇᕆ⋴⼔ߦ߅ߌࠆੱ᧚⢒ᚑ࡮࡝࡯࠳࡯ࠪ࠶ࡊ⢻ജߩะ਄߇ᔅⷐߢ޽ࠆߣ⠨߃ߡ޿ࠆ‫ޕ‬ᚑੱ∛㧘㓚ኂ⠪ߦߣߞߡࠬࡐ࡯࠷ߪ࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦߣߒߡߩᗧ⟵߇޽ࠅ㧘ࠬࡐ࡯࠷කቇߪஜ
ᐽჇㅴ߆ࠄ┹ᛛࠬࡐ࡯࠷߹ߢ᏷ᐢߊ㑐ਈߒߡ޿ࠆ߇㧘ࠬࡐ࡯࠷৻⥸ߦߪ⋴⼔ߩ㑐ਈߪ㕖Ᏹߦ⭯ߊ㧘⃻⁁ߢߪࠬࡐ࡯࠷⃻႐ߢߩᢇ⼔㧘ࠬࡐ࡯࠷කቇ⎇ⓥߩࠨࡐ࡯࠻ߦᱛ߹ߞߡ޿ࠆ‫⃻ߒ߆ߒޕ‬႐ߢߪ㧘ක≮ࠍᔅⷐߣߔࠆ႐วߢ߽ක≮⡯߇޿ߥ޿ߚ߼ߦ࠻࡟࡯࠽࡯ߥߤઁߩ⡯⒳ߦ㗬ࠆߎߣ߇ᄙߊ㧘කቇ⊛⍮⼂ • ᛛⴚࠍᜬߜ⃻႐ߩㄭߊߢ⷗቞ࠆක≮⡯ߪᔅⷐߣ⠨߃ࠄࠇࠆ‫ޕ‬㧔ᕆᕈᦼ㧕ᚑੱ⋴⼔ቇಽ㊁ߢߪ㧘ᄙߊߩࠬࡐ࡯࠷㑐ㅪ⡯⒳ߣߣ߽ߦ㧘ࠬࡐ࡯࠷ࠍߔࠆੱߩ┙႐ߦ┙ߞߚක≮⠪ߣߒߡ㧘⺑᣿ߢ߈ࠆක
≮ࠍዷ㐿ߔࠆ⋴⼔Ꮷࠍ㙃ᚑߔߴߊ㧘ߘߩၮ␆ߣߥࠆ⋴⼔ߩℂ⺰⊛ᬌ⸛ߩḰ஻ࠍᆎ߼ߚ‫ߩߎޕ‬ᣇ㕙ߩ೨଀ߪߥߊ㧘߿ߪࠅ૕⢒ቇ㧘ㆇേ↢ℂቇ㧘ᩕ㙃ቇ㧘ᔃℂቇ㧘කቇߩቇ㓙⊛ขࠅ⚵ߺ߇ᔅⷐߣ⠨߃ߡ޿ࠆ‫ޕ‬Ԛ ࿾ၞ⋴⼔ቇಽ㊁࿾ၞ⋴⼔ቇಽ㊁ߪ㧘౏ⴐⴡ↢⋴⼔ቇ㧘↥ᬺ଻ஜ㧘࿷ቛ⋴⼔ቇ㧘♖␹⋴⼔ቇ㧘ᘟᕈᦼ⋴⼔ቇ㧘⠧ᐕ⋴⼔ቇߥߤࠍ฽ߺ㧘ᐢ▸࿐ߥኾ㐷ಽ㊁ߢ᭴ᚑߐࠇߡ޿ࠆ‫ޕ‬
ᐔᚑ 18 ᐕᐲ߆ࠄᐔᚑ 20 ᐕᐲ߹ߢߩᔕ൐⠪ᢙߪ 20 ੱߢ޽ࠅ㧘ߘߩ߁ߜ␠ળੱߪ 16 ੱߣ㧘ᔕ൐⠪ߩ 80% ࠍභ߼ߡ޿ߚ‫ޕ‬หᦼ㑆ߩ౉ቇ⠪ᢙߪ 12 ੱ㧘ߘߩ߁ߜ␠ળੱߪ 11 ੱߣ 91.7% ࠍභ߼㧘ᱴߤߩᄢቇ㒮↢߇␠ળੱߢ޽ߞߚ‫ߩࠄࠇߎޕ‬ᄢቇ㒮↢ߪ㧘଻ஜᚲ࡮Ꮢ↸᧛㧘⸰໧⋴⼔ࠬ࠹࡯࡚ࠪࡦ㧘࿾ၞ൮᜝ᡰេ࠮ࡦ࠲࡯㧘∛㒮㧘੐ᬺᚲߥߤߩ଻ஜᏧ߿⋴⼔Ꮷߢ޽ࠅ㧘㕖Ᏹߦᄙᓀߥ⢛᥊ࠍᜬߞߡ޿ߚ‫ ߪ↢ੌୃޕ‬19 ᐕᐲߦ 4 ੱ޽ࠅ㧘ฦ⥄ߩ⡯႐ߢᵴべߒߡ޿ࠆ‫ޕ‬ᄢቇ㒮↢ߪኾ㐷⹹߳ߩ⺰ᢥឝタ߿ቇળ⊒⴫ߥߤ߽ⴕߞߡ߈ߡ޿ࠆ‫ޕ‬࿾ၞ⋴⼔ቇಽ㊁ߩ⎇ⓥ࠹࡯ࡑߩ߭ߣߟߢ޽ࠆሶߤ߽ߩ⯦ᓙ㒐ᱛߦ߻ߌߚ଻ஜᏧᵴേߦ㑐ߒߡ㧘వㅴ⊛ขࠅ⚵ߺߢታ❣ࠍ޽ߍߡ޿ࠆࠕࡔ࡝ࠞࠝ࡟ࠧࡦᎺ߆ࠄ଻ஜᏧߩขࠅ⚵ߺࠍ⚫੺ߔࠆ⻠Ṷળߣീᒝળࠍ㐿௅ߒߚ‫ ߪࠇߎޕ‬, ᄢቇ㒮↢ࠍਥߥኻ⽎ߦߒߚ߽ߩߢ㧘⎇ⓥ࠹࡯ࡑߦහߒߚ߽ߩߣߥߞߡ
޿ࠆ‫ޕ‬ߐࠄߦ㧘2008 ᐕᐲ߆ࠄߪ㧘⸰໧⋴⼔ࠬ࠹࡯࡚ࠪࡦߩలታߦะߌߚࡕ࠺࡞⊛ขࠅ⚵ߺߣߒߡ㧘ጘ㒂⋵ౝߩ⸰໧⋴⼔ࠬ࠹࡯࡚ࠪࡦࠍࡈࠖ࡯࡞࠼ߦߒߡᄢቇ㒮↢߽฽߼ߚ⎇ⓥᵴേࠍዷ㐿ߒߡ޿ࠆ‫߹ޕ‬ߚ㧘♖␹⋴⼔ቇߦߟ޿ߡߪ㧘♖␹ක≮⥄૕߇⥃ᐥ߆ࠄ࿾ၞ߳ࠪࡈ࠻ߒߡ߈ߡ޿ࠆ߇㧘⋴⼔Ꮷ߿଻ஜᏧߩ♖␹଻ஜᵴേ߇චಽߦᯏ⢻ߒߡ޿ߥ޿⃻⁁߇޽ࠅ㧘ᄙᓀߥ⎇ⓥᵴേ߇ᔅⷐߢ޽ࠆ㧚ߎࠇߦߟ޿
ߡߪ㧘ጘ㒂⋵ౝߩ♖␹଻ஜᵴേᬌ⸛ળߦᄢቇ㒮ቇ↢߽ෳടߒ㧘ታ〣⊛ߦ⎇ⓥߦขࠅ⚵߻ߎߣ߇ߢ߈
ߡ޿ࠆ㧚ᄢቇ㒮ቇ↢߇࿾ၞ⋴⼔ቇಽ㊁ߦᏗᦸߔࠆ⎇ⓥ࡮ᢎ⢒߳ߩⷐᦸ߽ᄙ᭽ߢ޽ࠆ‫ޕ‬੹ᓟ㧘ߐࠄߦ㧘౏ⴐⴡ↢⋴⼔ቇ㧘࿷ቛ⋴⼔߿⛮⛯⋴⼔㧘∛㒮߿ᣉ⸳ߥߤߩ⥃ᐥ⋴⼔ߥߤ㧘ߘࠇߙࠇߩኾ㐷ᕈࠍ↢߆ߒߚ⎇ⓥ࡮ᢎ⢒ࠍㅊⓥߒ㧘ᄢቇ㒮ᢎ⢒ࠍᦝߦలታߐߖࠆߎߣ߇⺖㗴ߢ޽ࠆ‫ޕ‬㧙㧙[ߘߩઁ㑐ㅪᣉ⸳╬⎇ⓥᵴേ]㧔1㧕㒝ዻ∛㒮ャⴊㇱ
1㧚⎇ⓥߩ᭎ⷐ
ャⴊ≮ᴺߪ⃻ઍක≮ߦਇนᰳߥᴦ≮ᚻᲑߢ޽ࠆ߇, ߘߩታᘒߪᦨ߽᥉෸ߒߚ‫ޟ‬⒖ᬀක≮‫ੱઁޕࠆ޽ߢޠ‬ߩ⤳ེ㧔ㅧⴊ࡮఺∉♽࡮ᐙ⚦⢩㧕ࠍᦨዋ㒢ߩᬌᩏߢ⒖౉ߔࠆߩߢ㧘⥌ᱫ⊛ߥ೽૞↪࡮ว૬∝߿㔍ᴦᕈ㧔⥌ᱫᕈ㧕ᣂ⥝࡮ౣ⥝ᗵᨴ∝ߩવ៝ߥߤ㧘ߥ߅੹ᓟ߽ᒁ߈⛯޿ߡస᦯ߔࠆߴ߈ᣂߚߥ⺖㗴ߪ಴⃻ߔࠆߣ੍ᗐߐ
ࠇࠆ‫ޕ‬ᣢ⍮ߩ࠙ࠗ࡞ࠬᗵᨴ∝ߩ࠙ࠗࡦ࠼࠙ᦼ₂ⴊ㧘ࠬࠢ࡝࡯࠾ࡦࠣᴺ߇ᧂ㐿⊒㧘޽ࠆ޿ߪ໧⸻ߩήലᕈߩ
᡿ߦ㧘ઁᣇߢߪ㧘ᦨዊ㊂ߩャⴊ≮ᴺ޽ࠆ޿ߪ቟ోߥઍᦧ≮ᴺࠍᮨ⚝ߖߑࠆࠍ߃ߥ޿‫⥄ޕ‬Ꮖⴊャⴊ≮ᴺ߿ࠨ
ࠗ࠻ࠞࠗࡦߩ೑↪㧘ੱᎿⴊᶧߥߤߩ㐿⊒ߢ޽ࠆ‫ޕ‬ᒰ㒮ߢߪ⥄Ꮖⴊャⴊ≮ᴺࠍャⴊㇱਥዉߢ᜛ᄢߒߚ⚿ᨐ㧘ᚻⴚᖚ⠪ߩ߁ߜฃⴊ⠪ߩ߅ࠃߘ 90% ߪ⥄Ꮖⴊ⾂ⴊߒ㧘⾂ⴊߒߚᖚ⠪ߩ 90% એ਄߇ห⒳ⴊࠍ࿁ㆱߢ߈㧘቟ోߥャⴊ≮ᴺߩ৻ߟߣߒߡ⏕┙ߒ㧘20 ᐕߦᷰߞߡᜰዉߒߚ⚿ᨐ㧘ャⴊ≮ᴺߩ৻↹ߣߒߡઍᦧਇ⢻ߦ߹ߢቯ⌕ߒߚ‫ߩߎޕ‬੐ߪㆡᱜߥ㧘ᦨዊ㒢ߩャⴊ≮ᴺࠍផㅴߔࠆ਄ߢၮ␆ߣߥߞߚ‫ޕ‬ᒰャⴊㇱߢߪ․ߦ⥌ᱫ⊛ャⴊ೽૞↪ߢ޽ࠆャⴊᓟ⒖ᬀ ኻኋਥ∛ߩ⊒∝ࡔࠞ࠾࠭ࡓߦߟ޿ߡ⎇ⓥࠍⴕߞߡ߈ߚ⚿ᨐ㧘⃻࿷߽ߥ߅ߎߩ⥌ᱫ⊛ߥว૬∝ߦኻߔࠆ᦭ലߥᴦ≮ᴺߪ⏕┙ߢ߈ߕ㧘ⴊᶧᾖ኿ߣ޿߁੍㒐એᄖߦኻಣᣇᴺߪߥߊ㧘ోߡߩฃⴊ⠪㧘✚ߡߩ⚦⢩⵾೷ߦᾖ኿ߒߡ੍㒐ߒߡ
޿ࠆ‫ޕ‬
2㧚ฬ★
⻠Ꮷ㧦

ᄢႦ▵ሶ

Setsuko Otsuka

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ⦁ᚭ㆏ᓼ㧘ᄢႦ▵ሶ㧘ℙየᵏౖ. ╙ 5 ┨ S. ャⴊߩታ㓙㧦MFICU ㅪ⛊ද⼏ળ✬ [MFICU ࡑ࠾ࡘࠕ࡞]
ᄢ㒋㧦ࡔ࠺ࠗࠞ಴ 㧧2008 ᐕ㧦368㧙374㧚
⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
ߥߒ✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 㜞ᯅ㜞༑㧘Ⓑ⪲㗉৻㧘ඨ↰⺈㧘ဈᧄਭᶈ㧘Ყ⇐㑆ẖ㧘ᴡේ๺ᄦ㧘᧻ፒ㆏↵㧘┄↰⦟ᰴ㧘⒟ේ᩵ሶ㧘੹ਛ㓶৻㧘ᄢႦ▵ሶ㧘♿㊁ୃ৻㧘㜞᧻⚐᮸㧘૒Ꮉ౏⍶㧚2004 ᐕᐲャⴊ㑐ㅪ✚᜝ࠕࡦࠤ࡯࠻⺞ᩏႎ๔̆ャⴊ▤ℂ૕೙㧘ャⴊ≮ᴺᆔຬળ߅ࠃ߮ⴊᶧߩㆡᱜ૶↪ផㅴߦ㑐ߔࠆ⺞ᩏ̆ ᣣᧄャⴊቇળ⹹ 2006 ᐕ㧧52 Ꮞ㧦414
㧙421㧚
2㧕 㜞ᯅ㜞༑㧘Ⓑ⪲㗉৻㧘ඨ↰⺈㧘ဈᧄਭᶈ㧘Ყ⇐㑆ẖ㧘ᴡේ๺ᄦ㧘᧻ፒ㆏↵㧘┄↰⦟ᰴ㧘⒟ේ᩵ሶ㧘੹ਛ㓶৻㧘ᄢႦ▵ሶ㧘♿㊁ୃ৻㧘㜞᧻⚐᮸㧘૒Ꮉ౏⍶㧚2005 ᐕᐲャⴊ㑐ㅪ✚᜝ࠕࡦࠤ࡯࠻⺞ᩏႎ๔̆ャⴊ▤ℂ૕೙㧘ャⴊ≮ᴺᆔຬળ߅ࠃ߮ⴊᶧߩㆡᱜ૶↪ផㅴߦ㑐ߔࠆ⺞ᩏ̆ ᣣᧄャⴊ࡮⚦⢩ᴦ≮ቇળ⹹ 2007 ᐕ㧧53
Ꮞ㧦365㧙373㧚
ේ⪺㧔᰷ᢥ㧕
1㧕 Arai M, Misao Y, Nagai H, Kawasaki M, Nagashima K, Suzuki K, Tsuchiya K, Otsuka S, Uno Y,
Takemura G, Nishigaki K, Minatoguchi S, Fujiwara H. Granulocyte colony-stimulating factor –anoninvasive regeneration therapy for treating atherosclerotic peripheral artery disease. Cir J
2006;70:1093-1098.
IF 2.373

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦㜞ᯅቁ༑㧘⎇ⓥಽᜂ⠪㧦ᄢႦ▵ሶ㧧ෘ↢ഭ௛⑼ቇ⎇ⓥ⎇ⓥ⾌⵬ഥ㊄ ක⮎ຠ࡮ක≮ᯏེ╬࡟ࠡࡘ࡜࠻࡝࡯ࠨࠗࠛࡦࠬ✚ว⎇ⓥ੐ᬺ‫ⴊޟ‬ᶧᣂᴺߦ઻߁ャⴊ▤ℂ૕೙ߣ቟ో▤ℂ࡮ㆡᱜ૶↪
ࡑࡀࠫࡔࡦ࠻ࠪࠬ࠹ࡓߩ᭴▽‫ޠ‬㧧ᐔᚑ 17㧙18 ᐕᐲ㧧900 ජ౞(500㧦400 ජ౞)㧙㧙2㧕ฃ⸤⎇ⓥ
ߥߒ
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬᄢႦ▵ሶ㧦
1㧕 ᣣᧄャⴊ࡮⚦⢩ᴦ≮ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄャⴊ࡮⚦⢩ᴦ≮ቇળ୶ℂᆔຬળ(㨪⃻࿷)3㧕 ᣣᧄャⴊ࡮⚦⢩ᴦ≮ቇળㆡᱜᆔຬળ I&A ዊᆔຬળ(㨪⃻࿷)4㧕 ᣣᧄャⴊ࡮⚦⢩ᴦ≮ቇળャⴊ≮ᴺᆔຬળ I&A ዊᆔຬળ(㨪⃻࿷)5㧕 ャⴊ࡮⚦⢩ᴦ≮ቇળෂᯏ▤ℂ࡮ᄢ㊂಴ⴊ࡮↥⑼಴ⴊᆔຬળ(↥⑼ෂᯏ⊛಴ⴊ߳ߩኻᔕࠟࠗ࠼࡜ࠗࡦ૞
ᚑߩߚ߼ߩ 5 ቇળวหᆔຬળ(ᐔᚑ 19 ᐕᐲ㨪⃻࿷)6㧕 ャⴊ࡮⚦⢩ᴦ≮ቇળ᧲ᶏᡰㇱળᐙ੐(㨪⃻࿷)7㧕 ャⴊ࡮⚦⢩ᴦ≮ቇળ᧲ᶏᡰㇱળ I&A ᆔຬળ(㨪⃻࿷)8㧕 ᣣᧄࠕࡈࠚ࡟࡯ࠪࠬቇળਛㇱ࿾ᣇળ਎⹤ੱ(㨪⃻࿷)9㧕 ᣣᧄⴊᶧઍᦧ‛ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ᄢႦ▵ሶ㧦
1㧕 ╙ 21 ࿁ Transfusion Medicine Conference(ᐔᚑ 18 ᐕ 1 ᦬㧘␹ᄹᎹ㧘ࠪࡦࡐࠫ࠙ࡓ㧦The
Haemovigilance, Section 2. 4) Haemovigilance in Europe㧘5) ☨࿖ߦ߅ߌࠆ⃻⁁㧘6) Serious
Hazard of Transfusion(SHOT㧘⧷࿖)㧘7) 㖧࿖ߦ߅ߌࠆ⃻⁁ ᐳ㐳)2㧕 ╙ 48 ࿁ᣣᧄャⴊ࡮⚦⢩ᴦ≮ቇળ᧲ᶏ࿾ᣇળ(ᐔᚑ 18 ᐕ 10 ᦬㧘ฬฎደ㧘⻠Ṷળ‫ޟ‬ャⴊࠍߣࠅ߹ߊᦨ
ㄭߩ⁁ᴫ‫⻠ޠ‬Ṷ 1.‫ޟ‬ャⴊ▤ℂᢱߦߟ޿ߡ‫⻠ޠ‬Ṷ 2.‫ޟ‬ャⴊ↪ⴊᶧ࡮ಽ↹⵾೷ߩ৻ర▤ℂߦߟ޿ߡ‫⻠ޠ‬Ṷ 3.‫ޟ‬CD36 ᛫૕㓁ᕈ࠼࠽࡯PC ャⴊߦࠃࠆャⴊ㑐ㅪᕆᕈ⢖㓚ኂ(TRALI)ߩ৻∝଀‫ޠ‬ᐳ㐳)
3㧕 ╙ 50 ࿁ᣣᧄャⴊ࡮⚦⢩ᴦ≮ቇળ᧲ᶏᡰㇱળቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓ‫․ޟ‬ᱶ⁁ᴫਅߩⴊᶧ⵾೷ߩ૶↪‫ޠ‬1.‫ޟ‬ᢇᕆක≮‫ޠ‬2.‫ޟ‬㓸ਛᴦ≮ㇱ‫ޠ‬3.‫ⴊޟ‬ᶧ∔ᖚ‫ޠ‬4.‫ޟ‬ಽᇂᤨ‫ ޠ‬ᐳ㐳)૒⮮ᒏ჻ᦶ㧦
1㧕 ╙ 46 ࿁ਛㇱකቇᬌᩏቇળ(ᐔᚑ 19 ᐕ 9 ᦬㧘ᄢ၂㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ャⴊ▤ℂᢱขᓧߦะߌߡߩࠪࠬ࠹
ࡓ᭴▽‫ޠ‬1㨪6 ᐳ㐳)2㧕 ╙ 50 ࿁ᣣᧄャⴊ࡮⚦⢩ᴦ≮ቇળ᧲ᶏᡰㇱળቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ጘ㒂㧘ᢎ⢒࠮࠶࡚ࠪࡦ‫ޟ‬㔚ሶࠞ࡞࠹ߣャⴊ▤ℂ૕೙ߦߟ޿ߡ‫ޠ‬Ṷ⠪)Ꮭ૒శᵗ㧦
1㧕 ╙ 47 ࿁ਛㇱකቇᬌᩏቇળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ንጊ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ャⴊ▤ℂㇱ㐷߆ࠄ⥃ᐥ߳ߩࠕࡊ
ࡠ࡯࠴‫ޠ‬1. ✕ᕆャⴊᤨ(ෂᯏ⊛಴ⴊᤨ)ߩኻᔕߦߟ޿ߡ㧘Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ
ߥߒ

㧙㧙

9㧚␠ળᵴേᄢႦ▵ሶ㧦
1㧕 㛽㜑⒖ᬀផㅴ⽷࿅ߩ⺞ᢛකᏧ(㨪⃻࿷)2㧕 ጘ㒂⋵ャⴊᙣ⹤ળ(≮ᴺᆔຬળวหᆔຬળ)ᆔຬ(㨪⃻࿷)3㧕 ጘ㒂⥃ᐥャⴊ⎇ⓥળ੐ോዪ㧒਎⹤ੱ(㨪⃻࿷)4㧕 ⹺ቯャⴊᬌᩏᛛᏧ೙ᐲᜰቯᣉ⸳(㨪⃻࿷)5㧕 ャⴊකቇ⹺ቯක೙ᐲ⹺ቯᣉ⸳(㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ᄢႦ▵ሶ㧦ᐔᚑ 18 ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄ಽᜂႎ๔ᦠ
11㧚ႎ㆏ߥߒ12㧚⥄Ꮖ⹏ଔ
⹏ଔ⻠Ꮷ 1 ฬߩቯຬߦߡ㧘ャⴊᴦ≮ߩ቟ో㧘ㆡᱜ㧘᦭ലᕈߩᜂ଻ߩߚ߼ߦ⸻≮࡮ᢎ⢒࡮⎇ⓥࠍᜂߞߡ߈ߚ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ኻᔕ╷ャⴊᴦ≮ߩ቟ో㧘ㆡᱜ㧘᦭ലᕈߩᜂ଻ߩߚ߼ߦߪ㧘߹ߕᢎ⢒߇ᦨ㊀ⷐߢ޽ࠆ‫⻠ߪߢ⁁⃻ޕ‬Ꮷ 1 ฬߩቯຬߦߡ㧘ㅢᐕ㧘ㅳ 5 ᣣߩᄖ᧪⸻≮ࠍᜂ޿ߥ߇ࠄ㧘ਛᄩ⸻≮ㇱ㐷ߩ▤ℂߩߺߥࠄߕ㧘ත೨࡮තᓟᢎ⢒ࠍᜂᒰߒߡ޿ࠆ‫ߩߎޕ‬ಽ㊁ߦ߅ߌࠆ⥃ᐥකߩ⍮⼂ߩᰳᅤߣ㧘ャⴊකቇಽ㊁ߦ߅ߌࠆੱ᧚㧔⎇ⓥ⠪㧕ߩዋߥߐߪ⴫ⵣ৻૕ߢ޽ࠆ‫ޕ‬⥌ᱫ⊛ߥ෻ᔕࠍ฽߻ャⴊߦࠃࠆහᤨဳ෻ᔕߩ 90%એ਄߇ᧄ㇌╙৻ߩኾ㐷⎇ⓥᯏ㑐ߩ⹦⚦ߥᬌ⸛ߦ߽߆
߆ࠊࠄߕ㧘੹ᣣߢ߽ේ࿃ਇ᣿ߩ߹߹ߢ޽ࠆ‫ߚ߹ޕ‬㧘ャⴊߦࠃࠆㆃᑧဳ೽૞↪࡮ว૬∝ߩㅊ〔㧘ⵍャⴊᖚ⠪ߩㆡಾߥࠆࡈࠜࡠ࠙ࠕ࠶ࡊߪャⴊක≮ߦ߅޿ߡ଀ᄖ⊛ߦߒ߆ὑߐࠇߡ޿ߥ޿ߩ߇⃻⁁ߢ޽ࠆ‫ޕ‬ᱧผ⊛ߦߪャⴊࠍේ࿃ߣߔࠆ㊀◊߆ߟ⥌ᱫ⊛ߥ೽૞↪ࠍઁߩᣢ⍮∔ᖚߣ⺋⸻ߒ⷗ㅏߒߡ߈ߚน⢻ᕈ߇޽ࠆ‫ߒޕ‬߆ߒ㧘৻ᣇߢ㧘ࡅ࠻ߢߪ⒖ᬀࠍᏀฝߔࠆࡅ࠻⚵❱ㆡว᛫ේ㧔HLA㧕߇ャⴊߩ೽૞↪ߩේ࿃᛫ේߣߒߡ⊒⷗ߐࠇߚ⚻✲߇޽ࠆߎߣ߆ࠄ್ࠆࠃ߁ߦ㧘᦭ኂߥ೽૞↪ࠍ⋴ㆊߖߕ㧘⎇ⓥኻ⽎ߣߔࠆߎߣ߇ଐὼߣߒߡ
㊀ⷐߣ⠨߃ࠄࠇࠆ‫ޕ‬ᓥߞߡ㧘ャⴊක≮ߩㆡᱜ࡮᦭ല࡮቟ోᕈߩㅊ᳞ߦߪャⴊකቇᢎ⢒࡮⸻≮࡮⎇ⓥߩల
ታ߇ਇนᰳߢ޽ࠆ‫ޕ‬
2002 ᐕ 7 ᦬ߦᚑ┙ߒߚㅢ⒓‫ⴊޟ‬ᶧᣂᴺ‫ߡߞࠃߦޠ‬ャⴊߦࠃࠆ೽૞↪ႎ๔߇⟵ോൻߒߚ‫ޕ‬㧔⥌ᱫ⊛㧕㕖
ṁⴊᕈャⴊ೽૞↪ߩ߁ߜ㧘ዋᢙߥ߇ࠄ৻ㇱߢߪ㧘TRALI㧔transfusion related acute lung injury㧕߿㘃ૃ෻ᔕߦ߅޿ߡ㧘᛫ HLA ᛫૕߿᛫㗰☸⃿᛫૕߇ේ࿃ߣߒߡᬌ಴ߐࠇࠆࠃ߁ߦߥߞߡ߈ߚ߇㧘ଐὼߣߒߡ
ߘߩ⹦⚦ߪᧂ⸃᣿ߢ޽ࠆ߇㧘⒳‫ߩ⷗⊒ᧂߩޘ‬᛫૕߇㑐ਈߒߡ޿ࠆ੐߇ផ᷹ߐࠇߡ޿ࠆ‫ޕ‬21 ਎♿ߦ౉ߞߡ߽ዏ㧘᰷☨ߩャⴊኾ㐷⹹ߪ⸒ࠊߕ߽߇ߥ㧘New Engl J Med㧘JAMA ╬ߩ৻ᵹ⥃ᐥකቇ㔀⹹ߦ⥌ᱫ⊛ャⴊ೽૞↪ߩ 1 ଀ႎ๔߇ឝタߐࠇࠆ⃻⁁߇⛯޿ߡ޿ࠆ‫ޕ‬ጘ㒂⋵⿒චሼⴊᶧ࠮ࡦ࠲࡯ߩᬌᩏㇱ㐷ߣ⵾೷ㇱ㐷߇ᗲ⍮⋵ἑᚭᏒߦ⛔วߐࠇߡਭߒ޿‫ޕ‬ฎౖ⊛ャⴊ೽૞↪ߢ޽ࠆṁⴊ෻ᔕࠍᦨㄭ㧘┙⛯ߌߦ⚻㛎ߒߚ㧧ABO ဳ߿ Rho㧔D㧕ဳએᄖߩ᛫ේ᛫૕෻ᔕߦࠃࠆහᤨ
ဳ෸߮ㆃᑧဳṁⴊ෻ᔕߪ㧘౒ߦャⴊ೨ߩਇⷙೣ᛫૕㓁ᕈ⚿ᨐࠍᓧߥ߇ࠄ᛫૕ߩ․⇣ᕈ㧔ߣ⥃ᐥ⊛㊀ⷐᕈ㧕ࠍหቯߢ߈ߕ㧘ਇㆡวャⴊࠍ㒐߉ᓧߕ㧘ᓟ⠪ߢߪ⥌ᱫ⊛ォᏫࠍขߞߚ‫⚻ޕ‬ᷣ⊛ℂ↱ߦࠃࠆᬺോߩ⛔วߦࠃߞߡⴊᶧ࠮ࡦ࠲࡯ߩ Reference Laboratory ᯏ⢻ߪ⪺ߒߊ⴮ㅌߒ㧘ᬌᩏ⚿ᨐߪᬌ૕ឭ಴ᓟ㧘2 ㅳ㑆ᓟ㧔ᖚ⠪ᱫ੢ᓟ 2 ㅳ㑆ᓟ㧕ߦ౉ᚻߐࠇ㧘ታലᕈࠍᰳ޿ߡ޿ࠆ‫ޕ‬Ꮢ⽼ߐࠇߡ޿ࠆ⚦⢩⹜⮎ߪਥߦ USA ⵾㧔⊕ੱ↪㧕ߢ޽ࠅ㧘ㆮવ⊛ߥ⢛᥊ߩ⇣ߥࠆᣣᧄੱ↪ߩ⚦⢩⹜⮎ࠍᏱᤨᔅⷐߣߒߡ޿ࠆߦ߽߆߆ࠊࠄߕ㧘ᴺ⊛ࡃ࡝ࠕ࡯ߩߚ߼౉ᚻਇ⢻߇ᢙචᐕ⛯޿ߡ޿ࠆ⃻⁁߇޽ࠅ㧘߹ߚャⴊㇱࠍᢛ஻ߒߡ⥄ࠄ Reference Laboratory ߣߒߡలታߒߥ޿㒢ࠅ㧘቟ోߥャⴊ≮ᴺࠍឭଏ಴᧪ߥ޿੐߇್ߞߚ‫ޕ‬੹ᓟߩዷᦸㄭᐕ㧘≸ᖚ⠪ߩౣ⊒ߦኻߒߡ DLT㧔donor lymphocyte transfusion㧕ߥߤߩ⚦⢩ᴦ≮߇᦭ലߥᚻᲑߣ
ߥߞߡ߈ߚ‫ޕ‬ャⴊක≮ߩ቟ోᕈߦኻߔࠆ࿖᳃ߩᒝ޿ ᔨߣ㑐ᔃߩ㜞߹ࠅߦട߃㧘੹ᓟߪ DNA ࡟ࡌ࡞ߢHLA㧔human leukocyte antigens㧕ࠍ৻⥌ߐߖߚ࠼࠽࡯ߩ࡝ࡦࡄ⃿ャᵈߦࠃࠆ࿕ᒻ≸ᴦ≮ߥߤ㧘ᦝߥࠆᴦ≮ᴺߩ㐿⊒㧘⎇ⓥߩᔅⷐᕈߪ㜞޿‫ޕ‬ᒰ㒮ߪ㕖ⴊ✼㑆㛽㜑ណข࡮⒖ᬀ∛㒮ߩ⹺ቯࠍฃߌߚ⚿ᨐ㧘ห⒳ㅧⴊᐙ⚦⢩⒖ᬀ߿⥄Ꮖ㛽㜑ᐙ⚦⢩ࠍ⒖㧙㧙ᬀߔࠆⴊ▤ᣂ↢ᴦ≮╬ߩ⚦⢩ᴦ≮߇੹ᓟჇടߔࠆߎߣ߇⷗ㄟ߹ࠇࠆ‫ޕ‬ᦝߦߪ㧘ౣ↢ක⑼ቇኾ᡹࡮⚵❱ེቭᒻᚑಽ㊁߅ࠃ߮ญ⣧ᄖ⑼ߦ⧯ᐕ⠪ߩ⍮ᱤᱤ㜑ࠃࠅ᛽಴ߐࠇߚ㑆⪲♽ᐙ⚦⢩ 200 ઙ߇଻ሽߐࠇ㧘዁᧪ߩ⥃ᐥᔕ↪㧔iPS ⚦⢩ࡃࡦࠢ㧕ࠍ⋡ᜰߒߡ㧘ャⴊㇱߦߪࡃࡦࠢᬺോ߳
ߩ㑐ਈࠍⷐ⺧ߐࠇߡ޿ࠆ‫ޕ‬ታ⃻ߦߪ㧘዁᧪⊛ߦߪ⚦⢩ࡊࡠ࠮࠶ࠪࡦࠣ࠮ࡦ࠲࡯ㆇ༡ߩࠟࠗ࠼࡜ࠗࡦ㧔૞ᚑਛ㧕ߦᓥ޿㧘⚦⢩≮ᴺ჻㧔઒⒓㧕⋧ᒰߩੱ᧚߇ᔅⷐߢ޽ࠅ㧘߆ߟ ଻ሽߦߐ޿ߒߡ㧘ᗵᨴ∝ߩ࠴ࠚ࠶ࠢߩߺߥࠄߕ㧘ⴊᶧဳߩ৻ߟߢ޽ࠆ⚵❱ㆡวᕈᬌᩏ߇ਇนᰳߢ޽ࠆߚ߼㧘ャⴊㇱߦ߅ߌࠆੱ᧚ߩ⏕଻㧘ᬌᩏㆀⴕ⢻ജߩะ਄߇ᔅ㗇ߣߥࠆߣᕁࠊࠇࠆ‫ޕ‬㧙㧙㧔2㧕㒝ዻ∛㒮∛ℂㇱ
1㧚⎇ⓥߩ᭎ⷐ
1㧕ࡕ࠺࡞േ‛ࠍ↪޿ߚ࿕ᒻ≸ߩ⊒↢ࡔࠞ࠾࠭ࡓ⸃ᨆ
ታ㛎⊛ൻቇ⊒≸ࡕ࠺࡞㧔ᄢ⣺࡮⢗ߥߤ㧕ࠍ↪޿ߡ㧘․ߦ⢈ḩ࡮♧ዩ∛࡮㜞⢽ⴊ∝㑐ㅪ࿃ሶߦᵈ⋡ߒߚ⊒߇ࠎࡔࠞ࠾࠭ࡓ⸃ᨆࠍⴕߞߚ‫ޕ‬
2㧕㜞ᐲవㅴක≮ⅣႺߦ߅ߌࠆ∛ℂ⸻ᢿ⥃ᐥฦ⑼ߩ㜞ᐲవㅴක≮㧔࠮ࡦ࠴ࡀ࡞࡝ࡦࡄ▵ߩⴚਛㄦㅦ࡮೨┙⣼≸ዊ✢Ḯ≮ᴺ࡮⒖ᬀක≮࡮FNA ᬌ૕ߥߤ㧕ߦኻᔕߒߡ㧘∛ℂ⸻ᢿᛛⴚߩะ਄෸߮⥃ᐥ⊛࠾࡯࠭ࠍḩߚߔႎ๔᭽ᑼߩᡷༀࠍⴕߞߚ‫ޕ‬
3㧕∛ᄌߩ morphology-based ߥಽሶ∛ℂ⸻ᢿ
Immunohistochemistory࡮in situ hybridization࡮laser capture microdisection ߥߤࠍ㚟૶ߒߚ≸ߩ✚ว⊛ಽሶ∛ᘒ⸻ᢿࠍ⋡ᜰߒ㧘ᚻᆎ߼ߦ੃≸ߦ߅ߌࠆࡎ࡞ࡕࡦฃኈ૕఺∉⚵❱ൻቇ࡮HER2 ఺∉⚵❱ൻቇ࡮HER2 ㆮવሶ ISH ࠍ㒮ౝߢᣉⴕ㐿ᆎߒߚ‫ޕ‬2㧚ฬ★
ᢎ᝼(૬છ)㧦㜞⷗ ೰ᑝἑ ༀା
ಎᢎ᝼㧦⥃ᐥ⻠Ꮷ(૬છ)㧦 ᵻ㊁ ᄹ⟤

Tsuyoshi Takami
Yoshinobu Hirose
Asano Nami

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
ߥߒ⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 ᑝἑༀା㧚⤟⣲≌ߩᄖ⑼∛ℂ ᦨㄭߩ⹤㗴㧚⥃ᐥ↹௝ 2006 ᐕ㧧22 Ꮞ㧦1306㧙1313.
2㧕 ᓟ⮮⵨ᄦ㧘᧖ፒ࿻ሶ㧘ᤊඳᤘ㧘ᑝἑༀା㧚ẩ≌≚∥㧫㧚ᣣᧄᶖൻེ߇ࠎᬌ⸻ቇળ㔀⹹ 2007 ᐕ㧧45 Ꮞ㧦
445㧙449.
3㧕 ㄭ⮮ᶈผ㧘౗᧻㓷ਯ㧘੖ፉ⡡㧘ᨷᬀ⵨੺㧘㐳↰⌀ੑ㧘ዊ᫪ల༹㧘ᑝἑༀା㧚Misdiagnosis ߦቇ߱ ⴚ೨⸻ᢿ ☼ᶧ↥↢⢙▤⚦⢩≸㧚ᶖൻེ↹௝ 2007 ᐕ㧧9 Ꮞ㧦91㧙94.
4㧕 ጊญ๺਽㧘ዊ᫪ల༹㧘᧻੗⡡㧘૒‫⟵ᧁޘ‬ਯ㧘↰ਛ⑲ౖ㧘ᓼጊᵏᴦ㧘ဈਅᢥᄦ㧘㜞ᯅቁᄦ㧘㐳የᚑᢅ㧘㐳↰⌀ੑ㧘቟㆐ᵗ␭㧘⨹ᧁኡม㧘ᑝἑༀା㧚⢗࡮චੑᜰ⣺ߩ⣲≌ᕈ∔ᖚ ⒘ߥ⚵❱ဳߩ⢗ߩ⣲≌㧘ᄖ⑼ᴦ≮ 2007
ᐕ㧧96 ᏎჇೀ㧦467㧙472.
✚⺑㧔᰷ᢥ㧕
1㧕 Kanematsu M, Kondo H, Goshima S, Kato H, Tsuge U, Hirose Y, Kim MJ, Moriyama N. Imaging liver
metastases: Review and update. Eur J Radiol. 2006;58:217-228.
2㧕 Kato H, Kanematsu M, Ando K, Mizuta K, Ito Y, Hirose Y, Hoshi H. Ossifying pleomorphic adenoma of
the parotid gland: a case report and review. Australas Radiol. 2007;51 Suppl:B173-B175.
3㧕 Mori H, Yamada Y, Hirose Y, Hara A. Precancerous conditions of the colon; multistage carcinogenesis
in animal models. Int J Cancer Prev. 2008;2:363-373.
ේ⪺㧔๺ᢥ㧕
1㧕 ጊፒஜ〝㧘⨹ᧁኡม㧘ᄢፉ㕏ᐢ㧘⊕ᧁ੫㧘⑔ፉ⑲᮸㧘቟↰৻ᦶ㧘᳗ᧁᱜੳ㧘ട⮮ೣᑝ㧘᫪⣁ਭ㓉㧘ᑝἑༀା㧚චੑᜰ⣺㒱ಳဳ⣼⣲ߩ 1 ଀㧚ᣣᧄᶖൻེౝⷞ㏜ቇળ㔀⹹ 2006 ᐕ㧧48 Ꮞ㧦1228㧙1232.
2㧕 ጤਅᜏม㧘቟↰৻ᦶ㧘ਛ੗ታ㧘ᄢፉ㕏ᐢ㧘⊕ᧁ੫㧘᫪⣁ਭ㓉㧘᧻የᶈ㧘㑐㊁⠨ผ㧘ጊ↰ථ਽㧘ᑝἑༀା㧚ਥ⤟▤⁜⓰ࠍ߈ߚߒߚ⤟ౝಽᴲ⣲≌ߩ 1 ଀㧚⢄⢙⤟ᴦ≮⎇ⓥળ⹹ 2006 ᐕ㧧4 Ꮞ㧦63㧙68㧚
3㧕 ㊁ਛਁ␭ሶ㧘ਤ⠀ᙗม㧘᳓㊁ᥓሶ㧘ᣣᳯ੗㚅ઍሶ㧘ᑝἑༀା㧘₹⥢ノᒾ㧚ሶች㗪ㇱ large-cell neuroendocrine
carcinoma ߩ 1 ଀㧚᧲ᶏ↥⑼ᇚੱ⑼ቇળ㔀⹹ 2006 ᐕ㧧43 Ꮞ㧦171㧙174.
4㧕 ↰ਛ㗔㧘ᄢ㊁⾆ᢅ㧘ᄢ㊁⟵ᐘ㧘ᷡ᳓సᤨ㧘⷏ᧄ⵨㧘ᑝἑༀା㧘᧻᳗⎇๋㧚ᧃ▵㛽㛽⣲≌ߩ 1 ଀㧚᧲ᶏ㛽エㇱ⣲≌ 2006 ᐕ㧧18 Ꮞ㧦43㧙44.
5㧕 ട⮮ඳၮ㧘ᤊඳᤘ㧘ጊ↰ධᤊ㧘㕍ᧁ⻞ᄥ㧘᳓↰໪੺㧘દ⮮౎ᰴ㧘᧻᳗⎇๋㧘ᑝἑༀା㧚৻஥⡊ਅ⣼ߦ⊒↢ߒߚᄙ⊒⡊ਅ⣼ౝ␹⚻㕽⣲ߩ 1 ଀㧚⥃ᐥ᡼኿✢ 2007 ᐕ㧧52 Ꮞ㧦312㧙317.
6㧕 ᧻ᧄ⌀੺㧘ጤ↰ዏ㧘⊕ᯅᐘᵗ㧘ᑝἑༀା㧘᳓㊁ศ㓷㧘᧻੗㓷ผ㧘┻᧛ඳᢥ㧚FDG-PET ߢ⇣ߥࠆᚲ⷗ࠍ␜
ߒߚ⢖⎬ൻᕈⴊ▤⣲ߩ 2 ଀㧚ᣣᧄ๭ๆེᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧21 Ꮞ㧦86㧙91.
7㧕 ᓼጊᵏᴦ㧘㐳↰⌀ੑ㧘૒‫⟵ᧁޘ‬ਯ㧘੹੗ኼ㧘᧻੗⡡㧘ዊ᫪ల༹㧘㜞੗శᴦ㧘ౝᧁ㓉ᢥ㧘੹੗ஜੑ㧘ㄭ⮮ᶈผ㧘੖ፉ⡡㧘౗᧻㓷ਯ㧘ᑝἑༀା㧚ⴚ೨ߦ⢄⚦⢩≸ߣߩ㐓೎߇໧㗴ߣߥߞߚ⢄⚦⢩⣼⣲ߩ 1 ଀㧚⢄⢙⤟ᴦ㧙㧙≮⎇ⓥળ⹹ 2007 ᐕ㧧5 Ꮞ㧦35㧙40.
8㧕 ૒⮮ᕺℂሶ㧘ਤ⠀ᙗม㧘ੑችᦸᵗ㧘᳓㊁ᥓሶ㧘ട⮮ผ㐷㧘ട⮮ඳၮ㧘ᑝἑༀା㧘੹੗◊ᔒ㧚ⴚ೨⸻ᢿน⢻ߢ޽ߞߚሶች⡺⣲ߩ 2 ଀㧚᧲ᶏ↥⑼ᇚੱ⑼ቇળ㔀⹹ 2007 ᐕ㧧44 Ꮞ㧦111㧙116.
9㧕 㜞ᯅቁᄦ㧘ᓼጊᵏᴦ㧘ဈਅᢥᄦ㧘㐳የᚑᢅ㧘ጊญ๺਽㧘㐳↰⌀ੑ㧘⨹ᧁኡม㧘᧖ጊ଻ᐘ㧘ን↰ᒄਯ㧘ᑝἑༀା㧚ਅㇱ⋥⣺ᚳᐔ਄⊹≸߇਄ㇱ⋥⣺ߦหᤨᕈოౝォ⒖ࠍ߈ߚߒߚ 1 ಾ㒰଀㧚ᣣᧄᄢ⣺⢂㐷∛ቇળ㔀⹹
2008 ᐕ㧧61 Ꮞ㧦33㧙38.
10㧕 㝩㗡ാテ㧘ᵄᄙ㊁⵨৻㇢㧘᧻᳗⎇๋㧘ᑝἑༀା㧘ᢪየᓕ⋥㧘᧻ᧄ⌀੺㧘⊕ᯅᐘᵗ㧘ጤ↰ዏ㧘㜞⷗೰㧚
Micronodular thymoma with lymphoid stroma ߩ 1 ଀㧚⸻ᢿ∛ℂ 2008 ᐕ㧧25 Ꮞ㧦267㧙271㧚
11㧕 ⩵ᳰ⟤ᄹ㧘੉੗ା๋㧘቞ጊᵗม㧘࿯ደ᦮ᄢ㧘ਃベᅢ↢㧘ᮮ੗❥᣿㧘ખ㊁ᱜඳ㧘ᳯේ⧷ବ㧘಴ญ㓉㧘ᑝἑༀା㧚FOLFOX4(ࠝࠠࠨ࡝ࡊ࡜࠴ࡦ㧘ࡠࠗࠦࡏ࡝ࡦ㧘5-FU)ࠍⴚ೨᛫≸ൻቇ≮ᴺߦ↪޿ߚዩ⤑▤≸ߩ 1 ଀㧚ᴲዩེ⑼♿ⷐ 2008 ᐕ㧧54 Ꮞ㧦557㧙559.
ේ⪺㧔᰷ᢥ㧕
1㧕 Hata K, Tanaka T, Kohno H, Suzuki R, Qiang SH, Kuno T, Hirose Y, Hara A, Mori H. Lack ofenhancing effects of degraded lambda-carrageenan on the development of beta-catenin-accumulated
crypts in male DBA/2J mice initiated with azoxymethane. Cancer Lett. 2006;238:69-75.
IF2㧕 Hata K, Tanaka T, Kohno H, Suzuki R, Qiang SH, Yamada Y, Oyama T, Kuno T, Hirose Y, Hara A,
Mori H. eta-Catenin-accumulated crypts in the colonic mucosa of juvenile Apc(Min/+) mice. Cancer
Lett. 2006;239:123-128.
IF
3㧕 Kuno T, Hirose Y, Yamada Y, Hata K, Qiang SH, Asano N, Oyama T, Zhi H, Iwasaki T, Kobayashi H,
Mori H. Chemoprevention of mouse urinary bladder carcinogenesis by fermented brown rice and ricebran. Oncol Rep. 2006;15:533-538.
IF4㧕 Tanaka O, Kiryu T, Hirose Y, Fujikake R, Sakurai K, Hoshi H. Chest wall Castleman's disease: CT and
MRI findings. Radiat Med. 2006;24:529-533.
5㧕 Suzuki R, Kohno H, Yasui Y, Hata K, Sugie S, Miyamoto S, Sugawara K, Sumida T, Hirose Y, Tanaka T.
Diet sypplemented with citrus unshiu segment membrane suppresses chemically induced colonicpreneoplastic lesions and fatty liver in male db/db mice. Int J Cancer. 2006;120:252-258.
IF
6㧕 Tomita H, Yamaguchi K, Matsuo M, Ohno T, Nishimoto Y, Hirose Y. Metastatic myxoid liposarcoma inthe mesentery: what is debated? Case report and a review of the literature. Am Surg. 2006;72:68-70.
IF
7㧕 Sheng H, Hirose Y, Hata K, Zheng Q, Kuno T, Asano N, Yamada Y, Hara A, Osawa T, Mori H.
Modifying effect of dietary sesaminol glucosides on the formation of azoxymethane-inducedpremalignant lesions of rat colon. Cancer Lett. 2007;246:63-68.
IF8㧕 Mizuno T, Imai A, Hirose Y. Skeletal muscle metastatic and pelvic leiomyosarcomas following
hysterectomy. Int J Gynaecol Obstet. 2007;96:49-50.
IF
9㧕 Kato H, Kanematsu M, Kusunoki Y, Shibata T, Murakami H, Mizuta K, Ito Y, Hirose Y. Nasoalveolar
cyst: imaging findings in three cases. Clin Imag. 2007;31:206-209.
IF
10㧕 Manabe T, Hirose Y, Kiryuu T, Koudo H, Hoshi H. Magnetic resonance imaging of endometrial cancer
and clear cell cancer. J Comput Assist Tomo. 2007;31:229-235.
IF
11㧕 Zhi H, Yamada Y, Hirose Y, Kato K, Sheng H, Zheng Q, Oyama T, Asano N, Kuno T, Hara A, Mori H.
Effect of 2-(carboxyphenyl) retinamide and genistein on the formation of early lesions in
1,2-dimethylhydrazine-induced colon carcinogenesis in rats. Asian Pac J Cancer Prev. 2007;8:33-38.
12㧕 Asano N, Kuno T, Hirose Y, Yamada Y, Yoshida K, Tomita H, Nakamura Y, Mori H. Preventive effects
of a flavonoid myricitrin on the formation of azoxymethane-induced premalignant lesions in colons ofrats. Asian Pac J Cancer Prev. 2007;8:73-76.
13㧕 Niwa K, Hirose R, Mizuno T, Hirose Y, Tamaya T. Pseudomyxoma peritonei and mucinous pyometral
fluid arising from an ovarian borderline mucinous tumor: case report. Eur J Gynaecol Oncol.
2007;28:145-146.
IF
14㧕 Phuoc NB, Ehara H, Gotoh T, Nakano M, Yokoi S, Deguchi T, Hirose Y. Immunohistochemical
analysis with multiple antibodies in search of prognostic markers for clear cell renal cell carcinoma.
Urology. 2007;69:843-848.
IF
15㧕 Tomita H, Yamada Y, Oyama T, Hata K, Hirose Y, Hara A, Kunisada T, Sugiyama Y, Adachi Y, Linhart
H, Mori H. Development of gastric tumors in Apc(Min/+) mice by the activation of the beta-catenin/Tcf
signaling pathway. Cancer Res. 2007;67:4079-4087.
IF
16㧕 Mizutani K, Ehara H, Yokoi S, Phunc NB, Deguchi T, Hirose Y. Treatment-related ureteral cancer
following stage II testicular seminoma. Int J Clin Oncol. 2007;12:469-471.
17㧕 Niwa K, Onogi K, Yun W, Hirose Y, Tamaya T. Primary lymphoma of the uterine corpus: an unusual
location for a common disease—case report. Eur J Gynaecol Oncol. 2007;28:522-523.
IF
18㧕 Kato H, Kanematsu M, Mizuta K, Ito Y, Hirose Y. Carcinoma ex pleomorphic adenoma of the parotid
gland: radiologic-pathologic correlation with MR imaging including diffusion-weighted imaging. Am J
Neuroradiol. 2008;29:865-867.
IF
19㧕 Doi S, Yasuda I, Iwashita T, Ibuka T, Fukushima H, Araki H, Hirose Y, Moriwaki H. Needle tract
implantation on the esophageal wall after EUS-guided FNA of metastatic mediastinal
lymphadenopathy. Gastrointest Endosc. 2008;67:988-990.
IF

㧙㧙

3.398

3.398

1.597

4.555
1.241

3.398
1.144
0.742
1.509

0.587

2.134

7.672

0.587

2.338

5.888

20㧕 Iwashita T, Yasuda I, Doi S, Kato T, Sano K, Yasuda S, Nakashima M, Hirose Y, Takami T, Moriwaki H.
The yield of endoscopic ultrasound-guided fine needle aspiration for histological diagnosis on patientssuspected of stage I sarcoidosis. Endoscopy. 2008;40:400-405.
21㧕 Kato H, Kanematsu M, Kiryu T, Iwata H, Shiraishi K, Matsumoto S, Hirose Y, Matsutomo H, Sasaoka
I. Nonfunctional mediastinal parathyroid cyst: imaging findings in two cases. Clin Imag.
2008;32:310-313.
22㧕 Phunc NB, Ehara H, Gotoh T, Nakano M, Kamei S, Deguchi T, Hirose Y. Prognostic value of theco-expression of carbonic anhydrase IX and vascular endothelial growth factor in patients with clear
cell renal cell carcinoma. Oncol Rep. 2008;20:525-530.
23㧕 Kato H, Kanematsu M, Furui T, Imai A, Hirose Y, Kondo H, Goshima S, Tsuge Y. Carcinosarcoma of
the uterus: radiologic-pathologic correlations with magnetic resonance imaging including
diffusion-weighted imaging. Magn Reson Imaging. 2008;26:1446-1450.

IF 4.166

IF 0.742

IF 1.597

IF 1.486

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦‐ፉବ๺㧘⎇ⓥಽᜂ⠪㧦ᑝἑༀା㧧ෘ↢ഭ௛⋭߇ࠎ⎇ⓥഥᚑ㊄㧦୘૕࡟ࡌ࡞ߦ߅ߌࠆ
ᄙᲑ㓏⊒߇ࠎߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18 ᐕᐲ㧧1,700 ජ౞2㧕 ⎇ⓥઍ⴫⠪㧦㜞ᯅ⌀⟤㧘⎇ⓥಽᜂ⠪㧦ᑝἑༀା㧧ෘ↢ഭ௛⋭߇ࠎ⎇ⓥഥᚑ㊄㧦⢈ḩ࡮㜞⢽ⴊ∝࡮♧ዩ∛ࡕ࠺࡞േ‛ߩ⊒߇ࠎᗵฃᕈߣ⊒߇ࠎᯏ᭴ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 19 ᐕᐲ㧧1,500 ජ౞3㧕 ⎇ⓥઍ⴫⠪㧦㜞ᯅ⌀⟤㧘⎇ⓥಽᜂ⠪㧦ᑝἑༀା㧧ෘ↢ഭ௛⋭߇ࠎ⎇ⓥഥᚑ㊄㧦⢈ḩ࡮㜞⢽ⴊ∝࡮♧ዩ∛ࡕ࠺࡞േ‛ߩ⊒߇ࠎᗵฃᕈߣ⊒߇ࠎᯏ᭴ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 20 ᐕᐲ㧧1,500 ජ౞
2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬᑝἑ ༀା㧦1㧕 ᣣᧄ∛ℂቇળਛㇱᡰㇱᐙ੐(ᐔᚑ 20 ᐕ 12 ᦬㨪⃻࿷)2㧕 ᣣᧄ⥃ᐥ⚦⢩ቇળ᧲ᶏㅪวળᐙ੐(ᐔᚑ 20 ᐕ 12 ᦬㨪⃻࿷)2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ᑝἑ ༀା㧦1㧕 ╙ 40 ࿁ᣣᧄᇚੱ⑼⣲≌ቇળቇⴚ⻠Ṷ(ᐔᚑ 18 ᐕ 7 ᦬㧘ጘ㒂㧘∛ℂ∝଀ᬌ⸛ળ 2‫ޟ‬ሶች૕ㇱ‫ޠ‬ᐳ㐳)2㧕 ╙৻࿁઻ଛേ‛ߩ⥃ᐥකቇ⎇ⓥળ߅ࠃ߮╙ 38 ࿁ᣣᧄᲧセ⥃ᐥකቇળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ጟፒ㧘ࠪࡦࡐࠫ࠙ࡓ‫∛ߩࠎ߇੃ޟ‬ℂቇ⊛᭎ⷐ㧘ࡅ࠻੃⣼⣲≌ߩ∛ℂ‫ޠ‬Ṷ⠪)3㧕 ╙ੑ࿁઻ଛേ‛ߩ⥃ᐥකቇ⎇ⓥળ(ᐔᚑ 20 ᐕ 12 ᦬㧘ጟፒ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬㛽エ㛽⣲≌ߩ∛ℂቇ⊛᭎ⷐ‫ޠ‬Ṷ⠪)
8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ
ߥߒ

㧙㧙

9㧚␠ળᵴേ
ߥߒ
10㧚ႎ๔ᦠ
1㧕 ‐ፉବ๺㧘Ⴆᧄᔀ຦㧘⪭ว㓷ሶ㧘ᮘ㊁⥝ᄦ㧘㟱ᷗ⧷ᯏ㧘ᧁධಒ㧘↰ᴧ㗅৻㧘ዊᎹൎᵗ㧘ᑝἑༀା㧘ᧄ↰ᶈ┨㧘⛯ノਭ㧘દ᧲ᢥ↢㧘❱↰ାᒎ㧘੹੗ବᄦ㧦୘૕࡟ࡌ࡞ߦ߅ߌࠆᄙᲑ㓏⊒߇ࠎߦ㑐ߔࠆ⎇ⓥ㧦ෘ↢ഭ௛⋭߇ࠎ⎇ⓥഥᚑ㊄ߦࠃࠆ⎇ⓥႎ๔㓸 ᐔᚑ 17 ᐕᐲ(‐ፉ᢬)㧦12㧙15(2006 ᐕ 9 ᦬)2㧕 ‐ፉବ๺㧘Ⴆᧄᔀ຦㧘⪭ว㓷ሶ㧘ᮘ㊁⥝ᄦ㧘㟱ᷗ⧷ᯏ㧘ᧁධಒ㧘↰ᴧ㗅৻㧘ዊᎹൎᵗ㧘ᑝἑༀା㧘ᧄ↰ᶈ┨㧘⛯ノਭ㧘દ᧲ᢥ↢㧘ᤐ↰㓷ਯ㧘❱↰ାᒎ㧦୘૕࡟ࡌ࡞ߦ߅ߌࠆᄙᲑ㓏⊒߇ࠎߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⋭߇ࠎ⎇ⓥഥᚑ㊄ ෘ↢ഭ௛⋭߇ࠎ⎇ⓥഥᚑ㊄ߦࠃࠆ⎇ⓥႎ๔㓸 ᐔᚑ
18 ᐕᐲ(‐ፉ᢬)㧦11㧙14(2007 ᐕ 9 ᦬)
3㧕 㜞ᯅ⌀⟤㧘ᑝἑༀା㧘੹੗ବᄦ㧘ਭ㊁ኼ਽㧘⪭ว㓷ሶ㧘੉੗ᐽ౷㧘ᴛ᧛㆐਽㧦⢈ḩ࡮㜞⢽ⴊ∝࡮♧ዩ∛ࡕ࠺࡞േ‛ߩ⊒߇ࠎᗵฃᕈߣ⊒߇ࠎᯏ᭴ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 19 ᐕᐲෘ↢ഭ௛⋭߇ࠎ⎇ⓥഥᚑ㊄ߦࠃࠆ⎇ⓥႎ๔㓸 ᐔᚑ 19 ᐕᐲ(㜞ᯅ⃰)㧦279㧙283(2008 ᐕ 9 ᦬)
11㧚ႎ㆏
1㧕 ᑝἑༀା㧦‫⎇ޟ‬ⓥቶ߆ࠄ ᄢቇߪ޿߹‫ޠ‬ㆮવሶᄌൻࠍട๧ߒߡ⸻ᢿ㧦ጘ㒂ᣂ⡞(2007 ᐕ 8 ᦬ 14 ᣣ)
2㧕 ∛ℂㇱ㧦IT ߢ⸻≮ᖱႎࠍ౒᦭ ⋵࡮⋵කᏧળ࡮ጘ㒂ᄢ∛㒮㧦ጘ㒂ᣂ⡞(2007 ᐕ 10 ᦬ 17 ᣣ)
3㧕 ∛ℂㇱ㧦ጘ㒂⋵㧘19 ᣣ߆ࠄ∛㒮ߣㅪ៤ਃ੐ᬺ㧦⺒ᄁᣂ⡞(2007 ᐕ 10 ᦬ 17 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔ࿕ᒻ≸㧔․ߦᄢ⣺≸㧕ߦ߅ߌࠆ⢈ḩ㑐ㅪ࿃ሶߦࠃࠆୃ㘼૞↪ߦߟ޿ߡߪ㧘ࠦࡦࠬ࠲ࡦ࠻ߦ⍮⷗ࠍ⫾Ⓧ
ߒߡ㧘ߘࠇࠍᬺ❣⊒⴫෸߮ᄖㇱ⎇ⓥ⾌₪ᓧߦߟߥߍࠆߎߣ߇ߢ߈ߚ‫ޕ‬
FNA ᬌ૕ߦઍ⴫ߐࠇࠆ㜞ᐲవㅴක≮ߦߟ޿ߡߪ㧘⥃ᐥ⑼ߣߩදജߩਅ㧘ᬺ❣⊒⴫ࠍⴕ߁ߎߣ߇಴᧪ߚ‫ޕ‬ᒻᘒ⸻ᢿߣಽሶ⸻ᢿߩⲢวߦ㑐ߒߡߪ㧘HER2 ㆮવሶߩ in situ hybridization ߹ߢࠍ⁛⥄ߢᣉⴕߒ㧘ታ❣ߦߟߥߍࠆߎߣ߇಴᧪ߚ‫ޕ‬⃻⁁ߩ໧㗴ὐߣߘߩኻᔕ╷⌕ታߥᬺ❣⊒⴫߇ߢ߈ࠆࠃ߁ߦߥߞߚ߇㧘✚ߓߡ∛ℂㇱ߇⊒ାరߦߥࠆᬺ❣߇ዋߥ޿ὐ߇໧㗴ߣߒߡ޽ߍࠄࠇࠆ‫੹ޕ‬ᓟߪ⥄೨ߢߩ⺰ᢥ⊒⴫߅ࠃ߮ቇળ⊒⴫ࠍⓍᭂ⊛ߦⴕߞߡ޿ߊߎߣ߇ᔅⷐߣᕁࠊࠇࠆ‫ޕ‬੹ᓟߩዷᦸᄢ⣺⊒߇ࠎߦ߅ߌࠆ⢈ḩ㑐ㅪ࿃ሶߩୃ㘼૞↪ߦߟ޿ߡߪ㧘ᒁ߈⛯߈േ‛ࡕ࠺࡞ࠍ↪޿ߡߘߩේ࿃࿃ሶ
․ቯߦㄼࠆࠃ߁ߥዷ㐿ࠍߒߡ޿ߊ‫ޕ‬੹ᓟ߽ߐࠄߥࠆ㜞ᐲක≮߇⥃ᐥᔕ↪ߐࠇࠆߎߣ߇ᗐቯߐࠇࠆߚ߼㧘ߘߩㇺᐲ㧘⥃ᐥ⊛࠾࡯࠭ߦᔕߓࠄ
ࠇࠆࠃ߁ߥදജ㑐ଥߩ᭴▽ߣਇᢿߩḰ஻ࠍᔃ ߌߡ޿ߊ‫ޕ‬․ߦ⢖࡮ᄢ⣺࡮エㇱ⣲≌ߥߤߦߟ޿ߡ㧘ㆮવሶᖱႎࠍ⋓ࠅㄟࠎߛ∛ℂ⸻ᢿߩ᭴▽ߦᒁ߈⛯޿ߡദജߒ
ߡ޿ߊ‫ޕ‬㧙㧙㧔3㧕࿾ၞක≮කቇ࠮ࡦ࠲࡯㧔ౝ⑼♽ಽ㊁㧕1㧚⎇ⓥߩ᭎ⷐ
ᒰ࠮ࡦ࠲࡯ߪ㧘ᐔᚑ 19 ᐕ 4 ᦬ߦᣂ⸳ߐࠇߚ‫ޕ‬ᄢቇ㒮කቇ♽⎇ⓥ⑼࡮කቇㇱߩ৻ㇱ㐷ߢߪ޽ࠆ߇㧘ߘߩ૶๮ߪઁߩ⥃ᐥ♽⻠ᐳ࡮ಽ㊁ߣห᭽ߦ㧘⸻≮࡮ᢎ⢒࡮⎇ⓥߩ 3 ᧄᩇࠍၮᧄߣߒߡ޿ࠆ‫ౕޕ‬૕⊛ߦߪ㧘Ԙ㧦ᒰ㕙ߩ࿾ၞක≮፣უࠍㆱߌࠆߚ߼ߦ㧘නߦකᏧᢙߩ⏕଻ߦ㗬ࠆߩߢߪߥߊ㧘࿾ၞක≮ᣉ⸳㑆ㅪ៤㧘⥄ᴦ૕߿࿾ၞ૑᳃ߣߩදജ૕೙ߥߤࠍ㚟૶ߒߡ‫ޟ‬ක≮ߩ⏕଻‫ޕ߁ⴕࠍޠ‬ԙ㧦࿾ၞᨒផ⮈౉⹜ߥߤ㧘කቇㇱቯຬჇࠍផㅴߔࠆߣߣ߽ߦ㧘ᣢሽߩࠞ࡝ࠠࡘ࡜ࡓߩਛߢ㧘࿾ၞක≮ߩ⃻႐ࠍᦨᄢ㒢ߦᵴ↪ߒߡත೨㨪තᓟ৻⽾ߒߚ‫ޟ‬࿾ၞක≮ߦ⽸₂ߢ߈ࠆੱ᧚⢒ᚑ‫ࠍޠ‬ᜂᒰߔࠆ‫ߪ᧚ੱ߁޿ߢߎߎޕ‬න৻ߩ⸻≮⑼ߩኾ㐷කࠍ⢒ߡ਄ߍࠆߩߺߢߥߊ㧘޽ࠆ⒟ᐲ᏷ᐢ޿ක≮ᛛⴚࠍりߦઃߌߚ‫ޟ‬ᮮᢿ⊛✚ว⸻≮ක‫ࠍߣߎߩޠ‬ᜰߒ㧘߹ߚකᏧߩߺߢ
ߥߊ⋴⼔Ꮷ㧘ߘߩઁߩࠦࡔ࠺ࠖࠞ࡞ߩ⢒ᚑࠍ߽฽߻‫ޕ‬කቇㇱߩᦨᄢߩ૶๮ߪක≮ੱߩ⢒ᚑߢ޽ࠅ㧘ߎߩߎߣߦᦨᄢ㒢ߩ⾗Ḯࠍᛩ౉ߔࠆ‫ޕ‬Ԛ㧦Ԙԙࠍታⴕߔࠆߦ޽ߚߞߡߩක≮ㅪ៤ࠪࠬ࠹ࡓ߿㧘࿾ၞක≮ੱ⢒ᚑࠞ࡝ࠠࡘ࡜ࡓߩ㐿⊒ߥߤ㧘࿾ၞක≮ࠍ⏕଻ߔࠆߚ߼ߩᣇ╷ࠍ⎇ⓥߔࠆߣߣ߽ߦ㧘࿾ၞߩ․⇣⊛ߥ∔ᖚߦ㑐ߔࠆ⎇ⓥߥߤ߽ᜂᒰߒߡ޿ߊ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦

᧛਄໪㓶

Nobuo Murakami

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ᧛਄໪㓶㧚ਛ᧛ ⼾✬㧚NST ࡂࡦ࠼ࡉ࠶ࠢ㧘᧲੩㧦ࡔ࠺ࠖࠞ࡞ࡆࡘ࡯␠㧧2006 ᐕ㧚
2㧕 ᧛਄໪㓶㧚᫪⣁ਭ㓉㧚‫ޟ‬⢄ᕈ⣖∝ߩ⸻ᢿၮḰߣ∛ဳಽ㘃‫ޠ‬㧦᫟ᣇᤘඳ㧘ዊᳰ๺ᒾ㧘↰ዥਭ㓶✬㧚⢄ ⥃ᐥߦᓎ┙ߟᶖൻེ∔ᖚߩ⸻ᢿၮḰ࡮∛ဳಽ㘃࡮㊀∝ᐲߩ↪޿ᣇ㧘᧲੩㧦ࡔ࠺ࠖࠞ࡞࠮ࡦ࠲࡯␠㧧2006 ᐕ㧦227
㧙231㧚
3㧕 ᧛਄໪㓶㧚␹⼱ ᤩ㧘የኅ㊀ᴦ✬㧚⮎೷Ꮷߩߚ߼ߩᗵᨴ೙ᓮᮡḰ࠹ࠠࠬ࠻㧘᧲੩㧦ߓ߶߁㧧2008 ᐕ㧚
4㧕 ᧛਄໪㓶㧚Τ┨ ਥⷐ∔ᖚߩᩕ㙃▤ℂ 7. ․ᱶߥ∛ᘒߢߩᩕ㙃▤ℂ D. ᗵᨴ∝㧦ਛደ ⼾✬㧚∛ᘒᩕ㙃ኾ㐷කࠟࠗ࠼ࡉ࠶ࠢ㧘᧲੩㧦ධᳯၴ㧧2008 ᐕ㧦218㧙223㧚
⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 ᧛਄໪㓶㧚ICD ᵴേႎ๔ᦠ 㨪ICD’s Pearls㨪, ICT ߣ NST ࠍ⛔วߒߚᖚ⠪⸻≮ᡰេ㧘INFECTIONCONTROL 2006 ᐕ㧧15 Ꮞ㧦181㧙184㧚
2㧕 ᧛਄໪㓶㧘⑔ፉ⑲᮸㧘⊕ᧁ ੫㧘㢬⷗ ኼ㧘᧻ᶆసᒾ㧘ᷓየ੝↱⟤㧘ᧁਅᐘሶ㧘᧛ἑ૫ઍሶ㧘㋈ᧁ㤗Ꮧሶ㧘᫪⣁ਭ㓉㧚ቇળ࡟ࡐ࡯࠻㧘╙ 21 ࿁ᣣᧄ㕒⣂⚻⣺ᩕ㙃ቇળ ᩕ㙃⹏ଔߣᴦ≮ 2006 ᐕ㧧23 Ꮞ㧦174㧙176㧚
3㧕 ᧛਄໪㓶㧚╙ 1 ․㓸 ⍮ߞߡ߅߈ߚ޿ NST ߩၮ␆⍮⼂̆ߐ߹ߑ߹ߥ㗔ၞߢߩขࠅ⚵ߺߩታ㓙̆ⶖ≙࡮ᗵᨴ੍㒐ࠍߺߔ߃ߚ NST㧘⥃ῼ⋴⼔ 2006 ᐕ㧧32 Ꮞ㧦824㧙830㧚
4㧕 ᧛਄໪㓶㧘⑔ፉ⑲᮸㧘⊕ᧁ ੫㧘᫪⣁ਭ㓉㧚․㓸 ᩕ㙃ᛩਈ࡞࡯࠻ߩᎿᄦߣㅴᱠ̆ක≮቟ో▤ℂ߆ࠄߺߚᩕ㙃ᛩਈ ࡞࡯࠻ߩᄌ㕟ߣ᦭↪ᕈ㧘ᩕ㙃⹏ଔߣᴦ≮ 2006 ᐕ㧧23 Ꮞ㧦426㧙431㧚
5㧕 ⺪⸰ື਽㧘ᧁਅᐘሶ㧘ᷓየ੝↱⟤㧘᧛਄໪㓶㧚⍮ߞߡ߅߈ߚ޿ᣂߒ޿ක≮̆කቇ᭎⺰̆ⶖ≙ኻ╷࠴࡯ࡓ㧘
ᣣᧄౝ⑼ቇળ㔀⹹ 2007 ᐕ㧧96 Ꮞ㧦1758㧙1764㧚
6㧕 ᧛਄໪㓶㧘᫪⣁ਭ㓉㧚․㓸㧦⢄ਇో 2㧚ᘟᕈ⢄ਇో 1) ⢄ᕈ⣖∝ߩ⊒∝ᯏᐨߣᴦ≮㧘ᴦ≮ቇ 2007 ᐕ㧧
41 Ꮞ㧦363㧙367㧚
7㧕 ᧛਄໪㓶㧘ᷓየ੝↱⟤㧚․㓸 వㅴ⊛ߥ∛㒮ߦ߅ߌࠆᗵᨴ೙ᓮ ጘ㒂ᄢቇ∛㒮ߦ߅ߌࠆᗵᨴ೙ᓮᵴേ㨪㔚ሶࠞ࡞࠹ߣ㔚ሶൻࠨ࡯ࡌࠗ࡜ࡦࠬ㨪㧘ᗵᨴ೙ᓮ 2007 ᐕ㧧3 Ꮞ㧦231㧙236㧚
8㧕 ᧛਄໪㓶㧘ᷓየ੝↱⟤㧚․㓸 㒮ౝᗵᨴኻ╷࿾ၞࡀ࠶࠻ࡢ࡯ࠢߩ᭴▽̆ጘ㒂⋵࿾ၞࡀ࠶࠻ࡢ࡯ࠢߩᵴേ㧘ᗵᨴ೙ᓮ 2008 ᐕ㧧4 Ꮞ㧦27㧙32㧚
9㧕 ᧛਄໪㓶㧚․㓸 㜞㦂⠪⢖Ἳ ⺋ྚᕈ⢖Ἳࠍਛᔃߦၮ␆ߣ⢛᥊࿃ሶ̆ 2) 㜞㦂⠪⢖Ἳߩኋਥⷐ࿃㧙㗼ᕈ⺋ྚߣਇ㗼ᕈ⺋ྚ㧘ᴦ≮ቇ 2008 ᐕ㧧42 Ꮞ㧦1205㧙1210㧚
10㧕 ᧛਄໪㓶㧚‫ޟ‬ൕോකਇ⿷(3)‫̆ޠ‬ጘ㒂ᄢቇකቇㇱ࿾ၞක≮කቇ࠮ࡦ࠲࡯㧔CRM㧕ߩขࠅ⚵ߺ㧘ጘ㒂⋵කᏧળ
ႎ 2008 ᐕ㧧683 Ꮞ㧦13㧚✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ᧻ᯅᑧᄈ㧘౎ᐈ๺ᙗ㧘ᳰ੉↱㚅㧘᪀ේ⑲ᰴ㧘┻᧛ᱜ↵㧘᧛਄໪㓶㧘⼾↰ ᴰ㧘ዊୖ⌀ᴦ㧚Ǫ-D-ࠣ࡞ࠞࡦ୯
ࠍᜰᮡߣߒߚᷓ࿷ᕈ⌀⩶∝ߦኻߔࠆࡒࠞࡈࠔࡦࠡࡦߩ᦭ലᕈߩᬌ⸛㧘ᣣᧄ㓸ਛᴦ≮කቇળ⹹ 2007 ᐕ㧧14㧙㧙Ꮞ㧦77㧙80㧚
2㧕 ᾢ↰ᕺ੺㧘ศ↰㓉ᶈ㧘⼾↰ᴰ㧘ዊୖ⌀ᴦ㧘ጊ↰ථ਽㧘᧛਄໪㓶㧘ዊୖ⌀ᴦ㧚࿾ᣇߦ߅ߌࠆᢇᕆක≮૕೙ߩ⃻⁁ߣ໧㗴ὐ ੹㧘૗߇ᔅⷐߢ޽ࠆ߆㧘߳߈࿾࡮㔌ፉᢇᕆක≮⎇ⓥળ⹹ 2008 ᐕ㧧9 Ꮞ㧦75㧙78㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Wakahara T, Shiraki M, Murase K, Fukushima H, Matsuura K, Fukao A, Kinoshita S, Kaifuku N,
Arakawa N, Tamura T, Iwasa J, Murakami N, Deguchi T, Moriwaki H. Nutritional screening withsubjective global assessment predicts hospital stay in patients with digestive deseases. Nutrition.
2007:23;634-639.
IF 2.1044㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄ߥߒ
2㧕ฃ⸤⎇ⓥ1㧕 ᫪⣁ਭ㓉㧘᧛਄໪㓶㧘㢬⷗ ኼ㧦HIV ᗵᨴ⠪╬଻ஜ⑔␩⋧⺣ផㅴ⎇ⓥ ⎇ⓥᜂᒰ⠪㧔ታോ㧕㧧ᐔᚑ
13㧙18 ᐕᐲ㧧325 ජ౞㧦੍ࠛࠗ࠭㒐⽷࿅ฃ⸤⎇ⓥ
2㧕 ᧛਄໪㓶㧘ᷓየ੝↱⟤㧦㨬㒮ౝᗵᨴኻ╷⎇ⓥ੐ᬺ(ᐔᚑ 17 ᐕᐲ㨪)‫ޠ‬㧧ᐔᚑ 18㧙20 ᐕᐲ㧧150 ජ౞(500㧦
500㧦500 ජ౞)㧦ጘ㒂⋵ක≮ᢛ஻⺖ฃ⸤⎇ⓥ
3㧕౒ห⎇ⓥ1㧕 ᧛਄໪㓶㧦࿖┙ᄢቇකቇㇱ㒝ዻ∛㒮౒ㅢ࠰ࡈ࠻̌ᗵᨴ∝▤ℂࠪࠬ࠹ࡓ̍ࠍ↪޿ߚో⥄േో㕙㔚ሶൻක≮㑐ㅪᗵᨴࠨ࡯ࡌࠗ࡜ࡦࠬߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 12 ᐕ㨪⃻࿷㧧0 ౞㧧⟲㚍ᄢቇ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬ᧛਄໪㓶㧦
1㧕 ᣣᧄᗵᨴ∝ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄⅣႺᗵᨴቇળ⹏⼏ຬ(ᐔᚑ 19 ᐕ 2 ᦬㨪⃻࿷)
3㧕 ᣣᧄ∛ᘒᩕ㙃ቇળ⹏⼏ຬ(ᐔᚑ 18 ᐕ 1 ᦬㨪⃻࿷)
4㧕 ᣣᧄ∛ᘒᩕ㙃ቇળ NST ታᣉᆔຬળᆔຬ㧘∛ᘒᩕ㙃ኾ㐷Ꮷ⹺ቯ⾗ᩰᬌ⸛ᆔຬળᆔຬ(ᐔᚑ 19 ᐕ 4 ᦬㨪⃻࿷)
5㧕 ᣣᧄౝ⑼ቇ⑼᧲ᶏᡰㇱ⹏⼏ຬ(㨪⃻࿷)6㧕 ᣣᧄᗵᨴ∝ቇળᐔᚑ 20 ᐕᐲᣉ⸳ౝᗵᨴኻ╷⋧⺣⓹ญ࿁╵⠪(㨪⃻࿷)2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳᧛਄໪㓶㧦
1㧕 ╙ 21 ࿁ᣣᧄ㕒⣂⚻⣺ᩕ㙃ቇળ(ᐔᚑ 18 ᐕ 1 ᦬㧘ጘ㒂㧘วหࠪࡦࡐࠫ࠙ࡓ‫ޟ‬NST ߩࠕ࠙࠻ࠞࡓ⹏ଔ‫ޠ‬ᐳ㐳)
2㧕 ╙ 21 ࿁ᣣᧄⅣႺᗵᨴቇળ✚ળ(ᐔᚑ 18 ᐕ 2 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᗵᨴ∝ኻ╷ߩ㔚ሶൻ‫ޠ‬ᐳ㐳)
3㧕 ╙ 3 ࿁࡝ࠬࠢࡑࡀࠫࡔࡦ࠻࠮ࡒ࠽࡯(J&J)(ᐔᚑ 18 ᐕ 9 ᦬㧘ጘ㒂㧘․೎⻠Ṷ 1㧘‫ޟ‬ᚻⴚቶߦ߅ߌࠆ⡯‫ޟ‬ᒰ⑼ߦ߅ߌࠆᚻⴚቶߢߩᗵᨴ㒐ᱛኻ╷‫ޠ‬ᐳ㐳)ᬺᗵᨴߩ⃻⁁ߣኻ╷‫ޠ‬2㧘
4㧕 ╙ 89 ࿁ᣣᧄ⚦⩶ቇળ㑐᧲ᡰㇱ✚ળࡒ࠾ࠪࡦࡐࠫ࠙ࡓ(ᐔᚑ 18 ᐕ 11 ᦬㧘⟲㚍㧘․೎⻠Ṷ‫ޟ‬࿖┙ᄢቇකቇㇱ㒝ዻ∛㒮౒ㅢ࠰ࡈ࠻‫ޟ‬ᗵᨴ∝▤ℂࠪࠬ࠹ࡓ‫ߚ޿↪ࠍޠ‬㔚ሶൻ∛㒮ᗵᨴࠨ࡯ࡌࠗ࡜ࡦࠬࠍ㐿ᆎߒߡ‫ޠ‬Ṷ⠪)㧙㧙5㧕 ╙ 22 ࿁ᣣᧄⅣႺᗵᨴቇળ✚ળ(ᐔᚑ 19 ᐕ 2 ᦬㧘ᮮᵿ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬NST㧘ഃ்ࠤࠕ㧘ⶖ≙࠴࡯ࡓ㧘ⴚᓟᗵᨴኻ╷ߥߤߩ㒮ౝኾ㐷࠴࡯ࡓߣᗵᨴ೙ᓮ‫ޠ‬ᐳ㐳)
6㧕 ╙ 5 ࿁੩ṑࠨ࡯ࡌࠗ࡜ࡦࠬ⎇ⓥળ(ᐔᚑ 19 ᐕ 4 ᦬㧘੩ㇺ㧘․೎⻠Ṷ‫ޟ‬㔚ሶൻࠨ࡯ࡌࠗ࡜ࡦࠬߦࠃࠆ
ක≮㑐ㅪᗵᨴኻ╷‫ޠ‬Ṷ⠪)7㧕 ╙ 6 ࿁ᣣᧄᢇᕆකቇળਛㇱ࿾ᣇળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ጘ㒂㧘᜗⡜⻠Ṷ‫ޟ‬ᢇᕆ㗔ၞߦ߅ߌࠆක≮㑐ㅪᗵᨴኻ╷ߩၮᧄ‫ޠ‬Ṷ⠪)8㧕 ╙ 4 ࿁ᣣᧄญ⣧ࠤࠕቇળቇⴚᄢળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ᗲ⍮㧘ᢎ⢒⻠Ṷ‫ޟ‬ญ⣧ࠤࠕߣ⺋ྚᕈ⢖Ἳ‫ޠ‬Ṷ⠪)9㧕 ᧲ᶏ 3 ⋵߳߈࿾ක≮⎇ୃળ(ᐔᚑ 20 ᐕ 2 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ጘ㒂⋵ߩ࿾ၞක≮ߩ⺖㗴ߣ࿾ၞක≮කቇ࠮ࡦ࠲࡯ߩᓎഀߦߟ޿ߡ‫ޠ‬Ṷ⠪)10㧕 ╙ 6 ࿁ᢇᕆ㗔ၞᗵᨴኻ╷࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘ᗵᨴኻ╷ࠪ࡝࡯࠭⻠Ṷ‫ޟ‬ᢇᕆᄖ᧪ߦ߅ߌ
ࠆᗵᨴኻ╷‫ޠ‬ᐳ㐳)11㧕 APIC ࠻ࡇ࠶ࠢࠬ࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 8 ᦬㧘᧲੩㧘᜗⡜⻠Ṷ‫ޟ‬ᣣᧄ߆ࠄߩṶ㗴ߦࠃࠆෳട࡟ࡐ࡯࠻‫ޠ‬Ṷ⠪)12㧕 ╙ 10 ࿁࿖┙ᄢቇ㒝ዻ∛㒮ᗵᨴኻ╷ද⼏ળ(ᐔᚑ 20 ᐕ 11 ᦬㧘␹ᚭ㧘․೎⻠Ṷ‫ࠃ߅࠻࠶ࠫࡆ࠻ࠗࠨޟ‬߮Პὼᡰេߩႎ๔‫ޠ‬ᐳ㐳)13㧕 ࠫࠚ࠾࠽࠶ࠢ⊒ᄁ 1 ๟ᐕ⸥ᔨ⻠Ṷળ(ᐔᚑ 20 ᐕ 11 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬๭ๆེᗵᨴ∝ߦኻߔࠆ⚻ญ
᛫⩶⮎≮ᴺ㧙࠾ࡘ࡯ࠠࡁࡠࡦ⮎ࠍਛᔃߦ㧙ᣂᏒਛ⢖Ἳࠟࠗ࠼࡜ࠗࡦࠍ⠨ᘦߒߡ‫ޠ‬ᐳ㐳)
14㧕 ╙ 10 ࿁ᔒ៺ᗵᨴ∝⎇ⓥળ(ᐔᚑ 20 ᐕ 11 ᦬㧘ਃ㊀㧘․೎⻠Ṷ‫ޟ‬ᣣᏱ⸻≮ߢᓎ┙ߟᗵᨴኻ╷ߩࡐࠗࡦ࠻‫ޠ‬Ṷ⠪)
15㧕 ᣣක↢ᶦᢎ⢒දജ⻠ᐳ࠮ࡒ࠽࡯㧦࠙ࠗ࡞ࠬᗵᨴ∝ߦ߅ߌࠆ੍㒐ߣኻ╷(ᐔᚑ 20 ᐕ 11 ᦬㧘ጘ㒂㧘․೎
⻠Ṷ‫ޟ‬ᣂߒ޿ࡢࠢ࠴ࡦ㧙Hib ࡢࠢ࠴ࡦ㧘⚿วဳ⢖Ἳ⃿⩶ࡢࠢ࠴ࡦ㧘ሶች㗪≸ࡢࠢ࠴ࡦ㧙‫ޠ‬ᐳ㐳)16㧕 ෘ↢ഭ௛⋭ᆔ⸤੐ᬺ㧦ᣣᧄᗵᨴ∝ቇળ㒮ౝᗵᨴኻ╷⻠⠌ળ(ᐔᚑ 20 ᐕ 12 ᦬㧘␹ᚭ㧘᜗⡜⻠Ṷ‫ޟ‬㒮ౝᗵᨴኻ╷ߩࠪࠬ࠹ࡓൻ‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ1㧕 ᧛਄໪㓶㧦╙ 89 ࿁ᣣᧄ⚦⩶ቇળ㑐᧲ᡰㇱ✚ળ Best Presentation ⾨(ᐔᚑ 18 ᐕᐲ)
9㧚␠ળᵴേ᧛਄໪㓶㧦
1㧕 ࿖┙ᄢቇකቇㇱ㒝ዻ∛㒮ᗵᨴኻ╷ද⼏ળᆔຬ(㨪⃻࿷)2㧕 ห ࠟࠗ࠼࡜ࠗࡦ૞ᬺㇱળᆔຬ㐳(ᐔᚑ 20 ᐕᐲ㨪⃻࿷)3㧕 ጘ㒂࿾ᣇⵙ್ᚲኾ㐷ᆔຬ(㨪⃻࿷)4㧕 ጘ㒂⋵ᗵᨴ∝੍㒐ᆔຬળᖱႎኻ╷ㇱળ⸃ᨆዊᆔຬળᆔຬ(㨪⃻࿷)5㧕 ጘ㒂⋵ᗵᨴ∝੍㒐ᆔຬળ੍㒐ធ⒳ㇱળᆔຬ(ᐔᚑ 20 ᐕᐲ㨪⃻࿷)6㧕 ጘ㒂⋵੍㒐ធ⒳ஜᐽⵍኂ⺞ᩏኾ㐷කᏧ㓸࿅ኾ㐷කᏧ(㨪⃻࿷)7㧕 ጘ㒂⋵ᗵᨴ∝੍㒐⸘↹ᬌ⸛ᆔຬળᆔຬ㐳(ᐔᚑ 19 ᐕᐲ)
8㧕 ጘ㒂⋵㒮ౝᗵᨴኻ╷ද⼏ળᆔຬ(㨪⃻࿷)9㧕 ጘ㒂⋵㒮ౝᗵᨴኻ╷⋧⺣⓹ญ࿁╵⠪(㨪⃻࿷)10㧕 ጘ㒂⋵࿖᳃ஜᐽ଻㒾⸻≮ႎ㈽ክᩏᆔຬળᆔຬ(㨪⃻࿷)10㧚ႎ๔ᦠߥߒ11㧚ႎ㆏
1㧕 ᧛਄໪㓶㧦ᗵᨴߣᶖᲥ Vol.13 No.2㧦ᐘᦠᚱ(2006 ᐕ 10 ᦬ 30 ᣣ)
2㧕 ᧛਄໪㓶㧦ਛㇱߩක≮㧦ࠗࡦࡈ࡞ࠛࡦࠩԜ‫ޡ‬ฃ㛎↢ߪ੍㒐ធ⒳ࠍ‫ޢ‬㧦⺒ᄁᣂ⡞(2006 ᐕ 11 ᦬ 27 ᣣ)
3㧕 ᧛਄໪㓶㧦੹ᵹⴕߩ࠙ࠗ࡞ࠬߦߟ޿ߡ㧦ጘ㒂᡼ㅍ㧔ጘ㒂࡜ࠫࠝ㧕(2006 ᐕ 12 ᦬ 7 ᣣ)
4㧕 ᧛਄໪㓶㧦ኅᐸකቇߩᤨ㑆㧧ࠗࡦࡈ࡞ࠛࡦࠩߩ੍㒐㧦ᢥൻ᡼ㅍ(2006 ᐕ 12 ᦬ 10 ᣣ)
5㧕 ᧛਄໪㓶㧦੹౻ߩࠗࡦࡈ࡞ࠛࡦࠩ㧦ጘ㒂᡼ㅍ㧔ጘ㒂࡜ࠫࠝ㧕(2006 ᐕ 12 ᦬ 10 ᣣ)
6㧕 ᧛਄໪㓶㧦⋵ౝ ‫ࠆߥ߁ߤޡ‬㧘ߤ߁ߔࠆ‫ޢ‬㨪ࡁࡠ࠙ࠗ࡞ࠬߦ㑐ߒߡ㧦⺒ᄁᣂ⡞(2006 ᐕ 12 ᦬ 13 ᣣ)
7㧕 ᧛਄໪㓶㧦ᣂဳࠗࡦࡈ࡞ࠛࡦࠩ㧦ጘ㒂᡼ㅍ࠹࡟ࡆ(2007 ᐕ 3 ᦬ 2 ᣣ)
8㧕 ᧛਄໪㓶㧦࿾ၞක≮ࠍᡰ߃ߡ ጘ㒂ᄢቇ࿾ၞක≮කቇ࠮ࡦ࠲࡯㧦ጘ㒂᡼ㅍ࠹࡟ࡆ(2008 ᐕ 2 ᦬ 13 ᣣ)
9㧕 ᧛਄໪㓶㧦ᣂဳࠗࡦࡈ࡞ࠛࡦࠩߦ஻߃ߡ㧦ጘ㒂⋵଻㒾කᣂ⡞(2008 ᐕ 12 ᦬ 10 ᣣ)㧙㧙12㧚⥄Ꮖ⹏ଔ
⹏ଔ࡮ ࿾ၞක≮කቇ࠮ࡦ࠲࡯ߩ⸳┙㧔19 ᐕ 4 ᦬㧘ᢎ⢒࡮⸻≮࡮⎇ⓥࠍㅢߒߡ࿾ၞක≮ߩ⏕଻ߦ⽸₂㧘ቇౝភ⟎㧧ᢎ᝼ 5 ฬ㧘ഥᢎ 2 ฬ㧕࡮ ࿾ၞᨒផ⮈౉⹜㧔20 ᐕ 1 ᦬㧘10 ฬ㧕ߩታᣉ࡮ ጘ㒂⋵ߣߩㅪ៤ᒝൻ㧦⋵ነ㒝⻠ᐳ‫ޟ‬࿾ၞක≮ቇ⻠ᐳ‫ߣ⟎⸳ߩޠ‬࿾ၞක≮කቇ࠮ࡦ࠲࡯ౝㇱ㐷ൻ㧔࿾ၞ࡮߳߈࿾ක≮ㇱ㐷㧕
㧔19 ᐕ 11 ᦬㧕ጘ㒂⋵කቇ↢ୃቇ⾗㊄ഃ⸳ߦଥࠆදജᡰេ㧔⟵ോᐕ㒢ൕോࠦ࡯࠺ࠖࡀ࡯࠻㧕ోቇ⊛ߥ⡯ຬ੤ᵹߩ৻⽾ߣߒߡߩጘ㒂⋵⡯ຬߢ޽ࠆ⥄ᴦක⑼ᄢቇතᬺ↢╬ߣߩㅪ៤㧔ቴຬᢎቭߣߒ
ߡ࿾ၞක≮කቇ࠮ࡦ࠲࡯ᬺോᡰេ㧘20 ᐕ 8 ᦬㨪㧕ጘ㒂⋵࿾ၞක≮ኻ╷ද⼏ળ߅ࠃ߮㘧㛗࿾ၞක≮ㅪ៤ળ⼏߳ో㕙⊛ෳട㧔⼏㐳㧘ㇱળ㐳㧕࡮දജ࡮ ጘ㒂⋵✚วක≮࠮ࡦ࠲࡯㧘ጘ㒂Ꮢ᳃∛㒮ߣߩㅪ៤ߦࠃࠆࡕ࠺࡞࿾඙߳߈࿾ක≮᜚ὐ∛㒮ᵴᕈൻ㧦㧔ጘ㒂⋵┙ਅํ᷷ᴰ∛㒮㧘㜞ጊ⿒චሼ∛㒮㧕ೋᦼ⥃ᐥ⎇ୃߦ߅ߌࠆ‫ޟ‬࿾ၞක≮⎇ୃ‫ߩޠ‬ታᣉ㧔1 ࡩ᦬Ფᵷ㆜㧕ጘ㒂ᄢቇ߅ࠃ߮ጘ㒂⋵✚วක≮࠮ࡦ࠲࡯߆ࠄ㧘ᜰዉක࡮ኾ㐷කࠍᵷ㆜ߒ㧘⸻≮࡮⎇ୃකᜰዉࠨ࠹࡜ࠗ࠻⸻≮ᚲ߿ᄢቇߣߩ㑆ߩ⸻≮ㅪ៤ࠪࠬ࠹ࡓߩ᭴▽ߦ㑐ߔࠆ⎇ⓥ㧔ࡋ࡝⒖ㅍ߽฽߻㧕࡮ 㘧㛗࿾ၞฦᏒߩ∛㒮࡮කᏧળߣᧄቇߩㅪ៤ߦࠃࠆዊఽᢇᕆ⸻≮࠮ࡦ࠲࡯㧔㘧㛗࿾ၞߢߩᄛ㑆࡮ભᣣ⸻≮ߦኻᔕ㧕⸳┙ߦଥࠆදജᡰេ࡮ ጘ㒂⋵✚ว๟↥ᦼᲣሶක≮࠮ࡦ࠲࡯෸߮↥⑼ᢇᕆ៝ㅍࠪࠬ࠹ࡓ㧔20 ᐕ 2 ᦬⸳┙㧕߳ߩㆇ༡ᡰេ࡮ ࿷ቇ↢ߦኻߔࠆጘ㒂⋵කቇ↢ୃቇ⾗㊄ฃ⛎ᅑബ㧦㧔╙ 1 ⒳㧧࿾ၞᨒ౉ቇ↢ 10 ฬਛ 10 ฬ 100㧑ฃ⛎㧘╙ 2 ⒳㧧࿾ၞᨒ౉ቇ↢એᄖ㧦1 ᐕ↢ 17 ฬ㧘2 ᐕ↢ 3 ฬ㧘3 ᐕ↢ 3 ฬ㧘4 ᐕ↢ 2 ฬ㧘5 ᐕ↢ 4 ฬ㧘6 ᐕ↢ 3 ฬ㧘ว⸘ 33 ฬฃ⛎㧕࡮ ࿾ၞක≮ߦ㑐ߔࠆࠞ࡝ࠠࡘ࡜ࡓߩలታ㧔࿾ၞᨒ౉ቇ↢ࠍ฽ࠎߛోකቇ⑼ቇ↢߇ኻ⽎㧕㧦
1 ᐕ↢㧦ೋᦼ૕㛎ታ⠌㧔ቇᄖක≮㑐ㅪ⻉ᣉ⸳㧧⡲ቇᩞ㧘⋤ቇᩞ㧘㜞㦂⠪ᣉ⸳㧘ᶖ㒐⟑㧘ⴊᶧ࠮ࡦ࠲
࡯╬㧕߅ࠃ߮࿾ၞ⸻≮ᚲታ⠌ోቇᐕኻ⽎࿾ၞක≮࠯ࡒ㧔⺖ᄖ᝼ᬺ㧕ోቇᐕኻ⽎ᄐቄભᥜਛ࿾ၞ૕㛎ታ⠌㧔ጘ㒂⋵ౝ߳߈࿾ක≮᜚ὐ∛㒮߅ࠃ߮⸻≮ᚲ㧕࿾ၞක≮කቇ࠮ࡦ࠲࡯ᢎቭߦࠃࠆ࿾ၞᨒ౉ቇ↢ߩ‫ޟ‬㉿ⷫ೙ᐲ‫ޠ‬ታᣉ⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷࡮ ࠮ࡦ࠲࡯ࡔࡦࡃ࡯ߪ৻ㇱኾછ⡯ຬߣߥߞߡ޿ࠆ߽ߩߩ㧘ታ㓙ߪฦኾ㐷ಽ㊁ߩ⻠ᐳᬺോߣ౗ോߒߡ޿ࠆ
⁁ᘒߢ޽ࠅ㧘ታ⾰⊛ߥኾછ⡯ຬ߇޿ߥ޿‫ޕ‬ᒰ࠮ࡦ࠲࡯ߩᬺോࠍࠃࠅ৻ጀలታߔࠆߚ߼ߦߪ㧘⌀ߩኾછ⡯ຬߩ㈩⟎߇㊀ⷐߢ޽ࠆ‫ޕ‬࡮ ᒰ࠮ࡦ࠲࡯ߦߪ੍▚㈩ಽ߇ోߊߥ޿‫ޕ‬ነ㒝⻠ᐳߩ੍▚ߪਥߦੱઙ⾌ߦలᒰߐࠇߡ߅ࠅ㧘ㆇ༡࡮⎇ⓥ⾌
ߣߒߡㆇ↪ߢ߈ࠆ⁁ᘒߦߥ޿‫ޕ‬ᤚ㕖ߣ੍߽▚㈩ಽࠍⷐ᳞ߒߚ޿‫ޕ‬࡮ ᒰ࠮ࡦ࠲࡯ߩᬺോߪ㧘ߔߴߡߩ⻠ᐳ㧘⸻≮⑼ߩᬺോߣ౒ㅢߒߚࠅ㧘ዋߥ߆ࠄߕᓇ㗀ࠍ෸߷ߒߚࠅߔࠆ
ߎߣ߇⠨߃ࠄࠇࠆ‫⃻ޕ‬࿷ CRM ㆇ༡ᆔຬળߢ⺞ᢛࠍ࿑ߞߡ޿ࠆߣߎࠈߢ޽ࠆ߇㧘තᓟ⥃ᐥ⎇ୃ࠮ࡦ࠲࡯㧘ක≮ㅪ៤࠮ࡦ࠲࡯ߥߤࠍߪߓ߼ߣߒߚ∛㒮ߩㇱ㐷߿ᢎോෘ↢ᆔຬળ㧘౉⹜ᆔຬળߥߤߩࡔࡦࡃ࡯
߇৻ၴߦળߒߡ⸛⼏ߔࠆᆔຬળߢ޽ࠆߴ߈ߣ⠨߃ࠄࠇࠆ‫ ߪ޿ࠆ޽ޕ‬CRM ߽฽߼ߚ࿾ၞක≮ߩ⸻≮࡮ᢎ⢒࡮⎇ⓥߦ㑐ࠊࠆᆔຬળ࡮ળ⼏߇ᔅⷐߢ޽ࠈ߁‫ޕ‬࡮ ࿾ၞක≮ࠍᜂ߁ක≮ੱࠍ⢒ᚑߔࠆᜰዉ⠪ߩᆫ൓ߩ⛔৻ൻ߇ਇචಽߢ޽ࠆ‫ޕ‬ቇౝᄖߩ⋵ౝฦක≮ᣉ⸳ߩᜰዉ⠪߇৻ਣߣߥߞߡ࿾ၞක≮ੱࠍ⢒ᚑߔࠆࡑࠗࡦ࠼ࠍ৻ߟߦߔߴߊ࿾㆏ߥദജ߇ᔅⷐߢ޽ࠆ‫ޕ‬੹ᓟߩዷᦸ٤੹ᓟߩข⚵ߺ㧔ᣂߚߦขࠅ⚵߻߽ߩ߿੹ᓟ㧘లታߔࠆ߽ߩ㧕࡮ ‫ߩ⁁⃻ޟ‬ข⚵ߺ‫߮ࠃ߅⛯⛮ߩߡߴߔޠ‬లታ࡮ ࿾ၞක≮ߦ㑐ߔࠆࠞ࡝ࠠࡘ࡜ࡓߩߐࠄߥࠆలታ㧔࿾ၞᨒ౉ቇ↢ࠍ฽ࠎߛోකቇ⑼ቇ↢߇ኻ⽎㧕㧦
3 ᐕ↢㧦3 ࡩ᦬㑆࿾ၞක≮ᣉ⸳߳ߩ㈩ዻ㧔ㆬᛯᕈ㧕
5㧙6 ᐕ↢㧦ቇᄖ⥃ᐥታ⠌ߩ᜛ల㧔᜚ὐ∛㒮ߦട߃㧘߳߈࿾⸻≮ᚲ߽߳ታ⠌දജⷐ⺧㧕࡮ ጘ㒂ᄢቇකቇㇱ㒝ዻ∛㒮ߦ߅ߌࠆೋᦼ⥃ᐥ⎇ୃࡊࡠࠣ࡜ࡓߩ⾰⊛ᡷༀ㧦⥃ᐥ⎇ୃࡊࡠࠣ࡜ࡓߦ㑐ߔࠆࡕ࠺࡞੐ᬺߢ㧘⃻࿷කᏧਇ⿷߇ᷓೞߥዊఽ⑼㧘↥ᇚੱ⑼㧘ᢇᕆ㧘ౝ⑼㧘
ᄖ⑼ߩߘࠇߙࠇߦߟ޿ߡ㧘․೎ࠦ࡯ࠬߩ⎇ୃࡊࡠࠣ࡜ࡓࠍᣂ⸳

㧙㧙⧯ᚻᢎຬࠍਛᔃߣߒߚ‫ ࠻ࠢࠚࠫࡠࡊޟ‬30‫ߜ┙ߩޠ‬਄ߍ㧧ᧄቇߢߩೋᦼ⥃ᐥ⎇ୃߩࡑ࠶࠴ࡦࠣታ❣ࠍ㜞߼ࠆߚ߼ߩᣇ╷㧔ᜰዉ૕೙ߩ⾰⊛ะ਄㧕ߩ⛮⛯ᬌ⸛࡮ ᓟᦼ⎇ୃࡊࡠࠣ࡜ࡓߦ߅ߌࠆ࿾ၞක≮ࡈࠖ࡯࡞࠼ߩᵴ↪
‫ޟ‬ጘ㒂⋵⦟කࡊࡠࠫࠚࠢ࠻‫ޟޠ‬㘧㛗⿒߆߱ක⠪ࡊࡠࠫࠚࠢ࠻‫ޠ‬㧧ᓟᦼ⎇ୃࡊࡠࠣ࡜ࡓߣߒߡ㧘࿾ၞක≮ߦ㑐ࠊࠆฦක≮ᣉ⸳ߢ᏷ᐢ޿⥃ᐥᛛⴚࠍりߦߟߌߚᮮᢿ⊛✚ว⥃ᐥකߩ⢒ᚑࠍⴕ߁࡮ ࡕ࠺࡞࿾඙࿾ၞਛᩭ∛㒮╬ߢߩ⸻≮ᡰេߩ᜛ల㧔ਛỚ࡮᧲Ớ࡮⷏Ớක≮࿤߳㗅ᰴ᜛ల㧕࡮ ቇౝߩߺߥࠄߕ㧘⋵ౝක≮ᣉ⸳ߩක≮ੱ⢒ᚑᜰዉ⠪ࠍኻ⽎ߣߒߚ FD ߩታᣉ࡮ ో࿖ߩ࿾ၞක≮㑐ଥ⻠ᐳߣߩㅪ៤࡮දജ૕೙ߩ⏕┙㧔࿾ၞක≮㑐ㅪ⻠ᐳࡀ࠶࠻ࡢ࡯ࠢ㧕㧙㧙㧔4㧕࿾ၞක≮කቇ࠮ࡦ࠲࡯㧔ᄖ⑼ᢇᕆ♽ಽ㊁㧕
1㧚⎇ⓥߩ᭎ⷐ
࿾ၞක≮කቇ࠮ࡦ࠲࡯ߢߪ㧘࿾ᣇߦ߅ߌࠆᢇᕆක≮૕೙ߩ⃻⁁ߣ໧㗴ὐ㧘ਛጊ㑆࿾ၞࠍߐߐ߃ࠆࡋ࡝ࠦ
ࡊ࠲࡯៝ㅍߩ㊀ⷐᕈ㧘⣻ㇱᄢേ⣂≜⎕ⵚᢇ๮ߩߚ߼ߩᢇᕆ៝ㅍߩ㊀ⷐᕈ㧘࿾ၞᨒ౉⹜ቇ↢ߩࠠࡖ࡝ࠕࠕ࠶
ࡊߩߚ߼ߩኾ㐷ක⎇ୃࠕࡦࠤ࡯࠻⺞ᩏ╬ࠍ⎇ⓥႎ๔ߒߡ޿ࠆ‫ޕ‬߹ߚ㧘ᶖൻེᄖ⑼ߩ⎇ⓥಽ㊁ߢߪ㓚ኂ⢄ߩᴦ≮߿ⴚᓟ⢄ౣ↢ߦ㑐ߔࠆ⎇ⓥࠍਛᔃߦㅴ߼ߡ޿ࠆ‫ޕ‬㓚ኂ⢄ߩᴦ≮ߪ㧘NASH ⢄⎬ᄌߦኻߒ h-HGF ࠍㆮવሶዉ౉ߔࠆߎߣߦࠃࠅ⢄✢⛽ൻߩᛥ೙߇น⢻ߢ޽ࠆߎߣࠍ
⏕⹺ߒߚ‫ⴚޕ‬ᓟ⢄ౣ↢ߦ㑐ߔࠆ⎇ⓥߪ㧘⢄⒖ᬀᤨߩ⢄㕒⣂ౣᑪਇ⦟ߢ໧㗴ߣߥࠆ߁ߞⴊߦࠃࠆ⢄ౣ↢ਇ⦟ㇱಽࠍ G-CSF ߢᡷༀߢ߈ࠆߎߣࠍ␜ߒߚ‫ߚ߹ޕ‬㧘ᄢ㊂⢄ಾ㒰೨ߦⴕ߁㐷⣂ႧᩖⴚࠍੑᲑ㓏ߦಽߌߡⴕ߁
ߎߣߦࠃࠅ㧘ࠃࠅᄢ߈ߥ⢄ౣ↢߇ᓧࠄࠇࠆߎߣࠍ᣿ࠄ߆ߦߒߚ‫⃻ޕ‬࿷ NFNB 㒖ኂ೷ߦࠃࠆ NASH ⢄ߩ⯯ⴊ⠴ኈ⢻ᡷༀ㧘LPS ᗵ૞ߦࠃࠆⴚᓟ⢄ਇో੍㒐㧘ᄢᑪਛḡߦࠃࠆᄢ㊂⢄ಾ㒰ᓟ⢄ౣ↢ᡷༀ㧘PGI2 ߦࠃࠆ㐽Ⴇᕈᄢ⣺Ἳߩᴦ≮㧘᛫⩶ࡍࡊ࠴࠼ߦࠃࠆ૕ౝੱᎿ‛ᗵᨴߩᴦ≮ࠍ⎇ⓥਛߢ޽ࠆ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
ጊ↰ථ਽
⥃ᐥ⻠Ꮷ㧦 ᾢ↰ᕺ੺

Takuya Yamada
Keisuke Kumada

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
ߥߒ⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 ችේ೑ⴕ㧘㘵↰ㄖ⟤㧘᳓⼱ᙗᆭ㧘቟᧛ᐙᄩ㧘ጊ↰ථ਽㧘┻᧛ඳᢥ㧚3 ᐲߩ㐿⣻ᚻⴚߦࠃࠅᢇ๮ߒߚ഍∝ဳࠕࡔ࡯ࡃᕈᄢ⣺Ἳߩ 1 ଀㧘ᣣᧄ⥃ᐥᄖ⑼ቇળ㔀⹹ 2006 ᐕ㧧67 Ꮞ㧦122㧙126㧚
2㧕 ችේ೑ⴕ㧘㘵↰ㄖ⟤㧘᳓⼱ᙗᆭ㧘቟᧛ᐙᄩ㧘ጊ↰ථ਽㧘┻᧛ඳᢥ㧚⿥㖸ᵄౝⷞ㏜ਅๆᒁ⚦⢩⸻߇᦭ലߢ޽
ߞߚ㕖ᯏ⢻ᕈ⤟ፉ⚦⢩⣲ߩ 1 ଀㧘ᣣᧄ⥃ᐥᄖ⑼ቇળ㔀⹹ 2006 ᐕ㧧67 Ꮞ㧦429㧙433㧚
3㧕 ችේ೑ⴕ㧘㘵↰ㄖ⟤㧘ᓟ⮮ోብ㧘᳓⼱ᙗᆭ㧘቟᧛ᐙᄩ㧘᫜ᯅବ੺㧘ጊ↰ථ਽㧘┻᧛ඳᢥ㧚㥘ᓘࡋ࡞࠾ࠕ߇
㑐ਈߒߚߣ⠨߃ࠄࠇࠆ㊎㊄ߦࠃࠆ࿁⣺⓫ሹߩ 1 ଀㧘ᣣᧄ⣻ㇱᢇᕆකቇળ㔀⹹ 2006 ᐕ㧧26 Ꮞ㧦455㧙458㧚
4㧕 ᧻የ ᶈ㧘ጊ↰ථ਽㧘㑸㊁⠨ผ㧘ศ↰⋥ఝ㧘ᧁጊ ⨃㧘ጤ↰ ዏ㧘⊕ᯅᐘᵗ㧘┻᧛ඳᢥ㧚Hand-assisted
laparoscopic surgery(HALS)ਅߦ⣛⤳៰಴ⴚࠍⴕߞߚ⣛Ἳ∝ᕈன⣲≌ߩ 1 ଀㧘ᣣᧄౝⷞ㏜ᄖ⑼ቇળ㔀⹹
2006 ᐕ㧧11 Ꮞ㧦185㧙189㧚
5㧕 ᧁ᧛⌀᮸㧘ጊ↰ථ਽㧘㑸㊁⺈ผ㇢㧘ᧁጊ ⨃㧘ฬ⍮ ␽㧘㑸㊁⠨ผ㧘㒋ᧄ⎇৻㧘┻᧛ඳᢥ㧚ⴚᓟ 4 ᐕ㑆ήౣ⊒↢ሽਛߢ޽ࠆ⍹Ἧൻ⢗≸ߩ 1 ଀㧘ᣣᧄᄖ⑼♽ㅪวቇળ⹹ 2006 ᐕ㧧31 Ꮞ㧦841㧙844㧚
6㧕 ችේ೑ⴕ㧘ᧁጊ ⨃㧘᧻የ ᶈ㧘㑸㊁⠨ผ㧘ጊ↰ථ਽㧘┻᧛ඳᢥ㧚D-fetoprotein ↥↢⚿⣺≸ߩ 1 ଀㧘ᣣᧄ
⥃ᐥᄖ⑼ቇળ㔀⹹ 2006 ᐕ㧧67 Ꮞ㧦149㧙153㧚
7㧕 ᧁ᧛⌀᮸㧘ጊ↰ථ਽㧘ᧁጊ ⨃㧘㑸㊁⠨ผ㧘᧻የ ᶈ㧘┻᧛ඳᢥ㧚⤟ౝ೽⣛ߦว૬ߒߚ㘃਄⊹⣲ߩ 2 ଀㧘ᣣᧄ⥃ᐥᄖ⑼ቇળ㔀⹹ 2006 ᐕ㧧67 Ꮞ㧦196㧙200㧚
8㧕 ጊ↰ථ਽㧘㑸㊁⠨ผ㧘᧻የ ᶈ㧘੗ේ 㗉㧘ᧁ᧛⌀᮸㧘ᧁጊ ⨃㧘┻᧛ඳᢥ㧚ೋ࿁ᚻⴚᄢ㊂಴ⴊᓟ㧘ੑᦼ⊛ߦಾ㒰ߒߚ㛽⋚⊒↢ Solitary fibrous tumor ߩ 1 ଀㧘ᣣᧄ⣻ㇱᢇᕆකቇળ㔀⹹ 2006 ᐕ㧧26 Ꮞ㧦889
㧙892㧚
9㧕 㑸㊁⠨ผ㧘ጊ↰ථ਽㧘ศ↰⋥ఝ㧘ችේ೑ⴕ㧘ᧁጊ ⨃㧘┻᧛ඳᢥ㧚ᕆᕈ㛽㜑න⃿ᕈ⊕ⴊ∛ᴦ≮ਛߦ⊒↢ߒߚ⢄⤥≌ߦኻߒ㧘⣻⣧㏜ਅ⤥≌㐿⓹ⴚࠍᣉⴕߒߚ 1 ଀㧘ᣣᧄᄖ⑼♽ㅪวቇળ⹹ 2006 ᐕ㧧31 Ꮞ㧦975㧙978㧚10㧕 ᧁ᧛⌀᮸㧘ጊ↰ථ਽㧘ᧁጊ ⨃㧘㑸㊁⠨ผ㧘┻᧛ඳᢥ㧚ERCP ᓟ⤟Ἳߩᓟߦ⢄Ꮐ⪲ಾ㒰ⴚࠍᣉⴕߒⴚᓟ⤟⤥≌ࠍ⊒↢ߒߚ⢄ౝ⢙▤≸ߩ 1 ଀㧘ᣣᧄᄖ⑼♽ㅪวቇળ⹹ 2006 ᐕ㧧31 Ꮞ㧦979㧙982㧚
11㧕 ᣧᎹ㤗ℂሶ㧘᧛ἑ૫ઍሶ㧘ጊ↰ථ਽㧘ጤ↰ዏ㧘┻᧛ඳᢥ㧚ዊఽ㗔ၞߦ߅ߌࠆ NST(ᩕ㙃ࠨࡐ࡯࠻࠴࡯ࡓ)ߩ
⃻⁁ߣ໧㗴ὐ ዊఽ NST ߦ߅ߌࠆᩕ㙃჻ߩᓎഀ ᩕ㙃㓚ኂᖚఽߦኻߔࠆ๟ⴚᦼᩕ㙃▤ℂ㧘ዊఽᄖ⑼
2007 ᐕ㧧39 Ꮞ㧦823㧙827㧚
12㧕 ᾢ↰ᕺ੺㧘ศ↰㓉ᶈ㧘⼾↰ᴰ㧘ጊ↰ථ਽㧘᧛਄໪㓶㧘ዊୖ⌀ᴦ㧚࿾ᣇߦ߅ߌࠆᢇᕆක≮૕೙ߩ⃻⁁ߣ໧㗴ὐ ੹㧘૗߇ᔅⷐߢ޽ࠆ߆㧘߳߈࿾࡮㔌ፉᢇᕆක≮⎇ⓥળ⹹ 2008 ᐕ㧧9 Ꮞ㧦75㧙78㧚
13㧕 ᾢ↰ᕺ੺㧘ዊୖ⌀ᴦ㧘⑔↰లብ㧚㔚ሶࠞ࡞࠹ߪ⚕ࠞ࡞࠹ࠍ⿧߃ࠆߎߣ߇ߢ߈ࠆ߆㧘ᣣᧄක੐ᣂႎ 2007 ᐕ㧧
4360㧦80㧙84㧚
14㧕 ᾢ↰ᕺ੺㧘⑔↰లብ㧘ዊୖ⌀ᴦ㧘ጊፒ㕒ᄦ㧚ᶖ㒐㒐ἴࡋ࡝ࠍ೑↪ߒߚᢇᕆ៝ㅍ㧘ᣣᧄ⥶ⓨක≮ቇળ⹹ 2007
ᐕ㧧8 Ꮞ㧦15㧙19㧚
15㧕 ᾢ↰ᕺ੺㧘ዊୖ⌀ᴦ㧘⑔↰లብ㧚ⓨ᷼ἴኂߦ߅ߌࠆ✕ᕆක≮૕೙ߩ໧㗴ὐ㧘ᣣᧄ⥃ᐥක≮ቇળ⹹ 2007 ᐕ㧧
10 Ꮞ㧦603㧙608㧚㧙㧙

16㧕 Kumada K, Fukuda F. Successful treatment of penetrating cardiac injury㧘㜞⍮ක≮࠮ࡦ࠲࡯කቇળ⹹
2008 ᐕ㧧2 Ꮞ㧦23㧙26㧚
17㧕 ᾢ↰ᕺ੺㧘⼾↰ ᴰ㧘ዊୖ⌀ᴦ㧚ᖱႎᛛⴚࠍ೑↪ߒߚᢇᕆක≮ᡰេ࡮ᢇᕆᖱႎ౒᦭ࠪࠬ࠹ࡓߩ᭴▽ℂᗐߣߐࠇࠆ⣖තਛᖱႎ౒᦭ࠪࠬ࠹ࡓ㧘ᣣᧄ㆙㓒ක≮ቇળ㔀⹹ 2008 ᐕ㧧4 Ꮞ㧦222㧙223㧚
18㧕 ᾢ↰ᕺ੺㧘ዊୖ⌀ᴦ㧘⑔↰లብ㧚ᄐߦࠃߊ⷗ࠄࠇࠆ∔ᖚ ᾲਛ∝㧘Emergency care 2008 ᐕ㧧21 Ꮞ㧦36
㧙43㧚
19㧕 ᾢ↰ᕺ੺㧘ዊୖ⌀ᴦ㧘⑔↰లብ㧚ᄐߦࠃߊ⷗ࠄࠇࠆ∔ᖚ ṃ᳓㧘Emergency care 2008 ᐕ㧧21 Ꮞ㧦44㧙
50㧚
20㧕 ᾢ↰ᕺ੺㧘ዊୖ⌀ᴦ㧘⑔↰లብ㧚ᄐߦࠃߊ⷗ࠄࠇࠆ∔ᖚ 㘩ਛᲥ㧘Emergency care 2008 ᐕ㧧21 Ꮞ㧦51
㧙57㧚21㧕 ᾢ↰ᕺ੺㧚๭ๆེ♽ߩ✕ᕆಣ⟎ ᳇▤ᝌ▤㧘੹ᣣߩᴦ≮ᜰ㊎ 2008  2008 ᐕ㧦78㧙80㧚✚⺑㧔᰷ᢥ㧕
1㧕 Kumada K, Toyoda I, Ogura S, Fukuda A. A case of traumatic sinus thrombosis. Neurosurg Emerg㧚
2008;13:94-97.
ේ⪺㧔๺ᢥ㧕
ߥߒේ⪺㧔᰷ᢥ㧕
1㧕 Yoshida N, Iwata H, Yamada T, Sekino T, Matsuo H, Shirahashi K, Miyahara S, Kiyama S, Takemura
H. Improvement of the survival rate after rat massive hepatectomy due to the reduction of apoptpsis
by caspase inhibitor. J Gastroen Hepatol. 2007;22:2015-2021㧚
IF 1.673
2㧕 Kiyama S, Yamada T, Iwata H, Kimura M, Miyahara T, Umeda Y, Yahida N, Matsuo H, Sekino T,
Miyazaki J, Kosugi K, Matsumoto K, Takemura H. Reduction of fibrosis in fatty cirrhosis liver byhuman HGF gene transfection using electroporation. J Gastroen Hepatol. 2008;23:471-476.
IF 1.673

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦ጊ↰ථ਽㧘⎇ⓥಽᜂ⠪㧦ጤ↰ ዏ㧘㑐㊁⠨ผ㧘ᧁ᧛⌀᮸㧧⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦
ⴚ೨ൻቇ≮ᴺᓟ⢽⢌ᕈ⢄Ἳߦኻߔࠆ᛫ࡅ࠻ TNFDࡕࡁࠢࡠ࠽࡯࡞᛫૕≮ᴺߩ㐿⊒㧧ᐔᚑ 19㧙21 ᐕ
ᐲ㧧4,820 ජ౞(4,420㧦300㧦100 ජ౞)
2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬጊ↰ථ਽㧦
1㧕 ᣣᧄᄖ⑼ቇળઍ⼏ຬ(㨪ᐔᚑ 20 ᐕ 2 ᦬)
2㧕 ᣣᧄ⢄⢙⤟ᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ⢗≸ቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᧲ᶏᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)ᾢ↰ᕺ੺㧦1㧕 ᣣᧄᢇᕆකቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ⥃ᐥᢇᕆකቇળ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅ߥߒ㧙㧙

3㧕ቇⴚ㔀⹹ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ጊ↰ථ਽㧦
1㧕 International College of Surgeons 17th Joint Congress of Asia & Pacific Federations & 53rd
Annual Congress of the Japan Section (2007, Kyoto, Simposist) 2㧕 ╙ 107 ࿁ᣣᧄᄖ⑼ቇળ(ᐔᚑ 19 ᐕ 4 ᦬㧘ᄢ㒋㧘࠺ࠫ࠲࡞ࡐࠬ࠲࡯࠮࠶࡚ࠪࡦ‫(⤟ޟ‬ᕆᕈ⤟Ἳ࡮ߘߩઁ)‫ޠ‬ᐳ㐳)
3㧕 ╙ 108 ࿁ᣣᧄᄖ⑼ቇળ(ᐔᚑ 20 ᐕ 5 ᦬㧘㐳ፒ㧘‫ޟ‬⢗(ㆮવሶ⸻ᢿ)‫ޠ‬ᐳ㐳)
4㧕 ᶖൻེ≸ൻቇ≮ᴺࠪࡦࡐࠫ࠙ࡓ-࠴࡯ࡓක≮(ᐔᚑ 20 ᐕ 5 ᦬㧘ጘ㒂㧘╙ 1 ㇱ ⻠Ṷ 1 Ṷ⠪ ੩ㇺᄢቇ ᧻ᧄ❥Ꮘ)ᐳ㐳)
5㧕 ╙ 35 ࿁ CNP ⎇ⓥળ(ᣣᧄ⥃ᐥᩕ㙃≮ᴺ⎇ⓥળ)(ᐔᚑ 20 ᐕ 12 ᦬㧘ᗲ⍮㧘‫ޟ‬ᩕ㙃▤ℂߦᔅⷐߥᶖൻེ
ᄖ⑼ߩ⍮⼂‫ޠ‬Ṷ⠪)ᾢ↰ᕺ੺㧦
1㧕 ╙ 10 ࿁ᣣᧄ⥃ᐥᢇᕆකቇળ✚ળ(ᐔᚑ 19 ᐕ 5 ᦬㧘␹ᚭ㧘‫࡞ࡃࡦࡏޟ‬ᯏ⢵૕⌕㒽ߦ߅ߌࠆኻᔕ‫ޠ‬Ṷ⠪)‫ࠢ࠶࠲ࠕࡦࠗ࡟ࡉޟ‬⣖ࠍᢇ߅߁‫ޠ‬Ṷ⠪)
2㧕 ╙ 10 ࿁⣖තਛࠪࡦࡐࠫ࠙ࡓ(ᐔᚑ 19 ᐕ 5 ᦬㧘㜞⍮㧘
3㧕 ╙ 14 ࿁ᣣᧄ⥶ⓨක≮ቇળ✚ળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ජ⪲㧘‫ޟ‬ⓨ᷼ἴኂ߳ߩක≮ኻᔕ‫ޠ‬Ṷ⠪)
4㧕 ╙ 35 ࿁ᣣᧄ㓸ਛᴦ≮කቇળ✚ળ(ᐔᚑ 20 ᐕ 2 ᦬㧘᧲੩㧘‫ޟ‬㔚ሶࠞ࡞࠹ࠪࠬ࠹ࡓߩ໧㗴ὐ‫ޠ‬Ṷ⠪)‫ޟ‬ᖱႎᛛⴚࠍ೑↪ߒߚᢇᕆක≮ᡰេ‫ޠ‬Ṷ⠪)
5㧕 ᐔᚑ 20 ᐕᐲᣣᧄ㆙㓒ක≮ቇળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ጘ㒂㧘
6㧕 ╙ 36 ࿁ᣣᧄᢇᕆකቇળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ർᶏ㆏㧘‫▤ޟ‬ℂ࡮ㆇ༡㧠‫ޠ‬ᐳ㐳)7㧕 ╙ 15 ࿁ᣣᧄ⥶ⓨක≮ቇળ(ᐔᚑ 20 ᐕ 11 ᦬㧘᧻ᳯ㧘‫ޟ‬ਛጊ㑆࿾ၞࠍߐߐ߃ࠆࡋ࡝ࠦࡊ࠲࡯៝ㅍ‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേ
ߥߒ
10㧚ႎ๔ᦠ
1㧕 ጊ↰ථ਽㧘㑐㊁⠨ผ㧘᧻የ ᶈ㧦ࠗࡦࡇ࡯࠳ࡦࠬ CT ࠍ↪޿ߚ࠮ࡦ࠴ࡀ࡞࡝ࡦࡄ▵ᬌ಴ᴺߩ⏕┙ߦ㑐ߔࠆ⎇ⓥ ᐔᚑ 15 ᐕᐲ㧙18 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)⎇ⓥᚑᨐႎ๔ᦠ(2007 ᐕ 3 ᦬)
11㧚ႎ㆏1㧕 ጊ↰ථ਽㧦ዊᨋᑪม㧘㜞ᯅቁᄦ㧘ጊ↰ථ਽㧘⨹ᧁኡม㧘ട⮮ᶈ᮸㧘⿷┙ዅੳ㧘᧻੗ᐽม㧦‫ޟ‬ᄢ⣺≸ൻቇ ≮ ᴺ ߩ ⃻ ⁁ ߣ ੹ ᓟ ‫  ޠ‬ጘ 㒂 ࿾ ඙ ߦ ߅ ߌ ࠆ ᄢ ⣺ ≸ ൻ ቇ ≮ ᴺ ߩ ᥉ ෸ ߣ ቯ ⌕  㧦 MEDICAMENT
NEWS(2007 ᐕ 9 ᦬ 15 ᣣ)
2㧕 ጊ↰ථ਽㧦ዊᨋᑪม㧘㜞ᯅቁᄦ㧘ጊ↰ථ਽㧘⨹ᧁኡม㧘ട⮮ᶈ᮸㧘⿷┙ዅੳ㧘᧻੗ᐽม㧦‫ޟ‬ᄢ⣺≸ൻቇ ≮ ᴺ ߩ ⃻ ⁁ ߣ ੹ ᓟ ‫  ޠ‬ጘ 㒂 ࿾ ඙ ߦ ߅ ߌ ࠆ ᄢ ⣺ ≸ ൻ ቇ ≮ ᴺ ߩ ᥉ ෸ ߣ ቯ ⌕  㧦 MEDICAMENT
NEWS(2007 ᐕ 9 ᦬ 15 ᣣ)
3㧕 ጊ↰ථ਽㧦࿾ၞක≮කቇ࠮ࡦ࠲࡯ ᄖ⑼ᢇᕆ♽ಽ㊁ ᢎ᝼ዞછ᜿ᜦ㧦ጘ㒂⋵∛㒮ᤨႎ╙ 45 ภ(2008ᐕ 3 ᦬ 31 ᣣ)
4㧕 ጊ↰ථ਽㧦‫⎇ޟ‬ⓥቶ߆ࠄᄢቇߪ੹‫ޠ‬⢄⤳≸ᚻⴚ㧘ౣ↢ࠍ⠨ᘦ㧦ጘ㒂ᣂ⡞(2008 ᐕ 7 ᦬ 22 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔᢎ⢒ᵴേߦߟ޿ߡ࡮ ਅํ᷷ᴰ∛㒮⎇ୃකᄖ⑼♽ࠞ࡝ࠠࡘ࡜ࡓࠍ૞ᚑߒߚ‫ޕ‬࡮ MEDC ߩදജߩ߽ߣߦ㧘ጘ㒂ᄢቇౝߩቇ↢ߣ⎇ୃක߳ะߌߡ㧘ᄖ⑼ቇ↢⧷⺆∝଀⊒⴫㧘Alan Leforవ↢ߣߩࡈ࡝࡯࠺ࠖࠬࠞ࠶࡚ࠪࡦߣ࡟ࠢ࠴ࡖ࡯ࠍⴕߥߞߚ‫ޕ‬࡮ 㒮ᄖᵴേߣߒߡ㧘ጘ㒂⋵┙ਅํ᷷ᴰ∛㒮කዪ࠮ࡒ࠽࡯ߦ߅޿ߡ㧘ਅํ᷷ᴰ∛㒮ߢߩ⎇ୃකᢎ⢒ࠍⴕߞߚ‫ޕ‬ౝኈߪ㨬Surgical Site Infection ߦኻߔࠆ Best Practice‫ޠ‬෸߮㧘ቴຬᢎ᝼ Alan Lefor వ↢ߣߩࡈ㧙㧙࡝࡯࠺ࠖࠬࠞ࠶࡚ࠪࡦࠍⴕߞߚ㧔2007.11.2 ਅํ㧕‫ޕ‬࡮ ╙ 4 ࿁⸻≮ෳടဳ⥃ᐥታ⠌ዉ౉ߩߚ߼ߩࠢ࡝࠾ࠞ࡞࡮ࠢ࡜࡯ࠢࠪ࠶ࡊᜰዉ⠪㙃ᚑࡢ࡯࡚ࠢࠪ࠶ࡊߦෳ
ട㧘ୃੌߒߚ㧔2007.10.4-6 ⵿㊁㧕‫ޕ‬࡮ ጘ㒂ᄢቇකቇㇱ࿾ၞᨒ౉⹜⺑᣿ળ㧘ጘ㒂ᄢቇ৻ᰴ⹜㛎⋙〈㧘࿾ၞᨒ౉⹜㕙ធࠍⴕߞߚ㧔2007.11.5㧕
‫ޕ‬࡮ ╙ 20 ᐕᐲ౒↪⹜㛎කቇ♽ CBT ໧㗴 ࿾ၞක≮ಽ㊁ࠍ૞ᚑߒߚ‫ޕ‬‫ޕ‬࡮ ጘ㒂ᄢቇ⥃ᐥ⎇ୃᜰዉක⻠⠌ળࠍୃੌߒߚ㧔2008.8.26㧕
⎇ⓥߦߟ޿ߡ
࡮ ╙ 13 ࿁ጘ㒂ᄢቇࠪࡦࡐࠫ࠙ࡓߦෳടߒߚ㧔2007.12.15 ጘ㒂㧕‫ޕ‬࡮ ╙ 44 ࿁ᣣᧄ⣻ㇱᢇᕆකቇળ✚ળ ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ ⣻ㇱᢇᕆ㗔ၞߦ߅ߌࠆ࠴࡯ࡓක≮ߦ߅޿ߡ㧘‫ޟ‬⣻ㇱᄢേ⣂≜⎕ⵚߦኻߔࠆ࠴࡯ࡓක≮ᚢ⇛‫ ޠ‬࿾ၞක≮ߢߩࡋ࡝ࠦࡊ࠲࡯ᢇᕆ៝ㅍߩ㊀ⷐᕈࠍ⊒⴫ߒߚ㧔2008.3.14 ᮮᵿ㧕‫ޕ‬⸻≮ᵴേߦߟ޿ߡ࡮ ਅํ᷷ᴰ∛㒮ߦ 1 ࡩ᦬ߦ 1 ࿁ߩᚻⴚදജࠍቯᦼ⊛ߦⴕߞߚ‫ޕ‬࡮ ቇળ⹺ቯᣉ⸳╬ࠕࡦࠤ࡯࠻⺞ᩏࠍᣉⴕߒߚ‫ޕ‬࡮ M4,M5,M6 ߩቇ↢ߣ⎇ୃකࠍኻ⽎ߣߒߚᄖ⑼ᚻⴚᚻᛛ࠮ࡒ࠽࡯㧔࠼࡜ࠗ࡜ࡏ㧘࠙ࠚ࠶࠻࡜ࡏ㧕ࠍ 2࿁㐿௅ߒߚ‫ޕ‬ቇౝᵴേߦߟ޿ߡ࡮ ࿾ၞක≮කቇ࠮ࡦ࠲࡯ㆇ༡ᆔຬળ㧘CRM ࠬ࠲࠶ࡈળ⼏ߦቯᦼෳടߒߚ‫ޕ‬࡮ M4,M5 ㅴ〝ᜰዉ߅ࠃ߮තᓟ⎇ୃวหᆔຬળ㧔2008.1.9㧕ෳടߒߚ‫ޕ‬࡮ ᐔᚑ 20 ᐕᐲጘ㒂ᄢቇකቇㇱ㒝ዻ∛㒮ᓟᦼ⥃ᐥ⎇ୃ⺑᣿ળ ࿾ၞකቇ࠮ࡦ࠲࡯ࠍ⚫੺ߒߚ‫ޕ‬␠ળᵴേߦߟ޿ߡ࡮ ࿾ၞක≮ᝄ⥝දળጘ㒂⋵ᡰㇱળ㧔2007.12.1 ጘ㒂㧕ߢ࿾ၞකቇ࠮ࡦ࠲࡯ࠍ⚫੺ߒߚ‫ޕ‬࡮ 㘧㛗࿾ၞක≮ㅪ៤Ḱ஻ᙣ⺣ળ㧔2007.9.7 㜞ጊ㧕㧘╙ 3 ࿁㘧㛗࿾ၞක≮ㅪ៤ળ⼏࡮㘧㛗ർㇱ࿾ၞක≮ㅪ៤දቯ✦⚿ᑼ㧔2008.4.25 㜞ጊ㧕╙ 4 ࿁㘧㛗࿾ၞක≮ㅪ៤ળ⼏㧔2008.11.13 㜞ጊ㧕ߦෳടߒߚ‫ޕ‬࡮ ࿾ၞක≮කቇ࠮ࡦ࠲࡯ࡎ࡯ࡓࡍ࡯ࠫࠍ㐿⸳ߒߚ‫ޕ‬ో૕ߩ⹏ଔߣߒߡ࡮ ᢎ⢒ᵴേߪ㧘ో૕ߣߒߡ㗅⺞ߦⴕߞߚߣ⠨߃ࠆ‫ޕ‬࡮ ⎇ⓥᵴേߪ㧘Უ૕ಽ㊁ߩ⎇ⓥߩߺߢߥߊ㧘࿾ၞක≮කቇ࠮ࡦ࠲࡯ߣߒߡߩ⎇ⓥᬺ❣ࠍ਄ߍߡ޿ߊᔅⷐ
߇޽ࠆ‫ޕ‬࡮ ⸻≮ᵴേߪ㧘߽߁ዋߒᄖ⑼⸻≮ᡰេߩ㊂ࠍჇ߿ߒ㧘ౝኈߣߒߡ㏜ⷞਅᚻⴚ╬߽ᐢ߼ߡ޿ߊᔅⷐ߇޽ࠆ‫ޕ‬࡮ ቇౝᵴേ㧘␠ળᵴേ߽㧘ߐࠄߦⓍᭂ⊛ߦෳടߔࠆᔅⷐ߇޽ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷࡮ ࿾ၞᨒቇ↢ࠍਛᔃߣߒߚᄖ⑼ᢇᕆ♽࿾ၞ⎇ୃᢎ⢒ࡊࡠࠣ࡜ࡓࠍ╷ቯߔࠆᔅⷐ߇޽ࠆ‫ޕ‬࡮ ⺰ᢥᬺ❣߇ਇ⿷ߢ޽ߞߚ‫ޕ‬ᢇᕆ៝ㅍ╬ߩߺߢߥߊ㧘ጘ㒂⋵ౝߩᄖ⑼ᚻᛛߩဋ╬ൻ㧘ᴦ≮ߩဋ╬ൻߦߟ޿ߡ㧘ቇળ⊒⴫࡮⺰ᢥ૞ᚑࠍㅴ߼ߚ޿‫ޕ‬࡮ ⃻࿷ߩ⢄ౣ↢ߩ⎇ⓥߦߟ޿ߡߪ㧘ᓟㅴߩᜰዉߦ޽ߚࠅ㧘ߔߢߦ㧘⊒⴫ߒߡ޿ࠆ⢄ಾ㒰ᴺ㧘ᚻⴚㇱ૏ᗵᨴ╬ߩ⥃ᐥ⎇ⓥ߽⺰ᢥᬺ❣ߣߒߡᱷߔࠃ߁ߦദ߼ߚ޿‫ࠍ⾌⎇⑼ޕ‬₪ᓧߒߚⴚ೨ൻቇ≮ᴺᓟ⢽⢌ᕈ⢄Ἳߦኻߔࠆ᛫ࡅ࠻ TNFDࡕࡁࠢࡠ࠽࡯࡞᛫૕≮ᴺߩ㐿⊒ߦߟ޿ߡߪ㧘⍴ᦼߢᬺ❣ࠍᱷߔࠃ߁ߦദ߼ߚ޿‫ޕ‬࡮ ਅํ᷷ᴰ∛㒮ߩᚻⴚ⸻≮ᡰេߪ㧘ᄢቇ∛㒮ߣਅํ᷷ᴰ∛㒮ߩᛛⴚ੤ᵹߣ޿߁ᗧ๧ߢ᦭↪ߢ޽ߞߚߣ⠨߃ߡ޿ࠆ‫੹ޕ‬ᓟߪቯᦼᡰេએᄖߦⷐ⺧߇޽ߞߚ႐วߦߪ㧘ోߡኻᔕߒߚ޿‫ޕ‬࡮ ቇળ⹺ቯᣉ⸳╬ࠕࡦࠤ࡯࠻⺞ᩏߪ㧘੹ᓟߩ࿾ၞᨒቇ↢ߩࠠࡖ࡝ࠕࠕ࠶ࡊߩᜰ㊎߇૞ࠇࠆࠃ߁ߦ㧘ߐࠄߦㅴ߼ߡ޿߈ߚ޿‫ޕ‬੹ᓟߩዷᦸ࡮ ᢎ⢒ᵴേߪ㧘ෳടဳ⥃ᐥታ⠌ߩታ〣ࠍㅴ߼ߡ޿ߊߣ౒ߦ㧘࿾ၞᨒផ⮈౉⹜ቇ↢ࠍኻ⽎ߦ㧘࠮ࡒ࠽࡯߿
⋥ធᜰዉࠍㅢߒߡ㧘ታ〣⊛ߥ࿾ၞක≮ࠍᢎ⢒ߔࠆ‫ߚ߹ޕ‬㧘⃻࿷ⴕߞߡ޿ࠆᄖ⑼ᚻⴚᚻᛛ࠮ࡒ࠽࡯ࠍ⊒ዷߐߖ㧘േ‛ታ㛎᫟ࠍ೑↪ߒߡࠕ࠾ࡑ࡞࡜ࡏ߇น⢻ߣߥࠆࠃ߁ߦ⸘↹ߒߡ޿ࠆ‫ޕ‬࡮ 㘧㛗ർㇱ࿾ၞක≮ㅪ៤දቯ✦⚿ߪᄢቇ㑆࡮∛㒮㑆ࠍ⿧߃ߚ࿾ၞක≮ߩᢎ⢒૕೙ߩ⏕┙ߦ᦭↪ߢ޽ࠅ㧘੹ᓟ߽㘧㛗࿾ၞක≮ᡷༀߩߚ߼㘧㛗࿾ၞක≮ㅪ៤ද⼏ળߦ⛮⛯ෳടߒߡ޿ߊ੍ቯߢ޽ࠆ‫ޕ‬㧙㧙㧔5㧕࿾ၞක≮කቇ࠮ࡦ࠲࡯㧔ዊఽ♽ಽ㊁㧕
1㧚⎇ⓥߩ᭎ⷐ
ᄙߊߩ∔ᖚߪ㧘ㆮવ⊛ⷐ࿃ߣⅣႺⷐ࿃ߩਔ⠪ߦࠃࠅߘߩ⊒∝߇ⷙቯߐࠇߡ޿߹ߔ‫ޕ‬ㆮવ⊛ⷐ࿃ߣᲧセߔࠆߣⅣႺⷐ࿃ߦߟ޿ߡߪ㧘ᄙߊߩ࿃ሶ߇㑐ਈߔࠆߎߣ߽޽ࠅ㧘ਇ᣿ߥὐ߇ዋߥߊ޽ࠅ߹ߖࠎ‫ޕ‬Ყセ⊛ဋ৻ߥ࿾ၞࠍኻ⽎ߦㆬ߮Ყセߔࠆߎߣߢ㧘∔∛ߩㆮવⷐ࿃㧘ⅣႺⷐ࿃ߩ㑐ਈࠍ᣿ࠄ߆ߦߒ߹ߔ‫ޕ‬ᗵᨴ∝㧘ࠕ࡟࡞ࠡ࡯㧘఺∉㧘↢ᵴ⠌ᘠ∛㧘ᖡᕈ⣲≌ߥߤ߶ߣࠎߤߔߴߡߩ∔ᖚࠍኻ⽎ߣߒ߹ߔ‫ޕ‬ᶏᄖߢߪ࿾ၞක≮ᖱႎߩࡀ࠶࠻ࡢ࡯ࠢൻ߇ߔߢߦㅴⴕߒߡ޿߹ߔ߇㧘ᶏᄖߩᖱႎ߽ෳ⠨ߦ㧘࿾ၞක≮ߦ߅ߌࠆ IT ᛛⴚ╬ߩࠪࠬ࠹ࡓߦ㑐ߒߡߩ⎇ⓥ߽ⴕߥߞߡ޿߹ߔ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦

㊄ሶ⧷㓶

Hideo Kaneko

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ㊄ሶ⧷㓶㧚Chediak-Higashi ∝୥⟲㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ✬㧚ዊఽ⑼ቇ ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008
ᐕ㧦865㧙866㧚
2㧕 ㊄ሶ⧷㓶㧚Griscelli㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ✬㧚ዊఽ⑼ቇ ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦866.
3㧕 ㊄⧷⧷㓶㧚X ㅪ㎮࡝ࡦࡄჇᱺᕈ∔ᖚ㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ✬㧚ዊఽ⑼ቇ ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008
ᐕ㧦866㧙867㧚
4㧕 ㊄ሶ⧷㓶㧚ߘߩઁߩ఺∉⺞▵ਇోߩ∔ᖚ㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ✬㧚ዊఽ⑼ቇ ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧
2008 ᐕ㧦867㧚
5㧕 ㊄ሶ⧷㓶㧚⛯⊒ᕈ఺∉ਇో∝㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ✬㧚ዊఽ⑼ቇ ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦879
㧙883
6㧕 ㊄ሶ⧷㓶㧚ࡌ࡯࠴ࠚ࠶࠻∛㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ✬㧚ዊఽ⑼ቇ ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦910
㧙912
7㧕 ㊄ሶ⧷㓶㧚ࠪࠚ࡯ࠣ࡟ࡦ∝୥⟲㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ✬㧚ዊఽ⑼ቇ ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦
912㧙913㧚
8㧕 ㊄ሶ⧷㓶㧚⢷⤑Ἳ࡮⤥⢷㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ✬㧚ዊఽ⑼ቇ ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦865㧙
866㧚
9㧕 ㊄ሶ⧷㓶㧚఺∉ᯏ᭴㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦1018㧙1020㧚
10㧕 ㊄ሶ⧷㓶㧚ⶄว఺∉ਇో∝㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦338㧙339㧚
11㧕 ㊄ሶ⧷㓶㧚X ㅪ㎮ήࠟࡦࡑࠣࡠࡉ࡝ࡦⴊ∝㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦343㧙344㧚
12㧕 ㊄ሶ⧷㓶㧚ಽ㘃ਇ⢻ဳ఺∉ਇో∝㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦345㧙346㧚
13㧕 ㊄ሶ⧷㓶㧚IgA ᰳਲ∝̆ㆬᛯ⊛ IgG ࠨࡉࠢ࡜ࠬᰳਲ∝㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦347㧙348㧚⪺ᦠ㧔᰷ᢥ㧕
1㧕 Kondo N, Matsui E, Kaneko H, Fukao T, Teramoto T, Kato Z, Ohnishi H, Nishimura A. Genetics ofpediatric asthma. In: Pawankar R, Holgate ST, Rosenwasser LJ, eds. Allergy Frontiers, pt1.
Epigenetics, Allergens and Risk Factors, Heidelberg : Springer; 2009:S189-203.
✚⺑㧔๺ᢥ㧕
1㧕 ㊄ሶ⧷㓶㧚ᶧᕈ఺∉ߩ⇣Ᏹߦࠃࠆ఺∉ਇో∝̆ߎߎ߹ߢಽ߆ߞߡ޿ࠆ఺∉ਇో∝୥⟲㧘ዊఽ⑼⸻≮ 2008
ᐕ㧧61 Ꮞ㧦1775㧙1782㧚
2㧕 ㊄ሶ⧷㓶㧚ಽ㘃ਇ⢻ဳ఺∉ਇో∝̆ේ⊒ᕈ఺∉ਇో∝୥⟲㧘ࠕ࡟࡞ࠡ࡯࡮఺∉ 2008 ᐕ㧧15 Ꮞ㧦48㧙55㧚
3㧕 ᄢ⷏⑲ౖ㧘ട⮮ༀ৻㇢㧘᧘ᗲ⬒㧘ᧁ᧛⽕㧘ฬ↰ආ೑㧘ᓼ⷗ືม㧘⋧㚍๺૫㧘᧻੗᳗ሶ㧘㊄ሶ⧷㓶㧘ㄭ⮮⋥ታ㧘ᩔየ⽕ੱ㧘⊕Ꮉ᣽ብ㧚ಽሶ↢‛ቇ⊛ࠕࡊࡠ࡯࠴ߩ⥃ᐥ߳ߩࠗࡦࡄࠢ࠻࡯IL-18 ෸߮ࠪࠣ࠽࡞વ㆐♽࠲ࡦࡄࠢ⾰᭴ㅧ⸃ᨆߦၮߠߊഃ⮎߳ߩࠕࡊࡠ࡯࠴. ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ⹹ 2008 ᐕ㧧22 Ꮞ㧦1㧚
4㧕 ㊄ሶ⧷㓶㧚Ataxia-telangiectasia ߣߘߩ㘃✼∔ᖚ̆ዊఽ∔ᖚ⸻≮ߩߚ߼ߩ∛ᘒ↢ℂ㧚╙ 4 ዊఽౝ⑼
2008 ᐕ㧧40 Ꮞ(Ⴧೀภ)㧦1314㧙1317.
✚⺑㧔᰷ᢥ㧕ߥߒ㧙㧙ේ⪺㧔๺ᢥ㧕1㧕 ㄭ⮮⋥ታ㧘ᐔጊ⠹৻㇢㧘᧻੗᳗ሶ㧘ኹᧄ⾆⧷㧘㊄ሶ⧷㓶㧘ᷓየᢅᐘ㧘᛬ዬᑪᴦ㧘Ꮉᧄ⟤ᄹሶ㧘⥵ᚭ㆏ᓼ㧘
ᄢ⷏⑲ౖ㧘Ꮉᧄౖ↢㧘᫪↰⑲ⴕ㧘ᧁ᧛⽕㧘ฬ↰ආ೑㧘ᓼ⷗ືม㧘ၳ෹ඳ㧘ᷰㆻ୶ሶ㧚ዊఽ᳇▤ᡰ༎ᕷᖚఽ
ߣⷫ෶ߪ଻⼔⠪ߩ QOL ⺞ᩏ␿◲ᤃᡷ⸓ 2008(GIFU)㧘ࠕ࡟࡞ࠡ࡯ 2008 ᐕ㧧57 Ꮞ㧦10221033㧚
ේ⪺㧔᰷ᢥ㧕
1㧕 Kondo M, Fukao T, Omoya K, Kawamoto N, Aoki M, Teramoto T, Kaneko H, Kondo N. Protein-losing
enteropathy associated with egg allergy in a 5-month-old boy. J Investig Allergol Clin Immunol.
2008;18:63-66.
2㧕 Funato M, Kaneko H, Ozeki M, Kanda K, Fukao T, Kondo N. Anaphylactoid transfusion reactions
associated with a positively charged white-cell reduction filter a case report. Transfus Apher Sci.
2008;38:199-201.
3㧕 Jin R, Kaneko H, Suzuki H, Arai T, Teramoto T, Fukao T, Kondo N. Age-related changes in BAFF andAPRIL profiles and upregulation of BAFF and APRIL expression in patients with primary antibody
deficiency.Int J Mol Med. 2008;21:233-238㧚
4㧕 Bai CY, Matsui E, Ohnishi H, Kimata K, Kasahara K, Kaneko H, Kato Z, Fukao T, Kondo N. A novel
polymorphism in the 5-lipoxygenase gene associated with bronchial asthma in Japanese children. Int
J Mol Med. 2008;21:139-144.
5㧕 Kondo M, Kaneko H, Fukao T, Suzuki K, Sakaguchi H, Shinoda S, Kato Z, Matsui E, Teramoto T,
Nakano T, Kondo N. The response of bovine beta-lactoglobulin-specific T-cell clones to single aminoacid substitutions of T-cell core epitope. Pediatric Allergy Immu. 2008;19:592-598.
6㧕 Funato M, Kaneko H, Ozeki M, Kanda K, Fukao T, Kondo N. Pediatric synovial sarcoma of the rightmasseter muscle. A case report and review of the literature. Int J Pediatr Otorhi. 2008;3:105-108.
7㧕 Suzuki H, Kaneko H, Rong J, Kawamoto N, Asano T, Matsui E, Kasahara K, Fukao T, Kondo N.
Induction of 1 and 2 gene expression in selective IgA deficiency. Mol Med. 2008;1:395-399.
8㧕 Kawamoto M, Matsui E, Kaneko H, Fukao T, Teramoto T, Kasahara K, Kondo N. IL-10 plays animportant role as an immune-modulator in the pathogenesis of atopic diseases. Mol Med.
2008;1:837-842.
9㧕 Arai T, Kaneko H, Ohnishi H, Matsui E, Fukao T, Kawamoto N, Kasahara K, Kondo N. Hypothermia
augments NF-kappaB activity and the production of IL-12 and IFN-gamma. Allergol Int. 2008;57:4.
10㧕 Taneichi H, Kanegane H, Sira MM, Futatani T, Agematsu K, Sako M, Kaneko H, Kondo N, Kaisho T,
Miyawaki T. Toll-like receptor signaling is impaired in dendritic cell from patients with X-linked
agammaglobulinemia. Clin Immunol. 2008;126:148-154㧚
11㧕 Matsukuma E, Kato Z, Orii K, Asano T, Orii K, Matsui E, Kaneko H, Kondo N. Acute mumps
cerebellitis .withabnormal findings in MRI diffusion weighted images. EUR J Pediatr.
2008;167:829-830

IF 1.252

IF 0.970

IF 1.847

IF 1.847

IF 2.454
IF 0.851

IF 3.551

IF 1.2274㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦㊄ሶ⧷㓶㧦⁛┙ⴕ᡽ᴺੱㄘᬺ࡮↢‛♽․ቯ↥ᬺᛛⴚ⎇ⓥᯏ᭴ ↢‛♽․ቯ↥ᬺᛛⴚ⎇ⓥᡰេ࠮ࡦ࠲࡯ ↢‛♽↥ᬺഃ಴ߩߚ߼ߩ⇣ಽ㊁Ⲣว⎇ⓥᡰេ੐ᬺ㧦㘩‛ࠕ࡟࡞ࠡ࡯ᖚ⠪ߩ⥃ᐥ௝ߩ⸃᣿߅ࠃ߮ᣂⷙᴦ≮ᴺߩ㐿⊒㧧ᐔᚑ 17㧙21 ᐕᐲ㧧95,000 ජ౞(19,000㧦19,000㧦19,000㧦19,000㧦19,000ජ౞)2㧕 ⎇ⓥઍ⴫⠪㧦㊄ሶ⧷㓶㧦⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦᛫૕↥↢ਇో∝ߦ߅ߌࠆᣂߚߥ∛ᘒߩ⸃᣿ߣ⥃ᐥ௝ߣߩ㑐ㅪ㧧ᐔᚑ 20㧙22 ᐕᐲ㧧4,110 ජ౞(2,110㧦1,000㧦900 ජ౞)
2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫ
ߥߒ

㧙㧙

6㧚ቇળᵴേ
1㧕ቇળᓎຬ
㊄ሶ⧷㓶㧦
1㧕 ᣣᧄࠕ࡟࡞ࠡ࡯ቇળઍ⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄࠕ࡟࡞ࠡ࡯දળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄዊఽ⑼ቇળ᧲ᶏ࿾ᣇળᐙ੐(ᐔᚑ 18 ᐕ 4 ᦬㨪⃻࿷)
4㧕 ᣣᧄዊఽ⑼ቇળઍ⼏ຬ(ᐔᚑ 18 ᐕ 4 ᦬㨪⃻࿷)2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳
㊄ሶ⧷㓶㧦
1㧕 Pathogenesis of primary antibody deficiency Symposium for PID in Asia Riken RCAI (2008. 12
Yokohama, Ṷ⠪)2㧕 ╙ 18 ࿁ጘ㒂⋵ߎߤ߽ߩஜᐽࠍ⠨߃ࠆߟߤ޿(ᐔᚑ 19 ᐕ 10 ᦬㧘ጘ㒂㧘‫ޟ‬ጘ㒂࿾ၞߩዊఽක≮ߣዊఽ଻ஜ̆ጘ㒂⋵ߦ߅ߌࠆዊఽߩ࿾ၞක≮ߣ࿾ၞ଻ஜߩ⏕┙‫ޠ‬Ṷ⠪)
3㧕 ╙ 45 ࿁ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ(ᐔᚑ 20 ᐕ 12 ᦬㧘ᮮᵿ㧘ࡒ࠾ࠪࡦࡐࠫ࠙ࡓ 4‫ߦ࡯ࠡ࡞࡟ࠕ੃‐ޟ‬߅ߌࠆ⚻ญ఺∉ኡኈ⺃ዉ㘩ຠߩ૞ᚑ̆㘩‛ࠕ࡟࡞ࠡ࡯⸻≮ߩᣂߒ޿ዷ㐿‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ
1㧕 ㊄ሶ⧷㓶㧦╙ 9 ࿁ዊఽකቇᎹ㊁⾨ዊఽၮ␆කቇಽ㊁(ᐔᚑ 20 ᐕᐲ)
9㧚␠ળᵴേ
㊄ሶ⧷㓶㧦
1㧕 ጘ㒂࿾ၞዊఽᢇᕆක≮૕೙ㅪ⛊ળ⼏ᆔຬ(㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ㊄ሶ⧷㓶㧘㋈ᧁ໪ሶ㧘㊄ᩕ㧘ᷓየᢅᐘ㧘ㄭ⮮⋥ታ㧦IgA ᰳ៊∝ߩ∛ᘒߣ∛࿃ㆮવሶߩ⸃ᨆ㧦ෘ↢ഭ௛⋭ 㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ ේ⊒ᕈ఺∉ਇో∝୥⟲ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ ᐔᚑ 18 ᐕᐲ ╙ 1 ࿁⃰ળ⼏✚ળࡊࡠࠣ࡜ࡓ㧦6(2007 ᐕ 1 ᦬)
2㧕 ㊄ሶ⧷㓶㧘㋈ᧁ໪ሶ㧘ᷓየᢅᐘ㧘ㄭ⮮⋥ታ㧦IgA ᰳ៊∝ߩ∛ᘒߣ∛࿃ㆮવሶߩ⸃ᨆ㧦ෘ↢⑼ቇ⎇ⓥ
⾌⵬ഥ㊄ 㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ ේ⊒ᕈ఺∉ਇో∝୥⟲ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ ᐔᚑ 18 ᐕᐲ ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ(ች⣁⃰)㧦41㧙43(2007 ᐕ 3 ᦬)11㧚ႎ㆏ߥߒ12㧚⥄Ꮖ⹏ଔ
ዊఽ⑼⎇ୃਛߩೋᦼ⎇ୃක߇ 1㧙2 ㅳ㑆㧘ਅํ᷷ᴰ∛㒮╬ߩ࿾ၞਛᩭ∛㒮ߢ⎇ୃߔࠆߎߣߢ㧘ᄢቇ∛㒮ߢߪ⚻㛎ߢ߈ߥ޿࿾ၞߩዊఽක≮ࠍ⚻㛎ߔࠆߎߣ߇ߢ߈ࠆࠃ߁ߦߥࠅ㧘࿾ၞක≮ߩ㊀ⷐᕈࠍ⹺⼂ߢ߈ࠆࠃ߁ߦߥߞߡ߈ߡ޿߹ߔ‫ߚ߹ޕ‬㧘ᜰዉක߽⎇ୃකࠍᜰዉߔࠆߎߣߢ㧘⍮⼂ߩᢛℂ߿ᗧ⼂ߩะ਄ߥߤ߇⹺
߼ࠄࠇߡ޿߹ߔ‫ޕ‬㘧㛗࿾඙ߩ㜞ጊᣣ⿒㧘ෘ↢ㅪਭ⟤ᗲ∛㒮㧘㘧㛗Ꮢ᳃∛㒮ߣ޿ߞߚᲣ૕ಽ㊁߇⇣ߥࠆ∛㒮㑆ߢ㧘කᏧߩⴕ߈᧪߇ߢ߈ࠆࠃ߁ߦߒ㧘ක≮ߩ⏕଻ߦߟߥߍࠆߎߣ߇ߢ߈߹ߒߚ‫ޕ‬ጘ㒂⋵ਅߩዊఽක
≮ߩౣ✬ࠍ㧘ዊఽ⑼කዪߣㅪ⛊ࠍኒߦߣࠅߥ߇ࠄㅴ߼ߡ޿߹ߔ‫ߚ߹ޕ‬㧘ᣣᧄዊఽ⑼ቇળ߇ឭ໒ߒߡ޿ࠆ㧘
ዊఽ⑼࠮ࡦ࠲࡯∛㒮ߦߟ޿ߡߩ╷ቯ߽ㅴ߼㧘ጘ㒂⋵ో૕ߩዊఽ⸻≮૕೙ߩၮ⋚ߠߊࠅࠍផㅴߒߡ޿߹ߔ‫ޕ‬੹ᓟ㧘ౕ૕⊛ߥὐߦߟ޿ߡߪ㧘ߐࠄߦㅴ߼ࠆᔅⷐ߇޽ࠅ߹ߔ߇㧘એ਄ߩᵴേࠍㅢߓߡ㧘ጘ㒂⋵ߩ࿾ၞක≮ߦචಽ⽸₂ߒߡ޿ࠆߣ⠨߃߹ߔ‫ޕ‬㧙㧙㧔6㧕࿾ၞක≮කቇ࠮ࡦ࠲࡯㧔↥⑼♽ಽ㊁㧕1㧚⎇ⓥߩ᭎ⷐ
↥ᇚੱ⑼කߩ⃻⁁ߪ㧘↥ᇚੱ⑼ක≮ߩ․ᱶᕈߦട߃㧘ක≮ߩ㜞ᐲൻ߳ߩኻᔕ㧘ᖚ⠪߳ߩ⺑᣿㧘ห௥කᏧߩᷫዋ㧘ߐࠄߦߪ᳃੐࡮ೃ੐⸷⸩ߩჇട╬ᖚ⠪ߣߩ࠻࡜ࡉ࡞ߩჇടߦࠃࠅ㧘ഭ௛ⅣႺߪ߹ߔ߹ߔᖡൻߒߡ
޿ࠆ‫ޕ‬ᐘ޿ߥߎߣߦ㧘ጘ㒂⋵ߢߪ৻ㇱߩ⋵ߢ↢ߓߡ޿ࠆ‫↥߅ޟ‬㔍᳃ߩ⊒↢‫ޠ‬‫ޟ‬SOS ᤨߩฃߌ⋁߇ߥ޿‫ߣޠ‬޿߁⁁ᘒߦߪ⥋ߞߡ޿ߥ޿߇㧘ߘߩෂᯏߦἄߒߡ޿ࠆߎߣ߽੐ታߢ޽ࠆ‫ߩߘޕ‬ኻ╷ߦߪ㧘቟ోߥ↥⑼ක≮ࠍ⛽ᜬߔࠆߚ߼ߦߪಽᇂขࠅᛒ޿ᣉ⸳㓸⚂ൻ߇ਇนᰳ‫ޕ‬࡮౏⊛∛㒮ߛ߆ࠄߎߘ಴᧪ࠆක≮߇಴᧪ߥ޿ߚ߼㧘ࡕ࠴ࡌ࡯࡚ࠪࡦߩૐਅߦ❬߇ߞߡ޿ࠆ‫ޕ‬ᱜᏱᅧᆼ࡮ᱜᏱಽᇂߣ޿߁ߩߪ޽ߊ߹ߢ⚿ᨐ⺰ߢ޽ࠅ㧘ߤࠎߥߦᵈᗧࠍᛄߞߡ߽㧘৻ቯߩ⏕┙ߢᲣ૕ᕆᄌ㧘ᄢ㊂಴ⴊ㧘ᣂ↢ఽ઒ᱫ߇⿠ߎࠅ߁ࠆ‫ޕ‬ᓥߞߡ㧘Ᏹᤨ✕ᕆᏢ₺ಾ㐿߇ⴕ߃ࠆ૕೙㧘ߟ߹ࠅᏱൕක߇ 3 ฬએ਄ᔅⷐߦߥࠆ‫ߒ߆ߒޕ‬㧘⃻ታ໧㗴ߣߒߡ㧘ߎߩ᧦ઙࠍߔߴߡߩᣉ⸳ߢࠢ࡝ࠕߔࠆߎߣߪ࿎㔍ߥߚ߼㧘ㆊᷰᦼ⊛ߦ‫ߊ߆ߦߣޟ‬Ᏹൕක 1 ฬߪ⛘ኻㆱߌࠆ‫⋡ࠍߣߎޠ‬ᜰߒߚ‫ޕ‬‫ޟ‬㒢ࠄࠇߚ 㧔ੱ㧘⢻ജ㧕ߩή㚝㆜޿ࠍ㒐߉㧘᦭ലᵴ↪ߔࠆ‫ߦ߼ߚޠ‬㧘Უ૕៝ㅍߩࠪࠬ࠹ࡓࠍ⏕┙ߔࠆߎߣ߇ᔅⷐ‫ޕ‬ㆡಾߥᣉ⸳ߦ៝ㅍߐࠇߥ޿ߣ
࡮Უ૕࡮⢝ఽߦߣߞߡਇ೑⋉࡮ฃߌ౉ࠇᣉ⸳ߩ∛ᐥ࡮ੱຬߩᶉ⾌࡮ᣉ⸳ߩᓧᗧಽ㊁㧔ജ㊂㧕߇↢߆ߐࠇߥ޿
࡮៝ㅍవߣ៝ㅍరߣߩା㗬㑐ଥߩ፣უߣ޿߁໧㗴߇↢ߓࠆ‫ޕ‬⸻≮ฃ⸻ߩࠃ߁ߦ৻⥸ੱ߇៝ㅍవࠍㆬᛯߔࠆߩߢߪߥߊ㧘ቇળ⹺ቯኾ㐷ක࡮Უ૕଻⼔ᴺᜰቯකᏧ߇៝ㅍ
ߔࠆߩߢ㧘⏕┙ߒߚᲣ૕៝ㅍࡑ࠾ࡘࠕ࡞߇޽ࠇ߫㧘ㆡಾߥᣉ⸳ߦ៝ㅍߐࠇߥ޿ߣ޿߁੐ᘒߪㆱߌࠄࠇࠆ‫ޕ‬Უ૕៝ㅍࠪࠬ࠹ࡓ㧘කᏧߩ㓸⚂ൻ㧘↥ᓟ࡮ሶ⢒ߡਛߩᅚකᡰេߥߤࠍ⎇ⓥ⺖㗴ߣߒߚ޿‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦

੹੗◊ᔒ

Atsushi Imai3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ੹੗◊ᔒ㧚ᣣᧄ↢ᱺකቇળ✬㧘ࠣ࡞ࠦࠦ࡞࠴ࠦࠗ࠼ᛩਈᴺ㧦ᣂߒ޿↢ᱺක≮ᛛⴚߩࠟࠗ࠼࡜ࠗࡦ ╙ 3 ᧲੩㧦㊄ේ಴ 㧧2007 ᐕ㧦184㧙187㧚
2㧕 ฎ੗ㄖ㇢㧘੹੗◊ᔒ㧚↥ᇚੱ⑼ᄖ᧪ࡌࠬ࠻࠽ࡆࠥ࡯࡚ࠪࡦ㧨ή᦬⚻㧪㧦⥃ᐥᇚੱ⑼↥⑼ 61 ᧲੩㧦කቇᦠ㒮㧧2007 ᐕ㧦403㧙413㧚
3㧕 ੹੗◊ᔒ㧚ක⠪߇ߔߔ߼ࠆኾ㐷∛㒮̆ጘ㒂ᄢቇකቇㇱ㒝ዻ∛㒮↥⑼ᇚੱ⑼㧚᧲੩㧦࡜ࠗࡈડ↹㧧2008 ᐕ㧦
324㧙324㧚⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 ฎ੗ㄖ㇢㧘੹੗◊ᔒ㧘₹⥢ノᒾ㧚↢ᱺකቇߦ߅ߌࠆ࡝࠱ࡎࠬࡈࠔ࠴ࠫࡦ㉄ߩᓎഀ㧘᧲ᶏ↥⑼ᇚੱ⑼ቇળ㔀⹹ 2007 ᐕ㧧43 Ꮞ㧦1㧙7㧚
2㧕 ੹੗◊ᔒ㧚ጘ㒂࿾඙ߦ߅ߌࠆ๟↥ᦼක≮ࠍ⠨߃ࠆ㧔Უ૕៝ㅍߣ㓸⚂ൻ㧕㧘޿ߜ޿ 2007 ᐕ㧧49 Ꮞ㧦18㧙21㧚
3㧕 ੹੗◊ᔒ㧚ጘ㒂⋵↥⑼ᇚੱ⑼ක≮ߩ໧㗴ὐ(1)㧘޿ߜ޿ 2007 ᐕ㧦50 Ꮞ㧦23㧙26㧚
4㧕 ੹੗◊ᔒ㧚Უ૕៝ㅍᢇᕆࡑ࠾ࡘࠕ࡞࡯↥⑼ක߆ࠄߩⷞὐ—㧘ጘ㒂⋵කᏧળႎ 2008 ᐕ㧧676 ภ㧦18㧙20㧚✚⺑㧔᰷ᢥ㧕
1㧕 Imai A, Furui T, Yamamoto A. Preservation of female fertility during cancer treatment. Reprod Med
Biol. 2008;7:17-27.
ේ⪺㧔๺ᢥ㧕
1㧕 ጊ↰ᣂዏ㧘ዊဈ੗ᕺሶ㧘ᣣᳯ੗㚅ઍሶ㧘᳓㊁ᥓሶ㧘ዊ㊁ᧁ੩ሶ㧘↰਄ᘮሶ㧘૒⮮ᵏ᣽㧘ᮮጊᐽብ㧘੹੗◊ᔒ㧚ᅧᆼ 27 ㅳߢሶች⎕ⵚߦ⥋ߞߚ೨⟎≹⌕⢝⋚ߩ 1 ଀㧘⥃ᐥᇚੱ⑼↥⑼ 2008 ᐕ㧧62 Ꮞ㧦875㧙878㧚㧙㧙ේ⪺㧔᰷ᢥ㧕1㧕 Imai A, Matsunami K, Takagi H. Preoperative value of CT angiography in the laparoscopic removal of
rudimentary uterine horn. Gynecol Surg. 2007;4:199-200.
2㧕 Imai A, Toyoki H, Furui T. Electronic door interference mimicking distress in fetal monitoring. Int J
Gynecol Obstet. 2007;60-61.
3㧕 Furui T, Ohno T, Imai A. Preterm labor in cases with high testosterone condition. J Obstet Gnecol
2007;27:155-156.
4㧕 Imai A, Itoh N, Matsusi K. Direct extension of a sigmoid colon cancer to a uterine leiomyoma andadherent small intestine. Oncologie. 2007;4:1-2.
5㧕 Furui T, Imai A, Ohno T. Pre-term labour in cases with high maternal testosterone levels. J Obstet
Obstet Gynecol. 2007;27:155-156.
6㧕 Mizuno T, Imai A, Hirose Y. Skeletal muscle metastatic and pelvic leiomyosarcomas following
hysterectomy. Int J Gynecol Obstet. 2007;96:49-50.
7㧕 Kato H, Kanematsu M, Furui T, Imai A, Hirose Y, Kondo, H, Goshima S, Tsuge, Y. Carcinosarcom a of
the uterus: radiologic-pathologic correlations with magnetic resonance imaging including
diffusion-weighted imaging. Magn Resonan Ima. 2008;26:1446-1450.

IF 0.779
IF 1.724
IF 0.779
IF 1.078

IF 1.486

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦੹੗◊ᔒ㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌㧔⎇ⓥ㧕㧦⤑ฃኈ૕࡝ࠟࡦ࠼ߩ⚦⢩Ქᕈࠕ࠽ࡠࠣࠍ↪޿ߚ᛫≸ൻቇ≮ᴺߣࡔࠞ࠾࠭ࡓ㧧ᐔᚑ 19 ᐕᐲ㧧1,130 ජ౞
2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥ1㧕 ੹੗◊ᔒ㧦㇭਄Ꮢߦ߅ߌࠆ↥⑼ක≮ߩ⃻⁁ߣᡷༀ㧧2000 ජ౞㧦㇭਄Ꮢ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬ੹੗◊ᔒ㧦
1㧕 ᣣᧄ↥⑼ᇚੱ⑼ቇળઍ⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ↢ᱺකቇળઍ⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄౝಽᴲቇળઍ⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄ↢ᱺౝಽᴲቇળ⹏⼏ຬ(㨪⃻࿷)5㧕 ᣣᧄᇚੱ⑼⣲≮ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳੹੗◊ᔒ㧦
1㧕 ╙ 1 ࿁᧲੩੃߇ࠎࡈࠜ࡯࡜ࡓ(ᐔᚑ 19 ᐕ 2 ᦬㧘᧲੩㧘․೎⻠Ṷ‫ޟ‬ᅚᕈࡎ࡞ࡕࡦߣ੃߇ࠎ Q & A‫ޠ‬Ṷ⠪)
2㧕 ╙ 8 ࿁ RMB (Reproductive Medicine and Biology)(ᐔᚑ 19 ᐕ 7 ᦬㧘᧲੩㧘․೎⻠Ṷ‫ޟ‬ൻቇ≮ᴺਛߩ⣼଻⼔‫ޠ‬Ṷ⠪)3㧕 ጘ㒂↥⑼ᇚੱ⑼⎇ⓥળ㧙↢ᱺකቇ㧙(ᐔᚑ 19 ᐕ 9 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫⥄ޟ‬ὼ㐽⚻߳ߩㅏߍㄟߺ≮ߣ↢ᱺකቇ Q & A‫ޠ‬Ṷ⠪)4㧕 ጘ㒂⋵↥ᇚੱ⑼කળ࡮ቇળวห✚ળ(ᐔᚑ 19 ᐕ 12 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ጘ㒂ጘ㒂⋵๟↥ᦼක≮ߩ⁁ߣ੹ᓟ‫ޠ‬Ṷ⠪)㧙㧙5㧕 ᐔᚑ 19 ᐕᐲጘ㒂ዊఽᢇᕆ⎇ୃળ(ᐔᚑ 19 ᐕ 1 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬Უ૕ᢇᕆ៝ㅍࠪࠬ࠹ࡓߩ੹ᓟ‫ޠ‬Ṷ⠪)
6㧕 ᐔᚑ 20 ᐕᐲጘ㒂⋴⼔දળഥ↥Ꮷળ⎇ୃ(ᐔᚑ 20 ᐕ 6 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ጘ㒂⋵๟↥ᦼක≮ߩ⁁ߣ੹ᓟ‫ޠ‬Ṷ⠪)7㧕 ᐔᚑ 20 ᐕᐲጘ㒂⮎⑼ᄢቇ㒝ዻ⮎ዪ(ᐔᚑ 20 ᐕ 11 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ሶችౝ⤑∝:∛ᘒ,∝⁁,ᴦ≮‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേ੹੗◊ᔒ㧦
1㧕 ጘ㒂࿾ᣇⵙ್ᚲኾ㐷ᆔຬ(ᐔᚑ 16 ᐕ 7 ᦬㨪ᐔᚑ 20 ᐕ 6 ᦬)
2㧕 ጘ㒂⋵․ቯਇᅧᴦ≮ഥᚑ੐ᬺᜰቯක≮ᯏ㑐ክᩏᆔຬ(ᐔᚑ 19 ᐕ 12 ᦬㨪⃻࿷)3㧕 ጘ㒂⋵๟↥ᦼක≮ද⼏ળᆔຬ(ᐔᚑ 19 ᐕ 7 ᦬㨪⃻࿷)4㧕 ጘ㒂⋵කᏧળᲣ૕଻⼔ᴺᜰቯකክᩏᆔຬળᆔຬ(ᐔᚑ 20 ᐕ 5 ᦬㨪⃻࿷)10㧚ႎ๔ᦠߥߒ11㧚ႎ㆏
1㧕 ੹੗◊ᔒ㧦ᚻⴚᢙߢࠊ߆ࠆ޿޿∛㒮(ో࿖㧒࿾ᣇ೎࡜ࡦࠠࡦࠣ)㧦ㅳೀᦺᣣ⥃ᤨჇೀภ(2007 ᐕ 3 ᦬ 5ᣣ)2㧕 ੹੗◊ᔒ㧦⋵ౝ 6 ∛㒮 ↥⑼ 3 ∛㒮ߦ㓸⚂㧦ਛᣣᣂ⡞(2007 ᐕ 10 ᦬ 4 ᣣ)
3㧕 ੹੗◊ᔒ㧦⠀ፉᏒ᳃∛㒮↥⑼㧘ᐕౝߢભᱛ‫ޟ‬ㄭ㓞ߦ∛㒮లታ‫ޠ‬㧦ጘ㒂ᣂ⡞(2007 ᐕ 10 ᦬ 11 ᣣ)
4㧕 ੹੗◊ᔒ㧦⠀ፉᏒ᳃∛㒮಴↥ኻᔕ㧦ਛᣣᣂ⡞(2007 ᐕ 10 ᦬ 11 ᣣ)
5㧕 ੹੗◊ᔒ㧦⠀ፉᏒ᳃∛㒮޽ࠅᣇᆔຬળ㧦↥⑼ભᱛ㧘㓸⚂:Ფᣣᣂ⡞(2007 ᐕ 10 ᦬ 11 ᣣ)
6㧕 ੹੗◊ᔒ㧦3 ∛㒮߇↥⑼ભᱛ㧦⺒ᄁᣂ⡞(2007 ᐕ 10 ᦬ 11 ᣣ)
7㧕 ੹੗◊ᔒ㧦ᅧᇚ៝ㅍవ කᏧ߇್ᢿ ߚࠄ޿࿁ߒ㒐ᱛ㧦ᦺᣣᣂ⡞(2007 ᐕ 10 ᦬ 19 ᣣ)
8㧕 ੹੗◊ᔒ㧦ක≮ߪ੹‫ޟ‬ᅧᇚฃߌ౉ࠇ࿎㔍 ᰴߩ៝ㅍవ‫ޠ‬㧦ਛᣣᣂ⡞(2007 ᐕ 10 ᦬ 23 ᣣ)
9㧕 ੹੗◊ᔒ㧦߅↥ߩ቟ోߪ㧦ᦺᣣᣂ⡞(2007 ᐕ 10 ᦬ 26 ᣣ)
10㧕 ੹੗◊ᔒ㧦ᅧᇚ៝ㅍవ㧘↥⑼ක߇್ᢿ㧦⋵ౝోၞߦ᜛ᄢ߳㧦ᦺᣣᣂ⡞(2007 ᐕ 11 ᦬ 23 ᣣ)
11㧕 ੹੗◊ᔒ㧦∛㒮ߩታജ㧔ᇚੱ⑼≸㧕㧦⺒ᄁᣂ⡞(2007 ᐕ 12 ᦬ 23 ᣣ)
12㧕 ੹੗◊ᔒ㧦∛㒮ߩታജ㧔ᇚੱ⑼≸㧕㧦⺒ᄁᣂ⡞(2007 ᐕ 12 ᦬ 23 ᣣ)
13㧕 ੹੗◊ᔒ㧦⋵ౝᅧᇚ៝ㅍࠪࠬ࠹ࡓ㧦ጘ㒂ᣂ⡞(2007 ᐕ 12 ᦬ 25 ᣣ)
14㧕 ੹੗◊ᔒ㧦‫ޣ‬07 ߉߰ࠍᝄࠅ㄰ࠆ‫ޤ‬㧨11㧪ᅧᇚߩߚࠄ޿࿁ߒ໧㗴㧦ᦺᣣᣂ⡞(2007 ᐕ 12 ᦬ 28 ᣣ)
15㧕 ੹੗◊ᔒ㧦޿޿∛㒮 2008㧦ㅳೀᦺᣣ MOOK(2007 ᐕ 12 ᦬ 28 ᣣ)
16㧕 ੹੗◊ᔒ㧦ኾ㐷ක߇ផ⮈‫᧲ޟ‬ᶏ࡮↲ା⿧ߩኅᐸක‫ޠ‬25 ੱ㧦AERA(2008 ᐕ 2 ᦬ 18 ᣣ)
17㧕 ੹੗◊ᔒ㧦ೋ⚻(ೋầ)ߩㆃࠇ㧦ጘ㒂⋵කᏧળ࡜ࠫࠝࡎ࡯ࡓ࠼ࠢ࠲࡯(2008 ᐕ 4 ᦬ 24 ᣣ)
18㧕 ੹੗◊ᔒ㧦ዊఽᦼߩᕈེ಴ⴊ㧦ጘ㒂⋵කᏧળ࡜ࠫࠝࡎ࡯ࡓ࠼ࠢ࠲࡯(2008 ᐕ 4 ᦬ 25 ᣣ)
19㧕 ੹੗◊ᔒ㧦๮ࠍߟߥߋ㧨ਇᅧᴦ≮ߩⓨ⊕࿾Ꮺ㧪㧦ጘ㒂ᣂ⡞(2008 ᐕ 5 ᦬ 9 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔᒰೋߩ⋡⊛ߢ޽ࠆ‫⑼↥ޟ‬ⅣႺߩᢛ஻‫ߪޠ‬ᢛ஻ߐࠇߟߟ޽ࠆ‫ߦ․ޕ‬Უ૕ᢇᕆ៝ㅍࡑ࠾ࡘࠕ࡞ߪో࿖⊛߽⹏ଔߐࠇߡ޿ࠆ‫⊛ੱޕ‬㓸⚂ൻ㧔3 ᣉ⸳㧕߽ቢੌߒߚ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻ╷৻ᣇ㧘ߘߩ෻േߢ 1㧕㘧㛗࿾඙ߩ↥⑼૕೙ߩᢛ஻߇ㆃࠇߡ޿ࠆߎߣ㧘2㧕⣲≌ක≮߿ਇᅧ∝ߩࠤࠕߦߒ
ࠊነߖ߇෸ࠎߢ޿ࠆߎߣߪุቯߢ߈ߥ޿‫ޕ‬੹ᓟߩዷᦸ⋵ో૕ߩ࿾ၞᩰᏅߩᤚᱜ㧘ᇚੱ⑼⸻≮ߩᐔဋൻ߇੹ᓟߩ⺖㗴ߢ޽ࠆ‫ޕ‬㧙㧙㧔7㧕࿾ၞක≮කቇ࠮ࡦ࠲࡯㧔✚ว⥃ᐥ♽ಽ㊁㧕
1㧚⎇ⓥߩ᭎ⷐ
ߎࠇ߹ߢߣห᭽‫ޕ‬࿾ၞක≮ߦ߅ߌࠆᄢቇߩᓎഀ㧔࿾ၞߩ࠾࡯࠭ߣᄢቇߩ㑐ਈᣇᴺߥߤ㧕ߦߟ޿ߡᬌ⸛ߔ
ࠆ‫ޕ‬
2㧚ฬ★
⥃ᐥ⻠Ꮷ㧦 ศ↰㓉ᶈTakahiro Yoshida3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
ߥߒ⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
ߥߒ✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
ߥߒේ⪺㧔᰷ᢥ㧕ߥߒ

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄ߥߒ
2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬ
ߥߒ
2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ߥߒ
8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ
ߥߒ

㧙㧙

9㧚␠ળᵴേ
ߥߒ
10㧚ႎ๔ᦠߥߒ11㧚ႎ㆏ߥߒ12㧚⥄Ꮖ⹏ଔ
⹏ଔቇળᵴേߥߤ㧘ᢎຬߣߒߡߩ⹏ଔߢߪᢇᕆἴኂᢎຬߣߒߡߩ㧘ᄖ்ᢎ⢒ࠍⴕ߁ߥߤߒߡ޿ࠆ߇㧘࿾ၞක≮ߣߒߡߪ㧘ቇળᵴേߥߤߪߥ޿߇㧘㜞ጊ㧘ਅํߥߤ㧘ታോߦߟ޿ߡߪ᦬ 6 ࿁⒟ᐲⴕߞߡ߅ࠅ㧘ߎࠇߪᄢቇߢߩᵴേߣᐔⴕߒߡ߅ߎߥ߁ߎߣߪ㧘߆ߥࠅᄢᄌߢ޽ࠅ㧘⹏ଔߐࠇࠆߴ߈߽ߩߣ⠨߃ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ቇળᵴേ࡮⹏⺰ߥߤ߇චಽߦⴕ߃ߡ޿ߥ޿ߩߢ㧘ߘߜࠄߦߟ޿ߡߪ㧘ᢎ⢒ᵴേߩࠕࡦࠤ࡯࠻⚿ᨐ߿࿾ၞක≮ߩ⃻⁁ࠍ࠺࡯࠲ൻߒ㧘޿ߕࠇ߆ߩ႐㕙ߢ⊒⴫ߒߚ޿‫ޕ‬੹ᓟߩዷᦸ✚ว⥃ᐥ♽߇⃻࿷৻ੱߢߩᵴേߢ޽ࠅ㧘ੱ᧚Ⴧടߥࠄ߽߫߁ዋߒ⦡‫ߣࠆ߈ߢ߇ߣߎߥޘ‬⠨߃ࠆ߇㧘⃻⁁ߢߪ㧘ታ⁁ႎ๔⒟ᐲߩᵴേߒ߆ߢ߈ߥ޿ߚ߼㧘࿾㆏ߦขࠅ⚵߻ߒ߆ߥ޿‫ޕ‬㧙㧙㧔8㧕࿾ၞක≮කቇ࠮ࡦ࠲࡯㧔࿾ၞ߳߈࿾✚วක≮ಽ㊁㧕
1㧚⎇ⓥߩ᭎ⷐ
ᧄㇱ㐷ߪጘ㒂⋵߇⸳⟎ߔࠆነઃ⻠ᐳ‫ޟ‬࿾ၞක≮ቇ‫ߣޠ‬ㅪ៤ߒ߳߈࿾╬ߦ߅ߌࠆක≮ߩ⏕଻ߦ㑐ߔࠆਅ⸥ߩ⺞ᩏ⎇ⓥࠍⴕߞߡ޿ࠆ‫ޕ‬
1.߳߈࿾ࠍ฽߻࿾ၞߦ߅ߌࠆක≮࠾࡯࠭ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ
2.✚ว⊛ߥ⸻≮⢻ജࠍᜬߞߚකᏧࠍ㙃ᚑߔࠆߚ߼ߩᢎ⢒ߦ㑐ߔࠆ⎇ⓥ
3.߳߈࿾ක≮ࠍᡰេߔࠆߚ߼ߩࠪࠬ࠹ࡓߦ㑐ߔࠆ⎇ⓥ‫⎇ޣ‬ⓥ╬ߩౕ૕⊛ౝኈ‫ޤ‬⃻࿷ᧄ⋵ߩߺߥࠄߕో࿖ฦ࿾ߢක≮፣უ߇ต߫ࠇ㧘࿾ၞߦࠃߞߡᔅⷐߥක≮߇ฃߌࠄࠇߥ޿⁁ᴫ߇↢߹ࠇߡ޿ࠆ‫ߥࠎߘޕ‬ਛߢ࿾ၞߏߣߦ㒢ࠄࠇߚක≮⾗Ḯࠍᵴ↪ߒߡല₸⊛ߦක≮ࠨ࡯ࡆࠬࠍឭଏߔࠆ઀⚵ߺ૞ࠅ߇ᕆ߇ࠇߡ޿ࠆ‫⎇ᧄޕ‬ⓥߢߪ࿾ၞක≮ߣ޿߁ⷞὐ߆ࠄౕ૕⊛ߥᣇ╷ࠍឭ⸒ߔࠆߎߣࠍ⋡ᜰߒߡ޿ࠆ‫ޕ‬
1.߳߈࿾ࠍ฽߻࿾ၞߦ߅ߌࠆක≮࠾࡯࠭ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ
㧔1㧕⋡⊛߳߈࿾╬ࠍ฽߻࿾ၞߦ߅޿ߡᔅⷐߥක≮ឭଏࠪࠬ࠹ࡓࠍ᭴▽ߔࠆߚ߼ߤߩࠃ߁ߥක≮࠾࡯࠭߇޽ࠆ
߆ࠍ⺞ᩏߔࠆ‫ޕ‬
㧔2㧕ౝኈߣᚻᴺ
Ԙ߳߈࿾╬ߦ߅ߌࠆஜᐽ໧㗴ߩ㗫ᐲ⺞ᩏ߳߈࿾╬ߦ߅޿ߡᣣᏱ⊛ߦ⊒↢ߔࠆஜᐽ໧㗴ߦߟ޿ߡ㧘߳߈࿾╬ߩක≮ᯏ㑐ฃ⸻ߔࠆᖚ⠪ߩฃ⸻ℂ↱㧘∔∛╬ࠍ⺞ᩏߔࠆ‫ޕ‬ԙ߳߈࿾ࠍ฽߻࿾ၞߩੑᰴක≮ᯏ㑐ߩ౉㒮ᖚ⠪ߩ∔∛⺞ᩏ࿾ၞߩੑᰴ∛㒮ߢߩ౉㒮ᖚ⠪ߩ⸻≮㍳╬ࠍ⺞ᩏߔࠆ‫ޕ‬
㧔3㧕ᦼᓙߐࠇࠆലᨐ
࿾ၞߢቢ⚿ߔߴ߈ක≮࠾࡯࠭ࠍ⺞ᩏߔࠆߎߣߦࠃߞߡ㧘࿾ၞߦᔅⷐߥක≮ឭଏߩ࡟ࡌ࡞ߣࠨ࡯ࡆࠬ㊂ࠍ⏕⹺ߔࠆ‫ޕ‬
2.✚ว⊛ߥ⸻≮⢻ജࠍᜬߞߚකᏧࠍ㙃ᚑߔࠆߚ߼ߩᢎ⢒ߦ㑐ߔࠆ⎇ⓥ
㧔1㧕⋡⊛
߳߈࿾╬ߢዋߥ޿කᏧᢙߢᄙ᭽ߥක≮࠾࡯࠭ߦᔕ߃ࠆߚ߼ߦߪ㧘৻ੱߩකᏧ߇✚ว⊛ߦኻᔕߔࠆߎߣ
߇ᔅⷐߢ㧘ߘ߁޿ߞߚකᏧࠍ㙃ᚑߔࠆߚ߼ߩᣇ╷ߦߟ޿ߡ⎇ⓥߔࠆ‫ޕ‬
㧔2㧕ౝኈߣᚻᴺ
Ԙ߳߈࿾⸻≮ᚲකᏧߩታᘒ⺞ᩏ⃻࿷߳߈࿾⸻≮ᚲߦൕോߔࠆකᏧ߆ࠄ㧘߳߈࿾ක≮ࠍᜂ߁ߚ߼ߩᔅⷐߥᛛ⢻㧘⍮⼂ߦߟ޿ߡ⺞ᩏߔࠆ‫ޕ‬ԙ✚ว⊛ߥ⸻≮⢻ജࠍᜬߟකᏧࠍ⢒ᚑߔࠆᢎ⢒⎇ୃߦ㑐ߔࠆ⺞ᩏ⎇ⓥో࿖ߢขࠅ⚵߹ࠇߡ޿ࠆ㧘✚ว⊛ߥ⸻≮⢻ജࠍᜬߟකᏧߩߚ߼ߩත೨ᢎ⢒߿තᓟ⎇ୃߦߟ޿ߡታᘒ
ࠍ⺞ᩏߔࠆ‫ޕ‬Ԛ✚วක⢒ᚑࡊࡠࠣ࡜ࡓߩ╷ቯᧄቇߦ߅޿ߡታⴕߢ߈ࠆත೨ᢎ⢒ߦ߅ߌࠆ࿾ၞක≮ታ⠌㧘තᓟ⎇ୃߦ߅ߌࠆ࿾ ၞක≮⎇ୃ㧘✚วකࠍ⋡ᜰߔᓟᦼ⎇ୃࡊࡠࠣ࡜ࡓࠍ╷ቯߔࠆ‫ޕ‬
㧔3㧕ᦼᓙߐࠇࠆലᨐ
዁᧪⋵ౝߩ࿾ၞක≮ࠍⓍᭂ⊛ߦᜂ߅߁ߣߔࠆකᏧࠍ㙃ᚑߔࠆߎߣ߇น⢻ߣߥࠆ‫ޕ‬
2㧚ฬ★
․છᢎ᝼㧦 ጊ↰ 㓉

Takashi Yamada

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ጊ↰㓉ม㧚⃻႐߆ࠄߩឭ⸒㧙ක≮ౣ↢߳ߩࡆ࡚ࠫࡦ㧦කᏧਇ⿷ߣ࿾ၞක≮ߩ፣უ 2㧘 ᧲੩㧦ᣣᧄක≮ડ↹㧧2008 ᐕ㧦250㧙266㧚⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 ጊ↰㓉ม㧚࿾ၞක≮ࠍ቞ࠆߚ߼ߦ㧙කᏧߩ┙႐߆ࠄ㧙㧘࿖㓙ᢥൻ⎇ୃ 2008 ᐕ㧧60 ภ㧦56㧙60㧚㧙㧙

2㧕 ጊ↰㓉ม㧚⠧ᐕ✚วකߩዷᦸ㧙ኅᐸක≮࡮߳߈࿾ක≮ߩ┙႐߆ࠄ㧙㧘ᣣᧄ⠧ᐕකቇળ⹹ 2008 ᐕ㧚✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
ߥߒේ⪺㧔᰷ᢥ㧕
ߥߒ

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄ߥߒ
2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬጊ↰㓉ม㧦
1㧕 ᣣᧄኅᐸක≮ቇળઍ⴫ℂ੐(㨪⃻࿷)2㧕 ᣣᧄࡊ࡜ࠗࡑ࡝࡮ࠤࠕቇળ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅ጊ↰㓉ม㧦
1㧕 ╙ 29 ࿁කቇᢎ⢒⎇ୃ࠮ࡒ࠽࡯࡮ࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 19 ᐕ 8 ᦬㧘ጘ㒂)2㧕 ╙ 2 ࿁߳߈࿾࡮࿾ၞක≮ቇળ(ᐔᚑ 20 ᐕ 8 ᦬㧘᧲੩)
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ጊ↰㓉ม㧦
1㧕 කᏧ⥃ᐥ⎇ୃ೙ᐲ࡮⎇ୃ▤ℂᆔຬળ࡮ᆔຬ㐳⎇ୃ(ᐔᚑ 20 ᐕ 1 ᦬㧘ၯ₹㧘․೎⻠Ṷ೎‫ޟ‬࿾ၞ߆ࠄ⷗
ߚᄢቇߩขࠅ⚵ߺ́࿾ၞක≮ቇ⻠ᐳ(ጘ㒂⋵ነ㒝⻠ᐳ)ߩᓎഀ‫ޠ‬Ṷ⠪)
2㧕 ╙ 34 ࿁ජ⪲᧲ᵗකቇࠪࡦࡐࠫ࠙ࡓ(ᐔᚑ 20 ᐕ 3 ᦬㧘ජ⪲㧘․೎⻠Ṷ‫ߗߥ੹ޟ‬ኅᐸක࡮✚วක߇᳞߼
ࠄࠇߡ޿ࠆߩ߆‫ޠ‬Ṷ⠪)
3㧕 ╙ 8 ࿁ᗲᇫࡊ࡜ࠗࡑ࡝ࠤࠕ⎇ⓥળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ᗲᇫ㧘․೎⻠Ṷ‫ޟ‬࿾ၞක≮ߣ✚วක‫ޠ‬Ṷ⠪)4㧕 COML ක≮ࡈࠜ࡯࡜ࡓ 2008(ᐔᚑ 20 ᐕ 5 ᦬㧘ᄢ㒋㧘ࠪࡦࡐࠫ࠙ࡓ‫ߩߢ✢৻╙ޟ‬ℂᗐߩᖚ⠪࡮ක≮⠪㑐ଥ‫ޠ‬Ṷ⠪)
5㧕 ╙ 59 ࿁⟲ᤊᴒ✽⥃ᐥᢎ⢒࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 11 ᦬㧘ᴒ✽㧘᜗⡜⻠Ṷ‫ޟ‬㔌ፉ࡮߳߈࿾ක≮ߣ✚วක‫ޠ‬Ṷ⠪)
6㧕 ක≮ߦ߅ߌࠆ቟ᔃ࡮Ꮧᦸ⏕଻ߩߚ߼ߩኾ㐷ක࡮ኅᐸක㧔කᏧᓟᦼ⎇ୃ೙ᐲ㧕ߩ޽ࠅᣇߦ㑐ߔࠆ⎇ⓥ⃰(ᐔᚑ 20 ᐕ 12 ᦬㧘᧲੩㧘․೎⻠Ṷ‫ޟ‬࿾ၞක≮ߣ✚วක‫ޠ‬Ṷ⠪)7㧕 21 ਎♿ṽᣇකቇࡈࠜ࡯࡜ࡓ(ᐔᚑ 20 ᐕ 12 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ‫✚ޟ‬วකߦ߅ߌࠆṽᣇᢎ⢒ࠍ⠨߃ࠆ‫ޠ‬Ṷ⠪)㧙㧙8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേ
ߥߒ
10㧚ႎ๔ᦠߥߒ11㧚ႎ㆏
1㧕 ጊ↰㓉ม㧦කᏧߣᖚ⠪ߩା㗬߇ߟߜ߆ࠊࠇࠆ႐ᚲ㧙࿾ၞක≮ߩⷞὐ߆ࠄ⠨߃ࠆකᏧਇ⿷໧㗴㧦ࠝࡦ࡜ࠗࡦࡑࠟࠫࡦ(2008 ᐕ 1 ᦬ 28 ᣣ)2㧕 ጊ↰㓉ม㧦ᖚ⠪ߦㆡߒߚല₸⊛ߥක≮ߩឭଏࠍ⋡ᜰߒߡ㧙ᖚ⠪࡮ኅᣖ࡮࿾ၞࠍᾫ⍮ߔࠆኅᐸකࠍ⢒ᚑ㧙㧦⮎੐ᣣႎ(2008 ᐕ 2 ᦬)
3㧕 ጊ↰㓉ม㧦⑔␩ࡀ࠶࠻ࡢ࡯ࠢ㧦NHK ᢎ⢒(2008 ᐕ 2 ᦬ 12 ᣣ)
4㧕 ጊ↰㓉ม㧦ੱ㧦ᣣᧄක੐ᣂႎ(2008 ᐕ 10 ᦬ 25 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔᒰㇱ㐷ߪ㐿⸳㑆߽ߥ޿ߎߣ߆ࠄ⎇ⓥߦߟ޿ߡ⺞ᩏ⎇ⓥߩᬺ❣ߪዋߥ޿ߎߣߪุ߼ߥ޿⃻࿷ߪ࿾ၞᨒቇ
↢ߩࠞ࡝ࠠࡘ࡜ࡓᄖߢߩ੺㧘ౕ૕⊛ߦߪ࿾ၞක≮ߦ㑐ߔࠆ࠯ࡒ࠽࡯࡞ߩቯᦼ㐿௅߿㧘ቇᄖߢߩ࿾ၞක≮ߦ㑐ߔࠆળว߳ߩෳടߥߤࠍⓍᭂ⊛ߦⴕ޿㧘዁᧪࿾ၞක≮ߦะ߆߁කቇ↢ߩ⢒ᚑߦߟ޿ߡขࠅ⚵ࠎߢ޿ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷⎇ⓥ㧘ᢎ⢒ߦߟ޿ߡߪ߹ߛቯဳ⊛ߥขࠅ⚵ߺߦߪ⥋ߞߡ޿ߥ޿‫ޕ‬ጘ㒂⋵㧘⥄ᴦක⑼ᄢቇතᬺ↢ߣㅪ៤ߒ㧘ౕ૕⊛ߥ⎇ⓥ㧘ᢎ⢒ߦ⌕ᚻߔࠆ੍ቯߢ޽ࠆ‫ޕ‬੹ᓟߩዷᦸ੹ᓟකቇㇱ࿾ၞᨒቇ↢߇⏕ታߦჇ߃ߡߊࠆߎߣ߆ࠄ߽ᒰㇱ㐷෸߮࿾ၞක≮ቇ⻠ᐳߩ㊀ⷐᕈߪჇߒߡߊ
ࠆߣᕁࠊࠇࠆ‫ోߚ߹ޕ‬࿖ߩห᭽ߩㇱ㐷ߣࡀ࠶࠻ࡢ࡯ࠢࠍ᭴▽ߒߡ࿾ၞක≮ߦ㑐ߔࠆ⾰ߩ㜞޿⎇ⓥߣᢎ⢒ߦ⽸₂ߒߡ޿߈ߚ޿‫ޕ‬㧙㧙㧔9㧕කቇᢎ⢒㐿⊒⎇ⓥ࠮ࡦ࠲࡯㧔࠴ࡘ࠻࡯࡝ࠕ࡞ㇱ㐷㧕1㧚⎇ⓥߩ᭎ⷐ
කቇᢎ⢒ߦ߅ߌࠆో࿖౒ห೑↪ᣉ⸳ߣߒߡ㧘
㧔1㧕ᣂߒ޿කቇᢎ⢒ߩ㐿⊒⎇ⓥߣ᥉෸㧘
㧔2㧕කቇᢎ⢒ߦ⽸₂ߢ߈ࠆੱ᧚⢒ᚑ㧘
㧔3㧕࿖ౝᄖߩකቇᢎ⢒ᯏ㑐ߣߩㅪ៤࡮౒ห⎇ⓥ㧘ࠍᄢ߈ߥࡒ࠶࡚ࠪࡦߣߒߡขࠅ⚵ࠎߢ޿ࠆ‫ޕ‬
ԘPBL ࠹ࡘ࠻࡯࡝ࠕ࡞ᢎ⢒㧦ᄖㇱߦะߌߚ PBL ߦ㑐ߔࠆ࠮ࡒ࠽࡯࡮ࡢ࡯࡚ࠢࠪ࠶ࡊࠍડ↹ߔࠆߣߣ߽
ߦ㧘ጘ㒂ᄢቇߦ߅ߌࠆ࠹ࡘ࠻࡯࡝ࠕ࡞ᢎ⢒ 10 ᐕߩ⚻㛎ࠍᬌ⸽ߒ㧘ࠃࠅㅴൻߒߚ PBL ࠹ࡘ࠻࡯࡝ࠕ࡞ᢎ
⢒ࠪࠬ࠹ࡓߩ᭴▽ࠍ߼ߑߒߡ޿ࠆ‫ޕ‬ԙࠗࡦ࠲࡯ࡀ࠶࠻ PBL㧦ᄢቇ߿ቇㇱߩ၂ᩮࠍ⿧߃㧘޿ߟߢ߽㧘ߤߎ߆ࠄߢ߽ෳടߢ߈ࠆ⢻േ⊛෺ᣇะᕈ Web-PBL ࠪࠬ࠹ࡓࠍ㧘ో࿖ߩᢎຬ࡮ቇ↢ߣදജߒߥ߇ࠄ㐿⊒ߒ㧘ታ↪ൻߩᲑ㓏ߦ౉ߞߡ޿ࠆ‫ޕ‬ቇㇱ↢ࠦ࡯ࠬߩઁߦ㧘⧷⺆ࠦ࡯ࠬ㧘ᄢቇ㒮ࠦ࡯ࠬ㧘⥃ᐥࠦ࡯ࠬߥߤ㧘ᄙᓀߥࡊࡠࠣ࡜ࡓࠍ↪ᗧߒߡ޿ࠆ‫ޕ‬Ԛක≮ࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦ࡮ࡊࡠࡈࠚ࠶࡚ࠪ࠽࡝࠭ࡓᢎ⢒㧦ᮨᡆᖚ⠪ߦࠃࠆක≮㕙ធᢎ⢒ᴺߩ⎇ⓥߣታ〣ࠍㅴ߼ߡ޿ࠆ‫ޕ‬4 ᐕ↢࡮5 ᐕ↢ߦኻߔࠆක≮㕙ធታ⠌㧘ᄖㇱߦะߌߚ࠮ࡒ࠽࡯࡮
㧘21 ᐕᐲ߆ࠄ 2ࡢ࡯࡚ࠢࠪ࠶ࡊࠍታᣉߒߡ޿ࠆ‫ޕ‬ᐔᚑ 20 ᐕᐲ߆ࠄ 1 ᐕ↢ߦኻߔࠆ࿾ၞ૕㛎ታ⠌㧔8 ㅳ㑆㧕ᐕ↢ߦኻߔࠆකᏧᖚ⠪㑐ଥߩ᝼ᬺߥߤ㧘੹ᓟ㧘♽⛔⊛ߥⴕേ⑼ቇᢎ⢒ߩዉ౉ࠍ⋡ᜰߒߡ޿ࠆ‫ޕ‬ԛ⥃ᐥࠪࡘࡒ࡟࡯࡚ࠪࡦᢎ⢒ߣࡃ࡯࠴ࡖ࡞ᢎ᧚ߩ㐿⊒㧦⥃ᐥ౉㐷߆ࠄතᓟᢎ⢒ߦ⥋ࠆ᏷ᐢ޿ᤨᦼߦ㧘ലᨐ⊛ߥࠪࡒࡘ࡟࡯࡚ࠪࡦᢎ⢒߇ⴕ߃ࠆࠃ߁ߦ㧘ࡂ࡯࠼࡮࠰ࡈ࠻ਔ㕙߆ࠄࡕ࠺࡞ߣߥࠅ߁ࠆ⥃ᐥࠬࠠ࡞࡮ࠪࡒࡘ࡟࡯࡚ࠪ
ࡦ࠮ࡦ࠲࡯ߩ᭴▽ࠍ߼ߑߒߡ޿ࠆ‫ߚ߹ޕ‬り૕⸻ኤ߿㕙ធ߇น⢻ߥᖚ⠪ࡠࡏ࠶࠻㧘ࡔ࠺ࠖࠞ࡞࡮ࠗ࡜ࠬ࠻㧘Web ⥄Ꮖቇ⠌ᢎ᧚ߥߤߩ㐿⊒ࠍㅴ߼ߡ޿ࠆ‫ޕ‬ᐔᚑ 19 ᐕᐲ߆ࠄ⃻ઍ⊛ᢎ⢒࠾࡯࠭ข⚵ᡰេࡊࡠࠣ࡜ࡓ‫⥃ޟ‬ᐥකቇᢎ⢒ࠍᒝൻะ਄ߐߖࠆ ICT‫߇ޠ‬ណᛯߐࠇ㧘⎇ⓥ੐ᬺߩଦㅴ߇࿑ࠄࠇߡ޿ࠆ‫ޕ‬Ԝᣂ⥃ᐥታ⠌ࠪࠬ࠹ࡓߩ⎇ⓥ㐿⊒㧦੹ᐕ߆ࠄᆎ߹ߞߚᣂ᭴ᗐߩጘ㒂ᄢቇဳࠢ࡝࠾ࠞ࡞࡮ࠢ࡜࡯ࠢࠪ࠶ࡊࠍផㅴ࡮ᬌ⸽ߒ㧘ࠪࠬ࠹ࡓߣߒߡ⏕┙ߐߖࠆ⎇ⓥࠍⴕߞߡ޿ࠆ‫ޕ‬ԝකቇᢎ⢒࠮ࡒ࠽࡯㧒ࡢ࡯࡚ࠢࠪ࠶ࡊ㧦ᐕ 4 ࿁㧘ㅢ▚ 30 ࿁㐿௅ߒ㧘ߩߴෳട⠪ᢙߪ 3000 ฬࠍ⿧߃ߡ޿ࠆ‫ޕ‬කቇᢎ⢒ಽ㊁ߩో࿖ FD ߣߒߡቯ⹏ࠍᓧ㧘౒ห⎇ⓥߩផㅴߦ߽ᄢ߈ߥᓎഀࠍᨐߚߒߡ޿ࠆ‫ޕ‬Ԟකቇᢎ⢒࡙࠾࠶࠻ߩળ㧦ㄭᐕ㧘ฦᄢቇߢ⸳┙ߐࠇߚකቇᢎ⢒ㇱ㐷㧔࡙࠾࠶࠻㧕ߩㅪ៤⚵❱ࠍᒻᚑߒ㧘ᖱႎ੤឵࡮౒ห⎇ⓥߩଦㅴࠍ࿑ߞߡ޿ࠆ‫ޕ‬කቇᢎ⢒ቇ⎇ⓥߣᄢቇ㒮࡟ࡌ࡞ߩᢎ⢒ߩࠦࡦ࠰࡯ࠪࠕࡓᒻᚑࠍ߼ߑߒߡ޿ࠆ‫ޕ‬ԟᖱႎ⊒ା㧦ࡎ࡯ࡓࡍ࡯ࠫࠍᵴ↪ߒߡ㧘ࠗࡦ࠲࡯ࡀ࠶࠻࡮࠹
ࡘ࠻࡯࡝ࠕ࡞㧘ක≮㕙ធታ⠌㧘࠮ࡒ࠽࡯㧒ࡢ࡯࡚ࠢࠪ࠶ࡊ㧘ቇോ੐ോᖱႎ㧘ࠗࡦ࠲࡯ࡀ࠶࠻࡮ࠫࡖ࡯࠽࡞
ߥߤߩᦨᣂᖱႎࠍ⊒ାߒߡ޿ࠆ‫ޕ‬Ԡᄢቇ㒮‫ޟ‬කቇᢎ⢒ಽ㊁‫ߩޠ‬㐿⸳㧦ᐔᚑ 20 ᐕᐲ㧔2008 ᐕ 4 ᦬㧕ࠃࠅጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼ක≮▤ℂቇ⻠ᐳߦ‫ޟ‬කቇᢎ⢒ቇ‫ޠ‬ಽ㊁߇㐿⻠ߒ㧘ᄢቇ㒮↢ 1 ฬߩ౉ቇ߇޽ߞߚ‫ޕ‬ԡ࿖㓙੤ᵹ㧦Ფᐕ 1 ฬߩቴຬᢎ᝼ࠍ᜗⡜ߒ㧘࿖ౝߦ߅ߌࠆකቇᢎ⢒⎇ⓥߩផㅴߣ࿖㓙੤ᵹߦ⽸₂ߒߡ޿ࠆ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
㋈ᧁᐽਯ
ᢎ᝼(૬છ)㧦 ਤ⠀㓷ਯ
ട⮮ᥓ⟤
ഥᢎ㧦
⧯ᨋ⧷᮸
ഥᢎ㧦

Yasuyuki Suzuki
Masayuki Niwa
Tomomi Kato
Hideki Wakabayashi

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’05 ౻㧙╙ 15 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2006 ᐕ㧦1㧙94㧚
2㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’05 ᤐ㧙╙ 16 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2006 ᐕ㧦1㧙124㧚
3㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’05 ᄐ㧙╙ 17 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2006 ᐕ㧦1㧙211㧚
4㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’05 ⑺㧙╙ 18 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2006 ᐕ㧦1㧙112㧚
5㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’06 ౻㧙╙ 19 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2006 ᐕ㧦1㧙110㧚
6㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’06 ᤐ㧙╙ 20 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2006 ᐕ㧦1㧙185㧚
7㧕 ㋈ᧁᐽਯ㧚ࡓࠦᄙ♧∝ 1 ဳ㧦㛽♽⛔∔ᖚࡑ࠾ࡘࠕ࡞ᡷ⸓╙ 2 㧘᧲੩㧦ධᳯၴ㧧2008 ᐕ㧦120㧙121㧚
8㧕 ㋈ᧁᐽਯ㧚ࡓࠦᄙ♧∝ 2 ဳ㧦㛽♽⛔∔ᖚࡑ࠾ࡘࠕ࡞ᡷ⸓╙ 2 㧘᧲੩㧦ධᳯၴ㧧2008 ᐕ㧦122㧙123㧚
9㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’06 ᄐ㧙╙ 21 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2007 ᐕ㧦1㧙237㧚
10㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’06 ⑺㧙╙ 22 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ

㧙㧙࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2007 ᐕ㧦1㧙89㧚
11㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’07 ౻㧙╙ 23 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2007 ᐕ㧦1㧙120㧚
12㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’07 ᤐ㧙╙ 24 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2007 ᐕ㧦1㧙152㧚
13㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’07 ᄐ㧙╙ 25 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2007 ᐕ㧦1㧙121㧚
14㧕 ਤ⠀㓷ਯ㧚ਛᨔ␹⚻૞↪⮎㧦ᬀ᧻ବᒾ㧘㊄ਣశ㓉✬㧚ᣂ૕♽⋴⼔ቇోᦠ 5 ∔∛ߩᚑࠅ┙ߜߣ࿁ᓳߩଦㅴԚ
⮎ℂቇ㧘᧲੩㧦ࡔ࠵ࠞ࡞ࡈ࡟ࡦ࠼␠㧧2007 ᐕ㧦73㧙101㧚
15㧕 ਤ⠀㓷ਯ㧚ᶖൻེ૞↪⮎㧦ᬀ᧻ବᒾ㧘㊄ਣశ㓉✬㧚ᣂ૕♽⋴⼔ቇోᦠ 5 ∔∛ߩᚑࠅ┙ߜߣ࿁ᓳߩଦㅴԚ⮎ℂቇ㧘᧲੩㧦ࡔ࠵ࠞ࡞ࡈ࡟ࡦ࠼␠㧧2007 ᐕ㧦143㧙153㧚
16㧕 ਤ⠀㓷ਯ㧚᛫ᖡᕈ⣲≌⮎㧔᛫≸⮎㧕㧦ᬀ᧻ବᒾ㧘㊄ਣశ㓉✬㧚ᣂ૕♽⋴⼔ቇోᦠ 5 ∔∛ߩᚑࠅ┙ߜߣ࿁ᓳߩ
ଦㅴԚ⮎ℂቇ㧘᧲੩㧦ࡔ࠵ࠞ࡞ࡈ࡟ࡦ࠼␠㧧2007 ᐕ㧦191㧙203㧚
17㧕 ਤ⠀㓷ਯ㧚᛫Ἳ∝⮎࡮⸃ᾲ㎾∩⮎࡮᛫ࠕ࡟࡞ࠡ࡯⮎࡮఺∉ᛥ೙⮎㧦ᬀ᧻ବᒾ㧘㊄ਣశ㓉✬㧚ᣂ૕♽⋴⼔ቇ
ోᦠ 5 ∔∛ߩᚑࠅ┙ߜߣ࿁ᓳߩଦㅴԚ⮎ℂቇ㧘᧲੩㧦ࡔ࠵ࠞ࡞ࡈ࡟ࡦ࠼␠㧧2007 ᐕ㧦205㧙224㧚
18㧕 ㋈ᧁᐽਯ㧚⢽⾰⫾Ⓧ∝㧔࡝ࡇ࠼࡯ࠪࠬ㧕㧦⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦230㧙231㧚
19㧕 ㋈ᧁᐽਯ㧚ᩭ㉄ઍ⻢⇣Ᏹ∝㧔Lesch-Nyhan ∝୥⟲㧕㧦⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦
232㧙233㧚
20㧕 ㋈ᧁᐽਯ㧚කቇᢎ⢒㧦ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦309㧙313㧚
21㧕 ㋈ᧁᐽਯ㧚adrenoleukodystrophy (ALD)㧦ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦484㧙486.
22㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’07 ⑺㧙╙ 26 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2008 ᐕ㧦1㧙100㧚
23㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’08 ౻㧙╙ 27 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2008 ᐕ㧦1㧙130㧚
24㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’08 ᤐ㧙╙ 28 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2008 ᐕ㧦1㧙152㧚
25㧕 ਤ⠀㓷ਯ㧚⸃ᾲ㎾∩⮎࡮᛫Ἳ∝⮎㧦㊁᧛㓉⧷㧘⍹Ꮉ⋥ਭ✬㧚ࠪࡦࡊ࡞⮎ℂቇ‫ޣ‬ᡷ⸓╙ 4 ‫ޤ‬㧘᧲੩㧦ධᳯၴ㧧
2008 ᐕ㧦229㧙245㧚⪺ᦠ㧔᰷ᢥ㧕
1㧕 Suzuki Y, Niwa M, Shibata T, Chirasak K, Ariyawardana A, Ramesh JC, Evans P, Takahashi Y.
Internet PBL: International Collaborative Learning Experiences In: Oon-Seng Tan, ed. Problem-based
Learning in E-learning Breakthroughs. Singapore: Thomson Learning; 2007:131-146.
2㧕 Hara A, Niwa M, Aoki H, Taguchi A, Yamada Y, Mori H. New research on neuronal networks. In:
Neuronal Network Research Horizons, ed. Weiss ML: Nova Science Publish; 2007:99-118.
3㧕 Hara A, Oka N, Aoki H, Taguchi A, Yamada Y, Niwa M, Mori H. OCT-3/4 Expressing Cells as Cancer
Stem Cells in Human Immature Teratoma: Cancer Differentiation Potential. In: Saitama H ed. New
Cell Differentiation Research Topics. New York: Nova Science Publisher; 2008:1-6.
✚⺑㧔๺ᢥ㧕
1㧕 ਅỈિⴕ㧘㋈ᧁᐽਯ㧚ࡍ࡞ࠝࠠࠪ࠰࡯ࡓ∛-ࠊ߇࿖ߢ∛㒮߇⸃᣿ߐࠇߚవᄤઍ⻢⇣Ᏹ∝㧘ዊఽ⑼⸻≮ 2006
ᐕ㧧69 Ꮞ㧦1646㧙1652㧚
2㧕 ㋈ᧁᐽਯ㧚㛽∝⁁ߢ⷗ߟ߆ࠆవᄤઍ⻢⇣Ᏹ∝-ᣣᏱ⸻≮ߢߩవᄤઍ⻢⇣Ᏹ∝㧘ዊఽ⑼⸻≮ 2006 ᐕ㧧69 Ꮞ㧦
1590㧙1594㧚
3㧕 ਅỈિⴕ㧘㋈ᧁᐽਯ㧚ࡍ࡞ࠝࠠࠪ࠰࡯ࡓᒻᚑ⇣Ᏹ∝ –Zellweger ∝୥⟲ࠍਛᔃߦ㧘ዊఽౝ⑼ 2007 ᐕ㧦39
ภ㧦536㧙538㧚
4㧕 ㋈ᧁᐽਯ㧚ࡓࠦᄙ♧∝㧘ዊఽౝ⑼ 2007 ᐕ㧦39 ภ㧦503㧙504㧚
✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ㋈ᧁᐽਯ㧚ጘ㒂ᄢቇකቇㇱකቇᢎ⢒㐿⊒⎇ⓥ࠮ࡦ࠲࡯㧔ో࿖౒ห೑↪ᣉ⸳㧕࡮කቇᢎ⢒ડ↹㐿⊒ቶ㧘කቇᢎ⢒ 2006 ᐕ㧧37 Ꮞ㧦54㧙55㧚
2㧕 ㋈ᧁᐽਯ㧘㜞ᯅቁ㓶㧘ਛ⇌㦖ବ㧘ᅏጊ⋿♿ሶ㧘᧻የ㓷ᢥ㧘ႇ ⵨ᐘ㧘੖ච፲㓉㧘ᴡ㊁㓁৻㧘ฎᎹ ẋ㧘ේኼ㇢㧚ᣣᧄዊఽ⑼ቇળᢎ⢒ᆔຬળႎ๔ ዊఽ⑼ත೨⥃ᐥታ⠌ߦ㑐ߔࠆࠕࡦࠤ࡯࠻⺞ᩏ⚿ᨐ㧘ᣣᧄዊఽ⑼ቇ
ળ㔀⹹ 2008 ᐕ㧧112 Ꮞ㧦793㧙801㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Kato T, Isogai K, Orii K, Kuratsubo I, Kondo N, Orii T, Suzuki Y. Portal hypertension in a patient withHunter disease. J Inherit Metab Dis. 2006;29:686.
IF 1.668
2㧕 Funato M, Shimozawa N, Nagase T, Takemoto Y, Suzuki Y, Imamura Y, Matsumoto T, Tsukamoto T,
Kojidani T, Osumi T, Fukao T, Kondo N. Aberrant peroxisome morphology in peroxisomal㧙㧙beta-oxidation enzyme deficiencies. Brain Dev. 2006;28:287-292.
3㧕 Hara A, Niwa M, Kumada M, Aoki H, Kunisada T, Oyama T, Yamamoto T, Kozawa O, Mori H.
Intraocular injection of folate antagonist methotrexate induces neuronal differentiation of embryonicstem cells transplanted in the adult mouse retina. Brain Res. 2006;1085:33-42.
4㧕 Hara A, Niwa M, Aoki H, Kumada M, Kunisada T, Oyama T, Yamamoto T, Kozawa O, Mori H. A newmodel of retinal photoreceptor cell degeneration induced by a chemical hypoxia-mimicking agent,cobalt chloride. Brain Res. 2006;1109:192-200.
5㧕 Niwa M, Hotta K, Hara A, Hirade K, Ito H, Kato K, Kozawa O. TNF-alpha decreases hsp 27 in humanblood mononuclear cells: involvement of protein kinase C. Life Sci. 2006;80:181-186.
6㧕 Kato T, Kato Z, Kuratsubo I, Ota T, Orii T, Kondo N, Suzuki Y. Evaluation of ADL in patients withHunter disease using FIM score. Brain Dev. 2007;29:298-305.
7㧕 Ochiai T, Suzuki Y, Kato T, Shichino H, Chin M, Mugishima H, Orii T. Natural history of extensive
Mongolian spots in mucopolysaccharidosis type II (Hunter syndrome): a survey amond 52 Japanesepatients. J Eur Acad Dermatol Venereol. 2007;21:1082-1085.
8㧕 Takahashi N, Morita M, Maeda T, Harayama Y, Shimozawa N, Suzuki Y, Furuya H, Sato R,
Kashiwayama Y, Imanaka T. Adrenoleukodystrophy: subcellular localization and degradation ofadrenoleukodystrophy protein (ALDP/ABCD1) with naturally occurring missense mutations. J
Neurochem. 2007;101:1632-1643.
9㧕 Aoki H, Hara A, Niwa M, Motohashi T, Suzuki T, Kunisada T. An in vitro mouse model for retinal
ganglion cell replacement therapy using eye-like structures differentiated from ES cells. Exp Eye Res.
2007;84:868-875.
10㧕 Hara A, Taguchi A, Niwa M, Aoki H, Yamada Y, Ito H, Nagata K, Kunisada T, Mori H. Localization of
septin 8 in murine retina, and spatiotemporal expression of septin 8 in a murine model ofphotoreceptor cell degeneration. Neurosci Lett. 2007;423:205-210.
11㧕 Evans P, Suzuki Y. “Beyond Competence”. Why Should Outcomes be Adopted in Favour ofCompetences? Medical Education (Japan). 2008;39:87-91.
12㧕 Evans P, Suzuki Y. “Beyond Competence”, Assessment for Capability. Medical Education (Japan).
2008;39:93-96.
13㧕 Evans P, Suzuki Y, Begg M, Lam W. Can medical students from two cultures learn effectively from ashared web-based learning environment? Medical Education. 2008;42:27-33.
14㧕 Kuratsubo I, Suzuki Y, Shimozawa N, Kondo N. Parents of Childhood X-linked Adrenoleukodystrophy:
High Risk for Depression and Neurosis. Brain Dev. 2008;30:477-482.
15㧕 Morita M, Kanai M, Mizuno S, Iwashima M, Hayashi T, Shimozawa N, Suzuki Y, Imanaka T.
Baicalein 5,6,7-trimethyl ether activates peroxisomal but not mitochondrial fatty acid beta-oxidation.
J Inherit Metab Dis. 2008;31:442-449.
16㧕 Aoki H, Hara A, Niwa M, Motohashi T, Suzuki T, Kunisada T. Transplantation of cells from eye-likestructures differentiated from embryonic stem cells in vitro and in vivo regeneration of retinal
ganglion-like cells. Graefes Arch Clin Exp Ophthalmol. 2008;246:255-265.
17㧕 Hara A, Aoki H, Taguchi A, Niwa M, Yamada Y, Kunisada T, Mori H. Neuron-like differentiation andselective ablation of undifferentiated embryonic stem cells containing suicide gene with Oct-4
promoter. Stem Cells Dev. 2008;17:619-627.
18㧕 Taguchi A, Hara A, Saito K, Hoshi M, Niwa M, Seishima M, Mori H. Localization and spatiotemporal
expression of IDO following transient forebrain ischemia in gerbils. Brain Res. 2008;1217:78-85.

IF 1.464

IF 2.218

IF 2.218
IF 2.257
IF 1.464

IF 1.437

IF 4.451

IF 2.651

IF 2.085

IF 2.562
IF 1.464

IF 1.668

IF 1.590

IF 3.224
IF 2.2184㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦㜞ᯅఝਃ㧧ᢥㇱ⑼ቇ⋭․⦡޽ࠆᄢቇᢎ⢒ᡰេࡊࡠࠣ࡜ࡓ㧔․⦡ GP㧕㧦⢻േ࡮ᕁ⠨ଦㅴဳࠍᩇߣߔࠆోੱ⊛කቇᢎ⢒㧧ᐔᚑ 15㧙18 ᐕᐲ㧧60,000 ජ౞(15,000㧦15,000㧦15,000㧦15,000ජ౞)2㧕 ⎇ⓥઍ⴫⠪㧦㜞ᯅఝਃ㧘⎇ⓥදജ⠪㧦ਤ⠀㓷ਯ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌ၮ⋚⎇ⓥ(B)(2)㧦ࠦࠕ࡮ࠞ࡝
ࠠࡘ࡜ࡓኻᔕဳߩකቇታ⠌ᢎ᧚ߩ㐿⊒ߣ᥉෸㧧ᐔᚑ 16㧙17 ᐕᐲ㧧12,400 ජ౞(6,200㧦6,200 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦㋈ᧁᐽਯ㧘⎇ⓥදജ⠪㧦ਤ⠀㓷ਯ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌ၮ⋚⎇ⓥ(B)(2)㧦ో࿖೑↪น⢻ߥ⢻േ⊛ዊఽකቇᢎ⢒ࠪࠬ࠹ࡓߩ᭴▽㧧ᐔᚑ 16㧙17 ᐕᐲ㧧12,800 ජ౞(8,200㧦4,600 ජ౞)
4㧕 ⎇ⓥઍ⴫⠪㧦ⴡ⮮⟵ൎ㧘ಽᜂ⎇ⓥ⠪㧦㋈ᧁᐽਯ㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄㧔㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ㧕㧦࡜ࠗ࠰࠱࡯ࡓ∛㧔ࡈࠔࡉ࡝࡯∛฽߻㧕ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ⃰㧧ᐔᚑ 16㧙18 ᐕᐲ㧧3,550 ජ
౞(1,350㧦1,000㧦1,200 ජ౞)
5㧕 ⎇ⓥઍ⴫⠪㧦⷏Ỉᱜ⼾㧘ಽᜂ⎇ⓥ⠪㧦㋈ᧁᐽਯ㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌㧔㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ㧕㧦ㆇേᄬ⺞ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ⃰㧧ᐔᚑ 17㧙19 ᐕᐲ㧧3,700 ජ౞(1,300㧦1,300㧦1,100 ජ౞)
6㧕 ⎇ⓥઍ⴫⠪㧦ጊญᷡᰴ㧘ಽᜂ⎇ⓥ⠪㧦᛬ዬᔘᄦ㧘⎇ⓥදജ⠪㧦㋈ᧁᐽਯ㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌㧔ሶߤ߽ኅᐸ✚ว⎇ⓥ੐ᬺ㧕㧦ᚒ߇࿖ߩ 21 ਎♿ߦ߅ߌࠆᣂ↢ఽࡑࠬࠬࠢ࡝࡯࠾ࡦࠣߩ޽ࠅᣇߦ㑐ߔࠆ⎇㧙㧙ⓥ㧧ᐔᚑ 17㧙19 ᐕᐲ㧧600 ජ౞(200㧦200㧦200 ජ౞)
7㧕 ⎇ⓥઍ⴫⠪㧦ਤ⠀㓷ਯ㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌㧦CoCl2 ߩㆬᛯ⊛ⷞ␹⚻㓚ኂࡕ࠺࡞ߩ⏕┙㧧ᐔᚑ 18 ᐕᐲ㧧900 ජ౞8㧕 ⎇ⓥઍ⴫⠪㧦᧻ේᵗ৻㧘ಽᜂ⎇ⓥ⠪㧦ᅏጊ⯥ਯ㧘⎇ⓥදജ⠪㧦㋈ᧁᐽਯ㧧ᚑ⢒ක≮ᆔ⸤⎇ⓥ⾌㧦వᄤઍ⻢⇣Ᏹ∝ߩ⸻ᢿࡀ࠶࠻ࡢ࡯ࠢࠍ੺ߒߚ㐳ᦼ੍ᓟㅊ〔ࠪࠬ࠹ࡓߩ᭴▽㧧ᐔᚑ 18㧙19 ᐕᐲ㧧400 ජ౞(200㧦200 ජ౞)
9㧕 ⎇ⓥઍ⴫⠪㧦ጊญᷡᰴ㧘⎇ⓥಽᜂ⠪㧦᛬ዬᔘᄦ㧘⎇ⓥදജ⠪㧦㋈ᧁᐽਯ㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌㧔ሶߤ߽ኅᐸ✚ว⎇ⓥ੐ᬺ㧕㧦ࠊ߇࿖ߩ 21 ਎♿ߦ߅ߌࠆᣂ↢ఽࡑࠬࠬࠢ࡝࡯࠾ࡦࠣߩ޽ࠅᣇߦ㑐ߔࠆ⎇ⓥ⃰㧧ᐔᚑ 19㧙21 ᐕᐲ(200㧦150 ජ౞㧦ᧂቯ)㧦10㧕 ⎇ⓥઍ⴫⠪㧦ⴡ⮮⟵ൎ㧘⎇ⓥಽᜂ⠪㧦㋈ᧁᐽਯ㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌㧔․ቯ∔ᖚኻ╷⎇ⓥ੐ᬺ㧕࡜ࠗ࠰࠱࡯ࡓ∛ߩ∛ᘒߩ⸃᣿෸߮ᴦ≮ᴺߩ㐿⊒ߦ㑐ߔࠆ⎇ⓥ⃰㧧ᐔᚑ 19㧙21 ᐕᐲ㧧4,050 ජ౞(1,350㧦1,350㧦1,350 ජ౞)
11㧕 ⎇ⓥઍ⴫⠪㧦ਤ⠀㓷ਯ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌ၮ⋚⎇ⓥ(C)(2)㧦ࠦࡃ࡞࠻ࠢࡠ࡜ࠗ࠼⺃⊒ⷞ⚦⢩ㆬᛯ⊛㓚ኂࡕ࠺࡞ߩ⊒⃻ᯏᐨ⸃᣿ߥࠄ߮ߦߘߩ㒐ᓮ࡮ᴦ≮㧧ᐔᚑ 19㧙20 ᐕᐲ㧧3,500 ජ౞(2,700㧦800ජ౞)12㧕 ⎇ⓥઍ⴫⠪㧦㜞ᯅఝਃ㧘⎇ⓥදജ⠪㧦ਤ⠀㓷ਯ㧧⍮⊛ࠢ࡜ࠬ࠲࡯ഃᚑ੐ᬺ㧦‫ࡑ࡯࠹ޟ‬Σ㧦ૐଚⷅᓸ⚦ᚻⴚᡰេ࡮ᢎ⢒⸠✵ࠪࠬ࠹ࡓߩ㐿⊒㧦ක≮ᢎ⢒⸠✵ࡠࡏ࠶࠻‫ޠ‬㧧ᐔᚑ 19㧙20 ᐕᐲ㧧46,432 ජ౞(23,200㧦23,232 ජ౞)
13㧕 ⎇ⓥઍ⴫⠪㧦㋈ᧁᐽਯ㧧ᐔᚑ 19 ᐕᐲ ⃻ઍ⊛ᢎ⢒࠾࡯࠭ข⚵ᡰេࡊࡠࠣ࡜ࡓ㧔⃻ઍ GP㧕㧦‫⥃ޟ‬ᐥකቇ
ᢎ⢒ࠍᒝൻะ਄ߐߖࠆ ICT㧦e-Learning ߢၭ߁කߩᔃߣᛛ‫ޠ‬㧧ᐔᚑ 19㧙21 ᐕᐲ㧧69,973 ජ౞(23,993㧦
21,980㧦24,000 ජ౞)
14㧕 ⎇ⓥઍ⴫⠪㧦㋈ᧁᐽਯ㧘⎇ⓥಽᜂ⠪㧦ട⮮ᥓ⟤㧘㒙ㇱᕺሶ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)(৻⥸)㧦ዊఽ㗔ၞߦ߅ߌࠆቴⷰ⊛⥃ᐥ⢻ജ⹏ଔࠪࠬ࠹ࡓߩ㐿⊒㧧ᐔᚑ 20㧙22 ᐕᐲ㧧4,800 ජ౞(2,300㧦
1,100㧦700 ජ౞)
15㧕 ⎇ⓥઍ⴫⠪㧦ᅏጊ⯥ਯ㧘ಽᜂ⎇ⓥ⠪㧦㋈ᧁᐽਯ㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌㧔ක≮ᛛⴚታ↪ൻ✚ว⎇ⓥ੐ᬺ㧕㧦ᣂⷙᴦ≮ᴺ߇㐿⊒ߐࠇߚዊఽᏗዋ㔍∛ߩ∉ቇ⺞ᩏߣ㐳ᦼࡈࠜࡠ࡯ࠕ࠶ࡊ૕೙ߩ⏕┙㧧ᐔᚑ 20ᐕᐲ㧧2,000 ජ౞
16㧕 ⎇ⓥઍ⴫⠪㧦⷏Ỉᱜ⼾㧘⎇ⓥಽᜂ⠪㧦㋈ᧁᐽਯ㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌㧔․ቯ∔ᖚኻ╷⎇ⓥ੐ᬺ㧕㧦ㆇേᄬ⺞ߦ㑐ߔࠆ⺞ᩏ෸߮∛ᘒᯏᐨߦ㑐ߔࠆ⎇ⓥ⃰㧧ᐔᚑ 20㧙22 ᐕᐲ㧧3,000 ජ౞(1,000㧦1,000㧦
1,000 ජ౞)2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬ
㋈ᧁᐽਯ㧦1㧕 ᣣᧄකቇᢎ⢒ቇળℂ੐(㨪⃻࿷)2㧕 ᣣᧄዊఽ⑼ቇળઍ⼏ຬ(ᐔᚑ 20 ᐕ 4 ᦬㨪⃻࿷)
3㧕 ᣣᧄవᄤઍ⻢⇣Ᏹቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄੱ㘃ㆮવቇળ⹏⼏ຬ(㨪⃻࿷)5㧕 ᧲ᶏ⥃ᐥㆮવ࡮ઍ⻢ᙣ⹤ળ਎⹤ੱ(㨪⃻࿷)ਤ⠀㓷ਯ㧦1㧕 ᣣᧄ⮎ℂቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄἻ∝࡮ౣ↢කቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄකቇᢎ⢒ቇળ⹏⼏ຬ(㨪⃻࿷)㧙㧙4㧕 ᣣᧄ⥃ᐥ⮎ℂቇળ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅
㋈ᧁᐽਯ㧦1㧕 ╙ 19 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 18 ᐕ 1 ᦬㧘ጘ㒂)2㧕 ╙ 20 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 18 ᐕ 4 ᦬㧘ߟߊ߫)3㧕 ╙ 21 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 18 ᐕ 8 ᦬㧘ጘ㒂)
4㧕 ╙ 22 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 18 ᐕ 10 ᦬㧘ᮮᵿ)
5㧕 ╙ 23 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 19 ᐕ 1 ᦬㧘ጘ㒂)
6㧕 ╙ 24 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 19 ᐕ 4 ᦬㧘᧲੩)7㧕 ╙ 25 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ㧛╙ 7 ࿁ᣣᧄዊఽකቇᢎ⢒⎇ⓥળ(ᐔᚑ 19 ᐕ 7 ᦬㧘ጘ㒂)8㧕 ╙ 26 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 19 ᐕ 10 ᦬㧘ᓼፉ)9㧕 ╙ 27 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 20 ᐕ 1 ᦬㧘ฬฎደ)10㧕 ╙ 28 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 20 ᐕ 5 ᦬㧘ᄢ㒋)11㧕 ጘ㒂ᄢቇᮨᡆᖚ⠪ߩળ 10 ๟ᐕ⸥ᔨࠪࡦࡐࠫ࠙ࡓ(ᐔᚑ 20 ᐕ 6 ᦬㧘ጘ㒂)12㧕 ╙ 29 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 20 ᐕ 8 ᦬㧘ጘ㒂)13㧕 ╙ 30 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 20 ᐕ 10 ᦬㧘᧲੩)
3㧕ቇⴚ㔀⹹
㋈ᧁᐽਯ㧦1㧕 Medical Education: Editor(2008 ᐕ㨪⃻࿷)7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳
㋈ᧁᐽਯ㧦
1㧕 ᐔᚑ 17 ᐕᐲᄢቇ∛㒮ᖱႎࡑࡀ࡯ࠫࡔࡦ࠻ㇱ㐷ㅪ⛊ળ⼏ಽ⑼ળ 3‫∛ޟ‬㒮ᖱႎࠪࠬ࠹ࡓߩ‫ޔ‬ᢎ⢒ߣ EBM
ߦ߅ߌࠆଔ୯‫(ޠ‬ᐔᚑ 18 ᐕ 1 ᦬㧘ᵿ᧻,‫≮⸻ޟ‬ෳടဳ⥃ᐥታ⠌ߣ㔚ሶࠞ࡞࠹ㆇ↪ߦ㑐ߔࠆࠟࠗ࠼࡜ࠗ
ࡦ㧔᩺㧕‫ޠ‬ᐳ㐳㧘Ṷ⠪)2㧕 ⚻ᷣ↥ᬺ⋭ഥᚑ࡮ක≮⚻༡ੱ⢒ᚑࡊࡠࠣ࡜ࡓ㐿⊒ࡊࡠࠫࠚࠢ࠻วห FD ⻠Ṷળ(ᐔᚑ 18 ᐕ 2 ᦬㧘ᄢ㒋㧘‫ޟ‬ක≮ᢎ⢒ߦ߅ߌࠆࡐ࡯࠻ࡈࠜ࡝ࠝ⹏ଔ‫ޠ‬Ṷ⠪)3㧕 6th Asian-Pacific Conference on PBL, Symposium 2 “E-PBL”(2006.05, Tokyo, Introductory
remarks for e-PBL; Chairman, Symposist)4㧕 ╙ 6 ࿁ዊఽකቇᢎ⢒⎇ⓥળࠪࡦࡐࠫ࠙ࡓ 2‫ߥ࠼࡯࠳ࡦ࠲ࠬ࡞ࡃ࡯ࡠࠣޟ‬ዊఽ⑼ኾ㐷ක㙃ᚑߦะߌߡ
૗ࠍߥߔߴ߈߆‫(ޠ‬ᐔᚑ 18 ᐕ 7 ᦬㧘᧲੩㧘‫ޟ‬ᄢቇ∛㒮߅ࠃ߮කቇᢎ⢒ኾ㐷ኅߣߒߡߩ⚻㛎߆ࠄ‫ޠ‬Ṷ⠪)
5㧕 ╙ 21 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 18 ᐕ 8 ᦬㧘ጘ㒂㧘‫ޟ‬PBL revisited: ၮᧄߦ┙ߜ㄰ࠈ߁‫ޠ‬Ṷ⠪)6㧕 ╙ 30 ࿁ㆮવࠞ࠙ࡦ࠮࡝ࡦࠣ࡝ࡈ࡟࠶ࠪࡘ࠮ࡒ࠽࡯‫ࠦࡓޟ‬ᄙ♧∝(MPS)ߩㆮવࠞ࠙ࡦ࠮࡝ࡦࠣ‫(ޠ‬ᐔ
ᚑ 19 ᐕ 6 ᦬㧘᧲੩㧘‫ࠦࡓޟ‬ᄙ♧∝ߩ∛ᘒ࡮⸻ᢿ࡮ᴦ≮‫ޠ‬Ṷ⠪)7㧕 ╙ 39 ࿁ᣣᧄකቇᢎ⢒ቇળᄢળ(ᐔᚑ 19 ᐕ 7 ᦬㧘⋓ጟ㧘ࠪࡦࡐࠫ࠙ࡓ II‫ޟ‬࿾ၞක≮ߣත೨කቇᢎ⢒ߩ࿷ࠅᣇ‫ޠ‬ᐳ㐳)8㧕 ╙ 39 ࿁ᣣᧄකቇᢎ⢒ቇળᄢળ(ᐔᚑ 19 ᐕ 7 ᦬㧘⋓ጟ㧘ࠪࡦࡐࠫ࠙ࡓ߹ߣ߼‫ޟ‬࿾ၞක≮ߣකቇ࡮ක≮ᢎ⢒ߩ໧㗴ὐ‫ޠ‬Ṷ⠪)9㧕 ╙ 111 ࿁ᣣᧄዊఽ⑼ቇળቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 4 ᦬㧘᧲੩㧘ᄢቇ∛㒮ߩ┙႐߆ࠄ⷗ߚᢎ⢒࡮⎇ⓥߦ߅ߌࠆ∛⸻ㅪ៤㧚✚วࠪࡦࡐࠫ࠙ࡓ 5‫࡮≮⸻ޟ‬ᢎ⢒࡮⎇ⓥࠍ߰߹߃ߚ∛⸻ㅪ៤ߩ⃻⁁ߣᧂ᧪‫ޠ‬Ṷ⠪)10㧕 23rd Annual Meeting of Korean Society of Medical Education. (2008.05, Seoul, Plenary Lecture:
Medical Education in Japan: past, present and future; Performer)
11㧕 ᧲ᶏർ㒽࿾඙⥃ᐥ⎇ୃ∛㒮⺑᣿ળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ฬฎደ㧘‫ߩ᧪ᧂޟ‬ᣣᧄࠍഃࠆዊఽ⑼ක‫ޠ‬Ṷ⠪)12㧕 ᐔᚑ 20 ᐕᐲጘ㒂⋵⋴⼔ᢎ⢒ㅪ⛊ද⼏ળ✚ળ(ᐔᚑ 20 ᐕ 6 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫⼔⋴ޟ‬ᢎ⢒ߦ߅ߌࠆᮨ
ᡆᖚ⠪ዉ౉ߩᗧ⟵‫ޠ‬Ṷ⠪)
13㧕 ᐔᚑ 20 ᐕᐲవᄤᕈઍ⻢⇣Ᏹ∝╬ᬌᩏᛛⴚ⠪⎇ୃળ(ᐔᚑ 20 ᐕ 7 ᦬㧘᧲੩㧘࡜ࠗ࠰࠱࡯ࡓ∛ I㧔ࡓࠦᄙ♧∝㧕—ၮ␆ߣ⥃ᐥ‫ޔ‬ᣂ↢ఽࠬࠢ࡝࡯࠾ࡦࠣ࡯ Ṷ⠪)
14㧕 ╙ 40 ࿁ᣣᧄකቇᢎ⢒ቇળᄢળ(ᐔᚑ 20 ᐕ 7 ᦬㧘᧲੩㧘Medical Education in Korea: The Historicalbackground and the influence of U.S. by Myung-Hyun Chung. ᐳ㐳)15㧕 ╙ 122 ࿁ᣣᧄዊఽ⑼ቇળጤᚻ࿾ᣇળ(ᐔᚑ 20 ᐕ 12 ᦬㧘⋓ጟ㧘‫ޟ‬කቇᢎ⢒ߦ߅ߌࠆዊఽ⑼කߩᓎഀ‫ޠ‬

㧙㧙

Ṷ⠪)
ਤ⠀ 㓷ਯ㧦1㧕 6th Asia-Pacific Conference on Problem-Based Learning,࡮Symposium 2 “E-PBL”(2006.01, Tokyo,
Web-based Internet PBL-tutorial 'Rakuichi The Tutorial; Symposist)2㧕 ╙ 45 ࿁ᣣᧄ⮎ቇળਛ࿖྾࿖ᡰㇱ଀ળ(ᐔᚑ 18 ᐕ 6 ᦬㧘⑔ጊ㧘ቇળ᜗ᓙ⻠Ṷ‫ޟ‬ᣂߒ޿ක≮♽ᢎ⢒ߩᵹࠇߣ PBL/࠹ࡘ࠻࡯࡝ࠕ࡞‫ޠ‬Ṷ⠪)3㧕 వ┵ഃ⮎ක≮ࠪࡦࡐࠫ࠙ࡓ(ᐔᚑ 20 ᐕ 10 ᦬㧘ጘ㒂㧘⻠Ṷ‫⚦ޟ‬⢩ᱫߣ∛᳇‫ߩߘޔ‬ౣ↢‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേ
㋈ᧁ ᐽਯ㧦
1㧕 ෘ↢ഭ௛⋭╙ 102 ࿁කᏧ࿖ኅ⹜㛎 ⹜㛎ᆔຬ(㨪⃻࿷)2㧕 ᣣᧄࡓࠦᄙ♧∝ⷫߩળ㘈໧(㨪⃻࿷)
3㧕 ALD ⷫߩળ㘈໧(㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ㋈ᧁᐽਯ㧘ട⮮ᥓ⟤㧘ୖဝ๺ᴰ㧘᛬ዬᔘᄦ㧦ࡓࠦᄙ♧∝ߩ㊀∝ᐲߣㆇേ࡮⹺⍮㕙ߩ ADL ⹏ଔ㧦ᐔᚑ
17 ᐕᐲෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌㧔․ቯ∔ᖚኻ╷⎇ⓥ੐ᬺ㧕࡜ࠗ࠰࠱࡯ࡓ∛㧔ࡈࠔࡉ࡝࡯∛฽߻㧕ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ⃰ ✚᜝⎇ⓥႎ๔ᦠ㧦12㧙14(2006 ᐕ 3 ᦬)
2㧕 ㋈ᧁᐽਯ㧘ਅỈિⴕ㧦೽⣢⊕⾰ࠫࠬ࠻ࡠࡈࠖ࡯߅ࠃ߮ࡍ࡞ࠝࠠࠪ࠰࡯ࡓ∛ߩᣧᦼ⸻ᢿࠪࠬ࠹ࡓ᭴▽ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 17 ᐕᐲෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌㧔․ቯ∔ᖚኻ╷⎇ⓥ੐ᬺ㧕ㆇേᄬ⺞∝ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ⃰⎇ⓥႎ๔ᦠ㧦21㧙24(2006 ᐕ 3 ᦬)
3㧕 ᄢ⷏ᒄ㜞㧘㋈ᧁᐽਯ㧦╙ 24 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ㧦කቇᢎ⢒ 38㧦282(2007 ᐕ 1 ᦬)
4㧕 ਤ⠀㓷ਯ㧦╙ 24 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ ࠕ࠽࠙ࡦࠬࡔࡦ࠻㧦කቇᢎ⢒ 38㧦121(2007ᐕ 1 ᦬)
5㧕 ਤ⠀㓷ਯ㧦╙ 25 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ ࠾ࡘ࡯࠭㧦කቇᢎ⢒ 38㧦334(2007 ᐕ 10
᦬)6㧕 ਤ⠀㓷ਯ㧦╙ 26 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ ࠕ࠽࠙ࡦࠬࡔࡦ࠻㧦කቇᢎ⢒ 38㧦354(2007ᐕ 10 ᦬)7㧕 ਤ⠀㓷ਯ㧦╙ 27 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ ࠕ࠽࠙ࡦࠬࡔࡦ࠻㧦කቇᢎ⢒ 38㧦410(2007ᐕ 12 ᦬)8㧕 㒙ㇱᕺሶ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ㧘㋈ᧁᐽਯ㧘Phillip Evans㧦⁛⥄ᕈ⼾߆ߥ SP 㙃ᚑࡊࡠࠣ࡜ࡓ-ࠬࠦ࠶࠻࡜ࡦ࠼ 5 ᄢቇⷞኤႎ๔-㧦කቇᢎ⢒ 39㧦199㧙204(2008 ᐕ)
9㧕 ㋈ᧁᐽਯ㧘ୖဝ๺ᴰ㧘᛬ዬᔘᄦ㧘ട⮮ᥓ⟤㧦ࡓࠦᄙ♧∝ II ဳ㊀∝ဳߩ⥄ὼᱧߣ BMT ߩലᨐߦ㑐ߔࠆᬌ⸛㧦ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌㧔㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ㧕࡜ࠗ࠰࠱࡯ࡓ∛㧔ࡈࠔࡉ࡝࡯∛฽߻㧕ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ⃰ ᐔᚑ 19 ᐕᐲ⎇ⓥႎ๔ᦠ㧦35㧙36(2008 ᐕ 3 ᦬)
10㧕 ㋈ᧁᐽਯ㧘ਅỈિⴕ㧘ୖဝ๺ᴰ㧦ዊఽᄢ⣖ဳ೽⣢⊕⾰ࠫࠬ࠻ࡠࡈࠖ࡯ߩᣧᦼ⸻ᢿᴦ≮ߣኅᣖߩࡔࡦ
࠲࡞ࡋ࡞ࠬ㧦ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌㧔㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ㧕ㆇേᄬ⺞∝ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ⃰ ᐔ
ᚑ 19 ᐕᐲ⎇ⓥႎ๔ᦠ㧦27㧙29(2008 ᐕ 3 ᦬)
11㧕 ㋈ᧁᐽਯ㧘ਅỈિⴕ㧘ୖဝ๺ᴰ㧦೽⣢⊕⾰ࠫࠬ࠻ࡠࡈࠖ࡯ߩਔⷫߩࡔࡦ࠲࡞ࡋ࡞ࠬ㧦ෘ↢ഭ௛⑼ቇ
⎇ⓥ⾌㧔㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ㧕ㆇേᄬ⺞∝ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ⃰ ᐔᚑ 17 ᐕᐲ㧙19 ᐕᐲ✚ว ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ㧦79㧙81(2008 ᐕ 3 ᦬)
12㧕 ㋈ᧁᐽਯ㧘᛬ዬᔘᄦ㧘↰ਛ޽ߌߺ㧘ᅏጊ⯥ਯ㧘ⴡ⮮⟵ൎ㧘੗↰ඳᐘ㧦ࡓࠦᄙ♧∝ I ဳ࡮II ဳߩో࿖ታᘒ⺞ᩏ̆ࡑࠬࠬࠢ࡝࡯࠾ࡦࠣߦะߌߡ̆㧦ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌㧔ሶߤ߽ኅᐸ✚ว⎇ⓥ੐ᬺ㧕࠲ࡦ࠺ࡓࡑࠬ╬ߩᣂᛛⴚࠍዉ౉ߒߚᣂߒ޿ࡑࠬࠬࠢ࡝࡯࠾ࡦࠣ૕೙ߩ⏕┙ߦ㑐ߔࠆ⎇ⓥ⃰ ᐔᚑ 19 ᐕᐲ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ㧦53㧙54(2008 ᐕ 3 ᦬)
13㧕 ᛬ዬᔘᄦ㧘ᣧဈ๺ሶ㧘↰ㇱ⟤Ⓞ㧘᛬ዬᕡᴦ㧘㋈ᧁᐽਯ㧦ࡓࠦᄙ♧∝ߩዩߦࠃࠆࠬࠢ࡝࡯࠾ࡦࠣᚑ❣
‫ޟ‬ㆊ෰ 20 ᢙᐕ㑆ߩ⚻㛎‫ޠ‬㧦ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌㧔ሶߤ߽ኅᐸ✚ว⎇ⓥ੐ᬺ㧕࠲ࡦ࠺ࡓࡑࠬ╬ߩᣂᛛⴚࠍዉ౉ߒߚᣂߒ޿ࡑࠬࠬࠢ࡝࡯࠾ࡦࠣ૕೙ߩ⏕┙ߦ㑐ߔࠆ⎇ⓥ⃰ ᐔᚑ 19 ᐕᐲ✚᜝࡮ಽᜂ⎇ⓥႎ
๔ᦠ㧦49㧙52(2008 ᐕ 3 ᦬)㧙㧙14㧕 ᚭ᧻ବᴦ㧘ࠕ࠼࡝ࠕ࡯࠽࡮ࡕࡦ࠲࡯࠾࡚㧘ዊᾢᢅᐢ㧘㋈ᧁᐽਯ㧘᛬ዬᔘᄦ㧘૒ୖિᄦ㧘⑔჻ ൎ㧘ጊญᷡᰴ㧦ࡓࠦᄙ♧∝ߩᣂ↢ఽࠬࠢ࡝࡯࠾ࡦࠣ㐿⊒㧦ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌㧔ሶߤ߽ኅᐸ✚ว⎇ⓥ੐ᬺ㧕࠲ࡦ࠺ࡓࡑࠬ╬ߩᣂᛛⴚࠍዉ౉ߒߚᣂߒ޿ࡑࠬࠬࠢ࡝࡯࠾ࡦࠣ૕೙ߩ⏕┙ߦ㑐ߔࠆ⎇ⓥ⃰ ᐔ
ᚑ 19 ᐕᐲ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ㧦55㧙57(2008 ᐕ 3 ᦬)
15㧕 ਤ⠀㓷ਯ㧦╙ 28 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ ࠕ࠽࠙ࡦࠬࡔࡦ࠻㧦කቇᢎ⢒ 38㧦86(2008ᐕ 3 ᦬)
16㧕 ਤ⠀㓷ਯ㧦╙ 29 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ ࠾ࡘ࡯࠭㧦කቇᢎ⢒ 38㧦359(2008 ᐕ 10
᦬)17㧕 ਤ⠀㓷ਯ㧦╙ 30 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ ࠕ࠽࠙ࡦࠬࡔࡦ࠻㧦කቇᢎ⢒ 39㧦346(2008ᐕ 10 ᦬)18㧕 ਤ⠀㓷ਯ㧦╙ 31 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ ࠕ࠽࠙ࡦࠬࡔࡦ࠻㧦කቇᢎ⢒ 39㧦469(2008ᐕ 12 ᦬)11㧚ႎ㆏
1㧕 ㋈ᧁᐽਯ㧦ࠬ࡯ࡄ࡯․ႎ‫ޟ‬ALD ೽⣢⊕⾰ࠫࠬ࠻ࡠࡈࠖ࡯‫ޠ‬㧦ࡈࠫ࠹࡟ࡆ㧔࠭࡯ࡄ࡯࠾ࡘ࡯ࠬౝ㧕(2007ᐕ 4 ᦬ 25 ᣣ)2㧕 ㋈ᧁᐽਯ㧦․ᝡ‫ޟ‬ALD ೽⣢⊕⾰ࠫࠬ࠻ࡠࡈࠖ࡯‫ޠ‬㧦࠹࡟ࡆᦺᣣ(2007 ᐕ 10 ᦬ 20 ᣣ)
3㧕 ㋈ᧁᐽਯ㧦․㓸ࠦ࡯࠽࡯‫ࠦࡓޟ‬ᄙ♧∝‫ޠ‬㧦ਛ੩࠹࡟ࡆ㧔࠾ࡘ࡯ࠬ࡝ࠕ࡞࠲ࠗࡓౝ㧕(2007 ᐕ 10 ᦬ 31
ᣣ)4㧕 ਤ⠀㓷ਯ㧦‫ޟ‬ᄢቇߪ޿߹-⎇ⓥቶ߆ࠄ‫ޠ‬㧦ጘ㒂ᣂ⡞(2007 ᐕ 11 ᦬ 13 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔ
2001 ᐕߦකቇㇱߣߒߡೋߩో࿖౒ห೑↪ᣉ⸳ߣߒߡ⸳⟎ߐࠇߡએ᧪㧘
㧔1㧕ᣂߒ޿කቇᢎ⢒ߩ㐿⊒⎇ⓥ
ߣ᥉෸㧘㧔2㧕කቇᢎ⢒ߦ⽸₂ߢ߈ࠆੱ᧚⢒ᚑ㧘㧔3㧕࿖ౝᄖߩකቇᢎ⢒ᯏ㑐ߣߩㅪ៤࡮౒ห⎇ⓥ㧘ࠍਥߥࡒ࠶࡚ࠪࡦߣߒߡ㧘࿾૏ߩ⏕┙ߦദ߼ߡ߈ߚ‫ޕ‬ᐘ޿ߥߎߣߦකቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩਥ௅
╬ࠍㅢߓߡ㧘ో࿖ߩකቇㇱ࡮ක≮♽ᢎ⢒ᯏ㑐ߦ⹺⍮ߐࠇ㧘ᡰᜬࠍᓧࠄࠇࠆࠃ߁ߦߥߞߚ‫ߚ߹ޕ‬ᶏᄖߩ⪺ฬߥකቇᢎ⢒⠪ࠍᲤᐕ᜗⡜ߔࠆߎߣߦࠃߞߡ㧘࿖㓙⊛ߦ߽ᒰ࠮ࡦ࠲࡯ߩሽ࿷߇⍮ࠄࠇࠆࠃ߁ߦߥߞߚ‫ޕ‬ㄭᐕ㧘ฦᄢቇߦකቇᢎ⢒ㇱ㐷⸳⟎ߩേ߈߇ᐢ߹ߞߡ޿ࠆ߇㧘ߎࠇࠄߩ⚵❱ߣߩㅪ៤߽ᒝ߹ࠅߟߟ޽ࠆ‫ޕ‬
ᐔᚑ 20 ᐕᐲ߆ࠄᄢቇ㒮߽⸳⟎ߐࠇ㧘ੱ᧚⢒ᚑ㧘⎇ⓥ૕೙߇ᢛ޿ߟߟ޽ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷කቇᢎ⢒ᣇᴺߩ㐿⊒⎇ⓥߦ㑐ߒߡߪ㧘౨㗡ߢ୘‫ߩޘ‬ขࠅ⚵ߺߦߟ޿ߡㅀߴߚ‫᦭ࠍࠄࠇߎޕ‬ᯏ⊛ߦ⛔วߒ㧘ᣂߚߥකቇᢎ⢒ࠞ࡝ࠠࡘ࡜ࡓࠍឭ᩺ߔࠆߎߣ߇੹ᓟߩ⺖㗴ߢ޽ࠆ‫ޕ‬ᐔᚑ 20 ᐕᐲ߆ࠄዉ౉ߐࠇߚᣂࠞ
࡝ࠠࡘ࡜ࡓߩਛߢ㧘ߘߩታ⃻ߦദജߔࠆߣߣ߽ߦ㧘࿖ౝᄖ߳⊒ାߒߡⴕߊ੍ቯߢ޽ࠆ‫ోޕ‬࿖⊛ߥකᏧਇ⿷߆ࠄකቇㇱቇ↢ቯຬჇ໧㗴߇ᕆᶋ਄ߒߡ޿ࠆ߇㧘ᢎ⢒ߩੱ⊛࡮⚻ᷣ⊛ߥⵣߠߌߪᭂ߼ߡ㊀ⷐߥ⺖㗴ߣߥߞߡ߅ࠅ㧘ᢎ⢒ࠍᜂᒰߔࠆ┙႐߆ࠄឭ⸒ߒߡⴕ߈ߚ޿‫᧚ੱޕ‬⢒ᚑߦ㑐ߒߡߪ㧘⃻࿷ߩᢎ⢒ࠬ࠲࠶ࡈో
⥸ߩ FD ផㅴߣ዁᧪ߩකቇᢎ⢒ቇࠍᡰ߃ࠆੱ᧚⢒ᚑࠍᐔⴕߒߡㅴ߼ࠆᔅⷐ߇޽ࠆ‫ޕ‬ᓟ⠪ߦߟ޿ߡߪ㧘ᄢቇ㒮߇⸳⟎ߐࠇ૕೙߇ߢ߈ߚ߇㧘࿖ౝᄖߩකቇᢎ⢒ㇱ㐷ߣߩㅪ៤ࠍ৻ጀᒝൻߐߖࠆᔅⷐ߇޽ࠆ‫ޕ‬੹ᓟߩዷᦸකቇᢎ⢒ߩಽ㊁ߢ⸃᳿ߔߴ߈⺖㗴ߪጊⓍߒߡ޿ࠆ‫ޕ‬ᢎ⢒ߩ㊀ⷐᕈߪ⺕ߒ߽߇⹺⼂ߒߡ޿ࠆ߇㧘ታ㓙ߦߪ⒳‫ߩޘ‬೙⚂ߦࠃߞߡ㧘ߘࠇ߇ታ⃻ߢ߈ߥ޿⃻⁁߇޽ࠆ‫ޕ‬කቇ࡮ක≮⇇ో૕߇⥄Ꮖ㕟ᣂࠍ⛯ߌߥ߇ࠄ㧘ᢎ⢒ߩ㊀ⷐᕈࠍ␠ળߦኻߒߡ⊒ାߒ㧘ᦸ߹ߒ޿ᢎ⢒ߩታ⃻߇น⢻ߣߥࠆࠃ߁ദജߒߡࠁ߈ߚ޿‫ޕ‬㧙㧙㧔10㧕කቇᢎ⢒㐿⊒⎇ⓥ࠮ࡦ࠲࡯㧔ࡃ࡯࠴ࡖ࡞ࠬࠠ࡞ㇱ㐷㧕1㧚⎇ⓥߩ᭎ⷐ
ᒰㇱ㐷ߢߪ㧘ක≮ࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦᢎ⢒㧘ᮨᡆᖚ⠪࠻࡟࡯࠾ࡦࠣ㧘り૕⸻ኤࠍ฽߼ߚᮨᡆ⸻ኤߩ㐿⊒࡮
⎇ⓥࠍⴕߞߡ޿ࠆ‫ߚ߹ޕ‬㧘ࠪࡒࡘ࡟࡯࠲࡯ࠍ↪޿ߚり૕⸻ኤߪ⹜ⴕᲑ㓏ߦ౉ߞߡ޿ࠆ‫ޕ‬කቇ⧷⺆ߪၮᧄ߆ࠄࠃࠅታ〣⊛ߥ࡟ࡌ࡞ߩᢎ⢒߇ߢ߈ࠆࠃ߁Ḱ஻ࠍㅴ߼ߡ޿ࠆ‫ߚ߹ޕ‬㧘ᰴᐕᐲએ㒠ߦ߻ߌ㧘ⴕേ⑼ቇᢎ⢒ߣߒߡ‫ޟ‬ᖚ⠪කᏧ‫߮ࠃ߅ࠬ࡯ࠦޠ‬㧘‫ߩࠬ࡯ࠦޠ࡞ࠢࠗࠨࡈࠗ࡜ޟ‬Ḱ஻࡮૞ᚑࠍⴕߞߡ޿ࠆ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
ഥᢎ㧦

⮮ፒ๺ᒾ
㒙ㇱᕺሶ

Kazuhiko Fujisaki
Keiko Abe3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’05 ౻㧙╙ 15 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2006 ᐕ㧦1㧙94㧚
2㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’05 ᤐ㧙╙ 16 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2006 ᐕ㧦1㧙124㧚
3㧕 ⮮ፒ๺ᒾ㧘↰ች⩿ᄹሶ㧘ጊᧄ⑲᮸✬㧚␠ળߣஜᐽ࡮∔∛ߣߩ㑐ଥ㧦ࠦࠕ࡮ࠞ࡝ࠠࡘ࡜ࡓኻᔕ කቇ࡮ක≮ߣ␠ળ㧘੩ㇺ㧦㊄⧐ၴ㧧2006 ᐕ㧦1㧙4㧚
4㧕 ⮮ፒ๺ᒾ㧚ో࿖ᖚ⠪ળ㓚ኂ⠪࿅૕ⷐⷩ✬㓸ቶ✬㧚ක≮ߦ߅ߌࠆᖚ⠪ળ㧦ో࿖ᖚ⠪ળ㓚ኂ⠪࿅૕ⷐⷩ ╙ 3㧘ᄢ㒋㧦ࡊ࡝ࡔ࠼␠㧧2006 ᐕ㧦10㧙13㧚
5㧕 ⮮ፒ๺ᒾ㧚කቇᢎ⢒ቇળ✬㧚ක≮ߩᄌൻߣකቇᢎ⢒㧦කቇᢎ⢒⊕ᦠ 2006 ᐕ 㧦◉ේ಴ ᣂ␠㧧2006 ᐕ㧦
118㧙121㧚
6㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’05 ᄐ㧙╙ 17 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2006 ᐕ㧦1㧙211㧚
7㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’05 ⑺㧙╙ 18 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2006 ᐕ㧦1㧙112㧚
8㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’06 ౻㧙╙ 19 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2006 ᐕ㧦1㧙110㧚
9㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’06 ᤐ㧙╙ 20 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2006 ᐕ㧦1㧙185㧚
10㧕 ⮮ፒ๺ᒾ㧚කቇᢎ⢒ߣ⺆ࠅ㧦ᳯญ㊀ᐘ㧘ᢪ⮮ᷡੑ㧘㊁᧛⋥᮸✬㧚࠽࡜࠹ࠖࡧߣක≮㧦㊄೰಴ 㧧2006 ᐕ㧦
107㧙112㧚
11㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’06 ᄐ㧙╙ 21 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2007 ᐕ㧦1㧙237㧚
12㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’06 ⑺㧙╙ 22 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2007 ᐕ㧦1㧙89㧚
13㧕 ㊁ํᐞਭሶ㧘㒙ㇱᕺሶ㧘⍹Ꮉ߭ࠈߩ㧚ක≮ࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦಽᨆߩᣇᴺ—The Roter Method ofInteraction Process Analysis System (RIAS)—㧘ฬฎደ㧦ਃᕺ␠㧧2007 ᐕ㧦1㧙71㧚
14㧕 㒙ㇱᕺሶ㧚╙ 4 ┨㧦ᖚ⠪ߣකᏧߩࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦ㧦⍹Ꮉ߭ࠈߩ㧘ᱞ↰⵨ሶ⋙⸶㧚in Debra L. Roter,
Judith A Hall㧚කᏧߣᖚ⠪ߩࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦߦᓇ㗀ࠍਈ߃ࠆᖚ⠪ߩ․ᕈ㧘◉ේ಴ ᣂ␠㧧2007 ᐕ㧦
59㧙74㧚
15㧕 ⮮ፒ๺ᒾ㧚shared decision making(ᗧᕁ᳿ቯߩ޽ࠅᣇ)ࠍᡰ߃ࠆකᏧߩ⢻ജ㙃ᚑߩ⃻⁁ߣ⺖㗴㧦᧻↰੫ਃ㧘᧻ፉ੩㧘᫟ዬᓼሶ✬㧚ක≮࡮⑔␩ߦ߅ߌࠆ࿾ၞ࡮૑᳃ࠛࡦࡄࡢࡔࡦ࠻́ታ〣✬́㧦┙๮㙚ᄢቇੱ㑆⑼ቇ⎇ⓥᚲ㧧2007 ᐕ㧦43㧙79㧚
16㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’07 ౻㧙╙ 23 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2007 ᐕ㧦1㧙120㧚
17㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’07 ᤐ㧙╙ 24 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2007 ᐕ㧦1㧙152㧚
18㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’07 ᄐ㧙╙ 25 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2007 ᐕ㧦1㧙121㧚
19㧕 ⮮ፒ๺ᒾ㧚කᏧߩ࠹ࠢ࠾࠶ࠢ㧔ᛛ⢻㧕⹏ଔ㧦ฬㇹ⋥᮸⋙ୃ㧚ዊ⼱๺ᒾ㧘ᦺ੗㕏ᒾ㧘ධㇹᩕ⑲㧘የ⮮⺈ม✬㧚⸻ኤ࡮ᬌᩏ㧦⟠࿯␠㧧2007 ᐕ㧦16㧙23㧚
20㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’07 ⑺㧙╙ 26 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2008 ᐕ㧦1㧙100㧚
21㧕 ⮮ፒ๺ᒾ㧚ⴕേᄌኈࠍ߁ߥ߇ߔߚ߼ߩ㕙ធࠬࠠ࡞଻ஜᜰዉኻੱេഥࠬࠠ࡞ߩቇ⠌㧦ᣣᧄ↢ᵴදห⚵วㅪวળක≮ㇱળ㧧2008 ᐕ㧦1㧙45㧚
22㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’08 ౻㧙╙ 27 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2008 ᐕ㧦1㧙130㧚㧙㧙

23㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’08 ᤐ㧙╙ 28 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2008 ᐕ㧦1㧙152㧚
24㧕 ⮮ፒ๺ᒾ㧚ᖚ⠪㧙ක≮⠪㑐ଥ㧙㧦ᣣᧄ↥ᬺࠞ࠙ࡦ࠮࡝ࡦࠣቇળ✬㧚↥ᬺࠞ࠙ࡦ࠮࡝ࡦࠣㄉౖ㧦㊄ሶᦠᚱ㧧2008 ᐕ㧦74㧚⪺ᦠ㧔᰷ᢥ㧕
1㧕 Yoshida T, Fujisaki K. Interpersonal Communication Training in Dental Education. In: David I.
Mostofsky and Albert G. Forgione eds. Behavioral Dentistry. Iowa: Blackwell Pub Professional;
2006:255-263.
✚⺑㧔๺ᢥ㧕
1㧕 ⮮ፒ๺ᒾ㧚NBM ߩၮ␆࡮ℂ⺰—ක≮ੱ㘃ቇ㧘⸻ᢿߣᴦ≮ 2006 ᐕ㧧94 Ꮞ㧦232㧙236㧚
2㧕 ⮮ፒ๺ᒾ㧚ߎࠇ߆ࠄߩ⮎೷Ꮷߦ᳞߼ࠄࠇࠆක≮ࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦߣߪ㧘᦬ೀ⮎੐ 2006 ᐕ㧧48 Ꮞ㧦501
㧙506㧚
3㧕 ⮮ፒ๺ᒾ㧚ක≮‫ޡ‬ᡷ㕟‫ߣޢ‬ක≮ᓥ੐⠪ߩᓎഀ㧘᦬ೀ࿖᳃ක≮ 2007 ᐕ㧧234 Ꮞ㧦2㧙24㧚
4㧕 ⮮ፒ๺ᒾ㧚⹣߼ㄟߺဳකቇᢎ⢒߆ࠄ⺖㗴⸃᳿ဳᢎ⢒߳ߩォ឵㧘ੱ㑆ߣᢎ⢒ 2007 ᐕ㧧54 Ꮞ㧦112㧙123㧚
5㧕 ⮮ፒ๺ᒾ㧚කቇㇱߢㅴ߻ታ〣⊛ᢎ⢒߳ߩᡷ㕟㧘BERD 2007 ᐕ㧧9 Ꮞ㧦22㧙27㧚
6㧕 ⮮ፒ๺ᒾ㧚ක≮␠ળቇߦߟ޿ߡ㧘᦬ೀ࠽࡯ࠪࡦࠣ 2007 ᐕ㧧27 Ꮞ㧦63㧙67㧚
7㧕 ⮮ፒ๺ᒾ㧚ⴕേᄌኈࠍ↢߻ᖚ⠪ࠕࡊࡠ࡯࠴㧘᦬ೀ଻࿅ㅪ 2007 ᐕ㧧952 Ꮞ㧦70㧙82㧚
8㧕 Ꮉ਄ߜ߭ࠈ㧘⮮ፒ๺ᒾ㧚ᮨᡆᖚ⠪ߩߚ߼ߩ‫ߩޠ࠻࡯ࠪࠢ࡯ࡢࠢ࠶ࡃ࠼࡯ࠖࡈޟ‬ឭ᩺㧘කቇᢎ⢒ 2008 ᐕ㧧
39 Ꮞ㧦417㧙420㧚
9㧕 ᮯ↰⟤㓶㧘ጟ↰శᒄ㧘੖ච፲⚛ሶ㧘ችፒᓀሶ㧘⌀㍿㒽ᄥ㇢㧘⮮ፒ๺ᒾ㧘ർ᧛㓉ᙗ㧘㜞ጊᥓሶ㧘ᄥ↰⢻㧘₹⟎ବᤩ㧘ኹ᎑ศ଻㧘㒙ㇱᥓᕺሶ㧘ፉ↰ᤘੳ㧘ዊᴰ⑲᮸㧚㜞╬ᢎ⢒ᡷ㕟ߩ⋧੕ⴕὑಽᨆ㧙ࡆ࠺ࠝ࡮ࠛࠬࡁࠣ
࡜ࡈࠖ࡯⎇ⓥߩ⁓޿ߣᎿቇㇱㇺᏒᎿቇṶ⠌ߩታ㓙㧙㧘ᄢቇᢎ⢒⎇ⓥࠫࡖ࡯࠽࡞ 2008 ᐕ㧧5 ภ㧦93㧙104㧚✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 㒙ㇱᕺሶ㧘㋈ᧁን㓶㧘⮮ፒ๺ᒾ㧘઻ାᄥ㇢㧚ᮨᡆᖚ⠪ߩ⃻ᴫ෸߮ḩ⿷ᗵߣ⽶ᜂᗵ̆ో࿖ᗧ⼂⺞ᩏ╙৻ႎ̆㧘කቇᢎ⢒ 2007 ᐕ㧧38 Ꮞ㧦301㧙307㧚
2㧕 㒙ㇱᕺሶ㧘⮮ፒ๺ᒾ㧘઻ାᄥ㇢㧚ᮨᡆᖚ⠪ߩදജࠍᓧߚり૕⸻ኤታ⠌ߩ੹ᓟߩᣇะᕈ㧘ᣣᧄ଻㒾ක≮ⴕേ⑼ቇቇળᐕႎ 2008 ᐕ㧧23 Ꮞ㧦59㧙73㧚ේ⪺㧔᰷ᢥ㧕
ߥߒ

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦㜞ᯅఝਃ㧧ᢥㇱ⑼ቇ⋭․⦡޽ࠆᄢቇᢎ⢒ᡰេࡊࡠࠣ࡜ࡓ(․⦡ GP)㧦⢻േ࡮ᕁ⠨ଦㅴဳࠍᩇߣߔࠆోੱ⊛කቇᢎ⢒㧧ᐔᚑ 15㧙18 ᐕᐲ㧧60,000 ජ౞(15,000㧦15,000㧦15,000㧦15,000 ජ౞)2㧕 ⎇ⓥઍ⴫⠪㧦ᮯ↰⟤㓶(ᓼፉᄢቇ✚ว⑼ቇㇱ)㧘⎇ⓥಽᜂ⠪㧦⮮ፒ๺ᒾ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(B)(৻⥸)㧦㜞╬ᢎ⢒ᡷ㕟ߩࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦಽᨆ㧙⃻႐ߦ߅ߌࠆᢥൻᄌኈߩ⾰⊛ᬌ⸛㧙㧧
ᐔᚑ 18㧙20 ᐕᐲ㧧14,500 ජ౞(5,100㧦4,800㧦4,800 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦㋈ᧁን㓶(ฬฎደᄢቇකቇㇱ㒝ዻ∛㒮✚ว⸻≮ㇱ)㧘⎇ⓥಽᜂ⠪㧦㒙ㇱᕺሶ㧘઻ାᄥ㇢㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦ᣣᧄߩකቇᢎ⢒ߦ߅ߌࠆ 6 ᐕ㑆⛔วဳⴕേ⑼ቇᢎ⢒ࡊࡠࠣ࡜ࡓߩ㐿⊒ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18㧙20 ᐕᐲ㧧3,400 ජ౞(1,300㧦900㧦1,200 ජ౞)
4㧕 ⎇ⓥઍ⴫⠪㧦ᬀ᧛๺ᱜ(ฬฎደᄢቇකቇㇱකቇᢎ⢒࠮ࡦ࠲࡯)㧘⎇ⓥಽᜂ⠪㧦㒙ㇱᕺሶ㧘⨃ᧁ৾㚅㧧ᢥ
ㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦කቇ↢ߩ‫ޟ‬ᱫߩᢎ⢒‫ߩ߳ޠ‬ᮨᡆᖚ⠪ዉ౉ߩᢎ⢒⊛ലᨐߩ⎇ⓥ㧧ᐔᚑ 19㧙20 ᐕᐲ㧧2,870 ජ౞(1,417㧦1,453 ජ౞)
5㧕 ⎇ⓥઍ⴫⠪㧦㋈ᧁᐽਯ㧧ᐔᚑ 19 ᐕᐲ ⃻ઍ⊛ᢎ⢒࠾࡯࠭ข⚵ᡰេࡊࡠࠣ࡜ࡓ(⃻ઍ GP)㧦‫⥃ޟ‬ᐥකቇ
ᢎ⢒ࠍᒝൻะ਄ߐߖࠆ ICT㧦e-Learning ߢၭ߁කߩᔃߣᛛ‫ޠ‬㧧ᐔᚑ 19㧙21 ᐕᐲ㧧69,973 ජ౞(23,993㧦21,980㧦24,000 ජ౞)
6㧕 ⎇ⓥઍ⴫⠪㧦㋈ᧁᐽਯ㧘⎇ⓥಽᜂ⠪㧦ട⮮ᥓ⟤㧘㒙ㇱᕺሶ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦
ዊఽ㗔ၞߦ߅ߌࠆቴⷰ⊛⥃ᐥ⢻ജ⹏ଔࠪࠬ࠹ࡓߩ㐿⊒㧧ᐔᚑ 20㧙22 ᐕᐲ㧧4,800 ජ౞(2,300㧦1,100㧦
700 ජ౞)㧙㧙2㧕ฃ⸤⎇ⓥ
ߥߒ
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬ⮮ፒ๺ᒾ㧦
1㧕 ᣣᧄ଻ஜක≮ⴕേ⑼ቇળળ㐳(㨪ᐔᚑ 19 ᐕ 10 ᦬)
2㧕 ․ቯ㕖༡೑ᵴേᴺੱᣣᧄኅᐸක≮ቇળℂ੐(㨪ᐔᚑ 20 ᐕ 6 ᦬)
3㧕 ᣣᧄකቇᢎ⢒ቇળ⹏⼏ຬ࡮ℂ੐(㨪⃻࿷)4㧕 ᣣᧄකቇᢎ⢒ቇળᢎ᧚㐿⊒࡮SP ዊᆔຬળᆔຬ㐳(㨪⃻࿷)5㧕 ක≮ࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦ⎇ⓥળળ㐳(㨪⃻࿷)6㧕 ᣣᧄ␠ળකቇળ⹏⼏ຬ(㨪⃻࿷)7㧕 ᣣᧄක≮⚻ᷣቇળᐙ੐(㨪⃻࿷)
8㧕 RIAS ⎇ⓥળળ㐳(ᐔᚑ 18 ᐕ 4 ᦬㨪⃻࿷)㒙ㇱᕺሶ㧦
1㧕 ᣣᧄකቇᢎ⢒ቇળ࡮ⴕേ⑼ቇੱ㑆㑐ଥᆔຬળ(㨪ᐔᚑ 18 ᐕ 3 ᦬)
2㧕 Association of Standardized Patient Educators, International committee member (ᐔᚑ 19 ᐕ 11᦬㨪⃻࿷)3㧕 RIAS ⎇ⓥળᆔຬ(ᐔᚑ 18 ᐕ 4 ᦬㨪⃻࿷)2㧕ቇળ㐿௅
කቇᢎ⢒㐿⊒⎇ⓥ࠮ࡦ࠲࡯㧦1㧕 ╙ 19 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 18 ᐕ 1 ᦬㧘ጘ㒂)2㧕 ╙ 20 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 18 ᐕ 4 ᦬㧘ߟߊ߫)3㧕 ╙ 21 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 18 ᐕ 8 ᦬㧘ጘ㒂)
4㧕 ╙ 22 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 18 ᐕ 10 ᦬㧘ᮮᵿ)
5㧕 ╙ 23 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 19 ᐕ 1 ᦬㧘ጘ㒂)
6㧕 ╙ 24 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 19 ᐕ 4 ᦬㧘᧲੩)7㧕 ╙ 25 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ㧛╙ 7 ࿁ᣣᧄዊఽකቇᢎ⢒⎇ⓥળ(ᐔᚑ 19 ᐕ 7 ᦬㧘ጘ㒂)8㧕 ╙ 26 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 19 ᐕ 10 ᦬㧘ᓼፉ)9㧕 ╙ 27 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 20 ᐕ 1 ᦬㧘ฬฎደ)10㧕 ╙ 28 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 20 ᐕ 5 ᦬㧘ᄢ㒋)11㧕 ጘ㒂ᄢቇᮨᡆᖚ⠪ߩળ 10 ๟ᐕ⸥ᔨࠪࡦࡐࠫ࠙ࡓ(ᐔᚑ 20 ᐕ 6 ᦬㧘ጘ㒂)12㧕 ╙ 29 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 20 ᐕ 8 ᦬㧘ጘ㒂)13㧕 ╙ 30 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 20 ᐕ 10 ᦬㧘᧲੩)⮮ፒ๺ᒾ㧦
1㧕 ╙ 10 ࿁ක≮ࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦ⎇ⓥળ(ᐔᚑ 18 ᐕ 6 ᦬㧘ฬฎደ)2㧕 ╙ 11 ࿁ක≮ࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦ⎇ⓥળ(ᐔᚑ 18 ᐕ 12 ᦬㧘ฬฎደ)3㧕 ╙ 12 ࿁ක≮ࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦ⎇ⓥળ(ᐔᚑ 19 ᐕ 6 ᦬㧘ฬฎደ)
4㧕 ╙ 13 ࿁ක≮ࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦ⎇ⓥળ(ᐔᚑ 19 ᐕ 12 ᦬㧘ฬฎደ)⮮ፒ๺ᒾ㧘㒙ㇱᕺሶ㧦
1㧕 ╙ 1 ࿁ RIAS ࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 18 ᐕ 12 ᦬㧘ฬฎደ)2㧕 ╙ 2 ࿁ RIAS ࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 19 ᐕ 11 ᦬㧘ฬฎደ)3㧕 ╙ 3 ࿁ RIAS ࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 20 ᐕ 10 ᦬㧘ฬฎደ)㧙㧙3㧕ቇⴚ㔀⹹ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳⮮ፒ๺ᒾ㧦
1㧕 ᐔᚑ 17 ᐕᐲ࿾ၞ଻ஜ✚วផㅴ੐ᬺ⊒⴫ળ(ᐔᚑ 18 ᐕ 3 ᦬㧘᧲੩㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ‫ޟ‬࿾ၞߦ߅ߌࠆᣂ⥃ᐥකᏧ⎇ୃߦߟ޿ߡ‫ޠ‬Ṷ⠪ ‫ޟ‬කቇᢎ⢒ߩⷞὐ߆ࠄ⷗ߚ࿾ၞߦ߅ߌࠆᣂ⥃ᐥකᏧ⎇ୃ‫ޠ‬Ṷ⠪)2㧕 2006 ᐕᐲᣣᧄᴺ␠ળቇળቇⴚᄢળ(ᐔᚑ 18 ᐕ 5 ᦬㧘⷏ች㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬Ꮢ᳃ߣᴺኾ㐷ᢎ⢒㧙ࡠ࡯ࠬࠢ࡯࡞ߦ߅ߌࠆታᛛᢎ⢒ߩ⺖㗴‫ޠ‬Ṷ⠪ ‫ޟ‬කቇㇱߦ߅ߌࠆᮨᡆᖚ⠪ߩᢎ⢒ෳടߩ⃻⁁ߣߘߩᚑᨐ‫ޠ‬Ṷ⠪)3㧕 ᐔᚑ 18 ᐕጘ㒂ᄢቇකቇㇱห⓹ળ(ᐔᚑ 18 ᐕ 5 ᦬㧘ጘ㒂㧘ᢎ⢒⸥ᔨ⻠Ṷ‫ޟ‬਎⇇⊛ߥකቇᢎ⢒ᡷ㕟ߩേะߣጘ㒂ᄢቇකቇㇱකቇᢎ⢒㐿⊒⎇ⓥ࠮ࡦ࠲࡯ߩᓎഀ‫ޠ‬Ṷ⠪)
4㧕 ╙ 30 ࿁ᣣᧄක≮⚻ᷣቇળᄢળ(ᐔᚑ 18 ᐕ 9 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬කᏧߩਇ⿷࡮஍࿷‫ࠖ࠺ࡔࠦޔ‬ࠞ࡞㙃ᚑߩ⃻⁁ߣ໧㗴ὐ‫ޠ‬ᐳ㐳㧘Ṷ⠪)
5㧕 ╙ 39 ࿁ᣣᧄ⮎೷Ꮷળቇⴚᄢળ(ᐔᚑ 18 ᐕ 10 ᦬㧘⑔੗㧘․೎ࡊࡠࠣ࡜ࡓ⻠Ṷ‫⮎ޟ‬೷Ꮷߣߒߡ᳞߼ࠄ
ࠇࠆ⥃ᐥࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦࠬࠠ࡞ߣߘߩᢎ⢒‫ޠ‬Ṷ⠪)
6㧕 ╙ 13 ࿁਄✚࿖㓙㜞ᐲኾ㐷⡯ᢎ⢒⎇ⓥቇળᢎ⢒࡮⎇ⓥ㓸ળ(ᐔᚑ 18 ᐕ 10 ᦬㧘ንጊ㧘ၮ⺞⻠Ṷ‫ޟ‬ᣂකᏧ⎇ୃ೙ᐲߩశߣᓇ‫ޠ‬Ṷ⠪)7㧕 ╙ 5 ࿁ࡈࠔ࡯ࡑࠪࡘ࡯࠹ࠖࠞ࡞ࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦ⎇ⓥળ(ᐔᚑ 18 ᐕ 11 ᦬㧘ᧅᏻ㧘ၮ⺞⻠Ṷ‫ޟ‬ක≮ੱ⢒ᚑߦ߅ߌࠆࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦᢎ⢒ߩ⃻࿷ߣᧂ᧪‫ޠ‬Ṷ⠪)8㧕 ᣣᧄᱤ⑼කቇᢎ⢒ቇળᱤቇᢎ⢒ࠪࡦࡐࠫ࠙ࡓ(ᐔᚑ 18 ᐕ 12 ᦬㧘᧲੩㧘᜗ᓙ⻠Ṷ‫ޟ‬ක≮ࠦࡒࡘ࠾ࠤ࡯
࡚ࠪࡦᢎ⢒ߣᮨᡆᖚ⠪ߩ㙃ᚑߦߟ޿ߡ‫ޠ‬Ṷ⠪)9㧕 ╙ 27 ࿁ᣣᧄකቇળ✚ળ(ᐔᚑ 19 ᐕ 4 ᦬㧘ᄢ㒋㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ‫ޟ‬කቇᢎ⢒ࠍ⠨߃ࠆ㧙᣿ᣣߩฬකࠍߤ߁⢒ߡࠆ߆㧙‫ޠ‬ᐳ㐳)10㧕 ╙ 107 ࿁ᣣᧄᄖ⑼ቇળቯᦼቇⴚ㓸ળතᓟᢎ⢒࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 4 ᦬㧘ᄢ㒋㧘⻠Ṷ‫ޟ‬ක≮㕙ធߣࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦᢎ⢒‫ޠ‬Ṷ⠪)11㧕 ╙ 20 ࿁ᣣᧄญ⣧⸻ᢿቇળ✚ળ(ᐔᚑ 19 ᐕ 4 ᦬㧘ᮮ㗇⾐㧘․೎⻠Ṷ‫ޟ‬කቇᢎ⢒ߦ߅ߌࠆ⸻≮㍳⸥タ‫ޠ‬Ṷ⠪)12㧕 ᐔᚑ 19 ᐕᐲో࿖ℂቇ≮ᴺ჻࡮૞ᬺ≮ᴺ჻ቇᩞㅪ⛊ද⼏ળ✚ળ(ᐔᚑ 19 ᐕ 6 ᦬㧘␹ᚭ㧘⻠Ṷ‫⥃ޟ‬ᐥታ⠌ߩ⹏ଔߩା㗬ᕈߣᅷᒰᕈ㧔OSCE ࠍ฽߼ߡ㧕‫ޠ‬Ṷ⠪)
13㧕 ╙ 17 ࿁ᣣᧄක≮⮎ቇળᐕળࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 19 ᐕ 9 ᦬㧘೨ᯅᏒ㧘⻠Ṷ‫ޟ‬ᮨᡆᖚ⠪දജဳ⎇ୃߦ߅ߌࠆࡈࠖ࡯࠼ࡃ࠶ࠢ⢻ജࠍ⏴ߊ㧍‫ޠ‬Ṷ⠪)⮮ፒ๺ᒾ㧘㒙ㇱᕺሶ㧦
1㧕 5th Asia Pacific Regional Meeting “Mental Health” Agenda of Impaired Healers Workshop (2007㧚
03, Osaka ; Performer)㒙ㇱᕺሶ㧦
1㧕 ฬฎደᄢቇ╙৻࿁ SP ࠪࡦࡐࠫ࠙ࡓ(ᐔᚑ 18 ᐕ 3 ᦬㧘ฬฎደ㧘‫ޟ‬ᣣᧄߣ☨࿖ߦ߅ߌࠆᮨᡆᖚ⠪ᵴേ㧦⃻⁁࡮໧㗴ὐ࡮੹ᓟߩ⺖㗴‫ޠ‬Ṷ⠪)
2㧕 ᧲੩ᄢቇ RIAS ࠪࡦࡐࠫ࠙ࡓ(ᐔᚑ 18 ᐕ 3 ᦬㧘᧲੩㧘‫ޟ‬ᣣᧄߦ߅ߌࠆ RIAS ዉ౉‫ޠ‬Ṷ⠪)
3㧕 ╙ 10 ࿁ක≮ࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦ⎇ⓥળ(ᐔᚑ 18 ᐕ 6 ᦬㧘ฬฎደ㧘‫ޟ‬ᣣ☨ߩᮨᡆᖚ⠪ߩ⃻⁁ߣ੹ᓟߩᣇะᕈ‫ޠ‬Ṷ⠪)
4㧕 ฬฎደᏒ┙ᄢቇ∛㒮⋴⼔Ꮷ࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 10 ᦬㧘ฬฎደ㧘‫ߪߌߛࠇߎޟ‬⍮ߞߡ᰼ߒ޿ࠦࡒࡘ࠾
ࠤ࡯࡚ࠪࡦߩၮᧄ‫ޠ‬Ṷ⠪)
5㧕 ╙ 11 ࿁ක≮ࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦ⎇ⓥળ(ᐔᚑ 18 ᐕ 12 ᦬㧘ฬฎደ㧘‫ ࠆߌ߅ߦࠬ࡝ࠡࠗޟ‬SP ੐ᖱ‫ޠ‬Ṷ⠪)‫♧ޟ‬ዩ∛ᖚ⠪ߩ࠽࡜࠹ࠖࡉߩ⸥ㅀ߇ᣣ
6㧕 ฬฎደᏒ┙ᄢቇ࠽࡜࠹ࠖࡉ⎇ⓥળ(ᐔᚑ 18 ᐕ 12 ᦬㧘ฬฎደ㧘Ᏹ⸻≮ߦ෸߷ߔᓇ㗀‫ޠ‬Ṷ⠪)7㧕 ਭ⇐☨ᄢቇ SP ࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 12 ᦬㧘ਭ⇐☨㧘‫ޟ‬SP ߩ⃻⁁㧦ᣣ☨ߩᗧ⼂⺞ᩏࠃࠅ‫ޠ‬Ṷ⠪)8㧕 ╙ਃ࿁ฬၔᄢቇ⥃ᐥ⮎ቇᢎ⢒⥃ᐥᛛ⢻࠻࡟࡯࠾ࡦࠣࡊࡠࠣ࡜ࡓࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦࡢ࡯࡚ࠢࠪ࠶ࡊ
‫⮎ޟ‬ቇಽ㊁ߩࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦᢎ⢒ߦ߅ߌࠆലᨐ⊛ߥࡈࠖ࡯࠼ࡃ࠶ࠢߩᣇᴺ㧦ࡈࠔࠪ࡝࠹࡯࠲

㧙㧙࡯࡮SP ߆ࠄቇ↢߳૗ࠍ㄰ߔ߆‫߁ߤޔ‬㄰ߔ߆‫(ޠ‬ᐔᚑ 19 ᐕ 1 ᦬㧘ฬฎደ㧘‫ߩࠢ࠶ࡃ࠼࡯ࠖࡈޟ‬ၮᧄ‫ޠ‬Ṷ⠪)
9㧕 ᣣᧄࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦ⎇ⓥ⠪ળ⼏(ᐔᚑ 19 ᐕ 5 ᦬㧘ฬฎደ㧘‫ޟ‬ක≮ߦ߅ߌࠆࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦᢎ
⢒㧦ၮᧄ߆ࠄኾ㐷߳‫ޔ‬ᛛ⢻⠌ᓧ߆ࠄᘒᐲᢎ⢒߳ߩំࠅᚯߒ‫ޠ‬Ṷ⠪)‫ߩࠢ࠶ࡃ࠼࡯ࠖࡈޟ‬ၮᧄ‫ޠ‬Ṷ⠪)10㧕 ╙ 1 ࿁ၯᮨᡆᖚ⠪㙃ᚑ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 11 ᦬㧘ၯ₹㧘11㧕 ╙ 21 ࿁⮮↰଻ஜⴡ↢ᄢቇකቇㇱකቇᢎ⢒ࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 19 ᐕ 12 ᦬㧘ฬฎደ㧘‫⥃ޟ‬ᐥታ⠌߿තᬺ⹺ቯߩߚ߼ߩᛛ⢻࡮ᘒᐲ⹏ଔ Advanced OSCE ߩዉ౉ߩ⠨߃ᣇ‫ޠ‬Ṷ⠪)12㧕 ╙ 1 ࿁ක≮ࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦ࡮ࡈࠔࠪ࡝࠹࡯࠲࡯㙃ᚑ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 12 ᦬㧘ฬฎደ㧘‫ޟ‬਎⇇
ߩ SP ੐ᖱ‫ޠ‬Ṷ⠪)
13㧕 ᗲ⍮ක⑼ᄢቇ SP 㙃ᚑ࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 8 ᦬㧘ฬฎደ㧘⻠Ṷ‫ޟ‬ᣣᧄߣ਎⇇ߩ SP ੐ᖱ‫ޠ‬Ṷ⠪)
14㧕 Association for Medical Education in Europe, Pre-conference :“High stakes, low stakes, the proof
is in the pudding: preparation for quality SP programs” (by ASPE International committee
member)(2008.08, in Prague, Czech Republic)
15㧕 International Conference on Communication in Healthcare 2008 by European Association forCommunication in Healthcare (2008.09, Oslo, Norway, Symposium: Developing a global networkof national RIAS centres; Title “RIAS Japan” Symposiast)16㧕 ᐔᚑ 18㧙20 ᐕᣣᧄቇⴚᝄ⥝ળ⑼ቇ⎇ⓥ⵬ഥ㊄੤ઃ⎇ⓥ‫ޟ‬ᣣᧄߩකቇㇱᢎ⢒ߦ߅ߌࠆ 6 ᐕ㑆⛔วဳⴕ
േ⑼ቇᢎ⢒ࡊࡠࠣ࡜ࡓߩ㐿⊒ߦ㑐ߔࠆ⎇ⓥ‫ࡓ࠙ࠫࡐࡦࠪޠ‬㧦ත೨කቇᢎ⢒ߦ߅ߌࠆⴕേ⑼ቇᢎ⢒ࠪࡦࡐࠫ࠙ࡓ in NAGOYA(ᐔᚑ 20 ᐕ 11 ᦬㧘ฬฎደ㧘⻠Ṷ‫ޟ‬࿾ၞߢߩࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦᢎ⢒߇ᖱേߦਈ߃ࠆᓇ㗀ߣኅᣖ࡜ࠗࡈࠨࠗࠢ࡞ߣ޿߁ⷞὐߩᔅⷐᕈ㧦࿦ఽ࡮ᅧᇚߣߩ⛮⛯⊛੤ᵹ߆ࠄ‫ޠ‬Ṷ⠪)17㧕 ╙ 2 ࿁ၯᮨᡆᖚ⠪㙃ᚑ࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 11 ᦬㧘ၯ₹㧘‫ߩࠢ࠶ࡃ࠼࡯ࠖࡈޟ‬ၮᧄ‫ޠ‬Ṷ⠪)18㧕 ╙ 11 ࿁ᣣᧄࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦቇળਛㇱ྾࿖ᡰㇱᄢળ࡮ක≮ࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦᢎ⢒⎇ⓥ࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 11 ᦬㧘ᐢፉ㧘‫ޟ‬਎⇇ߩ SP ᵴേ㧦SP ߩṶᛛ࡮ࡈࠖ࡯࠼ࡃ࠶ࠢ‫ޠ‬Ṷ⠪)
19㧕 ╙ 15 ࿁ක≮ࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦ⎇ⓥળ(ᐔᚑ 20 ᐕ 11 ᦬㧘ฬฎደ㧘‫ޟ‬AMEE࡮EACH ቇળႎ๔‫ޠ‬Ṷ
⠪)20㧕 ╙ 2 ࿁ක≮ࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦ࡮ࡈࠔࠪ࡝࠹࡯࠲࡯㙃ᚑ࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 12 ᦬㧘ฬฎደ㧘‫ޟ‬਎⇇
ߩ SP ᵴേ‫ޠ‬Ṷ⠪)⧯ᨋ⧷᮸㧦
1㧕 ᐔᚑ 18㧙20 ᐕᣣᧄቇⴚᝄ⥝ળ⑼ቇ⎇ⓥ⵬ഥ㊄੤ઃ⎇ⓥ‫ޟ‬ᣣᧄߩකቇㇱᢎ⢒ߦ߅ߌࠆ 6 ᐕ㑆⛔วဳⴕ
േ⑼ቇᢎ⢒ࡊࡠࠣ࡜ࡓߩ㐿⊒ߦ㑐ߔࠆ⎇ⓥ‫ࡓ࠙ࠫࡐࡦࠪޠ‬㧦ත೨කቇᢎ⢒ߦ߅ߌࠆⴕേ⑼ቇᢎ⢒ࠪࡦࡐࠫ࠙ࡓ in NAGOYA(ᐔᚑ 20 ᐕ 11 ᦬㧘ฬฎደ㧘⻠Ṷ‫ޟ‬ᣣᧄߦ߅ߌࠆ੹ᓟߩ⛔วဳⴕേ⑼ቇᢎ⢒ࠍ⠨߃ࠆ‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ1㧕 㒙ㇱᕺሶ㧦ࡉ࡞࡯࡝ࡏࡦ⾨㧛౒ห⎇ⓥㇱ㐷ᦨఝ⑲⾨(The 5th Association of Standardized Patient
Educators conference㧦╙ 5 ࿁ᮨᡆᖚ⠪ᢎ⢒⠪ቇળ㧘ᐔᚑ 18 ᐕᐲ)
9㧚␠ળᵴേ⮮ፒ๺ᒾ㧦
1㧕 ක≮♽ᄢቇ㑆౒↪⹜㛎ታᣉ⹏ଔᯏ᭴කቇ♽ OSCE ੐ᓟ⹏ଔ⸃ᨆዊᆔຬળᆔຬ㧘ቇ⠌࡮⹏ଔ㗄⋡╬ᡷ⸓ኾ㐷ㇱળᆔຬ㧘⺖㗴ᡷ⸓ኾ㐷ㇱળᆔຬ(㨪⃻࿷)2㧕 ᄢቇၮḰදળ‫ࠆ޽⦡․ޟ‬ᄢቇᢎ⢒ᡰេࡊࡠࠣ࡜ࡓ‫(࡯࡝ࠚࡈ࡟࡯ࡄ࡯ࡍޠ‬㨪⃻࿷)3㧕 ෘ↢ഭ௛⋭╙ 101 ࿁කᏧ࿖ኅ⹜㛎 ⹜㛎ᆔຬ(㨪⃻࿷)4㧕 ෘ↢ഭ௛⋭╙ 102 ࿁කᏧ࿖ኅ⹜㛎 ⹜㛎ᆔຬ(㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ⮮ፒ๺ᒾ㧦ஜᐽߠߊࠅࠍ૑᳃ߩᚻߢ㧙૑᳃ਥ૕ߩᵴേࠍᡰ߃ࠆ଻ஜᏧߩᓎഀ㧦╙ 27 ࿁ో࿖࿾ၞ଻ஜ
Ꮷቇⴚ⎇ⓥળ⻠Ṷ෼㍳㓸㧦28㧙60(2006 ᐕ 1 ᦬)
2㧕 ઻ାᄥ㇢㧘㒙ㇱᕺሶ㧦ක≮㕙ធ෸߮り૕⸻ኤߦ⽸₂ߔࠆᮨᡆᖚ⠪㙃ᚑߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 15࡮16࡮
17 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄⎇ⓥ ✚᜝࡮ಽᜂႎ๔ᦠ㧦1㧙214 (2006 ᐕ 2 ᦬)
3㧕 ⮮ፒ๺ᒾ㧘㒙ㇱᕺሶ㧦IMPROVING MEDICAL EDUCATION㧙Enhancing the Behavioral andSocial Science Content of Medical School Curricula Institute of Medicine 2005㧘ࠦࡒࡘ࠾ࠤ࡯ࠪ

㧙㧙࡚ࡦࠥ࡯ࡓ㧦ᣣᧄකቇᢎ⢒ቇળⴕേ⑼ቇ࡮ੱ㑆㑐ଥᢎ⢒ᆔຬળႎ๔ᦠ‫ⴕޟ‬േ⑼ቇᢎ⢒ࠍ⠨߃ࠆ㧙ࡊࡠࡈࠚ࠶࡚ࠪ࠽࡞ߩᢎ⢒ࠍ߼ߑߒߡ‫ޠ‬㧦18㧙20㧘80㧙81(2006 ᐕ 3 ᦬)
4㧕 ⮮ፒ๺ᒾ㧦࿖ኅ⹜㛎 OSCE ߦ߅ߌࠆᮨᡆᖚ⠪㧘Advanced OSCE ߢߩࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦ⺖㗴㧦2005
ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ‫ޟ‬OSCE ࠻࡜ࠗࠕ࡞ߩታᣉ╬කᏧ࿖ኅ⹜㛎ߩᡷༀߦ߆߆ࠆ⎇ⓥ‫ޠ‬ಽᜂ⎇ⓥ‫ޟ‬࿖ኅ⹜㛎 OSCE ࠻࡜ࠗࠕ࡞ߩታᣉߦଥࠆ⎇ⓥ‫ޠ‬2005 Advanced OSCE ႎ๔ᦠ㧦289㧙293㧘313㧙
317(2006 ᐕ 3 ᦬)
5㧕 㒙ㇱᕺሶ㧦”Student Perception of Feedback from Simulated Patient during Communication
Training Sessions” ࠍ᜙⺒ߒߡ‫ߺ߇ߡޔ‬㧦කቇᢎ⢒ 38㧦299(2007 ᐕ 1 ᦬)
6㧕 㒙ㇱᕺሶ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ㧘㋈ᧁᐽਯ㧘Phillip Evans㧦⁛⥄ᕈ⼾߆ߥ SP 㙃ᚑࡊࡠࠣ࡜ࡓ-ࠬࠦ࠶࠻࡜ࡦ࠼ 5 ᄢቇⷞኤႎ๔-㧦කቇᢎ⢒ 39㧦199㧙204(2008 ᐕ)
7㧕 㒙ㇱᕺሶ㧘㋈ᧁን㓶㧘⮮ፒ๺ᒾ㧘઻ାᄥ㇢㧦ᮡḰᮨᡆᖚ⠪ߩ✵⠌⁁ᴫߣ OSCE ߦኻߔࠆᗧ⼂ ో࿖⺞ᩏ╙ 2 ႎ㧦කቇᢎ⢒ 39㧦259㧙266(2008 ᐕ)
8㧕 ⮮ፒ๺ᒾ㧦⥃ᐥ୶ℂታ〣ߩߚ߼ߩࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦ㧦ᣣᧄකቇᢎ⢒ቇળ୶ℂ࡮ⴕേ⑼ቇዊᆔຬળ
╙ 3 ࿁⥃ᐥ⎇ୃᜰዉ⠪ߩߚ߼ߩ୶ℂᢎ⢒ࡢ࡯࡚ࠢࠪ࠶ࡊႎ๔ᦠ㧦55㧙58(2008 ᐕ 1 ᦬)
9㧕 ⮮ፒ๺ᒾ㧘਄↸੝Ꮧሶ㧦⮎ቇㇱ 6 ᐕ೙߳㧙ߎࠇ߆ࠄߩ⮎೷Ꮷߦ᳞߼ࠄࠇࠆࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦࠬࠠ
࡞㧦㒋␹࡮᷆〝ᄢ㔡ἴᓟߩ࿾ၞ␠ળߣߩ౒↢ࠍ߼ߑߒߚᄢቇߩᣂߒ޿ᓎഀߦ㑐ߔࠆታ〣⊛⎇ⓥႎ๔
ᦠ╙ 27 ภ㧦1㧙50(2008 ᐕ 1 ᦬)
11㧚ႎ㆏
1㧕 ⮮ፒ๺ᒾ㧦৻✜ߦᱠ߻කᏧ ᢎ⢒ࠍ㧦ାỚᲤᣣᣂ⡞(2006 ᐕ 2 ᦬ 1 ᣣ)
2㧕 ⮮ፒ๺ᒾ㧦૑᳃ෳടߩஜᐽߠߊࠅᡰេ㧦ጘ㒂ᣂ⡞(2006 ᐕ 8 ᦬ 8 ᣣ)
3㧕 ⮮ፒ๺ᒾ㧦⺕߽߇ฃߌࠄࠇࠆක≮ࠍ㧦Ფᣣᣂ⡞(2006 ᐕ 8 ᦬ 23 ᣣ)
4㧕 ⮮ፒ๺ᒾ㧦⮎೷Ꮷߣߒߡ᳞߼ࠄࠇࠆ⥃ᐥࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦࠬࠠ࡞ߣߘߩᢎ⢒㧦⮎ዪᣂ⡞(2006 ᐕ
10 ᦬ 18 ᣣ)
5㧕 ⮮ፒ๺ᒾ㧦↢߆ߐࠇߡ↢߈ࠆ༑߮ߩ↢ᵴߣ⮎೷Ꮷ㧦⺞೷ߣᖱႎ.Vol.12.No.12.(2006 ᐕ 11 ᦬)
6㧕 ⮮ፒ๺ᒾ㧦⥃ᐥࠍ⺆ࠇࠆ⮎೷Ꮷߦߥߞߡ߶ߒ޿㧦Pharma Next(2007 ᐕ 5 ᦬)
7㧕 ⮮ፒ๺ᒾ㧦ᖚ⠪ᧄ૏߳‫ޟ‬කߪ໧⸻ജ‫ޠ‬㧦ᦺᣣᣂ⡞(2007 ᐕ 5 ᦬ 10 ᣣ)
8㧕 ⮮ፒ๺ᒾ㧦ᖚ⠪ߩᗐ޿ߩࠨࠗࡦࠍ⷗ㅏߒߡ޿߹ߖࠎ߆㧫㧦S.M.C No.9(2007 ᐕ 9 ᦬)
9㧕 ⮮ፒ๺ᒾ㧦ᢎ⢒࡞ࡀ࠶ࠨࡦࠬ‫ޟ‬ක≮ੱࠍ⢒ߡࠆ(5) ᖚ⠪ᓎ‫ߩޠࡠࡊޟ‬ᔃᓧ‫ޠ‬㧦⺒ᄁᣂ⡞(2007 ᐕ 12 ᦬
22 ᣣ)
10㧕 ⮮ፒ๺ᒾ㧦Ꮢ᳃߇ᮨᡆᖚ⠪ߣߒߡෳടߔࠆකቇᢎ⢒㧦Medical Tribune(2008 ᐕ 2 ᦬ 21 ᣣ)
11㧕 ⮮ፒ๺ᒾ㧦ᧂ᧪ߩකᏧ߇᧪ߥ޿㨪⎇ୃක࠯ࡠߩⴣ᠄㨪㧦NHK ࠽ࡆࠥ࡯࡚ࠪࡦ ࠬ࠲ࠫࠝ⸃⺑(2008ᐕ 6 ᦬ 6 ᣣ)
12㧕 㒙ㇱᕺሶ㧘⮮ፒ๺ᒾ㧦ᖚ⠪ࠍ↢߈ࠆ ᮨᡆᖚ⠪ ᖱႎ✬㧦ᦺᣣᣂ⡞(2008 ᐕ 10 ᦬ 5 ᣣ)
13㧕 ⮮ፒ๺ᒾ㧦ᖚ⠪ࠍ↢߈ࠆ ᮨᡆᖚ⠪ ᖱႎ✬㧦ᦺᣣᣂ⡞(2008 ᐕ 10 ᦬ 10 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔක≮ࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦᢎ⢒ߩታ⠌ᣇᴺߪ⏕┙ߐࠇߡ߈ߚ߇㧘ࠃࠅቇ⠌⠪ਛᔃߢ㧘ࠃࠅലᨐ⊛ߥታ⠌ߣߥࠆࠃ߁ᡷ⦟ࠍⴕߞߡ߈ߚ‫ޕ‬කቇ⧷⺆ߪ㧘1 ᐕ↢ኻ⽎ߩၮᧄක≮ળ⹤ߩ⻠ᐳ߅ࠃ߮㧘4㨪6 ᐕ↢ኻ⽎ߩ⥃ᐥታ〣⊛ߥ࡟ࡌ࡞ߩᢎ⢒࠮࠶࡚ࠪࡦࠍᢙ࿁ᜬߟߎߣ߇ߢ߈ߚ‫ߚ޿↪ࠍ࠲࡯࡟ࡘࡒࠪޕ‬り૕⸻ኤታ⠌ߩࡊࡠࠣ࡜ࡓߪ㧘ߎࠇ߹ߢᢙ࿁ߩ࠻࡜ࠗࠕ࡞࠮࠶࡚ࠪࡦࠍⴕ޿㧘ᢎຬߩ㑆ߢᝄ㄰ࠅ⼏⺰ߒߡ߈ߚ‫ࠄࠇߎޕ‬޿ߕࠇ߽㧘ࡑ࡯ࠬ࠻࡝ࡅ࠻ᄢቇ㧔ࠝ࡜ࡦ࠳㧕㧘ࠣ࡜ࠬࠧ࡯ᄢቇ㧔⧷࿖㧕㧘⥄ᴦක⑼ᄢቇ㧘ᣣᧄᄢቇߥߤ࿖
ౝᄖߩቴຬᢎຬߣߩ੤ᵹ࡮⼏⺰ࠍ㊀ߨߥ߇ࠄⴕߞߡ߈ߚ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ㄭᐕ㧘࿖㓙⊛ߥකቇᢎ⢒ಽ㊁ߢߪ㧘ᢎ⢒ߩࠕ࠙࠻ࠞࡓࠍቴⷰ⊛ߦ⹏ଔߔࠆߎߣ㧘ࠛࡆ࠺ࡦࠬߦၮߠ޿
ߚᢎ⢒߇ߥߐࠇࠆߎߣ߇㊀ⷞߐࠇߡ޿ࠆ‫ޕ‬ᒰ࠮ࡦ࠲࡯ߢ㐿⊒ߒߡ߈ߚᣂߒ޿ᵹࠇߩකቇᢎ⢒ߪ゠㆏ߦਸ਼
ߞߡ߈ߚߣߎࠈߢ޽ࠆ߇㧘࿖㓙⊛ߥ࡟ࡌ࡞ߩ⹏ଔ߇߹ߛචಽߦ౏⴫ߢ߈ߡ޿ߥ޿‫ߦࠇߎޕ‬ኻߒߡߪ࡝ࠨ
࡯࠴ߩᣇᴺ⺰ߦജὐࠍ⟎ߊߥߤߩኻᔕ߇น⢻ߢ޽ࠆ‫ޕ‬߹ߚ㧘⥃ᐥታ〣ߦ⋥⚿ߔࠆㇱಽߩ౒ㅢᢎ⢒㧘ߔߥࠊߜ㧘ක≮㕙ធ߆ࠄり૕⸻ኤ㧘⥃ᐥផ⺰㧘⸻ᢿᴦ≮ᴺߩ┙᩺ߦ޿ߚࠆၮᧄ⊛⥃ᐥ⢻ജߪ㧘߹ߛචಽߥὶὐ߇⟎߆ࠇࠆߦߪ⥋ߞߡ޿ߥ޿‫ߪߡ޿ߟߦࠇߎޕ‬㧘ቇౝᄖߩ⥃ᐥᢎ⢒⠪ߣߩㅪ៤ࠍ࿑ࠅ㧘ࠦ࡯࠺ࠖࡀࠗ࠲࡯ࠍോ߼ࠆߎߣ߇᦭⋉ߢ޽ࠈ߁‫ޕ‬㧙㧙੹ᓟߩዷᦸ
੹ᓟ߽⃻ઍ␠ળߩ࠾࡯࠭ߦᔕ߃ࠄࠇࠆࠃ߁ߥකᏧ࡮කቇ⎇ⓥ⠪ࠍ㙃ᚑߔࠆߚ߼ߦ㧘1㧕ࠃࠅലᨐ⊛ߥකቇᢎ⢒ࠍ㐿⊒ߒߘߩലᨐࠍቴⷰ⊛ߦ⹏ଔߒߡ޿ߊ㧘2㧕ᜰዉജߣੱ㑆๧ߩ޽ࠆකቇᢎ⢒ߩᓟ⛮⠪ࠍ⢒ᚑߔࠆ㧘3㧕࿖ౝᄖߩකቇᢎ⢒ߦ㑐ࠊࠆᢎຬ㧘ᜰዉකߣߩ੤ᵹࠍߐࠄߦᷓ߼ࠆ㧘ߣ޿߁ߎߣ߇੹ᓟߩዷᦸߢ޽
ࠆ‫ޕ‬

㧙㧙

㧔11㧕ነ㒝⻠ᐳ‫ޟ‬ஜᐽ㓚ኂඨᷫ⻠ᐳ㧔ጘ㒂⋵㧕‫ޠ‬1㧚⎇ⓥߩ᭎ⷐ
ጘ㒂⋵ߣᄢቇ߇ㅪ៤ߒ㧘⋵ౝߩ↢ᵴ⠌ᘠ∛ߩ⺞ᩏ⎇ⓥࠍⴕ߁ߣߣ߽ߦ㧘․ߦ᦭∛₸߇ᄙ޿ߣߐࠇࠆ♧ዩ∛ߦߟ޿ߡߪ㧘∉ቇ⊛ߥ⎇ⓥߣ଻ஜᜰዉ╬ߦࠃࠆ੍㒐ߦࠃࠅ∛⟕ᖚ⠪ߩᷫዋࠍ࿑ࠆ‫ޕ‬2㧚ฬ★
ಎᢎ᝼⋧ᒰ㧦 ㋈ᧁ⧷ม
ഥᢎ⋧ᒰ㧦
ᄢᐸᔒ㊁

Eiji Suzuki
Shino Oba3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ㋈ᧁ⧷ม㧚ၮ␆✬㧦PWV ࠍ⍮ࠆ ⤳ེ࡮ᯏ⢻㓚ኂߣ PWV㧚ਅ⢇ᓴⅣߣ PWV㧦ࡂࡦ࠭ࠝࡦࡉ࠶ࠢ PWVࠍ⍮ࠆ PWV ߢ⸻ࠆ ᧲੩㧦ਛጊᦠᐫ㧧2006 ᐕ㧦132㧙138㧚⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
ߥߒ✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ㋈ᧁ⧷ม㧚♧ዩ∛ࡑࠢࡠࠕࡦࠡࠝࡄࠪ࡯ߩᬌᩏ࡮⸻ᢿᴺߩㅴᱠ ⏛᳇౒㡆ᴺߦࠃࠆᣂߒ޿⸻ᢿᴺ㧘ᣣᧄ⥃ᐥ 2006 ᐕ㧧64 Ꮞ㧦2062㧙2068㧚
2㧕 ㋈ᧁ⧷ม㧚Technics Guide ⏛᳇౒㡆ࠍ↪޿ߚࡈ࠶࠻ࡊࡠ࠻ࠦ࡞ߦࠃࠆ♧ዩ∛⿷∛ᄌߩᣧᦼ⊒⷗㧘Diabetes
Journal 2006 ᐕ㧧35 Ꮞ㧦31㧙35㧚
3㧕 ㋈ᧁ⧷ม㧚ᧃ᪳ᓴⅣ㓚ኂߦኻߔࠆᣂߒ޿ࠕࡊࡠ࡯࠴㧘Diabetes In The News (DITN) 2007 ᐕ㧧353 Ꮞ㧦
8㧚4㧕 ㋈ᧁ⧷ม㧚♧ዩ∛ᖚ⠪ߦ߅ߌࠆᧃ᪳ᓴⅣ㓚ኂߦኻߔࠆᣂߒ޿ࠕࡊࡠ࡯࠴㧘Angiology Frontier 2007 ᐕ㧧
6 Ꮞ㧦96㧙103㧚
5㧕 ㋈ᧁ⧷ม㧚♧ዩ∛ߣᧃ᪳ᓴⅣ㓚ኂ㧘৻ችකႎ 2008 ᐕ㧧172 Ꮞ㧦12㧙17㧚
6㧕 ㋈ᧁ⧷ม㧚C㧚♧ዩ∛ߩ∉ቇ࡮∛ᘒ࡮⸻ᢿቇߩㅴᱠ V㧚♧ዩ∛ᬌᩏቇߩㅴᱠ ♧ዩ∛㑐ㅪ⻉ᬌᩏ㧙᷹ቯᴺ㧘⥃ᐥ⊛ᗧ⟵㧘⹏ଔᴺ㧙↹௝ᬌᩏ MRA㧘ᣂᤨઍߩ♧ዩ∛ቇ 2 Ꮞ㧘ᣣᧄ⥃ᐥ 2008 ᐕ㧧66 Ꮞ(Ⴧೀภ 4)㧦
546㧙550㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Oba S, Shimizu N, Nagata C, Shimizu H, Kametani M, Takeyama N, Ohnuma T, Matsushita S. The
relationship between the consumption of meat, fat, and coffee and the risk of colon cancer: aprospective study in Japan. Cancer Lett. 2006;244:260-267.
2㧕 Nagata C, Oba S, Shimizu H. Associations of menstrual cycle length with intake of soy, fat, and dietaryfiber in Japanese women. Nutr Cancer. 2006;54:166-170.
3㧕 Yoshimura T, Suzuki E, Egawa K, Nishio Y, Maegawa H, Morikawa S, Inubushi T, Hisatomi A,
Fujimoto K, Kashiwagi A. Low blood flow estimates in lower-leg arteries predict cardiovascular eventsin Japanese patients with type 2 diabetes with normal ankle-brachial indexes. Diabetes Care.
2006;29:1884-1890.
4㧕 Oba S, Nagata C, Shimizu N, Shimizu H, Kametani M, Takeyama N, Ohnuma T, Matsushita S. Soy
product consumption and the risk of colon cancer: a prospective study in Takayama, Japan. Nutr
Cancer. 2007;57:151-157.
5㧕 Tanaka T, Nagata C, Oba S, Takatsuka N, Shimizu H. Prospective cohort study of body mass index inadolescence and death from stomach cancer in Japan. Cancer Sci. 2007;98:1785-1789.
6㧕 Oba S, Nakamura K, Sahashi Y, Hattori A, Nagata C. Consumption of vegetables alters morning
urinary 6-sulfatoxymelatonin concentration. J Pineal Res. 2008;45:17-23.
7㧕 Nakamura K, Nagata C, Oba S, Takatsuka N, Shimizu H. Fruit and vegetable intake and mortality
from cardiovascular disease are inversely associated in Japanese women but not in men. J Nutr.
2008;138:1129-1134.
8㧕 Nagata C, Nakamura K, Fujii K, Kawachi T, Takatsuka N, Oba S, Shimizu H. Smoking and risk ofcedar pollinosis in Japanese men and women. Int Arch Allergy Immunol. 2008;147:117-124.
9㧕 Nagata C, Nakamura K, Fujii K, Kawachi T, Takatsuka N, Oba S, Shimizu H. Soy isoflavone intake is㧙㧙

IF 3.398
IF 2.361

IF 7.851

IF 2.361
IF 3.165
IF 4.098

IF 3.771
IF 2.160

not associated with the development of cedar pollinosis in adults. J Nutr. 2008;138:1372-1376.
10㧕 Oba S, Nagata C, Nakamura K, Takatsuka N, Shimizu H. Self-reported diabetes mellitus and risk ofmortality from all causes, cardiovascular disease, and cancer in Takayama: a population-based
prospective cohort study in Japan. J Epidemiol. 2008;18:197-203.
11㧕 Yoshimura T, Suzuki E, Ito I, Sakaguchi M, Uzu T, Nishio Y, Maegawa H, Morikawa S, Inubushi T,
Hisatomi A, Fujimoto K, Takeda J, Kashiwagi A. Impaired peripheral circulation in lower-leg arteriescaused by higher arterial stiffness and greater vascular resistance associates with nephropathy in type2 diabetic patients with normal ankle-brachial indices. Diabetes Res Clin Pract. 2008;80:416-423.
12㧕 Hirota T, Suzuki E, Ito I, Ishiyama M, Goto S, Horikawa Y, Asano T, Kanematsu M, Hoshi H, Takeda J.
Coronary artery calcification, arterial stiffness and renal insufficiency associate with serum levels oftumor necrosis factor-alpha in Japanese type 2 diabetic patients. Diabetes Res Clin Pract.
2008;82:58-65.

IF 3.771

IF 1.906

IF 1.823

IF 1.8234㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦ᄢᐸᔒ㊁㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(C)㧦੃≸ᖚ⠪ߩ≸ߩ࿃ᨐ㑐ଥⷰߣ≸߳ߩㆡᔕᐲ
ߦߟ޿ߡ㧧ᐔᚑ 17㧙18 ᐕᐲ㧧3,400 ජ౞(1,600㧦1,800 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦ᄢᐸᔒ㊁㧧⎇ⓥᵴᕈൻ(ක)ߩߚ߼ߩᡰេ੐ᬺ⚻⾌㧦৻⥸૑᳃ߦ߅ߌࠆฃേ༛ᾍߣ♧ዩ∛Ⴚ⇇ဳߩ㑐ㅪ㧧ᐔᚑ 18 ᐕᐲ㧧200 ජ౞3㧕 ⎇ⓥઍ⴫⠪㧦ᄢᐸᔒ㊁㧘⎇ⓥಽᜂ⠪㧦᳗↰⍮㉿㧘ጊᧄ⋿↱⟤㧘㋈ᧁ⧷ม㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦⢻േ෸߮ฃേ༛ᾍߣ♧ઍ⻢⢻ߩᜰᮡߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 20㧙22 ᐕᐲ㧧4,050 ජ౞(1,950㧦
1,400㧦700 ජ౞)
4㧕 ⎇ⓥઍ⴫⠪㧦ᄢᐸᔒ㊁㧧⎇ⓥ⑼㐳࡮කቇㇱ㐳ⵙ㊂⚻⾌ߦࠃࠆ⎇ⓥ⾌ߩ㊀ὐ⊛㈩ಽ㧦৻⥸૑᳃ߦ߅ߌ
ࠆ៨㘩෸߮ዞኢᤨೞߦଥࠆ↢ᵴ⠌ᘠߣⴊ♧୯෸߮♧ઍ⻢⢻ߩ㑐ㅪ㧧ᐔᚑ 20 ᐕᐲ㧧250 ජ౞
2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬ
㋈ᧁ⧷ม㧦1㧕 ᣣᧄ♧ዩ∛ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ߥߒ
8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേߥߒ㧙㧙

10㧚ႎ๔ᦠ
1㧕 ᄢᐸᔒ㊁㧦੃≸ᖚ⠪ߩ≸ߩ࿃ᨐ㑐ଥⷰߣ≸߳ߩㆡᔕᐲߦߟ޿ߡ㧦ᐔᚑ 17 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ႎ๔ᦠ㧦1㧙2(2006 ᐕ 1 ᦬)11㧚ႎ㆏ߥߒ12㧚⥄Ꮖ⹏ଔ
⹏ଔ޿ࠊࠁࠆ♧ዩ∛੍஻ァߦኻߔࠆ଻ஜᜰዉᣇᴺߩត⚝ߣ㧘♧ዩ∛᦭∛⠪ࠍᷫዋߐߖࠆߎߣߦߟ޿ߡߩ⎇ⓥ㧘♧ዩ∛ࠍ฽߻↢ᵴ⠌ᘠ∛ߩലᨐ⊛ߥ੍㒐ᣇᴺ╬ߩᖱႎ෼㓸ߣ⎇ⓥ㧘ਥⷐߥ↢ᵴ⠌ᘠ∛ߦ㑐ߔࠆవ┵ක≮߿⵬ቢ࡮ઍᦧක≮ߦߟ޿ߡߩᢥ₂⊛⎇ⓥᚑᨐߩᖱႎឭଏ㧘ߥߤߩ⎇ⓥࠍⴕߞߚ‫ޕ‬2006 ᐕ 1 ᦬㨪2008
ᐕ 12 ᦬߹ߢߩᧄ⻠ᐳߩ⎇ⓥᚑᨐߣߒߡ㧘ቇⴚ⺰ᢥߪ๺ᢥ 6 ႎߣ⧷ᢥ 12 ႎ㧘✚⺑ߣ⪺ᦠߪ๺ᢥ 1 ႎߩႎ๔߇ⴕࠊࠇߚ‫⻠ᧄޕ‬ᐳߩ⎇ⓥᚑᨐߪ㧘࿖ౝᄖߦะߌߡ㕖Ᏹߦᵴ⊒ߦႎ๔ߐࠇߚ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ᐔᚑ 21 ᐕ 3 ᦬ᧃߢ㧘ᒰೋ੍ቯߩ⻠ᐳ㐿⸳ᦼ㑆߇⚳ੌߔࠆ‫ޕ‬ᐔᚑ 21 ᐕ 4 ᦬એ㒠ߪ㧘ࡃ࠶ࠢࠕ࠶ࡊ⻠ᐳߢ޽ࠆ∉ቇ࡮੍㒐කቇಽ㊁ߦߡ⎇ⓥࠍ⛮⛯ߔࠆ੍ቯߢ޽ࠆ‫ޕ‬੹ᓟߩዷᦸߎࠇ߹ߢߣห᭽㧘↢ᵴ⠌ᘠ∛ߩ੍㒐ᣇᴺ╬ࠍ⺞ᩏ⎇ⓥߒߡ⌕ታߦᚑᨐࠍ޽ߍࠆߣߣ߽ߦ㧘⎇ⓥᚑᨐࠍ
ಽ߆ࠅ߿ߔߊ৻⥸ะߌߦ౏㐿ߒߡ㧘⋵᳃ߩஜᐽჇㅴߦነਈߔࠆ‫ޕ‬㧙㧙㧔12㧕ነ㒝⻠ᐳ‫ޟ‬㛽㑐▵ౣᑪᄖ⑼ቇ⻠ᐳ㧔ࠫࡦࡑ࡯㧕‫ޠ‬1㧚⎇ⓥߩ᭎ⷐ
⎇ⓥߪ⣄ᬁ⣄㜑ౣᑪᄖ⑼ߦ㑐ߔࠆ߽ߩ(ችᧄಎᢎ᝼ᜂᒰ)㧘ᘟᕈ㑐▵࡝࠙ࡑ࠴ߦ㑐ߔࠆ߽ߩ㧔૒⮮ᱜᄦഥᢎᜂᒰ㧕ߩ 2 ߟࠍࡔࠗࡦ࠹࡯ࡑߣߒߡⴕߞߡ߅ࠅ㧘એਅ߇⃻࿷ㅴⴕਛߩࡊࡠࠫࠚࠢ࠻ߢ޽ࠆ‫ޕ‬1㧕ᬁ㑆᧼⚵❱ߦ߅ߌࠆࠞ࡞ࡄࠗࡦߩዪ࿷ߩᬌ⸽
࠙ࠪ෸߮ࡅ࠻ߩᬁ㑆᧼⚵❱ߦ߅޿ߡ㧘ࠞ࡞ࡄࠗࡦߩዪ࿷ߩᬌ⸽ࠍⴕߞߚ‫ޕ‬ᬁ㑆᧼ᄌᕈߣࠞ࡞ࡄࠗࡦߩ
⊒⃻߇㑐ㅪߒߡ޿ࠆߎߣ߇᣿ࠄ߆ߣߥߞߚ‫ޕ‬
2㧕ᘟᕈ㑐▵࡝࠙ࡑ࠴ᖚ⠪ߦኻߔࠆ↢‛⵾೷ࠍ↪޿ߚᴦ≮ߦ߅ߌࠆ૕ౝࠨࠗ࠻ࠞࠗࡦߩᄌേߦߟ޿ߡߩ⎇ⓥ
3㧕ᬁ㑆᧼⚦⢩ᄖၮ⾰ઍ⻢ߦ߅ߌࠆࠞ࡞ࡄࠗࡦߩᓎഀߣ⸃᣿
࠙ࠪ෸߮ࡅ࠻ߩᬁ㑆᧼⚦⢩ࠍ↪޿㧘Ἳ∝࡮ᬁ㑆᧼ᄌᕈߣ޿߁ዪ㕙ߦ߅޿ߡࠞ࡞ࡄࠗࡦ߇ᬁ㑆᧼ၮ⾰ಽ⸃ߦ޿߆ߦ㑐ਈߔࠆ߆ߦߟ޿ߡ⎇ⓥࠍߔߔ߼ߡ޿ࠆ‫ޕ‬
4㧕ᘟᕈ㑐▵࡝࠙ࡑ࠴ᖚ⠪ߦኻߔࠆ↢‛⵾೷ࠍ↪޿ߚᴦ≮ߦ߅ߌࠆ೽૞↪ߩ⊒⃻㧘ߘߩ੍㒐ߦ㑐ߔࠆ⎇ⓥ
5㧕ࡅ࠻⣶ᬁ⩄㊀⽶⩄ߦ߅ߌࠆᬁ㑆᧼࡮ᬁ㑆㑐▵ߩᒻᘒᄌൻߦ㑐ߔࠆ⎇ⓥ
ࡅ࠻⣶ᬁߩ┙૏⩄㊀⁁ᘒࠍࠪࡒࡘ࡟࡯࠻ߔࠆⵝ⟎ࠍ૶↪ߒ㧘CT ᠟ᓇߦࠃߞߡᓧࠄࠇߚ⣶ᬁ↹௝ࠍ 3ᰴర⸃ᨆߒ㧘ᬁ㑆᧼࡮ᬁ㑆㑐▵ߩ 3 ᰴర⊛ᒻᘒᄌൻࠍ⸃ᨆߒߡ޿ࠆ‫ޕ‬
6㧕⣶ᬁⵝౕߩ૕ᐙ૏⟎ⷡ㧘ࠬࡐ࡯࠷ࡄࡈࠜ࡯ࡑࡦࠬߦਈ߃ࠆᓇ㗀ߩᬌ⸛⣶ᬁⵝౕ߇߽ߟ૕ᐙ૏⟎ⷡะ਄ലᨐ߇ࠬࡐ࡯࠷ࡄࡈࠜ࡯ࡑࡦࠬ(ࠧ࡞ࡈ㧘࠙ࠜ࡯ࠠࡦࠣ╬)ߦ޿߆ߥࠆ
ᓇ㗀ࠍਈ߃ࠆ߆ࠍ 3 ᰴరേ૞⸃ᨆߦߡᬌ⸽ߒߡ޿ࠆ‫ޕ‬7㧕⣶ᬁᄌᕈ஥ᒭ∝ߦኻߔࠆᓟᣇᬁ૕㑆࿕ቯⴚߦࠃࠆᄌᒻ⍶ᱜߩ 3 ᰴర⸃ᨆ⣶ᬁᄌᕈ஥ᒭ∝ߦኻߔࠆࡉ࡯ࡔ࡜ࡦဳࠬࡍ࡯ࠨ࡯ࠍ↪޿ߚᓟᣇᬁ૕㑆࿕ቯⴚߦࠃࠆᄌᒻ⍶ᱜ߇ᬁ㑆᧼ⷺ㧘ᬁ㑆㑐▵ᒻᘒߦਈ߃ࠆലᨐࠍ 3 ᰴర↹௝⸃ᨆߦࠃࠅᬌ⸽ߒߡ޿ࠆ‫ޕ‬8㧕ࡅ࠻㗪ᬁߩዮᦛિዷേᘒߦ߅ߌࠆ⎬⤑▤࡮㗪ㇱ⣄㜑ߩ 3 ᰴర⊛േᘒ⸃ᨆ⣄㜑ㅧᓇᬌᩏᓟߩࡈࠔࡦ࡚ࠢࠪ࠽࡞ CT ࠍ↪޿㧘ࡅ࠻㗪ᬁߩዮᦛિዷേᘒߦ߅ߌࠆ⎬⤑▤࡮㗪ㇱ⣄㜑
ߩ 3 ᰴర⊛േᘒ⸃ᨆࠍฦ⒳∛ᘒߣߩ㑐ㅪߦߡᬌ⸽ߒߡ޿ࠆ‫ޕ‬
9㧕⣶ᬁᄌᕈ஥ᒭ∝ߦኻߔࠆᓟᣇᬁ૕㑆࿕ቯⴚߦࠃࠆᄌᒻ⍶ᱜߩ 3 ᰴర⸃ᨆ⣶ᬁᄌᕈ஥ᒭ∝ߦኻߔࠆࡉ࡯ࡔ࡜ࡦဳࠬࡍ࡯ࠨ࡯ࠍ↪޿ߚᓟᣇᬁ૕㑆࿕ቯⴚߦࠃࠆᄌᒻ⍶ᱜ߇ᬁ㑆᧼ⷺ㧘ᬁ㑆㑐▵ᒻᘒߦਈ߃ࠆലᨐࠍ 3 ᰴర↹௝⸃ᨆߦࠃࠅᬌ⸽ߒߡ޿ࠆ‫ޕ‬10㧕㗪ᬁ㒰࿶ᚻⴚ(೨ᣇ㒰࿶㧘ᓟᣇ㒰࿶)߇⎬⤑▤࡮㗪ㇱ⣄㜑ߦਈ߃ࠆᒻᘒᄌൻߩᬌ⸛
㗪ᬁ೨ᣇ㒰࿶ⴚ㧘㗖ᬁᓟᣇ㒰࿶ⴚߩ 2 ⴚᑼ߇⎬⤑▤࡮㗪ㇱ⣄㜑ߦਈ߃ࠆᒻᘒᄌൻߩ⋧㆑ߦߟ޿ߡ
ultrasonography ࠍ↪޿ߡ㧘⥃ᐥᚑ❣ߣ㑐ㅪߐߖߡᬌ⸛ߒߡ޿ࠆ‫ޕ‬
11㧕MRI ߣ⣄㜑ㅧᓇᓟ CT ߩ⎬⤑▤࡮⣄㜑࡮㚍የ␹⚻ᒻᘒ⹏ଔߩ⋧㆑ߦ㑐ߔࠆ⎇ⓥ⣄ᬁ⣄㜑∔ᖚߦኻߔࠆ↹௝⸻ᢿߦ߅ߌࠆ 2 ߟߩઍ⴫⊛ᚻᴺߢ޽ࠆ MRI ߣ⣄㜑ㅧᓇᓟ CT ߦߟ޿ߡ㧘⎬⤑▤࡮⣄㜑࡮㚍የ␹⚻ᒻᘒ⹏ଔߩ⾰⊛࡮㊂⊛⋧㆑ࠍ᣿ࠄ߆ߦߒߚ‫ޕ‬12㧕ࡅ࠻⣄㜑ᶧߦ߅ߌࠆㆶరဳ࡮㉄ൻဳࠕ࡞ࡉࡒࡦߩേᘒߩ⎇ⓥ
ࡅ࠻⣖⣄㜑ᶧߦ߅ߌࠆㆶరဳ࡮㉄ൻဳࠕ࡞ࡉࡒࡦߩሽ࿷Ყ₸ߦߟ޿ߡ㧘ᐕ㦂㧘∔ᖚ╬ߩ࿃ሶࠍ฽߼ߡ
ᬌ⸽ࠍⴕߞߡ޿ࠆ(ಽሶ↢ℂቇ⻠ᐳߣ౒ห⎇ⓥ)‫ޕ‬
2㧚ฬ★
ಎᢎ᝼⋧ᒰ㧦 ችᧄ ᢘ
ഥᢎ⋧ᒰ㧦
૒⮮ᱜᄦ

Kei Miyamoto
Masao Sato3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
ߥߒ⪺ᦠ㧔᰷ᢥ㧕
1㧕 Shimizu K, Miyamoto K. Inflammatory Diseases of the Spine: Juvenile Rheumatoid Arthritis. In:
Surgery of the Pediatric Spine. New York: Thieme;2007:375-380.
✚⺑㧔๺ᢥ㧕ߥߒ㧙㧙✚⺑㧔᰷ᢥ㧕ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘ችᧄ ᢘ㧘⷏ᧄඳᢥ㧚㛽☻㝃∝ᕈ㛽᛬ߦኻߔࠆ⣄ᬁ⍴❗ⴚߩⴚᓟ⚻ㆊ㧘ਛㇱᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2006 ᐕ㧧49 Ꮞ㧦967㧙968㧚
2㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘ችᧄ ᢘ㧘⷏ᧄඳᢥ㧚㗖ᬁᓟ❑㕤Ꮺ㛽ൻ∝ߦኻߔࠆⴚᑼㆬᛯ㧘ᣣᧄ⣄ᬁ⣄㜑∛ቇળ㔀⹹ 2006 ᐕ㧧17 Ꮞ㧦525㧚3㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘㊄᫪ᐽᄦ㧘ችᧄ ᢘ㧘ዊේ ᣿㧚⣶ᬁᄌᕈߔߴࠅ∝ߦኻߔࠆ⚻ᬁ㑆ሹ⣶ᬁᬁ૕㑆࿕ቯⴚ(cantilever-TLIF)㧙PLIF ߣߩᲧセ㧙㧘ᣣᧄᢛᒻᄖ⑼ቇળ㔀⹹ 2006 ᐕ㧧80 Ꮞ㧦S285㧚
4㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘ችᧄ ᢘ㧘ጤ੗ᥓ቞↵㧚⣶ᬁᄌᕈ஥ᒗ∝ߦኻߔࠆ⚻ᬁ㑆ሹ⣶ᬁᬁ૕㑆࿕ቯⴚ㧘ਛㇱᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧50 Ꮞ㧦353㧙354㧚
5㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘ችᧄ ᢘ㧘⑔↰┨ੑ㧘ጤ੗ᥓ቞↵㧚㗖ㇱ⣄㜑∝ᚻⴚߩว૬∝㧙೨ᣇᴺ‫ޔ‬
ᓟᣇᴺߩᲧセ㧙㧘ਛㇱᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧50 Ꮞ㧦579㧙580㧚
6㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘ችᧄ ᢘ㧘⑔↰┨ੑ㧘ጤ੗ᥓ቞↵㧚㛽☻㝃∝ᕈᬁ૕㛽᛬ߦኻߔࠆࡀࠬࡊ
ࡠࡦࠤ࡯ࡉ࡞ࠍ૶↪ߒߚ⣄ᬁ⍴❗ⴚ㧘ᣣᧄ⣄ᬁࠗࡦࠬ࠻࠘࡞ࡔࡦ࠹࡯࡚ࠪࡦቇળ⹹ 2007 ᐕ㧧6 Ꮞ㧦25㧙
28㧚
7㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘ችᧄ ᢘ㧘ጤ੗ᥓ቞↵㧘⑔↰┨ੑ㧚⣶ᬁᄌᕈ஥ᒗ∝ߦኻߔࠆ⚻ᬁ㑆ሹ⣶ᬁᬁ૕㑆࿕ቯ㧘ᣣᧄ⣄ᬁ⣄㜑∛ቇળ㔀⹹ 2007 ᐕ㧧18 Ꮞ㧦223㧚
8㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘ችᧄ ᢘ㧘⑔↰┨ੑ㧘ጤ੗ᥓ቞↵㧚㛽☻㝃∝ᕈᬁ૕㛽᛬ߦኻߔࠆࡀࠬࡊ
ࡠࡦࠤ࡯ࡉ࡞ࠍ૶↪ߒߚ⣄ᬁ⍴❗ⴚ㧘ᣣᧄ⣄ᬁࠗࡦࠬ࠻࠘࡞ࡔࡦ࠹࡯࡚ࠪࡦቇળ⹹ 2007 ᐕ㧧6 Ꮞ㧦25㧙
28㧚
9㧕 ྾ᚭ㓉ၮ㧘૒⮮ᱜᄦ㧘㚍႐ጪ჻㧘ⷺ↰ ᕡ㧚ࡉࠪ࡜ࡒࡦ߇ᄼഞߒߚ㜞㦂⊒∝㑐▵࡝࠙ࡑ࠴߆ߩ 1 ଀߆ࠄ੹ᓟߩ࡝࠙ࡑ࠴ᴦ≮ࠍ⠨߃ࠆ㧘Pharma Medica 2008 ᐕ㧧26 Ꮞ㧦156㧙157㧚
10㧕 ૒⮮ᱜᄦ㧘྾ᚭ㓉ၮ㧘㚍႐ጪ჻㧘ⷺ↰ ᕡ㧘ጟ᧛⑲ੱ㧘㋈ᧁ ᷡ㧚LCS ੱᎿ⤒㑐▵⟎឵ⴚᓟߦ⣊㛽ࡌࠕ࡝ࡦࠣߩ⣕ォࠍ᧪ߚߒߚ 1 ଀㧘ጘ㒂ੱᎿ㑐▵ࡈࠜ࡯࡜ࡓ⹹ 2008 ᐕ㧧11 Ꮞ㧦9㧙12㧚
11㧕 ጟ᧛⑲ੱ㧘⮮ზ␭⟤㧘↰၂ᢕᦶ㧘྾ᚭ㓉ၮ㧘૒⮮ᱜᄦ㧚↢‛ቇ⊛⵾೷ߣ࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦߢ⪺᣿ߥ ADL
ߩᡷༀ߇ᓧࠄࠇߚ㑐▵࡝࠙ࡑ࠴(class 4)ߩ৻଀㧘ᣣᧄ RA ߩ࡝ࡂࡆ࡝⎇ⓥળ⹹ 2008 ᐕ㧧22 Ꮞ㧦89㧙92㧚
12㧕 ૒⮮ᱜᄦ㧘྾ᚭ㓉ၮ㧘㚍႐ጪ჻㧘ⷺ↰ ᕡ㧘ጟ᧛⑲ੱ㧘ᷡ᳓సᤨ㧚ක≮ᓥ੐⠪ߦ߅ߌࠆ⣶∩᦭⸷₸㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2008 ᐕ㧧51 Ꮞ㧦207㧙208㧚
13㧕 ྾ᚭ㓉ၮ㧘૒⮮ᱜᄦ㧘㚍႐ጪ჻㧘ⷺ↰ ᕡ㧚㜞㦂⠪ᄢ⣽㛽ㄭ૏ㇱ㛽᛬ᖚ⠪ߩട≮⁁ᴫ‫ޔ‬ㄭᐕߩᄌൻ㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2008 ᐕ㧧51 Ꮞ㧦419㧙420㧚
14㧕 ૒⮮ᱜᄦ㧘┻᧛ᱜ↵㧘྾ᚭ㓉ၮ㧘ᢧ⮮㇌᣿㧘ᷡፉ ḩ㧚᛫ CCP ᛫૕ߪ↢‛ቇ⊛⵾೷ߩലᨐ್ቯߦ᦭↪ߢ޽ࠆ߆㧫㧘ਛㇱ࡝࠙ࡑ࠴ 2008 ᐕ㧧39 Ꮞ㧦24㧙25㧚
15㧕 ↰ਛ 㗔㧘૒⮮ᱜᄦ㧘┻᧛ᱜ↵㧘྾ᚭ㓉ၮ㧘ᢧ⮮㇌᣿㧘ᷡፉ ḩ㧘ᷡ᳓సᤨ㧚㑐▵࡝࠙ࡑ࠴ߦ߅ߌࠆ Infliximabᴦ≮ലᨐߣⴊᷡࠠ࠿࡟࠾ࡦỚᐲߩᄌൻ㧘ਛㇱ࡝࠙ࡑ࠴ 2008 ᐕ㧧39 Ꮞ㧦26㧙27㧚
16㧕 ྾ᚭ㓉ၮ㧘૒⮮ᱜᄦ㧘㚍႐ጪ჻㧘ⷺ↰ ᕡ㧚㜞㦂⠪ᄢ⣽㛽ㄭ૏ㇱ㛽᛬ߩ࿷㒮ᣣᢙߦ㑐ߔࠆ࿾ၞᩰᏅ㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2008 ᐕ㧧51 Ꮞ㧦623㧙624㧚
17㧕 ૒⮮ᱜᄦ㧘྾ᚭ㓉ၮ㧘┻᧛ᱜ↵㧘ᷡፉ ḩ㧘ᢧ⮮㇌᣿㧚㑐▵࡝࠙ࡑ࠴ߦኻߔࠆࠨ࡜࠱ࠬ࡞ࡈࠔࡇ࡝ࠫࡦૐ
↪㊂ᛩਈߩᬌ⸛㧘⥃ᐥ࡝࠙ࡑ࠴ 2008 ᐕ㧧20 Ꮞ㧦188㧙193㧚
18㧕 ૒⮮ᱜᄦ㧘྾ᚭ㓉ၮ㧘㚍႐ጪ჻㧘ⷺ↰ ᕡ㧘ᷡ᳓సᤨ㧚↢‛ቇ⊛⵾೷ᴦ≮ߦ߅ߌࠆ∛⸻ㅪ៤㧘ਛㇱᣣᧄᢛ
ᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2008 ᐕ㧧51 Ꮞ㧦943㧙944㧚
19㧕 ྾ᚭ㓉ၮ㧘૒⮮ᱜᄦ㧘㚍႐ጪ჻㧘ⷺ↰ ᕡ㧚㜞㦂⠪ᄢ⣽㛽ㄭ૏ㇱ㛽᛬ᖚ⠪ߩᐕ㦂඙ಽߦࠃࠆᴦ≮ᚑ❣㧘᧲ᶏᢛᒻᄖ⑼ᄖ்⎇ⓥળ⹹ 2008 ᐕ㧧21 Ꮞ㧦96㧙98㧚
20㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘ችᧄᢘ㧘↰ਛஜ৻㇢㧘ጤ੗ᥓ቞↵㧘⑔↰┨ੑ㧚㛽☻㝃∝ᕈᬁ૕࿶ẩߦኻߔࠆᬁᑿࠍ
ߣࠄ߃ࠆ⣄ᬁ⍴❗ⴚ㧙ⴚᓟ㛽᛬ߣᓟᒗ㧙㧘ਛㇱᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ⹹ 2008 ᐕ㧧51 Ꮞ㧦643㧙644㧚
21㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘ችᧄᢘ㧘⑔↰┨ੑ㧘ጤ੗ᥓ቞↵㧚㗖ᬁ੝ో៰೨ᣇ࿕ቯⴚᓟߩ⣦㛽ቯ⌕ߣౝ࿕ቯ᧚ᢱߩᄌൻ㧙X ✢⹏ଔ㧙㧘⣄ᬁ࡮⣄㜑␹⚻ᚻⴚᚻᛛ ࡌࠬ࠻ࡍ࡯ࡄ࡯⾨ 2008 ᐕ㧧10 Ꮞ㧦117㧙119㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Masuda T, Miyamoto K, Hosoe H, Sakaeda H, Tanaka M, Shimizu K. Surgical treatment with spinal
instrumentation for pyogenic spondylodiscitis due to methicillin-resistant Staphylococcus aureus(MRSA): a report of five cases. Arch Orthop Trauma Surg. 2006;126:339-345.
2㧕 Masuda T, Miyamoto K, Shimizu K. Intramuscular hemodynamics in bilateral erector spinae muscles
in symmetrical and asymmetrical postures with and without loading. Clin Biomecha. 2006;21:245-253.
3㧕 Ohara A, Miyamoto K, Naganawa T, Matsumoto K, Shimizu K. Sagittal alignment of the cervicalspine: comparison of five standard methods of measurement. Spine. 2006;31:2585-2591.
4㧕 Fushimi K, Miyamoto K, Nishimoto H, Hosoe H, Kodama H, Shimizu K. Clinical outcomes ofmultilevel anterior corpectomy and fusion as a revision surgery of the cervical spine. Report of sevencases. Spinal Cord. 2006;44:449-456.
5㧕 Miyamoto K, Masuda K, Inoue N, Okuma M, Meuhlmem C, An HS. Anti-adhesion properties ofthrombin-based hemostatic gelatin in a canine laminectomy model. –a biomechanical, biochemical,
and histological study. Spine. 2006;31:E91-E97.

㧙㧙

IF 0.913
IF 1.642
IF 2.499

IF 1.578

IF 2.499

6㧕 Hosoe H, Miyamoto K, Wada E, Shimizu K. A surgical treatment of scoliosis in Larsen’s syndrome withbilateral hip dislocation: A case report. Spine. 2006;31:E302-E306.
7㧕 Ohnishi K, Miyamoto K, Hashimoto K, Hosoe H, Shimizu K. Mixed connective tissue disease (MCTD)
associated with atlantoaxial subluxation. A case report. Orthopaedics. 2006;29:369-370.
8㧕 Sasaki T, Miyamoto K, Hosoe H, Shimizu K. Transoral Anterior Approach Used for Extensive Anterior
Decompression of C3 Vertebrae Level in a Patient with Severe Atlantoaxial Vertical Subluxation andRheumatoid Arthritis - A Case Report -. Spinal Cord. 2006;44:52-55.
9㧕 Shimizu T, Miyamoto K, Masuda K, Miyata T, Hori H, Shimizu K, Maeda M. The clinical significanceof impaction at the femoral neck fracture site in the elderly. Arch Orthop Trauma Surg.
2007;127:515-521.
10㧕 Hosoe H, Shimizu K, Miyamoto K, Fukuta S, Iwai C. Cantilever-TLIF for patients with degenerative
scoliosis. Eur Spine J. 2007;16:S51.
11㧕 Aoki T, Terashima H, Itokazu M, Miyamoto K, Shimizu K. Stimulation of Music Prolonged
Disturbance of Consciousness Patients in Early Rehabilitation. J Saitama Kenou Rehabilitation.
2007;7:50-53.
12㧕 Nagano A, Miyamoto K, Fushimi K, Hosoe H, Shimizu K. Failure of reconstruction surgery using
anterior fibular strut grafting for postlaminectomy kyphosis A case report. J Clin Neurosci.
2007;14:376-379.
13㧕 Inoue T, Miyamoto K, Kodama H, Hosoe H, Shimizu K. Total spondylectomy for treatment of asymptomatic hemangioma of the lumbar spine - A case report. J Clin Neurosci. 2007;14:806-809.
14㧕 Yamada K, Miyamoto K, Hosoe H, Mizutani M, Shimizu K. Scoliosis associated with Prader-Willi
syndrome A case report. Spine J. 2007;7:345-348.
15㧕 Miyamoto K, Shimizu K, Matsumoto S, Sumida H, Iida H, Hosoe H. Surgical treatment of scoliosis
associated with central core disease: Minimizing the effects of malignant hyperthermia withprovocation tests - Report of a case -. J Pediatric Orthop B. 2007;16:239-242.
16㧕 Shimizu T, Miyamoto K, Masuda K, Miyata Y, Hori H, Shimizu K, Maeda M. The clinical significanceof impaction at the femoral neck fracture site in the elderly. Arch Orthop Trauma Surg.
2007;127:515-521.
17㧕 Shinohe R, Sato M, Takemura M, Shimizu K, Koishi K, Tanaka R, Saito K, Seishima M. Cytokine
profiles in mice with arthritis induced by anti-type II collagen monoclonal antibody plus
lipopolysaccharide. Jap J Clin Chem. 2008;37:53-62.
18㧕 Oguri K, Fujimoto H, Sugimori H, Miyamoto K, Tachi T, Nagasaki S, Kato Y, Matsuoka T. Pronounced
muscle deoxygenation during supramaximal exercise under simulated hypoxia in sprint athletes. J
Sport Sci Med. 2008;7:512-519.
19㧕 Kikuike K, Miyamoto K, Hosoe H, Kushima Y, Shimizu K. Double-level posterior spinal shortening forparalytic osteoporotic vertebral collapse of two vertebral bodies with a normal vertebra in between: acase report. Arch Orthop Trauma Surg. 2008;128:E221-224.
20㧕 Miyamoto K, Iinuma N, Ueki S, Shimizu K. Effects of Abdominal Belts on the Cross-Sectional Shape of
the Trunk during Intense Contraction of the Trunk Muscles Observed by Computer Tomography. Clin
Biomecha. 2008;23:1220-1226.
21㧕 Terabayashi N, Miyamoto K, Sakai H, Hosoe H, Shimizu K. Multiple steroid-induced vertebral
fracture with paraparesis associated with Wegener’s granulomatosis treated with posterior spinal
instrumentation. J Neurological Sciences (Turkish). 2008;25:67-71.
22㧕 Hioki A, Miyamoto K, Hosoe H, Fukuta S, Shimizu K. Two-stage decompression for combined epiconus
and cauda equina syndrome due to multilevel spinal canal stenosis of the thoracolumbar spine: a casereport. Arch Orthop Trauma Surg. 2008;128:955-958.
23㧕 Yamamoto T, Miyamoto K, Iinuma N, Sugiyama S, Nozawa S, Hosoe H, Shimizu K. Segmental Wire
Fixation for Lumbar Spondylolysis Associated with Spina Bifida Occulta. Arch Orthop Trauma Surg.
2008;128:1177-1182.
24㧕 Chi D, Miyamoto K, Hosoe H, Kawai G, Ohnishi K, Suzuki N, Sumi H, Shimizu K. Symptomatic
Lumbar Mobile Segment with Spinal Canal Stenosis in a Fused Spine Associated with Diffused
Idiopathic Skeletal Hyperostosis: A Case Report. Spine J. 2008;8:1019-1023.
25㧕 Hirakawa A, Miyamoto K, Ohno Y, Hioki A, Ogawa H, Nishimoto H, Yokoi T, Hosoe H, Shimizu K.
Two-Stage (posterior and anterior) surgical treatment of spinal osteomyelitis due to atypicalmycobacteria and associated thoracolumbar kyphoscoliosis in a non-immunocompromised patient.
Spine. 2008;32:E221-224.
26㧕 Hioki A, Ohnishi K, Miyamoto K, Hosoe H, Shimizu K. Spondylolysis of the Second Lumbar Vertebra
Treated with Segmental Wiring and Bone Grafting: A case report. Orthopaedics. 2008;31:287.
27㧕 Hioki A, Miyamoto K, Hosoe H, Shimizu K. Two-staged decompression for thoracic paraparesis due tothe combined ossification of the posterior longitudinal ligament and the ligamentum flavum: A casereport. Arch Orthop Trauma Surg. 2008;127:175-177.
28㧕 Hashimoto K, Miyamoto K, Hosoe H, Kawai G, Kikuike K, Shimokawa K, Suzuki N, Matsuo M,
Kodama H, Shimizu K. Solitary fibrous tumor in the cervical spine with destructive vertebral㧙㧙

IF 2.499
IF 0.581

IF 1.578

IF 0.913
IF 2.021

IF 0.801
IF 0.801

IF 0.619

IF 0.793

IF 0.290

IF 0.913

IF 1.642

IF 0.913

IF 0.913

IF 2.499
IF 0.581

IF 0.913

involvement: a case report and review of the literature. Arch Orthop Trauma Surg. 2008;128:1111-1116. IF 0.913
29㧕 Yamamoto T, Iinuma N, Miyamoto K, Sugiyama S, Nozawa S, Hosoe H, Shimizu K. Segmental wire
fixation for lumbar spondylolysis associated with spina bifida occulta. Arch Orthop Trauma Surge.
2008;128:1177-1182.
IF 0.793

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦ᄢ㊁⾆ᢅ㧘⎇ⓥಽᜂ⠪㧦ᧁ᧛ᱜᔒ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦㛽エㇱ⣲≌ߩࠝ࡯ࡠ࡜ࠠ࠽࡯࠯ߩ⸃ᨆ㧧ᐔᚑ 18㧙20 ᐕᐲ㧧3,600 ජ౞(2,600㧦500㧦500 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦⚦ᳯ⧷ᄦ㧘⎇ⓥಽᜂ⠪㧦ᄢ㊁⾆ᢅ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄⪚⧘⎇ⓥ㧦࡙࡯ࠗࡦࠣ⡺⣲ࡑ࠙ࠬࡕ࠺࡞ߩ᮸┙ߣ⸃ᨆ㧧ᐔᚑ 18㧙19 ᐕᐲ㧧3,300 ජ౞(2,600㧦700 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦Ⴧ↰೰ብ㧦ᐔᚑ 18 ᐕᐲጘ㒂ᄢቇᵴᕈൻ⎇ⓥ⾌㧦㛽エㇱ⣲≌ߦ߅ߌࠆ Aurora Kinaseߩ⸃ᨆ㧧ᐔᚑ 18 ᐕᐲ㧧200 ජ౞4㧕 ⎇ⓥઍ⴫⠪㧦Ⴧ↰೰ብ㧦ᢛᒻἴኂᄖ⑼ቇ⎇ⓥഥᚑ⽷࿅ ᐔᚑ 18 ᐕᐲ⎇ⓥഥᚑ㊄⑼⎇⵾⮎ᅑബ⾨㧦㛽エㇱ⣲≌ߦ߅ߌࠆࠝ࡯ࡠ࡜ࠠ࠽࡯࠯ߩᓎഀ㧧ᐔᚑ 18 ᐕᐲ㧧1,000 ජ౞5㧕 ⎇ⓥઍ⴫⠪㧦ጤ੗ᥓ቞↵㧧ᐔᚑ 19 ᐕᐲጘ㒂ᄢቇᵴᕈൻ⚻⾌㧦࡙࡯ࠗࡦࠣ⡺⣲ߦኻߔࠆⴊ▤ౝ⊹Ⴧᱺ࿃ሶࠍᮡ⊛ߣߒߚಽሶᮡ⊛ᴦ≮ߩ⎇ⓥ㧧ᐔᚑ 19 ᐕᐲ㧧1,120 ජ౞6㧕 ⎇ⓥઍ⴫⠪㧦ችᧄᢘ㧘⎇ⓥಽᜂ⠪㧦ᷡ᳓సᤨ㧧ᐔᚑ 19 ᐕᐲᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌ၮ⋚⎇ⓥ(C)㧦ౝ࿃ᕈἻ∝ᕈࠨࠗ࠻ࠞࠗࡦߩ೙ᓮࠍ࿑ߞߚᣂߒ޿ᬁ㑆᧼ౣ↢ࠕࡊࡠ࡯࠴㧧ᐔᚑ 18㧙20 ᐕᐲ㧧2,900 ජ
౞(1,100㧦1,100㧦700 ජ౞)
7㧕 ⎇ⓥઍ⴫⠪㧦᧻ጟᢅ↵㧘⎇ⓥಽᜂ⠪㧦ችᧄᢘ㧧ᣣᧄቇⴚᝄ⥝ળ⑼ቇ⎇ⓥ⾌ၮ⋚⎇ⓥ(C)㧦ਛ㜞㦂⠪ߩૐ㉄⚛ⅣႺਅ(ૐ㉄⚛ቶ)ߩㆇേ߇ࠛࡀ࡞ࠡ࡯ᶖ⾌㊂෸߮╭ߦ෸߷ߔᓇ㗀㧧ᐔᚑ 19㧙20 ᐕᐲ㧧2,860
ජ౞(1,560㧦1,300 ජ౞)
2㧕ฃ⸤⎇ⓥ
1㧕 ⎇ⓥઍ⴫⠪㧦ችᧄᢘ㧘⎇ⓥಽᜂ⠪㧦ᷡ᳓సᤨ㧧⚻ญ࡝ࡑࡊࡠࠬ࠻ߩ⣶ㇱ⣄ᩇ▤⁜⓰∝㐳ᦼᛩਈߩᣣ
Ᏹ↢ᵴᵴേᕈ‫ޔ‬QOL ߦኻߔࠆലᨐߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 20 ᐕᐲ㧧1,000 ජ౞㧦ዊ㊁⮎ຠᎿᬺ(ᩣ)
2㧕 ⎇ⓥઍ⴫⠪㧦ችᧄᢘ㧘⎇ⓥಽᜂ⠪㧦ᷡ᳓సᤨ㧧⚻ญ࡝࠮࠼ࡠࡀ࡯࠻⵾೷ߩㅳ৻᦯↪⵾೷෸߮Ფᣣ᦯
↪⵾೷ߩ㛽☻㝃ᖚ⠪ߦ߅ߌࠆ᦯⮎ࠦࡦࡊ࡜ࠗࠕࡦࠬߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 20 ᐕᐲ㧧1,000 ජ౞㧦ᱞ↰⮎ຠᎿᬺ(ᩣ)3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬችᧄᢘ㧦
1㧕 ጘ㒂⣄ᬁ⣄㜑ᙣ⹤ળ਎⹤ੱ(ᐔᚑ 18 ᐕᐲ㨪⃻࿷)2㧕 ጘ㒂⣄ᬁ࠮ࡒ࠽࡯਎⹤ੱ(ᐔᚑ 18 ᐕᐲ㨪⃻࿷)
3㧕 ᧲ᶏ⣄ᬁᄖ⑼⎇ⓥળᐙ੐(ᐔᚑ 20 ᐕᐲ㨪⃻࿷)૒⮮ᱜᄦ㧦
1㧕 ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ↹௝කቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ࡝࠙ࡑ࠴ቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ਛㇱᣣᧄ࡝࠙ࡑ࠴ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅ߥߒ㧙㧙3㧕ቇⴚ㔀⹹ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ችᧄ ᢘ㧦
1㧕 ╙ 9 ࿁ጘ㒂⣄ᬁ࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 7 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ᄌᕈᬁ㑆᧼߳ߩౣ↢ක≮ࠕࡊࡠ࡯࠴‫ޠ‬Ṷ⠪)
2㧕 ╙ 21 ࿁ᣣᧄᢛᒻᄖ⑼ቇળၮ␆ቇⴚ㓸ળ ࠪࡦࡐࠫ࠙ࡓ ࡔࠞ࠾ࠞ࡞ࠬ࠻࡟ࠬߣ㛽エ㛽ઍ⻢(ᐔᚑ 18
ᐕ 10 ᦬㧘㐳ፒ㧘Ṷ㗴‫ޟ‬EXPOSURE TO PULSED LOW INTENSITY ULTRASOUND STIMULATESMETABOLISM OF BOVINE INTERVERTEBRAL DISC CELLS CULTURED IN ALGINATEBEADS‫ޠ‬Ṷ⠪)
3㧕 ᐔᚑ 18 ᐕᐲ ጘ㒂ᄢቇᢛᒻᄖ⑼ቇᢎቶห㐷ળ✚ળ(ᐔᚑ 18 ᐕ 12 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ᬁ㑆᧼߳ߩౣ↢ᴦ≮ࠕࡊࡠ࡯࠴- 3 ᐕ㑆ߩ Chicago ⇐ቇࠍ⚳߃ߡ -‫ޠ‬Ṷ⠪)4㧕 ∩ߺߣἻ∝ 2007(ᐔᚑ 19 ᐕ 3 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬਎⇇ࠍ߼ߑߖ㧍ጘ㒂ߩ⣄ᬁ⥃ᐥ‫ޠ‬Ṷ⠪)
5㧕 ╙ 4 ࿁ጘ㒂ㆇേེࡊ࡜ࠗࡑ࡝࡯ࠤࠕ࡮࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 3 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬㗖ᬁ∔ᖚߩ∛⸻ㅪ៤㧙ߚ߆߇⢋ߎࠅ‫ߤࠇߐޔ‬⢋ߎࠅ㧙‫ޠ‬Ṷ⠪)
6㧕 ࡌࡀ࠶࠻ Weeklyjy ㍤ᣂ⊒ᄁ⸥ᔨ⻠Ṷળ(ᐔᚑ 19 ᐕ 6 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬㛽☻㝃∝ߦ઻߁⣶∩ߩ
QOL ⹏ଔ‫ޠ‬ᐳ㐳)7㧕 ੩ㇺᄢቇ⧯ᚻ⣄ᬁᄖ⑼කߩળ(ᐔᚑ 20 ᐕ 4 ᦬㧘ᄢ㒋Ꮢ㧘․೎⻠Ṷ‫ޟ‬㛽☻㝃ᕈ⣄ᬁ㛽᛬࿶ẩߦኻߔࠆ
ᄖ⑼⊛ᴦ≮‫ޠ‬Ṷ⠪)8㧕 ᐔᚑ 20 ᐕᐲᣣᧄ᧚ᢱቇળ↢૕࡮ක≮᧚ᢱㇱ㐷⻠Ṷળ(ᐔᚑ 20 ᐕ 12 ᦬㧘੩ㇺᏒ㧘․೎⻠Ṷ‫ޟ‬⣄ᬁߦ
ኻߔࠆ㊄ዻࠗࡦࡊ࡜ࡦ࠻ࠍ↪޿ߚᚻⴚᴦ≮ ́ㆊ෰࡮⃻࿷࡮ᧂ᧪́‫ޠ‬Ṷ⠪)૒⮮ᱜᄦ㧦
1㧕 ╙ 10 ࿁ጘ㒂ᄢቇᢛᒻᄖ⑼ᢎ⢒⎇ୃળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ᦨޟ‬ㄭߩ㑐▵࡝࠙ࡑ࠴⮎‛≮ᴺ‫ޠ‬ᐳ㐳)2㧕 ╙ 83 ࿁ጘ㒂⋵ᢛᒻᄖ⑼㓸⺣ળ(ᐔᚑ 20 ᐕ 6 ᦬㧘ጘ㒂㧘ᢎ⢒⎇ୃ⻠Ṷ‫ޟ‬㑐▵࡝࠙ࡑ࠴ᚻ∛ᄌߦኻߔࠆ
ᴦ≮‫ޠ‬ᐳ㐳)3㧕 ╙ 18 ࿁ਅํᏒ⮎೷Ꮷળቇⴚ⻠Ṷળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ਅํ㧘․೎⻠Ṷ‫ޟ‬㑐▵࡝࠙ࡑ࠴ߦ߅ߌࠆ⮎‛≮ᴺ‫ޠ‬Ṷ⠪)
8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ1㧕 ችᧄᢘ㧦New Investigator Recognition Award/ 52nd Ortopaedic Research Society (2006)2㧕 ችᧄᢘ㧦Russell Hibbs Award for the Best Basic Science Paper / The 41st Annual Meeting of
Scoliosis Research Society (2006)3㧕 ችᧄᢘ㧦CSRS Basic Science Research Award 3rd Prize / The 34th Annual Meeting of Cervical
Spine Research Society (2006)4㧕 ችᧄᢘ㧦ጘ㒂⣄ᬁ⣄㜑ᙣ⹤ળ ╙ 5 ࿁ᄢᱜࠕࡢ࡯࠼(ᐔᚑ 18 ᐕᐲ)‫ޟ‬ᬁ㑆᧼ࡃࠠࡘ࡯ࡓ⃻⽎ߩ⥃ᐥ⊛ᗧ⟵‫ ╙ޠ‬109 ࿁ਛㇱᣣᧄ
5㧕 ༑ਭ↢ஜᄥ㧘ችᧄᢘ㧘ㆃᄢ᣿㧘ᷡ᳓సᤨ㧦
ᢛᒻᄖ⑼࡮ἴኂᄖ⑼ቇળ ળ㐳ᅑബ⾨(ᐔᚑ 19 ᐕᐲ)
6㧕 ችᧄᢘ㧦╙ 15 ࿁ᣣᧄ⣄ᬁ࡮⣄㜑␹⚻ᚻⴚᚻᛛቇળ best paper ⾨(ᐔᚑ 20 ᐕᐲ)
9㧚␠ળᵴേችᧄᢘ㧦
1㧕 ጘ㒂⋵࡜ࠣࡆ࡯ࡈ࠶࠻ࡏ࡯࡞දળකോᆔຬળ೽ᆔຬ㐳(㨪⃻࿷)2㧕 ጘ㒂⋵ቇ↢ᨵ㆏ㅪ⋖ᐙ੐(ᐔᚑ 18 ᐕᐲ㨪⃻࿷)3㧕 ጘ㒂⋵ᨵ㆏ㅪ⋖කോᆔຬળᆔຬ(ᐔᚑ 20 ᐕᐲ㨪⃻࿷)10㧚ႎ๔ᦠ
ߥߒ
11㧚ႎ㆏
ߥߒ

㧙㧙

12㧚⥄Ꮖ⹏ଔ
⹏ଔၮ␆⎇ⓥ㧘⥃ᐥ⎇ⓥߩᚑᨐࠍ⧷ᢥ⺰ᢥߣߒߡႎ๔ߒߡ߈ߚ‫ߪߡ޿ߟߦࠇߎޕ‬㧘ࡑࡦࡄࡢ࡯߇ਇ⿷ߒߡ
޿ࠆߥ߆㧘චಽߦஜ㑵ߒߡ޿ࠆߣᕁࠊࠇࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ࠬ࠲࠶ࡈ߇⥃ᐥᵴേߣ⎇ⓥᵴേࠍਗⴕߒߡⴕߞߡ޿ࠆߩߢ㧘ᤨ㑆㧘ࡑࡦࡄࡢ࡯߇⿷ࠅߥ޿ᗵ߇޽ࠆ‫ޕ‬ߎࠇߦߟ޿ߡߪฦ⒳㑐ㅪᯏ㑐ߣߩኒߥ࠴࡯ࡓࡢ࡯ࠢ㧘౒ห૞ᬺ╬ߦߡ⵬޿ߚ޿‫ޕ‬੹ᓟߩዷᦸㄭᐕߩ㜞㦂⠪ߩභ߼ࠆഀว߇㜞޿ੱญᲧࠍ⠨߃ࠆߣ࿖᳃ߦ㗫ᐲߩ㜞޿⣄ᬁ∔ᖚ㧘ߘߒߡ㜞ᐲߩኾ㐷⊛ක≮ᛛⴚࠍⷐߔࠆᘟᕈ㑐▵࡝࠙ࡑ࠴ߦኻߔࠆᴦ≮ࠍࡔࠗࡦ࠹࡯ࡑߣߒߡ㧘⎇ⓥ࡮ᢎ⢒࡮⸻≮ࠍⴕߥߞߡ
޿ߊ૕೙ߢ޽ࠆ‫ߪߦࡈ࠶࠲ࠬޕ‬⣄ᬁ∔ᖚ㧘࡝࠙ࡑ࠴ᕈ∔ᖚࠍኾ㐷ߣߔࠆ 2 ฬࠍᠩߒ㧘ၮ␆⎇ⓥ࡮ᢎ⢒ߦ߅޿ߡጘ㒂⋵ߩ࠮ࡦ࠲࡯⊛ᓎഀࠍ᦭ߔࠆᯏ㑐ߣߒߡᯏ⢻ߒ㧘߆ߟጘ㒂ᄢቇ߳ߩ⽸₂ࠍⴕߞߡ޿߈ߚ޿‫ޕ‬ᄙ᭽ߥࡊࡠࠫࠚࠢ࠻ࠍ᦭ߒߡ߅ࠅ㧘ᄙߊߩ⥃ᐥක㧘⎇ⓥ⠪㧘කቇ↢㧘ડᬺߥߤ߇ෳടߒߡ޿ࠆ‫ࡓ࡯࠴ޕ‬ࡢ࡯ࠢ㧘⋧੕⽸₂ߩ♖␹ࠍ㊀ⷞߒ㧘⎇ⓥߩᵴേᕈ߇ߐࠄߦ޽߇ࠆࠃ߁ߦዧജࠍⴕ޿ߚ޿‫ޕ‬ၮ␆⎇ⓥ㧘⥃ᐥ⎇ⓥ㧘෸߮࠻࡜ࡦࠬ࡟࡯࡚ࠪ࠽࡞ߥ૏⟎ߠߌߩ⎇ⓥࠍ⛮⛯ߒߡⴕ޿㧘ᒰ⹥ಽ㊁ߦ߅ߌࠆ࠻࠶ࡊࠫࡖ࡯
࠽࡞߳ߩᛩⓂࠍ⋡ᜰߒߡദജࠍ㊀ߨߚ޿‫ߚ߹ޕ‬㧘ߎࠇ߹ߢߦߪᲧセ⊛ᚻ⭯ߢ޽ߞߚฦ⒳࿖ౝ࿖ᄖቇળᵴ
േ߽ᵴ⊒ߦⴕ޿㧘ᓧࠄࠇߚ⍮⷗ࠍᐢ߼ࠆദജࠍⴕ޿ߚ޿‫ߪߡ޿ߒޕ‬㧘ጘ㒂߆ࠄᣣᧄ㧘਎⇇ߦ߻ߌߡ⣄ᬁ㛽㑐▵ౣᑪᴦ≮ߩࠬ࠲ࡦ࠳࡯࠼ࠍ⊒ାߔࠆߎߣࠍ⋡⊛ߣߒߚ޿‫ޕ‬㧙㧙㧔13㧕ነ㒝⻠ᐳ‫ޟ‬࿾ၞක≮ቇ⻠ᐳ㧔ጘ㒂⋵㧕‫ޠ‬1㧚⎇ⓥߩ᭎ⷐ
ᧄ⻠ᐳߪ㧘એਅߩ⢛᥊ߩ߽ߣ㧘ጘ㒂⋵߇✚ോ⋭ߩหᗧࠍᓧߡᡰ಴ߔࠆነ㒝㊄ߦࠃࠅ⸳⟎ߐࠇ㧘ਅ⸥ౝኈߦߟ޿ߡ⺞ᩏ࡮⎇ⓥ࡮ታ〣ࠍⴕߞߡ޿ࠆ‫ޕ‬‫ޣ‬⢛᥊‫ޤ‬ᐔᚑ 16 ᐕᐲ߆ࠄ⟵ോൻߐࠇߚකᏧ⥃ᐥ⎇ୃ೙ᐲዉ౉એ㒠㧘ㇺᏒㇱߩ∛㒮ߢ⎇ୃࠍฃߌࠆකᏧ߇Ⴧടߒ㧘ᄢቇ∛㒮ߢ⎇ୃࠍฃߌࠆ߽ߩ߇ᷫዋߒߚ‫߼ߚߩߎޕ‬㧘ᧄ⋵ߦ߅޿ߡ߽ᄢቇකቇㇱ߆ࠄ࿾ᣇߩ∛㒮߳ߩකᏧᵷ㆜ᯏ⢻߇ૐਅߒ㧘࿾ၞක≮ߦᓥ੐ߔࠆකᏧߩਇ⿷߇ㅴߺ㧘࿾ၞߩක≮ឭଏ૕೙ߦᷓೞߥᓇ㗀߇಴ߡ߈ߚ‫ޕ‬ߎߩߚ߼㧘㒢ࠄࠇߚක≮⾗Ḯࠍ᦭ലߦᵴ↪ߒ㧘ක≮ᯏ㑐⋧੕ߩᯏ⢻ಽᜂߣㅪ៤ߦࠃࠅකᏧߩലᨐ⊛ߥ㈩⟎ࠍⴕ߁ߣߣ߽ߦ㧘৻ᣇߢ࿾ၞක≮ߦᾲᗧࠍᜬߞߚකᏧࠍ㙃ᚑߔࠆߎߣ߇ᕆോߣߥߞߡ޿ࠆ‫ޕ‬1㧕ੑᰴක≮࿤ߦ߅ߌࠆක≮ឭଏ૕೙ߩ⺖㗴ߣ⸃᳿╷ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ
1㧕⋡⊛࿾ၞߩၮᐙ⊛∛㒮ࠍਛᔃߣߒߚක≮ᯏ㑐⋧੕ߩᯏ⢻ಽᜂߣㅪ៤ߦࠃࠆല₸⊛ߥක≮ឭଏ૕೙ߣකᏧ
ߩലᨐ⊛ߥ㈩⟎ࠪࠬ࠹ࡓࠍ᭴▽ߔࠆߎߣࠍ⋡⊛ߣߔࠆ‫ޕ‬
2㧕ౝኈߣᚻᴺ
ੑᰴක≮࿤ߏߣߦᰴߩᚻᴺߦࠃࠅ㧘⺖㗴ߣ⸃᳿╷ࠍ⎇ⓥߔࠆ‫ޕ‬Ԙ ∔∛േะ⺞ᩏߣ૑᳃࠾࡯࠭ߩᛠីԙ ၮᐙ⊛∛㒮ࠍਛᔃߣߒߚ࿾ၞක≮ㅪ៤૕೙ߩ᭴▽Ԛ ㆡᱜߥක≮ኾ㐷⡯⒳㈩⟎ࠪࠬ࠹ࡓߩ㐿⊒
3㧕ᦼᓙߐࠇࠆലᨐ
ല₸⊛ߥක≮ឭଏ૕೙ߣലᨐ⊛ߥකᏧ㈩⟎ࠪࠬ࠹ࡓߥߤߦࠃࠅ㧘㒢ࠅ޽ࠆක≮⾗Ḯࠍᦨᄢ㒢ߦ᦭ലᵴ↪ߐࠇࠆߎߣߦࠃࠅ㧘࿾ၞක≮ߩలታߦߟߥߍࠆ‫ޕ‬
2㧕࿾ၞߩၮᐙ⊛∛㒮ࠍࡈࠖ࡯࡞࠼ߣߒߚ࿾ၞක≮ቇߩ⎇ⓥߣ࿾ၞක≮ࠍᜂ߁කᏧߩ㙃ᚑ1㧕⋡⊛
Ԙ ࿾ၞ․᦭ߩ∔∛ኻ╷ߩଦㅴߣ൮᜝ක≮ߩឭଏࠍ⋡⊛ߣߒߚ࿾ၞක≮ቇߩ⎇ⓥࠍታᣉߔࠆ‫ޕ‬ԙ ࿾ၞක≮ࠍᜂ߁කᏧߩ㙃ᚑࠍ⋡⊛ߣߒߡ㧘࿾ၞකኅቇߩ⎇ⓥࠍ฽߼ߚ㝯ജ⊛ߥ✚ว⥃ᐥක⢒ᚑࡊࡠࠣ࡜ࡓࠍ╷ቯߔࠆ‫ޕ‬
2㧕ౝኈߣᚻᴺ
Ԙ࿾ၞකኅቇߩ⎇ⓥ
٤࿾ၞ․᦭ߩ∔∛⊒↢ⷐ࿃ߦ㑐ߔࠆ࿾ၞ∉ቇ⎇ⓥԙ࿾ၞක≮ࠍᜂ߁කᏧߩ㙃ᚑ٤✚ว⥃ᐥක⢒ᚑࠞ࡝ࠠࡘ࡜ࡓߩ╷ቯ٤೨⸥ࠞ࡝ࠠࡘ࡜ࡓࠍ⛔วߒ㧘ㇺᏒㇱߩᄢⷙᮨ∛㒮ߢߩ㜞ᐲኾ㐷ක≮ߣ࿾ၞ࡮߳߈࿾ߩක≮ᯏ㑐ߢߩ෺ᣇ߇⎇ୃน⢻ߥጘ㒂⋵ᣇᑼߩ✚วක⢒ᚑࠞ࡝ࠠࡘ࡜ࡓࠍ╷ቯߔࠆ‫ޕ‬٤਄⸥ߦࠃࠅ㧘⥃ᐥ⎇ୃක╬ߦ࿾ၞක≮㨯කቇߩ㊀ⷐᕈࠍ⹺⼂ߐߖ⥝๧ࠍᜬߚߖࠆ‫ޕ‬
3㧕ᦼᓙߐࠇࠆലᨐ
࿾ၞ․᦭ߩ∔∛੍㒐ኻ╷ߣ൮᜝ක≮ߩឭଏ߇ଦㅴߐࠇࠆߣߣ߽ߦ㧘లታߒߚ✚ว⥃ᐥක⢒ᚑࠞ࡝ࠠࡘ
࡜ࡓߩ╷ቯߦࠃࠅ㧘࿾ၞක≮ࠍᜂ߁කᏧߩ㙃ᚑߩଦㅴߦߟߥ߇ࠆ‫ޕ‬
2㧚ฬ★
ᢎ᝼⋧ᒰ㧦
ቝ㊁ཅᒄ
ಎᢎ᝼⋧ᒰ㧦 Ꮉญ㗅ᢘ

Yoshihiro Uno
Yoshihiro Kawaguchi

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
ߥߒ⪺ᦠ㧔᰷ᢥ㧕ߥߒ㧙㧙✚⺑㧔๺ᢥ㧕ߥߒ✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ᨋ⟤૫㧘ጤᧁඳ⟤㧘᫪↰ᶈਯ㧘ḡ਄⧷⤿㧘ቝ㊁ཅᒄ㧘᫃↰๺↵㧘᧻ᧄ㓷⟤㧘ᳰ↰⾆⧷㧘᫪৻㇢㧘᧻ේஜᴦ㧘๺↰␭Ὼ㧘⍹Ⴆ㆐ᄦ㧚࿷ቛஜᐽ▤ℂࠪࠬ࠹ࡓߦࠃࠆ㒠࿶ലᨐ㧙ஜᐽ⸻ᢿߢߩ㕖೑↪⠪ߣߩᲧセ⎇ⓥ㧙㧘ᣣᧄ㆙㓒ක≮ቇળ㔀⹹ 2006 ᐕ㧧2 Ꮞ㧦222㧙223㧚
2㧕 ጤᧁඳ⟤㧘ᨋ⟤૫㧘᫪↰ᶈਯ㧘ḡ਄⧷⤿㧘ቝ㊁ཅᒄ㧘᫃↰๺↵㧘᧻ᧄ㓷⟤㧘ᳰ↰⾆⧷㧘᫪৻㇢㧘᧻ේஜᴦ㧘๺↰␭Ὼ㧘⍹Ⴆ㆐ᄦ㧚࿷ቛஜᐽ▤ℂࠪࠬ࠹ࡓߩ᦭↪ᕈ㧙ᔃ㔚࿑ߦࠃࠆਇᢛ⣂ߩ᦬೎࡮ᐕઍ೎ᄌേ㧙㧘ᣣᧄ㆙㓒ක≮ቇળ㔀⹹ 2006 ᐕ㧧2 Ꮞ㧦224㧙225㧚
3㧕 ᫪↰ᶈਯ㧘ቝ㊁ཅᒄ㧘⍹Ⴆ㆐ᄦ㧘଻૑ഞ㧘›Ⴆ⾆㧚කቇ↢ߦࠃࠆ⸰໧⋴⼔૕㛎ታ⠌ߩ⹏ଔ㧘කቇᢎ⢒ 2006ᐕ㧧37 Ꮞ㧦311㧙315㧚
4㧕 ᫪↰ᶈਯ㧘᳓㊁ᥓሶ㧘᫃↰๺↵㧘ቝ㊁ཅᒄ㧘ᳰ↰⾆⧷㧘᫪৻㇢㧘᧻ේஜᴦ㧘᧻ᧄ㓷⟤㧘㐳੗ቁᄥ㇢㧘⍹Ⴆ㆐ᄦ㧚ਔ஥ߦ೽⣢⊹⾰⣼⣲߇⷗ࠄࠇߚේ⊒ᕈࠕ࡞࠼ࠬ࠹ࡠࡦ∝ߩ 1 ଀㧙ฝࠕ࡞࠼ࠬ࠹ࡠࡦ↥↢⣼⣲ߣᏀ㕖ᯏ⢻ᕈ⣼⣲㧙㧘ᣣᧄౝಽᴲቇળ㔀⹹ ╙ 16 ࿁⥃ᐥౝಽᴲઍ⻢ Update Proceeding 2006 ᐕ㧧82 Ꮞ(Ⴧೀ)㧦
61㧙63㧚
5㧕 ㊁ᣇᢥ㓶㧘ቝ㊁ཅᒄ㧘᫪↰ᶈਯ㧘⍹Ⴆ㆐ᄦ㧘ᴡ᧛ᵗሶ㧘ᮮ↰ᐽᚑ㧘ਅਛᥓ㧘↰ਛ㕏ື㧚ஜᐽ㜞㦂⠪ᬌᩏࠪࠬ࠹ࡓߩ㐿⊒㧘ᣣᧄࠦࡦࡇࡘ࡯࠲ᄖ⑼ቇળ㔀⹹ 2006 ᐕ㧧8 Ꮞ㧦134㧙135㧚
6㧕 ᧻ේஜᴦ㧘᫪৻㇢㧘ᳰ↰⾆⧷㧘᧻ᧄ㓷⟤㧘᧖ጊජ਎㧘᫃↰๺↵㧘ቝ㊁ཅᒄ㧘᫪↰ᶈਯ㧘⍹Ⴆ㆐ᄦ㧚㐳ኼߦᓇ㗀ࠍਈ߃ࠆ࿃ሶߩᬌ⸛ ࿖ᐭ࡮⟤ጊ࿾඙Ყセ⎇ⓥ㧘ጘ㒂⋵ౝ⑼කળ㔀⹹ 2007 ᐕ㧧21 Ꮞ㧦19㧙21㧚
7㧕 ⍹Ⴆ㆐ᄦ㧘Ḋญା਽㧘⑔ᴛཅቁ㧘ൎᧁ㗼㧘ቝ㊁ཅᒄ㧚ࡔ࠲ࡏ࡝࠶ࠢࠪࡦ࠼ࡠ࡯ࡓ㧙ኾ㐷㗔ၞ߆ࠄߩࡔ࠶࠮
࡯ࠫߣ⸛⺰㧙ᣣᧄౝ⑼ቇળኾ㐷කㇱળᡰㇱ࠮ࡒ࠽࡯߆ࠄ㧘ᣣᧄౝ⑼ቇળ㔀⹹ 2007 ᐕ㧧96 Ꮞ㧦174㧙180㧚
8㧕 ᫪↰ᶈਯ㧘ᨋ⟤૫㧘ቝ㊁ཅᒄ㧘᫃↰๺↵㧘⮮ጟ࿻㧘᫪৻㇢㧘ᳰ↰⾆⧷㧘᧻ේஜᴦ㧘๺↰␭Ὼ㧘ጤᧁඳ⟤㧘ḡ਄⧷⤿㧘⍹Ⴆ㆐ᄦ㧚࿷ቛஜᐽ▤ℂࠪࠬ࠹ࡓ೑↪ߦࠃࠆ↢ᵴ⠌ᘠ∛㑐ㅪᜰᮡ߳ߩലᨐ㧙ஜᐽ⸻ᢿߢߩ㕖೑↪⠪ߣߩᲧセ⎇ⓥ㧙㧘ᣣᧄ㆙㓒ක≮ቇળ㔀⹹ 2007 ᐕ㧧3 Ꮞ㧦229㧙230㧚
9㧕 ᳰ↰⾆⧷㧘᫪↰ᶈਯ㧘ቝ㊁ཅᒄ㧘᫃↰๺↵㧘ችౝ࡞ࡒሶ㧘᫪৻㇢㧘⮮ጟ࿻㧘ጟ↰⧷ਯ㧘⮮ដ⾆ᢅ㧘๺↰␭Ὼ㧘⍹Ⴆ㆐ᄦ㧘ᄢႦዅ㧚㆙㓒ක≮ߩ࠾࡯࠭ߣ࠲࡯ࠥ࠶࠻㧙ጊ㑆࿾ၞߢߩ࿷ቛஜᐽ▤ℂࠪࠬ࠹ࡓᄾ⚂⠪߳ߩࠕࡦࠤ࡯࠻⺞ᩏ㧙㧘ᣣᧄ㆙㓒ක≮ቇળ㔀⹹ 2008 ᐕ㧧4 Ꮞ㧦306㧙307㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Takahashi M, Minatoguchi S, Nishigaki K, Kawasaki M, Arai M, Uno Y, Fujiwara H. Long-term andstrict blood pressure lowering by imidapril reverses left ventricular hypertrophy in patients withessential hypertension: an evaluation using a novel indicator of burden on the left ventricle.
Hypertens Res. 2006;29:89-94.
2㧕 Lu C, Arai M, Misao Y, Chen X, Wang N, Onogi H, Kobayashi H, Uno Y, Takemura G, Minatoguchi S,
Fujiwara T, Fujiwara H. Autologous bone marrow cell transplantation improves left ventricularfunction in rabbit hearts with cardiomyopathy via myocardial regeneration-unrelated mechanisms.
Heart Vessels. 2006;21:180-187.
3㧕 Suzuki K, Nagashima K, Arai M, Uno Y, Misao Y, Takemura G, Nishigaki K, Minatoguchi S, Watanabe
S, Tei C, Fujiwara H. Effect of granulocyte colony-stimulating factor treatment at a low dose but for along duration in patients with coronary heart disease. Circ J. 2006;70:430-437.
4㧕 Arai M, Misao Y, Nagai H, Kawasaki M, Nagashima K, Suzuki K, Tsuchiya K, Otsuka S, Uno Y,
Takemura G, Nishigaki K, Minatoguchi S, Fujiwara H. Granulocyte colony-stimulating factor: anoninvasive regeneration therapy for treating atherosclerotic peripheral artery disease. Circ J.
2006;70:1093-1098.
5㧕 Onogi H, Minatoguchi S, Chen XH, Bao N, Kobayashi H, Misao Y, Yasuda S, Yamaki T, Maruyama R,
Uno Y, Arai M, Takemura G, Fujiwara H. Edaravone reduces myocardial infarct size and improves
cardiac function and remodelling in rabbits. Clin Exp Pharmacol Physiol. 2006;33:1035-1041.
6㧕 Sugiyama C, Ishizawa M, Kajita K, Morita H, Uno Y, Matsubara K, Matsumoto M, Ikeda T, Ishizuka T.
Platelet aggregation in obese and diabetic subjects: association with leptin level. Platelets.
2007;18:128-134.
7㧕 Chen X, Minatoguchi S, Arai M, Wang N, Lu C, Narentuoya B, Uno Y, Misao Y, Takemura G, Fujiwara
T, Fujiwara H. Celiprolol, a selective beta1-blocker, reduces the infarct size through production of
nitric oxide in a rabbit model of myocardial infarction. Circ J. 2007;71:574-579.
8㧕 Ishizuka T, Miura A, Kajita K, Matsumoto M, Sugiyama C, Matsubara K, Ikeda T, Mori I, Morita H,
Uno Y, Mune T, Kanoh Y, Ishizawa M. Effect of dehydroepiandrosterone on insulin sensitivity in
Otsuka Long-Evans Tokushima fatty rats. Acta Diabetol. 2007;44:219-226.
9㧕 Kajita K, Mune T, Ikeda T, Matsumoto M, Uno Y, Sugiyama C, Matsubara k, Morita H, Takemura M,
Seishima M, Takeda J, Ishizuka T. Effect of fasting on PPARǫand AMPK activity in adipocytes.
Diabetes Res Clin Pract. 2008;81:144-149.

㧙㧙

IF 2.951

IF 1.043

IF 2.373

IF 2.373

IF 2.038

IF 1.915

IF 2.373

IF 1.619

IF 1.823

10㧕 Mori I, Ishizuka T, Morita H, Matsumoto M, Uno Y, Kajita K, Ikeda T, Fujioka K, Matsubara K.
Comparison of biochemical data, blood pressure and physical activity between longevity andnon-longevity districts in Japan. Circ J. 2008;72:1680-1684.
IF 2.373

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦᫪↰ᶈਯ㧘⎇ⓥಽᜂ⠪㧦⍹Ⴆ㆐ᄦ㧘ቝ㊁ཅᒄ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(B)(2)㧦㐳ኼߣ↢ᵴ⠌ᘠ㧙ጘ㒂↢ᵴ⠌ᘠ⺞ᩏ࡮੺౉ࡊࡠࠫࠚࠢ࠻㧙㧧ᐔᚑ 16㧙19 ᐕᐲ㧧14,900 ජ౞(7,600㧦4,000㧦1,900㧦1,400 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦㊁ᣇᢥ㓶㧘⎇ⓥಽᜂ⠪㧦᫪↰ᶈਯ㧘ቝ㊁ཅᒄ㧘㘵↰ብ᮸㧘㘵↰⌀⟤㧘ᮮ↰ᐽᚑ㧘⍹Ⴆ㆐ᄦ㧘ᷡፉḩ㧧⍮⊛ࠢ࡜ࠬ࠲࡯ഃ↢੐ᬺ㧙ࡠࡏ࠹࠶ࠢవ┵ක≮ࠢ࡜ࠬ࠲࡯㧙㧦ක≮⸻ᢿᡰេࠪࠬ࠹
ࡓߩ㐿⊒㧙േ⣂⎬ൻ⸃ᨆ࡮⸻ᢿࠪࠬ࠹ࡓ㧙㧧ᐔᚑ 17㧙20 ᐕᐲ 50,409 ජ౞(9,500㧦20,000㧦7,500㧦
13,409 ජ౞)
2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥ1㧕 ⍹Ⴆ㆐ᄦ㧘᫪↰ᶈਯ㧘ቝ㊁ཅᒄ㧘᫃↰๺↵㧘᧻ේஜᴦ㧘᧻ᧄ㓷⟤㧘ᳰ↰⾆⧷㧘᫪৻㇢㧦ጘ㒂⋵ౝߩ㐳ኼ࿾ၞߣ㕖㐳ኼ࿾ၞߢߩ㧘り૕߅ࠃ߮↢ᵴ⠌ᘠ(㘩੐㧘ㆇേ╬)ߩ∉ቇ⊛⺞ᩏߦࠃࠆේ࿃ߩ⸃᣿㧧ᐔ
ᚑ 18 ᐕᐲ㧧2,000 ජ౞㧦ࠗ࠮࠶࠻(ᩣ)
2㧕 ⍹Ⴆ㆐ᄦ㧘᫪↰ᶈਯ㧘ቝ㊁ཅᒄ㧘᫃↰๺↵㧘ᳰ↰⾆⧷㧘᫪৻㇢㧘⮮ጟ࿻㧘ችౝ࡞ࡒሶ㧦ᵹേ㘩㐳ᦼ៨ขߦࠃࠆࡔ࠲ࡏ࡝࠶ࠢ∝୥⟲ߩ੍㒐࡮ᡷༀലᨐ㧧ᐔᚑ 19 ᐕᐲ㧧2,970 ජ౞㧦᫪᳗੃ᬺ(ᩣ)
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫ
1㧕 ㊁ᣇᢥ㓶㧘᫪↰ᶈਯ㧘ቝ㊁ཅᒄ㧦⵬ᱜⵝ⟎(⊒᣿)㧧ᐔᚑ 19 ᐕ(․㗿 2006-003862)
6㧚ቇળᵴേ
1㧕ቇળᓎຬ
ቝ㊁ཅᒄ㧦
1㧕 ᣣᧄౝ⑼ቇળ᧲ᶏᡰㇱ⹏⼏ຬ(㨪⃻࿷)Ꮉญ㗅ᢘ㧦1㧕 ᣣᧄ੃≸ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳
ቝ㊁ཅᒄ㧦
1㧕 ᐔᚑ 20 ᐕᐲᣣᧄ㆙㓒ක≮ቇળᄢળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬࿾ၞක≮‫ޠ‬ᐳ㐳)Ꮉญ㗅ᢘ㧦
1㧕 ੃≸ቇળ᧲ᶏ࿾ᣇળ(ᐔᚑ 20 ᐕ 8 ᦬㧘㊄ᴛ㧘৻⥸Ṷ㗴‫ޟ‬ൻቇ≮ᴺ‫ޠ‬ᐳ㐳)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേߥߒ㧙㧙

10㧚ႎ๔ᦠ
ߥߒ
11㧚ႎ㆏
1㧕 ቝ㊁ཅᒄ㧘㊁ᣇᢥ㓶㧦5 ಽߢಽ߆ࠆⴊ▤ᐕ㦂 ጘ㒂ᄢ߇ᬌᩏࠪࠬ࠹ࡓ㐿⊒㧦ਛᣣࠬࡐ࡯࠷(2006 ᐕ 5
᦬ 31 ᣣ)2㧕 ቝ㊁ཅᒄ㧘㊁ᣇᢥ㓶㧦േ⣂⎬ൻᬌᩏ 5 ಽߦ⍴❗ ጘ㒂ᄢࠣ࡞࡯ࡊ㐿⊒㧦⺒ᄁᣂ⡞(2007 ᐕ 1 ᦬ 15 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔ
ᐔᚑ 19 ᐕ 11 ᦬ߦ⊒⿷ߒߚᒰ⻠ᐳߪ㧘߹ߛ㐿⸳㑆߽ߥ޿ߎߣ߆ࠄᒰ⻠ᐳࠝ࡝ࠫ࠽࡞ߩᬺ❣ߪዋߥ޿߇㧘੹ᓟߪ࿾ၞ߳߈࿾✚วක≮ಽ㊁ߣߒߡ␠ળ⊛ߥ⹺⍮߿⁛┙ᕈࠍ⠨߃㧘․⦡޽ࠆ⺰ᢥᬺ❣㧘⎇ⓥࠍㅴ߼ߡ޿߈ߚ޿‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷߹ߛ⊒⿷㑆߽ߥߊ㧘⎇ⓥ┙᩺㧘࠺࡯࠲෼㓸࡮⸃ᨆ㧘⺰ᢥ⸥タߥߤ⎇ⓥߦ⾌߿ߔᤨ㑆߇߆ߥࠅਇ⿷ߒߡ
޿ࠆߩ߇⃻⁁ߢ޽ࠆ‫ޕ‬ᒰᢎቶ‫ޟ‬࿾ၞ߳߈࿾✚วක≮ಽ㊁‫ߩޠ‬ᓎഀ߿㝯ജࠍలಽߦ⹺⼂ߒߡ߽ࠄ߃ࠆࠃ߁
ߦദജߒߡࠁߊ‫␠ޕ‬ળ⊛ߥ⹺⍮ᐲਇ⿷ߦኻߒߡߪ㧘੹ᓟቇળߢߩ⊒⴫߿⺰ᢥൻߣߣ߽ߦ㧘ነ㒝⻠ᐳߣߒߡጘ㒂⋵ߣදജߒߡ࿾ၞක≮ᵴേߦⓍᭂ⊛ߦᵴേߒߡࠁߊ‫ޕ‬
੹ᓟߩዷᦸ
2008 ᐕ 4 ᦬߆ࠄ㧘කቇㇱ࿾ၞᨒ౉ቇ↢ 10 ੱ߇౉ቇ㧘2009 ᐕ 4 ᦬߆ࠄߪหᣂ౉↢߇ 15 ੱߦჇຬߐࠇ
౉ቇߒߡߊࠆߎߣࠃࠅ㧘߹ߔ߹ߔᒰ⻠ᐳߩᢎ⢒ߦ߅ߌࠆ㊀ⷐᕈ߇᳞߼ࠄࠇߡߊࠆߣ⠨߃㧘ቇ↢ᢎ⢒ࠍਛᔃߦ࿾ၞᡰេ࡮⥃ᐥ⎇ⓥࠍផㅴߒߡࠁ߈ߚ޿‫ޕ‬߹ߚ㧘ో࿖⊛ߦᣂ⸳ߐࠇߡ߈ߡ޿ࠆฦ⋵ߩነ㒝⻠ᐳߢ޽ࠆ࿾ၞක≮ቇ⻠ᐳߣ࠲ࠗࠕ࠶ࡊߒߡᄙᣉ⸳ߢ
ߩ౒ห⎇ⓥࠍⴕ޿㧘ో࿖⊛ߦ࿾ၞක≮ߩᡷༀ࡮⊒ዷߦ㑐ਈߒߡࠁ߈ߚ޿‫ޕ‬㧙㧙㧔14㧕଻ஜ▤ℂ࠮ࡦ࠲࡯㧔ቇౝᣉ⸳㧕1㧚⎇ⓥߩ᭎ⷐ
⢈ḩߣ↢ᵴ⠌ᘠ∛㧘ญ⣧ౝᚲ⷗ߣ↢ᵴ⠌ᘠ㧘ቇ↢ߩ♖␹り૕⺞ᩏ㧘ᄢቇ↢ߩஜᐽታᘒ⺞ᩏߥߤࠍਛᔃߦ
⎇ⓥߦขࠅ⚵ࠎߢ޿ࠆ‫ޕ‬ቇ↢ᡰេ GP㧔ᣂߚߥ␠ળ⊛࠾࡯࠭ߦኻᔕߒߚቇ↢ᡰេࡊࡠࠣ࡜ࡓ㧕ߦࠃࠅ㧘‫↢ޟ‬ᶦஜᐽᢎ⢒ߩផㅴߣஜᐽᡰេߩలታ‫⑼ߩ߼ߚߩޠ‬ቇ⊛ᩮ᜚ࠍㅊ᳞ߒ㧘ౝᄖ߳ᖱႎ⊒ାߒߡ޿ࠆ‫ࠍࠇߎޕ‬ㅢ
ߓߡ࿾ၞ⽸₂ߦ߽ജࠍ౉ࠇߡ޿ࠆ‫ޕ‬2㧚ฬ★
ᢎ᝼(૬છ)㧦 ᷡ᳓సᤨ
ጊᧄ⋿↱⟤
ᢎ᝼㧦
↰ਛ↢㓷
ಎᢎ᝼㧦
ᵻ↰ୃᏒ
ഥᢎ㧦
૒ᷰᔘᵗ
ഥᢎ㧦

Katuji Shimizu
Mayumi Yamamoto
Mika Tanaka
Syuichi Asada
Tadahiro Sado

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ⚦ᳯ⧷ᄦ㧚⣶ㇱ⣄ᩇ▤⁜⓰∝ߩᴦ≮㧦ᷡ᳓సᤨ✬㧚ߎࠇߛߌߪ⍮ߞߡ߅߈ߚ޿ ⿷⣶ߩ∩ߺߩ⥄Ꮖ▤ℂ㧙⣶ㇱ⣄ᩇ▤⁜⓰∝ߩℂ⸃ߩߚ߼ߦ㧙㧘ᄢ㒋㧦ක⮎ࠫࡖ࡯࠽࡞㧧2006 ᐕ㧦22㧙37㧚
2㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧚⣄ᩇ஥ᒗ∝㧦⩵࿾⤿৻㧘ਛ᧛೑ቁ㧘⿧ᥓశᄦ✬㧚ᢛᒻᄖ⑼ኾ㐷කࠍ߼ߑߔߚ߼ߩ ⚻㛎ߔߴ߈ᄖ்࡮∔ᖚ 97㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2006 ᐕ㧦127㧙133㧚
3㧕 ጊᧄ⋿↱⟤㧚╙Σ▵ ஜᐽ⸻ᢿ㧦ጘ㒂⋵ᄢቇ଻ஜ▤ℂ⎇ⓥળ✬㧚ࠠࡖࡦࡄࠬ࡜ࠗࡈߩஜᐽ▤ℂ㧘ጘ㒂㧦ጘ㒂ᣂ⡞␠㧧2006 ᐕ㧦8㧙11㧚
4㧕 ጊᧄ⋿↱⟤㧚╙Χ▵ ᗵᨴ∝㧦ጘ㒂⋵ᄢቇ଻ஜ▤ℂ⎇ⓥળ✬㧚ࠠࡖࡦࡄࠬ࡜ࠗࡈߩஜᐽ▤ℂ㧘ጘ㒂㧦ጘ㒂ᣂ⡞␠㧧2006 ᐕ㧦89㧙92㧚
5㧕 ጊᧄ⋿↱⟤㧚ઃ㍳ 1 ක≮࡮⑔␩೙ᐲ㧦ጘ㒂⋵ᄢቇ଻ஜ▤ℂ⎇ⓥળ✬㧚ࠠࡖࡦࡄࠬ࡜ࠗࡈߩஜᐽ▤ℂ㧘ጘ㒂㧦ጘ㒂ᣂ⡞␠㧧2006 ᐕ㧦111㧙113㧚
6㧕 ⚦ᳯ⧷ᄦ㧚⣶ㇱ⣄ᩇ▤⁜⓰∝ߩᴦ≮㧦ᷡ᳓సᤨ✬㧚ࡐࠤ࠶࠻  ߎࠇߛߌߪ⍮ߞߡ߅߈ߚ޿ ⿷⣶ߩ∩ߺߩ⥄Ꮖ▤ℂ㧙⣶ㇱ⣄ᩇ▤⁜⓰∝ߩℂ⸃ߩߚ߼ߦ㧙㧘ᄢ㒋㧦ක⮎ࠫࡖ࡯࠽࡞㧧2007 ᐕ㧦38㧙66㧚
7㧕 ᷡ᳓సᤨ✬⪺㧚⣶ᬁᄌᕈߔߴࠅ∝㧙⑳ߩࠗࡦࡈࠜ࡯ࡓ࠼ࠦࡦ࠮ࡦ࠻㧦࠻࡜ࡉ࡞ߦߥࠄߥ޿ᢛᒻᄖ⑼ࠗࡦࡈ
ࠜ࡯ࡓ࠼ࠦࡦ࠮ࡦ࠻㧘᧲੩㧦㊄ේ಴ 㧧2007 ᐕ㧦212㧙213㧚
8㧕 ਛ᧛ᱜ↢㧘ᷡ᳓సᤨ✬⪺㧚⣶ㇱ⣄ᬁ⣄ᩇ▤⁜⓰∝㧙⸻ᢿߣᴦ≮㧙㧦⠧ᐕකቇ update 2007-08㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2007 ᐕ㧦14㧙24㧚
9㧕 㕍ᧁ㓉᣿㧘ᷡ᳓సᤨ✬⪺㧚⣶∩ߩㆇേ≮ᴺ㧦⣶∩⍮ࠆ⸻ࠆᴦߔ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦130
㧙155㧚
10㧕 ጊᧄ⋿↱⟤㧚╙ 7 ┨⚵❱ߩᵴᕈൻ‫غ‬
1 ੱ᧚▤ℂ㧦ක≮⚻༡ᢎ⢒ද⼏ળ✬㧚ක≮ࡑࡀࠫࡔࡦ࠻́ක≮ߩ⾰ะ਄ߩߚ߼ߩක≮⚻༡ቇ́㧘᧲੩㧦ᣣ⚻ࡔ࠺ࠖࠞ࡞㐿⊒㧧2008 ᐕ㧦148㧙169㧚
11㧕 ጊᧄ⋿↱⟤㧚╙ 7 ┨⚵❱ߩᵴᕈൻ‫غ‬
3 ࠻࡯࠲࡞ࠢࠝ࡝࠹ࠖࡑࡀࠫࡔࡦ࠻(TQM)㧦ක≮⚻༡ᢎ⢒ද⼏ળ✬㧚ක≮ࡑࡀࠫࡔࡦ࠻́ක≮ߩ⾰ะ਄ߩߚ߼ߩක≮⚻༡ቇ́㧘᧲੩㧦ᣣ⚻ࡔ࠺ࠖࠞ࡞㐿⊒㧧2008 ᐕ㧦191㧙205㧚⪺ᦠ㧔᰷ᢥ㧕
1㧕 Shimizu K, Miyamoto K. Inflammatory diseases of the spine-juvenile rheumatoid arthritis. In:
Surgery of the Pediatric Spine. New York: Thieme;2007:375-380.
✚⺑㧔๺ᢥ㧕
1㧕 ᷡ᳓సᤨ㧚․㓸 ᚻߩ∩ߺߩ⸻ᢿߣᴦ≮ ᐨ㧘∩ߺߣ⥃ᐥ 2006 ᐕ㧧6 Ꮞ㧦1㧚
2㧕 ㊄᫪ᐽᄦ㧘ᷡ᳓సᤨ㧚⣶∩ ᕆᕈ⣶∩ߣᘟᕈ⣶∩㧘⥃ᐥߣ⎇ⓥ 2006 ᐕ㧧83 Ꮞ㧦12㧙15㧚
3㧕 ᷡ᳓సᤨ㧚ࠪࡦࡐࠫ࠙ࡓ ⣶ㇱ⣄ᩇ▤⁜⓰∝㧙ᦨㄭߩㅴᱠ㧙 ✜⸒㧘⥃ᐥᢛᒻᄖ⑼ 2006 ᐕ㧧41 Ꮞ㧦852㧚
4㧕 ᷡ᳓సᤨ㧚ᣣᧄ⣄ᬁ⣄㜑∛ቇળߣർ☨⣄ᬁ㑐ㅪቇળߣߩ੤ᵹ 㧙Spine Across the Sea ႎ๔㧙㧘⣄ᬁ⣄㜑ࠫࡖ࡯࠽࡞ 2006 ᐕ㧧19 Ꮞ㧦1174㧙1175㧚
5㧕 ᷡ᳓సᤨ㧚ጘ㒂⟤Ớ⥄ォゞ↢ᵴ㧘ᢛᒻᄖ⑼ 2006 ᐕ㧧57 Ꮞ㧦1798㧚
6㧕 ጊᧄ⋿↱⟤㧚ൕഭ⠪ߩ♧ዩ∛ߩ∛ᘒߣ੍㒐㧘ᕺ㇊කᏧળߛࠃࠅ 2006 ᐕ㧧50 Ꮞ㧦35㧙41㧚
7㧕 ጊᧄ⋿↱⟤㧚੍㒐ធ⒳ߦߟ޿ߡ㧘ጘᄢ߭ࠈ߫ 2006 ᐕ㧧47 Ꮞ㧦8㧙10㧚
8㧕 ᷡ᳓సᤨ㧚৻⥸ౝ⑼ක߇⍮ߞߡ߅߈ߚ޿⣶∩ߩ⸻ᢿᴦ≮㧘ጘ㒂ᏒකᏧળߛࠃࠅ 2007 ᐕ㧧39 Ꮞ㧦25㧙27㧚
9㧕 ⑔↰┨ੑ㧘ᷡ᳓సᤨ㧚⣄ᬁ㛽㜑Ἳߩ⸻ᢿߣᴦ≮㧘㛽࡮㑐▵࡮㕤Ꮺ 2007 ᐕ㧧20 Ꮞ㧦455㧙461㧚
10㧕 ᷡ᳓సᤨ㧚⣄ᬁౝⷞ㏜ਅᚻⴚ㧙ၮᧄᚻᛛ߆ࠄᛛⴚ⹺ቯ߹ߢ㧘ᢛᒻᄖ⑼ 2007 ᐕ㧧58 Ꮞ㧦1656㧚
11㧕 ᷡ᳓సᤨ㧚⣶ߩ∩ߺ(⣶ㇱ⣄ᩇ▤⁜⓰∝)ࠍ㒐ߋ㧘ࠢ࠶ࠢ㧒࡜ࠗࡈ 2007 ᐕ㧧433 Ꮞ㧦8㧙9㧚
12㧕 ጊᧄ⋿↱⟤㧚ᮡḰ⊛ߥஜ⸻࡮଻ஜᜰዉࡊࡠࠣ࡜ࡓߩታᣉߣ♧ዩ∛੍㒐ኻ╷㧘ᕺ㇊කᏧળߛࠃࠅ 2007 ᐕ㧧
55 Ꮞ㧦17㧙20㧚
13㧕 ೨ේ⑲੫㧘ᷡ᳓సᤨ㧚ࠞ࡞ࡄࠗࡦߣᄌᕈᕈ㑐▵∝㧘೎ౠᢛᒻᄖ⑼‫ޛ‬ᄌᕈᕈ㑐▵∝㧙ᦨㄭߩ⍮⼂‫ ޜ‬2008 ᐕ㧧㧙㧙53 Ꮞ㧦38㧙41㧚
14㧕 ᧻ᧄ቞㓶㧘ජ⪲৻⵨㧘ᚭጊ⧐ᤘ㧘┻ਅసᔒ㧘ᤊ࿾੝ㇺม㧘ਛ᧛⠹ਃ㧘᦭᳓ ᷕ㧘⮮ᨋବ੺㧘ᐔᨋ ⨃㧘ᐔ㊁ ᔀ㧘ጤፒᐙቄ㧘㊄ጟᕡᴦ㧘Ꮉญༀᴦ㧘੗ዥᐘᚑ㧘೨↰ ᑪ㧘᧻ጊᐘᒄ㧘ਃ਄㕏ᄦ㧘᧛਄⧷᮸㧘᳗ፉ⧷᮸㧘᳗↰⷗↢㧘ਛේㅴਯ੺㧘㊁ේ ⵨㧘ጟ ผᦶ㧘㒋ᧄ᩵ㅧ㧘₎ᯅᐽ㓶㧘╣↢ ⼾㧘ᷡ᳓సᤨ㧘↰ญᢅᒾ㧘㜞ᯅ ⺈㧘↰ਛ㕏ਭ㧘⼱ ବ৻㧘ᓼᯅᵏ᣿㧘ౝ↰⎇ㅧ㧘ጊᧄ⻞๋㧘ጊፒᱜᔒ㧘ᮮጊ ᔀ㧘ศ↰ቬੱ㧘⷏⣁␭ม㧚⢷ᬁᓟ❑㕤Ꮺ㛽ൻ∝ߦኻߔࠆᚻⴚᚑ❣ߦᓇ㗀ࠍਈ߃ࠆ࿃ሶߩᬌ⸛㧙ઁᣉ⸳ᓟࠈะ߈⎇ⓥ㧙 ⹹਄ࠪࡦࡐࠫ࠙ࡓ ⢷ᬁᓟ❑㕤Ꮺ㛽ൻ∝ߩᴦ≮㧙ᦨㄭߩㅴᱠ㧘⥃ᐥᢛᒻᄖ⑼ (೎೚) 2008 ᐕ㧧43 Ꮞ㧦531㧙538㧚
15㧕 ᷡ᳓సᤨ㧚㗖ᬁ∝㧘OPLL ߩᚻⴚᴦ≮㧘ฬฎደ㧦ਛㇱធ㛽ቇળ⹹ 2008 ᐕ㧧89 Ꮞ㧦19㧚✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘㊄᫪ᐽᄦ㧚㗖ᬁᓟ❑㕤Ꮺ㛽ൻ∝ߦኻߔࠆᣂߒ޿ゲᬁㇱᓟᣇ㒰࿶ᴺ㧘⣄ᬁ࡮⣄㜑␹⚻ᚻⴚᚻᛛ 2006 ᐕ㧧8 Ꮞ㧦79㧙82㧚
2㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘㊄᫪ᐽᄦ㧘ዊේ᣿㧚⣶ᬁᄌᕈߔߴࠅ∝ߦኻߔࠆ⚻ᬁ㑆ሹ⣶ᬁᬁ૕㑆࿕ቯⴚ(cantilever㧙TLIF)ߩ⚻㛎㧘ਛㇱᢛἴ⹹ 2006 ᐕ㧧49 Ꮞ㧦31㧙32㧚
3㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘ችᧄ ᢘ㧘⷏ᧄඳᢥ㧚㛽☻㝃∝ᕈ㛽᛬ߦኻߔࠆ⣄ᬁ⍴❗ⴚߩⴚᓟ⚻ㆊ㧘ਛㇱᢛἴ⹹ 2006 ᐕ㧧49 Ꮞ㧦967㧙968㧚
4㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘ችᧄ ᢘ㧘⷏ᧄඳᢥ㧚㗖ᬁᓟ❑㕤Ꮺ㛽ൻ∝ߦኻߔࠆⴚᑼㆬᛯ㧘ᣣᧄ⣄ᬁ⣄㜑∛ቇળ㔀⹹ 2006 ᐕ㧧17 Ꮞ㧦525㧚
5㧕 ↰ਛ㗔㧘ᄢ㊁⾆ᢅ㧘ᄢ㊁⟵ᐘ㧘ᷡ᳓సᤨ㧘⷏ᧄ⵨㧘ᑝἑༀା㧘᧻᳗⎇๋㧚ᧃ▵㛽㛽⣲≌ߩ 1 ଀㧘᧲ᶏ㛽エㇱ⣲≌ 2006 ᐕ㧧18 Ꮞ㧦43㧙44㧚
6㧕 ㋈ᧁ⋥᮸㧘㊄᫪ᐽᄦ㧘᧖ጊ⺈৻㧘⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧚਄૏⣶ᬁᬁ㑆᧼ࡋ࡞࠾ࠕᓟᣇ៰಴ⴚᓟߦ೨ᣇ࿕ቯ
ࠍⷐߒߚ 1 ଀㧘᧲ᶏ⣄ᬁᄖ⑼ 2006 ᐕ㧧20 Ꮞ㧦5㧙9㧚
7㧕 ㋈ᧁ⋥᮸㧘㊄᫪ᐽᄦ㧘᧖ጊ⺈৻㧘⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧚⣶ᬁᄌᕈ஥ᒗߦ೨ᣇ࿕ቯࠍⴕߞߚ 2 ∝଀㧘᧲ᶏ⣄
ᬁᄖ⑼ 2006 ᐕ㧧20 Ꮞ㧦102㧙108㧚
8㧕 ᷡ᳓సᤨ㧘⚦ᳯ⧷ᄦ㧘᧖ጊ⺈৻㧘⧯ᨋ ⧷㧘㊁‫⻀᧛ޘ‬㚅㧚Informed Consent ߩታ㓙㧘ᣣᢛળ⹹ 2006 ᐕ㧧
80 Ꮞ㧦33㧙34㧚
9㧕 Ⴧ↰೰ብ㧘ᷡ᳓సᤨ㧚ᗵᨴᕈ⣄ᬁἻߦኻߔࠆ⣄ᬁࠗࡦࠬ࠷࡞ࡔࡦ࠹㧙࡚ࠪࡦᚻⴚ㧘Orthopaedics 2006ᐕ㧧19 Ꮞ㧦25㧙32㧚
10㧕 ㊁Ỉ ⡡㧘ᷡ᳓సᤨ㧚ࠬࡐ࡯࠷ㆬᚻߦ߅ߌࠆ⣶ᬁಽ㔌∝ߦኻߔࠆᚻⴚ≮ᴺ㧙segmental wire fixation ᴺ㧙㧘
Orthopaedics 2006 ᐕ㧧19 Ꮞ㧦15㧙21㧚
11㧕 ફ⷗৻ᚑ㧘ᷡ᳓సᤨ㧚ᄌᒻᕈ㑐▵∝エ㛽ߦ߅ߌࠆࠞ࡞ࡄࠗࡦߩ⊒⃻㧘ጘ㒂⋵කᏧળකቇ㔀⹹ 2006 ᐕ㧧19
Ꮞ㧦81㧙84㧚
12㧕 ᧻ᧄ ๺㧘દ⮮⧐Პ㧘♻ᢙਁᱜ㧘ᱞౝ┨ੑ㧘ᷡ᳓సᤨ㧚㒸ᣥᕈ೸㔌㛽 ߦࠃࠅ↢ߓߚ⤒⬄㛽੝⣕⥓ߩ 1 ଀㧘ᢛᒻᄖ⑼ 2006 ᐕ㧧57 Ꮞ㧦1623㧙1625㧚
13㧕 ᧻ᧄ ๺㧘દ⮮⧐Პ㧘⑔↰ 㓷㧘♻ᢙਁᱜ㧘ᷡ᳓సᤨ㧚Smith-Petersen ㅴ౉ᴺ߇᦭↪ߢ޽ߞߚੱᎿ⢆㑐▵ౣ⟎឵ⴚߩ 2 ଀㧘Hip Joint ೎೚ 2006 ᐕ㧧32 Ꮞ㧦411㧙414㧚
14㧕 㕍ᧁ㓉᣿㧘ኹፉብ᣿㧘♻ᢙਁᱜ㧘ᷡ᳓సᤨ㧘ਤ⠀᡽⟤㧘ዊ㊁Ⴆኪ㧚⣶ㇱ⣄ᩇ▤⁜⓰∝ᖚ⠪ߩ⚻ญ PGE1 ⺃ዉ૕⵾೷ᛩਈߦ߅ߌࠆ࠻࡟࠶࠼ࡒ࡞⹏ଔ㧘ᣂ⮎ߣ⥃ᐥ 2006 ᐕ㧧55 Ꮞ㧦74㧙76㧚
15㧕 ᄢ㊁⟵ᐘ㧘ᐔᎹ᣿ᒄ㧘ᷡ᳓సᤨ㧚ᚻ㑐▵⚿ᩭߩᚻⴚᴦ≮ߩ⚻㛎㧘ᣣᧄ㛽࡮㑐▵ᗵᨴ∝ቇળ㔀⹹ 2006 ᐕ㧧
20 Ꮞ㧦29㧙31㧚
16㧕 ᄢ㊁⟵ᐘ㧘ᐔᎹ᣿ᒄ㧘ᷡ᳓సᤨ㧚ᧃ▵㛽߇㔺಴ߒߚᜰውㇱ⊹⤏ᰳ៊ߦኻߔࠆㆆ㔌⊹ᑯ⒖ᬀߩ⚻㛎㧘ᣣᧄᚻ
ߩᄖ⑼ቇળ㔀⹹ 2006 ᐕ㧧23 Ꮞ㧦209㧙212㧚
17㧕 ᓮ↰᧛⋧ᮨ㧘㐳ἑᳯ೑㧘ᧄᄙᕶሶ㧘↰ਛ↢㓷㧘ᵻ↰ୃᏒ㧘ᱞ↰⚐㧘ጊᧄ⋿↱⟤㧚ጘ㒂ᄢቇߦ߅ߌࠆ⑌ᾍኻ
╷ߩ᦭ലᕈߩᬌ⸛㧙࠾ࠦ࠴ࡦࡄ࠶࠴ߩቇ↢ήఘឭଏࠍ⹜ߺߡ㧙㧘Campus Health 2006 ᐕ㧧43 Ꮞ㧦160㧚
18㧕 ᧄᄙᕶሶ㧘ᓮ↰᧛⋧ᮨ㧘㐳ἑᳯ೑㧘↰ਛ↢㓷㧘ᵻ↰ୃᏒ㧘’↰ᶈ᮸㧘࿯੗↰⺈㧘ᩊ↰ᢅਯ㧘ᱞ↰⚐㧘ጊᧄ⋿↱⟤㧚ᄢቇ↢ߩญ⣧ஜ⸻⚿ᨐߩᬌ⸛㧘Campus Health 2006 ᐕ㧧43 Ꮞ㧦211㧚
19㧕 㐳ἑᳯ೑㧘ᓮ↰᧛⋧ᮨ㧘ᧄᄙᕶሶ㧘↰ਛ↢㓷㧘ᵻ↰ୃᏒ㧘ᱞ↰⚐㧘ጊᧄ⋿↱⟤㧚ᄢቇ↢ߩ㗡∩ߩታᘒ⺞ᩏ
㧙▤ℂᜰዉ૕೙ߦ㑐ߔࠆᬌ⸛㧙㧘Campus Health 2006 ᐕ㧧43 Ꮞ㧦238㧚
20㧕 ↰ਛ↢㓷㧘᫃Ꮉᐘ਎㧘ᧄᄙᕶሶ㧘ᓮ↰᧛⋧ᮨ㧘㐳ἑᳯ೑㧘ᬀᧁ໪ᢥ㧘ᱞ↰⚐㧘ጊᧄ⋿↱⟤㧚UPI ߣ GHQ60
ߩหᤨ⺞ᩏ⚿ᨐࠃࠅ㧘ቇ↢ஜᐽ⺞ᩏߦ߅ߌࠆ UPI ᦭↪ᕈߩᬌ⸛㧘Campus Health 2006 ᐕ㧧43 Ꮞ㧦269㧚
21㧕 ጊᧄ⋿↱⟤㧘ᱞ↰⚐㧘♿ࡁቯ଻⤿㧚♧ዩ∛⸻≮ߩᣂᤨઍߣ IT㧙ోᯏ⒳ߩ⥄Ꮖⴊ♧᷹ቯེߩ࠺࡯࠲ࠍጘ㒂ᄢቇ∛㒮ߩ㔚ሶࠞ࡞࠹਄ߢㆇ↪ߐߖࠆ⹜ߺ㧘⢈ḩߣ♧ዩ∛ 2006 ᐕ㧧5 Ꮞ㧦47㧙51㧚
22㧕 ↰ਛ↢㓷㧘ጊᧄ⋿↱⟤㧚ᄢቇ↢ᵴߣࡔࡦ࠲࡞ࡋ࡞ࠬࠨࡐ࡯࠻㧙2005 ᐕጘ㒂ᄢቇቯᦼஜᐽ⸻ᢿᤨ UPI ⺞ᩏࠃࠅ⠨ኤ㧘߉߰♖␹଻ஜ⑔␩ 2006 ᐕ㧧42 Ꮞ㧦47㧙52㧚
23㧕 ጊᧄ⋿↱⟤㧚ጘ㒂⋵ߦ߅ߌࠆ♧ዩ∛ኻ╷ߩขࠅ⚵ߺߦߟ޿ߡ㧙♧ዩ∛ߩࡑࡀ࡯ࠫࡔࡦ࠻ࠍਛᔃߦ㧘ጘ㒂⋵කᏧળකቇ㔀⹹ 2006 ᐕ㧧19 Ꮞ㧦63㧙68㧚
24㧕 ጟ቟િੑ㧘ᱞ↰⚐㧘ጊᧄ⋿↱⟤㧚ࠗࡦࠬ࡝ࡦߩ቟ో▤ℂ૕೙ᡷༀࠍ⋡⊛ߣߒߚ㒮ౝᮡḰᦠߩ૞ᚑߣߘߩ⹏
ଔ㧘ࡊ࡜ࠢ࠹ࠖࠬ 2006 ᐕ㧧23 Ꮞ㧦464㧙468㧚
25㧕 ↰ਛ↢㓷㧚ᔃ᳇㓚ኂߦኻߒߡ㧘ࡃࠗࠝࡈࠖ࡯࠼ࡃ࠶ࠢᴺࠍ૬↪ߒߚฃേ⊛㖸ᭉ≮ᴺ߇᦭ലߢ޽ߞߚ৻∝଀,ጘ㒂⋵කᏧળකቇ㔀⹹ 2006 ᐕ㧧19 Ꮞ㧦95㧙99㧚㧙㧙26㧕 ᄢፉᐽม㧘ਃቛᥓ㧘ᷡ᳓సᤨ㧘ᄢ㊁⾆ᢅ㧘⷏ᧄ⵨㧚㛽ේ⊒ⴊ▤⡺⣲ߩ৻೬ᬌ଀㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ
⑼ቇળ㔀⹹ 2007 ᐕ㧧3 Ꮞ㧦463㧙464㧚
27㧕 ⑔↰┨ੑ㧘ᄢ㊁⾆ᢅ㧘⷏ᧄ⵨㧘ᷡ᳓సᤨ㧚⿷⢛ߦ⊒↢ߒߚ⍹Ἧൻࠍ઻ߞߚᏂᄢߥⴊ▤ᐔṖ╭⣲ߩ৻଀㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧3 Ꮞ㧦515㧙516㧚
28㧕 ᳗㊁ᤘੳ㧘ᄢ㊁⾆ᢅ㧘⷏ᧄ⵨㧘ጊ↰৻ᚑ㧘ᷡ᳓సᤨ㧚㛽ᄖᕈ㛽⡺⣲ߩ 1 ೬ᬌ଀㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ
⑼ቇળ㔀⹹ 2007 ᐕ㧧3 Ꮞ㧦525㧙526㧚
29㧕 ᄢ㊁⾆ᢅ㧘ᄢፉᐽม㧘ᷡ᳓సᤨ㧘⷏ᧄ⵨㧚ੱᎿ㛽ࠍ↪޿ߚ⦟ᕈ㛽⣲≌ߩⴚᓟᚑ❣㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂ
ᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧4 Ꮞ㧦627㧙628㧚
30㧕 ᮮ↰ᴦ㧘ᄢ㊁⾆ᢅ㧘ᄢ㊁⟵ᐘ㧘ᷡ᳓సᤨ㧘⷏ᧄ⵨㧘ᑝἑༀା㧘᧻᳗⎇๋㧚ᄢ⣽エㇱ⣲≌ߩ 1 ଀㧘᧲ᶏ㛽エㇱ⣲≌ 2007 ᐕ㧧19 Ꮞ㧦1㧙2㧚
31㧕 ᄢፉᐽม㧘ᢧ⮮ḩ㧘ᄢ㊁⟵ᐘ㧘ᷡ᳓సᤨ㧘ᄢ㊁⾆ᢅ㧘⷏ᧄ⵨㧘㜞⷗⑲৻㇢㧘᧻᳗⎇๋㧘ᑝἑༀା㧚ᏀᲚㇱ⣲≌ߩ 1 ଀㧘᧲ᶏ㛽エㇱ⣲≌ 2007 ᐕ㧧19 Ꮞ㧦37㧙38㧚
32㧕 ᄢ㊁⟵ᐘ㧘ᐔᎹ᣿ᒄ㧘ᷡ᳓సᤨ㧚ᛥ೙Ꮺߦࠃࠅ⊒↢ߒߚᚻߦ㒢ዪߒߚ㒖ⴊᕈ᜔❗ߩ 1 ଀㧘ਛㇱᣣᧄᢛᒻᄖ
⑼ἴኂᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧50 Ꮞ㧦861㧙862㧚
33㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘ችᧄ ᢘ㧘ጤ੗ᥓ቞↵㧚⣶ᬁᄌᕈ஥ᒗ∝ߦኻߔࠆ⚻ᬁ㑆ሹ⣶ᬁᬁ૕㑆࿕ቯⴚ㧘ਛㇱᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧50 Ꮞ㧦353㧙354㧚
34㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘ችᧄ ᢘ㧘⑔↰┨ੑ㧘ጤ੗ᥓ቞↵㧚㗖ㇱ⣄㜑∝ᚻⴚߩว૬∝㧙೨ᣇᴺ㧘
ᓟᣇᴺߩᲧセ㧙 ਛㇱᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧50 Ꮞ㧦579㧙580㧚
35㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘ችᧄ ᢘ㧘⑔↰┨ੑ㧘ጤ੗ᥓ቞↵㧚㛽☻㝃∝ᕈᬁ૕㛽᛬ߦኻߔࠆࡀࠬࡊ
ࡠࡦࠤ࡯ࡉ࡞ࠍ૶↪ߒߚ⣄ᬁ⍴❗ⴚ㧘ᣣᧄ⣄ᬁࠗࡦࠬ࠻࠘࡞ࡔࡦ࠹࡯࡚ࠪࡦቇળ⹹ 2007 ᐕ㧧6 Ꮞ㧦25㧙
28㧚
36㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘ችᧄ ᢘ㧘ጤ੗ᥓ቞↵㧘⑔↰┨ੑ㧚⣶ᬁᄌᕈ஥ᒗ∝ߦኻߔࠆ⚻ᬁ㑆ሹ⣶ᬁᬁ૕㑆࿕ቯ㧘ᣣᧄ⣄ᬁ⣄㜑∛ቇળ㔀⹹ 2007 ᐕ㧧18 Ꮞ㧦223㧚
37㧕 㕍ᧁ㓉᣿㧘ᷰㄝ๺ሶ㧘ਤ⠀᡽⟤㧘⮮↰㓷ᢥ㧘♻ᢙਁᱜ㧘ᷡ᳓సᤨ㧘ዊ㊁Ⴆኪ㧚functionalMRI ߇᦭↪ߢ޽ߞߚᘟᕈᦼ⣖᪪Ⴇ 㤗∽ߩ 1 ∝଀㧘J Clin Rehabil 2007 ᐕ㧧6 Ꮞ㧦558㧙561㧚
38㧕 ⍹ਣᄢ࿾㧘ᄢ㊁⾆ᢅ㧘ዊᎹኡᕶ㧘⷏ᧄ⵨㧘ᷡ᳓సᤨ㧚ᓟ㗖ㇱߦ⊒↢ߒߚ infantile fibromatosis ߩ৻଀㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧50 Ꮞ㧦90㧙91㧚
39㧕 ᧻ᧄ ๺㧘♻ᢙਁᱜ㧘દ⮮⧐Პ㧘⑔↰ 㓷㧘Ꮉ੗ ⽕㧘ᷡ᳓సᤨ㧚ㅘᨆᖚ⠪ߦኻߔࠆੱᎿ⢆㑐▵ᚻⴚߩ๟ⴚᦼว૬∝㧘ᢛᒻᄖ⑼ 2007 ᐕ㧧58 Ꮞ㧦511㧙515㧚
40㧕 㕍ᧁ㓉᣿㧘ᷰㄝ๺ሶ㧘ਤ⠀᡽⟤㧘⮮↰㓷ᢥ㧘♻ᢙਁᱜ㧘ᷡ᳓సᤨ㧘ዊ㊁Ⴆ ታ㧚Functional MRI ߇᦭↪
ߢ޽ߞߚᘟᕈᦼ⣖᪪Ⴇ 㤗∽ߩ 1 ∝଀㧘J Clin Rehabil ೎೚ 2007 ᐕ㧧16 Ꮞ㧦558㧙561㧚
41㧕 ↰ਛ 㗔㧘૒⮮ᱜᄦ㧘┻᧛ᱜ↵㧘྾ᚭ㓉ၮ㧘ᢧ⮮㇌᣿㧘ᷡ᳓ సᤨ㧘ᷡፉ ḩ㧚㑐▵࡝࠙ࡑ࠴ߦኻߔࠆ↢‛ቇ⊛⵾೷ᴦ≮ߣ࠻࡝ࡊ࠻ࡈࠔࡦઍ⻢ߦߟ޿ߡ㧘ਛㇱ࡝࠙ࡑ࠴ ೎೚ 2007 ᐕ㧧38 Ꮞ㧦12㧙13㧚
42㧕 ਭፉᵏੳ㧘⍹੗శ৻㧘ᷡ᳓సᤨ㧘૒‫ᤩᧁޘ‬㧘ጊᧄᙗม㧘ᱞౝ┨ੑ㧘ᣣᲧ㊁శ↵㧘ᬢ ਛੳ㧘ᷡ᳓ᢅੱ㧘ᄢᯅീ㧘⥓੗ᱜ᣿㧘⪉↰ ⼾㧘੹੗⑲ᴦ㧘Ᏹ↰᣽ᒄ㧘㋈ᧁ⹷㧘ᐔ᧻ື㧘⋉↰๺᣿㧘የਅ૫ผ㧘⑔↰㓷㧘਄᧛ୃ৻㧘ᷰㄝᢙੱ㧘᫪ஜᄥ㇢㧘⠀႐ℂᒾ㧘⷏ၳᒄ⸥㧚ේ⊒ᕈ㛽☻㝃∝ߦኻߔࠆ࡝࠮࠼ࡠࡀ࡯࠻ߣࡆ࠲ࡒࡦ K2
ߩ૬↪ലᨐߦ㑐ߔࠆᄙᣉ⸳౒ห⎇ⓥ㧙1 ᐕ⚻ㆊ∝଀ߩਛ㑆⸃ᨆ㧙㧘Osteoporosis Japan 2007 ᐕ㧧15 Ꮞ㧦
104㧙107㧚
43㧕 ᳗㊁ᤘੳ㧘㋈ᧁ⋥᮸㧘㊄᫪ᐽᄦ㧘⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧚ᕆᕈ㛽㜑ᕈ⊕ⴊ∛ൻቇ≮ᴺਛߦ⊒∝ߒߚ⣄ᬁ㛽㜑
Ἳߩ 1 ଀㧘ᢛᒻᄖ⑼ 2007 ᐕ㧧58 Ꮞ㧦1699㧙1702㧚
44㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘ችᧄ ᢘ㧘⑔↰┨ੑ㧘ጤ੗ᥓ቞↵㧚㛽☻㝃∝ᕈᬁ૕㛽᛬ߦኻߔࠆࡀࠬࡊ
ࡠࡦࠤ࡯ࡉ࡞ࠍ૶↪ߒߚ⣄ᬁ⍴❗ⴚ㧘ᣣᧄ⣄ᬁࠗࡦࠬ࠻࠘࡞ࡔࡦ࠹࡯࡚ࠪࡦቇળ⹹ 2007 ᐕ㧧6 Ꮞ㧦25㧙
28㧚
45㧕 ጊᧄ⌀↱⟤㧚࿾ၞක≮ㅪ៤ߣ↢ᵴᜰዉߩ੺౉㧘ౝಽᴲ࡮♧ዩ∛⑼ 2007 ᐕ㧧24 Ꮞ㧦32㧙37㧚
46㧕 ጊᧄ⌀↱⟤㧘ᱞ↰⚐㧘♿ࡁቯ଻⤿㧚SMBG ࠺࡯࠲ߩ㔚ሶࠞ࡞࠹਄ߢߩㆇ↪ߪ㧫㧙⥄Ꮖⴊ♧᷹ቯེߩ࠺࡯࠲
ࠍ㔚ሶࠞ࡞࠹਄ߢㆇ↪ߐߖࠆ⹜ߺߦߟ޿ߡᢎ߃ߡߊߛߐ޿㧙㧘⢈ḩߣ♧ዩ∛‫ޟ‬IT ߢߤߎ߹ߢࠊ߆ࠆ߆㧫‫ޠ‬
2007 ᐕ㧧6 Ꮞ㧦475㧙477㧚
47㧕 ጊᧄ⋿↱⟤㧘ᓮ↰᧛⋧ᮨ㧘㐳ἑᳯ೑㧘↰ਛ↢㓷㧘ᵻ↰ୃᏒ㧘૒ᯅᢥੳ㧘’↰ᶈ᮸㧘࿯੗↰⺈㧘ᩊ↰ᢅਯ㧘ᱞ↰⚐㧚ጘ㒂ᄢቇ↢ߦᱤ⑼ஜᐽ⸻ᢿࠍታᣉߒߡ㧘Campus Health 2007 ᐕ㧧44 Ꮞ㧦109㧙114㧚
48㧕 ᧄᄙᕶሶ㧘૒ᯅᢥੳ㧘ᓮ↰᧛⋧ᮨ㧘㐳ἑᳯ೑㧘⥓੗ࠆࠅሶ㧘↰ਛ↢㓷㧘’↰ᶈ᮸㧘࿯੗↰⺈㧘ᩊ↰ᢅਯ㧘ᱞ↰⚐㧘ጊᧄ⋿↱⟤㧚ᄢቇ↢ߦ߅ߌࠆญ⣧ߩஜᐽ⁁ᘒߣ↢ᵴ⠌ᘠߣߩ㑐ㅪߦߟ޿ߡ㧘ቇᩞ଻ஜ⎇ⓥ 2007
ᐕ㧧49 Ꮞ㧦112㧙116㧚
49㧕 ጊᧄ⋿↱⟤㧘↰ਛ↢㓷㧘ᱞ↰⚐㧘㤥ᧁ⊓ᔒᄦ㧚ᄢቇߩቇ↢࡮⡯ຬోຬߦᣉⴕߒߚᢝ࿾ౝో㕙⑌ᾍߦ㑐ߔࠆή⸥ฬ⥄⸥ᑼ⺞ᩏ㧘⑌ᾍ⑼ቇ 2007 ᐕ㧧1 Ꮞ㧦10㧙15㧚
50㧕 ጊᧄ⋿↱⟤㧘↰ਛ↢㓷㧘ᱞ↰⚐㧘㤥ᧁ⊓ᔒᄦ㧚ᄢቇ⡯ຬߩ༛ᾍ⠪ࠍኻ⽎ߦታᣉߒߚ༛ᾍߩታᘒ⺞ᩏ㧙ᢝ࿾ౝో㕙⑌ᾍᣉⴕ 2 ᐕࠍ⚻ㆊߒߡ㧙㧘⑌ᾍ⑼ቇ 2007 ᐕ㧧1 Ꮞ㧦18㧙24㧚
51㧕 ⥓੗ࠆࠅሶ㧘↰ਛ↢㓷㧘૒ᯅᢥੳ㧘ᓮ↰᧛⋧ᮨ㧘㐳ἑᳯ೑㧘ᱞ↰⚐㧘ጊᧄ⋿↱⟤㧚ஜᐽ⸻ᢿߩ⾰ߩะ਄ࠍ⋡ᜰߒߡ㧙ቇ↢ߩฃ⸻ḩ⿷ᐲߩⷰὐ߆ࠄ㧙㧘Campus Health 2007 ᐕ㧧44 Ꮞ㧦125㧚
52㧕 ૒ᯅᢥੳ㧘↰ਛ↢㓷㧘ᓮ↰᧛⋧ᮨ㧘㐳ἑᳯ೑㧘⥓੗ࠆࠅሶ㧘ᱞ↰⚐㧘ጊᧄ⋿↱⟤㧚ቇ↢㧘⡯ຬోຬߦᣉⴕ
ߒߚቇౝ⑌ᾍߩࠕࡦࠤ࡯࠻⺞ᩏ㧙ᢝ࿾ౝ⑌ᾍታᣉ 2 ᐕࠍ⚻ㆊߒߡ㧙㧘Campus Health 2007 ᐕ㧧44 Ꮞ㧦
149㧚
53㧕 ↰ਛ↢㓷㧘᫃Ꮉᐘ਎㧘ᧄᄙᕶሶ㧘ᓮ↰᧛⋧ᮨ㧘㐳ἑᳯ೑㧘⥓੗ࠆࠅሶ㧘ᱞ↰⚐㧘ጊᧄ⋿↱⟤㧚ቇ↢↢ᵴߢ᳞߼ࠄࠇࠆ଻ஜ▤ℂ࠮ࡦ࠲࡯㧙ࡔࡦ࠲࡞ࡋ࡞ࠬࠨࡐ࡯࠻ߩᓎഀߦ㑐ߔࠆᬌ⸛㧙㧘Campus Health 2007㧙㧙ᐕ㧧44 Ꮞ㧦196㧚
54㧕 ᫃Ꮉᐘ਎㧘↰ਛ↢㓷㧘Ꮉፉᕺሶ㧘Ꮉㄝᢘሶ㧘૒ᯅᢥੳ㧘ᓮ↰᧛⋧ᮨ㧘㐳ἑᳯ೑㧘ᱞ↰⚐㧘ጊᧄ⋿↱⟤㧚UPIᓧὐߣ↢ᵴ⠌ᘠ⺞ᩏߩ㑐ㅪߦߟ޿ߡ㧘Campus Health 2007 ᐕ㧧44 Ꮞ㧦198㧚
55㧕 ਛ᧛ᱜ↢㧘ᷡ᳓సᤨ㧚⣶ਅ⢇∩ࠍ઻߁㛽☻㝃∝∝଀ߦኻߔࠆᣣᧄ⺆
Roland㧙Morris Disability
Questionnaire ࠍ↪޿ߚ QOL ⹏ଔ㧙ࠛ࡞ࠞ࠻࠾ࡦ⵾೷ᛩਈਅߢߩ−∩ߦ㑐ㅪߔࠆ QOL ᡷༀߦߟ޿ߡߩᬌ
⸛㧙㧘Osteoporosis Japan (೎೚) 2008 ᐕ㧧16 Ꮞ㧦207㧙215㧚
56㧕 ጊᧄ⋿↱⟤㧘♿ࡁቯ଻⤿㧘㜞Ⴆ⋥⢻㧚ක≮ኾ㐷⡯ߩࡑࡀࠫࡔࡦ࠻ᢎ⢒ߦ߅ߌࠆ IT ᵴ↪ߩน⢻ᕈ㧘ᣂක≮
2008 ᐕ㧧35 Ꮞ㧦54㧙57㧚
57㧕 ↰ਛ↢㓷㧘᫃Ꮉᐘ਎㧘ᓮ↰᧛⋧ᮨ㧘㐳ἑᳯ೑㧘ዊ಴ᶈਯ㧘ᱞ↰⚐㧘ጊᧄ⋿↱⟤㧚ጘ㒂ᄢቇᄢቇ↢ࡔࡦ࠲࡞ࡋ࡞ࠬ⋧⺣ߩᄌㆫߣᦨㄭߩേะ㧙ጘ㒂ᄢቇ଻ஜ▤ℂ࠮ࡦ࠲࡯ࠕࡦࠤ࡯࠻⺞ᩏ߅ࠃ߮ቇ↢ߩஜᐽ⊕ᦠ
2005(ᧄቇ⚿ᨐ)ࠃࠅ㧙㧘ጘ㒂ᄢቇකቇㇱ♿ⷐ 2008 ᐕ㧧55 Ꮞ㧦43㧙50㧚
58㧕 ጟ቟િੑ㧘ਅ↰ᶈᰵ㧘♿ࡁቯ଻⤿㧘ᱞ↰⚐㧘ጊᧄ⋿↱⟤㧚ࠗࡦࠬ࡝ࡦߩ቟ో▤ℂߦ㑐ߔࠆ㔚ሶࠞ࡞࠹ᯏ⢻ߩ᦭↪ᕈߣ໧㗴ὐ㧘⢈ḩߣ♧ዩ∛‫ޟ‬Chronic illness ߣߒߡߩ♧ዩ∛ߩ⥄Ꮖ▤ℂ‫ޠ‬2008 ᐕ㧧7 Ꮞ㧦28㧙35㧚
59㧕 ጊᧄ⋿↱⟤㧘Ꮉ಴㕏ᒾ㧘ᚭ⼱ℂ⧷ሶ㧘ᱞ↰⚐㧘᪢ᧄᢘᄦ㧘♿ࡁቯ଻⤿㧚ጘ㒂⋵කᏧળ∛⸻ㅪ៤ࠪࠬ࠹ࡓߦ
߅ߌࠆ㧘♧ዩ∛∛⸻ㅪ៤ࠨࡐ࡯࠻ࠪࠬ࠹ࡓߩ⹜૞㧘⢈ḩߣ♧ዩ∛‫ޟ‬Chronic illness ߣߒߡߩ♧ዩ∛ߩ⥄Ꮖ▤ℂ‫ ޠ‬2008 ᐕ㧧7 Ꮞ㧦56㧙61㧚
60㧕 ਅ↰ᶈᰵ㧘ጟ቟િੑ㧘♿ࡁቯ଻⤿㧘ᱞ↰⚐㧘ጊᧄ⋿↱⟤㧚㔚ሶࠞ࡞࠹ᖱႎ߆ࠄಽᨆߔࠆᄢቇ∛㒮ߩ♧ዩ∛∛᫟ᖚ⠪ߩ․ᓽಽᨆߩ⹜ⴕ㨪ᬺോࠍนⷞൻߔࠆ᦭↪ᕈߦߟ޿ߡ㨪㧘⢈ḩߣ♧ዩ∛‫ޟ‬Chronic illness ߣߒߡߩ♧ዩ∛ߩ⥄Ꮖ▤ℂ‫ ޠ‬2008 ᐕ㧧7 Ꮞ㧦89㧙93㧚
61㧕 ጊᧄ⋿↱⟤㧘ᱞ↰⚐㧘♿ࡁቯ଻⤿㧚♧ዩ∛ߩ㆙㓒∛⸻ㅪ៤ࠍᡰេߔࠆጘ㒂⋵කᏧળ∛⸻ㅪ៤ࠪࠬ࠹ࡓ᭴▽ߩႎ๔㧘ᣣᧄ㆙㓒ක≮ቇળ㔀⹹ 2008 ᐕ㧧4 Ꮞ㧦325㧙327㧚
62㧕 㐳ἑᳯ೑㧘ᓮ↰᧛⋧ᮨ㧘↰ਛ↢㓷㧘ᱞ↰⚐㧘ጊᧄ⋿↱⟤㧚ᄢቇ↢ࠍኻ⽎ߦታᣉߒߚ㗡∩ታᘒ⺞ᩏ㧘ቇᩞ଻ஜ⎇ⓥ 2008 ᐕ㧧50 Ꮞ㧦264㧙269㧚
63㧕 ૒ᷰᔘᵗ㧚ࠗࡔ࡯ࠫ⼾߆ߥᅚሶ㜞ᩞ 2 ᐕ↢ߣߩ㑐ࠊࠅ́࠮࡜ࡇࠬ࠻ߣߒߡߩࠗ࠾ࠪࠛ࡯࡚ࠪࡦ́㧘ጘ㒂ᄢቇᔃℂᢎ⢒⋧⺣⎇ⓥ 2008 ᐕ㧧7 Ꮞ㧦31㧙40㧚
64㧕 ૒ᷰᔘᵗ㧘㋈ᧁჾ㧚┹ᛛ⠪ߩ⥄ᚒߩᒝߐߣ⥄ᚒႺ⇇ߩᬌ⸛́ࡠ࡯࡞ࠪࡖ࠶ࡂᴺߦࠃࠆ৻⥸ቇ↢ߣߩᲧセ߆ࠄ́㧘⥃ᐥᔃℂり૕ㆇേቇ⎇ⓥ 2008 ᐕ㧧10 Ꮞ㧦1㧙10㧚
65㧕 ↰ਛ↢㓷㧘᫃Ꮉᐘ਎㧘ᓮ↰᧛⋧ᮨ㧘㐳ἑᳯ೑㧘ᵻ↰ୃᏒ㧘ጊᧄ⾆ሶ㧘ᱞ↰⚐㧘ጊᧄ⋿↱⟤㧚ᄢቇ↢ߩ߁ߟ∛ߦ㑐ߔࠆቇ⠌ᯏળߣ଻ஜ▤ℂ࠮ࡦ࠲࡯೑↪ߦ㑐ߔࠆᬌ⸛㧘Campus Health 2008 ᐕ㧧45 Ꮞ㧦295㧙297㧚
66㧕 ጊᧄ⋿↱⟤㧘↰ਛ↢㓷㧘᫃Ꮉᐘ਎㧘Ꮉፉᕺሶ㧘Ꮉㄝᢘሶ㧘ᓮ↰᧛⋧ᮨ㧘㐳ἑᳯ೑㧘ጊᧄ⾆ሶ㧘ᱞ↰⚐㧚ᱤ
⑼⋧⺣࡮⢈ḩᜰዉ࡮ቇ↢⋧⺣╬ߩᬺോ࠾࡯࠭ߩ޽ࠆቇ↢ߦ߅ߌࠆ UPI ᓧὐߩ․ᓽߦߟ޿ߡ㧘Campus Health
2008 ᐕ㧧45 Ꮞ㧦268㧙270㧚
ේ⪺㧔᰷ᢥ㧕
1㧕 Hosoe H, Miyamoto K, Wada E, Shimizu K. A surgical treatment of scoliosis in Larsen's syndrome withbilateral hip dislocation- A case report. Spine. 2006;31:E302-306.
2㧕 Morita M, Banno Y, Dohjima T, Nozawa S, Fushimi K, Fan D, Ohno T, Miyazawa K, Liu N, Shimizu K.
Ǵ-Calpain is involved in the regulation of TNF--induced matrix metalloproteinase-3 release in arheumatoid synovial cell line. Biochem Biophys Res Commun. 2006;343:937-942.
3㧕 Ohnishi K, Miyamoto K, Hashimoto K, Hosoe H, Shimizu K. Surgical Treatment for Atlantoaxial
Subluxation Associated With Mixed Connective Tissue Disease. Orthopedics. 2006;29:369-370.
4㧕 Masuda T, Miyamoto K, Shimizu K. Intramuscular hemodynamics in bilateral erector spinase muscles
in symmetrical and asymmetrical postures with and without loading. Clin Biomecha. 2006;21:245-253.
5㧕 Matsumoto K, Kamiya N, Suwan K, Atsumi F, Shimizu K, Shinomura T, Yamada Y, Kimata K,
Watanabe H. Identification and Characterization of Versican/PG-M Aggregates in Cartilage. J Biol
Chem. 2006;281:18257-18263.
6㧕 Yoshida M, Kida K, Kodama H, Itokazu M, Shimizu K. Calcitonin treatment for calcifying tendinitis of
the shoulder. J Orthopaed Traumatol. 2006;7:6-11.
7㧕 Masuda T, Miyamoto K, Hosoe H, Sakaeda H, Tanaka M, Shimizu K. Surgical treatment with spinal
instrumentation for pyogenic spondylodiscitis due to menthicillin-resistant Staphylococcus
aureus(MRSA): a report of five cases. Arch Orthop Trauma Surg. 2006;126:339-349.
8㧕 Kamiya N, Watanabe H, Habuchi H, Takagi H, Shinomura T, Shimizu K, Kimata K. Versican/PG-M
Regulates Chondrogenesis as an Extracellular Matrix Molecule Crucial for Mesenchymal
Condensation. J Biol Chem. 2006;281:2390-2400.
9㧕 Matsumoto K, Wakahara K, Sumi H, Shimizu K. Central Cord Syndrome in Patients With Klippel-Feil
Syndrome Resulting From Winter Sports. Am J Sports Med. 2006;34:1685-1689.
10㧕 Wakahara K, Matsumoto K, Sumi H, Sumi Y, Shimizu K. Traumatic Spinal Cord Injuries From
Snowboarding. Am J Sports Med. 2006;34:1670-1674.
11㧕 Ogawa H, Itokazu M, Ito Y, Fukuta M, Shimizu K. The therapeutic outcome of minimally invasive
synovectomy assisted witharthroscopy in the rheumatoid knee. Mod Rheumatol. 2006;16:360-363.
12㧕 Matsumoto K, Itokazu M, Uemura S, Takigami I, Naganawa T, Shimizu K. Successful joint
arthroplasty after treatment of destructive MRSA arthritis of the knee using antibiotic-loadedhydroxyapatite blocks: a case report. Arch Orthop Trauma Surg. 2006;127:47-50.

㧙㧙

IF 2.499

IF 2.749
IF 0.581
IF 1.642

IF 5.581

IF 0.913

IF 5.581
IF 3.397
IF 3.397

IF 0.913

13㧕 Ogawa H, Itokazu M, Ito Y, Fukuta M, Simizu K. An unusual meniscal ganglion cyst that triggered
recurrent hemarthrosis of the knee. Arthroscopy. 2006;22:455.e1-4.
14㧕 Ohara A, Miyamoto K, Naganawa T, Matsumoto K, Shimizu K. Sagittal alignment of the cervicalspine: comparison of five standard methods of measurement. Spine. 2006;31:2585-2591.
15㧕 Fushimi K, Miyamoto K, Nishimoto H, Hosoe H, Kodama H, Shimizu K. Clinical outcomes ofmultilevel anterior corpectomy and fusion as a revision surgery of the cervical spine. Report of sevencases. Spinal Cord. 2006;44:449-456.
16㧕 Sasaki T, Miyamoto K, Hosoe H, Shimizu K. Transoral Anterior Approach Used for Extensive Anterior
Decompression of C3 Vertebrae Level in a Patient with Severe Atlantoaxial Vertical Subluxation andRheumatoid Arthritis - A Case Report. Spinal Cord. 2006;44:52-55.
17㧕 Shimizu T, Miyamoto K, Masuda K, Miyata T, Hori H, Shimizu K, Maeda M. The clinical significanceof impaction at the femoral neck fracture site in the elderly. Arch Orthop Trauma Surg.
2007;127:515-21.
18㧕 Aoki T, Terashima H, Itokazu M, Miyamoto K, Shimizu K. Stimulation of Music Prolonged
Disturbance of Consciousness Patients in Early Rehabilitation. J Saitama Kenou Rehabilitation.
2007;7:50-53.
19㧕 Ogawa H, Nishimoto H, Hosoe H, Suzuki N, Kanamori Y, Shimizu K. Clinical outcome after segmental
wire fixation and bone grafting for repair of the defects in multiple level lumbar spondylolysis. J
Spinal Disord Tech. 2007;20:521-525.
20㧕 Nagano A, Miyamoto K, Fushimi K, Hosoe H and Shimizu K. Failure of reconstruction surgery using
anterior fibular strut grafting for postlaminectomy kyphosis A case report. J Clin Neurosci .
2007;14:376-379.
21㧕 Inoue T, Miyamoto K, Kodama H, Hosoe H and Shimizu K. Total spondylectomy for treatment of asymptomatic hemangioma of the lumbar spine - A case report. J Clin Neurosci. 2007;14:806-809.
22㧕 Yamada K, Miyamoto K, Hosoe H, Mizutani M and Shimizu K. Scoliosis associated with Prader-Willi
syndrome A case report. Spine J. 2007;7:345-348.
23㧕 Miyamoto K, Shimizu K, Matsumoto S, Sumida H, Iida H and Hosoe H. Surgical treatment of scoliosis
associated with central core disease: Minimizing the effects of malignant hyperthermia withprovocation tests - Report of a case -. J Pediatric Orthop B. 2007;16:239-242.
24㧕 Shimizu T, Miyamoto K, Masuda K, Miyata Y, Hori H, Shimizu K, Maeda M. The clinical significanceof impaction at the femoral neck fracture site in the elderly. Arch Orthop Trauma Surg.
2007;127:515-521.
25㧕 Fushimi K, Nakashima S, You F, Takigawa M, Shimizu K. Prostaglandin E2 Downregulates TNF-DInduced Production of Matrix Metalloproteinase-1 in HCS-2/8 Chondrocytes by Inhibiting
Raf-1/MEK/ERK Cascade Through EP4 Prostanoid Receptor Activation. J Cell Biochem.
2007;100:783-793.
26㧕 Maehara H, Suzuki K, Sasaki T, Oshita H, Wada E, Inoue T , Shimizu K. G1-G2 Aggrecan Productthat can be Generated by M-calpain on Truncationat 709-Ala710 is Present Abundantly in Human
Articular Cartilage. J Biochem. 2007;141:469-477.
27㧕 Takeuchi A, Yamamoto Y, Tsuneyama K, Cheng C, Yonekura H, Watanabe T, Shimizu K, Tomita K,
Yamomoto H, Tsuchiya H. Endogenous secretory receptor for advanced glycation endproducts as anovel prognostic marker in chondrosarcoma. Cancer. 2007;9:2532-2540.
28㧕 Ogawa H, Nishimoto H, Hosoe H, Suzuki N, Kanamori Y, Shimizu K. Clinical outcome aftersegmental wire fixation and bone grafting for repair of the defects in multiple level lumbar
spondylolysis. J Spinal Disord Tech. 2007;20:521-525.
29㧕 Matsumoto K, Itokazu M, Uemura S, Takigami I, Naganawa T, Shimizu K. Successful joint
arthroplasty after treatment of destructive MRSA arthritis of the knee using antibiotic-loadedhydroxyapatite blocks -a case report-. Arch Orthop Trauma Surg. 2007;127:47-50.
30㧕 S Kuriyama, Y Miwa, H Fukushima, H Nakamura, K Toda, M Shiraki, M Nagaki, M Yamamoto, E
Tomita, H Moriwaki. Prevalence of diabetes and incidence of angiopaathy in patients with chronicviral liver disease. J Clin Biochem Nutr. 2007;40:116-122.
31㧕 Hioki A, Miyamoto K, Hosoe H, Shimizu K. Two-staged decompression for thoracic paraparesis due tothe combined ossification of the posterior longitudinal ligament and the ligamentum flavum a casereport. Arch Orthop Trauma Surg. 2008;128:175-177.
32㧕 Yamamoto T,Inoue N, Miyamoto K, Sugiyama S, Nozawa S, Hosoe H, Shimizu K. Segmental wire
fixation for lumbar spondylolysis associated with spina bifida occulta. Arch Orthop Trauma Surg.
2008;128:1177-1182.
33㧕 Hashimoto K, Miyamoto K, Hosoe H, Kawai G, Kikuike K, Shimokawa K, Suzuki N, Matsuo M,
Kodama H, Shimizu K. Solitary fibrous tumor in the cervical spine with destructive vertebral
involvement:A case report and review of the literature. Arch Orthop Trauma Surg. 2008;128:1111-1116.
34㧕 Takigami I, Itoh Y, Itokazu M, Shimizu K. Radio-opaque marker of a surgical sponge appearing as an
intra-articular foreign body after total hip arthroplasty. Arch Orthop Trauma Surg.
2008;128:1167-1168.

㧙㧙

IF 2.296
IF 2.499

IF 1.578

IF 1.578

IF 0.913

IF 1.303

IF 0.801
IF 0.801

IF 0.619

IF 0.913

IF 3.381

IF 2.020

IF 4.632

IF 1.303

IF 0.913

IF 0.630

IF 0.913

IF 0.913

IF 0.913

IF 0.913

35㧕 Chi D, Miyamoto K, Hosoe H, Kawai G, Ohnishi K, Suzuki N, Sumi H, Shimizu K. Symptomatic
lumbar mobile segment with spinal canal stenosis in fused spine associated with diffused idiopathic
skeletal hyperostosis A case report. Spine J. 2008;8:1019-1023.
36㧕 Hioki A, Ohnishi K, Miyamoto K, Hosoe H and Shimizu K. Spondylolysis of the second lumbar
vertebra treated with segmental wiring and bone grafting:a case report. Orthopaedics. 2008;31:287.
37㧕 Terabayashi N, Miyamoto K, Sasaki H, Hosoe H, Shimizu K. Multiple steroid-induced vertebral
fracture with paraparesis associated with Wegener’s granulomatosis treated with posterior spinal
instrumentation. Journal of Neurological Sciences(Turkish). 2008;25:67-71.
38㧕 Hioki A, Miyamoto K, Hosoe H, Fukuta S, Shimizu K. Two-stage decompression for combined epiconus
and cauda equina syndrome due to multilevel spinal canal stenosis of the thoracolumbar spine-a casereport. Arch Orthop Trauma Surg. 2008;128:955-958.
39㧕 Kawaguchi A, Chiba K, Tanimura Y, Motohashi T, Aoki H, Takeda T, Hayashi S, Shimizu K and
Kunisada T. Isolation and characterization of Kit-independent melanocyte precursors induced in theskin of Steel factor transgenic mice. Dev Growth Differ. 2008;50:63-69.
40㧕 Shinohe R. Sato M, Takemura M, Shimizu K, Koishi H, Tanaka R, Saito K, Seishima M. Cytokine
profiles in mice with arthritis induced by anti-type Τ collagen monoclonal antibody plus
lipopolysaccharide. Japanese Journal of Clinical Chemistry. 2008;37:53-62.
41㧕 Hirakawa A, Miyamoto K, Ohno Y, Hioki A, Ogawa H, Nishimoto H, Yokoi H, Shimizu K. Two-stage(posterior and anterior) surgical treatment of spinal osteomyelitis due to antypical mycobacteria andassociated thoracolumbar kyphoscoliosis in a nonimmunocompromised patient. Spine.
2008;33:E221-224.
42㧕 Takigami I, Itokazu M, Itoh Y, Matsumoto K, Yamamoto T, Shimizu K. Limb-length measurement in
total hip arthroplasty using a calipers dual pin retractor. Bulletin of the NYU Hospital for Joint
Diseases. 2008;66:107-110.
43㧕 Matsumoto M, Chiba K, Toyama Y, Takeshita K, Seichi A, Nkamura K, Arimizu J, Fujibayashi S,
Hirabayashi S, Hirano T, Iwasaki M, Kaneoka K, Kawaguchi Y, Ijiri K, Maeda T, Matsuyama
Y,Mikami Y, Murakami H, Nagashima H, Nagata K, Nakahara S, Nohara Y, Oka S, Sakamoto K,
Saruhashi Y, Sasao Y, Shimizu K, Taguchi T, Takahashi M, Tanaka Y, Tani T, Tokuhashi Y, Uchida K,
Yamamoto K, Yamazaki M, Yokoyama T, Yoshida M,and Nishiwaki Y. Surgical results and related
factors for ossification of prosterior longitudinal ligament of the thoracic spinea multi-institutional
retrospective study. Spine. 2008;33:1034-1041. 
44㧕 Miyamoto K, Iinuma N, Ueki S, Shimizu K. Effects of abdominal belts on the cross-sectional shape ofthe trunk during intense contraction of the trunk muscles observed by computer tomography. Clin
Biomech (Bristol, Avon). 2008;23:1220-1226.

IF 0.581

IF 0.913

IF 1.908

IF 2.499

IF 2.499

IF 1.6424㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦ਛ᧛⠹ਃ㧘⎇ⓥಽᜂ⠪㧦ᷡ᳓సᤨ㧧ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄㧦⣄ᬁᩇ㕢Ꮺ㛽ൻ∝ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ㧧ᐔᚑ 17㧙18 ᐕᐲ㧧1,300 ජ౞(500㧦800 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦ጊᧄ⋿↱⟤㧧 (⽷)ጘ㒂⋵ஜᐽ㐳ኼ⽷࿅⎇ⓥ੐ᬺഥᚑ㊄㧦㕍ᐕᦼߦ߅ߌࠆ⢈ḩ⠪ኻ╷ߩߚ߼ߩ⺞ᩏ⎇ⓥ㧧ᐔᚑ 17㧙18 ᐕᐲ㧧700 ජ౞(350㧦350 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦ጊᧄ⋿↱⟤㧘⎇ⓥಽᜂ⠪㧦ᱞ↰⚐㧘↰ਛ↢㓷㧘ᄢᐸᔒ㊁㧧⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦
ᄢቇ↢ߩ⢈ḩߣ૕⾰ߩ㑐ଥ⺞ᩏ㧦዁᧪ߩ↢ᵴ⠌ᘠ∛ߩ⊒∝ࠍ੍㒐ߔࠆߚ߼ߦ㧧ᐔᚑ 17㧙19 ᐕᐲ㧧
3,640 ජ౞(1,200㧦1,400㧦1,040 ජ౞)
4㧕 ⎇ⓥઍ⴫⠪㧦ጊᧄ⋿↱⟤㧘⎇ⓥಽᜂ⠪㧦Ꮉጯ⥜ᔒ↵㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌(ᢎ⢒)㧦ஜᐽ⑼ቇ࡮଻ஜ૕
⢒(ోቇ౒ㅢᢎ⢒)㧧ᐔᚑ 18 ᐕᐲ㧧500 ජ౞5㧕 ⎇ⓥઍ⴫⠪㧦ጊᧄ⋿↱⟤㧧ጘ㒂ᄢቇᛛⴚ੤ᵹ⎇ⓥળᵴേᡰេ⾌㧦⥄Ꮖⴊ♧᷹ቯ୯ࠍ㔚ሶࠞ࡞࠹਄ߢ
ㆇ༡ߔࠆࠪࠬ࠹ࡓ㐿⊒㧧ᐔᚑ 18 ᐕᐲ㧧150 ජ౞6㧕 ⎇ⓥઍ⴫⠪㧦ጊᧄ⋿↱⟤㧧ጘ㒂⋵කᏧળൕോකㇱળ⎇ⓥഥᚑ㊄㧦ጘ㒂⋵ߩᄢቇ↢ߩ⢈ḩߦ㑐ߔࠆታᘒ⺞ᩏ㧙዁᧪ߩஜᐽ㓚ኂࠍ㒐ߋߚ߼ߩ㕍ᐕᦼߩஜᐽࠨࡐ࡯࠻ߪߤ߁޽ࠆߴ߈߆㧙㧧ᐔᚑ 18 ᐕᐲ㧧300ජ౞
7㧕 ✚᜝੐ᬺઍ⴫⠪㧦ጊᧄኈᱜ(ᄢ㒋ᄢቇ)㧘✚᜝೽ઍ⴫⠪㧦ጊᧄ⋿↱⟤(ጘ㒂ᄢቇ)㧧⎇ⓥᜂᒰ⠪㧦♿ࡁቯ଻⤿㧘㜞Ⴆ⋥⢻㧘᪢᧛዁ᄦ㧦⚻ᷣ↥ᬺ⋭‫ޟ‬ක≮⚻༡ੱ᧚⢒ᚑࡊࡠࠫࠚࠢ࠻‫ޠ‬ක≮⚻༡ੱ᧚⢒ᚑࡊࡠࠣ࡜ࡓ㐿⊒ࡊࡠࠫࠚࠢ࠻㧧ᐔᚑ 18 ᐕᐲ㧧5,000 ජ౞8㧕 ⎇ⓥઍ⴫⠪㧦ጊᧄ⋿↱⟤㧘⎇ⓥಽᜂ⠪㧦♿ࡁቯ଻⤿㧘ᱞ↰⚐㧧ጘ㒂ᄢቇ↥ቭቇⲢว࠮ࡦ࠲࡯㊀ὐ⎇ⓥഥᚑ㧦⥄Ꮖ᷹ቯஜᐽ▤ℂ࠺࡯࠲ࠍ㔚ሶࠞ࡞࠹਄ߢㆇ↪ߔࠆࠪࠬ࠹ࡓߩ㐿⊒㧧ᐔᚑ 18㧙20 ᐕᐲ㧧
2,150 ජ౞(1,000㧦650㧦500 ජ౞)
9㧕 ⎇ⓥઍ⴫⠪㧦ਛ᧛⠹ਃ(᧲੩ᄢቇ)㧘⎇ⓥಽᜂ⠪㧦ᷡ᳓సᤨ㧧ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄㧦⣄ᩇ㕢Ꮺ㛽㧙㧙ൻ∝ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ㧧ᐔᚑ 19 ᐕᐲ㧧1,000 ජ౞
10㧕 ⎇ⓥઍ⴫⠪㧦ጊᧄ⋿↱⟤㧧(⽷)ጘ㒂⋵ஜᐽ㐳ኼ⽷࿅⎇ⓥ੐ᬺഥᚑ㊄㧦㕍ᐕᦼߦ߅ߌࠆ⢈ḩ⠪ᷫዋߩ⺞ᩏ⎇ⓥ㧧ᐔᚑ 19 ᐕᐲ㧧350 ජ౞
11㧕 ⎇ⓥઍ⴫⠪㧦ጊᧄ⋿↱⟤㧧⚻ᷣ↥ᬺ⋭‫ޟ‬ක≮⚻༡ੱ᧚⢒ᚑ੐ᬺߦ߅ߌࠆࠤ࡯ࠬࠬ࠲࠺ࠖᢎ᧚㐿⊒ࡊࡠࠫࠚࠢ࠻‫ޠ‬㧦㜞ᐲක≮ᢎ⢒ࠦࡦ࠰࡯ࠪࠕࡓ ක≮⚻༡ᢎ⢒ታ⸽ࡊࡠࠫࠚࠢ࠻㧧ᐔᚑ 19 ᐕᐲ㧧2,380ජ౞
12㧕 ⎇ⓥઍ⴫⠪㧦ㅦ᳓ᖗ㧘⎇ⓥಽᜂ⠪㧦ጊᧄ⋿↱⟤㧧⽷࿅ᴺੱጘ㒂⋵⎇ⓥ㐿⊒⽷࿅ᐔᚑ 19 ᐕᐲ⍮⊛ࠢ࡜ࠬ࠲࡯ഃᚑ੐ᬺ㧦ක≮⸻ᢿᡰេࠪࠬ࠹ࡓߩ㐿⊒́ࡑ࡞࠴ࡕ࡯࠳࡞ක≮⸻ᢿᡰេࠪࠬ࠹ࡓߩ㐿⊒́㧧ᐔᚑ 19 ᐕᐲ㧧2,820 ਁ౞
13㧕 ⎇ⓥઍ⴫⠪㧦↰ਛ↢㓷㧘⎇ⓥಽᜂ⠪㧦ጊᧄ⋿↱⟤㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌(⎇ⓥ)㧦ᄢቇ↢ߩࡔࡦ࠲࡞ࡋ
࡞ࠬߦ㑐ߔࠆㅊ〔⺞ᩏг♖␹ක≮ᯏ㑐೑↪ߣୃቇ⁁ᴫߦߟ޿ߡг(ⅣႺ㧘ᢎ⢒)㧧ᐔᚑ 19 ᐕᐲ㧧1,000ජ౞
14㧕 ⎇ⓥઍ⴫⠪㧦ጊᧄ⋿↱⟤㧘⎇ⓥಽᜂ⠪㧦Ꮉጯ⥜ᔒ↵㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌(ᢎ⢒)㧦ஜᐽ⑼ቇ࡮ోࠬࡐ
࡯࠷Ṷ⠌(ోቇ౒ㅢᢎ⢒)㧧ᐔᚑ 19㧙20 ᐕᐲ㧧1,000 ජ౞(500㧦500 ජ౞)
15㧕 ੐ᬺផㅴઍ⴫⠪㧦᫪⑲᮸㧘੐ᬺផㅴ⽿છ⠪㧦ฎ↰ༀષ㧘ታⴕᆔຬ㧦ጊᧄ⋿↱⟤㧘↰ਛ↢㓷㧧ᣂߚߥ␠ળ⊛࠾࡯࠭ߦኻᔕߒߚቇ↢ᡰេࡊࡠࠣ࡜ࡓ㧦↢ᶦஜᐽࠍ⋡ᜰߒߚቇ↢ஜᐽᡰេࡊࡠࠣ࡜ࡓ㧧ᐔᚑ
19㧙20 ᐕᐲ㧧48,972 ජ౞
16㧕 ⎇ⓥઍ⴫⠪㧦೨↰೑ਯ(㒋ධᄢቇ⚻༡ᖱႎቇㇱ)㧘⎇ⓥಽᜂ⠪㧦ጊᧄ⋿↱⟤㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(A)㧦ක≮⚵❱ߢ៤Ꮺ┵ᧃߩᵴ↪ߦࠃࠆක≮࡝ࠬࠢ㒐ᱛߩߚ߼ߩ⎇ⓥ㧧ᐔᚑ 19㧙21 ᐕᐲ㧧15,860
ජ౞
17㧕 ⎇ⓥઍ⴫⠪㧦ጊᧄ⋿↱⟤㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌(࿾ၞㅪ៤㧦৻⥸)㧦ጘ㒂⋵ߦ߅ߌࠆᄢቇ଻ஜ▤ℂᬺോ
ߥࠄ߮ߦ⎇ⓥߩ⊒ዷࡊࡠࠫࠚࠢ࠻㧧ᐔᚑ 20 ᐕᐲ㧧1,000 ජ౞
18㧕 ਥ⎇ⓥᜂᒰ⠪㧦ㅦ᳓ᖗ㧘ಽᜂ⎇ⓥ⠪㧦ጊᧄ⋿↱⟤㧧⽷࿅ᴺੱጘ㒂⋵⎇ⓥ㐿⊒⽷࿅ᐔᚑ 20 ᐕᐲ⍮⊛ࠢ࡜ࠬ࠲࡯ഃᚑ੐ᬺ㧦ක≮⸻ᢿᡰេࠪࠬ࠹ࡓߩ㐿⊒㧙ࡑ࡞࠴ࡕ࡯࠳࡞ක≮⸻ᢿᡰេࠪࠬ࠹ࡓߩ㐿⊒㧙㧧ᐔᚑ 20 ᐕᐲ㧧29,819 ජ౞
19㧕 ⎇ⓥઍ⴫⠪㧦ᱞ↰⚐㧘⎇ⓥಽᜂ⠪㧦ጊᧄ⋿↱⟤㧧ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄(ᓴⅣེ∔ᖚ╬↢ᵴ⠌ᘠ∛ኻ╷✚ว⎇ⓥ੐ᬺ)㧦ᓴⅣེ࡝ࠬࠢߣ⠴♧⢻㓚ኂߩല₸⊛ߥஜ⸻ࡑ࡯ࠞ࡯ߩត⚝㧧ᐔᚑ 20㧙23 ᐕᐲ㧧18,945 ජ౞
2㧕ฃ⸤⎇ⓥ1㧕 ጊᧄ⋿↱⟤㧦⥄Ꮖ᷹ቯஜᐽ▤ℂ࠺࡯࠲ࠍ㔚ሶࠞ࡞࠹਄ߢㆇ↪ߔࠆࠪࠬ࠹ࡓߩ㐿⊒㧧ᐔᚑ 18 ᐕᐲ㧧
1,000 ජ౞㧦PBJ ᩣᑼળ␠3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬᷡ᳓సᤨ㧦
1㧕 ᣣᧄᚻߩᄖ⑼ቇળ୶ℂᆔຬળᆔຬ(ᐔᚑ 18 ᐕ 5 ᦬㨪⃻࿷)2㧕 ᣣᧄᚻߩᄖ⑼ቇળ⹏⼏ຬ(ᐔᚑ 18 ᐕ 5 ᦬㨪⃻࿷)3㧕 member scientific committee of inspiration 6th INSPIRATION MEETING(2006.10.13~10.14)
4㧕 ᣣᧄᢛᒻᄖ⑼ቇળ╙ 19 ࿁ኾ㐷ක⹜㛎ญ㗡⹜㛎ᆔຬ(ᐔᚑ 18 ᐕ 10 ᦬ 18 ᣣ)
5㧕 ╙ 5 ࿁ᢛᒻᄖ⑼㐳⦟࡝ࡃ࡯ࠨࠗ࠼ࡈࠜ࡯࡜ࡓઍ⴫਎⹤ੱ(ᐔᚑ 19 ᐕ 1 ᦬ 20 ᣣ)
6㧕 ᣣᧄ⣄ᬁ⣄㜑∛ቇળ⹏⼏ຬ(ᐔᚑ 19 ᐕ 4 ᦬㨪⃻࿷)7㧕 ᣣᧄᚻߩᄖ⑼ቇળ୶ℂᆔຬળᆔຬ(ᐔᚑ 19 ᐕ 5 ᦬)
8㧕 ᣣᧄ⣄ᬁ⣄㜑∛ቇળᜰዉක೙ᐲᬌ⸛ᆔຬળᆔຬ(ᐔᚑ 19 ᐕ 6 ᦬)
9㧕 ᣣᧄ⣄ᬁ⣄㜑∛ቇળ࿖㓙ᆔຬળᆔຬ(ᐔᚑ 19 ᐕ 6 ᦬㨪⃻࿷)10㧕 ᣣᧄ⣄ᬁ⣄㜑∛ቇળ୶ℂᆔຬળᆔຬ(ᐔᚑ 19 ᐕ 6 ᦬㨪⃻࿷)11㧕 ᣣᧄ⣄ᬁ⣄㜑∛ቇળ⽷ോᆔຬળᆔຬ(ᐔᚑ 19 ᐕ 6 ᦬㨪⃻࿷)㧙㧙

12㧕 Fighting Vascular Events in Gifu ᐔᚑ 19 ਎⹤ੱ(ᐔᚑ 19 ᐕ 6 ᦬ 9 ᣣ)
13㧕 ╙ 37 ࿁ᣣᧄ⣄ᬁ⣄㜑∛ቇળࡊࡠࠣ࡜ࡓᆔຬ(ᐔᚑ 19 ᐕ 10 ᦬㨪ᐔᚑ 20 ᐕ 4 ᦬)
14㧕 ᣣᧄᢛᒻᄖ⑼ቇળ╙ 20 ࿁ኾ㐷ක⹜㛎ญ㗡⹜㛎ᆔຬ(ᐔᚑ 19 ᐕ 10 ᦬ 24 ᣣ)
15㧕 ╙ 1 ࿁᧲ᶏ㕒⣂ⴊᩖႧᩖ∝(VTE)੍㒐ࡀ࠶࠻ࡢ࡯ࠢࠪࡦࡐࠫ࠙ࡓ਎⹤ੱ(ᐔᚑ 19 ᐕ 12 ᦬ 8 ᣣ)
16㧕 ᐔᚑ 20 ᐕᐲᣣᧄᚻߩᄖ⑼ቇળ⹏⼏ຬ(ᐔᚑ 20 ᐕ 5 ᦬㨪⃻࿷)17㧕 ᐔᚑ 20 ᐕᐲᣣᧄᚻߩᄖ⑼ቇળ୶ℂᆔຬળᆔຬ(ᐔᚑ 20 ᐕ 5 ᦬㨪⃻࿷)18㧕 ᣣᧄᢛᒻᄖ⑼ቇળ╭㛽ᩰ♽ TAG ⚵❱ᆔຬળᆔຬ(ᐔᚑ 20 ᐕ 11 ᦬㨪⃻࿷)19㧕 ᣣᧄᢛᒻᄖ⑼ቇળ╙ 21 ࿁ኾ㐷ක⹜㛎ญ㗡⹜㛎ᆔຬ(ᐔᚑ 20 ᐕ 10 ᦬㨪⃻࿷)ጊᧄ⋿↱⟤㧦
1㧕 ᣣᧄౝ⑼ቇળ᧲ᶏ࿾ᣇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄౝಽᴲቇળઍ⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ⥃ᐥᩕ㙃ቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄ∛ᘒᩕ㙃ቇળ⹏⼏ຬ(㨪⃻࿷)5㧕 ᣣᧄᴤൻቇળ᧲ᶏᡰㇱᏱછᐙ੐(㨪⃻࿷)6㧕 ᣣᧄ♧ዩ∛ቇળቇⴚ⹏⼏ຬ(㨪⃻࿷)7㧕 ᧲ᶏ࡮ർ㒽࿾඙ࡔࡦ࠲࡞ࡋ࡞ࠬ⎇ⓥද⼏ળታⴕᆔຬળᆔຬ(ᐔᚑ 18 ᐕᐲ)
8㧕 ᴤൻቇળ⻠Ṷળ‫ޟ‬ᯏ⢻ᕈ㘩ຠߩ⑼ቇߣዷᦸ‫ޠ‬ᣣᧄᴤൻቇળᜂᒰᐙ੐(ᐔᚑ 18 ᐕᐲ)
9㧕 ᣣᧄ㕒⣂⚻⣺ᩕ㙃ቇળ TNT ጘ㒂⎇ୃળታⴕᆔຬ(ᐔᚑ 19 ᐕᐲ)
10㧕 ᐔᚑ 20 ᐕᐲో࿖ᄢቇ଻ஜ▤ℂදળ᧲ᶏർ㒽࿾ᣇㇱળታⴕᆔຬ(ᐔᚑ 20 ᐕᐲ)
11㧕 ో࿖ᄢቇ଻ஜ▤ℂ⎇ⓥળ⹏⼏ຬ(ᐔᚑ 20 ᐕ 12 ᦬㨪⃻࿷)↰ਛ↢㓷㧦
1㧕 ᐔᚑ 18 ᐕᐲ᧲ᶏ࡮ർ㒽࿾඙ࡔࡦ࠲࡞ࡋ࡞ࠬ⎇ⓥද⼏ળታⴕᆔຬ㐳(ᐔᚑ 18 ᐕᐲ)
2㧕 ᐔᚑ 19 ᐕᐲ᧲ᶏ࡮ർ㒽࿾඙ࡔࡦ࠲࡞ࡋ࡞ࠬ⎇ⓥද⼏ળታⴕᆔຬ(ᐔᚑ 19 ᐕᐲ)
3㧕 ᐔᚑ 20 ᐕᐲో࿖ᄢቇ଻ஜ▤ℂදળ᧲ᶏർ㒽࿾ᣇㇱળታⴕᆔຬ(ᐔᚑ 20 ᐕᐲ)
4㧕 ᐔᚑ 20 ᐕᐲࡔࡦ࠲࡞ࡋ࡞ࠬ⎇ⓥද⼏ળㆇ༡ᆔຬ(ᐔᚑ 20 ᐕᐲ)૒ᷰᔘᵗ㧦
1㧕 ᣣᧄ⥃ᐥᔃℂり૕ㆇേቇળ╙ 11 ࿁ᄢળታⴕᆔຬ(ᵿ᧻ᄢቇ)(ᐔᚑ 19 ᐕ 1 ᦬㨪ᐔᚑ 20 ᐕ 1 ᦬)
2㧕ቇળ㐿௅ᷡ᳓సᤨ㧦
1㧕 ╙ 8 ࿁ጘ㒂ᢛᒻᄖ⑼තᓟᄐᦼ࠮ࡒ࠽࡯2006(ᐔᚑ 18 ᐕ 7 ᦬㧘ጘ㒂)2㧕 ╙ 9 ࿁ጘ㒂ᢛᒻᄖ⑼තᓟᄐᦼ࠮ࡒ࠽࡯2007(ᐔᚑ 19 ᐕ 7 ᦬㧘ጘ㒂)
3㧕 ╙ 10 ࿁ጘ㒂ᢛᒻᄖ⑼තᓟᄐᦼ࠮ࡒ࠽࡯2008(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂)
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ᷡ᳓సᤨ㧦1㧕 ጘ㒂⋵කᏧળஜᐽࠬࡐ࡯࠷කቇ⎇ୃળ(ᐔᚑ 18 ᐕ 1 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫࠷࡯ࡐࠬޟ‬ㆬᚻߦ߅ߌࠆ⣶ᬁಽ㔌∝‫ޠ‬Ṷ⠪)2㧕 ጘ㒂⋵ᄖ்ᢇ๮ᢇᕆ࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 1 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫⃻ޟ‬ઍߩ㜞ᐲᄖ்ක≮‫ޠ‬ᐳ㐳)3㧕 ᴒ✽⣶∩࡮ਅ⢇∩ࡈࠜ࡯࡜ࡓ 2006(ᐔᚑ 18 ᐕ 1 ᦬㧘ᴒ✽㧘․೎⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩᴦ≮‫ޠ‬Ṷ
⠪)
4㧕 ችፒ⋵⣶ㇱ⣄ᩇ▤⁜⓰∝ࡈࠜ࡯࡜ࡓ(ᐔᚑ 18 ᐕ 2 ᦬㧘ችፒ㧘․೎⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩᴦ≮‫ޠ‬Ṷ⠪)
5㧕 ╙ 16 ࿁⑔ፉ⋵ᢛᒻᄖ⑼කߩ㓸޿(ᐔᚑ 18 ᐕ 2 ᦬㧘⑔ፉ㧘․೎⻠Ṷ‫ޟ‬⣄ᬁࠗࡦࠬ࠻࠘࡞ࡔࡦ࠹࡯࡚ࠪ
ࡦߦࠃࠆᄌᒻ⍶ᱜ‫ޠ‬Ṷ⠪)
6㧕 ⣶∩࡮ਅ⢇∩∔ᖚࡈࠜ࡯࡜ࡓ in ᾢᧄ(ᐔᚑ 18 ᐕ 2 ᦬㧘ᾢᧄ㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)7㧕 ጘ㒂⋵⥃ᐥᢛᒻᄖ⑼කળ⻠Ṷળ(ᐔᚑ 18 ᐕ 3 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ዊఽߩ⣄ᩇᄌᒻ‫ޠ‬Ṷ⠪)㧙㧙8㧕 ╙ 392 ࿁ጤᚻᢛᒻἴኂᄖ⑼ᙣ⺣ળ(ᐔᚑ 18 ᐕ 4 ᦬㧘ጤᚻ㧘․೎⻠Ṷ‫࠷࡯ࡐࠬޟ‬ㆬᚻߦ߅ߌࠆ⣶ᬁಽ㔌∝ߩᚻⴚ‫ޠ‬Ṷ⠪)9㧕 ╙ 35 ࿁㐿᡼ဳ∛ᐥࠞࡦࡈࠔ࡟ࡦࠬ(ᐔᚑ 18 ᐕ 4 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)10㧕 ╙ 79 ࿁ᣣᧄᢛᒻᄖ⑼ቇળቇⴚ✚ળ(ᐔᚑ 18 ᐕ 5 ᦬㧘␹ᄹᎹ㧘ᢎ⢒⎇ୃ⻠Ṷ‫ޟ‬⢋ߎࠅߩකቇ‫ޠ‬ᐳ㐳)11㧕 ╙ 8 ࿁ጘ㒂ᄢቇᢛᒻᄖ⑼ᢎ⢒⎇ୃળ(ᐔᚑ 18 ᐕ 5 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ᄌᒻᕈ㑐▵∝ߩ∛ᘒߣᴦ≮‫ޠ‬ᐳ㐳)12㧕 ⣶∩࠮ࡒ࠽࡯in ၔධ(ᐔᚑ 18 ᐕ 6 ᦬㧘᧲੩㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)
13㧕 ⟲㚍⋵⣶࡮⿷ߩߒ߮ࠇ∩ߺ࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 6 ᦬㧘⟲㚍㧘․೎⻠Ṷ‫ޟ‬⣶ㇱᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)
14㧕 ╳ᓟ⥃ᐥᢛᒻᄖ⑼කળቇⴚ⻠Ṷળ(ᐔᚑ 18 ᐕ 7 ᦬㧘⑔ጟ㧘․೎⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩᴦ≮‫ޠ‬Ṷ
⠪)15㧕 ╙ 33 ࿁ࠬࡐ࡯࠷කቇ⎇ୃળ(ᐔᚑ 18 ᐕ 8 ᦬㧘᧲੩㧘․೎⻠Ṷ‫ޟ‬⣄ᩇ㧘⢷࡮⣶ᬁߩᄖ்ߣ㓚ኂ‫ޠ‬Ṷ⠪)
16㧕 ⣶∩࡮ਅ⢇∩∔ᖚࡈࠜ࡯࡜ࡓᾢᧄ(ᐔᚑ 18 ᐕ 9 ᦬㧘ᾢᧄ㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)17㧕 ࠝࠬ࠹ࠝࡐࡠ࡯ࠪࠬ࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 9 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬㛽☻㝃∝ᕈ⣄ᬁ㛽᛬ߩᴦ≹ㆊ⒟߆
ࠄߺߚᚢ⇛⊛଻ሽ࡮ᚻⴚᴦ≮ߩታ㓙ߣዷᦸ‫ޠ‬ᐳ㐳)18㧕 㛽☻㝃∝ᦨᣂ⻠Ṷળ(ᐔᚑ 18 ᐕ 9 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬㛽☻㝃∝ߩࠣࡠ࡯ࡃ࡞ࠬ࠲ࡦ࠳࡯࠼ߣᚒ࿖
ߩ⃻⁁‫ޠ‬ᐳ㐳)
19㧕 ጘ㒂⋵⣶∩ࡈࠜ࡯࡜ࡓ(ᐔᚑ 18 ᐕ 9 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)20㧕 ╙ 107 ࿁ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ(ᐔᚑ 18 ᐕ 10 ᦬㧘౓ᐶ㧘‫ޟ‬㛽☻㝃∝ᕈ࿶ㄼ㛽᛬ߦኻߔࠆᴦ
≮‫ޠ‬ᐳ㐳)21㧕 㒋␹ LCS ࡈࠜ࡯࡜ࡓ(ᐔᚑ 18 ᐕ 10 ᦬㧘౓ᐶ㧘․೎⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩᴦ≮‫ޠ‬Ṷ⠪)22㧕 ╙ 5 ࿁ጘ㒂࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦ⎇ⓥળ(ᐔᚑ 18 ᐕ 11 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫╭ޟ‬ജჇᒝലᨐߩࠛࡆ࠺ࡦ
ࠬ‫ޠ‬ᐳ㐳)23㧕 ╙ 87 ࿁๺᱌ጊ⥃ᐥᢛᒻᄖ⑼කળ⎇ୃળ(ᐔᚑ 18 ᐕ 11 ᦬㧘․೎⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩᴦ≮‫ޠ‬Ṷ
⠪)24㧕 ╙ 34 ࿁᧲ᶏ࿾඙ᢛᒻᄖ⑼ᢎ⢒⎇ୃળ(ᐔᚑ 18 ᐕ 11 ᦬㧘ᗲ⍮㧘․೎⻠Ṷ‫ޟ‬⢆㑐▵ߣ⣄ᬁߦ߅ߌࠆᚻ
ⴚᚻᛛߩᎿᄦߣታ㓙‫ޠ‬ᐳ㐳)25㧕 ࡊ࡜ࠗࡑ࡝࡮ࠤࠕ࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 12 ᦬㧘੩ㇺ㧘․೎⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩ∛ᘒ㧘⸻ᢿߣᴦ≮㧙⸻ᢿࠨࡐ࡯࠻࠷࡯࡞ࠍ฽߼ߡ㧙‫ޠ‬Ṷ⠪)26㧕 ⣶∩∔ᖚ࠮ࡒ࠽࡯2006(ᐔᚑ 18 ᐕ 12 ᦬㧘ṑ⾐㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)27㧕 ╙ 8 ࿁ Latest Orthopedics ⎇ⓥળ(ᐔᚑ 18 ᐕ 12 ᦬㧘ጟጊ㧘․೎⻠Ṷ‫ޟ‬⣄ᬁ㛽㜑Ἳߩ⸻ᢿߣᴦ≮‫ޠ‬Ṷ⠪)28㧕 ╙ 166 ࿁⑔ጊᄖ⑼ળ(ᐔᚑ 18 ᐕ 12 ᦬㧘ᐢፉ㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)29㧕 ╙ 5 ࿁ᢛᒻᄖ⑼㐳⦟࡝ࡃ࡯ࠨࠗ࠼ࡈࠜ࡯࡜ࡓ(ᐔᚑ 19 ᐕ 1 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ߦ࡞࡯ࡎ࠻࠶ࡇޟ‬፰ࠄߥ޿⿷∔ᖚ࡮ᄖ்ߩ⷗ᣇ‫ޠ‬ᐳ㐳)30㧕 ╙ 6 ࿁ጘ㒂㛽☻㝃∝ࡈࠜ࡯࡜ࡓ(ᐔᚑ 19 ᐕ 1 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬㜞㦂⠪ߦ߅ߌࠆ᦯⮎ᜰዉߩታ〣㨪㛽☻㝃∝ᴦ≮⮎ࠍਛᔃߦ㨪‫ޠ‬ᐳ㐳)31㧕 㖧ᣣ⣄ᬁᄖ⑼ᙣ⹤ળ(ᐔᚑ 19 ᐕ 2 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬㖧࿖ߦ߅ߌࠆ⣄ᬁᄖ⑼࠻ࡇ࠶ࠢࠬ‫ޠ‬ᐳ㐳)32㧕 2 ᦬ౝ⑼ળ(ᐔᚑ 19 ᐕ 2 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫⥸৻ޟ‬ౝ⑼ක߇⍮ߞߡ߅߈ߚ޿⣶∩ߩ⸻ᢿᴦ≮‫ޠ‬Ṷ⠪)33㧕 ╙ 5 ࿁৾㓊 LCS ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 2 ᦬㧘⑔ጟ㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)34㧕 ╙ 3 ࿁ጘ㒂ㆇേེ㩖ࡊ࡜ࠗࡑ࡝࡯ࠤࠕ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 2 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ᣣᏱㆣㆄߔࠆエㇱ⣲≌㧙⸻≮ߩⷐὐߣ⋤ὐ㧙‫ޠ‬ᐳ㐳)35㧕 ವ㙚ᢛᒻᄖ⑼ળቇⴚ⻠Ṷળ(ᐔᚑ 19 ᐕ 3 ᦬㧘ವ㙚㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)36㧕 ╙ 10 ࿁ጘ㒂⣄ᬁ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 3 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬⣄ᬁ㛽㜑Ἳߩ⸻ᢿߣᴦ≮‫ޠ‬Ṷ⠪)37㧕 Medical Tribune ࡊ࡜ࠗࡑ࡝࡯ࠤࠕ࡮࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 3 ᦬㧘ฬฎደ㧘․೎⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩ∛ᘒ㧘⸻ᢿߣᴦ≮㧙⸻ᢿࠨࡐ࡯࠻࠷࡯࡞ࠍ฽߼ߡ㧙‫ޠ‬Ṷ⠪)38㧕 ࡊ࡜ࠗࡑ࡝࡮ࠤࠕ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 3 ᦬㧘ฬฎደ㧘․೎⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩ∛ᘒ㧘⸻ᢿߣᴦ≮㧙⸻ᢿࠨࡐ࡯࠻࠷࡯࡞ࠍ฽߼ߡ㧙‫ޠ‬Ṷ⠪)39㧕 ⥄ォゞߦࠃࠆஜᐽߠߊࠅ⻠Ṷળ(ᐔᚑ 19 ᐕ 3 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫⥄ޟ‬ォゞߣஜᐽ‫ޠ‬Ṷ⠪)40㧕 ╙ 4 ࿁ጘ㒂ㆇേེࡊ࡜ࠗࡑ࡝࡯ࠤࠕ࡮࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 3 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬㗖ᬁ∔ᖚߩ∛⸻ㅪ៤㧙ߚ߆߇⢋ߎࠅ㧘ߐࠇߤ⢋ߎࠅ㧙‫ޠ‬ᐳ㐳)41㧕 ╙ 4 ࿁ጘ㒂ㆇേེࡊ࡜ࠗࡑ࡝࡯ࠤࠕ࡮࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 3 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬⣶∩⸻ᢿߩ⪭ߣߒⓣ‫ޠ‬ᐳ㐳)42㧕 ╙ 108 ࿁ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 4 ᦬㧘ᐢፉ㧘․೎⻠Ṷ‫ޟ‬਄૏㗖ᬁㇱ்㧙㧙∛ߩ⸻≮ߩⷐὐ‫ޠ‬ᐳ㐳)43㧕 ⠀ፉ㇭ࡔ࠺ࠖࠞ࡞࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 4 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫⥸৻ޟ‬ౝ⑼ක߇⍮ߞߡ߅߈ߚ޿⣶∩ߩ⸻ᢿᴦ≮‫ޠ‬Ṷ⠪)44㧕 ╙ 6 ࿁߮ࠊߎࠬࡐ࡯࠷㓚ኂࡈࠜ࡯࡜ࡓ(ᐔᚑ 19 ᐕ 4 ᦬㧘ᄢᵤ㧘․೎⻠Ṷ‫ޟ‬⣶ߩ∩ߺߣࠬࡐ࡯࠷㓚ኂ‫ޠ‬Ṷ⠪)45㧕 ࠪࠞࠧ㨯ጘ㒂 ⣄ᬁ⣄㜑∛࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 4 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ᄌᕈᬁ㑆᧼ߩᴦ≮ ☨࿖ߢߩᦨㄭߩ⹤㗴߆ࠄ‫ޠ‬ᐳ㐳)46㧕 ╙ 9 ࿁ጘ㒂ᄢቇᢛᒻᄖ⑼ᢎ⢒⎇ୃળ(ᐔᚑ 19 ᐕ 5 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫࠷࡯ࡐࠬ⤒ޟ‬㓚ኂᴦ≮ߩ࠻ࡇ࠶ࠢࠬ‫ޠ‬ᐳ㐳)47㧕 Inspiration Asia(2007.06㧘Bali㧘Long term complications after cervical fusion; chairperson)48㧕 Fighting Vascular Events in Gifu 2007(ᐔᚑ 19 ᐕ 6 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝⸻ᢿߩⷞὐ߆ࠄߺߚ㧘ABI ߩᝒ߃ᣇ‫ޠ‬ᐳ㐳)49㧕 Fighting Vascular Events in Gifu 2007(ᐔᚑ 19 ᐕ 6 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬PAD ߦኻߔࠆᄖ⑼ᴦ≮ᚢ⇛㧙ઁ⑼ߣߩㅪ៤ߦࠃࠆ integrated therapy㧙‫ޠ‬ᐳ㐳)50㧕 ╙ 63 ࿁⷏ᣣᧄ⣄ᬁ⎇ⓥળ(ᐔᚑ 19 ᐕ 6 ᦬㧘⑔ጟ㧘․೎⻠Ṷ‫ޟ‬⣶ᬁᄌᕈ஥ᒭ∝ߩᚻⴚ‫ޠ‬Ṷ⠪)51㧕 ጘ㒂 Biological ⎇ⓥળ(ᐔᚑ 19 ᐕ 6 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ᣂߒ޿ RA ᴦ≮ߩน⢻ᕈ㧙↢‛ቇ⊛⵾೷ߣエ㛽⎕უ㧙‫ޠ‬ᐳ㐳)52㧕 ╙ 7 ࿁ ATST ࡒ࡯࠹ࠖࡦࠣ(ᐔᚑ 19 ᐕ 6 ᦬㧘᧲੩㧘․೎⻠Ṷ‫ޟ‬⣶ᬁᄌᕈ∔ᖚ߳ߩࡠ࡯ࡊࡠࡈࠔࠗ࡞
ࠪࠬ࠹ࡓߦߟ޿ߡ‫ޠ‬ᐳ㐳)53㧕 The 17th Korean-Japanese Combined Orthpaedic Symposium(2007.07, Soul, Free paper
12:Spine 1; chairperson)
54㧕 ᄢಽ⣶ㇱ⣄ᩇ▤⁜⓰∝ࡈࠜ࡯࡜ࡓ 2007(ᐔᚑ 19 ᐕ 7 ᦬㧘ᄢಽ㧘․೎⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩᴦ≮‫ޠ‬Ṷ⠪)55㧕 ጘ㒂㛽☻㝃∝ᴦ≮⎇ⓥળ․೎⻠Ṷળ(ᐔᚑ 19 ᐕ 7 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ਛਅ૏㗖ᬁߩ೨ᣇᚻⴚ‫ޠ‬Ṷ
⠪)56㧕 SICOT ࿖㓙ᢛᒻᄖ⑼ቇળ(2007.08, Morocco, Surgical treatment for spondylolysis in young
athletes; Lecturer)
57㧕 SICOT ࿖㓙ᢛᒻᄖ⑼ቇળ(2007.08, Morocco, Session 05: Spine degenerative; chairperson)
58㧕 ╙ 14 ࿁ᣣᧄ⣄ᬁ࡮⣄㜑␹⚻ᚻⴚᚻᛛቇળ(ᐔᚑ 19 ᐕ 9 ᦬㧘ฬฎደ㧘․೎⻠Ṷ‫ޟ‬㜞㦂⠪㗖㜑∝ߩ∛ᘒ߅ࠃ߮೨ᣇ㒰࿶࿕ቯⴚߩᚑ❣-dynamic plate ߩ᦭↪ᕈߦߟ޿ߡ-‫ޠ‬ᐳ㐳)59㧕 ╙ 14 ࿁ᣣᧄ⣄ᬁ࡮⣄㜑␹⚻ᚻⴚᚻᛛቇળ(ᐔᚑ 19 ᐕ 9 ᦬㧘ฬฎደ㧘․೎⻠Ṷ‫ޟ‬ABC 㗖ᬁ࠳ࠗ࠽ࡒ
࠶ࠢࡊ࡟࡯࠻ߩᚻⴚᚻᛛߩ⚫੺ߣᵈᗧὐ(ࡂࡦ࠭ࠝࡦ࠮࠶࡚ࠪࡦ B)‫ޠ‬ᐳ㐳)60㧕 ࠝࠬ࠹ࠝࡐࡠ࡯ࠪࠬ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 9 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬㛽☻㝃∝ߦ઻߁㛽᛬ߩ੍㒐‫ޠ‬ᐳ㐳)61㧕 ╙ 109 ࿁ᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 10 ᦬㧘ᄹ⦟㧘․೎⻠Ṷ‫ޟ‬ᄢ੽࠮ࡒ࠽࡯9 ⣶∩ᴦ≮ Up to Date 㧙⣶ㇱ⣄ᩇ▤⁜⓰∝ࠍਛᔃߦ㧙‫ޠ‬ᐳ㐳)62㧕 ၯ₹⣶∩ࡈࠜ࡯࡜ࡓ 2007(ᐔᚑ 19 ᐕ 10 ᦬㧘ᎹญᏒ㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)63㧕 6th Combined Meeting of Orthopaedic Reseach Societies(2007.10, Hawaii, Session 22:
Intervertebral Disc; chairperson)64㧕 ╙ 36 ࿁᧲ᶏ࿾඙ᢛᒻᄖ⑼ᢎ⢒⎇ୃળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ฬฎደ㧘․೎⻠Ṷ‫ޟ‬⣶ᬁᬁ㑆᧼㓚ኂߩၮ␆ߣ⥃ᐥ‫ޠ‬ᐳ㐳)65㧕 㛽☻㝃∝ࡈࠜ࡯࡜ࡓ(ᐔᚑ 19 ᐕ 11 ᦬㧘⑔੗㧘․೎⻠Ṷ‫ޟ‬㛽☻㝃∝ᕈᬁ૕㛽᛬ߩᚻⴚ‫ޠ‬ᐳ㐳)66㧕 ᐔᚑ 19 ᐕᐲ╙ 4 ࿁᧲੩ㇺ⥃ᐥᢛᒻᄖ⑼කળ⛔ว⎇ୃળ(ᐔᚑ 19 ᐕ 11 ᦬㧘᧲੩㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)67㧕 ASEAN OA27 VOA06 SSHV12(2007.12, Vietnam, Two staged(posterior and anterior) surgicaltreatment for pyogenic abd tuberculotic spondylitis; Lecturer)
68㧕 ╙ 110 ࿁ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 4 ᦬㧘ᄢᵤ㧘⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩ∛ᘒߣᴦ≮‫ޠ‬ᐳ㐳)69㧕 ⼾↰ട⨃ᢛᒻᄖ⑼ቇⴚ⻠Ṷળ(ᐔᚑ 20 ᐕ 4 ᦬㧘⼾↰㧘⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)70㧕 ␹ᄹᎹ LCS ࡈࠜ࡯࡜ࡓ 2008(ᐔᚑ 20 ᐕ 4 ᦬㧘ᮮᵿ㧘⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ⁜⓰∝ߩᴦ≮‫ޠ‬Ṷ⠪)71㧕 ╙ 14 ࿁ጊญ⋵⣶∩⎇ⓥળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ጊญ㧘․೎⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩᚻⴚ⊛ᴦ≮‫ޠ‬Ṷ⠪)72㧕 ╙ 10 ࿁ጘ㒂ᄢቇᢛᒻᄖ⑼ᢎ⢒⎇ୃળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬਄⢇ߩ⛉ᛗᕈᧃ᪳␹⚻㓚ኂߦߟ޿ߡ‫ޠ‬ᐳ㐳)73㧕 ጘ㒂㛽☻㝃∝࡝ࡃ࡯ࠨࠗ࠼ࠞࡦࡈࠔ࡟ࡦࠬ(ᐔᚑ 20 ᐕ 6 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬㜞㦂⠪ߩ㛽᛬੍㒐ߣォୟ㧙㧙੍‫ޠ‬ᐳ㐳)74㧕 APOA,the Spine and Pediatric Sections 2008(2008.06, Jeju Island, Symposium 2㧦Cervicalspondylotic myelopethy; chairperson)
75㧕 APOA,the Spine and Pediatric Sections 2008(2008.06, Jeju Island, Surgical treatment forspondylolysis in young Athletes. Lecture)76㧕 The 18th Japanese-Korean Combined Orthopaedic Symposium(2008.07, Nagasaki, Symposium
1:spondyloarthropathy following hemodialysis. chairperson)77㧕 ጘ㒂⋵ VTE ੍㒐࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘‫ޟ‬ᒰ㒮ߦ߅ߌࠆࡈࠜࡦ࠳ࡄ࡝࠿ࠢࠬߩ૶↪⚻㛎‫ޠ‬‫ޟ‬ਅ⢇ᢛᒻᄖ⑼๟ⴚᦼ੍㒐ߩᦨᣂࠬ࠻࡜࠹ࠫ࡯‫ޠ‬ᐳ㐳)78㧕 ᄖ⑼කㇱળ࡮ഭἴᜰቯකㇱળวห⻠Ṷળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬⣄ᬁߩࠬࡐ࡯࠷㓚ኂ‫ޠ‬Ṷ⠪)ᢎ⢒⎇ୃ⻠Ṷ
‫ޟ‬Current status79㧕 ╙ 41 ࿁ᣣᧄᢛᒻᄖ⑼ቇળ㛽࡮エㇱ⣲≌ቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ᵿ᧻㧘
of spinal tumors in the USA‫ޠ‬ᐳ㐳)80㧕 ᢛᒻᄖ⑼ቇⴚ⻠Ṷળ(ᐔᚑ 20 ᐕ 7 ᦬㧘㇊ⷓ㧘⻠Ṷ‫ޟ‬⣄ᬁᗵᨴ∝ߩ⸻ᢿߣᴦ≮‫ޠ‬Ṷ⠪)81㧕 ጘ㒂⋵࿖᳃ஜᐽ଻㒾ㆇ༡ද⼏ળળ㐳ㅪ⛊ද⼏ળ(ᐔᚑ 20 ᐕ 8 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬⣶∩㧙ㆇേེߩ↢ᵴ⠌ᘠ∛‫ޠ‬Ṷ⠪)82㧕 ╙ 7 ࿁የᒛ↢ᵴ⠌ᘠ∛⎇ⓥળ(ᐔᚑ 20 ᐕ 8 ᦬㧘ฬฎደ㧘⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)83㧕 ᄢ↰⣶ㇱ⣄ᩇ▤⁜⓰∝࠮ࡒ࠽࡯2008(ᐔᚑ 20 ᐕ 8 ᦬, ᄢ↰(Korea), Hospital-clinic partership in low
back pain practice. Lecture)84㧕 SICOT/SIROT2008 XX Φ
Triennial World Congress (2008.08, Hong Kong, Free
Papers-Spine:Cervical Spine Τ. chairperson)85㧕 ∩ߺߩᴦ≮ࡈࠜ࡜ࡓ in ጘ㒂(ᐔᚑ 20 ᐕ 9 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬⣶∩ߩ∛ᘒߣᴦ≮㧙ᣂߒ޿᭎ᔨߣᚢ⇛㧙‫ޠ‬Ṷ⠪)86㧕 ߉߰㊄⪇ጊᢛᒻᄖ⑼࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 9 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬ᢛᒻᄖ⑼කߩ⍮ߞߡ߅ߊߴ߈ක≮⸷⸩ߣ࡝ࠬࠢࡑࡀࠫࡔࡦ࠻ߩ⍮⼂㧙ᢛᒻᄖ⑼කߣᖚ⠪ߩ቟ోߣ቟ᔃߩߚ߼ߦ㧙‫ޠ‬ᐳ㐳)87㧕 ╙ 6 ࿁ᢛᒻᄖ⑼㐳⦟࡝ࡃ࡯ࠨࠗ࠼ࡈࠜ࡯࡜ࡓ(ᐔᚑ 20 ᐕ 9 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬⢋↲Ꮺ⣲≌ߩౣᑪߣᯏ
⢻‫ޠ‬ᐳ㐳)88㧕 ╙ 15 ࿁ᣣᧄ⣄ᬁ࡮⣄㜑␹⚻ᚻⴚᚻᛛቇળቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 9 ᦬㧘ᄢᵤ㧘․೎⻠Ṷ‫ޟ‬Percutaneousvertebroplasty‫ޠ‬ᐳ㐳)89㧕 ╙ 42 ࿁ᣣᧄ஥ᒭ∝ቇળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ᄹ⦟㧘⻠Ṷ‫ޟ‬஥ᒗ∝ᴦ≮ߩࠦ࠷ ᚻⴚ(೨ᣇᴺ)‫ޠ‬Ṷ⠪)90㧕 8th Inspiration Meeting(2008.10~11, Rome, Round-table discussionn of clinical cases : Anteriorstabilization of degenerative cervical spinal lesions. chairperson )91㧕 ╙ 43 ࿁᧲ᶏធ㛽ቇળ࡮╙ 90 ࿁ਛㇱធ㛽ቇળ(ᐔᚑ 20 ᐕ 11 ᦬㧘⠀ፉ㧘․೎⻠Ṷ‫ޟ‬㗖ᬁ∝㧘OPLL ߩᚻⴚᴦ≮‫ޠ‬Ṷ⠪)92㧕 ฬᏒᄢᢛᒻᄖ⑼࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 12 ᦬㧘ฬฎደ㧘․೎⻠Ṷ‫࠷࡯ࡐࠬޟ‬ㆬᚻߩ⣶ᬁಽ㔌∝‫ޠ‬Ṷ⠪)93㧕 ଻㒾⸻≮ߦ㑐ߔࠆ⻠⠌ળ(ᐔᚑ 20 ᐕ 12 ᦬㧘ጘ㒂㧘⻠Ṷ‫଻ޟ‬㒾කߣ⸻≮ႎ㈽ߩክᩏ‫ޠ‬ᐳ㐳)ጊᧄ⋿↱⟤㧦
‫♧ޟ‬ዩ∛੍㒐ߩ㊀ⷐᕈߦߟ޿ߡ‫ޠ‬Ṷ⠪)1㧕 ࿖଻੐ᬺផㅴ࠻࠶ࡊ࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 1 ᦬㧘ጘ㒂㧘
2㧕 㜞ᐲක≮ࠦࡦ࠰࡯ࠪࠕࡓ(ᐔᚑ 18 ᐕ 2 ᦬㧘ᄢ㒋㧘‫ࡓ࡯࠴ޟ‬ක≮ߣක≮ࡕ࠺࡞㧙♧ዩ∛⸻≮ࡕ࠺࡞‫ޠ‬Ṷ⠪)‫♧ޟ‬ዩ∛ߩᩕ㙃ᜰዉࠍߤ߁⚵ߺ┙ߡࠆ߆‫ޠ‬Ṷ⠪)3㧕 ጘ㒂⋵ᩕ㙃჻ળ(ᐔᚑ 18 ᐕ 8 ᦬㧘ጘ㒂㧘‫♧ޟ‬ዩ∛੍㒐ߦะߌߚขࠅ⚵ߺߦߟ޿ߡ‫ޠ‬Ṷ⠪)
4㧕 ࿖଻੐ᬺផㅴ࠻࠶ࡊ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 1 ᦬㧘ጘ㒂㧘
5㧕 ో࿖ᄢቇ଻ஜ▤ℂදળ ᧲ᶏ࡮ർ㒽࿾ᣇㇱળ⎇ⓥ㓸ળ(ᐔᚑ 19 ᐕ 7 ᦬㧘㊄ᴛ㧘‫ࠬࡄࡦࡖࠠޟ‬ౝ⑌ᾍ 2ᐕࠍ⚻ㆊߒߡ㧙⃻⁁ߣ⺖㗴㧙‫ޠ‬Ṷ⠪)‫♧ޟ‬ዩ∛ߩว૬∝ߣߘߩ੍㒐࡮ᴦ≮‫ޠ‬Ṷ⠪)6㧕 ጘ㒂⋵ᩕ㙃჻ળ(ᐔᚑ 19 ᐕ 8 ᦬㧘ጘ㒂㧘
7㧕 ᐔᚑ 19 ᐕᐲ࿖଻੐ᬺផㅴ࠻࠶ࡊ࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 1 ᦬㧘ጘ㒂㧘‫ߟߦࡓ࡯ࡠ࠼ࡦࠪࠢ࠶࡝ࡏ࠲ࡔޟ‬޿ߡ‫ޠ‬Ṷ⠪)8㧕 ᣣᧄஜᐽ࡮ᩕ㙃ࠪࠬ࠹ࡓቇળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘‫♧ޟ‬ዩ∛‫ޠ‬Ṷ⠪)9㧕 ጘ㒂⋵ᩕ㙃჻ળ(ᐔᚑ 20 ᐕ 9 ᦬㧘ጘ㒂㧘‫♧ޟ‬ዩ∛ߥࠄ߮ߦ♧ዩ∛੍஻ァߩᜰዉ㧙♧ዩ∛ኻ╷੐ᬺ㧘․ቯஜᐽ⸻ᢿᬺോߩℂ⸃ࠍᢛℂߔࠆ㧙‫ޠ‬Ṷ⠪)‫ޟ‬㆙㓒ක≮ߦ߅ߌࠆ‫ޡ‬ᩕ㙃≮ᴺ‫ߩޢ‬น⢻ᕈߣ⺖㗴‫ޠ‬ᐳ㐳)10㧕 ᣣᧄ㆙㓒ක≮ቇળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ጘ㒂㧘
11㧕 ᐔᚑ 20 ᐕᐲ(╙ 46 ࿁)ో࿖ᄢቇ଻ஜ▤ℂදળ ᧲ᶏ࡮ർ㒽࿾ᣇㇱળ⎇ⓥ㓸ળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘‫଻࡮ࡦ࡚ࠪ࠶ࠞࠬࠖ࠺࡞ࡀࡄޟ‬ஜ▤ℂᜂᒰ⡯⎇ⓥળႎ๔‫ޠ‬ᐳ㐳)㧙㧙

12㧕 ᐔᚑ 20 ᐕᐲ(╙ 46 ࿁)ో࿖ᄢቇ଻ஜ▤ℂදળ ᧲ᶏ࡮ർ㒽࿾ᣇㇱળ⎇ⓥ㓸ળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ቇ↢ᡰេߦ߅ߌࠆ IT ൻߩ዁᧪ߦߟ޿ߡ‫ޠ‬ᐳ㐳)13㧕 ᐔᚑ 20 ᐕᐲ(╙ 35 ࿁)ో࿖ᄢቇ଻ஜ▤ℂදળ ᧲ᶏ࡮ർ㒽࿾ᣇㇱળ଻ஜ▤ℂᜂᒰ⡯⎇ⓥળ(ᐔᚑ 20 ᐕ
7 ᦬㧘ጘ㒂㧘᜗ᓙṶ⠪‫․ޟ‬ቯஜ⸻ߣ․ቯ଻ஜᜰዉߦ߆߆ࠊࠆ⹤㗴ߣቇ↢ߩࡔ࠲ࡏ࡝࠶ࠢࠪࡦ࠼ࡠ࡯ࡓ
੍㒐‫ޠ‬Ṷ⠪)↰ਛ↢㓷㧦
1㧕 ᐔᚑ 18 ᐕᐲ(╙ 44 ࿁)ో࿖ᄢቇ଻ஜ▤ℂදળ᧲ᶏ㨯ർ㒽࿾ᣇㇱળ⎇ⓥ㓸ળ(ᐔᚑ 18 ᐕ 7 ᦬㧘ᵿ᧻㧘ࠪࡦࡐࠫ࠙ࡓ‫଻ޟ‬ஜ▤ℂ࠮ࡦ࠲࡯(଻ஜቶ)ߦ᳞߼ࠄࠇࠆ଻ஜࠨ࡯ࡆࠬ߳ߩኻᔕ‫ޠ‬Ṷ⠪)
2㧕 ᐔᚑ 20 ᐕᐲ(╙ 46 ࿁)ో࿖ᄢቇ଻ஜ▤ℂදળ᧲ᶏ㨯ർ㒽࿾ᣇㇱળ⎇ⓥ㓸ળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ‫ޟ‬ቇ↢ߩࡔࡦ࠲࡞ࡋ࡞ࠬߦ㑐ߔࠆᦨㄭߩ⹤㗴‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേᷡ᳓సᤨ㧦
1㧕 ⁛┙ⴕ᡽ᴺੱᣣᧄቇⴚᝄ⥝ળ⑼ቇ⎇ⓥ⾌ᆔຬળኾ㐷ᆔຬ(ᐔᚑ 18 ᐕᐲ)
2㧕 ᣣᧄࠬ࠻࡜ࠗࠞ࡯ᩣᑼળ␠⥃ᐥ㐿⊒ㇱ⥃ᐥᴦ㛎ߦ㑐ߔࠆකቇኾ㐷ኅ(ᐔᚑ 18 ᐕᐲ)
3㧕 ㆇേེߩ 10 ᐕᣣᧄᆔຬળ࿖㓙ᆔຬળᆔຬ(ᐔᚑ 18 ᐕᐲ)
4㧕 ⥃ᐥᴦ㛎ߦ㑐ߔࠆකቇኾ㐷ኅ(㨪⃻࿷)5㧕 ᢛᒻἴኂᄖ⑼ቇ⎇ⓥഥᚑ⽷࿅ㆬ⠨ᆔຬ(㨪⃻࿷)6㧕 ᢛᒻἴኂᄖ⑼⑼ቇ⎇ⓥഥᚑ⽷࿅ડ↹㨯൐㊄ᆔຬળᆔຬ(ᐔᚑ 19 ᐕ 5 ᦬)
7㧕 ⽷࿅ᴺੱᢛᒻἴኂ⑼ቇ⎇ⓥഥᚑ⽷࿅ℂ੐(ᐔᚑ 19 ᐕ 5 ᦬㨪⃻࿷)8㧕 ጘ㒂㔍∛ㅪ㔍∛ක≮⑔␩⋧⺣ળ⋧⺣ຬ(ᐔᚑ 20 ᐕ 10 ᦬)
9㧕 ╙ 10 ࿁࿖㓙࠹࠾ࠬ࡮ࠬࡐ࡯࠷කቇળ⼏⚵❱ᆔຬ(ᐔᚑ 20 ᐕ 10 ᦬)ጊᧄ⋿↱⟤㧦
1㧕 ጘ㒂↢ᵴ⠌ᘠ∛ㆇേ≮ᴺ⎇ⓥળ਎⹤ੱ(㨪⃻࿷)2㧕 ጘ㒂⋵଻ஜක≮ផㅴද⼏ળᆔຬ(㨪⃻࿷)3㧕 ᕺ㇊࿾ၞ♧ዩ∛ද⼏ળᆔຬ(㨪⃻࿷)4㧕 ጘ㒂Ꮢஜᐽ↥ᬺᝄ⥝ಽ⑼ળᆔຬ(ᐔᚑ 19 ᐕᐲ)
5㧕 ጘ㒂⋵଻ஜක≮ផㅴද⼏ળ࿾ၞ଻ஜ⸘↹ㇱળᆔຬ(㨪⃻࿷)6㧕 ጘ㒂⋵ᚑੱ∛ஜ⸻▤ℂᜰዉද⼏ળᓴⅣེ∔ᖚ╬ᆔຬ(㨪ᐔᚑ 19 ᐕ 3 ᦬)
7㧕 ␠࿅ᴺੱో࿖ᄢቇ଻ஜ▤ℂදળ⹏⼏ຬ(ᐔᚑ 20 ᐕ 12 ᦬㨪⃻࿷)8㧕 ᐔᚑ 20 ᐕᐲᣂߚߥ␠ળ⊛࠾࡯࠭ߦኻᔕߒߚቇ↢ᡰេࡊࡠࠣ࡜ࡓ࡟ࡈࠚ࡝࡯(ᐔᚑ 20 ᐕᐲ)
9㧕 ጘ㒂⋵කᏧળ♧ዩ∛ኻ╷ᆔຬળᆔຬ㐳(㨪⃻࿷)↰ਛ↢㓷㧦1㧕 ᧲ᶏ࡮ർ㒽࿾඙ࡔࡦ࠲࡞ࡋ࡞ࠬ⎇ⓥද⼏ળታⴕᆔຬળᆔຬ㐳(ᐔᚑ 18 ᐕᐲ)
2㧕 ጘ㒂⋵㓚ኂ⠪ᣉ╷ផㅴද⼏ળᆔຬ(㨪⃻࿷)3㧕 ጘ㒂⋵ኅᐸߦ߅ߌࠆ᥸ജ㒐ᱛද⼏ળ㈩஧⠪᥸ജ╬㒐ᱛኾ㐷ㇱળᆔຬ(㨪⃻࿷)4㧕 ጘ㒂㓚ኂ⠪⡯ᬺ࠮ࡦ࠲࡯ᜰዉຬ(㨪ᐔᚑ 20 ᐕ 3 ᦬)
5㧕 ጘ㒂ഭ௛ዪ࠮ࠢࡂ࡜ࠞ࠙ࡦ࠮࡜࡯(ᐔᚑ 19 ᐕ㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ↰ਛ↢㓷㧦ጘ㒂ᄢቇ଻ஜ▤ℂ࠮ࡦ࠲࡯ቯᦼஜᐽ⸻ᢿᤨࠕࡦࠤ࡯࠻⺞ᩏࠃࠅ㧦ో࿖ᄢቇ଻ஜ▤ℂදળ᧲ᶏ㨯ർ㒽࿾ᣇㇱળႎ๔ᦠ㧦45(2006 ᐕ)
2㧕 ጊᧄ⋿↱⟤㧘♿ࡁቯ଻⤿㧘㋈ᧁᐽਯ㧘㜞Ⴆ⋥⢻㧦ක≮ᖱႎ▤ℂࠪࠬ࠹ࡓߣ⸻≮ࡕ࠺࡞-♧ዩ∛-㧦ක≮⚻༡ੱ᧚⢒ᚑᢎ⢒ࡊࡠࠣ࡜ࡓ㐿⊒ࡊࡠࠫࠚࠢ࠻ 㜞ᐲක≮ᢎ⢒ࠦࡦ࠰࡯ࠪࠕࡓ㧦ᐔᚑ 17 ᐕᐲ⚻ᷣ↥ᬺ⋭‫ޟ‬ක≮⚻༡ੱ᧚⢒ᚑ੐ᬺㆇ༡ߦଥࠆᢎ⢒ࡊࡠࠣ࡜ࡓ‫ޠ‬ታ❣ႎ๔ᦠ㧦141㧙176(2006 ᐕ 3 ᦬)
3㧕 ጊᧄ⋿↱⟤㧦ࠠࡖࡦࡄࠬᢝ࿾ౝో㕙⑌ᾍ 2 ᐕࠍ⚻ㆊߒߡ㧙ࠠ࡯ࡢ࡯࠼ߪቇ↢ߩஜᐽ㧙㧦ో࿖ᄢቇ଻
ஜ▤ℂදળ ᧲ᶏ࡮ർ㒽࿾ᣇㇱળႎ๔ᦠ(ᐔᚑ 19 ᐕᐲ)㧦28㧙31(2007 ᐕ)㧙㧙4㧕 ጊᧄ⋿↱⟤㧦♧ዩ∛੍㒐ߦะߌߚขࠅ⚵ߺߦߟ޿ߡ㧦ጘ㒂⋵࿖᳃ஜᐽ଻㒾࿅૕ㅪวળ ࿖଻੐ᬺផㅴ
࠻࠶ࡊ࠮ࡒ࠽࡯⻠Ṷ⸥㍳㧦24㧙31(2007 ᐕ 1 ᦬)
5㧕 㜞Ⴆ⋥⢻㧘Ꮉญ㗅ᢘ㧘㜞ᯅቁᄦ㧘♿ࡁቯ଻⤿㧘ጊᧄ⌀↱⟤㧦․ቯᯏ⢻∛㒮ᶖൻེᄖ⑼ߦ߅ߌࠆ∛ᐥࡑࡀ࡯ࠫࡔࡦ࠻㧦ᐔᚑ 18 ᐕᐲ⚻ᷣ↥ᬺ⋭‫ޟ‬ක≮⚻༡ੱ᧚⢒ᚑ੐ᬺㆇ༡ߦଥࠆᢎ⢒ࡊࡠࠣ࡜ࡓ‫ޠ‬ႎ๔ᦠ㧦578㧙619(2007 ᐕ 1 ᦬)
6㧕 ᷡ᳓సᤨ㧦㗖ᬁ੝ో៰೨ᣇ࿕ቯⴚᓟߩ⣦㛽ቯ⌕ߣౝ࿕ቯ᧚ᢱߩᄌൻߦ㑐ߔࠆ⎇ⓥ㧦ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ 㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ⣄ᩇ㕤Ꮺ㛽ൻ∝ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ ᐔᚑ 19 ᐕᐲ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ㧦106㧙107(2008 ᐕ 3 ᦬)
7㧕 㐳ἑᷡ㧘㜞Ⴆ⋥⢻㧘♿ࡁቯ଻⤿㧘ጊᧄ⌀↱⟤㧦ᕆᕈᦼ∛㒮⚻༡ߦ߅ߌࠆᚻⴚㇱࡑࡀࠫࡔࡦ࠻㧙․ቯ
ᯏ⢻∛㒮ᚻⴚቶߩࠤ࡯ࠬ㧙㧦ᐔᚑ 19 ᐕᐲ⚻ᷣ↥ᬺ⋭‫↥ࠬࡆ࡯ࠨޟ‬ᬺੱ᧚⢒ᚑ੐ᬺ‫ޠ‬ႎ๔ᦠ(2008 ᐕ
3 ᦬)
8㧕 ጊᧄ⋿↱⟤㧦ᄢቇ↢ߩ⢈ḩߣ૕⾰ߩ㑐ଥ⺞ᩏ́዁᧪ߩ↢ᵴ⠌ᘠ∛ߩ⊒∝ࠍ੍㒐ߔࠆߚ߼ߦ́㧦ᐔᚑ
17 ᐕᐲ㧙ᐔᚑ 19 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)⎇ⓥᚑᨐႎ๔ᦠ(2008 ᐕ 5 ᦬)
9㧕 ጊᧄ⋿↱⟤㧦ቇ↢ᡰេߦ߅ߌࠆ IT ൻߩ዁᧪ߦߟ޿ߡ㧦ో࿖ᄢቇ଻ஜ▤ℂදળ ᧲ᶏ࡮ർ㒽࿾ᣇㇱળႎ๔ᦠ㧦49(2008 ᐕ 12 ᦬)
10㧕 ጊᧄ⋿↱⟤㧦․ቯஜ⸻ߣ․ቯ଻ஜᜰዉߦ߆߆ࠊࠆ⹤㗴ߣቇ↢ߩࡔ࠲ࡏ࡝࠶ࠢࠪࡦ࠼ࡠ࡯ࡓ੍㒐㧦ో࿖ᄢቇ଻ஜ▤ℂදળ ᧲ᶏ࡮ർ㒽࿾ᣇㇱળႎ๔ᦠ㧦88㧙92(2008 ᐕ 12 ᦬)
11㧕 ↰ਛ↢㓷㧦♖␹ක≮ᯏ㑐ฃ⸻ਛߩቇ↢ߩᄢቇ߳ߩㆡᔕ㧦ో࿖ᄢቇ଻ஜ▤ℂදળ ᧲ᶏ࡮ർ㒽࿾ᣇㇱળႎ๔ᦠ㧦30㧙31(2008 ᐕ 12 ᦬)
11㧚ႎ㆏1㧕 ጊᧄ⋿↱⟤㧦㜞ᐲක≮ᢎ⢒ࠦࡦ࠰࡯ࠪࠕࡓ዁᧪ߩක≮ឭଏ૕೙ߩ࿷ࠅᣇࠍ⺰⼏㧦ᣣೀ⮎ᬺ(2006 ᐕ 3
᦬ 7 ᣣ)
2㧕 ጊᧄ⋿↱⟤㧦ක≮ߩല₸ൻ⠨߃ࠆ ጘ㒂ᄢߣච౐㌁ⴕ IT ᵴ↪ߢ࠮ࡒ࠽࡯㧦ጘ㒂ᣂ⡞(2006 ᐕ 12 ᦬ 8ᣣ)3㧕 ↰ਛ↢㓷㧦଻ஜ▤ℂ࠮ࡦ࠲࡯ߣࡔࡦ࠲࡞ࡋ࡞ࠬгᄢቇ↢ߩᔃߩ㘑᥊ߣቇ↢⋧⺣ߦ᳞߼ࠄࠇࠆ߽ߩг㧦ጘ㒂⋵଻㒾කᣂ⡞㧦╙ 358 ภ(2007 ᐕ 1 ᦬)
4㧕 ᷡ᳓సᤨ㧦⥄ォゞߢᔃ߽ஜᐽߦ ࠷ࠕ࡯࡮ࠝࡉ࡮ࠫࡖࡄࡦ㐿௅⸥ᔨ㧦ጘ㒂ᣂ⡞(2007 ᐕ 3 ᦬ 2 ᣣ)
5㧕 ጊᧄ⋿↱⟤㧦ጘ㒂ᄢቇ㧙ቇ↢ᡰេ GP ߦㆬቯ㧙↢ᶦஜᐽࠍ⋡ᜰߒߚቇ↢ஜᐽᡰេࡊࡠࠣ࡜ࡓ㧦ਛᣣᣂ⡞(2007 ᐕ 9 ᦬ 30 ᣣ)
6㧕 ጊᧄ⋿↱⟤㧦ጘ㒂ᄢቇ㧙ቇ↢ᡰេ GP ߦណᛯ㧙ᄢቇߪ↢ᶦஜᐽߩࠬ࠲࡯࠻࿾ὐ㧦ᦺᣣᣂ⡞(2007 ᐕ
10 ᦬ 4 ᣣ)
7㧕 ጊᧄ⋿↱⟤㧦ጘ㒂ᄢቇ㧙↢ᶦஜᐽࠍ⋡ᜰߒߚቇ↢ஜᐽᡰេࡊࡠࠣ࡜ࡓ㧙↢ᶦஜᐽᢎ⢒ߩផㅴߣஜᐽ
ᡰេߩలታ㧦ᦺᣣᣂ⡞(2007 ᐕ 10 ᦬ 31 ᣣ)
8㧕 ጊᧄ⋿↱⟤㧦ጘ㒂ᄢቇ⑂ߩ቟ోⴡ↢▤ℂߦߟ޿ߡ㧦CBC(2008 ᐕ 7 ᦬ 2 ᣣ)
9㧕 ጊᧄ⋿↱⟤㧦ቇ࿦⑂ߩⴡ↢▤ℂ㧘⋙ⷞ૕೙ᒝൻ߳㧘ጘ㒂ᄢታⴕᆔ㧙㘩ਛᲥ㒐ᱛߦ⻠⠌ળ㧙㧦ਛᣣᣂ⡞(2008 ᐕ 7 ᦬ 3 ᣣ)
10㧕 ጊᧄ⋿↱⟤㧦ቇ↢ߩஜᐽ▤ℂ㧘ጘ㒂ߢ⎇ⓥ㓸ળ 㧙᧲ᶏ࡮ർ㒽ߩㇱળ㧙㧦ਛᣣᣂ⡞(2008 ᐕ 7 ᦬ 25
ᣣ)11㧕 ᷡ᳓సᤨ㧦ࡑ࡞ࡎᢛᒻᄖ⑼࠮ࡒ࠽࡯㧦࡜ࠫࠝ NIKKEI ᧄ␠ࠬ࠲ࠫࠝ(2008 ᐕ 9 ᦬ 3 ᣣ᡼ㅍ)12㧚⥄Ꮖ⹏ଔ
⹏ଔᬺോ㕙ߢߪቇ↢ߩஜᐽࠍ቞ࠅ㧘዁᧪ߩ∔∛੍߽㒐ߔࠆஜᐽᢎ⢒ߦߟ޿ߡචಽߥᚑᨐࠍ޽ߍߡ޿ࠆ‫ޕ‬ቇ↢ᡰេ GP ߩ੍▚⊛⢛᥊߇޽ࠆߚ߼㧘࿖ౝᄖ߳ߘߩታ❣ࠍ౏⴫ߢ߈ࠆߣߎࠈ߳᧪ߡ޿ࠆ‫ޕ‬⎇ⓥ㕙ߢߪ㧘ᄢቇ↢ߩஜᐽߦὶὐࠍ޽ߡߚ㧘࡙࠾࡯ࠢߥ⎇ⓥ⺖㗴ߦขࠅߊࠎߢ޿ࠆ‫↢ޕ‬ᵴ⠌ᘠ∛㧘ญ⣧ౝஜᐽ㧘ᘟᕈ㗡∩㧘♖␹∛ℂ㧘ᔃℂಽᨆߥߤߩ஥㕙߆ࠄ㧘࠺࡯࠲߽⫾Ⓧߒ㧘ቇળ⊒⴫╬ߔߔ߼ߡ߈ߚ‫ޕ‬⃻࿷㧘⧷ᢥ⺰ᢥߩ⊒⴫ࠍḰ஻ਛߢ޽ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ᧄቇቇ↢ߩஜᐽᡰេߩ࠾࡯࠭ߪᐕ‫ޘ‬Ⴧߒߡ߅ࠅ㧘ቇ↢ᡰេᬺോߣ⎇ⓥߣߩਔ┙ߦ㔍ᷦߒߡ޿ࠆ‫ޕ‬㧙㧙੹ᓟߩዷᦸ
ᄢቇතᬺ↢ߩ⛮⛯⊛ߥஜᐽ⺞ᩏࠍታᣉߔࠆ㧔almni cohort study㧕ߩߪ㧘਎⇇⊛ߦᢙࡩᚲߒ߆ߥ޿‫ᧄޕ‬ቇߢ⎇ⓥࡈࠖ࡯࡞࠼ߣߒߡ⏕┙ߐߖߚ޿‫ޕ‬㧙㧙㧔15㧕↢๮⑼ቇ✚ว⎇ⓥᡰេ࠮ࡦ࠲࡯㧔ࠥࡁࡓ⎇ⓥಽ㊁㧕1㧚⎇ⓥߩ᭎ⷐ
ࠥࡁࡓ⎇ⓥಽ㊁ߢߪቇౝߦ߅ߌࠆࠥࡁࡓ࡮ࡊࡠ࠹ࠝ࡯ࡓ⸃ᨆߩ᜚ὐߣߒߡࠪ࡯ࠤࡦࠨ࡯㧘࡝ࠕ࡞࠲ࠗࡓ
PCR㧘DNA ࡑࠗࠢࡠࠕ࡟ࠗ㧘MALDI-TOF/TOF ⾰㊂ಽᨆⵝ⟎ߥߤߦട߃ߡ౒ὶὐ࡟࡯ࠩ࡯ࠬࠠࡖࡦ㗼ᓸ㏜㧘ࡃࠗࠝࠗࡦࡈࠜࡑ࠹ࠖࠢࠬ㑐ㅪᯏེࠍᢛ஻ߒ㧘ࠪ࡯ࠢࠛࡦࠬฃ⸤ࠨ࡯ࡆࠬߣߣ߽ߦቇౝ↢๮⑼ቇ⎇ⓥᡰេࠍⴕߞߡ޿ࠆ‫ ߦࠄߐޕ‬2 ߟߩ᡼኿ᕈห૏ర⚛ታ㛎ᣉ⸳߽߆߆߃ߡ߅ࠅ㧘ᢎຬߪߎࠇࠄߩ▤ℂㆇ༡ࠍⴕ޿ߥ߇ࠄ⥄ࠄ߽ᵴ↪ߒߡ㧘ࡅ࠻ઍ⻢∛㧘⣺ౝ⚦⩶㧘ᬀ‛∛ේ⩶㧘ᓸ↢‛േᘒߦࠃࠆⅣႺࡕ࠾࠲࡝ࡦࠣߥ
ߤࠍ࠹࡯ࡑߦࠥࡁࡓ࡮ࡊࡠ࠹ࠝ࡯ࡓ⸃ᨆࠍਛᔃߣߔࠆ⎇ⓥࠍⴕߞߡ޿ࠆ‫ޕ‬1㧕ࡍ࡞ࠝࠠࠪ࠰࡯ࡓߩࠥࡁࡒࠢࠬ࡮ࡊࡠ࠹ࠝࡒࠢࠬ࡮ࡔ࠲ࡏࡠࡒࠢࠬߦࠃࠆ⸻ᢿ㧘∛ᘒ⸃᣿㧘ᴦ≮ᴺߩ㐿⊒࿖ౝ໑৻ߩࡍ࡞ࠝࠠࠪ࠰࡯ࡓ∛⸻ᢿ⎇ⓥ࠮ࡦ࠲࡯ߣߒߡో࿖ࠃࠅㅍࠄࠇߡ߈ߚࠨࡦࡊ࡞ߩ⢽⢌㉄ಽᨆ㧘࠲ࡦࡄࠢ࡮ㆮવሶ⸃ᨆߦࠃࠆ⸻ᢿࠪࠬ࠹ࡓߦട߃ߡ㧘ᖚ⠪⚦⢩ࠍ↪޿ߡㆮવሶዉ౉߿ siRNA㧘ࡑࠗࠢࡠࠕ࡟ࠗ⸃ᨆ╬ࠍ㚟૶ߒߡ∛ᘒ⸃᣿㧘ᴦ≮ᴺߩ㐿⊒ࠍⴕߞߡ޿ࠆ‫ోߦࠄߐޕ‬࿖ߩᬌᩏᯏ㑐ߣ߽දജߒߡ࿖ౝ
ోߡߩࡍ࡞ࠝࠠࠪ࠰࡯ࡓ∛ᖚ⠪ࠍ✂⟜ߒߡ㧘࠺࡯࠲ࡌ࡯ࠬߦ⊓㍳ߒߡ⸻ᢿ㧘ࡈࠜࡠ࡯ࠕ࠶ࡊߩࡀ࠶࠻ࡢ࡯
ࠢࠍᒻᚑߒ㧘ᖚ⠪ QOL ߩะ਄ࠍ⋡ᜰߒߡ޿ࠆ‫ߚ߹ޕ‬⢽⢌⚵❱߿␹⚻⚵❱ߦ߅ߌࠆࡍ࡞ࠝࠠࠪ࠰࡯ࡓߩ↢ℂ⊛ᯏ⢻ࠍ⸃ᨆߒ㧘ࡔ࠲ࡏ࡝࠶ࠢࠪࡦ࠼ࡠ࡯ࡓߥߤߩ↢ᵴ⠌ᘠ∛߿␹⚻ᄌᕈ∔ᖚߦኻߒߡࡍ࡞ࠝࠠࠪ࠰࡯
ࡓࠍਛᔃߣߒߚࡔ࠲ࡏࡠ࡯ࡓ⸃ᨆߩ౒ห⎇ⓥࠍㅴ߼ߡ∛ᘒ⸃᣿㧘ᴦ≮ᴺߩ㐿⊒ߦขࠅ⚵ߺ㧘ࡍ࡞ࠝࠠࠪ࠰
࡯ࡓ߇↢૕ߦ߅޿ߡᭂ߼ߡࡔࠫࡖ࡯ߥࠝ࡞ࠟࡀ࡜ߢ޽ࠆߎߣࠍጘ㒂ᄢቇ߆ࠄ⊒ାߒߡ޿ࠆ‫ޕ‬
2㧕⣺ౝ⚦⩶ߩࠥࡁࡓ⸃⺒ࡊࡠࠫࠚࠢ࠻ —⣺ౝ఺∉ࠪࠬ࠹ࡓߩ⸃᣿ߣක⮎ຠ㧘ஜᐽ㘩ຠߩ㐿⊒ࡅ࠻ߩ⣺▤ߪ 100 ళߣ޿ࠊࠇࠆ߶ߤߩ⚦⩶߇↢ᕷߒߡᏂᄢߥ↢ᘒ♽ࠍ૞ࠅ㧘ᗵᨴ㧘ࠕ࡟࡞ࠡ࡯ߥߤߩ
఺∉♽ߦ㑐ਈߒߡ߅ࠅ㧘ߘߩࡔ࠲ࠥࡁࡓ⸃ᨆߦࠃࠆක⮎ຠ߿⎇ⓥ㘩ຠߩ㐿⊒ၮ⋚ߩ⏕┙ࠍ⋡ᜰߒߡ޿ࠆ‫ޕ‬
3㧕ᬀ‛∛ේ⩶ߩࠥࡁࡓ࡮ࡊࡠ࠹ࠝ࡯ࡓ⸃ᨆߦࠃࠆ↢ᘒ⸃᣿ —㘩ߩ቟ోᕈߩ⏕┙࿯ფ∛ኂࠍ⿠ߎߔᬀ‛∛ේᕈ Fusarium ⩶ߩࠥࡁࡓ࡮ࡊࡠ࠹ࠝ࡯ࡓ⸃ᨆߦࠃࠆ∛ේᕈߩ⸃᣿ߦࠃࠅ㧘㘩ߩ቟ో㧘቟ቯߒߚ㘩♳↢↥㧘ߐࠄߦߪᣣ๺⷗ᗵᨴߩ⿠࿃⩶ኻ╷ߣߒߡක≮ߩಽ㊁߳ߩ⽸₂߽⋡ᜰߒߡ޿ࠆ‫ޕ‬
2㧚ฬ★
ਅỈિⴕ
ᢎ᝼㧦
ಎᢎ᝼㧦 㗇⾐᥍ਭ㐳ἑ᦮ሶഥᢎ㧦Nobuyuki Shimozawa
Haruhisa Suga
Tomoko Nagase3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ਅỈિⴕ㧚Zellweger ∝୥⟲㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ✬㧚ዊఽ⑼ቇ ╙ 3
㧙484㧚㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦481⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 ਅỈિⴕ㧘㋈ᧁᐽਯ㧚ࡍ࡞ࠝࠠࠪ࠰࡯ࡓ∛㧘ዊఽ⑼⸻≮ 2006 ᐕ㧧69 Ꮞ㧦1646㧙1652㧚
2㧕 㗇⾐᥍ਭ㧚ࡓࠡ㘃⿒߆߮∛⩶ߦ߅ߌࠆㄭᐕߩ⎇ⓥേะ㧘ᣣᧄᬀ‛∛ℂቇળႎ 2006 ᐕ㧧72 Ꮞ㧦121㧙134㧚
3㧕 ਅỈિⴕ㧘㋈ᧁᐽਯ㧚ࡍ࡞ࠝࠠࠪ࠰࡯ࡓᒻᚑ⇣Ᏹ∝гZellweger ∝୥⟲ࠍਛᔃߦ㧘ዊఽౝ⑼ 2007 ᐕ㧧Ⴧೀ 39 ภ㧦536㧙538㧚
✚⺑㧔᰷ᢥ㧕
1㧕 Suga H. Genetic diversity in Fusarium spp. causing Fusarium head blight of wheat and barley and its
paradoxes. Soil Microorganisms. 2006;60:99-103.
2㧕 Shimozawa N. Molecular and clinical aspects of peroxisomal diseases. J Inherit Metab Dis.
2007;30:193-197.
ේ⪺㧔๺ᢥ㧕
ߥߒේ⪺㧔᰷ᢥ㧕
1㧕 Funato M, Shimozawa N, Nagase T, Takemoto Y, Suzuki Y, Imamura Y, Matsumoto T, Tsukamoto T,
Kojidani T, Osumi T, Fukao T, Kondo N. Aberrant peroxisome morphology in peroxisomal㧙㧙beta-oxidation enzyme deficiencies. Brain Dev. 2006;28:287-292.
2㧕 Shiozawa K, Goda N, Shimizu T, Mizuguchi K, Kondo N, Shimozawa N, Shirakawa M, Hiroaki H. The
common phospholipid binding activity of the N-terminal domains of PEX1, VCP/p97. FEBS J.
2006;273:4959-4971.
3㧕 Sawada T, Hashimoto T, Nakano H, Suzuki T, Ishida H, Kiso M. Why does avian influenza A virus
hemagglutinin bind to avian receptor stronger than to human receptor? Ab initio fragment molecularorbital studies. Biochem Biophys Res Commun. 2006;351:40-43.
4㧕 Magesh S, Suzuki T, Miyagi T, Ishida H, Kiso M. Homology modeling of human sialidase enzymes
NEU1, NEU3 and NEU4 based on the crystal structure of NEU2: Hints for the design of selective
NEU3 inhibitors. J Mol Graph Model. 2006;25:196-207.
5㧕 Villa NO, Kageyama K, Asano T, Suga H. Phylogenetic relationships of Pythium and Phytophthora
species based on ITS rDNA, cytochrome oxidase II and b-tubulin gene sequences. Mycologia.
2006;98:410-422.
6㧕 Takahashi N, Morita M, Maeda T, Harayama Y, Shimozawa N, Suzuki Y, Furuya H, Sato R,
Kashiwayama Y, Imanaka T. Adrenoleukodystrophy: subcellular localization and degradation ofadrenoleukodystrophy protein (ALDP/ ABCD1) with naturally occurring missense mutations. J
Neurochem. 2007;101:1632-1643.
7㧕 Starkey DE, Ward TJ, Aoki T, Gale LR, Kistler HC, Geiser DM, Suga H, Toth B, Varga J, O’Donnell K.
Global molecular surveillance reveals novel Fusarium head blight species and trichothecene toxin
diversity. Fungal Genet Biol. 2007;44:1191-1204.
8㧕 Moriyasu Y, Maruyama-Funatsuki W, Kikuchi A, Ichimi K, Zhong B, Yan J, Zhu Y, Suga H, Watanabe
Y, Ichiki-Uehara T, Shimizu T, Hagiwara K, Kamiunten H, Akutsu K, Omura T. Molecular analysis of
the genome segments S1, S4, S6, S7 and S12 of a Rice gall dwarf virus isolate fromThailand;completion of the genomic sequence. Arch Virol. 2007;152:1315-1322.
9㧕 Kageyama K, Senda M, Asano T, Suga H, Ishiguro K. Intra-isolate hetelogeneity of the ITS region of
rDNA in Pythium helicoids. Mycol Res. 2007;111:416-423.
10㧕 Sawada T, Hashimoto H. Nakano T, Suzuki Y, Kawaoka H, Ishida H, Kiso M. Influenza viralhemagglutinin complicated shape is advantageous to its binding affinity for sialosaccharide receptor.
Biochem Biophys Res Commun. 2007;355:6-9.
11㧕 Kuratsubo I, Suzuki Y, Shimozawa N, Kondo N. Parents of Childhood X-linked
Adrenoleukodystrophy : High Risk for Depression and Neurosis. Brain Dev. 2008;30:477-482.
12㧕 Morita M, Kanai M, Mizuno S, Iwashima M, Hayashi T, Shimozawa N, Suzuki Y, Imanaka T. Bicalein
5,6,7- trimethyl ether activates peroxisomal but not mitochondrial fatty acid beta-oxidation. J Inherit
Metab Dis. 2008;31:442-449.
13㧕 Al-Dirbashi OY, Santa T, Rashed MS, Al-Hassnan Z, Shimozawa N, Chedrawi A, Jacob M,
Al-Mokhadab M. Rapid UPLC-MS/MS method for routine analysis of plasma pristanic, phytanic andvery-long chain fatty acid markers of peroxisomal disorders. J Lipid Res. 2008;49:1855-1862.
14㧕 Saito M, Yamashita S, Shimozawa N, Mizuguchi M, Iwamori M. Changes in the amounts of myelin
lipids and molecular species of plasmalogen PE in the brain of an autopsy case with d-bifunctional
protein deficiency. Neurosci Lett. 2008;442:4-9.
15㧕 Suga H, Karugia GW, Ward T, Gale LR, Tomimura K, Nakajima T, Miyasaka A, Koizumi S, Kageyama
K, Hyakumachi M. Molecular characterization of the Fusarium graminearum species complex in
Japan. Phytopathology. 2008;98:159-166.

IF 1.464

IF 3.396

IF 2.796

IF 1.932

IF 1.808

IF 4.451

IF 3.425

IF 1.839
IF 1.861

IF 2.796
IF 1.464

IF 1.668

IF 4.336

IF 2.085

IF 2.3774㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦ਅỈિⴕ㧧⑼ቇ⎇ⓥ⾌ၮ⋚⎇ⓥ(C)(2)㧦ࡕ࠺࡞േ‛ࠍ↪޿ߚࡍ࡞ࠝࠠࠪ࠰࡯ࡓઍ⻢㓚ኂߦၮߠߊ⊒↢⇣Ᏹߣ↢ᵴ⠌ᘠ∛ߩ∛ᘒ⸃᣿㧧ᐔᚑ 18 ᐕᐲ㧧1,200 ජ౞2㧕 ⎇ⓥઍ⴫⠪㧦㋈ᧁ ᔀ㧧⑼ቇ⎇ⓥ⾌․ቯ㗔ၞ㧦࠹࡯࡜࡯ࡔ࡯࠼ࡊࡠࡃࠗࠝ࠹ࠖࠢࠬࠍ⋡ᜰߒߚࡆࡈ
ࠖ࠭ࠬ⩶ዻߩୄ⍑⊛ࠥࡁࡓ⸃㧧ᐔᚑ 18㧙19 ᐕᐲ㧧8,100 ජ౞(4,000㧦4,100 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦㗇⾐᥍ਭ㧧⑼ቇ⎇ⓥ⾌⧯ᚻ⎇ⓥ(B)㧦ࡓࠡ㘃ࡑࠗࠦ࠻ࠠࠪࡦᳪᨴ㒐ᱛߩߚ߼ߩ DNA ࡑ࡯ࠞ࡯ࠍ૶ߞߚ∛ේ⩶ߩേᘒ⸃᣿㧧ᐔᚑ 18 ᐕᐲ㧧700 ජ౞4㧕 ⎇ⓥಽᜂ⠪㧦㗇⾐᥍ਭ㧧⑼ቇ⎇ⓥ⾌ၮ⋚⎇ⓥ(B)㧦࿯ფ♻⁁⩶ߦࠃࠆⅣႺࡕ࠾࠲࡝ࡦࠣࠪࠬ࠹ࡓߩ㐿⊒㧧ᐔᚑ 18 ᐕᐲ㧧3,520 ජ౞5㧕 ⎇ⓥಽᜂ⠪㧦㗇⾐᥍ਭ㧧⑼ቇ⎇ⓥ⾌ၮ⋚⎇ⓥ(B)㧦᦭↪ᓸ↢‛㑆ߩ⋧੕૞↪ߣᬀ‛ߦ߅ߌࠆ↢૕㒐ᓮᯏ᭴ߩ⸃᣿㧧ᐔᚑ 18 ᐕᐲ㧧3,700 ජ౞6㧕 ⎇ⓥઍ⴫⠪㧦ਅỈિⴕ㧧⑼ቇ⎇ⓥ⾌⪚⧘⎇ⓥ㧦ઍ⻢ࡀ࠶࠻ࡢ࡯ࠢߦၮߠ޿ߚࠪࠬ࠹ࡓࡃࠗࠝࡠࠫ࡯
ߦࠃࠆㆮવ∛⊒∝ⷙቯ࿃ሶߩត⚝㧧ᐔᚑ 19㧙20 ᐕᐲ㧧3,200 ජ౞(2,200㧦1,000 ජ౞)㧙㧙2㧕ฃ⸤⎇ⓥ
1㧕 ਅỈિⴕ㧦వᄤઍ⻢⇣Ᏹ∝ߩ⸻ᢿࡀ࠶࠻ࡢ࡯ࠢࠍ੺ߒߚ㐳ᦼ੍ᓟㅊ〔ࠪࠬ࠹ࡓߩ᭴▽㧧ᐔᚑ 18㧙20
ᐕᐲ㧧3,000 ජ౞(1,000㧦1,000㧦1,000 ජ౞)㧦ᚑ⢒ක≮⎇ⓥᆔ⸤੐ᬺ⎇ⓥ
2㧕 ㋈ᧁ ᔀ㧦ቇㇱࠍ⿥߃ߚᓸ↢‛ቇᢎ⢒ߩㅪ៤ቇㇱࠍ⿥߃ߚᓸ↢‛ቇᢎ⢒ߩㅪ៤㧦ᐔᚑ 18 ᐕᐲ㧧500ජ౞㧦ጘ㒂ᄢቇᢎ⢒⎇ⓥᵴᕈൻ⚻⾌
3㧕 ㋈ᧁ ᔀ㧦࠙ࡠࡦ㉄ൻࠠࠪࡠࠝ࡝ࠧ♧ߩ㜞⚐ᐲ⵾ㅧᴺ㧧ᐔᚑ 18 ᐕᐲ㧧3,000 ජ౞㧦⑼ቇᛛⴚᝄ⥝ᯏ
᭴⵬ഥ㊄࠺࡯࠲⵬ቢ
4㧕 㗇⾐᥍ਭ㧦቟ోߢା㗬ᕈ㧘ᯏ⢻ᕈ߇㜞޿㘩ຠ࡮ㄘ↥‛ଏ⛎ߩߚ߼ߩ⹏ଔ࡮▤ℂᛛⴚߩ㐿⊒㧘⮎೷(࠴ࠝࡈࠔࡀ࡯࠻ࡔ࠴࡞)⠴ᕈࠍᜬߟ⿒߆߮∛⩶ߩㆮવሶ⸻ᢿᛛⴚߩ㐿⊒㧧ᐔᚑ 18㧙19 ᐕᐲ㧧4,500 ජ౞(2,000㧦2,500 ජ౞)㧦ㄘᬺ࡮㘩ຠ↥ᬺᛛⴚ✚ว⎇ⓥᯏ᭴
5㧕 ㋈ᧁ ᔀ㧦⣺ౝ⚦⩶ߩࠗ࠰ࡈ࡜ࡏࡁࠗ࠼ઍ⻢ㆮવሶ⸃ᨆ㧧ᐔᚑ 19 ᐕᐲ㧧600 ජ౞㧦ጘ㒂⋵↢‛Ꮏቇ⎇ⓥᚲ
6㧕 ਅỈિⴕ㧦࡜ࠗ࠰࠱࡯ࡓ∛(ࡈࠔࡉ࡝∛฽߻)ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ㧧ᐔᚑ 19㧙20 ᐕᐲ㧧3,000 ජ౞(1,500㧦1,500 ජ౞)㧦ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄(㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ)7㧕 ਅỈિⴕ㧦Dravet ∝୥⟲ߩ Na ࠴ࡖࡀ࡞ㆮવሶ⇣Ᏹߩ⎇ⓥ㧧ᐔᚑ 20 ᐕᐲ㧧1,000 ජ౞㧦࿖┙∛㒮ᯏ᭴㕒ጟߡࠎ߆ࠎ࡮␹⚻ක≮࠮ࡦ࠲࡯8㧕 㗇⾐᥍ਭ㧦↢↥࡮ᵹㅢ࡮ടᎿᎿ⒟ߦ߅ߌࠆ૕♽⊛ߥෂኂⷐ࿃ߩ․ᕈ⸃᣿ߣ࡝ࠬࠢૐᷫᛛⴚߩ㐿⊒㧘⮎೷⠴ᕈࠍᜬߟ㤈㘃⿒߆߮∛⩶ߩㆮવሶ⸻ᢿߣવ᠞ᛥ೙ᛛⴚߩ㐿⊒㧧ᐔᚑ 20 ᐕᐲ㧧4,000 ජ౞㧦ㄘᬺ࡮㘩ຠ↥ᬺᛛⴚ✚ว⎇ⓥᯏ᭴
3㧕౒ห⎇ⓥ1㧕 ਅỈિⴕ㧦ࠨ࠙ࠫࠕ࡜ࡆࠕߦ߅ߌࠆࡍ࡞ࠝࠠࠪ࠰࡯ࡓ∛ߩ⸻ᢿߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 20 ᐕᐲ㧧ࠨ࠙ࠫࠕ࡜ࡆࠕ࡮ࠠࡦࠣࡈࠔࠗࠨ࡞ኾ㐷∛㒮࡮⎇ⓥ࠮ࡦ࠲࡯5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬਅỈિⴕ㧦
1㧕 ᣣᧄዊఽ␹⚻ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄੱ㘃ㆮવቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄዊఽㆮવቇળᐙ੐(㨪⃻࿷)4㧕 ᣣᧄవᄤઍ⻢⇣Ᏹቇળ⹏⼏ຬ(㨪⃻࿷)5㧕 ᣣᧄዊఽ⑼ቇળ᧲ᶏ࿾ᣇળᐙ੐(㨪⃻࿷)㗇⾐᥍ਭ㧦1㧕 ᬀ‛∛ኂ↢ᘒ⎇ⓥળᐙ੐(㨪⃻࿷)2㧕 ᬀ‛∛ේ⩶㘃⺣⹤ળᐙ੐(㨪⃻࿷)2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ਅỈિⴕ㧦
1㧕 10th. International Congress of Inborn Errors of Metabolism (2006.09, Chiba, Plenary lecture:
Molecular and clinical aspects of peroxisomal disease; Speaker)
2㧕 ╙ 48 ࿁ᣣᧄዊఽ␹⚻ቇળ(ᐔᚑ 18 ᐕ 6 ᦬㧘ᶆ቟㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ‫ޟ‬ㆮવᕈ␹⚻╭∔ᖚߩ⸻ᢿ࡮ᴦ≮ᚢ⇛‫ޠ‬㧚‫⸻ߩ∛ࡓ࡯࠰ࠪࠠࠝ࡞ࡍޟ‬ᢿߣᴦ≮‫ޠ‬Ṷ⠪)
3㧕 ╙ 49 ࿁ᣣᧄవᄤઍ⻢⇣Ᏹቇળ㧘╙ 6 ࿁ࠕࠫࠕవᄤઍ⻢⇣Ᏹቇળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ጊᒻ㧘ࡢ࡯ࠢࠪ㧙㧙࡚࠶ࡊ‫ޟ‬వᄤઍ⻢⇣Ᏹ∝ߦ߅ߌࠆᴦ≮ߩㅴᱠ‫ޠ‬㧚‫ޟ‬೽⣢⊕⾰ࠫࠬ࠻ࡠࡈࠖ࡯ߩㅧⴊᐙ⚦⢩⒖ᬀ≮ᴺߩ⃻⁁ߣ໧㗴ὐ‫ޠ‬Ṷ⠪)㗇⾐᥍ਭ㧦
1㧕 ╙ 14 ࿁ᣣᧄᓸ↢‛⾗Ḯቇળ(ᐔᚑ 19 ᐕ 6 ᦬㧘ᧅᏻ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ㆮવ⊛ᄙ᭽ᕈߩ⸃ᨆߢ၂㑆⷗߃ߡ߈ߚࡓࠡ㘃⿒߆߮∛⩶ߩㅴൻ࡮↢ᘒ‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേਅỈિⴕ㧦
1㧕 ጘ㒂⋵ఽ┬⑔␩ክ⼏ળఽ┬ಣㆄኾ㐷ㇱળᆔຬ(㨪⃻࿷)2㧕 ⁛┙ⴕ᡽ᴺੱක⮎ၮ⋚⎇ⓥᚲၮ␆⊛⎇ⓥ⹏ଔᆔຬળኾ㐷ᆔຬ(㨪⃻࿷)㗇⾐᥍ਭ㧦1㧕 ࠨࠗࠛࡦࠬࡄ࡯࠻࠽࡯ࠪ࠶ࡊࡊࡠࠣ࡜ࡓ੐ᬺ‫ߩ⾰ࠢࡄࡦ࠲ޟ‬ቯᕈታ㛎ߣ⸃⺑‫(ޠ‬ᐔᚑ 20 ᐕ 10 ᦬ 14
ᣣ)2㧕 వ┵⑼ቇᛛⴚ૕㛎⻠ᐳ‫ޟ‬ㆮવሶ⚵឵߃ߢᄢ⣺⩶߇శࠆ‫(ޠ‬ᐔᚑ 20 ᐕ 12 ᦬ 4 ᣣ)
3㧕 ࠨࠗࠛࡦࠬࡄ࡯࠻࠽࡯ࠪ࠶ࡊࡊࡠࠣ࡜ࡓ੐ᬺ‫ޟ‬ㆮવሶ߇⺆ࠆ↢๮⃻⽎‫(ޠ‬ᐔᚑ 20 ᐕ 12 ᦬ 13 ᣣ)ࠥࡁࡓ⎇ⓥಽ㊁㧦
1㧕 㜞ᩞ↢ߩߚ߼ߩ↢๮⑼ቇ૕㛎ࡊࡠࠣ࡜ࡓ‫ߡߞࡓࡁࠥޟ‬૗㧫‫(ޠ‬ᐔᚑ 18 ᐕ 8 ᦬ 7 ᣣ㧘8 ᣣ)
2㧕 ਛቇ↢ߩߚ߼ߩ⥄ὼ᡼኿✢ታ㛎⻠ᐳ(ᐔᚑ 18 ᐕ 8 ᦬ 11 ᣣ)3㧕 ℂ⑼♽ᢎᏧߩߚ߼ߩ⚵឵߃ DNA ታ㛎ᢎ⢒⎇ୃળ(ᐔᚑ 18 ᐕ 8 ᦬ 22 ᣣ㧘23 ᣣ)
4㧕 ᐔᚑ 18 ᐕᐲጘ㒂ᄢቇ౏㐿⻠ᐳ‫↢ࠆ߆ࠊߊࠃޟ‬๮⑼ቇ㨪⎇ⓥߩᚑᨐ߇ߤߩࠃ߁ߦ↢߆ߐࠇߡ޿ࠆ߆㨪‫ޠ‬(ᐔᚑ 18 ᐕ 10 ᦬ 1 ᣣ)
5㧕 㜞ᩞ↢ߩߚ߼ߩ↢๮⑼ቇ૕㛎ࡊࡠࠣ࡜ࡓ‫ߡߞࡓࡁࠥޟ‬૗㧫‫(ޠ‬ᐔᚑ 19 ᐕ 8 ᦬ 8 ᣣ㧘9 ᣣ)
6㧕 ਛቇ↢ߩߚ߼ߩ⥄ὼ᡼኿✢ታ㛎⻠ᐳ(ᐔᚑ 19 ᐕ 8 ᦬ 10 ᣣ)7㧕 ℂ⑼♽ᢎᏧߩߚ߼ߩ⚵឵߃ DNA ታ㛎ᢎ⢒⎇ୃળ(ᐔᚑ 19 ᐕ 8 ᦬ 23 ᣣ㧘24 ᣣ)
8㧕 ᐔᚑ 19 ᐕᐲጘ㒂ᄢቇ౏㐿⻠ᐳ‫↢ࠆ߆ࠊߊࠃޟ‬๮⑼ቇ㨪⎇ⓥߩᚑᨐ߇ߤߩࠃ߁ߦ↢߆ߐࠇߡ޿ࠆ߆‫ޠ‬(ᐔᚑ 19 ᐕ 9 ᦬ 30 ᣣ)
9㧕 㜞ᩞ↢ߩߚ߼ߩ↢๮⑼ቇ૕㛎ࡊࡠࠣ࡜ࡓ‫ߡߞࡓࡁࠥޟ‬૗㧫‫(ޠ‬ᐔᚑ 20 ᐕ 8 ᦬ 5 ᣣ㧘6 ᣣ)
10㧕 ਛቇ↢ߩߚ߼ߩ↢๮⑼ቇ૕㛎ࡊࡠࠣ࡜ࡓ‫ޟ‬ำߦ߽ߢ߈ࠆ DNA 㐓ቯ‫(ޠ‬ᐔᚑ 20 ᐕ 8 ᦬ 20 ᣣ)
11㧕 ਛቇ↢ߩߚ߼ߩ⥄ὼ᡼኿✢ታ㛎⻠ᐳ(ᐔᚑ 20 ᐕ 8 ᦬ 22 ᣣ)
10㧚ႎ๔ᦠ
1㧕 ਅỈિⴕ㧦ࡍ࡞ࠝࠠࠪ࠰࡯ࡓઍ⻢⇣Ᏹ∝ߦ߅ߌࠆ⊒∝ᯏᐨߩ⸃᣿ߣᴦ≮ᴺߩ㐿⊒㧦਄ේ⸥ᔨ↢๮⑼ቇ⽷࿅⎇ⓥႎ๔㓸㧦144㧙147(ᐔᚑ 18 ᐕ)
2㧕 ਅỈિⴕ㧦ࡕ࠺࡞േ‛ࠍ↪޿ߚࡍ࡞ࠝࠠࠪ࠰࡯ࡓઍ⻢㓚ኂߦၮߠߊ⊒↢⇣Ᏹߣ↢ᵴ⠌ᘠ∛ߩ∛ᘒ⸃᣿㧦ᐔᚑ 17㧙18 ᐕᐲ⑼ቇ⎇ⓥ⾌ၮ⋚⎇ⓥ(C)(2)㧦1㧙71(ᐔᚑ 19 ᐕ 3 ᦬)
3㧕 ਅỈિⴕ㧦ㆮવᕈࡍ࡞ࠝࠠࠪ࠰࡯ࡓ∛ᐥ଀ߩ㐳ᦼ੍ᓟㅊ〔ߩߚ߼ߩ࠺࡯࠲ࡌ࡯ࠬ૞ᚑ㧦ᐔᚑ 17㧙19ᐕᐲෘ↢ഭ௛⋭ᚑ⢒ක≮⎇ⓥᆔ⸤੐ᬺ⎇ⓥႎ๔ᦠ(᧻ේ⃰)㧦254㧙255(ᐔᚑ 19 ᐕ 4 ᦬)
11㧚ႎ㆏1㧕 ᝼ᬺߢ DNA ታ㛎㧦ਛᣣᣂ⡞(2006 ᐕ 2 ᦬ 1 ᣣ)
2㧕 㜞ᩞ↢߇ㆮવሶቇ߱㧦ਛᣣᣂ⡞(2006 ᐕ 8 ᦬ 10 ᣣ)
3㧕 㜞ᩞ↢㧘ࠥࡁࡓࠍቇ⠌㧦ጘ㒂ᣂ⡞(2006 ᐕ 8 ᦬ 10 ᣣ)
4㧕 ㆮવሶ߆ࠄ∛ᘒ⸃᣿⋡ᜰߔ㧦ጘ㒂ᣂ⡞(2006 ᐕ 8 ᦬ 15 ᣣ)
5㧕 ⥄ὼ᡼኿✢ࠍⷰኤ㧦ਛᣣᣂ⡞(2006 ᐕ 8 ᦬ 16 ᣣ)6㧕 ⎇ⓥᚑᨐࠍ੤߃‫↢ޟ‬๮⑼ቇ‫੺⚫ޠ‬㧦ਛᣣᣂ⡞(2006 ᐕ 10 ᦬ 2 ᣣ)
7㧕 ኾ㐷⊛ߦࠥࡁࡓ૕ᗵ㧦ਛᣣᣂ⡞(2007 ᐕ 8 ᦬ 8 ᣣ)
8㧕 ጘᄢߣࠨ࠙ࠫ㔍∛స᦯ㅪ៤ࡍ࡞ࠝࠠࠪ࠰࡯ࡓ∛ᴦ≮⎇ⓥ㧦ਛᣣᣂ⡞(2008 ᐕ 11 ᦬ 18 ᣣ)㧙㧙12㧚⥄Ꮖ⹏ଔ
⹏ଔోቇ⊛ߥᢎ⢒⎇ⓥᡰេᬺോߣߒߡߪ↢๮⑼ቇ✚ว⎇ⓥᡰេ࠮ࡦ࠲࡯ߣᡷ⒓ߒߡࠃࠅ⎇ⓥᡰេߩ┙႐ࠍ᣿⏕ߦߒ㧘ጘ㒂ᄢቇߦ߅ߌࠆᢎ⢒⎇ⓥߩၮ⋚⊛⸳஻ߩᢛ஻ࠍⴕ߁ߣߣ߽ߦ㧘↢๮⑼ቇߦ㑐ߔࠆၮ␆⎇ⓥߩ⥃ᐥᔕ↪߳ߩዷ㐿ࠍㅴ߼ߡ޿ࠆ‫⎇ޕ‬ⓥ㕙ߢߪో࿖໑৻ߩࡍ࡞ࠝࠠࠪ࠰࡯ࡓ∛⸻ᢿ⎇ⓥ࠮ࡦ࠲࡯ߣߒߡ
⸻ᢿࠪࠬ࠹ࡓ㧘ᖚ⠪㐳ᦼࡈࠜࡠ࡯ࠕ࠶ࡊࠪࠬ࠹ࡓࠍ⏕┙ߒ㧘࿖ౝᄖߩ⎇ⓥᯏ㑐ߣ౒หߢ∛ᘒ⸃᣿㧘ᴦ≮ᴺߩ㐿⊒ߦ❬߇ࠆ⎇ⓥࠍⴕߞߚ‫ޕ‬1㧕ጘ㒂ᄢቇߩࠥࡁࡓ࡮ࡊࡠ࠹ࠝ࡯ࡓ⎇ⓥᡰេ㧦ࠥࡁࡓ࡮ࡊࡠ࠹ࠝ࡯ࡓ⸃ᨆᯏེߦ౒ὶὐ࡟࡯ࠩ࡯㗼ᓸ㏜㧘
ࡃࠗࠝࠗࡦࡈࠜࡑ࠹ࠖࠢࠬ㑐ㅪ⸳஻╬ࠍᢛ஻ߒߡోቇ߆ࠄߩ೑↪ߦኻᔕߔࠆߣߣ߽ߦ㧘ฃ⸤ࠪ࡯ࠢࠛ
ࡦࠬࠨ࡯ࡆࠬߢߪቇౝ LAN ࠍ↪޿ߡㄦㅦߦ⚿ᨐࠍ㈩ାߒߡ⎇ⓥᡰេࠍⴕߞߡ޿ࠆ‫ޕ‬
2㧕ࠥࡁࡓ⎇ⓥಽ㊁ RI කቇᣉ⸳ߩ㐿⸳ߦࠃࠅ㧘ቇౝߦ㓸⚂ߒߚ 2 ᣉ⸳ߢోቇ⊛ߦ቟ో߆ߟりㄭߥ RI ታ㛎߇น⢻ߥᢎ⢒⎇ⓥⅣႺࠍᢛ஻ߒߚ‫ޕ‬
3㧕ࡍ࡞ࠝࠠࠪ࠰࡯ࡓ∛ߩ࿖ౝ⸻ᢿࠪࠬ࠹ࡓࠍ⏕┙ߒ㧘ࡍ࡞ࠝࠠࠪ࠰࡯ࡓᰳ៊∝ߢߪ࿖ౝో∝଀ߩ࠲ࡦࡄ
ࠢ࡮ㆮવሶ࡟ࡌ࡞ߢߩ⸻ᢿ㧘ᣂⷙ∛࿃ㆮવሶߩ⸃᣿㧘ጘ㒂ᄢቇߩಽ㘃ࠍ⊒⴫ߔࠆߣߣ߽ߦ㧘ࡍ࡞ࠝࠠࠪ࠰࡯ࡓߣ␹⚻⊒↢ߩ㑐ࠊࠅ߿ᴦ≮ᴺߩ㐿⊒ߦߟ޿ߡ౒ห⎇ⓥࠍዷ㐿ߒߡႎ๔ߒߚ‫ޕ‬
4㧕⎇ⓥᚑᨐߩ␠ળ߳ߩㆶరߥࠄ߮ߦ␠ળ⽸₂ߣߒߡࠨ࠙ࠫࠕ࡜ࡆࠕߩࡍ࡞ࠝࠠࠪ࠰࡯ࡓ∛⸻ᢿᡰេࠪ
ࠬ࠹ࡓࠍࠨ࠙ࠫࠕ࡜ࡆࠕ࿖┙∛㒮ߣ౒หߢ⏕┙ߒߚ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷1㧕↢๮⑼ቇᛛⴚߩㅴᱠߣߣ߽ߦࠪࠬ࠹ࡓࡃࠗࠝࡠࠫ࡯㑐ㅪ⸃ᨆᯏེߩㅴᱠ߽⋡ⷡ߹ߒߊ㧘ቇౝߦ߅ߌࠆ
↢๮⑼ቇߩᢎ⢒⎇ⓥ᳓Ḱࠍ㜞ᐲߦ⛽ᜬߔࠆߚ߼ߦߪ㧘㓸⚂ൻߒߚᣉ⸳ߦ⸳஻߿ᄢဳᯏེࠍ⸳⟎ߒߡᦝᣂߒߡ೑↪ࠍᐢߍ㧘ቇౝߦ߅ߌࠆ࠰ࡈ࠻߿ࡂ࡯࠼㕙ߢߩ⎇ⓥᖱႎࠪࠬ࠹ࡓࠍᢛ஻ߒߡㇱዪߩ၂ᩮࠍ⿧
߃ߚోቇ⊛ߥᢎ⢒⎇ⓥߩផㅴ߇ᦸ߹ࠇࠆ‫ޕ‬
2㧕RI ታ㛎ᣉ⸳ߦ㑐ߒߡߪ 2 ᣉ⸳ߩ቟ቯߒߚㆇ༡ߣ RI ߦ♖ㅢߒߚኾછᢎቭߩ㈩ዻ߇ਇนᰳߢ޽ࠆ‫ޕ‬
3㧕⎇ⓥᡰេ࠮ࡦ࠲࡯ߩㆇ༡ߦᓥ੐ߒߥ߇ࠄ⎇ⓥ⠪ߣߒߡߩࡕ࠴ࡌ࡯࡚ࠪࡦࠍ଻ߟߚ߼ߦߪ㧘⥄ࠄ߇₸వߒߡ⎇ⓥ࠹࡯ࡑࠍ⸳ቯߒߡ౒ห⎇ⓥࠍዷ㐿ߒ㧘ᄢቇ㒮߽฽߼ߚ⎇ⓥ⠪ߩᢎ⢒࡮⢒ᚑߦ㑐ࠊࠆᆫ൓߇ᔅ
ⷐߣᕁࠊࠇࠆ‫ޕ‬੹ᓟߩዷᦸ
1㧕ጘ㒂⮎⑼ᄢቇߩ⒖ォ߽㐓ߺ㧘‫ޟ‬࿾ၞߩ⍮ߩ᜚ὐ‫ߡߒߣޠ‬ㇱዪ㧘ᄢቇߩᨒࠍ⿧߃ߚጘ㒂ᄢቇ࿾඙ߩ↢๮⑼ቇ⎇ⓥߩ᜚ὐߣߒߡᣉ⸳㧘⸳஻㧘⚵❱ࠍᢛ஻ߒߡ౒ห⎇ⓥࠍᡰេߒ㧘ၮ␆ߣ⥃ᐥߩ᨞ߌᯅࠍ⋡ᜰߔ‫ޕ‬
2㧕ࡍ࡞ࠝࠠࠪ࠰࡯ࡓ∛ࠍߪߓ߼ߣߔࠆㆮવᕈઍ⻢∛ߩ⸻ᢿ⎇ⓥߩ᜚ὐߣߒߡන৻ㆮવሶ∛߆ࠄ↢ᵴ⠌ᘠ∛߹ߢ∛ᘒ⸃᣿㧘ᴦ≮ᴺߩ㐿⊒ࠍⴕ޿㧘ጘ㒂ᄢቇࠃࠅ‫⊒ࠍޠࡓ࡯࠰ࠪࠠࠝ࡞ࡍޟ‬ାߒߡ޿ߊ‫ޕ‬㧙㧙㧔16㧕↢๮⑼ቇ✚ว⎇ⓥᡰេ࠮ࡦ࠲࡯㧔ህ᳇ᕈ⩶⎇ⓥಽ㊁㧕1㧚⎇ⓥߩ᭎ⷐ
ᒰಽ㊁ߢߪ㧘⥃ᐥᓸ↢‛ቇߩ┙႐߆ࠄ㧘ህ᳇ᕈ⩶࡮ህ᳇ᕈ⩶ᗵᨴ∝ߦ㑐ߔࠆၮ␆⊛࡮⥃ᐥ⊛⎇ⓥࠍㅴ߼ߡ޿ࠆ‫ౕޕ‬૕⊛ߦߪ⎕்㘑㧘ࠟࠬუ∓㧘ࡏ࠷࡝࠿ࠬ∝ߥߤᲥ⚛↥↢ᕈߩህ᳇ᕈ⩶ߦࠃࠆᄖ࿃ᕈߩᗵᨴ∝㧘߅߽ߦⴚᓟߦ⷗ࠄࠇࠆህ᳇ᕈ⩶ߣㅢᕈ⩶߇⋧ਸ਼⊛ߦ∛ේᕈࠍ⊒ើߔࠆౝ࿃ᕈߩⶄᢙ⩶ᗵᨴ∝㧘⧘⢩ࠍ߽ߟ
ህ᳇ᕈ⩶ߦࠃࠆ㒮ౝᗵᨴ∝ߥߤߩህ᳇ᕈ⩶߇㑐ଥߔࠆᄙ⒳ᄙ᭽ߩᗵᨴ∝ߩ⸻ᢿ㧘ᴦ≮㧘ߘߒߡ੍㒐ߦᓎߛߟࠃ߁ߥ⎇ⓥࠍ⚦⩶ቇ⊛ߥ┙႐߆ࠄⴕߞߡ޿ࠆ‫ޕ‬ህ᳇ᕈ⩶ߩಽ㔌ၭ㙃หቯᴺߩᡷ⦟㧘ህ᳇ᕈ⩶ߩ∛ේ࿃ሶ㧘
ህ᳇ᕈ⩶ߩ᛫⩶⮎ᗵฃᕈߩ᷹ቯߣߘߩ᷹ቯᴺߩᡷ⦟㧘᛫ህ᳇ᕈ⩶૞↪ࠍ᦭ߔࠆ‛⾰ߩត⚝ߣߘࠇࠄߩ᛫⩶ജߩ⹏ଔ㧘ህ᳇ᕈ⩶ߩ᛫⩶⮎ߦኻߔࠆ⠴ᕈ⃻⽎ߩ⸃᣿㧘ߘߒߡ㧘ህ᳇ᕈ⩶߇ఝ൓ߥࡅ࠻࿕᦭⚦⩶ฌߩ⇣Ᏹൻ߇ේ࿃ߣߥߞߡ߅ߎࠆ⒳‫ޟߩޘ‬21 ਎♿∛‫⎇ߩߡ޿ߟߦޠ‬ⓥߥߤࠍዷ㐿ߒߡ޿ࠆ‫ޕ‬
2㧚ฬ★
ᷰㆺ㇌෹
ᢎ᝼㧦
ಎᢎ᝼㧦 ↰ਛ㚅߅㉿
ᓟ⮮㓉ᰴ
ഥᢎ㧦

Kunitomo Watanabe
Kaori Tanaka
Takatsugu Goto3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ਃ㡞ᑝ❥㧚Q27 ᄖ⑼㗔ၞߢᵈᗧߔߴ߈⌀⩶∝ߣ࡝ࠬࠢߪ㧫㧦὇ጊཅિ㧘㐷↰቞ੱ㧘〔⷗⵨✬㧚ᷓ࿷ᕈ⌀⩶∝ Q&A㧘ᄢ㒋㧦ක⮎ࠫࡖ࡯࠽࡞␠㧧2006 ᐕ㧦84㧙86㧚
2㧕 ਃ㡞ᑝ❥㧚╙Υ┨ Ꮢਛᗵᨴ∝ߦኻߔࠆᚻⴚᤨߩ᛫⩶⮎ߩ૶޿ᣇ D㧚↥ᇚੱ⑼∔ᖚ㧦὇ጊཅિ✬㧚๟ⴚᦼᗵᨴኻ╷ࡑ࠾ࡘࠕ࡞ ᛫⩶⮎૶↪ᴺ߆ࠄ๟ⴚᦼ▤ℂ߹ߢ㧘᧲੩㧦ධᳯၴ㧧2006 ᐕ㧦62㧙67㧚
3㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧚╙ 1 ┨ ∝⁁࡮∝୥߆ࠄߤࠎߥᬌ૕ࠍណขߒߤߩࠃ߁ߦ⸻ᢿࠍㅴ߼ࠆ
߆ 7 ↥ᇚੱ⑼㗔ၞߩᗵᨴ∝߇⇼ࠊࠇߚߣ߈㧦ᴡ㊁⨃㧘ᐔẟᵗ৻✬㧚ࡌ࠶࠼ࠨࠗ࠼ߢᓎ┙ߟᓸ↢‛ᬌᩏࠟࠗ࠼ ૗ߩᬌᩏࠍߔࠆ߆࡮⚿ᨐࠍߤ߁⹏ଔߔࠆ߆㧘᧲੩㧦ᢥశၴ㧧2006 ᐕ㧦50㧙57㧚
4㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧚ࡏ࠷࡝࠿ࠬਛᲥߩ․ᓽߣኻᔕ㧦ᷰㄝᴦ㓶✬㧚㘩ਛᲥᬌᩏ࡮⸻≮ߩࠦ࠷ߣ⪭ߣߒⓣ㧘᧲੩㧦ਛጊᦠᐫ㧧2006 ᐕ㧦20㧙21.
5㧕 ᷰㆺ㇌෹㧚4 ᗵᨴ∝߅ࠃ߮ነ↢⯻∔ᖚ 4㧙5 ৻⥸⚦⩶ᗵᨴ∝ 1)ࠣ࡜ࡓ㓁ᕈ⃿⩶ᗵᨴ∝(4)⎕்㘑⩶㧘(5)ࠟ
ࠬუ∓⩶⟲㧘(6)࠺ࡈࠖࠪ࡞⩶㧘4)ࠣ࡜ࡓ㒶ᕈ⚦⩶ᗵᨴ∝ 20)ࡃࠢ࠹ࡠࠗ࠺ࠬ╬ߩή⧘⢩ህ᳇ᕈ⩶߇㑐ਈߔ
ࠆⶄᢙ⩶ᗵᨴ∝㧦᧖ᧄᕡ᣿㧘⍫ፒ⟵㓶✬㧚ౝ⑼ቇ╙ 9 㧘᧲੩㧦ᦺୖᦠᐫ㧧2007 ᐕ㧦303㧙305㧘324㧙325㧚
6㧕 ᷰㆺ㇌෹㧚ᗵᨴ∝ᬌᩏ ᗵᨴ∝ㆮવሶᬌᩏ ࠢࡠࠬ࠻࡝ࠫ࠙ࡓ࡮࠺ࠖࡈࠖࠪ࡟ㆮવሶᬌᩏ ᓸ↢‛↥↢‛࡮ઍ⻢↥‛ ࡏ࠷࡝࠿ࠬᲥ⚛㧘CD ࠻ࠠࠪࡦ㧘࠹࠲ࡁࠬࡄࠬࡒࡦ㧦㜞ਭਭ㤚⋙ୃ㧚⥃ᐥᬌᩏ࠺࡯࠲ࡉ࠶ࠢ 2007
㧙2008㧘᧲੩㧦කቇᦠ㒮㧧2007 ᐕ㧦491㧙492㧘524㧙528㧚
7㧕 ᷰㆺ㇌෹㧚3.ᗵᨴ∝ ή⧘⢩ህ᳇ᕈ⩶ᗵᨴ∝㧦ጊญᔀ㧘ർේశᄦ㧘⑔੗ᰴ⍫✚✬㓸㧚੹ᣣߩᴦ≮ᜰ㊎㧘᧲੩㧦කቇᦠ㒮㧦2007 ᐕ㧦166㧙167㧚
8㧕 ᷰㆺ㇌෹㧚╙ 3 ┨ 1 ᦨᣂߩህ᳇ᕈ⩶ߩಽ㘃࡮๮ฬ㧘╙ 3 ┨ 2 Ᏹ࿷⚦⩶ฌࠍ᭴ᚑߔࠆህ᳇ᕈ⩶㧦ᣣᧄൻቇ≮ᴺቇળ㧘ᣣᧄህ᳇ᕈ⩶ᗵᨴ∝⎇ⓥળ✬㧚ህ᳇ᕈ⩶ᗵᨴ∝⸻ᢿ࡮ᴦ≮ࠟࠗ࠼࡜ࠗࡦ 2007㧘᧲੩㧦౒๺ડ↹㧧
2007 ᐕ㧦192㧙209㧚
9㧕 ↰ਛ㚅߅㉿㧚╙ 1 ┨ 3 ⮎೷ᗵฃᕈ⹜㛎㧘╙ 3 ┨ 3 ⠴ᕈህ᳇ᕈ⩶㧦ᣣᧄൻቇ≮ᴺቇળ㧘ᣣᧄህ᳇ᕈ⩶ᗵᨴ∝⎇ⓥળ✬㧚ህ᳇ᕈ⩶ᗵᨴ∝⸻ᢿ࡮ᴦ≮ࠟࠗ࠼࡜ࠗࡦ 2007㧘᧲੩㧦౒๺ડ↹㧧2007 ᐕ㧦30㧙37㧘210㧙213㧚
10㧕 ᷰㆺ㇌෹㧚3㧚ህ᳇ᕈ⩶ᗵᨴ∝㧦੗᧛⵨ᄦ✬㓸ਥᐙ㧚ࠊ߆ࠅ߿ߔ޿ౝ⑼ቇ ╙ਃᗵᨴ∝ ᧲੩ ಽశၴ2008 ᐕ㧦485㧙487㧚
11㧕 ᷰㆺ㇌෹㧚3㧚ህ᳇ᕈ⩶ᗵᨴ∝㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ✚✬㓸㧚ዊఽ⑼ቇ ᧲੩ කቇᦠ㒮 2008 ᐕ㧦809
㧙811㧚
⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 ↰ਛ㚅߅㉿㧘ਃ㡞ᑝ❥㧘ᷰㆺ㇌෹㧚ࡃࠢ࠹ࡠࠗ࠺ࠬዻ㧘ᗵᨴߣ᛫⩶⮎ 2006 ᐕ㧧9 Ꮞ㧦2㧙4.
2㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧚ᓸ↢‛ቇ⷗࿾߆ࠄߺߚ᛫⩶⮎ߩㆡᱜ૶↪ᴺߣ⮎೷⠴ᕈ⩶೙ᓮߩߚ߼ߩ
ᚢ⇛㧘࡝࠙ࡑ࠴⑼ 2006 ᐕ㧧35 Ꮞ㧦63㧙68㧚
3㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧚MRSA ᗵᨴ∝ߦ߅ߌࠆ࡝ࡀ࠱࡝࠼ߩ᦭ലᕈ㧘ᴦ≮ቇ 2006 ᐕ㧧40 Ꮞ㧦
83㧙84㧚
4㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧚ᵈᗧߔߴ߈ᗵᨴ∝ߣኻ╷ 5㧚↥ᇚੱ⑼㗔ၞߩᗵᨴ∝ߣኻ╷㧘ᢇᕆකቇ
2006 ᐕ㧧30 Ꮞ㧦216㧙220㧚
5㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧚ህ᳇ᕈ⩶ߦࠃࠆ࠮ࡊࠪࠬߪሽ࿷ߔࠆ߆㧘ᴦ≮ቇ 2006 ᐕ㧧40 Ꮞ㧦521
㧙524㧚

㧙㧙

6㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧚๟↥ᦼߦ߅ߌࠆ B ⟲ㅪ㎮⃿⩶ᗵᨴ∝ߩ੍㒐ߦ㑐ߔࠆ CDC ߩᡷ⸓ࠟࠗ
࠼࡜ࠗࡦ ᣂߒߊ⊒⴫޽ࠆ޿ߪᡷ⸓ߐࠇߚᗵᨴ∝ߦ㑐ߔࠆࠟࠗ࠼࡜ࠗࡦ㧘ൻ≮ߩ㗔ၞ 2006 ᐕ㧧22 Ꮞ
Suppl. 1㧦134㧙137㧚
7㧕 ਃ㡞ᑝ❥㧚↥ᇚੱ⑼㗔ၞߦ߅ߌࠆ๟ⴚᦼߩᗵᨴ೙ᓮ㧘PHYSICIAN’S THERAPY MANUAL 2006 ᐕ㧧5Ꮞ㧦1㧙2㧚
8㧕 ਃ㡞ᑝ❥㧚ࠃߊㆣㆄߔࠆᗵᨴ∝‫߇޿ߒ⃟ޔ‬⍮ߞߡ߅߈ߚ޿ᗵᨴ∝ ᇚੱ⑼㧘INFECTION FRONT 2006
ᐕ㧧7 Ꮞ㧦12㧙13㧚
9㧕 ਃ㡞ᑝ❥㧚․ᱶ∛ᘒߦ߅ߌࠆ᛫⩶ൻቇ≮ᴺ ᅧᇚ㧘ᣣᧄౝ⑼ቇળ㔀⹹ 2006 ᐕ㧧95 Ꮞ㧦2208㧙2213㧚
10㧕 ਃ㡞ᑝ❥㧘ᷰㆺ㇌෹㧚⣪Ᏹ࿷⩶ 㨪ߘߩሽ࿷ᗧ⟵ߣᓎഀ㨪㧚ᣣᧄ⣺ౝ⥃ᐥᓸ↢‛ቇળળ⹹ 2006 ᐕ㧧8 Ꮞ㧦
31㧙34.
11㧕 ᷰㆺ㇌෹㧘ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧚ẩ≌ᕈᄢ⣺Ἳߩᚑ࿃߅ࠃ߮Ⴧᖡߦ㑐ࠊࠆ⚦⩶࿃ሶߩ৻ߟߣߒߡߩ⎫㉄ㆶర⚦⩶ ᣣᧄ⥃ᐥ 2007 ᐕ㧧65 Ꮞ㧦1337㧙1346.
12㧕 ᷰㆺ㇌෹㧚ญ⣧ౝ⚦⩶ฌ᭴ᚑህ᳇ᕈ⩶ߣህ᳇ᕈ⩶ᗵᨴ∝㧘ᣣᧄญ⣧ᗵᨴ∝ቇળ㔀⹹ 2007 ᐕ㧧14 Ꮞ㧦3㧙
8.
13㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹.᛫⩶⮎ࠍㆬᛯߔࠆ਄ߢ⍮ߞߡ߅߈ߚ޿ህ᳇ᕈ⩶ᗵᨴ∝ߣህ᳇ᕈ⩶ߩ⠴ᕈൻ ࠕࠬ࠹࡜ࠬ⵾⮎‫ޟ‬ᗵᨴ∝‫ ޠ‬2007 ᐕ㧧37 Ꮞ㧦41㧙48.
14㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧚․㓸 ᛫⩶⮎ߩ․ᕈࠍ↢߆ߒߡ਄ᚻߦ૶߁ߎߟ ᛫⩶⮎ߩ PK/PD ࠍᵴ߆ߔᴦ≮⁁ᴫߣߪ㧚ᗵᨴߣ᛫⩶⮎ 2007 ᐕ㧧10 Ꮞ㧦102㧙110.
15㧕 ᷰㆺ㇌෹. ஍ᕈህ᳇ᕈ⩶ᗵᨴ∝ߩၮ␆ߣ⥃ᐥ஍ᕈህ᳇ᕈ⩶ߩಽ㘃 ⥃ᐥߣᓸ↢‛ 2008 ᐕ㧧35 Ꮞ㧦21
㧙28.
✚⺑㧔᰷ᢥ㧕
1㧕 Nagayama A, Yamaguchi K, Watanabe K, Tanaka M, Kobayashi I, Nagasawa Z. Final report fromthecommittee on Antimicrobial Susceptibility Testing, Japanese Society of Chemotherapy, on the agar
dilution method (2007). J Infect Chemother. 2008;14:383-392.
ේ⪺㧔๺ᢥ㧕
1㧕 ਃ㡞ᑝ❥㧘₹⥢ノᒾ㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧦ࠢ࡜ࡒࠫࠕຜ㗡ᗵᨴߩ⃻⁁ߣᴦ≮ᣇᴺߦ㑐ߔࠆᬌ⸛㧘Jpn J
Antibiotics㧚2006 ᐕ㧧59 Ꮞ㧦35㧙40㧚
2㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧚⠴ᕈൻ㒐ᱛߩߚ߼ߩ᛫⩶⮎૶↪ ᛫⩶⮎ࠨࠗࠢ࡝ࡦࠣ≮ᴺ㧘᦬ೀ⮎੐
2006 ᐕ㧧48 Ꮞ㧦1521㧙1527㧚
3㧕 ਃ㡞ᑝ❥㧚PK/PD ߦၮߠ޿ߚ᛫⩶⮎ߩㆡᱜߥᛩਈ⸳⸘㧘PHYSICIAN’S THERAPY MANUAL (PTM)
2006 ᐕ㧧5 Ꮞ㧦9㧚
4㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧘ጊጟ৻ᷡ㧘ਃベ߹ࠁߺ㧘Ỉ᧛ᴦ᮸㧘᧻Ꮉᵗሶ㧘૒ષᶈ๺㧘ᵻ㊁⵨ሶ㧘⍹ㇹầ⟤㧘ᧃ᧻ኡਯ㧘᧻ේ⨃ⷙ㧘ᯅᷰᒾౖ㧘ኹ࿾⌀ᑿ㧘ች㉿ᱜ༹㧘ᏒᎹᖝม㧚ጘ㒂⋵ਅߦ߅޿ߡಽ㔌ߐࠇߚ✛⤥⩶ߦ㑐ߔࠆ∉ቇ⊛ᬌ⸛ 㨪2004 ᐕ㨪㧘Jpn J Antibiot㧚2006 ᐕ㧧59 Ꮞ㧦355㧙363㧚
5㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧘₹⥢ノᒾ㧘๺ᴰቁᴦ㧚PK/PD ℂ⺰ߦၮߠ޿ߚࠟ࠴ࡈࡠࠠࠨࠪࡦߩᛩਈ
ᣇᴺߦ㑐ߔࠆ⥃ᐥ⊛ᬌ⸛㧘Jpn J Antibiot㧚2006 ᐕ㧧59 Ꮞ㧦364㧙372㧚
6㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧦⢖Ἳ⃿⩶߅ࠃ߮ࠗࡦࡈ࡞ࠛࡦࠩ⩶ߦኻߔࠆ⚻ญࠠࡁࡠࡦ⮎ߩ Monte
Carlo Simulation ࠍ↪޿ߚ᦭ലᕈ⹏ଔ㧘Jpn J Antibiot㧚2006 ᐕ㧧59 Ꮞ㧦468㧙473㧚
7㧕 ↰ਛ㚅߅㉿㧘ખየ⾫৻㧘ਃ㡞ᑝ❥㧘ᷰㆺ㇌෹㧦ࡑࠗࠢࡠ࡝ࡦࠣ AN ࠍ↪޿ߚህ᳇ᕈή⧘⢩ࠣ࡜ࡓ㓁ᕈ᪝⩶⟲ߩ࡟ࡌ࡞ 1 ◲ᤃหቯߩឭ᩺㧘Rinsho Biseibutshu Jinsoku Shindan Kenkyukai Shi㧚2006 ᐕ㧧17 Ꮞ㧦
115㧙124.
8㧕 ੗਄ᣇ᥍㧘⩵ᳰ⨊↭㧘ዊ᫪⼱෹⛗㧘๺ᴰ೰㧘ᷰㆺ㇌෹㧘␹㊁⧷Პ㧚Clostridium perfringens ǩᲥ⚛↥↢ㆮવሶߩࠢࡠ࡯࠾ࡦࠣߣᄢ⣺⩶ߦ߅ߌࠆ⚵ߺ឵߃࠲ࡦࡄࠢ⾰ߩ⊒⃻ߣಽᴲ㧘⥃ᐥᓸ↢‛ㄦㅦ⸻ᢿ⎇ⓥળ⹹
2007 ᐕ㧧18 Ꮞ㧦127㧙135.
9㧕 ຠᎹ㐳ᄦ㧘↰ਛ㚅߅㉿㧘ਃ㡞ᑝ❥㧘ᷰㆺ㇌෹㧘┻ጊᑝశ㧘ᮮጊ㓉㧘ᱞᧃ⧐↢㧘⼱ญᱜື㧦⓫ሹᕈ⣻⤑Ἳ߆ࠄߩಽ㔌⩶ߣߘߩ⮎೷ᗵฃᕈ㧘The Japanese Journal of Antibiotics 2007 ᐕ㧧60 Ꮞ㧦206㧙220.
10㧕 ਃ㡞ᑝ❥㧘₹⥢ノᒾ㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧦 ∝଀ႎ๔ ሶችౝㆱᅧౕེࠍⵝ⌕ਛߦሶች㗪ㇱߦ⊒∝ߒߚ
Actinomyces israelii ߦࠃࠆ᡼✢⩶∝ߩ 1 ଀㧚ᣣᧄᄖ⑼ᗵᨴ∝ቇ㔀⹹ 2007 ᐕ㧧4 Ꮞ㧦139㧙141.
11㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧚⢖Ἳ⃿⩶߅ࠃ߮ࠗࡦࡈ࡞ࠛࡦࠩ⩶ߦࠃࠆᗵᨴ∝ߦኻߔࠆฦ⒳ࠞ࡞ࡃࡍ
ࡀࡓ⮎ߩࡕࡦ࠹ࠞ࡞ࡠ࡮ࠪࡒࡘ࡟࡯࡚ࠪࡦߦࠃࠆ᦭ലᕈ⹏ଔ㧘The Japanese Journal of Antibiotics 2007
ᐕ㧧60 Ꮞ㧦47㧙57.
12㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧚Monte Carlo Simulation ᴺࠍ↪޿ߚህ᳇ᕈ⩶ᗵᨴ∝ߦኻߔࠆࡈ࡞ࠝࡠ
ࠠࡁࡠࡦ♽⮎ߩ᦭↪ᕈ੍᷹㧘The Japanese Journal of Antibiotics 2007 ᐕ㧧60 Ꮞ㧦335㧙343.
13㧕 ᴡ↰ᐘ㆏㧘⍹ේື㧘᧻੗㓉㧘ᵤᎹ᣽਽㧘᧻ᧄືᦶ㧘ᷰㆺ㇌෹㧘ਛፉశᅢ㧚ⶄ㔀ᕈዩ〝ᗵᨴ∝ࠍኻ⽎ߣߒߚ
Sitafloxacin ߣ Levofloxacin ߩੑ㊀⋤ᬌᲧセ⹜㛎㧘ᣣᧄൻቇ≮ᴺቇળ㔀⹹ 2008 ᐕ㧧56 Ꮞ(Ⴧೀ 1 ภ)㧦
S81㧙91.
ේ⪺㧔᰷ᢥ㧕
1㧕 Tanaka K, Mikamo H, Nakao K, WatanabeK. In vitro antianaerobic activity of DX-619, a new
des-fluoro(6) quinolone. Antimicrob Agents and Chemother. 2006;50:3908-3913.
IF 4.3902㧕 Matsubara K, Mikamo H, Numa M, Yamamoto G, Kusano H, Takamine Y. Three fatal cases of invasive㧙㧙serotype VI group B streptococcal infection. J Infect. 2006;53:139-142.
3㧕 Ishida Y, Hayashi T, Goto T, Kimura A, Akimoto S, Mukaida N, Kondo T. Essential involvement of
CX3CR1-mediated signals in the bactericidal host defense during septic peritonitis. J Immunol.
2008;181:4208-4218.
4㧕 Sakai A, Watanabe K, Koketsu M, Akuzawa K, Yamada R, Li Z, Sadanari H, Matsubara K,
MurayamaT. Anti-human cytomegalovirus activity of constituents from Sasa albo-marginata{Kumazasa in Japan}. Anti Chem Chemother. 2008;19:125-132.
5㧕 Takumi S, Komatsu M, Aoyama K, Watanabe K, Takeuchi T. Oxygen induces mutation in a strict
anaerobe, Prevotella melaninogenica. Free Rad Biol Medi. 2008;44:1857-1862.
6㧕 Yasui K, Kano Y, Tanaka K, Watanabe K, Shimizu-Kadota M, Yoshikawa H, Suzuki T. Improvement ofBacterial transformation efficiency using plasmid artificial modification. Nuc Acids Res. 2008,1-7.

IF 2.849

IF 6.068

IF 4.813
IF 6.954

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦౎ᧁື਽(࿖┙㐳ኼක≮࠮ࡦ࠲࡯∛㒮)㧘⎇ⓥಽᜂ⠪㧦↰ਛ㚅߅㉿㧧㐳ኼක≮⎇ⓥᆔ⸤⾌㧦㔍ᴦᕈߩ㜞㦂⠪⢖Ἳߦኻߔࠆ቟ోߢ᦭ലߥᴦ≮ᴺߦ㑐ߔࠆ⎇ⓥ(ಽᜂ⎇ⓥ⺖㗴ฬ ⺋ྚᕈ⢖Ἳߩ⿠Ἳ⩶ߩ⚦⩶ቇ⊛ᬌ⸛ߣߘߩ∛ᘒ߳ߩ㑐ਈߩᬌ⸛)㧧ᐔᚑ 19 ᐕᐲ㧧1,500 ජ౞
2㧕ฃ⸤⎇ⓥ1㧕 ᷰㆺ㇌෹㧦㔍ᴦᕈߩ㜞㦂⠪⢖Ἳߦኻߔࠆ቟ోߢ᦭ലߥᴦ≮ᴺߦ㑐ߔࠆ⎇ⓥ(ಽᜂ⎇ⓥ⺖㗴ฬ ⺋ྚᕈ⢖Ἳߩ⿠Ἳ⩶ߩ⚦⩶ቇ⊛ᬌ⸛ߣߘߩ∛ᘒ߳ߩ㑐ਈߩᬌ⸛)㧧ᐔᚑ 18 ᐕᐲ㧧1,100 ජ౞㧦࿖┙㐳ኼක≮࠮ࡦ࠲࡯
2㧕 ਃ㡞ᑝ❥㧦ࡈ࡞ࠝࡠࠠࡁࡠࡦ⮎߇ Clostridium difficile ߩ⚦⢩Ქ⚛↥↢ߦ෸߷ߔᓇ㗀ߦߟ޿ߡ㧧ᐔᚑ18 ᐕᐲ㧧4,538.625 ජ౞㧦╙৻⵾⮎ᩣᑼળ␠ ⎇ⓥ㐿⊒ᧄㇱ ഃ⮎╙৻⎇ⓥᚲ
3㧕 ᷰㆺ㇌෹㧘ਃ㡞ᑝ❥㧦CS-023 ߩ⚦⩶ቇ⊛⹏ଔߦ㑐ߔࠆฃ⸤⎇ⓥ㧧ᐔᚑ 18㧙19 ᐕᐲ㧧4,000 ජ౞(2,000㧦2,000 ජ౞)㧦ਃ౒ᩣᑼળ␠ ╙ੑ↢‛⎇ⓥᚲ
4㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧦ᣂⷙࠞ࡞ࡃࡍࡀࡓൻว‛ SMP-601 ߩฦ⒳ህ᳇ᕈ⩶ߦኻߔࠆ᦭ലᕈߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 19㧙20 ᐕ㧦1,000 ජ౞㧦ᄢᣣᧄ૑෹⵾⮎ᩣᑼળ␠ ⎇ⓥᧄㇱ3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬᷰㆺ㇌෹㧦
1㧕 ᣣᧄᗵᨴ∝ቇળ⹏⼏ຬ࡮ਛᣣᧄ࿾ᣇળℂ੐(㨪⃻࿷)2㧕 ⥃ᐥᓸ↢‛ㄦㅦ⸻ᢿ⎇ⓥળᐙ੐(㨪⃻࿷)3㧕 ᣣᧄൻቇ≮ᴺቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄ⥃ᐥ⣺ౝᓸ↢‛ቇળℂ੐(ᐔᚑ 20 ᐕ 9 ᦬㨪⃻࿷)
5㧕 ᣣᧄ⚦⩶ቇળ⹏⼏ຬ(ᐔᚑ 18 ᐕ㨪⃻࿷)
6㧕 ᣣᧄ⥃ᐥᓸ↢‛ቇળ⹏⼏ຬ(㨪⃻࿷)7㧕 ᣣᧄൻቇ≮ᴺቇળࡉ࡟ࠗࠢࡐࠗࡦ࠻ᬌ⸛ᆔຬળᆔຬ(㨪ᐔᚑ 20 ᐕ 5 ᦬)
8㧕 ᣣᧄൻቇ≮ᴺቇળህ᳇ᕈ⩶ᗵᨴᴦ≮ߩࠟࠗ࠼࡜ࠗࡦᆔຬળᆔຬ(ᐔᚑ 18 ᐕ 7 ᦬㨪ᐔᚑ 20 ᐕ 5 ᦬)
9㧕 ᣣᧄൻቇ≮ᴺቇળህ᳇ᕈ⩶ᗵᨴᴦ≮ߩࠟࠗ࠼࡜ࠗࡦᡷ⸓ᆔຬળᆔຬ(ᐔᚑ 20 ᐕ 9 ᦬㨪⃻࿷)ਃ㡞ᑝ❥㧦
1㧕 ᣣᧄᗵᨴ∝ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄൻቇ≮ᴺቇળ⹏⼏ຬ࡮᛫⌀⩶⮎⥃ᐥ⹏ଔᆔຬળᆔຬ(㨪⃻࿷)3㧕 ᣣᧄ⥃ᐥᓸ↢‛ቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄᕈᗵᨴ∝ቇળ⹏⼏ຬ(㨪⃻࿷)5㧕 ᣣᧄⅣႺᗵᨴቇળ⹏⼏ຬ(㨪⃻࿷)6㧕 ᣣᧄ⥃ᐥ⣺ౝᓸ↢‛ቇળ⹏⼏ຬ(㨪⃻࿷)㧙㧙7㧕 ᣣᧄᄖ⑼ᗵᨴ∝ቇળ⹏⼏ຬ(㨪⃻࿷)↰ਛ㚅߅㉿㧦
1㧕 ᣣᧄൻቇ≮ᴺቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄൻቇ≮ᴺቇળህ᳇ᕈ⩶ᗵᨴᴦ≮ߩࠟࠗ࠼࡜ࠗࡦᆔຬળᆔຬ(ᐔᚑ 18 ᐕ 7 ᦬㨪ᐔᚑ 20 ᐕ 5 ᦬)
3㧕 ᣣᧄൻቇ≮ᴺቇળህ᳇ᕈ⩶ᗵᨴᴦ≮ߩࠟࠗ࠼࡜ࠗࡦᡷ⸓ᆔຬળᆔຬ(ᐔᚑ 20 ᐕ 9 ᦬㨪⃻࿷)
4㧕 ᣣᧄ⥃ᐥᓸ↢‛ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹ᷰㆺ㇌෹㧦
1㧕 ⥃ᐥᓸ↢‛ㄦㅦ⸻ᢿ⎇ⓥળ⹹(JARMAM)㧧✬㓸ᆔຬ(㨪⃻࿷)ਃ㡞ᑝ❥㧦1㧕 ᣣᧄൻቇ≮ᴺቇળ㧧✬㓸ᆔຬ(㨪⃻࿷)2㧕 ᣣᧄᄖ⑼ᗵᨴ∝ቇળ㧧✬㓸ᆔຬ(㨪⃻࿷)↰ਛ㚅߅㉿㧦
1㧕 ᣣᧄ⥃ᐥᓸ↢‛ቇળ㧧✬㓸ᆔຬ(㨪ᐔᚑ 20 ᐕ 3 ᦬)
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ᷰㆺ㇌෹㧦
1㧕 ╙ 51 ࿁ᣣᧄญ⣧ᄖ⑼ቇળ✚ળ(ᐔᚑ 18 ᐕ 10 ᦬㧘ർ਻ᎺᏒ㧘᜗ᓙ⻠Ṷ‫ޟ‬ᾢ╣ߩ㜞࿶ടᾲಣℂᶧߩᜬ
ߟ᛫⩶૞↪ߣක≮߳ߩᔕ↪‫ޠ‬Ṷ⠪)
2㧕 ╙ 43 ࿁ᣣᧄ⚦⩶ቇળਛㇱᡰㇱ✚ળ(ᐔᚑ 18 ᐕ 10 ᦬㧘ጘ㒂Ꮢ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᓸ↢‛ᗵᨴ߇ේ࿃࡮
Ⴧᖡ࿃ሶߣߥࠆ∔ᖚߦߟ޿ߡߩᦨㄭߩ⹤㗴‫ޠ‬ᐳ㐳)
3㧕 ╙ 15 ࿁ᣣᧄญ⣧ᗵᨴ∝ቇળ✚ળ(ᐔᚑ 18 ᐕ 11 ᦬㧘ᄢ㒋Ꮢ㧘᜗ᓙ⻠Ṷ‫ޟ‬ญ⣧ౝ⚦⩶ฌ᭴ᚑ⩶ߣህ᳇
ᕈ⩶ᗵᨴ∝ߦ㑐ߔࠆ⹤㗴㨪ህ᳇ᕈ⩶ಽ㘃๮ฬߩᄌൻߣ⃻࿷ߩ᛫⩶ൻቇ≮ᴺߦኻᔕߒߡ㨪‫ޠ‬Ṷ⠪)
4㧕 ╙ 37 ࿁ᣣᧄህ᳇ᕈ⩶ᗵᨴ∝⎇ⓥળ(ᐔᚑ 19 ᐕ 3 ᦬㧘ᄹ⦟Ꮢ㧘ᢎ⢒⻠Ṷ‫࠻ࡅޟ‬૕ౝᏱ࿷ህ᳇ᕈ⩶⎇ⓥ
ߩᣂዷ㐿‫ޠ‬ᐳ㐳)
5㧕 ╙ 10 ࿁⥃ᐥ⣺ౝᓸ↢‛ቇળቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 9 ᦬㧘㐳ፒᏒ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬⣺ౝ⚦⩶೙ᓮߣ∔ᖚ੍㒐࡮ᴦ≮‫ޠ‬ᐳ㐳)
6㧕 ╙ 20 ࿁⥃ᐥᓸ↢‛ㄦㅦ⸻ᢿ⎇ⓥળ✚ળ(ᐔᚑ 19 ᐕ 7 ᦬㧘੩ㇺᏒ㧘ࠪࡦࡐࠫ࠙ࡓ‫ߩࠄ߆ࠇߎޟ‬ᓸ↢‛ㄦㅦ⸻ᢿߩᣇะ‫ޠ‬ᐳ㐳)7㧕 ᣣᧄㄘ⧓ൻቇቇળਛㇱᡰㇱ╙ 153 ࿁଀ળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ฬฎደ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ή㉄⚛ߢ௛ߊᓸ↢‛̆ህ᳇ᕈ⩶ߩ਎⇇㨪ⅣႺߣஜᐽߩⷞὐ߆ࠄ㨪‫ޠ‬Ṷ⠪)8㧕 ╙ 51 ࿁ᣣᧄᗵᨴ∝ቇળਛᣣᧄ࿾ᣇળቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 10 ᦬㧘ᄢ㒋㧘․೎⻠Ṷ‫⮎ޟ‬೷⠴ᕈᯏ᭴̆ၮ␆⎇ⓥߢࠊ߆ߞߡ߈ߚߎߣ‫ޠ‬ᐳ㐳)ਃ㡞ᑝ❥㧦
1㧕 ╙ 21 ࿁ᣣᧄⅣႺᗵᨴቇળቇⴚ㓸ળ(ᐔᚑ 18 ᐕ 2 ᦬㧘᧲੩㧘᜗ᓙࠪࡦࡐࠫ࠙ࡓ‫ޟ‬੐଀߆ࠄቇ߱㒮ౝᗵᨴኻ╷ Bacillus cereus group ߦࠃࠆࠕ࠙࠻ࡉ࡟ࠗࠢ߇⇼ࠊࠇߚ߇ࠕ࠙࠻ࡉ࡟ࠗࠢߣᢿቯߢ߈ߥ߆
ߞߚ੐଀‫ޠ‬Ṷ⠪)
2㧕 ╙ 54 ࿁ᣣᧄൻቇ≮ᴺቇળ✚ળ(ᐔᚑ 18 ᐕ 5 ᦬㧘੩ㇺ㧘᜗ᓙࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ህ᳇ᕈ⩶ᗵᨴ∝ᴦ≮ߩࠟࠗ࠼࡜ࠗࡦ‫ޠ‬มળ࡮Ṷ⠪)3㧕 ╙ 19 ࿁⥃ᐥᓸ↢‛ㄦㅦ⸻ᢿ⎇ⓥળ(ᐔᚑ 18 ᐕ 6 ᦬㧘᧻ጊ㧘᜗ᓙࠪࡦࡐࠫ࠙ࡓ‫ᧄߡߞࠇߘޟ‬ᒰߦᧄᒰ㧫ㄦㅦ⸻ᢿ㧍㧍 ↥ᇚੱ⑼㗔ၞ‫ޠ‬Ṷ⠪)
4㧕 ╙ 43 ࿁ᣣᧄ⚦⩶ቇળਛㇱᡰㇱ✚ળ(ᐔᚑ 18 ᐕ 10 ᦬㧘ጘ㒂㧘᜗ᓙࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᓸ↢‛ᗵᨴ߇ේ࿃࡮
Ⴧᖡ࿃ሶߣߥࠆ∔ᖚߦߟ޿ߡߩᦨㄭߩ⹤㗴 ẩ≌ᕈᄢ⣺Ἳᚻⴚᓟߦ⿠ߎࠆ࿁⣺ྙἻߦ߅ߌࠆ⎫ൻ᳓⚛ㆶర⚦⩶ߩ㑐ਈ‫ޠ‬Ṷ⠪)
5㧕 ╙ 54 ࿁ᣣᧄൻቇ≮ᴺቇળ⷏ᣣᧄᡰㇱ✚ળ(ᐔᚑ 18 ᐕ 12 ᦬㧘⑔ጟ㧘᜗ᓙࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᗵᨴ೙ᓮቇ

㧙㧙߆ࠄߺߚൻቇ≮ᴺߩ޽ࠅᣇ ᛫⩶⮎㑐ㅪਅ∯∝/⣺Ἳߩ⃻⁁ߣ⺖㗴‫ޠ‬Ṷ⠪)↰ਛ㚅߅㉿㧦
1㧕 ╙ 46 ࿁ਛㇱකቇᬌᩏቇળ(ᐔᚑ 19 ᐕ 9 ᦬㧘ᄢ၂Ꮢ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ህ᳇ᕈ⩶ࠍ⍮ߞߡ㧘ᢛℂᢛ㗐ࡐࠗࡦ࠻ࠍߟ߆߽߁‫ޠ‬Ṷ⠪)
2㧕 ╙ 50 ળᣣᧄᗵᨴ∝ቇળਛᣣᧄ࿾ᣇળቇⴚ㓸ળ࡮╙ 55 ળᣣᧄൻቇ≮ᴺቇળ⷏ᣣᧄᡰㇱ✚ળ(ᐔᚑ 19
ᐕ 10 ᦬㧘␹ᚭᏒ㧘࡟ࠢ࠴ࡖ࡯࠮࠶࡚ࠪࡦ 2‫⩶⚦ޟ‬ᬌᩏ-⮎೷ᗵฃᕈߣህ᳇ᕈ⩶ߦߟ޿ߡߩၮ␆⍮⼂‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ1㧕 ↰ਛ㚅߅㉿㧘ખየ⾫৻㧘ਃ㡞ᑝ❥㧘ᷰㆺ㇌෹㧦╙ 17 ࿁ JARMAM(ㄦㅦᓸ↢‛ㄦㅦ⸻ᢿ⎇ⓥળ)⾨(2007ᐕᐲ)
9㧚␠ળᵴേᷰㆺ㇌෹㧦
1㧕 ጘ㒂⋵㒮ౝᗵᨴኻ╷ද⼏ળᆔຬ(ᐔᚑ 18 ᐕᐲ)ਃ㡞ᑝ❥㧦1㧕 ᐔᚑ 18 ᐕᐲጘ㒂⋵ᢎ⢒ᆔຬળ ቇᩞ࡮࿾ၞ଻ஜផㅴ੐ᬺ⻠Ꮷ(ᐔᚑ 18 ᐕᐲ)
2㧕 ጘ㒂⋵කᏧળ STD(ᕈᗵᨴ∝)ታᘒ⺞ᩏᬌ⸛ᆔຬળ೽ᆔຬ㐳(ᐔᚑ 18 ᐕᐲ)
3㧕 ጘ㒂⋵㒮ౝᗵᨴኻ╷ද⼏ળᆔຬ(ᐔᚑ 18 ᐕᐲ)
4㧕 ጘ㒂⋵ࠬࡐ࡯࠷⑼ቇ࠻࡟࡯࠾ࡦࠣ࠮ࡦ࠲࡯ ࠬࡐ࡯࠷࠼ࠢ࠲࡯(ᐔᚑ 18 ᐕᐲ)
5㧕 ␠࿅ᴺੱᣣᧄᗵᨴ∝ቇળኾ㐷ක໧㗴૞ᚑᆔຬ(ᐔᚑ 18 ᐕᐲ)
10㧚ႎ๔ᦠ
1㧕 ㋈ᧁᔀ㧘ᷰㆺ㇌෹㧘↰ਛ㚅߅㉿㧦࠹࡯࡜࡯ࡔ࡯࠼ࡊࡠࡃࠗࠝ࠹ࠖࠢࠬࠍ⋡ᜰߒߚࡆࡈࠖ࠭ࠬ⩶ዻߩୄ⍑⊛ࠥࡁࡓ⸃ᨆ㧦2006 ᐕᢥㇱ⑼ቇ⋭⎇ⓥ⵬ഥ㊄ ․ቯ㗔ၞ⎇ⓥ㨬ࠥࡁࡓ㨭4 㗔ၞᐲႎ๔ᦠ㧦295 (2007ᐕ 3 ᦬)11㧚ႎ㆏ߥߒ12㧚⥄Ꮖ⹏ଔ
⹏ଔ⎇ⓥ࡮ᢎ⢒࡮⸻≮ᡰេߪචಽߦߘߩ⽿ോࠍᨐߚߒߡ޿ࠆߣ⠨߃ࠆ߇㧘ᢎຬߩ⎇ⓥ㕙ߦ߅޿ߡߪ㆐ᚑ₸߇ૐ޿ߎߣࠍ⹺߼ߑࠆࠍᓧߥ޿‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷⃻⁁ߢߪ㧘ಽ㊁ߩኾછᛛⴚ⡯ຬ߇ሽ࿷ߒߥ޿ߚ߼㧘ಽ㊁ߩᢎຬߩߺߢ㧘ߔߴߡߩ᩺ઙߦኻᔕߒߥߌࠇ
߫ߥࠄߥ޿‫↢ޕ‬๮⑼ቇ✚ว⎇ⓥᡰេ࠮ࡦ࠲࡯ߣߒߡߩ⽿ോߢ޽ࠆᡰេᬺോࠍᨐߚߔߎߣߦ߶ߣࠎߤߩᤨ
㑆߇ഀ߆ࠇ㧘චಽߥ⎇ⓥ૕೙߇ߣࠇߡ޿ߥ޿ߎߣ߇ᦨᄢߩ⺖㗴ߢ޽ࠆ‫ޕ‬੹ᓟߩዷᦸ೨ㅀߒߚ໧㗴ὐࠍ⸃᳿ߔࠆߚ߼ߦ㧘ኾછߩᛛⴚ⡯ຬࠍ 2 ฬ㈩⟎ߒߡ޿ߚߛߌࠆࠃ߁௛߈߆ߌߡ޿ࠆ‫ޕ‬ቇౝᡰេ࠮ࡦ࠲࡯ߣߒߡߩ⽿ോએᄖߦ㧘ዋߒߢ߽ߘࠇߙࠇߩᢎຬ⁛⥄ߩ⎇ⓥࠍㅴ߼ࠆߚ߼ߩ૕೙૞ࠅࠍ
⠨߃ߡ޿ࠆ‫ޕ‬㧙㧙㧔17㧕ੱ₞ᗵᨴ㒐ᓮ⎇ⓥ࠮ࡦ࠲࡯㧔ࡊ࡝ࠝࡦ⎇ⓥㇱ㐷㧕1㧚⎇ⓥߩ᭎ⷐ
Ԙᣂⷙ᛫ࡊ࡝ࠝࡦൻว‛ࠍ⚂ 200 ⒳㘃᦭ᯏวᚑߒߚ‫ޕ‬ԙᒰೋߩ࡝࡯࠼ൻว‛ߢ޽ࠆ GN8 ࠃࠅ߽ᵴᕈߩ㜞޿ᣂⷙൻว‛ࠍ⚂ 20 ⒳㘃⷗಴ߒߚ‫ޕ‬Ԛ᛫ࡊ࡝ࠝࡦൻว‛ࠍᦨㆡൻߔࠆߎߣߦࠃࠅ㧘࡝࡯࠼ࠃࠅ߽ᵴᕈ߇৻ᩴ㜞޿ൻว‛ߩഃ⵾ߦᚑഞߒߡ߅ࠅ㧘⎇ⓥߩㅴዷߦᔕߓߡᵴᕈ߇ะ਄ߒߡ޿ࠆ⁁ᴫߦ޽ࠆ‫ޕ‬ԛࡊ࡝ࠝࡦ࠲ࡦࡄࠢ⾰ߣฦ⒳᛫ࡊ࡝ࠝࡦൻว‛ߣߩ⚿วㇱ૏ࠍหቯߒ㧘ᦨㆡൻߩᣇะࠍ᣿ࠄ߆ߦߒߚ‫ޕ‬Ԝ࡝࡯࠼ൻว‛ߣߪ㛽ᩰߩ⇣ߥࠆ᛫ࡊ࡝ࠝࡦൻว‛ࠍ 4 ⒳㘃⷗಴ߒߚ‫ޕ‬ԝࡊ࡝ࠝࡦߩㇱಽࡍࡊ࠴࠼ߩ✢⛽ᒻᚑࠍ⸃ᨆߔࠆߎߣߦࠃࠅ㧘ࡊ࡝ࠝࡦߩ⇣Ᏹൻߦ㑐ਈߔࠆߣ⠨߃ࠄࠇࠆㇱ૏ࠍหቯߒߚ‫ޕ‬Ԟ࠲ࡦࡄࠢ⾰ߣൻว‛ߣߩ⋧੕૞↪ࠍㇱ૏ߏߣߦ㧘෩ኒߦ⹏ଔߔࠆߚ߼ߩࡈ࡜ࠣࡔࡦ࠻ MO ᴺࡊࡠࠣ࡜ࡓ㧔PAICS㧕ࠍᣂⷙߦ㐿⊒ߒ㧘࡝ࠝࡦ࠲ࡦࡄࠢ⾰ߣ᛫ࡊ࡝ࠝࡦ‛⾰ߣߩ⋧੕૞↪ߦㆡ↪ߒߚ‫ޕ‬ԟൻቇ‛⾰ߩⰮ⊕⾰ߦኻߔࠆࠁࠄ߉ᛥ೙૞↪ࠍ⹏ଔߔࠆߚ߼ߩ☻ⷞൻࡊࡠࠣ࡜ࡓࠍᣂⷙߦ㐿⊒ߒ㧘᛫ࡊ࡝ࠝࡦ‛⾰ߩࡊ࡝ࠝࡦⰮ⊕⾰ߩࠁࠄ߉ߦኻߔࠆലᨐࠍ⺞ߴߚ‫ޕ‬Ԡಽሶ゠㆏ᴺߦࠃࠅ㧘␹⚻ᄌᕈࠍᒁ߈⿠ߎߔૐಽሶ‛⾰㧘ࠢࡊ࡝࠱ࡦߣ㌃ࠗࠝࡦߣߩ⋧੕૞↪ࠍ⸃ᨆߒ㧘㌃ࠗࠝࡦߩ⩄㔚⁁ᘒߦ⇣Ᏹ߇޽ࠆߎߣࠍ⓭߈ᱛ߼ߚ‫ޕ‬ԡ᛫ࡊ࡝ࠝࡦ‛⾰ߣࡊ࡝ࠝࡦⰮ⊕⾰ߣߩ⋧੕૞↪ࠍಽሶേജቇᴺߦࠃࠅ⸃ᨆߒ㧘᛫ࡊ࡝ࠝࡦᵴᕈ߇㜞ߊߥࠆේ࿃ࠍ⸃᣿ߒߚ‫ޕ‬Ԣ⺰ℂ⊛ഃ⮎ᴺߩㆡ↪ߦࠃࠅ㧘᛫ࠗࡦࡈ࡞ࠛࡦࠩ࠙ࠗ࡞ࠬ૞↪ࠍ᦭ߔࠆ‛⾰ࠍⶄᢙ⊒⷗ߒߚ‫ޕ‬ԣ⺰ℂ⊛ഃ⮎ᴺߩㆡ↪ߦࠃࠅ㧘᛫ AIDS ૞↪ࠍ᦭ߔࠆ‛⾰ࠍⶄᢙ⊒⷗ߒߚ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
ഥᢎ㧦
ഥᢎ㧦
ഥᢎ㧦
ഥᢎ㧦
ഥᢎ㧦
ഥᢎ㧦

᪀↰৻ᄦ
㎨⿷㓶ม
ᱞ⮮ᷕੑ
ᧁ᧛ ജ
ጊᧄౖผ
ਛ᧛ኡೣ
⍹Ꮉጪᔒ

Kazuo Kuwata
Yuji Kamatari
Junji Muto
Tsutomu Kimura
Norifumi Yamamoto
Hironori Nakamura
Takeshi Ishikawa

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ᪀↰৻ᄦ㧚ࡊ࡝ࠝࡦ㧦ᴡ㊁ ⨃✬㧚࠙ࠗ࡞ࠬࡂࡦ࠼ࡉ࠶ࠢ No.16 ਛᨔ␹⚻♽࠙ࠗ࡞ࠬ㧘᧲੩㧦ᩣᑼળ␠ᣣ
ᧄකቇ㙚㧧2008 ᐕ㧦44㧙45㧚⪺ᦠ㧔᰷ᢥ㧕
1㧕 Kuwata K. Semi-classical quantization of protein dynamics: Novel NMR relaxation formalism and its
application to prion. In: Kitamoto T, ed. PRIONS- Food and drug safety, Tokyo: Springer;
2006:155-170.
✚⺑㧔๺ᢥ㧕
1㧕 ᪀↰৻ᄦ㧚Ǫ-࡜ࠢ࠻ࠣࡠࡉ࡝ࡦಽሶߩ┙૕᭴ㅧᒻᚑ෻ᔕ ᐔᚑ 19 ᐕᐲᣣᧄ㈼ㄘ⑼ቇࠪࡦࡐࠫ࠙ࡓ‫੃‐ޟ‬㧘Milk Science 2007 ᐕ㧧56 Ꮞ㧦61
ǩ-࡜ࠢ࠻ࠕ࡞ࡉࡒࡦߣǪ-࡜ࠢ࠻ࠣࡠࡉ࡝ࡦߩ᭴ㅧߣᯏ⢻ߩᣂዷ㐿‫ޠ‬㧙64㧚
2㧕 ᧻ᧄ෹ᴦ㧘㎨⿷㓶ม㧘ᱞ⮮ᷕੑ(⚦Ꮉ)㧘ਛ᧛ኡೣ㧘᪀↰৻ᄦ㧚᭴ㅧ࠳ࠗ࠽ࡒࠢࠬ߆ࠄ↢߹ࠇߚ᛫ࡊ࡝ࠝࡦ
ൻว‛㧙⺰ℂ⊛ࠕࡊࡠ࡯࠴ߦࠃࠆഃ⮎⎇ⓥ㧘ൻቇ 2008 ᐕ㧧63 Ꮞ㧦40㧙44㧚
3㧕 ᪀↰৻ᄦ㧚ࡊ࡝ࠝࡦ∛ᴦ≮⮎ߩ⺰ℂ⊛㐿⊒ࠍ߼ߑߒߡ㧙Ⱞ⊕⾰ߩ࠳ࠗ࠽ࡒࠢࠬ⸃ᨆ߆ࠄ᭴ㅧᄌ឵೙ᓮ‛⾰ߩត⚝߳ Rational drug discovery for prion diseases㧙㧘Ⱞ⊕⾰ ᩭ㉄ ㉂⚛ 2008 ᐕ㧧53 Ꮞ㧦727㧙732㧚
4㧕 ᪀↰৻ᄦ㧚ࡊ࡝ࠝࡦ㧘Ⱞ⊕⾰࡮ᩭ㉄࡮㉂⚛ 6 ᦬ภჇೀ‫࠼࡯ࡢ࡯ࠠޟ‬㧦Ⱞ⊕⾰ߩ৻↢‫ ޠ‬2008 ᐕ㧧53 Ꮞ㧦
991㧚
5㧕 ᪀↰৻ᄦ㧚࠳ࠗ࠽ࡒࠢࠬߣ቟ቯᕈ߇੤෷ߔࠆ㗔ၞߩᾲജቇ㧙㊂ሶᥧภᾲജቇߣࡊ࡝ࠝࡦ㧙㧘ᾲ᷹ቯ 2008
ᐕ㧧35 Ꮞ㧦140㧙147㧚
✚⺑㧔᰷ᢥ㧕ߥߒ㧙㧙ේ⪺㧔๺ᢥ㧕1㧕 ᪀↰৻ᄦ㧚ㅪタ ⹤㗴ߩ࠙ࠗ࡞ࠬ No.12 ࡊ࡝ࠝࡦ㧘Drug Delivery System (DDS) 2006 ᐕ㧧21 Ꮞ㧦156
㧙157㧚
2㧕 ᪀↰৻ᄦ㧚ࡃࠗࠝࠗࡦࡈࠜ࡯ࡑ࠹ࠖࠢࠬߦࠃࠆࡊ࡝ࠝࡦ∛ᴦ≮⮎ߩ㐿⊒㧘ൻቇ≮ᴺߩ㗔ၞ 2006 ᐕ㧧22
Ꮞ㧦87㧙93㧚
3㧕 ጊญ࿻৻㧘᧻ᧄ෹ᴦ㧘ఽ₹⠹ᄥ㧘ጯ ⋥ੱ㧘᪀↰৻ᄦ㧚ࡊ࡝ࠝࡦ∛ߩ⊒∝ߣવ᠞ᯏ᭴㧙․㓸 ࠕࡒࡠࠗ࠼ߩ
⻘ߪ⸃ߌࠆ߆㧫㧦ࡊ࡝ࠝࡦ∛࡮ࠕ࡞࠷ࡂࠗࡑ࡯∛࡮ㅘᨆࠕࡒࡠࠗ࠼࡯ࠪࠬߥߤߩ∛ᘒࠍ⚌⸃ߊ㧙㧘⚦⢩Ꮏ
ቇ 2007 ᐕ㧧26 Ꮞ㧦151㧙155㧚
4㧕 ᓟ⮮␭ఽ㧘᪀↰৻ᄦ㧘㑐ፉ⦟᮸㧘↰ਛర㓷㧘ౝᧁብᑧ㧘᳗੗⟵㓉㧘᧻ፒൎᏈ㧘ᮘญ੩৻㧚ࠕࡒࡠࠗ࠼࡯ࠪ
ࠬ⊒∝ߩಽሶᯏ᭴⸃᣿ࠍ⋡ᜰߒߡ㧦⃻⁁ߣዷᦸ㧘ᄞ㧙․㓸 ࠕࡒࡠࠗ࠼ߩ⻘ߪ⸃ߌࠆ߆㧫㧦ࡊ࡝ࠝࡦ∛࡮ࠕ࡞࠷ࡂࠗࡑ࡯∛࡮ㅘᨆࠕࡒࡠࠗ࠼࡯ࠪࠬߥߤߩ∛ᘒࠍ⚌⸃ߊ㧙㧘 ⚦⢩Ꮏቇ 2007 ᐕ㧧26 Ꮞ㧦181㧙185㧚
5㧕 ᱞ⮮ᷕੑ㧔⚦Ꮉ㧕㧘㎨⿷㓶ม㧘᧻ᧄ෹ᴦ㧘ਛ᧛ኡೣ㧘᪀↰৻ᄦ㧦ᱜᏱဳࡊ࡝ࠝࡦⰮ⊕⾰᭴ㅧ቟ቯൻ߳ߩ᜸ᚢ
㧙․㓸 ⇣Ᏹဳࡊ࡝ࠝࡦⰮ⊕⾰߳ߩ᜸ᚢ㧔ᓟ✬㧕㧙㧘⥃ᐥ₞ක 2007 ᐕ㧧25 Ꮞ㧦10㧙14㧘41㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Kimura K, Nagaki M, Nishihira J, Kuwata K, Moriwaki H. Role of macrophage migration inhibitory
factor for CTL-induced liver injury in hepatitis B transgenic mice. Clin Vaccine Immunol.
2006;13:415-419.
2㧕 Kimura K, Moriwaki H, Nagaki M, Saio M, Nakamoto Y, Naito M, Kuwata K, Chisari FV. Pathogenicrole of B cells in anti-CD40 caused necroinflammatory liver disease. Am J Pathol. 2006;168:786-795.
3㧕 Kodama K, Shoji Y, Nakashima H, Katayama Y. The features and shortcomings for gene delivery of
current non-viral carriers. Curr Med Chem. 2006;13:2155-2161.
4㧕 Oishi J, Kawamura K, Kang HJ, Kodama K, Sonoda T, Murata M, Niidome T, Katayama Y. An
intracellular kinase signal-responsible gene carrier for disordered cell-specific gene therapy. J Control
Release. 2006;110:431-436.
5㧕 Sukegawa KH, Kato Z, Nakamura H, Tomatsu S, Fukao T, Kuwata K, Orii T, Kondo N. Effect ofHunter disease (mucopoly saccharidosis typeII) mutations on molecular phenotypes of
iduronate-2-sulfatase : Enzymatic activity, protein processing and structural analysis. J Inherit MetabDis. 2006;29:755-761.
6㧕 Kimura K, Moriwaki H, Nagaki M, Saio M, Nakamoto Y, Naito M, Kuwata K, Chisari FV. Pathogenicrole of B cells in anti-CD40-induced necroinflammatory liver disease. Am J Pathol. 2006;168:786-795.
7㧕 Kremer W, Kachel N, Kuwata K, Akasaka K, Kalbitzer HR. Species specific differences in theintermediate states of human and hamster prion protein detected by high pressure NMR spectroscopy.
J Biol Chem. 2007;282:22689-22698.
8㧕 Kuwata K, Nishida N, Matsumoto T, Kamatari YO, Hosokawa-Muto J, Kodama K, Nakamura HK,
Kimura K, Kawasaki M, Takakura Y, Shirabe S, Takata J, Kataoka Y, Katamine S. Hot spots in prion
protein for pathogenic conversion. Proc Natl Acad Sci USA. 2007;104:11921-11926.
9㧕 Nakamura HK, Takano M, Kuwata K. Modeling of a propagation mechanism of infectious prion protein;a hexamer as the minimum infectious unit. Biochem Biophys Res Commun. 2007;361:789-793.
10㧕 Kamatari YO, Nakamura HK, Kuwata K. Strange kinetic phase in the extremely early folding processof Ǫ-lactoglobulin. FEBS Lett. 2007;581:4463-4467.
11㧕 Kimura K, Nagaki M, Kakimi K, Saio M, Saeki T, Okuda Y, Kuwata K, Moriwaki H. Critical role ofCD44 in hepatotoxin-mediated liver injury. J Hepatol. 2008;48:952-961.
12㧕 Kato Z, Stern JN, Nakamura HK, Kuwata K, Kondo N, Strominger JL. Positioning of autoimmune
TCR-Ob.2F3 and TCR-Ob.3D1 on the MBP85-99/HLA-DR2 complex. Proc Natl Acad Sci USA.
2008;105:15523-15528.
13㧕 Yamaguchi K, Matsumoto T, Kuwata K. Critical region for amyloid fibril formation of mouse prion
protein: unusual amyloidogenic properties of helix 2 peptide. Biochemistry. 2008;47:13242-13251.

IF 1.995
IF 5.487
IF 4.944

IF 4.756

IF 1.668
IF 5.487

IF 5.581

IF 9.598
IF 2.749
IF 3.263
IF 6.642

IF 9.598
IF 3.3684㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦᪀↰৻ᄦ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄․ቯ㗔ၞ⎇ⓥ㧦ේሶಽ⸃⢻߆ߟ࠽ࡁ⑽ᤨ㑆ಽ⸃⢻ߢߩࡊ࡝ࠝࡦ࡮ࡈࠜ࡯࡞࠺ࠖࡦࠣ෻ᔕߩ᷹ⷰ㧧ᐔᚑ 18㧙19 ᐕᐲ㧧11,300 ජ౞(5,500㧦5,800 ජ౞)2㧕 ⎇ⓥઍ⴫⠪㧦᳓Ỉ⧷ᵗ(᧲੩ක⑼ᱤ⑼ᄢቇᄢቇ㒮⣖␹⚻∛ᘒቇ(␹⚻ౝ⑼))㧘⎇ⓥಽᜂ⠪㧦᪀↰৻ᄦ㧧ෘ↢ഭ௛⋭㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ㧦ࡊ࡝ࠝࡦ∛෸߮ㆃ⊒ᕈ࠙ࠗ࡞ࠬᗵᨴ∝ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ㧔H16㔍ᴦ-013㧕㧧ᐔᚑ 18㧙20 ᐕᐲ㧧6,000 ජ౞(2,000㧦2,000㧦2,000 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦᪀↰৻ᄦ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄․ቯ㗔ၞ⎇ⓥ㧧⚦⢩ౝࡊ࡝ࠝࡦ࠲ࡦࡄࠢ⾰ߩ┙૕᭴ㅧ㧘࠳ࠗ࠽ࡒࠢࠬ㧘෸߮┙૕᭴ㅧᄌ឵෻ᔕߩ⸃᣿㧧ᐔᚑ 20㧙21 ᐕᐲ㧧5,800 ජ౞(2,900㧦2,900
ජ౞)

㧙㧙

4㧕 ⎇ⓥઍ⴫⠪㧦ᱞ⮮ᷕੑ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄⪚⧘⎇ⓥ㧦ࡊ࡝ࠝࡦⰮ⊕⾰ߩ࠺ࡘࠕ࡞ࡇࡦࡐ
ࠗࡦ࠻Ⱟశᮡ⼂ᴺߩ⏕┙ߣߘߩᔕ↪ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 19㧙20 ᐕᐲ㧧3,600 ජ౞(1,800㧦1,800 ජ౞)5㧕 ⎇ⓥઍ⴫⠪㧦ጊᧄౖผ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦ࡊ࡝ࠝࡦ∛⊒∝ࡔࠞ࠾࠭ࡓߩ⸃᣿㧦ࡊ࡝ࠝࡦⰮ⊕⾰࡮⢵ࠗࠝࡦⶄว૕ߩ᭴ㅧߣᕈ⾰㧧ᐔᚑ 20 ᐕᐲ㧧2.860 ජ౞6㧕 ⎇ⓥઍ⴫⠪㧦⍹Ꮉጪᔒ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(ࠬ࠲࡯࠻ࠕ࠶ࡊ)㧦ࡊࡠࠣ࡜ࡓ㐿⊒ߣࡊ࡝ࠝࡦ࠲ࡦࡄࠢ⾰ߩ⋧੕૞↪⸃ᨆ߳ߩᔕ↪㧧ᐔᚑ 20 ᐕᐲ㧧1,140 ජ౞7㧕 ⎇ⓥઍ⴫⠪㧦ጊญ࿻৻㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦ࡊ࡝ࠝࡦߩࠕࡒࡠࠗ࠼✢⛽ߦㆬᛯ⊛ߦ⚿วߔࠆૐಽሶൻว‛ߩត⚝ߣߘߩ૞↪ᯏ᭴ߩ⸃᣿㧧ᐔᚑ 19㧙20 ᐕᐲ㧧3,300 ජ౞(2,100㧦
1,200 ජ౞)2㧕ฃ⸤⎇ⓥ1㧕 ᪀↰৻ᄦ㧦⺰ℂ⊛ഃ⮎ߦࠃࠆⰮ⊕⾰┙૕᭴ㅧ೙ᓮᴺߩ⏕┙ߣࡊ࡝ࠝࡦ∛ᴦ≮⮎㐿⊒߳ߩᔕ↪㧧ᐔᚑ
18㧙22 ᐕᐲ㧧361,000 ජ౞(80,000㧦80,000㧦67,000㧦67,000㧦67,000 ජ౞)㧦⁛┙ⴕ᡽ᴺੱක⮎ၮ⋚⎇ⓥᚲ
2㧕 ⎇ⓥઍ⴫⠪㧦ർየᓆᦶ(᧲੩ᄢቇಽሶ⚦⢩↢‛ቇ⎇ⓥᚲ⚦⢩ᯏ⢻ᖱႎ⎇ⓥ࠮ࡦ࠲࡯ഃ↢⎇ⓥಽ㊁)㧘⎇ⓥಽᜂ⠪㧦᪀↰৻ᄦ㧧ᐔᚑ 19 ᐕᐲᚢ⇛⊛ഃㅧ⎇ⓥផㅴ੐ᬺ㧔CREST ࠲ࠗࡊ㧕⎇ⓥ㗔ၞ‫ࠬ࠴࡞ࡑޟ‬ࠤ࡯࡞࡮ࡑ࡞࠴ࡈࠖࠫ࠶ࠢࠬ⃻⽎ߩ⛔วࠪࡒࡘ࡟࡯࡚ࠪࡦ‫⎇ޠ‬ⓥ⺖㗴‫ࠝࠗࡃޟ‬ಽሶ㑆⋧੕૞↪ᒻᘒߩ㓏ጀ⊛ࡕ࠺࡝ࡦࠣ‫ޠ‬㧧ᐔᚑ 19㧙23 ᐕᐲ㧧27,000 ජ౞(3,000㧦6,000㧦6,000㧦6,000㧦6,000 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦⪤ේᱜᢅ(᧲੩ක⑼ᱤ⑼ᄢቇ࡮ᄢቇ㒮∔ᖚ↢๮⑼ቇ⎇ⓥㇱ/㔍ᴦ∔ᖚ⎇ⓥᚲ)㧘⎇ⓥಽᜂ⠪㧦᪀↰৻ᄦ㧧ᐔᚑ 19 ᐕᐲ⑼ቇᛛⴚ⹜㛎⎇ⓥᆔ⸤੐ᬺ‫ޟ‬㔍ᴦᗵᨴ∝ߦኻߔࠆᣂⷙᴦ≮⮎㐿⊒ߩߚ߼ߩࠗࡔ࡯ࠫࡦࠣ⎇ⓥ‫ޠ‬㧧ᐔᚑ 19㧙23 ᐕᐲ㧧19,500 ජ౞(6,500㧦6,500㧦6,500 ජ౞)
4㧕 ਛ᧛ኡೣ㧦ᐔᚑ 19 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄᡽╷ഃ⮎✚ว⎇ⓥ੐ᬺ‫⺰ޟ‬ℂ⊛ഃ⮎ᚻᴺߦࠃࠆ
HIV-1 ࡊࡠ࠹ࠕ࡯࠯ੑ㊂૕ൻࠍ㒖ኂߔࠆૐಽሶൻว‛ߩត⚝‫ޠ‬㧧ᐔᚑ 18㧙20 ᐕᐲ㧧12,000 ජ౞(4,000㧦4,000㧦4,000 ජ౞)
3㧕౒ห⎇ⓥ1㧕 ᪀↰৻ᄦ㧦⺰ℂ⊛ഃ⮎ߦࠃࠆⰮ⊕⾰┙૕᭴ㅧ೙ᓮᴺߩ⏕┙ߣࡊ࡝ࠝࡦ∛ᴦ≮⮎㐿⊒߳ߩᔕ↪㧧ᐔᚑ
18㧙22 ᐕᐲ㧧361,000 ජ౞(80,000㧦80,000㧦67,000㧦67,000㧦67,000 ජ౞)㧦㐳ፒᄢቇ2㧕 ᪀↰৻ᄦ㧘ጊญ࿻৻㧦ࠕࡒࡠࠗ࠼ߩ᭴ㅧ↢‛ቇ⎇ⓥ㧧ᐔᚑ 18㧙20 ᐕᐲ㧧6,000 ජ౞(2,000㧦2,000㧦
2,000 ජ౞)㧦ᄢ㒋ᄢቇⰮ⊕⾰⎇ⓥᚲ
3㧕 ᪀↰৻ᄦ㧦ࡑ࡞࠴ࠬࠤ࡯࡞࡮ࡑ࡞࠴ࡈࠖࠫ࠶ࠢࠬ⃻⽎ߩ⛔วࠪࡒࡘ࡟࡯࡚ࠪࡦ㧧ᐔᚑ 19㧙23 ᐕᐲ㧧
27,000 ජ౞(3,000㧦6,000㧦6,000㧦6,000㧦6,000 ජ౞)㧦᧲੩ᄢቇ4㧕 ᪀↰৻ᄦ㧘ਛ᧛ኡೣ㧦ᣂⷙ᛫ࠗࡦࡈ࡞ࠛࡦࠩ⮎ߩ㐿⊒㧧ᐔᚑ 19㧙23 ᐕᐲ㧧19,500 ජ౞(6,500㧦6,500㧦
6,500 ජ౞)㧦ℂൻቇ⎇ⓥᚲ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫ
1㧕 ਛ᧛ኡೣ㧦ࡅ࠻఺∉ਇో࠙ࠗ࡞ࠬߩჇᱺ㒖ኂ೷(․⸵)㧧ᐔᚑ 20 ᐕ(․㗿 2008-226642)
6㧚ቇળᵴേ
1㧕ቇળᓎຬ᪀↰৻ᄦ㧦
1㧕 ᣣᧄ↢ℂቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ⏛᳇౒㡆කቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ⥃ᐥࠬ࠻࡟ࠬᔕ╵ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹ߥߒ㧙㧙

7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳᪀↰৻ᄦ㧦
1㧕 ᣣᧄ↢‛‛ℂቇળ ․ቯ㗔ၞ⎇ⓥ‫ޟ‬᳓ߣ↢૕ಽሶ߇❱ࠅᚑߔ↢๮⃻⽎ߩൻቇ‫ ╙ޠ‬3 ࿁౏㐿ࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 18 ᐕ 1 ᦬㧘ጟፒ㧘᜗ᓙ⻠Ṷ‫ޟ‬Dynamics of Prion in Water‫ޠ‬Ṷ⠪)
2㧕 ␠࿅ᴺੱ ᣣᧄ⡊㥦ຜ༄⑼ቇળ ╙ 56 ࿁ਛㇱ࿾ᣇㇱળㅪวળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘᜗ᓙ⻠Ṷ‫⺰ޟ‬ℂ⊛ഃ⮎ᴺߩ⏕┙ߣࡊ࡝ࠝࡦ∛߳ߩᔕ↪‫ޠ‬Ṷ⠪)
3㧕 ᣣᧄࡅ࠻ࡊࡠ࠹ࠝ࡯ࡓᯏ᭴╙ 6 ࿁ᄢળ‫ޟ‬ഃ⮎㧘ࡃࠗࠝࡑ࡯ࠞ࡯ត⚝ߦะߌߡ‫(ޠ‬ᐔᚑ 20 ᐕ 7 ᦬㧘็↰㧘᜗ᓙ⻠Ṷ‫⺰ߣ∛ࡦࠝ࡝ࡊޟ‬ℂ⊛ഃ⮎㧙Application of Dynamics Based Drug Discovery (DBDD)
to Prion Diseases㧙‫ޠ‬Ṷ⠪)4㧕 ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ 㔍⍮ᕈ∔ᖚస᦯⎇ⓥ੐ᬺ ࠕࡒࡠࠗ࠼࡯ࠪࠬߦ㑐ߔࠆ⺞ᩏ⎇ⓥ⃰‫ ࠬࠪ࡯࠼ࠗࡠࡒࠕޟ‬ᄐߩࡢ࡯࡚ࠢࠪ࠶ࡊ 2008‫(ޠ‬ᐔᚑ 20 ᐕ 8 ᦬㧘㊄ᴛ㧘᜗ᓙ⻠Ṷ‫┙ߩࠢࡄࡦ࠲ޟ‬૕᭴ㅧࠍ೙ᓮߔࠆൻว‛ࠍ࠺ࠩࠗࡦߔࠆ‫ޠ‬Ṷ⠪)
5㧕 ℂ⺰ഃ⮎࠮ࡒ࠽࡯㧔౏㐿⻠ᐳ㧕(ᐔᚑ 20 ᐕ 11 ᦬㧘᧲੩㧘᜗ᓙ⻠Ṷ‫ޟ‬ℂ⺰⊛ߦ࠺ࠩࠗࡦߐࠇߚૐಽሶ
ൻว‛ߦࠃࠆ࠲ࡦࡄࠢ⾰ߩࠦࡦࡈࠜ࡯ࡔ࡚ࠗࠪࡦ೙ᓮ 㧙21 ਎♿කቇߩᣂᚢ⇛㧙‫ޠ‬Ṷ⠪)6㧕 ┙๮㙚ᄢቇℂᎿቇ⎇ⓥᚲࠪࡦࡐࠫ࠙ࡓ ‫ ⾰ࠢࡄࡦ࠲ޟ‬NMR ⎇ⓥߩᦨ೨✢‫(ޠ‬ᐔᚑ 20 ᐕ 11 ᦬㧘⨲ᵤ㧘᜗ᓙ⻠Ṷ‫ޟ‬ૐಽሶൻว‛ߦࠃࠅ㧘࠲ࡦࡄࠢ⾰ߩࠦࡦࡈࠜ࡯ࡔ࡚ࠗࠪࡦࠍ೙ᓮߔࠆ‫ޠ‬Ṷ⠪)7㧕 ᖱႎ⸘▚ൻቇ↢‛ቇળ㧔CBI ቇળ㧕╙ 292 ࿁ CBI ⎇ୃ⻠Ṷળ‫⚻␹ޟ‬ᄌᕈ∔ᖚߩᮡ⊛ߣഃ⮎㧙Σ‫(ޠ‬ᐔ
ᚑ 20 ᐕ 12 ᦬㧘᧲੩㧘᜗ᓙ⻠Ṷ‫ޟ‬᭴ㅧ↢‛ቇ⊛ࠕࡊࡠ࡯࠴ߦࠃࠆ᛫ࡊ࡝ࠝࡦൻว‛ߩ㐿⊒‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ1㧕 ᪀↰৻ᄦ㧦╙౐࿁᧖↰₵⊕⾨ ᅑബ⾨(ᐔᚑ 19 ᐕᐲ)
2㧕 ᪀↰৻ᄦ㧦magic bullet ⾨(ᐔᚑ 20 ᐕᐲ)
9㧚␠ળᵴേ᪀↰৻ᄦ㧦
1㧕 ᧲੩㜞╬ⵙ್ᚲ㧘᧲੩࿾ᣇⵙ್ᚲ෸߮ᄢ㒋࿾ᣇⵙ್ᚲᚲዻኾ㐷ᆔຬ(ᐔᚑ 19 ᐕᐲ㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ᪀↰৻ᄦ㧦ේሶಽ⸃⢻߆ߟ࠽ࡁ⑽ᤨ㑆ಽ⸃⢻ߢߩࡊ࡝ࠝࡦ࡮ࡈࠜ࡯࡞࠺ࠖࡦࠣ෻ᔕߩ᷹ⷰ㧦ᐔᚑ 19
ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ․ቯ㗔ၞ⎇ⓥ‫ޟ‬᳓ߣ↢૕ಽሶ߇❱ࠅᚑߔ↢๮⃻⽎ߩൻቇ‫⎇ޠ‬ⓥ⁁ᴫႎ๔ᦠ㧦
92㧙93(2007 ᐕ 3 ᦬)
2㧕 ᪀↰৻ᄦ㧦ࡊ࡝ࠝࡦㇱಽࡍࡊ࠴࠼߇૞ࠆࠝ࡝ࠧࡑ࡯ߩ┙૕᭴ㅧ᳿ቯ㧦ᐔᚑ 14 ᐕᐲ㧙ᐔᚑ 18 ᐕᐲᢥ
ㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ․ቯ㗔ၞ⎇ⓥ‫⎇ޠ↢৻ߩ⾰ࠢࡄࡦ࠲ޟ‬ⓥᚑᨐႎ๔ᦠ㧦112(2007 ᐕ 5 ᦬)
3㧕 ᪀↰৻ᄦ㧦ේሶಽ⸃⢻߆ߟ࠽ࡁ⑽ᤨ㑆ಽ⸃⢻ߢߩࡊ࡝ࠝࡦ࡮ࡈࠜ࡯࡞࠺ࠖࡦࠣ෻ᔕߩ᷹ⷰ㧦ᐔᚑ 19
ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ․ቯ㗔ၞ⎇ⓥ‫ޟ‬᳓ߣ↢૕ಽሶ߇❱ࠅᚑߔ↢๮⃻⽎ߩൻቇ‫⎇ޠ‬ⓥᚑᨐႎ๔ᦠ㧦
32(2008 ᐕ 3 ᦬)
4㧕 ᪀↰৻ᄦ㧦ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ 㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ‫∛ࡦࠝ࡝ࡊޟ‬෸߮ㆃ⊒ᕈ࠙ࠗ࡞ࠬ
ᗵᨴ∝ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ‫ޠ‬ᐔᚑ 17 ᐕᐲ㧙ᐔᚑ 19 ᐕᐲಽᜂ⎇ⓥႎ๔ᦠ㧦47㧙50(2008 ᐕ 3 ᦬)
5㧕 ᪀↰৻ᄦ㧘᧻ᧄ෹ᴦ㧘ጊญ࿻৻㧘㎨⿷㓶ม㧘ਛ᧛ኡೣ㧘ጊᧄౖผ㧘⍹ୖቁ৻㧘ᧁ᧛ജ㧘ᱞ⮮ᷕੑ㧦
⁛┙ⴕ᡽ᴺੱ ක⮎ၮ⋚⎇ⓥᚲ ଻ஜක≮ಽ㊁ߦ߅ߌࠆၮ␆⎇ⓥផㅴ੐ᬺ‫⺰ޟ‬ℂ⊛ഃ⮎ߦࠃࠆⰮ⊕⾰┙૕᭴ㅧ೙ᓮᴺߩ⏕┙ߣࡊ࡝ࠝࡦ∛ᴦ≮⮎㐿⊒߳ߩᔕ↪‫ޠ‬ᐔᚑ 19 ᐕᐲႎ๔ᦠ㧦1㧙42㧘65㧙
115(2008 ᐕ 4 ᦬)
6㧕 ᪀↰৻ᄦ㧦ේሶಽ⸃⢻߆ߟ࠽ࡁ⑽ᤨ㑆ಽ⸃⢻ߢߩࡊ࡝ࠝࡦ࡮ࡈࠜ࡯࡞࠺ࠖࡦࠣ෻ᔕߩ᷹ⷰ㧦ᐔᚑ 20
ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ․ቯ㗔ၞ⎇ⓥ‫ޟ‬᳓ߣ↢૕ಽሶ߇❱ࠅᚑߔ↢๮⃻⽎ߩൻቇ‫⎇ޠ‬ⓥᚑᨐ╬ߩႎ๔ᦠ㧦56(2008 ᐕ 7 ᦬)
7㧕 ጘ㒂ᄢቇ ੱ₞ᗵᨴ㒐ᓮ⎇ⓥ࠮ࡦ࠲࡯ ╙ 1 ࿁ᄖㇱ⹏ଔႎ๔ᦠ(2007 ᐕ 11 ᦬)
11㧚ႎ㆏1㧕 ᪀↰৻ᄦ㧦ࡗࠦࡉ∛ ᴦ≮⮎߳೨ㅴ㧦ᣣᧄ⚻ᷣᣂ⡞(2007 ᐕ 7 ᦬ 3 ᣣ)
2㧕 ᪀↰৻ᄦ㧦⇣Ᏹࡊ࡝ࠝࡦᛥ೙‛⾰㧦ਛᣣᣂ⡞(2007 ᐕ 7 ᦬ 3 ᣣ)
3㧕 ᪀↰৻ᄦ㧦ࡊ࡝ࠝࡦ⇣Ᏹ߆㒐ߋ‛⾰⊒⷗㧦ᦺᣣᣂ⡞(2007 ᐕ 7 ᦬ 3 ᣣ)
4㧕 ᪀↰৻ᄦ㧦ᗵᨴᕈࡊ࡝ࠝࡦ߳ߩᄌൻ㒐ᱛ BSE ᴦ≮ߦᦼᓙ㧦Ფᣣᣂ⡞(2007 ᐕ 7 ᦬ 3 ᣣ)
5㧕 ᪀↰৻ᄦ㧦ࡊ࡝ࠝࡦ⇣Ᏹൻᛥ೙ ࡗࠦࡉ∛‫ޔ‬BSE ᴦ≮ߦ㆏㧦ጘ㒂ᣂ⡞(2007 ᐕ 7 ᦬ 4 ᣣ)㧙㧙

6㧕 ᪀↰৻ᄦ㧦ᗵᨴᕈࡊ࡝ࠝࡦ߳ߩᄌൻ㒐ߋ‛⾰㧦Ფᣣᣂ⡞(2007 ᐕ 7 ᦬ 4 ᣣ)
7㧕 ᪀↰৻ᄦ㧦᛫ࡊ࡝ࠝࡦ‛⾰ࠍ㐿⊒ ࿖㓙ቇળ⾨ࠍฃ⾨㧦ጘ㒂ᣂ⡞(2008 ᐕ 10 ᦬ 17 ᣣ)
8㧕 ᪀↰৻ᄦ㧦࿖㓙ቇળߢฃ⾨㧦Ფᣣᣂ⡞(2008 ᐕ 10 ᦬ 16 ᣣ)
9㧕 ᪀↰৻ᄦ㧦࿖㓙ቇળߩ‫ޠ⾨࠻࠶࡟ࡃࠢ࠶ࠫ࠶ࡑޟ‬ฃ⾨ BSE ․ല⮎㐿⊒ࠍ⎇ⓥ㧦ਛᣣᣂ⡞(2008 ᐕ
10 ᦬ 25 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔੱ₞ᗵᨴ㒐ᓮ⎇ⓥ࠮ࡦ࠲࡯ߩ⋡⊛࡮⸘↹߇㧘㗅⺞ߦ㆐ᚑߐࠇߡ޿ࠆ㧘ߣ⹏ଔߔࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ੱ₞ᗵᨴ㒐ᓮ⎇ⓥ࠮ࡦ࠲࡯ߦߪ㧘NMR3 บ㧔500, 600, 800㧔੍ቯ㧕MHz㧕㧘X ✢࿁᛬ⵝ⟎‫ࠗ࡜ࠢޔ‬ࠝ㔚㗼㧔200kV㧕㧘ࡆࠕࠦࠕ╬㧘කቇ⎇ⓥߦ᦭↪ߥᦨవ┵ߩታ㛎ⵝ⟎߇ᄙᢙ޽ࠅ㧘౒ห೑↪߇น⢻ߣߥߞߡ޿ࠆ‫੹ޕ‬ᓟ㧘කቇ⎇ⓥ⑼ࠍ฽߻ቇౝᄖߩ⎇ⓥᯏ㑐╬ߣߩ౒ห೑↪࡮౒ห⎇ⓥࠍផㅴߒߚ޿‫ޕ‬੹ᓟߩዷᦸ∔ᖚ㑐ㅪ࠲ࡦࡄࠢ⾰ࠍᮡ⊛ߣߔࠆ⺰ℂ⊛ഃ⮎ࠍ㧘࿖ౝᄖߩ⎇ⓥᯏ㑐ߣߩ౒ห⎇ⓥࠍㅢߓߡផㅴߔࠆ‫ޕ‬㧙㧙㧔18㧕ᄢቇ㒮ㅪวഃ⮎ක≮ᖱႎ⎇ⓥ⑼㧔ක≮ᖱႎቇኾ᡹㧕1㧚⎇ⓥߩ᭎ⷐ
ᧄ⎇ⓥ⑼ߪ㧘ࡐࠬ࠻ࠥࡁࡓᤨઍߩഃ⮎⑼ቇ㧘ක≮⑼ቇ෸߮↢‛࡮↢๮⑼ቇߩಽ㊁ࠍᎿቇ㧘⮎ቇ㧘කቇߥߤߩቇ໧㗔ၞ߆ࠄ‫ޟ‬ഃ⮎‫ߡߒߣࡑ࡯࠹ࠍޠ‬㧘↢૕࠺࡯࠲߿ઍ⻢ᖱႎ㧘ᖚ⠪ᖱႎߥߤߩ‫ޟ‬ක≮ᖱႎ‫ࠅࠃߦޠ‬⸃ᨆߔࠆ㜞ᐲߥᢎ⢒⎇ⓥࠍⴕ߁‫ࠅࠃߦߣߎߩߎޕ‬㧘⥄ࠄ߇⸃᣿㧘ഃㅧ㧔㐿⊒㧕㧘ᬌ⸽㧘ᔕ↪ߦዷ㐿ߢ߈ࠆੱ᧚ߣߥࠅ㧘ੱ㘃ߩஜᐽჇㅴߣ↢๮࡮ஜᐽ⑼ቇ㗔ၞߩ⊒ዷߦነਈߢ߈ࠆ୶ℂⷰߦንࠎߛ㜞ᐲኾ㐷⡯ᬺੱ෸߮⎇ⓥ⠪ࠍ㙃ᚑߔࠆߎߣࠍ⋡ᮡߣߒߡ޿ࠆ‫ޕ‬એਅ㧘ᄢቇ㒮ㅪวഃ⮎ක≮ᖱႎ⎇ⓥ⑼ක≮ᖱႎቇኾ᡹ߩ߁ߜ
කቇㇱᚲዻᢎຬߦߟ޿ߡ⸥ߔ‫ޕ‬1㧕ࠤ࠻ࡦ૕ઍ⻢⇣Ᏹ∝㧔⢽⢌㉄ઍ⻢⇣Ᏹ∝ࠍ฽߻㧕ࠤ࠻ࡦ૕ઍ⻢⇣Ᏹ∝ߩಽ㊁ߢߪ਎⇇⊛ߦ߽ጘ㒂ᄢቇߣ޿ࠊࠇߡ߅ࠅ㧘ࠨࠢࠪ࠾࡞-CoA:3-ࠤ࠻㉄ CoA ࠻࡜ࡦࠬࡈࠚ࡜࡯࠯㧔SCOT㧕߅ࠃ߮Ǫࠤ࠻࠴ࠝ࡜࡯࠯ᰳ៊∝ߦߟ޿ߡߪ਎⇇ฦ࿾ࠃࠅ⥃ᐥ࠺࡯࠲࡯෸߮⚦⢩߇㓸߹ࠅ㧘phenotype/genotype ߩ㑐ㅪߥߤߩ⎇ⓥࠍ਎⇇ߦవ㚟ߌㅴ߼ߡ޿ࠆ‫࡯࡞ࠣߩ࠼ࡦ࡜ࡦࠖࡈޕ‬ࡊߣߩ౒ห⎇ⓥߢ㧘ࡅ࠻࠴ࠝ࡜࡯࠯ߩ 3 ᰴ᭴ㅧ᳿ቯ㧘ᄌ⇣Ⱞ⊕ߩ᭴ㅧ⊛⸃ᨆࠍ߅ߎߥߞߡ߅ࠅ㧘߹ߚፉᩮᄢቇߣߩ౒ห⎇ⓥߢ㧘⢽⢌㉄Ǫ㉄ൻ♽⇣Ᏹ∝ߩⰮ⊕ㆮવሶ⸃ᨆ߽ⴕߞߡᚑᨐ߇಴ߡ޿ࠆ‫ޕ‬
2㧕ࠕ࡟࡞ࠡ࡯
ዊఽ∛ᘒቇᢎቶߢ㧘ࠕ࡟࡞ࠡ࡯ኾ㐷කߣߒߡࠕ࡟࡞ࠡ࡯ߩ⥃ᐥߦ៤ࠊࠅߥ߇ࠄ㧘ࠕ࡟࡞ࠡ࡯ߣ㑐ㅪߔࠆㆮવሶᄙဳߩ⎇ⓥߦෳടߒ㧘޿ߊߟ߆ߩ୥⵬ㆮવሶᄙဳࠍႎ๔ߒߡ߈ߚ‫ޕ‬2004 ᐕ߆ࠄߪ㧘ࠕ࡟࡞ࠡ࡯∔ᖚߩ⊒∝ߩ੍⍮੍㒐ߦ㑐ߔࠆ಴↢ࠦࡎ࡯࠻⎇ⓥࠍ㐿ᆎߒ㧘ᧄᐕߢ 3 ᐕ߹ߢߩࡈࠜࡠ࡯߇⚳ੌߒ㧘⃻࿷⚿ᨐࠍ߹ߣ߼ߡ޿ࠆߣߎࠈߢ޽ࠆ‫ߦ࡯ࡇ࠻ࠕޕ‬㑐ㅪߔࠆㆮવሶᄙဳߩ⸃ᨆ㧘⤯Ꮺⴊ㧘↢ᓟ 6 ࡩ᦬㧘1 ᱦ 2 ࡩ᦬ߩណⴊ⚿ᨐ߿ 1 ᱦ 2 ࡩ᦬ߩኢౕਛߩ၎ਛߩ᛫ේ㊂ߩ᷹ቯ㧘∔ᖚ⊒∝ߥߤߩ㑐ㅪߢ⥝๧ᷓ޿⚿ᨐ߇಴ߡ߈ߡ
޿ࠆ‫ޕ‬3㧕వᄤᕈ఺∉ਇో∝
IgG ࠨ ࡉ ࠢ ࡜ ࠬ ᰳ ៊ ∝ ߩ ∛ ࿃ ߣ ߥ ࠆ ㆮ વ ሶ ⇣ Ᏹ ࠍ ਎ ⇇ ߦ వ 㚟 ߌ ᣿ ࠄ ߆ ߦ ߒ 㧔 J Clin Invest 㧕
Ataxia-telangiectasia ߩ∛࿃ㆮવሶ ATM ߦߟ޿ߡߩ⸃ᨆߢ߽޿ߊߟ߆ߩᚑᨐࠍ಴ߒߡ߈ߚ㧔Blood,
Oncogene, Gene Chromosome Cancer ߥߤ㧕‫ޕ‬4㧕ዊఽ␹⚻∔ᖚ⣄㜑ᕈ╭⪜❗∝ߩේ࿃Ⱞ⊕ SMN ߩᯏ⢻ߦߟ޿ߡߩ⸃ᨆࠍࠬ࠲࡯࠻ߒߡ޿ࠆ‫ޕ‬
5㧕␹⚻⚦⢩㓚ኂߩ⊒⃻ᯏᐨ⸃᣿㧘ਗ߮ߦߘߩ㒐ᓮߦ㑐ߔࠆ⎇ⓥ
Ԙㆃ⊒ᕈ␹⚻⚦⢩ᱫ㧦৻ㆊᕈ೨⣖⯯ⴊᓟᶏ㚍 CA1 ⚦⢩ߦ․⇣⊛ߦ⊒⃻ߔࠆㆃ⊒ᕈ␹⚻⚦⢩ᱫߪታ㛎⊛⣖⯯ⴊࡕ࠺࡞ߣߒߡ᳢↪ߐࠇߡ޿ࠆ߇ߘߩ⊒⃻ᯏᐨߪ⸃᣿ߐࠇߡ޿ߥ޿‫ޕ‬ᚒ‫ߩߘߪޘ‬ᯏᐨࠍ᣿ࠄ߆ߦߔࠆߣߣ߽ߦ㧘ഃ⮎ߩⷰὐ߆ࠄ㧘ߘߩ⊒⃻੍㒐࡮ᴦ≮ࠍ⹜ߺߡ޿ࠆ‫ޕ‬ԙ✂⤑␹⚻⚦⢩ᱫ㧦⯯ⴊౣẑᵹߦߣ߽ߥ߁✂⤑⚦⢩ᱫࡕ࠺࡞ߩ㐿⊒ࠍᚻ߇ߌ㧘ᦨㄭߢߪൻቇ‛⾰ࠍ↪޿ߚⷞ⚦⢩ㆬᛯ⊛⚦⢩ᱫࡕ࠺࡞ഃ⵾߽㐿⊒ߒߚ‫޿↪ࠍ࡞࠺ࡕߩࠄࠇߎޕ‬㧘✂⤑␹⚻⚦⢩ᱫߩࡔࠞ࠾࠭ࡓࠍ᣿ࠄ߆ߦߔࠆߣߣ߽ߦ㧘੍㒐࡮ᴦ≮⮎ߩ㐿⊒ߦขࠅ⚵ࠎߢ޿ࠆ‫ޕ‬
6㧕ES ⚦⢩ߦࠃࠆ␹⚻㓚ኂౣ↢ߦ㑐ߔࠆ⎇ⓥౣ↢ක≮ߩၮ␆⊛⎇ⓥߩ৻Ⅳߣߒߡ㧘✂⤑␹⚻⚦⢩㓚ኂࡕ࠺࡞ߦࡑ࠙ࠬ↱᧪ ES ⚦⢩߿ࡅ࠻↱᧪ ES ⚦⢩ࠍ⒖ᬀߒ㧘ߘߩ↢⌕₸ߩ੣ㅴ㧘ࠟࡦൻߩᛥ೙㧘␹⚻߳ߩಽൻߩଦㅴࠍ߼ߑߒߚ⎇ⓥࠍⴕߞߡ޿ࠆ‫੹ޕ‬ᓟ㧘ࡅ࠻↱᧪ੱᎿᄙ⢻ᕈᐙ⚦⢩㧔iPS ⚦⢩㧕ߢߩᬌ⸛߽ⴕ߁‫ޕ‬7㧕ᅢਛ⃿ߩᵴᕈൻߥࠄ߮ߦࠕࡐ࠻࡯ࠪࠬ⊒⃻ᯏᐨߩ⸃᣿
ᅢਛ⃿ߪᵴᕈ㉄⚛⒳ࠍ↥↢ߒ㧘↢૕㒐ᓮ⢻ࠍ᦭ߔߣߣ߽ߦ⚵❱㓚ኂᕈࠍ૬ߖᜬߟ‫ޕ‬ᅢਛ⃿ߩᵴᕈൻᯏ
᭴࡮ࠕࡐ࠻࡯ࠪࠬᒻᚑ⢻ࠍ⸃᣿ߒ∛ᘒߣߩ㑐ㅪ㧘ഃ⮎߳ߩᔕ↪ߦขࠅ⚵ࠎߢ޿ࠆ‫ޕ‬8㧕ක≮♽ᄢቇ↢࡮ᄢቇ㒮↢ߩᣂߚߥࠆᢎ⢒ᴺߩ⎇ⓥ࡮㐿⊒࡮ታ〣ጘ㒂ᄢቇකቇㇱ߇వ㚟⊛ߦขࠅ⚵ࠎߢ߈ߚ㧘໧㗴⸃᳿ဳቇ⠌ߢ޽ࠆ PBL ࠹ࡘ࠻࡯࡝ࠕ࡞ߩ㐳ᚲࠍ↢߆ߒ㧘ᰳὐࠍ⵬߁ᣂߚߥࠆᢎ⢒ᴺߩ㐿⊒ࠍᚻ߇ߌߡ޿ࠆ‫ޕ‬ᣢߦࠗࡦ࠲࡯ࡀ࠶࠻ࠍᵴ↪ߒߚ෺ᣇะဳቇ⠌ᴺ‫ޟ‬ᭉ૏⟎ᭉ The Tutorial‫ࠍޠ‬㐿⊒࡮ታ〣ߒߡ߈ߚ߇㧘ߎߩᄢቇ㒮ᢎ⢒ߢߩᔕ↪ࠍ⋡ᜰߒߡ޿ࠆ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
ᢎ᝼㧦

ᷓየ ᢅᐘ
ਤ⠀ 㓷ਯ

Toshiyuki Fukao
Masayuki Niwa

㧙㧙

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ᷓየᢅᐘ㧚᦭ᯏ㉄ઍ⻢⇣Ᏹ∝㧦ᄢ㑐ᱞᒾ㧘ฎᎹ ẋ㧘ᮮ↰ବ৻㇢✬㧚੹ᣣߩዊఽᴦ≮ᜰ㊎ ╙ 14 㧘᧲੩㧦කቇᦠ㒮㧧2006 ᐕ㧦168㧙169㧚
2㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ̈05 ⑺㧚╙ 18 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯ࠢࠪ
࡚࠶ࡊߩ⸥㍳㧘ฬฎደ㧦ਃᕺ␠㧧2006 ᐕ㧦112㧚
3㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ̉06 ౻࡮╙ 19 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯ࠢࠪ
࡚࠶ࡊߩ⸥㍳㧘ฬฎደ㧦ਃᕺ␠㧧2006 ᐕ㧦110㧚
4㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ̉06 ᤐ࡮╙ 20 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯ࠢࠪ
࡚࠶ࡊߩ⸥㍳㧘ฬฎደ㧦ਃᕺ␠㧧2006 ᐕ㧦185㧚
5㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ̉06 ᄐ࡮╙ 21 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯ࠢࠪ
࡚࠶ࡊߩ⸥㍳㧘ฬฎደ㧦ਃᕺ␠㧧2007 ᐕ㧦237㧚
6㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ̉06 ⑺࡮╙ 22 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯ࠢࠪ
࡚࠶ࡊߩ⸥㍳㧘ฬฎደ㧦ਃᕺ␠㧧2007 ᐕ㧦89㧚
7㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ̉07 ౻࡮╙ 23 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯ࠢࠪ
࡚࠶ࡊߩ⸥㍳㧘ฬฎደ㧦ਃᕺ␠㧧2007 ᐕ㧦120㧚
8㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ̉07 ᤐ࡮╙ 24 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯ࠢࠪ
࡚࠶ࡊߩ⸥㍳㧘ฬฎደ㧦ਃᕺ␠㧧2007 ᐕ㧦152㧚
9㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ̉07 ᄐ࡮╙ 25 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯ࠢࠪ
࡚࠶ࡊߩ⸥㍳㧘ฬฎደ㧦ਃᕺ␠㧧2007 ᐕ㧦121㧚
10㧕 ਤ⠀㓷ਯ㧚ਛᨔ␹⚻૞↪⮎㧦ᬀ᧻ବᒾ㧘㊄ਣశ㓉✬㧚ᣂ૕♽⋴⼔ቇోᦠ 5 ∔∛ߩᚑࠅ┙ߜߣ࿁ᓳߩଦㅴԚ
⮎ℂቇ㧘᧲੩㧦ࡔ࠵ࠞ࡞ࡈ࡟ࡦ࠼␠㧧2007 ᐕ㧦73㧙101㧚
11㧕 ਤ⠀㓷ਯ㧚ᶖൻེ૞↪⮎㧦ᬀ᧻ବᒾ㧘㊄ਣశ㓉✬㧚ᣂ૕♽⋴⼔ቇోᦠ 5 ∔∛ߩᚑࠅ┙ߜߣ࿁ᓳߩଦㅴԚ⮎ℂቇ㧘᧲੩㧦ࡔ࠵ࠞ࡞ࡈ࡟ࡦ࠼␠㧧2007 ᐕ㧦143㧙153㧚
12㧕 ਤ⠀㓷ਯ㧚᛫ᖡᕈ⣲≌⮎(᛫≸⮎)㧦ᬀ᧻ବᒾ㧘㊄ਣశ㓉✬㧚ᣂ૕♽⋴⼔ቇోᦠ 5 ∔∛ߩᚑࠅ┙ߜߣ࿁ᓳߩ
ଦㅴԚ⮎ℂቇ㧘᧲੩㧦ࡔ࠵ࠞ࡞ࡈ࡟ࡦ࠼␠㧧2007 ᐕ㧦191㧙203㧚
13㧕 ਤ⠀㓷ਯ㧚᛫Ἳ∝⮎࡮⸃ᾲ㎾∩⮎࡮᛫ࠕ࡟࡞ࠡ࡯⮎࡮఺∉ᛥ೙⮎㧦ᬀ᧻ବᒾ㧘㊄ਣశ㓉✬㧚ᣂ૕♽⋴⼔ቇ
ోᦠ 5 ∔∛ߩᚑࠅ┙ߜߣ࿁ᓳߩଦㅴԚ⮎ℂቇ㧘᧲੩㧦ࡔ࠵ࠞ࡞ࡈ࡟ࡦ࠼␠㧧2007 ᐕ㧦205㧙224㧚
14㧕 ᷓየᢅᐘ㧚DNA㧘ㆮવሶ㧘ࠥࡁࡓ㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦181㧙184㧚
15㧕 ᷓየᢅᐘ㧚ㆮવᕈ∔ᖚߩಽ㘃ߣ㗫ᐲ㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦185㧙187㧚
16㧕 ᷓየᢅᐘ㧚න৻ㆮવሶ∛㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦188㧙190㧚
17㧕 ᷓየᢅᐘ㧚ዩ⚛ࠨࠗࠢ࡞⇣Ᏹ∝㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦221㧙222㧚
18㧕 ᷓየᢅᐘ㧚♧ઍ⻢⇣Ᏹ∝㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦223㧙226㧚
19㧕 ᷓየᢅᐘ㧚ࡆ࡝࡞ࡆࡦઍ⻢⇣Ᏹ∝ߣࡐ࡞ࡈࠖ࡝ࡦઍ⻢⇣Ᏹ∝㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦237㧙239㧚
20㧕 ᷓየᢅᐘ㧚Ძ⚦ⴊ▤᜛ᒛᕈᄬ⺞∝㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦355㧙356㧚
21㧕 ᷓየᢅᐘ㧚ߘߩઁߩ఺∉⇣Ᏹ∝㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦359㧙360㧚
22㧕 ᷓየᢅᐘ㧚ᭂ㐳㎮ࠕࠪ࡞-CoA ⣕᳓⚛㉂⚛ᰳ៊∝㧘㐳㎮ 3-ࡅ࠼ࡠࠠࠪࠕࠪ࡞-CoA ⣕᳓⚛㉂⚛ᰳ៊∝㧘⍴㎮3-ࡅ࠼ࡠࠠࠪࠕࠪ࡞-CoA ⣕᳓⚛㉂⚛ᰳ៊∝ਛ㎮ࠕࠪ࡞-CoA ⣕᳓⚛㉂⚛ᰳ៊∝㧘⍴㎮ࠕࠪ࡞-CoA ⣕᳓⚛㉂⚛ᰳ៊∝㧘2㧘4 ࠫࠛࡁࠗ࡞-CoA ㆶర㉂⚛ᰳ៊∝㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ✚✬㓸㧚ዊఽ⑼ቇ ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦475㧙479㧚
23㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ̉07 ⑺࡮╙ 26 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯ࠢࠪ
࡚࠶ࡊߩ⸥㍳㧘ฬฎደ㧦ਃᕺ␠㧧2008 ᐕ㧦100㧚
24㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ̉08 ౻࡮╙ 27 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯ࠢࠪ
࡚࠶ࡊߩ⸥㍳㧘ฬฎደ㧦ਃᕺ␠㧧2008 ᐕ㧦130㧚
25㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ̉08 ᤐ࡮╙ 28 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯ࠢࠪ
࡚࠶ࡊߩ⸥㍳㧘ฬฎደ㧦ਃᕺ␠㧧2008 ᐕ㧦152㧚
26㧕 ਤ⠀㓷ਯ㧚⸃ᾲ㎾∩⮎࡮᛫Ἳ∝⮎㧦㊁᧛㓉⧷࡮⍹Ꮉ⋥ਭ✬㧚ࠪࡦࡊ࡞⮎ℂቇ ᡷ⸓╙ 4 㧘᧲੩㧦ධᳯၴ㧧
2008 ᐕ㧦229㧙245㧚⪺ᦠ㧔᰷ᢥ㧕
1㧕 Kondo N, Kato Z, Kaneko H, Fukao T, Matsui E, Aoki M. Molecular mechanisms of hygiene hypothesis.
In: (Holgate S, Matone G, Ring J eds. Cellular and Melecular Targets in Allergy and Clinical
Immunology. Cambridge: Hogrefe & Huber Publishers; 2007:36-37.
2㧕 Hara A, Niwa M, Aoki H, Taguchi A, Yamada Y, Mori H. New research on neuronal networks. In:㧙㧙Neuronal Network Research Horizons, ed Weiss ML, Nova Science Publish; 2007:99-118.
3㧕 Suzuki Y, Niwa M, Shibata T, Chirasak K, Ramesh JC, Evans P, Takahashi Y. Internet PBL:
International Collaborative Learning Experiences, Title of the book: Problem-Based Learning ineLearning Breakthroughs, ed. Tan O-S, Singapore: Publisher: Thomson Learning; 2007:131-146.
4㧕 Hara A, Oka N, Aoki H, Taguchi A, Yamada Y, Niwa M, Mori H. OCT-3/4 Expressing Cells as Cancer
Stem Cells in Human Immature Teratoma: Cancer Differentiation Potential. In: Saitama H (ed); New
Cell Differentiation Research Topics. New York: Nova Science Publisher ; 2008:1-6.
✚⺑㧔๺ᢥ㧕
1㧕 ᷓየᢅᐘ㧘ㄭ⮮⋥ታ㧚ᵈ⋡ߔߴ߈ࠕ࡟࡞ࠥࡦߣߘߩ∛ᘒ ࠗ࠿㧘ࡀࠦ㘺⢒ߣࠕ࡟࡞ࠡ࡯ߩ⊒∝㧘⥃ᐥ఺∉࡮ࠕ࡟࡞ࠡ࡯⑼ 2006 ᐕ㧧46 Ꮞ㧦604㧙612㧚
2㧕 ᛬ዬᕡᴦ㧘ᷓየᢅᐘ㧚ߌ޿ࠇࠎ㧘ᗧ⼂㓚ኂࠍ⿠ߎߔ∔ᖚߩᴦ≮࡮▤ℂߩࡐࠗࡦ࠻㧚᦭ᯏ㉄ઍ⻢⇣Ᏹ∝㧘ዊఽౝ⑼ 2006 ᐕ㧧38 Ꮞ㧦452㧙454㧚
3㧕 ᷓየᢅᐘ㧚ዊఽ∔ᖚߩ⸻ᢿᴦ≮ၮḰ ataxia telangiectasia㧘ዊఽౝ⑼ 2006 ᐕ㧧38 Ꮞ㧔⥃ᤨჇೀภ㧕㧦
232㧙233㧚
4㧕 ኹᧄ⾆⧷㧘㕍ᧁ⟤ᄹሶ㧘᧻੗᳗ሶ㧘ㄭ⮮ ᙥ㧘Ꮉᧄౖ↢㧘㊄ሶ⧷㓶㧘ᷓየᢅᐘ㧘ㄭ⮮⋥ታ㧚RS ࠙ࠗ࡞ࠬᗵ
ᨴߣ༎ᕷ⊒∝̅ᗵᨴߦࠃࠆ༎ᕷߩ⊒∝㧘Ⴧᖡߩᯏᐨ㧘ࠕ࡟࡞ࠡ࡯࡮఺∉ 2006 ᐕ㧧13 Ꮞ㧦1031㧙1037㧚
5㧕 ੹੗৾㊀㧘⑔ን⌀ᥓሶ㧘᭑ᧄ߭ߣߺ㧘ᐔᨋ⹞ሶ㧘ጤ⿧ᶈሶ㧘ᧁ᧛ ⽕㧘ዊỈ ੫㧘ᰞ੗㉿⟤㧘ᷓየᢅᐘ㧘⑔ንᖈ㧘᛬ዬᔘᄦ㧚∛ఽ଻⢒࿦ߢߩ଻⢒ਛߩ∝⁁ߩᄌൻߦߟ޿ߡߩᬌ⸛㧘଻⢒ߣ଻ஜ 2006 ᐕ㧧12 Ꮞ㧦
31㧙33㧚
6㧕 ⑔ን ᖈ㧘ฬ↰ආ೑㧘㕍ᧁ㓶੺㧘㋈ᧁ໪ሶ㧘ᣂ੗㓉ᐢ㧘ᷓየᢅᐘ㧘ㄭ᧻↱⟤ሶ㧘ጤ⿧ᶈሶ㧚㤗㤛ḡߩࠗࡦࡈ࡞ࠛࡦࠩߩว૬∝⁁ߦኻߔࠆലᨐߩᬌ⸛㧘ṽᣇߣ఺∉࡮ࠕ࡟࡞ࠡ࡯ 2006 ᐕ㧧20 Ꮞ㧦44㧙53㧚
7㧕 ㄭ⮮⋥ታ㧘᧻੗᳗ሶ㧘᪀ේᗲ⟤㧘Ꮉᧄౖ↢㧘㕍ᧁ⟤ᄹሶ㧘ኹᧄ⾆⧷㧘㊄ሶ⧷㓶㧘ᷓየᢅᐘ㧚᳇▤ᡰ༎ᕷߩ⊒∝੍㒐㧘ᣣᧄዊఽ⑼ቇળ㔀⹹ 2007 ᐕ㧧111 Ꮞ㧦23㧙27㧚
8㧕 ㄭ⮮⋥ታ㧘᧻੗᳗ሶ㧘㕍ᧁ⟤ᄹሶ㧘ᣂ੗㓉ᐢ㧘㊄ሶ⧷㓶㧘ᷓየᢅᐘ㧘᪀ේᗲ⟤㧚ⅣႺ߇↢૕ߦ෸߷ߔᓇ㗀㧘ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ⹹ 2007 ᐕ㧧21 Ꮞ㧦92㧙95㧚
9㧕 ᷓየᢅᐘ㧚ࠤ࠻ࡦ૕ઍ⻢⇣Ᏹ∝ ․ߦࠕ࠮࠻ࡦⴊᕈཌྷฯ∝ߣ㐓೎ߔߴ߈ࠨࠢࠪ࠾࡞-CoA㧦3-ࠤ࠻㉄ CoA ࠻࡜ࡦࠬࡈࠚ࡜࡯࠯ᰳ៊∝ࠍਛᔃߦ㧘ᣣᧄዊఽ⑼ቇળ㔀⹹ 2007 ᐕ㧧111 Ꮞ㧦727㧙739㧚
10㧕 ᷓየᢅᐘ㧚ࡍ࠶࠻㘺⢒ⅣႺߣዊఽࠕ࡟࡞ࠡ࡯㧘ࠕ࡟࡞ࠡ࡯ߩ⥃ᐥ 2007 ᐕ㧧356 Ꮞ㧦129㧙135㧚
11㧕 Ꮉᧄౖ↢㧘ᷓየᢅᐘ㧘᧻੗᳗ሶ㧘Ꮉᧄ⟤ᄹሶ㧘㊄ሶ⧷㓶㧘ㄭ⮮⋥ታ㧚⤯Ꮺⴊࠍ↪޿ߚ಴↢ࠦࡎ࡯࠻⎇ⓥߦ
ࠃࠆዊఽࠕ࡟࡞ࠡ࡯∔ᖚߩ⹏ଔ㧘ࠕ࡟࡞ࠡ࡯ߩ⥃ᐥ 2007 ᐕ㧧27 Ꮞ㧦77㧙82㧚
12㧕 ᧻੗᳗ሶ㧘Ꮉᧄౖ↢㧘ᷓየᢅᐘ㧘ㄭ⮮⋥ታ㧚੃ᐜఽᦼߩ఺∉ᔕ╵ᕈߩᄌㆫߣࠕ࡟࡞ࠡ࡯∔ᖚ⊒∝㧘ࠕ࡟࡞ࠡ࡯࡮఺∉ 2008 ᐕ㧧15 Ꮞ㧦170㧙174㧚
13㧕 ᷓየᢅᐘ㧚⾰⇼ᔕ╵ ዊఽߩࠤ࠻࡯ࠪࠬ㧘ᣣᧄක੐ᣂႎ 2008 ᐕ㧧4329 Ꮞ㧦89㧙90㧚✚⺑㧔᰷ᢥ㧕
1㧕 Matsui E, Kaneko H, Fukao T, Teramoto T, Kondo N. Tailor-made Medicine and GenePolymorphisms
in Bronchial Asthma. International Review of Asthma. 2006;8:64-72.
ේ⪺㧔๺ᢥ㧕
1㧕 ㄭ⮮⋥ታ㧘ᐔጊ⠹৻㇢㧘᧻੗᳗ሶ㧘ኹᧄ⾆⧷㧘㊄ሶ⧷㓶㧘ᷓየᢅᐘ㧘᛬ዬᑪᴦ㧘Ꮉᧄ⟤ᄹሶ㧘⥵ᚭ㆏ᓼ㧘
ᄢ⷏⑲ౖ㧘Ꮉᧄౖ↢㧘᫪↰⑲ⴕ㧘ᧁ᧛⽕㧘ฬ↰ආ೑㧘ᓼ⷗ືม㧘ၳ෹ඳ㧘ᷰㆻ୶ሶ㧚ዊఽ᳇▤ᡰ༎ᕷᖚఽ
ߣⷫ෶ߪ଻⼔⠪ߩ QOL ⺞ᩏ␿◲ᤃᡷ⸓ 2008(GIFU)㧘ࠕ࡟࡞ࠡ࡯ 2008 ᐕ㧧57 Ꮞ㧦1022㧙1033㧚
2㧕 ᐔᨋ⹞ሶ㧘᎑੗⌀ᄹ⟤㧘⨹Ꮉౖሶ㧘⑔ን⌀ᥓሶ㧘ጤ⿧ᶈሶ㧘ᷓየᢅᐘ㧘቟⮮ᕺ⟤ሶ㧘ኹỈᄢ␭㧘ዊ㑐㆏ᄦ㧘⑔ንᖈ㧚∛ఽ଻⢒ߦ߅ߌࠆ∝⁁ߦวࠊߖߚㆆ߮ߩᬌ⸛㧘଻⢒ߣ଻ஜ 2008 ᐕ㧧14 Ꮞ㧦46㧙49㧚
3㧕 ᫪↰⑲ⴕ㧘㊄ሶ⧷㓶㧘ᄢ⷏⑲ౖ㧘ㄭ⮮ᙥ㧘᧻੗᳗ሶ㧘ᷓየᢅᐘ㧘ㄭ⮮⋥ታ㧚఺∉ኡኈ⺃ዉߩߚ߼ߩ㘩‛ࠕ࡟࡞ࠡ࡯ਥⷐ᛫ේ࠲ࡦࡄࠢߩၮ␆⊛ᬌ⸛㧘ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ⹹ 2008 ᐕ㧧22 Ꮞ㧦233㧙238㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Gueven N, Fukao T, Luff J, Paterson C, Kay G, Kondo N, Lavin MF. Regulation of the Atm promoter invivo. Genes Chromosomes Cancer. 2006;45:61-71.
2㧕 Funato M, Shimozawa N, Nagase T, Takemoto Y, Suzuki Y, Imamura Y, Matsumoto T, Tsukamoto T,
Kojidani T, Osumi T, Fukao T, Kondo N. Aberrant peroxisome morphology in peroxisomal
beta-oxidation enzyme deficiencies. Brain Dev. 2006;28:287-292.
3㧕 Teramoto T, Fukao T, Tomita Y, Terauchi Y, Hosoi K, Matsui E, Aoki M, Kondo N, Mikawa H.
Pharmacokinetics of beclomethasone dipropionate in an hydrofluoroalkane-134a propellant system injapanese children with bronchial asthma. Allergol Int. 2006;55:317-320.
4㧕 Zhang G, Fukao T, Sakurai S, Yamada K, Michael Gibson K, Kondo N. Identification of Alu-mediated,large deletion-spanning exons 2-4 in a patient with mitochondrial acetoacetyl-CoA thiolase deficiency.
Mol Genet Metab. 2006;89:222-226.
5㧕 Kawamoto N, Kaneko H, Takemura M, Seishima M, Sakurai S, Fukao T, Kasahara K, Iwasa S, Kondo
N. Age-related changes in intracellular cytokine profiles and Th2 dominance in allergic children.
Pediatr Allergy Immunol. 2006;17:125-133.

㧙㧙

IF 4.532

IF 1.464

IF 2.550

IF 2.454

6㧕 Fukao T, Sakurai S, Rolland MO, Zabot MT, Schulze A, Yamada K, Kondo N. A 6-bp deletion at the
splice donor site of the first intron resulted in aberrant splicing using a cryptic splice site within exon 1
in a patient with succinyl-CoA: 3-ketoacid CoA transferase (SCOT) deficiency. Mol Genet Metab.
2006;89:280-282.
7㧕 Sukegawa-Hayasaka K, Kato Z, Nakamura H, Tomatsu S, Fukao T, Kuwata K, Orii T, Kondo N. Effectof Hunter disease (mucopolysaccharidosis type II) mutations on molecular phenotypes of
iduronate-2-sulfatase: enzymatic activity, protein processing and structural analysis. J Inherit MetabDis. 2006;29:755-761.
8㧕 Hara A, Niwa M, Kumada M, Aoki H, Kunisada T, Oyama T, Yamamoto T, Kozawa O, Mori H.
Intraocular injection of folate antagonist methotrexate induces neuronal differentiation of embryonicstem cells transplanted in the adult mouse retina. Brain Res. 2006;1085:33-42.
9㧕 Hara A, Niwa M, Aoki H, Kumada M, Kunisada T, Oyama T, Yamamoto T, Kozawa O, Mori H. A newmodel of retinal photoreceptor cell degeneration induced by a chemical hypoxia-mimicking agent,cobalt chloride. Brain Res. 2006;1109:192-200.
10㧕 Niwa M, Hotta K, Hara A, Hirade K, Ito H, Kato K, Kozawa O. TNF-alpha decreases hsp 27 in humanblood mononuclear cells: involvement of protein kinase C. Life Sci. 2006;80:181-186.
11㧕 Sakurai S, Fukao T, Haapalainen AM, Zhang G, Yamada S, Lilliu F, Yano S, Robinson P, Gibson MK,
Wanders RJA, Mitchell GA, Wierenga RK, Kondo N. Kinetic and Expression Analyses of Seven Novel
Mutations in Mitochondrial Acetoacetyl-CoA Thiolase (T2): Identification of a Km Mutant and an
Analysis of the Mutational Sites in the Structure. Mol Genet Metab. 2007;90:370-378.
12㧕 Kondo M, Fukao T, Shinoda S, Kawamoto N, Kaneko H, Kato Z, Matsui E, Teramoto T, Nakano T,
Kondo N. Lymphocyte responses to chymotrypsin- or trypsin V-digested Ǫ-lactoglobulin in patientswith cow’s milk allergy. Allergy Asthma Clin Immunol. 2007;3:1-9.
13㧕 Yamada K, Fukao T, Zhang G, Sakurai S, Ruiter JPN, Wanders RJA, Kondo N. Single-basesubstitution at the last nucleotide of exon 6 (c.671G >A), resulting in the skipping of exon 6, and exons
6 and 7 in human Succinyl-CoA:3-ketoacid CoA transferase (SCOT) gene. Mol Genet Metab.
2007;90:291-297.
14㧕 Haapalainen A, Merilinen G, Piril P, Kondo N, Fukao T, Wierenga R. Crystallographic and kinetic
studies of human mitochondrial acetoacetyl-CoA thiolase (T2): the importance of potassium andchloride ions for its structure and function. Biochemistry. 2007;46:4305-4321.
15㧕 Yamada K, Fukao T, Suzuki H, Inoue R, Kondo T, Kondo N. Vitamin K-Deficient Intracranial
Hemorrhage as the First Symptom of Cytomegalovirus Hepatitis with Cholestasis. Tohoku J Exp Med.
2007;212:335-339.
16㧕 Funato M, Kaneko H, Matsui E, Teramoto T, Kato Z, Fukao T, Okusu K, Kondo N. Refractoryosteomyelitis caused by bacille Calmette-Guerin vaccination: a case report. Diagn Microbiol Infect Dis.
2007;59:89-91.
17㧕 Aoki M, Fukao T, Kaneko H, Mizunaga S, Mitsuyama J, Sawamura H, Seishima M, Kondo N. Clinicaland bacteriological evaluation of the efficacy of piperacillin in children with pneumonia. J InfectChemother. 2007;13:224-229.
18㧕 Fukao T, Zhang G, Aoki Y, Arai T, Teramoto T, Kaneko H, Sugie H, Kondo N. Identification of
Alu-mediated, large deletion-spanning introns 19-26 in PHKA2 in a patient with X-linked liver
glycogenosis (hepatic phosphorylase kinase deficiency). Mol Genet Metab. 2007;92:179-182.
19㧕 Ozeki M, Funato M, Kanda K, Ito M, Teramoto T, Kaneko H, Fukao T, Kondo N. Clinical improvementof diffuse lymphangiomatosis with pegylated interferon alfa-2b therapy: Case report and review of theliterature. Pediatr Hematol Oncol. 2007;24:513-524.
20㧕 Funato M, Kaneko H, Ozeki M, Suzuki H, Orii K, Teramoto T, Fukao T, Kondo N.A positive
Donath-Landsteiner test in paroxysmal cold haemoglobinuria. Eur J Haematol. 2007;79:462.
21㧕 Fukao T, Kursula P, Owen EP, Kondo N. Identification and characterization of a temperature-sensitive
R268H mutation in the human succinyl-CoA:3-ketoacid CoA transferase (SCOT) gene. Mol Genet
Metab. 2007;92:216-221.
22㧕 Fukao T, Zhang G, Rolland M-O, Zabot M-T, Guffon N, Aoki Y, Kondo N. Identification of an
Alu-mediated tandem duplication of exons 8 and 9 in a patient with mitochondrial acetoacetyl-CoA
thiolase (T2) deficiency. Mol Genet Metab. 2007;92:375-378.
23㧕 Gobin-Limballe S, Djouadi F, Aubey F, Olpin S, Andresen BS, Yamaguchi S, Mandel H, Fukao T,
Ruiter JP, Wanders RJ, McAndrew R, Kim JJ, Bastin J.Genetic basis for correction of very-long-chain
acyl-coenzyme A dehydrogenase deficiency by bezafibrate in patient fibroblasts: toward a
genotype-based therapy. Am J Hum Genet. 2007;81:1133-1143.
24㧕 Aoki H, Hara A, Niwa M, Motohashi T, Suzuki T, Kunisada T. An in vitro mouse model for retinal
ganglion cell replacement therapy using eye-like structures differentiated from ES cells. Exp Eye Res.
2007;84:868-875.
25㧕 Hara A, Taguchi A, Niwa M, Aoki H, Yamada Y, Ito H, Nagata K, Kunisada T, Mori H. Localization of
septin 8 in murine retina, and spatiotemporal expression of septin 8 in a murine model ofphotoreceptor cell degeneration. Neurosci Lett. 2007;423:205-210.

㧙㧙

IF 2.550

IF 1.688

IF 2.218

IF 2.218
IF 2.257

IF 2.550

IF 2.550

IF 3.368

IF 1.133

IF 2.553

IF 2.550

IF 0.720
IF 2.163

IF 2.550

IF 2.550

IF 11.092

IF 2.651

IF 2.08526㧕 Kondo M, Fukao T, Omoya K, Kawamoto N, Aoki M, Teramoto T, Kaneko H, Kondo N. Protein-losing
enteropathy associated with egg allergy in a 5-month-old boy. J Investig Allergol Clin Immunol.
2008;18:63-66.
27㧕 Funato M, Kaneko H, Ozeki M, Kanda K, Fukao T, Kondo N: Anaphylactoid transfusion reactions
associated with a positively charged white-cell reduction filter: a case report. Transfus Apher Sci.
2008;38:199-201.
28㧕 Jin R, Kaneko H, Suzuki H, Arai T, Teramoto T, Fukao T, Kondo N. Age-related changes in BAFF andAPRIL profiles and upregulation of BAFF and APRIL expression in patients with primary antibody
deficiency. Int J Mol Med. 2008;21:233-238.
29㧕 Bai CY, Matsui E, Ohnishi H, Kimata K, Kasahara K, Kaneko H, Kato Z, Fukao T, Kondo N. A Novel
Polymorphism in the 5-lipoxygenase Gene Associated with Bronchial Asthma in Japanese Children.
Int J Mol Med. 2008;21:139-144.
30㧕 Kondo M, Kaneko H, Fukao T, Suzuki K, Sakaguchi H, Shinoda S, Kato Z , Matsui E, Teramoto T,
Nakano T, Kondo N. The response of bovine beta-lactoglobulin-specific T-cell clones to single aminoacid substitutions of T-cell core epitope. Pediatr Allergy Immunol. 2008;19:592-598.
31㧕 Yamada K, Yamamoto Y, Uchiyama A, Ito R, Aoki Y, Uchida Y Nagasawa H, Kimura H, Ichiyama T,
Fukao T, Kohno Y. A successfully treated case of neonatal herpes simplex type 1 infection complicatedby hemophagocytic lymphohistiocytosis and acute hepatic failure. Tohoku J Exp Med. 2008;214:1-5.
32㧕 Funato M, Kaneko H, Ozeki M, Kanda K, Fukao T, Kondo N. Pediatric synovial sarcoma of the rightmasseter muscle: A case report and review of the literature. Int J Pediatr Otorhi Extra.
2008;3:105-108.
33㧕 Suzuki H, Kaneko H, Rong J, Kawamoto N, Asano T, Matsui E, Kasahara K, Fukao T, Kondo N.
Induction of 1 and 2 gene expression in selective IgA deficiency. Molecular Medicine Report.
2008;1:395-399.
34㧕 Yotsumoto Y, Hasegawa Y, Fukuda S, Kobayashi H, Endo M, Fukao T, Yamaguchi S. Clinical andmolecular investigations of Japanese cases of glutaric acidemia type 2. Mol Genet Metab.
2008;94:61-67.
35㧕 Fukao T, Boneh A, Aoki Y, Kondo N. A Novel Single-Base Substitution (c.1124A>G) that Activates a
5-Base Upstream Cryptic Splice Donor Site within Exon 11 in the Human Mitochondrial
Acetoacetyl-CoA Thiolase Gene. Mol Genet Metab. 2008;94:417-421.
36㧕 Kuratsubo I, Suzuki Y, Shimozawa N, Kondo N. Parents of childhood X-linked adrenoleukodystrophy:
High risk for depression and neurosis. Brain Dev. 2008;30:477-482.
37㧕 Orii KE, Fukao T, Song X-Q, Mitchell GA, Kondo N. Liver-Specific Silencing of the Human Gene
Encoding Succinyl-CoA: 3-Ketoacid CoA Transferase. Tohoku J Exp Med. 2008;215:227-236.
38㧕 Ozeki M, Funato M, Kanda K, Ito M, Teramoto T, Kaneko H, Fukao T, Kondo N. Clinical Improvementof Diffuse Lymphangiomatosis with Pegylated Interferon ALFA-2B Therapy. Pediatr Hemat Oncol.
2008;24:513-524.
39㧕 Purevsuren J, Fukao, T, Hasegawa Y; Fukuda S, Kobayashi H, Yamaguchi S. Study of deep intronic
sequence exonization in a Japanese neonate with a mitochondrial trifunctional protein deficiency. Mol
Genet Metab. 2008;95:46-51.
40㧕 Kawamoto M, Matsui E, Kaneko H, Fukao T, Teramoto T, Kasahara K, Kondo N. IL-10 plays animportant role as an immune-modulator in the pathogenesis of atopic diseases. Molecular Medicine
Reports. 2008;1:837-842.
41㧕 Arai T, Kaneko H, Ohnishi H, Matsui E, Fukao T, Kawamoto N, Kasahara K, Kondo N. Hypothermia
Augments NF-kappa B Activity and the Production of IL-12 and IFN-gamma. Allergol Int.
2008;57:331-338.
42㧕 Teramoto T, Fukao T, Hirayama K, Asano T, Aoki Y, Kondo N. Escherichia coli O-157-induced
hemolytic uremic syndrome: Usefulness of SCWP score for the prediction of neurological complication.
Pediatrics International. 2008;50:1-3.
43㧕 Aoki H, Hara A, Niwa M, Motohashi T, Suzuki T, Kunisada T. Transplantation of cells from eye-likestructures differentiated from embryonic stem cells in vitro and in vivo regeneration of retinal
ganglion-like cells. Graefes Arch Clin Exp Ophthalmol. 2008;246:255-265.
44㧕 Hara A, Aoki H, Taguchi A, Niwa M, Yamada Y, Kunisada T, Mori H. Neuron-like differentiation andselective ablation of undifferentiated embryonic stem cells containing suicide gene with Oct-4
promoter. Stem Cells Dev. 2008;17:619-627.
45㧕 Taguchi A, Hara A, Saito K, Hoshi M, Niwa M, Seishima M, Mori H. Localization and spatiotemporal
expression of IDO following transient forebrain ischemia in gerbils. Brain Res. 2008;1217:78-85.

IF 1.254

IF 0.970

IF 1.847

IF 1.847

IF 2.454

IF 1.133

IF 0.851

IF 2.550

IF 2.550
IF 1.464
IF 1.133

IF 0.720

IF 2.550

IF 0.737

IF 1.590

IF 3.224
IF 2.2184㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦ᷓየᢅᐘ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦ࠤ࠻ࡦ૕ઍ⻢⇣Ᏹ∝ߩಽሶ∛ᘒ㧙Ⱞ⊕ 3 ᰴᯏㅧᄌൻߣࠬࡊ࡜ࠗࠪࡦࠣ⇣Ᏹࠍਛᔃߦ㧙㧧ᐔᚑ 18㧙19 ᐕᐲ㧧3,500 ජ౞(1,900㧦1,600

㧙㧙

ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦ጊญᷡᰴ㧘⎇ⓥදജ⠪㧦ᷓየᢅᐘ㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ሶߤ߽ኅᐸ✚ว⎇ⓥ੐ᬺ㧦࠲ࡦ࠺ࡓࡑࠬ╬ߩᣂᛛⴚࠍዉ౉ߒߚᣂߒ޿ᣂ↢ఽࡑࠬࠬࠢ࡝࡯࠾ࡦࠣ૕೙ߩ⏕┙ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 19㧙20 ᐕᐲ㧧700 ජ౞(400㧦300 ජ౞)
3㧕 ᢥㇱ⑼ቇ⋭․⦡޽ࠆᄢቇᢎ⢒ᡰេࡊࡠࠣ࡜ࡓ(․⦡ GP)㧦⢻േ࡮ᕁ⠨ଦㅴဳࠍᩇߣߔࠆోੱ⊛කቇᢎ⢒㧦ᐔᚑ 15㧙18 ᐕᐲ㧧60,000 ජ౞(15,000㧦15,000㧦15,000㧦15,000 ජ౞)
4㧕 ⎇ⓥઍ⴫⠪㧦ਤ⠀㓷ਯ㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌㧦CoCl2 ߩㆬᛯ⊛ⷞ␹⚻㓚ኂࡕ࠺࡞ߩ⏕┙㧧ᐔᚑ 18 ᐕᐲ㧧900 ජ౞5㧕 ⎇ⓥઍ⴫⠪㧦ਤ⠀㓷ਯ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌ၮ⋚⎇ⓥ(C)(2)㧦ࠦࡃ࡞࠻ࠢࡠ࡜ࠗ࠼⺃⊒ⷞ⚦⢩ㆬᛯ⊛㓚ኂࡕ࠺࡞ߩ⊒⃻ᯏᐨ⸃᣿ߥࠄ߮ߦߘߩ㒐ᓮ࡮ᴦ≮㧧ᐔᚑ 19̆20 ᐕᐲ㧧3,500 ජ౞(2,700㧦800
ජ౞)6㧕 ⎇ⓥઍ⴫⠪㧦㜞ᯅఝਃ㧘⎇ⓥදജ⠪㧦ਤ⠀㓷ਯ㧧⍮⊛ࠢ࡜ࠬ࠲࡯ഃᚑ੐ᬺ‫ࡑ࡯࠹ޟ‬Σ㧦ૐଚⷅᓸ⚦ᚻⴚᡰេ࡮ᢎ⢒⸠✵ࠪࠬ࠹ࡓߩ㐿⊒㧦ක≮ᢎ⢒⸠✵ࡠࡏ࠶࠻‫ޠ‬㧧ᐔᚑ 19㧙20 ᐕᐲ㧧46,432 ජ౞(23,200㧦23,232 ජ౞)
7㧕 ᐔᚑ 19 ᐕᐲ ⃻ઍ⊛ᢎ⢒࠾࡯࠭ข⚵ᡰេࡊࡠࠣ࡜ࡓ(⃻ઍ GP)ណᛯ‫⥃ޟ‬ᐥකቇᢎ⢒ࠍᒝൻะ਄ߐߖࠆ
ICT㧦e-Learning ߢၭ߁කߩᔃߣᛛ‫ޠ‬㧧ᐔᚑ 19㧙21 ᐕᐲ㧧69,973 ජ౞(23,993㧦21,980㧦24,000 ජ౞(੍ቯ))
2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬᷓየᢅᐘ㧦
1㧕 ᣣᧄవᄤઍ⻢⇣Ᏹቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄੱ㘃ㆮવቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄዊఽ⑼ቇળ᧲ᶏ࿾ᣇળᐙ੐(ᐔᚑ 18 ᐕ 4 ᦬㨪⃻࿷)
4㧕 ᣣᧄੱ㘃ㆮવቇળᜰዉක(ᐔᚑ 18 ᐕ 4 ᦬㨪⃻࿷)
5㧕 ᣣᧄዊఽ⑼ቇળઍ⼏ຬ(ᐔᚑ 20 ᐕ 4 ᦬㨪⃻࿷)ਤ⠀㓷ਯ㧦
1㧕 ᣣᧄ⮎ℂቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄἻ∝࡮ౣ↢කቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄකቇᢎ⢒ቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄ⥃ᐥ⮎ℂቇળ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅ਤ⠀㓷ਯ㧦
1㧕 ╙ 19 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 18 ᐕ 1 ᦬㧘ጘ㒂)2㧕 ╙ 20 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 18 ᐕ 4 ᦬㧘ߟߊ߫)3㧕 ╙ 21 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 18 ᐕ 8 ᦬㧘ጘ㒂)
4㧕 ╙ 22 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 18 ᐕ 10 ᦬㧘ᮮᵿ)
5㧕 ╙ 23 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 19 ᐕ 1 ᦬㧘ጘ㒂)
6㧕 ╙ 24 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 19 ᐕ 4 ᦬㧘᧲੩)7㧕 ╙ 25 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ㧛╙ 7 ࿁ᣣᧄዊఽකቇᢎ⢒⎇ⓥળ(ᐔᚑ 19 ᐕ 7 ᦬㧘ጘ㒂)8㧕 ╙ 26 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 19 ᐕ 10 ᦬㧘ᓼፉ)9㧕 ╙ 27 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 20 ᐕ 1 ᦬㧘ฬฎደ)㧙㧙

10㧕 ╙ 28 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 20 ᐕ 5 ᦬㧘ᄢ㒋)11㧕 ╙ 29 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 20 ᐕ 8 ᦬㧘ጘ㒂)12㧕 ╙ 30 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 20 ᐕ 10 ᦬㧘᧲੩)
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ᷓየᢅᐘ㧦
1㧕 10th International congress of inborn errors of metabolism(2006.09, Chiba,‫ޟ‬Mutation update ofhuman mitochondrial acetoacetyl-CoA thiolase (T2) deficiency‫ޠ‬Ṷ⠪)2㧕 10th International congress of inborn errors of metabolism(2006.09, Chiba,‫ޟ‬Mutation update of
succinyl-CoA:3-ketoacid CoA transferase deficiency‫ޠ‬Ṷ⠪)3㧕 2008 Annual symposium of Society for the Study of Inborn Errors of Metabolism (2008.08,‫ޟ‬CpG
islands around exon 1 in succinyl-CoA:3-ketoacid CoA transferase (SCOT) gene were
hypomethylated even in human and mouse hepatic tissues where SCOT gene expression wascompletely suppressed‫ޠ‬speaker)
4㧕 2008 Annual symposium of Society for the Study of Inborn Errors of Metabolism(2008.08,‫ޟ‬A
novel single-base substitution(c.1124A>G)that activates 5-base upstream cryptic splice donorsite within exon 11 in the human mitochondrial acetoacetyl-CoA thiolase gene‫ޠ‬speaker)
5㧕 ╙ 11 ࿁ᐢፉవᄤઍ⻢⇣Ᏹ⎇ⓥળ(ᐔᚑ 20 ᐕ 2 ᦬㧘ᐢፉ㧘․೎⻠Ṷ‫ࡦ࠻ࠤޟ‬૕ઍ⻢ߣߘߩ⇣Ᏹ∝‫ޠ‬Ṷ
⠪)
6㧕 ╙ 7 ࿁᧲ർઍ⻢⇣Ᏹ∝ᴦ≮⎇ⓥળ(ᐔᚑ 20 ᐕ 7 ᦬㧘઄บ㧘․೎⻠Ṷ‫ࡦ࠻ࠤޟ‬૕ઍ⻢ߣߘߩ⇣Ᏹ∝‫ޠ‬Ṷ⠪)7㧕 ╙ 10 ࿁ጘ㒂ࡊ࡜ࠗࡑ࡝࡯ࠤࠕࠞࡦࡈࠔ࡜ࡦࠬ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ૐⴊ♧㧘㜞ࠕࡦࡕ࠾ࠕⴊ∝㧘ઍ⻢ᕈࠕࠪ࠼࡯ࠪࠬ‫ޠ‬Ṷ⠪)8㧕 వ┵ഃ⮎ක≮ࠪࡦࡐࠫ࠙ࡓ(ᐔᚑ 20 ᐕ 10 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬ㆮવሶߣ∛᳇‫ޠ‬Ṷ⠪)9㧕 ╙ 45 ࿁ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ(ᐔᚑ 20 ᐕ 12 ᦬㧘ᮮᵿ㧘ࠪࡦࡐࠫ࠙ࡓ 10‫ߩࡦࠥ࡞࡟ࠕޟ‬ᗧ⟵ߣߘߩᄙ᭽ߥᯏ⢻‫ޠ‬Ṷ⠪)ਤ⠀㓷ਯ㧦
1㧕 6th Asia-Pacific Conference on Problem-Based Learning(2006.01, Tokyo, Symposium 2 “E-PBL”:‫ޟ‬Web-based Internet PBL-tutorial/Rakuichi The Tutorial‫ޠ‬Symposist)2㧕 ╙ 45 ࿁ᣣᧄ⮎ቇળਛ࿖྾࿖ᡰㇱ଀ળ(2006 ᐕ 6 ᦬㧘⑔ጊ㧘ቇળ᜗ᓙ⻠Ṷ‫ޟ‬ᣂߒ޿ක≮♽ᢎ⢒ߩᵹࠇߣ PBL/࠹ࡘ࠻࡯࡝ࠕ࡞‫ޠ‬Ṷ⠪)3㧕 వ┵ഃ⮎ක≮ࠪࡦࡐࠫ࠙ࡓ(ᐔᚑ 20 ᐕ 10 ᦬㧘ጘ㒂㧘⻠Ṷ‫⚦ޟ‬⢩ᱫߣ∛᳇㧘ߘߩౣ↢‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേᷓየᢅᐘ㧦
1㧕 ጘ㒂⋵ዊఽ଻ஜදળᏱછℂ੐(㨪⃻࿷)2㧕 ጘ㒂⋵੍㒐ធ⒳ஜᐽⵍኂ⺞ᩏኾ㐷කᏧ㓸࿅ኾ㐷කᏧ(㨪⃻࿷)3㧕 ጘ㒂Ꮢ଻⢒ᚲఽ┬ߩஜᐽࠍ⠨߃ࠆળᆔຬ ᆔຬ㐳(㨪⃻࿷)4㧕 ጘ㒂⋵ዊఽᢇᕆක≮ද⼏ળᆔຬ(㨪⃻࿷)5㧕 ጘ㒂Ꮢ଻ஜක≮ክ⼏ળᆔຬ(㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ㄭ⮮⋥ታ㧘㊄ሶ⧷㓶㧘ㄭ⮮ᙥ㧘ᷓየᢅᐘ㧘◉↰⚩ม㧘ട⮮ༀ৻㇢㧘㕍ᧁ⟤ᄹሶ㧘Ꮉᧄౖ↢㧦㘩‛╬ߦࠃࠆࠕ࠽ࡈࠖ࡜ࠠࠪ࡯෻ᔕߩේ࿃‛⾰(ࠕ࡟࡞ࠥࡦ)ߩ⏕ቯ㧘੍㒐࡮੍⍮ᴺߩ⏕┙ߦ㑐ߔࠆ⎇ⓥ 㘩‛ࠕ࡟࡞ࠥࡦߩ఺∉ᔕ╵߅ࠃ߮㕖හᤨဳ෻ᔕߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 17 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄⎇ⓥႎ๔ᦠ╙ 1 ಽౠ(ᶏ⠧Ỉ⃰)㧦90㧙92(2006 ᐕ 3 ᦬)㧙㧙

2㧕 ㄭ⮮⋥ታ㧘㊄ሶ⧷㓶㧘ㄭ⮮ᙥ㧘ᷓየᢅᐘ, ◉↰⚩ม㧘ട⮮ༀ৻㇢㧘㕍ᧁ⟤ᄹሶ㧘Ꮉᧄౖ↢㧦㘩‛ࠕ࡟࡞ࠥࡦߩ఺∉ᔕ╵߅ࠃ߮㕖හᤨဳ෻ᔕߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 17 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ✚ว࡮ಽᜂ⎇ⓥႎ๔ᦠ(ᶏ⠧Ỉ⃰)㧦22㧙24(2006 ᐕ 3 ᦬)
3㧕 ㄭ⮮⋥ታ㧘㊄ሶ⧷㓶㧘ㄭ⮮ᙥ㧘ᷓየᢅᐘ, ◉↰⚩ม㧘ട⮮ༀ৻㇢㧘㕍ᧁ⟤ᄹሶ㧘Ꮉᧄౖ↢㧦㘩‛ࠕ࡟࡞ࠥࡦߩ఺∉ᔕ╵߅ࠃ߮㕖හᤨဳ෻ᔕߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 15 ᐕᐲ㧙17 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ✚ว⎇ⓥႎ๔ᦠ(ᶏ⠧Ỉ⃰)㧦22㧙24(2006 ᐕ 3 ᦬)
4㧕 ᛬ዬᑪᴦ㧘ᷓየᢅᐘ, ㊄ሶ⧷㓶, ㄭ⮮⋥ታ㧦Ataxia telangiectasia(Ძ⚦ⴊ▤᜛ᒛᕈㆇേᄬ⺞∝)ߩ∛ᘒߦ㑐ߔಽሶ↢‛ቇ⊛⸃ᨆ㧦ᐔᚑ 17 ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄ 㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ ✚᜝࡮ಽ
ᜂ⎇ⓥႎ๔ᦠ(ች⣁⃰)㧦49㧙51(2006 ᐕ 3 ᦬)
5㧕 ㊄ሶ⧷㓶㧘㋈ᧁ໪ሶ㧘㊄ ᩕ㧘ᷓየᢅᐘ㧘ㄭ⮮⋥ታ㧦IgA ᰳ៊∝ߩ∛ᘒߣ∛࿃ㆮવሶߩ⸃ᨆ㧦ෘ↢ഭ௛⋭ 㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ ේ⊒ᕈ఺∉ਇో∝୥⟲ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ ᐔᚑ 18 ᐕᐲ╙ 1 ࿁⃰ળ⼏✚ળࡊࡠࠣ࡜ࡓ(ች⣁⃰)㧦6(2007 ᐕ 1 ᦬)
6㧕 ㄭ⮮⋥ታ㧘ᷓየᢅᐘ㧘᧻੗᳗ሶ㧘㊄ሶ⧷㓶㧘㕍ᧁ⟤ᄹሶ㧘ㄭ⮮ ᙥ㧘Ꮉᧄౖ↢㧦ࠕ࡟࡞ࠡ࡯ᕈ∔ᖚߩ⊒∝࡮㊀∝ൻߩ੍⍮ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ળᛞ㍳㓸(ᶏ⠧Ỉ⃰)㧦125(2007 ᐕ 2 ᦬)
7㧕 ㄭ⮮⋥ታ㧘ᷓየᢅᐘ㧘㊄ሶ⧷㓶㧘᧻੗᳗ሶ㧘㕍ᧁ⟤ᄹሶ㧦ࠕ࠻ࡇ࡯ᕈ⊹⤏Ἳ⊒∝ߣᲣ੃ߩ㑐ㅪ㧘․ߦᲣ੃ᚑಽߩ⸃ᨆߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ળᛞ㍳㓸(ᴡ㊁⃰)㧦143(2007 ᐕ 2 ᦬)
8㧕 ㊄ሶ⧷㓶㧘㋈ᧁ໪ሶ㧘ᷓየᢅᐘ㧘ㄭ⮮⋥ታ㧦IgA ᰳ៊∝ߩ∛ᘒߣ∛࿃ㆮવሶߩ⸃ᨆ ේ⊒ᕈ఺∉ਇో∝୥⟲ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ㧦ᐔᚑ 18 ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄ 㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ(ች⣁⃰)㧦41㧙43(2007 ᐕ 3 ᦬)
9㧕 ㄭ⮮⋥ታ㧘ᷓየᢅᐘ㧘ጤ⍾⋿৻㧘⊕ᧁ ⺈㧘᧻੗᳗ሶ㧘㊄ሶ⧷㓶㧘㕍ᧁ⟤ᄹሶ㧘ㄭ⮮ ᙥ㧘Ꮉᧄౖ↢㧦ࠕ࡟࡞ࠡ࡯∔ᖚߩ⊒∝࡮㊀∝ൻߩ੍⍮ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ(ᶏ⠧Ỉ⃰)㧦9㧙11(2007 ᐕ 3 ᦬)
10㧕 ㄭ⮮⋥ታ㧘ᷓየᢅᐘ㧘ጤ⍾⋿৻㧘⊕ᧁ ⺈㧘᧻੗᳗ሶ㧘㊄ሶ⧷㓶㧘㕍ᧁ⟤ᄹሶ㧘ㄭ⮮ ᙥ㧘Ꮉᧄౖ↢㧦ࠕ࡟࡞ࠡ࡯ᕈ∔ᖚߩ⊒∝࡮㊀∝ൻߩ੍⍮ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ᦠ ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ੐ോዪ ⊒ⴕ ╙ 3 ಽౠ(ᶏ⠧Ỉ⃰)㧦161㧙163(2007 ᐕ 3 ᦬)
11㧕 ㄭ⮮⋥ታ㧘ᷓየᢅᐘ㧘㊄ሶ⧷㓶㧘᧻੗᳗ሶ㧘㕍ᧁ⟤ᄹሶ㧦ࠕ࠻ࡇ࡯ᕈ⊹⤏Ἳ⊒∝ߣᲣ੃ߩ㑐ㅪ㧘․ߦᲣ੃ᚑಽߩ⸃ᨆߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ᦠ ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ੐ോዪ ⊒ⴕ ╙ 3 ಽౠ(ᴡ㊁⃰)㧦210㧙212(2007 ᐕ 3 ᦬)
12㧕 ㄭ⮮⋥ታ㧘◉↰⚩ม㧘㊄ሶ⧷㓶㧘㕍ᧁ⟤ᄹሶ㧘᧻੗᳗ሶ㧘ኹᧄ⾆⧷㧘ᷓየᢅᐘ㧦఺∉ᯏ⢻ૐਅࠍ᦭ߔࠆዊఽߦኻߔࠆ੍㒐ធ⒳ߩᬌ⸛(╙ 3 ႎ)఺∉⛽ᜬߦ㑐ߔࠆᬌ⸛㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌
⵬ഥ㊄ ක⮎ຠ࡮ක≮ᯏེ╬࡟ࠡࡘ࡜࡯ࠨࠗࠛࡦࠬ✚ว⎇ⓥ੐ᬺ ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ(ਅ↰⃰)㧦
85㧙87(2007 ᐕ 4 ᦬)
13㧕 ㄭ⮮⋥ታ㧘ᷓየᢅᐘ㧘㊄ሶ⧷㓶㧘᧻੗᳗ሶ㧘㕍ᧁ⟤ᄹሶ㧦ࠕ࠻ࡇ࡯ᕈ⊹⤏Ἳ⊒∝ߣᲣ੃ߩ㑐ㅪ㧘․ߦᲣ੃ᚑಽߩ⸃ᨆߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ(ᴡ㊁⃰)㧦20㧙22(2007 ᐕ 4 ᦬)
14㧕 ㄭ⮮⋥ታ㧘ᷓየᢅᐘ㧘᧻੗᳗ሶ㧘㊄ሶ⧷㓶㧘Ꮉᧄ⟤ᄹሶ㧘Ꮉᧄౖ↢㧦ࠕ࡟࡞ࠡ࡯ᕈ∔ᖚߩ⊒∝࡮㊀∝ൻߩ੍⍮ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 19 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ળᛞ㍳㓸(ᶏ⠧Ỉ⃰)㧦98(2008 ᐕ 2 ᦬)
15㧕 ㄭ⮮⋥ታ㧘◉↰⚩ม㧘᧻੗᳗ሶ㧘Ꮉᧄ⟤ᄹሶ㧦ዊఽ༎ᕷ QOL ⎇ⓥߩ✚᜝ ࠟࠗ࠼࡜ࠗࡦ᥉෸ߩߚ߼
ߩኻ╷ߣߘࠇߦ઻߁ QOL ߩะ਄ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 19 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ળᛞ㍳㓸(㗇↲⃰)㧦73(2008 ᐕ 2 ᦬)
16㧕 ㄭ⮮⋥ታ㧘Ꮉᧄ⟤ᄹሶ㧘ᷓየᢅᐘ㧘㊄ሶ⧷㓶㧘᧻੗᳗ሶ㧘ᄢ⷏⑲ౖ㧦ࠕ࠻ࡇ࡯ᕈ⊹⤏Ἳ⊒∝ߣᲣ੃ߩ㑐ㅪ㧘․ߦᲣ੃ᚑಽߩ⸃ᨆߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 19 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ળᛞ㍳㓸(ᴡ㊁⃰)㧦8(2008 ᐕ 2 ᦬)
17㧕 ਤ⠀㓷ਯ㧦╙ 24 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ㧘ࠕ࠽࠙ࡦࠬࡔࡦ࠻㧦කቇᢎ⢒ 38 Ꮞ 121(2007ᐕ 1 ᦬)
18㧕 ਤ⠀㓷ਯ㧦╙ 25 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ㧘࠾ࡘ࡯࠭㧦කቇᢎ⢒ 38 Ꮞ 334(2007 ᐕ 10
᦬)19㧕 ਤ⠀㓷ਯ㧦╙ 26 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ㧘ࠕ࠽࠙ࡦࠬࡔࡦ࠻㧦කቇᢎ⢒ 38 Ꮞ 354(2007㧙㧙ᐕ 10 ᦬)20㧕 ਤ⠀㓷ਯ㧦╙ 27 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ㧘ࠕ࠽࠙ࡦࠬࡔࡦ࠻㧦කቇᢎ⢒ 38 Ꮞ 410(2007ᐕ 12 ᦬)21㧕 ਤ⠀㓷ਯ㧦╙ 28 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ㧘ࠕ࠽࠙ࡦࠬࡔࡦ࠻㧦කቇᢎ⢒ 38 Ꮞ 86(2008ᐕ 4 ᦬)
22㧕 ਤ⠀㓷ਯ㧦╙ 29 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ㧘࠾ࡘ࡯࠭㧦කቇᢎ⢒ 38 Ꮞ 359(2008 ᐕ 10
᦬)23㧕 ਤ⠀㓷ਯ㧦╙ 30 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ㧘ࠕ࠽࠙ࡦࠬࡔࡦ࠻㧦කቇᢎ⢒ 39 Ꮞ 346(2008ᐕ 10 ᦬)24㧕 ਤ⠀㓷ਯ㧦╙ 31 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ㧘ࠕ࠽࠙ࡦࠬࡔࡦ࠻㧦කቇᢎ⢒ 39 Ꮞ 469(2008ᐕ 12 ᦬)11㧚ႎ㆏
1㧕 ᷓየᢅᐘ㧦‫⎇ޟ‬ⓥቶ߆ࠄ ᄢቇߪ޿߹‫ޠ‬㧦ጘ㒂ᣂ⡞(2006 ᐕ 4 ᦬ 4 ᣣ)
2㧕 ㅪวഃ⮎ක≮ᖱႎ⎇ⓥ⑼㧙⎇ⓥቶ⚫੺㧦ᣣ⚻ᣂ⡞㧘ᦺᣣᣂ⡞(2007 ᐕ 6 ᦬ 27 ᣣ)
3㧕 ਤ⠀㓷ਯ㧦‫⎇ޟ‬ⓥቶ߆ࠄ ᄢቇߪ޿߹‫ޠ‬㧦ጘ㒂ᣂ⡞(2007 ᐕ 11 ᦬ 13 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔ⎇ⓥᚑᨐߪ㊂⊛ߦ޽ࠆ⒟ᐲߩ⚿ᨐࠍ␜ߖߚߣᕁ߁߇㧘⾰⊛ߦߪᦝߥࠆദജ߇ᔅⷐߢ޽ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ㅪวഃ⮎ක≮ᖱႎ⎇ⓥ⑼ߪ 2007 ᐕ 4 ᦬ 1 ᣣߦ⊒⿷ߒߚ߫߆ࠅߢቇᐕㅴⴕਛߩ⎇ⓥ⑼ߢ޽ࠆ‫⎇ޕ‬ⓥᵴ
േߩ᜚ὐߣ߽ߥࠆᣉ⸳߽⃻࿷઒૑߹޿ߢ޽ࠅ㧘ᧄᩰ⊛ߥᵴേߪ᧪ᐕᐲකቇㇱࠠࡖࡦࡄࠬౝߦቢᚑ੍ቯߩጘ㒂⮎⑼ᄢቇ߳ߩ⒖ォᓟߣߥࠄߑࠆࠍᓧߥ޿‫⎇ߚ߹ޕ‬ⓥ⑼ࠬ࠲࠶ࡈ㑆ߢߩ౒ห⎇ⓥ߿ߘߩᣇะᕈ߇߹ߛ
ਇචಽߢ޽ࠅ㧘⃻⁁ߢߪᲣ૕ಽ㊁ߩ⎇ⓥ߇ਥߣߥߞߡ޿ࠆ‫ޕ‬⒖ォᓟߪᲣ૕ಽ㊁ߩ․ᕈࠍߐࠄߦ㜞߼ࠆߣߣ߽ߦ㧘⎇ⓥ⑼ߣߒߡᣂߚߥࡊࡠࠫࠚࠢ࠻ߩ┙ߜ਄ߍ╬ࠍㅢߓ㧘㗔ၞ࡮ኾ᡹ࠍ⿥߃ߚᢎຬ㑆ߩㅪ៤ࠍ㜞߼ࠆᔅⷐ߇޽ࠆ‫ޕ‬੹ᓟߩዷᦸ੹ᓟߐࠄߦකቇ࡮Ꮏቇ࡮⮎ቇߣߩㅪ៤ߩᒝߺࠍ↢߆ߒߚ⎇ⓥࠍㅴ߼㧘ഃ⮎߳ߩ⿷߇߆ࠅࠍ࿕߼ߚ޿‫ޕ‬

㧙㧙

2

ᢎຬ⚵❱

1. ኾછᢎຬߣ㕖Ᏹൕ⻠Ꮷ╬ߩ㈩⟎⁁ᴫ㧔1㧕ኾછᢎຬߩ㈩⟎⁁ᴫ╬ᐔᚑ 17 ᐕᐲએ㒠㧘ᧄቇߢߪᓥ᧪ߩቯᢙ೙ᐲ߆ࠄࡐࠗࡦ࠻೙ᐲ㧔✚ࡐࠗࡦ࠻ߩ▸࿐ౝߥࠄ㧘⡯⒳㧔ᢎ᝼㧩 100P㧘ಎᢎ᝼㧩 78P㧘⻠Ꮷ㧩 73P㧘ഥᢎ㧩 60P㧕㧘ੱᢙߪቇㇱߩ್ᢿߦᆔߨࠄࠇߡ޿ࠆ‫ޕ‬㧕߇ዉ౉ߐࠇ㧘߹ߚ㧘ᧄ⎇ⓥ⑼ߢߪ㧘18 ᐕᐲㅜਛ߆ࠄᄖㇱ⾗㊄ߦࠃࠅ㓹↪ߔࠆᢎຬ㧔ᒰೋߪഥᢎߩߺߢ޽ߞ
ߚ߇㧘19 ᐕᐲㅜਛ߆ࠄ⻠Ꮷ࡮ಎᢎ᝼߹ߢ᜛ᄢߒߚ‫ޕ‬㧕೙ᐲ߇ዉ౉ߐࠇߚ‫ޕ‬
ฦಽ㊁㧔ㇱ㐷㧕ߩ㈩⟎⁁ᴫߪ㧘ᰴߩߣ߅ࠅߢ޽ࠆ‫ޕ‬
ಽ㊁㧔ㇱ㐷㧕╬೎ኾછᢎຬ࡮㕖Ᏹൕ⻠Ꮷߩ㈩⟎⁁ᴫ㧔ฦᐕᐲߣ߽ 4 ᦬ 1 ᣣ⃻࿷㧕
⻠ᐳ

ಽ
ሶ
࡮
᭴
ㅧ
ቇ

∛
ᘒ
೙
ᓮ
ቇ

␹
⚻
⛔
ᓮ
ቇ

⣲
≌
೙
ᓮ
ቇ

ක
≮
▤
ℂ
ቇ

ౣ‫↢ޓ‬
ಽ‫ޓ‬ሶ
⛔ᓮቇ
ౣ‫↢ޓ‬
Ꮏ‫ޓ‬ቇ

඙ಽ / ᐕᐲ
ಽ㊁㧔ㇱ㐷 ) ╬ᣥ⻠ᐳ╬⚦ ⢩ ᖱ ႎ ቇ ↢ൻቇಽ ሶ ↢ ℂ ቇ ↢ ℂ ቇ ╙ 2⮎ ℂ ∛ ᘒ ቇ ⮎
ℂ
ቇ
ነ
↢
⯻
ቇ ነ
↢
⯻
ቇ
ㆮ વ ⊒ ↢ ቇ㧙ౝಽᴲઍ⻢∛ᘒቇ ౝ ⑼ ቇ ╙ 3
ዊ ఽ ∛ ᘒ ቇ ዊఽ⑼ቇ∛ᘒᖱႎ⸃ᨆකቇ ⥃ ᐥ ᬌ ᩏ ක ቇ⸃೬ቇ ⸃ ೬ ቇ ╙ 1
ಽ ሶ ∛ ᘒ ቇ ಽ ሶ ∛ ᘒ ቇ㜞ᐲవㅴᄖ⑼ቇ ᄖ ⑼ ቇ ╙ 1
ᢛ ᒻ ᄖ ⑼ ቇ ᢛ ᒻ ᄖ ⑼ ቇ⊹ ⤏ ∛ ᘒ ቇ ⊹⤏⑼ቇᴲ ዩ ེ ⑼ ቇ ᴲ ዩ ེ ⑼ ቇ
㤗㈮࡮−∩೙ᓮቇ 㤗 ㈮ ࡮ ⯃ ↢ ቇ⯃↢࡮㓸ਛᴦ≮ቇ㧙ญ ⣧ ∛ ᘒ ቇ ญ ⣧ ᄖ ⑼ ቇ㜞ᰴ␹⚻ᒻᘒቇ ⸃ ೬ ቇ ╙ 2↢ℂ
ቇ ↢ ℂ ቇ ╙ 1
ࠬ ࡐ ࡯ ࠷ ක ⑼ ቇ ࠬࡐ࡯࠷ක࡮⑼ቇ
␹⚻ౝ⑼࡮⠧ᐕቇ 㜞㦂කቇ♖ ␹ ∛ ℂ ቇ ␹ ⚻ ♖ ␹ ක ቇ⣖ ␹ ⚻ ᄖ ⑼ ቇ ⣖ ␹ ⚻ ᄖ ⑼ ቇ⡊ 㥦 ຜ ༄ ⑼ ቇ ⡊ 㥦 ຜ ༄ ⑼ ቇ
⌒
⑼
ቇ ⌒
⑼
ቇ
⣲ ≌ ∛ ℂ ቇ ∛ ℂ ቇ ╙ 1
఺ ∉ ∛ ℂ ቇ ∛ ℂ ቇ ╙ 2⣲ ≌ ᄖ ⑼ ቇ ᄖ ⑼ ቇ ╙ 2
ᶖ ൻ ེ ∛ ᘒ ቇ ౝ ⑼ ቇ ╙ 1
ⴊ ᶧ ∛ ᘒ ቇ㧙
↥ ⑼ ᇚ ੱ ⑼ ቇ ↥ ⑼ ᇚ ੱ ⑼ ቇ᡼ ኿ ✢ ක ቇ ᡼ ኿ ✢ ක ቇ∉ቇ࡮੍㒐කቇ ౏ ⴐ ⴡ ↢ ቇ⥃ ᐥ ⣲ ≌ ቇ㧙ක ≮ ᖱ ႎ ቇ ක ≮ ᖱ ႎ ㇱ✚ว∛ᘒౝ⑼ቇ ✚ ว ⸻ ≮ ㇱ⥃ ᐥ ⮎ ೷ ቇ ⮎೷ㇱක ≮ ⚻ ᷣ ቇ㧙ᢇᕆ࡮ἴኂකቇ
㧙
ᴺ
ක
ቇ ᴺ
ක
ቇ
↥ ᬺ ⴡ ↢ ቇ ⴡ ↢ ቇ 㧔 2 㧕⚵❱࡮ེቭᒻᚑ ⴡ ↢ ቇ 㧔 1 㧕␹⚻↢‛ ෻ ኿ ⎇ ⓥ ᣉ ⸳∛ ේ ૕ ೙ ᓮ ቇ ᓸ↢‛ቇ↢ ๮ ᯏ ⢻ ಽ ሶ ⸳ ⸘ 㧔Ꮏ㧕↢૕‛⾰Ꮏቇ⍮ ⢻ ࠗ ࡔ ࡯ ࠫ ᖱ ႎ 㧔Ꮏ㧕 ↹ ௝ ᖱ ႎ

ᐔᚑ 15 ᐕᐲᐔᚑ 16 ᐕᐲᐔᚑ 17 ᐕᐲᐔᚑ 18 ᐕᐲᐔᚑ 19 ᐕᐲᐔᚑ 20 ᐕᐲ

ኾછ

㕖Ᏹേ

ኾછ

㕖Ᏹേ

ኾછ

㕖Ᏹേ

ኾછ

㕖Ᏹേ

ኾછ

㕖Ᏹേ

ኾછ

㕖Ᏹേ

2
4
2
2

2
4
5
3

㧙
4
3
3
3
3
2
4
3
3
3

㧙
9
4
1
1
2
7
5
10
10
10

㧙
3
3
3
3
3
3
3
4
4
4
3
3
3

㧙
2
0
4
3
0
4
5
7
8
0
2
4
4

㧙
4
4
4

㧙
6
2
4

2
4
4
2
1
3
2
3
3
3
4
3
5
3
4
1
3
3
3
3
3
3
4
3
4
3
3
3
4
1
4
4
2

2
2
2
3
0
4
4
1
2
2
7
5
10
11
12
0
2
1
3
3
0
4
6
3
8
0
1
0
4
0
7
2
3

3
3
2
3
1
3
3
3
3
3
4
3
5
4
3
0
3
3
3
3
3
3
3
3
4
2
3
3
4
1
3
4
1

1
1
2
1
0
4
2
1
1
1
4
5
5
4
8
0
2
1
1
1
0
4
4
3
7
0
1
0
4
0
5
2
1

3
3
2
4
1
3
3
3
3
3
4
3
4
4
4
0
3
3
3
3
3
4
3
3
3
2
4
4
3
1
3
3
1

1
1
1
1
0
4
2
1
1
1
5
5
5
7
7
0
2
1
1
1
1
0
4
4
7
0
1
0
4
0
5
3
1

3
3
2
4
1
3
2
3
2
3
3
3
4
3
4
0
3
3
2
3
3
3
3
3
3
2
3
2
4
1
2
4
2

1
1
1
1
0
4
2
4
1
1
4
5
3
7
7
0
2
1
1
1
1
0
4
4
7
0
1
0
4
0
7
4
1

㧙
㧙
㧙
㧙
㧙
1
3
1
4
4
3
3
3

㧙
㧙
㧙
㧙
㧙
0
0
1
3
0
0
0
0

㧙
2
3
1
1
2
3
1
3
3
4
3
3

㧙
0
7
0
0
0
0
1
0
0
0
0
0

㧙
2
3
1
1
3
3
1
3
4
4
3
3

㧙
0
2
0
0
3
0
1
2
1
0
0
0

㧙
1
3
0
1
3
3
1
3
4
3
3
3

㧙
0
2
0
0
5
0
1
2
1
0
0
0

㧙
2
3
1
1
4
2
1
3
4
3
3
3

㧙
0
2
0
0
9
0
1
2
1
0
0
0

3
3
2
3
0
3
2
3
2
3
2
3
4
3
4
0
3
3
2
3
4
2
3
3
3
2
3
4
3
1
1
3
2
1
2
3
1
1
3
2
1
3
3
3
2
3

2
1
1
0
0
5
2
3
0
0
4
5
3
9
7
0
2
1
1
1
1
0
3
4
7
0
0
0
4
0
7
4
1
0
0
2
0
0
8
0
1
3
1
0
1
1

㧙㧙

⻠ᐳ

඙ಽ / ᐕᐲ
ಽ㊁㧔ㇱ㐷 ) ╬ᣥ⻠ᐳ╬

ᓴ Ⅳ ∛ ᘒ ቇ ౝ ⑼ ቇ ╙ౣ‫↢ޓ‬๭ ๆ ∛ ᘒ ቇ㧙ᔕ↪ቇකቇ♽୶ℂ࡮␠ળක
㧙࿾ၞක≮කቇ࠮ࡦ࠲࡯࡮࿾ၞකቇㇱ㐷ዊ‫⸘ޓޓޓޓޓޓޓޓޓ‬2

ᐔᚑ 15 ᐕᐲᐔᚑ 16 ᐕᐲᐔᚑ 17 ᐕᐲᐔᚑ 18 ᐕᐲᐔᚑ 19 ᐕᐲᐔᚑ 20 ᐕᐲ

ኾછ

㕖Ᏹേ

ኾછ

㕖Ᏹേ

ኾછ

㕖Ᏹേ

ኾછ

㕖Ᏹേ

ኾછ

㕖Ᏹേ

ኾછ

㕖Ᏹേ

4

28

㧙
2

㧙
0

2
1
2

30
0
0

2
1
2

6
0
1

3
1
2

6
0
1

2
1
2

8
0
1

㧙
123

㧙
160

㧙
134

㧙
152

㧙
131

㧙
92

㧙
130

㧙
98

㧙
124

㧙
104

3
1
2
6
125

4
0
1
4
104

කቇᢎ⢒㐿⊒⎇ⓥ࠮ࡦࠢ࡯ㅪวഃ⮎ක≮ᖱႎ⎇ⓥ⑼

6

6

6

2

5

2

6

1

㧙

㧙

㧙

㧙

㧙

㧙

㧙

㧙

4
2

2
9

5
2

1
10

⋴⼔ቇ⑼ ၮ␆⋴⼑ቇ⻠ᐳᲣሶ⌕⼔ቇ⻠ᐳᚑੱ࡮⠧ᐕ⋴⼔ቇ⻠ᐳ࿾ၞ࡮♖␹⋴⼔ቇ⻠ᐳዊ‫⸘ޓޓޓޓޓޓޓޓޓ‬

10
5
11
6
32

3
1
2
7
13

10
6
12
7
35

10
0
4
5
19

10
8
14
9
41

15
2
4
7
28

10
7
13
8
38

12
1
4
8
25

10
8
14
9
41

7
3
3
5
18

9
8
11
7
35

5
19
3
3
30

ว‫⸘ޓޓޓޓޓޓޓޓޓ‬

161

179

175

173

177

122

174

124

171

133

167

145

̪ᐔᚑ 19 ᐕᐲએ㒠ߩኾછᢎຬߦߪ㧘ᄖㇱ⾗㊄㓹↪ᢎຬࠍ฽߻‫ޕ‬

ᐔᚑ 20 ᐕᐲ㧔12 ᦬ 1 ᣣ⃻࿷㧕ߩᄢቇ㒮කቇ♽⎇ⓥ⑼࡮කቇㇱ࡮කቇᢎ⢒㐿⊒⎇ⓥ࠮ࡦ࠲࡯෸߮㒝ዻ∛㒮ߩ✚ࡐࠗࡦ࠻㧘૶↪ࡐࠗࡦ࠻෸߮ల⿷₸ߪᰴߩߣ߅ࠅߢ޽ࠆ‫ޕ‬඙‫ޓޓޓޓ‬ಽ✚ࡐࠗࡦ࠻૶↪ࡐࠗࡦ࠻

ల⿷₸කቇ♽⎇ⓥ⑼10,418

9,953

95.5%

⋴⼔ቇ⑼

3,187

2,869

90.0%

498

480

96.4%

6,229

5,879

94.4%

කቇᢎ⢒㐿⊒⎇ⓥ࠮ࡦ࠲࡯㒝ዻ∛㒮㧔2㧕㕖Ᏹൕ⻠Ꮷߩ㈩⟎⁁ᴫᧄቇㇱකቇ⑼෸߮⋴⼔ቇ⑼ߦᲤᐕੑ⊖ᢙචฬߩ㕖Ᏹൕ⻠Ꮷࠍ㈩⟎ߒߡ߅ࠅ㧘ಽ㊁㧔ㇱ㐷㧕㧘ฦࠦ࡯ࠬߦࠃߞߡߪ㈩⟎ᢙߦ߫ࠄߟ߈߇޽ࠆ‫ޕ‬ߥ߅㧘ᐔᚑ 20 ᐕᐲߩ✚ᢙߪ㧘217 ฬ 1,305 ᤨ㑆ߢ޽ࠆ‫ޕ‬කቇㇱකቇ⑼࠹ࡘ࠻࡯࡝ࠕ࡞╬ߩࠦ࡯ࠬ೎㕖Ᏹൕ⻠Ꮷߩ㈩⟎⁁ᴫࠦ࡯ࠬฬࡊ࡟࠹ࡘ࠻࡯࡝ࠕ࡞

ᐔᚑ 16 ᐕᐲ ᐔᚑ 17 ᐕᐲ ᐔᚑ 18 ᐕᐲ ᐔᚑ 19 ᐕᐲ ᐔᚑ 20 ᐕᐲ
5

5

5

3

2

ੱ૕᭴ㅧቇ

4

4

4

1

2

ઍ⻢࡮ᯏ⢻ቇ

7

8

8

7

8

ㆮવ࡮⊒↢࡮⊒㆐ቇ

2

5

4

4

4

∛ේ૕ቇ

2

4

4

5

4

⮎ℂ࡮ਛᲥቇ

4

4

5

5

5

∛ℂቇ

1

1

1

1

1

࠹ࡘ࠻࡯࡝ࠕ࡞

␹⚻࡮♖␹࡮ⴕേቇ

6

7

8

9

7

ᓴⅣེ࡮๭ๆེቇ

6

9

11

11

11

ⴊᶧቇ

1

1

1

1

1

ᶖൻེ࡮ᬌᩏකቇ

4

1

1

1

ౝಽᴲઍ⻢කቇ

9

4

4

4

5

㧙㧙

ࠦ࡯ࠬฬ

ᐔᚑ 16 ᐕᐲ ᐔᚑ 17 ᐕᐲ ᐔᚑ 18 ᐕᐲ ᐔᚑ 19 ᐕᐲ ᐔᚑ 20 ᐕᐲ

⣢࡮ዩ〝ቇ

3

3

5

5

5

ㆇേེቇ

6

6

6

6

6

⊹⤏⑼ቇ

2

2

2

2

2

ᗵེⷡකቇ

3

3

3

3

4

఺∉࡮ᔕ╵ቇ

1

4

3

3

3

↥⑼ᇚੱ⑼ቇ

3

4

4

4

4

㤗㈮࡮ᢇᕆ࡮−∩ቇ

2

5

5

6

5

᡼኿✢කቇ

2

1

1

1

1

࿾ၞ࡮↥ᬺ଻ஜ

3

4

4

4

1

⥃ᐥታ⠌౉㐷

11

11

1

1

1

77

86

90

87

82

ว‫⸘ޓޓޓޓ‬㧔3㧕ቴຬ⥃ᐥ♽කቇᢎ᝼╬ක≮⃻႐ߢᵴേߐࠇߡ޿ࠆቇᄖߩකᏧߦ㧘⼾ንߥ⥃ᐥ⚻㛎ࠍ⥃ᐥ♽කቇಽ㊁ߩᢎ⢒㧔ቇౝ㧕ߦදജࠍଐ㗬ߔࠆߚ߼㧘ᐔᚑ 8 ᐕᐲ߆ࠄ‫ޟ‬ቴຬ⥃ᐥ♽කቇᢎ᝼෸߮ቴຬ⥃ᐥ♽කቇಎᢎ᝼‫ߩޠ‬೙ᐲࠍ㧘߹ߚ㧘
ᐔᚑ 10 ᐕᐲ߆ࠄ 6 ᐕᰴቇ↢ߩቇᄖ⥃ᐥታ⠌ࠍ㐿ᆎߒߚߎߣߦ઻޿㧘ቇᄖታ⠌ࠍኻ⽎ߣߔࠆቴຬ⥃ᐥ♽කቇᢎ᝼╬೙ᐲࠍ⸳ߌߚ‫ޕ‬߹ߚ㧘ᐔᚑ 19 ᐕᐲߦ࿾ၞක≮කቇ࠮ࡦ࠲࡯߇⸳⟎ߐࠇ㧘࿾ၞක≮ߦ․ൻߒߚ⥃ᐥᢎ⢒ࠍⴕ߁ߚ߼㧘ห࠮ࡦ࠲࡯ߦ߽࿾ၞක≮කቇ♽ቴຬ⥃ᐥᢎ᝼╬೙ᐲࠍ⸳ߌߚ‫ޕ‬
㧔4㧕⥃ᐥᢎ᝼╬ᧄ⎇ⓥ⑼㧔කቇᢎ⢒㐿⊒⎇ⓥ࠮ࡦ࠲࡯෸߮㒝ዻ∛㒮฽߻‫ޕ‬㧕ߢߪ㧘⥃ᐥ࡮⎇ⓥ࡮ᢎ⢒ߦߟ޿ߡ㧘ఝ
⑲ߥੱ᧚ࠍ⏕଻ߔࠆߣߣ߽ߦ㧘ᵴᕈൻࠍ࿑ࠆߚ߼㧘ᐔᚑ 17 ᐕᐲㅜਛ߆ࠄ⥃ᐥᢎ᝼෸߮⥃ᐥಎᢎ᝼ߩ
⒓ภઃਈ೙ᐲࠍ⸳ߌߚ‫ޕ‬

2. ᢎ⢒⵬ഥ⠪ߣ⎇ⓥ⵬ഥ⠪ߩ㈩⟎⁁ᴫ㧔1㧕࠹ࠖ࡯࠴ࡦࠣ࡮ࠕࠪࠬ࠲ࡦ࠻ߩታᣉ෸߮ᵴ↪⁁ᴫ
ᐔᚑ 5 ᐕ 3 ᦬㐿௅ߩ⎇ⓥ⑼ᆔຬળߦ߅޿ߡ㧘ඳ჻⺖⒟ߩఝ⑲ߥቇ↢ߦኻߒᢎ⢒⊛㈩ᘦߩਅߦᢎ⢒⵬ഥᬺോࠍⴕࠊߖࠆߎߣ߇ᛚ⹺ߐࠇ㧘ታᣉߐࠇߡ޿ࠆ‫ޕ‬ᰴ⴫ߦ␜ߔߣ߅ࠅᦨㄭ 5 ᐕ㑆ߩᓥ੐⠪ᢙߦᄢ߈ߥᄌൻߪߥ޿߇㧘⋴⼔ቇኾ᡹ߦ޽ߞߡߪ , ߶ߣࠎߤ߇␠ળੱቇ↢ߢ޽ࠆߚ߼ , ቇㇱᢎ⢒ߩలታߩߚ߼ߦណ↪ߒߚ޿ߣߎࠈߢ޽ࠆ߇㧘ൕോߩㇺว਄㧘ᜂᒰߐߖࠆߎߣ߇ߢ߈ߥ޿⁁ᴫߦ޽ࠆ‫ޕ‬㧔න૏㧦ੱ㧕
16 ᐕᐲ

17 ᐕᐲ

18 ᐕᐲ

19 ᐕᐲ

20 ᐕᐲ

ක⑼ቇኾ᡹㧔ඳ჻㧕

18

19

19

21

18

ౣ↢ක⑼ቇኾ᡹㧔ඳ჻೨ᦼ㧕

7

5

4

5

8

ౣ↢ක⑼ቇኾ᡹㧔ඳ჻ᓟᦼ㧕

9

10

11

14

9

⋴⼔ቇኾ᡹㧔ୃ჻㧕

㧙
34

0

0

4

2

34

34

44

37

඙‫ޓޓޓޓ‬ಽ⸘㧙㧙㧔2㧕࡝ࠨ࡯࠴࡮ࠕࠪࠬ࠲ࡦ࠻ߩ㈩⟎⁁ᴫᐔᚑ 8 ᐕߦ⸳ߌࠄࠇߚߎߩ೙ᐲߪ㧘࿖┙ᄢቇߦ߅ߌࠆ⎇ⓥࡊࡠࠫࠚࠢ࠻╬ߦఝࠇߚᄢቇ㒮↢ࠍ⎇ⓥ⵬ഥ⠪ߣߒߡෳ↹ߐߖࠆ߽ߩߢ㧘⎇ⓥᵴേߩലᨐ⊛ផㅴ㧘⎇ⓥ૕೙ߩలታ෸߮⧯ᚻ⎇ⓥ⠪ߩ⢒ᚑߦᚑᨐࠍ਄ߍߡ޿ࠆ‫ޕ‬ᰴ⴫ߦ␜ߔߣ߅ࠅᦨㄭ 5 ᐕ㑆ߩᓥ੐⠪ᢙߦᄢ߈ߥᄌൻߪߥ޿‫ޕ‬㧔න૏㧦ੱ㧕
16 ᐕᐲ

17 ᐕᐲ

18 ᐕᐲ

19 ᐕᐲ

20 ᐕᐲ

ක⑼ቇኾ᡹㧔ඳ჻㧕

6

11

8

11

9

ౣ↢ක⑼ቇኾ᡹㧔ඳ჻ᓟᦼ㧕

4

5

6

8

5

⸘

10

16

14

19

14

඙‫ޓޓޓޓ‬ಽ

3. ណ↪㧘᣹છ╬ߩᣇᴺ
㧔1㧕ណ↪㧘᣹છߩㆬ⠨ၮḰߣㆬ⠨ᣇᴺ
ᄢቇ㒮කቇ♽⎇ⓥ⑼ᢎຬߩណ↪࡮᣹છߩၮḰߦߟ޿ߡߪ㧘ጘ㒂ᄢቇ⡯ຬណ↪ⷙ⒟ߩਛߦቯ߼ࠄࠇߡ߅
ࠅ㧘ߎࠇࠍฃߌߡ㧘ጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼ᢎ᝼ㆬ⠨ⷙ⒟㧘ጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼ᢎ᝼ㆬ⠨ⷙ⒟ߦ㑐ߔࠆ↳วߖ෸߮ጘ㒂ᄢቇ⡯ຬណ↪ⷙ⒟ᄢቇ㒮කቇ♽⎇ⓥ⑼ౝⷙ╬ߩⷙ⒟߇ቯ߼ࠄࠇߡ޿ࠆ‫ޕ‬ᢎ᝼ߩណ↪࡮᣹છߦߟ޿ߡߪ㧘ో࿖ߩ㑐ଥᯏ㑐ߦኻߒ౏൐ࠍⴕ޿㧘ጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼ᢎ᝼
ㆬ⠨ⷙ⒟ߦၮߠߊᢎ᝼ㆬ⠨ᆔຬળߢ㧘ᢎ᝼୥⵬⠪ߦߟ޿ߡᔅⷐߥ⻉੐㗄ࠍ⺞ᩏߒ㧘ᢎ᝼ળ⼏ߦႎ๔ߔࠆ
ߎߣ߇ቯ߼ࠄࠇߡ޿ࠆ‫ޕ‬ᢎ᝼ળ⼏ߪ㧘ᢎ᝼ㆬ⠨ᆔຬળߩႎ๔ࠍෳ⠨ߣߒߡᢎ᝼୥⵬⠪ࠍㆬ⠨ߔࠆ‫ޕ‬ಎᢎ᝼㧘⻠Ꮷ㧘ഥᢎߩណ↪࡮᣹છߦߟ޿ߡߪ㧘ጘ㒂ᄢቇ⡯ຬណ↪ⷙ⒟ᄢቇ㒮කቇ♽⎇ⓥ⑼ౝⷙߦၮߠ
߈ᒰ⹥ಽ㊁ߩਥછᢎ᝼ߩផ⮈ߒߚ୥⵬⠪ߦߟ޿ߡ㧘ጁᱧ੐㗄㧘ᬺ❣╬ࠍෳ⠨ߣߒ㧘ᢎ᝼ળ⼏ߢㆬ⠨ߔࠆ‫ޕ‬߹ߚ㧘⋴⼔ቇ⑼ߩᢎຬߦߟ޿ߡߪ㧘ጘ㒂ᄢቇකቇㇱ⋴⼔ቇ⑼ᢎ⢒⡯ຬㆬ⠨ขᛒⷙ⒟㧘หⷙ⒟ታᣉ⚦ೣ㧘ጘ㒂ᄢቇකቇㇱ⋴⼔ቇ⑼ᢎ⢒⡯ຬㆬ⠨ၮḰ෸߮หㆬ⠨ၮḰߦ㑐ߔࠆ↳วߖࠍቯ߼ߡ㧘౏൐ߦࠃࠅ୥
⵬⠪ࠍㆬ⠨ߒߡ޿ࠆ‫ޕ‬
㧔2㧕㕖Ᏹൕ⻠Ꮷߩㆬ⠨ၮḰߣㆬ⠨ᣇᴺ㕖Ᏹൕ⻠Ꮷߩㆬ⠨ၮḰߣㆬ⠨ᣇᴺߦߟ޿ߡߪ㧘ጘ㒂ᄢቇ⡯ຬណ↪ⷙ⒟╬ࠍḰ↪ߒ㧘ᢎോෘ↢ᆔຬળ╬ߢክ⼏ߩ਄㧘ᢎ᝼ળ⼏ߢㆬ⠨ߔࠆ‫ޕ‬

4. ౗ᬺ࡮౗⡯ߩၮḰߣ⁁ᴫ㧔1㧕౗ᬺ࡮౗⡯ߩၮḰ⡯ຬ߇ႎ㈽ࠍᓧߡ㧘ᧄቇએᄖߩ੐ᬺߩ࿅૕ߩᓎຬ㧘㘈໧⧯ߒߊߪ⹏⼏ຬߩ⡯ࠍ౗ߨ㧘ߘߩઁ޿߆ߥ
ࠆ੐ᬺߦᓥ੐ߒ㧘⧯ߒߊߪ੐ോࠍⴕ߁ߦ߽㧘޽ࠄ߆ߓ߼ㇱዪ㐳ߩ⸵นࠍᓧߡᓥ੐ߔࠆߎߣ߇ߢ߈ࠆ‫ޕ‬߹ߚ㧘ᰴߦឝߍࠆၮḰߩߔߴߡߦ⹥ᒰߔࠆ႐วߦߪ㧘ൕോᤨ㑆ౝߦ⡯ോߣߒߡᓥ੐㧔౗⡯㧕ߔࠆߎߣ߇ߢ߈ࠆ‫ޕ‬Ԙ ࿖㧘࿖┙ᄢቇᴺੱ෶ߪ࿾ᣇ౏౒࿅૕ߦ߅߆ࠇࠆክ⼏ળᆔຬ෶ߪᢎ⢒㧘ቇⴚ㧘ᢥൻ㧘ࠬࡐ࡯࠷ߩᝄ
⥝ࠍ࿑ࠆߎߣࠍ⋡⊛ߣߔࠆ․ᱶᴺੱ㧘౏⋉ᴺੱ╬ߩฦ⒳ᆔຬ╬ߩᬺോߢ․ߦ౏⋉ᕈ߇㜞޿ߣ⹺߼ࠄࠇࠆ߽ߩߢ޽ࠆߎߣ‫ޕ‬ԙήႎ㈽ߢ޽ࠆߎߣ‫ޕ‬

㧙㧙

Ԛ

ᓥ੐࿁ᢙ߇ᐕ㑆ᢙ࿁⒟ᐲߢ޽ࠆߎߣ‫ߤߥޕ‬

㧔2㧕౗ᬺ࡮౗⡯ߩ⁁ᴫ
ㆊ෰ 5 ᐕ㑆ߩ౗ᬺ࡮౗⡯ߩ⁁ᴫߪ㧘ᰴ⴫ߩߣ߅ࠅߢ޽ࠆ‫ޕ‬ᐕ‫ޓޓޓ‬ᐲ3㕖Ᏹൕ⻠Ꮷ㕖ᏱൕකᏧ ฦ⒳ክ⼏ળᆔຬ╬

ᴦ㛎㑐ଥ

౗‫ޓ‬⡯

ว‫⸘ޓ‬

ᐔᚑ 15 ᐕᐲ

173

381

137

16

707

ᐔᚑ 16 ᐕᐲ

166

412

162

22

762

ᐔᚑ 17 ᐕᐲ

172

424

135

8

45

784

ᐔᚑ 18 ᐕᐲ

103

400

134

6

44

687

ᐔᚑ 19 ᐕᐲ

111

431

140

5

41

728

ᣉ⸳࡮⸳஻

1㧚 ᣉ⸳࡮⸳஻ߩ⃻⁁࡮ᢛ஻⁁ᴫ
㧔1㧕කቇㇱ࡮㒝ዻ∛㒮ߩ⒖ォᢛ஻ߩ⚻✲㐳ᐕߩ ᩺ߢ޽ࠅ㧘ᖤ㗿ߢ߽޽ߞߚකቇㇱ࡮ห㒝ዻ∛㒮ߩ⒖ォᢛ஻ߦߟ޿ߡߪ㧘ᤘ๺ 62 ᐕ 5 ᦬ߦකቇㇱᢎ᝼ળ࡮㒝ዻ∛㒮⑼㐳ળ⼏ߦ߅޿ߡ㧘⛔ว⒖ォࠍၮᧄ᭴ᗐߣߔࠆ‫ޟ‬ጘ㒂ᄢቇකቇㇱ࡮ห㒝ዻ∛㒮㐳ᦼ⸘↹‫߇ޠ‬ᛚ⹺ߐࠇ㧘ᐔᚑ 4 ᐕ 9 ᦬╙ 35 ࿁዁᧪⸘↹ᆔຬળߦ߅޿ߡ㧘කቇㇱ࡮ห㒝ዻ∛㒮ᢛ஻ᬌ⸛ኾ㐷ᆔຬળ߇ขࠅ߹ߣ߼ߚ‫ޟ‬ጘ㒂ᄢቇකቇㇱ࡮ห㒝ዻ∛㒮ߩᢛ஻ߦߟ޿ߡ‫⚳ᦨߩޠ‬ႎ๔ᦠ߇ᛚ⹺
ߐࠇ㧘╙ 655 ࿁⹏⼏ળߦ߅޿ߡ㧘਄⸥ᦨ⚳ႎ๔ᦠ߇ᛚ⹺ߐࠇߚ‫ޕ‬ߘߩᓟ㧘ᐔᚑ 8 ᐕ 8 ᦬ߦᢥㇱ⋭ߩੌ⸃ࠍᓧߡ㧘ᐔᚑ 10 ᐕ 4 ᦬ᧄቇ㧘ጘ㒂⋵㧘ጘ㒂Ꮢ㧘ጘ㒂Ꮢ࿯࿾㐿⊒౏␠ߩ 4 ⠪ߦࠃࠆ‫ޟ‬ጘ㒂ᄢቇකቇㇱ࡮ห㒝ዻ∛㒮෸߮ක≮ᛛⴚ⍴ᦼᄢቇㇱߩ⒖ォߦ㑐ߔࠆⷡᦠ‫ޠ‬ࠍขࠅ੤ࠊߒ㧘කቇㇱ࡮ห㒝ዻ∛㒮ߩ⒖ォᢛ஻⸘↹߇ౕ૕ൻߒߚ‫ޕ‬ߎߩࠃ߁ߦ㧘⒖ォᢛ஻ߪ㕖Ᏹߦ㐳޿ᱧผߣᄙߊߩੱ‫޿ߥ߹ࠁߚߩޘ‬ദജߦࠃࠅታ⃻ߒߚ‫ޕ‬‫ ޚ‬කቇㇱ࡮ห㒝ዻ∛㒮ߩ⒖ォᢛ஻ߩ⚻✲ᤘ๺ 62 ᐕ 5 ᦬කቇㇱᢎ᝼ળߦ߅޿ߡ‫ޟ‬කቇㇱ࡮ห㒝ዻ∛㒮ߩ㐳ᦼ⸘↹‫╷ࠍޠ‬ቯ

ᐔᚑ 4 ᐕ 9 ᦬ጘ㒂ᄢቇ⹏⼏ળߦ߅޿ߡ‫ޟ‬කቇㇱ࡮ห㒝ዻ∛㒮ߩᢛ஻ߦߟ޿ߡ‫ߩޠ‬ႎ๔ᦠࠍᛚ⹺

ᐔᚑ 8 ᐕ 8 ᦬ᢥㇱ⋭߆ࠄ⒖ォᢛ஻⸘↹ߩᛚ⹺

ᐔᚑ 12 ᐕ 5 ᦬㒝ዻ∛㒮᫟‫ޓ‬Ꮏ੐⌕Ꮏ

ᐔᚑ 14 ᐕ 7 ᦬කቇㇱ⥃ᐥ⎇ⓥ᫟‫ޓ‬Ꮏ੐⌕Ꮏ

ᐔᚑ 14 ᐕ 8 ᦬කቇㇱ✚ว⎇ⓥ᫟‫ޓ‬Ꮏ੐⌕Ꮏ

ᐔᚑ 15 ᐕ 12 ᦬㒝ዻ∛㒮᫟‫ࠎࠀߒޓ‬Ꮏ

ᐔᚑ 16 ᐕ 1 ᦬කቇㇱᧄ㙚㧔⥃ᐥ⎇ⓥ᫟㧘✚ว⎇ⓥ᫟㧕‫ࠎࠀߒޓ‬Ꮏᐔᚑ 16 ᐕ 4 ᦬කቇㇱ࡮ห㒝ዻ∛㒮⒖ォ㐿ᆎ

ᐔᚑ 16 ᐕ 5 ᦬කቇㇱ࡮ห㒝ዻ∛㒮⒖ォቢੌᐔᚑ 16 ᐕ 6 ᦬㒝ዻ∛㒮㐿㒮

ᐔᚑ 16 ᐕ 12 ᦬කቇㇱᢎ⢒࡮⑔೑᫟‫ޓ‬Ꮏ੐⌕Ꮏ

ᐔᚑ 18 ᐕ 3 ᦬
ᐔᚑ 16 ᐕ 12 ᦬කቇㇱᢎ⢒࡮⑔೑᫟‫ࠎࠀߒޓ‬Ꮏකቇㇱ⸥ᔨળ㙚‫ޓ‬Ꮏ੐⌕Ꮏ㧙㧙‫ ޚ‬කቇㇱ࡮ห㒝ዻ∛㒮ߩ⒖ォᢛ஻ߩ⚻✲ᐔᚑ 18 ᐕ 8 ᦬කቇ࿑ᦠ㙚‫ޓ‬Ꮏ੐⌕Ꮏ

ᐔᚑ 18 ᐕ 3 ᦬කቇㇱ⸥ᔨળ㙚‫ࠎࠀߒޓ‬Ꮏ

ᐔᚑ 19 ᐕ 2 ᦬කቇ࿑ᦠ㙚‫ࠎࠀߒޓ‬Ꮏ

㧔2㧕කቇ⎇ⓥ⑼࡮කቇㇱᣂᣉ⸳ߩ․⦡
ᐔᚑ 16 ᐕ 4 ᦬ߦᄢቇ㒮කቇ⎇ⓥ⑼ࠍㇱዪൻߒߚකቇ⎇ⓥ⑼࡮කቇㇱߪ㧘หᐕ 6 ᦬㒝ዻ∛㒮ߣ౒ߦᩉᚭ࿾඙ߦ⒖ォ࡮ᣂ▽ߒߚ‫ޕ‬කቇㇱᧄ㙚ߪ㧘㜞ᐲൻ࡮ᄙ᭽ൻߔࠆᢎ⢒࡮⎇ⓥߦኻᔕߢ߈ࠆࠃ߁㧘ᐔ㕙⸘↹ߪ 4 ߟߩࡉࡠ࠶ࠢߢ᭴
ᚑߒߚᄢㇱደᣇᑼߣߒ㧘⸳஻⸘↹ߦ߅޿ߡ߽዁᧪ߩ᜛ల࡮ᄌൻ෸߮⊒ዷߦ߽ᨵエߦኻᔕߢ߈ࠆ᭴ㅧߢ
޽ࠅ㧘ฦ㓏ߦ࡝ࡈ࡟࠶ࠪࡘࠬࡍ࡯ࠬࠍ㈩⟎ߒ㧘ࠁߣࠅߣẢ޿ߩ޽ࠆⓨ㑆ࠍⓍᭂ⊛ߦขࠅ౉ࠇ㧘⎇ⓥቶ
ߣᑈਅߩ㑆઀ಾოࠍߔࠅࠟ࡜ࠬߣߔࠆߎߣߢ㐿᡼⊛ߥਛᑈਅߣߒߚ‫ߚ߹ޕ‬㧘කቇㇱฦᣉ⸳߳ߪ⒖േߒ
߿ߔ޿ࠃ߁ߦ㧘࠺࠶ࠠ⁁ߩㅪ⛊ㅢ〝㧔ࠗࡦ࠹࡝ࠫࠚࡦ࠻ࡕ࡯࡞㧕ࠍ⸳ߌ㧘කቇㇱᧄ㙚ౝߦ߅ߌࠆ⥃ᐥ⎇ⓥㇱ㐷ߪߢ߈ࠆ㒢ࠅ∛᫟ߦㄭធߐߖ㧘∛᫟ߣߩᷰࠅᑈਅࠍ੺ߒߡࠃࠅㅪ⛯ᕈࠍ⏕଻ߒߚ‫ޕ‬1 ᐕㆃࠇߢ⒖ォߔࠆߎߣߣߥߞߚ⸃೬ታ⠌ᣉ⸳㧘േ‛ታ㛎ᣉ⸳㧘RI ᣉ⸳ߪ㧘කቇㇱᧄ㙚ߩධ㓞ࠅߦᐔᚑ 17 ᐕ
3 ᦬ߦ⒖ォ࡮ᣂ▽ߒߚකቇㇱ↢๮⑼ቇ᫟ߦ㈩⟎ߐࠇ㧘࠺࠶ࠠ⁁ߩㅪ⛊ㅢ〝ߢ❬߇ߞߡ޿ࠆ‫ޕ‬ߥ߅㧘ᢎ⢒࡮⑔೑᫟ߪ㧘㑄㕒ߥደᄖ੤ᵹⓨ㑆ߢ޽ࠆࡎࠬࡇ࠲࡞ࡄ࡯ࠢߦ㕙ߒߡ⸳ߌ㧘ੱߣߩࠦࡒࡘ
࠾ࠤ࡯࡚ࠪࡦࠍㅢߓක≮ੱߣߒߡߩੱ㑆ᕈࠍ㙃߃ࠆࠃ߁⑔೑ᣉ⸳߽ขࠅㄟࠎߛⶄวᣉ⸳ߣߒߡᐔᚑ
18 ᐕ 4 ᦬߆ࠄߩ೑↪ࠍ⋡ᜰߒߡᐔᚑ 16 ᐕ 12 ᦬ߦ⌕Ꮏߒߚ‫ޕ‬
㧔3㧕ᣂ∛㒮ߩ․ᓽ╬㒝ዻ∛㒮ߪ㧘ᐔᚑ 16 ᐕ 6 ᦬ߦ⒖ォ࡮ᣂ▽ߒ㐿㒮ߒߚ‫ޕ‬ᣂ∛㒮ᣉ⸳ߪ㧘ᣥᢝ࿾ߩ⚂ 4 ୚ߣߥࠆ 12 ਁ
5 ජটߩකቇㇱ࡮ห㒝ዻ∛㒮ߩᢝ࿾ౝߦ㧘ࡃ࡝ࠕࡈ࡝࡯ߦ㈩ᘦߒߚ఺㔡᭴ㅧ࿾਄ 9 㓏ᑪߡߢ㧘∛᫟࡮ਛᄩ⸻≮ㇱ࡮ᄖ᧪߇᫟ߣߒߡ৻૕ൻߒߚⶄวᣉ⸳ߢ޽ࠅ㧘⚂ 500 บ߇෼ኈߢ߈ࠆᖚ⠪↪㚢ゞ႐߇⸳⟎ߐࠇߡ޿ࠆ‫ߚ߹ޕ‬㧘1 㓏ࠕ࠻࡝࠙ࡓ㧔ᐥᥦᚱ㧕߿ᄙ⋡⊛ࡎ࡯࡞㧔ක≮ࠟࠬ╬㈩஻㧕ߪ㧘ᄢⷙᮨἴኂᤨ
ߩᴦ≮ࠬࡍ࡯ࠬߣߒߡᵴ↪ߢ߈ࠆ᭴ㅧߢ㧘ደ਄ߦ⸳⟎ߒߚࡋ࡝ࡐ࡯࠻ߪ㧘ࡋ࡝ࠦࡊ࠲࡯ߦࠃࠆᢇᕆᖚ
⠪ߩ៝ㅍߦᵴ↪ߒߡ޿ࠆ‫ޕ‬ᣂ∛㒮㐿㒮ߣหᤨߦᣂක≮ᖱႎࠪࠬ࠹ࡓ㧔㔚ሶࠞ࡞࠹ࠍ฽߻‫ޕ‬㧕ࠍⒿേߐߖ㧘⸻≮⑼࡮ㇱ㐷ߩᨒࠍ⿧߃ߚ㧝ᖚ⠪㧝ࠞ࡞࠹ߦࠃࠅ⸻≮ᖱႎߩ౒᦭ࠍ࿑ࠆߣߣ߽ߦ㧘ቢో㔚ሶࠞ࡞࠹ൻߦࠃࠆࡍ࡯ࡄ࡯࡟
ࠬ࡮ࡈࠖ࡞ࡓ࡟ࠬࠍታ⃻ߒߚ‫ߚ߹ޕ‬㧘ో࿖ᦨᄢⷙᮨߩ㜞ᰴᢇ๮ᴦ≮࠮ࡦ࠲࡯ࠍ⸳⟎ߒ㧘24 ᤨ㑆૕೙ߢ㜞ᐲߥᢇ๮ᢇᕆක≮ࠍឭଏߒߡ޿ࠆ‫≮⸻ޕ‬૕೙ߣߒߡߪ㧘⤳ེ೎⸻≮૕೙ߩ⏕┙㧘࿾ၞක≮ߣߩㅪ៤ᒝൻ㧘੍⚂࠮ࡦ࠲࡯ߩ⸳⟎ߥߤࠍⴕߞߚ‫ߩߘޕ‬ᓟ㧘࠮ࠞࡦ࠼࡮ࠝࡇ࠾ࠝࡦᄖ᧪ߩዉ౉㧘ᄖ᧪ൻቇ≮ᴺ
ቶߩ⸳⟎ߥߤ㧘⸻≮ᯏ⢻ߩᒝൻࠍ࿑ߞߚ‫ޕ‬ᒰ∛㒮ߪ㧘∛㒮ߩℂᔨ࡮ၮᧄᣇ㊎㧘ᖚ⠪ߩᮭ೑ት⸒㧘୘ੱᖱႎ଻⼔ᣇ㊎෸߮⡯ᬺ୶ℂ✁㗔ࠍ೙ቯߒ㧘ᖚ⠪ਛᔃߩࠃࠅ⦟޿ක≮ߩឭଏߦജࠍᵈߋߣߣ߽ߦ㧘㜞ᐲవㅴක≮ߩ⎇ⓥ㐿⊒߿․ᓽ޽ࠆవㅴක≮ߩዉ౉ߦߟ޿ߡ੍▚ភ⟎ࠍߔࠆߥߤⓍᭂ⊛ߦขࠅ⚵ࠎߢ޿ࠆ‫ޕ‬
㧔4㧕කቇㇱ⋴⼔ቇ⑼ᣂᣉ⸳ߩ․⦡
ᣢߦᩉᚭ࿾඙ߦ⒖ォߒߡ޿ߚකቇㇱ⋴⼔ቇ⑼෸߮කቇ♽⎇ⓥ⑼⋴⼔ቇኾ᡹ߩᣉ⸳ߪ㧘ᑪ⸳ਛߩකቇ
ㇱᢎ⢒࡮⑔೑᫟ߦ㕙ߒߚࡎࠬࡇ࠲࡞ࡄ࡯ࠢߩ᧲ߦㄭធߒ㧘ᐔᚑ 15 ᐕ 3 ᦬ߦߪ㧘ᣢ⸳ᩞ⥢ߩ᧲஥ߦධ
ർߦ㈩⟎ߒ㧘ㅪ⛊ㅢ〝ߢ❬޿ߛ✚ว⎇ⓥ᫟ࠍᣂ▽ߒߚ‫ޕ‬㧙㧙✚ว⎇ⓥ᫟ߪ㧘࠮ࡒ࠽࡯ቶ㧘ታ㛎࡮ታ⠌ቶ㧘ᢎቭ⎇ⓥቶ╬ࠍ㈩⟎ߒߚ৻૕ဳᑪ‛ߢ㧘ฦࡈࡠࠕ࡯౒
ᣢ⸳ߩᑪ‛ߣߩേ✢ࠍ࿑ߞߡ޿ࠆ‫ޕ‬
2 㓏߆ࠄ 6 㓏ߦ࡝ࡈ࡟࠶ࠪࡘࠦ࡯࠽࡯ࠍ⸳⟎ߒ㧘߹ߚ㧘5 㓏ߪోቇߢ౒↪ߢ߈ࠆࡊࡠࠫࠚࠢ࠻⊛ߥᢎ⢒⎇ⓥᵴേߦଏߔࠆࠬࡍ࡯ࠬࠍ᦭ߔࠆ౒หᢎ⢒⎇ⓥቶ╬ࠍ㈩⟎ߒߡ޿ࠆ‫ޕ‬

4

࿖㓙੤ᵹ

1. ⇐ቇ↢ߩฃ౉ࠇ૕೙ߣ⁁ᴫጘ㒂ᄢቇߢߪ࿖㓙੤ᵹࠍ㊀ὐ⺖㗴ߩ৻ߟߣߒߡขࠅ਄ߍߡ߅ࠅ㧘කቇ♽⎇ⓥ⑼㧘කቇㇱߦ߅޿ߡ߽
ᄖ࿖ੱ⇐ቇ↢ࠍⓍᭂ⊛ߦฃߌ౉ࠇߡ޿ࠆ‫ޕ‬ㆊ෰ 5 ᐕ㑆ߩᄖ࿖ੱ⇐ቇ↢ߩฃߌ౉ࠇ⁁ᴫߪᰴ⴫ߩߣ߅ࠅ
ߢ޽ࠅ㧘ฃ౉ቇ↢ᢙߦᄢ߈ߥᄌേߪߥ޿߇㧘ᐔᚑ㧝㧤ᐕᐲ߆ࠄ㧘ᧄቇߩቇⴚ੤ᵹදቯᄢቇߦ࿷☋ߔࠆᄢቇ㒮↢ࠍ․೎⎇ⓥቇ↢ߣߒߡฃߌ౉ࠇߚ‫ޕ‬

ㆊ෰ 5 ᐕ㑆ߩᄖ࿖ੱ⇐ቇ↢ᢙ
ᐔᚑ 16 ᐕᐲ඙ಽ

ᐔᚑ 17 ᐕᐲᐔᚑ 18 ᐕᐲᐔᚑ 19 ᐕᐲᐔᚑ 20 ᐕᐲ

࿖ ⋵ ⑳
࿖ ⋵ ⑳
࿖ ⋵ ⑳
࿖ ⋵ ⑳
࿖ ⋵ ⑳
⸘
⸘
⸘
⸘
⸘
⾌ ⾌ ⾌
⾌ ⾌ ⾌
⾌ ⾌ ⾌
⾌ ⾌ ⾌
⾌ ⾌ ⾌

ቇㇱ↢
ᄢቇ㒮↢

8

⎇ⓥ↢

1

2

2

23 31
1

2
5

2

2

23 28
3

2
5

3

2

2

17 22

3

4

4

1

2

1

2

4

4

16 19

2

18 20

5

7

1

3

4

2

1

1

1

1

1

1

1

4

4

1

․೎⡬⻠ቇ↢․೎⎇ⓥቇ↢
࿖೎ౝ⸶
ᄢ㖧᳃࿖
บḧ

1

1

1

1

ਛ⪇ੱ᳃౒๺࿖

5

19 24

࠲ࠗ₺࿖

1

1

ࡒࡖࡦࡑ࡯

2

2

2

3
2

1
2

1

22 24

2

20 22

1

21 22

20 20

1

1

1

1

1

1

1

1

1

1

1

1

2

2

1

2

3

1

1

2

2

1

3

2

1

3

3

5

28 33

5

25 30

4

ࠪ࡝ࠕ
ࡃࡦࠣ࡜࠺ࠪࡘ

1

ࡌ࠻࠽ࡓ

2

3

3

3

3

26 29

ࠕࡔ࡝ࠞวⴐ࿖
ࡉ࡜ࠫ࡞
⸘

9

1

1

1

25 35

㧙㧙

1

1

1

24 29

2. ⇐ቇ↢ߩᢎ⢒࡮⎇ⓥᜰዉߩᣇᴺߣ૕೙
㧔1㧕⇐ቇ↢࠮ࡦ࠲࡯ጘ㒂ᄢቇߦߪ㧘ᣣᧄ⺆ᢎ⢒ߣ⇐ቇ↢ᜰዉߩߚ߼ߦ⇐ቇ↢࠮ࡦ࠲࡯߇⸳⟎ߐࠇߡ߅ࠅ㧘ᄢቇ↢ᵴߦᔅⷐߥᣣᧄ⺆⢻ജࠍિ߫ߔߎߣࠍ⋡⊛ߣߒߚᣣᧄ⺆⵬⻠߿㧘ᣣᧄ⺆⎇ୃࠦ࡯ࠬ㧘ᣣᧄ⺆࡮ᣣᧄᢥൻ⎇ୃࠦ࡯ࠬߥߤ߇ታᣉߐࠇߡ޿ࠆ‫ޕ‬
㧔2㧕࠹ࡘ࡯࠲࡯
⇐ቇ↢ߩ୘೎ᜰዉߦ㑐ߒߡߪ࠹ࡘ࡯࠲࡯೙߇ណࠄࠇߡ߅ࠅ㧘࠹ࡘ࡯࠲࡯ߦࠃࠆ⇐ቇ↢․೎ᜰዉߦࠃ
ࠅ㧘ᣣᧄ⺆㧘ኾ㐷ᢎ⢒⵬లߩਔ㕙߆ࠄലᨐ⊛ߥᜰዉ߇ⴕࠊࠇߡ޿ࠆ‫ޕ‬කቇㇱ㧘කቇ♽⎇ⓥ⑼ߦ߅ߌࠆ
⇐ቇ↢ߩኾ㐷ᢎ⢒ߦ㑐ߒߡߪ㧘ၮᧄ⊛ߦߪᣣᧄੱቇ↢ߩ႐วߣ⇣ߥࠆߎߣߥߊ㧘ቇㇱߦ߅޿ߡߪ᝼ᬺ
ࠍㅢߓߡฦᢎຬ߇ᢎ⢒࡮ᜰዉࠍⴕ޿㧘කቇ♽ᄢቇ㒮ߦ߅޿ߡߪฦ⎇ⓥ⑼ߩᜰዉᢎຬ߇⎇ⓥࠍᜰዉߒߡ
޿ࠆ‫ޕ‬

3. ࿷ቇ↢ߩᶏᄖ⇐ቇ࡮⎇ୃߩ⁁ᴫකቇ⑼ቇ↢ߩᶏᄖ⇐ቇߪ㧘කቇㇱࠞ࡝ࠠࡘ࡜ࡓߩ․ᱶᕈ߆ࠄ㧘ၮᧄ⊛ߦߪભቇߦࠃࠅ⇐ቇߔࠆߎߣ
ߣߥࠆ߇㧘⧷⺆⢻ജ߇৻ቯߩၮḰ㧔TOEFL550 ὐએ਄㧕ࠍࠢ࡝ࠕߒߡ޿ࠆ႐วߦߪ 6 ᐕᰴߩࠢ࡝࠾
ࠞ࡞ࠢ࡜࡯ࠢࠪ࠶ࡊ㧔㧠㨪㧤ㅳ㑆㧕ࠍᄖ࿖ߢฃߌࠆߎߣ߇ߢ߈ࠆ‫ޕ‬ᐔᚑ 17 ᐕᐲએ೨ߪ 1 ฬ⒟ᐲߢ޽ߞ
ߚ߇㧘කቇ⧷⺆ᢎ⢒ߩలታߦࠃߞߡᐔᚑ 18 ᐕᐲએ㒠ߪᲤᐕ 3 㨪 4 ฬ߇ᶏᄖߢ⥃ᐥታ⠌ࠍฃߌߡ޿ࠆ‫ޕ‬Ꮻ࿖ߒߚቇ↢ߪ⊒⴫ળࠍડ↹ߒ㧘ᓟヘߦߘߩવ⛔ࠍᒁ߈⛮ߋࠃ߁ߦߥߞߡ޿ࠆ‫ޕ‬19 ᐕᐲ߆ࠄߪ UCLAߩ⥃ᐥታ⠌߳ߩ↳ߒㄟߺ߇น⢻ߣߥߞߚ‫ޕ‬
17 ᐕᐲ‫ޓ‬1 ฬ㧔ࠝ࡯ࠬ࠻࡜࡝ࠕ㧕18 ᐕᐲ‫ޓ‬4 ฬ㧔☨࿖㧟ฬ㧘ࠞ࠽࠳㧝ฬ㧕
19 ᐕᐲ‫ޓ‬3 ฬ㧔☨࿖㧞ฬ㧘ࡈ࡜ࡦࠬ㧝ฬ㧕
20 ᐕᐲ‫ޓ‬3 ฬ㧔☨࿖㧟ฬ㧕ᄢቇ㒮ቇ↢ߦߟ޿ߡߪ㧘2 ᐕએౝߦ㒢ࠅ㧘ᄖ࿖ߦ߅ߌࠆ⎇ⓥᜰዉࠍ࿷ቇᦼ㑆ߦ▚౉ߔࠆߎߣ߇⹺߼
ࠄࠇߡ޿ࠆ‫ޕ‬

4. ᢎຬߩ࿷ᄖ⎇ⓥߩ⁁ᴫጘ㒂ᄢቇ࿷ᄖ⎇ⓥຬᵷ㆜೙ᐲߦࠃࠆᶏᄖߢߩ⺞ᩏ⎇ⓥߩઁߦ㧘ᢎຬߩᶏᄖ⎇ୃ߽⋓ࠎߢ޽ࠆ‫ޕ‬࿷ᄖ⎇ⓥຬߩ⁁ᴫ‫ޓ‬㧔ᐔᚑ 17 ᐕᐲ㨪ᐔᚑ 19 ᐕᐲ )
᳁‫ޓ‬ฬ

ਥṛ࿷࿖
ᵷ㆜⎇ⓥᯏ㑐ᵷ㆜ᦼ㑆⺞ᩏ⎇ⓥ⺖㗴

஻‫ޓ‬⠨

ᄢᳯ⋥ⴕ

ࠬࠗࠬ
࠴ࡘ࡯࡝ࡅᄢቇ

H18.3.20 㨪
H18.6.18⣖⣲≌ᚻⴚᴺߩᡷ⦟

ጘ㒂ᄢቇ

㒙ㇱᕺሶ

ࠗࠡ࡝ࠬ
ࠛࠫࡦࡃ࡜ᄢቇ

H19.8.20 㨪
H19.8.30

ࡊࡠࡈࠚ࠶࡚ࠪ࠽࡝࠭ࡓࠍ
㜞߼ࠆකቇᢎ⢒ጘ㒂ᄢቇ๟‫ޓ‬ะᩕ

ࠕࡔ࡝ࠞวⴐ࿖
ࠨ࠙ࠬࠞࡠ࡜ࠗ࠽ᄢቇ

H20.2.1 㨪
H20.3.31

૕ᐙㇱCT↹௝߆ࠄߩੱ૕⸃
೬ቇ⊛᭴ㅧߩ⥄േ⹺⼂ߣ㔚
ሶൻ

ጘ㒂ᄢቇ

㧙㧙

ㆊ෰ 5 ᐕ㑆ߩᶏᄖᷰ⥶⁁ᴫ඙‫ޓޓ‬ಽ

ᐔᚑ 15 ᐕᐲᐔᚑ 16 ᐕᐲᐔᚑ 17 ᐕᐲᐔᚑ 18 ᐕᐲᐔᚑ 19 ᐕᐲ

ᄖ࿖಴ᒛ

104

116

141

179

163

ᶏᄖ⎇ୃ

38

37

29

31

34

⸘

142

153

170

210

197

5. ᄖ࿖ੱ⎇ⓥ⠪ߩ᜗⥌ߩ⁁ᴫ࿖㓙␠ળߩਛߢ⚻ᷣᄢ࿖ߢ޽ࠅ㧘ߒ߆߽㜞ᐲవㅴ࿖ߣߒߡ⹏ଔߩ㜞޿ᚒ߇࿖ߢߩ⎇ⓥ߿⎇ⓥදജࠍ
Ꮧᦸߔࠆᄖ࿖ੱ⎇ⓥ⠪ߪ㕖Ᏹߦᄙߊ㧘ᧄ⎇ⓥ⑼ߦ߅޿ߡ߽ᰴߩߣ߅ࠅ㑐ㅪ㗔ၞߩ⎇ⓥ⠪߇ኾ㐷ಽ㊁ߢߩᏗᦸߔࠆ⎇ⓥᛛⴚୃᓧ޽ࠆ޿ߪᖱႎ੤឵╬ࠍ⋡⊛ߣߒߡ᧪ቇߒߡ޿ࠆ‫ޕ‬ᄖ࿖ੱ⎇ⓥ⠪᜗⥌⁁ᴫ‫ޓ‬㧔ᐔᚑ 17 ᐕᐲ㨪ᐔᚑ 19 ᐕᐲ )᳁‫ޓޓ‬ฬ

࿖‫☋ޓ‬㧔ᚲዻ࡮⡯ฬ )⋡‫⊛ޓޓ‬

ࠗࡦࠟ࡯‫࠼࡞ࠖࡅ࡯࠻ޓ‬
ࠣ࡜ࡓ

ࡁ࡞࠙ࠚ࡯
࠻ࡠࡓ࠰࡯ᄢቇ࡮ᢎ᝼

౒ห⎇ⓥᛂวߖ㧘࠮ࡒ࠽࡯ࡂࠛࠠࡘ࡯‫ࡓࠠޓ‬㖧࿖㊍ጊᄢቇ࡮ᢎ᝼

∛㒮ࠪࠬ࠹ࡓ⷗ቇ

ࠦ࠙‫ࠕࡘ࡛ࠪޓ‬㚅᷼⎇ୃࡄࡔ࡜࡛ࡦ࠺∛㒮࡮කᏧ

H17.6.13 㨪 6.16

ࠬࡉࡂ‫࠾ࡑ࡜ޓ‬ࠕࡔ࡝ࠞวⴐ࿖
ࡏࠬ࠻ࡦᄢቇ࡮ಎᢎ᝼

H17.7.25 㨪 7.25

⻠Ṷ㧘ឭ⸒ᜰዉ

ࠕࡔ࡝ࠞวⴐ࿖
⎇ⓥᛂวߖ
ࠪࠞࠧᄢቇࡂࡢ࡯࠼
ࡅࡘ࡯࠭ක⑼ቇ⎇ⓥᚲ࡮ᢎ᝼࡝࡝ࡖ࡯࠽‫ ࡠࠣࡀ࠹ࡦࡕ࡮ࠕࡆ࡞࠮ ࠶࠾ࡠࡈ࠰ޓ‬ቇⴚ੤ᵹࠢ‫ࠢ࠶ࠖࡧࡌࠨࡠࡒޓ‬ᩭࠛࡀ࡞ࠡ࡯ᔕ↪⎇ⓥᚲ࡮ਥછᦼ‫ޓޓ‬㑆
H17.4.8 㨪 4.8
H17.5.30 㨪 5.30

ࠣ࡜࡯ࡓ‫࡞ࡌޓࠗࠕޓ‬H17.8.2 㨪 8.3

H17.10.3 㨪 10.19

ࡠ࡯ࠩ‫࡯࠾࠳ࠕޓ‬ࡂࡦࠟ࡝࡯౒ห⎇ⓥ㧘ᄢቇ㒮․೎
࠺ࡉ࡟࠶࠷ࠛࡦᄢቇකቇ ⻠⟵ㇱ࡮ᢎ᝼

H17.10.22 㨪 10.28

ࡑ࡯ࠫ࠶࠻‫࠭࡯࡜ࡃޓ‬ࡂࡦࠟ࡝࡯౒ห⎇ⓥ㧘ᄢቇ㒮․೎
࠺ࡉ࡟࠶࠷ࠛࡦᄢቇකቇ ⻠⟵ㇱ࡮ᢎ᝼

H17.10.22 㨪 10.28

࡜࠶ࠪࡠ‫ࠬࠖ࠺࡯ࡕޓ‬

ࡂࡦࠟ࡝࡯
౒ห⎇ⓥ
࠺ࡉ࡟࠶࠷ࠛࡦᄢቇකቇ
ㇱ࡮ᢎ᝼

H17.10.22 㨪 10.28

ࡗ࡯ࡁࠬ‫࠴࠶ࡠ࠭ޓ‬

ࡂࡦࠟ࡝࡯
౒ห⎇ⓥ
࠺ࡉ࡟࠶࠷ࠛࡦᄢቇකቇ
ㇱ࡮ᢎ᝼

H17.10.22 㨪 10.28

࠰ࡦ‫ࡦࡘࠫࡋޓ‬㖧࿖㜞㤀ᄢቇ࡮ᢎ᝼

⎇ⓥߩᗧ⷗੤឵

H17.11.19 㨪 11.24

ࠣ࡜࡯ࡓ‫࡞ࡌޓ‬ࠕࡔ࡝ࠞวⴐ࿖
ࠪࠞࠧᄢቇ࡮ᢎ᝼

౒ห⎇ⓥᛂวߖ㧘⻠Ṷ࠮࡞ࠥࠗ‫ࡃ࡯ࡘࠫޓ‬ࠕࡔ࡝ࠞวⴐ࿖
ࠦࡠࡦࡆࠕᄢቇ࡮ඳ჻⎇ⓥຬ⻠Ṷ෸߮⎇ⓥߦኻߔࠆឭ⸒ᜰዉ
H18.1.19 㨪 1.19

㧙㧙

H17.12.16 㨪 12.17

᳁‫ޓޓ‬ฬࡑ࡯࠹ࠖࡦ‫ࡦࡆ࡜ޓ‬࿖‫☋ޓ‬㧔ᚲዻ࡮⡯ฬ )⋡‫⊛ޓޓ‬

ࠝ࡯ࠬ࠻࡜࡝ࠕ
Queensland Institute ofMedical Science,Vicedirector౒ห⎇ⓥᛂวߖ㧘⻠Ṷᦼ‫ޓޓ‬㑆
H18.2.3 㨪 2.6

ࠞ࡞ࡠ‫࡝࠮ࡦࡇޓ‬ࠗ࠲࡝ࠕ⎇ⓥᛂวߖ㧘⻠Ṷࡕ࠺࠽࡮࡟ࠫࠝࠛࡒ࡝ࠕ
ᄢቇ࡮ᢎ᝼

H18.3.13 㨪 3.16

ࠕ࡜ࡦ‫ࠬࡦࠥ࡯ࡂޓ‬ࠕࡔ࡝ࠞวⴐ࿖
⻠Ṷ࡮⸛⺰ࠞ࡞ࡈࠜ࡞࠾ࠕᄢቇ࡮ᢎ
᝼

H18.4.27 㨪 4.28

࠲ࡦ‫ࡦ࠮ޓࡦࠝޓ‬ࠪࡦࠟࡐ࡯࡞
⻠Ṷ࡮⸛⺰࠽ࡦࡗࡦ‫ࠞࠫࡠࡁࠢ࠹ޓ‬࡞ᄢቇ࡮ᢎ᝼

H18.5.25 㨪 5.26

ࡈ࡜‫ࠛࠗޓࠛࠗޓ‬ࡑ࡟࡯ࠪࠕࠗࡦ࠲࡯࠽࡚ࠪ࠽࡞ ࡔ࠺ࠖࠞ࡞ᄢቇ࡮ᢎ᝼

⻠Ṷ࡮⸛⺰

H18.5.25 㨪 5.26

⿥‫ޓ‬ᄢື

ਛ࿖ਛ࿖᧲ർᄢቇ࡮ᢎ᝼⻠Ṷ࡮⸛⺰ࡄ࠙ࡠ‫࠾࡯࠴ࡦ࠱ࡑޓ‬ࠕ࠯ࡌ࠼‫ࠬࠤ࡞ࡑޓ‬ࡉ࡜ࠫ࡞ࠨࡦࡄ࠙ࡠᄢቇ࡮ᢎ᝼

⻠Ṷ࡮⸛⺰ࠕࡦ࠼࡝ࡘ࡯‫࡯ࠖ࠺ޓ‬ࠛ࡯‫࠻ࡦࡔ࠼ࠗࡔޓ‬ࠕࡔ࡝ࠞวⴐ࿖
ࡍࡦࠪ࡞ࡃ࠾ࠕᄢቇ࡮ಎ
ᢎ᝼

⻠Ṷ࡮⸛⺰

ࠞ࡞ࡠ‫࡝࠮ࡦࡇޓ‬ࠗ࠲࡝ࠕࡕ࠺࠽ᄢቇ࡮ᢎ᝼

⎇ⓥ࡮౒ห⎇ⓥ࡝ࡘ࠙‫ࡦࡒࠗࠤޓ‬บḧ㜞㓶කቇᄢቇ࡮ᢎ᝼

⻠Ṷ࡮⸛⺰ࠛ࡝ࠩࡌࠬ‫࡯࡜ࡒޓ‬ࠕࡔ࡝ࠞวⴐ࿖
ࡂ࡯ࡃ࡯࠼ᄢቇ࡮⻠Ꮷ⻠Ṷ࡮⸛⺰ࠣ࡜ࡦ࠻‫࡞ࠚ࠴࠶ࡒޓ‬ࠞ࠽࠳ࡕࡦ࠻࡝ࠝ࡯࡞ᄢቇ࡮ഥ
ᢎ᝼⎇ⓥ࡮౒ห⎇ⓥ⼄‫ޓ‬ᔒ᣿

ਛ࿖⎇ⓥ࡮౒ห⎇ⓥ
਄ᶏᄢቇ߇ࠎ࠮ࡦ࠲࡯࡮
ಎᢎ᝼

H18.10.5 㨪 10.11

࡝࠶ࠢ‫ࠟࡦ࡟ࠛࡆޓ‬ࡈࠖࡦ࡜ࡦ࠼
ࠝ࠙࡞ᄢቇ࡮ᢎ᝼

⎇ⓥ࡮౒ห⎇ⓥ

H18.10.22 㨪 10.26

ࡑࡅࡄ࡯࠻ࡦ‫࠽࠴ޓ‬࠲ࠗࡑࡅ࠼࡯࡞ᄢቇ࡮࠺࡟ࠢ
࠲࡯ᖱႎ෼㓸࡮ⷞኤ╬ࡀ࡞࠰ࡦ ࠬ࠻࡯ࡦ

ࠕࡔ࡝ࠞวⴐ࿖
ዊ✢Ḯᴦ≮ߦኻߔࠆᛛ
ࡑ࠙ࡦ࠻ࠨࠗ࠽ࠗ∛㒮ᴲ ⴚᜰዉ
ዩེ⑼࡮᡼኿✢⑼࡮ᢎ᝼

H18.12.5 㨪 12.5

ࡑ࡯ࠫࡖ࡝࡯‫ࡦ࡟ࡋޓ‬
࠺࡯ࡆࠬ

ࠗࠡ࡝ࠬ
࠳ࡦ࠺ࠖ࡯ᄢቇ࡮ᢎ᝼

⻠Ṷ࡮⸛⺰

H19.3.14 㨪 3.15

࠰ࡦ‫࠙ࠦࠗࠤޓ‬ਛ࿖ਛ࿖㚂ㇺක⑼ᄢቇ࡮⻠Ꮷ⎇ⓥ࡮౒ห⎇ⓥ

ࡒ࠶࠴ࠚ࡞‫ࡦࡠࡃޓ‬ࠕࡔ࡝ࠞวⴐ࿖
⻠Ṷ෸߮ࡢ࡯࡚ࠢࠪ࠶
࡚ࠫࡦࡎࡊࠠࡦࠬᄢቇ࡮ ࡊ
ᢎ᝼

㧙㧙

H18.7.3 㨪 7.3
H18.7.4 㨪 7.4
H18.7.6 㨪 7.6
H18.7.12 㨪 7.17
H18.8.25 㨪 8.27
H18.8.25 㨪 8.27
H18.9.16 㨪 9.18

H18.10.31 㨪 10.31

H19.3.16 㨪 3.16
H19.7.13 㨪 7.15

᳁‫ޓޓ‬ฬ࿖‫☋ޓ‬㧔ᚲዻ࡮⡯ฬ )ࡀ࡞࠰ࡦ ࠬ࠻࡯ࡦ

ࠕࡔ࡝ࠞวⴐ࿖
ࡑ࠙ࡦ࠻ࠨࠗ࠽ࠗ∛㒮࡮
ᢎ᝼

⻠Ṷ࡮⸛⺰

ࡈࠖ࡝࠶ࡊ‫ࠬࡦࡃࠛޓ‬ࠗࠡ࡝ࠬࠣ࡜ࠬࠧ࡯ᄢቇ࡮ᢎ᝼

⻠Ṷ

Changwon Kee㖧࿖SungKyunKwan ᄢቇ࡮ᢎ᝼ᖱႎ෼㓸࡮ⷞኤ╬Chung kwon yoo㖧࿖
Korea ᄢቇ࡮⻠Ꮷᖱႎ෼㓸࡮ⷞኤ╬࠺࠾ࠬ‫ࠢ࠶ࡃࡁޓ‬ࠕࡔ࡝ࠞวⴐ࿖
⻠Ṷ࠼࡟ࠢ࠮࡞ක⑼ᄢቇ࡮ᢎ
᝼⋡‫⊛ޓޓ‬

ᦼ‫ޓޓ‬㑆
H19.7.17 㨪 7.17
H19.12.15 㨪 12.15
H19.12.20 㨪 12.21
H20.1.7 㨪 1.31
H20.2.14 㨪 2.14

6. ᶏᄖߩᄢቇߣߩቇⴚ੤ᵹදቯߩ✦⚿⁁ᴫකቇ♽⎇ⓥ⑼࡮කቇㇱߢߪ 20 ᢙᐕ೨߆ࠄቇᄖ࡮ᶏᄖදജᆔຬળ߇࿖㓙੤ᵹߩᓎഀࠍᜂߞߡ߈ߚ߇㧘ጘ㒂ᄢቇ࿖㓙੤ᵹᆔຬળ㧘⇐ቇ↢࠮ࡦ࠲࡯ߩ⸳⟎ߦ઻޿㧘⃻࿷ߢߪጘ㒂ᄢቇ࿖㓙੤ᵹᆔຬળ㧘⇐ቇ↢੤ᵹᆔຬળ㧘⇐ቇ↢࠮ࡦ࠲࡯ㆇ༡ᆔຬળߦᆔຬࠍᵷ㆜ߒߡ޿ࠆ‫ޕ‬ᄢቇ㑆ߢߩቇⴚ੤ᵹදቯߪ 14 ࠞ࿖ 36 ᄢቇ㧔ᐔᚑ 21 ᐕ 1 ᦬⃻࿷㧕ߣ㧘කቇ♽⎇ⓥ⑼࡮කቇㇱߣߒߡߩㇱዪ㑆੤ᵹߪਛ⪇ੱ᳃౒๺࿖ߩᵽᳯᄢቇකቇㇱ㧘࠲ࠗ₺࿖ߩࠦࡦࠤࡦᄢቇකቇㇱߣ✦⚿ߒߡ޿ߚ߇㧘ᐔᚑ 20 ᐕ 11 ᦬ 18 ᣣߦᣂߚߦ☨࿖ࠦࡠ࡜࠼Ꮊ┙ᄢቇߣ✦⚿ߒ㧘⇐ቇ↢ߩฃ౉ࠇ㧘ᧄቇቇ↢ߩᵷ㆜㧘⎇ⓥ⠪ߩ੤ᵹ㧘౒ห⎇ⓥߥߤ߇ⴕࠊࠇߡ޿ࠆ‫੹ޕ‬ᓟ߽ߐࠄߦᣂߚߥ✦⚿ࠍ฽߼㧘ㇱዪ㑆੤ᵹࠍផㅴߒߡ޿ߊ੍ቯߢ޽ࠆ‫ޕ‬

5␠ળߣߩㅪ៤

1. ౏㐿⻠ᐳߩ㐿⸳ߩᣇ㊎ߣ⁁ᴫ౏㐿⻠ᐳߪ࿾ၞ␠ળߣߩㅪ៤࡮දജ㧘࿾ၞ૑᳃ߣߩ⋧੕ℂ⸃ߥߤࠍᓧࠆ਄ߢ߭ߣߟߩ᦭⋉ߥᣇᴺߢ
޽ࠅ㧘ᧄቇㇱ෸߮㒝ዻ∛㒮ߦ⫾Ⓧߐࠇߚකቇߩ⍮⼂ࠍᐢߊ࿾ၞ␠ળߦ㐿᡼ߔࠆߎߣߦࠃࠅ㧘࿾ၞ૑᳃ߩකቇ⍮⼂ߩะ਄ߦ⾗ߔࠆߎߣࠍ⋡⊛ߣߒߡ޿ࠆ‫ޕ‬ᧄቇㇱ౏㐿⻠ᐳߪ㧘৻⥸␠ળੱࠍኻ⽎ߦᤘ๺ 59 ᐕᐲ߆ࠄᲤᐕ㐿⻠ߒߡ߅ࠅ㧘ᐔᚑ 14 ᐕᐲ߆ࠄߪ࿾
ၞ૑᳃ߩᦝߥࠆℂ⸃ࠍᓧࠆߚ߼౏㐿⻠ᐳࠍකቇᏒ᳃⻠ᐳߣ⒓ߒߡήᢱ㐿⻠ߒߡ޿ࠆ‫ޕ‬൐㓸ੱຬߦኻߔ
ࠆฃ⻠⠪ᢙߪ㧘ήᢱ㐿⻠ࠍᆎ߼ߡએ᧪߶߷ 100㧑㧔ᐔᚑ 19 ᐕᐲߪᄢ᏷ߦ൐㓸ੱຬࠍჇ߿ߒߚߚ߼⧯
ᐓਅ࿁ߞߡ޿ࠆ߇㧕ߢ޽ࠅ㧘ᧄቇㇱߩ౏㐿⻠ᐳ߇࿾ၞ૑᳃ߦᶐㅘߒℂ⸃ࠍᓧࠄࠇߡ᧪ߚߎߣࠍ␜ߒߡ
޿ࠆ‫ߚ߹ޕ‬㧘ᐕ㦂᭴ᚑߪਛ࡮㜞ᐕጀߦ㓸ਛߒߡ޿ࠆߚ߼㧘ࠕࡦࠤ࡯࠻ߥߤࠍෳ⠨ߦ㧘࠹࡯ࡑ߿㐿⻠ᣣ╬ߦᎿᄦࠍߒߡ㧘ࠃࠅ৻ጀ㧘᏷ᐢߊ㧘࿾ၞ␠ળߦฃߌ౉ࠇࠄࠇࠆ౏㐿⻠ᐳࠍ⋡ᜰߒߡ޿ࠆ‫ޕ‬㧙㧙౏㐿⻠ᐳߩታᣉ⁁ᴫ࠹‫ࡑޓ࡯ޓ‬

൐㓸
ੱຬ

ᐔᚑ 13
ᐕ ᐲ

↢ᵴ⠌ᘠ∛㨪ߥࠄߥ޿ߚ߼ߦ㧘ߥߞߚࠄߤ߁ߔࠆ㨪

70

ᐔᚑ 14
ᐕ ᐲ

ᔃりߣ߽ߦஜ߿߆ߥ
ሶଏߦ㨪ⷫߩ㗿޿㨪

70

ᐔᚑ 15
ᐕ ᐲ

ᔃߩஜᐽߣ∛᳇

70

ᐔᚑ 16
ᐕ ᐲ

りߦߟߌߚ޿ᢇᕆᔕ
ᕆᚻᒰ

70

ᐔᚑ 17
ᐕ ᐲ

♧ዩ∛

70

ᐔᚑ 18
ᐕ ᐲ

߇ࠎ

90

ᐔᚑ 19
ᐕ ᐲ

ࡔ࠲ࡏ࡝࠶ࠢࠪࡦ࠼ࡠ࡯ࡓ

150

ᐔᚑ 20
ᐕ ᐲ

⹺⍮∝

150

↳‫ޓ‬ㄟ‫ޓ‬⠪‫ޓ‬ᢙ
↵

ᅚ

27

24

52.90% 47.10%
1660

21.10% 78.90%
28

56

33.3%

66.7%

22

47

31.9%

68.1%

27

44

38.0%

62.0%

41

49

45.5%

54.5%

72

69

51.1%

48.9%

78

88

47.0%

53.0%

⸘
51
76
84
69
71
90
141
166

ᐕ‫ޓޓޓ‬㦂‫ޓޓޓ‬᭴‫ޓޓޓ‬ᚑ
10 ᱦ
ઍ
㧙

20 ᱦ
ઍ
3
5.90%

3

11

30 ᱦ
ઍ

40 ᱦ
ઍ

50 ᱦ
ઍ

60 ᱦ
ઍ

70 ᱦ
ઍ

4

6

15

15

8

7.80% 11.80% 29.40% 29.40% 15.70%
11

24

17

8

2

3.90% 14.50% 14.50% 31.60% 22.40% 10.50% 2.60%
1

5

6

14

30

20

8

1.2%

6.0%

7.1%

16.7%

35.7%

23.8%

9.5%

1

9

3

7

16

22

11

1.4%

13.0%

4.4%

10.2%

23.2%

31.9%

15.9%

1

4

2

7

14

31

12

1.4%

5.6%

2.8%

9.9%

19.7%

43.7%

16.9%

㧙
㧙
㧙

7

4

14

20

27

15

7.8%

4.4%

15.6%

22.2%

30%

16.7%

7

6

22

23

49

32

5.0%

4.3%

15.6%

16.3%

34.8%

22.7%

1

8

24

28

56

45

0.6%

4.8%

14.5%

16.9%

33.7%

27.1%

̪ᵈ‫ޓ‬ᐕ㦂᭴ᚑߪᧂ࿁╵⠪෸߮྾ᝥ੖౉ߒߡ޽ࠆߚ߼ว⸘ߒߡ߽ 100% ߦߥࠄߥ޿႐ว߇޽ࠅ߹ߔ‫ޕ‬

2. ࿾ၞ␠ળߢߩᵴേ⁁ᴫ‫ޓ‬ઁᄢቇ╬ߩ㕖Ᏹൕ⻠Ꮷ෸߮∛㒮㧘⸻≮ᚲߩ㕖ᏱൕකᏧߣߒߡᵴേߒߡ޿ࠆ‫ޕ‬߹ߚ㧘ጘ㒂⋵߿ઁ⋵ߩ⋴⼔දળߩᢎ⢒ߦ㑐ߔࠆડ↹߿∛㒮ߩ⋴⼔⡯ߥߤ߳ߩ⃻છ⠪ᢎ⢒ߦ⻠Ꮷߣߒߡᵴേ෸߮∛㒮ߩ⋴⼔⡯ߦኻߔࠆ⎇ⓥᜰዉࠍⴕߞߡ޿ࠆ‫ޕ‬

3. ↢ᶦቇ⠌߳ߩኻᔕ⁁ᴫක≮ࠍขࠅᏎߊ⢛᥊߇ᕆㅦߦㅴᱠߒߡ޿ࠆਛߢ㧘৻⥸ੱߩஜᐽߦኻߔࠆ㑐ᔃߩ㜞߹ࠅߣ౒ߦ㧘කቇ࡮⋴⼔ߪ␠ળੱᢎ⢒ߩ㊀ⷐߥ࠹࡯ࡑߩ৻ߟߣߥߞߡ߈ߡ߅ࠅ㧘ߎࠇߦኻߒߡ㧘࿾ၞ߿ฦ⒳࿅૕╬ߦ߅ߌࠆ↢ᶦቇ⠌߳ߩදജߦߟ޿ߡⓍᭂ⊛ߦኻᔕߒߡ޿ࠆ‫ޕ‬ҋᐔᚑ 20 ᐕᐲߦ߅ߌࠆ⻠Ꮷߣߒߡߩኻᔕ⁁ᴫҌ㧔කቇ㧕٤⎇ⓥળ㧔ో࿖ᄢቇ଻ஜ▤ℂදળ᧲ᶏ࡮ർ㒽࿾ᣇㇱળ଻ஜ▤ℂᜂᒰ⡯╬ᡷ▽⎇ⓥળ㧘ጘ㒂࿾඙༎ᕷኻ╷ද⼏ળ⎇ⓥળ㧘ጘ㒂⋵଻㒾කදળ㧘⢄ߣ఺∉⎇ⓥળ㧘የᒛ↢ᵴ⠌ᘠ∛⎇ⓥળ㧘ᐢፉᅚቇ㒮ਛቇ㜞╬ቇᩞ㧘᧲ർઍ⻢⇣Ᏹ∝ᴦ≮⎇ⓥળ㧘ක≮ᴺੱᄢ㓶ળ㧘⠧ᐕ∔ᖚ⎇ⓥળ㧘ᗲ⍮ 㧹㧰㧿 ⎇ⓥળ㧘␠࿅ᴺੱ߽ߣߔකᏧળ㧘㧺㧼㧻 ᴺੱ⥃ᐥ⎇ⓥ࡮ᢎ⢒ᡰេ࠮ࡦ࠲࡯ක≮⚻༡ᢎ⢒⎇ⓥળ㧘౓ᐶ⋵ࠕ࠹࡟࠶ࠢ
⎇ⓥળ㧘ጘ㒂ᔃ⤳∛⎇ⓥળ㧘ጘ㒂≸⎇ⓥᙣ⹤ળ㧘㧳㨁 ⎇ⓥળ㧘ᣣᧄᶖൻེ∛ቇળ᧲ᶏᡰㇱ㧘⥃ᐥࠕ࡟࡞ࠡ࡯ቇળ⎇ⓥળ㧔㑐⷏㧕㧘ᣣᧄࠕ࡟࡞ࠡ࡯දળ㑐⷏ᡰㇱ㧘ጘ㒂⋵⡊㥦ຜ༄ળකળ㧘ጊญ⋵⣶∩⎇ⓥળ㧘㕒ጟ⋵∛㒮⮎೷Ꮷળ⷏ㇱᡰㇱ㧘ጘ㒂ஜᐽኼ๮ࠍ⠨߃ࠆળ㧘ጘ㒂↥⑼ᇚੱ⑼⎇ⓥળ㧘࠺ࠖ࠽ࠥࠬ࠻
⎇ⓥળ㧘⴫⊹⚦⢩⎇ⓥળ㧘ጘ㒂⢄Ἳࡈࠜ࡯࡜ࡓ㧘ጘ㒂ࡑ࡞࠴ࡊ࡞࡝ࠬࠢࡈࠔࠢ࠲࡯⎇ⓥળ㧘᛫ࠨࠗ࠻
ࠞࠗࡦ≮ᴺ⎇ⓥળ㧘ጘ㒂ᔃ⤳ⴊ▤⎇ⓥળ㧘ᣣᧄࠢ࡜ࡒࠫࠕ⎇ⓥળ㧘ળᵤ᳇ಽ㓚ኂ⎇ⓥળ㧘ർ㒽ᓴⅣ㓚ኂ⎇ⓥળ㧘ࡠ࠽࠮ࡦ⎇ⓥળ㧘ጘ㒂⤟⤳ᄖ⑼⎇ⓥળ㧘᧲ᶏࠢࡕ⤑ਅ಴ⴊ⎇ⓥળ㧘᧲੩ࡠࠗࠦ࠻࡝ࠛࡦ⎇ⓥળ㧘ጘ㒂ᔃ⤳∛⎇ⓥળ㧘ጘ㒂ਇᢛ⣂⎇ⓥળ㧘ጘ㒂⋵⊹⤏⑼㧘ጘ㒂࠼ࡊ࡜࡮ᔃࠛࠦ࡯⎇ⓥળ㧘␹⚻⮎ℂ⎇ⓥળ㧘ጘ㒂ᴲዩེ⑼ᚻⴚᚻᛛ⎇ⓥળ㧘ዊ⢩૕ࠬ࠻࡟ࠬ⎇ⓥળ㧘஻ᓟ਄ㇱᶖൻ▤∔ᖚ⎇ⓥળ㧘ࡉ࡟ࠗࡦࠕ࠲࠶ࠢࠞࡦࡈࠔ࡟ࡦࠬ⎇ⓥળ㧘࠾ࠦ࡜ࡦࠫ࡞⎇ⓥળ㧘᧲ᶏ⥃ᐥㆮવ࡮ઍ⻢ᙣ⹤ળ㧘ፉᩮዩ〝∔㧙㧙ᖚ⎇ⓥળ㧘᧲ᶏࡄ࡯ࠠࡦ࠰ࡦ∛⎇ⓥળ㧘ጘ㒂ᘟᕈ⢄∔ᖚ∛ᘒᴦ≮⎇ⓥળ㧘ߟ߈ߓ᡼኿✢⎇ⓥળ㧘ጘ㒂↢ᵴ⠌ᘠ∛ᙣ⹤ળ㧘᧲ᶏ㗡㗪ㇱ≸ൻቇ≮ᴺ⎇ⓥળ㧘ᗲᇫ⢄ਇో⎇ⓥળ㧘⢄ਇోᴦ≮▤ℂ⎇ⓥળ㧘ጘ㒂㧿㧲㧵 ⎇ⓥળ㧘ጘ㒂ࠛࡇ࡟ࡊࠪ࡯⎇ⓥળ㧘ጘ㒂ⴊᶧ∔ᖚ⎇ⓥળ㧘᧲ർ⣖ 㧿㧼㧱㧯㨀 ⎇ⓥળ㧘ጘ㒂♧ዩ∛≮ᴺ⎇ⓥળ㧘᧲ᶏ Vacular Medicine ⎇ⓥળ㧘ฬฎደ⥃ᐥᴲዩེ⑼ᙣ⹤ળ㧘ጘ㒂 㨂㧿㧭 ⎇ⓥળ㧘
㕒ጟක⑼ᱤ⑼ㅪ៤ߩળ㧘߻ߨߣ߅ߥ߆ߩකቇࠍቇ߱ળ㧘ጘ㒂ᔃਇో⎇ⓥળ㧘ᾢᧄ↹௝⸻ᢿ࠹ࠢࡁࡠ
ࠫ࡯⎇ⓥળ㧘⢄⤳∛⎇ⓥળ㧘ᣣᧄ㓸ਛᴦ≮කቇળ᧲ᶏർ㒽࿾ᣇળ㧘ᄹ⦟✚ว⸻≮⎇ⓥળ㧘ጘ㒂ឃዩ㓚ኂ⎇ⓥળ㧘ጘ㒂ᓴⅣེ∔ᖚ⎇ⓥળ㧘᧲ᶏ 㧴㧵㨂 ᗵᨴ∝⎇ⓥળ㧘᧲ᶏ⸻≮ᔃ⤳∛ᙣ⹤ળ㧘৻ችᏒකᏧ
ળ㧘ጘ㒂๭ๆེౝ⑼⎇ⓥળ㧘♧ዩ∛ᕈ࠻࡝ࠝࡄ࠴࡯⎇ⓥળ㧘ዩ〝ᖡᕈ⣲≌⎇ⓥળ㧘ࠝࡈ࠲࡞ࡕ࠾ࡘ࡯
ࡊࡠ࠹࡚ࠢࠪࡦ⎇ⓥળ㧘༎ᕷ࡝ࡕ࠺࡝ࡦࠣ⎇ⓥળ㧘ർା♖␹⑼⸻≮ᚲකળ㧘஻ᓟ⢄⢙⤟⎇ⓥળ㧘੩ㇺᶖൻེ≸ᴦ≮⎇ⓥળ㧘᧲ᶏࠬ࠻࡯ࡑ࡝ࡂࡏ࡝࠹࡯࡚ࠪࡦ⎇ⓥળ㧘ጘ㒂 㧯㨂㧰 ᄖ⑼⎇ⓥળ㧘ጘ㒂⣢ਇో⎇ⓥળ㧘ጘ㒂࠼ࡊ࡜࡮ᣣᧄญ⣧ᄖ⑼ቇળਛㇱ࿾ᣇળ㧘ጘ㒂ዊఽࠕ࡟࡞ࠡ࡯࡮༎ᕷ⎇ⓥળ㧘⑔੗ᓴⅣེหᅢળቇⴚ⎇ⓥળ㧘ጘ㒂ᴲዩེ⑼౒ห⎇ⓥળ㧘ጘ㒂ᄖ⑼ଚⷅ⎇ⓥળ㧘㧞ᰴᕈ㜞ⴊ࿶ࠍ⠨߃ࠆળ㧘㧽㧻㧸 ⎇ⓥળ㧘ጘ㒂⹺⍮∝ࡀ࠶࠻ࡢ࡯ࠢ⎇ⓥળ㧘ጘ㒂ᔃ࡮ⴊ▤⎇ⓥળ㧘೽↲⁁⣼ᯏ⢻⎇ⓥળ㧘⤔⾰ャⴊ≮ᴺߦ㑐ߔࠆ⎇ⓥળ㧘ᄢಽ߼߹޿⎇ⓥળ㧘㜞ጊᏒකᏧળ㧘ጘ㒂⋵∛㒮⮎೷Ꮷળ㧘ጘ㒂ᄢ⣺∔ᖚ⎇ⓥળ㧘ጘ㒂⥃ᐥャⴊ⎇ⓥળ㧘ጘ㒂⣖⣲≌⎇ⓥળ㧘᧲ᶏ㔍ᴦᕈⴊᶧ⎇ⓥળ )٤⻠Ṷળ㧔⠀ፉᏒකᏧળ㧘⠀ፉ㇭කᏧળ㧘․ቯ㕖༡೑ᵴേᴺੱࠕ࡟࡞ࠡ࡯ᡰេࡀ࠶࠻ࡢ࡯ࠢ㧘ᄢ၂ࡠ࡯࠲࡝࡯ࠢ࡜ࡉ㧘ᣣᧄዊఽ⑼ቇળጤᚻ࿾ᣇળ㧘ጘ㒂࿾඙ᄖ⑼ᙣ⺣ળ㧘ฦോේᏒ␠ળ⑔␩ද⼏ળ⯃ේධㇱᡰㇱ㧘ฦോේᏒ␠ળ⑔␩ද⼏ળየፒᡰㇱ㧘ጘ㒂⋵කᏧળ㧘㚅Ꮉ⋵ᄢᚻ೨㜞᧻ਛቇ࡮㜞╬ቇᩞ㧘ᄢጘකળ㧘␹ᚭᏒ⌒⑼කળ㧘ጘ㒂⋵ౝ⑼කળ㧘⟤ỚᏒ㧘ᣣᧄ⣖␹⚻ⴊ▤ౝᴦ≮ቇળ㧘㘧㛗Ꮢቇᩞ଻ஜળ㧘ၯ₹⋵⌒⑼කળ㧘␠࿅ᴺੱᣣᢛ᧲ᶏࡉࡠ࠶ࠢળ㧘ਛㇱធ㛽ቇળ㧘ฦോේᏒකᏧળ㧘ጘ㒂ᏒකᏧળ♖␹⑼කળ㧘␠࿅ᴺੱጘ㒂⋵ෂ㒾‛቟ోදળ㧘ᣣᧄ↢ᵴදห⚵ળㅪวળኅᐸක≮ቇ㐿⊒࠮ࡦ࠲࡯㧘⮮↰଻ஜⴡ↢ᄢቇ㧘ਃ㊀♖␹කળ㧘๺᱌ጊ⋵┙ᣣ㜞╬ቇᩞ㧘ጘ㒂⋵┙ጘ㒂㜞╬ቇᩞ㧘ጘ㒂Ꮢ଻ஜᚲ㧘ᄢญ↸ߊࠄߒ෹ߩળ㧘ᣣᧄᴲዩེ⑼ቇળ᧲ᶏ࿾ᣇળ㧘␠࿅ᴺੱᣣᧄ㤗㈮⑼ቇળ㧘ਅํᏒකᏧળ㧘␠࿅ᴺੱឳ
᢫㇭කᏧળ㧘ฦോේᏒ┙⯃ේ╙ੑዊቇᩞ㧘㑐⷏ක⑼ᄢቇ㧘ጘ㒂ධࡠ࡯࠲࡝࡯ࠢ࡜ࡉ㧘ጘ㒂⋵ஜᐽ⑔␩ㇱ㧘ጘ㒂⋵ᢎ⢒ᆔຬળ㧘ᄹ⦟⋵┙ක⑼ᄢቇ㧘ᣣᧄᢇᕆ⋴⼔ቇળ㧘ጘ㒂⋵┙ጘ㒂ㄘᨋ㜞╬ቇᩞ㧘৻ችᏒ┙ᧁᦥᎹᏒ᳃∛㒮㧘ᄢ၂∛㒮㧘⷏Ớ∛㒮㧘ጘ㒂⋵කᏧળᄖ⑼කㇱળ㧘ጘ㒂⋵කᏧળഭἴᜰቯකㇱળ㧘
␠࿅ᴺੱጘ㒂∛㒮㧘ߩߙߺߩਐࡎࠬࡇ࠲࡞㧘㚅Ꮉ⋵ᴲዩེ⑼කળ㧘ᄢḟ∛㒮㧘㑐⷏ක⑼ᄢቇ㧘ᘏᕺਛᄩ∛㒮㧘᧙㊁ળฦോේ∛㒮㧘ਇ⎕ࡁ㑐∛㒮㧘ో࿖ᄢቇ଻ஜ▤ℂදળ᧲ᶏ࡮ർ㒽࿾ᣇㇱળ㧘⡛චሼ∛㒮㧘ਅํ⼱ᢝ∛㒮㧘㗇↰∛㒮㧘㤥㊁∛㒮㧘㔍⡬ᐜఽㅢ࿦ᣉ⸳ߺ߿ߎ࿦㧘․ቯ㕖༡೑ᵴേᴺੱ⥃ᐥ⹜㛎⎇ⓥ
ᡰេᯏ᭴㧘ጘ㒂⋵⌒⑼ቇળ㧘ጘ㒂⋵♖␹⑼∛㒮දળ㧘Ꮢ┙ᕺ㇊∛㒮㧘ᧁᴛ⸥ᔨ∛㒮㧘ਛㇱᣣᧄᢛᒻᄖ
⑼ἴኂᄖ⑼ቇળ㧘⥃ᐥᶖൻེ∛ࡈࠜ࡯࡜ࡓ㧘߆ߕߐ⣖ⴊ▤㓚ኂᙣ⹤ળ㧘ጘ㒂⋵⡊㥦ຜ༄⑼කળ㧘ጘ㒂ᗵᨴ∝࡮ൻ≮ࡈࠜ࡯࡜ࡓ㧘∛ᘒࠍᡷༀߔࠆ♧ዩ∛ᴦ≮ᐳ⺣ળ㧘㗖േ⣂∔ᖚࡈࠜ࡯࡜ࡓ㧘ጘ㒂Ꮢౝ⑼ળ㧘ᵤᏒ⌒⑼⥃ᐥᙣ⹤ળ㧘ᣣᧄᶖൻེ∛ቇળ᧲ᶏᡰㇱ㧘⑔ጟධㇱ⣖␹⚻ᄖ⑼ᙣ⹤ળ㧘ᣣᧄකᏧળ㧘ጘ㒂๭ๆེᙣ⹤ળ㧘ጘ㒂⋵ߩᔃ∔ᖚࠍ⠨߃ࠆળ㧘ർᶏ㆏කᏧળ㧘ᧅᏻᏒකᏧળ㧘ጘ㒂⮎⑼ᄢቇ )٤ቇⴚ⻠Ṷળ㧔ᴒ✽⌒⑼කળ㧘㐳ፒ⋵⌒⑼කળ㧘᧲ᶏ࠮ࡠ࠻࠾ࡦ⎇ⓥળ㧘ጘ㒂⋵⣖තਛ࡮ⴊ▤ౝᴦ≮ᙣ⹤ળ )
٤⎇ୃળ㧔␠࿅ᴺੱጘ㒂⋵⮎೷Ꮷળ㧘␠࿅ᴺੱጊ᪸⋵⋴⼔දળ㧘ጘ㒂⋵ᶖ㒐ቇᩞ㧘ጘ㒂⋵කᏧળ㧘ጘ㒂⋵㔍ᴦ∛ක≮ㅪ⛊ද⼏ળ㧘࿖᳃ஜᐽ଻㒾㑐ࡩේ∛㒮㧘ጘ㒂⋵଻⢒⎇ⓥද⼏ળ㧘ฦോේᏒ᳃↢ᆔຬఽ┬ᆔຬද⼏ળ㡻ᴧਛ࿾඙㧘␠࿅ᴺੱጘ㒂⋵⋴⼔දળ㧘ਛㇱ࿾඙⥃ᐥᬌᩏᛛᏧળ㧘㕒ጟ⋵┙✚ว∛㒮㧘ጘ㒂⋵⼊ኤᧄㇱ㧘ᅏ⠀ᄢቇᱤቇㇱᣂẟ⋵ᡰㇱ㧘ᄢ၂Ꮢ᳃∛㒮㧘ᣣᧄ∛㒮⮎೷Ꮷળ㧘ᣣᧄ⛎㘩⚻༡▤ℂቇળ㧘␠࿅ᴺੱ౓ᐶ⋵⋴⼔දળ㧘྾࿖▤඙⼊ኤቇᩞ㧘᦭㒢⽿છਛ㑆ᴺੱᣣᧄஜᐽ࡮ᩕ㙃ࠪࠬ࠹ࡓቇળ㧘
␠ળ⑔␩ᴺੱᕲ⾦⽷࿅Უሶᗲ⢒ળ✚วᲣሶ଻ஜ࠮ࡦ࠲࡯㧘ጘ㒂⋵කᏧળ↥ᬺකㇱળ㧘ࠡࡈࠤࡦᢎ⢒ᆔ㧙㧙ຬળᢎ⢒⎇ୃ⺖㧘ጘ㒂⋵଻⢒⎇ⓥද⼏ળ㧘ጘ㒂⋵␠ળ⑔␩ද⼏ળᣉ⸳࿅૕ᝄ⥝ㇱ㧘ߩߙߺߩਐࡎࠬࡇ
࠲࡞㧘᧲ᶏ࿾඙ᢛᒻᄖ⑼ᢎ⢒⎇ୃળ㧘ጘ㒂⋵✚วක≮࠮ࡦ࠲࡯㧘ṑ⾐⋵ක⑼ᄢቇ㧘ᣣᧄ♖␹⑼∛㒮දળ )٤⻠⠌ળ㧔⨙ၔ⋵කᏧ⥃ᐥ⎇ୃㅪ⛊ද⼏ળ㧘␠࿅ᴺੱᣣᧄᗵᨴ∝ቇળ㧘޽޿ߜዊఽ଻ஜක≮✚ว࠮ࡦ࠲࡯଻ஜ࠮ࡦ࠲࡯଻ஜቶ㧘ጘ㒂Ꮢ଻ஜᚲ㧘ᗲ⍮⋵ᤨ⠌㙚㜞╬ቇᩞ㧘⷏ᣣᧄ߇ࠎ⎇ⓥᯏ᭴㧘ጘ㒂ᄢቇ࿾ၞ⑼ቇㇱ㧘␠࿅ᴺੱᣣᧄ੤ㅢ⑔␩දળ㧘㧺㧼㧻 ᴺੱ⮎ቇ౒↪⹜㛎࠮ࡦ࠲࡯㧘Ꮲ੩ᄢቇ⮎ቇㇱ㧘␠࿅
ᴺੱጘ㒂⋵⋴⼔දળ㧘ో࿖ᱤ⑼ⴡ↢჻ᢎ⢒ද⼏ળ㧘ਛᵤᎹᏒ᳃∛㒮㧘㆏〝Ꮏ੐቟ోᛛⴚᆔຬળ㧘)٤⹺⍮∝㜞㦂⠪ኻᔕ੺⼔ᡰេኾ㐷ຬ⎇ୃ㧔␠ળ⑔␩ᴺੱጘ㒂⋵␠ળ⑔␩ද⼏ળ )٤౏㐿⻠ᐳ࡮Ꮢ᳃⻠ᐳ㧔੺⼔⠪ኅᣖߩળ㧘⑺↰⋵┙⣖ⴊ▤⣖⎇࠮ࡦ࠲࡯㧘ᣣᧄ๭ๆེቇળ᧲ᶏᡰㇱળ㧘᣿ᣣߩ੃߇ࠎࠍ⠨߃ࠆળ㧘㜞ጊᏒᓎᚲஜᐽផㅴ⺖㧕٤ታ࿾ᜰዉ㧔ጘ㒂⋵ஜᐽ⑔␩ㇱ㧕㧔⋴⼔㧕٤⻠Ṷળ㧔ဈ␸↸ᢎ⢒ᆔຬળ㧘␠࿅ᴺੱጘ㒂⋵⋴⼔දળ㧘ਛᄩഭ௛ἴኂ㒐ᱛදળጘ㒂⋵ᡰㇱ㧘ጘ㒂⋵ஜᐽ࡟ࠢ࡝ࠛ࡯࡚ࠪࡦදળ㧕٤⎇ୃળ㧔᧲੩ㇺ↥ᬺ଻ஜஜᐽ⸻ᢿᯏ㑐ㅪ⛊ද⼏ળ㧘␠࿅ᴺੱጘ㒂⋵⋴⼔දળ㧘␠࿅ᴺੱᣣᧄ♖␹⑼⋴⼔ᛛⴚදળጘ㒂ᡰㇱ㧘␠࿅ᴺੱ㕒ጟ⋵⋴⼔දળ㧘ᦺᣣᄢቇᱤቇㇱ㒝ዻ᧛਄⸥ᔨ∛㒮㧘ጘ㒂⋵කᏧળ↥ᬺකㇱળ㧘㑐ਛᄩ∛㒮㧘ጘ㒂⋵✚วක≮࠮ࡦ࠲࡯㧘ጘ㒂⋵଻ஜක≮⺖ஜᐽჇㅴ㧕٤⻠⠌ળ㧔␠࿅ᴺੱጘ㒂⋵⋴⼔දળ㧘ᗲ⍮⋵⋴⼔⎇ୃ࠮ࡦ࠲࡯㧕٤Ꮢ᳃⻠ᐳ㧔␠࿅ᴺੱᢕ⾐ᏒකᏧળ㧕

4. ᅏⓄ㜞ጪᄐጊ⸻≮ᚲ
ᅏⓄ㜞ጪᄐጊ⸻≮ᚲߪ㧘ጘ㒂⋵┙ක⑼ᄢቇᤨઍߩ 1958 ᐕ 7 ᦬ߦ㐿⸳ߐࠇ㧘੹ᐕߢ 51 ࿁⋡ߩ⸻≮⃰ࠍᵷ㆜ߒߚߎߣߦߥࠆ‫ޕ‬ೋᐕᐲߪ⾗㊄㕙ߢߩ⧰ഭ߽޽ߞߚ߇㧘9 ⃰✬ᚑߢ 7 ᦬ 10 ᣣ߆ࠄ 8 ᦬ᧃ߹ߢᶏᛮ 3,000m ߩ㔕ߩ਄ߢᄙߊߩᖚ⠪ߩᚻᒰߡࠍⴕߞߚ‫ޕ‬ߎߩᄐጊ⸻≮ᚲߪ㧘੹↰㊀ᄥ㇢᳁㧔ᐔᚑ 5 ᐕ 8 ᦬ 31 ᣣㅤ෰ 94 ᱦ㧕ߩ౻ቄㆱ㔍ዊደߢ޽ࠅ㧘ήఘߢឭଏߒߡ޿ߚߛ޿ߚ‫ޕ‬ᄐጊ⸻≮ᚲߩᵴേߪ㧘NHK ߩᣣᧄ߹ࠎߥ߆♿ⴕ‫ޟ‬㔕ߩ਄ߩ⸻≮ᚲ㨪ർࠕ࡞ࡊ
ࠬᅏⓄ㜞ጪ㨪‫ߦޠ‬ขࠅ਄ߍࠄࠇࠆߥߤ㧘ߘߩᵴേߪቇౝᄖߦ⍮ࠄࠇࠆߣߎࠈߣߥࠅ㧘ᧄቇߦߣߞߡ৻
ߟߩ㊀ⷐߥ␠ળ⽸₂੐ᬺߣߥߞߡ޿ࠆ‫ޕ‬ߎߩࠃ߁ߦ⸻≮ᵴേߩഞ❣߇⹺߼ࠄࠇ㧘⃻࿷㧘⾗㊄㕙ߢߪ㧘GM ળ㧔ጘ㒂ᄢቇකቇㇱකቇ⑼ᓟេ
ળ㧕㧘⽷࿅ᴺੱ⺈ੳળ㧘ጘ㒂⋵ጊጪㆣ㔍㒐ᱛኻ╷ද⼏ળ㧘㐳㊁⋵ጊጪㆣ㔍㒐ᱛኻ╷දળ㧘ᅏⓄ㜞ጪጊ⨿෸߮㜞ጊᏒ߆ࠄߩេഥ߇ᓧࠄࠇࠆࠃ߁ߦߥߞߚ‫ޕ‬⸻≮ᚲߩㆇ༡ߦߟ޿ߡߪ㧘1976 ᐕߦ‫ޟ‬ᅏⓄ㜞ጪᄐጊ⸻≮ᚲㆇ༡ߦ㑐ߔࠆ↳วߖ‫ࠍޠ‬೙ቯ㧘ߐࠄߦ㧘
2001 ᐕߦߪ‫ޟ‬ጘ㒂ᄢቇකቇㇱᅏⓄ㜞ጪᄐጊ⸻≮ᚲⷙ⒟‫ࠍޠ‬೙ቯߒߡ㧘หᐕ⸳⟎ߒߚࠬࡐ࡯࠷ක⑼ቇ
ಽ㊁ߦࠃࠆ㜞ጊ∛ߩታᘒㅊ〔⺞ᩏߥߤ㧘ቇㇱࠍ਄ߍߡขࠅ⚵ࠎߢ޿ࠆ‫ޕ‬⸻≮⃰ߪ㧘කᏧ 2 ੱ㧘⋴⼔Ꮷ 1 ੱ㧘ቇ↢ 4 ੱࠍ 1 ⃰ߣߔࠆ 8 ⃰ࠍ✬ᚑߒߡ 7 ᦬ 20 ᣣ߆ࠄ 8 ᦬ 20ᣣ߹ߢ⸻≮ᵴേࠍⴕߞߡ߈ߚ‫ߚ߹ޕ‬㧘⷏ᣣᧄක⑼ቇ↢૕⢒ᄢળߦෳടߔࠆቇ↢ߩㇺว╬ߦࠃࠅ㧘1992ᐕ߆ࠄߪ 7 ⃰✬ᚑߢ 7 ᦬ 25 ᣣ߆ࠄታᣉߒߡ޿ߚ߇㧘7 ᦬ 21 ᣣߩભᣣ೨ᓟࠍႺߦ౉ጊ⠪߇Ⴧടߔࠆ⁁ᴫ߽޽ࠅ㧘2000 ᐕ߆ࠄߪ㧘8 ⃰✬ᚑߦࠃࠆ 7 ᦬ 20 ᣣ߆ࠄߩᵷ㆜ߦᚯߒߡ޿ࠆ‫ޕ‬ᄐጊ⸻≮ᚲߣߒߡ೑↪ߒߡ޿ࠆ౻ቄㆱ㔍ዊደߪ㧘1995 ᐕߦ✚᪍ㅧࠅߢᑪߡᦧ߃ࠄࠇ㧘ᐢߐ߽ᓥ᧪
ߩ 1.5 ୚ߣߥࠅർࠕ࡞ࡊࠬ㓐৻ߩᣉ⸳ߣߥߞߚ‫ޕ‬㧙㧙ෳട⠪ߩಣㆄ╬ߦ໧㗴ὐ߽޽ࠆ߇㧘㍈ᗧദജߒߡ⸃᳿ࠍ࿑ࠅ㧘⡯ຬ㧘ቇ↢ߩදജࠍᓧߡ࿾ర㧘⊓ጊ⠪╬ߩᏗᦸߦᔕ߃ߡ੹ᓟ߽⛮⛯ߒߡ޿߈ߚ޿‫ޕ‬ߥ߅㧘1998 ᐕ 11 ᦬ 25 ᣣߦ㧔⽷㧕࠰ࡠࡊ࠴ࡒࠬ࠻ᣣᧄ⽷࿅ࠃࠅ㧘‫ޟ‬ᐔᚑ 10 ᐕᐲ㕍ዋᐕࡏ࡜ࡦ࠹ࠖ
ࠕ⾨‫ࠍޠ‬ฃ⾨ߒߡ޿ࠆ‫ߚ߹ޕ‬㧘2008 ᐕ 11 ᦬ 30 ᣣߦߪ㧘㐿⸳ 50 ๟ᐕ㧔2007 ᐕ㧕ࠍ⸥ᔨߒߡ㧘ጘ㒂ㇺࡎ࠹࡞ߦ߅޿ߡ㑐ଥ⠪෸߮৻⥸ߩᣇ‫ࠍޘ‬ኻ⽎ߦ㧘੹↰⧷㓶᳁㧔ᅏⓄ㜞ጪጊ⨿ࠝ࡯࠽࡯㧕ߦࠃࠆ⸥ᔨ
⻠Ṷળࠍ㐿௅ߒߚ‫ߦࠄߐޕ‬㧘⃻࿷ 50 ๟ᐕ⸥ᔨ⹹ߩ⊒ⴕḰ஻ࠍㅴ߼ߡ޿ࠆߣߎࠈߢ޽ࠆ‫ޕ‬

6▤ℂㆇ༡㧘⽷᡽

1. ᢎ᝼ળ㧔ᢎ᝼ળ⼏㧕㧘ฦ⒳ᆔຬળߩ᭴ᚑߣᵴേ⁁ᴫ
㧔1㧕ᢎ᝼ળ㧔ᢎ᝼ળ⼏㧕ߩ᭴ᚑຬ㧘છോ㧘ᗧᔒ᳿ቯᣇᴺ㧘ᗧᔒવ㆐ᣇᴺ
ᢎ᝼ળ㧔ᢎ᝼ળ⼏㧕ᢎ⢒⎇ⓥᯏ㑐ߣߒߡߩකቇㇱߩ▤ℂ࡮ㆇ༡ߦ㑐ߔࠆ㊀ⷐ੐㗄ࠍክ⼏࡮᳿ቯߔࠆᦨ㜞ክ⼏ᯏ㑐ߣߒߡ㧘߹ߚᧄቇㇱߩ⥄ਥ⊛⥄ᓞ⊛ᗧᕁᒻᚑߔߥࠊߜ⥄ᴦߩၮ␆ࠍߥߔክ⼏ᯏ㑐ߣߒߡකቇㇱᢎ᝼ળ߇⟎߆ࠇߡ޿ߚ߇㧘⋴⼔ቇ⑼ߩ⸳⟎㧔ᐔᚑ 12 ᐕ 10 ᦬㧕㧘කቇ⑼ߩᄢቇ㒮ㇱዪൻ㧔⻠ᐳൻ㧕ߦࠃࠆකቇ⎇ⓥ⑼ߩᡷ⚵㧔ᐔᚑ 16 ᐕ 4 ᦬㧕㧘ᦝߦ㧘⋴⼔ቇኾ᡹ୃ჻⺖⒟ߩ⸳⟎㧔ᐔᚑ 17 ᐕ 4 ᦬㧕෸߮หኾ᡹ߩ⸳⟎ߦ઻޿කቇ⎇ⓥ⑼ࠍකቇ♽⎇ⓥ⑼ߦᡷ⒓ߒ㧘කቇ♽⎇ⓥ⑼࡮කቇㇱߘࠇߙࠇߩ⥄ਥᕈࠍዅ㊀ߒߡ㧘ጘ㒂ᄢቇㆇ༡⚵❱ⷙೣ╙ 18 ᧦╙ 6 㗄ߩⷙቯߦၮߠ߈㧘කቇ♽⎇ⓥ⑼෸߮කቇㇱᢎ᝼ળߦઍ⼏ຬળ╬ߩ૏⟎ߠߌߣߒߡකቇ⎇ⓥ⑼࡮⋴⼔ቇኾ᡹ᢎ᝼ળ⼏ਗ߮ߦකቇ⑼࡮⋴⼔ቇ⑼ᢎ᝼ળ⼏ࠍ⟎߈㧘ߘࠇߙࠇߩኾ᡹࡮ቇ⑼ߩᦨ㜞ክ⼏ᯏ㑐ߣߒߡ޿ࠆ‫ޕ‬ߥ߅㧘ᢎ᝼ળߪ㧘ᔅⷐ߇↢ߓߚ႐วߦකቇ♽⎇ⓥ⑼ᢎ᝼ળߪකቇ♽⎇ⓥ⑼㐳߇㧘කቇㇱᢎ᝼ળߪක
ቇㇱ㐳߇ߘࠇߙࠇถ㓸ߒ㧘㐿௅ߔࠆߎߣߣߒߚ‫ޕ‬⚵❱ㆇ༡╬ߦߟ޿ߡߪ㧘ጘ㒂ᄢቇㆇ༡⚵❱ⷙೣ㧘ጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼࡮කቇㇱㆇ༡⚵❱ⷙ⒟㧘ጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼ᢎ᝼ળⷙ⒟෸߮ጘ㒂ᄢቇකቇㇱᢎ᝼ળⷙ⒟ߦࠃࠅ᣿ᢥൻߒߡ޿ࠆ‫ޕ‬ᢎ᝼ળ⼏ߢߪ㧘ਛᦼ⸘↹෸߮ᐕᐲ⸘↹㧘੍▚㈩ಽ෸߮᳿▚㧘ᢎ⢒♽⡯ຬੱ੐㧘ᢎ⢒⎇ⓥᚢ⇛㧘ᢎ⢒⎇ⓥᣇᴺ෸߮ᢎ⢒⎇ⓥ⚵❱㧘ᢎ⢒⺖⒟ߩ✬ᚑ㧘ቇ↢ߩ౉ቇ㧘තᬺ෶ߪ⺖⒟ߩୃੌ㧘࿷☋෸߮ቇ૏ߩ᝼
ਈ෸߮ᢎ⢒෶ߪ⎇ⓥߦ㑐ߔࠆ㊀ⷐ੐㗄ࠍਛᔃߣߒߚ▤ℂㆇ༡਄ᔅⷐߥ੐㗄߇ክ⼏ߐࠇࠆ‫ߚ߹ޕ‬㧘ᢎ᝼ળ⼏ߢክ⼏ߐࠇࠆ੐㗄ߩਛߩ㊀ⷐߥ᩺ઙߦߟ޿ߡߪ㧘ጘ㒂ᄢቇਗ߮ߦකቇ♽⎇ⓥ⑼࡮කቇㇱߦᏱ⟎ߐࠇߡ޿ࠆฦ⒳ᆔຬળߢክ⼏ߐࠇߚౝኈߩႎ๔ࠍฃߌ㧘ߐࠄߦ㧘කቇ⎇ⓥ⑼ᢎ᝼ળ⼏ߦ߅޿ߡߪ㧘ᔅⷐߦᔕߓಎᢎ᝼࡮⻠Ꮷળ㧔ಎ⻠ળ㧕෸߮ഥᢎળߦ⻁໧ߒ㧘ߘߩ╵↳ࠍฃߌ㧘ߘࠇࠄࠍෳ⠨ߣߒߡߘࠇߙ
ࠇߩᢎ᝼ળ⼏ߢክ⼏ߒ㧘කቇ♽⎇ⓥ⑼࡮කቇㇱߣߒߡߩᗧᔒࠍ᳿ቯߒ㧘߆ߟ㧘᳿ቯߐࠇߚ᩺ઙߦߟ޿
ߡߪ㧘ߘࠇߙࠇฦಽ㊁࡮⻠ᐳ╬ߦવ㆐ߐࠇߡ޿ࠆ‫ޕ‬⚵❱1㧚ᢎ᝼ળ⼏
㧔1㧕 ⎇ⓥ⑼㐳࡮ኾ᡹㐳෸߮ቇ⑼㐳߇ถ㓸ߔࠆ‫ޕ‬
㧔2㧕 ᢎ᝼ળⷙ⒟╙ 3 ᧦ߦⷙቯߔࠆክ⼏੐㗄ߩ߁ߜ㧘ᢎ᝼ળ߇ቯ߼ࠆ੐㗄ߦߟ޿ߡߪ㧘ᢎ᝼ળ⼏ߢክ⼏ߒߚ⚿ᨐࠍ߽ߞߡᢎ᝼ળߩ⼏᳿ߣߔࠆߎߣ߇ߢ߈ࠆ߽ߩߣߔࠆ‫ޕ‬
㧔3㧕 ᭴ᚑຬ㧦කቇ⎇ⓥ⑼ᢎ᝼ળ⼏㧔කቇ♽⎇ⓥ⑼෸߮කቇᢎ⢒㐿⊒⎇ⓥ࠮ࡦ࠲࡯ߩኾછߩᢎ᝼㧕⋴⼔ቇ⑼ᢎ᝼ળ⼏㧔⋴⼔ቇ⑼ߩኾછߩᢎ᝼㧕㧙㧙㧔4㧕 ᚑ┙ⷐઙ㧦᭴ᚑຬߩ 3 ಽߩ 2 એ਄
㧔5㧕 ⼏᳿ⷐઙ㧦಴Ꮸ⠪ߩㆊඨᢙ‫ߒߛߚޕ‬㧘㊀ⷐߥ੐㗄㧔ਥߦᢎຬੱ੐㧕ߦ޽ߞߡߪ಴Ꮸ⠪ߩ 3
ಽߩ 2 એ਄
ੱ੐1㧚කቇ♽⎇ⓥ⑼㐳ߣකቇ⑼㐳ߩ౗છߦߟ޿ߡ
කቇ♽⎇ⓥ⑼㐳ߪ㧘කቇ⑼㐳ࠍ౗છߒ㧘කቇ♽⎇ⓥ⑼ᢎ᝼ળߩ⼏㐳ߣߥࠆ‫ޕ‬
2㧚ᢎຬㆬ⠨
㧔1㧕 කቇ⎇ⓥ⑼෸߮⋴⼔ቇ⑼ߩ⥄ਥᕈࠍዅ㊀ߔࠆߚ߼㧘ᢎ᝼એਅోߡߩᢎຬㆬ⠨ࠍߘࠇߙࠇߩ
ᢎ᝼ળ⼏ߩክ⼏੐㗄ߣߔࠆ‫ޕ‬
㧔2㧕 ㆬ⠨ⷙ⒟╬ߦߟ޿ߡߪ㧘කቇ⎇ⓥ⑼෸߮⋴⼔ቇ⑼ߢ⁛⥄ߦ೙ቯߔࠆ‫ޕ‬
㧔2㧕ฦ⒳ᆔຬળߩ⸳⟎ᐕᐲ㧘છോ㧔ㆇ༡ᣇ㊎㧕㧘ᗧᔒ᳿ቯᣇᴺ㧘ᗧᔒવ㆐ᣇᴺ
ᢎ᝼ળ⼏ߩᗧᔒ᳿ቯࠍ౞Ṗߦߒ㧘කቇ♽⎇ⓥ⑼෸߮⋴⼔ቇ⑼ߩ⚵❱ߩᯏ⢻ࠍචಽߦᨐߚߔߚ߼㧘ጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼࡮කቇㇱᏱ⟎ᆔຬળⷙ⒟ߦࠃࠅ㧘ߘࠇߙࠇ෸߮౒ㅢߩฦ⒳ᆔຬળ߇⚵❱ߐࠇߡ޿ࠆ‫ޕ‬ฦ⒳ᆔຬળߩㆇ༡╬ߪㇱዪౝ⚦ೣ╬ߦࠃࠅ᣿ᢥൻߐࠇ㧘ฦᆔຬળߩክ⼏⚿ᨐ╬ߪ㧘ฦᢎ᝼ળ⼏ߦ⻁ࠄࠇߚᓟ㧘ฦಽ㊁࡮⻠ᐳ╬ߦવ㆐ߐࠇߡ޿ࠆ‫߅ߥޕ‬㧘ᐔᚑ 21 ᐕᐲߦᆔຬળ⚵❱ࠍ৻ㇱ⷗⋥ߔ੍ቯߢ޽ࠆ‫ޕ‬
ฦ⒳ᆔຬળ৻ⷩ
㧔කቇ♽⎇ⓥ⑼࡮කቇㇱ㧕
ฬ⒓

છᦼ

ੱᢙ

ክ⼏੐㗄╬

⸳⟎ᐕᐲ

ડ↹ᆔຬળ

㧙

10 ੱ

කቇ♽⎇ⓥ⑼࡮කቇㇱߩ౞Ṗߥ▤ℂㆇ༡ߦ㑐ߔࠆߎߣ‫ޕ‬

ᐔᚑ 16 ᐕᐲ⥄Ꮖ⹏ଔᆔຬળ

2ᐕ

15 ੱ

ਛᦼ⋡ᮡ෸߮ਛᦼ⸘↹ߦ㑐ߔࠆߎߣ‫ޕ‬

ᐔᚑ 16 ᐕᐲ

ᖱႎᆔຬળ

2ᐕ

11 ੱ

ᖱႎࡀ࠶࠻ࡢ࡯ࠢࠪࠬ࠹ࡓߩ೑
↪㧘ᐢႎᵴേ෸߮࿖㓙੤ᵹ╬ߦ㑐ߔࠆߎߣ‫ޕ‬ᐔᚑ 16 ᐕᐲⅣႺ⸳஻࡮౒ㅢࠬࡍ࡯ࠬ
ᆔຬળ

2ᐕ

6ੱ

ⅣႺ଻ోߩታᣉ෸߮ᣉ⸳⸳஻ߩᵴ
↪ߦ㑐ߔࠆߎߣ‫ޕ‬

ᐔᚑ 16 ᐕᐲ

ቇോᆔຬળ

1ᐕ

10 ੱ

ቇ↢ߩᢎോ࡮ෘ↢෸߮ቇ૏᝼ਈߦ
㑐ߔࠆߎߣ‫ޕ‬ᐔᚑ 16 ᐕᐲേ‛ታ㛎ክᩏᆔຬળ

2ᐕ

9ੱേ‛ታ㛎ᣉ⸳ߩ೑↪෸߮ⅣႺ଻ోߦ㑐ߔࠆߎߣ‫ޕ‬

ᐔᚑ 16 ᐕᐲකቇ⎇ⓥ╬୶ℂክᩏᆔຬ
ળ

2ᐕ

11 ੱ

⎇ⓥߩ⋡⊛෸߮⸘↹ߦߟ޿ߡ㧘୶
ℂ⊛࡮␠ળ⊛ⷰὐ߆ࠄክᩏߔࠆߎߣ‫ޕ‬

ᐔᚑ 16 ᐕᐲࡅ࠻ ES ⚦⢩ߦ㑐ߔࠆ୶
ℂክᩏᆔຬળ

2ᐕ

6ੱ

ࡅ࠻ ES ⚦⢩ߦ㑐ߔࠆ⎇ⓥߩ⋡⊛෸߮⸘↹ߦߟ޿ߡ㧘୶ℂ⊛࡮␠ળ⊛ⷰὐ߆ࠄክᩏߔࠆߎߣ‫ޕ‬

ᐔᚑ 16 ᐕᐲකቇㇱ࡮ห㒝ዻ∛㒮วห㒐ἴ▤ℂᆔຬળ

2ᐕ

14 ੱ

ᢎോෘ↢ᆔຬળ

1ᐕ

11 ੱ

ቇ↢ߩᢎോ෸߮ෘ↢ߦ㑐ߔࠆߎߣ‫ޕ‬

ᐔᚑ 16 ᐕᐲ౉ቇ⹜㛎ᆔຬળ

1ᐕ

7ੱ

౉ቇ⠪ㆬᛮߣታᣉᣇ㊎ߦ㑐ߔࠆߎߣ‫ޕ‬

ᐔᚑ 16 ᐕᐲࠞ࡝ࠠࡘ࡜ࡓᆔຬળ

2ᐕ8ੱᢎ⢒⺖⒟ߦ㑐ߔࠆߎߣ‫ޕ‬

ᐔᚑ 16 ᐕᐲ

㒐ἴ▤ℂߦ㑐ߔࠆߎߣ‫ޕ‬㧙㧙

ᐔᚑ 16 ᐕᐲฦ⒳ᆔຬળ৻ⷩ
㧔කቇ♽⎇ⓥ⑼࡮කቇㇱ㧕
ฬ⒓

છᦼ

ੱᢙ

ክ⼏੐㗄╬

౗ᬺክᩏᆔຬળ

2ᐕ

6ੱ⡯ຬߩ౗ᬺߩขᛒ޿ߦ㑐ߔࠆߎߣ‫ޕ‬

ᐔᚑ 16 ᐕᐲකቇ⎇ⓥ⑼࡮කቇㇱࠝ࡯ࡊࡦ࡜ࡏ࡜࠻࡝࡯೑↪ክ
ᩏᆔຬળ

2ᐕ

8ੱ

ࠝ࡯ࡊࡦ࡜ࡏ࡜࠻࡝࡯૶↪⠪ߩ⹏ଔㆬ⠨ᣇ㊎ߦၮߠߊክᩏߦ㑐ߔࠆߎߣ‫ޕ‬

ᐔᚑ 16 ᐕᐲකቇᢎ⢒㐿⊒⎇ⓥ࠮ࡦ
࠲࡯ㆇ༡ද⼏ળ2ᐕ

13 ੱ੐ᬺߩၮᧄᣇ㊎㧘⎇ⓥ⸘↹෸߮౒ห೑↪ߦ㑐ߔࠆߎߣ‫ޕ‬

ᐔᚑ 16 ᐕᐲකቇᢎ⢒㐿⊒⎇ⓥ࠮ࡦ
࠲࡯ㆇ༡ᆔຬળ

2ᐕ

12 ੱ

කቇᢎ⢒㐿⊒⎇ⓥ࠮ࡦ࠲࡯ߩ⚵❱ㆇ༡╬෸߮ੱ੐ߦ㑐ߔࠆߎߣ‫ޕ‬

ᐔᚑ 16 ᐕᐲකቇ♽⎇ⓥ⑼࡮කቇㇱ቟ోⴡ↢▤ℂᆔຬળ

2ᐕ

9ੱ⡯ຬߩ቟ోⴡ↢ߩ⏕଻෸߮ᡷༀߦ
㑐ߔࠆߎߣ‫ޕ‬ᐔᚑ 17 ᐕᐲㆮવሶᴦ≮⥃ᐥᬌᩏߦߟ޿ߡ↢๮
10 ੱએ਄ ୶ℂ෸߮ක≮ߩ୶ℂߦ㑐ߔࠆ੐㗄
20 ੱએౝ ߇ᴺ઎╬ࠍㆩ቞ߒߡ޿ࠆ߆ክᩏߔ
ࠆߎߣ‫ޕ‬
ၞක≮කቇ࠮ࡦ࠲࡯ߩᬺോ࡮ㆇ༡
෸߮ੱ੐ߦ㑐ߔࠆߎߣ‫ޕ‬
20 ੱ

⸳⟎ᐕᐲ

කቇ♽⎇ⓥ⑼ㆮવሶᴦ≮⥃ᐥ⎇ⓥ୶ℂክᩏᆔຬળ

2ᐕකቇ♽⎇ⓥ⑼࡮කቇㇱ࿾ၞක≮කቇ࠮ࡦ࠲࡯ㆇ༡
ᆔຬળ2ᐕකቇ♽⎇ⓥ⑼࡮කቇㇱ዁᧪⸘↹ᆔຬળ㧙7ੱਛᦼ⋡ᮡ⸘↹ߣ዁᧪᭴ᗐ෸߮ಽ㊁╬ߩᣂ⸳࡮ᢛ஻ߦ㑐ߔࠆߎߣ‫ޕ‬

ᐔᚑ 20 ᐕᐲ

છᦼ

ੱᢙ

ክ⼏੐㗄╬

⸳⟎ᐕᐲ

ቇോᆔຬળ

2ᐕ

6ੱ

ቇ↢ߩᢎോ࡮ෘ↢෸߮ቇ૏᝼ਈߦ
㑐ߔࠆߎߣ‫ޕ‬ᐔᚑ 17 ᐕᐲᢎോෘ↢ᆔຬળ

2ᐕ

10 ੱቇ↢ߩᢎോ෸߮ෘ↢ߦ㑐ߔࠆߎߣ‫ޕ‬

ᐔᚑ 13 ᐕᐲ౉ቇ⹜㛎ᆔຬળ

2ᐕ

7ੱ

౉ቇ⠪ㆬᛮߦ㑐ߔࠆߎߣ‫ޕ‬

ᐔᚑ 12 ᐕᐲᐔᚑ 19 ᐕᐲᐔᚑ 19 ᐕᐲ㧔⋴⼔ቇኾ᡹࡮⋴⼔ቇ⑼㧕
ฬ⒓

ታ⠌ᆔຬળ

2ᐕ

11 ੱ

⥃࿾ታ⠌ߦ㑐ߔࠆߎߣ‫ޕ‬

ᐔᚑ 14 ᐕᐲ዁᧪⸘↹ᆔຬળ

2ᐕ

10 ੱ዁᧪᭴ᗐߦ㑐ߔࠆߎߣ‫ޕ‬

ᐔᚑ 13 ᐕᐲᐢႎ࡮ᖱႎಣℂᆔຬળ

2ᐕ

6ੱᐢႎ࡮ᖱႎಣℂߦ㑐ߔࠆߎߣ‫ޕ‬

ᐔᚑ 13 ᐕᐲ੍▚㈩ಽᆔຬળ

2ᐕ

8ੱ੍▚㈩ಽߦ㑐ߔࠆߎߣ‫ޕ‬

ᐔᚑ 15 ᐕᐲᯏ⒳ㆬቯᆔຬળ

2ᐕ

7ੱ‛ຠߩ઀᭽㧘ⷙᩰߣᢎ⢒࡮⎇ⓥ⋡⊛ߣߩ㑐ㅪߦ㑐ߔࠆߎߣ‫ޕ‬

ᐔᚑ 15 ᐕᐲቇ↢ߩ⎇ⓥ⸘↹ߩክᩏ㧘ታᣉਛߩ
5 ੱએ਄ ⎇ⓥ╬ߦߟ޿ߡߩ⎇ⓥ⸘↹ߩᄌ
6 ੱએౝ ᦝ㧘⎇ⓥਛᱛ╬ߩᗧ⷗ߩㅴ⸒╬ߦ㑐ߔࠆߎߣ‫ޕ‬ᐔᚑ 17 ᐕᐲ㧲㧰 ߦ㑐ߔࠆᵴേߩડ↹㧘ታᣉ㧘ᡰេ㧘ផㅴ෸߮ᖱႎ෼㓸ߦ㑐ߔࠆߎߣ‫ޕ‬

ᐔᚑ 19 ᐕᐲୃ჻⺰ᢥ୶ℂክᩏዊᆔຬ
ળ1ᐕࡈࠔࠞ࡞࠹ࠖ࡮࠺ࠖࡌ
ࡠ࠶ࡊࡔࡦ࠻ᆔຬળ

2ᐕ

5ੱ

2. ᢎ⢒࡮⎇ⓥߦ㑐ߔࠆᗧᔒ᳿ቯᣇᴺߣ૕೙
㧔1㧕ᢎ⢒ߦ㑐ߔࠆᗧᔒ᳿ቯࠪࠬ࠹ࡓ㧙㧙ᢎ⢒ౝኈߦߟ޿ߡߪ㧘౉ቇ⹜㛎㧘ᢎ⢒ࠞ࡝ࠠࡘ࡜ࡓߩၮ␆᭴ᚑ߿዁᧪⸘↹ߦߟ޿ߡකቇ♽⎇ⓥ⑼෶
ߪ⋴⼔ቇ⑼ߢ⚵❱ߔࠆߘࠇߙࠇߩ዁᧪⸘↹ᆔຬળ㧘ᢎോෘ↢ᆔຬળ㧘౉ቇ⹜㛎ᆔຬળ㧘෸߮කቇ♽⎇ⓥ⑼࡮කቇㇱડ↹ᆔຬળ㧘⋴⼔ቇ⑼ታ⠌ᆔຬળ╬ߩክ⼏ߦၮߠ޿ߡ㧘ฦᢎ᝼ળ⼏ߢᦨ⚳⊛ߦ᳿ቯߒߡ
޿ࠆ‫ޕ‬㧔2㧕⎇ⓥߦ㑐ߔࠆᗧᔒ᳿ቯࠪࠬ࠹ࡓ
⎇ⓥౝኈߦߟ޿ߡߪ㧘ฦಽ㊁࡮⻠ᐳ࡮⸻≮⑼࡮ᢎ⢒⎇ⓥᣉ⸳╬ߢᬌ⸛ߒ㧘᳿ቯߒߡ޿ࠆ‫ޕ‬ߥ߅㧘කቇ♽⎇ⓥ⑼࡮කቇㇱో૕ߦ౒ㅢߔࠆ੐㗄ߪ㧘කቇ♽⎇ⓥ⑼࡮කቇㇱડ↹ᆔຬળ㧘කቇ⎇ⓥ╬୶ℂክᩏᆔຬળ╬ߩᆔຬળߢߩᬌ⸛ߦၮߠ߈㧘කቇ♽⎇ⓥ⑼ᢎ᝼ળ෶ߪකቇㇱᢎ᝼ળߢᦨ⚳᳿ቯߒߡ޿ࠆ‫ޕ‬

3㧚 ੐ോ⚵❱ߣ੐ോ⡯ຬߩ㈩⟎⁁ᴫ㧔1㧕⃻⁁ᤘ๺ 57 ᐕᐲߦකቇㇱ෸߮ห㒝ዻ∛㒮ߩ੐ോㇱࠍ⛔วߒߚකቇㇱ੐ോㇱ 4 ⺖૕೙ࠍ㧘࿖┙ᄢቇߩᴺੱൻߦ઻޿㧘කቇ⎇ⓥ⑼࡮කቇㇱ੐ോㇱߣ੐ോዪ∛㒮ㇱ㧔ᐔᚑ 17 ᐕ 4 ᦬ࠃࠅ∛㒮੐ോㇱ㧕ߦಽ㔌࡮ᡷ✬ߒߚ‫ޕ‬කቇ⎇ⓥ⑼࡮කቇㇱߩ੐ോ⚵❱ߪ㧘੐ോ㐳ߩ߽ߣ੐ോ㐳⵬૒෸߮․๮ߩኾ㐷ຬ╬ਗ߮ߦ 6 ଥ૕೙ߣߒߚ߇㧘ല₸⊛ߥ▤ℂㆇ༡ࠍ࿑ࠆߚ߼㧘ᐔᚑ 16 ᐕ 7 ᦬ߦߪ․๮ߩኾ㐷ຬ╬ࠍᑄᱛߒ㧘10 ଥ૕೙ߣߒ
ߚ‫ޕ‬ᐔᚑ 17 ᐕ 4 ᦬߆ࠄߪ㧘කቇ⎇ⓥ⑼࡮කቇㇱ੐ോㇱߦ߅޿ߡᜂᒰߒߡ޿ߚੱ੐㑐ଥ੐ോࠍකቇㇱߣ㒝ዻ∛㒮ߦಽ㔌ߒ㧘∛㒮ੱ੐ᜂᒰଥࠍ㒝ዻ∛㒮੐ോㇱߦ⒖ⴕ╬ㅴ߼ 9 ଥߣߒ㧘߹ߚ㧘⋴⼔ቇኾ᡹ߩ⸳⟎ߦ઻޿੐ോㇱߩฬ⒓ࠍ‫ޟ‬කቇ♽⎇ⓥ⑼࡮කቇㇱ੐ോㇱ‫ߣޠ‬ᡷ⒓㧘ᐔᚑ 18 ᐕ 3 ᦬ߦᛛⴚቶࠍ⸳⟎㧘
ᐔᚑ 18 ᐕ 4 ᦬ߦߪ㧘ᬺോߩ⛔ᑄวߦ઻޿⎇ⓥදജଥ෸߮ડ↹ଥߩ 2 ଥࠍᑄᱛߒ 7 ଥߣߒ㧘ᐔᚑ 19 ᐕ
8 ᦬ߦ⎇ⓥᡰេ૕೙ᒝൻߩߚ߼ᣂߚߦ⎇ⓥᡰេଥࠍ⸳⟎㧘8 ଥ෸߮ᛛⴚቶߩ૕೙ߢ⃻࿷ߦ⥋ߞߡ޿ࠆ‫ޕ‬੐ോㇱߣߒߡߐࠄߦല₸ൻࠍ࿑ࠆߚ߼㧘ଥ╬ߩ⛔วౣ✬ࠍㅴ߼ࠆߴߊᐔᚑ 16 ᐕᐲ߆ࠄㅴ߼ߡ޿ࠆ
ᜂᒰㇱዪߣߩ᛬ⴣࠍ੹ᓟ߽⛮⛯ߒߡ޿ߊ‫ޕ‬৻ᣇ㧘කቇ♽⎇ⓥ⑼ߩ⻠ᐳ࡮ಽ㊁╬ߦ߅ߌࠆ⎇ⓥ⵬ഥ෸߮੐ോ⵬ഥߩߚ߼㧘੐ോ♽෸߮ᛛⴚ࡮ᛛ⢻♽⡯ຬ߇㈩⟎ߐࠇߡ޿ࠆ߇㧘㜞㗵ߩੱઙ⾌ࠍᛥ೙ߔࠆߚ߼㧘ಽ㊁ઃ߈ࡄ࡯࠻⡯ຬߩ೥ᷫߦะߌߡⓍᭂ⊛ߦขࠅ⚵ࠎߢ޿ࠆ‫ޕ‬
㧔2㧕ὐᬌ࡮⹏ଔ
੍▚࡮ੱ੐╬߇੤㍲ߔࠆකቇㇱ෸߮ห㒝ዻ∛㒮ߩ੐ോࠍಽ㔌ߔࠆߎߣߦࠃࠆࡔ࡝࠶࠻࡮࠺ࡔ࡝࠶࠻
ࠍ⠨ᘦߒߟߟ㧘∛㒮⚻༡ߦ㈩ᘦߒ੐ോ૕೙ߩല₸ൻࠍ࿑ࠆߎߣ߇ᔅⷐߢ޽ࠅ㧘ੱ੐ࡑࡀࠫࡔࡦ࠻ߩⷰ
ὐ߆ࠄ∛㒮ੱ੐ᜂᒰଥࠍᐔᚑ 17 ᐕᐲ߆ࠄ㒝ዻ∛㒮੐ോㇱߦ⒖ߔߥߤߩ⹏ଔ࡮⷗⋥ߒࠍታᣉߒߡ߈ߚ‫ޕ‬කቇ♽⎇ⓥ⑼࡮කቇㇱ੐ോㇱߣߒߡߪ㧘ᢎ⢒⡯ຬߩ⎇ⓥ࡮ᢎ⢒࡮⸻≮ࠍࠨࡐ࡯࠻ߔࠆߚ߼ᬺോߩ⷗⋥ߒ࡮ὐᬌࠍㅴ߼ߡ޿ࠆ‫ޕ‬
㧔3㧕ᡷༀ࡮ᡷ㕟ߣዷᦸ⎇ⓥ⑼㐳ߩᜰዉߩਅ㧘⎇ⓥදജ੐ോ࡮౉⹜੐ോ╬ߩᡷༀࠍⴕߞߚ‫ޕ‬කቇㇱ෸߮ห㒝ዻ∛㒮ߩ੐ോߩ౒ㅢ੐㗄ߦߟ޿ߡߪ㧘౒หߒߡᬺോߦᒰߚࠆ╬ߩᬺോߦᒰߚߞߡ߅ࠅ㧘੹ᓟ߽ᬺോߩᡷༀ࡮⚵❱ᡷ㕟╬㧘․ߦ౉⹜㑐ଥ੐ോߩᒝൻߦߟ޿ߡⓍᭂ⊛ߦㅴ߼ߡ޿ߊߎߣߣߒߡ޿ࠆ‫ޕ‬㧙㧙4㧚 ੍▚✬ᚑߣၫⴕ㧔㈩ಽ㧕ߩᣇ㊎ߣ⁁ᴫ
ᐔᚑ 15 ᐕᐲ߹ߢߩකቇ♽⎇ⓥ⑼࡮කቇㇱ෸߮㒝ዻ∛㒮ߩ੍▚ߪ㧘࿖┙ቇᩞ․೎ળ⸘ߦࠃࠅ㧘ㆇ༡ߦᔅⷐߥ⚻⾌߇ᱦ಴੍▚ߣߒߡ㧘߹ߚ㧘㒝ዻ∛㒮෼౉࡮᝼ᬺᢱ෼౉╬߇ᱦ౉੍▚ߣߒߡ⸘਄ߐࠇ㧘੍▚ߩ✬ᚑߦߟ޿ߡߪ㧘ᢥㇱ⑼ቇ⋭߆ࠄ␜ߐࠇߚ᭎▚ⷐ᳞ߩᣇ㊎ߦၮߠ߈㧘කቇ♽⎇ⓥ⑼࡮කቇㇱߦߟ޿ߡߪ㧘ᢎ᝼ળ㧘㒝ዻ∛㒮ߦߟ޿ߡߪ⑼㐳ળ⼏ߦ߅޿ߡᬌ⸛ߒ㧘ᢥㇱ⑼ቇ⋭ߦ᭎▚ⷐ᳞ࠍⴕߞߡ޿ߚ‫ޕ‬࿖┙ᄢቇᴺੱߣߥߞߚ੹㧘੍▚ߩ✬ᚑߦߟ޿ߡߪ㧘ᢥㇱ⑼ቇ⋭߆ࠄ㈩ಽߐࠇࠆㆇ༡⾌੤ઃ㊄ߣ㒝ዻ∛㒮෼౉࡮᝼ᬺᢱ෼౉╬ߩ⥄Ꮖ෼౉ߦࠃࠅㆇ༡ߦᔅⷐߥᱦ಴⚻⾌ࠍ⾔߁ߎߣߣߥࠅ㧘ᒰ⹥ᐕᐲߩ੐ᬺ
⸘↹ߦၮߠ߈੍▚㗵ߩ⏕ቯᓟߦ੐ോዪߦ߅޿ߡᄢቇ౒ㅢ⚻⾌߇ប㒰ߐࠇ㧘ㇱዪߩ੍▚߇⏕ቯߔࠆ‫ߎޕ‬ࠇࠍฃߌߡ㧘කቇ♽⎇ⓥ⑼࡮කቇㇱߦߟ޿ߡߪฦᣉ⸳╬ߩㆇ༡⾌ࠍ฽߼ડ↹ᆔຬળߢክ⼏ߒ㧘ᢎ᝼ળ⼏ߦ߅޿ߡክ⼏᳿ቯߐࠇߚ੍▚㈩ಽᣇᑼߦࠃࠅฦಽ㊁ߦ㈩ಽࠍⴕ߁‫ޕ‬ᒰೋ੍▚ߩ㈩ಽߦߟ޿ߡߪ㧘એ਄ߩߣ߅ࠅߢ޽ࠆ߇㧘ᒰೋ੍▚એᄖߩ੍▚ߦߟ޿ߡߪ㧘ߘࠇߙࠇߩ
੐㗄ᜰቯߩ⋡⊛ߦᓥ޿㈩ಽߔࠆ‫ޕ‬කቇㇱ⋴⼔ቇ⑼ߩ੍▚ߦߟ޿ߡߪ㧘ฦᣉ⸳╬ߩㆇ༡⾌ࠍ฽߼੍▚㈩ಽᆔຬળߢክ⼏ߒ㧘ᢎ᝼ળ⼏ߦ߅޿ߡክ⼏᳿ቯߐࠇߚ੍▚㈩ಽᣇᑼߦࠃࠅ㈩ಽࠍⴕ߁‫ޕ‬ߥ߅㧘⋴⼔ቇ⑼ߩ㈩ಽᣇ㊎ߩ᭎ⷐߪએਅߩߣ߅ࠅߢ޽ࠆ‫ޕ‬␜㆐ߐࠇߚ੍▚㗵߆ࠄ⋴⼔ቇ⑼ߩ౒ㅢ⚻Ᏹ⚻⾌ࠍ㒰޿ߚ੍▚㗵ࠍቇ↢㑐ଥ⚻⾌㧘ᢎ⢒⎇ⓥ⚻⾌෸߮․೎⚻⾌ߦಽߌ⋡⊛ߦᓥ޿㈩ಽߔࠆ‫ߩߘޕ‬ਛߢ㧘ᢎ⢒⎇ⓥ⚻⾌ߦߟ޿ߡߪ㧘ฦᢎຬߏߣߦ㈩ಽߒߡ޿ࠆ‫ޕ‬߹ߚ㧘ᒰೋ੍▚એᄖߩ੍▚ߦߟ޿ߡߪ㧘ߘࠇߙࠇߩ੐㗄ᜰቯߩ⋡⊛ߦᓥ޿㈩ಽߔࠆ‫ޕ‬⃻࿷߹ߢߩᡷༀ⷗⋥ߒߦߟ޿ߡ
⁛┙ⴕ᡽ᴺੱൻߦࠃࠅ㧘ߐࠄߥࠆᄢቇᡷ㕟߇᳞߼ࠄࠇߡ޿ࠆਛ㧘කቇ♽⎇ⓥ⑼࡮කቇㇱߦ޽ߞߡߪ㧘శᾲ᳓ᢱߩ▵ᷫ╬ࠍⴕ߁ߥߤߒߡ৻⥸▤ℂ⾌ߩ೥ᷫߦขࠅ⚵߻╬㧘ല₸ߩࠃ޿੍▚✬ᚑ෸߮ၫⴕߩታ
⃻ߦะߌߡขࠅ⚵ࠎߢ߈ߚ‫੹ޕ‬ᓟ߽ᒁ߈⛯߈㧘⚻⾌ߩ▵ᷫ╬ᡷ㕟ᡷༀߦขࠅ⚵ߺታ⃻ࠍ࿑ࠆߎߣߣߒ
ߡ޿ࠆ‫ޕ‬⋴⼔ቇ⑼ߦ޽ߞߡߪߘߩ⁛⥄ᕈࠍ↢߆ߔߚ߼㧘ല₸ߩࠃ޿੍▚✬ᚑ෸߮ၫⴕߩታ⃻ߦะߌߡขࠅ⚵ࠎߢ߈ߚ‫੹ޕ‬ᓟ߽ᒁ߈⛯߈㧘ᡷ㕟ᡷༀߦขࠅ⚵ߺታ⃻ࠍ࿑ࠆߎߣߣߒߡ޿ࠆ‫ޕ‬੹ᓟߦะߌߡߩឭ⸒
ᄢቇࠍขࠅᏎߊ␠ળ⊛ⅣႺߪ㧘ᴺੱൻ෸߮ක≮೙ᐲᡷ㕟ߥߤߣ⋧߹ߞߡ㧘㕖Ᏹߦ෩ߒ޿߽ߩߣߥߞ
ߡ޿ࠆ‫ޕ‬
ߎ߁ߒߚ⁁ᴫߩਛ㧘කቇ♽⎇ⓥ⑼࡮කቇㇱ෸߮㒝ዻ∛㒮ߪ㧘ᐔᚑ 16 ᐕ 6 ᦬ߦጘ㒂ᄢቇᩉᚭ࿅࿾⷏
㓞ߦ⒖ォ࡮ᣂ▽ߒ㐿㒮ߒߚ߇㧘⒖ォᓟߩᑪ‛㕙Ⓧ㧘ᯏ᪾࡮⸳஻╬ߩⷙᮨ߇ᄢ᏷ߦჇടߒߡ߅ࠅ㧘శᾲ᳓ᢱ㧘ᬺോᆔ⸤⾌㧘⸳஻଻቞ᢱ╬ߩ▤ℂㆇ༡⚻⾌߇ᄢ᏷ߦჇടߒߡ޿ࠆ‫ޕ‬ᴺੱൻᓟߩㆇ༡⾌ߪ࿖߆ࠄ㈩ಽߐࠇࠆㆇ༡⾌੤ઃ㊄ߣ᝼ᬺᢱ࡮∛㒮෼౉╬ߩ⥄Ꮖ෼౉ߢ⾔߁ߚ߼㧘ߘߩਛߢ߽∛㒮෼౉ߩභ߼ࠆഀว߇㜞ߊ㧘ᄢቇߩ౞Ṗߥㆇ༡ࠍ࿑ࠆߚ߼ߦߪ㧘∛㒮ߩ⚻༡ᡷༀ╬ߦࠃࠆ෼౉Ⴧኻ╷߇ᕆോߣߥߞߡ޿ࠆ‫ޕ‬ߎߩࠃ߁ߦ㒢ࠄࠇߚ੍▚ߩਛߢᄢቇㆇ༡ࠍⴕ߁ߚ߼㧘੍▚✬ᚑߦ߅޿ߡߪᢎ⢒⎇ⓥߩలታ࡮ᵴᕈൻ
ࠍ࿑ࠆߚ߼㧘ߐࠄߥࠆ⚻⾌ߩวℂൻ㧘▵ᷫൻߦദ߼ࠆߎߣߣߒߡ޿ࠆ‫ޕ‬㧙㧙Υ‫ޓ‬කቇㇱකቇ⑼1ᢎ⢒ߩℂᔨ࡮⋡ᮡ╬1㧚 ᢎ⢒ߩℂᔨߣ⋡ᮡකቇ⑼ߪ㧘ቇ↢߇዁᧪ߘࠇߙࠇ଻ஜ࡮ක≮ߦ⽸₂ߒ㧘කቇߩ⊒ዷߦነਈߔࠆߎߣ߇ߢ߈ࠆࠃ߁ߦ㧘એਅߩ 4 㗄⋡ࠍ㆐ᚑߔࠆߎߣࠍᢎ⢒ߩℂᔨ࡮⋡ᮡߣߒߡ޿ࠆ‫ޕ‬Ԙ዁᧪කቇ㑐ଥߩ޿ߕࠇߩ㗔ၞߦㅴ߻߁߃ߦ߽ᔅⷐߥ㧘ၮ␆⊛⍮⼂ߣၮᧄ⊛ᛛ⢻ࠍୃᓧߔࠆ‫ޕ‬ԙ ↢ᶦߦࠊߚߞߡ⊒ዷߐߖࠆߴ߈㧘଻ஜ࡮ක≮ߩኾ㐷⡯ߦᔅⷐߥၮᧄ⊛ᘒᐲ࡮⠌ᘠࠍりߦߟߌࠆ‫ޕ‬Ԛකቇ⊛໧㗴ࠍᱜߒߊߣࠄ߃㧘⥄ὼ⑼ቇ⊛ߩߺߥࠄߕ㧘␠ળ⊛࡮ᔃℂ⊛ᣇᴺࠍ⛔วߒߡ⸃᳿ߔࠆ

ߚ߼ߩၮᧄ⊛⢻ജࠍୃᓧߔࠆ‫ޕ‬ԛ⍮⼂࡮ᛛ⢻࡮ᘒᐲࠍ⥄ࠄ⹏ଔߒ㧘߆ߟ⥄⊒⊛ቇ⠌ߣୃ✵ߦࠃߞߡ㧘ߘࠇࠄࠍะ਄ߒ⛯ߌࠆ⠌ᘠࠍりߦߟߌࠆ‫ޕ‬2㧚 ᢎ⢒ߩᵴᕈൻߣలታߩ⚻ㆊකቇ࡮ක≮ߩᕆㅦߥㅴዷ෸߮ᄙ᭽ൻߔࠆ␠ળ⊛ⷐ⺧ߦᔕ߃ࠆߎߣ߇ߢ߈ࠆߣᦼᓙߐࠇࠆකᏧ࡮ഃㅧ
ജ⼾߆ߥකቇ⎇ⓥ⠪ࠍ⢒ᚑߔࠆߚ߼㧘Ᏹߦ㧘ၮ␆⊛ߥಽᨆ⢻ജᛛⴚߩୃᓧ㧘᏷ᐢ޿කቇ㧘ක≮ߩ⃻⁁⹺⼂㧘ᱧผ⊛⊒ዷㆊ⒟ߩᛠី෸߮዁᧪߳ߩዷᦸࠍᗧ⼂ߐߖࠆߣߣ߽ߦ໧㗴⸃᳿߳ߩᔕ↪⢻ജߩ㐿⊒ߦജࠍᵈ޿ߢ޿ࠆ‫ޕ‬ߎߩߚ߼ 1 ᐕᰴ↢߆ࠄකቇ࡮ක≮߳ߩ㑐ᔃࠍ㜞߼ࠆᣇ╷ߣߒߡ㧘කቇ⑼ኾછᢎຬߦࠃࠆකቇ᭎⺰㧘
කቇၮ␆⑼⋡㧘↢๮⑼ቇታ⠌㧘ೋᦼ૕㛎ታ⠌㧘࿾ၞ૕㛎ታ⠌㧘කቇ⧷⺆ߥߤߩ᝼ᬺ⑼⋡ࠍ㐿⻠ߒߡ޿ࠆ‫ޕ‬⃻ⴕߩකቇ⑼ߩᢎ⢒ᒻᘒߪ㧘කቇ⑼ࠞ࡝ࠠࡘ࡜ࡓᆔຬળ㧔ᓥ೨㧦කቇ⑼ᢎോෘ↢ᆔຬળࠞ࡝ࠠࡘ࡜
ࡓㇱળ㧕ߦ߅޿ߡ㍈ᗧᬌ⸛ߩ਄㧘ߘߩၮᧄᣇ㊎߇⏕┙ߐࠇߚ߽ߩߢ㧘ᐔᚑ 7 ᐕᐲ߆ࠄ‫ޟ‬⢻േဳ࡮ᕁ⠨ଦㅴဳ‫ޠ‬ᢎ⢒ᚻᴺߢ޽ࠆ࠹ࡘ࠻࡯࡝ࠕ࡞ᢎ⢒ࠍਥ૕ߣߒߚዋੱᢙᢎ⢒ࠍណ↪࡮ታᣉߒߡ޿ࠆ‫ޕ‬߹ߚ㧘ᐔᚑ 9 ᐕ 4 ᦬߆ࠄ 5 ᐕᰴߩోቇᦼࠍࠢ࡝࠾ࠞ࡞࡮ࠢ࡜࡯ࠢࠪ࠶ࡊဳ⥃ᐥታ⠌ߣߒ㧘ห 10 ᐕᐲ߆ࠄ 6 ᐕᰴ 1 ቇᦼߩ⚂ 40 ᣣ㑆ࠍቴຬ⥃ᐥ♽කቇᢎ᝼╬ߩᜰዉߩਅߢ㧘㑐ㅪᢎ⢒∛㒮ߢߩ㒮ᄖታ⠌㧔ቇᄖታ⠌㧕ࠍታᣉߒߡ޿ࠆ‫ޕ‬ᐔᚑ 13 ᐕ 3 ᦬ߩකቇߦ߅ߌࠆᢎ⢒ࡊࡠࠣ࡜ࡓ⎇ⓥ࡮㐿⊒੐ᬺᆔຬળ߆
ࠄឭ␜ߐࠇߚ‫ޟ‬කቇᢎ⢒ࡕ࠺࡞࡮ࠦࠕ࡮ࠞ࡝ࠠࡘ࡜ࡓ‫ߦޠ‬ၮߠ߈㧘ߘߩౝኈߦᴪߞߚᢎ⢒ౝኈߩ⷗⋥ߒࠍⴕߞߡ޿ࠆ‫ޕ‬ᐔᚑ 16 ᐕᐲߩࠠࡖࡦࡄࠬ⒖ォ㧘ᣂ∛㒮ߩ㐿㒮ߦ઻޿㧘㒮ౝ⥃ᐥታ⠌ࠍ㧠ㅳ㑆㧝ࡉࡠ࠶ࠢߣߒߡ㧘ࠢ࡜࡯ࠢࠪ࠶ࡊߩ৻ጀߩផㅴࠍ⸘ߞߡ޿ࠆ‫ޕ‬ᐔᚑ 20 ᐕᐲ߆ࠄቇ↢ቯຬ߇ 80 ฬ߆ࠄ 90
ฬߦ㧘21 ᐕᐲ߆ࠄߪ 100 ฬߦჇടߒ㧘࿾ၞᨒ౉⹜߇ዉ౉ߐࠇߚߎߣߦ઻޿㧘ᦨᣂߩ⍮⷗ߦၮߠߊࠞ
࡝ࠠࡘ࡜ࡓߩౣᐲߩᄢ᏷ߥ⷗⋥ߒ߇ⴕࠊࠇ㧘⥃ᐥታ⠌ߩᦝߥࠆలታ㧘⎇ⓥ૕㛎ߣㆬᛯ᝼ᬺߩ᜛ల㧘㧢ᐕ৻⽾ߩࡊࡠࡈࠚ࠶࡚ࠪ࠽࡞ᢎ⢒߇㐿ᆎߐࠇߚ‫ޕ‬એ਄ߩࠃ߁ߥᢎ⢒૕೙ߩᡷ㕟ߦࠃࠅ㧘6 ᐕ㑆ߩකቇᢎ⢒ࠍ㓸ᄢᚑߒ㧘ቇ↢߇㧘⥄ࠄቇ⠌ߔࠆᆫ൓ࠍ
ୃᓧߔࠆߎߣ෸߮୘‫ߩޘ‬ᖚ⠪ࠍㅢߒߡ㓸ቇ⊛ߦቇ⠌ߢ߈ࠆࠪࠬ࠹ࡓ߇ᢛߞߚ‫ߩߘޕ‬ലᨐ߇޽ߞߡ㧘ᐔ
ᚑ 12 ᐕᐲතᬺߩ࠹ࡘ࠻࡯࡝ࠕ࡞ 1 ᦼ↢߆ࠄකᏧ࿖ኅ⹜㛎วᩰ₸ߪᏱߦ⦟ᅢߥᚑ❣ࠍ㆐ᚑߒߡ޿ࠆ‫ޕ‬㧙㧙3㧚 ᢎ⢒ߩ዁᧪᭴ᗐ
㧔1㧕ၮᧄℂᔨㄭᐕߩవ┵ᛛⴚࠍ฽߻ᐢ▸ߥ⑼ቇᛛⴚߩㅴᱠߦ઻߁කቇ࡮ක≮ߩㅴᱠਗ߮ߦ㜞㦂ൻ␠ળߩ೔᧪߿↢ᵴ᭽ᑼߩᄌൻߦ઻߁∔∛᭴ㅧߩᄌൻߥߤ㧘කቇᢎ⢒࡮⎇ⓥߩਔ㕙ߦ߅ߌࠆ⾰⊛࡮㊂⊛ߥᄌൻߦߪ⪺ߒ޿߽ߩ߇޽ࠅ㧘ߎߩ௑ะߪ 21 ਎♿ߦ౉ߞߚߎࠇ߆ࠄ߽৻ጀㅴ߻߽ߩߣ⠨߃ࠄࠇࠆ‫ޕ‬ߎࠇࠄߦኻᔕߔߴߊ㧘ᐢ▸ߢ㧘ߒ߆߽㜞ᐲߥකቇ⍮⼂࡮ᛛⴚࠍ♖ㆬߒߡୃᓧߐߖࠆߎߣ߽ᔅ㗇ߢߪ޽ࠆ߇㧘ᄙ᭽ൻߔࠆ␠ળ⊛ⷐ⺧ߦᔕ߃ᓧࠆੱ㑆ᕈ⼾߆ߢ୶ℂⷰߦን߻⦟߈කᏧ㧘ഃㅧജ⼾߆ߥකቇ⎇ⓥ⠪ߩ⢒ᚑࠍකቇᢎ⢒ߩၮᧄℂᔨߣߒߡ޿ࠆ‫ޕ‬
㧔2㧕ᢎ⢒૕೙
⍮࡮ᖱ࡮ᗧ߇⺞๺ߒ㧘߆ߟ㧘ోੱ⊛┙႐ߦ┙ߞߡ߽ߩࠍ⷗ࠆߎߣ߇ߢ߈ࠆකᏧ࡮කቇ⎇ⓥ⠪⢒ᚑࠍ⋡ᜰߒߚᢎ⢒ࠍߔࠆߎߣࠍ⋡ᮡߦߔࠆ‫ߚ߹ޕ‬㧘਎⇇ߩਛߩᣣᧄ㧘ᣣᧄߩਛߩ᧲ᶏ࿾ᣇ㧘᧲ᶏ࿾ᣇߩਛ
ߩጘ㒂ߣ޿߁૏⟎ઃߌࠍ⠨ᘦߒߥ߇ࠄ㧘࿾ၞߦኒ⌕ߒߚක≮ߦ⽸₂ߢ߈ࠆකᏧߩ⢒ᚑ߽ᔨ㗡ߦ߅߈㧘↢๮⑼ቇߣߒߡߩකቇߩߺߥࠄߕකߩ୶ℂ࡮ක≮⚻ᷣ╬㧘␠ળ⑼ቇ⊛஥㕙ࠍ㊀ⷞߒߡᢎ⢒ߔࠆ‫ޕ‬એ਄ߩᣇ㊎ࠍၮߦ㧘ᰴߩὐࠍ⠨ᘦߒߡᢎ⢒ߔࠆߎߣ߇ᔅⷐߢ޽ࠆ‫ޕ‬Ԙ කቇ࡮ක≮ߩㅴዷߦ઻ߞߡ㧘ߘߩኾ㐷ൻ࡮⚦ಽൻ߇ㅴࠎߢ޿ࠆߣߣ߽ߦකቇߩᨒ⚵ࠍ⿥߃ߚቇ㓙⊛ߥ㗔ၞߩ㊀ⷐᕈ߽Ⴧߒߡ߈ߚߚ߼㧘ᔅὼ⊛ߦᄙ㊂ߩ⍮⼂෸߮ᛛⴚࠍୃᓧߐߖࠆᔅⷐ߇↢ߓߡ߈ߡ޿ࠆ‫ࠄ߇ߥߒ߆ߒޕ‬㧘නߥࠆ⍮⼂෸߮ᛛⴚࠍ⫾Ⓧߐߖࠆߎߣߦ஍ࠆߎߣߥߊ㧘ਥ૕ᕈ߿ഃㅧᕈߩ⢒ᚑ㧘໧㗴⸃᳿⢻ജߩᶩ㙃㧘කቇ࡮ක≮ߦኻߔࠆ✚ว⊛ⷞ㊁ࠍᜬߟੱ᧚ߩ⢒ᚑ╬ߦචಽ㈩ᘦߔࠆ‫ޕ‬ԙ ಽሶ↢‛ቇ࡮ಽሶㆮવቇࠍᆎ߼ߣߒߡකቇ๟ㄝ⑼ቇߩ⪺ߒ޿ㅴዷߣߘࠇࠄߩකቇ࡮ක≮߳ߩዉ౉ߦࠃߞߡ㧘߿߿߽ߔࠆߣᛛⴚఝవߩ௑ะ߇⷗ࠄࠇࠆ߇㧘ᔃりਔ㕙߆ࠄߩ൮᜝⊛කቇ࡮ක≮ࠍ⋡ᜰߒ㧘↢๮ߦኻߒߡᷓ޿⇊ᢘߩᔨࠍ߽ߜ㧘ᖚ⠪߿ᖚ⠪ߩኅᣖߩ┙႐ߦ┙ߞߡ⸻≮ࠍⴕ߃ࠆੱ㑆ᕈ⼾߆ߥකᏧߩ⢒ᚑ㧘ߔߥࠊߜකᏧߣߒߡߩ୶ℂⷰߩ㉯ᚑ㧘ੱᩰᒻᚑߦ㈩ᘦߔࠆ‫ޕ‬Ԛකቇ࡮ක≮ߩㅴዷߦኻߒߡᏱᤨ㑐ᔃࠍᜬߜ㧘ᣂߒ޿⍮⼂࡮ᛛⴚߩㆡ↪ߦ㑐ߒߡ⊛⏕ߥ್ᢿജࠍၭ

߁ߚ߼ߦ㧘↢ᶦߦࠊߚߞߡቇ⠌ࠍ⛮⛯ߒߡ޿ߊ⠌ᘠߣᐢߊ㑐ㅪ⻉⑼ቇߦ߽Ᏹߦะቇᔃࠍᜬߟᘒᐲࠍ
ୃᓧߐߖࠆߎߣߦ㈩ᘦߔࠆ‫ޕ‬ԛ ࿾ၞක≮ߦ㑐ᔃࠍነߖ㧘࿾ၞ૑᳃ߩ∔∛ߩ੍㒐߆ࠄᴦ≹ᓟߩ␠ળᓳᏫߦ⥋ࠆක≮ో⥸ߦ⽿છࠍ᦭ߔࠆߎߣࠍ⥄ⷡߐߖࠆ‫ޕ‬ᔅⷐߦᔕߓߡ࿾ၞක≮ߩਛߢߩᢎ⢒⊛ᓎഀࠍᨐߚߒߡ޿ߊߎߣ߇ᔅⷐߢ޽
ࠆ‫ߚ߹ޕ‬㧘࿾ၞක≮ߦ⽸₂ߔࠆߚ߼ߦ߽ࡊ࡜ࠗࡑ࡝࡮ࠤࠕࠍ㊀ⷞߒ㧘✚ว⊛ߦකቇࠍୃᓧߐߖࠆߎ
ߣߦ㈩ᘦߔࠆ‫ޕ‬Ԝකቇ࡮ක≮ߩ႐ߦ߅ߌࠆ࿖㓙੤ᵹ߽ᕆỗߦჇടߒߡ߅ࠅ㧘߹ߚ㧘㐿⊒ㅜ਄࿖ߦኻߔࠆ࿖㓙ක≮දജߩᔅⷐᕈ߽㜞߹ߞߡ߈ߡ޿ࠆ‫ߡߞ߇ߚߒޕ‬㧘ߎࠇࠄ࿖㓙⊛ߦ߽ᵴべߢ߈ࠆකᏧ࡮කቇ⎇ⓥ⠪ߩ⢒ᚑߦ㈩ᘦߔࠆ‫ޕ‬

㧙㧙

2

ᢎ⢒ᵴേ

1㧚 ቇ↢ߩฃ౉ࠇ
㧔1㧕ቇ↢൐㓸ߩᣇᴺԘቇോㇱ౉⹜⺖߆ࠄ㧘ోቇ৻᜝ߢቇ↢൐㓸ⷐ㗄෸߮౉ቇ⠪ㆬᛮߦ㑐ߔࠆⷐ㗄ࠍ⋵ਅฦ㜞╬ቇᩞࠍਛᔃߦㇷㅍ㈩Ꮣߔࠆߣߣ߽ߦ㧘Ꮧᦸ⠪ߦኻߒ⋥ធ෶ߪㇷㅍߢหⷐ㗄ࠍ㈩Ꮣߒߡ޿ࠆ‫ޕ‬ԙකቇ⑼⚫੺ࡄࡦࡈ࡟࠶࠻‫ޟ‬කቇࠍᔒߔ⊝ߐࠎ߳㧔කቇ↢ߦᦸ߹ߒ޿⾗⾰㧕‫ޠ‬෸߮‫ࠕ࡝࡯࠻ࡘ࠹ޟ‬࡞࡮ࠪࠬ࠹ࡓ‫ࠍޠ‬૞ᚑߒ㧘ࠝ࡯ࡊࡦࠠࡖࡦࡄࠬෳട⠪෸߮㜞╬ቇᩞ㧘੍஻ᩞ╬ߦ㈩Ꮣߒߡ޿ࠆ‫ޕ‬Ԛ ࠝ࡯ࡊࡦࠠࡖࡦࡄࠬߦ߅޿ߡ㧘කቇㇱ㐳㧘කቇ⑼ᢎോෘ↢ᆔຬ㐳ߩ᭎ⷐ⺑᣿㧘ᮨᡆ᝼ᬺ㧘ᣉ⸳⷗ቇ╬ࠍታᣉߒ㧘ߐࠄߦലᨐ⊛ߥ⚫੺ߣߔࠆߚ߼ෳട⠪߆ࠄߩࠕࡦࠤ࡯࠻ࠍෳ⠨ߦ㧘කቇ⑼ᢎോෘ↢ᆔຬળߦ߅޿ߡ⸘↹┙᩺ࠍⴕߞߡ޿ࠆ‫ޕ‬ԛ㜞╬ቇᩞߩ✚ว᝼ᬺߩ৻Ⅳߣߒߡߢߪ޽ࠆ߇㧘ጘ㒂⋵ਅߩ㜞╬ቇᩞ߳಴ะ߈㧘ᧄቇ⑼ᢎຬߩ⎇ⓥ࠹࡯ࡑ߿࠻ࡇ࠶ࠢࠬߩ⚫੺ࠍ಴೨᝼ᬺߣߒߡⴕߞߡ޿ࠆ‫ޕ‬Ԝ ᖱႎ੤឵ߩ႐ߣߒߡ㧘ጘ㒂⋵ਅ㧘ᗲ⍮⋵෸߮ਃ㊀⋵ߩ㜞╬ቇᩞߩㅴ〝ᜰዉᜂᒰߩᢎ⻀ߣߩᙣ⺣ળࠍᲤᐕ㐿௅ߒߡ޿ࠆ‫ޕ‬ԝ࿾ၞᨒ౉⹜ߦ㑐ߔࠆᖱႎឭଏߩߚ߼ߦ㧘㜞ᩞ↢ࠍኻ⽎ߣߒߚ⺑᣿ળࠍታᣉߒߡ޿ࠆ‫ޕ‬Ԟ ߘߩઁ㧘ฃ㛎㔀⹹␠╬ߩᾖળߦኻᔕߔࠆߣߣ߽ߦ㧘⑳Ⴖਥ௅ߩ౉⹜⺑᣿ળߦකቇ⑼ᢎോෘ↢ᆔຬ㧘කቇ⑼౉ቇ⹜㛎ᆔຬࠍᵷ㆜ߒ㧘Ⓧᭂ⊛ߦขࠅ⚵ࠎߢ޿ࠆ‫ޕ‬
㧔2㧕౉ቇ⠪ㆬᛮߩᣇᴺߣᣇ㊎කቇ↢ߣߒߡᦸ߹ߒ޿ቇ↢ࠍ౉ቇߐߖࠆߚ߼㧘౉ቇ⠪ߩㆬᛮߦߟ޿ߡߪ㐳ᐕ⎇ⓥࠍ㊀ߨ㧘౉⹜ᢎ⑼࡮
⑼⋡ߩㆬቯࠍⴕߞߡ޿ࠆ‫ޕ‬ᄢቇ౉⹜࠮ࡦ࠲࡯⹜㛎ࠍዉ౉ߒߚᐔᚑ 2 ᐕᐲએ㒠ߩផ⒖ߪᰴߩߣ߅ࠅߢ޽ࠆ‫ޕ‬
ᐔᚑ 2 ᐕᐲԘ ផ⮈ㆬᛮࠍዉ౉

൐㓸ੱຬ

5 ੱએౝ

൐㓸ⷐઙ

㜞ᩞቇ⠌ᚑ❣᭎⹏ផ⮈ᨒ

2 ੱએౝ㧔1 ᩞߦߟ߈㧕

ㆬᛮᣇᴺ౉⹜࠮ࡦ࠲࡯⹜㛎㧘㕙ធ㧘ዊ⺰ᢥԙ ୘೎ቇജᬌᩏߩᢎ⑼෸߮࠮ࡦ࠲࡯⹜㛎ࠍ฽߻ᢎ⑼೎㈩ὐߩ⷗⋥ߒ
ℂ⑼ࠍ୘೎ቇജᬌᩏ߆ࠄ೥㒰ߒ㧘౉⹜࠮ࡦ࠲࡯⹜㛎㧔ᢙቇ㧘ᄖ࿖⺆㧕ߩ௑ᢳ㈩ὐ
ᐔᚑ 5 ᐕᐲԘ ផ⮈ㆬᛮߩ⷗⋥ߒ ൐㓸ੱຬ൐㓸ⷐઙ5ੱ㜞ᩞቇ⠌ᚑ❣᭎⹏ A એ਄ផ⮈ᨒ᠗ᑄԙ‫ޓ‬ಽ㔌࡮ಽഀ೙ߩዉ౉
೨ᦼᣣ⒟൐㓸ੱຬ‫ޓ‬65 ੱ

ㆬᛮᣇᴺ౉⹜࠮ࡦ࠲࡯⹜㛎㧘୘೎⹜㛎㧔ᢙቇ㧘ᄖ࿖⺆㧕෸߮⺞ᩏᦠ
ᓟᦼᣣ⒟൐㓸ੱຬ‫ޓ‬10 ੱ

ᐔᚑ 7 ᐕᐲ

൐㓸ੱຬߩ⷗⋥ߒ

ㆬᛮᣇᴺ౉⹜࠮ࡦ࠲࡯⹜㛎㧘ዊ⺰ᢥ㧘㕙ធ෸߮⺞ᩏᦠ

ផ⮈౉ቇ

15 ੱ

㧙㧙

ᐔᚑ 9 ᐕᐲ

೨ᦼᣣ⒟

55 ੱ

ᓟᦼᣣ⒟

10 ੱ

୘೎ቇജᬌᩏߩᢎ⑼෸߮౉⹜࠮ࡦ࠲࡯⹜㛎ࠍ฽߻ᢎ⑼೎㈩ὐߩ⷗⋥ߒ
ℂ⑼ࠍ୘೎ቇജᬌᩏߦขࠅ౉ࠇ㧘౉⹜࠮ࡦ࠲࡯⹜㛎㧔ᢙቇ㧘
ℂ⑼㧘ᄖ࿖⺆㧕ߩ௑ᢳ㈩ὐ

ᐔᚑ 14 ᐕᐲផ⮈౉ቇΤ․೎ㆬᛮ‫ޓޓ‬௑ᢳ㈩ὐߒߚ౉⹜࠮ࡦ࠲࡯⹜㛎㧔ᢙቇ㧘ℂ⑼㧘ᄖ࿖⺆㧕ߩ
ว⸘ 85㧑ࠍၮḰὐߣߒߡ౏⴫

ᐔᚑ 19 ᐕᐲ৻⥸ㆬᛮߩ൐㓸ੱຬߩᄌᦝ
೨ᦼᣣ⒟‫ޓ‬55 ੱЈ 30 ੱ‫ޓ‬ᓟᦼᣣ⒟‫ޓ‬10 ੱЈ 35 ੱᐔᚑ 20 ᐕᐲԘ࿾ၞᨒផ⮈ߩዉ౉‫ޓޓ‬ផ⮈౉ቇΤ․೎ㆬᛮߣߒߡ 10 ੱ
ㆬᛮᣇᴺ㧦࠮ࡦ࠲࡯⹜㛎㧘㕙ធ㧘ዊ⺰ᢥផ⮈ᨒ㧦㧝ᩞ㧝ฬԙ౉ቇቯຬߩჇട‫ޓޓޓ‬࿾ၞᨒ 10 ੱㅊടߦࠃࠅ౉ቇቯຬ 80 ੱЈ 90 ੱ

ᐔᚑ 21 ᐕᐲԘ࿾ၞᨒផ⮈౉ቇ‫ޓޓޓ‬ቯຬߩჇട‫ޓ‬10 ੱЈ 15 ੱផ⮈ᨒ㧦㧝ᩞ㧞ฬએౝ
ԙᓟᦼᣣ⒟‫ޓޓޓޓޓޓ‬൐㓸ੱຬߩჇട‫ޓ‬35 ੱЈ 40 ੱԚ౉ቇቯຬߩჇട‫ޓޓޓ‬90 ੱЈ 100 ੱ㧔3㧕ቇ↢ߩฃ౉ࠇ⁁ᴫቇ↢ቯຬల⿷⁁ᴫ㧦ㆊ෰ 9 ᐕ㑆ߩ౉ቇ㧔ᔒ㗿⠪࡮౉ቇ⠪㧕ߦ㑐ߔࠆ⁁ᴫߪ㧘ᰴ⴫ߩߣ߅ࠅߢ޽ࠆ‫ޕ‬
඙ಽ

12 ᐕᐲ

13 ᐕᐲ

14 ᐕᐲ

15 ᐕᐲ

16 ᐕᐲ

17 ᐕᐲ

18 ᐕᐲ

ᕈ೎

ᔒ㗿⠪ᢙ ฃ㛎⠪ᢙ ౉ቇ⠪ᢙ౉ቇ⠪಴り⋵೎ౝ⸶
ጘ㒂⋵

ᗲ⍮⋵

ਃ㊀⋵

ߘߩઁ

↵

336

278

48

18

22

1

7

ᅚ

237

201

32

11

10

1

10

⸘

573

479

80

29

32

2

17

↵

446

382

48

15

20

1

12

ᅚ

293

266

32

9

15

⸘

739

648

80

24

35

↵

361

307

51

18

14

ᅚ

267

232

30

9

8

13

⸘

628

539

81

27

22

32

↵

425

361

59

14

29

ᅚ

240

210

21

5

10

⸘

665

571

80

19

39

↵

504

438

48

11

21

16

ᅚ

248

217

32

7

18

7

⸘

752

655

80

18

39

23

↵

436

350

50

16

18

1

15

ᅚ

237

201

31

8

15

0

8

⸘

673

551

81

24

33

1

23

↵

863

751

61

15

19

1

26

1

30

ᅚ

327

294

19

4

11

⸘

1190

1045

80

19

30

㧙㧙

8
1

20
19

2

14
6

2

20

4

඙ಽ

19 ᐕᐲ

20 ᐕᐲ

ᔒ㗿⠪ᢙ ฃ㛎⠪ᢙ ౉ቇ⠪ᢙᕈ೎౉ቇ⠪಴り⋵೎ౝ⸶
ጘ㒂⋵

ᗲ⍮⋵

ਃ㊀⋵

ߘߩઁ

↵

2592

1981

63

12

18

ᅚ

788

645

17

4

6

1

6

⸘

3380

2626

80

16

24

1

39

↵

2296

1845

66

20

19

2

25

2

32

ᅚ

751

626

24

9

8

⸘

3047

2471

90

29

27

33

7

㧔4㧕✬౉ቇ೙ᐲߣታᘒ
ቇೣߦ߅޿ߡ㧘ౣ౉ቇ㧘✬౉ቇ෸߮ォ౉ቇߦࠃࠆቇ↢ߩฃ౉೙ᐲࠍቯ߼ߡ޿ࠆ߇㧘කቇㇱකቇ⑼ߢ
ߪᒰ೙ᐲߪⴕߞߡ޿ߥ޿‫ߒ߆ߒޕ‬㧘ઁᄢቇઁቇㇱࠍතᬺߒߚቇ↢߇Ფᐕᢙฬ౉ቇߒߡ޿ࠆ‫ޕ‬
㧔5㧕⎇ⓥ↢ߩฃ౉ࠇߣታᘒ
ㆊ෰ 9 ᐕ㑆ߦࠊߚࠆ⎇ⓥ↢ߩฃ౉⁁ᴫߪ㧘ᰴ⴫ߩߣ߅ࠅߢ޽ࠆ‫ޕ‬඙‫ޓ‬ಽ౉‫ޓ‬ቇ‫ޓ‬⠪‫ޓ‬ᢙᦼ㑆ᑧ㐳⠪ᢙ

⸘

ၮ␆♽

⥃ᐥ♽

␠ળකቇ♽

ၮ␆♽

⥃ᐥ♽

␠ળකቇ♽

12 ᐕᐲ

9㧔1㧕

59㧔2㧕

05㧔2㧕

24

227

06

330㧔5㧕

13 ᐕᐲ

8㧔3㧕

56㧔1㧕

02㧔0㧕

07

191

24

288㧔4㧕

11㧔0㧕

05

180

19

285㧔4㧕

10

131

19

195㧔5㧕

01㧔0㧕

09

116

14

181㧔4㧕

14 ᐕᐲ

4㧔2㧕

66㧔2㧕

15 ᐕᐲ

2㧔1㧕

33㧔4㧕

16 ᐕᐲ

8㧔3㧕

33㧔1㧕

17 ᐕᐲ

2㧔1㧕

27㧔1㧕

022

91

22

164㧔2㧕

01㧔0㧕

020

65

3

111㧔3㧕

61

4

98㧔7㧕

01㧔0㧕

12㧔1㧕
14

42㧔1㧕

4

75㧔4㧕

18 ᐕᐲ

1㧔0㧕

21㧔3㧕

19 ᐕᐲ

2㧔1㧕

19㧔5㧕

20 ᐕᐲ

1㧔1㧕

13㧔2㧕

㧔‫ޓ‬㧕ౝߪ㧘⇐ቇ↢ࠍౝᢙߢ␜ߔ‫ޕ‬ᄢቇ㒮⎇ⓥ↢ࠍ฽߻‫ޕ‬

2㧚 ࠞ࡝ࠠࡘ࡜ࡓ
㧔1㧕ࠞ࡝ࠠࡘ࡜ࡓߩ✬ᚑᣇ㊎ࠞ࡝ࠠࡘ࡜ࡓߩၮᧄ⊛ߥ✬ᚑᣇ㊎ߪ㧘ᰴߩࠃ߁ߥⷞὐߦ┙ߜⴕߞߡ޿ࠆ‫ޕ‬Ԙᢎ㙃ᢎ⢒ߣኾ㐷ᢎ⢒ߩ᦭ᯏ⊛ㅪ៤ߦࠃߞߡ 6 ᐕ৻⽾ᢎ⢒ࠍలታߔࠆ‫ޕ‬ԙࠞ࡝ࠠࡘ࡜ࡓߩ✬ᚑߦᒰߚߞߡߪ㧘ฦኾ㐷ಽ㊁ߩㅪ៤ࠍᒝൻߔࠆߣߣ߽ߦቇ㓙⊛ಽ㊁ࠍ߽⠨ᘦߒߟߟ㧘කቇᢎ⢒ߩ✚วᕈߩ⏕┙෸߮ቇ⠌ല₸ߩะ਄ࠍ࿑ࠆ‫ޕ‬Ԛኾ㐷ᢎ⢒ߦ߅޿ߡߪၮ␆කቇታ⠌㧘␠ળකቇታ⠌෸߮⥃ᐥකቇታ⠌ࠍ㊀ⷞߒ㧘࠹ࡘ࠻࡯࡝ࠕ࡞ࠪ

ࠬ࠹ࡓਥ૕ߩᢎ⢒ߣߔࠆ‫ߚ߹ޕ‬㧘࠮ࡒ࠽࡯╬ߩዋੱᢙᢎ⢒ࠍᵴ↪ߒߡ㧘ᖱേ㕙ࠍ฽߻ᢎຬߣቇ↢ߩ✕ኒൻ෸߮⸛⼏ߦࠃࠆ⢻േ⊛ቇ⠌ߦࠃߞߡ໧㗴⸃᳿⢻ജߩ㉯ᚑࠍ࿑ࠅ㧘ኒᐲߩỚ޿⍮⼂⠌ᓧࠍ߼ߑߔ‫ޕ‬ᐔᚑ 20 ᐕᐲ߆ࠄࠞ࡝ࠠࡘ࡜ࡓߩో૕⊛⷗⋥ߒࠍⴕ޿㧘࠹ࡘ࠻࡯࡝ࠕ࡞ࠦ࡯ࠬ╬ߩ✬ᚑࠍᄌᦝߔࠆ⸘↹ߢ޽ࠆ‫ޕ‬ԛ᝼ᬺߩታᣉߦᒰߚߞߡߪ㧘ࠦࡦࡇࡘ࡯࠲㧘ࡆ࠺ࠝ╬ߩቇ⠌ߦലᨐ⊛ߥᢎ⢒ᯏེߩᵴ↪ࠍ࿑ࠆߣߣ㧙㧙߽ߦ㧘ቇ↢ߩ⥄ਥ⊛೑↪ࠍផㅴߒ㧘ᢎ⢒ߩല₸ൻߦ⾗ߒߡ޿ࠆ‫ޕ‬6 ᐕ৻⽾ᢎ⢒ߣߒߡ࠹ࡘ࠻࡯࡝ࠕ
࡞ᢎ⢒ߩࠞ࡝ࠠࡘ࡜ࡓߦട߃㧘කቇࠍቇ߱ߦᒰߞߡߩേᯏࠍ㜞߼㧘࠹ࡘ࠻࡯࡝ࠕ࡞㐿ᆎ೨ߩၮ␆⍮⼂ߩ₪ᓧࠍ⋡⊛ߣߒߡ㧘කቇ᭎⺰㧘ೋᦼ૕㛎ታ⠌㧘කቇ⧷⺆㧘ၮ␆↢ℂቇ㧘ၮ␆↢ൻቇ㧘↢๮⑼ቇ
ታ⠌㧘࿾ၞ૕㛎ታ⠌ߥߤߩ᝼ᬺࠍ㐿⻠ߒߡ޿ࠆ‫ޕ‬කቇ᭎⺰ߪ㧘㧝ᐕᰴቇ↢㧔කቇ⑼㧘⋴⼔ቇ⑼วห㧕ࠍኻ⽎ߣߒ㧘කቇㇱ㐳㧘∛㒮㐳߽ടࠊࠅ㧘6ᐕ㑆ߩකቇᢎ⢒⺖⒟ߩ㐿ᆎߦᒰࠅ㧘කቇߣߪ૗߆㧘ੱ㑆㧔↢๮㧕ߩᧄ⾰ߣߪ૗߆㧘කቇߩᚑࠅ┙ߜ㧘කቇߣ⋴⼔ߣߩ㑐ଥ㧘කቇߩ⃻⁁ߣ዁᧪ߩዷᦸ㧔㜞ᐲవㅴකቇ㧘࿾ၞක≮ߥߤ㧕㧘ක≮ੱߣߒߡ᳞
߼ࠄࠇࠆ⢻ജ㧘࿖࡮࿾ၞ࡮࿖㓙␠ળߩ઀⚵ߺߣකቇߩ㑐ଥ㧘⮎ኂⵍኂ⠪ߩჿߥߤ㧘කቇߩᩮᧄߦ㑐ࠊࠆ੐㗄ࠍℂ⸃ߔࠆߎߣࠍ⋡ᮡߦታᣉߒߡ޿ࠆ‫ߚ߹ޕ‬㧘කቇ⑼ 1 ᐕᰴߢߩೋᦼ૕㛎ታ⠌ߢߪ㧘∛㒮㧘⑔␩ᣉ⸳㧘଻ஜᣉ⸳╬ߩ⷗ቇߦߣߤ߹ࠄߕ㧘ታ㓙ߦ੺⼔૕㛎ߥߤࠍⴕ߁‫ޕ‬㧝ᐕᰴᓟᦼߩ࿾ၞ૕㛎ታ⠌ߢߪ଻⢒ᚲ࿦ఽ㧘ᅧ↥ᇚ㧘㜞㦂⠪ߥߤߣ㧢ㅳ㑆ߦࠊߚࠅ⛮⛯⊛ߦ㑐ࠊࠅ㧘ࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦߩ
ขࠅᣇࠍቇ߮㧘࡜ࠗࡈࠨࠗࠢ࡞ߦኻߔࠆℂ⸃ࠍᷓ߼ࠆ‫ోޕ‬ቇ౒ㅢᢎ⢒ߢߪ㧘୘೎⑼⋡㧔ᔃℂቇ㧘ືቇ╬㧕㧘✚ว⑼⋡㧔ක≮ߩⴕേ⑼ቇ㧘ක≮ߣ↢๮㧕╬ࠍකቇ⑼ቇ↢ߦㆡวߢ߈ࠆࠃ߁ߦ⚵ߺ౉ࠇߡታᣉߒߡ޿ࠆ‫✚ޕ‬ว⑼⋡ߦߪᣢሽߩන⁛⻠ᐳߢߪ⚵߼ߥ޿⑼⋡ࠍ޽ߡߪ߼ࠆ‫ߜࠊߥߔޕ‬㧘ㆮવකቇ㧘వ┵ၮ␆කቇ㧘⥃ᐥ఺∉ቇ㧘࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦකቇ㧘ࠬࡐ࡯࠷කቇ㧘᷷ᴰකቇ㧘ᢇᕆකቇ㧘⠧ᐕකቇ㧔࠲࡯ࡒ࠽࡞࡮ࠤࠕࠍ฽߻㧕㧘⥃ᐥᩕ㙃ቇ╬ߦ㑐ߒߡ㧘ⶄᢙߩ㑐ㅪ⻠ᐳߣߩ⺞ᢛࠍ࿑ࠅߥ߇ࠄ㧘൮᜝⊛ߥࠞ࡝ࠠࡘ࡜ࡓࠍ⚵߻ߎߣߣߒߡ޿ࠆ‫ޕ‬٤࠹ࡘ࠻࡯࡝ࠕ࡞ࠦ࡯ࠬᜂᒰᢎຬ╬㧔ᐔᚑ 20 ᐕᐲ㧕
ࠦ࡯ࠬฬ

ࠦ࡯ࠬਥછ

᝼ᬺㅳᢙ

1

ੱ૕᭴ㅧቇ

٤ᣧᎹ

11

2

ઍ⻢࡮ᯏ⢻ቇ

٤ᗆ⦟㧘ጟ㊁㧘᫪↰㧘ਛፉ

73

ㆮવ࡮⊒↢࡮⊒㆐ቇ

٤ㄭ⮮

5

4

∛ේ૕ቇ

٤㜞ᯅ㧘ᳯፒ㧘಴ญ㧘ᷰㆺ

6

5⮎ℂ࡮ਛᲥቇ

٤ዊỈ㧘࿯⢈

4

6

∛ℂቇ

٤㜞⷗

3

7

␹⚻࡮♖␹࡮ⴕേቇ

٤દ⮮㧔๺㧕
㧘Ⴎ౉㧘ጤ㑆㧘›Ⴆ

108ᶖൻེ࡮⥃ᐥᬌᩏකቇ

٤᫪⣁㧘ᷡፉ㧘ᩊ↰㧘ศ↰

59ౝಽᴲઍ⻢ቇ

٤ᱞ↰㧘ᷡፉ

410ⴊᶧቇ٤㜞⷗㧘᫪⣁㧘ㄭ⮮㧘ർፉ

2

11

ᓴⅣེ࡮๭ๆེቇ

٤Ḋญ㧘┻᧛

7

12

⣢࡮ዩ〝ቇ

٤Ḋญ㧘಴ญ

3

13

ㆇേེቇ

٤ᷡ᳓㧔స㧕
㧘᧻ጟ

3

14

⊹⤏⑼ቇ

٤ർፉ

2

15

ᗵེⷡቇ

٤દ⮮㧔౎㧕
㧘ጊᧄ

4

16

఺∉ᔕ╵ቇ

٤ᱞ↰㧘㜞⷗㧘ㄭ⮮㧘⍹Ⴆ㧘ർፉ317↥⑼࡮ᇚੱ⑼ቇ

٤੹੗

3

18

㤗㈮࡮ᢇᕆ࡮−∩ቇ٤࿯⢈㧘ዊୖ

3

19

᡼኿✢කቇ

٤ᤊ

2

20

࿾ၞ࡮↥ᬺ଻ஜቇ

٤᳗↰㧘᧻ጟ㧘ർፉ㧘⍹Ⴆ

2

21↢๮୶ℂ࡮ᴺකቇ٤ᱞౝ㧘Ⴆ↰

2⸘٤ශߪ㧘ࠦ࡯ࠬਥછઍ⴫ࠍ␜ߔ‫ޕ‬

㧙㧙

91

㧔2㧕ᢎ⢒ᵴേߩታᣉౝኈߣᣇᴺ
කቇ⑼ߢߪකቇᢎ⢒ߩ⋡ᮡߣߒߡ㧘ੱ㑆ᕈ⼾߆ߢ↢ᶦቇ⠌ߔࠆක≮ੱ෸߮వ┵⊛ߢഃㅧ⊛⎇ⓥࠍផ
ㅴߔࠆකቇ⎇ⓥ⠪ߩ⢒ᚑߦࡐࠗࡦ࠻ࠍ⟎߈㧘↢๮⑼ቇߣߒߡߩකቇߩ߶߆ߦ㧘කߩ୶ℂ࡮ක≮⚻ᷣ╬
ߩᔃℂ࡮␠ળ⑼ቇ⊛஥㕙ࠍ㊀ⷞߔࠆ‫ޕ‬ቇ↢߇዁᧪ߘࠇߙࠇ଻ஜ࡮ක≮෸߮කቇಽ㊁ߦ⽸₂ߒ㧘කቇߩ⊒ዷߦነਈߔࠆߎߣ߇ߢ߈ࠆࠃ߁ߦߥࠆߚ߼ߦ㧘තᬺᤨߦએਅߩ 5 㗄⋡ࠍ㆐ᚑߔࠆߎߣࠍߨࠄ޿ߣߔࠆ‫ޕ‬Ԙ዁᧪කቇ㑐ଥߩ޿ߕࠇߩ㗔ၞߦㅴ߻਄ߦ߽ᔅⷐߥ㧘ၮ␆⍮⼂‫ޟ‬㧔ࠗ㧕ੱ㑆ߩᔃりߩᱜᏱߥ⊒⢒࡮᭴ㅧ࡮ᯏ⢻㧘㧔ࡠ㧕⊒⢒࡮᭴ㅧ࡮ᯏ⢻ߩ㜞㗫ᐲߩ⇣⁁㧘㧔ࡂ㧕଻ஜ࡮ක≮ߦ߅ߌࠆੱ㑆ߣ࿾ၞ࡮ᢥൻ࡮
␠ળ࡮ⅣႺ㧘
㧔࠾㧕ੱ㑆ߦ᦭⋉෶ߪ᦭ኂߦ૞↪ߔࠆ‛ℂ⊛࡮ൻቇ⊛࡮↢‛⊛࡮ᔃℂ⊛࡮␠ળ⊛࡮ᢥൻ⊛⻉࿃ሶ㧘
㧔ࡎ㧕㜞㗫ᐲ∔ᖚ࡮ਥⷐ∔ᖚߩ⸻ᢿߣߘࠇࠄߩᴦ≮ߩ᭎⇛㧘㧔ࡋ㧕✕ᕆ∔ᖚߩ⸻ᢿߣᔕ
㧔࠴㧕࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦ㧘㧔࡝㧕଻ஜ࡮ක≮ࠪࠬ࠹ࡓ㧔଻ஜ࡮⑔␩⾗ᕆಣ⟎㧘㧔࠻㧕∔ᖚߩ੍㒐㧘Ḯࠍ฽߻㧕‫ߣޠ‬ၮᧄᛛ⢻‫ޟ‬㧔ࠗ㧕໧⸻㧘
㧔ࡠ㧕ℂቇ⊛ᣇᴺߦࠃࠆᱜᏱߣ⇣Ᏹߩ㐓೎㧘㧔ࡂ㧕৻⥸⊛ⵝ⟎ࠍ↪޿ࠆ⸻ᢿᴺ㧘㧔࠾㧕ၮᧄ⊛⥃ᐥᬌᩏߩታᣉᴺ࡮ㆬᛯ࡮⸃㉼ߣ․ᱶᬌᩏᴺߩㆬᛯ࡮⸃㉼㧘㧔ࡎ㧕⥃ᐥ࠺࡯࠲ߩ෼㓸࡮ᢛℂ࡮⸥㍳㧘㧔ࡋ㧕⥃ᐥ໧㗴ߩ⹺⼂ߣ⸻ᢿ⸘↹ߩ⸳ቯߣ⹏ଔ㧘㧔࠻㧕ၮᧄ⊛ᴦ≮ᚻᛛ㧘㧔࠴㧕ᖚ⠪࡮ኅᣖߣߩࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦ‫ୃࠍޠ‬ᓧߔࠆ‫ޕ‬ԙ↢ᶦߦࠊߚߞߡ⊒ዷߐߖࠆߴ߈଻ஜ࡮ක≮ߩኾ㐷⡯ߦᔅⷐߥၮᧄ⊛ᘒᐲ࡮⠌ᘠ‫ޟ‬㧔ࠗ㧕කቇ࡮଻ஜ࡮ක≮ߩ໧㗴ߦขࠅ⚵߻Ⓧᭂ⊛ᘒᐲ㧘㧔ࡠ㧕කቇ࡮଻ஜ࡮ක≮ߩኾ㐷⡯ߣߒߡߩ␠ળ߳ߩ⽿છᗵ㧘㧔ࡂ㧕␠ળ࡮ⅣႺߩਛߩⶄว⊛ሽ࿷ߣߒߡੱ㑆ࠍᛠីߔࠆᘒᐲ㧘㧔࠾㧕଻ஜ࡮੍㒐࡮␠ળᓳᏫࠍ฽߻
൮᜝⊛ߥ߽ߩߣߒߡක≮ࠍᛠីߔࠆᘒᐲ㧘㧔ࡎ㧕ᖚ⠪෸߮ߘߩኅᣖߦኻߔࠆℂ⸃⊛ᘒᐲ㧘㧔ࡋ㧕ᖚ⠪෸߮ߘߩኅᣖߣߩା㗬㑐ଥࠍ㉯ᚑߔࠆ⠌ᘠ㧘㧔࠻㧕✚ว⊛࡮⑼ቇ⊛߆ߟᴉ⌕࡮಄㕒ߥ໧㗴⸃᳿ᘒᐲ㧘㧔࠴㧕⥄Ꮖߩ⢻ജ㒢⇇ߩ⹺⼂ߣㆡಾߥኾ㐷ኅߦኻߒߡഥ⸒ࠍଐ㗬ߔࠆ⠌ᘠ㧘㧔࡝㧕࠴࡯ࡓක≮࡮࠴࡯ࡓ⎇ⓥߦ߅ߌࠆද⺞⊛ߥ޿ߒᜰዉ⊛ᘒᐲ‫ࠍޠ‬りߦߟߌࠆ‫ޕ‬Ԛකቇ⊛໧㗴ࠍᱜߒߊߣࠄ߃㧘⥄ὼ⑼ቇߩߺߥࠄߕ㧘␠ળ⊛࡮ᔃℂቇ⊛ᣇᴺࠍ⛔วߒߡ⸃᳿ߔࠆߚ

߼ߩၮᧄ⊛⢻ജࠍୃᓧߔࠆ‫ޕ‬ԛ⍮⼂࡮ᛛ⢻࡮ᘒᐲࠍ⥄ࠄ⹏ଔߒ㧘߆ߟ⥄⊒⊛ቇ⠌ߣୃ✵ߦࠃߞߡ㧘ߘࠇࠄࠍะ਄ߒ⛯ߌࠆ⠌ᘠࠍりߦߟߌࠆ‫ޕ‬Ԝ 5 ᐕ↢ߢߩ⥃ᐥታ⠌ࠍฃߌࠆߦ޽ߚࠅ㧘4 ᐕᰴ 2 ᦬㧔࠹ࡘ࠻࡯࡝ࠕ࡞ 21 ࠦ࡯ࠬ⚳ੌᓟ㧕ߦⴕ߁⥃ᐥታ⠌⾗ᩰ✚ว್ቯ⹜㛎㧔ᐔᚑ 17 ᐕᐲ߆ࠄߪ㧘౒↪⹜㛎 CBT,OSCE ࠍዉ౉࡮ታᣉ㧕ࠍฃ㛎ߒ㧘วᩰߒߥߌࠇ߫ߥࠄߥ޿‫ޕ‬
ᧄቇ⑼ߢߪ 6 ᐕ৻⽾ᢎ⢒૕೙ࠍߣࠅ㧘౉ቇᓟߩᣧ޿ᤨᦼ߆ࠄකቇ↢ߣߒߡߩ⥄ⷡࠍଦߒ㧘⥄ਥ⊛࡮
Ⓧᭂ⊛ߥቇ⠌ᘒᐲ߿කᏧߣߒߡߩၮᧄ⊛ᘒᐲࠍりߦߟߌࠆߚ߼ߦ㧘ೋᦼ૕㛎ታ⠌㧘࿾ၞ૕㛎ታ⠌ࠍታᣉߒߡ߅ࠅ㧘ߐࠄߦቇ↢ߩ⥄ਥ⊛ቇ⠌ᘒᐲࠍ⢒ߡ㧘කቇ⎇ⓥ߳ߩᗧ᰼ࠍ㙃߁ߚ߼ߦ㧘࠹ࡘ࠻࡯࡝ࠕ࡞
ㆬᛯࠦ࡯ࠬߣߒߡቇ↢ࠍ⎇ⓥቶߦ㈩ዻߐߖ⥄↱⎇ⓥߩᦼ㑆ࠍ⸳ߌߡ޿ࠆ‫↢ߦࠄߐޕ‬๮୶ℂ࡮ක≮୶ℂቇ㧘ක≮␠ળቇ╬ߩኾ㐷㑐ㅪ⑼⋡߽කቇኾ㐷ᢎ⢒ߣᐔⴕߒߡⴕࠊࠇߡ޿ࠆ‫ޕ‬කቇᢎ⢒ᣇᴺߦߟ޿ߡߪ㧘⥄ਥቇ⠌ߣ໧㗴⸃᳿ဳᢎ⢒ࠍ㊀ⷞߒ㧘⻠⟵ᤨ㑆ߩ⍴❗ߣ㊀ⷐ੐㗄ߩ㊀ὐᢎ⢒㧘ዋੱᢙࠣ࡞࡯ࡊߦࠃࠆ
࠹ࡘ࠻࡯࡝ࠕ࡞ᢎ⢒ࠍផㅴߒߡ޿ࠆ‫ߦࠄߐޕ‬㧘␠ળ⊛ⷐ⺧߇ᒝ޿ᢎ⢒㗄⋡㧘ߔߥࠊߜ㧘ක≮୶ℂ㧘␠ળකቇ㧘ᖱႎකቇ㧘ක↪Ꮏቇ㧘ᢇᕆකቇ㧘ࡊ࡜ࠗࡑ࡝࡮ࠤࠕ㧘⠧ᐕකቇߥߤࠍ㊀ⷞߒߡ޿ࠆ‫⥃ޕ‬ᐥታ⠌ߪࠢ࡝࠾ࠞ࡞࡮ࠢ࡜࡯ࠢࠪ࠶ࡊᣇᑼࠍ㊀ⷞߒ㧘㒮ౝᄖߩㆬᛯታ⠌ߩ᜛లߦദ߼ߡ޿ࠆ߇㧘⥃ᐥታ⠌ߩలታߩߚ߼ߦߪᢎ⢒ߦ㑐ਈߔࠆᢎຬߩ⏕଻㧘ᢎ⢒⚵❱ߩᢛ஻㧘㒝ዻ∛㒮ߣ㑐ㅪ∛㒮ߦ߅ߌࠆ⥃ᐥᢎ⢒ࠬ࠲࠶ࡈߩ⏕଻߇੹ᓟߩ໧㗴ߢ޽ࠆ‫ޕ‬ᄢቇ∛㒮ߩ⚵❱࡮ᣉ⸳࡮ᢛ஻ߥߤߩᢛ஻᜛ల෸߮㑐ㅪ⎇ୃ∛㒮ߣߩදജ૕೙ߪත೨⥃ᐥታ⠌ߩઁ㧘↢ᶦᢎ⢒ࠍ฽߼ߡߩ⥃ᐥ⎇ୃߩߚ߼ߦ㊀ⷐߢ޽ࠆ‫ޕ‬㧙㧙⼾ንߥ⥃ᐥ⚻㛎ࠍ᦭ߔࠆቇᄖߩකᏧߦ㧘⥃ᐥᢎ⢒߳ߩදജࠍଐ㗬ߔࠆߚ߼㧘ᐔᚑ 8 ᐕᐲ߆ࠄ‫ޟ‬ቴຬ⥃ᐥ♽කቇᢎ᝼㧘ቴຬ⥃ᐥ♽කቇഥᢎ᝼෸߮ቴຬ⥃ᐥ♽කቇ⻠Ꮷ‫ߩޠ‬೙ᐲࠍ⸳ߌߚ‫ޕ‬ᐔᚑ 10 ᐕᐲ߆ࠄߪ㧘6 ᐕᰴቇ↢ߩቇᄖ⥃ᐥታ⠌ࠍ㐿ᆎߒߚߎߣߦ઻޿㧘ቇᄖታ⠌ࠍኻ⽎ߣߔࠆቴຬ⥃ᐥ♽කቇᢎ᝼╬ߩ೙ᐲࠍ⸳ߌߚ‫ޕ‬ᐔᚑ 12 ᐕ 10 ᦬ 1 ᣣߩකቇㇱ⋴⼔ቇ⑼⸳⟎ߦ઻޿㧘‫ޟ‬ጘ㒂ᄢቇකቇㇱකቇ⑼ቴຬ
⥃ᐥ♽කቇᢎ᝼╬ߩ⒓ภߩઃਈߦ㑐ߔࠆㆬ⠨ၮḰ‫ࠍޠ‬ᢛ஻ߒߚ‫ޕ‬
ᐔᚑ 12 ᐕᐲએ㒠ߩ⒓ภઃਈ⠪ᢙߣߘߩౝ⸶ߪ㧘ᰴ⴫ߩߣ߅ࠅߢ޽ࠆ‫ޕ‬٤ ቴຬ⥃ᐥ♽කቇᢎ᝼╬⒓ภઃਈᢙ඙‫ޓޓ‬ಽ

⥃ᐥᢎ᝼

⥃ᐥഥᢎ᝼

⥃ᐥ⻠Ꮷ

⸘

12 ᐕᐲ

25

30

35

90

13 ᐕᐲ

26

33

41

100

14 ᐕᐲ

26

32

39

97

15 ᐕᐲ

28

35

43

106

16 ᐕᐲ

29

34

43

106

17 ᐕᐲ

32

37

46

115

18 ᐕᐲ

35

39

47

121

19 ᐕᐲ

39

37

47

123

20 ᐕᐲ

64

36

43

143

㧔3㧕⺖㗴ߣዷᦸ
කቇᢎ⢒ߪᓥ᧪㧘⻠ᐳ೎ߦ᝼ᬺ⑼⋡߇⸳ቯߐࠇ㧘❑ഀࠅߩ᝼ᬺ߇ታᣉߐࠇߡ޿ߚ߇㧘ᧄቇߢߪᐔᚑ
7 ᐕᐲ߆ࠄ࠹ࡘ࠻࡯࡝ࠕ࡞ᢎ⢒ᴺࠍዉ౉ߒ㧘ၮ␆࡮⥃ᐥߩ⻠ᐳߩᨒࠍขࠅᛄߞߚ⛔วဳߩᢎ⢒ᴺࠍో
࿖ߩකቇㇱߦవ㚟ߌߡታᣉߒߡ߈ߚ‫ޕ‬หᢎ⢒ᴺࠍዉ౉ᓟ㧘ᣢߦ 13 ᐕ߇⚻ㆊߒ㧘ߘߩ㑆㧘ᢎຬߩᢎ⢒⚻㛎߽⫾Ⓧߐࠇ㧘ࠃࠅ⊛⏕ߢലᨐ⊛ߥᢎ⢒࡮ᜰዉ߇น⢻ߣߥࠅ㧘ࠞ࡝ࠠࡘ࡜ࡓߩᢎ᧚㐿⊒߽ㅴࠎߢ߈
ߚ‫ޕ‬ቇ↢ߩ࠹ࡘ࠻࡯࡝ࠕ࡞ߦኻߔࠆኻᔕ߽ቯ⌕ߒߡ߈ߚ߇㧘ᢎຬߩ⇣േ߿⺖㗴ߩᄌᦝߦ઻޿㧘ᐕᐲߏߣߦ⊒↢ߔࠆ᭽‫ߥޘ‬໧㗴ὐߦኻᔕߒ㧘ᡷ㕟ࠍ⛮⛯ߒߡ޿ࠆ‫ޕ‬ዉ౉ೋᦼߩࠦ࡯ࠬߩᄌᦝ㧘⛔ᑄว㧘ᦼ㑆ߩᄌᦝ╬㧘ᡷ㕟ࠍ㊀ߨ㧘⃻࿷ 21 ࠦ࡯ࠬ㧘91 ㅳߩ࠹ࡘ࠻࡯࡝ࠕ࡞߇ታᣉߐࠇߡ޿ࠆ‫ޕ‬ߎߩࠃ߁ߥකቇ⑼ߩࠞ࡝ࠠࡘ࡜ࡓߩᡷ㕟ߦߪ㧘㐳ᦼ⊛ዷᦸߦߚߞߡࠞ࡝ࠠࡘ࡜ࡓߩ࿷ࠅᣇࠍᬌ⸛ߔ
ࠆකቇ⑼ࠞ࡝ࠠࡘ࡜ࡓᆔຬળࠍᏱ⸳ߒ㧘කቇᢎ⢒㐿⊒⎇ⓥ࠮ࡦ࠲࡯㧔MEDC㧕㧘කቇᢎ⢒ડ↹㐿⊒ቶ㧘ᢎോෘ↢ᆔຬળߣදജߒ㧘ᡷ㕟ߦᒰߞߡ޿ࠆ‫ޕ‬⃻࿷㧘කቇㇱߩࠞ࡝ࠠࡘ࡜ࡓᡷ㕟ߩᄢ߈ߥᵹࠇߪ㧘⥃ᐥᢎ⢒ߩᡷༀ㧘කᏧߣߒߡߩࡊࡠࡈࠚ࠶࡚ࠪ
࠽࡞ᢎ⢒㧘කቇ⎇ⓥ⠪ߩ⢒ᚑ㧘࿾ၞක≮ߥߤߦะ޿ߡ߅ࠅ㧘␠ળߩᣂߒ޿ⷐ᳞ߦᴪߞߡ㧘ਅ⸥ߩࠃ߁
ߥ㊀ὐ⺖㗴ࠍឝߍߡᢎ⢒ᡷ㕟ࠍផㅴߒߡ߈ߚ‫ޕ‬1㧕 ⥃ᐥታ⠌㐿ᆎ೨ߩ⥃ᐥḰ஻ᢎ⢒ߩ᜛లߣߘߩ⹏ଔࠪࠬ࠹ࡓߩዉ౉
2㧕 ࠢ࡝࠾ࠞ࡞࡮ࠢ࡜࡯ࠢࠪ࠶ࡊߩ৻ጀߩផㅴ
3)ᄢቇ∛㒮߅ࠃ߮࿾ၞක≮ᯏ㑐ߦ߅ߌࠆㆬᛯ⥃ᐥታ⠌ߩ᜛ల

4㧕 ࠪࡒࡘ࡟࡯࡚ࠪࡦᢎ⢒ߣᮨᡆᖚ⠪ߩዉ౉5)㧢ᐕ৻⽾ߩࡊࡠࡈࠚ࠶࡚ࠪ࠽࡞ᢎ⢒ߩዉ౉

6)࠹ࡘ࠻࡯࡝ࠕ࡞ㆬᛯࠦ࡯ࠬߦ߅ߌࠆ⎇ⓥ૕㛎ߩ᜛ల

7)࿾ၞ૕㛎ታ⠌㧘࿾ၞ㈩ዻߥߤߩዉ౉

㧙㧙࠹ࡘ࠻࡯࡝ࠕ࡞࡮ࠪࠬ࠹ࡓߪ⥄ቇ⥄⠌ࠍၮᧄߦߒߡ߅ࠅ㧘ᓥ೨ߦ߽Ⴧߒߡ㧘ല₸ൻߒߚකቇ࡮ක≮ᖱႎឭଏࠪࠬ࠹ࡓ╬ߩቇ⠌ᡰេ૕೙߇ᔅⷐߢ޽ࠅ㧘࠹ࡘ࠻࡯࡝ࠕ࡞∝଀࡮ࠪ࡜ࡃࠬߩឭ␜㧘OSCE࡮ࠪࡒࡘ࡟࡯࡚ࠪࡦᢎ⢒↪േ↹ߥߤࠍឭଏߢ߈ࠆࠨ࡯ࡃ࡯ࠪࠬ࠹ࡓࠍ᭴▽ߒߟߟ޽ࠆ‫ޕ‬3㧚 ᢎ⢒ᣇ㊎㧔1㧕ᢎ⢒ᡷ㕟
21 ਎♿ߦ߅ߌࠆක≮ੱ⢒ᚑߩ⠨߃ᣇߪ㧘ᐔᚑ 8 ᐕ 6 ᦬ 13 ᣣߩ 21 ਎♿කቇ࡮ක≮ᙣ⺣ળߩ╙৻ᰴႎ๔‫ޟ‬21 ਎♿ߩ๮ߣஜᐽࠍ቞ࠆක≮ੱߩ⢒ᚑࠍ⋡ᜰߒߡ‫ߦޠ‬એਅߩߣ߅ࠅ␜ߐࠇߡ޿ࠆ‫ޕ‬࡮ ක≮ੱߣߒߡߩ⢻ജ࡮ㆡᕈߦ⇐ᗧߒߚੱ᧚ㆬ⠨࡮ ੱ㑆ᕈ⼾߆ߥක≮ੱ࡮ ᖚ⠪ਛᔃ㧘ᖚ⠪ᧄ૏ߩ┙႐ߦ┙ߞߚක≮ੱ࡮ ᄙ᭽ߥⅣႺߩਛߢ⢒ߟක≮ੱ࡮ ↢ᶦቇ⠌ߔࠆක≮ੱ࡮ ࿾⃿ੱߣߒߡᵴേߔࠆක≮ੱߘߩᓟ㧘╙ 2 ᰴႎ๔㧔ᐔᚑ 9 ᐕ 2 ᦬㧕㧘╙ 3 ᰴႎ๔㧔ᐔᚑ 9 ᐕ 7 ᦬㧕෸߮╙ 4 ᰴႎ๔㧔ᐔᚑ 11 ᐕ 2᦬㧕߇౏⴫ߐࠇ㧘ߎߩឭ⸒ࠍవขࠅߔࠆᒻߢᧄቇߩᢎ⢒ᡷ㕟߇ߥߐࠇߡ߈ߚ‫ޕ‬⤘ᄢߥකቇ⍮⼂ࠍනߦᢎ᝼ߒ㧘⹣߼ㄟ߻ߛߌߩᢎ⢒ߢߪᕆㅦߥකቇߩㅴᱠߣ␠ળߩ࠾࡯࠭ߦኻᔕߢ
߈ࠆකᏧ㧘කቇ⠪ࠍ⢒ᚑߔࠆߎߣߪਇน⢻ߢ޽ࠆ‫ᧄޕ‬ቇㇱߦ߅޿ߡߪ㧘ᦼᓙߐࠇࠆක≮ੱߩ⢒ᚑࠍ⋡ᜰߒߡቇㇱᢎ⢒ߩᡷༀߦ㍈ᗧขࠅ⚵ߺ㧘ᐔᚑ 7 ᐕᐲ౉ቇ↢߆ࠄ㧘ዋੱᢙ࡮໧㗴⸃᳿ဳᢎ⢒ߢ޽ࠆ࠹ࡘ
࠻࡯࡝ࠕ࡞ࠪࠬ࠹ࡓࠍዉ౉ߒ㧘⥃ᐥᢎ⢒ߩᡷ㕟ߦ߽ขࠅ⚵ࠎߢ߈ߚ‫ޕ‬
ᐔᚑ 7 ᐕᐲ౉ቇ↢߆ࠄዉ౉ߒߚࠞ࡝ࠠࡘ࡜ࡓߢߪ㧘એਅߩࠃ߁ߥᡷ㕟߇ߥߐࠇߚ‫ޕ‬࡮ ዋੱᢙ࡮໧㗴⸃᳿ဳ࠹ࡘ࠻࡯࡝ࠕ࡞࡮ࠪࠬ࠹ࡓ㧔㧞㨪㧠ᐕᰴ㧕࡮ ක≮ੱߣߒߡߩ⋡⊛ᗧ⼂ࠍ㜞߼ࠆߚ߼ߩೋᦼ૕㛎ታ⠌Σ㧔Early Exposure I㧕㧔㧝ᐕᰴ㧕࡮ ࡝ࠨ࡯࠴ࡑࠗࡦ࠼ࠍ㉯ᚑߔࠆߚ߼ߩೋᦼ૕㛎ታ⠌Τ㧔ၮ␆කቇ࡮␠ળකቇ࠮ࡒ࠽࡯㧕㧔㧞ᐕᰴ㧕࡮ ක≮ੱߦᔅ㗇ߥකቇ⧷⺆㧔㧝ᐕᰴ㧕࡮ ⍮⼂࡮ᘒᐲ࡮ᛛ⢻ߩ⠌ᓧࠍ⋡ᜰߒߚ⸻≮ෳടဳࠢ࡝࠾ࠞ࡞࡮ࠢ࡜࡯ࠢࠪ࠶ࡊ㧔㧡㨪㧢ᐕᰴ㧕࡮ ᄙ᭽ߥ࿾ၞක≮ⅣႺߩਛߢߩቇ⠌⚻㛎ࠍ࿑ࠆቇᄖ⥃ᐥታ⠌㧔㧢ᐕᰴ㧕ߎߩࠞ࡝ࠠࡘ࡜ࡓߩᩭߣߥࠆ࠹ࡘ࠻࡯࡝ࠕ࡞ࠪࠬ࠹ࡓߪ㧘ᥧ⸥ߦ㗬ࠆㆊ೾ߥᢿ ⊛⍮⼂㧘ၮ␆කቇߣ⥃ᐥකቇߩਵ㔌㧘ቇ↢߇Ⓧᭂ⊛ߦ᝼ᬺෳടߒߥ޿╬ߩᢎ⢒਄ߩᰳ㒱ࠍᡷༀߔߴߊዉ౉ߐࠇߚ߽
ߩߢ㧘ᖚ⠪ᖱႎࠍࡕ࠺࡞ൻߒߚ⺖㗴ࠍㅢߒߡ㧘ቇ⠌߳ߩേᯏࠍ㜞឴ߒ㧘໧㗴⊒⷗⢻ജ㧘໧㗴⸃᳿⢻
ജ෸߮ᵢኤജࠍ㜞߼㧘↢ᶦቇ⠌ߦߟߥ߇ࠆ⥄Ꮖቇ⠌ߩ⠌ᘠࠍ㙃޿㧘ࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦߩᾫ✵ࠍ࿑ࠆᢎ⢒ᣇ⇛ߢ޽ࠆ‫ޕ‬
㧔2㧕ోቇ౒ㅢᢎ⢒ጘ㒂ᄢቇߢߪ㧘ᐔᚑ 8 ᐕ 9 ᦬ߦᢎ㙃ㇱ߇ᑄᱛߐࠇ㧘࿾ၞ⑼ቇㇱߩ⊒⿷ߦ઻޿㧘ᐔᚑ 9 ᐕᐲ߆ࠄోቇ
૕೙ߩᢎ㙃ᢎ⢒㧘ߔߥࠊߜోቇ౒ㅢᢎ⢒߇ታᣉߐࠇߡ޿ࠆ‫ޕ‬ᄢቇ⸳⟎ၮḰ╙ 19 ᧦‫ޟ‬ᢎ⢒⺖⒟ߩ✬ᚑߦᒰߚߞߡߪ㧘ᄢቇߪ㧘ቇㇱ╬ߩኾ᡹ߦଥࠆኾ㐷ߩቇ⧓ࠍᢎ᝼ߔࠆߣߣ߽ߦ㧘᏷ᐢߊᷓ޿ᢎ㙃෸߮✚ว⊛ߥ್ᢿജࠍၭ޿㧘⼾߆ߥੱ㑆ᕈࠍᶩ㙃ߔࠆࠃ߁ㆡಾߦ㈩ᘦߒߥߌࠇ߫ߥࠄߥ޿‫ࠍޠޕ‬ዅ㊀ߒ㧘␠ળߩ࠾࡯࠭ߦᔕ߃ࠆߎߣ߇ߢ߈ࠆᢎ㙃ᢎ⢒߇ࠬ࠲࡯࠻ߒߚ‫ޕ‬ᐔᚑ 12 ᐕᐲ߆ࠄߪ㧘‫ోޟ‬ᢎຬදജ૕೙‫ޠ‬ߩᣂߒ޿ోቇ౒ㅢᢎ⢒߇ᆎ߹ߞߚ‫✚ޕ‬วᄢቇߩ೑ὐࠍ↢߆ߒ㧘ಽ㊁ߩ⇣ߥࠆᢎຬ߇ෳടߒߡ㧘
‫ੱޟ‬㘃

㧙㧙

߿⥄ὼߣߩ౒↢ࠍផߒㅴ߼ࠆߚ߼ߩᢎ⢒‫ޠ‬㧘‫ޟ‬ቇ໧ߣ␠ળߣߩ㐿߆ࠇߚ㑐ଥࠍ᭴▽ߔࠆߚ߼ߩᢎ⢒‫ࠍޠ‬᭴▽ߒߡ޿ࠆ‫ޕ‬
㧔3㧕ฦ࠹ࡘ࠻࡯࡝ࠕ࡞ࠦ࡯ࠬߩ᝼ᬺ⸘↹㧔ࠪ࡜ࡃࠬ㧕ߩ૞ᚑ෸߮ቇ⠌ౝኈߩ⺞ᢛ᝼ᬺ⸘↹ߦߟ޿ߡߪ㧘ࠞ࡝ࠠࡘ࡜ࡓᆔຬળ㧘කቇ⑼ᢎോෘ↢ᆔຬળ㧘ડ↹㐿⊒ቶߢၮᧄᣇ㊎ࠍ᳿ቯߒ㧘࠹ࡘ࠻࡯࡝ࠕ࡞ࠦ࡯ࠬਥછࠍਛᔃߦࠦ࡯ࠬߏߣߦ૞ᚑߒ㧘ߘߩ᭎ⷐࠍ᝼ᬺ᩺ౝߦឝタߒߡቇ↢ߦ๟⍮ߒߡ޿ࠆ‫ޕ‬ᐔᚑ 14 ᐕᐲ߆ࠄߪ㧘ฦ⥄߇ᔅⷐߥࡍ࡯ࠫࠍශ೚ߢ߈ࠆࠃ߁ߦ㧘᝼ᬺ᩺ౝߦ CD ࠍᷝઃߒߡ޿ࠆ‫ޕ‬ฦࠦ࡯ࠬߩ᝼ᬺౝኈߩ⺞ᢛߪ㧘ࠦ࡯ࠬߏߣߩ⹤ߒว޿ߣડ↹㐿⊒ቶߦࠃࠆฦࠦ࡯ࠬ FDߦࠃࠅߥߐࠇߡ޿ࠆ‫ޕ‬
㧔4㧕⥃ᐥታ⠌ᧄቇㇱߢߪ㧘ࠢ࡝࠾ࠞ࡞࡮ࠢ࡜࡯ࠢࠪ࠶ࡊߩዉ౉ࠍਛᔃߣߒߚ⥃ᐥታ⠌ߩᡷ㕟ࠍⴕߞߚ‫ ߢ߹ࠇޕ‬5
ᐕᰴ 3 ቇᦼ߆ࠄ 6 ᐕᰴ 2 ቇᦼ߹ߢߢ޽ߞߚ⥃ᐥታ⠌ᦼ㑆ࠍ㧡ᐕᰴ㧝ቇᦼ߆ࠄ㧢ᐕᰴ㧝ቇᦼ߹ߢߦ᜛ల
ߒ㧘4 ᐕᰴቇᦼᧃߦ‫⥃ޟ‬ᐥታ⠌⾗ᩰ✚ว್ቯ⹜㛎‫ߡߒ⺖ࠍޠ‬ㅴ⚖್ቯࠍⴕ޿㧘⥃ᐥታ⠌౉㐷ࠦ࡯ࠬ߇ᣂ⸳ߐࠇߚ‫್ߩߎޕ‬ቯ⹜㛎ߪ⃻࿷㧘౒↪⹜㛎 CBT ߣ OSCE ߦࠃߞߡⴕࠊࠇߡ޿ࠆ‫⃻ޕ‬࿷㧘5 ᐕᰴ 1ቇᦼ߆ࠄ 3 ቇᦼ߹ߢቇౝߢࠢ࡝࠾ࠞ࡞࡮ࠢ࡜࡯ࠢࠪ࠶ࡊ߇ⴕࠊࠇ㧘6 ᐕᰴߦ 60 ᣣ㑆 (12 ㅳ㑆 ) ߩቇᄖ࡮ቇౝㆬᛯ⥃ᐥታ⠌߇ⴕࠊࠇߡ޿ࠆ‫ޕ‬⥃ᐥታ⠌ߩᡷ㕟ߦ޽ߚߞߡߪ㧘ᣣᧄකቇᢎ⢒ቇળ⥃ᐥ⢻ജ⹏ଔࡢ࡯ࠠࡦࠣࠣ࡞࡯ࡊߩ⥃ᐥᢎ⢒ߩᢎ⢒⋡ᮡ㧔᩺㧕ߦࠃࠆ৻⥸⋡ᮡ‫ޟ‬዁᧪㧘කቇක≮ߩ޿ߕࠇߩಽ㊁ߦㅴ߻ߦߖࠃ㧘තᓟ⎇ୃࠍലᨐ⊛ߦߔࠆߚ߼ߦ㧘ၮᧄ⊛⥃ᐥ⢻ജࠍりߦߟߌࠆ‫ࠍޠ‬ෳ⠨ߣߒߚ‫ߚ߹ޕ‬㧘⥃ᐥታ⠌೨ߩ⢻ജ್ቯߩᔅⷐᕈ㧘⥃ᐥታ⠌ߩ㐿ᆎᤨᦼߣᤨ㑆ᢙ㧘㊀ὐ㈩⟎㧔ࠦࠕᢎ⢒㧕ߣࡠ࡯࠹࡯࡚ࠪࡦᣇᴺ㧘ࠢ࡜࡯ࠢࠪ࠶ࡊߩዉ౉ߥ
ߤߦߟ޿ߡᬌ⸛ߐࠇߚ‫⚿ߩߘޕ‬ᨐ㧘ත೨⥃ᐥታ⠌౉㐷෸߮⥃ᐥታ⠌⾗ᩰ✚ว್ቯ⹜㛎ߩዉ౉㧘ታ⠌㐿ᆎᤨᦼߩ➅ࠅ਄ߍ㧘ࠢ࡜࡯ࠢࠪ࠶ࡊߩዉ౉㧘ታ⠌ᤨ㑆ᢙߩჇട㧘㑐ㅪᢎ⢒∛㒮ߢߩ㒮ᄖታ⠌ߩዉ౉߇᳿ቯߐࠇߚ‫ޕ‬ᐔᚑ 16 ᐕߩᣂ∛㒮㐿㒮ᓟ㧘ᐔᚑ 17 ᐕᐲ߆ࠄ 4 ㅳ㑆㧝ࡉࡠ࠶ࠢߩታ⠌ࡠ࡯࠹࡯࡚ࠪࡦࠍ
ዉ౉ߒ㧘⸻≮⑼⋡ߩ㊀ὐ㈩⟎ࠍዉ౉ߒߚ‫ޕ‬
㧔5㧕ᣂ౉↢วኋ⎇ୃ
ᐔᚑ 7 ᐕᐲ߆ࠄ 1 ᴱ 2 ᣣߩ‫ޟ‬ᣂ౉↢วኋ⎇ୃ‫ࠍޠ‬ዉ౉ߒߚ‫ޕ‬ห⎇ୃߪᄢቇ↢ᵴࠬ࠲࡯࠻ᤨߦ㧘කቇ↢ߣߒߡ዁᧪කᏧ㧘⎇ⓥ⠪ߣߥࠆߚ߼ߩቇജୃᓧ㧘ੱ㑆ᒻᚑ⏕┙╬ߩ㊀ⷐᕈࠍ⹺⼂ߐߖࠆ⋡⊛ߢ౉ቇᑼ⋥ᓟߦⴕࠊࠇࠆ‫ޕ‬ߎߩ⎇ୃߩౝኈߪ㧘‫ޟ‬කቇㇱ㐳⻠⹤㧘ోቇ౒ㅢᢎ⢒෸߮ኾ㐷ᢎ⢒ࠟࠗ࠳ࡦࠬ㧘ቇ↢↢ᵴࠟࠗ࠳ࡦࠬ㧘࠺ࠖࡌ࡯࠻㧘࠮ࡒ࠽࡯㧘ࠣ࡞࡯ࡊ⸛⺰㧘㊁ᄖታ⠌㧘ᢎຬߣߩ੤ᵹળ‫ޕࠆ޽ߢ╬ޠ‬
㧔6㧕࿷ቇ↢วኋ⎇ୃቇ↢߇ోੱ⊛ක≮ࠍ〯߹߃ߚ⥃ᐥታ⠌ࠍ᦭ലߦㆀⴕߢ߈ࠆࠃ߁ߦ㧘ᐔᚑ 7 ᐕᐲ߆ࠄ‫ޟ‬5 ᐕ↢วኋ⎇ୃ‫ࠍޠ‬ዉ౉ߒߚ‫ޕ‬KJ ᴺࠍ૶ߞߡ㧘∛᳇ߩ๔⍮㧘ᖚ⠪ߩ቞⒁⟵ോ㧘࠴࡯ࡓක≮㧘21 ਎♿ߩකቇ࡮ක≮ߩᣇะᕈ╬߳ߩ໧㗴ᗧ⼂ߩ㐿ᜏ෸߮ࡠ࡯࡞ࡊ࡟ࠗ㧘ᮨᡆᖚ⠪ߦࠃࠆක≮㕙ធߩ⸠✵ࠍⴕߞߡ߈ߚ‫ޕ‬20ᢙฬߩᢎോෘ↢ᆔຬ㧘⥃ᐥ♽ᢎቭ߇ෳടߒߡቇ↢ߩᜰዉߦᒰߚࠆኒᐲߩ㜞޿⎇ୃߢ޽ࠆ‫ޕ‬ᐔᚑ 13 ᐕᐲ߆ࠄߪ⎇ୃౝኈߣߒߡ OSCE ࠍขࠅ౉ࠇ㧘ᐔᚑ 14 ᐕᐲߦߪਃ㊀ᄢቇߣߩ㑆ߢ౒↪⹜㛎 OSCE ߩ╙
2 ࿁࠻࡜ࠗࠕ࡞ߦ߅޿ߡ⹏ଔ⠪ߩ⋧੕ਸ਼ࠅ౉ࠇࠍⴕ޿㧘ᒰ⎇ୃߢታᣉߒߚ‫ޕ‬ᐔᚑ 16 ᐕᐲ߆ࠄߪ㧘4 ᐕᰴቇ↢ࠍኻ⽎ߣߒߡᒰ⎇ୃࠍᲤᐕⴕߞߡ޿ࠆ‫ޕ‬㧙㧙㧔7㧕⥃ᐥታ⠌⾗ᩰ✚ว್ቯ⹜㛎㧔౒↪⹜㛎 CBT, OSCE㧕ᐔᚑ 3 ᐕ 5 ᦬ߩ‫ޟ‬ෘ↢⋭⥃ᐥታ⠌ᬌ⸛ᆔຬળᦨ⚳ႎ๔‫ߦޠ‬ᴪߞߡ㧘කⴕὑߩ᜛ᄢߣࠢ࡝࠾ࠞ࡞࡮ࠢ
࡜࡯ࠢࠪ࠶ࡊߩዉ౉ߩ᧦ઙߣߒߡ㧘ᐔᚑ 8 ᐕ 2 ᦬㧔╙ 4 ᐕᰴ 3 ቇᦼ㧕߆ࠄ⥃ᐥታ⠌⾗ᩰ✚ว್ቯ⹜㛎ࠍዉ౉ߒߚ‫ޕ‬ᐔᚑ 17 ᐕᐲ߆ࠄߪ㧘౒↪⹜㛎 CBT,OSCE ࠍዉ౉ߒߎࠇߦࠃߞߡ 5 ᐕᰴ߳ߩㅴ⚖್ቯࠍⴕߞߡ޿ࠆ‫ޕ‬
㧔8㧕ઁᄢቇߦ߅ߌࠆ᝼ᬺ⑼⋡ߩጁୃߩᣇ㊎ߣ⁁ᴫ㧢ᐕᰴߩㆬᛯ⥃ᐥታ⠌ߢᶏᄖߩᄢቇ࡮ᢎ⢒∛㒮ߢߩ⥃ᐥታ⠌ࠍᏗᦸߒ㧘⾗ᩰ޽ࠅߣ್ቯߐࠇߚቇ↢ߪ㧘ᶏᄖߢߩታ⠌ࠍ⸵นߒߡ㧘㧢ᐕ↢ߩታ⠌ߣߒߡ⹺߼ߡ޿ࠆ‫ޕ‬㧔9㧕࿷☋㧘⇐ᐕ㧘ભቇ㧘ㅌቇߩ⁁ᴫ
ㆊ෰ 8 ᐕ㑆ߩ⁁ᴫߪᰴ⴫ߩߣ߅ࠅߢ޽ࠆ‫ޕ‬කቇ⑼ߦ߅ߌࠆㆊ෰ 8 ᐕ㑆ߩ⇐ᐕߩഀวߪ 2.3㧑ߢ޽ࠅ㧘ભቇߩഀวߪ 1.7㧑ߢ޽ࠆ‫ޕ‬ㅌቇ⠪ߪߎߩ 8 ᐕ㑆ߢ 4 ฬߢ޽ࠆ‫ޕ‬඙‫ޓޓ‬ಽ

࿷‫☋ޓޓ‬⇐‫ޓޓ‬ᐕ

ભ‫ޓޓ‬ቇ

ㅌቇ㧔㒰☋ࠍ฽߻㧕ᐔᚑ 12 ᐕᐲ

487

21

8

0

ᐔᚑ 13 ᐕᐲ

489

11

22

1

ᐔᚑ 14 ᐕᐲ

498

10

12

1

ᐔᚑ 15 ᐕᐲ

495

7

1

0

ᐔᚑ 16 ᐕᐲ

495

8

4

0

ᐔᚑ 17 ᐕᐲ

492

11

4

0

ᐔᚑ 18 ᐕᐲ

488

10

6

0

ᐔᚑ 19 ᐕᐲ

488

14

10

2

㧔10㧕ᢎ⢒ᣉ⸳࡮⸳஻ߩ⃻⁁඙‫ޓޓޓޓ‬ಽ㕙 Ⓧ⻠⟵ቶ㧔4 ቶ㧕㧞㧘㧟㧘㧠ᐕ↢ᢎቶᐔᚑ㧝㧤ᐲ㧟᦬
කቇ⑼ ࡮⑔೑᫟ቢᚑ
ߦ઻޿㧘㧠᦬߆ࠄ೑↪
㐿ᆎ㧡࡮㧢ᐕ↢ᢎቶකቇㇱᧄ㙚⻠⸳‫ޓޓޓޓޓޓޓ‬஻⟵

151.2 ট / ቶAV ⵝ⟎৻ᑼ

124.0 ট࠹ࡘ࠻࡯࡝ࠕ࡞ቶ㧔30 ቶ㧕ᐔᚑ㧝㧤ᐲ㧟᦬
කቇ⑼ ࡮⑔೑᫟ቢᚑ
ߦ઻޿㧘㧠᦬߆ࠄ೑↪
㐿ᆎ↪ ‫ޓ‬ㅜ

࠹ࡘ࠻࡯࡝ࠕ࡞
࡮ࠦࠕ࠲ࠗࡓ

21.7 ট / ቶࡄ࠰ࠦࡦ㧘ࡆ࠺ࠝ㧘ࡎࡢࠗ࠻ࡏ࡯࠼㧘ࠪࡖ࡯ࠞ࠹ࠬࡦ㧘කቇኾ㐷࿑ᦠࠍ⸳⟎࠹ࡘ࠻࡯࡝ࠕ࡞
࡮ࠦࠕ࠲ࠗࡓ⥄ቇ • ⥄⠌ቶট⥃ᐥᛛ⢻ᢎ⢒AV ⵝ⟎৻ᑼ㧘ࡄ࠰ࠦࡦ㧘ᚻᵞ޿ⵝ⟎ฦ⒳ࠪࡒࡘ࡟࡯࠲࡯ࠍ⸳⟎⸃೬ታ⠌ቶ㧔↢๮⑼ቇ᫟㧝㓏㧕284 ট

⸃ ೬ ታ ⠌AV ភ⟎৻ᑼ㧘⸃೬บ⚵❱࡮∛ℂታ⠌ቶ 㧔2N22㧕

277 ট

ታ⠌࡮⻠⟵

AV ⵝ⟎৻ᑼ㧘㗼ᓸ㏜

ࠬࠠ࡞ࠬ࡜ࡏ

㧙㧙

㕙 Ⓧ

඙‫ޓޓޓޓ‬ಽ↪ ‫ޓ‬ㅜ

⸳‫ޓޓޓޓޓޓޓ‬஻↢ൻቇ࡮∛ේᘒታ⠌ቶ 㧔4S02㧕

261 ট

ታ⠌࡮⻠⟵

AV ⵝ⟎৻ᑼ㧘㗼ᓸ㏜㧘ታ㛎บ↢૕ᯏ⢻♽ታ⠌ቶ 㧔8N22㧕

238 ট

ታ⠌࡮⻠⟵

AV ⵝ⟎৻ᑼ㧘ታ㛎บᖱႎಣℂṶ⠌ቶ204 ট

ᖱ ႎ ಣ ℂࡄ࠰ࠦࡦ㧔100 บ㧕㧘AV ⵝ⟎৻ᑼ

㧔2S㧕

㧔11㧕ᚑ❣ߩ⹏ଔ㧘⹺ቯߩၮḰᚑ❣ߩ⹏ଔ࡮⹺ቯߦߟ޿ߡߪ㧘කቇㇱⷙ⒟㧔╙ 5 ᧦㨪╙ 13 ᧦㧕ߦࠃࠅⴕࠊࠇߡ߅ࠅ㧘⹜㛎ߩᚑ❣
߇ 60 ὐᧂḩࠍਇวᩰߣߔࠆ‫∛ޕ‬᳇ߘߩઁ߿߻ࠍᓧߥ޿ℂ↱ߩߚ߼㧘⹜㛎ࠍฃ㛎ߢ߈ߥ߆ߞߚ႐วߪ㧘
ߘߩℂ↱ࠍ↳ߒ಴ߚ⠪ߦ㒢ࠅ㧘ㅊ⹜㛎ࠍฃߌࠆߎߣ߇ߢ߈ࠆ‫ޕ‬⹜㛎ߩ⚿ᨐ߇ਇวᩰߣ್ቯߐࠇߚ⠪ߪ 1 ࿁ߦ㒢ࠅ㧘ౣ⹜㛎ࠍฃߌࠆߎߣ߇ߢ߈ࠆ‫ޕ‬᝼ᬺ⑼⋡ߩᚑ❣ߩ߁ߜ㧘ఝ㧘⦟෸߮นߪวᩰߣߒ㧘ਇนߪਇวᩰߣߔࠆ‫ޕ‬
5 ᐕᰴ߆ࠄ 6 ᐕᰴ߳ߩㅴ⚖ߦߪᚑ❣⹏ଔࠍⷐߔࠆ᧦ઙߪߥ޿߇㧘ઁߩቇᐕᰴ߳ߩㅴ⚖ߦߪ㧘ᚑ❣⹏ଔ࡮⹺ቯߩ᧦ઙ߇ᰴߩࠃ߁ߦ⸳ߌࠄࠇߡ޿ࠆ‫ޕ‬Ԙ

1 ᐕᰴ߆ࠄ 2 ᐕᰴ߳ߩㅴ⚖ᒰ⹥ቇᐕߦ⺖ߖࠄࠇࠆකቇㇱᜂᒰᢎ⢒㧘ోቇ౒ㅢᢎ⢒ߩᔅⷐන૏ࠍୃᓧߒߥߌࠇ߫ߥࠄߥ޿‫ޕ‬

ԙ 2 ᐕᰴ߆ࠄ 3 ᐕᰴ߳㧘3 ᐕᰴ߆ࠄ 4 ᐕᰴ߳㧘4 ᐕᰴ߆ࠄ 5 ᐕᰴ߳ߩㅴ⚖ᒰ⹥ቇᐕߦ⺖ߖࠄࠇࠆ࠹ࡘ࠻࡯࡝ࠕ࡞ࠦ࡯ࠬߩ߁ߜ㧘2 ࠦ࡯ࠬਇ⹺ቯߩ႐วߪ 1 ᐕ㑆ߩ⇐ᐕࠍ⺖ߒ㧘ౣᐲหࠦ࡯ࠬࠍጁୃߐߖࠆߎߣߣߒߡ޿ࠆ‫ޕ‬1 ࠦ࡯ࠬਇ⹺ቯߩ႐วߪ઒ㅴ⚖ߣߒ㧘⠉ᐕ߹ߢߦวᩰߔࠆߎߣࠍ᧦ઙߣߔࠆ‫߅ߥޕ‬㧘࠹ࡘ࠻࡯࡝ࠕ࡞࡮ࠦࠕ࠲ࠗࡓߩ಴Ꮸ₸ 80㧑ࠍࠦ࡯ࠬ⚳ੌᤨߩ✚ว್ቯ⹜㛎ߩฃ㛎⾗ᩰߣߒߡ޿ࠆ‫ߦࠄߐޕ‬㧘5 ᐕᰴ߳ߩㅴ⚖ߦߪ㧘ߔߴߡߩ࠹ࡘ࠻࡯࡝ࠕ࡞ࠦ࡯ࠬ
ߦวᩰߒ㧘౒↪⹜㛎 CBT, OSCE ߦวᩰߒ㧘߆ߟ㧘⥃ᐥታ⠌౉㐷ࠍୃᓧߔࠆߎߣࠍ⟵ോઃߌߡ޿ࠆ‫ޕ‬
㧔12㧕කᏧ࿖ኅ⹜㛎วᩰ⁁ᴫකᏧ࿖ኅ⹜㛎ߪ㧘⃻࿷ߩක≮૕೙ߦ᳞߼ࠄࠇࠆකᏧߦᔅⷐߥකቇ⍮⼂ࠍ⹜㛎ߦࠃߞߡ㧘කᏧߩ⢻ജࠍ␠ળ⊛ߦ଻⸽ߒࠃ߁ߣߒߡ޿ࠆ೙ᐲߢ޽ࠆߣᕁࠊࠇࠆ߇㧘කቇᢎ⢒ߩᚑᨐߩ 1 ߟߣߒߡ㧘࿖ኅ⹜㛎ߩวᩰ₸߽シⷞߔࠆߎߣߪߢ߈ߥ޿‫ޕ‬
ㆊ෰ 8 ᐕ㑆ߩวᩰ⁁ᴫߪ㧘ᰴ⴫ߩߣ߅ࠅߢ޽ࠅ㧘࠹ࡘ࠻࡯࡝ࠕ࡞ᢎ⢒ࠍዉ౉ᓟߩวᩰ₸ߪ⦟ᅢߦផ
⒖ߒߡ޿ࠆ‫ޕ‬කᏧ࿖ኅ⹜㛎วᩰ₸඙‫ޓޓޓ‬ಽᣢ‫ޓ‬ත‫ޓ‬⠪ᣂ‫ޓ‬ත‫ޓ‬⠪

12 ᐕᐲ㧔 95 ࿁㧕

80.0%

97.4%

94.6%

⸘

13 ᐕᐲ㧔 96 ࿁㧕

25.0%

100.0%

95.8%

14 ᐕᐲ㧔 97 ࿁㧕

25.0%

100.0%

96.4%

15 ᐕᐲ㧔 98 ࿁㧕

0%

97.4%

93.8%

16 ᐕᐲ㧔 99 ࿁㧕

50.0%

90.5%

87.8%

17 ᐕᐲ㧔100 ࿁㧕

36.4%

97.6%

90.5%

18 ᐕᐲ㧔101 ࿁㧕

12.5%

96.3%

88.6%

19 ᐕᐲ㧔102 ࿁㧕

62.5%

97.5%

94.3%

㧙㧙

4㧚 ቇ↢↢ᵴ߳ߩ㈩ᘦ
㧔1㧕ᅑቇ㊄ߩ⒳㘃ߣណᛯ⁁ᴫ
ㆊ෰ 9 ᐕ㑆ߩ࠺࡯࠲ߪᰴ⴫ߩߣ߅ࠅߢ޽ࠆ‫ޕ‬
ᅑቇ㊄ߩฃ⛎ౝኈߪ㧘ᣣᧄੱቇ↢ࠍኻ⽎ߦߒߚ߽ߩߪߘߩ߶ߣࠎߤ߇⾉ਈߢ޽ࠅ㧘⇐ቇ↢ߪ⛎ਈߢ޽ࠆ‫ߚ߹ޕ‬㧘⇐ቇ↢ะߌߩᅑቇ㊄ߪᏗᦸ⠪ߦᲧߴߘߩ⒳㘃߇㕖Ᏹߦዋߥ޿ߩ߇⃻⁁ߢ޽ࠆ‫ޕ‬ᣣᧄቇ↢ᡰេᯏ᭴ᅑቇ㊄╙1⒳඙‫ޓޓޓ‬ಽߘߩઁߩᅑቇ㊄

╙2⒳

↳⺧⠪ᢙ

ណ↪⠪ᢙ

↳⺧⠪ᢙ

ណ↪⠪ᢙ

8

8

8

8

12 ᐕᐲ

↳⺧⠪ᢙ

ណ↪⠪ᢙ

13 ᐕᐲ

22

7

32

7

3

3

14 ᐕᐲ

21

6

26

15

2

2

15 ᐕᐲ

12

5

8

8

0

0

16 ᐕᐲ

26

11

25

24

0

0

17 ᐕᐲ

14

8

19

18

0

0

18 ᐕᐲ

18

14

20

20

1

1

19 ᐕᐲ

22

11

21

17

2

2

20 ᐕᐲ

21

9

17

17

0

0

̪ᐔᚑ㧝㧢ᐕ㧠᦬ߦ㧘ᣣᧄ⢒⧷ળߪᑄᱛߐࠇᣣᧄቇ↢ᡰេᯏ᭴ᅑቇ㊄ߣߥߞߚ‫ߚ߹ޕ‬㧘‫߁߷߈ޟ‬㧞㧝ࡊ࡜ࡦ‫╙ޟ߇ޠ‬ੑ⒳ᅑ
ቇ㊄‫ߦޠ‬ᄌࠊߞߚ‫ޕ‬٤ᄖ࿖ੱ⇐ቇ↢ฦ⒳ᅑቇ㊄ฃ⛎⠪ᢙ඙‫ޓޓޓ‬ಽડᬺ╬ᅑቇ㊄
ᔒ㗿⠪ᢙ

ฃ⛎⠪ᢙ

12 ᐕᐲ

3

1

13 ᐕᐲ

3

1

14 ᐕᐲ

7

3

15 ᐕᐲ

45

14

16 ᐕᐲ

45

18

17 ᐕᐲ

47

11

18 ᐕᐲ

31

8

19 ᐕᐲ

36

6

20 ᐕᐲ

29

10

٤ ጘ㒂⋵කቇ↢ୃቇ⾗㊄೙ᐲᐔᚑ㧞㧜ᐕᐲࠃࠅ࿾ၞක≮ࠍᜂ߁ੱ᧚⢒ᚑࠍ⋡⊛ߣߒߡ㧘਄⸥೙ᐲ߇⸳ߌࠄࠇߚ‫╙ޕ‬㧝⒳ߪ࿾ၞ
ᨒផ⮈౉⹜วᩰ⠪ࠍኻ⽎ߦ౉ቇ㊄࡮᝼ᬺᢱߣ↢ᵴ⾗㊄߇ᡰ⛎ߐࠇࠆ‫╙ޕ‬㧞⒳ߪ৻⥸ߩጘ㒂⋵಴り⠪ࠍኻ⽎ߦ↢ᵴ⾗㊄߇ᡰ⛎ߐࠇࠆ‫ޕ‬තᬺᓟ㧘৻ቯᦼ㑆㧘ጘ㒂⋵ౝߩක≮ߦ⽸₂ߔࠆߎߣߦࠃࠅ㄰ᷣ߇
఺㒰ߐࠇࠆ‫ޕ‬ೋᐕᐲߪ╙㧝⒳ 10 ฬ㧘╙㧞⒳ 35 ฬߩᨒߦኻߒߡว⸘ 60 ฬߩᔕ൐߇޽ࠅ㧘․଀ߣߒ
ߡ㧘ోຬߦᡰ⛎ߐࠇࠆߎߣ߇᳿ቯߒߚ‫ޕ‬㧙㧙㧔2㧕᝼ᬺᢱߩ఺㒰ߩ⁁ᴫㆊ෰ 9 ᐕ㑆ߩ᝼ᬺᢱ఺㒰⠪ߪᰴ⴫ߩߣ߅ࠅߢ޽ࠆ‫ޕ‬଀ᐕ㧘↳⺧⠪ߩ߁ߜ⚂ 7 ഀએ਄߇ో㗵෶ߪඨ㗵ࠍ఺㒰ߐࠇߡ޿ࠆ‫ޕ‬
೨ቇᦼ
඙‫ޓ‬ಽ

࿷☋⠪ᢙ

↳⺧

ᓟቇᦼ
఺㒰

ో㗵

ඨ㗵

↳⺧

఺㒰
ో㗵

ඨ㗵

12 ᐕᐲ

487

34㧔2㧕

25㧔1㧕

03㧔0㧕

36㧔03㧕

26㧔1㧕

04㧔0㧕

13 ᐕᐲ

489

43㧔2㧕

22㧔0㧕

11㧔0㧕

34㧔01㧕

18㧔0㧕

13㧔0㧕

14 ᐕᐲ

498

39㧔1㧕

19㧔1㧕

37㧔03㧕

17㧔1㧕

15 ᐕᐲ

495

27㧔1㧕

11㧔1㧕

29㧔02㧕

18㧔1㧕

16 ᐕᐲ

495

24㧔0㧕

17 ᐕᐲ

492

26㧔1㧕

18 ᐕᐲ

488

19 ᐕᐲ

488

20 ᐕᐲ

498

19㧔0㧕

22㧔10㧕

18㧔0㧕

2 0㧕

17㧔1㧕

26㧔01㧕

4 0㧕

17㧔1㧕

29㧔1㧕

2 0㧕

13㧔0㧕

29㧔01㧕

2 0㧕

19㧔0㧕

40㧔0㧕

10㧔0㧕

16㧔0㧕

36 㧔0㧕

12㧔0㧕

17㧔0㧕

36㧔1㧕

13㧔0㧕

13㧔1㧕

27 㧔0㧕

11㧔0㧕

15㧔1㧕

㧔‫ޓ‬㧕ౝߪ㧘⇐ቇ↢ࠍౝᢙߢ␜ߔ‫ޕ‬

㧔3㧕ቇ↢↢ᵴ⋧⺣ߩ૕೙ߣታᘒ
කቇ⑼ߦ߅޿ߡߪ㧘ቇ↢ߩጁୃ㧘ㅴ⚖෸߮ቇ↢↢ᵴߦ㑐ߔࠆ⋧⺣ਗ߮ߦᄢቇߦ߅ߌࠆ⻉໧㗴ߦߟ޿ߡ㧘ቇോ╙৻ଥ߇⓹ญߣߥߞߡኻᔕߒߡ޿ࠆ‫ޕ‬୘ੱ⊛෸߮ಽ㊁࡟ࡌ࡞ߢߩᜰዉ੐㗄ߦߟ޿ߡߪ㧘ᐔᚑ 15 ᐕᐲߦ೙ቯߒዉ౉ߒߡ޿ࠆ‫ޟ‬ᜰዉᢎຬ೙‫ޠ‬ߦࠃࠅ㧘කቇ⑼ᢎോෘ↢ᆔຬળᆔຬ㐳㧘ೋᦼ૕㛎ታ⠌Τߩಽ㊁ਥછ෸߮ㇱᵴേ㘈໧߇⋧⺣ຬߣߒߡᒰ
ߚߞߡ޿ࠆ‫ޕ‬ᐔᚑ 18 ᐕᐲ߆ࠄߪ‫ޟ‬㉿ⷫ೙ᐲ‫ࠍޠ‬ᣂ⸳ߒ㧘ฦಽ㊁ߩᢎ᝼߇ಽᜂߒߡቇ↢ߩ⋧⺣ߦਸ਼ߞߡ޿ࠆ‫ޕ‬
߹ߚ㧘ᄢቇో૕ߩ೙ᐲߣߒߡ㧘ീቇ਄߿ቇ↢↢ᵴߢ࿎ߞߡ޿ࠆߎߣ㧘෹ੱ㑐ଥ߿࠮ࠢࠪࡘࠕ࡞࡮ࡂ
࡜ࠬࡔࡦ࠻ߦ㑐ߔࠆ⋧⺣ߩ⓹ญߣߒߡࠠࡖࡦࡄࠬ࡮ࡋ࡞ࡄ࡯೙߇⸳ߌࠄࠇߡ߅ࠅ㧘ฦቇㇱ㧘ቇോㇱ㧘ోቇ౒ㅢᢎ⢒੐ോቶ╬ߩᢎ⡯ຬ߇⋧⺣ຬߣߥߞߡ޿ࠆ‫ޕ‬
㧔4㧕⺖ᄖᵴേߩታᘒ
කቇㇱߦ߅޿ߡߪ㧘⺖ᄖᵴേࠍᅑബߔࠆߚ߼ߦ㧘ߘࠇߦଥࠆቇ↢࿅૕ࠍ⸵นߒߡ޿ࠆ߇㧘ᢎ⢒⋡⊛ߦᴪߞߚකቇㇱ↢㧔කቇ⑼㧘⋴⼔ቇ⑼㧕ࠍኻ⽎ߣߔࠆ࿅૕ߩ႐วߦߪ㧘⺖ᄖᵴേ࿅૕ߣߒߡᢎോෘ↢ᆔຬળ߇⹺ቯߒ㧘ߘߩᵴേࠍ⹺߼ߡ޿ࠆ‫ޕ‬ߎࠇࠄߩ࿅૕߳ߩቇ↢ߩട౉⁁ᴫࠍᰴ⴫ߦ␜ߔ‫ޕ‬㧙㧙٤ ⺖ᄖᵴേട౉⁁ᴫ඙‫ޓ‬ಽ૕⢒♽ࠨ࡯ࠢ࡞

ᢥൻ♽ࠨ࡯ࠢ࡞

⸘12 ᐕᐲ

354㧔1㧕

223㧔1㧕

577㧔2㧕

13 ᐕᐲ

348㧔0㧕

206㧔2㧕

554㧔2㧕

14 ᐕᐲ

360㧔0㧕

219㧔3㧕

579㧔3㧕

15 ᐕᐲ

437㧔2㧕

348㧔0㧕

785㧔2㧕

16 ᐕᐲ

438㧔3㧕

277㧔1㧕

715㧔4㧕

17 ᐕᐲ

432㧔0㧕

181㧔0㧕

613㧔0㧕

18 ᐕᐲ

411㧔0㧕

155㧔0㧕

566㧔0㧕

19 ᐕᐲ

396㧔0㧕

220㧔0㧕

616㧔0㧕

20 ᐕᐲ

436㧔2㧕

212㧔0㧕

648㧔2㧕

㧔‫ޓ‬㧕ౝߪ㧘⇐ቇ↢ࠍౝᢙߢ␜ߔ‫ޕ‬㧙㧙Φ‫ޓ‬කቇㇱ⋴⼔ቇ⑼1ᢎ⢒࡮⎇ⓥߩℂᔨ࡮⋡ᮡ╬

1. ᢎ⢒࡮⎇ⓥߩℂᔨߣ⋡ᮡㄭᐕߩක≮࡮⑔␩ࠍขࠅᏎߊⅣႺߩᄌൻߦኻᔕߒ㧘ᄙ᭽ߥ␠ળ⊛ⷐ⺧ߦᔕ߃ࠆߚ߼㧘21 ਎♿ߩක≮ߦะߌߡ㧘⼾߆ߥᗵᕈߣੱ㑆ᕈࠍ஻߃㧘ᣣ‫ޘ‬ㅴᱠߔࠆ⍮⼂߿ᛛⴚࠍୃᓧ࡮⊒ዷߐߖࠆ⢻ജ߿㧘࿾ၞߦහߒߚ଻ஜක≮ᵴേߩਛᔃ⊛ᓎഀࠍᨐߚߔߎߣߩߢ߈ࠆ⾗⾰ߩ㜞޿⋴⼔⡯ࠍ⢒ᚑߔࠆߎߣࠍ⋡⊛ߦએਅߩ࠺ࠖࡊࡠࡑࡐ࡝ࠪ࡯ࠍ⸳ቯߒߡ޿ࠆ‫ޕ‬Ԙੱᮭߣ↢๮ߩዅ෩ߦኻߔࠆᢘᗲ㧘⼾߆ߥᗵᕈߣ୶ℂⷰߩୃᓧԙ✚ว⊛࡮ోੱ⊛ߦੱ㑆ࠍℂ⸃ߔࠆ⢻ജԚ⥄ਥᕈߣഃㅧജࠍᜬߜ㧘ਥ૕⊛ߦ್ᢿ࡮ታ〣߇ߢ߈ࠆ໧㗴⸃᳿⢻ജԛ⋴⼔ኾ㐷⡯ߣߒߡ㧘⑼ቇ⊛⍮⼂࡮ᛛⴚࠍୃᓧߒ㧘ߘࠇࠍត᳞ߒߡ޿ߊߎߣ߇ߢ߈ࠆ⢻ജԜ ⋴⼔ߩᓎഀࠍ⹺⼂ߒ㧘ࠤࠕ࠴࡯ࡓߩ৻ຬߣߒߡᵴべߢ߈ࠆ⢻ജԝ࿖㓙⊛ߥⷞ㊁ߣ࿾ၞක≮߳ߩ⽸₂ࠍⷞ㊁ߦ౉ࠇߚ⋴⼔ࠍ⊒ዷߢ߈ࠆ⢻ജ

2. ᢎ⢒࡮⎇ⓥߩᵴᕈൻߣలታߩ⚻ㆊᕆㅦߥዋሶ࡮㜞㦂ൻߦࠃࠆੱญ᭴ᚑߩᄌൻ㧘∔∛᭴ㅧߩᄌൻ㧘߹ߚੱ‫ߩޘ‬ஜᐽ߳ߩ㑐ᔃߩ㜞߹ࠅߥߤߦࠃࠅ㧘ක≮ࠍขࠅᏎߊ␠ળⅣႺߪ⪺ߒߊᄌ⽩ߒߡ߈ߡ޿ࠆ‫ޕ‬ᘟᕈ∔ᖚ߿⠧ൻߦࠃࠆ㓚ኂࠍᛴ߃ߡ
↢ᵴߔࠆੱ‫߇ޘ‬Ⴧടߔࠆߦߟࠇ㧘≮㙃↢ᵴߩ⾰㧘↢๮ߩዅ෩ߩᧄ⾰߇ᡷ߼ߡ໧޿⋥ߐࠇࠆࠃ߁ߦߥߞ
ߚ‫ߦ߁ࠃߩߎޕ‬᜛ᄢߒⶄ㔀ൻߔࠆ␠ળ⊛࠾࡯࠭ߦᔕ߃ߡ޿ߌࠆ⋴⼔⠪ࠍ⢒ᚑߔࠆߦߪ㧘⼾߆ߥᗵᕈߣ
ᷓ޿୶ℂⷰߦⵣઃߌࠄࠇߚੱ㑆ᕈ㧘ኾ㐷⊛⍮⼂࡮ᛛⴚߣታ〣ജࠍ஻߃㧘໧㗴⸃᳿⢻ജ㧘߹ߚ㧘࿖㓙⊛
ߥⷞ㊁ߣ࿾ၞක≮߳ߩ⽸₂ࠍⷞ㊁ߦ౉ࠇߚ⋴⼔ࠍ⊒ዷߢ߈ࠆ⢻ജࠍりߦߟߌࠆߎߣ߇⺖㗴ߣߥࠆ‫ޕ‬ߎߩߚ߼ 1 ᐕᰴ↢߆ࠄක≮࡮⋴⼔߳ߩ㑐ᔃࠍ㜞߼ࠆߚ߼㧘ೋᦼ૕㛎ታ⠌߿✚ว⑼⋡㧔ක≮ߣ↢๮㧕㧘߹ߚ㧘කቇ᭎⺰ߪකቇ⑼ቇ↢ߣߩวห᝼ᬺࠍ㐿⻠ߒߡ޿ࠆ‫ߚ߹ޕ‬㧘ኾ㐷ᢎ⢒ߩၮ⋚ߣߥࠆᢎ㙃ᢎ⢒ߪ
1㧘2 ᐕᰴߦోቇㇱ↢ࠍኻ⽎ߣߒߚోቇ౒ㅢᢎ⢒ࠍฃ⻠ߔࠆ‫ޕ‬໧㗴⸃᳿⢻ജ㧘ਥ૕⊛ߦቇ⠌ߔࠆ⢻ജ⢒ᚑߩߚ߼ߦ 1 ᐕᰴ߆ࠄ࠹ࡘ࠻࡯࡝ࠕ࡞ᢎ⢒ߦၮߠ޿ߚዋੱ
ᢙᢎ⢒ࠍታᣉߒߡ޿ࠆ‫ߚ߹ޕ‬㧘ᐔᚑ 18 ᐕߦࠞ࡝ࠠࡘ࡜ࡓࠍᡷᱜߒ㧘࿖㓙⊛ߥⷞ㊁ߣ࿾ၞක≮߳ߩ⽸
₂ࠍⷞ㊁ߦ౉ࠇߚ⋴⼔ࠍ⊒ዷߢ߈ࠆ⢻ജߩ⢒ᚑ㧘⋴⼔⎇ⓥߩၮ␆⊛⢻ജߩలታߦะߌߡ‫⊒ޡ‬ዷ⋴⼔ቇ‫ޢ‬ࠍኾ㐷⑼⋡ߩਛߦ㈩⟎ߒߚ‫ޕ‬

3. ᢎ⢒࡮⎇ⓥߩ዁᧪᭴ᗐ
㧔1㧕ၮᧄℂᔨࠊ߇࿖ߦ߅ߌࠆක≮࡮⑔␩ߩ⁁ᴫߪ㧘ㄭᐕᄢ߈ߊᄌൻߒߡ޿ࠆ‫ޕ‬කቇߩㅴᱠߣකቇࠍขࠅᏎߊ⻉⑼ቇߩ⊒ዷ㧘ߐࠄߦᕆㅦߥ㜞㦂ൻߥߤߩ␠ળⅣႺߩᄌൻߦ઻޿㧘ක≮ߩ਎⇇߽ᄙ᭽ൻߒ㧘ᴦ≮ߣߣ߽ߦេഥࠨ࡯ࡆࠬ߇㊀ⷞߐࠇࠆࠃ߁ߦߥߞߡ߈ߚ‫ޕ‬ක≮ߦ߅ߌࠆ⋴⼔ߩᓎഀߪ㧘੹ᓟߐࠄߦ᜛ᄢ࡮ⶄ㔀ൻߒߡ޿ߊߎߣߪ᣿ࠄ߆ߢ޽ࠅ㧘⼾߆ߥᗵᕈߣੱ㑆ᕈࠍ஻߃ߚ⾗⾰ߩ㜞޿⋴⼔⡯ߩ⢒ᚑ߇ਇนᰳߣߥࠆ‫ޕ‬ߎࠇࠄߩ␠ળ⊛ⷐ⺧ߦᔕ߃ࠆߚ߼㧘ᣣ‫ޘ‬ㅴᱠߔࠆක≮ߩ⍮⼂࡮ᛛⴚߦኻᔕߒ㧘ߐࠄߦ⊒ዷߐߖࠆ⢻ജࠍᜬߞߚੱ᧚㧘࿾ၞߩታᖱߦහߒߚ߈߼⚦߿߆ߥ଻ஜක≮ᵴേߩਛᔃ⊛ᓎഀ߇ᨐߚߖࠆੱ᧚ࠍ㙃ᚑ㧙㧙ߔࠆߣߣ߽ߦ㧘⋴⼔ᢎ⢒෸߮⎇ⓥ࡮⎇ୃߩ᜚ὐߣߥࠅ㧘↢ᶦቇ⠌ߦ⽸₂ߔࠆߎߣߩߢ߈ࠆ㧘␠ળߦ㐿߆ࠇߚ⋴⼔ቇ⑼ࠍ⋡ᜰߔߎߣࠍၮᧄℂᔨߣߔࠆ‫ޕ‬
㧔2㧕ᢎ⢒૕೙
21 ਎♿ߩක≮ߪ㧘ᴦ≮᳓Ḱߩะ਄ߣߣ߽ߦ㧘޽ࠄࠁࠆஜᐽ࡟ࡌ࡞ߩੱ‫ࠍޘ‬ኻ⽎ߣߒߚ㧘଻ஜ࡮ක≮࡮⑔␩߇ㅪ៤ߒߚ⦟⾰ߢ߈߼⚦߿߆ߥេഥࠨ࡯ࡆࠬ߇ⷐ⺧ߐࠇࠆ‫ޕ‬ක≮ߦ߅ߌࠆ⋴⼔ߩ⽿છߪ੹ᓟ߹ߔ߹ߔ㊀ߊ㧘␠ળߩⷐ⺧ߦᔕ߃ࠆߚ߼㧘ᰴߩࠃ߁ߥੱ᧚ߩ⢒ᚑߣቇ໧⊛ၮ⋚ߩ⏕┙ࠍ⋡ᮡߣߔࠆ‫ޕ‬Ԙ ోੱ⊛ක≮ࠍᜂ޿ᓧࠆ⼾߆ߥᗵᕈߣੱ㑆ᕈࠍ஻߃ߚੱ᧚ԙ 㜞ᐲක≮ߩ৻Ⅳࠍᜂ޿ᓧࠆ⾗⾰ߩ㜞޿ੱ᧚Ԛ ଻ஜ࡮ක≮ᵴേߦᜰዉ⊛ᓎഀࠍᨐߚߖࠆੱ᧚ԛ ⋴⼔ቇߦ߅ߌࠆቇ໧⊛ၮ⋚ࠍ⏕┙ߢ߈ࠆੱ᧚Ԝ ᐢ޿ⷞ㊁ࠍᜬߜ㧘࿖ౝᄖߢᵴべߢ߈ࠆੱ᧚
කቇㇱකቇ⑼ߣߩ✕ኒߥදജ૕೙ࠍ▽߈㧘✚วᄢቇߣߒߡߩࡔ࡝࠶࠻ࠍలಽߦ↢߆ߒߚᢎ⢒࡮⎇ⓥࠍⴕߞߡ޿ߊ‫ޕ‬‫ޟ‬ஜᐽ‫ⷞࠍޠ‬ᐳߦߔ߃ߚ⛔วࠞ࡝ࠠࡘ࡜ࡓߢ⢒ߞߚ໧㗴⸃᳿⢻ജ߿್ᢿ⢻ജ㧘ᔕ↪⢻ജߩ޽ࠆੱ᧚ߩ⢒ᚑߦࠃࠅ㧘࿾ၞߢ଻ஜක≮ߦଥࠊࠆੱ‫ࠍࡓ࡯࠴ࠕࠤߦ߽ߣߣޘ‬૞ࠅ㧘↢ᶦቇ⠌ࠍ⛯ߌߡ޿ߌࠆ૕೙ᢛ஻ࠍ⋡ᜰߔ‫ޕ‬㧔3㧕⎇ⓥ૕೙
⋴⼔ቇߩ⎇ⓥߪ㧘㑐ㅪ⻉⑼ቇߣߩㅪ៤㧘․ߦ଻ஜ࡮ක≮ಽ㊁ߣߩ౒ห⎇ⓥߪᔅ㗇ߢ޽ࠆ‫⥃ޕ‬ᐥ㧘࿾ၞߦ߅ߌࠆ⋴⼔⡯ߣߩ⎇ⓥߪ⋴⼔ߩ⎇ⓥߩᧄ⾰⊛ᗧ⟵ࠍ᦭ߔࠆ߽ߩߢ޽ࠅ㧘ฦ⻠ᐳ㧘ಽ㊁ߩ․⦡ߩਛ
ߢផㅴߒߡ޿ߊ‫ߩ⼔⋴ޕ‬ኻ⽎߿ᓎഀߩ᜛ᄢߦࠃࠅ㧘ஜᐽᡰេ߿↢ᵴ߳ߩេഥ߆ࠄ㧘ᢎ⢒࡮⑔␩࡮⚻ᷣ࡮ᖱႎߥߤߣㅪ៤ߒߡ޿ߊᔅⷐᕈ߇㜞߹ߞߡ޿ࠆ‫ޕ‬ቇౝᄖߦ߅޿ߡ㑐ㅪߔࠆቇ໧ಽ㊁㧘ઁߩኾ㐷⡯ߣߩㅪ៤ࠍኒߦߒ㧘ቇ㓙⊛߆ߟല₸⊛ߥ౒ห⎇ⓥࠍផㅴߒߡ޿ߊ‫ߚ߹ޕ‬㧘ᄢቇ㒮ୃ჻⺖⒟㧔⋴⼔ቇኾ᡹㧕ࠍ㐿⸳ߒߚߎߣߦࠃࠅ㧘ࠃࠅ㜞޿ኾ㐷ᕈࠍㅊ෸ߒߚᢎ⢒࡮⎇ⓥߩలታࠍ࿑ߞߡ޿ࠆ‫ޕ‬

2

ᢎ⢒ᵴേ

1. ቇ↢ߩฃ౉ࠇ
㧔1㧕ቇ↢൐㓸ߩᣇᴺԘ ቇ↢൐㓸ⷐ㗄෸߮౉ቇ⠪ㆬᛮߦ㑐ߔࠆⷐ㗄ߦߟ޿ߡߪ㧘ቇോㇱ߆ࠄోቇ৻᜝ߢ⋵ਅ㜞╬ቇᩞࠍਛᔃߦㇷㅍ㈩Ꮣߔࠆߣߣ߽ߦ㧘Ꮧᦸ⠪ߦኻߒߡߪቇോ╙ੑଥ߆ࠄ⋥ធ෶ߪㇷㅍߢ㈩Ꮣߒߡ޿ࠆ‫ޕ‬ԙ⋴⼔ቇ⑼⚫੺ࡄࡦࡈ࡟࠶࠻‫ޟ‬ጘ㒂ᄢቇකቇㇱ⋴⼔ቇ⑼᩺ౝ‫ࠍޠ‬૞ᚑߒ㧘ᄢቇ⚫੺㧔ࡊ࠴ • ࠝ࡯ࡊࡦࠠࡖࡦࡄࠬ㧘ࠝ࡯ࡊࡦࠠࡖࡦࡄࠬ㧕ෳട⠪ߦ㈩Ꮣߒߡ޿ࠆ‫ޕ‬Ԛ ᄢቇ⚫੺㧔ࡊ࠴ • ࠝ࡯ࡊࡦࠠࡖࡦࡄࠬ㧘ࠝ࡯ࡊࡦࠠࡖࡦࡄࠬ㧕ߦ߅޿ߡ㧘⋴⼔ቇ⑼㐳ߩ᭎ⷐ⺑᣿ਗ߮ߦฦ⻠ᐳߩᮨᡆታ⠌╬ࠍታᣉߔࠆߣߣ߽ߦ㧘ࠃࠅലᨐ⊛ߥ⚫੺ߣߔࠆߚ߼㧘ෳട⠪߆ࠄࠕࡦࠤ࡯࠻ࠍߣߞߡ⋴⼔ቇ⑼ᢎോෘ↢ᆔຬળߦ߅ߌࠆ⸘↹┙᩺ߩෳ⠨ߣߒߡ޿ࠆ‫ޕ‬ԛ⋴⼔ቇ⑼ోᢎຬ߇ጘ㒂⋵ࠍਛᔃߦ㜞╬ቇᩞࠍ⸰໧ߒ㧘⋴⼔ቇ⑼⚫੺෸߮ㅴ〝ᜰዉᜂᒰߩవ↢ߣᖱႎ੤឵ࠍታᣉߒߡ޿ࠆ‫ޕ‬

㧙㧙

Ԝ

⑳Ⴖਥ௅ߩ౉⹜⺑᣿ળߦᢎຬࠍᵷ㆜ߔࠆߎߣ߿㧘㜞╬ቇᩞߦኻߔࠆ‫ޟ‬಴೨⻠⟵‫ߤߥ߁ⴕࠍޠ‬㧘
Ⓧᭂ⊛ߦขࠅ⚵ࠎߢ޿ࠆ‫ޕ‬

㧔2㧕౉ቇ⠪ㆬᛮߩᣇᴺߣᣇ㊎ੱࠍᗲߒ↢๮ࠍዅ߮㧘ోߡߩੱ‫ߩޘ‬ஜᐽߩะ਄ߦነਈߔࠆ⋴⼔⡯ࠍ⢒ᚑߔࠆߚ߼ߦએਅߩࠃ߁ߥࠕ
࠼ࡒ࠶࡚ࠪࡦࡐ࡝ࠪ࡯ࠍ⸳ቯߒ㧘ቇ↢ࠍ᳞߼ߡ޿ࠆ‫ޕ‬Ԙ⋴⼔߳ߩ㑐ᔃ߇޽ࠅ㧘⋴⼔ቇߩୃᓧߦᔅⷐ㧘߆ߟ㧘චಽߥၮ␆⊛ቇജࠍ᦭ߔࠆߎߣ‫ޕ‬ԙ ᭽‫ߦ⽎⃻ߥޘ‬ኻߒߡ㧘޽ࠄࠁࠆⷺᐲ߆ࠄⷰߡ⠨߃㧘⌀ታࠍ⍮ࠈ߁ߣ޿߁⑼ቇ⊛ត᳞ᔃߦንߺ㧘⥄Ꮖቇ⠌ᗧ᰼߇ᣰ⋓ߢ޽ࠆߎߣ‫ޕ‬Ԛ ઁ⠪ߩᗧ⷗ࠍ௑⡬ߒ㧘ߘߩ᳇ᜬߜࠍℂ⸃ߢ߈ࠆࠃ߁ߦദ߼㧘⥄Ꮖߩᗧ⷗ࠍ⴫⃻ߢ߈ࠆ⢻ജࠍᜬߞߡ޿ࠆߎߣ‫ޕ‬ԛ⥄Ꮖߩᓎഀࠍ⹺⼂ߒ㧘⽿છᗵࠍᜬߞߡ޿ࠆߎߣ‫ޕ‬Ԝ⥄Ꮖߩᔃりߩஜᐽߦ⇐ᗧߒⴕേߢ߈ࠆജࠍᜬߞߡ޿ࠆߎߣ‫ޕ‬‫ޣ‬㧟ᐕᰴ✬౉‫ޤ‬ߔߢߦ⋴⼔ߦ㑐ߔࠆቇ⑼෶ߪ⺖⒟ߦ߅޿ߡቇ⠌ߒߡ߈ߚቇ↢ࠍኻ⽎ߦ㧘ࠃࠅ㜞ᐲߥ⋴⼔ታ〣⢻ജߣ᏷ᐢ޿ᢎ㙃ߣ⼾߆ߥੱ㑆ᕈࠍりߦߟߌࠃ߁ߣߔࠆߎߣߦᒝ޿ᗧ᰼ࠍ᦭ߔࠆ⠪ࠍ᳞߼ߡ޿ࠆ‫ޕ‬਄⸥ߩࠃ߁ߥ⋴⼔ቇ↢ߣߒߡᦸ߹ߒ޿ቇ↢ࠍ౉ቇߐߖࠆߎߣߦട߃㧘ᔕ൐⠪ᢙߩჇടࠍ⋡⊛ߦ౉⹜⑼⋡ߩ⷗⋥ߒࠍታᣉߒߚ‫ߡߞࠃߦߣߎߩߎޕ‬㧘ᐔᚑ 18 ᐕᐲ൐㓸߆ࠄߪᢥ♽߆ࠄ߽ℂ♽߆ࠄ߽ฃ㛎ߒ߿ߔ޿ࠃ߁ߦ㧘⑼⋡ࠍㆬᛯߢ߈ࠆᣇᴺߦᄌᦝߒߚ‫ޕ‬߹ߚ㧘౉⹜ᣇᴺߣ࿷ᩞ↢ߩᚑ❣ߣߩ㑐ଥߦߟ޿ߡߪ㧘ㇱಽ⊛ߥᬌ⸛ߪታᣉߒߡ޿ࠆ߇ో૕⊛ߥᬌ⸛ࠍߐࠄߦⴕ߁੍ቯߢ޽ࠆ‫ޕ‬
3 ᐕᰴ✬౉ቇ⹜㛎ߦߟ޿ߡߪᲤᐕ 10 ฬࠍฃߌ౉ࠇߡ޿ࠆ‫ޕ‬
㧔3㧕ቇ↢ߩฃ౉ࠇ⁁ᴫቇ↢ቯຬల⿷⁁ᴫ : ᐔᚑ 18 ᐕᐲ߆ࠄ 20 ᐕᐲ߹ߢߩ 3 ᐕ㑆ߩ౉ቇ㧔ᔒ㗿⠪࡮౉ቇ⠪㧕ߦ㑐ߔࠆ⁁ᴫߪᰴ⴫ߩߣ߅ࠅߢ޽ࠆ‫ޕ‬
ᔒ㗿⠪ᢙ

ฃ㛎⠪ᢙ

౉ቇ⠪

↵

23

19

ᐔᚑ 18 ᐕᐲ ᅚ

324

⸘

347

඙ಽ

⋵೎ౝ⸶
ጘ㒂⋵

ᗲ⍮⋵

ਃ㊀⋵

ߘߩઁ

4

3

1

0

0

248

77

51

17

1

8

267

81

54

18

1

8

↵

39

29

5

4

0

0

1

ᐔᚑ 19 ᐕᐲ ᅚ

309

233

75

40

29

2

4

⸘

348

262

80

44

29

2

5

↵

16

14

5

3

2

0

0

ᐔᚑ 20 ᐕᐲ ᅚ

274

215

75

43

28

1

3

⸘

290

229

80

46

30

1

3

㧙㧙

ᖺᗘูᚿ㢪⪅䞉ཷ㦂⪅≧ἣ

㻟㻡㻜
㻟㻜㻜

㻟㻠㻤

㻟㻠㻣

㻞㻥㻜

㻞㻡㻜
㻞㻢㻣

㻞㻢㻞
㻞㻞㻥

㻞㻜㻜
㻝㻡㻜

ᚿ㢪⪅ᩘ
ཷ㦂⪅ᩘ

㻝㻜㻜
㻡㻜
㻜

ᖹᡂ䠍䠔ᖺᗘ

ᖹᡂ䠍䠕ᖺᗘ

ᖹᡂ䠎䠌ᖺᗘ

ධᏛ⪅ฟ㌟┴ูෆヂ

㻥㻜㻑
㻤㻜㻑

㻟

㻡

㻤

㻝㻜㻜㻑

㻝

㻞

㻝
㻝㻤

㻟㻜

㻞㻥

㻣㻜㻑
䛭䛾௚
୕㔜┴
ឡ▱┴
ᒱ㜧┴

㻢㻜㻑
㻡㻜㻑
㻠㻜㻑

㻡㻠

㻠㻢

㻠㻠

㻟㻜㻑
㻞㻜㻑
㻝㻜㻑
㻜㻑

ᖹᡂ䠍䠔ᖺᗘ

ᖹᡂ䠍䠕ᖺᗘ

ᖹᡂ䠎䠌ᖺᗘ

㧔4㧕✬౉ቇ೙ᐲߣታᘒ
⋴⼔ቇ⑼ߢߪ㧘ߔߢߦ⋴⼔ߦ㑐ߔࠆቇ⑼޽ࠆ޿ߪ⺖⒟ߦ߅޿ߡቇ⠌ߒߡ߈ߚቇ↢ࠍኻ⽎ߦ㧘✬౉ቇ㧔╙ 3 ᐕᰴ㧕ߦࠃࠆቇ↢ߩฃߌ౉ࠇ೙ᐲࠍ⸳ߌߡ޿ࠆ‫ޕ‬
ᐔᚑ 18 ᐕᐲ㨪ᐔᚑ 20 ᐕᐲߩ✬౉ቇ㧔ᔒ㗿⠪࡮౉ቇ⠪㧕ߦ㑐ߔࠆ⁁ᴫߪᰴ⴫ߩߣ߅ࠅߢ޽ࠆ‫ޕ‬
඙ಽ

ᔒ㗿⠪ᢙ

ฃ㛎⠪ᢙ

౉ቇ⠪

↵

1

1

0

ᐔᚑ 18 ᐕᐲ ᅚ

52

47

10

⸘

53

48

10

↵

3

2

1

ᐔᚑ 19 ᐕᐲ ᅚ

50

41

9

⸘

53

43

10

㧙㧙

඙ಽ

ᔒ㗿⠪ᢙ

ฃ㛎⠪ᢙ

౉ቇ⠪

↵

2

2

0

ᐔᚑ 20 ᐕᐲ ᅚ

57

48

9

⸘

59

50

9

㧔5㧕⎇ⓥ↢ߩฃ౉ࠇߣታᘒ
ቇೣߦ߅޿ߡ⎇ⓥ↢ߩฃߌ౉ࠇ೙ᐲࠍ⸳ߌߡ޿ࠆ‫ޕ‬
ᐔᚑ 16 ᐕᐲߦࡉ࡜ࠫ࡞߆ࠄ⋵⾌ߩ⎇ⓥ↢ 1 ฬࠍฃߌ౉ࠇߚ‫ޕ‬

2. ࠞ࡝ࠠࡘ࡜ࡓ
⋴⼔⡯ߩၮ␆⊛⢻ജߣ㧘⑼ቇ⊛ᕁ⠨ߦⵣߠߌࠄࠇߚ⋴⼔ታ〣⢻ജ㧘଻ஜ࡮ක≮࡮⑔␩ో⥸ߦࠊߚࠆᐢ޿⷗⼂㧘ߘߒߡ᏷ᐢ޿ᢎ㙃ߣ⼾߆ߥੱ㑆ᕈࠍ㙃߁ߎߣࠍ⋡⊛ߣߒߡ㧘ᢎ㙃ᢎ⢒ߣኾ㐷ᢎ⢒㧔ၮ␆⑼⋡ߣኾ㐷⑼⋡㧕ࠍ㐿⻠ߒߡ޿ࠆ‫ޕ‬
㧔1㧕ࠞ࡝ࠠࡘ࡜ࡓߩ․ᓽԘ ᢎ㙃⑼⋡ߪ㧘ోቇ౒ㅢᢎ⢒⑼⋡ߣߒߡ㐿⻠
୘೎⑼⋡㧔ੱᢥ⑼ቇ♽㧘␠ળ⑼ቇ♽㧘⥄ὼ⑼ቇ♽㧘ࠬࡐ࡯࠷࡮ஜᐽ⑼ቇ♽㧕㧘✚ว⑼⋡㧘ᄖ࿖⺆⑼⋡߿⥄↱ㆬᛯ⑼⋡߇㐿⻠ߐࠇ㧘ᔅⷐන૏ࠍ⠨ᘦߒߥ߇ࠄ㧘ߎࠇࠄߩ⑼⋡߆ࠄ⥄ಽߩቇ߮ߚ
޿⑼⋡ࠍㆬᛯߔࠆ‫ޕ‬ԙ ࿾ၞ⑼ቇㇱ࡮ᢎ⢒ቇㇱߩ⑼⋡ߩฃ⻠ၮ␆⑼⋡ߦߪ⋴⼔⁛⥄ߩ⑼⋡ߩઁߦ㧘࿾ၞ⑼ቇㇱ߿ᢎ⢒ቇㇱ߇㐿⻠ߔࠆ⑼⋡߇޽ࠅ㧘ߘࠇߙࠇߩቇㇱߩቇ↢ߣ৻✜ߦቇ߱‫ޕ‬Ԛ කቇㇱߣߩวห⻠⟵㧔කቇ᭎⺰㧕ోੱ⊛ක≮߿ක≮⡯⒳ߩᓎഀߥߤߦ㑐ߒߡቇ߱‫ޕ‬ԛታ⠌߿૕㛎ߦၮߠ޿ߚቇ⠌ߩ㊀ⷞኾ㐷⑼⋡ߪ㧘⻠⟵ߛߌߢߥߊ૕㛎ࠍ〯߹߃ߚቇ⠌ࠍታᣉߔࠆ‫ޕ‬

㧔2㧕ࠞ࡝ࠠࡘ࡜ࡓߩ᭴▽Ԙ⋴⼔ታ〣⢻ജߩ⢒ᚑࠍ⋡ᜰߒߡࠞ࡝ࠠࡘ࡜ࡓߩ᭴▽࡮ ⋴⼔ቇ჻⺖⒟ᢎ⢒ߪ㧘ᢥㇱ⑼ቇ⋭ߩ⷗⸃ߦଐࠇ߫㧘⋴⼔ߩታോኅߩ⢒ᚑ߇⋡⊛ߢ޽ࠆߣㅀߴࠄ
ࠇߡ޿ࠆ‫⼔⋴ޕ‬ቇᢎ⢒ౝኈࠟࠗ࠼࡜ࠗࡦߣߒߡ㧞㧜㧜㧠ᐕߦ‫⼔⋴ޟ‬ታ〣⢻ജ⢒ᚑߦะߌߚᄢቇ
තᬺᤨߩ೔㆐⋡ᮡ‫⼔⋴ߪߦࠇߎޕߚࠇߐ␜߇ޠ‬ታ〣⢻ജߩ㧡ߟߩ᭴ᚑⷐ⚛࡮㧝㧥㗄⋡࡮㧣㧢⚦㗄⋡ߦḰ᜚ߒߚ㗄⋡߇਄ߍࠄࠇߡ޿ࠆ‫ޕ‬ጘ㒂ᄢቇකቇㇱ⋴⼔ቇ⑼ߢߪ㧘␜ߐࠇߚ⋴⼔ታ〣⢻ജ߇ୃᓧߢ߈ࠆࠃ߁ߦᢎ⢒ౝኈࠍฦ⻠ᐳ㑆ߢ᦭ᯏ⊛ߦ㑐ㅪߐߖߥ߇ࠄ㧘⋴⼔ኾ㐷ᢎ⢒ࠍ㧠ᐕ৻⽾ᢎ⢒ߣߒߡታᣉߔࠆࠃ߁ߦࠞ࡝ࠠࡘ࡜ࡓࠍ᭴▽ߒߡ޿ࠆ‫ޕ‬࡮ 㧝ᐕᰴ↢߆ࠄ㧠ᐕᰴ↢߹ߢߩ㑆ߦ㧘⋴⼔ቇታ⠌㧔ೋᦼ૕㛎ታ⠌㧘ၮ␆⋴⼔ቇታ⠌㧘ᕆᕈᦼ⋴⼔ቇታ⠌㧘ᘟᕈᦼ⋴⼔ቇታ⠌㧘⠧ᐕ⋴⼔ቇታ⠌Σ࡮Τ㧘♖␹⋴⼔ቇታ⠌㧘ዊఽ⋴⼔ቇታ⠌㧘Უᕈ⋴⼔ቇታ⠌㧘࿷ቛ⋴⼔ቇታ⠌㧘࿾ၞ⋴⼔ቇታ⠌㧘⛔วታ⠌㧕ࠍㅢߓߡ⋴⼔ߩ⸘↹⊛ߥዷ㐿⢻ജ㧘․ቯߩஜᐽ໧㗴ࠍ߽ߟኻ⽎߳ߩታ〣⢻ജ㧘ࠤࠕ࠴࡯ࡓߩ৻ຬߣߒߡᵴべߢ߈ࠆၮ␆⊛ߥ⢻ജ߇ୃᓧߢ߈ࠆࠃ߁ߦታ⠌ࠍ㈩⟎ߒߡ޿ࠆ‫ޕ‬ԙ ࿖ኅ⹜㛎ฃ㛎⾗ᩰ߇ขᓧߢ߈ࠆࠞ࡝ࠠࡘ࡜ࡓ᭴▽㧝ᐕᰴ↢߆ࠄ㧠ᐕᰴ↢߹ߢߩ㑆ߦ㧘౒ㅢᢎ⢒෸߮ኾ㐷ᢎ⢒ߩฦᢎ⑼⋡ࠍቇ⠌ߒ㧘㧠ᐕᰴቇᐕᧃ

㧙㧙ߦታᣉߐࠇࠆ⋴⼔Ꮷ࿖ኅ⹜㛎࡮଻ஜᏧ࿖ኅ⹜㛎ߩฃ㛎ⷐઙࠍḩߚߔలಽߥ⑼⋡ߣන૏ᢙߦ㈩ᘦ
ߒߚࠞ࡝ࠠࡘ࡜ࡓࠍ᭴▽ߒߡ޿ࠆ‫ߚ߹ޕ‬ഥ↥ߦ㑐ߒߡߪ㧘ㆬᛯ⑼⋡ߣߒߡഥ↥Ꮷ࿖ኅ⹜㛎ߩฃ㛎ⷐઙࠍḩߚߔࠞ࡝ࠠࡘ࡜ࡓࠍ᭴▽ߒߡ޿ࠆ‫ޕ‬Ԛ࠴ࡘ࠻࡯࡝ࠕ࡞ᢎ⢒ࠍขࠇ౉ࠇߚࠞ࡝ࠠࡘ࡜ࡓࠍ᭴▽౉ቇᒰೋ߆ࠄ␠ળ߿ක≮ߩᄌൻߦ઻޿↢⿠ߔࠆᄙ᭽ߢⶄ㔀ߥஜᐽ໧㗴ߦኻߒߡ⋴⼔⡯ߣߒߡ⥄ࠄ⺖㗴ࠍត᳞㧘ߘߩ⺖㗴ߩ⸃᳿ߦะߌߡቇ⠌ߢ߈ࠆ⢻ജߩ₪ᓧࠍ⋡ᜰߒߡ࠴ࡘ࠻࡯࡝ࠕ࡞ᢎ⢒ࠍขࠅ౉ࠇߚࠞ࡝ࠠࡘ࡜ࡓ᭴▽ࠍߒߡ޿ࠆ‫ޕ‬ԛ⊒ዷ⑼⋡ߣߒߡ㧘⋴⼔ቇኾ㐷⑼⋡ߩ৻ㇱߣߒߡ૏⟎ߠߌ㧘⋴⼔ታ〣⢻ജ⢒ᚑߦะߌߡቇ⠌ߔࠆᯏળࠍ⸳ߌࠆߎߣ㧘ߐࠄߦ㧘⑼ቇ⊛ᕁ⠨ߩୃᓧߣ዁᧪߳ߩ⊒ዷࠍᦼᓙߒߡ㧘⎇ⓥᣇᴺߩ⻠⟵෸߮තᬺ⎇ⓥߩታ㓙ࠍㅢߒߡ㧘ၮ␆⊛⢻ജߩୃᓧࠍⴕ߁ࠃ߁ߦ૏⟎ߠߌߡ޿ࠆ‫ޕ‬

㧔3㧕⺖㗴ߣዷᦸ
ෘ↢ഭ௛⋭߇଻ஜᏧᢎ⢒࡮ഥ↥Ꮷᢎ⢒࡮⋴⼔Ꮷᢎ⢒ߦ߅ߌࠆ⋴⼔ၮ␆ᢎ⢒ߦ߅ߌࠆᛛⴚ㗄⋡ߩතᬺᤨߩ೔㆐ᐲࠍ᣿␜ߒߚ‫ࠍࠄࠇߎޕ‬ฃߌߡጘ㒂ᄢቇකቇㇱ⋴⼔ቇ⑼ߩࠞ࡝ࠠࡘ࡜ࡓ߽㧘ዋሶ㜞㦂ൻߩㅴዷ㧘ක≮ᛛⴚߩㅴᱠ㧘࿖᳃ߩᗧ⼂ߩᄌൻ㧘⋴⼔ᢎ⢒᳓Ḱߩะ਄ߥߤᤨઍߩⷐ⺧ߦᔕ߃ߡ㧘ᢎ⢒ౝኈ㧘
ᢎ᝼ᣇᴺߦߟ޿ߡᬌ⸛ࠍߒ㧘ᐔᚑ 21 ᐕᐲ߆ࠄᣂߒ޿ࠞ࡝ࠠࡘ࡜ࡓࠍታᣉߔࠆ੍ቯߢ޿ࠆ‫ޕ‬߹ߚ㧘⋴⼔ቇ⑼ߦ߅޿ߡߪ㧘଻ஜᏧߣ⋴⼔Ꮷߣߩ 2 ߟߩᢎ⢒⺖⒟ߦട߃㧘ㆬᛯߢߪ޽ࠆ߇ഥ↥Ꮷߩ᝼ᬺ⑼⋡߽޽ࠅ㧘තᬺߦߪ㕖Ᏹߦᄙߊߩขᓧන૏ᢙࠍᔅⷐߣߒߡ޿ࠆߣ޿ߞߚ໧㗴߇޽ࠆ‫ోޕ‬࿖⊛ߦߪዋᢙߢ޽ࠆ߇㧘ഥ↥Ꮷᢎ⢒ࠍᄢቇ㒮ୃ჻⺖⒟㧘ኾ㐷⡯ᄢቇ㒮㧘ᄢቇߩኾ᡹⑼ߥߤߢⴕ߁ᄢቇ߽಴ߡ
߈ߡ޿ࠆ‫⼔⋴ᧄޕ‬ቇ⑼ߦ߅޿ߡ߽㧘ഥ↥Ꮷߩ᝼ᬺ⑼⋡ߦ㑐ߒߡ㧘ᢎ⢒਄ᦸ߹ߒ޿૏⟎ߠߌࠍ㧘⃻࿷ᬌ⸛ߒߡ޿ࠆ‫ޕ‬

3. ᢎ⢒ᣇ㊎㧔1㧕ᢎ⢒ᡷ㕟⋴⼔ቇ⑼ߢߪ㧘ᐔᚑ 18 ᐕᐲߦࠞ࡝ࠠࡘ࡜ࡓᡷᱜࠍⴕߞߚ‫ࡓ࡜ࡘࠠ࡝ࠞޕ‬ᡷᱜߦ޽ߚߞߡߪ㧘4 ᐕ㑆ߩᢎ⢒ታ❣ࠍ〯߹߃એਅߩᡷᱜࠍⴕߞߚ‫ޕ‬Ԙ⋴⼔ቇߩၮ␆⊛ᢎ⢒ࠍၮߦ዁᧪ࠍ⷗ᝪ߃ߚኾ㐷ಽ㊁ࠍ⊒ዷ⊛ߦቇ⠌ߔࠆ⋡⊛ߢ‫⊒ޟ‬ዷ⋴⼔ቇ‫⊒ߩߎޕߚߒ⟎⸳ࠍޠ‬ዷ⋴⼔ቇߪ㧘⎇ⓥᣇᴺ⺰㧘තᬺ⎇ⓥ㧘࿖㓙⋴⼔੐ᖱߥߤߩ᝼ᬺ⑼⋡ߢ᭴ᚑߒߚ‫ޕ‬ԙᓥ᧪ߩኾ㐷⑼⋡ࠍ⷗⋥ߒ㧘ਇ⿷ߔࠆ᝼ᬺ⑼⋡ࠍᣂ⸳ߒ㧘ኾ㐷
⑼⋡ߩలታࠍ࿑ߞߚ‫ޕ‬Ԛᢎ㙃⑼⋡ߩలታߩߚ߼ߦ㧘ขᓧන૏ᢙࠍჇടߒߚ‫ޕ‬߹ߚ㧘ᐔᚑ 21 ᐕᐲ߆ࠄᜰቯⷙೣߩᄌᦝߦၮߠ޿ߚᡷᱜࠞ࡝ࠠࡘ࡜ࡓࠍࠬ࠲࡯࠻ߐߖࠆ‫ߪߦࠄߐޕ‬㧘
ᐔᚑ 22 ᐕᐲ߆ࠄߪ࿾ၞ⑼ቇㇱ࡮ᔕ↪↢‛ቇ࡮Ꮏቇㇱ࡮⋴⼔ቇ⑼ߩදหߢ㙃⼔ᢎ⻀⺖⒟ࠍ㐿⻠ߔࠆ੍ቯߢ޽ࠆ‫ޕ‬㧔2㧕ోቇ౒ㅢᢎ⢒ᄢቇߢߪ㧘ኾ㐷ߦߟ޿ߡᷓߊቇ߱ߣߣ߽ߦ㧘ᢎ㙃ࠍቇ߱ߎߣ߇ᔅⷐߢ޽ࠆ‫ࠍ⊛⋡ߩߎޕ‬㆐ᚑߔࠆߚ
߼㧘4 ᐕ৻⽾ᢎ⢒૕೙ߩ߽ߣߦ㧘ᢎ㙃ᢎ⢒ߣኾ㐷ᢎ⢒ࠍਗⴕߒߡⴕߞߡ޿ࠆ‫ޕ‬ᢎ㙃⑼⋡ߦߟ޿ߡߪ㧘ోቇ૕೙ߩ߽ߣߦోቇ౒ㅢᢎ⢒ߣߒߡㅴ߼ࠄࠇߡ޿ࠆ‫ޕ‬㧙㧙٤ోቇ౒ㅢᢎ⢒ߩᦨૐୃᓧන૏ᢙ
තᬺⷐઙୃᓧන૏ᢙ

⑼‫ޓޓ⋡ޓޓ‬඙‫ޓޓ‬ಽ

ᄖ
࿖
⺆
⑼
⋡

୘೎⑼⋡

14 න૏એ਄

✚ว⑼⋡4 න૏એ਄

ᣢୃᄖ࿖⺆♽㧔ᔅୃ㧕

4 න૏એ਄

ᧂୃᄖ࿖⺆♽㧔ᔅୃ㧕

2 න૏એ਄

ᣢୃᄖ࿖⺆♽㧔ㆬᛯᔅୃ㧕

2 න૏એ਄

ᧂୃᄖ࿖⺆♽㧔ㆬᛯᔅୃ㧕⥄↱ㆬᛯ⑼⋡
ቇㇱ㐿⻠ੱᢥ⑼ቇ♽‫ޓ‬6 න૏એ਄␠ળ⑼ቇ♽‫ޓ‬4 න૏એ਄⥄ὼ⑼ቇ♽‫ޓ‬2 න૏એ਄ࠬࡐ࡯࠷࡮ஜᐽ⑼ቇ♽‫ޓ‬2 න૏એ਄2 න૏એ਄

࠮ࡒ࠽࡯

2 න૏એ਄

ว‫⸘ޓޓޓޓޓޓޓ‬30 න૏٤ోቇ౒ㅢᢎ⢒ߩ㐿⻠ᤨ㑆ᨒ
1 ᐕᰴ೨ቇᦼ

1 ᐕᰴᓟቇᦼ

ᦐᣣ‫ᤨޓ‬㒢

1

2

3

4

5

ᦐᣣ‫ᤨޓ‬㒢

1

2

3

4

5

᦬

٧

٧

٧

٧

٧

᦬

٧

٧

٧

٧

٧

Ἣ

٧

٧

٧

٧

٧

Ἣ

٧

٧

٧

٧

٧

᳓

٧

٧

᳓

٧

٧

ᧁ

ᧁ

㊄

㊄

٧‫ޓ‬㧦ోቇ౒ㅢᢎ⢒ߩ㐿⻠ᤨ㑆ᨒⓨ⊕㧦ኾ㐷ᢎ⢒ߩ㐿⻠ᨒ㧔3㧕ኾ㐷ᢎ⢒㧔࠹ࡘ࠻࡯࡝ࠕ࡞ᢎ⢒࡮⥃ᐥታ⠌㧕Ԙ࠹ࡘ࠻࡯࡝ࠕ࡞ᢎ⢒ኾ㐷ᢎ⢒ߩ 3 ⻠ᐳߢ 1 ࠣ࡞࡯ࡊ 8 㨪 10 ੱߩ 8 㨪 10 ࠣ࡞࡯ࡊߢ࠹ࡘ࠻࡯࡝ࠕ࡞ᢎ⢒ࠍታᣉߒߡ޿ࠆ‫ޕ‬
ၮ␆⋴⼔ቇߢߪ㧘‫↢ޟ‬ᵴⴕേ߆ࠄ⷗ࠆり૕‫ ࠍޠ‬1 ᐕᰴᓟᦼ㧘ᚑੱ࡮⠧ᐕ⋴⼔ቇߢߪ 2007 ᐕᐲ߹ߢߪ‫ޟ‬ᚑੱ • ⠧ᐕ੐଀ዷ㐿‫ ࠍޠ‬2 ᐕᰴᓟᦼ •3 ᐕᰴ೨ᦼߦ㧘2008 ᐕᐲ߆ࠄߪ 3 ᐕᰴ೨ᦼߦ᝼ᬺ⑼⋡ߏߣߦឭ␜ߐࠇߚ੐଀ߦߟ޿ߡਥ૕⊛ߦቇ⠌ࠍㅴ߼ߡ޿ࠆ‫ޕ‬࿾ၞ࡮♖␹⋴⼔ቇߢߪ‫ޟ‬࿾ၞߦ߅ߌࠆஜᐽ໧㗴ߣេഥΣ‫ ࠍޠ‬2 ᐕᰴᓟᦼߦ㧘‫ޟ‬࿾ၞߦ߅ߌࠆஜᐽ໧㗴ߣេഥΤ‫ ࠍޠ‬4 ᐕᰴ೨ᦼߦ㐿⻠੍ቯߢ޽ࠆ‫ޟߦ․ޕ‬࿾ၞߦ߅ߌࠆஜᐽ໧㗴ߣេഥΤ‫ߪޠ‬㧘࿾ၞ⋴⼔ቇታ⠌ߦ߅ߌࠆ࿾ၞ⸻ᢿࠍ
ਛᔃߦᝒ߃㧘ታ〣ߣ࠴ࡘ࡯࠻࡝ࠕ࡞ቇ⠌ߣࠍㅪ៤ߒߚቇ⠌߇ߢ߈ࠆࠃ߁ߦ㈩⟎ߒߚ‫⼔⋴ޕ‬ቇ⑼ߪ㧘
ᐔᚑ 15 ᐕ 3 ᦬ߦ✚ว⎇ⓥ᫟߇ቢᚑߒ㧘࠮ࡒ࠽࡯ቶ߇⏕଻ߐࠇߚߎߣ߆ࠄቇ⠌ⅣႺ߇ᢛ஻ߐࠇߟ
ߟ޽ࠆ߇㧘ᢎ᧚߿࿑ᦠ㧘ࠦࡦࡇࡘ࡯࠲ߥߤߩలታ߇੹ᓟߩ⺖㗴ߢ޽ࠆ‫ޕ‬ԙ⋴⼔ቇ⥃࿾ታ⠌ᔅୃ⑼⋡ߢ޽ࠆ⥃࿾ታ⠌㧔25 න૏㧕ߪ㧘තᬺⷐઙන૏ᢙ㧔133 න૏એ਄㧕ߩ߁ߜ 20% ᒙࠍභ߼ࠆ㕖Ᏹߦ㊀ⷐߥኾ㐷ᢎ⢒⑼⋡ߢ޽ࠅ㧘⋴⼔Ꮷ࡮଻ஜᏧ㙃ᚑߦߪᰳ߆ߖߥ޿߽ߩߢ޽ࠆ‫ߚߩߘޕ‬߼㧘ቇ↢ߩၮ␆⑼⋡߿ኾ㐷⑼⋡ߩቇ⠌ㅴᐲߦวࠊߖ㧘㧝ᐕᰴߩೋᦼ૕㛎ታ⠌ߦࠃࠆേᯏઃߌ㧘㧞ᐕ↢ߩၮ␆⋴⼔ቇታ⠌ߦ߅ߌࠆᖚ⠪ߩ࠾࡯࠼ᛠីߣ⋴⼔ㆊ⒟ߩℂ⸃㧘㧟ᐕᰴ߆ࠄ㧠ᐕᰴߦ߆ߌߡ
ߩಽ㊁೎ታ⠌ߦ߅ߌࠆ⋴⼔ㆊ⒟ߩዷ㐿ߩቇ⠌ߣ޿߁ࠃ߁ߦ᭴ᚑߒߡ߈ߚ‫⥃ޕ‬࿾ታ⠌ߦ㑐ࠊࠆᆔຬ㧙㧙ળߣߒߡታ⠌ᆔຬળ߇޽ࠅ㧘ᰴ਎ઍߩ⋴⼔ࠍᜂ߁⢻ജࠍᜬߞߚੱ᧚ࠍ⢒ᚑߔࠆߚ߼ߦએਅߩᵴേ
ࠍⴕߞߡ߈ߚ‫ޕ‬࡮ ⥃࿾ታ⠌ᣉ⸳ߣߩ⺞ᢛߣ⥃࿾ታ⠌ᜰዉ⠪ળ⼏ߩડ↹߅ࠃ߮㐿௅࡮ ᐕᐲߏߣߩ⥃࿾ታ⠌⸘↹⴫ߩ૞ᚑ࡮ ⥃࿾ታ⠌ⷐ㗄ߩ૞ᚑߣ㈩Ꮣ࡮ ⥃࿾ታ⠌ࠟࠗ࠳ࡦࠬߩડ↹ߣㆇ༡࡮ ⥃࿾ታ⠌ਛߦ߅ߌࠆἴኂ⊒↢ᤨኻಣࡑ࠾ࡘࠕ࡞ߩ૞ᚑ
࡮ HB ᗵᨴ∝ߣዊఽᗵᨴ∝ߩ᛫૕ᬌᩏߣᬌᩏ⚿ᨐߩ▤ℂ૕೙ߩ⏕┙࡮ HB ᗵᨴ∝ߣዊఽᗵᨴ∝ࡢࠢ࠴ࡦធ⒳ߩ൘ᅑ
࡮ ቇ↢ࠍኻ⽎ߣߒߚᗵᨴ੍㒐ኻ╷ߦ㑐ߔࠆ․೎⻠⟵ߩ㐿௅࡮ ᖚ⠪߅ࠃ߮ቇ↢ߩ୘ੱᖱႎ଻⼔ߦ㑐ߔࠆታ⠌⸥㍳╬ขࠅᛒ޿ࡑ࠾ࡘࠕ࡞ߩ૞ᚑ࡮ ⥃࿾ታ⠌ߦ઻߁੍▚ߦ㑐ߔࠆᬌ⸛ᐔᚑ 19 ᐕ߆ࠄߪ㧘౻ᦼߩࠗࡦࡈ࡞ࠛࡦࠩߩᵹⴕߦࠃߞߡ⥃࿾ታ⠌ߦ㓚ኂ߇ߢߥ޿ࠃ߁ߦࠗࡦ
ࡈ࡞ࠛࡦࠩࡢࠢ࠴ࡦߩធ⒳൘ᅑߛߌߢߥߊ㧘3 ᐕ↢ߣ㧠ᐕ↢ߩᏗᦸቇ↢ࠍ൐ࠅ㧘කቇ⑼ߩቇ↢ߣߩ㓸࿅ធ⒳ߦ㑐ࠊߞߡ޿ࠆ‫ޕ‬࿾ၞ⋴⼔ቇߣᲣᕈ⋴⼔ቇ㧘ഥ↥ቇߩታ⠌ߪ㧘ฃߌ౉ࠇᣉ⸳ߩ࿕ቯൻ߇㔍ߒߊ㧘ᣉ⸳ߩᄌᦝ߇ᄙ
޿ߎߣ߇໧㗴ὐߣߒߡ޽ߍࠄࠇࠆ߇㧘ઁߩಽ㊁ߢߪ㒝ዻ∛㒮એᄖߩᣉ⸳ߦ㑐ߒߡ߶߷቟ቯߒߡ߈
ߡ߅ࠅ㧘ᣉ⸳ߦ߅ߌࠆᜰዉ૕೙ߩ቟ቯൻߦࠃߞߡታ⠌ߦ߅ߌࠆቇ⠌ലᨐࠍ㜞߼ߡ޿ߊߎߣ߇น⢻ߦߥߞߡ߈ߚ‫੹ޕ‬ᓟ㧘ታ⠌ᜰዉߦ㑐ࠊࠆᢎຬߩߐࠄߥࠆᜰዉ⢻ജߩะ਄㧘ታ⠌ᣉ⸳ߣߩㅪ៤ߩల
ታࠍ࿑ࠆߎߣߦࠃߞߡ㧘࠺ࠖࡊࡠࡑࡐ࡝ࠪ࡯ߦวߞߚቇ↢ࠍࠃࠅᄙߊ⢒ᚑߒߡ޿ߊߎߣ߇⺖㗴ߢ޽ࠆ‫ޕ‬㧔4㧕ઁᄢቇߦ߅ߌࠆ᝼ᬺ⑼⋡ߩጁୃᣇ㊎ߣ⁁ᴫቇೣ╙ 59 ᧦ߩⷙቯ‫ޟ‬ᢎ⢒਄᦭⋉ߣ⹺߼ࠆߣ߈ߪ㧘ઁߩᄢቇ෶ߪ⍴ᦼᄢቇߣߩද⼏ߦၮߠ߈㧘ቇ↢ߦᒰ⹥ઁᄢቇ╬ߩ᝼ᬺ⑼⋡ࠍጁୃߐߖࠆߎߣ߇ߢ߈ࠆ‫ޕ‬‫߇ࠆ޽ߣޠ‬㧘ኾ㐷⑼⋡ߦߟ޿ߡߩታ❣ߪߥ޿‫ޕ‬
㧔5㧕࿷☋㧘⇐ᐕ㧘ભቇ㧘ㅌቇߩ⁁ᴫ
ㆊ෰ 2 ᐕ㑆ߩ⁁ᴫߪᰴ⴫ߩߣ߅ࠅߢ޽ࠆ‫ޕ‬඙‫ޓޓ‬ಽ

࿷‫☋ޓޓ‬⇐‫ޓޓ‬ᐕ

ભ‫ޓޓ‬ቇ

ㅌቇ㧔㒰☋ࠍ฽߻‫ޕ‬㧕

ᐔᚑ 18 ᐕᐲ

341

8

3

2

ᐔᚑ 19 ᐕᐲ

346

3

3

4

㧔6㧕ᢎ⢒ᣉ⸳࡮⸳஻ߩ⃻⁁඙‫ޓޓޓޓޓ‬ಽ㕙‫ޓ‬Ⓧ↪‫ޓޓޓޓޓ‬ㅜᧄ㙚 1 㓏‫⟵⻠ޓ‬ቶ 1

134 ট

⻠

ᧄ㙚 3 㓏‫⟵⻠ޓ‬ቶ 2

105 ট

‫ޖ‬

ࡊࡠࠫࠚࠢ࠲࡯㧘ࡆ࠺ࠝᛩᓇⵝ
⟎㧘ࡑࠗࠢ⸳஻㧘⾗ᢱឭ␜ⵝ⟎ᧄ㙚 3 㓏‫⟵⻠ޓ‬ቶ 3

111 ট

‫ޖ‬

ࡊࡠࠫࠚࠢ࠲࡯㧘ࡆ࠺ࠝᛩᓇⵝ
⟎㧘ࡑࠗࠢ⸳஻㧘⾗ᢱឭ␜ⵝ⟎ᧄ㙚 4 㓏‫⟵⻠ޓ‬ቶ 4

90 ট

‫ޖ‬

ࡊࡠࠫࠚࠢ࠲࡯㧘ࡆ࠺ࠝᛩᓇⵝ
⟎㧘ࡑࠗࠢ⸳஻㧘⾗ᢱឭ␜ⵝ⟎

㧙㧙

⟵

⸳‫ޓޓޓޓޓ‬஻ࡊࡠࠫࠚࠢ࠲࡯㧘ࡆ࠺ࠝᛩᓇⵝ
⟎㧘ࡑࠗࠢ⸳஻㧘⾗ᢱឭ␜ⵝ⟎඙‫ޓޓޓޓޓ‬ಽ㕙‫ޓ‬Ⓧ↪‫ޓޓޓޓޓ‬ㅜ⸳‫ޓޓޓޓޓ‬஻ᧄ㙚 5 㓏‫⟵⻠ޓ‬ቶ 5

68 ট

‫ޖ‬

ࡊࡠࠫࠚࠢ࠲࡯㧘ࡆ࠺ࠝᛩᓇⵝ
⟎ᣂ᫟ 1 㓏‫࡯࠽ࡒ࠮ޓ‬ቶ╙㧝㨪╙㧥ቶ
26 ট㨪 47 ট࠹ࡘ࠻࡯࡝ࠕ࡞ᢎ⢒ೋ ᦼ ૕ 㛎 ታ ⠌ࡄ࠰ࠦࡦ㧘ࡊ࡝ࡦ࠲࡯㧘ࠬࠠࡖ࠽࡯㧘ᦠ᫜ ( ᝼ᬺ↪ኾ㐷ᦠ )ᣂ᫟ 3 㓏‫ޓ‬ᄢቇ㒮⻠⟵ቶ 2࡮32ቶ
23 ট㨪 24 ট⻠⟵ᣂ᫟ 3 㓏‫ޓ‬ᄢቇ㒮↢⎇ⓥቶ

2ቶ
23 ট㨪 24 ট⎇ⓥ

ᧄ㙚 2 㓏‫ޓ‬ၮ␆⋴⼔ታ⠌ቶ 1258 ট

ၮ ␆ ⋴ ⼔ ታ ⠌ࡆ࠺ࠝᛩᓇⵝ⟎㧘ࡑࠗࠢ⸳஻㧘⾗ᢱឭ␜ⵝ⟎㧘ࠟࠬੇ῎ᯏᧄ㙚 2 㓏‫ޓ‬⠧ᐕ࿷ቛታ⠌ቶ

92 ট⠧ ᐕ ࿷ ቛ ታ ⠌ࡃ࡝ࠕࡈ࡝࡯ࡕ࠺࡞࡞࡯ࡓ

ᣂ᫟ 2 㓏‫ޓ‬ᚑੱ⋴⼔ታ⠌ቶ 123 ট

ᚑ ੱ ⋴ ⼔ ታ ⠌ᣂ᫟ 2 㓏‫ޓ‬ᚑੱ⋴⼔ታ⠌ቶ 2106 ট

ᚑ ੱ ⋴ ⼔ ታ ⠌ࡆ࠺ࠝᛩᓇⵝ⟎㧘ࡑࠗࠢ⸳஻㧘⾗ᢱឭ␜ⵝ⟎

ᣂ᫟ 2 㓏‫ޓ‬ᚑੱ⋴⼔ታ⠌ቶ 326 ট

ᚑ ੱ ⋴ ⼔ ታ ⠌ᦠ᫜ᣂ᫟ 2 㓏‫ޓ‬ၮ␆⋴⼔ታ⠌ቶ 247 ট

ၮ ␆ ⋴ ⼔ ታ ⠌ࡆ࠺ࠝᛩᓇⵝ⟎㧘ࡑࠗࠢ⸳஻㧘⾗ᢱឭ␜ⵝ⟎

ᣂ᫟ 3 㓏‫ޓ‬࿾ၞ⋴⼔ታ⠌ቶ

94 ট

࿾ ၞ ⋴ ⼔ ታ ⠌ᣂ᫟ 3 㓏‫⼔⋴␹♖ޓ‬ታ⠌ቶ 153 ট♖ ␹ ⋴ ⼔ ታ ⠌ᣂ᫟ 3 㓏‫⼔⋴␹♖ޓ‬ታ⠌ቶ 226 ট♖ ␹ ⋴ ⼔ ታ ⠌ᧄ㙚 4 㓏‫ޓ‬ℂൻቇታ⠌ቶ90 টℂ ൻ ቇ ታ ⠌

ᧄ㙚 4 㓏‫ޓ‬ᄢቇ㒮⻠⟵ቶ 1

90 ট

⻠

ᣂ᫟ 4 㓏‫ޓ‬Უᕈ࡮ዊఽ⋴⼔ታ⠌ቶ 1

147 টᲣᕈ࡮ዊఽ⋴⼔ታ⠌

ᣂ᫟ 4 㓏‫ޓ‬Უᕈ࡮ዊఽ⋴⼔ታ⠌ቶ 2

26 ট

ᣂ᫟ 4 㓏‫ޓ‬ഥ↥ቇታ⠌ቶ
ᣂ᫟ 4 㓏‫ޓ‬Უᕈ࡮ዊఽ⋴⼔ታ㛎ቶ 193 ট

଻಄ᐶ㧘ࡈ࡝࡯ࠩ࡯㧘㆙ᔃಽ㔌ᯏ㧘ࠨ࡯ࡑ࡞ࠨࠗࠢ࡜࡯

⟵ᴍᶎᮏ㧘ੇ῎ᯏᲣᕈ࡮ዊఽ⋴⼔ታ⠌ഥ ↥ ቇ ታ ⠌ᴍᶎᮏᲣᕈ࡮ዊఽ⋴⼔ታ⠌㧵㧴 ࠢ࠶ࠠࡦࠣࡅ࡯࠲࡯

㧔7㧕ᚑ❣ߩ⹏ଔ㧘⹺ቯߩၮḰᚑ❣ߪ㧘⹜㛎╬ߩ⚿ᨐࠍ✚วߒߡએਅߩ඙ಽߢ⹏ଔߔࠆ‫ޕ‬ఝ㧔100 ὐ㨪 80 ὐ㧕วᩰ⦟㧔79 ὐ㨪 70 ὐ㧕วᩰ
น㧔69 ὐ㨪 60 ὐ㧕วᩰਇน㧔60 ὐᧂḩ㧕ਇวᩰ∛᳇ߘߩઁᱜᒰߥℂ↱ߦࠃࠅቯᦼ⹜㛎ࠍฃߌࠄࠇߥ߆ߞߚ⠪ߦߟ޿ߡ㧘㗿޿಴ߦࠃࠅㅊ⹜㛎ࠍฃߌࠆߎߣ߇ߢ߈ࠆ‫ޕ‬ቯᦼ⹜㛎෸߮ㅊ⹜㛎ߦਇวᩰߣߥߞߚ⠪ߦߟ޿ߡ㧘1 ࿁ߦ㒢ࠅౣ⹜㛎ࠍฃߌࠆߎߣ
߇ߢ߈ࠆ‫ޕ‬㧙㧙㧔8㧕⋴⼔Ꮷ╬࿖ኅ⹜㛎วᩰ⁁ᴫㆊ෰㧞ᐕ㑆ߩวᩰ⁁ᴫߪᰴ⴫ߩߣ߅ࠅߢ޽ࠆ‫ޕ‬
ฃ㛎⠪

วᩰ⠪

วᩰ₸

ో࿖วᩰ₸

଻ஜᏧ

83

83

100

99.0

ഥ↥Ꮷ

7

6

85.7

94.3

⋴⼔Ꮷ

73

73

100

90.6

଻ஜᏧ

89

87

97.8

91.1

ഥ↥Ꮷ

8

8

100

98.1

⋴⼔Ꮷ

79

18

98.7

90.3

඙ಽ
ᐔᚑ
18 ᐕᐲ
ᐔᚑ
19 ᐕᐲ

㧔9㧕ቇ↢ߩዞ⡯⁁ᴫ
ㆊ෰ 2 ᐕ㑆ߩතᬺ↢ߩዞ⡯⁁ᴫߪᰴ⴫ߩߣ߅ࠅߢ޽ࠆ‫ޕ‬
඙ಽ

⋴⼔Ꮷ

଻ஜᏧ

ഥ↥Ꮷ

ㅴቇ

ߘߩઁ

ᐔᚑ 18 ᐕᐲ

62

13

7

1

0

ᐔᚑ 19 ᐕᐲ

57

18

8

2

2

4. ቇ↢↢ᵴ߳ߩ㈩ᘦ
㧔1㧕ᅑቇ㊄ߩ⒳㘃ߣណᛯ⁁ᴫ
ㆊ෰ 2 ᐕ㑆ߩ࠺࡯࠲ߪᰴ⴫ߩߣ߅ࠅߢ޽ࠆ‫ޕ‬ᣣᧄቇ↢ᡰេᯏ᭴
╙1⒳඙‫ޓޓޓ‬ಽߘߩઁߩᅑቇ㊄

߈߷߁ 21

↳⺧⠪ᢙ

ណ↪⠪ᢙ

↳⺧⠪ᢙ

ណ↪⠪ᢙ

↳⺧⠪ᢙ

ណ↪⠪ᢙ

ᐔᚑ 18 ᐕᐲ

18

17

14

14

1

1

ᐔᚑ 19 ᐕᐲ

16

15

17

15

0

0

㧔2㧕᝼ᬺᢱߩ఺㒰ߩ⁁ᴫ
ㆊ෰ 2 ᐕ㑆ߩ⁁ᴫߪᰴ⴫ߩߣ߅ࠅߢ޽ࠆ‫ޕ‬
೨ቇᦼ
඙‫ޓ‬ಽ

࿷☋⠪ᢙ

↳⺧

ᓟቇᦼ
఺㒰

ో㗵

ඨ㗵

↳⺧

఺㒰
ో㗵

ඨ㗵

ᐔᚑ 18 ᐕᐲ

341

29

0

24

35

1

28

ᐔᚑ 19 ᐕᐲ

346

40

17

17

37

18

18

㧔3㧕ቇ↢↢ᵴ⋧⺣ߩ૕೙ߣታᘒ
ቇ↢ߩ୘ੱ⊛ߥ↢ᵴߦ㑐ߔࠆ⋧⺣ߦߟ޿ߡߪ㧘ቇോ╙ੑଥ߇⓹ญߣߒߡኻᔕߒߡ޿ࠆ‫ޕ‬୘ੱ⊛⋧⺣ߦߟ޿ߡߪቯ߼ࠄࠇߚᜂᒰᢎຬ߇ᔕߓ㧘⻠ᐳ࡟ࡌ࡞ߢߩᜰዉ੐㗄ߥߤߦߟ޿ߡߪᒰ⹥⻠ᐳߩᢎຬߦࠃࠅኻᔕߒ㧘✚ว⊛ߦߪ⋴⼔ቇ⑼ᢎോෘ↢ᆔຬળߦ߅޿ߡኻᔕߒߡ޿ࠆ‫ޕ‬㧙㧙㧔4㧕⺖ᄖᵴേߩታᘒ
⋴⼔ቇ⑼ߢ⸵นߒߡ޿ࠆቇ↢࿅૕ߪሽ࿷ߒߥ޿߇㧘ጘ㒂ᄢቇᄢቇᢎ⢒ᆔຬળߩ⹺߼ࠆ૕⢒♽෸߮ᢥ⑼♽ࠨ࡯ࠢ࡞㧘߹ߚጘ㒂ᄢቇකቇㇱᢎോෘ↢ᆔຬળߩ⹺߼ࠆකቇㇱ૕⢒♽෸߮ᢥ⑼♽ࠨ࡯ࠢ࡞ߦᚲዻ
ߒᵴേߔࠆቇ↢ߪዋߥߊߥ޿‫ޕ‬ࠠࡖࡦࡄࠬ࡜ࠗࡈ߇᦭ᗧ⟵ߢ㧘ஜోߥ߽ߩߣߥࠆࠃ߁ߦ⺖ᄖᵴേࠍⴕ߁ቇ↢ᢙߩታᘒߪᰴ⴫ߩߣ߅
ࠅߢቇᐕㅴⴕߣߣ߽ߦჇടߒߡ޿ࠆ‫ޕ‬඙‫ޓ‬ಽోቇࠨ࡯ࠢ࡞
૕⢒♽කቇㇱࠨ࡯ࠢ࡞

ᢥൻ♽

૕⢒♽
46㧔8㧕

23

20㧔7㧕

10

ᐔᚑ 18 ᐕᐲ33

24

ᐔᚑ 19 ᐕᐲ3720

̪ 1‫ޓ‬ฦᐕᐲߩ 4 ᦬ 1 ᣣઃߌߩㇱຬᢙߢ޽ࠅ㧘ᣂ౉ㇱຬᢙߪ฽߹ߥ޿‫ޕ‬2‫ޓ‬㧔‫ޓ‬㧕ౝߪ㧘ᅏⓄ㜞ጪ⸻≮ᚲࠢ࡜ࡉㇱຬᢙ㧔ᄖᢙ㧕ߢ㧘7 ᦬ᤨὐߢߩㇱຬᢙߢ޽ࠆ‫ޕ‬

㧙㧙

ᢥൻ♽

5㧚 ⎇ⓥᵴേާၮ␆⋴⼔ቇ⻠ᐳި
㧔1㧕ၮ␆⋴⼔ቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
ၮ␆⋴⼔ቇಽ㊁ߢߪ㧘⋴⼔ၮ␆ᢎ⢒ߣ⋴⼔⛮⛯ᢎ⢒ߣߩ㑐ㅪᕈߩਛߢ㧘ߘߩᱧผ⊛⢛᥊ࠍ߰߹߃ߟߟ㧘⋴⼔Ꮷߦᔅⷐߥេഥᛛⴚߦ㑐ߔࠆ⎇ⓥ㧘⋴⼔ⷰ߿୶ℂⷰߦ㑐ߔࠆ⎇ⓥࠍⴕߞߡ޿ࠆ‫ߚ߹ޕ‬㧘⃻ઍߩ␠ળ⁁ᴫߦวࠊߖᗵᨴ▤ℂࠍ฽߻⋴⼔▤ℂߦ㑐ߔࠆ⎇ⓥߦขࠅ⚵ࠎߢ޿ࠆ‫ޕ‬1㧕⋴⼔⡯ߩ⛮⛯ᢎ⢒ߦ㑐ߔࠆᱧผ⊛⎇ⓥࠍ⛮⛯ߒߡⴕߞߡ޿ࠆ‫ޕ‬
2㧕࿷ቛߦ߅ߌࠆᗵᨴ▤ℂߦ㑐ߔࠆᢎ⢒ࡊࡠࠣ࡜ࡓߩലᨐᬌ⸽ߣ࿷ቛ࠲㧙ࡒ࠽࡞ߦ㑐ߔࠆᢎ⢒ࡊࡠࠣ࡜ࡓ
ߩ㐿⊒ࠍ࠹࡯ࡑߦ⎇ⓥߦขࠅ⚵ࠎߢ޿ࠆ‫ޕ‬
3㧕⋴⼔▤ℂ߿ක≮⚻ᷣ⊛ߥⷞὐࠍ฽߼ߚ⋴⼔Ꮷߩ⾗⾰ะ਄ߦ߻ߌߡߩࠠࡖ࡝ࠕࠕ࠶ࡊߦ㑐ߔࠆ⎇ⓥࠍⴕ
ߞߡ޿ࠆ‫ޕ‬4㧕⋴⼔Ꮷߩ㔌⡯ߦὶὐࠍᒰߡ㔌⡯ߦᓇ㗀ࠍਈ߃ࠆⷐ࿃ߩㅊⓥ㧘⋴⼔Ꮷ߇⡯႐ߢߩ⡯ോ⛮⛯૶↪ߣߔࠆᤨߩᗧᔒ᳿ቯߦᓇ㗀ߔࠆⷐ࿃ࠍ᣿ࠄ߆ߦߔࠆߎߣߦขࠅ⚵ࠎߢ޿ࠆ‫ޕ‬
5㧕࠽ࠗ࠴ࡦࠥ࡯࡞ߦ㑐ߔࠆ⋴⼔߅ࠃ߮⋴⼔ⷰ࡮୶ℂⷰ࡮㆏ᓼⷰ࡮ቬᢎⷰࠍ฽߼ߚੱ‛ߩ⎇ⓥ㧘ਗ߮ߦ⋴⼔ߩ✚⺰╬ߩ⎇ⓥࠍⴕߞߡ޿ࠆ‫ޕ‬
6㧕⧷ᢥቇߢߪࡧࠖࠢ࠻࡝ࠕᦺᤨઍࠍਛᔃߦ Charles Dickens, Thomas Hardy, Jane Austen, E.M.
Forster ╬ߩ૞ຠ⎇ⓥࠍⴕߞߡ޿ࠆ‫ޕ‬7㧕⋴⼔Ꮷߩ୶ℂ⊛ᗵฃᕈߦ㑐ߔࠆ⎇ⓥࠍⴕߞߡ޿ࠆ‫ޕ‬8㧕ᖚ⠪ߩᮭ೑ᠩ⼔ߦ㑐ߔࠆ⎇ⓥࠍߘࠇߙࠇߩᢎຬ߇ਛᔃߣߥߞߡ⛮⛯ߒߡⴕߞߡ޿ࠆ‫ޕ‬9㧕⋴⼔ᛛⴚᢎ⢒ߦ㑐ߒ㧘․ߦᩕ㙃ߦ㑐ߔࠆេഥᛛⴚߦ㑐ߒߡߩ⎇ⓥࠍⴕߞߡ޿ࠆ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
ᢎ᝼㧦
ಎᢎ᝼㧦
ಎᢎ᝼㧦
ಎᢎ᝼㧦
ഥᢎ㧦
ഥᢎ㧦

Ṛౝ 㓉ሶႦේ ▵ሶ
ἑᚭፒᐽሶዊ᧻ ᅱሶ⿷┙ߺࠁ߈ጟᧄ ජ዆
ⱃ↰ ⟤⾆Takako Takiuti
Setsuko Tukahara
Yasuko Setozaki
Taeko Komatsu
Miyuki Adati
Chihiro Okamoto
Miki Hiruta

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ဈᧄ₵ሶ㧘Ṛౝ㓉ሶઁ㧚∛ኅ㗇⍮ ⠡ೞ⸶ᵈ▻਄㧘ㄘᢥද㧘2006 ᐕ㧚
2㧕 ဈᧄ₵ሶ㧘Ṛౝ㓉ሶઁ㧚∛ኅ㗇⍮ ⠡ೞ⸶ᵈ▻ਅ㧘ㄘᢥද㧘2006 ᐕ㧚
3㧕 ဈᧄ₵ሶ㧘Ṛౝ㓉ሶઁ㧚∛ኅ㗇⍮ ⎇ⓥ⾗ᢱ▻㧘ㄘᢥද㧘2006 ᐕ㧚⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 ᄢᵤᑝሶ㧚⋴⼔ᛛⴚߩᾫ✵ߣࠗࡦ࠮ࡦ࠹ࠖࡉ㧘ᣣᧄ⋴⼔ක≮ቇળ⹹㧘2006 ᐕ㧧8 Ꮞ㧦44㧙51㧚
2㧕 ਛᎹ⌀Ꮤ㧘Ṛౝ㓉ሶ㧘㊄⧯⟤ᐘ㧚ᵞ㜬ゞࠍ↪޿ߚᵞ㜬ߦ߅ߌࠆ↢૕⽶ᜂ̆᳓ᐔઔ⥁ᐥߣ਄ඨり 20° ᜼਄૏ߩᲧセ̆㧘ᣣᧄ⋴⼔ᛛⴚቇળ⹹㧘2006 ᐕ㧧5 Ꮞ㧦51㧙57㧚
3㧕 ೨↰ୃሶ㧘Ṛౝ㓉ሶ㧘ዊ᧻ᅱሶ㧚ᗵᨴ▤ℂߦ㑐ߔࠆ⍮⼂࡮ᛛⴚߦኻߔࠆ⸰໧⋴⼔ᓥ੐⠪ߩᝒ߃ᣇ㧘ᣣᧄ⋴⼔⎇ⓥቇળ⹹ 2006 ᐕ㧧29 Ꮞ㧦103㧙111㧚
4㧕 ೨↰ୃሶ㧘Ṛౝ㓉ሶ㧘᳓ፉࠁ߆ࠅ㧚࿷ቛߦ߅ߌࠆක≮ಣ⟎ߦኻߔࠆක≮࡮ⴡ↢᧚ᢱߩ⏕଻ߦ㑐ߔࠆ⹺⼂̆࿷ቛක≮ߦ៤ࠊࠆකᏧ࡮⋴⼔Ꮷࠍኻ⽎ߣߒߡ̆㧘⸰໧⋴⼔ߣ੺⼔ 2006 ᐕ㧧11 Ꮞ㧦593㧙599㧚
5㧕 ೨↰ୃሶ㧘Ṛౝ㓉ሶ㧘᳓ፉࠁ߆ࠅ㧚࿷ቛ≮㙃⠪߳ߩක≮࡮ⴡ↢᧚ᢱߦะߌߡߩ⺖㗴㧘≸ߣൻቇ≮ᴺ 2006ᐕ㧧33 Ꮞ㧦2733㧙275㧚
6㧕 ೨↰ୃሶ㧘Ṛౝ㓉ሶ㧘ዊ᧻ᅱሶ㧚⸰໧⋴⼔ߦᔅⷐߥᗵᨴ▤ℂࠍቇ߱ ⸰໧⋴⼔Ꮷࠍኻ⽎ߣߒߚᗵᨴ▤ℂߦ
㑐ߔࠆᢎ⢒ߩ⃻⁁㧙ߤ߁ߔࠇ߫ቇߴࠆߩ㧫ᗵᨴ▤ℂ㧙㧘᧲੩㧦කቇᦠ㒮 2007 ᐕ㧦450㧙459㧚
7㧕 ዊ᧻ᅱሶ㧘Ṛౝ㓉ሶ㧘೨↰ୃሶ㧚⸰໧⋴⼔ߦᔅⷐߥᗵᨴ▤ℂࠍቇ߱ ‫⸰ޟ‬໧⋴⼔Ꮷะߌᗵᨴ▤ℂߦ㑐ߔࠆ㧙㧙ᢎ⢒ࡊࡠࠣ࡜ࡓ‫ߩޠ‬૞ᚑ㧙⸰໧⋴⼔Ꮷߦᔅⷐߥ⍮⼂㨯ᛛⴚࠍലᨐ⊛ߦቇ߱ߚ߼ߦ㧙㧘᧲੩㧦කቇᦠ㒮 2007
ᐕ㧦460㧙465㧚
8㧕 ዊ᧻ᅱሶ㧘Ṛౝ㓉ሶ㧘೨↰ୃሶ㧚⸰໧⋴⼔ߦᔅⷐߥᗵᨴ▤ℂࠍቇ߱ ⸰໧⋴⼔ࠬ࠹࡯࡚ࠪࡦߢ㐿௅ߔࠆᗵᨴ▤ℂߩ⎇ୃળ㧙‫ޟ‬ᚻᵞ޿࡮߁߇޿‫ߩޠ‬ቇ⠌ലᨐࠍ᜼ߍࠆḰ஻㨯Ꮏᄦ㧙㧘᧲੩㧦කቇᦠ㒮 2007 ᐕ㧦466
㧙469㧚
9㧕 ೨↰ୃሶ㧘Ṛౝ㓉ሶ㧘ዊ᧻ᅱሶ㧚⸰໧⋴⼔ߦᔅⷐߥᗵᨴ▤ℂࠍቇ߱ ‫ޟ‬ᚻᵞ޿࡮߁߇޿‫ୃ⎇ޠ‬ળߩታ㓙㧙⸰໧⋴⼔ߦ߅ߌࠆ‫ޟ‬ᚻᵞ޿࡮߁߇޿‫࠻ࡦࠗࡐߩޠ‬㧙㧘᧲੩㧦කቇᦠ㒮㧧2007 ᐕ㧦470㧙482㧚
✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ᄢᵤᑝሶ㧘ᦸ᦬┨ሶ㧘⿷┙ߺࠁ߈㧘ᷰㄝ੝♿ሶ㧚⋴⼔ᢎຬߩജ㊂ᒻᚑߦᓇ㗀ࠍਈ߃ࠆⷐ࿃ಽᨆ㧘ᣣᧄ⋴⼔ක≮ቇળ㔀⹹ 2006 ᐕ㧧8 Ꮞ㧦21㧙30㧚
2㧕 Ṛౝ㓉ሶ㧚භ㗔ᦼߦ߅ߌࠆ⋴⼔⡯ߩ࡝ࡈ࡟࠶ࠪࡖ࡯ࠦ࡯ࠬߦ㑐ߔࠆ⎇ⓥ ̆⋴⼔ᢎ⢒ᜰዉ⠪⻠⠌ળ̆㧘✚ว᡽╷ቇળ㧘2007 ᐕ㧧9 Ꮞ㧦83㧙92㧚
3㧕 Ṛౝ㓉ሶ㧚භ㗔ᦼߦ߅ߌࠆ⋴⼔⡯ߩ࡝ࡈ࡟࠶ࠪࡖ࡯ࠦ࡯ࠬߦ㑐ߔࠆ⎇ⓥ ̆⵬⠌ᢎ⢒̆㧘✚ว᡽╷⎇ⓥቇ
ળ㧘2007 ᐕ㧧10 Ꮞ㧦29㧙40㧚
4㧕 ዊ᧻ᅱሶ㧘Ṛౝ㓉ሶ㧘೨↰ୃሶ㧚⸰໧⋴⼔ᓥ੐⠪ߩᗵᨴ▤ℂߦ㑐ߔࠆቇ⠌ߩ⃻⁁ߣⷐᦸ㧘ⅣႺᗵᨴ 2007
ᐕ㧧22 Ꮞ㧦41㧙45㧚
5㧕 ᷰㆺ੝♿ሶ㧚♧ዩ∛ࠍᛴ߃ࠆ♧ዩ∛ᖚ⠪ߩᕁ޿̆ᢎ⢒౉㒮ㅌ㒮ᓟ 3 ߆᦬ߣ 1 ᐕᓟߩ㕙ធ߆ࠄ㧙㧘PRACTICE
2007 ᐕ㧧324㧦226㧙230㧚
6㧕 ೨↰ୃሶ㧘Ṛౝ㓉ሶ㧘᳓ፉࠁ߆ࠅ㧘ਛጊᩕ⚐㧘ᵻ⷗⟤ජᳯ㧚㨬࿷ቛߦ߅ߌࠆᗵᨴ▤ℂߦ㑐ߔࠆࡑ࠾ࡘࠕ࡞㨭ߩౝኈߦ㑐ߔࠆ⹏ଔ ̆⸰໧⋴⼔Ꮷࠍኻ⽎ߣߒߚ⺞ᩏࠃࠅ̆㧘ᣣᧄ࿷ቛࠤࠕቇળ⹹ 2007 ᐕ㧧10 Ꮞ㧦91
㧙98㧚
7㧕 ೨↰ୃሶ㧘Ṛౝ㓉ሶ㧘ዊ᧻ᅱሶ㧚⸰໧⋴⼔Ꮷߩୃᓧ⁁ᴫ⺞ᩏ⚿ᨐ߆ࠄ‫ޟ‬ᚻᵞ޿࡮߁߇޿‫ୃ⎇ޠ‬ળቇ⠌ౝኈ㨯
ᣇᴺߩᬌ⸛㧘ⅣႺᗵᨴ 2007 ᐕ㧧22 Ꮞ㧦137㧙143㧚
8㧕 የ↰ ᗲ㧘᫪ ᐘ⟤㧘ਛጊ⹗⟤㧘ጊ↰⟤㚅㧘Ⴆේ▵ሶ㧚≸ൻቇ≮ᴺࠍฃߌࠆᖚ⠪߇≹ߐࠇࠆߣ߈㧘╙ 38࿁ᣣᧄ⋴⼔ቇળ⺰ᢥ㓸(ᚑੱ⋴⼔Τ) 2007 ᐕ㧦121㧙122㧚
9㧕 ጊᎹ㓷ሶ㧘☨ᴛ⌀Ꮧሶ㧘ጊ↰ᥓઍ㧘ศጟᄹ⟤㧘ၳ⟤ᩕሶ㧘Ⴆේ▵ሶ㧚⚻㛎ᐕᢙ 3 ᐕᧂḩߩ⋴⼔Ꮷߩᛥ೙ߦ
ኻߔࠆ⹺⼂㧘╙ 38 ࿁ᣣᧄ⋴⼔ቇળ⺰ᢥ㓸㧔⋴⼔✚ว㧕 2007 ᐕ㧦303㧙305㧚
10㧕 ೨↰ୃሶ㧘Ṛౝ㓉ሶ㧘ዊ᧻ᅱሶ㧚⸰໧⋴⼔Ꮷࠍኻ⽎ߣߒߚ‫ޟ‬ᚻᵞ޿࡮߁߇޿‫ୃ⎇ޠ‬ળߩലᨐᬌ⸽㧘ⅣႺᗵᨴ 2008 ᐕ㧧23 Ꮞ㧦41㧙47㧚
11㧕 ጤၔ⋥ሶ㧘Ⴆේ▵ሶ㧚‫␠ࠆߌ߅ߦ⼔⋴ޟ‬ળ⊛ࠬࠠ࡞‫ߣޠ‬㑐ㅪߔࠆⷐ࿃ߩᬌ⸛㧘⍹Ꮉ⋴⼔㔀⹹ 2008 ᐕ㧧5Ꮞ㧦75㧙84㧚
12㧕 Ṛౝ㓉ሶ㧚භ㗔ᦼߦ߅ߌࠆ⋴⼔⡯ߩ⛮⛯ᢎ⢒ߦ㑐ߔࠆ⎇ⓥ∛㒮ౝߦ߅ߌࠆౣᢎ⢒㧘✚ว᡽╷ቇળ ✚ว᡽╷⎇ⓥ 2008 ᐕ㧧10 Ꮞ㧦141㧙150㧚
13㧕 ೨↰ୃሶ㧘Ṛౝ㓉ሶ㧘ዊ᧻ᅱሶ㧚࿷ቛࠤࠕߩᗵᨴ▤ℂߦ㑐ߔࠆ⎇ⓥߩേะߣ੹ᓟߩ⺖㗴1992㨪2006 ᐕߩ
࿖ౝᢥ₂߆ࠄ㧘ⅣႺᗵᨴ 2008 ᐕ㧧23 Ꮞ㧦350㧙354㧚
14㧕 ૒ષਭᕺ㧘ጊ↰⟤㚅㧘㜞ፉ↱⟤㧘ᳰ↰↱㚅㧘㜞ᯅ⟤ሶ㧘Ⴆේ▵ሶ㧚⥃ᐥ⋴⼔Ꮷ߇㒮ᄖ⊒⴫ࠍ૕㛎ߒߚߎߣߢᛴߊ⎇ⓥ߳ߩᕁ޿㧘╙ 38 ࿁ᣣᧄ⋴⼔ቇળ⺰ᢥ㓸㧔⋴⼔▤ℂ㧕 2008 ᐕ㧧300㧙302㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Yasuko Setozaki. The Light Side of A Tale of Two Cities. Journal of Humanities, Language & Culture& Literature. XXVIII. 2007:1-39.

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦ᷰㆺ੝♿ሶ㧧ᢥㇱ⑼ቇ⋭⎇ⓥ⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦♧ዩ∛ᖚ⠪ߩ㘩੐≮ᴺߦኻߔࠆ⪾⮮ߩᗧ๧ࠍ⠨ᘦߒߚ⋴⼔េഥᣇᴺߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 16㧙18 ᐕᐲ㧧3,300 ජ౞(900㧦1,000㧦1,400 ජ౞)2㧕 ⎇ⓥઍ⴫⠪㧦⿷┙ߺࠁ߈㧘⎇ⓥಽᜂ⠪㧦ᄢᵤᑝሶ㧘ችᨋ㇚ሶ㧘ᷰㆺ੝♿ሶ㧧ᢥㇱ⑼ቇ⋭⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦⋴⼔Ꮷߩ୶ℂ⊛ᗵฃᕈߣ୶ℂ⊛ᗧᕁ᳿ቯㆬᅢⷐ࿃ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18㧙19 ᐕᐲ㧧
3,400 ජ౞(1,200㧦2,200 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦೨↰ୃሶ㧘⎇ⓥಽᜂ⠪㧦Ṛౝ㓉ሶ㧘ዊ᧻ᅱሶ㧦⑼ቇ⎇ⓥ⾌ၮ⋚⎇ⓥ(C)(2)㧦‫⸰ޟ‬໧⋴⼔Ꮷࠍኻ⽎ߣߒߚᗵᨴ▤ℂᢎ⢒ࡊࡠࠣ࡜ࡓ‫ߩޠ‬ታ⸽ߣౣ᭴▽ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 19㧙21 ᐕᐲ㧧3,864
ජ౞(1,111㧦1,422㧦1,331 ජ౞)
4㧕 ⎇ⓥઍ⴫⠪㧦᧛ਛ㓁ሶ㧘⎇ⓥಽᜂ⠪㧦⿷┙ߺࠁ߈㧧ᢥㇱ⑼ቇ⋭⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦ක≮ߦ߅ߌࠆ࡝ࠬࠢᗵᕈࠍ㜞߼ࠆߚ߼ߩᢎ᧚㐿⊒㧧ᐔᚑ 19㧙22 ᐕᐲ㧧3,300 ජ౞(1,200㧦500㧦1,100㧦500
ජ౞㧕

㧙㧙

5㧕 ⎇ⓥઍ⴫⠪㧦ዊ᧻ᅱሶ㧘⎇ⓥಽᜂ⠪㧦Ṛౝ㓉ሶ㧘೨↰ୃሶ㧦⑼ቇ⎇ⓥ⾌ၮ⋚⎇ⓥ(C)(2)㧦⸰໧⋴⼔Ꮷኻ⽎ߩ‫ޟ‬࿷ቛ࠲㧙ࡒ࠽࡞ࠤࠕ‫ߦޠ‬㑐ߔࠆᢎ⢒ࡊࡠࠣ࡜ࡓ㐿⊒㧧ᐔᚑ 20㧙22 ᐕᐲ㧧3,937 ජ౞(1,097㧦
1,338㧦1,502 ජ౞)6㧕 ⎇ⓥઍ⴫⠪㧦૒⮮౏⟤ሶ㧘⎇ⓥಽᜂ⠪㧦Ṛౝ㓉ሶ㧘ဝ੗⦟ሶ㧘ᅏችᥙሶ㧦⑼ቇ⎇ⓥ⾌ၮ⋚⎇ⓥ(C)(2)㧦
භ㗔ᦼߩ⋴⼔▤ℂ᡽╷ߦ㑐ߔࠆ⠨ኤGHQ㧛SCAP ᢥᦠߦࠃࠆᱧผ⊛ಽᨆ㧧ᐔᚑ 20㧙22 ᐕᐲ㧧
4,058 ජ౞(1,605㧦1,483㧦970 ජ౞)
7㧕 ⎇ⓥઍ⴫⠪㧦ችᨋ㇚ሶ㧘⎇ⓥಽᜂ⠪㧦ᣣ㜞⦣ሶ㧘ች⣁⟤଻ሶ㧘⿷┙ߺࠁ߈㧧ᢥㇱ⑼ቇ⋭⎇ⓥ⵬ഥ㊄⪚⧘⎇ⓥ㧦࡝࡯࠳࡯ࠪ࠶ࡊߣ࠺࡝ࠥ࡯࡚ࠪࡦ⢻ജ߇ᄢත⋴⼔Ꮷߩ‫઀ޟ‬੐ߩ߿ࠅ߇޿‫ߦޠ‬෸߷ߔᓇ㗀ᐔᚑ 19㧙20 ᐕᐲ㧧3,100 ජ౞(2600㧦500 ජ౞)
2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬዊ᧻ᅱሶ㧦
1㧕 ╙ 39 ࿁ᐔᚑ 20 ᐕᐲᣣᧄ⋴⼔ቇળ㧙⋴⼔ᢎ⢒㧙ቇⴚ㓸ળ ቇળḰ஻ᆔຬળ೽ᆔຬ㐳(ᐔᚑ 19 ᐕᐲ㨪ᐔ
ᚑ 20 ᐕ 9 ᦬)
2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳Ṛౝ㓉ሶ㧦
1㧕 ╙ 43 ࿁Ᏹ✚࿖㓙㜞ᐲኾ㐷⡯ᢎ⢒⎇ⓥળቇળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ንጊ㧘᜗ᓙ⻠Ṷ‫⼔⋴ޟ‬ᢎ⢒ߩ⃻࿷‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ1㧕 Ṛౝ㓉ሶ࡮ઁ‫ޡ‬㨬∛ኅ㗇⍮‫ޟ߇ޢ‬⍫ᢙකผቇ⾨‫ޠ‬ฃ⾨(ᐔᚑ 18 ᐕᐲ)
9㧚␠ળᵴേ
ߥߒ
10㧚ႎ๔ᦠ
1㧕 Ṛౝ㓉ሶ㧘೨↰ୃሶ㧘ዊ᧻ᅱሶ㧧࿷ቛߦ߅ߌࠆᗵᨴ▤ℂ੺౉ߣᢎ⢒ࡊࡠࠣ࡜ࡓߩ㐿⊒㧦ᐔᚑ 16 ᐕᐲ㧙ᐔᚑ 17 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄㧦1㧙46(2006 ᐕ 3 ᦬)
2㧕 ⿷┙ߺࠁ߈㧘ᄢᵤᑝሶ㧘ችᨋ㇚ሶ㧘ᷰㆺ੝♿ሶ㧦⋴⼔Ꮷߩ୶ℂ⊛ᗵฃᕈߩታᘒ⺞ᩏߣߘߩ⊒㆐ࡊࡠ࠮ࠬߩ᭴ㅧൻ㧦ᐔᚑ 17 ᐕᐲ㧙ᐔᚑ 18 ᐕᐲ⑼ቇ⎇ⓥഥᚑ㊄ႎ๔ᦠ㧦1㧙15(2006 ᐕ)3㧕 ᄢᵤᑝሶ㧘ᄢᣣᐽผ㧘⿷┙ߺࠁ߈㧘ᷰㆺ੝♿ሶ㧦㜞㦂⠪ߩක≮ᯏ㑐ߩฃ⸻ⴕേߣㆬᅢⷐ࿃ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 16 ᐕᐲ㧙ᐔᚑ 17 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄㧦1㧙57(2006 ᐕ)
4㧕 ᷰㆺ੝♿ሶ㧦♧ዩ∛ᖚ⠪ߩ㘩੐≮ᴺߦኻߔࠆ⪾⮮ߩᗧ๧ࠍ⠨ᘦߒߚ⋴⼔េഥᣇᴺߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 16㨪18 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄(⧯ᚻ⎇ⓥ(B))ႎ๔ᦠ(2007 ᐕ 1 ᦬)
5㧕 ⿷┙ߺࠁ߈㧘ᄢᵤᑝሶ㧘ችᨋ㇚ሶ㧘ᷰㆺ੝♿ሶ㧦⋴⼔Ꮷߩ୶ℂ⊛ᗵฃᕈߩታᘒ⺞ᩏߣߘߩ⊒㆐ࡊࡠ࠮ࠬߩ᭴ㅧൻ㧦ᢥㇱ⑼ቇ⋭⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)ႎ๔ᦠ(2007 ᐕ 3 ᦬)㧙㧙

6㧕 Ⴆේ▵ሶ㧦M-GTA ീᒝળࠍਛᔃߣߒߚ‫⎇⊛⾰ޟ‬ⓥหᅢળ‫ޠ‬ႎ๔㧦M-GTA News letter no.29(2008ᐕ 6 ᦬)
7㧕 Ⴆේ▵ሶ㧦‫࡯ࠟ࡞ࡍࠬࠕޟ‬㓚ኂఽߩ㙃⢒ߣࠨࡐ࡯࠻ߦኻߔࠆᲣⷫߩ⹺⍮⊛ᄌൻߦ㑐ߔࠆ⾰⊛⎇ⓥ‫ߦޠ‬ኻߔࠆ SV ࠦࡔࡦ࠻ႎ๔㧦M-GTA News letter no.31(2008 ᐕ 9 ᦬)
11㧚ႎ㆏1㧕 Ṛౝ㓉ሶ㧦⋴⼔ߩ࡞࡯࠷ࠍ᳞߼ߡ㧦ጘ㒂ᣂ⡞(2006 ᐕ 1 ᦬ 31 ᣣ)
2㧕 Ⴆේ▵ሶ㧦ᄖ்ᕈ㜞ᰴ⣖ᯏ⢻㓚ኂ߇Ⴧട㧦ጘ㒂ᣂ⡞(2008 ᐕ 3 ᦬ 24 ᣣ)
3㧕 ዊ᧻ᅱሶ㧦‫ޟ‬ᗵᨴ▤ℂߩቇ⠌ᣇᴺ‫ޠ‬㐿⊒:ጘ㒂ᣂ⡞(2008 ᐕ 5 ᦬ 27 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔ1㧕ၮ␆⋴⼔ಽ㊁ߢߪ⋴⼔ᛛⴚ⠌ᓧߩߚ߼ߩᢎ⢒⎇ⓥߦജࠍ౉ࠇ㧘ߘߩਛߢߩቇ↢ߩቇ⠌ᗧ᰼ߦߟߥ߇ࠆ
ᢎ⢒ᚻᴺࠍ⎇ⓥ࠹࡯ࡑߦขࠅ⚵ߺ㧘ቇౝߢߩᢎ⢒ߣ⥃࿾ታ⠌ߢߩታ⠌ᜰዉߦ৻⽾ᕈࠍᜬߚߖࠆߎߣ߇
ߢ߈ࠆ᭽ദജߒߡ޿ࠆ‫ޕ‬2㧕3 ᐕ㑆ߢߩᧄಽ㊁ߩ᭴ᚑຬߩ⇣േ╬ߢ㧘৻ቯߩ⡯႐ⅣႺ㧘ᢎ⢒ᵴേࠍ㜞߼ࠆߎߣߦ⠡ᑲߒ㧘චಽߥ⎇ⓥᵴേߩߢ߈ࠆⅣႺࠍᢛ߃ࠆߎߣߪలಽߣߪ⸒޿߈ࠇߥ߆ߞߚ‫ޕ‬
3㧕⎇ⓥᵴേߦ߅޿ߡߪએ೨߆ࠄߩ⛮⛯⎇ⓥࠍਛᔃߦㅴ߼ࠄࠇߡߪ޿ࠆ߇㧘ᣂߚߥࡈࠖ࡯࡞࠼ߩ㐿ᜏ╬ߦ໧㗴߽޽ࠅᚑᨐ߇ᓧࠄࠇߥ޿⁁ᴫߢ޽ࠆ‫ޕ‬
4㧕⋴⼔⡯ߩ⛮⛯ᢎ⢒ߦ㑐ߔࠆᱧผ⊛⎇ⓥߪ㧘භ㗔ᦼߦὶὐࠍᒰߡቇળ⊒⴫߿⺰ᢥߣߒߡᚑᨐࠍ಴ߔߎߣ
߇ߢ߈ߚ‫ߚ߹ޕ‬㧘࿷ቛߩᗵᨴ▤ℂߦ㑐ߔࠆ⎇ⓥߪ㧘ቇળ⊒⴫߿⺰ᢥએᄖߦ㧘․㓸ߣߒߡឝタߐࠇࠆߥߤߩᚑᨐࠍ಴ߔߎߣ߇ߢ߈ߚ‫੹ޕ‬ᓟߪ࿷ቛ࠲࡯ࡒ࠽࡞ࠤࠕߦ㑐ߔࠆ⎇ⓥߩᚑᨐ߽಴ߒߡ޿ߊᔅⷐ߇޽ࠆ‫ޕ‬5㧕⸰໧⋴⼔Ꮷኻ⽎ߩᗵᨴ▤ℂᢎ⢒ࡊࡠࠣ࡜ࡓߩലᨐᬌ⸽ߪ㧘⎇ⓥ⚿ᨐࠍ㗅ᰴ㧘⺰ᢥߣቇળ⊒⴫ߦࠃࠅ౏
⴫ߢ߈ߚ‫ߩࠕࠤ࡞࠽ࡒ࡯࠲ޕ‬ᢎ⢒ࡊࡠࠣ࡜ࡓ㐿⊒ߩᚑᨐ౏⴫ߦะߌ㧘⎇ⓥଦㅴ߇ᔅⷐߢ޽ࠈ߁‫ޕ‬
6㧕⋴⼔Ꮷߩ⾗⾰ะ਄ߦ㑐ߔࠆ⎇ⓥ߅ࠃ߮ࠠࡖ࡝ࠕࠕ࠶ࡊߣ㔌⡯ߣߩ㑐ㅪߩ⎇ⓥࠍ⛮⛯ਛߢ޽ࠆ‫ޕ‬ቇળ⊒⴫╬ߢߪ㧘⋴⼔⡯ߩ㔌⡯߿㧘⡯ോ⛮⛯ᗧᔒߦᓇ㗀ࠍਈ߃ࠆⷐ࿃ߩಽᨆ╬ࠍⴕߞߡ߈ߚ߇㧘⺰ᢥߦ߹ߣ߼ࠆߣߎࠈ߹ߢߦߪ⥋ߞߡ޿ߥ޿‫⼔⋴ޕ‬⡯ߩ࡝ࠬࠢࡑࡀࠫࡔࡦ࠻ᗧ⼂ߦߟ޿ߡᬌ⸛ਛߢ޽ࠆ߇㧘ౕ૕⊛ߥᣇะᕈ߇ᧂߛቯ߹ߞߡ޿ߥ޿⁁ᴫߢ޽ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷1㧕⎇ⓥ࠹࡯ࡑએᄖߦ㧘ၮ␆⋴⼔ቇಽ㊁ߣߒߡᢎ⢒ౝኈ࡮ᣇᴺ㧘ᢎ᧚㐿⊒ߦ㑐ߔࠆ⎇ⓥࠍදหߢขࠅ⚵ࠎߢ޿ߊᔅⷐ߇޽ࠆ‫ޕ‬
2㧕⸰໧⋴⼔Ꮷኻ⽎ߩ⎇ⓥᚑᨐߪᦠ☋╬ߦ߹ߣ߼ታ〣ߦᵴ↪ߢ߈ࠆᣇะߢᬌ⸛ߔࠆ‫ޕ‬
3㧕ࠞ࡝ࠠࡘ࡜ࡓᡷᱜࠍฃߌ㧘ၮ␆⋴⼔ቇಽ㊁ߩᢎ⢒ౝኈ࡮ᣇᴺߦ㑐ߔࠆ⎇ⓥ߽ଦㅴߔࠆ‫ޕ‬
4㧕⧷ᢥᛞ⺒ߦኻߔࠆቇ↢ߩᗧ⼂߇⭯޿᭽ߦᗵߓࠄࠇࠆ‫ޕ‬ත⺰߿ୃ⺰ߦߪ᰷ᢥ⺰ᢥߩᵴ↪ࠍㅴ߼ࠆᔅⷐ߇޽ࠆ‫ޕ‬5㧕⋴⼔ၮ␆ᢎ⢒߇㧘⋴⼔ታ〣⢻ജߦ෸߷ߔᓇ㗀߽㐓ߺ㧘ߐࠄߦ⋴⼔⛮⛯ᢎ⢒ߣߩ㑐ㅪᕈ߽ᗧ⼂ߒߟߟᢎ⢒ᣇᴺ߿ᢎ᧚㐿⊒ߦ㑐ߔࠆ⎇ⓥߦขࠅ⚵߻ᔅⷐ߇޽ࠆ‫ޕ‬੹ᓟߩዷᦸ
1㧕ၮ␆⋴⼔ቇߩᢎ⢒ᵴേߩలታߦะߌߚᢎ⢒ౝኈ㧘ᣇᴺ㧘ᢎ᧚㐿⊒ߦ㑐ߔࠆ⎇ⓥࠍផㅴߔࠆ‫ޕ‬
2㧕⋴⼔▤ℂ⊛ⷞὐ߆ࠄߩᢎ⢒ࡊࡠࠣ࡜ࡓߩ㐿⊒ߦ㑐ߔࠆ⎇ⓥࠍⴕ߁‫ޕ‬
3㧕ࡊࡠࠫࠚࠢ࠻ࡑࡀࠫࡖ࡯ߩ⾗⾰ะ਄ߦะߌߚᢎ⢒ᣇᴺߦ㑐ߔࠆ⎇ⓥࠍㅴ߼ࠆ‫ޕ‬
4㧕ࠞ࡝ࠠࡘ࡜ࡓᡷᱜߩᗧ࿑ࠍ〯߹߃㧘ၮ␆⋴⼔ቇಽ㊁ߩᢎ⢒ౝኈ㨯ᣇᴺߩలታࠍ࿑ࠆ‫ޕ‬㧙㧙㧔2㧕↢๮ᯏ⢻ቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
ᧄಽ㊁ߢߪ㧘㔚ሶ㗼ᓸ㏜߿Ⱟశ㗼ᓸ㏜ߦട߃㧘↢‛‛ℂቇ㧘ಽሶ↢‛ቇߩᛛⴚࠍ↪޿ߡ㧘⚵❱ᒻᘒ߆ࠄಽሶߩ࡟ࡌ࡞ߦ߹ߢ⥋ࠆ⎇ⓥࠍⴕߞߡ޿ࠆ‫ޕ‬ᒻᘒ࡟ࡌ࡞ߩ⎇ⓥߢߪ㧘ฦ⒳ູ੃േ‛ߩ⥠੃㗡෸߮਄⊹೸㔌ᓟߩ⚿ว⚵❱ߩ⴫㕙᭴ㅧࠍ⿛ᩏဳ㔚ሶ㗼ᓸ㏜ߦࠃࠅⷰኤߒ㧘ਥߦᲧセ⸃೬ቇ⊛஥㕙߆ࠄ㘩‛෸߮๰ྨᣇᴺ
ߣߩ㑐ଥߦߟ޿ߡ⎇ⓥߒߡ޿ࠆ‫৻ޕ‬ᣇ㧘ಽሶ࡟ࡌ࡞ߩ⎇ⓥߣߒߡߪ㧘GFP Ⲣว࠲ࡦࡄࠢ⾰ߩㆮવሶ⊒⃻ߦࠃࠅ㧘⚦⢩ౝߦ߅ߌࠆฦ⒳࠲ࡦࡄࠢ⾰ߩ᜼േࠍ↢߈ߚ⚦⢩ࠍ↪޿ߡ⸃ᨆߒߡ޿ࠆ‫ߦࠄߐޕ‬㧘⚦⢩ౝߢߩ࠲ࡦࡄࠢ⾰㑆⋧੕૞↪㧔⚿ว㧙⸃㔌㧕ߦߟ޿ߡ᣿ࠄ߆ߦߔࠆߚ߼ߦ㧘GFP ᄌ⇣૕ࠍ↪޿ߚⰯశ౒㡆ࠛࡀ
࡞ࠡ࡯⒖േᴺ㧔FRET㧕ߦࠃࠆ᷹ቯ߽ⴕߞߡ޿ࠆ‫ᧄޕ‬ᴺߪᄙ᭽ߥ࠲ࡦࡄࠢ⾰㑆⋧੕૞↪ߦㆡ↪น⢻ߢ޽ࠆߚ߼㧘3 ᰴర FRET ߩ㐿⊒߿఺∉ᨴ⦡߳ߩⰯశ౒㡆ࠛࡀ࡞ࠡ࡯⒖േᴺߩᔕ↪ߦߟ޿ߡ߽⎇ⓥߒߡ޿ࠆ‫߹ޕ‬ߚ㧘ਛᔃ૕᭴ᚑ࠲ࡦࡄࠢ⾰ߩㆮવሶࠍหቯߒ㧘ߘߩ࠲ࡦࡄࠢ⾰ዪ࿷߿ᯏ⢻⸃ᨆࠍⴕ߁ߎߣߦࠃࠅ㧘ਛᔃ૕߇ᱜ⏕ߦⶄ⵾ߔࠆࡔࠞ࠾࠭ࡓ߿⚦⢩ಽⵚߩ೙ᓮᯏ᭴ߣߩ㑐ㅪ╬ࠍ⎇ⓥߒߡ޿ࠆ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
ᢎ᝼㧦

ᳯ᧛ᱜ৻
ᱞ⮮ศᓼ

Shoichi Emura
Yoshinori Muto

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
ߥߒ⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
ߥߒ✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ᳯ᧛ᱜ৻㧘Hery Wijayanto㧘㒙㐽ᵏ㇢㧚ࠫࡖࡢࠝࠝࠦ࠙ࡕ࡝⥠੃㗡ߩ⚿ว❱⧌ߩⷰኤ㧘ູ੃㘃⑼ቇ 2007
ᐕ㧧47 Ꮞ㧦227㧙230㧚
2㧕 ᳯ᧛ᱜ৻㧘ᅏ᧛ᐕᒾ㧘㒸 ⪇ጪ㧚࠾ࡎࡦࠩ࡞⥠੃㗡ߩ⚿ว❱⧌ߩⷰኤ㧘ᒻᘒ㨯ᯏ⢻ 2007㧧5 Ꮞ㧦69㧙73㧚
3㧕 ᳯ᧛ᱜ৻㧚࠻ࡆߩ⥠੃㗡ߣߘߩ⚿ว❱⧌ߩ⿛ᩏဳ㔚ሶ㗼ᓸ㏜ߦࠃࠆⷰኤ, කቇߣ↢‛ቇ 2008 ᐕ㧧152
Ꮞ㧦43㧙47㧚
4㧕 ᳯ᧛ᱜ৻㧚ࡈࠚ࡟࠶࠻ߣ࠴࡚࠙࠮ࡦࠗ࠲࠴ߩ⥠੃㗡ߣߘߩ⚿ว❱⧌ߩ⿛ᩏဳ㔚ሶ㗼ᓸ㏜ߦࠃࠆⷰኤ, කቇߣ↢‛ቇ 2008 ᐕ㧧152 Ꮞ㧦48㧙56㧚
5㧕 ᳯ᧛ᱜ৻㧚ࠠࠫߩ⥠੃㗡ߣߘߩ⚿ว❱⧌ߩ⿛ᩏဳ㔚ሶ㗼ᓸ㏜ߦࠃࠆⷰኤ, කቇߣ↢‛ቇ 2008 ᐕ㧧152
Ꮞ㧦129㧙133㧚
6㧕 ᳯ᧛ᱜ৻㧚ࠝࠣࡠࡊ࡟࡯࡝࡯࠼࠶ࠣߩ⥠੃㗡ߣߘߩ⚿ว❱⧌ߩ⿛ᩏဳ㔚ሶ㗼ᓸ㏜ߦࠃࠆⷰኤ, කቇߣ↢‛ቇ 2008 ᐕ㧧152 Ꮞ㧦134㧙142㧚
7㧕 ᳯ᧛ᱜ৻㧚ࡂࠢ࠴࡚࠙ߩ⥠੃㗡ߣߘߩ⚿ว❱⧌ߩ⿛ᩏဳ㔚ሶ㗼ᓸ㏜ߦࠃࠆⷰኤ㧘කቇߣ↢‛ቇ 2008 ᐕ㧧
152 Ꮞ㧦379㧙385㧚
8㧕 ᳯ᧛ᱜ৻㧚ࠞࡇࡃ࡜ߩ⥠੃㗡ߣߘߩ⚿ว❱⧌ߩ⿛ᩏဳ㔚ሶ㗼ᓸ㏜ߦࠃࠆⷰኤ㧘කቇߣ↢‛ቇ 2008 ᐕ㧧152
Ꮞ㧦386㧙393㧚
9㧕 ᳯ᧛ᱜ৻㧚ࡓࠨࠨࡆ⥠੃㗡ߩ⚿ว❱⧌ߩⷰኤ, කቇߣ↢‛ቇ 2008 ᐕ㧧152 Ꮞ㧦517㧙522㧚
10㧕 ᳯ᧛ᱜ৻㧘ᅏ᧛ᐕᒾ㧘㒸 ⪇ጪ㧚ࠝࠝ࠲ࠞߩ⥠੃㗡ߣߘߩ⚿ว❱⧌ߩ⿛ᩏဳ㔚ሶ㗼ᓸ㏜ߦࠃࠆⷰኤ㧘⸃೬ቇ㔀⹹ 2008 ᐕ㧧83 Ꮞ㧦77㧙80㧚
11㧕 ᳯ᧛ᱜ৻㧘ᅏ᧛ᐕᒾ㧘㒸 ⪇ጪ㧚ࠬ࠭ࡔߩ⥠੃㗡ߣߘߩ⚿ว❱⧌ߩ⿛ᩏဳ㔚ሶ㗼ᓸ㏜ߦࠃࠆⷰኤ, ᒻᘒ࡮ᯏ⢻ 2008 ᐕ㧧7 Ꮞ㧦7㧙12㧚
12㧕 ᳯ᧛ᱜ৻㧘Srihadi Agungpriyono㧘㒙㐽ᵏ㇢㧚ࠫࡖࡢࡑࡔࠫࠞ⥠੃㗡ߩ⚿ว❱⧌ߩⷰኤ㧘ູ੃㘃⑼ቇ 2008
ᐕ㧧48 Ꮞ㧦25㧙29㧚
13㧕 ᳯ᧛ᱜ৻㧘ᅏ᧛ᐕᒾ㧘㒸 ⪇ጪ㧚࠲࠿ࠠ߅ࠃ߮ࡂࠢࡆࠪࡦ⥠੃㗡ߩ⚿ว❱⧌ߩ⿛ᩏဳ㔚ሶ㗼ᓸ㏜ߦࠃࠆⷰኤ, ᒻᘒ࡮ᯏ⢻ 2008 ᐕ㧧6 Ꮞ㧦75㧙81㧚
14㧕 ᳯ᧛ᱜ৻㧚࠷ࡒ߅ࠃ߮ࡒࠨࠧߩ⥠੃㗡ߣߘߩ⚿ว❱⧌ߩ⿛ᩏဳ㔚ሶ㗼ᓸ㏜ߦࠃࠆⷰኤ, කቇߣ↢‛ቇ
2008 ᐕ㧧152 Ꮞ㧦523㧙528㧚㧙㧙ේ⪺㧔᰷ᢥ㧕1㧕 Chen H, Emura S, Shoumura S. Ultrastructure of the water-clear cell in the parathyroid gland of
SAM6 mice. Tissue Cell. 2006;38:187-192.
2㧕 Chen H, Yao X.F, Emura S, Shoumura S. Morphological changes of skeletal muscle, tendon andperiosteum in thesenescence-accelerated mouse(SAMP6):A murine model for senile osteoporosis.
Tissue Cell. 2006;38:325-335.
3㧕 Chen H, Shoumura S, Emura S. Bilateral thoracic ducts with coexistent persistent left superior vena
cava. Clinical Anatomy. 2006;19;350-353.
4㧕 Emura S, Okumura T, Chen H, Shoumura S. Morphology of the lingual papillae in the raccoon dog andfox. Okajimas Folia Anat Jpn. 2006;19:73-76.
5㧕 Kuwata H, Yoshioka T, Muto Y, Kuwata K, Okano Y. Structural and functional characterization of
NP25, a single CH domain protein. Acta Schol Med Univ Gifu. 2006;54:1-7.
6㧕 Emura S, Okumura T, Chen H. Morphology of the lingual papillae in the Japanese marten. Okajimas
Folia Anat Jpn. 2007;84:77-82.
7㧕 Yoshimura K, Muto Y, Shimizu M, Matsushima Nishiwaki R, Okuno M, Takano Y, Tsurumi H, Kojima
S, Okano Y, Moriwaki H. Phosphorylated retinoid X receptor alpha loses its heterodimeric activity
with retinoic acid receptor beta. Cancer Sci. 2007;98:1868-1874.
8㧕 Chen H, Okumura T, Emura S, Shoumura S. Scanning electron microscopic study of the human
auditory ossicles. Ann Anat. 2008;190:53-58.
9㧕 Chen H, Shoumura S, Emura S, Bunai Y. Regional variations of vertebral trabecular bone
microstructure with age and gender. Osteoporos Int. 2008;19:1473-1483.
10㧕 Emura S, Okumura T, Chen H. Morphology of the lingual papillae and their connective tissue cores in
the cape hyrax. Okajimas Folia Ana Jpn. 2008;85:29-34.
11㧕 Emura S, Okumura T, Chen H. Scanning electron microscopic study of the tongue in the pregrine
falcon and common kestrel. Okajimas Folia Anat Jpn. 2008;85:11-15.
12㧕 Emura S, Chen H. Scanning electron microscopic study of the tongue in the owl (Strix uralensis). Anat
Histol Embryol. 2008;37:475-478.
13㧕 Muto Y, Yoshioka T, Kimura M, Matsunami M, Saya H, Okano Y. An evolutionarily conserved
leucine-rich repeat protein CLERC is a centrosomal protein required for spindle pole integrity. Cell
Cycle. 2008;7:2738-2748.

IF 1.237

IF 1.237
IF 0.626

IF 3.165
IF 0.817
IF 3.793

IF 0.554

IF 3.3144㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦ᱞ⮮ศᓼ㧘⎇ⓥಽᜂ⠪㧦ጟ㊁ᐘ㓶㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌(⎇ⓥ)㧦ᣂߚߦ⷗಴ߒߚਛᔃ૕
࠲ࡦࡄࠢ⾰ HsVfl1 ߩᯏ⢻⸃ᨆ㧧ᐔᚑ 18 ᐕᐲ㧧1,200 ජ౞
2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬᳯ᧛ᱜ৻㧦
1㧕 ᣣᧄ⸃೬ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ⥃ᐥಽሶᒻᘒቇળ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
ᱞ⮮ศᓼ㧦1㧕 Advances in Planar Lipid Bilayers and Liposomes: Member of Editorial Board (㨪⃻࿷)㧙㧙7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ߥߒ
8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേ
ߥߒ
10㧚ႎ๔ᦠߥߒ11㧚ႎ㆏ߥߒ12㧚⥄Ꮖ⹏ଔ
⹏ଔ⎇ⓥౝኈߪ㧘⚵❱ᒻᘒ߆ࠄ↢૕ಽሶߩ࡟ࡌ࡞߹ߢᐢ▸࿐ߦਗ਼ࠆ߇㧘ಽ㊁ౝߩᢎຬ㑆ߢߩ౒ห⎇ⓥߪὑ
ߐࠇߡ޿ߥ޿‫ߚ߹ޕ‬㧘⎇ⓥᚑᨐߪᒻᘒ෸߮↢૕ಽሶ࡟ࡌ࡞౒ߦዋᢙߥ߇ࠄ࿖㓙⊛ߦߺߡ߽⁛⥄ߩᚑᨐ߇౏⴫ߐࠇߡ޿ࠆ‫ߒ߆ߒޕ‬㧘ዋੱᢙߩಽ㊁ߢ޽ࠆߎߣ߽޽ࠅ㧘಴ ᢙߪᲧセ⊛ዋߥ޿‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ᒻᘒ㗔ၞ㧔㔚ሶ㗼ᓸ㏜㧕ߦ߅ߌࠆ⎇ⓥߩㅴⴕㅦᐲߪ㧘⎇ⓥ᧚ᢱߣߒߡߩേ‛ߩེቭ෸߮⚵❱ߩ⏕଻ᰴ╙ߢ޽ࠅ㧘੹ᓟߎࠇ߹ߢએ਄ߦో࿖ߩേ‛࿦෸߮ฦ⥄ᴦ૕ߩදജࠍᓧߚ޿ߣ⠨߃ߡ޿ࠆ‫৻ޕ‬ᣇ㧘ਛᔃ૕࠲ࡦࡄࠢ⾰ߦ㑐ߔࠆ⎇ⓥߢߪ㧘ᒰಽ㊁ߢ⷗޿ߛߒߚᣂⷙਛᔃ૕࠲ࡦࡄࠢ⾰ CLERC ߣ⋧੕૞↪ߔࠆ࠲ࡦࡄࠢ⾰ߩหቯ߇ᔅ㗇ߢ޽ࠆ‫ߪߦ߼ߚߩߎޕ‬㧘㉂Უ two-hybrid ᴺ߿⾰㊂ಽᨆᴺ╬ߩ೑↪߇᦭ലߢ޽ࠅ㧘ߎࠇࠄࠍᵴ↪ߒߡ⚿ว࠲ࡦࡄࠢ⾰ߩหቯࠍน⢻ߦߒߚ޿‫ޕ‬੹ᓟߩዷᦸ㔚ሶ㗼ᓸ㏜ߦࠃࠅ㊁↢ູ੃േ‛ߩ⥠ᒻᘒࠍߐࠄߦᄙߊⷰኤߒ㧘⥠ߩ᭴ㅧߣ㘩ᕈߣߩ㑐ଥࠍ᣿ࠄ߆ߦߒ
ߚ޿‫ઁޕ‬ᣇ㧘ᣂⷙਛᔃ૕࠲ࡦࡄࠢ⾰ߢ޽ࠆ CLERC ߩᯏ⢻⸃ᨆࠍⴕ޿㧘ਛᔃ૕ⶄ⵾߿⚦⢩ಽⵚߦ߅ߌࠆ
ᓎഀࠍ᣿ࠄ߆ߦߒߚ޿‫ߚ߹ޕ‬㧘ㆮવሶ࡟ࡌ࡞ߩ⎇ⓥߦߟ޿ߡ߽ቇౝߩઁߩ⎇ⓥቶߣߩⓍᭂ⊛ߥ౒ห⎇ⓥ
ࠍⴕ޿㧘⎇ⓥᚑᨐߩᅏⴕ߈ࠍᷓ߼ࠆᣇㅜࠍ⷗޿ߛߒߚ޿‫ޕ‬㧙㧙ާᲣሶ⋴⼔ቇ⻠ᐳި
㧔1㧕Უᕈ⋴⼔ቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
Უᕈ⋴⼔࡮ഥ↥ቇಽ㊁ߦ߅޿ߡߪ㧘࡜ࠗࡈࠨࠗࠢ࡞ࠍㅢߓߚᅚᕈߩஜᐽᡰេߦ㑐ߔࠆ⎇ⓥ㧘๟↥ᦼࠤࠕߦ㑐ߔࠆ⎇ⓥ㧘߅ࠃ߮Უᕈ⋴⼔ቇᢎ⢒㧘ഥ↥ቇᢎ⢒ߦ㑐ߔࠆ⎇ⓥ╬㧘⎇ⓥ㗔ၞߪᄙጘߦࠊߚߞߡ޿ࠆ‫ޕ‬ኻ⽎ߣߒߡߪᲣᕈ࡮ᅚᕈߦߣߤ߹ࠄߕᐢߊኅᣖ࡮࿾ၞࠍ฽߼ߚஜᐽᡰេࠍ⠨߃ࠆ߽ߩߢ޽ࠆ‫ޕ‬ਥߥ⎇ⓥ࠹࡯ࡑ㧧Ԙੑಽ⣄ᬁᅚᕈߩ᦬⚻ߣᕈߩஜᐽߦ㑐ߔࠆ൮᜝⊛ࠤࠕߦߟ޿ߡߩ⎇ⓥԙഥ↥ታ〣⢻ജߩ⢒ᚑߣ೔㆐ᐲߦ㑐ߔࠆ⎇ⓥԚᕁᤐᦼߩ STI ੍㒐ߦ㑐ߔࠆ⎇ⓥԛੱ㑆Ꮏቇ⊛ᚻᴺࠍ↪޿ߚᲣᕈ࡮ഥ↥㗔ၞߦ߅ߌࠆ⋴⼔ᛛⴚ߿ᢎ⢒ᣇᴺߦ㑐ߔࠆ⎇ⓥԜ੃ᚱࡑ࠶ࠨ࡯ࠫ㧘ᛴ߈ᣇ࡮ๆ⌕ߩࠤࠕࠍฃߌߚⶖᇚߩ੃᳝ಽᴲ࡮⥄ᓞ␹⚻♽߳ߩലᨐߦ㑐ߔࠆ⎇ⓥԝ᦬⚻↪Ꮣ࠽ࡊࠠࡦߦ㑐ߔࠆ⎇ⓥ㧧᦬⚻૕㛎߅ࠃ߮቟ోᕈߣᔟㆡᕈߦߟ޿ߡ㧘⊹⤏∔ᖚᖚ⠪߳ߩല↪
Ԟሶ⢒ߡᡰេߦ㑐ߔࠆ⎇ⓥ
ԟ૕㊀▤ℂߦὶὐࠍ޽ߡߚᅧᇚߩり૕௝ߦߟ޿ߡߩ⎇ⓥ
Ԡᅧᆼ࡮಴↥ߩᤨᦼߣᗲ⌕㧘Უⷫᓎഀⴕേ㧘ᄦᇚ㑐ଥߦ㑐ߔࠆ⎇ⓥ
2㧚ฬ★
ᢎ᝼㧦
ഥᢎ㧦
ഥᢎ㧦
ഥᢎ㧦
ഥᢎ㧦

㊁↰ᵗሶ
੹↰⪲ሶ
᧻㊁ᥓ㚅ሶ
ᷰㆻ⋥ሶ
㋈ᧁᐘሶ

Yoko Noda
Yoko Imada
Chikako Matsuno
Naoko Watanabe
Sachiko Suzuki

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ㊁↰ᵗሶ㧚╙ 5 ┨ ᅚᕈߩ࡜ࠗࡈࠨࠗࠢ࡞ߦ߅ߌࠆᕈߣ↢ᱺߦ㑐ߔࠆஜᐽ໧㗴ߣេഥ A ᕁᤐᦼᅚᕈ߳ߩេ
ഥ㧦ၳౝᚑሶ✬㧚ഥ↥ቇ⻠ᐳ 5 ഥ↥⸻ᢿ࡮ᛛⴚቇΣ㧘᧲੩㧦කቇᦠ㒮㧧2007 ᐕ㧦192㧙220㧚
2㧕 ㊁↰ᵗሶ㧚╙Φ┨ 4 ᅚᕈߣ᦬⚻㧦ศᴛ⼾੍ሶ㧘㋈ᧁᐘሶ✬㧚ᅚᕈ⋴⼔ቇ㧘᧲੩㧦ࡔ࠵ࠞ࡞ࡈ࡟ࡦ࠼␠㧧2008ᐕ㧦170㧙186㧚⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
ߥߒ✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ㊁‫ޘ‬ጊᧂᏗሶ㧘㊁↰ᵗሶ㧘⍹Ꮉ㓁ሶ߶߆㧚ᕈᗵᨴ∝੍㒐ߦ߅ߌࠆࠦࡦ࠼࡯ࡓ૶↪࠮࡞ࡈࠛࡈࠖࠞࠪ࡯ࠬࠤ
࡯࡞ߩᬌ⸽㧘ᣣᧄᕈᗵᨴ∝ቇળ⹹ 2007 ᐕ㧧18 Ꮞ㧦58㧙63㧚
2㧕 ੉↰ᐘᨑ㧘ፉ↰໪ሶ㧘ർᎹ⌀ℂሶ㧘૒⮮ᒄሶ㧘㜞ᯅᒄሶ㧘ᐔỈ⟤ᕺሶ㧘㊁↰ᵗሶ㧚ഥ↥Ꮷᢎ⢒ߦ߅ߌࠆࠦ
ࠕౝኈߩᬌ⸛ ࠺࡞ࡈࠔࠗᴺߦḰߓߚ⹺⼂⺞ᩏ߆ࠄ㧘⋴⼔ᢎ⢒ 2007 ᐕ㧧48 Ꮞ㧦442㧙447㧚
3㧕 ർᎹ⋿ℂሶ, ੉↰ᐘᨑ, ૒⮮ᒄሶ, ፉ↰໪ሶ, 㜞ᯅᒄሶ, ㊁↰ᵗሶ, ᐔỈ⟤ᕺሶ㧚ഥ↥Ꮷᢎ⢒ߦ߅ߌࠆࠦࠕ
ౝኈߩᬌ⸛ ࡒ࠾ࡑࡓ࡮࡝ࠢࡢࠗࠕࡔࡦ࠷ߩ⸳ቯ, ⋴⼔ᢎ⢒ 2008 ᐕ㧧49 Ꮞ㧦332㧙337㧚ේ⪺㧔᰷ᢥ㧕
ߥߒ

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦㊁↰ᵗሶ㧘⎇ⓥಽᜂ⠪㧦⿷┙ਭሶ㧘ᳰ⼱ዏ೰㧘ᷰㇱടᕺ(ᐔᚑ 18㧙19 ᐕᐲ)㧘᧻㊁ᥓ㚅ሶ(ᐔᚑ 20 ᐕᐲ)㧘㋈ᧁᐘሶ(ᐔᚑ 20 ᐕᐲ)㧘⎇ⓥㅪ៤⠪㧦ዊ㊁ᢅሶ㧘═੗↱⟤ሶ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄㧙㧙ၮ⋚⎇ⓥ(C)㧦ੑಽ⣄ᬁ∝ᅚᕈߩ᦬⚻ߣᕈߩஜᐽߦ㑐ߔࠆ൮᜝⊛ࠤࠕࡊࡠࠣ࡜ࡓߩ㐿⊒㧧ᐔᚑ 18㧙20
ᐕᐲ㧧3,840 ජ౞(1,500㧦1,040㧦1,300 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦੹↰⪲ሶ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦ೋቇ⠪ߦ߅ߌࠆᴍᶎᛛⴚߩᣧᦼ⠌ᓧߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18㧙20 ᐕᐲ㧧2,000 ජ౞(800㧦1,200 ජ౞)(19 ᐕᐲߪ⢒ఽભᥜ)
2㧕ฃ⸤⎇ⓥ1㧕 ੐ᬺታᣉઍ⴫⠪㧦ᐔỈ⟤ᕺሶ㧘ᆔຬ㧦ᐔỈ⟤ᕺሶ㧘ፉ↰໪ሶ㧘㜞ᯅᒄሶ㧘㊁↰ᵗሶ㧘ർᎹ⌀ℂሶ㧘⬿ᧄ⋥ሶ㧧ᢥㇱ⑼ቇ⋭ᄢቇ⹏ଔ⎇ⓥᆔ⸤੐ᬺ㧦ᄢቇߦ߅ߌࠆഥ↥ታ〣⢻ജߩ⢒ᚑߣ೔㆐ᐲߦ㑐ߔࠆഥ↥ᢎ⢒⹏ଔ⎇ⓥ㧧ᐔᚑ 19 ᐕᐲ㧧6,379 ජ౞
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬ㊁↰ᵗሶ㧦
1㧕 ᣣᧄᲣᕈⴡ↢ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ጘ㒂⋵Უᕈⴡ↢ቇળᐙ੐(㨪⃻࿷)3㧕 ో࿖ഥ↥Ꮷᢎ⢒ද⼏ળℂ੐(㨪⃻࿷)4㧕 ๟↥ᦼࡔࡦ࠲࡞ࡋ࡞ࠬ⎇ⓥળ⋙੐(㨪⃻࿷)੹↰⪲ሶ㧦1㧕 ᣣᧄੱ㑆Ꮏቇળ⹏⼏ຬ(ᐔᚑ 19 ᐕ㨪⃻࿷)2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ߥߒ
8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേ㊁↰ᵗሶ㧦
1㧕 ᕈߩஜᐽකቇ⽷࿅⹏⼏ຬ(㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ᐔᢘሶ㧘㊁↰ᵗሶ㧘⊕⍹቟↵㧘᩵߈ࠃߺ㧘೨Ỉ㜞ሶ㧘㜞ᯅടᕺ㧦ᅚሶቇ↢ߩࡋ࡞ࠬ࡝ࠬࠢⴕേߣ
࡝ࡊࡠ࠳ࠢ࠹ࠖࡉࡋ࡞ࠬߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 16 ᐕᐲ㧙ᐔᚑ 17 ᐕᐲᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)⎇ⓥႎ๔ᦠ(2006 ᐕ 3 ᦬)
2㧕 ፉ↰໪ሶ㧘੉↰ᐘᨑ㧘ർᎹ⌀ℂሶ㧘૒⮮ᒄሶ㧘㜞ᯅᒄሶ㧘㊁↰ᵗሶ㧘ᐔỈ⟤ᕺሶ㧦ഥ↥Ꮷᢎ⢒ߩࠦࠕౝኈߦ߅ߌࠆ minimum requirements 㗄⋡ߩ଀␜ߦ㑐ߔࠆᬌ⸛(ਛ㑆ႎ๔)㧦ో࿖ഥ↥Ꮷᢎ⢒ද⼏
ળᐔᚑ 17 ᐕᐲ੐ᬺᵴേႎ๔ᦠ㧦1㧙17(2006 ᐕ 5 ᦬)
3㧕 ፉ↰໪ሶ㧘੉↰ᐘᨑ㧘ർᎹ⌀ℂሶ㧘㜞ᯅᒄሶ㧘㊁↰ᵗሶ㧘ᐔỈ⟤ᕺሶ㧦ഥ↥Ꮷᢎ⢒ߩࠦࠕౝኈߣࡒ
࠾ࡑࡓ࡮࡝ࠢࡢࠗࠕࡔࡦ࠷ߩ଀␜ߦ㑐ߔࠆᬌ⸛(2006 ✚᜝ႎ๔)㧦ో࿖ഥ↥Ꮷᢎ⢒ද⼏ળᐔᚑ 18 ᐕᐲ੐ᬺᵴേႎ๔ᦠ㧦1㧙20(2007 ᐕ 5 ᦬)㧙㧙

4㧕 ፉ↰໪ሶ㧘ർᎹ⌀ℂሶ㧘㜞ᯅᒄሶ㧘㊁↰ᵗሶ㧘ᐔỈ⟤ᕺሶ㧘⬿ᧄ⋥ሶ㧦ഥ↥Ꮷᢎ⢒ߩᡷༀߦะߌߚ
࿷ࠅᣇᬌ⸛ ࠦࠕ࡮ࠦࡦࡇ࠹ࡦࠪ࡯࠭ୃᓧߩၮ⋚㧦ో࿖ഥ↥Ꮷᢎ⢒ද⼏ળᢎ⢒ᬌ⸛ᆔຬળ ᐔᚑ 19ᐕᐲ੐ᬺᵴേႎ๔ᦠ㧦1㧙52(2008 ᐕ 5 ᦬)
5㧕 ᐔỈ⟤ᕺሶ㧘ፉ↰໪ሶ㧘㜞ᯅᒄሶ㧘㊁↰ᵗሶ㧘ർᎹ⌀ℂሶ㧘⬿ᧄ⋥ሶ㧦ᢥㇱ⑼ቇ⋭ᄢቇ⹏ଔ⎇ⓥᆔ⸤੐ᬺ㧘ᐔᚑ 19 ᐕᐲ‫ޟ‬ᄢቇߦ߅ߌࠆഥ↥ታ〣⢻ജߩ⢒ᚑߣ೔㆐ᐲ㑐ߔࠆഥ↥ᢎ⢒⹏ଔ⎇ⓥ‫ޠ‬ႎ๔ᦠ㧦1㧙66(2008 ᐕ 3 ᦬)11㧚ႎ㆏ߥߒ12㧚⥄Ꮖ⹏ଔ
⹏ଔᲣᕈ⋴⼔ቇಽ㊁ߩᢎຬ᭴ᚑߪ㧘Ფᐕᄌൻߒ㧘ᐔᚑ 20 ᐕᐲߪᣂછ 3 ฬࠍട߃ߚ 5 ฬߣߥߞߡ޿ࠆ‫⎇ޕ‬ⓥᚑᨐߣߒߡߪቇળ⊒⴫߇ᄙߊ㧘ේ⪺⺰ᢥ૞ᚑ߹ߢߦ޿ߚߞߡ޿ߥ޿‫ޕ‬ᄖㇱ⾗㊄ߣߒߡ㧘⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ၮ⋚⎇ⓥ(C)߅ࠃ߮⧯ᚻ⎇ⓥ(B)㧔೨છᩞ߆ࠄ㧕ࠍߘࠇߙࠇ 1 ઙ₪ᓧߒߡ߅ࠅ㧘ᣂછᢎຬࠍ฽߼ߡಽ
㊁ౝߢ⎇ⓥࠍ౒หߒߡ⛮⛯ߢ߈ߚߎߣߪ⹏ଔߐࠇࠆ‫ోߚ߹ޕ‬࿖ഥ↥Ꮷᢎ⢒ද⼏ળᢎ⢒⋵╬ᆔຬળ╬ߦ߅ߌࠆ౒ห⎇ⓥߩᚑᨐߩഥ↥Ꮷᢎ⢒ߦᨐߚߔᓎഀߪ⹏ଔߐࠇࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ᢎຬߩ⒖േ㧘ቯ⌕₸ߩ໧㗴߆ࠄᢎຬߩ⎇ⓥᚑᨐࠍේ⪺⺰ᢥߣߒߡ⊒⴫ߔࠆ߹ߢߦ⥋ࠄߥ߆ߞߚ߽ߩ߇
ᄙߊ㧘ᰴᐕᐲߦᱷߐࠇߚ⺖㗴ߢ޽ࠆ‫ߚ߹ޕ‬ᐔᚑ 20 ᐕᐲߪᢎ᝼ 1 ഥᢎ 4 ߢᲣᕈ⋴⼔࡮ഥ↥࡮ᄢቇ㒮ࠍᜂᒰߒߚߎߣ߆ࠄ㧘ᢎ⢒ᵴേߦਥ⌒߇⟎߆ࠇ⎇ⓥᵴേ㧘⺰ᢥၫ╩ߩᤨ㑆⊛૛⵨߇ߥ߆ߞߚ߇㧘ᰴᐕᐲ߆ࠄߪ
ᢎຬߩల⿷㧔ᢎ᝼ 1㧘ಎᢎ᝼ 1㧘ഥᢎ 4㧕ߦࠃࠅ⎇ⓥⅣႺ߽⧯ᐓᢛ߃ࠄࠇࠆ߽ߩߣᦼᓙߔࠆ‫ޕ‬੹ᓟߩዷᦸ✚วᄢቇߩࡔ࡝࠶࠻ࠍ↢߆ߒߚቇౝߢߩ౒ห⎇ⓥߩน⢻ᕈߩㅊ᳞㧘߹ߚᢎ⢒࡮ታ〣ߦ⚿߮ߟ޿ߚታ〣⊛⎇ⓥ㧘࿖ౝᄖߩᄢቇ࡮⎇ⓥᯏ㑐ߣߩቇⴚ੤ᵹ㧘౒ห⎇ⓥߩផㅴࠍ࿑ࠅߚ޿‫ޕ‬ᄖㇱ⾗㊄ߩ₪ᓧߣߒߡߪ
⑼ቇ⎇ⓥ⾌ߦߣߤ߹ࠄߕ㧘ฦ⒳࿅૕ߩ⎇ⓥഥᚑ߳ߩ↳⺧߅ࠃ߮↥ቇ౒ห⎇ⓥࠍⓍᭂ⊛ߦផㅴߒߚ޿‫ޕ‬น⢻ߢ޽ࠆߥࠄ⧯ᚻᢎຬߩౝ࿾⇐ቇ㧘޽ࠆ޿ߪ࿷ᄖ⎇ୃ߳ߩᵷ㆜߽⠨ᘦߐࠇࠆ߇㧘߹ߕᢎຬߩቯ⌕₸ࠍ਄ߍࠆߎߣ߇⎇ⓥߩ⛮⛯ߦ㊀ⷐߣ⠨߃ࠆ‫ޕ‬㧙㧙㧔2㧕ዊఽ⋴⼔ቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
ዊఽ⋴⼔ቇಽ㊁ߢߪ㧘᳇▤ᡰ༎ᕷ߿ࠕ࠻ࡇ࡯ᕈ⊹⤏Ἳ㧘㘩‛ࠕ࡟࡞ࠡ࡯ߥߤߩࠕ࡟࡞ࠡ࡯∔ᖚ߿㧘ߡࠎ߆ࠎ߿వᄤᕈᔃ∔ᖚ㧘り૕⊛ߥ㓚ኂࠍ߽ߟሶߤ߽ߣኅᣖߩ QOL ߦ⌕⋡ߒ㧘․ߦ࿷ቛ≮㙃႐㕙ߦ߅ߌࠆ⋴⼔⡯ߩេഥᣇᴺߦ㑐ߔࠆ⎇ⓥࠍⴕߞߡ߈ߚ‫⎇ޕ‬ⓥߪጘ㒂ᄢቇౝߩቇㇱ㑆ߩㅪ៤ߦߣߤ߹ࠄߕ㧘ฬฎደᄢቇ㧘ਛㇱᄢቇߣߩ౒ห⎇ⓥ߽ⴕߞߡ߈ߚ‫⎇ޕ‬ⓥߩࡈࠖ࡯࡞࠼߽㧘ጘ㒂ᄢቇකቇㇱઃዻ∛㒮ߩઁߦ߽޽޿ߜዊఽ
଻ஜක≮✚ว࠮ࡦ࠲࡯ߣ޿ߞߚኾ㐷∛㒮߿୘ੱዊఽ⑼ක㒮ߣᄙጘߦࠊߚࠆ‫ߚ߹ޕ‬㧘࿷ቛ≮㙃ࠍߔࠆሶߤ߽
ߩኅᐸ߽ࡈࠖ࡯࡞࠼ߣߒߚ‫ౕޕ‬૕⊛ߦߪ㧘㊀ᐲ㓚ኂ߿㔍∛ࠍ߽ߟሶߤ߽ߩⷫࠍࠨࡐ࡯࠻ߔࠆߚ߼ߩ࿾ၞᡰ
េࠪࠬ࠹ࡓߩ᭴▽ߩၮ␆ࠍ࿕߼ࠆᣇะᕈࠍ᣿⏕ߦߒߚߎߣߩઁߦ㧘᳇▤ᡰ༎ᕷࠍ߽ߟቇ┬⥄り߇ᗵߓࠆ⥄⸥ᑼߩ QOL ⺞ᩏ␿ࠍ㐿⊒ߒߡో࿖⺞ᩏࠍ߅ߎߥߞߚ⚿ᨐ߆ࠄା㗬ᕈߣᅷᒰᕈࠍᬌ⸽ߒߚ‫੹ޕ‬ᓟᚑᨐࠍ⊒⴫ߔࠆ੍ቯߢ޽ࠆ߇㧘㘩‛ࠕ࡟࡞ࠡ࡯ߩሶߤ߽ߩᲣⷫ߇߅߆ࠇߡ޿ࠆ⃻⁁ߣ⽶ᜂߦߟ޿ߡ߽⾰໧⚕⺞ᩏ߆ࠄ᣿ࠄ߆ߦߒߡ޿ࠆ‫ߦࠄߐޕ‬㧘߹ߛ⎇ⓥᚑᨐߣߒߡ⊒⴫ߢ߈ࠆᒻߢߪߥ޿߇㧘ࠕ࡟࡞ࠡ࡯∔ᖚߥߤߩᘟᕈ
∔ᖚࠍ߽ߟቇ┬ᦼߩሶߤ߽ߩ⥄Ꮖ▤ℂߦะߌߚេഥߦߟ޿ߡ߽⎇ⓥࠍㅴ߼ߡ޿ࠆ‫ߚ߹ޕ‬㧘ㆊ෰ߩ⚻㛎߿⎇ⓥᚑᨐࠍ߽ߣߦߒߡஜᐽ㓚ኂࠍ߽ߟሶߤ߽ߩ⋴⼔ㆊ⒟ࠍ⋴⼔ቇ↢ߦ߽ಽ߆ࠅ߿ߔ޿ᒻߢၫ╩ߒߚ‫ޕ‬ߘߩᕈᩰ਄⎇ⓥߣ޿߁ᒻߦߔࠆߎߣ߇࿎㔍ߢߪ޽ࠆ߇㧘࠷ࠗࡦࡑࠩ࡯ࠬࠢ࡜ࡉߥߤߩጘ㒂⋵߿ᗲ⍮⋵ߢᵴേߔࠆᖚఽߩኅᣖળߣߩធὐࠍᜬߜ㧘㓸ળߩડ↹ㆇ༡߿㓸ળᒰᣣߩࠕ࠼ࡃࠗࠩ࡯ߣߒߡታ〣⊛ߥ㑐ࠊࠅࠍⴕ߁ਛߢ㧘ሶߤ߽ߣኅᣖߩ⠨߃ᣇ߿ⴕേߩᄌኈࠍᝒ߃ߡ߈ߚ‫ޕ‬⎇ⓥ࠹࡯ࡑ㧦
࡮ࠕ࡟࡞ࠡ࡯ࠍᜬߟሶߤ߽ߩ QOL ะ਄ߦ㑐ߔࠆ⋴⼔Ꮷߩᓎഀ࡮㘩‛ࠕ࡟࡞ࠡ࡯ࠍ߽ߟ੃ᐜఽߩኅᣖ߳ߩᡰេ
࡮࿷ቛ≮㙃ࠍߔࠆዊఽߩ࿾ၞᡰេ
࡮ⴕὑ㓚ኂࠍ᦭ߔࠆߡࠎ߆ࠎᖚఽߩቇᩞ↢ᵴᜰዉ࡮㓚ኂఽߩ࿷ቛࠤࠕߦ߅ߌࠆኅᣖ߳ߩᡰេ૕೙ᒝൻ
࡮㓚ኂࠍ߽ߟ෺ሶߩ⢒ఽ࡮੺⼔ࠍߔࠆኅᣖ߳ߩᡰេ
2㧚ฬ★
ᢎ᝼㧦
ഥᢎ㧦

᧖ᶆᄥ৻
૒ว⌀♿

Taichi Sugiura
Maki Sago3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ᪀↰ᒄ⟤㧚వᄤ⊛ߥ໧㗴ࠍ߽ߟሶߤ߽ߣኅᣖ㧦Ꮢᳯ๺ሶ✬⪺㧚⋴⼔♽ᮡḰᢎ⑼ᦠ ዊఽ⋴⼔ቇ㧘᧲੩㧦ࠝ࡯ࡓ␠㧧2007 ᐕ㧦243㧙248㧚
2㧕 ᪀↰ᒄ⟤㧚ᔃり㓚ኂߩ޽ࠆሶߤ߽ߣኅᣖ㧦Ꮢᳯ๺ሶ✬⪺㧚⋴⼔♽ᮡḰᢎ⑼ᦠ ዊఽ⋴⼔ቇ㧘᧲੩㧦ࠝ࡯ࡓ␠㧧2007 ᐕ㧦249㧙257㧚
3㧕 ᧖ᶆᄥ৻⸶㧚㛽㜑Ἳ㧦࠮ࠪ࡝࡯࡮L࡮ࡌ࠶࠷㧘࡝ࡦ࠳࡮A࡮ࠨ࠙࠺ࡦ✬⪺㧚⍹㤥ᓀሶ㧘ጊ↰⍮ሶ⋙⸶㧚ዊఽ⋴⼔ࡂࡦ࠼ࡉ࠶ࠢ㧙∛ᘒ↢ℂߣ⋴⼔⸻ᢿ ╙ 2 㧘᧲੩㧦කቇᦠ㒮㧧2007 ᐕ㧦155㧙160㧚
4㧕 ᧖ᶆᄥ৻⸶㧚㛽⡺⣲ߣಾᢿⴚ㧦࠮ࠪ࡝࡯࡮L࡮ࡌ࠶࠷㧘࡝ࡦ࠳࡮A࡮ࠨ࠙࠺ࡦ✬⪺㧚⍹㤥ᓀሶ㧘ጊ↰⍮ሶ⋙⸶㧚ዊఽ⋴⼔ࡂࡦ࠼ࡉ࠶ࠢ㧙∛ᘒ↢ℂߣ⋴⼔⸻ᢿ ╙ 2 㧘᧲੩㧦කቇᦠ㒮㧧2007 ᐕ㧦169㧙176㧚
5㧕 ᧖ᶆᄥ৻⸶㧚♻⃿૕⣢Ἳ㧦࠮ࠪ࡝࡯࡮L࡮ࡌ࠶࠷㧘࡝ࡦ࠳࡮A࡮ࠨ࠙࠺ࡦ✬⪺㧚⍹㤥ᓀሶ㧘ጊ↰⍮ሶ⋙⸶㧚ዊఽ⋴⼔ࡂࡦ࠼ࡉ࠶ࠢ㧙∛ᘒ↢ℂߣ⋴⼔⸻ᢿ ╙ 2 㧘᧲੩㧦කቇᦠ㒮㧧2007 ᐕ㧦211㧙215㧚
6㧕 ᧖ᶆᄥ৻⸶㧚⧯ᐕᕈ㑐▵࡝࠙ࡑ࠴㧦࠮ࠪ࡝࡯࡮L࡮ࡌ࠶࠷㧘࡝ࡦ࠳࡮A࡮ࠨ࠙࠺ࡦ✬⪺㧚⍹㤥ᓀሶ㧘ጊ↰⍮ሶ⋙⸶㧚ዊఽ⋴⼔ࡂࡦ࠼ࡉ࠶ࠢ㧙∛ᘒ↢ℂߣ⋴⼔⸻ᢿ ╙ 2 㧘᧲੩㧦කቇᦠ㒮㧧2007 ᐕ㧦222㧙232㧚
7㧕 ᧖ᶆᄥ৻⸶㧚(ᕆᕈ)⣢ਇో㧦࠮ࠪ࡝࡯࡮L࡮ࡌ࠶࠷㧘࡝ࡦ࠳࡮A࡮ࠨ࠙࠺ࡦ✬⪺㧚⍹㤥ᓀሶ㧘ጊ↰⍮ሶ⋙⸶㧚ዊఽ⋴⼔ࡂࡦ࠼ࡉ࠶ࠢ㧙∛ᘒ↢ℂߣ⋴⼔⸻ᢿ ╙ 2 㧘᧲੩㧦කቇᦠ㒮㧧2007 ᐕ㧦264㧙274㧚
8㧕 ᧖ᶆᄥ৻⸶㧚(ᘟᕈ)⣢ਇో㧦࠮ࠪ࡝࡯࡮L࡮ࡌ࠶࠷㧘࡝ࡦ࠳࡮A࡮ࠨ࠙࠺ࡦ✬⪺㧚⍹㤥ᓀሶ㧘ጊ↰⍮ሶ⋙⸶㧚ዊఽ⋴⼔ࡂࡦ࠼ࡉ࠶ࠢ㧙∛ᘒ↢ℂߣ⋴⼔⸻ᢿ ╙ 2 㧘᧲੩㧦කቇᦠ㒮㧧2007 ᐕ㧦275㧙284㧚
9㧕 ᧖ᶆᄥ৻⸶㧚ਛᲥ㧦࠮ࠪ࡝࡯࡮L࡮ࡌ࠶࠷㧘࡝ࡦ࠳࡮A࡮ࠨ࠙࠺ࡦ✬⪺㧚⍹㤥ᓀሶ㧘ጊ↰⍮ሶ⋙⸶㧚ዊఽ⋴⼔ࡂࡦ࠼ࡉ࠶ࠢ㧙∛ᘒ↢ℂߣ⋴⼔⸻ᢿ ╙ 2 㧘᧲੩㧦කቇᦠ㒮㧧2007 ᐕ㧦414㧙417㧚
10㧕 ᧖ᶆᄥ৻⸶㧚੃ᐜఽᘟᕈ⢖∔ᖚ㧦࠮ࠪ࡝࡯࡮L࡮ࡌ࠶࠷㧘࡝ࡦ࠳࡮A࡮ࠨ࠙࠺ࡦ✬⪺㧚⍹㤥ᓀሶ㧘ጊ↰⍮ሶ⋙⸶㧚ዊఽ⋴⼔ࡂࡦ࠼ࡉ࠶ࠢ㧙∛ᘒ↢ℂߣ⋴⼔⸻ᢿ ╙ 2 㧘᧲੩㧦කቇᦠ㒮㧧2007 ᐕ㧦484㧙491㧚
11㧕 ᧖ᶆᄥ৻⸶㧚ዩ〝ᗵᨴ∝㧦࠮ࠪ࡝࡯࡮L࡮ࡌ࠶࠷㧘࡝ࡦ࠳࡮A࡮ࠨ࠙࠺ࡦ✬⪺㧚⍹㤥ᓀሶ㧘ጊ↰⍮ሶ⋙⸶㧚ዊఽ⋴⼔ࡂࡦ࠼ࡉ࠶ࠢ㧙∛ᘒ↢ℂߣ⋴⼔⸻ᢿ ╙ 2 㧘᧲੩㧦කቇᦠ㒮㧧2007 ᐕ㧦492㧙496㧚
12㧕 ᧖ᶆᄥ৻⸶㧚ࡀࡈࡠ࡯࠯∝୥⟲㧦࠮ࠪ࡝࡯࡮L࡮ࡌ࠶࠷㧘࡝ࡦ࠳࡮A࡮ࠨ࠙࠺ࡦ✬⪺㧚⍹㤥ᓀሶ㧘ጊ↰⍮ሶ⋙⸶㧚ዊఽ⋴⼔ࡂࡦ࠼ࡉ࠶ࠢ㧙∛ᘒ↢ℂߣ⋴⼔⸻ᢿ ╙ 2 㧘᧲੩㧦කቇᦠ㒮㧧2007 ᐕ㧦507㧙516㧚
13㧕 ᧖ᶆᄥ৻⸶㧚ዊఽߩᮡḰ⊛ߥⴊ࿶᷹ቯᣇᴺ㧦࠮ࠪ࡝࡯࡮L࡮ࡌ࠶࠷㧘࡝ࡦ࠳࡮A࡮ࠨ࠙࠺ࡦ✬⪺㧚⍹㤥ᓀሶ㧘㧙㧙ጊ↰⍮ሶ⋙⸶㧚ዊఽ⋴⼔ࡂࡦ࠼ࡉ࠶ࠢ㧙∛ᘒ↢ℂߣ⋴⼔⸻ᢿ ╙ 2 㧘᧲੩㧦කቇᦠ㒮㧧2007 ᐕ㧦716㧙
723㧚
14㧕 ᧖ᶆᄥ৻⸶㧚࠙ࠛࠬ࠻ߩ⸘▚࿑⴫㧦࠮ࠪ࡝࡯࡮L࡮ࡌ࠶࠷㧘࡝ࡦ࠳࡮A࡮ࠨ࠙࠺ࡦ✬⪺㧚⍹㤥ᓀሶ㧘ጊ↰⍮ሶ⋙⸶㧚ዊఽ⋴⼔ࡂࡦ࠼ࡉ࠶ࠢ㧙∛ᘒ↢ℂߣ⋴⼔⸻ᢿ ╙ 2 㧘᧲੩㧦කቇᦠ㒮㧧2007 ᐕ㧦743㧙744㧚
15㧕 ᧖ᶆᄥ৻㧚∔ᖚ߆ࠄߺߚዊఽ⋴⼔ㆊ⒟ߩዷ㐿 ࡀࡈࡠ࡯࠯∝୥⟲㧦⍹㤥ᓀሶ㧘ᵻ㊁ߺߤࠅ✬⪺㧚⊒㆐Ბ㓏߆ࠄߺߚዊఽ⋴⼔ㆊ⒟㧗∛ᘒ㑐ㅪ࿑㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦338㧙353㧚
16㧕 ᧖ᶆᄥ৻㧚∔ᖚ߆ࠄߺߚዊఽ⋴⼔ㆊ⒟ߩዷ㐿 ᕆᕈ♻⃿૕⣢Ἳ㧦⍹㤥ᓀሶ㧘ᵻ㊁ߺߤࠅ✬⪺㧚⊒㆐Ბ㓏߆ࠄߺߚዊఽ⋴⼔ㆊ⒟㧗∛ᘒ㑐ㅪ࿑㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦525㧙536㧚
17㧕 ᧖ᶆᄥ৻㧚∔ᖚ߆ࠄߺߚዊఽ⋴⼔ㆊ⒟ߩዷ㐿 ⧯ᐕᕈ․⊒ᕈ㑐▵Ἳ(⧯ᐕᕈ㑐▵࡝࠙ࡑ࠴)㧦⍹㤥ᓀሶ㧘ᵻ
㊁ߺߤࠅ✬⪺㧚⊒㆐Ბ㓏߆ࠄߺߚዊఽ⋴⼔ㆊ⒟㧗∛ᘒ㑐ㅪ࿑㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦570㧙583㧚
18㧕 ᧖ᶆᄥ৻㧚∔ᖚ߆ࠄߺߚዊఽ⋴⼔ㆊ⒟ߩዷ㐿 㛽᛬㧦⍹㤥ᓀሶ㧘ᵻ㊁ߺߤࠅ✬⪺㧚⊒㆐Ბ㓏߆ࠄߺߚዊఽ
⋴⼔ㆊ⒟㧗∛ᘒ㑐ㅪ࿑㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦588㧙599㧚
19㧕 ૒ว⌀♿㧚∔ᖚ߆ࠄߺߚዊఽ⋴⼔ㆊ⒟ߩዷ㐿 ․⊒ᕈⴊዊ᧼ᷫዋᕈ⚡᢬∛(ITP)㧦⍹㤥ᓀሶ㧘ᵻ㊁ߺߤࠅ✬⪺㧚⊒㆐Ბ㓏߆ࠄߺߚዊఽ⋴⼔ㆊ⒟㧗∛ᘒ㑐ㅪ࿑㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦308㧙316㧚
20㧕 ૒ว⌀♿㧚∔ᖚ߆ࠄߺߚዊఽ⋴⼔ㆊ⒟ߩዷ㐿 㜑⤑Ἳ㧦⍹㤥ᓀሶ㧘ᵻ㊁ߺߤࠅ✬⪺㧚⊒㆐Ბ㓏߆ࠄߺߚዊ
ఽ⋴⼔ㆊ⒟㧗∛ᘒ㑐ㅪ࿑㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦384㧙394㧚
21㧕 ૒ว⌀♿㧚∔ᖚ߆ࠄߺߚዊఽ⋴⼔ㆊ⒟ߩዷ㐿 ࠕ࠻ࡇ࡯ᕈ⊹⤏Ἳ㧦⍹㤥ᓀሶ㧘ᵻ㊁ߺߤࠅ✬⪺㧚⊒㆐Ბ㓏߆ࠄߺߚዊఽ⋴⼔ㆊ⒟㧗∛ᘒ㑐ㅪ࿑㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦436㧙446㧚
22㧕 ᪀↰ᒄ⟤㧚∔ᖚ߆ࠄߺߚዊఽ⋴⼔ㆊ⒟ߩዷ㐿 ᳓㗡∝㧦⍹㤥ᓀሶ㧘ᵻ㊁ߺߤࠅ✬⪺㧚⊒㆐Ბ㓏߆ࠄߺߚዊ
ఽ⋴⼔ㆊ⒟㧗∛ᘒ㑐ㅪ࿑㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦167㧙182㧚
23㧕 ᪀↰ᒄ⟤㧚∔ᖚ߆ࠄߺߚዊఽ⋴⼔ㆊ⒟ߩዷ㐿 ⣖⣲≌㧦⍹㤥ᓀሶ㧘ᵻ㊁ߺߤࠅ✬⪺㧚⊒㆐Ბ㓏߆ࠄߺߚዊ
ఽ⋴⼔ㆊ⒟㧗∛ᘒ㑐ㅪ࿑㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦228㧙246㧚
24㧕 ᪀↰ᒄ⟤㧚∔ᖚ߆ࠄߺߚዊఽ⋴⼔ㆊ⒟ߩዷ㐿 ∨ᡨᕈ∔ᖚ㧦⍹㤥ᓀሶ㧘ᵻ㊁ߺߤࠅ✬⪺㧚⊒㆐Ბ㓏߆ࠄߺߚዊఽ⋴⼔ㆊ⒟㧗∛ᘒ㑐ㅪ࿑㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦359㧙378㧚
25㧕 ᪀↰ᒄ⟤㧚∔ᖚ߆ࠄߺߚዊఽ⋴⼔ㆊ⒟ߩዷ㐿 ⣖ᕈ㤗∽㧦⍹㤥ᓀሶ㧘ᵻ㊁ߺߤࠅ✬⪺㧚⊒㆐Ბ㓏߆ࠄߺߚዊఽ⋴⼔ㆊ⒟㧗∛ᘒ㑐ㅪ࿑㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦542㧙563㧚
⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 ᧖ᶆᄥ৻㧚ዊఽ߇ࠎ࡮㔍ᴦᕈ∔ᖚࠤࠕߦᔅⷐߥⷞὐߣኅᣖኻᔕ㧘ߎߤ߽ࠤࠕ 2008 ᐕ㧧2 Ꮞ㧦42㧙49㧚
2㧕 ᧖ᶆᄥ৻㧘૒ว⌀♿㧚⋴⼔ࠤࠕߩࡐࠗࡦ࠻ ࠕ࡟࡞ࠡ࡯∔ᖚࠍ߽ߟሶߤ߽ߩ㘩ⴕേ㧘ዊఽ⋴⼔ 2008 ᐕ㧧
31 Ꮞ㧦1103㧙1108㧚
3㧕 ᧖ᶆᄥ৻㧚․㓸ߦ޽ߚߞߡ ᄌࠊࠄߥߌࠇ߫ߥࠄߥ޿ሶߤ߽ߚߜߣ଻⼔⠪㧘ߘߒߡක≮㑐ଥ⠪㧘ዊఽ⋴⼔
2008 ᐕ㧧31 Ꮞ㧦1323㧚
4㧕 ችፒ⟤଻㧘ᄢਭ଻ߣߺሶ㧘᧖ᶆᄥ৻㧚ታ〣⊛ขࠅ⚵ߺ ᳇▤ᡰ༎ᕷߢ౉㒮ߒߡ޿ࠆሶߤ߽߳ߩេഥ㧙౉㒮ೋᦼ߆ࠄㅌ㒮ߦะߌߡߩ⋴⼔េഥ㧙㧘ዊఽ⋴⼔ 2008 ᐕ㧧31 Ꮞ㧦1377㧙1383㧚
✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ᪀↰ᒄ⟤㧚㓚ኂఽߩ࿷ቛࠤࠕߦ߅ߌࠆኅᣖ߳ߩᡰេ૕೙ᒝൻߦ㑐ߔࠆ⺞ᩏ⎇ⓥ(Υ)㧙㔍∛߿㓚ኂࠍᜬߟሶ
ߣኅᣖ߳ߩᡰេߩᣇะᕈ㧙㧘ᣣᧄ⋴⼔ቇળ⺰ᢥ㓸 ࿾ၞ⋴⼔ 2006 ᐕ㧧36 ภ㧦132㧙134㧚
2㧕 ጊ↰⍮ሶ㧘ᵻ㊁ߺߤࠅ㧘᧖ᶆᄥ৻㧘ਃᶆᷡ਎⟤㧘⍹㤥ᓀሶ㧚ක≮ᓥ੐⠪ߣߩද௛ߦ㑐ߔࠆᕁᤐᦼ༎ᕷఽߩ
⹺⼂㧘ᣣᧄዊఽ⋴⼔ቇળ⹹ 2006 ᐕ㧧15 Ꮞ㧦68㧙75㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Asano M, Sugiura T, Miura K, Torii S, Ishiguro A. Reliability and Validity of the Self-report Quality ofLife Questionnaire for Japanese School-aged Children with Asthma (JSCA-QOL v.3). Allergol Int.
2006;55:59-65.

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦᪀↰ᒄ⟤㧘⎇ⓥಽᜂ⠪㧦᧖ᶆᄥ৻㧘ᓟ㑄ኈሶ㧘㊁↰ᵗሶ㧘⍹ේᄙ૫ሶ㧘૒ว⌀♿㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦࿷ቛ≮㙃ࠍߔࠆዊఽߩ࿾ၞᡰេࠪࠬ࠹ࡓߩ᭴▽ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18㧙20 ᐕᐲ㧧3,400 ජ౞(1,900㧦700㧦800 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦᧖ᶆᄥ৻㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄⪚⧘⎇ⓥ㧦⥄Ꮖ⺞ᢛℂ⺰ࠍ↪޿ߚᄖ᧪ߦ߅ߌࠆ
᳇▤ᡰ༎ᕷࠍ߽ߟቇ┬߳ߩ≮㙃ⴕേᢎ⢒ߩലᨐ㧧ᐔᚑ 18㧙20 ᐕᐲ㧧1,100 ජ౞(500㧦400㧦200 ජ
౞)

㧙㧙

2㧕ฃ⸤⎇ⓥ
ߥߒ
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬ᧖ᶆᄥ৻㧦
1㧕 ᣣᧄ⋴⼔⎇ⓥቇળ⹏⼏ຬ(ᐔᚑ 19 ᐕ 4 ᦬㨪⃻࿷)2㧕 ᣣᧄ⋴⼔ක≮ቇળ⹏⼏ຬ(ᐔᚑ 20 ᐕ 4 ᦬㨪⃻࿷)2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳᧖ᶆᄥ৻㧦
1㧕 ╙ 7 ࿁ሶߤ߽ߩ≮㙃ⅣႺ⎇ⓥળ(2006 ᐕ 6 ᦬㧘ᗲ⍮㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬24 ᤨ㑆㕙ળߣ∛㒮ߩ቟ో▤ℂ‫ޠ‬ᐳ㐳)
8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേ᪀↰ᒄ⟤㧦
1㧕 ቇᩞᴺੱၔർቇ࿦߆ߋ߿╙ੑᐜ⒩࿦⹏⼏ຬ(㨪ᐔᚑ 20 ᐕᐲ)
10㧚ႎ๔ᦠߥߒ11㧚ႎ㆏
1㧕 ᧖ᶆᄥ৻㧦‫⎇ޟ‬ⓥቶ߆ࠄᄢቇߪ੹‫ޠ‬ሶߤ߽ߣኅᣖߩஜᐽ⋡ᜰߔ㧦ጘ㒂ᣂ⡞(2008 ᐕ 2 ᦬ 19 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔ
ᐔᚑ 20 ᐕ㧔2008 ᐕ㧕ߩ 3 ᦬߹ߢߪಎᢎ᝼ 2 ฬߣഥᢎ 1 ฬ߆ࠄߥࠆᢎ᝼ਇ࿷ߩಽ㊁ߢ޽ߞߚ߇㧘4 ᦬߆ࠄᢎ᝼ 1 ฬ㧘ಎᢎ᝼ 1 ฬ㧘ഥᢎ 1 ฬ߆ࠄ᭴ᚑߐࠇࠆಽ㊁ߣߥߞߚ‫ߒ߆ߒޕ‬㧘ᄐߦߪᢎຬߩ⒖േ߇޽ࠅ㧘⃻࿷ߪ㧘ᢎ᝼ 1 ฬ㧘ഥᢎ 1 ฬߩ 2 ฬ૕೙ߢ⻠⟵㧘ታ⠌ᜰዉ㧘⎇ⓥᵴേࠍⴕߞߡ޿ࠆ‫ޕ‬వߩ‫⺖ߣ⁁⃻ޟ‬㗴‫ޠ‬ߢ੹ᓟߩ⺖㗴ߣߒߚ⪺ᦠߦ㑐ߒߡߪ㧘ᢎຬ 3 ฬߣ߽ߦ⪺ᦠߩಽᜂၫ╩ࠍⴕ߁ߎߣ߇ߢ߈ߚ‫ߥ⊛⚳ᦨޕ‬ᚑᨐ⊒⴫ߪߎࠇ߆ࠄߢ޽ࠆ߇㧘┹੎⊛ᄖㇱ⾗㊄ߩ₪ᓧ⁁ᴫ߽ḩ⿷ߢ߈ࠆ⁁ᴫߣ޿߃ࠆ‫ ߩߎޕ‬3 ᐕ㑆ߩ⪺ᦠએᄖߩᚑᨐ⊒⴫ߩ⁁ᴫߣߒߡߪ㧘✚⺑㧔๺ᢥ㧕4 ✬㧘ේ⪺㧔๺ᢥ㧕2 ✬㧘ේ⪺㧔᰷ᢥ㧕1 ✬ߣߥߞߡ޿ࠆ
߇㧘ಽ㊁ߩᢎຬ߇╙ 1 ⪺⠪ߦߥߞߡ޿ࠆ⺰ᢥ߇ዋߥ޿ߎߣ߇໧㗴ὐߣߒߡ޽ߍࠄࠇࠆ‫⃻ޕ‬࿷ㅴⴕਛߩ⎇ⓥᚑᨐߦߟ޿ߡߪ㧘ߔߢߦቇળ⊒⴫ࠍ⚳߃ߡ߅ࠅ㧘ᐔᚑ 21 ᐕ㧔2009 ᐕ㧕એ㒠ቇⴚ㔀⹹ߦᛩⓂ੍ቯߣߒߡ޿ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷┹੎⊛ᄖㇱ⾗㊄ߪᐔᚑ 20 ᐕᐲ߇ᦨ⚳ᐕᐲߢ޽ࠆߚ߼㧘ᐔᚑ 21 ᐕᐲએ㒠߽⛮⛯ߒߡ⾗㊄ߩ₪ᓧࠍߒߡ㧙㧙޿ߊߎߣ߇⺖㗴ߣߥࠆ‫ޕ‬ቇᄖߣߩ౒ห⎇ⓥߦ߅޿ߡ߽㧘ᒰಽ㊁߇ਥዉߔࠆᒻߢⴕߞߡ޿ߊߎߣ߇ߢ߈ߡ
޿ߥ޿ߎߣ߇໧㗴ὐߣߒߡ޽ߍࠄࠇ㧘⺰ᢥ⊒⴫߽ᒰಽ㊁ߩᢎຬ߇╙ 1 ⪺⠪ߣߥߞߡ޿ࠆ߽ߩ߇ዋߥ޿‫ޕ‬
ᐔᚑ 21 ᐕᐲએ㒠ߪ㧘╙ 1 ⪺⠪ߣߒߡ⎇ⓥᚑᨐࠍ⺰ᢥᛩⓂߎߣ߇⺖㗴ߢ޽ࠆ‫ޕ‬ዊఽ⋴⼔ቇᢎ⢒ߩ⹏ଔߪ㧘ߐ߹ߑ߹ߥⷺᐲ߆ࠄಽᨆߒ㧘ቇળ⊒⴫ߛߌߢߥߊᢎ⑼ᦠ߿ᢎ᧚ߣ޿߁ᒻߢ
ᚑᨐࠍ⊒⴫ߒߡ޿ߊᔅⷐ߇޽ࠆߣߒߡ޿ߚ߇㧘ᢎ᧚ߣߒߡ૶↪ߢ߈ࠆᧄߩၫ╩ߦߣߤ߹ߞߡ޿ࠆ‫੹ޕ‬ᓟߎߩᧄࠍߤߩࠃ߁ߦᢎ⢒ߦᵴ߆ߒߡ޿ߊ߆ߣ޿߁ߎߣߣ㧘⎇ⓥߣߒߡ߹ߣ߼ࠆߦߪ୶ℂ㕙߿ᅷᒰᕈ࡮ା
㗬ᕈߥߤߩ໧㗴ὐ߽ᄙ޿߇ዊఽ⋴⼔ቇߩᢎ⢒ലᨐߦ㑐ߔࠆ⎇ⓥࠍㅴ߼ࠆᔅⷐ߇޽ࠆ‫ޕ‬┹੎⊛ᄖㇱ⾗㊄ߢⴕߞߡ߈ߚ㧘‫ޟ‬ጘ㒂࿾ၞߢ࿷ቛ≮㙃ࠍߔࠆዊఽߩ࿾ၞᡰេࠪࠬ࠹ࡓߩ᭴▽‫ߛ߹ߪߦޠ‬⺖㗴߽ᄙߊ㧘੹ᓟߤߩࠃ߁ߦ⊒ዷߐߖߡ޿ߊ߆߇⺖㗴ߢ޽ࠅ㧘ዊఽ⋴⼔ቇߩಽ㊁ࠍ⿧߃ߚߐ߹ߑ߹ߥಽ
㊁ߣߩㅪ៤ࠍᒝ߼ࠆᔅⷐࠍᗵߓߡ޿ࠆ‫ޕ‬੹ᓟߩዷᦸ
ᐔᚑ 21 ᐕᐲ߆ࠄᄢቇ㒮කቇ♽⎇ⓥ⑼⋴⼔ቇኾ᡹ߦዊఽ⋴⼔ቇߩୃ჻⺖⒟߇㐿߆ࠇࠆ੍ቯߢ޽ࠅ㧘౉ቇ↢߽ㆬᛮߐࠇߡ޿ࠆ‫੹ޕ‬ᓟߪ㧘ᄢቇ㒮ߦ߅ߌࠆ㒮↢ߩ⎇ⓥࠍ฽߼㧘ሶߤ߽ߣኅᣖ߇ࠃࠅஜᐽߦ↢ᵴߢ߈ࠆࠃ߁ߥᡰេߦߟ޿ߡ⎇ⓥࠍㅴ߼ߡ޿ߊ੍ቯߢ޽ࠅ㧘⎇ⓥᚑᨐߩ⊒⴫ߩᯏળ߽Ⴧ߃ࠆߎߣ߇੍᷹ߢ߈ࠆ‫ޕ‬⋴⼔ᢎ⢒ߪ㧘ᢎຬ߇ቇ↢ߣ㑐ࠊࠆᤨ㑆߇㕖Ᏹߦᄙ޿ߎߣ߇․ᓽߢ޽ࠆ‫ߚ߹ޕ‬㧘⋴⼔⎇ⓥߪ㧘ታ㛎ቶߢⴕ߃ࠆ⎇ⓥ߇߶ߣࠎߤߥߊ㧘ሶߤ߽߿ኅᣖߣߩ㑐ࠊࠅࠍ߽ߟߚ߼ߩࡈࠖ࡯࡞࠼ߦ಴ࠆߎߣ߇㊀ⷐߣߥࠆ‫ޕ‬ߎࠇࠄߩߎߣࠍ〯߹߃㧘ሶߤ߽߿ኅᣖߣ⋥ធ߆߆ࠊࠆࠃ߁ߥቇㇱ↢߿㒮↢߳ߩᢎ⢒ߩ⾰ࠍ⪭ߣߐߕߦ㧘ࡈࠖ࡯࡞࠼ߦ಴ߡ⎇ⓥߔࠆߎߣߦ૶↪ߢ߈ࠆᤨ㑆ࠍ⏕଻ߔࠆߎߣ߇⺖㗴ߢ޽ࠅ㧘Ⓧᭂ⊛ߦኻᔕߒߡ޿߈
ߚ޿‫ޕ‬

㧙㧙

ާᚑੱ࡮⠧ᐕ⋴⼔ቇ⻠ᐳި
㧔1㧕ᚑੱ⋴⼔ቇಽ㊁㧔ᘟᕈᦼ㧕1㧚⎇ⓥߩ᭎ⷐ
⥃ᐥߦ߅ߌࠆ⋴⼔ߩ⾰ߩ⏕଻ߣะ਄ߩߚ߼ߦ⥃ᐥߢᓧࠄࠇߚ⍮ߩ⑼ቇ⊛ಽᨆ㧘ߐࠄߦᘟᕈ⋴⼔ቇߩቇ໧ߩ⏕┙ߣ⊒ዷߦ⽸₂ߢ߈ࠆࠃ߁⎇ⓥߦขࠅ⚵ࠎߢ߈ߚ‫ౕޕ‬૕⊛ߦߪ㧘ᴦ≹࿎㔍ߥᘟᕈ⊛ߥ∛ࠍᜬߜߥ߇ࠄ
㐳ᦼ㑆ߦࠊߚࠅᣣᏱ࡮␠ળ↢ᵴࠍㅍࠄߥߌࠇ߫ߥࠄߥ޿ᚑੱᦼߦ޽ࠆᖚ⠪ߩஜᐽߦ㑐ㅪߒߚ QOL
㧔HRQOL㧕ࠍ໧㗴ߣߒߚ HRQOL ߩ⛽ᜬ㧘ะ਄޽ࠆ޿ߪౣ᭴▽ߦ᳞߼ࠄࠇࠆ⋴⼔ߩℂ⺰⊛ត⚝ߣߘࠇߦၮߠߊᣂߚߥℂ⺰ߩ㐿⊒㧘㔍∛ߦ㑐ߔࠆ⋴⼔㧘ઍ⴫⊛ߥᘟᕈ∛ߢ޽ࠆ♧ዩ∛ᖚ⠪ߩ QOL ߩૐਅߦᦨ߽㑐ଥߔࠆว૬∝੍㒐ߦㆡ↪ߐࠇࠆᦨ߽ᦸ߹ߒ޿⋴⼔ߩត᳞ߥߤߢ޽ࠆ‫ߡߒߘޕ‬㧘⋴⼔ታ〣⢻ജߩ⢒ᚑߩߚ߼
ᘟᕈᦼಽ㊁⥃࿾ታ⠌ߦ߅ߌࠆᢎ⢒ౝኈߩᬌ⸛ߥߤᘟᕈ⋴⼔ቇߩᢎ⢒ะ਄ߦ㑐ߔࠆ⎇ⓥ߽ⴕߞߡ޿ࠆ‫⎇ޕ‬ⓥߥߤߢᓧࠄࠇߚᚑᨐߪ㧘⋴⼔ᢎ⢒߿⥃ᐥߩ႐ߦㆶరߢ߈ࠆࠃ߁ദജߒߡ޿ࠆ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
ಎᢎ᝼㧦
ഥᢎ㧦
ഥᢎ㧦

⿷┙ਭሶ
⑔ේ㓉ሶ
દ⮮⢒ሶ
ᕡᎹ⢒ઍ

Hisako Adachi
Takako Fukuhara
Ikuko Ito
Ikuyo Tsunekawa

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ⑔ේ㓉ሶ㧚⑔੗⋵┙∛㒮␹⚻㔍∛⋴⼔࠴࡯ࡓ㧧⋴⼔ㆊ⒟ࠟࠗ࠳ࡦࠬ‫ޟ‬ALS‫ޠ‬㧘࠽࡯ࠪࡦࠣࠞ࡟࠶ࠫ 2007
ᐕ㧧11 Ꮞ㧦46㧙63㧚
2㧕 ⑔ේ㓉ሶ㧚ታ⠌ࠕ࠮ࠬࡔࡦ࠻㨯ࠞ࡯࠼‫∔ߩ╭࡮⚻␹ޟ‬ᖚ‫ޠ‬㧘࠽࡯ࠪࡦࠣࠞ࡟࠶ࠫ 2008 ᐕ㧧12 Ꮞ㧚⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
ߥߒ✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ⿷┙ਭሶ㧚SF-36 ࠍ↪޿ߚ♧ዩ∛ᖚ⠪ߩஜᐽ⁁ᘒ⹏ଔ㧘ࡅࡘ࡯ࡑࡦ࡮ࠤࠕ⎇ⓥ 2006 ᐕ㧧7 Ꮞ㧦11㧙19㧚
2㧕 ⿷┙ਭሶ㧚ᄖ᧪ㅢ㒮ਛߩ♧ዩ∛ᖚ⠪ߩ HRQOL ߦਈ߃ࠆஜᐽ⹏ଔߩᓇ㗀㧘ᣣᧄ⋴⼔⑼ቇቇળ⹹ 2006 ᐕ㧧
26 Ꮞ㧦39㧙47㧚
3㧕 ᕡᎹ⢒ઍ㧚2 ဳ♧ዩ∛ᖚ⠪ߩᔃ╭᪪Ⴇ߅ࠃ߮⣖᪪Ⴇว૬੍㒐ߩߚ߼ߩ↢ᵴ⠌ᘠߣⴕേ․ᕈߩᬌ⸛㧘ᣣᧄ♧ዩ∛ᢎ⢒࡮⋴⼔ቇળ⹹ 2008 ᐕ㧧12 Ꮞ㧦4㧙16㧚
4㧕 ⿷┙ਭሶ㧚♧ዩ∛ᖚ⠪ߩ HRQOL ߩ⹏ଔߦᓇ㗀ࠍਈ߃ࠆⷐ࿃ߩಽᨆ㧘ᣣᧄ⋴⼔⑼ቇቇળ⹹ 2008 ᐕ㧧28Ꮞ㧦8㧙16㧚ේ⪺㧔᰷ᢥ㧕
ߥߒ

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦㊁↰ᵗሶ, ⎇ⓥಽᜂ⠪㧦ዊ㊁ᢅሶ, ⿷┙ਭሶ㧧⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦ੑಽ⣄ᬁ∝ᅚᕈߩ᦬⚻ߣᕈߩஜᐽߦ㑐ߔࠆ൮᜝⊛ࠤࠕࡊࡠࠣ࡜ࡓߩ㐿⊒㧧ᐔᚑ 18㧙20 ᐕᐲ㧧3,300 ජ౞(1,500㧦800㧦1,000 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦દ⮮⢒ሶ㧧⑼ቇ⎇ⓥ⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦ᣣᧄੱะߌߩ♧ዩ∛⿷∛ᄌ੍㒐ߩߚ߼ߩ⋴⼔ࡊࡠࠣ࡜ࡓ૞ᚑߣߘߩ᦭↪ᕈߩᬌ⸽㧧ᐔᚑ 19㧙21 ᐕᐲ㧧3,250 ජ౞(1,000㧦1700㧦500 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦ᕡᎹ⢒ઍ㧧⑼ቇ⎇ⓥ⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦↵ᕈ 2 ဳ♧ዩ∛ᖚ⠪ߩᔃ╭᪪Ⴇ੍㒐ߦะߌߚ࠰࡯ࠪࡖ࡞ࠨࡐ࡯࠻ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 20㧙22 ᐕᐲ㧧2,000 ජ౞(600㧦600㧦800 ජ౞)㧙㧙2㧕ฃ⸤⎇ⓥ
ߥߒ
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬ⿷┙ਭሶ㧦
1㧕 ᣣᧄᘟᕈ⋴⼔ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ⋴⼔⎇ⓥቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄࡅࡘ࡯ࡑࡦ࡮ࠤࠕᔃℂቇળℂ੐(㨪⃻࿷)2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ߥߒ
8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേ⑔ේ㓉ሶ㧦
1㧕 ጘ㒂⋵ಎ⋴⼔Ꮷ⹜㛎ᆔຬ࡮໧㗴⺞ᢛᆔຬ(ᐔᚑ 19 ᐕ㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ⿷┙ਭሶ㧘TimeTrade-Off ᴺߦࠃࠆ♧ዩ∛ᖚ⠪ߩஜᐽ⁁ᘒߩ⹏ଔߦ㑐ߔࠆ⥃ᐥ⊛⎇ⓥ㧘ᐔᚑ 15 ᐕᐲ㧙ᐔᚑ 17 ᐕᐲᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ၮ⋚⎇ⓥ(C)(2) ⎇ⓥᚑᨐႎ๔ᦠ㧦1㧙66(2006 ᐕ 3 ᦬)
2㧕 ች࿾⵨ᢥ㧘⑔ේ㓉ሶ㧘ᑪㇱᣧ⧣㧘┻ౝ᣿⟤㧘⍹㤥㉿⟤㧘ᑝㇱ⍓㧘ศᎹౖሶ㧦ALS࡮࡟ࠬࡄࠗ࠻౉㒮ᖚ⠪ฃߌ౉ࠇᤨߩ⋴⼔ᬺോߩᬌ⸛㧙࠲ࠗࡓࠬ࠲࠺ࠖ⺞ᩏࠍ߽ߣߦ㧙㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ
⾌⵬ഥ㊄㧘㊀∝㔍∛ᖚ⠪ߩ࿾ၞක≮૕೙ߩ᭴▽ߦ㑐ߔࠆ⎇ⓥႎ๔ᦠ㧦55㧙60(2007 ᐕ 1 ᦬)
11㧚ႎ㆏
1㧕 ⿷┙ਭሶ㧦‫⎇ޟ‬ⓥቶ߆ࠄ ᄢቇߪ޿߹‫ޠ‬㧦ጘ㒂ᣂ⡞(2007 ᐕ 5 ᦬ 1 ᣣ)
2㧕 ⑔ේ㓉ሶ㧦Ꮢ᳃౏㐿⻠ᐳ㧙ࠃࠅࠃ޿࿷ቛ੺⼔ࠍ⋡ᜰߒߡ㧦Ꭸධࠤ࡯ࡉ࡞࠹࡟ࡆ RCN(᡼ㅍᣣ㧦2008
ᐕ 12 ᦬ 6㧘7㧘13㧘14㧘20㧘21㧘27㧘28 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔ
ᘟᕈᦼಽ㊁ߣߒߡߩ౒ห⎇ⓥߩᬺ❣߿ฦᢎຬߩ⪺⠪߿✚⺑ࠍ฽߻⺰ᢥߥߤߩᬺ❣߇ዋߥ޿‫ߢ߹ࠇߎޕ‬㧘
ᘟᕈᦼಽ㊁ߩ᝼ᬺౝኈߩలታ߿ᣇᴺߩᄌᦝߥߤᘟᕈᦼ⋴⼔ቇߩᢎ⢒ߩะ਄ߦജࠍᵈ޿ߢ߈ߚ‫⃻ޕ‬࿷ߪ㧘ߘߩᚑᨐࠍᓢ‫߼ߣ߹ߦޘ‬㧘⊒⴫ߩḰ஻Ბ㓏ߦ޽ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷໧㗴ὐߣߒߡ㧘⪺ᦠ߿⊒⴫⺰ᢥߥߤߩᬺ❣߇ዋߥ޿ߎߣ㧘ᘟᕈᦼ⋴⼔ቇߩᢎ⢒ߩะ਄ߦ㑐ߔࠆ⎇ⓥ߇
⃻࿷ⴕࠊࠇߡ޿ߥ޿ߎߣ߇᜼ߍࠄࠇࠆ‫ޕ‬ኻᔕ╷ߣߒߡ㧘ᘟᕈᦼಽ㊁ߢߎࠇ߹ߢⴕߞߡ߈ߚ᝼ᬺౝኈ߿ᣇ

㧙㧙ᴺߩలታߥߤߩᢎ⢒ߦ㑐ߔࠆᚑᨐࠍ౒หߢ⎇ⓥ⊒⴫ࠍߒߡ޿ߊߎߣߢ޽ࠆ‫ޕ‬੹ᓟߩዷᦸ
ಽ㊁ߩ౒ห⎇ⓥߣߒߡߩᘟᕈᦼ⋴⼔ቇߩᢎ⢒ߩะ਄ߦ㑐ߔࠆ⎇ⓥߩታᣉ㧘␠ળ⽸₂ߥߤߩᬺ❣ࠍჇ߿ߔࠃ߁ദജߒߚ޿‫ޕ‬㧙㧙㧔2㧕ᚑੱ⋴⼔ቇಽ㊁㧔ᕆᕈᦼ㧕1㧚⎇ⓥߩ᭎ⷐ
ᚑੱ⋴⼔ቇᕆᕈᦼಽ㊁ߢߪ㧘⋴⼔ቇᢎ⢒࡮⋴⼔ታ〣ߦᵴ߆ߔߎߣࠍ⋡⊛ߣߒߚ⎇ⓥ⺖㗴ࠍ⸳ቯߒ㧘ᢎ᧚㐿⊒߿ታᘒ⺞ᩏ㧘ታ㛎/Ḱታ㛎╬ࠍⴕߞߡ޿ࠆ‫⎇ޕ‬ⓥߩኻ⽎ߪ㧘ᚻⴚࠍฃߌࠆᖚ⠪ߣኅᣖ߿ᢇᕆ࡮ࠢ࡝࠹
ࠖࠞ࡞ࠤࠕࠍᔅⷐߣߔࠆᖚ⠪ߣኅᣖ㧘࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦࠍᔅⷐߣߔࠆᖚ⠪ߣኅᣖ㧘ࠬࡐ࡯࠷╬ߩㆇേࠍⴕ߁⠪ߢ޽ࠆ‫⼔⋴ޕ‬ቇᢎ⢒ߦ㑐ߒߡߪ㧘⃻࿷ᢎຬ߇㐿⊒ߒߚࠦࡦࡇࡘ࡯࠲⋴⼔ᢎ᧚ࠍ CD ߿ AIMS-Gifuߩ೑↪ߦࠃࠅ⥄Ꮖቇ⠌ߔࠆⅣႺࠍᢛ߃㧘ቇ↢୘‫⥄ߩޘ‬ਥ⊛࡮ਥ૕⊛ቇ⠌ࠍᡰេߒߡ޿ࠆ‫ߦߢ߹ࠇߎޕ‬㧘㐿⊒ߒߚᢎ᧚‫ⴚޟ‬ᓟ 24 ᤨ㑆ߩ⋴⼔‫ޠ‬㧘‫ޟ‬ᚻⴚቶ౉ቶࠝ࡝ࠛࡦ࠹࡯࡚ࠪࡦ‫ޠ‬㧘‫ⴚޟ‬ᓟቶߩḰ஻‫ޠ‬㧘‫ޟ‬㤗㈮ዉ౉߹ߢߩ⋴⼔‫ߡ޿ߟߦޠ‬ᢎ⢒ലᨐߩᬌ⸽ࠍⴕߞߡ߈ߚ߇㧘⃻࿷ߪ‫ⴚޟ‬೨✵⠌‫ޟޠ‬ᢇᕆᢇ๮‫ߦޠ‬㑐ߔࠆᢎ᧚㐿⊒㧘૞ᚑߒߚᢎ᧚ߩቇ⠌ലᨐߩᬌ⸽㧔ቴⷰ⊛࠺࡯࠲ߦၮߠߊ⹏ଔ⎇ⓥ㧕߅ࠃ߮ᢎ᧚ߩᡷ⦟╬߳ߣ⎇ⓥࠍㅴ߼ߡ޿ࠆ‫⼔⋴ޕ‬ታ〣ߦ㑐ߔࠆ⎇ⓥߢߪ㧘ⴚᓟᖚ⠪ߩᕆᕈᷙੂ࡮㍲ੂ੍㒐ߣᣧᦼ⊒⷗ߩߚ߼ߩ⋴⼔ࠍ᣿ࠄ߆ߦߔ
ࠆߚ߼ߩၮ␆⎇ⓥࠍⴕߞߡ߈ߚ‫ⴚޕ‬ᓟߖࠎᅦߦ㑐ߔࠆᣣᧄ⺆ ࠬࠤ࡯࡞㧔NEECHAM Confusion Scale㧕ߩା㗬ᕈߣᅷᒰᕈߩᬌ⸛㧘߅ࠃ߮ⴚᓟߖࠎᅦߩ⊒∝ㆊ⒟ߣ⊒∝࿃ሶߩಽᨆߦ㑐ߔࠆࠕ࡞ࠧ࡝࠭ࡓߩ㐿⊒ߦขࠅ⚵ࠎߢ޿ࠆ‫߁޿ߣޠ⼔⋴࠷࡯ࡐࠬޟߚ߹ޕ‬㗔ၞߩᗧ⟵ࠍ໧߁ߴߊ㧘┹ᛛࠬࡐ࡯࠷㧘㓚ኂ⠪ࠬࡐ࡯࠷㧘ஜᐽჇㅴㆇേߦ㑐ࠊࠆฦ⒳⡯⒳ߣߩද௛ߩ਄ߢߩ⋴⼔Ꮷߩᓎഀߦߟ޿ߡታᘒ⺞ᩏࠍⴕߞߡ޿ࠆ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
ᢎ᝼㧦
ಎᢎ᝼㧦
ഥᢎ㧦

⷏ᧄ ⵨
᧻↰ᅢ⟤
㜟ᯅ↱⿠ሶ
᪢᧛ବᓆ

Yutaka Nishimoto
Yoshimi Matsuda
Yukiko Takahashi
Toshiaki Umemura

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ⷏ᧄ ⵨㧘ᄢ㊁⾆ᢅ㧚㘃㛽㛽⣲㧘㛽⧘⚦⢩⣲㧦ศᎹ⑲᮸✬㧚ᦨᣂᢛᒻᄖ⑼ቇ૕♽╙ 20 Ꮞ㧙㛽࡮エㇱ⣲≌߅ࠃ߮㑐ㅪ∔ᖚ 2 ┨㧙㛽⣲≌ฦ⺰㧙㧘᧲੩㧦ਛጊᦠᐫ㧧2007 ᐕ㧦201㧙205㧚
2㧕 ⷏ᧄ ⵨㧘ᄢ㊁⾆ᢅ㧚㕖㛽ൻᕈ✢⛽⣲(✢⛽ᕈ㛽⊹⾰ᰳ៊)㧦ศᎹ⑲᮸✬㧚ᦨᣂᢛᒻᄖ⑼ቇ૕♽╙ 20 Ꮞ㧙㛽࡮エㇱ⣲≌߅ࠃ߮㑐ㅪ∔ᖚ 2 ┨㧙㛽⣲≌ฦ⺰㧘᧲੩㧦ਛጊᦠᐫ㧧2007 ᐕ㧦233㧙236㧚
3㧕 ┻ౝ⊓⟤ሶ㧚ᖚ⠪૕㛎ߦቇ߱੃߇ࠎߩ⋴⼔㧦ၯ₹㧘ߔ߯߆ᦠᚱ㧧2007 ᐕ㧚⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 ✎⽾ᚑ᣿㧘㈬੗㇚ሶ㧘ኹౝ⧷⌀㧚ᕆᕈᦼ∛㒮ߦ߅ߌࠆߖࠎᅦࠤࠕߩᡷༀߣࠪࠬ࠹ࡓൻ ⥄ಽ߆ࠄᄌࠊࠆ㧘੹߆ࠄᄌ߃ࠆ‫ࠎߖޟ‬ᅦࠤࠕ‫ߩޠ‬⠨߃ᣇ㧘⋴⼔▤ℂ 2007 ᐕ㧧17 Ꮞ㧦566㧙573㧚
✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 Ꮉ㦮᥍ਭ㧘ᧁ᧛ብ᮸㧘દ⮮ ⡡㧘⷏ᧄ ⵨㧘ᨋ ᶈਯ㧘ᩕᨑ⵨ᢥ㧚ᚻᜰ࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦᡰេࠪࠬ࠹ࡓ
ߩ⎇ⓥ(╙ 1 ႎ㧘᭎ᔨߣ 1 ଀⹜㛎ႎ๔)㧘ᣣᧄᯏ᪾ቇળ⺰ᢥ㓸 2006 ᐕ㧧720㧙C㧦228㧙233㧚
2㧕 ዊᨋノਯ㧘↰᧛ື༹㧘ㅦ᳓ᖗ㧘⷏ᧄ⵨㧚ࠗࡦࡈࠜ࡯ࡓ࠼㨯ࠦࡦ࠮ࡦ࠻ߩߚ߼ߩ࠲ࡉ࡟࠶࠻ PC ೑↪ࠪࠬ࠹ࡓߩ㐿⊒㧘ක≮ᖱႎቇ 26 ࿁ㅪวᄢળ⺰ᢥ㓸 2006 ᐕ㧧577㧙578㧚
3㧕 ᨋ㓶ੑ㇢㧘↰᧛ື༹㧘ㅦ᳓ᖗ㧘⷏ᧄ⵨㧚࠺ࠫ࠲࡞ࡍࡦߣᢥሼ⹺⼂ࠍ↪޿ߚ⋴⼔Ꮷࡔࡕᦠ߈ᡰេࠪࠬ࠹ࡓߩ
㐿⊒㧘ක≮ᖱႎቇ 26 ࿁ㅪวᄢળ⺰ᢥ㓸 2006 ᐕ㧧967㧙970㧚
4㧕 ᳗੗ኼᒎ㧘┻ౝ⊓⟤ሶ㧘⍫㊁ᱜሶ㧚ࡄࡦࡈ࡟࠶࠻ᣇᑼߣ CAI ᣇᑼߦࠃࠆ⢗ಾ㒰ᖚ⠪߳ߩ㘩੐ᜰዉߩലᨐߦ㑐ߔࠆᲧセ⎇ⓥ㧘ᣣᧄ⋴⼔⎇ⓥቇળ㔀⹹ 2007 ᐕ㧧30 Ꮞ㧦23㧙30㧚
5㧕 ᄢፉᐽม㧘ਃቛᥓ㧘ᷡ᳓సᤨ㧘ᄢ㊁⾆ᢅ㧘⷏ᧄ⵨㧚㛽ේ⊒ⴊ▤⡺⣲ߩ৻೬ᬌ଀ ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ
⑼ቇળ㔀⹹ 2007 ᐕ㧧50 Ꮞ㧦463㧙464㧚
6㧕 ⑔↰┨ੑ㧘ᄢ㊁⾆ᢅ㧘⷏ᧄ⵨㧘ᷡ᳓సᤨ㧚⿷⢛ߦ⊒↢ߒߚ⍹Ἧൻࠍ઻ߞߚᏂᄢߥⴊ▤ᐔṖ╭⣲ߩ৻଀㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧50 Ꮞ㧦515㧙516㧚
7㧕 ᳗㊁ᤘੳ㧘ᄢ㊁⾆ᢅ㧘⷏ᧄ⵨㧘ጊ↰৻ᚑ㧘ᷡ᳓సᤨ㧚㛽ᄖᕈ㛽⡺⣲ߩ 1 ೬ᬌ଀ ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ
⑼ቇળ㔀⹹ 2007 ᐕ㧧50 Ꮞ㧦525㧙526㧚
8㧕 ᄢ㊁⾆ᢅ㧘ᄢፉᐽม㧘ᷡ᳓సᤨ㧘⷏ᧄ⵨㧚ੱᎿ㛽ࠍ↪޿ߚ⦟ᕈ㛽⣲≌ߩⴚᓟᚑ❣㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂ
ᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧50 Ꮞ㧦627㧙628㧚㧙㧙9㧕 ᮮ↰ᴦ㧘ᄢ㊁⾆ᢅ㧘ᄢ㊁⟵ᐘ㧘ᷡ᳓సᤨ㧘⷏ᧄ⵨㧘ᑝἑༀା㧘᧻᳗⎇๋㧚ᄢ⣽エㇱ⣲≌ߩ৻଀㧘᧲ᶏ㛽エㇱ⣲≌ 2007 ᐕ㧧19 Ꮞ㧦1㧙2㧚
10㧕 ᄢፉᐽม㧘ᢧ⮮ḩ㧘ᄢ㊁⟵ᐘ㧘ᷡ᳓సᤨ㧘ᄢ㊁⾆ᢅ㧘⷏ᧄ⵨㧘㜞⷗⑲৻㇢㧘᧻᳗⎇๋㧘ᑝἑༀା㧚ᏀᲚㇱ⣲≌ߩ৻଀㧘᧲ᶏ㛽エㇱ⣲≌ 2007 ᐕ㧧19 Ꮞ㧦37㧙38㧚
11㧕 Ꮉ㦮᥍ਭ㧘ᩕᨑ⵨ᢥ㧘ጤ᧛⌀੐㧘◉ፒ᣽ੱ㧘ᧁ᧛ብ᮸㧘⷏ᧄ⵨㧘દ⮮⡡㧚ࡃ㧙࠴ࡖ࡞࡝ࠕ࡝࠹ࠖࠍᔕ↪ߒߚᚻᜰ࡝ࡂࡆ࡝࠹㧙࡚ࠪࡦᡰេࠪࠬ࠹ࡓߩ⎇ⓥ㧘VR කቇ 2007 ᐕ㧧5 Ꮞ㧦32㧙39㧚
12㧕 ⷏ᧄ⵨㧘᧻↰ᅢ⟤㧘ᧄ㑆ජᕺ⟤㧘ጊ⾐ኡ㧘ᷰㄝ㇚㓶㧚┹ᛛࠬࡐ㧙࠷ߦ߅ߌࠆ⋴⼔Ꮷߩᓎഀ㧦࿖૕ㆬᚻߥߤ
ߦኻߔࠆࠕࡦࠤ㧙࠻⺞ᩏߦࠃࠆᬌ⸛㧘ጘ㒂ᄢቇකቇㇱ♿ⷐ 2008 ᐕ㧧9 Ꮞ㧦1㧙16㧚
13㧕 ┻ౝ⊓⟤ሶ㧘᧻↰ᅢ⟤㧘㜟ᯅ↱⿠ሶ㧘ኹౝ⧷⌀㧘⷏ᧄ⵨㧘ዊỈ๺ᒄ㧘ጟᧄᕺ㉿㧚⥃ᐥ⋴⼔ታ〣⢻ജࠍ㜞߼ࠆ Web ᢎ᧚ߩㆬቯߣ⋴⼔ᢎ⢒ᡰេࠪࠬ࠹ࡓߩ᭴▽ߦ㑐ߔࠆ⎇ⓥ㧘ጘ㒂ᄢቇකቇㇱ♿ⷐ 2008 ᐕ㧧9 Ꮞ㧦
17㧙25㧚
14㧕 ኹౝ⧷⌀㧘✎⽾ᚑ᣿㧘┻ౝ⊓⟤ሶ㧘ᄢᴧᛔਭሶ㧘᧻↰ᅢ⟤㧘㜟ᯅ↱⿠ሶ㧚⸻≮⸥㍳߆ࠄߺߚⴚᓟߖࠎᅦࠤ
ࠕ࡮ࠕ࡞ࠧ࡝࠭ࡓߩ⥃ᐥ⊛᦭↪ᕈߩ੍஻⊛ᬌ⸽㧘ጘ㒂ᄢቇකቇㇱ♿ⷐ 2008 ᐕ㧧55 Ꮞ㧦26㧙31.
15㧕 ᧻↰ᅢ⟤㧘┻ౝ⊓⟤ሶ㧘ኹౝ⧷⌀㧘㜟ᯅ↱⿠ሶ㧚ᣣᧄ⺆ NEECHAM ᷙੂ/㍲ੂ⁁ᘒ⁁ᘒࠬࠤ㧙࡞ߩ᦭↪
ᕈ㧘ጘ㒂ᄢቇකቇㇱ♿ⷐ 2008 ᐕ㧧55 Ꮞ㧦32㧙42㧚
16㧕 㜟ᯅ↱⿠ሶ㧘᧻↰ᅢ⟤㧘┻ౝ⊓⟤ሶ㧘ട⮮⋥᮸㧚AIMS㧙Gifu ቇ⠌ᡰេࠪࠬ࠹ࡓߦࠃࠆ⏕⹺࠹ࠬ࠻ࠍ೑↪
ߒߚⴚ೨ᜰዉ↪ࠦࡦࡇࡘ㧙࠲ᢎ᧚ߩቇ⠌ലᨐ㧘ᣣᧄක≮ᖱႎቇળ⋴⼔ቇⴚᄢળ⺰ᢥ㓸 2008 ᐕ㧧9 Ꮞ㧦50
㧙53㧚
17㧕 㜟ᯅ↱⿠ሶ㧘ട⮮⋥᮸㧘᧻↰ᅢ⟤㧚ⴚ೨ᜰዉ↪ࠦࡦࡇࡘ㧙࠲ᢎ᧚ߩ㐿⊒ߣᛛⴚṶ⠌ߩ⹏ଔ㧘ጘ㒂ᄢቇࠞ࡝ࠠࡘ࡜ࡓ㐿⊒⎇ⓥ 2008 ᐕ㧧25 Ꮞ㧦65㧙71㧚
18㧕 ⍹᭒ᐽᒾ㧘Ꮉፒ᥍ਭ㧘⷏ᧄ⵨㧘቟୚ၮᐘ㧚ᚻᜰ਄⢇࡝ࡂࡆ࡝ᡰេࠪࠬ࠹ࡓߩ᭎ⷐߣ੹ᓟߩ੐ᬺዷ㐿㧚ࡠࡏ࠶࠻㧘2008 ᐕ㧧185 Ꮞ㧦17㧙23㧚
19㧕 ⍹ਣᄢ࿾㧘ᄢ㊁⾆ᢅ㧘ዊᎹኡᕶ㧘⷏ᧄ⵨㧘ᷡ᳓సᤨ㧚ᓟ㗖ㇱߦ⊒↢ߒߚ infantile fibromatosis ߩ৻଀㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2008 ᐕ㧧51 Ꮞ㧦93㧙94㧚
20㧕 ᄢ㊁⾆ᢅ㧘ᄢፉᐽม㧘ᷡ᳓సᤨ㧘⷏ᧄ⵨㧚㘃㛽㛽⣲ߦኻߔࠆ CT ࠟࠗ࠼ਅ࡜ࠫࠝᵄ὾ἳⴚߦࠃࠆૐଚⷅᚻ
ⴚߩ⚻㛎㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2008 ᐕ㧧51 Ꮞ㧦913㧙914㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Futani H㧘Minamizaki T㧘Nishimoto Y㧘Abe S㧘Yabe H㧘Ueda T㧚Long-Term Follow-up After Limb
Salvage in Skeletally Immature Children with a Primary Malignant Tumor of the Distal End of the
Femur. J Bone Joint Surg Am. 2006;88:595-603.
2㧕 Kawasaki H, Ito S, Ishigure Y, Nishimoto Y, Aoki T, Mouri T, Sakaeda H, Abe M. Development ofHand Motion Assist Robot for Rehabilitation Therapy by Patient Self-Motion Control. Proceedings ofInternational Conference on Robot Rehabilitation. (ICORR2007), 234-240.
3㧕 Mouri T, Kawasaki H, Nishimoto Y, Aoki T, Ishigure Y. Development of Robot Hand for Therapist
Education/Training on Rehabilitation. Proceedings of the 2007 IEEE/RSJ International Conference onIntelligent Robots and Systems (IROS2007), 2295-2300.
4㧕 Mouri T, Kawasaki H, Aoki T, Nishimoto Y, Ito S, Ueki S. Tele-rehabilitation for Fingers and Hand.
Proceedings of the 15th International Conference on Automatic Control. 2008,965-967.

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦᧻↰ᅢ⟤㧘⎇ⓥಽᜂ⠪㧦ዊୖ⌀ᴦ㧘ኹౝ⧷⌀㧘┻ౝ⊓⟤ሶ㧘㜟ᯅ↱⿠ሶ㧧⑼ቇ⎇ⓥ⵬
ഥ㊄ၮ⋚⎇ⓥ(C)㧦ᢇᕆ⋴⼔ߦ߅ߌࠆ⋴⼔ታ〣⢻ജߩะ਄ࠍ⋡⊛ߣߒߚࠦࡦ࠹ࡦ࠷෸߮ᢎ᧚㐿⊒ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 17㧙18 ᐕᐲ㧧3,400 ජ౞(2,200㧦1,200 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦㜟ᯅ↱⿠ሶ㧘⎇ⓥಽᜂ⠪㧦┻ౝ⊓⟤ሶ㧘᧻↰ᅢ⟤㧘⷏ᧄ⵨㧘ട⮮⋥᮸㧧⑼ቇ⎇ⓥ⵬ഥ
㊄ၮ⋚⎇ⓥ(C)(2)㧦⥃ᐥ⋴⼔ታ〣⢻ജࠍ㜞߼ࠆⴚ೨ᜰዉ↪ Web ᢎ᧚㐿⊒ߣ E ࡜࡯࠾ࡦࠣᵴ↪ߦࠃࠆቇ⠌ലᨐ㧧ᐔᚑ 17㧙19 ᐕᐲ㧧2,200 ජ౞(1200㧦500㧦500 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦ኹౝ⧷⌀㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦ᔃ⤳ⴊ▤ᄖ⑼㗔ၞߩᚻⴚᖚ⠪ߦ߅ߌࠆⴚᓟ
ߖࠎᅦ⊒∝੍᷹ߦ㑐ߔࠆၮ␆⊛⎇ⓥ㧧ᐔᚑ 17㧙19 ᐕᐲ㧧2,500 ජ౞(900㧦900㧦700 ජ౞)
4㧕 ⎇ⓥઍ⴫⠪㧦᧻↰ᅢ⟤㧦ጘ㒂ᄢቇᵴᕈൻ⚻⾌(ᢎ⢒)㧦ᢇᕆ⋴⼔(ቇㇱ᝼ᬺ⑼⋡)ᕆᕈᦼ⋴⼔ᣇᴺΣ(ቇㇱ᝼ᬺ⑼⋡)ᢇᕆක≮ߣ⋴⼔(ᄢቇ㒮᝼ᬺ⑼⋡)㧧ᐔᚑ 19 ᐕᐲ㧧480 ජ౞5㧕 ⎇ⓥઍ⴫⠪㧦᧻↰ᅢ⟤㧘⎇ⓥಽᜂ⠪㧦ኹౝ⧷⌀㧘┻ౝ⊓⟤ሶ㧘㜟ᯅ↱⿠ሶ㧧⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦CAI ᢎ᧚ࠍ೑↪ߒߚᔃ⢖⯃↢ᴺߩ⍮⼂࡮ᛛⴚ࡮ታᣉ߳ߩᗧᕁߩ଻ᜬ࡮ᒝൻߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 19㧙21 ᐕᐲ㧧3,100 ජ౞(2,000㧦600㧦500 ජ౞)
6㧕 ⎇ⓥઍ⴫⠪㧦┻ౝ⊓⟤ሶ㧘⎇ⓥಽᜂ⠪㧦᧻↰ᅢ⟤㧘㜟ᯅ↱⿠ሶ㧘ዊỈ๺ᒄ㧧⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦ታ〣ജߩะ਄ࠍ߼ߑߒߚⴚᓟ⋴⼔↪ࠦࡦࡇࡘ࡯࠲ᢎ᧚ߩቇ⠌ലᨐ෸߮୘ੱ․ᕈߣߩ㑐ଥ㧧
ᐔᚑ 18㧙20 ᐕᐲ㧧2,480 ජ౞(1,000㧦780㧦700 ජ౞)
7㧕 ⎇ⓥઍ⴫⠪㧦᧻↰ᅢ⟤㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌(ᢎ⢒)㧦ᢇᕆ⋴⼔(ቇㇱ᝼ᬺ⑼⋡)ᕆᕈᦼ⋴⼔ᣇᴺΣ(ቇㇱ㧙㧙᝼ᬺ⑼⋡)ᢇᕆක≮ߣ⋴⼔(ᄢቇ㒮᝼ᬺ⑼⋡)↢ᵴ࡮๮ߣ⋴⼔(ోቇ౒ㅢᢎ⢒)㧧ᐔᚑ 20 ᐕᐲ㧧470 ජ౞8㧕 ⎇ⓥઍ⴫⠪㧦ጟᧄᕺ㉿㧘⎇ⓥಽᜂ⠪㧦┻ౝ⊓⟤ሶ㧘㊄Ỉኡ᣿㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦
ࡈࠖࠫࠞ࡞ࠕ࠮ࠬࡔࡦ࠻↪ PC ᢎ᧚ߩ㐿⊒ߣᵴ↪෸߮⋴⼔ᛛⴚṶ⠌ߦࠃࠆቇ⠌ലᨐߩᬌ⸽㧧ᐔᚑ 19
㧙21 ᐕᐲ㧧2,200 ජ౞(1,000㧦700㧦500 ජ౞)
2㧕ฃ⸤⎇ⓥ
1㧕 ⎇ⓥઍ⴫⠪㧦⮮ᳯᱜస㧘Ꮉ㦮᥍ਭ㧘⎇ⓥಽᜂ⠪㧦㊁↰ඳ㧘ਅ᧛ዏਯ㧘ᩕᨑ⵨ᢥ㧘⷏ᧄ⵨㧘቟୚ၮᐘ㧦ᣂࠛࡀ࡞ࠡ࡯࡮↥ᬺᛛⴚ✚ว㐿⊒ᯏ᭴ ੱ㑆ᡰេဳࡠࡏ࠶࠻ታ↪ൻၮ⋚ᛛⴚ㐿⊒੐ᬺ㧘ࠗࡔ࡯ࠫ࠻
࡟࡯࠾ࡦࠣᯏ⢻ઃ߈ᚻᜰ਄⢇࡝ࡂࡆ࡝ᡰេࠪࠬ࠹ࡓߩ⎇ⓥ㐿⊒㧧ᐔᚑ 17㧙19 ᐕᐲ㧧7,580 ජ౞(328㧦
4,854㧦2,398 ජ౞)㧦ਣን♖Ꮏ(ᩣ)
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬ
┻ౝ⊓⟤ሶ㧦
1㧕 ᣣᧄ⋴⼔⎇ⓥቇળ⹏⼏ຬ(ᐔᚑ 19 ᐕᐲ)
2㧕 ᣣᧄ⋴⼔⑼ቇቇળ⹏⼏ຬ(ᐔᚑ 20 ᐕᐲ)⷏ᧄ ⵨㧦
1㧕 ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄᢛᒻᄖ⑼ቇળઍ⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳┻ౝ⊓⟤ሶ㧦
1㧕 ਻Ꮊᄢቇ⃻ઍ GP ࠪࡦࡐࠫ࠙ࡓ(ᐔᚑ 18 ᐕ 11 ᦬㧘⑔ጟ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻‫ޟ‬ක≮♽ߩᢎ⢒ߦ߅ߌࠆe-࡜࡯࠾ࡦࠣߩ⃻⁁ߣᧂ᧪‫ޠ‬Ṷ⠪)
2㧕 ╙ 17 ࿁ᣣᧄ⋴⼔ቇᢎ⢒ቇળቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 8 ᦬㧘⑔ጟ㧘ቇળ᜗ᓙ⻠Ṷ‫ޟ‬ᖱႎ␠ળ߇໧߁⋴⼔ၮ␆ᢎ⢒‫ޠ‬Ṷ⠪)⷏ᧄ ⵨㧦
1㧕 ⷏Ớ⥃ᐥᢛᒻᄖ⑼කળ(ᐔᚑ 18 ᐕ 11 ᦬㧘ᄢ၂㧘ᢎ⢒⎇ୃ⻠Ṷ‫ޟ‬㛽㨯エㇱ⣲≌ᴦ≮ߩࠦ࠷ߣ⪭ߣߒⓣ‫ޠ‬Ṷ⠪)2㧕 ╙ 115 ࿁஻ᓟᢛᒻᄖ⑼කળ(ᐔᚑ 20 ᐕ 4 ᦬㧘⑔ጊ㧘⻠Ṷ‫ޟ‬㛽㨯エㇱ⣲≌㧙⸻ᢿ߆ࠄ㓚ኂ⠪ࠬࡐ࡯࠷߹
ߢ㧙‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേ⷏ᧄ ⵨㧦
1㧕 ጘ㒂⋵␠ળ଻㒾⸻≮ႎ㈽⺧᳞ᦠክᩏᆔຬળክᩏᆔຬ(㨪⃻࿷)2㧕 ጘ㒂⋵૕⢒දળක⑼ቇᆔຬ(ᐔᚑ 19 ᐕ㨪⃻࿷)㧙㧙3㧕 ጘ㒂ഭ௛ዪഭἴ଻㒾⸻≮ද⼏ળᆔຬ(ᐔᚑ 20 ᐕ㨪⃻࿷)᧻↰ᅢ⟤㧦
1㧕 ࿖㓙දജ੐ᬺ࿅(JICA)࠙࠭ࡌࠠࠬ࠲ࡦ⋴⼔ᢎ⢒ᡷༀࡊࡠࠫࠚࠢ࠻߳ኾ㐷ኅߣߒߡෳട(㨪⃻࿷)2㧕 ␠࿅ᴺੱጘ㒂⋵⋴⼔දળ ጘ㒂⋵⋴⼔ᢎຬ㙃ᚑ⻠⠌ળ⻠Ꮷ(ᐔᚑ 19 ᐕ㨪ᐔᚑ 20 ᐕ)┻ౝ⊓⟤ሶ㧦
1㧕 ␠࿅ᴺੱᣣᧄ⋴⼔දળ␹ᚭ⎇ୃ࠮ࡦ࠲࡯ ⹺ቯ⋴⼔Ꮷᢎ⢒⺖⒟⻠Ꮷ(㨪ᐔᚑ 20 ᐕ)
2㧕 ␠࿅ᴺੱጘ㒂⋵⋴⼔දળ ⹺ቯ⋴⼔▤ℂ⠪೙ᐲࡈࠔ࡯ࠬ࠻࡟ࡌ࡞ᢎ⢒⻠Ꮷ(㨪ᐔᚑ 20 ᐕ)
10㧚ႎ๔ᦠ
1㧕 ┻ౝ⊓⟤ሶ㧘᧻↰ᅢ⟤㧘㜟ᯅ↱⿠ሶ㧘᧛ἑᐽ৻㇢㧘ዊỈ๺ᒄ㧦⥃ᐥ⋴⼔ታ〣⢻ജࠍ㜞߼ࠆ Web ᢎ᧚ߩ㐿⊒ߣ⋴⼔ᢎ⢒ᡰេࠪࠬ࠹ࡓߩ᭴▽ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 15 ᐕᐲ㧙17 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)⎇ⓥᚑᨐႎ๔ᦠ㧦1㧙83(2006 ᐕ 3 ᦬)
2㧕 ᧻↰ᅢ⟤㧘┻ౝ⊓⟤ሶ㧘㜟ᯅ↱⿠ሶ㧦ⴚᓟߖࠎᅦߩ੍㒐෸߮ᣧᦼ⊒⷗ࠍ⋡⊛ߣߒߚᣣᧄ⺆ NCS ߩା㗬ᕈ࡮ᅷᒰᕈߩᬌ⸽㧦ᐔᚑ 14 ᐕᐲ㧙16 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)⎇ⓥᚑᨐႎ๔ᦠ㧦1㧙
43(2006 ᐕ 3 ᦬)
3㧕 ᧻↰ᅢ⟤㧦࿖㓙දജ੐ᬺ࿅(JICA)⋴⼔ᢎ⢒ᡷༀࡊࡠࠫࠚࠢ࠻㧦⋴⼔ᢎ⢒ᡷༀࡊࡠࠫࠚࠢ࠻(࠙࠭ࡌࠠࠬ࠲ࡦ౒๺࿖㧘࠲ࠪࠤࡦ࠻)ኾ㐷ኅᬺോቢੌႎ๔ᦠ(ᚑੱ⠧ᐕ⋴⼔)㧦1㧙9(2006 ᐕ 9 ᦬)
4㧕 ᧻↰ᅢ⟤㧦⋴⼔ᢎ⢒ᡷༀࡊࡠࠫࠚࠢ࠻㧦⋴⼔ᢎ⢒ᡷༀࡊࡠࠫࠚࠢ࠻(࠙࠭ࡌࠠࠬ࠲ࡦ౒๺࿖㧘࠲ࠪࠤࡦ࠻)ኾ㐷ኅᬺോቢੌႎ๔ᦠ(ᚑੱ⠧ᐕ⋴⼔)㧦1㧙13㧘(ߘߩ 2)1㧙2(2007 ᐕ 1 ᦬)
5㧕 ᧻↰ᅢ⟤㧦࿖㓙දജ੐ᬺ࿅(JICA)⋴⼔ᢎ⢒ᡷༀࡊࡠࠫࠚࠢ࠻㧦⋴⼔ᢎ⢒ᡷༀࡊࡠࠫࠚࠢ࠻(࠙࠭ࡌࠠࠬ࠲ࡦ౒๺࿖㧘࠲ࠪࠤࡦ࠻)ኾ㐷ኅᬺോቢੌႎ๔ᦠ(ᚑੱ⠧ᐕ⋴⼔)㧦1㧙4(2007 ᐕ 4 ᦬)
6㧕 ♿ࡁቯ଻⤿㧘᪢ᧄᢘᄦ㧘⊕㠽⟵ቬ㧘┻ౝ⊓⟤ሶ㧦ᰴ਎ઍဳ㔚ሶࠞ࡞࠹ࠪࠬ࠹ࡓߦࠃࠆ⸻≮Ꮏ⒟࡮∛㒮ㆇ༡Ꮏ⒟ߩ⛔วಽᨆⅣႺߩ᭴▽ߣ⸃ᨆ㧘ᐔᚑ 17 ᐕᐲ㧙18 ᐕᐲᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ᚑᨐႎ๔ᦠၮ⋚⎇ⓥ(B)(2007 ᐕ 3 ᦬)
7㧕 ଻૑ഞ㧘›Ⴆ⾆㧘↰ਛఝม㧘ᧁ᧛ᥙᄦ㧘㜞↰⍮ੑ㧘┻ౝ⊓⟤ሶ㧘ጟᧄᕺ㉿㧦㔍∛ᖚ⠪ߩ࠾࡯࠭ߦㆡ
วߒߚ IT ᯏེߩᵴ↪ߣᔃߩࠤࠕߦ㑐ߔࠆࡀ࠶࠻ࡢ࡯ࠢߩ᭴▽㧘ᐔᚑ 17 ᐕᐲ㧙18 ᐕᐲᢥㇱ⑼ቇᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ᚑᨐႎ๔ᦠ ⪚⧘⎇ⓥ(2007 ᐕ 3 ᦬)
8㧕 ᧻↰ᅢ⟤㧘ዊୖ⌀ᴦ㧘ኹౝ⧷⌀㧘┻ౝ⊓⟤ሶ㧘㜟ᯅ↱⿠ሶ㧦ᢇᕆ⋴⼔ߦ߅ߌࠆ⋴⼔ታ〣⢻ജߩะ਄ࠍ⋡⊛ߣߒߚࠦࡦ࠹ࡦ࠷෸߮ᢎ᧚㐿⊒ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 17 ᐕᐲ㧙18 ᐕᐲᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ
㊄ၮ⋚⎇ⓥ(C) ⎇ⓥᚑᨐႎ๔ᦠ㧦1㧙61(2008 ᐕ 3 ᦬)
9㧕 㜟ᯅ↱⿠ሶ㧘┻ౝ⊓⟤ሶ㧘᧻↰ᅢ⟤㧘⷏ᧄ⵨㧘ട⮮⋥᮸㧦⥃ᐥ⋴⼔ታ〣឴ജࠍ㜞߼ࠆⴚ೨ᜰዉ↪ Webᢎ᧚㐿⊒ߣ E ࡜࡯࠾ࡦࠣᵴ↪ߦࠃࠆቇ⠌ലᨐ㧦ᐔᚑ 17 ᐕᐲ㧙19 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄(ၮ⋚⎇ⓥ(C))⎇ⓥᚑᨐႎ๔ᦠ㧦1㧙45(2008 ᐕ 3 ᦬)
10㧕 ᧻↰ᅢ⟤㧦ᢇᕆ⋴⼔(ቇㇱ᝼ᬺ⑼⋡)ᕆᕈᦼ⋴⼔ᣇᴺΣ(ቇㇱ᝼ᬺ⑼⋡)ᢇᕆක≮ߣ⋴⼔(ᄢቇ㒮᝼ᬺ⑼⋡)㧦ᐔᚑ 19 ᐕᐲጘ㒂ᄢቇᵴᕈൻ⚻⾌(ᢎ⢒)ᚑᨐႎ๔ᦠ㧦1㧙4(2008 ᐕ 12 ᦬)
11㧚ႎ㆏1㧕 ⷏ᧄ⵨㧦⎇ⓥቶ߆ࠄ㧘ᄢቇߪ޿߹ 㧙ᄢಾߥᕆᕈᦼߩ࡝ࡂࡆ࡝㧙㧦ጘ㒂ᣂ⡞(2006 ᐕ 6 ᦬ 20 ᣣ)
2㧕 ┻ౝ⊓⟤ሶ㧦‫ޠ⼔⋴ߩࠎ߇੃ޟ‬಴ጘ㒂ᄢකቇㇱᢎ᝼ ᖚ⠪ߩᚻ⸥ၮߦ⸃⺑㧦ጘ㒂ᣂ⡞(2007 ᐕ 10
᦬ 20 ᣣ)3㧕 ┻ౝ⊓⟤ሶ㧦࡜ࠫࠝࠗࡦ࠲ࡆࡘ࡯ ੃߇ࠎ㧦ጘ㒂᡼ㅍ(2007 ᐕ 10 ᦬ 30 ᣣ)
4㧕 ┻ౝ⊓⟤ሶ㧦੃߇ࠎߩᣧᦼ⊒⷗ߦᓎ┙ߡߡ㧦ർᣣᧄᣂ⡞(2007 ᐕ 10 ᦬ 31 ᣣ)
5㧕 ᧻↰ᅢ⟤㧦⎇ⓥቶ߆ࠄ㧘ᄢቇߪ޿߹ 㧙ᔃ⢖⯃↢ᴺߩᢎ⢒ߦജ㧙㧦ጘ㒂ᣂ⡞(2008 ᐕ 4 ᦬ 8 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔ
ߎߩ 3 ᐕ㑆ߪฦ⥄߇ߘࠇߙࠇ⎇ⓥ࠹࡯ࡑࠍᜬߜ㧘ዋߥ޿ߥ߇ࠄ⎇ⓥ⾗㊄ࠍ₪ᓧߒ㧘ಽ㊁ో૕ߢදജߒ
ߥ߇ࠄ⎇ⓥࠍታ〣ߒߡ߈ߚ‫✚ޕ‬ว⊛⹏ଔߣߒߡ߅߅߻ߨ⋡ᮡࠍ㆐ᚑߢ߈ߚߣ⠨߃ߡ޿ࠆ‫ߒ߆ߒޕ‬㧘ᐔᚑ
20 ᐕ 3 ᦬ߢ 2 ฬߩಽ㊁ࡔࡦࡃ࡯߇⒖☋ߒߚߚ߼㧘ᣂߒ޿ࡔࡦࡃ࡯ߣ౒ߦ⎇ⓥᵴേߩᦝߥࠆዷ㐿ࠍഃㅧߔࠆᔅⷐ߇޽ࠆ‫ޕ‬㧙㧙⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷⃻࿷ᕆᕈᦼ⋴⼔ಽ㊁ࡔࡦࡃ࡯ߪ 4 ฬߢ޽ࠆ߇㧘㑐ᔃ㗔ၞ߇ᄙጘߦࠊߚߞߡ߅ࠅ㧘ಽ㊁ߣߒߡߩ౒ㅢ࠹
࡯ࡑߦᴪߞߚ⎇ⓥᵴേ߇ૐㅅߒߡ޿ࠆ‫ޕ‬ฦ‫ߩޘ‬ኾ㐷ᕈࠍ↢߆ߒߚ౒ห⎇ⓥࠍផㅴߒߡ޿ߊ੍ቯߢ޽ࠆ‫ޕ‬੹ᓟߩዷᦸࠦࡦࡇࡘ࡯࠲ᢎ᧚ߩ㐿⊒࡮ᡷ⦟㧘ᢎ⢒ലᨐߩᬌ⸽ࠍ⛯ⴕߔࠆߣ౒ߦ㧘ฦࡔࡦࡃ࡯ߘࠇߙࠇߩ⎇ⓥ࠹࡯
ࡑߢߩᵴേࠍⴕߞߡ޿ߊ‫ޕ‬ฦ‫ߩޘ‬ኾ㐷ᕈࠍ⠨߃ࠆߣᣂࡔࡦࡃ࡯ߩ৻ੱߪᎿቇ♽ߦᒝߊࠦࡦࡇࡘ࡯࠲ᢎ᧚
⎇ⓥ╬ߩផㅴ߇ᦼᓙߢ߈ࠆ‫ߚ߹ޕ‬㧘✚วᄢቇߢ޽ࠆߎߣකቇㇱߦ૬⸳ߐࠇߚ⋴⼔ቇ⑼ߢ޽ࠆߎߣߩ೑ὐ
ࠍ↢߆ߒ㧘ઁቇㇱߣߩ౒ห⎇ⓥࠍᮨ⚝ߒߡ޿ߊ‫ߦ․ޕ‬කቇ⎇ⓥ⑼࡮㒝ዻ∛㒮㧘ࠦࡦࡇࡘ࡯࠲ᢎ᧚૞ᚑߦ
߅޿ߡߪᢎ⢒ቇㇱ╬ߣߩ౒ห⎇ⓥࠍផㅴߒߡ޿߈ߚ޿‫ޕ‬㧙㧙㧔3㧕⠧ᐕ⋴⼔ቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
⠧ᐕ⋴⼔ቇಽ㊁ߢߪ㧘⿥㜞㦂ൻᤨઍߦ⓭౉ߒߟߟ޽ࠆᤨઍߦ߅޿ߡ㧘୘ੱ߿ኅᣖߩଔ୯ⷰߩᄙ᭽ᕈࠍ〯߹߃ߚ㜞㦂⠪ߩᡰេ߿ஜᐽߩ⛽ᜬ߇㊀ⷐߥ໧㗴ߣ⠨߃ߡ޿ࠆ‫ޕ‬⎇ⓥ࠹࡯ࡑߣߒߡߪ㧘‫↢޿ߒࠄੱߩߘޟ‬ᵴߩ⛽ᜬ‫ߩ߳ޠ‬ᡰេࠍၮ⋚ߣߒߡ‫ࠆߡ߽ޟ‬ജ‫ࠍޠ‬㊀ⷞߒ㧘QOL
ࠍ⛽ᜬ࡮ะ਄ߔࠆߚ߼ߩᣇ╷ߦ㑐ߔࠆ⎇ⓥࠍⴕߞߡ޿ࠆ‫ޕ‬⋴⼔ᢎ⢒ߦ㑐ߔࠆ⎇ⓥߣߒߡߪ㧘ቇ↢ߩታ〣ᔕജߩะ਄ࠍᗧ࿑ߒ㧘ߣߊߦ޽ࠅߩ߹߹ߩ㜞㦂⠪ࠍℂ⸃ߒ
ታ〣ߔࠆߚ߼ߩⷞὐߣߒߡ㧘‫ࠆߡ߽ޟ‬ജ‫ࠍޠ‬ᗧ⼂⊛ߦⷰࠆߎߣ߇ߢ߈ࠆߚ߼ߩᣇ╷ߣߒߡߩ⥃࿾ታ⠌ߦ㑐ߔࠆ⎇ⓥࠍⴕߞߡ޿ࠆ‫ߚ߹ޕ‬㧘ᄢቇ㒮ߦ㑐ߔࠆౝኈߣߒߡ㧘තᓟ⛮⛯ᢎ⢒ߦ߅ߌࠆᛛⴚ⠌ᓧߦ㑐ߔࠆߎߣ߿㧘⋴⼔ᢎ⢒೙ᐲߦ㑐ߔࠆ⎇ⓥߦ߽ขࠅ⚵ࠎߢ޿ࠆ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
ಎᢎ᝼㧦
ഥᢎ㧦
ഥᢎ㧦

▘ᶆߣ߈ሶ
᧻ᵄ⟤♿
᷷᳓ℂ૫
ศᎹ⟤଻

Tokiko Minoura
Miki Matsunami
Rika Nukumizu
Miho Yoshikawa

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ↢㊁❥ሶ㧘ၔࡩ┵ೋሶ㧘▘ᶆߣ߈ሶઁ㧚⋴⼔࡮੺⼔ߩߚ߼ߩၮᧄ߆ࠄቇ߱㜞㦂⠪ࠤࠕ㧘੩ㇺ㧦㊄⧐ၴ㧧2006
ᐕ㧦157㧙165㧘183㧙193㧚
2㧕 㒙ㇱ⧐ᳯ㧘㑐ᚭᅢሶ㧘▘ᶆߣ߈ሶઁ㧚㜞㦂⠪ࠤࠕ‫⇼ޟ‬໧ߔߞ߈ࠅ‫ޠ‬ଢ೑੐ౖ㧙࿷ቛ✬㧙㧘੩ㇺ㧦㊄⧐ၴ㧧
2006 ᐕ㧦53㧙58㧚
3㧕 㒙ㇱ⧐ᳯ㧘▘ᶆߣ߈ሶ㧘᧻ᵄ⟤♿ઁ㧚㜞㦂⠪ࠤࠕ‫⇼ޟ‬໧ߔߞ߈ࠅ‫ޠ‬ଢ೑੐ౖ㧘੩ㇺ㧦㊄⧐ၴ㧧2006 ᐕ㧦93
㧙98㧘171㧙174㧚
4㧕 ૒⮮⊓⟤㧘▘ᶆߣ߈ሶ㧚⋴⼔ቇ᭎⺰㧘᧲੩㧦ࡔ࠺ࠖࠞ࡞ࡈ࡟ࡦ࠼␠㧧2006 ᐕ㧦107㧙181㧚
5㧕 ጊ᧛␆㧘ൎ㊁ߣࠊሶ㧘▘ᶆߣ߈ሶઁ㧚࠽࡯ࠪࡦࠣࠣ࡜ࡈࠖࠞ ၮ␆⋴⼔ቇ ၮ␆⋴⼔ᛛⴚ ╙ 2 㧘᧲੩㧦ࡔ࠺ࠖࠞ಴ 㧧2008 ᐕ㧦438㧙441㧚
6㧕 ᄢ⷏๺ሶ㧘ᅏ㊁⨃ઍ㧘▘ᶆߣ߈ሶ㧘㜞ᯅᵏሶઁ㧚⠧ᐕ⋴⼔ᛛⴚ㧘᧲੩㧦࠿࡯ࡌ࡞ࡅࡠࠞࡢ㧧2008 ᐕ㧦36
㧙41㧚⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 ▘ᶆߣ߈ሶ㧘᧻ᵄ⟤♿㧘᷷᳓ℂ૫㧘ศᎹ⟤଻㧚㜞㦂ᖚ⠪ߐࠎ߳ߩኻᔕߣࠤࠕ㧘ࡊ࠴࠽࡯ࠬ 2006 ᐕ㧧15
Ꮞ㧦35㧙49㧚✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ⷏ጊᥓᤐ㧘ᄢቶᓞሶ㧘▘ᶆߣ߈ሶઁ㧚⋴⼔ቇߩᢎ⑼ᦠ࡮ෳ⠨ᦠߦߺࠆ‫ޟ‬ዊఽߩ㘩੐េഥ‫ޠ‬ᢎ⢒ౝኈߩಽᨆ㧘᩿↢⍴ᦼᄢቇ♿ⷐ 2006 ᐕ㧧17 Ꮞ㧦203㧙207㧚
2㧕 ᧻ᵄ⟤♿㧘▘ᶆߣ߈ሶ㧘᷷᳓ℂ૫㧘ศᎹ⟤଻㧚㜞㦂ᖚ⠪ߩ̌ᜬߡࠆജ̍ߩᵴ↪ࠍᒝ⺞ߒߚ⠧ᐕ⋴⼔ቇታ⠌ߩᬌ⸛㧙ታ⠌⸥㍳ߩಽᨆ߆ࠄ㧙㧘⠧ᐕ⋴⼔ቇ 2008 ᐕ㧧12 Ꮞ㧦60㧙67㧚
3㧕 ᧻ᧄᐘᨑ㧘Ꮣᣉජ⨲㧘▘ᶆߣ߈ሶ㧘໊ᴛᴰ㧘ဈ↰੖᦬㧘ᄢቶᓞሶ㧚࿷ቛ⹺⍮㜞㦂⠪ߩᕆᕈᦼߩ౉㒮ߦ߅ߌࠆක≮࡮੺⼔ᡰេ૕೙ߩታᘒ㧙੺⼔ኅᣖߩࠗࡦ࠲ࡆࡘ࡯ࠍߣ߅ߒߡ㧙㧘╙ 38 ࿁ᣣᧄ⋴⼔ቇળ⺰ᢥ㓸㧙࿾ၞ⋴⼔㧙 2008 ᐕ㧦70㧙72㧚
4㧕 ဈ↰੖᦬㧘ᄢቶᓞሶ㧘໊ᴛᴰ㧘Ꮣᣉජ⨲㧘᧻ᧄᐘᨑ㧘▘ᶆߣ߈ሶ㧚ᣂੱ⋴⼔⡯ຬߩ㕒⣂ᵈ኿ᛛⴚߩ⠌ᓧߦᓇ㗀ࠍ෸߷ߔⷐ࿃㧘╙ 38 ࿁ᣣᧄ⋴⼔ቇળ⺰ᢥ㓸㧙⋴⼔▤ℂ㧙 2008 ᐕ㧦71㧙73㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Muto Y, Yoshioka T, Kimura M, Matsunami M, Saya H, Okano Y㧚An evolutionarily conserved
leucine-rich repeat protein CLERC is a sentrosomal protein required for spindle pole integrity. Cell
Cycle. 2008;7:2738-2748㧚
IF 3.314㧙㧙4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦᷷᳓ℂ૫㧘ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦⹺⍮∝㜞㦂⠪ߩ QOL ࠍ㜞߼ࠆߚ߼ߩⵍ᦯ⴕേ߳ߩ੺౉⎇ⓥ㧧ᐔᚑ 19㧙20 ᐕᐲ㧧2,400 ජ౞(1,400㧦1,000 ජ౞)
2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬ
▘ᶆߣ߈ሶ㧦
1㧕 ᣣᧄ⠧ᐕⴕേ⑼ቇળᏱછℂ੐(㨪⃻࿷)᧻ᵄ⟤♿㧦1㧕 ᣣᧄ⋴⼔⸻ᢿቇળ(㨪ᐔᚑ 19 ᐕ 7 ᦬)
2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
▘ᶆߣ߈ሶ㧦
1㧕 ᣣᧄ⠧ᐕⴕേ⑼ቇળ⹹(㨪⃻࿷)2㧕 ᣣᧄ⋴⼔ቇᢎ⢒ળ⹹(ᐔᚑ 18 ᐕ 8 ᦬㨪⃻࿷)7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳▘ᶆߣ߈ሶ㧦
1㧕 ᣣᧄേ‛⋴⼔ቇળ(ᐔᚑ 19 ᐕ 7 ᦬㧘᧲੩㧘᜗ᓙ⻠Ṷ‫ੱޟ‬ක≮ߦቇ߱㧙ߘߩㅴዷ⚻✲ߣ⡯ᬺⷰߦቇ߱࡮
ኅᣖ⋴⼔ቇߣേ‛⋴⼔ቇߩធὐࠍ⠨߃ࠆ㧙‫ޠ‬Ṷ⠪)
2㧕 ᣣᧄ⋴⼔ቇળ ᢎ⢒ಽ⑼ળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘‫⃻ޟ‬ઍ⧯⠪ߩ․ᓽࠍℂ⸃ߒߚ⋴⼔ᢎ⢒‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേ᧻ᵄ⟤♿㧦
1㧕 ጘ㒂Ꮢ⹺⍮∝࿾ၞᡰេ૕೙᭴▽ࡕ࠺࡞੐ᬺ ࠦ࡯࠺ࠖࡀ࡯࠲࡯(ᐔᚑ 19 ᐕᐲ㨪ᐔᚑ 20 ᐕᐲ)
10㧚ႎ๔ᦠߥߒ11㧚ႎ㆏ߥߒ12㧚⥄Ꮖ⹏ଔ
⹏ଔઁᄢቇߩᢎຬߣߩ⎇ⓥ㧘ቇౝߢߩ౒ห⎇ⓥߪ৻ㇱታᣉߒߡ޿ࠆ߇㧘ࠃࠅᄙߊߩ⎇ⓥࠍߔࠆߎߣ߇ᦸ߹
ߒ޿ߣ⠨߃ߡ޿ࠆ‫ߚ߹ޕ‬㧘⠧ᐕ⋴⼔ቇಽ㊁ߣߒߡߩ౒ห⎇ⓥߦ㑐ߒߡ߽㧘߹ߛ߹ߛዋߥ޿⁁ᴫߦ޽ࠆߩ㧙㧙ߢ㧘ߐࠄߦలታߐߖߡ޿ߊᔅⷐ߇޽ࠆߣᕁࠊࠇࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷⠧ᐕ⋴⼔ቇಽ㊁ߩ⥃࿾ታ⠌ߪ 4 ᐕ↢߇೨ᦼ 2 න૏㧘3 ᐕ↢߇ᓟᦼ 2 න૏ߣ㧘ᐕ㑆ࠍߣ߅ߒߡታ⠌߇ⴕࠊࠇߡ޿ࠆ⁁ᴫߦ޽ࠅ㧘⎇ⓥᤨ㑆ߩ₪ᓧ߇࿎㔍ߥ⁁ᴫ߇⛮⛯ߒߡ޿ࠆ‫߼ߚߩߘޕ‬㧘೨ᦼߩታ⠌ᣉ⸳ࠍ 2ࠞᚲ߆ࠄ 4 ࠞᚲߦჇ߿ߒ㧘1 ࡩ᦬㑆ߩ⍴❗ࠍታᣉߔࠆߦᄌᦝߒߚ‫ࠍߣߎߩߘޕ‬฽߼㧘⎇ⓥᚑᨐߦᄙዋߥ
ࠅߣ߽෻ᤋߢ߈ࠆߩߢߪߥ޿߆ߣᦼᓙߒߡ޿ࠆᚲߢ޽ࠆ‫ޕ‬੹ᓟߩዷᦸ⿥㜞㦂␠ળ߇⋡೨ߦㄼߞߡ޿ࠆ⃻࿷㧘㜞㦂⠪⥄りߦ㑐ߔࠆߎߣ߿੺⼔ߦ㑐ߔࠆߎߣߥߤ㧘ක≮࡮⑔␩ߦ߅ߌࠆ⺖㗴߿㧘ዊ࡮ਛቇ↢ࠍ฽߻৻⥸ߩੱ‫ߩޘ‬㜞㦂⠪ߦ㑐ߔࠆ໪⫥ࠍ࿑ࠆߎߣߩᔅⷐᕈ߅ࠃ߮ߘߩᣇ
ᴺߦߟ޿ߡߩ⎇ⓥࠍផㅴߔࠆᔅⷐ߇޽ࠆߣ⠨߃ߡ޿ࠆ‫ߚ߹ޕ‬㧘⹺⍮∝ߦ㑐ߔࠆኻᔕ߽㊀ⷐߥ⺖㗴ߢ޽ࠅ㧘࿾ၞߢߩㅪ៤ࠍߤߩࠃ߁ߦផㅴߒߡ޿ߊ߆߇⺖㗴ߣߒߡ᳞߼ࠄࠇߡ޿ࠆ‫ߚ߹ޕ‬㧘ߎࠇ߹ߢߩ⋴⼔ᢎ⢒೙ᐲߦࠃࠅ⠧ᐕ⋴⼔ቇࠍቇ໧ߣߒߡቇࠎߢ޿ߥ޿ක≮ᓥ੐⠪߽ᄙ޿ߎߣ߆ࠄ㧘ߣߊߦ⋴⼔⡯߳ߩ໪⫥ᵴേ߽ታᣉߒ㧘ട߃ߡ࿾ၞ૑᳃ߩᣇ‫ߩ߳ޘ‬໪⫥߽Ⓧᭂ⊛ߦផㅴߔࠆᔅⷐᕈࠍᗵߓߡ޿ࠆ‫ޕ‬
21 ᐕᐲ߆ࠄߪකቇ♽⎇ⓥ⑼⋴⼔ቇኾ᡹ߩࠞ࡝ࠠࡘ࡜ࡓ߇ᄌᦝߦߥࠅ㧘࿾ၞஜᐽេഥቇಽ㊁ߦ‫ޟ‬⠧ᐕ⋴⼔ቇ‫ߪߣߎߩߎޕࠆ޿ߡߞߥߦߣߎࠆࠇࠄߌ߁߽߇ޠ‬㧘ቇㇱߣᄢቇ㒮ߩᢎ⢒ౝኈߩ৻⽾ᕈࠍ࿑ࠆߎߣ߇
ߢ߈ࠆߎߣߦߥࠅ㧘ࠃࠅ⠧ᐕ⋴⼔ቇߦὶὐൻߒߚ⎇ⓥࠍㅴ߼ߡ޿ߌࠆߩߢߪߥ޿߆ߣ⠨߃ߡ޿ࠆ‫ޕ‬㧙㧙ާ࿾ၞ࡮♖␹⋴⼔ቇ⻠ᐳި
㧔1㧕࿾ၞ⋴⼔ቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
ߎࠇ߹ߢߣห᭽㧘ᒰಽ㊁ߦ߅ߌࠆၮ␆⊛㧘ኾ㐷⊛⎇ⓥߪ޿ߕࠇ߽଻ஜක≮ߩಽ㊁ߢ޽ࠆ࿾ၞ଻ஜ㧘↥ᬺ଻ஜ㧘࿷ቛ⋴⼔㧘ቇᩞ଻ஜߥߤߩ⃻႐ߦ┙⣉ߒߡ޿ࠆ߽ߩߢ޽ࠅ㧘ߘߩᚑᨐߪ⃻႐ߩᵴേߦㆶరߐࠇࠆ߽
ߩ߇ᄙ޿‫ߚ߹ޕ‬㧘ߎࠇࠄߩ⎇ⓥߪ㧘ᐢߊ౏ⴐⴡ↢ቇ෸߮⋴⼔ቇߩౝኈߣߘߩ⎇ⓥᚻᴺߦၮߠ޿ߡⴕࠊࠇߡ
޿ࠆ߽ߩߢ޽ࠆ‫⎇ޕ‬ⓥߩ࠹࡯ࡑߪ㧘ዊఽ㧘㕍ᐕ㧘ᚑੱ㧘㜞㦂⠪ߥߤฦᐕઍߦࠊߚࠆੱ‫ࠍޘ‬ኻ⽎ߦߒߚ߽ߩ
ߢ޽ࠅ㧘଀߃߫㧘ዋሶ㜞㦂ൻߩ࿾ၞߦ߅ߌࠆ⢒ఽߦ㑐ߔࠆᲣⷫߩ⥄ഥࠣ࡞࡯ࡊ߿㜞㦂⠪ߩஜᐽჇㅴߦ㑐ߔࠆ࿾ၞࠨࡐ࡯࠻ࠪࠬ࠹ࡓ᭴▽ߩㆊ⒟߿⹏ଔߦ㑐ߔࠆ⎇ⓥߥߤߪ㧘࿾ၞߩ․ᕈߦኻᔕߒߚ౏ⴐⴡ↢⋴⼔ቇߩ
ℂᔨߦၮߠ޿ߚታ〣⊛ߥ⎇ⓥߢ޽ࠆ‫ߚ߹ޕ‬㧘↥ᬺ଻ஜߦ߅ߌࠆஜᐽ▤ℂߦ㑐ߔࠆ⎇ⓥߢߪ㧘ᚑੱࠍਛᔃߣ
ߒߚᐕઍߦ߅ߌࠆஜᐽჇㅴ㧘ஜᐽ㓚ኂ੍㒐ߥߤ∉ቇ⊛ᚻᴺࠍ↪޿ߚ⎇ⓥߢ޽ࠆ‫ߦࠄߐޕ‬㧘⸰໧⋴⼔ߦ߅ߌࠆ⋴⼔⡯ߩ⃻⁁ࠍ࡝ࠬࠢࡑࡀࠫࡔࡦ࠻ߩⷞὐ߆ࠄⴕ߁⎇ⓥߪ㧘⸰໧⋴⼔ߣ޿߁ᣂߚߥ࿾ၞ⋴⼔ቇಽ㊁ߦ߅ߌࠆ⎇ⓥಽ㊁ߢ߽޽ࠆ‫ޕ‬ߎߩࠃ߁ߦ࿾ၞ⋴⼔ቇಽ㊁ߦ߅ߌࠆ⎇ⓥߪ㧘޽ࠄࠁࠆᐕઍߩੱ‫ࠍޘ‬ኻ⽎ߣߒߚ㧘ஜᐽჇㅴ㧘ஜᐽߠߊࠅ㧘∛᳇ߩ੍㒐ߣᣧᣁ⊒⷗࡮ᣧᦼᴦ≮㧘␠ળᓳᏫߣ޿ߞߚᄙ᭽ߥಽ㊁ߦ߅ߌࠆ⎇ⓥ߇ߥߐࠇߡ߅ࠅ㧘੹ᓟ߽᦭⋉ߥታ〣⊛ߥ⎇ⓥᵴൕࠍ⋡ᜰߔ‫ޕ‬㧨ਥߥ⎇ⓥ࠹࡯ࡑ㧪1㧕⡯ၞߦ߅ߌࠆஜᐽ▤ℂߦ㑐ߔࠆ⎇ⓥ
ൻቇ‛⾰ߦࠃࠆஜᐽ㓚ኂ੍㒐ኻ╷㧘ൻቇ‛⾰એᄖߩ⡯ᬺᕈ∔∛ߩ੍㒐ኻ╷㧘૞ᬺ㑐ㅪ∔ᖚ╬ߩ੍㒐ኻ╷ߩ⺖㗴ߦขࠅ⚵ࠎߢ޿ࠆ‫ޕ‬
2㧕࿾ၞ㜞㦂⠪ߩ㐽ߓߎ߽ࠅ੍㒐ߦ㑐ߔࠆ⎇ⓥ
㜞㦂⠪ߪ QOL ߩૐਅ߿ⅣႺ᧦ઙߥߤߦ઻޿㐽ߓߎ߽ࠅ௑ะ߇ߺࠄࠇ㧘ߘߩ⚿ᨐ੺⼔ࠍᔅⷐߣߔࠆ⁁ᘒߦߥࠆࠃ߁ߥ႐ว߽ᄙ޿‫ޕ‬࿾ၞߦ߅ߌࠆ㜞㦂⠪ߩ㐽ߓߎ߽ࠅ੍㒐ߩߚ߼ߩᡰេ╷ߩታᣉߣߘߩ᦭↪ᕈߩᬌ⸽ࠍⴕߞߡ޿ࠆ‫ޕ‬
3㧕଻ஜᏧߩᵴൕ߿㈩⟎ߦ㑐ߔࠆ⎇ⓥ
ਥߦᏒ↸᧛ߩ଻ஜᏧߩᓎഀߣᯏ⢻ߦߟ޿ߡ㧘ⴕ᡽߿␠ળߩᄌൻߣኻᔕߒߡߤߩࠃ߁ߥ⃻⁁ߢ޽ࠆ߆㧘ߤߩ᭽ߥᓎഀ߿ᯏ⢻߇ᦼᓙߐࠇߡ޿ࠆ߆㧘ㆡᱜߥ଻ஜᏧߩ㈩⟎ߪߤߩࠃ߁ߥ߽ߩ߆ߣ޿ߞߚ⎇ⓥࠍⴕߞߡ޿ࠆ‫ޕ‬4㧕⸰໧⋴⼔ࠬ࠹࡯࡚ࠪࡦߦ߅ߌࠆ࡝ࠬࠢࡑࡀࠫࡔࡦ࠻
⸰໧⋴⼔ࠬ࠹࡯࡚ࠪࡦߩ⋴⼔⡯ߩ࡝ࠬࠢߩ⃻⁁ߣኻಣߦ㑐ߔࠆ⎇ⓥࠍⴕ޿㧘⸰໧⋴⼔ߩ⾰ߩะ਄ߦነਈ
ߔࠆߎߣࠍ⋡ᜰߒߡ⎇ⓥߒߡ޿ࠆ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
ᢎ᝼㧦
ಎᢎ᝼㧦
ഥᢎ㧦
ഥᢎ㧦

’㊁⨃ᓼ
ᓟ㑄ኈሶ
⍹ේᄙ૫ሶ
₹⟎⌀ℂሶ
➚➓᦮ᒎ

Shigenori Makino
Yoko Gokan
Takako Ishihara
Mariko Tamaoki
Tomomi Kouketsu

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ೨Ꮉෘሶ㧘ᩒỈዏઍ ઁ㧚㈩㘩ࠨ࡯ࡏࡆࠬᓥ੐⠪⎇ୃ↪࠹ࠠࠬ࠻㧘᧲੩㧦ਛᄩᴺⷙ㧧2006 ᐕ㧦56㧙84㧚
2㧕 ᓟ㑄ኈሶ㧚࿾ၞ଻ஜߩࠠ࡯ࡢ࡯࠼㧘࿾ၞ଻ஜᵴേߩᱧผ㧘ஜᐽᢎ⢒㧘଻ஜᏧߩᵴേߣ୶ℂ⊛໧㗴㧦⨹⾐⋥ሶ㧘ᓟ㑄ኈሶ✬⪺㧚╙ 2 㧘࿾ၞ⋴⼔ቇ ╙ 2 㧘᧲੩㧦ࠗࡦ࠲࡯ࡔ࠺ࠗࠞ࡞㧧2007 ᐕ㧦23㧙35㧘42㧙57㧘
197㧙2017㧘430㧙436㧚
3㧕 ᩉỈዏઍ㧚࡜ࠗࡈࠨࠗࠢ࡞߆ࠄߺࠆ࿾ၞ⋴⼔ᵴേ㧘ஜᐽ໧㗴࡮⺖㗴ߣ࿾ၞ⋴⼔㧦⑔ፉ㆏ሶ✬㓸㧚࿾ၞ⋴⼔ቇΤ(ᵴേߩዷ㐿)㧘᧲੩㧦ࠝ࡯ࡓ␠㧧2007 ᐕ㧦1㧙29㧘68㧙69.
4㧕 ⍹ේᄙ૫ሶ㧚ᱤ⑼଻ஜᵴേ㧘㓚ኂఽ(⠪)଻ஜᵴേ㧦⨹⾐⋥ሶ㧘ᓟ㑄ኈሶ✬⪺㧘࿾ၞ⋴⼔ቇ ╙ 2 㧘᧲੩㧦ࠗࡦ࠲࡯ࡔ࠺ࠖࠞ࡞㧧2007 ᐕ㧦301㧙316㧘363㧙369㧚
5㧕 ’㊁⨃ᓼ ઁ㧚ࠢࠛࠬ࠴࡚ࡦ࡮ࡃࡦࠢ଻ஜᏧ࿖ኅ⹜㛎໧㗴⸃⺑ 2009㧘᧲੩㧦ࡔ࠺ࠖ࠶ࠢࡔ࠺ࠖࠕ㧧2008
ᐕ㧚

㧙㧙

⪺ᦠ㧔᰷ᢥ㧕ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 ᓟ㑄ኈሶ㧚࿷ቛߦ߅ߌࠆࡎࠬࡇࠬ࡮✭๺ࠤࠕ㧘⥃ᐥ⋴⼔㧘2007 ᐕ㧧33 Ꮞ㧦707㧙711㧚
2㧕 ⨹⾐⋥ሶ㧘੹੗⌬ሶ㧘ᅏጊೣሶ㧘ᓟ㑄ኈሶ㧘㋈ᧁࠆࠅሶ㧘ችౝᷡሶ㧚଻ஜᏧᢎ⢒ߩᛛⴚ㗄⋡ߣතᬺᤨߩ೔
㆐ᐲ(᩺)ߩឭ᩺㧘଻ஜᏧࠫࡖ࡯࠽࡞㧘2007 ᐕ㧧63 Ꮞ㧦1000㧙1005㧚
✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ’㊁⨃ᓼ㧚ᐔᚑ 17 ᐕ᦭ᚲ⷗₸⺞ᩏ⚿ᨐ㧘᧲੩ߐࠎ߸ 21 2006 ᐕ㧧29 ภ㧦7㧙11㧚
2㧕 ศᧄᾖሶ㧘ᩒỈዏઍ㧚㈩㘩ࡏ࡜ࡦ࠹ࠖࠕߩ⹺⼂ߦ߽ߣߠߊ㜞㦂⠪ߩ⥄┙ᡰេߩߒߊߺߠߊࠅߩታᘒߣ⺖㗴㧘଻ஜᏧࠫࡖ࡯࠽࡞ 2006 ᐕ㧧62 Ꮞ㧦390㧙393㧚
3㧕 ⨹⾐⋥ሶ㧘ᓟ㑄ኈሶઁ㧚ో࿖଻ஜᏧᢎ⢒ᯏ㑐ද⼏ળ߇૞ᚑߒߚ଻ஜᏧᢎ⢒⹜᩺㧘଻ஜᏧࠫࡖ࡯࠽࡞ 2006ᐕ㧧62 Ꮞ㧦558㧙563㧚
4㧕 ’㊁⨃ᓼ㧘₹⟎⌀ℂሶ㧚ડᬺⷙᮨߦࠃࠆቯᦼஜᐽ⸻ᢿ᦭ᚲ⷗₸⺞ᩏ⚿ᨐ㧘ጘ㒂ක≮⑼ቇᄢቇ♿ⷐ 2007 ᐕ㧧
1 ภ㧦1㧙7㧚
5㧕 ’㊁⨃ᓼ㧚ᐔᚑ 18 ᐕ᦭ᚲ⷗₸⺞ᩏ⚿ᨐ㧘᧲੩ߐࠎ߸ 21 2007 ᐕ㧧33 ภ㧦2㧙5.
6㧕 ’㊁⨃ᓼ㧚ㆬ೎⡬ജᬌᩏߩ᦭ᚲ⷗₸⺞ᩏ㧘ᣣᧄ⡯ᬺ࡮ἴኂකቇળળ⹹ 2007 ᐕ㧧55 Ꮞ㧦20㧙28㧚
7㧕 ᩉỈዏઍ㧘ศᧄᾖሶ㧘ᵄᎹ੩ሶઁ㧚ਛጊ㑆࿾ߩ㈩㘩ࠨ࡯ࡆࠬߦ߅ߌࠆࡏ࡜ࡦ࠹ࠖࠕᵴേ⠪ߩ໧㗴⹺⼂ߣ଻ஜ⑔␩ߩᐢႎߦኻߔࠆᦼᓙ㧘ᣣᧄ౏ⴐⴡ↢ቇળ⹹ 2007 ᐕ㧧53 Ꮞ㧦890㧙899㧚
8㧕 ’㊁⨃ᓼ㧚ᐔᚑ 19 ᐕ᦭ᚲ⷗₸⺞ᩏ⚿ᨐ㧘᧲੩ߐࠎ߸ 21 2008 ᐕ㧧37 ภ㧦2㧙5㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Makino S㧘Iwata H. Studies on prevention against disorders due to harmful chemical substances in theworkplace by the scale of establishment. Acta Sch Med Univ Gifu. 2006;54:24-30㧚
2㧕 Ishihara T㧘Tukuda Y㧘Saeki. K㧘Kido T㧚The meaning of “getting together”to older-elderly women ina mountainous community. Journal of Tsuruma Health Science Society. 2007;30:71-79.

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦₹⟎⌀ℂሶ㧧⑼ቇ⎇ⓥ⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦ᐜఽ෸߮ߘߩ଻⼔⠪ࠍኻ⽎ߦߒߚ༛ᾍ㒐ᱛᢎ⢒ᣇᴺߩ㐿⊒ߣߘߩ⹏ଔ㧧ᐔᚑ 18㧙19 ᐕᐲ㧧2,600 ජ౞(1,700㧦900 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦᧛᎑ᐘઍ㧘ಽᜂ⎇ⓥ⠪㧦ᓟ㑄ኈሶ㧘⍹ේᄙ૫ሶ㧧ᐔᚑ 19 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄(㐳ኼ⑼ቇ✚ว⎇ⓥ੐ᬺ)․೎㙃⼔⠧ੱࡎ࡯ࡓ߳ߩ⸰໧⋴⼔ߩឭଏലᨐߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 19 ᐕ
ᐲ㧧6,650 ජ౞㧚3㧕 ⎇ⓥઍ⴫⠪㧦⍹ේᄙ૫ሶ㧘⎇ⓥಽᜂ⠪㧦ᓟ㑄ኈሶ㧘₹⟎⌀ℂሶ㧘⍹ේᢅ⑲㧧⑼ቇ⎇ⓥ⵬ഥ㊄⪚⧘⎇ⓥ㧦૑᳃ද௛ߦࠃࠆቇ┬ᦼ߆ࠄߩ㜞㦂⠪⯦ᓙ৻ᰴ੍㒐ࡊࡠࠣ࡜ࡓߩ㐿⊒㧧ᐔᚑ 20㧙22 ᐕᐲ㧧3,200
ජ౞(900㧦1,200㧦1,100 ජ౞)
4㧕 ⎇ⓥઍ⴫⠪㧦₹⟎⌀ℂሶ㧧⑼ቇ⎇ⓥ⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦࿾ၞ଻ஜᵴേߩ㨻㨽㩎㩉㨺㩆㩧㩂㩨߇෸߷ߒߚⴕ᡽
଻ஜᏧ߳ߩᓇ㗀㧧ᐔᚑ 20㧙22 ᐕᐲ㧧3,200 ජ౞(1,300㧦1,000㧦900 ජ౞)
5㧕 ⎇ⓥઍ⴫⠪㧦➚➓᦮ᒎ㧧⑼ቇ⎇ⓥ⵬ഥ㊄⧯ᚻ⎇ⓥ(ࠬ࠲࡯࠻ࠕ࠶ࡊ)㧦↥ᓟߩౣ༛ᾍ㒐ᱛࠍ⋡⊛ߣߒߚ⑌ᾍࠨࡐ࡯࠻ᣇᴺߩᬌ⸛㧙ᄦߩ༛ᾍⴕേߦὶὐࠍᒰߡߡ㧙㧧ᐔᚑ 20㧙21 ᐕᐲ㧧2,390 ජ౞(1,340㧦
1,050 ජ౞)6㧕 ⎇ⓥઍ⴫⠪㧦ᓟ㑄ኈሶ㧘⎇ⓥಽᜂ⠪㧦⍹ේᄙ૫ሶ㧘₹⟎⌀ℂሶ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦ⴕ᡽ᄌ㕟ᤨߩ଻ஜᏧߩᓎഀౣ᭴▽̆transition ℂ⺰ࠍ↪޿ߚ❑ᢿ⊛⎇ⓥ㧧ᐔᚑ 20 ᐕᐲ㧙22 ᐕᐲ㧧3,500
ජ౞(1,300㧦700㧦1,500 ජ౞)
2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫ
ߥߒ

㧙㧙

6㧚ቇળᵴേ
1㧕ቇળᓎຬ
’㊁⨃ᓼ㧦
1㧕 ᣣᧄ↥ᬺⴡ↢ቇળઍ⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ↥ᬺⴡ↢ቇળ᧲ᶏ࿾ᣇળℂ੐(㨪⃻࿷)3㧕 ᣣᧄⴡ↢ቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄ᳃ᣖⴡ↢ቇળ⹏⼏ຬ(㨪⃻࿷)ᓟ㑄ኈሶ㧦1㧕 ᣣᧄ᳃ᣖⴡ↢ቇળ⹏⼏ຬ(㨪⃻࿷)₹⟎⌀ℂሶ㧦
1㧕 ᧲ᶏ౏ⴐⴡ↢ቇળ⹏⼏ຬ(ᐔᚑ 18 ᐕᐲ㨪⃻࿷)2㧕ቇળ㐿௅
’㊁⨃ᓼ㧦
1㧕 ᐔᚑ 18 ᐕᐲᣣᧄ↥ᬺⴡ↢ቇળ᧲ᶏ࿾ᣇળቇળ(2006 ᐕ 11 ᦬㧘ጘ㒂)
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳
’㊁⨃ᓼ㧦
1㧕 ᐔᚑ 18 ᐕᐲᣣᧄ↥ᬺⴡ↢ቇળ᧲ᶏ࿾ᣇળ(2006 ᐕ 11 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬࿾ၞ଻ஜߣ⡯ၞ଻ஜߩㅪ៤‫ޠ‬ᐳ㐳)2㧕 ᣣᧄ㆙㓒ක≮ቇળቇⴚᄢળ(2008 ᐕ 10 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓ‫․ޟ‬ቯஜ⸻࡮․ቯ଻ஜᜰዉ‫ޠ‬Ṷ⠪)ᓟ㑄ኈሶ㧦
1㧕 ╙ 66 ࿁ᣣᧄ౏ⴐⴡ↢ቇળ✚ળ(2007 ᐕ 10 ᦬㧘ᗲᇫ㧘ࡈࠜ࡯࡜ࡓ 4‫଻ޟ‬ஜᏧᢎ⢒ߩ⥃࿾ታ⠌ߣතᓟᢎ⢒‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേ
’㊁⨃ᓼ㧦
1㧕 ‫ ߰߉ࡦ࡜ࡊࠬ࡞ࡋޟ‬21‫ޠ‬ផㅴળ⼏ᆔຬ(㨪⃻࿷)2㧕 ‫ ߰߉ࡦ࡜ࡊࠬ࡞ࡋޟ‬21‫ޠ‬ផㅴળ⼏࿾ၞ࡮⡯ၞㅪ៤ផㅴㇱળᆔຬ(ᐔᚑ 18 ᐕᐲ㨪⃻࿷)ᓟ㑄ኈሶ㧦
1㧕 ጘ㒂⋵⋴⼔දળ⹺ቯ⋴⼔Ꮷ೙ᐲ࠮ࠞࡦ࠼࡟ࡌ࡞ᢎ⢒⺖⒟ㆇ༡ᆔຬળᆔຬ㐳(ᐔᚑ 18 ᐕᐲ㨪⃻࿷)2㧕 ో࿖଻ஜᏧᢎ⢒ᯏ㑐ද⼏ળ೽ળ㐳(㨪⃻࿷)ᩉỈዏઍ㧦1㧕 ଻ஜᏧ⸥㍳ߦ㑐ߔࠆ⥄ᴦ૕ߩࠕ࠼ࡃࠗࠨ࡯(㨪⃻࿷)⍹ේᄙ૫ሶ㧦
1㧕 ጘ㒂Ꮢ੺⼔⹺ቯክᩏᆔຬ(㨪⃻࿷)
2㧕 NPO ᴺੱ߉߰⑔␩ࠨ࡯ࡆࠬ೑↪⠪࠮ࡦ࠲࡯߮࡯ߔߌߞߣℂ੐(㨪⃻࿷)3㧕 ጘ㒂⋵┙㓁శ࿦⚻༡ᆔຬ(㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ᓟ㑄ኈሶ㧘⍹ේᄙ૫ሶ㧦․೎㙃⼔⠧ੱࡎ࡯ࡓ߳ߩ⸰໧⋴⼔ߩឭଏലᨐߦ㑐ߔࠆ⎇ⓥ㧦⎇ⓥઍ⴫⠪㧘㧙㧙᧛᎑ᐘઍ㧘ᐔᚑ 19 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄(㐳ኼ⑼ቇ✚ว⎇ⓥ੐ᬺ)ⶄᢙߩ⸰໧⋴⼔ࠬ࠹࡯࡚ࠪࡦߦࠃࠆ࿾ၞන૏ߩ 24 ᤨ㑆⸰໧੺⼔࡮⋴⼔ߩലᨐ⊛࡮ല₸⊛ߥታᣉᣇᴺߩ㐿⊒⎇ⓥ ಽᜂႎ๔㧦
129㧙246(2008 ᐕ 3 ᦬)
11㧚ႎ㆏1㧕 ᩒỈዏઍ㧦࿾ၞ૑᳃ߣஜᐽߠߊࠅ࿑ࠆ㧦ጘ㒂ᣂ⡞(2006 ᐕ 8 ᦬ 29 ᣣ)2㧕 ⍹ේᄙ૫ሶ㧦⸰໧⋴⼔లታ߳૕೙តࠆ㧦ጘ㒂ᣂ⡞(2008 ᐕ 12 ᦬ 16 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔ⋴⼔ቇ⑼ߩㆇ༡ߦ߆߆ࠊࠆ⻉ᵴേ㧘࿾ၞ⋴⼔ቇಽ㊁ߦ㑐ㅪߔࠆᢎ⢒ᵴേߦਛᔃࠍ߅޿ߡ㧘లታߒߚᵴ
േ߇ߢ߈ߚߣ⹏ଔߔࠆ‫ߩࠄࠇߎޕ‬ᢎ⢒ᵴേߦߪ㧘ฦ⎇ⓥ⠪ߩ⎇ⓥᵴേߩᚑᨐ߇෻ᤋߐࠇߡ޿ࠆߣ⠨߃ࠄࠇࠆ‫ߦ․ޕ‬㧘࿾ၞ⋴⼔ቇߢߪ㧘↥ᬺ଻ஜ㧘࿾ၞ଻ஜ㧘࿷ቛ⋴⼔ߥߤߩ㑐ㅪಽ㊁ߦ߅ߌࠆታ〣⠪ߣߩ౒ห⎇ⓥ߇ߥߐࠇߡ޿ࠆߎߣߪ⹏ଔߦ୯ߔࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ᢎ⢒ᵴേߣߒߡߪ㧘ᐔᚑ 21 ᐕᐲᢎ⢒⺖⒟ߩᡷ⸓߇ߥߐࠇߚߩߢ㧘ᣂߒ޿ᢎ⢒⺖⒟ߦ߅ߌࠆ࿾ၞ⋴⼔ቇ߅ࠃ߮࿷ቛ⋴⼔ቇߩᢎ⢒ᵴേ㧘․ߦታ⠌ߩలታ߇ߐࠄߦᔅⷐߣ⠨߃ࠄࠇࠆ‫੹ޕ‬ᓟߐࠄߦ㧘࿾ၞ⋴⼔ቇಽ
㊁ߦ߅ߌࠆᢎ⢒ߩలታࠍ࿑ࠆߎߣ߇⺖㗴ߢ޽ࠆ‫ޕ‬࿾ၞ⋴⼔ቇ㧘↥ᬺ଻ஜಽ㊁ߦ㑐ㅪߔࠆ⎇ⓥᵴേߣߒߡߪ㧘ታ〣ߣㆆ㔌ߒߥ޿⎇ⓥᵴേ߇㊀ⷐߢ޽ࠆߣ
⠨߃ࠄࠇࠆߩߢ㧘⎇ⓥࡈࠖ࡯࡞࠼ߩ᜛లߦദ߼ߚ޿‫ޕ‬੹ᓟߩዷᦸᢎຬฦ⥄ߩ⎇ⓥ࠹࡯ࡑࠍᜬߟߎߣߣ౒ߦ㧘ಽ㊁ߦ߅ߌࠆ౒ㅢߒߚ⎇ⓥ⺖㗴ࠍ߽ߜ㧘⎇ⓥᵴേࠍᵴ⊒ൻߔࠆߎߣࠍዷᦸߩ৻ߟߦ᜼ߍࠆ‫ޕ‬㧙㧙㧔2㧕♖␹⋴⼔ቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
♖␹⋴⼔ቇߪ㧘␠ળߦ߅ߌࠆࡔࡦ࠲࡞ࡋ࡞ࠬߦߟ޿ߡߩ⻉໧㗴߅ࠃ߮୘‫ߩޘ‬ஜᐽ㓚ኂࠍᜬߟੱ‫ߦޘ‬ኻߔࠆ⋴⼔ࠕࡊࡠ࡯࠴ߩᣇᴺࠍតⓥߔࠆಽ㊁ߢ޽ࠆߣ⠨߃ߡ޿ࠆ‫ߩࠈߎߎޕ‬௛߈ߣᣣᏱ↢ᵴߣߩ㑐ㅪߦὶὐࠍ
ᒰߡߚ♖␹⋴⼔ߩⷞὐ߆ࠄ㧘ߎߎࠈߩஜᐽ㧘ஜᐽ㓚ኂߦߟ޿ߡ⠨ኤߔࠆߣߣ߽ߦ㧘ᔃりࠍ∛߻ੱ‫♖ߩ߳ޘ‬␹⋴⼔ቇߩ᭎ᔨࡕ࠺࡞߅ࠃ߮ᣇᴺ⺰㧘ᛛⴚ⺰ߩታ⸽⊛ߥ⎇ⓥࠍ⋡ᜰߒߡ޿ࠆ‫ߚ߹ޕ‬㧘࿾ၞߦ߅ߌࠆࡔࡦ࠲
࡞ࡋ࡞ࠬࠤࠕࠪࠬ࠹ࡓߩᬌ⸛㧘ࡁ࡯ࡑ࡜ࠗ࠯࡯࡚ࠪࡦߩℂᔨߩరߦ♖␹㓚ኂ⠪ߩℂ⸃ߩଦㅴ㧘߅ࠃ߮♖␹㓚ኂ⠪߳ߩࠨࡐ࡯࠻ߦ㑐ߔࠆᬌ⸛ࠍⴕߞߡ޿ߊߎߣࠍ⎇ⓥಽ㊁ߣߒߡ޿ࠆ‫ޕ‬㧨ਥߥ⎇ⓥ࠹࡯ࡑ㧪1㧕♖␹⑼࠺ࠗࠤࠕ࡮૞ᬺᚲߦㅢᚲਛߩ♖␹㓚ኂ⠪ߩ⃻⁁ߦ㑐ߔࠆ⎇ⓥࡁ࡯ࡑ࡜ࠗ࠯࡯࡚ࠪࡦߩℂᔨߩ߽ߣ㧘ᄙߊߩ♖␹㓚ኂ⠪߇␠ળߦᚯࠅ౒ߦ↢ᵴߔࠆࠃ߁ߦߥߞߡ߈ߡ޿
ࠆ㧚♖␹⑼࠺ࠗࠤࠕߦㅢᚲߒߡ޿ࠆ♖␹㓚ኂ⠪ߩ␠ળ↢ᵴߩ⃻⁁ߦߟ޿ߡ㧘ෳടⷰኤᴺߣ㕙ធᴺߦࠃߞߡߘߩ૕㛎ࠍℂ⸃ߒ㧘␠ળߩਛߢߩᓐࠄ߳ߩᡰេߦߟ޿ߡᬌ⸛ߒߡ޿ࠆ‫ޕ‬
2㧕♖␹㓚ኂ⠪ߩ࿁ᓳㆊ⒟ߦ߅ߌࠆᴦ≮⊛ߥ߆߆ࠊࠅߦ㑐ߔࠆ⎇ⓥ♖␹⑼∛㒮ߦ౉㒮ߒߡ޿ࠆᖚ⠪ߦኻߒ㧘ᴦ≮⊛ߥⅣႺߣߒߡߤߩࠃ߁ߥ⋴⼔Ꮷߩ߆߆ࠊࠅ߇ᔅⷐ߆ᬌ⸛
ߒߡ޿ࠆ‫ޕ‬ᕆᕈᦼ߆ࠄᘟᕈᦼߩ޽ࠄࠁࠆ∛ᦼߩ♖␹㓚ኂߩ૕㛎਎⇇ߦߟ޿ߡ㧘↢ᵴߩታᘒߣᓐࠄߩ⃻ታ⹺⼂ߣߩߕࠇ߆ࠄ㧘♖␹ᯏ⢻ߩ㓚ኂ߇↢ᵴ߿ኻੱ㑐ଥߩ⢻ജߦ෸߷ߔᓇ㗀ࠍᬌ⸽ߒ㧘ߘߎߢߩ㑐ࠊࠅߩᗧ๧
ࠍ᣿⏕ߦߒߡ޿ߊ⺖㗴ߦขࠅ⚵ࠎߢ޿ࠆ‫ޕ‬
3㧕ᄢቇ↢ߩࠬ࠻࡟ࠬߦ㑐ߔࠆ⎇ⓥ⃻ઍߪࠬ࠻࡟ࠬ␠ળߣ⸒ࠊࠇ㧘ᄙߊߩੱ߇ߐ߹ߑ߹ߥࠬ࠻࡟ࠬࠍᛴ߃ߡ↢ᵴࠍߒߡ޿ࠆ‫ޕ‬ᄢቇ↢߽଀ᄖߢߪߥߊ㧘ࠬ࠻࡟ࠬࠍಣℂߢ߈ߕ㧘ߎߎࠈࠍ∛߻ቇ↢߇ᄙߊߥߞߡ޿ࠆ‫⃻ޕ‬ઍߩᄢቇ↢ߩࠬ࠻࡟ࠬ⁁ᴫߣߘࠇߦᓇ㗀ߔࠆⷐ࿃ߦߟ޿ߡ㧘ᄙᣇ㕙߆ࠄᬌ⸛ࠍⴕߞߡ޿ࠆ‫ޕ‬
4㧕♖␹⋴⼔ߦ߅ߌࠆ⋴⼔Ꮷߩࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦᛛⴚߩಽᨆߦ㑐ߔࠆ⎇ⓥࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦߪ♖␹⋴⼔ࠍⴕ߁਄ߢ㕖Ᏹߦ㊀ⷐߥ⋴⼔ᛛⴚߩ৻ߟߢ޽ࠆ‫ߒ߆ߒޕ‬㧘ⷞⷡ⊛⏕⹺ߩߢ߈ߥ޿ᛛⴚߢ޽ࠆߚ߼㧘ቴⷰ⊛⹏ଔ߇ߒߠࠄߊ㧘ฦ୘ੱߩ․ᕈߦᄢ߈ߥᓇ㗀ࠍฃߌࠆ߽ߩߢ޽ࠆ‫⼔⋴ޕ‬Ꮷߩࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦᛛⴚߩታᘒߣᛛⴚߦᓇ㗀ࠍ෸߷ߔⷐ࿃ߦߟ޿ߡᬌ⸛ࠍⴕߞߡ޿ࠆ‫ޕ‬5㧕♖␹⑼࠺ࠗࠤࠕߩㅢᚲೋᦼᲑ㓏ߦ߅ߌࠆ೑↪⛮⛯ⷐ࿃ߦ㑐ߔࠆ⎇ⓥ♖␹㓚ኂ⠪ߩᴦ≮ၮ⋚߇㧘‫∛␹♖ޟ‬㒮߆ࠄ࿾ၞ߳‫߁޿ߣޠ‬ᵹࠇ߇ߟߊࠄࠇ㧘ㅌ㒮ᓟߦ♖␹⑼࠺ࠗࠤࠕߢ
ⴕࠊࠇࠆᴦ≮⊛ࠕࡊࡠ࡯࠴߇⋉‫ޘ‬㊀ⷐߣߥߞߡ߈ߡ޿ࠆ‫ߦ⛯⛮ࠕࠤࠗ࠺ޕ‬ᓇ㗀ߔࠆⷐ࿃ࠍ᣿⏕ߦߒߡ޿ߊ
ߎߣߦࠃߞߡ㧘⛮⛯ࠍ᳿ቯߠߌࠆᤨᦼߩࠕࡊࡠ࡯࠴ࠍ⏕┙ߒߡ޿ߊ⺖㗴ߦขࠅ⚵ࠎߢ޿ࠆ‫ޕ‬
2㧚ฬ★
ᅏ᧛ᄥᔒ
ᢎ᝼㧦
ಎᢎ᝼㧦 ᧖ᶆᶈሶ
ਃຠᒄมഥᢎ㧦

Hutoshi Okumura
Hiroko Sugiura
Hiroshi Mishina

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ᅏ᧛ᄥᔒ㧚♖␹㓚ኂ⠪ߩℂ⸃ߣ⋴⼔ߦ㑐ߔࠆ⎇ⓥ㧘᧲੩㧦㓶᧻಴

㧧2008 ᐕ㧚⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
ߥߒ✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ᧖ᶆᤐ㓶 㧘᧖ᶆᶈሶ㧚 Voluntary running exercise is associated with enhanced macrophage andlymphocyte cytokine in young mice㧘ஜᐽ࡟ࠢ࡝ࠛ࡯࡚ࠪࡦ⎇ⓥળ㔀⹹ 2006 ᐕ㧧3 Ꮞ㧦11㧙21㧚
2㧕 ᧖ᶆᤐ㓶㧘᧖ᶆᶈሶ㧘ᬀደ៺♿㧘ᬀደᖝ↵㧚Chronic exercise associated with enhanced macrophage andlymphocyte cytokine production in young mice㧘✚ว⑔␩ 2006 ᐕ㧧3 Ꮞ㧦9㧙18㧚
3㧕 ᧖ᶆᶈሶ㧘┻ౝ㤗ਫ㧘᧖ᶆᤐ㓶㧚ࠬ࠻࡟ࠬ෻ᔕ߅ࠃ߮ኻੱᕟᔺᔃᕈ߇ᄢቇ↢ߩ࠰࡯ࠪࡖ࡞ࠬࠠ࡞ߦ෸߷ߔ㧙㧙ᓇ㗀㧘ஜᐽ࡟ࠢ࡝ࠛ࡯࡚ࠪࡦ⎇ⓥળ㔀⹹ 2007 ᐕ㧧4 ภ㧦5㧙14㧚
4㧕 ᧖ᶆᶈሶ㧘᧖ᶆᢥ㚅㧘᧖ᶆᤐ㓶㧚ⷫߩ㙃⢒ᘒᐲ߇ᄢቇ↢ߩ࠰࡯ࠪࡖ࡞ࠬࠠ࡞ߦ෸߷ߔᓇ㗀㧘ஜᐽ࡟ࠢ࡝ࠛ
࡯࡚ࠪࡦ⎇ⓥળ㔀⹹ 2007 ᐕ㧧4 ภ㧦15㧙27㧚
5㧕 ᷦ⼱⩿Ⓞሶ㧘ᅏ᧛ᄥᔒ㧘ዊ═ේᤘᒾ㧚⋴⼔Ꮷࠍኻ⽎ߣߒߚ Rathus Assertiveness Schedule ᣣᧄ ߩ૞ᚑ㧘ᣣᧄ⋴⼔⎇ⓥቇળ⹹ 2007 ᐕ㧧30 Ꮞ㧦79㧙88㧚
6㧕 ᅏ᧛ᄥᔒ㧘᧖ᶆᶈሶ㧘ਃຠᒄม㧚㓁ᕈ∝⁁ߩ޽ࠆ⛔วᄬ⺞∝ᖚ⠪߳ߩ♖␹≮ᴺ⊛ኻᔕ㧘ᣣᧄ♖␹⑼⋴⼔ቇળ ╙ 13 ࿁ ᕆᕈᦼ♖␹⑼⋴⼔ቇળ⹹ 2007 ᐕ㧦33㧙37㧚
7㧕 ਸ᧛ఝ㧘ᅏ᧛ᄥᔒ㧘⚦㊁ኈሶ㧚߁ߟ∛ᖚ⠪ߩ࿁ᓳㆊ⒟ߩℂ⸃ߣ⋴⼔ߦߟ޿ߡߩ⠨ኤ㧙ઁ⠪ߦ᳇ࠍ㆜޿ߔ߉ࠆ௑ะߦᄌൻࠍ߽ߚࠄߒߚ౉㒮૕㛎㧙㧘ᣣᧄ♖␹⑼⋴⼔ቇળ ╙ 13 ࿁ ♖␹⑼࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦ⋴⼔ቇ
ળ⹹ 2007 ᐕ㧦34㧙38㧚
8㧕 ᅏ᧛ᄥᔒ㧘᧖ᶆᶈሶ㧘ਃຠᒄม㧚♖␹⑼∛㒮ߦ㐳ᦼ౉㒮ߔࠆߣ޿߁૕㛎ߣ⋴⼔ߦߟ޿ߡߩᬌ⸛㧘ᣣᧄ♖␹⑼⋴⼔ቇળ ╙ 14 ࿁ ⠧ᐕᦼ♖␹⑼⋴⼔ቇળ⹹ 2007 ᐕ㧦76㧙80㧚
9㧕 ጟፒᢅᦶ㧘᧖ᶆᶈሶ㧘੗਄⋿ੱ㧘᧖ᶆᤐ㓶㧚࡟ࠢ࡝ࠛ࡯࡚ࠪࡦᡰេᛛ㊂߇᳇ಽᄌኈߦਈ߃ࠆᓇ㗀 㧙㨪ࠫࡖࡦࠤࡦࠥ࡯ࡓᡰេߩᛛ㊂Ꮕߩ㆑޿߇෸߷ߔᓇ㗀ߦߟ޿ߡ㧙㧘ᣣᧄஜᐽකቇળ㔀⹹ 2008 ᐕ㧦16 Ꮞ㧧21㧙
27㧚
10㧕 ᧖ᶆᶈሶ㧘ቝ↰᩶ሶ㧘᧖ᶆᤐ㓶㧚ᄢቇ↢ࠍኻ⽎ߣߒߚࠬ࠻࡟ࠬ෻ᔕߩ㜞ૐߦࠃࠆ⹺⍮⊛⹏ଔߩᏅ⇣ߩᬌ⸛㧘ஜᐽ࡟ࠢ࡝ࠛ࡯࡚ࠪࡦ⎇ⓥળ㔀⹹ 2008 ᐕ㧧5 ภ㧦19㧙24㧚
11㧕 ᧖ᶆᶈሶ㧘㐳ደᕺ㧘᧖ᶆᤐ㓶㧚ᄢቇ↢ߩࠗࡦ࠲࡯ࡀ࠶࠻਄ߩ෹ੱ㑐ଥߣࠨࡐ࡯࠻ᦼᓙߩታᘒ߅ࠃ߮ࠬ࠻࡟
ࠬߩ㜞ૐߦࠃࠆᲧセ㧘ஜᐽ࡟ࠢ࡝ࠛ࡯࡚ࠪࡦ⎇ⓥળ㔀⹹ 2008 ᐕ㧧5 ภ㧦25㧙34㧚
12㧕 ਸ᧛ఝ㧘ᅏ᧛ᄥᔒ㧘᧖ᶆᶈሶ㧚⥄Ꮖᛕ್⊛ߥᅚᕈ߁ߟ∛ᖚ⠪ߩ౉㒮૕㛎ߣ⋴⼔ߩᬌ⸛㧙ෳടⷰኤᴺߣඨ᭴
ᚑ⊛㕙ធᴺߦࠃࠆౝኈߩಽᨆ߆ࠄ㧙㧘ᣣᧄ♖␹⑼⋴⼔ቇળ ╙ 15 ࿁ ኾ㐷ቇળΤቇળ⹹ 2008㧧11㧙15㧚ේ⪺㧔᰷ᢥ㧕
ߥߒ

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ઍ⴫⠪㧦᧖ᶆᶈሶ㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌(࿾ၞㅪ៤)㧦㘧㛗࿾ၞߦ߅ߌࠆ⋴⼔⎇ⓥᡰេࡊࡠࠫࠚࠢ࠻㧧ᐔᚑ 19 ᐕᐲ㧧400 ජ౞
2㧕 ઍ⴫⠪㧦᧖ᶆᶈሶ㧘⎇ⓥಽᜂ⠪㧦ᅐ᧛ᄥᔒ㧘ਃຠᒄม㧦⑼ቇ⎇ⓥ⾌⵬ഥ㊄(⪚⧘⎇ⓥ)㧧♖␹⋴⼔ߦ߅ߌࠆࡔ࠶࠮࡯ࠫߩฃା࡮ಣℂᛛ⢻ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 20㧙22 ᐕᐲ㧧1,500 ජ౞(700㧦300㧦500 ජ౞)2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥ1㧕 ઍ⴫⠪㧦ේ↰ቱਭ(ࢃ࠾࠺࠶ࠢ)㧘⎇ⓥಽᜂ⠪㧦ዊᳰ㜞ᒄ㧘⷏㊁ඳᔒ㧘⒳↰ⴕ↵㧘᧖ᶆᤐ㓶㧘੗਄⋿ੱ㧘᧖ᶆᶈሶ㧘ઁ㧦ዊⷙᮨ੐ᬺ⠪ᣂ੐ᬺో࿖ዷ㐿ᣂ੐ᬺ㧧߇߹ߏ߅ࠅࡑ࡝ࡦ࡮ࠕࡦ࠴ࠛࠗࠫࡦࠣផㅴ੐
ᬺ㧦ᐔᚑ 18 ᐕᐲ㧧9,000 ජ౞
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬ
ߥߒ
2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳
ߥߒ

㧙㧙

8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേ
ߥߒ
10㧚ႎ๔ᦠ
1㧕 ᧖ᶆᶈሶ㧘᧖ᶆᤐ㓶㧘੗਄⋿ੱ㧦ࡑ࡝ࡦࠕࠢ࠹ࠖࡆ࠹ࠖߩࠬ࠻࡟ࠬシᷫ߅ࠃ߮࡝࡜ࠢ࠯࡯࡚ࠪࡦല
ᨐߦ㑐ߔࠆ⎇ⓥ㧘ᐔᚑ 18 ᐕᐲዊⷙᮨ੐ᬺ⠪ᣂ੐ᬺో࿖ዷ㐿ᡰេ੐ᬺ㧘߇߹ߏ߅ࠅࡑ࡝ࡦ࡮ࠕࡦ࠴ࠛ
ࠗࠫࡦࠣផㅴ੐ᬺᚑᨐႎ๔ᦠ㧦1㧙81(2007 ᐕ)
11㧚ႎ㆏
1㧕 ᅏ᧛ᄥᔒ㧦ℂ⺰ߣታ〣ࠍߟߥߋᬌ⸛ળ㧦ጘ㒂ᣂ⡞(2007 ᐕ 12 ᦬ 11 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔඨᦼߦᷰࠆ⥃ᐥታ⠌ᜰዉࠍᛴ߃㧘⎇ⓥᵴേߦචಽߥᤨ㑆ࠍഀߊߎߣ߇ߢ߈ߥ޿⁁ᴫߦߪ޽ࠆ߇㧘ዋߒߢ߽⎇ⓥᵴേ߇ⴕ߃ࠆࠃ߁ߦᤨ㑆⊛࡮ᬺോ⊛⺞ᢛࠍⴕ޿㧘⎇ⓥߦขࠅ⚵ࠎߢ߈ߚ‫৻ޕ‬ㇱߢߪ޽ࠆ߇㧘ኾ㐷⹹߳ߩᛩⓂ߿⪺ᦠߣߒߡ౏⴫ߒ㧘৻ቯߩᚑᨐࠍ޽ߍߡ߈ߡ޿ࠆ‫ߚ߹ޕ‬㧘ዋ㗵ߢߪ޽ࠆ߇⎇ⓥ⾌߽⏕଻ߔࠆߎߣ߇ߢ߈㧘⎇ⓥ૕೙ߪᢛ޿ߟߟ޽ࠆ‫ߒ߆ߒޕ‬㧘ಽ㊁ߣߒߡ⋡ᜰߔߣߎࠈߪࠃࠅታ〣⊛ߥ⎇ⓥߢ޽ࠅ㧘ߐࠄߥࠆ⎇ⓥࡈࠖ࡯࡞࠼ߩ⏕଻߿දജ૕೙ࠍ᭴▽ߔࠆᔅⷐ߇޽ࠆ‫⃻ޕ‬࿷ߪߘߩၮ⋚૞ࠅߣߒߡ㧘⥃ᐥ⋴⼔Ꮷ߅ࠃ߮ઁᄢቇߣදหߒߡ੐଀ᬌ⸛ળ߿♖␹⋴⼔ߦ㑐ߔࠆቇ⠌ળࠍⴕߞߡ߅ࠅ㧘ᓢ‫ߦޘ‬᜛߇ࠅࠍ⷗ߖߡ߈ߡ޿ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ੱຬ߇ዋߥ޿ߎߣ㧘ᢎ⢒ߦᛩߓࠆᤨ㑆߇ᄙ޿ߎߣߦࠃࠅ㧘⎇ⓥᤨ㑆ߩ⏕଻߇㔍ߒ޿⁁ᴫߦ޽ࠆ‫⃻ޕ‬࿷ߪ㧘୘‫ᤨߦޘ‬㑆ࠍ⺞ᢛߒߡ⎇ⓥࠍㅴ߼ߡ޿ࠆߎߣ߇ᄙ޿ߚ߼㧘੹ᓟߪല₸ᕈߣ⎇ⓥߩ⾰ࠍ㜞߼ࠆߎߣࠍ
⠨߃㧘ಽ㊁ో૕ߣߒߡߩ⎇ⓥ⺖㗴ࠍᜬߜ㧘⎇ⓥ૕೙ߩ⺞ᢛࠍ࿑ࠅߚ޿‫ޕ‬੹ᓟߩዷᦸ⃻࿷ⴕߞߡ޿ࠆ⥃ᐥ߿ઁᄢቇߣߩ౒หቇ⠌ળࠍ੹ᓟ߽⛮⛯ߒ㧘⥃ᐥߣߩ౒ห⎇ⓥ߳ߣ⊒ዷߐߖߡ޿߈
ߚ޿‫ޕ‬

㧙㧙

Χ‫ޓ‬㒝ዻ∛㒮ߩ⃻⁁ߣ⺖㗴

1∛㒮ߩℂᔨ࡮⚵❱࡮ㆇ༡╬

1㧚 ℂᔨ࡮ၮᧄᣇ㊎
㧔1㧕ℂᔨ
ᐔᚑ 15 ᐕ 6 ᦬ߦ㒝ዻ∛㒮ߩၮᧄℂᔨࠍᰴߩߣ߅ࠅ೙ቯߒߚ‫∛ޕ‬㒮⡯ຬߪߎߩℂᔨߦၮߠ޿ߡ⸻≮ᬺോߦᒰߚߞߡ޿ࠆ‫ޕ‬‫ޓޓޓ‬ၮᧄℂᔨ‫ߩߣߚߥ޽ޓޓޓޓ‬ኻ⹤߇ഃࠆା㗬ߣ቟ᔃߩ∛㒮
㧔2㧕ၮᧄᣇ㊎㒝ዻ∛㒮ߩၮᧄᣇ㊎ߪ㧘∛㒮ߩၮᧄℂᔨߣหᤨߦ೙ቯߒ㧘ߎߩᣇ㊎ߦၮߠ޿ߡ∛㒮ㆇ༡ࠍⴕߞߡ޿ࠆ‫ޕ‬1ᖚ⠪ਛᔃߩ࠴࡯ࡓක≮ࠍឭଏߒ߹ߔ‫ޕ‬2ੱ㑆ᕈ⼾߆ߥක≮ੱࠍ⢒ᚑߒ߹ߔ‫ޕ‬

3వㅴක≮ߩ⎇ⓥ࡮㐿⊒࡮ឭଏࠍታ〣ߒ߹ߔ‫ޕ‬

4࿾ၞක≮߳ߩⓍᭂ⊛ෳ↹ߣㅪ៤ᒝൻࠍ࿑ࠅ߹ߔ‫ޕ‬

㧔3㧕⡯ᬺ୶ℂ
ᐔᚑ 17 ᐕ 12 ᦬ 19 ᣣߦጘ㒂ᄢቇ∛㒮⡯ᬺ୶ℂ✁㗔෸߮⥃ᐥߦ߅ߌࠆ୶ℂᜰ㊎ࠍ೙ቯߒ㧘∛㒮⡯ຬߦ๟⍮ߒߚ‫ޕ‬㧔4㧕⥃ᐥᜰ㊎
ᐔᚑ 17 ᐕ 12 ᦬ 19 ᣣߦ⸻≮਄ߩၮᧄᣇ㊎෸߮කᏧߩ⸻≮ᬺോᜰ㊎ࠍ೙ቯߒ㧘∛㒮⡯ຬߦ๟⍮ߒߚ‫ޕ‬

2㧚 ⚵❱㧘ㆇ༡
㧔1㧕⚵❱
ᐔᚑ 16 ᐕ 4 ᦬㧘කቇㇱࠍᄢቇ㒮㊀ὐൻߒ㧘⻠ᐳ╬ߩ⚵❱ࠍᄢቇ㒮කቇ⎇ⓥ⑼ߦᡷ✬ߒߚߎߣߦ઻
޿㧘ਥߚࠆᢎຬߪᄢቇ㒮කቇ⎇ⓥ⑼ᚲዻߣߥߞߚ‫ޕ‬૬ߖߡ㒝ዻ∛㒮ߩක≮ᖱႎㇱ෸߮✚ว⸻≮ㇱߩᢎ⢒⡯ຬਗ߮ߦ⮎೷ㇱ㐳ߪ㧘ᄢቇ㒮කቇ⎇ⓥ⑼ᚲዻߣߥߞߚ‫ޕ‬߹ߚ㧘∛㒮㐳ߩⶄ㔀߆ߟᄙ᭽ߥᬺോࠍ⵬૒ߒ㧘∛㒮ߩ▤ℂㆇ༡૕೙ߩలታࠍ࿑ࠆߚ߼㧘ᐔᚑ 14 ᐕ
4 ᦬߆ࠄ 3 ฬ㧔ౝ⑼♽⸻≮⑼㐳㧘ᄖ⑼♽⸻≮⑼㐳㧘⋴⼔ㇱ㐳㧕ߩ೽∛㒮㐳ࠍ㒮ౝភ⟎ߢ㈩⟎ߒ㧘∛㒮㐳ߩ⵬૒૕೙ࠍᒝൻߒߚ‫ޕ‬ᴺੱൻᓟߩᐔᚑ 16 ᐕ 4 ᦬߆ࠄߪ㧘∛㒮㐳ߩᜰዉജࠍߐࠄߦᒝൻߔࠆߚ߼㧘೽∛㒮㐳ࠍቇ㐳⊒઎ߣߒ㧘ߘߩᓎഀߣᮭ㒢ࠍ᣿⏕ൻ㧔⸻≮ᜂᒰ㧘∛㒮⚻༡ᜂᒰ㧘ᖚ⠪ࠨ࡯ࡆࠬᜂᒰ㧕ߒߚ‫ޕ‬૬ߖߡ∛㒮㐳߇⡯ോߦኾᔨߢ߈ࠆࠃ߁㧘∛㒮㐳߇ᚲዻߔࠆ⻠ᐳ࡮ಽ㊁ߦᣂߚߦഥᢎ᝼ 1 ฬࠍ㈩⟎ߒߚ‫ޕ‬ߐࠄߦ㧘ᐔᚑ 16 ᐕ 8 ᦬߆ࠄ∛㒮⚻༡ಽᨆ෸߮⚻༡ડ↹ߦ㑐ߔࠆࠕ࠼ࡃࠗࠩ࡯ߣߒߡ㧘ᄖㇱߩ౏⹺
ળ⸘჻ 1 ฬࠍ∛㒮㐳⵬૒ߦᆔབྷߒ㧘⑼㐳ળ⼏ߦ಴Ꮸ㗿޿∛㒮⚻༡㕙߆ࠄ∛㒮㐳⵬૒૕೙ࠍᒝൻߒߚ‫ޕ‬㧔ߎࠇߦߟ޿ߡߪ㧘ᐔᚑ 20 ᐕᐲ߆ࠄ౏⹺ળ⸘჻ᚲዻߩળ⸘੐ോᚲ߇ᄢቇᧄㇱߣᄾ⚂ߔࠆߎߣߣߥߞߚ
ߚ߼㧘ᐔᚑ 20 ᐕᐲએ㒠ߪ∛㒮㐳⵬૒ߩ⊒઎ࠍ఺ߓ㧘㓐ᤨ಴Ꮸߒߡ⚻༡⁁ᴫߦߟ޿ߡ⺑᣿޿ߚߛߊߎ

㧙㧙ߣߣߒߚ‫ޕ‬㧕߹ߚ㧘ᐔᚑ 18 ᐕ 1 ᦬ߦߪක≮ᖱႎㇱߩᯏ⢻෸߮ක≮ᖱႎࠪࠬ࠹ࡓߩ⷗⋥ߒ࡮లታࠍ࿑ࠆ
ߚ߼㧘㔚ሶ⸻≮㍳ᜂᒰߩ∛㒮㐳⵬૒ 1 ฬࠍછ๮ߒߚ‫ޕ‬
ᐔᚑ 19 ᐕ 10 ᦬߆ࠄߪ㧘ࠃࠅ቟ోߥක≮૕೙ࠍ࿑ࠆߚ߼㧘ක≮቟ో▤ℂቶߦኾછߩᢎຬࠍ㈩⟎ߒ㧘૕೙ߩలታࠍ࿑ߞߚ‫ޕ‬߹ߚ㧘ߎࠇ߹ߢ⸻≮⑼㐳ߦߟ޿ߡߪ⥃ᐥකቇࠍᜂᒰߔࠆ‫ޟ‬ᢎ᝼‫ߡߞ߽ࠍޠ‬లߡߡ޿ߚ߽ߩࠍ㧘කቇ
♽⎇ⓥ⑼㧘∛㒮ߩኾછߩ‫ޟ‬ᢎ᝼‫ޠ‬෶ߪ‫ޟ‬ഥᢎ᝼㧔ಎᢎ᝼㧕‫∛ࠄ߆ߜ߁ߩޠ‬㒮㐳߇ᜰฬߔࠆ߽ߩߣⷙ⒟ࠍᡷᱜߒ㧘∛㒮㐳ߩᮭ㒢ࠍᒝൻߔࠆߣߣ߽ߦ㧘⁁ᴫߦࠃࠅᨵエߥኻᔕࠍน⢻ߣߔࠆߎߣߣߒߚ‫ޕ‬
㧔2㧕⑼㐳ળ⼏㒝ዻ∛㒮ߩ▤ℂ࡮ㆇ༡ߦ㑐ߔࠆ㊀ⷐ੐㗄ࠍክ⼏࡮᳿ቯߔࠆ∛㒮ౝߩᦨ㜞ክ⼏ᯏ㑐ߣߒߡ⑼㐳ળ⼏߇⟎߆ࠇߡ޿ࠆ‫⑼ޕ‬㐳ળ⼏ߩ⚵❱ㆇ༡ߦߟ޿ߡߪ㧘ጘ㒂ᄢቇකቇㇱ㒝ዻ∛㒮⑼㐳ળ⼏ⷙ⒟ߦ᣿ᢥൻߒߡ
޽ࠅ㧘∛㒮㐳㧘೽∛㒮㐳㧘ฦ⸻≮⑼㐳㧘ਛᄩ⸻≮ᣉ⸳╬ߩฦㇱ㐳㧘ฦ࠮ࡦ࠲࡯㐳㧘㜞ᰴᢇ๮ᴦ≮࠮ࡦ࠲࡯ߩฦㇱ㐷㐳㧘⮎೷ㇱ㐳㧘⋴⼔ㇱ㐳෸߮੐ോㇱ㐳ࠍ߽ߞߡ⚵❱ߐࠇߡ޿ࠆ‫ޕ‬∛㒮ߩ▤ℂ࡮ㆇ༡ߦߟ޿ߡߪ㧘∛㒮ࠍขᏎߊⅣႺߩᄌൻ߿ᖚ⠪࠾࡯࠭ߩᄙ᭽ൻߦࠃࠅ㧘⊛⏕߆ߟㄦㅦߥኻᔕ߇᳞߼ࠄࠇ㧘․ߦ㧘ᴺੱൻᓟߩ∛㒮ㆇ༡࡮⚻༡߿∛㒮ᡷ㕟ߩផㅴߦߟ޿ߡߪ㧘ࠃࠅᐢ▸࿐ߥ⁁ᴫߩᛠី߿ᣇะᕈߩ⷗ᭂ߼╬㧘⑼㐳ળ⼏ߦ⺖ߖࠄࠇߚ⽿ോߪᄙᄢߢ޽ࠆ‫ޕ‬߹ߚ㧘∛㒮ߩ▤ℂ࡮ㆇ༡ߩ౞Ṗൻࠍ࿑ࠆߚ߼㧘Ფ᦬㧝࿁කዪ㐳㧘ᄖ᧪ක㐳㧘∛᫟ක㐳วหળ⼏ࠍ㐿௅ߒ㧘∛㒮㐳߆ࠄ⑼㐳ળ⼏ߢክ⼏ߒߚ᩺ઙ╬ߦߟ޿ߡ⺑᣿ߒ㧘∛㒮⡯ຬ߳ߩ๟⍮࡮ᔀᐩࠍ࿑ߞߡ޿ࠆ‫ޕ‬
㧔3㧕∛㒮ㆇ༡ળ⼏∛㒮ㆇ༡ࠍᯏേ⊛ߦⴕ߁⚵❱ߣߒߡ㧘ᐔᚑ 17 ᐕ 6 ᦬ߦ∛㒮ㆇ༡ળ⼏ࠍ⸳⟎ߒߚ‫ޕ‬∛㒮ㆇ༡ળ⼏ߪ㧘⃻࿷㧘∛㒮㐳㧘೽∛㒮㐳㧔3 ฬ㧕㧘⋴⼔ㇱ㐳㧘੐ോㇱ㐳෸߮∛㒮㐳⵬૒㧔⸻≮㍳ᜂᒰ㧕ߦࠃࠅ᭴ᚑߐࠇߡ޿ࠆ‫ޕ‬หળ⼏ߪ∛㒮ㆇ༡ో⥸ߦ㑐ߔࠆડ↹┙᩺ࠍߒ㧘⚻༡ડ↹ળ⼏෸߮⑼㐳ળ⼏ߣ⺞ᢛࠍⴕߞߡ޿ࠆ‫ࠅࠃߦࠇߎޕ‬㧘∛㒮㐳ߩ࡝࡯࠳࡯ࠪ࠶ࡊࠍჇᒝߒ㧘ᮭ㒢ࠍࠃࠅᒝ࿕ߥ߽ߩߣߒ
ߚ‫ޕ‬ߎߩળ⼏ߪ㧘Ფ᦬ 2 ࿁㐿௅ߒߡ߅ࠅ㧘∛㒮ㆇ༡ߦଥࠆ㊀ⷐߥ᩺ઙߦߟ޿ߡߪ㧘ߎߩળ⼏ߦ߅޿ߡክ
⼏ߒߡ޿ࠆ‫ޕ‬㧔4㧕∛㒮⚻༡ડ↹ળ⼏㒝ዻ∛㒮ߩ▤ℂㆇ༡ࠍㄦㅦ㧘ㆡಾ߆ߟ౞Ṗߦⴕ߁ߚ߼㧘ᐔᚑ 15 ᐕ 4 ᦬ߦ‫∛ޟ‬㒮⚻༡ડ↹ળ⼏‫ࠍޠ‬⸳⟎ߒߚ‫ޕ‬⚻༡ડ↹ળ⼏ߪᲤ᦬ 2 ࿁㐿௅ߒ㧘⚵❱ߩᡷᑄ㧘▤ℂㆇ༡࡮੍▚㧘⚻༡㧘∛㒮ࡑࡀࠫࡔࡦ࠻ᡷ㕟㧘ᖚ⠪ࠨ࡯ࡆࠬ㧘ෂᯏ▤ℂ㧘ฦ⒳ᆔຬળߣߩㅪ⛊⺞ᢛߥߤࠍክ⼏࡮ၫⴕߒߡ߈ߚ‫ޕ‬
ᐔᚑ 17 ᐕ 6 ᦬㧘∛㒮ㆇ༡ળ⼏ߩ⸳⟎ߦ઻޿㧘⚻༡ડ↹ળ⼏ߩክ⼏੐㗄╬ࠍ⷗⋥ߒ㧘∛㒮⚻༡ᚢ⇛ߦ㑐ߔࠆ⻉ᣉ╷㧘⽷ോ෸߮ㆇ༡ߦߟ޿ߡද⼏㧘ᗧ⷗⡬ขࠍߔࠆߎߣߣߒ㧘Ფ᦬ 1 ࿁ߩ㐿௅ߦᡷ߼ߚ‫ޕ‬㧘∛㒮㐳⵬૒㧘කߎߩળ⼏ߪ㧘∛㒮㐳㧘೽ቇ㐳 ( 㒝ዻ∛㒮ᜂᒰ )㧘ቇ㐳․೎㘈໧㧘೽∛㒮㐳㧔3 ฬ㧕≮ᖱႎㇱ㐳㧘⮎೷ㇱ㐳㧘੐ോㇱ㐳㧘ᄖㇱߩ᦭⼂⠪㧔౏⹺ળ⸘჻㧘ᑯ⼔჻㧘᳃㑆∛㒮ߩ㒮㐳㧕ߩ 13 ฬߢ᭴ᚑߒߡ޿ࠆ‫߅ߥޕ‬㧘ற⡬⠪ߣߒߡቇ㐳㧘ᄢቇ㒮කቇ⎇ⓥ⑼㐳ߩ಴Ꮸࠍᓧߡ޿ࠆ‫ޕ‬㧙㧙㧔5㧕㒝ዻ∛㒮ฦ⒳ᆔຬળߩ⸳⟎ᐕᐲ㧘છോ㧔ㆇ༡ᣇ㊎㧕㧘ᗧᔒ᳿ቯᣇᴺ㧘ᗧᔒવ㆐ᣇᴺ㒝ዻ∛㒮⑼㐳ળ⼏╬ߩᗧᕁ᳿ቯࠍ౞Ṗߦߒ㧘⚵❱ߩᯏ⢻ࠍචಽߦᨐߚߔߚ߼㧘ฦ⒳ᆔຬળ߇⚵❱ߐࠇߡ޿ࠆ‫ޕ‬ฦ⒳ᆔຬળߩㆇ༡╬ߪቇౝⷙ⒟╬ߦࠃࠅ᣿ᢥൻߐࠇ㧘ฦᆔຬળߩክ⼏⚿ᨐ╬ߪ㧘㒝ዻ∛㒮⑼㐳ળ⼏ߦ⻁ࠄࠇߚᓟ㧘ฦ⸻≮⑼࡮ㇱ㐷╬ߦવ㆐ߒߡ޿ࠆ‫ޕ‬㒝ዻ∛㒮ฦ⒳ᆔຬળ৻ⷩ
ฬ‫ޓޓޓ‬⒓

છ‫ᦼޓޓ‬

ᆔຬᢙ⎇ୃ▤ℂᆔຬળ

2ᐕ

32 ੱතᓟ⥃ᐥ⎇ୃ෸߮⎇ୃකߦ㑐ߔࠆߎ ᐔᚑ 16 ᐕᐲߣ‫ޕ‬තᓟ⥃ᐥ⎇ୃ
࠮ࡦ࠲࡯ㆇ༡ᆔຬળ

2ᐕ

31 ੱ

තᓟ⥃ᐥ⎇ୃ࠮ࡦ࠲࡯ߩㆇ༡ߦ㑐ߔ ᐔᚑ 16 ᐕᐲࠆߎߣ‫ޕ‬᡼኿✢▤ℂㆇ༡
ᆔຬળ

2ᐕ

43 ੱ

᡼኿✢ขᛒᣉ⸳ߩ▤ℂㆇ༡㧘⸳஻ߩ ᐔᚑ 16 ᐕᐲᢛ஻㧘᡼኿✢㓚ኂߩ㒐ᱛ╬ߦ㑐ߔࠆߎߣ‫ޕ‬㓁㔚ሶᢿጀ᠟ᓇ⸻≮↪᡼኿ᕈห૏ర⚛૶↪ߦ㑐ߔࠆ቟ోዊᆔ
ຬળ

2ᐕ

9ੱ

FDG-PET ᬌᩏߦ㑐ߔࠆ▤ℂㆇ༡㧘 ᐔᚑ 19 ᐕᐲⵝ⟎ߩຠ⾰଻⸽㧘ຠ⾰▤ℂ෸߮ක≮੐᡿㒐ᱛኻ╷╬ߦ㑐ߔࠆߎߣ‫ޕ‬⤳ེឭଏߦଥࠆ⺞ᢛ
ᆔຬળ

2ᐕ

10 ੱ

⤳ེឭଏࡑ࠾ࡘࠕ࡞ߩ╷ቯ㧘⸥㍳㐿 ᐔᚑ 16 ᐕᐲ␜㧘⤳ེ⒖ᬀߩㆡᱜߥታᣉߦ㑐ߔࠆߎߣ‫ޕ‬⥃ᐥୃ✵ᄖ࿖කᏧ
ฃ౉ᆔຬળ

2ᐕ

6ੱ

⥃ᐥୃ✵කߩฃߌ౉ࠇ╬ߦ㑐ߔࠆߎ ᐔᚑ 16 ᐕᐲߣ‫ޕ‬ⅣႺኻ╷ᆔຬળ

2ᐕ

7ੱ

ⅣႺ଻ో෸߮౏ኂ㒐ᱛߦ㑐ߔࠆߎߣ‫ޕ‬ක≮ࠟࠬ቟ో▤ℂ
ᆔຬળ

2ᐕ

10 ੱ

ක≮ࠟࠬ⸳஻ߩ቟ో▤ℂߦ㑐ߔࠆߎ ᐔᚑ 16 ᐕᐲߣ‫ޕ‬ක≮ᖱႎㇱㆇ༡
ᆔຬળ

2ᐕ

36 ੱ

ක≮ᖱႎㇱߩ▤ℂㆇ༡ߦ㑐ߔࠆߎߣ‫ޕ‬ࠢ࡝࠾ࠞ࡞ࡄࠬ
ᆔຬળ

2ᐕ

14 ੱ

ࠢ࡝࠾ࠞ࡞ࡄࠬో⥸ߦ㑐ߔࠆߎߣ‫ ޕ‬ᐔᚑ 16 ᐕᐲ

ᯏ⒳ㆬቯᆔຬળ

1ᐕ

9ੱ‛ຠߩ⺞㆐ᄾ⚂ߦ߅ߌࠆᯏ⒳ߩㆬቯ ᐔᚑ 16 ᐕᐲߦ㑐ߔࠆߎߣ‫ޕ‬ක⮎ຠ╬ฃ⸤⎇ⓥክᩏᆔຬળ

2ᐕ

12 ੱ

ක⮎ຠ╬ߩฃ⸤⎇ⓥߦߟ޿ߡߩᅷᒰ ᐔᚑ 16 ᐕᐲᕈ㧘᦭↪ᕈ෸߮቟ోᕈ╬ߦ㑐ߔࠆߎߣ‫ޕ‬ᴦ㛎▤ℂ࠮ࡦ࠲࡯
ㆇ༡ᆔຬળ

2ᐕ

11 ੱ

ᴦ㛎▤ℂ࠮ࡦ࠲࡯ߩ▤ℂㆇ༡ߦ㑐ߔ ᐔᚑ 16 ᐕᐲࠆߎߣ‫ޕ‬

ක≮቟ో▤ℂᆔຬળ

2ᐕ

17 ੱ

ක≮ߩ቟ో⏕଻ߣක≮੐᡿㒐ᱛኻ╷ ᐔᚑ 16 ᐕᐲ╬ߦ㑐ߔࠆߎߣ‫ޕ‬29 ੱ㜞ᐲవㅴක≮ߦߟ޿ߡߩክᩏ㧘⹏ଔ ᐔᚑ 16 ᐕᐲ෸߮ᜰዉߦ㑐ߔࠆߎߣ‫ޕ‬వㅴක≮ኾ㐷ᆔຬળ‫ޓ‬ክ‫ޓ⼏ޓ‬੐‫ޓ‬㗄‫╬ޓ‬⸳⟎ᐕᐲ

ᐔᚑ 16 ᐕᐲᐔᚑ 16 ᐕᐲవㅴක≮ኾ㐷
ᆔຬળዊᆔຬળ

2ᐕ㧔ඨᢙᡷㆬ㧕

8ੱ㜞ᐲవㅴක≮ߩ↳⺧╬ߦ㑐ߔࠆߎߣ‫ޕ‬

ᐔᚑ 16 ᐕᐲ⣖ᱫ್ቯᆔຬળ

2ᐕ

4ੱ⣖ᱫ್ቯߩㆡᱜߥታᣉߦ㑐ߔࠆߎߣ‫ޕ‬

ᐔᚑ 16 ᐕᐲ36 ੱ⸻≮㍳෸߮ߎࠇߦ㒝㓐ߔࠆ⸥㍳╬ߩ ᐔᚑ 16 ᐕᐲ▤ℂߦ㑐ߔࠆߎߣ‫ޕ‬⸻≮㍳▤ℂᆔຬળ
⸻≮ᖱႎឭଏᆔຬળ

2ᐕ

10 ੱ

⸻≮ᖱႎߩឭଏߦ㑐ߔࠆߎߣ‫ޕ‬␠ળ଻㒾ᆔຬળ

2ᐕ

35 ੱ

␠ળ଻㒾⸻≮ߩขᛒ޿ߩᡷༀ෸߮ᜰ ᐔᚑ 16 ᐕᐲዉߦ㑐ߔࠆߎߣ‫ޕ‬㧙㧙

ᐔᚑ 16 ᐕᐲ㒝ዻ∛㒮ฦ⒳ᆔຬળ৻ⷩ
ฬ‫ޓޓޓ‬⒓

છ‫ᦼޓޓ‬

ᆔຬᢙ‫ޓ‬ክ‫ޓ⼏ޓ‬੐‫ޓ‬㗄‫╬ޓ‬⸳⟎ᐕᐲක≮੐᡿ኻ╷ᆔຬળ2ᐕ

8ੱක≮੐᡿෸߮ක੐⚗੎ߩ㒐ᱛ෸߮ኻ ᐔᚑ 16 ᐕᐲ╷ߦ㑐ߔࠆߎߣ‫ޕ‬ߐࠊ߿߆ࠨ࡯ࡆࠬ
ᆔຬળ

2ᐕ

13 ੱ

㒝ዻ∛㒮ߦ߅ߌࠆ౏౒ᣉ⸳೑↪ࠨ࡯ ᐔᚑ 16 ᐕᐲࡆࠬߩᡷༀߦ㑐ߔࠆߎߣ‫ޕ‬ᬌᩏㇱㆇ༡ᆔຬળ

2ᐕ

39 ੱᬌᩏㇱߩ▤ℂㆇ༡ߦ㑐ߔࠆߎߣ‫ޕ‬᡼኿✢ㇱㆇ༡ᆔຬળ

2ᐕ

40 ੱ

᡼኿✢ㇱߩ▤ℂㆇ༡ߦ㑐ߔࠆߎߣ‫ ޕ‬ᐔᚑ 16 ᐕᐲᐔᚑ 16 ᐕᐲ᧚ᢱㇱㆇ༡ᆔຬળ

2ᐕ

38 ੱ᧚ᢱㇱߩ▤ℂㆇ༡ߦ㑐ߔࠆߎߣ‫ޕ‬

ᐔᚑ 16 ᐕᐲャⴊㇱㆇ༡ᆔຬળ

2ᐕ

38 ੱャⴊㇱߩ▤ℂㆇ༡ߦ㑐ߔࠆߎߣ‫ޕ‬

ᐔᚑ 16 ᐕᐲ

ャⴊ≮ᴺᆔຬળ

2ᐕ

15 ੱ

ャⴊ≮ᴺߩㆡᱜൻߦ㑐ߔࠆߎߣ‫ޕ‬

ᐔᚑ 16 ᐕᐲ✚ว⸻≮ㇱㆇ༡
ᆔຬળ

2ᐕ

36 ੱ

✚ว⸻≮ㇱߩ▤ℂㆇ༡ߦ㑐ߔࠆߎߣ‫ޕ‬

ᐔᚑ 16 ᐕᐲశቇක≮⸻≮ㇱㆇ༡
ᆔຬળ

2ᐕ

13 ੱ

శቇක≮⸻≮ㇱߩ▤ℂㆇ༡ߦ㑐ߔࠆ ᐔᚑ 16 ᐕᐲߎߣ‫ޕ‬ಽᇂㇱㆇ༡ᆔຬળ

2ᐕ

10 ੱಽᇂㇱߩ▤ℂㆇ༡ߦ㑐ߔࠆߎߣ‫ޕ‬

ᐔᚑ 16 ᐕᐲᐔᚑ 16 ᐕᐲ∛ℂㇱㆇ༡ᆔຬળ

2ᐕ

26 ੱ∛ℂㇱߩ▤ℂㆇ༡ߦ㑐ߔࠆߎߣ‫ޕ‬࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦ
ㇱㆇ༡ᆔຬળ

2ᐕ

8ੱ࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦㇱߩ▤ℂㆇ༡ߦ ᐔᚑ 16 ᐕᐲ㑐ߔࠆߎߣ‫ޕ‬ක≮ᯏེ࠮ࡦ࠲࡯
ㆇ༡ᆔຬળ

2ᐕ

15 ੱ

ක≮ᯏེ࠮ࡦ࠲࡯ߩ▤ℂㆇ༡ߦ㑐ߔ ᐔᚑ 16 ᐕᐲࠆߎߣ‫ޕ‬

ක≮ㅪ៤࠮ࡦ࠲࡯ㆇ
༡ᆔຬળ

2ᐕ

24 ੱ

ක≮⑔␩ᡰេ࠮ࡦ࠲࡯ߩ▤ℂㆇ༡ߦ ᐔᚑ 16 ᐕᐲ㑐ߔࠆߎߣ‫ޕ‬↢૕ᡰេ࠮ࡦ࠲࡯
ㆇ༡ᆔຬળ

2ᐕ

22 ੱ

↢૕ᡰេ࠮ࡦ࠲࡯ߩ▤ℂㆇ༡ߦ㑐ߔ ᐔᚑ 16 ᐕᐲࠆߎߣ‫ޕ‬

ᩕ㙃▤ℂኾ㐷ᆔຬળ

2ᐕ

30 ੱ

ᖚ⠪↪㘩੐ߩᩕ㙃▤ℂߦ㑐ߔࠆߎߣ‫ޕ‬㒮ౝᗵᨴኻ╷ኾ㐷
ᆔຬળ

2ᐕ

37 ੱ

㒮ౝⅣႺߩะ਄㧘㒮ౝߩᗵᨴ੍㒐㧘 ᐔᚑ 16 ᐕᐲ㒮ౝᗵᨴ㒐ᱛߦ㑐ߔࠆ⺞ᩏ෸߮ኻ╷ߦ㑐ߔࠆߎߣ‫ޕ‬㒮ౝᗵᨴኻ╷
ዊᆔຬળ

2ᐕ

14 ੱ

㒮ౝᗵᨴኻ╷ߦ㑐ߔࠆߎߣ‫ޕ‬㜞ᰴᢇ๮ᴦ≮
࠮ࡦ࠲࡯ㆇ༡ᆔຬળ

2ᐕ

32 ੱ

㜞ᰴᢇ๮ᴦ≮࠮ࡦ࠲࡯ߩ▤ℂㆇ༡ߦ ᐔᚑ 16 ᐕᐲ㑐ߔࠆߎߣ‫ޕ‬㜞ᰴᢇ๮ᴦ≮
࠮ࡦ࠲࡯ㆇ༡ᆔຬળ
ᚻⴚㇱ㐷ㇱળ

2ᐕ

35 ੱ㜞ᰴᢇ๮ᴦ≮࠮ࡦ࠲࡯ᚻⴚㇱ㐷ߩㆇ ᐔᚑ 16 ᐕᐲ༡ߦ㑐ߔࠆߎߣ‫ޕ‬

⮎੐ᆔຬળ

2ᐕ

37 ੱ

૶↪ක⮎ຠ㧘ⴊᶧ⵾೷㧘ᬌᩏ⹜⮎㧘 ᐔᚑ 16 ᐕᐲක≮᧚ᢱߩណ↪╬ߦ㑐ߔࠆߎߣ‫ޕ‬ᖚ⠪ⴕേ೙㒢ᦨዊൻᆔຬળ7ੱක≮଻⼔౉㒮╬ߩ౉㒮ᖚ⠪ߩⴕേ೙ ᐔᚑ 17 ᐕᐲ㒢╬ߦ㑐ߔࠆߎߣ‫ޕ‬කቇ♽⎇ⓥ⑼࡮
කቇㇱᖱႎᆔຬળ
∛㒮ㇱળ

10 ੱ

∛㒮ߩᐢႎߦ㑐ߔࠆߎߣ‫ޕ‬

ᐔᚑ 16 ᐕᐲᐔᚑ 16 ᐕᐲᐔᚑ 17 ᐕᐲක≮ᖱႎ࠮ࠠࡘ࡝࠹ࠖᆔຬળ

2ᐕ

10 ੱ

ᖱႎ࠮ࠠࡘ࡝࠹ࠖࡐ࡝ࠪ࡯࡮ࡑࡀࠫ ᐔᚑ 18 ᐕᐲࡔࡦ࠻ߦ㑐ߔࠆߎߣ‫ޕ‬⣲≌࠮ࡦ࠲࡯
ㆇ༡ᆔຬળ

2ᐕ

18 ੱ

⣲≌࠮ࡦ࠲࡯ߩ▤ℂㆇ༡࡮ᣉ⸳⸳஻ ᐔᚑ 18 ᐕᐲߦ㑐ߔࠆߎߣ‫ޕ‬ࠛࠗ࠭ኻ╷ផㅴ
࠮ࡦ࠲࡯ㆇ༡ᆔຬળ

2ᐕ

6ੱ

ࠛࠗ࠭ኻ╷ផㅴ࠮ࡦ࠲࡯ߩ▤ℂㆇ
༡࡮੍▚ߦ㑐ߔࠆߎߣ‫ޕ‬㧙㧙ᐔᚑ 19 ᐕᐲ

㧔6㧕੐ോ⚵❱ߣ੐ോ⡯ຬߩ㈩⟎⁁ᴫ1㧕 ⃻⁁࿖┙ᄢቇߩᴺੱൻࠍᄾᯏߦ㧘කቇㇱߩ੐ോ⚵❱ࠍᄢቇߩ੐ോߣ∛㒮ߩ੐ോߦಽ㔌࡮ᡷ✬ߒߚ‫ޕ‬∛㒮ߩ੐ോߦߟ޿ߡߪ㧘∛㒮ߩㆇ༡࡮⚻༡▤ℂߩలታࠍ࿑ࠆߎߣ෸߮ᴺੱൻߦኻᔕߔࠆߚ߼㧘ᐔ
ᚑ 16 ᐕ 4 ᦬ߦ∛㒮੐ോߦ․ൻߒߚ੐ോ⚵❱ߣߒߡ੐ോዪߦ‫∛ޟ‬㒮ㇱ‫ߒ⟎⸳ࠍޠ‬㧘∛㒮ㇱ㐳ߩ߽ߣ✚ോ⺖㧘⚻༡▤ℂ⺖෸߮ක≮ࠨ࡯ࡆࠬ⺖ߩ 3 ⺖૕೙ߣߒߚ‫ߚ߹ޕ‬㧘ߎࠇߣ૬ߖߡోቇߩ౒ㅢ⊛ߥ੐ോ㧔ᄾ⚂࡮ᣉ⸳㑐ଥ╬㧕ߩ৻రൻ෸߮㓸ਛൻࠍ࿑ࠆߚ߼㧘ᄾ⚂࡮ᣉ⸳࡮⸳஻㑐ଥ੐ോࠍ੐ോ
ዪߩ⽷ോㇱ෸߮ᣉ⸳▤ℂㇱߢಣℂߔࠆߎߣߣߒߚ‫ࠄ߇ߥߒ߆ߒޕ‬㧘੐ോ⚵❱ߩಽ㔌࡮ᡷ✬ᓟ 1 ᐕ㑆ߩ⁁ᴫ߆ࠄ㧘㒝ዻ∛㒮ߩ੐ോ੐ᬺࠍㆀⴕߔࠆ਄ߢ㧘ᡷ✬ᓟߩ੐ോ⚵❱ߢߪ∛㒮ߩㆇ༡਄⒳‫ߩޘ‬ᡰ㓚߇޽ࠆߎߣ߇್᣿ߒߚߚ߼㧘ᐔᚑ 17 ᐕ 4 ᦬ߦ੐ോዪ߆ࠄ∛㒮ㇱࠍಾࠅ㔌ߒ㧘∛㒮㐳ߩ߽ߣ∛㒮੐ോㇱࠍ⸳⟎ߒߡ㧘✚ോ⺖㧘▤ℂ⺖㧘⺞㆐⺖෸߮ක≮ࠨ࡯ࡆࠬ⺖ߩ 4 ⺖ਗ߮ߦ⚻༡ಽᨆਥᐙ
ࠍ㈩⟎ߔࠆ૕೙ߦౣ✬ᚑߒߚ‫ߚ߹ޕ‬㧘ᐔᚑ 18 ᐕ 4 ᦬ߦߪ▤ℂ⺖ߣ⺞㆐⺖ࠍ⛔วߒ੐ോߩวℂൻࠍ࿑ߞߚ‫ߦࠄߐޕ‬㧘ක≮ᖱႎߩല₸⊛ߥㆇ↪ࠍ࿑ࠆߚ߼ක≮ᖱႎㇱߩᯏ⢻ࠍ⷗⋥ߒ㧘ᐔᚑ 19 ᐕ
4 ᦬ߦᣂߚߦᖱႎડ↹⺖ࠍ⸳⟎ߒ㧘ࠃࠅ∛㒮ߩ⸻≮ᖱႎ╬ࠍല₸⊛ߦㆇ↪ߢ߈ࠆࠃ߁⚵❱ࠍᡷ✬ߒߚ‫ޕ‬‫∛ޟ‬㒮੐ോ⚵❱ౣ✬ᚑߩ㛽ሶ‫ޠ‬ࠕ ੐ോዪ߆ࠄ∛㒮ㇱࠍಾࠅ㔌ߒౣ✬ᚑߒ㧘∛㒮㐳ߩ߽ߣߦ∛㒮੐ോㇱࠍ⟎ߊ‫ޕ‬ࠗ৻రൻ෸߮㓸ਛൻߩᑷኂࠍ⸃ᶖߔࠆߚ߼㧘ᄾ⚂㑐ଥ੐ോࠍ⽷ോㇱ߆ࠄ∛㒮੐ോㇱߦขࠅ

ㄟ߻‫ޕ‬
࠙

ᣉ⸳࡮⸳஻㑐ଥߩ৻ㇱ㧔ᣣᏱߩᑪ‛࡮⸳஻ߩ▤ℂ᫟ᬺോ㧕ࠍᣉ⸳▤ℂㇱ߆ࠄ∛㒮੐ോㇱߦขࠅㄟ߻‫ޕ‬2㧕 ὐᬌ࡮⹏ଔ
੐ോ⚵❱ࠍౣ✬ᚑߒ⋥ߒߚߎߣߦࠃࠅ㧘∛㒮ㆇ༡਄ߩ⒳‫ߩޘ‬ᡰ㓚ߩᐞߟ߆ߪᡷༀߐࠇߚ‫ߚ߹ޕ‬㧘∛㒮ߩㆇ༡෸߮⚻༡▤ℂߩలታࠍ࿑ࠆߚ߼ߦߪ㧘੐ോߩ∛㒮․ൻᐲߩ࡜ࡦࠢઃߌࠍߒ㧘․ൻᐲߩ
㜞޿੐ോࠍᜂᒰߔࠆࠬࡍࠪࡖ࡝ࠬ࠻ࠍ⢒ᚑߔࠆߚ߼㧘੐ോ⡯ຬߩ⢻ജ⹏ଔ෸߮Ꮧᦸߦࠃࠆේೣ∛㒮ౝߢߩੱ੐⇣േߣߔࠆኾ㐷⡯ൻࠍㅴ߼ࠆߎߣ㧘ක੐ᬺോ෸߮⚻༡▤ℂᬺോߦ♖ㅢߒߚහᚢജߩ
ੱ᧚ࠍ⏕଻ߔࠆߚ߼㧘ߎࠇࠄߩ᦭⾗ᩰ⠪߿ᄖㇱක≮ᯏ㑐╬ߩࠠࡖ࡝ࠕ⡯ຬࠍㆬ⠨ណ↪ߔࠆߥߤ㧘੐ോ⡯ຬߩੱ੐㈩⟎ߩ⷗⋥ߒࠍㅴ߼ߚ‫ࠅࠃߦࠄࠇߎޕ‬㧘ᐔᚑ 16 ᐕᐲߦߪࡔ࠺ࠖࠞ࡞࡮࠰࡯ࠪࡖ
࡞࡮ࡢ࡯ࠞ࡯ࠍ 1 ฬ㧘ᐔᚑ 17 ᐕᐲߦ⸻≮ᖱႎ▤ℂ჻ࠍ㓹↪ߒ㧘∛㒮ߩᯏ⢻ࠍలታߐߖࠆߎߣࠍ
น⢻ߣߒߚ‫ߚ߹ޕ‬㧘ᐔᚑ 17 ᐕᐲએ㒠㧘ቯᐕㅌ⡯⠪ߩ⵬లߦ⸻≮ႎ㈽੐ോߩ⾗ᩰࠍᜬߞߚ⠪ߩㆬ⠨ណ↪ࠍⴕ߁╬ߦࠃࠅ㧘ࠃࠅ∛㒮ㆇ༡ࠍలታߐߖࠆߎߣߣߒߡ߈ߚ‫ޕ‬
3㧕 ᡷༀ࡮ᡷ㕟ߣዷᦸ∛㒮ߩㆇ༡෸߮⚻༡▤ℂߩలታࠍ࿑ࠆߚ߼ߦߪ㧘∛㒮੐ോ⚵❱ߩలታߣᬺോߦ♖ㅢߒߚੱ᧚ߩ
⏕଻߇㊀ⷐߢ޽ࠅ㧘੹ᓟ߽੐ോ⚵❱ߩ⷗⋥ߒ෸߮∛㒮ᬺോߦ♖ㅢߒߚੱ᧚ߩ⊓↪ߥߤࠍㅴ߼ࠆߎ
ߣߣߒߡ޿ࠆ‫ޕ‬

㧙㧙

2

⸻≮ᵴേߩ⃻⁁ߣ⺖㗴1㧚 ⸻≮૕೙
㧔1㧕⤳ེ೎⸻≮㒝ዻ∛㒮߇ᐔᚑ㧝㧢ᐕ㧢᦬ߦᣂ▽࡮⒖ォߒߚߩࠍᄾᯏߦ㧘ᣥ᧪ߩ࠽ࡦࡃ࡯⑼߆ࠄ⤳ེ೎⸻≮૕೙ߦᄌᦝߒ㧘㒮ౝ⴫␜߽⤳ེ೎⴫␜ߣߔࠆߎߣߦࠃࠅᖚ⠪᩺ౝࠍಽ߆ࠅ߿ߔߊߒߚ‫ޕ‬ᄖ᧪⸻≮⑼ࠍౝ⑼࠱࡯ࡦߣᄖ⑼࠱࡯ࡦߦಽߌ⤳ེ೎ߦ㈩⟎ߒ㧘ߘࠇߙࠇߩ࠱࡯ࡦߦਛᄩಣ⟎ቶࠍ⸳⟎ߔࠆߎߣߦࠃࠅੱຬ෸߮ಣ⟎ቶߩല₸⊛ㆇ↪ࠍ࿑ߞߚ‫ޕ‬∛᫟ߦ߅޿ߡߪᶖൻེᄖ⑼㧘ᶖൻེౝ⑼෸߮ⴊᶧᗵᨴ∝ౝ⑼ࠍ㧘߹ߚᔃ⤳ⴊ▤ᄖ⑼㧘๭ๆེᄖ⑼㧘
ᓴⅣེౝ⑼㧘๭ๆེౝ⑼෸߮㤗㈮⑼−∩ᴦ≮⑼ࠍߘࠇߙࠇࡢࡦࡈࡠࠕߦ㈩⟎ߒ∛᫟㑆ߩㅪ៤߇࿑ࠇࠆ
ࠃ߁ߦߒߚ‫ޕ‬㧔2㧕⸻≮⑼ߩㅪ៤
㒝ዻ∛㒮߇ᐔᚑ㧝㧢ᐕ㧢᦬ߦᣂ▽࡮⒖ォࠍᯏߦోߡߩ㒮ౝ⸻≮ᖱႎࠍࡍ࡯ࡄ࡯࡟ࠬ࡮ࡈࠗ࡞ࡓ࡟ࠬ
ߢ৻ర▤ℂߔߴߊ㧘ᣂක≮ᖱႎࠪࠬ࠹ࡓࠍዉ౉ߒߚ‫ߩߘޕ‬㓙㧘ᓥ᧪ߩ⚕ࠞ࡞࠹߆ࠄ㔚ሶࠞ࡞࠹ߦ⒖ⴕߒ㧘ో⸻≮⑼ߢᖚ⠪ᖱႎࠍ౒᦭ൻߢ߈ࠆ઀⚵ߺߣߒߚ‫ޕ‬㔚ሶࠞ࡞࠹ൻߐࠇߚߎߣߦࠃࠅ㧝ᖚ⠪㧝ࠞ࡞࠹ߣߥࠅ⸻≮⑼㑆ߢߩᖱႎߩ߿ࠅขࠅ߇ࠬࡓ࡯࠭ߦⴕࠊࠇ㧘ᖱႎߩ౒᦭ൻࠍㅢߒߡ⸻≮⑼㑆ߩ޿ࠊࠁࠆ၂ᩮࠍૐߊߔࠆߎߣࠍน⢻ߦߒߚ‫ߦࠄߐޕ‬㧘⸻≮⑼㑆ߩㅪ៤ߩߺߢߥߊਛᄩ⸻≮ㇱ㐷ߥߤᄙ⡯⒳㑆
ߢߩᖱႎ౒᦭߽ㅴߺ㧘࠴࡯ࡓක≮ߩផㅴߦᄢ߈ߊነਈߒߡ޿ࠆ‫ޕ‬ߥ߅㧘ᖱႎߩ৻ర▤ℂ߇น⢻ߣߥߞߚߎߣߦࠃࠅ㧘ߤߎߦ޿ߡ߽㧘૗⑼ߩකᏧ࡮⋴⼔Ꮷߢ޽ߞߡ߽
ᖱႎࠍ౒᦭ߢ߈ࠆߚ߼㧘ᖱႎࠍᓧࠆߚ߼ߦ㒮ౝࠍ⿛ࠅ࿁ࠆߎߣ߇ߥߊߥࠅᬺോߩല₸ൻߩὐߢ߽ᄢ߈
ߥᡷༀࠍߺߡ޿ࠆ‫ޕ‬
㧔3㧕㜞ᐲᢇ๮ᢇᕆ࠮ࡦ࠲࡯
ᐔᚑ 16 ᐕ 4 ᦬㧘㜞ᰴᢇ๮ᢇᕆක≮ࠍⴕ߁ߚ߼㧘ᢇᕆㇱ㧘㓸ਛᴦ≮ㇱ㧘ᚻⴚㇱ෸߮ੱᎿ⣢ቶࠍᡷ⚵ߒ㧘ᣂߚߥ⚵❱ߣߒߡ࿾ၞἴኂ෸߮ᢇᕆක≮ߦ 24 ᤨ㑆ኻᔕน⢻ߥ‫ޟ‬㜞ᰴᢇ๮ᴦ≮࠮ࡦ࠲࡯‫⟎⸳ࠍޠ‬ߒߚ‫ޕ‬㜞ᰴᢇ๮ᴦ≮࠮ࡦ࠲࡯ߪ㧘ᢇᕆ㧘ᚻⴚ㧘㓸ਛᴦ≮෸߮ⴊᶧᵺൻᴦ≮ߩ 4 ㇱ㐷ߢ᭴ᚑߒߚ࿖ౝᦨ
ᄢⷙᮨߩᢇ๮ᴦ≮࠮ࡦ࠲࡯ߢ޽ࠅ㧘ᐔᚑ 16 ᐕ 6 ᦬ߩᣂ∛㒮㐿㒮ߣหᤨߦᵴേࠍ㐿ᆎߒߚ‫ޕ‬ᒰ∛㒮ߪ㧘ᐔᚑ 15 ᐕ 12 ᦬߆ࠄጘ㒂Ꮢߣߩ㑆ߢ‫ޟ‬ᢇᕆゞකᏧหਸ਼ࠪࠬ࠹ࡓߦ㑐ߔࠆදቯᦠ‫⚿✦ࠍޠ‬ߒ㧘ߐࠄߦᐔᚑ 16 ᐕ 6 ᦬㧘‫ޟ‬ᢇᕆ⥄േゞ߳ߩකᏧ៞ਸ਼ߦଥࠆታᣉⷐ✁ߦ㑐ߔࠆᄾ⚂ᦠ‫ޕߚߒ⚿✦ࠍޠ‬߹ߚ㧘ᐔᚑ 16 ᐕ 5 ᦬㧘ጘ㒂⋵ߣߩ㑆ߢ‫ޟ‬㒐ἴࡋ࡝ࠦࡊ࠲࡯ߩකᏧ╬៞ਸ਼ߦ㑐ߔࠆදቯᦠ‫ߔ⚿✦ࠍޠ‬ࠆߥߤ㧘㜞ᰴᢇ๮ᴦ≮࠮ࡦ࠲࡯߇ਛᔃߣߥࠅ㧘ጘ㒂⋵෸߮ጘ㒂࿾ၞߩᢇᕆක≮ߦⓍᭂ⊛ߦขࠅ⚵ࠎߢ߈ߚ‫ޕ‬ᒰ∛㒮ߩᢇᕆක≮ߩข⚵ߺ߿ታ❣߇⹺߼ࠄࠇ㧘ᐔᚑ 16 ᐕ 11 ᦬ߦ‫ޟ‬ᢇ๮ᢇᕆ࠮ࡦ࠲࡯‫ߦޠ‬ᜰቯߐࠇ㧘ߐࠄߦᐔᚑ 18 ᐕ 2 ᦬ߦߪጘ㒂⋵ਅߢ໑৻㧘ਛㇱ 9 ⋵ߢ 2 ᣉ⸳⋡ߣߥࠆ‫ޟ‬㜞ᐲᢇ๮ᢇᕆ࠮ࡦ࠲࡯‫ߦޠ‬⹺ቯߐࠇߚ‫ޕ‬ᒰ∛㒮ߪ㧘ಾᢿᜰߩౣធ⌕߿ᐢ▸࿐ᾲ∝㧘ᕆᕈਛᲥߥߤߩ․ᱶ∔ᖚߦኻᔕߢ߈ࠆ㧘㜞ᐲߩᢇᕆක≮૕೙ࠍᢛ߃ߚᣉ⸳ߢ޽ࠆߣߩጘ㒂⋵߆ࠄߩ↳⺧ߦၮߠ߈㧘ෘ↢ഭ௛⋭ߩክᩏࠍ⚻ߡጘ㒂⋵߆ࠄ⹺ቯߐࠇߚ߽ߩߢ޽ࠆ‫ޕ‬੹ᓟ㧘ࠃࠅ৻ጀߩᢇᕆක≮૕೙ࠍផㅴߔࠆߚ߼ߦ㧘࠼ࠢ࠲࡯ࡋ࡝ߩዉ౉ࠍ⸘↹ਛߢ޽ࠆ‫ޕ‬㧙㧙

2㧚 ᵴേ⁁ᴫ
㧔1㧕╙৻ౝ⑼1㧚⸻≮ߩ᭎ⷐ
1㧕ᶖൻ▤∔ᖚ㧦਄ਅㇱᶖൻ▤ౝⷞ㏜ࠍ↪޿ߚ⸻ᢿ㧘ᴦ≮߇ਛᔃߣߥࠆ߇㧘ᶖൻ▤ߩᣧᦼ≸ߦኻߒߡߪ⿥
㖸ᵄౝⷞ㏜㧔EUS㧕ࠍ೑↪ߒߚᱜ⏕ߥ⸻ᢿߩᓟ㧘ౝⷞ㏜⊛☼⤑ਅጀ೸㔌ⴚ㧔ESD㧕ߥߤࠍⓍᭂ⊛ߦⴕߞߡ޿ࠆ‫ߚ߹ޕ‬㧘ᦨㄭߢߪዊ⣺ౝⷞ㏜㧘ࠞࡊ࠮࡞ౝⷞ㏜ࠍዉ౉ߒ㧘ᓥ᧪⸻ᢿ߇࿎㔍ߣߐࠇߚዊ⣺∛ᄌߩ⸻ᢿ߽น⢻ߣߥߞߡ޿ࠆ‫ޕ‬ฯⴊ࡮ਅⴊߥߤߩ✕ᕆ∝଀ߦኻߒߡߪⓍᭂ⊛ߦ✕ᕆౝⷞ㏜ࠍᣉⴕߒ㧘଻ሽ⊛ᱛⴊࠍⴕߞߡ޿ࠆ‫ޕ‬ㄭᐕ㧘ㅴᱠߩ⋡ⷡ߹ߒ޿ᶖൻ▤ᖡᕈ⣲≌ᴦ≮ߦ߅޿ߡߪ㧘ౝⷞ㏜⊛ᴦ≮ߦട߃ߡൻቇ≮ᴺ߽
Ⓧᭂ⊛ߦขࠅ౉ࠇߡ޿ࠆ‫ߦ․ޕ‬㧘ㄭᐕჇട௑ะߩ޽ࠆᶖൻ▤ᖡᕈ࡝ࡦࡄ⣲ߦߪ㧘ⴊᶧౝ⑼ߣදജߒߡᓥ᧪
ߩൻቇ≮ᴺߩߺߥࠄߕಽሶᮡ⊛≮ᴺ߿ㅧⴊᐙ⚦⢩⒖ᬀ߹ߢⷞ㊁ߦ౉ࠇߚᴦ≮ࠍⴕߞߡ޿ࠆ‫ޕ‬ẩ≌ᕈᄢ⣺Ἳ߿ࠢࡠ࡯ࡦ∛ߦߪ㧘ᓥ᧪ߩ⮎‛≮ᴺߦട߃ߡ⊕ⴊ⃿㒰෰≮ᴺ߿ಽሶᮡ⊛ᴦ≮ߥߤࠍዉ౉ߒߡ޿ࠆ‫ޕ‬
2㧕⢄⤳∔ᖚ㧦㊀∝⢄ἻߦߪᓴⅣ▤ℂ߽฽߼ߚోり▤ℂࠍਛᔃߦኻಣߒߡ޿ࠆ‫∉఺ߦ․ޕ‬ቇ⊛ⷰὐߦ┙⣉ߒߡ࡝ࡦࡄ⃿⴫㕙ࡑ࡯ࠞ࡯⸃ᨆ߿ࠨࠗ࠻ࠞࠗࡦ≮ᴺߥߤ߽ዉ౉ߒߡ޿ࠆ‫ޕ‬ᘟᕈ⢄Ἳ߿⢄⎬ᄌߦߪ㧘Ⓧᭂ⊛ߦࠗࡦ࠲࡯ࡈࠚࡠࡦߥߤߩ᛫࠙ࠗ࡞ࠬ≮ᴺࠍᣉⴕߒߡ޿ࠆ‫ޕ‬⢄≸ߦߪ㧘⣻ㇱ⿥㖸ᵄᬌᩏߦࠃࠅᓸዊ⢄≸ߩ⊒⷗㧘⸻ᢿߦദ߼ߡ޿ࠆ‫ޕ‬ᴦ≮ߦߪ㧘ⴊ▤ㅧᓇࠍ೑↪ߒߚ⢄േ⣂Ⴇᩖⴚ㧔TAE㧕߿ᾲಝ࿕≮ᴺ㧔࡜ࠫࠝᵄ㧕ߥߤࠍⴕߞߡ޿ࠆ‫৻߽ࠇߕ޿ޕ‬ㇱߩ∝଀ߢߪో࿖ⷙᮨߩᄙᣉ⸳౒ห⥃ᐥ⹜㛎ߦෳടߒ㧘ᣂߚߥࠆࠛࡆ࠺ࡦ
ࠬ⏕┙߳ะߌߡദജߒߡ޿ࠆ‫ޕ‬
3㧕⢙⤟∔ᖚ㧦ౝⷞ㏜⊛੃㗡ಾ㐿ⴚ㧔EST㧕㧘ౝⷞ㏜⊛ࡃ࡞࡯ࡦ੃㗡᜛ᒛⴚ㧔EPBD㧕ߥߤࠍ↪޿ߡ㧘ᚻⴚߦ㗬ࠄߥ޿⢙⍹ᴦ≮ࠍⴕߞߡ޿ࠆ‫ߚ߹ޕ‬㧘⢙㆏♽ᖡᕈ⣲≌ߦኻߒߡߪ QOL ࠍ㊀ⷞߒߡ㧘ౝⷞ㏜⊛ߦࠬ࠹ࡦ࠻ᴦ≮ࠍⴕ߁‫ߚ߹ޕ‬㧘⢙⤟∔ᖚߩ⾰⊛⸻ᢿߦߪ↢ᬌ߇ᔅⷐߢ޽ࠆ߇㧘ߘߩᚻᲑߣߒߡ⿥㖸ᵄౝⷞ㏜ਅๆᒁ㊎↢ᬌ㧔EUS-FNA㧕ࠍዉ౉ߒߡ޿ࠆ‫ޕ‬EUS-FNA ߪ㧘ᧄ㗔ၞએᄖߦ߽ᔕ↪ߢ߈㧘߹ߚߘߩᛛⴚߪ਎⇇⊛⹏ଔࠍᓧߡ޿ࠆ‫ޕ‬
4㧕ᩕ㙃ᴦ≮㧦⢄∔ᖚࠍߪߓ߼ߣߒߡᶖൻེ∔ᖚో⥸ࠍኻ⽎ߦ㧘㑆ធࠞࡠ࡝࡯ࡔ࡯࠲࡯ߥߤࠍ↪޿ߚᱜ⏕ߥᩕ㙃ࠕ࠮ࠬࡔࡦ࠻ࠍⴕ޿㧘ᦨㆡߥᩕ㙃ᴦ≮ࠍⴕߞߡ޿ࠆ‫ޕ‬
5㧕ⴊᶧ∔ᖚ㧦⽺ⴊᕈ∔ᖚ㧘ߣߊߦㅧⴊߩਛᔃߣߥࠆ㛽㜑ߩ⇣Ᏹߦၮߠߊౣ↢ਇ⦟ᕈ⽺ⴊ߿㛽㜑⇣ᒻᚑ∝୥⟲߅ࠃ߮⊕ⴊ∛㧘ᖡᕈ࡝ࡦࡄ⣲㧘ᄙ⊒ᕈ㛽㜑⣲ߥߤߩㅧⴊེᖡᕈ⣲≌ߦኻߔࠆ⸻≮ࠍⴕߞߡ޿ࠆ‫౉ޕ‬㒮ኻ⽎ߦߥࠆ∔ᖚߩᄙߊߪㅧⴊེᖡᕈ⣲≌ߢ޽ࠆ߇㧘࿕ᒻ≸ߣߪ⇣ߥࠅ㧘ൻቇ≮ᴺ߇․ߦᄼഞߔࠆ‫ߚߩߎޕ‬߼ᴦ≹ࠍ⋡ᜰߔൻቇ≮ᴺߩᒝᐲߪో૕⊛ߦ㜞ᐲߣߥࠅ㧘ߘߩ▤ℂ㧘ᡰᜬ≮ᴺߪᭂ߼ߡ㊀ⷐߢ޽ࠆ‫ߦࠄߐޕ‬৻ㇱߩ∔ᖚߦߪㅧⴊᐙ⚦⢩⒖ᬀ㧔ห⒳㛽㜑⒖ᬀ㧘㕖ⴊ✼⠪㑆㛽㜑⒖ᬀ㧘ห⒳⤯Ꮺⴊ⒖ᬀ㧘ห⒳࡮⥄ኅᧃ᪳ⴊᐙ⚦⢩⒖ᬀ㧕ࠍዉ౉ߒߡ޿ࠆ‫ޕ‬ᖡᕈ࡝ࡦࡄ⣲㧘ᄙ⊒ᕈ㛽㜑⣲ߥߤߦ߅޿ߡߪᄖ᧪ൻቇ≮ᴺ߽Ⓧᭂ⊛ߦⴕ޿㧘ኅᣖߣ౒ߦ↢ᵴߒ㧘ᴦ≮߇ㆀⴕߢ߈ࠆࠃ߁ߥ㈩ᘦ߽ߒߡ޿ࠆ‫ޕ‬ၮᧄ⊛ߦߪࠛࡆ࠺ࡦࠬߦၮߠߊᴦ≮ࠍਛᔃߦⴕߞߡ޿ࠆ߇㧘৻ㇱߪᒰ࿾඙⁛⥄ߩ⥃ᐥ⹜㛎߿ో࿖ⷙᮨߩᄙᣉ⸳౒หߩ⥃ᐥ⹜㛎ߦ߽ෳടߒ㧘ᣂߚߥࠆࠛࡆ࠺ࡦࠬࠍ⏕┙ߔࠆߴߊദജࠍⴕߞߡ޿ࠆ‫ޕ‬
6㧕ᗵᨴ∝ౝ⑼㧦㒮ౝᗵᨴ∝ࠍ฽߻ฦ⒳ᗵᨴ∝ߩ⸻≮ࠍⴕߞߡ޿ࠆ߇㧘⚿ᩭߩࠃ߁ߥᗵᨴ∝ߦ㑐ߒߡߪ㑐ㅪ∛㒮ߣㅪ៤ߒߥ߇ࠄ⸻≮ࠍⴕߞߡ޿ࠆ‫࠭ࠗࠛߦ․ޕ‬ᴦ≮ߪᤘ๺ 63 ᐕߩጘ㒂⋵╙৻଀⋡ߩᖚ⠪߆ࠄ⛮⛯⊛ߦ⸻≮ࠍⴕߞߡ޿ࠆ‫ޕ‬ᒰ㒮ߪጘ㒂⋵ߩࠛࠗ࠭ᴦ≮᜚ὐ∛㒮ߦᜰቯߐࠇߡ߅ࠅ㧘ጘ㒂⋵ߩ HIV ᗵᨴ∝ᖚ⠪ߩㆊඨᢙߩ⸻≮ࠍⴕߞߡ޿ࠆ‫࠭ࠗࠛޕ‬ᖚ⠪ߦ߅޿ߡߪߐ߹ߑ߹ߥว૬∝ࠍ઻߁ߎߣ߇ዋߥߊߥߊ㧘ᄙߊߩ⸻≮⑼ߩදജ߇ᔅⷐߢ޽ࠆ߇㧘߶߷ో⑼ߢߩฃߌ౉ࠇ૕೙߇ਁోߥ⁁ᘒߢ޽ࠆߎߣߪ․╩ߢ߈ࠆ‫ޕ‬㒮ౝߦߪࠛࠗ࠭ኻ╷ផㅴ࠮ࡦ࠲࡯߽⸳⟎ߐࠇߡ߅ࠅ㧘⸻≮ߩߺߥࠄߕኾ㐷ࠞ࠙ࡦ࠮࡜࡯ߦࠃࠆࠞ࠙ࡦ࠮࡝ࡦࠣ
ᵴേ߿ᢎ⢒⎇ୃᵴേ߽Ⓧᭂ⊛ߦⴕߞߡ޿ࠆ‫ߪ࠭ࠗࠛޕ‬ਇᴦߩ∛ߢߪߥߊߥߞߡ߅ࠅ㧘ㄭᐕߢߪᘟᕈ∔ᖚߣߒߡᝒ߃ࠄࠇࠆࠃ߁ߦߥߞߡ޿ࠆ߆ࠄߎߘ㧘♖␹⊛ࠤࠕߥߤ߇․ߦ㊀ⷐߢ޽ࠆ‫ޕ‬㧔ࠛࠗ࠭ኻ╷ផㅴ࠮ࡦ࠲
࡯ߩ㗄ࠍෳᾖ㧕߹ߚ㧘㊎ೝߒ੐᡿ߩኻᔕߪ↢૕ᡰេ࠮ࡦ࠲࡯߇ਛᔃߣߥߞߡ޿ࠆ߇㧘ᒰ⑼߇ฃ⸻⓹ญߣߥߞߡ޿ࠆ‫ޕ‬2㧚ᢎ⢒ᣉ⸳
1㧕 ᣣᧄౝ⑼ቇળ⹺ቯ⎇ୃᣉ⸳
2㧕 ᣣᧄᶖൻེ∛ቇળ⹺ቯᣉ⸳
3㧕 ᣣᧄ⢄⤳ቇળ⹺ቯᣉ⸳
4㧕 ᣣᧄᶖൻེౝⷞ㏜ቇળ⹺ቯᣉ⸳
5㧕 ᣣᧄ⥃ᐥ⣲≌ቇળ⹺ቯᣉ⸳
6㧕 ᣣᧄ߇ࠎᴦ≮⹺ቯකᯏ᭴⎇ୃᣉ⸳㧙㧙7㧕 ᣣᧄⴊᶧቇળ⹺ቯ⎇ୃᣉ⸳8㧕 ᣣᧄ๭ๆེቇળ⹺ቯᣉ⸳
9㧕 ᣣᧄ߇ࠎᴦ≮⹺ቯකᯏ᭴⹺ቯ⎇ୃᣉ⸳
10㧕 ⤯Ꮺⴊ⒖ᬀታᣉᣉ⸳
11㧕 㕖ⴊ✼⠪㑆㛽㜑⒖ᬀታᣉᣉ⸳
3㧚⸻≮㐿⊒
1㧕 ⸻≮ฬ 㧦ዊ⣺ౝⷞ㏜ߦࠃࠆ⸻ᢿߣᴦ≮⸻≮ౝኈ㧦ේ࿃ਇ᣿ߩᶖൻ▤಴ⴊ߿ᶖൻ▤ᖡᕈ࡝ࡦࡄ⣲ࠍኻ⽎ߦዊ⣺ౝⷞ㏜ࠍታᣉ㧘ᱜ⏕ߥ⸻ᢿߣᴦ
≮ࠍⴕ߁‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦ጘ㒂⋵ౝߢߪᒰ㒮ߣ᧛਄⸥ᔨ∛㒮ߦዉ౉‫ޕ‬࿖ౝ⊛⹏ଔ㧦ߎࠇ߹ߢ⸻ᢿਇ⢻ߣ⸒ࠊࠇߚዊ⣺ߩ⸻ᢿ࡮ᴦ≮߇น⢻ߣߥߞߚߎߣߪ↹ᦼ⊛ߢ޽ࠆ‫ޕ‬࿖㓙⊛⹏ଔ㧦ห਄‫ޕ‬2㧕 ⸻≮ฬ 㧦⿥㖸ᵄౝⷞ㏜ਅ↢ᬌ㧔EUS-FNA㧕⸻≮ౝኈ㧦૕⴫ࠃࠅ⓫ೝਇ⢻ߥ⣲≌ᕈ∛ᄌ߿࡝ࡦࡄ▵∛ᄌߦኻߒߡ㧘⿥㖸ᵄౝⷞ㏜ࠟࠗ࠼ਅߦߡ㊎↢ᬌࠍⴕ߁‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦ᒰ㒮߇ᜰዉ⊛┙႐ߦߥࠅ㧘⋵ౝߢߪጘ㒂Ꮢ᳃∛㒮ߥߤߦߡᣉⴕ‫ޕ‬࿖ౝ⊛⹏ଔ㧦ߎࠇ߹ߢߪ㧘㐿⣻޽ࠆ޿ߪ㐿⢷ⴚߦࠃࠅ⸻ᢿߒߡ޿ߚᷓㇱ∛ᄌߦኻߒߡᲧセ⊛㕖ଚⷅ⊛ߦ⸻ᢿ߇น⢻ߣߥࠅ㧘ᭂ߼ߡ᦭↪ߥ⸻ᢿᛛⴚߢ޽ࠆ‫ޕ‬࿖㓙⊛⹏ଔ㧦ห਄‫ޕ‬3㧕 ⸻≮ฬ 㧦ห⒳⤯Ꮺⴊ⒖ᬀ⸻≮ౝኈ㧦⤯Ꮺⴊࡃࡦࠢࠃࠅ౉ᚻߒߚ⤯Ꮺⴊࠍ↪޿ߡᚑੱߩㅧⴊེᖚ⠪ࠍኻ⽎ߣߒߡห⒳⤯Ꮺⴊ⒖ᬀࠍⴕ߁‫ޕ‬
ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦ጘ㒂⋵ౝߢߪᒰ㒮ߣጘ㒂Ꮢ᳃∛㒮ዊఽ⑼ߩߺ‫ޕ‬࿖ౝ⊛⹏ଔ㧦⒖ᬀน⢻ߥ⤯Ꮺⴊߩ౉ᚻߪ⒖ᬀᏗᦸᖚ⠪ߩ 90%ߢน⢻ߢ޽ࠆ‫߼ߚߩߎޕ‬ห⒳㛽㜑⒖ᬀࠍ᳞߼ࠆᖚ⠪ߢ࠼࠽࡯߇޿ߥ޿႐วߦߪ㧘⤯Ꮺⴊ⒖ᬀ߇ઍᦧᴦ≮ߦߥࠆ‫ߚ߹ޕ‬㧘⤯Ꮺⴊ⒖ᬀ
ߪࠦ࡯࠺ࠖࡀ࡯࠻ߦᤨ㑆߇߆߆ࠄߥ޿ߚ߼㧘✕ᕆߦ⒖ᬀࠍᔅⷐߣߔࠆᖚ⠪ߦߣߞߡߪᭂ߼
ߡ㝯ജ⊛ߢ޽ࠆ‫ߦ߁ࠃߩߎޕ‬㛽㜑⒖ᬀߩઍᦧᴦ≮ߣߒߡ࿖ౝ⊛⹏ଔߪ⏕┙ߒߡ޿ࠆ‫ޕ‬࿖㓙⊛⹏ଔ㧦ᚑੱ⤯Ꮺⴊ⒖ᬀߩᚑ❣ߪᧄ㇌߇਎⇇⊛ߦ߽㜞᳓Ḱߢ޽ࠆ‫ޕ‬4㧕 ⸻≮ฬ 㧦㕖ⴊ✼⠪㑆㛽㜑⒖ᬀ⸻≮ౝኈ㧦ห⢩ߦ⒖ᬀ࠼࠽࡯߇޿ߥ޿႐วߦ㧘㛽㜑ࡃࡦࠢࠍ೑↪ߒߡༀᗧߩஜᏱ࠼࠽࡯߆ࠄ㛽㜑ࠍឭଏߒߡ޿ߚߛ߈㧘㛽㜑⒖ᬀࠍⴕ߁‫ߡߖࠊ޽ޕ‬㛽㜑ࡃࡦࠢ߆ࠄଐ㗬ߐࠇߚஜᏱ࠼࠽࡯߆ࠄߩ
㛽㜑ណข߽ⴕߞߡ޿ࠆ㧔㤗㈮⑼ࠍਛᔃߦᄙߊߩᄖ⑼♽⸻≮⑼ߩදജࠍᓧߡ޿ࠆ㧕‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦㕖ⴊ✼⠪㑆㛽㜑⒖ᬀน⢻ߥᣉ⸳ߪᒰ㒮ߩᒰ⑼ߩߺߢ޽ࠆ‫ޕ‬࿖ౝ⊛⹏ଔ㧦ห⢩࠼࠽࡯ਇ࿷ߩ㓙ߩ㛽㜑ࡃࡦࠢ೑↪ߩห⒳ㅧⴊᐙ⚦⢩⒖ᬀߣߒߡߪ㕖ⴊ✼⠪㑆㛽㜑⒖ᬀߩ᦭↪ᕈߪ⏕┙ߒߡ޿ࠆ‫ޕ‬࿖㓙⊛⹏ଔ㧦ห਄‫ޕ‬5㧕 ⸻≮ฬ 㧦ࡒ࠾⒖ᬀ߹ߚߪ Reduced intensity stem cell transplantation㧔RIST㧕⸻≮ౝኈ㧦㜞㦂⠪߿૗ࠄ߆ߩว૬∝ߩߚ߼ㅢᏱ⒖ᬀ߇ߢ߈ߥ޿ᖚ⠪ࠍኻ⽎ߣߒߡ㧘೨ಣ⟎ࠍ✭๺ߒߡ
ห⒳ㅧⴊᐙ⚦⢩⒖ᬀࠍⴕ߁‫ޕ‬GVL㧔⒖ᬀ ኻ⊕ⴊ∛㧕ലᨐ߽ᦼᓙߐࠇ㧘఺∉≮ᴺߣߒߡ߽૏⟎ઃߌࠄࠇߡ޿ࠆ‫ޕ‬ᄙߊߪ⥃ᐥ⹜㛎ߣߒߡⴕࠊࠇࠆ‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦ጘ㒂⋵ߢߪᒰ㒮ߩߺ‫ޕ‬࿖ౝ⊛⹏ଔ㧦ㆡᔕߦ㑐ߒߡߪ⼏⺰߇޽ࠆ߇㧘৻ㇱߩ∝଀ߦ߅ߌࠆലᨐߪ⹺⍮ߐࠇߡ޿ࠆ‫ޕ‬࿖㓙⊛⹏ଔ㧦ห਄‫ޕ‬
4㧚ኾ㐷ක࡮⹺ቯක࡮ᜰዉක
᫪⣁ਭ㓉㧦ᣣᧄౝ⑼ቇળ⹏⼏ຬ࡮ᜰዉක࡮ౝ⑼⹺ቯක㧘ᣣᧄᶖൻེ∛ቇળ⹏⼏ຬ࡮ᜰዉක࡮ኾ㐷ක㧘ᣣᧄᶖൻེౝⷞ㏜ቇળᜰዉක࡮ኾ㐷ක㧘ᣣᧄ⢄⤳ቇળᜰዉක࡮ኾ㐷ක㧘ᣣᧄ⥃ᐥ⣲≌ቇળ⹏⼏ຬ࡮ᥳቯᜰዉක㧘ᣣᧄ߇ࠎᴦ≮⹺ቯකᯏ᭴ᥳቯᢎ⢒ක㧘ᣣᧄ≸ቇળ⹏⼏ຬ᧛਄໪㓶㧦ᣣᧄౝ⑼ቇળᜰዉක࡮⹺ቯක㧘ᣣᧄᶖൻེ∛ቇળኾ㐷ක㧘ᣣᧄᶖൻེౝⷞ㏜ቇળኾ㐷ක㧘ᣣᧄ๭ๆེቇળኾ㐷ක㧘ᣣᧄᗵᨴ∝ቇળኾ㐷ක᳗ᧁᱜੳ㧦ᣣᧄౝ⑼ቇળ᧲ᶏ࿾඙⹏⼏ຬ࡮ᜰዉක࡮ౝ⑼⹺ቯක㧘ᣣᧄᶖൻེ∛ቇળ⹏⼏ຬ࡮ᜰዉක࡮ኾ㐷ක㧘ᣣᧄᶖൻེౝⷞ㏜ቇળᜰዉක࡮ኾ㐷ක㧘ᣣᧄ⢄⤳ቇળ⹏⼏ຬ࡮ᜰዉක࡮ኾ㐷ක㧙㧙㢬⷗ ኼ㧦ᣣᧄౝ⑼ቇળ᧲ᶏ࿾඙⹏⼏ຬ࡮ᜰዉක࡮✚วౝ⑼ኾ㐷ක࡮ౝ⑼⹺ቯක㧘ᣣᧄⴊᶧቇળઍ⼏ຬ࡮ᜰዉක࡮ኾ㐷ක㧘ᣣᧄ⥃ᐥ⣲≌ቇળᥳቯᜰዉක࡮߇ࠎ⮎‛≮ᴺኾ㐷ක㧘ᣣᧄ߇ࠎᴦ≮⹺ቯකᯏ᭴ᥳቯᢎ⢒ක࡮⹺ቯක㧘ᣣᧄᶖൻེౝⷞ㏜ቇળኾ㐷ක㧘ᣣᧄ⥃ᐥౝ⑼කળኾ㐷ක⊕㠽⟵ቬ㧦ᣣᧄౝ⑼ቇળ᧲ᶏ࿾඙⹏⼏ຬ࡮ᜰዉක࡮ౝ⑼⹺ቯක㧘ᣣᧄᶖൻེ∛ቇળ᧲ᶏᡰㇱ⹏⼏ຬ࡮ᜰዉක࡮ኾ㐷ක㧘ᣣᧄ⢄⤳ቇળ⷏ㇱ⹏⼏ຬ࡮ᜰዉක࡮ኾ㐷ක㢬⷗ ኼ㧦ᣣᧄౝ⑼ቇળ᧲ᶏ࿾඙⹏⼏ຬ࡮ᜰዉක࡮✚วౝ⑼ኾ㐷ක࡮ౝ⑼⹺ቯක㧘ᣣᧄⴊᶧቇળઍ⼏ຬ࡮ᜰዉක࡮ኾ㐷ක㧘ᣣᧄ⥃ᐥ⣲≌ቇળᥳቯᜰዉක࡮߇ࠎ⮎‛≮ᴺኾ㐷ක㧘ᣣᧄ߇ࠎᴦ≮⹺ቯකᯏ᭴ᥳቯᢎ⢒ක࡮⹺ቯක㧘ᣣᧄᶖൻེౝⷞ㏜ቇળኾ㐷ක㧘ᣣᧄ⥃ᐥౝ⑼කળኾ㐷ක⨹ᧁኡม㧦ᣣᧄౝ⑼ቇળ᧲ᶏ࿾඙⹏⼏ຬ࡮ᜰዉක࡮ౝ⑼⹺ቯක㧘ᣣᧄᶖൻེ∛ቇળᜰዉක࡮ኾ㐷ක㧘ᣣᧄᶖൻེౝⷞ㏜ቇળᜰዉක࡮ኾ㐷ක㧘ᣣᧄ⥃ᐥ⣲≌ቇળᥳቯᜰዉක㧘ᣣᧄ߇ࠎᴦ≮⹺ቯකᯏ᭴ᥳቯᢎ⢒ක቟↰৻ᦶ㧦ᣣᧄౝ⑼ቇળ᧲ᶏ࿾඙⹏⼏ຬ࡮ᜰዉක࡮ౝ⑼⹺ቯක㧘ᣣᧄᶖൻེ∛ቇળᜰዉක࡮ኾ㐷ක㧘ᣣᧄᶖൻེౝⷞ㏜ቇળᜰዉක࡮ኾ㐷ක㧘ᣣᧄ߇ࠎᴦ≮⹺ቯකᯏ᭴ᥳቯᢎ⢒කౝᧁ㓉ᢥ㧦ᣣᧄౝ⑼ቇળᜰዉක࡮ౝ⑼⹺ቯක㧘ᣣᧄᶖൻེ∛ቇળኾ㐷ක㧘ᣣᧄ⢄⤳ቇળኾ㐷කේ ᱞᔒ㧦ᣣᧄౝ⑼ቇળᜰዉක࡮✚วౝ⑼ኾ㐷ක࡮ౝ⑼⹺ቯක㧘ᣣᧄⴊᶧቇળᜰዉක࡮ኾ㐷ක㧘ᣣᧄ⥃ᐥ⣲≌ቇળᥳቯᜰዉක࡮߇ࠎ⮎‛≮ᴺኾ㐷ක㧘ᣣᧄ߇ࠎᴦ≮⹺ቯකᯏ᭴ᥳቯᢎ⢒ක࡮⹺ቯක
ᷡ᳓㓷ੳ㧦ᣣᧄౝ⑼ቇળᜰዉක࡮ౝ⑼⹺ቯක㧘ᣣᧄᶖൻེౝⷞ㏜ቇળኾ㐷ක═ේජ༹㧦ᣣᧄౝ⑼ቇળ⹺ቯක㧘ᣣᧄⴊᶧቇળኾ㐷ක㧘ᣣᧄ⥃ᐥ⣲≌ቇળ߇ࠎ⮎‛≮ᴺኾ㐷ක㧘ᣣᧄ߇ࠎᴦ≮⹺ቯකᯏ᭴ᥳቯᢎ⢒ක࡮⹺ቯක⊕ᧁ ੫㧦ᣣᧄౝ⑼ቇળ⹺ቯක
㜞੗శᴦ㧦ᣣᧄౝ⑼ቇળ⹺ቯක
ศᎹᱞᔒ㧦ᣣᧄౝ⑼ቇળ⹺ቯක
ᓟ⮮ዏ⛗㧦ᣣᧄౝ⑼ቇળ⹺ቯක㧘ᣣᧄⴊᶧቇળኾ㐷ක㧘ᣣᧄ⥃ᐥ⣲≌ቇળ߇ࠎ⮎‛≮ᴺኾ㐷ක㧘ᣣᧄ߇ࠎᴦ≮⹺ቯකᯏ᭴⹺ቯක㧘ᣣᧄᶖൻེౝⷞ㏜ቇળኾ㐷ක౗᧛ାብ㧦ᣣᧄౝ⑼ቇળ✚วౝ⑼ኾ㐷ක࡮ౝ⑼⹺ቯක㧘ᣣᧄⴊᶧቇળኾ㐷ක㧘ᣣᧄ⥃ᐥ⣲≌ቇળ߇ࠎ⮎‛≮ᴺኾ㐷ක㧘ᣣᧄ߇ࠎᴦ≮⹺ቯකᯏ᭴⹺ቯක੗ᷓ⾆჻㧦ᣣᧄౝ⑼ቇળ⹺ቯක㧘ᣣᧄᶖൻེౝⷞ㏜ቇળኾ㐷කጤਅᜏม㧦ᣣᧄౝ⑼ቇળ⹺ቯක㧘ᣣᧄᶖൻེ∛ቇળኾ㐷ක㧘ᣣᧄᶖൻེౝⷞ㏜ቇળኾ㐷කർᎹ㗅৻㧦ᣣᧄౝ⑼ቇળ⹺ቯක㧘ᣣᧄ߇ࠎᴦ≮⹺ቯකᯏ᭴⹺ቯක
5㧚⥄Ꮖ⹏ଔ
⹏ଔ
ᶖൻེౝ⑼㧦ᦨᣂߩක≮ᛛⴚߣߒߡౝⷞ㏜⊛☼⤑ਅጀ೸㔌ⴚ㧔ESD㧕㧘ዊ⣺ౝⷞ㏜㧘⿥㖸ᵄౝⷞ㏜ਅ↢ᬌ㧔EUS-FNA㧕ߥߤࠍⓍᭂ⊛ߦዉ౉ߒ㧘⋵ౝᄖ߆ࠄᢙᄙߊߩᖚ⠪ߩ⚫੺ࠍ㗂޿ߡ޿ࠆ‫ᧄޕ‬ᛛⴚࠍ᥉෸ߔ
ࠆߴߊᜰዉ⊛┙႐ߦ޽ࠅ㧘⻠⠌ળ㧘⎇ୃળߩଐ㗬߽ᄙ޿‫ߚ߹ޕ‬㧘৻ㇱߪ⺰ᢥߦ౏⴫ߒ㧘࿖㓙⊛⹏ଔ߽ᓧߡ
޿ࠆ‫ޕ‬ⴊᶧౝ⑼㧦ⴊᶧౝ⑼ߣߒߡߩᱧผߪᲧセ⊛ᣂߒ޿߇㧘Ⓧᭂ⊛ߦห⢩߆ࠄߩห⒳㛽㜑⒖ᬀ߿ห⒳ᧃ᪳ⴊᐙ
⚦⢩⒖ᬀߩ⚻㛎ࠍߟߺ㧘⤯Ꮺⴊࡃࡦࠢ೑↪ߩ⤯Ꮺⴊ⒖ᬀታᣉᣉ⸳㧔2005 ᐕ㧕߅ࠃ߮㛽㜑ࡃࡦࠢ೑↪ߩ㕖ⴊ✼⠪㑆㛽㜑⒖ᬀታᣉᣉ⸳㧔2008 ᐕ㧕ߩ⹺ቯࠍฃߌࠆߎߣ߇ߢ߈ߚ‫⋵ޕ‬ౝߢ໑৻ߩ⹺ቯᣉ⸳ߢ޽ࠅ㧘⹏ଔߦ୯ߔࠆߣᕁࠊࠇࠆ‫ߒߛߚޕ‬㧘ᄙߊߩቇౝㇱ⟑㧔⋴⼔ㇱ㧘ᚻⴚㇱ㧘㤗㈮⑼㧘ャⴊㇱ㧘ᬌᩏㇱ㧘⮎೷ㇱߥߤ㧕ߩදജߦࠃࠅ㧘⒖ᬀᣉ⸳⹺ቯࠍฃߌࠆߎߣ߇ߢ߈ߚߎߣࠍᒝ⺞ߒߡ߅߈ߚ޿‫ޕ‬߹ߚ㧘ᄙߊߩ⥃ᐥ⹜㛎ࠍㆀⴕ㧘ᦨㄭߢߪ࡝ࡦࡄ⣲ߦኻߔࠆ THP-COP ≮ᴺ߿ Rituximab ૬↪ THP-COP≮ᴺߥߤߩᚑ❣ࠍ⺰ᢥߦ౏⴫ߒߡ㧘࿖㓙⊛⹏ଔࠍᓧߚ‫ޕ‬ᕆᕈ⊕ⴊ∛ߦ߅޿ߡߪ㧘ጘ㒂⋵ߣ޿߁࿾ᣇㇺᏒߩ․ᓽߢ߽޽ࠆ߇㜞㦂⠪߇Ყセ⊛ᄙߊ㧘వߩㅧⴊᐙ⚦⢩⒖ᬀߥߤߩታᣉߪ࿎㔍ߥ∝଀߇ᄙ޿‫ޕ‬ᮡḰ⊛ߥᒝജ
ൻቇ≮ᴺㆀⴕ߇࿎㔍ߥ∝଀ࠍኻ⽎ߦࠨࠗ࠻ࠞࠗࡦ૬↪ߩዋ㊂ൻቇ≮ᴺߩ⥃ᐥ⹜㛎ࠍታᣉߒ㧘⺰ᢥߦ౏⴫ߒ
ߡ࿖㓙⊛⹏ଔࠍᓧߚ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ᶖൻེౝ⑼㧦ᛛⴚ⊛ߦᬌᩏ࡮ᴦ≮ߩ࿎㔍ߥ∝଀߽޽ࠆὐߣᖚ⠪߳ߩଚⷅ߇ዋߥ߆ࠄߕ޽ࠆὐ߇໧㗴ߢ޽ࠆ‫ߪߡߞࠃߦ଀∝ޕ‬㧘ߤ߁ߒߡ߽ᤨ㑆ࠍⷐߔࠆߎߣ߽޽ࠆ߇㧘ࠃࠅ቟ోߦ㧘ߘߒߡᖚ⠪ߦ⧰∩ࠍਈ߃ࠆߎ
ߣߩߥ޿ࠃ߁ߥᛛⴚߩะ਄ߦദ߼ߚ޿‫ޕ‬
ⴊᶧౝ⑼㧦㜞㦂⠪߇ᄙ޿ߣ޿߁࿾ၞᕈ߽޽ࠅ㧘ᕆᕈ⊕ⴊ∛߿ᖡᕈ࡝ࡦࡄ⣲ߦ߅޿ߡᮡḰ⊛ᴦ≮ߩㆀⴕ߇࿎㔍ߥ∝଀߇ዋߥߊߥ޿‫ߚ߹ޕ‬㧘ផቯߐࠇࠆ੍ᓟߦࡃ࡜࠷߽ࠠ޽ࠅ㧘↹৻ᴦ≮ߦ⇼໧߇߽ߚࠇࠆ∝଀߽ᄙ㧙㧙ߊ⚻㛎ߔࠆ‫߼ߚߩߎޕ‬㧘ว૬∝߿੍ᓟ࿃ሶ㧘ᐕ㦂ߥߤߦၮߠߊጀ೎ൻᴦ≮߇ᦼᓙߐࠇࠆ‫ޕ‬੹ᓟߩዷᦸᶖൻེౝ⑼㧦ࠃࠅ቟ోߢ㧘ࠃࠅ♖ᐲߩ㜞޿⸻ᢿ߇ߢ߈ࠆࠃ߁ߥౝⷞ㏜ᛛⴚࠍዉ౉ߒߚ޿‫ߚ߹ޕ‬㧘ࠃࠅᩮᴦᐲߩ㜞޿ౝⷞ㏜ᴦ≮ࠍផㅴߐߖߚ޿‫ޕ‬
ⴊᶧౝ⑼㧦ጀ೎ൻᴦ≮ߩߚ߼ߦߪ቟ቯߒߚ੍ᓟ࿃ሶߩ᛽಴߇ᔅⷐߢ޽ࠆ‫⃻ޕ‬࿷㧘⊕ⴊ∛߿࡝ࡦࡄ⒳ࠍኻ
⽎ߦ㧘ߐ߹ߑ߹ߥ੍ᓟ࿃ሶߩត⚝ࠍⴕߞߡ޿ࠆ‫ߚ߹ޕ‬㧘ᣂߚߥࠆࠛࡆ࠺ࡦࠬࠍ⏕┙ߔࠆߴߊߐ߹ߑ߹ߥ⥃ᐥ⹜㛎㧔phase II, phase III ⹜㛎㧕ࠍㅴ߼ߚ޿‫৻ޕ‬ᣇ㧘ᴦ≹ᜰะߩᮡḰᴦ≮߇ታᣉߢ߈ߥ޿∝଀ߦኻߒߡ
ߪ㧘QOL ࠍ㊀ⷞߒߚᴦ≮ߩࠛࡆ࠺ࡦࠬࠍ⏕┙ߒߚ޿‫ޕ‬㧙㧙㧔2㧕╙ੑౝ⑼1㧚⸻≮ߩ᭎ⷐ
ᒰ⑼ߪᓴⅣེ㧘๭ๆེ෸߮⣢⤳∛ࠍኾ㐷ߣߔࠆ⸻≮⑼ߢ޽ࠅ㧘ᄖ᧪㧘౉㒮ߣ߽ߦᒰ㒮ߢ㧘৻㧘ੑࠍ┹߁ᢙߩᖚ⠪ߐࠎࠍ⸻≮ߒߡ޿ࠆ‫ޕ‬ᄖ᧪ㇱ㐷ߢߪ㧘ᓴⅣེ㧘๭ๆེ෸߮⣢⤳∛ߘࠇߙࠇߩኾ㐷ᄖ᧪ࠍ⸳ߌߡ޿ࠆ߫߆ࠅߢߥߊ㧘ߎࠇࠄߩ⸻
≮ߣኒធߦ㑐ਈߔࠆ⑌ᾍᄖ᧪߿ṽᣇ޽ࠆ޿ߪ㎞ἲߥߤߩ․ᱶᄖ᧪߽⸳⟎ߒߡ޿ࠆ‫ޕ‬ᄖ᧪ߪ᦬ᦐ߆ࠄ㊄ᦐ߹ߢᲤᣣࠝ࡯ࡊࡦߒߡ޿ߡ㧘ೋ⸻ߪᲤᣣ 2㧙3 ੱߩೋ⸻කࠍߚߡ㧘ㅦ߿߆ߥ⸻≮ߦ⇐ᗧߒߡ޿ࠆ‫ޕ‬ౣ⸻ߪߔߴߡ੍⚂೙ߢ޽ࠅ㧘ᖚ⠪ߐࠎߩᓙߜᤨ㑆ߪ㕖Ᏹߦዋߥߊᅢ⹏ࠍᓧߡ޿ࠆ‫ޕ‬౉㒮ㇱ㐷ߢߪ㧘ห᭽ߦᓴⅣེ㧘๭ๆེ෸߮⣢⤳∛ߩ౉㒮ᖚ⠪߇ᄢㇱಽࠍභ߼ߡ޿ࠆ‫ޕ‬ᓴⅣེౝ⑼ߩᖚ⠪ߪᜂᒰකᏧߩദജߦࠃࠅᔃ⤳ࠞ࠹࡯࠹࡞ᬌᩏᢙ߽⪺᣿ߦჇടߒㅳ 15㧙20 ଀ߦ㆐ߔࠆ‫ࠍ࡞࠹࡯࠹ࠞߚ߹ޕ‬↪޿ߚ౰േ⣂ᒻᚑⴚߥߤߩᴦ≮߽ࠦࡦࠬ࠲ࡦ࠻ߦᲤㅳ 4㧙5 ଀ⴕࠊࠇࠆࠃ߁ߦߥߞߚ‫߼ߚߩߎޕ‬ਛᄩ᡼኿✢ㇱߩㅪ⛯ⴊ▤ቶߩ૶↪ᨒࠍჇ߿ߒߡ㗂޿ߡኻᔕߒߡ޿ࠆ‫ޕ‬ᐔᚑ 11 ᐕᐲᧃ߆ࠄߪᄢቇ∛㒮ߩవㅴᕈࠍ↢߆ߒߡᔃ⤳౰േ⣂ౝߩౝⷞ㏜ߦࠃࠆⷰኤ෸߮౰ⴊ▤ౝࠛࠦ࡯ߩ integrated backscatter ߩ᷹ቯߦࠃࠆേ⣂⎬ൻᎽߩ⹦⚦ߥಽᨆࠍⴕ޿㧘ߎࠇࠄߩࠞ࠹࡯࠹࡞ᴦ≮ߦᓎ┙ߡࠆߣ޿߁వㅴක≮ࠍⴕߞߡ޿ࠆ‫ޕ‬⣨േ⣂߆ࠄߩᔃࠞ࠹࡮PCI ଦㅴ߅ࠃ߮ࠢ࡝࠾ࠞ࡞ࡄࠬߩᔀᐩൻߦࠃࠆᖚ⠪ߩᣧᦼㅌ㒮ࠍౕ૕⊛ߥᣇ╷ߣߒߡ޿ࠆ‫ޕ‬๭ๆེࠣ࡞࡯ࡊߪਥߦ⢖≸߿ᘟᕈ㐽Ⴇᕈ⢖∔ᖚߥߤࠍᴦ≮ߒ㧘ߘߩኻ⽎ߪᄙጘߦࠊߚࠆ‫ޕ‬Ფㅳᣉⴕߐࠇࠆ
᳇▤ౝⷞ㏜ᬌᩏߪᐕ㑆 250 ଀એ਄ߦࠊߚࠅ㧘CT ࠟࠗ࠼ਅ⣲≌↢ᬌ㧘ዪᚲ㤗㈮ਅ⢷⣧㏜ᬌᩏ㧘᳇▤ᡰ⿥㖸ᵄ⸻ᢿ㧘ࠟࠗ࠼ࠪ࡯ࠬᴺࠍ↪޿ߚᓸዊ∛ᄌ⸻ᢿ㧘࡟࡯ࠩ࡯ᴦ≮㧘ࠬ࠹ࡦ࠻ᴦ≮╬ߩᦨᣂߩ⸻≮ᛛⴚࠍ↪޿
ߚ⸻ᢿᴺࠍขࠅ౉ࠇߡ޿ࠆ‫ߚ߹ޕ‬㧘๭ๆེࠞࡦࡈࠔ࡟ࡦࠬߦࠃࠅ㧘චಽߥ࠺ࠖࠬࠞ࠶࡚ࠪࡦߩ߽ߣߦᴦ≮ᴺࠍㆬᛯߒߡ޿ࠆ‫⼔⋴ޕ‬Ꮷ㧘⮎೷Ꮷߣኒធߦㅪ⛊ߒߥ߇ࠄᖚ⠪ߐࠎߩ QOL ࠍ㊀ⷞߒߚක≮ࠍ⋡ᜰߒ㧘㒰
∩≮ᴺߪ․ߦⓍᭂ⊛ߦኻᔕߒߡ޿ࠆ‫ޕ‬⣢⤳ࠣ࡞࡯ࡊߪ♻⃿૕⣢Ἳ㧘࡞࡯ࡊࠬ⣢Ἳߥߤ⣢⤳∔ᖚߪᄙ޿߇㧘⿥㖸ᵄࠟࠗ࠼ਅߩ⣢↢ᬌࠍⓍᭂ⊛ߦᣉⴕߒ㧘ㆡಾߥ⸻ᢿࠍⴕ޿㧘ᴦ≮ᴺࠍㆬᛯߒ㧘ㅘᨆᖚ⠪ߐࠎߦߪ⣢⤳ౝ⑼ක⥄ࠄࠪࡖࡦ࠻ᚻⴚ߿⣻⤑ㅘᨆ╬ࠍⴕߞߡ޿ࠆ‫ߚ߹ޕ‬㧘⣢⤳ౝ⑼ߘߩਛߢ߽ᦨㄭ⪺Ⴧߒߡ޿ࠆ♧ዩ∛ᕈ⣢∝ߩᴦ≮ߦ․ߦജࠍ౉ࠇߡ޿ࠆ‫ޕ‬
2㧚ᢎ⢒ᣉ⸳
1㧕 ᣣᧄౝ⑼ቇળ⹺ቯකᢎ⢒∛㒮
2㧕 ᣣᧄᓴⅣེቇળᓴⅣེኾ㐷ක⎇ୃᣉ⸳
3㧕 ᣣᧄ๭ๆེቇળ⹺ቯᣉ⸳
4㧕 ᣣᧄ๭ๆེౝⷞ㏜ቇળ⹺ቯᣉ⸳
5㧕 ᣣᧄ⥃ᐥ⣲≌ቇળ⹺ቯ⎇ୃᣉ⸳
6㧕 ᣣᧄ߇ࠎᴦ≮⹺ቯකᯏ᭴⹺ቯ⎇ୃᣉ⸳7㧕 ᣣᧄ⣢⤳ቇળ⎇ୃᣉ⸳8㧕 ᣣᧄᩭකቇળ⹺ቯකᢎ⢒∛㒮
3㧚⸻≮㐿⊒
1㧕 ⸻≮ฬ 㧦MDCT㧔multi-detector CT㧕ࠍ↪޿ߚ㕖ଚⷅ⊛౰േ⣂∛ᄌ⸻ᢿࠪࠬ࠹ࡓߩ㐿⊒࡮ዉ౉̆IB-IVUS ߣߩᲧセ̆⸻≮ౝኈ㧦ᚒ‫ ߢࡓࠗ࠲࡞ࠕ࡝ߪޘ‬2 ᰴర౰േ⣂⚵❱ᕈ⁁㧔⁜⓰ᐲ࡮lipid core size࡮❫⛽ൻ࡮⍹Ἧൻ㗔ၞ╬㧕⸻ᢿน⢻ߥ IB-IVUS㧔ᓟᣇᢔੂ㧙ⴊ▤ౝ⿥㖸ᵄ㧕ⵝ⟎ߩ㐿⊒ߦ਎⇇ߢೋ߼ߡᚑഞߒ㧘⃻࿷ߎߩⵝ⟎ࠍ࿖ౝ࡮࿖ᄖߦะߌߡ⊒ᄁߔࠆߣߎࠈߢ޽ࠆ‫ ⚂ޕ‬100 ଀ߩ PCI ᖚ⠪ࠍኻ⽎ߦᦨㄭ⪺ߒߊㅴᱠߒߚ౰േ⣂ߩ MDCT㧔multi-detector CT㧕↹௝ࠍଚⷅ⊛ᬌᩏߢ޽ࠆ
IB-IVUS ਗ߮ߦ౰േ⣂ㅧᓇ㧔CAG㧕ᚲ⷗ߣᲧセߔࠆߎߣߦࠃࠅ MDCT ߦࠃࠆᣂⷙ㕖ଚⷅ⊛౰േ⣂∛ᄌ⸻ᢿࠪࠬ࠹ࡓߩ㐿⊒ࠍ⋡ᜰߔ‫ޕ‬࿖ౝ⊛⹏ଔ㧦㕖ଚⷅ⊛ⵝ⟎ߢ޽ࠆ MDCT ߆ࠄᓧࠄࠇࠆ౰േ⣂ოߩ↹௝߇ߤߩࠃ߁ߥേ⣂⎬ൻ⚵❱᭴ㅧࠍ෻ᤋߒߡ޿ࠆ߆ࠍ⸻ᢿߔࠆߚ߼ߦߪࠦࡦ࠻ࡠ࡯࡞ߣߥࠆᚒ‫߇ޘ‬㐿⊒ߒߚ IB-IVUS ᚲ⷗߇ᔅ㗇ߢ޽ࠆ‫ޕ‬ᚒ‫ ߩޘ‬IB-IVUS ⎇ⓥߦኻߒ 2003 ᐕߦߪ Banyu Fellowship Award ߿ࡃࠗࠛ࡞⥃ᐥⴊ▤ᯏ⢻⎇ⓥഥᚑߩᦨఝ⑲⾨ࠍ₪ᓧߒߚࠃ߁ߦ㜞޿࿖ౝ⹏ଔࠍᓧߡ޿ࠆ‫ޕ‬࿖㓙⊛⹏ଔ㧦౰േ⣂∛ᄌࠍ CAG ߿ IVUS ߩࠃ߁ߥଚⷅ⊛ᬌᩏߦࠃࠄߕ㧘㕖ଚⷅ⊛ߦ⸻ᢿߔࠆߎߣߪ
ੱ㘃ߩ㐳޿ᄞߢ޽ߞߚ‫ޕ‬MDCT ᚲ⷗ࠍ CAG࡮IB-IVUS ᚲ⷗ߣᲧセߒߎߩᄞߦㄭߠߊߎߣ
ߪᕆᕈ౰∝୥⟲ߩ੍㒐ࠍߪߓ߼㧘ᖚ⠪ߦߣߞߡᄢ߈ߥ೑ὐ߇޽ࠆ‫ޕ‬IB-IVUS ߩᚒ‫ߩޘ‬ᚑ❣
ߪߔߢߦ Circulation㧘J Am Col Cardiol ╬ߩ৻ᵹ⹹ߦᄙᢙ⊒⴫ߐࠇߡ߅ࠅ㧘࿖㓙⊛⹏ଔ㧙㧙ߪ㜞޿‫ޕ‬4㧚ኾ㐷ක࡮⹺ቯක࡮ᜰዉක
Ḋญା਽㧦ᣣᧄᓴⅣེቇળኾ㐷ක㧘ᣣᧄౝ⑼ቇળ⹺ቯක࡮✚วౝ⑼ኾ㐷ක࡮⎇ୃකᜰዉක㧘ᣣᧄ⥃ᐥ⮎ℂቇળ⹺ቯක࡮ᜰዉක㧘ᣣᧄකᏧળ⹺ቯ↥ᬺක㧘ᣣᧄ㜞ⴊ࿶ቇળኾ㐷ක㧘ᣣᧄᔃ⤳࡝ࡂࡆ࡝࠹࡯
࡚ࠪᜰዉ჻┻᧛రਃ㧦ᣣᧄᓴⅣེቇળኾ㐷ක㧘ᣣᧄౝ⑼ቇળ⹺ቯක࡮✚วౝ⑼ኾ㐷ක࡮⎇ୃකᜰዉක
⷏၂๺ᒾ㧦ᣣᧄᓴⅣེቇળኾ㐷ක㧘ᣣᧄౝ⑼ቇળ⹺ቯක࡮⎇ୃකᜰዉක㧘ᣣᧄᓴⅣེቇળ⹺ቯ ACLS ࠗࡦࠬ࠻࡜ࠢ࠲࡯㧘ᣣᧄකᏧળ⹺ቯ↥ᬺක㧘ᣣᧄකᏧળ⹺ቯஜᐽࠬࡐ࡯࠷࠼ࠢ࠲࡯㧘ᣣᧄᔃⴊ▤ࠞ࠹࡯࠹࡞ᴦ≮ቇળ⹺ቯᜰዉක㧘ᣣᧄਇᢛ⣂ቇળ ICD/CRT ⹺ቯක㧘ᣣᧄᔃ⤳࡝ࡂࡆ࡝࠹࡯࡚ࠪ
ࡦᜰዉ჻㧘ෘ↢ഭ௛⋭⹺ቯ⥃ᐥ⎇ୃᜰዉක㧘☨࿖ᔃ⤳දળ㧔AHA㧕⹺ቯ BLS/ACLS ࠗࡦࠬ࠻࡜ࠢ࠲࡯Ꮉፒ㓷ⷙ㧦ᣣᧄᓴⅣེቇળኾ㐷ක㧘ᣣᧄౝ⑼ቇળ⹺ቯක࡮⎇ୃකᜰዉක㧘ᣣᧄ⿥㖸ᵄකቇળ⿥㖸ᵄኾ㐷ක㕍ጊ℉⏴㧦ᣣᧄᓴⅣེቇળኾ㐷ක㧘ᣣᧄౝ⑼ቇળ⹺ቯක࡮ᜰዉක
ᄢ㊁ ᐽ㧦ᣣᧄౝ⑼ቇળ⹺ቯක࡮✚วౝ⑼ኾ㐷ක࡮⎇ୃකᜰዉක㧘ᣣᧄ๭ๆེቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄ๭ๆེౝⷞ㏜ቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄ⥃ᐥ⣲≌ቇળᥳቯᜰዉක㧘ᣣᧄ߇ࠎ⹺ቯᯏ᭴ᥳቯᢎ⢒ක‐⿧ඳᤘ㧦ᣣᧄᓴⅣེቇળኾ㐷ක㧘ᣣᧄౝ⑼ቇળ⹺ቯක࡮✚วౝ⑼ኾ㐷ක࡮ᜰዉක㧘ᣣᧄකᏧળ⹺ቯ↥ᬺක㊄᫪ኡల㧦ᣣᧄᓴⅣེቇળኾ㐷ක㧘ᣣᧄౝ⑼ቇળ⹺ቯක
Ꮉ᧛৻ᄥ㧦ᣣᧄౝ⑼ቇળ⹺ቯක࡮✚วౝ⑼ኾ㐷ක㧘ᣣᧄᓴⅣེቇળኾ㐷ක㧘ᣣᧄᩭකቇળኾ㐷ක㧘ᣣᧄᔃ⤳࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦᜰዉ჻
⥱ญ␸ᒾ㧦ᣣᧄౝ⑼ቇળ⹺ቯක࡮✚วౝ⑼ኾ㐷ක㧘ᣣᧄ๭ๆེቇળኾ㐷ක㧘ᣣᧄ๭ๆེౝⷞ㏜ቇળኾ㐷ක㧘ᣣᧄ߇ࠎ⹺ቯකᯏ᭴ᢎ⢒කਭ଻↰⍮Ꮧ㧦ᣣᧄౝ⑼ቇળ⹺ቯක㧘ᣣᧄᓴⅣེቇળኾ㐷ක㧘ICD ⹺ቯක㧘CRT ⹺ቯක᫪ ⑲ᴺ㧦ᣣᧄౝ⑼ቇળ⹺ቯක
ᣧᎹ↱㚅㧦ᣣᧄౝ⑼ቇળ⹺ቯක
5㧚⥄Ꮖ⹏ଔ
⹏ଔౣ↢කቇ࡮ක≮ߥࠄ߮ߦ IB-IVUS ߩ⎇ⓥ߇㗅⺞ߦㅴⴕߒ㧘৻ᵹߩࠫࡖ࡯࠽࡞ߦ publish ߐࠇ㧘2006 ᐕߪ⧷ᢥ⺰ᢥᢙ 23 ߢࠗࡦࡄࠢ࠻ࡈࠔࠢ࠲࡯߇ 94.891 ὐ㧘2007 ᐕߪ⧷ᢥ⺰ᢥᢙ 26 ߢࠗࡦࡄࠢ࠻ࡈࠔࠢ࠲
࡯߇ 102.353 ὐ㧘2008 ᐕߪ⧷ᢥ⺰ᢥᢙ 15 ߢࠗࡦࡄࠢ࠻ࡈࠔࠢ࠲࡯߇ 37.786 ὐߢ޽ߞߚ‫ߚ߹ޕ‬㧘IB-IVUSࠍ਎⇇ߢೋ߼ߡታ↪ൻߒ㧘⃻࿷㧘ⵝ⟎ࠍᄁࠅ಴ߒߡ޿ࠆ߇㧘ౝᄖߢ㜞޿⹏ଔࠍฃߌߡ޿ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ᄙᢙߩᄢቇ㒮↢߿⎇ⓥ⠪ࠍᛴ߃ߡ߅ࠅ㧘࠺ࠬࠢ߿ࠬࡍ࡯ࠬࠍ⏕଻ߔࠆ੐ߦ࿎㔍ߒߡ޿ࠆ‫ߦࠄߐޕ‬㧘ᓴⅣེ㧘๭ๆེ㧘⣢⤳ߣ 3 ߟߩಽ㊁ࠍᜂᒰߒߡ޿ࠆ߇㧘ഥᢎએ਄ߩࡐ࡚ࠫࠪࡦ߇ዋߥ޿ߚ߼ੱ᧚⏕଻ߦߟ޿ߡ
࿎㔍ࠍ઻߁‫ߚ߹ޕ‬㧘⥃ᐥ㧘ᢎ⢒㧘⎇ⓥߩߤߜࠄߦ߽ᤨ㑆ࠍ⾌߿ߒߡ޿ࠆߚ߼㧘⎇ⓥߦචಽߥᤨ㑆߇޽ࠆߣߪ⸒޿㔍޿‫ޕ‬੹ᓟߩዷᦸ⃻࿷㧘ᓴⅣེ∔ᖚ㧘๭ๆེ∔ᖚ㧘⣢⤳∔ᖚߪ߹ߔ߹ߔჇടߔࠆ௑ะߦ޽ࠅ㧘ߘࠇߙࠇߩ∛᳇ߩࡔࠞ࠾࠭
ࡓࠍേ‛ታ㛎㧘⥃ᐥ⎇ⓥࠍㅢߓߡ⸃᣿ߒ㧘ᴦ≮ߦᔕ↪ߒߡ޿ߊߎߣ߇㊀ⷐߣ⠨߃ࠄࠇࠆ‫੹ޕ‬ᓟ㧘ᓴⅣེ∔ᖚ㧘๭ๆེ∔ᖚ㧘⣢⤳∔ᖚߩಽ㊁ߦ߅޿ߡ⚦⢩ᱫࠍ᳿ቯߔࠆࠕࡐ࠻࡯ࠪࠬ㧘⚦⢩ࠍౣ↢ߔࠆౣ↢කቇߥߤ߇ࠃࠅ㊀ⷐߥ⎇ⓥ࠹࡯ࡑߣߥࠆߎߣ߇੍ᗐߐࠇࠆ‫ޕ‬ᓥߞߡ㧘ᚒ‫ߩߎߪޘ‬ὐࠍචಽ⹺⼂ߒ㧘ಽሶ↢‛ቇ⊛ᚻ
ᴺࠍ㚟૶ߒ㧘ߐࠄߥࠆᵴ⊒ߥ⎇ⓥᵴേࠍⴕߞߡ޿߆ߥߊߡߪߥࠄߥ޿ߣ⠨߃ࠆ‫ޕ‬㧙㧙㧔3㧕╙ਃౝ⑼1㧚⸻≮ߩ᭎ⷐ
♧ዩ∛ઍ⻢ౝ⑼ߢߪ㧘♧ዩ∛ࠍਛᔃߣߒߡࠗࡦࠬ࡝ࡦዉ౉㧘㜞ᐲߥว૬∝ߩᴦ≮㧘ߐࠄߦേ⣂⎬ൻ∝ߥ
ߤߩቯ㊂ᬌᩏߣ੍㒐㧘♧ዩ∛࡮↢ᵴ⠌ᘠ∛ᢎ⢒౉㒮ߥߤࠍⴕߥߞߡ޿ࠆ‫࡮∉఺ޕ‬ౝಽᴲౝ⑼ߢߪ㧘ోりᕈࠛ࡝࠹ࡑ࠻࡯࠺ࠬߥߤߩ⤔ේ∛㧘࡝࠙ࡑ࠴ᕈ∔ᖚࠍᜂᒰߒߡ޿ࠆ‫ ޕ‬ᴦ≮ߦ㔍ᷦߔࠆߎߣ߇ᄙߊࠬ࠹ࡠࠗ
࠼㧘఺∉ᛥ೙೷ߥߤࠍㆡಾߦ૶↪ߒᖚ⠪ߩኡ⸃ࠍ߼ߑߒߡ޿ࠆ‫ᦨޕ‬ㄭߩ↹௝⸻ᢿߩㅴᱠߢ㧘஧⊒⊛ߦߺߟ߆ࠆਅု૕㧘೽⣢ߩ⣲≌ᕈ∛ᄌ߽ᄙߊߥࠅ㧘ฦ⒳ࡎ࡞ࡕࡦ⽶⩄ᬌᩏߥߤ⊛⏕ߦ⸻ᢿߒઁ⑼ߣㅪ៤ߒߡᴦ≮ߦ޽ߚߞߡ޿ࠆ‫ޕ‬
2㧚ᢎ⢒ᣉ⸳
1㧕 ᣣᧄౝ⑼ቇળ⹺ቯౝ⑼ኾ㐷කᢎ⢒ᣉ⸳
2㧕 ᣣᧄ♧ዩ∛ቇળ⹺ቯᢎ⢒ᣉ⸳
3㧕 ᣣᧄౝಽᴲቇળ⹺ቯᢎ⢒ᣉ⸳
4㧕 ᣣᧄੱ㘃ㆮવቇળ⹺ቯᢎ⢒ᣉ⸳
3㧚⸻≮㐿⊒
1㧕 ⸻≮ฬ 㧦േ⣂⎬ൻᄖ᧪㧔ࡔ࠲ࡏ࡝࠶ࠢࠪࡦ࠼ࡠ࡯ࡓ⸻≮㧕⸻≮ౝኈ㧦ᣂߒ޿ࡔ࠲ࡏ࡝࠶ࠢࠪࡦ࠼ࡠ࡯ࡓߩ⸻ᢿၮḰࠍዉ౉ߒ㧘ࠕ࠺ࠖࡐࠨࠗ࠻ࠞࠗࡦ᷹ቯ㧘౰േ⣂ CT 㗖േ⣂ࠛࠦ࡯ߥߤߩ㕖ଚⷅ⊛േ⣂⎬ൻቯ㊂ᬌᩏࠍ߽ߜ޿ߡ㧘േ⣂⎬ൻᕈᔃⴊ▤∛ߩ⊒∝޽ࠆ޿ߪㅴዷߩ੍㒐ߩߚ߼ലᨐ⊛ߥஜᐽᜰዉ㧘㘩੐ᜰዉ㧘⮎‛≮ᴺߥߤࠍⴕ߁‫ޕ‬࿖ౝ⊛⹏ଔ㧦ో࿖ᱫ࿃⛔⸘ߢߪേ⣂⎬ൻߦࠃࠆ⣖ⴊ▤∔ᖚ㧘ᔃⴊ▤∛߇ 30%ࠍභ߼ࠆ‫ᦨޕ‬ㄭߩ⎇ⓥߢ♧ዩ∛㧘㜞⢽ⴊ∝㧘㜞ⴊ࿶∝ߦട߃⣻⣧ౝ⢽⢌⫾Ⓧ߇േ⣂⎬ൻ⊒∝ߩේ࿃ߣߒߡ㊀ⷐߢ޽ࠆߎߣ߇᣿ࠄ߆ߣߥࠅ㧘ࡔ࠲ࡏ࡝࠶ࠢࠪࡦ࠼ࡠ࡯ࡓߩ᭎ᔨ߇↢߹ࠇߚ‫ޕ‬േ⣂⎬ൻᕈᔃⴊ▤∛੍㒐ࠍ⋡⊛ߦ㧘㕖ଚⷅ⊛േ⣂⎬ൻቯ㊂ᬌᩏᴺࠍㅪേߐߖ㧘ᣂߒ޿േ⣂⎬ൻᄖ᧪ߩ߆ߚߜ
ࠍዷ㐿ߒߡ޿ߊߎߣߪଔ୯޽ࠆߣᕁࠊࠇࠆ‫ޕ‬࿖㓙⊛⹏ଔ㧦േ⣂⎬ൻߩේ࿃ߣߒߡ㜞ࠦ࡟ࠬ࠹ࡠ࡯࡞ⴊ∝߇޽ࠆߩߪ๟⍮ߩߎߣߢ޽ࠆ߇㧘ㄭᐕᶏᄖߢߪࠗࡦࠬ࡝ࡦᛶ᛫ᕈ㧘਄ඨり⢈ḩߥߤ߇േ⣂⎬ൻߩ࡝ࠬࠢߣߒߡឭ໒ߐࠇߚ‫࡝ࡏ࠲ࡔޕ‬࠶ࠢࠪࡦ࠼ࡠ࡯ࡓߪᣣᧄੱߩࠛࡆ࠺ࡦࠬߦၮߠߊ⸻ᢿၮḰߣߒߡᣂߒߊឭ໒ߐࠇߚ߽ߩߢ޽ࠆ‫ޕ‬4㧚ኾ㐷ක࡮⹺ቯක࡮ᜰዉක
ᱞ↰ ⚐㧦ᣣᧄౝ⑼ቇળ⹺ቯකᜰዉක㧘ᣣᧄ♧ዩ∛ቇળ♧ዩ∛ኾ㐷ක࡮ᜰዉක㧘ᣣᧄੱ㘃ㆮવቇળ⥃ᐥㆮવኾ㐷ක࡮ᜰዉක㧘ᣣᧄ∛ᘒᩕ㙃ቇળ⹺ቯ NST ࠦ࡯࠺ࠖࡀ࡯࠲࡯㧘ᣣᧄౝಽᴲቇળౝಽᴲઍ
⻢․଀ᜰዉක
㋈ᧁ⧷ม㧦ᣣᧄౝ⑼ቇળ⹺ቯකᜰዉක㧘ᣣᧄ♧ዩ∛ቇળ♧ዩ∛ኾ㐷ක࡮ᜰዉක㧘කᏧળ⹺ቯ↥ᬺකၳᎹᐘ↵㧦ᣣᧄౝ⑼ቇળ⹺ቯකᜰዉක㧘ᣣᧄ♧ዩ∛ቇળ♧ዩ∛ኾ㐷ක࡮ᜰዉක㧘ᣣᧄ∛ᘒᩕ㙃ቇળ⹺ቯ
NST ࠦ࡯࠺ࠖࡀ࡯࠲࡯
ട⚊సᓼ㧦ᣣᧄౝ⑼ቇળ⹺ቯౝ⑼ኾ㐷ක࡮ᜰዉක㧘ᣣᧄ♧ዩ∛ቇળ♧ዩ∛ኾ㐷ක㧘ᣣᧄ࡝࠙ࡑ࠴ቇળኾ㐷ක⺪⸰ື਽㧦ᣣᧄౝ⑼ቇળ⹺ቯౝ⑼ኾ㐷ක࡮ᜰዉක㧘ᣣᧄ♧ዩ∛ቇળ♧ዩ∛ኾ㐷ක㧘ᣣᧄౝಽᴲቇળౝಽᴲ
ઍ⻢ኾ㐷ක࡮ᜰዉක
૒‫ᧁޘ‬ᤘᒾ㧦ᣣᧄౝ⑼ቇળ⹺ቯකᜰዉක㧘ᣣᧄ♧ዩ∛ቇળ♧ዩ∛ኾ㐷ක㧘ᣣᧄᶖൻེౝⷞ㏜ቇળኾ㐷කᎹ࿾ᘕ৻㧦ᣣᧄౝ⑼ቇળ⹺ቯౝ⑼ኾ㐷ක࡮ᜰዉක㧘ᣣᧄ♧ዩ∛ቇળ♧ዩ∛ኾ㐷ක࡮ᜰዉක㧘ᣣᧄౝಽᴲቇ
ળౝಽᴲઍ⻢ኾ㐷ක࡮ᜰዉක㧘ᣣᧄᶖൻེౝⷞ㏜ቇળኾ㐷කႮ⼱⌀↱⟤㧦ᣣᧄౝ⑼ቇળ⹺ቯක㧘ᣣᧄකቇ᡼኿✢ቇળኾ㐷කᑝ↰ථ↵㧦ᣣᧄౝ⑼ቇળ⹺ቯౝ⑼ኾ㐷ක㧘ᣣᧄ♧ዩ∛ቇળ♧ዩ∛ኾ㐷කફ⷗ትବ㧦ᣣᧄౝ⑼ቇળ⹺ቯౝ⑼ኾ㐷ක㧘ᣣᧄᶖൻེౝⷞ㏜ቇળኾ㐷ක㧘ᣣᧄᶖൻེ∛ቇળኾ㐷ක㤥↰⧷༹㧦ᣣᧄౝ⑼ቇળ⹺ቯౝ⑼ኾ㐷කằ⼱㜞ᔒ㧦ᣣᧄౝ⑼ቇળ⹺ቯක㧙㧙5㧚⥄Ꮖ⹏ଔ
⹏ଔ࠴࡯ࡓක≮ߩታ〣ߣኾ㐷⊛ࠦࡔ࠺ࠖࠞ࡞ߩ⢒ᚑߦࠃࠅ㧘ࠃࠅ⾰ߩ㜞޿ක≮߇ឭଏߢ߈ߡ޿ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷♧ዩ∛ߩჇടߦ઻޿㧘ో⑼ߦᖚ⠪߇ሽ࿷ߒ㧘♧ዩ∛ᄖ᧪߿ᢎ⢒౉㒮ᴦ≮ߛߌߢߪኻᔕߒ߈ࠇߥߊߥߞߡ
߈ߡ޿ࠆ‫ⶄߚ߹ޕ‬㔀ߥว૬∝଀߇ᄙߊઁ⑼ߩදജߩ߽ߣ⸻≮ࠍⴕߥߞߡ޿ࠆ‫੹ޕ‬ᓟߪ㒮ౝ⻠⠌ળߩડ↹㧘
ઁ⑼ߩකᏧ㧘ࠦࡔ࠺ࠖࠞ࡞ࠬ࠲࠶ࡈߣࠃࠅㅪ៤ࠍᷓ߼ߡ޿ߊᔅⷐᕈ߇޽ࠆ‫♧ߚ߹ޕ‬ዩ∛ᢎቶߪᜂᒰ∛᫟ߩߺߢߥߊ㒮ౝ㒮ᄖߦ߽ᐢߊዷ㐿ߒߡ޿ߊ‫ޕ‬੹ᓟߩዷᦸ♧ዩ∛ߥߤߩ↢ᵴ⠌ᘠ∛ߦኻߒ㧘ጘ㒂Ꮢ㧘කᏧળߥߤࠍ฽߻ฦ⒳⥄ᴦ૕ߣㅪ៤ߒ㧘࿾ၞో૕ߢ∔ᖚߩℂ⸃㧘੍㒐ක≮ࠍዷ㐿ߒߡ޿ߊ‫ߦࠄߐޕ‬ㆮવሶ⸻ᢿߦၮߠߊࠝ࡯࠳࡯ࡔࠗ࠼ක≮ࠍ⏕┙ߐߖࠆ‫ޕ‬㧙㧙㧔4㧕␹⚻ౝ⑼࡮⠧ᐕ⑼1㧚⸻≮ߩ᭎ⷐ
㗡∩㧘߼߹޿㧘ߒ߮ࠇ㧘ᚻ⿷ߩਇ⥄↱㧘߽ߩᔓࠇߥߤᣣᏱ⊛ߥ໧㗴߆ࠄ㧘Ყセ⊛Ꮧߥ␹⚻㔍∛ߩ⏕ቯ⸻ᢿ߿ᴦ≮ࠍⴕߞߡ޿ࠆ‫ޕ‬ᄢቇ∛㒮߇㔍∛᜚ὐ∛㒮ߦᜰቯߐࠇߚߎߣߦࠃࠅ⸳⟎ߐࠇߚ㔍∛ኾ㐷ຬߣදജߒ
ߥ߇ࠄ㧘㔍∛ᖚ⠪߳ߩ␠ળ⾗Ḯߩㆡᔕ⺞ᢛ߹ߢ᏷ᐢߊኻᔕߒߡ޿ࠆ‫∛ࡦ࠰ࡦࠠ࡯ࡄޕ‬㧘⣖ⴊ▤㓚ኂ㧘⹺⍮∝ߥߤ㜞㦂ߩᖚ⠪߇ᄙߊ⠧ᐕౝ⑼ߣߒߡߩ஥㕙߽ᄢ߈޿‫ޕ‬⣖Ἳ࡮⣖∝ߥߤߩ␹⚻ᢇᕆߦ߽㜞ᰴᢇᕆߣㅪ៤
ߒߡኻᔕߒߡ޿ࠆ߇㧘ੱຬਇ⿷ߩߚ߼⣖ⴊ▤㓚ኂᕆᕈᦼߩᄙߊߪ⣖␹⚻ᄖ⑼ߩ߅਎⹤ߦߥߞߡ޿ࠆ‫ޕ‬කᏧ㧘⋴⼔Ꮷ㧘ㅪ៤࠮ࡦ࠲࡯㧘⮎೷Ꮷ㧘ℂቇ/૞ᬺ≮ᴺ჻ࠍ੤߃ߚቯᦼ⊛∛᫟ળ⼏㧘࿾ၞߩක≮/⑔␩ࠬ࠲࠶ࡈࠍ
੤߃ߚ᜛ᄢࠞࡦࡈࠔ࡟ࡦࠬ࡜ࡦࠬߩ㓐ᤨ㐿௅㧘߆߆ࠅߟߌකߣߩ⸻≮ㅪ៤㧘࿾ၞߢߩ㔍∛㑐ㅪࠬ࠲࠶ࡈᢎ
⢒ࠍㅴ߼ߡ߈ߡ߅ࠅ㧘ౝㇱ⊛ߦߪ࿷㒮ᣣᢙߩ⍴❗ൻ╬ߩല₸⊛ㆇ༡㧘ኻᄖ⊛ߦߪ∛㒮೨࡮∛㒮ᄖߩኻᔕജ
ࠍ⢒ᚑߦߟߥߍߡ߈ߚ‫ߚߒ߁ߎޕ‬ദജߪੱᚻਇ⿷ߩᄢቇ∛㒮ߩ␹⚻ౝ⑼⸻≮࡮⥃ᐥᢎ⢒ജࠍ⏕଻ߔࠆߚ߼
ߦ㊀ⷐߢ޽ࠆߣ⠨߃ߡ޿ࠆ‫ޕ‬
2㧚ᢎ⢒ᣉ⸳
1㧕 ᣣᧄౝ⑼ቇળ ⹺ቯᢎ⢒ᣉ⸳
2㧕 ᣣᧄ␹⚻ቇળ ⹺ቯᢎ⢒ᣉ⸳
3㧕 ᣣᧄ⠧ᐕකቇળ ⹺ቯᣉ⸳4㧕 ᣣᧄ⣖තਛቇળ ⹺ቯ⎇ୃᢎ⢒∛㒮
3㧚⸻≮㐿⊒
1㧕 ⸻≮ฬ 㧦⚻㗡⬄ೝỗߦࠃࠆࠫࠬ࠻࠾ࠕ࡮⣄㜑ዊ⣖ᄌᕈ∝ߩᴦ≮⸻≮ౝኈ㧦ࠫࠬ࠻࠾ࠕߪߘߩ∛࿃߇ᄙጘߦࠊߚࠅᴦ≮ߣߒߡ⮎‛ᴦ≮߇ⴕࠊࠇࠆ߇⥃ᐥ਄ᴦ≮ߦ㔍ᷦߔࠆߎߣ߇ᄙߊ㧘⣄㜑ዊ⣖ᄌᕈ∝ߦ߅޿ߡ߽⮎‛ᴦ≮߇ⴕࠊࠇࠆ߇ലᨐ⊛ߥᴦ≮ᴺߪਲߒ޿‫⚻ޕ‬㗡⬄ೝỗᴺߪᄢ⣖⊹⾰ߩ⥝ᅗᕈࠍᄌൻߐߖࠆߎߣ߇⏕⹺ߐࠇߡ߅ࠅ㧘㔍ᴦᕈߩ␹⚻∔ᖚߢ޽ࠆࠫࠬ࠻࠾ࠕ߿⣄㜑ዊ⣖ᄌᕈ∝ߩᴦ≮߳ߩᔕ↪ᕈ߇ᦼᓙߐࠇߡ޿ࠆ‫ޕ‬࿖ౝ⊛⹏ଔ㧦ෘ↢ഭ௛⋭ߩ㔍ᴦᕈ∔ᖚస᦯੐ᬺߩ‫ޟ‬⣄㜑ዊ⣖ᄌᕈ∝ߩ↹ᦼ⊛⸻ᢿ࡮ᴦ≮ߦ㑐ߔࠆ⎇ⓥ‫ޠ‬ߦ߅޿ߡ㧘ߘߩ᦭ലᕈ߇␜ໂߐࠇߡ޿ࠆ‫ᤨ⃻ޕ‬ὐߢઁߦ᦭ലߥᴦ≮ᴺ߇ዋߥ޿ߎߣ߆ࠄ㧘ᴦ≮߳ߩᦼᓙߪᄢ߈޿߽ߩ‫ޕ‬࿖㓙⊛⹏ଔ㧦␹⚻ቇߩਥⷐߥ࿖㓙⹹ߦ㧘⚻㗡⬄ೝỗߦࠃࠆࠫࠬ࠻࠾ࠕ࡮⣄㜑ዊ⣖ᄌᕈ∝ߩᴦ≮ߩ᦭ലᕈࠍ␜ໂߔࠆႎ๔߇ᢔ⷗ߐࠇࠆ‫ޕ‬
4㧚ኾ㐷ක࡮⹺ቯක࡮ᜰዉක
›Ⴆ ⾆㧦ᣣᧄౝ⑼ቇળ⹺ቯౝ⑼ක࡮ᜰዉක㧘ᣣᧄ␹⚻ቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄ⠧ᐕකቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄ⠧ᐕ♖␹කቇળ⹺ቯක଻૑ ഞ㧦ᣣᧄౝ⑼ቇળ✚วౝ⑼ኾ㐷ක࡮ᜰዉක㧘ᣣᧄ␹⚻ቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄ⠧ᐕකቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄ⠧ᐕ♖␹කቇળ⹺ቯක㧘ᣣᧄੱ㘃ㆮવቇળኾ㐷ක㧘ᣣᧄ㗡∩ቇળኾ㐷ක↰ਛఝม㧦ᣣᧄౝ⑼ቇળ✚วౝ⑼ኾ㐷ක࡮ᜰዉක㧘ᣣᧄ␹⚻ቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄ⣖තਛቇળኾ㐷ක㧘ᣣᧄᶖൻེ∛ቇળኾ㐷ක㧘ᣣᧄᢇᕆකቇળኾ㐷කᧁ᧛ᥙᄦ㧦ᣣᧄౝ⑼ቇળ✚วౝ⑼ኾ㐷ක࡮ᜰዉක㧘ᣣᧄ␹⚻ቇળኾ㐷ක࡮ᜰዉකᨋ ␭৻㧦ᣣᧄౝ⑼ቇળ⹺ቯౝ⑼ක࡮ᜰዉක㧘ᣣᧄ␹⚻ቇળኾ㐷ක㧘ᣣᧄ⠧ᐕකቇળኾ㐷කᰞ੗ጪ㇢㧦ᣣᧄౝ⑼ቇળ⹺ቯౝ⑼ක㧘ᣣᧄ␹⚻ቇળኾ㐷කጊ↰ ᕺ㧦ᣣᧄౝ⑼ቇળ⹺ቯౝ⑼ක
5㧚⥄Ꮖ⹏ଔ
⹏ଔ㒢ࠄࠇߚᢎຬ/කຬᢙߣ∛ᐥᢙߢⷙᮨ⊛ߦߪ㒢⇇߇޽ࠆ߇㧘ᄢቇ∛㒮ߦ߅ߌࠆ⸻≮ౝኈߪ⼾ንߢ㧘␹⚻ᢇᕆ߆ࠄ␹⚻㔍∛ߩ⏕ቯ⸻ᢿ࡮␠ળ⾗Ḯߩ⺞ᢛ߹ߢ᏷ᐢߊኻᔕߒߡ߈ߚ‫ޕ‬ૉߒ㧘ੱຬਇ⿷ߩߚ߼⣖ⴊ▤㓚
ኂ߳ߩⓍᭂ⊛ኻᔕ߿㜞ᰴᢇ๮ᴦ≮࠮ࡦ࠲࡯߳ߩ಴ะ⽸₂߇ߢ߈ߡ޿ߥ޿‫ ߩߎޕ‬3 ᐕ㑆㧘ᒰಽ㊁↢߃ᛮ߈ߩ␹⚻ౝ⑼ኾ㐷ක߇ 4 ฬ㧘⠧ᐕ∛ኾ㐷ක 2 ฬ߇޿ߕࠇ߽⹜㛎ࠍ 1 ࿁ߢวᩰߒߡ⺀↢ߒߚ‫ޕ‬කᏧ㧘⋴⼔Ꮷ㧘ㅪ៤࠮ࡦ࠲࡯㧘⮎೷Ꮷ㧘ℂቇ/૞ᬺ≮ᴺ჻ࠍ੤߃ߚቯᦼ⊛∛᫟ળ⼏㧘࿾ၞߩක≮/⑔␩ࠬ࠲࠶ࡈࠍ੤߃ߚ᜛ᄢ
ࠞࡦࡈࠔ࡟ࡦࠬ࡜ࡦࠬߩ㓐ᤨ㐿௅㧘߆߆ࠅߟߌකߣߩ⸻≮ㅪ៤㧘࿾ၞߢߩ㔍∛㑐ㅪࠬ࠲࠶ࡈᢎ⢒ߦ⽸₂ߒ㧘ߘߩ⚿ᨐ㧘ቇౝᄖߩ␹⚻ౝ⑼⸻≮ߪ᣿ࠄ߆ߦෘߺࠍჇߒߚ‫ޕ‬㧙㧙ᄢቇ∛㒮߇㔍∛᜚ὐ∛㒮ߦᜰቯߐࠇ㧘㔍∛ኾ㐷ຬ߇⸳⟎ߐࠇߚߎߣ߆ࠄ␹⚻㔍∛ߩኻᔕߪᩰᲑߦᡷༀߐ
ࠇߚ‫ޕ‬㔍∛ኾ㐷ຬߣ౒หߒߡ⑔␩ⴕ᡽ࠬ࠲࠶ࡈ㧘⸰໧⋴⼔Ꮷ࡮ࡋ࡞ࡄ࡯ߩᢎ⢒߇ㅴࠎߢ޿ࠆ‫ߦࠄߐޕ‬ጘ㒂⋵㔍∛ㅪߩขࠅ⚵ߺߦ߽Ⓧᭂ⊛ߦෳടߒ࿾ၞߩ␹⚻㔍∛ኻᔕߩᐩ਄ߍߦ⽸₂ߒߡ߈ߚ‫⚻␹ޕ‬㔍∛╬ߦ߅޿ߡ㧘߆߆ࠅߟߌකߣߩㅪ៤ࠍᷓ߼ 2 ੱਥᴦක೙ࠍផㅴߒߡ␹⚻ౝ⑼ක≮ࠍᐢ߼ࠆߣߣ߽ߦ㧘ᄢቇ∛㒮ߩᣂᖚ࡮㊀∝⠪ኻᔕജࠍ⏕଻ߒߡ߈ߚ‫ߌߟࠅ߆߆ޕ‬කߩ⹺⍮∝ኻᔕജะ਄⎇ୃ㧘࿾ၞߩ⹺⍮∝ࡀ࠶࠻ࡢ࡯ࠢߟ
ߊࠅߩᵴേߦ㧘⻠Ꮷ߿ડ↹ߩ৻ㇱࠍᜂᒰߔࠆߥߤⓍᭂ⊛ߦෳടߒ㧘ጘ㒂⋵ߩ⹺⍮∝ኻᔕߩၮ⋚૞ࠅߦ⽸₂ߒߡ߈ߚ‫ޕ‬ቇౝᄖߩ⋴⼔Ꮷ㧘≮ᴺ჻ߩ㙃ᚑߦ߽⻠⟵╬ߦࠃࠅⓍᭂ⊛ߦ⽸₂ߒߚ‫∛ޕ‬㒮೨࡮∛㒮ᄖߩ␹⚻ౝ
⑼∔ᖚኻᔕജࠍ⢒ߡࠆߎߣߦࠃߞߡ߽㧘ᄢቇ∛㒮ߩ⸻≮࡮⥃ᐥᢎ⢒ജࠍ⏕଻ߒߡ߈ߚ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷૗ࠃࠅ߽ੱ᧚ߩ⏕଻߇໧㗴ߢ޽ࠆ‫⎇ޕ‬ⓥ࡮⸻≮࡮ᢎ⢒╬㧘૗ࠍ߿ࠆߦߒߡ߽߹ߕੱ᧚ߢ޽ࠆ‫⚻␹ޕ‬ౝ⑼ක≮߇࿾ၞߦᢛ஻ߐࠇߡ޿ߥ޿ᚲ߶ߤ㧘࿾ၞߩ∛㒮⎇ୃකߦ౉ዪߩ௛߈߆ߌ߇ߢ߈ߕ㧘ߐࠄߦᢛ஻߇ㆃࠇ
ࠆ᭴࿑ߪ㧘ᣂකᏧ⥃ᐥ⎇ୃ೙ᐲ߇ᚒ‫ߚߒࠄߚ߽ߦޘ‬෩ߒߔ߉ࠆ⹜✵ߢ޽ࠆߣᗵߓߡ޿ࠆ‫ޕ‬ኻ╷ߣߒߡߪ㧘ᣢߦขࠅ⚵ࠎߢ߈ߚߎߣߢߪ޽ࠆ߇㧘ታ⠌╬ߢߩቇ↢ߣߩ✕ኒߥធ⸅ߣߘߩ⛮⛯ࠍ࿑ࠆߎߣߢ޽ࠆ‫ߛߚޕ‬තᓟ⎇ୃߩ 2 ᐕ㑆㧘లಽߥࠕࡊࡠ࡯࠴߇ߢ߈ߥ޿ߎߣߪଐὼ໧㗴ߢ޽ࠆ‫ޕ‬એਅߩ໧㗴ὐߦ౒ㅢߔࠆߩߪੱ᧚ਇ⿷ߢ޽ࠆ‫ޕ‬1㧕ᄖ᧪ኻᔕജ߇ਇචಽߢ޽ࠅᣂᖚ੍⚂ᦼ㑆㧘⸻ኤᓙߜᤨ㑆߇㐳ߊᡷༀ߇᳞߼ࠄࠇߡ޿ࠆߎߣ‫ߩߎޕ‬ὐߪ㧘߆߆ࠅߟߌකߣߩㅪ៤ࠍߐࠄߦᷓ߼ࠆᔅⷐ߽޽ࠆ‫ޕ‬2㧕౉㒮࿷㒮ᣣᢙ߇߿߿㐳ߊ㧘౉㒮ᓙᯏ⠪߇Ᏹᤨᄙ޿ߎߣ‫ߩߎޕ‬ὐߪㅪ៤࠮ࡦ࠲࡯ߣㅌ㒮⺞ᢛࠍߐࠄߦㅴ߼ࠆ‫ޕ‬
3㧕⣖ⴊ▤㓚ኂ߳ߩⓍᭂ⊛ኻᔕ߿㜞ᰴᢇ๮ᴦ≮࠮ࡦ࠲࡯߳ߩ಴ะ⽸₂߇ߢ߈ߡ޿ߥ޿ߎߣ‫ޕ‬4㧕࿾ၞߩ␹⚻ౝ⑼ኾ㐷ක߇㕖Ᏹߦਇ⿷ߒߡ߅ࠅ㧘࿾ၞක≮ᯏ㑐߳ߩࡄ࡯࠻಴ᒛ⸻≮ࠨࡐ࡯࠻߽࠾࡯࠭ߦㅊ޿ߟ޿ߡ޿ߥ
޿ߎߣ‫ޕ‬5㧕ቇ↢ᢎ⢒ߦ߅޿ߡ 5 ᐕ↢ߩࠢ࡝࠾ࠞ࡞ࠢ࡜࡯ࠢࠪ࠶ࡊߩቢోታᣉߦߪ߹ߛ㆙޿ߎߣ‫ޕ‬6㧕⸻≮ߩᄙᔔൻߩߚ߼⥃ᐥᢎ⢒࡮⎇ⓥߦኾᔨߢ߈ࠆᤨ㑆߇㒢ࠄࠇࠆߎߣ‫ޕ‬એ਄㧘ੱ᧚ߩ⏕଻ߣ૬ߖߡ∛㒮ᬺോ࡮⥃ᐥታ⠌ߦᔅ㗇ߩᢎຬࡐࠬ࠻㧔⃻࿷⥃ᐥ⻠Ꮷ 1 ߩߺ㧕ߩჇ⸳߇㊀ⷐߢ޽ࠆ‫ޕ‬੹ᓟߩዷᦸోജࠍ޽ߍߡ૗ߣߒߡ߽ㄭ޿዁᧪㧘ᣂߚߥ౉ዪ⠪ࠍ᱑ㄫߒߚ޿‫ޕ‬ᄙ⡯⒳ߦࠃࠆቯᦼ⊛∛᫟ળ⼏㧘߆߆ࠅߟߌකߣߩㅪ៤ࠍᦝߦㅴ߼㧘࿷㒮ᣣᢙߩ⍴❗ൻ㧘ᣣᏱ߅ࠃ߮ᢇᕆ⸻≮ኻᔕജࠍ⏕଻ߒߡ޿ߊ‫≮⸻ߦࠄߐޕ‬߅ࠃ߮⥃ᐥታ⠌ߦᔅⷐߥ∛㒮ߩᢎຬࡐࠬ࠻ߩჇ⸳ࠍ᳞߼ߡ޿ߊ‫ߚ߹ޕ‬㧘㔍∛ኾ㐷ຬߣදജߒߡ࿾ၞ␠ળߩ
㔍∛ኻᔕജࠍ㜞߼ࠆദജ㧘࿾ၞߩ⹺⍮∝ኻᔕജߩะ਄㧘ࠦࡔ࠺㨲ࠞ࡞ࠬ࠲࠶ࡈߩ␹⚻ౝ⑼࡮⠧ᐕ⑼ᢎ⢒ࠍ੹ᓟ߽ᒁ߈⛯߈⛮⛯ߒ㧘∛㒮೨࡮∛㒮ᄖߩኻᔕജࠍ⢒ߡࠆߎߣߦࠃߞߡ߽㧘ᄢቇ∛㒮ߩ⸻≮࡮⥃ᐥᢎ⢒ജࠍ⏕଻ߒߡ޿ߊ‫ੱޕ‬ᚻ߇⏕଻ߢ߈ࠇ߫㧘⣖␹⚻ᄖ⑼ߣදജߒߡ㜞ᐲᢇ๮ᢇᕆ࠮ࡦ࠲࡯ߢߩ SCU ⸳⟎ߦദജߒߡ޿߈ߚ޿‫ޕ‬㧙㧙㧔5㧕✚วౝ⑼1㧚⸻≮ߩ᭎ⷐ
ߎࠇ߹ߢߣห᭽㧘✚วౝ⑼කߩ㓸࿅ߣߒߡౝ⑼ో⥸ߦࠊߚࠆ⸻≮ࠍⴕߞߡ޿ࠆ‫ޕ‬ㄭᐕߩකቇߩㅴᱠߣߣ
߽ߦ㧘කᏧߩኾ㐷ൻ࡮⚦ಽൻ߇ㅴࠎߢ޿ࠆ‫৻ޕ‬ᣇߢ㧘␠ળߩ㜞㦂ൻߣߣ߽ߦⶄᢙߩ∔ᖚࠍ૬ߖᜬߟᖚ⠪߽Ⴧടߒߡ߈ߡ޿ࠆ‫ߜࠊߥߔޕ‬㧘ᖚ⠪ߩ࠾࡯࠭ߣකᏧߩᔒะߦࡒࠬࡑ࠶࠴߇ߺࠄࠇࠆ‫⚿ߩߘޕ‬ᨐ㧘ਥᴦකߣߒߡ߽ኾ㐷એᄖߩ⸻≮߇ਇචಽߢ޽ߞߚࠅ㧘ኾ㐷ᄖߩ∔ᖚߢ޽ࠆߣ⸻≮ࠍᜎุߒߚࠅߔࠆߣ޿߁⃻ታߦߒ߫ߒ߫ㆣㆄߔࠆࠃ߁ߦߥߞߡ߈ߡ޿ࠆ‫߼ߚߩߘޕ‬㧘ਥᴦකߣߒߡోੱ⊛࡮✚ว⊛ߥ⸻≮߇ߢ߈ࠆකᏧ߇ᄙ
ߊߩ∛㒮ߢ߽᳞߼ࠄࠇࠆࠃ߁ߦߥߞߡ߈ߡ޿ࠆ‫ߚ߹ޕ‬㧘ࡊ࡜ࠗࡑ࡝࡮ࠤࠕߦኻᔕߢ߈ࠆߛߌߢߥߊ㧘ේ࿃ਇ᣿ߥ∔ᖚߦኻߒߡ∛ᘒ↢ℂቇ⊛ߥ⷗࿾߆ࠄ⊛⏕ߥ⸻ᢿࠍⴕ߁ߎߣ߇ߢ߈ࠆ⸻ᢿ⢻ജߩ㜞޿කᏧߩ㙃ᚑ
߽㊀ⷐߦߥߞߡ߈ߡ޿ࠆ‫ޕ‬✚วౝ⑼࡮✚ว⸻≮ㇱߪ㧘⸻≮㕙ߢߪ㧘1㧕ೋ⸻ᖚ⠪ߩ⸻ᢿߣᴦ≮ߣ㧘ᔅⷐ߇޽ࠇ߫ኾ㐷⸻≮⑼߳ߩ⚫
੺㧘2㧕common diseases ߿ⶄᢙߩ∔ᖚࠍ᦭ߔࠆᖚ⠪ߩ⸻ᢿߣᴦ≮㧘3㧕⸻≮ᤨ㑆ౝߩ 1࡮2 ᰴᢇᕆᖚ⠪ߩ⸻≮㧘4㧕ኾ㐷⸻≮⑼߆ࠄߩේ࿃ਇ᣿∔ᖚߩଐ㗬⸻≮ߥߤࠍⴕ޿㧘ᄢቇ∛㒮ߦ߅ߌࠆਛᩭ⊛ߥᓎഀࠍᜂ߁
ߎߣߦࠃߞߡ㧘ኾ㐷⸻≮⑼ߩ⸻≮ല₸ࠍ㜞߼ߡ޿ࠆ‫ޕ‬ᢎ⢒㕙ߢߪ㧘1㧕ක≮㕙ធߣ⸻ኤࠍ㊀ⷐⷞߒߚත೨࡮
තᓟ⥃ᐥ⎇ୃߩታ〣㧘2㧕ᓟᦼ⥃ᐥ⎇ୃකࠍኻ⽎ߣߒߚ✚วౝ⑼කߩ㙃ᚑ㧘3㧕࿾ၞකᏧળߣߩ↢ᶦᢎ⢒ߦ㑐ߔࠆㅪ៤ߥߤߦ៤ࠊߞߡ޿ࠆ‫ߚ߹ޕ‬㧘2004 ᐕᐲ߆ࠄᆎ߹ߞߚතᓟ⥃ᐥ⎇ୃ೙ᐲߦวࠊߖ㧘ቇౝ࡮ቇᄖ
ߩ⎇ୃකᢎ⢒ࠍ⋡⊛ߣߒߚࡊ࡜ࠗࡑ࡝ࠤࠕ࡮ࠞࡦࡈࠔ࡟ࡦࠬߣ޿߁ᢎ⢒ࡊࡠࠣ࡜ࡓࠍ㧘ᐕ 3 ࿁ጘ㒂⋵ౝߩ⥃ᐥ⎇ୃᜰቯ∛㒮ߣߣ߽ߦ㐿௅ߒߡ޿ࠆ‫ޕ‬
2㧚ᢎ⢒ᣉ⸳
1㧕 ᣣᧄౝ⑼ቇળ⹺ቯᢎ⢒ᣉ⸳
2㧕 ᣣᧄ♧ዩ∛ቇળ⹺ቯᢎ⢒ᣉ⸳
3㧕 ᣣᧄᶖൻེౝⷞ㏜ቇળᜰዉᣉ⸳
4㧕 ᣣᧄᓴⅣེቇળ⎇ୃᣉ⸳
5㧕 ᣣᧄᶖൻེ∛ቇળ⹺ቯᣉ⸳
6㧕 ᣣᧄ࡝࠙ࡑ࠴ቇળᢎ⢒ᣉ⸳7㧕 ᣣᧄ⠧ᐕකቇળ⹺ቯᣉ⸳
8㧕 ᣣᧄࠕ࡟࡞ࠡ࡯ቇળḰ⹺ቯᢎ⢒ᣉ⸳
3㧚⸻≮㐿⊒
1㧕 ⸻≮ฬ 㧦ਇ᣿ᾲᄖ᧪
⸻≮ౝኈ㧦ઁ㒮ߢߩ⸻≮ߦ߅޿ߡේ࿃߇ਇ᣿ߢ޽ߞߚ⊒ᾲࠍਥ⸷ߣߔࠆᖚ⠪ߦኻߒ㧘⊛⏕ߦ⸻ᢿࠍߒ㧘ㄦㅦߦᴦ≮ᣇ㊎ࠍ᳿ቯߔࠆ‫ޕ‬ኾ㐷⊛ߥᴦ≮߇ᔅⷐߥ޿႐วߦߪ㧘ߘߩ߹߹✚วౝ⑼ᄖ᧪߽
ߒߊߪ∛᫟ߦߡᴦ≮ࠍⴕ߁‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦⃻࿷㧘ਇ᣿ᾲᄖ᧪ࠍᮡ᭙ߒߡ޿ࠆ∛㒮ߪ㧘ᚒ‫ߚߴ⺞߇ޘ‬㒢ࠅߥ޿‫ޕ‬࿖ౝ⊛⹏ଔ㧦ࠬ࠲࠶ࡈߩᄙߊ߇✚วౝ⑼ኾ㐷කࠍขᓧߒߡ޿ࠆ‫ޕ‬ਇ᣿ᾲߩේ࿃ߩ 1 ߟߢ޽ࠆ⤔ේ∛ߦኻߒߡ㧘࡝࠙ࡑ࠴ኾ㐷කࠍ᫪↰೽⑼㐳߇ขᓧߒߡ޿ࠆ‫ޕ‬࿖㓙⊛⹏ଔ㧦੹ᓟ㧘㊀∝ᕆᕈ๭ๆེ∝୥⟲㧔SARS㧕߿㠽ࠗࡦࡈ࡞ࠛࡦࠩߥߤ㧘࿖㓙⊛ߥᗵᨴ∝ߩᵹⴕ߇੍᷹ߐࠇߡ޿ࠆ‫ޕ‬หᗵᨴ∝ࠍ⇼߁ᖚ⠪ߩฃߌ⋁ߣߥࠆਇ᣿ᾲᄖ᧪ߩᮡ᭙ߪ㧘࿖㓙⊛࠾࡯࠭ߦᔕ߃ࠆ߽ߩߣ⠨߃ࠄࠇࠆ‫ޕ‬2㧕 ⸻≮ฬ 㧦࡝࠙ࡑ࠴࡮⤔ේ∛ᄖ᧪⸻≮ౝኈ㧦࡝࠙ࡑ࠴࡮⤔ේ∛ߩ⸻ᢿᴦ≮ߪ㜞ᐲవㅴක≮ߩታ〣ߦਇนᰳߢ޽ࠆ‫ޕ‬ਇ᣿ᾲᄖ᧪ߢ⸻ᢿߐ
ࠇߚ࡝࠙ࡑ࠴࡮⤔ේ∛ߪ㧘㔍∛ߦ⧰ߒ߻ᖚ⠪ߦߣߞߡ㊀ⷐߥ⺖㗴ߢ޽ࠆ‫⃻ޕ‬࿷㧘ౝ⑼࠱࡯
ࡦߢ↢‛ቇ⊛⵾೷ߦࠃࠆᴦ≮ᖚ⠪ࠍᦨ߽ᄙߊᛴ߃ߡ߅ࠅ㧘․ߦ㑐▵࡝࠙ࡑ࠴ߪᢛᒻᄖ⑼㗔
ၞߣ౒หߒߡᴦ≮ߔࠆᔅⷐ߇޽ࠆ‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦᧲ᶏ࿾ᣇߢߪ଻ஜⴡ↢ᄢቇ㧘ᗲ⍮ක⑼ᄢቇߦኾ㐷ᄖ᧪ߪ޽ࠆ߇ጘ㒂⋵ਅߩਛᩭ∛㒮ߢߪ⠀ፉᏒ᳃∛㒮એᄖߦߪߥ޿‫ޕ‬࿖ౝ⊛⹏ଔ㧦ᣣᧄ࡝࠙ࡑ࠴ቇળ✚ળߦߪᲤᐕ⥃ᐥ⊛ᚑᨐࠍ⊒⴫ߒߡ޿ࠆ‫ޕ‬࿖㓙⊛⹏ଔ㧦☨࿖㧘࡛࡯ࡠ࠶ࡄ࡝࠙ࡑ࠴ቇળߣ౒หߒߡ㧘ᣣᧄ࡝࠙ࡑ࠴ቇળ߽⥃ᐥ∉ቇ⎇ⓥ߇ㅴⴕߒߟߟ޽ࠆ‫ޕ‬㧙㧙4㧚ኾ㐷ක࡮⹺ቯක࡮ᜰዉක
⍹Ⴆ㆐ᄦ㧦ᣣᧄౝ⑼ቇળ⹺ቯක࡮ኾ㐷ක࡮ᜰዉක㧘ᣣᧄᶖൻེ∛ቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄᶖൻེౝⷞ㏜
ቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄ♧ዩ∛ቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄౝಽᴲቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄ⠧ᐕකቇળᜰዉක㧘ᣣᧄ∛ᘒᩕ㙃ቇળ NST ࠦ࡯࠺ࠖࡀ࡯࠲࡯ᷡፉ ḩ㧦ᣣᧄౝ⑼ቇળ⹺ቯක㧘ᣣᧄᶖൻེ∛ቇળኾ㐷ක㧘ᣣᧄ⢄⤳ቇળኾ㐷ක㧘ᣣᧄ⥃ᐥᬌᩏቇળኾ㐷ක᫪↰ᶈਯ㧦ᣣᧄౝ⑼ቇળ⹺ቯක࡮ኾ㐷ක࡮ᜰዉක㧘ᣣᧄౝಽᴲቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄ♧ዩ∛ቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄ࡝࠙ࡑ࠴ቇળኾ㐷ක㧘ᣣᧄ⠧ᐕකቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄ∛ᘒᩕ㙃ቇળ
NST ࠦ࡯࠺ࠖࡀ࡯࠲࡯㧘ᣣᧄࠕ࡟࡞ࠡ࡯ቇળኾ㐷ක
ቝ㊁ཅᒄ㧦ᣣᧄౝ⑼ቇળ⹺ቯක࡮ኾ㐷ක࡮ᜰዉක㧘ᣣᧄᓴⅣེቇળኾ㐷ක㧘ᣣᧄ♧ዩ∛ቇળኾ㐷ක᫃↰๺↵㧦ᣣᧄౝ⑼ቇળ⹺ቯක࡮ᜰዉක㧘ᣣᧄ♧ዩ∛ቇળኾ㐷ක࡮ᜰዉක
๺↰␭Ὼ㧦ᣣᧄౝ⑼ቇળ⹺ቯක࡮ኾ㐷ක㧘ᣣᧄᶖൻེౝⷞ㏜ቇળኾ㐷ක㧘ᣣᧄ♧ዩ∛ቇળኾ㐷කᳰ↰⾆⧷㧦ᣣᧄౝ⑼ቇળ⹺ቯක᫪ ৻㇢㧦ᣣᧄౝ⑼ቇળ⹺ቯක⮮ጟ ࿻㧦ᣣᧄౝ⑼ቇળ⹺ቯක
5㧚⥄Ꮖ⹏ଔ
⹏ଔ
2004 ᐕߩᣂ∛㒮㐿㒮ߦวࠊߖߡ㧘ᄖ᧪ㇱ㐷ߦ߅޿ߡߪ㐿㒮ᒰᤨߩ᦬㑆ᐔဋᖚ⠪ᢙ 600 ੱบ߆ࠄ 1,100ੱบ߹ߢᓢ‫ߦޘ‬Ⴧടߒߡ߈ߡ߅ࠅ㧘✚ว⸻≮ᄖ᧪ߣߒߡߩᓎഀࠍචಽߦᨐߚߒߡ޿ࠆߣ⠨߃ߡ޿ࠆ‫ߚ߹ޕ‬㧘㐿ᬺක߿ઁ㒮߆ࠄߩ⚫੺ᖚ⠪߽Ⴧടߒߡ߈ߡ߅ࠅ㧘ᐔဋ⚫੺₸߽ 25㧑⒟ᐲ߹ߢࠕ࠶ࡊߒߡ߈ߡ޿ࠆ‫౉ޕ‬㒮ㇱ㐷ߢ߽㧘᧲ 7 㓏∛᫟ߦ 4 ᐥߢᣂⷙ㐿⸳ߒ㧘2007 ᐕ 4 ᦬߆ࠄߪ 7 ᐥߦჇᐥߦߥߞߚ߇㧘ߘߩᓟ߽∛ᐥ
Ⓙ௛₸ߪ 150㧑೨ᓟ㧘ᐔဋ࿷㒮ᣣᢙ 14 ᣣ೨ᓟߣߥߞߡ߅ࠅ㧘Ⓙ௛₸࡮࿷㒮ᣣᢙߣ߽㗅⺞ߢ޽ࠆߣ⠨߃ߡ޿ࠆ‫ޕ‬Ყセ⊛✕ᕆ౉㒮߇ᄙߊ㧘⸻≮ᤨ㑆ౝߩ 1 ᰴ 2 ᰴᢇᕆߦኻᔕߒߡ޿ࠆ⚿ᨐߣ⠨߃ߡ޿ࠆ‫৻ޕ‬ᣇ㧘ᢎ⢒ㇱ㐷ߢߪ㧘ቇ↢ታ⠌ߦട߃㧘߶߷Ფ᦬ⶄᢙߩ⥃ᐥ⎇ୃකࠍฃߌ౉ࠇ㧘ၮᧄ⊛ߥ⥃ᐥࠬࠠ࡞߇⠌ᓧߢ߈ࠆࠃ
߁ߥࡊࡠࠣ࡜ࡓࠍታ〣ߒߡ߅ࠅ㧘ቇ↢߿⎇ୃකߩ㑆ߩ⹏ଔ߽㜞޿‫ߦࠄߐޕ‬㧘තᓟ⎇ୃක೙ᐲߦวࠊߖߚቇ
ౝ࡮ቇᄖߩ⎇ୃකᢎ⢒⋡⊛ߩ⎇ⓥળߢ޽ࠆࡊ࡜ࠗࡑ࡝ࠤࠕ࡮ࠞࡦࡈࠔ࡟ࡦࠬࠍ㧘2005 ᐕ߆ࠄᐕ 3 ࿁౒௅ߒߡ߅ࠅ㧘ጘ㒂⋵ౝߩ⥃ᐥ⎇ୃᜰቯ∛㒮ߢߩ⎇ୃකᢎ⢒ߦ৻ᓎࠍᜂߞߡ޿ࠆ‫ߚ߹ޕ‬㧘ቇ↢߿⎇ୃකߣኻ⽎ߣߒߚീᒝળ߿∝଀ᬌ⸛ળ߽ቯᦼ⊛ߦቇౝߢ㐿௅ߒߡ޿ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷2004 ᐕᐲ߆ࠄතᓟ⥃ᐥ⎇ୃ߇ᔅ㗇ൻߐࠇ㧘ߘߩߥ߆ߢ߽ࡊ࡜ࠗࡑ࡝࡮ࠤࠕߩታ〣߇ᒝ⺞ߐࠇߡ޿ࠆ‫ޕ‬✚วౝ⑼࡮✚ว⸻≮ㇱߪߘߩਛᔃ⊛ߥᓎഀࠍᜂ߁ߴ߈┙႐ߦ޽ࠅ㧘ᄖ᧪ㇱ㐷ߪᲧセ⊛లታߒߚ⁁ᴫߦ޽ࠆ߇㧘౉㒮ㇱ㐷ߪ࿕ቯ∛ᐥᢙ߇ 7 ᐥߣઁߩ⸻≮⑼ߦᲧߒ࿶ୟ⊛ߦዋߥߊ∛ᐥⒿ௛₸߽㜞޿ߚ߼㧘․ߦ✕ᕆ౉㒮߇޽ࠆᤨߥߤ㧘౉㒮ࡌ࠶࠼ߩ⏕଻ߦ⧰ഭߔࠆߎߣ߇ᄙ޿‫߼ߚߩߘޕ‬㧘ᖚ⠪ߦ౉㒮ᓟߩォᐥߥߤߩਇㇺวࠍ߆ߌࠆߎߣ߇޽ࠅ㧘ࡌ࠶࠼߇ಽᢔߒߡ޿ࠆߚ߼⸻≮ߦਇㇺวࠍᗵߓࠆߎߣ߽ߒ߫ߒ߫޽ࠆ‫∛ޕ‬ᐥⒿ௛₸ߪో⸻≮⑼ߢߪᦨ߽㜞ߊ㧘࿷㒮ᣣᢙ߽ᐔဋ࡟ࡌ࡞ߢ޽ࠆߚ߼㧘੹ᓟ߽Ⓧᭂ⊛ߦჇᐥߩᔅⷐᕈࠍ∛㒮஥ߦ⸷߃ߡࠁߊ‫ޕ‬੹ᓟߩዷᦸጘ㒂⋵ߩ․ᓽߩ 1 ߟߦጊ㑆ㇱ߇ᄙ޿ߎߣ߇᜼ߍࠄࠇࠆ‫ੱޕ‬ญ߇ᐔ㊁ㇱߦᲧߴዋߥ޿ߚ߼㧘Ყセ⊛ዊⷙᮨߩ∛㒮߇ᄙߊሽ࿷ߔࠆ‫ߚ߹ޕ‬㧘ⶄᢙߩ∔ᖚࠍ૬ߖᜬߟ㜞㦂⠪߇ᄙ޿ߩ߽․ᓽߢ޽ࠆ‫ߚߒ߁ߎޕ‬࿾඙߿∛㒮ߦ߅޿ߡ㧘ᦨ߽࠾࡯࠭߇㜞޿කᏧߪ㧘޽ࠆ․ቯߩಽ㊁ߦᷓ޿⍮⼂ߣᛛ⢻ࠍᜬߟኾ㐷⊛ߥකᏧߢߪߥߊ㧘߻ߒࠈ᏷ᐢ޿කቇ⍮⼂ߣᛛ⢻ࠍᜬߞߚࡅࡘ࡯ࡑ࠾࠹ࠖ޽߰ࠇࠆ✚วౝ⑼කߢ޽ࠅ㧘ᄙߊߩቇ↢߿⎇ୃක߇ℂᗐߣߔࠆකᏧ௝ߩ 1 ߟߢ߽޽ࠆ‫৻ޕ‬ᣇ㧘ᄢቇ∛㒮ࠍߪߓ߼ߣߔࠆㇺᏒㇱߩᄢ∛㒮ߦߪ㧘ේ࿃߇ਇ᣿ߩᧂ⸻
ᢿߩᖚ⠪߽ᄙߊ⚫੺ߐࠇߡߊࠆ‫ޕ‬ኾ㐷⸻≮⑼ߩല₸⊛ߥㆇ༡ߩߚ߼ߦ߽㧘✚ว⊛ߥ⷗࿾߆ࠄ⸻≮ߦᒰߚࠆߎߣ߇ߢ߈ࠆ✚วౝ⑼ක߇ᔅⷐߣߥߞߡߊࠆ‫✚ޕ‬วౝ⑼࡮✚ว⸻≮ㇱߢߪ㧘㜞޿⸻ᢿ⢻ജࠍᜬߜ㧘৻ੱߩᖚ⠪ߩⶄᢙߩ∔ᖚߦหᤨߦኻᔕ߇ߢ߈ࠆ⧯޿ఝ⑲ߥ✚วౝ⑼කߩ㙃ᚑߦోജࠍዧߊߒ㧘ጘ㒂⋵ߩ␠ળ⊛࠾࡯࠭ߦ╵߃ߡࠁ߈ߚ޿‫ޕ‬㧙㧙㧔6㧕╙৻ᄖ⑼1㧚⸻≮ߩ᭎ⷐ
ᒰ⑼ߪᔃ⤳ⴊ▤ᄖ⑼㧘๭ๆེᄖ⑼㧘ᶖൻེᄖ⑼㧔৻⥸ᄖ⑼㧘↲⁁⣼ᄖ⑼㧘੃⣼ᄖ⑼ࠍ฽߻㧕ߩ 3 ࠴࡯ࡓ߆ࠄ᭴ᚑߐࠇ㧘ᄖ⑼߇ኻ⽎ߣߔࠆ⤳ེߔߴߡࠍᴦ≮ኻ⽎ߣߒߡ޿ࠆ‫ో߽ࠬࡦ࡜ࠔࡈࡦࠞޕ‬ຬߢ⸛⼏ߒ㧘ⴚ೨ᬌ⸛ߦ߅޿ߡ㧘ኾ㐷એᄖߩ⋡ߢߺߚ໧㗴ὐ߽ᜰ៰ߐࠇ㧘ࠃࠅ቟ోߥⴚ೨ⴚਛⴚᓟ▤ℂ߇น⢻ߣߥߞߡ޿
ࠆ‫ߦߊߣޕ‬ᖚ⠪᭽ߩ㜞㦂ൻ㧘㊀∝ൻߦ઻޿㧘ⴚ೨▤ℂߪᄢᄌ㊀ⷐ⺖㗴ߢ޽ࠆ‫߃ߣߚࠅࠃߦࡓ࠹ࠬࠪߩߎޕ‬߫㧘౰േ⣂ࡃࠗࡄࠬⴚߣ⢗ಾ㒰ⴚ㧘ᑯ⤑ᚻⴚߣ⢖⪲ಾ㒰㧘᳇⢷ᚻⴚߣᄢ⣺ಾ㒰ⴚߥߤ㧘ੑᦼ⊛ᚻⴚࠍᓙߡ
ߥ޿ᖚ⠪᭽ߢ߽ട≮น⢻ߣߥࠆ‫ޕ‬ᔃ⤳ⴊ▤ᄖ⑼ߢߪ㧘౰േ⣂∔ᖚ㧘ᑯ⤑∔ᖚ㧘ਇᢛ⣂∔ᖚ㧘ᄢേ⣂∔ᖚ㧘ᧃ᪳േ⣂∔ᖚ㧘㕒⣂∔ᖚࠍኻ⽎
ߦᄖ⑼ᚻⴚࠍⴕߞߡ޿ࠆ‫ޕ‬౰േ⣂ࡃࠗࡄࠬⴚߢߪ㧘ੱᎿᔃ⢖ࠍ↪޿ߥ޿ᔃᜉേਅ౰േ⣂ࡃࠗࡄࠬⴚࠍ╙৻ㆬᛯߦ㧘േ⣂ࠣ࡜ࡈ࠻ࠍᄙ↪ߒߡⴕߞߡ޿ࠆ‫ޕ‬ᔃᯏ⢻ૐਅ∝଀ߥߤߢߪ㧘ࡒ࠾ࠨ࡯ࠠ࠶࠻ੱᎿᔃ⢖ࠍ↪޿ߚ on-pump ߩᔃᜉേਅߢࡃࠗࡄࠬࠍⴕߞߡ޿ࠆ‫߈ߴࠆߌߐ߽ᦨޕ‬ว૬∝ߩ⣖᪪Ⴇ㒐ᱛߩኻ╷ࠍߣࠅ㧘ᐘ޿ߥߎߣߦ౰േ⣂ࡃࠗࡄࠬⴚߦ߅޿ߡ⣖᪪Ⴇว૬ߪ⊝ήߢ޽ࠆ‫ޕ‬௯Ᏺᑯ∔ᖚߢߪੱᎿᑯࠍᜬߜߥ޿ᒻᚑⴚ
ࠍ㜞₸ߦᣉⴕߒߡ߅ࠅ㧘߹ߚᑯውࠍಾ㒰ߒߥ޿ᣂߒ޿ⴚᑼ߽ዉ౉ߒߡ޿ࠆ‫ޕ‬⢷ㇱ߿⣻ㇱᄢേ⣂ߩ⎕ⵚߥߤߩ✕ᕆᚻⴚ߽⋵ోၞ߆ࠄ៝ㅍߐࠇߡ߅ࠅ㧘ߘࠇࠄߦኻߒߡ߽ᢇᕆ࠮ࡦ࠲࡯ߣදജߒߥ߇ࠄ⦟ᅢߥᚑ❣ࠍ޽ߍߡ޿ࠆ‫ޕ‬๭ๆེᄖ⑼ߢߪ⢖ᖡᕈ⣲≌ߩ∝଀߇Ⴧടߒߡ߅ࠅ㧘ߘߩⷐ࿃ߦ⢷⣧㏜㧔⵬ഥ㧕ਅ⢖⪲ಾ㒰߇น⢻ߦߥߞߚߎߣ߇޽ߍࠄࠇࠆ‫ߩߘޕ‬ૐଚⷅᐲߪᄢ߈ߊ㧘ⴚਛ಴ⴊ㧘ⴚᓟ−∩ߩシᷫ߇࿑ࠄࠇߡ޿ࠆ‫ߚ߹ޕ‬඙ၞಾ㒰ߪᦝߥࠆૐଚⷅⴚᑼߢ޽ࠆ߇㧘⁛⥄ߩᣇᴺߦࠃࠆ඙ၞ᳿ቯᴺ߇᦭ലߢ㧘⏕ታ቟ోߥⴚᑼ߇น⢻ߣߥߞߡ޿
ࠆ‫ޕ‬ᶖൻེᄖ⑼ߢߪ 1998 ᐕ߆ࠄዉ౉ߒߡ޿ࠆᣧᦼᄢ⣺≸ߣᣧᦼ⢗≸ߦኻߔࠆ⣻⣧㏜ਅᚻⴚࠍⓍߺ㊀ߨߡ߅ࠅ㧘⃻࿷ߢߪㅴⴕᄢ⣺≸ߦ߽ㆡᔕࠍ᜛ᄢߒ㧘⢷⣧㏜ਅ㘩㆏≸ᚻⴚ߽ⴕߞߡ޿ࠆ‫ߚ߹ޕ‬㧘⢄ಾ㒰ⴚߦ߅޿ߡ
಴ⴊ㊂ࠍᷫዋߐߖࠆߚ߼ߩߐ߹ߑ߹ߥᚻᛛࠍዉ౉ߒ㧘ᦨㄭ 3 ᐕ㑆ߩᐔဋ಴ⴊ㊂ߪએ೨ߩ⚂ඨ㊂ߣߥߞߚ‫ޕ‬⤟ಾ㒰ߢߪㅴⴕ≸ߦኻߔࠆ㐷⣂ว૬ಾ㒰ߩᯏળ߇Ⴧടߒߚߚ߼㧘৻ᤨ⊛㐷⣂ᄢᓴⅣࠪࡖࡦ࠻ࠍ૶↪ߒ㧘቟ోߦ㐷⣂ౣᑪࠍⴕ߁ߎߣ߇ߢ߈ߡ޿ࠆ‫ޕ‬1990 ᐕ߆ࠄขࠅ⚵ࠎߢ޿ࠆᔃ∔ᖚߣᶖൻེ≸ߩหᤨᚻⴚ߽㧘ૐଚⷅߢน⢻ߣߥࠅ㧘Ყセ⊛቟ోߦᣉⴕߢ߈ࠆᚻⴚߣߥߞߚ‫ޕ‬
2㧚ᢎ⢒ᣉ⸳
1㧕 ᣣᧄᄖ⑼ቇળᄖ⑼ኾ㐷ක೙ᐲୃ✵ᣉ⸳
2㧕 ᣣᧄ⢷ㇱᄖ⑼ቇળᜰቯᣉ⸳
3㧕 ᣣᧄᶖൻེᄖ⑼ቇળኾ㐷කୃ✵ᣉ⸳
4㧕 ᣣᧄ๭ๆེᄖ⑼ቇળᜰዉක೙ᐲ㑐ㅪᣉ⸳
5㧕 ਃቇળ᭴ᚑᔃ⤳ⴊ▤ᄖ⑼ኾ㐷ක⹺ቯᯏ᭴ၮᐙᣉ⸳ၮᐙᣉ⸳
3㧚⸻≮㐿⊒
1㧕 ⸻≮ฬ 㧦ᔃਇోว૬⯯ⴊᕈᔃ∔ᖚߦኻߔࠆⴊ▤ᣂ↢࡮ᔃ╭ౣ↢ක≮⸻≮ౝኈ㧦㊀∝ߩᔃਇోว૬⯯ⴊᕈᔃ∔ᖚ㧘ૐᏀᔃᯏ⢻∝଀ߦኻߒߡ㧘ᓴⅣེౝ⑼ߣ౒หߢ㧘ⴊⴕౣᑪน⢻ߥㇱ૏ߦߪࡃࠗࡄࠬࠍⴕ޿㧘ⴊⴕౣᑪਇน⢻ߥㇱ૏ߦߪࠛ࡝ࠬࡠࡐࠗࠛ࠴ࡦᛩਈߦ
ࠃࠆⴊ▤ᣂ↢࡮ᔃ╭ౣ↢ߩ⥃ᐥᔕ↪ࠍ⋡ᜰߔ‫߇ࠬࡄࠗࡃߚ߹ޕ‬ਇน⢻ߥ∝଀ߦߪ⢷⣧㏜ਅ
ߢߩࠛ࡝ࠬࡠࡐࠗࠛ࠴ࡦᔃ╭ౝᛩਈ߽น⢻ߣߒߚ޿‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦ࠛ࡝ࠬࡠࡐࠗࠛ࠴ࡦߦࠃࠆᔃ╭ౣ↢ߪጘ㒂ᄢቇᓴⅣེౝ⑼ߩ⊒᩺ߢ޽ࠅ㧘ઁ∛㒮ߢߩዉ౉ߪߐࠇߡߥ޿‫ޕ‬࿖ౝ⊛⹏ଔ㧦ᔃ╭ౣ↢㧘ⴊ▤ᣂ↢ߪઁߩⴊ▤ᣂ↢ଦㅴ࿃ሶߢߩ⎇ⓥ߇ߎߎߦ߈ߡ஗ṛߒߡ޿ࠆ‫࡝ࠛޕ‬ࠬࡠࡐࠗࠛࡦ࠴ࡦߪ㧘⥃ᐥ਄᦭ኂ੐⽎ߪシᓸߣ⠨߃ࠄࠇ㧘ߘߩലᨐߪၮ␆⊛⎇ⓥߢ⏕⹺ߐࠇߡ޿ࠆ‫ޕ‬࿖㓙⊛⹏ଔ㧦ࠛ࡝ࠬࡠࡐࠗࠛ࠴ࡦߦࠃࠆ⥃ᐥᔕ↪ߪ଀߇ߥߊ㧘ᣂߒ޿ᴦ≮૕♽ߣߥࠅ߁ࠆ‫ޕ‬2㧕 ⸻≮ฬ 㧦ᣂߒ޿඙ၞ㕙ߩหቯᴺࠍ↪޿ߚ⢖≸ߦኻߔࠆ⢷⣧㏜ਅ඙ၞಾ㒰ⴚ⸻≮ౝኈ㧦ᒰ⑼ߢᣉⴕߒߡ߈ߡ޿ࠆ⢖≸ߦኻߔࠆ⢷⣧㏜ਅ⢖⪲ಾ㒰ⴚ߆ࠄ㧘ࠃࠅ๭ๆᯏ⢻ࠍ᷷ሽߒߚ
ߢ඙ၞಾ㒰ᚻⴚࠍᚒ‫ߦ⥄⁛ޘ‬⠨᩺ߒߚᣇᴺࠍᣉⴕߔࠆߎߣߦࠃࠅ㧘ᖚ⠪ߐ߹ߩ QOL ࠍࠃࠅ㜞߼ࠆ‫ޕ‬⢖⪲ಾ㒰ⴚߪ㧘⢖≸ߦኻߔࠆᮡḰⴚᑼߢ޽ࠆ߇㧘ㄭᐕ㧘ࠃࠅಾ㒰⢖ࠍዋߥߊߔ
ࠆ඙ၞಾ㒰ߩᅷᒰᕈ߇ᬌ⸛ߐࠇߡ߈ߡ߅ࠅ㧘ᚒ‫ߩߎ߽ޘ‬ᚻⴚࠍ⢷⣧㏜ਅߦᣉⴕߔࠆᣇᴺࠍ
⠨᩺ߒࠃࠅ㜞ᐲߥක≮ࠍᖚ⠪᭽ߦଏ⛎ߔࠆߎߣࠍ⋡⊛ߦߒߡ޿ࠆ‫ޕ‬㧙㧙ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦⢖≸ߦ߅ߌࠆⓍᭂ⊛඙ၞಾ㒰ⴚߪ㧘⥃ᐥ⎇ⓥ߽㐿ᆎߐࠇߡ߅ࠅ㧘ߘߩᅷᒰᕈ߽
⹺߼ࠄࠇߡ޿ࠆ߇㧘⢷⣧㏜ਅߦᣉⴕߒߡ޿ࠆᣉ⸳ߪో࿖ߢ߽ዋᢙߢ޽ࠆ‫ޕ‬࿖ౝ⊛⹏ଔ㧦ᒰ⑼ߩ⢷⣧㏜ਅᚻⴚߪ㧘᧲ᶏ࿾ᣇߢߪవㅴ⊛ߥ┙႐ߦ޽ࠆߣ⥄⽶ߒߡ޿ࠆ‫ߩ⥄⁛ޕ‬඙ၞಾ㒰ߪ㧘ో࿖ቇળߦߡ⊒⴫ߒߡ⹏ଔࠍᓧߡ޿ࠆ‫ޕ‬࿖㓙⊛⹏ଔ㧦࡛࡯ࡠ࠶ࡄ⢷ㇱᄖ⑼ቇળߦߡ 2007 ᐕ㧘2008 ᐕߣ⢷⣧㏜ਅᚻⴚ߅ࠃ߮඙ၞಾ㒰ⴚࠍࡆ࠺ࠝ⊒⴫ߒᅢ⹏ࠍᓧߚ‫ޕ‬3㧕 ⸻≮ฬ 㧦⢄⣲≌ߦኻߔࠆ⣻⣧㏜ਅ⢄ㇱಽಾ㒰ⴚ⸻≮ౝኈ㧦⢗ಾ㒰߿ᄢ⣺ಾ㒰ߢ߅ߎߥߞߡ޿ࠆ⣻⣧㏜ᛛⴚࠍᔕ↪ߔࠆߎߣߦࠃࠅ㧘ૐଚⷅ߆ߟᢛኈᕈ
ߦߔߋࠇߚ⢄ಾ㒰ⴚࠍ߅ߎߥ߁ߎߣ߇ߢ߈ࠆ‫⚿ߩߎޕ‬ᨐ㧘ᖚ⠪ߦߣߞߡḩ⿷ᐲߩ㜞޿ක≮ࠍឭଏߒ㧘ߐࠄߦ౉㒮ᦼ㑆ߩ⍴❗߇⷗ㄟ߼ࠆ‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦ෘ↢ഭ௛⋭ߩ㜞ᐲవㅴක≮ 21 ߦ⸥タߐࠇߚ㜞ᐲవㅴක≮ߢ㧘਻Ꮊᄢቇ∛㒮㧘ᐢፉᄢቇ∛㒮㧘ᄢಽᄢቇකቇㇱ㒝ዻ∛㒮㧘ᄢ㒋Ꮢ┙ᄢቇකቇㇱ㒝ዻ∛㒮߶߆⸘ 10 ᣉ⸳ߢᣉⴕߐࠇߡ޿ࠆ߇㧘ਛㇱක≮࿤ౝߩᣉ⸳ߢ↳⺧ߐࠇߚᣉ⸳ߪߥ޿‫ޕ‬࿖ౝ⊛⹏ଔ㧦⥃ᐥ⹜㛎⊛ߥዉ౉Ბ㓏ߢ޽ࠆ߇㧘⢄⣲≌ߩዪ࿷߿ᄢ߈ߐߦࠃߞߡߪ㧘ૐଚⷅߢᩮᴦ⊛ߥᴦ≮ߣߥࠅ߁ࠆ‫ޕ‬࿖㓙⊛⹏ଔ㧦ᓥ᧪ߩ⢄ಾ㒰ᴺߣߩᄢⷙᮨᲧセ⹜㛎ߪⴕࠊࠇߡ޿ߥ޿߇㧘ᢙ⊖଀න૏ߩ⥃ᐥᚑ❣߇␜ߐࠇߡ߅ࠅ㧘ਛ⍴ᦼᚑ❣ߪఝࠇߡ޿ࠆߣߐࠇߡ޿ࠆ‫ޕ‬
4㧚ኾ㐷ක࡮⹺ቯක࡮ᜰዉක
┻᧛ඳᢥ㧦ᣣᧄᄖ⑼ቇળᜰዉක࡮ኾ㐷ක࡮⹺ቯක㧘ᣣᧄ⢷ㇱᄖ⑼ቇળᜰዉක࡮⹺ቯක㧘ᣣᧄᓴⅣེቇળኾ㐷ක㧘ਃቇળ᭴ᚑᔃ⤳ⴊ▤ᄖ⑼ኾ㐷කጊ↰ථ਽㧦ᣣᧄᄖ⑼ቇળᜰዉක࡮ኾ㐷ක࡮⹺ቯක㧘ᣣᧄᶖൻེᄖ⑼ቇળᜰዉක࡮ኾ㐷ක࡮⹺ቯක
ጤ↰ ዏ㧦ᣣᧄᄖ⑼ቇળኾ㐷ක࡮⹺ቯක㧘ᣣᧄ⢷ㇱᄖ⑼ቇળ⹺ቯක㧘๭ๆེᄖ⑼ኾ㐷කፉⴼൎ਽㧦ᣣᧄᄖ⑼ቇળኾ㐷ක࡮⹺ቯක㧘ᣣᧄ⢷ㇱᄖ⑼ቇળ⹺ቯක㧘ᣣᧄᓴⅣེቇળኾ㐷ක㧘ਃቇળ᭴ᚑ
ᔃ⤳ⴊ▤ᄖ⑼ኾ㐷ක
㑸㊁⠨ผ㧦ᣣᧄᄖ⑼ቇળኾ㐷ක࡮⹺ቯක㧘ᣣᧄᶖൻེᄖ⑼ቇળኾ㐷ක㧘ᣣᧄᶖൻེ∛ቇળኾ㐷ක⊕ᯅᐘᵗ㧦ᣣᧄᄖ⑼ቇળኾ㐷ක࡮⹺ቯක㧘๭ๆེᄖ⑼ኾ㐷කศ↰⋥ఝ㧦ᣣᧄᄖ⑼ቇળኾ㐷ක࡮⹺ቯක㧘ᣣᧄᶖൻེᄖ⑼ቇળᜰዉක࡮ኾ㐷ක㧘ᣣᧄᶖൻེ∛ቇળኾ㐷ක⍹↰ᚑฮᵗ㧦ᣣᧄᄖ⑼ቇળኾ㐷ක࡮⹺ቯක
ᧁ᧛⌀᮸㧦ᣣᧄᄖ⑼ቇળኾ㐷ක࡮⹺ቯක㧘ᣣᧄᶖൻེᄖ⑼ቇળኾ㐷ක᧻෹዁⚐㧦ᣣᧄᄖ⑼ቇળኾ㐷ක࡮⹺ቯක
ฬ⍮ ␽㧦ᣣᧄᄖ⑼ቇળኾ㐷ක࡮⹺ቯක
᳓㊁ศ㓷㧦ᣣᧄᄖ⑼ቇળኾ㐷කട⮮༑ᒾ㧦ᣣᧄᄖ⑼ቇળ⹺ቯක
5㧚⥄Ꮖ⹏ଔ
⹏ଔ✚วᄖ⑼ࠍታ〣ߒߡ޿ࠆᒰ⑼ߪ㧘ᔃ⤳ⴊ▤ᄖ⑼㧘๭ๆེᄖ⑼㧘ᶖൻེᄖ⑼㗔ၞߦ߅޿ߡᄖ⑼ᴦ≮ࠍਛᔃߦ⸻≮ࠍⴕߞߡ߈ߚ‫ޕ‬ᴦ≮ౝኈߣߒߡߪᔃᜉേਅ౰േ⣂ࡃࠗࡄࠬⴚ㧘ᑯᒻᚑⴚ㧘ᑿㇱᄢേ⣂⟎឵ⴚ㧘⎕ⵚࠍ฽߼ߚ⣻ㇱᄢേ⣂≜ᚻⴚ㧘⢷⣧㏜ਅ⢖⪲ಾ㒰ⴚ㧘⢷⣧㏜ਅ⢷⣼ಾ㒰ⴚ㧘⣻⣧㏜ਅ⢗㧘⚿⣺ಾ㒰ⴚߥߤ㧘ߘߩⴚᑼ߿ᚑ❣ߪ࿖ౝᄖߩቇળ╬ߢ⊒⴫ߒ⹏ଔߐࠇߡ߈ߡ޿ࠆ‫ޕ‬ᚻⴚ∝଀ᢙߪ⃻⁁ߩᦨᄢ㒢ߣ⠨߃ࠄࠇ㧘ᄖ᧪ᓙߜᦼ㑆ߪᦨᄢ 3 ࡩ᦬ࠍߎ߃ࠆᤨᦼ߽޽ߞߚ‫੹ޕ‬ᓟߩ∛㒮ో૕ߩᚻⴚᨒჇടߦᦼᓙߒߚ޿‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ߣ੹ᓟߩዷᦸ
ᄖ⑼⸻≮ߦ⥝๧ࠍᜬߟቇ↢㧘⎇ୃක߇ᄙߊ޿ࠆߎߣߪ㑆㆑޿ߥ޿߇㧘⚿ᨐ⊛ߦᔒᦸߔࠆ⧯߈කᏧߪએ೨
ߦᲧߒ㧘ᷫዋߒߡ޿ࠆߎߣߪุ߼ߥ޿‫ޕ‬ᒰ⑼ߣߒߡ߽⻠⟵߿⥃ᐥታ⠌߿᭽‫࡯ࡖ࠴ࠢ࡟ߥޘ‬㧘࠮ࡒ࠽࡯ࠍ௅
ߒ㧘ቇ↢߿⎇ୃකߦᄖ⑼ߩ߅߽ߒࠈߐ㧘․ᓽ㧘෩ߒߐࠍવ߃ߡ߈ߚߟ߽ࠅߢ޽ࠆ‫ޕ‬ᣣ‫⥃ߩޘ‬ᐥߩߥ߆ߦ⧯
߈කᏧߚߜ߇⋡ᜰߒߚ޿ᆫࠍ੹ᓟ߽⷗ߖߡ޿߈ߚ޿‫߇᧚ੱޕ‬㓸߹ࠆߥ߆ߢ㧘ᄖ⑼⸻≮ߣߒߡߪᐕ‫⊒ޘ‬ዷㅴᱠ߇ᔅⷐߢ㧘቟ో⏕ታࠍ៊ߥࠊߥ޿㧘ߐࠄߥࠆૐଚⷅߩㅊ᳞ࠍⴕߞߡ޿ߊ‫ޕ‬ၮ␆⎇ⓥߣߩⲢวߩߥ߆ߢᣂ
ߒ޿ᴦ≮૕♽ࠍត᳞ߒߡ޿ߊ‫ޕ‬㧙㧙㧔7㧕╙ੑᄖ⑼1㧚⸻≮ߩ᭎ⷐ
ᶖൻེᄖ⑼࡮੃⣼ᄖ⑼ࠍኾ㐷ߣߒ㧘ߎߣߦᖡᕈ⣲≌ߦኻߔࠆᄖ⑼⊛ᴦ≮߇ਥߥ⸻≮ౝኈߢ޽ࠆ‫ޕ‬ᐔᚑ
19 ᐕߩᚻⴚ∝ઙᢙߪ㘩㆏≸㧦10㧘⢗≸㧦66㧘⚿⣺࡮⋥⣺≸㧦66㧘ේ⊒ᕈ࡮ォ⒖ᕈ⢄≸㧦26㧘⢙㆏࡮⤟≸㧦
18㧘੃≸㧦55 ߢ޽ߞߚ‫৻ޕ‬ᣇ⦟ᕈ∔ᖚߢߪ⢙ྙ៰಴ⴚ㧦41㧘㥘ᓘࡋ࡞࠾ࠕ㧦36 ଀ߢ޽ࠅ㧘⯻ုಾ㒰ⴚߥߤ✕ᕆ଀ߩߺߥࠄߕᇚੱ⑼㧘ᴲዩེ⑼╬ઁ⑼ߩᚻⴚߩᔕេߣߒߡⓍᭂ⊛ߦ㑐ਈߒߡ޿ࠆ‫ߦᦝޕ‬ᐔᚑ 20 ᐕᐲߦߪᖡᕈ⣲≌ߦኻߔࠆᚻⴚ∝଀ߪჇടߒ㧘㘩㆏≸㧦20㧘⢗≸㧦75㧘⚿⣺࡮⋥⣺≸㧦118㧘ේ⊒ᕈ࡮ォ⒖
ᕈ⢄≸㧦28㧘⢙㆏࡮⤟≸㧦21㧘੃≸㧦61 ଀ߢ޽ߞߚ‫ޕ‬ၮᧄ⊛ߦߪ⤳ེ೎࠴࡯ࡓࠍ✬ᚑߒ㧘ฦ㗔ၞߩኾ㐷ක߇ᚻⴚߣ๟ⴚᦼ▤ℂ߅ࠃ߮ᖡᕈ∔ᖚߦኻߔࠆൻቇ≮ᴺߥߤߦߟ߈㧘୘‫ߦ଀∝ߩޘ‬ᔕߓߡታᣉߒߡ޿ࠆ‫ޕ‬ฦ㗔ၞᖡᕈ⣲≌ߦኻߒᩮᴦⴚ߇น⢻ߣ್ᢿߒߚ∝଀ߦߪⓍᭂ⊛ߦᄖ⑼ᴦ≮ࠍ⹜ߺߡ޿ࠆ߇㧘ಾ㒰ਇ⢻଀ߦኻߒߡ߽㧘଀߃߫㘩㆏≸ߢߪ᡼኿✢࡮ൻቇ≮ᴺ㧔5FU+TXT㧕㧘⢗≸࡮ᄢ⣺≸ߦߪൻቇ≮ᴺ㧔TS-1 ޽ࠆ޿ߪ FOLFOX ߥߤ㧕ࠍᔕ↪ߒ㧘⣲≌❗ዊߦ઻ߥ޿ಾ㒰น⢻ߣߥߞߚ∝଀߽ᄙߊ⚻㛎ߒߡ߅ࠅ㧘Adjuvant
Surgery ߣߒߡᒰ⑼ࠍ⊒ାḮߣߒߚ᭎ᔨࠍᐢߊ࿖ౝߦឭ໒ߒߡ޿ࠆ‫৻ޕ‬ᣇߢ਄ㇱ࡮ਅㇱᶖൻ▤⣲≌ߩᄖ⑼ᴦ≮ߦ߅޿ߡߪ㧘ᣣᧄౝⷞ㏜ᄖ⑼ቇળᛛⴚ⹺ቯකࠍਛᔃߦ∛ᦼㅴⴕ߇Ყセ⊛ᣧᦼߢ޽ࠆ∝଀ߦኻߒߡଚⷅ
߇ዋߥ޿㏜ⷞਅᚻⴚࠍዉ౉ߒߡ޿ࠆ‫ߚ߹ޕ‬ਅㇱᶖൻ▤㗔ၞߢߪน⢻ߥ㒢ࠅ⥄ὼ⢂㐷᷷ሽᚻⴚ㧔᜝⚂╭᷷ሽᚻⴚ㧕ࠍⴕߞߡ޿ࠆߎߣߦട߃㧘߿߻ߥߊࠬ࠻࡯ࡑ㧔ੱᎿ⢂㐷㧕ㅧ⸳߇ᔅⷐߣߥߞߚ႐วߦߪ㧘ET㧘WOC࠽࡯ࠬߩදജߩਅߢࠬ࠻࡯ࡑᄖ᧪ࠍ㐿௅ߒฦ⒳⋧⺣ߦᔕߓߡ޿ࠆ‫ޕ‬⢄⢙⤟㗔ၞߢߪ㧘․ߦ㜞ᐲߦㅴⴕߒߡ
ಾ㒰ਇ⢻ߢ޽ࠆ⢄⤳≸ߦኻߒߡߪ㧘᛫⣲≌఺∉ߩ⾮ᵴࠍ⋡⊛ߣߒߚಓ⚿ᴦ≮ࠍⴕ޿㧘ߎࠇ߹ߢߩታ❣ࠍ〯߹߃㜞ᐲක≮ߣߒߡෘ↢ഭ௛⋭߳↳⺧ߒߡ޿ࠆ‫ߚ߹ޕ‬⢙⤟≸ߦኻߒߡߪ㧘ᶖൻེౝ⑼ߣߩදജߦߡ㧘ጘ㒂Ꮢౝߩਥⷐ㑐ㅪᣉ⸳วหߢ᡼኿✢࡮ൻቇ≮ᴺߩ᦭↪ᕈߦ㑐ߔࠆᴦ≮ౝኈࠍᬌ⸽ߔࠆࡊࡠ࠻ࠦ࡯࡞ࠍផㅴߒ
ߡ޿ࠆ‫ߦ≸੃ޕ‬ኻߒߡߪ㧘੃ᚱ᷷ሽ≮ᴺߥߤⴚᓟḩ⿷ᐲࠍ⛽ᜬߔࠆߎߣߦᔃ߇ߌࠆߩߺߥࠄߕ㧘࠮ࡦ࠴ࡀ࡞࡝ࡦࡄ▵߳ߩᬌ⸛ࠍᔕ↪ߒਇⷐߥ⣠┃࡝ࡦࡄ▵ㇳᷡࠍ࿁ㆱߔࠆദജࠍߒߡ޿ࠆ‫ޕ‬޿ߕࠇߩ⤳ེߩ≸ߦኻߒߡ߽㧘ၮᧄ⊛ߦൻቇ≮ᴺߪ࿖ౝߢߩᣂⷙᴦ㛎ߦදജ࡮⊓㍳ࠍਛᔃߣߒߡ⊒ዷߦነਈߔࠆࠃ߁ߦߒߡ޿ࠆ߇㧘ߘࠇએ਄ߦᒰ⑼ߢߩ⁛⥄ᕈࠍ⊒ើߔࠆ႐ߩዷ㐿ࠍᔃ߇ߌ㧘ጘ㒂߆ࠄ਎⇇߳ߩ⊒ାࠍ⋡ᮡߣߒߡ޿ࠆ‫ޕ‬
2㧚ᢎ⢒ᣉ⸳
1㧕 ᣣᧄᄖ⑼ቇળ⹺ቯක࡮ኾ㐷ක೙ᐲ⎇ୃᣉ⸳
2㧕 ᣣᧄᶖൻེᄖ⑼ቇળኾ㐷කୃ✵ᣉ⸳
3㧕 ᣣᧄ⢄⢙⤟ᄖ⑼ቇળ㜞ᐲᛛ⢻ኾ㐷කୃ✵ᣉ⸳
4㧕 ᣣᧄᄢ⣺⢂㐷∛ቇળኾ㐷කୃ✵ᣉ⸳
5㧕 ᣣᧄ੃≸ቇળ⎇ୃᣉ⸳
3㧚⸻≮㐿⊒
1㧕 ⸻≮ฬ 㧦㜞ᐲㅴⴕ⢄≸ߦኻߔࠆ᛫⣲≌఺∉⾮ᵴࠍ⋡⊛ߣߒߚಓ⚿ᴦ≮⸻≮ౝኈ㧦ᄖ⑼⊛ಾ㒰߇ਇ⢻ߣ್ᢿߐࠇߚ⢄⣲≌ߦኻߒ㧘⿥㖸ᵄࠍࠟࠗ࠼ߣߒߡዪᚲ㤗㈮ਅߦಓ⚿⓫ೝ㊎ࠍ૶↪ߔࠆߎߣߢಓ⚿უᱫࠍ⺃⊒ߔࠆ‫ޕ‬ᴦ≮ߪㅳ 1 ࿁ࠍේೣߣߒߡน⢻ߥ㒢ࠅ෻ᓳ࡮⛮⛯ߒ㧘᛫⣲≌఺∉ߩ⾮ᵴࠍଦߔ‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦ᒰ⑼⁛⥄ߩᴦ≮૕♽ߢ޽ࠅ㧘਎⇇⊛ߦ߽㘃ࠍߺߥ޿‫ޕ‬࿖ౝ⊛⹏ଔ㧦㊀◊ߥ᦭ኂ੐⽎߽ߥߊ㧘1 ᴱ౉㒮ߢ 1 ࿁ߩᴦ≮߇น⢻ߢ޽ࠆߎߣ߆ࠄ quality of life ࠍ៊ߥ߁ߎߣߥߊⴕ޿ᓧ㧘ߎࠇ߹ߢߦታᣉߒߡ߈ߚ 22 ଀ߩᴦ≮ౝኈߦߟ߈㧘ฦ⒳ቇળߢߩႎ
๔㧘⺰ᢥឝタࠍㅢߒᓢ‫ߦޘ‬ᶐㅘߒߡ޿ࠆ‫⃻ޕ‬࿷㜞ᐲක≮ߣߒߡෘ↢ഭ௛⋭߳↳⺧ᚻ⛯߈ਛߢ޽ࠆ‫ޕ‬
࿖㓙⊛⹏ଔ㧦ಓ⚿ᴦ≮ߘߩ߽ߩߪߎࠇ߹ߢߦ᰷߽☨ࠍߪߓ߼ᣉⴕߐࠇߡ߈ߚ⚻✲߇޽ࠆ߇㧘᛫⣲≌఺∉⾮ᵴࠍ⋡⊛ߣߔࠆ᭎ᔨߪ․⇣ߢ޽ࠅ㧘2008 ᐕߪ࿖㓙≸ቇળ߿࿖㓙ᶖൻེᄖ⑼ቇળ߳ߩ⊒⴫ࠍㅢߒߡ⹏ଔߐࠇߟߟ޽ࠆ‫ޕ‬2㧕 ⸻≮ฬ 㧦࠮ࡦ࠴ࡀ࡞࡝ࡦࡄ▵↢ᬌߦࠃࠆ⣠┃࡝ࡦࡄ▵ㇳᷡߩㆡᔕ್ቯ
⸻≮ౝኈ㧦੃≸∝଀ߦ߅޿ߡ⣲≌ᓘߩዊߐߥ႐วߦߪ㧘ᮡ⼂ࠕࠗ࠰࠻࡯ࡊࠍ⣲≌๟ㄝߦᵈ౉ߒߡ⣲≌߆ࠄᦨ߽ㄭߊᦨೋߦᵹ౉ߔࠆ࡝ࡦࡄ▵㧔࠮ࡦ࠴ࡀ࡞࡝ࡦࡄ▵㧕ࠍ៰಴ߒ㧘ⴚਛㄦㅦ∛ℂᬌᩏߦߡォ⒖ߩ᦭ήࠍ⏕⹺ߔࠆߎߣߢㇳᷡߩㆡᔕࠍ⹏ଔߒߡ޿ࠆ‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦ో࿖⊛ߦߪᮡḰౝኈߣߐࠇࠆ௑ะߦ޽ࠆ߇㧘ጘ㒂⋵ਅߢߪᧂߛᶐㅘߒߡ޿ࠆ⁁ᴫߢߪߥ޿‫ޕ‬㧙㧙࿖ౝ⊛⹏ଔ㧦੃≸⸻≮ࠍኾ㐷ߣߒߡ޿ࠆᣉ⸳ߢߪᮡḰౝኈߢ޽ࠅ⸻≮ࠟࠗ࠼࡜ࠗࡦߦ߽ߘߩᗧ⟵߇⹏ଔߐࠇߡ޿ࠆ‫ߒ߆ߒޕ‬቟ቯߒߚᚑ❣ߩ⏕଻ߦߪ৻ቯએ਄ߩ∝଀ᢙࠍⷐߔࠆὐ߽ᜰ៰ߐࠇߡ
߅ࠅ㧘ߘߩὐߦ㑐ߒߡߪᒰ⑼ߢߪߔߢߦ⏕┙ߒߚ⁁ᴫߣ⸒߃ࠆ‫ޕ‬࿖㓙⊛⹏ଔ㧦᰷☨ߢߪᣣᏱ⥃ᐥ਄㊀ⷐⷞߐࠇߡ޿ࠆ‫ޕ‬
4㧚ኾ㐷ක࡮⹺ቯක࡮ᜰዉක
ศ↰๺ᒄ㧦ᣣᧄᄖ⑼ቇળ⹺ቯක࡮ኾ㐷ක࡮ᜰዉක㧘ᣣᧄᶖൻེᄖ⑼ቇળ⹺ቯක࡮ኾ㐷ක࡮ᜰዉක㧘ᣣᧄౝⷞ㏜ᄖ⑼ቇળᛛⴚ⹺ቯක㧔ᶖൻེ࡮৻⥸ᄖ⑼࡮⢗≸㧕㧘ᣣᧄ੃≸ቇળ⹺ቯක㧘ᣣᧄ≸ᴦ≮ቇળ⥃ᐥ⹜㛎⊓㍳ක㧘ᣣᧄ≸ᴦ≮ᯏ᭴ᥳቯᢎ⢒ක㧘ࡑࡦࡕࠣ࡜ࡈࠖ࡯ᬌ⸻♖ᐲ▤ℂਛᄩᆔຬળ⺒ᓇ⹺ቯ㧘ᣣᧄ㘩㆏ቇળ㘩㆏⑼⹺ቯක㧘ᣣᧄᶖൻ▤ቇળ⢗⣺⑼⹺ቯක㧘ᶖൻེ߇ࠎᄖ⑼ᴦ≮⹺ቯකᎹญ㗅ᢘ㧦ᣣᧄᄖ⑼ቇળ⹺ቯක࡮ኾ㐷ක㧘ᣣᧄ੃≸ቇળ⹺ቯක࡮੃⣼ኾ㐷ක㧘ࡑࡦࡕࠣ࡜ࡈࠖ࡯ᬌ⸻♖ᐲ
▤ℂਛᄩᆔຬળ⺒ᓇ⹺ቯ㐳↰⌀ੑ㧦ᣣᧄᄖ⑼ቇળ⹺ቯක࡮ኾ㐷ක࡮ᜰዉක㧘ᣣᧄᶖൻེᄖ⑼ቇળ⹺ቯක࡮ኾ㐷ක࡮ᜰዉක㧘ᣣᧄ⢄⢙⤟ᄖ⑼ቇળ㜞ᐲᛛ⢻ᜰዉක㧘ᣣᧄ≸ᴦ≮ᯏ᭴ᥳቯᢎ⢒කጊญ๺਽㧦ᣣᧄᄖ⑼ቇળ⹺ቯක࡮ኾ㐷ක࡮ᜰዉක㧘ᣣᧄᶖൻེᄖ⑼ቇળ⹺ቯක࡮ኾ㐷ක࡮ᜰዉක㧘ᣣᧄౝⷞ㏜ᄖ⑼ቇળᛛⴚ⹺ቯක㧔ᶖൻེ࡮৻⥸ᄖ⑼࡮⢗≸㧕㧘ᶖൻེ߇ࠎᄖ⑼ᴦ≮⹺ቯක㧘ᣣᧄ≸ᴦ≮ᥳቯᢎ⢒ක
㜞ᯅቁᄦ㧦ᣣᧄᄖ⑼ቇળ⹺ቯක࡮ኾ㐷ක࡮ᜰዉක㧘ᣣᧄᶖൻེᄖ⑼ቇળ⹺ቯක࡮ኾ㐷ක㧘ᣣᧄᄢ⣺⢂㐷∛ቇળኾ㐷ක㧘ᶖൻེ߇ࠎᴦ≮⹺ቯක㧘ᣣᧄ≸ᴦ≮ᥳቯᢎ⢒ක㧘ᣣᧄ≸ᴦ≮⹺ቯක㧘ICD
ဈਅᢥᄦ㧦ᣣᧄᄖ⑼ቇળ⹺ቯක࡮ኾ㐷ක㧘ᣣᧄᶖൻེᄖ⑼ቇળ⹺ቯක࡮ኾ㐷ක㧘ᣣᧄ≸ᴦ≮⹺ቯකᯏ᭴⹺
ቯක࡮ᥳቯᢎ⢒ක
⚦㊁⧐᮸㧦ᣣᧄᄖ⑼ቇળ⹺ቯක࡮ኾ㐷ක㧘ᣣᧄ≸ᴦ≮⹺ቯකᯏ᭴ᥳቯᢎ⢒ක㧘ࡑࡦࡕࠣ࡜ࡈࠖ࡯ᬌ⸻♖ᐲ
▤ℂਛᄩᆔຬળ⺒ᓇ⹺ቯ㧘ᣣᧄකᏧળ⹺ቯ↥ᬺකᓼጊᵏᴦ㧦ᣣᧄᄖ⑼ቇળ⹺ቯක࡮ኾ㐷ක㧘ᣣᧄᶖൻེᄖ⑼ቇળ⹺ቯක࡮ኾ㐷ක㧘ᶖൻེ߇ࠎᄖ⑼ᴦ≮⹺ቯක㧘ᣣᧄ≸ᴦ≮⹺ቯᯏ᭴≸ᴦ≮⹺ቯක࡮ᥳቯᢎ⢒කᅏ᧛⋥᮸㧦ᣣᧄᄖ⑼ቇળ⹺ቯක࡮ኾ㐷ක㧘ᣣᧄᶖൻེᄖ⑼ቇળ⹺ቯක
↰ਛༀብ㧦ᣣᧄᄖ⑼ቇળ⹺ቯක࡮ኾ㐷ක㧘ᣣᧄᶖൻེᄖ⑼ቇળ⹺ቯක࡮ኾ㐷ක㧘ᣣᧄ㤗㈮⑼ቇળ⹺ቯක
ฬ๺ᱜੱ㧦ᣣᧄᄖ⑼ቇળኾ㐷ක㧘ᣣᧄᶖൻེᄖ⑼ቇળኾ㐷ක㧘ᣣᧄ੃≸ቇળ⹺ቯක㧘߇ࠎᴦ≮⹺ቯක੗Ꮉᗲሶ㧦ᣣᧄᄖ⑼ቇળኾ㐷ක㧘ᣣᧄ੃≸ቇળ੃⣼⹺ቯක⋿↰㓶Ꮢ㧦ᣣᧄᄖ⑼ቇળኾ㐷ක
5㧚⥄Ꮖ⹏ଔ
⹏ଔᣂ∛㒮߳ߩ⒖ォᓟ㧘ᄖ᧪࡮౉㒮⸻≮ߩ޿ߕࠇߦ߅޿ߡ߽㧘ᶖൻེ࡮੃⣼∔ᖚ∝଀ᢙߪߣ߽ߦჇടߩ৻ㅜ
ࠍߚߤߞߡ޿ࠆ‫ޕ‬ᚻⴚᛛⴚ߅ࠃ߮ߘߩౝኈߣߒߡ߽㧘ฦ∔ᖚ࡮⤳ེ㗔ၞ߳ߩಽൻߦࠃࠅ㜞޿ኾ㐷ᕈߦ઻߁࡟ࡌ࡞ߩะ਄߇ߺࠄࠇߡ߅ࠅ㧘࿖ౝߢ߽චಽ⹏ଔߐࠇࠆ⁁ᴫߢ޽ࠆ‫ߚ߹ޕ‬㜞ᰴᢇ๮࠮ࡦ࠲࡯ߣߩදജߩ߽
ߣ㧘ⴚᓟ▤ℂ૕೙ߦ߽቟ቯ߇ߺࠄࠇߡ޿ࠆ‫ޕ‬ᖡᕈ∔ᖚߦኻߔࠆⴚᓟ⵬ഥ≮ᴺߦ㑐ߒߡߪ㧘࿖ౝฦ⒳ᣂⷙᴦ
㛎߳ߩෳടߦࠃࠆࠛࡆ࠺ࡦࠬߩឭ໒ߦ㑐ߔࠆദജߩߺߥࠄߕ㧘㒝ዻ∛㒮⣲≌࠮ࡦ࠲࡯ߦ߅ߌࠆੱ⊛੤ᵹࠍㅢߒߚᄖ᧪ൻቇ≮ᴺㇱ㐷ߩ┙ߜ਄ߍߦ៤ࠊࠅ㧘৻ጀలታߒߚᣇะ߳⊒ዷߒߟߟ޽ࠆ‫ޕ‬એ਄ࠃࠅᶖൻེ࡮੃
⣼ߦ߅ߌࠆᖡᕈ⣲≌ߦኻߔࠆᴦ≮ߢߪ㧘ጘ㒂⋵߇ࠎ⸻≮ㅪ៤᜚ὐ∛㒮ߢ޽ࠆᄢቇ∛㒮ߩ৻⠢ࠍᜂ߁ߴߊ⣲≌ᄖ⑼ߣߒߡ㧘ߘߩᓎഀࠍᄙ޿ߦᨐߚߒߡ޿ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷1㧕∛ᐥᢙߦ೙㒢߇޽ࠅ㧘ᚻⴚ㧘ൻቇ≮ᴺߦട߃✕ᕆ౉㒮ߥߤߦ߅ߌࠆࡌ࠶࠼ߩ⏕଻ߦ࿎┆ߔࠆߎߣ߇ᄙ
޿‫⃻ߒ߆ߒޕ‬࿷ߪ㧘ࡌ࠶࠼ࠦࡦ࠻ࡠ࡯࡞ࠍ⋴⼔ㇱߦߡ▤ℂߒߡ޿ߚߛߌࠆࠃ߁දജ૕೙߇లታߒߡ߈
ߚߎߣ߽޽ࠅ㧘ߔߢߦ⸃᳿ߩᣇะߦ޽ࠆߣ⹏ଔߒ߁ࠆ‫ޕ‬
2㧕ᚻⴚ∝଀ߩჇടߦ઻޿ߺࠄࠇࠆࠃ߁ߦߥߞߚᚻⴚᨒߩ೙㒢߇ᦨ߽ᄢ߈ߥ໧㗴ὐߩ৻ߟߢ޽ࠆ‫ޕ‬ᒰ⑼ߣ
ߒߡߪ㧘߽ߜࠈࠎ቟ోᕈߩ⏕଻ࠍ㊀ⷞߒߟߟᚻⴚᤨ㑆ߩ⍴❗࡮ᚻⴚੱຬߩࠪࡈ࠻ߥߤߩദജࠍⴕߞߡ
߈ߚ⚿ᨐ㧘㤗㈮⑼߅ࠃ߮ᚻⴚㇱߩℂ⸃ߦࠃࠅᓥ᧪ߩቯᦼᚻⴚᣣ㧔Ἣᦐ࡮ᧁᦐ㧕ߦട߃৻ቯᨒࠍଏ⛎ߒߡ޿ߚߛ޿ߡ޿ࠆ‫ߥ߁ࠃ߆ߒ߆ߒޕ‬ᡷༀ╷ࠍ⻠ߓߚߣߎࠈߢ㧘ᚻⴚᓙߜᦼ㑆ߪᐔဋ 3 ߆ࠄ 4 ㅳ㑆ߢ޽ࠆߎߣ߇⃻ታߢ޽ࠆ‫ޕ‬
3㧕ో࿖⊛ߥ௑ะߣߒߡߺࠄࠇࠆ⧯ᚻකᏧߩᄖ⑼㔌ࠇ߇߿ߪࠅᷓೞߢ޽ࠆ‫ޕ‬ᄢቇ∛㒮ߢߩᮡḰએ਄ߩ⸻≮࡟ࡌ࡞ࠍ଻ߜߟߟ㧘৻⥸ᄖ⑼ߣߒߡ࿾ၞක≮߳ߩ⽸₂߇ᦼᓙߐࠇࠆᒰ⑼੐ᖱ߆ࠄ๟ㄝක≮࿤߳ߩੱ᧚㧙㧙ߩଏ⛎ߦ߽⽿છࠍᨐߚߔᔅⷐ߇޽ࠅ㧘⃻Ბ㓏ߢߪකዪຬߩ₂り⊛ߥദജߢߎࠇࠍ⵬ߞߡ޿ࠆ‫ߩߘޕ‬ኻᔕߣߒߡߪ⎇ୃකᏧߩ⏕଻ߦઁߥࠄߕ㧘ᄖ⑼ක≮ߩ೑ὐࠍ⺑߈ߟߟ㧘⃻⁁ᛂ㐿ߩᣇ╷ࠍ౒ߦ⠨߃ߡ޿ߌࠆࠃ߁ቇ↢ᤨઍ߆ࠄߩᗧ⼂࡟ࡌ࡞ߩࠕ࠶ࡊࠍߪ߆ࠆߴߊᢎ⢒ߦ߽ജࠍ౉ࠇߡ޿ࠆ‫ޕ‬੹ᓟߩዷᦸᶖൻེ࡮੃⣼ߩᖡᕈ⣲≌ࠍਛᔃߣߒߚ⸻≮߇੹ᓟ߽ਥ૕ߣߥࠆ‫ޕ‬ቇળߥߤߩേ߈ߣߒߡฦ㗔ၞߩኾ㐷කࠍ⸳ቯߔࠆᣇะߦ޽ࠅ㧘ୃ✵ᣉ⸳ߣߒߡߩ∝଀ᢙߩߺߥࠄߕ⸻≮ౝኈߩ⛽ᜬ߇㊀ⷐߢ㧘කዪຬߦኻߔࠆ⚻㛎ߩឭଏ߅ࠃ߮ᢎ⢒૕೙ߩలታ߇ᔅߕᔅⷐߣߐࠇࠆ‫ߩߘޕ‬਄ߢ㧘ቇળᵴേࠍ᜚ὐߣߒߚᦨᣂක≮ߩᛛⴚߩขࠅ౉ࠇ߿᭎ᔨߩℂ⸃ࠍ⛮⛯ߔࠆߎߣࠍ⋡ᮡߣߒߡ޿ࠆ‫ߦࠄߐޕ‬ᒰ⑼ߢߪߔߢߦ⏕┙ߒߚතᓟ⎇ୃࠪࠬ࠹ࡓࠍ߽Ᏹߦ⷗⋥ߒ㧘⁁ᴫߦೣߒߚౝኈࠍᏱߦᬌ⸛ߔࠆദജ߇ᔅⷐ
ߢ޽ࠆ‫ࠎࠈߜ߽ޕ‬ᖚ⠪ߐࠎߩ᳞߼ߦᔕߓߚోੱ⊛ߥᄖ⑼කߩ⢒ᚑ߇ߤߩᲑ㓏ߢ߽ᔅⷐߢ޽ࠆߎߣߪᒰὼߢ
޽ࠆ‫ޕ‬੹ᓟߣ߽ᣣᏱ⸻≮ߩߺߦ᣿ߌ᥵ࠇࠆ⥃ᐥ⑼ߣߒߡߩሽ࿷ߩߺߥࠄߕ㧘߇ࠎක≮ߦ㑐ߔࠆၮ␆⊛⎇ⓥㇱ㐷ߣߩᒝ࿕ߥ❬߇ࠅࠍ⛮⛯ߔࠆᔅⷐ߇޽ࠆ‫⃻ޕ‬࿷ߪᒰ⑼ࠬ࠲࠶ࡈߩᜰዉߦࠃࠅᄢቇ㒮↢߇⎇ⓥߩਛᔃߣߥߞ
ߡ޿ࠆ߇㧘ቇળ⊒⴫࡮⺰ᢥᛩⓂߦኻߔࠆ৻ቯߩ⹏ଔࠍ߽ߣߦ㧘කዪຬ৻ੱ৻ੱߩᗧ⼂ࠍࠃࠅะ਄ߐߖ㧘⚵❱ో૕ߣߒߡߩ⊒ዷࠍ⥃ߺߚ޿‫ޕ‬㧙㧙㧔8㧕↥⑼ᇚੱ⑼1㧚⸻≮ߩ᭎ⷐ
ߎࠇ߹ߢߣห᭽‫ޕ‬ᇚੱ⑼⣲≌ߩᚻⴚ≮ᴺ࡮ౝ⑼⊛ᴦ≮㧘↢ᱺ↢ℂ⊛∔ᖚ㧔ਇᅧ∝㧘ᕁᤐᦼ㧘ౝಽᴲ∔ᖚ㧘ᦝᐕᦼ㧕㧘ᗵᨴ∝㧘ᇚੱ⑼ᔃり∝߅ࠃ߮๟↥ᦼ⸻ᢿ࡮ᴦ≮ߦ㑐ߒߡ࿾ၞක≮ᯏ㑐ߣߩㅪ៤ࠍขࠅߥ߇ࠄⴕ
ߞߡ޿ࠆ‫ޕ‬2㧚ᢎ⢒ᣉ⸳
1㧕 ᣣᧄ↥⑼ᇚੱ⑼ቇળ⹺ቯᣉ⸳
2㧕 ᣣᧄᇚੱ⑼⣲≌ቇળ⹺ቯᣉ⸳
3㧕 Უ૕଻⼔ᴺᜰቯᣉ⸳
3㧚⸻≮㐿⊒
1㧕 ⸻≮ฬ 㧦≸ൻቇ≮ᴺᤨߩᕈ⣼ᯏ⢻㓚ኂߦኻߔࠆ GnRH ࠕ࠽ࡠࠣߩ଻⼔૞↪
⸻≮ౝኈ㧦≸ൻቇ≮ᴺ೷ߦࠃࠆᕈ⣼࠳ࡔ࡯ࠫ߆ࠄߩ࿁ㆱᯏ᭴ߩ╙৻ᱠߣߒߡᧄ⎇ⓥߢߪ GnRH ࠕ࠽ࡠࠣߩෆᎽ໧⾰⚦⢩଻⼔૞↪ࠍ⥃ᐥ⊛ߦ᣿ࠄ߆ߦߔࠆ੐ࠍ⹜ߺߚ‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦1㧕଻㒾ㆡ↪߇ߥ޿ߎߣ㧘2㧕⥃ᐥ⹜㛎㧔ᄢⷙᮨ㧕߇ߥ޿ߚ߼㧘⥃ᐥᔕ↪߇ߥߐࠇߡ޿ߥ޿‫⹜ߩߎޕ‬㛎ߩ㐿⊒ߪᄢቇ∛㒮ߩ૶๮ߢ޽ࠆ‫ޕ‬࿖ౝ⊛⹏ଔ㧦GnRH ࠕ࠽ࡠࠣߪෆᎽߦ⋥ធ૞↪ߒ㧘ൻቇ≮ᴺ೷ߦኻߔࠆ෻ᔕᕈࠍૐਅߐߖࠆߣ⌕⋡ߒߚ⁛ഃᕈߪ㜞޿‫߽߆ߒޕ‬㧘GnRH ࠕ࠽ࡠࠣߪᕈࠬ࠹ࡠࠗ࠼ଐሽᕈ∔ᖚߩᴦ≮⮎ߣߒߡᐢߊ
૶↪ߐࠇߡ߅ࠅ㧘⋥ߜߦ⥃ᐥᔕ↪಴᧪ࠆน⢻ᕈࠍ⒁߼ߡ޿ࠆ‫⊒ޕ‬ዷᕈ߇ᦼᓙ಴᧪ࠆ⎇ⓥ⺖㗴ߢ޽ࠆ‫ޕ‬ᕈ⣼ߩൻቇ≮ᴺ೷ߦኻߔࠆᗵฃᕈ߇㜞ߊ㧘ᴦ≮ᓟߦੑᰴ⊛ߥᕈ⣼࠳ࡔ࡯ࠫࠍ߈
ߚߔ੐߇ᄙ޿‫ߩߎޕ‬ᕈ⣼㓚ኂߪਇนㅒ⊛ߢ޽ࠅ㧘⧯ᐕ⠪ߦߣߞߡᭂ߼ߡᷓೞߥว૬∝ߣߥߞߡ޿ࠆ‫ޕ‬ൻቇ≮ᴺᤨߩ⚦⢩Ქᕈ߆ࠄᕈ⣼ࠍ଻⼔ߔࠆ੐ߪ㧘዁᧪⊛ߥ↢ᱺ⢻ജࠍ଻ᜬߔࠆ
਄ߢ㊀ⷐߢ޽ࠆ‫ޕ‬࿖㓙⊛⹏ଔ㧦✚⺑㧔Reprod. Med. Biol. 2008;7:17-27㧕ߣߒߡ⊒⴫ߒߚ‫ߚ߹ޕ‬㧘⻉ᄖ࿖ߢߪ⥃ᐥᔕ↪
߇ᆎ߹ߞߡ߅ࠅ㧘࿖㓙⊛ߥ૏⟎ઃߌߪ㜞޿‫ޕ‬2㧕 ⸻≮ฬ 㧦ᇚੱ⑼ᖡᕈ⣲∔ᖚ⠪ߩ⚦⢩⸻ࠍ↪޿ߚࠥࡁࡒࠢࠬߥߤߩಽᨆᛛᴺࠍ㚟૶ߒߚ⤳ེ߿୘ੱߩ
≸㑐ㅪಽሶ⊒⃻ࡊࡠࡈࠔࠗ࡞⸃ᨆߦၮߠߊ᧲ᵗකቇ߅ࠃ߮⷏ᵗකቇ⊛ࠝ࡯࠳࡯ࡔ࡯࠼ᴦ≮⸻≮ౝኈ㧦ᇚੱ⑼ᖡᕈ⣲≮߅ࠃ߮ߘߩ೨≸∛ᄌᖚ⠪߆ࠄ㧘⚦⢩⸻ࠍ⋥ធណขߒ㧘DNA ࠴࠶ࡊ߿TOF/MS ߆ࠄᓧࠄࠇࠆᖚ⠪ߩࠥࡁࡒ࠶ࠢ㨯ࡄ࠲࡯ࡦࠍ⸃ᨆߒߡ㧘᧲ᵗකቇߦ߅ߌࠆ⸽߿⷏
ᵗකቇߦ߅ߌࠆ∛ᘒߩᄌൻߦ․ᓽ⊛ߥࡑ࡯ࠞ࡯ࠍหቯߔࠆ‫ߣ࡯ࠞ࡯ࡑࠄࠇߎޕ‬ᖚ⠪ߩዻᕈᖱႎࠍ⛔วߒ㧘࠺࡯࠲ࡌ࡯ࠬൻߒߡ޿ߊ‫ࠅࠃߦࠇߎޕ‬㧘᧲ᵗකቇߦ߅ߌࠆ⸽߿⷏ᵗකቇߦ߅ߌࠆ≸ᖚ⠪ߩ∛ᘒߩᄌൻߩ⸻ᢿࠍᡰេߔࠆࠪࠬ࠹ࡓࠍ⚦⢩⸻⎇ⓥળ␠ߣ↥ቇ౒หߦߡ㐿⊒ߔࠆ‫ޕ‬
ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦࿖ౝઁ∛㒮ߢߪዉ౉ߐࠇߡ޿ߥ޿‫ޕ‬࿖ౝ⊛⹏ଔ㧦≸ᖚ⠪߿᧲ᵗකቇ⊛‫ࠢ࠶ࡒࡁࠥߩޠ⸽ޟ‬㨯ࡄ࠲࡯ࡦߩ⸃ᨆߪઁᣉ⸳㧔ንጊᄢ㧘ᐢፉᄢ╬㧕ߢㅴⴕਛߢ޽ࠆ߇㧘᧲ᵗකቇ߅ࠃ߮⷏ᵗකቇ⊛ߩ⛔วකቇ⊛⸃ᨆࠍ⠨ᘦߒߡ޿ࠆᣉ⸳ߪ࿖
ౝᄖߢ߽⊝ήߢ޽ࠆ‫ࠬ࡯ࡌ࠲࡯࠺ޕ‬ൻߐࠇߚࡑ࡯ࠞ࡯ߣᖚ⠪ߩዻᕈᖱႎࠍ⛔วߒ㧘᧲ᵗකቇߦ߅ߌࠆ⸽߿⷏ᵗකቇߦ߅ߌࠆ≸ᖚ⠪ߩ∛ᘒߩᄌൻߩ⸻ᢿࠍᡰេߔࠆࠪࠬ࠹ࡓࠍ㐿⊒ߔࠆߎߣߦࠃࠅ㧘୘‫ߩޘ‬ㅴⴕ≸ᖚ⠪ߦኻߔࠆ᡼኿✢㧘᛫≸೷ߩ᦭ലᕈ㧘⵬೷ࠍਛᔃߣߒߚṽᣇᴦ≮ߩ᦭↪ᕈߩ੍⷗޽ࠆ޿ߪೋᦼ≸ᖚ⠪ߦኻߔࠆዪᚲᴦ≮߿᷷ሽ≮ᴺߩ᦭ലᕈߩ੍⷗ߥ
ߤࠝ࡯࠳࡯ࡔ࡯࠼⊛ᴦ≮ߩታ〣น⢻ߣ⠨߃ࠆ‫ޕ‬࿖㓙⊛⹏ଔ㧦⻉ᄖ࿖ߢߪ⥃ᐥᔕ↪߇ᆎ߹ߞߡ߅ࠅ㧘࿖㓙⊛ߥ૏⟎ઃߌߪ㜞޿‫ޕ‬3㧕 ⸻≮ฬ 㧦ࠝ࡯ࡊࡦෳടဳ ↥ᇚੱ⑼⸻≮ߦ㑐ߔࠆᒰ㒮ߩขࠆߴ߈ᘒᐲߩᬌ⸛
⸻≮ౝኈ㧦ࠝ࡯ࡊࡦࠪࠬ࠹ࡓ㧦ጘ㒂࿾඙ߦ߅ߌࠆಽᇂ߅ࠃ߮ᇚੱ⑼ᚻⴚ∝଀ࠍ㧘⸻≮ᚲࠍਛᔃߣߒߚ
࿾ၞක≮ᯏ㑐ߣㅪ៤ࠍߣࠅ㧘ᒰ㒮ߩᣉ⸳㨯⸳஻㧘ߐࠄߦක≮ࠬ࠲࠶ࡈࠍ⸃᡼ߔࠆ੐ߢᒰ㒮ߦ߅ߌࠆᣉ⸳Ⓙ௛₸ߩჇട㧘࿾ၞකᏧߩੱ⊛⾗Ḯߩ᦭ലᵴ↪ࠍ࿑ࠆ‫ޕ‬࿖ߩක≮᡽╷߿৻⥸ߩᗧ⼂ߩᄌൻࠍᵈⷞߒߟߟ࿾ၞකᏧળߥߤߣߩㅪ៤ࠍߣࠅߥ߇ࠄ㧘5 ᐕ⒟ᐲߩḰ஻ᦼ㑆߇ᔅⷐߣ⠨߃ࠄࠇࠆ‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦࿖ౝઁ∛㒮ߢߪዉ౉ߐࠇߡ޿ߥ޿‫ޕ‬࿖ౝ⊛⹏ଔ㧦᦭ᐥ⸻≮ᚲߩ౉㒮ၮḰߩ෩ᩰൻ߇੹ᓟଦㅴߐࠇࠆ੐ߦࠃࠅ㧘ಽᇂࠍᆎ߼ߣߔࠆ↥⑼౉㒮ߩขࠅᛒ޿ᣉ⸳߇ᷫዋߔࠆ੐߇੍᷹ߐࠇࠆ‫ࠅࠃߦ↹⸘ᧄޕ‬㧘⸻≮ᚲൕോකᏧߩ↥⑼⸻≮ߩ㧙㧙㑐ਈ߇⛮⛯ߢ߈ࠆ‫ޕ‬කᏧ㨯ഥ↥Ꮷࠍᆎ߼ߣߒߚੱ⊛⾗Ḯ㧘ᣉ⸳࡮⸳஻ߩ㓸⚂ൻߦࠃࠆ⚻ᷣല₸ߩᡷༀ߇⷗ㄟ߹ࠇࠆ‫ߩߎޕ‬੐ࠍᇚੱ⑼∔ᖚߩ⸻≮ߦ߽᜛ᄢߔࠆ‫ߩߎޕ‬੐߇㧘⸻≮ᚲකᏧߦߣߞߡ߽㧘㊄㌛⊛࡝ࠬࠢ㧘ࠬ࠲࠶ࡈ▤ℂߩਇ቟ߥߤ߆ࠄ⸃᡼ߐࠇࠆ੐ߢࡔ࡝࠶࠻ߪᄢ߈
޿‫ߦࠄߐޕ‬㧘ᦨ⚳⊛ߦߪ㧘ฦ⸻≮ⴕὑߦ߅ߌࠆක≮ࠬ࠲࠶ࡈߩ⽶ᜂ߇シᷫߐࠇ቟ో߇⏕଻ߐࠇࠆ‫ࠄ߇ߥߒ߆ߒޕ‬㧘࿾ၞߩℂ⸃߅ࠃ߮දജ߇ᔅ㗇ߢ޽ࠅጘ㒂࿾඙ߢᧄࠪࠬ࠹ࡓ߇ฃኈ
ߐࠇࠆ߆ߤ߁߆ߩᬌ⸛߽ᔅⷐߢ޽ࠆ੐߿㧘ฃኈߐࠇߚ႐วߩࠝ࡯ࡊࡦࠪࠬ࠹ࡓߩᒻᘒ㧔ታ㓙ߩㆇ↪ᴺ↪ߦട߃ߡᒰ㒮߇ฃߌᜬߟᓎഀ߽฽߼ߡ㧕ߦߟ޿ߡ߽ᭂ߼ߡᘕ㊀ߦ⠨ᘦߔࠆ੐߇ᔅⷐߢ޽ࠆ‫ޕ‬࿖㓙⊛⹏ଔ㧦⻉ᄖ࿖ߢߪ⥃ᐥᔕ↪߇ᆎ߹ߞߡ߅ࠅ㧘࿖㓙⊛ߥ૏⟎ઃߌߪ㜞޿‫ޕ‬4㧕 ⸻≮ฬ 㧦࡝࠱ࡈࠜࠬࡈࠔ࠴ࠫࡦ㉄ࠍ↪޿ߚ⢦ၭ㙃ᴺߩ㐿⊒⸻≮ౝኈ㧦1㧕૕ᄖฃ♖㧔㗼ᓸ᝼♖ࠍ฽߻㧕ᓟ㧘߹ߚߪಓ⚿Ⲣ⸃⢦ߩೋᦼ㧘ಽഀ⢦ߩၭ㙃ߦߟ޿ߡ࡝
࠱ࡈࠜࠬࡈࠔ࠴ࠫࡦ㉄ߩᷝടࠍⴕ޿㧘⢦⋚⢩೔㆐₸㧘⌕ᐥ₸㧘⥃ᐥ⊛ᅧᆼ₸ߩᡷༀࠍ࿑ࠆ‫ޕ‬2㧕╙ 2 Ბ㓏ߣߒߡ㧘ᧂฃ♖ෆᧂᾫෆߩ૕ᄖᚑᾫᤨߩၭ㙃ᶧߣߒߡߩน⢻ᕈࠍត⚝ߔࠆ‫ޕ‬
3㧕ጘ㒂⋵㈩஧ሶ଻ሽ࠮ࡦ࠲࡯ߩ⸳┙㧔ઁ∔ᖚߩᴦ≮ߦࠃࠅᕈ⣼ᯏ⢻ߩᑄ⛘߇⷗ㄟ߹ࠇࠆ
ᖚ⠪ߩ㈩஧ሶࠍ଻ሽ㧕ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦࿖ౝઁ∛㒮ߢߪዉ౉ߐࠇߡ޿ߥ޿‫ޕ‬࿖ౝ⊛⹏ଔ㧦࿖ౝᄖ౒ㅢߦ↢ᱺ⵬ഥᛛⴚߩㅴᱠߪ߼ߑ߹ߒ޿߽ߩ߇޽ࠅ㧘ㆊ෰ߦߪᅧᆼߩน⢻ᕈ߇ߥ߆ߞߚᖚ⠪ߩᅧᆼ߽น⢻ߣߥߞߡ᧪ߡ޿ࠆ෻㕙㧘ᛛⴚ⊛ߥㅴᱠ߽㗡ᛂߜߦߥࠅߟߟ޽ࠆ‫ޕ‬ߘࠇߦ઻޿ᅧᆼ₸߽㗡ᛂߜߣߥߞߡ޿ࠆ‫ߚ߹ޕ‬㧘#3 ߦ㑐ߒߡ౏⊛ᯏ㑐߇৻ర⊛ߦ▤ℂߔࠆ
ࠪࠬ࠹ࡓߪ⃻࿷ߩᚲႎ๔߇ߥ޿‫ޕ‬࿖㓙⊛⹏ଔ㧦࡝࠱ࡈࠜࠬࡈࠔ࠴ࠫࡦ㉄ߩ⌕ᐥ⃻⽎ߦᓇ㗀ࠍ෸߷ߔน⢻ᕈ߇㧘Nature. 2005;435:104-108
ߦࠃߞߡ␜ߐࠇߚ‫ޕ‬5㧕 ⸻≮ฬ 㧦ሶች⒖ᬀߩ㐿⊒⸻≮ౝኈ㧦዁᧪ߩሶች⒖ᬀࠍ⋡ᜰߒߡ㧘േ‛ታ㛎ࠍㅢߒߡၮ␆⊛ߥᚻᛛ࡮⍮⷗ߩ⫾Ⓧࠍ⋡⊛ߣߒ㧘ዊേ‛㧔ኅ఻㧘㚌⩶㘃㧕ࠍ↪޿ߡ㧘୘૕㑆ߩሶች੤឵ࠍ⹜ߺࠆ‫ߩߘޕ‬㓙㧘่วߔߴ߈ⴊ▤߿㕢Ꮺ㧘⣧ᢿ┵ߩ㕙Ⓧ㧘఺∉ᛥ೙೷ߩᬌ⸛ࠍട߃ࠆ‫่ޕ‬วⴊ▤ߩᚻᛛୃᓧߦᤨ㑆ࠍⷐߔࠆߎ
ߣ߇੍ᗐߐࠇࠆ‫ེ⤳ઁޕ‬⒖ᬀߦ㑐ߔࠆᄙߊߩ⚻㛎߿⍮⷗ߪᧄ⎇ⓥߦᔕ↪ߔࠆߎߣ߇น⢻ߢ޽ࠅ㧘ታ↪ൻߦะߌߡᚻᛛߩ⠌ᓧએᄖߩ໧㗴ὐߪዋߥ޿ߣ⠨߃ࠄࠇࠆ‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦࿖ౝઁ∛㒮ߢߪዉ౉ߐࠇߡ޿ߥ޿‫ޕ‬࿖ౝ⊛⹏ଔ㧦ሶች៰಴ᣢᓔ߇޽ࠅ᜼ఽᏗᦸߩᒝ޿ᅚᕈߦሶች⒖ᬀࠍ⹜ߺߚႎ๔߇ᢙႎߥߐࠇߡ޿ࠆ߇㧘
޿ߕࠇ߽⒖ᬀᓟ 2㧙3 ᐕߢუᱫߦ㒱ࠅౣ៰಴ߐࠇߡ޿ࠆ‫ߚ߹ޕ‬㧘േ‛ታ㛎ߢᅧᆼᚑ┙㨯ಽᇂߦ⥋ߞߚ⎇ⓥႎ๔߇ᢔ⷗ߐࠇߡ޿ࠆ߇㧘㚌ᱤ㘃ߦኻߒߡ߇߶ߣࠎߤߢ޽ࠆ‫␠ޕ‬ળ⊛ߥ࠾࡯࠭߆ࠄ߽㧘㐿⊒ߦኻߔࠆⷐ᳞ᐲߩ㜞޿⎇ⓥ⺖㗴ߢ޽ࠆ‫ེ⤳ઁޕ‬⒖ᬀߦ㑐ߔࠆᄙߊߩ⚻㛎߿⍮⷗ߪᧄ⎇ⓥߦᔕ↪ߔࠆߎߣ߇น⢻ߢ޽ࠅ㧘ታ↪ൻߦ⥋ࠆน⢻ᕈߪ㜞޿‫↢ޕ‬ᱺ⵬ഥᛛⴚߩ
ㅴᱠߦ઻޿㧘ሶችࠍᄬߞߚᅚᕈߩ᜼ఽ߇ᚻᛛ਄ߪน⢻ߣߥߞߚ‫ߒ߆ߒޕ‬㧘ઍℂ಴↥߿ઍℂᲣߪ୶ℂ਄㨯ᚭ☋਄ߩ໧㗴ὐࠍᄙߊ฽ࠎߢ޿ࠆ‫ޕ‬ሶችߩ⒖ᬀ߇น⢻ߦߥࠇ߫㧘ᚒ߇࿖ߩ̈Უ
ⷫߩቯ⟵̉ࠍ⸃᳿ߔࠆߩߺߥࠄߕ㧘╙ਃ⠪ߩ࡝ࠬࠢࠍߥߊߔ਄ߢᭂ߼ߡ㊀ⷐߢ޽ࠆ‫ޕ‬࿖㓙⊛⹏ଔ㧦ࠕ࡜ࡆࠕ⻉࿖ߢႎ๔ߐࠇߡ޿ࠆߩߺߢ޽ࠆ‫ޕ‬6㧕 ⸻≮ฬ 㧦ᇚੱ⑼⣲≌ᕈ∛ᄌߦኻߔࠆⴊ▤ᣂ↢ᛥ೙ߦࠃࠆಽሶᮡ⊛ᴦ≮⸻≮ౝኈ㧦ᇚੱ⑼⣲≌ᕈ∛ᄌߦ߅޿ߡ㧘ᖚ⠪ߩ QOL ߦ㊀ᄢߥᓇ㗀ࠍਈ߃ࠆ≸ൻቇ≮ᴺ߿᡼኿✢≮ᴺ
ߦઍࠊࠅ㧘೽૞↪ߩዋߥ޿ᖚ⠪ߦఝߒ޿㧔⣲≌ࠍᩕ㙃ߔࠆᵴ⊒ߥⴊ▤♽ࠍ೙ᓮߒ㧘㑆ធ⊛ߦ⣲≌㧘․ߦౣ⊒Ꮍ߿ォ⒖ᎽߩჇᱺㅴዷࠍ೙ᓮߔࠆ㧕ᣂ↢ⴊ▤ᛥ೙≮ᴺࠍ㐿⊒ߔࠆ‫ߩߘޕ‬⚿ᨐߦၮߠ߈㧘⃻࿷߹ߢߦ࿖ౝߢ⹺นߐࠇߡ޿ࠆ⮎೷ߪዋߥ޿߇㧘୶ℂᆔຬળߢᛚ⹺ᓟ㧘ಽሶᮡ⊛⮎ࠍャ౉ߒ㧘ᖚ⠪ߦᛩਈߔࠆ‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦࿖ౝઁ∛㒮ߢߪዉ౉ߐࠇߡ޿ߥ޿‫ޕ‬࿖ౝ⊛⹏ଔ㧦ᇚੱ⑼⣲≌ᕈ∛ᄌߦ⊒⃻ߔࠆⴊ▤ᣂ↢࿃ሶߩ⎇ⓥߦ߅޿ߡ࿖ౝᄖߢ⹺߼ࠄࠇߡ޿ࠆ‫ޕ‬ሶች㗖≸ේ⊒Ꮍ߅ߌࠆ IL㧙8 ߿ thymidine phosphorylase㧔TP㧕ߩ⊒⃻ߩ⥃ᐥ⊛ᗧ⟵߅ࠃ߮࡝ࡦࡄ▵ォ⒖Ꮍߦ߅ߌࠆ TP ߩᗧ⟵㧘ෆᎽ≸ේ⊒Ꮍߦ߅ߌࠆ vascular endothelial growth
factor㧔VEGF㧕165 ߅ࠃ߮ෆᎽ≸㧘⣻⤑᠞⒳Ꮍߦ߅ߌࠆ VEGF ⊒⃻ߩ⥃ᐥ⊛ᗧ⟵㧘ሶችౝ⤑∝߅ࠃ߮ሶች૕≸ߦ߅ߌࠆ TP ߩ⊒⃻ߩ⥃ᐥ⊛ᗧ⟵㧘ሶች૕≸ߩ╭ጀᶐẢߦ߅ߌࠆIL-8 ߩ௛߈㧘ㅴⴕሶች૕≸ߩჇᱺㅴዷߦ߅ߌࠆ basic fibroblast growth factor㧔bFGF㧕
ߩ⊒⃻᭽ᑼࠍ᣿ࠄ߆ߦߒߡ߈ߚ‫ߚ߹ޕ‬㧘ߎࠇࠄߦ࡝ࡦࠢߔࠆォ౮࿃ሶ ETS-1 ߩ௛߈ߦ㑐ߒߡ߽᣿ࠄ߆ߦߒߡ߈ߚ‫ߪࠄࠇߎޕ‬㧘޿ߕࠇ߽࿖㓙⊛ߦ߽ᦨೋߩႎ๔ߢ޽ࠆ‫▤ⴊޕ‬ᣂ↢ᛥ೙㧙㧙≮ᴺߦࠃߞߡᦼᓙߐࠇࠆ⥃ᐥ௝ߪ㧘ォ⒖Ꮍࠍ᦭ߒߡ޿ߡ߽㧘ォ⒖ᎽࠍჇᱺㅴዷߐߖߥ޿ߢ
ભ⌁ߐߖࠆߎߣߦࠃߞߡ೙≸ߒ㧘ㆊ೾ߥᚻⴚଚⷅ߿ᗵฃᕈ߇ਇ቟ቯߥ≸ൻቇ≮ᴺ߿᡼኿✢≮ᴺߦࠃࠆ㊀◊ߥ೽૞↪߇ㆱߌࠄࠇߩߢ㧘QOL ߇㜞ߊ⦟޿੍ᓟ߇ᓧࠄࠇࠆ‫ߚ߹ޕ‬㧘ೋᦼᶐẢߣߣ߽ߦⴊ▤ᣂ↢߇ᵴᕈൻߐࠇࠆߩߢ㧘ߎߩᤨὐߢⴊ▤ᣂ↢ࠍ೙ᓮߔࠇ߫ォ⒖߽೙ᓮߢ߈ࠆ‫ߦࠄߐޕ‬㧘ᴦ≹ᚻⴚᓟߩౣ⊒ౣΆࠍ੍㒐ߩߚ߼ߦ㧘ࠃࠅ೽૞↪ߩዋߥ޿ᴦ≮߇ㆬᛯߢ߈ࠆ‫ޕ‬࿖㓙⊛⹏ଔ㧦✚⺑㧔Int J Clin Oncol. 2008;5:411-415.㧕ߣߒߡ⊒⴫ߒߚ‫ߚ߹ޕ‬㧘⻉ᄖ࿖ߢߪ⥃ᐥᔕ↪
߇ᆎ߹ߞߡ߅ࠅ㧘࿖㓙⊛ߥ૏⟎ઃߌߪ㜞޿‫ޕ‬
4㧚ኾ㐷ක࡮⹺ቯක࡮ᜰዉක
੹੗◊ᔒ㧦ᣣᧄ↥⑼ᇚੱ⑼ቇળኾ㐷ක㧘ᣣᧄᇚੱ⑼⣲≌ቇળᇚੱ⑼⣲≌ኾ㐷ක㧘ᣣᧄ߇ࠎᴦ≮ᯏ᭴߇ࠎᴦ
≮⹺ቯක㧘ᣣᧄౝಽᴲઍ⻢⑼ኾ㐷ක࡮ᜰዉක㧘ᣣᧄ↢ᱺකቇળ↢ᱺක≮ᜰዉක㧘Უ૕଻⼔ᴺᜰቯක⮮ᧄᰴ⦟㧦ᣣᧄ↥⑼ᇚੱ⑼ቇળኾ㐷ක㧘ᣣᧄ≸ᴦ≮ቇળ⥃ᐥ⹜㛎⊓㍳ක㧘ᣣᧄᇚੱ⑼⣲≌ቇળᇚੱ⑼⣲≌ኾ㐷ක㧘ᣣᧄ߇ࠎᴦ≮ᯏ᭴߇ࠎᴦ≮⹺ቯක㧘ᣣᧄౝಽᴲઍ⻢⑼ኾ㐷ක࡮ᜰዉක㧘ᣣᧄᦝᐕᦼක
ቇળ⹺ቯක㧘Უ૕଻⼔ᴺᜰቯකદ⮮⋥᮸㧦ᣣᧄ↥⑼ᇚੱ⑼ቇળኾ㐷ක㧘ᣣᧄᇚੱ⑼⣲≌ቇળᇚੱ⑼⣲≌ኾ㐷ක㧘ᣣᧄ߇ࠎᴦ≮ᯏ᭴߇ࠎᴦ
≮⹺ቯක㧘Უ૕଻⼔ᴺᜰቯකਤ⠀ᙗม㧦ᣣᧄ↥⑼ᇚੱ⑼ቇળኾ㐷ක㧘ᣣᧄᇚੱ⑼⣲≌ቇળᇚੱ⑼⣲≌ኾ㐷ක㧘ᣣᧄౝಽᴲઍ⻢⑼ኾ㐷ක࡮ᜰዉක㧘ᣣᧄ⥃ᐥ⚦⢩ቇળ⚦⢩⸻ኾ㐷ක㧘Უ૕଻⼔ᴺᜰቯකฎ੗ㄖ㇢㧦ᣣᧄ↥⑼ᇚੱ⑼ቇળኾ㐷ක㧘ᣣᧄᇚੱ⑼⣲≌ቇળᇚੱ⑼⣲≌ᥳቯᜰዉක㧘ᣣᧄ߇ࠎᴦ≮ᯏ᭴߇ࠎᴦ≮ᥳቯᢎ⢒ක㧘ᣣᧄ↢ᱺකቇળ↢ᱺක≮ᜰዉක㧘ࡑࡦࡕࠣ࡜ࡈࠖ࡯ᬌ⸻♖ᐲ▤ℂਛᄩᆔຬળᬌ⸻ࡑࡦࡕࠣ࡜ࡈࠖ࡯⺒ᓇ⹺ቯක㧘Უ૕଻⼔ᴺᜰቯකᏒฎ ື㧦ᣣᧄ↥⑼ᇚੱ⑼ቇળኾ㐷ක㧘Უ૕଻⼔ᴺᜰቯක⼾ᧁ ᑝ㧦ᣣᧄ↥⑼ᇚੱ⑼ቇળኾ㐷ක㧘Უ૕଻⼔ᴺᜰቯක᧖ጊਃ⍮ઍ㧦ᣣᧄ↥⑼ᇚੱ⑼ቇળኾ㐷ක㧘Უ૕଻⼔ᴺᜰቯක૒⮮⧷ℂሶ㧦ᣣᧄ↥⑼ᇚੱ⑼ቇળኾ㐷ක㧘Უ૕଻⼔ᴺᜰቯක
5㧚⥄Ꮖ⹏ଔ
⹏ଔᒰೋߩ⋡ᮡߪ㆐ᚑߒߟߟ޽ࠆ߇㧘ࡍ࡯ࠬ࠳࠙ࡦߩᗵߪߧߋ߃ߥ޿‫⑼↥ޕ‬ක≮ߩෂᯏ߇ต߫ࠇߡ޿ࠆᤨὐ
ߢߪ㧘‫ޟ‬น‫⹏ߣ߁ࠈ޽ߢޠ‬ଔߒߡ޿ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ࡑࡦࡄࡢ࡯ߩਇ⿷߇ᦨᄢߩ໧㗴ὐߢ޽ࠆ‫ޕ‬ᓟᦼ⎇ୃකψකዪຬߩ࡞࡯࠻߇⏕┙಴᧪ࠆ߹ߢߪ㧘ઁ⑼߆ࠄ
ߩォ⑼ක߿ U ࠲࡯ࡦකߩ⏕଻ߦࠃߞߡਸ਼ࠅಾࠅߚ޿‫ߩߘޕ‬ὑߦߪ㧘㝯ജ޽ࠆ⸻≮ౝኈ߿⥃ᐥ⎇ⓥߩⅣႺ߿࠹࡯ࡑ߇ᔅⷐߢ޽ࠆ‫ߢ߹੹ޕ‬એ਄ߦ㑐ㅪ∛㒮ߣኒធߥㅪ៤ࠍ଻ߜ㧔㑐ㅪ∛㒮⟲㧕㧘ᄢቇߣᏒਛ∛㒮෺ᣇߩࡔ࡝࠶࠻ࠍ౗ߨ஻߃ߚ⸻≮⑼ߣߒߚ޿‫ޕ‬ත೨㨯තᓟᢎ⢒߳ߩᖱᾲߣᣂ౉කዪຬߩᢙߪᲧ଀ߔࠆߚ߼㧘ᢎ⢒ߪ㑐ㅪ∛㒮ࠬ࠲࠶ࡈࠍ฽߼ߚᢎቶຬోຬߢⴕ޿ߚ޿‫ߥ߁ࠃߩߎޕ‬૕೙ࠍ⏕┙ߒ㧘಴ะࠬ࠲࠶ࡈ߿ห㐷ળࡔࡦࡃ࡯߇ታ࿾⥃ᐥߢ࿎㔍ߦ⋥㕙ߒߚᤨߦ㗬ࠅߣߥࠅା㗬ߐࠇࠆࠃ߁ߦߒߚ޿‫ޕ‬੹ᓟߩዷᦸᒰᣉ⸳ߩߺߢߪੱຬ߿⸳஻ߦ㒢ࠅ߇޽ࠅ㧘ᕆㅦߦᣂ⍮⷗߇᣿ࠄ߆ߦߥࠆ↥⑼ᇚੱ⑼∔ᖚߔߴߡߦኻᔕߔ
ࠆߎߣߪ࿎㔍ߢ޽ࠆ‫ޕ‬น⢻ߥ㒢ࠅઁ⑼߿࿾ၞߩઁක≮ᣉ⸳ߣߩㅪ៤ࠍ଻ߜ㧘ടㅦᐲ⊛ߦㅴᱠߔࠆකቇᖱႎ
ࠍല₸⊛ߦ⸻≮ߦขࠅ౉ࠇࠆߣߣ߽ߦ㧘ᦨవ┵ක≮ࠍ㐿⊒ߒߡ޿߈ߚ޿‫ߦ߼ߚߩߘޕ‬㧘㑐ㅪ∛㒮ߣߪኾ㐷ᕈߩ㜞޿ಽ㊁ߩ᫮ߺಽߌࠍ࿑ࠅߥ߇ࠄ㧘✕ኒߦኾ㐷㗔ၞࠍ⵬ቢߔࠆ૕೙ࠍ▽߈㧘ත೨㨯තᓟᢎ⢒ߩᲑ㓏߆ࠄࡠ࡯࠹࡯࡚ࠪࡦ߿ੱ⊛੤ᵹࠍㅢߒߡᢎቶߩలታࠍ࿑ࠅߚ޿‫ޕ‬ක⢒ᯏ㑐ߣ޿߁ߎߣࠍᔨ㗡ߦ⟎߈㧘ఝࠇߚක≮ੱࠍ⢒ᚑߔࠆᢎ⢒㧘㜞ᐲ㨯వㅴ⊛ߥක≮ࠍ㐿⊒ߢ߈ࠆ⎇ⓥ㧘ߘߒߡߘߩᚑᨐࠍㆶరߒታᣉߔࠆ⸻≮ߩࠪࠬ࠹ࡓࠍ⋡ᜰߒߚ޿‫ߩߎޕ‬૕೙ࠍㅢߒߡ㧘ਛᩭක≮ᣉ⸳ߣߒߡ࿾ၞߩකቇ㨯ක≮ߩ⊒ዷߦነਈߒߚ޿‫ޕ‬㧙㧙㧔9㧕ᢛᒻᄖ⑼1㧚⸻≮ߩ᭎ⷐ
ᒰ⑼∛᫟ߪ 40 ᐥ㧔㨪44 ᐥ㧕ࠍᜬߜ㧘ᜂᒰකߣᜰዉක㧔ኾ㐷ක㧕ߩ 2 ੱߩਥᴦක૕೙ߢ⸻≮ߦᒰߚߞߡ
޿ࠆ‫ߪࡊ࡯࡞ࠣޕ‬㑐▵㧘⣄ᬁ㧘⣲≌㧘ᚻߩ 4 ߟߩ⃰ߦಽߌࠄࠇ㧘ฦಽ㊁ߣ߽⥃ᐥ࡮⎇ⓥ࡮ᢎ⢒ߦࡃ࡜ࡦࠬ
ࠍ଻ߜߟߟᴦ≮ߦᒰߚߞߡ޿ࠆ‫੺⚫ޕ‬వߢ޽ࠆㄭ㓞ߩ㑐ㅪ∛㒮߿ઁᐭ⋵ߥߤ㆙ᣇߩ∛㒮ߣߩㅪ៤ࠍᄢಾߦ
߈߼⚦߆޿ᴦ≮ࠍ߼ߑߒߡ޿ࠆ‫ޕ‬ኾ㐷㗔ၞ㧔subspeciality㧕ߣߒߡߪ㧘ዊఽᢛᒻᄖ⑼㧘⣲≌ᄖ⑼㧘࡝࠙ࡑ࠴㑐▵ᄖ⑼㧘⣄ᬁ⣄㜑ᄖ⑼㧘ᧃ᪳␹⚻ᄖ⑼㧘ᚻߩᄖ⑼㧘ࡑࠗࠢࡠࠨ࡯ࠫࡖ࡝࡯㧘ᒻᚑᄖ⑼㧘ᄖ்ᄖ⑼㧘ࠬࡐ࡯࠷ᢛᒻᄖ⑼㧘㛽☻㝃∝㧘࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦߥߤ߇޽ࠆ‫ޕ‬Ფᦺ 7 ᤨඨ߆ࠄߩࡒ࡯࠹ࠖࡦࠣߦࠃࠅᚻⴚ
ᖚ⠪㧘ⴚᓟᖚ⠪㧘ᬌᩏ౉㒮ᖚ⠪ߩᬌ⸛㧘ฦኾ㐷ㇱળߩᬌ⸛ળ㧘⺒ᦠળߥߤࠍⴕߞߡ޿ࠆ‫ޕ‬
2㧚ᢎ⢒ᣉ⸳
1㧕 ᣣᧄᢛᒻᄖ⑼ቇળ⎇ୃᣉ⸳
2㧕 ᣣᧄ࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦකቇળ⎇ୃᣉ⸳
3㧕 ᣣᧄ࡝࠙ࡑ࠴ቇળᢎ⢒ᣉ⸳
3㧚⸻≮㐿⊒
1㧕 ⸻≮ฬ 㧦ᓟ❑㕤Ꮺ㛽ൻ∝ߦኻߔࠆ㗖ᬁ೨ᣇ㒰࿶࿕ቯⴚ⸻≮ౝኈ㧦ᬁ૕੝ో៰ߦࠃࠅ㛽ൻᎽࠍ៰಴ߔࠆⴚᑼ㧔ᩮᴦⴚ㧕ߢ޽ࠆ‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦ᒰ⑼߇᧲ᶏ࿾඙ߢߪᦨ߽ᄙߊᣉⴕߒߡ޿ࠆ‫ޕ‬࿖ౝ⊛⹏ଔ㧦ో࿖⊛ߦߪ㧘ᚻᛛ߇ኈᤃߥᓟᣇ㒰࿶ᚻⴚ㧔㑆ធ㒰࿶㧕߇ਥᵹߢ޽ࠆ‫⋥ޕ‬ធ㒰࿶ߢ޽ࠆ೨
ᣇ㒰࿶࿕ቯߪᾫ✵ߒߚᚻᛛ߇ᔅⷐߢో࿖⊛ߦߪᢙ∛㒮߇Ⓧᭂ⊛ߦⴕߞߡ޿ࠆ‫ޕ‬࿖㓙⊛⹏ଔ㧦☨࿖ߢߪ㧘ߎߩ೨ᣇ㒰࿶࿕ቯߩᱧผߪ㐳ߊ㧘⃻࿷߽⋓ࠎߦⴕࠊࠇߡ޿ࠆ‫ޕ‬2㧕 ⸻≮ฬ 㧦⣶ㇱ⣄ᩇ▤⁜⓰∝㧘⣄ᬁߔߴࠅ∝ߦኻߔࠆ㗖ᬁ㑆ሹ⣶ᬁᬁ૕㑆࿕ቯⴚ㧔TLIF㧕⸻≮ౝኈ㧦⣄ᬁ࿕ቯⴚߦߪ᭽‫ⴚߥޘ‬ᑼ߇޽ࠆ‫ ߩߎޕ‬TLIF ߣ޿߁ᣂߒ޿ⴚᑼߪ㧘㜞޿≹ว₸㧘ૐ޿ว૬∝߇․ᓽߢ޽ࠆ‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦᧲ᶏ࿾඙ߢߪᒰ㒮߇ 2001 ᐕߦᦨೋߦⴕ޿ᦨ߽ᄙߊᣉⴕߒߡ޿ࠆ‫ޕ‬࿖ౝ⊛⹏ଔ㧦TLIF ߩߥ߆ߢ߽ᒰ⑼ߢⴕߞߡ޿ࠆ C-TLIF ߣ޿߁࿕ቯⴚߪ㧘ᚻᛛ߇◲ଢߢߘߩ⦟ᅢߥ
ᚑ❣ࠍቇળߢႎ๔ߒᵈ⋡ߐࠇߡ޿ࠆ‫ޕ‬࿖㓙⊛⹏ଔ㧦☨࿖ߢߪ TLIF ߇ਥᵹߦߥࠅߟߟ޽ࠆ‫ޕ‬3㧕 ⸻≮ฬ 㧦㛽☻㝃∝ᕈᬁ૕࿶ẩߦኻߔࠆ⣄ᬁ⍴❗ⴚ⸻≮ౝኈ㧦㛽☻㝃∝ᖚ⠪ߪჇടߩ৻ㅜࠍߚߤߞߡ޿ࠆ‫ޕ‬⣄ᬁ㛽᛬ߪઍ⴫⊛ว૬∝ߢ޽ࠅ㧘߹ࠇߦ㛽᛬߇ᴦ≹ߖߕ㧘㤗∽߿ᜬ⛯ߔࠆ−∩ߩߚ߼ߦᚻⴚ߇ᔅⷐߣߥࠆ‫ޕ‬೨ᣇ߆ࠄẩࠇߚ⣄ᬁࠍౣᑪ
ߔࠆᣇᴺ߇એ೨ߪߣࠄࠇߡ޿ߚ߇㧘㜞㦂⠪ߦߪଚⷅ߇ᄢ߈ߊว૬∝߽ዋߥߊߥ߆ߞߚ‫ޕ‬ᓟᣇ߆ࠄᱷሽߔࠆ⣄ᬁࠍಾ㒰ߔࠆߎߣߦࠃࠅ⍴❗ߒ㧘ᓟᒗߒߚ⣄ᬁࠍᱜᏱߥᒻߦߒߡ࿕ቯߔ
ࠆᣇᴺߢ޽ࠆ‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦೨ᣇౣᑪⴚߦᲧセߒߡ㧘ว૬∝ߩዋߥ޿ⴚᑼߣߒߡᄙߊߩ⣄ᬁኾ㐷ᣉ⸳ߢⴕࠊ
ࠇߡ޿ࠆ‫ޕ‬࿖ౝ⊛⹏ଔ㧦ࡍ࠺ࠖࠢ࡞ࠬࠢ࡝ࡘ࡯ࠍ૶↪ߔࠆ⣄ᬁ⍴❗ⴚ߇৻⥸⊛ߢ޽ࠆ߇ᒰ⑼ߢߪ૶↪ߒߡ޿ߥ޿‫ޕ‬ࡍ࠺ࠖࠢ࡞ࠬࠢ࡝ࡘ࡯ߪ㛽☻㝃ᖚ⠪ߦ߅޿ߡߪ቟ోߥ࿕ቯᴺߣߪ⸒߃ߕ㧘ᒰ⑼ߢߪ⁛⥄ߩ
ᣇᴺߣߒߡᬁᑿߦࡢࠗࡗ࡯߽ߒߊߪ࠹࡯ࡊࠍㅢߒ㧘⣄ᬁࠍ⍴❗࿕ቯߒߡ޿ࠆ‫ᦨޕ‬ㄭߢߪᚻᛛ߽න⚐ൻߒᚻⴚᤨ㑆߿಴ⴊ㊂߽ዋߥߊ㧘㐳ᦼߦࠊߚࠅౣᚻⴚ₸߇ᭂ߼ߡዋߥ޿ᣇᴺߢ޽ࠆ‫ޕ‬࿖㓙⊛⹏ଔ㧦࿖㓙⊛ߦߪ㧘ᬁ૕ᒻᚑⴚߥߤ߹ߛ߹ߛ⼏⺰ߩᄙ޿ಽ㊁ߢ޽ࠆ߇㧘㜞㦂⠪ߩᦨ߽ᄙ޿ᣣᧄ
߆ࠄߎߩᣇᴺࠍᐢ߼ߡ޿ߊߴ߈ߢ޽ࠆ‫ޕ‬4㧕 ⸻≮ฬ 㧦㛽ᗵᨴ∝ߦኻߔࠆ᛫↢೷฽ଚࡂࠗ࠼ࡠࠠࠪࠕࡄ࠲ࠗ࠻≮ᴺ
⸻≮ౝኈ㧦ᒰ⑼ߢ⠨᩺ߒߚ⁛⥄ߩᣇᴺߢ޽ࠆ‫ੱޕ‬Ꮏ㛽ߣߒߡߩࡂࠗ࠼ࡠࠠࠪࠕࡄ࠲ࠗ࠻ߦ᛫↢೷ࠍߒߺߎ߹ߖߡ㧘ᗵᨴㇱ૏ߦ⸳⟎ߒᗵᨴ∝ࠍᴦߔᚻᛛߢ޽ࠆ‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦ᒰ⑼એᄖߢߪ߶ߣࠎߤⴕࠊࠇߡ޿ߥ޿‫ޕ‬࿖ౝ⊛⹏ଔ㧦㛽ᗵᨴ∝ߦኻߒߡߪ㧘ᜬ⛯ᵞᵺ≮ᴺ߇৻⥸⊛ߢ޽ࠆ߇ࡌ࠶࠼ߦ㊉ઃߌߣߥࠅᖚ⠪߳ߩ⽶ᜂߪᄢ߈޿‫ߩߎޕ‬ᣇᴺߢߪ⒖േ߇⥄↱ߢ޽ࠅ㧘ߘߩ᦭ലᕈ߽㆖⦡ߥߊᵈ⋡ߐࠇߡ޿ࠆ‫ޕ‬࿖㓙⊛⹏ଔ㧦㛽ᗵᨴ∝ߦኻߒߡߪ㧘߿ߪࠅᜬ⛯ᵞᵺ≮ᴺ߇৻⥸⊛ߢ޽ࠅ㧘ߎߩᣇᴺࠍᐢ߼ߡ޿ߊᔅⷐ
߇޽ࠆ‫ޕ‬㧙㧙5㧕 ⸻≮ฬ 㧦⿷ㇱᄌᒻߦኻߔࠆ〒㛽੝ో៰ⴚ⸻≮ౝኈ㧦ᒰ⑼ߢ⠨᩺ߒߚ⁛⥄ߩᣇᴺߢ޽ࠆ‫〒ޕ‬㛽ࠍㇱಽಾ㒰ߒ⍴❗ߒᄌᒻࠍ⍶ᱜߔࠆⴚᑼߢ޽ࠆ‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦ᒰ⑼એᄖߢߪ߶ߣࠎߤⴕࠊࠇߡ޿ߥ޿‫ޕ‬࿖ౝ⊛⹏ଔ㧦⿷ㇱᄌᒻߦኻߔࠆ⍶ᱜⴚߩ 1 ߟߣߒߡ◲ଢߥᣇᴺߢ޽ࠅᵈ⋡ߐࠇߡ޿ࠆ‫ޕ‬࿖㓙⊛⹏ଔ㧦⿷ㇱᄌᒻߦኻߔࠆ⍶ᱜⴚᑼߪᱧผ⊛ߦᭂ߼ߡᄙ޿ⴚᑼ߇⠨᩺ߐࠇߡ߈ߚ‫ߩߎޕ‬ᣇᴺߪ㧘੹ᓟߐࠄߦ∝଀ࠍ㊀ߨᐢ߼ߡ޿ߊᔅⷐ߇޽ࠆ‫ޕ‬6㧕 ⸻≮ฬ 㧦ᖡᕈ㛽エㇱ⣲≌ߦኻߔࠆᜬ⛯േ⣂ౝᵈ౉ൻቇ≮ᴺ
⸻≮ౝኈ㧦⣲≌ࠍᩕ㙃ߔࠆേ⣂ߦࠞ࠹࡯࠹࡞ࠍᝌ౉ߒ㧘ㆬᛯ⊛߆ߟోり⊛ߦ᛫≸೷ࠍᛩਈߔࠆᣇᴺߢ޽ࠆ‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦ᒰ⑼ߢో࿖ߦవ߇ߌዉ౉ߒߚᣇᴺߢ޽ࠆ‫ޕ‬࿖ౝ⊛⹏ଔ㧦᛫≸೷ᛩਈߩ 1 ߟߣߒߡᢙᣉ⸳ߢⴕࠊࠇߡ޿ࠆ‫ޕ‬࿖㓙⊛⹏ଔ㧦ห᭽ߦ㧘᦭ലߥᚻᲑߩ 1 ߟߣߒߡ⹺߼ࠄࠇߡ޿ࠆ‫ޕ‬7㧕 ⸻≮ฬ 㧦㛽エㇱ⣲≌ߩㆮવሶ⸃ᨆ
⸻≮ౝኈ㧦ㆮવሶ⸻ᢿ߅ࠃ߮࠹࡯࡜࡯ࡔࠗ࠼ක≮ߩ⏕┙ߦะߌߡ㧘㛽エㇱ⣲≌ߩㆮવሶ⸃ᨆࠍⴕߞߡ޿ࠆ‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦ㆮવሶ⸻ᢿࠍⴕߞߡ޿ࠆᣉ⸳ߪో࿖ߢ߽ዋߥ޿‫ޕ‬࿖ౝ⊛⹏ଔ㧦ઁᣉ⸳߆ࠄଐ㗬ࠍฃߌࠆߎߣ߽޽ࠆ‫ޕ‬࿖㓙⊛⹏ଔ㧦᰷☨ߩਥⷐߥ≸࠮ࡦ࠲࡯ߢߪ৻⥸ൻߐࠇߟߟ޽ࠆ‫ޕ‬8㧕 ⸻≮ฬ 㧦㛽エㇱ⣲≌ߦኻߔࠆಓ⚿ᴦ≮⸻≮ౝኈ㧦㛽エㇱ⣲≌ߦኻߒಓ⚿ᴦ≮ࠍⴕߞߡ޿ࠆ‫ޕ‬ૐଚⷅߥᴦ≮ߢ޽ࠅዪᚲ㤗㈮ߢⴕ߃ࠆߚ߼㧘ᄖ᧪ߢߩಣ⟎߇น⢻ߢ޽ࠆ‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦ᧄᴦ≮ࠍⴕߞߡ޿ࠆᣉ⸳ߪో࿖ߢ߽ዋߥ޿‫ޕ‬࿖ౝ⊛⹏ଔ㧦ૐଚⷅᴦ≮ߩ߭ߣߟߣߒߡ᦭↪ߥᴦ≮ᣇᴺߣ⹏ଔߐࠇߡ޿ࠆ‫ޕ‬࿖㓙⊛⹏ଔ㧦㛽エㇱ⣲≌ߩಓ⚿ᴦ≮ߦ㑐ߒߡߪ㧘߹ߛ߹ߣ߹ߞߚႎ๔߇ߥ޿‫ޕ‬9㧕 ⸻≮ฬ 㧦ㆆ㔌ⴊ▤ᨩઃ߈ⶄว⚵❱⒖ᬀⴚࠍ↪޿ߚฦ⒳⚵❱ᰳ៊㧘ᯏ⢻㓚ኂߦኻߔࠆౣᑪⴚ
⸻≮ౝኈ㧦ࡑࠗࠢࡠࠨ࡯ࠫࡖ࡝࡯ࠍ↪޿ߚㆆ㔌㧘߹ߚߪ᦭⨍ߩⶄว⚵❱⒖ᬀ㧔⊹⤏㧘╭㧘㛽㧘㑐▵㧘␹⚻㧘Ὺߥߤ㧕ߦࠃࠅฦ⒳ߩ⚵❱ᰳ៊߿ᯏ⢻㓚ኂߦኻߔࠆౣᑪᚻⴚࠍⴕ߁‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦ࡑࠗࠢࡠࠨ࡯ࠫࡖ࡝࡯ߪᢛᒻᄖ⑼㧘ᒻᚑᄖ⑼ߩਛߢ߽․ߦ࠻࡟࡯࠾ࡦࠣࠍⓍࠎ
ߛᄖ⑼කߩߺ߇น⢻ߥᚻⴚߢ޽ࠆ‫❱⚵ߚ޿↪ࠍ࡯࡝ࡖࠫ࡯ࠨࡠࠢࠗࡑޕ‬⒖ᬀߦࠃࠆౣᑪᚻ
ⴚߪᄙዋߩ࡝ࠬࠢࠍ઻߁ߚ߼㧘᧲ᶏ࿾ᣇߢߪጘ㒂ᄢቇ∛㒮ߩ߶߆ᄢቇ∛㒮ࠢ࡜ࠬߩ∛㒮ߢታᣉߐࠇߡ޿ࠆ‫ޕ‬ጘ㒂⋵ߢߪⓍᭂ⊛ߦᧄᚻⴚࠍⴕߞߡ޿ࠆᣉ⸳ߪᒰᄢቇએᄖߦߪߥ޿‫ޕ‬࿖ౝ⊛⹏ଔ㧦ㆆ㔌߽ߒߊߪ᦭⨍ߩⴊ▤ᨩઃ߈⚵❱⒖ᬀߩዉ౉ߦࠃࠅᓥ᧪ߢߪ⠨߃ࠄࠇߥ߆ߞߚࠃ߁ߥ
㜞ᐲߥౣᑪᚻⴚ߇น⢻ߦߥࠆ╬㧘↹ᦼ⊛ߥㅴᱠ߇߽ߚࠄߐࠇߚ‫⃻ޕ‬࿷ߢߪᒰᢛᒻᄖ⑼ߩ▸࿐ߦ⇐߹ࠄߕ㧘ߘߩᔕ↪ߪ㗡㗖ㇱౣᑪ㧔ญ⣧ᄖ⑼ߣวหߢⴕ߁ญ⣧≸ಾ㒰ᓟߩౣᑪ㧕㧘ᘟᕈ⊹⤏ẩ≌㧔⊹⤏⑼ࠃࠅଐ㗬㧕ߦኻߔࠆ㧔╭㧕⊹ᑯ⒖ᬀߥߤᄙጘߦࠊߚࠆౣᑪࠍᚻ߇ߌߡ޿
ࠆ‫ߚ߹ޕ‬㧘ోりߩ޽ࠄࠁࠆ⚵❱߇ⴊ▤ᨩઃ߈ߢណขߢ߈㧘ౣᑪᴺߪ㕖Ᏹߦࡃ࡝ࠛ࡯࡚ࠪࡦ
⼾ንߥߚ߼㧘ᖚ⠪ߐࠎߣ⋧⺣ߒߥ߇ࠄࠝ࡯࠳࡯ࡔࠗ࠼⊛ߥౣᑪᚻⴚ߇น⢻ߢ޽ࠆ‫ᦨߦ․ޕ‬ㄭߢߪᛛⴚߩะ਄ߦ઻޿㧘ࠃࠅ⚦߆޿ⴊ▤่ว߇น⢻ߦߥࠅ㧘ዊߐߥ⚵❱⒖ᬀ߽Ⓧᭂ⊛ߦⴕߞߡ޿ࠆ‫ߦ߁ࠃߩߎޕ‬ᓥ᧪ߩࡑࠗࠢࡠࠨ࡯ࠫࡖ࡝࡯ࠍᦝߦ᛼ߒㅴ߼ߚ࠙࡞࠻࡜ࡑࠗࠢࡠ
ࠨ࡯ࠫࡖ࡝࡯ࠍⴕߞߡ޿ࠆߩߪ᧲ᶏ࿾ᣇߢߪᒰ㒮ࠍ฽߼ߡ 1㧘2 ߒ߆ߥ޿‫ޕ‬࿖㓙⊛⹏ଔ㧦ᧄ㇌ߪਛ࿖㧘บḧ㧘ࠪࡦࠟࡐ࡯࡞㧘☨࿖ߣਗࠎߢࡑࠗࠢࡠࠨ࡯ࠫࡖ࡝࡯ߩవㅴ࿖ߩ৻ߟ
ߢ޽ࠅ㧘ᄢቇ∛㒮ࠢ࡜ࠬߩ∛㒮ߦ㒢ቯߐࠇߡ޿ࠆߣߪ⸒߃㧘਎⇇⊛ߦߪࡑࠗࠢࡠࠨ࡯ࠫࡖ
࡝࡯߇᥉෸ߒߡ޿ࠆ‫ߪ࡯࡝ࡖࠫ࡯ࠨࡠࠢࠗࡑ࡜࠻࡞࠙ޕ‬ᣣᧄߢ↢߹ࠇߚᚻᛛߢ޽ࠅ㧘਎⇇⊛ߦ⷗ߡ߽㒢ࠄࠇߚᣉ⸳ߢߒ߆ታᣉߐࠇߡ޿ߥ޿‫ޕ‬
4㧚ኾ㐷ක࡮⹺ቯක࡮ᜰዉක
ᷡ᳓సᤨ㧦ᣣᧄᢛᒻᄖ⑼ቇળኾ㐷ක㧘ᣣᧄᢛᒻᄖ⑼ቇળ⹺ቯ⣄ᬁ⣄㜑∛ක㧘ᣣᧄ⣄ᬁ⣄㜑∛ቇળᜰዉක㧘ᣣᧄ࡝࠙ࡑ࠴ቇળኾ㐷ක⚦ᳯ⧷ᄦ㧦ᣣᧄᢛᒻᄖ⑼ቇળኾ㐷ක㧘ᣣᧄᢛᒻᄖ⑼ቇળ⹺ቯ⣄ᬁ⣄㜑∛ක㧘ᣣᧄ⣄ᬁ⣄㜑∛ቇળᜰዉක⷏ᧄ ⵨㧦ᣣᧄᢛᒻᄖ⑼ቇળኾ㐷ක㧘ᣣᧄ૕⢒දળ౏⹺ࠬࡐ࡯࠷࠼ࠢ࠲࡯㧘ᣣᧄ㓚ኂ⠪ࠬࡐ࡯࠷දળ౏⹺
㓚ኂ⠪ࠬࡐ࡯࠷ක
ᄢ㊁⟵ᐘ㧦ᣣᧄᚻߩᄖ⑼ቇળኾ㐷ක㧘ᣣᧄᢛᒻᄖ⑼ቇળኾ㐷ක㧘ᣣᧄ૕⢒දળ౏⹺ࠬࡐ࡯࠷࠼ࠢ࠲࡯㧘ᣣᧄ࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦቇળ⥃ᐥ⹺ቯක㧘ᣣᧄᢛᒻᄖ⑼ቇળ⹺ቯ⣄ᬁ⣄㜑∛ක㧙㧙૒⮮ᱜᄦ㧦ᣣᧄᢛᒻᄖ⑼ቇળኾ㐷ක㧘ᣣᧄᢛᒻᄖ⑼ቇળ⹺ቯ࡝࠙ࡑ࠴ක㧘ᣣᧄᢛᒻᄖ⑼ቇળ⹺ቯࠬࡐ࡯࠷
ක㧘ᣣᧄᢛᒻᄖ⑼ቇળ⹺ቯ⣄ᬁ⣄㜑∛ක㧘ᣣᧄ࡝࠙ࡑ࠴⽷࿅⊓㍳ක㧘ᣣᧄ࡝࠙ࡑ࠴ቇળኾ㐷ක㧘ᣣᧄ࡝࠙ࡑ࠴ቇળᜰዉක㧘ᣣᧄ૕⢒දળ౏⹺ࠬࡐ࡯࠷ ࠼ࠢ࠲࡯㧘ᣣᧄ࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦක
ቇળ⥃ᐥ⹺ቯක࡮ኾ㐷කᄢ㊁⾆ᢅ㧦ᣣᧄᢛᒻᄖ⑼ቇળኾ㐷ක㧘∛ℂ⸃೬⹺ቯක㧘ᣣᧄᢛᒻᄖ⑼ቇળ⹺ቯ࡝࠙ࡑ࠴ක㧘ᣣᧄ࡝࠙ࡑ࠴
⽷࿅⹺ቯක㧘ᣣᧄᢛᒻᄖ⑼ቇળ⹺ቯ⣄ᬁ⣄㜑∛ක㧘ᣣᧄ࡝࠙ࡑ࠴ቇળኾ㐷කદ⮮⧐Პ㧦ᣣᧄᢛᒻᄖ⑼ቇળኾ㐷ක㧘ᣣᧄ࡝࠙ࡑ࠴ቇળኾ㐷ක㧘ᣣᧄᢛᒻᄖ⑼ቇળ⹺ቯ࡝࠙ࡑ࠴ක㧘ᣣᧄ
ᢛᒻᄖ⑼ቇળ⹺ቯࠬࡐ࡯࠷කችᧄ ᢘ㧦ᣣᧄᢛᒻᄖ⑼ቇળኾ㐷ක㕍ᧁ㓉᣿㧦ᣣᧄᢛᒻᄖ⑼ቇળኾ㐷ක㧘ᣣᧄ࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦቇળ⥃ᐥ⹺ቯක࡮ኾ㐷ක࡮ᜰዉක㧘ᣣᧄ૕⢒දળ౏⹺ࠬࡐ࡯࠷࠼ࠢ࠲࡯㧘ᣣᧄᢛᒻᄖ⑼ቇળ⹺ቯࠬࡐ࡯࠷࠼ࠢ࠲࡯㧘ᣣᧄᢛᒻᄖ⑼ቇળ⹺
ቯㆇേེ࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦක㧘㓚ኂ⠪ࠬࡐ࡯࠷⹺ቯක㧘࠼࡯ࡇࡦࠣࠦࡦ࠻ࡠ࡯࡞ࡔ࠺ࠖࠞ࡞
ࠝࡈࠖࠨ࡯㧘ᣣᧄකᏧળஜᐽࠬࡐ࡯࠷ක
ᄢፉᐽม㧦ᣣᧄᢛᒻᄖ⑼ቇળኾ㐷ක
5㧚⥄Ꮖ⹏ଔ
⹏ଔዋߥ޿ࠬ࠲࠶ࡈᢙߢ㐳ᤨ㑆ߦࠊߚࠆᄖ᧪ᬺോ㧘ᄙߊߩᚻⴚ∝଀ߦኻᔕߒߡ޿ࠆ‫ୃ⎇ޕ‬ක߇޿ߥ޿⃻⁁ߢߪਛၷකᏧߦᄙߊߩ⽶ᜂ߇߆߆ߞߡ޿ࠆ߇㧘⻠⟵㧘ࡐ࡝ࠢ࡝ߥߤߩᢎ⢒㧘߹ߚቇળ⊒⴫࡮⺰ᢥ࡮⻠Ṷߥߤߩ⎇ⓥᬺ❣߽ߘࠇ߶ߤૐਅߒߡ޿ߥ޿‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷㜞㦂ൻ␠ળߦߣ߽ߥ޿ᢛᒻᄖ⑼ߩᔅⷐᕈߪ㜞ߊ㧘ߤߩ㑐ㅪ∛㒮ߦ߅޿ߡ߽ᄖ᧪㧘ᚻⴚઙᢙߪჇടߩ৻ㅜ
ߢ޽ࠆ‫ޕ‬ᄢቇߢߩᚻⴚઙᢙࠍჇ߿ߔߎߣߪ㧘⋴⼔ࠬ࠲࠶ࡈᢙߩ໧㗴ߢኈᤃߢߪߥ޿߇㧘ᓢ‫ߦޘ‬ᡷༀߒߡ޿
ࠆ‫ޕ‬ᄢቇߦ⚫੺ߐࠇߡߊࠆᖚ⠪ߐࠎߩᄙߊ߇㧘ඨᐕએ਄ߩ㐳ᦼߩᓙᯏࠍ૛௾ߥߊߐߖࠄࠇߡ޿ࠆ‫⃻ޕ‬࿷㧘ㄭ㓞ߩ㑐ㅪ∛㒮ߣදജߒኻᔕߒߡ޿ࠆ߇㧘㑐ㅪ∛㒮⥄૕ߩᚻⴚઙᢙ߽Ⴧ߃㧘ࠬ࠲࠶ࡈᢙ߆ࠄ㒢⇇ߦㄭߠ޿ߡ޿ࠆ‫ޕ‬ᄢቇߢߩᚻⴚઙᢙߩჇടߣߣ߽ߦ㧘㑐ㅪ∛㒮ߣߩࠃࠅ⦟ᅢߥឭ៤ࠍⴕߞߡ޿ߊᔅⷐ߇޽ࠆ‫ޕ‬੹ᓟߩዷᦸో࿖⊛ߦߺࠆߣጘ㒂⋵ߪ߹ߛ߹ߛᢛᒻᄖ⑼කᢙ߇ 2-3 ഀዋߥߊ㧘㔛ⷐߦߟ޿ߡ޿ߌߥ޿⁁ᘒߢ޽ࠆ‫ޕ‬ᢙᐕ೨߹ߢߪᄙߊߩ౉ዪ⠪ߦᡰ߃ࠄࠇ㧘㑐ㅪ∛㒮ߩකᏧᢙࠍჇ߿ߔߎߣ߇ߢ߈㧘Ⴧടߔࠆᚻⴚઙᢙߦߥࠎߣ
߆ኻᔕߒߡ߈ߚ‫ߒ߆ߒޕ‬ᣂߒ޿තᓟ⎇ୃ೙ᐲ߇ᆎ߹ࠅ㧘౉ዪߪỗᷫߒ㧘㑐ㅪ∛㒮ߩකᏧᢙ߽ᷫዋߒᆎ߼ߚ‫ޕ‬ߒߚ߇ߞߡ㧘ᄢቇࠍਛᔃߣߒߚ㑐ㅪ∛㒮ࡀ࠶࠻ࡢ࡯ࠢߩ⛽ᜬߦ㑐ߒߡ㤛ାภ߇ߣ߽ߞߡ߅ࠅ㧘ߘߩࡀ࠶࠻
ࡢ࡯ࠢߩ⦟ᅢߥᯏ⢻ߩߚ߼ߦߪᄙߊߩᣂᢛᒻᄖ⑼කߩ⏕଻߇ᔅ㗇ߢ޽ࠆ‫ޕ‬㧙㧙㧔10㧕⣖␹⚻ᄖ⑼1㧚⸻≮ߩ᭎ⷐ
⣖␹⚻ᄖ⑼ߢߪ⣖තਛ㧔ߊ߽⤑ਅ಴ⴊ㧘⣖಴ⴊ㧘⣖᪪Ⴇ㧕߿㊀∝㗡ㇱᄖ்ߥߤߩਛᨔ␹⚻ᢇᕆ∔ᖚ㧘⣖⣲≌㧘㗻㕙ߌ޿ࠇࠎ߿ਃ෷␹⚻∩㧘ਇ㓐ᗧㆇേߥߤߩᯏ⢻⊛⣖∔ᖚ㧘ਛᨔ␹⚻♽ᄸᒻ㧘⣄㜑⣄ᬁ∔ᖚߩᴦ≮ࠍߪߓ߼ߣߒߡ㧘ᄖ᧪⸻≮ߢߪ㗡∩㧘߼߹޿㧘ߒ߮ࠇ㧘ᗧ⼂ᶖᄬ⊒૞ߥߤߩ⸻ᢿᴦ≮㧘ㄭᐕჇടߒߟߟ
޽ࠆ⣖᪪Ⴇߩෂ㒾࿃ሶ▤ℂ߿ੑᰴ੍㒐㧘ߡࠎ߆ࠎߦኻߔࠆ⮎‛ᴦ≮ߥߤࠍⴕߥߞߡ޿ࠆ‫ޕ‬
2㧚ᢎ⢒ᣉ⸳
1㧕 ᣣᧄ⣖␹⚻ᄖ⑼ቇળ㧔ኾ㐷ක⸠✵႐ᚲ㧔A 㗄㧕㧕
2㧕 ᣣᧄ⣖␹⚻ⴊ▤ౝᴦ≮ቇળ㧔ኾ㐷ක⸠✵႐ᚲ㧕
3㧕 ᣣᧄ⣖තਛቇળ㧔⎇ୃᢎ⢒∛㒮㧕
3㧚⸻≮㐿⊒
1㧕 ⸻≮ฬ 㧦Ⱟశ⦡⚛ࡈ࡞ࠝ࡟ࠨࠗ࠻ࠍ↪޿ߚᖡᕈ⣖⣲≌៰಴ⴚ⸻≮ౝኈ㧦ᖡᕈ⣖⣲≌ߣᱜᏱ⣖ߣߩႺ⇇ࠍⴚਛߦⷞⷡ⊛ߦࠊ߆ࠅ߿ߔߊߔࠆߚ߼Ⱟశ⦡⚛ߢ޽ࠆࡈ࡞
ࠝ࡟ࠨࠗ࠻ࠍⴚਛߦ㕒⣂ౝᛩਈߒ㧘⣲≌ߩ៰಴₸ࠍ਄ߍࠆ‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦หᴺࠍ↪޿ߚᖡᕈ⣖⣲≌ߩ៰಴ⴚߪ᧲ᶏ࿾ᣇߢߪᦨ߽⚻㛎⼾ንߢ޽ࠆ‫ޕ‬࿖ౝ⊛⹏ଔ㧦ߘߩઁߩⰯశ⦡⚛ߣᲧセߒ㧘౉ᚻ߇↪ᗧߢ᳢↪ߐࠇ߿ߔߊ㧘߹ߚⴚਛߦ࡝ࠕ࡞࠲ࠗࡓߦ
Ⱟశ⦡⚛ࠍⴚ㊁ߢ⏕⹺ߒ߿ߔ޿ߥߤߩ೑ὐ߇޽ࠅ㧘߹ߚ㊀◊ߥ೽૞↪߇߶ߣࠎߤߥ޿‫ޕ‬࿖㓙⊛⹏ଔ㧦ᒰᣉ⸳⁛⥄ߩᛩਈ㊂ߦࠃߞߡ㧘ࠃࠅⰯశ⦡⚛ߩ⹺⼂ᐲ߇㜞߹ࠅ㧘⣲≌ߩ៰಴₸߇㜞߹ߞߚߎߣࠍ࿖㓙⹹㧔Journal of Neurosurgery 2003;99:597-603㧕ߦႎ๔ߒߡ޿ࠆ‫ޕ‬2㧕 ⸻≮ฬ 㧦ࡔ࠴ࠝ࠾ࡦ PET ࠍ↪޿ߚቯ૏᡼኿✢ᴦ≮ߦ߅ߌࠆ✢㊂⸘↹⸻≮ౝኈ㧦⣖⣲≌ߩᐢ߇ࠅࠍ㍈ᢅߦᝒ߃ࠆࡔ࠴ࠝ࠾ࡦ PET㧔ਛㇱ≮⼔࠮ࡦ࠲࡯㧕ࠍቯ૏᡼኿✢ᴦ≮೨ߦⴕߞߡ߅߈㧘ߘߩ DICOM ࠺࡯࠲ࠍቯ૏᡼኿✢ᴦ≮ߩ✢㊂⸘↹ߩ㓙ߦࠦࡦࡇࡘ࡯࠲࡯ߦ
ขࠅㄟࠎߢ⣲≌߳ߩല₸⊛ߥᾖ኿▸࿐ߩ᳿ቯߦᓎ┙ߡߡ޿ࠆ‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦ࡔ࠴ࠝ࠾ࡦ PET ࠍ↪޿ߚ✢㊂⸘↹ߪ᧲੩ක⑼ᱤ⑼ᄢቇߢ߽ⴕࠊࠇߡ޿ࠆ߇㧘ࡔ࠴ࠝ࠾ࡦ PET ߩ DICOM ↹௝ࠍขࠅㄟ߻ᚻᴺߪቴⷰ⊛ߢᱜ⏕ᕈ߇㜞ߊᒰ㒮ߛߌߩขࠅ
⚵ߺߢ޽ࠆ‫ޕ‬࿖ౝ⊛⹏ଔ㧦⣲≌ߩᐢ߇ࠅࠍหቯߔࠆࡔ࠴ࠝ࠾ࡦ PET ߪᵈ⋡ᐲ߇㜞ߊ㧘ᦝߦߘࠇࠍቯ૏᡼኿✢ᴦ≮ߦᔕ↪ߔࠆขࠅ⚵ߺߪ⁛⥄ᕈ߇㜞޿‫ޕ‬࿖㓙⊛⹏ଔ㧦หᴺࠍ↪޿ߚᴦ≮߿ᚑ❣߇ㄭᐕ㧘࿖㓙⹹ߦᣂߚߥᚻᴺߣߒߡႎ๔ߐࠇߟߟ޽ࠆ‫ޕ‬
4㧚ኾ㐷ක࡮⹺ቯක࡮ᜰዉක
ጤ㑆 ੧㧦⣖␹⚻ᄖ⑼ቇળኾ㐷ක㧘⣖තਛቇળኾ㐷කศ᧛⚩৻㧦⣖␹⚻ᄖ⑼ቇળኾ㐷ක㧘⣖තਛቇળኾ㐷ක㧘⣖␹⚻ⴊ▤ౝᴦ≮ቇળᜰዉක
⍫㊁ᄢੳ㧦⣖␹⚻ᄖ⑼ቇળኾ㐷ක㧘⣖තਛቇળኾ㐷කᄢᳯ⋥ⴕ㧦⣖␹⚻ᄖ⑼ቇળኾ㐷ක㧘⣖තਛቇળኾ㐷කਛጊೣਯ㧦⣖␹⚻ᄖ⑼ቇળኾ㐷ක㧘⣖තਛቇળኾ㐷ක
㊁ਛ⵨ᐽ㧦⣖␹⚻ᄖ⑼ቇળኾ㐷ක㧘⣖තਛቇળኾ㐷ක⍹㤥శ♿㧦⣖␹⚻ᄖ⑼ቇળኾ㐷ක㧘⣖තਛቇળኾ㐷ක᭑ᧄ↱⾆ሶ㧦⣖␹⚻ᄖ⑼ቇળኾ㐷ක㧘⣖තਛቇળኾ㐷ක㧘⣖␹⚻ⴊ▤ౝᴦ≮ቇળኾ㐷කጟ↰ ⺈㧦⣖␹⚻ᄖ⑼ቇળኾ㐷ක㧘⣖තਛቇળኾ㐷ක
5㧚⥄Ꮖ⹏ଔ
⹏ଔ⣖තਛ߿㊀்㗡ㇱᄖ்ߥߤߩᢇᕆᖚ⠪ࠍⓍᭂ⊛ߦฃߌ౉ࠇࠆߣ౒ߦ㧘৻ᣇߢߪᘟᕈ⣖⯯ⴊᕈ∔ᖚ߿⣖⣲≌ᖚ⠪ߩ⚫੺ᖚ⠪ᢙ߽Ⴧടߒ㧘ฦࡊࡠ࠻ࠦ࡯࡞ߦೣߞߚᴦ≮߇゠㆏ߦਸ਼ߞߡ޿ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ᧄᘒᕈᝄᚢ߿ࡄ࡯ࠠࡦ࠰ࡦ∛ߥߤߦኻߔࠆᯏ⢻␹⚻ᄖ⑼߿ߡࠎ߆ࠎߩᄖ⑼㧘㗪ᬁ∝ߥߤߦኻߔࠆ⣄ᬁᄖ⑼㧘ዊఽᄸᒻߦኻߔࠆ㗡⬄ᒻᚑⴚߥߤߪᒰ⑼ߢߪᴦ≮⚻㛎߇ዋߥ޿‫ߒ߆ߒޕ‬㧘␹⚻ౝ⑼ߣ౒หߒߡᖚ⠪ߩㆬቯࠍⴕ߃߫㧘․ߦᧄᘒᕈᝄᚢ߿ࡄ࡯ࠠࡦ࠰ࡦ∛ߦኻߔࠆᄖ⑼ᴦ≮ᢙߪჇ߃ࠆ⷗ㄟߺ߇㜞޿‫ޕ‬ᒰ⑼ߢߪᯏ㧙㧙⢻␹⚻ᄖ⑼ߩ৻Ⅳߣߒߡቯ૏⣖ᚻⴚࠍⴕ߁ߚ߼࡟ࠢ࠮࡞ࡈ࡟࡯ࡓߩ⾼౉↳⺧ࠍⴕ޿ฃ⻌ߐࠇߚ‫ޕ‬੹ᓟߩዷᦸ᧪ᐕᐲએ㒠㧘ቯ૏⣖ᚻⴚࠍ゠㆏ߦਸ਼ߖ㧘ᯏ⢻␹⚻ᄖ⑼㗔ၞࠍ㐿ᜏߒߡ޿߈ߚ޿ߣ⠨߃ߡ޿ࠆ‫ޕ‬⣖ⴊ▤㓚ኂ߿㗡ㇱᄖ்㧘⣖⣲≌ߥߤߩ∔ᖚ߽ߎࠇ߹ߢએ਄ߦ∝଀ᢙߩჇടࠍ⷗ㄟ߻ߣ㧘ᚻⴚᨒߩ㒢⇇߿ᒰ⑼ߩੱຬ
㈩⟎ߩ໧㗴߽޽ࠅ⺞ᢛ߇ᔅⷐߣᕁࠊࠇࠆ‫ޕ‬㧙㧙㧔11㧕⌒⑼
1㧚⸻≮ߩ᭎ⷐ
ᐔᚑ 16 ᐕ 6 ᦬ߦ∛㒮⒖ォߣ㔚ሶࠞ࡞࠹ዉ౉એ㒠㧘ᄖ᧪ᖚ⠪✚ᢙࠍᷫዋߐߖࠆ㧔ᔅⷐߥᖚ⠪ߦኻߒ㧘ᄙߊߩᤨ㑆ࠍഀߊ㧕ߣ޿߁කዪߩᣇ㊎ߩਅ㧘Ყセ⊛㗅⺞ߦߎߩ⋡ᮡߪ㆐ᚑߐࠇߟߟ޽ࠆ‫౉ߚ߹ޕ‬㒮ᖚ⠪✚ᢙ
ߪᐔᚑ 17 ᐕᐲࠃࠅᷫዋ௑ะߦ޽ࠆ߇㧘࿷㒮ᣣᢙߩ⍴❗ߥߤߦࠃࠆᓇ㗀߇ᄢ߈޿ߣ⠨߃ߡ޿ࠆ‫ߠⵣߩߘޕ‬ߌߩ߭ߣߟߣߒߡ㧘⌒⑼౉㒮ᖚ⠪ߪᚻⴚኻ⽎ᖚ⠪ࠍਥߣߔࠆ߇㧘౉㒮ᚻⴚ✚ᢙߪᓸჇߩ௑ะߦ޽ࠆ‫ޕ‬ᒰ⑼ߢߪ㧘✛ౝ㓚㧘⊕ౝ㓚㧘✂⤑⎣ሶ૕∔ᖚ㧘ⷺ⤑∔ᖚ㧘ዊఽ⌒∔ᖚߥߤ᭽‫∔ߥޘ‬ᖚߩᖚ⠪ࠍട≮ߒߡ޿ࠆ‫ޕ‬․ߦ✛ౝ㓚ᖚ⠪߇ᄙ޿ߎߣ߇ᧄ∛㒮⌒⑼ߩ․ᕈߢ޽ࠅ㧘࿖ౝߦ߅ߌࠆߎߩಽ㊁ߩၮᐙ∛㒮ߢ޽ࠆߎߣߪᣣ
ᧄฦ࿾ߩ⌒⑼කߩ๟⍮ߔࠆߣߎࠈߣߥߞߡ޿ࠆ‫ޕ‬ᄖ᧪⸻≮ߦ߅޿ߡߪ㧘ೋ⸻ߥࠄ߮ߦౣ⸻ߪㅳ 4 ᣣ⸻≮ࠍේೣߣߒ㧘ኾ㐷ᄖ᧪ߪㅳ 3 ࿁ߩ✛ౝ㓚ᄖ᧪ࠍߪߓ߼㧘✂⤑⎣ሶ૕ᄖ᧪㧘ౝ⌒Ἳᄖ᧪㧘ⷺ⤑ᄖ᧪㧘⣲≌ᒻᚑᄖ᧪㧘ࠦࡦ࠲ࠢ࠻ᄖ᧪㧘ࡠ࡯ࡆ࡚ࠫࡦᄖ᧪ߥߤᄙጘߥ⌒∔ᖚߦኻᔕน⢻ߥ߽ߩߣߥߞߡ޿ࠆ‫౉ޕ‬㒮⸻≮ߪ㧘
21 ᐥߩ∛ᐥᢙߢⴕߞߡ߅ࠅ㧘ᚻⴚౝኈߣߒߡߪ✛ౝ㓚㧘✂⤑⎣ሶ૕㧘⊕ౝ㓚߇ᄙߊࠍභ߼ߡ޿ࠆ‫⤑✂ޕ‬⎣ሶ૕∔ᖚࠍߪߓ߼ߣߔࠆቯᦼᚻⴚએᄖߩ✕ᕆᚻⴚ߇ᄙ޿ߩ߽ᒰ⑼ߩ․ᓽߩ৻ߟߢ޽ࠆ‫ޕ‬ኋ⋥ߪ 365 ᣣ
24 ᤨ㑆૕೙ߢߩ 2 ᰴᢇᕆ⸻≮ߦኻᔕߒߡ߅ࠅ㧘ጘ㒂⋵ౝߩ⌒⑼ᢇᕆߩⷐߣߥߞߡ޿ࠆ‫ޕ‬
⴫1ᄖ᧪ᖚ⠪✚ᢙ
౉㒮ᖚ⠪✚ᢙ
౉㒮ᚻⴚ✚ᢙ

ᐔᚑ 17 ᐕᐲ24,3227,020
592

ᐔᚑ 18 ᐕᐲ25,1006917
661

ᐔᚑ 19 ᐕᐲ21,4695,812
660

2㧚ᢎ⢒ᣉ⸳
1㧕 ᣣᧄ⌒⑼ቇળ⹺ቯᣉ⸳
3㧚⸻≮㐿⊒
1㧕 ⸻≮ฬ 㧦✛ౝ㓚ᄖ᧪⸻≮ౝኈ㧦శᐓᷤᢿጀ⸘㧔optical Coherence tomography㧕ߪ㧘߽ߣ߽ߣ✂⤑޽ࠆ޿ߪⷞ␹⚻ᓸ⚦᭴ㅧࠍ⹦⚦ߦⷰኤߔࠆߚ߼ߦ⊒ዷߒߚᯏེߢ޽ࠆ‫ߩߎޕ‬ᯏེ߇೨⌒ㇱߦᔕ↪ߐࠇߚᯏེ߇㧘೨⌒ㇱ OCT ߢ޽ࠆ‫ߩߎޕ‬ᯏེߪ㧘㕖ធ⸅ဳߢ޽ࠅ㧘ᓥ᧪ߩ⸻ᢿᯏེߣᲧセߒࠃࠅ◲ଢߦᣉⴕน⢻ߢ޽ࠅ㧘ࠃࠅ⹦⚦ߥ೨⌒ㇱ᭴ㅧߣߊߦ㓈ⷺ᭴ㅧࠍᛠីߔࠆߎߣ߇น⢻ߢ޽ࠆ‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦⋵ౝߥߒ࿖ౝ⊛⹏ଔ㧦ᧄ㇌ߦ߅޿ߡᄙ޿ߣߐࠇࠆ㐽Ⴇ㓈ⷺ✛ౝ㓚ߪ㧘৻ᣤ⊒∝ߔࠆߣᄬ᣿ߔࠆෂ㒾ᕈߩ㜞޿∔ᖚߩ৻ߟߢ޽ࠆ‫ࠄ߇ߥߒ߆ߒޕ‬㧘ߘߩᚑ࿃ߦߟ޿ߡߪᧂߛలಽߦߪℂ⸃ߐࠇߡ޿ߥ޿‫ߎޕ‬ߩᯏེߪ㧘㐽Ⴇ㓈ⷺ✛ౝ㓚ߩ⊒∝ᯏᐨߩ⸃᣿㧘᭽‫ߥޘ‬ᴦ≮ലᨐߩ್ቯߦᭂ߼ߡ᦭↪ߣߩ⹏ଔߪ৻⥌ߒߡ޿ࠆ‫ߚ߹ޕ‬㧘✛ౝ㓚ኾ㐷ᣉ⸳ߦ߅޿ߡߪᔅⷐਇนᰳߥᬌᩏᯏེߢ޽ࠆ‫ޕ‬࿖㓙⊛⹏ଔ㧦᰷☨㧔⊕ੱ㧕ߦ߅޿ߡߪ㧘ᧄ㇌߶ߤ㐽Ⴇ㓈ⷺ✛ౝ㓚ߩ㗫ᐲߪ㜞ߊߪߥ޿‫ࠄ߇ߥߒ߆ߒޕ‬㧘ᦨㄭߣߊߦ᧲ධࠕࠫࠕߦ߅޿ߡ㐽Ⴇ㓈ⷺ✛ౝ㓚ߦ㑐ߔࠆ⎇ⓥߪ⪺᣿ߦჇടߒߡ޿ࠆ‫ޕ‬㐽Ⴇ㓈ⷺ✛ౝ㓚ߩ⊒∝ᯏᐨߩ⸃᣿㧘᭽‫ߥޘ‬ᴦ≮ലᨐ್ቯߦ᦭↪ߢ޽ࠆߣߔࠆႎ๔ߪᄙߊߺࠄࠇ
ࠆ‫ߚ߹ޕ‬᭽‫∔⤑ⷺߥޘ‬ᖚߦ߽ᔕ↪น⢻ߢ޽ࠅ㧘ߘߩ࿖㓙⊛⹏ଔߪ㜞޿‫ޕ‬
4㧚ኾ㐷ක࡮⹺ቯක࡮ᜰዉක
ጊᧄື਽㧦ᣣᧄ⌒⑼ቇળኾ㐷ක࡮ᜰዉක
Ꮉἑ๺⑲㧦ᣣᧄ⌒⑼ቇળኾ㐷ක࡮ᜰዉක
ᦸ᦬ᷡᢥ㧦ᣣᧄ⌒⑼ቇળኾ㐷ක࡮ᜰዉක
Ỉ↰ ᣿㧦ᣣᧄ⌒⑼ቇળኾ㐷කᧃ᫪᤯ౖ㧦ᣣᧄ⌒⑼ቇળኾ㐷කቝ࿯৻ᚑ㧦ᣣᧄ⌒⑼ቇળኾ㐷ක⊕ᧁ⢒⟤㧦ᣣᧄ⌒⑼ቇળኾ㐷කዊ࿡ ോ㧦ᣣᧄ⌒⑼ቇળኾ㐷කဈ 㓉⵨㧦ᣣᧄ⌒⑼ቇળኾ㐷ක㧙㧙5㧚⥄Ꮖ⹏ଔ
⹏ଔ
ᐔᚑ 16 ᐕ 6 ᦬ߦ∛㒮⒖ォߣ㔚ሶࠞ࡞࠹ዉ౉એ㒠㧘ᄖ᧪ᖚ⠪✚ᢙࠍᷫዋߐߖࠆ㧔ᔅⷐߥᖚ⠪ߦኻߒ㧘ᄙߊߩᤨ㑆ࠍഀߊ㧕ߣ޿߁කዪᣇ㊎ߩਅ㧘Ყセ⊛㗅⺞ߦߎߩ⋡ᮡߪ㆐ᚑߐࠇߟߟ޽ࠆ‫౉ߚ߹ޕ‬㒮ᖚ⠪✚ᢙߪ
ᐔᚑ 17 ᐕᐲࠃࠅᷫዋ௑ะߦ޽ࠆ߇㧘࿷㒮ᣣᢙߩ⍴❗ߥߤߦࠃࠆᓇ㗀߇ᄢ߈޿ߣ⠨߃ߡ޿ࠆ‫ߌߠⵣߩߘޕ‬ߩ߭ߣߟߣߒߡ㧘⌒⑼౉㒮ᖚ⠪ߪᚻⴚኻ⽎ᖚ⠪ࠍਥߣߔࠆ߇㧘౉㒮ᚻⴚ✚ᢙߪᓸჇߩ௑ะߦ޽ࠆ‫ޕ‬ᣂ⥃ᐥ⎇ୃකዉ౉ᓟ㧘කዪຬ✚ᢙ߇ᷫዋߒߚߦ߽߆߆ࠊࠄߕ㧘ߎߩᢙሼߪ⹏ଔߦ୯ߔࠆ߽ߩߢ޽ࠆߣ⠨߃ߡ޿ࠆ‫ޕ‬ߒ߆ߒߥ߇ࠄ㧘ጘ㒂⋵ౝߩၮᐙ∛㒮ߣߒߡߐࠄߦ⊒ዷߒߡ޿ߊߚ߼ߦߪ㧘⌒⑼කዪຬߥࠄ߮ߦⷞ⢻⸠✵჻ߥߤߩᬌᩏຬߩల⿷߇ਇนᰳߢ޽ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷⌒⑼⸻≮ߩ․ᓽߪ㧘ᄖ᧪ᖚ⠪ᢙ߇ᄙ޿㧘߹ߚ⥄⑼ᬌᩏ߇ᄙߊߘߩ਄ᬌᩏߪᤨ㑆߇߆߆ࠆ㧘✂⤑೸㔌ߥߤ⓭⊒ߒߚ∔ᖚߦኻߒߡ✕ᕆᚻⴚ߇ᄙ޿ߣ޿ߞߚߎߣ߇᜼ߍࠄࠇࠆ‫⃻ࠄ߇ߥߒ߆ߒޕ‬࿷㧘ᣂ⥃ᐥ⎇ୃක೙ᐲ⊒⿷ߥߤߩ⻉ේ࿃ߦࠃࠅᣂ౉ዪ߇ᷫዋߒ㧘ᘟᕈ⊛ߥࡑࡦࡄࡢ࡯ਇ⿷ߦ㒱ߞߡ޿ࠆ‫ޕ‬ᄖ᧪⸻≮ߦ߅޿ߡߪ㧘ᤓ੹ߩ᭽‫⸻⑼⌒ߥޘ‬ᢿᯏེߩ⊒ዷ߅ࠃ߮කᏧਇ⿷ߦ઻޿㧘⥄ὼߣᬌᩏᤨ㑆߽Ⴧടߔࠆ௑ะߦ޽ࠆ‫޿߁ߎޕ‬ߞߚ⸻ᢿᯏེᠲ૞ࠍකᏧߦ߆ࠊࠅ⵬߁ߩ߇ⷞ⢻⸠✵჻ߢ޽ࠆ߇㧘ⷞ⢻⸠✵჻ߥߤߩ⛎ਈ㕙ߥߤߩᓙㆄ߇ᄢ
ቇ∛㒮ߦ߅޿ߡߪᖡߊ㧘㔛ⷐߪ߅߅޿ߦ޽ࠆ߽ߩߩⷞ⢻⸠✵჻ߩᔕ൐߇ዋߥ޿‫ޕ‬਄⸥ߩᄙጘߦࠊߚࠆ໧㗴ߦࠃࠅ㧘⌒⑼ߦ߅ߌࠆᄖ᧪⸻≮ߪㅼㄼࠍᭂ߼ߡ޿ࠆ‫ޕ‬౉㒮ᖚ⠪⸻≮ߦ߅޿ߡߪ㧘ᚻⴚᖚ⠪߇ਥࠍභ߼ࠆ߇㧘ቯᦼᚻⴚᣣ߇ㅳ 1 ᣣߩߚ߼ߘߩᣣߦᚻⴚ߇ᄙߊ㓸Ⓧߒ㧘ᚻⴚ⚳ੌᤨ㑆߇ㆃߊߥࠆߣ޿ߞߚᖡᓴⅣ߇↢ߓߡ޿ࠆ‫ޕ‬ᚻⴚᣣࠍჇടߐߖࠆߎߣ߇㧘⸃᳿ߩᣧ㆏ߢ
޽ࠆߎߣߪ⥄᣿ߩℂߢ޽ࠆ߇㧘කᏧߩᘟᕈ⊛ਇ⿷ߩߚ߼⸃᳿ߩ♻ญ߇ឞ߼ߥ޿‫✕ޕ‬ᕆᚻⴚࠍⷐߔࠆᖚ⠪ߦኻߒߡߪ㧘ᤨ㑆ᄖᚻⴚߣߒߡኻᔕߒߡ޿ࠆ߇⚿ᨐߣߒߡකᏧߩ∋ഭჇടߦ❬߇ߞߡ޿ࠆ‫ޕ‬ᄖ᧪⸻≮߅ࠃ߮౉㒮ᖚ⠪⸻≮ߦ߅ߌࠆട㊀ഭ௛߇㧘ߐࠄߦ⎇ⓥ޽ࠆ޿ߪᢎ⢒ᵴേߦഀߊᤨ㑆⍴❗ߦ❬߇ߞߡ޿ࠆ‫ޕ‬߹ߚ㧘⌒⑼⸻≮ߦߪᄙߊߩᯏེ߇ᔅⷐߢ޽ࠆ߇㧘㜞㗵ߥߚ߼ߥ߆ߥ߆ᣂⷙ⾼౉ߢ߈ߕ⠴↪ᐕᢙࠍ⿥߃ߚ
ᯏེ߇ᄙ޿ߎߣ߇໧㗴ὐߣߒߡ᜼ߍࠆߴ߈߽ߩߢ޽ࠆ‫ޕ‬ߎࠇࠄߩኻᔕ╷ߣߒߡߪ㧘╙৻ߪ⌒⑼කߩ⏕଻ߦ޽ࠆ‫ޕ‬ቇ↢ߦኻߒߡ⌒⑼߇㝯ജ޽ࠆߎߣࠍ⺑߈⺃⥌ߔࠆ‫╙ޕ‬ੑߣߒߡߪⷞ⢻⸠✵჻ߩჇຬߢ޽ࠆ‫ⷞߪࠇߎޕ‬⢻⸠✵჻ߩ㊀ⷐᕈࠍ∛㒮஥ߦ⹺⍮ߐߖᓙㆄᡷༀࠍࠕ
ࡇ࡯࡞ߒߡ޿ߊᚻᲑߒ߆ߥ޿ࠃ߁ߦᕁࠊࠇࠆ‫╙ޕ‬ਃߪ⃻⁁ߣߒߡ㧘⌒⑼⊛ᚲ⷗ࠃࠅᄢቇ∛㒮ㅢ㒮ᔅⷐᕈߩ᦭ήࠍฦᖚ⠪ߢ್ᢿߒ㧘ᄢቇ∛㒮ㅢ㒮ᔅⷐᕈ߇ߥ޿ߣ್ᢿߒߚᖚ⠪ߪߔߺ߿߆ߦㄭකߦ⚫੺ߔࠆߎߣߢ㧘ᄖ᧪ᖚ⠪ᢙࠍᷫዋߐߖࠆ‫⸻∛߇ࠇߎޕ‬ㅪ៤ଦㅴߦ❬߇ࠅ㧘ೋ⸻⚫੺₸ࠍะ਄ߐߖࠆ⚿ᨐߣߥࠆ‫ޕ‬੹ᓟߩዷᦸ੹ᓟ߽ጘ㒂ᄢቇ㒝ዻ∛㒮⌒⑼ߪ㧘ጘ㒂⋵ౝߩ⥃ᐥ⸻≮ߩၮᐙ∛㒮ߣߒߡߛߌߢߥߊ㧘ᢎ⢒ᯏ㑐∛㒮ߣߒߡ߽߹ߚ㧘ఝࠇߚකቇ⎇ⓥߩ႐ߣߒߡ߽ᯏ⢻ߒߡ޿ߊᔅⷐ߇޽ࠆ‫ޕ‬ߘߩߚ߼ߦᄢቇ∛㒮ߢߩߺน⢻ߥవㅴක≮ࠍᖚ⠪ߦឭଏߔࠆߎߣ㧘߆߆ࠅߟߌකߣߩㅪ៤ࠍᒝൻߔࠆߎ
ߣ㧘ቇ↢ߥࠄ߮ߦ⎇ୃකߦᢎ⢒ߔࠆᤨ㑆ࠍ⸳ߌࠆߎߣ㧘කቇ⎇ⓥࠍ࡝࡯࠳࡯ࠪ࠶ࡊࠍ߽ߞߡㆀⴕߒߡ޿ߊ
ߎߣ߇⢄ⷐߢߪߥ޿߆ߣ⠨߃ࠄࠇࠆ‫ޕ‬ㅢᏱ⸻≮ߦ߅ߌࠆੱຬߩల⿷ࠍ࿑ࠆߎߣ߇㧘਄⸥ోߡߩ⋡ᮡࠍࠢ࡝ࠕ࡯ߦߒߡ޿ߊ਄ߦ߅޿ߡ㎛ߣߥࠆ‫ޕ‬㧙㧙㧔12㧕⡊㥦ຜ༄⑼1㧚⸻≮ߩ᭎ⷐ
ᄖ᧪ߩᐕ㑆ߩᑧߴᖚ⠪ᢙߪ⚂ 22000 ੱߢ޽ࠆ‫ޕ‬ᣂᖚߩ߶߶ 50㧙60㧑߇⚫੺ᖚ⠪ߢ޽ࠆ‫⥸৻ޕ‬ᄖ᧪ߣߣ߽ߦኾ㐷ᄖ᧪ߣߒߡ߼߹޿ᄖ᧪㧘⡊㡆࡮㔍⡬ᄖ᧪㧘⵬⡬ེᄖ᧪㧘೽㥦⣧࡮ࠕ࡟࡞ࠡ࡯ᄖ᧪㧘㗻㕙␹⚻ᄖ᧪㧘⌧⌁ᤨ๭ๆ㓚ኂᄖ᧪㧘ྚਅᄖ᧪ࠍ⸳ߌߡ޿ࠆ‫ޕ‬߼߹޿ᄖ᧪ߢߪ㧘৻⥸ᐔⴧᯏ⢻ᬌᩏߩઁߦ᷷ᐲೝỗᬌᩏ㧘㊀ᔃേំᬌᩏ㧘೨ᐸ⺃⊒╭㔚૏㧘ⷞᮡㅊ〔ᬌᩏ㧘ⷞㆇേೝỗᬌᩏ㧘⥄ᓞ␹⚻ᯏ⢻ᬌᩏ㧘೨ᐸ⌒෻኿ߦኻߔࠆᬌᩏࠍⴕߞߡ޿ࠆ‫ޕ‬๟ㄝ࿾ၞߩߺߥࠄߕ㆙
㓒࿾߆ࠄ߽⚫੺࡮ฃ⸻߇޽ࠅ㧘ጘ㒂ᄢቇ⡊㥦ຜ༄⑼ߩਛᔃ⊛ኾ㐷ᄖ᧪ߣߥߞߡ޿ࠆ‫ޕ‬⡊㡆࡮㔍⡬ᄖ᧪ߢߪ㧘㔍ᴦᕈ⡊㡆ߦኻߒߡ⒳‫ߩޘ‬ᴦ≮ࠍ⹜ߺߡ޿ࠆ‫⵬ޕ‬⡬ེᄖ᧪ߢߪ㧘㜞㦂ൻ␠ળߩ⑔
␩ࠍ⠨ᘦߒ㧘Ⓧᭂ⊛ߦ⵬⡬ེㆡวᬌᩏࠍⴕߞߡ޿ࠆ‫ޕ‬ᣂ↢ఽ⡬ⷡࠬࠢ࡝࡯࠾ࡦࠣߦ߅޿ߡߪ㧘2 ᰴක≮ᯏ㑐ߣߒߡ㧘㔍⡬ߩ♖ᩏࠍⴕߞߡ޿ࠆ‫ߚ߹ޕ‬㔍⡬߇⇼ࠊࠇࠆఽߦߪ ABR ࠍⴕ޿㧘㔍⡬ߩᣧᦼ⊒⷗ߦദ߼ߡ
޿ࠆ‫ޕ‬㔍⡬߇ᜰ៰ߐࠇߚᖚఽߦኻߒߡߪ㧘㔍⡬ᐜఽㅢ࿦ᣉ⸳ߢ޽ࠆߺ߿ߎ࿦ߦ⚫੺ߒ㧘ᣧᦼᜰዉ㧘⵬⡬ེߩᣧᦼⵝ↪ࠍㅴ߼ߡ޿ࠆ‫⵬ޕ‬⡬ེࠍㆡᔕߢ߈ߥ޿㜞ᐲ㔍⡬ᖚ⠪ߦኻߒߡੱᎿౝ⡊ᚻⴚߩㆡᔕࠍᬌ⸛ߒߡ޿ࠆ‫ޕ‬೽㥦⣧ᄖ᧪ߢߪ㧘ㄭᐕᕆㅦߦ⊒ዷߒߚౝⷞ㏜ਅ೽㥦⣧ᚻⴚߩㆡᔕߩ᳿ቯ㧘ⴚᓟߩቯᦼ⊛ߥ⚻ㆊⷰኤߥࠄ
߮ߦౝⷞ㏜ਅߩⴚᓟಣ⟎ࠍⴕߞߡ޿ࠆ‫⸃ޕ‬೬⊛ߦㅢᏱߩᚻⴚߢߪෂ㒾ᐲ߇㜞޿ㇱ૏߳ߩࠕࡊࡠ࡯࠴ߦߪ࠽
ࡆࠥ࡯࡚ࠪࡦࠍ૬↪ߒ㧘ૐଚⷅߥౝⷞ㏜ᚻⴚ߇น⢻ߦߥߞߡ޿ࠆ‫࡯ࠡ࡞࡟ࠕߦࠄߐޕ‬ᕈ㥦Ἳᖚ⠪ߦኻߔࠆᣣᏫࠅ࡟࡯ࠩ࡯ᚻⴚࠍᣉⴕߒߡ޿ࠆ‫ޕ‬⌧⌁ᤨ๭ๆ㓚ኂᄖ᧪ߢߪ㧘ᦨㄭ⹤㗴ߦߥߞߡ޿ࠆ⌧⌁ᤨή๭ๆ∝୥⟲ᖚ⠪ߦኻߒߡኅᐸߢߩ◲ᤃဳࠕࡊࡁࡕ࠾࠲࡯ߩ⾉ߒ಴ߒߣߘߩ⹏ଔ㧘߹ߚਛ╬ᐲ࡮㜞ᐲ㓚ኂᖚ⠪ߦኻߔࠆ౉㒮ߢߩ⚳ᄛ⌧⌁ࡐ࡝ࠣ࡜ࡈᬌᩏ
ߩㆡᔕࠍ᳿ቯߒ㧘ᬌᩏᓟߩᚻⴚㆡᔕ߿ nasal CPAP ㆡᔕߩ᳿ቯ㧘߅ࠃ߮ߘߩ⚻ㆊⷰኤࠍⴕߞߡ޿ࠆ‫ޕ‬ྚਅᄖ᧪ߢߪ㧘ྚਅ㓚ኂࠍ᧪ߒߡ޿ࠆᖚ⠪ߦౝⷞ㏜ᬌᩏߦട߃ߡ VTR ຜ㗡㘩㆏ㅘⷞࠍ⡊㥦ຜ༄⑼ක߇
ⴕ޿㧘ߘߩྚਅ㓚ኂߩ⹏ଔࠍߒ㧘ᴦ≮࡮࡝ࡂࡆ࡝ᣇ㊎ࠍ᳿ቯߒߡ޿ࠆ‫ޕ‬౉㒮ᖚ⠪ߪᐕ㑆ᑧߴ⚂ 13000 ੱߢ޽ࠆ‫ޕ‬㗡㗪ㇱᖡᕈ⣲≌ᖚ⠪߇ߘߩඨᢙએ਄ࠍභ߼ߡ޿ࠆ‫ࡦ࠮ࠎ߇ޕ‬࠲࡯ߩߥ޿ጘ㒂⋵ߦ߅޿ߡ㧘㗡㗪ㇱ㗔ၞߩ߇ࠎ࠮ࡦ࠲࡯⊛ᓎഀࠍᜂߞߡ޿ࠆ‫ޕ‬ᄖ⑼㧘⣖␹⚻ᄖ⑼ߣߩදജ
ߩ߽ߣߦ᜛ᄢᚻⴚࠍⓍᭂ⊛ߦⴕ޿㧘߹ߚᯏ⢻᷷ሽࠍ⋡ᜰߒౣᑪᚻⴚࠍหᤨߦⴕߞߡ޿ࠆ‫ޕ‬⡊⑼ᚻⴚ㧘೽㥦⣧ᚻⴚߦߪౝⷞ㏜ࠍⓍᭂ⊛ߦዉ౉ߒ㧘ࠕࡊࡠ࡯࠴߇㔍ߒ޿଀ߦߪ࠽ࡆࠥ࡯࡚ࠪࡦߩ૬↪ࠍⴕߞߡ޿ࠆ‫ޕ‬
ᒻᚑᄖ⑼⸻≮ࠍ㐿ᆎߒ㧘㗡㗪ㇱ߇ࠎߦኻߔࠆౣᑪߩߺߥࠄߕ㧘ઁߩ㗔ၞߩᖡᕈ⣲≌ಾ㒰ᓟߩౣᑪ㧘ᾲ்㧘㗻㕙㛽㛽᛬ࠍ฽߻㗻㕙ᄖ்㧘వᄤ⇣Ᏹ㧘⊹⤏⣲≌㧘்〔߿ࠤࡠࠗ࠼㧘㔍ᴦᕈẩ≌ߥߤߩᴦ≮ࠍⴕߞߡ޿ࠆ‫ޕ‬
2㧚ᢎ⢒ᣉ⸳
1㧕 ᣣᧄ⡊㥦ຜ༄⑼ቇળ⹺ቯ⎇ୃᣉ⸳
2㧕 ᣣᧄ᳇▤㘩㆏⑼ቇળ⹺ቯ⎇ୃᣉ⸳
3㧚⸻≮㐿⊒
1㧕 ⸻≮ฬ 㧦߼߹޿ᐔⴧ㓚ኂߩ࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦ
⸻≮ౝኈ㧦߼߹޿ᐔⴧ㓚ኂߩ ADL㧔ᣣᏱ↢ᵴേ૞⢻ജ㧕ᡷༀߩߚ߼㧘⮎‛≮ᴺߣᐔⴕߒߡℂቇ≮ᴺࠍⴕ߁‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦ᒰ㒮߇ో࿖⊛ߦ߽ೋᦼߦዉ౉ߒߚ‫⃻ޕ‬࿷ߪᣇᴺߦᏅߪ޽ࠆ߇ᄙᣉ⸳ߢዉ౉ߐࠇ
ߡ޿ࠆ‫ޕ‬
࿖ౝ⊛⹏ଔ㧦⃻࿷ߪᣇᴺ⺰⊛ߦ⹺߼ࠄࠇᄙᣉ⸳ߢᣉⴕߐࠇߡ޿ࠆ߇㧘ᒰ㒮ߩ㐳ᦼ⊛⚻㛎ߪ࿖ౝߢ⹺߼
ࠄࠇߡ޿ࠆ‫ޕ‬࿖㓙⊛⹏ଔ㧦᰷☨ߢߪ࡝ࡂࡆ࡝ㇱ㐷߇ⴕ߁৻⥸⊛≮ᴺߣߥߞߡ޿ࠆ‫ޕ‬2㧕 ⸻≮ฬ 㧦‫↹ޟ‬௝ᡰេ࠽ࡆࠥ࡯࡚ࠪࡦᚻⴚ‫ߩޠ‬㐿⊒⸻≮ౝኈ㧦࠽ࡆࠥ࡯࡚ࠪࡦࠍ↪޿ࠆߎߣߦࠃࠆ㧘ߎࠇ߹ߢᚻⴚࠕࡊࡠ࡯࠴߇࿎㔍㧘ෂ㒾ߥㇱ૏ߦࠕࡊࡠ࡯࠴߇น⢻ߣߔࠆᚻⴚᡰេࠪࠬ࠹ࡓࠍዉ౉ߔࠆߎߣߢ㧘Ყセ⊛቟ోߥᣇᴺࠍ㐿⊒ߔࠆ‫ޕ‬ߐࠄߦᄖ்߿Ἳ∝ߥߤߦࠃࠆⷞᯏ⢻㓚ኂߩ✕ᕆᚻⴚߢߩ቟ోߥዉ౉ࠍߪ߆ࠆ‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦ߔߢߦᄙߊߩᄢቇߢዉ౉߇ߐࠇߡ޿ࠆ߇㧘✕ᕆᚻⴚߥߤߢߩႎ๔ߪዋߥ޿‫ޕ‬࿖ౝ⊛⹏ଔ㧦⃻࿷ߪᣇᴺ⺰⊛ߦ⹺߼ࠄࠇᄙᣉ⸳ߢᣉⴕߐࠇߡ޿ࠆ߇㧘ᒰ⑼ߢߩᚑ❣ࠍቇળߥߤߢႎ๔
ߒߡ޿ࠆ‫ޕ‬㧙㧙4㧚ኾ㐷ක࡮⹺ቯක࡮ᜰዉක
દ⮮౎ᰴ㧦ᣣᧄ⡊㥦ຜ༄⑼ቇળ⹺ቯ⡊㥦ຜ༄⑼ኾ㐷ක㧘ᣣᧄ߼߹޿ᐔⴧකቇળኾ㐷ળຬ㧘ᣣᧄ᳇▤㘩㆏⑼ቇળ⹺ቯක᳓↰໪੺㧦ᣣᧄ⡊㥦ຜ༄⑼ቇળ⹺ቯ⡊㥦ຜ༄⑼ኾ㐷ක㧘ᣣᧄ߼߹޿ᐔⴧකቇળኾ㐷ળຬ㧘ᣣᧄ᳇▤㘩㆏⑼ቇળ⹺ቯක㕍ᧁశᐢ㧦ᣣᧄ⡊㥦ຜ༄⑼ቇળ⹺ቯ⡊㥦ຜ༄⑼ኾ㐷ක㧘ᣣᧄ߼߹޿ᐔⴧකቇળኾ㐷ળຬട⮮ਭ๺㧦ᣣᧄᒻᚑᄖ⑼ቇળኾ㐷ක㧘ᣣᧄ߇ࠎᴦ≮⹺ቯකਭ਎ᢥ਽㧦ᣣᧄ⡊㥦ຜ༄⑼ቇળ⹺ቯ⡊㥦ຜ༄⑼ኾ㐷කጊ↰ධᤊ㧦ᣣᧄ⡊㥦ຜ༄⑼ቇળ⹺ቯ⡊㥦ຜ༄⑼ኾ㐷ක಴ේ໪৻㧦ᣣᧄ⡊㥦ຜ༄⑼ቇળ⹺ቯ⡊㥦ຜ༄⑼ኾ㐷ක
5㧚⥄Ꮖ⹏ଔ
⹏ଔ⚫੺ᖚ⠪ߪჇടߒߡ޿ࠆ‫ޕ‬ᄖ᧪ฃ⸻ᖚ⠪ᢙ㧘∛᫟Ⓙ௛⁁ᴫ߽⦟޿‫ޕ‬ᣂක≮ߩ㐿⊒㧘ዉ౉߇චಽߣߪ޿߃
ߥ޿‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ᐔᚑ 10 ᐕᐲߦ⸒⺆⡬ⷡ჻ߩ࿖ኅ⾗ᩰ߇೙ᐲൻߐࠇ࿖ኅ⹜㛎߽ᣉⴕߐࠇߚ‫ޕ‬ቯຬჇߪᦼᓙߒߠࠄ޿ᤨઍ
ߢߪ޽ࠆ߇㧘㔍⡬߿㖸ჿ⸒⺆㓚ኂߦኻߔࠆኾછߩ⸒⺆⡬ⷡ჻ߩⶄᢙណ↪ߪ࿖᳃⑔␩ߣ޿߁ⷰὐ߆ࠄߗ߭ߣ
߽ᦸ߹ࠇࠆ‫ߚ߹ޕ‬㧘៨㘩࡮ྚਅ㓚ኂߦኻߔࠆ㑐ᔃ߇㜞߹ߞߡ߅ࠅ㧘↢ᵴߩ⾰ߩะ਄ߩߚ߼ߦߪߎߩ㓚ኂߩᡷༀߪਇนᰳߢ޽ࠆ‫⃻ޕ‬࿷⡊㥦ຜ༄⑼කߣ৻ㇱ࡝ࡂࡆ࡝ᜂᒰකᏧߢขࠅ⚵ࠎߢ޿ࠆ߇㧘੹ᓟ⋴⼔჻㧘⸒⺆⡬ⷡ჻ߥߤߣߩ࠴࡯ࡓක≮߇᳞߼ࠄࠇࠆ‫ޕ‬⌧⌁ᤨ๭ๆ㓚ኂߪࡑࠬࠦࡒߦขࠅ਄ߍࠄࠇࠆᯏળ߇Ⴧ߃㧘␠ળ⊛㑐ᔃ੐ߦߥߞߡ߅ࠅ㧘ẜ࿷⊛ᖚ⠪ᢙߪ߆ߥࠅᄙ޿ߣ⷗ㄟ߹ࠇࠆ‫ߩߎޕ‬ᖚ⠪ߦኻߒߡ⡊㥦ຜ༄⑼කߩߺߢᬌᩏߦኻᔕߒߡ޿ࠆ߇㧘ᄛ㑆ߩᬌᩏߢ޽
ࠆߎߣ߆ࠄᛒ߃ࠆᖚ⠪ᢙߪචಽߢߥ޿‫੹ޕ‬ᓟ⥃ᐥᬌᩏᛛᏧߩදജࠍᓧߡ∛㒮ో૕ߢߩขࠅ⚵ߺߣߔࠆᔅⷐ
ᕈ߇޽ࠆߣᕁࠊࠇࠆ‫ޕ‬ਥߦ㧘೽㥦⣧㗔ၞߩᚻⴚߦ߅޿ߡߪ㧘ૐଚⷅߩౝⷞ㏜ᚻⴚࠍᣧߊ߆ࠄዉ౉ߒ㧘ᴦ≮ᣇᴺࠍ⏕┙ߐߖߡ޿ࠆ‫ߩࡦ࡚ࠪ࡯ࠥࡆ࠽ߦࠄߐޕ‬૬↪ߦࠃࠅ㧘ෂ㒾ߥ⸃೬⊛ㇱ૏߳ߩ೔㆐ߦ߽ౝⷞ㏜ߢߩᚻⴚࠍน⢻ߦߒߡ߈ߡ޿ࠆ‫ޕ‬
߇ࠎ⸻≮ߦ߅޿ߡߪ㧘ᖚ⠪ߩ QOL ࠍ㊀ⷞߒ㧘ᯏ⢻᷷ሽ㧘⤳ེ᷷ሽࠍน⢻ߥ㒢ࠅ᳞߼ࠆᴦ≮ࠍⴕߞߡ޿
ࠆ‫ߪߦ߼ߚߩߘޕ‬㧘੹ᓟߐࠄߦ᦭ലߢ㧘቟ోߥᴦ≮ᴺߩ⏕┙ߣౣᑪⴚᑼߩะ਄ࠍߪ߆ࠆᔅⷐ߇޽ࠆߣᕁࠊ
ࠇࠆ‫ޕ‬
੹ᓟߩዷᦸ
㜞㦂ൻ㧘ዋሶൻ␠ળ߇߹ߔ߹ߔടㅦߔࠆ‫ޕ‬㜞㦂⠪߳ߩ⑔␩ߣߒߡ㧘ᓥ᧪ⴕߞߡ߈ߚ⵬⡬ེᄖ᧪ߩలታߣ
㜞㦂⠪ߩᐔⴧ⛽ᜬ㧘ォୟ໧㗴ߦኻߔࠆᐔⴧකቇ⊛ࠕࡊࡠ࡯࠴ࠍ⛮⛯࡮⊒ዷߐߖࠆ‫ߚ߹ޕ‬㧘៨㘩࡮ྚਅ㓚ኂߩ⹏ଔ࡮ᴦ≮ࠍ࡝ࡂࡆ࡝ߩ㊀ὐ⺖㗴ߩ৻ߟߣߒߡ㧘ઁ⑼࡮ࠦࡔ࠺ࠖࠞ࡞ߩදജߩ߽ߣߦࠪࠬ࠹ࡓ૞ࠅࠍታ
⃻ߔࠆ‫ޕ‬
ᣂ↢ఽ⡬ⷡࠬࠢ࡝࡯࠾ࡦࠣ߇ጘ㒂⋵ⴕ᡽੐ᬺߣߒߡࡄࠗࡠ࠶࠻⊛ߦᆎ߹ߞߚ‫ࠣࡦ࠾࡯࡝ࠢࠬޕ‬㧘㔍⡬ఽ⊒⷗ᓟߩ⡬⢻⸠✵߇౞ṖߦⒿ௛ߔࠆࠃ߁ߦጘ㒂ᄢቇ⡊㥦ຜ༄⑼߇ࠪࠬ࠹ࡓߩᜰዉ⊛ᓎഀࠍᨐߚߔ‫ޕ‬߇ࠎ᜚ὐ∛㒮ߣߒߡ㧘㜞ᐲߥᚻⴚᴦ≮ࠍⴕ߁ߣߣ߽ߦ㧘᦭ലᕈߩ㜞޿ᴦ≮ᣇᴺߩ⏕┙ࠍ⋡ᜰߔ‫ޕ‬㧙㧙㧔13㧕⊹⤏⑼
1㧚⸻≮ߩ᭎ⷐ
ᄖ᧪㧦⃻࿷৻⥸ᄖ᧪⸻≮㧔ೋ⸻࡮ౣ⸻㧕ߦട߃ߡኾ㐷ᄖ᧪ࠍ㐿⸳ߒߡ߅ࠅ㧘ਛᔃߦߥࠆᜂᒰකߪේೣߣ
ߒߡ࿕ቯߐࠇ㧘Ყセ⊛㐳ᦼߩᄖ᧪ᖚ⠪⸻ኤߦኻᔕߒߡ޿ࠆ‫ޕ‬ਥߥ߽ߩߪ㧘⣲≌ᄖ᧪㧔᦬࡮AM㧕㧘ੇ⊈ᄖ᧪㧔᦬࡮PM㧕㧘࡟࡯ࠩ࡯ᄖ᧪㧔᦬࡮PM㧕㧘⤔ේ∛ᄖ᧪㧔᳓࡮AM㧕㧘ࠕ࠻ࡇ࡯࡮⣕Ძᄖ᧪㧔᳓࡮PM㧕㧘᳓∊㧘శᴦ≮ᄖ᧪㧔᳓࡮AM㧒PM㧘㊄࡮AM㧕ߣߥߞߡ޿ࠆ‫ࠇߎޕ‬એᄖߦᄖ᧪ᚻⴚᣣ㧔὇㉄∝ᄖ᧪㧔᳓࡮PM㧕ࠟࠬ࡟࡯ࠩ࡯ᴦ≮ࠍ฽߻㧕ߣߒߡ᳓ᦐᣣ PM ߣᧁᦐᣣ AM㧘ࡄ࠶࠴࠹ࠬ࠻ᄖ᧪㧔᦬࡮PM㧕㧘ᶧ૕⓸⚛ᄖ᧪
㧔ᧁ࡮AM㧕߇޽ࠆ‫ޕ‬⣲≌ᄖ᧪ߢߪ⊹⤏ᖡᕈ⣲≌ߢᚻⴚ߿ൻቇ≮ᴺࠍฃߌߚᖚ⠪ߩ㐳ᦼߦࠊߚࠆࡈࠜࡠ࡯
ࠍⴕߞߡ޿ࠆ‫࡯ࠩ࡯࡟ޕ‬ᄖ᧪ߢߪ㧘⿒޽ߑ↪ߣ㤥޽ߑ↪ߩ 2 ⒳㘃ߩ࡟࡯ࠩ࡯߇޽ࠅ㧘ࠃࠅᄙߊߩ∔ᖚߦኻᔕߒߡ޿ࠆ‫⊈ੇޕ‬ᄖ᧪㧘ࠕ࠻ࡇ࡯ᄖ᧪߅ࠃ߮᳓∊∝ᄖ᧪ߢߪ㧘⵾⮎ળ␠߆ࠄߩଐ㗬ߦࠃࠆᴦ㛎߽㓐ᤨⴕߞߡ޿ࠆ‫ޕ‬శᴦ≮ᄖ᧪ߢߪᓥ᧪ߩ UVA ᾖ኿ᯏེߩ߶߆㧘narrow band UVB ᾖ኿ᯏེࠍዪᚲဳߣోりဳߩ 2⒳㘃ዉ౉ߔࠆߎߣߢ㧘ࠃࠅㆡᔕߦᔕߓߚᾖ኿߇ߢ߈ࠆࠃ߁ߦߥߞߚ‫ߚ߹ޕ‬㧘⣕Ძᄖ᧪ߢߪ SADBE㧘DPCP
ࠍ೑↪ߒߚዪᚲ఺∉≮ᴺࠍขࠅ౉ࠇ㧘⦟ᅢߥᚑᨐࠍ޽ߍߡ޿ࠆ‫ޕ‬Ἣᦐᣣߦᄖ᧪ࠞࡦࡈࠔ࡟ࡦࠬߣߒߡ㑐ㅪ∛㒮߆ࠄߩ⚫੺ᖚ⠪ߥߤߩ․೎⸻ኤࠍⴕ޿㧘∛⸻ㅪ៤ࠍలታߐߖߡ޿ࠆ‫∛ޕ‬᫟࿁⸻ᣣߢ޽ࠆἫᦐᣣߪ㧘ೋ⸻࡮ౣ⸻ߣ߽㧘߹ߚᚻⴚᣣߢ޽ࠆᧁᦐᣣߪౣ⸻ߩߺભ⸻ߣߥߞߡ޿ࠆ‫ߒ߆ߒޕ‬㧘ᤨ㑆㒢ቯ੍⚂ߩዉ౉ߢ৻
ㇱ⸻ኤࠍⴕ߁ߣߣ߽ߦ㧘ઁ⑼߆ࠄߩ㜞⸻╬ߦߪᜂᒰකࠍ߅߈ኻᔕߒߡ޿ࠆ‫ޕ‬౉㒮㧦ᒰ⑼∛ᐥᢙߪ 20 ᐥ㧔ᐔᚑ 19 ᐕᐲ߹ߢ 19 ᐥ㧕ߢ㧘Ⓙ௛₸ 85.6㧑㧔20 ᐥߢ▚಴㧕㧘ᐔဋ࿷㒮ᣣᢙ⚂ 13.04 ᣣ㧘౉㒮ᓙᯏᖚ⠪ᢙ⚂ 20 ੱߢ޽ࠆ‫ޕ‬ᐔဋ࿷㒮ᣣᢙߪᓢ‫ߦޘ‬⍴❗ߐࠇߡ޿ࠆ߇㧘Ⓙ௛₸ߪ⛽ᜬߐࠇߡ޿ࠆߚ߼㧘ᐕ㑆ߩ౉㒮ᖚ⠪ᢙߪᓢ‫ߦޘ‬Ⴧട௑ะߦ޽ࠆ‫∔ޕ‬ᖚ߽ᄙጘߦࠊߚࠅ㧘ᖡᕈ㤥⦡⣲㧘᦭᫚⚦⢩≸߅ࠃ߮⊹⤏ᖡᕈ࡝ࡦࡄ⣲ߥߤߩ⊹⤏ᖡᕈ⣲≌ᖚ⠪ߪ㧘ᄙߊߪᚻⴚᴦ≮㧔ᐢ▸࿐ಾ㒰㧘ᬀ⊹ⴚ޽ࠆ޿ߪ⊹ᑯᒻᚑⴚ㧘࡝ࡦࡄ▵ㇳᷡߥߤ㧕ࠍⴕ޿㧘ᔅⷐߦᔕߓߡൻቇ≮ᴺ߆ࠄ⚳ᧃᦼߩ✭๺ක≮߹ߢᐢߊⴕߞߡ޿ࠆ‫ޕ‬ߘߩઁ㧘ᚻⴚᖚ⠪ߪ≚∥ߩᒻᚑᚻⴚ㧘ዊఽߩᲣ᢬㧘޽ࠆ޿ߪዪᚲ㤗㈮ߩዊᚻⴚ߽ᄙߊⴕߞߡ޿ࠆ‫ࡇ࠻ࠕޕ‬࡯ᕈ⊹⤏Ἳߪቇ⠌౉㒮ߣ৻⥸౉㒮ߣಽߌߡ⸻≮ࠍⴕ޿㧘ቇ⠌౉㒮ߢߪᧄੱ޽ࠆ޿ߪኅᣖ߳↢ᵴᜰዉ㧘ᄖ↪
೷ߩ૶↪ᣇᴺߩ⺑᣿㧘∛᳇ߦߟ޿ߡߩ⻠⟵ߥߤࠍⴕߞߡ޿ࠆ‫⤔ޕ‬ේ∛ߪోりᕈᒝ⊹∝㧘⊹⤏╭Ἳ㧘ోりᕈࠛ࡝࠹ࡑ࠻࡯࠺ࠬߥߤߩ♖ᩏ㧘ട≮ࠍⴕߞߡ޿ࠆ‫⤔ޕ‬ේ∛߿ᓴⅣ㓚ኂߥߤ㔍ᴦᕈ⊹⤏ẩ≌ࠍ઻߁∝଀ߢߪⴊ▤᜛ᒛ೷ߩὐṢ߿ᬀ⊹ⴚ߽ⴕߞߡ޿ࠆ‫ޕ‬ᄤ∊≙㧘㘃ᄤ∊≙ߥߤ⥄Ꮖ఺∉ᕈ᳓∊∝ߪ㧘⊹⤏↢ᬌ࡮Ⱟశ᛫
૕ᴺ࡮ⴊᷡ∛ේ᛫૕᷹ቯߥߤࠍⴕ޿㧘㊀∝ᐲࠍ್ቯߒࠬ࠹ࡠࠗ࠼೷ࠍਛᔃߣߔࠆ఺∉ᛥ೙ᴦ≮ࠍ㊀∝ᐲផ
⒖ࠍ⷗ߥ߇ࠄᴦ≮ߒߡ޿ࠆ‫ޕ‬㊀∝଀ߢߪ㧘ࠬ࠹ࡠࠗ࠼೷ߦട߃఺∉ᛥ೙೷㧘ⴊẏ੤឵≮ᴺ㧘ᄢ㊂ࠟࡦࡑࠣࡠࡉ࡝ࡦ≮ᴺߥߤࠍ⚵ߺวࠊߖߡⴕߞߡ޿ࠆ‫ઁߩߘޕ‬㧘ᣣᏱ⊛ߥᏪ⁁∊∐߿ⱎ┃❱Ἳߥߤ߽౉㒮ᴦ≮ߒߡ޿ࠆ‫౉ޕ‬㒮ᖚ⠪ో૕ߩ⚂ 40%ߦࠢ࡝࠾ࠞ࡞ࡄࠬࠍㆡᔕߒක≮ߩᮡḰൻࠍ࿑ࠅߟߟ߽㧘৻ㇱߢߪవㅴක≮ࠍ૬↪ߒߡ⸻≮ࠍⴕߞߡ޿ࠆ‫ޕ‬
2㧚ᢎ⢒ᣉ⸳
1㧕 ᣣᧄ⊹⤏⑼ቇળ⹺ቯኾ㐷ක⎇ୃᣉ⸳
3㧚⸻≮㐿⊒
1㧕 ⸻≮ฬ 㧦࠮ࡦ࠴ࡀ࡞࡝ࡦࡄ▵↢ᬌ⸻≮ౝኈ㧦ㅢᏱ⷗ㅏߒߡߒ߹߁ᓸዊォ⒖ߩ⊒⷗ࠍ⋡⊛ߣߒߡᖡᕈ㤥⦡⣲ࠍਛᔃߦⴕߞߡ޿ࠆ‫ޕ‬᡼኿ᕈ‛⾰߿⦡⚛ࠍ↪޿ߡ࠮ࡦ࠴ࡀ࡞࡝ࡦࡄ▵ࠍᬌ಴࡮៰಴ࠍⴕߞߡ޿ࠆ‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦ᄢቇ∛㒮㧘࿖┙߇ࠎ࠮ࡦ࠲࡯ࠍਛᔃߦታᣉߐࠇߡ޿ࠆ‫ޕ‬࿖ౝ⊛⹏ଔ㧦వㅴක≮ߣߒߡ㧘⃻࿷ᄙᣉ⸳ߢ቟ోᕈߩ⏕⹺ࠍⴕߞߡ޿ࠆᦨਛߢ޽ࠆ㧔ෘ↢ഭ௛⋭⎇ⓥ⃰㧘ࡔ࡜ࡁ࡯ࡑ⎇ⓥ⃰ߣ࠮ࡦ࠴ࡀ࡞࡝ࡦࡄ▵⎇ⓥ⃰㧦޿ߕࠇ߽ᒰᢎቶߩർፉᢎ᝼߇⎇ⓥදജ⠪ߣߒߡෳട㧕‫ޕ‬2㧕 ⸻≮ฬ 㧦ࠤࡠࠗ࠼⢈ෘᕈ≚∥ߦኻߔࠆ࠳ࠗ࡟࡯ࠩ࡯߅ࠃ߮࠳ࠗࠝ࡯࠼࡟࡯ࠩ࡯ߩᴦ≮⸻≮ౝኈ㧦ೋᦼߩࠤࡠࠗ࠼࡮⢈ෘᕈ≚∥ߦኻߒߡ࠳ࠗ࡟࡯ࠩ࡯㧘࠳ࠗࠝ࡯࠼࡟࡯ࠩ࡯ࠍᾖ኿ߒߡᐔမ
ൻ࡮ᶖㅌࠍߪ߆ࠆ‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦࠳ࠗ࡟࡯ࠩ࡯ߩᾖ኿ߪ޿ߊߟ߆ߩᣉ⸳ߢᣉⴕߐࠇߡ޿ࠆ‫ޕ‬࿖ౝ⊛⹏ଔ㧦ቇળ╬ߦߡႎ๔ߐࠇߡ޿ࠆ‫ޕ‬3㧕 ⸻≮ฬ 㧦ᖚ⠪ⴊᷡਛߩ᛫ BP180 ᛫૕ߩ᷹ቯ㧘⥄Ꮖ᛫૕ߩ᛫ේ᳿ቯ
⸻≮ౝኈ㧦᳓∊ᕈ㘃ᄤ∊≙ᖚ⠪ߩ∛࿃᛫૕ BP180 ߩ᷹ቯࠍ㧘Ꮢ⽼ߩ ELISA ࠠ࠶࠻ࠍ↪޿ߡ᷹ቯߒ㧘
ᴦ≮ᴺ࡮ലᨐ್ቯ࡮∛൓ᛠីࠍⴕ߁‫ߚ߹ޕ‬㧘᳓∊∝ᖚ⠪ߦ߅޿ߡ଻㒾ㆡᔕߩ޽ࠆ Dsg1,3ߩ㒶ᕈᤨߦ㧘Ⱟశ᛫૕ᴺ࡮࠙ࠛࠬ࠲ࡦࡉࡠ࠶࠻ᴺߦࠃࠆ⏕ቯ⸻ᢿࠍⴕ߁‫ޕ‬㧙㧙ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦ᢙ▎ᚲߩᄢቇ㒝ዻ∛㒮ߢⴕࠊࠇߡ޿ࠆ߇㧘᧲ᶏ࿾඙ߢߪጘ㒂ᄢቇߩߺߢⴕࠊࠇ
ߡ޿ࠆ‫⃻ޕ‬࿷߽ㄭ㓞ߩ∛㒮߆ࠄߩଐ㗬ߢ৻ㇱᣉⴕߒߡ޿ࠆ‫ޕ‬࿖ౝ⊛⹏ଔ㧦᛫૕ߩ᦭↪ᕈߦߟ޿ߡߪߔߢߦ⏕┙ߒߡ߅ࠅ㧘ା㗬ᕈߪᓧࠄࠇߡ޿ࠆ‫ޕ‬ᬌᩏߦ߅޿ߡߪ
ၭ㙃⚦⢩㧘ᬌ಴ౕེ㧘ᾫ✵ߒߚ್ቯ⠪߇ᔅⷐߢ޽ࠅ㧘㒢ࠄࠇߚᣉ⸳ߢߩߺน⢻ߢ޽ࠆ‫ޕ‬࿖㓙⊛⹏ଔ㧦ᧄ᛫૕᷹ቯߩ㐿⊒ߪᣣᧄߩᄢቇࠍਛᔃߦⴕࠊࠇ㧘ᶏᄖߦ߅޿ߡ߽ቇળ࡮⺰ᢥ╬ߢ㜞޿⹏ଔࠍᓧߡ޿ࠆ‫ޕ‬4㧕 ⸻≮ฬ 㧦ࠕ࠻ࡇ࡯ᕈ⊹⤏Ἳቇ⠌౉㒮⸻≮ౝኈ㧦ࠕ࠻ࡇ࡯ᕈ⊹⤏Ἳᖚ⠪ߦ 10 ᣣ㑆౉㒮ߒߡ޿ߚߛ߈㧘ࠕ࠻ࡇ࡯ߦ㑐ߔࠆ⻠⟵࡮㘩੐ᩕᜰዉ㧘⮎೷ߦߟ޿ߡߩᜰዉ࡮⺑᣿࡮ಣ⟎ᣇᴺߩ⺑᣿࡮ᜰዉࠍ㧘ᩕ㙃჻࡮⮎೷Ꮷߣߩදജߢⴕߞߡ޿ࠆ‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦ᢙࠞᚲߩᄢቇ㒝ዻ∛㒮㧔ർᶏ㆏ᄢቇ࡮ᵿ᧻ක⑼ᄢቇ╬㧕ߢⴕࠊࠇߡ޿ࠆ‫ޕ‬࿖ౝ⊛⹏ଔ㧦ࠕ࠻ࡇ࡯ᕈ⊹⤏Ἳߦኻߒߡࠕ࠻ࡇ࡯ࡆࠫࡀࠬ㧘⹊᱂໡ᴺ╬߇ႎ๔ߐࠇ㧘ో࿖ߩᄢቇ∛㒮ߢዉ౉ߐࠇߟߟ޽ࠆ‫⊛ੱޕ‬໧㗴߆ࠄᄢቇ㒝ዻ∛㒮એᄖߢߪዉ౉࿎㔍ߣ⠨߃ࠄࠇࠆ‫ޕ‬ዉ౉ߦࠃࠆᚑᨐ╬ߪ⺰ᢥႎ๔ߐࠇߡ޿ࠆ‫ޕ‬
4㧚ኾ㐷ක࡮⹺ቯක࡮ᜰዉක
ർፉᐽ㓶㧦ᣣᧄ⊹⤏⑼ቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄක⌀⩶ቇળ⹺ቯኾ㐷ක㧘ᣣᧄ߇ࠎᴦ≮⹺ቯᯏ᭴ᥳቯᢎ⢒ක⹺ቯᏒૼༀ㇢㧦ᣣᧄ⊹⤏⑼ቇળኾ㐷ක␹⼱⑲༑㧦ᣣᧄ⊹⤏⑼ቇળኾ㐷ක㧘ᣣᧄ߇ࠎᴦ≮⹺ቯᯏ᭴ᥳቯᢎ⢒ක⹺ቯ㕍ጊ⵨⟤㧦ᣣᧄ⊹⤏⑼ቇળኾ㐷ක㓶ጊℰᩕ㧦ᣣᧄ⊹⤏⑼ቇળኾ㐷ක᳗੗⟤⾆㧦ᣣᧄ⊹⤏⑼ቇળኾ㐷කጤ↰ᶈ᣿㧦ᣣᧄ⊹⤏⑼ቇળኾ㐷ක๟ ౞ 㧦ᣣᧄ⊹⤏⑼ቇળኾ㐷කᄥ๺↰⍮㉿㧦ᣣᧄ⊹⤏⑼ቇળኾ㐷ක
5㧚⥄Ꮖ⹏ଔ
⹏ଔኾ㐷කขᓧ⁁ᴫ㧦⎇ୃᦼ㑆߇⚳ੌᓟ㧘߶߷ᦨ⍴ߢోຬ߇⊹⤏⑼ቇળኾ㐷කࠍขᓧߒߡ߅ࠅ㧘⎇ୃࠪࠬ࠹ࡓߪචಽߦᯏ⢻ߒߡ޿ࠆߣ⠨߃ߡ޿ࠆ‫ޕ‬‫ޕ‬ኾ㐷ᄖ᧪ߦ
ᄖ᧪⸻≮㧦ᄖ᧪ᖚ⠪ᢙߪ⒖ォᓟ߽Ⴧടࠍ⛯ߌ㧘∛㒮ౝߢ߽਄૏ߦ૏⟎ߒߡ޿ࠆ㧔1㨪3 ૏㧕ᜂᒰකࠍ࿕ቯߔࠆߎߣߢ㧘ห৻කᏧߦࠃࠆ㐳ᦼࡈࠜࡠ࡯߇น⢻ߣߥࠅ㧘ᖚ⠪஥߆ࠄߩା㗬ࠍᓧࠆߎߣ߇ߢ߈ߚ‫ޕ‬౉㒮⸻≮㧦∛ᐥᢙ߇Ⴧടߒߚ߇㧘Ⓙ௛₸ߪ߶߷ᮮ߫޿ߢ޽ࠆ߇㧘ᐔဋ࿷㒮ᣣᢙ߇⍴❗ߐࠇߡ޿ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ᄖ᧪㧦⚫੺₸߇િ߮ᖠࠎߢ޿ࠆ‫ߦߌߛ⑼⤏⊹ޕ‬㒢ࠄߕ㧘ౝ⑼ߥߤߩઁ⑼㐿ᬺකߥߤࠍ฽߼ߚ∛⸻ㅪ៤ߩ㓸ળࠍቯᦼ⊛ߦⴕ߁ߎߣߢᄢቇ∛㒮⊹⤏⑼ߩ․⦡ࠍࠃࠅᄙߊߩੱߦ⍮ߞߡ߽ࠄ޿㧘ߘࠇߦࠃߞߡ⚫੺₸ࠍ਄ߍࠆߥߤߩദജ߇ᔅⷐߢ޽ࠆ‫ߚ߹ޕ‬㧘੹ᓟ⟤ኈࠍ฽߼ߚ࡟࡯ࠩ࡯ᴦ≮࡮ࠤࡒࠞ࡞ࡇ࡯࡝ࡦࠣߥߤ㧘଻㒾ᄖ⸻≮ߦߟ޿ߡᬌ⸛߇ᔅⷐߢ޽ࠆ‫ޕ‬౉㒮㧦౉㒮ᦼ㑆ߩ⍴❗ߪᐕ‫ޘ‬ㅴࠎߢ޿ࠆ߇㧘ᓢ‫ߦޘ‬⍴❗߽࿎㔍ߦߥࠅߟߟ޽ࠆ‫ޕ‬ㅳᧃߦⒿ௛₸߇ૐਅߔࠆ௑ะߦ޽ࠆߚ߼㧘ㅳᧃࠍ೑↪ߒߚ⍴ᦼ౉㒮ߩଦㅴࠍ࿑ࠆ‫ޕ‬DPC ⸻≮ߢߪ㧘೑⋉₸ࠍ਄ߍࠆᎿᄦ߇ᔅⷐ
ߢ޽ࠅ㧘ᄖ᧪ߢน⢻ߥ⸻≮ߣ౉㒮ߒߡ߆ࠄߩ⸻≮ࠍಽ㔌ߒߡ޿ߊߎߣ߇ᔅⷐߢ޽ࠆ‫ޕ‬੹ᓟߩዷᦸᣢሽ⸳஻ߩ᦭ല೑↪㧘㒢ࠄࠇߚࠬ࠲࠶ࡈߢߩㆇ↪㧘ኾ㐷ක⎇ୃߩలታ㧘⎇ୃකߩᢎ⢒ߥߤ㧘㜞޿ක≮᳓Ḱࠍ଻ߜ㧘߆ߟ⾰ߩ㜞޿⥃ᐥකߩ㙃ᚑࠍߪ߆ࠆࠃ߁ߦᏱߦ⠨߃㧘ᡷༀߦขࠅ⚵ࠎߢ޿߈ߚ޿‫ߚ߹ޕ‬㧘ㄭ㓞ߩ∛㒮࡮⸻≮ᚲߣߩ∛⸻ㅪ៤ࠍㅴ߼ߡ޿߈ߚ޿‫ޕ‬㧙㧙㧔14㧕ᴲዩེ⑼1㧚⸻≮ߩ᭎ⷐ
1㧕ᄖ᧪⸻≮
᦬ᦐᣣ߆ࠄ㊄ᦐᣣ߹ߢඦ೨ߪ৻⥸⸻≮ࠍ㧘ඦᓟߪኾ㐷ᄖ᧪⧯ߒߊߪ․ᱶᬌᩏࠍⴕߞߡ޿ࠆ‫ޕ‬ኾ㐷ᄖ᧪ߣߒߡߪ㧘CAPD㧔⣻⤑ㅘᨆ㧕ᄖ᧪㧘⣢⒖ᬀᄖ᧪㧘ᅚᕈᴲዩེᄖ᧪㧘೨┙⣼⣲≌ᄖ᧪ࠍ㐿⸳ߒߡ޿ࠆ‫ޕ‬ᅚᕈᴲዩེᄖ᧪ߪᅚᕈ߇቟ᔃߒߡฃ⸻಴᧪ࠆࠃ߁ߦ㧘ㅳ 1 ࿁ቢో੍⚂೙ߢᅚᕈකᏧߦࠃࠆ⸻≮ࠍⴕߞߡ޿ࠆ‫ޕ‬․ᱶᬌᩏߢߪ㧘⣾⢲㔚ሶࠬࠦ࡯ࡊᬌᩏࠍ޿ߜߪ߿ߊขࠅ౉ࠇߡ߅ࠅ㧘㕖ᶐⷅᕈߩᬌᩏࠍᔃ߇ߌߡ޿ࠆ‫߹ޕ‬ߚ㧘Pressure flow study ߩᣉⴕߦࠃࠅឃዩ⁁ᘒߩᱜ⏕ߥ⹏ଔࠍⴕ޿㧘ᴦ≮ᴺߩㆬᛯߦ෻ᤋߐߖߡ޿ࠆ‫ޕ‬ጘ㒂⋵ਅߢߩ೨┙⣼≸ᬌ⸻ߩផㅴߩਛᔃ⊛ߥᓎഀࠍᨐߚߒߡ߅ࠅ㧘⋵ਅߩਥߥ∛㒮ߣߩදജߩਅߦ⛔৻ߒߚၮḰߢ 2 ᰴᬌᩏߩታᣉࠍⓍᭂ⊛ߦⴕߞߡ޿ࠆ‫ߦࠄߐޕ‬᡼኿✢⑼ߣㅪ៤ߒ㧘ᄖ᧪ߢߩ᡼኿✢ᄖᾖ኿≮ᴺ
㧔3D-CRT㧘IMRT㧕ࠍᣉⴕߒߡ޿ࠆ‫ ߚ߹ޕ‬2005 ᐕࠃࠅᄖ᧪ൻቇ≮ᴺቶ߇૬⸳ߐࠇߚߚ߼ᒰ⑼ߢ߽Ⓧᭂ⊛ߦᄖ᧪ൻቇ≮ᴺࠍዉ౉ߒߡ޿ࠆ‫ޕ‬
2㧕∛᫟⸻≮
ᴲዩེౝⷞ㏜ᚻⴚߩᕆㅦߥㅴᱠߦࠃࠅ㧘㐿⣻ᚻⴚߩᷫዋ߇⪺ߒ޿‫ޕ‬2005 ᐕߦዉ౉ߒߚࡎ࡞ࡒ࠙ࡓ࡟࡯
ࠩ࡯೨┙⣼ᩭ಴ⴚ㧔HoLEP㧕ߪ㧘⋵ౝ໑৻ߩዉ౉ᣉ⸳ߢᓥ᧪ߩࠧ࡯࡞࠼ࠬ࠲ࡦ࠳࡯࠼ߢ޽ߞߚ⚻ዩ㆏⊛೨┙⣼ಾ㒰ⴚ㧔TUR-P㧕ߦൎࠆ⥃ᐥᚑᨐࠍ޽ߍߡ޿ࠆ‫ޕ‬ᅚᕈᴲዩེߩಽ㊁ߢߪ㧘ᅚᕈߩዩᄬ⑌ߩ࠲ࠗࡊಽ
㘃ࠍᱜ⏕ߦⴕ߁ߚ߼ߩᬌᩏࠍⴕ޿㧘ේ࿃ߦᔕߓ⮎‛≮ᴺ㧘ⴕേ≮ᴺ㧘ᚻⴚ≮ᴺࠍⴕߞߡ޿ࠆ‫ޕ‬⣻࿶ᕈዩᄬ⑌ߦኻߔࠆᚻⴚ≮ᴺߣߒߡߪ㧘⃻࿷ࠬ࠲ࡦ࠳࡯࠼ߣߥߞߡ޿ࠆ TVT ᚻⴚߦઍࠊߞߡ㧘ࠃࠅଚⷅߩዋߥ޿
TOT ᚻⴚࠍⴕߞߡ޿ࠆ‫ߚ߹ޕ‬⣻࿶ᕈዩᄬ⑌ߣห᭽ߦ㧘㛽⋚ᐩᡰᜬ⚵❱ߩ⣀ᒙൻߦࠃߞߡ߅ߎࠆ㛽⋚⤳ེ⣕ߦኻߒߡߪ㧘2007 ᐕࠃࠅࡔ࠶ࠪࡘࠍ↪޿ߚ TVM ᚻⴚࠍⴕ޿⦟ᅢߥᚑ❣ࠍ෼߼ߡ޿ࠆ‫⚿ޕ‬⍹ᴦ≮ߦ㑐ߒߡߪ⎕⎈ല₸ߩ㜞޿ࠪ࡯ࡔࡦࠬ␠ߩ ESWL ࠍ㚟૶ߒන࿁ᴦ≮ߢ⦟ᅢߥᚑ❣ࠍᓧߡ޿ࠆ‫ޕ‬ESWL ኻ⽎ᄖߩ⚿⍹ߦኻߒߡ߽⚦ᓘߩౝⷞ㏜ߣ⎕⎈ല₸ߩ㜞޿ࡎ࡞ࡒ࠙ࡓ࡟࡯ࠩ࡯ࠍ↪޿ࠆߎߣߢ⎈⍹ߢ߈ߥ޿⚿⍹ߪ߶߷ή޿⁁ᴫߢ޽ࠆ‫ޕ‬1998 ᐕࠃࠅ೽⣢៰಴ⴚߦ⣻⣧㏜ᚻⴚࠍዉ౉ߒߡએ᧪㧘ౝಽᴲౝ⑼ߣߩㅪ៤߽޽
ࠅ⋵ਅߢ߽࠻࠶ࡊࠢ࡜ࠬߩᚻⴚઙᢙߢ޽ࠆ‫ߦࠄߐޕ‬㧘⦟ᕈ∔ᖚߩߺߥࠄߕ⣢ߩᖡᕈ⣲≌ߦኻߒߡ߽⣻⣧㏜
ࠍ↪޿ߚᚻⴚࠍⓍᭂ⊛ߦታᣉߒ㧘⋵ਅߢ߽ᦨᄙߩᚻⴚታ❣ࠍ᦭ߒߡ޿ࠆ‫ޕ‬೨┙⣼≸ߩᴦ≮ߦ߅޿ߡߪ㧘㒢ዪᕈ೨┙⣼≸ߦኻߒߡ 2004 ᐕ߆ࠄ᧲ᶏ࿾඙ߢߪߓ߼ߡዊ✢Ḯ≮ᴺࠍዉ౉ߒߡ޿ࠆ‫ޕ‬⣢⒖ᱺߢߪ㧘ᣂߒ޿఺∉ᛥ೙೷ࠍ↪޿ߚ఺∉ᛥ೙≮ᴺࠍዉ౉ߒ㧘↢⌕₸ߩᡷༀࠍ⹺߼ߡ߅ࠅ 1 ᐕ↢⌕₸98%㧘5 ᐕ↢⌕₸ 95%ࠍ⿥߃ߡ޿ࠆ‫↢޿઻ߦࠇߎޕ‬૕⣢⒖ᬀߩ଀ᢙ߇Ⴧടߒ㧘ᐕ㑆 20 ଀એ਄ߩ⣢⒖ᬀࠍ
ⴕߞߡ߅ࠅ㧘ߎࠇߪో࿖࿖┙ᄢቇ∛㒮ߩਛߢ߽࠻࠶ࡊࠢ࡜ࠬߩ∝଀ᢙߢ޽ࠆ‫ޕ‬㑐ㅪᣉ⸳ߣ౒หߒߡዩ〝↢ᱺེ≸ߩᴦ≮ᣇ㊎ࠍ╷ቯߒ㧘޿ߊߟ߆ߩಽ㊁ߢ clinical study ࠍታᣉਛߢ޽ࠆ‫ޕ‬2㧚ᢎ⢒ᣉ⸳
1㧕 ᣣᧄᴲዩེ⑼ቇળኾ㐷කᢎ⢒ᣉ⸳
2㧕 ᣣᧄㅘᨆකቇળᢎ⢒⹺ቯᣉ⸳3㧚⸻≮㐿⊒
1㧕 ⸻≮ฬ 㧦೨┙⣼⢈ᄢ∝ߦ߅ߌࠆૐଚⷅᚻⴚ㧦ࡎ࡞ࡒ࠙ࡓࡗࠣ࡟࡯ࠩ࡯ࠍ↪޿ߚ⚻ዩ㆏⊛೨┙⣼ᩭ಴ⴚ⸻≮ౝኈ㧦೨┙⣼⢈ᄢ∝ߦኻߒࡎ࡞ࡒ࠙ࡓࡗࠣ࡟࡯ࠩ࡯ࠍ↪޿ߚ⚻ዩ㆏⊛೨┙⣼ᩭ಴ⴚࠍⴕ߁‫⃻ޕ‬࿷
߹ߢ 70 ଀ߩࡎ࡞ࡒ࠙ࡓࡗࠣ࡟࡯ࠩ࡯ࠍ↪޿ߚ⚻ዩ㆏⊛೨┙⣼ᩭ಴ⴚࠍᣉⴕߒߡ߈ߚ߇㧘ㇱ૏ߦࠃߞߡߪ࡟࡯ࠩ࡯ߢߪᱛⴊ࿎㔍ߥߎߣ߇޽ࠆߚ߼㧘㔚᳇ࡔࠬߦࠃࠆᱛⴊࠍ૬↪ߔࠆ႐ว߽޽ࠅ↢ℂ㘩Ⴎ᳓ࠍ㕖㔚⸃⾰ẑᵹᶧߦ੤឵ߒߡ޿ࠆ⃻⁁ߢ޽ࠆ‫↢ޕ‬ℂ㘩Ⴎ᳓ߢ߽น⢻ߥౝⷞ㏜ࠪࠬ࠹ࡓࠍ૶↪ߢ޽ࠇ߫㧘ߎߩᚻⴚએᄖߦ߽ᔕ↪ߢ߈ TUR ෻ᔕߥߤߩว૬∝߽ήߊ⚻ᷣ⊛ߦ߽቟ଔߦน⢻ߣߥࠆ‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦ጘ㒂⋵ౝߢߩዉ౉ߪߥߐࠇߡ޿ߥ޿‫ޕ‬࿖ౝ⊛⹏ଔ㧦ᓥ᧪ߩౝⷞ㏜ᚻⴚߦᲧߴߡⴚਛߩ಴ⴊ㊂߇ዋߥߊࠞ࠹࡯࠹࡞⇐⟎ᦼ㑆߇⍴ߊ౉㒮ᦼ㑆߽⍴❗ߢ߈ࠆ‫ޕ‬ᢙ޽ࠆ೨┙⣼⢈ᄢ∝ߩૐଚⷅᚻⴚߣ⇣ߥࠅ⚵❱ߩ࿁෼ߦࠃࠆ∛ℂ⸻ᢿ߽น⢻ߢലᨐߪ⍴ᦼ⊛ߦ߽㐳ᦼ⊛ߦ߽ᓥ᧪ߩౝⷞ㏜ᚻⴚߣห╬߆ߘࠇએ਄ߣᦼᓙߢ߈ࠆ‫ޕ‬࿖㓙⊛⹏ଔ㧦ᓥ᧪ߪౝⷞ㏜ᚻⴚߪ࿎㔍ߢ㐿᡼ᚻⴚߣߐࠇߡ޿ߚᄢ߈ߥ೨┙⣼߳ߩኻᔕ߽น⢻ߢ޽ࠅ㧘ᖚ⠪ߩฃߌࠆᕲᕺߪᄢ߈ߊ␠ળ⊛⽸₂ᐲ߽㜞޿‫ޕ‬㧙㧙

2㧕 ⸻≮ฬ 㧦エᕈࡆ࠺ࠝዩ▤㏜ࠍ↪޿ߚዩ▤㏜ᬌᩏ㧘ߥࠄ߮ߦዩ〝⚿⍹ᚻⴚ⸻≮ౝኈ㧦ዩ▤߿⣢⋃ౝߩᓸዊ∛ᄌߩหቯߩߚ߼ߦ㜞↹⾰ߩエᕈࡆ࠺ࠝዩ▤㏜ࠍ↪޿ࠆ‫ޕ‬ዩ〝⚿⍹ߦኻߒエᕈࡆ࠺ࠝౝⷞ㏜ߣࡎ࡞ࡒ࠙ࡓࡗࠣ࡟࡯ࠩ࡯ࠍ↪޿ߚౝⷞ㏜ᚻⴚࠍⴕ߁‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦ጘ㒂⋵ౝߢߩዉ౉ߪߥߐࠇߡ߅ࠄߕ㧘⋵ਅೋ߼ߡߩዩ▤㏜ߩࡆ࠺ࠝൻ
࿖ౝ⊛⹏ଔ㧦ᓥ᧪ߩౝⷞ㏜ᚻⴚߦᲧߴߡ↹௝ࠍ࠺ࠫ࠲࡞ಣℂߒߡ߅ࠅ⚿⍹ᴦ≮ߩߺߥࠄߕ੹߹ߢ⸻ᢿ
ߢ߈ߥ߆ߞߚዩ▤߿⣢⋃ౝߩᓸዋߥ∛ᄌࠍᬌ಴น⢻ߣߥࠅ㧘ࠃࠅૐଚⷅߦᴦ≮࡮♖ኒᬌᩏ߇น⢻ߣߥࠆ‫⊒ߛ߹ޕ‬ᄁߐࠇߚ߫߆ࠅߢ࿖ౝߢ߽ᢙᣉ⸳ߒ߆ዉ౉ߐࠇߡ޿ߥ޿‫ޕ‬዁᧪⊛ߦ
ߪౝⷞ㏜ߪోߡࡆ࠺ࠝൻߩᣇะߦ޽ࠅ⋵ਅᦨೋߩዉ౉ᣉ⸳ߣߥࠆߎߣߪ⾰ߩ㜞޿ක≮ߩవ㚟ߌߣߥࠆ‫ޕ‬࿖㓙⊛⹏ଔ㧦࿖㓙⊛ߦ߽エᕈࡆ࠺ࠝዩ▤㏜ߪ 2 ␠߆ࠄߒ߆⊒ᄁߐࠇߡ߅ࠄߕ㧘߹ߛዉ౉ᣉ⸳ߪዋߥ޿
ߣᕁࠊࠇࠆ‫ޕ‬3㧕 ⸻≮ฬ 㧦⣢ᖡᕈ⣲≌ߦኻߔࠆ࡜ࠫࠝᵄ὾ἳ≮ᴺ
⸻≮ౝኈ㧦ᓥ᧪ߩᄖ⑼⊛ᴦ≮ᴺߩታᣉ߇࿎㔍ߥ߽ߩ෶ߪᄖ⑼⊛ᴦ≮ᴺߩታᣉߦࠃࠅᩮᴦᕈ߇ᦼᓙߢ߈
ߥ޿⣢ᖡᕈ⣲≌ߦኻߒߡ㧘⚻⊹⊛ߦ࡜ࠫࠝᵄ὾ἳ≮ᴺࠍⴕ߁‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦ጟጊᄢቇ∛㒮㧘੩ㇺᐭ┙ක⑼ᄢቇ㒝ዻ∛㒮㧘ਃ㊀ᄢቇකቇ㒝ዻ∛㒮࿖ౝ⊛⹏ଔ㧦㜞ᐲవㅴක≮ߢߪ਄⸥ 3 ᣉ⸳߇⊓㍳ߐࠇߡ߅ࠅⓍᭂ⊛ߦ࡜ࠫࠝᵄ὾ἳ≮ᴺࠍⴕߞߡ޿ࠆ‫ޕ‬߹ߚ㧘⃻࿷㧘⥃ᐥ⹜㛎߽ⴕࠊࠇߡ޿ࠆ㧔ᖡᕈ⣢⣲≌ߦኻߔࠆ⚻⊹⊛࡜ࠫࠝᵄಝ࿕≮ᴺߩ╙I/II ⋧⹜㛎 JIVROSG-0701㧕
‫੹ޕ‬ᓟ㧘ᄖ⑼⊛ᴦ≮࿎㔍∝଀ߩ╙৻ㆬᛯߣߥࠅᓧࠆᴦ≮ᴺߢ޽ࠆ‫ޕ‬࿖㓙⊛⹏ଔ㧦2000 ᐕߦႎ๔߇ᆎ߹ࠅ㧘2005 ᐕߩႎ๔ߢߪᄖ⑼⊛ಾ㒰ߦ඘ᢜߔࠆᴦ≮ᴺߢ޽ࠆߣߐࠇ
ߡ޿ࠆ‫ޕ‬
4㧚ኾ㐷ක࡮⹺ቯක࡮ᜰዉක಴ญ 㓉㧦ᣣᧄᴲዩེ⑼ቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄ߇ࠎᴦ≮⹺ቯකᯏ᭴ᥳቯᢎ⢒කᳯේ⧷ବ㧦ᣣᧄᴲዩེ⑼ቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄ߇ࠎᴦ≮⹺ቯකᯏ᭴ᥳቯᢎ⢒ක㧘ᣣᧄㅘᨆකቇળ⹺ቯ
ක࡮ᜰዉකદ⮮ᘕ৻㧦ᣣᧄᴲዩེ⑼ቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄㅘᨆකቇળ⹺ቯක࡮ᜰዉක
ખ㊁ᱜඳ㧦ᣣᧄᴲዩེ⑼ቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄ߇ࠎᴦ≮⹺ቯකᯏ᭴߇ࠎᴦ≮⹺ቯක࡮ᥳቯᢎ⢒ක㧘ᣣᧄᴲዩེ⑼ቇળ/ᣣᧄ Endourology࡮ESWL ቇળ⣻⣧㏜ᛛⴚ⹺ቯක㧘ᣣᧄౝⷞ㏜ᄖ⑼ቇળᛛⴚ
⹺ቯ[ᴲዩེ⣻⣧㏜]
ᮮ੗❥᣿㧦ᣣᧄᴲዩེ⑼ቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄᴲዩེ⑼ቇળ/ᣣᧄ Endourology࡮ESWL ቇળ⣻⣧㏜
ᛛⴚ⹺ቯක㧘ᣣᧄౝⷞ㏜ᄖ⑼ቇળᛛⴚ⹺ቯ[ᴲዩེ⣻⣧㏜]቟↰ ḩ㧦ᣣᧄᴲዩེ⑼ቇળኾ㐷ක࡮ᜰዉක㧘ICDධ⥪ ⻞㧦ᣣᧄᴲዩེ⑼ቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄ߇ࠎᴦ≮⹺ቯකᯏ᭴߇ࠎᴦ≮⹺ቯක㧘ICDጊᧄ⋥᮸㧦ᣣᧄᴲዩེ⑼ቇળኾ㐷ක࡮ᜰዉක
ਃベᅢ↢㧦ᣣᧄᴲዩེ⑼ቇળኾ㐷ක࡮ᜰዉක
࿯ደ᦮ᄢ㧦ᣣᧄᴲዩེ⑼ቇળኾ㐷ක㧘ᣣᧄㅘᨆකቇળ⹺ቯක
Ⴧᩕቁሶ㧦ᣣᧄᴲዩེ⑼ቇળኾ㐷ක
5㧚⥄Ꮖ⹏ଔ
⹏ଔవㅴ⊛ߥ⸻ᢿᴺ߿ᴦ≮ᴺࠍⓍᭂ⊛ߦዉ౉ߒߡᄢቇ∛㒮ߦ߅ߌࠆᴲዩེ⑼ߣߒߡߩᓎഀࠍᨐߚߒߡ޿ࠆ‫ޕ‬․ߦ㧘⣻⣧㏜ਅᚻⴚ㧘೨┙⣼≸ߩዊ✢Ḯ≮ᴺ㧘೨┙⣼⢈ᄢ∝ߦኻߔࠆ HoLEP㧘⣢⒖ᬀߦ㑐ߒߡߪ࿾ၞක
≮ࠍ࡝࡯࠼ߒߡ޿ࠆ‫ޕ‬ጘ㒂⋵㧘ᗲ⍮⋵㧘㕒ጟ⋵㧘ṑ⾐⋵ߦᷰࠆ㑐ㅪ∛㒮ࠍ߹ߣ߼㧘ᴲዩེ⑼ක≮ߩ⾰ߩะ਄ߣဋߡࠎ߆ࠍⴕ޿㧘ߐࠄߦ㧘ᄢⷙᮨߥ⥃ᐥ⎇ⓥࠍ⸘↹࡮ᣉⴕߒߡ޿ࠆ‫⧯ޕ‬ᚻᴲዩེ⑼කߩ⢒ᚑߦജࠍ౉
ࠇߡ޿ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ੱຬਇ⿷ߩߚ߼㧘ࠬ࠲࠶ࡈߩࠝ࡯ࡃ࡯ࡢ࡯ࠢ߇ᔃ㈩ߐࠇࠆ‫ޕ‬ห᭽ߩℂ↱ߢ㧘ኾ㐷ᄖ᧪ߩ᜛ల߇࿎㔍ߥ⁁ᴫߢ޽ࠆ‫ޕ‬㑐ㅪᣉ⸳ߣ⇣ߥࠅ㧘಴Ꮸߔߴ߈ળว߿ឭ಴ᦠ㘃߇ᄙ޿‫ߚ߹ޕ‬㧘એ೨߆ࠄකᏧ߳ߩ⥃ᐥ࡮ᢎ⢒એᄖߢߩᬺോ⽶ᜂ߇ᄙ߆ߞߚ߇㧘ᦨㄭ․ߦߎߩჇടࠍᗵߓࠆ‫ޕ‬એ਄ߩኻᔕ╷ߩ৻ߟߣߒߡ㧘ఝ⑲ߥࡊࡠࡈࠚ
࠶࡚ࠪ࠽࡞ߩࠢ࡜࡯ࠢߩ∛᫟㈩⟎߇ᦸ߹ࠇࠆ‫ޕ‬㧙㧙੹ᓟߩዷᦸ
ᴲዩེ⑼ߢߪ੹ᓟ߹ߔ߹ߔౝⷞ㏜ਅᚻⴚߩჇട߇੍᷹ߐࠇࠆ‫ޕ‬ᒰ⑼ߢ߽㧘ᴲዩེ⑼ᖡᕈ⣲≌ߦኻߒߡౝ
ⷞ㏜ਅᚻⴚ߇ዉ౉ߐࠇ߅ࠅ㧘ߘߩㆡᔕ᜛ᄢࠍ⋡ᜰߒߡ޿ࠆ‫ޕ‬ౝⷞ㏜ᚻⴚࠍ㑐ㅪ∛㒮߽߳᥉෸ߐߖࠆߚ߼ߩ
ᢎ⢒ࠪࠬ࠹ࡓߩᢛ஻ࠍ൘߼ߡ߈ߚ߇㧘ߐࠄߦ㧘੹ᓟߪઁᄢቇߣ߽੤ᵹߔࠆߎߣߦࠃࠅផߒㅴ߼ߡ޿ߊ‫ޕ‬ࠃࠅኾ㐷⊛ߥ⍮⼂߅ࠃ߮ᛛⴚࠍⷐߔࠆ∔ᖚߦኻߒߡߪ㧘ኾ㐷ᄖ᧪ࠍ⸳ߌߡᦨᣂߩ⸻ᢿ࡮ᴦ≮ᛛⴚࠍឭଏ
ߢ߈ࠆ૕೙ࠍ᭴▽ߔࠆ‫ޕ‬㧙㧙㧔15㧕♖␹␹⚻⑼
1㧚⸻≮ߩ᭎ⷐ
⃻ઍߩ␠ળ↢ᵴߩᄙ᭽ൻߦ઻ߞߡ㧘♖␹␹⚻⑼ߩᄖ᧪ࠍ⸰ࠇࠆᖚ⠪ጀ߽ᄙ᭽ൻߒߡ߈ߡ޿ࠆ‫߼ߚߩߎޕ‬㧘ዊఽ߆ࠄ⠧ᐕᦼߦ⥋ࠆ߹ߢߩ࡜ࠗࡈࠨࠗࠢ࡞ߦᔕߓߚ㧘ᄙ᭽ߥኻᔕ߇᳞߼ࠄࠇߡ޿ࠆ‫ߚ߹ޕ‬㧘ᒰ⑼ߩ․ᓽ
ߣߒߡ୘‫ߩੱޘ‬ᚑ⢒ᱧ߿ኅᐸⅣႺߥߤߦߟ޿ߡ⹦ߒߊᛠីߒ㧘ኻᔕߒߡ޿ߊߎߣ߇᳞߼ࠄࠇࠆߚ߼㧘౉㒮㨯ᄖ᧪ߣ߽ߦቢోਥᴦක೙ࠍណ↪ߒ㧘৻⽾ߒߚᴦ≮ࠍⴕ߁ࠃ߁ദ߼ߡ޿ࠆ‫ߚ߹ޕ‬ട߃ߡ㧘ㄭᐕჇടߔࠆఽ┬㨯ᕁᤐᦼߩ໧㗴ߦኻᔕߔࠆߚ߼㧘ᐔᚑ 13 ᐕ 4 ᦬ࠃࠅఽ┬ᄖ᧪ࠍ㐿⸳ߒ㧘᳓ᦐඦᓟߦ੍⚂೙ߢኾ㐷ߩකᏧߣ⥃ᐥᔃℂ჻߇ኻᔕߒߡ޿ࠆ‫ߦࠄߐޕ‬㧘ᐔᚑ 14 ᐕ 1 ᦬ࠃࠅ‫ߩ߽ޟ‬ᔓࠇᄖ᧪‫ࠍޠ‬㐿⸳ߒ㧘ኾ㐷ߩකᏧ߇⸻ኤ
ࠍⴕ߁ߎߣߢ㧘ㄭᐕᕆㅦߦㅴࠎߢ޿ࠆ㜞㦂␠ળߦ߅ߌࠆ᭽‫␹♖ߥޘ‬කቇ⊛໧㗴ߦ߽ኻಣߒߡ߈ߚ‫ޕ‬
2㧚ᢎ⢒ᣉ⸳
1㧕 ᣣᧄ♖␹␹⚻ቇળ♖␹⑼ኾ㐷ක⎇ୃᣉ⸳㧘ᣣᧄ✚ว∛㒮♖␹කቇળኾ㐷ක⎇ୃᣉ⸳㧘ᣣᧄ⠧ᐕ♖␹කቇળ⹺ቯᣉ⸳
3㧚⸻≮㐿⊒
1㧕 ⸻≮ฬ 㧦⑌ᾍߩ⛔ว⊛ᴦ≮⸻≮ౝኈ㧦⑌ᾍࠍ⛽ᜬߢ߈ߥ޿㧘޿ࠊࠁࠆ࠾ࠦ࠴ࡦଐሽߦኻߒ㧘⹺⍮≮ᴺߣ⡊੺ᴦ≮㧔Electro Medical
Stim Flex 400A ࠍ૶↪㧕ߩ૬↪ߦࠃࠆ⛔ว⊛ᴦ≮ࠍⴕ޿⑌ᾍ⛽ᜬ₸ࠍ㜞߼ࠆ‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦޿ߕࠇߩᣥ࿖┙ᄢቇකቇㇱ㒝ዻ∛㒮ߦ߅޿ߡ߽ዉ౉ߐࠇߡ޿ߥ޿‫ޕ‬࿖ౝ⊛⹏ଔ㧦ߎࠇ߹ߢ㧘࠾ࠦ࠴ࡦଐሽߦኻߔࠆ⹺⍮≮ᴺߣ⡊੺ᴦ≮ߪ㧘࿖ౝߢߪߏߊ৻ㇱߩක≮ᯏ㑐ߢߘࠇߙࠇ⹜㛎⊛ߦⴕࠊࠇߡ޿ࠆߦߔ߉ߥ޿߇㧘৻ቯߩലᨐߪ⹺߼ࠄࠇߡ޿ࠆ‫ޕ‬࿖㓙⊛⹏ଔ㧦᰷☨⻉࿖ߢߪ㧘࠾ࠦ࠴ࡦଐሽߦኻߔࠆ⹺⍮≮ᴺߪ୘ੱ࡟ࡌ࡞޽ࠆ޿ߪ㓸࿅࡟ࡌ࡞ߢⴕࠊ
ࠇߡ߅ࠅ㧘ߘߩ᦭ലᕈߪᐢߊ⹺߼ࠄࠇߡ޿ࠆ‫ߚ߹ޕ‬㧘⡊੺ᴦ≮ߪ☨࿖ߩ৻ㇱߩᎺߦ߅޿ߡ
଻㒾ㆡᔕߣߥߞߡ޿ࠆ‫ޕ‬
4㧚ኾ㐷ක࡮⹺ቯක࡮ᜰዉක
Ⴎ౉ବ᮸㧦ᣣᧄ♖␹␹⚻ቇળᜰዉක㧘ᣣᧄ⥃ᐥ♖␹␹⚻⮎ℂቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄ✚ว∛㒮♖␹කቇળኾ㐷ක㧘ෘ↢ഭ௛⋭♖␹଻ஜᜰቯක㜞ጟ ஜ㧦ᣣᧄ♖␹␹⚻ቇળᜰዉක㧘ᣣᧄఽ┬㕍ᐕ♖␹කቇળ⹺ቯක㧘ᣣᧄ✚ว∛㒮♖␹කቇળኾ㐷ක࡮ᜰዉක㧘ෘ↢ഭ௛⋭♖␹଻ஜᜰቯක
ᬀᧁ໪ᢥ㧦ᣣᧄ♖␹␹⚻ቇળᜰዉක㧘ࡊ࡜ࠗࡑ࡝ࠤࠕቇળ⹺ቯක㧘ᣣᧄ✚ว∛㒮♖␹කቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄ⠧ᐕ♖␹කቇળኾ㐷ක㧘ᣣᧄකᏧળ⹺ቯ↥ᬺක㧘ෘ↢ഭ௛⋭♖␹଻ஜᜰቯක
㜞↰⍮ੑ㧦ᣣᧄ♖␹␹⚻ቇળᜰዉක㧘ᣣᧄ⠧ᐕ♖␹කቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄ✚ว∛㒮♖␹කቇળኾ㐷ක࡮ᜰዉක㧘ෘ↢ഭ௛⋭♖␹଻ஜᜰቯක
ᷓየ ℉㧦ᣣᧄ♖␹␹⚻ቇળᜰዉක㧘ෘ↢ഭ௛⋭♖␹଻ஜᜰቯක
ᚭፒᘕᄥ㇢㧦ෘ↢ഭ௛⋭♖␹଻ஜᜰቯක
ᄤ㊁㓶ᐔ㧦ᣣᧄౝ⑼ቇળౝ⑼⹺ቯක㧘ᣣᧄකᏧળ⹺ቯ↥ᬺක
5㧚⥄Ꮖ⹏ଔ
⹏ଔᄖ᧪ߣߒߡߪᄙ᭽ߥᖚ⠪ߦኻᔕߢ߈ࠆࠃ߁ߥ૕೙߇ᢛ޿ߟߟ޽ࠆ߇㧘ᢎ⢒ᣉ⸳ߣߒߡᦝߥࠆలታࠍ࿑ࠅ㧘⎇ୃකᢎ⢒㧘ᓟᦼ⎇ୃߦ߽චಽߦ㝯ജ޽ࠆ૕೙ࠍᢛ߃ߡ޿ߊᔅⷐ߇޽ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ኾ㐷ᄖ᧪ߩࠬ࠲࠶ࡈߩ⢒ᚑ߅ࠃ߮ᄖㇱᯏ㑐ߣߩㅪ៤߇⺖㗴ߣߒߡ޽ߍࠄࠇࠆ‫ߚ߹ޕ‬㧘౉㒮ᴦ≮ߦ߅޿ߡ߽ᐔဋ࿷㒮ᣣᢙߩ⍴❗ൻࠍ⋡ᮡߣߒߡ޿ࠆ߇㧘ߎߩὐߦߟ޿ߡߪ↵ᕈ⋴⼔Ꮷߩᄢ᏷ߥჇຬࠍ฽߻㧘⋴⼔ㇱߣߩㅪ៤߇ਇนᰳߢ޽ࠆ‫ޕ‬ᐔဋ࿷㒮ᣣᢙߩ⍴❗ൻߦ㑐ߒߡߪᓢ‫ߦޘ‬ᡷༀ߇࿑ࠄࠇߡ޿ࠆߣߎࠈߢ޽ࠆ‫ޕ‬੹ᓟߩዷᦸ⃻ઍ␠ળߦ߅޿ߡ㧘♖␹⑼ක≮ߦኻߔࠆ㔛ⷐߪ߹ߔ߹ߔᄢ߈ߊߥߞߡࠁߊ߽ߩߣ⠨߃ࠄࠇߡ޿ࠆ‫ߚ߹ޕ‬㧘
ᐔᚑ 16 ᐕᐲࠃࠅታᣉߐࠇߡ޿ࠆᣂකᏧ⥃ᐥ⎇ୃක೙ᐲߢߪ㧘♖␹⑼⎇ୃߪᔅୃߣߥߞߡ޿ࠆ‫ࠇࠊࠇࠊޕ‬߇චಽߦߘߩᓎഀࠍᨐߚߖࠆࠃ߁㧘ኾ㐷ࠬ࠲࠶ࡈߩᛛⴚะ਄ߦദ߼㧘⾗ᩰขᓧࠍផㅴߒ㧘ᤨઍߩ࠾࡯࠭ߦ
ᔕ߃ߡࠁߊߎߣࠍ⋡ᮡߣߒߚ޿‫ޕ‬㧙㧙㧔16㧕ዊఽ⑼1㧚⸻≮ߩ᭎ⷐ
ዊఽߩోಽ㊁ߦࠊߚࠆኾ㐷ක≮ߣዊఽක≮৻⥸ࠍᜂᒰߒߡ޿ࠆ‫ ߚ߹ޕ‬3 ᰴ㧘2 ᰴߪ߽ߜࠈࠎߩߎߣ㧘1ᰴߩᢇᕆක≮߽ⴕߞߡ߅ࠅ㧘࿾ၞක≮߽߳ᄢ޿ߦ⽸₂ߒߡ޿ࠆ‫ޕ‬ᄖ᧪⸻≮ߢߪዊఽ⑼ో૕ߩᄖ᧪ᖚ⠪ᢙ߽ᐕ‫ޘ‬Ⴧടߒߡᐕ㑆 16,000 ੱࠍ⿥߃ߡ޿ࠆ‫৻ޕ‬ᣇ㧘౉㒮ᖚ⠪ᢙ߽ᐕ㑆 1,000 ੱࠍ⿥߃ߡ޿ࠆ‫ޕ‬365 ᣣ 24 ᤨ㑆ᖚ⠪ࠍⓍᭂ⊛ߦฃߌ౉ࠇߡ޿ࠆ‫ޕ‬45 ᐥߩࡌ࠶࠼ߩⒿ௛₸ߪᏱߦ 100㧑ࠍ⿥߃ߡ޿ߚ߇㧘ᦨㄭߪ⋴⼔૕೙ߩᡷᄌߦࠃࠅ޽ࠆ⒟ᐲ⺞▵ߒߡ޿ࠆ‫ߩߘޕ‬㗔ၞߪ㧘ዊఽ⑼ో⥸ߢ㧘৻⥸ߣߒߡ✚ว⸻≮⊛ⷐ⚛ࠍ߽ߟ৻ᣇߢ㧘ᭂ߼ߡ㜞޿ኾ㐷ᕈⷐ⚛ࠍ߽ߟ‫ߪࠄࠇߘߜࠊߥߔޕ‬㧘಴↢೨ዊఽ⑼ቇ㧘ዊఽߩᚑ㐳⊒㆐㧘ࠕ࡟࡞ࠡ࡯㧘఺∉㧘⤔ේ∛㧘ઍ⻢㧘ౝಽᴲ㧘␹⚻㧘ᔃり∝㧘ᓴⅣེ㧘๭ๆེ㧘⣢㧘⢄ᶖൻེ㧘ⴊᶧ⣲≌㧘ᗵᨴ㧘ᣂ↢ఽ㧘⸒⺆⊒㆐㧘ㆮવ⋧⺣ߥߤో㗔ၞߦ෸߱‫ߦࠄߐޕ‬એਅߩࠃ߁ߦ㧘㜞ᐲߥవㅴක≮ࠍⴕߞߡ޿ࠆ‫ޕ‬ࠕ࡟࡞ࠡ࡯࡮๭ๆེ
ࠕ࠻ࡇ࡯ᕈ⊹⤏Ἳ࡮᳇▤ᡰ༎ᕷ࡮ߓࠎ߹∐࡮㘩‛ࠕ࡟࡞ࠡ࡯࡮ㆇേ⺃⊒༎ᕷߥߤࠕ࡟࡞ࠡ࡯ో⥸‫ޕ‬਎⇇⊛ߥࠕ࠻ࡇ࡯ㆮવሶߩ⸃᣿ࠍⴕߞߡ߅ࠅ㧘ߘࠇߦ߽ߣߠߊㆮવሶ⸻ᢿ߅ࠃ੍߮⍮㧘੍㒐ߣࠝ࡯࠳࡯ࡔࠗ࠼
ᴦ≮ࠍⴕߞߡ޿ࠆ‫ޕ‬㘩‛ࠕ࡟࡞ࠡ࡯ߢߪ㧘਎⇇⊛ߥ࡟ࡌ࡞ߩ㜞޿∛ᘒ⸃ᨆ߆ࠄ㕖හᤨဳ෻ᔕߩ᭎ᔨࠍᛂߜ
಴ߒ㧘᛫ේ․⇣⊛࡝ࡦࡄ⃿ᐜ⧯ൻ෻ᔕ߅ࠃ߮ࠨࠗ࠻ࠞࠗࡦ↥↢㧘㘩‛⽶⩄⹜㛎ߥߤࠍ⸻≮ߦขࠅ౉ࠇ㧘ㆊᐲߥ㒰෰㘩≮ᴺࠍㆱߌࠆࠃ߁ߦദ߼ߡ޿ࠆ‫⚻ޕ‬ญ఺∉ኡኈ⺃ዉ≮ᴺࠍㅴ߼ߡ޿ࠆ‫ޕ‬᳇▤ᡰ༎ᕷߢߪ㧘ࠕ࡟࡞ࠡ࡯㧘⢖ᯏ⢻㧘ࠕ࡜ࠠ࠼ࡦ㉄ઍ⻢↥‛ߩ⸃ᨆߦࠃࠅ㧘∛ᘒߦᔕߓߚᴦ≮ߩㆬᛯࠍⴕߞߡ޿ࠆ‫ޕ‬㧔ࠝ࡯࠳࡯ࡔࠗ࠼ᴦ≮࡮੍㒐‫ޕ‬㧕̌᳇▤ᡰ༎ᕷߩ࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮▤ℂᴺߩߚ߼ߩᚻᒁ߈̍ࠍ૞ᚑߒߚ‫ޕ‬㊀∝ࠕ࠻ࡇ࡯ᕈ⊹⤏Ἳ࡮༎ᕷᖚ⠪ߢߪ㧘◲ᤃࠢ࡝࡯ࡦⵝ⟎ࠍ↪޿ߚᴦ≮ߢ⪺᣿ߥᡷༀࠍᓧߡ޿ࠆ‫ࠍఽࠢࠬ࡝ࠗࡂޕ‬ኻ⽎ߣߒߚ੍㒐ធ⒳߽ⴕߞߡ޿ࠆ‫ޕ‬๭ๆེߢߪ㧘᳇▤ᡰࡈࠔࠗࡃ࡯߽ⴕߞߡ޿ࠆ‫ޕ‬఺∉߅ࠃ߮ᗵᨴ
ᗵᨴ∝ో⥸ߩ⸻ᢿ࡮ᴦ≮ࠍⴕߞߡ޿ࠆ‫߿ߗ߆ޕ‬ᗵᨴ∝ߦ߆߆ࠅ߿ߔ޿ఽ㧘ේ⊒ᕈ఺∉ਇో∝㧘⥄Ꮖ఺∉∔ᖚ㧔⤔ේ∛㧕㧘⧯ᐕᕈ㑐▵࡝࠙ࡑ࠴ߥߤߩ⸻ᢿߣᴦ≮ࠍⴕߞߡ޿ࠆ‫ޕ‬ήࠟࡦࡑࠣࡠࡉ࡝ࡦⴊ∝ߦኻߒߡቯᦼ⊛ߦ⵬ల≮ᴺ㧘߹ߚ㧘఺∉ਇో∝ߦኻߒߡ㛽㜑⒖ᬀ߿⤯Ꮺⴊ⒖ᬀࠍⴕ޿ᚑᨐࠍ޽ߍߡ޿ࠆ‫ޕ‬వᄤᕈ఺∉ਇో∝ߩฦ∛ဳߩ∛࿃ㆮવሶ⸃᣿ߣㆮવሶ⸻ᢿߣᴦ≮ࠍ♖ജ⊛ߦⴕߞߡ޿ࠆ‫ߦ․ޕ‬㧘
Ataxia-telangiectasia, Bloom ∝୥⟲ߦኻߒലᨐ⊛ߥ⸻ᢿ࡮▤ℂࠍⴕߞߡ޿ࠆ‫ޕ‬਎⇇ߦవ㚟ߌߡ᣿ࠄ߆ߦ
ߒߚ IgG2 ᰳ៊∝ߩ∛࿃ߣߥࠆㆮવሶ⇣Ᏹ߽ㆮવሶ⸻ᢿߦᔕ↪ߐࠇߡ޿ࠆ‫ޕ‬ㄭᐕ㧘᣿ࠄ߆ߦߐࠇߡ߈ߚ⥄ᏆἻ∝∝୥⟲߿⥄ὼ఺∉♽ߩ⇣Ᏹߦߟ޿ߡ߽⸃ᨆߣᴦ≮㐿⊒ࠍᆎ߼ߡ޿ࠆ‫ޕ‬␹⚻࡮╭∔ᖚ
⸒⺆㧘ㆇേ⊒㆐ߩㆃࠇ߆ࠄᕆᕈ㧘ᘟᕈߩ␹⚻╭∔ᖚ㧘ߡࠎ߆ࠎᖚ⠪ߦ⥋ࠆ߹ߢ MRI࡮MRS࡮SPECTߥߤߩᦨᣂ↹௝ⵝ⟎߿㔚᳇↢ℂ㧘ࡆ࠺ࠝ⣖ᵄหᤨ⸥㍳ⵝ⟎ߐࠄߦߪㆮવሶ⸃ᨆ╬ࠍ↪޿ߡ⸻ᢿ࡮ᴦ≮ࠍⴕߞߡ޿ࠆ‫ޕ‬వᄤઍ⻢⇣Ᏹ∝ฦ⒳వᄤઍ⻢⇣Ᏹ∝ߩ⸻ᢿߣᴦ≮ࠍ᏷ᐢߊⴕߞߡ޿ࠆ‫∛ࡓ࡯࠰ࠪࠠࠝ࡞ࡍߦ․ޕ‬㧘࡝࠰࠱࡯ࡓ∛㧘᦭ᯏ㉄ઍ⻢⇣Ᏹ∝ߦߟ޿ߡߪ࿖ౝߢ߽᦭ᢙߩࠬࠢ࡝࡯࠾ࡦࠣ࡮⸻ᢿ࡮⎇ⓥ࠮ࡦ࠲࡯ߣߒߡᯏ⢻ࠍᨐߚߒߡ߅ࠅ㧘㧔㜞ᐲ㧕వㅴක≮㧔ၭ㙃⚦⢩ߦࠃࠆవᄤઍ⻢⇣Ᏹ⸻ᢿ㧕߽ታᣉߒߡ޿ߚ㧔⃻࿷ᡷ߼ߡవㅴක≮ߣߒߡ⊓㍳↳⺧Ḱ஻ਛ㧕‫ޕ‬ᴦ≮ߣߒߡ㉂⚛⵬ల≮ᴺ߿㛽㜑⒖ᬀߥߤ߽ⴕߞߡ޿ࠆ‫ޕ‬ㆮવ⋧⺣ᄖ᧪
એ೨ࠃࠅઍ⻢⇣Ᏹ࡮వᄤᕈ఺∉ਇో∝㧘ᨴ⦡૕⇣Ᏹߥߤߩ⸻ᢿߣㆮવ⋧⺣ࠍⴕߞߡ߈ߚ߇㧘ㄭᐕߩㆮવ
ሶක≮ߩㅴᱠߦኻᔕߒ㧘ᖚ⠪ߐࠎ߳ߩᱜ⏕ߥᖱႎવ㆐ߣࠞ࠙ࡦ࠮࡝ࡦࠣࠍ⋡⊛ߣߒߡ㧘↢߹ࠇߟ߈ߩ∛᳇ߛߌߢߥߊ㧘ᚑੱߒߡ߆ࠄ⊒∛ߔࠆㆮવ∛ߦߟ޿ߡ߽ኻᔕߒߡ޿ࠆ‫߅ޕ‬ሶߐࠎߩߎߣ㧘ߏ⥄ಽ߿ߏኅᣖߩ
ߎߣߢ㧘ㆮવߦߟ޿ߡ⹦ߒߊ⍮ࠅߚ޿㧘ᖠߺࠍ⋧⺣ߒߚ޿㧘ߣ޿߁ᣇߩߏ⋧⺣ߦᔕߓߡ޿ࠆ‫ޕ‬ᐔᚑ 20 ᐕᐲ߆ࠄጘ㒂ᄢቇකቇㇱ㒝ዻ∛㒮߇ో࿖ㆮવሶක≮ㇱ㐷ㅪ⛊ળ⼏ߩᱜᑼળຬߣߥࠅ㧘ᒰ㒮ߢߪ߹ߛㇱ㐷ߢߪߥ޿߇㧘ో࿖ߩㆮવሶක≮ㇱ㐷ߣߩㅪ⛊੤ᵹࠍ߽ߟߎߣߦߥߞߚ㧔̌ㇱ㐷̍ઍ⴫⠪ߣߒߡㄭ⮮⋥ታ㧘ᷓየᢅᐘߢ⊓㍳㧕‫ޕ‬ᔃり∝ఽ┬ߩᔃℂ⊛⢛᥊ࠍ߽ߟり૕∝⁁߿ⴕേ਄ߩ໧㗴㧘੃ᐜఽߩ⢒ఽߦ㑐ߔࠆᔃℂ⊛ߥ໧㗴ߦߟ޿ߡ㧘ᧄੱ߿ኅᣖߦኻߔࠆ⋧⺣ࠍⴕߞߡ޿ࠆ‫ޕ‬ⴊᶧ࡮⣲≌⊕ⴊ∛㧘ᖡᕈ࡝ࡦࡄ⣲㧘␹⚻⧘⚦⢩⣲ࠍߪߓ߼ߣߔࠆ࿕ᒻ⣲≌╬ߩᖡᕈ∔ᖚߩ⸻ᢿᴦ≮㧘߹ߚ⽺ⴊ㧘಴ⴊᕈ∔ᖚ㧘ṁⴊᕈዩᲥ∝∝୥⟲ߥߤⴊᶧ∔ᖚో⥸ߩ⸻ᢿᴦ≮߽ⴕߞߡ޿ࠆ‫∔ޕ‬ᖚߦᔕߓߡൻቇ≮ᴺߩઁߦ
㛽㜑⒖ᬀ߽ⴕߞߡ޿ࠆ‫ޕ‬

㧙㧙

ᓴⅣེ
ቇᩞᬌ⸻ߩ♖ᩏ㧘వᄤᕈᔃ∔ᖚ㧘ᓟᄤᕈᔃ∔ᖚ㧘ਇᢛ⣂㧘Ꮉፒ∛ߩᔃ⤳ว૬∝ߥߤᓴⅣེ∔ᖚో⥸ߦࠊߚࠅ᏷ᐢߊ⸻≮ߒߡ޿ࠆ‫ޕ‬ᬌᩏߪ࠼ࡊ࡜࡯ᔃࠛࠦ࡯㧘ㆇേ⽶⩄ᔃ㔚࿑㧘ᔃ⤳ࠞ࠹࡯࠹࡞╬ࠍⴕߞߡ޿ࠆ‫ޕ‬ᔃ∔ᖚఽߩቇᩞ↢ᵴ▤ℂߦߟ޿ߡ㧘ࡎ࡞࠲࡯ᔃ㔚࿑߿ㆇേ⽶⩄ᔃ㔚࿑ᬌᩏ╬ࠍ߽ߣߦㆡಾߥㆇേಣᣇࠍⴕ
ߞߡ޿ࠆ‫ޕ‬WPW ∝୥⟲ߥߤߩਇᢛ⣂∔ᖚߦኻߒ㧘㜞๟ᵄߦࠃࠆ㔚᳇⊛὾ἳⴚ㧔㜞๟ᵄࠞ࠹࡯࠹࡞ࠕࡉ࡟
࡚ࠗࠪࡦ㧕ࠍⴕߞߡ޿ࠆ‫ޕ‬⣢⤳ቇᩞᬌዩ╬ߦߡⷐ♖ኒᬌᩏߣߥߞߚ߅ሶߐࠎࠍ฽߼㧘ฦ⒳⣢∔ᖚߩᴦ≮࡮↢ᵴᜰዉࠍⴕߞߡ޿ࠆ‫ޕ‬ᣂ↢ఽ∛⊛ᣂ↢ఽߩ౉㒮▤ℂߣᣂ↢ఽᦼߦ౉㒮ࠍᔅⷐߣߐࠇߚ⿒ߜ߾ࠎࠍਥߣߒߡ㧘ߘߩᓟߩ⊒㆐ߦߟ޿ߡቯ
ᦼᬌ⸻߿ᜰዉࠍⴕߞߡ޿ࠆ‫ޕ‬ౝಽᴲዊੱ∝࡮ᕁᤐᦼᣧ⊒∝㧘♧ዩ∛㧘↲⁁⣼ᯏ⢻⇣Ᏹߥߤฦ⒳ౝಽᴲ⇣Ᏹߩ⸻ᢿ࡮ᴦ≮ࠍⴕߞߡ޿ࠆ‫ޕ‬⢄⤳㤛∏߇㐳ᒁߊ੃ఽ㧘⒳‫ࠬ࡞ࠖ࠙ߩޘ‬ᕈ⢄Ἳߩᴦ≮㧘⢄∔ᖚߩ⸻ᢿߣᴦ≮ࠍⴕߞߡ޿ࠆ‫ޕ‬⢄Ἳ࠙ࠖ࡞ࠬߩ
Უሶᗵᨴߩ੍㒐ߣᴦ≮߽ⴕߞߡ޿ࠆ‫ޕ‬ᶖൻེX ✢ㅧᓇ㧘ዊఽᄢ⣺ౝⷞ㏜ࠍ↪޿ߚᶖൻེ∔ᖚߩᬌᩏ࡮ᴦ≮ࠍⴕߞߡ޿ࠆ‫ޕ‬
2㧚ᢎ⢒ᣉ⸳
1㧕 ᣣᧄዊఽ⑼ቇળ⹺ቯᣉ⸳
2㧕 ᣣᧄࠕ࡟࡞ࠡ࡯ቇળ⹺ቯᣉ⸳
3㧕 ᣣᧄੱ㘃ㆮવቇળ⹺ቯᣉ⸳
3㧚⸻≮㐿⊒
1㧕 ⸻≮ฬ 㧦ࠕ࡟࡞ࠡ࡯ߩ࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮⸻≮ౝኈ㧦ࠕ࡟࡞ࠡ࡯෻ᔕߩ∛ᘒߩ⹦⚦߇⋧ᒰ᣿ࠄ߆ߦߥࠅ㧘᛫ේ㧔ࠕ࡟࡞ࠥࡦ㧕ߩ↢૕߳ߩଚ౉߆
ࠄ∝⁁⊒⃻ߦ⥋ࠆ∛ᘒߪ఺∉ቇ⊛ߥࠄ߮ߦಽሶㆮવቇ⊛ߦ⸃᣿ߐࠇߡ߈ߚ‫ߢߎߘޕ‬㧘୘ੱ୘ੱߩࠕ࡟࡞ࠡ࡯∔ᖚߩࡃ࠶ࠢࠣ࡜࠙ࡦ࠼ࠍㄦㅦ߆ߟ◲ଢߦ᣿ࠄ߆ߦߔࠆߎߣߢ㧘୘‫ߦޘ‬ᔕߓߚᴦ≮ᴺࠍㆬᛯߔࠆߎߣ߇ߢ߈㧘ᴦ≮ᴺߩㆬᛯ߇น⢻ߣߥࠆ‫ౕޕ‬૕⊛ߦߪ㧘ࠕ࠻ࡇ࡯ᕈ⊹⤏Ἳߦኻߔࠆࠢ࡝࡯ࡦ࡞࡯ࡓߩᵴ↪㧘LST ߩ⥃ᐥᔕ↪㧘⮎೷ߩ࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮㧘㘩‛ࠕ࡟࡞ࠡ࡯ߩ↹ᦼ⊛ߥ఺∉ኡኈ⃻⽎ߩᔕ↪ߥߤߢ޽ࠆ‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦ᒰ㒮ߦߡ㐿⊒ߒߚ⁛⥄ߩࠪࠬ࠹ࡓߢ޽ࠅ㧘ઁ∛㒮ߢߪዉ౉ߐࠇߡ޿ߥ޿
࿖ౝ⊛⹏ଔ㧦ㆮવሶ⸃ᨆߦ㑐ߒߡߪ㧘ࠗࡦࡌ࡯࠳࡯ࠕ࠶࠮ࠗᴺࠍ೑↪ߔࠆߎߣߢ㧘᣿ࠄ߆ߦߥߞߚⶄ
ᢙߩㆮવሶ⇣Ᏹࠍ⚵ߺวࠊߖ㧘ࡄࡀ࡞ൻߒㄦㅦߦ᷹ቯߔࠆߎߣ߇ߢ߈ࠆࠃ߁ߦ࠮࠶࠹ࠖࡦ
ࠣߒߚ‫ޕ‬㧔⃻࿷․⸵౏㐿ਛߢ޽ࠆ‫ޕ‬㧕ߎࠇߦࠃࠅ୘‫∔࡯ࠡ࡞࡟ࠕߩޘ‬ᖚߩ∛࿃∛ᘒߦᔕߓߚ
ᴦ≮ᴺߩㆬᛯ߇น⢻ߣߥࠆ‫ߚ߹ޕ‬㧘⊒∝೨ߩ႐วߪ㧘ⅣႺ࿃ሶ߳ߩචಽߥኻᔕࠍߪ߆ࠆߎ
ߣߦࠃࠅ⊒∝੍㒐ߦ߽ᄢ޿ߦᓎ┙ߟߣ⠨߃ࠆ‫ޕ‬࿖㓙⊛⹏ଔ㧦ࠕ࡟࡞ࠡ࡯ߩ∛ᘒ⸃ᨆࠃࠅ㧘ࠨࠗ࠻ࠞࠗࡦߩ↥↢ߣ෻ᔕᕈߩ⇣Ᏹ߇ሽ࿷ߔࠆߎߣࠍ᣿ࠄ
߆ߦߒߡ߈ߚ㧔Clin Exp Allergy , 2000㧕‫ߦࠄߐޕ‬㧘ࠨࠗ࠻ࠞࠗࡦߩࠪࠣ࠽࡞ߦ㑐ࠊࠆㆮવሶࠍ⸃ᨆߒ㧘IgE ↥↢ߩᛥ೙♽ߩਛߢ㧘IL-12 ࠪࠣ࠽࡝ࡦࠣਛߩㆮવሶᄌ⇣ߩ⸃ᨆࠍߔߔ
߼ߚ⚿ᨐ㧘޿ߊߟ߆ߩ୥⵬ㆮવሶߩหቯߦᚑഞߒߡ޿ࠆ㧔Biochem Biophys ResCommun,
1999㧘J Allergy Clin Immunol, 2002㧘Int J Mol Med, 2003 ઁ㧕‫ޕ‬2㧕 ⸻≮ฬ 㧦఺∉ၮ␆⎇ⓥߦၮߠߊ㘩‛ࠕ࡟࡞ࠡ࡯ኻ╷㘩ຠߩ↹ᦼ⊛ഃᚑ⸻≮ౝኈ㧦㘩‛ࠕ࡟࡞ࠡ࡯ᖚ⠪ࠍ⊛⏕ߦ⸻ᢿߒ㧘᛫ේࠛࡇ࠻࡯ࡊࠍ᣿ࠄ߆ߦߔࠆ‫ߦࠄߐޕ‬㧘੹߹ߢߪ㒰෰㘩≮ᴺߒ߆ߥ߆ߞߚ㘩‛ࠕ࡟࡞ࠡ࡯ߦኻߒߡ㧘޽ࠄߚߦ᛫ේࠛࡇ࠻࡯ࡊࠍୃ㘼ߒ㧘Ⓧᭂ⊛ߦ఺∉ኡኈࠍ⺃ዉߐߖ̌㘩ߴߡᴦߔ̍↹ᦼ⊛ࠕ࡟࡞ࠡ࡯ኻ╷㘩ຠߩ㐿⊒ࠍ߅ߎߥ޿㧘㘩‛ࠕ࡟࡞ࠡ࡯ࠍ੍㒐ᴦ≮ߔࠆ‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦ᒰ㒮ߦߡ‐੃ࠕ࡟࡞ࠡ࡯ߩ᛫ේࠛࡇ࠻࡯ࡊࠍ᣿ࠄ߆ߦߒߡ߅ࠅ㧘‐੃㧘ᄢ⼺㘩ຠߩ㐿⊒߽ᒰ㒮⁛⥄ߩ߽ߩߢ㧘ઁ∛㒮ߢߪ߅ߎߥࠊࠇߡ޿ߥ޿‫ޕ‬࿖ౝ⊛⹏ଔ㧦ߎߩ⸻≮㐿⊒ߪ↢‛♽↥ᬺഃ಴ߩߚ߼ߩ⇣ಽ㊁⎇ⓥᡰេ੐ᬺߦㆬቯߐࠇ㧘ࡆ࡯ࡦࠬ࠲࡯
ࠢࠬࡁ࡯ᩣᑼળ␠ߥߤߣ౒หߢࠕ࡟࡞ࠡ࡯ኻ╷㘩ຠߩ㐿⊒ࠍㅴ߼ߡ޿ࠆ‫ޕ‬࿖㓙⊛⹏ଔ㧦਎⇇ߢೋ߼ߡ‐੃ߩਥⷐࠕ࡟࡞ࠥࡦߢ޽ࠆE-࡜ࠢ࠻ࠣࡠࡉ࡝ࡦߩ᛫ේࠛࡇ࠻࡯ࡊࠍ᣿ࠄ

㧙㧙߆ߦߒߚ‫ޕ‬㘩‛ࠕ࡟࡞ࠡ࡯ᖚ⠪ߩ᛫ේࠛࡇ࠻࡯ࡊ㧘఺∉ቇ⊛⸃ᨆߦߟ޿ߡᢙᄙߊႎ๔ߒߡ
޿ࠆ㧔Clin Exp Allergy 31: 1126-1134, 2001; Clin Exp Allergy 32: 762-770, 2002; Clin
Exp Allergy 32: 1223-1230, 2002㧕‫ޕ‬
3㧕 ⸻≮ฬ 㧦వᄤᕈ఺∉ਇో∝୥⟲ߩㆮવሶ⸻ᢿ
⸻≮ౝኈ㧦Ataxia-telangiectasia ߅ࠃ߮ Bloom ∝୥⟲㧘ㆬᛯ⊛఺∉ࠣࡠࡉ࡝ࡦᰳਲ∝㧘⥄ὼ఺∉ਇో∝㧘⥄ᏆἻ∝ᕈ∔ᖚߥߤߩవᄤᕈ఺∉ਇో∝୥⟲ߩ⇼޿ߩ޽ࠆఽߦߟ޿ߡ㧘ߘߩ⥃ᐥ௝㧘ᬌᩏᚲ⷗߆ࠄ⇼ࠊࠇࠆේ࿃ㆮવሶߦߟ޿ߡㆮવሶ⸃ᨆࠍⴕ޿㧘⸻ᢿࠍ⏕ቯߔࠆ‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦⃻࿷ᣣᧄߢ Ataxia-telangiectasia ߅ࠃ߮ Bloom ∝୥⟲ߩㆮવሶ⸻ᢿࠍⴕߥߞ
ߡ޿ࠆᣉ⸳ߪዋߥ޿‫ޕ‬࿖ౝ⊛࡮࿖㓙⊛⹏ଔ㧦ᧄ⎇ⓥߪㆊ෰ 10 ᐕ㑆ߦࠊߚࠅ㧘ᣣᧄฦ࿾ࠃࠅଐ㗬ࠍฃߌ⎇ⓥ࡟ࡌ࡞ߢ⸃ᨆࠍ
ⴕߞߡ߈ߚ߽ߩߢ޽ࠅ㧘ߘߩᣇᴺ߿ㆮવሶᄌ⇣ᖱႎߦߟ޿ߡߪචಽߥ⫾Ⓧ߇޽ࠆ‫ߩߎޕ‬ㆮવሶ⸃ᨆߦߟ޿ߡߪㆊ෰ Fukao T, et al, Hum Mutat㧔Suppl 1㧕:S223-225, 1998;Fukao
T, et al, Hum Mutat 12:338-343, 1998; Kaneko H,et al, Leukemia and Lymphoma
27:539-542,1996; Kaneko H,et al, Int J Mol Med 14:439-442,2004 ߥߤߦႎ๔ߒߡ޿ࠆ‫ޕ‬4㧕 ⸻≮ฬ 㧦వᄤᕈࠤ࠻ࡦ૕ઍ⻢⇣Ᏹ∝ߩㆮવሶ⸻ᢿ
⸻≮ౝኈ㧦ࡒ࠻ࠦࡦ࠼࡝ࠕࠕ࠮࠻ࠕ࠮࠴࡞-CoA ࠴ࠝ࡜࡯࠯ᰳ៊∝߅ࠃ߮ࠨࠢࠪ࠾࡞-CoA:3keto ㉄
CoA ࠻࡜ࡦࠬࡈࠚ࡜࡯࠯ᰳ៊∝ߩ⇼޿ߩ޽ࠆఽߦߟ޿ߡ㧘ߘߩ⥃ᐥ௝㧘ᬌᩏᚲ⷗߆ࠄ⇼ࠊࠇࠆේ࿃ㆮવሶߦߟ޿ߡㆮવሶ⸃ᨆࠍⴕ޿㧘⸻ᢿࠍ⏕ቯߔࠆ‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦∔ᖚ⥄りߪ㗫ᐲߩ㜞޿∔ᖚߢߪߥ޿߇㧘వᄤᕈࠤ࠻ࡦ૕ઍ⻢⇣Ᏹ∝ߩ㉂⚛⸻ᢿߣㆮવሶ⸻ᢿߦ߅޿ߡߪ਎⇇ߢ໑৻ߩ⸻ᢿ࠮ࡦ࠲࡯ߣߒߡ⸃ᨆࠍ߅ߎߥߞߡ޿ࠆ‫ޕ‬࿖ౝ⊛࡮࿖㓙⊛⹏ଔ㧦ᧄ⎇ⓥߪㆊ෰ 15 ᐕ㑆ߦࠊߚࠅ㧘਎⇇ฦ࿾ࠃࠅଐ㗬ࠍฃߌ⎇ⓥ࡟ࡌ࡞ߢ⸃ᨆࠍ
߅ߎߥߞߡ߈ߚߩ߽ߩߢ޽ࠅ㧘ߘߩᣇᴺ߿ㆮવሶᄌ⇣ᖱႎߦߟ޿ߡߪචಽߥ⫾Ⓧ߇޽ࠆ‫ޕ‬వᄤᕈࠤ࠻ࡦ૕ઍ⻢⇣Ᏹ∝ߩ㉂⚛⸻ᢿߣㆮવሶ⸻ᢿߦ߅޿ߡߪ਎⇇ߢ໑৻ߩ⸻ᢿ࠮ࡦ࠲࡯
ߣߒߡ⸃ᨆࠍ߅ߎߥߞߡ߈ߡ޿ࠆ‫ޕ‬ᒰᢎቶ߆ࠄߩߎࠇࠄߩ∔ᖚߩㆮવሶ⸃ᨆߩ⺰ᢥ⊒⴫ߪᢙᄙ޿‫ޕ‬
4㧚ኾ㐷ක࡮⹺ቯක࡮ᜰዉක
ㄭ⮮⋥ታ㧦ᣣᧄዊఽ⑼ቇળኾ㐷ක࡮ᜰዉ⽿છක㧘ᣣᧄࠕ࡟࡞ࠡ࡯ቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄੱ㘃ㆮવቇળኾ㐷ක࡮ᜰዉක
ᷓየᢅᐘ㧦ᣣᧄዊఽ⑼ቇળኾ㐷ක㧘ᣣᧄࠕ࡟࡞ࠡ࡯ቇળኾ㐷ක㧘ᣣᧄੱ㘃ㆮવቇળኾ㐷ක࡮ᜰዉක
㊄ሶ⧷㓶㧦ᣣᧄዊఽ⑼ቇળኾ㐷ක㧘ᣣᧄࠕ࡟࡞ࠡ࡯ቇળኾ㐷ක㧘ᣣᧄⴊᶧቇળኾ㐷කട⮮ༀ৻㇢㧦ᣣᧄዊఽ⑼ቇળኾ㐷ක㧘ᣣᧄੱ㘃ㆮવቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄዊఽ␹⚻ቇળኾ㐷කኹᧄ⾆⧷㧦ᣣᧄዊఽ⑼ቇળኾ㐷ක㧘ᣣᧄࠕ࡟࡞ࠡ࡯ቇળኾ㐷ක᛬ዬᑪᴦ㧦ᣣᧄዊఽ⑼ቇળኾ㐷ක᧻੗᳗ሶ㧦ᣣᧄዊఽ⑼ቇળኾ㐷ක㧘ᣣᧄࠕ࡟࡞ࠡ࡯ቇળኾ㐷ක᛬ዬᑪᴦ㧦ᣣᧄዊఽ⑼ቇળኾ㐷කᎹᧄ⟤ᄹሶ㧦ᣣᧄዊఽ⑼ቇળኾ㐷ක,ᣣᧄࠕ࡟࡞ࠡ࡯ቇળኾ㐷ක
ᄢ⷏⑲ౖ㧦ᣣᧄዊఽ⑼ቇળኾ㐷ක⦁ᚭ㆏ᓼ㧦ᣣᧄዊఽ⑼ቇળኾ㐷ක㕍ᧁ㓶੺㧦ᣣᧄዊఽ⑼ቇળኾ㐷ක᫪↰⑲ⴕ㧦ᣣᧄዊఽ⑼ቇળኾ㐷ක
5㧚⥄Ꮖ⹏ଔ
⹏ଔߘࠇߥࠅߩታ❣ߪ⹏ଔߢ߈ࠆ‫ޕ‬ᄢቇߩ∛㒮ߢ޽ࠆߣ޿߁ⷞὐ߆ࠄ੹ᓟߩᦝߥࠆ㜞ᐲవㅴක≮㐿⊒ߩታ⃻߇ᦸ߹ࠇࠆ‫ޕ‬ᄢቇ∛㒮ౝߩ✚ว⹏ଔߢߪ㧘ᐕᐲߏߣߦ 1 ૏㧘2 ૏㧘3 ૏ߥߤᏱߦ 3 ૏એౝࠍ₪ᓧߒߡ޿ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻ╷ዊఽ⑼ቇᢎቶߪ 1 ᢎቶߩߺߢ޽ࠅ㧘⃻࿷ഥᢎએ਄ߩᢎቭᢙߪ 7㧔8㧕ฬߢ޽ࠆ‫ੱߩߎޕ‬ᢙߢᢎ⢒㧘㜞ᐲߥ⎇ⓥߦട߃ߡ㧘ዊఽ⑼ߩో㗔ၞߩኾ㐷ක≮㧘ߐࠄߦᢇᕆක≮ࠍⴕ߁ߎߣߪฦᢎቭߩഭ௛ᤨ㑆ߩᄢ᏷ߥᑧ
㐳ࠍ߽ߞߡߒߡ߽㧘ᭂ߼ߡ࿎㔍ߢ޽ࠆ‫ޕ‬කຬ㧘ᄢቇ㒮↢ߩჇຬߣකዪຬోຬߩദജߦ߆߆ߞߡ޿ࠆ‫ޕ‬ኻ╷
ߩ 1 ߟߣߒߡ┹ว⊛⾗㊄ߢ޽ࠆᄖㇱ⾗㊄㓹↪ഥᢎ㧘⻠Ꮷࠍዊఽ⑼ᢎቶߢⴕߞߡ޿ࠆ‫ޕ‬45 ᐥߩࡌ࠶࠼ᢙߢ
޽ࠆ‫ޕ‬ዊఽ⑼කਇ⿷ߦኻߔࠆኻᔕߣߒߡ 2004 ᐕ߆ࠄߩ version up ߣߒߡ̅ 2008 ᐕ㧘ᣂߚߦᡷᄌߒߚឭ㧙㧙᩺㧔කቇ⎇ⓥ⠪߅ࠃ߮࡝ࠨ࡯࠴ࡑࠗࡦ࠼ࠍ᦭ߔࠆ㜞ᐲߥ⾰ߩዊఽ⑼ኾ㐷✚วකᏧߩหᤨ৻૕⢒ᚑ⎇ⓥᢎ⢒ࠪࠬ࠹ࡓ‫ޕ‬Gifu ᣂዊఽ⑼කᏧ⢒ᚑࠪࠬ࠹ࡓ㧕ࠍⴕ޿ㅴ߼ߡ޿ࠆ‫ߩߘޕ‬᭎ⷐࠍ࿑ 1 ߦ␜ߔ‫ޕ‬੹ᓟߩዷᦸ৻⥸ዊఽ⑼ක≮ో⥸ߣฦኾ㐷ಽ㊁ߩක≮ߩᦝߥࠆలታ‫ߦࠄߐޕ‬㜞ᐲߦኾ㐷ൻߐࠇߚ 3 ᰴක≮㧔4 ᰴක≮
ߣ઒⒓ߔࠆ㧕ࠍㅊ᳞ߒߡ޿ࠆ‫ޕ‬ㆮવሶቇ⊛߆ߟ㧘᭴ㅧ↢‛ቇ⊛ක≮ߦၮߠߊ㧘ฦಽ㊁ߦ߅ߌࠆ↹ᦼ⊛ߥᴦ
≮ᴺߩ㐿⊒ࠍ⋡ᜰߔ㧔⎇ⓥߩ㗄ࠍෳᾖ㧕̌࿾ၞߣ࿾⃿㧔਎⇇㧘global㧕ߦะߌߚዊఽකቇ࡮ක≮̅ 21 ਎♿
ࠍ⢛⽶߁ሶଏ㆐ߦ̅ ̍ࠍ࠹࡯ࡑߦ‫ޕ‬㧙㧙㧔17㧕᡼኿✢⑼1㧚⸻≮ߩ᭎ⷐ
᡼኿✢⑼ߩಽ㊁ߪ㧘↹௝⸻ᢿߣ᡼኿✢ᴦ≮ߦᄢ߈ߊಽߌࠄࠇࠆ‫↹ޕ‬௝⸻ᢿ㗔ၞߢߪ㧘CT㧘MRI ߥߤᄢဳᯏེߩᕆㅦߥ⊒㆐ߦࠃࠅ㧘㜞♖ᐲߩ⸻ᢿ߇น⢻ߣߥߞߚߎߣߪ޿߁߹ߢ߽ߥ޿‫ޕ‬ฦ⒳↹௝⸻ᢿߩ᠟ᓇᴺ
ߩ᳿ቯ߅ࠃ߮↹௝ᚲ⷗ߩ⺒ᓇߪᄢ߈ߥᬺോߩ৻ߟߢ޽ࠆ‫ߚ߹ޕ‬㧘✕ᕆᬌᩏ߽Ⴧടߒߡ߅ࠅ㧘✕ᕆ IVR ߳ߩኻᔕ߽ᐔᣣ㧘ભᣣࠍ໧ࠊߕⴕߞߡ޿ࠆ‫ޕ‬ᬌᩏߩല₸ൻࠍ࿑ࠅ㧘ᯏེ⊒㆐ߦࠃࠅ㧘ᬌᩏᤨ㑆ߩ⍴❗߿ࠬ࡞࡯ࡊ࠶࠻ߪᄢ߈ߊᡷༀߒ㧘ᬌᩏઙᢙߪ㘧べ⊛ߦჇടߒߚ‫∛ߚ߹ޕ‬㒮ߩ㊀ⷐߥᬺോߢ޽ࠆ∛⸻ㅪ៤ߦߟ޿ߡ
߽㧘᡼኿✢⑼ߦ㑐ߔࠆᬺോࠍᜂߞߡ޿ࠆ‫ߜࠊߥߔޕ‬㧘CT㧘MRI㧘ᩭකቇᬌᩏࠍਥߦᜂᒰߒ㧘ᄖ᧪ߦߡ໧
⸻㧘⸻ኤࠍⴕߞߚᓟᬌᩏᣉⴕߒ㧘⸻ᢿ⚿ᨐߪ⚫੺ర߳හᣣႎ๔ࠍⴕߞߡ޿ࠆ‫ޕ‬᡼኿✢ᴦ≮߽ઙᢙߪჇടߩ৻ㅜߢ޽ࠆ‫✎ޕ‬ኒߥᴦ≮⸘↹ߩᓟ㧘ᄖᾖ኿ߢߪ㧘∛ᄌߩߺߦ㓸ਛߒߡᾖ኿ߔ
ࠆᣇᴺ߿∛ᄌㇱ߳ኒኽዊ✢Ḯࠍೝ౉ߔࠆ⚵❱ౝᾖ኿ࠍⴕߞߡ޿ࠆ‫ޕ‬೨┙⣼߇ࠎߦኻߔࠆዊ✢Ḯᴦ≮ߪ᧲ᶏ࿾඙ߢవ㚟ߌߡⴕߞߚᴦ≮ᴺߢ޽ࠆ‫ޕ‬౉㒮ᖚ⠪ߪ㧘IVR ᴦ≮ࠍⴕ߁ߚ߼ߩ⍴ᦼ౉㒮߇ਥߢ޽ࠆ‫ޕ‬࿁⸻ᤨߩࠞࡦࡈࠔ࡟ࡦࠬߢ㧘∝⁁㧘↹௝⸻ᢿ㧘⸻ᢿ㧘ᴦ≮ᣇ㊎ߩ᳿ቯߥߤࠍᬌ⸛ߒ㧘ࠗࡦࡈࠜ࡯ࡓ࠼࡮ࠦࡦ࠮ࡦ࠻ࠍචಽⴕ߁ࠃ߁⇐ᗧߒߡ޿ࠆ‫ޕ‬
2㧚ᢎ⢒ᣉ⸳
1㧕 ᡼኿✢⑼ኾ㐷කୃ✵ᯏ㑐
2㧕 ᣣᧄᩭකቇળኾ㐷කᢎ⢒∛㒮
3㧕 ᣣᧄࠗࡦ࠲࡯ࡌࡦ࡚ࠪ࠽࡞࡜ࠫࠝࡠࠫ࡯ቇળኾ㐷කୃ✵ᣉ⸳
3㧚⸻≮㐿⊒
1㧕 ⸻≮ฬ 㧦㜞♖ᐲ᡼኿✢ᴦ≮㧔IMRT㧘ቯ૏᡼኿✢ᴦ≮㧕⸻≮ౝኈ㧦㜞♖ᐲ᡼኿✢ᴦ≮ߣߒ IMRT㧘⣖㧘૕ᐙㇱቯ૏ᾖ኿㧔3 ᰴర㧘4 ᰴరᾖ኿㧕ࠍⴕ߁‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦ጘ㒂⋵ਅߢ 1 ࠞᚲߩߺ IMRT น⢻ߢ޽ࠆ߇㧘IMRT ߣ૕ᐙㇱቯ૏ᾖ኿ਔᣇ߇น
⢻ߥᣉ⸳ߪጘ㒂ᄢቇߩߺߢ޽ࠆ‫ޕ‬࿖ౝ⊛⹏ଔ㧦ጘ㒂ᄢቇߢߪ⣖ߦ㑐ߔࠆቯ૏ᾖ኿ߪ 2000 ᐕ߆ࠄ㐿ᆎߒߡ޿ࠆ‫ޕ‬㗡㗪ㇱߩቯ૏ᾖ኿ߪ
2004 ᐕ߆ࠄ㧘૕ᐙㇱቯ૏ᾖ኿ߪ 2007 ᐕ߆ࠄᣉⴕߒߡ߅ࠅ㧘቟ోߢ⦟ᅢߥᴦ≮ᴺߣߒߡ࿖ౝቇળߦ߽ႎ๔ߒߡ޿ࠆ‫ޕ‬2008 ᐕᐲߪ IMRT ߇೨┙⣼≸ߢ 7 ᦬߆ࠄ㐿ᆎߐࠇ㧘቟ోᕈࠍ⏕⹺ߒߟߟᐕౝ 10 ଀ቢㆀ੍ቯߣߒߡ޿ࠆ‫ޕ‬࿖㓙⊛⹏ଔ㧦☨࿖ߦ߅޿ߡߪ IMRT ߅ࠃ߮ቯ૏᡼኿✢ᴦ≮ߪ߆ߥࠅ᥉෸ߒߡ߈ߡ޿޿ࠆ߇㧘㕖Ᏹߦ㜞㗵ߥᴦ≮ߢ޽ࠆ㧔ෳ⠨㧦☨࿖ߢߪ IMRT 300 ਁ౞⒟ᐲ㧕‫ᧄޕ‬㇌ߦ߅޿ߡ߽଻㒾ㆡᔕߩ޽ࠆIMRT ߢߪ⣖ߣ㗡㗪ㇱ߅ࠃ߮೨┙⣼㧘ቯ૏ᾖ኿ߢߪ⣖㧘㗡㗪ㇱ㧘⢖㧘⢄⤳ߦ߅޿ߡ੹ᓟ᥉
෸ߔࠆߣ⠨߃ࠄࠇࠆ‫ߩઁߚ߹ޕ‬ㇱ૏ߩ≸ߦ߅޿ߡ߽੹ᓟߪ଻㒾ㆡᔕ߽᜛ᄢ߇੍ᗐߐࠇࠆ‫ޕ‬2㧕 ⸻≮ฬ 㧦⣢ᖡᕈ⣲≌ߦኻߔࠆ࡜ࠫࠝᵄ὾ἳ≮ᴺ
⸻≮ౝኈ㧦ᓥ᧪ߩᄖ⑼⊛ᴦ≮ᴺߩታᣉ߇࿎㔍ߥ߽ߩ෶ߪᄖ⑼⊛ᴦ≮ᴺߩታᣉߦࠃࠅᩮᴦᕈ߇ᦼᓙߢ߈
ߥ޿⣢ᖡᕈ⣲≌ߦኻߒߡ㧘⚻⊹⊛ߦ࡜ࠫࠝᵄ὾ἳ≮ᴺࠍⴕ߁‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦ጟጊᄢቇ∛㒮㧘੩ㇺᐭ┙ක⑼ᄢቇ㒝ዻ∛㒮㧘ਃ㊀ᄢቇකቇ㒝ዻ∛㒮ߥߤߢታᣉ
ߐࠇߡ޿ࠆ‫ޕ‬ጘ㒂⋵ౝߢߪጘ㒂ᄢቇ∛㒮ߩߺߢⴕߞߡ޿ࠆ‫ޕ‬࿖ౝ⊛⹏ଔ㧦㜞ᐲవㅴක≮ߢߪ਄⸥ 3 ᣉ⸳߇⊓㍳ߐࠇߡ߅ࠅⓍᭂ⊛ߦ࡜ࠫࠝᵄ὾ἳ≮ᴺࠍⴕߞߡ޿ࠆ‫ޕ‬߹ߚ㧘⃻࿷㧘⥃ᐥ⹜㛎߽ⴕࠊࠇߡ޿ࠆ㧔ᖡᕈ⣢⣲≌ߦኻߔࠆ⚻⊹⊛࡜ࠫࠝᵄಝ࿕≮ᴺߩ╙I/II ⋧⹜㛎 JIVROSG-0701㧕
‫੹ޕ‬ᓟ㧘ᄖ⑼⊛ᴦ≮࿎㔍∝଀ߩ╙৻ㆬᛯߣߥࠅᓧࠆᴦ≮ᴺߢ޽ࠆ‫ޕ‬࿖㓙⊛⹏ଔ㧦2000 ᐕߦႎ๔߇ᆎ߹ࠅ㧘2005 ᐕߩႎ๔ߢߪᄖ⑼⊛ಾ㒰ߦ඘ᢜߔࠆᴦ≮ᴺߢ޽ࠆߣߐࠇ
ߡ޿ࠆ‫ޕ‬
4㧚ኾ㐷ක࡮⹺ቯක࡮ᜰዉක
౗᧻㓷ਯ㧦ᣣᧄකቇ᡼኿✢ቇળኾ㐷ක㧘ᣣᧄⴊ▤ㅧᓇ࡮IVR ቇળᜰዉක㧘ᣣᧄ߇ࠎᴦ≮⹺ቯකᯏ᭴ᥳቯᢎ
⢒කᤊ ඳᤘ㧦ᣣᧄකቇ᡼኿✢ቇળኾ㐷ක㧘ᣣᧄᩭකቇળኾ㐷ක㧘ᣣᧄᩭකቇળ PET ᩭකቇ⹺ቯකᨋ ⌀਽㧦ᣣᧄකቇ᡼኿✢ቇળኾ㐷ක㧘ᣣᧄ᡼኿✢⣲≌ቇળ⹺ቯක
ᵻ㊁㓉ᒾ㧦ᣣᧄකቇ᡼኿✢ቇળኾ㐷ක㧘ᣣᧄᩭකቇળ PET ᩭකቇ⹺ቯක
ㄭ⮮ᶈผ㧦ᣣᧄකቇ᡼኿✢ቇળኾ㐷ක㧘ᣣᧄᩭකቇળ PET ᩭකቇ⹺ቯක㧘ᣣᧄⴊ▤ㅧᓇ࡮IVR ቇળᜰዉ㧙㧙ක㧘ᬌ⸻ࡑࡦࡕࠣ࡜ࡈࠖ⺒ᓇ⹺ቯක㧘ᣣᧄ߇ࠎᴦ≮⹺ቯකᯏ᭴ᥳቯᢎ⢒කട⮮ඳၮ㧦ᣣᧄකቇ᡼኿✢ቇળኾ㐷ක㧘ᣣᧄᩭකቇળ PET ᩭකቇ⹺ቯක㧘ᣣᧄⴊ▤ㅧᓇ࡮IVR ቇળᜰዉක㧘ᬌ⸻ࡑࡦࡕࠣ࡜ࡈࠖ⺒ᓇ⹺ቯක᧖ፒ࿻ሶ㧦ᣣᧄකቇ᡼኿✢ቇળኾ㐷ක㧘ᣣᧄᩭකቇળ PET ᩭකቇ⹺ቯක㧘ᬌ⸻ࡑࡦࡕࠣ࡜ࡈࠖ⺒ᓇ⹺ቯක੖ፉ ⡡㧦ᣣᧄකቇ᡼኿✢ቇળኾ㐷ක㧘ᣣᧄᩭකቇળ PET ᩭකቇ⹺ቯක㧘ᣣᧄⴊ▤ㅧᓇ࡮IVR ቇળᜰዉකᢧ⮮⡡ሶ㧦ᣣᧄකቇ᡼኿✢ቇળኾ㐷ක㧘ᬌ⸻ࡑࡦࡕࠣ࡜ࡈࠖ⺒ᓇ⹺ቯකᨷᬀ␭੺㧦ᣣᧄකቇ᡼኿✢ቇળኾ㐷ක㧘ᣣᧄᩭකቇળ PET ᩭකቇ⹺ቯක
’↰ᥓ⹷ሶ㧦ᬌ⸻ࡑࡦࡕࠣ࡜ࡈࠖ⺒ᓇ⹺ቯක
5㧚⥄Ꮖ⹏ଔ
⹏ଔ↹௝⸻ᢿ㗔ၞߢߪ㧘CT㧘MRI ߥߤᄢဳᯏེߩᕆㅦߥ⊒㆐ߦࠃࠅ㧘㜞♖ᐲߩ⸻ᢿ߇น⢻ߣߥߞߚ߇㧘ߘ
ߩ᠟ᓇᴺߪ⒳‫ࠅ޽߇ߩ߽ߩޘ‬㧘ฦ⒳∔ᖚߦኻߔࠆᦨㆡ᠟௝ᴺࠍ㐿⊒ߒ㧘ᦨༀߩ↹௝⸻ᢿࠍឭଏߒߡ޿ࠆ‫ޕ‬߹ߚ㧘ࠬ࡞࡯ࡊ࠶࠻ᡷༀߦࠃࠅ㧘ᬌᩏઙᢙߩ㘧べ⊛ߦ⽸₂ߒߚ‫ޕ‬ᬌᩏ੍⚂ᓟߩᓙߜᣣᢙ߇⍴޿ߩ߽ᄢ߈ߊ
ᡷༀߒߚὐߢ޽ࠆ‫⸻∛ޕ‬ㅪ៤ࠍขࠅ౉ࠇ㧘CT㧘MRI㧘ᩭකቇᬌᩏࠍฃߌ౉ࠇ㧘ᜂᒰߒ㧘⸻ᢿ⚿ᨐߩ⚫੺ర߳ߩහᣣႎ๔߽ታᣉߒߡ޿ࠆ‫ޕ‬᡼኿✢ᴦ≮߽ઙᢙߪ㘧べ⊛ߦჇടߒߡ޿ࠆ߇㧘೨┙⣼≸ߦኻߔࠆዊ✢Ḯᴦ≮߽ 2005 ᐕ 8 ᦬ࠃࠅ㐿ᆎߒ㧘᧲ᶏ࿾඙ߢ޿ߜᣧߊขࠅ౉ࠇߚ‫ߚ߹ޕ‬㧘⣖ߦ㑐ߔࠆቯ૏ᾖ኿ߪ 2000 ᐕ߆ࠄ㐿ᆎߒ㧘㗡㗪ㇱߩቯ૏ᾖ኿ߪ
2004 ᐕ߆ࠄ㧘૕ᐙㇱቯ૏ᾖ኿ߪ 2007 ᐕ߆ࠄᣉⴕߒߡ޿ࠆ‫ޕ‬2008 ᐕᐲߪ IMRT ߇೨┙⣼≸ߢ 7 ᦬߆ࠄ㐿ᆎߒ㧘ᐕౝ 10 ଀ቢㆀ੍ቯߣߒߡ޿ࠆ‫ޕ‬ኾ㐷කߩ⢒ᚑߢߪ㧘᡼኿✢ᴦ≮⑼ኾ㐷කୃ✵ᯏ㑐㧘ᣣᧄᩭකቇળኾ㐷කᢎ⢒∛㒮ߣߒߡ㧘ᦨㄭᄙߊߩኾ
㐷ක㧘⹺ቯකࠍ⢒ᚑߒߡ߈ߚ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷CT㧘MRI ߥߤ⸻ᢿᯏེߩㅴᱠߪ߼ߑ߹ߒ޿߽ߩ߇޽ࠆ߇㧘⥋ㆡ᠟௝ᴺ߿ᣂߒ޿᠟௝ᴺߪߐࠄߦᬌ⸛ߩ
૛࿾߇޽ࠆ‫ߚ߹ޕ‬㧘↹௝ᖱႎ㊂ߩᄢ㊂ൻ෸߮ⶄ㔀ൻߦ઻޿㧘⺒ᓇߦⷐߔࠆᤨ㑆߇Ⴧടߒ㧘3 ᰴర↹௝ߩᓟ
ಣℂ߿ߘߩ⺒ᓇߦⷐߔࠆᤨ㑆߽Ⴧടߒߡ޿ࠆ‫ߦࠄߐޕ‬㧘Interventional Radiology㧔IVR㧕ߦ߅޿ߡ߽ߘ
ߩᚻᛛ߇㜞ᐲൻ㧘ⶄ㔀ൻߒߡ߅ࠅ㧘৻ᖚ⠪ߩ⸻ᢿ㧘ᴦ≮ߦⷐߔࠆᤨ㑆߇Ⴧടߒߡ޿ࠆ‫ߩࠄࠇߎޕ‬໧㗴ࠍ⸃᳿ߔࠆߚ߼ߦߪ㧘⸻≮ߦ៤ࠊࠆකᏧߩᛛ㊂ߩ㜞޿᳓Ḱߢߩᐔဋൻ෸߮วℂ⊛ߥ⸻≮ⅣႺߩᢛ஻߇ᔅⷐߢ޽
ࠆ‫ߚ߹ޕ‬㧘⃻ᤨὐߢߪ᡼኿✢⑼ࠬ࠲࠶ࡈ߽ዋߥߊੱຬߩჇട㧘లታ߇ᦸ߹ࠇࠆ‫⥃ޕ‬ᐥ⎇ⓥ߇ਛᔃߣߥࠆ߇
ઁ⑼ߣߩ౒ห⎇ⓥߩ᜛ᄢ߇ࠃࠅᔅⷐߢ޽ࠆ‫ޕ‬੹ᓟߩዷᦸ⣻ㇱ⤳ེᖡᕈ⣲≌ߦߟ޿ߡߪᣧᦼ⸻ᢿߣ㧘IVR ࠍ฽߼ߚ㓸ቇ⊛ࠕࡊࡠ࡯࠴ࠍᔃ߇ߌߡ޿߈ߚ޿‫✕ޕ‬ᕆᬌᩏ߽ IVR ߦࠃࠆࠃࠅ㕖ଚⷅ⊛ᴦ≮ࠍផㅴߒߚ޿‫ޕ‬ฦ⒳ᖡᕈ⣲≌ߦኻߔࠆ᡼኿✢ᴦ≮ߦ߅޿ߡ߽㧘૕ᐙㇱ⣲≌ߦኻߔࠆ 3 ᰴరᴦ≮ߩᔕ↪㧘⥋ㆡᾖ኿ᴺߩ⎇ⓥࠍㅴ߼ࠆ‫੹ޕ‬ᓟߩᣇ㊎ߣߒߡ㧘ߐࠄߦ㕖ଚⷅ⊛ᴦ≮ߩផㅴߣ CT㧘MRI㧘PET ࠍ⵬ഥߣߔࠆᣂߚߥ⸻ᢿ࡮ᴦ≮ᴺߩ㐿⊒ࠍㅴ߼ࠆ‫ޕ‬EBM ߦၮߠߊ⸻≮㧘⎇ⓥߣ⸻≮ߩኒធߥⲢว㧘⸻≮ߩ⊒ዷߦߟߥ߇ࠆၮ␆⎇ⓥ㧘਎⇇ၮḰࠍᔨ㗡ߦ⟎޿ߚ⸻≮㧘⎇ⓥ߇੹ᓟߩዷᦸߢ
޽ࠆ‫ޕ‬

㧙㧙

㧔18㧕㤗㈮⑼−∩ᴦ≮⑼
1㧚⸻≮ߩ᭎ⷐ
㤗㈮⑼−∩ᴦ≮⑼ߩ⸻≮ߪએਅߩࠃ߁ߦᄙ⢇ߦ෸߱‫ޕ‬ᚻⴚߢߩ㤗㈮ࠨ࡯ࡆࠬ㧘ᚻⴚᓟ−∩ߩ▤ℂ㧘ዊఽ⑼࡮ౝ⑼ߦࠃࠆ㛽㜑⒖ᬀߩ㤗㈮㧘♖␹⑼ߦࠃࠆ㔚᳇∨ᡨ≮ᴺ╬㧘޽ࠄࠁࠆ㤗㈮▤ℂࠍᜂᒰߒߡ޿ࠆ‫ޕ‬ᄛ㑆ߩ✕ᕆᚻⴚߦኻߔࠆ㤗㈮▤ℂߪ൩⺰㧘ᤨߦ 24 ᤨ㑆એ਄ߦ෸߱ᚻⴚߩ㤗㈮ߦ߽ኻᔕߒ㧘ᐕ㑆 2,500 ઙએ਄ߦ቟ోߢ⾰ߩ㜞޿㤗㈮ࠍឭଏߒߡ޿ࠆ‫ޕ‬ᚻⴚᓟߩᕆᕈ
∩ߦኻߒߡߪᜬ⛯⎬⤑ᄖ㎾∩߿ࠛࠦ࡯ࠟࠗ࠼ਅߩᧃ᪳␹⚻ࡉࡠ࠶ࠢߥࠄ߮ߦࠝࡇࠝࠗ࠼ߩᜬ⛯㕒ᵈ╬ߦࠃࠆ−∩▤ℂࠍⴕߞߡ޿ࠆ‫ޕ‬−∩ᴦ≮ᄖ᧪ߪ㧘∩ߺࠍ⸷߃ߡ޿ࠆੱ߿␹⚻㤗∽ࠍᜬߞߚੱߩߚ߼ߩ✚วᄖ᧪ߢ޽ࠆ‫ޕ‬ᖚ⠪ߩ∛௝ߪᄙᓀߢ޽ࠅ㧘‫߇ޠߺ∩ޟ‬ਥߥ∝⁁ߩ∛᳇㧘޽ࠆ޿ߪ᭽‫ߥޘ‬⒳㘃㧘ⶄ㔀ߥⷐ⚛ࠍ߽ߞߚ∩ߺࠍ⸷߃ࠆᖚ⠪߇Ⴧ߃ߡ߈ߚ‫⃻ޕ‬࿷ߪᄖ᧪ᴦ≮ࡌ࠶࠼ 13 ᐥ㧘౉㒮ࡌ࠶࠼ 6 ᐥߩⅣႺߢ㧘᦬ᦐᣣߦߪᚻⴚቶߢ㧘߹ߚᧁᦐᣣߦ
ߪ᡼኿✢ㅘⷞቶߢ X ✢ㅘⷞࠍ↪޿ߡߩ␹⚻ࡉࡠ࠶ࠢࠍⴕߞߡ޿ࠆ‫ޕ‬✭๺ක≮࠴࡯ࡓߩ᭴ᚑ
ᒰᄢቇ∛㒮ߪ㧘ጘ㒂⋵߇ࠎ⸻≮ㅪ៤᜚ὐ∛㒮ߣߒߡᵴേߒߡ߅ࠅ㧘ߘߩ৻Ⅳߣߒߡ✭๺ක≮ߦ߽Ⓧᭂ⊛ߦขࠅ⚵ࠎߢ޿ࠆ‫ޕ‬ᒰ⑼ߪߘߩ✭๺ࠤࠕㇱ㐷ߩਛᔃ⊛ሽ࿷ߣߒߡઁ⸻≮⑼ߣㅪ៤ߩ߽ߣᵴേࠍⴕߞߡ޿ࠆ‫ޕ‬߹ߚ㧘౉㒮ᖚ⠪ߩߺߥࠄߕᄖ᧪ᖚ⠪ߦኻߒߡ߽᦬ᦐඦᓟߦ✭๺ࠤࠕᄖ᧪㧔੍⚂೙㧕ࠍ㐿⸳ߒ㧘⸻≮ࠍⴕߞߡ޿ࠆ‫ޕ‬
2㧚ᢎ⢒ᣉ⸳
1㧕 ᣣᧄ㤗㈮⑼ቇળ㤗㈮ᜰዉ∛㒮
2㧕 ᣣᧄࡍࠗࡦࠢ࡝࠾࠶ࠢቇળᜰቯ⎇ୃᣉ⸳
3㧚⸻≮㐿⊒
1㧕 ⸻≮ฬ 㧦㗪ㇱ࡮⣶ㇱ␹⚻ᩮ∝ߦኻߔࠆ pulsed radiofrequency ᴺ⸻≮ౝኈ㧦㗪ㇱ࡮⣶ㇱߩ␹⚻ᩮᕈ−∩ߦኻߒߡ㜞๟ᵄ㔚ᵹࠍ 42°C એਅߢ㑆ᰳ⊛ߦㅢ㔚ߒ−∩シᷫࠍ࿑ࠆᴦ≮ᚻᲑߢ޽ࠆ‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦᧲ᶏ࿾඙ߢߪᒰ㒮ߩߺߦዉ౉ߐࠇߡ޿ࠆ‫ޕ‬࿖ౝ⊛⹏ଔ㧦ᓥ᧪ߩ㜞๟ᵄᾲಝ࿕ᴺߣᲧߴߡ㧘⍮ⷡૐਅ࡮╭ജૐਅࠍ᧪ߚߒߦߊߊ−∩ᡷༀലᨐ߽ఝ
ࠇߡ޿ࠆߣ⠨߃ࠄࠇߡ޿ࠆ‫ޕ‬࿖㓙⊛⹏ଔ㧦᰷☨ߢߪ⒳‫ߩ∩⚻␹ߩޘ‬ᴦ≮ߦᢙᐕ೨߆ࠄዉ౉ߐࠇߡ߅ࠅ㧘╭ജૐਅࠍ᧪ߒߦߊ޿ߚ߼
ߦ㧘ᄙᬁ૕ߩ␹⚻ߦኻߒߡട≮߇น⢻ߣߥࠆߎߣߦട߃ߡ㧘␹⚻࿃ᕈ−∩ߦ߽᦭ലߢ޽ࠆ
ߣߩႎ๔ߦೣࠅ㧘ᐢߊᣉⴕߐࠇߡ޿ࠆ‫ޕ‬
4㧚ኾ㐷ක࡮⹺ቯක࡮ᜰዉක
࿯⢈ୃม㧦ᣣᧄ㤗㈮⑼ቇળᜰዉක࡮ኾ㐷ක㧘ᣣᧄࡍࠗࡦࠢ࡝࠾࠶ࠢቇળ⹺ቯක
㘵↰ብ᮸㧦ᣣᧄ㤗㈮⑼ቇળᜰዉක࡮ኾ㐷ක㧘ᣣᧄࡍࠗࡦࠢ࡝࠾࠶ࠢቇળ⹺ቯක
┻ਛరᐽ㧦ᣣᧄ㤗㈮⑼ቇળᜰዉක࡮ኾ㐷ක㧘ᣣᧄࡍࠗࡦࠢ࡝࠾࠶ࠢቇળ⹺ቯක
↰ㄝਭ⟤ሶ㧦ᣣᧄ㤗㈮⑼ቇળᜰዉක࡮ኾ㐷කᄢ⇗ඳੱ㧦ᣣᧄ㤗㈮⑼ቇળᜰዉක࡮ኾ㐷ක㐳ἑᷡ 㧦ᣣᧄ㤗㈮⑼ቇળᜰዉක࡮ኾ㐷ක㆏㊁᦮ᵗ㧦ᣣᧄ㤗㈮⑼ቇળኾ㐷කᾢỈ᣽ᒾ㧦ᣣᧄ㤗㈮⑼ቇળኾ㐷ක᧖ጊ㓁ሶ㧦ᣣᧄ㤗㈮⑼ቇળኾ㐷කᩉ⥪ን⟤㧦ᣣᧄ㤗㈮⑼ቇળኾ㐷ක
5㧚⥄Ꮖ⹏ଔ
⹏ଔᄢቇ∛㒮ߪ߽ߣࠃࠅ㑐ㅪ∛㒮ߩ㤗㈮⑼ߩᬺോߩჇടߥߤߦࠃࠆࡑࡦࡄࡢ࡯ਇ⿷ߢ㧘⎇ⓥߦㆱߌࠆᤨ㑆߇㕖Ᏹߦᷫߞߚߎߣߥߤ߇㊀ߥߞߡ㧘⎇ⓥ⺖㗴ߪలಽߦ㆐ᚑߢ߈ߥ߆ߞߚߣ⹏ଔߒߡ޿ࠆ‫≮⸻ޕ‬ᬺോߦ㑐ߒߡߪ㧘น⢻ߥ㒢ࠅኻᔕߒߡ߅ࠅ㧘ਛᄩ⸻≮ㇱ㐷ߣߒߡߩ઀੐ߪ߆ߥࠅߩ▸࿐ߢ㆐ᚑߢ߈ߡ޿ࠆߣ⹏ଔߒߡ
޿ࠆ‫ޕ‬

㧙㧙

⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷⃻⁁ߩ໧㗴ὐߩᄙߊߪ㧘ࡑࡦࡄࡢ࡯ਇ⿷ߦࠃࠆߣߎࠈ߇ᄢ߈޿߇㧘ߘߩల⿷ߪᔅ㗇ߢ޽ࠆ߇㧘ᄢቇ㒝ዻ∛㒮߇ఝࠇߚකᏧࠍ㑐ㅪߩઁක≮ᯏ㑐ߦᵷ㆜ߔࠆߣ޿߁␠ળ⊛⽿છ߇޽ࠆ߽ߩߩ㧘੹ᓟߪᄢቇౝߦఝࠇߚ
කᏧࠍ⏕଻ߔࠆߣ޿߁ⷞὐߢᢎቶࠍㆇ༡ߒߡ޿ߊᔅⷐ߽޽ࠆ‫ޕ‬ኾ㐷කࠍ㙃ᚑߔࠆߣ޿߁૶๮ߣ౒ߦ㧘㤗㈮⑼ኾ㐷කߩ⛘ኻᢙ߇ዋߥ޿ߣ޿߁ߎߩ࿾ၞߩ⃻⁁ߩ޽ߞߚ⃻ታ⊛ߥㆬᛯࠍߒߡ޿ߊ‫ߚ߹ޕ‬㧘ᅚᕈකᏧߩ᦭
ലߥᵴ↪ߪ੹ᓟߩ౞Ṗߥㆇ༡ߩᔅ㗇᧦ઙߣ⠨߃ߡ߅ࠅ㧘಴↥╬ߦ઻߁ભᥜᓟߩᓳᏫࡊࡠࠣ࡜ࡓࠍ⏕┙ߒ㧘቟ᔃߒߡ⢒ఽ࡮઀੐ߩਔ┙߇น⢻ߥⅣႺ૞ࠅߦദ߼ࠆᣇ㊎ߢ޽ࠆ‫ޕ‬੹ᓟߩዷᦸ᰷☨ߢߪ㧘․ߦࠕࡔ࡝ࠞߢߪᚻⴚߩ⚂ 50㧑߇ᄖ᧪ߢ㧘ᣣᏫࠅ㤗㈮࡮ᚻⴚߣߒߡⴕࠊࠇߡ޿ࠆ‫߇ࠊޕ‬࿖ߢߪᧂߛ∛㒮߇ߘߩࠃ߁ߥ૕೙ߦߪߥ޿߇㧘ᚻⴚㇱߩല₸⊛ߥㆇ↪ߦࠃߞߡ㧘ዊᚻⴚ߿ଚⷅ⊛ߥᬌᩏߦኻ
ߔࠆ⊛⏕ߢ቟ోߥ㤗㈮ᴺࠍ⏕┙ߒ㧘␠ળߩ࠾࡯࠭ߦኻᔕߒߚ㤗㈮⸻≮ࠍⴕ߁‫ߺ∩ߩߢࠢ࠶࠾࡝ࠢࡦࠗࡍޕ‬ߩᴦ≮ߦߪㄭ㇠ઁᄢቇ߆ࠄߩ⚫੺ᖚ⠪߽ᄙߊ⹏ଔࠍᓧߡ޿ࠆ߇㧘ᚻⴚᓟ∩ߩᴦ≮ߦ㑐ߒߡ߽㧘৻ᵹᣉ⸳ߦ
⋧ᔕߒ޿∩ߺߩ⸻≮ࠪࠬ࠹ࡓࠍ᭴▽㧔ᕆᕈ−∩▤ℂ࠴࡯ࡓ㧕ߒߡ޿ߊᔅⷐ߇޽ࠆ‫ߚ߹ޕ‬૛ജߩ⸵ߔ߆߉ࠅ㧘≸ᕈ−∩ߩ▤ℂ㧔✭๺ක≮ࠍ฽߻㧕ߦ߽ജࠍᵈߋߎߣࠍ⋡ᮡߦ㧘㒮ౝ࡮ᘟᕈߩ−∩▤ℂࠪࠬ࠹ࡓߩ⏕┙ࠍ⋡ᜰߔ‫ޕ‬

㧙㧙㧔19㧕ᱤ⑼ญ⣧ᄖ⑼1㧚⸻≮ߩ᭎ⷐ
ᒰ⑼ߢߪ㧘৻⥸ߩᱤ⑼࡮ญ⣧ᄖ⑼⊛∔ᖚߩᴦ≮ߣߣ߽ߦ㧘㗶࡮㗻㕙࡮ญ⣧ߦ㑐ࠊࠆ∔ᖚߦኻߒ⸻ᢿߣᴦ
≮ࠍⴕߞߡ޿ࠆ‫ޕ‬ญ⣧≸ߢߪ㧘ᧄ࿾ၞߦ߅ߌࠆ߇ࠎ⸻≮᜚ὐ∛㒮ߣߒߡߩᯏ⢻ࠍᵴ↪ߒ㧘᡼኿✢࡮ൻቇ≮ᴺ㧔฽߻േᵈൻቇ≮ᴺ㧕ߩ૬↪ߦࠃࠆ⚵❱᷷ሽ≮ᴺ߿ᐔᚑ 18 ᐕߦ⋵ౝ໑৻ߩᣉ⸳ߣߒߡ⹺นߐࠇߚవㅴ
ක≮㧔㗶㗻㕙⵬✄࡮ࠗࡦࡊ࡜ࡦ࠻⟵ᱤ㧕ࠍᵴ↪ߒߚ⾰ߩ㜞޿ᯏ⢻࿁ᓳࠍⴕߞߡ޿ࠆ‫ઁߩߘޕ‬㧘㗶ᄌᒻ∝ߩᣉ⸳ၮḰ㧔⍶ᱜᴦ≮࡮ᄖ⑼ᴦ≮ߩਔ⠪㧕߽ขᓧߒߡ߅ࠅ㧘৻⽾ߒߚᴦ≮ࠍዷ㐿ߒߡ޿ࠆ‫ޕ‬㗶ྙ⢩࡮⦟ᕈ⣲≌㧔ࠛ࠽ࡔ࡞਄⊹⣲╬㧕ߢߪ㧘㗶㛽ࠍ᷷ሽߔࠆᴦ≮ࠍⴕ޿㧘ญ⣧࡮㗶࡮㗻㕙ߩᯏ⢻ߣᒻᘒߩ଻ోࠍ࿑ߞߡ
޿ࠆ‫ޕ‬ญ⣧ੇ῎∝࡮⥠∩∝ߢߪኾ㐷ᄖ᧪ࠍ㐿⸳ߒᴦ≮ߦ޽ߚߞߡ޿ࠆ‫≮⸻ߩࠄࠇߎޕ‬ᵴേߦࠃࠅ㧘ઁߩ∛㒮ᱤ⑼࡮ญ⣧ᄖ⑼㧘⸻≮ᚲߦή޿⸻≮ᯏ⢻ߩᒝൻࠍ࿑ࠅߟߟ࿾ၞߦ߅ߌࠆญ⣧ක≮ߩ 3 ᰴᯏ㑐ߣߒߡߩ⽿ോࠍᨐߚߔߴߊᵴേߒߡ޿ࠆ‫ߦࠄߐޕ‬㧘⚫੺₸ะ਄ߩߚ߼࿾඙න૏ߩࡒ࠾⻠Ṷળ㧘⋵࡮Ꮢන૏ߩ⎇ⓥળࠍਥ௅ߒ⋧ᚻߩ㗻ߩ⷗߃ࠆ∛࡮⸻ㅪ៤ߩ᭴▽ߦദ߼㧘ጘ㒂Ꮢ߅ࠃ߮ጘ㒂⋵ౝߩᱤ⑼ක≮ᯏ㑐ߣㅪ៤ߒߚญ⣧ක≮ߩឭଏࠍⴕߞߡ޿ࠆ‫ޕ‬
2㧚ᢎ⢒ᣉ⸳
1㧕 㧔␠㧕ᣣᧄญ⣧ᄖ⑼ቇળᜰቯ⎇ୃᯏ㑐
2㧕 ᣣᧄ㗶㑐▵ቇળᜰቯ⎇ୃᯏ㑐
3㧕 ᱤ⑼කᏧ⥃ᐥ⎇ୃᣉ⸳㧔▤ℂဳ⎇ୃᣉ⸳㧕
3㧚⸻≮㐿⊒
1㧕 ⸻≮ฬ 㧦ࠗࡦࡊ࡜ࡦ࠻ኾ㐷ᄖ᧪⸻≮ౝኈ㧦ၒ౉ࠗࡦࡊ࡜ࡦ࠻ᢙߣߒߡ 100㨪150 ᧄ/ᐕߢផ⒖ߒ㧘వㅴක≮㧔ࠗࡦࡊ࡜ࡦ࠻⟵ᱤ㧕ߩታᣉක≮ᣉ⸳ߦ⹺ቯߐࠇߚᐔᚑ 18 ᐕએ㒠㧘ᕆㅦߥჇടߣߥߞߡ᧪ߡ޿ࠆ‫ޕ‬వㅴක≮㧔ࠗࡦࡊ࡜ࡦ࠻⟵ᱤ㧕ߩㆡᔕ଀ߢߪ㧘ࠗࡦࡊ࡜ࡦ࠻ၒ౉ߦ㑐ࠊࠆ⾌↪એᄖߩ⾌↪㧔ᬌᩏ࡮ᛩ⮎࡮౉㒮ᢱ╬㧕ࠍ଻㒾⸻≮ߢⴕ߁ߎߣ߇น⢻ߢ޽ࠆߚ߼㧘㛽⒖ᬀߥߤߩ㗶ႇᒻᚑࠍᔅⷐߣߔࠆ
଀߿ଚⷅߩᄢ߈޿ࠗࡦࡊ࡜ࡦ࠻ၒ౉╬ࠍ቟ోߦᣉⴕߔࠆ଀ࠍਛᔃߦ㧘ጘ㒂Ꮢ࡮ጘ㒂⋵ౝߩක≮ᯏ㑐ߣㅪ៤ߒߡታᣉߒߡ޿ࠆ‫ߚ߹ޕ‬㧘࠺ࡦ࠲࡞ CT ߅ࠃ߮↹௝⸃ᨆࠪࠬ࠹ࡓࠍᄖ᧪ߦ
⸳⟎ߒ㧘᠟ᓇ⋥ᓟߩ↹௝⸻ᢿߥߤ⹦⚦ߥ⸃ᨆࠍㄦㅦߦⴕ޿㧘቟ో߆ߟ੍⍮ᕈߩ㜞޿ᣉⴚࠍዷ㐿ߒߡ޿ࠆ‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦⋵ౝߦ߅޿ߡవㅴක≮㧔㗶㗻㕙⵬✄࡮ࠗࡦࡊ࡜ࡦ࠻⟵ᱤ㧕ߩ⹺นࠍฃߌߚᣉ⸳
ߪήߊ㧘ᒰ⑼߇໑৻ߩᣉ⸳ߣߥߞߡ޿ࠆ‫ޕ‬࿖ౝ⊛⹏ଔ㧦⃻࿷㧘࿖ౝᄖߦ߅޿ߡⴕࠊࠇߡ޿ࠆࠗࡦࡊ࡜ࡦ࠻ᴦ≮ߩ߶߷ోߡߩᚻᛛ࡮ᴦ≮ᴺߪᒰ⑼ߦ߅޿ߡน⢻ߥ⁁ᴫߣߥߞߡ߅ࠅ㧘∝଀ߩ㓸Ⓧߦࠃࠅߎߩಽ㊁ߦᣈߌࠆࡈࡠࡦ࠻࡜ࡦ࠽࡯
ߣߥࠆߣ⠨߃ߡ޿ࠆ‫ޕ‬࿖㓙⊛⹏ଔ㧦⃻࿷㧘࿖ౝᄖߦ߅޿ߡⴕࠊࠇߡ޿ࠆࠗࡦࡊ࡜ࡦ࠻ᴦ≮ߩ߶߷ోߡߩᚻᛛ࡮ᴦ≮ᴺߪᒰ⑼ߦ߅޿ߡน⢻ߥ⁁ᴫߣߥߞߡ߅ࠅ㧘∝଀ߩ㓸Ⓧߦࠃࠅߎߩಽ㊁ߦᣈߌࠆࡈࡠࡦ࠻࡜ࡦ࠽࡯
ߣߥࠆߣ⠨߃ߡ޿ࠆ‫ޕ‬2㧕 ⸻≮ฬ 㧦ญ⣧ੇ῎∝࡮⥠∩∝ᄖ᧪⸻≮ౝኈ㧦ࠪࠚ࡯ࠣ࡟ࡦ∝୥⟲ߩน⢻ᕈ߽⠨ᘦߒߚ♽⛔⊛ߥᬌᩏ㧔ࠨࠢ࠰ࡦ࠹ࠬ࠻㧘ໜᶧ⣼ࠪࡦ࠴ࠣ࡜ࡈࠖ࡯㧘ⴊᶧᬌᩏ㧘ໜᶧ⣼ㅧᓇ㧘ญໃ↢ᬌ㧘CT㧘MRI㧕߅ࠃ߮⌒⑼࡮⊹⤏⑼࡮⤔ේ∛ౝ⑼ߥߤ㑐ㅪ⻉⑼߳ߩኻ⸻ߦၮߠߊ⸻ᢿࠍⴕ޿㧘∛࿃ߦᔕߓߚㆡಾߥᴦ≮ᴺߩㆬᛯࠍⴕߥߞ
ߡ޿ࠆ‫ߚ߹ޕ‬㧘ໜᶧࠍ↪޿ߚญ⣧∛ᄌߩ㕖ଚⷅ⊛⸻ᢿᴺߩ⏕┙ߣ−∩⸘ࠍ↪޿ߚ⥠∩ߩቴⷰ⊛⹏ଔߩዉ౉ࠍ⋡ᜰߒߡ޿ࠆ‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦ਛㇱ࿤ౝ߅ࠃ߮ో࿖⊛ߦߺߡ㧘ᒰ⑼߶ߤᄙߊߩ∝଀ࠍ᦭ߒ㧘Ⓧᭂ⊛ߦขࠅ⚵ࠎߢ޿ࠆᣉ⸳ߪ߶ߣࠎߤߥ޿㧔150㨪200 ੱ㧛᦬ߩ follow up ߣᣂᖚࠍᜂᒰߒߡ޿ࠆ㧕‫ޕ‬࿖ౝ⊛⹏ଔ㧦ᣢߦቇળ⊒⴫㧘⻠Ṷ㧘⺰ᢥ╬ߢᚗࠆ⒟ᐲߩ࿖ౝ⊛⹏ଔࠍᓧߡ޿ࠆ߇㧘ో࿖⊛ߦ⷗ߡ߽㧘ญ⣧ੇ῎∝߿⥠∩∝ߦⓍᭂ⊛ߦขࠅ⚵ࠎߢ޿ࠆᣉ⸳ߪᲧセ⊛ዋߥ޿ߩߢ㧘ߐࠄߦ㜞޿⹏ଔࠍᓧࠄࠇࠆน⢻ᕈߪ㜞޿‫ޕ‬࿖㓙⊛⹏ଔ㧦࡜ࡈ࠴ࠫࡦߦࠃࠆ⥠∩ߩ✭๺ߦ㑐ߔࠆ⺰ᢥ߇࿖㓙⹹㧔J Oral Pathol Med㧕ߦฃℂߐࠇ
ߚ㧔2008 ᐕ 12 ᦬ 1 ᣣ⃻࿷㧕‫ߚ߹ޕ‬㧘ໜᶧࠍ↪޿ߚ㕖ଚⷅ⊛⸻ᢿᴺߩ㐿⊒߇ᚑഞߔࠇ߫㧘㜞޿࿖㓙⊛⹏ଔࠍᓧࠄࠇࠆߣ⠨߃ࠄࠇࠆ‫ޕ‬−∩⸘ࠍ↪޿ߚญ⣧ౝ−∩ߦ㑐ߔࠆ⎇ⓥ߽㕖Ᏹߦዋߥߊ㧘ߎߩዉ౉ߦࠃࠅᦝߦ⾰ߩ㜞޿ᚑᨐࠍᓧࠆߣ⠨߃ࠄࠇࠆ‫ޕ‬㧙㧙3㧕 ⸻≮ฬ 㧦ࠬ࠲ࡦ࠳࡯࠼࡮ࡊ࡝ࠦ࡯࡚ࠪࡦߩታᣉ
⸻≮ౝኈ㧦ࠬ࠲ࡦ࠳࡯࠼࡮ࡊ࡝ࠦ࡯࡚ࠪࡦߩ᭎ᔨߦၮߠߊ㒮ౝᗵᨴ੍㒐ࠍታ࿾ߔࠆ⸳஻ࠍᢛ߃㧘㜞ᰴක≮ᯏ㑐࡮ࠛࠗ࠭⸻≮᜚ὐ∛㒮ߦ߅ߌࠆญ⣧ක≮ࠍᜂ߁⸻≮૕೙࡮ࠪࠬ࠹ࡓࠍ᭴▽ߔࠆ‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦ᐔᚑ 16 ᐕߩ⺞ᩏߢߪ㧘ࠛࠗ࠭⸻≮᜚ὐ∛㒮ߢᱤ⑼ࠍ૬⸳ߒߡ޿ࠆᣉ⸳ߩਛߢ㧘ࡂࡦ࠼ࡇ࡯ࠬ╬ࠍᖚ⠪ߏߣߦขࠅᦧ߃ࠆߩߦᔅⷐߥᧄᢙߛߌߘࠈ߃ߡ޿ࠆߩߪ⚂ඨᢙߩᣉ⸳ߢ㧘޿߹ߛᧂᢛ஻ߣߥߞߡ޿ࠆ‫ޕ‬࿖ౝ⊛⹏ଔ㧦⃻࿷㧘૞ᚑߐࠇߟߟ޽ࠆ‫ޟ‬ᱤ⑼ߦ߅ߌࠆ㒮ౝᗵᨴኻ╷ࠟࠗ࠼࡜ࠗࡦ‫ޠ‬㧔࿖┙ᄢቇ㒝ዻ∛㒮ᗵᨴኻ╷ද⼏ળ✬㧕ߩౝኈࠍḩߚߔ࡟ࡌ࡞ߦ೔㆐ߒߡ᧪ߡ޿ࠆ‫ޕ‬࿖㓙⊛⹏ଔ㧦2003 ᐕߦᡷ⸓ߐࠇߚ CDC㧔☨࿖∔∛▤ℂ੍㒐࠮ࡦ࠲࡯㧕ߩ‫ޟ‬ᱤ⑼⥃ᐥߦ߅ߌࠆ㒮ౝᗵᨴ੍㒐ࠟࠗ࠼࡜ࠗࡦ 2003‫ߢޠ‬ផᅑߒߡ޿ࠆࠬ࠲ࡦ࠳࡯࠼࡮ࡊ࡝ࠦ࡯࡚ࠪࡦߦᴪߞߚ࡟ࡌ
࡞ߩ⸻≮૕೙࡮ࠪࠬ࠹ࡓ߇᭴▽ߐࠇߡ᧪ߡ޿ࠆ‫ޕ‬4㧕 ⸻≮ฬ 㧦ญ⣧ࠤࠕߩዉ౉
⸻≮ౝኈ㧦ᕆᕈᦼ∛㒮ߢ޽ࠆᒰ㒮ߦ߅޿ߡ㧘ᱤ⑼කᏧ㧘ᱤ⑼ⴡ↢჻ߦࠃࠆኾ㐷⊛ญ⣧ࠤࠕࠍዉ౉ߒ㧘᡼኿✢࡮ൻቇ≮ᴺᤨߩญౝἻ࡮ᱤᕈᗵᨴ∝╬ߩ಴⃻੍㒐㧘߅ࠃ߮๟ⴚᦼߩ⺋ྚᕈ⢖Ἳ࡮ᗵᨴߩシᷫࠍ࿑ࠅ㧘ᧄ᧪ߩᴦ≮ലᨐ㧘⾰⊛ะ਄ߦነਈߔࠆߎߣࠍ⋡⊛ߦዷ㐿ߒߡ޿ࠆ‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦࿖ౝߩ޿ߊߟ߆ߩᣉ⸳ߢߪⴕࠊࠇ㧘ലᨐ޽ࠅߣߩ࡟ࡐ࡯࠻߇ႎ๔ߐࠇߡ޿ࠆ‫ޕ‬ߒ߆ߒ㧘ጘ㒂⋵ౝߦ߅޿ߡࠪࠬ࠹ࡑ࠹ࠖࠢߦዷ㐿ߒߡ޿ࠆᣉ⸳ߪߥ޿‫ޕ‬࿖ౝ⊛⹏ଔ㧦ᕆᕈᦼ∛㒮ߦ߅޿ߡญ⣧ࠤࠕࠍవ㚟⊛ߦขࠅ⚵ࠎߢ޿ࠆ∛㒮߆ࠄⴚᓟ⢖Ἳߩᷫዋ߿ᖚ⠪ߩḩ⿷ᐲะ਄ߩႎ๔߇ LANCET ߥߤߦ߽ߥߐࠇߡ߅ࠅ㧘ญ⣧ࠤࠕߩ࠾࡯࠭ߣ⹏ଔ߇⹺⼂ߐࠇߟߟ޽ࠅ㧘ห᭽ߩࠤࠕࠍዷ㐿ߒߡ޿ࠆ‫ޕ‬࿖㓙⊛⹏ଔ㧦2004 ᐕߦ CDC㧔☨࿖∔∛▤ℂ੍㒐࠮ࡦ࠲࡯㧕߇౏㐿ߒߚ‫ޟ‬ක≮ࠤࠕ㑐ㅪ⢖Ἳ㒐ᱛߩߚ߼ߩࠟࠗ࠼࡜ࠗࡦ‫ߪߢޠ‬㧘VAP㧔ੱᎿ๭ๆེ㑐ㅪ⢖Ἳ㧕ኻ╷ߩ 1 ߟߣߒߡ㧘ੱᎿ๭ๆེⵝ
⌕ᖚ⠪ߦ߅ߌࠆญ⣧ࠤࠕߩ㊀ⷐᕈ߇ᒝ⺞ߐࠇߡ߅ࠅ㧘หߓᚻᛛߩዉ౉ࠍⴕ޿ዷ㐿ߒߡ޿ࠆ‫ޕ‬
4㧚ኾ㐷ක࡮⹺ቯක࡮ᜰዉක
ᩊ↰ᢅਯ㧦ᣣᧄญ⣧ᄖ⑼ቇળኾ㐷ක࡮ᜰዉක
࿯੗↰⺈㧦ᣣᧄญ⣧ᄖ⑼ቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄ∛ℂቇળ⹺ቯญ⣧∛ℂකጊਅ⍮Ꮘ㧦ᣣᧄญ⣧ᄖ⑼ቇળኾ㐷ක࡮ᜰዉක
ട⮮ᕺਃ㧦ᣣᧄญ⣧ᄖ⑼ቇળኾ㐷ක࡮ᜰዉක
’↰ᶈ᮸㧦ᣣᧄญ⣧ᄖ⑼ቇળኾ㐷ක⇗ጊᄢੑ㇢㧦ᣣᧄญ⣧ᄖ⑼ቇળኾ㐷ක
5㧚⥄Ꮖ⹏ଔ
⹏ଔ
1.㨪3.ߦ㑐ߒߡ㧘᭎ߨ⋡ᮡߪ㆐ᚑߐࠇߡ޿ࠆߣᕁࠊࠇࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ᄖ᧪ฃ⸻⠪ߩേะߣߒߡ㧘৻⥸ᱤ⑼ᴦ≮∝଀ߪᷫዋߒ㧘⚫੺㧔฽߻㒮ౝ⚫੺㧕ߦࠃࠆ․ᱶ∝଀߇Ⴧടߒ㧘ฃ⸻⠪ߩ⾰⊛࡮᭴ㅧ⊛ᄌൻ߇↢ߓߡ᧪ߡ޿ࠆ‫߇ࠆ޽ߪߢߣߎ޿ߒ߹ᦸߪ⽎⃻ߩߎޕ‬㧘ߎߩ߹߹ផ⒖ߔࠆߣ㧘⎇ୃකᢎ⢒ߦਇㇺว߇↢ߓࠆน⢻ᕈ߇ෂᗋߐࠇࠆ‫߼ߚߩߎޕ‬㧘৻⥸ᖚ⠪ߩჇᄢߦะߌߡᄢቇ଻ஜ▤ℂ࠮ࡦ
࠲࡯ߣߩㅪ៤ߦࠃࠅቇ↢࡮⡯ຬߩஜ⸻ࠍⴕߥߞߡ޿ࠆ‫৻ޕ‬ᣇ㧘౉㒮∝଀ߥ޿ߒ⚫੺∝଀ߪẋᰴჇട௑ะࠍ
␜ߔߎߣࠃࠅ㧘਄ㅀߔࠆദജࠍ⛮⛯࡮⊒ዷߐߖࠆߎߣ߇㊀ⷐߣ⠨߃ࠄࠇࠆ߇㧘⃻࿷㧘ᤨᦼߦࠃࠅ㧘౉㒮ᓙߜ㧔ᚻⴚᓙߜ㧕߇ 2㨪3 ߆᦬ߣߥࠆߚ߼㧘ᚻⴚᨒߩᒢജ⊛ߥ⏕଻߇ᦸ߹ࠇࠆኻ╷ߣߥߞߡ޿ࠆ‫ޕ‬੹ᓟߩዷᦸᒰ⑼ߩሽ࿷ᗧ⟵ߪ㧘ߎߩ࿾඙ߩญ⣧ක≮ߩੑᰴ㧘ਃᰴක≮ᯏ㑐ߣߒߡߩ⽿ോࠍᨐߚߔߣߣ߽ߦ㧘ࠃࠅ⾰ߩ㜞޿ญ⣧ක≮ࠍ቟ో߆ߟᔟㆡߦឭଏߔࠆߎߣߦ޽ࠆߣ⠨߃ߡ޿ࠆ‫ߡߞ߇ߚߒޕ‬㧘ߎࠇࠄߩ૶๮߇ᨐߚߖ
ߥ޿႐ว㧘੹ᓟߩዷᦸߪᦸ߼ߕ㧘ߎߩછࠍᨐߚߔߎߣߩߺ߇ዷᦸࠍᜏߊߣ⠨߃ߡ޿ࠆ‫ߚ߹ޕ‬㧘਄⸥ߩ૶๮
ࠍᨐߚߔߎߣߦࠃࠅ⑲ㅺߥ⥃ᐥක߇⢒ᚑߐࠇ㧘⋧ਸ਼ലᨐ⊛ߥ᣿ࠆ޿ዷᦸ߇㐿ߊ߽ߩߣ⠨߃㧘࿾㆏ߢߪ޽ࠆ
߇⏕ታߥᣇ╷ߣାߓᣣ‫ߩޘ‬ദജࠍⴕߥߞߡ޿ࠆ‫ޕ‬߹ߚ㧘ਛᦼ⊛㧔3 ᐕએౝ㧕ߩዷᦸߣߒߡ㧘ౣ↢ක≮㧔⚦⢩ࡊࡠ࠮ࠪࡦࠣ㧕ߩ᭴▽ߣߎࠇࠍᵴ↪ߒߚ⚦⢩ᴦ≮ߩዉ౉ࠍ⸘↹ߒߡ߅ࠅ㧘ߘߩ㆐ᚑߦࠃࠅᄢ߈ߥォ឵ᦼࠍㄫ߃ࠆߣᦼᓙߒߡ޿ࠆ‫ޕ‬㧙㧙㧔20㧕ᬌᩏㇱ1㧚⸻≮ߩ᭎ⷐ
1㧕ਛᄩណⴊቶ
2004 ᐕ 6 ᦬ߩ∛㒮⒖ォᤨߦᬌᩏㇱฃઃ㒝ㄭߦਛᄩណⴊቶࠍ⸳ߌ㧘ၮᧄ⊛ߦߪ 3 ࡟࡯ࡦߣߒ㧘ߘࠇߙࠇᬌᩏᛛᏧ㧘⋴⼔Ꮷ㧘⎇ୃකߢᜂᒰߒ㧘ᷙ㔀ᤨߦߪ 4 ࡟࡯ࡦߣߒߡᬌᩏㇱ߆⋴⼔ㇱ߆ࠄੱຬࠍ᜚಴ߔࠆ૕೙
ߢ㐿ᆎߒߚ‫ߩߘޕ‬ᓟ㧘ណⴊઙᢙ߇Ⴧടߔࠆߣߣ߽ߦ㧘ᖚ⠪ߐࠎߩᓙߜᤨ㑆߇ᑧ㐳ߔࠆ႐ว߇ᄙߊߥߞߚߚ
߼૕೙ࠍ⷗⋥ߔߎߣߣߒߚ‫ޕ‬2008 ᐕ 4 ᦬ࠃࠅ⎇ୃකߪᜂᒰ߆ࠄߪߕࠇ㧘ᬌᩏㇱߣ⋴⼔ㇱߢᜂᒰߔࠆߎߣ
ߣߒߚ‫⃻ޕ‬࿷ᦐᣣߦࠃߞߡᜂᒰ࡟࡯ࡦᢙߪ⇣ߥࠆ߇㧘ᐔဋߔࠆߣ 6㧦4 ߋࠄ޿ߢᬌᩏㇱ߇ᄙߊᜂᒰߒߡ޿
ࠆ‫ߚ߹ޕ‬㧘ណⴊቶ߇⁜㓖ߥߚ߼㧘ේೣߣߒߡዊఽߣゞ᫹ሶߩᖚ⠪ߐࠎߪᄖ᧪ࡉ࡯ࠬߢណⴊߒߡ߽ࠄ߁ߎߣ
ߦߥߞߡ޿ࠆ‫ޕ‬
2㧕৻⥸ᬌᩏ࡮ⴊᶧㇱ㐷৻⥸ᬌᩏ㧔ዩᬌᩏ㧕߽∛㒮⒖ォߣߣ߽ߦᣂⷙߦ┙ߜ਄ߍߚㇱ㐷ߢ޽ࠆ‫ޕ‬ᣥ∛㒮ߦ߅޿ߡߪฦ⸻≮⑼ߢዩ
ᬌᩏࠍߒߡ޿ߚ߇㧘ߎࠇࠍ㓸⚂ൻߔࠆߎߣߢ⸻≮ߩല₸ൻ߇ታ⃻ߢ߈ߚ‫ޕ‬ᄖ᧪߆ࠄߩⴊᶧ߽฽߼ߚࠝ࡯࠳
࡯ߢߪ㧘ዩᬌᩏ⚿ᨐ߇ᦨ߽ᣧߊႎ๔ߐࠇߡ޿ࠆ‫⥄ߪࠇߎޕ‬േಽᨆⵝ⟎ߢ᷹ቯߒߡ޿ࠆߚ߼ߢ޽ࠆ߇㧘࠺࡯࠲ࠍߘߩ߹߹㄰ߒߡ޿ࠆߩߢߪߥߊ㧘ቯᕈ෻ᔕߢ૗ࠄ߆ߩ⇣Ᏹࠍ߈ߚߒߡ޿ࠆዩᬌ૕ߦߟ޿ߡߪ 8 ഀߋࠄ޿ߪ⋡ⷞ㧔ታ㓙ߦዩᴉᷲࠍ㗼ᓸ㏜ߢⷰኤߔࠆߎߣ㧕ߒߡ߅ࠅ㧘♖ᐲߩ㜞޿⚿ᨐࠍႎ๔ߒߡ޿ࠆ‫ⴊޕ‬ᶧㇱ㐷
ߪ 2́3 ฬߢᜂᒰߒߡ߅ࠅ㧘ⴊᶧ৻⥸ߩ⚿ᨐ߽ዩᬌᩏߦᰴ޿ߢᣧߊႎ๔ߒߡ޿ࠆ‫ߦࠄߐޕ‬㛽㜑௝ߩᚲ⷗߽
⸥ߒߡ޿ࠆ‫ޕ‬
3㧕ᬌ૕ᬌᩏㇱ㐷↢ൻቇ㧘ⴊᷡㇱ㐷ߪᄢ߈޿⥄േಽᨆⵝ⟎߇ࠬࡍ࡯ࠬࠍභ߼㧘ᄙߊߩᬌᩏ㗄⋡ࠍಣℂߒߡ޿ࠆߩߢ 5 ฬ⒟ᐲ㈩⟎ߒߡ޿ࠆ‫ߦࠄߐޕ‬ਛᄩណⴊቶߩ❥ᔔ⁁ᴫߦᔕߓߚណⴊࠬ࠲࠶ࡈߩੱຬ㈩⟎㧘ฦ⸻≮⑼߆ࠄߩ໧޿ว
ࠊߖኻᔕ㧘ᬌᩏ㗄⋡ߩㅊടଐ㗬㧘㒮ᄖ߆ࠄߩ㔚⹤ኻᔕ㧘ࡄ࠾࠶ࠢ୯ߩਥᴦක߳ߩㅪ⛊ߥߤࠍ೽ᛛᏧ㐳߇ਛᔃߣߥߞߡⴕߞߡ޿ࠆ‫ޕ‬ᬌᩏࠬ࠲࠶ࡈߪ࠴ࠚ࠶ࠢࡠࠫ࠶ࠢߦ߆߆ߞߚ⚿ᨐߩ⏕⹺߿㧘Ꮧ㉼ౣᬌ㧘⏕⹺ౣᬌᜰ␜ߥߤࠍⴕߥ޿㧘ല₸⊛ߥㆇ༡ߦᔃដߌߡ޿ࠆ‫ޕ‬
4㧕↢ℂㇱ㐷
ᔃ㔚࿑㧘ᔃࠛࠦ࡯㧘⣖ᵄ㧘╭㔚࿑㧘⢖ᯏ⢻ᬌᩏߦട߃㧘ࠨ࡯ࡕࠣ࡜ࡈࠖ࡯߇ᣂߚߦᬌᩏ㗄⋡ߦടࠊߞߚ‫ޕ‬․ߦᦨㄭߪ⿥㖸ᵄᬌᩏߦജὐࠍ⟎߈㧘ߥࠆߴߊᄙߊߩ∝଀ࠍขࠅ౉ࠇࠆࠃ߁ࠝ࡯࠳࡯ᨒߩჇ⸳ࠍᬌ⸛ߒߡ
޿ࠆ‫ޕ‬หᤨߦᬌᩏᛛᏧߩ⢒ᚑߦ߽ജࠍ౉ࠇ㧘ᓴⅣེౝ⑼㧘ᶖൻེౝ⑼಴りߩᬌᩏㇱකᏧ߇㧘ᬌᩏ⚿ᨐࠍᦨ⚳࠴ࠚ࠶ࠢߒߡ޿ࠆ‫⃻ޕ‬࿷ߩ⿥㖸ᵄᬌᩏ჻⾗ᩰ⠪ 3 ฬߢ޽ࠅ㧘ߐࠄߦ᦭⾗ᩰ⠪ࠍჇ߿ߔ੍ቯߢ޽ࠆ‫ޕ‬
5㧕⚦⩶ㇱ㐷
㒮ౝᗵᨴኻ╷ߩ㕙߆ࠄߎߩㇱ㐷ߩ㊀ⷐᕈߪ㜞߹ߞߡ޿ࠆ‫⃻ޕ‬࿷ 2 ੱ૕೙ߢ޽ࠅ㧘⚿ᩭ⩶ၭ㙃ⵝ⟎߿㧘⩶หቯⵝ⟎ࠍዉ౉ߒ㧘ㄦㅦߥ⚿ᨐࠍ಴ߔࠃ߁ദ߼ߡ޿ࠆ‫ޕ‬ᬌ૕ߩฃߌઃߌ߽ 24 ᤨ㑆૕೙ߣߒ㧘⥃ᐥࠨࠗ࠼ߩⷐ᳞ߦኻᔕߒߡ޿ࠆ‫↢ޕ‬૕ᡰេ࠮ࡦ࠲࡯ߣᲤㅳࡒг ࠹ࠖࡦࠣࠍⴕ޿ߥ߇ࠄ㧘㒮ౝᗵᨴኻ╷ࠍਁోߥ߽ߩ
ߦߔࠆߴߊ㧘ദജߒߡ޿ࠆ‫ߚ߹ޕ‬㧘ක≮ᖱႎࡃ࡯࡚ࠫࡦࠕ࠶ࡊߩ⸘↹ߦᴪߞߡ㧘㒮ౝᗵᨴኻ╷࠰ࡈ࠻ߩዉ
౉ࠍ⸘↹ਛߢ޽ࠆ‫ޕ‬
6㧕ᬌᩏᖱႎㇱ㐷ᣂⷙ㗄⋡ߩ㒮ౝขࠅㄟߺ߿ᄖᵈൻߦ઻߁ࠝ࡯࠳࡯↹㕙ߩಣℂ㧘ฦ⥃ᐥ⑼ߩ࠮࠶࠻ᬌᩏ㗄⋡ߩᄌᦝߥߤߦ
㓐ᤨኻᔕߒߡ޿ࠆ‫ઁߩߘޕ‬Ᏹߦ∛㒮ක≮ᖱႎㇱߣㅪ៤ࠍขࠅߥ߇ࠄ઀੐ࠍㅴ߼ߡ޿ࠆ‫ߚ߹ޕ‬㧘ᬌᩏㇱ߆ࠄઁㇱ㐷ࠬ࠲࠶ࡈ߳ᖱႎࠍឭଏߔࠆ࠷࡯࡞ߣߒߡ㧘RefDB㧔࡝ࡈࠔ࡟ࡦࠬ࠺࡯࠲ࡌ࡯ࠬ㧕ࠍዉ౉ߒߚ‫ޕ‬ᬌᩏㇱ߆ࠄߩㅢ⍮߿㗄⋡࡝ࡈࠔ࡟ࡦࠬ㧘ᬌ૕ណขኈེ৻ⷩ㧘ICD10 ∛ฬᬌ⚝ߥߤ߇ᖱႎߣߒߡᓧࠄࠇࠆ‫ޕ‬කᏧ߿⋴⼔Ꮷߪ߽ߜࠈࠎකቇ↢߽ᄙߊ೑↪ߐࠇߡ߅ࠅ㧘੹ᓟߪਛᄩណⴊቶߢណⴊᓙߜߩᖚ⠪ߐࠎะߌߦᬌᩏ
ᖱႎࠍ⥄↱ߦ㑛ⷩߢ߈ࠆ┵ᧃࠍ⸳⟎ߔࠆߥߤ㧘ࠃࠅ⦟޿ⅣႺߩᢛ஻ࠍ⋡ᜰߒߡ޿ࠆ‫ޕ‬7㧕㜞ᐲవㅴක≮ᬌᩏㇱ㐷㧔․ᱶᬌᩏ㧕ߎ ߎ ߢ ߪ ⥃ ᐥ ⑼ ߆ ࠄ ․ ೎ ߦ ଐ 㗬 ߐ ࠇ ࠆ ᬌ ᩏ ߦ ߟ ޿ ߡ ኻ ᔕ ߒ ߡ ޿ ࠆ ‫ ⃻ ޕ‬࿷ ߩ ߣ ߎ ࠈ ߪ FCM
㧔flowcytometry㧕ࠍ↪޿ߚ᷹ቯ߇ᄙ޿߇㧘৻ㇱߦࡊࡠ࠹ࠝࡒࠢࠬߦࠃࠆ⾰㊂ಽᨆࠍⴕߥߞߡ޿ࠆ‫ੱߦ․ޕ‬ຬߩ㈩⟎ߪⴕߥࠊߕ㧘ᛛⴚࠍ᦭ߔࠆ⠪߇ㆡቱኻᔕߒߡ޿ࠆ‫ޕ‬
2㧚ᢎ⢒ᣉ⸳
1㧕 ᣣᧄ⥃ᐥᬌᩏකቇળ⹺ቯ∛㒮
3㧚⸻≮㐿⊒⃻࿷㧘ᬌᩏㇱ⁛⥄ߩ․⦡޽ࠆᬌᩏࠍḰ஻㧘ᬌ⸛ਛߢ޽ࠆ߇ታ⃻ߒߡ޿ߥ޿‫ޕ‬㧙㧙4㧚ኾ㐷ක࡮⹺ቯක࡮ᜰዉකᷡፉ ḩ㧦ᣣᧄ⥃ᐥᬌᩏකቇળኾ㐷ක㧘ᣣᧄᶖൻེ∛ቇળኾ㐷ක㧘ᣣᧄ⢄⤳ቇળኾ㐷ක㧘ᣣᧄౝ⑼ቇળ⹺ቯකદ⮮ᒄᐽ㧦ᣣᧄකᏧળ⹺ቯ↥ᬺක
㊄᫪ኡశ㧦ᣣᧄౝ⑼ቇળ⹺ቯ㧘ᣣᧄᓴⅣེ∛ቇળኾ㐷කᄢỈ㓁੺㧦ᣣᧄౝ⑼ቇળ⹺ቯක㧘ᣣᧄᶖൻེ∛ቇળኾ㐷ක㧘ᣣᧄౝⷞ㏜ቇળኾ㐷ක㧘ᣣᧄ⢄⤳ቇળኾ㐷ක
5㧚⥄Ꮖ⹏ଔ
⹏ଔᬌᩏᬺോߦ㑐ߔࠆߎߣ߇ࠄߢߪචಽߦ⹏ଔߢ߈ࠆ࡟ࡌ࡞ߢ޽ࠆߣ⠨߃ߡ޿ࠆ‫ߒ߆ߒޕ‬㧘ᬌᩏᛛᏧߩ⢒ᚑߦߟ޿ߡߪ✜ߦ⌕޿ߚ߫߆ࠅߢ޽ࠆὐ㧘ߘࠇߣᬌᩏㇱ⁛⥄ߩ․⦡޽ࠆᬌᩏߦߟ޿ߡ߽⒳‫ޘ‬ᬌ⸛ߒߡ޿ࠆߣ
ߎࠈߢ޽ࠆ߇㧘ታ⃻ߒߡ޿ߥ޿ὐ߇੹ᓟߩ⺖㗴ߢ޽ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ਛᄩណⴊቶߩࠃࠅ౞Ṗߥㆇ༡‫ᤨߪߢ⁁⃻ޕ‬㑆Ꮺߦࠃߞߡߪᖚ⠪ߐࠎ߇ណⴊቶ߆ࠄ޽߰ࠇߡ┙ߞߡᓙߞߡ
޿ࠆ⁁ᴫ߇⷗ࠄࠇࠆ‫ޕ‬ណⴊઙᢙߩᄙ޿ᦐᣣߪ੍᷹ߢ߈ࠆߩߢ㧘ណⴊᚻᛛߩ਄ᚻߥ⡯ຬࠍ㈩⟎ߔࠆࠃ߁ߦ⋴⼔ㇱ߆ࠄߩᔕេ߽฽߼ߡ 4 ࡟࡯ࡦࠍࡈ࡞Ⓙേߐߖߡኻᔕߒߡ޿ࠆ‫ߚ߹ޕ‬㧘ណⴊߢ߈ࠆ⡯ຬߩ⢒ᚑߣ㧘ߐࠄߥࠆࠬࠠ࡞ࠕ࠶ࡊߦฦ⥄ᔃដߌߡ޿ࠆ‫ޕ‬ᬌᩏ⚿ᨐߩ TAT㧔turnaround time㧕ߪ߅ࠃߘ 30 ಽ⒟ᐲࠍ⋡ᮡߣߒߡ޿ࠆ߇㧘⇣Ᏹ୯㧔޽ࠆ޿ߪ೨࿁୯ߣᲧセߒߡਵ㔌߇޽ࠆ႐ว㧕ࠍ␜ߒߚ႐วߪ⥄േ⊛ߦౣᬌߦ࿁ߔ઀⚵ߺߦߥߞߡ߅ࠅ㧘ᦨ⚳⊛ߦߘߩ㗄⋡ߩߺႎ๔߇ㆃߊߥࠆߎߣ߇޽ࠆ‫ޕ‬㗄⋡ߏߣߦౣᬌߩᔅⷐᐲ߽⇣ߥࠅ㧘ࠬࡓ࡯ࠬߥᄖ᧪⸻≮ࠍታ⃻ߔࠆߚ߼ߦౣᬌߩၮḰࠍ⷗⋥ߔᔅⷐ߇޽ࠆ‫ઁߩߘޕ‬㧘කᏧߦࠃࠆࠝ࡯࠳࡯ᔓࠇ߇޽ࠅ㧘ߎߩ႐วߪᖚ⠪ߐࠎ߇ฃߌઃߌߦ᧪ߡ߽ណⴊ߇ߢ߈ߥ޿ߩߢ㧘ᯏળ޽ࠆߏߣߦ⥃ᐥࠨࠗ࠼ߦ༐⿠ߒߡ޿ߊ‫ޕ‬੹ᓟߩዷᦸᬌᩏㇱߣߒߡ⋡ᜰߒߡ޿ࠆߩߪ㧘⸻ኤ೨ᬌᩏߦࠃࠆㄦㅦߥ⚿ᨐߩឭଏ㧘ࠦࠬ࠻ߩૐᷫ㧘⥃ᐥ⑼߳ߩઃട
ଔ୯ߩ޽ࠆ࠺࡯࠲ࠨ࡯ࡆࠬ㧘ᄢቇ∛㒮ߩᬌᩏㇱߣߒߡ㜞ᐲవㅴක≮ߦᷓߊ㑐ࠊߞߡ޿ߊߣ޿߁ᆫ൓ࠍᏱߦ
ࠠ࡯ࡊߒߡ㧘∛㒮ߦߣߞߡਇนᰳߥሽ࿷ߣߥࠆߎߣߢ޽ࠆ‫ౕޕ‬૕⊛ߦߪ㧔1㧕ㄦㅦᕈ㧘
㧔2㧕ᱜ⏕ᕈ㧘㧔3㧕⚻ᷣᕈ㧘
㧔4㧕⋭ജൻߦࠃࠆᬺോ᜛ᄢ㧘
㧔5㧕㜞ᐲవㅴක≮ࠍ࠲࡯ࠥ࠶࠻ߦផㅴߒߡ߈ߚ߇㧘ᐘ޿ᦼᓙㅢࠅߩ
޽ࠆ޿ߪߘࠇએ਄ߩᚑᨐ߇ᓧࠄࠇߡ߅ࠅ㧘ߘࠇߪ⥃ᐥࠨࠗ࠼߳ߩࠕࡦࠤ࡯࠻ߢ‫ޟ‬ḩ⿷ᐲߪᄢ߈޿‫߁޿ߣޠ‬⚿ᨐߦ⴫ࠇߡ޿ࠆ‫ޕ‬RefDB ߥߤ߽ᄙߊߩක≮ࠬ࠲࠶ࡈߦ೑↪ߐࠇߡ߅ࠅ㧘ߐࠄߦઃടଔ୯ߩ޽ࠆᖱႎࠍ
⊒ାߢ߈ࠆࠃ߁ߦߒߚ޿ߣ⠨߃ߡ޿ࠆ‫ઁߩߘޕ‬㧘ᦨㄭߢߪㄭ㓞ߩ IT ⅣႺ߽ᢛ஻ߐࠇߡ߈ߡ߅ࠅ㧘ጘ㒂࿾ၞో૕ߩၮḰ୯ߩ⸳ቯ㧘࠺࡯࠲ߩ౒᦭ൻࠍ⋡ᜰߒߡᒰᬌᩏㇱߢቯᦼ⊛ߦળวࠍ㐿޿ߡ޿ࠆ‫੹ޕ‬ᓟ߽ᄢቇ∛㒮ᬌᩏㇱߣߒߡߩ૶๮ࠍᨐߚߒߟߟ㧘ߘߩ৻ᣇߢ࿾ၞක≮ߦ⽸₂ߢ߈ࠆᬌᩏㇱࠍ⋡ᜰߔ‫ޕ‬㧙㧙㧔21㧕ᚻⴚㇱ1㧚⸻≮ߩ᭎ⷐ
ᚻⴚㇱߪ, ᐔᚑ 20 ᐕ 7 ᦬ߦ㜞ᰴᢇ๮ᴦ≮࠮ࡦ࠲࡯ᚻⴚㇱ㐷߆ࠄಽ㔌ߒᣂ⸳ߐࠇߚ‫․ޕ‬ቯᯏ⢻∛㒮ߢ޽ࠅᕆᕈᦼක≮ࠍᜂ߁ጘ㒂ᄢቇකቇ㒝ዻ∛㒮ߩၮᐙㇱ⟑ߢ޽ࠆߚ߼, ೽∛㒮㐳߇ᚻⴚㇱ㐳ࠍ౗ോߒ, ∛㒮⚻༡ᣇ㊎ߦวࠊߖㄦㅦߦ ᩺੐㗄ߦኻಣߢ߈ࠆᬺോ૕೙ࠍᢛ߃ߚ‫ޕ‬ᧄ㒮ߦ߅ߌࠆᚻⴚߪ, ㄭᐕߩක≮ㅴᱠߦᓥ޿㜞ᐲߢ㔍ᤃᐲߩ㜞޿ᚻⴚᖚ⠪߇ᄙߊ, ߹ߚ 8 ᤨ㑆ࠍ⿥߃ࠆ㐳ᤨ㑆ᚻⴚ߇ᄙ޿․ᓽ߇޽ࠆ‫ⶄޕ‬ᢙ⸻≮⑼ߦ߹ߚ߇ࠆⶄ㔀ߥⴚᑼ߽ᄙߊ, ᦨవ┵ߩක≮ឭଏ߽⋡ᜰߒߡ޿ࠆ‫ޕ‬㜞ᰴᢇ๮ᴦ≮࠮ࡦ࠲࡯ࠍ૬⸳ߔࠆߚ߼, ⿥✕ᕆᚻⴚ߿ᄙ⊒ᄖ், ㊀∝ᾲ்╬ߩᚻⴚᴦ≮߽Ⓧᭂ⊛ߦⴕߞߡ޿ࠆ‫ޕ‬ᚻⴚㇱߪ᭽‫ߥޘ‬ᚻⴚᖚ⠪ࠍኻ⽎ߣߒ, ੍ቯᚻⴚ࡮✕ᕆᚻⴚࠍ໧ࠊߕฦ⒳ⴚᑼࠍᗐቯߒߡᚻⴚቶࠬ࠲࠶ࡈ
߿ක≮ᯏེ߇㈩⟎ߐࠇߡ޿ࠆ‫ޕ‬㒢ࠄࠇߚੱ⊛⾗ḮߩਛߢᏱᤨහᔕ૕೙ߩ⏕଻߇ኻᄖ⊛ߦ߽᳞߼ࠄࠇߡ߅ࠅ,⿥✕ᕆᚻⴚߢ޽ߞߡ߽ᷓᄛભᣣࠍ໧ࠊߕኻᔕߢ߈ࠆࠃ߁ᚻⴚⅣႺࠍ⏕଻ߒߡ޿ࠆ‫߼ߚߩߎޕ‬ᚻⴚ⋴⼔Ꮷ߽✕ᕆᓙᯏ๭߮಴ߒ߇ⴕࠊࠇ, ߎߩὐߢߪᚻⴚㇱߪ㒮ౝߢ߽଀ᄖ⊛ߥㇱ⟑ߢ޽ࠆ‫ޕ‬એ਄ࠃࠅ, ᚻⴚㇱߩ⸻≮ߪ, 㒮ౝઁㇱ⟑ߣߩㅪ៤ߒߥ߇ࠄᄖ⑼♽⸻≮⑼ක߿㤗㈮⑼කߣදജߔࠆߎߣߢ,ᒰ㒮ߩᚻⴚᖚ⠪߇ߘߩᕲᕺࠍሽಽߦ੨ฃߢ߈ࠆࠃ߁ߦ޽ࠄࠁࠆⅣႺࠍᢛ߃ߡ޿ࠆ‫ޕ‬
2㧚ᢎ⢒ᣉ⸳
ߥߒ
3㧚⸻≮㐿⊒
1㧕 ⸻≮ฬ 㧦ᰴᦼᚻⴚㇱ㐷ࠪࠬ࠹ࡓߩ㐿⊒⃻࿷ߩᚻⴚㇱߪ, ක≮ߩ⾰ࠍ⏕଻ߒߟߟല₸ൻ߿ᮡḰൻࠍㅊ᳞ߔࠆߚ߼, ᚻⴚㇱ㐷ࠪࠬ࠹ࡓߥߤࠍㅢߓߚฦ⒳࠺࡯࠲ࡌ࡯ࠬࠍ⸃ᨆߒᬺോಽᨆࠍⴕߞߡ޿ࠆ‫ߪࠇߎޕ‬ቴⷰ⊛੐ታߦၮߠ޿ߚᚻⴚㇱㆇ༡ࠍታᣉߔࠆߎߣߢ, ήℂߩߥ޿ᬺോ⸘↹ࠍ┙᩺ߒ, ᚻⴚㇱߦ߅ߌࠆᦨ㊀ⷐ⺖㗴ߢ޽ࠆ቟ోߥᚻⴚ߳ߣ㈩ᘦߒߡ޿ࠆ‫৻ޕ‬ᣇ, ⚻༡ᜰᮡ߿ੱ᧚▤ℂ, ౕ૕⊛ᬺോಽᨆࠍㄦㅦߦ⹏ଔߒㅦ߿߆ߥᡷༀߦߟߥ߇ࠆࠃ߁ߦ, ⋴⼔ᡰេࠪࠬ࠹ࡓߣߩኒធߥㅪ៤ࠍㅢߒ
ߚᣂߒ޿ᚻⴚㇱ㐷ࠪࠬ࠹ࡓߩ㐿⊒ࠍㅴ߼ߡ޿ࠆ‫ޕ‬
4㧚ኾ㐷ක࡮⹺ቯක࡮ᜰዉක
ጤ㑆 ੧㧦ᣣᧄ⣖␹⚻ᄖ⑼ቇળኾ㐷ක, ᣣᧄ⣖තਛቇળኾ㐷ක㐳ἑ ᷡ㧦ᣣᧄ㤗㈮⑼ቇળኾ㐷ක࡮ᜰዉක
᳓㊁ศ㓷㧦ᣣᧄᄖ⑼ቇળኾ㐷ක
5㧚⥄Ꮖ⹏ଔ
⹏ଔᣂ∛㒮㐿⸳એᓟ, ጘ㒂ᄢቇ㒝ዻ∛㒮ߩⒿ௛ታ❣ߣᐔⴕߔࠆࠃ߁ߦᚻⴚઙᢙߪỗჇߒߡ޿ࠆ‫ޕ‬ᐔᚑ 16 ᐕᐲᣂ∛㒮㐿㒮ᤨߦᐕ㑆 3114 ઙߢ޽ߞߚᚻⴚઙᢙߪ, ᐔᚑ 20 ᐕߪ 4672 ઙߣ 5 ഀㄭ޿Ⴧടࠍ␜ߒ, ⁛┙ᴺੱൻߐࠇ⚻༡ᡷༀߦദജߔࠆᣥ࿖┙ᄢቇ㒝ዻ∛㒮ߩਛߢ߽࠻࠶ࡊࠍ੎߁Ⴧട₸ߢ޽ࠆ‫ޕ‬ᤤᄛࠍ໧ࠊߕᚻⴚ
ቶߪⒿ௛ߒ, ࿾ၞක≮ߩ᜚ὐߢ޽ࠆᄢቇ∛㒮ߣߒߡߩ૶๮ࠍਅᡰ߃ߒߡ޿ࠆ‫ޕ‬߹ߚᕆᕈᦼ∛㒮ߦ߅޿ߡᚻⴚߪߘߩਛᔃߣߥࠆߴ߈ක≮ⴕὑߢ޽ࠅ, ߹ߚ∛㒮⚻༡਄߽㜞޿෼⋉ࠍ↢ߺ಴ߒ, ߐࠄߦߪጘ㒂ᄢቇකቇㇱ㒝ዻ∛㒮ߩࡉ࡜ࡦ࠼ജࠍഃㅧߔࠆේേജߢ޽ࠆ‫߼ߚߩߎޕ‬ᚻⴚઙᢙߪߓ
߼ᚻⴚౝኈߪᚻⴚㇱߩ⹏ଔߢ߽޽ࠅߥ߇ࠄᒰ㒮ߩ⹏ଔߘߩ߽ߩߢ޽ࠅ, ᚻⴚઙᢙჇടߪᒰ㒮ߩࡉ࡜ࡦ࠼
ࠍ㜞߼ࠆ㊀ⷐߥⷐ⚛ߢ޽ࠆ‫ޕ‬৻ᣇߢᚻⴚㇱߪ, ᚻⴚઙᢙჇടߦ߆߆ࠊࠄߕࠬ࠲࠶ࡈჇ߇㔍ߒ޿ⅣႺߩਛߢ, ߘߩᬺോ㊂ߦኻಣߒߥ߇
ࠄ૶๮ᗵࠍ⏕଻ߔࠆߎߣ߇᳞߼ࠄࠇߡ޿ࠆ‫ߥ߁ࠃߩߎޕ‬࿎㔍ߥⅣႺߢⓍᭂ⊛ߦᚻⴚක≮ߦ⽸₂ߢ߈ߚߎߣ
ߪ, ᚻⴚㇱߩ⹶ࠅߢ޽ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ක≮ࠍขࠅᏎߊⅣႺ߇෩ߒ޿ਛߢ, ᒰ㒮ߪ⾰ߩ㜞޿ᚻⴚක≮ࠍឭଏߒ, ቟ోߢක≮ㆊ⺋ߩߥ޿ᚻⴚࠍ⋡ᜰߒ, ല₸ൻ߿ᮡḰൻࠍផㅴߒߡ޿ࠆ‫⋡ߩߎޕ‬ᮡߦᓥ޿ᚻⴚㇱߪ, ᚻⴚ੍ቯᤨ㑆ࠍ෩቞ߢ߈ࠆࠃ߁✎ኒߥᚻⴚ⸘↹ߩ┙᩺ࠍଦߔ‫ޟ‬3 ᤨ㑆࡞࡯࡞‫ࠍޠ‬ዉ౉ߒ, ᚻⴚߩ⾰ࠍᜂ଻ߒᚻⴚቶߩല₸೑↪ࠍ࿑ࠅ, ߘߩ⚿ᨐౣᚻⴚ₸ߪૐਅߒߚ‫ޕ‬㧙㧙߹ߚᮡḰൻ߿ല₸ൻࠍផㅴߔࠆߎߣߢ, ᄖ⑼♽⸻≮⑼ක߿㤗㈮⑼, ߐࠄߦᚻⴚቶ⋴⼔ᏧᢙߩჇຬ߇ᦸ߼
ߥ޿ਛߢ, ቟ోߦᚻⴚઙᢙߩჇടࠍ㆐ᚑߒߡ޿ࠆ‫ߦࠄߐޕ‬቟ోኻ╷, ᗵᨴኻ╷ߣ޿ߞߚၮᧄ⊛࡞࡯࡞߽㒮ౝ⛔৻ၮḰߦᓥ޿ࠦࡦࡊ࡜ࠗࠕࡦࠬࠍㆩ቞ߒ, ᚻⴚ⋴⼔߽⛘߃ߕᡷༀࠍ㊀ߨࠆߎߣߢဋ৻ߥᚻⴚⅣႺ߇
ឭଏߢ߈ࠆࠃ߁ߦ, ᚻⴚㇱ⚵❱ో૕ߩࡏ࠻ࡓࠕ࠶ࡊߦദ߼ߡ޿ࠆ‫ޕ‬ᚻⴚቶߩᣣൕᏪⒿ௛₸ߪ 80%ᓟඨ߆ࠄ 90%ߣ㕖Ᏹߦ㜞޿୯ࠍ␜ߒߡ޿ࠆ‫ ߪߦ⊛⥸৻ޕ‬70%ߩⒿ௛₸߇⋡ᮡߣߐࠇࠆਛߢߩߎߩ୯ߪ, ⃻⁁ߩⒿ௛ 7 ᨒߦ෼ኈߢ߈ߥ޿ᚻⴚ߹ߢ߽߇ⷙቯᨒએ਄ߦಣℂߐࠇߡ޿ࠆ
ߎߣࠍ␜ߒ, ㆊ೾ߥᚻⴚઙᢙࠍㄼࠄࠇߡ޿ࠆᚻⴚㇱߩ⃻⁁ࠍ┵⊛ߦ⴫⃻ߒߡ޿ࠆᢙ୯ߢ޽ࠆ‫ޕ‬቟ోࠍ‶†ߦߒߥ޿ࠃ߁ߦ, ᣣ‫⧰ߩޘ‬ഭ߇⛯޿ߡ޿ࠆ‫ޕ‬߹ߚᚻⴚㇱㆇ༡ߪᚻⴚㇱන⁛ߢߥߒᓧࠆ߽ߩߢߪߥߊ, ᄖ⑼♽⸻≮⑼߿㤗㈮⑼ߩදജߢᚑࠅ┙ߞߡ޿ࠆ‫ߩߎޕ‬ਛߢ, ో૕ߩᦨㆡൻߩⷰὐ߆ࠄᚻⴚㇱߩ෩ߒ޿ࠬࠤࠫࡘ࡯࡞ࠍ᭴ᚑߔࠆߚ߼, ᄙߊߩ⸻≮⑼ߦᚻ
ⴚࠬࠤࠫࡘ࡯࡞ߩⲢㅢࠍଐ㗬ߔࠆߎߣߢᚻⴚㇱⒿ௛߇ᚑ┙ߒߡ޿ࠆ‫ޕ‬ฦᄖ⑼♽⸻≮⑼ߦߪᚻⴚࠬࠤࠫࡘ࡯
࡞૞ᚑߦ߅޿ߡᚻⴚㇱߩㇺวࠍఝవߖߑࠆࠍᓧߥ޿⃻⁁ߦਇḩ߽޽ࠆਛߢ, ᄙᄢߥߏℂ⸃ࠍ㗂޿ߡ޿ࠆ⃻⁁ߦᗵ⻢ߒߡ޿ࠆ‫ޕ‬ߎߩࠃ߁ߦᄙߊߩᬺോᡷༀࠍ㊀ߨࠆߎߣߢᄢ߈ߥ෼⋉ࠍዉ߈∛㒮⚻༡ߦ⽸₂ߒߡ߈ߚ߇, ߿ߪࠅᚻⴚ
ㇱࠬ࠲࠶ࡈߩߺߩദജߛߌߢߪ㒢⇇ߦㄭߠ߈ߟߟ޽ࠅ, ⃻⁁ߩ⡯႐ⅣႺߪㅼㄼߒߡ޿ࠆ‫ޕ‬዁᧪ߩ∛㒮⚻༡ᣇ㊎ࠍ⠨ᘦߔࠆ਄ߢ, ᕆᕈᦼ∛㒮ߣߒߡࠃࠅⓍᭂ⊛ߦᚻⴚක≮ࠍ⋡ᜰߔߩߢ޽ࠇ߫, ߎࠇ߹ߢߩᚑᨐ߽⠨ᘦߒߚ਄ߢ, ᚻⴚㇱߪੱຬ, ᓙㆄ㕙ߢⓍᭂ⊛ߦ⹏ଔߐࠇࠆߴ߈ߢ޽ࠆ‫ޕ‬੹ᓟߩዷᦸᒰ㒮ߢᚻⴚࠍᏗᦸߔࠆᖚ⠪ᢙߩჇട߿, ᄖ⑼♽ᖚ⠪ߩ࿷㒮ᣣᢙ⍴❗ߦࠃࠅᄖ⑼∛᫟ߩ∛ᐥ೑↪₸߇ะ਄ߒᚻⴚน⢻ᖚ⠪ᢙ߇Ⴧടߒߡ޿ࠆ‫߼ߚߩߎޕ‬ᚻⴚᓙߜᦼ㑆߽ᑧ㐳ߒ, ࠃࠅᄙߊߩᚻⴚᨒߩឭଏࠍᄖ⑼♽⸻≮⑼߆ࠄ᳞߼ࠄࠇߡ޿ࠆ‫ߩ⁁⃻ߒ߆ߒޕ‬ᚻⴚㇱߦߘߩ૛⵨ߪߥߊ, ᚻⴚㇱߩ዁᧪ዷᦸߪᧄ㒮ߩ⚻༡ᣇ㊎ߦᆔߨࠄࠇߡ޿ࠆ‫ޕ‬㧙㧙㧔22㧕᡼኿✢ㇱ
1㧚⸻≮ߩ᭎ⷐ
᡼኿✢ㇱߪ㧘ᖚ⠪ߩ቟ోࠍ╙৻ߦ⠨߃㧘↹௝⸻ᢿ㧘᡼኿✢ᴦ≮㧘ᩭකቇᬌᩏߩ 3 㗔ၞߦଥࠆⵝ⟎ࠍ⸳⟎ߒ㧘ฦ⸻≮⑼෸߮⸻≮ㇱ╬ߩ⸻≮૕೙ࠍࠨࡐ࡯࠻ߒߡ޿ࠆ‫ޕ‬Ᏹߦᣂߒ޿ᛛⴚࠍขࠅ౉ࠇ㧘㜞ᐲߥ⸻≮ౝኈߣᖱႎࠍឭଏߒߡ޿ࠆ↹௝⸻ᢿߩ㗔ၞߦ߅޿ߡߪ㧘৻⥸᠟ᓇ㧘CT ᬌᩏ㧘MR ᬌᩏ㧘ฦ⒳ㅧᓇᬌᩏߣⴊ▤ㅧᓇߦട߃㧘᳇▤ᡰౝⷞ㏜⊛ᴦ≮߿ⴊ▤ౝᚻⴚ㧘⢷⣧ౝ࡮⣻⣧ౝⴊ▤Ⴇᩖⴚ෸߮േᵈᴦ≮ߩ Interventional Radiology ࠍ฽߼ߚᐢ▸ߥ㗔ၞ߹ߢ೑↪ߐࠇߡ޿ࠆ‫߹ޕ‬ߚ㧘64 ೉ߩ CT ⵝ⟎ߦࠃࠆᔃ⤳ CT ߽ⴕ߁੍ቯߢ޽ࠆ‫ޕ‬᡼኿✢ᴦ≮㗔ၞߦ߅޿ߡߪ㧘MR㧘CT ↹௝ࠍ↪޿ߚ㜞♖ᐲߩᄖㇱᾖ኿㧘⣧ౝᾖ኿㧘⚵❱ౝᾖ኿ࠍⴕ޿㧘ᩮᴦߒᓧࠆㆡᔕ∔ᖚߩ᜛ᄢߣᴦ≮ᚑ❣ߩะ਄ߦദ߼ߡ޿ࠆ‫ߦࠄߐޕ‬㧘ቯ૏᡼኿✢ᴦ≮߿ᒝᐲᄌ⺞᡼኿✢ᴦ≮㧔IMRT㧕߽ⴕߞߡ޿ࠆ‫ޕ‬ᩭකቇᬌᩏߩ㗔ၞߦ߅޿ߡߪ㧘⤳ེࠗࡔ࡯ࠫࡦࠣߦࠃࠆ⣲≌ሽ࿷⸻ᢿ㧘⤳ེᯏ⢻⸻ᢿ㧘⤳ེⴊᵹ㊂ቯ㊂᷹ቯࠍታᣉߒ㧘ᴦ≮ᴺߩㆬᛯ㧘ᴦ≮ലᨐߩ⹏ଔ╬ߦ೑↪ߐࠇߡ޿ࠆ‫ߚ߹ޕ‬㧘ᐔᚑ 19 ᐕᐲࠃࠅ㓁㔚ሶ᡼኿
ᢿጀᴺ㧔PET㧕ⵝ⟎ߦࠃࠆᬌᩏ߽㐿ᆎߒߡ޿ࠆ‫ޕ‬ᬺോߩㆀⴕߦ޽ߚߞߡߪ㧘ක≮ᖱႎࠪࠬ࠹ࡓߦࠃࠅోߡߩᬌᩏߦ߅޿ߡ㧘ࠝ࡯࠳࡝ࡦࠣࠪࠬ࠹ࡓߦࠃߞ
ߡ੍⚂߆ࠄળ⸘ಣℂᬺോߐࠄߦ⛔⸘ᬺോ߹ߢല₸⦟ߊㆇ↪ߐࠇߡ޿ࠆ‫ޕ‬
2㧚ᢎ⢒ᣉ⸳
1㧕 ᡼኿✢⑼ኾ㐷කୃ✵ᯏ㑐
2㧕 ᣣᧄᩭකቇળኾ㐷කᢎ⢒∛㒮
3㧚⸻≮㐿⊒
ߥߒ4㧚ኾ㐷ක࡮⹺ቯක࡮ᜰዉක
౗᧻㓷ਯ㧦ᣣᧄකቇ᡼኿✢ቇળኾ㐷ක㧘ᣣᧄⴊ▤ㅧᓇ࡮IVR ቇળᜰዉක
ᵻ㊁㓉ᒾ㧦ᣣᧄකቇ᡼኿✢ቇળኾ㐷ක㧘ᣣᧄᩭකቇળ PET ᩭකቇ⹺ቯක㧘ᣣᧄᩭකቇળᩭකቇኾ㐷කട⮮ඳၮ㧦ᣣᧄකቇ᡼኿✢ቇળኾ㐷ක㧘ᣣᧄᩭකቇળ PET ᩭකቇ⹺ቯක㧘ᣣᧄⴊ▤ㅧᓇ࡮IVR ቇળᜰዉකዊፉኼਭ㧦ᣣᧄකቇ᡼኿✢ቇળ⹺ቯක㧘ᣣᧄᩭකቇળ PET ᩭකቇ⹺ቯක
ᵻ↰ୃᏒ㧦ᣣᧄකቇ᡼኿✢ቇળኾ㐷ක
5㧚⥄Ꮖ⹏ଔ
⹏ଔ
ᐔᚑ 16 ᐕ 6 ᦬ߦᣂ∛㒮㐿㒮ᓟ㧘᡼኿✢ㇱߪ㧘ਛᄩ⸻≮ᣉ⸳ߣߒߡ㧘৻⥸න⚐᠟ᓇ㧘CT㧘MRI㧘੃ᚱ᠟ᓇቶ㧘㛽ኒᐲ᷹ቯቶ㧘ᩭකቇᬌᩏቶ㧘X-✢ㅘⷞቶ㧘ⴊ▤ㅧᓇቶ㧘᡼኿✢ᴦ≮߇ߔߴߡ 1 㓏ߦ㓸ਛߒߡ㈩⟎ߐࠇߡ޿ࠆߚ߼㧘േ✢਄߽ല₸⊛ㆇ↪ߦᄢ޿ߦ⾗ߒߡ޿ࠆ‫ޕ‬ᐔᚑ 19 ᐕ 11 ᦬ߦߪᩭකቇᬌᩏቶߦ PET/CTⵝ⟎ࠍዉ౉ߒ㧘㒮ౝ∝଀ߩߺߥࠄߕ∛⸻ㅪ៤ࠍ੺ߒߡ㒮ᄖ∝଀߽ FDG-PET/CT ᬌᩏࠍ㐿ᆎߒߡ޿ࠆ‫ޕ‬
ᐔᚑ 19 ᐕᐲߩ CT ᬌᩏ✚ᢙߪ߅ࠃߘ 24,000 ઙ㧘
MRI ᬌᩏ✚ᢙߪ߅ࠃߘ 11,000 ઙߢ޽ࠅ㧘ߘࠇߙࠇ 600
ᐥⷙᮨߩ⁛┙ᴺੱൻ࿖┙ᄢቇ∛㒮ᐔဋߩ߅ࠃߘ 1.61 ୚㧘1.79 ୚ߣ㕖Ᏹߦᄙߊߩᬌᩏઙᢙࠍታᣉߒߡ޿ࠆ‫ޕ‬
ᐔᚑ 20 ᐕᐲࠃࠅዉ౉ߐࠇߚ↹௝▤ℂട▚ 2 ߩ▚ቯࠍḩߚߔߴߊ㧘CT࡮MRI࡮RI ᬌᩏߩ 80%એ਄ࠍ᡼኿✢⑼ኾ㐷කߦࠃࠆ⺒ᓇࠍⴕߞߡ޿ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷1㧕ࠨ࡯ࡃ࡯ߩ࠳࠙ࡦߥߤߩ੍ᦼߢ߈ߥ޿㓚ኂߩ⊒↢߇⿠߈ࠆߎߣ߇޽ࠅ㧘⚕ㆇ↪߿ࡈࠖ࡞ࡓ╬ߦࠃࠅኻᔕߒߡ޿ࠆ߇㧘ᤨߣߒߡᬌᩏ࡮ᴦ≮ߦᡰ㓚ࠍ߈ߚߔߎߣ߇޽ࠆ‫ޕ‬
2㧕᡼኿✢ᯏེߩ㜞ᕈ⢻ൻߣ⸻≮ⷐ᳞ౝኈߩ㜞ᐲൻߦ઻޿㧘ߘࠇߦኻᔕߔߴߊ⸻≮᡼኿✢ᛛᏧߩᛛⴚ⎇ୃ߇ᔅⷐߢ޽ࠅ㧘ᤨ㑆⊛ਇ⿷ࠍ⵬ߞߡචಽߥ⎇ୃ߇ⴕ߃ࠆࠃ߁ኻᔕߒߡ޿߆ߥߌࠇ߫ߥࠄߥ޿‫ߚ߹ޕ‬㧘ᛛᏧ
ߪ 3 ᐕ㓹↪⡯ຬ߇Ⴧຬߐࠇߚ߇㧘੹ᓟᄾ⚂⡯ຬߩቯຬൻ߇ᔅⷐߢ޽ࠆ‫ޕ‬
3㧕CT ቶ㧘MRI ቶ㧘᡼኿✢ᴦ≮᫟ߥߤ߳ߩ⋴⼔Ꮷߩ㈩⟎߇ਇలಽߢ޽ࠆ‫ޕ‬
4㧕ࠝ࡯࠳࡝ࡦࠣࠪࠬ࠹ࡓߪ㧘ోᬌᩏ㧘ᴦ≮ߢⴕߞߡ޿ࠆ߇㧘ᩭකቇᬌᩏߪᖚ⠪᭽߇ฃઃߦ⋥ធ᧪ߡ޿ߚ
ߛ޿ߡ㧘ᬌᩏᣣߩ⏕ቯࠍⴕߞߡ޿ࠆ‫੹ޕ‬ᓟߪᄖ᧪ߦߡᬌᩏᣣߩ⏕ቯ߇಴᧪ࠆࠃ߁ᡷ⦟߇ᔅⷐߢ޽ࠆ‫ޕ‬㧙㧙5㧕หⷙᮨߩ࿖┙ᄢቇ∛㒮ߣᲧセߒ㧘CT࡮MRI ᬌᩏ✚ᢙߩㆊᄙࠍᜰ៰ߐࠇߡ޿ࠆ‫੹ޕ‬ᓟ㐳ᦼ⊛ߦㆡᱜߥᬌᩏᢙ߳ߣᤚᱜߔࠆᔅⷐ߇޽ࠆ‫ޕ‬੹ᓟߩዷᦸ
ᐔᚑ 21 ᐕ 4 ᦬ߦ㧘64 ೉ CT ⵝ⟎ࠍዉ౉ߒ㧘ᧄᩰ⊛ߦᔃ⤳ CT ߩⒿേࠍ੍ቯߒߡ޿ࠆ‫ޕ‬੹ᓟ㧘ߐࠄߦᛛᏧ㧘⋴⼔Ꮷ㧘කᏧߩੱ⊛⏕଻ࠍ⋡ᜰߒ㧘ᣂߒ޿ⵝ⟎ߩዉ౉ࠍ࿑ࠅ㧘ല₸⊛ㆇ↪ࠍ⋡ᜰߒߡ޿ߊᔅⷐ߇޽ࠆ‫ޕ‬㧙㧙㧔23㧕᧚ᢱㇱ1㧚⸻≮ߩ᭎ⷐ
᧚ᢱㇱߪ㧘߆ߟߡߪ㧘৻ㇱߩઁߩㇱ⟑ߦߡ⁛⥄ߩṌ⩶ᬺോ߇ⴕࠊࠇߡ޿ߚߚ߼㧘Ṍ⩶ᬺോࠍⴕ߁ᦨᄢߩ
ㇱ⟑ߣߒߡਛᄩ᧚ᢱㇱߣ๭߫ࠇߡ޿߹ߒߚ‫ࠄ߇ߥߒ߆ߒޕ‬ㄭᐕߩⶄ㔀ൻߔࠆක≮⃻႐ߦ߅ߌࠆṌ⩶ᬺോࠍ
ਛᄩൻߔࠆᔅⷐ߇޽ࠅ㧘1 ▎ᚲߦᯏ⢻ࠍ㓸⚂ߒ㧘᧚ᢱㇱߩฬ⒓ߣߥࠅ߹ߒߚ‫ޕ‬㊀ⷐߥᬺോߩౝኈߣߒߡߪ
2 ߟ᜼ߍࠆߎߣ߇ߢ߈߹ߔ‫ޕ‬1 ߟ⋡ߪṌ⩶ᵞᵺᬺോߢߔ‫ౕޕ‬૕⊛ߦߪ㧘ᵞᵺṌ⩶ᬺോߪ㧘ౣ૶↪ߔࠆක᧚ࠍ⥄ᣉ⸳ߢᵞᵺṌ⩶ಣℂߔࠆ⥄ኅ⵾Ṍ⩶ක᧚ߩ૞ᚑᬺോߢ޽ࠅ㧘ߐࠄߦଏ⛎࿁෼ᬺോߣߒߡ㧘⥃ᐥߩ႐ߦᔅⷐߦᔕߓߡㆡಾߦක᧚ࠍឭଏߒ㧘߆ߟ㧘૶↪ᷣߺߩක᧚ࠍ࿁෼ߒᰴߩṌ⩶ߦ஻߃ߡᵞᵺ╬ߩṌ⩶೨ಣ⟎ࠍⴕ߁ᬺോ߽ᐔⴕߒߡⴕߞߡ޿߹ߔ‫ޕ‬2 ߟ⋡ߪ㧘ක≮᧚ᢱߩㆬቯᬺോߢߔ‫ߩߎޕ‬ㇱ㐷ߪ㧘ᄢቇ∛㒮߇⁛┙ᴺੱൻߒ㧘ක≮⚻༡ߩല₸ൻ߇㊀ⷐⷞߐࠇࠆ⃻࿷㧘㕖Ᏹߦ㊀ⷐߢ޽ࠅ⽿ോߩ޽ࠆᬺോߣߥߞߡ߅ࠅ߹ߔ‫ޕ‬ౕ૕⊛ߦߪ㧘ක≮ᛛⴚߩ㜞ᐲൻߦ઻߁ᣂⷙක≮᧚ᢱߩㆬቯࠍ᧚ᢱㇱᆔຬળߢⴕ޿㧘2005 ᐕ 8 ᦬ࠃࠅ㧘ᣂߚߦ⚵❱ߐࠇߚ⺞㆐ଥ෸߮‛ᵹ࠮ࡦ࠲࡯ߦࠃࠅ․ቯක≮᧚ᢱ㧘৻⥸ක≮᧚ᢱ㧘৻⥸ᶖ⠻ຠߩ⾼౉ࠍ㧘㒮ౝߩ࿷ᐶࠍᛥ೙ߔࠆߴߊ‛ᵹࡑࠬ࠲࡯ߦၮߠ޿ߡ⾼౉ߒ㧘ක≮᧚ᢱ⾼౉ߩല₸ൻ㧘౞Ṗൻࠍ࿑ࠆᬺോߢߔ‫ޕ‬
2㧚ᢎ⢒ᣉ⸳
ߥߒ
3㧚⸻≮㐿⊒
ߥߒ4㧚ኾ㐷ක㧘⹺ቯක㧘ᜰዉකߥߒ5㧚⥄Ꮖ⹏ଔ
⹏ଔ∛㒮ߩᣂ⸳ߦ઻޿㧘Ṍ⩶ߩࠪࠬ࠹ࡓߪᦨᣂ㍈ߩᯏེߦᄌࠊࠅ㧘Ṍ⩶ᬺോߪᄖᵈߦߥࠅ㧘ࠃࠅ቟ోߢല₸⊛ߥṌ⩶‛ຠߩឭଏ߇น⢻ߦߥߞߚߣ⠨߃ߡ߅ࠅ߹ߔ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ㄭᐕ㧘෩ߒߊߥࠆක≮⚻༡ࠍ⢛᥊ߦ㧘ో࿖ߩઁߩ࿖┙ᄢቇ∛㒮ߦ߅޿ߡ߽∛㒮ో૕ߣߒߡోജߢขࠅ⚵ࠎߢ޿ࠆߩ߇ක≮᧚ᢱߩ⾼౉ߩ▤ℂߢߔ‫ޕ‬ක≮᧚ᢱߩᐕ㑆ߩ⾼౉㗵ߪ∛㒮ో૕ߢᢙం౞ߦߩ߷ࠅ㧘ਇⷐ࿷ᐶࠍᅤ૗ߦ೥ᷫߒߡ޿ߊ߆߇㧘∛㒮ߩ෼ᡰࠍ⠨߃ࠆ਄ߢ㊀ⷐߥ⺖㗴ߣߥߞߡ߈߹ߔ‫᧚ޕ‬ᢱㇱߣߒߡߪᄢቇ
∛㒮ߣߒߡߩක≮࡟ࡌ࡞ࠍ⪭ߣߔߎߣߥߊ㧘ක≮᧚ᢱߩ⾼౉㗵ࠍᛥ߃ࠆߣ޿߁㧘⋧෻ߔࠆ㔍㗴ࠍస᦯ߒߥ
ߌࠇ߫ߥࠅ߹ߖࠎ‫ߢߎߘޕ‬㧘⃻࿷ߪᣂⷙක≮᧚ᢱߩណ↪ߪ㧘ห╬ߩ⵾ຠ߇޽ࠆ㓙ߦߪ㧘ᓥ᧪ߩ⵾ຠߩ⾼౉ࠍߒߥ޿ߣ޿߁ේೣߩၮߦᣂⷙක≮᧚ᢱߩណ↪ࠍⴕߞߡ߅ࠅ߹ߔ‫ౕޕ‬૕⊛ߥኻ╷ߣߒߡ㧘2005 ᐕ 4 ᦬ࠃࠅ⚻⾌೥ᷫࡊࡠࠫࠚࠢ࠻ࠍⴕ޿㧘ߘߎߢᬌ⸛ߐࠇߚࡊࡠࠫࠚࠢ࠻߇ㅴⴕߒߡ޿߹ߔ‫ޕ‬1 ߟ⋡ߪ⾼౉ຠ⋡ߩ࠹ࡦࡊ࡟࡯࠻ߢ޽ࠆක≮᧚ᢱࡑࠬ࠲࡯ߩౣ᭴▽ߢ޽ࠅ㧘ᣥ∛㒮ᤨઍߦή೙㒢ߦ⤘ᒛߒߚක≮᧚ᢱࡑࠬ࠲࡯
ߪ 4 ਁ‛ຠࠍ⿧߃ߡ޿߹ߒߚ૶↪ታ❣ߩߥ޿‛ຠࠍ೥㒰ߒߚߣߎࠈ 1 ਁ߹ߢ㧘ࡑࠬ࠲࡯ߩຠ⋡ࠍ೥ᷫߔࠆ
ߎߣ߇ߢ߈߹ߒߚ‫ޕ‬2 ߟ⋡ߪක≮᧚ᢱߩቯᢙ㈩⟎ߩㆡᱜൻߢ޽ࠅ㧘ฦ∛᫟㧘ㇱ㐷ߩቯᢙ߇ㆡᱜߢߥ޿႐ว㧘ਇⷐ࿷ᐶ㧘ᦼ㒢ಾࠇߩ৻࿃ߣߥࠆߚ߼㧘⊒ᵈ⁁ᴫ㧘ቯᢙ⵬ల⁁ᴫࠍᬌ⸛ߒ㧘ㆡᱜൻࠍ࿑ߞߡ޿ߊ⹜ߺࠍߒ
ߡ޿߹ߔ‫ޕ‬3 ߟ⋡ߪ㧘ක≮᧚ᢱߩ࠻࡟࡯ࠨࡆ࡝࠹ࠖ࡯ߩᡷༀߢ޽ࠅ㧘2005 ᐕߩ⮎੐ᴺߩᡷᱜߦ઻޿ࠗࡦ
ࡊ࡜ࡦ࠻᧚ᢱߩㅊ〔߇੹ᓟᔅⷐߦߥߞߡ߈߹ߒߚ‫▤ࠍ࡯ࡃࡦ࠽࡞ࠕ࡝ࠪߩ࠻ࡦ࡜ࡊࡦࠗޕ‬ℂߔࠆࠪࠬ࠹ࡓ
߇㧘⃻ⴕߩ㔚ሶࠞ࡞࠹਄ߢߪ߁߹ߊ૞േߒߥ޿ߚ߼㧘ኻᔕ╷ࠍᬌ⸛ߒߡ޿ࠆ⁁ᴫߢߔ‫৻ޕ‬ᣇ㧘Ṍ⩶ᬺോߣߒߡߪ㧘ᯏེߦᔕߓߚㆡಾߥṌ⩶ᣇᴺߩ⏕┙㧘Ṍ⩶ߩ⸥㍳ߩ଻ሽࠍ㊀ὐ⊛ߦⴕߞߡ޿߹ߔ‫ޕ‬ᄖᵈൻએᓟߩ໧㗴ὐߣߒߡ㧘ᐕᐲᲤߦᄖᵈᬺ⠪߇ᄌࠊࠆน⢻ᕈ߇޽ࠅ㧘ᬺോߦ⠌ᾫߒߚੱ᧚ߩ⏕଻߇ᣂߚߥ໧㗴ὐߣߒߡ਄ߍࠆߎߣ߇ߢ߈߹ߔ‫ޕ‬੹ᓟߩዷᦸ⃻࿷㧘ో࿖ߩᄢቇ∛㒮ߩ᧚ᢱㇱߩ⺖㗴ߣߒߡߪ㧘1㧕೨ㅀߒߚක≮᧚ᢱߩ‛ᵹ▤ℂ㧔࠻࡟࡯ࠨࡆ࡝࠹ࠖ
࡯㧕߇ߤߎ߹ߢߢ߈ࠆ߆ߣ޿߁⺖㗴‫ޕ‬2㧕Single use device ߩᄙ↪ߦࠃࠆⅣႺ଻⼔ߣṌ⩶ౣ↢૶↪ߩ໧㗴ὐ‫ޕ‬3㧕ࠦࠬ࠻೥ᷫߣ㧘ല₸⊛ࠍ‛ຠ▤ℂ㧔SPD㧕ߩᔅⷐᕈ߆ࠄ↢ߓߡ߈ߚ㧘SPD ߩᄖᵈൻߩ໧㗴ߣ዁᧪ᕈ‫ ߚߞ޿ߣޕ‬3 ߟ߇᜼ߍࠄࠇߡ޿ࠆ‫ޕ‬1㧕㧘2㧕ߦ㑐ߒߡ᧪ᐕᐲࠃࠅᣂⷙߩ‛ᵹࠪࠬ࠹ࡓߩ᭴▽ࠍ⸘↹ߒߡ㧙㧙޿ࠆ‫ޕ‬3㧕ߦ㑐ߒߡ߽᧪ᐕᐲࠃࠅ SPD ߩቢోᄖᵈൻࠍ⸘↹ߒߡ߅ࠅࠦࠬ࠻೥ᷫ‫ޔ‬ല₸ൻࠍᦼᓙ಴᧪ࠆߣ⠨߃ߡ޿ࠆ‫ޕ‬Ṍ⩶ᬺോߦ㑐ߒߡߪ㧘ߎࠇ߽⚻༡ߩല₸ൻࠍਥ⌒ߣߒߡᚻⴚㇱߩࡈ࡞Ⓙ௛߇ᦼᓙߐࠇߡ߅ࠅ㧘ߘࠇߦ઻޿Ṍ⩶ᬺോߩჇᄢ߽ߒߊߪ㧘ᔅⷐ‛ຠߩቯᢙߩჇᄢ߇੍ᗐߐࠇ㧘ߘࠇߦኻᔕߔࠆੱຬߩ㈩⟎㧘⸳஻ߩ᜛ᄢ
߇ᔅⷐߣ⠨߃ࠄࠇ߹ߔ‫ޕ‬ක≮ᖱ൓ߩⶄ㔀ൻߦ઻޿ක≮ᬺോߩ቟ోᕈߩߐࠄߥࠆ⏕଻㧘ᮡḰൻ㧘ࠦࠬ࠻ࡄࡈࠜ࡯ࡑࡦࠬߩ਄᣹ࠍ⋡ᜰߒ㧘∛㒮ౝߢߩ᧚ᢱㇱߩᨐߚߔᓎഀߪ㧘ߐࠄߦᄢ߈ߥ‛ߦߥߞߡ޿ߊߣ⠨߃ࠄࠇ߹ߔ‫ޕ‬㧙㧙㧔24㧕ャⴊㇱ
1㧚⸻≮ߩ᭎ⷐ
ャⴊ⚦⢩≮ᴺߩ቟ో㧘ㆡᱜ㧘᦭ലᕈࠍ⏕଻ߔࠆߚ߼㧘⸻≮࡮ᢎ⢒࡮⎇ⓥࠍⴕ߁‫ޕ‬ャⴊ≮ᴺߪ⃻ઍක≮ߦਇนᰳߥᴦ≮ᚻᲑߢ޽ࠆ߇㧘ߘߩታᘒߪᦨ߽᥉෸ߒߚ‫ޟ‬⒖ᬀක≮‫ੱઁޕࠆ޽ߢޠ‬ߩ⤳ེ㧔ㅧⴊ࡮఺∉♽㧕ࠍᦨዋ㒢ߩᬌᩏߢ⒖౉ߔࠆߩߢ㧘⥌ᱫ⊛ߥ೽૞↪࡮ว૬∝߿㔍ᴦᕈ㧔⥌ᱫᕈ㧕ᗵᨴ∝ߩવ៝ߥߤ㧘ߥ߅੹ᓟ߽ᒁ߈⛯޿ߡస᦯ߔࠆߴ߈ᣂߚߥ⺖㗴ߪ಴⃻ߔࠆߣ੍ᗐߐࠇࠆ‫߼ߚߩߎޕ‬㧘ઁᣇߢߪ㧘ᦨዊ㊂ߩャⴊ≮ᴺ޽ࠆ޿ߪ቟ోߥઍᦧ≮ᴺࠍᮨ⚝ߖߑࠆࠍ߃ߥ޿‫⥄ޕ‬Ꮖⴊャⴊ≮ᴺ߿ࠨࠗ࠻ࠞࠗ
ࡦߩ೑↪㧘ੱᎿⴊᶧߥߤߩ㐿⊒ߢ޽ࠆ‫ޕ‬⃻࿷㧘ጘ㒂ᄢቇ∛㒮ߢߪ㧘ᚻⴚᖚ⠪ߩ߁ߜャⴊࠍฃߌࠆᖚ⠪ߩ 90㧑ߪ⥄ᏆⴊࠍャⴊㇱᏧߩ⽿છߩరߦ⾂ⴊߒ㧘⾂ⴊߒߚᖚ⠪ߩ 90㧑ߪห⒳ⴊࠍ࿁ㆱߢ߈ߡ޿ࠆ‫߫߃ߣߚޕ‬㧘ᶖེᄖ⑼ᖚ⠪ߩ⿒ⴊ⃿૶↪㊂㧔⥄Ꮖⴊ෸߮ห⒳ⴊߩว⸘㧕ߪẋᷫߒ㧘․ߦห⒳⿒ⴊ⃿ャⴊߪ 5 ᐕ㑆৻⽾ߒߡᷫዋߒ⛯ߌߚ‫ޕ‬ෘ↢⋭ක⮎቟ోዪߦࠃࠆో࿖৻ᢧ⺞ᩏ㧔ᐔᚑ 10 ᐕ 11 ᦬ 1 ࡨ㑆㧕ߢߪ㧘ጘ㒂ᄢቇ∛㒮ౝߢ૶↪ߐࠇࠆ⿒ⴊ⃿ャⴊߩ߁ߜ 4ഀ߇⥄Ꮖ↱᧪ߢ޽ࠅ㧘ᧄ㇌╙৻ߩ⥄Ꮖⴊャⴊߩታᣉ₸ߣߥߞߡ޿ࠆ㧔ᢙᐕᲤߦౣ⺞ᩏߒߡ߽㧘ߎߩ௑ะߪ
ਇᄌߢ޽ࠆ㧕‫ޕ‬ㆡᔕ∝଀෸߮ណข㊂ߪㄭᐕߐࠄߦჇടߒ㧘ᒰ㒮ߦ߅ߌࠆᐕ㑆⥄Ꮖⴊ⾂ⴊ㊂ߪ 4,000 න૏㧔2007㧕ߣჇടߒߚ‫ޕ‬ห᭽ߦ㧘ㅧⴊᐙ⚦⢩ណข࡮⒖ᬀᖚ⠪ᢙߣઙᢙߪჇടߒߡ޿ࠆ‫ޕ‬ャⴊㇱකᏧߪㆊ෰ 20 ᐕ㑆ߦᷰߞߡᦨዊャⴊ㊂ߩᢎ⢒ߩ৻Ⅳߣߒߡ⥄Ꮖⴊャⴊ≮ᴺࠍᜰዉߒ㧘⾂ⴊ࡮Ꮧ㉼࡮࿁෼ߩ 3 ᴺࠍታ〣ߒߡ⸻≮ᡰេߒߡ߈ߚߦ߽߆߆ࠊࠄߕ㧘৻ᣇߢ㧘ห⒳ߩャⴊ⚦⢩ᴦ≮ߪ੹ߥ߅Ⴧട
ߒߡ޿ࠆߩ߇⃻⁁ߢ޽ࠆ‫ߩੱઁޕ‬㛽㜑♽߅ࠃ߮఺∉♽⤳ེࠍ฽߻ⴊᶧߩ⒖౉ߩᐕ㑆ታᣉᢙߪ⿒ⴊ⃿⵾೷
5,395 න૏㧔1999㧕߆ࠄ 6,931 න૏㧔2007㧕ߣჇടߒߚ‫ޕ‬2008 ᐕߢߪ⿒ⴊ⃿ߣ FFP ⵾೷ߩિ߮₸ߪ೨ᐕ
Ყ 15㨪17㧑Ⴧߦኻߒߡ㧘ⴊዊ᧼⵾೷ߪ೨ᐕᲧ 33㧑Ⴧ 15,425 න૏㧔4㨪12 ᦬㧕ߣᕆჇߒߡ޿ࠆ‫ޕ‬ᒰ㒮ߢߪߎࠇࠄ⚦⢩⵾೷ߩోߡߦ᡼኿✢ᾖ኿ߒߡ⥌ᱫ⊛ャⴊ೽૞↪ߢ޽ࠆャⴊᓟ⒖ᬀ ኻኋਥ∛ࠍ㒐ᱛߒߡ޿ࠆ‫ޕ‬ャⴊㇱߩਥዉߢ 1988 ᐕೋ㗡ᾖ኿ࠍ㐿ᆎߒ㧘⥃ᐥ⎇ⓥߩ⚿ᨐࠍ〯߹߃㧘ቢోታᣉࠍ⋡ᜰߒߡ⥌ᱫ⊛೽૞↪ߩሽ࿷ࠍ໪⫥࡮ᢎ⢒ߒߡ߈ߚ߇㧘ห೽૞↪߇ක≮⸷⸩ߩኻ⽎ߦߥࠆߦ⥋ߞߡࠃ߁߿ߊ㧘1996 ᐕ 6 ᦬
1 ᣣ㧘ᾖ኿₸ࠍ 100%ߣ᳿ቯ࡮ታᣉߢ߈ߚ‫৻ޕ‬ᣇߢ㧘ਇㆡᱜߥャⴊ㧔කቇ⊛ㆡᔕߦว⥌ߒߥ޿ㆊ೾ャⴊ㧕ߪᄢቇ∛㒮ࠍ฽߻ᄢᄙᢙߩ∛㒮ߦ߅޿ߡߏߊ৻⥸⊛ߦߺࠄࠇࠆ߽ߩߢ޽ࠅ㧘ห᭽ߦᒰ㒮ߦ߅޿ߡ߽৻ㇱߪᘠ⠌⊛ߥⴕὑߣߥߞߡ޿ࠆߩߢ㧘ャⴊㇱකᏧߦࠃࠆᜰዉߦࠃࠅᤚᱜߩദജࠍ 10 ᐕ૛ߦᷰߞߡⴕߞߚ⚿ᨐ㧘
FFP Ყߪ 1.0 એ਄߆ࠄ 0.6 ࡋߣᷫዋߒ㧘ࠕ࡞ࡉࡒࡦᲧߪ৻⥸⊛ߥᄢቇ∛㒮ߦ߅ߌࠆᜰᢙ 3㨪4 ߆ࠄ㧘2.25
߹ߢࠕ࡞ࡉࡒࡦ૶↪㊂߇ᷫዋߒߚ‫ޕ‬ャⴊ▤ℂᢱߩ▚ቯⷐઙߢ޽ࠆ FFP Ყ 0.8 ᧂḩ㧘ࠕ࡞ࡉࡒࡦᲧ 2.0 ᧂḩߦ೔㆐ߒߟߟ޽ࠆ‫ޕ‬
2㧚ᢎ⢒ᣉ⸳
1㧕 ⹺ቯャⴊᬌᩏᛛᏧ೙ᐲᜰቯᣉ⸳
2㧕 ャⴊකቇ⹺ቯක೙ᐲ⹺ቯᣉ⸳
3㧚⸻≮㐿⊒
1㧕 ⸻≮ฬ 㧦⥄Ꮖࡈࠖࡉ࡝ࡦ♟ߩ⵾ㅧ⸻≮ౝኈ㧦⥄Ꮖ FFP ࠍ಄ಓ଻ሽߒߚᓟ㧘಄⬿⸃ಓߔࠆߣᴉốߒߡߊࠆಝ࿕࿃ሶߩỚ❗‛ࠍ↢૕ធ⌕㧘ⴊ▤߆ࠄߩ಴ⴊ㊂ߩᷫዋߩߚ߼ߦ↪޿ࠆ‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦ᐕ㑆 361 ઙߩ⵾ㅧ㊂ߪ࿖౏┙ᄢቇ∛㒮ਛ╙ 2 ૏ߦᄙ޿㧔2008 ᐕߦߪ 510 ઙߣჇട㧕‫ޕ‬
࿖ౝ⊛⹏ଔ㧦⵾ㅧߒߡ޿ࠆ࿖౏┙ᄢቇ∛㒮 10 ᩞߦㆊ߉ߥ޿‫ޕ‬࿖㓙⊛⹏ଔ㧦ห⒳⵾೷ߣߒߡߩ⹏ଔߪ☨࿖╬ߢ⏕ቯߐࠇߡ޿ࠆߣᕁࠊࠇࠆ‫ޕ‬2㧕 ⸻≮ฬ 㧦⥄Ꮖⴊዊ᧼♟ߩ⵾ㅧ⸻≮ౝኈ㧦ోⴊߢ⥄Ꮖⴊࠍណขᓟ㧘ή⩶⊛ߦᄙⴊዊ᧼ⴊẏࠍಽ㔌ଏ⛎ߔࠆ‫ⴊޕ‬ዊ᧼߇ಽᴲߔࠆ⚵❱ᚑ㐳࿃ሶࠍ㛽ㅧᚑⴚߩߚ߼ߦᵴ↪ߔࠆ‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦ᧄ㒮ߢߪญ⣧ᄖ⑼ߩଐ㗬ߦࠃߞߡ 2006 ᐕࠃࠅዉ౉ߒߚ‫ޕ‬⵾ㅧߒߡ޿ࠆ࿖౏┙ᄢቇ∛㒮 4 ᩞߦㆊ߉ߥ޿‫ޕ‬࿖ౝ⊛⹏ଔ㧦2000 ᐕએ㒠㧘࿖ౝߩ৻ㇱߩᄢቇ∛㒮╬ߦዉ౉߇ᆎ߹ߞߚ‫ޕ‬࿖㓙⊛⹏ଔ㧦1990 ᐕᓟඨߦญ⣧ᄖ⑼㗔ၞߦᔕ↪ߐࠇᆎ߼ߚ‫੹ޕ‬ᓟߩ⹏ଔࠍⷐߔࠆ‫ޕ‬
4㧚ኾ㐷ක࡮⹺ቯක࡮ᜰዉක
ᄢႦ▵ሶ㧦ᣣᧄャⴊකቇળ⹺ቯක㧘ᣣᧄ㤗㈮ቇળᜰዉක㧘ᣣᧄ㤗㈮ቇળ⹺ቯක㧘ᣣᧄකᏧળ↥ᬺක㧙㧙5㧚⥄Ꮖ⹏ଔ
⹏ଔャⴊ≮ᴺߩ቟ో㧘ㆡᱜ㧘᦭ല↢ࠍ⏕଻ߔࠆߚ߼㧘⸻≮࡮ᢎ⢒࡮⎇ⓥߦ㑐ߒߡ㧘৻ቯߩᚑᨐࠍ㆐ᚑߒߡ޿
ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ᢎ⢒ᵴേ㧦ෘ↢ഭ௛⋭ⴊᶧኻ╷⺖ߩⷐ⺧ߦ┵ࠍ⊒ߒߡ㧘ᢥ⑼⋭⺖㐳ࠃࠅቇ㐳ተߦャⴊකቇᢎ⢒ߩ⸠␜߇޽ߞߚ㧔㜞╬ᢎ⢒ዪᢎ⢒⺖㐳ㅢ⍮ 2005.04.20㧘17 㜞කᢎ╙ 3 ภ㧕‫ޕ‬㒮ౝߩ⹺ቯක 1 ฬ㧘⹺ቯᬌᩏᛛᏧ 1 ฬߣᣂછߩᬌᩏᛛᏧ 1 ฬ෸߮⵬Ᏹൕ㧔ᣂත㧕ߩ 4 ฬ߇ャⴊㇱߩో᭴ᚑຬߢ޽ࠆ‫ޕ‬ᄢቇ∛㒮ߣߒߡߪዋߥ޿㧔20 ᐕ೨ߩ࿖ౝᄢቇ∛㒮ߩャⴊㇱᬌᩏᛛᏧߩᐔဋߪ 3.0 ฬ㧛600
ᐥߢ޽ࠅ㧘㕖ኾ㐷ߩᬌᩏᛛᏧߦߪ್ቯࡒࠬ╬߇ᄙ޿ߣᜰ៰ߐࠇߡ߈ߚ㧕‫⹺ߩߎޕ‬ቯක࡮⻠Ꮷ 1 ฬߢ㧘㒮ౝ
ߩකᏧ 304 ੱࠍኻ⽎ߦ㧘ත೨࡮තᓟᢎ⢒ࠍᜂ߁੐ߪ࿎㔍ߢ޽ࠆ‫⹺ޕ‬ቯᬌᩏᛛᏧ 1 ฬߢ㧘ᣣᏱᬺോࠍㆀⴕߒ
ߥ߇ࠄ㕖ኾ㐷ߩᬌᩏᛛᏧ 30 ฬࠍᢎ⢒ߔࠆߦ߽࿎㔍ࠍ઻߁‫⥄ޕ‬േൻᯏེߩᠲ૞ࠍୃᓧߔࠆ੐ߦਥ⌒߇߅߆ࠇ㧘ャⴊකቇ߹ߢ⥋ࠄߥ޿߆ࠄߢ޽ࠆ‫ޕ‬࿖ౝᄢቇ∛㒮ߦ߅ߌࠆャⴊㇱᬌᩏᛛᏧߩᐔဋߪ 5.2 ੱߢ㧘߁ߜ⹺ቯᛛᏧߪ 2.2 ੱߢ޽ࠆ‫ޕ‬⸻≮ᵴേ㧦‫ޟ‬ャⴊㇱᬌᩏ‫ޠ‬ᬺോ㧘
ABO ဳਇㆡวャⴊ╬ߩක≮੐᡿ߪ㒐ᱛߢ߈ࠆ߆㧫੐᡿㒐ᱛߦߪ㧘ャⴊቇળߦࠃߞߡផᅑߐࠇߚᚻ㗅ᦠߦ␜ߐࠇࠆߏߣߊ㧘ABO ဳߩ࠳ࡉ࡞࠴ࠚ࠶ࠢ߇ᦨ
㊀ⷐߢ޽ࠆ‫ᤨޕ‬㑆ᄖߩߺߥࠄߕ㧘ᤨ㑆ౝ߽ߒ߫ߒ߫ᬌᩏᛛᏧ৻ੱ૕೙ߢߪ㧘⥄േൻᯏེ߇ߎߩਇ⿷ߒߡ޿
ࠆᛛᏧߩᄌࠊࠅࠍߒߡ޿ࠆ‫ޕ‬Ԙ⥄േൻᯏེ߇᡿㓚࡮஗ᱛߒߚᤨߦ߽ኻᔕน⢻ߥᢎ⢒ࠍฃߌߚᬌᩏᛛᏧߪ㧘⃻ャⴊㇱ 24 ᤨ㑆೙ߦ߅޿ߡ㧘ᔕេᬌᩏㇱᛛᏧ 30 ฬࠍ฽߼ߚ 32 ฬਛ㧘2 ฬߦㆊ߉ߥ޿‫ޕ‬ԙ㜞ᰴᢇߩᢇᕆᖚ⠪ࡋߩኻᔕߣߒߡ㧘ࡑ࠾ࡘࠕ࡞ࠍㆩ቞ߔࠆߎߣߦ߹ߕਥ⌒ࠍ⟎ߊᬌᩏᛛᏧߣ㧘‫ࡘ࠾ࡑޟ‬ࠕ࡞ࠍ⍮ߞߡߪ޿ࠆ‫ߣޠ‬ਥᒛߒ㧘ߎࠇࠍ⿥⿧ߒߚ಴ᐶⷐ᳞ࠍߒ߇ߜߥකᏧߣߩࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦࠡࡖ
࠶ࡊ߇⊒↢ߒߡ޿ࠆ‫ޕ‬Ԛᢇᕆߢߪ ABO ဳߩ࠳ࡉ࡞࠴ࠚ࠶ࠢߩේೣ߇ήⷞߐࠇ߇ߜߢ޽ࠆ㧔࠳ࡉ࡞࠴ࠚ࠶ࠢ↪ߩᬌ૕ߩឭ಴ࠍⷐ
‫ޕ‬᳞ߒ⛯ߌߡ㧘ẋߊᢙᤨ㑆ᓟߦᬌ૕߇ዯߊ㧛ᬌᩏㇱߦ߽ャⴊㇱߦ߽ේೣࠍḩߚߔߚ߼ߩᬌ૕߇ή޿㧕ԛ߹ߚ㧘㔚ሶࠞ࡞࠹ߩℂ⸃ਇ⿷߆ࠄ㧘ࠝ࡯࠳࡯ߩᲤߦᷝઃߐࠇࠆ ABO ဳᬌᩏଐ㗬ࠍ೥㒰ߒߥ޿ߚ߼ߦ㧘
ABO ဳᬌᩏ↪ߩ࡜ࡌ࡞߇ឃ಴ߒ㧘ߘࠇࠍᰴߩᖚ⠪ߩⴊᶧࠬࡇ࠶࠷ߦ⾍ઃߌࠆߣ⻐߁⺋ࠅ߽⊒↢ߒߡ޿ࠆ‫ޕ‬ԜᮡḰ 20 ಽߢⴊᶧ߇↪ᗧߐࠇࠆᢇᕆᣉ⸳߇ᄙ޿ਛߢ㧘‫ޟ‬1 ᤨ㑆ࠍⷐߔࠆ‫ޕࠆ޿ߡߒ↢⊒߇ࡓ࡯࡟ࠢ߁⻐ߣޠ‬ԝᢇᕆㇱ㐷㊀ⷞߩᒰ㒮ࠍᡰ߃ࠆャⴊㇱ㐷ߣߒߡߪኾ㐷ߩᬌᩏᛛᏧ߇᳿ቯ⊛ߦਇ⿷ߒߡ޿ࠆ‫ޕ‬‫ޟ‬ャⴊ▤ℂቇ‫ޠ‬ᬺോ
1㧕ࡂ࡯࠼ߢߪߥߊㆇ↪ߦࠃߞߡએਅߩ⃻⁁ࠍߐࠄߦᡷༀน⢻ߢ޽ࠆ‫ޕ‬Ԙⴊᶧ⵾೷⎕᫈₸㧦ోⴊ 0%㧘⿒ⴊ⃿ 3.5%㧘ⴊዊ᧼ 0.93%㧘FFP0.99%㧘Albumin0%‫ޕ‬ԙⴊᶧ⵾೷⎕᫈㗵㧦ᐕ㑆 650 ਁ౞߇ 24 ᤨ㑆૕೙ߦࠃߞߡඨᷫߒ㧘ߘߩᓟᐕ㑆 272 ਁ౞‫ޕ‬Ԛㆊ෰ඨᐕ㑆ߩャⴊ↪ⴊᶧ଻㒾ᩏቯ㗵㧦92.9 ਁ౞㧘ᩏቯ₸ 2.19%‫ޕ‬
2㧕޿ࠊࠁࠆⴊᶧᣂᴺ㧔2003 ᣉⴕ㧕߆ࠄᣂߚߥᛛⴚᢱ‫ޟ‬ャⴊ▤ℂᢱ‫଻ߩޠ‬㒾෼タ㧔2006㨪㧕߹ߢ‫ޕ‬Ԙ‫ⴊޟ‬ᶧᣂᴺ‫ߡߞࠃߦޠ‬㧘ක≮ᯏ㑐ߦߪ೽૞↪ᖱႎߩ෼㓸ႎ๔ߣ‫ޟ‬ㆡᱜ૶↪‫⟵߇ޠ‬ോൻߐࠇߚ‫ޕ‬೽૞↪ߦ㑐ߒߡߪਛ╬ᐲ߆ࠄ㊀∝ߩ೽૞↪ߩቯ⟵ߩᶐㅘ㧘޽ࠆ޿ߪ TRALI ╬⥌ᱫ⊛෻ᔕ߇⊒↢ߒᓧࠆߣ⻐߁ᢎ⢒ࠍ৻⥸ක≮ᓥ੐⠪ߦᆎ߼ߥߌࠇ߫ߥࠄߥ޿⃻⁁ߢ޽ࠆ‫ޕ‬ԙෘഭ⋭ߩක≮⾌೥ᷫ᡽╷ߦ߽߆߆ࠊࠄߕ㧘‫ޟ‬ャⴊ▤ℂᢱ‫ߚࠇࠄ߼⹺߇ޠ‬⢛᥊ߦߪㆡᱜߥャⴊ≮ᴺߦࠃߞߡ㧘ዋሶ㜞㦂ൻߦࠃࠆャⴊᶧߩଏ⛎ਇ⿷ࠍ⸃ᶖߒ㧘‫ⴊޟ‬ᶧᣂᴺ‫ߩޠ‬ઃᏪ੐㗄㧔ⴊẏಽ↹⵾೷ߩ 2008 ᐕ߹ߢߩቢో࿖ౝ⥄⛎ൻ㧕ࠍḩߚߔⷐ߇޽ߞߚ㧔⃻⥄⛎₸ 60㧑㧕‫ޕ‬Ԛ‫ޟ‬ャⴊ▤ℂᢱ‫ⷐߩޠ‬ઙ㧘FFP/MAP 0.8 ᧂḩ㧘(Alb g÷3)න૏/MAP ߇ 2 ᧂḩߦኻߒߡ⋥ㄭߩᒰ㒮ߩታ❣
ߪ FFP/MAP 0.56 ߣḩߚߒ㧘(Alb g÷3)න૏/MAP 2.25 ߣ⸻≮⑼ߩദജ╬ߦࠃߞߡ 1 ᐕᓟߦߪ▤ℂᢱข
ᓧߩታ⃻น⢻ߥᢙ୯ࠍ␜ߒߡ޿ࠆ‫ߚ߹ޕ‬㧘ャⴊ≮ᴺᆔຬળࠍᐕ 6 ࿁એ਄㐿௅ߔࠆߩ߇ⷐઙߢ޽ࠅታᣉߒ
ߡ޿ࠆ‫ޕ‬
ԛෘഭ⋭⎇ⓥ⃰ࠃࠅ⎇ⓥදജଐ㗬ߦᔕߓߡ೽૞↪⋙ⷞᜰቯᣉ⸳ߣߒߡ⊓㍳ᷣߺߢ޽ࠆߦ߽߆߆ࠊࠄߕ㧘ቢోࡍ࡯ࡄ࡯࡟ࠬ㔚ሶࠞ࡞࠹ߦ઻ߞߡ㧘⥃ᐥ⃻႐ߦ⊒↢ߔࠆ೽૞↪ᖱႎ߇ real time ߦャⴊㇱ㐷ߦ㈩ାߐ
ࠇߥ޿⁁ᘒ߇⛯޿ߡ޿ࠆߚ߼㧘ࡂ࡯࠼ߩὐᬌ╬ᖱႎㇱ㐷ߩេഥࠍⷐߔࠆ‫ߚ߹ޕ‬㧘‫ޟ‬ャⴊᜰ㊎ߩᡷቯ‫ޠ‬㧙㧙㧔2005. 9.㧕ߦࠃߞߡ೽૞↪ᖱႎߩ෼㓸ߩߚ߼ߦⓨࡃ࠶ࠢࠍ࿁෼ߔࠆࠃ߁ᜰዉߐࠇߡ޿ࠆߣߎࠈߢ޽ࠆ
߇㧘⒖ォ೨ߦㆇ༡ᆔຬળߦ߅޿ߡᛚ⹺ᷣߺߦ߽߆߆ࠊࠄߕ㧘ᗵᨴኻ╷ቶ㧔ᣥ㧕ߩ෻ኻߦࠃࠅታⴕߐࠇࠆ
ߦ⥋ߞߡ޿ߥ޿‫ޕ‬೽૞↪⊒↢ᤨߦ߅޿ߡ㧘ଏⴊ⠪ߩⴊᶧဳ㧛DNA ဳ㧘⚦⩶ᳪᨴ╬ߩᬌ⚝ߩߚ߼ߦߪⓨࡃ࠶ࠢߦ㒝㓐ߔࠆଏⴊ⠪ߩ⚦⢩╬ߩᬌ૕߇ᔅ㗇ߢ޽ࠆ‫ޕ‬Ԝቇળ╬ߢ authorize ߐࠇߡᵹᏓߐࠇߡ޿ࠆⴊᶧ࠮ࡦ࠲࡯㓸⸘ߩ೽૞↪⊒↢₸ߩ 60㨪100 ୚߇ታ㓙ߦߪ⊒↢ߒߡ޿ࠆߣ⻐ࠊࠇߡ޿ࠆ߇㧘⚦⩶ᗵᨴ࡮TRALI ╬ߩ⊒∝₸㧘ߘߩઁߩ೽૞↪ߩ∛ᘒߦߟ޿ߡߪਇ᣿
ߩ߹߹ߢ޽ࠆ‫ᧄޕ‬㒮ߦߪャⴊ೽૞↪ߩේ࿃⺞ᩏ૕೙߇ᢛ஻ߐࠇߡ޿ߥ޿⃻⁁ߢ޽ࠅ㧘ੱຬ㈩⟎ࠍⷐߔࠆ‫ޕ‬ԝャⴊ㗔ၞߦ߅޿ߡߪ㧘⹜⮎ߩຠ⾰▤ℂ㧦ᮡḰൻ㧘QC ࠦࡦ࠻ࡠ࡯࡞߇ᧂߛὑߐࠇߡ޿ߥ޿‫ޕ‬Ԟෘ↢ഭ௛⋭╬ࠍ੺ߔࠆ⹦⚦ߥャⴊ㑐ㅪࠕࡦࠤ࡯࠻⺞ᩏ߇㧘2 ࡩ᦬ߦ 1 ࿁⒟ᐲ⺖ߐࠇࠆ‫ޕ‬ԟャⴊᓟᗵᨴ∝ᬌᩏ㧘ᣣ⿒㆚෸⺞ᩏ㧘↢‛↱᧪⵾ຠᗵᨴ╬ⵍኂᢇᷣ೙ᐲ㧔2004㧕ߦኻᔕߒߡ㧘ᣧᕆߦャⴊ೨଻ሽᬌ૕㧔PCR ኻᔕ㧕ࠍ㔚ሶࠞ࡞࠹ൻߔࠆᔅⷐ߇޽ࠆ‫ޕ‬
3㧕‫ޟ‬ャⴊㇱᄖ᧪⸻≮‫ޠ‬⥄Ꮖⴊᄖ᧪㧦⸻≮⑼ߣߒߡ౏ᑼߢߪߥ޿߇㧘ታ⾰਄㧘⥄Ꮖⴊᄖ᧪ࠍㅳ 5 ᣣ㐿⸳ߒߡ޿ࠆ㧔1989 ᐕ㨪㧕‫ޕ‬ᐕ㑆ណข㊂ 1,000 න૏ࠍ⿧ߔ੐߆ࠄ㧘ャⴊㇱߪ‫ⴊޟ‬ᶧ㌁ⴕ‫ޠ‬ᬺോࠍᜂߞߡ޿ࠆ‫ޕ‬Ԙᜂ߁කᏧߪ 1 ฬ㧘⋴⼔Ꮷ 0.5 ฬ㧔ᢇᕆ޽ࠆ޿ߪណⴊቶ౗ോ߇ᜂ߁㧕㧘ᬌᩏᛛᏧ 3 ฬ‫ޕ‬ԙ㒮ౝណข㊂㧔2008 ᐕ㧕㧧⥄Ꮖⴊ 4,000 න૏⵾ㅧ㧘⥄Ꮖࡈࠖࡉ࡝ࡦ♟ 510 ⴼ⵾ㅧ‫ޕ‬
Ԛ2006 ᐕ߆ࠄߪญ⣧ᄖ⑼ߩଐ㗬ߦᔕߓߡ⥄Ꮖ PRP㧔platelet rich plasma㧕⵾ㅧࠍ㐿ᆎ‫ޕ‬
4㧕‫ޟ‬ᄖㇱ߆ࠄߩᬌᩏ╬ߩᬺോଐ⸤ߩ⺧⽶‫ޠ‬Ԙ๟↥ᦼኾ㐷ኅ߆ࠄࠃࠅ㧘⿒ⴊ⃿ਇⷙೣ᛫૕ᬌᩏ㧔ᐔᚑ 17 ᐕ㨪㧕‫ޕ‬ԙ㛽㜑ࡃࡦࠢ⽷࿅ࠃࠅ⺞ᢛකᏧᬺോ㧔ᐔᚑ 18 ᐕ㨪㧕
‫ޕ‬
੹ᓟߩዷᦸ
ᢥㇱ⑼ቇ⋭ߦࠃߞߡ㧘‫ޟ‬ᬌᩏᬺോߩᄖᵈൻ‫߇ޠ‬໒ዉߐࠇߚߣߎࠈߢ޽ࠆ߇㧘ャⴊ㑐ㅪᬌᩏᢱߩૐ㗵ߣߘߩ⚿ᨐߩ㊀ᄢᕈ࡮ෂ㒾ᕈ߆ࠄ㧘ᄖᵈߦᔕߓࠆᄖㇱᬺ⠪ߪ⊝ήߣᗐቯߐࠇߡ޿ࠆ‫ޕ‬ャⴊ≮ᴺߩ቟ో㧘ㆡᱜ㧘᦭ല↢ࠍ଻⸽ߒ㧘ᬌ⸽ߔࠆߚ߼ߦߪ㧘⸻≮ߪ⻐߁ߦ෸߫ߕ㧘ᢎ⢒ߣ⎇ⓥᵴേ߇
㊀ⷐߥߩߢ㧘ߎࠇࠍᜂ߁ੱຬߩ㈩⟎߇ᔅ㗇ߢ޽ࠆ‫ޕ‬‫ޟ‬ᣣᧄャⴊቇળ‫߇ޠ‬㧘2006 ᐕ߆ࠄ㧘‫ޟ‬ᣣᧄャⴊ⚦⢩≮ᴺቇળ‫ߣޠ‬ᡷ⒓ߒߚ‫ޕ‬ᒰャⴊㇱ߽㧘⚦⢩≮ᴺࠍ቟ోߦᣉⴕߢ߈ࠆࠃ߁ߦᢛ஻ߐࠇࠆߴ߈ߢ޽ࠆ‫ޕ‬ౣ↢ක⑼ቇኾ᡹࡮⚵❱ེቭᒻᚑಽ㊁߆ࠄߪ㧘ᱤ㜑ࠃࠅ᛽಴ߐࠇߚ㑆⪲♽ᐙ⚦⢩ࡃࡦࠢᬺോࠍⷐ⺧ߐࠇߡ޿ࠆ‫ޕ‬዁᧪⊛ߦߪ⚦⢩ࡊࡠ࠮࠶ࠪࡦࠣ࠮ࡦ࠲࡯ㆇ༡ߩࠟࠗ࠼࡜ࠗࡦ㧔૞ᚑਛ㧕ߦᓥ޿㧘⚦⢩≮ᴺ჻㧔઒⒓㧕⋧ᒰߩੱ᧚߇ᔅⷐߢ޽ࠆ‫ޕ‬㧙㧙㧔25㧕∛ℂㇱ
1㧚⸻≮ߩ᭎ⷐ
∛ℂㇱߪ㧘ᄢቇ∛㒮ౝߩ∛ℂᬌ૕ߩ⸻ᢿ㧔ⴚਛㄦㅦࠍ฽߻⚵❱⸻࡮⚦⢩⸻㧕ᬺോ㧘෸߮∛ℂቇ⻠ᐳߩදജߩਅߦ∛ℂ⸃೬ᬺോࠍᜂߞߡ޿ࠆ‫ߩߘޕ‬ㆇ༡ℂᔨߣߒߡߪ㧘‫ޟ‬ㅦ߿߆ߦ਌ߟ⏕ታߥ∛ℂ⸻ᢿࠍ⥃ᐥ஥ߦឭଏߔࠆߚ߼ߦ㧘∛ℂᬺോో⥸ߦࠊߚࠆࠬࡇ࡯࠼ߣ♖ᐲߩߚࠁ߹ߥ޿ᡷༀߩ 2 ὐߦߎߛࠊࠅࠍᜬߟ‫ߣߎޠ‬ߣߒߡ޿ࠆ‫ޕ‬ታ❣ߣߒߡߪਅ࿑ߦ␜ߔࠃ߁ߦ㧘ᐕ㑆ઙᢙߢ∛ℂ⚵❱ 8000 ଀߶ߤ㧔߁ߜㄦㅦᬌᩏ 400 ઙએ਄㧕㧘⚦⢩⸻ 6000 ઙ߶ߤ㧘∛ℂ⸃೬ 40 ଀૛ࠅࠍᣉⴕߒߡ޿ࠆ‫ޕ‬⚵❱⸻ઙᢙⴚਛㄦㅦઙᢙ
⚦⢩⸻ઙᢙ
∛ℂ⸃೬ᢙ

2006 ᐕ
7575
477
5774
38

2007 ᐕ
7908
460
6357
33

2008 ᐕ
8224
490
6381
38

2㧚ᢎ⢒ᣉ⸳
1㧕 ᣣᧄ∛ℂቇળ⹺ቯᣉ⸳
2㧕 ᣣᧄ⥃ᐥ⚦⢩ቇળ⹺ቯᣉ⸳
3㧚⸻≮㐿⊒
ߥߒ4㧚ኾ㐷ක࡮⹺ቯක࡮ᜰዉක㜞⷗ ೰㧦ᣣᧄ∛ℂቇળኾ㐷කᑝἑༀା㧦ᣣᧄ∛ℂቇળኾ㐷ක㧘ᣣᧄ⥃ᐥ⚦⢩ቇળኾ㐷ක
5㧚⥄Ꮖ⹏ଔ
⹏ଔ
ℂᔨߦ߽޽ࠆࠬࡇ࡯࠺ࠖ࡯ߥ⚿ᨐႎ๔ߩߚ߼ߦ㧘ㇱౝߢߩ࠲࡯ࡦࠕ࡜࠙ࡦ࠼࠲ࠗࡓߩദജ⋡ᮡࠍ↢ᬌ᧚
ᢱ 3 ᣣએౝ࡮ᚻⴚ᧚ᢱ 7 ᣣએౝ࡮⚦⢩⸻ 3 ᣣએౝߦ⸳ቯߒߚ‫ޕ‬ታ㓙ߩ࠲࡯ࡦࠕ࡜࠙ࡦ࠼࠲ࠗࡓࠍㆡᤨࡕ࠾
࠲࡯ߒߚ⚿ᨐ㧘↢ᬌ᧚ᢱ෸߮⚦⢩⸻ߦ߅޿ߡߪ㧘⋡ᮡߦ᭎ߨㄭ޿ᢙሼࠍᱷߔߎߣ߇಴᧪ߚ‫ޕ‬ᬌ૕ᢙ߇ẋჇߔࠆਛߢߎߩ⋡ᮡࠍ᭎ߨ㆐ᚑߢ߈ߚߎߣߪ⹏ଔߢ߈ࠆ‫ޕ‬∛ℂ⸻ᢿߩ♖ᐲะ਄㧘ᬌᩏో⥸ߩലᨐ⊛ߥㆇ↪ߣ⥃ᐥㆶరߩߚ߼ߦ㧘޿ߊߟ߆ߩቯᦼࠞࡦࡈࠔ࡜ࡦࠬࠍ
ታᣉ࡮ෳടߒߚ‫♖ߕ߹ޕ‬ᐲࠕ࠶ࡊߩߚ߼㧘∛ℂකߩߚ߼ߩ㒮ౝ∝଀ᬌ⸛ળࠍᲤㅳⴕ޿㧘᭽‫ߥޘ‬㔍⸃∝଀࡮ౖဳ∝଀࡮⾆㊀∝଀ࠍ৻ห߇࠺ࠖࠬࠞ࠶࡚ࠪࡦ㗼ᓸ㏜ࠍ⷟߈ߥ߇ࠄ࡟ࡆࡘ࡯ߒߚ‫ߚ߹ޕ‬㧘∛ℂකߣ∛ℂᛛ
Ꮷߩߚ߼ߩ⚦⢩⸻⚵❱⸻ീᒝળࠍᲤㅳⴕ޿㧘⚦⢩௝ߣ⚵❱௝ߩᾖࠄߒ޽ࠊߖࠍ࠺ࠖࠬࠞ࠶࡚ࠪࡦ㗼ᓸ㏜
ߢᬌ㏜ߒߥ߇ࠄⴕߞߚ‫ޕ‬ട߃ߡ㧘ㇱౝߢߩ․ᱶᨴ⦡࡮఺∉ᨴ⦡ീᒝળ߽Ფㅳ㐿߈㧘∛ℂᬺോߩ࿯บߢ޽ࠆᨴ⦡ߩේℂ࡮ᣇᴺ࡮ᗧ⟵࡮ᨴ⦡ᘒᐲ࡮Ꮏᄦὐߥߤࠍౣ⏕⹺ߒߚ‫ࠇߘޕ‬એᄖߦ㧘∛ℂ⸃೬ߩߚ߼ߩ CPC ࠍ㐿௅ߒ㧘㒮ౝߢߩวหࠞࡦࡈࠔ࡜ࡦࠬ࡮⎇ⓥળ㧔ᶖൻེࠣ࡞࡯ࡊ㧘ᢛᒻᄖ⑼㧘⣖ᄖ⑼㧕߳ߩෳടࠍⓍᭂ⊛ߦⴕߞߚ‫∛ޕ‬ℂᬌᩏߩ♖ᐲߩ⃻ᴫߪ⹏ଔߒߦߊ޿߇㧘ߎࠇࠄߩቯᦼࠞࡦࡈࠔ࡜ࡦࠬߪ♖ᐲࠕ࠶ࡊߦዋߥ߆
ࠄߕ⽸₂ߒߚ߽ߩߣᕁࠊࠇࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ᚻⴚᬌ૕ߩ࠲࡯ࡦࠕ࡜࠙ࡦ࠼࠲ࠗࡓߪ 910 ᣣߢ޽ࠅ㧘੹ᓟߩ⺖㗴ߣᕁࠊࠇߚ‫ޕ‬ᮡᧄ૞⵾ㆊ⒟ߩᡷༀ࡮
⷗⋥ߒ╬ߦࠃߞߡ㧘ߐࠄߥࠆᤨ㑆⍴❗ࠍ⸘ߞߡ޿ߊ‫ޕ‬⸻≮㐿⊒ߩ㕙߇․⸥ߔࠆߎߣ߇ή޿⁁ᘒ߽໧㗴ὐߣߒߡ᜼ߍࠄࠇࠆ‫ߦ․ޕ‬ㆮવሶ⸻ᢿߥߤߩ∛ℂ⸻ᢿ߳ߩᄖᝌߦࠃࠆ⸻ᢿ♖ᐲߩะ਄ߥߤ߇ߘߩ୥⵬ߦ᜼߇ࠄࠇ㧘ߘߩታㆇ↪ߦะߌߡᒁ߈⛯߈ദജߒߡ޿ߊߎߣ
ߣߔࠆ‫ޕ‬
੹ᓟߩዷᦸ∛ℂㇱߩㆇ༡ℂᔨߣߒߡឝߍߚ‫∛ޟ‬ℂᬺോో⥸ߦࠊߚࠆࠬࡇ࡯࠼ߣ♖ᐲߩߚࠁ߹ߥ޿ᡷༀߩ 2 ὐߦߎߛࠊࠅࠍᜬߟ‫ߦ߼ߚޠ‬㧘ߐࠄߦ⛮⛯ߒߡദജߔࠆ‫ߦ․ޕ‬㧘⸻ᢿ♖ᐲะ਄ߩߚ߼㧘㒮ౝᄖߢߩ⎇ⓥળ࡮ᬌ⸛ળ࡮
ࠞࡦࡈࠔ࡜ࡦࠬ߳ߩᦝߥࠆⓍᭂ⊛ߥෳട࡮⊒⴫ࠍⴕߞߡ޿ߊ‫ߚ߹ޕ‬㧘ಽሶᮡ⊛⮎ߩ⥃ᐥᔕ↪╬ߦ⷗ࠄࠇࠆ㧙㧙ࠃ߁ߦ㧘∔ᖚ㧔․ߦ⣲≌㧕⸻ᢿߦ߅ߌࠆㆮવሶᖱႎߩᔅⷐᕈ߇㜞߹ߞߡ޿ࠆ‫≮⸻ޕ‬㐿⊒ߣߒߡ㧘∛ℂ⸻ᢿ
ߦ߅ߌࠆㆮવሶ⸻ᢿߩ૬↪ࠍ․ߦദജ⋡ᮡߣߒߡឝߍߡ޿ߊ‫ߦࠄߐޕ‬㧘ᢎ⢒ᯏ㑐ߣߒߡߩ⥄ⷡߩਅ㧘ࡐ࡝ࠢ࡝࡮⎇ୃක࡮⧯ᚻ∛ℂක࡮ᬌᩏᛛᏧߩᢎ⢒ో⥸ߦ߽ജࠍᵈߋ‫ޕ‬㧙㧙㧔26㧕✚ว⸻≮ㇱ
1㧚⸻≮ߩ᭎ⷐ
ߎࠇ߹ߢߣห᭽㧘✚วౝ⑼කߩ㓸࿅ߣߒߡౝ⑼ో⥸ߦࠊߚࠆ⸻≮ࠍⴕߞߡ޿ࠆ‫ޕ‬ㄭᐕߩකቇߩㅴᱠߣߣ
߽ߦ㧘කᏧߩኾ㐷ൻ࡮⚦ಽൻ߇ㅴࠎߢ޿ࠆ‫৻ޕ‬ᣇߢ㧘␠ળߩ㜞㦂ൻߣߣ߽ߦⶄᢙߩ∔ᖚࠍ૬ߖᜬߟᖚ⠪߽Ⴧടߒߡ߈ߡ޿ࠆ‫ߜࠊߥߔޕ‬㧘ᖚ⠪ߩ࠾࡯࠭ߣකᏧߩᔒะߦࡒࠬࡑ࠶࠴߇ߺࠄࠇࠆ‫⚿ߩߘޕ‬ᨐ㧘ਥᴦකߣߒߡ߽ኾ㐷એᄖߩ⸻≮߇ਇචಽߢ޽ߞߚࠅ㧘ኾ㐷ᄖߩ∔ᖚߢ޽ࠆߣ⸻≮ࠍᜎุߒߚࠅߔࠆߣ޿߁⃻ታߦߒ߫ߒ߫ㆣㆄߔࠆࠃ߁ߦߥߞߡ߈ߡ޿ࠆ‫߼ߚߩߘޕ‬㧘ਥᴦකߣߒߡోੱ⊛࡮✚ว⊛ߥ⸻≮߇ߢ߈ࠆකᏧ߇ᄙ
ߊߩ∛㒮ߢ߽᳞߼ࠄࠇࠆࠃ߁ߦߥߞߡ߈ߡ޿ࠆ‫ߚ߹ޕ‬㧘ࡊ࡜ࠗࡑ࡝࡮ࠤࠕߦኻᔕߢ߈ࠆߛߌߢߥߊ㧘ේ࿃ਇ᣿ߥ∔ᖚߦኻߒߡ∛ᘒ↢ℂቇ⊛ߥ⷗࿾߆ࠄ⊛⏕ߥ⸻ᢿࠍⴕ߁ߎߣ߇ߢ߈ࠆ⸻ᢿ⢻ജߩ㜞޿කᏧߩ㙃ᚑ
߽㊀ⷐߦߥߞߡ߈ߡ޿ࠆ‫ޕ‬✚วౝ⑼࡮✚ว⸻≮ㇱߪ㧘⸻≮㕙ߢߪ㧘1㧕ೋ⸻ᖚ⠪ߩ⸻ᢿߣᴦ≮ߣ㧘ᔅⷐ߇޽ࠇ߫ኾ㐷⸻≮⑼߳ߩ⚫
੺㧘2㧕common diseases ߿ⶄᢙߩ∔ᖚࠍ᦭ߔࠆᖚ⠪ߩ⸻ᢿߣᴦ≮㧘3㧕⸻≮ᤨ㑆ౝߩ 1࡮2 ᰴᢇᕆᖚ⠪ߩ⸻≮㧘4㧕ኾ㐷⸻≮⑼߆ࠄߩේ࿃ਇ᣿∔ᖚߩଐ㗬⸻≮ߥߤࠍⴕ޿㧘ᄢቇ∛㒮ߦ߅ߌࠆਛᩭ⊛ߥᓎഀࠍᜂ߁
ߎߣߦࠃߞߡ㧘ኾ㐷⸻≮⑼ߩ⸻≮ല₸ࠍ㜞߼ߡ޿ࠆ‫ޕ‬ᢎ⢒㕙ߢߪ㧘1㧕ක≮㕙ធߣ⸻ኤࠍ㊀ⷐⷞߒߚත೨࡮
තᓟ⥃ᐥ⎇ୃߩታ〣㧘2㧕ᓟᦼ⥃ᐥ⎇ୃකࠍኻ⽎ߣߒߚ✚วౝ⑼කߩ㙃ᚑ㧘3㧕࿾ၞකᏧળߣߩ↢ᶦᢎ⢒ߦ㑐ߔࠆㅪ៤ߥߤߦ៤ࠊߞߡ޿ࠆ‫ߚ߹ޕ‬㧘2004 ᐕᐲ߆ࠄᆎ߹ߞߚතᓟ⥃ᐥ⎇ୃ೙ᐲߦวࠊߖ㧘ቇౝ࡮ቇᄖ
ߩ⎇ୃකᢎ⢒ࠍ⋡⊛ߣߒߚࡊ࡜ࠗࡑ࡝ࠤࠕ࡮ࠞࡦࡈࠔ࡟ࡦࠬߣ޿߁ᢎ⢒ࡊࡠࠣ࡜ࡓࠍ㧘ᐕ 3 ࿁ጘ㒂⋵ౝߩ⥃ᐥ⎇ୃᜰቯ∛㒮ߣߣ߽ߦ㐿௅ߒߡ޿ࠆ‫ޕ‬
2㧚ᢎ⢒ᣉ⸳
1㧕 ᣣᧄౝ⑼ቇળ⹺ቯᢎ⢒ᣉ⸳
2㧕 ᣣᧄ♧ዩ∛ቇળ⹺ቯᢎ⢒ᣉ⸳
3㧕 ᣣᧄᶖൻེౝⷞ㏜ቇળᜰዉᣉ⸳
4㧕 ᣣᧄᓴⅣེቇળ⎇ୃᣉ⸳
5㧕 ᣣᧄᶖൻེ∛ቇળ⹺ቯᣉ⸳
6㧕 ᣣᧄ࡝࠙ࡑ࠴ቇળᢎ⢒ᣉ⸳7㧕 ᣣᧄ⠧ᐕකቇળ⹺ቯᣉ⸳
8㧕 ᣣᧄࠕ࡟࡞ࠡ࡯ቇળḰ⹺ቯᢎ⢒ᣉ⸳
3㧚⸻≮㐿⊒
1㧕 ⸻≮ฬ 㧦ਇ᣿ᾲᄖ᧪
⸻≮ౝኈ㧦ઁ㒮ߢߩ⸻≮ߦ߅޿ߡේ࿃߇ਇ᣿ߢ޽ߞߚ⊒ᾲࠍਥ⸷ߣߔࠆᖚ⠪ߦኻߒ㧘⊛⏕ߦ⸻ᢿࠍߒ㧘ㄦㅦߦᴦ≮ᣇ㊎ࠍ᳿ቯߔࠆ‫ޕ‬ኾ㐷⊛ߥᴦ≮߇ᔅⷐߥ޿႐วߦߪ㧘ߘߩ߹߹✚วౝ⑼ᄖ᧪߽
ߒߊߪ∛᫟ߦߡᴦ≮ࠍⴕ߁‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦⃻࿷㧘ਇ᣿ᾲᄖ᧪ࠍᮡ᭙ߒߡ޿ࠆ∛㒮ߪ㧘ᚒ‫ߚߴ⺞߇ޘ‬㒢ࠅߥ޿‫ޕ‬࿖ౝ⊛⹏ଔ㧦ࠬ࠲࠶ࡈߩᄙߊ߇✚วౝ⑼ኾ㐷කࠍขᓧߒߡ޿ࠆ‫ޕ‬ਇ᣿ᾲߩේ࿃ߩ 1 ߟߢ޽ࠆ⤔ේ∛ߦኻߒߡ㧘࡝࠙ࡑ࠴ኾ㐷කࠍ᫪↰೽⑼㐳߇ขᓧߒߡ޿ࠆ‫ޕ‬࿖㓙⊛⹏ଔ㧦੹ᓟ㧘㊀∝ᕆᕈ๭ๆེ∝୥⟲㧔SARS㧕߿㠽ࠗࡦࡈ࡞ࠛࡦࠩߥߤ㧘࿖㓙⊛ߥᗵᨴ∝ߩᵹⴕ߇੍᷹ߐࠇߡ޿ࠆ‫ޕ‬หᗵᨴ∝ࠍ⇼߁ᖚ⠪ߩฃߌ⋁ߣߥࠆਇ᣿ᾲᄖ᧪ߩᮡ᭙ߪ㧘࿖㓙⊛࠾࡯࠭ߦᔕ߃ࠆ߽ߩߣ⠨߃ࠄࠇࠆ‫ޕ‬2㧕 ⸻≮ฬ 㧦࡝࠙ࡑ࠴࡮⤔ේ∛ᄖ᧪⸻≮ౝኈ㧦࡝࠙ࡑ࠴࡮⤔ේ∛ߩ⸻ᢿᴦ≮ߪ㜞ᐲవㅴක≮ߩታ〣ߦਇนᰳߢ޽ࠆ‫ޕ‬ਇ᣿ᾲᄖ᧪ߢ⸻ᢿߐ
ࠇߚ࡝࠙ࡑ࠴࡮⤔ේ∛ߪ㧘㔍∛ߦ⧰ߒ߻ᖚ⠪ߦߣߞߡ㊀ⷐߥ⺖㗴ߢ޽ࠆ‫⃻ޕ‬࿷㧘ౝ⑼࠱࡯
ࡦߢ↢‛ቇ⊛⵾೷ߦࠃࠆᴦ≮ᖚ⠪ࠍᦨ߽ᄙߊᛴ߃ߡ߅ࠅ㧘․ߦ㑐▵࡝࠙ࡑ࠴ߪᢛᒻᄖ⑼㗔
ၞߣ౒หߒߡᴦ≮ߔࠆᔅⷐ߇޽ࠆ‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦᧲ᶏ࿾ᣇߢߪ଻ஜⴡ↢ᄢቇ㧘ᗲ⍮ක⑼ᄢቇߦኾ㐷ᄖ᧪ߪ޽ࠆ߇ጘ㒂⋵ਅߩਛᩭ∛㒮ߢߪ⠀ፉᏒ᳃∛㒮એᄖߦߪߥ޿‫ޕ‬࿖ౝ⊛⹏ଔ㧦ᣣᧄ࡝࠙ࡑ࠴ቇળ✚ળߦߪᲤᐕ⥃ᐥ⊛ᚑᨐࠍ⊒⴫ߒߡ޿ࠆ‫ޕ‬࿖㓙⊛⹏ଔ㧦☨࿖㧘࡛࡯ࡠ࠶ࡄ࡝࠙ࡑ࠴ቇળߣ౒หߒߡ㧘ᣣᧄ࡝࠙ࡑ࠴ቇળ߽⥃ᐥ∉ቇ⎇ⓥ߇ㅴⴕߒߟߟ޽ࠆ‫ޕ‬㧙㧙4㧚ኾ㐷ක࡮⹺ቯක࡮ᜰዉක
⍹Ⴆ㆐ᄦ㧦ᣣᧄౝ⑼ቇળ⹺ቯක࡮ኾ㐷ක࡮ᜰዉක㧘ᣣᧄᶖൻེ∛ቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄᶖൻེౝⷞ㏜
ቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄ♧ዩ∛ቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄౝಽᴲቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄ⠧ᐕකቇળᜰዉක㧘ᣣᧄ∛ᘒᩕ㙃ቇળ NST ࠦ࡯࠺ࠖࡀ࡯࠲࡯ᷡፉ ḩ㧦ᣣᧄౝ⑼ቇળ⹺ቯක㧘ᣣᧄᶖൻེ∛ቇળኾ㐷ක㧘ᣣᧄ⢄⤳ቇળኾ㐷ක㧘ᣣᧄ⥃ᐥᬌᩏቇળኾ㐷ක᫪↰ᶈਯ㧦ᣣᧄౝ⑼ቇળ⹺ቯක࡮ኾ㐷ක࡮ᜰዉක㧘ᣣᧄౝಽᴲቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄ♧ዩ∛ቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄ࡝࠙ࡑ࠴ቇળኾ㐷ක㧘ᣣᧄ⠧ᐕකቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄ∛ᘒᩕ㙃ቇળ
NST ࠦ࡯࠺ࠖࡀ࡯࠲࡯㧘ᣣᧄࠕ࡟࡞ࠡ࡯ቇળኾ㐷ක
ቝ㊁ཅᒄ㧦ᣣᧄౝ⑼ቇળ⹺ቯක࡮ኾ㐷ක࡮ᜰዉක㧘ᣣᧄᓴⅣེቇળኾ㐷ක㧘ᣣᧄ♧ዩ∛ቇળኾ㐷ක᫃↰๺↵㧦ᣣᧄౝ⑼ቇળ⹺ቯක࡮ᜰዉක㧘ᣣᧄ♧ዩ∛ቇળኾ㐷ක࡮ᜰዉක
๺↰␭Ὼ㧦ᣣᧄౝ⑼ቇળ⹺ቯක࡮ኾ㐷ක㧘ᣣᧄᶖൻེౝⷞ㏜ቇળኾ㐷ක㧘ᣣᧄ♧ዩ∛ቇળኾ㐷කᳰ↰⾆⧷㧦ᣣᧄౝ⑼ቇળ⹺ቯක᫪ ৻㇢㧦ᣣᧄౝ⑼ቇળ⹺ቯක⮮ጟ ࿻㧦ᣣᧄౝ⑼ቇળ⹺ቯක
5㧚⥄Ꮖ⹏ଔ
⹏ଔ
2004 ᐕߩᣂ∛㒮㐿㒮ߦวࠊߖߡ㧘ᄖ᧪ㇱ㐷ߦ߅޿ߡߪ㐿㒮ᒰᤨߩ᦬㑆ᐔဋᖚ⠪ᢙ 600 ੱบ߆ࠄ 1,100ੱบ߹ߢᓢ‫ߦޘ‬Ⴧടߒߡ߈ߡ߅ࠅ㧘✚ว⸻≮ᄖ᧪ߣߒߡߩᓎഀࠍචಽߦᨐߚߒߡ޿ࠆߣ⠨߃ߡ޿ࠆ‫ߚ߹ޕ‬㧘㐿ᬺක߿ઁ㒮߆ࠄߩ⚫੺ᖚ⠪߽Ⴧടߒߡ߈ߡ߅ࠅ㧘ᐔဋ⚫੺₸߽ 25㧑⒟ᐲ߹ߢࠕ࠶ࡊߒߡ߈ߡ޿ࠆ‫౉ޕ‬㒮ㇱ㐷ߢ߽㧘᧲ 7 㓏∛᫟ߦ 4 ᐥߢᣂⷙ㐿⸳ߒ㧘2007 ᐕ 4 ᦬߆ࠄߪ 7 ᐥߦჇᐥߦߥߞߚ߇㧘ߘߩᓟ߽∛ᐥ
Ⓙ௛₸ߪ 150㧑೨ᓟ㧘ᐔဋ࿷㒮ᣣᢙ 14 ᣣ೨ᓟߣߥߞߡ߅ࠅ㧘Ⓙ௛₸࡮࿷㒮ᣣᢙߣ߽㗅⺞ߢ޽ࠆߣ⠨߃ߡ޿ࠆ‫ޕ‬Ყセ⊛✕ᕆ౉㒮߇ᄙߊ㧘⸻≮ᤨ㑆ౝߩ 1 ᰴ 2 ᰴᢇᕆߦኻᔕߒߡ޿ࠆ⚿ᨐߣ⠨߃ߡ޿ࠆ‫৻ޕ‬ᣇ㧘ᢎ⢒ㇱ㐷ߢߪ㧘ቇ↢ታ⠌ߦട߃㧘߶߷Ფ᦬ⶄᢙߩ⥃ᐥ⎇ୃකࠍฃߌ౉ࠇ㧘ၮᧄ⊛ߥ⥃ᐥࠬࠠ࡞߇⠌ᓧߢ߈ࠆࠃ
߁ߥࡊࡠࠣ࡜ࡓࠍታ〣ߒߡ߅ࠅ㧘ቇ↢߿⎇ୃකߩ㑆ߩ⹏ଔ߽㜞޿‫ߦࠄߐޕ‬㧘තᓟ⎇ୃක೙ᐲߦวࠊߖߚቇ
ౝ࡮ቇᄖߩ⎇ୃකᢎ⢒⋡⊛ߩ⎇ⓥળߢ޽ࠆࡊ࡜ࠗࡑ࡝ࠤࠕ࡮ࠞࡦࡈࠔ࡟ࡦࠬࠍ㧘2005 ᐕ߆ࠄᐕ 3 ࿁౒௅ߒߡ߅ࠅ㧘ጘ㒂⋵ౝߩ⥃ᐥ⎇ୃᜰቯ∛㒮ߢߩ⎇ୃකᢎ⢒ߦ৻ᓎࠍᜂߞߡ޿ࠆ‫ߚ߹ޕ‬㧘ቇ↢߿⎇ୃකߣኻ⽎ߣߒߚീᒝળ߿∝଀ᬌ⸛ળ߽ቯᦼ⊛ߦቇౝߢ㐿௅ߒߡ޿ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷2004 ᐕᐲ߆ࠄතᓟ⥃ᐥ⎇ୃ߇ᔅ㗇ൻߐࠇ㧘ߘߩߥ߆ߢ߽ࡊ࡜ࠗࡑ࡝࡮ࠤࠕߩታ〣߇ᒝ⺞ߐࠇߡ޿ࠆ‫ޕ‬✚วౝ⑼࡮✚ว⸻≮ㇱߪߘߩਛᔃ⊛ߥᓎഀࠍᜂ߁ߴ߈┙႐ߦ޽ࠅ㧘ᄖ᧪ㇱ㐷ߪᲧセ⊛లታߒߚ⁁ᴫߦ޽ࠆ߇㧘౉㒮ㇱ㐷ߪ࿕ቯ∛ᐥᢙ߇ 7 ᐥߣઁߩ⸻≮⑼ߦᲧߒ࿶ୟ⊛ߦዋߥߊ∛ᐥⒿ௛₸߽㜞޿ߚ߼㧘․ߦ✕ᕆ౉㒮߇޽ࠆᤨߥߤ㧘౉㒮ࡌ࠶࠼ߩ⏕଻ߦ⧰ഭߔࠆߎߣ߇ᄙ޿‫߼ߚߩߘޕ‬㧘ᖚ⠪ߦ౉㒮ᓟߩォᐥߥߤߩਇㇺวࠍ߆ߌࠆߎߣ߇޽ࠅ㧘ࡌ࠶࠼߇ಽᢔߒߡ޿ࠆߚ߼⸻≮ߦਇㇺวࠍᗵߓࠆߎߣ߽ߒ߫ߒ߫޽ࠆ‫∛ޕ‬ᐥⒿ௛₸ߪో⸻≮⑼ߢߪᦨ߽㜞ߊ㧘࿷㒮ᣣᢙ߽ᐔဋ࡟ࡌ࡞ߢ޽ࠆߚ߼㧘੹ᓟ߽Ⓧᭂ⊛ߦჇᐥߩᔅⷐᕈࠍ∛㒮஥ߦ⸷߃ߡࠁߊ‫ޕ‬੹ᓟߩዷᦸጘ㒂⋵ߩ․ᓽߩ 1 ߟߦጊ㑆ㇱ߇ᄙ޿ߎߣ߇᜼ߍࠄࠇࠆ‫ੱޕ‬ญ߇ᐔ㊁ㇱߦᲧߴዋߥ޿ߚ߼㧘Ყセ⊛ዊⷙᮨߩ∛㒮߇ᄙߊሽ࿷ߔࠆ‫ߚ߹ޕ‬㧘ⶄᢙߩ∔ᖚࠍ૬ߖᜬߟ㜞㦂⠪߇ᄙ޿ߩ߽․ᓽߢ޽ࠆ‫ߚߒ߁ߎޕ‬࿾඙߿∛㒮ߦ߅޿ߡ㧘ᦨ߽࠾࡯࠭߇㜞޿කᏧߪ㧘޽ࠆ․ቯߩಽ㊁ߦᷓ޿⍮⼂ߣᛛ⢻ࠍᜬߟኾ㐷⊛ߥකᏧߢߪߥߊ㧘߻ߒࠈ᏷ᐢ޿කቇ⍮⼂ߣᛛ⢻ࠍᜬߞߚࡅࡘ࡯ࡑ࠾࠹ࠖ޽߰ࠇࠆ✚วౝ⑼කߢ޽ࠅ㧘ᄙߊߩቇ↢߿⎇ୃක߇ℂᗐߣߔࠆකᏧ௝ߩ 1 ߟߢ߽޽ࠆ‫৻ޕ‬ᣇ㧘ᄢቇ∛㒮ࠍߪߓ߼ߣߔࠆㇺᏒㇱߩᄢ∛㒮ߦߪ㧘ේ࿃߇ਇ᣿ߩᧂ⸻
ᢿߩᖚ⠪߽ᄙߊ⚫੺ߐࠇߡߊࠆ‫ޕ‬ኾ㐷⸻≮⑼ߩല₸⊛ߥㆇ༡ߩߚ߼ߦ߽㧘✚ว⊛ߥ⷗࿾߆ࠄ⸻≮ߦᒰߚࠆߎߣ߇ߢ߈ࠆ✚วౝ⑼ක߇ᔅⷐߣߥߞߡߊࠆ‫✚ޕ‬วౝ⑼࡮✚ว⸻≮ㇱߢߪ㧘㜞޿⸻ᢿ⢻ജࠍᜬߜ㧘৻ੱߩᖚ⠪ߩⶄᢙߩ∔ᖚߦหᤨߦኻᔕ߇ߢ߈ࠆ⧯޿ఝ⑲ߥ✚วౝ⑼කߩ㙃ᚑߦోജࠍዧߊߒ㧘ጘ㒂⋵ߩ␠ળ⊛࠾࡯࠭ߦ╵߃ߡࠁ߈ߚ޿‫ޕ‬㧙㧙㧔27㧕ක≮ᖱႎㇱ
1㧚⸻≮ߩ᭎ⷐ
ක≮ᯏ㑐ߩ ICT ൻ߇ᐢ߇ࠅߟߟ޽ࠆ‫ޕ‬ක≮ᖱႎㇱߪ∛㒮ౝߩ ICT ൻࠍផㅴߔࠆᲣ૕ߢ޽ࠅ㧘㔚ሶࠞ࡞࠹ࠪࠬ࠹ࡓߩ⸳⸘࡮ᔟᵴ࡮ㆇ↪ࠍᜂᒰߒߡ޿ࠆ‫ޕ‬㔚ሶࠞ࡞࠹ࠪࠬ࠹ࡓߩㆇ↪ߦࠃࠅ⸻≮⸥㍳߿↹௝ᖱႎ╬ߪߔߴߡ㔚ሶൻߐࠇ㧘ࡍ࡯ࡄ࡟ࠬ㧛ࡈࠖ࡞ࡓ࡟ࠬߩ㔚ሶൻ∛㒮ߣߒߡ⃻ᤨὐߢ߽਎⇇ᦨవ┵ߩ⁁ᘒߦ޽ࠆ‫ޕ‬ߎߩࠃ߁ߥ ICT ൻߐࠇߚ∛㒮ߩㆇ༡ࠍᡰ߃ࠆߚ߼ߦߪ㧘㔚ሶࠞ࡞࠹ࠪࠬ࠹ࡓߩ቟ቯⒿ௛㧘ฦ⒳ࡑࠬ࠲࡯
㘃ߩᢛ஻ߣ▤ℂ㧘⫾Ⓧߐࠇߚᖚ⠪ᖱႎߩ㐳ᦼߦਗ਼ࠆ቟ቯߒߚ▤ℂ૕೙ߩ᭴▽ߣ⛽ᜬ߇ਇนᰳߢ޽ࠆ‫ޕ‬ක≮ᖱႎㇱߪߎߩࠃ߁ߥᣣᏱ⸻≮ࠍᡰ߃ࠆ ICT ൻⅣႺߩ⛽ᜬ࡮▤ℂ࡮ㆇ༡ߦദജࠍߒߡ޿ࠆ‫ޕ‬
2㧚ᢎ⢒ᣉ⸳
ߥߒ
3㧚⸻≮㐿⊒
ߥߒ4㧚ኾ㐷ක࡮⹺ቯක࡮ᜰዉක
⊕㠽⟵ቬ㧦ᣣᧄౝ⑼ቇળ⹺ቯක࡮ᜰዉක㧘ᣣᧄᶖൻེ∛ቇળኾ㐷ක㧘ᣣᧄ⢄⤳ቇળኾ㐷ක࡮ᜰዉක
5㧚⥄Ꮖ⹏ଔ
⹏ଔ㔚ሶࠞ࡞࠹ࠪࠬ࠹ࡓߣߒߡߪ਎⇇ᦨవ┵ߩ⹏ଔࠍᓧߡ޿ࠆ‫ߚ߹ޕ‬㧘ක≮ᖱႎㇱߩᵴേߣߒߡߪᣣᏱ⸻≮ࠍᡰ߃ࠆࠪࠬ࠹ࡓߩ቟ቯⒿ௛ߦ⽸₂ߢ߈ߚߣ⠨߃ߡ޿ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ᣣᏱ⸻≮ߩㆇ༡ࠍ቟ቯߒߡᡰ߃ࠆ㔚ሶࠞ࡞࠹ࠪࠬ࠹ࡓࠍ⛽ᜬ࡮▤ℂߔࠆߚ߼ߦߪ⚵❱ߣߒߡߩ૕೙ࠍల
ታߐߖࠆߎߣ߇⺖㗴ߢ޽ࠆ‫ߦ․ޕ‬㧘㔚ሶࠞ࡞࠹ࠪࠬ࠹ࡓߪᛛⴚㅴᱠߩᣧ޿ ICT ಽ㊁ߢ޽ࠆߚ߼㧘ߘࠇࠍᡰ߃ࠆක≮ᖱႎㇱࠬ࠲࠶ࡈߩᢎ⢒߇ਇนᰳߢ޽ࠆ‫ߒ߆ߒޕ‬㧘ߎࠇ߹ߢߪ㔚ሶࠞ࡞࠹ࠪࠬ࠹ࡓߩ቟ቯⒿ௛ࠍఝవߒ㧘ᦨవ┵ߩ ICT ᛛⴚ╬ߦⓍᭂ⊛ߦ⸅ࠇࠆᯏળࠍలಽߦਈ߃ߡߎߥ߆ߞߚ‫੹ޕ‬ᓟߪ㧘ක≮ᖱႎㇱࠬ࠲࠶ࡈ߇⥄Ꮖ⎇㐭ߢ߈ࠆⅣႺߩ᭴▽ߣలታߦദജߒߚ޿ߣ⠨߃ߡ޿ࠆ‫ޕ‬
੹ᓟߩዷᦸ
⫾Ⓧߐࠇߚ⤘ᄢߥ⸻≮࠺࡯࠲ࠍ∛㒮ߩㆇ༡߿⸻≮ߩ⾰ะ਄ߦᵴ↪ߔࠆߎߣ߇᳞߼ࠄࠇߡ޿ࠆ‫߼ߚߩߘޕ‬ߦߪ㧘⸻≮࠺࡯࠲ߩ᛽಴࡮ಽᨆ࡮⸻≮ᡰេᯏ⢻߳ߩࡈࠖ࡯࠼ࡃ࠶ࠢࠍⓍᭂ⊛ߦផㅴߔࠆᔅⷐ߇޽ࠆ‫ߚ߹ޕ‬㧘⸻≮࠺࡯࠲ߩಽᨆ߿⸻≮ࡊࡠ࠮ࠬߩಽᨆࠍᜂᒰߔࠆੱ᧚ߩ⢒ᚑ߇ᕆോߩ⺖㗴ߢ޽ࠆ‫ޕ‬ක≮ᖱႎㇱߪ㧘੹ᓟߎߩࠃ߁ߥᵴേߦኻߒⓍᭂ⊛ߦኻᔕߒߚ޿ߣ⠨߃ߡ޿ࠆ‫ޕ‬㧙㧙㧔28㧕శቇක≮⸻≮ㇱ
1㧚⸻≮ߩ᭎ⷐ
I. ⢗⣺∔ᖚ࡮ ᶖൻ▤ߩᣧᦼ≸ߦኻߒߡߪ㧘⿥㖸ᵄౝⷞ㏜ᬌᩏ߿ NBI ߥߤߩ․ᱶశࠍ૬↪ߒߚ᜛ᄢౝⷞ㏜ⷰኤࠍ↪޿ߡᱜ⏕ߦ⸻ᢿߒ㧘㘩㆏≸㧘⢗≸㧘ᄢ⣺≸㧘ᄢ⣺⣼⣲ߦኻߒౝⷞ㏜⊛☼⤑ਅጀ೸㔌ⴚ㧔ESD㧕ࠍⓍᭂ⊛ߦⴕ߁‫ޕ‬㜞㦂⠪߿㊀◊ߥၮ␆∔ᖚࠍ᦭ߔࠆ∝଀ߦߪ㧘ࠃࠅૐଚⷅߩࠕ࡞ࠧࡦࡊ࡜࠭ࡑಝ࿕ⵝ⟎㧔APC㧕ࠍ↪޿ߚ὾ἳⴚ߽ⴕ߁‫ߚ߹ޕ‬ㅴⴕ≸ߦߪൻቇ≮ᴺ߿ࠬ࠹ࡦ࠻⇐⟎ⴚࠍⴕ߁‫ޕ‬࡮ ᶖൻ▤಴ⴊ଀ߦߪ✕ᕆౝⷞ㏜ᬌᩏࠍⴕ޿ౝⷞ㏜⊛ᱛⴊⴚࠍᣉⴕߔࠆ‫ޕ‬㘩㆏⢗㕒⣂≜ߦኻߒߡߪౝⷞ㏜⊛⎬ൻ≮ᴺ㧔EIS㧕߿⚿⚤ⴚ㧔EVL㧕ࠍⴕ߁‫ޕ‬࡮ ߹ߚᦨㄭߢߪ㧘ߎࠇ߹ߢ⸻ᢿ߇࿎㔍ߢ޽ߞߚዊ⣺∛ᄌߦኻߒߡ࠳ࡉ࡞ࡃ࡞࡯ࡦዊ⣺ౝⷞ㏜㧘ࠞࡊ࠮࡞
ౝⷞ㏜ࠍዉ౉ߒ㧘ࠃࠅᱜ⏕ߥ⸻ᢿࠍᓧࠆࠃ߁ߦߒߡ޿ࠆ‫ޕ‬Ἳ∝ᕈ⣺∔ᖚߦኻߒߡߪ㧘ౝⷞ㏜ࠍ↪޿Ⓧᭂ⊛ߦ⸻ᢿ㧘㊀∝ᐲ್ቯࠍⴕ޿㧘ㆡಾߥᴦ≮ࠍⴕ߁ߎߣߣߒߡ޿ࠆ‫ޕ‬࡮ ߘߩઁ㧘⒳‫∔ߩޘ‬ᖚߦࠃࠆ⚻ญ៨ขਇ⢻ᖚ⠪ߦኻߒౝⷞ㏜⊛⚻⊹⊛⢗≪Ⴧ⸳ⴚ㧔PEG㧕ࠍⴕ߁޿㧘ᶖൻ▤⁜⓰଀ߦߪౝⷞ㏜ਅߢߩࡃ࡞࡯ࡦ᜛ᒛⴚࠍⴕ߁‫ޕ‬II. ⢙⤟∔ᖚ࡮ ⤟⢙㆏∔ᖚߦኻߒߡߪ㧘⿥㖸ᵄౝⷞ㏜߅ࠃ߮ౝⷞ㏜⊛ㅒⴕᕈ⤟⢙▤ㅧᓇࠍᔕ↪ߒߚᚻᛛߦࠃࠅ㧘ࠃࠅᱜ⏕ߥ⸻ᢿࠍⴕߞߡ޿ࠆ‫ߚ߹ޕ‬㧘⿥㖸ᵄౝⷞ㏜ࠍᔕ↪ߒߡ㧘⤟઒ᕈྙ⢩࡮⤟⤥≌࡮ᗵᨴᕈ⤟უᱫߦኻߔࠆ࠼࡟࠽࡯ࠫ߿≸ᕈ−∩ߦኻߔࠆ⣻⣧␹⚻ฌࡉࡠ࠶߽ࠢⴕߞߡ޿ࠆ‫ޕ‬Ყセ⊛㗫ᐲߩ㜞޿∔ᖚߣߒߡ㧘✚⢙▤⚿⍹ߦኻߒߡߪౝⷞ㏜⊛੃㗡ಾ㐿ⴚ㧔EST㧕߿ౝⷞ㏜⊛ࡃ࡞࡯ࡦ੃㗡᜛ᒛⴚ㧔EPBD㧕ࠍ⁁ᴫߦࠃߞߡ૶޿ಽߌᴦ≮ࠍⴕ޿㧘߹ߚᏂᄢ⚿⍹ߥߤߩౝⷞ㏜ᴦ≮࿎㔍଀ߦኻߒߡߪ㧘૕ᄖⴣ᠄ᵄࠍ૬↪ߔࠆߎߣߦࠃࠅㆡᔕࠍᐢߍߡ޿ࠆ‫ޕ‬ߐࠄߦ⦟ᕈ޽ࠆ޿ߪᖡᕈ⢙㆏㐽Ⴇߦኻߒߡߪ㧘ౝⷞ㏜⊛ߦ⢙㆏ࠬ࠹ࡦ࠻ࠍ⇐⟎ߔࠆߎߣߦࠃࠅ㧘㕖ଚⷅ⊛ߥᴦ≮ࠍⴕߞߡ޿ࠆ‫ޕ‬III. ๭ๆེ∔ᖚ㧔⢖≸㧕
1㧕 ᓥ᧪㧘᳇▤ᡰౝⷞ㏜⊛⸻ᢿ߇࿎㔍ߢ޽ߞߚ㧘⢖ᧃ᪳∛ᄌߦኻߒߡߪ㧘ࠟࠗ࠼ࠪ࡯ࠬᴺࠍ↪޿ߚㅘⷞਅ
↢ᬌ㧔᳇▤ᡰౝⷞ㏜ਅߦㅘⷞਅ⺃ዉሶࠍ↪޿ߡࠟࠗ࠼ࠪ࡯ࠬࠍᝌ౉ߒ㧘ࠪ࡯ࠬౝߦ᳇▤ᡰౝⷞ㏜ࠛࠦ
࡯ࠍᝌ౉ߒ㧘⣲≌ㇱ૏ࠍหቯߔࠆ‫ࠍ࡯ࠦࠛޕ‬ᛮ෰ᓟ㧘↢ᬌ߿ࡉ࡜࠶ࠪࡦࠣࠍᣉⴕߔࠆ㧕ߎߣߦࠃࠅ⸻
ᢿ₸ะ਄ߦദ߼ߡ޿ࠆ‫ޕ‬
2㧕 ᣧᦼ⢖≸ߩਛߢૐ⢖ᯏ⢻߿ోり⁁ᘒਇ⦟ߦߡᚻⴚ࿎㔍ߥ∝଀ߦኻߒߡߪ㧘⿥㖸ᵄౝⷞ㏜ᬌᩏࠍ↪޿ߡㅴ㆐ᐲ⸻ᢿߒ㧘PDT㧔Photo dynamic therapy㧕߿ౝⷞ㏜࡟࡯ࠩ࡯ᴦ≮ࠍᣉⴕߔࠆ‫ߚ߹ޕ‬㧘ਛᨔ᳇▤ᡰ⊒↢⢖≸ߦኻߒߡߪ᳇▤ᡰ⣧ౝ᡼኿✢ᴦ≮ࠍᣉⴕߒߡ޿ࠆ‫৻ޕ‬ᣇ㧘᳇㆏⁜⓰ࠍ᧪ߚߔࠃ߁ߥㅴⴕ≸ߦߪ᳇▤ᡰࡃ࡞࡯࠾ࡦࠣߦࠃࠆ᜛ᒛ߿ࠬ࠹ࡦ࠻⇐⟎ⴚࠍⴕ߁‫ߚ߹ޕ‬㧘✕ᕆ໼ⴊ଀ߦߪᱛⴊ↪ࡃ࡞࡯ࡦߦࠃࠆౝⷞ㏜⊛ᱛⴊⴚ߿᳇▤ᡰേ⣂Ⴇᩖⴚ╬ࠍⴕ߁‫ޕ‬3㧕 ❑㓒࡝ࡦࡄ▵ォ⒖⸻ᢿ߿❑㓒ဳ⢖≸㧘❑㓒⣲≌ߦኻߒߡߪ㧘᳇▤ᡰ⿥㖸ᵄ᳇▤ᡰౝⷞ㏜ਅ↢ᬌ㧔EBUS-TBNA㧕ࠍᣉⴕߒ㧘ࠛࠦ࡯ࠟࠗ࠼ਅߦ↢ᬌࠍᣉⴕߔࠆᣂߚߥ᳇▤ᡰౝⷞ㏜⸻ᢿᴺࠍขࠅ౉ࠇ
ߚ⸻ᢿࠍⴕߞߡ޿ࠆ‫ޕ‬
4㧕 ᦨㄭߢߪ㧘ߎࠇ߹ߢ⸻ᢿ߇࿎㔍ߢ޽ߞߚ⢖ᧃ᪳ᓸዊ⢖⣲≌∛ᄌߦኻߒߡ㧘ᭂ⚦ᓘ᳇▤ᡰ㏜ࠍ↪޿ߚ㧘
CT ࠟࠗ࠼ਅ᳇▤ᡰౝⷞ㏜ᬌᩏࠍዉ౉ߒ㧘ࠃࠅᱜ⏕ߥ⸻ᢿࠍᓧࠆࠃ߁ߦߒߡ޿ࠆ‫ޕ‬
IV. ๭ๆེ∔ᖚ㧔߮߹ࠎᕈ⢖∔ᖚ㧕
1㧕 ․⊒ᕈ㑆⾰ᕈ⢖Ἳ߿ࠨ࡞ࠦ࡯࠼࡯ࠪࠬ㧘ේ࿃ਇ᣿ߩ߮߹ࠎᕈ⢖∔ᖚ߿๭ๆེᗵᨴ∝ߦኻߒߡ㧘᳇▤ᡰౝⷞ㏜ਅߦ BAL㧔᳇▤ᡰ⢖⢩ᵞᵺᴺ㧕ࠍᣉⴕߒ㧘⚦⢩ᚑಽ㧘ฦ⒳ࠨࠗ࠻ࠞࠗࡦ㧘ฦ⒳࠙ࠗ࡞ࠬ㧘⚦⩶ᬌᩏࠍᣉⴕߒ㧘∛࿃ࠍ⸻ᢿߔࠆ‫ߚ߹ޕ‬㧘ㅘⷞਅߦ⢖↢ᬌࠍᣉⴕߒ㧘ᬌᩏ⢖⚵❱ࠍ㒶࿶ߢ⤘ࠄ߹ߖ㧘߮߹ࠎᕈ⢖∔ᖚߩ⸻ᢿࠍⴕ߁‫ޕ‬
2㧚ᢎ⢒ᣉ⸳
1㧕 ᣣᧄౝ⑼ቇળ⹺ቯౝ⑼ኾ㐷කᢎ⢒ᣉ⸳
2㧕 ᣣᧄᶖൻེ∛ቇળ⹺ቯᣉ⸳
3㧕 ᣣᧄ⢄⤳ቇળ⹺ቯᣉ⸳
4㧕 ᣣᧄᶖൻེౝⷞ㏜ቇળᜰቯᣉ⸳
5㧕 ᣣᧄ๭ๆེ∛ቇળ⹺ቯᣉ⸳
6㧕 ᣣᧄ๭ๆེౝⷞ㏜ቇળ⹺ቯᣉ⸳
7㧕 ᣣᧄ⥃ᐥ⣲≌ቇળ⹺ቯ⎇ୃᣉ⸳㧙㧙8㧕 ᣣᧄ߇ࠎᴦ≮⹺ቯකᯏ᭴⹺ቯ⎇ୃᣉ⸳
3㧚⸻≮㐿⊒
1㧕 ⸻≮ฬ 㧦࠳ࡉ࡞ࡃ࡞࡯ࡦዊ⣺ౝⷞ㏜ߣࠞࡊ࠮࡞ౝⷞ㏜ߦࠃࠆ⸻ᢿߣᴦ≮⸻≮ౝኈ㧦ේ࿃ਇ᣿ߩᶖൻ▤಴ⴊᖚ⠪ߩዊ⣺㗔ၞߩ∔ᖚߦ㑐ߒౝⷞ㏜⊛ߦ⸻ᢿ࡮ᴦ≮ߔࠆ‫ޕ‬ઁ∛㒮ߢߩዉ౉㧦ጘ㒂⋵ౝߢߪ㧘࠳ࡉ࡞ࡃ࡞࡯ࡦዊ⣺ౝⷞ㏜ߪᦺᣣᄢቇ㒝ዻ᧛਄⸥ᔨ∛㒮ߦዉ౉㧘ࠞࡊ࠮࡞ౝⷞ㏜ߪ᧻ᵄ✚ว∛㒮㧘᧲ᶏਛᄩ∛㒮㧘࿯ጘᏒ┙✚ว∛㒮ߦዉ౉ߐࠇߡ޿ࠆ߇㧘ਔᣇߩᯏེࠍዉ౉ߒߡ޿ࠆߩߪᒰ㒮ߩߺ‫ޕ‬࿖ౝ⊛⹏ଔ㧦ዊ⣺∔ᖚߩ⸻ᢿߣᴦ≮ߦߪᭂ߼ߡ᦭↪ߥᣂߒ޿⸻ᢿᴦ≮ᛛⴚࠍߒߡ㧘࿖㓙⊛ߦ߽⎇ⓥ⹏
ଔ߇ㅴࠎߢ޿ࠆ‫ޕ‬࿖㓙⊛⹏ଔ㧦ห਄2㧕 ⸻≮ฬ 㧦⿥㖸ᵄౝⷞ㏜ਅ↢ᬌ㧔EUS-FNA㧕⸻≮ౝኈ㧦૕⴫ࠃࠅ⓫ೝਇน⢻ߥ⣲≌ᕈ∛ᄌ߿࡝ࡦࡄ▵∛ᄌߦኻߒߡ㧘ᶖൻ▤ࠃࠅ⿥㖸ᵄౝⷞ㏜ࠟࠗ
࠼ਅߦߡ㊎↢ᬌࠍⴕ߁‫ޕ‬ઁ∛㒮ߢߩዉ౉㧦ጘ㒂⋵ਅߢߪᣢߦ 3 ᣉ⸳㧔ጘ㒂Ꮢ᳃∛㒮㧘ጘ㒂⋵✚วක≮࠮ࡦ࠲࡯㧘㜞ጊ⿒චሼ∛㒮㧕߇ዉ౉ߒߡ޿ࠆ߇㧘ో࿖⊛ߦߪ߹ߛ᥉෸߇ㆃࠇߡ߅ࠅ㧘৻⥸⥃ᐥ࡟ࡌ࡞ߢⴕߞߡ޿ࠆ
ᣉ⸳ߪ㧘50 ᣉ⸳ߦḩߚߥ޿‫ޕ‬࿖ౝ⊛⹏ଔ㧦ᒰᣉ⸳ߢߪᐕ㑆⚂ 200 ଀ߦኻߒߡᧄᬌᩏࠍⴕߞߡ߅ࠅ㧘࿖ౝߢߪᦨᄙߩ∝଀ᢙࠍ⹶ࠆ‫ޕ‬߹ߚ㧘ߎࠇࠄߩ⸻ᢿ࡮ᴦ≮ᚑ❣ߪᶏᄖߩ࠻࠶ࡊࠫࡖ࡯࠽࡞ߦᄙᢙឝタߐࠇߡ߅ࠅ㧘࿖ౝᄖ߆ࠄߩ⷗ቇ⠪߽ᄙᢙ⸰ࠇࠆߥߤ࿖㓙⊛ߥ⹏ଔ߽㜞޿‫ޕ‬࿖㓙⊛⹏ଔ㧦ห਄3㧕 ⸻≮ฬ 㧦᳇▤ᡰౝⷞ㏜ߦࠃࠆ⸻ᢿߣᴦ≮⸻≮ౝኈ㧦᳇▤ᡰౝⷞ㏜ࠛࠦ࡯ᬌᩏࠍ↪޿ߚ⢖⣲≌ߩ⚵❱ᕈ⁁ߩ⎇ⓥߦߡ H20 ᐕᐲᣣᧄౝⷞ㏜⽷࿅ࠃࠅ⎇ⓥഥᚑ㊄ࠍ޿ߚߛ߈㧘᳇▤ᡰౝⷞ㏜ࠛࠦ࡯ᬌᩏߦߡ㧘⣲≌ߩ⚵❱ᕈ⁁㧘ㅴ㆐ᐲ㧘࡝ࡦࡄ▵ォ⒖᦭ήߦኻߒߡ⾰⊛⸻ᢿࠍⴕ߁‫ޕ‬ઁ∛㒮ߢߩዉ౉㧦⃻࿷㧘⥃ᐥᔕ↪ߐࠇߡ޿ࠆ๭ๆེౝⷞ㏜ࠛࠦ࡯ᬌᩏߪጘ㒂⋵ౝߢߪጘ㒂Ꮢ᳃∛㒮㧘㐳⦟ක≮࠮ࡦ࠲࡯ߢዉ౉ߐࠇߡ޿ࠆ‫ޕ‬࿖ౝ⊛⹏ଔ㧦ᐔᚑ 17 ᐕᣣᧄ๭ๆེౝⷞ㏜ቇળ✚ળߦߡ๭ๆེߣౣ↢කቇߦ㑐ߔࠆࠪࡦࡐࠫࠬ࠻ߣߒ
ߡ⊒⴫ࠍⴕ޿㧔੹࿁⃻⁁ߣ⺖㗴ߩᦼ㑆ߣ⇣ߥࠆߣ޿߁ߎߣߢ޽ࠇ߫⋭޿ߡ޿ߚߛ޿ߡ߽᭴
޿߹ߖࠎ㧕㧘ᐔᚑ 20 ᐕᐲᣣᧄౝⷞ㏜⽷࿅ࠃࠅ᳇▤ᡰౝⷞ㏜ᓟᣇ᜛ᢔࠛࠦ࡯ᴺࠍ↪޿ߚ㧘⣲≌ߩ⚵❱ᕈ⁁⸻ᢿ㧘ㅴ㆐ᐲ㧘࡝ࡦࡄ▵ォ⒖⸻ᢿߦ㑐ߔࠆ⎇ⓥഥᚑ㊄ࠍฃߌߚ‫ޕ‬࿖㓙⊛⹏ଔ㧦੹ᓟ㧘ౝⷞ㏜ߦ㑐ߔࠆ⎇ⓥᚑᨐࠍ᰷☨㔀⹹߳ߩᛩⓂ߿਎⇇᳇▤ᡰ㏜ቇળ߿☨࿖⢷ㇱቇળ╬ߩ࿖㓙ቇળߢ⊒⴫ࠍⴕ߁੍ቯߢ޽ࠆ‫ޕ‬4㧕 ⸻≮ฬ 㧦᳇▤ᡰ⿥㖸ᵄౝⷞ㏜ਅ↢ᬌ㧔EBUS-TBNA㧕⸻≮ౝኈ㧦ㅘⷞਅ⸻ᢿਇน⢻ߥ⣲≌ᕈ∛ᄌ߿࡝ࡦࡄ▵∛ᄌߦኻߒߡ㧘ਛᨔ᳇▤ᡰࠃࠅ⿥㖸ᵄౝⷞ㏜ࠟ
ࠗ࠼ਅߦߡ㊎↢ᬌࠍⴕ߁‫ޕ‬ઁ∛㒮ߢߩዉ౉㧦ᒰ⑼߅ࠃ߮߶߆ߩ޿ߊߟ߆ߩᣉ⸳ߢዉ౉‫ޕ‬࿖ౝ⊛⹏ଔ㧦ߎࠇ߹ߢߪ㐿⢷ⴚߦߡ⸻ᢿߒߡ޿ߚᷓㇱ∛ᄌߦኻߒߡ㧘㕖ଚⷅ⊛ߦ⸻ᢿ߇น⢻ߢ޽ࠅ㧘ᭂ߼ߡ᦭↪ߥᣂߒ޿⸻ᢿᛛⴚߢ޽ࠆ‫ޕ‬࿖㓙⊛⹏ଔ㧦ห਄4㧚ኾ㐷ක࡮⹺ቯක࡮ᜰዉක
᫪⣁ਭ㓉㧦ᣣᧄౝ⑼ቇળ⹺ቯක࡮ᜰዉක㧘ᣣᧄᶖൻེ∛ቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄ⢄⤳ቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄᶖൻེౝⷞ㏜ቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄ⥃ᐥ⣲≌ቇળᥳቯᜰዉක
᳗ᧁᱜੳ㧦ᣣᧄౝ⑼ቇળ⹺ቯක࡮ᜰዉක㧘ᣣᧄᶖൻེ∛ቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄ⢄⤳ቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄᶖൻེౝⷞ㏜ቇળኾ㐷ක⨹ᧁኡม㧦ᣣᧄౝ⑼ቇળ⹺ቯක㧘ᣣᧄᶖൻེ∛ቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄᶖൻེౝⷞ㏜ቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄ⥃ᐥ⣲≌ቇળ࡮ᥳቯᜰዉක㧘ᣣᧄ߇ࠎ⹺ቯකᯏ᭴࡮ᥳቯᢎ⢒ක቟↰৻ᦶ㧦ᣣᧄౝ⑼ቇળ⹺ቯක㧘ᣣᧄᶖൻེ∛ቇળኾ㐷ක㧘ᣣᧄᶖൻེౝⷞ㏜ቇળኾ㐷ක࡮ᜰዉක੗ᷓ⾆჻㧦ᣣᧄౝ⑼ቇળ⹺ቯක࡮ᣣᧄᶖൻེౝⷞ㏜ቇળኾ㐷කጤਅᜏม㧦ᣣᧄౝ⑼ቇળ⹺ቯක࡮ᣣᧄᶖൻེ∛ቇળኾ㐷ක࡮ᣣᧄᶖൻེౝⷞ㏜ቇળኾ㐷ක
ዊ㊁ᧁ┨ੱ㧦ᣣᧄౝ⑼ቇળ⹺ቯක࡮ᣣᧄᶖൻེౝⷞ㏜ቇળኾ㐷ක
ᄢ㊁ ᐽ㧦ᣣᧄౝ⑼ቇળ࡮⹺ቯක࡮ኾ㐷ක࡮ᜰዉක㧘ᣣᧄ๭ๆེ∛ቇળ࡮ኾ㐷ක࡮ᜰዉක㧘ᣣᧄ๭ๆེౝ

㧙㧙ⷞ㏜ቇળ࡮ኾ㐷ක࡮ᜰዉක㧘ᣣᧄ⥃ᐥ⣲≌ቇળ࡮ᥳቯᜰዉක㧘ᣣᧄ߇ࠎ⹺ቯකᯏ᭴࡮ᥳቯᢎ⢒ක⥱ญ␸ᒾ㧦ᣣᧄౝ⑼ቇળ࡮⹺ቯක࡮ኾ㐷ක㧘ᣣᧄ๭ๆེ∛ቇળ࡮ኾ㐷ක㧘ᣣᧄ๭ๆེౝⷞ㏜ቇળ࡮ኾ㐷ක㧘ᣣᧄ߇ࠎ⹺ቯකᯏ᭴࡮ᢎ⢒ක
᫪ ⑲ᴺ㧦ᣣᧄౝ⑼ቇળ⹺ቯක
5㧚⥄Ꮖ⹏ଔ
⹏ଔᶖൻེ㗔ၞߢߪ㧘ᦨᣂߩක≮ᛛⴚߣߒߡౝⷞ㏜⊛☼⤑ਅጀ೸㔌ⴚ㧔ESD㧕㧘ዊ⣺ౝⷞ㏜㧘⿥㖸ᵄౝⷞ㏜
ਅๆᒁ㊎↢ᬌ㧔EUS-FNA㧕ߥߤࠍⓍᭂ⊛ߦዉ౉ߒ㧘⋵ౝᄖ߆ࠄߏଐ㗬ࠍฃߌ㧘∝଀ߩ⫾Ⓧߒߡ޿ࠆ‫ޕ‬߹ߚ㧘๭ๆེ㗔ၞߢߪᦨᣂߩක≮ᛛⴚߣߒߡࠟࠗ࠼ࠪ࡯ࠬᴺࠍ↪޿ߚᧃ᪳⢖∛ᄌߩ⸻ᢿ㧘ᭂ⚦ᓘ᳇▤ᡰ
㏜ࠍ↪޿ߚ CT ࠟࠗ࠼ਅ᳇▤ᡰ㏜㧘ਛᨔ᳇▤ᡰߦኻߔࠆ᳇▤ᡰ⣧ౝᾖ኿㧘᳇▤ᡰ⿥㖸ᵄౝⷞ㏜ਅๆᒁ㊎↢ᬌ㧔EBUS-TBNA㧕ߥߤࠍⓍᭂ⊛ߦዉ౉ߒ㧘⋵ౝᄖ߆ࠄߏଐ㗬ࠍฃߌ㧘∝଀ߩ⫾Ⓧߒߡ޿ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ߅ࠃ߮ߘߩኻᔕ╷ᛛⴚ⊛ߦᬌᩏ࡮ᴦ≮ߩ࿎㔍ߥ∝଀߽޽ࠆὐߣᖚ⠪᭽߳ߩଚⷅ߇ዋߥ߆ࠄߕ޽ࠆὐ߇໧㗴‫ߡߞࠃߦ଀∝ޕ‬ߪߤ߁ߒߡ߽ᤨ㑆ࠍⷐߔࠆ߽ߩ߽޽ࠆ߇㧘ࠃࠅ቟ోߦ㧘ߘߒߡᖚ⠪᭽ߦ⧰∩ࠍਈ߃ߥ޿ࠃ߁ߥᛛⴚߩ⠌ᓧߦദ߼ߚ޿‫ޕ‬੹ᓟߩዷᦸࠃࠅ቟ో߆ߟᦨవ┵ߥᛛⴚࠍዉ౉ߔࠆߴߊദജߒߚ޿‫ޕ‬㧙㧙㧔29㧕㜞ᰴᢇ๮ᴦ≮࠮ࡦ࠲࡯1㧚⸻≮ߩ᭎ⷐ
ߎࠇ߹ߢߣห᭽‫ޕ‬ጘ㒂ᄢቇකቇㇱ㒝ዻ∛㒮ߩᕆᕈᦼ㊀∝ᖚ⠪ߩᴦ≮ߦᒰߚࠆਛᄩㇱ㐷ߢ޽ࠆ‫ޕ‬∛㒮ౝᄖߢ⊒↢ߔࠆ㊀∝ᖚ⠪㧘ઁߩක≮ᯏ㑐࡮ᢇᕆᢇ๮࠮ࡦ࠲࡯ߢኻಣߢ߈ߥ޿㜞ᐲߥᴦ≮ࠍᔅⷐߣߔ
ࠆᖚ⠪ߦኻߒߡ㧘24 ᤨ㑆૕೙ߢ✚ว⊛㧘㓸ቇ⊛ߥ㜞ᐲߥ⸻ᢿ࡮ᴦ≮ࠍⴕ߁‫ޕ‬
2㧚ᢎ⢒ᣉ⸳
1㧕 ᣣᧄᢇᕆකቇળᜰዉක⹺ቯᣉ⸳,2㧕 ᣣᧄ㓸ਛᴦ≮කቇળኾ㐷ක⹺ቯᣉ⸳
3㧕 ᣣᧄ⥶ⓨක≮ቇળ⹺ቯᣉ⸳
3㧚⸻≮㐿⊒
1㧕 ⸻≮ฬ 㧦࠼ࠢ࠲࡯ࡋ࡝੐ᬺ
⸻≮ౝኈ㧦㊀∝ᖚ⠪ߦኻߔࠆ⃻႐ᢇᕆ⸻≮ߣ៝ㅍઁ∛㒮ߢߩዉ౉⁁ᴫ㧦ᐔᚑ 21 ᐕ 1 ᦬⃻࿷ 14 ㇺ㆏ᐭ⋵ 15 ᯏ㧔ᧄᐕᐲߪ㕍᫪㧘⟲㚍㧘ᴒ✽ߩ 3 ⋵߇ዉ౉ߩ੐ᬺ⾌ࠍ੍▚ൻߒߡ޿ࠆ㧕࿖ౝ⊛⹏ଔ㧦௼࿾ක≮໧㗴㧘කᏧਇ⿷ߩ໧㗴ߥߤߦ߅޿ߡ߽㧘‫ᦨޟ‬ᓟߩಾࠅᧅ‫ߡߒߣޠ‬㧘ࡑࠬࠦࡒߥߤ
ߢᐞᐲߣߥߊ㧘ขࠅ਄ߍࠄࠇߡ޿ࠆ‫ޕ‬࿖㓙⊛⹏ଔ㧦☨࿖㧘⧷࿖㧘࠼ࠗ࠷㧘ࠝ࡜ࡦ࠳㧘ࠬࠗࠬ㧘ർ᰷ߥߤਥⷐవㅴ࿖ߦ߅޿ߡߪ㧘ㅢᏱߩක≮૕೙ߦ⚵ߺㄟ߹ࠇߡ޿ࠆ‫ޕ‬
4㧚ኾ㐷ක࡮⹺ቯක࡮ᜰዉක
ዊୖ⌀ᴦ㧦ᣣᧄ㤗㈮⑼ቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄᢇᕆකቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄ㓸ਛᴦ≮කቇળኾ㐷ක⼾↰ ᴰ㧦ᣣᧄᢇᕆකቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄ⣖␹⚻ᄖ⑼ቇળኾ㐷ක㧘㜞᳇࿶㉄⚛ᴦ≮▤ℂක㧘ᣣᧄ⥶ⓨක≮ቇળ⹺ቯᜰዉක㧔ࡈ࡜ࠗ࠻࠼ࠢ࠲࡯㧕ዊႮା੺㧦ᣣᧄᔃⴊ▤ࠗࡦ࠲࡯ࡌࡦ࡚ࠪࡦቇળᜰዉක㧘ᣣᧄᢇᕆකቇળኾ㐷ක⊕੗㇌ඳ㧦ᣣᧄᢇᕆකቇળኾ㐷ක࡮ᜰዉක
㊄↰⧷Ꮘ㧦ᣣᧄᄖ⑼ቇળ⹺ቯක㧘ᣣᧄ⢷ㇱᄖ⑼ቇળ⹺ቯක㧘ᣣᧄ㤗㈮⑼ቇળ⹺ቯකᣣᧄᢇᕆකቇળኾ㐷ක㧘ᣣᧄකᏧળ⹺ቯ↥ᬺක㧘ᣣᧄකᏧળ⹺ቯࠬࡐ࡯࠷ක
ศ↰⋭ㅧ㧦ᣣᧄᢇᕆකቇળኾ㐷කศ↰㓉ᶈ㧦ᣣᧄᄖ⑼ቇળኾ㐷ක㧘ᣣᧄᢇᕆකቇળኾ㐷කᾢ↰ᕺ੺㧦ᣣᧄᢇᕆකቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄ㓸ਛᴦ≮කቇળኾ㐷කჇ↰೰ብ㧦ᣣᧄᢛᒻᄖ⑼ቇળኾ㐷ක㧘ᣣᧄᢛᒻᄖ⑼ቇળ⣄ᬁ⣄㜑∛ක㥲⮮ผᦶ㧦ᣣᧄᄖ⑼ቇળኾ㐷ක㐳ደ⡡৻㇢㧦ᣣᧄ㤗㈮⑼ቇળ⹺ቯ㧘ᣣᧄዊఽ⑼ቇળኾ㐷ක㧘ᣣᧄᢇᕆකቇળኾ㐷ක࿯੗ᥓ┨㧦ᣣᧄᢇᕆකቇળኾ㐷ක㧘ᣣᧄᄖ⑼ቇળኾ㐷ක㧘ᣣᧄㅘᨆකቇળኾ㐷කട⮮ਭ᥏㧦ᣣᧄᢇᕆකቇળኾ㐷ක⧯ේ๺ᒾ㧦ᣣᧄᢛᒻᄖ⑼ቇળኾ㐷ක㧘ᣣᧄකᏧળ⹺ቯ↥ᬺකฬ⍮ ␽㧦ᣣᧄᄖ⑼ቇળኾ㐷කኾ㐷ක⍹㤥శ♿㧦ᣣᧄ⣖␹⚻ᄖ⑼ቇળኾ㐷ක
5㧚⥄Ꮖ⹏ଔ
⹏ଔ㜞ᐲᢇ๮ᢇᕆ࠮ࡦ࠲࡯ߣߒߡฬታߣ߽ߦਛㇱ࿾ᣇᢇᕆක≮ߩᦨᓟߩ⎏ߣߒߡ⹏ଔࠍฃߌߡ߅ࠅ㧘ጘ㒂⋵ߩߺߥࠄߕઁ⋵߆ࠄߩ⎇ୃ࡮ᖚ⠪៝ㅍࠍฃߌߡ޿ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ኻᄖ⊛ߥ⹏ଔߦᲧߒߡ㧘ቇ↢ࠍ฽߼ߚቇౝߢߩ⹺⍮߇ᧂߛਇ⿷ߒߡ߅ࠅ㧘੹ᓟቇౝߦ⹺⍮ࠍ㜞߼ࠆദജ߇ᔅⷐ‫ޕ‬
੹ᓟߩዷᦸጘ㒂⋵ߩ࠼ࠢ࠲࡯ࡋ࡝੐ᬺ߇㐿ᆎߒߚ᛬ߦߪਛᔃߣߥߞߡߘߩ੐ᬺࠍᡰ߃㧘ߐࠄߦࠃࠅࠃ޿ᢇᕆක≮૕೙ࠍᡰ߃ࠆ‫ޕ‬㧙㧙㧔30㧕ක≮ㅪ៤࠮ࡦ࠲࡯
1㧚⸻≮ߩ᭎ⷐ᭎ ⷐක≮ㅪ៤࠮ࡦ࠲࡯ߪએਅߩ⋡⊛ߢሽ࿷ߔࠆ‫ޕ‬
1. 㜞ᐲߥᄢቇ∛㒮ߩవㅴක≮ࠍ࿾ၞߩᖚ⠪߇቟ᔃߒߡ೑↪ߢ߈ࠆߚ߼ߩක≮ⅣႺߩ᭴▽
2. ᄢቇ∛㒮ක≮ߩᯏ⢻ಽᜂ᣿⏕ൻߣ∛⸻࡮∛∛ㅪ៤ߦࠃࠆല₸⊛ߥක≮߇ឭଏߢ߈ࠆ૕೙ߩలታ
3. ࠢ࡝࠾ࠞ࡞ࡄࠬផㅴߦࠃࠆ౉㒮ᦼ㑆ߩ⍴❗ߣല₸⊛ߥㅌ㒮ࠤࠕߩߢ߈ࠆ૕೙ߩᢛ஻
4. ᖚ⠪ߩᔃߩࠤࠕߦ߆߆ࠊࠆ⋧⺣૕೙ߩᢛ஻
5. ଻ஜ࡮ක≮࡮⑔␩ࠍ৻૕ൻߒߚ࿾ၞቢ⚿ဳ૕೙ߩలታ
6. ㇺ㆏ᐭ⋵߇ࠎ⸻≮ㅪ៤᜚ὐ∛㒮ߩਛᔃᬺോࠍᜂ߁⣲≌࠮ࡦ࠲࡯㧘ߘߩ⸻≮ㇱ㐷ߣㅪ៤ߒߡ޿ࠆ㜞ᰴ↹௝⸻ᢿ࠮ࡦ࠲࡯㧘㔍∛ක≮ㅪ៤᜚ὐ∛㒮ߩ㔍∛ක≮ㅪ⛊ද⼏ળߣ࿾ၞක≮ࡀ࠶࠻ࡢ࡯ࠢߩ࡝ࡦࠢ
7. ⢄∔ᖚ⸻≮ㅪ៤᜚ὐ∛㒮㧘ࠛࠗ࠭ᴦ≮ਛᩭ᜚ὐ∛㒮ߩ∛㒮⓹ญߣߒߡߩᡰេᬺോㆇ↪ౝኈ
1. ᭴ᚑ⡯ຬ㧦࠮ࡦ࠲࡯㐳㧘೽࠮ࡦ࠲࡯㐳㧘࠮ࡦ࠲࡯ኾછ⋴⼔Ꮷ㧘࠰࡯ࠪࡖ࡞ࡢ࡯ࠞ࡯㧘࠮ࡦ࠲࡯ኾછ੐ോ⡯ຬ
2. Ⓙേᣣ࡮ᤨ㑆㧦᦬㨪㊄ᦐᣣ 8 ᤨ 30 ಽ߆ࠄ 17 ᤨ㧔␸⑂ᣣߪⒿേ஗ᱛ㧕㧖 ࿾ၞක≮ㅪ៤ߩⒿ௛ᤨ㑆ߪઁ⸻≮ᯏ㑐ߩᄕᣇ⸻≮ߦวࠊߖߡ 17 ᤨ߹ߢㆇ༡‫ޕ‬
3. ᬺോౝኈ
1㧕∛⸻࡮∛∛ㅪ៤ߩߚ߼ߩᖚ⠪⚫੺࡮ㅒ⚫੺ࠪࠬ࠹ࡓԘ ᖚ⠪⚫੺ߩ౞Ṗൻઁ⸻≮ᯏ㑐߆ࠄߩᬌᩏ࡮౉㒮ߩߚ߼ߩᖚ⠪⚫੺ࠍ FAX㧔⚫੺ㅪ⛊࡮੍⚂↳ㄟ␿㧕ߢⴕ޿㧘ᬌᩏ࡮౉㒮ߩᣣᤨࠍහᐳߦ᳿ቯߒߚᓟ㧘ઁ⸻≮ᯏ㑐ߦ᳿ቯᣣᤨࠍ FAX ߢ㄰ାߒߡ㧘ᓙߜᤨ㑆⍴❗ߥߤߦࠃࠆ
ଢ೑ࠍ࿑ࠆ‫੺⚫ޕ‬ೋ⸻ᖚ⠪ߦኻߒߡ㧘ID ⇟ภࠍขᓧ࡮⸻ኤ೛ߩ⊒ⴕࠍⴕ޿㧘ೋ᧪㒮ߩ㓙ߪක≮ㅪ៤࠮ࡦ࠲࡯ߦߡ⸻ኤ೛ࠍᚻᷰߒߒ㧘ᬌᩏ࡮౉㒮ߩὑߩฃઃ߹ߢ᩺ౝߔࠆ‫ߦࠄߐޕ‬㧘⚫੺వߩකᏧߩ
㗻߇ࠊ߆ࠆߎߣࠍਥ⌒ߦ⟎޿ߚ∛㒮⚫੺ࡄࡦࡈ࡟࠶࠻ࠍ૞ᚑߒ㧘⚫੺ߩ౞Ṗൻࠍଦㅴߐߖࠆ‫ޕ‬ԙ ㅒ⚫੺ߩ౞Ṗൻ࡮ㅌ㒮ࡊ࡜ࡦ࠾ࡦࠣߩᡰេ
ㅒ⚫੺ࠍ౞Ṗൻ࡮ଦㅴߐߖࠆߚ߼㧘౉㒮࡮ᄖ᧪ᖚ⠪ߩㅒ⚫੺ක≮ᯏ㑐ࠍត⚝࡮⚫੺ߒ㧘ߘߩㅪ⛊࡮ᚻ⛯߈ࠍઍⴕߒߡⴕ߁‫ߚ߹ޕ‬㧘ㅒ⚫੺ߩߚ߼ߩක≮ᖱႎឭଏᦠߩㅍઃࠍⴕ߁‫ޕ‬ㅌ㒮ߦะߌߡߩ⺞ᢛ߇ᔅⷐߥ౉㒮ᖚ⠪߇޿ࠆ႐ว㧘࠮ࡦ࠲࡯㐳㧘೽࠮ࡦ࠲࡯㐳㧘ਥᴦක㧘⹥ᒰ⑼∛᫟ක㐳㧘⹥ᒰ⑼∛᫟⋴⼔Ꮷ㐳㧘ᜂᒰ⋴⼔Ꮷ㧘࠮ࡦ࠲࡯ኾછ⋴⼔Ꮷ㧘࠰࡯ࠪࡖ࡞ࡢ࡯ࠞ࡯㧘DPC ኾ㐷ຬߥߤߦࠃࠆㅌ㒮ᡰេࠞࡦࡈࠔ࡟ࡦࠬࠍⴕ޿㧘ㅌ㒮ߦะߌߡ૗߇ᔅⷐ߆㧘ߤߩࠃ߁ߥᚻ⛯߈ࠍⴕ޿㧘੹ᓟߤߩࠃ߁ߥࠤࠕ߇ᔅⷐ߆ߦߟ޿ߡ⸛⼏ߔࠆ‫ޕ‬
2㧕✚วක≮⋧⺣࡮ᅚᕈኾ㐷⋧⺣㧦ᅚᕈක≮ࠬ࠲࠶ࡈߦࠃࠆஜᐽ⋧⺣࡮ᔃߩ⋧⺣㧦≮㙃ߦ㑐ߔࠆ␠ળ⊛࡮ᔃℂ⊛ߥ⋧⺣࡮⋴⼔⋧⺣㧦ᖚ⠪᭽ߣߏኅᣖߩ≮㙃ߦߟ޿ߡߩ⋧⺣㧘࿷ቛ⋴⼔࡮ㅌ㒮ߦ઻߁⋧⺣࡮ක≮⑔␩⋧⺣㧦ක≮⾌㧘↢ᵴ⾌ߥߤߩ⚻ᷣ⊛໧㗴߿␠ળ⑔␩೙ᐲߩ⋧⺣㧘≮㙃↢ᵴ㧘ォ㒮㧘ㅌ㒮ߦ઻߁⋧⺣࡮߇ࠎ⋧⺣㧦‫ߦޠࠎ߇ޟ‬㑐ࠊࠆක≮߿㧘߇ࠎᖚ⠪ߩ↢ᵴߦߟ޿ߡߩ⋧⺣࡮㔍∛⋧⺣㧦㔍∛ᖚ⠪߇቟ᔃߒߡ૑ߺᘠࠇߚ࿾ၞߢ≮㙃ߢ߈ࠆߚ߼ߩ⋧⺣࡮࠮ࠞࡦ࠼ࠝࡇ࠾ࠝࡦ㧦⸻ᢿᴺ߿ᴦ≮ᴺߦߟ޿ߡਥᴦකએᄖߩᗧ⷗ࠍ⡞ߊߎߣߦ㑐ߔࠆ⋧⺣࡮ⷐᦸ࡮⧰ᖱ╬2㧚ᢎ⢒ᣉ⸳
ߥߒ
3㧚⸻≮㐿⊒
ߥߒ4㧚ኾ㐷ක࡮⹺ቯක࡮ᜰዉක
ᱞ↰ ⚐㧦ᣣᧄౝ⑼ቇળ⹺ቯක㧘ᣣᧄ♧ዩ∛ቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄౝಽᴲቇળ․଀ᜰዉක㧘ᣣᧄੱ㘃ㆮવቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄ∛ᘒᩕ㙃ቇળ⹺ቯ NST ࠦ࡯࠺ࠖࡀ࡯࠲࡯㧘ᣣᧄ♧ዩ∛දળ≮

㧙㧙

㙃ᜰዉක
ၳᎹᐘ↵㧦ᣣᧄౝ⑼ቇળ⹺ቯක㧘ᣣᧄ♧ዩ∛ቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄ∛ᘒᩕ㙃ቇળ⹺ቯ NST ࠦ࡯࠺ࠖࡀ࡯࠲࡯㧘ᣣᧄ♧ዩ∛දળ≮㙃ᜰዉක
5㧚⥄Ꮖ⹏ଔ
⹏ଔㄭ㓞ߩ㐿ᬺታ࿾කኅߩవ↢ᣇ߇ታ㓙ߦ⚫੺ߔࠆ㓙ߩᾘࠊߒ޿ᚻ⛯߈ߦ FAX ࠪࠬ࠹ࡓߣ޿߁ᣂ⚫੺ࠪࠬ࠹ࡓࠍዉ౉ߒߚࠅ㧘ೋ࿁⚫੺ᤨߩ∛⸻ㅪ៤ႎ๔ᦠ㧘ක≮ᖱႎឭଏᦠߩᢛ஻㧘ක≮ㅪ៤࠮ࡦ࠲࡯ౝኾછ⋴⼔჻߿࠰࡯ࠪࡖ࡞ࡢ࡯ࠞ࡯ߦࠃࠆㅌ㒮⺞ᢛࠍ᛼ߒㅴ߼ߚ‫ ⚂ޕ‬4800 ઙߩ೨ᣇᡰេ㧘ᓟᣇᡰេߣߒߡㅌ㒮⺞ᢛ
ઙᢙߪ 492 ઙߢ޽ߞߚ‫ߩߘޕ‬ౝ⸶ߪ࿷ቛᡰេ 302 ઙ㧘ォ㒮ᡰេ 144 ઙ㧘ᣉ⸳ 12 ઙ㧘ਛᢿ 34 ઙߢ޽ߞߚ‫ޕ‬ㅌ㒮೨ߩ࿾ၞ㑐ଥ⠪ߣߩࠤࠕࠞࡦࡈࠔ࡟ࡦࠬߩ㐿௅ߪ 60 ઙߢ㧘ක≮ଐሽᐲߩ㜞޿ᖚ⠪߿⚳ᧃᦼߩᖚ⠪╬ߦኻߒ㧘⸰໧⋴⼔ࠬ࠹࡯࡚ࠪࡦ߿࿷ቛ≮㙃ᡰេ⸻≮ᚲ㧘࿾ၞ൮᜝ᡰេ࠮ࡦ࠲࡯ߥߤߣㅪ៤ߒ㧘⛮⛯ߒߚක≮ࠨ࡯ࡆࠬ߇ฃߌࠄࠇࠆࠃ߁ߦ⺞ᢛߒߚ‫⚿ߩߘޕ‬ᨐ∛㒮ߣߒߡᐔᚑ 19 ᐕᐲߩᐔဋ∛ᐥⒿ௛₸ߪ 84.6㧑㧘ᐔဋ࿷㒮ᣣᢙߪ 14.6 ᣣߢ޽ߞߚ‫ޕ‬ᧄ㒮ߪᐔᚑ 17 ᐕᐲ 9 ᦬ߦ‫ޟ‬㔍∛ක≮ㅪ៤᜚ὐ∛㒮‫ߦޠ‬ᜰቯߐࠇߚߚ߼ᒰ࠮ࡦ࠲࡯ኾዻߩ㔍∛ක≮ኾ㐷ຬ߇㔍∛ක≮ߦ㑐ߔࠆ໪⊒ߣㅪ៤ᡰេᬺോࠍⴕߞߡ޿ࠆ߇㧘ᐔᚑ 18 ᐕᐲ 8 ᦬‫ޟ‬ㇺ㆏ᐭ⋵߇ࠎ⸻≮ㅪ៤᜚ὐ∛㒮‫߽ߦޠ‬ᜰቯߐࠇߚ‫ᧄޕ‬೙ᐲߪ߇ࠎኻ╷ၮᧄᴺߩ⿰ᣦߦၮߠ޿ߡ߅ࠅ㧘߇ࠎ⊓㍳ߦࠃࠆ⺞ᩏ㧘߇ࠎ⸻≮ߩဋߡࠎൻߥߤߦട߃㧘ᖚ⠪᭽ࠨࠗ࠼ߦ┙ߞߚක≮ᡰេߦ㊀߈߇⟎߆ࠇߡ޿ࠆ‫ߩߎޕ‬᜚ὐᬺോߩਛᔃࠍ
ᜂ߁ߴߊᧄ㒮ߦᐔᚑ 19 ᐕ 1 ᦬ߦ‫ޟ‬⣲≌࠮ࡦ࠲࡯‫ߒ⿷⊒߇ޠ‬㧘⸻≮ㅪ៤ㇱ㐷㧘ᢎ⢒⎇ୃㇱ㐷㧘ᖱႎ▤ℂㇱ㐷ߩ 3 ㇱ㐷ࠍ߽ߞߡ㧘✭๺ක≮㧘߇ࠎ⸻≮ᖱႎឭଏ㧘߹ߚ߇ࠎ⋧⺣ᡰេߥߤᣂߚߥᬺോߦ޽ߚߞߡ޿ࠆ‫ޕ‬ߐࠄߦหᤨߦᧄ㒮ߦߪ߽߁߭ߣߟᣂߚߦ‫ޟ‬㜞ᰴ↹௝⸻ᢿ࠮ࡦ࠲࡯‫ߪߢ࡯࠲ࡦ࠮ᧄޕߚࠇߐ┙⸳߇ޠ‬⒳‫ߩޘ‬߇ࠎ⸻ᢿ߇ᬺോߩਥߚࠆㇱಽࠍභ߼ࠆߎߣࠃࠅ⣲≌࠮ࡦ࠲࡯ߩ⸻≮ㅪ៤ㇱ㐷ߣㅪ៤ߒߡ޿ࠆ‫ ࠄࠇߎޕ‬2 ߟߩ࠮ࡦ࠲࡯⸳┙ߦࠃࠅ㧘৻⥸߆ࠄߩ߇ࠎ⋧⺣߿㧘࿾ၞක≮߆ࠄߩ߇ࠎ↹௝ᬌᩏ࡮⸻ᢿ࠾࡯࠭߳ߩ∛㒮⓹ญߣߒߡߩᡰេᬺോ߽⊒↢ߒߚ‫ޕ‬એ਄ࠃࠅ࿾ၞක≮ᯏ㑐ߣߩᄙ᭽ߥㅪ៤⁁ᴫ߇ᔅὼ⊛ߦ⊒↢ߒ㧘ᄢቇ∛㒮ߣ࿾ၞක≮ࡀ࠶࠻ࡢ࡯ࠢࠍ࡝ࡦࠢߐߖࠆᄢቇ஥⓹ญߩ⛔วߣ▤ℂࠪࠬ࠹ࡓ߇ᔅⷐߣߥࠅ㧘ᐔᚑ 19 ᐕ 1 ᦬ߦ‫ޟ‬ක≮⑔␩ᡰេ࠮ࡦ࠲࡯‫ޟࠄ߆ޠ‬ක≮ㅪ៤࠮ࡦ࠲࡯‫ߣޠ‬ᡷ⚵ߐࠇ㧘කᏧ 2 ฬ㧘⋴⼔ᇚ 4 ฬ㧘ක≮࠰࡯ࠪࡖ࡞ࡢ࡯ࠞ࡯1 ฬ㧘੐ോ♽⡯ຬ 3 ฬ߇ද௛ߒߡ᭽‫ߩޘ‬㒮ౝᄖߩㅪ៤ᬺോࠍⴕߞߡ޿ࠆ‫ޕ‬‫ޟ‬ක≮ㅪ៤࠮ࡦ࠲࡯‫ߪޠ‬ᓥ᧪ߩක≮⑔␩ᡰេߩᬺോߦട߃ߡ㒮ౝߩ⸻≮⑼ߩᯏ⢻ᖱႎࠍ⛔วߒឭଏߒߡ㧘࿾ၞක≮ߩలታߩߚ߼ߦ∛⸻࡮∛∛ㅪ៤ߩᒝൻࠍᜂᒰߒߡ޿ࠆ‫ߩߘޕ‬ᣂߚߥ⹜ߺߣߒߡ㧘࠙ࠖ࡞ࠬᕈ⢄Ἳ㧘ᔃ╭᪪Ⴇ㧘⣖තਛߩ‫ޟ‬ጘ㒂࿾ၞකᏧળㅪ៤ࡄࠬ‫ࠍޠ‬කᏧળߣ౒ߦ૞ᚑߒታᣉߒߡ޿ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ㄭᐕ㧘ක≮ߪකᏧ୘ੱ߇ⴕ߁නߥࠆක≮ⴕὑߣ޿߁߽ߩߢߪߥߊ㧘ක≮ᓥ੐⠪ߩ㓸࿅߇ᒻᚑߔࠆක≮ᯏ㑐߇ឭଏߔࠆ㧘޿ࠊ߫‫ࠆࠃߦࡓ࠹ࠬࠪޟ‬ක≮ⴕὑ㧘ࠨ࡯ࡆࠬ‫ߣޠ‬ᄌ㕟ࠍㆀߍߡ߈ߡ޿ࠆ‫ޕ‬ᓥߞߡ㧘ᧄ㒮ߦ߅޿ߡ߽ᖚ⠪ߐࠎߦߣߞߡฃ⸻ߒ߿ߔߊ㧘߹ߚ㧘⋵ౝᄖߩක≮ᯏ㑐ߦߣߞߡ⚫੺ߒ߿ߔ޿ᄖ᧪ࠍ߼ߑߒ㧘ᐢႎᵴേ㧘⋧⺣ᬺോߩలታ㧘ᖚ⠪⚫੺ࠪࠬ࠹ࡓߩ᭴▽ߥߤࠍⴕ߁ߩ߇వ᳿ߣ⠨߃ࠆ‫ޕ‬એਅߦ⃻⁁ߩ໧㗴ὐߣߘߩኻᔕ╷ࠍ⸥ߔ‫ޕ‬1㧕ක≮ㅪ៤࠮ࡦ࠲࡯߆ࠄߩᐢႎ᜛ᄢ
߹ߕ╙৻ߦ㧘ᐢႎᵴേߣߒߡᄢቇ∛㒮ߩᯏ⢻ߦߟ޿ߡߩᖱႎ⚫੺㧘∛㒮ൕോක⚫੺㧘ฦኾ㐷ಽ㊁ߏߣߩ⎇ⓥળ੍ቯ㧘ᄢቇߢⴕߞߡ޿ࠆฦ⑼ߩ⥃ᐥ⎇ⓥ࡮ࠦࡎ࡯࠻⎇ⓥߩ⚫੺㧘⮎ຠᖱႎ㧔ක⮎ຠ⼂೎ࠪࠬ࠹ࡓࠍ
฽߻㧕ߩᬌ⚝ߥߤࠍ⋓ࠅㄟࠎߛක≮ㅪ៤࠮ࡦ࠲࡯ߩࡎ࡯ࡓࡍ࡯ࠫߩలታࠍ⋡ᜰߔ‫ޕ‬వߕߪ੹ᦼ⃻⁁ᣂᯏ⢻ߦහߒߚࡎ࡯ࡓࡍ࡯ࠫߦᡷༀߒߚ‫ߦࠄߐޕ‬㧘ጘ㒂⋵කᏧળ㧘ጘ㒂ᏒකᏧળᐢႎ⹹߳ߩឝタࠍ↪޿ߚᧄ㒮ߩࠕࡇ࡯࡞ࠍᡰេߔࠆ‫ߚ߹ޕ‬㧘ᄢቇൕോකᏧ㧘ࠦࡔ࠺ࠖࠞ࡞ኻ⽎ߩ⻠Ṷળ㧘࠰࡯ࠪࡖ࡞ࡢ࡯ࠞ࡯ߦࠃࠆක≮⑔␩࡮␠ળ⑔␩೙ᐲߦ㑐ߔࠆ⻠Ṷ㧘ᖚ⠪ߩ≮㙃ߦ઻߁␠ળ⊛࡮ᔃℂ⊛ߥᄌ⺞ߦ㑐ߔࠆ⻠Ṷ߿≸๔⍮ߦ઻߁♖␹⊛ᡰេߦ㑐ߔࠆ⻠Ṷߥߤᄙᣇ㕙ߦᷰߞߡડ↹࡮ᡰេߔࠆ‫ޕ‬
2㧕࿾ၞක≮ㅪ៤ࡀ࠶࠻ࡢ࡯ࠢࠪࠬ࠹ࡓߩ⏕┙࿾రකᏧળ㧔ጘ㒂⋵㧘ጘ㒂Ꮢ㧕㧘ᢇᕆ㓌ߣߩㅪ៤ᒝൻࠍߪ߆ࠆߣߣ߽ߦ㧘ቯᦼ⊛ߦ⋵ਅߩක㒮࡮⸻≮ᚲߦኻߒ㧘⚫੺㗿߿ᄢቇ∛㒮ൕോකකᏧ⚫੺ࡄࡦࡈ࡟࠶࠻㧘ᄖ᧪ᜂᒰකᏧ৻ⷩ㧘ᄢቇ∛㒮ᐢႎߩ૞ᚑࠍⴕ޿㧘⚫੺࡮ㅒ⚫੺ߩߐࠄߥࠆଦㅴߦദ߼ࠆ‫ߦࠄߐޕ‬㧘ጘ㒂ᏒකᏧળߦ߅ߌࠆ Internet Web ߿⋵කᏧળߦࠃࠆ
Fax ⚫੺ࠪࠬ࠹ࡓ߳ߩෳടࠍㅢߒߡ㧘߆߆ࠅߟߌකផㅴㆇേߣකᏧ࡮ᖚ⠪߳ߩ໪⫥ㆇേߩ৻ᣤࠍᜂ߁‫ޕ‬ㅒ⚫੺ߩផㅴߦ㑐ߒߡߪ㧘ฦකᏧળߦක≮ᯏ㑐ᖱႎࠍឭଏߒߡ߽ࠄ޿⚫੺ߒ߿ߔ޿⁁ᴫࠍ૞ࠆߎߣ߿㧘ᬌᩏ୯ߩၮḰ୯⛔৻ൻߩផㅴߦදജ૕೙ࠍߣࠆ‫ޕ‬
3㧕ᖚ⠪ળߣߩㅪ៤ߩᒝൻ㧙㧙⃻࿷޽ࠆ㔍∛ߥߤ㓚ኂ⠪ߩળߩㆇ༡߿౉ળ൐㓸㧘࠮ࡒ࠽࡯⊒⴫ળߥߤߦදജߒ㧘ߐࠄߦ♧ዩ∛දળߩ෹ߩળߥߤ㧘↢ᵴ⠌ᘠ∛ߩᖚ⠪ળߩᢎ⢒⻠⠌ળࠍᓟេߔࠆ‫ޕ‬੹ᓟߩዷᦸ਄⸥ߩࠃ߁ߦ㧘‫ޟ‬ක≮⑔␩ᡰេ࠮ࡦ࠲࡯‫ߪޠ‬ක≮⑔␩⋧⺣ߥߤߩක≮ࠨ࡯ࡆࠬࠍⴕ߁✚วක≮⋧⺣ቶߩ஥㕙ߣ㧘࿾ၞක≮ᯏ㑐ߣኒធߥㅪ៤ࠍ࿑ࠅḩ⿷ߢ߈ࠆㆡᱜߢ⾰ߩ㜞޿౞Ṗߥක≮ࠍឭଏ಴᧪ࠆࠃ߁ߦᡰេ
ߔࠆߎߣࠍ⋡⊛ߣߒߚ࿾ၞක≮ㅪ៤ቶߩ஥㕙ࠍ౗ߨ஻߃㧘੹ᦼ‫ޟ‬ක≮ㅪ៤࠮ࡦ࠲࡯‫ߣޠ‬ᡷ⚵ߒߚ‫ߦࠇߎޕ‬ࠃࠅ㧘࿾ၞߩၮᐙ∛㒮ߣߒߡߩᄢቇ∛㒮ߩ૏⟎ߠߌࠍ᣿⏕ൻߒ㧘ߐࠄߦᚒ߇࿖ߩක≮૕೙ߩ໧㗴ὐࠍ⸃ᶖߔࠆ৻ഥߣߥࠅᓧࠆࠃ߁ߥᖚ⠪ᧄ૏ߩක≮ߩታ〣ࠍㅢߒߡ㧘‫ޟ‬ὐߩක≮߆ࠄ㕙ߩක≮߳ߩォ឵‫߁޿ߣޠ‬ක
≮ⅣႺߦㆡಾߦኻᔕߒߚᄢቇ∛㒮ࠍ⋡ᜰߒߚ޿‫৻ߩߘޕ‬Ⅳߣߒߡ∛⸻࡮∛∛ㅪ៤ߩᒝൻߣᣂᯏ⢻ߩㆀⴕߩߚ߼ߦ㧘࠙ࠖ࡞ࠬᕈ⢄Ἳ㧘ᔃ╭᪪Ⴇ㧘⣖තਛߩ‫ޟ‬ጘ㒂࿾ၞකᏧળㅪ៤ࡄࠬ‫ࠍޠ‬කᏧળߣ౒ߦ૞ᚑߒታᣉߒ
ߡ޿ࠆ߇㧘ߐࠄߦ⃻࿷↢ᵴ⠌ᘠ∛㑐ㅪߩ࿾ၞㅪ៤ࡄࠬߣߒߡ♧ዩ∛ࡄࠬߩ૞ᚑߣㆇ༡ߩḰ஻߽ㅴ߼ߡ޿ࠆ‫ޕ‬㧙㧙㧔31㧕↢૕ᡰេ࠮ࡦ࠲࡯
1㧚⸻≮ߩ᭎ⷐ
㧔ᗵᨴ೙ᓮㇱ㐷㧕㧙ICT㧦Infection Control TeamᣣᏱᬺോ࡮∛㒮ౝࠕ࠙࠻ࡉ࡟ࠗࠢ㧔ᗵᨴ∝ᄙ⊒㧕ߩᣧᦼ⊒⷗ߣኻ╷࡮ᬌᩏㇱ߆ࠄߩᬌᩏᖱႎߩᛠី㧔࡝ࠕ࡞࠲ࠗࡓ㧕࡮ᗵᨴ∝ႎ๔ᦠߦࠃࠆ⥃ᐥᖱႎߩᛠី
࡮∛㒮ౝ࡜࠙ࡦ࠼ߦࠃࠆᗵᨴኻ╷ߩᔀᐩ࡮ᗵᨴ∝ࠢ࡝࠾࠶ࠢ㧔ⴊᶧ࡮ᗵᨴ∝ౝ⑼ߦߡ㧕࡮ᗵᨴ∝ࠦࡦࠨ࡞࠹࡯࡚ࠪࡦ㧔∛㒮ᗵᨴኻ╷߅ࠃ߮ᗵᨴ∝ᴺ╬㧕
࡮㊎ೝߒ࡮☼⤑᥸㔺੐᡿╬ኻ╷㧔24 ᤨ㑆૕೙㧘⓹ญߪᶖൻེ㧛ⴊᶧ࡮ᗵᨴ∝ౝ⑼㧕
᦬଀ᬺോ࡮ᗵᨴ೙ᓮㇱ㐷ળ⼏࡮ᗵᨴኻ╷࠾ࡘ࡯ࠬߩ⊒ⴕ࡮ෘ↢ഭ௛⋭㒮ౝᗵᨴኻ╷ࠨ࡯ࡌࠗ࡜ࡦࠬ㧔JANIS㧕࠺࡯࠲૞ᚑ෸߮ႎ๔
࡮᛫⩶⮎૶↪㊂࠴ࠚ࠶ࠢ෸߮․ቯߩ⮎೷૶↪ᖚ⠪ߩ⥃ᐥᖱႎ࠴ࠚ࠶ࠢ
᛫⩶⮎ㆡᱜ૶↪ࠍ⋡ᮡߦ㧔⮎೷ㇱ㧘ක≮ᖱႎㇱߣߩㅪ៤㧕ߘߩઁߩㅢᏱᬺോ
࡮ࠨ࡯ࡌࠗ࡜ࡦࠬ㧔㔚▚ൻ㧦ᗵᨴ∝▤ℂࠪࠬ࠹ࡓ㧕࡮ᗵᨴኻ╷ࠟࠗ࠼࡜ࠗࡦߩᡷ⸓෸߮ㆩ቞ߩᔀᐩ
࡮ࡎ࡯ࡓࡍ࡯ࠫߩలታ
࡮⡯ോᗵᨴኻ╷㒐ᱛ╷ߩలታ㧔✚ോ⺖ੱ੐ଥߣߩ✕ኒߥㅪ៤㧕
ฦ⒳੍㒐ធ⒳㧔ࠗࡦࡈ࡞ࠛࡦࠩ㧘HB ࡢࠢ࠴ࡦߥߤ㧕ߩታᣉ෸߮⚿ᩭߥߤߩⓨ᳇ᗵᨴ੍㒐㧘㘧ᴜᗵᨴ੍㒐ߩᔀᐩ࡮ᢎ⢒࡮໪⫥ᵴേ࡮࿖┙ᄢቇකቇㇱ㒝ዻ∛㒮ᗵᨴኻ╷ද⼏ળ㧔ᢥㇱ⑼ቇ⋭㧕߳ߩෳട࡮ጘ㒂㒮ౝᗵᨴኻ╷ᬌ⸛ળߩਥ௅㧔ᐕ 2 ࿁㧘㑐ㅪ∛㒮ෳട㧕࡮ᗵᨴ∝ߩ੍㒐෸߮ᗵᨴ∝ߩᖚ⠪ߦኻߔࠆක≮ߦ㑐ߔࠆᴺᓞ㧔ᗵᨴ∝ᴺ㧕ߥߤ߳ߩኻᔕ
࡮᛫⩶⮎૶↪ၮḰߩ⸳ቯ㧔ࠟࠗ࠼࡜ࠗࡦ㧕
࡮ฦ⒳ࠢ࡝࠾ࠞ࡞࡮ࡄࠬ૞ᚑ߳ߩෳട
ᗵᨴ೙ᓮ૕೙
࡮Ⓙ௛ᣣ෸߮Ⓙേᤨ㑆ේೣߣߒߡ㧘ᐔᣣᣣൕᏪ㧔8㧦30㨪17㧦15㧕࡮ᤨ㑆ᄖ෸߮ભᣣ
ᄛൕᏧ㐳╬ࠍ੺ߒߡ࠮ࡦ࠲࡯ຬߣㅪ⛊ࠍขࠅว޿㧘24 ᤨ㑆૕೙ߢኻᔕ㧔฽㧦ᢇᕆᗵᨴ∝ᖚ⠪㧕࡮㊎ೝߒ࡮☼⤑᥸㔺੐᡿ߦߟ޿ߡߪ㧘ᶖൻེ㧛ⴊᶧ࡮ᗵᨴ∝ౝ⑼ᄖ᧪෸߮ᒰ⋥ක߇ 24 ᤨ㑆૕೙ߢኻᔕ
㧔੍㒐ធ⒳ㇱ㐷㧕࡮ጘ㒂⋵੍㒐ធ⒳࠮ࡦ࠲࡯ߣߒߡ⸳⟎࡮੍㒐ធ⒳ߩታᣉ㧔Ꮢ↸᧛߆ࠄߩଐ㗬ߦၮߠߊ 3 ᰴធ⒳ᯏ㑐ߣߒߡ㧕࡮੍㒐ធ⒳ߦ㑐ࠊࠆ⋧⺣੐ᬺߩታᣉ㧔Ꮢ↸᧛߿࿾ၞක≮ᣉ⸳߆ࠄߩ⋧⺣ߦኻᔕ㧕࡮੍㒐ធ⒳ߩ⍮⼂߿ᖱႎߩឭଏ
࡮ᶏᄖᷰ⥶⠪ߥߤߩ੍㒐ធ⒳ߩታᣉ㧔࠻࡜ࡌ࡜࡯࠭ࡢࠢ࠴ࡦ㧘ቇౝ࡮ቇᄖ㧕㧔ᩕ㙃ࠨࡐ࡯࠻ㇱ㐷㧕㧙NST㧦Nutrition Support Team࡮ᩕ㙃ࠕ࠮ࠬࡔࡦ࠻㧔り૕⸘᷹㧘ⴊᶧᬌᩏ╬ߦࠃࠆᖚ⠪ߩᩕ㙃⁁ᘒߩᛠី࡮ⷰኤ㧕࡮ᦨㆡߥᩕ㙃៨ข⚻〝ߩᜰዉ࡮ឭ⸒㧔⚻ญ࡮⚻▤࡮⚻㕒⣂ᩕ㙃ߩㆬᛯߣಣᣇ㧕࡮ᩕ㙃៨ข㊂ߩ▚಴ߣㆡಾߥࡔ࠾ࡘ࡯ߩឭ᩺
࡮ᩕ㙃≮ᴺࠢ࡝࠾࠶ࠢ㧔ᩕ㙃≮ᴺߩലᨐ್ቯߣว૬∝ߩ࠴ࠚ࠶ࠢ㧕࡮ᖚ⠪࡮ኅᣖ߳ߩᩕ㙃ᜰዉ㧔࿷ቛߢߩ▤ℂᣇᴺࠍ฽߼ߡ㧕࡮ᩕ㙃≮ᴺࠟࠗ࠼࡜ࠗࡦߩ೙ቯ߅ࠃ߮ㆩ቞ߩᔀᐩ
࡮ࡎ࡯ࡓࡍ࡯ࠫߩ૞ᚑ෸߮లታ

㧙㧙࡮ฦ⒳ࠢ࡝࠾ࠞ࡞࡮ࡄࠬ૞ᚑ߳ߩෳട
࡮ᩕ㙃ࠨࡐ࡯࠻ㇱ㐷ળ⼏࡮⡯ຬᢎ⢒࡮⎇ୃ㧔ᩕ㙃ࡑࡀࠫࡔࡦ࠻ㇱ㐷㧕࡮ᩕ㙃▤ℂቶᬺോో⥸࡮ᖚ⠪⛎㘩ߦ㑐ࠊࠆ▤ℂᬺോ㧔₂┙㧘⺞ℂ㧘ឭଏᣇᴺࠍ฽߼ߚ㧕࡮∔ᖚ೎∛㒮㘩ߥߤࡔ࠾ࡘ࡯ߩᡷༀ
࡮▤ℂᩕ㙃჻࡮ᩕ㙃჻ߦࠃࠆᩕ㙃ᜰዉ㧔ᄖ᧪࡮౉㒮㧕࡮▤ℂᩕ㙃჻࡮ᩕ㙃჻ߦࠃࠆ౉㒮ᖚ⠪ᩕ㙃≮ᴺ੺౉㧦ᩕ㙃ࠤࠕ࡮ࡑࡀࠫࡔࡦ࠻㧔NCM㧕૕೙࡮ᩕ㙃ࡑࡀࠫࡔࡦ࠻ㇱ㐷ળ⼏㧔ⶖ≙ኻ╷ㇱ㐷㧕㧙PUT㧦Pressure Ulcer Team࡮ో౉㒮ᖚ⠪ߩኢߚ߈ࠅᐲߩ⹏ଔ㧔ⶖ≙⊒↢࡝ࠬࠢࠕ࠮ࠬࡔࡦ࠻㧕࡮࡝ࠬࠢᖚ⠪߳ߩⶖ≙੍㒐ኻ╷ߩᔀᐩ࡮ⶖ≙ᖚ⠪ߩ࿁⸻߅ࠃ߮ᴦ≮ᣇᴺߩᬌ⸛ਗ߮ߦ⹏ଔ
࡮ਥᴦක㧘ᜂᒰ⋴⼔Ꮷߣߩㅪ៤࡮⸻≮ᡰេ࡮ⶖ≙ኻ╷ࠟࠗ࠼࡜ࠗࡦߩ╷ቯ߅ࠃ߮ㆩ቞ߩᔀᐩ
࡮ⶖ≙ኻ╷ㇱ㐷ળળ⼏㧔๭ๆ≮ᴺᡰេㇱ㐷㧕㧙RST㧦Respiration Support Team࡮๭ๆ≮ᴺ㧔ੱᎿ๭ๆ࡮㉄⚛࡮⢖ℂቇ࡮⮎‛ߥߤ㧕ߦ㑐ߔࠆ⸻≮ᡰេ࡮ੱᎿ๭ๆེ㑐ㅪ੐᡿㒐ᱛ૕೙ߩ⏕┙࡮ੱᎿ๭ๆེ▤ℂᖚ⠪ߩ࿁⸻߅ࠃ߮ᯏེὐᬌ
࡮๭ๆ≮ᴺࠟࠗ࠼࡜ࠗࡦߩ╷ቯ
࡮๭ๆ≮ᴺᡰេㇱ㐷ળ⼏࡮⡯ຬᢎ⢒࡮⎇ୃ㧔ᢎ⢒࡮⎇ⓥㇱ㐷㧕࡮කቇㇱකቇ⑼߅ࠃ߮⋴⼔ቇ⑼ቇ↢߳ߩᩕ㙃▤ℂᢎ⢒ߥࠄ߮ߦᗵᨴ೙ᓮᢎ⢒࡮⥃ᐥታ⠌ߦ߅ߌࠆ∛㒮ᗵᨴኻ╷ߩᔀᐩ࡮⥃ᐥታ⠌ߦ߅ߌࠆ㊎ೝߒ╬ᗵᨴ᥸㔺੐᡿ߦኻߔࠆㄦㅦߥኻᔕ
࡮කᏧ෸߮⋴⼔Ꮷ࡮ᩕ㙃჻߳ߩᩕ㙃▤ℂ࡮ᗵᨴ೙ᓮᢎ⢒࡮࿾ၞක≮ᯏ㑐߳ߩ NST㧛ICT ታ〣ߩߚ߼ߩᜰዉ෸߮ᢎ⢒࡮ICD㧔Infection Control Doctor㧕෸߮ ICN㧔Infection Control Nurse㧕ߩ⢒ᚑ࡮ฦ∔ᖚߦ߅ߌࠆ∛ᘒ࡮∛ᦼߩᩕ㙃≮ᴺߩᮡḰൻ㧔ࠟࠗ࠼࡜ࠗࡦ㧕╷ቯߩߚ߼ߩ⎇ⓥ࡮⮎೷⠴ᕈ⩶ᗵᨴ∝ኻ╷ߦ㑐ߔࠆ⎇ⓥ
࡮᛫⩶⮎ㆡᱜ૶↪ࠟࠗ࠼࡜ࠗࡦ╷ቯߩߚ߼ߩ⎇ⓥ࡮∛㒮⚻༡ല₸ߦ߅ߌࠆNST㧛ICT㧛PUT㧛RST╬࠴࡯ࡓක≮ߦࠃࠆᮮᢿ⊛⸻≮ᡰេ૕೙ߩᓎഀߦ㑐ߔࠆ⎇ⓥ࡮ో⥄േ㔚ሶൻᗵᨴ∝ࠨ࡯ࡌࠗ࡜ࡦࠬࠪࠬ࠹ࡓߩ⎇ⓥ࡮㐿⊒
2㧚ᢎ⢒ᣉ⸳
1㧕 ᣣᧄᗵᨴ∝ቇળ⎇ୃᣉ⸳
2㧕 ᣣᧄ๭ๆེቇળ⹺ቯᣉ⸳
3㧕 ᣣᧄᩕ㙃≮ᴺផㅴද⼏ળ NST㧔ᩕ㙃ࠨࡐ࡯࠻࠴࡯ࡓ㧕Ⓙ௛ᣉ⸳
4㧕 ᣣᧄ㕒⣂⚻⣺ᩕ㙃ቇળ NST㧔ᩕ㙃ࠨࡐ࡯࠻࠴࡯ࡓ㧕Ⓙ௛ᣉ⸳
5㧕 ᣣᧄ㕒⣂⚻⣺ᩕ㙃ቇળᩕ㙃ࠨࡐ࡯࠻࠴࡯ࡓ㧔NST㧕ኾ㐷≮ᴺ჻ขᓧߦ㑐ࠊࠆታ࿾ୃ✵ᣉ⸳
3㧚⸻≮㐿⊒
1㧕 ⸻≮ฬ 㧦‫ޟ‬ᗵᨴ∝▤ℂࠪࠬ࠹ࡓ‫ޠ‬㧔㔚ሶൻᗵᨴ∝ࠨ࡯ࡌࠗ࡜ࡦࠬࠪࠬ࠹ࡓ㧕⸻≮ౝኈ㧦ᗵᨴ∝▤ℂߦᔅⷐߥᖱႎ㧔ᖚ⠪ ID㧘⚦⩶ᬌᩏ⚿ᨐ㧘Ἳ∝㧔WBC, CRP ╬㧕෻ᔕ㧘ࡌ࠶࠼ᖱႎ㧘ၮ␆∔ᖚ㧘ක≮ౕེᝌ౉ᖱႎߥߤ㧕ࠍᣢሽ∛㒮ࠪࠬ࠹ࡓ߆ࠄ HL-7 㔚ᢥᒻᑼߦࠃߞ㧙㧙ߡ㧘Ფᣣ৻ቯߩᤨ㑆ߦ⥄േ⊛ߦ෼㓸㨯⫾Ⓧߢ߈ࠆ‫ޕ‬ᓧࠄࠇߚ࠺࡯࠲ߪ⥄േ⊛ߦ⸃ᨆߐࠇ㧘એਅߩ 3 ߟߩᯏ⢻߇ታ⃻ߢ߈ࠆ‫ޕ‬Ԙ Web ࠪࠬ࠹ࡓࠍㅢߒߡฦ⸻≮┵ᧃߢࠛࡦ࠼࡙࡯ࠩ࡯㧔ਥᴦක߿ᜂᒰࠬ࠲࠶ࡈ㧕߇೑↪
ߢ߈ࠆ㧔ㆊ෰৻ቯᦼ㑆ߩછᗧߩ᧦ઙߢߩ⚦⩶ᬌ಴⁁ᴫ߅ࠃ߮᛫⩶⮎ᗵฃᕈ㧘∛᫟න૏ߢߩᖚ⠪౉ቶ⁁ᴫ߅ࠃ߮㧘⚦⩶ᬌᩏ⚿ᨐߩᤨ♽೉⴫␜㧘⚦⩶ฬ߿᛫⩶⮎ฬࠍࠢ࡝࠶ࠢߔࠆ
ߣ⥄േ⊛ߦᢥ₂⊛⍮⼂ᖱႎ⸃⺑߇ࡐ࠶ࡊࠕ࠶ࡊߢ⴫␜ߥߤ㧕‫ޕ‬ԙ ICT ߣߒߡ㧘ᧄࠪࠬ࠹ࡓߩࠨ࡯ࡃߦߡ⚦⩶ߩ⇣Ᏹ㓸Ⓧ߇᦭ᗧ߆ุ߆್ቯߢ߈㧘໧㗴㧘⇼޿ߩ႐วߪ㧘ᗵᨴᖱႎ࡟ࡐ࡯࠻㧔ᖚ⠪࡝ࠬ࠻㧕߿᛫⩶⮎ᗵฃᕈ࡝ࠬ࠻㧘⊒↢∛᫟ߩ 3 ᰴర⴫␜╬ߩ⒳‫⸘⛔ߩޘ‬ಣℂ߇ㅦ߿߆ߦߢ߈ࠆ‫ࠄ߆࡯ࠩ࡯࡙࠼ࡦࠛߚ߹ޕ‬છᗧߩ⛔⸘⸃ᨆⷐᦸߩಣℂ߽น⢻ߢ޽ࠅ㧘ߐࠄߦ᦬ႎ૞ᚑߥߤᚻ૞ᬺߢⴕߞߡ߈ߚᄙߊߩᬺോߩ⥄േൻ߇น⢻ߣߥߞߚ‫ޕ‬Ԛ ෘ↢ഭ௛⋭ߩ JANIS 㒮ౝᗵᨴኻ╷ࠨ࡯ࡌࠗ࡜ࡦࠬ੐ᬺߩ࠺࡯࠲ࠍᚻ౉ജߥߒߢᇦ૕ߦ
ឃ಴ߢ߈ࠆ㧔ࡈࠜ࡯ࡑ࠶࠻ࠍ߶߷ߘߩ߹߹ណ↪㧕‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦ᒰ㒮ߪ⟲㚍ᄢቇߣߣ߽ߦో࿖ߢᦨೋߦዉ౉ߒߚ‫⃻ޕ‬࿷㧘ઁߦ㠽ขᄢቇ߇Ⓙ௛ਛ‫ޕ‬
2009 ᐕᐲએ㒠ߪ㧘ᧄࠪࠬ࠹ࡓࠍ⊒ዷ⊛ߦᡷ⦟ߒߚ‫ޟ‬Medlas-SHIPL㧦Medlas-Standardized
Hospital Infection Primary Lookout‫ᦝߦޠ‬ᣂߔߴߊ⺞ᢛਛ‫ޕ‬࿖ౝ⊛⹏ଔ㧦2001 ᐕᐲ߆ࠄ㐿⊒ߐࠇߚ߇, ᧄᩰⒿേߪ 2005 ᐕᐲ߆ࠄߢ޽ߞߚ‫ᤨޕ‬㑆ߣഭജߩ߆߆ߞ
ߡ޿ߚో∛㒮⊛ᗵᨴ∝ࠨ࡯ࡌࠗ࡜ࡦࠬࠍ㔚ሶࠞ࡞࠹ࠪࠬ࠹ࡓߣද⺞ߒߡో㕙㔚ሶൻߒߚࠪ
ࠬ࠹ࡓߪઁߦ㘃߇ߥߊ, ᄢ߈ߥ⹏ଔࠍฃߌߚ‫ޕ‬㧔ᐔᚑ 18 ᐕ 11 ᦬ 17 ᣣ ╙ 89 ࿁ᣣᧄ⚦⩶ቇળ㑐᧲ᡰㇱ✚ળ Best Presentation ⾨ฃ⾨㧦‫ޟ‬࿖┙ᄢቇකቇㇱ㒝ዻ∛㒮౒ㅢ࠰ࡈ࠻“ᗵᨴ∝▤ℂࠪࠬ࠹ࡓ”ࠍ↪޿ߚ㔚ሶൻ∛㒮ᗵᨴࠨ࡯ࡌࠗ࡜ࡦࠬࠍ㐿ᆎߒߡ‫ޠ‬㧕࿖㓙⊛⹏ଔ㧦਎⇇⊛ߦ߽ߎߩࠃ߁ߥ⸻≮ᡰេ࡮ో⥄േᗵᨴ∝ࠨ࡯ࡌࠗ࡜ࡦࠬࠪࠬ࠹ࡓ㐿⊒ߪ଀߇ߥߊ㧘ᵈ⋡ߐࠇߡ޿ࠆ‫ޕ‬
4㧚ኾ㐷ක࡮⹺ቯක࡮ᜰዉක
᧛਄໪㓶㧦ᣣᧄౝ⑼ቇળ⹺ቯౝ⑼ක࡮⎇ୃකᜰዉක㧘ᣣᧄᗵᨴ∝ቇળᗵᨴ∝ኾ㐷ක࡮ᜰዉක㧘ICD ೙ᐲද⼏ળ⹺ቯ㧔ᣣᧄᗵᨴ∝ቇળផ⮈㧕ICD㧘ᣣᧄ๭ๆེቇળ๭ๆེኾ㐷ක࡮ᜰዉක㧘ᣣᧄᶖൻེ∛ቇળ⹺ቯᶖൻེ∛ኾ㐷ක࡮ᜰዉක㧘ᣣᧄ⢄⤳ቇળ⹺ቯ⢄⤳∛ኾ㐷ක㧘ᣣᧄᶖൻེౝⷞ㏜ቇળኾ㐷ක㧘ᣣᧄකᏧળ⹺ቯ↥ᬺක૒‫ᧁޘ‬ᤘᒾ㧦ᣣᧄౝ⑼ቇળ⹺ቯᜰዉක㧘ᣣᧄ♧ዩ∛ቇળ⹺ቯ♧ዩ∛ኾ㐷ක㧘ᣣᧄᶖൻེౝⷞ㏜ቇળ⹺ቯኾ
㐷ක═ේජ༹㧦ᣣᧄౝ⑼ቇળ⹺ቯౝ⑼ක㧘ᣣᧄⴊᶧቇળኾ㐷ක㧘ᣣᧄ⥃ᐥ⣲≌ቇળ≸⮎‛≮ᴺኾ㐷කᓼጊᵏᴦ㧦ᣣᧄᄖ⑼ቇળ⹺ቯᄖ⑼ኾ㐷ක㧘ᣣᧄᶖൻེᄖ⑼ቇળ⹺ቯᶖൻེᄖ⑼ኾ㐷ක㧘ᶖൻེ߇ࠎᄖ⑼ᴦ
≮⹺ቯක㧘ᣣᧄ≸ᴦ≮⹺ቯᯏ᭴߇ࠎᴦ≮⹺ቯක࡮ᥳቯᢎ⢒ක⊕ᧁ ੫㧦ᣣᧄౝ⑼ቇળ⹺ቯౝ⑼ක
5㧚⥄Ꮖ⹏ଔ
⹏ଔᒰ㒮ߩක≮㑐ㅪᗵᨴኻ╷ࠍᜂᒰߔࠆㇱ⟑ߣߒߡᐔᚑ 9 ᐕ 4 ᦬ߦഃ⸳ߐࠇߚᗵᨴኻ╷ቶࠍ೨りߣߒߡ㧘ᐔ
ᚑ 14 ᐕ 4 ᦬߆ࠄߪ㧘หቶࠍᩕ㙃▤ℂ߿ⶖ≙ኻ╷㧘࡝ࠬࠢࡑࡀࠫࡔࡦ࠻ߩᯏ⢻ࠍ޽ࠊߖ߽ߟ‫ޟ‬ᩕ㙃▤ℂ࡮ᗵᨴ೙ᓮࠨࡐ࡯࠻࠮ࡦ࠲࡯‫ޠ‬㧔㒮ౝភ⟎㧕ߣߒߡࠣ࡟࡯࠼ࠕ࠶ࡊߒ㧘ߐࠄߦᐔᚑ 15 ᐕ 4 ᦬߆ࠄߪฬ⒓ࠍ‫↢ޟ‬૕ᡰេ࠮ࡦ࠲࡯㧔NST/ICT㧕‫ߣޠ‬ᄌ߃㧘ᱜᑼߦਛᄩ⸻≮ㇱ㐷ߩ߭ߣߟߣߒߡ⁛┙ߒߚ‫߅ߥޕ‬㧘ᐔᚑ 20 ᐕ 4᦬߆ࠄߪ੍㒐ធ⒳ㇱ㐷㧔ጘ㒂⋵߆ࠄᆔ⸤ߐࠇߚ੍㒐ធ⒳࠮ࡦ࠲࡯ߣߒߡ㧕ࠍ㧘ߐࠄߦᐔᚑ 20 ᐕ 10 ᦬߆ࠄ
ߪ๭ๆ≮ᴺᡰេㇱ㐷㧔RST㧕ࠍჇ⸳ߒ㧘ࠃࠅᐢ▸࿐ߩᮮᢿ⊛⸻≮ᡰេࠍⴕߞߡ޿ࠆ‫ޕ‬ߔߥࠊߜ㧘⃻࿷ᒰ࠮ࡦ࠲࡯ߪ‫ޟ‬ᗵᨴ೙ᓮ‫ޠ‬‫੍ޟ‬㒐ធ⒳‫ޠ‬‫ޟ‬ᩕ㙃▤ℂ‫ޠ‬‫≙ⶖޟ‬ኻ╷‫ޠ‬‫ޟ‬๭ๆ≮ᴺᡰេ‫ ߩޠ‬5 ᧄᩇߢᬺോࠍㆀⴕߒߡ޿ࠆ‫ߩࠄࠇߎޕ‬ᬺോߪ㧘ᄙ⡯⒳߆ࠄ᭴ᚑߐࠇࠆ࠴࡯ࡓක≮ߩᒻᘒߢⴕࠊࠇࠆ⸻≮ᡰេߢ޽ࠅ㧘ో࿖⊛ߦ߽ߎߩࠃ߁ߥᮮᢿ⊛ਛᄩ⸻≮ㇱ㐷ࠍ⸳⟎ߒߡ޿ࠆ࿖┙ᄢቇ∛㒮ߪߥߊ㧘↹ᦼ⊛ߥ૕೙ࠍߣߞߡ޿ࠆߣ⸒߃ࠆ‫ޕ‬↢૕ᡰេ࠮ࡦ࠲࡯ߣ޿߁ࠊ߆ࠅߠࠄ޿ฬ⒓߽㧘⃻࿷ߢߪ㒮ౝߪ߽ߣࠃࠅቇᄖߢ߽⹺⍮ߐࠇࠆߦ⥋ߞߡ߅ࠅ㧘ߎࠇࠄߪᡰេ⡯ຬࠍ฽߼㧘㑐ਈߔࠆోࡔࡦࡃ࡯߇࿾㆏ߥദജࠍߒߡ߈ߚ߅߆ߍߣ⥄⽶ߒߡ޿ࠆ‫ޕ‬⃻࿷ߩࡔࡦࡃ࡯᭴ᚑߪ㧘એਅߩ✚൓ 50 ฬߣߥߞߡ޿ࠆ‫ޕ‬‫ڎ‬ኾછ⡯ຬ㧦7 ฬ
ᢎቭ 4 ฬ㧦⻠Ꮷ㧔ౝ⑼ක㧕1 ฬ㧘ഥᢎ 3 ฬ㧔ౝ⑼ක 2 ฬ㧘ᄖ⑼ක 1 ฬ㧕㧙㧙⋴⼔Ꮷ㐳 1 ฬ㧘೽⋴⼔Ꮷ㐳 1 ฬ੐ോ⵬૒ຬ 1 ฬ‫ڎ‬౗છ⡯ຬ㧦1 ฬ㧔࠮ࡦ࠲࡯㐳㧕ᢎቭ 1 ฬ㧔ᢎ᝼㧘ౝ⑼ක㧕‫ڎ‬ᡰេࡔࡦࡃ࡯㧦42 ฬ
ᢎቭ 11 ฬ㧔ᢎ᝼ 1 ฬ㧘ಎᢎ᝼ 2 ฬ㧘⻠Ꮷ 3 ฬ㧘ഥᢎ 5 ฬ㧕㧘ߘߩઁකᏧ 4 ฬ㧔කຬ 2 ฬ㧘ᄢቇ㒮↢ 2ฬ㧕㧘⋴⼔Ꮷ 4 ฬ㧔⋴⼔Ꮷ㐳 1 ฬ㧘೽⋴⼔Ꮷ㐳 1 ฬ㧘ߘߩઁ 2 ฬ㧕㧘⥃ᐥᬌᩏᛛᏧ 2 ฬ㧘⮎೷Ꮷ 6 ฬ㧘▤ℂᩕ㙃჻࡮ᩕ㙃჻ 6 ฬ㧘⺞ℂᏧ 6 ฬ㧘⥃ᐥᎿቇᛛ჻ 1 ฬ㧘ℂቇ≮ᴺ჻ 1 ฬ㧘੐ോቭ 1 ฬ⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷㧔1㧕 ⃻࿷㧘ฦ⒳ቇળ⹺ቯ߿⾗ᩰࠍ᦭ߔࠆࡔࡦࡃ࡯ߪᄙ⡯⒳ߦࠊߚߞߡᄙᢙ࿷☋ߒߡ޿ࠆ߽ߩߩ㧘ߔߴߡኾછߢߩᵴേߪߢ߈ߡ޿ߥ޿‫ߚ߹ޕ‬ኾછᢎቭ 4 ฬߪ⊓㍳ߐࠇߡ޿ࠆ߇㧘ታ⾰⊛ߦߪᲣ૕ಽ㊁ߩ઀੐ࠍ90㧑એ਄㧘ᒰ࠮ࡦ࠲࡯ߢߩᬺോ㊂ߪ 10㧑એਅߢ޽ࠆ‫ߪߣߎߩࠄࠇߎޕ‬㧘ᭂ߼ߡᄙጘߦࠊߚߞߡ޿ࠆ
ᒰ࠮ࡦ࠲࡯ߢᬺോ߇ሽ࿷ߔࠆߥ߆ߢ㧘⃻႐ߢߩ୘‫ߩޘ‬੐଀ߦኻߒߡ߈߼⚦߿߆ߦኻᔕߔࠆߎߣߦߪ㒢⇇߇޽ࠆߣ⸒ࠊߑࠆࠍᓧߥ޿‫ ߚ߹ޕ‬100㧑ᒰ࠮ࡦ࠲࡯ᬺോߦኾછߒߡ޿ࠆ 1 ฬߩ⋴⼔Ꮷ㐳ߦߪ㧘ᄙᄢ
ߥ⽶ᜂ߇߆߆ߞߡ޿ࠆߎߣ߽ᄢ߈ߥ໧㗴ὐߢ޽ࠆ‫ޕ‬
㧔2㧕 ߐࠄߦᡰេࡔࡦࡃ࡯ߩᬺോౝኈߪ㧘⚿ᨐ⊛ߦ᦬ 1 ࿁ߩฦㇱ㐷ળ⼏ߦෳടߔࠆߎߣߣ㧘↢૕ᡰេ࠮ࡦ࠲
࡯࠮ࡒ࠽࡯ߥߤ߳ߩදജߦ㒢ቯߐࠇߡ޿ࠆ‫ߪ᧪ᧄޕ‬ᄙ⡯⒳ߦࠃࠆฦ࠴࡯ࡓࡔࡦࡃ࡯߇⸻≮⃻႐ߦ࡜࠙ࡦ࠼ߒߡ⸻≮ᡰេࠍⴕ߁ᒻߎߘᦸ߹ߒ޿ᵴേ߇ᦼᓙߢ߈ࠆߣ⠨߃ࠄࠇࠆ߇㧘ߣߊߦ⥃ᐥᬌᩏᛛᏧ㧘⮎೷Ꮷ╬ߩࠦࡔ࠺ࠖࠞ࡞߿੐ോቭߩᬺോౝኈࠍࠃࠅ᣿⏕ߦߒߡ㧘ߘࠇߙࠇߩᓧᗧߣߔࠆᬺോࠍᅤ૗ߥߊ
⊒ើߢ߈ࠆࠃ߁ߦ㧘ᬺോᤨ㑆ߩ଻㓚ߣᚑᨐ⽿છߩ᣿⏕ൻߥߤ㧘ਛᄩ⸻≮ㇱ㐷ߩ৻ߟߣߒߡ⚵❱⊛ߦలታߔߴ߈ߢ޽ࠆ‫ߦߊߣޕ‬੐ോቭߦߟ޿ߡߪ㧘ኾ㐷⊛⍮⼂߿⚻㛎߽㊀ⷞߐࠇࠆߚ߼㧘ࠃࠅ㐳ᦼߦኾછᜂ
ᒰߔࠆߎߣ߇ᦸ߹ߒ޿‫ޕ‬
㧔3㧕 ⚿⺰⊛ߦߪ⃻⁁ߢߪਛᄩ⸻≮ㇱ㐷ߣ޿߁ߦߪᬺോ㊂ߩᄙߐ㧘ᄙᓀߐࠍ⠨ᘦߔࠆߣ૛ࠅߦ߽⚵❱⊛૕೙߇ਇචಽߢ޽ࠆߣ޿߁ὐ߇ᄢ߈ߥ໧㗴ὐߢ޽ࠆ‫࡯ࡃࡦࡔޕ‬છ๮૕೙߽฽߼㧘ᣧᕆߦ⷗⋥ߒ߇ᔅⷐߢ޽ࠆ‫ޕ‬㧔4㧕 ታ㓙ߩ⸻≮ᡰេ߽㧘⃻࿷ࠃࠅ〯ߺㄟࠎߛᒻߢߩ⸻≮ෳട߅ࠃ߮੺౉ࠪࠬ࠹ࡓࠍ⏕┙ߔߴ߈ᤨᦼߦ᧪ߡ޿ࠆ‫ޕ‬㧔5㧕 ᒰ࠮ࡦ࠲࡯߇ᜂᒰߔࠆ⸻≮ᡰេߪ㧘࠴࡯ࡓ࡜࠙ࡦ࠼߿ࡑ࠾ࡘࠕ࡞ߩలታߩߺߢߪ߶ߣࠎߤᗧ๧߇ߥ޿‫ޕ‬୘‫ߩޘ‬⡯ຬߩ࡟ࡌ࡞ࠕ࠶ࡊࠍ⛮⛯⊛ߦߪ߆ࠆߴ߈ߢ޽ࠅ㧘ත೨ᢎ⢒߽฽߼ߚᢎ⢒࡮⎇ୃ૕೙ࠍᡷༀߒ
ߥߌࠇ߫޿ߟ߹ߢ߽቟ో߆ߟㆡಾߥ⸻≮ࠍⴕ߁਄ߢߩ࡝ࠬࠢߪᷫዋߒߥ޿‫ߡߞ߇ߚߒޕ‬㧘ઁߩ㗔ၞ㧔ක≮቟ోߥߤ㧕߽฽߼∛㒮ో૕ߣߒߡ੐ോᣇ߇▤ℂߔࠆ⎇ୃ▤ℂ૕೙ߩ⏕┙߇ᦸ߹ࠇࠆ‫ޕ‬ක≮⋙ⷞ߿∛㒮ᯏ⢻⹏ଔ߳ߩኻᔕ㕙ߢ߽ߎߩ૕೙ߩ⏕┙ߪᕆോߣᕁࠊࠇࠆ‫ޕ‬
㧔6㧕 ߎࠇ߽ઁߩ㗔ၞߣห᭽ߩߎߣߢ޽ࠆ߇㧘㒮ౝߢߩᖱႎવ㆐૕೙߇ోߊߣ⸒ߞߡࠃ޿߶ߤਇචಽߢ޽ࠆ‫ޕ‬ᮮᢿ⊛⸻≮ᡰេᬺോߩㆡಾߥㆀⴕߦߪ㧘‫ޟ‬ᖱႎ౒᦭‫ߪޠ‬ਇนᰳߣ⸒޿ಾߞߡࠃ޿‫߿࡯࠲ࠢ࠼ࠢࡦ࡝ޕ‬࡝ࡦࠢ࠽࡯ࠬߩߺߢߪߥߊ㧘ᄖㇱᆔ⸤ᬺ⠪⡯ຬ߽฽߼㧘ߔߴߡߩ⡯ຬߦㄦㅦ߆ߟㆡಾߦ‫ޟ‬ᖱႎ౒᦭‫ޠ‬߇ߥߐࠇࠆࠃ߁ߦ㒮ౝᖱႎવ㆐૕೙ߩࠗࡦࡈ࡜ᢛ஻߇ᦸ߹ࠇࠆ‫ޕ‬੹ᓟߩዷᦸ޿ߕࠇߦߖࠃ㧘ฦ⒳੐଀ߦㄦㅦ߆ߟ⊛⏕ߦኻᔕߒߥ߇ࠄ㧘⸻≮⑼ᮮᢿ⊛ߦ㒮ౝߢ㗬ࠅߦߐࠇࠆ࠮ࡦ࠲࡯
ߣߒߡ⽸₂ߢ߈ࠆߴߊߐࠄߥࠆ♖ㅴࠍߒߡ޿߈ߚ޿‫ޕ‬਄⸥໧㗴ὐࠍዋߒߕߟ⸃ᶖߒ㧘ࠃࠅ቟ቯߒߚ⸻≮ᡰេᬺോ߇ዷ㐿ߢ߈ࠆࠃ߁ߦ㧘ੱ੐࡮⚵❱⊛ၮ⋚ߩ቟ቯൻ߇ᔅⷐߣᕁࠊࠇࠆ‫ޕ‬㧙㧙㧔32㧕⣲≌࠮ࡦ࠲࡯1㧚⸻≮ߩ᭎ⷐ
ㇺ㆏ᐭ⋵߇ࠎ⸻≮ㅪ៤᜚ὐ∛㒮ߦ⹺ቯߐࠇߚߎߣߦߣ߽ߥߞߡጘ㒂ᄢቇකቇㇱ㒝ዻ∛㒮ߦ⣲≌࠮ࡦ࠲࡯߇⸳┙ߐࠇ㧘⸻≮ㅪ៤ㇱ㐷㧘ᢎ⢒⎇ୃㇱ㐷㧘ᖱႎ▤ℂㇱ㐷ࠍ⸳⟎ߒߚ‫ޕ‬⸻≮ㅪ៤ㇱ㐷
࡮ ᄖ⑼ಾ㒰ࠍ฽߼ߚᮡḰᴦ≮ߩታᣉߦ㑐ߔࠆߎߣ㧦ฦ⑼⸻≮ౝኈߩ⏕⹺ߣታ❣ߩ⹏ଔ࡮ ߇ࠎൻቇ≮ᴺߩታᣉߦ㑐ߔࠆߎߣ࡮ ߇ࠎߩ᡼኿✢ᴦ≮ߦ㑐ߔࠆߎߣ࡮ ߇ࠎߩ✭๺ᴦ≮ߦ㑐ߔࠆߎߣ࡮ ⸻≮⑼ᮮᢿ⊛ᄖ⑼ᴦ≮ߩታᣉࠍ೨ឭߣߒߚࠠࡖࡦࠨ࡯ࡏ࡯࠼ߩㆇ༡࡮ ฦ⸻≮⑼ߣశቇ⸻≮ㇱ㧘∛ℂᬌᩏㇱ߅ࠃ߮↹௝⸻ᢿㇱߥߤਛᄩㇱ㐷ߣߩㅪ៤ᢎ⢒⎇ୃㇱ㐷࡮ ㅪ៤᜚ὐ∛㒮ߩ㊀ⷐߥછോߣߒߡ㒮ౝᄖߩฦㇱ㐷㧔කᏧ㧘⋴⼔Ꮷ㧘⮎೷Ꮷ㧘᡼኿✢ᛛᏧ㧘ᬌᩏᛛᏧ㧘੐ോ♽⡯ຬߥߤ㧕ߩࠬ࠲࠶ࡈᲤߩ⎇ୃ߿ᢎ⢒࡮⎇ୃળߩታᣉߦ㑐ߔࠆߎߣ࡮ ోක≮ᓥ੐⠪ࠍኻ⽎ߦ㧘߇ࠎ✚⺰㧘⥃ᐥ⹜㛎㧘᡼኿✢ᴦ≮㧘ฦ⒳߇ࠎ⸻≮ߩฦ⺰ߥߤߩ߇ࠎߩᖱႎࠍ
ᐢߊᐢႎߔࠆߎߣ࡮ ߇ࠎߩᮡḰᴦ≮ߩߺߥࠄߕᣂߚߥᴦ≮㐿⊒ߣߒߡߩ⥃ᐥ⹜㛎ߦ㑐ߔࠆᖱႎឭଏ࡮ ߇ࠎࡊࡠࡈࠚ࠶ࠪࠝ࠽࡞㙃ᚑࡊ࡜ࡦߦ઻߁ᢎ⢒⎇ୃߦ㑐ߔࠆߎߣ
ᖱႎ▤ℂㇱ㐷࡮ ߇ࠎ⊓㍳ᬺോ࡮ ߇ࠎ⊓㍳ኻ⽎ᖚ⠪ߩ⷗ઃߌ಴ߒ㧔᛽಴ߐࠇߚ⸻≮࠺࡯࠲߆ࠄߩᜪ޿಴ߒ૞ᬺ㧕࡮ ߇ࠎ⊓㍳㧔㒮ౝ߇ࠎ⊓㍳↪㧘ጘ㒂⋵߇ࠎ⊓㍳↪ߦߘࠇߙࠇ࠺࡯࠲౉ജ૞ᬺ㧕࡮ 㒮ౝ㓸⸘ߦ߅ߌࠆ߇ࠎ⛔⸘࠺࡯࠲૞ᚑ࡮ ࿖┙߇ࠎ࠮ࡦ࠲࡯߳ឭ಴ߔࠆ࠺࡯࠲ߩ૞ᚑ࡮ ጘ㒂⋵߳ឭ಴ߔࠆ࠺࡯࠲ߩ૞ᚑ࡮ ⸻≮⑼߳⛔⸘࠺࡯࠲╬ߩឭଏz ᣣᏱᬺോ࡮ ߇ࠎ⋧⺣㧔ኻ⽎㧦㒮ౝ෸߮㒮ᄖߩ߇ࠎᖚ⠪࡮ኅᣖ࡮ߘߩ㑐ଥ⠪㧕࡮ ࿾ၞㅪ៤ࡄࠬㆇ↪ᡰេ෸߮ࡕ࠾࠲࡯▤ℂz ᦬଀ᬺോ࡮ ක≮ㅪ៤࠮ࡦ࠲࡯ౝᬌ⸛ળ㧔᦬೎ߩ߇ࠎ⋧⺣ઙᢙ࡮࿾ၞㅪ៤ࡄࠬㆇ↪ઙᢙႎ๔㧕z ߘߩઁߩㅢᏱᬺോ࡮ ߇ࠎߦ㑐ߔࠆౠሶ࡮ࡐࠬ࠲࡯ߩ⸳⟎㧔₵㑐࡮ᄖ᧪࡮∛᫟㧕࡮ ߇ࠎߦ㑐ߔࠆ࿑ᦠߩ⸳⟎㧔㒮ౝ࿑ᦠቶ㧕࡮ ⋧⺣ቶߩలታ࡮ ߇ࠎ⋧⺣ߦᵴ↪ߔࠆ‫ߦࠎ߇ޟ‬㑐ߔࠆ Q & A‫ߩޠ‬ㆡቱᡷ⸓࡮ ߇ࠎ⸻≮ㅪ៤᜚ὐ∛㒮㧔ጘ㒂⋵㧕⋧⺣ᡰេ࠮ࡦ࠲࡯ᖱႎ੤឵ળߩ㐿௅㧔2 ࿁㧛ᐕ㧕
࡮ NPO ࿅૕߳ߩᡰេ㧔ᖚ⠪ࠨࡠࡦ㐿௅ߩᡰេ╬㧕࡮ ࡎ࡯ࡓࡍ࡯ࠫߩలታ࡮ ߇ࠎ⋧⺣⓹ญߩᐢႎ㧦࡝࡯ࡈ࡟࠶࠻ߩ⸳⟎㧔₵㑐࡮ᄖ᧪㧕࡮ ࿾ၞㅪ៤ࡄࠬㆇ↪ߦะߌߡߩᬌ⸛ળߩ㐿௅෸߮ઁ⡯⒳㑆ߩ⺞ᢛ࡮ ጘ㒂࿾ၞක≮ㅪ៤ቶታോ⠪ㅪ⛊ળ㧘ጘ㒂࿾ၞㅪ៤ࡄࠬࡢ࡯ࠠࡦࠣ߳ߩෳട࡮ ⣲≌࠮ࡦ࠲࡯ળ⼏ෳട
2㧚ᢎ⢒ᣉ⸳
1㧕 ㇺ㆏ᐭ⋵߇ࠎ⸻≮ㅪ៤᜚ὐ∛㒮
2㧕 ᣣᧄ⥃ᐥ⣲≌ቇળ⹺ቯ⎇ୃᣉ⸳
3㧕 ᣣᧄ߇ࠎᴦ≮⹺ቯᯏ᭴⹺ቯ⎇ୃᣉ⸳
4㧕 ᣣᧄᄖ⑼ቇળ࡮⹺ቯක࡮ᄖ⑼ኾ㐷ක೙ᐲୃ✵ᣉ⸳
5㧕 ᣣᧄᶖൻེᄖ⑼ቇળ࡮ኾ㐷කୃ✵ᣉ⸳
6㧕 ᣣᧄ⥃ᐥ⣲≌ቇળ࡮⹺ቯ⎇ୃᣉ⸳7㧕 ᣣᧄ੃≸ቇળ࡮⹺ቯᣉ⸳㧙㧙8㧕 ᣣᧄ⢄⢙⤟ᄖ⑼ቇળ࡮㜞ᐲᛛ⢻ኾ㐷ක⹺ቯᣉ⸳
3㧚⸻≮㐿⊒
1㧕 ⸻≮ฬ 㧦㜞ᐲㅴⴕ⢄≸ߦኻߔࠆ᛫⣲≌఺∉⾮ᵴࠍ⋡⊛ߣߒߚಓ⚿ᴦ≮⸻≮ౝኈ㧦ᄖ⑼⊛ಾ㒰߇ਇ⢻ߣ್ᢿߐࠇߚ⢄⣲≌ߦኻߒ㧘⿥㖸ᵄࠍࠟࠗ࠼ߣߒߡዪᚲ㤗㈮ਅߦಓ⚿⓫ೝ㊎ࠍ૶↪ߔࠆߎߣߢಓ⚿უᱫࠍ⺃⊒ߔࠆ‫ޕ‬ᴦ≮ߪㅳ 1 ࿁ࠍේೣߣߒߡน⢻ߥ㒢ࠅ෻ᓳ࡮⛮⛯ߒ㧘᛫⣲≌఺∉ߩ⾮ᵴࠍଦߔ‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦ᒰ⑼⁛⥄ߩᴦ≮૕♽ߢ޽ࠅ㧘਎⇇⊛ߦ߽㘃ࠍߺߥ޿‫ޕ‬࿖ౝ⊛⹏ଔ㧦㊀◊ߥ᦭ኂ੐⽎߽ߥߊ㧘1 ᴱ౉㒮ߢ 1 ࿁ߩᴦ≮߇น⢻ߢ޽ࠆߎߣ߆ࠄ quality of life ࠍ៊ߥ߁ߎߣߥߊⴕ޿ᓧ㧘ߎࠇ߹ߢߦታᣉߒߡ߈ߚ 22 ଀ߩᴦ≮ౝኈߦߟ߈㧘ฦ⒳ቇળߢߩႎ
๔㧘⺰ᢥឝタࠍㅢߒᓢ‫ߦޘ‬ᶐㅘߒߡ޿ࠆ‫⃻ޕ‬࿷㜞ᐲක≮ߣߒߡෘ↢ഭ௛⋭߳↳⺧ᚻ⛯߈ਛߢ޽ࠆ‫ޕ‬
࿖㓙⊛⹏ଔ㧦ಓ⚿ᴦ≮ߘߩ߽ߩߪߎࠇ߹ߢߦ᰷߽☨ࠍߪߓ߼ᣉⴕߐࠇߡ߈ߚ⚻✲߇޽ࠆ߇㧘᛫⣲≌఺∉⾮ᵴࠍ⋡⊛ߣߔࠆ᭎ᔨߪ․⇣ߢ޽ࠅ㧘2008ᐕߪ࿖㓙≸ቇળ߿࿖㓙ᶖൻེᄖ⑼ቇળ߳ߩ⊒⴫ࠍㅢߒߡ⹏ଔߐࠇߟߟ޽ࠆ‫ޕ‬2㧕 ⸻≮ฬ 㧦࠮ࡦ࠴ࡀ࡞࡝ࡦࡄ▵↢ᬌߦࠃࠆ⣠┃࡝ࡦࡄ▵ㇳᷡߩㆡᔕ್ቯ
⸻≮ౝኈ㧦੃≸∝଀ߦ߅޿ߡ⣲≌ᓘߩዊߐߥ႐วߦߪ㧘ᮡ⼂ࠕࠗ࠰࠻࡯ࡊࠍ⣲≌๟ㄝߦᵈ౉ߒߡ⣲≌߆ࠄᦨ߽ㄭߊᦨೋߦᵹ౉ߔࠆ࡝ࡦࡄ▵㧔࠮ࡦ࠴ࡀ࡞࡝ࡦࡄ▵㧕ࠍ៰಴ߒ㧘ⴚਛㄦㅦ∛ℂᬌᩏߦߡォ⒖ߩ᦭ήࠍ⏕⹺ߔࠆߎߣߢㇳᷡߩㆡᔕࠍ⹏ଔߒߡ޿ࠆ‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦ో࿖⊛ߦߪᮡḰౝኈߣߐࠇࠆ௑ะߦ޽ࠆ߇㧘ጘ㒂⋵ਅߢߪᧂߛᶐㅘߒߡ޿ࠆ⁁ᴫߢߪߥ޿‫ޕ‬࿖ౝ⊛⹏ଔ㧦੃≸⸻≮ࠍኾ㐷ߣߒߡ޿ࠆᣉ⸳ߢߪᮡḰౝኈߢ޽ࠅ⸻≮ࠟࠗ࠼࡜ࠗࡦߦ߽ߘߩᗧ⟵߇⹏ଔߐࠇߡ޿ࠆ‫ߒ߆ߒޕ‬቟ቯߒߚᚑ❣ߩ⏕଻ߦߪ৻ቯએ਄ߩ∝଀ᢙࠍⷐߔࠆὐ߽ᜰ៰ߐࠇߡ
߅ࠅ㧘ߘߩὐߦ㑐ߒߡߪᒰ⑼ߢߪߔߢߦ⏕┙ߒߚ⁁ᴫߣ⸒߃ࠆ‫ޕ‬࿖㓙⊛⹏ଔ㧦᰷☨ߢߪᣣᏱ⥃ᐥ਄㊀ⷐⷞߐࠇߡ޿ࠆ‫ޕ‬
4㧚ኾ㐷ක࡮⹺ቯක࡮ᜰዉක
᫪⣁ਭ㓉㧦ᣣᧄౝ⑼ቇળ⹺ቯౝ⑼ක࡮ᜰዉක㧘ᣣᧄᶖൻེ∛ቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄ⢄⤳ቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄᶖൻེౝⷞ㏜ቇળ⹺ቯක࡮ኾ㐷ක㧘ᣣᧄ⥃ᐥ⣲≌ቇળᥳቯᜰዉක
ศ↰๺ᒄ㧦ᣣᧄᄖ⑼ቇળ⹺ቯක࡮ኾ㐷ක࡮ᜰዉක㧘ᣣᧄᶖൻེᄖ⑼ቇળ⹺ቯක࡮ኾ㐷ක࡮ᜰዉක㧘ᣣᧄౝⷞ㏜ᄖ⑼ቇળᛛⴚ⹺ቯක㧔ᶖൻེ࡮৻⥸ᄖ⑼࡮⢗≸㧕㧘ᣣᧄ੃≸ቇળ⹺ቯක㧘ᣣᧄ≸ᴦ≮ቇળ⥃ᐥ⹜㛎⊓㍳ක㧘ᣣᧄ≸ᴦ≮ᯏ᭴ᥳቯᢎ⢒ක㧘ࡑࡦࡕࠣ࡜ࡈࠖ࡯ᬌ⸻♖ᐲ▤ℂਛᄩᆔຬળ⺒ᓇ⹺ቯ㧘ᣣᧄ㘩㆏ቇળ㘩㆏⑼⹺ቯක㧘ᣣᧄᶖൻ▤ቇળ⢗⣺⑼⹺ቯක㧘ᶖൻེ߇ࠎᴦ≮⹺ቯක㢬⷗ ኼ㧦ᣣᧄౝ⑼ቇળ᧲ᶏ࿾඙ᜰዉක࡮✚วౝ⑼ኾ㐷ක࡮ౝ⑼⹺ቯක㧘ᣣᧄⴊᶧቇળᜰዉක࡮ኾ㐷ක㧘ᣣᧄ⥃ᐥ⣲≌ቇળᥳቯᜰዉක࡮߇ࠎ⮎‛≮ᴺኾ㐷ක㧘ᣣᧄ߇ࠎᴦ≮⹺ቯකᯏ᭴ᥳቯᢎ⢒ක࡮⹺ቯක㧘ᣣᧄᶖൻེౝⷞ㏜ቇળኾ㐷ක㧘ᣣᧄ⥃ᐥౝ⑼කળኾ㐷ක⊕㠽⟵ቬ㧦ᣣᧄౝ⑼ቇળ⹺ቯౝ⑼ක࡮ᜰዉක㧘ᣣᧄᶖൻེ∛ቇળኾ㐷ක㧘ᣣᧄ⢄⤳ቇળኾ㐷ක࡮ᜰዉක㧘ᣣ ᧄ ߇ ࠎ ᴦ ≮ ⹺ ቯ ක ᯏ ᭴ ᥳ ቯ ᢎ ⢒ ක 㧘American Gastroenterological Association㧔 AGA
Fellow㧕ၳᎹᐘ↵㧦ᣣᧄౝ⑼ቇળ⹺ቯක㧘ᣣᧄ♧ዩ∛ቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄ∛ᘒᩕ㙃ቇળ⹺ቯ NST ࠦ࡯࠺ࠖࡀ࡯࠲࡯㧘ᣣᧄ♧ዩ∛දળ≮㙃ᜰዉක㐳↰⌀ੑ㧦ᣣᧄᄖ⑼ቇળ⹺ቯක࡮ᄖ⑼ኾ㐷ක࡮ᜰዉක㧘ᣣᧄᶖൻེᄖ⑼ቇળኾ㐷ක࡮⹺ቯක࡮ᜰዉක㧘ᣣᧄ⢄⢙⤟ᄖ⑼ቇળ㜞ᐲᛛ⢻ᜰዉක㧘ᣣᧄ߇ࠎᴦ≮⹺ቯᯏ᭴ᥳቯᢎ⢒ක౗᧻㓷ਯ㧦ᣣᧄකቇ᡼኿✢ቇળ⹺ቯ᡼኿✢⑼ኾ㐷ක㧘ᣣᧄⴊ▤ㅧᓇ࡮IVR ቇળ⹺ቯᜰዉක㧘ᣣᧄࠗࡦ࠲࡯
ࡌࡦ࡚ࠪ࠽࡞࡜ࠫࠝࡠࠫ࡯ቇળኾ㐷ක㧘ᣣᧄ߇ࠎᴦ≮⹺ቯකᯏ᭴ᥳቯᢎ⢒කේ ᱞᔒ㧦ᣣᧄౝ⑼ቇળᜰዉක࡮✚วౝ⑼ኾ㐷ක࡮ౝ⑼⹺ቯක㧘ᣣᧄⴊᶧቇળᜰዉක࡮ኾ㐷ක㧘ᣣᧄ⥃ᐥ⣲≌ቇળᥳቯᜰዉක࡮߇ࠎ⮎‛≮ᴺኾ㐷ක㧘ᣣᧄ߇ࠎᴦ≮⹺ቯකᯏ᭴ᥳቯᢎ⢒ක࡮⹺ቯක
5㧚⥄Ꮖ⹏ଔ
⹏ଔᒰ࠮ࡦ࠲࡯ߪㇺ㆏ᐭ⋵߇ࠎ⸻≮ㅪ៤᜚ὐ∛㒮ߦ⹺ቯߐࠇߚߎߣߦߣ߽ߥߞߡጘ㒂ᄢቇකቇㇱ㒝ዻ∛㒮ߦ⸳┙ߐࠇߚ‫ޕ‬⸻≮ㅪ៤ㇱ㐷ߣߒߡߪ㧘⸻≮⑼ߩᮮᢿ⊛ߥㅪ៤ࠍᒝൻߔࠆߎߣߢࠃࠅᐢ▸࿐ߥᴦ≮૕♽ࠍ⏕┙ߔࠆߎߣ㧙㧙ࠍ⋡⊛ߣߒߡ⸳⟎ߐࠇߚ‫ߦ․ޕ‬ㄭᐕߢߪᄙ᭽ൻߒߚൻቇ≮ᴺࠍኾ㐷කߣߒߡታᣉߒ㧘ߘߩ⸻≮૕೙ࠍ⮎೷Ꮷ㧘⋴⼔Ꮷߣߣ߽ߦ࠴࡯ࡓක≮ߣߒߡታ⃻ߒ㧘ᄖ᧪ൻቇ≮ᴺቶߩⒿ௛₸߿ᖚ⠪ᢙߩჇടߦߟߥ߇ߞߚ‫ߐޕ‬ࠄߦෘ↢ഭ௛⋭ஜᐽዪ㐳ㅢ⍮╙ 0301001 ภࠍฃߌߡ┙ߜ਄ߍߚࠠࡖࡦࠨ࡯ࡏ࡯࠼ߩలታࠍਥߥછോߣߒ
ߡ㧘ࠃࠅ᣿⏕ߥᵴേ߇✜ߦߟ޿ߚߣߎࠈߣ޿߃ࠆ‫ޕ‬৻ᣇᢎ⢒⎇ୃㇱ㐷ߣߒߡߪ㧘ጘ㒂߇ࠎ⮎‛≮ᴺ⎇ⓥળ߅ࠃ߮߇ࠎක≮ᓥ੐⠪⎇ୃળߪ㒮ౝ߅ࠃ߮ጘ㒂⋵ౝߩฦ∛㒮ߩ߇ࠎක≮ߦ៤ࠊࠆోක≮ᓥ੐⠪ࠍኻ⽎ߦ㧘߇ࠎ✚⺰㧘⥃ᐥ⹜㛎㧘᡼኿✢ᴦ≮㧘ฦ⒳߇ࠎ⸻≮ߩฦ⺰ߥߤߩ⻠Ṷળࠍ㐿௅ߒߚ‫৻ޕ‬ㇱߪ㧘⋴⼔ㇱᢎ⢒ᆔຬળ㧘ጘ㒂⋵∛㒮⮎೷Ꮷળߣߩ౒௅ߢ޽ࠆ‫⻠ޕ‬Ꮷߪ㧘ጘ㒂ᄢቇ∛㒮ౝߩฦ⸻≮⑼ߩవ↢ᣇࠍਛᔃߦ㧘⋵ౝ࿾ၞ᜚ὐ∛㒮ߩኾ㐷කߩవ↢ߦ߽߅㗿޿ߒߚ‫߹ޕ‬ߚ㧘ฦ⒳ડᬺਥ௅޽ࠆ޿ߪᒰ㒮⣲≌࠮ࡦ࠲࡯ߣߩ౒௅ߩ⻠⠌ળ࡮⎇ୃળߦߪ㧘ో࿖ߩߏ㜞ฬߥవ↢ᣇߦ⻠Ṷߒߡ㗂޿ߚ‫ߦࠄߐޕ‬㧘⣲≌࠮ࡦ࠲࡯ߩࠬ࠲࠶ࡈ߇ਛᔃߣߥࠅ㧘㜞ጊߦ಴ᒛ㧘⃻࿾ߦߡ࿾ၞߩ⎇ୃᵴേߣߒߡ㘧㛗⥃ᐥ⣲≌ࡈࠜ࡯࡜ࡓࠍડ↹㧘㐿௅ߒߚ‫ޕ‬
ᖱႎ▤ℂㇱ㐷ߣߒߡߪ㧘㒮ౝ߇ࠎ⊓㍳ߩలታߐࠄߦߪ࿾ၞ߇ࠎ⸻≮ㅪ៤᜚ὐ∛㒮ߣߩㅪ៤ࠍᮨ⚝ࠍ⷗ᒰߒߚ‫ߦ․߿⺣⋧ࠎ߇ߦࠄߐޕ‬ᖚ⠪ࠨࡠࡦߩታᣉ߿࿖┙߇ࠎ࠮ࡦ࠲࡯ߥߤߣߩ࠹࡟ࡆਛ⛮ࠞࡦࡈࠔ࡟ࡦࠬߩ
ታᣉߪ࿖┙ᄢቇ∛㒮ߣߒߡߪో࿖ೋ߼ߡߩ⹜ߺߢ޽ࠆߣ⠨߃ࠄࠇࠆ‫ޕ‬ߎࠇࠄߩߎߣࠃࠅᧄ࠮ࡦ࠲࡯߇ㇺ㆏ᐭ⋵߇ࠎ⸻≮᜚ὐ∛㒮ߩᓎഀࠍᜂ߁ߩߦචಽߥᯏ⢻ࠍᨐߚߒߡ޿
ࠆߣ⹏ଔߢ߈ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷⃻࿷ᄖ᧪ൻቇ≮ᴺቶߩⒿ௛ߦ㑐ߒߡ㧘ൻቇ≮ᴺߩ࡟ࠫࡔࡦ⊓㍳ߩలታ㧘੍⚂߅ࠃ߮ല₸ߩࠃ޿Ⓙ௛ࠍ⋡ⷞߒߡ޿ࠆ‫ޕ‬ൻቇ≮ᴺኾ㐷කߩలታ߿㧘ኾ㐷⮎೷Ꮷ㧘⋴⼔Ꮷߩ㈩஻߇ᕆോߢ޽ࠆߣ⠨߃ࠄࠇࠆ‫ߦࠄࠇߎޕ‬ኻߒߡߪ㧘࿖┙߇ࠎ࠮ࡦ࠲࡯ߥߤ߳ߩ⎇ୃߥߤߩኻ╷ࠍ⻠ߓߡ޿ࠆ‫ߚ߹ޕ‬㧘ൻቇ≮ᴺߩㆡᔕᄖ૶↪ߥߤߦ㑐ߒߡ߽㧘⣲≌࠮ࡦ࠲࡯ౝߢߩᆔຬળߢߩ⷗ᒰࠍ⟵ോߠߌࠆߎߣߢ EBM ߩታ〣ߦขࠅ⚵ࠎߛ‫ޕ‬৻ᣇ㧘⸻≮⑼㑆ߩ⸻≮ㅪ៤ߦ㑐ߒߡߪߎࠇ߹ߢߎߎߦⴕࠊࠇߡ޿ߚᬌ⸛ࠍ㧘ࠠࡖࡦࠨ࡯ࡏ࡯࠼ࠍ┙ߜ਄ߍࠆߎߣߢ㧘ࠃࠅᐢߊ㒮ౝᄖ߆ࠄߩෳടࠍน⢻ߦߒ㧘ࠃࠅᄙߊߩᗧ⷗ߩၮߢᖚ⠪ߐࠎ୘‫ᦨߦޘ‬ㆡߥᴦ≮ࠍឭଏߢ߈ࠆࠃ߁ߦኻ╷ࠍ⻠ߓߡ޿ࠆ‫ߦ․ޕ‬᛫≸೷߿㧘᡼኿✢ᴦ≮ࠍⴕ߁ߎߣߣߎࠇࠄߦᄖ⑼⊛ಾ㒰߇น⢻߆ߥߤߩ⸻≮⑼ࠍ⿥߃ߚࠞࡦࡈࠔ࡟ࡦࠬߩታᣉ߇㊀ⷐߢ޽ࠆߣ⠨߃ࠄࠇࠆ‫ޕ‬᡼኿✢ᴦ≮㧘✭๺ᴦ≮ߦ㑐ߒߡ߽߇ࠎᴦ≮ߩਛᔃ⊛ᓎഀߩ৻ߟߢ޽ࠆ‫੹ޕ‬ᓟߩߎࠇࠄߩක≮ࠍᜂ߁⧯޿
කᏧ߿ࡔ࠺ࠖࠞ࡞ࠬ࠲࠶ࡈߩలታ߇ᕆോߢ޽ࠆ‫ߪߦࠄߐޕ‬㧘࿾ၞߩ╙৻ᚢߢᵴべߐࠇߡ޿ࠆ߆߆ࠅߟߌක
ߩవ↢ᣇߣߩㅪ៤㧘ࠢ࡝࠾ࠞ࡞ࡄࠬߩలታߥߤߩኻ╷߇㊀ⷐߢ޽ࠅታ〣ߦขࠅ⚵ࠎߛ‫ޕ‬ᖚ⠪ߐࠎߩᵴേߦኻߔࠆᡰេ߿߇ࠎ⋧⺣ߦ㑐ߒߡ߽ੱ᧚ߩ⎇ୃᢎ⢒߇ᕆോߢ޽ࠆ‫ޕ‬ᖚ⠪ࠨࡠࡦߩ㐿⸳㧘Ꮢ᳃࠮ࡒ࠽࡯ߥߤߩᡰេࠍⴕߞߡ߈ߚ߇㧘੹ᓟߪߐࠄߦᐢߊ৻⥸ߩ⋵᳃ߦኻߒߡ㧘߇ࠎߩᣧᦼ⊒⷗߿ᬌ⸻ߩ㊀ⷐᕈߦ㑐ߒߡ㧘ࡇࡦࠢ࡝ࡏࡦࠠࡖࡦࡍ࡯ࡦ߿㧘࡝࡟࡯ࡈࠜ࡯࡜ࠗࡈߥߤߩᡰេ߇น⢻ߢ޽ࠆ߆ߥߤߩ
ኻᔕࠍⴕߞߡ޿ࠆ‫ޕ‬੹ᓟߩዷᦸጘ㒂⋵ߩ⌀ߩ߇ࠎ࠮ࡦ࠲࡯ᯏ⢻ࠍ᦭ߒߚ✚ว∛㒮࡮ᢎ⢒∛㒮ߣߒߡߩߐࠄߥࠆలታࠍ࿑ࠆߣߣ߽ߦ㧘ㇺ㆏ᐭ⋵߇ࠎ⸻≮ㅪ៤᜚ὐ∛㒮ߣߒߡߩ⚵❱ᡷ✬㧘ߐࠄߥࠆ⸻≮㧘⎇ⓥ㧘ᢎ⢒ߩలታࠍ࿑ߞߡ޿ߊ‫ޕ‬㧙㧙㧔33㧕⢄∔ᖚ⸻≮ᡰេ࠮ࡦ࠲࡯
1㧚⸻≮ߩ᭎ⷐ⢄⤳∔ᖚ࡮ ᕆᕈ⢄Ἳ㧦ᓴⅣ▤ℂ߽฽߼ߚోり▤ℂࠍਛᔃߦኻಣߔࠆ‫∉఺ߦ․ޕ‬ቇ⊛ⷰὐߦ┙⣉ߒߡ࡝ࡦࡄ⃿⴫㕙ࡑ࡯ࠞ࡯⸃ᨆ߿ࠨࠗ࠻ࠞࠗࡦ≮ᴺ߽ⷞ㊁ߦ౉ࠇߡ㧘24 ᤨ㑆ᜬ⛯ㅘᨆ㧔CHDF㧕߿ฦ⒳⵬ల≮ᴺࠍⴕߥ߁‫ߪߦࠄߐޕ‬㧘⥃ᐥᩕ㙃㕙ߩ⎇ⓥᚑᨐࠍၮ␆ߣߒߚ㑆ធࠞࡠ࡝࡯ࡔ࡯࠲ߩ᷹ቯࠍⴕ޿㧘ᦨㆡߥᩕ㙃ᴦ≮ࠍⴕߥ߁‫ޕ‬࡮ ᘟᕈ⢄Ἳ࡮⢄⎬ᄌ㧦ࠗࡦ࠲࡯ࡈࠚࡠࡦ≮ᴺߥߤࠍਛᔃߦ᛫࠙ࠖ࡞ࠬ≮ᴺࠍⴕߥ߁‫ߚ߹ޕ‬㧘ᣣᏱ▤ℂߦ
ߪනߦ⮎‛≮ᴺߛߌߢߪߥߊ㧘ᦨㆡߥᩕ㙃≮ᴺࠍⴕ޿㧘⦟ᅢߥ QOL ߩ⛽ᜬࠍ⋡ᜰߔ‫ޕ‬࡮ ⢄≸㧦㧔⸻ᢿ㧕ᓸዊߥ⣲≌ߩሽ࿷⸻ᢿ㧘⣲≌ߩᕈᩰ⸻ᢿ⢻ജߪᦨᣂߩ MRI ߿ PET ߩዉ౉ߦࠃࠅ㘧べ⊛ߦะ਄ߒߡ޿ࠆ‫ޕ‬ㅧᓇ⿥㖸ᵄࠍ૶↪ߔࠆߎߣߦࠃࠅ㧘੹߹ߢߩ⿥㖸ᵄߢߪᝒ߃ࠄࠇߥ߆ߞߚᓸዊߥ⢄≸ߩᬌ಴ߣ⣲≌ߩᕈᩰ⸻ᢿࠍⴕߥ߁‫ޕ‬㧔ᴦ≮㧕ߎߩㅧᓇ⿥㖸ᵄࠍ૶↪ߒ㧘ᓸዊߥ⢄≸߽࡜ࠫࠝᵄ὾ἳⴚ㧔RFA㧕ߦߡᴦ≮ߒߡ޿ࠆ‫ޕ‬ᄙ⊒⢄≸߿㐷⣂⣲≌ᩖߥߤᴦ≮࿎㔍∝଀ߦኻߒߡ߽㧘᡼኿✢ᴦ≮ࠍ૬↪ߔࠆߥߤ㓸ቇ⊛ᴦ≮ߦࠃࠅ㧘ᴦ≮ലᨐߩะ਄ࠍ⹜ߺߡ޿ࠆ‫ޕ‬࡮ 㑐ㅪ∛㒮ߢ߽කᏧߩᷫዋߦࠃࠅ㧘⢄≸ߩᴦ≮߇࿎㔍ߦߥߞߡ޿ࠆ‫ޕ‬ᖚ⠪ߩ౉㒮ฃߌ౉ࠇߛߌߢߥߊ㧘ක⠪ߩ಴ᒛᴦ≮ߥߤࠍⴕ޿㧘࿾ၞක≮ߩ⊒ዷߣੱ᧚⢒ᚑߦዧജߒߡ޿ࠆ‫ޕ‬࡮ ࿾ၞߩ㑐ㅪ∛㒮ߢ⢄≸ߩ࠺࡯࠲ࡌ࡯ࠬࠍ૞ᚑߒ㧘⢄≸ᖚ⠪✚ᢙ߿േᘒࠍᛠីߔࠆ‫ޕ‬࡮ ⢄Ἳࡄࠬ࡮⢄≸ࡄࠬࠍ૶↪ߔࠆߎߣߦࠃࠅ㧘∛㒮ߣ߆߆ࠅߟߌකߩㅪ៤ࠍᒝൻߒ㧘ᣣᏱ⸻≮ߪ߆߆ࠅߟߌකߢⴕ޿㧘ᬌᩏߪ∛㒮ߢⴕߥ߁ࠪࠬ࠹ࡓࠍ᭴▽ߔࠆ‫ޕ‬
2㧚ᢎ⢒ᣉ⸳
1㧕 ᣣᧄౝ⑼ቇળ⹺ቯౝ⑼ኾ㐷කᢎ⢒ᣉ⸳
2㧕 ᣣᧄᶖൻེ∛ቇળ⹺ቯᣉ⸳
3㧕 ᣣᧄ⢄⤳ቇળ⹺ቯᣉ⸳
4㧕 ᣣᧄᶖൻེౝⷞ㏜ቇળᜰቯᣉ⸳
3㧚⸻≮㐿⊒
1㧕 ⸻≮ฬ 㧦ㅴⴕ⢄⚦⢩≸ߦኻߔࠆ㓸ቇ⊛ᴦ≮ߩ⹜ߺ‫ޕ‬⸻≮ౝኈ㧦ㅴⴕߒߚ⢄⚦⢩≸ߦኻߒߡ㧘േᵈ↪ࠪࠬࡊ࡜࠴ࡦࠍ➅ࠅ㄰ߒേᵈߔࠆ‫ߚ߹ޕ‬㧘㐷⣂⣲≌ᩖߦኻߒߡߪ㧘᡼኿✢ᴦ≮߽૬↪ߔࠆ‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦㑐ㅪᣉ⸳ߦߡዉ౉߇ᆎ߹ߞߡ޿ࠆ‫ޕ‬࿖ౝ⊛⹏ଔ㧦ㅴⴕ⢄⚦⢩≸ߦኻߒߡߪ㧘േᵈ࡝ࠩ࡯ࡃ࡯⇐⟎ߦࠃࠆ⢄േᵈ߇ਥᵹߢ޽ࠅ㧘⇐⟎ᚻᛛߩᾘ㔀ߐߣ⇐⟎ᓟߩ▤ℂ߇໧㗴ߣߥߞߡ޿ߚ‫ߦࠇߎޕ‬ኻߒߡ㧘ᜂ≸േ⣂ߩߺߦേᵈࠍ➅ࠅ㄰ߒⴕߥ߁ߎߣߦࠃࠅ㧘ࠃࠅ⚦߆ߥᴦ≮߇น⢻ߣߥࠅ㧘ᓥ᧪ߩ࡝ࠩ࡯ࡃ࡯േᵈߣᄼല₸ߪห╬ߢ޽ࠆߎߣ߇⸽᣿ߐࠇߚ‫ޕ‬2㧕 ⸻≮ฬ 㧦C ဳᘟᕈ⢄Ἳߦኻߔࠆࡍࠣࠗࡦ࠲࡯ࡈࠚࡠࡦ㧗࡝ࡃࡆ࡝ࡦ૬↪㐳ᦼ≮ᴺᡷ⦟ߩ⹜ߺ
⸻≮ౝኈ㧦C ဳᘟᕈ⢄Ἳ㔍ᴦ∝଀㧔1 ဳ㧘㜞࠙ࠗ࡞ࠬ㊂㧕ߩ߁ߜ㧘ᴦ≮ᓟߩ࠙ࠗ࡞ࠬᶖᄬ߇ㆃ޿∝଀ߦኻߒߡ 48 ㅳએᓟߦ 24㨪48 ㅳ㑆ߩዋ㊂㐳ᦼ૬↪≮ᴺ㧔total 72㨪96 ㅳ㧕ࠍⴕ޿㧘ߘߩ᦭↪ᕈࠍ᣿ࠄ߆ߦߒߚ‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦㑐ㅪᣉ⸳ߣߩ౒ห⎇ⓥࠍⴕߞߡ޿ࠆ‫ޕ‬࿖ౝ⊛⹏ଔ㧦72 ㅳߩ᦭↪ᕈߩႎ๔߇⷗ࠄࠇࠆ߇㧘96 ㅳߩႎ๔ߩᬌ⸛ߪή޿‫ޕ‬࿖㓙⊛⹏ଔ㧦72 ㅳߩ᦭↪ᕈߩႎ๔߇⷗ࠄࠇࠆ߇㧘96 ㅳߩႎ๔ߩᬌ⸛ߪή޿‫ޕ‬
4㧚ኾ㐷ක࡮⹺ቯක࡮ᜰዉක
᳗ᧁᱜੳ㧦ᣣᧄౝ⑼ቇળ⹺ቯක࡮ᜰዉක㧘ᣣᧄᶖൻེ∛ቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄ⢄⤳ቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄᶖൻེౝⷞ㏜ቇળኾ㐷ක࡮ᜰዉක㧘ᣣᧄකᏧળ⹺ቯ↥ᬺක㜞੗శᴦ㧦ᣣᧄౝ⑼ቇળ⹺ቯක
ᅏ᧛⋥᮸㧦ᣣᧄᶖൻེᄖ⑼ቇળኾ㐷ක㧙㧙5㧚⥄Ꮖ⹏ଔ
⹏ଔᐕ‫⋵ޘ‬ౝᄖ߆ࠄߩᴦ≮ଐ㗬߇Ⴧടߒߡ޿ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ฃߌ౉ࠇ࿎㔍ߥ⁁ᴫ߇⊒↢ߒ㧘౉㒮ߦߟ޿ߡߪ৻ࡩ᦬ᓙߜߩ⁁ᘒߢ޽ࠆ‫ޕ‬น⢻ߥ㒢ࠅ౉㒮ᦼ㑆ࠍ⍴❗ߒ㧘ฃߌ౉ࠇᖚ⠪ᢙࠍჇ߿ߒߡ޿ࠆ‫ޕ‬੹ᓟߩዷᦸࠃࠅ቟ోߢ⏕ታߥᴦ≮ࠍ⋡ᜰߒ㧘ౣ⊒㒐ᱛ߽฽߼ߚోੱ⊛▤ℂࠍ⋡ᜰߔ‫ޕ‬㧙㧙㧔34㧕ࠛࠗ࠭ኻ╷ផㅴ࠮ࡦ࠲࡯
1㧚⸻≮ߩ᭎ⷐ
ࠛࠗ࠭⸻≮ߘߩ߽ߩߪ㧘ⴊᶧᗵᨴ∝ౝ⑼ࠍ⓹ญߣߒߡᜂᒰߐߖߡ㗂޿ߡ޿ࠆ߇㧘⸻≮਄ᔅⷐߦᔕߓߡ㧘
ઁ⑼ߩో㕙⊛ߥදജߩ߽ߣో⸻≮⑼߳ߩฃߌ౉ࠇ߽น⢻ߣߥߞߡ޿ࠆ‫ߚ߹ޕ‬㧘㊎ೝߒ੐᡿ߥߤߩᗵᨴኻ╷਄ߩⷰὐ߆ࠄ↢૕ᡰេ࠮ࡦ࠲࡯ߣߩදജ૕೙߽ਁోߢ޽ࠆ‫ޕ‬HIV ⸻≮ߪ㧘ᗵᨴߒߡ޿ࠆ߆ุ߆߆ࠄᆎ߹ࠆ‫ߚ߹ޕ‬ᗵᨴ߇᣿ࠄ߆ߦߥߞߚ႐วߪ㧘ߘߩᖚ⠪ߩ⁁ᘒߦᔕߓߡ᛫࠙ࠗ࡞ࠬ≮ᴺࠍ㐿ᆎߔࠆ‫ޕ‬ᣣ๺⷗ᗵᨴࠍ⊒∝ߒߚࠛࠗ࠭ߩ⁁ᘒߦ߅޿ߡߪᣣ๺⷗ᗵᨴߩᴦ≮߇ఝవߐࠇࠆ‫ޕ‬ᴦ≮ߪේೣߣߒߡᄖ᧪ߦߡⴕ޿㧘ᣣ๺⷗ᗵᨴࠍ⊒∝ߒߡ޿ࠆ႐วߦߪ౉㒮߇ᔅⷐߦߥࠆ߇㧘ᦨㄭߢߪᴦ≮߇ㅴᱠߒ㧘߶ߣࠎߤߩᖚ⠪ߪ␠ળᓳᏫน⢻ߢ޽ࠆ‫⥌߿ߪ߽ߪ࠭ࠗࠛߜࠊߥߔޕ‬ᱫ⊛ߥ∛᳇ߢߪߥߊᘟᕈ∔ᖚߣߒߡᝒ߃ࠄࠇࠆ‫ ߃ࠁࠇߘޕ‬HIV ⸻≮ߦߣߞߡ㊀ⷐߥߎߣߪ㧘කᏧߦࠃࠆ⸻≮ߩߺߥࠄߕ㧘ᖚ⠪ߩり૕⊛࡮♖␹⊛ࠤࠕߢ޽ࠅ㧘⋴⼔Ꮷߦࠃࠆ⸻≮ࠨࡐ࡯࠻㧘⮎೷Ꮷߦࠃࠆ᦯⮎ᡰេ㧘ኾ㐷ࠞ࠙ࡦ࠮࡜
࡯ߦࠃࠆࠞ࠙ࡦ࠮࡝ࡦࠣ૕೙ߩᢛ஻㧘࠰࡯ࠪࡖ࡞ࡢ࡯ࠞ࡯ߦࠃࠆ␠ળ⊛⑔␩ᡰេߥߤ߇᳞߼ࠄࠇ㧘ߎࠇࠄߩలታൻ߽㗅⺞ߦㅴࠎߢ߅ࠅ㧘ߘߩ૕೙ߪ߶߷⏕┙ߒߚ‫ޕ‬ᒰ㒮ߪᐔᚑ 7 ᐕ 5 ᦬ߦࠛࠗ࠭᜚ὐ∛㒮ߩᜰቯࠍฃߌ㧘ߐࠄߦᐔᚑ 19 ᐕ 12 ᦬ߦߪጘ㒂⋵ࠛࠗ࠭ᴦ≮ਛᩭ᜚ὐ∛㒮ߩᜰቯࠍฃߌߚ‫ߦࠇߎޕ‬ၮߠ߈ᐔᚑ 19 ᐕ 12 ᦬ߦጘ㒂ᄢቇකቇㇱ㒝ዻ∛㒮ࠛࠗ࠭ኻ╷ផㅴ࠮ࡦ࠲࡯߇⸳⟎ߐࠇ㧘ⴊᶧᗵᨴ∝ౝ⑼ਛᔃߩ⸻≮ߩߺߥࠄߕ㧘㒮ౝᄖ߳ߩᢎ⢒࡮⎇ୃᵴേ㧘ᖱႎឭଏᵴേߥߤ
߽ㅴ߼ߡ޿ࠆ‫ޕ‬
2㧚ᢎ⢒ᣉ⸳
1㧕 ጘ㒂⋵ࠛࠗ࠭ᴦ≮ਛᩭ᜚ὐ∛㒮
2㧕 ᣣᧄⴊᶧቇળ⹺ቯ⎇ୃ∛㒮
3㧚⸻≮㐿⊒
1㧕 ⸻≮ฬ 㧦ᒝജ᛫࠙ࠗ࡞ࠬ≮ᴺ㧔HAART㧕⸻≮ౝኈ㧦HIV ߦኻߔࠆ᛫࠙ࠗ࡞ࠬ≮ᴺ
ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦᰷☨ߢߩࠟࠗ࠼࡜ࠗࡦࠍෳ⠨ߦ૞ᚑߐࠇߚᧄ㇌ߢߩᴦ≮ࠟࠗ࠼࡜ࠗࡦߦḰ᜚ߒߡ㧘ࠛࠗ࠭᜚ὐ∛㒮ࠍਛᔃߦᣉⴕߐࠇߡ޿ࠆ‫ޕ‬࿖ౝ⊛⹏ଔ㧦ࠟࠗ࠼࡜ࠗࡦߢߪ޽ࠆ߇㧘ᧄ㗔ၞߩᴦ≮ᣇ㊎ߪ㧘᰷☨ߢߩᴦ㛎⚿ᨐߦࠃߞߡᲤᐕᄌᦝߐ
ࠇߡ޿ࠆ‫ᧄߜࠊߥߔޕ‬㗔ၞߩᴦ≮ߪ㧘ᣂⷙ⮎೷ߩዉ౉ߣߣ߽ߦᣣ‫ޘ‬ᄌㆫߒߡ߅ࠅ㧘ᮡḰᴦ≮ߩ⏕┙߹ߢߦߪ⥋ߞߡ޿ߥ޿‫ޕ‬࿖㓙⊛⹏ଔ㧦᰷☨ߢߩᴦ㛎⚿ᨐߦࠃߞߡࠟࠗ࠼࡜ࠗࡦߪᲤᐕᄌᦝߐࠇߡ޿ࠆ‫ޕ‬HIV ߦኻߔࠆ᛫࠙ࠗ࡞
ࠬ≮ᴺߪ㧘ㅴᱠߩ߼ߑ߹ߒ޿㗔ၞߢ޽ࠅ㧘⹏ଔߪ⛘߃ߕᄌേߒߡ޿ࠆ‫ޕ‬
4㧚ኾ㐷ක࡮⹺ቯක࡮ᜰዉක㢬⷗ ኼ㧦ᣣᧄౝ⑼ቇળ᧲ᶏ࿾඙⹏⼏ຬ࡮ᜰዉක࡮✚วౝ⑼ኾ㐷ක࡮ౝ⑼⹺ቯක㧘ᣣᧄⴊᶧቇળઍ⼏ຬ࡮ᜰዉක࡮ኾ㐷ක㧘ᣣᧄ⥃ᐥ⣲≌ቇળᥳቯᜰዉක࡮߇ࠎ⮎‛≮ᴺኾ㐷ක㧘ᣣᧄ߇ࠎᴦ≮⹺ቯකᯏ᭴ᥳቯᢎ⢒ක࡮⹺ቯක㧘ᣣᧄᶖൻེౝⷞ㏜ቇળኾ㐷ක㧘ᣣᧄ⥃ᐥౝ⑼කળኾ㐷ක
5㧚⥄Ꮖ⹏ଔ
⹏ଔࠛࠗ࠭ᴦ≮ߪએ೨ߪ․೎ߥක≮ᯏ㑐ߢߩߺⴕࠊࠇࠆߣᕁࠊࠇߡ޿ߚ߇㧘ᒰ㒮ߢߪᤘ๺ 63 ᐕߩ╙৻଀⋡ߩ∝଀߆ࠄ∛㒮ో૕ߣߒߡㅢᏱߩᖚ⠪ߣಽߌ㓒ߡߥߊ⸻≮ߢ߈ࠆ૕೙߇ߢ߈㧘߹ߚ⋵ౝߩᜰዉ⊛┙႐ߢ⸻≮ㅪ៤ߥߤ߇ߢ߈ࠆࠃ߁ߦߥߞߚߎߣߪ⹏ଔߢ߈ࠆߣᕁࠊࠇࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷੹ᓟᖚ⠪ߪჇടߔࠆߣᕁࠊࠇࠆ߇㧘ᧄ㗔ၞߦ⋥ធ៤ࠊࠆߎߣ߇ߢ߈ࠆኾ㐷ක≮ࠬ࠲࠶ࡈߩ⏕଻㧘లታ߇᳞߼ࠄࠇࠆ‫ޕ‬੹ᓟߩዷᦸ੹ᓟ㧘ጘ㒂⋵ߩߐࠄߥࠆࠛࠗ࠭⸻≮ߦ߅ߌࠆోੱ⊛ක≮૕೙ߩᢛ஻ࠍ⋡ᜰߒ㧘⡯ຬ߳ߩ HIV ᗵᨴ∝ߩᱜߒ޿⍮⼂ߩᶐㅘߣ⸻≮ᛛⴚะ਄ࠍផㅴߔࠆߣߣ߽ߦ㧘ࡉࡠ࠶ࠢ᜚ὐ∛㒮޽ࠆ޿ߪ࿾ၞߩઁߩක≮ᯏ㑐ߣߩㅪ៤ߥߤࠍࠃࠅ৻ጀలታൻߐߖߡ޿ߊ੍ቯߢ޽ࠆ‫ޕ‬㧙㧙㧔35㧕ಽᇂㇱ1㧚⸻≮ߩ᭎ⷐ
ߎࠇ߹ߢߣห᭽‫ޕ‬ᅧᆼ㜞ⴊ࿶∝୥⟲࡮♧ዩ∛࡮⥄Ꮖ఺∉∔ᖚ࡮ⴊᶧ∔ᖚ࡮⣲≌ߥߤว૬∝ᅧᆼߩ▤ℂ㧘
⢝ఽਛᨔ␹⚻♽࡮ᔃ⤳࡮⢖࡮⣻ㇱ࡮྾⢇࡮ⴊᶧߥߤߩ಴↢೨⸻ᢿߣ▤ℂ㧘ᅧᆼೋᦼߩᨴ⦡૕ᬌᩏ࡮ઍ⻢⇣Ᏹ⸻ᢿ㧔ዊఽ⑼ߣឭ៤㧕㧘⢝ఽሶችౝ⊒⢒ㆃᑧ࡮ᣧᦼ⊒∝෺⢝ఽ㑆ャⴊ∝୥⟲ߥߤࡂࠗ࡝ࠬࠢ⢝ఽ∝଀ߩ๟↥ᦼ▤ℂߥߤ࿾ၞක≮ᯏ㑐ߣߩㅪ៤ࠍขࠅߥ߇ࠄⴕߞߡ޿ࠆ‫ޕ‬ጘ㒂⋵๟↥ᦼක≮ߩᢇᕆ៝ㅍࡑ࠾ࡘࠕ࡞ߢߪ㧘ጘ㒂ᄢቇ∛㒮ߩ․⦡ࠍ↢߆ߒߡ㧘1. Უ૕ᢇ๮㧘2. ಴↢ផቯ૕㊀ 2500g એ਄ߩᣧ↥߅ࠃ߮ 3. ࠦࡦ࠻ࡠ࡯࡞࠲ࡢ࡯⊛ߥᓎഀࠍᜂߞߡ޿ࠆ‫ߩߎޕ‬ᢇᕆ૕೙ߪ⃻࿷໧㗴ߥߊⒿ௛ߒߡ޿ࠆ‫ޕ‬
2㧚ᢎ⢒ᣉ⸳
↥⑼ᇚੱ⑼ෳᾖ
3㧚⸻≮㐿⊒↥⑼ᇚੱ⑼ෳᾖ
4㧚ኾ㐷ක࡮⹺ቯක࡮ᜰዉක
↥⑼ᇚੱ⑼ෳᾖ
5㧚⥄Ꮖ⹏ଔ
⹏ଔว૬∝ᅧᆼߩ▤ℂ㧘಴↢೨⸻ᢿ㧘ࡂࠗ࡝ࠬࠢ⢝ఽ▤ℂߥߤߩ⸻≮ߪ࿾ၞ৻ᰴ࡮ੑᰴක≮ᯏ㑐ߩⷐ⺧ߦᔕ߃ߡ޿ࠆ‫ߚ߹ޕ‬㧘๟↥ᦼᲣ૕ᢇᕆࡑ࠾ࡘࠕ࡞ߩᓎഀ߽࠻࡜ࡉ࡞ߥߊⒿ௛ߒߡ޿ࠆ‫ߚ߹ޕ‬㧘⋵ో૕ߩ NICU
ਇ⿷ߩߚ߼㧘ಽᇂ߹ߢᓙᯏߢ߈ࠆ∝଀ߪᅧᆼㅳᢙ߇ዋߥߊߡ߽ฃߌ౉ࠇߡ߅ࠅ㧘⸻≮Ⓙ௛ߪ‫್ߣޠ⦟ޟ‬ᢿߐߖࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ጘ㒂ᄢቇ∛㒮ࠍ฽߼ߚ⋵ో૕ߩ NICU ਇ⿷߇⪺ߒߊ㧘ߎߩᢛ஻߇ఝవ⺖㗴ߢ޽ࠆ‫ߣࠇߘޕ‬ᐔⴕߒߡ㧘Ꮲ₺ಾ㐿ⴚߩჇടߦኻᔕߒߚᚻⴚᨒߩᡷༀ߇ᔅⷐߢ޽ࠆ‫ᦨߦᦝޕ‬ㄭ 5 ᐕ㑆ߢಽᇂᢙ߇ 1.5 ୚એ਄ߦჇടߒ
ߡ߅ࠅ㧘ߘࠇߣߣ߽ߦ↥⑼౉㒮ᖚ⠪ᢙߩჇട߇↥ᇚੱ⑼ో૕ߩ∛ᐥ▤ℂ਄ᄢ߈ߥ໧㗴ߣߥߞߡ޿ࠆ‫ߚ߹ޕ‬㧘࿾ၞක≮ᯏ㑐ߣߩ‫ߥ⊛ޠࡦࠗ࡜࠻࠶ࡎޟ‬ㅪ⛊✂ߩ᭴▽߽৻ᣇᴺ߆߽ߒࠇߥ޿‫ޕ‬੹ᓟߩዷᦸጘ㒂⋵๟↥ᦼක≮ߩਥߚࠆ৻ຬߣߒߡ㧘↥⑼ක≮ߩਛᔃࠍᜂ޿ߚ޿‫ߪߦ߼ߚߩߘޕ‬㧘ߎࠇ߹ߢ▽޿ߡ߈ߚᢇᕆ៝ㅍࡑ࠾ࡘࠕ࡞ࠍ⃻႐ߦೣߒߚࠃ߁ߦ㧘ᡷༀߒߡ޿߈ߚ޿‫ޕ‬㧙㧙㧔36㧕࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦㇱ1㧚⸻≮ߩ᭎ⷐ
ᒰㇱߪ㧘࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦኾ㐷කߩ߽ߣ 6 ੱߩℂቇ≮ᴺ჻ߣ 3 ੱߩ૞ᬺ≮ᴺ჻ߣ 2 ੱߩ⸒⺆⡬ⷡ჻ߢ࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦᴦ≮ߦᒰߚߞߡ޿ࠆ‫ޕ‬ᢛᒻᄖ⑼∔ᖚ㧘⣖ᄖ⑼∔ᖚ㧘๭ๆེ㧘ᓴⅣེ∔ᖚ㧘ዊఽ㧘␹⚻♽∔ᖚߩ࡝ࡂࡆ࡝ߦ⥋ࠆ᏷ᐢ޿ಽ㊁ߦขࠅ⚵ࠎߢ޿ࠆ‫ޕ‬߹ߚ㧘∔ᖚߦᔕߓߡ⿷ᐩ࿶᷹ቯ߿േ૞⸃ᨆ㧘ࠨ࡯ࡕࠣ࡜ࡈࠖ࡯㧘ࠛࠦ࡯ߥߤߩᬌᩏ᷹ቯࠍⴕ޿㧘ㆡಾߥ࡝ࡂࡆ࡝߇ⴕ߃ࠆࠃ߁⹏ଔߦᓎ┙ߡߡ޿ࠆ‫ޕ‬ቯᦼ⊛ߥ࡝ࡂࡆ࡝ࠞࡦࡈࠔ࡜ࡦࠬࠍߪߓ߼㧘㑐ㅪ∛㒮ߣߩീᒝળߥߤ࿾ၞߩ࡝ࡂࡆ࡝ᵴേߦⓍᭂ⊛ߦขࠅ⚵ߺ㧘㓚ኂ⠪ࠬࡐ࡯࠷ߣ޿ߞߚࡏ࡜ࡦ࠹ࠖࠕᵴേߦ߽ෳടߒ
ߡ޿ࠆ‫ޕ‬
2㧚ᢎ⢒ᣉ⸳
1㧕 ᣣᧄ࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦකቇળ⎇ୃᣉ⸳
2㧕 ℂቇ≮ᴺ჻㧘૞ᬺ≮ᴺ჻ታ⠌ᣉ⸳
3㧚⸻≮㐿⊒
1㧕 Ꮏቇㇱߣߩ౒ห㐿⊒ࠍߔߔ߼㧘਄⢇ᯏ⢻㓚ኂߦኻߒߡࠃࠅᣣᏱ↢ᵴേ૞ࠍะ਄ߐߖࠆߚ߼ߩࡠࡏ࠶࠻
ߩ㐿⊒ߦขࠅ⚵ࠎߢ޿ࠆ‫ߚ߹ޕ‬ᯏ⢻㓚ኂߦኻߔࠆ⸠✵ࡠࡏ࠶࠻ߩ㐿⊒߽ߔߔ߼ߡ޿ࠆ‫ޕ‬
2㧕 േ૞⸃ᨆࠍⴕ޿㧘࡝ࡂࡆ࡝ߩ⾰ะ਄߿㧘ᯏ⢻㓚ኂ߽ේ࿃ߩ⸃᣿ߦᓎ┙ߡߡ޿ࠆ‫ޕ‬
3㧕 ⿷ᐩ࿶᷹ቯ߿㧘㊀ᔃ᷹ቯ࡮ᱠⴕ⸃ᨆߦࠃࠆ㕦ⵝౕߩ㐿⊒࡮ᴦ≮ࠍᣉⴕߒߡ޿ࠆ‫ޕ‬4㧕 f-MRI ߦࠃࠅᯏ⢻ᡷༀߩ⹏ଔ߿੍ᓟ੍᷹࡮ᴦ≮ߩㅴ߼ᣇߥߤߩෳ⠨ߣߒߡ޿ࠆ‫ޕ‬5㧕 㖸ᭉ≮ᴺ߽ขࠅ౉ࠇᗧ⼂㓚ኂᖚ⠪ߩ⣖ೝỗᵴᕈᴦ≮ࠍᣉⴚߒߡ޿ࠆ‫ޕ‬
4㧚ኾ㐷ක࡮⹺ቯක࡮ᜰዉක
ᷡ᳓సᤨ㧦ᣣᧄᢛᒻᄖ⑼ቇળኾ㐷ක㧘ᣣᧄᢛᒻᄖ⑼ቇળ⹺ቯ⣄ᬁ⣄㜑∛ක㧘ᣣᧄ⣄ᬁ⣄㜑ቇળᜰዉක㧘ᣣᧄ࡝࠙ࡑ࠴ቇળኾ㐷ක⚦ᳯ⧷ᄦ㧦ᣣᧄߢᢛᒻᄖ⑼ቇળኾ㐷ක㧘ᣣᧄᢛᒻᄖ⑼ቇળ⹺ቯ⣄ᬁ⣄㜑∛ක㕍ᧁ㓉᣿㧦ᣣᧄ࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦቇળኾ㐷ක㧘ᜰዉක㧘ᣣᧄᢛᒻᄖ⑼ቇળኾ㐷ක㧘㓚ኂ⠪ࠬࡐ࡯࠷⹺ቯ
ක㧘ᣣᧄ૕⢒දળ౏⹺ࠬࡐ࡯࠷࠼ࠢ࠲࡯㧘࠼࡯ࡇࡦࠣࡔ࠺ࠖࠞ࡞ࠝࡈࠖࠨ࡯㧘ᣣᧄකᏧળஜᐽ
ࠬࡐ࡯࠷࠼ࠢ࠲࡯
5㧚⥄Ꮖ⹏ଔ
⹏ଔ1 ᣣ 18 න૏એ਄ߩᖚ⠪߳ߩ࡝ࡂࡆ࡝ኻᔕࠍⴕ޿㧘ᖚ⠪߳ߩ࡝ࡂࡆ࡝⹏ଔࠍᄙᣇ㕙߆ࠄขࠅ⚵ࠎߢ޿ࠆ‫ޕ‬⎇ⓥ㕙߿ⵝౕߩ㐿⊒㧘ቇળ⊒⴫ߦ߽Ⓧᭂ⊛ߦขࠅ⚵ߺ㧘㓚ኂ⠪߳ߩࡏ࡜ࡦ࠹ࠖࠕᵴേߦ߽ෳടߒߡ޿ࠆ‫ޕ‬߹ߚਛᩭ∛㒮ߣߒߡ࿾ၞߩ࡝ࡂࡆ࡝ᵴᕈൻࠍߪ߆ࠆߚ߼ߩീᒝળ߿⎇ⓥળࠍߔߔ߼ߡ޿ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷⃻࿷≮ᴺ჻ 1 ੱ޽ߚࠅ 1 ᣣ 18 න૏ࠍ⋡ᮡߣߒߡ޿ࠆ߇㧘ᖚ⠪ߦኻߔࠆ⸻≮ߪߘࠇએ਄ߢ޽ࠅ㧘ታ⾰ߩੱᢙߪዋߥ޿⁁ᘒߢⴕߞߡ޿ࠆ‫ޕ‬ᓴⅣེ࡝ࡂࡆ࡝ߦ㑐ߒߡߪ㧘ᓴⅣེౝ⑼ߣߩㅪ៤ߦࠃࠅᣉ⸳ࠍᢛ߃㧘ߔߔ߼ߡ޿ࠆᲑ㓏ߢ޽ࠆ‫ޕ‬੹ᓟߩዷᦸ੹ᓟࠬ࠲࠶ࡈߩలታࠍߐࠄߦߪ߆ࠅᣉ⸳ၮḰߩะ਄ࠍߪ߆ࠅ㧘ᖚ⠪߳ߩචಽߥ࡝ࡂࡆ࡝߇ߢ߈ࠆࠃ߁ദ
ജߔࠆ‫੹ޕ‬ᓟ߻߆߃ࠆ㜞㦂⠪␠ળߦ㧘ஜᐽኼ๮ߣߒߡߩ࡝ࡂࡆ࡝߇ឭଏߢ߈ࠆࠃ߁ߦߒߡࠁ߈ߚ޿‫ࠄߐޕ‬ߦ㓚ኂ⠪߳ߩࡏ࡜ࡦ࠹ࠖࠕᵴേߦ߽ෳടߒ㧘␠ળ⽸₂ߦ߽Ⓧᭂ⊛ߦขࠅ⚵ࠎߢࠁ߈ߚ޿‫ޕ‬㧙㧙㧔37㧕ක≮ᯏེ࠮ࡦ࠲࡯
1㧚⸻≮ߩ᭎ⷐ
ᐔᚑ 16 ᐕ㧘ᒰ㒮ߩᣂ∛㒮⒖ォߣหᤨߦ ME ࠮ࡦ࠲࡯ߣߒߡᧄᩰ⊛ߥⒿേࠍ㐿ᆎߒߚ‫ޕ‬㓸ਛᴦ≮߳ߩᛛⴚឭଏ㧘ᚻⴚᴦ≮߳ߩᛛⴚឭଏ㧘ක≮ᯏེߩਛᄩ▤ℂߥߤᄙߊߩᴦ≮߿ᯏེ▤ℂߦ⽸₂ߒߡ߈ߡ޿ࠆ‫ޕ‬ᢙᐕ೨߆ࠄߪ㧘ⴊᶧᵺൻቶᬺോ㧘ࡍ࡯ࠬࡔ࡯ࠞ࡯ᬺോ㧘ਇᢛ⣂ᴦ≮ߦ߅ߌࠆࠕࡉ࡟࡯࡚ࠪࡦᬺോࠍᣂߚߦ
ME ࠮ࡦ࠲࡯ᬺോߣߒߡㅊടߒߚ‫ޕ‬㓸ਛᴦ≮ㇱ㐷ߦ߅޿ߡߪ㧘㜞ᐲᢇ๮ᢇᕆ࠮ࡦ࠲࡯ߦ߅ߌࠆⴊᶧᵺൻᴦ≮ߦⓍᭂ⊛ߦขࠅ⚵ߺ㧘ᢌⴊ∝ߦኻߒߡߪ㧘DHP ߣ HDF ߩหᤨᴦ≮߇ᣉⴕน⢻ߥ․ᱶ࿁〝ࠍ૞ᚑߒ㧘᦭ലߥᴦ≮ࠍ⋡ᜰߒߡ޿ࠆ‫ޕ‬ᕆᕈᦼߦ߅ߌࠆⴊẏ੤឵≮ᴺߣߒߡ㧘PE ߢߪಽ㔌ਇน⢻ߥ㊀∝㜞⢽ⴊẏᖚ⠪ߦኻߒߡ㆙ᔃಽ㔌ᴺࠍ↪޿ߚⴊẏ੤឵≮ᴺࠍ⠨᩺ߒ㧘ᴦ≮ߦᚑഞߒߚ‫ߚ߹ޕ‬㧘⵬ഥᓴⅣ㧔PCPS㧘ECMO㧕ߩᴦ≮ߦ߽Ⓧᭂ⊛ߦෳടߒ㧘㜞ᐲᢇ๮ᢇᕆ࠮ࡦ࠲࡯ߩකᏧߣߣ߽ߦᴦ≮ߦ޽ߚߞߡ޿ࠆ‫⵬ޕ‬ഥᓴⅣߦ߅ߌࠆੱᎿ⢖ᯏ⢻ߩ㐳ᦼ⛽ᜬࠍ⋡ᮡߦ JV ࠍ↪޿ߚ O2 ࠦࡦ࠻ࡠ࡯࡞ߦขࠅ⚵ࠎߢ޿ࠆ‫ߚ߹ޕ‬㧘ੱᎿ๭ๆེ㔌⣕࿎㔍ߥᖚ⠪ߦኻߒ㧘㓁࡮㒶࿶ᑼ૕ᄖੱᎿ๭ๆེࠍ↪޿ߚ๭ๆ࡝ࡂࡆ࡝߽ታᣉߒߡ޿ࠆ‫ޕ‬ᚻⴚㇱ㐷߳ߩᛛⴚឭଏߣߒߡߪ㧘ᔃ⤳ᚻⴚߦ߅ߌࠆੱᎿᔃ⢖ᠲ૞㧘⥄Ꮖⴊᶧ࿁෼ᠲ૞㧘࡟࡯ࠩ࡯⸳ቯᠲ
૞ߥߤࠍⴕߞߡ޿ࠆ‫ੱޕ‬Ꮏᔃ⢖ᠲ૞ߪ㧘⿥ૐ૕᷷ᚻⴚߦ߅ߌࠆ⣖ಽ㔌ᚻⴚߥߤ․ᱶߥᠲ૞ᛛⴚࠍᔅⷐߣߔ
ࠆᚻⴚ߽ᄙߊ㧘ಽ㔌ᣇᴺߦࠃࠆⴊᵹ㊂⏕଻ߦ㑐ߒߡ㧘ME ࠮ࡦ࠲࡯⁛⥄ߦ⠨᩺ߒߚ࠺ࡃࠗࠬࠍ૶↪ߒ㧘቟ቯߒߚᚻᴺࠍ↪޿ࠆߎߣ߇น⢻ߣߥߞߡ޿ࠆ‫ߚ߹ޕ‬㧘CABG ߢߪ㧘Off Pomp ᚻⴚ߇ᄙ޿߇㧘ᕆㆰੱᎿᔃ
⢖߇ᔅⷐߦߥߞߚ႐วߢ߽㧘ㄦㅦߦ࿁〝Ḱ஻ࠍⴕ޿㧘ࠨ࠶ࠞ࡯㧘ࡌࡦ࠻߇૶↪น⢻ߥᄢቇ∛㒮⁛⥄ߩඨ㐽㎮࿁〝ࠍ⠨᩺ߒ㧘ᚻⴚߦᦸࠎߢ޿ࠆ‫ޕ‬ක≮ᯏེਛᄩ▤ℂߢߪ㧘ME ࠮ࡦ࠲࡯⊒⿷ᤨߪ㧘ੱᎿ๭ๆེ㧘ャᶧࡐࡦࡊ㧘ࠪ࡝ࡦࠫࡐࡦࡊߥߤߩ▤ℂ߆ࠄᆎ߹ࠅ㧘⃻࿷ߢߪ㧘ᯏ⒳ࠍჇᄢߒߡ▤ℂࠍⴕߞߡ޿ࠆ‫▤ޕ‬ℂᒰೋߪ㧘ක≮ᯏེߩᛠីߣ⛔৻㧘Ⓙ௛₸਄᣹㧘ᶖ⠻ຠ⛔৻ߥߤࠍ⋡ᮡߣߒߡ޿ߚ߇㧘੹ᣣ㧘ක≮ᯏེߩ቟ో╬߇㊀ⷐⷞߐࠇߡ޿ࠆߚ߼㧘▤ℂ㗄⋡ߩਛߦᓥ᧪ߩ૶↪ὐᬌ㧘᡿㓚ὐᬌ㧘ୃℂὐᬌߦട߃ߡ㧘ක≮ᯏེߩቯᦼὐᬌ㧘ቯᦼㇱຠ੤឵ߩ㗄⋡ࠍขࠅ౉ࠇߡ޿ࠆ‫ߦࠄߐޕ‬㧘ቯᦼὐᬌౝኈߣߒߡ㧘㔚᳇⊛቟ో࠴ࠚ࠶߽ࠢขࠅ౉ࠇ㧘ṳ㔚ᵹߥߤߩኻ╷߽ⴕߞߡ޿ࠆ‫ޕ‬ⴊᶧᵺൻቶᬺോߪ㧘ᘟᕈㅘᨆᖚ⠪ߦ߅ߌࠆᚻⴚᓙᯏᖚ⠪ࠍኻ⽎ߦㅘᨆࠍⴕߞߡ޿ࠆ‫ޕ‬ᔃ⤳∔ᖚ߿ᶖൻེ
♽ߦ߅ߌࠆᚻⴚᖚ⠪߽ᄙߊ㧘㕖Ᏹߦㅘᨆ࿎㔍ߥᖚ⠪ߦኻߒߡㅘᨆᴦ≮ࠍᣉⴕߒߡ޿ࠆ‫ߚ߹ޕ‬㧘ㅘᨆ࿎㔍∝଀ߩᖚ⠪߳ߩᴦ≮ㆬᛯߣߒߡ㧘HF㧘HDF ࠍߪߓ߼㧘ή㈶㉄ㅘᨆߩᴦ≮߽ᣉߖࠆࠃ߁ᛛⴚขᓧ㧘ⵝ⟎ᢛ஻ࠍⴕߞߡ޿ࠆ‫ޕ‬ࡍ࡯ࠬࡔ࡯ࠞ࡯ᬺോߣߒߡߪ㧘ၒ߼ㄟߺⴚࠍߪߓ߼ߣߒߡ㧘ᄖ᧪ࡍ࡯ࠬࡔ࡯ࠞ࡯࠴ࠚ࠶ࠢ㧘ࡍ࡯ࠬࡔ࡯
ࠞ࡯ၒ߼ㄟߺᖚ⠪ߩᚻⴚኻᔕ࠴ࠚ࠶ࠢ╬߽ᔅⷐߦᔕߓߡⴕߞߡ޿ࠆ‫ޕ‬ਇᢛ⣂ᴦ≮ߦ߅޿ߡߪ㧘ࠕࡉ࡟࡯ࠪ
࡚ࡦᴦ≮ߦ߅ߌࠆ⸃ᨆⵝ⟎㧘಴ജⵝ⟎ߩᠲ૞ࠍⴕߞߡ޿ࠆ‫ޕ‬
2㧚ᢎ⢒ᣉ⸳
1㧕 ᧲ᶏක≮⑼ቇኾ㐷ቇᩞ࡮⥃ᐥᎿቇ⑼⥃ᐥታ⠌ᣉ⸳
2㧕 ㋈㣮ක≮⑼ቇᄢቇ࡮⥃ᐥᎿቇ⑼⥃ᐥታ⠌ᣉ⸳
3㧚⸻≮㐿⊒
ߥߒ4㧚ኾ㐷ක࡮⹺ቯක࡮ᜰዉක
ᨹේ೑⥋㧦ᣣᧄੱᎿ⤳ེቇળ࡮૕ᄖᓴⅣᛛⴚ⹺ቯ჻㧘ME ቇળ࡮ME2 ⒳ᛛⴚ⹺ቯ჻
ᩊ↰ౖኼ㧦ME ቇળ࡮ME2 ⒳ᛛⴚ⹺ቯ჻
๺↰ౖሶ㧦ME ቇળ࡮ME2 ⒳ᛛⴚ⹺ቯ჻
ᄢ᫪┨ੑ㧦ME ቇળ࡮ME2 ⒳ᛛⴚ⹺ቯ჻
ᩑ↰⧷⊓㧦ME ቇળ࡮ME2 ⒳ᛛⴚ⹺ቯ჻
5㧚⥄Ꮖ⹏ଔ
⹏ଔකᏧߣߣ߽ߦᴦ≮ߦ޽ߚࠅ㧘ME ࠮ࡦ࠲࡯⁛⥄ߦᒰ⇟೙㧔ࠝࡦࠦ࡯࡞૕೙㧕ࠍᢛ߃ࠆߎߣߢ㧘ᢇᕆᖚ⠪ߦኻᔕߔࠆߎߣ߇น⢻ߣߥߞߡ޿ࠆ‫ޕ‬ਛᄩ▤ℂߦ߅޿ߡ߽ቯᦼὐᬌ㧔3 ࡩ᦬㧘ඨᐕ㧘1 ᐕ㧕ࠍⴕ߁ߎߣߢ
ක≮ᯏེߩ૶↪㗫ᐲࠍᛠីߒ㧘቟ోᕈߥߤߩ⏕଻߇น⢻ߣߥߞߡ޿ࠆ‫ޕ‬㓸ਛᴦ≮㗔ၞߦ߅޿ߡᕆᕈⴊᶧᵺ

㧙㧙ൻߪᰳ߆ߖߥ޿߽ߩߣߥߞߡ߅ࠅ㧘ᄙ⒳ᄙ᭽ߩᴦ≮ᛛⴚឭଏ߇ⴕ߃ࠆࠃ߁ߦᛛⴚะ਄ߦദ߼ߡ߈ߚ‫ޕ‬ਇᢛ⣂ᴦ≮߅ࠃ߮ࡍ࡯ࠬࡔ࡯ࠞ࡯ᬺോߪ㧘ኾዻߩࠬ࠲࠶ࡈࠍ⟎߈ᛛⴚ⠌ᓧߦ⽸₂ߢ߈ߡ޿ࠆߣ޿߃ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷⃻࿷㧘∛㒮ౝߦ߅ߌࠆ ME ࠮ࡦ࠲࡯ߩ૏⟎ߠߌߪਇ᣿⏕ߥ߽ߩߣߥߞߡ޿ࠆ‫੹ޕ‬ᓟ㧘ක≮ᯏེ߇⊒ዷߔࠆߣߣ߽ߦ㧘ᠲ૞ߔࠆੱ᧚ߩ⏕଻ߣᛛⴚ⏕଻߇ᔅⷐߣߥࠆߚ߼㧘∛㒮ౝߢߩ૏⟎ߠߌࠍ⏕┙ߒ㧘⥃ᐥᎿቇᛛ჻ߩჇຬ㧘⚵❱૞ࠅࠍㅴ߼ߡ޿߆ߥߌࠇ߫ߥࠄߥ޿‫ߪߦࠄߐޕ‬㧘ᛛⴚะ਄ߩߚ߼ߦቇળ㧘ᛛⴚ⻠⠌ળߥߤߩ߳ߩෳട߽Ⓧᭂ⊛ߦⴕ߁ᔅⷐ߇޽ࠆ‫ޕ‬㓸ਛᴦ≮ቇળ㧘ᣣᧄ૕ᄖᛛⴚቇળ㧘⥃ᐥᎿቇᛛ჻ળߥߤߩ߳Ṷ㗴㧘ࠪࡦࡐࠫ࠙ࡓߥߤߩෳടߪ޽ࠆ߇㧘੹ᓟኾ㐷⥃ᐥᎿቇᛛ჻ࠍ⊒⿷ߔࠆߦ޽ߚࠅ㧘ㅘᨆᛛⴚ⹺ቯ჻㧘ੱ
Ꮏ๭ๆ≮ᴺ⹺ቯ჻㧘૕ᄖᓴⅣ⹺ቯ჻ߣ޿ߞߚ⾗ᩰࠍขᓧߔࠆߚ߼ߦ㧘ቇળ߿࠮ࡒ࠽࡯╬߳ߩෳടࠍଦߒߡ
޿ߊߴ߈ߢ޽ࠆ‫ޕ‬੹ᓟߩዷᦸME ࠮ࡦ࠲࡯ߩ૏⟎ߠߌ㧘ᬺോౝኈࠍ᣿⏕ߥ߽ߩߣߒ㧘ᬺോߩㆀⴕࠍㄦㅦߥ߽ߩߣߒߡ޿ߊ‫ߚ߹ޕ‬㧘੹ᓟ㧘ᔃ⤳ࠞ࠹࡯࠹࡞ᬺോ߳ߩෳടߩჿ߽ᄙߊ㧘ᛛⴚឭଏࠍ⠨ᘦߒߡ޿ߊ‫ޕ‬㧙㧙㧔38㧕ᴦ㛎▤ℂ࠮ࡦ࠲࡯1㧚⸻≮ߩ᭎ⷐ
ᣂߒ޿ක⮎ຠߩ㐿⊒㧘ߔߥࠊߜᴦ㛎ߪ㧘ੱ㘃ߩஜᐽࠍ଻ߟߚ߼ߦᄢಾߥᓎഀࠍᨐߚߒߡ޿ࠆ‫ߥߒ߆ߒޕ‬߇ࠄ㧘ߎࠇࠄߩ⎇ⓥߪᦨ⚳⊛ߦࡅ࠻ࠍኻ⽎ߣߒߚ⹜㛎ߢ޽ࠆߚ߼㧘ᘕ㊀ߦታᣉߒߥߌࠇ߫ߥࠄߥ޿‫ޕ‬ෘ↢ഭ௛⋭ߪ㧘ᐔᚑరᐕߦ GCP㧔ක⮎ຠߩ⥃ᐥ⹜㛎ߩታᣉߦ㑐ߔࠆၮḰ㧕ࠍ⸳ߌ㧘ᦝߦᴦ㛎ߩ࿷ࠅᣇࠍᡷༀ
ߔࠆߚ߼ߦᐔᚑ 9 ᐕ 3 ᦬ߦᣂ GCP ࠍቯ߼㧘ᐔᚑ 10 ᐕ 4 ᦬ߦቢోᣉⴕߐࠇߚ‫ߡߒߘޕ‬㧘කᏧਥዉߩᴦ㛎߇೙ᐲൻߦ㑐ߔࠆⷙቯ߅ࠃ߮ᴦ㛎ᣉ⸳ᡰេᯏ㑐㧔SMO㧕ߩⷙቯ߇⋓ࠅㄟ߹ࠇߚᡷᱜ⋭઎ GCP ߇ᐔᚑ 15ᐕ 6 ᦬ߦᣉⴕߐࠇߚ‫ߪ⊛⋡ߩߘޕ‬㧘ᴦ㛎ߦ߅ߌࠆ⑼ቇᕈߩะ਄㧘࿖㓙⊛ߥ⹏ଔߦ⠴߃ࠆᴦ㛎㧘ߘࠇߦၮߠ
޿ߚ࿖㓙㑆ߩදജ㧘ߔߥࠊߜࡂ࡯ࡕ࠽ࠗ࠯࡚ࠗࠪࡦߩ⏕┙㧘ᦝߦ㊀ⷐߥߎߣߣߒߡⵍ㛎⠪ߩੱᮭ଻⼔ߩᒝൻߢ޽ࠆ‫ᧄޕ‬㒮ߦ߅޿ߡ߽㧘ᐔᚑ 14 ᐕ 4 ᦬ߦᴦ㛎▤ℂቶࠍ⊒ዷ⊛ߦ⸃ᶖߒ㧘ᴦ㛎▤ℂ࠮ࡦ࠲࡯ࠍ㒮ౝភ⟎ߢ⸳⟎ߒߚ‫ޕ‬ᴦ㛎▤ℂ࠮ࡦ࠲࡯ߢߪ㧘ⵍ㛎⠪ߩੱᮭ߿቟ోࠍ቞ࠅ㧘ㆡᱜ߆ߟ౞Ṗߦᴦ㛎߇ታᣉߐࠇࠆࠃ
߁ߦᡰេߒߡ޿ࠆ‫ޕ‬
2㧚ᢎ⢒ᣉ⸳
1㧕 ᣣᧄක≮⮎ቇળ⹺ቯ⮎೷Ꮷ೙ᐲ⎇ୃᣉ⸳
3㧚⸻≮㐿⊒
ߥߒ4㧚ኾ㐷ක࡮⹺ቯක࡮ᜰዉක
દ⮮ༀⷙ㧦ᣣᧄක≮⮎ቇળ⹺ቯ⮎೷Ꮷ࡮ᜰዉ⮎೷Ꮷᓟ⮮ජኼ㧦ᣣᧄක≮⮎ቇળ⹺ቯ⮎೷Ꮷ࡮ᜰዉ⮎೷Ꮷ㧘ICD㧘ᗵᨴ೙ᓮኾ㐷⮎೷Ꮷ㧘⹺ቯታോታ⠌ᜰዉ⮎೷Ꮷ⮮੗߆߅ࠅ㧦ᣣᧄ↢⮎ቇળṽᣇ⮎࡮↢⮎⹺ቯ⮎೷Ꮷ㧘ᣣᧄ⥃ᐥ⮎ℂቇળ⹺ቯ CRC
⷏၂⟤ᄹሶ㧦ᣣᧄ↢⮎ቇળṽᣇ⮎࡮↢⮎⹺ቯ⮎೷Ꮷ
5㧚⥄Ꮖ⹏ଔ
⹏ଔᴦ㛎▤ℂ࠮ࡦ࠲࡯ߦ߅޿ߡ㧘∛㒮ߩ㔚ሶࠞ࡞࠹ࠪࠬ࠹ࡓࠍᵴ↪ߒ㧘ᐔᚑ 18 ᐕ 1 ᦬߆ࠄᐔᚑ 20 ᐕ 12 ᦬ߩᦼ㑆ߦ DOCVIEW27 ࠪ࡯࠻㧘࠹ࡦࡊ࡟࡯࠻ 366 ࠪ࡯࠻㧘ࠢ࡝࠾ࠞ࡞ࡄࠬ 42 ࡄࠬࠍ૞ᚑߒ㧘ࡊࡠ࠻ࠦ࡯࡞ㆩ቞ߦਥ⌒ࠍ⟎߈㧘ᴦ㛎ߩታᣉࠍࠬࡓ࡯࠭ߦⴕߞߡ߈ߚ‫ߚ߹ޕ‬㧘ᐔᚑ 20 ᐕߦߪ㧘ᴦ㛎ࠍⴕߥ߁ߎߣ
߇಴᧪ࠆකᏧࠍ⢒ߡࠆߚ߼ߦ㧘ᴦ㛎࠮ࡒ࠽࡯ࠍ 3 ࿁㐿௅ߒ㧘34 ฬߩಽᜂකᏧߩ⾗ᩰࠍ᦭ߒߚකᏧࠍ⢒ᚑߒ㧘ᴦ㛎ታᣉ૕೙ߩᒝൻࠍⴕߥߞߚ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ᴦ㛎ߩฃ౉ઙᢙ߇㧘ᐔᚑ 16 ᐕߩ⒖ォએ᧪ᮮ߫޿⁁ᘒߢ޽ࠅ㧘ᴦ㛎ታᣉකᏧᢙ߽ᮮ߫޿ߩ⁁ᘒ߇⛯޿ߡ޿ࠆ‫ޕ‬⸃ᶖ╷ߣߒߡ㧘ᴦ㛎ಽᜂකᏧ⢒ᚑߩߚ߼㧘ᓥ᧪߹ߢಽᜂකᏧߩ᦭⾗ᩰߪකᏧ⚻㛎 7 ᐕࠍᔅⷐߣߒߡ޿ߚ
߇㧘ᐔᚑ 20 ᐕߦᴦ㛎࠮ࡒ࠽࡯ࠍ㐿௅ߒ㧘࠮ࡒ࠽࡯ฃ⻠⠪ߪ㧘කᏧ⚻㛎 2 ᐕߢᴦ㛎ࠍᜂᒰߢ߈ࠆㆇ↪ߣߒߚ‫੹ޕ‬ᓟ߽㧘ᴦ㛎ฃ౉ઙᢙჇടߦะߌ㧘ᴦ㛎ฃ౉૕೙ߩ᦭ലߥᢛ஻㧘ฦ⸻≮⑼߳ᴦ㛎ฃ౉ߩଦㅴ㧘ᴦ㛎ଐ㗬⠪߳ᴦ㛎ଐ㗬ߩଦㅴࠍ࿑ࠆ‫ޕ‬੹ᓟߩዷᦸᴦ㛎ࠍታᣉߔࠆ਄ߢ㧘⾰ߩ㜞޿࠺࡯࠲ࠍᓧ㧘ᣧߊᴦ㛎ࠍታᣉߔࠆߎߣ߇㊀ⷐߥߚ߼㧘੹ᓟ߽ࠢ࡝࠾ࠞ࡞
ࡄࠬࠍࡈ࡞ߦᵴ↪ߒ㧘DOCVIEW㧘࠹ࡦࡊ࡟࡯࠻ࠍᏁߺߦᔕ↪ߒߡ㧘ᴦ㛎࠺࡯࠲ߩࠞ࡞࠹߳ߩ⸥タࠍ◲ଢ߆ߟ⹦⚦ߦⴕ޿㧘⾰ߩ㜞޿࠺࡯࠲ࠍᱷߔ‫ޕ‬߹ߚ㧘ࠢ࡝࠾ࠞ࡞ࡄࠬࠍᔕ↪ߔࠆߎߣߢ㧘ᴦ㛎ߩታᣉࠍ◲ଢߦߒߡ㧘ᴦ㛎ታᣉ⚳ੌ߹ߢߩᦼ㑆ߩ⍴❗ࠍ⋡ᜰߔߚ߼㧘੹ᓟ㧘⸻≮⑼߳ߩࠢ࡝࠾ࠞ࡞ࡄࠬߩᵴ↪ߩ໪⫥ࠍⴕ߁‫ޕ‬એ਄ߦࠃࠅ㧘ᧄ㒮߳ߩᴦ㛎ታᣉⷐ⺧߇ᄙߊߥࠆߣ੍ᗐߐࠇࠆߚ߼㧘ᦝߥࠆᴦ㛎ታᣉ૕೙ߩᡷༀ෸߮ᴦ㛎ࠦ࡯࠺ࠖࡀ࡯࠲࡯ߩ㈩⟎ࠍ࿑ࠆᔅⷐ߇޽ࠆ‫ޕ‬㧙㧙㧔39㧕㜞ᰴ↹௝⸻ᢿ࠮ࡦ࠲࡯
1㧚⸻≮ߩ᭎ⷐ
ጘ㒂⋵ߦ߅ߌࠆ㜞ᐲ߆ߟవㅴ⊛ߥ↹௝⸻ᢿߩ᜚ὐߣߒߡ㧘㜞♖ᐲߥ↹௝⸻ᢿࠍᣣ‫ޘ‬ឭଏߔࠆߎߣߦࠃࠅ㧘࿾ၞක≮ㅪ៤ࠍផㅴߔࠆߎߣࠍ૶๮ߣߒߡ޿ࠆ‫ޕ‬ᄙ೉ᬌ಴ེ CT㧘3Tesla ⵝ⟎ࠍ฽߻㜞⏛႐ MRI㧘PET/CTⵝ⟎߿ SPECT/CT ⵝ⟎ࠍ฽߻ᩭකቇ⸻ᢿⵝ⟎㧘੃ᚱ X ✢᠟ᓇⵝ⟎㧘IVR-CT ࠍ↪޿ߡ㧘35 ฬߩ⸻≮᡼኿✢ᛛᏧߣ 13 ฬߩ᡼኿✢↹௝⸻ᢿක㧔ౝ 9 ฬߪ᡼኿✢⑼ኾ㐷ක㧘1 ฬߪ᡼኿✢⑼⹺ቯක㧕߇㜞᳓Ḱߩኾ㐷ᕈࠍ߽ߞߡᬌᩏ࡮⺒ᓇߦ޽ߚࠅ㧘⹦⚦߆ߟࠊ߆ࠅ߿ߔ޿↹௝⸻ᢿႎ๔ᦠࠍᣣ‫ޘ‬ឭଏߒߡ޿ࠆ‫ߚ߹ޕ‬㧘ක≮ㅪ៤࠮ࡦ࠲࡯ࠍ੺ߒ㧘ㄭ㓞∛㒮߆ࠄߩ CT ෸߮ MRI ᬌᩏ㧘FDG-PET/CT ߦࠃࠆ߇ࠎ⸻≮㧘↹௝⸻ᢿߦ㑐ߔࠆߏ⋧⺣ߦ߽ኻᔕߒߡ޿ࠆ‫ޕ‬㜞ᰴᢇ๮ᴦ≮࠮ࡦ࠲࡯ߣ౒หߢ✕ᕆ៝ㅍᖚ⠪ߩ⸻≮ߦᒰߚࠅ㧘24 ᤨ㑆ᘒ൓ߢ IVR ᬌᩏ࡮ᴦ≮ߦᒰߚߞߡ޿ࠆ‫ޕ‬↹௝⸻ᢿߦ㑐ߔࠆ↢ᶦቇ⠌ࠍ⋡⊛ߣߒߡ㧘ઁ⑼කᏧࠍ฽߻㒮ౝ࡮㒮ᄖකᏧ෸߮ቇ↢ࠍኻ⽎ߦ㧘ࠗࡦ࠲࡯ࡀ࠶࠻ߩࡆ࠺ࠝળ⼏ࠪࠬ࠹ࡓࠍ↪޿ߚઁ∛㒮ߣߩวห↹௝ࠞࡦࡈࠔ࡟ࡦࠬࠍᲤᣣ 45 ಽ㑆ታᣉߒߡ޿ࠆ‫ޕ‬
2㧚ᢎ⢒ᣉ⸳
1㧕 ᡼኿✢⑼ኾ㐷කୃ✵ᯏ㑐
2㧕 ᣣᧄᩭකቇળኾ㐷කᢎ⢒∛㒮
3㧚⸻≮㐿⊒
1㧕 ⸻≮ฬ 㧦CT colonography⸻≮ౝኈ㧦ᄙ೉ᬌ಴ဳ CT㧔MDCT㧕ࠍ↪޿ߡ㧘ᄢ⣺ࠍⷰኤߔࠆᚻᴺߢ޽ࠆ‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦࿖┙߇ࠎ࠮ࡦ࠲࡯ਛᄩ∛㒮ߦ߅޿ߡ㧘ᄢ⣺߇ࠎⴚ೨♖ᩏߣߒߡዉ౉ߐࠇߡ޿ࠆ‫ޕ‬
ක≮ᴺੱጊਅ∛㒮ߦ߅޿ߡ㧘࠼࠶ࠢߦዉ౉ߐࠇߡ޿ࠆ‫ޕ‬࿖ౝ⊛⹏ଔ㧦ᣣᧄ࿖ౝߢߪዉ౉ᣉ⸳ߪዋߥߊᦨవ┵ߩᬌᩏᚻᴺߢ޽ࠆ‫੹ޕ‬ᓟ⊒ዷߔࠆಽ㊁ߢ޽ࠆߣᕁ
ࠊࠇࠆ‫ޕ‬
࿖㓙⊛⹏ଔ㧦☨࿖ߢߪᄢ⣺߇ࠎࠬࠢ࡝࡯࠾ࡦࠣࠍ⋡⊛ߣߒߡ⎇ⓥ߇ㅴࠎߢ߅ࠅ㧘multicenter trial ߥߤߦࠃࠅ㧘ᄢ⣺ࡐ࡝࡯ࡊᬌ಴ߦ㑐ߔࠆᬌ⸛߇⋓ࠎߢ޽ࠆ‫⧷ޕ‬࿖ߢߪ㧘᦭∝⁁⠪ߦኻߔࠆᄢ
⣺߇ࠎ♖ᩏ⋡⊛ߦዉ౉ߐࠇߡ޿ࠆ‫ޕ‬
4㧚ኾ㐷ක࡮⹺ቯක࡮ᜰዉක
౗᧻㓷ਯ㧦ᣣᧄකቇ᡼኿✢ቇળኾ㐷ක㧘ᣣᧄⴊ▤ㅧᓇ࡮IVR ቇળᜰዉක
ᵻ㊁㓉ᒾ㧦ᣣᧄකቇ᡼኿✢ቇળኾ㐷ක㧘ᣣᧄᩭකቇળ PET ᩭකቇ⹺ቯක㧘ᣣᧄᩭකቇળᩭකቇኾ㐷කട⮮ඳၮ㧦ᣣᧄකቇ᡼኿✢ቇળኾ㐷ක㧘ᣣᧄᩭකቇળ PET ᩭකቇ⹺ቯක㧘ᣣᧄⴊ▤ㅧᓇ࡮IVR ቇળᜰዉක
5㧚⥄Ꮖ⹏ଔ
⹏ଔ
ᐔᚑ 20 ᐕᐲࠃࠅዉ౉ߐࠇߚ↹௝▤ℂട▚ 2 ߩ▚ቯࠍḩߚߔߴߊ㧘CT࡮MRI࡮RI ᬌᩏߩ 80%એ਄ࠍ᡼኿✢⑼ኾ㐷කߦࠃࠆ⺒ᓇࠍⴕߞߡ޿ࠆ‫ޕ‬✕ᕆ IVR ᬌᩏ࡮ᴦ≮ߦࠃࠅ㧘ᄙߊߩᢇᕆ៝ㅍᖚ⠪ߩᢇ๮ߦ⽸₂ߒߡ޿ࠆ‫ޕ‬ක≮ㅪ៤࠮ࡦ࠲࡯ࠍ੺ߒߚ∛⸻ㅪ៤ߦࠃࠆᄙ೉ CT ᬌᩏ㧘㜞⏛႐ MRI ᬌᩏ㧘FDG-PET/CT ᬌᩏߪ㧘ㄭ㓞∛㒮࡮ක㒮ࠃࠅᄙߊߩᬌᩏଐ㗬ࠍฃߌߡ߅ࠅ㧘ᬌᩏᒰᣣߥ޿ߒߪ⠉ᣣߦ↹௝⸻ᢿႎ๔ᦠࠍ㈩ାߒߡ޿ࠆ‫ޕ‬Ფᣣߩઁ∛㒮ߣߩวห↹௝ࠞࡦࡈࠔ࡟ࡦࠬߪ㕖Ᏹߦᅢ⹏ߢ޽ࠅ㧘㒮ౝߩቇ↢ߩߺߥࠄߕ㧘㒮ᄖታ⠌ਛߩቇ↢߿㧘ೋᦼ⥃ᐥ⎇ୃකߥߤߩෳട߇ᄙᢙ⷗ࠄࠇࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷᡼኿✢⑼ක߇ CT࡮MRI ෸߮ᩭකቇᬌᩏቶߦᏱ㚢ߒ㧘ㅧᓇᬌᩏ߿⮎೷ᛩਈߦᒰߚߞߡ߅ࠅ㧘කᏧߦߒ߆
ߢ߈ߥ޿ᬺോߩㆃṛߩⷐ࿃ߣߥߞߡ޿ࠆ‫ޕ‬ᧄᐕᐲࠃࠅዉ౉ߐࠇߚ↹௝▤ℂട▚ 2 ߩ▚ቯࠍḩߚߔߚ߼㧘⺒ᓇᬺോߦㅊࠊࠇ㧘᡼኿✢⑼කߩ∋ᑷ߇ ᔨߐࠇࠆ‫ޕ‬✕ᕆ IVR ᬌᩏ࡮ᴦ≮ߩߚ߼㧘ጘ㒂⋵ਛ߆ࠄᢇᕆᖚ⠪߇៝ㅍߐࠇߡ޿ࠆ߇㧘ᐕ‫ޘ‬Ⴧട௑ะߦ޽ࠅ㧘IVR
ᣉⴕකߩ⽶ᜂ߇Ⴧᄢߒߡ޿ࠆ‫ޕ‬㧙㧙੹ᓟߩዷᦸ
ᐔᚑ 21 ᐕ 4 ᦬ߦߪ㧘64 ೉ CT ⵝ⟎ࠍዉ౉ߒ㧘ᧄᩰ⊛ߦᔃ⤳ CT ߩⒿേࠍ੍ቯߒߡ޿ࠆ‫ޕ‬੹ᓟ㧘ߐࠄߦᛛᏧ㧘⋴⼔Ꮷ㧘කᏧߩੱ⊛⏕଻ࠍ⋡ᜰߒ㧘ᣂߒ޿ⵝ⟎ߩዉ౉ࠍ࿑ࠅ㧘㜞ᐲ߆ߟవㅴ⊛ߥ↹௝⸻ᢿࠍ⛮⛯ߒߡ޿ߊᚲሽߢ޽ࠆ‫ޕ‬㧙㧙㧔40㧕⮎೷ㇱ
1㧚⸻≮ߩ᭎ⷐ
⮎೷ㇱߢߪ⮎೷ឭଏߦ߅ߌࠆ቟ో⏕଻ߣኾ㐷ᕈࠍᵴ߆ߒߚ࠴࡯ࡓක≮߳ߩ⽸₂ࠍၮᧄℂᔨߣߒߡᓥ᧪
߆ࠄⴕߞߡ߈ߚ⺞೷㧘⮎೷▤ℂᜰዉ㧔᦯⮎ᜰዉ㧕㧘ᵈ኿೷⺞⵾㧘ක⮎ຠᖱႎឭଏ㧘⮎‛ⴊਛỚᐲ⸃ᨆ㧘㒮ౝ⵾೷㧘⮎ຠ▤ℂ㧘ᴦ㛎▤ℂߥߤߩᬺോߪ߽ߣࠃࠅࠗࡦࡈࠚ࡚ࠢࠪࡦࠦࡦ࠻ࡠ࡯࡞࠴࡯ࡓ㧔ICT㧕㧘ᩕ㙃ࠨࡐ࡯࠻࠴࡯ࡓ㧔NST㧕㧘✭๺ࠤࠕ࠴࡯ࡓߥߤߩ࠴࡯ࡓක≮ߩ৻ຬ߽ᜂߞߡ޿ࠆ‫ߪߦࠄߐޕ‬㧘ᄖ᧪ൻቇ≮ᴺቶ㧘♧ዩᢎቶ㧘ὐ⌒ᢎቶ߽߳Ⓧᭂ⊛ߦ㑐ࠊࠆߎߣߦࠃߞߡ㧘㒮ౝߩฦㇱ㐷ߢ⮎೷Ꮷߩኾ㐷ᕈࠍ⊒ើߔߴߊദജߒߡ޿ࠆ‫⺞ޕ‬೷ᬺോߢߪ㧘ࠦࡦࡇࡘ࡯࠲ߦࠃࠆ࠴ࠚ࠶ࠢࠪࠬ࠹ࡓࠍᧄ㒮⁛⥄ߢ㐿⊒ߒ㧘⺞೷ߩಣᣇ⋙ᩏߩలታࠍ࿑ࠆߣ౒ߦ㧘㍤೷ߩ৻࿁㊂൮ⵝ㧔৻൮ൻ㧕ᯏ߿ᵈ኿⮎ߩ⥄േᛄ޿಴ߒᯏߥߤߩක≮ᯏེߣㅪേ
ߐߖࠆߎߣߦࠃࠅᬺോߩല₸ൻ߿ឭଏߔࠆක⮎ຠߩ቟ోᕈ⏕଻ߦദ߼ߡ޿ࠆ‫⮎ޕ‬೷▤ℂᜰዉᬺോߢߪ㧘౉㒮ᖚ⠪ߐࠎߦኻߔࠆ᦯⮎ᜰዉߩߺߥࠄߕ㧘කᏧ࡮⋴⼔Ꮷߦኻߔࠆක⮎ຠᖱႎឭଏ㧘−∩ᴦ≮߿೽૞↪ኻ╷ߥߤᴦ≮ߩᡰេߦ߽㑐ࠊߞߡ޿ࠆ‫৻ޕ‬ㇱߩ∛᫟ߢߪ⮎೷Ꮷࠍኾછߣߒ㧘౉㒮ᤨ߆ࠄㅌ㒮߹ߢ৻⽾ߒߡᴦ≮ߦ㑐ࠊࠆߎߣߦࠃߞߡ⮎‛≮ᴺߩㆡᱜൻߦ៤ࠊߞߡ޿ࠆ‫ߦࠄߐޕ‬㧘ICU ߅ࠃ߮ HCU ߢߪో࿖ߦవ㚟ߌߡ⮎೷ᏧߩᏱ㚢ࠍⴕ޿㧘᛫ MRSA ⮎ߩ TDM ࠍㅢߒߡ㧘ಣᣇ⸳⸘ߩᡰេߥߤࠍⴕߞߡ޿ࠆ‫ޕ‬ᵈ኿೷⺞⵾ᬺോߢߪ㧘ో∛᫟ࠍኻ⽎ߦ᛫߇ࠎ೷㧘ਛᔃ㕒⣂ᩕ㙃೷ߩή⩶⺞⵾ࠍⴕߞߡ޿ࠆ‫ޕ‬ᐔᚑ 17 ᐕᐲ߆ࠄᄖ᧪ൻቇ≮ᴺ
ቶߢ↪޿ࠄࠇࠆ᛫߇ࠎ೷ߩή⩶⺞⵾ࠍ㐿ᆎߒ㧘ᐔᚑ 20 ᐕ 4 ᦬߆ࠄߪ⮎೷Ꮷ 2 ฬࠍ㈩⟎ߒ㧘᛫߇ࠎ೷ߩή
⩶⺞⵾ࠍ 100㧑ታᣉߒߡ޿ࠆ‫ߩࠄࠇߎޕ‬ή⩶⺞⵾ࠍᱜ⏕ߦⴕ߁ߚ߼ߦࠦࡦࡇࡘ࡯࠲ߦࠃࠆ⋙ᩏࠪࠬ࠹ࡓࠍ
ౝ⬿ߒߚࠢ࡝࡯ࡦࡌࡦ࠴࡮቟ోࠠࡖࡆࡀ࠶࠻ࠍ㐿⊒ߒ㧘ᱜ⏕ߥ⺞⵾ࠍⴕߞߡ޿ࠆ‫ޕ‬ක⮎ຠᖱႎឭଏᬺോߢ
ߪ㧘ࠗࡦ࠲࡯ࡀ࠶࠻෸߮㒮ౝߩࠗࡦ࠻࡜ࡀ࠶࠻ࠍ㚟૶ߒߡක⮎ຠᖱႎߩㄦㅦߥ෼㓸ߣឭଏࠍⴕߞߡ޿ࠆ‫ޕ‬⮎‛ⴊਛỚᐲ⸃ᨆᬺോߢߪ㧘ᬌᩏㇱߢ᷹ቯߐࠇߚⴊਛỚᐲ᷹ቯ୯ߦၮߠ޿ߡ⮎‛േᘒߩࠪࡒࡘ࡟࡯࡚ࠪࡦ
ࠍⴕ߁ߎߣߦࠃߞߡㆡᱜߥᛩਈ㊂ߥࠄ߮ߦᛩਈ㑆㓒ࠍ▚಴ߒ㧘කᏧߦኻߒߡᛩਈ⸳⸘ߩᡰេᖱႎࠍឭଏߒ
ߡ޿ࠆ‫ޕ‬㒮ౝ⵾೷ᬺോߢߪ㧘Ꮢ⽼ߐࠇߡ޿ߥ޿․ᱶ㒮ౝ⵾೷ߩ⺞⵾ߥߤࠍⴕ߁ߎߣߦࠃߞߡ㧘ᖚ⠪ߐࠎߩᴦ≮ߦ⽸₂ߒߡ޿ࠆ‫⮎ޕ‬ຠ▤ℂᬺോߢߪ㧘ಣᣇࠝ࡯࠳࡝ࡦࠣ࠺࡯࠲ࠍ೑↪ߒߡක⮎ຠߩ૶↪⁁ᴫࠍᛠីߒ㧘㒮ౝ⮎ຠ࿷ᐶߩㆡᱜൻߦദ߼ߡ޿ࠆ‫ޕ‬ฦ∛᫟࡮ᄖ᧪ߦߪ∛᫟⽿છ⮎೷Ꮷ߅ࠃ߮ᄖ᧪⽿છ⮎೷Ꮷࠍ㈩⟎ߒߡ࿷ᐶ⮎ຠߩ▤ℂࠍⴕߞߡ߅ࠅ㧘ᦼ㒢ಾࠇ߿ਇ⦟࿷ᐶߩ㒐ᱛߦദ߼ߡ޿ࠆ‫ޕ‬㤗⮎࡮ะ♖␹⮎ߦߟ޿ߡߪᴺⷙ
ߦၮߠ޿ߡ෩ኒߥ▤ℂࠍⴕߞߡ޿ࠆ‫ޕ‬ᴦ㛎▤ℂᬺോߢߪ㧘ᴦ㛎▤ℂ࠮ࡦ࠲࡯ߣㅪ៤ߒߡᴦ㛎⮎ߩ▤ℂ෸߮ಣᣇ▤ℂࠍⴕߞߡ޿ࠆ‫ߚ߹ޕ‬㧘ዋߥ޿ࠬ࠲࠶ࡈߥ߇ࠄ㧘㒮ౝߩฦ⒳ක≮࠴࡯ࡓ߽߳ෳ↹ߔࠆࠃ߁ߦߥࠅ㧘ዋߒߕߟߢߪ޽ࠆ߇㧘࠴࡯ࡓౝߢ⮎೷Ꮷߩኾ㐷ᕈ߇⊒ើߢ߈ࠆࠃ߁ദജߒߡ޿ࠆ‫ߦઁߩߘޕ‬㧘⮎೷Ꮷ߇ᴦ
㛎▤ℂ࠮ࡦ࠲࡯㧘↢૕ᡰេ࠮ࡦ࠲࡯㧘ක≮ㅪ៤࠮ࡦ࠲࡯㧘ࠛࠗ࠭ኻ╷ផㅴ࠮ࡦ࠲࡯㧘⣲≌࠮ࡦ࠲࡯㧘࡟ࠫࡔࡦᬌ⸛ㇱળ㧘ක≮቟ో▤ℂቶߩ᭴ᚑຬࠍ૬છߒߡ㧘㒮ౝߩᄙߊߩㇱ㐷ߩᬺോߦ߽㑐ࠊߞߡ޿ࠆ‫ޕ‬ኻᄖ⊛ߥᵴേߣߒߡߪ㧘ᣣᧄ∛㒮⮎೷Ꮷળ߇ࠎኾ㐷⮎೷Ꮷ⎇ୃ੐ᬺ⹺ቯ⎇ୃᣉ⸳ߣߒߡ⎇ୃ↢ߩฃߌ౉ࠇࠍⴕߞߡ߅ࠅ㧘߇ࠎኾ㐷⮎೷Ꮷߩ㙃ᚑߦ㑐ਈߒߡ޿ࠆ‫ߚ߹ޕ‬㧘ቯᦼ⊛ߦㇱౝߢ⎇ୃળࠍ㐿௅ߒ㧘⺞೷⮎ዪ⮎೷Ꮷߣߩ੤ᵹࠍ࿑ࠆߥߤ⮎⮎ㅪ៤߽ផㅴߒߡ޿ࠆ‫ޕ‬
2㧚ᢎ⢒ᣉ⸳
1㧕 ᣣᧄක≮⮎ቇળ⹺ቯ⮎೷Ꮷ೙ᐲ⎇ୃᣉ⸳
2㧕 ᣣᧄ∛㒮⮎೷Ꮷળ߇ࠎኾ㐷⮎೷Ꮷ⎇ୃ੐ᬺ⹺ቯ⎇ୃᣉ⸳
3㧚⸻≮㐿⊒
1㧕 ⸻≮ฬ 㧦ක⮎ຠ⹺⸽ᯏ⢻ࠍઃടߒߚᵈ኿೷ή⩶⺞⵾ᡰេࠪࠬ࠹ࡓ
⸻≮ౝኈ㧦ࠦࡦࡇࡘ࡯࠲㧘ࡕ࠾࠲࡯㧘ࡃ࡯ࠦ࡯࠼࡝࡯࠳࡯㧘㔚ሶᄤ⒊ࠍ៞タߒߚࠢ࡝࡯ࡦࡌࡦ࠴࡮቟
ోࠠࡖࡆࡀ࠶࠻ࠍ㐿⊒ߒ㧘ᵈ኿೷ߩή⩶⺞⵾ߩㆊ⒟ࠍ⋙ⷞߔࠆߎߣߦࠃߞߡᵈ኿೷⺞⵾ߩᱜ⏕ᕈะ਄ߦ⽸₂ߒߡ߈ߚ‫੹ޕ‬࿁㧘ක⮎ຠ߳ߩ RSS ࠦ࡯࠼ߩឝ␜ߦ઻޿㧘RSS ࠦ࡯࠼߆ࠄක⮎ຠߩ⹺⸽ࠍⴕ߁ᯏ⢻ࠍઃടߒ㧘ᯏ⢻ࠍలታߒߚ‫ޕ‬ઁ∛㒮ߢߩዉ౉⁁ᴫ㧦ᵈ኿೷ή⩶⺞⵾ᡰេࠪࠬ࠹ࡓߪ㧘ᧄ㒮⮎೷ㇱ߇ක≮ᯏེࡔ࡯ࠞ࡯ߣ౒หߢ㐿⊒ߒߚࠪࠬ࠹ࡓߢ޽ࠅ㧘ߔߢߦో࿖ߩ∛㒮ߢዉ౉߇ᆎ߹ߞߡ޿ࠆ‫ߚ߹ޕ‬㧘ක⮎ຠߩ⹺⸽ᯏ⢻ࠍ౗ߨ஻߃ߚᣂࠪࠬ࠹ࡓ߽ߔߢߦታ↪ൻ߇⚳ੌߒߡ߅ࠅ㧘㗅ᰴ㧘ઁ∛㒮ߦ߽ዉ౉ߐࠇࠆ੍
ቯߢ޽ࠆ‫ޕ‬࿖ౝ⊛⹏ଔ㧦2004 ᐕᐲߦ㐿⊒ߒߚᣥࠪࠬ࠹ࡓߪ㧘ᵈ኿೷⺞⵾ߩㆊ⒟ࠍࠦࡦࡇࡘ࡯࠲ߢ࠴ࠚ࠶ࠢߢ߈ࠆ
໑৻ߩࠪࠬ࠹ࡓߣߒߡක≮ㆊ⺋㒐ᱛߩⷰὐ߆ࠄ㜞ߊ⹏ଔߐࠇߡ߈ߚ‫ޕ‬ᣂߚߦᯏ⢻ઃടߒߚᧄࠪࠬ࠹ࡓߪ㧘ක⮎ຠߩขࠅ㑆㆑޿ࠍ㒐ᱛߔࠆߎߣ߇น⢻ߣߥࠅ㧘ߐࠄߦᵈ኿೷⺞⵾ߩᱜ⏕ᕈߥࠄ߮ߦ቟ోᕈߩะ਄߇ᦼᓙߐࠇࠆ‫ޕ‬㧙㧙࿖㓙⊛⹏ଔ㧦ᧂቯ
4㧚ኾ㐷ක࡮⹺ቯක࡮ᜰዉක
દ⮮ༀⷙ㧦ᣣᧄක≮⮎ቇળ⹺ቯ⮎೷Ꮷ࡮ᜰዉ⮎೷Ꮷᓟ⮮ජኼ㧦ᣣᧄක≮⮎ቇળ⹺ቯ⮎೷Ꮷ࡮ᜰዉ⮎೷Ꮷ㧘⹺ቯታോታ⠌ᜰዉ⮎೷Ꮷ㧘ᣣᧄ∛㒮⮎೷Ꮷળᗵᨴ೙
ᓮኾ㐷⮎೷Ꮷ㧘ࠗࡦࡈࠚ࡚ࠢࠪࡦࠦࡦ࠻ࡠ࡯࡞࠼ࠢ࠲࡯
᧻ᶆసᒾ㧦ᣣᧄක≮⮎ቇળ⹺ቯ⮎೷Ꮷ࡮ᜰዉ⮎೷Ꮷ㧘ᣣᧄ∛㒮⮎೷Ꮷળ߇ࠎኾ㐷⮎೷Ꮷ㧘ᣣᧄ㕒⣂⚻⣺ᩕ㙃ቇળᩕ㙃ࠨࡐ࡯࠻࠴࡯ࡓኾ㐷⮎೷Ꮷศጟผ㇢㧦ᣣᧄක≮⮎ቇળ⹺ቯ⮎೷Ꮷ࡮ᜰዉ⮎೷Ꮷ㧘ᣣᧄ♧ዩ∛≮㙃ᜰዉ჻㧘ᣣᧄ੺⼔ᡰេኾ㐷ຬදળ੺⼔ᡰេኾ㐷ຬ
ਅ↰ᶈᰵ㧦ᣣᧄ♧ዩ∛≮㙃ᜰዉ჻቟↰ᶈੑ㧦ᣣᧄක≮⮎ቇળ⹺ቯ⮎೷Ꮷጟ቟િੑ㧦ᣣᧄක≮⮎ቇળ⹺ቯ⮎೷Ꮷ㧘ᣣᧄ♧ዩ∛≮㙃ᜰዉ჻㧘⹺ቯታോታ⠌ᜰዉ⮎೷Ꮷਤ⠀ 㓉㧦ᣣᧄක≮⮎ቇળ⹺ቯ⮎೷Ꮷ࡮ᜰዉ⮎೷Ꮷ㘵ේᄢ⒤㧦ᣣᧄක≮⮎ቇળ⹺ቯ⮎೷Ꮷ㧘ᣣᧄ∛㒮⮎೷Ꮷળ߇ࠎኾ㐷⮎೷Ꮷ⍹ේᱜᔒ㧦ᣣᧄ㕒⣂⚻⣺ᩕ㙃ቇળᩕ㙃ࠨࡐ࡯࠻࠴࡯ࡓኾ㐷⮎೷Ꮷ⷏၂⟤ᄹሶ㧦ᣣᧄ↢⮎ቇળṽᣇ⮎࡮↢⮎⹺ቯ⮎೷Ꮷ⮮੗߆߅ࠅ㧦ᣣᧄ⥃ᐥ⮎ℂቇળ⹺ቯ CRC㧘ᣣᧄ↢⮎ቇળṽᣇ⮎࡮↢⮎⹺ቯ⮎೷Ꮷ
5㧚⥄Ꮖ⹏ଔ
⹏ଔ⮎೷ㇱߩቯຬ߽ᓢ‫߇ࠆ޽ߪߢߦޘ‬Ⴧ߃ߡ߈ߡ߅ࠅ㧘⮎೷▤ℂᜰዉઙᢙߩჇടߩߺߢߪߥߊ㧘−∩ᴦ≮߿೽૞↪ኻ╷ߩᴦ≮ᡰេߥߤ⮎೷Ꮷ߇ᴦ≮ߦᷓߊ੺౉ߔࠆᯏળ߇Ⴧ߃ߡ߈ߡ޿ࠆ‫ޕ‬ICU࡮HCU ߢߪ⮎೷ᏧࠍᏱ㚢ߐߖࠆߎߣߦࠃߞߡ㧘᛫ MRSA ⮎ߩಣᣇ⸳⸘㧘ᵈ኿⮎ߩ⺞⵾㧘⮎ຠ▤ℂߥߤක⮎ຠߩㆡᱜ૶↪ߥࠄ߮ߦ࡝ࠬࡑࡀࠫࡔࡦ࠻ߦ߅޿ߡ⹏ଔߐࠇߡ޿ࠆ‫ߚ߹ޕ‬㧘ᄖ᧪ൻቇ≮ᴺቶߢߪ᛫߇ࠎ೷⺞⵾ߩቢోታᣉ㧘ᖚ⠪ߐࠎ߳ߩᴦ≮⺑᣿߿᦯⮎ᜰዉ㧘೽૞↪ኻ╷ᡰេߥߤߦࠃࠅ቟ోᕈߩ⏕଻ߩߺߥࠄߕකᬺ෼⋉Ⴧടߦ߽
⽸₂ߢ߈ߚ‫✚ޕ‬ว⊛ߦ⹏ଔߒߡ㧘ක≮ߩ቟ోᕈߩ⏕଻ߥࠄ߮ߦ∛㒮෼౉ߦኻߒߡᄙߊߩ⽸₂߇ߢ߈ߡ޿ࠆ
ߣ⠨߃ࠆ‫ߚ߹ޕ‬㧘ㄭᐕ⮎೷Ꮷߩኾ㐷೙ᐲ߇ዉ౉ߐࠇ㧘⮎೷ㇱߢ߽ᗵᨴ೙ᓮ㧘ᩕ㙃ᴦ≮㧘߇ࠎᴦ≮ߩኾ㐷⮎೷Ꮷࠍ㙃ᚑߒ㧘࠴࡯ࡓක≮ߦ߽⽸₂ߒߡ߈ߡ޿ࠆ‫ߒ߆ߒޕ‬㧘ଐὼߣߒߡ⮎೷Ꮷᢙߪਇ⿷ߒߡ޿ࠆߚ߼㧘ో∛᫟ࠍኻ⽎ߦ⮎೷ᏧߩᏱ㚢ࠍⴕ߁ߎߣ߇ߢ߈ߡ߅ࠄߕ㧘ක⮎ຠߩㆡᱜ૶↪ߥࠄ߮ߦ቟ోᕈ⏕଻߇චಽߦታ
ᣉߢ߈ߡ޿ߥ޿ߩ߇⃻⁁ߢ޽ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ᓢ‫⮎ߦޘ‬೷Ꮷᢙ߽Ⴧടߒߡ߈ߡߪ޿ࠆ߇㧘ߘࠇએ਄ߦᣂߚߥᬺോ߇Ⴧടߒߡ޿ࠆߚ߼㧘ଐὼߣߒߡ⮎೷Ꮷᢙߪਇ⿷ߒߚ⁁ᘒߦ޽ࠅ㧘ᤨ㑆ᄖൕോߩჇട߿ભᥜ߇ᶖ⾌ߢ߈ߥ޿ߥߤ෩ߒ޿⁁ᴫߩߥ߆ߢߩൕോߣߥ
ߞߡ޿ࠆ‫ߚ߹ޕ‬㧘⮎೷Ꮷߩᓙㆄ߇ૐ޿ߚ߼㧘⮎೷Ꮷߩቯຬ߇Ⴧ߃ߡ൐㓸ࠍⴕߞߡ߽㧘⵬ల߇࿎㔍ߥ⁁ᴫߦ޽ࠅ㧘ߎࠇ߇ߐࠄߦᬺോࠍ෩ߒߊߒߡ޿ࠆ‫ޕ‬ක≮ߪ⋉‫ޘ‬㜞ᐲൻ߅ࠃ߮ኾ㐷ൻߒߡ߈ߡ߅ࠅ㧘ක≮ߩ቟ోᕈ⏕଻ߦ߅޿ߡ੹ᓟ㧘ߐࠄߦ⮎೷Ꮷߩ࠾࡯࠭߇㜞߹ࠆߎߣ߇੍᷹ߐࠇࠆ‫⃻ޕ‬࿷ߩක≮೙ᐲߢߪ⮎೷Ꮷᬺോߩ
ࡈࠖ࡯߇㕖Ᏹߦૐ޿ߚ߼෼౉㕙ߢ∛㒮ߩ⹏ଔࠍᓧࠆߎߣ߇࿎㔍ߥ⁁ᴫߦߪ޽ࠆ߇㧘ઁߩක≮ᓥ੐⠪ߣ skill
mix ࠍⴕ߁ߎߣߦࠃߞߡ∛㒮෼౉Ⴧടߦ⽸₂ߔࠆߎߣ㧘ߐࠄߦක≮ߩ⾰ߥࠄ߮ߦ቟ోᕈߩะ਄ߦ⽸₂ߔࠆߎߣߦࠃߞߡ⮎೷ᏧߩቯຬჇട㧘ൕോ᧦ઙ߿ᓙㆄߩᡷༀߦ㑐ߒߡ∛㒮஥߳ℂ⸃ࠍ᳞߼ߡ޿ߊߎߣ߇ᔅⷐߢ
޽ࠆ‫ޕ‬
੹ᓟߩዷᦸ
㜞ᐲൻ߅ࠃ߮ኾ㐷ൻߔࠆක≮ߦ߅޿ߡ቟ోᕈࠍ⏕଻ߔࠆߎߣߪ∛㒮ߦ߅޿ߡᄢ߈ߥ⺖㗴ߢ޽ࠆ‫⮎ޕ‬೷Ꮷߪ⮎ߩኾ㐷ኅߣߒߡ㒮ౝߩฦㇱ⟑ߦ߅޿ߡᵴべߔࠆߎߣ߇᳞߼ࠄࠇߡ޿ࠆ‫ޕ‬ㄭᐕ㧘⮎೷Ꮷߦ߅޿ߡ߽ኾ㐷ൻ߇ផㅴߐࠇߡ߈ߡ߅ࠅ㧘ኾ㐷⮎೷Ꮷࠍ㙃ᚑߔࠆߎߣߦࠃߞߡ੹ᓟߪో∛᫟ࠍኻ⽎ߦኾ㐷⮎೷Ꮷߩ㈩⟎ࠍⴕ޿㧘ߐࠄߦᷓߊ⮎‛≮ᴺߥࠄ߮ߦ೽૞↪ኻ╷߳੺౉ߔࠆߣ౒ߦ㧘ኾ㐷⮎೷Ꮷߦࠃࠆක≮࠴࡯ࡓ߳ߩ⽸₂ߥߤ㧘ᓥ᧪ߩ⮎೷Ꮷᬺോߩᨒࠍ⿧߃ߚಽ㊁ߢ⮎೷Ꮷ߇ᵴべߔࠆࠃ߁ദജߒߡ޿߈ߚ޿‫ߚ߹ޕ‬㧘ᣂⷙක⮎ຠߩ㐿⊒ߦ៤ࠊࠆߎߣߪᄢቇ∛㒮ߩ૶๮ߢ޽ࠅ㧘ᴦ㛎▤ℂ࠮ࡦ࠲࡯ߣኒធߦㅪ៤ߒߡ㧘ᴦ㛎ߩ౞Ṗߥផㅴߦነਈߒߚ޿‫ޕ‬㧙㧙㧔41㧕⋴⼔ㇱ
1㧚⋴⼔ㇱ᭎ⷐ
∛㒮ℂᔨ‫ߩߣߚߥ޽ޟ‬ኻ⹤߇ഃࠆା㗬ߣ቟ᔃߩ∛㒮‫ޠ‬⋴⼔ㇱℂᔨ‫ޟ‬቟ోߢ‫ߩ⼔⋴ࠆ޽ߩࠅ߿޿߽߅ޔ‬ታ〣‫ޠ‬ၮᧄᣇ㊎ 㧔1㧕ੱᩰߣᮭ೑ࠍዅ㊀ߒߚ⋴⼔ࠍታ〣ߔࠆ‫ޕ‬
㧔2㧕⊛⏕ߥ್ᢿߣᛛⴚߦၮߠ޿ߚ⋴⼔ࠍታ〣ߔࠆ‫ޕ‬
㧔3㧕࿾ၞߣㅪ៤ߒߚ⋴⼔ࠍዷ㐿ߔࠆ‫ޕ‬਄⸥ߩ∛㒮ℂᔨࠍฃߌ, ⋴⼔ㇱℂᔨ࡮ၮᧄᣇ㊎ࠍឝߍ, ⋴⼔ࠍㆀⴕߒߡ޿ࠆ‫ޕ‬ᒰ㒮ߪጘ㒂⋵໑৻ߩ․ቯ
ᯏ⢻∛㒮, 㜞ᐲᢇ๮ᢇᕆ࠮ࡦ࠲࡯, ᜚ὐ∛㒮㧔ㇺ㆏ᐭ⋵߇ࠎ⸻≮ㅪ៤, 㔍∛ක≮ㅪ៤, ࠛࠗ࠭ᴦ≮ਛᩭ, ⢄∔ᖚ⸻≮ㅪ៤㧕, 㕖ⴊ✼⠪㑆㛽㜑⒖ᬀ⹺ቯᣉ⸳ߣߒߡᯏ⢻ߒߡ޿ࠆ‫ޕ‬⋴⼔ㇱ߆ࠄߪ, ∛᫟ㇱ㐷㧔12 ⋴⼔න૏㧕, ᄖ᧪ㇱ㐷㧔1 ⋴⼔න૏㧕, ਛᄩ⸻≮ㇱ㐷㧔2 ⋴⼔න૏㧕, 㜞ᰴᢇ๮ᴦ≮࠮ࡦ࠲࡯㧔2 ⋴⼔න૏㧕, ᮮᢿ⊛⚵❱㧔቟ో▤ℂ࡮↢૕ᡰេ࡮ක≮ㅪ៤࡮ᴦ㛎▤ℂ㧕ߦ⋴⼔⡯ຬࠍ㈩⟎ߒߡ޿ࠆ‫ޕ‬㒢ࠄࠇߚ⋴⼔⡯ຬᢙ߆ࠄ∛ᐥ᭴ᚑࠍ⚂ 50 ᐥߣߒߚ∛᫟ߢ޽ࠆ‫ޕ‬⋴⼔⡯ߪ, ଻ஜᏧഥ↥Ꮷ⋴⼔Ꮷᴺߦⷙቯߐࠇ, ߆ߟ⋴⼔୶ℂߦၮߠ޿ߡ⋴⼔ࠍታ〣ߒߡ޿ࠆ‫ޕ‬ᄢ߈ߊಽߌߡ‫⵬ߩ≮⸻ޟ‬ഥߣ≮㙃਄ߩ਎⹤‫ޕࠆ޽߇ޠ‬ᒰ㒮ߢߪ⋴⼔ᬺോߔߴߡ㔚ሶൻߐࠇ, කᏧ߆ࠄߩᜰ␜ฃߌ߆ࠄ, ᖚ⠪⏕⹺߿ታᣉ⸥㍳߇㔚ሶᇦ૕ߢ޽ࠆ‫ޕ‬቟ోߦࠃࠅല₸⊛ߦ⋴⼔ᬺോ߇ㆀⴕߢ߈ࠆࠃ߁ߦขࠅ⚵ࠎߢ޿ࠆ‫ޕ‬ᴺੱൻᓟ߆ࠄ․ߦ∛㒮⚻༡ߦⓍᭂ⊛ߦෳ↹ߒ, ⋴⼔ㇱߢᢇᕆ߿∛᫟ࠍ฽߼ࠬࡓ࡯࠭ߥ∛ᐥㆇ↪ࠍⴕߞߡ޿ࠆ‫ޕ‬㜞㦂ᖚ⠪Ⴧߦଥࠄߕ, ᐔဋ࿷㒮ᣣᢙ⍴❗߇ㅴߺ, ㆊኒߢỚෘߥ⋴⼔ࠍ⍴ᦼ㑆ߦឭଏߔࠆߎߣ߇
ⷐ᳞ߐࠇߡ޿ࠆ‫ߦ߼ߚߩߘޕ‬, ᐔᚑ 17 ᐕᐲ߆ࠄ⋴⼔⡯ຬណ↪ࠍផㅴߒ, ᐔᚑ 20 ᐕᐲߦߪ, 7 ኻ 1 ౉㒮ၮᧄᢱขᓧⷐઙߩ⋴⼔⡯ຬჇࠍ࿑ߞߚ‫଻⾰ߩ⼔⋴ޕ‬㓚ߩߚ߼ߦ⋴⼔⡯ຬߦ㜞ᐲߥ⥃ᐥታ〣⢻ജ⠌ᓧߦะߌߡᢎ
⢒ࠍታ〣ߒߡ޿ࠆ‫ߦࠄߐޕ‬, ኾ㐷ಽ㊁ߩታ〣⢻ജ߇ⷐ᳞ߐࠇ, ኾ㐷⋴⼔Ꮷ࡮⹺ቯ⋴⼔Ꮷߩ⢒ᚑࠍ⸘↹⊛ߦⴕ޿, ⃻࿷ߪᗵᨴ, 㓸ਛࠤࠕ, ⊹⤏࡮ឃᴭࠤࠕ, ♧ዩ∛⋴⼔ߩ⹺ቯ⋴⼔Ꮷ߇ᵴേߒߡ޿ࠆ‫ߚ߹ޕ‬ᒰ㒮ࠍ೑↪
ߐࠇࠆᣇ‫߇ޘ‬, ቟ᔃߒߡ࿾ၞߦᚯࠇࠆࠃ߁౉㒮ᤨ߆ࠄㅌ㒮ࠍ⷗ᝪ߃ߡㅌ㒮⺞ᢛࠍⴕ޿, ઁᣉ⸳ߣߩㅪ៤ࠍ
࿑ࠅߟߟ, ⋴⼔ߩ⾰ะ਄ࠍ⋡ᜰߒߡ޿ࠆ‫ޕ‬
2㧚⃻⁁ߩ໧㗴෸߮ߘߩኻ╷ዋሶ㜞㦂, ක≮೙ᐲᡷ㕟, ࿖᳃ߩᮭ೑ᗧ⼂ߩ㜞឴, ᖱႎឭଏߩផㅴ, ක≮੐᡿, කᏧਇ⿷ߥߤ⋴⼔ߦᓇ㗀ࠍਈ߃ߡ޿ࠆ‫ޕ‬1㧕ᖚ⠪ߩ⿥㜞㦂ൻߦ઻޿, ㊀∝ൻ߿ᣣᏱ↢ᵴᡰេߩᖚ⠪ഀว߇㜞޿‫ޕ‬ᒰ㒮ߩ౉㒮ᖚ⠪ᐕ㦂ഀวߪ, ᐔᚑ 19 ᐕᐲ 65 ᱦએ਄ഀว߇ᐔᚑ 16 ᐕᐲᲧセߒߡ 2㧑Ⴧߩ 43㧑, 75 ᱦએ਄ഀว߇ 2㧑Ⴧߩ 18.8㧑ߢ޽ࠆ‫ޕ‬ട㦂ߦ઻߁ᯏ⢻ૐਅߪᴦ≮╬ߩㆊ⒟ߢ⦡‫ߥޘ‬႐㕙ࠍ๒ߒߡ޿ࠆ‫ޕ‬ᖚ⠪ߩ⷗቞ࠅ߿⹤ߒ⋧ᚻ╬, ᖚ⠪ߩ๟ㄝߦߪή⾗ᩰ⠪ߢน⢻ߥᬺോ߇ᄙߊ޽ࠆ‫⾗᦭ޕ‬ᩰ⠪ߩ⋴⼔Ꮷ࡮කᏧ╬߇ኾ㐷ᕈࠍචಽߦ⊒ើߢ߈ࠆࠃ߁ߦᬺോಽᜂ߿ද௛ߢ߈ࠆⅣႺߦᢛ஻ߔࠆᔅⷐ߇޽ࠆ‫ޕ‬
2㧕㜞ᐲක≮ߥࠄ߮ߦ᜚ὐ∛㒮ᯏ⢻ࠍ᦭ߔࠆߎߣߢ⋴⼔ᬺോ߇᜛ᄢߒߡ޿ࠆ‫ޕ‬ක≮ߩ㜞ᐲൻߦ઻޿㜞ᐲߥ⍮⼂࡮ᛛⴚࠍ᦭ߔࠆ⋴⼔Ꮷ⢒ᚑ߇ᕆോߢ޽ࠆ‫੹ޕ‬ᓟ, ․ቯߩ㗔ၞߦߟ޿ߡ⹺
ቯ࡮ኾ㐷⋴⼔Ꮷߩ⢒ᚑࠍ࿑ࠅ, ᮮᢿ⊛ߥᵴേࠍⴕ޿⋴⼔ߩ⾰ะ਄ࠍ࿑ࠆߎߣ߇⺖㗴ߢ޽ࠆ‫ޕ‬
3㧕ᣂੱ⋴⼔⡯ຬߩ⥃ᐥታ〣⢻ജ߇ૐਅߒߡ޿ࠆ‫ޕ‬⋴⼔ၮ␆ᢎ⢒ߢ⠌ᓧߔࠆ⋴⼔ታ〣⢻ജߣ⥃ᐥ⃻႐ߢᔅⷐߣߐࠇࠆ⥃ᐥታ〣⢻ജߩ㑆ߦਵ㔌߇޽ࠅ, ਛၷ⋴⼔Ꮷ߇ᣂੱᢎ⢒ߦᄙߊߩᤨ㑆ࠍⷐߒߡ޿ࠆߎߣ߆ࠄ⽶ᜂߣߥࠅ, ∋ᑷߒߡ޿ࠆ⃻⁁߇޽ࠆ‫ޕ‬ߘߩߚ߼ߦߪ, ⋴⼔ቇ⑼ߣㅪ៤ߒߚ⥃࿾ታ⠌ߩᎿᄦߣතᓟ⎇ୃࠍࠪࠬ࠹ࡓൻߔࠆߎߣ߇⺖㗴ߢ޽ࠆ‫ޕ‬
4㧕⋴⼔⡯ߩ࡜ࠗࡈࠨࠗࠢ࡞ߦᔕߓߚᨵエߥ㓹↪ᒻᘒ߇೙ᐲൻߐࠇߡ޿ߥ޿‫ޕ‬ᒰ⋴⼔ㇱ⡯ຬߩ 95㧑ߪᅚᕈߢ޽ࠆ‫ޕ‬⡯ຬᐔဋᐕ㦂ߪ 30 ᱦߢ޽ࠅ, ᐕઍ᭴ᚑഀวߪ 20 ᱦઍ 60㧑, 30 ᱦ
ઍ 25㧑ߢ޽ࠆ‫ޕ‬ㅌ⡯ℂ↱ߢߪ, ⚿ᇕ߿ᄛ㑆ൕോߩᄙᔔߐ, ઀੐ߣኅᐸ߿⢒ఽߩਔ┙߇಴᧪ߥ޿╬߇ 50㧑ߢ޽ࠆ‫ޕ‬ᅚᕈߩ⚿ᇕ࡮⢒ఽ࡮੺⼔ߣ࡜ࠗࡈࠗࡌࡦ࠻ߦᔕߓߡᨵエߥൕോ߇ߢ߈ࠆ㓹↪ᒻᘒߩ೙ᐲൻ߇ㆃ
ࠇߡ޿ࠆ‫ޕ‬ᣧᕆߦጘ㒂ᄢቇ࡮∛㒮߳ߩᰴ਎ઍ⢒ᚑᡰេ⸘↹ߣߒߡౕ૕⊛ߥឭ᩺߇⺖㗴ߢ޽ࠆ‫ޕ‬
3㧚੹ᓟߩዷᦸ
ᄢቇ∛㒮ߩ૶๮ߢ޽ࠆ⸻≮࡮ᢎ⢒࡮⎇ⓥߦ⋴⼔ㇱߣߒߡⓍᭂ⊛ߦ㑐ࠊߞߡ޿ߊߣߣ߽ߦ, ⋴⼔⡯ߩᗧ⼂ᄌ㕟ࠍ࿑ࠅ, ∛㒮⚻༡ߦෳ↹ߒߡ޿ߊߎߣߢ޽ࠆ‫∛ޕ‬㒮ߩℂᔨ࡮⋴⼔ㇱߩℂᔨታ⃻ߦะߌߡᖚ⠪߳ߩ⺑᣿
⽿છߣ቟ోߥ⋴⼔ࠍㆀⴕߔࠆߚ߼ߦᩮ᜚ߦၮߠ޿ߚ⋴⼔ታ〣ࠍ⋡ᜰߒߡ⋴⼔ߩ⾰ࠍ㜞߼ߚ޿ߣ⠨߃ߡ޿ࠆ‫ߪߦ߼ߚߩߘޕ‬ㅌ⡯₸ߪ 10㧑⒟ᐲߢ, ⡯႐ቯ⌕₸ࠍ㜞߼ࠆኻ╷߇ᔅⷐߢ޽ࠆ‫ߦ․ޕ‬, ጘ㒂⋵ߪᅚᕈߩ⋵ᄖㅴ಴߇ో࿖ᐔဋࠃࠅ㜞޿ߎߣ߇᣿⏕ߢ޽ࠆ‫ޕ‬ዋሶൻߢ⋴⼔ቇ↢ߩᷫዋ੍߽ᗐߐࠇ, ⋵ౝߦ⋴⼔Ꮷࠍ⏕㧙㧙଻࡮ቯ⌕ߐߖࠆߚ߼ߦ, ᒰ∛㒮⋴⼔ㇱ߽௛߈ߥ߇ࠄቇ⠌ߢ߈ࠆⅣႺᢛ஻ߣ, ࡜ࠗࡈࠗࡌࡦ࠻ߦᔕߓߚൕോ
ᒻᘒ߿⑔೑ෘ↢ߥߤߩഭ௛ⅣႺߩᢛ஻߇ᕆോߢ޽ࠆ‫ޕ‬੹ᓟ, ⋴⼔ㇱ⚵❱ߪ, ᯏ⢻ࠍ⊒ើߔࠆߎߣߦࠃߞߡᚑᨐࠍ↢ߺ಴ߔߎߣࠍ⋡⊛ߣߒߚᯏ⢻૕⚵❱߳ߩォ឵ࠍ࿑ࠆߎߣ߇⺖㗴ߢ޽ࠆ‫ޕ‬㧙㧙3㧚 ⸻≮ࠬ࠲࠶ࡈ㧔1㧕⸻≮ⷐຬߩ㈩⟎⁁ᴫᒰ∛㒮ߩ⸻≮ߪ㧘ᄢቇ㒮කቇ♽⎇ⓥ⑼ߦᚲዻߔࠆ⥃ᐥ♽⻠ᐳߩᢎ⢒⡯ຬ෸߮කቇㇱ㒝ዻ∛㒮ߦᚲዻߔࠆᢎ⢒⡯ຬ㧘߹ߚ㧘කቇㇱ㒝ዻ∛㒮ߦᚲዻߔࠆකຬ㧘කຬ㧔⎇ୃක㧕╬ߦࠃࠅⴕࠊࠇߡ޿ࠆ‫ޕ‬ᢎ⢒⡯ຬߦߟ޿ߡߪ㧘ઁᄢቇ∛㒮ߣห᭽㧘ᢎ᝼࡮ಎᢎ᝼࡮⻠Ꮷ࡮ഥᢎߦࠃࠅ⸻≮߇ⴕࠊࠇߡ޿ࠆ߇㧘ᐔᚑ 17 ᐕᐲ߆ࠄߪ⸻≮ߦ៤ࠊࠆഥᢎߦߟ޿ߡ㧘‫⥃ޟ‬ᐥ⻠Ꮷ‫߁޿ߣޠ‬๭⒓ࠍਈ߃ߚ㧔∛㒮㐳⊒઎ߦࠃࠆ㧕‫ߪࠇߎޕ‬㧘⻠Ꮷ⋧ᒰߩ⚻㛎ᐕᢙࠍ᦭ߔࠆഥᚻߦኻߒ㧘⻠Ꮷᩰઃߌߩ⛎ਈࠍᡰ⛎ߔࠆߎߣߦࠃߞߡ㧘ᒰ∛㒮ߩ⸻≮ᬺോߦ㧘ࠃࠅᗧ᰼ࠍᜬߞߡ៤ࠊࠆߎߣ߇಴᧪ࠆࠃ߁ភ⟎ߐࠇߚ߽ߩߢ޽ࠆ‫ޕ‬߹ߚ㧘ᐔᚑ 17 ᐕᐲ߆ࠄ㧘කຬߦߟ޿ߡߪᧄ㒮ߩᬺ❣ࠍ〯߹߃㧘⸻≮ᬺോߦኻߔࠆ⹏ଔߣੱ᧚ߩ⏕଻ߩߚ߼㧘⚂ 40% ⛎ਈࠍࠕ࠶ࡊߒ㧘කຬ㧔⎇ୃක㧕ߦߟ޿ߡߪ㧘᳃㑆∛㒮╬ߣߩ⛎ਈ╬ߩᩰᏅࠍᤚ
ᱜߔࠆߚ߼㧘᦬㗵 30 ਁ౞ࠍ⏕଻ߔࠆߚ߼ߩ⻉ᚻᒰ╬ࠍ฽߼ߚ⛎ਈߩᡰ⛎ࠍታᣉߒߚ‫ޕ‬
ᐔᚑ 20 ᐕᐲ⸻≮ࠬ࠲࠶ࡈߩ㈩⟎⁁ᴫߦߟ޿ߡߪਅ⸥ߩߣ߅ࠅߢ޽ࠆ‫ޕ‬⸻‫ޓ⑼ޓ≮ޓ‬ฬ
╙ 1 ౝ⑼╙ 2 ౝ⑼╙ 3 ౝ⑼␹⚻ౝ⑼࡮⠧ᐕ⑼✚วౝ⑼╙ 1 ᄖ⑼╙ 2 ᄖ⑼
↥⑼ᇚੱ⑼
ᢛᒻᄖ⑼
⣖␹⚻ᄖ⑼
⌒⑼
⡊㥦ຜ༄⑼
⊹⤏⑼
ᴲዩེ⑼
♖␹␹⚻⑼
ዊఽ⑼
᡼኿✢⑼
㤗㈮⑼⯃↢⑼ᱤ⑼ญ⣧ᄖ⑼
ᬌᩏㇱ
᡼኿✢ㇱ
ャⴊㇱ
ᚻⴚㇱ
ක≮ᖱႎㇱ
᧚ᢱㇱ
∛ℂㇱ
శቇක≮⸻≮ㇱ㜞ᰴᢇ๮ᴦ≮࠮ࡦ࠲࡯ක≮ㅪ៤࠮ࡦ࠲࡯
↢૕ᡰេ࠮ࡦ࠲࡯
⢄∔ᖚ⸻≮ᡰេ࠮ࡦ࠲࡯
තᓟ⥃ᐥ⎇ୃ࠮ࡦ࠲࡯

⎇ⓥ⑼ᚲዻ
ᢎຬੱᢙ
5
4
3
4
3
2
3
1
3
3
3
3
4
3
3
3
3
4
3
1

1
1
3

∛㒮ᚲዻ
ᢎຬੱᢙ
2
4
2
1

ነ㒝⻠ᐳ
ᚲዻੱᢙ

1
4
3
5
4
2
3
5
4
4
5
4
4
5
5
2
2
1
2
1
1
1
2
7
1
4
2
1

1
3

ක‫ ޓ‬ຬ
12
12
2
1
6
4
5
5
9
7
6
4
6
7
1
8
5
8
2

14

㧙㧙

කຬ
ว‫⸘ޓޓ‬
㧔⎇ୃක㧕
19
20
7
6
10
10
12
11
19
12
12
12
14
14
9
15
12
17
4
14
3
2
1
2
2
1
2
2
24
1
4
2
18
19

⸻‫ޓ⑼ޓ≮ޓ‬ฬ

⎇ⓥ⑼ᚲዻ
ᢎຬੱᢙ

ක≮቟ో▤ℂቶว‫⸘ޓޓ‬

66

∛㒮ᚲዻ
ᢎຬੱᢙ
1
94

ነ㒝⻠ᐳ
ᚲዻੱᢙ

ක‫ ޓ‬ຬ

5124

කຬว‫⸘ޓޓ‬
㧔⎇ୃක㧕
1
22
311

㧔2㧕⸻≮ᡰេⷐຬߩ㈩⟎⁁ᴫᐔᚑ 17 ᐕᐲ߆ࠄ⸻≮᡼኿✢ᛛᏧ࡮૞ᬺ≮ᴺ჻㧘ℂቇ≮ᴺ჻࡮⥃ᐥᎿቇᛛᏧ╬ࠍჇຬߔࠆߎߣߦࠃ
ࠅ㧘ᖚ⠪ࠨ࡯ࡆࠬ࡮⸻≮ᯏ⢻ߩࠃࠅ৻ጀߩะ਄㧘⸻≮ႎ㈽ߩჇ㗵ߦࠃࠆ∛㒮ㆇ༡ߩ⊒ዷߦነਈߔࠆߎ
ߣߣߥߞߚ‫ޕ‬߹ߚ㧘ᐔᚑ 18 ᐕ 1 ᦬߆ࠄක≮ᖱႎㇱߩᯏ⢻ࠍ⷗⋥ߒ㧘ක≮ᖱႎㇱ೽ㇱ㐳ߦᣂߚߦ㔚ሶ⸻≮㍳ᜂᒰߩ∛㒮㐳⵬૒ࠍ๮ߓ㧘߹ߚ㧘▤ℂ⺖ߦක≮ᖱႎቶࠍ⸳ߌࠆߎߣߦࠃߞߡ㧘㔚ሶࠞ࡞࠹ࠪࠬ࠹ࡓߩᠲ૞
ᕈߩะ਄߿⸻≮ႎ㈽ߣߩㅪ៤㧘ࠢ࡝࠾ࠞ࡞ࡄࠬߩዉ౉╬㧘∛㒮ㆇ༡ߩᩮᐙࠍߥߔ߽ߩߣߒߡߘߩᯏ⢻ߩ᜛లࠍ࿑ߞߚ‫ޕ‬
㧔3㧕⋴⼔ⷐຬߩ㈩⟎⁁ᴫᐔᚑ 16 ᐕᐲ߆ࠄ㓹↪ᒻᘒࠍછᦼઃ⡯ຬߣߒߡណ↪ߔࠆߎߣߦࠃߞߡ㧘∛㒮ᯏ⢻ߦᴪߞߚ⋴⼔⡯ࠍណ↪ߢ߈ߡ޿ࠆ‫ߚ߹ޕ‬㧘ᧄ㒮ߩၮᧄℂᔨࠍᨐߚߔߚ߼㧘ઁߩක≮ࡔࡦࡃ࡯ߣද௛ߒߥ߇ࠄᖚ⠪ਛᔃߩ⋴⼔ᵴേࠍⴕ߁ߎߣߦࠃࠅ㧘࿾ၞ␠ળߦ⽸₂ߔࠆߎߣࠍ૶๮ߣߒߡ޿ࠆ‫ޕ‬⃻࿷㧘⋴⼔Ꮷ㧘ഥ↥Ꮷ㧘⋴⼔ഥᚻࠍวࠊߖߡ⚂ 500 ੱ૕೙ߢᣣ‫⼔⋴ޘ‬ᬺോߦബࠎߢ޿ࠆ߇㧘છᦼઃ⡯ຬߦߟ޿ߡߪ 3 ᐕࠍ㒢ᐲߣߒߡ߅ࠅ㧘ㅌ⡯⠪ߩ⊒↢ߦࠃࠅ㧘㗅ᰴછᦼߩߥ޿⡯ຬߣߔࠆߎߣߦࠃߞ
ߡ㧘ࠃࠅ⦟޿ੱ᧚ࠍ⏕଻ߔࠆߎߣ߇น⢻ߣߥߞߡ޿ࠆ‫ޕ‬

4㧚 వㅴක≮㧔1㧕వㅴක≮వ‫ޓ‬ㅴ‫ޓ‬ක‫ޓ≮ޓ‬ฬ㗶㗻㕙⵬✄㧔ᣥ㜞ᐲవㅴ㧕

⹥ᒰ⸻≮⑼

ᢱ‫ޓ‬㊄

ᛚ⹺ᐕ᦬ᣣ

ᱤ⑼ญ⣧ᄖ⑼1 ⚖㧦104,380 ౞
2 ⚖㧦149,450 ౞

ᐔᚑ 12 ᐕ 9 ᦬ 1 ᣣࠗࡦࡊ࡜ࡦ࠻⟵ᱤ

ᱤ⑼ญ⣧ᄖ⑼238,400 ౞ᐔᚑ 19 ᐕ 2 ᦬ 1 ᣣ⿥㖸ᵄ㛽᛬ᴦ≮ᴺ

ᢛᒻᄖ⑼132,800 ౞ᐔᚑ 19 ᐕ 2 ᦬ 1 ᣣᖡᕈ㤥⦡⒳෶ߪ੃≸ߦ߅ߌࠆ࠮ࡦ࠴ࡀ࡞ ╙㧞ᄖ⑼࡝ࡦࡄ▵ߩหቯߣォ⒖ߩᬌ⚝⊹⤏⑼

97,000 ౞

ᐔᚑ 20 ᐕ 1 ᦬ 1 ᣣ

㧔2㧕వㅴක≮ᛛⴚߩ㐿⊒ዉ౉ฦ⸻≮⑼߇᦭ߔࠆ⥃ᐥ⎇ⓥᚑᨐࠍᛠីߔࠆߚ߼㧘ᐔᚑ 19 ᐕ 7 㨪 8 ᦬ߦ⸻≮⑼೎ߦ∛㒮㐳ࡅࠕ࡝ࡦࠣࠍታᣉߒߚ‫ߡ޿߅ߦࠣࡦ࡝ࠕࡅߩߎޕ‬㧘ฦ⸻≮⑼ߩขࠅ⚵ߺ޽ࠆ޿ߪขࠅ⚵߽߁ߣߔࠆవ┵ක≮ߦߟ޿ߡ㧘⺞ᩏ⴫ࠍၮߦ∛㒮㐳㧘೽∛㒮㐳╬ㆇ༡⚵❱ߦࠃࠆᗧ⷗⡬ขࠍⴕߞߚ‫ޕ‬ࡅࠕ࡝ࡦࠣߩ⚿ᨐࠍၮߦ㧘ฦ⸻≮⑼߇੹ᓟዉ౉ࠍᏗᦸߔࠆవㅴක≮ᛛⴚߦߟ޿ߡ㧘∛㒮㐳ਥዉߦࠃࠆ㐿⊒ዉ౉⚻⾌ࠍ㈩ಽߒߚ‫ޕ‬
ᐔᚑ 19 ᐕᐲవㅴක≮ߩ㐿⊒⚻⾌

2ઙ

12,100 ජ౞․⦡޽ࠆ⸻≮ߩ㐿⊒࡮ዉ౉3ઙ

24,900 ජ౞㧙㧙5㧚 ࿾ၞක≮ߩขࠅ⚵ߺ
㧔1㧕࿾ၞක≮ߩ⏕଻࿾ၞක≮ߩ⏕଻ߣߒߡ㧘Ԙጘ㒂࿾ၞߩකᏧਇ⿷ࠍ✭๺ߒ㧘ㆡᱜ㈩⟎ߔࠆߦߪൕോකߩ⛘ኻᢙ߇ᔅⷐ
ߢ޽ࠆߎߣ‫ޕ‬ԙ․ߦ㧘ߎࠇ߹ߢ࿾ၞߩකᏧ㙃ᚑࠍᜂߞߡ߈ߚᄢቇ㧔කዪ㧕㑐ㅪකᏧࡊ࡯࡞ߩ⏕଻߇ᔅ㗇ߢ޽ࠆߎߣ‫ޕ‬Ԛ߹ߚ㧘㜞ᐲవㅴක≮ࠍឭଏߒ㧘ߘߩ⢻ജࠍ஻߃ߚකᏧࠍ⢒ᚑߔࠆᄢቇ∛㒮ᓟᦼ⎇ୃකᏧߩ⏕଻߇ᔅⷐߢ޽ࠆߎߣ‫ ߩޕ‬3 ὐࠍ〯߹߃㧘කᏧਇ⿷ߦኻߔࠆᒰ∛㒮ߩข⚵ߺߣߒߡ㧘‫ޟ‬ጘ㒂ᣇ
ᑼߦࠃࠆᣂߚߥᓟᦼ⎇ୃකᏧ㙃ᚑࠪࠬ࠹ࡓ‫ޠ‬㧔∛㒮㐳⋥ዻකຬ೙ᐲ㧕ࠍዉ౉ߔࠆߎߣߦࠃࠅ㧘කዪ߳ߩ౉ዪࠍᢘ㆙ߔࠆೋᦼතᓟ⥃ᐥ⎇ୃୃੌකࠍᓟᦼ⎇ୃකߣߒߡណ↪ߔࠆߎߣߣߒߚ‫ޕ‬‫ޟ‬ጘ㒂ᣇᑼߦࠃࠆᣂߚߥᓟᦼ⎇ୃකᏧ㙃ᚑࠪࠬ࠹ࡓ‫ߪߡ޿ߟߦޠ‬㧘ጘ㒂࿾඙ 3 ∛㒮㧔ጘ㒂ᄢቇ∛㒮㧘⋵┙ጘ㒂∛㒮㧘ጘ㒂Ꮢ᳃∛㒮㧕߇౒หߢㆇ↪ߔࠆᓟᦼ⥃ᐥ⎇ୃක൐㓸ⷐ㗄ࠍᐔᚑ 18 ᐕᐲ߆ࠄታᣉߒ㧘ᢙᐕᓟߦߪጘ㒂ᄢቇ㑐ㅪ∛㒮ኾ㐷ක⚫੺ࠪࠬ࠹ࡓߣߒߡ⊒ዷߐߖ㧘∛㒮㐳⋥ዻኾ㐷කߣ㑐ㅪ∛㒮ߩዞ⡯ࡑ࠶࠴ࡦࠣࠍᜂ߁ NPO ᴺੱߩ⸳⟎ߥߤ㧘ጘ㒂⋵ਅߩකᏧਇ⿷ࠍ⸃ᶖߔࠆ৻ᣇ╷ߣߔࠆߎߣࠍᬌ⸛
ߒߡ޿ࠆ‫ޕ‬㧔2㧕㔍∛ක≮᜚ὐ∛㒮ߩᜰቯ⋵ౝߩၮᐙ∛㒮෸߮৻⥸දജ∛㒮߆ࠄߩⷐ⺧ߦᔕߓߡ㧘ਥߦ․ߦ㜞ᐲߩක≮ࠍⷐߔࠆ㔍∛ᖚ⠪ߩฃߌ౉ࠇࠍⴕ߁ߣߣ߽ߦ㧘ၮᐙ∛㒮ߦኻߒߡ㧘㔍∛ක≮ߦଥࠆᖱႎߩឭଏ෸߮⋧⺣ߦᔕߓࠆᓎഀࠍᜂ߁
‫ޟ‬㔍∛ක≮᜚ὐ∛㒮‫ߡߒߣޠ‬㧘ᐔᚑ 17 ᐕ 9 ᦬ߦጘ㒂⋵߆ࠄᜰቯࠍฃߌߚ‫ޕ‬ጘ㒂⋵ߪ㧘ᐔᚑ 18 ᐕᐲ߆ࠄ‫ޟ‬ጘ㒂⋵㔍∛ක≮ㅪ⛊ද⼏ળ੐ᬺ‫ࠍޠ‬ᒰ∛㒮߳ᬺോᆔ⸤ߔࠆߎߣߣߒߚ‫ޕ‬
㧔3㧕ㇺ㆏ᐭ⋵߇ࠎ⸻≮ㅪ៤᜚ὐ∛㒮ߩᜰቯ⾰ߩ㜞޿ኾ㐷⊛ߥ߇ࠎ⸻≮߿࿾ၞߩක≮ᯏ㑐ߣㅪ៤ߒߚක≮ߩឭଏ╬ࠍታᣉߔࠆߣߣ߽ߦ㧘ኾ㐷⊛ߥ߇ࠎක≮ࠍⴕ߁කᏧ࡮⮎೷Ꮷ࡮⋴⼔Ꮷ╬ࠍኻ⽎ߣߒߚ⎇ୃߩታᣉ߿࿾ၞ߇ࠎ⸻≮ㅪ៤᜚ὐ∛㒮╬ߦኻߔࠆᖱႎឭଏ㧘∝଀⋧⺣㧘⸻≮ᡰេࠍⴕ߁ߥߤ㧘⋵ߩ߇ࠎ⸻≮ᯏ⢻ߩਛᔃ⊛ᓎഀࠍᜂߞߡ޿ߊߎߣ
ࠍ⋡⊛ߦ㧘ᐔᚑ 18 ᐕ 8 ᦬ߦ‫ޟ‬ㇺ㆏ᐭ⋵߇ࠎ⸻≮ㅪ៤᜚ὐ∛㒮‫ߡߒߣޠ‬㧘ෘ↢ഭ௛⋭߆ࠄᜰቯࠍฃߌߚ‫ޕ‬
㧔4㧕ࠛࠗ࠭ਛᩭ᜚ὐ∛㒮ߩㆬቯࠛࠗ࠭ᴦ≮ߩਛᩭ᜚ὐ∛㒮ߣߒߡ㧘ᐔᚑ 19 ᐕ 3 ᦬ߦ‫࠭ࠗࠛޟ‬ᴦ≮ਛᩭ᜚ὐ∛㒮‫ߡߒߣޠ‬㧘ጘ㒂⋵߆ࠄㆬቯࠍฃߌߚ‫ޕ‬
㧔5㧕⢄∔ᖚ⸻≮ㅪ៤᜚ὐ∛㒮ߩㆬቯ⋵ౝߦ߅ߌࠆ⢄∔ᖚ⸻≮ࡀ࠶࠻ࡢ࡯ࠢߩਛᔃ⊛ߥᓎഀࠍᨐߚߔߚ߼㧘ᐔᚑ 19 ᐕ 11 ᦬ߦ‫ޟ‬⢄∔ᖚ⸻≮ㅪ៤᜚ὐ∛㒮‫ߡߒߣޠ‬㧘ጘ㒂⋵߆ࠄㆬቯࠍฃߌߚ‫ޕ‬
㧔6㧕ጘ㒂⋵੍㒐ធ⒳࠮ࡦ࠲࡯ߩᯏ⢻ጘ㒂⋵߆ࠄ㧘ᐔᚑ 20 ᐕ 4 ᦬ߦ⋵ౝߦ߅ߌࠆ੍㒐ធ⒳࠮ࡦ࠲࡯ᯏ⢻ࠍ᦭ߔࠆක≮ᯏ㑐ߣߒߡᧄ㒮߇ㆬቯߐࠇߚ‫ޕ‬
㧔7㧕ਃᰴ๟↥ᦼක≮ࡀ࠶࠻ࡢ࡯ࠢጘ㒂⋵੍㒐ធ⒳࠮ࡦ࠲࡯ߩᯏ⢻ᐔᚑ 20 ᐕ 4 ᦬ߦጘ㒂⋵๟↥ᦼක≮ࡀ࠶࠻ࡢ࡯ࠢ੐ᬺߦෳ↹ߒ㧘‫ޟ‬๟↥ᦼක≮ᡰេ∛㒮‫ߡߒߣޠ‬ෳ↹ߔࠆߎߣߣߥߞߚ‫ޕ‬㧙㧙㧔8㧕⤳ེឭଏㅪ⛊⺞ᢛຬߩ㈩⟎⋵ౝߩ∛㒮߇ᣣᏱ⊛ߦ⤳ེឭଏߦ㑐ߔࠆᖱႎࠍ㓸߼ߚࠅ㧘ᚲዻߔࠆᣉ⸳ߩ⡯ຬߦኻߒߡ⤳ེ⒖ᬀߦ
ߟ޿ߡߩ᥉෸࡮໪⊒෸߮⤳ེឭଏ߇޽ߞߚ㓙ߦ⤳ེ⒖ᬀࠦ࡯࠺ࠖࡀ࡯࠲࡯ߣ✕ኒߥㅪ៤ࠍᜬߞߡᖚ⠪ኅᣖ╬ࠍᡰេߔࠆߥߤ㧘⤳ེ⒖ᬀߦ㑐ߔࠆ੐ᬺߩផㅴࠍ࿑ࠆߚ߼ߩᓎഀࠍᜂ߁⤳ེឭଏㅪ⛊⺞ᢛຬߣߒߡ㧘ጘ㒂⋵߆ࠄᧄ㒮⡯ຬ 3 ฬ߇ᆔབྷߐࠇߚ‫ޕ‬

6㧚 තᓟ⥃ᐥ⎇ୃߩ⁁ᴫතᓟ⥃ᐥ⎇ୃ࠮ࡦ࠲࡯ߪ㧘තᓟ⥃ᐥ⎇ୃߩᔅୃൻߦ઻޿㧘ᐔᚑ㧝㧠ᐕ㧡᦬ߦ⸳⟎ߐࠇߚ‫ޕ‬ᐔᚑ㧞㧜ᐕ㧝㧜᦬ߦߪ㧘ⷙ⒟ࠍ৻ㇱᡷᱜߒ㧘ᓟᦼ⎇ୃකߩࠠࡖ࡝ࠕᒻᚑᡰេ࠮ࡦ࠲࡯ߣߒߡߩᯏ⢻ࠍᜬߚߖߚ‫ޕ‬
㧔1㧕ೋᦼ⥃ᐥ⎇ୃጘ㒂ᄢቇ∛㒮ࡊࡠࠣ࡜ࡓߩ․ᓽ
࡮ᧂ᧪ဳ∛㒮ߢ޽ࠆࠗࡦ࠹࡝ࠫࠚࡦ࠻ࡎࠬࡇ࠲࡞㧔ᣣᧄߢ㧝⇟వㅴ⊛ 㧵㨀 ∛㒮㧕ߦ߅޿ߡ㧘ᦨᣂߩᖱႎࠪࠬ࠹ࡓߩක≮ᵴ↪ࠍࡑࠬ࠲࡯ߐߖ㧘ᣂᤨઍࠍᜂ߁කᏧࠍ㙃ᚑߔࠆ‫ޕ‬࡮කዪߩᨒߦ❈ࠄࠇߕ㧘⎇ୃ࠮ࡦ࠲࡯ᚲዻߢ‫∛ޟ‬㒮ో૕ߩ⎇ୃක‫ߡߒߣޠ‬ᜰዉߔࠆ‫ޕ‬዁᧪㧘ၮᐙቇળߩ⹺ቯක࡮ኾ㐷ක↳⺧ߦኻᔕߢ߈ࠆࠃ߁∔ᖚ⟲࡮ᚻⴚ଀࡮೬ᬌ଀ࠍ⎇ୃ࠮ࡦ࠲࡯߇ㆡᱜߥ
∝଀㈩ಽࠍⴕ߁‫ޕ‬࡮㧞ᐕ৻⽾ᄢቇ∛㒮ߢ⎇ୃߔࠆ‫ޟ‬න⁛ࠦ࡯ࠬ‫ߣޠ‬㧘ᄢቇ∛㒮ߣදജဳ∛㒮ߩ㧞ᣉ⸳ߢ⎇ୃߔࠆ‫ߚޟ‬ߔ߈߇ߌࠦ࡯ࠬ‫ࠅ޽߇ޠ‬㧘ࠦ࡯ࠬㆬᛯߪᨵエ⊛ߢ޽ࠆ‫ޕ‬࡮㜞ᰴᢇ๮ᴦ≮࠮ࡦ࠲࡯ߪ㧘ᢇᕆᜰዉකߣᢇᕆኾ㐷කࠍ฽߼ߚኾᓥකᏧ߇⚂㧟㧜ฬ߅ࠅ㧘⸻≮⑼
ߩოࠍขࠅᛄߞߚ✚ว⊛ߥ㜞ᐲᢇᕆ⎇ୃ߇น⢻ߢ޽ࠆ‫ޕ‬࡮ᄙ᭽ߥ⎇ୃ࠾࡯࠭ߦኻᔕߢ߈ࠆ㧘ᄢቇ∛㒮ߩ․⦡㧔ฦ⒳ක≮࠮ࡦ࠲࡯㧕ࠍᵴ߆ߒߚࠝ࡯࠳࡯ࡔ
ࠗ࠼⎇ୃߢ޽ࠆ㧔᏷ᐢ޿⸻≮⑼ߣ⼾ንߥኾ㐷ࡊࡠࠣ࡜ࡓ߆ࠄߩࡔ࠾ࡘ࡯ㆬᛯ㧕‫ޕ‬࡮ᄢቇ∛㒮߇⼾ንߥᢎ⢒⾗Ḯࠍᜬߞߡ޿ࠆߎߣ߆ࠄ㧘⃻ⴕߩ⎇ୃࡊࡠࠣ࡜ࡓࠍᒢജൻߒ㧘⎇ୃಽ
㊁߿⎇ୃᦼ㑆ࠍ⷗⋥ߔߎߣ߇น⢻߆ߤ߁߆ߦߟ޿ߡߩၮ␆⾗ᢱࠍᓧࠆߚ߼ߩࡕ࠺࡞੐ᬺ߇൐㓸ߐࠇ㧘ᧄ㒮ߢߪᄖ⑼ߦ․ൻߒߚࡊࡠࠣ࡜ࡓ㧔㧔․೎ࠦ࡯ࠬ㧕ጘ㒂ᄢቇ∛㒮ᄖ⑼⎇ୃࡊࡠࠣ࡜ࡓ㧕ࠍ૞ᚑߒ㧘ᐔᚑ㧞㧝ᐕ㧠᦬߆ࠄ⎇ୃࠍ㐿ᆎߔࠆߎߣߣߥߞߚ‫ޕ‬㧙㧙ᐔᚑ㧞㧝ᐕᐲጘ㒂ᄢቇ∛㒮තᓟ⥃ᐥ⎇ୃࡊࡠࠣ࡜ࡓ
㧝㧚ࡊࡠࠣ࡜ࡓߩ൐㓸ቯຬࡊࡠࠣ࡜ࡓฬ൐㓸ቯຬጘ㒂ᄢቇ∛㒮ࡊࡠࠣ࡜ࡓ

៰‫ⷐޓ‬

㧟㧣ฬ

ࠦ࡯ࠬ㧝

㧔㧝㧠ฬ㧕

ጘ㒂ᄢቇකቇㇱ㒝ዻ∛㒮㧞ᐕ৻⽾⎇ୃ

ࠦ࡯ࠬ㧞

㧔㧝㧜ฬ㧕

㧝ᐕ⋡ጘ㒂ᄢቇකቇㇱ㒝ዻ∛㒮㧞ᐕ⋡දജဳ⥃ᐥ⎇ୃ∛㒮߆ࠄㆬᛯ

ࠦ࡯ࠬ㧟

㧔㧝㧜ฬ㧕

㧝ᐕ⋡දജဳ⥃ᐥ⎇ୃ∛㒮߆ࠄㆬᛯ㧞ᐕ⋡ጘ㒂ᄢቇකቇㇱ㒝ዻ∛㒮㧔․೎ࠦ࡯ࠬ㧕ጘ㒂ᄢቇ∛㒮ᄖ⑼⎇ୃࡊࡠࠣ࡜ࡓ

㧝ᐕ⋡ᄢቇ∛㒮㧘දജဳ∛㒮㧞ᐕ⋡ᄢቇ∛㒮㧘දജဳ∛㒮㧔㧢ࡩ᦬એౝ㧕

‫ޓ‬㧟ฬ

ว‫⸘ޓ‬

㧟㧣ฬ

⎇ୃࠬࠤࠫࡘ࡯࡞
㧝㧚ጘ㒂ᄢቇ∛㒮ࡊࡠࠣ࡜ࡓ
٤ࠦ࡯ࠬ㧘ࠦ࡯ࠬ㧞㧝ᐕ⋡ߩ⎇ୃࡠ࡯࠹࡯࡚ࠪࡦ㨇ጘ㒂ᄢቇ∛㒮㨉
㧟ࡩ᦬

㧥ࡩ᦬

㜞ᰴᢇ๮ᴦ≮࠮ࡦ࠲࡯࡮
㤗㈮⑼࡝ࡦࠢࠪࠬ࠹ࡓ

ౝ⑼ㆬᛯ࡮ᄖ⑼࡝ࡦࠢࠪࠬ࠹ࡓ

㧞ᐕ⋡ߩ⎇ୃࡠ࡯࠹࡯࡚ࠪࡦ [ ࠦ࡯ࠬ㧝㧦ጘ㒂ᄢቇ∛㒮㧘ࠦ࡯ࠬ㧞㧦දജဳ∛㒮 ]
㧞㨪㧟ࡩ᦬

㧝ࡩ᦬

㧞ࡩ᦬

㧝ࡩ᦬

㧡㨪㧢ࡩ᦬

ዊఽ⑼

♖␹⑼

↥ᇚੱ⑼

࿾ၞ଻ஜ࡮ක≮

ㆬᛯ⑼⋡

٤ࠦ࡯ࠬ㧟
㧝ᐕ⋡ߩ⎇ୃࡠ࡯࠹࡯࡚ࠪࡦ [ දജဳ∛㒮 ]
㧢ࡩ᦬

㧢ࡩ᦬

ౝ⑼

ᄖ⑼㧔ᢇᕆ࡮㤗㈮ࠍ฽߻㧕㧞ᐕ⋡ߩ⎇ୃࡠ࡯࠹࡯࡚ࠪࡦ [ ጘ㒂ᄢቇ∛㒮 ]
㧞㨪㧟ࡩ᦬

㧝ࡩ᦬

㧞ࡩ᦬

㧝ࡩ᦬

㧡㨪㧢ࡩ᦬

ዊఽ⑼

♖␹⑼

↥ᇚੱ⑼

࿾ၞ଻ஜ

ㆬᛯ

㧞㧚
㧔․೎ࠦ࡯ࠬ㧕ጘ㒂ᄢቇ∛㒮ᄖ⑼⎇ୃࡊࡠࠣ࡜ࡓ
㧝ᐕ⋡ߩ⎇ୃࡠ࡯࠹࡯࡚ࠪࡦ㧦㨇ጘ㒂ᄢቇකቇㇱ㒝ዻ∛㒮࡮දജဳ⎇ୃ∛㒮㨉
㧝ࡩ᦬

㧝ࡩ᦬

㧝ࡩ᦬

㧝ࡩ᦬

㧝ࡩ᦬

㧝ࡩ᦬

㧢ࡩ᦬

ᢇᕆ

ౝ⑼

ዊఽ⑼

↥ᇚੱ⑼

♖␹⑼

࿾ၞක≮

ㆬᛯ⑼⋡

㧙㧙

㧞ᐕ⋡ߩ⎇ୃࡠ࡯࠹࡯࡚ࠪࡦ㧦㨇ጘ㒂ᄢቇකቇㇱ㒝ዻ∛㒮࡮දജဳ⎇ୃ∛㒮㨉㧝㧞ࡩ᦬㧔දജဳ⎇ୃ∛㒮ߪ㧢ࡩ᦬એౝ㧕
ᄖ⑼㧟㧚දജဳ⎇ୃ∛㒮㧔㧝㧤∛㒮㧕ጘ㒂⋵✚วක≮࠮ࡦ࠲࡯⠀ፉᏒ᳃∛㒮

ጘ㒂Ꮢ᳃∛㒮

ጘ㒂⋵ෘ↢ㄘᬺදห⚵วㅪวળጘർෘ↢∛㒮

ක≮ᴺੱ⯃⷏ෘ↢ળ᧻ᵄ✚ว∛㒮ᦺᣣᄢቇᱤቇㇱ㒝ዻ᧛਄⸥ᔨ∛㒮ጘ㒂⋵┙ਅํ᷷ᴰ∛㒮̪㧝㧘̪㧞࿖᳃ஜᐽ଻㒾㑐ࠤේ∛㒮ጘ㒂⿒චሼ∛㒮ක≮ᴺੱ㚅ᓼળ㑐ਛᄩ∛㒮ጘ㒂⋵ෘ↢ㄘᬺදห⚵วㅪวળਭ⟤ᗲෘ↢∛㒮̪㧝ᄙᴦ⷗Ꮢ᳃∛㒮․ቯක≮ᴺੱෘ↢ળᧁᴛ⸥ᔨ∛㒮㜞ጊ⿒චሼ∛㒮̪㧝ጘ㒂⋵ෘ↢ㄘᬺදห⚵วㅪวળਛỚෘ↢∛㒮

᧖↰₵⊕⸥ᔨ‫┙౏ޓ‬ዊᵿ∛㒮ක≮ᴺੱ␠࿅ᔒ⡛ળ›ጊਛᄩ∛㒮࿖┙∛㒮ᯏ᭴㐳⦟ක≮࠮ࡦ࠲࡯̪㧞̪㧝ߪ㧞ᐕᰴߩ࿾ၞක≮⎇ୃߣߒߡㆬᛯน⢻ߥ∛㒮‫ޕ‬̪㧞ߪ㧞ᐕᰴߩ↥ᇚੱ⑼⎇ୃߦ߅ߌࠆ↥⑼⎇ୃߩදജᣉ⸳

㧠㧚දജᣉ⸳㧔㧞㧜ᣉ⸳㧕
␠࿅ᴺੱጘ㒂⋵ഭ௛ၮḰදળㅪวળഭ௛ⴡ↢࠮ࡦ࠲࡯ጘ㒂⋵ෘ↢ㄘᬺදห⚵วㅪวળឳ᢫ෘ↢∛㒮

ጘ㒂⋵⿒චሼⴊᶧ࠮ࡦ࠲࡯

․ቯක≮ᴺੱ⊕㡅ળ㣐⷗∛㒮

⽷࿅ᴺੱጘ㒂ஜᐽ▤ℂ࠮ࡦ࠲࡯ጘ㒂⋵⷏Ớ଻ஜᚲ

ጘ㒂Ꮢ଻ஜᚲ

․ቯක≮ᴺੱ㍳ਃળᄥ↰∛㒮

␠࿅ක≮ᴺੱ߆ߥ߼ળጊౝࡎࠬࡇ࠲࡞

ጘ㒂⋵᧲Ớ଻ஜᚲ

ጘ㒂⋵㘧㛗଻ஜᚲ

㇭਄Ꮢ࿖଻๺⦟∛㒮ጘ㒂⋵ጘ㒂଻ஜᚲ

Ꮢ┙ᕺ㇊∛㒮

ጘ㒂⋵㑐଻ஜᚲ

࿖᳃ஜᐽ଻㒾਄⍫૞∛㒮ጘ㒂⋵ਛỚ଻ஜᚲ

࿖᳃ஜᐽ଻㒾ဈਅ∛㒮ጘ㒂⋵ᕺ㇊଻ஜᚲ

ਅํᏒ┙㊄ጊ∛㒮

㧔2㧕ᓟᦼ⥃ᐥ⎇ୃೋᦼ⥃ᐥ⎇ୃߩୃੌ⠪ࠍኻ⽎ߣߒߡ㧘౉ዪ޽ࠆ޿ߪ㕖౉ዪߩ߆ߚߜߢኾ㐷ක≮ߩ⎇ୃ߿⎇ⓥࠍⴕ߁‫ޕ‬ၮᧄ⊛ߦ㧘ฦ⸻≮⑼ߦ߅޿ߡ‫ޟ‬ኾ㐷කࠦ࡯ࠬ‫ޟߣޠ‬ᄢቇ㒮ࠦ࡯ࠬ‫⸳߇ޠ‬ቯߐࠇߡ߅ࠅㆬᛯߐࠇࠆ‫ޕ‬೨⠪ߪቇળ⹺ቯߩኾ㐷කขᓧࠍ߽ߞߡ೔㆐⋡ᮡߣߔࠆ‫ޕ‬㕖౉ዪߩ႐วߪ∛㒮㐳⋥ዻᨒߦዻߔࠆߎߣߦ
ࠃߞߡᓟᦼ⥃ᐥ⎇ୃߦᓥ੐ߔࠆ‫ޕ‬㧙㧙ᐔᚑ 20 ᐕᐲߦ㧘ጘ㒂ᄢቇࠍ฽߻᧲ᶏ㧣ᄢቇߢᔕ൐ߒߚ‫ޟ‬ᄢቇ∛㒮ㅪ៤ဳ㜞ᐲක≮ੱ㙃ᚑផㅴ੐ᬺ‫ޠ‬ߦ߅޿ߡએਅߩࡊࡠࠣ࡜ࡓ߇ណᛯߐࠇߚߩߢ㧘หᐕᐲએ㒠ߪᧄࡊࡠࠣ࡜ࡓߦၮߠ޿ߡᓟᦼ⥃ᐥ⎇ୃࠍታᣉߔࠆߎߣߦߥߞߚ‫ޕ‬᧲ᶏ⧯ᚻකᏧࠠࡖ࡝ࠕᡰេࡊࡠࠣ࡜ࡓ
ㆬቯߐࠇߚ‫᧲ޟ‬ᶏ⧯ᚻකᏧࠠࡖ࡝ࠕᡰេࡊࡠࠣ࡜ࡓ‫ߪޠ‬㧘᧲ᶏ࿾ၞߦ߅ߌࠆ㧣ᄢቇߣߘߩ㑐ㅪ∛㒮ߩකᏧ⢒ᚑࠪࠬ࠹ࡓࠍ⋧੕ߦ⵬ቢߒߥ߇ࠄ㧘ᒰ࿾ၞߢ⎇ୃߔࠆోߡߩ⧯ᚻකᏧߦࠠࡖ࡝ࠕࡄࠬࠍឭ␜
ߒ㧘ᦨ⚳⊛ߦᒰ࿾ၞో૕ߦኾ㐷කࠍల⿷ߐߖࠆข⚵ߢ޽ࠆ‫ޕ‬ታ㓙ߦߪ㧘ࡎ࡯ࡓࡍ࡯ࠫ਄ߢ㧣ᄢቇߩ✚ᢙ 300 ߽ߩ⎇ୃࡊࡠࠣ࡜ࡓࠍนⷞൻߒ㧘⎇ୃ⠪ࠍ୘‫⊓ߦޘ‬㍳ߐߖߡኾ㐷ක≮ࠍᜰዉߔࠆ‫ޕ‬㧣ᄢቇ߇ਛᔃߣߥߞߡࠠࡖ࡝ࠕࡄࠬࠍឭ␜ߔࠆߎߣߢ㧘ᒰ࿾ၞߩ∛㒮ߢ⎇ୃਛߩߔߴߡߩ⎇ୃක߇᏷ᐢ޿ㆬᛯ⢇ࠍᓧࠆߩߺߥࠄߕ㧘ᄢቇ㒮ㅴቇࠍ߽ࠠࡖ࡝ࠕࡄࠬߦ⚵ߺㄟ߻ߎߣ߇ߢ߈ࠆ‫ߚ߹ޕ‬㧘ᒰ࿾
ၞߢߪ 7 ᄢቇߩ㑐ㅪ∛㒮ߩ㊀ⶄ߇ᄙߊ㧘㑐ㅪ∛㒮ߦ߅޿ߡઁᄢቇᜰዉක߆ࠄߩᜰዉࠍฃߌࠆߥߤ㧘⋧੕ߦ⎇㐭ߔࠆߎߣ߇ࠃࠅផㅴߐࠇࠆ‫ޕ‬ጘ㒂ᄢቇ∛㒮ߢߪ‫ࠕ࡝ࡖࠠޟ‬ᒻᚑᡰេ࠮ࡦ࠲࡯‫ࠍޠ‬තᓟ⥃ᐥ⎇ୃ࠮ࡦ࠲࡯ౝߦ⸳⟎ߒ㧘ࠦ࡯࠺ࠗࡀ࡯࠲࡯㧘ኾછߩᢎຬ㧘੐ോຬࠍ㈩⟎ߒߚ‫ޕ‬ᐔᚑ 20 ᐕᐲᧃ߆ࠄ⊓㍳૞ᬺ߇㐿ᆎߐࠇࠆ‫ޕ‬7㧚 ᄖ᧪ᖚ⠪ᢙ෸߮౉㒮ᖚ⠪ᢙ㧔1㧕ᄖ᧪ᖚ⠪ᢙ
ᐔᚑ 15 ᐕᐲᐔᚑ 16 ᐕᐲᐔᚑ 17 ᐕᐲᐔᚑ 18 ᐕᐲᐔᚑ 19 ᐕᐲᄖ᧪ᖚ⠪ᢙ279,549 ੱ

213,265 ੱ

293,084 ੱ

309,109 ੱ

314,609 ੱ

1 ᣣᐔဋᖚ⠪ᢙ

1,136 ੱ1,040 ੱ1,201 ੱ1,262 ੱ1,284 ੱ඙ಽ

㧔2㧕౉㒮ᖚ⠪ᢙ㧘∛ᐥⒿ௛₸෸߮ᐔဋ࿷㒮ᣣᢙ
606 ᐥߦߟ޿ߡㆊ෰ 5 ᐕ㑆ߩ౉㒮ᖚ⠪ᢙ㧘∛ᐥⒿ௛₸෸߮ᐔဋ࿷㒮ᣣᢙߩផ⒖
ᐔᚑ 15 ᐕᐲᐔᚑ 16 ᐕᐲᐔᚑ 17 ᐕᐲᐔᚑ 18 ᐕᐲᐔᚑ 19 ᐕᐲ∛ᐥⒿ௛₸

182,060 ੱ
82.10%

161,655 ੱ
77.50%

193,877 ੱ
87.65%

190,197 ੱ
85.99%

187,715 ੱ
84.63%

ᐔဋ࿷㒮ᣣᢙ

22.24 ᣣ19.66 ᣣ18.02 ᣣ16.07 ᣣ15.34 ᣣ඙ಽ౉㒮ᖚ⠪ᢙ8㧚 ⸻≮↪ᣉ⸳࡮⸳஻╬ߩᢛ஻ዉ౉ᐕᐲᣉ⸳࡮⸳஻╬

16 ᐕᐲ࠺ࠫ࠲࡞ 㨄 ✢ⴊ▤ㅧᓇ⸻ᢿᴦ≮ࠪࠬ࠹ࡓ૕ᄖⴣ᠄ᵄ⚿⍹⎕⎈ⵝ⟎㆙ᔃᑼỚ❗ᯏࠪࠬ࠹ࡓ
⏛᳇౒㡆ᢿጀ⸻ᢿⵝ⟎17 ᐕᐲੱᎿᔃ⢖ⵝ⟎⌒⑼ᚻⴚⵝ⟎

ቯ૏⣖ᚻⴚⵝ⟎19 ᐕᐲ㨀㨂 ળ⼏ࠪࠬ࠹ࡓ
ⴊ▤ౝ⿥㖸ᵄ⸻ᢿⵝ⟎ోり㤗㈮ེ

⒖േဳᄖ⑼↪ 㨄 ✢ⵝ⟎㜞⸃௝ᐲࡆ࠺ࠝ㔚ሶౝⷞ㏜ࠪࠬ࠹ࡓ㧙㧙9㧚 ∛㒮⚻༡࡮⽷ോߩ⁁ᴫ㧔1㧕∛㒮⚻༡ߦߟ޿ߡ
ᣂ∛㒮㐿㒮એ㒠ߩ∛㒮ㆇ༡ߪ㧘㜞ᰴᢇ๮ᴦ≮࠮ࡦ࠲࡯⸳⟎ߦࠃࠆᕆᕈᦼක≮૕೙ߩᢛ஻㧘‫ޟ‬ㇺ㆏ᐭ
⋵߇ࠎ⸻≮ㅪ៤᜚ὐ∛㒮‫ޠ‬‫ޟ‬⢄∔ᖚ⸻≮ㅪ៤᜚ὐ∛㒮‫ޠ‬‫ޟ‬㔍∛ක≮᜚ὐ∛㒮‫ߩޠ‬ᜰቯߥߤ∛∛࡮∛⸻ㅪ៤ߩផㅴ㧘⚻༡ᡷༀ⋡ᮡߣߒߡ‫ޟ‬㒢⇇೑⋉‫⸳ࠍޠ‬ቯߔࠆߥߤ㔚ሶࠞ࡞࠹࠺࡯࠲ࠍᵴ↪ߒߚㇱ㐷೎ේଔ⸘▚ߩዉ౉ߥߤ᭽‫⚻ߥޘ‬༡ᡷༀ╷ࠍⴕߞߡ߈ߚ⚿ᨐ㧘කᬺ෼⋉ߪᴺੱൻ೨ߩᐔᚑ 15 ᐕᐲߩ 102 ం 8ජਁ౞߆ࠄᐔᚑ 19 ᐕᐲ 136 ం 8 ජਁ౞ߣᴺੱൻ೨ߦᲧߴ㧘34 ం౞ߩჇ෼ࠍ㆐ᚑߒ㧘෼ᡰࡌ࡯ࠬߢ߽
10 ం 7 ජਁ౞ߩ૛೾㊄ࠍ↢ߺ಴ߒߚ‫⾌⚻ޕ‬೥ᷫߦߟ޿ߡ߽㧘ᄌേ⾌ߢߪක⮎ຠ⾌㧘⸻≮᧚ᢱ⾌ߩ೥ᷫࠍ࿑ࠆߚ߼㧘୯ᒁ₸ߩ᜛ᄢ߿᧚ᢱ⾌೥ᷫᬌ⸛ 㨃㧳 ߩ⸳⟎ߦࠃࠆᣢሽ‛ຠߩ⷗⋥ߒࠍⴕ޿㧘ᐔᚑ 16 㨪
19 ᐕᐲߩ 4 ᐕ㑆ߢ 5 ం 4 ජਁ౞ߩ▵ᷫࠍ࿑ߞߚ‫ޕ‬࿕ቯ⾌ߢߪ㧘ᄾ⚂ᣇᴺ࡮઀᭽ᦠߩ⷗⋥ߒ߿㧘ㅊ㍳
ߩ೥ᷫ㧘ᶖ⠻ຠߩ࡝ࠨࠗࠢ࡞ຠߣߩᲧセᬌ⸛ߥߤߦࠃࠅ㧘ᐔᚑ 16 ᐕ㨪 19 ᐕᐲߩ 4 ᐕ㑆ߢ 5 ජਁ౞ߩ⚻⾌▵ᷫࠍ࿑ߞߚ‫ޕ‬ߒ߆ߒ㧘ᐔᚑ 19 ᐕᐲߦߟ޿ߡߪ㧘7㧦1 ⋴⼔૕೙ߩታᣉߦะߌߚੱઙ⾌Ⴧ㧘⠧᧎ൻߒߚක≮ᯏེߩᄢⷙᮨୃℂߩ⊒↢߿㧘శᾲ᳓ᢱߩ୯਄ߍߥߤ⚻⾌࿶ㄼⷐ࿃߇㊀ߥࠅ㧘∛㒮෼ᡰߪٌ 2 ం౞ߩ⿒ሼߣߥߞߚ‫ޕ‬
ᐔᚑ 20 ᐕᐲߦߟ޿ߡߪ㧘⸻≮ႎ㈽ᡷቯ߳ߩኻᔕ߽฽߼ߚኻ╷ߣߒߡ㧘Ԙ 7㧦1 ⋴⼔૕೙ߩታᣉ㧘ԙ╙ੑ 㧵㧯㨁6 ᐥߩ⸳⟎ࠍⴕ߁ߎߣߣߒߡ޿ࠆ‫ޕ‬߹ߚ㧘ጘ㒂⋵੍㒐ធ⒳࠮ࡦ࠲࡯ߩ⸳⟎㧘3 ᰴ๟↥ᦼක≮ᯏ㑐ࡀ࠶࠻ࡢ࡯ࠢ߳ߩෳടߥߤ࿾ၞߩਛᩭ
᜚ὐ∛㒮ߣߒߡߩᯏ⢻ᒝൻ߽࿑ࠅ㧘ㆇ༡㕙㧘ක≮቟ో࡮⸻≮૕೙ߩలታࠍ࿑ࠆߣߣ߽ߦ㧘⚻⾌೥ᷫ╷ߦߟ޿ߡ߽㧘ᄌേ⾌ߩᦝߥࠆ୯ᒁ₸᜛ᄢ㧘⸻≮᧚ᢱߩຠ⋡ᢙ೥ᷫ㧘ࠫࠚࡀ࡝࠶ࠢක⮎ຠߩណ↪᜛ᄢ߿ᬺോᆔ⸤⾌ߩⶄᢙᐕᄾ⚂ߥߤࠍⴕ޿㧘∛㒮෼ᡰߩᡷༀࠍ࿑ࠆߎߣߣߒߡ޿ࠆ‫ޕ‬
ߒ߆ߒ㧘ᴺੱൻᤨὐߦᛚ⛮ߒߚௌോ߇ 42 ᄢቇ∛㒮ਛ 3 ⇟⋡ߩ 557 ం౞ߣᄙ㗵ߢ޽ࠅ㧘ߘߩௌോఘ
ㆶ߇ 27 ᐕᐲ߹ߢ⛯ߊߎߣߣߥࠆߚ߼㧘ߘߩ∛㒮෼⋉ߦኻߔࠆᓇ㗀ߪᄙᄢߢ޽ࠅ㧘⃻ⴕߩㆇ༡⾌੤ઃ
㊄▚ቯ࡞࡯࡞߇╙ 2 ਛᦼ⸘↹߹ߢ⛯ߊߣߔࠇ߫㧘ߎࠇ߹ߢߩࠃ߁ߥㆇ༡ᡷༀࠍ⛯ߌߥ߇ࠄჇ෼ࠍ࿑ࠅ㧘ᔅⷐߥ∛㒮⸳஻ߩᢛ஻ࠍⴕߞߡ޿ߊߎߣߪ㕖Ᏹߦ෩ߒ޿⁁ᴫߣߥߞߡ޿ࠆ‫ޕ‬㧙㧙㧔2㧕⽷ോ⁁ᴫ៊‫ᦠޓޓ▚ޓޓ⸘ޓޓ⋉ޓޓ‬‫ޣ‬㒝ዻ∛㒮‫ޤ‬㧔⥄‫ޓ‬ᐔᚑ 19 ᐕ 4 ᦬ 1 ᣣ‫ޓ⥋ޓ‬ᐔᚑ 20 ᐕ 3 ᦬ 31 ᣣ㧕

⚻Ᏹ⾌↪
ᬺോ⾌
ᢎ⢒⚻⾌
⎇ⓥ⚻⾌
⸻≮⚻⾌
ฃ⸤⎇ⓥ⾌
ฃ⸤੐ᬺ⾌
ᢎຬੱઙ⾌
⡯ຬੱઙ⾌
৻⥸▤ℂ⾌
⽷ോ⾌↪
ᡰᛄ೑ᕷ
⚻Ᏹ⾌↪ว⸘
⚻Ᏹ෼⋉ㆇ༡⾌੤ઃ㊄෼⋉㒝ዻ∛㒮෼⋉
ฃ⸤⎇ⓥ╬෼⋉࿖෶ߪ࿾ᣇ౏౒࿅૕߆ࠄߩฃ⸤⎇ⓥ෼⋉ઁߩਥ૕߆ࠄߩฃ⸤⎇ⓥ෼⋉ฃ⸤੐ᬺ╬෼⋉࿖෶ߪ࿾ᣇ౏౒࿅૕߆ࠄߩฃ⸤੐ᬺ෼⋉ઁߩਥ૕߆ࠄߩฃ⸤੐ᬺ෼⋉⵬ഥ㊄╬෼⋉
ነ㒝㊄෼⋉⾗↥⷗㄰⽶ௌᚯ౉
⾗↥⷗㄰ㆇ༡⾌੤ઃ㊄ᚯ౉⾗↥⷗㄰⵬ഥ㊄╬ᚯ౉⾗↥⷗㄰ነ㒝㊄ᚯ౉⾗↥⷗㄰‛ຠฃ⿅㗵ᚯ౉㔀⋉⎇ⓥ㑐ㅪ෼౉
ߘߩઁ⚻Ᏹ෼⋉ว⸘
⚻Ᏹ೑⋉⥃ᤨ៊ᄬߘߩઁ⥃ᤨ៊ᄬ
⥃ᤨ೑⋉ߘߩઁ⥃ᤨ෼⋉
ᒰᦼ⚐៊ᄬ
ᒰᦼ✚៊ᄬ

25,243226,052
11,622,575
80,687
14,6222,593,960
4,107,144㧔න૏㧦ජ౞㧕

18,670,285
142,449754,582

19,567,316

4,656,125
13,644,798
500
80,5648,550
6,071

81,064
14,622
14,27082,847

110,695
1,908
12,738552,872

678,214

1,845
2,215

4,060

̪⾉୫ኻᾖ⴫ߦߟ޿ߡߪᄢቇᴺੱ৻᜝▤ℂߩߚ߼૞ᚑߒߡ޿ߥ޿‫ޕ‬㧙㧙

19,176,003
ٌ 391,313

624

624

624

624
‫ ٌ ޓޓ‬391,312‫ ٌޓ ޓ‬391,312

10. ฦ⒳≮ᴺ╬ߩዯ಴⁁ᴫ‫ޓޓ‬ෘ↢ഭ௛ᄢ⤿߇ቯ߼ࠆᣉ⸳ၮḰ⁁ᴫ‫ޓ‬ᐔᚑ 20 ᐕ 12 ᦬ 1 ᣣ⃻࿷ฬ⒓
࿾ၞᱤ⑼⸻≮ᡰេ∛㒮ᱤ⑼ೋ⸻ᢱ
ᱤ⑼ᄖ᧪⸻≮ⅣႺ૕೙ട▚․ቯᯏ⢻∛㒮౉㒮ၮᧄᢱ㧔৻⥸∛᫟㧕․ቯᯏ⢻∛㒮౉㒮ၮᧄᢱ㧔♖␹∛᫟㧕⋴⼔⵬ഥട▚㧔♖␹∛᫟㧕⥃ᐥ⎇ୃ∛㒮౉㒮⸻≮ട▚㧔ක⑼㧕
⥃ᐥ⎇ୃ∛㒮౉㒮⸻

ᜰቯ᦬ᣣ

ᛚ⹺⇟ภ

ฬ⒓
ዊఽ㘩‛ࠕ࡟࡞ࠡ࡯

ᐔᚑ 18 ᐕ 4 ᦬ 1 ᣣ( ࿾ᱤೋ ) ╙ 6 ภ

ᐔᚑ 20 ᐕ 8 ᦬ 1 ᣣ( ᄖ᧪Ⅳ ) ╙ 91 ภ

ᐔᚑ 20 ᐕ 5 ᦬ 1 ᣣ( ․ቯ౉㒮 ) ╙ 2 ภ

ᐔᚑ 18 ᐕ 4 ᦬ 1 ᣣ( ․ቯ౉㒮 ) ╙ 3 ภ

ᐔᚑ 18 ᐕ 4 ᦬ 1 ᣣ( ⋴⵬ ) ╙ 166 ภᐔᚑ 17 ᐕ 3 ᦬ 1 ᣣ( ዊᬌ ) ╙ 6 ภ

ᐔᚑ 20 ᐕ 4 ᦬ 1 ᣣ( ↹ 2) ╙ 7 ภ

ᐔᚑ 20 ᐕ 6 ᦬ 1 ᣣ( ࡐࠫ ) ╙ 9࡮10 ภ

ᐔᚑ 16 ᐕ 5 ᦬ 20 ᣣ(C࡮M) ╙ 71 ภᄖ᧪ൻቇ≮ᴺട▚ 1

ᐔᚑ 20 ᐕ 4 ᦬ 1 ᣣ( ᄖൻ 1) ╙ 30 ภ

ή⩶⵾೷ಣℂᢱᐔᚑ 20 ᐕ 4 ᦬ 1 ᣣ( ⩶ ) ╙ 40 ภᐔᚑ 18 ᐕ 9 ᦬ 1 ᣣ( ⣖Σ ) ╙ 26 ภᐔᚑ 18 ᐕ 4 ᦬ 1 ᣣ( ㆇΣ ) ╙ 101 ภ

ᐔᚑ 18 ᐕ 4 ᦬ 1 ᣣ( ๭Σ ) ╙ 36 ภᐔᚑ 20 ᐕ 4 ᦬ 1 ᣣ( 㓸ࠦ ) ╙ 9 ภ

ᐔᚑ 18 ᐕ 1 ᦬ 1 ᣣ( ක≮଻⼔ ) ╙ 16 ภᐔᚑ 16 ᐕ 5 ᦬ 20 ᣣ

( ⣖ೝ ) ╙ 8 ภ

ᐔᚑ 16 ᐕ 5 ᦬ 20 ᣣ(ੱ)╙2ภ

ᐔᚑ 16 ᐕ 5 ᦬ 20 ᣣ( ࡍ ) ╙ 62 ภᐔᚑ 16 ᐕ 12 ᦬ 1 ᣣ( ਔࡍ ) ╙ 3 ภ

ᐔᚑ 16 ᐕ 12 ᦬ 1 ᣣ(㒰)╙5ภ

ᐔᚑ 16 ᐕ 5 ᦬ 20 ᣣ( ᄢ ) ╙ 30 ภᐔᚑ 16 ᐕ 12 ᦬ 1 ᣣ( ⵬ᔃ ) ╙ 4 ภ

ᐔᚑ 20 ᐕ 4 ᦬ 1 ᣣ( ⢙ ) ╙ 17 ภᐔᚑ 17 ᐕ 4 ᦬ 1 ᣣ( ⣢ ) ╙ 25 ภ↹௝⸻ᢿ▤ℂട▚ 2ࡐࠫ࠻ࡠࡦᢿጀ᠟ᓇ
෶ߪࡐࠫ࠻ࡠࡦᢿ
ጀ࡮ࠦࡦࡇࡘ࡯࠲࡯
ᢿጀⶄว᠟ᓇ
CT ᠟ᓇ෸߮ MRI ᠟ᓇ⣖ⴊ▤∔ᖚ࡝ࡂࡆ࡝
࠹࡯࡚ࠪࡦᢱ㧔Σ㧕

ᐔᚑ 18 ᐕ 4 ᦬ 1 ᣣ( ⥃ᐥ⎇ୃ ) ╙ 27 ภᐔᚑ 20 ᐕ 4 ᦬ 1 ᣣ( ⿥ᕆᕈᦼ ) ╙ 4 ภ

ᐔᚑ 20 ᐕ 4 ᦬ 1 ᣣ( ᅧ↥ᇚ ) ╙ 8 ภ

⸻≮㍳▤ℂ૕೙ട▚ᐔᚑ 18 ᐕ 4 ᦬ 1 ᣣ( ⸻≮㍳ ) ╙ 38 ภ㓸࿅ࠦࡒࡘ࠾ࠤ࡯

≮㙃ⅣႺട▚

ᐔᚑ 16 ᐕ 5 ᦬ 20 ᣣ( ≮ ) ╙ 12 ภ࡚ࠪࡦ≮ᴺᢱ

ᐔᚑ 17 ᐕ 5 ᦬ 1 ᣣ( ㊀ ) ╙ 42 ภ

ᐔᚑ 18 ᐕ 8 ᦬ 1 ᣣ( ♖ᔕ ) ╙ 2 ภ

ᐔᚑ 18 ᐕ 9 ᦬ 1 ᣣ( ߇ࠎ᜚ὐ ) ╙ 6 ภ≮ട▚㧔ᱤ⑼㧕
⿥ᕆᕈᦼ⣖තਛട▚ᅧ↥ᇚ✕ᕆ៝ㅍ౉㒮ട▚㊀∝⠪╬≮㙃ⅣႺ․೎ട▚♖␹⑼ᔕᕆ౉㒮ᣉ⸳
▤ℂട▚߇ࠎ⸻≮ㅪ៤᜚ὐ∛㒮ട▚ㆇേེ࡝ࡂࡆ࡝࠹࡯
࡚ࠪࡦᢱ㧔Σ㧕๭ๆེ࡝ࡂࡆ࡝࠹࡯
࡚ࠪࡦᢱ㧔Σ㧕ක≮଻⼔౉㒮╬⸻≮ᢱ⣖ೝỗⵝ⟎ᬀㄟⴚ
㧔㗡⬄ౝ㔚ᭂᬀㄟⴚࠍ฽߻‫ )ޕ‬෶ߪ⣖ೝỗⵝ⟎੤឵ⴚ , ⣄㜑ೝᩕ㙃▤ℂታᣉട▚ᐔᚑ 18 ᐕ 4 ᦬ 1 ᣣ( ᩕ㙃▤ℂ ) ╙ 22 ภỗⵝ⟎ᬀㄟⴚ෶ߪ⣄ක≮቟ోኻ╷ട▚ᐔᚑ 20 ᐕ 4 ᦬ 1 ᣣ( ක≮቟ో ) ╙ 4 ภ㜑ೝỗⵝ⟎੤឵ⴚ

ⶖ≙ᖚ⠪▤ℂട▚ᐔᚑ 18 ᐕ 4 ᦬ 1 ᣣ( ⶖ ) ╙ 96 ภੱᎿౝ⡊ၒㄟⴚ

ⶖ≙ࡂࠗ࡝ࠬࠢᖚ⠪ࠤࠕട▚ࡂࠗ࡝ࠬࠢᅧᆼ▤ℂട▚ᓟᦼ㜞㦂⠪ㅌ㒮⺞ᢛട▚࿾ၞᱤ⑼⸻≮ᡰេ∛㒮౉㒮ട▚ᢇ๮ᢇᕆ౉㒮ᢱ․ቯ㓸ਛᴦ≮ቶ▤ℂ

ᐔᚑ 18 ᐕ 6 ᦬ 1 ᣣ( ⶖ≙ࠤࠕ ) ╙ 5 ภ

ᐔᚑ 20 ᐕ 4 ᦬ 1 ᣣ( ࡂࠗᅧᆼ ) ╙ 13 ภᐔᚑ 20 ᐕ 4 ᦬ 1 ᣣ( ᓟᦼㅌ㒮 ) ╙ 17 ภᐔᚑ 20 ᐕ 4 ᦬ 1 ᣣ( ࿾ᱤ౉㒮 ) ╙ 6 ภ

ᐔᚑ 16 ᐕ 11 ᦬ 1 ᣣ( ᢇ ) ╙ 23࡮24 ภࡍ࡯ࠬࡔ࡯ࠞ࡯⒖ᬀⴚ㧘ࡍ࡯ࠬࡔ࡯ࠞ࡯
੤឵ⴚਔᔃቶࡍ࡯ࠬࡔ࡯
ࠞ࡯⒖ᬀⴚ㧘ਔᔃቶࡍ࡯ࠬࡔ࡯ࠞ࡯੤឵
ⴚၒㄟဳ㒰⚦േེ⒖ᬀ
ⴚ෸߮ၒㄟဳ㒰⚦േེ੤឵ⴚ

ᐔᚑ 16 ᐕ 11 ᦬ 1 ᣣ( 㓸 ) ╙ 10 ภ࠙ࠗ࡞ࠬ∔ᖚᜰዉᢱ

ᐔᚑ 18 ᐕ 4 ᦬ 1 ᣣ( ࠙ᜰ ) ╙ 1 ภ

ࡇࡦࠣᴺ㧔IABP ᴺ㧕㜞ᐲ㔍⡬ᜰዉ▤ℂᢱᐔᚑ 16 ᐕ 5 ᦬ 20 ᣣ( 㜞 ) ╙ 68 ภ⵬ഥੱᎿᔃ⤳♧ዩ∛ว૬∝▤ℂᢱᐔᚑ 20 ᐕ 7 ᦬ 1 ᣣ( ♧▤ ) ╙ 13 ภ૕ᄖⴣ᠄ᵄ⢙⍹⎕⎈

ᢱᄢേ⣂ࡃ࡞࡯ࡦࡄࡦ

ⴚ࿾ၞㅪ៤⸻≮⸘↹▤ℂᢱ㧘࿾ၞㅪ៤⸻≮ᐔᚑ 20 ᐕ 6 ᦬ 1 ᣣ( ࿾ㅪ៤ ) ╙ 50 ภ⸘↹ㅌ㒮ᤨᜰዉᢱ
⮎೷▤ℂᜰዉᢱ

૕ᄖⴣ᠄ᵄ⣢࡮ዩ▤⚿⍹⎕⎈ⴚ

ᐔᚑ 16 ᐕ 5 ᦬ 20 ᣣක≮ᯏེ቟ో▤ℂᢱ1 ᐔᚑ 20 ᐕ 4 ᦬ 1 ᣣᛚ⹺⇟ภᐔᚑ 18 ᐕ 4 ᦬ 1 ᣣ⽶⩄ᬌᩏ

( ⥃ᐥ⎇ୃ ) ╙ 15 ภᜰቯ᦬ᣣ( ⮎ ) ╙ 93 ภ

ห⒳ᱫ૕⣢⒖ᬀ

ᐔᚑ 20 ᐕ 4 ᦬ 1 ᣣ( ⣢⒖ ) ╙ 1 ภ( ᯏ቟ 1) ╙ 7 ภ↢૕⣢⒖ᬀⴚ

ᐔᚑ 20 ᐕ 4 ᦬ 1 ᣣ( ↢⣢ ) ╙ 1 ภ㧙㧙ෘ↢ഭ௛ᄢ⤿߇ቯ߼ࠆᣉ⸳ၮḰ⁁ᴫ‫ޓ‬ᐔᚑ 20 ᐕ 12 ᦬ 1 ᣣ⃻࿷ฬ⒓
ᱤ⑼ᴦ≮✚วක≮▤ℂᢱ
ⴊᶧ⚦⢩ᩭ㉄Ⴧ᏷ห

ᜰቯ᦬ᣣ

ᛚ⹺⇟ภ

ฬ⒓

ᐔᚑ 18 ᐕ 4 ᦬ 1 ᣣ( ᱤ✚ක ) ╙ 372 ภ

ᜰቯ᦬ᣣ

ᛚ⹺⇟ภ

ක⑼ὐᢙ⴫╙ 2 ┨╙10 ㇱᚻⴚߩㅢೣ 5 ෸
߮ 6㧔ᱤ⑼ὐᢙ⴫╙ᐔᚑ 20 ᐕ 4 ᦬ 1 ᣣ( ⴊ ) ╙ 12 ภᐔᚑ 20 ᐕ 4 ᦬ 1 ᣣ( ᬌΣ ) ╙ 136 ภᐔᚑ 20 ᐕ 4 ᦬ 1 ᣣ( ᬌΥ ) ╙ 29 ภᐔᚑ 20 ᐕ 4 ᦬ 1 ᣣ( ⴊౝ ) ╙ 6 ภ

ᐔᚑ 20 ᐕ 4 ᦬ 1 ᣣ(⤟)╙3ภ

ᐔᚑ 16 ᐕ 5 ᦬ 20 ᣣ(㐳)╙6ภ

␹⚻ቇ⊛ᬌᩏ

ᐔᚑ 20 ᐕ 7 ᦬ 1 ᣣ( ␹⚻ ) ╙ 23 ภ⵬✄‛⛽ᜬ▤ℂᢱᐔᚑ 16 ᐕ 5 ᦬ 20 ᣣ

( ⵬✄ ) ╙ 1120 ภ⵬⡬ེㆡวᬌᩏ

ᐔᚑ 16 ᐕ 5 ᦬ 20 ᣣ

( ⵬⡬ ) ╙ 6 ภ

ᱤ⑼⍶ᱜ⸻ᢿᢱ

ᐔᚑ 18 ᐕ 4 ᦬ 1 ᣣ( ⍶⸻ ) ╙ 14 ภᐔᚑ 20 ᐕ 4 ᦬ 1 ᣣ( ࠦࡦ 1) ╙ 199 ภ

ᐔᚑ 18 ᐕ 6 ᦬ 1 ᣣ( 㗶⸻ ) ╙ 13 ภ౉㒮ᤨ㘩੐≮㙃㧔Σ㧕 ᐔᚑ 18 ᐕ 4 ᦬ 1 ᣣ( 㘩 ) ╙ 279 ภቯᬌᩏᬌ૕ᬌᩏ▤ℂട▚㧔Σ㧕ᬌ૕ᬌᩏ▤ℂട▚㧔Υ㧕

2 ┨╙ 9 ㇱߩㅢೣ 4ࠃࠆ⻉ᬌᩏߩⴊ▤ౝੱᎿ⤟⤳㐳ᦼ⛮⛯㗡⬄ౝ⣖ᵄᬌᩏࠦࡦ࠲ࠢ࠻࡟ࡦ࠭ᬌ
ᩏᢱ 1

ᐔᚑ 20 ᐕ 4 ᦬ 1 ᣣ(GTR) ╙ 31 ภⴚ㧔ᚻⴚߪ೎ឝ㧕ᱤ๟⚵❱ౣ↢⺃ዉᚻ

ⷞ㏜ᬌᩏട▚( ㅢᚻ ) ╙ 100 ภࠍ฽߻‫ޕ‬㧕ߦឝߍࠆᚻ

ⴚᔃ⤳ࠞ࠹࡯࠹࡞ᴺߦ

ᐔᚑ 20 ᐕ 4 ᦬ 1 ᣣ

㤗㈮▤ℂᢱᐔᚑ 16 ᐕ 5 ᦬ 20 ᣣ

( 㤗▤ ) ╙ 49 ภ᡼኿✢ᴦ≮ኾછട▚ᐔᚑ 16 ᐕ 5 ᦬ 20 ᣣ

( ᡼ኾ ) ╙ 7 ภ

ᐔᚑ 16 ᐕ 5 ᦬ 20 ᣣ

( 㜞᡼ ) ╙ 11 ภᐔᚑ 16 ᐕ 8 ᦬ 1 ᣣ( ⋥ቯ ) ╙ 2 ภ㜞ࠛࡀ࡞ࠡ࡯᡼኿✢ᴦ≮⋥✢ടㅦེߦࠃࠆቯ
૏᡼኿✢ᴦ≮

㗶ญ⣧ᯏ⢻⸻ᢿᢱ
㧔㗶ᄌᒻ∝㧔㗶㔌ᢿ╬ߩᚻⴚࠍᔅⷐߣߔࠆ
߽ߩߦ㒢ࠆ㧕ߩᚻⴚ೨ᓟߦ߅ߌࠆᱤ⑼⍶ᱜߦଥࠆ߽ߩ㧕

㧙㧙

㧔೎ឝ㧕
ฬ‫ޓޓ‬⒓ዯ಴᦬ᣣක⑼ὐᢙ⴫╙ 2 ┨╙ 10 ㇱᚻⴚߩㅢೣ 5 ෸߮ 6㧔ᱤ⑼ὐ
ᢙ⴫╙ 2 ┨╙ 9 ㇱߩㅢೣ 4 ࠍ฽߻‫ޕ‬㧕ߦឝߍࠆᚻⴚ

඙ಽ 1

඙ಽ 2

඙ಽ 3

඙ಽ 1 㨪 3એᄖࠕ㗡⬄ౝ⣲≜៰಴ⴚ╬ࠗ㤛᢬ਅᚻⴚ╬

࠙㥏ቶᒻᚑᚻⴚ╬ᐔᚑ 20 ᐕ 4 ᦬ 1 ᣣ 㧔ㅢᚻ㧕╙ 100 ภᎿ⢖ᖡᕈ⣲≌ᚻⴚ╬ࠝ⚻⊹⊛ࠞ࠹࡯࠹࡞ᔃ╭὾ἳⴚࠕ㕤Ꮺᢿⵚᒻᚑᚻⴚ╬ࠗ᳓㗡∝ᚻⴚ╬

࠙㥦೽㥦⣧ᖡᕈ⣲≌ᚻⴚ╬Ꮏዩ㆏ᒻᚑᚻⴚ╬

ࠝ

ⷺ⤑⒖ᬀⴚ

ࠞ

⢄ಾ㒰ⴚ╬

ࠠ

ሶች㒝ዻེᖡᕈ⣲≌ᚻⴚ╬ࠕ਄㗶㛽ᒻᚑⴚ╬ࠗ࠙਄㗶㛽ᖡᕈ⣲≌ᚻⴚ╬ࡃ࠮࠼࠙↲⁁⣼ో៰ ( ੝ో៰ ) ⴚ㧔ਔ⪲㧕ᎿᲣᜰൻᚻⴚ╬

ࠝౝ෻⿷ᚻⴚ╬

ࠞ㘩㆏ಾ㒰ౣᑪⴚ╬ࠠ

ห⒳ᱫ૕⣢⒖ᬀⴚ╬ᛚ⹺⇟ภࠕੱᎿ㑐▵⟎឵ⴚ

ࠗ

੃ఽᄖ⑼ᣉ⸳ၮḰኻ⽎ᚻⴚ࠙ࡍ࡯ࠬࡔ࡯ࠞ࡯⒖ᬀⴚ෸߮ࡍ࡯ࠬࡔ࡯ࠞ࡯੤឵ⴚ

Ꮏ౰േ⣂㧘ᄢേ⣂ࡃࠗࡄࠬ⒖ᬀⴚ㧔ੱᎿᔃ⢖ࠍ૶↪ߒߥ޿߽ߩࠍ฽
߻‫ޕ‬㧕෸߮૕ᄖᓴⅣࠍⷐߔࠆᚻⴚ

ࠝ⚻⊹⊛౰േ⣂ᒻᚑⴚ㧘⚻⊹⊛౰േ⣂♄⣲ಾ㒰ⴚ෸߮⚻⊹⊛౰േ⣂ࠬ࠹ࡦ࠻⇐⟎ⴚ

11. ࠛࠗ࠭᜚ὐ∛㒮ߣߒߡߩ⸻≮૕೙‫ޓ‬ᒰ㒮ߪ㧘HIV ᗵᨴ∝࡮ࠛࠗ࠭⸻≮ߦ㑐ߒߡߪਁోߩฃߌ౉ࠇ૕೙ࠍߣߞߡ޿ࠆ‫ޕ‬ᤘ๺ 63 ᐕߦጘ㒂⋵ߣߒߡߪ╙৻଀⋡ߣߥࠆⴊ෹∛ᖚ⠪ߦ߅ߌࠆࠛࠗ࠭∝଀ࠍ⚻㛎ߒߡએ᧪㧘ߎࠇ߹ߢߦ⚂ 70 ଀ߩ⸻≮⚻㛎߇޽ࠅ㧘ጘ㒂⋵ߩㆊඨᢙߩ HIV࡮ࠛࠗ࠭ᖚ⠪ߩ⸻≮ࠍᜂᒰߒߡ޿ࠆ‫ߪߩ߽ߩߘ≮⸻࠭ࠗࠛޕ‬㧘ᒰೋߪ╙৻ౝ⑼ߢ㧘∛㒮⒖ォᓟߩᐔᚑ 16 ᐕ߆ࠄߪⴊᶧᗵᨴ∝ౝ⑼ߦߡᜂᒰߒߡ޿ࠆ߇㧘⸻≮਄ᔅⷐߦᔕߓߡ㧘ઁ⑼ߩో㕙⊛ߥදജߩ߽ߣ޽ࠄࠁࠆ⸻≮⑼߳ߩฃߌ౉ࠇ߽น⢻ߣߥߞߡ޿ࠆ‫ߚ߹ޕ‬㧘㊎ೝߒ੐᡿ߥߤߩᗵᨴኻ╷਄ߩⷰὐ߆ࠄ↢૕ᡰេ࠮ࡦ࠲࡯ߣදജ૕೙߽ਁోߢ޽ࠆ‫ޕ‬HIV ᴦ≮ߪㄭᐕᕆỗߦㅴᱠߒߡ߅ࠅ㧘ࠛࠗ࠭ߪ⥌ᱫ⊛ߥ∛᳇ߢߪߥߊᘟᕈ∔ᖚߣߒߡᝒ߃ࠄࠇࠆࠃ
߁ߦߥߞߡ߈ߡ޿ࠆ‫ ߃ࠁࠇߘޕ‬HIV ⸻≮ߦߣߞߡ㊀ⷐߥߎߣߪ㧘කᏧߦࠃࠆ⸻≮ߩߺߥࠄߕ㧘ᖚ⠪ߩり૕⊛࡮♖␹⊛ࠤࠕߢ޽ࠅ㧘⋴⼔Ꮷߦࠃࠆ⸻≮ࠨࡐ࡯࠻㧘⮎೷Ꮷߦࠃࠆ᦯⮎ᡰេ㧘ኾ㐷ࠞ࠙ࡦ࠮࡜࡯ߦࠃࠆࠞ࠙ࡦ࠮࡝ࡦࠣ૕೙ߩᢛ஻ߥߤ߇᳞߼ࠄࠇ㧘ߎࠇࠄߩలታൻ߽㗅⺞ߦㅴࠎߢ߅ࠅ㧘ߘߩ૕೙ߪ߶߷⏕┙ߒߚ‫ޕ‬㧙㧙৻ᣇ㧘ࠛࠗ࠭⸻≮ߦ㑐ߔࠆ✚ว⊛ක≮ߩឭଏߣᒰ࿾඙ߩઁߩක≮ᯏ㑐߳ߩᖱႎឭଏ㧘ක≮ᓥ੐⠪ᢎ⢒ߥߤࠍ⋡⊛ߦ㧘ᒰ㒮ߪᐔᚑ㧣ᐕ㧡᦬ߦጘ㒂⋵ߩࠛࠗ࠭᜚ὐ∛㒮ߩᜰቯࠍฃߌ㧘ߐࠄߦᐔᚑ 19 ᐕ 12᦬ߦߪጘ㒂⋵ࠛࠗ࠭ᴦ≮ਛᩭ᜚ὐ∛㒮ߩᜰቯࠍฃߌߚ‫ߦࠇߎޕ‬ၮߠ߈ᐔᚑ 19 ᐕ 12 ᦬ߦጘ㒂ᄢቇකቇㇱ㒝ዻ∛㒮ࠛࠗ࠭ኻ╷ផㅴ࠮ࡦ࠲࡯߇⸳⟎ߐࠇ㧘ⴊᶧᗵᨴ∝ౝ⑼ਛᔃߩ⸻≮ߩߺߥࠄߕ㧘㒮ౝᄖ߳ߩᢎ⢒࡮⎇ୃᵴേ㧘ᖱႎឭଏᵴേߥߤ߽ㅴ߼ߡ޿ࠆ‫ޕ‬੹ᓟ㧘ጘ㒂⋵ߩߐࠄߥࠆࠛࠗ࠭⸻≮ߦ߅ߌࠆోੱ⊛ක≮૕೙ߩᢛ஻ࠍ⋡ᜰߒ㧘⡯ຬ߳ߩ HIV ᗵᨴ∝ߩᱜߒ޿⍮⼂ߩᶐㅘߣ⸻≮ᛛⴚะ਄ࠍផㅴߔࠆߣߣ߽ߦ㧘ࡉࡠ࠶ࠢ᜚ὐ∛㒮޽ࠆ޿ߪ࿾ၞߩઁߩක
≮ᯏ㑐ߣߩㅪ៤ߥߤࠍࠃࠅ৻ጀలታൻߐߖߡ޿ߊ੍ቯߢ޽ࠆ‫ޕ‬12. ක≮㑐ㅪ㧔㒮ౝ㧕ᗵᨴኻ╷‫ޓ‬ක≮㑐ㅪᗵᨴኻ╷ߦߟ޿ߡߪ㧘ᐔᚑ 9 ᐕ 4 ᦬ഃ⸳ߩᗵᨴኻ╷ቶࠍታⴕᯏ㑐ߣߒߡ㧘ክ⼏ᯏ㑐ߢ޽ࠆ㒮ౝᗵᨴኻ╷ᆔຬળ㧔⃻㧦㒮ౝᗵᨴኻ╷ኾ㐷ᆔຬળ㧕߅ࠃ߮ߘߩਅㇱ⚵❱ߢ޽ࠆ MRSA 㒮ౝᗵᨴኻ╷ኾ㐷ㇱળ㧔⃻㧦㒮ౝᗵᨴኻ╷ዊᆔຬળ㧕ߣ✕ኒߦㅪ⛊ࠍߣࠅߥ߇ࠄⴕߞߡ߈ߚ‫ޕ‬ᐔᚑ 14 ᐕ 4 ᦬߆ࠄߪ㧘หቶࠍᩕ㙃▤ℂ߿ⶖ≙ኻ╷㧘࡝ࠬࠢࡑࡀࠫࡔࡦ࠻ߩᯏ⢻ࠍ޽ࠊߖ߽ߟ‫ޟ‬ᩕ㙃▤ℂ࡮ᗵᨴ೙ᓮࠨ
ࡐ࡯࠻࠮ࡦ࠲࡯‫ޠ‬㧔㒮ౝភ⟎㧕ߣߒߡ⊒ዷ⊛ߦ⸃ᶖߒ㧘ᐔᚑ 15 ᐕ 4 ᦬߆ࠄߪฬ⒓ࠍ‫↢ޟ‬૕ᡰេ࠮ࡦ
࠲࡯ (NST/ICT)‫ߣޠ‬ᄌ߃㧘ᱜᑼߦਛᄩ⸻≮ㇱ㐷ߩ߭ߣߟߣߒߡ⁛┙ߒߚ‫߅ߥޕ‬㧘ᐔᚑ 20 ᐕ 4 ᦬߆ࠄߪ੍㒐ធ⒳ㇱ㐷 ( ጘ㒂⋵߆ࠄᆔ⸤ߐࠇߚ੍㒐ធ⒳࠮ࡦ࠲࡯ߣߒߡ ) ࠍ㧘ߐࠄߦᐔᚑ 20 ᐕ 10 ᦬߆ࠄߪ๭ๆ≮ᴺᡰេㇱ㐷 (RST) ࠍჇ⸳ߒ㧘ࠃࠅᐢ▸࿐ߩᮮᢿ⊛⸻≮ᡰេࠍⴕߞߡ޿ࠆ‫ޕ‬ᒰ࠮ࡦ࠲࡯ᗵᨴ೙ᓮㇱ㐷㧘ߔߥࠊߜ ICT ߩ૶๮ࠍ೉᜼ߔࠆߣ㧘Ԙ㒮ౝᗵᨴ⊒↢⁁ᴫ⺞ᩏ㧔ࠨ࡯ࡌࠗ࡜ࡦࠬ㧕߅ࠃ߮ࠕ࠙࠻ࡉ࡟ࠗࠢߩᣧᦼ⊒⷗ߣኻᔕ ( ᦨఝవᬺോ )㧘ԙ‫ޟ‬ᗵᨴ∝▤ℂࠪࠬ࠹ࡓ‫ߚ޿↪ࠍޠ‬ో㔚ሶൻࠨ࡯ࡌࠗ࡜ࡦࠬ㧘Ԛ㒮ౝᗵᨴኻ╷ࠟࠗ࠼࡜ࠗࡦߩ૞ᚑ࡮ᦝᣂ㧔ᦨᣂ㧧ᐔᚑ 17 ᐕ 1 ᦬⊒ⴕ‫ޟ‬ጘ㒂ᄢቇකቇㇱ㒝ዻ∛㒮ᗵᨴኻ╷ࠟࠗ࠼࡜ࠗࡦ Ver. 2.1. 2006‫ޠ‬㧘⃻࿷ᡷ⸓૞ᬺਛ㧕㧘ԛᗵᨴ∝ࠢ࡝࠾࠶ࠢ߅ࠃ߮∛᫟Ꮌ࿁㧘Ԝᢎ⢒࡮ᐢႎᵴേ㧘ԝ⡯ᬺᗵᨴ㧔㊎ೝߒ੐᡿╬㧕㒐ᱛኻ╷㧘Ԟቇળ࡮⎇ⓥᵴേ㧘ԟ࿖┙ᄢቇකቇㇱ㒝ዻ∛㒮ᗵᨴኻ╷ද⼏ળ߳ߩෳട㧘Ԡෘ↢ഭ௛⋭㒮ౝᗵᨴࠨ࡯ࡌࠗ࡜ࡦࠬ੐ᬺ
߳ߩෳട㧘ԡጘ㒂⋵ౝߩ∛㒮ᗵᨴኻ╷ߩⷙᩰ⛔৻߅ࠃ߮ᖱႎ੤឵㧘∛⸻ㅪ៤ߥߤࠍ⋡⊛ߣߒߚ‫ޟ‬ጘ㒂‫ߩޠ‬ડ↹࡮ታᣉߥߤᄙጘߦࠊߚߞߡ޿ࠆ‫ߚ߹ޕ‬὇∓ߥߤߩࡃࠗࠝ࠹ࡠ
㒮ౝᗵᨴኻ╷ᬌ⸛ળ㧔ᐕ 2 ࿁㧕ኻ╷߿ SARS࡮ᣂဳࠗࡦࡈ࡞ࠛࡦࠩኻ╷ߥߤߩㄦㅦኻᔕ߽ᜂᒰߒߡ߈ߚ߇㧘੹ᓟ㧘߹ߔ߹ߔක≮߇㜞ᐲ࡮ⶄ㔀ൻߒ㧘∛㒮ᗵᨴߩ࡝ࠬࠢ߇Ⴧߔߣߣ߽ߦᣂߚߥᣂ⥝࡮ౣ⥝ᗵᨴ∝߳ߩኻᔕ߇ߐࠄߦ㊀ⷐൻߔࠆߎߣ߇੍ᗐߐࠇ㧘ICT ߩᬺോ▸࿐ߪ᜛ᄢߒ⛯ߌߡ޿ࠆ‫ⴕ┙⁛ߦࠄߐޕ‬᡽ᴺੱൻ㧘൮᜝ක≮ߥߤߩ⢛᥊ࠍ⠨ᘦߔࠆߣ㧘ᗵᨴ೙ᓮߦࠃࠆක≮⚻ᷣലᨐ߿࡝ࠬࠢࡑࡀࠫࡔࡦ࠻ߩㅊ᳞߇∛㒮ㆇ༡ߦߣߞߡ߽㊀ⷐ⺖㗴ߢ޽ࠆߎߣߪએ೨ߣᄌࠊࠅߥ޿‫ޕ‬⃻࿷㧘ICT ߩ᭴ᚑຬߪ↢૕ᡰេ࠮ࡦ࠲࡯㐳㧔౗ോ㧘ᣣᧄᗵᨴ∝ቇળᗵᨴ∝ኾ㐷ක߅ࠃ߮ ICD ೙ᐲද⼏ળ㧔ᣣᧄᗵᨴ∝ቇળផ⮈㧕ICD㧧Infection Control Doctor 㧕1 ฬ㧘ICT ኾછᢎቭ㧔ౝ⑼߅ࠃ߮ᄖ
⑼㧘ICD㧕2 ฬ㧘ኾછ⋴⼔Ꮷ㐳 ( ᣣᧄ⋴⼔දળ⹺ቯᗵᨴ▤ℂ⋴⼔Ꮷ㧦ICN) 1 ฬ㧘౗છ੐ോቭ 1 ฬߩ߶߆㧘ᡰេࡔࡦࡃ࡯ߣߒߡකቇㇱᓸ↢‛࡮ࡃࠗࠝࠗࡦࡈࠜࡑ࠹ࠖ࠶ࠢࠬㇱ㐷ߩᢎቭ 1 ฬ (ICD)㧘↢๮⑼ቇ✚วታ㛎࠮ࡦ࠲࡯ህ᳇ᕈ⩶ታ㛎ಽ㊁ߩᢎቭ 1 ฬ㧔ICD㧕㧘ᄖ⑼♽⸻≮⑼ 2 ฬ ( ᴲዩེ⑼ ICD ߅ࠃ߮⢷ㇱᄖ⑼ )㧘㜞ᰴᢇ๮ᴦ≮࠮ࡦ࠲࡯ᢎቭ 1 ฬ (ICD)㧘ක≮቟ో▤ℂቶᢎቭ 1 ฬ㧘GRM 1 ฬ ( ⋴⼔Ꮷ㐳)㧘ᬌᩏㇱ 2 ฬ (1 ฬߪ ICD) ߅ࠃ߮⮎೷ㇱߩ⡯ຬ 2 ฬ ( ޿ߕࠇ߽ ICD)㧘ᩕ㙃▤ℂቶ㐳 1 ฬ߅ࠃ߮ᛛ⢻⵬૒ຬ 1 ฬߩว⸘ 18 ฬߣߥߞߡ޿ࠆ‫ߜ߁ߩߎޕ‬㧘࠮ࡦ࠲࡯㐳߅ࠃ߮ኾછ⋴⼔Ꮷ㐳㧘ౝ⑼ኾછᢎቭ㧘ᴲ
ዩེ⑼ᢎቭ㧘⮎೷ㇱਥછߩ 5 ฬߪ ICT ߩਛߢ߽ࠬࡍࠪࡖ࡝ࠬ࠻ߣߒߡ㧘ࠃࠅ㜞ᐲߥᬺോࠍᜂᒰߒߡ޿
ࠆ (S-ICT)‫ޕ‬㧙㧙ߎߩࠃ߁ߦ㧘ኾછ⡯ຬࠍ฽߼ߚᄙ⡯⒳ߦࠃࠆ࠴࡯ࡓක≮ᵴേ߇ ICT ᵴേߣߒߡ߽ዷ㐿ߐࠇߡߪ޿ࠆ
߽ߩߩ㧘એਅߩ⺖㗴ࠍᜰ៰ߖߑࠆࠍᓧߥ޿‫ޕ‬(1) ⃻࿷ ICD ߩቇળ⹺ቯࠍฃߌߡ޿ࠆࡔࡦࡃ࡯ߪᄙ⡯⒳ߩ 9 ฬ࿷☋ߒߡ޿ࠆ߽ߩߩ㧘ߔߴߡኾછ
ߢߩᵴേߪߢ߈ߡ޿ߥ޿‫ߚ߹ޕ‬ኾછᢎቭ 2 ฬߪ⊓㍳ߐࠇߡ޿ࠆ߇㧘ታ⾰⊛ߦߪᲣ૕ಽ㊁ߩ઀੐ࠍ90㧑એ਄㧘ᒰ࠮ࡦ࠲࡯ߢߩᬺോ㊂ߪ 10㧑એਅߢ޽ࠆ‫ߪߣߎߩࠄࠇߎޕ‬㧘޿ߊࠄࡑ࠾ࡘࠕ࡞ࠍᢛ
஻ߒߡ޽ߞߡ߽㧘ࠕ࠙࠻ࡉ࡟ࠗࠢ߿⃻႐ߢߩ୘‫ߩޘ‬ᗵᨴ੐଀ߦኻߒߡ߈߼⚦߿߆ߦኻᔕߔࠆߎߣ
ߦߪ㒢⇇߇޽ࠆ‫ ߚ߹ޕ‬1 ฬߩኾછ⋴⼔Ꮷ㐳 (ICN) ߦߪᄙᄢߥ⽶ᜂ߇߆߆ߞߡ޿ࠆߎߣ߽ᄢ߈ߥ໧
㗴ὐߢ޽ࠆ‫ޕ‬(2) ߐࠄߦᡰេࡔࡦࡃ࡯ߩᬺോౝኈߪ㧘⚿ᨐ⊛ߦ᦬ 1 ࿁ߩ ICT ળ⼏ߦෳടߔࠆߎߣߣ㧘↢૕ᡰេ࠮ࡦ࠲࡯࠮ࡒ࠽࡯ߥߤ߳ߩදജߦ㒢ቯߐࠇߡ޿ࠆ‫ߪ᧪ᧄޕ‬ᄙ⡯⒳ߦࠃࠆ ICT ࡔࡦࡃ࡯߇⸻≮⃻႐ߦ࡜࠙ࡦ࠼ߒߡኻ╷ࠍ⻠ߓࠆᒻߎߘᦸ߹ߒ޿ᵴേ߇ᦼᓙߢ߈ࠆߣ⠨߃ࠄࠇࠆ‫⥃ߦߊߣޕ‬ᐥᬌᩏᛛᏧ㧘⮎೷Ꮷ㧘੐ോቭߩᬺോౝኈࠍࠃࠅ᣿⏕ߦߒߡ㧘ߘࠇߙࠇߩᓧᗧߣߔࠆᬺോࠍᅤ૗ߥߊ⊒ើߢ߈ࠆࠃ߁ߦ㧘ᤨ㑆ߩ଻㓚ߣᚑᨐ⽿છߩ᣿⏕ൻߥߤ㧘ਛᄩ⸻≮ㇱ㐷ߩ৻ߟߣߒߡ⚵❱⊛ߦ߽లታߔ
ߴ߈ߢ޽ࠆ‫ߦߊߣޕ‬੐ോቭߦߟ޿ߡߪኾ㐷⊛⍮⼂߿⚻㛎߽㊀ⷞߐࠇࠆߚ߼㧘ࠃࠅ㐳ᦼߦኾછᜂᒰ
ߔࠆߎߣ߇ᦸ߹ߒ޿‫ޕ‬(3) ⚿⺰⊛ߦߪ⃻⁁ߢߪਛᄩ⸻≮ㇱ㐷ߣ޿߁ߦߪᬺോ㊂ߩᄙߐ㧘ᄙᓀߐࠍ⠨ᘦߔࠆߣ૛ࠅߦ߽⚵❱⊛૕೙߇ਇචಽߢ޽ࠆߣ޿߁ὐ߇ᄢ߈ߥ໧㗴ὐߢ޽ࠆ‫࡯ࡃࡦࡔޕ‬છ๮૕೙߽฽߼㧘ᣧᕆߦ⷗⋥ߒ߇ᔅⷐߢ޽ࠆ‫ޕ‬(4) ᛫⩶⮎ߩㆡᱜ૶↪㧘ᗵᨴ∝⸻≮ߩ࡟ࡌ࡞ࠕ࠶ࡊ߇⺖㗴ߢ޽ࠅ㧘ߎࠇ߽ࠦࡦࠨ࡞࠹࡯࡚ࠪࡦ㧘ࠗࡦ࠲࡯ࡌࡦ࡚ࠪࡦߣ޿ߞߚᗵᨴ∝⸻≮߳ߩ ICT ߦࠃࠆ੺౉ࠪࠬ࠹ࡓࠍ⏕┙ߔߴ߈ᤨᦼߦ᧪ߡ޿ࠆ‫ޕ‬(5) ᗵᨴኻ╷ߪ㧘਄⸥ ICT ߿ࡑ࠾ࡘࠕ࡞ߩలታߩߺߢߪ߶ߣࠎߤᗧ๧߇ߥ޿‫ޕ‬⡯ຬߩ࡟ࡌ࡞ࠕ࠶ࡊ
ࠍ⛮⛯⊛ߦߪ߆ࠆߴ߈ߢ޽ࠅ㧘ත೨ᢎ⢒߽฽߼ߚᢎ⢒࡮⎇ୃ૕೙ࠍᡷༀߒߥߌࠇ߫޿ߟ߹ߢ߽࡝
ࠬࠢߪᷫዋߒߥ޿‫ߩઁߡߞ߇ߚߒޕ‬㗔ၞ ( ක≮቟ోߥߤ ) ߽฽߼∛㒮ో૕ߣߒߡ੐ോᣇ߇▤ℂߔࠆ⎇ୃ▤ℂ૕೙ߩ⏕┙߇ᦸ߹ࠇࠆ‫ޕ‬ක≮⋙ⷞ߿∛㒮ᯏ⢻⹏ଔ߳ߩኻᔕ㕙ߢ߽ߎߩ૕೙ߩ⏕┙ߪᕆോߣᕁࠊࠇࠆ‫ޕ‬(6) ߎࠇ߽ઁߩ㗔ၞߣห᭽ߩߎߣߢ޽ࠆ߇㧘㒮ౝߢߩᖱႎવ㆐૕೙߇ోߊߣ⸒ߞߡࠃ޿߶ߤਇචಽ
ߢ޽ࠆ‫ޕ‬ᗵᨴ೙ᓮߦᄢ߈ߥജࠍ⊒ើߔࠆߩߪ߹ߕߪ‫ޟ‬ᖱႎ౒᦭‫޿⸒ߣޠ‬ಾߞߡࠃ޿‫ࠢ࠼ࠢࡦ࡝ޕ‬࠲࡯߿࡝ࡦࠢ࠽࡯ࠬߩߺߢߪߥߊ㧘ᄖㇱᆔ⸤ᬺ⠪⡯ຬ߽฽߼㧘ߔߴߡߩ⡯ຬߦㄦㅦ߆ߟㆡಾߦ
‫ޟ‬ᖱႎ౒᦭‫ߦ߁ࠃࠆࠇߐߥ߇ޠ‬㒮ౝᖱႎવ㆐૕೙ߩࠗࡦࡈ࡜ᢛ஻߇ᦸ߹ࠇࠆ‫ޕ‬޿ߕࠇߦߖࠃ㧘ฦ⒳੐଀ߦㄦㅦ߆ߟ⊛⏕ߦኻᔕߒߥ߇ࠄ㧘⸻≮⑼ᮮᢿ⊛ߦ㒮ౝߢ㗬ࠅߦߐࠇࠆ
ICT ߣߒߡ⽸₂ߢ߈ࠆߴߊߐࠄߥࠆ♖ㅴࠍߒߡ޿߈ߚ޿‫ޕ‬

13. ක≮቟ోኻ╷᭎ⷐක≮቟ో▤ℂቶߪ㧘ᐔᚑ 14 ᐕ 4 ᦬ߦ㒮ౝߦኾછ࡝ࠬࠢࡑࡀࠫࡖ࡯㧔ኾᓥ⋴⼔Ꮷ㐳㧕㧝ฬ߇㈩⟎ߐࠇߚߎߣࠍᄾᯏߦ㧘㒮ౝߩක≮቟ోኻ╷ߩታോᯏ㑐ߣߒߡ⊒⿷ߒߚ߇㧘␠ળ⊛ߥක≮቟ో߳ߩ࠾࡯࠭
ߩ㜞߹ࠅ߿㧘ᐔᚑ 18 ᐕߩක≮ᴺᡷᱜࠍ⢛᥊ߦ㧘ᐔᚑ 19 ᐕ 10 ᦬߆ࠄߪᢎ⢒⡯ຬ㧔කᏧ㧕1 ฬࠍኾᓥ㈩⟎ߒ㧘৻ጀߩ૕೙ᒝൻࠍ࿑ߞߚߣߎࠈߢ޽ࠆ‫⃻ޕ‬࿷ߩቶຬ᭴ᚑߪ㧘ቶ㐳㧔ක≮቟ోᜂᒰ೽㒮㐳㧕㧘೽ቶ㐳㧔ኾᓥකᏧ㧕㧘ኾછ࡝ࠬࠢࡑࡀࠫࡖ࡯㧔ኾᓥ⋴⼔Ꮷ㐳㧕㧘∛᫟ක㐳ળ⼏⼏㐳㧘ᄖ᧪ක㐳ળ⼏⼏㐳㧘⮎೷ㇱ೽ㇱ㐳 1 ฬ㧘⋴⼔Ꮷ㐳 2 ฬ㧘ක≮ࠨ࡯ࡆࠬ⺖㐳⵬૒ 1 ฬ㧘ኾᓥ㕖Ᏹൕ੐ോ⡯ຬ 1 ฬߩ⸘ 10 ฬ㧙㧙ߢ᭴ᚑߐࠇߡ޿ࠆ‫ޕ‬ක≮቟ో▤ℂቶߪ㧘㒮ౝ⚵❱਄㧘⸻≮⑼㧘ਛᄩ⸻≮ᣉ⸳╬㧘੐ോㇱ㐷߆ࠄߪ⁛┙ߒߚᯏ㑐ߣߒߡ૏⟎ߠߌࠄࠇߡ޿ࠆ‫ޕ‬ਥߥᬺോߪ㧘⚵❱ᮮᢿ⊛ߦ㒮ౝߩ቟ో▤ℂࠍᜂ޿㧘ක≮੐᡿㒐ᱛ෸߮ක≮ߩ቟ోᕈߦ㑐ߒක≮቟ో▤ℂቶߩ᳿ቯ੐㗄ࠍታᣉߔࠆߣߣ߽ߦ㧘቟ో▤ℂߦ㑐ߔࠆ⺞ᩏ㧘ಽᨆ㧘ᜰዉ╬ࠍⴕ߁ߎߣߢ޽ࠆ‫ޕ‬ක≮቟ో▤ℂᆔຬળߪ㧘ක≮቟ో▤ℂኻ╷෸߮ක≮੐᡿㒐ᱛߦ㑐ߔࠆ㊀ⷐ੐㗄ߩክ⼏ࠍⴕ߁Ᏹ⸳ߩ
ᆔຬળߢ޽ࠆ‫ౕޕ‬૕⊛ߦߪ㧘ක≮ߩ቟ో▤ℂኻ╷ߩᬌ⸛෸߮ផㅴ㧘ක⮎ຠ࡮ක≮ᯏེ╬ߩ቟ో▤ℂߣ
ขᛒ޿㧘ක≮቟ో▤ℂߩߚ߼ߩ⡯ຬ⎇ୃ㧘ක≮੐᡿෸߮ࠗࡦࠪ࠺ࡦ࠻ႎ๔ߦ㑐ߔࠆᖱႎ෼㓸෸߮ಽᨆ㧘ක≮቟ోࡑ࠾ࡘࠕ࡞ߩ૞ᚑ╬ߦଥࠆක≮቟ో▤ℂቶ߆ࠄߩႎ๔෸߮ឭ᩺ߦߟ޿ߡክ⼏ߔࠆ‫ޕ‬
㧔4㧕ක≮቟ో
߹ߚ㧘ᐔᚑ 19 ᐕ 4 ᦬ߦ೙ቯߐࠇߚጘ㒂ᄢቇකቇㇱ㒝ዻ∛㒮ߩᙗ┨࡮ၮᧄᚢ⇛ߢߪ㧘ၮᧄᚢ⇛ߣߒߡ㧘࡮ᖚ⠪ෳടဳߩක≮቟ోኻ╷ࠍផㅴߔࠆ‫ޕ‬࡮⥄ࠄㅴࠎߢක≮⻠⠌ળߦෳടߒ㧘ක≮቟ోߦ㑐ߔࠆᗧ⼂ߣ⍮⼂ࠍ㜞߼ࠆ‫ޕ‬࡮ක≮቟ోะ਄ߩߚ߼ߩᡷༀ╷ࠍ㧘Ⓧᭂ⊛࡮ㅦ߿߆ߦขࠅ౉ࠇታ〣ߔࠆ‫ޕ‬
࡮Ⓧᭂ⊛ߦࠗࡦࠪ࠺ࡦ࠻࡟ࡐ࡯࠻ࠍឭ಴ߔࠆ‫ޕ‬࡮ක≮⡯⒳㑆ߩࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦࠍ౞Ṗൻߔࠆ‫ޕ‬࡮ࡑ࠾ࡘࠕ࡞ࠍᏱߦ⷗⋥ߒ๟⍮ᔀᐩࠍ࿑ࠆ‫ޕ‬
ߩ 6 㗄⋡ߩⴕേ⋡ᮡ߇ቯ߼ࠄࠇߚ‫ޕ‬ᐔᚑ 19 ᐕ 10 ᦬߆ࠄߪ‫ޟ‬ጘ㒂ᄢቇකቇㇱ㒝ዻ∛㒮ක≮቟ో▤ℂᜰ㊎‫∛߇ޠ‬㒮ࡎ࡯ࡓࡍ࡯ࠫߦឝタߐࠇ㧘⺕ߢ߽⥄↱ߦ㑛ⷩߢ߈ࠆ‫ޕ‬ߎߩ߶߆㧘ක≮ᴺᡷᱜߦ઻޿㧘ᐔᚑ 19 ᐕ 4 ᦬߆ࠄක⮎ຠ቟ో▤ℂ⽿છ⠪㧘ක≮ᯏེ቟ో▤ℂ⽿છ⠪߇⟎߆ࠇࠆߎߣߣߥࠅ㧘ක⮎ຠߩ቟ో૶↪ߩߚ߼ߩᬺോᚻ㗅ᦠ߿ක≮ᯏེ቟ో▤ℂࡑ࠾ࡘࠕ࡞߇╷ቯߐࠇߡ޿ࠆ‫ޕ‬㧔㧝㧕ࠗࡦࠪ࠺ࡦ࠻ႎ๔ߣߘߩኻ╷ࠗࡦࠪ࠺ࡦ࠻㧔incident㧕ߪ‫ޟ‬ᖚ⠪ߩ⸻≮߿ࠤࠕߦ߅޿ߡ㧘ᧄ᧪޽ࠆߴ߈ᆫ߆ࠄᄖࠇߚⴕὑ߿੐ᘒ
ߩ⊒↢‫ࠍޠ‬ᗧ๧ߒ㧘ోߡߩ∛㒮⡯ຬߦߪⓍᭂ⊛ߥႎ๔߇⟵ോઃߌࠄࠇߡ޿ࠆ‫ޕ‬ක≮቟ో▤ℂቶߢߪߎࠇࠄ㒮ౝ㓐ᚲ߆ࠄߩࠗࡦࠪ࠺ࡦ࠻ႎ๔ࠍฃߌ㧘ᔅⷐߥ੐଀ߦߟ޿ߡߪㅊടߢ⡞߈ขࠅ⺞ᩏࠍታᣉߒ㧘޽ࠆ޿ߪ㓸⸘ߒߚ਄ߢ⛔⸘ಣℂ߿ಽᨆࠍⴕߞߡ޿ࠆ‫ޕ‬ᐔᚑ 19 ᐕᐲߩ✚ႎ๔ઙᢙߪ 1624 ઙߢ㧘೨ᐕᐲߣᲧセߒ 114 ઙ㧔7.5㧑㧕ߩჇടߢ޽ߞߚ‫࠻ࡦ࠺ࠪࡦࠗߩࠄࠇߎޕ‬ႎ๔ߪ㧘ක≮቟ో▤ℂቶຬળ⼏㧔Ფㅳ᳓ᦐᣣ㐿௅㧕ߢ࡟ࡆࡘ࡯ߒ㧘㊀ⷐ੐଀ߩ᛽಴߿ࠗࡦࠪ࠺ࡦ࠻࡟ࡌ࡞ߩᬌ⸛㧘ㅊട⺞ᩏߩᔅⷐᕈߩ᦭
ή㧘ኻᔕᣇ㊎╬ࠍᬌ⸛ߒߡ޿ࠆ‫ߚ߹ޕ‬㧘✕ᕆᕈߩ㜞޿߽ߩߦߟ޿ߡߪක≮቟ో▤ℂቶߣᒰ⹥ㇱ⟑ߩ࡝ࠬࠢࡑࡀࠫࡖ࡯㑆ߢᖱႎ੤឵ߩ਄㧘቟ోኻ╷ࠍታᣉߒߡ޿ࠆ‫ޕ‬ක≮቟ో▤ℂቶౝߢᬌ⸛ߐࠇߚኻᔕᣇ
㊎߿ታ㓙ߦታᣉߒߚ቟ోኻ╷ߦߟ޿ߡߪ㧘ක≮቟ో▤ℂᆔຬળ㧔᦬ 1 ࿁㐿௅㧕ߦ߅޿ߡክ⼏ߐࠇ㧘ߘߩ⚿ᨐߦߟ޿ߡߪ⑼㐳ળ㧘කዪ㐳╬ᄖ᧪ක㐳࡮∛᫟ක㐳วหળ⼏㧘࡝ࠬࠢࡑࡀࠫࡖ࡯ળ⼏╬ߢႎ๔ߒ㧘߹ߚ㧘ක≮቟ో▤ℂቶ࠾ࡘ࡯ࠬࠍ⊒ⴕߒߡ⡯ຬߦ๟⍮ߒߡ޿ࠆ‫ޕ‬ᣣᧄක≮ᯏ⢻⹏ଔᯏ᭴߳ߩႎ๔ߔࠆߴ߈੐଀ߪ㧘ၮᧄ⊛ߦߪ࿖┙ᄢቇකቇㇱ㒝ዻ∛㒮ක≮቟ో▤ℂද⼏ળߢឭ␜ߐࠇߡ޿ࠆり૕ᓇ㗀࡟ࡌ࡞ 3b એ਄ߣߒߡ߅ࠅ㧘࡟ࡌ࡞ߩᦨ⚳⏕ቯߪක≮቟ో▤ℂቶߢ
ⴕߞߡ޿ࠆ‫ޕ‬∛㒮ߣߒߡߩኻᔕ߇ᔅⷐߥ੐଀ߦߟ޿ߡߪ㧘ක≮቟ో▤ℂቶ߆ࠄ∛㒮㐳߳ㅦ߿߆ߦႎ๔ߒߡක≮੐᡿ኻ╷ᆔຬળߩ᜗㓸ࠍ᳞߼㧘ߘߩᓟߩኻᔕࠍද⼏ߒߡ޿ࠆ‫ޕ‬ᐔᚑ 18 ᐕ 5 ᦬એ㒠㧘ᄖㇱᆔຬࠍട߃ߚ
ක≮੐᡿⺞ᩏᆔຬળࠍ㐿௅ߔࠆࠃ߁ߥ㊀ᄢ੐଀ߪ⊒↢ߒߡ޿ߥ޿߇㧘∛㒮㐳ߩᜰ␜ߦၮߠ߈᜛ᄢක≮቟ో▤ℂቶຬળ⼏ࠍ᜗㓸ߒ⺞ᩏ࡮ᬌ⸛ߒߚ੐଀ߪᲤᐕ 1 㨪 2 ઙ⒟ᐲ⊒↢ߒߡ޿ࠆ‫ޕ‬㧙㧙㧔㧞㧕ක≮቟ోߦଥࠆ⡯ຬᢎ⢒ක≮቟ోߦଥࠆ⎇ୃߪ㧘ක≮቟ో▤ℂቶ߇ਛᔃߣߥߞߡ㧘ᓥ᧪߆ࠄක≮ᴺߦቯ߼ࠄࠇߡ޿ࠆᐕ 2 ࿁ߩో⡯ຬࠍኻ⽎ߣߒߚ⎇ୃ㧘ᣂⷙណ↪⠪ኻ⽎ߩ⎇ୃ㧘ਛㅜណ↪⠪ኻ⽎ߩ⎇ୃ╬ࠍታᣉߒߡ޿ࠆ‫ࠇߎޕ‬߹ߢ⎇ୃᒰᣣߦㇺวߩߟ߆ߥ޿⡯ຬߦߟ޿ߡߪ㧘⎇ୃࠍࡆ࠺ࠝߦ㍳↹ߒߘࠇࠍᓟᣣ਄ᤋߔࠆߥߤߒߡ
ኻᔕߒߡ޿ߚ߇㧘ᐔᚑ 20 ᐕᐲߪ㧘↢૕ᡰេ࠮ࡦ࠲࡯ᗵᨴ೙ᓮㇱ㐷ߣวหߢ᦬ᦐᣣ㨪㊄ᦐᣣ߹ߢ 5 ᣣ㑆ห৻ߩ⎇ୃࠍㅪᣣታᣉߒ㧘ߐࠄߦ㕖Ᏹൕ⡯ຬࠍኻ⽎ߣߒߚㅊട⎇ୃ߽ታᣉߒߡฃ⻠₸ߩะ਄ࠍ࿑ߞ
ߡ޿ࠆ‫ߩୃ⎇ޕ‬ౝኈߣߒߡߪ㒮ౝߢ⊒↢ߒߚࠗࡦࠪ࠺ࡦ࠻੐଀߿ᣂߚߦක≮቟ో▤ℂᆔຬળߢขࠅ᳿
߼ߚ቟ోኻ╷ߩ⚫੺ࠍਛᔃߦⴕߞߡ޿ࠆ‫ߚ߹ޕ‬㧘⎇ୃකߩߺࠍኻ⽎ߣߒߚ⎇ୃࠍᐕᐲᧃߦታᣉߒߡ޿
ࠆ‫ߦࠄߐޕ‬㧘ᐔᚑ 20 ᐕᐲߪක≮቟ోో࿖౒หⴕേߩ㧘‫ⴕޟ‬േ⋡ᮡ 5㧦ක≮ᯏེߩ቟ోߥᠲ૞ߣ▤ℂ(a) ャᶧࡐࡦࡊ࡮ࠪ࡝ࡦࠫࡐࡦࡊߩ቟ో▤ℂ‫ࠅ޽߽ߣߎߚߒ࡯࡝࠻ࡦࠛߦޠ‬㧘ᣂណ↪ᤨߩ߶߆㧘⋴⼔ㇱࠍਛᔃߦᏗᦸߔࠆ⡯ຬߦኻߒߡ೎ㅜታᛛ⎇ୃࠍታᣉߒߡ޿ࠆ‫ੱ߆߶ߩߎޕ‬Ꮏ๭ๆེߦ㑐ߒߡߪ↢૕ᡰេ࠮ࡦ࠲࡯ RST㧘ߘߩઁߩක≮ᯏེߦߟ޿ߡߪක≮ᯏེ࠮ࡦ࠲࡯㧘ක⮎ຠߦ㑐ߒߡߪ⮎೷ㇱߣㅪ៤ߒߡ⎇ୃࠍⴕߞߡ޿ࠆ‫ޕ‬㧔㧟㧕㒮ౝ࡜࠙ࡦ࠼
ᐔᚑ 20 ᐕᐲ߆ࠄ㧘߅߅߻ߨㅳ 1 ࿁ߩ㒮ౝ࡜࠙ࡦ࠼ࠍታᣉߒߡ޿ࠆ‫ޕ‬㒮ౝ࡜࠙ࡦ࠼ߢߪ㧘ක≮቟ో਄໧㗴ߩ޽ࠆⴕὑ߿⁁ᘒߩ᦭ήߩ⏕⹺߿㧘ᢇᕆࠞ࡯࠻߿ක≮ᯏེߩὐᬌ⁁ᴫߩ⏕⹺㧘ࠗࡦࠪ࠺ࡦ࠻ႎ
๔ౝኈߩ⏕⹺㧘੐᡿ߩᕟࠇߩ޽ࠆක≮ᯏེߩ࿁෼㧘ක⮎ຠߩ▤ℂ⁁ᴫߩ⏕⹺╬ࠍታᣉߒߡ޿ࠆ‫ޕ‬㒮ౝ࡜࠙ࡦ࠼ߢ෼㓸ߒߚᖱႎߪ㧘ක≮቟ోኻ╷ߩ┙᩺߿ኻ╷ߩታᣉ⁁ᴫߩ⏕⹺ߦᓎ┙ߞߡ޿ࠆ‫ޕ‬㧔㧠㧕ක≮቟ోࡑ࠾ࡘࠕ࡞ߩ╷ቯ
ᐔᚑ 12 ᐕ 6 ᦬ߦ‫ޟ‬ක≮੐᡿╬㒐ᱛࡑ࠾ࡘࠕ࡞‫ޓ‬ᖚ⠪ਛᔃ࡮ᖚ⠪ਥ૕ߩක≮ࠍ⋡ᜰߒߡ‫ߐⴕ⊒߇ޠ‬ࠇ㧘ߘߩᓟᐔᚑ 16 ᐕᐲ߆ࠄߪ‫ޟ‬ක≮቟ోࡑ࠾ࡘࠕ࡞‫ߣޠ‬ᡷ㗴ߒ㧘Ფᐕᐲߏߣߦో૕⊛ߥ⷗⋥ߒࠍ࿑ߞߡ޿ࠆ‫ޟߚ߹ޕ‬ක≮቟ోࡑ࠾ࡘࠕ࡞‫ߪߦޠ‬ක≮቟ో▤ℂᆔຬળߢክ⼏᳿ቯߐࠇߚߐ߹ߑ߹ߥ቟ోኻ╷ࠍㅦ߿߆ߦ෻ᤋߔࠆߚ߼㧘㒮ౝߦ㈩Ꮣߐࠇߡ޿ࠆࡃࠗࡦ࠳࡯ౝߩౝኈߪ㓐ᤨᏅߒᦧ߃ߡᦨᣂߩ⁁ᘒࠍ଻ߟࠃ߁ߦߒߡ޿ࠆ‫ߚ߹ޕ‬㧘‫ޟ‬ක≮቟ోࡑ࠾ࡘࠕ࡞‫ߪޠ‬㒮ౝߔߴߡߩ㔚ሶࠞ࡞࠹┵ᧃ਄߆ࠄ߽ෳᾖߢ
߈ࠆ‫ޕ‬㧔㧡㧕࠾ࡘ࡯ࠬ࡮࠻ࡇ࠶ࠢࠬߩ⊒ⴕක≮቟ో▤ℂቶ߆ࠄߩᖱႎ⊒ାߣߒߡ㧘ᐔᚑ 19 ᐕᐲߪක≮቟ోᆔຬળ࠾ࡘ࡯ࠬࠍ 6 ࿁㧘ක≮቟ో࠻ࡇ࠶ࠢࠬࠍ 23 ࿁⊒ⴕߒߚ‫ޕ‬㧔㧢㧕࿖┙ᄢቇ∛㒮㑆⋧੕࠴ࠚ࠶ࠢ࡮ක≮ᴺ╙ 25 ᧦ߦࠃࠆ┙౉ᬌᩏ
ᐔᚑ 18 ᐕᐲߦ৻ᤨਛᢿߒߚ࿖┙ᄢቇ㒝ዻ∛㒮㑆ߢߩ‫ޟ‬ක≮቟ో࡮⾰ะ਄ߩߚ߼ߩ⋧੕࠴ࠚ࠶ࠢ‫ޠ‬ߪ㧘ᐔᚑ 19 ᐕᐲ߆ࠄౣ㐿ߐࠇ㧘࿖┙ᄢቇකቇㇱ㒝ዻ∛㒮ක≮቟ో▤ℂද⼏ળߢᜰቯߐࠇߚᜂᒰᄢቇ
߇ᒰ㒮ߩක≮቟ోߩታᣉ⁁ᴫࠍ⏕⹺ߒߡ޿ࠆ‫ߚ߹ޕ‬㧘᧲ᶏർ㒽ෘ↢ዪ㧘ጘ㒂⋵㧘ጘ㒂Ꮢ଻ஜᚲ߇౒ห
ߒߡⴕ߁‫ޟ‬ක≮ᴺ╙ 25 ᧦ߦࠃࠆ┙౉ᬌᩏ‫߽ߡ޿߅ߦޠ‬㧘ㄭᐕߪක≮቟ోߦ㑐ߔࠆ⏕⹺੐㗄߇Ⴧടߒߡ޿ࠆ‫ߢࠄࠇߎޕ‬ᜰ៰ࠍฃߌߚ㗄⋡ߩਛߢ㧘ක≮቟ో▤ℂቶߢኻᔕߔߴ߈߽ߩߦߟ޿ߡߪᡷༀ╷ࠍᬌ⸛ߒ㧘ක≮቟ో▤ℂᆔຬળߦ⻁ߞߚ਄ߢታᣉߒߡ޿ࠆ‫ޕ‬
⥄Ꮖ⹏ଔ
⹏ଔ

㧙㧙

කᏧߩኾᓥᜂᒰ⠪߇㈩⟎ߐࠇࡑࡦࡄࡢ࡯߇Ⴧടߒߚߎߣߦࠃࠅ㧘ᓥ᧪߆ࠄ᳞߼ࠄࠇߡ޿ߚ⒳‫ߩޘ‬ᵴേ߇ࠃ߁߿ߊዋߒߠߟታᣉߢ߈ࠆࠃ߁ߦߥߞߡ߈ߚὐߪ⹏ଔߢ߈ࠆ‫ߚ߹ޕ‬㧘ߎߩߣߎࠈක≮੐᡿߇ේ࿃ߢᱫ੢ߒߚᖚ⠪߇ߥ޿ߎߣߪᐘ޿ߢ޽ࠆ߇㧘ઁߩᣉ⸳ߣᲧセߒߡࠗࡦࠪ࠺ࡦ࠻ႎ๔ઙᢙ߇ዋߥߊ㧘ᦨㄭિ߮ᖠࠎߢ޿ࠆߎߣߦߟ޿ߡߪᭂ߼ߡㆮᙝߢ޽ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ࠗࡦࠪ࠺ࡦ࠻ႎ๔ߩႎ๔ઙᢙߪ㧘ߔߥࠊߜ⡯ຬߩක≮቟ోߦኻߔࠆᗧ⼂ࠍ␜ߒߡ޿ࠆߎߣߦ߶߆ߥ
ࠄߕ㧘ߎࠇߦߟ޿ߡᡷ㕟ࠍⴕ߁ߦߪ☼ࠅᒝߊ⎇ୃ╬ߩ໪⫥ᵴേࠍផㅴߒߡ޿ߊએᄖߥ޿‫ߚ߹ޕ‬㧘ฦㇱ⟑ߩ࡝ࠬࠢࡑࡀࠫࡖ࡯߳ߩᢎ⢒ߦߟ޿ߡߪ㧘ߎࠇ߹ߢᚻߟ߆ߕߩ⁁ᘒ߇⛯޿ߡ޿ࠆ‫ߦ․ޕ‬ฦ⸻≮⑼ක
Ꮷߩ࡝ࠬࠢࡑࡀࠫࡖ࡯ߦኻߒߡߤߩࠃ߁ߦᔅⷐߥ⾗⾰ࠍりߦߟߌߐߖࠆ߆ߪᄢ߈ߥ⺖㗴ߢ޽ࠆ‫ޕ‬කᏧਇ⿷ࠍ⢛᥊ߦ㕖Ᏹߦᄙᔔߥ⁁ᘒߦ⟎߆ࠇߡ޿ࠆᓐࠄߩ⋡ࠍක≮቟ోߦะߌߐߖࠆߎߣ߇ߢ߈ࠇ߫㧘⏕ታߦක≮੐᡿㒐ᱛߦߟߥ߇ࠆߣ⠨߃ࠄࠇࠆ‫ߚ߹ޕ‬㧘ኾછ࡝ࠬࠢࡑࡀࠫࡖ࡯ߩᓟછ⢒ᚑ߽㊀ⷐߥ⺖㗴ߢ
޽ࠆ‫ޕ‬
੹ᓟߩዷᦸ
ක≮቟ోၮᧄᚢ⇛߿ක≮቟ో▤ℂᜰ㊎ߦၮߠ޿ߚ⡯ຬ৻ੱ৻ੱߩක≮቟ోᕁᗐߩቯ⌕ࠍ⋡ᜰߔߚ߼㧘੹ᓟ߽⻠⠌ળ╬ߩ࿾㆏ߥᵴേ߇ၮᧄߢ޽ࠆ‫࠻ࡦ࠺ࠪࡦࠗߡߞࠃߦࠇߘޕ‬ႎ๔ઙᢙ߇Ⴧടߒ㧘㊀ᄢ
੐᡿ߩ⊒↢ࠍ㒐ᱛߔࠆߎߣߦߟߥ߇ࠆ‫ߚ߹ޕ‬㧘ක≮቟ో▤ℂᆔຬળߦ߅޿ߡ㧘ක≮቟ోၮᧄᚢ⇛ߩⴕേ⋡ᮡߩ߁ߜߎࠇ߹ߢ޽߹ࠅขࠅ⚵߹ࠇߡߎߥ߆ߞߚ㧘ᖚ⠪ෳടဳක≮቟ోኻ╷ߩផㅴߣක≮⡯⒳㑆
ߩࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦߩ౞Ṗൻߦߟ޿ߡߩ⼏⺰ࠍᷓ߼㧘ታലᕈߩ޽ࠆౕ૕᩺ࠍ╷ቯ࡮ታ〣ߒߡ㧘ߎࠇࠄߩⴕേ⋡ᮡ߇ታ⃻ߢ߈ࠆࠃ߁ߦขࠅ⚵߻‫ޕ‬

14. ౉㒮ၮᧄᢱ࡮౉㒮ᤨ㘩੐≮㙃ߩ⁁ᴫ
㧔1㧕౉㒮ၮᧄᢱ
඙ಽ

ၮᧄᢱߩ೎

৻⥸∛ᐥ

ዯ಴ᐕ᦬ᣣ

․ቯᯏ⢻∛㒮㧔7㧦1㧕

஻⠨

ᐔᚑ 20 ᐕ 5 ᦬ 1 ᣣ‫∛ޓ‬ᐥᢙ 569 ᐥ․ቯᯏ⢻∛㒮㧔15㧦1㧕 ᐔᚑ 18 ᐕ 4 ᦬ 1 ᣣ♖␹∛ᐥ‫∛ޓ‬ᐥᢙ 37 ᐥ⋴⼔⵬ഥട▚㧞ᐔᚑ 18 ᐕ 4 ᦬ 1 ᣣ

㧔2㧕౉㒮ᤨ㘩੐≮㙃
඙ಽ

ዯ಴ᐕ᦬ᣣ

౉㒮ᤨ㘩੐≮㙃㧔Σ㧕

ᐔᚑ 18 ᐕ 4 ᦬ 1 ᣣ

15. ∛㒮ࡏ࡜ࡦ࠹ࠖࠕ
ᖚ⠪ࠨ࡯ࡆࠬߩะ਄ߩߚ߼ߦᐔᚑ 10 ᐕ 4 ᦬ߦ㐿ᆎߒߚ∛㒮ࡏ࡜ࡦ࠹ࠖࠕᵴേߪ㧘ᐔᚑ 20 ᐕߦ 10ᐕࠍㄫ߃㧘⃻࿷ߦ⥋ߞߡ޿ࠆ‫ޕ‬ᵴേ⊓㍳⠪ߪᐔᚑ 20 ᐕ 12 ᦬⃻࿷ 49 ฬߢ޽ࠅ㧘㒮ౝ᩺ౝ㧘ᖚ⠪៝ㅍߩ੺ഥ㧘ゞ᫹ሶ╬ߩᷡ᝹࡮ୃℂ㧘∛᫟ߢߩ∛⴩ߩ㈩Ꮣ╬ࠬ࠲࠶ࡈߩᚻવ޿㧘㒮ౝ࿑ᦠቶߩ࿑ᦠᢛℂ㧘㧙㧙ฦ⒳ࠗࡌࡦ࠻ߩᚻવ޿╬㧘ߘߩᵴേߪᄙጘߦࠊߚࠅ㧘∛㒮ߩਛߢᰳߊߎߣߩߢ߈ߥ޿ሽ࿷ߣߥߞߡ޿
ࠆ‫ޕ‬ࡏ࡜ࡦ࠹ࠖࠕ㑆ߩ੤ᵹߣᵴേߩలታߩߚ߼ߦ㧘㒮ౝߦࡏ࡜ࡦ࠹ࠖࠕបቶ߇⸳⟎ߐࠇߡ޿ࠆ‫ߚ߹ޕ‬㧘࡝࡯࠳࡯࡮ᦐᣣ࡝࡯࠳࡯ࠍਛᔃߣߒߚࡏ࡜ࡦ࠹ࠖࠕߣߩᗧ⷗੤឵ળࠍᐕߦᢙ࿁ⴕ޿㧘㒮ౝᄖߩ⎇ୃߦ
߽Ⓧᭂ⊛ߦෳടߐߖ㧘⾰⊛ะ਄ࠍ࿑ߞߡ޿ࠆ‫ޕ‬

16. 㒮ౝቇ⚖㒮ౝቇ⚖ߪ㧘ጘ㒂⋵ᢎ⢒ᆔຬળ෸߮ጘ㒂Ꮢᢎ⢒ᆔຬળߣߩද⼏ࠍ⚻ߡ㧘ጘ㒂Ꮢ┙੩↸ዊቇᩞ㧘หદᄹᵄਛቇᩞߩ∛ᒙఽቇ⚖ߣߒߡ૏⟎ઃߌࠄࠇ㧘ᐔᚑ 8 ᐕ 4 ᦬ߦᣥ∛㒮ߩዊఽ⑼∛᫟ߩ৻ㇱࠍᡷⵝ㧘ォ↪ߒߡ㐿⸳ߒߚ‫ޕ‬㒮ౝቇ⚖ߪ‫߈ߩߊ߻ޟ‬ቇ⚖‫ߣޠ‬ฬઃߌࠄࠇߚ‫ޕ‬∛㒮ߩᣂ▽࡮⒖ォࠍᄾᯏߦ㧘ᣂ∛㒮 4 㓏ߩዊఽ⑼∛᫟ߦዊቇᩞᢎቶ 35 ট㧘ਛቇᩞᢎቶ 17 ট㧘⡯ຬ
ቶ 19 টߩ㒮ౝቇ⚖ࠍᣂߚߦ⸳ߌ㧘૬ߖߡ⸳஻ߩలታࠍ࿑ࠅ㧘ጘ㒂Ꮢᢎ⢒ᆔຬળߣߩ㑆ߢ‫ޟ‬ጘ㒂ᄢቇකቇㇱ㒝ዻ∛㒮ߩ౉㒮ఽ┬࡮↢ᓤߦኻߔࠆ⟵ോᢎ⢒ߩታᣉߦ㑐ߔࠆදቯᦠ‫ߒ⚿✦ࠍޠ‬㧘㐿⸳ߒߚ‫ޕ‬ߎߩ㒮ౝቇ⚖ߪ㧘ጘ㒂Ꮢ┙㤥㊁ዊቇᩞ㧘หጘർਛቇᩞߩ∛ᒙఽቇ⚖ߣ૏⟎ઃߌࠄࠇ㧘ᐔᚑ 21 ᐕ 1᦬⃻࿷ዊቇᩞᢎቶ 3 ੱ㧘ਛቇᩞᢎቶ 2 ੱߩఽ┬࡮↢ᓤ߇࿷☋ߒߡ޿ࠆ‫ޕ‬17. 㒮ౝ࿑ᦠቶ
౉㒮ᖚ⠪߿ߘߩኅᣖ߇೑↪ߢ߈ࠆࠃ߁㒮ౝ࿑ᦠቶ߇ᐔᚑ 10 ᐕ 4 ᦬ߦ㐿⸳ߐࠇߚ‫ޕ‬ᐔᚑ 16 ᐕ 6 ᦬ߩᧄ㒮⒖ォᓟߪ㧘∛᫟ 9 㓏ߦ㐿⸳ߐࠇ㧘᥊ⷰ߇ࠃߊ㧘ᖚ⠪߇⺒ᦠࠍᭉߒ߻ߣ޿߁ߛߌߦߣߤ߹ࠄߕ㧘ኅᣖ╬ߩᙑ޿ߩ႐ᚲߣߒߡߩᓎ⋡߽ᄢ޿ߦᨐߚߒߡ޿ࠆ‫ޕ‬࿑ᦠߪ㧘౉㒮ߐࠇߡ޿ߚᖚ⠪߿ࠬ࠲࠶ࡈ╬ᄙߊߩᣇ߆ࠄነ⿅ߐࠇ㧘⛗ᧄ㧘ఽ┬࿑ᦠ㧘ࠦࡒ࠶ࠢࠬ㧘ዊ⺑㧘㓐╩㧘⹏⺰㧘ㄉᦠ╬ᄙጘߦࠊߚࠅ㧘ࡏ࡜ࡦ࠹ࠖࠕߦࠃࠅ࿑ᦠߩᢛℂ߇ⴕࠊࠇߡ޿ࠆ‫ߚ߹ޕ‬㧘කቇ࡮⋴⼔ߦ㑐ߔࠆᖱႎࠍᓧߡ߽ࠄ߃ࠆࠃ߁㧘ኅᐸߩකቇ㑐ଥߩ࿑ᦠࠍ⾼౉ߒ㧘లታࠍ࿑ߞߡ޿ࠆ‫ޕ‬18. ක⮎ຠߩ⥃ᐥ⹜㛎ߩታᣉᣇ㊎ක⮎ຠߩ⥃ᐥ⹜㛎㧔ᴦ㛎㧕ߪ㧘ᣂ⮎ߩ㐿⊒ࠍㅢߓ㧘ක≮߿කቇߩ⊒ዷߦᄢ߈ߊ⽸₂ߒߡ߅ࠅ㧘․ቯ
ᯏ⢻∛㒮ߣߒߡ㜞ᐲߥක≮ࠍឭଏߔࠆᄢቇ∛㒮ߪ㧘ᴦ㛎ࠍታᣉߔࠆක≮ᯏ㑐ߣߒߡ㊀ⷐߥᓎഀࠍᜂߞ
ߡ޿ࠆ‫ޕ‬
ᴦ㛎ߪ㧘ᐔᚑ 9 ᐕ 4 ᦬ߦᣉⴕߐࠇߚක⮎ຠߩ⥃ᐥ⹜㛎ߩታᣉߦ㑐ߔࠆၮḰ㧔ᣂ GCP㧕ࠍㆩ቞ߒ㧘቟ోᕈ㧘᦭ലᕈ෸߮ᴦ㛎࠺࡯࠲ߩା㗬ᕈ߇⏕଻ߒߡⴕࠊࠇࠆᔅⷐ߇޽ࠆ‫ޕ‬ᒰ∛㒮ߦ߅޿ߡ߽㧘ߎߩߎߣࠍචಽߦ⹺⼂ߒ㧘୶ℂ⊛ߥ㈩ᘦߩ߽ߣߦ⑼ቇ⊛ߦ߹ߚㆡᱜߦᴦ㛎ࠍታᣉߒߡ޿ࠆߣߎࠈߢ޽ࠆ‫ޕ‬ᒰ∛㒮ߦ߅޿ߡߪ㧘ᴦ㛎ࠍ౞Ṗߦታᣉߔࠆߚ߼ߦ㧘ᐔᚑ 14 ᐕ 4 ᦬ߦᴦ㛎▤ℂቶࠍ⊒ዷ⊛ߦ⸃ᶖߒ㧘ᴦ㛎▤ℂ࠮ࡦ࠲࡯ࠍ㒮ౝភ⟎ߢ⸳⟎㧘ߐࠄߦᐔᚑ 14 ᐕᐲ߹ߢߪ૬છߩᴦ㛎ࠦ࡯࠺ࠖࡀ࡯࠲࡯㧔⮎೷Ꮷ㧘⋴⼔Ꮷฦ 1 ฬ㧕ߩ㈩⟎ߩߺߢ޽ߞߚ߇㧘ᐔᚑ 15 ᐕ 4 ᦬߆ࠄኾછߩᴦ㛎ࠦ࡯࠺ࠖࡀ࡯࠲࡯ࠍ㈩⟎ߒ㧘⃻࿷㧘⮎೷Ꮷ 2 ฬ㧘⥃ᐥᬌᩏᛛᏧ 1 ฬࠍ㈩⟎ߒߡ޿ࠆ‫ޕ‬ኾછߩᴦ㛎ࠦ࡯࠺ࠖࡀ࡯࠲࡯ߩ㈩⟎ߦࠃࠅ㧘ᴦ㛎⽿છකᏧ㧘ᴦ㛎ಽᜂකᏧ㧘ᴦ㛎දജ⠪╬෸߮ⵍ㛎⠪ߣߘߩኅᣖߣߩㅪ⛊࡮⺞ᢛࠍⴕ߁૕೙߇චಽߣߪ⸒߃ߥ޿߹ߢ߽ᢛ஻ߔࠆߎߣ߇ߢ߈ߚ‫ߚ߹ޕ‬㧘ᴦ㛎ࠦ࡯࠺ࠖࡀ࡯࠲࡯ߦࠃࠆᴦ㛎ታᣉ⸘↹ߩࠬࠤࠫࡘ࡯࡞▤ℂ߽৻ㇱⴕ߃ࠆࠃ߁ߦߥߞߚ߇㧘੹ᓟ㧘ࠃࠅ৻ጀ౞Ṗߦᴦ㛎ࠍታᣉߔࠆߚ߼ߦᦝߥࠆᴦ㛎ታᣉ૕೙෸߮ᴦ㛎ࠦ࡯࠺ࠖࡀ࡯࠲࡯ߩᢛ஻ࠍ࿑ࠆᔅ
ⷐ߇޽ࠆ‫ޕ‬㧙㧙߹ߚ㧘ᴦ㛎ߩฃ౉ࠇ߿ታᣉࠍ౞Ṗߦផㅴߔࠆߚ߼㧘ᴦ㛎ଐ㗬⠪߿ᖚ⠪ߐࠎ߳ߩࡎ࡯ࡓࡍ࡯ࠫࠍᢛ஻
ߒߚ‫ޕ‬ᐔᚑ 20 ᐕᐲߦߪ㧘ᴦ㛎ߩฃ౉ઙᢙଦㅴߩߚ߼㧘ᴦ㛎࠮ࡒ࠽࡯ࠍ㐿௅ߒ㧘ᴦ㛎ಽᜂකᏧᢙߩჇടଦ
ㅴࠍ࿑ߞߚ‫੹ޕ‬ᓟ߽㧘ᴦ㛎ฃ౉ઙᢙჇടߦะߌ㧘ᴦ㛎ฃ౉૕೙ߩ᦭ലߥᢛ஻㧘ฦ⸻≮⑼߳ᴦ㛎ฃ౉ߩଦㅴ㧘ᴦ㛎ଐ㗬⠪߳ᴦ㛎ଐ㗬ߩଦㅴࠍ࿑ߞߡ޿ߊ੍ቯߢ޽ࠆ‫ޕ‬19. ᐢႎ
㧔1㧕ኾ㐷කߩขࠅ⚵ߺ
ᐔᚑ 17 ᐕ 7 㨪 8 ᦬ߦ⸻≮⑼೎ߦታᣉߒߚ∛㒮㐳ࡅࠕ࡝ࡦࠣߩ㓙ฦ⸻≮⑼߆ࠄឭ಴㗿ߞߚ⺞ᩏ⴫ࠍၮߦ㧘කᏧߩ∔∛ߦኻߔࠆขࠅ⚵ߺ߿ኾ㐷කߩขࠅ⚵ߺ⁁ᴫߦߟ޿ߡ㧘ᐔᚑ 18 ᐕ 2 ᦬ߦᄢቇ∛㒮ࡎ࡯ࡓࡍ࡯ࠫ਄ߢ౏㐿ߒߚ‫ޕ‬
㧔2㧕ࡎ࡯ࡓࡍ࡯ࠫߩలታ
කቇ♽⎇ⓥ⑼࡮කቇㇱᖱႎᆔຬળߦᐔᚑ 17 ᐕ 11 ᦬ߦ⸳⟎ߒߚ㒝ዻ∛㒮ㇱળߢᬌ⸛ߩ⚿ᨐ㧘㒝ዻ∛㒮ߩ౏ᑼࡎ࡯ࡓࡍ࡯ࠫࠍ⷗⋥ߒ࡮లታߐߖࠆߎߣߦߥࠅ㧘ࡎ࡯ࡓࡍ࡯ࠫߩ૕ⵙ㧘ᬌ⚝ᯏ⢻ߩᡷༀ㧘ኾ㐷ක╬ߩᬌ⚝ᯏ⢻ߩㅊട㧘ࠨࠗ࠻ࡑ࠶ࡊ࡮ࡊ࡜ࠗࡃࠪ࡯ࡐ࡝ࠪ࡯ߩ⴫␜ߥߤ㧘ࡎ࡯ࡓࡍ࡯ࠫߩ࡝࠾ࡘ࡯
ࠕ࡞ࠍⴕߞߚ‫ޕ‬
㧔3㧕ᐢႎ⹹‫ޟ‬㡻⥱‫ߩޠ‬ౣೀ㒝ዻ∛㒮ᐢႎ⹹‫ޟ‬㡻⥱‫ߪޠ‬㧘ᐔᚑ 12 ᐕ 3 ᦬ 1 ᣣߦഃೀภࠍ⊒ⴕߒ㧘╙ 6 ภ㧔ᐔᚑ 16 ᐕ 3 ᦬ 1 ᣣ⊒ⴕ㧕ࠍ߽ߞߡ⊒ⴕࠍ৻ᤨભᱛߒߡ޿ߚ‫ޕ‬ᣂ∛㒮ߩᣂ▽⒖ォᦼ㑆ਛߪ㧘‫ޟ‬ጘ㒂ᄢቇකቇㇱ෸߮කቇㇱ㒝ዻ∛㒮ᐢႎᆔຬળ࠾ࡘ࡯ࠬ‫ߒⴕ⊒ࠍޠ‬㧘⒖ォߩᖱႎࠍਛᔃߦᐢႎߒߡ޿ߚ‫ޕ‬ᣂ∛㒮߇㐿㒮ߒㆇ༡߇゠㆏ߦਸ਼ࠅ㧘∛㒮ᖱႎࠍౝᄖߦ⊒ାߔࠆߎߣߪᴺੱൻᓟߩ∛㒮ㆇ༡ߦߣߞߡ
㊀ⷐߢ޽ࠆߚ߼㧘කቇ♽⎇ⓥ⑼࡮කቇㇱᖱႎᆔຬળߦ㒝ዻ∛㒮ㇱળࠍ⸳⟎ߒ㧘∛㒮ᐢႎߦߟ޿ߡᬌ⸛
ߩ⚿ᨐ㧘㒝ዻ∛㒮ߩ౏ᑼࡎ࡯ࡓࡍ࡯ࠫߩలታߣ૬ߖߡ㧘㒝ዻ∛㒮ᐢႎ⹹‫ޟ‬㡻⥱‫ࠍޠ‬ᐕᦨૐ 2 ࿁⊒ⴕߔࠆߎߣߣߒ㧘ᐔᚑ 21 ᐕ 3 ᦬⃻࿷╙ 12 ภ߹ߢ⊒ೀߒߡ޿ࠆ‫ޕ‬㧙㧙Ψ‫⥄ޓ‬Ꮖ⹏ଔ

1㧚ක⑼ቇኾ᡹࡮ౣ↢ක⑼ቇኾ᡹෸߮කቇㇱකቇ⑼ᄢቇ㒮කቇ♽⎇ⓥ⑼࡮කቇㇱߩ⥄Ꮖ⹏ଔᄢቇ㒮කቇ♽⎇ⓥ⑼㐳࡮කቇㇱ㐳‫›ޓ‬Ⴆ‫⾆ޓ‬ᢎ⢒ో࿖౒↪⹜㛎 CBT࡮OSCE ߩᚑ❣ߪ⦟ᅢߢ޽ࠅ㧘කᏧ࿖ኅ⹜㛎ߦ߅ߌࠆᣂත⠪ߩวᩰ₸߽㜞ߊ ( ⾗ᢱԘ )㧘කቇᢎ⢒ᯏ㑐ߣߒߡߩ᳓Ḱߪࠢ࡝ࠕߐࠇߡ޿ࠆ‫ޕ‬ቇ↢ߩ⢻േ⊛ቇ⠌⠌ᘠߩ⏕┙ࠍ⋡⊛ߦ࠹ࡘ࠻࡯
࡝ࠕ࡞ᢎ⢒߇ዉ౉ߐࠇߡ 10 ᐕએ਄⚻ㆊߒߚ߇㧘ߘߩ⹏ଔߪ࿖⹜วᩰ₸ߩჇട㧘᝼ᬺᘒᐲߩᡷༀߥߤ৻
ᤨ⊛ߥࠛࡇ࠰࡯࠼ߦ㒢ࠄࠇߡ߅ࠅ㧘ቇ↢ߦࠃࠆᧄᢎ⢒ߦኻߔࠆࠕࡦࠤ࡯࠻ ( ⾗ᢱԙ ) ߢߪᅢᖡඨ߫ߒߡ
޿ࠆ‫⹏ޕ‬ଔߩᣇᴺ⺰ࠍ฽߼㧘৻ቯߩ⚿⺰ࠍ಴ߒ㧘੹ᓟߩᧄࠪࠬ࠹ࡓߩᡷ⦟㧘ᚗ޿ߪᰴ਎ઍဳߩᣂߚߥ㐿⊒ߦߟߥߍߡ޿ߊᔅⷐ߇޽ࠆ‫ޕ‬ቇ↢ߦࠃࠆ᝼ᬺ⹏ଔߪ࠹ࡘ࠻࡯࡝ࠕ࡞ࠦ࡯ࠬߥߤ৻ㇱߦ㒢ࠄࠇߡ߅ࠅ㧘ᢎຬߩ᝼ᬺᡷༀߦ⥋ࠆ߹ߢߩࡈࠖ࡯࠼ࡃ࠶ࠢࠪࠬ࠹ࡓ߇ਇචಽߢ޽ࠆ‫ޕ‬࿾ၞක≮ෂᯏߦኻߔࠆ࿖ߩᣉ╷ߦᴪߞߡ㧘࿾ၞක≮ߦ⽸₂ߔࠆකᏧࠍ㙃ᚑߢ߈ࠆࠃ߁㧘2008 ᐕᐲ߆ࠄ࿾ၞᨒផ⮈౉⹜ࠍታᣉߒ㧘ో㕙⊛ߥࠞ࡝ࠠࡘ࡜ࡓߩ⷗⋥ߒࠍⴕ޿␠ળߩᦼᓙߦᔕ߃ߡ޿ࠆ‫ޕ‬ቯຬჇടߦኻߔࠆ⸳஻ߩᢛ஻ߪߣ߽߆ߊ㧘ᢎຬߩᚻᒰߪ 2009 ᐕᐲ߆ࠄࡐࠗࡦ࠻ᄖߩഥᢎ 2 ฬߩភ⟎᳿ቯߦߣߤ
߹ࠅ㧘ⷐ᳞ࠍ⛮⛯ߒߡ޿ߊᔅⷐ߇޽ࠆ‫ᧄޕ‬ቇㇱߢߪ 2007 ᐕ 4 ᦬ߦ࿾ၞක≮කቇ࠮ࡦ࠲࡯ࠍ⸳⟎ߒ㧘⋵߆ࠄߩ㑐ㅪነ㒝⻠ᐳ߽ടࠊߞߚ‫ߩ࡯࠲ࡦ࠮ᧄޕ‬ℂᔨߢ޽ࠆ‫ޟ‬නߦ࿾ၞߩක≮߳ߩኻᔕߛߌߢߥߊ㧘ᢎ⢒ߣ⾰ߩ㜞޿⎇ⓥߦⵣᛂߜߐࠇߚ߽ߩߦߔࠆ‫ࠍޠ‬ታ⃻ߔࠆߚ߼ߦ࿾ၞක≮ቇࠍቯ⌕ߐߖ㧘ౕ૕⊛ߥขࠅ⚵ߺ߇ᕆ߇ࠇࠆ‫ޕ‬
6 ᐕ↢ߩ⥃ᐥታ⠌ߢߪᶏᄖ⎇ୃࠍ⹺߼ߡ޿ࠆ߇ෳട⠪߇ዋߥ޿‫ޕ‬ෳടࠍᅑബ㧘ᡰេߒ㧘ቇㇱౝߩ࿖㓙ൻߦ߽ᵴ߆ߔߴ߈ߢ޽ࠆ‫ޕ‬⥃ᐥ⎇ୃක೙ᐲߩዉ౉એ᧪㧘⎇ⓥ߳ߩ㑐ᔃߣ㑐ࠊࠅ߇Ꮧ⭯ߦߥߞߡ޿ࠆ‫ޕ‬2008 ᐕᐲ߆ࠄߩᣂࠞ࡝ࠠࡘ
࡜ࡓߢߪၮ␆㈩ዻᦼ㑆ࠍᑧ㐳ߒ㧘ቇ↢߇ෳടߢ߈ࠆᄢቇ㒮ࠦ࡯ࠬ (MD-PhD ࠦ࡯ࠬ ) ߽⸳⟎ߔࠆߎߣߦ
ߒߚ߇㧘ߎࠇࠄࠍᡰេߒߡⴕߊᔅⷐ߇޽ࠆ‫ޕ‬ᢎຬߩቇ↢ߣߩ㑐ࠊࠅߪ᝼ᬺ㧘⺖ᄖᵴേ㧘㉿ⷫ೙ᐲߥߤᄙ㕙⊛ߦ↪ᗧߒߡ޽ࠆ߇㧘㉿ⷫ೙ᐲߪฦಽ㊁ߦࠃߞߡታ⾰ൻߦ᷷ᐲᏅ߇ᄢ߈޿‫ޕ‬ᢎຬߩ FD㧘੍▚ភ⟎ࠍ฽߼ᡷༀߒߡ޿ߊߎߣ߇㊀ⷐߢ޽ࠆ‫ޕ‬౉ቇ⹜㛎ߪ┹੎୚₸߇೨ᦼ㧘ᓟᦼ౒ߦో࿖ߩකቇ⑼ߩਛߢᦨ㜞ߣߥࠅ ( ⾗ᢱԚ )㧘ో࿖⊛ߦᵈ⋡ࠍฃߌ㧘ఝ⑲ߥቇ↢߇ో࿖߆ࠄ㓸߹ࠆࠃ߁ߦߥߞߚ‫⹜౉ޕ‬ᬺോߦߟ޿ߡߪቇౝᄖߩදജ૕೙᭴▽ߣ㧘ኾ㐷⊛⍮⼂࡮ᛛⴚߩᱜᒰߥ⹏ଔࠍ⋥ߜߦⴕ߁ߴ߈ߢ޽ࠆ‫ޕ‬⎇ⓥੱઙ⾌೥ᷫ߇ㅴⴕߒ㧘ᄙߊߩಽ㊁ߪ 3 ੱએਅߩᢎຬ᭴ᚑߣߥߞߚߣߎࠈߦ㧘ᣂ⥃ᐥ⎇ୃක೙ᐲ߇ዉ౉
ߐࠇ㧘ၮ␆⎇ⓥߦ߅ߌࠆ⧯޿⎇ⓥ⠪߇ᷫዋߒߚ‫ ޕ‬ᔨߐࠇߡ޿ߚߎߣߢ޽ࠆ߇㧘⎇ⓥߩ⚿ᨐߣߒߡ಴ߡ
ߊࠆ᰷ᢥේ⪺⺰ᢥߩᢙ㧘✚ࠗࡦࡄࠢ࠻ࡈࠔࠢ࠲࡯ (IF) ߇ᷫዋߒߚ‫⺰ߦࠄߐޕ‬ᢥᒰߚࠅߩ IF ߽ᷫዋߒߡ
߅ࠅ⾰ߩૐਅ߽␜ໂߐࠇࠆᷓೞߥ⁁ᴫߢ޽ࠆ ( ⾗ᢱԛ )‫┹ޕ‬੎⊛ᄖㇱ⾗㊄ߩ₪ᓧߦߟ޿ߡߪᄢဳߩ߽ߩߪ
࡝ࠬ࠻ࠕ࠶ࡊߒߡ޽ࠆ߇ ( ⾗ᢱԜ㧘ԝ )㧘✚㗵ߣߒߡᷫዋ௑ะߢ޽ࠆ‫⊒ޕ‬᣿㧘․⸵ߦߟ޿ߡ߽ห᭽ߢ޽ࠆ( ⾗ᢱԞ )‫੹ޕ‬ᓟ㧘ઁ⚵❱ߣߩ౒ห⎇ⓥ㧘ࡊࡠࠫࠚࠢ࠻ࠍゲߦߒߚ⥃ᯏᔕᄌߥ⎇ⓥ࠴࡯ࡓ✬ᚑ㧘ᄖㇱ⾗㊄₪ᓧߦࠃࠆࡐࠬ࠻⸳⟎㧘ᢎ᝼ㆬ⠨ߦ߅ߌࠆ⎇ⓥ㗔ၞߩᘕ㊀ߥᬌ⸛ߥߤⴕߞߡ޿ߊᔅⷐ߇޽ࠆ‫ ߚ߹ޕ‬COEߪߓ߼ᄢဳᚗ޿ߪ᡽╷ࡊࡠࠫࠚࠢ࠻ߩᖱႎ෼㓸ߣ౒ߦ޿ߟߢ߽ෳ↹ᔕ൐ߢ߈ࠆḰ஻߇㊀ⷐߢ޽ࠆ‫⎇ᧄޕ‬㧙㧙

ⓥ⑼ߢߪౣ↢ක⑼ቇኾ᡹ߦ߅ߌࠆౣ↢㧘කᎿቇ㧘߹ߚጘ㒂⮎⑼ᄢቇߣߩㅪ៤㗔ၞߥߤ㧘ઁᄢቇߦߥ޿ࡈ
ࡠࡦ࠻ࠍ᦭ߒߡ޿ࠆ߇㧘⎇ⓥ⑼ో૕ߢ੹ᓟ 5 ᐕ⒟ᐲߩᦼ㑆ߦߤߩࠃ߁ߥᣇะߩ⎇ⓥࠍ⋡ᜰߔߴ߈߆ᣧᕆ
ߦ⼏⺰ߒ㧘ߘࠇߦᴪߞߚੱ੐㧘ၮ⋚ߣߥࠆታ❣ࠍⓍߺ਄ߍߡ޿߆ߥߌࠇ߫ߥࠄߥ޿‫ޕ‬ၮ␆⎇ⓥߣ⥃ᐥᔕ↪ࠍߟߥߋ࠻࡜ࡦࠬ࡟࡯࡚ࠪ࠽࡞࡝ࠨ࡯࠴ߪකቇ♽⎇ⓥ⑼ߦᦨ߽⋧ᔕߒ޿⎇ⓥᚻᴺ࡮૕೙ߢ޽ࠅ㧘㔍ᴦᕈ∔ᖚߩ∛ᘒ⸃᣿ߣᴦ≮ᴺߩ⏕┙ߥߤߦะߌߡផㅴߒߡⴕߊߴ߈ߢ޽ࠆ‫ޕ‬⥃ᐥ㒝ዻ∛㒮ߪ㜞ᰴᢇ๮ᴦ≮࠮ࡦ࠲࡯߿ߐ߹ߑ߹ߥ∔ᖚߩ᜚ὐ∛㒮ߣߒߡ㧘߹ߚ․ቯᯏ⢻∛㒮ߣߒߡ࿾ၞ
ක≮ߩᦨᓟߩ⎏ߣߒߡᯏ⢻ߒߡ޿ࠆ ( ⾗ᢱԟ㧘Ԡ )‫ߚ߹ޕ‬㜞ᐲవㅴක≮ߩ㐿⊒㧘ၮ␆⎇ⓥߣ⥃ᐥᔕ↪ࠍߟߥߋ࠻࡜ࡦࠬ࡟࡯࡚ࠪ࠽࡞࡝ࠨ࡯࠴ࠍㆀⴕߔࠆ਄ߢᭂ߼ߡ㊀ⷐߥ႐ߣߥߞߡ޿ࠆ‫ࠍࠇߎޕ‬น⢻ߦߒߡ޿ࠆߩߪ㧘ᱧઍ∛㒮㐳ߪߓ߼∛㒮ࠬ࠲࠶ࡈߩദജߦࠃࠆ⦟ᅢߥ⚻༡ߣ቟ో⏕଻ߢ޽ࠆ‫ޕ‬
␠ળ⽸₂ᣣᏱ⊛ߥᢎ⢒ߦࠃࠆੱ᧚⢒ᚑ㧘⸻≮ߦࠃࠆ㜞ᐲవㅴක≮ߩታ〣㧘⎇ⓥᚑᨐߦࠃࠆකቇ࡮ක≮ߩㅴᱠࠍㅢߒߚ␠ળ⽸₂ߪᒰὼߩߎߣߢ޽ࠆ߇㧘࿖߿࿾ᣇ⥄ᴦ૕ߥߤߩⴕ᡽਄ߩኾ㐷ᆔຬߣߒߡ㧘߹ߚ࿾ၞߩᢥ
ᢎᣉ⸳ߥߤߩᢎ⢒ࠬ࠲࠶ࡈߣߒߡ㧘ߐࠄߦ࿾ၞߩ⸻≮ᣉ⸳ᡰេࠍ੺ߒߚ⋥ធ⊛ߥ␠ળ⽸₂߽ᨐߚߒߡ߈ߚ‫ޕ‬⾗ᢱԘᧄቇߩකᏧ࿖ኅ⹜㛎ߩᣂත⠪วᩰ₸㧔╙ 85 ࿁㨪╙ 102 ࿁㧕඙‫ޓޓ‬ಽ

ᣂත⠪วᩰ₸╙ 85 ࿁㧔ᐔᚑ 2 ᐕᐲ㧕

92.4㧑

╙ 86 ࿁㧔ᐔᚑ 3 ᐕᐲ㧕

91.4㧑

╙ 87 ࿁㧔ᐔᚑ 4 ᐕᐲ㧕

95.0㧑

╙ 88 ࿁㧔ᐔᚑ 5 ᐕᐲ㧕

87.8㧑

╙ 89 ࿁㧔ᐔᚑ 6 ᐕᐲ㧕

91.9㧑

╙ 90 ࿁㧔ᐔᚑ 7 ᐕᐲ㧕

94.3㧑

╙ 91 ࿁㧔ᐔᚑ 8 ᐕᐲ㧕

90.4㧑

╙ 92 ࿁㧔ᐔᚑ 9 ᐕᐲ㧕

98.8㧑

╙ 93 ࿁㧔ᐔᚑ 10 ᐕᐲ㧕

94.3㧑

╙ 94 ࿁㧔ᐔᚑ 11 ᐕᐲ㧕

84.1㧑

╙ 95 ࿁㧔ᐔᚑ 12 ᐕᐲ㧕

97.4㧑

╙ 96 ࿁㧔ᐔᚑ 13 ᐕᐲ㧕

100.0㧑

╙ 97 ࿁㧔ᐔᚑ 14 ᐕᐲ㧕

100.0㧑

╙ 98 ࿁㧔ᐔᚑ 15 ᐕᐲ㧕

97.4㧑

╙ 99 ࿁㧔ᐔᚑ 16 ᐕᐲ㧕

90.5㧑

╙ 100 ࿁㧔ᐔᚑ 17 ᐕᐲ㧕

97.6㧑

╙ 101 ࿁㧔ᐔᚑ 18 ᐕᐲ㧕

96.3㧑

╙ 102 ࿁㧔ᐔᚑ 19 ᐕᐲ㧕

97.5㧑

㧙㧙

࠹ࡘ࠻࡯࡝ࠕ࡞ᢎ⢒㧝ᦼ↢ߩතᬺ⾗ᢱԙࠞ࡝ࠠࡘ࡜ࡓߦ㑐ߔࠆࠕࡦࠤ࡯࠻㧔H19 ᐕᐲታᣉ࡮ᛮ☴㧕㧽 ࠹ࡘ࠻࡯࡝ࠕ࡞࡮ࠪࠬ࠹ࡓߪߤࠇߊࠄ޿᳇ߦ౉ߞߡ޿߹ߔ߆㧫
඙ಽ
කቇ⑼

ᅢ߈

ߤߜࠄ߆ߣ
⸒߃߫ᅢ߈

ߤߜࠄߢ߽
ߥ޿

ߤߜࠄ߆ߣ
޿߃߫ህ޿

28.9㧑

33.1㧑

22.3㧑

4.8㧑

ᄢህ޿

ή࿁╵

9㧑

1.8㧑

㧽 ੹ߩࠞ࡝ࠠࡘ࡜ࡓࠍ㧘ቇ↢ߩ⥄ਥᕈߦછߖߚࠃࠅ⢻േ⊛ߥ߽ߩߦߒߡ᰼ߒ޿ߢߔ߆㧫‫ޓ‬ߘࠇߣ߽㧘ਈ߃ࠄࠇࠆ߽ߩࠍᄙߊߒߡࠃࠅฃേ⊛ߥ߽ߩߦߒߡ᰼ߒ޿ߢߔ߆㧫඙ಽࠃࠅ⢻േ⊛ߦߒ
ߡ᰼ߒ޿ࠃࠅฃേ⊛ߦߒ
ߡ᰼ߒ޿

කቇ⑼

12㧑

22㧑

⃻⁁⛽ᜬ

ή࿁╵

60㧑

6㧑

⾗ᢱԚ
කቇㇱකቇ⑼ߩ౉ቇ⠪ㆬᛮߦߟ޿ߡ
౉ቇቯຬ
ᓟᦼᣣ⒟
10

ផ⮈㧔৻⥸㧕
15ផ⮈㧔࿾ၞᨒ㧕㧴18 ᐕᐲ

೨ᦼᣣ⒟55

㧴19 ᐕᐲ

30

35

15

90
100

㧙

㧴20 ᐕᐲ

30

35

15

㧙
10

㧴21 ᐕᐲ

30

40

15

15

೨ᦼᣣ⒟

ᓟᦼᣣ⒟

ផ⮈㧔৻⥸㧕

ផ⮈㧔࿾ၞᨒ㧕

ᔒ㗿⠪ᢙ

ᔒ㗿⠪ᢙ

ᔒ㗿⠪ᢙ

ᔒ㗿⠪ᢙ

㧔ฃ㛎⠪ᢙ㧕

㧔ฃ㛎⠪ᢙ㧕

㧔ฃ㛎⠪ᢙ㧕

㧔ฃ㛎⠪ᢙ㧕

ާᔒ㗿୚₸ި

ާᔒ㗿୚₸ި

ާᔒ㗿୚₸ި

ާᔒ㗿୚₸ި

‫ޝ‬ฃ㛎୚₸‫ޞ‬895‫ޝ‬ฃ㛎୚₸‫ޞ‬224‫ޝ‬ฃ㛎୚₸‫ޞ‬71‫ޝ‬ฃ㛎୚₸‫ޞ‬

(835)

(139)

(71)

ާ16.3ި

ާ22.4ި

ާ4.7ި

‫ޝ‬15.2‫ޞ‬583‫ޝ‬13.9‫ޞ‬2,760‫ޝ‬4.7‫ޞ‬
37

(573)

(2,053)

(36)

⸘
80
80

಴㗿⠪ᢙ㧔ฃ㛎⠪ᢙ㧕ᐕᐲ

㧴18 ᐕᐲ

㧴19 ᐕᐲ

㧴20 ᐕᐲ

㧴21 ᐕᐲ

⸘

1,190
㧙

(1,045)
ާ14.9ި
‫ޝ‬13.1‫ޞ‬
3,380

㧙

(2,662)

ާ19.4ި

ާ78.9ި

ާ2.5ި

‫ޝ‬19.1‫ޞ‬618‫ޝ‬58.7‫ޞ‬2,372‫ޝ‬2.4‫ޞ‬35

22‫ޝ‬33.3‫ޞ‬3,047

ާ42.3ި

(573)(1,841)

(35)

(22)

(2,471)

ާ20.6ި

ާ67.8ި

ާ2.3ި

ާ2.2ި

ާ33.9ި

‫ޝ‬19.1‫ޞ‬658‫ޝ‬52.6‫ޞ‬2,871‫ޝ‬2.3‫ޞ‬20‫ޝ‬2.2‫ޞ‬28‫ޝ‬27.5‫ޞ‬
3,577

(588)

(2,178)

(20)

(28)

(2,814)

ާ21.9ި

ާ71.8ި

ާ1.3ި

ާ1.9ި

ާ35.8ި

‫ޝ‬19.6‫ޞ‬‫ޝ‬54.5‫ޞ‬‫ޝ‬1.3‫ޞ‬‫ޝ‬1.9‫ޞ‬‫ޝ‬28.1‫ޞ‬

㧙㧙

⾗ᢱԛ
⺰ᢥᢙ
⪺ᦠ
๺ᢥ
ᐔᚑ 16 ᐕ 147
ᐔᚑ 17 ᐕ 143

✚⺑

ේ⪺

ዊ⸘

ว⸘

᰷ᢥ
12

๺ᢥ
215

᰷ᢥ
16

๺ᢥ
᰷ᢥ
๺ᢥ
236 283(911.69) 598

᰷ᢥ
311

21

190

18

216 332(833.43) 549

371

920

909

ᐔᚑ 18 ᐕ

215

17

221

10

152 317(838.41) 588

344

932

ᐔᚑ 19 ᐕ

108

16

206

6

224 331(703.76) 538

353

891

ᐔᚑ 20 ᐕ

224

10

140

16

215 261(624.72) 579

287

866

(‫ ) ޓ‬ౝߪࠗࡦࡄࠢ࠻ࡈࠔࠢ࠲࡯ࠍ␜ߔ‫ޕ‬⾗ᢱԜᄖㇱ⾗㊄ฃ౉⁁ᴫ
ᐔᚑ 16 ᐕᐲઙᢙ

ᐔᚑ 17 ᐕᐲᐔᚑ 18 ᐕᐲᐔᚑ 19 ᐕᐲ

㊄㗵
ઙᢙ
㊄㗵
ઙᢙ
㊄㗵
ઙᢙ
㊄㗵
㧔ජ౞㧕
㧔ජ౞㧕
㧔ජ౞㧕
㧔ජ౞㧕
521,979 496
496,560 577
492,252 518
483,699

ነ㒝㊄485

ฃ⸤⎇ⓥ ( ᴦ㛎 )83

92,06889

80,278 111

87,742 115

89,557ฃ⸤⎇ⓥ ( ߘߩઁ )16

196,52622

334,395

200,34721

243,833᳃㑆╬ߣߩ౒ห⎇ⓥ

30

25,90343

38,563

50

117,299

52

67,989ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄2287,30020

139,718

23

149,91124

180,576ߘߩઁഥᚑ㊄╬41

208,41840

178,851

29

220,38424

202,468⑼ቇ⎇ⓥ⾌⵬ഥ㊄110

501,910 102

423,45092

214,400

99

220,07022․ቯ㗔ၞ⎇ⓥ

858,5006

44,1007

49,200530,900ၮ⋚⎇ⓥ㧔A㧕2

17,8102

16,250

0

0

1

9,100

ၮ⋚⎇ⓥ㧔B㧕

16

82,40017

69,90013

66,3001050,830ၮ⋚⎇ⓥ㧔C㧕

46

60,50040

58,30035

45,20037

66,040ౝ ⪚⧘⎇ⓥ⸶ ⧯ᚻ⎇ⓥ㧔A㧕

12

14,90011

10,6007

11,00010

13,700

0

0

0

0

0

0

1

7,800

⧯ᚻ⎇ⓥ㧔B㧕

20

28,10022

25,70028

40,40030

36,600⧯ᚻ⎇ⓥ㧔ࠬ࠲࡯࠻ࠕ࠶ࡊ㧕

㧙
5,700

㧙
3

㧙
3,600

0

0

2

2,000

․೎⎇ⓥຬᅑബ⾨

㧙
5

2

2,300

3

3,100

ቇⴚഃᚑ⎇ⓥ⾌

1

234,000

1

195,000

0

0

0

0

ว⸘

787 1,634,104 812 1,691,815 904 1,482,335 853 1,488,192

㧙㧙

⾗ᢱԝ
┹੎⊛ᄢဳ⎇ⓥ⾌₪ᓧ⁁ᴫ↢‛ᣂᯏ⢻ߣഃ⮎ࠍ߼ߑߔ↢↢๮ᯏ⢻ಽሶ⸳
1,274,000 ජ౞ ᐔᚑ 13 㨪 18 ᐕᐲ
૕ౝಽሶ⑼ቇ
⸘ಽ㊁ᩭౝฃኈ૕Ⱞ⊕ࠍಽሶᮡ⊛ߣߒߚ⢄≸ൻቇ੍㒐ߦ㑐ߔࠆ⎇ⓥ

79,500 ජ౞ ᐔᚑ 17 㨪 22 ᐕᐲᶖൻེ∛ᘒቇಽ
㊁ᱜᏱ᭴ㅧߩℂ⸃ߦၮߠߊ⍮⊛㧯㧭㧰

56,000 ජ౞ ᐔᚑ 15 㨪 19 ᐕᐲ⍮⢻ࠗࡔ࡯ࠫᖱ
ႎಽ㊁ᢥㇱ⑼ቇ⋭⑼ቇ ᜛ᒛဳᔃ╭∝ߦኻߔࠆ㗰☸⃿ࠦࡠ࠾࡯ೝỗ࿃ሶࠍ↪޿ߚ㕖
⎇ⓥ⾌⵬ഥ㊄ଚⷅᕈౣ↢ක≮ߩ᜸ᚢ

43,940 ජ౞ ᐔᚑ 15 㨪 18 ᐕᐲ ᓴⅣ∛ᘒቇಽ㊁

㤗㈮࡮−∩ࠪࠣ࠽࡞વ㆐ߦ߅
ߌࠆࠗࠝࡦ࠴ࡖࡀ࡞ߣࠗࠝࡦ
࠻࡜ࡦࠬࡐ࡯࠲࡯ߩ೙ᓮᯏ᭴

32,110 ජ౞ ᐔᚑ 14 㨪 18 ᐕᐲ

㤗㈮࡮−∩೙ᓮ
ቇಽ㊁㤗㈮⮎ࠪࠣ࠽࡞વ㆐ᯏ᭴ߦ߅
ߌࠆ࠽࠻࡝࠙ࡓࠞ࡝࠙ࡓࡐࡦ
ࡊߩᓎഀߣߘߩ᭴ㅧᄌൻߩ⸃
ᨆ

26,130 ජ౞ ᐔᚑ 19 㨪 22 ᐕᐲ

㤗㈮࡮−∩೙ᓮ
ቇಽ㊁⒘ዋ㔍ᴦᕈ⊹⤏∔ᖚߦ㑐ߔࠆ⺞ᩏ⎇ⓥ

206,200 ජ౞ ᐔᚑ 14 㨪 20 ᐕᐲ ⊹⤏∛ᘒቇಽ㊁ࠕ࡟࡞ࠡ࡯∔ᖚߩᴦ≮෻ᔕᕈ੍᷹࿃ሶߩ⏕┙෸߮࠹࡯࡜࡯
ࡔࠗ࠼ᴦ≮ᴺߩ⏕┙

83,000 ජ౞ ᐔᚑ 16 㨪 19 ᐕᐲ ዊఽ∛ᘒቇಽ㊁ࠕ࡟࡞ࠡ࡯ߩ࠹࡯࡜࡯ࡔࠗ࠼
ෘ↢ഭ௛⋭⑼ቇ
ᴦ≮▤ℂࠟࠗ࠼࡜ࠗࡦߩ⏕┙⎇ⓥ⾌⵬ഥ㊄ߣታ↪ൻ

84,000 ජ౞ ᐔᚑ 19 㨪 22 ᐕᐲ ዊఽ∛ᘒቇಽ㊁૕⢽⢌ᷫዋ࿃ሶࠍ↪޿ߚ 2ဳ♧ዩ∛ߩᴦ≮150,800 ජ౞ ᐔᚑ 19 㨪 22 ᐕᐲౝಽᴲઍ⻢∛ᘒ
ቇಽ㊁ࠞ࡞ࡄࠗࡦ 10 㑐ㅪಽሶࠍ↪
޿ߚ 2 ဳ♧ዩ∛ㆮવሶ⸻ᢿ
ᴺߣᣂⷙᴦ≮ᴺߩ㐿⊒103,697 ජ౞ ᐔᚑ 16 㨪 19 ᐕᐲౝಽᴲઍ⻢∛ᘒ
ቇಽ㊁⁛┙ⴕ᡽ᴺੱㄘ
ᬺⴕ࡮↢‛♽․
ቯ↥ᬺᛛⴚ⎇ⓥ ఺∉ၮ␆⎇ⓥߦၮߠߊ㘩‛ࠕᯏ᭴࡟࡞ࠡ࡯ኻ╷㘩ຠߩ↹ᦼ⊛ഃ↢‛♽↥ᬺഃ಴ ↢ߩߚ߼ߩ⇣ಽ㊁Ⲣวᡰេ੐ᬺ

160,000 ජ౞ ᐔᚑ 17 㨪 22 ᐕᐲ ዊఽ∛ᘒቇಽ㊁⁛┙ⴕ᡽ᴺੱᣂ
♧ዩ∛ߩ⊒∝ᯏ᭴ߩ⸃᣿ߣㆮ
ࠛࡀ࡞ࠡ࡯࡮↥
વሶ⸻ᢿᴺߩ㐿⊒⎇ⓥࡊࡠᬺᛛⴚ✚ว㐿⊒ࠫࠚࠢ࠻ᯏ᭴

375,375 ජ౞ ᐔᚑ 18 㨪 23 ᐕᐲౝಽᴲઍ⻢∛ᘒቇಽ㊁⽷࿅ᴺੱࠝࠗࡦ ࡑࠗࠢࡠࠕ࡟ࠗࠍ↪޿ߚⅣႺ
࠳ࠬ࠻࡝࡯දળ ਛߩ∛ේᓸ↢‛╬ߩࡕ࠾࠲࡝
ࡦࠣᆔ⸤੐ᬺ

35,070 ජ౞ ᐔᚑ 16 㨪 19 ᐕᐲ∛ේ૕೙ᓮቇಽ
㊁⁛┙ⴕ᡽ᴺੱක SR Ⱞ⊕࡝ࡦ㉄ൻ㉂⚛㒖ኂᵴ⮎ຠක≮ᯏེ✚ ᕈࠍ᦭ߔࠆᣂߒ޿᛫࠙ࠖ࡞ࠬ
วᯏ᭴ᆔ⸤੐ᬺ ൻว‛ߩวᚑߦ㑐ߔࠆ⎇ⓥ

21,000 ජ౞ ᐔᚑ 16 㨪 20 ᐕᐲ↢๮ᯏ⢻ಽሶ⸳
⸘ಽ㊁

⽷࿅ᴺੱᣣᧄቝ ೨ᐸ㧙േ⣂ⴊ࿶⺞▵♽ߩน႟ቮࡈࠜ࡯࡜ࡓᆔ ᕈߦ㑐ߔࠆၮ␆⊛߅ࠃ߮⥃ᐥ⸤੐ᬺ
⊛⎇ⓥ

35,000 ජ౞ ᐔᚑ 17 㨪 20 ᐕᐲ ↢ℂቇಽ㊁

㧙㧙

⾗ᢱԞ
⊒᣿࡮․⸵ߩ಴㗿࡮⊓㍳ઙᢙ㧔කቇㇱ㒝ዻ∛㒮㧘කቇᢎ⢒㐿⊒⎇ⓥ࠮ࡦ࠲࡯㧘଻ஜ▤ℂ࠮ࡦ࠲࡯㧘ੱ₞ᗵᨴ㒐ᓮ⎇ⓥ࠮ࡦ࠲࡯ࠍ฽߻㧕
․⸵಴㗿
8

․⸵⊓㍳

ᐔᚑ 16 ᐕᐲ⊒᣿11

ᐔᚑ 17 ᐕᐲ

25

20

5

ᐔᚑ 18 ᐕᐲ

24

36

3

ᐔᚑ 19 ᐕᐲ

17

11

2

㧙㧙

⾗ᢱԟ

㧙㧙

⾗ᢱԠ

㧙㧙

㧙㧙

ጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼࡮කቇㇱᐔᚑ 17 ᐕ 4 ᦬㨪ᐔᚑ 20 ᐕ 3 ᦬✚᜝ႎ๔ጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼㐳࡮කቇㇱ㐳‫ޓ‬ㄭ⮮⋥ታ
ߎߩ 3 ᐕ㑆㧘ߏᜰዉߏᡰេߏදജࠍ⾦ࠅ㧘⺈ߦ᦭㔍߁ߏߑ޿߹ߒߚ‫ޕ‬ާࠬࡠ࡯ࠟࡦި
㜞ᐲߥ⎇ⓥߩផㅴߣ࿾ၞක≮ߩ⏕┙ߣߘࠇࠄߦၮߠߊੱ᧚⢒ᚑ࿾ၞߣ࿾⃿㧔਎⇇㧕ߦ⽸₂ߢ߈ࠆ⦟޿කᏧ㧘⦟޿⋴⼔Ꮷߣఝࠇߚකቇ⎇ⓥ⠪ߩ⢒ᚑੱ㑆ᕈ⼾߆ߢ᏷ᐢߊᅏᷓ޿⍮⼂ߣ㍈޿ᕁ⠨ജࠍ᦭ߔࠆකᏧ࡮කቇ⎇ⓥ⠪ߩ⢒ᚑާࠠ࡯ࡢ࡯࠼ި
ᡷ㕟㧘࡝࡯࠳࡯ࠪ࠶ࡊ㧘⊒ᗐജߣታⴕജ㧘⺞๺㧘⥄ഥദജ㧘NaSNeLCᮡ⺆㧦⒖ォ⛔วߒߡࡂ࡯࠼ߪ⚛᥍ࠄߒ޿ᣉ⸳ⅣႺߦߥߞߚ㧘ᓟߪ߽߁࠰ࡈ࠻㕙ߢ㗎ᒛࠆߩߺ‫ޕ‬ާᣉ⸳ިකቇㇱ⸥ᔨળ㙚ᐔᚑ 18 ᐕ 3 ᦬කቇ࿑ᦠ㙚ᐔᚑ 19 ᐕ 10 ᦬

ާ⚵❱ި
٤ ᄢቇ
ጘ㒂ᄢቇᄢቇ㒮ㅪวഃ⮎⎇ⓥ⑼ᐔᚑ 19 ᐕ 4 ᦬㧔એ਄ߪᄢቇ㧕㧔એਅߪㇱዪ㧕٤ කቇ♽⎇ⓥ⑼࡮කቇㇱ㧔⸻≮㧕‫ޓ‬ጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼࡮කቇㇱ࿾ၞක≮කቇ࠮ࡦ࠲࡯

ᐔᚑ 19 ᐕ 4 ᦬㐿ᆎౝ⑼♽ಽ㊁ᄖ⑼ᢇᕆ♽ಽ㊁࡮ ਅํ㧘㜞ጊߥߤ↥⑼♽ಽ㊁࡮ ↥⑼㧘ዊఽ⑼㧘

ዊఽ⑼♽ಽ㊁ᄖ⑼ߥߤ

✚ว⥃ᐥ♽ಽ㊁࿾ၞක≮ቇ⻠ᐳ ( ⋵ነ㒝⻠ᐳ )ᐔᚑ 19 ᐕ 11 ᦬㐿ᆎ㧔ᢎ⢒㧕ጘ㒂ᄢቇකቇㇱ‫ ޓ‬කቇᢎ⢒࡙࠾࠶࠻㧔⸃೬ቇ♽㧕

ᐔᚑ 19 ᐕ 11 ᦬㐿ᆎ㧔⎇ⓥ㧕ጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼ၮ␆කቇ⎇ⓥ࠮ࡦ࠲࡯᭴ᗐ᩺

ᐔᚑ 19 ᐕ 12 ᦬

1. ၮ␆කቇ⎇ⓥ⠪⢒ᚑㇱ㐷㧔࡙࠾࠶࠻㧕‫ޓ‬
2. ᦨవ┵⎇ⓥㇱ㐷㧔࠹ࡘ࠾ࠕ࡮࠻࡜࠶ࠢ᭴ᗐ㧕
3. ነ㒝⻠ᐳㇱ㐷㧙㧙㧔ㅴ〝ᜰዉ㧕ත೨තᓟㅴ〝ᜰዉ❑ᢿ⊛วหᆔຬળ㧔᜛ᄢડ↹ᆔຬળ㧕㧔ᤨߦ౏㐿㧕ߣዋੱᢙ೙ᜰዉ߅ࠃ߮ࡊࡠࠫࠚࠢ࠻ 30 ᩺ᐔᚑ 20 ᐕ 1 ᦬ާᣉ╷ި㧔කቇㇱᢎ⢒㧕1.

කቇㇱ౉⹜ᓟᦼࠪࡈ࠻㧔ᐔᚑ 19 ᐕ 3 ᦬ߩᚑᨐ‫ޓ‬78.9 ୚㧕2.

කቇㇱቯຬ 10 ੱჇ㧔࿾ၞᨒផ⮈౉⹜㧕㧔ᐔᚑ 20 ᐕ 4 ᦬ࠃࠅ㧕ᐔᚑ 19 ᐕ 10 ᦬3.

㧔⸘ 15 ੱ㧕᳿ቯ‫ޓ‬ᐔᚑ 19 ᐕ 10 ᦬කቇㇱቯຬ 5 ੱჇ㧔࿾ၞᨒផ⮈౉⹜㧕

4.

කቇㇱቇ↢㧔࿾ၞ㧕ᅑቇ㊄೙ᐲ㧔⋵ࠃࠅ㧕‫ޓ‬ᐔᚑ 19 ᐕ 10 ᦬

5.

කቇᢎ⢒࡙࠾࠶࠻ᢎ⢒⾌㈩ಽ‫ޓ‬ᐔᚑ 20 ᐕ 1 ᦬

6.

࿾ၞᨒ߅ࠃ߮⎇ⓥ⠪ᔒᦸ↪‫ޓ‬ㆬᛯᕈᣂࠞ࡝ࠠࡘ࡜ࡓ㧔ቇ↢ߩ࿾ၞ or ၮ␆߳ߩ಴౉ࠅផㅴ⸘↹㧕㧔ၮ␆㈩ߩᒝൻ㧕㧔㉿ⷫ೙㧕‫ޓ‬ᐔᚑ 19 ᐕ 12 ᦬

7.

࿾ၞᨒߦ㑐ߔࠆ㜞ᩞ↢߳ߩ⺑᣿ળ‫ޓ‬ᐔᚑ 19 ᐕ

8.

೽කቇㇱ㐳೙ዉ౉㧔೽⎇ⓥ⑼㐳ߦട߃ߡ㧕‫ޓ‬ᐔᚑ 19 ᐕ㧔ᄢቇ㒮ᢎ⢒㧕1.

ၮ␆කቇ⎇ⓥ⠪⢒ᚑ‫ࡊ࠶ࠪ࡜ࠞࠬޓ‬೙㧔ᦨ㜞 1000 ਁ㧕‫ޓ‬ᐔᚑ 17 ᐕ 6 ᦬

2.

ၮ␆කቇ♽ᄢቇ㒮౉ቇ↢‫ޓ‬ᅑቇ㊄೙㧔ᦨ㜞 242 ਁ㧕‫ޓ‬ᐔᚑ 20 ᐕ 1 ᦬

3.

ቇ૏⺰ᢥ⊒⴫ળߩ౏㐿ൻ

4.

ቇ૏ክᩏᆔຬ⷗⋥ߒ㧔ᜰዉᢎຬࠍ౉ࠇߥ޿㧕‫ޓ‬ᐔᚑ 20 ᐕ 2 ᦬㧔⎇ⓥ㧕
⎇ⓥᵴᕈൻ㧔ක㧕ߩߚ߼ߩᡰេ੐ᬺࠪ࡝࡯࠭‫ ߩߘޓ‬1 㨪 16޿ߕࠇ߽ᐔᚑ 17 ᐕᐲࠬ࠲࡯࠻‫ࠕ࠺ࠗࠕޓ‬㧘⎇ⓥ⾌㧘ࡑࡦࡄࡢ࡯ߩ࠻࡜ࠗࠕࡦࠣ࡞٤ ⊒ᗐ㧔ࠕࠗ࠺ࠕ㧕1.

࠻࡜ࡦࠬ࡟࡯࡚ࠪ࠽࡞࡝ࠨ࡯࠴⊛ⷞὐߩዉ౉

2.

․ቯߩᮮᢿ⊛⎇ⓥࡊࡠࠫࠚࠢ࠻┙਄ߍ

3.

⺰ᢥࠛࡇ࠰࡯࠼㓸⊒ೀ㧘ㅊೀ

4.

⎇ⓥ⑼ౝ㧘⎇ⓥ⑼㑐ㅪ㧘ቇⴚ⎇ⓥ⊒⴫੤ᵹળ⸳⟎㧔೎ฬ㧦NaSNeLC ⎇ⓥળ㧕‫ޓ‬㧔⎇ⓥ⾌㊀ὐ㈩ಽ㧘ഥᢎ㊀ὐ㈩ಽࠍਛᔃߦ㧕╙ 1 ࿁㨪╙ 3 ࿁5.

౒ห⎇ⓥࡊࡠࠫࠚࠢ࠻ࠬ࠲࡯࠻㧔ᣂߚߦ 4 ߟ㧕٤ ⎇ⓥ⾌෸߮ⅣႺ
6.

┹ว⊛ᄢဳ⎇ⓥ⾌₪ᓧᚢ⇛㧔․ቯߩᮮᢿ⊛⎇ⓥࡊࡠࠫࠚࠢ࠻┙ߜ਄ߍ㧕ౣ↢㧔ᐙ⚦⢩㧘␹⚻߽฽߻㧕㧘␹⚻∔ᖚ㧘⊹⤏∔ᖚ㧘࠲ࡦࡄࠢ᭴ㅧ࡮ഃ⮎㧔఺∉࡮ࠕ࡟࡞ࠡ࡯㧕㧘߇ࠎ㧘↢ᵴ⠌ᘠ∛㧘ⅣႺߣߩ㑐ㅪߥߤㅴⴕਛ

7.

⎇ⓥ⾌ߩㅢᏱ㈩ಽߦട߃ߡ㊀ὐ⊛㈩ಽ㧔⎇ⓥ⑼㐳ⵙ㊂⚻⾌ߦࠃࠆ㧕

8.

⎇ⓥ⠪⋧੕ߩ‛⊛࡮ᕁ⊛දജ૕೙ᒝൻ

9.

ಽ㊁߳ߩࡐࠗࡦ࠻࡮ࠗࡦ࠮ࡦ࠹ࠖࡉ೙৻ㇱዉ౉٤ ࡑࡦࡄࡢ࡯
10. ㊀ὐൻࡊ࡯࡞ഥᢎ㈩ಽ
11. ᢎຬࡐࠗࡦ࠻೙ዉ౉
12. ⥃ᐥᢎ᝼ߥߤⶄᢙᢎ᝼೙ዉ౉
13. ᄖㇱ⾗㊄㧔ነઃ㊄㧕㓹↪ᢎຬ㧔ಎᢎ᝼㧘⻠Ꮷ㧘ഥᢎ㧕
14. ၮ␆⎇ⓥ⠪⢒ᚑࠬࠞ࡜ࠪ࠶ࡊ㧔ห⓹ળၮ㊄㧕㧙㧙

15. 㕖Ᏹൕᛛ⢻⵬૒ຬ㓹↪ߩല₸ൻ
16. ⎇ⓥ⠪㧔ᢎຬ㧕ណ↪ᣇᴺ৻ⷩ૞ᚑ㧔ㆇ༡㧕1.

౒ㅢ⎇ⓥቶ෸߮ᯏེߩㆇ༡ߣ౒ㅢࠬࡍ࡯ࠬ᦭ല೑↪ᴺ2.

↢๮⑼ቇ✚ว⎇ⓥᡰេ࠮ࡦ࠲࡯ㆇ༡෸߮ߘߩᣇᴺߦ㑐ߔࠆදജߣ᦭ല㊀ὐ⊛೑↪

3.

⥄Ꮖ⹏ଔߩߚ߼ߩ⃻⁁ߣ⺖㗴㧔╙ 6 ภ㧕㧔ᐔᚑ 18 ᐕ 3 ᦬㧕⊒ೀߣߘࠇࠍᵴ↪ߒߚᬺ❣㧘ታ❣ߩ⺞ᩏߣ⹏ଔ߅ࠃ߮ᐔᚑ 18 ᐕᐲ㧘19 ᐕᐲᬺ❣㓸

4.

⎇ⓥᚑᨐߩ࿖㓙࠻࠶ࡊ⹹߳ߩឝタ㧔Nature, Science, New England Journal of Medicine,
Lancet, Cell̆NaSNeLC‫ߣࠢ࡞ࡀࠬ࠽ޓ‬ฬߠߌߚ̆ߥߤ߳ߩឝタ㧕ߣ․⸵₪ᓧߣ␠ળ⽸₂ߩᒝൻ㧔ႎ㆏߽฽߻㧕5.

ARIS ౉ജ 100%㧘කቇㇱ᫟ࠛࡦ࠻࡜ࡦࠬߩᢛ஻

6.

శᾲ⾌೥ᷫ⥄ഥദജާ⎇ⓥᚑᨐި٤ ᄢဳ⎇ⓥ⾌₪ᓧታ❣㧔ਥߥ߽ߩ㧕Ԙ↢๮ᯏ⢻ಽሶ⸳⸘ಽ㊁㧔㋈ᧁᱜᢎ᝼㧕ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄‫‛↢ޟ‬ᣂᯏ⢻ߣഃ⮎ࠍ߼ߑߔ↢૕ౝಽሶ⑼ቇ‫ޠ‬㧔ᐔᚑ 13 ᐕᐲ߆ࠄ㧡ᐕ㑆㧦1,274,000 ජ౞㧕ԙ ⊹⤏∛ᘒቇಽ㊁㧔ർፉᢎ᝼㧕ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄‫ޟ‬⒘ዋ㔍ᴦᕈ⊹⤏∔ᖚߦ㑐ߔࠆ⺞ᩏ⎇ⓥ‫ޠ‬㧔ᐔᚑ 14 ᐕᐲ߆ࠄ㧢ᐕ㑆㧦206,200 ජ౞㧕[ ⹏ଔ 7.17 ὐ㧔ᐔဋ 6.66㧕]Ԛዊఽ∛ᘒቇಽ㊁㧔ㄭ⮮ᢎ᝼࡮ട⮮⻠Ꮷ࡮᧻੗⻠Ꮷ㧕ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄‫࡯ࠡ࡞࡟ࠕޟ‬∔ᖚߩᴦ≮෻ᔕᕈ੍᷹࿃ሶߩ⏕┙෸߮࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮ᴺߩ⏕┙‫ޠ‬㧔ᐔᚑ 16 ᐕᐲ߆ࠄ 3 ᐕ
㑆㧦83,000 ජ౞㧕[ ⹏ଔ 7.27 ὐ㧔ቇⴚ㧘ᐔဋ 7.02㧕]‫ޓޓ‬ᮡ⺆㧦කᏧߦߣߞߡ૶޿ൎᚻߩ⦟޿⮎ࠍㆬ߱ߩߢߪߥߊ㧘ᖚ⠪ߐࠎߦߣߞߡ૶ࠊࠇൎᚻߩ⦟޿⮎ࠍㆬ߱ԛ ዊఽ∛ᘒቇಽ㊁㧔ㄭ⮮ᢎ᝼࡮᧻੗⻠Ꮷ㧕ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄‫࡯࡜࡯࠹ߩ࡯ࠡ࡞࡟ࠕޟ‬ࡔࠗ࠼ᴦ≮▤ℂࠟࠗ࠼࡜ࠗࡦߩ⏕┙ߣታ↪ൻ‫ޠ‬㧔ᐔᚑ 19 ᐕᐲ߆ࠄ 3 ᐕ㑆㧦84,000 ජ౞㧕Ԝዊఽ∛ᘒቇಽ㊁㧔ㄭ⮮ᢎ᝼࡮㊄ሶᢎ᝼㧕 ⁛┙ⴕ᡽ᴺੱㄘᬺⴕ࡮↢‛♽․ቯ↥ᬺᛛⴚ⎇ⓥᯏ᭴
↢‛♽↥ᬺഃ಴ߩߚ߼ߩ⇣ಽ㊁Ⲣวᡰេ੐ᬺ‫∉఺ޟ‬ၮ␆⎇ⓥߦၮߠߊ㘩‛ࠕ࡟࡞ࠡ࡯ኻ╷㘩ຠߩ↹ᦼ⊛ഃ↢‫ޠ‬㧔ᐔᚑ 17 ᐕᐲ߆ࠄ 5 ᐕ㑆㧦160,000 ජ౞㧕‫ޓޓ‬ᮡ⺆㧦㘩ߴߡᴦߔ㘩ຠࠍ㐿⊒㧔⚻ญ఺∉ኡኈ⺃ዉ㧕ԝ ౝಽᴲઍ⻢∛ᘒቇಽ㊁㧔ᱞ↰ᢎ᝼࡮ၳᎹಎᢎ᝼㧕⁛┙ⴕ᡽ᴺੱᣂࠛࡀ࡞ࠡ࡯࡮↥ᬺᛛⴚ✚ว㐿⊒ᯏ᭴‫♧ޟ‬ዩ∛ߩ⊒∝ᯏ᭴ߩ⸃᣿ߣㆮવሶ⸻ᢿᴺߩ㐿⊒⎇ⓥ‫࠻ࠢࠚࠫࡠࡊޠ‬㧔ᐔᚑ 18 ᐕᐲ߆ࠄ 5 ᐕ㑆㧦375,375 ජ౞㧕Ԟౝಽᴲઍ⻢∛ᘒቇಽ㊁㧔ᱞ↰ᢎ᝼㧕ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄‫ޟ‬૕⢽⢌ᷫዋ࿃ሶࠍ↪޿ߚ 2ဳ♧ዩ∛ߩᴦ≮‫ޠ‬㧔ᐔᚑ 19 ᐕᐲ߆ࠄ 3 ᐕ㑆㧦150,800 ජ౞㧕[ ⹏ଔ 5.8 ὐ㧔ቇⴚ㧘ᐔဋ 6.1㧕]ԟౝಽᴲઍ⻢∛ᘒቇಽ㊁㧔ၳᎹಎᢎ᝼㧕ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄‫ ࡦࠗࡄ࡞ࠞޟ‬10 㑐ㅪಽሶࠍ↪޿ߚ 2 ဳ♧ዩ∛ㆮવሶ⸻ᢿᴺߣᣂⷙᴦ≮ᴺߩ㐿⊒‫ޠ‬㧔ᐔᚑ 16 ᐕᐲ߆ࠄ 3 ᐕ㑆㧦103,697 ජ౞㧕Ԡ ∛ේ૕೙ᓮቇಽ㊁ ( ᳯፒᢎ᝼ ) ⽷࿅ᴺੱࠝࠗࡦ࠳ࠬ࠻࡝࡯දળᆔ⸤੐ᬺ‫↪ࠍࠗ࡟ࠕࡠࠢࠗࡑޟ‬㧔ᐔᚑ 16 ᐕᐲ߆ࠄ 3 ᐕ㑆㧦35,070 ජ౞㧕޿ߚⅣႺਛߩ∛ේᓸ↢‛╬ߩࡕ࠾࠲࡝ࡦࠣ‫ޠ‬ԡ ↢ℂቇಽ㊁ ( ᫪↰ᢎ᝼ ) ⽷࿅ᴺੱᣣᧄቝቮࡈࠜ࡯࡜ࡓᆔ⸤੐ᬺ‫ޟ‬೨ᐸ㧙േ⣂ⴊ࿶⺞▵♽ߩน႟ᕈߦ㑐ߔࠆၮ␆⊛߅ࠃ߮⥃ᐥ⊛⎇ⓥ‫ޠ‬㧔ᐔᚑ 17 ᐕᐲ߆ࠄ 3 ᐕ㑆㧦35,000 ජ౞㧕

㧙㧙

Ԣ

↢๮ᯏ⢻ಽሶ⸳⸘ಽ㊁ ( ㋈ᧁᱜᢎ᝼ ) ⁛┙ⴕ᡽ᴺੱක⮎ຠක≮ᯏེ✚วᯏ᭴ᆔ⸤੐ᬺ‫ޟ‬SR Ⱞ⊕࡝ࡦ㉄ൻ㉂⚛㒖ኂᵴᕈࠍ᦭ߔࠆᣂߒ޿᛫࠙ࠖ࡞ࠬൻว‛ߩวᚑߦ㑐ߔࠆ⎇ⓥ‫ޠ‬㧔ᐔᚑ 16 ᐕᐲ߆ࠄ 4 ᐕ㑆㧦21,000 ජ౞㧕ԣᶖൻེ∛ᘒቇಽ㊁㧔᫪⣁ᢎ᝼㧕ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄‫ޟ‬ᩭౝฃኈ૕Ⱞ⊕ࠍಽሶᮡ⊛ߣߒߚ⢄≸ൻቇ੍㒐ߦ㑐ߔࠆ⎇ⓥ‫ޠ‬㧔ᐔᚑ 17 ᐕᐲ߆ࠄ 5 ᐕ㑆㧦79,500 ජ౞㧕Ԥ⍮⢻ࠗࡔ࡯ࠫᖱႎ㧔⮮↰ᢎ᝼㧕ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄‫ޟ‬ᱜᏱ᭴ㅧߩℂ⸃ߦၮߠߊ⍮⊛㧯㧭㧰‫ޠ‬
㧔ᐔᚑ 15 ᐕᐲ߆ࠄ 4 ᐕ㑆㧦56,000 ජ౞㧕ԥᓴⅣ∛ᘒቇಽ㊁㧔⮮ේᢎ᝼㧕ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄‫ޟ‬᜛ᒛဳᔃ╭∝ߦኻߔࠆ㗰☸⃿ࠦࡠ࠾࡯ೝỗ࿃ሶࠍ↪޿ߚ㕖ଚⷅᕈౣ↢ක≮ߩ᜸ᚢ‫ޠ‬㧔ᐔᚑ 15 ᐕᐲ߆ࠄ 3 ᐕ㑆㧦43,940 ජ౞㧕Ԧ 㤗㈮࡮−∩೙ᓮቇಽ㊁㧔࿯⢈ᢎ᝼㧕ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄‫ޟ‬㤗㈮࡮−∩ࠪࠣ࠽࡞વ㆐ߦ
߅ߌࠆࠗࠝࡦ࠴ࡖࡀ࡞ߣࠗࠝࡦ࠻࡜ࡦࠬࡐ࡯࠲࡯ߩ೙ᓮᯏ᭴‫ޠ‬㧔ᐔᚑ 14 ᐕᐲ߆ࠄ 4 ᐕ㑆㧦32,110ජ౞㧕ԧ

㤗㈮࡮−∩೙ᓮቇಽ㊁㧔࿯⢈ᢎ᝼㧕ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄‫ޟ‬㤗㈮⮎ࠪࠣ࠽࡞વ㆐ᯏ᭴ߦ
㧔ᐔᚑ 19 ᐕᐲ߆ࠄ 3 ᐕ㑆㧦߅ߌࠆ࠽࠻࡝࠙ࡓࠞ࡝࠙ࡓࡐࡦࡊߩᓎഀߣߘߩ᭴ㅧᄌൻߩ⸃ᨆ‫ޠ‬26,130 ජ౞㧕Ԩ ነ↢⯻ቇಽ㊁㧔㜞ᯅᢎ᝼㧕ᢥㇱ⑼ቇ⋭‫ࠆ޽⦡․ޓ‬ᄢቇᢎ⢒ᡰេࡊࡠࠣ࡜ࡓ‫ޟ‬⢻േ࡮ᕁ⠨ଦㅴဳࠍᩇߣߔࠆోੱቇ⊛කቇᢎ⢒‫ޠ‬ᐔᚑ 16 ᐕᐲ㨪ᐔᚑ 18 ᐕᐲ 46,473 ජ౞㧔ᢎ⢒㧕ԩ කቇᢎ⢒㐿⊒⎇ⓥ࠮ࡦ࠲࡯㧔㋈ᧁᢎ᝼㧕ᢥㇱ⑼ቇ⋭‫⃻ޓ‬ઍ⊛ᢎ⢒࠾࡯࠭ข⚵ᡰេࡊࡠࠣ࡜ࡓ㧔⃻ઍ 㧳㧼㧕⥃ᐥකቇᢎ⢒ࠍᒝൻߐߖࠆ 㧵㧯㨀‫ޟ‬e-Learning ߢၭ߁කߩᔃߣᛛ‫ޠ‬ᐔᚑ 19 ᐕᐲ㨪ᐔᚑ 21 ᐕᐲ㧔੍ቯ㧕72,000 ජ౞㧔ᢎ⢒㧕ጘ㒂࡮ᄢ၂࿾ၞ⍮⊛ࠢ࡜ࠬ࠲࡯੐ᬺߣߒߡ㧘Ԙ⍮⢻ࠗࡔ࡯ࠫᖱႎಽ㊁㧔⮮↰ᢎ᝼㧕‫↹ޟ‬௝⸻ᢿᡰេࠪࠬ࠹ࡓ‫ޠ‬㧔ᐔᚑ 16 ᐕᐲ߆ࠄ 4 ᐕ㑆㧦278,559
ජ౞㧕෸߮‫⌒ޟ‬ᐩ┙૕↹௝ࠍ↪޿ߚ⌒⑼⸻ᢿᡰេࠪࠬ࠹ࡓߩ㐿⊒‫ޠ‬㧔ᐔᚑ 18 ᐕᐲ㧦834 ජ౞㧕㧔ᐔᚑ 16 ᐕᐲ߆ࠄ 2ԙ ነ↢⯻ቇಽ㊁㧔㜞ᯅᢎ᝼㧕‫࡞ࡖ࠴࡯ࡃޟ‬ක≮࡮ᢎ⢒⸠✵ࠪࠬ࠹ࡓߩ㐿⊒‫ޠ‬ᐕ㑆㧦44,953 ජ౞㧕෸߮‫ޟ‬ૐଚⷅᓸ⚦ᚻⴚᡰេ࡮ᢎ⢒⸠✵ࠪࠬ࠹ࡓ㧙ක≮ᢎ⢒⸠✵ࡠࡏ࠶࠻ߩ
㐿⊒㧙‫ޠ‬
㧔ᐔᚑ 18 ᐕᐲ߆ࠄ 2 ᐕ㑆㧦62,463 ජ౞㧕Ԛක≮ᖱႎቇಽ㊁ ( ♿ࡁቯᢎ᝼ )‫↹ޟ‬௝⸻ᢿᡰេࠪࠬ࠹ࡓ‫ޠ‬㧔ᐔᚑ 16 ᐕᐲ߆ࠄ 4 ᐕ㑆㧦73,189 ජ౞㧕ԛ㧔ᐔᚑ 16
㜞ᐲవㅴᄖ⑼ቇಽ㊁ ( ┻᧛ᢎ᝼ ) ‫ޟ‬ૐଚⷅᓸ⚦ᚻⴚᡰេ࡮ᢎ⢒⸠✵ࠪࠬ࠹ࡓߩ㐿⊒‫ޠ‬ᐕᐲ߆ࠄ 4 ᐕ㑆㧦22,398 ජ౞㧕⎇ⓥផㅴ⚻⾌㧔᭎▚ⷐ᳞㧕ߣߒߡ㧘Ԙ⚵❱࡮ེቭᒻᚑಽ㊁㧔࿡⽵ᢎ᝼㧕‫ ࠻ࡅޟ‬㧱㧿 ⚦⢩࡮⚵❱ᐙ⚦⢩ࠍ↪޿ߚ✂⤑ౣ↢ක≮ࡕ࠺࡞㧔േ‛ࡕ࠺࡞㧕ߩ⏕┙‫ޠ‬ᐔᚑ 18 ᐕᐲ߆ࠄ 3 ᐕ㑆㧦62,000 ජ౞㧕ߘߩઁᄙᢙ٤ ᄖㇱ⾗㊄₪ᓧ⁁ᴫᐔᚑ 16 ᐕᐲ‫✚ޓ‬㗵 1,634,104 ජ౞
ᐔᚑ 17 ᐕᐲ‫✚ޓ‬㗵 1,691,815 ජ౞ᐔᚑ 18 ᐕᐲ‫✚ޓ‬㗵 1,429,735 ජ౞ᐔᚑ 19 ᐕᐲ‫✚ޓ‬㗵

ජ౞

㧙㧙

٤ ⺰ᢥᢙߣࠗࡦࡄࠢ࠻ࡈࠔࠢ࠲࡯㧔IF㧕ᐔᚑ 16 ᐕᐲ✚⺰ᢥᢙ 909⧷ᢥ⺰ᢥᢙ 311

IFᐔᚑ 17 ᐕᐲ✚⺰ᢥᢙ 920

⧷ᢥ⺰ᢥᢙ 371

IFᐔᚑ 18 ᐕᐲ✚⺰ᢥᢙ 932⧷ᢥ⺰ᢥᢙ 344IFᐔᚑ 19 ᐕᐲ

✚⺰ᢥᢙ

⧷ᢥ⺰ᢥᢙ

IF

㧔ಽ㊁೎ߩᄖㇱ⾗㊄₪ᓧ⁁ᴫ߅ࠃ߮⺰ᢥᢙ߆ࠄ㓸⸘㧕ާᐕ⴫ި䚷䚷ᒱ㜧኱Ꮫ኱Ꮫ㝔་Ꮫ⣔◊✲⛉䞉་Ꮫ㒊䚷䚷䚷䚷䚷䚷䚷䚷䚷䚷䚷ᖺ⾲䚷䠄ᖹᡂ㻝㻣ᖺ㻠᭶䡚ᖹᡂ㻞㻜ᖺ㻟᭶䠅ᒱ㜧኱Ꮫ኱Ꮫ㝔་Ꮫ⣔◊✲⛉㛗䞉་Ꮫ㒊㛗㻌㻌㻌㏆⸨┤ᐇᖹᡂ㻝㻣ᖺᗘ
㻠᭶䚷ᖹᡂ㻝㻤ᖺᗘ
㻠᭶䚷䚷䚷ᖹᡂ㻝㻥ᖺᗘ㻠᭶䛊᪋タ䛋䚷䚷䚷䚷䚷䚷䚷䚷䚷䚷㻟᭶኱Ꮫ 㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌་Ꮫ㒊グᛕ఍㤋
䛊⤌⧊䛋
䚷䚷䚽኱Ꮫ

䚷䚷䚷䚷ᖹᡂ㻞㻜ᖺᗘ㻠᭶㻌㻌㻌㻌䚷䚷䚷䚷䚷䚷䚷㻝㻜᭶䚷䚷䚷䚷䚷䚷㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌་Ꮫᅗ᭩㤋㻠᭶㐃ྜ๰⸆◊✲⛉

䚷䚷䚽་Ꮫ⣔◊✲⛉䞉་Ꮫ㒊䚷䚷䚷䚷䠄デ⒪䠅䚷䚷䚷䚷䚷䚷䚷㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻥᭶䚷䚷䚷䚷䚷䚷䚷㻠᭶䚷䚷䚷㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌ᆅᇦ་⒪་Ꮫ䝉䞁䝍䞊䠄㻡㒊㛛䠅䠄㻝㻜ᖺ㛫䠅་ 䚷䚷䚷䚷䚷䚷㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻥᭶䚷䚷䚷䚷䚷䚷䚷䚷䚷䚷䚷䚷䚷㻌㻌㻌㻌㻌㻌㻌㻌㻌㻝㻝᭶Ꮫ䚷䚷䚷䚷䚷䚷䚷䚷䚷㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌ᆅᇦ་⒪་Ꮫㅮᗙ䠄㻡ᖺ㛫䠅⣔䚷䚷䚷䚷䚷䚷䚷䚷㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌䚷䠄┴ᐤ㝃ㅮᗙ䠅◊✲ 䚷䚷䚷䚷䠄ᩍ⫱䠅䚷䚷䚷䚷䚷䚷䚷䚷䚷䚷䚷䚷䚷䚷㻌㻞᭶ 䚷䚷䚷䚷䚷䚷䚷䚷䚷䚷㻝㻝᭶⛉䚷䚷䚷䚷䚷䚷䚷䚷䚷㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌་Ꮫᩍ⫱䝴䝙䝑䝖䚷䚷䚷䚷䠄◊✲䠅䚷䚷䚷䚷㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻣᭶㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻝㻞᭶䚷䚷䚷䚷䠄㐍㊰ᣦᑟ䠅㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌ᇶ♏་Ꮫ◊✲䝉䞁䝍䞊䠄㻟㒊㛛䠅ᵓ᝿᱌䚷䚷䚷䚷䚷䚷䚷䚷㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌䚷䚷㻌㻌㻝᭶㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌༞๓༞ᚋ㐍㊰ᣦᑟ⦪᩿ⓗྜྠጤဨ఍
ࠉࠉ㸦◚⥺ࡣ‽ഛᮇ㛫㸧 䚷䚷䚷䚷䚷䚷䚷䚷䚷䚷䚷䚷䠄ᣑ኱௻⏬ጤဨ఍䠅䛸ᑡேᩘไᣦᑟ᱌➼㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌⌧≧䛸ㄢ㢟䠄ᴗ⦼㞟䠅➨㻢ྕ䚷䚷䚷㻌㻌㻴㻝㻤ᖺᗘᴗ⦼㞟䚷䚷䚷䚷䚷䚷䚷㻌㻴㻝㻥ᖺᗘᴗ⦼㞟䛊᪋⟇䛋㻌䚷䚷䚷䚷䚷䚷䚷➨䠍ᅇ㻺㼍㻿㻺㼑㻸㻯◊✲఍䚷䚷䚷䚷䚷䚷䚷➨䠎ᅇ㻺㼍㻿㻺㼑㻸㻯◊✲఍䚷䚷䚷䚷䚷➨䠏ᅇ㻺㼍㻿㻺㼑㻸㻯◊✲఍㻌䚷㻌㻌㻌㻔◊✲᪋⟇㻕㻌㻌◊✲άᛶ໬䠄་䠅䛾䛯䜑䛾ᨭ᥼஦ᴗ䝅䝸䞊䝈㻌䛭䛾㻝䡚䛭䛾㻝㻢䚸㔜Ⅼ䝥䞊䝹ຓᩍ䚸እ㒊㈨㔠㞠⏝ᩍဨ䚸䚷䚷䚷䚷䚷䚷䚷㻌➇ྜⓗ◊✲㈝⋓ᚓ䚸Ꮫ㒊㛗⿢㔞⤒㈝㔜Ⅼ㓄ศ䚸ඹྠ◊✲䝥䝻䝆䜵䜽䝖䚸ㄽᩥ䜶䝢䝋䞊䝗㞟䚷௚㻌㻝㻢௳㻔ᩍ⫱᪋⟇㻕䚷་Ꮫ㒊ධヨᚋᮇ䝅䝣䝖䚸ᐃဨቑ㻝㻜ே䚸୍㒊㑅ᢥᛶ䜹䝸䜻䝳䝷䝮䚷௚㻌㻤௳䠄㐠Ⴀ᪋⟇䠅㻔 ኱ Ꮫ㝔 ᩍ ⫱ ᪋ ⟇ 㻕 䚷 ᇶ ♏ ་ Ꮫ◊ ✲ ⫱ ᡂ 䝇 䜹 䝷 䝅 䝑 䝥 䚷 ௚ 㻌㻠 ௳ާᢥ₂ިㄭ⮮⋥ታ㧦࿾ၞක≮⏕଻ߩߚ߼ߩ౐ߟߩ⊒ᗐォ឵㧙ጘ㒂ᄢ‫ޟ‬࿾ၞක≮කቇ࠮ࡦ࠲࡯‫┙⸳ߩޠ‬㧙㧚ᣣᧄක੐ᣂႎ‫ޓ‬4364㧘80-85㧔2007 ᐕ 12 ᦬ 15 ᣣ㧕ާ⾗ᢱި٤ጘ㒂ᄢቇකቇ♽⎇ⓥ⑼කቇㇱ࿾ၞක≮කቇ࠮ࡦ࠲࡯ᯏ᭴࿑㧔⾗ᢱ㧝㧕٤ጘ㒂ᄢቇකቇㇱකቇᢎ⢒࡙࠾࠶࠻⸳⟎ⷐ㗄‫⇛⋭ޓ‬٤ጘ㒂ᄢቇකቇ♽⎇ⓥ⑼ၮ␆කቇ⎇ⓥ࠮ࡦ࠲࡯ᯏ᭴࿑㧔ᐔᚑ㧞㧜ᐕ㧞᦬᩺㧕෸߮ⷐ㗄㧔ᐔᚑ㧞㧜ᐕ㧞᦬᩺㧕㧔⾗ᢱ㧞㧕৻ㇱ⋭⇛

㧙㧙

٤

ጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼╬ߦ߅ߌࠆᄖㇱ⾗㊄㓹↪ᢎຬߦ㑐ߔࠆขᛒⷐ㗄╬‫⇛⋭ޓ‬٤ඳ჻⺖⒟ቇ↢㧔ၮ␆කቇ♽㧕ᅑቇ↢൐㓸ⷐ㗄෸߮ጘ㒂ᄢቇකቇㇱකቇ⑼࡮⎇ⓥ⠪⢒ᚑࠬࠞ࡜ࠪ࠶
ࡊߦ㑐ߔࠆขᛒⷐ㗄‫⇛⋭ޓ‬٤ᄖㇱ⾗㊄ฃ౉⁁ᴫ෸߮⺰ᢥᢙ㧔⾗ᢱ㧟㧕٤ో૕ᯏ᭴࿑㧔⾗ᢱ㧠㧕ާකቇ♽⎇ⓥ⑼‫ޓ‬ᐔᚑ㧝㧣ᐕ㧚㧠᦬㨪㧞㧜ᐕ㧟᦬ި
⎇ⓥ⑼㐳㧦ㄭ⮮⋥ታ೽⎇ⓥ⑼㐳㧦ᱜ᧛ᢎ᝼㧘᫪↰ᢎ᝼㧘࿯⢈ᢎ᝼㧘ጟ㊁ᢎ᝼
੐ോ㐳㧦᫪ጊ‫┨ޓ‬㧘ᷡ᳓‫ޓ‬㕏ੱ㧘ർⵣ‫ޓ‬ඳ㧘੐ോ㐳⵬૒㧦⍹ጊ‫⵨ޓ‬㧘᧻ේ‫⑲ޓ‬᮸✚ോଥ㐳㧦㐳⼱Ꮉ‫⟵ޓ‬ೣ㧘↰ਛ‫ޓ‬ㅴ㧘ੱ੐ଥ㐳㧦㈬శ‫ޓ‬િཅ㧘ਅㅢ‫ޓ‬ਗ਼▤ℂଥ㐳㧦ችᎹ‫ޓ‬ቁ᣿㧘⎇ⓥᡰេଥ㐳㧦ศ↰‫⌀ޓ‬ੑ㧘ቇോ╙৻ଥ㐳㧦⧎ἑ‫ޓ‬ᢅቁ㧘၂⷗‫◊ޓ‬ᄢቇ㒮ଥ㐳㧦㐳ደ౎㊀ሶ㧘කቇㇱ㐳⒁ᦠ㧦ਛፉᐞਭ⟤㧘ᵻ㊁ජᏔ
ߘߩઁోᢎ⡯ຬߩᣇ‫ޘ‬㧔⾗ᢱ 1㧕

ᆅᇦ་⒪䛾☜ಖ䛾䛯䜑䛾⊂๰ⓗ䛛䛴⏬ᮇⓗゎỴ⟇䠉6䛴䛾Ⓨ᝿䛾㌿᥮䠉ᒱ㜧኱Ꮫ኱Ꮫ㝔་Ꮫ⣔◊✲⛉㛗䞉་Ꮫ㒊㛗ᒱ㜧኱Ꮫ኱Ꮫ㝔་Ꮫ⣔◊✲⛉䞉་Ꮫ㒊ᆅᇦ་⒪་Ꮫ䝉䞁䝍䞊 䝉䞁䝍䞊㛗ᒱ㜧኱Ꮫ኱Ꮫ㝔་Ꮫ⣔◊✲⛉䞉་Ꮫ㒊ᑠඣ⑓ែᏛ ᩍᤵ
㏆⸨ ┤ᐇ

1.
2.
3.
4.
5.
6.

་ᖌ䛾☜ಖ䛷䛿䛺䛟䚸་⒪䛾☜ಖ䛷䛒䜛䚹䛭䛾䛯䜑䛾ಶูᑐᛂ䛸䝅䝇䝔䝮໬䛜ᚲせ䛷䛒䜛䠄▷ᮇⓗゎỴ⟇䛸୰㛗ᮇⓗゎỴ⟇䚹᫂᪥䛛䜙䛷䜒ྍ⬟䛺䛣䛸䛜ᑡ䛺䛟䛺䛔䠅䚹ᩍ⫱䞉◊✲䛜䛒䜚䚸䛭䛧䛶་⒪☜ಖ䛜䛒䜛䠄୰㛗ᮇⓗゎỴ⟇䠅䚹⑌ᝈ䜢デ䜛䛾䛷䛿䛺䛟䚸⑌ᝈ䜢ᣢ䛴ᝈ⪅䜢デ䜛䛾䛷䛒䜚䚸䛥䜙䛻䛭䛾ᝈ⪅䛜⏕ά䛧䛶䛔䜛ᆅᇦ⎔ቃ䜢デ䜛䛸䛔䛖ᩍ⫱䚸◊✲䛭䛧䛶་⒪䚹
ᆅᇦ་⒪䛸ᆅᇦ་Ꮫ䛾㔜せᛶ䛾ㄆ㆑䛸⯆࿡䜢ᣢ䛳䛶䜒䜙䛖ᩍ⫱䚹ᶓ᩿ⓗ⥲ྜ⮫ᗋ་䛾⫱ᡂ䚹⊂๰ⓗ䛛䛴⏬ᮇⓗ䝉䞁䝍䞊䛷䛒䜛ᒱ㜧኱Ꮫ኱Ꮫ㝔་Ꮫ⣔◊✲⛉䞉་Ꮫ㒊 ᆅᇦ་⒪་Ꮫ䝉䞁䝍䞊䛾タ❧䚹㧙㧙㧔⾗ᢱ 2㧕
ᒱ㜧኱Ꮫ኱Ꮫ㝔་Ꮫ⣔◊✲⛉ᇶ♏་Ꮫ◊✲ࢭࣥࢱ࣮ᶵᵓᅗ
㸦ᖹᡂ㸰㸮ᖺ㸰᭶᱌㸧ᒱ㜧኱Ꮫ኱Ꮫ㝔་Ꮫ⣔◊✲⛉ᇶ♏་Ꮫ◊✲ࢭࣥࢱ࣮

㸦㸯㸧ᇶ♏་Ꮫ◊✲άᛶ໬࣭ⱝᡭ◊✲⪅⫱ᡂ㒊㛛㸯㸬➨㸯 ◊✲άᛶ໬ࣘࢽࢵࢺ㸦ࣉࣟࢪ࢙ࢡࢺࢳ࣮࣒㸧          ࣘࢽࢵࢺྡ䛊㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 䛋㻌㸰㸬➨㸰 ྠୖ㸱㸬➨㸱 ྠୖ㸦㸰㸧᭱ඛ➃㧗ᗘ◊✲㒊㛛㸯㸬➨㸯 ᭱ඛ➃◊✲ศ㔝          ศ㔝ྡ䛊㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 䛋㸰㸬➨㸰 ྠୖ㸦㸱㸧ᐤ㝃ㅮᗙ◊✲㒊㛛㸯㸬➨㸯 ᐤ㝃◊✲ࣘࢽࢵࢺ         ࣘࢽࢵࢺྡ䛊㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 䛋㸰㸬➨㸰 ྠୖጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼ၮ␆කቇ⎇ⓥ࠮ࡦ࠲࡯ⷐ㗄㧔ᐔᚑ㧞㧜ᐕ㧞᦬᩺㧕㧔⿰‫ޓ‬ᣦ㧕╙㧝᧦‫ⷐߩߎޓ‬㗄ߪ㧘ጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼ၮ␆කቇ⎇ⓥ࠮ࡦ࠲࡯㧔એਅ‫ޕ߁޿ߣޠ࡯࠲ࡦ࠮ޟ‬㧕ߦ㑐ߒᔅⷐߥ੐㗄ࠍቯ߼ࠆ߽ߩߣߔࠆ‫ޕ‬㧔⋡‫⊛ޓ‬㧕╙㧞᧦‫ߪ࡯࠲ࡦ࠮ޓ‬㧘ጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼ߩၮ␆කቇ♽ࠍਛᔃߦ㧘⎇ⓥ⑼ో૕ߩ⎇ⓥᵴᕈൻ෸߮ၮ␆කቇ♽⧯ᚻ⎇ⓥ⠪ߩ⢒ᚑࠍផㅴߔࠆߎ
ߣࠍ⋡⊛ߣߔࠆ‫ޕ‬㧔⹏‫ޓ‬ଔ㧕╙㧟᧦ ‫⹏❱⚵ޓ‬ଔߪ㧘⊒⿷ᓟ㧡ᐕࠍ⚻ㆊߒߚᤨὐߢකቇ♽⎇ⓥ⑼࡮කቇㇱડ↹ᆔຬળ߇⹏ଔߒ㧘කቇ⎇ⓥ⑼ᢎ᝼ળ⼏ߦ߅޿ߡ⷗⋥ߒࠍ฽߼ߡᬌ⸽ࠍⴕ߁‫ޕ‬㧞‫ޓ‬୘ੱ⹏ଔߪ㧘කቇ♽⎇ⓥ⑼࡮කቇㇱડ↹ᆔຬળ߇ⴕ߁ߎߣߣߒ㧘ᒰ⹥⹏ଔᣇᴺߪ㧘೎ߦቯ߼ࠆ‫ޕ‬㧔ᬺ‫ޓ‬ോ㧕╙㧠᧦‫ߪ࡯࠲ࡦ࠮ޓ‬㧘ᰴߩฦภߦឝߍࠆᬺോࠍⴕ߁‫ޕ‬‫⁛ޓ৻ޓ‬ഃ⊛߆ߟᄢဳߩ⎇ⓥᚑᨐࠍ޽ߍࠆߎߣ‫ޕ‬‫ޓ‬ੑ‫ޓ‬ၮ␆කቇ♽ࠍਛᔃߣߒߚ⎇ⓥ⑼ో૕ߩ⎇ⓥᵴᕈൻ㧘ᄢቇ㒮ᵴᕈൻ㧘ၮ␆කቇ♽⧯ᚻ⎇ⓥ⠪ߩ⢒ᚑߩᣉ╷ߣታᣉߦ㑐ߔࠆߎߣ‫ޕ‬‫ޓ‬ਃ‫ޓ‬කቇㇱቇ↢ߦኻߔࠆၮ␆කቇ♽⎇ⓥ⠪⢒ᚑ⸘↹ߩ┙᩺෸߮ታ〣ߦ㑐ߔࠆߎߣ‫ޕ‬‫ޓ‬྾‫ޓ‬ነ㒝⻠ᐳߩ⎇ⓥᵴᕈൻ෸߮⧯ᚻ⎇ⓥ⠪ߩ⢒ᚑߦ㑐ߔࠆߎߣ‫ޕ‬‫ޓ‬੖‫ޓ‬ᣂߚߥነ㒝⻠ᐳߩዉ౉ߦ㑐ߔࠆߎߣ‫ޕ‬㧔⚵‫❱ޓ‬㧕╙㧡᧦‫ߦ࡯࠲ࡦ࠮ޓ‬㧘ၮ␆කቇ♽⎇ⓥᵴᕈൻ㧘ၮ␆කቇ♽⧯ᚻ⎇ⓥ⠪ߩ⢒ᚑ㧘ᄢቇ㒮ᵴᕈൻ෸߮ᄙⷺ⊛ᚢ⇛⎇ⓥផㅴ㧔⁛ഃ⊛ㅪ៤ࠍផㅴ㧕ߩߚ߼ߩ‫ޟ‬ၮ␆කቇ⎇ⓥᵴᕈൻ࡮⧯ᚻ⎇ⓥ⠪⢒ᚑㇱ㐷‫ޠ‬㧘ᦨవ┵㜞ᐲ⎇ⓥផㅴߩߚ߼ߩ‫ᦨޟ‬వ┵㜞ᐲ⎇ⓥㇱ㐷‫ޠ‬෸߮ነ㒝⻠ᐳߩ⎇ⓥᵴᕈൻߩߚ߼ߩ‫ޟ‬ነ㒝⻠ᐳ⎇ⓥㇱ㐷‫ޕߊ⟎ࠍޠ‬㧞‫ޓ‬ฦㇱ㐷ߦ㑐ߒᔅⷐߥ੐㗄ߪ㧘೎ߦቯ߼ࠆ‫ޕ‬㧔⡯‫ޓ‬ຬ㧕╙㧢᧦‫ߦ࡯࠲ࡦ࠮ޓ‬㧘ᰴߩ⡯ຬࠍ⟎ߊ‫ޕ‬‫࡯࠲ࡦ࠮ޓ৻ޓ‬㐳‫ޓ‬ੑ‫ޓ‬೽࠮ࡦ࠲࡯㐳‫ޓ‬ਃ‫ޓ‬ኾછߩᢎ⢒♽⡯ຬ‫ޓ‬྾‫ޓ‬૬છߩᢎ⢒♽⡯ຬ‫ޓ‬੖‫ߩઁߩߘޓ‬⡯ຬ㧞‫ޓ‬೨㗄╙㧟ภߦⷙቯߔࠆ⡯ຬߩછᦼߪ㧘ጘ㒂ᄢቇᢎ⢒⡯ຬߩછᦼࠍቯ߼ࠆⷙ⒟╙㧞᧦╙㧝㗄╙㧟ภߩⷙቯࠍฃߌࠆ߽ߩߣߔࠆ‫ߒߛߚޕ‬㧘ᄖㇱ⾗㊄㓹↪ᢎຬߦߟ޿ߡߪ㧘ጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼╬ߦ߅ߌࠆᄖㇱ⾗㊄㓹↪ഥᢎຬߦ㑐ߔࠆขᛒ⚦ೣ╙㧠᧦ߩⷙቯࠍฃߌࠆ߽ߩߣߔࠆ‫ޕ‬㧟‫╙ޓ‬㧝㗄╙㧟ภ෸߮╙㧡ภߦⷙቯߔࠆ⡯ຬߩ㈩⟎෸߮ㆬ⠨ᣇᴺ╬ߪ㧘೎ߦቯ߼ࠆ‫ޕ‬㧠‫╙ޓ‬㧝㗄╙㧠ภߦⷙቯߔࠆ⡯ຬߪ㧘⎇ⓥ⑼㐳߇ᜰฬߒᆔབྷߔࠆ‫ޕ‬㧔࠮ࡦ࠲࡯㐳ߩ⡯ോ㧕╙㧣᧦‫࡯࠲ࡦ࠮ޓ‬㐳ߪ㧘࠮ࡦ࠲࡯ߩᬺോࠍ᝿ℂߔࠆ‫ޕ‬㧔࠮ࡦ࠲࡯㐳ߩㆬ⠨㧕╙㧤᧦‫࡯࠲ࡦ࠮ޓ‬㐳ߪ㧘කቇ⎇ⓥ⑼ߩᢎ᝼ߩ߁ߜ߆ࠄකቇ♽⎇ⓥ⑼㐳߇ᆔབྷߔࠆ‫ޕ‬㧞‫࡯࠲ࡦ࠮ޓ‬㐳ߩછᦼߪ㧘㧞ᐕߣߒ㧘ౣછࠍᅹߍߥ޿‫ߒߛߚޕ‬㧘࠮ࡦ࠲࡯㐳ߦᰳຬ߇↢ߓߚ႐วߩᓟછߩ࠮ࡦ࠲࡯㐳ߩછᦼߪ㧘೨છ⠪ߩᱷછᦼ㑆ߣߔࠆ‫ޕ‬㧔೽࠮ࡦ࠲࡯㐳ߩ⡯ോ㧕╙㧥᧦‫ޓ‬೽࠮ࡦ࠲࡯㐳ߪ㧘࠮ࡦ࠲࡯㐳ࠍ⵬૒ߔࠆ‫ޕ‬㧔೽࠮ࡦ࠲࡯㐳ߩㆬ⠨㧕╙㧝㧜᧦‫ޓ‬೽࠮ࡦ࠲࡯㐳ߪ㧘කቇ⎇ⓥ⑼ߩᢎ᝼ߩ߁ߜ߆ࠄකቇ♽⎇ⓥ⑼㐳߇ᜰฬߒᆔབྷߔࠆ‫ޕ‬㧞‫ޓ‬೽࠮ࡦ࠲࡯㐳ߩછᦼߪ㧘㧞ᐕߣߒ㧘ౣછࠍᅹߍߥ޿‫ߒߛߚޕ‬㧘೽࠮ࡦ࠲࡯㐳ߦᰳຬ߇↢ߓߚ႐วߩᓟછߩ೽࠮ࡦ࠲࡯㐳ߩછᦼߪ㧘೨છ⠪ߩᱷછᦼ㑆ߣߔࠆ‫ޕ‬㧔ㆇ༡ᆔຬળ㧕╙㧝㧝᧦‫ߦ࡯࠲ࡦ࠮ޓ‬㧘࠮ࡦ࠲࡯ߩᬺോ࡮ㆇ༡෸߮࠮ࡦ࠲࡯㐳߆ࠄ⻁໧ߐࠇߚ㊀ⷐ੐㗄╬ࠍክ⼏ߔࠆߚ߼㧘࠮ࡦ࠲࡯ㆇ༡ᆔຬળ㧔એਅ‫ޟ‬ㆇ༡ᆔຬળ‫ޠ‬ߣ޿߁‫ޕ‬㧕ࠍ⟎ߊ‫ޕ‬㧞‫ޓ‬ㆇ༡ᆔຬળߦ㑐ߒᔅⷐߥ੐㗄ߪ㧘೎ߦቯ߼ࠆ‫ޕ‬㒝‫ޓ‬ೣ‫ⷐߩߎޓ‬㗄ߪ㧘ᐔᚑ‫ޓޓ‬ᐕ‫ޓޓ᦬ޓޓ‬ᣣࠃࠅታᣉߔࠆ‫ޕ‬㧙㧙㧔⾗ᢱ 3㧕㧔⾗ᢱ 4㧕

ᇶ♏་Ꮫ◊✲䝉䞁䝍䞊䠄᳨ウ୰䠅་Ꮫᩍ⫱䝴䝙䝑䝖㧙㧙2㧚⋴⼔ቇኾ᡹෸߮කቇㇱ⋴⼔ቇ⑼ᄢቇ㒮කቇ♽⎇ⓥ⑼⋴⼔ቇኾ᡹࡮කቇㇱ⋴⼔ቇ⑼ߩ⥄Ꮖ⹏ଔ̆̆ᢎ⢒ߩ⾰ߩะ਄ࠍ⋡ᜰߒߡ̆̆
කቇㇱ⋴⼔ቇ⑼㐳‫ޓ‬ᓟ㑄ኈሶ⋴⼔ቇ⑼߅ࠃ߮⋴⼔ቇኾ᡹ߩᦨㄭ 3 ᐕ㑆ߦ߅ߌࠆᢎ⢒࡮⎇ⓥ࡮␠ળ⽸₂ߥߤ߆ࠄ⥄Ꮖ⹏ଔࠍ␜ߔ‫ޕ‬1㧚ᢎ⢒ᢎ⢒ߦ㑐ߒߡߪ㧘౉ቇ⠪ߦ߅ߌࠆㅌቇ⠪ᢙ㧘⇐ᐕ⠪ᢙߪฦᐕߦ߅޿ߡ㧞ੱ߆ࠄ㧟ੱߢ޽ࠅ㧘߶ߣࠎߤߩቇ↢ߪᮡḰ⊛ߥ 4 ᐕ㑆ߢ⋴⼔ቇ⑼ࠍ⚳ੌߒߡ޿ࠆ‫⼔⋴ޕ‬ቇ⑼ߩቇ↢ߦߣߞߡ㧘౉ቇᤨ߆ࠄߩ⋡⊛ߩ߭ߣߟ߇⋴⼔Ꮷ࡮଻ஜᏧ࡮ഥ↥Ꮷߩ⾗ᩰࠍขࠆߎߣߢ޽ࠆ‫⼔⋴ޕ‬ቇ⑼තᬺ↢ߩ⋴⼔Ꮷ࿖ኅ⹜㛎෸߮଻ஜᏧ
࿖ኅ⹜㛎ߩวᩰ₸ߪ㕖Ᏹߦࠃߊ㧘Ფᐕో࿖ᐔဋࠍᄢ߈ߊ਄࿁ߞߡ޿ࠆ‫ޕ‬ഥ↥Ꮷߪㆬᛯ⠪ߩߺߩฃ㛎ߢ޽ࠆ߇㧘߶ߣࠎߤ100%ߢ޽ࠆ‫ޕ‬
ᐔᚑ20ᐕ3᦬ߪ1ੱ߇࿖ኅ⹜㛎ߦਇวᩰߢ޽ߞߚ߇㧘⠉ᐕߦߪวᩰߒߡ޿ࠆ‫ޕ‬ߎߩࠃ߁ߥᢎ⢒ߩ⃻⁁ߢ޽ࠆ߇㧘ᢎ⢒ߩ⾰ߩะ਄ߦ㑐ߔࠆขࠅ⚵ߺߪߐࠄߦദജࠍⷐߔࠆߎߣߢ޽
ࠆ‫ᦨޕ‬ㄭ㧘ጘ㒂ᄢቇߩ⹏ଔߦ߅޿ߡ㧘⋴⼔ቇ⑼ߢߪᢎ⢒ߩ⾰ߩะ਄ߦኻߒߡ‫ޟ‬㧝‫⹏߁޿ߣޠ‬ଔࠍฃߌߚ‫ޕ‬ߎࠇߪ᝼ᬺ࡮ታ⠌ߥߤߩᢎ⢒ߦ㑐ߒߡ⚵❱⊛ߦขࠅ⚵ࠎߢ޿ߥ޿ߣ޿߁෩ߒ޿⹏ଔߢ޽ߞߚ‫ޕ‬FD ᆔຬળ߇⊒⿷ߒߡ޿ࠆ߇㧘߹ߛᢎຬ⎇ୃߩᲑ㓏ߢ޽ߞߡ㧘ᢎ⢒ߩ⾰ߩะ਄ߦะߌߚᵴേߪߥߐࠇߡ޿ߥ߆ߞ
ߚ‫߫߃଀ޕ‬㧘ቇ↢߿ᢎຬࠍኻ⽎ߣߒߚ᝼ᬺ⹏ଔࠍ૕♽⊛ߦⴕ޿㧘᝼ᬺߦ෻ᤋߒ㧘᝼ᬺߩ⾰ߩᡷༀߦദ߼
ࠆߎߣ㧘ᢎຬ㑆ߢ᝼ᬺࠍෳⷰߒ޽ߞߡ㧘ᢎ᝼ᛛᴺߩะ਄ߦߟߣ߼ࠆߎߣߥߤߢ޽ࠆ‫ޕ‬ฦᢎຬߪ୘ੱߢ᝼
ᬺ⹏ଔࠍⴕߞߡ߅ࠅ㧘୘ੱ⊛ߦߪ⥄ࠄߩ᝼ᬺߦ෻ᤋߔࠆࠃ߁ߦߒߡ޿ࠆ߇㧘ోᢎຬ߇㧘ߔߴߡߩ᝼ᬺߢ
ⴕߞߡ޿ࠆࠊߌߢߥ޿‫ޕ‬⋴⼔ቇ⑼ߢߪ㧘ታ⠌ߪ 23 න૏ࠍභ߼㧘ߐࠄߦ᝼ᬺߩਛߦ㧘ቇౝታ⠌߇฽߹ࠇࠆṶ⠌⑼⋡߇ᄙ޿‫ߎޕ‬ࠇࠄߩ⑼⋡ߢ㧘․ߦታ⠌ߪ㧘ోቇ↢ߦኻߒߡ㧘ߔߴߡߩታ⠌⑼⋡ߢ㧘ታ⠌⹏ଔࠍߒ㧘ቇ↢ߣ㕙ធߒߡ㧘⚿ᨐࠍ⺑᣿ߒ㧘ቇ⠌ߩലᨐࠍ਄ߍࠆࠃ߁ߦߒߡ޿ࠆ‫⹏ߩࠄࠇߎޕ‬ଔߪ㧘ታ⠌ᆔຬળߩᏨߢ㧘᭎ⷐࠍ౒᦭
ߒ㧘ቇ↢ᜰዉߦ↢߆ߒߡ޿ࠆ‫ޕ‬ߎࠇࠄߩߎߣࠍ᭎ⷰߒ㧘⋴⼔ቇ⑼ߩᢎ⢒ߩ⾰ߩะ਄ߦะߌߡ㧘੹ᓟ FD ᆔຬળࠍਛᔃߦ㧘ᡷༀߦ߻ߌ
ߡദജࠍߒߡ޿߈ߚ޿‫ޕ‬
2㧚⎇ⓥ⎇ⓥߦ㑐ߒߡߪ㧘⋴⼔ቇ⑼࡮⋴⼔ቇኾ᡹ߦ߅޿ߡ⪺ߒ޿ᬺ❣߇⹺߼ࠄࠇߥ߆ߞߚߩߪᱷᔨߢ޽ࠆ‫ޕ‬ਛߢ߽㧘⧯ᚻߣ޿ࠊࠇࠆᢎຬߦ߅޿ߡ㧘ේ⪺߿⎇ⓥ⊒⴫߇ዋߥ޿ߎߣߪ㧘⻠ᐳ߿ಽ㊁ߦ߅ߌࠆᢎ᝼࡮ಎᢎ
᝼ߦࠃࠆ⧯ᚻᢎຬ߳ߩᜰዉߦ੹ᓟ㧘ᦼᓙߒߚ޿‫⼔⋴ޕ‬ቇ⑼ߢߪ㧘୘ੱߩ⎇ⓥࠍዅ㊀ߔࠆ௑ะߪ⦟޿ߎߣ
ߢߪ޽ࠆ߇㧘⻠ᐳ߿ಽ㊁ߢ㧘౒ㅢߒߚ⺖㗴ࠍ⎇ⓥ࠹࡯ࡑߦߔࠆߥߤߒߡ㧘⧯ᚻᢎຬߩᜰዉࠍ฽߼ߡ㧘⎇ⓥᵴേࠍᵴ⊒ൻߔࠆᔅⷐ߇޽ࠆ‫ޕ‬੹࿁ߩ⹏ଔߦߪ㑆ߦวࠊߥ߆ߞߚ߇㧘⧯ᚻᢎຬߩේ⪺⺰ᢥ⊒⴫ߩ႐ߣߒߡ㧘ጘ㒂⋴⼔⎇ⓥળ⹹ࠍ⊒ೀߒߚ‫⼔⋴ߪࠇߎޕ‬ቇ⑼ߩᢎຬࠍਛᔃߦߒߚ㧘⎇ⓥળߢ޽ࠅ㧘⎇ⓥળ⹹ࠍ⊒ⴕߔࠆߎߣߦࠃߞߡ㧘⧯ᚻᢎຬߩ⎇ⓥ⊒⴫ߩᯏળࠍਈ߃ࠆߎߣࠍ⋡⊛ߦߒߡ޿ࠆ‫ޕ‬3㧚␠ળ⽸₂㧙㧙␠ળ⽸₂ߦ߅޿ߡߪ㧘୘‫ߩޘ‬ᢎຬ߇ߘࠇߙࠇߩኾ㐷ಽ㊁ߢⴕߞߡ޿ࠆ‫ౕޕ‬૕⊛ߦߪ㧘ጘ㒂⋵⋴⼔දળߩ⎇ୃ߿⋴⼔ቇቇળߩㆇ༡㧘⻠Ꮷ㧘ࠪࡦࡐࠫࠬ࠻ߥߤ㧘⋵ౝ⋴⼔♽ቇᩞߩኾ㐷ಽ㊁ߢߩ⻠⟵ߩᜂᒰ㧘࿾ᣇ⥄ᴦ૕ߩฦ⒳ㆇ༡ᆔຬળߥߤߩᆔຬ߿ᆔຬ㐳ߥߤ㧘ฦ⒳ኾ㐷ߩද⼏ળ㧔ో࿖଻ஜᏧᢎ⢒ᯏ㑐ද⼏ળ㧘ో࿖ഥ↥Ꮷᢎ⢒ᯏ㑐ද⼏ળߥߤ㧕߿ NPO ᴺੱߩᓎຬߥߤ㧘ᄙ⒳ᄙ᭽ߥಽ㊁ߢ␠ળ⽸₂ߒߡ޿ࠆ‫ޕ‬⋴⼔ቇ⑼ߩਛߢකᏧߩᢎຬߪ㧘ᤓ੹ߩකᏧਇ⿷߽޽ߞߡ㧘⸻≮ᵴേࠍߣ߅ߒߡ㧘␠ળߩක≮ߩ⾰ߩะ
਄ߦ⽸₂ߒߡ޿ࠆ‫ޕ‬㧙㧙

3㧚කቇㇱ㒝ዻ∛㒮කቇㇱ㒝ዻ∛㒮ߩ⥄Ꮖ⹏ଔකቇㇱ㒝ዻ∛㒮㐳‫ޓ‬᫪⣁ਭ㓉
ᐔᚑ 18࡮19 ᐕᐲߩ㆐ᚑᐲ⹏ଔߣ㧘20࡮21 ᐕᐲߩ೔㆐⋡ᮡߦ㑐ߔࠆਛ㑆⹏ଔࠍⴕߥ߁‫ޕ‬
ᐔᚑ 18࡮19 ᐕᐲߩ㆐ᚑᐲ⹏ଔ
᜚ὐ∛㒮ߩ₪ᓧ㧦⃻࿷น⢻ߥ᜚ὐߪ㔍∛㧘߇ࠎ㧘ࠛࠗ࠭㧘⢄∔ᖚ㧘㜞ᐲᢇ๮ߩోߡࠍ₪ᓧᷣߺ‫ޕ‬㜞ᐲߥ⸻≮ᯏ⢻ߩᢛ஻㧦7㧦1 ⋴⼔૕೙߳⒖ⴕᷣߺ㧔ᐔᚑ 20 ᐕ 5 ᦬㧕㧘㧟࠹ࠬ࡜ MRI㧘PET ࠍዉ౉ᷣߺ‫ޕ‬⥃ᐥ⎇ⓥ૕೙ߩᢛ஻㧔ᄖㇱ clinical research clerk ߩዉ౉㧕㧦ᧂೋᦼ࡮ᓟᦼ⎇ୃකߩ⏕଻㧦ೋᦼ⎇ୃකߦߟ޿ߡߪᐔᚑ 20 ᐕࠃࠅჇ൓ߦォߓߚ‫ޕ‬ᓟᦼ⎇ୃකߪᲤᐕ 50
ฬ೨ᓟࠍ⏕଻ߒߡ޿ࠆ߇㧘⸻≮⑼㑆ߩࡃ࡜࠷ࠠ߇໧㗴ߣߥࠅߟߟ޽ࠆ‫ޕ‬ஜో⚻༡ߩ⛽ᜬ㧦කᬺ෼⋉ߪᐔᚑ 17 ᐕᐲߩ 129 ం߆ࠄ 19 ᐕᐲߪ 136 ం߹ߢჇട㧘19 ᐕᐲᧃߩ૛೾
㊄ߪ 10.6 ం౞‫ޕ‬
ᐔᚑ 20࡮21 ᐕᐲߩਛ㑆⹏ଔ㧔ᐔᚑ 21 ᐕ 1 ᦬Ბ㓏㧕IT ࠪࠬ࠹ࡓߩᦝᣂ㧦઀᭽╷ቯࠍᐔᚑ 20 ᐕ 12 ᦬ߦ⚳ੌߒ㧘౉ᧅ⺑᣿ળ߹ߢᷣߺ‫ޕ‬ᣂࠪࠬ࠹ࡓ߳ߩ⒖ⴕࠍᐔᚑ 22 ᐕ 1 ᦬ 1 ᣣߦ੍ቯߒߡ޿ࠆ‫ޕ‬ࡊࡠࡈࠖ࠶࠻࠮ࡦ࠲࡯ߩᢛ஻㧦ਛᄩᚻⴚㇱ㐷ߣ ICU࡮CCU ߪࡂ࡯࠼㕙ߢߩᢛ஻ࠍᷣߺ㧘ߚߛߒੱຬ
㧔ߣߊߦ⋴⼔Ꮷ㧕ߪᧂߛਇ⿷ߒߡ޿ࠆ‫ޕ‬ᓴⅣེಽ㊁ߦߟ޿ߡߪ CT ࠍዉ౉ߩ߁߃ᔃ⤳࡝ࡂࡆ࡝ࠍ㐿ᆎߒ㧘⸻≮ౝኈߩォ឵ࠍ࿑ࠆߴߊ૞ᬺਛߢ޽ࠆ㧔ᐔᚑ 21 ᐕᐲ਄ඨᦼߦⒿേ㐿ᆎ੍ቯ㧕‫⥃ޕ‬ᐥ⣲≌ㇱ㐷ߪᄖ᧪ൻ
ቇ≮ᴺቶߥߤ╙ 1 ᰴᢛ஻ࠍ⚳ੌߒߚ߇㧘ߔߢߦࠠࡖࡄࠪ࠹ࠖ࡯ߩ㒢⇇߇ㄭઃ߈ߟߟ޽ࠅ㧘2 ᰴᢛ஻ߩᬌ
⸛ߦ౉ࠆᔅⷐ߇޽ࠆ‫ޕ‬
ᐔᚑ 20 ᐕᐲߩ෼ᡰ⋡ᮡ㧦⋡ᮡߩකᬺ෼⋉ 141 ం౞ࠍ਄࿁ࠆ 146 ం౞ࠍ㆐ᚑߢ߈ࠆ⷗ㄟߺߢ޽ࠆ‫ޕ‬એ਄㧘⋡ᮡ೔㆐ᐲߦ㑐ߔࠆ⥄Ꮖ⹏ଔߪ߅߅߻ߨ⦟ᅢߢ޽ࠆ‫⥃ߒߛߚޕ‬ᐥ⎇ⓥߦߟ޿ߡߪ㧘ᧂߛฦ⸻≮⑼ߩ₂り⊛ߥദജߦଐሽߔࠆ⁁ᴫ߇⛯޿ߡ߅ࠅ㧘∛㒮ߣߒߡో૕ࠍࠨࡐ࡯࠻ߢ߈ࠆࠪࠬ࠹ࡓ᭴▽ࠍᕆߋᔅⷐ߇޽ࠆ‫ޕ‬㧙㧙4㧚╙ 1 ᦼਛᦼ⋡ᮡᦼ㑆ߩᢎ⢒⎇ⓥ⹏ଔߦଥࠆ⃻ᴫ⺞ᩏ⴫ߩ⵬⿷⺑᣿ާᢎ⢒ި⾰ߩะ਄ᐲߦߟ޿ߡ㧔කቇㇱ㧕⹏ଔ⚿ᨐ‫ޓ‬Σ㧔ᡷༀ㧘ะ਄ߒߡ޿ࠆߣߪ⸒߃ߥ޿‫ޕ‬㧕ᧄቇㇱ߆ࠄ␜ߐࠇߚ੐଀ߪ㧤ઙߢ޽ࠅ㧘ߘߩਛߢ‫ޟ‬ᡷༀ㧘ะ਄ߒߡ޿ࠆߣߪ޿߃ߥ޿‫್ߣޠ‬ᢿߐࠇߚ੐଀߇޽ߞߚ‫ޕ‬⹥ᒰߔࠆ੐଀ߩ್ᢿℂ↱ߪએਅߩߣ߅ࠅߢ޽ࠆ‫ޕ‬කቇ⑼੐଀㧝‫ޟ‬࿾ၞක≮ߦኻߔࠆᢎ⢒⊛ข⚵ߺ‫ޠ‬㧔ಽᨆ㗄⋡Σ㧕࿾ၞߦ߅ߌࠆකᏧਇ⿷㧔ጘ㒂⋵ߪో࿖ߩ⛔⸘ߩਅ૏ 10 ⋵ߦ౉ߞߡ޿ࠆ㧕ߦኻᔕߔࠆߚ߼㧘ᐔᚑ
19 ᐕᐲᣂߚߦ࿾ၞක≮කቇ࠮ࡦ࠲࡯ࠍ⸳⟎ߒ㧘⛯޿ߡ࿾ၞක≮ቇ⻠ᐳ㧔ነઃ⻠ᐳ㧦ጘ㒂⋵㧕ࠍ⸳⟎ߒߚ‫ޕ‬ᓥ೨߆ࠄታᣉߒߡ޿ߚ㧝ᐕᰴ‫ޟ‬කቇ᭎⺰‫ࠆߌ߅ߦޠ‬࿾ၞක≮ߦ㑐ߔࠆ⻠⟵ߦട߃㧘࠮ࡦ࠲࡯ᢎ᝼߇ฦቇᐕߢ࿾ၞක≮ߦ㑐ߔࠆ⻠⟵ࠍታᣉߒߚ‫ޕ‬㧢ᐕᰴቇᄖ⥃ᐥታ⠌ߢߪ㧘ᣂߚߦឳ᢫㇭ർ⷏ㇱ࿾ၞක≮࠮ࡦ࠲࡯߿௼࿾ߩ∛㒮ࠍታ⠌ᣉ⸳ߦട߃㧘✚ว∛ᘒౝ⑼ቇߢߪ㐿ᬺකߢߩታ⠌߽㐿ᆎߒ㧘Ꮧᦸ⠪߇Ⴧടߒߚ‫ޕ‬ቇ↢ࠕࡦࠤ࡯࠻⺞ᩏߢ࿾ၞක≮ߦኻߔࠆ㑐ᔃᐲߩะ਄ࠍ⹺߼ߚ‫ޕ‬৻ᣇ㧘ᐔᚑ 20 ᐕᐲ߆ࠄታᣉߔࠆ࿾ၞᨒផ⮈౉⹜ߦ૬ߖ㧘࿾ၞ߇ᛴ߃ࠆ໧㗴ࠍᐢߊฃ㛎↢߿ߘߩ଻⼔⠪㧘㜞ᩞߩవ↢ᣇߦ⺑᣿ળߩਛߢ⸷߃ࠆߣߣ߽ߦ㧘ࠞ࡝ࠠࡘ࡜ࡓᡷᱜߦะߌߡᬌ⸛ࠍ㊀ߨߚ‫ޕ‬කቇᢎ⢒㐿⊒⎇ⓥ࠮ࡦ࠲࡯ߢߪ㧘ᐔᚑ 20 ᐕᐲߩᣂࠞ࡝ࠠࡘ࡜ࡓߦవ㚟ߌ㧘ᐔᚑ 19 ᐕᐲ‫⊛⛯⛮ޟ‬࿾ၞ૕㛎ቇ⠌‫ޠ‬㧘଻⢒࿦ታ⠌෸߮ᅧᇚታ⠌ࠍડ↹࡮ታᣉߒ㧘᝼ᬺᓟߩ⹏ଔߢࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦ⢻ജߩะ਄߇⹺߼ࠄࠇߚ‫ޕ‬࿾ၞක≮ߦኻߔࠆข⚵ߺߪ੹ᓟ߽᜛లߒߡ޿ߊᣇ㊎ߢ޽ࠆ‫ޕ‬㧢ᐕ↢ߦኻߔࠆ⻠⟵‫ޟ‬ጘ㒂⋵ߩ࿾ၞක≮ߩ⃻⁁ߣ⺖㗴࡮࿾ၞක≮කቇ࠮ࡦ࠲࡯ߩᓎഀ‫ޠ‬ᓟߩࠕࡦࠤ࡯࠻⚿ᨐߢߪ㧘ጘ㒂⋵ߢ⥃ᐥ⎇ୃߒߚ޿ߣ޿߁ቇ↢߇13%ߢ޽ߞߚߩ߇⻠⟵ᓟߢߪ45%ߣࠕ࠶ࡊߒ㧘ᧄขࠅ⚵ߺߩലᨐ߇਄߇ߞߡ޿ࠆ‫ޕ‬٤‫ޟ‬࿾ၞක≮ߦኻߔࠆᢎ⢒⊛ข⚵‫ߪߡ޿ߟߦޠ‬㧘ౕ૕⊛ߥᢙሼ߇᜼ߍࠄࠇߡ޿ߥ޿ߩߢ㧘ߤߩ⒟ᐲߎ
ߩ೙ᐲ߇೑↪ߐࠇߡ޿ࠆߩ߆㧫ታലᐲߪߤ߁߆㧫╬ߩ್ቯ߇ߢ߈ߥ޿‫ޕ‬એ਄ߩߎߣ߆ࠄ㧘ᡷༀ㧘ะ਄ߒߡ޿ࠆߣߪ⸒߃ߥ޿ߣ್ᢿߐࠇࠆ‫ޕ‬⵬⿷⺑᣿࿾ၞක≮ࠍᜂ߁කᏧߩ㙃ᚑ࡮⏕଻ߦะߌߡ㧘࿾ၞᨒߩ᜛ᄢߣᅑቇ㊄೙ᐲ㧘࿾ၞක≮ߦ㑐ߔࠆᢎ⢒ߩలታ╬ࠍㅴ߼ࠆਛߢ㧘ᐔᚑ㧝㧥ᐕᐲ߆ࠄකቇ⑼㧝ᐕ↢‫ޟ‬කቇ᭎⺰⻠⟵‫ޟߪߢޠ‬࿾ၞක≮‫࡯࠹ࠍޠ‬ࡑߦߒߚ⻠⟵㧔90 ಽ 3㧕㧔⵬⿷⾗ᢱ㧟㧕ࠍ㧘㧠ᐕ↢วኋ⎇ୃ㧔8 ᦬㧕ߢߪ‫ޟ‬࿾ၞක≮ߦߟ޿ߡ‫ߩޠ‬⻠⟵㧔60 ಽ㧕ࠍ⚵ㄟߺ㧘ጘ㒂⋵ߩ࿾ၞක≮ߦ㑐ߔࠆࠕࡦࠤ࡯࠻⺞ᩏ߽ታᣉߒ㧘⵬⿷⾗ᢱ㧝ߩᅤߊ࿾ၞක≮߳ߩ㑐ᔃᐲߩะ਄߇⷗ࠄࠇߡ޿ࠆ‫ޕ‬࿾ၞක≮ᢎ⢒ߦኻߔࠆⷐᦸ╬ߩ࿁╵ࠍಽᨆߒ੹ᓟߩᢎ⢒╬ߦᵴ↪ߒߡࠁߊ੍ቯߢ޽ࠆ‫ޕ‬㧢ᐕ↢ߦኻߒߡ߽࿾ၞක≮⺑᣿ળ㧔11 ᦬㧕ࠍታᣉ㧘⻠⟵ᓟ㧘ห᭽ߩࠕࡦࠤ࡯࠻⺞ᩏࠍታᣉߒ㧘࿾ၞක≮ᢎ⢒ߩ࿷ࠅᣇࠍⷞ㊁ߦ౉ࠇߚᗧ⼂⺞ᩏࠍⴕߞߡ޿ࠆ‫ޕ‬࿾ၞක≮ᢎ⢒ࠍలታߔࠆߚ߼ߦ㧘⋵ౝߩක≮ᣉ⸳╬ߦኻߒߡ࿾ၞක≮ታ⠌߳ߩදജࠍⷐ⺧ߒߡ߅ࠅ㧘㧢ᐕ↢ߩቇᄖ⥃ᐥታ⠌∛㒮ᢙߪ㧘18 ᐕᐲ 13 ᣉ⸳㧔ታ⠌ቇ↢ᢙᑧߴ 157 ฬ㧕
㧘19 ᐕᐲ 15 ᣉ⸳㧔ᑧߴ 155 ฬ㧕㧘20 ᐕᐲ 19 ᣉ⸳㧔ᑧߴ 148 ฬ㧕ߣ⌕ታߦჇടߒߡ߅ࠅ㧘․ߦ߳߈࿾ක≮ᯏ㑐ߩలታࠍ࿑ߞߡ޿ࠆ㧔⵬⿷⾗ᢱ㧠㧕
‫ޕ‬

㧙㧙

࿾ၞක≮කቇ࠮ࡦ࠲࡯ߪ㧘ᐔᚑ 18 ᐕᐲߦ᭴ᗐࠍ┙ߜ਄ߍ㧘19 ᐕᐲߦ࿾ၞක≮ቇ 1 ㇱ㐷 5 ಽ㊁߇⸳⟎ߐࠇ㧘ᦝߦ 19 ᐕ 11 ᦬ߦߪห࠮ࡦ࠲࡯ߦጘ㒂⋵ߩነ㒝⻠ᐳ㧔࿾ၞක≮කቇ⻠ᐳ㧕߇⸳⟎ߐࠇߚ‫ޕ‬
㧔20 ᐕᐲ߆ࠄ㧘ጘ㒂⋵ߪጘᄢකቇㇱߩቯຬჇߣ࿾ၞᨒߩ⸳ቯߦ૬ߖ㧘╙ 1 ⒳㧘╙ 2 ⒳ୃቇ⾗㊄⸘ 45
ฬߩකቇ↢ᅑቇ㊄೙ᐲࠍഃ⸳ߒߚ‫ޕ‬㧕㑐ㅪߒߡ㧘19 ᐕ 11 ᦬‫ޟ‬࿾ၞᨒផ⮈⺑᣿ળ‫ߡ޿߅ߦޠ‬㧘࿾ၞක≮ߩᛴ߃ࠆ໧㗴߿࿾ၞක≮ߦኻߔࠆᾲᗧ޽ࠆቇ↢ࠍ᳞߼ߡ⺑᣿߇޽ࠅ㧘120 ฬߩෳട߇޽ߞߚ‫ޕ‬⵬⿷⾗ᢱ㧔ᧄ⹹ߢߪ⾗ᢱ࠲ࠗ࠻࡞ߩߺ⴫⸥㧘ౝኈߪ⋭⇛㧕㧝‫ޟ⟵⻠ޓ‬ጘ㒂⋵ߩ࿾ၞක≮ߩ⃻⁁ߣ⺖㗴࡮࿾ၞක≮කቇ࠮ࡦ࠲࡯ߩᓎഀ‫ޠ‬㧞‫ޓ‬ႎ๔‫ޟ‬කቇ↢ߩࡊࡠࡈࠚ࠶࡚ࠪ࠽࡝࠭ࡓࠍ⢒ߡࠆߚ߼ߩ࿾ၞ૕㛎ቇ⠌ߩ⹜ߺߣߘߩലᨐ‫ޠ‬㧟‫ޓ‬ᐔᚑ㧞㧜ᐕᐲකቇ᭎⺰⻠⟵ᣣ⒟㧠‫ޓ‬කቇ⑼ቇᄖ⥃ᐥታ⠌∛㒮ߣታ⠌ቇ↢ᢙ੐଀㧟‫ޟ‬ᜰዉᢎຬ೙ߩታᣉ‫ޠ‬㧔ಽᨆ㗄⋡Υ㧕ᐔᚑ 18 ᐕᐲ౉ቇ↢߆ࠄ㧘ᜰዉᢎຬ೙ࠍዉ౉ߒߚ‫ߪࠇߎޕ‬㧘කቇㇱකቇ⑼ߩฦಽ㊁ߩᢎ᝼ࠍᜰዉ
ᢎຬߦᝪ߃ߥ߇ࠄ㧘ߘߩಽ㊁ߦቇ↢ࠍ㈩ዻߒ㧘ୃቇ߿ቇ↢↢ᵴߦߟ޿ߡᜰዉߔࠆ߽ߩߢ㧘౉ቇ⋥ᓟߦ㕙⺣ࠍߒ㧘ߘߩᓟㆡቱ੤ᵹࠍᜬߟߎߣߣߒߡ޿ࠆ‫ޕ‬ฦಽ㊁ߦ⚂㧟ฬߩቇ↢ࠍ㈩ዻߒߡ޿ࠆ‫ޕ‬ಽ㊁Ფߦߘߩኻᔕߪᆔߨࠄࠇߡ߅ࠅ㧘ᧂߛዉ౉ᓟᦼ㑆߇⍴޿ߚ߼ౕ૕⊛ߥ࠺࡯࠲ߪή޿߇㧘ቇ↢ߣᢎຬߣߩࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦ߇⦟ߊߪ߆ࠄࠇࠆࠃ߁ߦߥߞߡ߈ߡ޿ࠆߣ޿߁ᖱႎ߇ቇ↢߆ࠄᓧࠄࠇߡ
߅ࠅ㧘ᧄᜰዉᢎຬ೙ታᣉએ೨ߩቇ↢ߦᲧߒ㧘ߘߩ㑐ଥ߇ะ਄ߒߡ޿ࠆ‫ޕ‬٤‫ޟ‬ᜰዉᢎຬ೙ߩታᣉ‫ߪߡ޿ߟߦޠ‬㧘ౕ૕⊛ߥᢙሼ߇᜼ߍࠄࠇߡ޿ߥ޿ߩߢ㧘ߤߩ⒟ᐲߎߩ೙ᐲ߇೑
↪ߐࠇߡ޿ࠆߩ߆㧫ታലᐲߪߤ߁߆㧫╬ߩ್ቯ߇ߢ߈ߥ޿‫ޕ‬એ਄ߩߎߣ߆ࠄ㧘ᡷༀ㧘ะ਄ߒߡ޿ࠆ
ߣߪ⸒߃ߥ޿ߣ್ᢿߐࠇࠆ‫ޕ‬⵬⿷⺑᣿
කቇ⑼ߦ߅޿ߡ․ߦቇ↢ߩᜰዉᢎຬ೙ᐲߪߥ߆ߞߚ߇㧘ᐔᚑ 18 ᐕᐲ౉ቇ↢߆ࠄഥ⸒ᢎຬ㧔㉿ⷫ㧕೙ᐲࠍታᣉߒ㧘18 ᐕᐲ 25 ಽ㊁ 80 ฬ㧘19 ᐕᐲ 30 ಽ㊁ 80 ฬߦ᜛ᄢߒ㧘ቇ↢ߩ⎇ⓥᢎ⢒ࠍࠨࡐ࡯࠻
ߒߡ޿ࠆ‫ޕ‬੐଀㧠‫ޟ‬ᶏᄖ⥃ᐥታ⠌‫ޠ‬㧔ಽᨆ㗄⋡Υ㧕
කቇ⑼ߢߪ㧘㧢ᐕᰴቇᄖ⥃ᐥታ⠌㧔㧤ㅳ㑆㧕ࠍᶏᄖߢⴕ߁ߎߣࠍ⹺߼ߡ޿ࠆ‫ޕ‬ᐔᚑ 18 ᐕᐲ߆ࠄࠞ࡝ࡈࠜ࡞࠾ࠕᄢቇࡠࠬࠕࡦ࠯࡞ࠬᩞ㧔UCLA㧕ߦ߅ߌࠆ⥃ᐥታ⠌ߦෳടߢ߈ࠆࠃ߁௛߈߆ߌ㧘↳⺧߇น⢻ߣߥߞߚ‫ޕ‬UCLA ߢߩታ⠌ߪ߹ߛ଀߇ߥ޿߇㧘Ფᐕ㧘ᶏᄖߦ߅޿ߡ⥃ᐥታ⠌ࠍⴕ߁ቇ↢߇޽ࠅ㧘ቯ⌕ߒߡ޿ࠆ‫ߚ߹ޕ‬㧘ᄐቄભᬺᦼ㑆ਛߦ㧘☨࿖ߦ߅ߌࠆ⍴ᦼታ⠌ࠍડ↹ߒ㧘ߎࠇ߽ᅢ⹏ࠍᓧ
ߡ޿ࠆ‫ࠅࠃߦࠄࠇߎޕ‬ቇ↢ߩ⧷⺆ߦኻߔࠆࡕ࠴ࡌ࡯࡚ࠪࡦ߇ะ਄ߒ㧘⢻േ⊛ߦ⧷⺆⢻ജࠍ⠌ᓧߔࠆࠃ߁ߦߥߞߡ޿ࠆ‫ޕ‬٤‫ޟ‬ᶏᄖ⥃ᐥታ⠌‫ߪߡ޿ߟߦޠ‬㧘ౕ૕⊛ߥᢙሼ߇᜼ߍࠄࠇߡ޿ߥ޿ߩߢ㧘ߤߩ⒟ᐲߎߩ೙ᐲ߇೑↪ߐࠇߡ޿ࠆߩ߆㧫ታലᐲߪߤ߁߆㧫╬ߩ್ቯ߇ߢ߈ߥ޿‫ޕ‬એ਄ߩߎߣ߆ࠄ㧘ᡷༀ㧘ะ਄ߒߡ޿ࠆߣߪ
⸒߃ߥ޿ߣ್ᢿߐࠇࠆ‫ޕ‬⵬⿷⺑᣿ᶏᄖ⥃ᐥታ⠌ࠍᏗᦸߒ㧘৻ቯએ਄ߩ⧷⺆⢻ജ㧔TOEFL550 ὐએ਄㧕ࠍ᦭ߔࠆቇ↢ߪ 6 ᐕᰴߩㆬᛯ⥃ᐥታ⠌ 3 ࠢ࡯࡞㧔1 ࠢ࡯࡞ 4 ㅳ㑆㧕ߩ߁ߜ 1 㨪㧞ࠢ࡯࡞ࠍ㧘ᶏᄖߦ߅޿ߡታᣉߒߡ޿ࠆ‫ޕ‬ᐔᚑ
17 ᐕᐲએ೨ߪ 1 ฬ⒟ᐲߢ޽ߞߚ߇㧘කቇ⧷⺆ᢎ⢒ߩలታߦࠃߞߡᐔᚑ 18 ᐕᐲએ㒠ߪ 3 㨪 4 ฬ߇Ფᐕ㧘ᶏᄖߢታ⠌ࠍฃߌߡ޿ࠆ‫ޕ‬Ꮻ࿖ߒߚቇ↢ߪ⊒⴫ળࠍડ↹ߒ㧘ᓟヘߦߘߩવ⛔ࠍᒁ߈⛮ߋࠃ߁ߦ㧙㧙ߥߞߡ޿ࠆ‫ޕ‬19 ᐕᐲ߆ࠄߪ UCLA ߩ⥃ᐥታ⠌߳ߩ↳ߒㄟߺ߇น⢻ߣߥߞߚ‫ޕ‬
17 ᐕᐲ‫ޓ‬㧝ฬ㧔ࡔ࡞ࡏ࡞ࡦ‫∛ࡦ࠴ࠬ࡯ࠝޓ‬㒮㧕18 ᐕᐲ‫ޓ‬㧠ฬ㧔ࡁ࡯ࠬࠞࡠ࡜ࠗ࠽ᄢቇ∛㒮㧘ࡁ࡯ࠬࠞࡠ࡜ࠗ࠽‫∛࠼ࡔࠢ࡯ࠚ࠙ޓ‬㒮㧘ࡄ࡝‫ࠕޓ‬ࡔ࡝ࠞࡦ∛㒮㧘࠻ࡠࡦ࠻‫∛ࠢ࠶࡞ࡉ࡯࠾ࠨޓ‬㒮㧕
19 ᐕᐲ‫ޓ‬㧟ฬ㧔ࠪࡦࠪ࠽࠹ࠖᄢቇ∛㒮㧘ࡁ࡯ࠬࠞࡠ࡜ࠗ࠽‫∛࠼ࡔࠢ࡯ࠚ࠙ޓ‬㒮㧘ࡄ࡝ ࠕࡔ࡝ࠞࡦ∛㒮㧕20 ᐕᐲ‫ޓ‬㧟ฬ㧔ࠪࡦࠪ࠽࠹ࠖᄢቇ∛㒮㧘ࡁ࡯ࠬࠞࡠ࡜ࠗ࠽ᄢቇ∛㒮㧘ࡉ࡜࠙ࡦᄢቇ∛㒮㧕⵬⿷⾗ᢱ㧔ᧄ⹹ߢߪ⾗ᢱ࠲ࠗ࠻࡞ߩߺ⴫⸥㧘ౝኈߪ⋭⇛㧕㧡㧘㧢‫ޓ‬ቇ↢ᶏᄖ⎇ୃႎ๔⋴⼔ቇ⑼੐଀㧞‫ޟ‬Ფᐕᐲᧃߩ⥃࿾ታ⠌ද⼏ળ㐿௅㧘㒝ዻ∛㒮෸߮ታ⠌∛㒮⋴⼔ㇱߣߩㅪ៤ᒝൻ‫ޠ‬㧔ಽᨆ㗄⋡Τ㧕Ფᐕᐲᧃߦ㐿௅ߐࠇࠆ⥃࿾ታ⠌ද⼏ળ෸߮㒝ዻ∛㒮⋴⼔ㇱߣߩળ⼏ߢߪ㧘⥃࿾ታ⠌ߦ߅ߌࠆ⃻႐ߢߩቇ↢ᜰዉߩ⃻⁁ߣ⺖㗴ࠍಽᨆߒ㧘ᰴᐕᐲએ㒠ߩᜰዉᣇᴺᡷༀߦദ߼ߡ޿ࠆ‫ޕ‬ᦨㄭߪ᧍਄ߩቇ⠌⢻ജ߇޽ࠆߦ᜔߽ࠄߕ㧘⥃࿾ታ⠌ߦߥࠆߣ♖␹⊛ߦਇ቟ቯߦߥࠆቇ↢߇Ⴧ߃ߚߎߣ╬߇⹤㗴ߣߥࠅ㧘౉ቇᓟ߆ࠄ࠮ࡒ࠽࡯ᜂᒰᢎຬ㧔ᜰዉᢎຬ㧕㑆ߩᖱႎ੤឵߇ⴕࠊࠇࠆࠃ߁ߦ
ߥߞߚ‫ޕ‬
٤‫ޟ‬Ფᐕᐲᧃߩ⥃࿾ታ⠌ද⼏ળ㐿௅㧘㒝ዻ∛㒮෸߮ታ⠌∛㒮⋴⼔ㇱߣߩㅪ៤ᒝൻ‫ߪߡ޿ߟߦޠ‬㧘ౕ૕⊛ߥᢙሼ߇᜼ߍࠄࠇߡ޿ߥ޿ߩߢ㧘ߤߩ⒟ᐲߎߩ೙ᐲ߇೑↪ߐࠇߡ޿ࠆߩ߆㧫ታലᐲߪߤ߁߆㧫╬ߩ್ቯ߇ߢ߈ߥ޿‫ޕ‬એ਄ߩߎߣ߆ࠄ㧘ᡷༀ㧘ะ਄ߒߡ޿ࠆߣߪ⸒߃ߥ޿ߣ್ᢿߐࠇࠆ‫ޕ‬⵬⿷⺑᣿㧝㧚⥃࿾ታ⠌ද⼏ળߪᐔᚑ 16 ᐕᐲ߆ࠄᲤᐕᐲᧃߩ㧟᦬ߦ㐿௅ߒߡ޿ࠆ‫ޕ‬಴Ꮸᣉ⸳ᢙߪ଀ᐕ 40 ᒝ㧘಴Ꮸ⠪ᢙߪ 50 ฬ೨ᓟߢ޽ࠆ‫ޕ‬㧔ᷝઃ⾗ᢱߪᐔᚑ 19 ᐕᐲߩ⥃࿾ታ⠌ද⼏ળߩ಴Ꮸᣉ⸳࡮಴Ꮸ⠪ฬ★ߢ޽ࠆ‫ޕ‬ᐔᚑ 19 ᐕᐲߪ಴Ꮸᣉ⸳ᢙ 43㧘಴Ꮸ⠪ᢙ 47 ฬߢ޽ࠆ‫ޕ‬㧕ද⼏ળߢߪ⥃࿾ታ⠌ߦ߅ߌࠆ⃻႐ߢߩቇ↢ᜰዉߩ⃻⁁ߣ⺖㗴ࠍද⼏ߒ㧘ᰴᐕᐲએ㒠ߩᜰዉ૕೙ߦᵴ߆ߒߡ޿ࠆ‫ޕ‬ᐔᚑ 19 ᐕᐲ߆ࠄߪ㧘ቇ↢ߩ᳇⾰߿ᢎ⢒ᣇᴺߩ౒᦭ൻࠍ࿑ࠆߎߣࠍ⋡⊛ߦ⎇ୃળ߽⚵ߺㄟࠎߢ޿ࠆ‫ޕ‬ᐔᚑ 19 ᐕᐲߪ‫⃻ޟ‬ઍߩቇ↢᳇⾰‫ߒߣࡑ࡯࠹ࠍޠ‬㧘㜞ᩞᢎ⻀ࠍ᜗⡜ߒߡ⎇ୃળࠍ㐿௅ߒߚ‫ޕ‬㧞㧚ታ⠌ᜰዉ૕೙ߩᒝൻ㧘⥃࿾ታ⠌ߦ߅ߌࠆ⺖㗴ߩಽᨆߣᡷༀ╷ߩᬌ⸛ࠍ⋡⊛ߦ㧘ᐔᚑ 18 ᐕᐲ߆ࠄጘ㒂ᄢቇකቇㇱ㒝ዻ∛㒮⋴⼔ㇱߣ᦬㧝࿁ߩࡒ࡯࠹ࠖࡦࠣࠍ㐿௅ߒߡ޿ࠆ‫ޕ‬⵬⿷⾗ᢱ㧔ᧄ⹹ߢߪ⾗ᢱ࠲ࠗ࠻࡞ߩߺ⴫⸥㧘ౝኈߪ⋭⇛㧕㧣‫⥃ޓ‬࿾ታ⠌ද⼏ળ಴Ꮸ⠪ฬ★㧔ᐔᚑ㧝㧥ᐕᐲ㧕੐଀㧟‫ޟ‬᝼ᬺᤨ㑆ഀߣભ⻠࡮⵬⻠‫ޠ‬㧔ಽᨆ㗄⋡Υ㧕⋴⼔ቇ⑼ߩࠞ࡝ࠠࡘ࡜ࡓߪ㧘ᐕᐲ࡮ቇᦼߩㅜਛ߆ࠄታ⠌߇౉ࠆ╬㧘ᄌೣ⊛ߢ޽ࠆ߇ભ⻠╬߇޽ߞߡ߽ᔅߕⓨ߈ᤨ㑆ߢ⵬⻠ࠍⴕ޿㧘කቇㇱⷙೣߩᤨ㑆ᢙಽߩ⻠⟵ࠍⴕߞߡ޿ࠆ‫ߚ߹ޕ‬㧘ᐔᚑ 19 ᐕᐲ
߆ࠄⒿേߒߚ㔚ሶࠪ࡜ࡃࠬߦߟ޿ߡߪ㧘᝼ᬺᜂᒰᢎຬ߇⋥ធ౉ജߒ㧘ฃ⻠↢ߩߚ߼ߦ౏㐿ߐࠇߡ޿ࠆ‫ޕ‬ጁୃ↳⺧ߦߟ޿ߡ߽㧘ቇ↢ߩਥ૕⊛ߥቇ⠌߿ല₸⊛ߥቇ⠌ߦᵴ↪ߢ߈ࠆࠃ߁ߦߥߞߚ‫ޕ‬٤‫ޟ‬᝼ᬺᤨ㑆ഀߣભ⻠ • ⵬⻠‫ߪߡ޿ߟߦޠ‬㧘ౕ૕⊛ߥᢙሼ߇᜼ߍࠄࠇߡ޿ߥ޿ߩߢ㧘ߤߩ⒟ᐲߎߩ೙ᐲ
߇೑↪ߐࠇߡ޿ࠆߩ߆㧫ታലᐲߪߤ߁߆㧫╬ߩ್ቯ߇ߢ߈ߥ޿‫ޕ‬એ਄ߩߎߣ߆ࠄ㧘ᡷༀ㧘ะ਄ߒߡ޿ࠆߣߪ⸒߃ߥ޿ߣ್ᢿߐࠇࠆ‫ޕ‬⵬⿷⺑᣿⋴⼔ቇ⑼ߩᤨ㑆ഀߪભ⻠߇⊒↢ߒߥ޿ߎߣࠍ⠨ᘦߒߡ⻠Ꮷߣචಽߦᣣ⒟⺞ᢛࠍߒߚ߁߃ߢ૞ᚑ

㧙㧙ߒߡ޿ࠆߚ߼㧘㐿⸳ᐕᐲ߆ࠄભ⻠ߪዋߥߊ㧘⵬⻠ߪ⏕ታߦታᣉߐࠇߡ޿ࠆ‫ޕ‬Web ߢભ⻠࡮⵬⻠ࠍㅪ⛊ߔࠆࠃ߁ߦߥߞߚᐔᚑ 19 ᐕᐲᓟቇᦼߩ࠺࡯࠲㧔ᷝઃ⾗ᢱෳᾖ㧕ߢߪભ⻠㧟࿁㧘⵬⻠㧟࿁߇ታᣉߐࠇߡ߅ࠅ㧘ߎߩ೙ᐲߪචಽᵴ↪ߐࠇߡ޿ࠆ‫ޕ‬⵬⿷⾗ᢱ㧔ᧄ⹹ߢߪ⾗ᢱ࠲ࠗ࠻࡞ߩߺ⴫⸥㧘ౝኈߪ⋭⇛㧕㧤‫ޓ‬ᐔᚑ㧝㧥ᐕᐲᓟᦼભ⻠࡮⵬⻠৻ⷩާ⎇ⓥި
⾰ߩะ਄ᐲߦߟ޿ߡ㧔කቇㇱ࡮කቇ♽⎇ⓥ⑼㧕
⹏ଔ⚿ᨐ‫ޓ‬Σ㧔ᡷༀ㧘ะ਄ߒߡ޿ࠆߣߪ⸒߃ߥ޿‫ޕ‬㧕ᧄቇㇱ࡮⎇ⓥ⑼߆ࠄ␜ߐࠇߚ੐଀ߪ㧠ઙߢ޽ࠅ㧘ߘߩਛߢ‫ޟ‬ᡷༀ㧘ะ਄ߒߡ޿ࠆߣߪ޿߃ߥ޿‫್ߣޠ‬ᢿߐࠇߚ੐଀߇޽ߞߚ‫ޕ‬⹥ᒰߔࠆ੐଀ߣ್ᢿℂ↱ߪએਅߩߣ߅ࠅߢ޽ࠆ‫ޕ‬੐଀㧝‫ޟ‬කቇᢎ⢒㐿⊒⎇ⓥ࠮ࡦ࠲࡯ߣߣ߽ߦ↳⺧ߒߚ․⦡ GP࡮⃻ઍ GP 㧞ઙណᛯ‫ (ޠ‬ಽᨆ㗄⋡Τ )කቇᢎ⢒㐿⊒⎇ⓥ࠮ࡦ࠲࡯ߣߣ߽ߦ㧘ᐔᚑ 15 ᐕᐲ․⦡ GP‫ޟ‬⢻േ࡮ᕁ⠨ଦㅴဳࠍᩇߣߔࠆోੱ⊛කቇᢎ⢒㧔㧠ᐕ㑆㧕‫ޠ‬෸߮ᐔᚑ 19 ᐕᐲ⃻ઍ GP‫⥃ޟ‬ᐥකቇᢎ⢒ࠍᒝൻะ਄ߐߖࠆ ICT 㧙 e-Learningߢၭ߁කߩᔃߣᛛ㧙㧔㧟ᐕ㑆㧕‫⎇ߩޠ‬ⓥ⺖㗴ߦข⚵ߺ㧘ఝࠇߚ․⦡޽ࠆข⚵ߢ޽ࠆߣߩ⹏ଔࠍᓧߡ
޿ࠆ‫ޕ‬․⦡ GP ណᛯߪ㧘ጘ㒂ᄢቇකቇㇱᢎ᝼ળߩክ⼏ࠍ⚻ߡ㧘㧤ᐕߦਗ਼ࠆ⚵❱⊛ข⚵ߺᚑᨐߦࠃࠅ㧘⢻േ⊛ߦᕁ⠨ߒߥ߇ࠄ⥄ቇ⥄⠌ߔࠆᢎ⢒ⅣႺߩ㉯ᚑ⎇ⓥߦᄢ߈ߥᚑᨐࠍ਄ߍ㧘ઁᄢቇߩෳ⠨ߣߥࠆఝ
ࠇߚ․⦡⎇ⓥ੐଀ߢ޽ࠆ‫ޕ‬
ᐔᚑ 19 ᐕᐲ⃻ઍ GP ណᛯߪ㧘කቇᢎ⢒ߩᡷༀ⎇ⓥߣߒߡ㧘ో࿖ߦవ㚟ߌߚකቇᢎ⢒㐿⊒⎇ⓥ࠮
ࡦ࠲࡯෸߮⢻േဳ࠹ࡘ࠻࡯࡝ࠕ࡞ᢎ⢒ࠍᩭߣߒߡ㧘ICT 㧙 e-Learning ࠍᵴ↪ߒߚ➅ࠅ㄰ߒ⥄Ꮖቇ⠌ߦࠃࠅ㧘⸻≮ෳടဳ⥃ᐥታ⠌ߦ⥃߻ቇ↢ߩ⥃ᐥ⢻ജࠍะ਄ߐߖ㧘තᓟ⎇ୃ߽฽߼ߚోੱක≮ࠍታ〣ߢ߈ࠆකᏧ㙃ᚑࠍ⋡ᜰߔᣂߚߥ⎇ⓥߩข⚵ߺߣߒߡ⹏ଔߐࠇࠆ‫ޕ‬٤‫ޟ‬කቇᢎ⢒㐿⊒⎇ⓥ࠮ࡦ࠲࡯ߣߣ߽ߦ↳⺧ߒߚ․⦡ GP• ⃻ઍ GP 㧞ઙណᛯ‫ߪߡ޿ߟߦޠ‬㧘ᴺੱൻᤨὐߣߩᲧセᬌ⸽ߥߐࠇߡ޿ߥ޿ߚ߼㧘ᡷༀ㧘ะ਄ߒߡ޿ࠆ߆ࠍ⺒ߺขࠇߥ޿‫ޕ‬એ਄ߩߎߣ߆ࠄ㧘ᡷༀ㧘ะ਄ߒߡ޿ࠆߣߪ⸒߃ߥ޿ߣ್ᢿߐࠇࠆ‫ޕ‬⵬⿷⺑᣿․⦡ GP‫ޟ‬⢻േ࡮ᕁ⠨ଦㅴဳࠍᩇߣߔࠆోੱ⊛කቇᢎ⢒㧔ᐔᚑ 15 㨪 18 ᐕᐲ㧕‫⎇ߩޠ‬ⓥ⊛ข⚵㧔⵬⿷⾗ᢱ㧝㧙㧝㧕ߣߒߡߪ㧘໧㗴ၮ⋚ဳ࠹ࡘ࠻࡯࡝ࠕ࡞ᢎ⢒ߩ੐೨ᢎ⢒ࠍలታߔࠆߎߣߦࠃߞߡቇ↢ߩ໧㗴᛽಴࡮⸛⺰⢻ജߩะ਄߇␜ߐࠇ㧔⵬⿷⾗ᢱ㧝㧙㧞㧕㧘⥃ᐥታ⠌ࠞ࡝ࠠࡘ࡜ࡓߩᡷༀߦࠃߞߡ
ቇ↢ߩ⸻≮ෳടᐲߣᘒᐲߩะ਄߇⹺߼ࠄࠇߚ㧔⵬⿷⾗ᢱ㧝㧙㧟㧘㧝㧙㧠㧘㧝㧙㧡㧕‫ߩࠄࠇߎޕ‬ᚑᨐߪቇળ࡮⺰ᢥ⊒⴫ࠍㅢߓߡ࿖ౝᄖߩකቇᢎ⢒ᯏ㑐ߦᖱႎ⊒ାߒߚ‫ޕ‬⃻ઍ GP‫⥃ޟ‬ᐥකቇᢎ⢒ࠍᒝൻะ਄ߐߖࠆ ICT 㧙 e-Learning‫ߢޓ‬ၭ߁කߩᔃߣᛛ㧙㧔ᐔᚑ 19 㨪
21 ᐕᐲ㧕
‫⎇ߩޠ‬ⓥ⊛ข⚵㧔⵬⿷⾗ᢱ㧞㧙㧝㧕ߣߒߡߪ㧘e-learning ࠍ↪޿ߚ໧㗴⸃᳿ဳ⢻േቇ⠌ߩᚑᨐࠍකቇᢎ⢒ߩ࠻࠶ࡊࠫࡖ࡯࠽࡞ (Medical Education) ߦ⊒⴫ߒ㧔⵬⿷⾗ᢱ㧞㧙㧞㧕㧘ฦ⒳ࠪࡒࡘ
࡟࡯࡚ࠪࡦᢎ⢒↪ࠦࡦ࠹ࡦ࠷ߩ૞ᚑߣቇ↢߳ߩ㈩ାࠪࠬ࠹ࡓߩ᭴▽ࠍⴕߞߡ߅ࠅ㧔⵬⿷⾗ᢱ㧞㧙㧟㧘㧞㧙㧠㧕
㧘ቇ↢߆ࠄߩ෻ᔕߪ⦟ᅢߢ޽ࠆ߇㧘੹ᓟ㧘⎇ⓥ⊛ߦᬌ⸽ߒߡⴕߊ⸘↹ߢ޽ࠆ‫ޕ‬⵬⿷⾗ᢱ㧔ᧄ⹹ߢߪ⾗ᢱ࠲ࠗ࠻࡞ߩߺ⴫⸥㧘ౝኈߪ⋭⇛㧕㧙㧙㧝‫ ⦡․ޓ‬GP‫ޟ‬⢻േ࡮ᕁ⠨ଦㅴဳࠍᩇߣߔࠆోੱ⊛කቇᢎ⢒‫ޠ‬㧞‫⃻ޓ‬ઍ GP‫⥃ޟ‬ᐥකቇᢎ⢒ࠍᒝൻะ਄ߐߖࠆ ICT 㧙 e-Learning‫ߢޓ‬ၭ߁කߩᔃߣᛛ㧙‫ޠ‬‫ޓ‬੐଀㧞‫ޟ‬ಽ㊁ᮮᢿဳ⎇ⓥࡊࡠࠫࠚࠢ࠻ࠍផㅴ‫ (ޠ‬ಽᨆ㗄⋡Σ )⎇ⓥ⑼㐳ⵙ㊂⚻⾌ߩ㊀ὐ⊛ߦ㈩ಽߩਛߢ㧘ಽ㊁ᮮᢿဳ⎇ⓥࡊࡠࠫࠚࠢ࠻ࠍផㅴߒߡ߅ࠅ㧘
NaSNeLC ⎇ⓥળߣߒߡ৻ᵹ࿖㓙ቇⴚ㔀⹹㧔࠽ࠬࡀ࡞ࠢ㧘Nature ♽㧘Science㧘New Eng J Med㧘
Lancet㧘Cell㧕╬ big journal ߦឝタߐࠇࠆߎߣࠍ⎇ⓥᚑᨐ⋡ᮡߣߒߡ޿ࠆ‫ޕ‬ਛߢ߽‫ߩ♽⚻␹ޟ‬ၮ␆⎇ⓥߣౣ↢⎇ⓥࠍ↪޿ߚ␹⚻∛⸻ᢿᴦ≮㐿⊒ࡊࡠࠫࠚࠢ࠻‫⎇ߪޠ‬ⓥ⑼ౝ 10 ಽ㊁߆ࠄ 13 ߩ⎇ⓥ࠹࡯ࡑ߇ಽ㊁ࠍ⿥߃ߡឭ᩺ߐࠇ㧘⎇ⓥᖱႎ੤឵ળ߿⊒⴫ળࠍㅢߒߡផㅴߒߡ޿ࠆ‫৻╙ߪߦ⊛⚳ᦨޕ‬✢⚖ߩ࿖㓙㔀⹹⊓タࠍ⋡ᮡߦߒߡ޿ࠆ߇㧘2007 ᐕೀⴕߩ␹⚻㑐ଥ㔀⹹ߩ⧷ᢥේ⪺ 30 ႎߢ޽ࠆ‫ޕ‬٤‫ޟ‬ಽ㊁ᮮᢿဳ⎇ⓥࡊࡠࠫࠚࠢ࠻ࠍផㅴ‫ߪߡ޿ߟߦޠ‬㧘ᴺੱൻᤨὐߣߩᲧセᬌ⸽ߥߐࠇߡ޿ߥ޿ߚ߼㧘ᡷༀ㧘ะ਄ߒߡ޿ࠆ߆ࠍ⺒ߺขࠇߥ޿‫ޕ‬એ਄ߩߎߣ߆ࠄ㧘ᡷༀ㧘ะ਄ߒߡ޿ࠆߣߪ⸒߃ߥ޿ߣ್ᢿ
ߐࠇࠆ‫ޕ‬
⵬⿷⺑᣿
⎇ⓥ⑼㐳ⵙ㊂⚻⾌ߩ㈩ಽࠍฃߌߚ 10 ಽ㊁߆ࠄߩ⧷ᢥේ⪺⺰ᢥ✚ᢙߪ㧘ᴺੱൻᒰᤨߩᐔᚑ 15࡮16ᐕߩ㧞ᐕ㑆ߩᐔဋ߇ 82.5 ႎߢ޽ߞߚ߇㧘⚻⾌㈩ಽࠍฃߌߚᐔᚑ 17-19 ߩ㧟ᐕ㑆ߩᐔဋߪ 89 ႎߦჇ߃ߚ‫ޕ‬⵬⿷⾗ᢱ㧔ᧄ⹹ߢߪ⾗ᢱ࠲ࠗ࠻࡞ߩߺ⴫⸥㧘ౝኈߪ⋭⇛㧕㧟‫ޓ‬‫⁁⃻ޠ࠻ࠢࠚࠫࡠࡊ⚻␹ޟ‬ႎ๔੐଀㧟‫ ࠻ࡅޟ‬ES ⚦⢩ࠍ↪޿ߚౣ↢ක⑼ቇ⎇ⓥߩផㅴ‫ (ޠ‬ಽᨆ㗄⋡Τ )ᧄ⎇ⓥ⑼ౣ↢ක⑼ቇኾ᡹ߩ⚵❱࡮ེቭᒻᚑಽ㊁ߦ߅޿ߡ㧘⎇ⓥ⑼㐳ⵙ㊂⚻⾌╬ࠍ㊀ὐ⊛ߦ㈩ಽߒ
ߡ㜞ᐲߥ⎇ⓥࠍផㅴߒߡ޿ࠆ‫ޕ‬⃻࿷ߪ㧘ࡅ࠻ ES ⚦⢩߆ࠄ⋡⊛ߩ⚦⢩㧔✂⤑⚦⢩㧘ᔃ╭⚦⢩㧕ߩ⺃ዉߦᚑഞߒ㧘ታ↪ൻ߳ߩേ‛ࡕ࠺࡞ࠍ૞ᚑߒߡ޿ࠆ‫ޕ‬ᚑᨐߩ৻ㇱߪ࿖㓙⹹ߦ⺰ᢥ⊒⴫ߒߚ‫ޕ‬٤‫ ࠻ࡅޟ‬ES ⚦⢩ࠍ↪޿ߚౣ↢ක⑼ቇ⎇ⓥߩផㅴ‫ߪߡ޿ߟߦޠ‬㧘⸥ㅀౝኈߦౕ૕ᕈ߇ਲߒߊ㧘‫ޟ‬ᚑᨐߩ
৻ㇱߪ࿖㓙⹹ߦ⺰ᢥ⊒⴫ߒߚ‫ᦌߩ╬ޠ‬ᤒߥ⸥ㅀߢ޽ࠆὐߢ㧘ᡷༀ㧘ะ਄ߒߡ޿ࠆߣߪ⸒߃ߥ޿ߣ್
ᢿߐࠇࠆ‫ޕ‬⵬⿷⺑᣿⚵❱࡮ེቭᒻᚑಽ㊁߆ࠄߩ⧷ᢥේ⪺⺰ᢥᢙߪ㧘ᴺੱൻᒰᤨߩᐔᚑ 15࡮16 ᐕߩ㧞ᐕ㑆ߩᐔဋ߇ 6ႎߢ޽ߞߚ߇㧘⚻⾌㈩ಽࠍฃߌߚᐔᚑ 17-19 ߩ㧟ᐕ㑆ߩᐔဋߪ 11 ႎߦჇ߃ߚ‫ޕ‬⵬⿷⾗ᢱ㧔ᧄ⹹ߢߪ⾗ᢱ࠲ࠗ࠻࡞ߩߺ⴫⸥㧘ౝኈߪ⋭⇛㧕㧠‫ޓ‬ㅴ᝞⁁ᴫႎ๔ᦠ੐଀㧠‫ޟ‬࿾ၞක≮ߦ㑐ߔࠆ⎇ⓥ‫ (ޠ‬ಽᨆ㗄⋡Σ )ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⋭ߩ࿾ၞකᏧਇ⿷ߦଥࠆᣂකᏧ⏕଻✚วኻ╷ߦࠃࠅ㧘ጘ㒂ᄢቇ⁛⥄ߦ࿾ၞක≮කቇ࠮ࡦ࠲࡯ࠍ┙ߜ਄ߍ⋵ౝߩක≮⏕଻ࠍ࿑ࠆߣߣ߽ߦ㧘࿾ၞක≮කቇߩ⎇ⓥߦኻߒ㧘ᐔᚑ 19ᐕᐲߦ⋵߆ࠄ࿾ၞක≮ቇߩነ㒝⻠ᐳࠍฃ౉ࠇ㧘㧞ᰴක≮࿤ߦ߅ߌࠆ࿾ၞක≮ឭଏ૕೙ߩ⺖㗴ߣ⸃᳿╷ߩ⎇ⓥ㧘࿾ၞߩၮᐙ∛㒮ࠍࡈࠖ࡯࡞࠼ߣߒߚ࿾ၞක≮ቇߩ⎇ⓥ෸߮࿾ၞක≮ࠍᜂ߁කᏧ㧔ᮮᢿ⊛✚ว⥃ᐥක㧕ߩ㙃ᚑߦ㑐ߔࠆ⎇ⓥࠍⴕ߁‫ޕ‬ߥ߅㧘࿾ᣇ⥄ᴦ૕߆ࠄߩነ㒝ߦߟ޿ߡߪ࿾ᣇ⽷᡽ౣᑪଦㅴ․೎ភ⟎ᴺߦࠃࠆⷙ೙ࠍฃߌࠆ߇㧘⎇ⓥ⋡⊛ߦ㑐ߒߡ✚ോ⋭ߩ⸵น߇಴ߡ޿ࠆ‫ޕ‬㧙㧙٤‫ޟ‬࿾ၞක≮ߦ㑐ߔࠆ⎇ⓥ‫ߪߡ޿ߟߦޠ‬㧘⾗ᢱ߇ឭ␜ߐࠇߡ޿ߥ޿ὐߢ㧘ᡷༀ㧘ะ਄ߒߡ޿ࠆߣߪ⸒
߃ߥ޿ߣ್ᢿߐࠇࠆ‫ޕ‬⵬⿷⾗ᢱ㧔ᧄ⹹ߢߪ⾗ᢱ࠲ࠗ࠻࡞ߩߺ⴫⸥㧘ౝኈߪ⋭⇛㧕㧡‫ޓ‬࿾ၞක≮ߦขࠅ⚵߻ 㧯㧾㧹㧔࿾ၞක≮කቇ࠮ࡦ࠲࡯㧕ᢎຬߩ⎇ⓥ╬ᵴേታ❣

㧙㧙කቇ♽⎇ⓥ⑼࡮කቇㇱ⥄Ꮖ⹏ଔᆔຬળᆔຬฬ★

ᆔຬ㐳›‫ޓ‬Ⴆ‫⾆ޓޓޓ‬㧔⎇ⓥ⑼㐳㧕

ᷡ‫ޓ‬ፉ‫ޓޓޓ‬ḩ㧔೽⎇ⓥ⑼㐳㧕

ዊ‫ޓ‬Ỉ‫ୃޓޓޓ‬㧔೽⎇ⓥ⑼㐳㧕

᫪‫ޓ‬⣁‫ޓ‬ਭ‫ޓ‬㓉㧔∛㒮㐳㧕ᓟ‫ޓ‬㑄‫ޓ‬ኈ‫ޓ‬ሶ㧔⋴⼔ቇ⑼㐳㧕

㋈‫ޓᧁޓ‬ᐽ‫ޓ‬ਯ㧔කቇ⑼ᢎോෘ↢ᆔຬ㐳㧕Ṛ‫ޓ‬ౝ‫ޓ‬㓉‫ޓ‬ሶ㧔⋴⼔ቇ⑼ᢎോෘ↢ᆔຬ㐳㧕ጟ‫ޓ‬㊁‫ޓ‬ᐘ‫ޓ‬㓶㧔කቇ⎇ⓥ⑼ቇോᆔຬ㐳㧕⿷‫ޓ┙ޓ‬ਭ‫ޓ‬ሶ㧔⋴⼔ቇኾ᡹ቇോᆔຬ㐳㧕㜞‫ޓޓޓ⷗ޓ‬೰㧔කቇ♽⎇ⓥ⑼ᢎ᝼㧕દ‫ޓ౎ޓ⮮ޓ‬ᰴ㧔කቇ♽⎇ⓥ⑼ᢎ᝼㧕▘‫ޓ‬ᶆ‫߈ߣޓ‬ሶ㧔⋴⼔ቇ⑼዁᧪⸘↹ᆔຬ㐳㧕ᱞ‫ޓ‬ౝ‫ޓ‬ᐽ‫ޓ‬㓶㧔ጘ㒂ᄢቇ⹏ଔቶຬ㧕ർ‫ޓޓޓⵣޓ‬ඳ㧔කቇ⎇ⓥ⑼࡮කቇㇱ੐ോ㐳㧕ᒁ‫ޓ‬ሼ‫ޓ‬ൎ‫⟤ޓ‬㧔∛㒮✚ോ⺖㐳㧕

කቇ♽⎇ⓥ⑼࡮කቇㇱ⥄Ꮖ⹏ଔᆔຬળ‫⺖ߣ⁁⃻ޟ‬㗴‫ޠ‬૞ᬺㇱળᆔຬฬ★
ㇱળ㐳ዊ‫ޓ‬Ỉ‫ୃޓޓޓ‬㧔೽⎇ⓥ⑼㐳㧕

ศ‫ޓ↰ޓ‬๺‫ޓ‬ᒄ㧔කቇ♽⎇ⓥ⑼ᢎ᝼㧕ේ‫ޓޓޓޓޓ‬᣿㧔කቇ♽⎇ⓥ⑼ᢎ᝼㧕ᅏ‫ޓ᧛ޓ‬ᄥ‫ޓ‬ᔒ㧔⋴⼔ቇ⑼ᢎ᝼㧕ဈ‫ޓ‬㊁‫ޓ‬༑‫ޓ‬ሶ㧔කቇ♽⎇ⓥ⑼ಎᢎ᝼㧕ᣧ‫ޓ‬Ꮉ‫ޓ‬ᄢ‫ޓ‬テ㧔කቇ♽⎇ⓥ⑼ಎᢎ᝼㧕⍹‫ޓ‬ේ‫ޓ‬ᄙ૫ሶ㧔⋴⼔ቇ⑼ಎᢎ᝼㧕દ‫ޓ⮮ޓ‬ᒄ‫ޓ‬ᐽ㧔කቇ♽⎇ⓥ⑼⻠Ꮷ㧕᫃‫ޓ↰ޓ‬๺‫↵ޓ‬㧔කቇ♽⎇ⓥ⑼⻠Ꮷ㧕‐‫ޓ⿧ޓ‬ඳ‫ޓ‬ᤘ㧔කቇ♽⎇ⓥ⑼ഥᢎ㧕Ⴎ‫⟤↱⌀ޓ⼱ޓ‬㧔කቇㇱ㒝ዻ∛㒮ഥᢎ㧕ศ‫ޓ‬Ꮉ‫଻ޓ⟤ޓ‬㧔⋴⼔ቇ⑼ഥᢎ㧕㧙㧙